

Studie 035
(CTN035-FCE20124)

Studienbericht

Pharmacia

Document 9550089

Reboxetine

CLINICAL STUDY
035

30 January 1996

**Multicentre, Multinational Double-Blind Study of the Tolerability and
Activity of Reboxetine vs Imipramine in Elderly Patients Suffering
from Depressive Disorders**

(Phase III)

Final report of study
CTN035-FCE20124

Authors: Ban TA, Dubini A, Giorgetti C, Petroccione A,
Bercoff E, Chiu E, Katona C, Lawlor B,
Tack Ph, Versiani M, Woelk H

1 (2536)

Pharmacia

Document 9550089

STUDY CO-ORDINATION, MANAGEMENT AND REPORTING

Steering Committee

Prof. Thomas A. Ban
Professor of Psychiatry Emeritus
Vanderbilt University
Tennessee, USA

Thomas A. Ban February 7, 1996
signature date

Study Director

Adriana Dubini Pharm.D
Pharmacia, CNS R&D
Milan, Italy

Adriana Dubini Jan 30, 96
signature date

Medical Research Associate

Carla Giorgetti Biol.D
Pharmacia, CNS R&D
Milan, Italy

Carla Giorgetti 30-1-96
signature date

Statistics

Anna Petroccione MD
Pharmacia, Oncology R&D
Biometrics and Data Management
Milan, Italy


Anna Petroccione 30-1-96
signature date

Pharmacia

Document 9550089

Clinical Investigator:

Prof. E. Bercoff
Hôpital de Bois-Guillaume
Service de Gériatrie
Bois-Guillaume, France


signature

12/02/06
date

Pharmacia

Document 9550089

Clinical Investigator:

Prof. E. Chiu
Henry Pride Geriatric Centre
Kew, Victoria
Australia



signature

21/11/02


date

Pharmacia


Document 9550089

Clinical Investigator:

Prof. C. Katona
Princess Alexandra Hospital
Harlow, UK



signature




date

Pharmacia

Document 9550089

Clinical Investigator:

Dr. B. Lawlor
St. James' Hospital
Dublin, Ireland

 13-2-96
signature date


090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Pharmacia

Document 9550089

Clinical Investigator:

Dr. P. Tack
Sint Andries Ziekenhuis
Neuropsychiatrie
Tielt, Belgium


signature

20/2/96
date

Pharmacia

Document 9550089

Clinical Investigator:

Prof. M. Versiani
Institute of Psychiatry
Federal University
Ipanema - Rio de Janeiro, Brazil

 26/2/96
signature date

Pharmacia

Document 9550089

Clinical Investigator:

Prof. H. Woelk
Psychiatrisches Landeskrankenhaus
Gießen, Germany

U. Woelk 8.2.96
signature date

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

TABLE OF CONTENTS

	Page
COVER PAGE	1
STUDY CO-ORDINATION, MANAGEMENT AND REPORTING	2
TABLE OF CONTENTS	10
LIST OF ABBREVIATIONS AND TERMS	21
SYNOPSIS	22
1. INTRODUCTION	29
2. STUDY OBJECTIVES	31
3. INVESTIGATIONAL PLAN	31
3.1 Study Design and Plan - Description and Rationale	31
3.1.1 OVERVIEW AND JUSTIFICATION	31
3.1.2 PROTOCOL AMENDMENTS	32
3.2 Ethics	33
3.2.1 ETHICS COMMITTEE	33
3.2.2 PATIENT INFORMATION	33
3.3 Study Population	34
3.3.1 INCLUSION CRITERIA	34
3.3.2 EXCLUSION CRITERIA	34
3.3.3 WITHDRAWAL CRITERIA	35
3.3.4 SAMPLE SIZE - NUMBER OF PATIENTS PLANNED	36
3.4 Treatments	36
3.4.1 TREATMENTS TO BE COMPARED	36
3.4.2 IDENTITY OF TEST TREATMENTS	36
3.4.3 DOSE SELECTION AND TIMING	37
3.4.4 METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUPS	37
3.4.5 TREATMENT SUPPLY AND BLINDING	37
3.5 Treatment Procedures	38
3.5.1 CONCOMITANT THERAPY	38
3.5.2 TREATMENT ACCOUNTABILITY AND COMPLIANCE	38
3.6 Efficacy and Safety Variables	39
3.6.1 EFFICACY	39
3.6.1.1 Hamilton Depression Rating Scale	39
3.6.1.2 Clinical Global Impression	41
3.6.1.3 Montgomery and Asberg Depression Rating Scale	41
3.6.1.4 Geriatric Depression Rating Scale	42
3.6.2 SAFETY	42
3.6.2.1 Adverse Events	43

Pharmacia

Document 9550089

3.6.2.2 Clinical and Laboratory Tests	44
3.7 Study Procedures and Flow Chart	46
3.7.1 SCHEDULE OF ASSESSMENTS	46
3.7.2 PROCEDURES AT EACH VISIT	46
3.8 GCP Compliance, Data Quality Assurance	47
3.9 Statistical Analysis	47
3.9.1 SAMPLE SIZE CONSIDERATIONS	47
3.9.2 STATISTICAL AND ANALYTICAL PLANS	48
3.9.2.1 Baseline Comparability of Treatment Groups	48
3.9.2.2 Efficacy Analyses	48
3.9.2.3 Safety	49
3.9.2.4 Changes in the Conduct of the Study or Planned Analysis	51
3.10 Data Management	52
4. STUDY PATIENTS	53
4.1 Disposition of Patients	53
4.2 Protocol Deviations	54
4.3 Demographic Data and Psychiatric Anamnesis	56
4.3.1 COGNITIVE FUNCTION	57
4.3.2 DIAGNOSIS AND HISTORY OF THE DEPRESSIVE DISORDER	57
4.3.3 SEVERITY OF DEPRESSION	58
4.3.4 PREVIOUS ANTIDEPRESSANT TREATMENTS	60
4.3.5 MEDICAL HISTORY	61
5. STUDY MEDICATION AND COMPLIANCE	62
6. CONCOMITANT MEDICATIONS	64
7. EFFICACY RESULTS	66
7.1 Hamilton Depression Rating Scale	66
7.2 Clinical Global Impression	68
7.2.1 SEVERITY OF ILLNESS	68
7.2.2 GLOBAL IMPROVEMENT	68
7.2.3 EFFICACY INDEX	70
7.3 Montgomery and Asberg Depression Rating Scale	70
7.4 Geriatric Depression Rating Scale	70
7.5 Efficacy Conclusions	71

8. SAFETY RESULTS	72
8.1 Safety Population and Extent of Exposure	72
8.1.1 NUMBER OF PATIENTS IN SAFETY ANALYSIS	72
8.1.2 TOTAL DRUG EXPOSURE	72
8.2 Adverse Events	72
8.2.1 ANALYSIS OF ADVERSE EVENTS	72
8.2.1.1 End-Point Analysis	73
8.2.1.2 Absolute and Per Cent Frequency	73
8.2.1.3 Occurrence	75
8.2.1.4 Cumulative Risk for Individual Events	76
8.2.1.5 Dose Relationship	76
8.2.1.6 Maximal Severity	76
8.2.1.7 Duration	77
8.2.1.8 Symptomatic Treatment	77
8.2.1.9 Modification of Study Medication and Patient Outcome	77
8.2.1.10 Prevalence	78
8.2.1.11 Relationship Between Adverse Events and Study Medication	79
8.2.1.12 Adverse Events Occurred in Patients with Creatinine Clearance <30 ml/min	79
8.2.2 ADVERSE EVENT SUMMARY	80
8.2.2.1 Severity of Adverse Events	80
8.2.2.2 Age- and Gender-Related Effects	80
8.2.2.3 Frequently Reported Adverse Events	81
8.2.3 SERIOUS ADVERSE EVENTS, DEATHS AND ADVERSE EVENTS ASSOCIATED WITH WITHDRAWAL	84
8.2.3.1 Serious Adverse Events and Deaths	84
8.2.3.2 Adverse Events Associated with Withdrawal	84
8.3 Laboratory Tests	88
8.3.1 SUMMARY STATISTICS OF LABORATORY VALUES	88
8.3.2 URINALYSIS	88
8.3.3 ABNORMAL LABORATORY VALUES	88
8.3.4 ABNORMAL LABORATORY VALUES OF CLINICAL RELEVANCE	89
8.4 Vital Signs	89
8.4.1 BLOOD PRESSURE AND HEART RATE	89
8.4.2 BODY WEIGHT	90
8.5 Electrocardiogram	90
8.6 Safety Conclusions	91
9. DISCUSSION	94
10. CONCLUSION	98
11. REFERENCES	99

Pharmacia

Document 9550089

Tables	page	102
Table 1	Number of patients by centre, visit and treatment	103
Table 2	Patient disposition	107
Table 3	End of study: reasons for discontinuation and visit at which discontinuation occurred, by assigned treatment	108
Table 4	Protocol violations at admission	111
Table 5	Protocol violations at admission: creatinine clearance	112
Table 6	Randomisation: assigned treatment vs randomised treatment	113
Table 7	Compliance to schedule time as per protocol	114
Table 8	Concomitant drugs not allowed by protocol grouped by active principle. Number of patients	120
Table 9	Concomitant drugs not allowed by protocol grouped by class. Number of patients	122
Table 10	Demography by assigned treatment and diagnosis - age, weight, height	123
Table 11	Demography by assigned treatment and diagnosis - race and sex	124
Table 12	Mini Mental State - total score	125
Table 13	Diagnosis and history of mental disorders by diagnosis and assigned treatment	126
Table 14	Diagnosis and history of mental disorders by diagnosis and assigned treatment (index episode)	128
Table 15	Previous antidepressive treatment by active principle	131
Table 16	Medical history and admission examination findings of screened patients by diagnosis and assigned treatment	133
Table 17	Medical history and admission examination findings of screened patients by body system, diagnosis and assigned treatment	144
Table 18	Experimental treatment: number of patients according to dose taken on each day and on days of assessment during therapy by assigned treatment	145
Table 19	Experimental treatment: number of patients who switched from low to high dose by assigned treatment	149
Table 20	Experimental treatment: distribution of patients according to capsules taken by assigned treatment	150
Table 21	Concomitant drugs by active principle: number of patients taking at least one concomitant medication by assigned treatment and diagnosis	151

Pharmacia

Document 9550089

Table 21a	Concomitant drugs by active principle: number of patients taking at least one concomitant medication by class of drug, assigned treatment and diagnosis	184
Table 22	Hamilton Depression Rating Scale: summary statistics on total score according to time interval by assigned treatment	219
Table 23	Hamilton Depression Rating Scale: frequency of each item score by assigned treatment	222
Table 24	Factorialisation Hamilton Depression Rating Scale: summary statistics on score of each factor according to time interval by assigned treatment	285
Table 25	Hamilton Depression Rating Scale: summary statistics on total score at last assessment by assigned treatment	303
Table 26	Factorialisation Hamilton Depression Rating Scale: summary statistics on score of each factor at last assessment by assigned treatment	306
Table 27	Hamilton Depression Rating Scale: difference on total score at last assessment with respect to baseline	324
Table 28	Efficacy: classification of patients according to protocol criteria on total score of Hamilton Depression Rating Scale over time by assigned treatment and diagnosis	325
Table 29	Efficacy: classification of patients according to protocol criteria on total score of Hamilton Depression Rating Scale at last assessment vs Day 0 by assigned treatment and diagnosis	328
Table 30	HAMD scale: frequency of remission by severity at baseline of the 17 specific items by assigned treatment	331
Table 31	Clinical Global Impression: Severity of Illness according to time interval by assigned treatment	334
Table 32	Clinical Global Impression: Severity of Illness at last assessment by assigned treatment	337
Table 33	Clinical Global Impression: Severity of Illness shift table (last value vs Day 0) by assigned treatment	340
Table 34	Clinical Global Impression: Global Improvement according to time interval by assigned treatment	343
Table 35	Clinical Global Impression: Global Improvement at last assessment by assigned treatment	346
Table 36	CGI at last assessment: frequency of much and very much improved in the two treatment groups	349
Table 37	Clinical Global Impression: Efficacy Index according to time interval by assigned treatment	350

Pharmacia

Document 9550089

Table 38	Clinical Global Impression: Efficacy Index at last assessment by assigned treatment	353
Table 39	Montgomery Asberg Depression Rating Scale: summary statistics on total score according to time interval by assigned treatment	356
Table 40	Montgomery Asberg Depression Rating Scale: summary statistics on total score at last assessment by assigned treatment	359
Table 41	Geriatric Depression Rating Scale: summary statistics on total score according to time interval by assigned treatment	362
Table 42	Geriatric Depression Rating Scale: summary statistics on total score at last assessment by assigned treatment	365
Table 43	Adverse events: frequency (95% CI) of patients who complained of at least one adverse event during therapy by sex and assigned treatment	368
Table 44	Adverse events: frequency (95% CI) of patients who complained of at least one adverse event during therapy by age and assigned treatment	369
Table 45	Adverse events: frequency (95% CI) of patients who complained of at least one adverse event during therapy by DSM-III-R classification and assigned treatment	370
Table 46	Adverse events: number of adverse events and patients who complained of them during therapy by assigned treatment and sex	371
Table 47	Adverse events: number of adverse events and patients who complained of them during therapy by assigned treatment, body system and sex	380
Table 48	Adverse events: number of adverse events and patients who complained of them during therapy by assigned treatment, body system and diagnosis	402
Table 49	Adverse events: number of adverse events and patients who complained of them during therapy by assigned treatment and sex, grouped by body system	423
Table 50	Frequency of patients complaining of at least one adverse event	425
Table 51	Adverse events: occurrence of adverse events according to time of onset by assigned treatment	426
Table 52	Adverse events: occurrence of adverse events according to time of onset by assigned treatment and body system	434
Table 53	Adverse events: occurrence of adverse events according to time of onset by assigned treatment and grouped by body system	455

Pharmacia

Document 9550089

Table 54	Adverse events: number of adverse events according to dose taken the day of onset and three days before by severity and assigned treatment	457
Table 55	Adverse events: number of patients who complained of at least one adverse event by maximal severity level, sex, age, DSM-III-R	479
Table 56	Number of patients who complained of adverse events by maximal severity level, sex and assigned treatment	480
Table 57	Number of patients who complained of adverse events, grouped by body system, by maximal severity level, sex and assigned treatment	496
Table 58	Number of patients who complained of adverse events, grouped by body system, by maximal severity level, diagnosis and assigned treatment	500
Table 59	Adverse events: duration of episodes by assigned treatment	505
Table 60	Adverse events: number of adverse events by symptomatic treatment and assigned treatment	513
Table 61	Adverse events by action on study drug and assigned treatment	519
Table 62	Adverse events: disappeared after action on study drug and reappeared on resuming treatment by assigned treatment	527
Table 63	Adverse events: outcome of events at the end of the therapy by action on study drug and assigned treatment	531
Table 64	Adverse events: prevalence of adverse events according to time interval by assigned treatment	540
Table 65	Adverse events: prevalence of adverse events according to time interval by assigned treatment and body system	551
Table 66	Adverse events: prevalence of adverse events according to time interval by assigned treatment and grouped by body system	573
Table 67	Adverse events by relationship to the experimental treatment and assigned treatment	576
Table 68	Adverse events: number of patients complaining of at least one adverse event with definite or probable relationship	584
Table 69	Adverse events present at last day of treatment and their relationship to study medication (only patients who withdrew from the study for adverse events)	586
Table 70	Laboratory test: haematology and blood chemistry statistical analysis according to time interval by assigned treatment	591
Table 71	Urinalysis: number and percentage of patients according to time interval, by assigned treatment and sex	609

Pharmacia

Document 9550089

Table 72	Urinalysis: number and percentage of patients at last assessment, by assigned treatment and sex	611
Table 73	Urinalysis: shift table - number of patients with abnormal or normal urinalysis value at each evaluation time as compared to pre-treatment evaluation, by assigned treatment	613
Table 74	Urinalysis: shift table - number of patients with abnormal or normal urinalysis value at last assessment as compared to pre-treatment evaluation, by assigned treatment	615
Table 75	Urinalysis: shift table - number of patients with abnormal or normal urinalysis value at each evaluation time as compared to pre-treatment evaluation, by assigned treatment (specific gravity)	617
Table 76	Urinalysis: shift table - number of patients with abnormal or normal urinalysis value at last assessment as compared to pre-treatment evaluation, by assigned treatment (specific gravity)	619
Table 77	Laboratory test: haematology and blood chemistry - shift table. Number of patients with values below, within or above the normal range according to time interval as compared to pre-treatment, by assigned treatment	621
Table 78	Laboratory test: number and percentage of patients with laboratory abnormalities of clinical relevance	629
Table 79	Blood pressure and heart rate: summary statistics according to time interval by assigned treatment	635
Table 80	Blood pressure and heart rate: summary statistics on changes from baseline observed during treatment according to time interval by assigned treatment	637
Table 81	Blood pressure and heart rate: number and percentage of patients with decrease or increase vs baseline of clinical relevance according to time interval by assigned treatment	639
Table 82	Blood pressure and heart rate: absolute number of patients showing clinically relevant changes, compared to baseline, once, twice or more times during the therapy, by assigned treatment	641
Table 83	Blood pressure: number and percentage of patients with orthostatic hypotension before and during the study according to time interval by assigned treatment	642
Table 84	Body weight: summary statistics according to time interval by assigned treatment and sex	643
Table 85	Body weight: number and percentage of patients with values lower or higher than pre-treatment at each evaluation time, by assigned treatment and sex	645

Pharmacia

Document 9550089

Table 86	ECG: number and percentage of patients with abnormal ECG according to time intervals, by assigned treatment and sex	647
Table 87	ECG: shift table - number of patients with normal or abnormal ECG value at each evaluation time as compared to pre-treatment evaluation, by assigned treatment	648
Table 88	ECG: shift table - number of patients with normal or abnormal ECG value at last assessment as compared to pre-treatment evaluation, by assigned treatment	649
Table 89	ECG: number and percentage of ECG abnormalities observed during the study, by assigned treatment	650
Table 90	ECG: shift table - number of patients with absent or present ECG abnormalities at last assessment as compared to pre-treatment evaluation, by assigned treatment	652
Table 91	ECG: number and percentage of ECG abnormalities, by abnormality group, observed during the study by assigned treatment	662
Table 92	ECG: shift table - number of patients with absent or present ECG abnormalities, by abnormality group, at last assessment as compared to pre-treatment evaluation, by assigned treatment	663
Figures		664
Figure 1	Cumulative risk of developing hypotension and related symptoms	665
Figure 2	Percentage of patients with at least one adverse event when exposed to treatment according to time intervals	668

Pharmacia

Document 9550089

12	Appendices	671
12.1	Study Information	672
12.1.1	Protocol and Protocol Amendments	673
12.1.2	CRF Sample	747
12.1.3	Ethics Committees or Investigational Review Boards: Approvals, List of Members, Patient Information and Consent Forms	748
12.1.4	Clinical Investigators List, Signatures and Curricula Vitae	749
12.1.5	Certificates of Analysis	753
12.1.6	Audit Certificate	764
12.1.7	Randomisation List	766
12.1.8	Laboratory Reference Values and Criteria Used to Judge Laboratory Abnormalities as Clinically Relevant	802
12.1.9	Adverse Events Grouped in Clusters	805
12.1.10	Statistical Analysis Programs Listings	807
12.1.11	Selection of Statistical Analysis Outputs	813
12.1.12	ECG Codes	886
12.2	Patient Information	888
12.2.1	Serious Adverse Events - Case Histories	889
12.2.2	Individual Data Listings	906
Listing 1.0	Patient identification	
Listing 2.0	History of mental disorder and present episode	
Listing 3.0	DSM-III-R diagnostic criteria for major depressive episode	
Listing 3.1	DSM-III-R diagnostic criteria for dysthymia	
Listing 4.0	Medical history and admission examination findings	
Listing 5.0	Chest X-ray	

Pharmacia

Document 9550089

- Listing 6.0 Previous antidepressive treatment
- Listing 6.1 Drug-free wash-out period
- Listing 7.0 Inclusion/exclusion criteria
- Listing 8.0 Concomitant drugs
- Listing 9.0 Experimental treatment: daily dose and cumulative compliance
Experimental treatment: daily and cumulative compliance
- Listing 10.0 Assigned vs randomised treatment
- Listing 11.0 Reasons for discontinuation of the treatment
- Listing 12.0 Hamilton Depression Rating Scale
- Listing 12.1 Hamilton Depression Rating Scale: factors and total score
- Listing 13.0 Montgomery Asberg Depression Rating Scale
- Listing 15.0 Geriatric Depression Scale
- Listing 16.0 Clinical Global Impression
- Listing 17.0 Adverse events: detail and summary
- Listing 18.0 Laboratory data
- Listing 18.1 Creatinine and creatinine clearance values calculated as per protocol
Creatinine and tested creatinine clearance values
- Listing 19.0 Urinalysis
- Listing 20.0 Vital signs and assessment dates
- Listing 21.0 ECG tracings

12,2,3

CRFs

2536

LIST OF ABBREVIATIONS AND TERMS

AUC	Area under the plasma levels curve
b.i.d	twice daily
BUN	blood urea nitrogen
CGI	clinical global impression
CI	confidence interval
CRF	case record form
DSM-III-R	diagnostic and statistical manual - third edition - revised
DYS	dysthymia
ECG	electrocardiogram
ECT	electroconvulsive therapy
gamma GT	gamma glutamyl transpeptidase
GCP	good clinical practice
GDS	geriatric depression rating scale
HAMD	Hamilton depression rating scale
IRB	institutional review board
MADRS	Montgomery and Asberg depression rating scale
MDD	major depressive episode/disorder
MMS	mini mental state examination
OR	odds ratio
REM	rapid eye movement
SD	standard deviation
SGOT	serum glutamic-oxaloacetic transaminase
SGPT	serum glutamic-pyruvic transaminase
T4	thyroxine
TSH	thyroid-stimulating hormone

Pharmacia

Document 9550089

**REBOXETINE - PROTOCOL 20124/035
SYNOPSIS**

Name of Company: Pharmacia Spa	Individual study table referring to part IV of the dossier	(For national authority use only)
Name of finished product:	Ref.:	
Name of active ingredient(s): Reboxetine	Vol.:	
	Page:	
Title of study: Multicentre, multinational double-blind study of the tolerability and activity of reboxetine vs imipramine in elderly patients suffering from Depressive Disorders.		
Investigators: Prof E Chiu, Dr D Ames, Prof J Snowdon, Dr B Russell, Prof M Van Moffaert, Dr R Spiers, Dr J Bolton, Dr F Roelandts, Prof JA Costa e Silva, Prof M Versiani, Dr JP Charmes, Dr Y Quenet, Dr J Daumer, Prof P Delswailly, Dr R Pagot, Prof. E Bercoff, Dr G Clerc, Dr RA Castiglioni, Dr H Berzewski, Prof KL Taschner, Prof HJ Moeller, Dr J Morgner, Prof B Pflug, Prof HJ Schierle, Prof H Woelk, Dr M O'Connolly, Dr H Wiswedel, Dr G Stumpf, Dr K Schroter, Dr P Adler, Dr SV Korgaonkar, Dr B Lawlor, Prof C Katona, Dr L Luke, Dr P Bourgeois, Dr Ph Tack, Dr IKI Ibrahim, Dr R Bullock, Dr T Venkat, Dr T George, Dr M Smout, Prof Bulpitt, Dr J Mullin, Prof D O'Connor.		
Study centres: Academic Unit for Psychiatry of Old Age, Mont Park Hospital Campus, Private Bag 1, Rosanna Victoria 3084, Australia; Royal Park Psychiatric Hospital, Private Bag 3, Parkville Victoria 3052, Australia; Dept of Psychogeriatrics, The Rozelle Hospital, P.O. Box 1, Rozelle NSW 2039, Australia; Dept of Rehabilitation and Geriatrics, Royal North Shore Hospital, Pacific Highway, St Leonards NSW 2065, Australia; Universitair Ziekenhuis Gent, Psychiatrische Klinik, De Pintelaan 185, 9000 Gent, Belgium; St. Camillus Ziekenhuis, Beukenlaan 20, 9280 St Denijs-Westrem, Belgium; Sancta Maria Psychiatr. Ziekenhuis, Melverencentrum 11, 3800 Sint Truiden, Belgium; Stichting voor de Psychogeriatric, Gentssesteenweg 1050, 1080 Bruxelles, Belgium; Santa Casa Da Misericordia, Rua Santa Luzia 206, 22461 Rio de Janeiro, Brazil; Inst of Psychiatry Federal Univ., Av Copacabana 1133, s. 1303, 22070 Rio de Janeiro, Brazil; Hôpital Jean Rebeyrol, Service de Gériatrie, Av du Buisson, 87042 Limoges Cedex, France; Centre National de Gériatrie, 78320 La Verrière, France; CHS Charcot, 56850 Caudan, France; Centre de Soins pour Personnes Agées, 23, rue des Bateliers, 59037 Lille Cedex, France; CHS, 56896 Saint-Ave Cedex, France; Hôpital de Boisguillaume, Service de Gériatrie, 147, rue du Maréchal Juin, 76320 Boisguillaume, France; Hôpital de Pontorson, 7, La Chaussée de Villecherel, 50170 Pontorson, France; Hôpital Saint Marguerite, Service de Psychiatrie, 270, bd. Ste Marguerite, 13275 Marseille Cedex, France; Universitätsklinikum Steglitz, Freie Universität Berlin, Hindenburgdamm 30, 12203 Berlin-West 45, Germany; Bürgerhospital, Psychiatrische Klinik, Tunzhofer Str 14-16, 70191 Stuttgart, Germany; Psychiatrische Universitätsklinik, Sigmund Freud Str. 25, 53127 Bonn, Germany; Bezirkskrankenhaus, Neuropsych. Klinik Oberloschwitz, Alpenstr. 1, 01326 Dresden, Germany; Zentrum für Psychiatrie am Klinikum der JW Goethe Univ, Heinrich Hoffmann Str. 10, 60528 Frankfurt, Germany; Puisseaux Platz 2, 63110 Rodgau, Germany; Haimendorferstr. 4, 91126 Schwabach-Wolkersdorf, Germany; Friedenstr. 12, 90765 Fürth/Bay, Germany; Volkacher Str 31, 90427 Nürnberg, Germany; Altdorfer Str 11, 91207 Lauf/Pegnitz, Germany; Schnieglingerstr. 36a, 90419 Nürnberg, Germany; Weller Wing, Bedford General Hospital, Kempston Road, Bedford MK42 9DJ, UK; St James Hospital, Dublin, Ireland; Princess Alexandra Hospital, Harlow, Essex, UK; Luton and Dunstable Hospital, Lewsey Road, Luton, Beds, LU4 0DT, UK / Fairfield Hospital, Stottfield Road, Hitchin, Herts, SG5 4AA, UK; Heilig Hart Ziekenhuis, Wilgenstraat 2, 8800 Roesselare, Belgium; St Andreis Ziekenhuis, Neuropsychiatrie, Krommewalstraat 11, 8700 Tiel, Belgium; Farnham Hospital, Hale Road, Farnham, Surrey, UK / Frimley Park Hospital, Portsmouth Road, Frimley, Camberley, Surrey, UK; Victoria Hospital, Okus Road, Swindon, Wilts, UK; Conquest Hospital, St Anne's Centre, 729 The Ridge, St Leonard-on-Sea, East Sussex, UK; The Prince Charles Hospital, Chermiside, QLD 4032, Australia; Pembury Hospital, Tonbridge Wells, Kent TN2 4 QJ, UK; Hammersmith Hospital, Du Cane Road, London W12 0NN, UK; De La Pole Hospital, Willerby-Hull HU10 6ED, UK; Academic Unit of Psychogeriatrics, Heatherton Hospital, Kingston Road, Heatherton, Vic 3202, Australia.		

Pharmacia

Document 9550089

Name of Company: Pharmacia Spa Name of finished product: Name of active ingredient(s): Reboxetine	Individual study table referring to part IV of the dossier Ref.: Vol.: Page:	(For national authority use only)
Publication (reference): None		
Study period: September 1992 - May 1994	Clinical Phase: III	
Objectives: To assess the tolerability and activity of reboxetine in comparison with imipramine in elderly patients suffering from Depressive Disorders.		
Methodology: In this prospective, double-blind, randomised, controlled, parallel group, multicentre and multinational trial, patients underwent an initial wash-out period of 4-28 days (≥ 3 weeks in case of fluoxetine administration) after which they received reboxetine 2 mg b.i.d. or imipramine 75 mg/day (25 mg in the morning and 50 mg in the evening) for eight weeks (imipramine was given at a dose of 25 mg b.i.d. for the first three days of the study). At the end of the initial 3 weeks' treatment, patients could be switched to a higher dose regimen, corresponding to 6 mg/day reboxetine and 100 mg/day imipramine up to the end of treatment. Patients willing to continue after completion of 8 weeks' treatment were maintained on the same medication until the last patient recruited had completed the study and all the CRFs had been collected. The response to treatment was assessed using the Hamilton Depression Rating scale (HAMD), Clinical Global Impression (CGI), Montgomery and Asberg Depression Rating Scale (MADRS) and the Geriatric Depression Rating Scale (GDS). Safety and tolerability were assessed by the reporting of any adverse events and assessment of vital signs (supine and standing blood pressure and heart rate), laboratory tests, and ECG.		
Number of subjects (planned and analysed): Three hundred patients were to be recruited in the study. Three hundred and forty-seven patients from 46 centres were randomised to treatment with either reboxetine (176) or imipramine (171).		
Diagnosis and main criteria for inclusion: Patients were diagnosed according to the DSM-III-R classification. The severity of depression was evaluated using the HAMD scale. Criteria for inclusion were as follows: (1) Patients of either sex, of any race, aged over 65 years, with a diagnosis of Major Depressive Episodes or Dysthymia, not accompanied by psychotic features (DSM-III-R); (2) Initial (pre-treatment) total score for the 21-item HAMD ≥ 18 and the total score for Mini Mental Status (MMS) ≥ 22 .		
Test product: capsules containing reboxetine methanesulphonate tablets Unit dose: 2 mg or 4 mg (two 2 mg tablets) of reboxetine (free base) Mode of administration: by oral route, b.i.d. Batch no.: SF1308, A06G01 (2 mg); SF1264, A06G02 (4 mg)		
Duration of treatment: 8 weeks		
Reference therapy: Indistinguishable capsules containing imipramine tablets Unit dose: 25 or 50 mg imipramine Mode of administration: by oral route, b.i.d. Batch no.: SF1321, A27G01 (25 mg); SF1265, SF1323, SF1353, A27G02 (50 mg)		
Criteria for evaluation: Efficacy Difference of HAMD total score at last assessment vs baseline, frequency of patients who achieved response (HAMD total score decrease $\geq 50\%$ vs baseline value) or remission (HAMD total score ≤ 10 as absolute value), frequency of clinical improvement scored as 'much to very much improved' on the CGI-Global Improvement were evaluated. HAMD total scores and factor scores, MADRS total scores, GDS total scores and CGI classification.		

Pharmacia

Document 9550089

<p>Name of Company: Pharmacia Spa</p> <p>Name of finished product: Reboxetine</p>	<p>Individual study table referring to part IV of the dossier</p> <p>Ref:</p> <p>Vol.:</p> <p>Page:</p>	<p>(For national authority use only)</p>
<p>Safety</p> <p><i>Study end-point:</i> relative chance of developing at least one adverse event.</p> <p>Adverse events, vital signs (supine and standing blood pressure and heart rate), laboratory tests and ECG.</p> <p>Clinically relevant modifications of blood pressure (BP) and heart rate (HR) ($\geq 20\%$ vs baseline), or such modifications associated with critical values (≥ 160 or ≤ 100 mmHg for systolic BP; ≥ 100 or ≤ 70 mmHg for diastolic BP; ≥ 100 or ≤ 50 beats/min for HR). Orthostatic hypotension (decrease for systolic BP >20 mmHg from lying to standing). Clinically relevant changes of laboratory tests and abnormal ECG findings according to standard criteria.</p>		
<p>Statistical Method:</p> <p>Efficacy</p> <p>HAMD and MADRS total scores, as well as CGI, were summarised by descriptive statistics at each visit and at the last valid observation. Ninety-five per cent confidence interval of the difference between treatments in the mean HAMD decrease at last assessment was calculated.</p> <p>The difference of response/remission rate between treatments, at last assessment, was computed (95% CI).</p> <p>Ninety-five per cent confidence interval of the difference between rates of 'much to very much improved' patients, according to CGI-Global Improvement, was calculated.</p> <p>The same sets of analyses were carried out on the total patient sample and on each subpopulation identified by the stratification factor, i.e. patients with Major Depressive Episode/Disorder (MDD) and Dysthymia (DYS).</p> <p>Safety</p> <p>The chance of developing at least one adverse event was analysed by the Mantel-Haenszel test, applied in order to compute the odds ratio (OR) and its confidence intervals using the diagnosis as stratification factor. Homogeneity across strata was tested by Breslow-Day test.</p> <p>Additionally, where applicable, events or cluster of events of particular relevance in terms of frequency of occurrence were analysed in the same way.</p> <p>The cumulative risk of developing individual events or cluster of individual events was estimated by the Kaplan-Meier method and the difference between the two treatments was tested by the log-rank test. The analysis was carried out in the total patient sample and in the MDD and DYS subpopulations.</p> <p>For all the laboratory tests, the frequency of patients shifted from values below, within or above the normal range at baseline to values below, within or above the normal range at each visit were computed. The Stuart Maxwell test was applied to test the changes in the distribution across categories at each visit vs baseline.</p> <p>Continuous values of laboratory tests were standardised according to a method proposed by Chuang-Stein and the Wilcoxon Rank Signed test for paired data was applied in order to compare the values during treatment with those recorded at baseline.</p>		

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Pharmacia

Document 9550089

<p>Name of Company: Pharmacia Spa</p> <p>Name of finished product:</p> <p>Name of active ingredient(s): Reboxetine</p>	<p>Individual study table referring to part IV of the dossier</p> <p>Ref.:</p> <p>Vol.:</p> <p>Page:</p>	<p>(For national authority use only)</p>
<p>Results</p> <p>Three hundred and forty-seven patients (263 females and 84 males, with a mean age of 73.8 years) entered the study. During the study, 176 patients received reboxetine (109 in the MDD stratum; 67 in the DYS stratum), and 171 imipramine (109 in the MDD stratum; 62 in the DYS stratum). One hundred and twenty-seven reboxetine and 126 imipramine recipients completed the study, while 49 (27.8%) and 45 (26.3%) dropped out of the study, respectively. Newly emerged adverse events or intercurrent illnesses were the main reasons for discontinuation in 20 (11.4%) and 27 (15.8%) patients of the reboxetine and imipramine groups, respectively. In the MDD subgroup of patients, the difference in drop-out rate for adverse events between the two treatment groups was maximal (12.8% on reboxetine and 19.3% on imipramine), while in the DYS subpopulation the drop-out rate for adverse events was similar in the two treatment groups (9.0% and 9.7%, respectively).</p>		
<p>Efficacy</p> <p>The mean HAM-D total score was reduced from 26.6 at Day 0 to 14.8 at last assessment in the 172 patients treated with reboxetine who had at least one assessment in addition to baseline and to 11.4 at Day 56 in the 127 patients who completed the study. In the 168 patients who were treated with imipramine, with at least one assessment in addition to baseline, the mean HAM-D total score was reduced from 26.1 at Day 0 to 12.9 at last assessment and to 8.8 at Day 56 in the 126 patients who completed the study. The difference between the two treatments in the mean HAM-D decrease at last assessment was of -1.5 points (95% CI, -3.6 ÷ 0.6 points). Similarly, in the MDD subgroup of patients, this difference was of -0.4 points (95% CI, -3.2 ÷ 2.4 points), while in the DYS subpopulation the difference was in favour of imipramine (-3.4 points; 95% CI, -6.5 ÷ -0.2 points).</p> <p>At last assessment, 54.1% of the reboxetine-treated patients and 56.5% of the imipramine-treated patients were classified as responders, while 42.4% and 49.4%, respectively, were seen to be in remission. A similar pattern of response and remission rate was observed in the MDD subpopulation, whilst there was a higher proportion of patients classified as responders and in remission on imipramine than on reboxetine in the DYS subpopulation.</p> <p>The analysis of the 17 specific items of the HAM-D scale at baseline showed that the proportion of patients eventually in remission was higher among the less severe cases (minimum score level) at baseline for the vast majority of items. For few items the frequency of patients eventually in remission was particularly low among severely ill (maximum score level) patients at baseline. This occurred in both treatment groups for Insomnia Middle, Agitation and, mainly in the reboxetine group, for Hypochondriasis. In all cases, the prevalence of severely ill patients at admission was higher in the reboxetine than in the imipramine group. These results were consistent in the diagnostic subpopulations, but extreme differences were observed in the DYS subgroup, particularly for Agitation and Hypochondriasis.</p> <p>At last assessment, the percentage of patients who were 'much to very much improved' (CGI - Global Improvement) was similar in both groups (56.9% in the reboxetine group and 59.4% in the imipramine group). The between treatment difference at last assessment was -2.5% (95% CI, -12.9% ÷ 7.9%).</p> <p>In the MDD subgroup of patients, the proportion of patients judged 'much to very much improved' at last assessment was slightly higher on reboxetine than on imipramine (58.9% vs 52.3%). The between treatment difference at last assessment was 6.6% (95% CI, -6.0% ÷ 19.8%). On the contrary, in the DYS subpopulation, the proportion of 'much to very much improved' patients was higher on imipramine than on reboxetine (72.1% vs 53.7%) and the between treatment difference at last assessment was -18.4% (95% CI, -34.8% ÷ -2.0%).</p> <p>The proportion of cases with moderate to marked efficacy in absence of side-effects (CGI - Efficacy Index: 3 to 4) was similar on reboxetine and on imipramine in the total patients sample. While in the MDD subpopulation, this proportion was slightly higher on reboxetine (40.2%) than on imipramine (34.9%), in the DYS subgroup this condition was judged to be present in 52.5% of the patients on imipramine vs 38.8% of those on reboxetine. The mean total MADRS score was reduced from 29.7 at Day 0 to 15.5 at last assessment in the 171 reboxetine</p>		

Pharmacia

Document 9550089

<p>Name of Company: Pharmacia Spa</p> <p>Name of finished product: Reboxetine</p> <p>Name of active ingredient(s): Reboxetine</p>	<p>Individual study table referring to part IV of the dossier</p> <p>Ref.:</p> <p>Vol.:</p> <p>Page:</p>	<p>(For national authority use only)</p>
<p>Efficacy (continued)</p> <p>group patients who had at least one assessment in addition to baseline, and to 11.7 in the 128 patients who had the assessment at Day 56. In patients treated with imipramine, values changed from 30.0 at Day 0 to 14.0 at last assessment (168 patients), and to 8.9 at Day 56 (126 assessed patients). A slightly higher reduction of the total score was observed on imipramine (from 27.9 to 9.8) than on reboxetine (from 28.0 to 14.6) in the DYS subpopulation.</p> <p>The mean total GDS score was reduced from 23.1 at Day 0 to 14.0 at last assessment in the 172 reboxetine group patients with at least one assessment in addition to baseline, and to 11.4 in the 128 reboxetine patients who had the assessment at Day 56. In patients treated with imipramine, values changed from 23.4 at Day 0 to 12.9 at last assessment (168 patients), and to 9.2 at Day 56 (125 assessed patients). As above, in the DYS subpopulation the reduction of the total score at last assessment was slightly higher on imipramine (from 22.9 to 9.9) than on reboxetine (from 23.0 to 13.6).</p> <p>The results of the additional analyses on the MDD and DYS sub-populations indicate that both treatments were similarly effective in terms of improvement of the clinical picture in patients diagnosed as having a Major Depressive Episode/Disorder, while in dysthymic patients imipramine was more effective than reboxetine in terms of frequency and extent of improvement.</p>		
<p>Safety:</p> <p>All the patients who received study treatment were included in the safety analysis, i.e. 347 patients (176 reboxetine, 171 imipramine).</p> <p>The occurrence of newly reported adverse events was similar in both groups during the study: 120/176 (68.2%) reboxetine group patients reported 307 adverse events compared with 122/171 (71.3%) imipramine patients who reported 338 adverse events. The relative chance of developing at least one adverse event, as estimated by the OR, was similar in the two treatment groups [OR= 0.86 (95% CI, 0.55 ÷ 1.36)]. However, in the MDD subgroup, the relative chance of adverse events was slightly higher on imipramine than on reboxetine [OR= 0.70 (95% CI, 0.39 ÷ 1.26)], while in the DYS subpopulation, the relative chance was slightly higher on reboxetine than on imipramine [OR= 1.20 (95% CI, 0.57÷2.55)].</p> <p>The proportion of patients with adverse events in the different weeks of treatment was slightly higher on imipramine than on reboxetine. This difference was more evident in the MDD subpopulation, while in the DYS subgroup the prevalence of adverse events was higher on reboxetine than on imipramine during the initial 4 weeks of treatment.</p> <p>Discontinuation due to a newly emerged adverse event was more frequent on imipramine (15.8%) than on reboxetine (11.4%), mainly in the MDD subgroup of patients (19.3% on imipramine vs 12.8% on reboxetine).</p> <p>On the whole, the frequency of individual events was very similar in the reboxetine and imipramine group with the exception of insomnia, more frequent on reboxetine (6% vs 3%) and of hypotension and related symptoms, more frequent on imipramine (16% vs 7%). Hypotension and related symptoms showed a risk of development significantly higher on imipramine than on reboxetine. This latter result was confirmed in the MDD subgroup and not in the DYS subpopulation.</p> <p>In patients with or without cardiovascular disorders at admission, the frequency of cardiovascular adverse events was higher on imipramine than on reboxetine. However, while the presence of cardiovascular disorders at baseline seemed not to facilitate the emergence of cardiovascular adverse events and, in particular, of hypotension and related symptoms, on reboxetine, patients on imipramine suffered from newly emerged cardiovascular adverse events and, in particular, of hypotension and related symptoms, more frequently when affected by cardiovascular disorders at baseline (26% and 21%, respectively) than when not affected (17% and 12%, respectively). The differences in favour of reboxetine are mainly evident in the former population (12%</p>		

Pharmacia

Document 9550089

<p>Name of Company: Pharmacia Spa</p> <p>Name of finished product:</p> <p>Name of active ingredient(s): Reboxetine</p>	<p>Individual study table referring to part IV of the dossier</p> <p>Ref:</p> <p>Vol.:</p> <p>Page:</p>	<p>(For national authority use only)</p>
<p>Safety (continued):</p> <p>vs 26% for cardiovascular adverse events and 5% vs 21% for hypotension and related symptoms).</p> <p>Moderate or severe adverse events were somewhat more frequent on imipramine than on reboxetine (73% vs 65%).</p> <p>Males and females suffered from adverse events with similar frequency on reboxetine and on imipramine. The most relevant between-gender difference was related to the frequency of hypotension and related symptoms, which were complained of mainly by male patients in both treatment groups (22.2% of male patients vs 13.5% of female patients on imipramine; 10.3% of male patients vs 6.6% of female patients on reboxetine) and urinary hesitancy/retention, which was complained of mainly by male patients in both treatment groups (15.6% of male patients vs 2.4% of female patients on imipramine; 10.3% of male patients vs 2.2% of female patients on reboxetine). Increased sweating was complained of mainly by female patients in both treatment groups (10.9% of female patients vs 2.6% of male patients on reboxetine; 10.3% of female patients vs 4.4% of male patients on imipramine). Dry mouth was complained of mainly by female patients on reboxetine (24.8% of female patients vs 12.8% of male patients).</p> <p>The proportion of patients complaining of at least one adverse event with probable to definite relationship was somewhat higher on imipramine (43%) than on reboxetine (33%).</p> <p>One patient died (suicide) during the study period. Three further patients died (bronchopneumonia, pulmonary edema and apoplexy) 12, 6 and 11 days respectively after the end of the study. All deaths were on imipramine. Twelve serious adverse events were reported, 2 on reboxetine (meningioma, acute confusional state and fall) and 10 on imipramine (postural hypotension, sudden faint, atrial fibrillation, right bundle branch block and A-V block first degree, 2 cases of fracture of the neck of the femur, fall and fracture of the knee, convulsive episode, drowsy and jerky movements in legs and urinary retention).</p> <p>There was no indication of modifications in laboratory tests that was of clinical significance.</p> <p>As for vital signs, major differences between reboxetine and imipramine were observed in the absolute frequency of clinically relevant decrease of diastolic blood pressure, higher on imipramine than on reboxetine on standing (22% and 13% of evaluated patients, respectively) and in the frequency of relevant increase of diastolic blood pressure, slightly higher in the reboxetine group on lying (13% and 7% of evaluated patients, respectively). The vast majority of relevant decreases and increases were reported once during the study.</p> <p>Lying and standing heart rate increased during treatment to values ≥ 100 beats/min in a slightly higher proportion of patients on reboxetine than on imipramine particularly on standing (12% vs 6%). However, the majority of those relevant increases occurred occasionally (reported once).</p> <p>Newly emerged abnormalities in ECG recordings were mainly related to rhythm disorders (11.7% and 6.4% in the reboxetine and imipramine group, respectively) and conduction disorders (6.0% and 3.9% in the reboxetine and imipramine group, respectively). However, in all cases the proportion of patients with newly emerged abnormalities was consistently lower than the proportion of normalised cases.</p>		

Pharmacia

Document 9550089

Name of Company: Pharmacia Spa Name of finished product: Name of active ingredient(s): Reboxetine	Individual study table referring to part IV of the dossier Ref: Vol: Page:	(For national authority use only)
Conclusions: The efficacy of reboxetine therapy in elderly patients suffering from Depressive Disorders, as evaluated by the improvement of HAM-D, CGI, MADRS, and GDS scales, was not different from that of imipramine. This was particularly the case in the MDD subpopulation, while in the DYS subpopulation, the frequency and extent of improvement was higher on imipramine than on reboxetine. This finding could be connected with imbalances between the two treatment groups at baseline for the somatic component of the psychopathology, more severe in the reboxetine group, rather than with a diagnostic specificity. The overall tolerability of reboxetine was highly acceptable, as shown in the minimal modification of vital signs, haematology and blood chemistry tests, and ECG examinations. The overall frequency of adverse events was similar on reboxetine and imipramine, thus not allowing the rejection of the hypothesis of equal tolerability of reboxetine and imipramine as stated in the protocol. However, the frequency of moderate to severe adverse events and of serious adverse events, the frequency of patients with probable to definite adverse events and the discontinuation rate in view of adverse events were higher on imipramine than on reboxetine. In addition, the rate of occurrence of cardiovascular disorders, in particular hypotension and related symptoms, was significantly lower on reboxetine than on imipramine.		

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

1. INTRODUCTION

Reboxetine (FCE 20124 or (2 RS, α RS)-2-[α -(2-ethoxy-phenoxy) benzyl] morpholine) is a new chemical compound which is highly potent in the pharmacological and biochemical tests predictive of antidepressant efficacy such as reserpine antagonism, norepinephrine re-uptake inhibition and REM sleep latency increase [1]. Reboxetine also demonstrates the ability to prevent the effects of clonidine, an α_2 noradrenergic receptors agonist, after a single oral dose in an animal model where tricyclic antidepressants were active only upon repeated administration [1]. Therefore, reboxetine was hypothesized to exert antidepressant efficacy of faster onset than the antidepressants currently available in depressed patients. In addition, comparison with imipramine 75 mg in healthy volunteers revealed that reboxetine does not possess the marked sedative activity of imipramine, but rather psychostimulating properties [2, 3].

The pharmacokinetic properties of reboxetine were evaluated in healthy volunteers [4]. Average peak levels were observed at 2 hours after oral administration, with remarkably stable levels 1-6 hours after administration; its plasma half-life was estimated as 13.2 hours and 73% of the AUC following an oral dose was accounted for by unchanged reboxetine.

An early phase II, 4-week, multicentre study in 98 patients, in which reboxetine was administered at fixed-changing doses with maximum doses of between 4 and 12 mg, showed that it was well tolerated at doses of up to 10 mg/day [5].

A double-blind, parallel, multicentre study in 258 patients hospitalised due to a major depressive episode compared maximum doses of 8 mg reboxetine with 200 mg of desipramine and placebo over a period of 4 weeks [6]. Reboxetine was found to be more effective than placebo with decreases of $\geq 50\%$ in Hamilton Depression Rating Scale (HAMD) at the end of treatment in 63% of patients compared with 36% for placebo and 46% for desipramine. These decreases were present after 14 days of treatment in 31% of reboxetine patients and 22% of desipramine patients. More reboxetine patients complained of headache and urinary retention, whereas more desipramine patients experienced dry mouth, sweating and blurred vision. Cardiovascular adverse events were relatively rare and appeared with slightly higher frequency in the desipramine group (hypotension and tachycardia).

Phase II results obtained in controlled conditions in patients suffering from Major Depressive Disorders indicate that reboxetine is an effective antidepressant agent with a favourable therapeutic index with respect to desipramine.

An open, scaling-up, repeated doses study was carried out in 12 elderly patients suffering from Depressive Disorders [7] in order to evaluate the activity, tolerability and pharmacokinetics of reboxetine administered for 4 weeks at daily doses, increased at weekly intervals, from 1 to 4 mg b.i.d. The pharmacokinetic results indicated dose-

Pharmacia

Document 9550089

proportionality over the explored range, and C_{max} and AUC_{0-12h} higher than those found in healthy young subjects who had received reboxetine in the same dose range. The maximum foreseen dose of 4 mg b.i.d. was well tolerated in 8 out of 9 elderly patients exposed. However, the attainment of this dose was prevented in 3 patients because of the emergence of cardiac rhythm acceleration or other rhythm disorders. The results of this study suggested that daily doses of 2 to 3 mg b.i.d. should have been used in subsequent controlled studies of the antidepressant efficacy and tolerability of reboxetine in the elderly population. This present study was designed to collect comparative evidence of reboxetine's safety and efficacy vs the tricyclic antidepressant imipramine in elderly patients with Depressive Disorders and to extend information obtained from other controlled studies [8, 9].

2. STUDY OBJECTIVES

To assess the tolerability and activity of reboxetine in comparison with imipramine in elderly patients suffering from Depressive Disorders.

3. INVESTIGATIONAL PLAN

3.1 Study Design and Plan - Description and Rationale

3.1.1 OVERVIEW AND JUSTIFICATION

This phase III study was designed as a prospective, double-blind, randomised, controlled, parallel-group, multicentre trial. Its aim was to compare the tolerability and efficacy of reboxetine with that of imipramine, administered orally for 8 weeks, in elderly patients with Depressive Disorders. The design of the study is shown overleaf.

A total of 300 elderly patients affected by a Major Depressive Episode/Disorder or Dysthymia (DSM-III-R) was to be recruited in accordance with the inclusion and exclusion criteria, and an informed consent obtained from each patient prior to screening.

At screening, a full medical history and physical examination, including chest X-ray or pulmonary function test and electrocardiogram (ECG), were carried out and vital signs and laboratory values were measured. Patients were classified according to the DSM-III-R classification and their cognitive function was evaluated by the Mini Mental State Examination scale (MMS). The severity of depression was evaluated using the Hamilton Depression (HAMD) and Clinical Global Impression (CGI) rating scales.

After an initial wash-out period of 4-28 days, patients were randomised to treatment with either reboxetine or imipramine according to a randomisation list balanced within centre and stratified for the two subpopulations of Major Depressive Episode/Disorder (MDD) and Dysthymia (DYS). Treatments consisted of oral reboxetine 2 mg b.i.d., or oral imipramine 25 mg in the morning and 50 mg in the evening (imipramine was given at a dose of 25 mg b.i.d. for the first three days of the study) for 8 weeks. In the case of inefficacy or unsatisfactory response, combined with good tolerability, after 3 weeks of treatment, the total daily dose was allowed to increase up to 6 mg/day for reboxetine and 100 mg/day for imipramine for the remaining 5 weeks of the study. In those patients who then displayed poor tolerance at this increased dose, the dose was reduced to the previously well tolerated level.

This study was primarily a safety assessment of reboxetine compared with imipramine in elderly patients. Safety and tolerability were assessed by the reporting of any adverse events and measurements of vital signs (blood pressure and heart rate, supine and standing), ECG and laboratory tests.

Pharmacia

Document 9550089


Additionally, efficacy was evaluated by the HAMD total score decrease vs Day 0 at last assessment and by the response (a decrease of at least 50% in the total HAMD score) and remission (a total HAMD score of 10 or less, absolute value) rate at last assessment. The improvement of clinical picture of Clinical Global Impression - Global Improvement, scored as 'very much improved' or 'much improved', at last assessment vs Day 0 was considered to be an index of response.

Other variables used for evaluating efficacy were the Montgomery and Asberg Depression Rating Scale (MADRS) and Geriatric Depression Rating Scale (GDS).

Patients willing to continue receiving the test treatment after completion of the 8-week treatment period were maintained on the same medication under blind conditions until the completion of the last patient in the study and collection of the Case Record Forms (CRFs).

A follow-up visit was to be carried out for each patient one month after treatment discontinuation in order to monitor possible withdrawal reactions and collect information on any events since treatment discontinuation.

A copy of the final protocol can be found in Appendix 12.1.1.



3.1.2 PROTOCOL AMENDMENTS

There were no protocol amendments which were valid for all the countries involved in the study. There were, however, amendments required by local Ethics Committees in Australia, France and UK. In Australia, there were two amendments: the first amendment modified the exclusion criterion for the presence of kidney disease, increasing the minimum of creatinine clearance of 30 ml/min to 50 ml/min for the definition of moderate to medium renal impairment. The second amendment added, as an exclusion criterion, patients on medication which could cause hypotension. In France,

there was one amendment: this required that in the case of a severe adverse event a blood sample should be taken which allowed the evaluation of the plasma level of the antidepressive drugs. However, the amendment was not implemented. In the UK, there were two amendments: the first amendment better specified the ethical aspects of the protocol (Section 15.0 of Appendix 12.1.1); the second amendment required the plasma level of imipramine to be measured at steady state (Day 56 or end of study) in order to correlate tolerability and efficacy to imipramine level. However, as samples were taken only occasionally, the correlation level/efficacy was not done.

3.2 Ethics

3.2.1 ETHICS COMMITTEE

Approval from the Ethics Committees or Institutional Review Boards (IRBs) of the participating centres, in accordance with the regulations and requirements of individual countries, had to be obtained before the study could be undertaken. It was the responsibility of each of the investigators to submit the study protocol with its attachments to the Ethics Committee/IRB. Central approval was required and obtained in Ireland and local approvals were required and obtained in all the countries participating to the study. For Australian centres number 1 and 3 (Melbourne and Sydney, respectively) the approval was obtained on a draft version of the protocol, different from the final one focusing on the definition of adverse events as moderate to severe instead of mild to severe in the Section Statistical Consideration (Section 14.0 of Appendix 12.1.1).

The notifications of approval are kept in the trial master file.

The written approval of the Ethics Committee or IRB had to include the names and professions of all its members. In accordance with local requirements, the investigators were responsible for informing the Ethics Committees of any emergent problems, serious adverse events or protocol amendments.

3.2.2 PATIENT INFORMATION

Before entering the study, an explanation of the nature, duration, purpose of the study and action of the compound had to be given to each patient in such a manner that he/she was made aware of the potential risks, inconveniences or adverse events that could occur, and could express his/her informed consent to participation. The proposed consent form is enclosed (Enclosure 5 of Appendix 12.1.1). The translations in the national languages and the individual centres forms containing the possible changes requested by the Ethics Committees, if any, are kept in the study master file. The forms were signed by the patient or the next of kin, and/or the investigator. In the latter case, the signature of a witness was required to testify that full information was given to the patient.

All unpublished documentation including the protocol, the CRF and the Investigator's Brochure was confidential. These documents could not be disclosed to a third party without the written consent of the Sponsor. The submission of these documents to the Ethics Committee was expressly permitted. The investigators agreed that the Sponsor maintained the right to utilise the results of this study, in their original form and/or in a global report, for submission to the governmental and regulatory authorities of any country.

3.3 Study Population

Elderly depressed patients in acceptable physical condition who were under in-patient care or attending out-patient clinics of the participating centres were selected in accordance with the following inclusion and exclusion criteria.

3.3.1 INCLUSION CRITERIA

The criteria for participation in this study were as follows:

- Patients of either sex, of any race, aged over 65 years
- Fulfilment of the DMS-III-R [10] criteria for Major Depressive Episode/Disorder or Dysthymia
- The initial (pre-treatment) total score for the 21-item HAMD [11] had to be ≥ 18
- The initial (pre-treatment) total score for the MMS (Enclosure 4 of Appendix 12.1.1) had to be ≥ 22
- Informed consent was obtained from the patient or next of kin, and/or the investigator (see Section 3.2.2)

3.3.2 EXCLUSION CRITERIA

Exclusion criteria for patients recruited to this study were as follows:

- Resistance to antidepressant treatment (defined as lack of response to at least two previous courses of antidepressant therapy given at full doses for more than 1 month)
- Clinically relevant abnormal findings in the physical examination and/or laboratory tests at admission
- History of major depressive disorder associated with endocrine disorders: hypo- or hyperthyroidism (defined as values at least 10% outside normal parameters for TSH and T₄), adrenal insufficiency, etc.
- Past history of drug hypersensitivity

Pharmacia

Document 9550089

- History or presence of gastrointestinal disease likely to cause impairment of gastrointestinal absorption, liver disease (hepatic insufficiency defined as clinically relevant abnormal findings of the following tests: hemolytic markers - SGOT and SGPT; cholestasis markers - total bilirubin, gamma-GT, alkaline phosphatase; mesenchymal activation markers - serum protein electrophoresis), kidney disease (renal insufficiency defined as moderate to medium renal impairment with creatinine clearance not lower than 30 ml/min) or other conditions known to interfere with absorption, distribution, metabolism and excretion of drugs.
- Participation in a clinical study with an investigational compound in the 4 weeks preceding the study
- Evidence of Substance Use Disorder (DSM-III-R), currently or within the past 6 months
- Chronic respiratory insufficiency (excluded by physical examination and pulmonary function test or X-ray)
- History of seizures or brain injury; current evidence of clinically important haematopoietic or cardiovascular diseases; current evidence of urinary retention or glaucoma
- Electroconvulsive therapy (ECT) in the previous 6 months
- High risk of suicide

3.3.3 WITHDRAWAL CRITERIA

Patients could be withdrawn from the study at any time for the following reasons:

- Voluntary withdrawal by the patient
- Unacceptable toxicity, defined as the occurrence of serious adverse events (see Section 3.6.2.1)
- Lack of efficacy, defined as worsening of the global clinical picture (CGI - see Section 3.6.1.2) after at least 3 weeks of treatment
- Shift to mania

In the case of treatment discontinuation, the final set of tests was carried out wherever possible.

3.3.4 SAMPLE SIZE - NUMBER OF PATIENTS PLANNED

Each of the planned 31 centres participating in the study were to recruit, within a period of 1 year, a sample of 6 to 12 patients, so that a total of 300 patients were to be recruited overall.

Few of the centres which initially agreed to participate in the study never did so for logistical reasons and were replaced with other centres. During the study, 9 centres in the UK, 5 in Belgium and 2 in Australia were recruited in order to reach the foreseen patient sample.

As shown in the Clinical Investigators and Affiliation List (Appendix 12.1.4), 46 centres in 7 countries (Australia, Belgium, Brazil, France, Germany, Ireland and the UK) participated in the study. In 23 centres the number of patients admitted was lower than 6, while recruitment was extended in 1 centre (number 36). Recruitment was stopped after randomisation of 347 patients, slightly above the calculated sample size for an 'intent to treat' analysis.

Patients who dropped out of the study for any reason were not substituted. For those patients selected for the study who dropped out at any time documentation was provided.

3.4 Treatments

3.4.1 TREATMENTS TO BE COMPARED

After an initial wash-out period of 4-28 days (21-28 days in the case of previous fluoxetine therapy) patients received one of 2 possible treatments for 8 weeks: oral reboxetine 2 mg b.i.d. or oral imipramine 25 mg in the morning and 50 mg in the evening (imipramine was given at a dose of 25 mg b.i.d. for the first three days of the study). In the case of inefficacy or unsatisfactory response, combined with good tolerability, after 3 weeks of treatment, the dose of reboxetine was allowed to increase up to 6 mg daily (4 mg in the morning and 2 mg in the evening) and the dose of imipramine up to 50 mg b.i.d. for the remaining 5 weeks of the study.

3.4.2 IDENTITY OF TEST TREATMENTS

Indistinguishable capsules containing either reboxetine 2 mg or 4 mg (two x 2 mg tablets) (Batch No: SF1308, A06G01 [2 mg]; SF1264, A06G02 [4 mg]) or imipramine 25 mg or 50 mg (two x 25 mg tablets) (Batch No: SF1321, A27G01 [25 mg]; SF1265, SF1323, SF1353, A27G02 [50 mg]) were supplied by the Sponsor. Copies of certificates of analysis for the test treatments are presented in Appendix 12.1.5.

3.4.3 DOSE SELECTION AND TIMING

All patients recruited for the study received either one capsule of reboxetine 2 mg b.i.d. (morning and evening), or one capsule of imipramine 25 mg (morning) plus one capsule of imipramine 50 mg (evening) for 8 weeks. For the first three days of the study, imipramine was given as one 25 mg capsule in the morning and one 25 mg capsule in the evening. For patients who showed an ineffective or unsatisfactory response (worsening, no change or minimal improvement in the CGI; see Section 3.6.1.2) with good tolerability, the dose of reboxetine was allowed to increase, after 3 weeks of treatment, to 6 mg daily (4 mg in the morning and 2 mg in the evening) and the dose of imipramine to 50 mg b.i.d., for the remaining 5 weeks of the study. In those patients who then displayed poor tolerance at this increased dose, the dose was reduced to the previously well tolerated level.

The treatment was to be administered at least 2 hours before or after meals.

Daily doses of the experimental treatments were selected taking into consideration the reported greater response, particularly in terms of intolerance, to antidepressant drugs in the elderly, possibly connected with pharmacodynamic, as well as pharmacokinetic, changes in this population [8]. In addition, the daily dose of reboxetine was chosen on the basis of results of the previously mentioned scaling-up, repeated doses study in 12 elderly patients [7] which showed that the maximum tolerated dose of reboxetine was 6 mg/day in 8 out of the 12 subjects. The daily dose of imipramine was selected on the basis of published evidence from controlled studies [8, 9] and of manufacturer recommendations [12].

3.4.4 METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUPS

A randomisation list balanced within centre and stratum (i.e. Dysthymia and Major Depressive Episode/Disorder) and every 4 assignment per stratum was originally generated for patient allocation either to reboxetine or imipramine. The test treatments were labelled according to the randomisation sequence number within centre and stratum. Each randomised patient was then identified by the corresponding centre, stratum (MD for Major Depressive Episode/Disorder and DT for Dysthymia) and treatment number.

Patient allocation to treatment was done by the investigator at the end of the wash-out period on the basis of the patient's time of entry into the study.

3.4.5 TREATMENT SUPPLY AND BLINDING

To ensure the double-blind nature of the study, indistinguishable test treatment in identical cartons was to be identified using double labels indicating the protocol number, patient number, treatment period, batch number and expiry date (Enclosure 6 of

Appendix 12.1.1). The detachable half of the label was to be included in the appropriate place in the CRF when used.

Eighteen glass amber bottles showing the patient number and the appropriate day or week of treatment (Days 1-3, Days 4-7, from Week 2 to Week 8) were prepared for each patient. For the first week two 'morning' and two 'evening' bottles were provided: two bottles contained medication for Days 1-3 (morning and evening) and the other bottles contained medication for Days 4-7 (morning and evening). Each 'morning' and 'evening' bottle for the treatment from Week 2 to Week 8 contained the medication necessary for 7 days' treatment i.e. 8 capsules (7 capsules plus 1 for possible losses). Additional 5 cartons showing the patient number, the appropriate week of treatment (Week 4-8) and the level of dosage (dose 2) were prepared for each patient in case of possible dosage increases during the last 5 weeks of the study.

3.5 Treatment Procedures

The investigators were given individual sealed envelopes containing the information on patient's treatment, and these were to be opened only in case of emergency necessitating treatment identification. In the event of an emergency, the investigators were to notify the study monitor immediately (within 24 hours), and were to report a full description of the reasons for opening the code on the Adverse Event Form in the CRF. The sealed individual codes were to be returned to the Sponsor at the end of the study.

3.5.1 CONCOMITANT THERAPY

Concomitant medications considered essential were allowed at admission to the study. In the case of events arising during the course of the study, non-psychotropic medications which were considered necessary for the patient's welfare could be administered and were not considered protocol violations. A short-acting benzodiazepine, chloral hydrate or chlormethiazole was permitted at bed-time as a sleep inducer on an 'as required' basis. The medication, dosage and frequency of administration were recorded on the CRF.

3.5.2 TREATMENT ACCOUNTABILITY AND COMPLIANCE

All drug supplies were handled under the direct responsibility of the investigators and held by the Hospital Pharmacy. The study monitors checked drug storage conditions during site visits.

The investigators were responsible for drug accountability and kept a record of the test compounds received from the Sponsor as well as the drugs dispensed to each patient on the occasion of each visit. The upper label from each of the weekly bottles dispensed to each patient was detached and fixed in the appropriate space in the CRF. On the same occasion, bottles of the previous supply were returned by the patient. These used bottles were returned to the study monitors during site visits. All unused medication was to be returned to the Sponsor at the end of the study.

3.6 Efficacy and Safety Variables

At screening, a full medical history and physical examination (including chest X-ray or pulmonary function test and ECG) were carried out and vital signs and laboratory values were measured. Patients were classified according to the DSM-III-R classification and the MMS. The severity of depression was evaluated using the HAMD scale and CGI.

3.6.1 EFFICACY

Every randomised patient was evaluable for efficacy analysis.

Patients were seen at regular intervals throughout the study and the following efficacy assessments carried out at the specified intervals. All psychiatric evaluations and ratings were to be carried out by the same observer for a given patient, and in the same setting and at the same time of day if possible.

3.6.1.1 Hamilton Depression Rating Scale

The severity of depression was evaluated using the HAMD scale at screening, and on Days 0, 7, 14, 21, 28, 35, 42, 49 and 56.

The HAMD scale [11] contained 21 items, each of which was scored (0-2, 0-3 or 0-4) to reflect whether the symptom was absent, mild, moderate or severe. Some of the items were more heavily weighted than others. The scores for all the symptoms were added together to give a global judgement of the severity of the depression.

A decrease of at least 50% in the total HAMD score compared with Day 0 was considered to be a response, whereas a total HAMD score of 10 or less was considered a remission.

Pharmacia

Document 9550089

The 21-item list of the HAMD used in this study is as follows:

	<u>Item</u>	<u>Score range</u>	<u>Factor</u>
1.	Depressed mood	(0-4)	V
2.	Feelings of guilt	(0-4)	III
3.	Suicide	(0-4)	III
4.	Insomnia early	(0-2)	VI
5.	Insomnia middle	(0-2)	VI
6.	Insomnia late	(0-2)	VI
7.	Work and activities	(0-4)	V
8.	Retardation	(0-4)	V
9.	Agitation	(0-4)	III
10.	Anxiety (psychic)	(0-4)	I
11.	Anxiety (somatic)	(0-4)	I
12.	Somatic symptoms gastrointestinal	(0-2)	I
13.	Somatic symptoms general	(0-2)	I
14.	Genital symptoms	(0-2)	V
15.	Hypochondriasis	(0-4)	I
16.	Loss of weight	(0-2)	II
17.	Insight	(0-2)	I
18.	Diurnal variation	(0-2)	IV
19.	Depersonalisation and derealisation	(0-4)	III
20.	Paranoid symptoms	(0-3)	III
21.	Obsessional symptoms	(0-2)	III

More detailed definitions of the items included in the scale can be found in Enclosure 3 of Appendix 12.1.1.

Factorialisation was carried out according to the ECDEU manual [13], to yield 6 factors: Anxiety/Somatisation (I), Weight (II), Cognitive Disturbances (III), Diurnal Variation (IV), Retardation (V), Sleep Disturbances (VI).

Pharmacia

Document 9550089

3.6.1.2 Clinical Global Impression

Severity of illness was assessed by the investigator using the CGI [13] on Days 0, 7, 14, 21, 28, 35, 42, 49 and 56. The following scale was used

1. = normal, not at all ill
2. = borderline mentally ill
3. = mildly ill
4. = moderately ill
5. = markedly ill
6. = severely ill
7. = amongst the most extremely ill patients

The investigator also evaluated the effect of treatment at each visit (Global Improvement), with reference to the patients' condition at the start of the study, according to the following scale:

1. = very much improved
2. = much improved
3. = minimally improved
4. = no change
5. = minimally worse
6. = much worse
7. = very much worse

An Efficacy Index was then assessed by the investigator, as described in [13], as the ratio between the evaluation of improvement, scored from 1 (unchanged or worsened) to 4 (marked improvement), and the evaluation of tolerability from 1 (no side effects) to 4 (side effects outweigh therapeutic effect). The Efficacy Index score ranges from 0.25 (no global benefit) to 4 (maximal global benefit).

3.6.1.3 Montgomery and Asberg Depression Rating Scale

The MADRS [14] was measured on Days 0, 7, 14, 21, 28, 35, 42, 49 and 56.

Pharmacia

Document 9550089

This scale consists of ten items relating to depression selected from the 67 items in the Comprehensive Psychiatric Rating Scale [15]. The items contained in the MADRS were selected on the grounds that they were sensitive to change. The ten items were as follows:

1. Apparent sadness
2. Reported sadness
3. Inner tension
4. Reduced sleep
5. Reduced appetite
6. Concentration difficulties
7. Lassitude
8. Inability to feel
9. Pessimistic thoughts
10. Suicidal thoughts

The scale requires a structured interview for completion. A score of 0 to 6 for each item was used as in reference 15.

More detailed definitions of the items included in the scale can be found in Enclosure 15 of Appendix 12.1.1.

3.6.1.4 Geriatric Depression Rating Scale

The severity of depression was evaluated using the GDS on Days 0, 7, 14, 21, 28, 35, 42, 49 and 56. The GDS scale [16] contained 30 questions each of which required a 'yes' or 'no' answer. The scores for all the questions were added together to give a global judgement of the severity of the depression.

The questions included in the scale can be found in Enclosure 16 of Appendix 12.1.1.

3.6.2 SAFETY

Every patient who received one dose of test treatment was included in the safety evaluation.

Pharmacia

Document 9550089

3.6.2.1 Adverse Events

Spontaneously Reported

Patients were notified of any possible adverse events they might experience and were instructed to report any such adverse event to the investigators immediately.

The occurrence of adverse events was recorded on Days 0, 7, 14, 21, 28, 35, 42, 49 and 56.

Any newly observed sign or symptom (including clinically relevant laboratory abnormalities), noticed by the investigators or reported by the patients were reported, regardless of presumed relationship to the study medication, in the appropriate section of the CRF (Adverse Event Report Form - Enclosure 10 of Appendix 12.1.1).

For each adverse event, the following information was entered in the CRF: description, date of onset, date of stopping, severity, drug cause-effect relationship, outcome, effect of withdrawal of treatment and re-challenge. The investigators also had to note if the double-blind code had been broken, the action taken regarding the test drug (none, dose reduced or discontinued) and any treatment given as a result of the adverse event.

Severity was coded as follows:

1. = mild - awareness of sign or symptom, but easily tolerated
2. = moderate - discomfort enough to cause interference with usual activity
3. = severe - incapacitating with inability to work or do usual activity
4. = unknown

Relationship to test drug was coded as definite, probable, possible, doubtful, unknown or not related; as a guideline to coding the Karch and Lasagna modified criteria were used as shown in Enclosure 11 of Appendix 12.1.1.

Pharmacia

Document 9550089

All serious* and/or unexpected** adverse events had to be reported to study monitors immediately (within 24 hours), and the details recorded on an Adverse Event Report Form. **Serious adverse event** was defined as any experience that was (potentially) fatal or life-threatening, disabling, incapacitating, requiring inpatient hospitalisation, causing a congenital anomaly or cancer, or due to an overdose. **Unexpected adverse event** was defined as any adverse experience that was not identified in nature, severity or frequency in the current Investigator's Brochure for the study.

The same procedure applied for all patients who died during the course of the study or within 30 days of completion, irrespective of whether the event was judged as related to treatment. If an autopsy was performed, a copy of the pathological report was to be sent to the Sponsor.

Adverse events reported through a check-list

The presence or absence of selected adverse events was solicited through a check-list especially designed for the identification of events frequently reported in patients on antidepressant medication. The check-list is shown in Enclosure 9 of Appendix 12.1.1. These events could be either reported by the patient or observed by the investigator.

For each adverse event, the same procedure as for spontaneously reported adverse events was followed in terms of recording of information in the CRF (Adverse Event Report Form) and reporting of the 'serious' or 'unexpected' adverse event to the Sponsor.

3.6.2.2 Clinical and Laboratory Tests

Vital signs

Body weight and temperature as well as blood pressure and heart rate (supine and standing) were measured at screening and on Days 0, 7, 14, 21, 28, 35, 42, 49 and 56.

Supine blood pressure and heart rate were measured in the morning after 5 minutes in the supine position and standing blood pressure and heart rate were measured 1-2 minutes after standing up.

Chest X-ray or pulmonary function tests

An X-ray, or a pulmonary function test, was performed at screening.

* Code of Federal Regulation, Vol 21, Part 312. Revised as of April 1 1987, page 75.

** Bem JL, Breckenridge AM, Mann RD, Rawlins MD. Review of yellow cards (1986): report to the Committee on the Safety of Medicines. BR J Clin Pharmacol 1988; 26: 679-689.

Pharmacia

Document 9550089

ECG

An ECG was recorded at screening and on Days 28 and 56.

ECG was also recorded for patients who withdrew prematurely because of a serious adverse event.

Laboratory tests

Laboratory tests were recorded at screening and on Days 28 and 56.

The laboratory tests comprised the following: full blood count, serum electrolytes, liver enzymes, urinalysis, blood sugar, serum alkaline phosphatase, blood urea nitrogen (BUN), serum creatinine, uric acid, total bilirubin, total serum protein and electrophoresis, serum cholesterol and triglycerides, and at screening only, TSH and T₄. In addition, at screening only, the creatinine clearance was directly examined or calculated by using the formula reported in the protocol (Section 11.1 of Appendix 12.1.1).

Laboratory tests were also measured for patients who withdrew prematurely because of a serious adverse event.

Pharmacia

Document 9550089

3.7 Study Procedures and Flow Chart

3.7.1 SCHEDULE OF ASSESSMENTS

Assessment	Pre-Treatment Screening	Treatment Day									
		0	7	14	21	28	35	42	49	56	
Diagnosis: DSM-III-R	x										
MMS	x										
Medical history	x										
Physical examination	x										
Chest X-ray or pulmonary function	x										
ECG	x					x					x
Laboratory tests	x					x					x
Vital signs	x	x	x	x	x	x	x	x	x	x	x
21-item HAMD	x	x	x	x	x	x	x	x	x	x	x
CGI		x	x	x	x	x	x	x	x	x	x
GDS		x	x	x	x	x	x	x	x	x	x
MADRS		x	x	x	x	x	x	x	x	x	x
Compliance check			x	x	x	x	x	x	x	x	x
Dispensing medication		x	x	x	x	x	x	x	x		
Adverse events		x	x	x	x	x	x	x	x	x	x

3.7.2 PROCEDURES AT EACH VISIT

At screening, a full medical history and physical examination (including chest X-ray or pulmonary function test and ECG) were carried out and vital signs and laboratory values were measured. Patients were classified according to DSM-III-R; their cognitive function was rated by the MMS and the severity of depression was evaluated using the HAMD scale.

One month after treatment discontinuation, a follow-up visit was carried out for each patient in order to monitor possible withdrawal reactions and to collect information on

any adverse events that had occurred during this period. For ethical reasons, patients willing to continue receiving study drug after completion of the 8-week treatment period were maintained on the same medication in blind conditions until the study was completed in the last patient and the CRFs were collected. Efficacy was assessed by HAMD and CGI at monthly visits. Adverse events and vital signs were also recorded at monthly intervals and ECG and laboratory values at 3-monthly intervals. The medications were prepared as described in Section 3.4.5, but in monthly, instead of weekly units.

3.8 GCP Compliance, Data Quality Assurance

The study started after the formal adoption of GCPs by European Regulatory Authorities. Company SOPs were released and implemented during the conduct of the study and maximal efforts were done in order to make the study as much compliant as possible with them. Operating procedures for study monitoring and co-ordination were defined and are described in Attachment A of Appendix 12.1.1. Inter-rater reliability sessions with training purpose on the instrument used for the assessment of change, and particularly on the HAMD, were carried out during the investigators meetings organised by country and/or the monitoring visits by employing 4 videotaped interviews.

During the study, monitoring visits were made at regular intervals at which the monitor validated the content of the CRF against source documents on the basis of the agreed procedures.

Site, trial master file and report audits were carried out by the Company Quality Assurance Unit.

3.9 Statistical Analysis

3.9.1 SAMPLE SIZE CONSIDERATIONS

In elderly patients suffering from Depressive Disorders reboxetine was expected to show comparable efficacy to imipramine, with a more favourable tolerability profile. The current study aimed at showing such a better tolerability profile, measured as the ratio between the number of patients experiencing at least one treatment emergent adverse event out of the total number of randomised patients, whichever the nature and the degree of severity.

Accordingly, the system of hypotheses set was the following:

$$H_0 : \delta = 0$$

$$H_1 : \delta \neq 0$$

where δ is the true between treatment difference in adverse event rate.

Difference $\geq 20\%$ between the treatments was considered clinically relevant. In the absence of a precise estimate about the rate defined as above, sample size was maximised considering a adverse event rate of 40% and 60%, respectively, for the two groups. Under this

assumption, 260 patients were required to detect a difference of 20% or higher at the 0.05 two-tails-alpha level of statistical significance and with a power ≥ 0.90 . The size of the trial was enlarged according to Fleming O'Brien method [17], in order to adjust for one interim analysis after the first 67 patients in each arm were recruited. Overall the study was to recruit approximately 270 patients; this figure was rounded up to 300 in order to provide power coverage in case the variability might have increased due to the drop out rate.

Recruitment was stopped after randomisation of 347 patients, a sample not surprisingly 15.7% higher than foreseen, in view of the large number of participating centres (46) to be coordinated in the recruitment termination procedure.

3.9.2 STATISTICAL AND ANALYTICAL PLANS

3.9.2.1 Baseline Comparability of Treatment Groups

Baseline characteristics (e.g. age, diagnosis, age at onset, number of previous episodes) which might have influenced the main end-point of the study were summarised for all those patients who entered into the study and who were subsequently randomised either to reboxetine or to imipramine. Descriptive statistics by treatment were presented both for the total patient sample, and for each subgroup identified by the stratification factor, i.e. patients with Major Depressive Episode/Disorder and Dysthymia.

3.9.2.2 Efficacy Analyses

Definitions

The following definitions apply to the set of data analysed:

HAMD decrease	the difference between the end of treatment and baseline measurements of 21-item HAMD total score. Either the last per-protocol assessment, when the patient regularly completes the study, or the last assessment before dropping out of it was taken as the end of treatment.
Remission	21-item HAMD total score lower than or equal to 10 (absolute value).
Response	<u>according to 21-item HAMD scoring system:</u> 21-item HAMD total score decrease equal to or greater than 50% of the pre-treatment value (Baseline: visit 0). According to this definition, and based on the inclusion criterion which required a 21-item HAMD total score at entry at least equal to or greater than 18, not all the patients who achieved a remission (as defined above) were included into the broader category of response ($18 \cdot 0.5 = 9$).

According to CGI - Global Improvement classification system:
CGI - Global Improvement score of 1 or 2, very much and much improved, respectively, at last assessment.

Methods

Efficacy variables, including total score of HAMD and MADRS, as well as CGI, were summarised by descriptive statistics (mean, median, standard deviation [SD], minimum, maximum, or distribution of frequency of scores) as calculated both at each visit and using the last valid observation, for both groups. In particular, in order to describe the time pattern of last valid observation values, one table reports descriptive statistics visit by visit only for those patients who dropped out of the study at that particular visit. The frequency of the patients who were improved, unchanged or deteriorated for the CGI - Severity of Illness at last assessment compared to baseline was also presented.

All the above mentioned tabulations as well as the inferential statistics described below, were presented for the total sample, and for each subgroup identified by the stratification factor, i.e. patients with Major Depressive Episode/Disorder and Dysthymia.

Two-tails 95% confidence intervals of the between treatment differences of HAMD decrease [18], and of the rates of 'much improved' and 'very much improved' according to CGI score [19], were the basis of the efficacy conclusions. Complementary to the quantitative analysis of 21-item HAMD total score, the qualitative analysis classifying the patients according to the above definitions (Responses/Remissions) at the last valid assessment was carried out. Ninety-five per cent confidence intervals (two-tailed) of the proportions in each treatment were computed.

3.9.2.3 Safety

End-point analysis

The adjusted odds ratio and its confidence interval was calculated using the Mantel-Haenszel method [20]. Although not protocolled, the illness diagnosis rather than the centre was taken as the stratification factor, not only because there were more centres than expected, with often too few patients in many of them, but also because diagnosis unexpectedly seemed to unevenly influence the adverse event rate in the treatment groups. Homogeneity across strata was tested by Breslow-Day test [20]. Additionally, the same analysis was applied to events or cluster of events of particular relevance in terms of frequency of occurrence. Time to event analysis was included as part of the regular analysis of safety as described below.

Other safety analyses

Vital signs as measured at each assessment time were summarised by descriptive statistics. Decreases in standing systolic blood pressure considered clinically relevant

(decrease ≥ 20 mmHg) were listed and the frequency of patients showing these decreases in each treatment group computed. Patients with orthostatic hypotension (a decrease ≥ 30 mmHg of systolic blood pressure from lying to standing) were described. Moreover, the frequency of patients showing clinically relevant (20% or more vs baseline) or such a modification accompanied by absolute critical values (≥ 160 or ≤ 100 mmHg for systolic blood pressure; ≥ 100 or ≤ 70 mmHg for diastolic blood pressure; ≥ 100 or ≤ 50 beats/min for heart rate) at each evaluation time were tabulated.

ECG have been summarised in frequency tables showing normal/abnormal findings at each visit. Changes from baseline (i.e. normal to abnormal and vice versa, or changes in type of abnormality) have been displayed.

For all the laboratory examinations and within each of the two treatments, the following analyses have been provided:

- frequency and percentage of patients whose values were below, equal or above the normal range at each visit. Either MacNemar test or Stuart Maxwell test [21] has been applied in order to test if the distribution across categories at baseline differs from the distribution at each visit.
- continuous values of laboratory tests were standardised according to a method proposed by Chuang-Stein [22], using as reference values mainly the ones reported in Cecil's Textbook of Medicine (Appendix 12.1.8) [23]; the Wilcoxon Rank Signed test for paired data was applied in order to compare the values during treatment with those recorded at baseline.

The use of statistical tests in this framework aimed mainly at providing screening tools for selecting those changes, within each single examination, to this purpose the tests were considered as statistically significant if $p < 0.01$. In addition, abnormal values of laboratory tests defined as clinically relevant were specially considered and listed. Criteria used to judge values as clinically relevant are reported in Appendix 12.1.8.

All the safety analyses mentioned above only included patients who had both the baseline assessment and at least one post-baseline assessment during the treatment period.

In the analysis of the adverse events, the attention has been concentrated on treatment emergent signs and symptoms (i.e. events which were not present at baseline and appeared during treatment or, if present at baseline, became more severe during treatment). These analyses are essentially descriptive and, for each treatment group, were performed in terms of both patients complaining of adverse events, and the events themselves.

The analyses were performed taking into account (i) the occurrence of at least one sign or symptom, (ii) the occurrence of at least one event for each body system or for selected

aggregation of symptoms (cluster) likely to share the same underlying mechanism or described with synonyms and (iii) in detail, the occurrence of each type of sign or symptom. When severity of the events was considered, the worst reported degree was selected. In order to explore possible differences, patients were also classified by sex and age.

The cumulative risk of developing an individual adverse event and adverse event clusters (newly emerged in 5% or more of patients in at least one treatment group) was estimated by Kaplan-Meier method and the between treatment comparisons were carried out by the log-rank test [24]. Furthermore, the weekly frequency of patients experiencing adverse events (either because of the onset of new events or because of the persistence of those previously developed) was assessed.

The events have been described by frequency tables according to duration, onset time, symptomatic treatment, relationship to study medication, study drug adjustment, dechallenge/rechallenge after action on study drug and outcome. The duration of any event was computed as the number of days from its onset up to its recovery or, in the absence of recovery date, up to the last reporting date (approximate duration).

3.9.2.4 Changes in the Conduct of the Study or Planned Analysis

No deviation in the analysis of the main end-point was introduced, but the fact that diagnosis rather than centre was taken as stratification factor. Diagnosis was included even though not mentioned into the protocol in order to make the analysis consistent with the stratified design selected. On the contrary, centres were not taken as strata due to their large number, higher than anticipated. Should they had been considered, the number of empty cells would have invalidated the analysis. Finally, notwithstanding the recognised failure by the present trial of rejecting the null hypothesis of equal tolerability, the results were presented as Odds Ratios (OR) and corresponding confidence intervals in order to provide anyhow some insight in the size of relative impact of reboxetine on clinical safety profile.

In general, analyses carried out were consistent with the ones anticipated in the protocol with the following exceptions:

- a) additional to the criterion for evaluating efficacy specified into the protocol (i.e. the proportion of patients scored as very much improved or much improved), the one based on HAMD score was introduced in order to provide descriptive and inferential statistical analyses comparable with the ones provided for the adult population. Concordance between the two classification criteria in the studied population is discussed in the section of results.

- b) since the main end-point of the study focused on safety, no method for analysing efficacy was specified into the protocol. In fact, efficacy analysis was carried out introducing confidence interval of estimates of HAMD decrease and response rate at last assessment in a similar fashion to the analyses carried out for the studies in a non-elderly population.
- c) safety was presented in a more articulated fashion than that anticipated into the protocol.

The deviations were introduced to give a better picture of the product profile and no extra claim is being done on the results obtained.

3.10 Data Management

Data management was carried out in the Biometrics and Data Management Department of Pharmacia, Milan. CRFs data were entered into a IBM 3090 computer (according to the arrival flow) through data entry masks generated by SAS FSP release 6.06 and 6.07. Subsequently, data were scrubbed by an electronic procedure set up for this purpose which generated listings of discrepancies between the actual value entered and predefined algorithms. Computer programs generated to this purpose are archived in Biometrics and Data Management Department. These listings were reviewed by clinical personnel and editing of CRFs was requested at the investigator site, whenever appropriate. Corrections were entered iterating the loop until the files were completely cleaned.

Creatinine Clearance was either directly measured at the centres or calculated according to the following formula:

$$[(140 - \text{age}) * \text{weight (kg)}] / [\alpha * \text{serum creatinine (mg/dl)}]$$

where α is a sex-related coefficient corresponding to 72 for males and 85 for females.

ECG tracings were classified and subsequently grouped according to the codes reported in Appendix 12.1.12. Previous and concomitant diseases were coded according to ICD9 dictionary [25]; concomitant drugs according to the Drug Reference List [26] and subsequently grouped according to the ATC System Classification [27]; adverse events according to the WHO-ART dictionary [28]. The WHO-ART dictionary does not include the terms 'urinary hesitancy' and 'blurred vision' which were, consequently, coded as 'micturition disorder' and 'vision abnormal', respectively. While in the tables the two events are reported according to the WHO-ART codes, in the text they are presented as 'urinary hesitancy' and 'blurred vision'.

Reporting, as well as statistical analyses, were carried out with SAS PROCs (version 6.07), apart from Stuart-Maxwell test and confidence interval calculation. The programs relevant to the latter ones are appended in Appendix 12.1.10. A selection of statistical analyses outputs is shown in Appendix 12.1.11.

4. STUDY PATIENTS

4.1 Disposition of Patients

The copy of the randomisation list is given in Appendix 12.1.7.

Three hundred and forty-seven patients were admitted to the study from September 1992 to May 1994 and randomised to treatment (176 received reboxetine and 171 imipramine) by investigators at 46 centres, as shown in Table 1. Of the 347 patients, 218 were randomised to the MDD stratum (109 patients in reboxetine and 109 in imipramine group) and 129 to the DYS stratum (67 patients in reboxetine and 62 in imipramine group).

As shown in Table 2, a total of 253 patients (72.9%) completed the study and 94 (27.1%) withdrew, 49 (27.8%) in the reboxetine group and 45 (26.3%) in the imipramine group. Among the reboxetine patients withdrawn, one patient dropped out of the study having performed the efficacy assessments at Day 56. In the MDD subpopulation the proportion of patients withdrawing was slightly higher on imipramine than on reboxetine (35.8% vs 30.3%, respectively), while in the DYS subpopulation this proportion was in favour of imipramine (9.7% vs 23.9% on reboxetine). Frequency and timing of withdrawal are shown as primary reason for withdrawal in Table 3.


Adverse events or intercurrent illnesses were the main reason for withdrawal in 23 patients of the reboxetine group and in 28 patients of the imipramine group. In addition, one patient on imipramine committed suicide. In 3 cases on reboxetine, and 2 cases on imipramine, the events (agitation/insomnia and insomnia on reboxetine; lassitude on imipramine) and the intercurrent illnesses (suspected multiple myeloma [subsequently not confirmed] on reboxetine, and hysterectomy for endometrium carcinoma on imipramine) causing discontinuation had emerged before starting the experimental treatment. Therefore, the discontinuation rate for newly emerged adverse events was 11.4% on reboxetine and 15.8% (including the death) on imipramine. Adverse events associated with discontinuation in individual cases are discussed in the Adverse Event Section (see Section 8.2.3.2). Deterioration was the main reason for withdrawal in 10 patients per treatment group. Remaining cases mainly included uncooperative patients (12 and 3 cases on reboxetine and imipramine, respectively).

In Table 3 the frequency and timing of withdrawal as primary reason are also shown by diagnosis. In the MDD subpopulation, adverse events or intercurrent illnesses were the main reason of withdrawal in 14 cases (15 minus the 1 case in which event/concomitant illness emerged before the study start) on reboxetine (12.8%) and 21 (23 minus the 2 cases in which event/concomitant illness emerged before the study start) on imipramine (19.3%). In the DYS subpopulation, the proportion of patients having adverse events or intercurrent illnesses as the main reason of withdrawal was very similar in the two groups: 9.0% on reboxetine (8 minus the 2 cases in which event/concomitant illness emerged before the study start) and 9.7% on imipramine (6 cases, including the occurred

death). Uncooperative cases were more frequent on reboxetine in both the diagnostic subgroups.

The disposition of patients is shown in the following chart and in Table 2.

Disposition of patients



4.2 Protocol Deviations

Compliance with entry criteria

The frequency of non-compliance with inclusion/exclusion criteria of relevance for inferential purpose is given in Tables 4 and 5. The most frequent reason for possible non-compliance with one of the exclusion criteria was related to abnormalities of thyroid function tests, possibly suggestive of an underlying, undiagnosed endocrine disorder: 7.2% in the reboxetine group (12 out of 166 assessed) and 5.0% in the imipramine group (8 out of 159 assessed). Concomitant medications not allowed according to the protocol during the wash-out period were administered to 18.8% of the reboxetine group patients and 19.3% of the imipramine group patients. On the whole, non-compliance with these entry criteria was infrequent and similarly represented in both treatment groups, with the exception of those patients aged under 65 years (4 in the reboxetine group and none in the imipramine group). Information on creatinine clearance, either calculated or tested,

is available for 172 of the 176 patients treated with reboxetine and for 169 of the 171 patients treated with imipramine. Table 5 shows the frequency of patients with values of creatinine clearance < 30 ml/min, possibly suggestive of moderate to medium renal insufficiency: the proportion of patients with this critical value was similar in the two treatment groups (4.6% and 6.8%, in the reboxetine and imipramine group, respectively, in the sample of patients having the creatinine clearance calculated, and 0% in both treatment groups in the sample of patients having the creatinine clearance tested).

No major differences were seen in frequency of non-compliance with inclusion/exclusion criteria in the MDD and DYS subpopulations, with the exception of the concomitant medications not allowed during the wash-out period, which were administered to a higher proportion of patients in the reboxetine than in the imipramine group in the DYS subpopulation (17.9% vs 14.5%, respectively) (Table 4).

Randomisation

Distribution and use of study medication were to be done, as previously mentioned, according to centre and stratum. However, owing to minimise the waste of drug, it was shipped to centres in full blocks of 4 treatments for each stratum. In order to provide a discrepancy log with respect to randomisation sequence, patients were listed according to their study entry date within centre and stratum and the treatment foreseen to be assigned according to the random sequence was matched by a sequential criterion. Mismatching between the foreseen treatment and the treatment actually received was identified as a randomisation error.

As reported in Table 6, errors in randomisation procedures led to administration of non-randomised treatment to a number of patients, at a similar frequency in both treatment groups and diagnosis. Of the 170 patients who, according to randomisation allocation, should have been allocated to reboxetine, 39 received imipramine; of the 177 patients who should have been allocated to imipramine, 45 received reboxetine.

The frequency of randomisation errors was similar in the two treatment groups and in the two diagnostic subpopulations, MDD and DYS.

Assessment intervals

The summary statistics of the efficacy and safety assessment intervals in days from treatment start are shown in Table 7. There were a few deviations from scheduled times and were mainly related to laboratory tests and ECG evaluations at screening and at last assessment. The deviation rate was similar in both treatment groups.

Concomitant medications

The frequency of administration during the study of non-protocolled concomitant medications (because of their psychotropic properties) is given by active principle in

Table 8, and by class and diagnosis in Table 9. As shown in the latter table, long-acting benzodiazepines were administered to 34 reboxetine group patients and 35 imipramine group patients. Overall, unprotocolled psychotropic medications were administered to 35 reboxetine group patients and 37 imipramine group patients. Neuroleptics were administered to 6 reboxetine treated patients (4 of them in the MDD subgroup) and 1 imipramine treated patient. The main difference observed between the MDD and DYS subpopulations concerns the proportion of long-acting benzodiazepines, which were administered at least once more frequently to patients on reboxetine than on imipramine (14 and 9, respectively) in the DYS subgroup and more frequently to patients on imipramine than on reboxetine (26 and 20, respectively) in the MDD subgroup.

4.3 Demographic Data and Psychiatric Anamnesis

Summary statistics of demographic data are given by treatment group in Table 10 (age, weight and height by diagnosis) and Table 11 (race and sex by diagnosis), and summarised below.

Summary of Demographic Data

		Reboxetine		Imipramine	
		n	(%)	n	(%)
Sex	Female	137	77.8	126	73.7
	Male	39	22.2	45	26.3
	Total	176	100.0	171	100.0
Race	Caucasian	175	99.4	170	99.4
	Black	1	0.6	1	0.6
	Total	176	100.0	171	100.0
		mean	SD*	mean	SD*
Age (years)		73.8	6.4	74.5	7.0
Height (cm)		162.4	7.4	164.0	9.1
Weight (kg)		64.0	11.8	66.9	12.7

*SD standard deviation

The majority of patients, in both groups and subpopulations (MDD and DYS), were female; the ratio of females to males was similar in both groups of treatment. The vast majority of patients were Caucasian. The treatment groups and the two subpopulations were well-matched for age, height, weight, sex and race.

4.3.1 COGNITIVE FUNCTION

Summary statistics of the MMS total score are given by treatment and diagnosis in Table 12. There was no relevant difference between the treatment groups and the two subpopulations (MDD and DYS), at admission, with regard to the mean MMS total score.

4.3.2 DIAGNOSIS AND HISTORY OF THE DEPRESSIVE DISORDER

The frequency of the DSM-III-R diagnostic classifications, the summary statistics of the history of the depressive disorder, and the characteristics of the index episode are given by treatment, and diagnosis, in Tables 13 and 14. Major Depressive Disorders account for 62% and 64% of the reboxetine and imipramine study sample, whilst Dysthymia cases account for 38% and 36%, respectively. In the MDD subgroup, Recurrent Major Depressive Disorder (DSM-III-R 296.3) was diagnosed for 58% of the reboxetine and 67% of the imipramine subgroup patients, while the first Major Depressive Episode (DSM-III-R 296.2) was diagnosed more frequently (41%) in the reboxetine than in the imipramine subgroup (33%). One patient (reboxetine) was diagnosed as having Bipolar Depressive Disorder (DSM-III-R 296.5). In contrast, in the DYS subpopulation (see Table 14), the index episode represented the first occurrence of the disorder more frequently in the imipramine (34%) than in the reboxetine subgroup (24%). In addition, recurrence of a similar previous episode (probably corresponding to the DSM-III-R Dysthymia with intermittent course condition) was more frequently diagnosed in the reboxetine subgroup (22%) than in the imipramine subgroup (10%).

The age of onset, the median number of previous episodes of depression, the median duration of the last episode and the median duration of the present episode of the patients at entry into the study are shown below by diagnosis.

Previous History of Depression

	Major Depressive Disorder			
	Reboxetine		Imipramine	
	n	Median (range)	n	Median (range)
Age at onset (years)	100	67.0 (24 - 90)	102	67.0 (22 - 94)
Number of previous episodes	57	2.0 (1 - 18)	69	2.0 (1 - 40)
Duration of the last episode (weeks)	59	16.0 (4 - 172)	69	12.0 (3 - 676)
Duration of the present episode (weeks)	109	12.0 (2 - 188)	109	8.0 (1 - 128)

Previous History of Depression (continued)

	Dysthymia			
	Reboxetine		Imipramine	
	n	Median (range)	n	Median (range)
Age at onset (years)	55	66.0 (18 - 85)	55	68.0 (28 - 88)
Number of previous episodes	21	3.0 (1 - 12)	18	2.5 (1 - 12)
Duration of the last episode (weeks)	26	42.0 (4 - 208)	20	58.0 (4 - 156)
Duration of the present episode (weeks)	65	108.0 (2 - 2080)	62	104.0 (3 - 416)

The treatment groups were well matched with regard to the number of previous episodes of depression and the age at onset. In the MDD subgroup, the median duration of the last episode and the median duration of the present episode of depression were slightly lower in the imipramine group than in the reboxetine group, while in the DYS subgroup, the median duration of the last episode was slightly lower in the reboxetine group and the median duration of the index episode was similar in the two treatment groups.

As shown in Table 14, in the MDD subgroup, the onset of the index episode was acute or subacute in the majority of patients (64% and 62% of the reboxetine and imipramine subgroup patients, respectively). A precipitating external stress was absent more frequently in the imipramine group (59%) than in the reboxetine group (48%).

In the DYS subgroup, the index episode was characterised by exacerbation of chronic conditions in 52% and 57% of reboxetine and imipramine subgroup patients, respectively. The onset of the index episode was defined as insidious in the majority of the patients (66% of both the reboxetine and imipramine subgroup patients), although 3 patients in the reboxetine subgroup were reported to have had an acute onset of the Dysthymia disorder. A precipitating external stress was absent more frequently in the reboxetine group (64%) than in the imipramine group (58%).

4.3.3 SEVERITY OF DEPRESSION

The severity of the depression, according to the HAMD, MADRS and CGI scales, at the various assessment intervals during the study is displayed, in terms of summary statistics, in Tables 22 to 40 and summarised below. There was no significant difference between the treatment groups and the diagnosis at Day 0 with regard to the initial CGI and MADRS scores. Similarly, there were no significant group differences for the mean HAMD total scores in the whole population and in the two subgroups. On the whole, the

Pharmacia

Document 9550089

proportion of severe cases (maximum score level 2 or 3 to 4) for each item of the HAMD scale at baseline (Table 23) was similar in the two treatment groups for the vast majority of items with the only exception of **Insomnia Early** (score 2: 51% of imipramine vs 63% of reboxetine patients). In the subpopulations, though no significant group difference was observed for the mean HAMD total scores, the frequency of the severe cases (maximum score levels 2 or 3 to 4) was slightly different for few items, particularly in the DYS subgroup.

In the DYS subgroup, major differences were observed for **Anxiety Somatic** (score 3 to 4: 15% of imipramine vs 25% of reboxetine patients), **Somatic Gastrointestinal** (score 2: 15% of imipramine vs 31% of reboxetine patients), **Somatic General** (score 2: 43% of imipramine vs 52% of reboxetine patients) and for **Hypochondriasis** (score 3 to 4: 15% of imipramine vs 28% of reboxetine patients). In the MDD subpopulation, differences were seen for **Insomnia Early** (score 2: 54% of imipramine vs 71% of reboxetine patients) and **Insomnia Middle** (score 2: 39% of imipramine vs 53% of reboxetine patients).

Severity of Depression at Day 0

	Major Depressive Disorder					
	Reboxetine			Imipramine		
	n	mean	SD*	n	mean	SD*
HAMD	105	27.0	4.9	108	26.9	5.4
MADRS	104	30.7	7.7	108	31.2	6.8
		n	(%)		n	(%)
CGI Severity						
Normal		0	(0%)		0	(0%)
Borderline mentally ill		0	(0%)		0	(0%)
Mildly ill		11	(10.3%)		6	(5.5%)
Moderately ill		21	(19.6%)		29	(26.6%)
Markedly ill		55	(51.4%)		51	(46.8%)
Severely ill		19	(17.8%)		21	(19.3%)
Extremely ill		1	(0.9%)		2	(1.8%)

* SD standard deviation

4.3.5 MEDICAL HISTORY

The medical history and medical examination findings at entry of the study are summarised by single disease entity and diagnosis in Table 16, and by affected body system and diagnosis in Table 17. The majority of the patients had a history or presence of diseases other than the affective disorder at admission, the most common being circulatory system disorders, specifically hypertension (19% reboxetine, 22% imipramine). Circulatory system disorders were more frequently present in imipramine patients (45%) than in reboxetine patients (38%). The difference was mainly evident in the MDD subpopulation (44% vs 34%). On the contrary, digestive system disorders were more frequently present in the reboxetine than in the imipramine group patients, in the MDD subpopulation (23% vs 16%, respectively). No other imbalances among the two treatment groups and the two diagnoses are apparent.

5. STUDY MEDICATION AND COMPLIANCE

The frequency of administration of different doses of each experimental treatment on each study day is given by treatment in Table 18. The per protocol dose was administered to the vast majority of the patients. On Day 1, 15/176 (8.5%) of the reboxetine group patients and 18/171 (10.5%) of the imipramine group patients received half of the protocolled number of daily capsules, because they started their treatment in the evening. This resulted in a Day 1 dose of 2 mg of reboxetine and 25 mg of imipramine. In addition, one patient in the imipramine group received, in error, 150 mg imipramine on Day 1 due to a mistaken intake of a double number of capsules in the morning and evening of the 75 mg dose. Over the next few days a maximum of 9 and 8 patients per day (reboxetine and imipramine group, respectively) had their number of daily capsules decreased (for the reasons indicated in the individual data listing for the experimental treatment). These were mainly missed intake, lost medication or emergence of signs/symptoms of intolerance. Over the same period, a maximum of 2 patients per day on reboxetine (one in each diagnostic subpopulation) and 1 on imipramine (in the MDD subgroup) had their daily dose increased to 6 mg/day reboxetine and to a maximum of 150 mg/day imipramine. These were due to a mistaken intake of twice the expected number of capsules in the morning and/or evening.

As summarised in Table 19, at the end of the initial 3 weeks of treatment, 42 patients in the reboxetine group (23.9% of those admitted) and 33 of the imipramine group (19.3% of those admitted) had their daily dose increased according to the protocol provisions to a dose corresponding to 6 mg/day of reboxetine and 100 mg/day of imipramine (level 2 dose). In the following weeks, 8 additional patients on reboxetine and 7 on imipramine were switched to dose level 2. On the whole, a slightly higher proportion of reboxetine treated patients switched to the high dose regimen in both DYS and MDD subpopulations.

Over the last five weeks, a maximum of 6 patients per day in the reboxetine group and a maximum of 6 patients in the imipramine group, had their number of daily capsules decreased (for the reasons indicated in the individual data listing for the experimental treatment). These were mainly missed intake, lost medication or emergence of signs/symptoms of intolerance.

During the same period, on a few treatment days, a maximum of 1 patient per day on both reboxetine and imipramine mistakenly had their daily dose increased to a maximum of 10 mg/day reboxetine and a maximum of 150 mg/day imipramine, due to intake of twice the number of expected capsules in the morning and/or evening. In both treatment groups one patient per group was treated up to Day 63; on reboxetine this was achieved by dispensing the capsules of missing intake and on imipramine this was achieved by dispensing the spare capsules.

Pharmacia

Document 9550089

In the case of overdosage, signs of intolerance were reported only with reboxetine and consisted, in one case, of moderate insomnia (see Adverse Event Section).

Comparison of the daily dose administered (as reported in the compliance section of the CRF in terms of number of capsules taken per day) with the expected dose (as indicated in the Experimental Treatment Section of the CRF in terms of number of capsules foreseen per day) allowed calculation of the compliance with the treatment regimen. Full compliance was defined where there was full agreement between the dose prescribed (the per protocol dose, or a lower prescribed dose mainly in the case of adverse events) and the dose reported to have been taken. The total compliance over the treatment period was calculated for each patient and the patients were classified accordingly (Table 20). One hundred per cent compliance was reported in 61.4% of the reboxetine group patients and 67.8% of the imipramine group patients. Only in a few cases the reported compliance was lower than 80%, or between 80% and 89% (6 reboxetine treated patients, and 2 imipramine treated patients, in both instances).

A higher proportion of patients with full compliance was reported in DYS subpopulation compared to MDD subgroup in both treatment groups (70% vs 56% on reboxetine and 74% vs 64% on imipramine). In addition, in DYS subgroup a compliance lower than 90% was reported only in the reboxetine group (5 patients).

6. CONCOMITANT MEDICATIONS

The frequency of patients who received medications before the study start and during the treatment period as a newly introduced concomitant medications for treatment of emergent events, is shown in Table 21 by active principle and diagnosis and in Table 21a by class of drugs grouped according to the ATC System Classification and diagnosis.

As shown in Table 21a, the frequency of patients who were receiving at least one medication at admission to the study was similar in the reboxetine and imipramine groups for each class of drugs. During the study, the main difference between treatment groups was seen in the DYS subpopulation for central nervous system drugs, received by 19% and 3% of reboxetine and imipramine treated patients, respectively. Among those patients, as shown below, the vast majority of reboxetine patients and all imipramine patients received psycholeptic drugs (15% and 3%, respectively), including long-acting benzodiazepines, as already mentioned in Section 4.2.

A similar proportion of reboxetine and imipramine patients was receiving cardiovascular drugs at admission, though cardiovascular disorders were more frequently present in imipramine than in reboxetine patients and being the difference particularly evident in the MDD subpopulation, as previously discussed in Medical history (Section 4.3.5). However, as shown below, a higher proportion of patients on imipramine than on reboxetine received cardiac therapy at admission in the MDD subpopulation and beta-blocking agents in the DYS subgroup. During the study, in the MDD subpopulation, at least one newly introduced cardiovascular drug was administered to 7% of imipramine patients and 4% of reboxetine patients and, as shown below, particularly cardiac therapy was administered more frequently to imipramine than to reboxetine treated patients (5% vs 1%).

Percent frequency of patients taking at least one central nervous system or cardiovascular system medication

		Before Treatment				During Treatment			
		Major Depressive Disorder		Dysthymia		Major Depressive Disorder		Dysthymia	
System	Sub-Class of Drug	IMI	RBX	IMI	RBX	IMI	RBX	IMI	RBX
CNS	At least one	53	51	39	40	17	16	3	19
	Psycholeptics	48	44	31	28	16	10	3	15
	Analgesics	11	16	11	16	6	6	2	5

Pharmacia

Document 9550089

Percent frequency of patients taking at least one central nervous system or cardiovascular system medication (continued)

		Before Treatment				During Treatment			
		Major Depressive Disorder		Dysthymia		Major Depressive Disorder		Dysthymia	
System	Sub-Class of Drug	IMI	RBX	IMI	RBX	IMI	RBX	IMI	RBX
CNS	Other Neurological	4	5	2	5	1	0	0	0
	Anti Parkinson	0	2	0	2	0	0	0	3
	Antiepileptics	2	1	2	0	0	0	0	0
	Psychoanaleptics	1	1	0	0	0	0	0	0
	Anaesthetics	0	0	0	0	1	0	0	0
	Other	0	1	0	0	1	1	0	0
CV	At least one	38	39	48	48	7	4	0	2
	Cardiac Therapy	16	13	13	13	5	1	0	0
	Antihypertensives	13	15	16	18	0	1	0	0
	Diuretics	11	13	13	12	0	0	0	2
	Beta-blocking Agents	8	6	16	9	3	2	0	0
	Peripheral Vasodilators	2	6	13	12	0	0	0	0
	Vasoprotectives	1	2	5	2	1	0	0	0

7. EFFICACY RESULTS

7.1 Hamilton Depression Rating Scale

Summary statistics of HAMD assessment at each visit in the observed cases are shown in Table 22 (total scores) Table 23 (frequency distribution of items scores) and Table 24 (factors). Summary statistics of the last assessment are given in Table 25 (total scores) and Table 26 (factors). The mean difference of HAMD total score between the two treatments at last assessment and the 95% CI is shown in Table 27. The mean HAMD total score was reduced from 26.6 at Day 0 to 14.8 at last assessment (mean decrease 11.8, SD 10.0), in the 172 patients treated with reboxetine who had at least one assessment in addition to baseline (4 patients had only baseline data), and to 11.4 at Day 56 in the 127 patients who completed the study. In the 168 patients treated with imipramine who had at least one assessment in addition to the baseline (3 patients had only baseline data) the mean HAMD total score was reduced from 26.1 at Day 0 to 12.9 at last assessment (mean decrease 13.3, SD 9.7), and to 8.8 at Day 56 in the 126 patients who completed the study. The difference between the two treatments in the mean HAMD decrease at last assessment was of -1.5 points (95% CI, -3.6 ÷ 0.6 points).

The mean decrease at last assessment in the MDD subpopulation was similar on reboxetine and imipramine, being the between treatment difference of -0.4 points (95% CI, -3.2 ÷ 2.4 points). In the DYS subpopulation a difference in favour of imipramine was present: -3.4 points (95% CI, -6.5 ÷ -0.2 points), being the mean HAMD decrease at last assessment 11.1 (SD 9.4) on reboxetine and 14.5 (SD 8.5) on imipramine (Table 27).

The pattern of improvement of HAMD factors was similar in the reboxetine-treated and imipramine-treated patients. On the whole, at last assessment, the only difference seen was in Factor V (Retardation) (median difference vs Day 0 of 0.75 [reboxetine group] and 1.25 [imipramine group]). A similar difference was present in the MDD and DYS subgroups. In the DYS subpopulation, small differences were also seen in Factor I (Anxiety/Somatisation) (median difference vs Day 0 of 0.67 [reboxetine group] and 0.83 [imipramine group]) and Factor VI (Sleep Disturbance) (median difference vs Day 0 of 0.33 [reboxetine group] and 0.67 [imipramine group]).

Absolute and per cent frequency of patients who fulfilled the definition of response or remission is shown (with 95% confidence intervals) by treatment group over time in Table 28 and at last assessment in Table 29. A slightly higher proportion of patients treated with imipramine were classified as responder or in remission at the end of the study. A similar pattern of response and remission rate was observed in the MDD and DYS subpopulations during and at the end of the study.

At last assessment (Table 29), 54.1% (95% CI, 46.3% ÷ 61.7%) of the reboxetine-treated patients and 56.5% (95% CI, 48.7% ÷ 64.2%) of the imipramine-treated patients

were classified as responders, according to the definition of response based on 50% decrease of HAMD score, while 42.4% (95% CI, 35.0% ÷ 50.2%) and 49.4% (95% CI, 41.6% ÷ 57.2%), respectively, were seen to be in remission. The proportion of response and remission cases was very similar on imipramine and on reboxetine in the MDD subgroup. Instead, the proportion of response [65.0% (95% CI, 51.6% ÷ 76.9%) on imipramine vs 56.7% (95% CI, 44.0% ÷ 68.8%) on reboxetine] and remission cases [58.3% (95% CI, 44.9% ÷ 70.9%) vs 41.8% (95% CI, 29.8% ÷ 54.5%), respectively] was higher on imipramine than on reboxetine in the DYS subgroup of patients.

The frequency of remission and non remission cases by severity (maximum score level) at baseline for each of the 17 specific items of the HAMD scale is shown in Table 30. The frequency by severity of the last items of the HAMD scale is not presented in the table being those items, on the whole, less frequently scored and similarly in both treatment groups. On the whole, the proportion of patients eventually in remission was higher among the less severe cases at baseline for the vast majority of items, with few exceptions mainly severe at baseline in a small proportion of cases. However, for few items the proportion of patients eventually in remission was particularly low among severely ill patients at baseline. This was the case in both treatment groups for Insomnia Middle (39.1% of the patients in remission vs 60.9% not in remission among the severe cases on imipramine; 35.8% of the patients in remission vs 64.2% not in remission among the severe cases on reboxetine), Agitation (27.3% of the patients in remission vs 72.7% not in remission on imipramine; 22.2% of the patients in remission vs 77.8% not in remission on reboxetine) and, particularly in the reboxetine group, for Hypochondriasis (41.9% of the patients in remission vs 58.1% not in remission on imipramine; 15.0% of the patients in remission vs 85.0% not in remission on reboxetine). In all cases, the prevalence of severely ill patients at admission was higher in the reboxetine group than in the imipramine group, particularly in the case of Insomnia Middle (46.0% vs 37.4%) and Hypochondriasis (22.7% vs 18.1%).

These results are consistent in the two diagnostic subpopulations. However, extreme differences are apparent in Dysthymia in both treatment groups for Insomnia Middle (36.4% of the patients eventually in remission vs 63.6% not in remission among the severe cases on imipramine; 28.0% of the patients in remission vs 72.0% not in remission among the severe cases on reboxetine) and Agitation (28.6% of the patients in remission vs 71.4% not in remission on imipramine; 0.0% of the patients in remission vs 100.0% not in remission on reboxetine) and, in the reboxetine group, for Hypochondriasis (5.3% of the severe patients eventually in remission vs 94.7% not in remission). In the latter case the prevalence of severely ill patients at admission was higher in the reboxetine group (28.4%) than in the imipramine group (14.5%).

7.2 Clinical Global Impression

7.2.1 SEVERITY OF ILLNESS

The distribution of the CGI severity scores at each visit in the observed cases is presented by treatment group in Table 31, while the distribution of the scores at last assessment during the study are provided in Table 32. The distribution pattern is similar in both treatment groups. At last assessment, the proportion of normal or borderline mentally ill cases was slightly lower on reboxetine (42.0%) than on imipramine (49.4%), while the proportion of mildly ill patients was higher in the reboxetine group (21.3%) compared to the imipramine group (10.6%). In the MDD subgroup, the proportion of normal or borderline mentally ill cases was similar in the reboxetine and imipramine groups, while the proportion of mildly ill cases was slightly higher on reboxetine (17.8% vs 11.9%) and the proportion of markedly to extremely ill patients was slightly higher on imipramine (27.5% vs 24.3%). In the DYS subpopulation, the proportion of normal or borderline mentally ill cases was higher on imipramine (62.3% vs 41.8%), while the proportion of mildly ill cases was higher on reboxetine (26.9% vs 8.2%).

A shift table of the last value vs Day 0 (Table 33) showed that the CGI Severity of Illness had decreased in 71.3% of reboxetine group patients, increased in 9.8% and remained the same for 19.0%, whereas the CGI Severity of Illness had decreased in 71.2% of imipramine group patients, increased in 5.3% and remained the same in 23.5%. The proportion of patients showing a decreased CGI Severity of Illness was higher in the DYS subpopulation than in the MDD subgroup of patients in both treatment groups, particularly on imipramine (80.3% vs 66.1%) but also on reboxetine (76.1% vs 68.2%).

7.2.2 GLOBAL IMPROVEMENT

The distribution of Global Improvement scores in CGI at each visit is shown by treatment group in Table 34. The distribution of last assessment scores is shown in Table 35. The proportion of patients judged 'much to very much improved' at last assessment and the between treatment difference (95% CI) are given in Table 36.

The overall distribution pattern was similar in the two treatment groups. The percentage of patients who were 'much to very much improved' was, at last assessment, 56.9% in the reboxetine group and 59.4% in the imipramine group. The between treatment difference at last assessment was -2.5% (95% CI, -12.9% ÷ 7.9%).

In the MDD subpopulation, the percentage of patients who were 'much to very much improved' was, at last assessment, slightly higher in the reboxetine group (58.9%) than in the imipramine group (52.3%). The between treatment difference at last assessment was 6.6% (95% CI, -6.0% ÷ 19.8%).

In the DYS subpopulation, the percentage of patients who were 'much to very much improved' was, at last assessment, higher in the imipramine group (72.1%) than in the

Pharmacia

Document 9550089

reboxetine group (53.7%). The between treatment difference at last assessment was -18.4% (95% CI, -34.8 % ÷ -2.0%).

In agreement with the results obtained on the HAMD score, imipramine appeared to be more effective on patients with Dysthymia, while such a difference between treatments is not evident in patients suffering from MDD.

The concordance between the response evaluated according to CGI - Global Improvement classification and the response evaluated according to the HAMD total score decrease of $\geq 50\%$, was estimated. Only the patients rated for both the assessment instruments at last available assessment could be considered. The results are summarised in the table below.

Concordance between the response according to CGI-GI and HAMD scale

	Major Depressive Disorder		Dysthymia		Total	
	Imipramine	Reboxetine	Imipramine	Reboxetine	Imipramine	Reboxetine
Patients Evaluated	107	102	60	66	167	168
Responders*	52	55	37	32	89	87
Non Responders*	46	39	14	25	60	64
Concordance	98/107	94/102	51/60	57/66	149/167	151/168
%	92	92	85	86	89	90

* according to both HAMD and CGI-GI

In the overall population, the results of the two assessment instruments were concordant in 151 and 149 patients, respectively on reboxetine and on imipramine, therefore showing a concordance of $\geq 89\%$. Among those patients, 87 and 89, respectively, were classified as responders, while 64 and 60 patients, respectively, were classified as non responders according to the definitions based on both the HAMD scale and the CGI - Global Improvement. As shown in the table, the concordance was very similar on both treatments and slightly higher in the MDD subpopulation.

7.2.3 EFFICACY INDEX

The CGI Efficacy Index, which was assessed in order to relate therapeutic efficacy and tolerability, is shown by treatment group at each visit in Table 37. The distribution of last assessment values is shown in Table 38. At last assessment no global benefit (index: <1) was reported in 17.2% of the reboxetine patient group and 20.0% of the imipramine patient group. The proportion of cases where moderate to marked efficacy was present in the absence of side-effects (index: 3 to 4) was similar in the two treatment groups (39.7% on reboxetine and 41.2% on imipramine). However, in the MDD subpopulation the proportion of patients in the latter condition corresponded to 40.2% of the cases on reboxetine vs 34.9% of the cases on imipramine. In contrast, in the DYS subpopulation, this condition was judged to be present in 52.5% of the patients on imipramine vs 38.8% of those on reboxetine.

7.3 Montgomery and Asberg Depression Rating Scale

Summary statistics of MADRS assessment at each visit in the observed cases are shown in Table 39 (total scores). Summary statistics of the last assessment are given in Table 40 (total scores).

The mean MADRS score was reduced from 29.7 at Day 0 to 15.5 at last assessment in the 171 reboxetine patients who had at least one assessment in addition to baseline, and to 11.7 in the 128 patients who had had the assessment at Day 56. In patients treated with imipramine, the mean MADRS score was reduced from 30.0 at Day 0 to 14.0 at last assessment in the 168 patients who had at least one assessment in addition to baseline, and to 8.9 at Day 56 in the 126 patients who completed the study.

The subgroup analysis of MADRS assessments shows a similar pattern of response in the MDD subpopulation. In the DYS subgroup of patients there was a suggestion of a higher reduction of the total score on imipramine than on reboxetine at last assessment (imipramine: from 27.9 to 9.8; reboxetine: from 28.0 to 14.6).

7.4 Geriatric Depression Rating Scale

Summary statistics of GDS assessment at each visit in the observed cases are shown in Table 41 (total scores). Summary statistics of the last assessment are given in Table 42 (total scores).

The mean GDS score was reduced from 23.1 at Day 0 to 14.0 at last assessment in the 172 reboxetine group patients who had at least one assessment in addition to baseline, and to 11.4 in the 128 patients who had the assessment at Day 56. In patients treated with imipramine, the mean total GDS score was reduced from 23.4 at Day 0 to 12.9 at last assessment in the 168 patients who had at least one assessment in addition to baseline, and to 9.2 in the 125 patients who had the assessment at Day 56. There were no clinically relevant differences in GDS scores at each visit between the reboxetine and

imipramine groups in the total population and in the subgroup populations. However, at last assessment, in the DYS subpopulation there was a suggestion of a higher reduction of the total score on imipramine than on reboxetine (imipramine: from 22.9 to 9.9; reboxetine: from 23.0 to 13.6).

7.5 Efficacy Conclusions

The efficacy of reboxetine therapy in elderly patients suffering from Depressive Disorders, as evaluated by the improvement of HAMD, CGI, MADRS and GDS scales, appeared not different to that of imipramine.

The results of the additional analyses on the subpopulations of patients diagnosed as having Major Depressive Episode/Disorder or Dysthymia, indicate that both treatments were similarly effective in terms of improvement of the clinical picture in the MDD subgroup of patients. In the DYS subpopulation, frequency and extent of improvement was higher on imipramine than on reboxetine.

8. SAFETY RESULTS

8.1 Safety Population and Extent of Exposure

8.1.1 NUMBER OF PATIENTS IN SAFETY ANALYSIS

All the patients who received study treatment were included in the safety analysis, i.e. 176 reboxetine patients and 171 imipramine patients. For the laboratory tests, vital signs and ECG, those patients with at least one assessment in addition to baseline were evaluated.

8.1.2 TOTAL DRUG EXPOSURE

As shown in Table 18, of the 176 and 171 patients exposed to reboxetine and imipramine, 143 and 138, respectively, were treated for at least 4 weeks, while 127 and 126 were treated for 8 weeks, therefore completing the study.

8.2 Adverse Events

8.2.1 ANALYSIS OF ADVERSE EVENTS

The number of patients with adverse events and the number of adverse events during the study are grouped by sex in Table 43, by age classes in Table 44, and by DSM-III-R diagnosis in Table 45. Sixty-eight point two per cent of the reboxetine-treated patients and 71.3% of the imipramine-treated patients had 307 and 338 adverse events and an average of 2.6 and 2.8 adverse events (per patient with adverse events), respectively. No relevant gender difference in the overall frequency of adverse events was present in either treatment groups (67.9% of females and 69.2% of males on reboxetine; 69.8% of females and 75.6% of males on imipramine). As for the different age groups, patients less than 70 years old at admission, and patients aged 70 to 79 years old, had adverse events slightly more frequently on imipramine than on reboxetine (79.3% and 73.8% respectively on imipramine; 63.2% and 69.4% respectively on reboxetine). In contrast, patients 80 years old or older suffered from adverse events more frequently on reboxetine than on imipramine (75.0% vs 58.3%).

Patients diagnosed as having Major Depressive Episode/Disorder (DSM-III-R 296.2 and 296.3) complained of adverse events somewhat more frequently on imipramine (73.4%) than on reboxetine (66.1%), while patients diagnosed as having Dysthymia (DSM-III-R 300.4) complained of adverse events slightly more frequently on reboxetine (71.6%) than on imipramine (67.7%). In both treatment groups, patients with the first major depressive episode (DSM-III-R 296.2) complained of adverse events more frequently than recurrent cases (DSM-III-R 296.3): 83.3% vs 68.5% on imipramine and 77.8% vs 58.7% on reboxetine.

8.2.1.1 End-Point Analysis

Results of the end-point analysis are summarised below. On the whole, the probability of developing at least one adverse event was similar in the two treatment groups and the odds ratio (OR: reboxetine/imipramine) was 0.86 (95% CI, 0.55 ÷ 1.36). No difference was apparent in the subpopulations, though in the MDD subgroup of patients the frequency of patients complaining of at least one adverse event was slightly higher on imipramine than on reboxetine [OR = 0.7 (95% CI, 0.39 ÷ 1.26) and in the DYS subpopulation this frequency was slightly higher on reboxetine than on imipramine [OR = 1.20 (95% CI, 0.57 ÷ 2.55)].

Frequency of patients complaining of at least one adverse event

	Major Depressive Disorder		Dysthymia		Total	
	Imipramine	Reboxetine	Imipramine	Reboxetine	Imipramine	Reboxetine
Patients Exposed	109	109	62	67	171	176
Patients with any AE	80	72	42	48	122	120
%	73	66	68	72	71	68
Odds Ratio (95% CI)	0.70 (0.39 ÷ 1.26)		1.20 (0.57 ÷ 2.55)		0.86 (0.55 ÷ 1.36)	

8.2.1.2 Absolute and Per Cent Frequency

The absolute and per cent frequency of patients suffering from adverse events and of adverse events is grouped by frequency and time interval in Tables 46 (all events), 47 (split by body system with relevant event grouped in clusters), 48 (split by body system, with relevant event grouped in clusters, and diagnostic subpopulations) and by body system and sex in Table 49. The relative chance of developing at least one adverse event among the most frequent of reported events in the two treatment groups (≥5% of exposed patients in at least one group) is evaluated by OR and shown in Table 50. The frequency of the events often reported in patients on antidepressant medication was very similar in the two treatment groups. Dry mouth was complained of by 22.2% and 22.8% of patients on reboxetine and on imipramine, respectively; constipation by 17.6% and 18.1% of patients, respectively; nausea and related symptoms by 11.4% and 9.9%, respectively; increased sweating by 9.1% and 8.8% of patients, respectively; headache/migraine by 6.3% and 5.3% and urinary hesitancy/retention by 4.0% and 5.8%, respectively. Accordingly, the odds ratios were very close to 1 (Table 50). Insomnia was the only event more frequently reported on reboxetine than on imipramine [6.3% vs 2.9%; OR = 2.25 (95% CI, 0.78 ÷ 6.51)]. Hypotension and related symptoms were

more frequently reported on imipramine than on reboxetine (15.8% vs 7.4%) and the odds ratio [OR = 0.43 (95% CI, 0.21 ÷ 0.85)] indicates that the chance of developing hypotension and related symptoms was higher on imipramine than on reboxetine.

Amongst the most frequently reported events, few differences were seen between the two diagnostic subpopulations (Table 48). In the MDD subpopulation, the most relevant differences were related to the frequency of dry mouth, more frequently reported on imipramine than on reboxetine (22.9% vs 16.5%, respectively); hypotension and related symptoms (20.2% on imipramine vs 10.1% on reboxetine) and tachycardia (4.6% on imipramine vs 1.8% on reboxetine). In the DYS subpopulation, events more frequently reported on reboxetine than on imipramine were: dry mouth (31.3% vs 22.6%, respectively); insomnia (6.0% vs 0%, respectively); tremor (6.0% vs 1.6%, respectively), while events more frequently reported on imipramine than on reboxetine were: constipation (17.7% vs 13.4%, respectively); hypotension and related symptoms (8.1% vs 3.0%, respectively); urinary hesitancy/retention (8.1% vs 1.5%, respectively) and somnolence (4.8% vs 0%, respectively).

The most relevant between-gender difference (Table 47) was related to the frequency of hypotension and related symptoms, which were complained of mainly by male patients in both treatment groups (22.2% of male patients vs 13.5% of female patients on imipramine; 10.3% of male patients vs 6.6% of female patients on reboxetine) and urinary hesitancy/retention, which was complained of mainly by male patients in both treatment groups (15.6% of male patients vs 2.4% of female patients on imipramine; 10.3% of male patients vs 2.2% of female patients on reboxetine). Increased sweating was complained of mainly by female patients in both treatment groups (10.9% of female patients vs 2.6% of male patients on reboxetine; 10.3% of female patients vs 4.4% of male patients on imipramine). Dry mouth was complained of mainly by female patients on reboxetine (24.8% of female patients vs 12.8% of male patients).

The most frequent, therefore, were disorders of the gastrointestinal (GI) system (31.8% and 30.4% on reboxetine and imipramine, respectively) and autonomic nervous system (NS) (27.3% and 28.7%, respectively). Cardiovascular (CV) disorders more frequently affected patients on imipramine than on reboxetine (21.1% vs 12.5%, respectively), and this was also true for urinary system disorders (12.3% vs 8.5%) and general disorders (11.7% vs 6.8%). Psychiatric disorders affected more frequently patients on reboxetine than on imipramine (13.6% vs 9.9%) (Table 49).

As more patients on imipramine than on reboxetine suffered from cardiovascular disorders at admission (45% vs 38%, respectively), as already discussed in Medical History (Section 4.3.5), the frequency of patients affected by at least one cardiovascular adverse event was investigated in patients with or without cardiovascular disorders at baseline. Results are summarised below.

Pharmacia

Document 9550089

Frequency of patients complaining of at least one cardiovascular event or hypotension and related symptoms among patients with or without cardiovascular disorders at baseline

Baseline CV Disorders		Cardiovascular Adverse Events		Hypotension and Related Symptoms	
		Imipramine	Reboxetine	Imipramine	Reboxetine
Absent	Patients Exposed	94	109	94	109
	Patients with AE	16	14	11	10
	%	17	13	12	9
Present	Patients Exposed	77	67	77	67
	Patients with AE	20	8	16	3
	%	26	12	21	5

In patients with or without cardiovascular disorders at admission, the frequency of cardiovascular adverse events was higher on imipramine than on reboxetine. However, while the presence of cardiovascular disorders at baseline seemed not to facilitate the emergence of cardiovascular adverse events and, in particular, of hypotension and related symptoms, on reboxetine, patients on imipramine suffered from newly emerged cardiovascular adverse events and, in particular, of hypotension and related symptoms, more frequently when affected by cardiovascular disorders at baseline (26% and 21%, respectively) than when not affected (17% and 12%, respectively). The differences in favour of reboxetine are mainly evident in the former population (12% vs 26% for cardiovascular adverse events and 5% vs 21% for hypotension and related symptoms).

On the whole, imipramine-treated patients suffered from newly emerged cardiovascular adverse events more frequently than reboxetine-treated patients; nevertheless, only 5% of patients exposed to imipramine vs 3% of those exposed to reboxetine received at least one cardiovascular concomitant drug during treatment (Table 21a).

8.2.1.3 Occurrence

The occurrence of adverse events is grouped by week of onset and event or body system in Tables 51, 52 and 53. The most frequent events on reboxetine and on imipramine emerged early during treatment (within the first week): gastrointestinal disorders (47.5%

and 41.1% on reboxetine and imipramine, respectively), autonomic nervous system disorders (56.1%, 59.3%) and psychiatric disorders (26.5%, 42.1%).

There was a suggestion that general cardiovascular disorders occurred slightly sooner in the imipramine group (first week 49.0%, second week 10.2%) compared to the reboxetine group (first week 29.2%, second week 25.0%). This was mainly due to hypotension and related symptoms, the frequency of which was high during the first and second week on reboxetine (35.7% and 21.4%, respectively), while it was more frequently reported during the first week on imipramine (47.1% vs 8.8% during the second week).

8.2.1.4 Cumulative Risk for Individual Events

The cumulative risk of developing individual events or cluster of individual events, reported in $\geq 5\%$ patients in at least one treatment group, was described according to the Kaplan-Meier method and analysed by the log-rank test. Results are presented only for events with a significantly different risk between the two treatment groups, while the analysis and figures corresponding to all the other events are enclosed in Appendix 12.1.1.1. On the whole, the only difference seen concerned the cumulative risk of developing hypotension and related symptoms, which was significantly higher ($p = 0.0142$) on imipramine than on reboxetine (Figure 1). This result was confirmed in the MDD subpopulation ($p = 0.0326$) but not in the DYS subgroup. No other significant differences were seen in the two subpopulations.

8.2.1.5 Dose Relationship

The absolute frequency of adverse events is grouped by maximal severity and by dose taken on the onset day and in the three preceding days in Table 54. There is no indication that any event occurred at an increased severity or frequency in patients (Tables 18, 19) switched according to the protocol to the higher dose level of reboxetine (corresponding to 6 mg/day) and of imipramine (corresponding to 100 mg/day), with the exception of mild/moderate headache and mild urinary hesitancy in the imipramine group.

8.2.1.6 Maximal Severity

The maximal severity of adverse events in each patient is grouped by sex, age and DSM-III-R classification in Table 55, by event or body system in Tables 56 and 57, respectively, and by body system and diagnosis in Table 58. The prevalence of at least one moderate or severe event was higher on imipramine (73.0%) than on reboxetine (65.0%). Female patients had moderate to severe adverse events more frequently than male patients on imipramine (80.7% vs 52.9%) but not on reboxetine (64.5% vs 66.7%). Mild events were more frequently reported by patients on reboxetine than by patients on imipramine (35.0% vs 27.0%, respectively). There was an increased prevalence of severe adverse events with age in both groups, from 14.0% of patients with events aged < 70 years to 48.1% of patients aged ≥ 80 years in the reboxetine groups, and 21.7% of

patients with events aged < 70 years to 57.1% of patients aged ≥ 80 years in the imipramine group.

However, in both groups, mildness characterised the severity of events for the most frequently affected body systems: 39.3% and 48.1% of the patients on reboxetine and imipramine, respectively, for GI disorders, 50.0% and 44.9% for autonomic NS disorders and 40.0% and 33.3% for central and peripheral NS disorders (Table 57). Possible exceptions were the events related to CV disorders, most frequently moderate on reboxetine (45.5%) and mild on imipramine (36.1%), though severe events were reported more frequently on imipramine (33.3% of the affected patients) than on reboxetine (22.7%); and the events related to psychiatric disorders (mainly agitation/anxiety/nervousness), most frequently severe on reboxetine (41.7%) and mild on imipramine (52.9%).

On the whole, the severity of adverse events was not different in the diagnostic subgroups on both reboxetine and imipramine with the exception of severe events, more frequent in the MDD than in the DYS subgroup on both reboxetine and imipramine (33.3% vs 25.0% and 33.8% vs 26.2%, respectively), and of mild events more frequent in the DYS subgroup on reboxetine (39.6% vs 31.9% in the MDD subgroup) (Table 58). In addition, events related to cardiovascular disorders were more frequently severe in DYS than in MDD patients on imipramine (42.9% vs 31.0%).

8.2.1.7 Duration

Summary statistics of the duration of adverse events are described in Table 59. The median duration was 10 days for reboxetine and 8 days for imipramine. Among the most frequent events, the median duration was higher in the reboxetine group than in the imipramine group for dry mouth (24 days, 19 days), and tachycardia (29 days, 10 days). The median duration was higher in the imipramine group than the reboxetine group for urinary tract infection (14 days, 8 days), somnolence (12 days, 7 days), urinary hesitancy (34 days, 13 days) and anorexia (19 days, 7 days).

8.2.1.8 Symptomatic Treatment

As shown in Table 60, 24.8% and 23.4% of the events on reboxetine and imipramine, respectively, required symptomatic treatment in 38.3% and 32.8% of the affected patients. Urinary tract infection in both treatment groups, and hypotension on imipramine, were the events most likely to require symptomatic treatment.

8.2.1.9 Modification of Study Medication and Patient Outcome

As shown in Table 61, no change in study medication was required for 76.5% and 70.4% of the events on reboxetine and on imipramine, respectively, while the daily dose was reduced in 2.3% and 1.2% of the cases, respectively, or the treatment temporarily interrupted in 2.0% and 2.4%. According to the adverse event outcome reported by the

investigators, 17.6% and 21.9% of the cases in the reboxetine and imipramine groups, respectively, contributed to withdrawal. Among the most common events, this was most frequently seen on reboxetine and on imipramine for hypotension and related symptoms (3 out of 14 events and 7 out of 34 events, respectively), for increased sweating (5 out of 16 events on both treatment groups) and for urinary hesitancy/retention (3 out of 8 events and 8 out of 10 events, respectively). In the case of fall, 1 out of the 3 events on reboxetine and 3 out of the 9 events on imipramine contributed to withdrawal.

The individual cases of patients withdrawn due to adverse events are described in Section 8.2.3.2.

As shown in Table 62, of the 67 and 86 events requiring modification of the study medication in the reboxetine and imipramine group, 50.7% and 66.3% respectively, disappeared following the modification of the regimen, while 38.8% and 19.8%, respectively, did not change. The patient outcome, grouped by event and action taken on study medication in Table 63, corresponds to full recovery in 50.7% of the reboxetine and 72.1% of the imipramine cases following modification of the treatment regimen, the event being still present at last observation in 41.8% and 20.9%, respectively. In particular, 77.8% of the cases of hypotension and related symptoms (7 out of 9 events) on imipramine vs 20.0% of the cases on reboxetine (1 out of 5 events) recovered following the modification of the regimen, suggesting a more close correlation with imipramine than with reboxetine. Similarly, 87.5% and 66.7% cases of urinary hesitancy/retention were recovered following the modification of the regimen on imipramine and reboxetine, respectively.

Full recovery occurred in 67.9% of both reboxetine and imipramine cases following unchanged study medication, the event still being present at last assessment in 20.0% and 16.7%, respectively, of the latter cases.

8.2.1.10 Prevalence

The prevalence of adverse events is grouped by week of treatment and event, event cluster or body system in Tables 64, 65 and 66. Among the most frequent events, in keeping with the selection of the most tolerant population over the treatment period, the proportion of affected patients tended to decrease during treatment for dry mouth, nausea and insomnia in both treatment groups. However, in a number of the common events there was either no change over the treatment period (constipation, in both treatment groups; increased sweating and dizziness, in the reboxetine group) or there tended to be an increase during the treatment period (urinary hesitancy and increased sweating, in the imipramine group; tremor, in the reboxetine group).

The overall prevalence of adverse events in both treatment groups is shown in Figure 2. The proportion of patients affected by at least one adverse event during the different weeks of treatment was slightly higher on imipramine than on reboxetine, particularly in the intermediate weeks. This difference was more evident in the MDD subpopulation,

while in the DYS subgroup the prevalence of adverse events was higher on reboxetine than on imipramine during the initial 4 weeks of treatment.

8.2.1.11 Relationship Between Adverse Events and Study Medication

The relationship between adverse events and study medication, as judged by the investigators on the basis of Karch and Lasagna modified criteria (Enclosure 11 of Appendix 12.1.1) is described in Table 67. The patients complaining of at least one adverse event with probable to definite relationship are tabulated in Table 68. The majority of events on reboxetine and imipramine (35.8%, 29.6%, respectively) were judged possibly related, while 28.3% and 29.3%, respectively, were judged probably related and 3.3% and 9.2%, respectively, were judged definitely related. On the whole, therefore, 38.5% of the events which emerged on imipramine were judged definitely/probably related to the drug, compared to 31.6% of the events which emerged on reboxetine. Among the most frequent events, the maximal frequency of definite/probable relationship was present (reboxetine and imipramine) for dry mouth (58.5%, 72.1%), constipation (38.9%, 35.7%), nausea and related symptoms (40.9%, 50.0%) and urinary hesitancy/retention (62.5%, 80.0%) and on imipramine for hypotension and related symptoms (50.0% vs 28.6%).

As shown in Table 68, the proportion of patients complaining of at least one adverse event with probable to definite relationship was higher on imipramine (42.7%) than on reboxetine (33.0%). Among the most frequent events, this proportion was slightly higher on imipramine than on reboxetine for dry mouth (17.5% vs 13.6%, respectively), hypotension and related symptoms (8.8% vs 2.3%, respectively) and urinary hesitancy/retention (4.7% vs 2.3%, respectively). These differences were more evident in the MDD subgroup for dry mouth (17.4% vs 10.1% on reboxetine) and hypotension and related symptoms (11.9% vs 3.7% on reboxetine) and in the DYS subpopulation for urinary hesitancy/retention (8.1% vs 1.5% on reboxetine).

8.2.1.12 Adverse Events Occurred in Patients with Creatinine Clearance < 30 ml/min

Seven patients on reboxetine and 10 patients on imipramine (Table 5) were admitted to the study with a calculated creatinine clearance of < 30 ml/min, suggestive of moderate to medium renal insufficiency with a possibility of this leading to interference with the elimination of both compounds, both of which have urinary excretion as the preferential elimination route. On reboxetine 5/7 patients and on imipramine 5/10 patients had, respectively, 10 and 20 adverse events, being the frequency of event per patient higher on imipramine than on reboxetine. Two patients on imipramine suffered from 3 serious adverse events (sudden faint, fracture of the neck of the femur following a fall, drowsy and jerky movements in legs).

8.2.2 ADVERSE EVENT SUMMARY

Of the 176 reboxetine patients and 171 imipramine patients who received study medication, 120 (68.2%) and 122 (71.3%) patients reported a total of 307 and 338, adverse events, respectively (2.6 and 2.8 average per patient with adverse events) (Table 43). On the whole population, the probability of developing at least one adverse event was similar in the two treatment groups. Overall, no statistical difference was found in the subpopulations, though in the MDD subgroup the frequency of patients complaining of at least one adverse event was slightly higher on imipramine than on reboxetine, while in the DYS subgroup this frequency was slightly higher on reboxetine than on imipramine. Insomnia was the only event more frequently reported on reboxetine than on imipramine [6,3% vs 2,9%; OR = 2.25 (95% CI, 0.78 ÷ 6.51)]. Hypotension and related symptoms were more frequently reported on imipramine than on reboxetine (15.8% vs 7.4%) and the odds ratio [OR = 0.43 (95% CI, 0.21 ÷ 0.85)] indicates that the chance of developing them was higher on imipramine than on reboxetine. For the whole population, the prevalence of adverse events during the study indicates a slightly higher proportion of patients with adverse events in the imipramine group than in the reboxetine group, particularly in the intermediate weeks (Figure 2). This difference was more evident in the MDD subgroup, while in the DYS subgroup the prevalence of adverse events was higher on reboxetine than on imipramine during the initial 4 weeks of treatment.

8.2.2.1 Severity of Adverse Events

The maximum severity of adverse events is presented in Tables 55 to 57 and summarised as follows:

Severity of Adverse Events

No. of patients					
Reboxetine			Imipramine		
Mild	Moderate	Severe	Mild	Moderate	Severe
42	42	36	33	51	38

The majority of adverse events were mild or moderate in both groups. However, moderate to severe events were more common on imipramine than on reboxetine (89 patients vs 78, respectively).

8.2.2.2 Age- and Gender-Related Effects

No major gender-related differences in adverse events frequency were apparent (Table 43). As for the different age groups, patients less than 70 years old at admission, and patients aged 70 to 79 years, had adverse events slightly more frequently on

imipramine than on reboxetine (79% and 74% respectively on imipramine; 63% and 69% respectively on reboxetine). On the contrary, patients 80 years old or older suffered from adverse events more frequently on reboxetine than on imipramine (75% vs 58%) (Table 44). The most relevant between-gender difference was related to the frequency of hypotension and related symptoms, which were complained of mainly by male patients in both treatment groups (22.2% of male patients vs 13.5% of female patients on imipramine; 10.3% of male patients vs 6.6% of female patients on reboxetine) and urinary hesitancy/retention complained of mainly by male patients in both treatment groups (15.6% of male patients vs 2.4% of female patients on imipramine; 10.3% of male patients vs 2.2% of female patients on reboxetine). Increased sweating was complained of mainly by female patients in both treatment groups (10.9% of female patients vs 2.6% of male patients on reboxetine; 10.3% of female patients vs 4.4% of male patients on imipramine). Dry mouth was complained of mainly by female patients on reboxetine (24.8% of female patients vs 12.8% of male patients) (Table 47).

8.2.2.3 Frequently Reported Adverse Events

Adverse events which occurred in 5% or more of the patients of the MDD and DYS subpopulations during the study (Table 48), are presented by body system in the following table:

Pharmacia

Document 9550089

Adverse Events Occurring in 5% or More of Patients - MDD Subpopulation

Body system	Adverse event	Reboxetine (n=109)		Imipramine (n=109)	
		No. of patients with event	% of patients exposed	No. of patients with event	% of patients exposed
GI disorders	Nausea and related symptoms	11	10	8	7
	Constipation	22	20	20	18
Autonomic NS disorders	Dry mouth	18	17	25	23
	Increased sweating	11	10	8	7
Psychiatric disorders	Insomnia	7	6	5	5
General CV disorders	Hypotension and related symptoms	11	10	22	20
	Tachycardia	2	2	5	5
Central and peripheral NS disorders	Headache / migraine	8	7	7	6
	Tremor	3	3	5	5
Urinary disorders	Urinary hesitancy / retention	6	6	5	5
	Urinary tract infection	5	5	7	6

Pharmacia

Document 9550089

Adverse Events Occurring in 5% or More of Patients - DYS Subpopulation

Body system	Adverse event	Reboxetine (n=67)		Imipramine (n=62)	
		No. of patients with event	% of patients exposed	No. of patients with event	% of patients exposed
GI disorders	Nausea and related symptoms	9	13	9	15
	Constipation	9	13	11	18
Autonomic NS disorders	Dry mouth	21	31	14	23
	Increased sweating	5	8	7	11
Psychiatric disorders	Insomnia	4	6	0	0
	Agitation / anxiety / nervousness	3	5	1	2
	Somnolence	0	0	3	5
General CV disorders	Hypotension and related symptoms	2	3	5	8
Central and peripheral NS disorders	Headache / migraine	3	5	2	3
	Tremor	4	6	1	2
	Confusion	3	5	1	2
	Paraesthesia	3	5	1	2
Vision disorders	Blurred vision	2	3	3	5
Body as a whole/General disorders	Asthenia / fatigue	1	2	3	5
Urinary disorders	Urinary hesitancy / retention	1	2	5	8
	Urinary tract infection	1	2	3	5

83 (2536)

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

8.2.3 SERIOUS ADVERSE EVENTS, DEATHS AND ADVERSE EVENTS ASSOCIATED WITH WITHDRAWAL

8.2.3.1 Serious Adverse Events and Deaths

One patient died (suicide) during the study period and three died (bronchopneumonia, pulmonary edema and apoplexy) 12, 6 and 11 days, respectively, after the end of the treatment period. All deaths were on imipramine. In addition, 12 serious adverse events were reported, 2 under reboxetine and 10 under imipramine, complained of by 2 and 9 patients, respectively. On reboxetine, the 2 cases were: meningioma and acute confusional state and fall. On imipramine, 4 cases concerned cardiovascular disorders: postural hypotension, sudden faint, atrial fibrillation and right bundle branch block and A-V block first degree; in all cases patients were affected by relevant cardiovascular disorders at anamnesis. The other cases concerned: 2 cases of fracture of the neck of the femur, one of them following a fall; a fall and fracture of the knee; a convulsive episode; drowsy and jerky movements in legs and urinary retention.

On reboxetine, the acute confusional state followed by a fall caused discontinuation of the treatment, while the patient who was operated to remove the meningioma withdrew from the study for neurological worsening. On imipramine, 4 serious adverse events (sudden faint, right bundle branch block and A-V block first degree and the 2 cases of fracture of the neck of the femur) occurred during the treatment and one (atrial fibrillation) 7 days after the end of the treatment period. Five serious adverse events (postural hypotension, urinary retention, drowsy and jerky movements in legs, a convulsive episode and a fall and fracture of the knee) caused the treatment interruption.

Case histories for these patients are provided in Appendix 12.2.1.

8.2.3.2 Adverse Events Associated with Withdrawal

Forty-five patients (20 on reboxetine; 25 on imipramine) had adverse events or intercurrent illnesses as the main reason of withdrawal from the study (Table 69). In addition, on imipramine, 2 patients had adverse events as the main reason for withdrawal but the events (Number 3MD, Centre 35 - urinary tract infection; Number 4MD, Centre 381 - insomnia) were not present at the end of treatment, being recovered in association with symptomatic medication. Therefore, 20 patients on reboxetine (11.4%), and 27 patients on imipramine, (15.8% including the occurred death) had adverse events or intercurrent illnesses as the main reason for withdrawal. The nature of the adverse events is summarised as follows:

Pharmacia

Document 9550089

Adverse Events Associated with Withdrawal - MDD Subpopulation

Treatment	Centre no.-Patient no.	Adverse event	Relationship to study drug
Reboxetine	30-2, 32-5, 35-1	Increased sweating	Possible, Probable, Probable
	5-1, 32-5, 35-1	Dry mouth	Possible, Probable, Probable
	20-3, 46-4	Confusion	Probable, Probable
	30-2, 32-4	Headache	Probable, Probable
	15-111, 5-1	Urinary retention	Doubtful, Possible
	14-1, 32-5	Abdominal pain	Probable, Probable
	5-1, 35-1	Constipation	Possible, Probable
	36-19	Dizziness	Definite
	36-19	Nausea	Definite
	32-4	Insomnia	Probable
	293-12	Urinary hesitancy	Probable
	5-1	Neuropathy	None
	14-1	Anxiety	Probable
	25-1	Extrasystoles	Unknown
	32-4	Somnolence	Probable
	36-13	Hypokalaemia	Possible
	36-13	Arterial thrombosis	None
	381-2	Palpitations	Probable
	46-4	Fracture	Possible
	46-4	Pulmonary carcinoma	None
46-4	Fall	Possible	
Imipramine	6-2, 9-7, 382-10	Dizziness	Probable, Probable, Probable
	16-3, 31-1	Fall	Possible, Probable
	6-2, 382-10	Increased sweating	Probable, Probable
	23-6, 35-2	Constipation	Possible, Possible
	15-2, 3302-6	Paraesthesia	Probable, Doubtful
	31-1, 31-3	Postural hypotension	Probable, Probable
	6-2, 381-4	Insomnia	Possible, Probable
	23-6, 35-3	Urinary tract infection	None, Doubtful
	382-10	Malaise	Probable

Pharmacia

Document 9550089

Adverse Events Associated with Withdrawal - MDD Subpopulation (continued)

Treatment	Centre no.-Patient no.	Adverse event	Relationship to study drug
Imipramine	30-5	Urinary retention	Definite
	9-6	Nausea	Probable
	6-2	Agitation	Probable
	8-3	Coma	None
	8-3	Cerebrovascular disorder	None
	16-3	Fracture	Possible
	9-6	Abdominal pain	Probable
	23-6	Anorexia	Doubtful
	23-6	Paranoid reaction	Probable
	31-3	Tachycardia	Probable
	31-3	Myocardial infarction	Possible
	35-2	Convulsions	Probable
	36-1	Pneumonia	None
	36-12	Confusion	Probable
	382-10	Palpitation	Probable
	382-8	Dyskinesia	Possible
	382-8	Syncope	Possible
	382-8	Somnolence	Possible
	41-1	Headache	Possible
	45-2	Bronchitis	Unknown
291-1	Dry mouth	Definite	

Pharmacia

Document 9550089

Adverse Events Associated with Withdrawal - DYS Subpopulation

Treatment	Centre no.-Patient no.	Adverse event	Relationship to study drug
Reboxetine	5-4, 17-1	Nervousness	Doubtful, Possible
	35-7	Increased sweating	Possible
	17-1	Confusion	Possible
	381-3	Headache	Possible
	36-7	Dizziness	Possible
	36-7	Nausea	Possible
	5-4	Insomnia	Doubtful
	5-5	Hyperkinesia	Unknown
	35-7	Hypoaesthesia	Possible
	35-7	Neuritis	Doubtful
	381-3	Pain	Doubtful
Imipramine	382-7	Dizziness	Definite
	382-7	Fall	Definite
	382-7	Malaise	Definite
	382-7	Ataxia	Definite
	382-7	Fatigue	Probable
	5-10	Urinary retention	Probable
	16-1	Nausea	Possible
	16-3	Hypertension	Doubtful
	291-3	Pruritus	Probable
	36-5	Suicide attempt	None

Further 3 patients in the reboxetine group and 2 in the imipramine group withdrew from the study because of an adverse event/intercurrent illness, without this being a newly emerged adverse event, rather these were adverse events/ intercurrent illnesses present at baseline which persisted without increasing in severity during the treatment period. On reboxetine, Patient 2DT (Centre 42) dropped out due to agitation and insomnia which had already been reported at Day 0 at the same severity; similarly, Patient 9DT (Centre 382) withdrew because of insomnia which had started long before the treatment commenced. The third patient on reboxetine (1MD; Centre 3301) withdrew for suspected multiple myeloma which emerged from laboratory abnormalities noted at admission; the diagnosis was not confirmed by bone marrow analysis. On imipramine, Patient 2MD (Centre 46) dropped out due to lassitude which had already been present at Day 0, and Patient 7MD (Centre 35) withdrew due to a hysterectomy which had already been planned for the treatment of an endometrium carcinoma present at admission.

On the whole, general cardiovascular disorders contributed to the withdrawal of 9 patients on imipramine and 5 on reboxetine and autonomic nervous system disorders to the withdrawal of 3 patients on imipramine and 5 on reboxetine.

8.3 Laboratory Tests

8.3.1 SUMMARY STATISTICS OF LABORATORY VALUES

As shown in Table 70, in the reboxetine group, compared to baseline, there was a significant ($p < 0.01$) increase, after 4 and 8 weeks of treatment, in haemoglobin (median difference 0.10 g/dl and 0.18 g/dl) and platelets (median difference $13.57 \times 10^3/\text{mm}^3$ and $12.14 \times 10^3/\text{mm}^3$). In addition, there was a significant increase in alkaline phosphatase (median difference 4.47 U/l) after 8 weeks of treatment and in serum phosphate after 4 weeks of treatment (median difference 0.05 mEq/l). There was a significant decrease after 4 and 8 weeks of treatment in serum sodium (median difference -1.00 mEq/l and -0.91 mEq/l).

Similarly, in the imipramine group, compared to baseline, there was a significant increase, after 4 weeks of treatment, in erythrocytation rate (first hour and second hour) (median difference 1.50 mm/h and 2.50 mm/h). In addition, there was a significant increase in alkaline phosphatase (median difference 5.31 U/l and 8.15 U/l) after 4 and 8 weeks of treatment. Blood triglycerides and serum phosphate significantly increased (median difference 5.02 mg/dl and 0.05 mEq/l) after 8 weeks of treatment. Serum sodium and chloride significantly decreased after 4 weeks of treatment (median difference -1.00 mEq/l and -0.80 mEq/l).

8.3.2 URINALYSIS

Frequency of abnormal findings at baseline and during the treatment period or at last assessment are shown in Tables 71 and 72, respectively. No indication of increased frequencies of abnormal findings as compared to baseline emerges. In fact, there is no indication of increased proportions of patients shifted from baseline to presence of albumin, sugar, WBC and RBC compared to baseline both at the various assessment intervals (Table 73) and at last available assessment (Table 74). The same consideration holds for specific gravity (Tables 75 and 76).

8.3.3 ABNORMAL LABORATORY VALUES

The number and percentage of patients shifted from values within, below or above the normal range to values within, below or above the latter are given by period in Table 77. There were no statistically significant shifts ($p < 0.01$) in the distribution of the frequencies (either towards the higher or lower values) in the reboxetine group. In the imipramine group a statistically significant shift in the distribution of the frequencies toward lower values was found for serum sodium after 4 weeks of treatment and toward higher values for triglycerides after 8 weeks of treatment ($p < 0.01$; Maxwell's test).

8.3.4 ABNORMAL LABORATORY VALUES OF CLINICAL RELEVANCE

The distribution pattern of patients with clinically relevant abnormal values is given by variable and period of treatment in Table 78. Frequency of clinically relevant abnormal values was similarly low in the two treatment groups over the study period; no significantly increased frequency over baseline was present for any of the variables measured in the reboxetine and imipramine patient groups.

8.4 Vital Signs

8.4.1 BLOOD PRESSURE AND HEART RATE

Summary statistics of blood pressure and heart rate values and changes vs baseline at each visit during the study are presented in Tables 79 to 83. There were no important trends apparent in mean and median blood pressure and heart rate values and changes during the study.

The absolute and per cent frequency of patients showing at each visit a modification of 20% or more vs baseline is given in Table 81, while the frequency of patients showing such a modification accompanied by absolute critical values (≥ 160 or ≤ 100 mm Hg for systolic blood pressure; ≥ 100 or ≤ 70 mm Hg for diastolic blood pressure; ≥ 100 or ≤ 50 beats/min for heart rate) once, twice or more times is given in Table 82.

As shown in Table 81, as for the lying and standing systolic blood pressure, the proportion of patients showing a decrease was higher than those showing the opposite, the maximal difference being observed in standing position mainly on imipramine (3-10% vs 2-6% on reboxetine). As for the lying and standing diastolic blood pressure, the proportion of patients showing a decrease was similar to the proportion of patients showing an increase and this was observed in both treatment groups.

As shown in Table 82, the main difference between reboxetine and imipramine was observed in the absolute frequency of clinically relevant decrease, associated with the above described critical values, of diastolic blood pressure which was higher on imipramine than on reboxetine on standing (38 vs 22 cases, representing 22% and 13% of evaluated patients, respectively). In addition, the frequency of relevant decrease of both systolic and diastolic blood pressure on standing, was higher on imipramine than on reboxetine (10 vs 4 cases, respectively).

The frequency of relevant increase of systolic and diastolic blood pressure was similar in the two treatment groups; however, the maximal difference between reboxetine and imipramine was seen in the frequency of diastolic blood pressure increase, slightly higher in the reboxetine group in lying position (22 vs 11 cases, representing 13% and 7% of evaluated patients, respectively). The vast majority of relevant decreases and increases occurred occasionally (reported once).

As for the lying and standing heart rate, in both treatment groups the proportion of patients showing a decrease of possible clinical relevance was lower than the proportion of patients showing an increase. A similar proportion of patients with at least 20% increased values was observed during treatment in the reboxetine (5%-12% of patients) and imipramine groups (2%-10%) (Table 81).

As reported in Table 82, the absolute frequency of clinically relevant increase of heart rate, associated with values ≥ 100 beats/min, was higher in the reboxetine than in the imipramine group, the maximal difference being observed on standing (19 vs 10 cases, representing 12% and 6% of evaluated patients, respectively). The majority of those relevant increases occurred occasionally (reported once).

The number and percentage of patients with orthostatic hypotension at each visit is presented in Table 83. At baseline the event was present in 12 patients (7.1%) in the reboxetine group and 2 patients (1.2%) in the imipramine group. Subsequently, in the reboxetine group, the event had a frequency lower than baseline at all visits, affecting a maximum of 5.0% of patients on Day 14. In the imipramine group, the event affected a maximum of 6.5% of the patients on Day 7.

8.4.2 BODY WEIGHT

Summary statistics of the body weight values (Kg) at the various assessment intervals are given in Table 84, while the absolute and per cent frequency of patients showing higher (> 2.5 Kg), lower (< 2.5 Kg) or similar values vs baseline at the various assessment intervals is given in Table 85. No trends toward modification were apparent in the reboxetine and imipramine groups.

8.5 Electrocardiogram

As shown in Table 86, 290 patients had their ECG recorded at baseline, 29% of whom showed at least one ECG abnormality (29% reboxetine and 30% imipramine). During the study, 281 patients had their ECG recorded within the first 4 weeks of treatment (Days 1 to 28), and 245 within the next 4 weeks of treatment (Days 29 to 56). In the reboxetine group, 31% and 33% of the evaluated patients had at least one ECG abnormality recorded within the first 4 weeks and the next 4 weeks of treatment, respectively. The equivalent proportions in the imipramine group were 28% and 23%, respectively. As shown in Table 87, during the study, the frequency of normalisation of ECG recordings in patients with at least one abnormality at entry was always higher than the frequency of at least one newly emerged abnormality in patients with normal tracing at baseline in both treatment groups. At last assessment of the study (Table 88), of the 85 patients (43 reboxetine and 42 imipramine) who had had at least one abnormality at baseline, 16.3% on reboxetine and 40.5% on imipramine were reported as normal. Among the 205 patients (105 reboxetine and 100 imipramine) with normal tracings at baseline, 16.2% on reboxetine and 12.0% on imipramine showed at least one abnormality at last assessment.

The frequency of individual abnormalities at admission and during the study is shown by treatment group in Table 89. At screening, individual abnormalities are present in a maximum of 6.1% (sinus bradycardia, < 60 beats/min) of the 148 evaluated cases of the reboxetine and in 4.2% (left ventricular hypertrophy) of the 142 evaluated cases in the imipramine group. During treatment, the frequencies of all observed abnormalities were not modified to any significant extent in either treatment group. As shown in Table 90, at last assessment, for all abnormalities and both treatment groups, the proportion of newly observed cases among normal baseline cases is lower than the proportion of normalised cases among abnormal baseline cases. Newly emerged abnormalities occurred with a slightly higher frequency in the reboxetine compared with the imipramine group; the most common of these were sinus tachycardia (8 reboxetine and 5 imipramine cases), occasional ventricular ectopic beats (5 imipramine and 3 reboxetine cases) and left anterior hemiblock (6 reboxetine cases).

The frequencies of randomised patients with at least one abnormality by abnormality group during the study is shown in Table 91 and at last assessment in Table 92. At screening, from 6.8% (ischaemic signs) to 13.5% (rhythm disorders) of the evaluated patients in the reboxetine group and 4.9% (ischaemic signs) to 12.0% (rhythm disorders) in the imipramine group showed at least one abnormality of the indicated groups. During treatment, the frequencies were not modified to any significant extent in any of the treatment groups. As shown in Table 92, newly emerged abnormalities were related to rhythm disorders (11.7% and 6.4% of the patients with normal tracings for this disorder at baseline in the reboxetine and imipramine groups, respectively), conduction disorders (6.0% and 3.9%, respectively), ischemic signs (4.3% and 3.0%, respectively) or other disorders (2.2% of the patients in the reboxetine group). However, in all cases, the proportion of patients with newly emerged abnormalities was consistently lower than the proportion of normalised cases.

8.6 Safety Conclusions

All the 347 patients who received study treatment were included in the safety analysis (176 reboxetine, 171 imipramine).

The relative chance of developing at least one adverse event, adjusted by diagnosis, was similar in the two treatment groups. Overall, no statistical difference was found in the subpopulations, though in the MDD subgroup the chance of developing at least one adverse event was slightly higher on imipramine than on reboxetine and in the DYS subpopulation this probability was slightly higher on reboxetine than on imipramine. Insomnia was the only event more frequently reported on reboxetine than on imipramine [6.3% vs 2.9%; OR = 2.25 (95% CI, 0.78 ÷ 6.51)]. Hypotension and related symptoms were more frequently reported on imipramine than on reboxetine (15.8% vs 7.4%) and the odds ratio [OR = 0.43 (95% CI, 0.21 ÷ 0.85)] indicates that the chance of developing them was higher on imipramine than on reboxetine.

The occurrence of newly reported adverse events was similar in all groups during the study; 120/176 reboxetine group patients reported 307 adverse events compared with 122/171 imipramine patients who reported 338 adverse events. However, patients diagnosed as having Major Depressive Episode/Disorder (DSM-III-R 296.2 and 296.3) complained of adverse events somewhat more frequently on imipramine (73.4%) than on reboxetine (66.1%), while patients diagnosed as having Dysthymia (DSM-III-R 300.4) complained of adverse events slightly more frequently on reboxetine (71.6%) than on imipramine (67.7%). The prevalence of adverse events was slightly higher on imipramine than on reboxetine and this difference was more evident in the MDD subpopulation, while in the DYS subgroup the prevalence of adverse events was higher on reboxetine than on imipramine during the initial 4 weeks of treatment. Discontinuation due to newly emerged adverse events was more frequent on imipramine (15.8%) than on reboxetine (11.4%), mainly in the MDD subgroup of patients (19.3% vs 12.8%, respectively). On the whole, the frequency of the events often reported under antidepressant medication, was very similar in the reboxetine and imipramine group and only hypotension and related symptoms showed a risk of development significantly higher on imipramine than on reboxetine. This latter difference was confirmed in the MDD subpopulation but not in the DYS subgroup of patients.

Patients on imipramine suffered from newly emerged cardiovascular adverse events and, in particular, of hypotension and related symptoms, more frequently when affected by cardiovascular disorders at baseline (26% and 21%, respectively) than when not affected (17% and 12%, respectively), while on reboxetine the presence of cardiovascular disorders at baseline seemed not to facilitate the emergence of cardiovascular adverse events, in particular of hypotension and related symptoms. The differences in favour of reboxetine are mainly evident in the population with cardiovascular disorders present at admission (12% vs 26% for cardiovascular adverse events and 5% vs 21% for hypotension and related symptoms).

Moderate or severe adverse events were more frequent on imipramine than on reboxetine (73% vs 65%). Males and females suffered from adverse events with similar frequency on reboxetine and on imipramine. The most relevant between-gender difference was related to the frequency of hypotension and related symptoms and urinary hesitancy/retention (complained of mainly by male patients in both treatment groups); increased sweating (complained of mainly by female patients in both treatment groups); and dry mouth (complained of mainly by female patients on reboxetine).

One patient died (suicide) during the study period and three died (bronchopneumonia, pulmonary edema and apoplexy) 12, 6 and 11 days, respectively, after the end of the treatment period. All deaths were on imipramine. In addition, 12 serious adverse events were reported. Two patients suffered from serious adverse events on reboxetine and 9 patients on imipramine, one of them suffering from two serious adverse events. On reboxetine, the two cases were: meningioma and acute confusional state and fall. On imipramine, 4 cases concerned cardiovascular disorders: postural hypotension, sudden

Pharmacia

Document 9550089

faint, atrial fibrillation and right bundle branch block and A-V block first degree; in all cases patients were affected by relevant cardiovascular disorders at anamnesis. The other cases concerned: 2 cases of fracture of the neck of the femur, one of them following from a fall; fall and fracture of the knee; a convulsive episode; drowsy and jerky movements in legs and urinary retention.

There was no indication of modifications in laboratory tests that were of clinical significance.

As for vital signs, major differences between reboxetine and imipramine were observed in the absolute frequency of clinically relevant decrease of diastolic blood pressure, higher on imipramine than on reboxetine on standing (22% and 13% of evaluated patients, respectively) and in the frequency of relevant increase of diastolic blood pressure, slightly higher in the reboxetine group on lying (13% and 7% of evaluated patients, respectively). The vast majority of relevant decreases and increases were reported once during the study.

The absolute frequency of heart rate, increased during treatment to values ≥ 100 beats/min, was slightly higher in the reboxetine than in the imipramine group and the maximal difference was observed on standing (12% and 6% of evaluated patients, respectively). However, the majority of these relevant increases occurred occasionally (reported once).

As for ECG recordings, newly emerged abnormalities were related to rhythm disorders (11.7% and 6.4% of the patients with normal tracings for this disorder at baseline in the reboxetine and imipramine groups, respectively), conduction disorders (6.0% and 3.9%, respectively), ischemic signs (4.3% and 3.0%, respectively) or other disorders (2.2% of the patients in the reboxetine group). However, in all cases, the proportion of patients with newly emerged abnormalities was consistently lower than the proportion of normalised cases.

9. DISCUSSION

Three hundred and forty-seven elderly patients suffering from Depressive Disorders entered the study, 176 patients received reboxetine, and 171 imipramine. Of the 347 patients, 218 (109 reboxetine, 109 imipramine) were randomised to the MDD stratum and 129 (67 reboxetine, 62 imipramine) to the DYS stratum. A total of 253 patients (72.9%) completed the study and 94 (27.1%) withdrew, 49 (27.8%) of the reboxetine group patients and 45 (26.3%) of the imipramine group patients, respectively. In the MDD subpopulation the proportion of patients withdrawing was slightly higher in the imipramine group (35.8%) than in the reboxetine group (30.3%). In the DYS subpopulation the proportion of withdrawing was higher in the reboxetine group (23.9%) than in the imipramine group (9.7%). Newly emerged adverse events or intercurrent illnesses were the main reason for discontinuation in 20 (11.4%) of the reboxetine and 27 (15.8%) of the imipramine patients. In the MDD subgroup these proportions were 12.8% (reboxetine) and 19.3% (imipramine) and in the DYS subgroup they were 9.0% (reboxetine) and 9.7% (imipramine).

The mean HAMD total score was reduced from 26.6 at Day 0 to 14.8 at last assessment in the 172 patients treated with reboxetine who had at least one assessment in addition to the baseline and to 11.4 at Day 56 in the 127 patients who completed the study. In the 168 patients who were treated with imipramine with at least one assessment in addition to baseline the mean HAMD total score was reduced from 26.1 at Day 0 to 12.9 at last assessment and to 8.8 at Day 56 in the 126 patients who completed the study. The difference between the two treatments in the mean HAMD decrease, at last assessment, was not clinically relevant (-1.5 points; 95% CI, -3.6 ÷ 0.6 points). However, in the DYS subpopulation, the difference between the two treatments in the mean HAMD decrease was clearly in favour of imipramine, being of -3.4 points (95% CI, -6.5 ÷ -0.2 points).

At last assessment, 54.1% of the reboxetine-treated patients and 56.5% of the imipramine-treated patients were classified as responders, while 42.4% and 49.4%, respectively, were seen to be in remission. A similar pattern of response and remission rate was observed in the MDD subpopulation, whilst there was a higher proportion of patients classified as responders and in remission on imipramine than on reboxetine in the DYS subpopulation.

At last assessment, on the whole population, the percentage of patients who were 'much to very much improved' (CGI - Global Improvement) was similar in both groups (56.9% in the reboxetine group and 59.4% in the imipramine group) and the between treatment difference was -2.5% (95% CI, -12.9% ÷ 7.9%). In the MDD subgroup, the proportion of 'much to very much improved' patients at last assessment was slightly higher on reboxetine than on imipramine (58.9% vs 52.3%) and the between treatment difference was 6.6% (95% CI, -6.0% ÷ 19.8%). On the contrary, in the DYS subpopulation, the proportion of 'much to very much improved' patients was in favour of imipramine

(72.1% vs 53.7% on reboxetine) being the between treatment difference -18.4% (95% CI, -34.8% ÷ -2.0%). Similarly, the proportion of cases with moderate to marked efficacy in absence of side-effects (CGI - Efficacy Index: 3 to 4) was slightly higher on reboxetine (40.2%) than on imipramine (34.9%) in the MDD subpopulation, while in the DYS subgroup this condition was reported in 52.5% of the patients on imipramine vs 38.8% of those on reboxetine.

The mean total MADRS score was reduced from 29.7 at Day 0 to 15.5 at last assessment in the 171 reboxetine group patients who had at least one assessment in addition to baseline, and to 11.7 in the 128 patients who had the assessment at Day 56. In patients treated with imipramine, values changed from 30.0 at Day 0 to 14.0 at last assessment (168 patients), and to 8.9 at Day 56 (126 assessed patients). Also for this rating scale a slightly higher reduction of the total score was observed on imipramine (from 27.9 to 9.8) than on reboxetine (from 28.0 to 14.6) in the DYS subpopulation.

The mean total GDS score was reduced from 23.1 at Day 0 to 14.0 at last assessment in the 172 reboxetine group patients with at least one assessment in addition to baseline, and to 11.4 in the 128 reboxetine patients who had the assessment at Day 56. In patients treated with imipramine, values changed from 23.4 at Day 0 to 12.9 at last assessment (168 patients), and to 9.2 at Day 56 (125 assessed patients). As above, in the DYS subpopulation the reduction of the total score at last assessment was slightly higher on imipramine (from 22.9 to 9.9) than on reboxetine (from 23.0 to 13.6).

In conclusion, therefore, while the results of the global analysis of efficacy assessments could not evidenciate differences of any relevance between the two treatments in terms of outcome, the results of the additional analyses on the MDD and DYS subpopulations indicate that both treatments were similarly effective in terms of improvement of the clinical picture in patients diagnosed as having a Major Depressive Episode/Disorder, while in dysthymic patients imipramine resulted more effective than reboxetine in terms of frequency and extent of improvement.

The analysis of the 17 specific items of the HAMD scale reported at baseline in the remission and non remission cases, showed that, as expected, the proportion of patients eventually in remission was higher among the less severe cases at baseline for the vast majority of items. For few items, however, the frequency of patients eventually in remission among severely ill patients (maximum score level) at baseline was particularly low in both treatment groups. This was the case for Insomnia Middle and Agitation and, mainly in the reboxetine group, for Hypochondriasis. In all cases, the prevalence of severely ill patients at baseline was higher in the reboxetine than in the imipramine group. These results are consistently present in the two subpopulations. However, extreme differences are apparent in the DYS subgroup of patients either in both treatment groups for Insomnia Middle and Agitation or, mainly in reboxetine group, for Hypochondriasis (5% of the severe patients at baseline eventually in remission vs 95% not in remission). In this latter case, severely ill patients at baseline were twice as frequent in the reboxetine

group (28.4%) than in the imipramine group (14.5%). These findings suggest that imbalances in the severity of the two treatment groups at baseline for few dimensions of the psychopathology, mainly related to the somatic component, more than a diagnostic specificity could explain the differences observed in the two subpopulations. In fact, a diagnostic specificity could hardly be taken into consideration in view of the known heterogeneity of the disorders subsumed in the DSM-III-R classification of Dysthymia [29].

All 347 patients who received study treatment were included in the safety analysis. The occurrence of newly reported adverse events was similar in both groups during the study; 120/176 (68.2%) reboxetine group patients reported 307 adverse events compared with 122/171 (71.3%) imipramine patients who reported 338 adverse events; however, the prevalence of adverse events was higher in the imipramine group than in the reboxetine group, with this difference being more evident in the MDD subpopulation. In the DYS subgroup, the prevalence of adverse events was higher in the reboxetine group than in the imipramine group during the initial 4 weeks of treatment. Discontinuation due to a newly emerged adverse event was more frequent on imipramine (15.8%) than on reboxetine (11.4%), mainly occurring in the MDD subgroup of patients (19.3% imipramine; 12.8% reboxetine).

The relative chance of developing at least one adverse event was not different in the two treatment groups [OR = 0.86 (95% CI, 0.55 ÷ 1.36)]; however, in the MDD subgroup of patients, the frequency of patients complaining of at least one adverse event was slightly higher in the imipramine than in the reboxetine group [OR = 0.70 (95% CI, 0.39 ÷ 1.26)], whilst in the DYS subgroup the frequency was slightly higher in reboxetine group [OR = 1.20 (95% CI, 0.57 ÷ 2.55)]. On the whole, the frequency of the events often reported under antidepressant medication was very similar in the reboxetine and imipramine groups, with only hypotension and related symptoms showing a cumulative risk of development significantly higher on imipramine than on reboxetine. This latter result was confirmed in the MDD subpopulation and not in the DYS subgroup.

In view of the small size of the Dysthymia sample (67 and 62 patients on reboxetine and imipramine), and of the contrasting results of other studies where both MDD and DYS non-elderly [30] or elderly [31] patients were included, not confirming a different frequency of adverse events on reboxetine in the two diagnostic subpopulations, any conclusion about a possible different proneness to adverse events on reboxetine of the two diagnostic subgroups seems hardly proposable. On the contrary, the greater prevalence in the reboxetine group of severely ill patients for few dimensions of the psychopathology, mainly related to the somatic component, as discussed above, should be considered in the interpretation of the findings.

In patients with or without cardiovascular disorders at admission, the frequency of cardiovascular adverse events was higher on imipramine than on reboxetine. However,

while on reboxetine the presence of cardiovascular disorders at baseline seemed not to facilitate the emergence of cardiovascular adverse events, in particular of hypotension and related symptoms, patients on imipramine suffered from newly emerged cardiovascular adverse events and, in particular, of hypotension and related symptoms, more frequently when affected by cardiovascular disorders at baseline (26% and 21%, respectively) than when not affected (17% and 12%, respectively). The differences in favour of reboxetine are mainly evident in the former population (12% vs 26% for cardiovascular adverse events and 5% vs 21% for hypotension and related symptoms).

Moderate or severe adverse events were more frequent on imipramine than on reboxetine (73% vs 65%). Males and females suffered from adverse events with similar frequency on reboxetine and on imipramine. The most relevant between-gender differences were related to the frequency of dry mouth, complained of mainly by female patients on reboxetine, increased sweating, complained of mainly by female patients in both treatment groups, hypotension and related symptoms and urinary hesitancy/retention, complained of mainly by male patients particularly on imipramine but also on reboxetine. The proportion of patients complaining of at least one adverse event with probable to definite relationship was higher on imipramine (43%) than on reboxetine (33%).

One patient died (suicide) during the study period and 3 further patients died few days after the end of the study (bronchopneumonia, pulmonary edema and apoplexy). All deaths were on imipramine. In addition, 12 serious adverse events were reported, 2 on reboxetine (meningioma, acute confusional state and fall) and 10 on imipramine (postural hypotension, sudden faint, atrial fibrillation, right bundle branch block and A-V block first degree, 2 cases of fracture of the neck of the femur, fall and fracture of the knee, convulsive episode, drowsy and jerky movements in legs and urinary retention).

There was no indication of modifications in laboratory tests that were of clinical significance. As for vital signs, major differences between reboxetine and imipramine were observed in the absolute frequency of clinically relevant decrease of diastolic blood pressure, higher on imipramine than on reboxetine on standing (22% and 13% of evaluated patients, respectively) and in the frequency of relevant increase of diastolic blood pressure, slightly higher in the reboxetine group on lying (13% and 7% of evaluated patients, respectively). The vast majority of relevant decreases and increases were reported once during the study. Lying and standing heart rate increased during treatment to values ≥ 100 beats/min in a slightly higher proportion of patients on reboxetine than on imipramine particularly on standing (12% vs 6%). However, the majority of these relevant increases occurred occasionally (reported once).

Newly emerged abnormalities in ECG recordings were mainly related to rhythm disorders (12% and 6% of patients with normal tracing for this disorder at baseline in reboxetine and imipramine group, respectively) and conduction disorders (6% and 4%, respectively).

10. CONCLUSION

The efficacy of reboxetine therapy in elderly patients suffering from Depressive Disorders, as evaluated by the improvement of HAMD, CGI, MADRS and GDS scales, appeared not different to that of imipramine. This was particularly the case in the MDD subpopulation, while in the DYS subgroup imipramine was slightly more effective than reboxetine. This finding could be connected with imbalances between the two treatment groups at baseline for the somatic component of the psychopathology, more severe in the reboxetine group, rather than with a diagnostic specificity. The overall tolerability of reboxetine was highly acceptable, as shown in the minimal modification of vital signs, haematology and blood chemistry tests, and ECG examinations. The overall frequency of adverse events was similar on reboxetine and imipramine, thus not allowing the rejection of the hypothesis of equal tolerability of reboxetine and imipramine as stated in the study protocol. However, the frequency of moderate to severe adverse events and of serious adverse events, the prevalence of adverse events during the treatment period and the discontinuation rate in view of adverse events was higher on imipramine than on reboxetine. In addition, the rate of occurrence of cardiovascular disorders, in particular hypotension and related symptoms, was significantly lower on reboxetine than on imipramine.

11. REFERENCES

1. Reboxetine Investigator's Brochure, Farmitalia Carlo Erba, CNS Line, July 1988.
2. Herrman WM, Schneider J, Boden S, Wagner W, Rohmel J, Grunmach J. Safety and tolerance of reboxetine in healthy male volunteers - A single rising dose tolerance study. Pharmacia Internal Report FCE 20124/602i, June 1984.
3. Herrman WM, Schneider J, Irrgang U, Rosener B, Willman J, Rohmel J, et al. Reboxetine - Quantitative pharmaco-EEG and pharmaco-psychological study. Pharmacia Internal Report FCE 20124/603i, January 1985.
4. Dubini A, Goldaniga GC, Montesanti L, Savoia L, Tamassia V, Vicario GP. Disposition and fate of ¹⁴C-reboxetine administered orally to healthy volunteers. Pharmacia Internal Report FCE 20124/604i, March 1985.
5. Dubini A, Ban T. Open dose range finding study in patients hospitalised for Major Depressive Disorders. Pharmacia Internal Report FCE 20124/701i, April 1989.
6. Dubini A, Ban T, Morey LC. Phase II controlled study of the activity and tolerability of reboxetine in comparison with placebo and desipramine in patients hospitalised for Major Depressive Disorders. Pharmacia Internal Report FCE 20124/702i, February 1991.
7. Dubini A, Andreoli V, Carbognin G. Open dose-range findings efficacy, tolerability (and pharmacokinetics) of reboxetine in elderly patients suffering from Depressive Disorders. Pharmacia Internal Report FCE 20124/703i CL, January 1994.
8. Gerner R, Estabrook W, Steuer J, Jarvik L. Treatment of Geriatric Depression with Trazodone, Imipramine, and Placebo: A Double-Blind Study. J Clin Psychiatry 1980; 41:216-220.
9. Merideth CH, Feighner JP, Hendrickson G. A Double-Blind Comparative Evaluation of Efficacy and Safety of Nomifensine, Imipramine, and Placebo in Depressed Geriatric Outpatients. J Clin Psychiatry 1984; 45: 73-77.
10. American Psychiatric Association. Mood disorders. In: Diagnostic and Statistical Manual of Mental Disorders. Third edition revised, American Psychiatric Association, Washington DC, 1987.
11. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
12. Tofranil. In: Physicians' Desk Reference (PDR). 43 edition, Medical Economics Company Inc, Oradell, NJ, 1989.

13. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration. Rockville, Maryland: 1976.
14. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. *Br J Psychiatry* 1979; 134: 382-389.
15. Asberg M, Montgomery SA, Perris C, Schalling D, Sedvall G. A comprehensive psychopathological psychiatric rating scale (CPRS). *Acta Psychiatrica Scand (Suppl)* 1978; 271: 5-27.
16. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M et al. Development and validation of a geriatric depression screening scale: a preliminary report. *J Psychiatr Res* 1983; 17: 37-49.
17. O'Brien PC, Fleming TR. A Multiple Testing Procedure for Clinical Trials. *Biometrics* 1979; 35: 549-556.
18. Gill JL. *Design and Analysis of Experiments in the Animal and Medical Sciences*. Ames, Iowa, USA: The Iowa State University Press, 1978: 53-56.
19. Peace KE. *Biopharmaceutical Statistics for Drug Development*. New York: Marcel Dekker, Inc, 1988: 478.
20. Breslow NE, Day NE. *Statistical Methods in Cancer Research*. Lyon: World Health Organization, 1980; 1: 122-159.
21. Fleiss JL. *Statistical Methods for Rates and Proportions*. New York: John Wiley & Sons, 1973: 72-80.
22. Chuang-Stein C. Summarizing laboratory data with different reference ranges in multi-center clinical trials. *Drug Information Journal* 1992; 26: 77-84.
23. Wyngaarden JB, Smith LH, Bennett JC, Editors. *Cecil Textbook of Medicine*. Philadelphia: Saunders, 1988.
24. Kalbfleisch JD, Prentice RL. *The Statistical Analysis of Failure Time Data*. New York: John Wiley & Sons, 1980: 16-19.
25. Collaborating Center for International Drug Monitoring. *Manual of the international statistical classification of diseases, injuries, and causes of death*. Geneva: World Health Organization, 1977.
26. Collaborating Center for International Drug Monitoring. *Drug Reference List*. Geneva: World Health Organization, 1989.

Pharmacia

Document 9550089

27. Guideline for ATC Classification. NORDIC Statistics on Medicine, NORDIC Council on Medicine Box 607, S-751 25 Uppsala, Sweden 1985.
28. Collaborating Center for International Drug Monitoring. Adverse Reactions Terminology. International monitoring of adverse reactions to drugs. Geneva: World Health Organization, 1989.
29. Kocsis JH. Treatment of Dysthymia - Overview of therapy options. Focus on Depression 1993; 4: 59-61.
30. Dubini A, Di Nicolò P, Petroccione A, Gaussares C, Jakovlievic M, Svestka J et al. Multicentre, multinational, uncontrolled study of the activity and tolerability of reboxetine in the continuation therapy of Depressive Disorders. Pharmacia Internal Report 9550086, December 1995.
31. Dubini A, Di Nicolò P, Petroccione A, Jakovlievic M, Aguglia E. Multicentre, multinational, open study of the activity and tolerability of reboxetine in the continuation therapy of Depressive Disorders in elderly patients. Preliminary analysis. Pharmacia Internal Report 9550088, January 1996.

Pharmacia

Document 9550089

TABLES

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No. : 1
NUMBER OF PATIENTS BY CENTRE, VISIT AND TREATMENT

104

Centre/Assigned treatment	Screen	Visit													
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56					
16	Reboxetine	3	3	3	3	3	3	3	3	3	3	3	3	3	3
17	Imipramine	4	4	4	4	4	4	4	4	4	4	4	4	4	4
18	Reboxetine	6	6	6	6	6	6	6	6	6	6	6	6	6	6
	Imipramine	3	3	3	3	3	3	3	3	3	3	3	3	3	3
	Reboxetine	3	3	3	3	3	3	3	3	3	3	3	3	3	3
20	Reboxetine	1	1	1	1	1	1	1	1	1	1	1	1	1	1
22	Reboxetine	1	1	1	1	1	1	1	1	1	1	1	1	1	1
23	Imipramine	4	4	4	4	4	4	4	4	4	4	4	4	4	4
	Reboxetine	2	2	2	2	2	2	2	2	2	2	2	2	2	2
25	Imipramine	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Reboxetine	1	1	1	1	1	1	1	1	1	1	1	1	1	1
26	Imipramine	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Reboxetine	1	1	1	1	1	1	1	1	1	1	1	1	1	1
27	Imipramine	1	1	1	1	1	1	1	1	1	1	1	1	1	1
28	Imipramine	4	4	4	4	4	4	4	4	4	4	4	4	4	4
	Reboxetine	4	4	4	4	4	4	4	4	4	4	4	4	4	4
30	Imipramine	3	3	3	3	3	3	3	3	3	3	3	3	3	3
	Reboxetine	2	2	2	2	2	2	2	2	2	2	2	2	2	2
31	Imipramine	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	Reboxetine	2	2	2	2	2	2	2	2	2	2	2	2	2	2
32	Imipramine	3	3	3	3	3	3	3	3	3	3	3	3	3	3
	Reboxetine	3	3	3	3	3	3	3	3	3	3	3	3	3	3
35	Imipramine	8	8	8	8	8	8	8	8	8	8	8	8	8	8
	Reboxetine	8	8	8	8	8	8	8	8	8	8	8	8	8	8

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 1

105

NUMBER OF PATIENTS BY CENTRE, VISIT AND TREATMENT

Centre/Assigned treatment	Visit															
	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	Day 70	Day 77	Day 84	Day 91	Day 98
36		16	16	15	14	14	14	14	14	14	14	14	14	14	14	14
	Imipramine															
	Reboxetine	16	16	14	13	12	11	11	10	10						
37		1	1													
	Reboxetine															
	Imipramine	2	2	1	1	1	1	1	1	1						
41		3	3	3	3	3	3	3	3	3						
	Reboxetine															
	Imipramine	3	3	3	3	3	3	3	3	3						
42		2	2	1	1	1	1	1	1	1						
	Reboxetine															
	Imipramine	2	2	1	1	1	1	1	1	1						
43		4	4	4	4	4	4	4	4	4						
	Imipramine															
	Reboxetine	2	2	2	2	2	2	2	2	2						
44		2	2	2	2	2	2	2	2	2						
	Imipramine															
	Reboxetine	2	2	2	2	2	2	2	2	2						
45		3	3	3	3	3	3	3	3	3						
	Imipramine															
	Reboxetine	2	2	2	2	2	2	2	2	2						
46		1	1	1	1	1	1	1	1	1						
	Imipramine															
	Reboxetine	1	1	1	1	1	1	1	1	1						
48		2	2	2	2	2	2	2	2	2						
	Imipramine															
	Reboxetine	2	2	2	2	2	2	2	2	2						
291		2	2	2	2	2	2	2	2	2						
	Imipramine															
	Reboxetine	1	1	1	1	1	1	1	1	1						
292		6	6	6	6	6	6	6	6	6						
	Imipramine															
	Reboxetine	6	6	6	6	6	6	6	6	6						
293		8	8	8	8	8	8	8	8	8						
	Imipramine															
	Reboxetine	8	8	8	8	8	8	8	8	8						
294		4	4	4	4	4	4	4	4	4						
	Imipramine															
	Reboxetine	4	4	4	4	4	4	4	4	4						
295		4	4	4	4	4	4	4	4	4						
	Imipramine															
	Reboxetine	4	4	4	4	4	4	4	4	4						
296		8	8	8	8	8	8	8	8	8						
	Imipramine															
	Reboxetine	8	8	8	8	8	8	8	8	8						

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No. 1 2
 PATIENT DISPOSITION

	Treatment assigned						Total	
	Imipramine			Reboxetine				
	No.	Z	%	No.	Z	%	No.	Z
Major Depressive Disorder	Screened	109	100.00	109	100.00	218	100.00	
	Exposed	109	100.00	109	100.00	218	100.00	
	Completed	70	64.22	76	69.72	146	66.97	
	Dropped	39	35.78	33	30.28	72	33.03	
Dysthymia	Screened	62	100.00	67	100.00	129	100.00	
	Exposed	62	100.00	67	100.00	129	100.00	
	Completed	56	90.32	51	76.12	107	82.95	
	Dropped	6	9.68	16	23.88	22	17.05	
Total	Screened	171	100.00	176	100.00	347	100.00	
	Exposed	171	100.00	176	100.00	347	100.00	
	Completed	126	73.68	127	72.16	253	72.91	
	Dropped	45	26.32	49	27.84	94	27.09	

PHARMACIA CNS 550089

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 3

END OF STUDY: REASONS FOR DISCONTINUATION AND VISIT AT WHICH DISCONTINUATION OCCURRED, BY ASSIGNED TREATMENT

Diagnosis: Total

Assigned treatment / Reasons		Total		Last visit															
				Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56	
		No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%
Inipramine	ADVERSE EVENT (*)	28	100	11	39.3	7	25.0	4	14.3			3	10.7	1	3.6	1	3.6	1	3.6
	DEATH	1	100	1	100														
	PROTOCOL VIOLATION	1	100			1	100												
	LOST TO FOLLOW UP	1	100			1	100												
	DETERIORATION	10	100	1	10.0	2	20.0	1	10.0	2	20.0	3	30.0	1	10.0				
	PATIENT UNCOOPERATIVE	3	100			1	33.3					1	33.3			1	33.3		
	OTHER	1	100						1	100									
	Total	45	100	13	28.9	12	26.7	5	11.1	3	6.7	7	15.6	2	4.4	2	4.4	1	2.2
Reboxetine	ADVERSE EVENT (*)	23	100	6	26.1	2	8.7	5	21.7	6	26.1	3	13.0	1	4.3				
	PROTOCOL VIOLATION	1	100	1	100														
	LOST TO FOLLOW UP	3	100					1	33.3	1	33.3							1	33.3
	DETERIORATION	10	100	1	10.0			1	10.0	2	20.0	3	30.0	2	20.0	1	10.0		
	PATIENT UNCOOPERATIVE	12	100	3	25.0	2	16.7	2	16.7					2	16.7	2	16.7	1	8.3
	OTHER																		
	Total	49	100	11	22.4	4	8.2	9	18.4	9	18.4	6	12.2	5	10.2	3	6.1	2	4.1

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

(*) ADVERSE EVENT: to be considered as adverse event or intercurrent medical problems

PHARMACIA CNS 840089

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 3

END OF STUDY: REASONS FOR DISCONTINUATION AND VISIT AT WHICH DISCONTINUATION OCCURED, BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder

Assigned treatment / Reasons		Total		Last visit															
				Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56	
		No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%
Imipramine	ADVERSE EVENT (*)	23	100	8	34.8	5	21.7	4	17.4			3	13.0	1	4.3	1	4.3	1	4.3
	PROTOCOL VIOLATION	1	100			1	100												
	LOST TO FOLLOW UP	1	100			1	100												
	DETERIORATION	10	100	1	10.0	2	20.0	1	10.0	2	20.0	3	30.0	1	10.0				
	PATIENT UNCOOPERATIVE	3	100			1	33.3					1	33.3			1	33.3		
	OTHER	1	100							1	100								
	Total	39	100	9	23.1	10	25.6	5	12.8	3	7.7	7	17.9	2	5.1	2	5.1	1	2.6
Reboxetine	ADVERSE EVENT (*)	15	100	4	26.7	2	13.3	3	20.0	3	20.0	2	13.3	1	6.7				
	LOST TO FOLLOW UP	1	100															1	100
	DETERIORATION	8	100	1	12.5			1	12.5	1	12.5	2	25.0	2	25.0	1	12.5		
	PATIENT UNCOOPERATIVE	9	100	3	33.3	1	11.1	2	22.2					1	11.1	1	11.1	1	11.1
	Total	33	100	8	24.2	3	9.1	6	18.2	4	12.1	4	12.1	4	12.1	2	6.1	2	6.1

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

(*) ADVERSE EVENT: to be considered as adverse event or intercurrent medical problems

PHARMACIA CNS 9560089

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 3

END OF STUDY: REASONS FOR DISCONTINUATION AND VISIT AT WHICH DISCONTINUATION OCCURED, BY ASSIGNED TREATMENT

Diagnosis: Dysthymia

Assigned treatment / Reasons		Last visit															
		Total		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49	
		No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%
Imipramine	ADVERSE EVENT (*)	5	100	3	60.0	2	40.0										
	DEATH	1	100	1	100												
	Total	6	100	4	66.7	2	33.3										
Reboxetine	ADVERSE EVENT (*)	8	100	2	25.0			2	25.0	3	37.5	1	12.5				
	PROTOCOL VIOLATION	1	100	1	100												
	LOST TO FOLLOW UP	2	100					1	50.0	1	50.0						
	DETERIORATION	2	100							1	50.0	1	50.0				
	PATIENT UNCOOPERATIVE	3	100			1	33.3							1	33.3	1	33.3
	Total	16	100	3	18.8	1	6.3	3	18.8	5	31.3	2	12.5	1	6.3	1	6.3

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Table No.: 4

PROTOCOL VIOLATIONS AT ADMISSION

	DYSRHYTHMIA		MAJOR DEPRESSIVE DISORDER		TOTAL	
	IMPRAMINE	REBOXETINE	IMPRAMINE	REBOXETINE	IMPRAMINE	REBOXETINE
	No.	%	No.	%	No.	%
PATIENTS EXPOSED	62	100.00	109	100.00	171	100.00
THYROID FUNCTION TEST ABNORMAL*	1	(1.69)†	7	(7.01)†	8	(5.03)†
THYROID FUNCTION TEST MISSING	3	4.84	9	8.26	12	7.02
MIMS LOWER THAN 22			2	1.83	2	1.16
EVIDENCE OF SUBSTANCE USE DISORDER			1	0.92	1	0.58
NOT ALLOWED CONCOMITANT MEDICATION DURING WASH-OUT PERIOD	9	14.52	24	22.02	33	19.30
AGE UNDER 65 YEARS						
			1	1.49		
			3	2.75		
					4	2.27

* relative deviation from limits of normal range < 10% and > 10%
† % frequency out of assessed

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/035
TABLE No. : 5

PROTOCOL VIOLATION AT ADMISSION: CREATININE CLEARANCE

		Dysthymia		Major Depressive Disorder		Total	
		Imipramine	Reboxetine	Imipramine	Reboxetine	Imipramine	Reboxetine
Creatinine clearance calculated as per protocol	Evaluated	52	55	95	96	147	151
	< 30 mL/min	3	1	7	6	10	7
	%	5.77	1.82	7.37	6.25	6.80	4.64
Creatinine clearance tested	Evaluated	10	10	12	11	22	21
	< 30 mL/min	0	0	0	0	0	0
	%	0.00	0.00	0.00	0.00	0.00	0.00
Total	Evaluated	62	65	107	107	169	172
	< 30 mL/min	3	1	7	6	10	7
	%	4.84	1.54	6.54	5.61	5.92	4.07

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No. : 6

RANDOMIZATION: ASSIGNED TREATMENT vs RANDOMIZED TREATMENT

Diagnosis / Assigned treatment	Randomized treatment		Total
	Imipramine	Reboxetine	
Major Depressive Disorder	85	24	109
	28	81	109
Total	113	105	218
Dysthymia	47	15	62
	17	50	67
Total	64	65	129

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 7

COMPLIANCE TO SCHEDULE TIME AS PER PROTOCOL

Diagnosis: Total
AND Assigned treatment: Reboxetine

	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56
Assessment time	No.	176	165	161	152	143	137	132	129	127
	Min	-35	7	12	19	26	34	36	43	50
	Max	1	10	17	26	31	46	73	56	69
	Median	-6	0	7	14	28	35	42	49	56
	95th percentile	1	1	8	15	22	30	37	44	50
Laboratory test	No.	176				138				124
	Min	-116				15				49
	Max	2				43				83
	Median	-5				29				56
	95th percentile	1				32				62
E.C.G.	No.	176				135				116
	Min	-101				25				50
	Max	9				38				83
	Median	-6				29				56
	95th percentile	1				32				62

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No. : 7

COMPLIANCE TO SCHEDULE TIME AS PER PROTOCOL

Diagnosis: Total
AND Assigned treatment: Imipranine

	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56
Assessment time	No.	171	158	146	141	138	131	129	127	126
	Min	-41	7	14	20	27	35	42	48	55
	Max	1	10	17	26	33	40	52	58	62
	Median	-6	7	14	21	28	35	42	49	56
	95th percentile	1	8	16	23	30	37	44	51	58
Laboratory test	No.	171				133				127
	Min	-81				21				51
	Max	2				38				69
	Median	-6				28				56
	95th percentile	1				31				60
E.C.G.	No.	170				133				122
	Min	-300				21				44
	Max	1				36				63
	Median	-5				28				56
	95th percentile	1				32				59

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 7

COMPLIANCE TO SCHEDULE TIME AS PER PROTOCOL

Diagnosis: Major Depressive Disorder
AND Assigned treatment: Reboxetine

	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56
Assessment time	No.	109	101	98	92	88	84	80	78	76
	Min	-33	-3	12	19	26	34	36	43	50
	Max	1	2	17	24	31	46	48	56	69
	Median	-6	0	14	21	28	35	42	49	56
	95th percentile	1	1	15	22	30	38	44	51	59
Laboratory test	No.	109				86				75
	Min	-33				26				49
	Max	2				43				69
	Median	-5				29				56
	95th percentile	1				31				59
E.C.G.	No.	109				86				69
	Min	-39				26				50
	Max	1				38				76
	Median	-6				29				56
	95th percentile	1				32				60

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/035
TABLE No. : 7

COMPLIANCE TO SCHEDULE TIME AS PER PROTOCOL

Diagnosis: Major Depressive Disorder
AND Assigned treatment: Imipramine

	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56
Assessment time	No.	109	100	90	85	82	75	73	71	70
	Min	-41	-3	14	21	27	35	42	48	55
	Max	1	2	17	26	31	40	52	58	62
	Median	-6	0	14	21	28	35	42	49	56
	95th percentile	1	1	16	23	30	37	44	52	58
Laboratory test	No.	109				79				71
	Min	-81				21				53
	Max	2				38				63
	Median	-5				28				56
	95th percentile	1				31				60
E.C.G.	No.	108				79				67
	Min	-31				24				44
	Max	1				36				63
	Median	-5				28				57
	95th percentile	1				32				59

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 7

COMPLIANCE TO SCHEDULE TIME AS PER PROTOCOL

Diagnosis: Dysthymia
AND Assigned treatment: Reboxetine

	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56
Assessment time	No.	67	64	63	60	55	53	52	51	51
	Min	-35	7	14	20	26	34	41	48	55
	Max	1	8	16	26	31	37	73	51	68
	Median	-6	0	14	21	29	35	43	49	56
	95th percentile	1	1	8	15	22	29	36	44	50
Laboratory test	No.	67				52				49
	Min	-116				15				53
	Max	1				34				83
	Median	-6				29				57
	95th percentile	1				32				68
E.C.G.	No.	67				49				47
	Min	-101				25				51
	Max	9				34				83
	Median	-5				29				56
	95th percentile	1				32				64

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 7

COMPLIANCE TO SCHEDULE TIME AS PER PROTOCOL

Diagnosis: Dysthymia
AND Assigned treatment: Imipramine

	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56
Assessment time	No.	62	58	56	56	56	56	56	56	56
	Min	-34	7	14	20	27	35	42	49	55
	Max	1	10	17	25	33	39	47	54	61
	Median	-6	7	15	22	29	36	43	50	57
	95th percentile	1	8	15	23	29	37	44	51	59
Laboratory test	No.	62				54				56
	Min	-67				21				51
	Max	1				35				69
	Median	-6				29				56
	95th percentile	1				31				65
E.C.G.	No.	62				54				55
	Min	-300				21				50
	Max	1				36				63
	Median	-6				29				56
	95th percentile	1				34				61

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Table No. 1 8

CONCOMITANT DRUGS NOT ALLOWED BY PROTOCOL GROUPED BY ACTIVE PRINCIPLE
NUMBER OF PATIENTS

Class / Active principle	Assigned treatment			
	Reboxetine	Imipramine		
BDZ long acting	LORMETAZEPAM	21	19	
	LORAZEPAM	8	6	
	FLUNITRAZEPAM	4	2	
	NITRAZEPAM	2	2	
	LOPRAZOLAM	3	1	
	DIAZEPAM	1	2	
	OXAZEPAM		3	
	ALPRAZOLAM	2	1	
	FLURAZEPAM	1	1	
	CLORAZEPIC ACID		1	
	Total	42	38	
	Neuroleptics	HALOPERIDOL	3	
		CHLORPROTHIXENE		1
PROMAZINE		1		
CHLORMEZANONE		1		
SULPIRIDE		1		
Total		6	1	
Antiepileptics	CARBAMAZEPINE		2	
	PHENYTOIN	1		
	CLONAZEPAM		1	
Total	1	3		
Alcohol	ETHANOL		1	
	Total		1	

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Table No.: 8

CONCOMITANT DRUGS NOT ALLOWED BY PROTOCOL GROUPED BY ACTIVE PRINCIPLE
NUMBER OF PATIENTS

Class / Active principle	Assigned treatment	
	Reboxetine	Imipramine
General anaesthetics		1
Total		1

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE NO.: 9

CONCOMITANT DRUGS NOT ALLOWED BY PROTOCOL GROUPED BY CLASS
NUMBER OF PATIENTS

	At least one	Assigned treatment	
		Imipramine	Reboxetine
Major Depressive Disorder	At least one	27	21
	Alcohol	1	
	Antiepileptics	2	1
	BD2 long acting	26	20
	General anaesthetics	1	
	Neuroleptics	1	4
Dysthymia	At least one	10	14
	Antiepileptics	1	
	BD2 long acting	9	14
	Neuroleptics		2
Total	At least one	37	35
	Alcohol	1	
	Antiepileptics	3	1
	BD2 long acting	35	34
	General anaesthetics	1	
	Neuroleptics	1	6

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACTA CMS RED
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 10

DEMOGRAPHY BY ASSIGNED TREATMENT AND DIAGNOSIS - AGE, HEIGHT, HEIGHT

Assigned treatment	Age			Height			Height		
	N.D.D.	Dysthymia	Total	N.D.D.	Dysthymia	Total	N.D.D.	Dysthymia	Total
Imipramine	No	109	62	171	109	62	171	62	171
	Missing	0	0	0	0	0	0	0	0
	Mean	74.44	74.73	74.54	66.34	67.85	66.88	163.86	163.96
	S.D.	6.39	6.95	6.95	13.32	11.56	12.70	9.33	9.12
	Min	65.00	65.00	65.00	39.00	39.00	39.00	140.00	140.00
	Max	94.00	91.00	94.00	113.00	92.00	113.00	185.00	195.00
Reboxetine	No	109	67	176	109	66	175	67	174
	Missing	0	0	0	0	1	1	2	2
	Mean	73.75	73.88	73.80	63.13	65.36	63.97	162.38	162.36
	S.D.	6.41	6.41	6.39	11.92	11.63	11.83	7.75	7.38
	Min	56.00	63.00	56.00	36.00	38.00	36.00	138.00	138.00
	Max	90.00	89.00	90.00	92.80	90.00	92.80	180.00	180.00
Total	No	218	129	347	218	128	346	129	345
	Missing	0	0	0	0	1	1	2	2
	Mean	74.10	74.29	74.17	64.73	66.56	65.41	163.13	163.15
	S.D.	6.70	6.66	6.68	12.71	11.62	12.33	8.59	8.31
	Min	56.00	63.00	56.00	36.00	38.00	36.00	138.00	138.00
	Max	94.00	91.00	94.00	113.00	92.00	113.00	185.00	195.00

weight and height at screening visit

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 2012A/035

TABLE No.: 11

DEMOGRAPHY BY ASSIGNED TREATMENT AND DIAGNOSIS - RACE AND SEX

Assigned treatment / Diagnosis	Race				Sex				Total		
	Caucasian		Black		Female		Male		No.	%	
	No.	%	No.	%	No.	%	No.	%			
Imipramine	Major Depressive Disorder	108	99.08	1	0.92	79	72.48	30	27.52	109	100.00
	Dysthymia	62	100.00			47	75.81	15	24.19	62	100.00
	Total	170	99.42	1	0.58	126	73.68	45	26.32	171	100.00
Reboxetine	Major Depressive Disorder	108	99.08	1	0.92	82	75.23	27	24.77	109	100.00
	Dysthymia	67	100.00			55	82.09	12	17.91	67	100.00
	Total	175	99.43	1	0.57	137	77.84	39	22.16	176	100.00
Total	Major Depressive Disorder	216	99.08	2	0.92	161	73.85	57	26.15	218	100.00
	Dysthymia	129	100.00			102	79.07	27	20.93	129	100.00
	Total	345	99.42	2	0.58	263	75.79	84	24.21	347	100.00

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No. 1 12
 MINI MENTAL STATE - TOTAL SCORE

	Inipramine		Reboxetine	
	Major Depressive Disorder	Dysthymia	Major Depressive Disorder	Dysthymia
No.	108	62	109	67
Mean	26.51	26.85	26.71	26.91
STD	2.91	2.48	2.59	2.42
Median	27.00	27.00	27.00	27.00
Min	18	22	22	21
Max	30	30	30	30

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 13

DIAGNOSIS AND HISTORY OF MENTAL DISORDERS BY DIAGNOSIS AND ASSIGNED TREATMENT

DSM-III-R diagnosis (*)	Major Depressive Disorder			Dysthymia			Total		
	Imipramine	Reboxetine	Total	Imipramine	Reboxetine	Total	Imipramine	Reboxetine	Total
296.2 No.	36	45	81				36	45	81
296.3 No.	73	63	136				73	63	136
296.5 No.		1	1					1	1
300.4 No.				62	67	129		62	129
Total No.	109	109	218	62	67	129	171	176	347
Age of onset (years)	102	100	202	55	55	110	157	155	312
Unknown	7	9	16	7	12	19	14	21	35
Total No.	109	109	218	62	67	129	171	176	347
Mean	63.64	63.79	63.71	66.02	62.80	64.41	64.47	63.44	63.96
STD	15.31	14.85	15.05	13.24	14.97	14.16	14.62	14.85	14.72
Median	67.00	67.00	67.00	68.00	66.00	66.50	67.00	66.00	67.00
Min	22	24	22	28	18	18	22	18	18
Max	94	90	94	88	85	88	94	90	94
No.	69	57	126	18	21	39	87	78	165
Total No.	109	109	218	62	67	129	171	176	347
Mean	3.81	2.89	3.40	3.83	3.95	3.90	3.82	3.18	3.52
STD	5.69	3.17	4.72	3.24	3.06	3.10	5.26	3.16	4.39
Median	2.00	2.00	2.00	2.50	3.00	3.00	2.00	2.00	2.00
Min	1	1	1	1	1	1	1	1	1
Max	40	18	40	12	12	12	40	18	40

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.5=Major Depressive Disorder, Bipolar
296.3=Major Depressive Disorder, Multiple Episode
300.4=Dysthymia

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 13

DIAGNOSIS AND HISTORY OF MENTAL DISORDERS BY DIAGNOSIS AND ASSIGNED TREATMENT

	Major Depressive Disorder			Dysthymia			Total		
	Imipramine	Reboxetine	Total	Imipramine	Reboxetine	Total	Imipramine	Reboxetine	Total
Duration of last episode (weeks)									
No.	69	59	128	20	26	46	89	85	174
Total No.	109	109	218	62	67	129	171	176	347
Mean	32.57	22.12	27.75	72.60	60.27	65.63	41.56	33.79	37.76
STD	83.20	23.99	63.22	56.14	54.95	55.19	79.45	40.11	63.30
Median	12.00	16.00	14.00	58.00	42.00	52.00	16.00	16.00	16.00
Min	3	4	3	4	4	4	3	4	3
Max	676	172	676	156	208	208	676	208	676
Duration of present episode (weeks)									
No.	109	109	218	62	65	127	171	174	345
Total No.	109	109	218	62	67	129	171	176	347
Mean	15.64	16.26	15.95	121.98	183.38	153.41	54.20	78.69	66.55
STD	19.54	24.62	22.18	77.45	347.77	255.51	70.88	227.36	169.21
Median	8.00	12.00	8.50	104.00	108.00	106.00	16.00	16.00	16.00
Min	1	2	1	3	2	2	1	2	1
Max	128	188	188	416	2.080	2.080	416	2.080	2.080

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARHACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 14
 DIAGNOSIS AND HISTORY OF MENTAL DISORDERS BY DIAGNOSIS AND ASSIGNED TREATMENT (INDEX EPISODE)

All patients

	Imipramine		Reboxetine		Total		
	No	%	No	%	No	%	
Charact. of present episode	Exacerbation of chronic cond.	46	26.90	49	27.84	95	27.38
	Recurrence of similar prev. cond.	68	39.77	61	34.66	129	37.18
	Different from any prev. cond.	2	1.17	7	3.98	9	2.59
	First occurrence	55	32.16	59	33.52	114	32.85
	Total	171	100.00	176	100.00	347	100.00
Onset of present episode	Acute (< 2 weeks)	11	6.43	18	10.23	29	8.36
	Subacute (>= 2 weeks)	76	44.44	75	42.61	151	43.52
	Insidious (>= 3 months)	83	48.54	82	46.59	165	47.55
	Unknown	1	0.58	1	0.57	2	0.58
	Total	171	100.00	176	100.00	347	100.00
Precipit. external stress	Absent	100	58.48	95	53.98	195	56.20
	Probably present	48	28.07	49	27.84	97	27.95
	Definitely present	22	12.87	31	17.61	53	15.27
	Unknown	1	0.58	1	0.57	2	0.58
Total	171	100.00	176	100.00	347	100.00	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 14

DIAGNOSIS AND HISTORY OF MENTAL DISORDERS BY DIAGNOSIS AND ASSIGNED TREATMENT (INDEX EPISODE)

Diagnosis: Major Depressive Disorder

	Inipranine		Reboxetine		Total		
	No	%	No	%	No	%	
Charact. of present episode	Exacerbation of chronic cond.	11	10.09	14	12.84	25	11.47
	Recurrence of similar prev. cond.	62	56.88	46	42.20	108	49.54
	Different from any prev. cond.	2	1.83	6	5.50	8	3.67
	First occurrence	34	31.19	43	39.45	77	35.32
	Total	109	100.00	109	100.00	218	100.00
Onset of present episode	Acute (< 2 weeks)	11	10.09	15	13.76	26	11.93
	Subacute (>= 2 weeks)	56	51.38	55	50.46	111	50.92
	Insidious (>= 3 months)	42	38.53	38	34.86	80	36.70
	Unknown			1	0.92	1	0.46
	Total	109	100.00	109	100.00	218	100.00
Precipit. external stress	Absent	64	58.72	52	47.71	116	53.21
	Probably present	32	29.36	33	30.28	65	29.82
	Definitely present	13	11.93	23	21.10	36	16.51
	Unknown			1	0.92	1	0.46
Total	109	100.00	109	100.00	218	100.00	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PEARREACTA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 14

DIAGNOSIS AND HISTORY OF MENTAL DISORDERS BY DIAGNOSIS AND ASSIGNED TREATMENT (INDEX EPISODE)

Diagnosis: Dysthymia

	Imipramine		Reboxetine		Total		
	No	Z	No	Z	No	Z	
Charact. of present episode	Exacerbation of chronic cond.	35	56.45	35	52.24	70	54.26
	Recurrence of similar prev. cond.	6	9.68	15	22.39	21	16.28
	Different from any prev. cond.			1	1.49	1	0.78
	First occurrence	21	33.87	16	23.88	37	28.68
	Total	62	100.00	67	100.00	129	100.00
Onset of present episode	Acute (< 2 weeks)			3	4.48	3	2.33
	Subacute (>= 2 weeks)	20	32.26	20	29.85	40	31.01
	Insidious (>= 3 months)	41	66.13	44	65.67	85	65.89
	Unknown	1	1.61			1	0.78
	Total	62	100.00	67	100.00	129	100.00
Precipit. external stress	Absent	36	58.06	43	64.18	79	61.24
	Probably present	16	25.81	16	23.88	32	24.81
	Definitely present	9	14.52	8	11.94	17	13.18
	Unknown	1	1.61			1	0.78
	Total	62	100.00	67	100.00	129	100.00

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE – PROTOCOL 20124/035
 TABLE No.: 15

PREVIOUS ANTIDEPRESSIVE TREATMENT BY ACTIVE PRINCIPLE

	Assigned treatment												Total		
	Reboxetine						Imipramine						No	Z	Z
	No	Z	z	No	Z	z	No	Z	z	No	Z	z			
Screened patient	176		100.0	171		100.0	347		100.0			347		100.0	
AMITRIPTYLINE	25		14.2	17		9.9	42		12.1			42		12.1	
DOSULEPIN	19		10.8	16		9.4	35		10.1			35		10.1	
MIANSERIN	12		6.8	17		9.9	29		8.4			29		8.4	
CLONIPRAMINE	16		9.1	13		7.6	29		8.4			29		8.4	
FLUOXETINE	13		7.4	12		7.0	25		7.2			25		7.2	
MAPROTIline	10		5.7	4		2.3	14		4.0			14		4.0	
DOXEFIN	11		6.3	3		1.8	14		4.0			14		4.0	
TRAZODONE	7		4.0	7		4.1	14		4.0			14		4.0	
LOFEPRAMINE	5		2.8	8		4.7	13		3.7			13		3.7	
SETRALINE	4		2.3	4		2.3	8		2.3			8		2.3	
IMIPRAMINE	2		1.1	4		2.3	6		1.7			6		1.7	
PAROXETINE	4		2.3	3		1.8	7		2.0			7		2.0	
CITALOPRAM	2		1.1	4		2.3	6		1.7			6		1.7	
TRINIPRAMINE	4		2.3	2		1.2	6		1.7			6		1.7	
TIANEPTINE	4		2.3	1		0.6	5		1.4			5		1.4	
VILOXAZINE	4		2.3	1		0.6	5		1.4			5		1.4	
OPIPRAMOL	1		0.6	4		2.3	5		1.4			5		1.4	
AMINEPTINE	1		0.6	3		1.8	4		1.2			4		1.2	
NORTRIPTYLINE	2		1.1	2		1.2	4		1.2			4		1.2	
AMOXAPINE	3		1.7	1		0.6	4		1.2			4		1.2	
NOCLOBENHIDE	2		1.1	1		0.6	3		0.9			3		0.9	
DIBENZEPIN	2		1.1	1		0.6	3		0.9			3		0.9	

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No. : 15
 PREVIOUS ANTIDEPRESSIVE TREATMENT BY ACTIVE PRINCIPLE

	Assigned treatment						Total	
	Reboxetine			Imipramine				
	No	Z	1.7	No	Z	1.8	No	Z
FLUVOXAMINE	3						3	0.9
LITHIUM				3			3	0.9
NIALAMIDE	2		1.1				2	0.6
NOMIFENSINE				1			1	0.3
VENLAFAXINE				1			1	0.3
PHENELZINE				1			1	0.3

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 16
MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS OF SCREENED PATIENTS BY DIAGNOSIS AND ASSIGNED TREATMENT

Previous diseases	Major Depressive Disorder						Dysthymia						Total											
	Imipramine			Reboxetine			Imipramine			Reboxetine			Total			Imipramine			Reboxetine			Total		
	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.
Screened patients	109	100	109	100	218	100	62	100	67	100	129	100	171	100	176	100	347	100						
HYPERTENSION NOS	21	19.3	17	15.6	38	17.4	16	25.8	16	23.9	32	24.8	37	21.6	33	18.8	70	20.2						
DIABETES MELLITUS UNCOMP	4	3.7	3	2.8	7	3.2	7	11.3	6	9.0	13	10.1	11	6.4	9	5.1	20	5.8						
OSTEOARTHRITIS NOS	6	5.5	5	4.6	11	5.0	3	4.8	2	3.0	5	3.9	9	5.3	7	4.0	16	4.6						
ABN BLOOD CHEMISTRY NEC	3	2.8	6	5.5	9	4.1	1	1.6	2	3.0	3	2.3	4	2.3	8	4.5	12	3.5						
ATRIAL FIBRILL/FLUTTER	5	4.6			5	2.3			1	1.5	1	0.8	5	2.9	1	0.6	6	1.7						
HYPERPLASIA OF PROSTATE	5	4.6	5	4.6	10	4.6	1	1.6	2	3.0	3	2.3	6	3.5	7	4.0	13	3.7						
CHR ISCHEMIC HRT DIS NOS	4	3.7	1	0.9	5	2.3			2	3.0	2	1.6	4	2.3	3	1.7	7	2.0						
OTHER GU NEOPLASH NOS	1	0.9	4	3.7	5	2.3	1	1.6	2	3.0	3	2.3	2	1.2	6	3.4	8	2.3						
HYPERLIPIDEMIA NEC/NOS	3	2.8	4	3.7	7	3.2	4	6.5	3	4.5	7	5.4	7	4.1	7	4.0	14	4.0						
DIAPHRAGMATIC HERNIA	2	1.8	4	3.7	6	2.8	3	4.8	1	1.5	4	3.1	5	2.9	5	2.8	10	2.9						
CHOLELITHIASIS NOS	2	1.8	4	3.7	6	2.8	2	3.2	2	3.0	4	3.1	4	2.3	6	3.4	10	2.9						
ARTROPATHY NOS			4	3.7	4	1.8	2	3.2			2	1.6	2	1.2	4	2.3	6	1.7						
SPONDYLOSIS NOS	3	2.8	4	3.7	7	3.2	3	4.8	2	3.0	5	3.9	6	3.5	6	3.4	12	3.5						
PURE HYPERCHOLESTEROLEM	1	0.9	2	1.8	3	1.4	4	6.5	2	3.0	6	4.7	5	2.9	4	2.3	9	2.6						
CEREBROVASC DISEASE NOS	1	0.9	3	2.8	4	1.8	4	6.5	1	1.5	5	3.9	5	2.9	4	2.3	9	2.6						
STRUCTURE OF ARTERY	1	0.9	3	2.8	4	1.8	4	6.5	1	1.5	5	3.9	5	2.9	4	2.3	9	2.6						
CHR ISCHEMIC HRT DIS NEC	1	0.9	2	1.8	3	1.4	2	3.2	4	6.0	6	4.7	3	1.8	6	3.4	9	2.6						
URIN TRACT INFECTION NOS	3	2.8	2	1.8	5	2.3	2	3.2	4	6.0	6	4.7	5	2.9	6	3.4	11	3.2						
IRON DEFICIENCY ANEMIAS	3	2.8	1	0.9	4	1.8							3	1.8	1	0.6	4	1.2						
CONGESTIVE HEART FAILURE	3	2.8	2	1.8	5	2.3	1	1.6			1	0.8	4	2.3	2	1.1	6	1.7						
CVA	3	2.8	3	2.8	6	2.8	1	1.6			1	0.8	4	2.3	3	1.7	7	2.0						

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 16
MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS OF SCREENED PATIENTS BY DIAGNOSIS AND ASSIGNED TREATMENT

Previous diseases	Major Depressive Disorder						Dysthymia						Total					
	Imipramine			Reboxetine			Imipramine			Reboxetine			Imipramine			Reboxetine		
	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.		
VENOUS THROMBOSIS NOS	3	2.8			3	1.4								3	1.8		3	0.9
OSTEOPOROSIS	3	2.8	2	1.8	5	2.3	3	4.8	2	3.0	5	3.9	6	3.5	4	2.3	10	2.9
UTERINE LEIOMYOMA	1	0.9	3	2.8	4	1.8							1	0.6	3	1.7	4	1.2
OBESITY	1	0.9	3	2.8	4	1.8			1	1.5	1	0.8	1	0.6	4	2.3	5	1.4
ACUTE MYOCARDIAL INFARCT			3	2.8	3	1.4			1	1.5	1	0.8	4	2.3	4	1.2	7	2.0
CORONARY ATHEROSCLEROSIS	2	1.8	3	2.8	5	2.3			2	3.0	2	1.6	2	1.2	5	2.8	7	2.0
STOMACH ULCER NOS	2	1.8	3	2.8	5	2.3	1	1.6	2	3.0	3	2.3	3	1.8	5	2.8	8	2.3
DIVERTICULA OF COLON	2	1.8	3	2.8	5	2.3	1	1.6			1	0.8	3	1.8	3	1.7	6	1.7
HEART DISEASE NOS	2	1.8	1	0.9	3	1.4	3	4.8			3	2.3	5	2.9	1	0.6	6	1.7
OLD MYOCARDIAL INFARCT	2	1.8	1	0.9	3	1.4	1	1.6	3	4.5	4	3.1	3	1.8	4	2.3	7	2.0
TRANSIENT CEREB. ISCHEMIA	1	0.9	2	1.8	3	1.4	2	3.2	3	4.5	5	3.9	3	1.8	5	2.8	8	2.3
ESOPHAGITIS			2	1.8	2	0.9	2	3.2	3	4.5	5	3.9	2	1.2	5	2.8	7	2.0
PULMONARY TB NOS	2	1.8	2	1.8	4	1.8							2	1.2	2	1.1	4	1.2
HYPOTHYROIDISM NOS	2	1.8			2	0.9							2	1.2			2	0.6
HEMIPLEGIA NOS	2	1.8	1	0.9	3	1.4	1	1.6			1	0.8	3	1.8	1	0.6	4	1.2
OPEN-ANGLE GLAUCOMA	2	1.8			2	0.9							2	1.2			2	0.6
ANGINA PECTORIS	2	1.8	1	0.9	3	1.4	1	1.6			1	0.8	3	1.8	1	0.6	4	1.2
HYPOTENSION NOS	2	1.8	2	1.8	4	1.8							2	1.2	2	1.1	4	1.2
CIRCULATORY DISEASE NOS	2	1.8	1	0.9	3	1.4	2	3.2			2	1.6	4	2.3	1	0.6	5	1.4
DUODENAL ULCER NOS	2	1.8	2	1.8	4	1.8	1	1.6	1	1.5	2	1.6	3	1.8	3	1.7	6	1.7
GASTRITIS/DUODENITIS NOS	2	1.8	1	0.9	3	1.4			1	1.5	1	0.8	2	1.2	2	1.1	4	1.2
RENAL UNETERAL DIS NOS	2	1.8	1	0.9	3	1.4							2	1.2	1	0.6	3	0.9

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 16
MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS OF SCREENED PATIENTS BY DIAGNOSIS AND ASSIGNED TREATMENT

Previous diseases	Major Depressive Disorder						Dysthymia						Total													
	Imipramine			Reboxetine			Imipramine			Reboxetine			Total			Imipramine			Reboxetine			Total				
	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.	No	% on Pt.		
FEM GENITAL SYMPTOMS NOS	2	1.8			2	0.9											2	1.2					2	0.6		
HONORARTHRITIS NOS	2	1.8			2	0.9			2	3.2	1	1.5	3	2.3	4	2.3	1	0.6					5	1.4		
SLEEP DISTURBANCES	2	1.8	2	1.8	4	1.8											2	1.2					4	1.2		
URINOSTOMY STATUS NEC	2	1.8			2	0.9											2	1.2					2	0.6		
MALIGN REDEPL BREAST NOS	1	0.9	2	1.8	3	1.4											1	0.6					3	0.9		
ANEMIA NOS			2	1.8	2	0.9																	2	0.6		
PARALYSIS ACUTANS			2	1.8	2	0.9																	4	1.2		
CATARACT NOS			2	1.8	2	0.9			1	1.6			1	0.8	1	0.6	2	1.1					3	0.9		
HEARING LOSS NOS	1	0.9	2	1.8	3	1.4											1	0.6					3	0.9		
THROMBOPHLEBITIS LEG NOS			2	1.8	2	0.9																	2	0.6		
BRONCHITIS NOS			2	1.8	2	0.9			1	1.6			1	0.8	1	0.6	2	1.1					3	0.9		
ASTHMA NOS			2	1.8	2	0.9			1	1.6			1	0.8	1	0.6	2	1.1					3	0.9		
APPENDICITIS NOS	1	0.9	2	1.8	3	1.4			1	1.6			1	0.8	2	1.2	2	1.1					4	1.2		
CONSTIPATION	1	0.9	2	1.8	3	1.4							1	1.5	1	0.6	3	1.7					4	1.2		
CHOLELITH W CHOLECYSTIS NEC	1	0.9	2	1.8	3	1.4			1	1.6			1	0.8	1	0.6	3	1.7					4	1.2		
RHEUMATISM NOS	1	0.9	2	1.8	3	1.4							1	1.5	1	0.6	3	1.7					4	1.2		
JOINT REPLACEMENT NEC			2	1.8	2	0.9							1	1.5	1	0.6	3	1.7					3	0.9		
INTESTINAL BYPASS STATUS	1	0.9	2	1.8	3	1.4							2	3.0	2	1.6	4	2.3					5	1.4		
CARDIAC DYSRHYTHMIA NOS									2	3.2			2	1.6	2	1.2							2	0.6		
ASCVD									2	3.2			2	1.6	2	1.2							2	0.6		
GENERAL OSTEOARTHRITIS	1	0.9	1	0.9	2	0.9			2	3.2			1	1.5	3	2.3	3	1.8				2	1.1	5	1.4	
THYROTOXICOSIS NOS	1	0.9	1	0.9	2	0.9							2	3.0	2	1.6	1	0.6					3	1.7	4	1.2

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 16
MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS OF SCREENED PATIENTS BY DIAGNOSIS AND ASSIGNED TREATMENT

Previous diseases	Major Depressive Disorder						Dysthymia						Total												
	Imipramine			Reboxetine			Imipramine			Reboxetine			Total			Imipramine			Reboxetine			Total			
	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	
ALCOHOL DEPENDENCE SYNDR			1	0.9	1	0.5			2	3.0	2	1.6			3	1.7	3	0.9							
DISC DISPLACEMENT NOS			1	0.9	1	0.5			2	3.0	2	1.6			3	1.7	3	0.9							
MALARIA NOS	1	0.9				1	0.5								1	0.6		1	0.3						
LEPTOSPIROSIS NOS	1	0.9				1	0.5								1	0.6		1	0.3						
MALIG NEO SOFT PALATE	1	0.9				1	0.5								1	0.6		1	0.3						
MALIGNANT NEO COLON NOS	1	0.9	1	0.9	2	0.9			1	1.5	1	0.8			2	1.1	3	0.9							
MAL NEO BRONCH/LUNG NOS	1	0.9				1	0.5								1	0.6		1	0.3						
MALIG NEO SKIN NOS	1	0.9				1	0.5								1	0.6		1	0.3						
MALIG NEO CORPUS UTERI	1	0.9				1	0.5								1	0.6		1	0.3						
MALIG NEOPL PROSTATE	1	0.9	1	0.9	2	0.9									2	1.2	2	0.6							
MALIG NEOPL KIDNEY	1	0.9				1	0.5								1	0.6		1	0.3						
MALIGNANT NEOPLASM NOS	1	0.9				1	0.5								1	0.6		1	0.3						
MULTIPLE MYELOMA	1	0.9				1	0.5								1	0.6		1	0.3						
BENIGN NEOPLASM LG BOWEL	1	0.9				1	0.5								1	0.6		1	0.3						
BENIGN NEOPLASM BREAST	1	0.9				1	0.5								1	0.6		1	0.3						
BENIGN NEO CORPUS UTERI	1	0.9	1	0.9	2	0.9									2	1.2	2	0.6							
BENIGN NEO UTERUS NOS	1	0.9				1	0.5								1	0.6		1	0.3						
BEN NEO CEREBR MENINGES	1	0.9				1	0.5			1	1.5	1	0.8		1	0.6	1	0.6	2	0.6					
DIGESTIVE NEOPLASM NOS	1	0.9	1	0.9	2	0.9									2	1.2	2	0.6							
NONTOX NODUL GOITER NOS	1	0.9	1	0.9	2	0.9									2	1.2	2	0.6							
EXTRAPYRAMIDAL DIS NEC/NOS	1	0.9				1	0.5								1	0.6	1	0.6	2	0.6					
MIGRAINE NOS	1	0.9	1	0.9	2	0.9			1	1.6					2	1.2	3	0.9							

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
TABLE No. : 16
MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS OF SCREENED PATIENTS BY DIAGNOSIS AND ASSIGNED TREATMENT

Previous diseases	Major Depressive Disorder						Dythyrimia						Total							
	Imipramine			Reboxetine			Imipramine			Reboxetine			Imipramine			Reboxetine				
	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.				
CARPAL TUNNEL SYNDROME	1	0.9			1	0.5									1	0.6		1	0.3	
DEGENERATION OF MACULA	1	0.9			1	0.5									1	0.6		1	0.3	
BORDERLINE GLAUCOMA	1	0.9			1	0.5									1	0.6		1	0.3	
GLAUCOMA NOS	1	0.9			1	0.5									1	0.6		1	0.3	
SENILE CATARACT	1	0.9			1	0.5			1	1.5					1	0.6	1	0.6	2	0.6
RHEUM FEV W/O BRT INVOLV	1	0.9			1	0.5									1	0.6		1	0.3	
HYPERTR OBSTR CARDIOMYOP	1	0.9			1	0.5									1	0.6		1	0.3	
LEFT BB BLOCK NEC	1	0.9			1	0.5									1	0.6		1	0.3	
PREMATURE BEATS	1	0.9			1	0.5									1	0.6		1	0.3	
CARDIAC DYSRHYTHIAS NEC	1	0.9			2	0.9									1	0.6	1	0.6	2	0.6
INTRACEREBRAL HEMORRHAGE	1	0.9			1	0.5									1	0.6		1	0.3	
CEREBRAL ATHEROSCLEROSIS	1	0.9			1	0.5									1	0.6		1	0.3	
ORTHOSTATIC HYPOTENSION	1	0.9			1	0.5			1	1.5					1	0.6	1	0.6	2	0.6
ACUTE TONSILLITIS	1	0.9			1	0.5									1	0.6		1	0.3	
PNEUMONIA, ORGANISM NOS	1	0.9			1	0.5									1	0.6		1	0.3	
CHR AIRWAY OBSTRUCT NEC	1	0.9			2	0.9									1	0.6	1	0.6	2	0.6
ABSCESS OF LUNG	1	0.9			1	0.5									1	0.6		1	0.3	
LUNG DISEASE NEC	1	0.9			1	0.5									1	0.6		1	0.3	
PEPTIC ULCER NOS	1	0.9			1	0.5			1	1.6					1	0.6	2	1.2	2	0.6
STOMACH FUNCTION DIS NEC	1	0.9			1	0.5									1	0.6		1	0.3	
INGUINAL HERNIA NOS	1	0.9			1	0.5			1	1.6					2	1.2	1	0.6	3	0.9
CIRRHOSIS OF LIVER NOS	1	0.9			1	0.5									1	0.6		1	0.3	

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 16
MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS OF SCREENED PATIENTS BY DIAGNOSIS AND ASSIGNED TREATMENT

Previous diseases	Major Depressive Disorder						Dysthymia						Total											
	Imipramine			Reboxetine			Imipramine			Reboxetine			Imipramine			Reboxetine								
	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.	No	Z on Pt.								
HEPATITIS NOS	1	0.9	1	0.9	2	0.9					1	1.5	1	0.8	1	0.6	2	1.1	3	0.9				
CHOLELITH M AC CHOLECYST	1	0.9	1	0.9	2	0.9											1	0.6	1	0.6	2	0.6		
SOLITARY CYST OF BREAST	1	0.9				1	0.5										1	0.6				1	0.3	
PROLAPSE OF VAGINAL WALL	1	0.9	1	0.9	2	0.9	1	1.6						1	0.8	2	1.2	1	0.6	3	0.9			
EFFUSION OF JOINT	1	0.9				1	0.5										1	0.6				1	0.3	
SPINAL STENOSIS NEC	1	0.9				1	0.5										1	0.6				1	0.3	
OSTEOMYELITIS NOS	1	0.9				1	0.5	1	1.6					1	0.8	2	1.2				2	0.6		
OSTEITIS DEFORMANS NOS	1	0.9				1	0.5										1	0.6				1	0.3	
OSTEITIS DEFORMANS NOS	1	0.9				1	0.5							1	0.8	2	1.2				2	0.6		
DIZZINESS AND GIDDINESS	1	0.9				1	0.5	1	1.6					1	0.8	2	1.2				2	0.6		
MALaise AND FATIGUE	1	0.9				1	0.5										1	0.6				1	0.3	
ABN INVOLUN MOVEMENT NEC	1	0.9				1	0.5	1	1.6					1	0.8	2	1.2				2	0.6		
FX HUMERUS SHAFT/NOS-CL	1	0.9				1	0.5										1	0.6				1	0.3	
FX FEMUR SHAFT/NOS-CLOSE	1	0.9				1	0.5										1	0.6				1	0.3	
TOX EFF NONMED SUBST NEC	1	0.9				1	0.5										1	0.6				1	0.3	
ARTRODESIS STATUS	1	0.9				1	0.5										1	0.6				1	0.3	
CANDIDAL VULVOVAGINITIS						1	0.9	1	0.5												1	0.6	1	0.3
OTH MALIG NEO GI/PERITON						1	0.9	1	0.5												1	0.6	1	0.3
LIPOMA						1	0.9	1	0.5												1	0.6	1	0.3
TOXIC DIFFUSE GOITER						1	0.9	1	0.5												1	0.6	1	0.3
CHR LYMPHOCT THYROIDIT						1	0.9	1	0.5												1	0.6	1	0.3
HOMOCLON PARAPROTEINEMIA						1	0.9	1	0.5												1	0.6	1	0.3
GOUT NOS						1	0.9	1	0.5	1	1.6			1	0.8	1	0.6				2	0.6		

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No. : 16
MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS OF SCREENED PATIENTS BY DIAGNOSIS AND ASSIGNED TREATMENT

Previous diseases	Major Depressive Disorder						Dysthymia						Total					
	Imipramine			Reboxetine			Imipramine			Reboxetine			Imipramine			Reboxetine		
	No	Z on Pt.	Total	No	Z on Pt.	Total	No	Z on Pt.	Total	No	Z on Pt.	Total	No	Z on Pt.	Total	No	Z on Pt.	Total
HYPOVOLEMIA		1 0.9	1 0.5													1 0.6	1 0.3	
PERNICIOUS ANEMIA		1 0.9	1 0.5													1 0.6	1 0.3	
TOBACCO USE DISORDER		1 0.9	1 0.5													1 0.6	1 0.3	
PSYCHOGEN CARDIOVASC DIS		1 0.9	1 0.5													1 0.6	1 0.3	
SPINAL CORD DISEASE NOS		1 0.9	1 0.5													1 0.6	1 0.3	
PARAPLEGIA NOS		1 0.9	1 0.5			1 1.5	1 0.8									2 1.1	2 0.6	
IDIO PERIPH NEURPHY NOS		1 0.9	1 0.5	1 1.6												1 0.6	2 0.6	
RETINAL VASC OCCLUSION		1 0.9	1 0.5													1 0.6	1 0.3	
PROFOUND IMPAIR-ONE EYE		1 0.9	1 0.5													1 0.6	1 0.3	
ECTROPION		1 0.9	1 0.5													1 0.6	1 0.3	
AORTIC VALVE DISORDER		1 0.9	1 0.5													1 0.6	1 0.3	
HEART FAILURE NOS		1 0.9	1 0.5	1 1.6												1 0.6	2 0.6	
CARDIOMEGALY		1 0.9	1 0.5													1 0.6	1 0.3	
VARICOSE VEIN OF LEG NOS		1 0.9	1 0.5	1 1.6												1 0.6	2 0.6	
COMPRESSION OF VEIN		1 0.9	1 0.5													1 0.6	1 0.3	
CHRONIC SINUSITIS NOS		1 0.9	1 0.5	1 1.6												1 0.6	2 0.6	
ALLERGIC RHINITIS NOS		1 0.9	1 0.5													1 0.6	1 0.3	
CHRONIC BRONCHITIS NOS		1 0.9	1 0.5													1 0.6	1 0.3	
AC APPEND M PERITONITIS		1 0.9	1 0.5													1 0.6	1 0.3	
FEMORAL HERNIA		1 0.9	1 0.5													1 0.6	1 0.3	
DIVERTICULA SM INTESTINE		1 0.9	1 0.5													1 0.6	1 0.3	
RECTAL PROLAPSE		1 0.9	1 0.5													1 0.6	1 0.3	

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE – PROTOCOL 20124/035
TABLE No.: 16
MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS OF SCREENED PATIENTS BY DIAGNOSIS AND ASSIGNED TREATMENT

Previous diseases	Major Depressive Disorder						Dythyimia						Total					
	Imipramine			Reboxetine			Imipramine			Reboxetine			Imipramine			Reboxetine		
	No	Z on Pt.	Total	No	Z on Pt.	Total	No	Z on Pt.	Total	No	Z on Pt.	Total	No	Z on Pt.	Total	No	Z on Pt.	Total
CHOLECYSTITIS NEC		1 0.9	1 0.5	1 1.6			1 0.8	1 0.6	1 0.6	1 0.6	1 0.6	2 0.6				1 0.6	1 0.6	2 0.6
PROSTATIC DISORDER NOS		1 0.9	1 0.5									1 0.3				1 0.6	1 0.6	1 0.3
SPERMATOCELE		1 0.9	1 0.5									1 0.3				1 0.6	1 0.6	1 0.3
FEMALE GENITAL DIS NOS		1 0.9	1 0.5									1 0.3				1 0.6	1 0.6	1 0.3
LUMBAGO		1 0.9	1 0.5	1 1.6			1 0.8	1 0.6	1 0.6	1 0.6	1 0.6	2 0.6				1 0.6	1 0.6	2 0.6
BACKACHE NOS		1 0.9	1 0.5									1 0.3				1 0.6	1 0.6	1 0.3
ENTHESOPATHY NOS		1 0.9	1 0.5	1 1.6			1 0.8	1 0.6	1 0.6	1 0.6	1 0.6	2 0.6				1 0.6	1 0.6	2 0.6
OTH MUSCLE/LIGAMENT DIS		1 0.9	1 0.5									1 0.3				1 0.6	1 0.6	1 0.3
OSTEOCHONDROPATHY NOS		1 0.9	1 0.5	1 1.6			1 0.8	1 0.6	1 0.6	1 0.6	1 0.6	2 0.6				1 0.6	1 0.6	2 0.6
SCOLIOSIS		1 0.9	1 0.5									1 0.3				1 0.6	1 0.6	1 0.3
CYSTIC KIDNEY DISEASE		1 0.9	1 0.5									1 0.3				1 0.6	1 0.6	1 0.3
CONGEN HIP DISLOCATION		1 0.9	1 0.5									1 0.3				1 0.6	1 0.6	1 0.3
ANOMALIES OF SPINE		1 0.9	1 0.5	1 1.6			1 0.8	1 0.6	1 0.6	1 0.6	1 0.6	2 0.6				1 0.6	1 0.6	2 0.6
SYNCOPE AND COLLAPSE		1 0.9	1 0.5									1 0.3				1 0.6	1 0.6	1 0.3
CONVULSIONS		1 0.9	1 0.5									1 0.3				1 0.6	1 0.6	1 0.3
SKIN SENSATION DISTURB		1 0.9	1 0.5									1 0.3				1 0.6	1 0.6	1 0.3
ANOREXIA		1 0.9	1 0.5									1 0.3				1 0.6	1 0.6	1 0.3
INCONTINENCE OF URINE		1 0.9	1 0.5									1 0.3				1 0.6	1 0.6	1 0.3
ELEVATED SEDIMENT RATE		1 0.9	1 0.5									1 0.3				1 0.6	1 0.6	1 0.3
ABNORMAL REFLEX		1 0.9	1 0.5								1 1.5	1 0.8				2 1.1	2 1.1	2 0.6
FX DORSAL VERTEBRA-CLOSE		1 0.9	1 0.5									1 0.3				1 0.6	1 0.6	1 0.3
FX LUMBAR VERTEBRA-CLOSE		1 0.9	1 0.5									1 0.3				1 0.6	1 0.6	1 0.3

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 16
MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS OF SCREENED PATIENTS BY DIAGNOSIS AND ASSIGNED TREATMENT

Previous diseases	Major Depressive Disorder						Dysthymia						Total					
	Imipramine			Reboxetine			Imipramine			Reboxetine			Imipramine			Reboxetine		
	No	Z on Pt.	Total	No	Z on Pt.	Total	No	Z on Pt.	Total	No	Z on Pt.	Total	No	Z on Pt.	Total	No	Z on Pt.	Total
FX LOWER RADIUS/ULNA-CL		1 0.9	1 0.5													1 0.6	1 0.3	
TRASCERV FX FEKUR-CLOSE		1 0.9	1 0.5			1 1.5	1 0.8					2 1.1	2 0.6					
TRAUMATIC BRAIN HEM NEC		1 0.9	1 0.5													1 0.6	1 0.3	
TOXIC EFFECT METALS NEC		1 0.9	1 0.5													1 0.6	1 0.3	
SUICIDE/SELF-INJURY NOS		1 0.9	1 0.5													1 0.6	1 0.3	
EYE REPLACEMENT NEC		1 0.9	1 0.5													1 0.6	1 0.3	
CARDIAC PACEMAKER STATUS		1 0.9	1 0.5													1 0.6	1 0.3	
ENTERITIS OF INFECT ORIG								1 1.6				1 0.8	1 0.3					
MALIG NEO SKIN TRUNK								1 1.6				1 0.8	1 0.3					
BEN NEO GI TRACT NEC/NOS								1 1.6				1 0.8	1 0.3					
UNCERT BEHAV NEO UTERUS								1 1.6				1 0.8	1 0.3					
GOLTER NOS								1 1.6	1 1.5	2 1.6	1 0.6	1 0.6	2 0.6					
SYRINGOMYELIA								1 1.6				1 0.8	1 0.3					
NEUROPATHY IN DIABETES								1 1.6	1 1.5	2 1.6	1 0.6	1 0.6	2 0.6					
KERATITIS NOS								1 1.6				1 0.8	1 0.3					
DEGEN/VASCULAR DIS EAR								1 1.6				1 0.8	1 0.3					
RT BUNDLE BRANCH BLOCK								1 1.6				1 0.8	1 0.3					
ENTRACRANIAL HEMORR NOS								1 1.6				1 0.8	1 0.3					
VERTEBRAL ART OCCLUSION								1 1.6				1 0.8	1 0.3					
CEREBR ARTERY OCCCLUS NOS								1 1.6				1 0.8	1 0.3					
SYNDROME RAYNAUD								1 1.6				1 0.8	1 0.3					
POLYP OF NASAL CAVITY								1 1.6				1 0.8	1 0.3					

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No. : 46

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS OF SCREENED PATIENTS BY DIAGNOSIS AND ASSIGNED TREATMENT

Previous diseases	Major Depressive Disorder						Dysthymia						Total					
	Imipramine			Reboxetine			Imipramine			Reboxetine			Imipramine			Reboxetine		
	No	Z on Pt.	Total	No	Z on Pt.	Total	No	Z on Pt.	Total	No	Z on Pt.	Total	No	Z on Pt.	Total	No	Z on Pt.	Total
IRRITABLE COLON							1	1.6	1	1.5	2	1.6	1	0.6	1	0.6	2	0.6
RENAL SCLEROSIS NOS							1	1.6			1	0.8	1	0.6			1	0.3
CALCULUS OF KIDNEY							1	1.6			1	0.8	1	0.6			1	0.3
SYMPTOMS IN BREAST							1	1.6			1	0.8	1	0.6			1	0.3
UTERINE PROLAPSE							1	1.6			1	0.8	1	0.6			1	0.3
CIRCUMSCRIBE SCLERODERMA							1	1.6			1	0.8	1	0.6			1	0.3
KERATODERMA, ACQUIRED							1	1.6			1	0.8	1	0.6			1	0.3
SHOULDER REGION DIS NEC							1	1.6			1	0.8	1	0.6			1	0.3
EDEMA							1	1.6			1	0.8	1	0.6			1	0.3
PALPITATIONS							1	1.6			1	0.8	1	0.6			1	0.3
CARPAL FRACTURE							1	1.6			1	0.8	1	0.6			1	0.3
FX NECK OF FEMUR NOS-CL							1	1.6	1	1.5	2	1.5	1	0.6	1	0.6	2	0.6
CONCUSSION							1	1.6			1	0.8	1	0.6			1	0.3
TRAUM SUBARACHNOID BEN							1	1.6			1	0.8	1	0.6			1	0.3
BRAIN INJURY NEC							1	1.6			1	0.8	1	0.6			1	0.3
MALIGNANT NEOPL RECTUM									1	1.5	1	0.8			1	0.6	1	0.3
BREAST NEOPLASH NOS									1	1.5	1	0.8			1	0.6	1	0.3
SIMPLE GOITER									1	1.5	1	0.8			1	0.6	1	0.3
PROTOZOAL ENCEPHALITIS									1	1.5	1	0.8			1	0.6	1	0.3
FACIAL NERVE DIS NOS									1	1.5	1	0.8			1	0.6	1	0.3
ATHEROSCLEROSIS NOS									1	1.5	1	0.8			1	0.6	1	0.3
AORTIC ANEURYSM NOS									1	1.5	1	0.8			1	0.6	1	0.3

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No. : 16

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS OF SCREENED PATIENTS BY DIAGNOSIS AND ASSIGNED TREATMENT

Previous diseases	Major Depressive Disorder						Dysthymia						Total						
	Imipramine			Reboxetine			Total			Imipramine			Reboxetine			Total			
	No	X on Pt.	Z on Pt.	No	X on Pt.	Z on Pt.	No	X on Pt.	Z on Pt.	No	X on Pt.	Z on Pt.	No	X on Pt.	Z on Pt.	No	X on Pt.	Z on Pt.	
GIANT CELL ARTERITIS																			
OBSTRUCT CHR BRONCHITIS																			
ATROPHIC GASTRITIS																			
CHRONIC LIVER DIS NEC																			
RHEUMATOID ARTHRITIS																			
CERVICAL DISC DISPLACMNT																			
ESOPHAGEAL ANOMALY NEC																			
TACHICARDIA NOS																			
FX UPPER HUMERUS-CLOSED																			
FALL NEC NOS																			
BX-MAJOR CARDIOVASC SURG																			
COLOSTOMY STATUS																			

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 17

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS OF SCREENED PATIENTS BY BODY SYSTEM, DIAGNOSIS AND ASSIGNED TREATMENT

Previous diseases (body system)	Major Depressive Disorder						Dysthymia						Total									
	Imipramine			Reboxetine			Imipramine			Reboxetine			Imipramine			Reboxetine						
	No	X on Pt.	Z on Pt.	No	X on Pt.	Z on Pt.	No	X on Pt.	Z on Pt.	No	X on Pt.	Z on Pt.	No	X on Pt.	Z on Pt.	No	X on Pt.	Z on Pt.				
Screened Patients	109	100	100	109	100	100	218	100	100	62	100	100	129	100	100	171	100	100	347	100	100	
CIRCULATORY SYSTEM	48	44.0	37	33.9	85	39.0	29	46.8	30	44.8	59	45.7	77	45.0	67	38.1	144	41.5	144	41.5	144	41.5
ENDOCR., NUTRIT. AND METAB. DISEASES	11	10.1	14	12.8	25	11.5	13	21.0	14	20.9	27	20.9	24	14.0	28	15.9	52	15.0	52	15.0	52	15.0
MUSCULOSKELETAL SYS. AND CONNECTIVE TISSUE	14	12.8	17	15.6	31	14.2	13	21.0	10	14.9	23	17.8	27	15.8	27	15.3	54	15.6	54	15.6	54	15.6
SYMPTOMS, SIGNS AND ILL DEFINED CONDITIONS	7	6.4	13	11.9	20	9.2	5	8.1	4	6.0	9	7.0	12	7.0	17	9.7	29	8.4	29	8.4	29	8.4
GENITOURINARY SYSTEM	13	11.9	9	8.3	22	10.1	7	11.3	6	9.0	13	10.1	20	11.7	15	8.5	35	10.1	35	10.1	35	10.1
NEOPLASM	15	13.8	13	11.9	28	12.8	4	6.5	5	7.5	9	7.0	19	11.1	18	10.2	37	10.7	37	10.7	37	10.7
DIGESTIVE SYSTEM	17	15.6	25	22.9	42	19.3	11	17.7	12	17.9	23	17.8	28	16.4	37	21.0	65	18.7	65	18.7	65	18.7
BLOOD AND BLOOD-FORMING ORGANS	3	2.8	4	3.7	7	3.2											3	1.8	4	2.3	7	2.0
INFECTIOUS AND PARASITIC DISEASE	3	2.8	3	2.8	6	2.8	1	1.6			1	0.8	4	2.3	3	1.7	7	2.0	7	2.0	7	2.0
NERVOUS SYSTEM AND SENSE ORGANS	11	10.1	12	11.0	23	10.6	7	11.3	8	11.9	15	11.6	18	10.5	20	11.4	38	11.0	38	11.0	38	11.0
OTHER	4	3.7	7	6.4	11	5.0			5	7.5	5	3.9	4	2.3	12	6.8	16	4.6	16	4.6	16	4.6
RESPIRATORY SYSTEM	5	4.6	8	7.3	13	6.0	3	4.8	1	1.5	4	3.1	8	4.7	9	5.1	17	4.9	17	4.9	17	4.9
MENTAL DISORDERS			3	2.8	3	1.4			2	3.0	2	1.6			5	2.8	5	1.4	5	1.4	5	1.4
INJURY AND POISONING	3	2.8	5	4.6	8	3.7	3	4.8	2	3.0	5	3.9	6	3.5	7	4.0	13	3.7	13	3.7	13	3.7
CONGENITAL ANOMALIES			3	2.8	3	1.4	1	1.6	1	1.5	2	1.6	1	0.6	4	2.3	5	1.4	5	1.4	5	1.4
SKIN AND SUBCUTANEOUS TISSUE							2	3.2			2	1.6	2	1.2			2	0.6	2	0.6	2	0.6

PHARMACIA CNS-388
9530089

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 18

EXPERIMENTAL TREATMENT: NUMBER OF PATIENTS ACCORDING TO DOSE TAKEN ON EACH DAY AND ON DAYS OF ASSESSMENT DURING THERAPY BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

days of treatment	Dose (mg/day)												Total	
	0		2		4		6		8		10			
	No	%	No	%	No	%	No	%	No	%	No	%	No	%
Day 0	1		15	8.5	161	91.5							176	100
2			3	1.7	171	98.3							174	100
3			5	2.9	166	96.5	1	0.6					172	100
4	2	1.2	2	1.2	165	96.5	2	1.2					171	100
5	2	1.2	1	0.6	166	97.6	1	0.6					170	100
6	1	0.6	7	4.1	161	94.7	1	0.6					170	100
7	1	0.6	2	1.2	162	97.6	1	0.6					166	100
8					8	100							8	100
Day 7	1	0.6			163	98.8	1	0.6					165	100
2	1	0.6	3	1.8	160	97.6							164	100
3	2	1.2	2	1.2	160	97.6							164	100
4	1	0.6	4	2.4	159	97.0							164	100
5			5	3.0	159	97.0							164	100
6	1	0.6	1	0.6	159	98.8							161	100
7	1	0.6	3	1.9	152	97.4							156	100
8			1	14.3	6	85.7							7	100
Day 14	1	1.2	1	0.6	158	98.1							161	100
2	1	0.6	3	1.9	157	97.5							161	100
3	1	0.6	4	2.5	156	96.9							161	100
4	2	1.2	4	2.5	155	96.3							161	100
5	1	0.6	4	2.5	155	96.9							160	100
6	1	0.6	8	5.0	150	94.3							159	100
7	2	1.3	2	1.3	148	96.7	1	0.7					153	100
8	1	50.0			1	50.0							2	100
Day 21	1		2	1.3	114	75.0	36	23.7					152	100
2	1	0.7	1	0.7	109	72.2	40	26.5					151	100
3	3	2.0	4	2.6	104	68.9	40	26.5					151	100
4	2	1.3	4	2.7	104	69.3	40	26.7					150	100
5	2	1.3	2	1.3	105	70.5	40	26.8					149	100
6	2	1.4	2	1.4	104	70.3	40	27.0					148	100
7	3	2.1	2	1.4	99	68.3	40	27.6			1	0.7	145	100
8	1	12.5			5	62.5	2	25.0					8	100
9					1	100							1	100
Day 28	1	0.7			97	67.8	44	30.8			1	0.7	143	100
2			2	1.4	94	66.2	46	32.4					142	100
3					96	67.6	46	32.4					142	100
4	1	0.7			95	67.4	45	31.9					141	100
5			2	1.4	94	66.7	45	31.9					141	100
6			1	0.7	96	68.1	44	31.2					141	100
7			1	0.7	91	67.9	42	31.3					134	100
8	1	10.0			6	60.0	3	30.0					10	100
9	1	100											1	100
Day 35	1				94	68.6	42	30.7			1	0.7	137	100
2	1	0.7	3	2.2	88	64.7	44	32.4					136	100
3			1	0.7	92	67.6	43	31.6					136	100
4	1	0.7	1	0.7	90	66.2	44	32.4					136	100
5			1	0.7	91	66.9	44	32.4					136	100
6			2	1.5	89	66.4	43	32.1					134	100
7					86	65.2	46	34.8					132	100
8			1	33.3	1	33.3	1	33.3					3	100
Day 42	1				90	68.2	42	31.8					132	100
2			1	0.8	89	67.4	42	31.8					132	100
3	2	1.5			87	66.4	42	32.1					131	100
4			2	1.5	88	67.2	41	31.3					131	100
5			1	0.8	87	66.9	42	32.3					130	100
6					88	67.7	42	32.3					130	100
7					88	70.4	37	29.6					125	100
8							1	100					1	100
Day 49	1	0.8			88	68.2	40	31.0					129	100
2	1	0.8	2	1.6	87	67.4	39	30.2					129	100
3	1	0.8	1	0.8	87	67.4	40	31.0					129	100
4	2	1.6	1	0.8	86	66.7	39	30.2	1	0.8			129	100
5	1	0.8			88	68.2	40	31.0					129	100
6	1	0.8			88	68.8	39	30.5					128	100
7	1	0.8	2	1.6	86	67.7	38	29.9					127	100
8	1	6.3	5	31.3	10	62.5							16	100
Day 56	1				1	100							1	100
2					1	100							1	100
3					1	100							1	100
4					1	100							1	100

(CONTINUED)

PHARMACIA CN-440
953089

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 18

EXPERIMENTAL TREATMENT: NUMBER OF PATIENTS ACCORDING TO DOSE TAKEN ON EACH DAY AND ON DAYS OF ASSESSMENT DURING THERAPY BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

days of treatment	Dose (mg/day)												Total	
	0		2		4		6		8		10			
	No	%	No	%	No	%	No	%	No	%	No	%	No	%
Day 5					1	100							1	100
6					1	100							1	100
7					1	100							1	100

PHARMACIA CNS-448
530089

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 18

EXPERIMENTAL TREATMENT: NUMBER OF PATIENTS ACCORDING TO DOSE TAKEN ON EACH DAY AND ON DAYS OF ASSESSMENT DURING THERAPY BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

days of treatment	Dose (mg/day)																
	0		25		50		75		100		125		150		Total		
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	
Day 0	1		18	10.5	152	88.9									171	100	
2	2	1.2	3	1.8	166	97.1									171	100	
3			5	2.9	165	97.1									170	100	
4			1	0.6	4	2.4	161	96.4					1	0.6	167	100	
5	1	0.6	4	2.4	1	0.6	161	96.4							167	100	
6	1	0.6	4	2.4	1	0.6	159	96.4							165	100	
7	2	1.2	4	2.5	2	1.2	153	94.4					1	0.6	162	100	
8							9	100							9	100	
9							2	100							2	100	
Day 7	1		2	1.3			156	98.7							158	100	
2	1	0.6	6	3.8	1	0.6	149	94.3	1	0.6					158	100	
3			4	2.6	3	1.9	148	95.5							155	100	
4	1	0.6	2	1.3			151	98.1							154	100	
5	1	0.6	3	1.9			150	97.4							154	100	
6	2	1.3	4	2.6			146	96.1							152	100	
7	2	1.3	2	1.3	1	0.7	145	96.7							150	100	
8	1	10.0	2	20.0			7	70.0							10	100	
Day 14	1	0.7	2	1.4			143	97.9							146	100	
2	1	0.7	1	0.7	2	1.4	142	97.3							146	100	
3	3	2.1	2	1.4	1	0.7	139	95.9							145	100	
4	1	0.7	1	0.7			143	98.6							145	100	
5	1	0.7	1	0.7	1	0.7	142	97.9							145	100	
6	1	0.7	2	1.4			141	97.2	1	0.7					145	100	
7			2	1.4			137	98.6							139	100	
8			1	20.0			4	80.0							5	100	
Day 21	1	0.7					108	76.6	32	22.7					141	100	
2			1	0.7	1	0.7	107	75.9	32	22.7					141	100	
3			1	0.7	1	0.7	107	75.9	32	22.7					141	100	
4			1	0.7	2	1.4	105	75.0	32	22.9					140	100	
5			2	1.4	1	0.7	103	74.1	33	23.7					139	100	
6			1	0.7			104	75.4	33	23.9					138	100	
7			4	3.0			99	73.3	32	23.7					135	100	
8							2	40.0	3	60.0					5	100	
Day 28	1	0.7	1	0.7	2	1.4	97	70.3	36	26.1	1	0.7			138	100	
2			1	0.7	2	1.5	96	70.1	38	27.7					137	100	
3			2	1.5	1	0.7	95	69.3	39	28.5					137	100	
4			2	1.5	3	2.2	94	68.6	38	27.7					137	100	
5			2	1.5	1	0.7	93	68.4	40	29.4					136	100	
6			2	1.5	1	0.7	94	69.6	38	28.1					135	100	
7	2	1.6	2	1.6	2	1.6	89	69.0	33	25.6	1	0.8			129	100	
8	1	11.1					5	55.6	3	33.3					9	100	
Day 35	1	0.8	2	1.5			91	69.5	38	29.0					131	100	
2	1	0.8	2	1.5	2	1.5	89	67.9	37	28.2					131	100	
3	2	1.5	3	2.3	1	0.8	89	67.9	36	27.5					131	100	
4			2	1.5			91	70.0	37	28.5					130	100	
5			2	1.6	1	0.8	89	69.0	37	28.7					129	100	
6			2	1.6			90	69.8	37	28.7					129	100	
7			2	1.6			87	69.0	37	29.4					126	100	
8							5	83.3	1	16.7					6	100	
Day 42	1	0.8	1	0.8			91	70.5	37	28.7					129	100	
2			1	0.8	2	1.6	89	69.5	36	28.1					128	100	
3			1	0.8	1	0.8	90	70.3	36	28.1					128	100	
4			1	0.8			90	70.3	37	28.9					128	100	
5			2	1.6	1	0.8	88	68.8	37	28.9					128	100	
6			2	1.6			89	69.5	37	28.9					128	100	
7							86	69.9	36	29.3	1	0.8			123	100	
8							2	100							2	100	
Day 49	1	0.8	1	0.8			90	70.9	36	28.3					127	100	
2			1	0.8	2	1.6	89	70.1	35	27.6					127	100	
3	1	0.8	3	2.4	1	0.8	86	67.7	36	28.3					127	100	
4	2	1.6	2	1.6	2	1.6	86	68.3	34	27.0					126	100	
5	2	1.6	1	0.8			88	69.8	35	27.8					126	100	
6	1	0.8	1	0.8			87	69.6	36	28.8					125	100	
7	1	0.8	1	0.8			86	69.9	34	27.6				1	0.8	123	100
8			8	47.1	3	17.6	4	23.5	2	11.8					17	100	
Day 56	1						1	100							1	100	
2							1	100							1	100	
3							1	100							1	100	
4							1	100							1	100	
5							1	100							1	100	

(CONTINUED)

PHARMACIA ~~CV-228~~
5530089

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 18

EXPERIMENTAL TREATMENT: NUMBER OF PATIENTS ACCORDING TO DOSE TAKEN ON EACH DAY
AND ON DAYS OF ASSESSMENT DURING THERAPY BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

days of treatment	Dose (mg/day)														Total		
	0		25		50		75		100		125		150				
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	
Day 56	6							1	100							1	100
	7							1	100							1	100
	8							1	100							1	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 19

EXPERIMENTAL TREATMENT: NUMBER OF PATIENTS WHO SWITCHED FROM LOW TO HIGH DOSE BY ASSIGNED TREATMENT

		Total		visit of first change in dose					
		No	%	Day 0	Day 21	Day 28	Day 35	Day 42	Day 49
Major Depressive Disorder	Imipramine	85	77.98	85					
	at least one high dose	24	22.02		19	5			
	Total	109	100.0	85	19	5			
	Reboxetine	79	72.48	79					
	at least one high dose	30	27.52		23	5	2		
	Total	109	100.0	79	23	5	2		
Dysthymia	Imipramine	46	74.19	46					
	at least one high dose	16	25.81		14	2			
	Total	62	100.0	46	14	2			
	Reboxetine	47	70.15	47					
	at least one high dose	20	29.85		19	1			
	Total	67	100.0	47	19	1			
Total	Imipramine	131	76.61	131					
	at least one high dose	40	23.39		33	7			
	Total	171	100.0	131	33	7			
	Reboxetine	126	71.59	126					
	at least one high dose	50	28.41		42	6	2		
	Total	176	100.0	126	42	6	2		

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No. 1 20

EXPERIMENTAL TREATMENT: DISTRIBUTION OF PATIENTS ACCORDING TO CAPSULES TAKEN BY ASSIGNED TREATMENT

	Compliance												Total	
	< 80 %		80 - 89 %		90 - 95 %		95 - 99 %		100 %				No	%
	No	%	No	%	No	%	No	%	No	%	No	%		
Major Depressive Disorder	Imipramine	2	1.8	2	1.8	9	8.3	26	23.9	70	64.2	109	100.0	
	Reboxetine	3	2.8	4	3.7	8	7.3	33	30.3	61	56.0	109	100.0	
	Total	5	2.3	6	2.8	17	7.8	59	27.1	131	60.1	218	100.0	
Dysthymia	Imipramine					5	8.1	11	17.7	46	74.2	62	100.0	
	Reboxetine	3	4.5	2	3.0	2	3.0	13	19.4	47	70.1	67	100.0	
	Total	3	2.3	2	1.6	7	5.4	24	18.6	93	72.1	129	100.0	
Total	Imipramine	2	1.2	2	1.2	14	8.2	37	21.6	116	67.8	171	100.0	
	Reboxetine	6	3.4	6	3.4	10	5.7	46	26.1	108	61.4	176	100.0	
	Total	8	2.3	8	2.3	24	6.9	83	23.9	224	64.6	347	100.0	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 21
 CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
 BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline						During treatment						Total	
	Reboxetine		Imipramine		Total		Reboxetine		Imipramine		Total		Reboxetine	Imipramine
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
TEMAZEPAM	M.D.D.	17	19	3	1	20								
	Dysthymia	6	4	2		8								
	Total	23	23	5	1	28								
LORNETAZEPAM	M.D.D.	12	12		2	14								
	Dysthymia	6	5	3		9								
	Total	18	17	3	2	21								
ACETYLSALICYLIC ACID	M.D.D.	12	9		1	12								
	Dysthymia	7	6	1		8								
	Total	19	15	1	2	20								
LACTULOSE	M.D.D.	4	7	5	3	9								
	Dysthymia	1	5	5	1	6								
	Total	5	12	10	4	15								
CHLORAL HYDRATE	M.D.D.	5	7	1	6	13								
	Dysthymia		2	2		4								
	Total	5	9	3	6	15								
PARACETANOL	M.D.D.	4	3	3	3	7								
	Dysthymia	2	1			3								
	Total	6	4	3	3	9								
ISOSORBIDE DINITRATE	M.D.D.	3	6	1	1	4								
	Dysthymia	2	2			4								
	Total	5	8	1	1	6								
ALLOPURINOL	M.D.D.	4	2	1		5								

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 21
 CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
 BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline		During treatment		Total	
	Reboxetine	Imipramine	Reboxetine	Imipramine	Reboxetine	Imipramine
	No.	No.	No.	No.	No.	No.
ALLOPURINOL	Dysthymia	2	5		2	5
	Total	6	7	1	7	7
	M.D.D.	5	6		5	6
DIGOXIN	Dysthymia	1	2		1	2
	Total	6	8		6	8
	M.D.D.	3	2	1	4	3
LORAZEPAM	Dysthymia	3	2	1	4	2
	Total	6	4	2	8	5
	M.D.D.	5	3		5	3
HYDROGIN	Dysthymia	2	1		2	1
	Total	7	4		7	4
	M.D.D.	4	1	1	5	2
METOCLOPRAMIDE	Dysthymia			2	2	1
	Total	4	1	3	7	3
	M.D.D.	3	2	1	4	2
OMEPRAZOLE	Dysthymia	1	2		1	3
	Total	4	4	1	5	5
	M.D.D.	4	3		4	3
MODURETIC	Dysthymia	1	1		1	1
	Total	5	4		5	4
	M.D.D.	1	2		1	2
NIFEDIPINE	Dysthymia	3	3		3	3

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 21
 CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline		During treatment		Total	
	Reboxetine	Imipramine	Reboxetine	Imipramine	Reboxetine	Imipramine
	No.	No.	No.	No.	No.	No.
NIFEDIPINE	Total	4	5		4	5
	M.D.D.	2	3		2	4
	Dysthymia	2	1		2	1
DICLOFENAC	Total	4	4	1	4	5
	M.D.D.	1	2	1	2	2
	Dysthymia	2	2		2	2
PROPRANOLOL	Total	3	4	1	4	4
	M.D.D.	3	2		3	2
	Dysthymia	3			3	
FUROSEMIDE	Total	6	2		6	2
	M.D.D.	2	3		2	3
	Dysthymia	1	2		1	2
DIAZIDE	Total	3	5		3	5
	M.D.D.	1		3	4	3
	Dysthymia			1	1	
SERRA	Total	1	4	4	5	3
	M.D.D.	2	3		2	3
	Dysthymia	1	2		1	2
CAPTOPRIL	Total	2	1		2	1
	M.D.D.	2	4		2	4
	Dysthymia	2	1		2	1
ANETHOLE	Total	4	4		4	4
	M.D.D.	2		2	2	2
	Dysthymia	2		2	2	2
	Total	2		2	4	4
	M.D.D.	2		2	2	2
	Dysthymia	2		2	2	2

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 21
 CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline			During treatment			Total		
	Reboxetine	Imipramine	No.	Reboxetine	Imipramine	No.	Reboxetine	Imipramine	No.
	No.	No.	No.	No.	No.	No.	No.	No.	No.
ZOLPIDER	N.D.D.	3	2	1			4		2
	Dysthymia	2					2		
	Total	5	2	1			6		2
DEXTROROPROXYPHENE	N.D.D.	2	1		1		2		2
	Dysthymia	1	1	1			2		1
	Total	3	2	1	1		4		3
PAYNOCIL	N.D.D.	2	2				2		2
	Dysthymia	2	1				2		1
	Total	4	3				4		3
GLIBENCLAMIDE	N.D.D.	2	1				2		1
	Dysthymia	1	3				1		3
	Total	3	4				3		4
SODIUM PICO SULFATE	N.D.D.	1				2	1		2
	Dysthymia			2		2	2		2
	Total	1		2		4	3		4
ATENOLOL	N.D.D.	2	2	1			3		2
	Dysthymia		2						2
	Total	2	4	1			3		4
NORFLOXACIN	N.D.D.	1		1		3	2		3
	Dysthymia					2	2		2
	Total	1		1		5	2		5
ZOPICLONE	N.D.D.		4			2			6

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline		During treatment		Total	
	Reboxetine	Imipramine	Reboxetine	Imipramine	Reboxetine	Imipramine
	No.	No.	No.	No.	No.	No.
ZOPICLONE	Dysthymia	1				1
	Total	1	4		2	1
	M.D.D.	3			1	3
GLYCERYL TRINITRATE	Dysthymia		2			2
	Total	3	2	1	3	3
	M.D.D.	1	3	2		1
IRON	Total	1	3	2	1	5
	M.D.D.	1	3	2		1
	Total	1	3	2	2	5
NITROFURANTOIN	M.D.D.			1	1	1
	Dysthymia	1	1	1	1	2
	Total	1	1	2	2	3
MEBEVERINE	M.D.D.	1	1	1		2
	Dysthymia	1	2			1
	Total	2	3	1		3
FLUNITRAZEPAN	M.D.D.	1	2	2		3
	Dysthymia	1				1
	Total	2	2	2		4
RANITIDINE	M.D.D.	2	2			2
	Dysthymia	1	1			1
	Total	3	3			3
ENALAPRIL	M.D.D.	3	1			3
	Dysthymia		2			2
	Total	3	3			3

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline		During treatment		Total	
	Reboxetine	Imipramine	Reboxetine	Imipramine	Reboxetine	Imipramine
	No.	No.	No.	No.	No.	No.
POTASSIUM	M.D.D.			1	1	1
	Dysthymia	1		2		3
	Total	1		3		4
LEVOTHYROXINE	M.D.D.		2		2	
	Dysthymia	2				2
	Total	2	2	1	2	3
GINKGO TREE LEAVES EXTRACT	Dysthymia	2	3			3
	Total	2	3			3
	M.D.D.	2	1			1
CINNETIDINE	Dysthymia	1	1			1
	Total	3	2			3
	M.D.D.	1	1			1
BROMAZEPAM	Dysthymia		2		1	3
	Total	1	3		1	4
	M.D.D.	2	1		1	2
DOMPERIDONE	Dysthymia		1			1
	Total	2	2		1	3
	M.D.D.	3	1			3
FRUMIL	Dysthymia		1			1
	Total	3	2			3
	M.D.D.	2	1			2
THEOPHYLLINE	Dysthymia	1				1

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21
CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline		During treatment		Total	
	Reboxetine	Imipramine	Reboxetine	Imipramine	Reboxetine	Imipramine
	No.	No.	No.	No.	No.	No.
THEOPHYLLINE	Total	3	1		3	1
	M.D.D.	1	1		1	1
	Dysthymia	1	1		1	1
VERAPAMIL	Total	2	2		2	2
	M.D.D.	1	1		1	1
	Dysthymia		2			2
DIGITOXIN	Total	1	1		1	1
	M.D.D.		2			2
	Dysthymia	1	3		1	3
CLONETHIAZOLE	Total	1	1	2	2	2
	M.D.D.	1	1	2	2	2
	Dysthymia	1	1	1	1	2
HEPARIN	Total	1	1	1	1	2
	M.D.D.	1	1	1	1	2
	Dysthymia	1	1	1	1	3
ISFAGHULA	Total	1	1	1	1	2
	M.D.D.	1	1	1	1	2
	Dysthymia	1	1	1	1	1
NYSTATIN	Total	1	1	1	1	2
	M.D.D.	1	1	1	1	2
	Dysthymia	1	1	1	1	3
DIPYRIDANOLE	Total	1	2	2	1	2
	M.D.D.	1	2	2	1	2
	Dysthymia	1	1	1	1	2
DOCUSATE	Total	2	2	2	1	2
	M.D.D.	1	1	2	1	2
	Dysthymia	1	1	2	1	2

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 21
 CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
 BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline			During treatment			Total	
	Reboxetine	Imipramine	No.	Reboxetine	Imipramine	No.	Reboxetine	Imipramine
	No.	No.	No.	No.	No.	No.	No.	
DOCUSATE	Dysthymia		1					1
	Total	1	1		2		1	3
	M.D.D.				1			1
BACTRIN	Dysthymia			1	2		1	2
	Total			1	3		1	3
	M.D.D.	1	1		1		1	2
Dysthymia	Total	1	1		1		1	2
	M.D.D.							
	Total	2	1		1		2	3
GLICLAZIDE	Dysthymia							
	Total	1	3				1	3
	M.D.D.							
DILTIAZEM	Dysthymia	1	3					
	Total	1	3				1	3
	M.D.D.		2					2
Dysthymia	Total		2					2
	M.D.D.							
	Total		4					4
AUGMENTIN	Dysthymia	1			2		1	2
	Total	1			1		1	2
	M.D.D.							
BISOPROLOL	Dysthymia	2					2	2
	Total	2					2	2
	M.D.D.	4					4	4
QUINAPRIL	Dysthymia	1					1	1
	Total	3					3	3
	M.D.D.							

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21
CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline			During treatment			Total		
	Reboxetine	Imipramine	No.	Reboxetine	Imipramine	No.	Reboxetine	Imipramine	No.
QUINAPRIL	Total		4						4
	M.D.D.		1						1
	Dysthymia		1						1
SINVASTATIN	Total		2						2
	M.D.D.		1						1
	Total		1						1
DIAZEPAM	Total		1			2			2
	M.D.D.		1			2			2
	Total		1			1			2
HALOPERIDOL	Total		1			1			2
	M.D.D.		1			1			2
	Dysthymia		1			1			1
NITRAZEPAM	Total		1			2			3
	M.D.D.		1			1			2
	Total		1			1			2
OXAZEPAM	Total		1			1			2
	M.D.D.		2			1			3
	Total		2			1			3
DIHYDROCODEINE	Total		2			2			4
	M.D.D.		2			2			4
	Dysthymia		1						1
BISACODYL	Total		1			2			3
	M.D.D.		1			1			2
	Dysthymia		1						1
ACETYLCYSTEINE	Total		2			1			3
	M.D.D.		1			1			2
	Dysthymia		1						1
Total	Total		1			1			2
	M.D.D.		1			1			2
	Dysthymia		1			1			2

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 21
 CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
 BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline			During treatment			Total		
	Reboxetine	Inipramine	No.	Reboxetine	Inipramine	No.	Reboxetine	Inipramine	No.
	No.	No.	No.	No.	No.	No.	No.	No.	No.
ETILEFRINE	M.D.D.								3
	Total								3
	M.D.D.			1					1
STAURODOR	Dysthymia	1		1					2
	Total	1		2					3
	M.D.D.	2				1			2
SALBUTAMOL	Total	2				1			2
	M.D.D.								1
	Dysthymia								1
CLONIDINE	Total								2
	M.D.D.								1
	Dysthymia								1
CALCIUM GLUBIONATE	Total								2
	M.D.D.								1
	Dysthymia	2							2
NAFTIDROFURYL	Total	2		1					2
	M.D.D.								1
	Dysthymia	1							1
AMOXICILLIN	Total	1							2
	M.D.D.	1							1
	Dysthymia	1							1
	Total	2							2
	M.D.D.								1
	Dysthymia								1

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 21

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or Baseline			During treatment			Total	
	Reboxetine	Imipramine	No.	Reboxetine	Imipramine	No.	Reboxetine	Imipramine
	No.	No.	No.	No.	No.	No.	No.	
MADOPAR	M.D.D.		2					2
	Dysthymia		1					1
	Total		3					3
TAMOXIFEN	M.D.D.		2					2
	Total		2					2
	M.D.D.		1					1
NICERGOLINE	Dysthymia		1					1
	Total		1					1
	M.D.D.							
MANDELONITRILE GLUCOSIDE	Dysthymia							
	Total							
	M.D.D.							
FENOFIBRATE	Dysthymia							
	Total							
	M.D.D.							
PIROXICAN	Dysthymia							
	Total							
	M.D.D.							
BEZAFIBRATE	Dysthymia							
	Total							
	M.D.D.							
NEDGENYL	Dysthymia							
	Total							
	M.D.D.							
ALPRAZOLAN	Dysthymia							
	Total							
	M.D.D.							

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 21
 CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline			During treatment			Total		
	Reboxetine	Imipramine	No.	Reboxetine	Imipramine	No.	Reboxetine	Imipramine	No.
	No.	No.	No.	No.	No.	No.	No.	No.	No.
ALPRAZOLAM	Total	2	1				2	1	
	M.D.D.			1			1		
	Dysthymia			1			1		
ANLODIPINE	Total			2	1		2	1	
	M.D.D.	1					1		
	Dysthymia	2					2		
CORTISONE	Total	3					3		
	M.D.D.		1			1			2
	Total		1			1			2
DIHYDROERGOTAMINE	Total					1	1		1
	M.D.D.					1	1		1
	Total					1	1		1
ERYTHRONYCIN	Total					1			1
	M.D.D.					1			1
	Dysthymia					1			1
PROMETHAZINE	Total			1			1		1
	M.D.D.					1			1
	Dysthymia					1			1
CYPROHEPTADINE	Total		1				1		1
	M.D.D.					1			1
	Total		1			1			1
PILOCARPINE	Total								2
	M.D.D.					2			2
	Total					2			2
CARBAMAZEPINE	Total					1			1
	M.D.D.					1			1
	Total					1			1

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 21

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline			During treatment			Total	
	Reboxetine	Imipramine		Reboxetine	Imipramine		Reboxetine	Imipramine
		No.	No.		No.	No.		
CARBAZEPINE			1					1
	Total		2					2
	M.D.D.	1						1
THIAMINE								
	Total							
	M.D.D.							
ANTAZOLINE								
	Total							
	M.D.D.							
HYDROXYZINE								
	Total							
	M.D.D.							
ESTROGENS CONJUGATED								
	Total							
	M.D.D.							
PHEVAZOPYRIDINE								
	Total							
	M.D.D.							
AGARDOL								
	Total							
	M.D.D.							
BETHANECHOL								
	Total							
	M.D.D.							
AMIODARONE								
	Total							
	M.D.D.							
BETAHISTINE								
	Total							
	M.D.D.							

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline				During treatment				Total	
	Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine	Imipramine
	No.	No.	No.	No.	No.	No.	No.	No.	No.	
BETAHISTINE	Dysthymia	1							1	
	Total	2							2	
	M.D.D.	1							1	
TRIMETHOPRIM	Dysthymia				1					1
	Total	1			1				2	
	M.D.D.	1			1				2	
DOBBANEX	Total	1			1				2	
	M.D.D.	1			1				2	
	Total	1			1				2	
ESTRIOL	M.D.D.	1							1	
	Dysthymia						1			1
	Total	1					1		2	
APOREX	Dysthymia	1								2
	Total	1							2	
	M.D.D.	1							2	
NETILDIGOXIN	Dysthymia	1							1	1
	Total	1							1	1
	M.D.D.	1							1	1
GAVISCON	Total				1			1		1
	M.D.D.				1			1		1
	Total				1			1		1
FLURAZEPAN	M.D.D.				1			1		1
	Total				1			1		1
	M.D.D.				1			1		1
CANRENOIC ACID	Total				1			1		1
	Dysthymia	1								1
	Total	1			1				1	1
PENTOXIFYLLINE	M.D.D.	1								1
	Dysthymia	1								1
	Total	1							1	1

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 21
 CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
 BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline		During treatment		Total	
	Reboxetine	Imipramine	Reboxetine	Imipramine	Reboxetine	Imipramine
	No.	No.	No.	No.	No.	No.
PENTOXIFYLLINE	Total	2			2	
	M.D.D.			1		1
	Dysthymia		1			1
MICROLAX	Total		1		1	
	M.D.D.					
	Dysthymia		1			1
HEPTANINOL	Total			1		1
	M.D.D.					
	Dysthymia	1				1
PIRACETAM	Total	1			1	
	M.D.D.	1			1	
	Dysthymia			1		1
TIMOLOL	Total	1			1	
	M.D.D.					
	Dysthymia					
IPRATROPIUM	Total		2			2
	M.D.D.	1			1	
	Dysthymia					
CLOTLAPINE	Total	1			1	
	M.D.D.		1			1
	Dysthymia					
ACEBUTOLOL	Total		1			1
	M.D.D.					
	Dysthymia	1				1
LABETALOL	Total	1			1	
	M.D.D.	1			1	
	Dysthymia					
DIHYDROERGOTOXINE	Total	1			1	
	M.D.D.					
	Dysthymia		2			2
Total	Total					
	M.D.D.					
	Dysthymia		2			2

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTDCL 20124/035
 TABLE No.: 21
 CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or Baseline			During treatment			Total	
	Reboxetine No.	Imipramine No.	Total No.	Reboxetine No.	Imipramine No.	Total No.	Reboxetine	Imipramine
							No.	No.
TRIAZOLAM	M.D.D.	1					1	
	Dysthymia		1					1
	Total	1	1				1	1
TRIMETAZIDINE	M.D.D.	1					1	
	Dysthymia	1					1	
	Total	2					2	
ALDACTAZINE	M.D.D.	1					1	
	Dysthymia		1					1
	Total	1	1				1	1
REFACT	M.D.D.	2					2	
	Total	2					2	
	M.D.D.	1					1	
ACIFUGAN	Total	1					1	
	M.D.D.	1					1	
	Total	1					1	
PROPAFENONE	M.D.D.		1					1
	Dysthymia		1					1
	Total		2					2
MOLSIDOMINE	M.D.D.	1					1	
	Dysthymia	1					1	
	Total	2					2	
FOLINIC ACID	M.D.D.		1					1
	Total		1				1	
	M.D.D.	1					1	
MAXI-B 5000	Total	1					1	
	M.D.D.		1					1
	Total	1	1				1	1

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21
CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline		During treatment		Total	
	Reboxetine	Imipramine	Reboxetine	Imipramine	Reboxetine	Imipramine
	No.	No.	No.	No.	No.	No.
MAXI-B 5000	Total	1	1		1	1
	M.D.D.	1				1
	Dysthymia	1				1
ACETYLDIGOXIN	Total	2			2	
	M.D.D.	1			1	
	Dysthymia		1			1
BUFLONEDIL	Total	1			1	
	M.D.D.		1			1
	Dysthymia	1			1	
URTICA EXTRACT	Total	1	1		1	1
	M.D.D.	1	1		1	1
	Total	1	1		1	1
FAMOTIDINE	M.D.D.	1			1	
	Dysthymia		1		1	
	Total	1	1		2	
ISRADIPINE	M.D.D.		2			2
	Total		2			2
	M.D.D.	1		1		2
OFLOXACIN	Total	1		1		2
	Dysthymia		2			2
	Total		2			2
BROTIZOLAM	M.D.D.	1			1	
	Dysthymia		1		1	
	Total	1	1		2	
NITRENDIPINE	M.D.D.		1			1

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 21
 CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
 BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline			During treatment			Total	
	Reboxetine	Imipramine	No.	Reboxetine	Imipramine	No.	Reboxetine	Imipramine
	No.	No.	No.	No.	No.	No.	No.	
NITRENDIPIFINE	Dysthymia		1					1
	Total		2					2
	H.D.D.	1					1	
ALVITYL	Total	1					1	
	Dysthymia		2					2
	Total	1					1	
KYTTA-SEDATIVUM	Dysthymia		2					2
	Total		2					2
	H.D.D.	1					1	
LISINAPRIL	Total	1					1	
	Dysthymia		1					1
	Total	1					1	
NU-LAX	Dysthymia			1		1		1
	Total			1		1		1
	H.D.D.	1					1	
ENOXAPARIN	Dysthymia							1
	Total	1					1	
	H.D.D.		1					1
CARVEDILOL	Dysthymia							2
	Total		2					2
	H.D.D.	1					1	
SEDINAL	Dysthymia			1		1		1
	Total			1		1		1
	H.D.D.	1					1	
RECTOPAMBILINE	Dysthymia							1
	Total	1					1	
	H.D.D.		1					1
MILVADIPINE	Dysthymia							1
	Total	1					1	
	H.D.D.		1					1

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline			During treatment			Total	
	Reboxetine No.	Imipramine No.	Total No.	Reboxetine No.	Imipramine No.	Total No.	Reboxetine No.	Imipramine No.
ALPIDEM	M.D.D.	1					1	
	Total	1					1	
AMPICILLIN	M.D.D.				1			1
	Total				1			1
PHENOXYMETHYLPENICILLIN	M.D.D.			1			1	
	Total			1			1	
ETHANOL	M.D.D.				1			1
	Total				1			1
INDOMETACIN	M.D.D.	1					1	
	Total	1					1	
ACTIFED	M.D.D.							1
	Total							1
SPIRONOLACTONE	M.D.D.	1					1	
	Total	1					1	
BENDROFLUMETHIAZIDE	M.D.D.					1		1
	Total					1		1
CHLORAMPHENICOL	M.D.D.				1			1
	Total				1			1
CHLORPROTHIXENE	M.D.D.						1	1
	Total						1	1
CODEINE	M.D.D.	1						1
	Total	1						1

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21
CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline				During treatment				Total	
	Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine	Imipramine
	No.	No.	No.	No.	No.	No.	No.	No.	No.	
XANTINOL NICOTINATE			1							1
	Total		1							1
	M.D.D.						1			1
PETHIDINE	Total						1			1
	M.D.D.									
	Total						1			1
PHENYTOIN	M.D.D.	1								1
	Total	1								1
	M.D.D.						1			1
ESBERIVEN FORTE	Total									1
	M.D.D.						1			1
	Total									1
THIAZOLE	M.D.D.	1								1
	Total	1								1
	M.D.D.						1			1
SULFAMETHOXAZOLE	Total									1
	M.D.D.						1			1
	Total									1
GLUCOSE INJECTION	M.D.D.						1			1
	Total						1			1
	M.D.D.									1
OXYTETRACYCLINE	Total									1
	M.D.D.						1			1
	Total									1
INSULIN	Dysthymia	1								1
	Total	1								1
	Dysthymia									1
LIDOCAINE	Total						1			1
	Dysthymia									1
	Total						1			1
LOMOTIL	M.D.D.								1	1
	Total							1		1
	M.D.D.								1	1

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 21
 CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
 BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline				During treatment				Total	
	Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine	Imipramine
	No.	No.	No.	No.	No.	No.	No.	No.	No.	
PHENPROQUON	M.D.D.		1							1
	Total		1							1
MORPHINE	M.D.D.				1					1
	Total				1					1
MYLANTA	M.D.D.				1					1
	Total				1					1
CYCLOPENTHAZIDE	M.D.D.	1								1
	Total	1								1
LEVOPROMAZINE	Dysthymia					1				1
	Total					1				1
NORFENEFRINE	M.D.D.					1				1
	Total					1				1
PREDNISON	Dysthymia	1								1
	Total	1								1
PROPANTHELINE	Dysthymia									1
	Total									1
ESTRADIOL	Dysthymia							1		1
	Total							1		1
OXYCODONE	M.D.D.						1			1
	Total						1			1
QUININE	M.D.D.	1								1
	Total	1								1

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 21
 CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
 BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline			During treatment			Total		
	Reboxetine	Imipramine	No.	Reboxetine	Imipramine	No.	Reboxetine	Imipramine	No.
	No.	No.	No.	No.	No.	No.	No.	No.	No.
SALURES-K	Dysthymia					1			1
	Total					1			1
	M.D.D.	1							
PROHAZINE	Total	1							1
	M.D.D.	1							1
	Total	1							1
CHLORHEZANONE	Total	1							1
	M.D.D.	1							1
	Total	1							1
TROXERUTIN	Total	1							1
	M.D.D.	1							1
	Total	1							1
DOXYCYCLINE	Dysthymia						1		1
	Total						1		1
	M.D.D.								
CYANOCOBALAMIN	Dysthymia					1			1
	Total					1			1
	M.D.D.	1							
PYRIDOXINE	Total	1							1
	M.D.D.	1							1
	Total	1							1
BUCLIZINE	Dysthymia						1		1
	Total						1		1
	M.D.D.								
FUSIDIC ACID	Dysthymia						1		1
	Total						1		1
	M.D.D.	1							1
METFORMIN	Total	1							1
	M.D.D.	1							1
	Total	1							1
GERUROL	Total					1			1
	M.D.D.					1			1
	Total					1			1

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS RED
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline			During treatment			Total	
	Reboxetine	Imipramine	No.	Reboxetine	Imipramine	No.	Reboxetine	Imipramine
	No.	No.	No.	No.	No.	No.	No.	
MAALOX	M.D.D.		1					1
	Total		1					1
FRAMYCETIN	M.D.D.				1			1
	Total				1			1
VENOSTASIN FORTE	M.D.D.	1					1	
	Total	1					1	
ALPRENDLOL	Dysthymia		1					1
	Total		1					1
NOVOTRAL	M.D.D.	1					1	
	Total	1					1	
CINNARIZINE	Dysthymia		1					1
	Total		1					1
METHOTREXATE	M.D.D.				1			1
	Total				1			1
MUCAINE	M.D.D.				1			1
	Total				1			1
CEFRALOSPORIN C	Dysthymia			1				1
	Total			1				1
MYCOLOG	M.D.D.				1			1
	Total				1			1
CHLORHEXIDINE	M.D.D.				1			1
	Total				1			1

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline			During treatment			Total	
	Reboxetine No.	Imipramine No.	Total No.	Reboxetine No.	Imipramine No.	Total No.	Reboxetine No.	Imipramine No.
BRISERIN	M.D.D.		1					1
	Total		1					1
CODIPRONT	M.D.D.			1		1		
	Total			1		1		
OMPRENOLOL	M.D.D.	1						1
	Total	1						1
DANTRON	M.D.D.						1	1
	Total						1	1
NIFURTOLINOL	M.D.D.			1		1		
	Total			1		1		
FENTANYL	M.D.D.						1	1
	Total						1	1
NEUROBION FOR INJECTION	Dysthymia							1
	Total							1
CALCIUM PHOSPHATE	Dysthymia	1						1
	Total	1						1
FERROGRAD C	M.D.D.						1	1
	Total						1	1
PIMOZIDE	M.D.D.						1	1
	Total						1	1
BECLOMETASONE	M.D.D.	1						1
	Total	1						1

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R8D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No. : 21
 CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
 BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline			During treatment			Total		
	Reboxetine	Imipramine	No.	Reboxetine	Imipramine	No.	Reboxetine	Imipramine	No.
	No.	No.	No.	No.	No.	No.	No.	No.	No.
FLUCLOXACILLIN	M.D.D.					1			1
	Total					1			1
CLORAZEPIC ACID	M.D.D.							1	1
	Total							1	1
KATOVIT	M.D.D.					1			1
	Total					1			1
DISOPYRAMIDE	M.D.D.					1			1
	Total					1			1
CARYLOFIN	M.D.D.					1			1
	Total					1			1
VITAMIN B-COMPLEX FORTE	Dysthymia								1
	Total								1
	M.D.D.								1
LEFAX	M.D.D.							1	1
	Total							1	1
CLONAZEPAM	M.D.D.					1			1
	Total					1			1
AGIOLAX	M.D.D.							1	1
	Total							1	1
BUMETANIDE	M.D.D.							1	1
	Total							1	1
MICONAZOLE	M.D.D.							1	1
	Total							1	1

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 21

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline				During treatment				Total	
	Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine	Imipramine
	No.	No.	No.	No.	No.	No.	No.	No.	No.	
SULPIRIDE	Dysthymia				1				1	
	Total				1				1	
	M.D.D.									
METIPRANOLOL	Total						1			1
	Dysthymia						1			1
	Total						1			1
FRIBLASE CALCIUM FORTE	Dysthymia		1							1
	Total		1							1
	M.D.D.									
FENOTEROL	Dysthymia	1								1
	Total	1								1
	M.D.D.									
PRAZOSIN	Dysthymia	1								1
	Total	1								1
	M.D.D.									
INDAPAMIDE	Dysthymia	1								1
	Total	1								1
	M.D.D.									
DOREGRIPPIN	Dysthymia	1								1
	Total	1								1
	M.D.D.									
LINDIGOA DEPOT	Dysthymia		1							1
	Total		1							1
	M.D.D.									
PRAZEPAK	Dysthymia	1								1
	Total	1								1
	M.D.D.									
SINEMET	Dysthymia						1			1
	Total						1			1
	M.D.D.									
DEXETIMIDE	Dysthymia						1			1
	Total						1			1
	M.D.D.									

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 21
 CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
 BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline		During treatment		Total	
	Reboxetine	Imipramine	Reboxetine	Imipramine	Reboxetine	Imipramine
	No.	No.	No.	No.	No.	No.
LOPERAMIDE	M.D.D.			1		1
	Total			1		1
URAL	M.D.D.	1				1
	Total	1				1
GLIPIZIDE	M.D.D.	1				1
	Total	1				1
OXYCARDIN	M.D.D.				1	
	Total				1	
NEFOFAM	M.D.D.	1				1
	Total	1				1
POLYBION	M.D.D.			1		1
	Total			1		1
BURINEX K	M.D.D.				1	
	Total				1	
CISPLATIN	M.D.D.				1	
	Total				1	
SIMECO	M.D.D.	1				1
	Total	1				1
DIOSMIN	M.D.D.				1	
	Total				1	
SALINA	M.D.D.			1		1
	Total			1		1

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline		During treatment		Total	
	Reboxetine	Imipramine	Reboxetine	Imipramine	Reboxetine	Imipramine
	No.	No.	No.	No.	No.	No.
PRENPAK	M.D.D.	1				1
	Total	1				1
TOLU TINCTURE	M.D.D.		1		1	
	Total		1		1	
NADOLOL	M.D.D.		1		1	
	Total		1		1	
TENORETIC	M.D.D.		1		1	
	Total		1		1	
PINAVERIUM	M.D.D.	1			1	
	Total	1			1	
PIPERIDIC ACID	M.D.D.			1	1	
	Total			1	1	
LIQUIFILM TEARS	M.D.D.			1	1	
	Total			1	1	
GLIQUIDONE	Dysthymia		1		1	
	Total		1		1	
ACENETACIN	Dysthymia		1		1	
	Total		1		1	
OXYBUTYRIN	M.D.D.			1	1	
	Total			1	1	
CHOLAGOCIN NATTERMANN	Dysthymia		1		1	
	Total		1		1	

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS 880
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 21
 CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline			During treatment			Total	
	Reboxetine	Imipramine	No.	Reboxetine	Imipramine	No.	Reboxetine	Imipramine
GUANFACINE	M.D.D.		1					1
	Total		1					1
ISOFLORANE	M.D.D.				1			1
	Total				1			1
OHIBIONTA	M.D.D.		1					1
	Total		1					1
IPECACUANHA SYRUP	M.D.D.				1			1
	Total				1			1
OXATONIDE	M.D.D.	1						1
	Total	1						1
ISOSORBIDE	M.D.D.		1					1
	Total		1					1
TIAPROFENIC ACID	M.D.D.				1			1
	Total				1			1
TERFENADINE	M.D.D.				1			1
	Total				1			1
CALCIFEDIOL	M.D.D.							
	Total							
ETOFENAMATE	M.D.D.		1					1
	Total		1					1
EFFORTIL PLUS	M.D.D.	1						1
	Total	1						1

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 21
 CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
 BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline				During treatment				Total	
	Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine	Imipramine
	No.	No.	No.	No.	No.	No.	No.	No.	No.	
PYRIDOXAL PHOSPHATE MAGNESIUM GLUTAMINAT	Dysthymia		1							1
	Total		1							1
	M.D.D.									
ATRACURIUM	Total				1					1
	M.D.D.									
	Total				1					1
CLOTLAZEPAM	M.D.D.	1							1	
	Total	1							1	
	M.D.D.									
VALORON N	Total									
	M.D.D.									
	Total									
PIRETANIDE	Dysthymia	1								1
	Total	1								1
	M.D.D.									
MIDAZOLAM	Total									
	M.D.D.									
	Total									
TEARS NATURALE	Dysthymia		1							1
	Total		1							1
	M.D.D.	1								1
NICARDIPINE	Total	1								1
	M.D.D.									
	Total	1								1
NEOTRI	Dysthymia	1								1
	Total	1								1
	M.D.D.									
GALLOPAMIL	Dysthymia									
	Total									
	M.D.D.									
FELODIPINE	Total									
	M.D.D.									
	Total									

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or Baseline		During treatment		Total	
	Reboxetine	Imipramine	Reboxetine	Imipramine	Reboxetine	Imipramine
	No.	No.	No.	No.	No.	No.
FELODIPINE						
	Total		1			1
MAGNESIUM VERLA DRAGEES		1				1
	Total	1				1
LONARID N				1		1
	Total			1		1
VERTIGOHEEL						
	Dysthymia		1			1
	Total		1			1
PIRISUDANOL		1				1
	Total	1				1
BETAXOLOL						
	M.D.D.			1		1
	Total			1		1
CAPOZIDE						
	M.D.D.		1			1
	Total		1			1
GOSERELIN						
	M.D.D.			1		1
	Total			1		1
HESALAZINE						
	M.D.D.		1			1
	Total		1			1
MUPIROCI						
	M.D.D.			1		1
	Total			1		1
INFLANEF						
	Dysthymia			1		1
	Total			1		1
PEFLOXACIN						
	M.D.D.			1		1

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21
CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline				During treatment				Total	
	Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine	Imipramine
	No.	No.	No.	No.	No.	No.	No.	No.	No.	
PEFLOXACIN										
OL-AMINE										
	Total									
	M.D.D.		1							1
	Total		1							1
CELIPROLOL										
	Dysthymia		1							1
	Total		1							1
CILAZAPRIL										
	Dysthymia		1							1
	Total		1							1
CISAPRIDE										
	M.D.D.		1							1
	Total		1							1
CITRULLINE MALATE										
	Dysthymia		1							1
	Total		1							1
MULTIVIT										
	M.D.D.									1
	Total									1
RAMIPRIL										
	M.D.D.		1							1
	Total		1							1
TAMARINE										
	M.D.D.		1							1
	Total		1							1
FOSINOPRIL										
	M.D.D.		1							1
	Total		1							1
CICLETANINE										
	Dysthymia		1							1
	Total		1							1
VERATIDE										
	M.D.D.		1							1

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 21

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY ASSIGNED TREATMENT AND DIAGNOSIS

Concomitant drugs	Present at screen or baseline		During treatment				Total	
	Reboxetine		Imipramine		Reboxetine		Imipramine	
	No.	No.	No.	No.	No.	No.	No.	
VERATIDE		1					1	

9550089

090177e1803f200fApproved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21a

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

ATC-System class/Concomitant drugs	Total						Before treatment						During treatment					
	Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine			
	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.		
CENTRAL NERVOUS SYSTEM	At least one		93	52.84	90	52.63	83	47.16	82	47.95	30	17.05	21	12.28				
	Total		60	55.05	65	59.63	56	51.38	58	53.21	17	15.60	19	17.43				
TEMAZEPAN	Dysthymia		33	49.25	25	40.32	27	40.30	24	38.71	13	19.40	2	3.23				
	Total		28	15.91	24	14.04	23	13.07	23	13.45	5	2.84	1	0.58				
LORNETAZEPAN	Dysthymia		20	18.35	20	18.35	17	15.60	19	17.43	3	2.75	1	0.92				
	Total		8	11.94	4	6.45	6	8.96	4	6.45	2	2.99						
ACETYSALICYLIC ACID	Dysthymia		21	11.93	19	11.11	18	10.23	17	9.94	3	1.70	2	1.17				
	Total		12	11.01	14	12.84	12	11.01	12	11.01			2	1.83				
CHLORAL HYDRATE	Dysthymia		9	13.43	5	8.06	6	8.96	5	8.06	3	4.48						
	Total		16	9.09	15	8.77	15	8.52	13	7.60	1	0.57	2	1.17				
PARACETANOL	Dysthymia		10	9.17	8	7.34	10	9.17	7	6.42			1	0.92				
	Total		6	8.96	7	11.29	5	7.46	6	9.68	1	1.49	1	1.61				
LORAZEPAN	Dysthymia		8	4.55	15	8.77	5	2.84	9	5.26	3	1.70	6	3.51				
	Total		6	5.50	13	11.93	5	4.59	7	6.42	1	0.92	6	5.50				
HYDREIN	Dysthymia		2	2.99	2	3.23			2	3.23	2	2.99						
	Total		9	5.11	7	4.09	6	3.41	4	2.34	3	1.70	3	1.75				
HYDREIN	Dysthymia		7	6.42	6	5.50	4	3.67	3	2.75	3	2.75	3	2.75				
	Total		2	2.99	1	1.61	2	2.99	1	1.61								
HYDREIN	Dysthymia		8	4.55	5	2.92	6	3.41	4	2.34	2	1.14	1	0.58				
	Total		4	3.67	3	2.75	3	2.75	2	1.83	1	0.92	1	0.92				
HYDREIN	Dysthymia		4	5.97	2	3.23	3	4.48	2	3.23	1	1.49						
	Total		7	3.98	4	2.34	7	3.98	4	2.34								

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21a

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

ATC-System class/Concomitant drugs	Total																			
	Reboxetine			Imipramine			Reboxetine			Imipramine			Reboxetine			Imipramine				
	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.		
CENTRAL NERVOUS SYSTEM	HYDERGIN	M.D.D.	5	4.59	3	2.75	5	4.59	3	2.75										
		Dysthymia	2	2.99	1	1.61	2	2.99	1	1.61										
		Total	1	0.57	6	3.51	1	0.57	4	2.34										
	ZOLPIDEN	M.D.D.			6	5.50														
		Dysthymia	1	1.49			1	1.49												
		Total	6	3.41	2	1.17	5	2.84	2	1.17	1	0.57								
BROMAZEPAM	M.D.D.	4	3.67	2	1.83	3	2.75	2	1.83											
	Dysthymia	2	2.99			2	2.99													
	Total	1	0.57	4	2.34	1	0.57	3	1.75											
DENTROPROFOPYRONE	M.D.D.	1	0.92	1	0.92	1	0.92	1	0.92											
	Dysthymia			3	4.84															
	Total	4	2.27	3	1.75	3	1.70	2	1.17	1	0.57									
PARNOCIL	M.D.D.	2	1.83	2	1.83	2	1.83	2	1.83											
	Dysthymia	2	2.99	1	1.61	1	1.49	1	1.61											
	Total	4	2.27	3	1.75	4	2.27	3	1.75											
FLUNITRAZEPAN	M.D.D.	2	1.83	2	1.83	2	1.83	2	1.83											
	Dysthymia	2	2.99	1	1.61	2	2.99	1	1.61											
	Total	4	2.27	2	1.17	2	1.14	2	1.17	2	1.14									
OXAZEPAM	M.D.D.	3	2.75	2	1.83	1	0.92	2	1.83											
	Dysthymia	1	1.49			1	1.49													
	Total			3	1.75			2	1.17											
M.D.D.			3	2.75			2	1.83												

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21a

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE, NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

ATC-System class/Concomitant drugs	Total						Before treatment						During treatment						
	Reboxetine		Imipramine		Total		Reboxetine		Imipramine		Total		Reboxetine		Imipramine		Total		
	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	
CENTRAL NERVOUS SYSTEM	HALOPERIDOL		3	1.70			1	0.57			2	1.14							
	H.D.D.		2	1.83			1	0.92			1	0.92							
	Dysthymia		1	1.49															
	Total		3	1.70			1	0.57			2	1.14							
	M.D.D.		1	0.92															
	Dysthymia		2	2.99			1	1.49			1	1.49							
STAUDOROM		3	1.70			3	1.70			3	1.70								
M.D.D.		2	1.83			2	1.83			2	1.83								
Dysthymia		1	1.49			1	1.49			1	1.49								
Total		1	0.57	2	1.17	1	0.57			2	1.17								
M.D.D.		1	0.92	2	1.83	1	0.92			2	1.83								
Dysthymia		2	1.14	2	1.17	1	0.57			2	1.17								
Total		2	1.83	2	1.83	1	0.92			2	1.83								
M.D.D.		1	0.57	2	1.17	1	0.57			2	1.17								
Total				2	1.83					2	1.83								
M.D.D.		1	1.49			1	1.49			1	1.49								
Dysthymia				2	1.17					2	1.17								
Total				2	1.83					2	1.83								
M.D.D.				2	1.83					2	1.83								
Dysthymia				2	1.17					2	1.17								
Total				2	1.83					2	1.83								
M.D.D.				2	1.17					2	1.17								
Dysthymia				2	3.23					2	3.23								
Total				2	1.17					2	1.17								
M.D.D.				1	0.92					1	0.92								

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21a

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

ATC-System class/Concomitant drugs	Total						Before treatment						During treatment							
	Reboxetine		Imipramine		Z on exp.		Reboxetine		Imipramine		Z on exp.		Reboxetine		Imipramine		Z on exp.			
	N	Z on exp.	N	Z on exp.	N	Z on exp.	N	Z on exp.	N	Z on exp.	N	Z on exp.	N	Z on exp.	N	Z on exp.	N	Z on exp.		
CENTRAL NERVOUS SYSTEM	CARBAMAZEPINE																			
	NITRAZEPAM																			
	BETHANECHOL																			
	APOREX																			
	ALPRAZOLAM																			
	LOPRAZOLAM																			
	BROTIZOLAM																			
	CHLORPROTHIXENE																			
	PETHIDINE																			
	DIHYDROERGOTAMINE																			
	PROMETHAZINE																			
		Dysthymia																		
		Total	2	1.14	1	0.58	1	0.57	1	0.57	1	0.57	1	0.57	1	0.57	1	0.57	1	0.58
		M.D.D.	2	1.83	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92
		Total	2	1.14	1	0.57	1	0.57	1	0.57	1	0.57	1	0.57	1	0.57	1	0.57	1	0.57
	M.D.D.	2	1.83	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	
	Total	2	1.14	1	0.57	1	0.57	1	0.57	1	0.57	1	0.57	1	0.57	1	0.57	1	0.57	
	Dysthymia	2	2.99	1	1.49	1	1.49	1	1.49	1	1.49	1	1.49	1	1.49	1	1.49	1	1.49	
	Total	2	1.14	1	0.58	2	1.14	1	0.58	2	1.14	1	0.58	2	1.14	1	0.58	2	1.14	
	Dysthymia	2	2.99	1	1.61	2	2.99	1	1.61	2	2.99	1	1.61	2	2.99	1	1.61	2	2.99	
	Total	2	1.14	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	
	M.D.D.	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	
	Dysthymia	1	1.49	1	1.61	1	1.61	1	1.61	1	1.61	1	1.61	1	1.61	1	1.61	1	1.61	
	Total	2	1.14	1	0.57	1	0.57	1	0.57	1	0.57	1	0.57	1	0.57	1	0.57	1	0.57	
	M.D.D.	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	
	Dysthymia	1	1.49	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	
	Total	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	
	M.D.D.	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	
	Total	1	0.57	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	
	M.D.D.	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	
	Total	1	0.57	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 21a

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

ATC-System class/Concomitant drugs	Total						Before treatment						During treatment									
	Reboxetine			Imipramine			Reboxetine			Imipramine			Reboxetine			Imipramine						
	N	% on exp.		N	% on exp.		N	% on exp.		N	% on exp.		N	% on exp.		N	% on exp.					
CENTRAL NERVOUS SYSTEM	PRONETHAZINE	M.D.D.					1	0.92														
		Dysthymia																				
		Total		1	1.49																	
	HYDROXYZINE	M.D.D.					1	0.58														
		Total		1	0.92																	
	FENTANYL	M.D.D.					1	0.92														
		Total		1	0.58																	
	PINOZIDE	M.D.D.					1	0.92														
		Total		1	0.58																	
	CLORAZEPIC ACID	M.D.D.					1	0.92														
		Total		1	0.58																	
	FLURAZEPAM	M.D.D.					1	0.92														
		Total		1	0.57																	
	CLONAZEPAM	M.D.D.					1	0.92														
	Total		1	0.92																		
PIRACETAM	M.D.D.					1	0.92															
	Total		1	0.57																		
PRAZEPAM	M.D.D.					1	0.92															
	Total		1	0.58																		
OXYBUTYRIN	M.D.D.					1	0.92															
	Total		1	0.92																		
ISOFLURANE	M.D.D.					1	0.92															
	Total		1	0.58																		
	M.D.D.					1	0.92															
	Total		1	0.92																		

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21a

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

183

ATC-System class/Concomitant drugs	Total						Before treatment						During treatment					
	Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine			
	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.		
CENTRAL NERVOUS SYSTEM	VALORON N			1	0.58										1	0.58		
	M.D.D.			1	0.92										1	0.92		
MIDAZOLAM	Total			1	0.58										1	0.58		
	M.D.D.			1	0.92										1	0.92		
LONARID N	Total			1	0.58										1	0.58		
	M.D.D.			1	0.92										1	0.92		
CINNARIZINE	Total			1	0.58										1	0.58		
	M.D.D.			1	0.92										1	0.92		
TRIAZOLAM	Total			1	0.57										1	0.57		
	M.D.D.			1	0.92										1	0.92		
ALPIDEH	Total			1	0.57										1	0.57		
	M.D.D.			1	0.92										1	0.92		
PHENYTOIN	Total			1	0.57										1	0.57		
	M.D.D.			1	0.92										1	0.92		
MORPHINE	Total			1	0.57										1	0.57		
	M.D.D.			1	0.92										1	0.92		
OXYCODONE	Total			1	0.57										1	0.57		
	M.D.D.			1	0.92										1	0.92		
PROMAZINE	Total			1	0.57										1	0.57		
	M.D.D.			1	0.92										1	0.92		
DOREGRIPPIN	Total			1	0.57										1	0.57		
	M.D.D.			1	0.92										1	0.92		

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 21a

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

ATC-System class/Concomitant drugs	Total						Before treatment				During treatment					
	Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine	
	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.
CARDIOVASCULAR SYSTEM	ISOSORBIDE DINITRATE															
	Total	6	3.41	9	5.26	5	2.84	8	4.68	1	0.57	1	0.58			
	M.D.D.	4	3.67	7	6.42	3	2.75	6	5.50	1	0.92	1	0.92			
	Dysthymia	2	2.99	2	3.23	2	2.99	2	3.23							
	Total	6	3.41	8	4.68	6	3.41	8	4.68							
	M.D.D.	5	4.59	6	5.50	5	4.59	6	5.50							
	Dysthymia	1	1.49	2	3.23	1	1.49	2	3.23							
	Total	6	3.41	2	1.17	6	3.41	2	1.17							
	M.D.D.	3	2.75	2	1.83	3	2.75	2	1.83							
	Dysthymia	3	4.48			3	4.48									
	Total	3	1.70	5	2.92	3	1.70	5	2.92							
	M.D.D.	2	1.83	3	2.75	2	1.83	3	2.75							
	Dysthymia	1	1.49	2	3.23	1	1.49	2	3.23							
	Total	4	2.27	5	2.92	4	2.27	5	2.92							
	M.D.D.	1	0.92	2	1.83	1	0.92	2	1.83							
	Dysthymia	3	4.48	3	4.84	3	4.48	3	4.84							
	Total	5	2.84	4	2.34	5	2.84	4	2.34							
	M.D.D.	4	3.67	3	2.75	4	3.67	3	2.75							
	Dysthymia	1	1.49	1	1.61	1	1.49	1	1.61							
	Total	4	2.27	4	2.34	3	1.70	4	2.34	1	0.57					
	M.D.D.	2	1.83	2	1.83	1	0.92	2	1.83	1	0.92					
	Dysthymia	2	2.99	2	3.23	2	2.99	2	3.23							
	Total	3	1.70	4	2.34	2	1.14	4	2.34	1	0.57					

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21a
CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

1-
9
82

ATC-System class/Concomitant drugs	Total											
	Reboxetine						Imipramine					
	Before treatment			During treatment			Before treatment			During treatment		
	N	% on exp.		N	% on exp.		N	% on exp.		N	% on exp.	
CARDIOVASCULAR SYSTEM	ATENOLOL											
	H.D.D.	3	2.75	2	1.83	2	1.83	2	1.83	1	0.92	
	Dysthymia			2	3.23			2	3.23			
	Total			4	2.34			4	2.34			
	DILTIAZEM											
	H.D.D.			2	1.83			2	1.83			
	Dysthymia			2	3.23			2	3.23			
	Total	4	2.27	4	2.34	4	2.27	4	2.34			
	M.D.D.											
	Dysthymia	2	1.83	3	2.75	2	1.83	3	2.75			
	Total	4	2.27	1	1.61	2	2.99	1	1.61			
	BISOPROLOL											
	H.D.D.	2	1.83			2	1.83					
	Dysthymia	2	2.99			2	2.99					
	Total	4	2.27			4	2.27					
	QUINAPRIL											
	H.D.D.	1	0.92			1	0.92					
	Dysthymia	3	4.48			3	4.48					
Total			3	1.75					3	1.75		
M.D.D.												
Total	2	1.14	3	1.75	2	1.14	3	1.75				
DYSTHYMIA												
Total	3	1.70	3	1.75	3	1.70	2	1.17			1 0.58	
M.D.D.												
Dysthymia	3	2.75	1	0.92	3	2.75			2	3.23	1 0.92	
Total	1	0.57	3	1.75	1	0.57	3	1.75				

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21a

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE, NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

ATC-System class/Concomitant drugs	Total						Before treatment				During treatment								
	Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine				
	N	X on exp.	N	X on exp.	N	X on exp.	N	X on exp.	N	X on exp.	N	X on exp.	N	X on exp.	N	X on exp.			
CARDIOVASCULAR SYSTEM	DIGITOXIN	M.D.D.	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92							
		Dysthymia			2	3.23			2	3.23									
		Total	3	1.70	3	1.75	3	1.70	3	1.75									
	ENALAPRIL	M.D.D.	3	2.75	1	0.92	3	2.75	1	0.92									
		Dysthymia			2	3.23													
		Total	3	1.70	2	1.17	3	1.70	2	1.17									
	FRUMIL	M.D.D.	3	2.75	1	0.92	3	2.75	1	0.92									
		Dysthymia			1	1.61			1	1.61									
		Total	3	1.70	1	0.58	3	1.70	1	0.58									
	THEOPHYLLINE	M.D.D.	2	1.83	1	0.92	2	1.83	1	0.92									
		Dysthymia			1	1.49			1	1.49									
		Total	3	1.70			3	1.70											
ANLODIPINE	M.D.D.	1	0.92			1	0.92												
	Dysthymia			2	2.99			2	2.99										
	Total	2	1.14	2	1.17	2	1.14	2	1.17										
DIPYRIDAMOLE	M.D.D.	1	0.92	2	1.83	1	0.92	2	1.83										
	Dysthymia			1	1.49			1	1.49										
	Total	2	1.14	2	1.17	2	1.14	2	1.17										
METOPROLOL	M.D.D.	1	0.92	2	1.83	1	0.92	2	1.83										
	Dysthymia			1	1.49			1	1.49										
	Total	1	0.92	2	1.83	1	0.92	2	1.83										
ISRADIPINE	M.D.D.	1	1.49			1	1.49												
	Dysthymia			2	1.17			2	1.17										
	Total	1	1.49	2	1.17	1	1.49	2	1.17										
M.D.D.				2	1.83			2	1.83										
	Total			2	1.83			2	1.83										

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 21a
 CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
 BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

194

ATC-System class/Concomitant drugs	Total						Before treatment						During treatment					
	Reboxetine		Imipramine		Z on exp.		Reboxetine		Imipramine		Z on exp.		Reboxetine		Imipramine		Z on exp.	
	N	Z on exp.	N	Z on exp.	N	Z on exp.	N	Z on exp.	N	Z on exp.	N	Z on exp.	N	Z on exp.	N	Z on exp.	N	Z on exp.
CARDIOVASCULAR SYSTEM	DIHYDROERGOTOXINE		Total		2	1.17					2	1.17						
	Dysthymia																	
	VERAPAMIL		Total		2	1.14			2	1.14	2	1.17						
	M.D.D.		1	0.92	1	0.92	1	0.92	1	0.92	1	0.92						
	Dysthymia		1	1.49	1	1.61	1	1.49	1	1.61	1	1.61						
	HEPARIN		Total		1	0.57	2	1.17	1	0.57	1	0.58					1	0.58
	M.D.D.				1	0.92											1	0.92
	Dysthymia		1	1.49	1	1.61	1	1.49	1	1.61	1	1.61						
	CLONIDINE		Total		1	0.57	2	1.17			2	1.17	1	0.57				
	M.D.D.		1	0.92	1	0.92	1	0.92			1	0.92	1	0.92				
	Dysthymia				1	1.61					1	1.61						
	NAFTIDROFURYL		Total		1	0.57	2	1.17	1	0.57	2	1.17						
	M.D.D.				1	0.92					1	0.92						
	Dysthymia		1	1.49	1	1.61	1	1.49	1	1.61	1	1.61						
	TINDOLOL		Total				2	1.17			2	1.17						
	M.D.D.				1	0.92					1	0.92						
	Dysthymia				1	1.61					1	1.61						
	PROFENONE		Total		2	1.17					2	1.17						
	M.D.D.				1	0.92					1	0.92						
	Dysthymia				1	1.61					1	1.61						
	NITRENDIPINE		Total				2	1.17			2	1.17						
	M.D.D.				1	0.92					1	0.92						

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21a

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

195

ATC-System class/Concomitant drugs	Total						Before treatment						During treatment							
	Reboxetine		Imipramine		Z on exp.		Reboxetine		Imipramine		Z on exp.		Reboxetine		Imipramine		Z on exp.			
	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.		
CARDIOVASCULAR SYSTEM	NITRENDIPINE																			
	CARVEDILOL																			
		Dysthymia			1	1.61														
		Total			2	1.17														
		M.D.D.			1	0.92														
		Dysthymia			1	1.61														
		Total	2	1.14			2	1.14												
		M.D.D.	1	0.92			1	0.92												
		Dysthymia	1	1.49			1	1.49												
		Total	2	1.14			2	1.14												
		M.D.D.	1	0.92			1	0.92												
		Dysthymia	1	1.49			1	1.49												
	Total	2	1.14			2	1.14													
	M.D.D.	1	0.92			1	0.92													
	Dysthymia	1	1.49			1	1.49													
	Total	2	1.14			2	1.14													
	M.D.D.	1	0.92			1	0.92													
	Dysthymia	1	1.49			1	1.49													
	Total	2	1.14			2	1.14													
	M.D.D.	1	0.92			1	0.92													
	Dysthymia	1	1.49			1	1.49													
	Total	2	1.14			2	1.14													
	M.D.D.	1	0.92			1	0.92													
	Dysthymia	1	1.49			1	1.49													
	Total	2	1.14			2	1.14													
	M.D.D.	1	0.92			1	0.92													
	Dysthymia	1	1.49			1	1.49													
	Total	2	1.14			2	1.14													
	M.D.D.	1	0.92			1	0.92													
	Dysthymia	1	1.49			1	1.49													
	Total	2	1.14			2	1.14													
	M.D.D.	1	0.92			1	0.92													
	Dysthymia	1	1.49			1	1.49													
	Total	2	1.14			2	1.14													
	M.D.D.	1	0.92			1	0.92													
	Dysthymia	1	1.49			1	1.49													
	Total	2	1.14			2	1.14													
	M.D.D.	1	0.92			1	0.92													
	Dysthymia	1	1.49			1	1.49													
	Total	2	1.14			2	1.14													
	M.D.D.	1	0.92			1	0.92													
	Dysthymia	1	1.49			1	1.49													
	Total	2	1.14			2	1.14													
	M.D.D.	1	0.92			1	0.92													
	Dysthymia	1	1.49			1	1.49													
	Total	2	1.14			2	1.14													
	M.D.D.	1	0.92			1	0.92													
	Dysthymia	1	1.49			1	1.49													
	Total	2	1.14			2	1.14													
	M.D.D.	1	0.92			1	0.92													
	Dysthymia	1	1.49			1	1.49													
	Total	2	1.14			2	1.14													
	M.D.D.	1	0.92			1	0.92													
	Dysthymia	1	1.49			1	1.49													
	Total	2	1.14			2	1.14													
	M.D.D.	1	0.92			1	0.92													
	Dysthymia	1	1.49			1	1.49													
	Total	2	1.14			2	1.14													
	M.D.D.	1	0.92			1	0.92													
	Dysthymia	1	1.49			1	1.49													
	Total	2	1.14			2	1.14													
	M.D.D.	1	0.92			1	0.92													
	Dysthymia	1	1.49			1	1.49													
	Total	2	1.14			2	1.14													
	M.D.D.	1	0.92			1	0.92													
	Dysthymia	1	1.49			1	1.49													
	Total	2	1.14			2	1.14													
	M.D.D.	1	0.92			1	0.92													
	Dysthymia	1	1.49			1	1.49													
	Total	2	1.14			2	1.14													
	M.D.D.	1	0.92			1	0.92													
	Dysthymia	1	1.49			1	1.49													
	Total	2	1.14			2	1.14													
	M.D.D.	1	0.92			1	0.92													
	Dysthymia	1	1.49			1	1.49													
	Total	2	1.14			2	1.14													
	M.D.D.	1	0.92			1	0.92													
	Dysthymia	1	1.49			1	1.49													
	Total	2	1.14			2	1.14													
	M.D.D.	1	0.92			1	0.92													
	Dysthymia	1	1.49			1	1.49													
	Total	2	1.14			2	1.14													
	M.D.D.	1	0.92			1	0.92													
	Dysthymia	1	1.49			1	1.49													
	Total	2	1.14			2	1.14													
	M.D.D.	1	0.92			1	0.92													
	Dysthymia	1	1.49			1	1.49													
	Total	2	1.14			2	1.14													
	M.D.D.	1	0.92			1	0.92													
	Dysthymia	1	1.49			1	1.49													
	Total	2	1.14			2	1.14													
	M.D.D.	1	0.92			1	0.92													
	Dysthymia	1	1.49			1	1.49													
	Total	2	1.14			2	1.14													
	M.D.D.	1	0																	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21a

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

ATC-System class/Concomitant drugs	Total						Before treatment						During treatment					
	Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine			
	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.		
CARDIOVASCULAR SYSTEM	BENDROFLUMETHIAZIDE		Total	1	0.58													
			M.D.D.	1	0.92													
			Total	1	0.58													
	ESBERIVEN FORTE		M.D.D.	1	0.92													
			Total	1	0.58													
	NORFENEFRINE		M.D.D.	1	0.92													
			Total	1	0.58													
	BRISERIN		M.D.D.	1	0.92													
			Total	1	0.58													
	DISOPYRAMIDE		M.D.D.	1	0.92													
			Total	1	0.58													
	BUMETANIDE		M.D.D.	1	0.92													
			Total	1	0.58													
	HEPTAMINDL		M.D.D.	1	0.92													
			Total	1	0.57	1	0.58	1	0.57							1	0.58	
	Dysthymia		M.D.D.	1	1.49													
		Total	1	0.57														
HETIPRANLOLOL		M.D.D.	1	0.92														
		Total	1	0.57	1	0.58	1	0.57							1	0.58		
LABETALOL		M.D.D.	1	0.92														
		Total	1	0.92	1	0.92	1	0.92										
NADLOLOL		M.D.D.	1	0.58														
		Total	1	0.92	1	0.92	1	0.92										
TENORETIC		M.D.D.	1	0.58														
		Total	1	0.58	1	0.58	1	0.58										

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 21a

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

ATC-System class/Concomitant drugs	Total						Before treatment						During treatment							
	Reboxetine		Imipramine		Total		Reboxetine		Imipramine		Total		Reboxetine		Imipramine		Total			
	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.		
CARDIOVASCULAR SYSTEM	OXYCARDIN																			
	ACEBUTOLOL	1	0.57	1	0.58	1	0.57	1	0.58	1	0.57	1	0.58	1	0.57	1	0.58	1	0.57	
		Dysthymia																		
		Total	1	0.57	1	0.58	1	0.57	1	0.58	1	0.57	1	0.58	1	0.57	1	0.58	1	0.57
	BURINEX Z	1	1.49	1	1.61	1	1.49	1	1.61	1	1.49	1	1.61	1	1.49	1	1.61	1	1.49	
		Dysthymia																		
		Total	1	1.49	1	1.61	1	1.49	1	1.61	1	1.49	1	1.61	1	1.49	1	1.61	1	1.49
	DIOSMIN	1	0.58	1	1.61	1	0.58	1	1.61	1	0.58	1	1.61	1	0.58	1	1.61	1	0.58	1
		Dysthymia																		
		Total	1	0.58	1	1.61	1	0.58	1	1.61	1	0.58	1	1.61	1	0.58	1	1.61	1	0.58
	ALDACTAZINE	1	0.57	1	0.58	1	0.57	1	0.58	1	0.57	1	0.58	1	0.57	1	0.58	1	0.57	1
		Total	1	0.57	1	0.58	1	0.57	1	0.58	1	0.57	1	0.58	1	0.57	1	0.58	1	0.57
		H.D.D.																		
		Dysthymia																		
		Total	1	0.57	1	0.58	1	0.57	1	0.58	1	0.57	1	0.58	1	0.57	1	0.58	1	0.57
BUFLONEDIL	1	0.92	1	1.61	1	0.92	1	1.61	1	0.92	1	1.61	1	0.92	1	1.61	1	0.92	1	
	Total	1	0.92	1	1.61	1	0.92	1	1.61	1	0.92	1	1.61	1	0.92	1	1.61	1	0.92	
	Dysthymia																			
	Total	1	0.92	1	1.61	1	0.92	1	1.61	1	0.92	1	1.61	1	0.92	1	1.61	1	0.92	
GALLOPAMIL	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	
	Total	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	
CELIPROLOL	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	
	Total	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	
CILAZAPRIL	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	
	Total	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	
CICLETANINE	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	
	Total	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	
	Dysthymia																			
	Total	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	1	0.58	
SPIRONOLACTONE	1	0.57	1	1.61	1	0.57	1	1.61	1	0.57	1	1.61	1	0.57	1	1.61	1	0.57	1	
	Total	1	0.57	1	1.61	1	0.57	1	1.61	1	0.57	1	1.61	1	0.57	1	1.61	1	0.57	

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 21a

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

1 0 0

ATC-System class/Concomitant drugs	Total						Before treatment				During treatment					
	Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine	
	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.
CARDIOVASCULAR SYSTEM	SPIRONOLACTONE	M.D.D.	1	0.92					1	0.92						
		Total	1	0.57					1	0.57						
	CYCLOPENTHIAZIDE	M.D.D.	1	0.92					1	0.92						
		Total	1	0.57					1	0.57						
	TROXERUTIN	M.D.D.	1	0.92					1	0.92						
		Total	1	0.92					1	0.92						
	VENOSTASIN FORTE	M.D.D.	1	0.57					1	0.57						
		Total	1	0.92					1	0.92						
	DXPRENOLOL	M.D.D.	1	0.57					1	0.57						
		Total	1	0.92					1	0.92						
	PRAZOSIN	M.D.D.	1	0.57					1	0.57						
		Total	1	0.92					1	0.92						
	INDAPAMIDE	M.D.D.	1	0.57					1	0.57						
		Total	1	0.92					1	0.92						
	EFFORTIL PLUS	M.D.D.	1	0.57					1	0.57						
		Total	1	0.92					1	0.92						
NICARDIPINE	M.D.D.	1	0.57					1	0.57							
	Total	1	0.92					1	0.92							
FELODIPINE	M.D.D.	1	0.57					1	0.57							
	Total	1	0.92					1	0.92							
PIRISUDANOL	M.D.D.	1	0.57					1	0.57							
	Total	1	0.92					1	0.92							
RAMIPRIL	M.D.D.	1	0.57					1	0.57							
	Total	1	0.92					1	0.92							

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21a
CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

200

ATC-System class/Concomitant drugs	Total						Before treatment						During treatment					
	Reboxetine		Imipramine		Total		Reboxetine		Imipramine		Total		Reboxetine		Imipramine		Total	
	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.
CARDIOVASCULAR SYSTEM	BAMIPIRIL	1	0.92				1	0.92										
	FOSINOPRIL	1	0.57				1	0.57										
	VERATIDE	1	0.92				1	0.92										
		1	0.57				1	0.57										
		1	0.92				1	0.92										
		1	0.57				1	0.57										
		1	1.49				1	1.49										
		1	0.57				1	0.57										
		1	1.49				1	1.49										
		1	0.57				1	0.57										
		1	1.49				1	1.49										
	ALIMENTARY TRACT AND METABOLISM	At least one	58	32.95	56	32.75		39	22.16	43	25.15		28	15.91	21	12.28		
		37	33.94	33	30.28		25	22.94	23	21.10		18	16.51	15	13.76			
		21	31.34	23	37.10		14	20.90	20	32.26		10	14.93	6	9.68			
		15	8.52	16	9.36		5	2.84	12	7.02		10	5.68	4	2.34			
		9	8.26	10	9.17		4	3.67	7	6.42		5	4.59	3	2.75			
		6	8.96	6	9.68		1	1.49	5	8.06		5	7.46	1	1.61			
		7	3.98	3	1.75		4	2.27	1	0.58		3	1.70	2	1.17			
		5	4.59	2	1.83		4	3.67	1	0.92		1	0.92	1	0.92			
		2	2.99	1	1.61							2	2.99	1	1.61			

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21a
CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

201

ATC-System class/Concomitant drugs	Total						Before treatment						During treatment					
	Reboxetine		Imipramine		Total		Reboxetine		Imipramine		Total		Reboxetine		Imipramine		Total	
	N	Z on exp.	N	Z on exp.	N	Z on exp.	N	Z on exp.	N	Z on exp.	N	Z on exp.	N	Z on exp.	N	Z on exp.	N	Z on exp.
ALIMENTARY TRACT AND METABOLISM	Total	5	2.84	5	2.92	4	2.27	4	2.34	1	0.57	1	0.57	1	0.58			
	M.D.D.	4	3.67	2	1.83	3	2.75	2	1.83	2	1.83	1	0.92					
SENA	Dysthymia	1	1.49	3	4.84	1	1.49	2	3.23									
	Total	5	2.84	3	1.75	1	0.57							4	2.27	3	1.75	
M.D.D.	Dysthymia	4	3.67	3	2.75	1	0.92							3	2.75	3	2.75	
	Total	1	1.49											1	1.49			
GLIBENCLAMIDE	Total	3	1.70	4	2.34	3	1.70	4	2.34									
	M.D.D.	2	1.83	1	0.92	2	1.83	1	0.92									
Dysthymia	Total	1	1.49	3	4.84	1	1.49	3	4.84									
	Total	3	1.70	4	2.34	1	0.57							2	1.14	4	2.34	
SODIUM PICOSULFATE	M.D.D.	1	0.92	2	1.83	1	0.92											
	Dysthymia	2	2.99	2	3.23									2	2.99	2	3.23	
ANETHOLE	Total	4	2.27	4	2.34	2	1.14							2	1.14	4	2.34	
	M.D.D.	2	1.83	2	1.83									2	1.83	2	1.83	
Dysthymia	Total	2	2.99	2	3.23	2	2.99											
	Total	4	2.27	1	0.58	1	0.57							3	1.70	1	0.58	
POTASSIUM	M.D.D.	1	0.92	1	0.92									1	0.92	1	0.92	
	Dysthymia	3	4.48			1	1.49											
GLICLAZIDE	Total	1	0.57	3	1.75	1	0.57	3	1.75									
	M.D.D.			3	2.75			3	2.75									
Dysthymia	Total	1	1.49			1	1.49											
	Total	1	0.57	3	1.75	1	0.57	1	0.57					1	0.57	1	0.58	2
DOCUSATE	Total	1	0.57	3	1.75	1	0.57	1	0.57									
	Total	1	0.57	3	1.75	1	0.57	1	0.57									

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 21a
 CONCOMITANT DRUGS BY ACTIVE PRINCIPLE, NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
 BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

ATC-System class/Concomitant drugs	Total						Before treatment				During treatment						
	Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine		
	N	Z on exp.	N	Z on exp.	N	Z on exp.	N	Z on exp.	N	Z on exp.	N	Z on exp.	N	Z on exp.	N	Z on exp.	
ALIMENTARY TRACT AND METABOLISM	Total	1	0.57	2	1.17												
	M.D.D.			1	0.92												
	Dysthymia	1	1.49	1	1.61												
DORBANEX	Total	2	1.14			1	0.57			1	1.49			1	1.61		
	M.D.D.	2	1.83			1	0.92			1	0.57			1	0.92		
	Total	2	1.14			2	1.14			2	1.14			2	1.14		
BEFACT	M.D.D.	2	1.83			2	1.83			2	1.83			2	1.83		
	Total	2	1.14	1	0.58	2	1.14	1	0.58	2	1.14	1	0.58	2	1.14	1	0.58
	M.D.D.			1	0.92			1	0.92			1	0.92			1	0.92
CALCIUM GLUBIONATE	Total	2	2.99			2	2.99			2	2.99			2	2.99		
	M.D.D.	2	1.14			2	1.14			2	1.14			2	1.14		
	Dysthymia	2	1.14			2	1.14			2	1.14			2	1.14		
THIAMINE	Total	2	1.14			2	1.14			2	1.14			2	1.14		
	M.D.D.	1	0.92			1	0.92			1	0.92			1	0.92		
	Dysthymia	1	1.49			1	1.49			1	1.49			1	1.49		
FAMOTIDINE	Total	2	1.14			2	1.14			2	1.14			2	1.14		
	M.D.D.	1	0.92			1	0.92			1	0.92			1	0.92		
	Dysthymia	1	1.49			1	1.49			1	1.49			1	1.49		
LOROTIL	Total	1	0.58			1	0.58			1	0.58			1	0.58		
	M.D.D.			1	0.92			1	0.92			1	0.92			1	0.92
	Total	1	0.57	1	0.58					1	0.57	1	0.58			1	0.57
CYPROHEPTADINE	Total	1	0.92			1	0.92			1	0.92			1	0.92		
	M.D.D.	1	0.92			1	0.92			1	0.92			1	0.92		
	Total	1	0.58			1	0.58			1	0.58			1	0.58		
NALOX	Total	1	0.92			1	0.92			1	0.92			1	0.92		
	M.D.D.			1	0.58			1	0.58			1	0.58			1	0.58
	Total	1	0.92			1	0.92			1	0.92			1	0.92		

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/085
TABLE No.: 21a

204

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

ATC-System class/Concomitant drugs	Total												
	Before treatment						During treatment						
	Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine		
N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.		
ALIMENTARY TRACT AND METABOLISM	Total	1	0.57	1	0.58					1	0.57	1	0.58
	M.D.D.	1	0.92	1	0.92					1	0.92	1	0.92
DANTRON	Total			1	0.58							1	0.58
	M.D.D.			1	0.92							1	0.92
GAVISCON	Total	1	0.57	1	0.58					1	0.57	1	0.58
	M.D.D.	1	0.92	1	0.92					1	0.92	1	0.92
LEFAX	Total			1	0.58							1	0.58
	M.D.D.			1	0.92							1	0.92
AGIOLAX	Total	1	0.58									1	0.58
	M.D.D.	1	0.92									1	0.92
MAXI-B 5000	Total	1	0.57	1	0.58	1	0.57	1	0.58				
	M.D.D.	1	0.92	1	0.92	1	0.92	1	0.92				
OMNIBIONTA	Total			1	0.58					1	0.58		
	M.D.D.			1	0.92					1	0.92		
MESALAZINE	Total			1	0.58					1	0.58		
	M.D.D.			1	0.92					1	0.92		
OL-AMINE	Total			1	0.58					1	0.58		
	M.D.D.			1	0.92					1	0.92		
ALVITYL	Total	1	0.57	1	0.58	1	0.57	1	0.58				
	M.D.D.	1	0.92	1	0.92	1	0.92	1	0.92				
MULTIIVIT	Total			1	0.58							1	0.58
	M.D.D.			1	0.92							1	0.92

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21a

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

ATC-System class/Concomitant drugs	Total						Before treatment						During treatment					
	Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine			
	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.		
ALIMENTARY TRACT AND METABOLISM	Total	1	0.57	1	0.58													
	M.D.D.	1	0.92	1	0.92													
TAMARINE	Total			1	0.58					1	0.58							
	M.D.D.			1	0.92					1	0.92							
RECTOPANBILINE	Total			1	0.58					1	0.58							
	Dysthymia			1	1.61					1	1.61							
PROPANTHELINE	Total			1	0.58					1	0.58							
	Dysthymia			1	1.61					1	1.61							
NEURORION FOR INJECTION	Total			1	0.58					1	0.58							
	Dysthymia			1	1.61					1	1.61							
MICROLAX	Total	1	0.57	1	0.58					1	0.58			1	0.57			
	M.D.D.	1	0.92											1	0.92			
FRUFIASE CALCIUM FORTE	Total			1	1.61					1	1.61							
	Dysthymia			1	0.58					1	0.58							
GLIQUIDONE	Total			1	1.61					1	1.61							
	Dysthymia			1	0.58					1	0.58							
CHOLAGOGUM NATTERMANN	Total			1	0.58					1	0.58							
	Dysthymia			1	1.61					1	1.61							
NVLANTA	Total	1	0.57															
	M.D.D.	1	0.92															
PYRIDOXINE	Total	1	0.57							1	0.57							

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21a
CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

2
C
C

ATC-System class/Concomitant drugs	Total						Before treatment						During treatment					
	Reboxetine		Imipramine		Total		Reboxetine		Imipramine		Total		Reboxetine		Imipramine		Total	
	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.
ALIMENTARY TRACT AND METABOLISM	PYRIDOXINE	1	0.92					1	0.92									
	Total	1	0.57					1	0.57									
METFORMIN	M.D.D.	1	0.92					1	0.92									
	Total	1	0.57					1	0.57									
HUCAINE	M.D.D.	1	0.92					1	0.92									
	Total	1	0.57					1	0.57									
KATOVIT	M.D.D.	1	0.92					1	0.92									
	Total	1	0.57					1	0.57									
CANYLOFIN	M.D.D.	1	0.92					1	0.92									
	Total	1	0.57					1	0.57									
LOPERAMIDE	M.D.D.	1	0.92					1	0.92									
	Total	1	0.57					1	0.57									
GLIPIZIDE	M.D.D.	1	0.92					1	0.92									
	Total	1	0.57					1	0.57									
POLYBION	M.D.D.	1	0.92					1	0.92									
	Total	1	0.57					1	0.57									
SIMECO	M.D.D.	1	0.92					1	0.92									
	Total	1	0.57					1	0.57									
PINAVERIUM	M.D.D.	1	0.92					1	0.92									
	Total	1	0.57					1	0.57									
MAGNESIUM VERLA DRAGEES	M.D.D.	1	0.92					1	0.92									
	Total	1	0.57					1	0.57									
CISAPRIDE	M.D.D.	1	0.92					1	0.92									
	Total	1	0.57					1	0.57									

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 21a
 CONCOMITANT DRUGS BY ACTIVE PRINCIPLE, NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
 BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

207

ATC-System class/Concomitant drugs	Total						Before treatment						During treatment					
	Reboxetine		Inipramine		Z on exp.		Reboxetine		Inipramine		Z on exp.		Reboxetine		Inipramine		Z on exp.	
	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.
ALIMENTARY TRACT AND METABOLISM	CISAPRIDE	1	0.92					1	0.92									
	INSULIN	1	0.57					1	0.57									
			1.49					1	1.49									
	CALCIUM PHOSPHATE	1	0.57					1	0.57									
			1.49					1	1.49									
	VITAMIN B-COMPLEX FORTE	1	0.57					1	0.57									
			1.49					1	1.49									
	CALCIFEDIOL	1	0.57					1	0.57									
			1.49					1	1.49									
	CITRULLINE MALATE	1	0.57					1	0.57									
		1.49					1	1.49										
BLOOD AND BLOOD FORMING ORGANS	At least one	9	5.11	17	9.94	6	3.41	13	7.60	4	2.27	4	2.27	4	2.34			
		7	6.42	10	9.17	5	4.59	7	6.42	3	2.75	3	2.75	3	2.75			
		2	2.99	7	11.29	1	1.49	6	9.68	1	1.49	1	1.49	1	1.61			
	IRON	1	0.57	5	2.92	1	0.57	3	1.75	3	2.75	2	1.17	2	1.17			
		1	0.92	5	4.59	1	0.92	3	2.75	3	1.75	2	1.83	2	1.83			
	BEZAFIBRATE			3	1.75			3	1.75									
				3	4.84			3	4.84									
	NEOGENYL	1	0.57	2	1.17			1	0.58	1	0.57	1	0.57	1	0.58			
		1	0.92	2	1.83			1	0.92	1	0.92	1	0.92	1	0.92			
	HEPARIN			1	0.58			1	0.58									
			1	0.92			1	0.92										

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21a

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE, NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

ATC-System class/Concomitant drugs	Total						Before treatment				During treatment					
	Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine	
	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.
BLOOD AND BLOOD FORMING ORGANS	SINIVASTATIN		Total		2	1.14	2	1.17	2	1.14	2	1.17				
			M.D.D.		1	0.92	1	0.92	1	0.92	1	0.92				
			Dysthymia		1	1.49	1	1.61	1	1.49	1	1.61				
			Total		2	1.14	1	0.58	2	1.14	1	0.58				
			M.D.D.		2	1.83			2	1.83						
			Dysthymia				1	1.61			1	1.61				
			Total				1	0.58			1	0.58				
			M.D.D.				1	0.92			1	0.92				
			Total				1	0.58			1	0.58				
			Dysthymia				1	1.61			1	1.61				
MUSCULO-SKELETAL SYSTEM	ENOXAPARIN		Total		1	0.57	1	0.58	1	0.57					1	0.58
			M.D.D.		1	0.92			1	0.92						
			Dysthymia				1	1.61							1	1.61
			Total				1	0.57							1	0.57
			M.D.D.				1	1.61							1	1.61
			Total		1	0.57								1	0.57	
			M.D.D.		1	0.92								1	0.92	
			Total		1	0.57								1	0.57	
			M.D.D.		1	0.92								1	0.92	
			Total		1	0.92								1	0.92	
At least one	CYANOCOBALAMIN		Total		1	1.49									1	1.49
			Dysthymia												1	1.49
			Total		17	9.66	15	8.77	14	7.95	13	7.60	4	2.27	2	1.17
			M.D.D.		12	11.01	9	8.26	10	9.17	7	6.42	3	2.75	2	1.83

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 21a

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

202

ATC-System class/Concomitant drugs	Total						Before treatment						During treatment					
	Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine			
	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.		
MUSCULO-SKELETAL SYSTEM	At least one		Dysthymia		Total		Dysthymia		Total		Dysthymia		Total		Dysthymia			
	5	7.46	6	9.68	4	5.97	6	9.68	1	1.49	1	1.49	1	1.49	1	1.49		
	ALLOPURINOL		Total		M.D.D.		Dysthymia		Total		M.D.D.		Dysthymia		Total			
	7	3.98	7	4.09	6	3.41	7	4.09	1	0.57	1	0.57	1	0.57	1	0.57		
	5	4.59	2	1.83	4	3.67	2	1.83	1	0.92	1	0.92	1	0.92	1	0.92		
	DICLOFENAC		Total		M.D.D.		Dysthymia		Total		M.D.D.		Dysthymia		Total			
	2	2.99	5	8.06	2	2.99	5	8.06	2	2.99	1	1.61	2	2.99	1	1.61		
	4	2.27	5	2.92	4	2.27	4	2.34	1	0.58	1	0.58	1	0.58	1	0.58		
	2	1.83	4	3.67	2	1.83	3	2.75	1	0.92	1	0.92	1	0.92	1	0.92		
	FIROXICAM		Total		M.D.D.		Dysthymia		Total		M.D.D.		Dysthymia		Total			
	2	2.99	1	1.61	2	2.99	1	1.61	1	1.49	1	1.49	1	1.49	1	1.49		
	2	1.14	1	0.58					2	1.14	1	0.58	2	1.14	1	0.58		
	1	0.92	1	0.92					1	0.92	1	0.92	1	0.92	1	0.92		
	ACIFUGAN		Total		M.D.D.		Dysthymia		Total		M.D.D.		Dysthymia		Total			
	1	1.49							1	1.49	1	1.49	1	1.49	1	1.49		
	1	0.57	1	0.58	1	0.57	1	0.58	1	0.57	1	0.57	1	0.57	1	0.57		
	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92		
	ETOFENAMATE		Total		M.D.D.		Dysthymia		Total		M.D.D.		Dysthymia		Total			
			1	0.58					1	0.58	1	0.58	1	0.58	1	0.58		
			1	0.92					1	0.92	1	0.92	1	0.92	1	0.92		
	ATRACURIUM		Total		M.D.D.		Dysthymia		Total		M.D.D.		Dysthymia		Total			
			1	0.58					1	0.58	1	0.58	1	0.58	1	0.58		
			1	0.92					1	0.92	1	0.92	1	0.92	1	0.92		
	ACEMETACIN		Total		M.D.D.		Dysthymia		Total		M.D.D.		Dysthymia		Total			
			1	0.58					1	0.58	1	0.58	1	0.58	1	0.58		
			1	1.61					1	1.61	1	1.61	1	1.61	1	1.61		
	INDOMETACIN		Total		M.D.D.		Dysthymia		Total		M.D.D.		Dysthymia		Total			
	1	0.57			1	0.57			1	0.57			1	0.57				
	1	0.92			1	0.92			1	0.92			1	0.92				
	QUININE		Total		M.D.D.		Dysthymia		Total		M.D.D.		Dysthymia		Total			
	1	0.57			1	0.57			1	0.57			1	0.57				
	1	0.92			1	0.92			1	0.92			1	0.92				

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21a
CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

2
10

ATC-System class/Concomitant drugs	Total						Before treatment			During treatment			
	Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine		
	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	
MUSCULO-SKELETAL SYSTEM	Total	1	0.57			1	0.57						
	M.D.D.	1	0.92			1	0.92						
TIAPROFENIC ACID	Total	1	0.57							1	0.57		
	M.D.D.	1	0.92							1	0.92		
At least one	Total	15	8.52	16	9.36	6	3.41			11	6.25	16	9.36
	M.D.D.	12	11.01	10	9.17	5	4.59			8	7.34	10	9.17
Dysthymia	Total	3	4.48	6	9.68	1	1.49			3	4.48	6	9.68
	M.D.D.	2	1.14	5	2.92	1	0.57			1	0.57	5	2.92
NORFLOXACIN	Total	2	1.83	3	2.75	1	0.92			1	0.92	3	2.75
	M.D.D.	2	1.83	3	2.75	1	0.92			1	0.92	3	2.75
Dysthymia	Total	1	0.57	3	1.75							2	3.23
	M.D.D.	1	0.57	3	1.75					1	0.57	3	1.75
BACTRIM	Total	1	0.57	1	0.92							1	0.92
	M.D.D.	1	0.57	1	0.92							1	0.92
Dysthymia	Total	1	1.49	2	3.23					1	1.49	2	3.23
	M.D.D.	2	1.14	2	1.17	1	0.57			1	0.57	2	1.17
AUGMENTIN	Total	1	0.92	2	1.83							2	1.83
	M.D.D.	1	0.92	2	1.83							2	1.83
Dysthymia	Total	1	1.49							1	1.49		
	M.D.D.	2	1.14			1	0.57			1	0.57		
OFLOXACIN	Total	2	1.83			1	0.92			1	0.92		
	M.D.D.	2	1.83			1	0.92			1	0.92		
TRIMETHOPRIM	Total	2	1.14			1	0.57			1	0.57		
	M.D.D.	1	0.92			1	0.92			1	0.92		
Dysthymia	Total	1	1.49									1	1.49
	M.D.D.	1	1.49							1	1.49		
AMOXICILLIN	Total	2	1.14	1	0.58	2	1.14					1	0.58
	M.D.D.	2	1.14	1	0.58	2	1.14					1	0.58

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21a

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE, NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

ATC-System class/Concomitant drugs	Total						Before treatment						During treatment					
	Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine			
	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.		
GENERAL ANTIINFECTIVES FOR SYSTEMIC USE																		
	AMOXICILLIN	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	
	M.D.D.																	
	Dysthymia	1	1.49			1	1.49											
	Total			1	0.58										1	0.58		
	M.D.D.			1	0.92										1	0.92		
	Total			1	0.58										1	0.58		
	M.D.D.			1	0.92										1	0.92		
	Total			1	0.58										1	0.58		
	M.D.D.			1	0.92										1	0.92		
	Total	1	0.57	1	0.58								1	0.57	1	0.58		
	M.D.D.	1	0.92										1	0.92				
	Dysthymia			1	1.61										1	1.61		
	Total			1	0.58										1	0.58		
	Dysthymia			1	1.61										1	1.61		
	Total			1	0.58										1	0.58		
	M.D.D.			1	0.58										1	0.58		
	Total			1	1.61										1	1.61		
	M.D.D.			1	0.57										1	0.57		
	Total	1	0.92											1	0.92			
	M.D.D.			1	0.57										1	0.57		
	Total	1	0.92											1	0.92			
	M.D.D.			1	0.92										1	0.92		
	Total	1	0.57											1	0.57			
	M.D.D.			1	0.57										1	0.57		
	Total	1	0.57											1	0.57			
	M.D.D.			1	0.92										1	0.92		
	Total	1	0.57											1	0.57			
	M.D.D.			1	0.92										1	0.92		
	Total	1	0.57											1	0.57			

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21a

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

ATC-System class/Concomitant drugs	Total						Before treatment						During treatment					
	Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine			
	N	X on exp.	N	X on exp.	N	X on exp.	N	X on exp.	N	X on exp.	N	X on exp.	N	X on exp.	N	X on exp.		
GENERAL ANTIINFECTIVES FOR SYSTEMIC USE	M.D.D.	1	0.92															
	Total	1	0.57															
	M.D.D.	1	0.92															
	Total	1	0.57															
RESPIRATORY SYSTEM	Dysphymia	1	1.49															
	Total	11	6.25	8	4.68	7	3.98	3	1.75	4	2.27	5	2.92					
	M.D.D.	9	8.26	6	5.50	5	4.59	2	1.83	4	3.67	4	3.67					
	Total	2	2.99	2	3.23	2	2.99	1	1.61									
DIHYDROCODEINE	Total	1	0.57	2	1.17	1	0.57	2	1.17									
	M.D.D.			2	1.83			2	1.83									
	Dysphymia	1	1.49			1	1.49											
	Total	1	0.57	2	1.17	1	0.57	1	0.58									
ACETYLCYSTEINE	Total	1	0.92	1	0.92	1	0.92	1	0.92									
	M.D.D.			1	1.61			1	1.61									
	Dysphymia			1	1.61			1	1.61									
	Total	2	1.14	1	0.58	2	1.14											
SALBUTANOL	Total	2	1.83	1	0.92	2	1.83											
	M.D.D.			1	0.92	2	1.83											
	Dysphymia			1	0.58													
	Total	1	0.57	1	0.58													
ANTAZOLINE	M.D.D.	1	0.92	1	0.92													
	Total			1	0.58													
	Dysphymia			1	0.92													
	Total			1	0.58													
BUCLIZINE	Total			1	0.58													
	M.D.D.			1	0.92													
	Dysphymia			1	0.58													
	Total			1	0.58													
IPRATROPIUM	Total	1	0.57	1	0.58	1	0.57											
	M.D.D.	1	0.92	1	0.92	1	0.92											
	Dysphymia			1	0.58													
	Total			1	0.58													

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21a

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

ATC-System class/Concomitant drugs	Total						Before treatment						During treatment					
	Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine			
	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.		
RESPIRATORY SYSTEM	TERFENADINE																	
		Total		1	0.58												1	0.58
		M.D.D.		1	0.92												1	0.92
	ACTIFED																	
		Total		1	0.58												1	0.58
		Dysthymia		1	1.61												1	1.61
	CODIPRONT																	
		Total		1	0.57												1	0.57
		M.D.D.		1	0.92												1	0.92
	BECLONETASONE																	
	Total		1	0.57												1	0.57	
	M.D.D.		1	0.92												1	0.92	
FENTEROL																		
	Total		1	0.57												1	0.57	
	M.D.D.		1	0.92												1	0.92	
SALINA																		
	Total		1	0.57												1	0.57	
	M.D.D.		1	0.92												1	0.92	
TOLU TINCTURE																		
	Total		1	0.57												1	0.57	
	M.D.D.		1	0.92												1	0.92	
OXATONIDE																		
	Total		1	0.57												1	0.57	
	M.D.D.		1	0.92												1	0.92	
CODEINE																		
	Total		1	0.57												1	0.57	
	Dysthymia		1	1.49												1	1.49	
At least one			9	5.11		10	5.85		5	2.84		6	3.51		4	2.27	4	2.34
	M.D.D.		6	5.50		6	5.50		4	3.67		4	3.67		2	1.83	2	1.83
Dysthymia			3	4.48		4	6.45		1	1.49		2	3.23		2	2.99	2	3.23
Total			3	1.70		3	1.75		1	0.57		1	0.58		2	1.14	2	1.17

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21a
CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION
BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

ATC-System class/Concomitant drugs	Total						Before treatment						During treatment					
	Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine			
	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.		
GENITO URINARY SYSTEM AND SEX HORMONES	M.D.D.	1	0.92	1	0.92													
	Dysthymia	2	2.99	2	3.23	1	1.49	1	1.61	1	1.49	1	1.49	1	1.61			
	Total			2	1.17			2	1.17									
PHENAZOPYRIDINE	M.D.D.			2	1.83													
	Total	2	1.14			1	0.57			1	0.57			1	0.57			
	M.D.D.	1	0.92			1	0.92											
ESTRIOL	Dysthymia	1	1.49															
	Total																	
	M.D.D.																	
URAL	Dysthymia																	
	Total			1	0.58					1	0.58							
	M.D.D.			1	0.92					1	0.92							
PIPEMIDIC ACID	Total			1	0.58										1	0.58		
	M.D.D.			1	0.92										1	0.92		
	M.D.D.			1	0.92										1	0.92		
URTICA EXTRACT	Total	1	0.57	1	0.58	1	0.57	1	0.58	1	0.57	1	0.58					
	M.D.D.	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92					
	Total			1	0.58										1	0.58		
ESTRADIOL	Dysthymia			1	1.61													
	Total	1	0.57	1	0.58	1	0.57	1	0.58	1	0.57	1	0.58					
	M.D.D.	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92					
ESTROGENS CONJUGATED	Dysthymia			1	1.61													
	Total	1	0.57	1	0.58	1	0.57	1	0.58	1	0.57	1	0.58					
	M.D.D.	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92	1	0.92					
NIFURTOIOL	Dysthymia			1	1.61													
	Total	1	0.57											1	0.57			
	M.D.D.	1	0.92											1	0.92			
PREMPAK	Total	1	0.57			1	0.57											
	M.D.D.	1	0.92			1	0.92											
	M.D.D.	1	0.92			1	0.92											

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21a

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

ATC-System class/Concomitant drugs	Total						Before treatment				During treatment					
	Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine	
	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.
VARIOUS	At least one		2	1.14	6	3.51			2	1.17	2	1.14	4	2.94		
	M.D.D.		2	1.83	4	3.67			1	0.92	2	1.83	3	2.75		
	Dysthymia				2	3.23			1	1.61			1	1.61		
	Total				2	1.17			1	0.58			1	0.58		
	M.D.D.				2	1.83			1	0.92			1	0.92		
	Total		1	0.57	2	1.17					1	0.57	2	1.17		
	M.D.D.		1	0.92	1	0.92					1	0.92	1	0.92		
	Dysthymia				1	1.61									1	1.61
	Total				1	0.58									1	0.58
	M.D.D.				1	0.92					1	0.92	1	0.92		
SYSTEMIC HORMONAL PREP, EXCL SEX HORMONES	At least one		1	0.57												
	M.D.D.		1	0.92												
	Total				1	1.61										
	M.D.D.				1	0.58										
	Total				1	0.58					1	0.58				
	Dysthymia				1	1.61					1	1.61				
	Total		1	0.57												
	M.D.D.		1	0.92												
	Total				5	2.84			5	2.84	3	1.75			2	1.17
	M.D.D.		2	1.83	5	4.59			2	1.83	3	2.75			2	1.83
LEVOHYDROXINE	Dysthymia		3	4.48					3	4.48						
	Total		2	1.14	3	1.75	2	1.14	2	1.17	2	1.83	1	0.58		
	M.D.D.				3	2.75			2	1.83			1	0.92		
	Dysthymia		2	2.99			2	2.99								
CORTISONE	Total				2	1.17			1	0.58			1	0.58		
	M.D.D.				2	1.83			1	0.92			1	0.92		

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21a

216

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

ATC-System class/Concomitant drugs	Total						Before treatment						During treatment								
	Reboxetine		Imipramine		Total		Reboxetine		Imipramine		Total		Reboxetine		Imipramine		Total				
	N	z on exp.	N	z on exp.	N	z on exp.	N	z on exp.	N	z on exp.	N	z on exp.	N	z on exp.	N	z on exp.	N	z on exp.			
SYSTEMIC HORMONAL PREP, EXCL SEX HORMONES	Total	1	0.57																		
	M.D.D.	1	0.92																		
	Total	1	0.57																		
	M.D.D.	1	0.92																		
	Total	1	0.57																		
	Dysthymia	1	1.49																		
DERMATOLOGICALS	At least one	5	2.84	4	2.34	4	2.34	1	0.57												
	M.D.D.	2	1.83	4	3.67																
	Dysthymia	3	4.48																		
	Total	3	1.70	1	0.58	1	0.57														
	M.D.D.	1	0.92	1	0.92																
	Dysthymia	2	2.99																		
FRAMYCETIN	Total			1	0.58																
	M.D.D.			1	0.92																
	Total			1	0.58																
HYCOLOG	Total			1	0.92																
	M.D.D.			1	0.92																
	Total			1	0.58																
CHLORHEXIDINE	Total			1	0.58																
	M.D.D.			1	0.92																
	Total			1	0.58																
MICONAZOLE	Total			1	0.92																
	M.D.D.			1	0.57																
	Total			1	0.92																
LIDOCAINE	Total			1	0.57																
	M.D.D.			1	1.49																
	Total			1	1.49																

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 21a

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS TAKING AT LEAST ONE CONCOMITANT MEDICATION BY CLASS OF DRUG, ASSIGNED TREATMENT AND DIAGNOSIS

ATC-System class/Concomitant drugs	Total												
	Reboxetine						Imipramine						
	Before treatment			During treatment			Before treatment			During treatment			
	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	N	% on exp.	
SENSORY ORGANS	At least one												
	Total	1	0.57	4	2.34			3	1.75	1	0.57	1	0.58
	M.D.D.	1	0.92	2	1.83			2	1.83	1	0.92		
	Dysthymia			2	3.23			1	1.61			1	1.61
	Total			2	1.17			2	1.17				
	M.D.D.			2	1.83			2	1.83				
	Total			1	0.58			1	0.58				
	Dysthymia			1	1.61			1	1.61				
	Total			1	0.58							1	0.58
	Dysthymia			1	1.61							1	1.61
ANTINEOPLASTIC AND IMMUNOSUPPRESSIVE AGENTS	At least one												
	Total	1	0.57										
	M.D.D.	1	0.92										
	Total			1	0.57								
	M.D.D.			1	0.92								
	Total	2	1.14	3	1.75	2	1.14	1	0.58	2	1.17	2	1.17
	M.D.D.	2	1.83	3	2.75	2	1.83	1	0.92	2	1.83	2	1.83
	Total	2	1.14	1	0.58	2	1.14	1	0.58				
	M.D.D.	2	1.83	1	0.92	2	1.83	1	0.92				
	Total			1	0.58							1	0.58
M.D.D.			1	0.92							1	0.92	
Total			1	0.58							1	0.58	
M.D.D.			1	0.92							1	0.92	
Total			1	0.58							1	0.58	
M.D.D.			1	0.92							1	0.92	
Total			1	0.58							1	0.58	
M.D.D.			1	0.92							1	0.92	
Total			1	0.58							1	0.58	

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 22

HAMILTON DEPRESSION RATING SCALE: SUMMARY STATISTICS ON TOTAL SCORE ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Diagnosis: Total

	Screen	Visit													
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56					
Imipramine	No	168	167	157	144	139	131	129	126	126					
	Mean	26.06	23.19	19.85	17.10	14.41	12.28	10.93	10.03	8.81					
	STD	4.88	6.12	7.62	8.25	7.70	8.06	7.98	7.71	6.98					
	Median	26	23	20	17	14	11	10	9	7					
	Min	18.00	16.00	14.00	12.00	10.00	9.00	8.00	7.00	6.00					
	Max	44.00	38.00	30.00	24.00	18.00	14.00	11.00	10.00	9.00					
Mean diff. vs day0 (*)		2.95	6.24	9.03	11.63	13.67	15.10	15.83	16.97						
Reboxetine	No	172	171	165	159	152	139	134	131	127					
	Mean	26.26	23.76	21.25	18.86	16.88	13.94	12.58	11.73	11.35					
	STD	5.26	6.59	7.04	8.04	8.67	8.21	7.67	7.94	8.42					
	Median	26	24	21	18	16	13	12	10	9					
	Min	18.00	17.00	15.00	13.00	11.00	10.00	9.00	8.00	7.00					
	Max	43.00	42.00	41.00	41.00	44.00	40.00	35.00	35.00	38.00					
Mean diff. vs day0 (*)		2.83	5.41	7.72	9.76	12.58	13.66	14.77	15.06						

Mean (*): mean of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 22

HAMILTON DEPRESSION RATING SCALE: SUMMARY STATISTICS ON TOTAL SCORE ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder

	Screen	Visit												
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56				
Imipramine	No	108	107	99	88	83	76	73	70	70				
	Mean	26.68	23.81	20.25	17.84	14.72	12.33	10.74	9.83	8.56				
	STD	5.02	6.93	7.24	7.68	7.22	7.71	8.07	8.25	7.00				
	Median	26	27	24	20	15	12	11	9	8				
	Min	18.00	8.00	5.00	0.00	1.00	0.00	0.00	0.00	0.00				
	Max	44.00	38.00	40.00	41.00	33.00	33.00	43.00	42.00	31.00				
Mean diff. vs day0 (*)		3.08	6.56	9.05	12.06	14.45	16.14	16.79	17.90					
Reboxetine	No	105	105	101	97	92	85	83	80	77				
	Mean	26.92	23.91	21.34	18.74	16.51	14.29	12.84	11.13	11.35				
	STD	4.98	4.89	6.73	7.22	8.04	8.63	7.92	7.93	8.89				
	Median	26	26	24	21	18	15	13	12	10				
	Min	18.00	3.00	5.00	0.00	1.00	0.00	0.00	0.00	0.00				
	Max	43.00	43.00	42.00	41.00	44.00	40.00	32.00	31.00	38.00				
Mean diff. vs day0 (*)		3.09	5.68	8.34	10.62	13.01	14.35	16.15	15.95					

Mean (*): mean of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No. : 22

HAMILTON DEPRESSION RATING SCALE: SUMMARY STATISTICS ON TOTAL SCORE ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Diagnosis: Dysthymia

	Screen	Visit													
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56					
Imipramine	No	60	60	60	58	56	56	55	56	56	56	56	56	56	
	Mean	24.95	24.78	22.07	19.16	15.93	13.95	12.22	11.18	10.29	9.13	7.00	7.00	7.00	
	STD	4.45	4.54	5.61	8.25	9.02	8.41	8.59	7.93	7.04	7.00	7.00	7.00	7.00	
	Median	25	24	21	20	17	13	10	9	9	9	9	9	7	
	Min	19.00	16.00	7.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Max	35.00	34.00	34.00	34.00	34.00	34.00	33.00	31.00	27.00	27.00	28.00	28.00	28.00	28.00
Mean diff. vs day0 (*)			2.72	5.71	9.00	10.98	12.60	13.75	14.64	15.80	15.80	15.80	15.80	15.80	
Reboxetine	No	67	67	66	64	62	60	54	51	51	51	51	51	50	
	Mean	25.22	25.91	23.52	21.11	19.05	17.43	13.37	12.16	12.69	11.34	11.34	11.34	11.34	
	STD	5.54	5.92	6.40	6.80	8.10	8.78	7.64	7.28	7.93	7.73	7.73	7.73	7.73	
	Median	24	25	23	21	19	17	13	12	12	12	12	12	9	
	Min	18.00	17.00	8.00	7.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	
	Max	38.00	45.00	40.00	38.00	38.00	43.00	35.00	35.00	35.00	35.00	35.00	35.00	35.00	
Mean diff. vs day0 (*)			2.42	4.97	6.76	8.45	11.89	13.06	12.61	13.68	13.68	13.68	13.68		

Mean (*): mean of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Total
AND Item: DEPRESSED MOOD

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56					
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z				
Imipramine	0				1	0.60	10	6.37	21	14.6	27	19.4	43	32.8	55	42.6	63	50.0	67	53.2				
	1	4	2.38	7	4.17	10	5.99	32	20.4	34	23.6	55	39.6	44	33.6	40	31.0	36	28.6	34	27.0			
	2	43	25.6	41	24.4	62	37.1	59	37.6	56	38.9	39	28.1	25	19.1	22	17.1	19	15.1	17	13.5			
	3	93	55.4	89	53.0	70	41.9	45	28.7	27	18.8	18	12.9	18	13.7	11	8.53	7	5.56	8	6.35			
	4	28	16.7	31	18.5	24	14.4	11	7.01	6	4.17			1	0.76	1	0.78	1	0.79					
Total	168	100	168	100	167	100	157	100	144	100	139	100	131	100	129	100	126	100	126	100	126	100		
Reboxetine	0				2	1.17	4	2.42	9	5.66	19	12.5	37	26.6	35	26.1	44	33.6	42	32.1	47	37.0		
	1	14	8.14	15	8.72	28	16.4	35	21.2	45	28.3	49	32.2	40	28.8	50	37.3	42	32.1	29	22.1	23	18.1	
	2	38	22.1	37	21.5	44	25.7	62	37.6	55	34.6	42	27.6	37	26.6	34	25.4	29	22.1	13	10.2	13	10.2	
	3	98	57.0	99	57.6	81	47.4	51	30.9	37	23.3	33	21.7	18	12.9	13	9.70	12	9.16	4	3.05	3	2.36	
	4	22	12.8	21	12.2	16	9.36	13	7.88	13	8.18	9	5.92	7	5.04	2	1.49	4	3.05	3	2.36	3	2.36	
Total	172	100	172	100	171	100	165	100	159	100	152	100	139	100	134	100	131	100	131	100	127	100	127	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Total
AND Item: GUILT

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z		
Imipramine	0	35	20.8	34	20.2	41	24.6	52	33.1	57	39.6	70	50.4	74	56.5	85	65.9	85	67.5	91	72.2	
	1	56	33.3	58	34.5	61	36.5	61	38.9	55	38.2	47	33.8	47	35.9	34	26.4	33	26.2	30	23.8	
	2	55	32.7	57	33.9	50	29.9	34	21.7	25	17.4	18	12.9	8	6.11	9	6.98	6	4.76	5	3.97	
	3	20	11.9	18	10.7	15	8.98	10	6.37	7	4.86	4	2.88	2	1.53	1	0.78	2	1.59			
	4	2	1.19	1	0.60																	
Total	168	100	168	100	167	100	157	100	144	100	139	100	131	100	129	100	126	100	126	100	126	100
Reboxetine	0	50	29.1	49	28.5	53	31.0	60	36.4	62	39.0	70	46.1	71	51.1	78	58.2	86	65.6	88	69.3	
	1	49	28.5	46	26.7	48	28.1	49	29.7	62	39.0	53	34.9	56	40.3	43	32.1	34	26.0	29	22.8	
	2	52	30.2	55	32.0	50	29.2	39	23.6	23	14.5	20	13.2	11	7.91	12	8.96	10	7.63	9	7.09	
	3	19	11.0	20	11.6	17	9.94	16	9.70	10	6.29	8	5.26	1	0.72	1	0.75	1	0.76	1	0.79	
	4	2	1.16	2	1.16	3	1.75	1	0.61	2	1.26	1	0.66									
Total	172	100	172	100	171	100	165	100	159	100	152	100	139	100	134	100	131	100	131	100	127	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH IYER SCORE BY ASSIGNED TREATMENT

Diagnosis: Total
AND Item: SUICIDE

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%		
Imipramine	0	57	33.9	61	36.3	76	45.5	86	54.8	86	59.7	94	67.6	101	77.1	103	79.8	103	81.7	107	84.9	
	1	62	36.9	62	36.9	55	32.9	43	27.4	42	29.2	36	25.9	23	17.6	21	16.3	18	14.3	15	11.9	
	2	43	25.6	39	23.2	27	16.2	26	16.6	14	9.72	8	5.76	7	5.34	5	3.88	5	3.97	4	3.17	
	3	6	3.57	6	3.57	9	5.39	2	1.27	2	1.39	1	0.72									
	Total	168	100	168	100	167	100	157	100	144	100	139	100	131	100	129	100	126	100	126	100	126
Reboxetine	0	67	39.0	66	38.4	83	48.5	92	55.8	97	61.0	94	61.8	101	72.7	101	75.4	101	77.1	101	78.0	
	1	48	27.9	58	33.7	47	27.5	45	27.3	41	25.8	37	24.3	26	18.7	22	16.4	22	16.8	20	15.7	
	2	49	28.5	39	22.7	32	18.7	21	12.7	14	8.81	15	9.87	11	7.91	10	7.46	7	5.34	7	5.51	
	3	7	4.07	8	4.65	9	5.26	7	4.24	7	4.40	5	3.29	1	0.72	1	0.75	1	0.76	1	0.79	
	4	1	0.58	1	0.58							1	0.66									
Total	172	100	172	100	171	100	165	100	159	100	152	100	139	100	134	100	131	100	131	100	127	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITER SCORE BY ASSIGNED TREATMENT

Diagnosis: Total
AND Item: INSOMNIA EARLY

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	
Imipramine	0	31	18.5	32	19.0	40	24.0	50	31.8	55	38.2	58	41.7	64	48.9	59	45.7	65	51.6	73	57.9
	1	51	30.4	50	29.8	67	49.1	59	37.6	55	38.2	57	41.0	47	35.9	55	42.6	52	41.3	40	31.7
	2	86	51.2	86	51.2	60	35.9	48	30.6	34	23.6	24	17.3	20	15.3	15	11.6	9	7.14	13	10.3
	Total	168	100	168	100	167	100	157	100	144	100	139	100	131	100	129	100	126	100	126	100
Reboxetine	0	30	17.4	26	15.1	32	18.7	36	21.8	46	28.9	46	30.3	54	38.8	51	38.1	58	44.3	61	48.0
	1	35	20.3	37	21.5	54	31.6	58	35.2	60	37.7	69	45.4	82	44.6	61	45.5	54	41.2	47	37.0
	2	107	62.2	109	63.4	85	49.7	71	43.0	53	33.3	37	24.3	23	16.5	22	16.4	19	14.5	19	15.0
	Total	172	100	172	100	171	100	165	100	159	100	152	100	139	100	134	100	131	100	127	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Total
AND Item: INSOMNIA MIDDLE

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	
Imipramine	0	40	23.8	41	24.4	48	28.7	58	36.9	67	46.5	74	53.2	72	55.0	74	57.4	76	60.3	82	65.1
	1	72	42.9	63	37.5	74	44.3	64	40.8	57	39.6	49	35.3	46	35.1	48	37.2	40	31.7	39	31.0
	2	56	33.3	64	38.1	45	26.9	35	22.3	20	13.9	16	11.5	13	9.92	7	5.43	10	7.94	5	3.97
	Total	168	100	168	100	167	100	157	100	144	100	139	100	131	100	123	100	126	100	126	100
Reboxetine	0	44	25.6	33	19.2	28	16.4	38	23.0	40	25.2	48	31.6	58	41.7	59	44.0	65	49.6	66	52.0
	1	57	33.1	58	33.7	76	44.4	77	46.7	76	47.8	64	42.1	50	36.0	55	41.0	46	35.1	45	35.4
	2	71	41.3	81	47.1	67	39.2	50	30.3	43	27.0	40	26.3	31	22.3	20	14.9	20	15.3	16	12.6
	Total	172	100	172	100	171	100	165	100	159	100	152	100	139	100	134	100	131	100	127	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Total
AND Item: INSOMNIA LATE

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z		
Imipramine	0	36	21.4	34	20.2	42	25.1	53	33.8	57	39.6	67	48.2	77	58.8	78	60.5	79	62.7	90	71.4	
	1	64	38.1	62	36.9	65	38.9	65	41.4	57	39.6	52	37.4	39	29.8	38	29.5	35	27.8	27	21.4	
	2	68	40.5	72	42.9	60	35.9	39	24.8	30	20.8	20	14.4	15	11.5	13	10.1	12	9.52	9	7.14	
	Total	168	100	168	100	167	100	157	100	144	100	139	100	131	100	129	100	126	100	126	100	126
Reboxetine	0	47	27.3	43	25.0	39	22.8	43	26.1	45	28.3	57	37.5	58	41.7	57	42.5	64	48.9	64	50.4	
	1	45	26.2	48	27.9	63	36.8	71	43.0	74	46.5	59	38.8	59	42.4	58	43.3	53	40.5	47	37.0	
	2	80	46.5	81	47.1	69	40.4	51	30.9	40	25.2	36	23.7	22	15.8	19	14.2	14	10.7	16	12.6	
	Total	172	100	172	100	171	100	165	100	159	100	152	100	139	100	134	100	131	100	127	100	127

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/095
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Total
AND Item: RORR AND ACTIVITIES

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z		
Imipramine	0	1	0.60	2	1.19	1	0.60	9	5.73	15	10.4	23	16.5	29	22.1	41	31.8	44	34.9	53	42.1	
	1	9	5.36	9	5.36	16	9.58	29	18.5	41	28.5	44	31.7	50	38.2	45	34.9	46	36.5	43	34.1	
	2	52	31.0	47	28.0	58	34.7	59	37.6	47	32.6	45	32.4	33	25.2	32	24.8	24	19.0	22	17.5	
	3	80	47.6	77	45.8	66	39.5	49	31.2	32	22.2	22	15.8	13	9.92	10	7.75	11	8.73	7	5.56	
	4	26	15.5	33	19.6	26	15.6	11	7.01	9	6.25	5	3.60	6	4.58	1	0.78	1	0.79	1	0.79	
Total	168	100	168	100	167	100	157	100	144	100	139	100	131	100	129	100	126	100	126	100	126	100
Reboxetine	0	2	1.16	1	0.58	4	2.34	6	3.64	12	7.55	23	15.1	27	19.4	34	25.4	39	29.8	37	29.1	
	1	9	5.23	8	4.65	18	10.5	26	15.8	35	22.0	37	24.3	42	30.2	36	26.9	39	29.8	46	36.2	
	2	39	22.7	47	27.3	48	28.1	52	31.5	48	30.2	48	31.6	45	32.4	44	32.8	34	26.0	26	20.5	
	3	95	55.2	89	51.7	81	47.4	67	40.6	53	33.3	36	23.7	17	12.2	17	12.7	15	11.5	13	10.2	
	4	27	15.7	27	15.7	20	11.7	14	8.48	11	6.92	8	5.26	8	5.76	3	2.24	4	3.05	5	3.94	
Total	172	100	172	100	171	100	165	100	159	100	152	100	139	100	134	100	131	100	127	100	127	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Total
AND Item: RETARDATION

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%		
Imipramine	0	32	19.0	37	22.2	49	31.2	55	38.2	66	47.5	75	57.3	79	61.2	84	66.7	90	71.4			
	1	57	33.9	59	35.1	76	45.5	70	44.6	63	43.8	54	38.8	40	31.0	34	27.0	29	23.0			
	2	63	37.5	60	35.7	47	28.1	33	21.0	23	16.0	17	12.2	12	9.16	8	6.20	6	4.76			
	3	16	9.52	16	9.52	7	4.19	4	2.55	3	2.08	2	1.44	1	0.76	2	1.55	1	0.79			
	4	1	0.60					1	0.64													
Total	168	100	168	100	167	100	157	100	144	100	139	100	131	100	129	100	126	100	126	100		
Reboxetine	0	45	26.2	40	23.3	47	27.5	51	30.9	64	40.3	69	45.4	77	55.4	88	65.7	87	66.4	87	68.5	
	1	54	31.4	59	34.3	67	39.2	69	41.8	63	39.6	62	40.8	51	36.7	38	28.4	36	27.5	31	24.4	
	2	62	36.0	60	34.9	46	26.9	38	23.0	25	15.7	18	11.8	19	13.0	8	5.97	8	6.11	8	6.30	
	3	11	6.40	13	7.56	11	6.43	6	3.64	7	4.40	2	1.32	1	0.72					1	0.79	
	4							1	0.61			1	0.66									
Total	172	100	172	100	171	100	165	100	159	100	152	100	139	100	134	100	131	100	127	100		

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/095
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Total
AND Item: AGITATION

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z		
Imipramine	0	51	30.4	48	28.6	51	30.5	57	36.3	62	43.1	68	48.9	76	58.0	77	59.7	78	61.9	85	67.5	
	1	40	23.8	40	23.8	60	35.9	62	39.5	53	36.8	48	34.5	39	29.8	41	31.8	37	29.4	33	26.2	
	2	53	31.5	58	34.5	46	27.5	34	21.7	27	18.8	22	15.8	13	9.92	9	6.98	8	6.35	6	4.76	
	3	24	14.3	18	10.7	10	5.99	3	1.91	2	1.39	1	0.72	3	2.29	1	0.78	2	1.59	1	0.79	
	4	4	2.38					1	0.64							1	0.78	1	0.79	1	0.79	
Total	168	100	168	100	167	100	157	100	144	100	139	100	131	100	129	100	126	100	126	100	126	100
Reboxetine	0	59	34.3	53	30.8	56	32.7	59	35.8	67	42.1	72	47.4	78	56.1	84	62.7	86	65.6	82	64.6	
	1	43	25.0	46	26.7	50	29.2	56	33.9	51	32.1	49	32.2	39	28.1	33	24.6	33	25.2	28	22.0	
	2	51	29.7	46	26.7	47	27.5	39	23.6	33	20.8	25	16.4	20	14.4	16	11.9	8	6.11	13	10.2	
	3	18	10.5	23	13.4	15	8.77	9	5.45	7	4.40	4	2.63	1	0.72	1	0.75	3	2.29	2	1.57	
	4	1	0.58	4	2.33	3	1.75	2	1.21	1	0.63	2	1.32	1	0.72			1	0.76	2	1.57	
Total	172	100	172	100	171	100	165	100	159	100	152	100	139	100	134	100	131	100	131	100	127	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Total
AND Item: ANXIETY PSYCHIC

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	
Imipramine	0	3 1.79	4 2.38	9 5.39	16 10.2	20 13.9	22 15.8	36 27.5	43 33.3	44 34.9	47 37.3										
	1	33 19.6	28 16.7	43 25.7	41 26.1	46 31.9	61 43.9	52 39.7	54 41.9	49 38.9	49 38.9										
	2	61 36.3	71 42.3	74 44.3	76 48.4	61 42.4	47 33.8	33 25.2	28 21.7	29 23.0	26 20.6										
	3	61 36.3	53 31.5	39 23.4	22 14.0	16 11.1	9 6.47	10 7.63	4 3.10	3 2.38	4 3.17										
	4	10 5.95	12 7.14	2 1.20	2 1.27	1 0.69															
Total	168 100	168 100	167 100	157 100	144 100	139 100	131 100	129 100	126 100	126 100											
Reboxetine	0	8 4.65	7 4.07	12 7.02	16 9.70	24 15.1	30 19.7	32 23.0	39 29.1	38 29.0	39 30.7										
	1	24 14.0	23 13.4	38 22.2	45 27.3	49 30.8	48 31.6	60 43.2	57 42.5	52 39.7	54 42.5										
	2	80 46.5	81 47.1	76 44.4	78 47.3	69 43.4	55 36.2	38 27.3	32 23.9	38 29.0	28 22.0										
	3	49 28.5	52 30.2	42 24.6	22 13.3	12 7.55	16 10.5	6 4.32	6 4.48	2 1.53	6 4.72										
	4	11 6.40	9 5.23	3 1.75	4 2.42	5 3.14	3 1.97	3 2.16		1 0.76											
Total	172 100	172 100	171 100	165 100	159 100	152 100	139 100	134 100	131 100	127 100											

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Total
AND Item: ANXIETY SOMATIC

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%		
Imipramine	0	19	11.3	14	8.33	22	13.2	19	12.1	28	19.4	34	24.5	41	31.3	48	37.2	51	40.5	55	43.7	
	1	46	27.4	53	31.5	51	30.5	61	38.9	63	43.8	70	50.4	57	43.5	57	44.2	51	40.5	53	42.1	
	2	70	41.7	71	42.3	65	38.9	56	35.7	36	25.0	29	20.9	30	22.9	22	17.1	19	15.1	16	12.7	
	3	27	16.1	22	13.1	25	15.0	17	10.8	17	11.8	6	4.32	3	2.29	2	1.55	5	3.97	2	1.59	
	4	6	3.57	8	4.76	4	2.40	4	2.55													
Total	168	100	168	100	167	100	157	100	144	100	139	100	131	100	129	100	126	100	126	100	126	100
Reboxetine	0	5	2.91	3	1.74	13	7.60	17	10.3	25	15.7	36	23.7	47	33.8	47	35.1	49	37.4	55	43.3	
	1	49	28.5	52	30.2	56	32.7	68	41.2	66	41.5	67	44.1	60	43.2	60	44.8	52	39.7	44	34.6	
	2	72	41.9	71	41.3	72	42.1	67	40.6	56	35.2	39	25.7	26	18.7	22	16.4	24	18.3	20	15.7	
	3	42	24.4	41	23.8	29	17.0	12	7.27	12	7.55	8	5.26	5	3.60	4	2.99	6	4.58	7	5.51	
	4	4	2.33	5	2.91	1	0.58	1	0.61			2	1.32	1	0.72	1	0.75			1	0.79	
Total	172	100	172	100	171	100	165	100	159	100	152	100	139	100	134	100	131	100	131	100	127	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Total
AND Item: SOMATIC GASTROINTESTINAL

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	
Imipramine	0	29	17.3	30	17.9	35	21.0	46	29.3	55	38.2	61	43.9	71	54.2	72	55.8	75	59.5	84	66.7
	1	101	60.1	95	56.5	101	60.5	86	54.8	74	51.4	67	48.2	53	40.5	50	38.8	44	34.9	36	28.6
	2	38	22.6	43	25.6	31	18.6	25	15.9	15	10.4	11	7.91	7	5.34	7	5.43	7	5.56	6	4.76
	Total	168	100	168	100	167	100	157	100	144	100	139	100	131	100	129	100	126	100	126	100
Reboxetine	0	24	14.0	24	14.0	31	18.1	36	21.8	59	37.1	59	38.8	60	43.2	68	50.7	70	53.4	75	59.1
	1	59	34.1	91	52.9	95	55.6	94	57.0	69	43.4	69	45.4	62	44.6	56	41.8	51	38.9	42	33.1
	2	55	32.0	57	33.1	45	26.3	35	21.2	31	19.5	24	15.8	17	12.2	10	7.46	10	7.63	10	7.87
	Total	172	100	172	100	171	100	165	100	159	100	152	100	139	100	134	100	131	100	131	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Total
AND Item: SOMATIC GENERAL

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	
Imipramine	0	12	7.14	13	7.74	15	8.98	25	15.9	33	22.9	46	33.1	51	38.9	57	44.2	56	44.4	64	50.8
	1	80	47.6	76	45.2	84	50.3	83	52.9	73	50.7	60	43.2	60	45.8	56	43.4	53	42.1	45	35.7
	2	76	45.2	79	47.0	68	40.7	49	31.2	38	26.4	33	23.7	20	15.3	16	12.4	17	13.5	17	13.5
	Total	168	100	168	100	167	100	157	100	144	100	139	100	131	100	129	100	126	100	126	100
Reboxetine	0	11	6.40	7	4.07	11	6.43	18	10.9	29	18.2	38	25.0	40	28.8	46	34.3	46	35.1	50	39.4
	1	79	45.9	81	47.1	86	50.3	86	52.1	79	49.7	63	41.4	67	48.2	64	47.8	60	45.8	53	41.7
	2	82	47.7	84	48.8	74	43.3	61	37.0	51	32.1	51	33.6	32	23.0	24	17.9	25	19.1	24	18.9
	Total	172	100	172	100	171	100	165	100	159	100	152	100	139	100	134	100	131	100	127	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Total
AND Item: GENITAL SYMPTOMS

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	
Imipramine	0	92	54.8	90	53.6	88	52.7	89	56.7	83	57.6	88	63.3	84	64.1	83	64.3	83	65.9	83	65.9
	1	42	25.0	45	26.8	46	27.5	43	27.4	40	27.8	37	26.6	35	26.7	37	28.7	36	28.6	39	31.0
	2	34	20.2	33	19.6	33	19.8	25	15.9	21	14.6	14	10.1	12	9.16	9	6.98	7	5.56	4	3.17
	Total	168	100	168	100	167	100	157	100	144	100	133	100	131	100	129	100	126	100	126	100
Reboxetine	0	97	56.4	99	57.6	108	63.2	102	61.8	97	61.0	93	61.2	88	63.3	85	63.4	87	66.4	82	64.6
	1	46	26.7	44	25.6	32	18.7	37	22.4	41	25.8	41	27.0	38	27.3	36	26.9	34	26.0	40	31.5
	2	29	16.9	29	16.9	31	18.1	26	15.8	21	13.2	18	11.8	19	9.85	13	9.70	10	7.63	5	3.94
	Total	172	100	172	100	171	100	165	100	159	100	152	100	139	100	134	100	131	100	127	100

NS
CS
S

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Total
AND Item: HYPOCHONDRIASIS

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z		
Imipramine	0	37	22.0	36	21.4	40	24.0	42	26.8	52	36.1	51	36.7	53	40.5	59	45.7	67	53.2	66	52.4	
	1	40	23.8	38	22.6	38	22.8	51	32.5	47	32.6	57	41.0	51	38.9	46	35.7	42	33.3	43	34.1	
	2	57	33.9	63	37.5	64	38.3	51	32.5	36	25.0	28	20.1	24	18.3	21	16.3	14	11.1	15	11.9	
	3	33	19.6	30	17.9	23	13.8	11	7.01	7	4.86	3	2.16	2	1.53	2	1.55	2	1.59	2	1.59	
	4	1	0.60	1	0.60	2	1.20	2	1.27	2	1.39			1	0.76	1	0.78	1	0.79			
Total	168	100	168	100	167	100	157	100	144	100	139	100	131	100	129	100	126	100	126	100	126	100
Reboxetine	0	30	17.4	28	16.3	35	20.5	41	24.8	55	34.6	57	37.5	62	44.6	60	44.8	63	48.1	66	52.0	
	1	38	22.1	43	25.0	48	28.1	46	27.9	42	26.4	43	28.3	42	30.2	45	33.6	40	30.5	38	29.9	
	2	63	36.6	61	35.5	63	36.8	56	33.9	48	30.2	39	25.7	22	15.8	19	14.2	19	14.5	13	10.2	
	3	38	22.1	36	20.9	25	14.6	21	12.7	13	8.18	13	8.55	13	9.35	10	7.46	9	6.87	10	7.87	
	4	3	1.74	4	2.33			1	0.61	1	0.63											
Total	172	100	172	100	171	100	165	100	159	100	152	100	139	100	134	100	131	100	131	100	127	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Total
AND Item: LOSS OF WEIGHT

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z		
Imipramine	0	87	51.8	99	58.9	128	76.6	127	80.9	123	85.4	120	86.3	116	88.5	112	86.8	114	90.5	115	91.3	
	1	37	22.0	30	17.9	26	15.6	19	12.1	16	11.1	13	9.35	8	6.11	10	7.75	4	3.17	6	4.76	
	2	41	24.4	36	21.4	13	7.78	11	7.01	5	3.47	6	4.32	6	4.58	6	4.65	7	5.56	5	3.97	
	3	3	1.79	3	1.79									1	0.76	1	0.78	1	0.79			
Total	168	100	168	100	167	100	157	100	144	100	139	100	131	100	129	100	126	100	126	100	126	100
Reboxetine	0	87	50.6	103	59.9	133	77.8	144	87.3	134	84.3	127	83.6	119	85.6	112	83.6	116	88.5	113	89.0	
	1	33	19.2	28	16.3	21	12.3	13	7.88	14	8.81	19	12.5	12	8.63	15	11.2	12	9.16	11	8.66	
	2	48	27.9	36	20.9	15	8.77	8	4.85	9	5.66	6	3.95	7	5.04	6	4.48	3	2.29	3	2.36	
	3	4	2.33	5	2.91	2	1.17			2	1.26			1	0.72	1	0.75					
Total	172	100	172	100	171	100	165	100	159	100	152	100	139	100	134	100	131	100	131	100	127	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Total
AND Item: INSIGHT

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	
Imipramine	0	87	51.8	86	51.2	93	55.7	97	61.8	88	61.1	94	67.6	92	70.2	86	66.7	92	73.0	98	77.8
	1	72	42.9	71	42.3	65	38.9	51	32.5	47	32.6	39	28.1	35	26.7	35	27.1	28	22.2	22	17.5
	2	9	5.36	11	6.55	9	5.39	9	5.73	9	6.25	6	4.32	4	3.05	8	6.20	6	4.76	6	4.76
	Total	168	100	168	100	167	100	157	100	144	100	139	100	131	100	123	100	126	100	126	100
Reboxetine	0	94	54.7	88	51.2	96	56.1	94	57.0	104	65.4	103	67.8	103	74.1	104	77.6	101	77.1	101	79.5
	1	70	40.7	73	42.4	64	37.4	57	34.5	48	30.2	39	25.7	30	21.6	23	17.2	23	17.6	21	16.5
	2	8	4.65	11	6.40	11	6.43	14	8.48	7	4.40	10	6.58	6	4.32	7	5.22	7	5.34	5	3.94
	Total	172	100	172	100	171	100	165	100	159	100	152	100	139	100	134	100	131	100	127	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Total
AND Item: DIURNAL VARIATION

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	
Imipramine	0	65	38.7	64	38.1	68	40.7	70	44.6	69	47.9	72	51.8	84	64.1	88	68.2	89	70.6	92	73.0
	1	74	44.0	72	42.9	76	45.5	64	40.8	61	42.4	57	41.0	41	31.3	37	28.7	34	27.0	31	24.6
	2	29	17.3	32	19.0	23	13.8	23	14.6	14	9.72	10	7.19	6	4.58	4	3.10	3	2.38	3	2.38
	Total	168	100	168	100	167	100	157	100	144	100	139	100	131	100	129	100	126	100	126	100
Reboxetine	0	78	45.3	73	42.4	74	43.3	78	47.3	84	52.8	93	61.2	86	61.9	87	64.9	94	71.8	93	73.2
	1	66	38.4	70	40.7	75	43.9	68	41.2	59	37.1	49	32.2	47	33.8	45	33.6	36	27.5	29	22.8
	2	28	16.3	29	16.9	22	12.9	19	11.5	16	10.1	10	6.58	6	4.32	2	1.49	1	0.76	5	3.94
	Total	172	100	172	100	171	100	165	100	159	100	152	100	139	100	134	100	131	100	127	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Total
AND Item: DEPERSONALIZATION

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	
Imipramine	114	67.9	116	69.0	119	71.3	120	76.4	115	79.9	111	79.9	111	84.7	112	86.8	113	89.7	114	90.5	
	35	20.8	34	20.2	35	21.0	27	17.2	23	16.0	21	15.1	18	13.7	16	12.4	12	9.52	12	9.52	
	16	9.52	15	8.93	12	7.19	9	5.73	5	3.47	7	5.04	2	1.53							
	3	1.79	2	1.19	1	0.60	1	0.64	1	0.69											
	1	0.60																			
Total	168	100	168	100	167	100	157	100	144	100	139	100	131	100	129	100	126	100	126	100	
Reboxetine	110	64.0	107	62.2	113	66.1	117	70.9	121	76.1	121	79.6	116	83.5	113	84.3	112	85.5	106	83.5	
	36	20.9	37	21.5	37	21.6	35	21.2	21	13.2	27	17.8	19	13.7	17	12.7	16	12.2	19	15.0	
	22	12.8	24	14.0	19	11.1	11	6.67	16	10.1	2	1.32	2	1.44	4	2.99	3	2.29	2	1.57	
	4	2.33	4	2.33	2	1.17	2	1.21	1	0.63	2	1.32	2	1.44							
	172	100	172	100	171	100	165	100	159	100	152	100	139	100	134	100	131	100	127	100	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No. : 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Total
AND Item: PARANOID

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56	
	No	X	No	X	No	X	No	X	No	X	No	X	No	X	No	X	No	X	No	X
Imipramine	130	77.4	131	78.0	136	81.4	133	84.7	122	84.7	123	87.8	114	87.0	113	87.6	114	90.5	119	94.4
	34	20.2	32	19.0	28	16.8	22	14.0	21	14.6	16	11.5	16	12.2	16	12.4	11	8.73	7	5.56
	3	1.79	4	2.38	2	1.20	1	0.64					1	0.76			1	0.79		
	1	0.60	1	0.60	1	0.60	1	0.64	1	0.69	1	0.72								
Total	168	100	168	100	167	100	157	100	144	100	139	100	131	100	129	100	126	100	126	100
Reboxetine	138	80.2	139	80.8	144	84.2	141	85.5	139	87.4	135	88.8	129	92.8	126	94.0	123	93.9	117	92.1
	26	15.1	26	15.1	23	13.5	19	11.5	18	11.3	14	9.21	9	6.47	8	5.97	8	6.11	10	7.87
	8	4.65	7	4.07	3	1.75	4	2.42	2	1.26	3	1.97	1	0.72						
	1	0.60	1	0.60	1	0.58	1	0.61												
Total	172	100	172	100	171	100	165	100	159	100	152	100	139	100	134	100	131	100	127	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Total
AND Item: OBSESSIONAL/COMPULSIVE

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z		
Imipramine	0	113	67.3	113	68.9	112	71.3	110	76.4	106	76.3	107	81.7	104	80.6	106	84.1	106	84.1	106	84.1	
	1	40	23.8	39	23.2	37	22.2	34	21.7	23	16.0	24	17.3	16	12.2	19	14.7	16	12.7	16	12.7	
	2	15	8.93	16	9.52	15	8.98	11	7.01	11	7.64	9	6.47	8	5.11	6	4.65	4	3.17	4	3.17	
Total	168	100	168	100	167	100	157	100	144	100	139	100	131	100	129	100	126	100	126	100	126	100
Reboxetine	0	107	62.2	108	62.8	107	62.6	113	68.5	112	70.4	115	75.7	112	80.6	105	78.4	103	75.6	98	77.2	
	1	54	31.4	52	30.2	58	33.9	46	27.9	43	27.0	32	21.1	26	18.7	28	20.3	27	20.6	28	22.0	
	2	11	6.40	12	6.98	6	3.51	6	3.64	4	2.52	5	3.29	1	0.72	1	0.75	1	0.76	1	0.79	
Total	172	100	172	100	171	100	165	100	159	100	152	100	139	100	134	100	131	100	127	100	127	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder
AND Item: DEPRESSED MOOD

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	
Imipramine	0						5	5.05	5	5.68	10	12.0	21	27.6	29	39.7	35	50.0	35	50.0	
	1	2	1.85	4	3.70	5	4.67	19	19.2	25	28.4	38	45.8	28	36.8	26	35.6	22	31.4	22	31.4
	2	24	22.2	23	21.3	39	36.4	39	39.4	38	43.2	24	28.9	16	21.1	13	17.8	8	11.4	9	12.9
	3	59	54.6	56	51.9	43	40.2	28	28.3	15	17.0	11	13.3	10	13.2	4	5.48	4	5.71	4	5.71
	4	23	21.3	25	23.1	20	18.7	8	8.08	5	5.68			1	1.32	1	1.37	1	1.43		
Total	108	100	108	100	107	100	99	100	88	100	83	100	76	100	75	100	70	100	70	100	
Reboxetine	0				2	1.90	3	2.97	4	4.12	10	10.9	21	24.7	21	25.3	29	36.3	25	32.5	
	1	10	9.52	11	10.5	16	15.2	20	19.8	30	30.9	31	33.7	25	29.4	27	32.5	23	28.7	30	39.0
	2	20	19.0	22	21.0	25	23.8	35	34.7	29	29.9	21	22.8	18	21.2	22	26.5	16	20.0	9	11.7
	3	59	56.2	57	54.3	48	45.7	33	32.7	24	24.7	23	25.0	16	18.8	11	13.3	8	10.0	10	13.0
	4	16	15.2	15	14.3	14	13.3	10	9.90	10	10.3	7	7.61	5	5.88	2	2.41	4	5.00	3	3.90
Total	105	100	105	100	105	100	101	100	97	100	92	100	85	100	83	100	80	100	77	100	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder
AND Item: GUILT

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z		
Imipramine	0	25	23.1	24	22.2	28	26.2	34	34.3	32	36.4	42	50.6	44	57.9	51	69.9	49	70.0	53	75.7	
	1	33	30.6	35	32.4	38	35.5	39	39.4	37	42.0	31	37.3	29	38.2	20	27.4	18	25.7	16	22.9	
	2	38	35.2	40	37.0	33	30.8	21	21.2	16	18.2	10	12.0	3	3.95	1	1.37	1	1.43	1	1.43	
	3	11	10.2	9	8.33	8	7.48	5	5.05	3	3.41					1	1.37	2	2.86			
	4	1	0.93																			
Total	108	100	108	100	107	100	99	100	88	100	83	100	76	100	73	100	70	100	70	100	70	100
Reboxetine	0	36	34.3	35	33.3	38	36.2	42	41.6	41	42.3	50	54.3	46	54.1	48	57.8	55	68.8	53	68.8	
	1	29	27.6	31	29.5	33	31.4	34	33.7	40	41.2	27	29.3	34	40.0	28	33.7	19	23.7	18	23.4	
	2	31	29.5	29	27.6	24	22.9	17	16.8	11	11.3	11	12.0	5	5.88	7	8.43	6	7.50	6	7.79	
	3	8	7.62	9	8.57	9	8.57	8	7.92	4	4.12	4	4.35									
	4	1	0.95	1	0.95	1	0.95			1	1.03											
Total	105	100	105	100	105	100	101	100	97	100	92	100	85	100	83	100	80	100	80	100	77	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder
AND Item: SUICIDE

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	X	No	X	No	X	No	X	No	X	No	X	No	X	No	X	No	X	No	X		
Imipramine	0	28	25.9	30	27.8	41	38.3	52	52.5	51	58.0	54	65.1	58	76.3	57	78.1	57	81.4	61	87.1	
	1	46	42.6	46	42.6	44	41.1	30	30.3	28	31.8	26	31.3	15	19.7	13	17.8	10	14.3	7	10.0	
	2	31	28.7	28	25.9	15	14.0	16	16.2	8	9.09	3	3.61	3	3.95	3	4.11	3	4.29	2	2.86	
	3	3	2.78	4	3.70	7	6.54	1	1.01	1	1.14											
	Total	108	100	108	100	107	100	99	100	88	100	83	100	76	100	73	100	70	100	70	100	77
Reboxetine	0	39	37.1	41	39.0	52	49.5	57	56.4	63	64.9	59	64.1	64	75.3	64	77.1	64	80.0	62	80.5	
	1	28	26.7	33	31.4	28	26.7	29	28.7	22	22.7	21	22.8	16	18.8	14	16.9	13	16.2	12	15.6	
	2	32	30.5	25	23.8	19	18.1	10	9.90	7	7.22	9	9.78	4	4.71	4	4.82	2	2.50	2	2.60	
	3	5	4.76	5	4.76	6	5.71	5	4.95	5	5.15	3	3.26	1	1.18	1	1.20	1	1.25	1	1.30	
	4	1	0.95	1	0.95																	
Total	105	100	105	100	105	100	101	100	97	100	92	100	85	100	83	100	80	100	80	100	77	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No. : 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder
AND Item: INSOMNIA EARLY

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%		
Imipramine	0	18	16.7	18	16.7	25	23.4	28	28.3	31	35.2	33	39.8	35	46.1	33	45.2	40	57.1	44	62.9	
	1	33	30.6	32	29.6	41	38.3	41	41.4	36	40.9	35	42.2	30	39.5	31	42.5	25	35.7	18	25.7	
	2	57	52.8	58	53.7	41	38.3	30	30.3	21	23.9	15	18.1	11	14.5	9	12.3	5	7.14	8	11.4	
Total	108	100	108	100	107	100	99	100	88	100	83	100	76	100	73	100	70	100	70	100	70	100
Reboxetine	0	12	11.4	10	9.52	16	15.2	18	17.8	28	28.9	26	28.3	32	37.6	31	37.3	38	47.5	37	48.1	
	1	20	19.0	20	19.0	36	34.3	38	37.6	34	35.1	44	47.8	38	44.7	36	43.4	29	36.3	25	32.5	
	2	73	69.5	75	71.4	55	50.5	45	44.6	35	36.1	22	23.9	15	17.6	16	19.3	13	16.2	15	19.5	
Total	105	100	105	100	105	100	101	100	97	100	92	100	85	100	83	100	80	100	80	100	77	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder
AND Item: INSOMNIA MIDDLE

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%		
Imipramine	0	21	19.4	20	18.5	22	20.6	28	28.3	33	37.5	37	44.6	38	50.0	40	54.8	42	60.0	45	64.3	
	1	51	47.2	46	42.6	57	53.3	50	50.5	44	50.0	39	47.0	32	42.1	29	39.7	22	31.4	22	31.4	
	2	36	33.3	42	38.9	28	26.2	21	21.2	11	12.5	7	8.43	6	7.89	4	5.48	6	8.57	3	4.29	
Total	108	100	108	100	107	100	99	100	88	100	83	100	76	100	73	100	70	100	70	100	70	100
Reboxetine	0	21	20.0	14	13.3	13	12.4	20	19.8	23	23.7	28	30.4	34	40.0	38	45.8	40	50.0	41	53.2	
	1	37	35.2	35	33.3	47	44.8	50	49.5	46	47.4	37	40.2	31	36.5	32	38.6	28	35.0	26	33.8	
	2	47	44.8	56	53.3	45	42.9	31	30.7	28	28.9	27	29.3	20	23.5	13	15.7	12	15.0	10	13.0	
Total	105	100	105	100	105	100	101	100	97	100	92	100	85	100	83	100	80	100	80	100	77	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder
AND Item: INSOMNIA LATE

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%		
Imipramine	0	17	15.7	15	13.9	19	17.8	25	25.3	26	29.5	33	39.8	42	55.3	38	52.1	41	58.6	47	67.1	
	1	39	36.1	38	35.2	41	38.3	47	47.5	37	42.0	35	42.2	23	30.3	25	34.2	20	28.6	17	24.3	
	2	52	48.1	55	50.9	47	43.9	27	27.3	25	28.4	15	18.1	11	14.5	10	13.7	9	12.9	6	8.57	
Total	108	100	108	100	107	100	99	100	88	100	83	100	76	100	73	100	70	100	70	100	70	100
Reboxetine	0	18	17.1	18	17.1	16	15.2	23	22.8	23	23.7	32	34.8	33	38.8	31	37.3	36	45.0	36	46.8	
	1	27	25.7	26	24.8	40	38.1	42	41.6	46	47.4	38	41.3	37	43.5	38	45.8	34	42.5	29	37.7	
	2	60	57.1	61	58.1	49	46.7	36	35.6	28	28.9	22	23.9	15	17.6	14	16.9	10	12.5	12	15.6	
Total	105	100	105	100	105	100	101	100	97	100	92	100	85	100	83	100	80	100	80	100	77	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder
AND Item: WORK AND ACTIVITIES

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	Z	No	X	No	X	No	X	No	X	No	X	No	X	No	X	No	X	No	X		
Imipramine	0	1	0.93	1	0.93	1	0.93	6	6.06	8	9.09	12	14.5	15	19.7	23	31.5	25	35.7	27	38.6	
	1	7	6.48	7	6.48	10	9.35	15	15.2	22	25.0	27	32.5	31	40.8	26	35.6	26	37.1	27	38.6	
	2	31	28.7	28	25.9	32	29.9	39	39.4	31	35.2	28	33.7	19	25.0	18	24.7	12	17.1	12	17.1	
	3	47	43.5	45	41.7	44	41.1	31	31.3	18	20.5	12	14.5	5	6.58	5	6.85	6	8.57	3	4.29	
	4	22	20.4	27	25.0	20	18.7	8	8.08	9	10.2	4	4.82	6	7.89	1	1.37	1	1.43	1	1.43	
Total	108	100	108	100	107	100	99	100	88	100	83	100	76	100	73	100	70	100	70	100	70	100
Reboxetine	0	1	0.95				2	1.90	3	2.97	6	6.19	13	15.3	17	20.5	24	30.0	23	29.9		
	1	6	5.71	5	4.76	11	10.5	17	16.8	25	25.8	23	25.0	26	30.6	22	26.5	26	32.5	28	36.4	
	2	20	19.0	27	25.7	29	27.6	26	25.7	27	27.8	28	30.4	29	34.1	29	34.9	19	23.7	14	18.2	
	3	56	53.3	52	49.5	47	44.8	44	43.6	30	30.9	22	23.9	10	11.8	12	14.5	8	10.0	7	9.09	
	4	22	21.0	21	20.0	16	15.2	11	10.9	9	9.28	6	6.52	7	8.24	3	3.61	3	3.75	5	6.49	
Total	105	100	105	100	105	100	101	100	97	100	92	100	85	100	83	100	80	100	80	100	77	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBEXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder
AND Item: RETARDATION

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56	
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z
Imipramine	17	15.7	15	13.9	18	16.8	28	28.3	30	34.1	40	48.2	43	56.6	46	63.0	48	68.6	50	71.4
	33	30.6	35	32.4	47	43.9	44	44.4	40	45.5	31	37.3	26	34.2	22	30.1	18	25.7	17	24.3
	48	44.4	46	42.6	36	33.6	23	23.2	17	19.3	11	13.3	7	9.21	4	5.48	3	4.29	3	4.29
	10	9.26	11	10.2	6	5.61	3	3.03	1	1.14	1	1.20			1	1.37	1	1.43		
	1	0.93					1	1.01												
Total	108	100	108	100	107	100	99	100	88	100	83	100	76	100	73	100	70	100	70	100
Reboxetine	23	21.9	19	18.1	25	23.8	30	29.7	40	41.2	45	48.9	46	54.1	54	65.1	53	66.3	52	67.5
	32	30.5	36	34.3	44	41.9	43	42.6	38	39.2	35	38.0	32	37.6	24	28.9	23	28.7	19	24.7
	44	41.9	41	39.0	28	26.7	23	22.8	12	12.4	11	12.0	6	7.06	5	6.02	4	5.00	5	6.49
	6	5.71	9	8.57	8	7.62	4	3.96	7	7.22	1	1.09	1	1.18					1	1.30
	1	0.99					1	0.99												
Total	105	100	105	100	105	100	101	100	97	100	92	100	85	100	83	100	80	100	77	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS RED

REBOXETINE - PROTOCOL 20124/035
TABLE NO.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder
AND Item: AGITATION

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z		
Imipramine	0	30	27.8	29	26.9	31	29.0	34	34.3	38	43.2	39	47.0	43	56.6	43	58.9	44	62.9	48	68.6	
	1	26	24.1	27	25.0	39	36.4	41	41.4	32	36.4	29	34.9	23	30.3	23	31.5	20	28.6	18	25.7	
	2	35	32.4	37	34.3	29	27.1	21	21.2	17	19.3	15	18.1	9	11.8	7	9.59	5	7.14	4	5.71	
	3	17	15.7	12	11.1	8	7.48	2	2.02	1	1.14			1	1.32			1	1.43			
	4			3	2.78			1	1.01													
Total	108	100	108	100	107	100	99	100	88	100	83	100	76	100	73	100	70	100	70	100	70	100
Reboxetine	0	37	35.2	33	31.4	35	33.3	38	37.6	41	42.3	47	51.1	47	55.3	52	62.7	52	65.0	50	64.9	
	1	24	22.9	28	26.7	30	28.6	33	32.7	32	35.0	29	31.5	21	24.7	21	25.3	20	25.0	15	19.5	
	2	28	26.7	23	21.9	27	25.7	21	20.8	16	16.5	12	15.0	15	17.6	9	10.8	5	6.25	9	11.7	
	3	15	14.3	19	18.1	11	10.5	7	6.93	7	7.22	3	3.26	1	1.18	1	1.20	2	2.50	1	1.30	
	4	1	0.95	2	1.90	2	1.90	2	1.98	1	1.03	1	1.09	1	1.18			1	1.25	2	2.60	
Total	105	100	105	100	105	100	101	100	97	100	92	100	85	100	83	100	80	100	80	100	77	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No. 1 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder
AND Item: ANXIETY PSYCHIC

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	
Imipramine	0	2 1.85	3 2.78	6 5.61	10 10.1	12 13.6	13 15.7	21 27.6	23 31.5	25 35.7	28 40.0										
	1	22 20.4	19 17.6	28 26.2	27 27.3	27 30.7	32 38.6	26 34.2	31 42.5	22 31.4	24 34.3										
	2	41 38.0	49 45.4	45 42.1	46 46.5	37 42.0	31 37.3	20 26.3	16 21.9	20 28.6	16 22.9										
	3	37 34.9	29 26.9	27 25.2	14 14.1	11 12.5	7 8.43	9 11.8	3 4.11	2 2.86	2 2.86										
	4	6 5.56	8 7.41	1 0.93	2 2.02	1 1.14				1 1.43											
Total	108	100	108	100	107	100	99	100	88	100	83	100	76	100	73	100	70	100	70	100	
Reboxetine	0	5 4.76	6 5.71	9 8.57	13 12.9	17 17.5	22 23.9	24 28.2	27 32.5	29 36.3	27 35.1										
	1	17 16.2	14 13.3	26 24.8	28 27.7	30 30.9	26 28.3	30 35.3	27 32.5	27 33.8	26 33.8										
	2	47 44.8	51 48.6	46 43.8	46 45.5	39 40.2	34 37.0	24 28.2	24 28.2	23 27.7	21 26.2										
	3	30 28.6	30 28.6	22 21.0	12 11.9	8 8.25	8 8.70	5 5.88	6 7.23	2 2.50	5 6.49										
	4	6 5.71	4 3.81	2 1.90	2 1.98	3 3.09	2 2.17	2 2.35		1 1.25											
Total	105	100	105	100	105	100	101	100	97	100	92	100	85	100	83	100	80	100	77	100	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 25

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder
AND Item: ANXIETY SOMATIC

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56	
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z
Imipramine	14	13.0	11	10.2	17	15.9	13	13.1	16	18.2	21	25.3	24	31.6	27	37.0	31	44.3	34	48.6
	30	27.8	38	35.2	33	30.8	40	40.4	41	46.6	43	51.8	35	46.1	34	46.6	27	38.6	27	38.6
	43	39.8	38	35.2	38	35.5	31	31.3	18	20.5	13	15.7	15	19.7	12	16.4	10	14.3	9	12.9
	18	16.7	17	15.7	16	15.0	12	12.1	13	14.8	6	7.23	2	2.63						
	3	2.78	4	3.70	3	2.80	3	3.03												
Total	108	100	108	100	107	100	99	100	88	100	83	100	76	100	73	100	70	100	70	100
Reboxetine	5	4.76	3	2.86	9	8.57	13	12.9	16	16.5	20	21.7	28	32.9	29	34.9	34	42.5	35	45.5
	29	27.6	29	27.6	36	36.3	42	41.6	41	42.3	43	46.7	38	44.7	38	45.8	31	38.8	27	35.1
	43	41.0	44	41.9	41	39.0	36	35.6	31	32.0	21	22.8	14	16.5	12	14.5	12	15.0	9	11.7
	26	24.8	25	23.8	18	17.1	9	8.91	9	9.28	6	6.52	4	4.71	3	3.61	3	3.75	6	7.79
	2	1.90	4	3.81	1	0.95	1	0.99			2	2.17	1	1.18	1	1.20				
Total	105	100	105	100	105	100	101	100	97	100	92	100	85	100	83	100	80	100	80	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124-035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder
AND Item: SOMATIC GASTROINTESTINAL

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	
Imipramine	0	13	12.0	14	13.0	17	15.9	23	23.2	30	34.1	34	41.0	40	52.6	40	54.8	43	61.4	47	67.1
	1	66	61.1	60	55.6	66	61.7	58	58.6	47	53.4	41	49.4	32	42.1	29	39.7	22	31.4	20	28.6
	2	29	26.9	34	31.5	24	22.4	18	18.2	11	12.5	8	9.64	4	5.26	4	5.48	5	7.14	3	4.29
	Total	108	100	108	100	107	100	99	100	88	100	83	100	76	100	73	100	70	100	70	100
Reboxetine	0	8	7.62	8	7.62	13	12.4	19	18.8	35	36.1	36	39.1	35	41.2	44	59.0	46	57.5	45	58.4
	1	61	58.4	61	58.1	66	62.9	61	60.4	43	44.3	41	44.6	36	42.4	31	37.3	29	36.3	24	31.2
	2	36	34.3	36	34.3	26	24.8	21	20.8	19	19.6	15	16.3	14	16.5	8	9.64	5	6.25	8	10.4
	Total	105	100	105	100	105	100	101	100	97	100	92	100	85	100	83	100	80	100	77	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARNACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder
AND Item: SOMATIC GENERAL

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z		
Imipramine	0	8	7.41	8	7.41	9	8.41	15	15.2	17	19.3	25	30.1	32	42.1	35	47.9	30	42.9	35	50.0	
	1	51	47.2	47	43.5	53	49.5	52	52.5	44	50.0	34	41.0	31	40.8	29	39.7	28	40.0	22	31.4	
	2	49	45.4	53	49.1	45	42.1	32	32.3	27	30.7	24	28.9	13	17.1	9	12.3	12	17.1	13	18.6	
Total	108	100	108	100	107	100	99	100	88	100	83	100	76	100	73	100	70	100	70	100		
Reboxetine	0	4	3.81	2	1.90	4	3.81	8	7.92	18	18.6	24	26.1	24	28.2	27	32.5	28	35.0	30	39.0	
	1	51	48.6	54	51.4	56	53.3	55	54.5	49	50.5	36	39.1	39	45.9	40	48.2	36	45.0	31	40.3	
	2	50	47.6	49	46.7	45	42.9	38	37.6	30	30.9	32	34.8	22	25.9	16	19.3	16	20.0	16	20.8	
Total	105	100	105	100	105	100	101	100	97	100	92	100	85	100	83	100	80	100	80	100	77	100

22 01 01

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder
AND Item: GENITAL SYMPTOMS

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	
Imipramine	0	56	51.9	55	50.9	55	51.4	57	57.6	49	55.7	52	62.7	48	63.2	46	63.0	47	67.1	46	65.7
	1	27	25.0	31	28.7	30	28.0	25	25.3	24	27.9	22	26.5	21	27.6	22	30.1	19	27.1	21	30.0
	2	25	23.1	22	20.4	23	20.6	17	17.2	15	17.0	9	10.8	7	9.21	5	6.85	4	5.71	3	4.29
	Total	108	100	107	100	99	100	83	100	88	100	83	100	76	100	73	100	70	100	70	100
Reboxetine	0	59	56.2	61	58.1	67	63.8	63	62.4	60	61.9	60	65.2	58	68.2	56	67.5	56	70.0	50	64.9
	1	29	27.6	27	25.7	20	19.0	21	20.8	24	24.7	21	22.8	17	20.0	18	21.7	17	21.2	23	23.9
	2	17	16.2	17	16.2	18	17.1	17	16.8	13	13.4	11	12.0	10	11.8	9	10.8	7	8.75	4	5.19
	Total	105	100	105	100	105	100	101	100	97	100	92	100	85	100	83	100	80	100	77	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 2012A/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder
AND Item: HYPOCHONDRIASIS

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%		
Imipramine	0	26	24.1	26	24.1	29	27.1	28	28.3	33	37.5	30	36.1	34	44.7	36	49.3	41	58.6	37	52.9	
	1	28	25.9	23	21.3	25	23.4	31	31.3	31	35.2	39	47.0	29	38.2	25	34.2	19	27.1	26	37.1	
	2	30	27.8	37	34.3	37	34.6	31	31.3	19	21.6	12	14.5	11	14.5	10	13.7	7	10.0	6	8.57	
	3	23	21.3	21	19.4	14	13.1	7	7.07	3	3.41	2	2.41	1	1.32	1	1.37	2	2.86	1	1.43	
	4	1	0.93	1	0.93	2	1.87	2	2.02	2	2.27			1	1.32	1	1.37	1	1.43			
Total	108	100	108	100	107	100	99	100	88	100	83	100	76	100	73	100	70	100	70	100	70	100
Reboxetine	0	18	17.1	18	17.1	22	21.0	28	27.7	37	38.1	35	38.0	40	47.1	39	47.0	44	55.0	46	59.7	
	1	28	26.7	33	31.4	32	30.5	29	28.7	26	26.8	27	29.3	24	28.2	28	33.7	25	31.3	21	27.3	
	2	39	37.1	33	31.4	41	39.0	32	31.7	27	27.8	22	23.9	11	12.9	10	12.0	7	8.75	5	6.49	
	3	18	17.1	19	18.1	10	9.52	11	10.9	7	7.22	8	8.70	10	11.8	6	7.23	4	5.00	5	6.49	
	4	2	1.90	2	1.90			1	0.99													
Total	105	100	105	100	105	100	101	100	97	100	92	100	85	100	83	100	80	100	80	100	77	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOSETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder
AND Item: LOSS OF WEIGHT

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%		
Imipramine	0	47	43.5	56	51.9	77	72.0	79	79.8	71	80.7	67	80.7	64	84.2	61	83.6	63	90.0	62	88.6	
	1	27	25.0	22	20.4	16	16.8	12	12.1	12	13.6	10	12.0	7	9.21	6	8.22	2	2.86	3	4.29	
	2	32	29.6	28	25.9	12	11.2	8	8.08	5	5.68	6	7.23	4	5.26	5	6.85	4	5.71	5	7.14	
	3	2	1.85	2	1.85									1	1.32	1	1.37	1	1.43			
Total	108	100	108	100	107	100	99	100	88	100	83	100	76	100	73	100	70	100	70	100	70	100
Reboxetine	0	44	41.9	56	53.3	78	74.3	87	86.1	80	82.5	77	83.7	71	83.5	66	79.5	68	85.0	67	87.8	
	1	22	21.0	19	18.1	16	15.2	8	7.92	10	10.3	12	13.0	9	10.6	12	14.5	10	12.5	9	11.7	
	2	37	35.2	28	26.7	9	8.57	6	5.94	6	6.19	3	3.26	4	4.71	4	4.82	2	2.50	1	1.30	
	3	2	1.90	2	1.90	2	1.90			1	1.03			1	1.18	1	1.20					
Total	105	100	105	100	105	100	101	100	97	100	92	100	85	100	83	100	80	100	80	100	77	100

2
3
8

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder
AND Item: INSIGHT

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	
Imipramine	0	63	58.3	60	55.6	65	60.7	66	66.7	60	58.2	64	77.1	59	77.6	56	76.7	56	80.0	58	82.9
	1	40	37.0	41	38.0	37	34.6	28	28.3	25	28.4	18	21.7	16	21.1	16	21.9	14	20.0	10	14.3
	2	5	4.63	7	6.48	5	4.67	5	5.05	3	3.41	1	1.20	1	1.32	1	1.37			2	2.86
	Total	108	100	108	100	107	100	99	100	88	100	83	100	76	100	73	100	70	100	70	100
Reboxetine	0	68	64.8	62	59.0	65	61.9	62	61.4	67	69.1	67	72.8	66	77.6	68	81.9	66	82.5	63	81.8
	1	30	28.6	35	33.3	30	28.6	29	28.7	25	25.8	19	20.7	17	20.0	12	14.5	10	12.5	10	13.0
	2	7	6.67	8	7.62	10	9.52	10	9.90	5	5.15	6	6.52	2	2.35	3	3.61	4	5.00	4	5.19
	Total	105	100	105	100	105	100	101	100	97	100	92	100	85	100	83	100	80	100	77	100

22
07
00

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder
AND Item: DIURNAL VARIATION

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	
Imipramine	0	37	34.3	36	33.3	39	36.4	37	37.4	36	40.9	38	45.8	45	59.2	47	64.4	49	70.0	51	72.9
	1	49	45.4	47	43.5	49	45.8	44	44.4	42	47.7	36	43.4	26	34.2	23	31.5	19	27.1	17	24.3
	2	22	20.4	25	23.1	19	17.8	18	18.2	10	11.4	9	10.8	5	6.58	3	4.11	2	2.86	2	2.86
	Total	108	100	108	100	107	100	99	100	88	100	83	100	76	100	73	100	70	100	70	100
Reboxetine	0	46	43.8	42	40.0	42	40.0	46	45.5	52	53.6	58	63.0	59	62.4	55	66.3	61	76.3	58	75.3
	1	38	36.2	41	39.0	46	43.8	38	37.6	31	32.0	27	29.3	27	31.8	27	32.5	19	23.7	16	20.8
	2	21	20.0	22	21.0	17	16.2	17	16.8	14	14.4	7	7.61	5	5.88	1	1.20			3	3.90
	Total	105	100	105	100	105	100	101	100	97	100	92	100	85	100	83	100	80	100	77	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder
AND Item: DEPERSONALIZATION

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%		
Imipramine	0	74	68.5	75	69.4	80	74.8	82	82.8	75	85.2	71	85.5	66	89.5	66	90.4	65	92.9	65	92.9	
	1	25	23.1	25	23.1	21	19.6	13	13.1	11	12.5	10	12.0	8	10.5	6	8.22	4	5.71	5	7.14	
	2	6	5.56	5	4.63	5	4.67	3	3.03	1	1.14	2	2.41					1	1.43			
	3	3	2.78	2	1.85	1	0.93	1	1.01	1	1.14											
	4	1	0.93																			
Total	108	100	108	100	107	100	99	100	88	100	83	100	76	100	73	100	70	100	70	100	70	100
Reboxetine	0	67	63.8	64	61.0	68	64.8	71	70.3	76	78.4	77	83.7	70	82.4	73	88.0	71	88.8	65	84.4	
	1	22	21.0	26	24.8	24	22.9	22	21.8	14	14.4	14	15.2	13	15.3	9	10.8	8	10.0	11	14.3	
	2	13	12.4	13	12.4	12	11.4	6	5.94	6	6.19					1	1.20	1	1.25	1	1.30	
	3	3	2.86	2	1.90	1	0.95	2	1.98	1	1.03	1	1.09	2	2.35							
	Total	105	100	105	100	105	100	101	100	97	100	92	100	85	100	83	100	80	100	80	100	77

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PEARNAZIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No. : 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder
AND Item: PARANOID

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z		
Imipramine	0	85	78.7	85	78.7	90	84.1	85	85.9	76	86.4	76	91.6	68	89.5	67	91.3	63	90.0	67	95.7	
	1	21	19.4	21	19.4	16	15.0	14	14.1	12	13.6	7	8.43	7	9.21	6	8.22	6	8.57	3	4.29	
	2	2	1.85	2	1.85	1	0.93							1	1.32			1	1.43			
	Total	108	100	108	100	107	100	99	100	88	100	83	100	76	100	73	100	70	100	70	100	
Reboxetine	0	83	79.0	87	82.9	90	85.7	88	87.1	85	87.6	84	91.3	78	91.8	78	94.0	75	93.8	72	93.5	
	1	16	15.2	13	12.4	11	10.5	9	8.91	11	11.3	6	6.52	6	7.06	5	6.02	5	6.25	5	6.49	
	2	6	5.71	5	4.76	3	2.86	3	2.97	1	1.03	2	2.17	1	1.18							
	3					1	0.95	1	0.99													
Total	105	100	105	100	105	100	101	100	97	100	92	100	85	100	83	100	80	100	80	100	77	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder
AND Item: OBSESSIONAL/COMPULSIVE

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	
Imipramine	0	74	68.5	72	66.7	74	69.2	72	72.7	69	78.4	65	78.3	66	86.8	62	84.9	61	87.1	62	88.6
	1	29	26.9	29	26.9	28	26.2	23	23.2	14	15.9	16	19.3	9	11.8	11	15.1	8	11.4	7	10.0
	2	5	4.63	7	6.48	5	4.67	4	4.04	5	5.68	2	2.41	1	1.32			1	1.43	1	1.43
	Total	108	100	106	100	107	100	99	100	88	100	83	100	76	100	73	100	70	100	70	100
Reboxetine	0	70	66.7	70	66.7	70	66.7	69	68.3	70	72.2	73	79.3	72	84.7	66	79.5	67	83.8	61	79.2
	1	29	27.6	29	27.6	34	32.4	29	28.7	26	26.8	17	18.5	12	14.1	16	19.3	12	15.0	15	19.5
	2	6	5.71	6	5.71	1	0.95	3	2.97	1	1.03	2	2.17	1	1.18	1	1.20	1	1.25	1	1.30
	Total	105	100	105	100	105	100	101	100	97	100	92	100	85	100	83	100	80	100	77	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Dysthymia
AND Item: DEPRESSED MOOD

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	
Imipramine	0				1	1.67	5	8.62	16	28.6	17	30.4	22	40.0	26	46.4	28	50.0	32	57.1	
	1	2	3.33	3	5.00	5	8.33	13	22.4	9	16.1	17	30.4	16	29.1	14	25.0	14	25.0	12	21.4
	2	19	31.7	18	30.0	23	38.3	20	34.5	18	32.1	15	26.8	9	16.4	9	16.1	11	19.6	8	14.3
	3	34	56.7	33	55.0	27	45.0	17	29.3	12	21.4	7	12.5	8	14.5	7	12.5	3	5.36	4	7.14
	4	5	8.33	6	10.0	4	6.67	3	5.17	1	1.79										
Total	60	100	60	100	60	100	58	100	56	100	56	100	55	100	56	100	56	100	56	100	
Reboxetine	0						1	1.56	5	8.06	9	15.0	16	29.6	14	27.5	15	29.4	16	32.0	
	1	4	5.97	4	5.97	12	18.2	15	23.4	15	24.2	18	30.0	15	27.8	23	45.1	19	37.3	17	34.0
	2	18	26.9	15	22.4	19	28.8	27	42.2	26	41.9	21	35.0	19	35.2	12	23.5	13	25.5	14	28.0
	3	39	58.2	42	62.7	33	50.0	18	28.1	13	21.0	10	16.7	2	3.70	2	3.92	4	7.84	3	6.00
	4	6	8.96	6	8.96	2	3.03	3	4.69	3	4.84	2	3.33	2	3.70						
Total	67	100	67	100	66	100	64	100	62	100	60	100	54	100	51	100	51	100	50	100	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No. : 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Dysthymia
AND Item: GUILT

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z		
Imipramine	0	10	16.7	10	16.7	13	21.7	18	31.0	25	44.6	28	50.0	30	54.5	34	60.7	36	64.3	38	67.9	
	1	23	38.3	23	38.3	23	38.3	22	37.9	18	32.1	16	28.6	18	32.7	14	25.0	15	26.8	14	25.0	
	2	17	28.3	17	28.3	17	28.3	13	22.4	9	16.1	8	14.3	5	9.09	6	14.3	5	8.93	4	7.14	
	3	9	15.0	9	15.0	7	11.7	5	8.62	4	7.14	4	7.14	2	3.64							
	4	1	1.67	1	1.67																	
Total	60	100	60	100	60	100	58	100	56	100	56	100	55	100	56	100	56	100	56	100	56	100
Reboxetine	0	14	20.9	14	20.9	15	22.7	18	28.1	21	33.9	20	33.3	25	46.3	30	58.8	31	60.8	35	70.0	
	1	20	29.9	15	22.4	15	22.7	15	23.4	22	35.5	26	43.3	22	40.7	15	29.4	15	29.4	11	22.0	
	2	21	31.3	26	38.8	26	39.4	22	34.4	12	19.4	9	15.0	6	11.1	5	9.80	4	7.84	3	6.00	
	3	11	16.4	11	16.4	8	12.1	8	12.5	6	9.68	4	6.67	1	1.85	1	1.96	1	1.96	1	2.00	
	4	1	1.49	1	1.49	2	3.03	1	1.56	1	1.61	1	1.67									
Total	67	100	67	100	66	100	64	100	62	100	60	100	54	100	51	100	51	100	51	100	50	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITER SCORE BY ASSIGNED TREATMENT

Diagnosis: Dysthymia
AND Item: SUICIDE

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%		
Imipramine	0	29	48.3	31	51.7	35	58.3	34	58.6	35	62.5	40	71.4	43	76.2	46	82.1	46	82.1	46	82.1	
	1	16	26.7	16	26.7	11	18.3	13	22.4	14	25.0	10	17.9	8	14.5	8	14.3	8	14.3	8	14.3	
	2	12	20.0	11	18.3	12	20.0	10	17.2	6	10.7	5	8.93	4	7.27	2	3.57	2	3.57	2	3.57	
	3	3	5.00	2	3.33	2	3.33	1	1.72	1	1.79	1	1.79									
	Total	60	100	60	100	60	100	58	100	56	100	56	100	55	100	56	100	56	100	56	100	
Reboxetine	0	28	41.8	25	37.3	31	47.0	35	54.7	34	54.8	35	58.3	37	68.5	37	72.5	37	72.5	37	74.0	
	1	20	29.9	25	37.3	19	28.8	16	25.0	19	30.6	16	26.7	10	18.5	8	15.7	9	17.6	8	16.0	
	2	17	25.4	14	20.9	13	19.7	11	17.2	7	11.3	6	10.0	7	13.0	6	11.8	5	9.80	5	10.0	
	3	2	2.99	3	4.48	3	4.55	2	3.13	2	3.23	2	3.33									
	4											1	1.67									
Total	67	100	67	100	66	100	64	100	62	100	60	100	54	100	51	100	51	100	51	100	50	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Dysthymia
AND Item: INSOMNIA EARLY

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	
Imipramine	0	13	21.7	14	23.3	15	25.0	22	37.9	24	42.9	25	44.6	29	52.7	26	46.4	25	44.6	29	51.8
	1	18	30.0	18	30.0	26	43.3	18	31.0	19	33.9	22	39.3	17	30.9	24	42.9	27	48.2	22	39.3
	2	29	48.3	28	46.7	19	31.7	18	31.0	13	23.2	9	16.1	9	16.4	6	10.7	4	7.14	5	8.93
	Total	60	100	60	100	60	100	58	100	56	100	56	100	55	100	56	100	56	100	56	100
Reboxetine	0	18	26.9	16	25.9	16	24.2	18	28.1	18	29.0	20	33.3	22	40.7	20	39.2	20	39.2	24	48.0
	1	15	22.4	17	25.4	18	27.3	20	31.3	26	41.9	25	41.7	24	44.4	25	49.0	25	49.0	22	44.0
	2	34	50.7	34	50.7	32	48.5	26	40.6	18	29.0	15	25.0	8	14.8	6	11.8	6	11.8	4	8.00
	Total	67	100	67	100	66	100	64	100	62	100	60	100	54	100	51	100	51	100	51	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Dysthymia
AND Item: INSOMNIA MIDDLE

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z		
Imipramine	0	19	31.7	21	35.0	26	43.3	30	51.7	34	60.7	37	66.1	34	61.8	34	60.7	34	60.7	37	66.1	
	1	21	35.0	17	28.3	17	28.3	14	24.1	13	23.2	10	17.9	14	25.5	19	33.9	18	32.1	17	30.4	
	2	20	33.3	22	36.7	17	28.3	14	24.1	9	16.1	9	16.1	7	12.7	3	5.36	4	7.14	2	3.57	
Total	60	100	60	100	60	100	58	100	56	100	56	100	55	100	56	100	56	100	56	100	56	100
Reboxetine	0	23	34.3	19	28.4	15	22.7	18	28.1	17	27.4	20	33.3	24	44.4	21	41.2	25	49.0	25	50.0	
	1	20	29.9	23	34.3	29	43.9	27	42.2	30	48.4	27	45.0	19	35.2	23	45.1	18	35.3	19	38.0	
	2	24	35.8	25	37.3	22	33.3	19	29.7	15	24.2	13	21.7	11	20.4	7	13.7	8	15.7	6	12.0	
Total	67	100	67	100	66	100	64	100	62	100	60	100	54	100	51	100	51	100	51	100	50	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXYLINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Dysthymia
AND Item: INSOMNIA LATE

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	
Imipramine	0	19	31.7	23	38.3	28	48.3	31	55.4	34	60.7	35	63.6	40	71.4	38	67.9	43	76.8		
	1	25	41.7	24	40.0	24	40.0	18	31.0	20	35.7	17	30.4	16	29.1	13	23.2	15	26.8	10	17.9
	2	16	26.7	17	28.3	13	21.7	12	20.7	5	8.93	5	8.93	4	7.27	3	5.36	3	5.36	3	5.36
	Total	60	100	60	100	60	100	58	100	56	100	56	100	55	100	56	100	56	100	56	100
Reboxetine	0	29	43.3	25	37.3	23	34.8	20	31.3	22	35.5	25	41.7	25	46.3	26	51.0	28	54.9	28	56.0
	1	18	26.9	22	32.8	23	34.8	29	45.3	28	45.2	21	35.0	22	40.7	20	39.2	19	37.3	18	36.0
	2	20	29.9	20	29.9	20	30.3	15	23.4	12	19.4	14	23.3	7	13.0	5	9.80	4	7.84	4	8.00
	Total	67	100	67	100	66	100	64	100	62	100	60	100	54	100	51	100	51	100	50	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No. : 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Dysthymia
AND Item: MDRK AND ACTIVITIES

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z		
Imipramine	0		1	1.67			3	5.17	7	12.5	11	19.6	14	25.5	18	32.1	19	33.9	26	46.4		
	1	2	3.33		6	10.0	14	24.1	19	33.9	17	30.4	19	34.5	19	33.9	20	35.7	16	28.6		
	2	21	35.0	19	31.7	26	43.3	20	34.5	16	28.6	17	30.4	14	25.5	14	25.0	12	21.4	10	17.9	
	3	33	55.0	32	53.3	22	36.7	18	31.0	14	25.0	10	17.9	8	14.5	5	8.93	5	8.93	4	7.14	
	4	4	6.67	6	10.0	6	10.0	3	5.17			1	1.79									
Total	60	100	60	100	60	100	58	100	56	100	56	100	55	100	56	100	56	100	56	100	56	100
Reboxetine	0	1	1.49		2	3.03	3	4.69	6	9.68	10	16.7	14	25.9	17	33.3	15	29.4	14	28.0		
	1	3	4.48	3	4.48	7	10.6	9	14.1	10	16.1	14	23.3	16	29.6	14	27.5	13	25.5	18	36.0	
	2	19	28.4	20	29.9	19	28.8	26	40.6	21	33.9	20	33.3	16	29.6	15	29.4	15	29.4	12	24.0	
	3	39	58.2	37	55.2	34	51.5	23	35.9	23	37.1	14	23.3	7	13.0	5	9.80	7	13.7	6	12.0	
	4	5	7.46	6	8.96	4	6.06	3	4.69	2	3.23	2	3.33	1	1.85			1	1.96			
Total	67	100	67	100	66	100	64	100	62	100	60	100	54	100	51	100	51	100	50	100	50	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PIARNACIA CHS RED

REBOSINETINE - PROTOCOL 20124/095
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Dysthymia
AND Item: RETARDATION

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	
Imipramine	0	15	25.0	17	28.3	19	31.7	21	36.2	25	44.6	26	46.4	32	58.2	33	58.9	36	64.3	40	71.4
	1	24	40.0	24	40.0	29	48.3	26	44.8	23	41.1	23	41.1	17	30.9	18	32.1	16	28.6	12	21.4
	2	15	25.0	14	23.3	11	18.3	10	17.2	6	10.7	6	10.7	5	9.09	4	7.44	3	5.36	3	5.36
	3	6	10.0	5	8.33	1	1.67	1	1.72	2	3.57	1	1.79	1	1.82	1	1.79	1	1.79	1	1.79
	Total	60	100	60	100	60	100	58	100	56	100	56	100	55	100	56	100	56	100	56	100
Reboksetine	0	22	32.8	21	31.3	22	33.3	21	32.8	24	36.7	24	40.0	31	57.4	34	66.7	34	66.7	35	70.0
	1	22	32.8	23	34.3	23	34.8	26	40.6	25	40.3	27	45.0	19	35.2	14	27.5	13	25.5	12	24.0
	2	18	26.9	19	28.4	18	27.3	15	23.4	13	21.0	7	11.7	4	7.41	3	5.88	4	7.84	3	6.00
	3	5	7.46	4	5.97	3	4.55	2	3.13			1	1.67								
	4											1	1.67								
Total	67	100	67	100	66	100	64	100	62	100	60	100	54	100	51	100	51	100	51	100	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No. 1 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Dysthymia
AND Item: AGITATION

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	
Imipramine	0	21	35.0	19	31.7	20	33.3	23	39.7	24	42.9	29	51.8	33	60.0	34	60.7	34	60.7	37	66.1
	1	14	23.3	13	21.7	21	35.0	21	36.2	21	37.5	19	33.9	16	29.1	18	32.1	17	30.4	15	26.8
	2	18	30.0	21	35.0	17	28.3	13	22.4	10	17.9	7	12.5	4	7.27	2	3.57	3	5.36	2	3.57
	3	7	11.7	6	10.0	2	3.33	1	1.72	1	1.79	1	1.79	2	3.64	1	1.79	1	1.79	1	1.79
	4			1	1.67											1	1.79	1	1.79	1	1.79
Total	60	100	60	100	60	100	58	100	56	100	56	100	55	100	56	100	56	100	56	100	
Reboxetine	0	22	32.8	20	29.9	21	31.8	21	32.8	26	41.9	25	41.7	31	57.4	32	62.7	34	66.7	32	64.0
	1	19	28.4	18	26.9	20	30.3	23	35.9	19	30.6	20	33.3	18	33.3	12	23.5	13	25.5	13	26.0
	2	23	34.3	23	34.3	20	30.3	18	28.1	17	27.4	19	21.7	5	9.26	7	13.7	3	5.88	4	8.00
	3	3	4.48	4	5.97	4	6.06	2	3.13			1	1.67					1	1.96	1	2.00
	4			2	2.99	1	1.52					1	1.67								
Total	67	100	67	100	66	100	64	100	62	100	60	100	54	100	51	100	51	100	51	100	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITER SCORE BY ASSIGNED TREATMENT

Diagnosis: Dysthymia
AND Item: ANXIETY PSYCHIC

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z		
Imipramine	0	1	1.67	1	1.67	3	5.00	6	10.3	8	14.3	9	16.1	15	27.3	20	35.7	19	33.9	19	33.9	
	1	11	18.3	9	15.0	15	25.0	14	24.1	19	33.9	29	51.8	26	47.3	23	41.1	27	48.2	25	44.6	
	2	20	33.3	22	36.7	29	48.3	30	51.7	24	42.9	16	28.6	13	23.6	12	21.4	9	16.1	10	17.9	
	3	24	40.0	24	40.0	12	20.0	8	13.8	5	8.93	2	3.57	1	1.82	1	1.79	1	1.79	2	3.57	
	4	4	6.67	4	6.67	1	1.67															
Total	60	100	60	100	60	100	58	100	56	100	56	100	55	100	56	100	56	100	56	100	56	100
Reboxetine	0	3	4.48	1	1.49	3	4.55	3	4.69	7	11.3	8	13.3	8	14.8	12	23.5	9	17.6	12	24.0	
	1	7	10.4	9	13.4	12	18.2	17	26.6	19	30.6	22	36.7	30	55.6	30	56.8	25	49.0	28	56.0	
	2	33	49.3	30	44.8	30	45.5	32	50.0	30	48.4	21	35.0	14	25.9	9	17.6	17	33.3	9	18.0	
	3	19	28.4	22	32.8	20	30.3	10	15.6	4	6.45	8	13.3	1	1.85					1	2.00	
	4	5	7.46	5	7.46	1	1.52	2	3.13	2	3.23	1	1.67	1	1.85							
Total	67	100	67	100	66	100	64	100	62	100	60	100	54	100	51	100	51	100	51	100	50	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Dysthymia
AND Item: ANXIETY SOMATIC

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	X	No	X	No	X	No	X	No	X	No	X	No	X	No	X	No	X	No	X		
Imipramine	0	5	8.33	3	5.00	5	8.33	6	10.3	12	21.4	13	23.2	17	30.9	21	37.5	20	35.7	21	37.5	
	1	16	26.7	15	25.0	18	30.0	21	36.2	22	39.9	27	48.2	22	40.0	23	41.1	24	42.9	26	46.4	
	2	27	45.0	33	55.0	27	45.0	25	43.1	18	32.1	16	28.6	15	27.3	10	17.9	9	16.1	7	12.5	
	3	9	15.0	5	8.33	9	15.0	5	8.62	4	7.14			1	1.82	2	3.57	3	5.36	2	3.57	
	4	3	5.00	4	6.67	1	1.67	1	1.72													
Total	60	100	60	100	60	100	58	100	56	100	56	100	55	100	56	100	56	100	56	100	56	100
Reboxetine	0				4	6.06	4	6.25	9	14.5	16	26.7	19	35.2	18	35.3	15	29.4	20	40.0	20	40.0
	1	20	29.9	23	34.3	20	30.3	26	40.6	25	40.3	24	40.0	22	40.7	22	43.1	21	41.2	17	34.0	
	2	29	43.3	27	40.3	31	47.0	31	48.4	25	40.3	18	30.0	12	22.2	10	19.6	12	23.5	11	22.0	
	3	16	23.9	16	23.9	11	16.7	3	4.69	3	4.84	2	3.33	1	1.85	1	1.96	3	5.88	1	2.00	
	4	2	2.99	1	1.49																	
Total	67	100	67	100	66	100	64	100	62	100	60	100	54	100	51	100	51	100	51	100	50	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOZETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Dysthymia
AND Item: SONATIC GASTROINTESTINAL

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	
Imipramine	0	16 26.7	16 26.7	18 30.0	23 39.7	25 44.6	27 48.2	31 56.4	32 57.1	32 57.1	32 57.1	32 57.1	32 57.1	32 57.1	32 57.1	32 57.1	32 57.1	32 57.1	32 57.1	32 57.1	37 66.1
	1	35 58.3	35 58.3	35 58.3	28 48.3	28 48.3	27 48.2	26 46.4	21 38.2	21 38.2	21 38.2	21 38.2	21 38.2	21 38.2	21 38.2	21 38.2	21 38.2	21 38.2	21 38.2	21 38.2	16 28.6
	2	9 15.0	9 15.0	7 11.7	7 12.1	4 7.14	3 5.36	3 5.36	3 5.45	3 5.45	3 5.45	3 5.45	3 5.45	3 5.45	3 5.45	3 5.45	3 5.45	3 5.45	3 5.45	3 5.45	3 5.36
	Total	60 100	60 100	60 100	58 100	56 100	56 100	56 100	55 100	55 100	55 100	56 100	56 100	56 100	56 100	56 100	56 100	56 100	56 100	56 100	56 100
Rebozetine	0	16 23.9	16 23.9	18 27.3	17 26.6	24 38.7	23 38.3	25 46.3	24 47.1	24 47.1	24 47.1	24 47.1	24 47.1	24 47.1	24 47.1	24 47.1	24 47.1	24 47.1	24 47.1	24 47.1	30 60.0
	1	32 47.8	30 44.8	29 43.9	33 51.6	26 41.9	28 46.7	26 48.1	25 49.0	25 49.0	25 49.0	25 49.0	25 49.0	25 49.0	25 49.0	25 49.0	25 49.0	25 49.0	25 49.0	25 49.0	18 36.0
	2	19 28.4	21 31.3	19 28.8	14 21.9	12 19.4	9 15.0	3 5.56	2 3.92	2 3.92	2 3.92	2 3.92	2 3.92	2 3.92	2 3.92	2 3.92	2 3.92	2 3.92	2 3.92	2 3.92	2 4.00
	Total	67 100	67 100	66 100	64 100	62 100	60 100	60 100	54 100	54 100	54 100	54 100	54 100	54 100	54 100	54 100	54 100	54 100	54 100	54 100	50 100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOZETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Dysthymia
AND Item: SOMATIC GENERAL

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56	
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%
Imipramine	4	6.67	5	8.33	6	10.0	10	17.2	16	28.6	21	37.5	19	34.5	22	39.3	26	46.4	29	51.8
	29	48.3	29	48.3	31	51.7	31	53.4	29	51.8	26	46.4	29	52.7	27	48.2	25	44.6	23	41.1
	27	45.0	26	43.3	23	38.3	17	29.3	11	19.6	9	16.1	7	12.7	7	12.5	5	8.93	4	7.14
Total	60	100	60	100	60	100	58	100	56	100	56	100	55	100	56	100	56	100	56	100
Rebozetine	7	10.4	5	7.46	7	10.6	10	15.6	11	17.7	14	23.3	16	29.6	19	37.3	18	35.3	20	40.0
	28	41.8	27	40.3	30	45.5	31	48.4	30	48.4	27	45.0	28	51.9	24	47.1	24	47.1	22	44.0
	32	47.8	35	52.2	29	43.9	23	35.9	21	38.9	19	31.7	10	18.5	8	15.7	9	17.6	8	16.0
Total	67	100	67	100	66	100	64	100	62	100	60	100	54	100	51	100	51	100	50	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Dysthymia
AND Item: GENITAL SYMPTOMS

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	
Imipramine	0	36	60.0	35	58.3	33	55.0	32	55.2	34	60.7	36	64.3	36	65.5	37	66.1	36	64.3	37	66.1
	1	15	25.0	14	23.3	16	26.7	18	31.0	16	28.6	15	26.8	14	25.5	15	26.8	17	30.4	18	32.1
	2	9	15.0	11	18.3	11	18.3	8	13.8	6	10.7	5	8.93	5	9.09	4	7.14	3	5.36	1	1.79
	Total	60	100	60	100	60	100	58	100	56	100	56	100	55	100	56	100	56	100	56	100
Reboxetine	0	58	56.7	38	56.7	41	62.1	39	60.9	37	59.7	33	55.0	30	55.6	29	56.9	31	60.8	32	64.0
	1	17	25.4	17	25.4	12	18.2	16	25.0	17	27.4	20	33.3	21	38.9	18	35.3	17	33.3	17	34.0
	2	12	17.9	12	17.9	13	19.7	9	14.1	8	12.9	7	11.7	3	5.56	4	7.84	3	5.88	1	2.00
	Total	67	100	67	100	66	100	64	100	62	100	60	100	54	100	51	100	51	100	50	100

277

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Dysthymia
AND Item: HYPOCHONDRIASIS

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	
Imipramine	0	11	18.3	10	16.7	11	18.3	14	24.1	19	33.9	21	37.5	19	34.5	23	41.1	26	46.4	29	51.8
	1	12	20.0	15	25.0	13	21.7	20	34.5	16	28.6	18	32.1	22	40.0	21	37.5	23	41.1	17	30.4
	2	27	45.0	26	43.3	27	45.0	20	34.5	17	30.4	16	28.6	13	23.6	11	19.6	7	12.5	9	16.1
	3	10	16.7	9	15.0	9	15.0	4	6.90	4	7.14	1	1.79	1	1.82	1	1.79				
	Total	60	100	60	100	60	100	58	100	56	100	56	100	55	100	56	100	56	100	56	100
Reboxetine	0	12	17.9	10	14.9	13	19.7	19	29.3	18	29.0	22	36.7	22	40.7	21	41.2	19	37.3	20	40.0
	1	10	14.9	10	14.9	16	24.2	17	26.6	16	25.8	16	26.7	18	33.3	17	33.3	15	29.4	17	34.0
	2	24	35.8	28	41.8	22	33.3	24	37.5	21	33.9	17	28.3	11	20.4	9	17.6	12	23.5	8	16.0
	3	20	29.9	17	25.4	15	22.7	10	15.6	6	9.68	5	8.33	3	5.56	4	7.84	5	9.80	5	10.0
	4	1	1.49	2	2.99					1	1.61										
Total	67	100	67	100	66	100	64	100	62	100	60	100	54	100	51	100	51	100	51	100	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/095
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Dysthymia
AND Item: LOSS OF WEIGHT

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	
Imipramine	0	40 66.7	43 71.7	51 85.0	48 82.8	52 92.9	53 94.6	52 94.5	51 91.1	51 91.1	51 91.1	53 94.6	52 94.5	51 91.1	51 91.1	51 91.1	53 94.6	53 94.6	53 94.6	53 94.6	53 94.6
	1	10 16.7	8 13.3	8 13.3	7 12.1	4 7.14	3 5.36	1 1.82	4 7.14	3 5.36	4 7.14	2 3.57	1 1.82	2 3.57	2 3.57	2 3.57	3 5.36	3 5.36	3 5.36	3 5.36	3 5.36
	2	9 15.0	8 13.3	1 1.67	3 5.17																
	3	1 1.67	1 1.67																		
Total	60 100	60 100	60 100	58 100	56 100	56 100	56 100	55 100	56 100	56 100	56 100	56 100	55 100	56 100	56 100	56 100	56 100	56 100	56 100	56 100	
Reboxetine	0	43 64.2	47 70.1	55 83.3	57 89.1	54 87.1	50 83.3	48 88.9	46 80.2	46 80.2	46 80.2	48 94.1	46 80.2	48 94.1	46 80.2	48 94.1	46 80.2	48 94.1	46 80.2	46 80.2	46 80.2
	1	11 16.4	9 13.4	5 7.58	5 7.81	4 6.45	7 11.7	3 5.56	3 5.56	3 5.56	3 5.56	2 3.92	3 5.56	2 3.92	2 3.92	2 3.92	2 3.92	2 3.92	2 3.92	2 3.92	2 3.92
	2	11 16.4	8 11.9	6 9.09	2 3.13	3 4.84	3 5.00	3 5.00	3 5.56	3 5.56	3 5.56	2 3.92	3 5.56	2 3.92	2 3.92	2 3.92	2 3.92	2 3.92	2 3.92	2 3.92	2 3.92
	3	2 2.99	3 4.48			1 1.61															
Total	67 100	67 100	66 100	64 100	62 100	62 100	60 100	64 100	62 100	62 100	60 100	64 100	64 100	64 100	64 100	64 100	64 100	64 100	64 100	64 100	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/095
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Dysthymia
AND Item: INSIGHT

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	
Imipramine	0	24	40.0	26	43.3	28	46.7	31	53.4	28	50.0	30	53.6	33	60.0	30	53.6	36	64.3	40	71.4
	1	32	53.3	30	50.0	28	46.7	23	39.7	22	39.3	21	37.5	19	34.5	19	33.9	14	25.0	12	21.4
	2	4	6.7	4	6.7	4	6.7	4	6.90	6	10.7	5	8.33	3	5.45	7	12.5	6	10.7	4	7.14
	Total	60	100	60	100	60	100	58	100	56	100	56	100	55	100	56	100	56	100	56	100
Reboxetine	0	26	38.8	26	38.8	31	47.0	32	50.0	37	59.7	36	60.0	37	68.5	36	70.6	35	68.6	38	76.0
	1	40	59.7	38	56.7	34	51.5	28	43.8	23	37.1	20	33.3	13	24.1	11	21.6	13	25.5	11	22.0
	2	1	1.49	3	4.48	1	1.52	4	6.25	2	3.23	4	6.67	4	7.41	4	7.84	3	5.88	1	2.00
	Total	67	100	67	100	66	100	64	100	62	100	60	100	54	100	51	100	51	100	51	100

280

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Dysthymia
AND Item: DIURNAL VARIATION

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56	
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z
Imipramine	28	46.7	28	46.7	29	48.3	33	56.9	33	58.9	34	60.7	39	70.9	41	73.2	40	71.4	41	73.2
	25	41.7	25	41.7	27	45.0	20	34.5	19	33.9	21	37.5	15	27.3	14	25.0	15	26.8	14	25.0
	7	11.7	7	11.7	4	6.67	5	8.62	4	7.14	1	1.79	1	1.82	1	1.79	1	1.79	1	1.79
	60	100	60	100	60	100	58	100	56	100	56	100	55	100	56	100	56	100	56	100
Reboxetine	32	47.8	31	46.3	32	48.5	32	50.0	32	51.6	35	58.3	33	61.1	32	62.7	33	64.7	35	70.0
	28	41.8	29	43.3	29	43.9	30	46.9	28	45.2	22	36.7	20	37.0	18	35.3	17	33.3	13	26.0
	7	10.4	7	10.4	5	7.58	2	3.13	2	3.23	3	5.00	1	1.85	1	1.96	1	1.96	2	4.00
	67	100	67	100	66	100	64	100	62	100	60	100	54	100	51	100	51	100	50	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE – PROTOCOL 20124/095
TABLE No. : 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Dysthymia
AND Item: DEPERSONALIZATION

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	
Imipramine	0	40	66.7	41	68.3	39	65.0	38	65.5	40	71.4	40	71.4	43	78.2	46	82.1	48	85.7	49	87.5
	1	10	16.7	9	15.0	14	23.3	14	24.1	12	21.4	11	19.6	10	18.2	10	17.9	8	14.3	7	12.5
	2	10	16.7	10	16.7	7	11.7	6	10.3	4	7.14	5	8.93	2	3.64						
	Total	60	100	60	100	60	100	58	100	56	100	56	100	55	100	56	100	56	100	56	100
Reboxetine	0	43	64.2	43	64.2	45	68.2	46	71.9	45	72.6	44	73.3	46	85.2	40	78.4	41	80.4	41	82.0
	1	14	20.9	11	16.4	13	19.7	13	20.3	7	11.3	13	21.7	6	11.1	8	15.7	8	15.7	8	16.0
	2	9	13.4	11	16.4	7	10.6	5	7.81	10	16.1	2	3.33	2	3.70	3	5.88	2	3.92	4	2.00
	3	1	1.49	2	2.99	1	1.52					1	1.67								
Total	67	100	67	100	66	100	64	100	62	100	60	100	54	100	51	100	51	100	51	100	

22
00
22

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Dysthymia
AND Item: PARANOID

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56	
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z
Imipramine	45	75.0	46	76.7	46	76.7	48	82.8	46	82.1	46	82.1	46	83.6	46	82.1	51	91.1	52	92.9
	13	21.7	11	18.3	12	20.0	8	13.8	9	16.1	9	16.1	9	16.4	10	17.9	5	8.99	4	7.14
	1	1.67	2	3.33	1	1.67	1	1.72												
	1	1.67	1	1.67	1	1.67	1	1.72	1	1.79	1	1.79								
Total	60	100	60	100	60	100	58	100	56	100	56	100	55	100	56	100	56	100	56	100
Reboxetine	55	82.1	52	77.6	54	81.8	53	82.8	54	87.1	51	85.0	51	94.4	48	94.1	48	94.1	45	90.0
	10	14.9	13	19.4	12	18.2	10	15.6	7	11.3	8	13.3	3	5.56	3	5.88	3	5.88	5	10.0
	2	2.99	2	2.99			1	1.56	1	1.61	1	1.67								
	67	100	67	100	66	100	64	100	62	100	60	100	54	100	51	100	51	100	50	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBONETINE - PROTOCOL 20124/035
TABLE No.: 23

HAMILTON DEPRESSION RATING SCALE:
FREQUENCY OF EACH ITEM SCORE BY ASSIGNED TREATMENT

Diagnosis: Dysthymia
AND Item: OBSESSIONAL/COMPULSIVE

Assigned treatment / Score	Screen		Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	
Imipramine	0	39	65.0	41	68.3	41	68.3	40	69.0	41	73.2	41	73.2	41	74.5	42	75.0	45	80.4	44	78.6
	1	11	18.3	10	16.7	9	15.0	11	19.0	9	16.1	8	14.3	7	12.7	8	14.3	8	14.3	9	16.1
	2	10	16.7	9	15.0	10	16.7	7	12.1	6	10.7	7	12.5	7	12.7	6	10.7	3	5.36	3	5.36
	Total	60	100	60	100	60	100	58	100	56	100	56	100	55	100	56	100	56	100	56	100
Rebonetine	0	37	55.2	38	56.7	37	56.1	44	68.8	42	67.7	42	70.0	40	74.1	39	76.5	36	70.6	37	74.0
	1	25	37.3	23	34.3	24	36.4	17	26.6	17	27.4	15	25.0	14	25.9	12	23.5	15	29.4	13	26.0
	2	5	7.46	6	8.96	5	7.58	3	4.69	3	4.84	3	5.00								
	Total	67	100	67	100	66	100	64	100	62	100	60	100	54	100	51	100	51	100	50	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 24

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Factor: ANXIETY/SOMATIZATION
AND Diagnosis: Total

Assigned treatment	Screen	Visit										
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56		
Imipramine	No	168	167	157	144	139	131	129	126	126		
	Median	1.33	1.33	1.17	1.00	0.83	0.67	0.67	0.67	0.50		
	Min	0.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
	Max	2.67	2.50	2.67	2.67	2.00	2.00	1.83	2.50	1.67		
	Median diff. vs day0 (*)		0.17	0.17	0.33	0.50	0.67	0.83	0.83	0.83		
Reboxetine	No	172	171	165	159	152	139	134	131	127		
	Median	1.50	1.33	1.17	1.17	1.00	0.67	0.67	0.67	0.67		
	Min	0.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
	Max	2.50	2.33	2.50	2.50	2.50	2.50	2.17	2.17	2.33		
	Median diff. vs day0 (*)		0.17	0.17	0.33	0.50	0.67	0.67	0.67	0.83		

20
00
01

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 24

FACTUALIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Factor: WEIGHT
AND Diagnosis: Total

Assigned treatment	Screen	Visit												
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56				
Imipramine	No	168	167	157	144	139	131	129	126	126				
	Median	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
	Max	3.00	2.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00				
	Median diff. vs day0 (*)		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
Reboxetine	No	172	171	165	159	152	139	134	131	127				
	Median	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
	Max	3.00	3.00	2.00	3.00	2.00	3.00	3.00	3.00	2.00				
	Median diff. vs day0 (*)		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/095
TABLE No.: 24

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Factor: COGNITIVE DISTURBANCE
AND Diagnosis: Total

Assigned treatment	Screen	Visit										
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56		
Imipramine	No	168	167	157	144	139	131	129	126	126	126	
	Median	0.67	0.67	0.50	0.33	0.33	0.17	0.17	0.17	0.17	0.17	
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	Max	2.00	2.00	2.00	2.17	2.00	2.00	1.83	1.83	1.83	1.17	
	Median diff. vs day0 (*)		0.00	0.17	0.33	0.33	0.33	0.50	0.50	0.50	0.50	
Reboxetine	No	172	171	165	159	152	139	134	131	127		
	Median	0.67	0.67	0.50	0.50	0.33	0.17	0.17	0.17	0.17		
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
	Max	2.00	2.00	2.00	2.00	2.50	1.83	1.83	1.83	1.83		
	Median diff. vs day0 (*)		0.00	0.17	0.17	0.33	0.50	0.50	0.50	0.50		

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 24

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Factor: DIURNAL VARIATION
AND Diagnosis: Total

Assigned treatment	Screen	Visit												
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56				
Imipramine	No	168	167	157	144	139	131	129	126	126				
	Median	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
	Median diff. vs day0 (*)		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Reboxetine	No	172	171	165	159	152	139	134	131	127				
	Median	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
	Median diff. vs day0 (*)		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	

2008

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 24

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Factor: RETARDATION
AND Diagnosis: Total

Assigned treatment	Screen	Visit												
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56				
Imipramine	No	168	167	157	144	139	131	129	126	126				
	Median	1.75	1.75	1.50	1.25	1.00	0.75	0.50	0.50	0.50				
	Min	1.00	0.75	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
	Max	3.25	3.25	3.25	3.00	3.00	3.00	3.25	3.25	3.25				
	Median diff. vs day0 (*)		0.00	0.25	0.75	1.00	1.00	1.25	1.25	1.25				
Reboxetine	No	172	171	165	159	152	139	134	131	127				
	Median	1.75	1.75	1.50	1.25	1.00	1.00	0.75	0.75	0.75				
	Min	0.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
	Max	3.25	3.00	3.25	3.00	3.00	2.75	2.75	2.75	2.75				
	Median diff. vs day0 (*)		0.00	0.25	0.50	0.50	1.00	1.00	1.00	1.00				

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 24

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Factor: SLEEP DISTURBANCE
AND Diagnosis: Total

Assigned treatment	Screen	Visit										
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56		
Imipramine	No	168	167	157	144	139	131	129	126	126		
	Median	1.33	1.00	1.00	0.67	0.67	0.67	0.33	0.33	0.33	0.33	0.33
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
	Median diff. vs day0 (*)		0.00	0.33	0.33	0.33	0.67	0.67	0.67	0.67	0.67	0.67
Reboxetine	No	172	171	165	159	152	139	134	131	127		
	Median	1.33	1.33	1.33	1.00	1.00	0.67	0.67	0.67	0.67	0.67	0.67
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
	Median diff. vs day0 (*)		0.00	0.00	0.00	0.33	0.33	0.33	0.67	0.67	0.67	0.67

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 2012/4/035
TABLE No.: 24

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Factor: ANXIETY/SOMATIZATION
AND Diagnosis: Major Depressive Disorder

Assigned treatment	Visit													
	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56				
Imipramine	No	108	107	99	88	83	76	73	70	70				
	Median	1.33	1.33	1.17	1.00	0.83	0.67	0.67	0.50	0.50				
	Min	0.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
	Max	2.67	2.50	2.33	2.67	2.00	2.00	1.83	2.50	1.67				
	Median diff. vs day0 (*)			0.17	0.33	0.33	0.50	0.67	0.83	0.83				
Reboxetine	No	105	105	101	97	92	85	83	80	77				
	Median	1.50	1.33	1.17	1.00	1.00	0.83	0.67	0.67	0.67				
	Min	0.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
	Max	2.50	2.33	2.50	2.50	2.50	2.50	2.17	2.17	2.17				
	Median diff. vs day0 (*)			0.17	0.17	0.33	0.50	0.67	0.67	0.83				

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 24

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Factor: HEIGHT
AND Diagnosis: Major Depressive Disorder

Assigned treatment	Screen	Visit												
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56				
Imipramine	No	108	107	99	88	83	76	73	70	70				
	Median	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
	Max	3.00	2.00	2.00	2.00	2.00	3.00	3.00	3.00	2.00				
	Median diff. vs day0 (*)		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
Reboxetine	No	105	105	101	97	92	85	83	80	77				
	Median	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
	Max	3.00	3.00	2.00	3.00	2.00	3.00	3.00	2.00	2.00				
	Median diff. vs day0 (*)		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				

292

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PEARNAZIA CNS R&D

REBOZETINE - PROTOCOL 20124/035
TABLE No.: 24

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Factor: COGNITIVE DISTURBANCE
AND Diagnosis: Major Depressive Disorder

Assigned treatment	Screen	Visit													
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56					
Imipramine	No	108	107	99	88	83	76	73	70	70					
	Median	0.67	0.67	0.50	0.33	0.33	0.17	0.17	0.17	0.00					
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00					
	Max	2.33	1.83	2.00	2.17	1.17	1.00	1.83	1.83	1.17					
	Median diff. vs day0 (*)		0.00	0.33	0.33	0.33	0.50	0.50	0.50	0.50					
Rebozetine	No	105	105	101	97	92	85	83	80	77					
	Median	0.67	0.67	0.50	0.33	0.33	0.17	0.17	0.17	0.17					
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00					
	Max	2.00	1.83	2.00	2.00	2.17	1.50	1.17	1.17	1.50					
	Median diff. vs day0 (*)		0.00	0.17	0.17	0.33	0.33	0.50	0.50	0.50					

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 24

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Factor: DIURNAL VARIATION
AND Diagnosis: Major Depressive Disorder

Assigned treatment	Screen	Visit										
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56		
Imipramine	No	108	107	99	88	83	76	73	70	70		
	Median	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00		
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00		
	Median diff. vs day0 (*)		0.00	0.00	0.00	0.00	0.00	1.00	0.00	1.00		
Reboxetine	No	105	105	101	97	92	85	83	80	77		
	Median	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00		
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00		
	Median diff. vs day0 (*)		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RBD
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 24

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Factor: RETARDATION
AND Diagnosis: Major Depressive Disorder

Assigned treatment	Screen	Visit												
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56				
Imipramine	No	108	107	99	88	83	76	73	70	70				
	Median	2.00	1.75	1.50	1.25	1.00	0.75	0.75	0.50	0.50				
	Min	1.00	0.75	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
	Max	3.25	3.25	3.25	3.00	3.00	3.00	3.25	3.25	2.00				
	Median diff. vs day0 (*)		0.00	0.50	0.75	1.00	1.13	1.25	1.50	1.50				
Reboxetine	No	105	105	101	97	92	85	83	80	77				
	Median	2.00	1.75	1.50	1.25	1.13	1.00	0.75	0.75	0.75				
	Min	0.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
	Max	3.25	3.00	3.25	3.00	3.00	2.75	2.75	2.75	2.50				
	Median diff. vs day0 (*)		0.00	0.25	0.50	0.50	1.00	1.00	1.25	1.25				

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No. : 24

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Factor: SLEEP DISTURBANCE
AND Diagnosis: Major Depressive Disorder

Assigned treatment	Screen	Visit													
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56					
Imipramine	No	108	107	99	88	83	76	73	70	70					
	Median	1.33	1.00	1.00	1.00	0.67	0.67	0.67	0.50	0.33					
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00					
	Max	2.00	2.00	2.00	2.00	2.00	2.00	1.67	1.67	2.00					
	Median diff. vs day0 (*)		0.00	0.33	0.33	0.67	0.67	0.67	0.67	1.00					
Reboxetine	No	105	105	101	97	92	85	83	80	77					
	Median	1.67	1.33	1.33	1.00	1.00	0.67	0.67	0.67	0.67					
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00					
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00					
	Median diff. vs day0 (*)		0.00	0.00	0.33	0.33	0.67	0.67	0.67	0.67					

296

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R2D

REBOXETINE - PROTOCOL 20124/035
TABLE NO.: 24

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Factor: ANXIETY/SOMATIZATION
AND Diagnosis: Dysthymia

Assigned treatment	Visit												
	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 56		
Imipramine	No	60	60	58	56	56	55	56	56	56	56		
	Median	1.50	1.33	1.17	1.00	0.83	0.83	0.67	0.67	0.67	0.67		
	Min	0.67	0.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
	Max	2.50	2.50	2.17	2.00	1.83	1.83	1.67	1.67	1.67	1.50		
	Median diff. vs day0 (*)		0.00	0.17	0.33	0.58	0.50	0.67	0.83	0.83	0.83		
Reboxetine	No	67	66	64	62	60	54	51	51	50			
	Median	1.50	1.42	1.33	1.17	1.00	0.67	0.67	0.83	0.67			
	Min	0.67	0.33	0.17	0.00	0.00	0.00	0.00	0.00	0.00			
	Max	2.50	2.67	2.33	2.17	2.00	2.00	1.83	1.83	2.00	2.33		
	Median diff. vs day0 (*)		0.08	0.17	0.33	0.50	0.67	0.67	0.67	0.67	0.83		

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 24

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Factor: WEIGHT
AND Diagnosis: Dysthymia

Assigned treatment	Screen	Visit										
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56		
Imipramine	No	60	60	58	56	56	55	56	56	56	56	56
	Median	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Max	3.00	3.00	2.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	1.00
	Median diff. vs day0 (*)		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Reboxetine	No	67	67	64	62	60	54	51	51	50	50	
	Median	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	Max	3.00	3.00	2.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	
	Median diff. vs day0 (*)		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No. : 24

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Factor: COGNITIVE DISTURBANCE
AND Diagnosis: Dysthymia

Assigned treatment	Screen	Visit												
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56				
Imipramine	No	60	60	58	56	56	55	56	56	56	56	56	56	56
	Median	0.67	0.67	0.50	0.50	0.33	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17
	Min	0.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.67	1.33	1.17	1.17	1.17	1.17
	Median diff. vs day0 (*)		0.00	0.17	0.17	0.17	0.33	0.33	0.42	0.50	0.50	0.50	0.50	0.50
Reboxetine	No	67	66	64	62	60	54	51	51	51	50	50	50	
	Median	0.67	0.67	0.50	0.50	0.33	0.33	0.17	0.17	0.17	0.17	0.17	0.17	
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	Max	2.00	2.50	2.00	2.00	2.50	1.83	1.83	1.83	1.83	1.83	1.83	1.83	
	Median diff. vs day0 (*)		0.00	0.17	0.17	0.17	0.33	0.50	0.50	0.50	0.50	0.50	0.50	

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RBD

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 24

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Factor: DIURNAL VARIATION
AND Diagnosis: Dysthymia

Assigned treatment	Screen	Visit										
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56		
Imipramine	No	60	60	58	56	56	55	56	56	56	56	56
	Median	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
	Median diff. vs day0 (*)		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Reboxetine	No	67	67	64	62	60	54	51	51	50	50	
	Median	1.00	1.00	0.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
	Median diff. vs day0 (*)		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 24

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Factor: RETARDATION
AND Diagnosis: Dysthymia

Assigned treatment	Screen	Visit													
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56					
Imipramine	No	60	60	58	56	56	55	56	56	56	56	56	56	56	56
	Median	1.75	1.50	1.50	1.00	1.00	0.75	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.38
	Min	1.00	0.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.75	2.50	2.50	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.00	2.00	2.00
	Median diff. vs day0 (*)		0.00	0.25	0.50	0.75	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.25
Reboxetine	No	67	66	64	62	60	54	51	51	50	50	50	50	50	
	Median	1.75	1.63	1.50	1.25	1.00	1.00	0.75	0.75	0.75	0.75	0.75	0.75	0.75	
	Min	0.75	0.75	0.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	Max	2.75	2.50	2.50	2.50	2.50	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.25	
	Median diff. vs day0 (*)		0.00	0.25	0.50	0.50	0.50	1.00	1.00	1.00	1.00	1.00	1.00	1.00	

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 24

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Factor: SLEEP DISTURBANCE
AND Diagnosis: Dysthymia

Assigned treatment	Screen	Visit										
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56		
Imipramine	No	60	60	58	56	56	55	56	56	56	56	
	Median	1.00	0.67	0.67	0.50	0.33	0.33	0.33	0.33	0.33	0.33	
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
	Median diff. vs day0 (*)		0.00	0.00	0.00	0.33	0.33	0.67	0.67	0.67	0.67	
Reboxetine	No	67	66	64	62	60	54	51	51	50		
	Median	1.00	1.33	1.00	1.00	1.00	0.67	0.67	0.67	0.67		
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00		
	Median diff. vs day0 (*)		0.00	0.00	0.00	0.00	0.33	0.33	0.33	0.33	0.33	

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CHS RED
REBOXETINE - PROTOCOL 20124/035
TABLE NO. : 25

HAMILTON DEPRESSION RATING SCALE: SUMMARY STATISTICS ON TOTAL SCORE AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Diagnosis: Total

	Total	Last assessment													
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56						
Imipramine	No	168	11	13	5	4	4	2	3	126					
	Mean	12.85	26.64	24.15	27.40	26.50	22.25	20.00	23.00	8.81					
	STD	10.03	7.27	7.14	8.73	4.80	6.95	5.66	18.08	6.98					
	Median	11	26	24	27	26	21	20	21	7					
	Min	0.00	18.00	13.00	18.00	22.00	16.00	16.00	6.00	0.00					
	Max	42.00	38.00	34.00	41.00	33.00	32.00	24.00	42.00	31.00					
Mean diff. vs day0 (*)	13.30	-1.00	2.00	1.00	0.50	2.00	13.50	8.00	17.00						
Reboxetine	No	172	7	6	7	12	4	4	5	127					
	Mean	16.78	27.29	25.33	21.71	28.25	28.50	18.25	16.00	11.35					
	STD	10.11	7.41	2.58	4.50	8.42	7.85	6.29	9.85	8.42					
	Median	13	24	26	20	27	26	19	17	9					
	Min	0.00	20.00	21.00	17.00	14.00	23.00	11.00	0.00	0.00					
	Max	44.00	42.00	28.00	30.00	44.00	40.00	24.00	27.00	38.00					
Mean diff. vs day0 (*)	11.80	-2.00	0.00	1.00	1.00	-2.00	7.50	10.00	16.00						

Mean (*): mean of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 25

HAMILTON DEPRESSION RATING SCALE: SUMMARY STATISTICS ON TOTAL SCORE AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder

	Total	Last assessment													
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56						
Imipramine															
No	108	9	11	5	4	4	2	3	70						
Mean	14.24	27.56	22.73	27.40	26.50	22.25	20.00	23.00	8.56						
STD	10.67	7.60	6.77	8.73	4.80	6.95	5.66	18.08	7.00						
Median	13	26	21	27	26	21	20	21	8						
Min	0.00	18.00	13.00	18.00	22.00	16.00	16.00	6.00	0.00						
Max	42.00	38.00	32.00	41.00	33.00	32.00	24.00	42.00	31.00						
Mean diff. vs day0 (*)	12.66	-2.00	3.00	1.00	0.50	2.00	13.50	8.00	18.50						
Reboxetine															
No	105	4	4	5	6	3	3	3	77						
Mean	14.73	30.00	26.75	20.40	26.33	30.00	20.67	11.33	11.35						
STD	10.45	8.49	1.26	3.21	9.93	8.89	4.93	9.81	8.89						
Median	13	27	27	20	26	27	23	17	8						
Min	0.00	24.00	25.00	17.00	14.00	23.00	15.00	0.00	0.00						
Max	44.00	42.00	28.00	25.00	44.00	40.00	24.00	17.00	38.00						
Mean diff. vs day0 (*)	12.27	-2.50	-1.50	6.00	-1.00	-2.00	2.00	10.00	17.00						

Mean (*): mean of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/095
 TABLE No.: 26

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
 SUMMARY STATISTICS ON SCORE OF EACH FACTOR AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Factor: ANXIETY/SOMATIZATION
 AND Diagnosis: Total

Assigned treatment	Total	Last assessment										
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56			
Imipramine	No	168	11	13	5	4	4	2	3	126		
	Median	0.67	1.17	1.17	1.17	1.58	1.08	1.42	1.33	0.50		
	Min	0.00	0.67	0.83	1.00	1.00	0.67	1.17	0.00	0.00		
	Max	2.67	2.33	2.17	2.67	1.83	1.50	1.67	2.33	1.67		
	Median diff. vs day0 (*)	0.67	0.00	0.17	0.00	0.08	0.17	0.58	0.50	0.83		
Reboxetine	No	172	7	6	7	12	4	4	5	127		
	Median	0.83	1.67	1.42	1.17	1.58	1.58	0.92	1.00	0.67		
	Min	0.00	1.17	1.00	1.00	1.00	1.33	0.67	0.00	0.00		
	Max	2.50	2.17	2.17	1.83	2.50	2.50	1.83	1.83	2.33		
	Median diff. vs day0 (*)	0.67	0.00	0.00	0.00	0.00	0.08	0.50	0.67	0.83		

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 26

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Factor: WEIGHT
AND Diagnosis: Total

	Last assessment									
	Total	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	
Assigned treatment										
Imipramine	168	11	13	5	4	4	2	3	126	
Median	0.00	0.00	0.00	0.00	0.50	1.00	1.50	0.00	0.00	
Min	0.00	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00	
Max	3.00	2.00	2.00	2.00	2.00	3.00	2.00	2.00	2.00	
Median diff. vs day0 (*)	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00	0.00	
Reboxetine	172	7	6	7	12	4	4	5	127	
Median	0.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	
Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
Max	3.00	2.00	2.00	3.00	2.00	0.00	1.00	1.00	2.00	
Median diff. vs day0 (*)	0.00	0.00	0.00	0.00	0.00	1.50	0.00	1.00	0.00	

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 26

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Factor: COGNITIVE DISTURBANCE
AND Diagnosis: Total

	Assigned treatment							Last assessment							
	Total	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	Day 70	Day 77	Day 84	Day 91	Day 98
Imipramine	No	168	11	13	5	4	2	3	126						
	Median	0.17	0.67	0.67	0.67	0.83	0.33	1.00	0.17						
	Min	0.00	0.33	0.00	0.33	0.17	0.33	0.00	0.00						
	Max	2.17	1.33	1.00	2.17	1.17	0.83	0.33	1.83	1.17					
	Median diff. vs day0 (*)	0.33	0.00	0.17	0.00	0.17	0.08	0.50	0.17	0.50					
Reboxetine	No	172	7	6	7	12	4	5	127						
	Median	0.25	0.67	0.67	0.50	0.83	0.33	0.33	0.17						
	Min	0.00	0.17	0.50	0.17	0.00	0.50	0.00	0.00						
	Max	2.50	1.67	0.83	0.83	2.50	1.50	0.67	0.50	1.83					
	Median diff. vs day0 (*)	0.42	-0.17	0.00	0.33	-0.08	-0.25	0.42	0.50	0.50					

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 26

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Factor: DIURNAL VARIATION
AND Diagnosis: Total

Assigned treatment	Last assessment										
	Total	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56		
Imipramine	No	168	11	13	5	4	2	3	126		
	Median	0.00	1.00	0.00	0.00	0.50	1.00	0.50	0.00	0.00	0.00
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.00	2.00	2.00	0.00	1.00	2.00	1.00	1.00	1.00	2.00
	Median diff. vs day0 (*)	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	0.00
Reboxetine	No	172	7	6	7	12	4	5	127		
	Median	0.00	1.00	1.00	1.00	1.00	0.50	0.50	0.00	0.00	0.00
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	2.00	2.00
	Median diff. vs day0 (*)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No. : 26

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Factor: RETARDATION
AND Diagnosis: Total

Assigned treatment	Last assessment												
	Total	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56				
Imipramine	No	168	11	13	5	4	4	2	3	126			
	Median	0.75	2.00	2.00	2.25	2.13	1.88	1.00	1.00	0.50			
	Min	0.00	1.25	0.50	1.25	1.50	1.50	0.25	0.75	0.00			
	Max	3.25	3.25	2.25	2.75	3.00	2.50	1.75	3.25	2.00			
	Median diff. vs day0 (*)	1.25	0.00	0.00	0.00	0.13	0.25	1.13	0.50	1.25			
Reboxetine	No	172	7	6	7	12	4	4	5	127			
	Median	1.00	1.75	2.00	1.50	1.75	1.75	1.13	1.50	0.75			
	Min	0.00	1.00	1.50	1.25	0.75	1.50	0.25	0.00	0.00			
	Max	3.00	2.25	2.75	2.50	3.00	2.50	2.00	1.75	2.50			
	Median diff. vs day0 (*)	0.75	0.00	0.00	0.00	0.25	-0.38	0.50	0.25	1.25			

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RAD

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 26

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Factor: SLEEP DISTURBANCE
AND Diagnosis: Total

Assigned treatment	Total	Last assessment										
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56			
Imipramine	No	11	13	5	4	4	2	3	126			
	Median	1.67	1.67	1.67	1.17	0.83	1.17	1.00	0.33			
	Min	0.00	0.00	1.00	0.33	0.33	1.00	0.33	0.00			
	Max	2.00	2.00	2.00	1.33	1.67	1.33	1.00	2.00			
	Median diff. vs day0 (*)	0.67	0.00	0.00	0.33	0.33	0.50	0.33	0.67			
Reboxetine	No	7	6	7	12	4	4	5	127			
	Median	1.67	1.17	1.00	1.17	1.33	1.50	0.67	0.67			
	Min	1.00	0.33	0.00	0.00	1.00	1.00	0.00	0.00			
	Max	2.00	1.67	2.00	2.00	2.00	2.00	2.00	2.00			
	Median diff. vs day0 (*)	0.33	0.00	0.17	0.00	0.00	0.00	1.00	0.67			

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 26

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Factor: ANXIETY/SOMATIZATION
AND Diagnosis: Major Depressive Disorder

Assigned treatment	Last assessment											
	Total	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56			
Imipramine	No	108	9	11	5	4	2	3	70			
	Median	0.67	1.17	1.17	1.17	1.58	1.08	1.42	1.33	0.50		
	Min	0.00	0.67	0.83	1.00	1.00	0.67	1.17	0.00	0.00		
	Max	2.67	2.33	2.17	2.67	1.83	1.50	1.67	2.33	1.67		
	Median diff. vs day0 (*)	0.67	-0.17	0.17	0.00	0.08	0.17	0.58	0.50	0.83		
Reboxetine	No	105	4	4	5	6	3	3	77			
	Median	0.67	1.67	1.67	1.00	1.58	1.67	1.00	0.67	0.67		
	Min	0.00	1.50	1.17	1.00	1.00	1.50	0.63	0.00	0.00		
	Max	2.50	2.17	2.17	1.83	2.50	2.50	1.63	1.00	2.17		
	Median diff. vs day0 (*)	0.67	-0.17	-0.08	0.00	-0.08	0.00	0.50	0.67	0.83		

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124/035
TABLE No.: 26

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Factor: HEIGHT
AND Diagnosis: Major Depressive Disorder

Assigned treatment	Total	Last assessment									
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 70	
Imipramine	No	108	9	11	5	4	4	2	3	70	
	Median	0.00	0.00	0.00	0.00	0.50	1.00	1.50	0.00	0.00	
	Min	0.00	0.00	0.00	0.00	0.00	1.00	1.00	0.00	0.00	
	Max	3.00	2.00	2.00	2.00	3.00	2.00	2.00	2.00	2.00	
	Median diff. vs day0 (*)	0.00	1.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00	
Reboxetine	No	105	4	4	5	6	3	3	3	77	
	Median	0.00	1.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00	
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	Max	2.00	2.00	2.00	1.00	2.00	1.00	1.00	0.00	2.00	
	Median diff. vs day0 (*)	0.00	0.00	0.00	0.00	0.00	2.00	0.00	1.00	0.00	

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/025
TABLE No.: 26

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Factor: COGNITIVE DISTURBANCE
AND Diagnosis: Major Depressive Disorder

Assigned treatment	Last assessment										
	Total	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 70	Day 77
Imipramine	No	108	9	11	5	4	4	2	3	3	70
	Median	0.33	0.83	0.67	0.67	0.83	0.50	0.33	1.00	1.00	0.00
	Min	0.00	0.33	0.00	0.33	0.17	0.17	0.33	0.00	0.00	0.00
	Max	2.17	1.33	1.00	2.17	1.17	0.83	0.33	1.83	1.83	1.17
	Median diff. vs day0 (*)	0.33	0.00	0.17	0.00	0.17	0.08	0.50	0.17	0.17	0.50
Reboxetine	No	105	4	4	5	6	3	3	3	3	77
	Median	0.33	0.75	0.75	0.33	0.50	0.83	0.33	0.33	0.33	0.17
	Min	0.00	0.33	0.67	0.17	0.00	0.50	0.33	0.00	0.00	0.00
	Max	2.17	1.67	0.83	0.67	2.17	1.50	0.67	0.50	1.50	1.50
	Median diff. vs day0 (*)	0.33	-0.08	0.00	0.33	0.08	-0.17	0.33	0.17	0.17	0.50

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS RED

REBOSETINE - PROTOCOL 20124/035
TABLE No. : 26

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Factor: DIURNAL VARIATION
AND Diagnosis: Major Depressive Disorder

Assigned treatment	Total	Last assessment												
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 70				
Imipramine	No	108	9	11	5	4	4	2	3	70				
	Median	0.00	1.00	0.00	0.50	1.00	0.50	0.00	0.00	0.00				
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
	Max	2.00	2.00	2.00	1.00	2.00	1.00	1.00	1.00	1.00				
	Median diff. vs day0 (*)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
Reboksetine	No	105	4	4	5	6	3	3	3	77				
	Median	0.00	1.00	0.50	0.00	0.50	0.00	1.00	0.00	0.00				
	Min	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
	Max	2.00	2.00	2.00	1.00	2.00	2.00	1.00	1.00	1.00				
	Median diff. vs day0 (*)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No. 1 26

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Factor: RETARDATION
AND Diagnosis: Major Depressive Disorder

	Last assessment									
	Total	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 70
Assigned treatment Imipramino	No	108	9	11	5	4	4	2	3	70
	Median	0.88	2.00	1.75	2.25	2.13	1.88	1.00	1.00	0.50
	Min	0.00	1.50	0.50	1.25	1.50	1.50	0.25	0.75	0.00
	Max	3.25	3.25	2.25	2.75	3.00	2.50	1.75	3.25	2.00
	Median diff. vs day0 (*)	1.00	0.00	0.25	0.00	0.13	0.25	1.13	0.50	1.50
Assigned treatment Reboxetine	No	105	4	4	5	6	3	3	3	77
	Median	1.00	1.88	2.00	1.50	1.88	1.75	1.25	1.50	0.75
	Min	0.00	1.00	1.50	1.25	1.00	1.50	1.00	0.00	0.00
	Max	3.00	2.25	2.75	2.50	3.00	2.50	2.00	1.75	2.50
	Median diff. vs day0 (*)	0.75	0.00	0.00	0.00	0.13	-0.25	0.00	0.50	1.25

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/095
TABLE No.: 26

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Factor: SLEEP DISTURBANCE
AND Diagnosis: Major Depressive Disorder

Assigned treatment	Total	Last assessment										
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56			
Imipramine	No	108	9	11	5	4	4	2	3	70		
	Median	0.67	1.67	1.00	1.67	1.17	0.83	1.17	1.00	0.33		
	Min	0.00	0.00	0.00	1.00	0.33	0.33	1.00	0.33	0.00		
	Max	2.00	2.00	2.00	2.00	1.33	1.67	1.33	1.00	2.00		
Median diff. vs day0 (*)	0.67	0.00	0.00	0.00	0.33	0.33	0.50	0.33	1.00			
Reboxetine	No	105	4	4	5	6	3	3	3	77		
	Median	1.00	1.67	1.00	1.00	1.17	1.67	1.00	0.67	0.67		
	Min	0.00	1.33	0.33	0.67	0.00	1.00	1.00	0.00	0.00		
	Max	2.00	2.00	1.33	2.00	2.00	2.00	2.00	1.33	2.00		
Median diff. vs day0 (*)	0.67	0.00	0.17	0.67	0.00	0.00	0.67	1.00	1.00			

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 26

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Factor: ANXIETY/SOMATIZATION
AND Diagnosis: Dysthymia

	Assigned treatment							Last assessment										
	Total	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Total	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56
Imipramine	60	2	2						56									0.67
Median	0.67	1.42	2.00															0.00
Min	0.00	1.17	1.83															1.50
Max	2.17	1.67	2.17															0.83
Median diff. vs day0 (*)	0.83	0.00	-0.50															
Reboxetine	67	3	2	2	6	1	1	2	50									0.67
Median	0.83	1.17	1.08	1.42	1.67	1.33	0.67	1.75										0.00
Min	0.00	1.17	1.00	1.33	1.50	1.33	0.67	1.67										2.33
Max	2.33	2.17	1.17	1.50	2.00	1.33	0.67	1.83										0.83
Median diff. vs day0 (*)	0.67	0.00	0.42	0.08	0.33	0.17	1.33	0.33										

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/095
TABLE No.: 26

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Factor: WEIGHT
AND Diagnosis: Dysthymia

Assigned treatment	Last assessment									
	Total	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	
Imipramine	No	60	2	2						56
	Median	0.00	0.00	1.50						0.00
	Min	0.00	0.00	1.00						0.00
	Max	2.00	0.00	2.00						1.00
	Median diff. vs day0 (*)	0.00	0.00	-1.50						0.00
Reboxetine	No	67	3	2	2	6	1	2	50	
	Median	0.00	0.00	0.00	2.00	0.00	0.00	0.50	0.00	
	Min	0.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00	
	Max	3.00	0.00	0.00	3.00	1.00	0.00	1.00	2.00	
	Median diff. vs day0 (*)	0.00	0.00	1.50	-1.50	0.00	0.00	0.00	1.00	

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 26

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Factor: COGNITIVE DISTURBANCE
AND Diagnosis: Dysthymia

	Assigned treatment							Last assessment							
	Total	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56						
Imipramine															
No	60	2	2												56
Median	0.17	0.58	0.67												0.17
Min	0.00	0.50	0.50												0.00
Max	1.17	0.67	0.83												1.17
Median diff. vs day0 (*)	0.50	0.08	-0.42												0.50
Reboxetine															
No	67	3	2	2	6	1	1	2	50						
Median	0.17	0.33	0.58	0.75	1.00	0.83	0.00	0.33	0.17						
Min	0.00	0.17	0.50	0.67	0.83	0.83	0.00	0.33	0.00						
Max	2.50	0.83	0.67	0.83	2.50	0.83	0.00	0.33	1.83						
Median diff. vs day0 (*)	0.50	-0.17	0.92	0.17	-0.17	-0.33	0.67	0.58	0.50						

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 26

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Factor: DIURNAL VARIATION
AND Diagnosis: Dysthymia

Assigned treatment	Total	Last assessment												
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56					
Imipramine	No	60	2	2										56
	Median	0.00	0.50	0.00										0.00
	Min	0.00	0.00	0.00										0.00
	Max	2.00	1.00	0.00										2.00
	Median diff. vs day0 (*)	0.00	0.00	0.00										0.00
Reboxetine	No	67	3	2	2	6	1	1	2	50				
	Median	0.00	1.00	1.00	1.50	1.00	1.00	0.00	1.00	0.00				
	Min	0.00	0.00	1.00	1.00	0.00	0.00	0.00	1.00	0.00				
	Max	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00				
	Median diff. vs day0 (*)	0.00	0.00	-0.50	-0.50	0.00	0.00	0.00	0.00	0.50				

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 26

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Factor: RETARDATION
AND Diagnosis: Dysthymia

Assigned treatment	Last assessment									
	Total	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	
Imipramine	No	60	2	2						56
	Median	0.50	1.50	2.13						0.38
	Min	0.00	1.25	2.00						0.00
	Max	2.25	1.75	2.25						2.00
	Median diff. vs day0 (*)	1.25	-0.13	-0.13						1.25
Reboxetine	No	67	3	2	2	6	1	2	50	
	Median	1.00	1.25	1.88	1.75	1.63	1.75	1.50	0.75	0.75
	Min	0.00	1.25	1.50	1.50	0.75	1.75	1.50	0.00	0.00
	Max	2.50	2.25	2.25	2.00	2.50	1.75	1.50	2.25	2.25
	Median diff. vs day0 (*)	0.75	0.00	0.38	-0.25	0.25	-0.50	1.25	0.13	1.00

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RBD

REBOXETINE – PROTOCOL 20124/035
TABLE No.: 26

FACTORIZATION HAMILTON DEPRESSION RATING SCALE
SUMMARY STATISTICS ON SCORE OF EACH FACTOR AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Factor: SLEEP DISTURBANCE
AND Diagnosis: Dysthymia

Assigned treatment	Last assessment											
	Total	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56			
Imipramine	No	60	2	2								56
	Median	0.33	1.33	2.00								0.33
	Min	0.00	1.00	2.00								0.00
	Max	2.00	1.67	2.00								2.00
	Median diff. vs day0 (*)	0.67	0.00	-0.50								0.67
Reboxetine	No	67	3	2	2	6	1	2	50			
	Median	0.67	1.67	1.33	0.50	1.33	1.00	2.00	0.67			
	Min	0.00	1.00	1.00	0.00	1.00	1.00	2.00	0.00			
	Max	2.00	2.00	1.67	1.00	2.00	1.00	2.00	2.00			
	Median diff. vs day0 (*)	0.33	0.00	0.50	0.00	0.00	0.00	-1.00	1.00			

Median (*): median of differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Pharmacia CNS R&D

Reboxetine - Protocol 20124/035

TABLE No. : 27

HAMILTON DEPRESSION RATING SCALE: DIFFERENCE ON TOTAL SCORE AT LAST ASSESSMENT WITH RESPECT TO BASELINE

Diagnosis	Treatment	Mean \pm SD (N)	Between treatment difference (95% C.I.)
Major depressive episodes	Reboxetine	12.3 \pm 10.4 (105)	
	Imipramine	12.7 \pm 10.3 (108)	-0.4 (-3.2 \div 2.4)
Dysthymia	Reboxetine	11.1 \pm 9.4 (67)	
	Imipramine	14.5 \pm 8.5 (60)	-3.4 (-6.5 \div -0.2)
Total	Reboxetine	11.8 \pm 10.0 (172)	
	Imipramine	13.3 \pm 9.7 (168)	-1.5 (-3.6 \div 0.6)

PHARMACIA CNS 350089

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 28

EFFICACY: CLASSIFICATION OF PATIENTS ACCORDING TO PROTOCOL CRITERIA ON TOTAL SCORE OF HAMILTON DEPRESSION RATING SCALE OVER TIME BY ASSIGNED TREATMENT AND DIAGNOSIS

Diagnosis: Total

Assigned treatment		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56
Imipramine	Patients No.	167	157	144	139	131	129	126	126
	Responders No.	7	25	46	65	75	80	84	94
	Responders %	4.2	15.9	31.9	46.8	57.3	62.0	66.7	74.6
	95% L.L.	1.7	10.6	24.4	38.3	48.3	53.1	57.7	66.1
	95% U.L.	8.4	22.6	40.2	55.4	65.9	70.4	74.8	81.9
	Remissions No.	4	18	37	44	62	67	75	82
	Remissions %	2.4	11.5	25.7	31.7	47.3	51.9	59.5	65.1
	95% L.L.	0.7	6.9	18.8	24.0	38.5	43.0	50.4	56.1
	95% U.L.	6.0	17.5	33.6	40.1	56.2	60.8	68.2	73.4
Reboxetine	Patients No.	171	165	159	152	139	134	131	127
	Responders No.	6	18	35	55	67	75	81	89
	Responders %	3.5	10.9	22.0	36.2	48.2	56.0	61.8	70.1
	95% L.L.	1.3	6.6	15.8	28.6	39.7	47.1	52.9	61.3
	95% U.L.	7.5	16.7	29.3	44.4	56.8	64.5	70.2	77.9
	Remissions No.	2	11	24	39	54	59	67	72
	Remissions %	1.2	6.7	15.1	25.7	38.8	44.0	51.1	56.7
	95% L.L.	0.1	3.4	9.9	18.9	30.7	35.5	42.3	47.6
	95% U.L.	4.2	11.6	21.6	33.4	47.5	52.9	60.0	65.5

PHARMACIA CN 550089

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 28

EFFICACY: CLASSIFICATION OF PATIENTS ACCORDING TO PROTOCOL CRITERIA ON TOTAL SCORE OF HAMILTON DEPRESSION RATING SCALE OVER TIME BY ASSIGNED TREATMENT AND DIAGNOSIS

Diagnosis: Major Depressive Disorder

Assigned treatment	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56
Imipramine	Patients No.	107	99	88	83	76	73	70
	Responders No.	4	15	25	36	45	48	51
	Responders %	3.7	15.2	28.4	43.4	59.2	65.8	72.9
	95% L.L.	1.0	8.7	19.3	32.5	47.3	53.7	60.9
	95% U.L.	9.3	23.8	39.0	54.7	70.4	76.5	82.8
	Remissions No.	2	8	20	21	34	36	44
	Remissions %	1.9	8.1	22.7	25.3	44.7	49.3	62.9
	95% L.L.	0.2	3.6	14.5	16.4	33.3	37.4	50.5
	95% U.L.	6.6	15.3	32.9	36.0	56.6	61.3	74.1
Reboxetine	Patients No.	105	101	97	92	85	83	80
	Responders No.	5	12	21	37	40	44	52
	Responders %	4.8	11.9	21.6	40.2	47.1	53.0	65.0
	95% L.L.	1.6	6.3	13.9	30.1	36.1	41.7	53.5
	95% U.L.	10.8	19.8	31.2	51.0	58.2	64.1	75.3
	Remissions No.	1	7	14	24	33	37	44
	Remissions %	1.0	6.9	14.4	26.1	38.8	44.6	55.0
	95% L.L.	0.0	2.8	8.1	17.5	28.4	33.7	43.5
	95% U.L.	5.2	13.8	23.0	36.3	50.0	55.9	66.2

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CN580089

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 2a

EFFICACY: CLASSIFICATION OF PATIENTS ACCORDING TO PROTOCOL CRITERIA ON TOTAL SCORE OF HAMILTON DEPRESSION RATING SCALE OVER TIME BY ASSIGNED TREATMENT AND DIAGNOSIS

Diagnosis: Dysthymia

Assigned treatment	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56
Imipramine	Patients No.	60	58	56	56	55	56	56
	Responders No.	3	10	21	29	30	32	39
	Responders %	5.0	17.2	37.5	51.8	54.5	57.1	69.6
	95% L.L.	1.0	8.6	24.9	38.0	40.6	43.2	55.9
	95% U.L.	13.9	29.4	51.5	65.3	68.0	70.3	81.2
	Remissions No.	2	10	17	23	28	31	35
	Remissions %	3.3	17.2	30.4	41.1	50.9	55.4	62.5
	95% L.L.	0.4	8.6	18.8	28.1	37.1	41.5	48.5
	95% U.L.	11.5	29.4	44.1	55.0	64.6	68.7	75.1
Reboxetine	Patients No.	66	64	62	60	54	51	50
	Responders No.	1	6	14	18	27	31	35
	Responders %	1.5	9.4	22.6	30.0	50.0	60.8	70.0
	95% L.L.	0.0	3.5	12.9	18.8	36.1	46.1	55.4
	95% U.L.	8.2	19.3	35.0	43.2	63.9	74.2	82.1
	Remissions No.	1	4	10	15	21	22	28
	Remissions %	1.5	6.3	16.1	25.0	38.9	43.1	56.0
	95% L.L.	0.0	1.7	8.0	14.7	25.9	29.3	41.3
	95% U.L.	8.2	15.2	27.7	37.9	53.1	57.8	70.0

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
TABLE No. : 29

EFFICACY: CLASSIFICATION OF PATIENTS ACCORDING TO PROTOCOL CRITERIA ON TOTAL SCORE OF HAMILTON DEPRESSION RATING SCALE AT LAST ASSESSMENT VS DAY 0 BY ASSIGNED TREATMENT AND DIAGNOSIS

Diagnosis: Total

	Assigned treatment	
	Imipramine	Reboxetine
Patients No.	168	172
Responders No.	95	93
Responders %	56.5	54.1
95% L.L.	48.7	46.3
95% U.L.	64.2	61.7
Remissions No.	83	79
Remissions %	49.4	42.4
95% L.L.	41.6	35.0
95% U.L.	57.2	50.2

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No. : 29

EFFICACY: CLASSIFICATION OF PATIENTS ACCORDING TO PROTOCOL CRITERIA ON TOTAL SCORE OF HAMILTON DEPRESSION RATING SCALE AT LAST ASSESSMENT VS DAY 0 BY ASSIGNED TREATMENT AND DIAGNOSIS

Diagnosis: Major Depressive Disorder

	Assigned treatment	
	Imipramine	Reboxetine
Patients No.	108	105
Responders No.	56	55
Responders %	51.9	52.4
95% L.L.	42.0	42.4
95% U.L.	61.6	62.2
Remissions No.	48	45
Remissions %	44.4	42.9
95% L.L.	34.9	33.2
95% U.L.	54.3	52.9

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RBD
 REBOXETINE - PROTOCOL 20124/035
 TABLE No. : 29

EFFICACY: CLASSIFICATION OF PATIENTS ACCORDING TO PROTOCOL CRITERIA ON TOTAL SCORE OF HAMILTON DEPRESSION RATING SCALE AT LAST ASSESSMENT VS DAY 0 BY ASSIGNED TREATMENT AND DIAGNOSIS

Diagnosis: Dysthymia

	Assigned treatment	
	Imipramine	Reboxetine
Patients No.	60	67
Responders No.	39	38
Responders %	65.0	56.7
95% L.L.	51.6	44.0
95% U.L.	76.9	68.8
Remissions No.	35	28
Remissions %	58.3	41.8
95% L.L.	44.9	29.8
95% U.L.	70.9	54.5

PHARMACIA CNS 550089

REBOXETINE - PROTOCOL 20124/035

TABLE No. :30
HAND SCALE: FREQUENCY OF REMISSION BY SEVERITY AT BASELINE OF THE 17 SPECIFIC ITEMS BY ASSIGNED TREATMENT

TOTAL		Imipramine				Reboxetine			
		remission							
		NO		YES		NO		YES	
		No	%	No	%	No	%	No	%
item									
DEPRESSED MOOD	absent/low severity	21	43.8	27	56.3	29	55.8	23	44.2
	high severity	64	53.3	56	46.7	70	58.3	50	41.7
GUILT	absent/low severity	74	49.7	75	50.3	85	56.7	65	43.3
	high severity	11	57.9	8	42.1	14	63.6	8	36.4
SUICIDE	absent/low severity	83	51.2	79	48.8	95	58.3	68	41.7
	high severity	2	33.3	4	66.7	4	44.4	5	55.6
INSOMNIA EARLY	absent/low severity	38	46.3	44	53.7	34	54.0	29	46.0
	high severity	47	54.7	39	45.3	65	59.6	44	40.4
INSOMNIA MIDDLE	absent/low severity	46	44.2	58	55.8	47	51.6	44	48.4
	high severity	39	60.9	25	39.1	52	64.2	29	35.8
INSOMNIA LATE	absent/low severity	41	42.7	55	57.3	53	58.2	38	41.8
	high severity	44	61.1	28	38.9	46	56.8	35	43.2
WORK AND ACTIVITIES	absent/low severity	27	46.6	31	53.4	31	55.4	25	44.6
	high severity	58	52.7	52	47.3	68	58.6	48	41.4
RETARDATION	absent/low severity	78	51.7	73	48.3	94	59.1	65	40.9
	high severity	7	41.2	10	58.8	5	38.5	8	61.5
AGITATION	absent/low severity	69	47.3	77	52.7	78	53.8	67	46.2
	high severity	16	72.7	6	27.3	21	77.8	6	22.2
ANXIETY PSYCHIC	absent/low severity	49	47.6	54	52.4	61	55.0	50	45.0
	high severity	36	55.4	29	44.6	38	62.3	23	37.7
ANXIETY SOMATIC	absent/low severity	71	51.4	67	48.6	72	57.1	54	42.9
	high severity	14	46.7	16	53.3	27	58.7	19	41.3
SOMATIC GASTROINTESTINAL	absent/low severity	59	47.2	66	52.8	65	56.5	50	43.5
	high severity	26	60.5	17	39.5	34	59.6	23	40.4
SOMATIC GENERAL	absent/low severity	44	49.4	45	50.6	48	54.5	40	45.5
	high severity	41	51.9	38	48.1	51	60.7	33	39.3
GENITAL SYMPTOMS	absent/low severity	69	51.1	66	48.9	87	60.8	56	39.2
	high severity	16	48.5	17	51.5	12	41.4	17	58.6
HYPOCHONDRIASIS	absent/low severity	67	48.9	70	51.1	65	49.2	67	50.8
	high severity	18	58.1	13	41.9	34	85.0	6	15.0
LOSS OF HEIGHT	absent/low severity	82	49.7	83	50.3	95	56.9	72	43.1
	high severity	3	100			4	80.0	1	20.0
INSIGHT	absent/low severity	78	49.7	79	50.3	90	55.9	71	44.1
	high severity	7	63.6	4	36.4	9	81.8	2	18.2

PHARMACIA CNS 350089

REBOXETINE - PROTOCOL 20124/035

TABLE No. :30
HAMD SCALE: FREQUENCY OF REMISSION BY SEVERITY AT BASELINE OF THE 17 SPECIFIC ITEMS BY ASSIGNED TREATMENT

diagnosis: Major Depressive Disorder

Item		Imipramine				Reboxetine			
		Remission				Remission			
		NO		YES		NO		YES	
		No	%	No	%	No	%	No	%
DEPRESSED MOOD	absent/low severity	14	51.9	13	48.1	16	48.5	17	51.5
	high severity	46	56.8	35	43.2	44	61.1	28	38.9
GUILT	absent/low severity	54	54.5	45	45.5	55	57.9	40	42.1
	high severity	6	66.7	3	33.3	5	50.0	5	50.0
SUICIDE	absent/low severity	59	56.7	45	43.3	59	59.6	40	40.4
	high severity	1	25.0	3	75.0	1	16.7	5	83.3
INSOMNIA EARLY	absent/low severity	26	52.0	24	48.0	15	50.0	15	50.0
	high severity	34	58.6	24	41.4	45	60.0	30	40.0
INSOMNIA MIDDLE	absent/low severity	35	53.0	31	47.0	26	53.1	23	46.9
	high severity	25	59.5	17	40.5	34	60.7	22	39.3
INSOMNIA LATE	absent/low severity	27	50.9	26	49.1	27	61.4	17	38.6
	high severity	33	60.0	22	40.0	33	54.1	28	45.9
WORK AND ACTIVITIES	absent/low severity	20	55.6	16	44.4	18	56.3	14	43.8
	high severity	40	55.6	32	44.4	42	57.5	31	42.5
RETARDATION	absent/low severity	55	57.3	41	42.7	57	59.4	39	40.6
	high severity	5	41.7	7	58.3	3	33.3	6	66.7
AGITATION	absent/low severity	49	52.7	44	47.3	45	53.6	39	46.4
	high severity	11	73.3	4	26.7	15	71.4	6	28.6
ANXIETY PSYCHIC	absent/low severity	35	49.3	36	50.7	38	53.5	33	46.5
	high severity	25	67.6	12	32.4	22	64.7	12	35.3
ANXIETY SOMATIC	absent/low severity	47	54.0	40	46.0	43	56.6	33	43.4
	high severity	13	61.9	8	38.1	17	58.6	12	41.4
SOMATIC GASTROINTESTINAL	absent/low severity	39	52.7	35	47.3	39	56.5	30	43.5
	high severity	21	61.8	13	38.2	21	58.3	15	41.7
SOMATIC GENERAL	absent/low severity	30	54.5	25	45.5	29	51.8	27	48.2
	high severity	30	56.6	23	43.4	31	63.3	18	36.7
GENITAL SYMPTOMS	absent/low severity	49	57.0	37	43.0	53	60.2	35	39.8
	high severity	11	50.0	11	50.0	7	41.2	10	58.8
HYPOCHONDRIASIS	absent/low severity	47	54.7	39	45.3	44	52.4	40	47.6
	high severity	13	59.1	9	40.9	16	76.2	5	23.8
LOSS OF HEIGHT	absent/low severity	58	54.7	48	45.3	59	57.3	44	42.7
	high severity	2	100			1	50.0	1	50.0
INSIGHT	absent/low severity	54	53.5	47	46.5	53	54.6	44	45.4
	high severity	6	85.7	1	14.3	7	87.5	1	12.5

PHARMACIA CNS 0089

REBOXETINE - PROTOCOL 20124/035

TABLE No. :30
HAND SCALE: FREQUENCY OF REMISSION BY SEVERITY AT BASELINE OF THE 17 SPECIFIC ITEMS BY ASSIGNED TREATMENT

diagnosis: Dysthymia

Item		Imipramine				Reboxetine			
		Remission				Remission			
		NO		YES		NO		YES	
		No	%	No	%	No	%	No	%
DEPRESSED MOOD	absent/low severity	7	33.3	14	66.7	13	68.4	6	31.6
	high severity	18	46.2	21	53.8	26	54.2	22	45.8
GUILT	absent/low severity	20	40.0	30	60.0	30	54.5	25	45.5
	high severity	5	50.0	5	50.0	9	75.0	3	25.0
SUICIDE	absent/low severity	24	41.4	34	58.6	36	56.3	28	43.8
	high severity	1	50.0	1	50.0	3	100		
INSOMNIA EARLY	absent/low severity	12	37.5	20	62.5	19	57.6	14	42.4
	high severity	13	46.4	15	53.6	20	58.8	14	41.2
INSOMNIA MIDDLE	absent/low severity	11	28.9	27	71.1	21	50.0	21	50.0
	high severity	14	63.6	8	36.4	18	72.0	7	28.0
INSOMNIA LATE	absent/low severity	14	32.6	29	67.4	26	55.3	21	44.7
	high severity	11	64.7	6	35.3	13	65.0	7	35.0
WORK AND ACTIVITIES	absent/low severity	7	31.8	15	68.2	13	54.2	11	45.8
	high severity	18	47.4	20	52.6	26	60.5	17	39.5
RETARDATION	absent/low severity	23	41.8	32	58.2	37	58.7	26	41.3
	high severity	2	40.0	3	60.0	2	50.0	2	50.0
AGITATION	absent/low severity	20	37.7	33	62.3	33	54.1	28	45.9
	high severity	5	71.4	2	28.6	6	100		
ANXIETY PSYCHIC	absent/low severity	14	43.8	18	56.3	23	57.5	17	42.5
	high severity	11	39.3	17	60.7	16	59.3	11	40.7
ANXIETY SOMATIC	absent/low severity	24	47.1	27	52.9	29	58.0	21	42.0
	high severity	1	11.1	8	88.9	10	58.8	7	41.2
SOMATIC GASTROINTESTINAL	absent/low severity	20	39.2	31	60.8	26	56.5	20	43.5
	high severity	5	55.6	4	44.4	13	61.9	8	38.1
SOMATIC GENERAL	absent/low severity	14	41.2	20	58.8	19	59.4	13	40.6
	high severity	11	42.3	15	57.7	20	57.1	15	42.9
GENITAL SYMPTOMS	absent/low severity	20	40.8	29	59.2	34	61.8	21	38.2
	high severity	5	45.5	6	54.5	5	41.7	7	58.3
HYPOCHONDRIASIS	absent/low severity	20	39.2	31	60.8	21	43.8	27	56.3
	high severity	5	55.6	4	44.4	18	94.7	1	5.26
LOSS OF WEIGHT	absent/low severity	24	40.7	35	59.3	36	56.3	28	43.8
	high severity	1	100			3	100		
INSIGHT	absent/low severity	24	42.9	32	57.1	37	57.8	27	42.2
	high severity	1	25.0	3	75.0	2	66.7	1	33.3

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 31

CLINICAL GLOBAL IMPRESSION: SEVERITY OF ILLNESS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Diagnosis: Total

Assigned treatment/Severity of illness	Visit																		
	Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	
Imipramine	NORMAL				2	1.3	11	7.6	21	15.1	33	24.8	40	31.0	44	34.6	49	38.9	
	BORDERLINE MENTALLY ILL			2	1.2	11	7.0	18	12.5	24	17.3	26	19.5	26	20.2	30	23.6	34	27.0
	MILDLY ILL	12	7.1	22	12.9	32	20.4	34	23.6	33	23.7	26	19.5	23	17.8	22	17.3	17	13.5
	MODERATELY ILL	47	27.6	47	27.6	46	29.3	33	22.9	32	23.0	25	18.8	25	19.4	17	13.4	14	11.1
	MARKEDLY ILL	83	48.8	77	45.3	49	31.2	40	27.8	25	18.0	21	15.8	13	10.1	13	10.2	12	9.5
	SEVERELY ILL	26	15.3	22	12.9	15	9.6	7	4.9	4	2.9	2	1.5	2	1.6	1	0.8		
EXTREMELY ILL	2	1.2			2	1.3	1	0.7											
Total	170	100.0	170	100.0	157	100.0	144	100.0	139	100.0	133	100.0	129	100.0	127	100.0	126	100.0	
Reboxetine	NORMAL			1	0.6	1	0.6	5	3.1	14	9.2	23	16.4	25	18.4	37	28.2	40	31.3
	BORDERLINE MENTALLY ILL			3	1.7	10	6.1	11	6.9	21	13.8	20	14.3	31	22.8	26	19.8	31	24.2
	MILDLY ILL	15	8.6	26	15.0	35	21.2	42	26.2	32	21.1	39	27.9	38	27.9	34	26.0	29	22.7
	MODERATELY ILL	47	27.0	52	30.1	52	31.5	56	35.0	49	32.2	34	24.3	26	19.1	18	13.7	11	8.6
	MARKEDLY ILL	86	49.4	64	37.0	54	32.7	32	20.0	27	17.8	18	12.9	13	9.6	13	9.9	13	10.2
	SEVERELY ILL	25	14.4	24	13.9	12	7.3	13	8.1	7	4.6	5	3.6	3	2.2	3	2.3	3	2.3
EXTREMELY ILL	1	0.6	3	1.7	1	0.6	1	0.6	2	1.3	1	0.7					1	0.8	
Total	174	100.0	173	100.0	165	100.0	160	100.0	152	100.0	140	100.0	136	100.0	131	100.0	128	100.0	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No. : 51

CLINICAL GLOBAL IMPRESSION: SEVERITY OF ILLNESS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder

Assigned treatment/Severity of illness	Visit																			
	Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z		
Imipramine	NORMAL							1	1.1	8	9.6	16	20.5	21	28.8	22	31.0	26	37.1	
	BORDERLINE MENTALLY ILL		1	0.9	6	6.1	11	12.5	13	15.7	14	16.7	14	19.2	17	23.9	19	27.1		
	MILDLY ILL	6	5.5	13	11.9	17	17.2	23	26.1	23	27.7	20	25.6	16	21.9	16	22.5	12	17.1	
	MODERATELY ILL	29	26.6	29	26.6	33	33.3	23	26.1	22	26.5	15	19.2	13	17.8	8	11.3	6	8.6	
	MARKEDLY ILL	51	46.8	46	42.2	29	29.3	23	26.1	14	16.9	13	16.7	8	11.0	7	9.9	7	10.0	
	SEVERELY ILL	21	19.3	20	18.3	12	12.1	6	6.8	3	3.6	1	1.3	1	1.4	1	1.4			
	EXTREMELY ILL	2	1.8			2	2.0	1	1.1											
Total	109	100.0	109	100.0	99	100.0	88	100.0	83	100.0	78	100.0	73	100.0	71	100.0	70	100.0		
Reboxetine	NORMAL		1	0.9	1	1.0	3	3.1	9	9.8	13	15.1	15	17.9	23	28.7	25	32.5		
	BORDERLINE MENTALLY ILL		2	1.9	6	5.9	5	5.1	12	13.0	8	9.3	17	20.2	16	20.0	19	24.7		
	MILDLY ILL	11	10.3	18	16.8	22	21.8	25	25.5	17	18.5	27	31.4	23	27.4	19	23.7	14	18.2	
	MODERATELY ILL	21	19.6	27	25.2	30	29.7	36	36.7	32	34.8	23	26.7	19	22.6	12	15.0	7	9.1	
	MARKEDLY ILL	55	51.4	36	33.6	31	30.7	17	17.3	15	16.3	10	11.6	8	9.5	8	10.0	9	11.7	
	SEVERELY ILL	19	17.8	20	18.7	10	9.9	11	11.2	6	6.5	4	4.7	2	2.4	2	2.5	2	2.6	
	EXTREMELY ILL	1	0.9	3	2.8	1	1.0	1	1.0	1	1.1	1	1.2					1	1.3	
Total	107	100.0	107	100.0	104	100.0	98	100.0	92	100.0	86	100.0	84	100.0	80	100.0	77	100.0		

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 31

CLINICAL GLOBAL IMPRESSION: SEVERITY OF ILLNESS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Diagnosis: Dysthymia

Assigned treatment/Severity of illness	Visit																			
	Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%		
Imipramine	NORMAL																			
	BORDERLINE MENTALLY ILL			1	1.6	5	8.6	7	12.5	11	19.6	13	23.6	12	21.4	13	23.2	15	26.8	
	MILDLY ILL	6	9.8	9	14.8	15	25.9	11	19.6	10	17.9	6	10.9	7	12.5	6	10.7	5	8.9	
	MODERATELY ILL	18	29.5	18	29.5	13	22.4	10	17.9	10	17.9	10	18.2	12	21.4	9	16.1	8	14.3	
	MARKEDLY ILL	32	52.5	31	50.8	20	34.5	17	30.4	11	19.6	8	14.5	5	8.9	6	10.7	5	8.9	
SEVERELY ILL	5	8.2	2	3.3	3	5.2	1	1.8	1	1.8	1	1.8	1	1.8						
Total	64	100.0	61	100.0	58	100.0	56	100.0	56	100.0	55	100.0	56	100.0	56	100.0	56	100.0	56	100.0
Reboxetine	NORMAL							2	3.2	5	8.3	10	18.5	10	19.2	14	27.5	15	29.4	
	BORDERLINE MENTALLY ILL			1	1.5	4	6.3	6	9.7	9	15.0	12	22.2	14	26.9	10	19.6	12	23.5	
	MILDLY ILL	4	6.0	8	12.1	13	20.3	17	27.4	15	25.0	12	22.2	15	28.8	15	29.4	15	29.4	
	MODERATELY ILL	26	38.8	25	37.9	22	34.4	20	32.3	17	28.3	11	20.4	7	13.5	6	11.8	4	7.8	
	MARKEDLY ILL	31	46.3	28	42.4	23	35.9	15	24.2	12	20.0	8	14.8	5	9.6	5	9.8	4	7.8	
SEVERELY ILL	6	9.0	4	6.1	2	3.1	2	3.2	1	1.7	1	1.9	1	1.9	1	2.0	1	2.0		
EXTREMELY ILL																				
Total	67	100.0	66	100.0	64	100.0	62	100.0	60	100.0	54	100.0	52	100.0	51	100.0	51	100.0	51	100.0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 52

CLINICAL GLOBAL IMPRESSION: SEVERITY OF ILLNESS AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Diagnosis: Total

Assigned treatment/Severity of illness	Total		Last Visit																
	No	Z	Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
			No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	
Imipramine	NORMAL	50	29.4																
	BORDERLINE MENTALLY ILL	34	20.0																
	MILDLY ILL	18	10.6		1	7.7													
	MODERATELY ILL	31	18.2	5	38.5	5	38.5	2	40.0										
	MARKEDLY ILL	21	12.4	3	23.1	2	15.4	1	20.0										
	SEVERELY ILL	15	8.8	5	38.5	5	38.5	1	20.0	3	100.0								
EXTREMELY ILL	1	0.6					1	20.0											
Total	170	100.0	13	100.0	13	100.0	5	100.0	3	100.0	5	100.0	2	100.0	3	100.0	126	100.0	
Reboxetine	NORMAL	41	23.6																
	BORDERLINE MENTALLY ILL	32	18.4																
	MILDLY ILL	37	21.3	2	22.2	2	40.0	2	25.0	1	9.1								
	MODERATELY ILL	27	15.5	3	33.3	1	20.0	4	50.0	4	36.4	1	25.0	1	20.0	2	50.0	11	8.6
	MARKEDLY ILL	23	13.2	2	22.2	2	40.0			3	27.3	2	50.0	1	20.0			13	10.2
	SEVERELY ILL	11	6.3	1	11.1			2	25.0	2	18.2	1	25.0	1	20.0	1	25.0	3	2.3
EXTREMELY ILL	3	1.7	1	11.1					1	9.1							1	0.8	
Total	174	100.0	9	100.0	5	100.0	8	100.0	11	100.0	4	100.0	5	100.0	4	100.0	128	100.0	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 32

CLINICAL GLOBAL IMPRESSION: SEVERITY OF ILLNESS AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder

Assigned treatment/Severity of illness	Total		Last Visit																
	No	%	Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
			No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	
Imipramine	NORMAL	27	24.8												1	33.3	26	37.1	
	BORDERLINE MENTALLY ILL	19	17.4														19	27.1	
	MILDLY ILL	13	11.9		1	9.1											12	17.1	
	MODERATELY ILL	20	18.3	2	20.0	5	45.5	2	40.0			2	40.0	2	100.0	1	33.3	6	8.6
	MARKEDLY ILL	16	14.7	3	30.0	2	18.2	1	20.0			3	60.0					7	10.0
	SEVERELY ILL	13	11.9	5	50.0	3	27.3	1	20.0	3	100.0					1	33.3		
	EXTREMELY ILL	1	0.9					1	20.0										
Total	109	100.0	10	100.0	11	100.0	5	100.0	3	100.0	5	100.0	2	100.0	3	100.0	70	100.0	
Reboxetine	NORMAL	26	24.3												1	33.3	25	32.5	
	BORDERLINE MENTALLY ILL	19	17.8														19	24.7	
	MILDLY ILL	19	17.8	1	16.7	1	33.3	2	33.3				1	25.0			14	18.2	
	MODERATELY ILL	17	15.9	2	33.3	1	33.3	2	33.3	2	40.0	1	33.3	1	25.0	1	33.3	7	9.1
	MARKEDLY ILL	14	13.1	1	16.7	1	33.3			1	20.0	1	33.3	1	25.0			9	11.7
	SEVERELY ILL	10	9.3	1	16.7			2	33.3	2	40.0	1	33.3	1	25.0	1	33.3	2	2.6
	EXTREMELY ILL	2	1.9	1	16.7													1	1.3
Total	107	100.0	6	100.0	3	100.0	6	100.0	5	100.0	3	100.0	4	100.0	3	100.0	77	100.0	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 52

CLINICAL GLOBAL IMPRESSION: SEVERITY OF ILLNESS AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Diagnosis: Dysthymia

Assigned treatment/Severity of illness	Total			Last Visit															
	No	Z	%	Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56	
				No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z
Imipramine	NORMAL	23	37.7															23	41.1
	BORDERLINE MENTALLY ILL	15	24.6															15	26.8
	MILDLY ILL	5	8.2															5	8.9
	MODERATELY ILL	11	18.0	3	100.0													8	14.3
	MARKEDLY ILL	5	8.2															5	8.9
	SEVERELY ILL	2	3.3			2	100.0												
Total	61	100.0	3	100.0	2	100.0											56	100.0	
Reboxetine	NORMAL	15	22.4															15	29.4
	BORDERLINE MENTALLY ILL	13	19.4											1	100.0			12	23.5
	MILDLY ILL	18	26.9	1	33.3	1	50.0		1	16.7								15	29.4
	MODERATELY ILL	10	14.9	1	33.3			2	100.0	2	33.3					1	100.0	4	7.8
	MARKEDLY ILL	9	13.4	1	33.3	1	50.0		2	33.3	1	100.0						4	7.8
	SEVERELY ILL	1	1.5															1	2.0
EXTREMELY ILL	1	1.5							1	16.7									
Total	67	100.0	3	100.0	2	100.0	2	100.0	6	100.0	1	100.0	1	100.0	1	100.0	51	100.0	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R6D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 33

CLINICAL GLOBAL IMPRESSION: SEVERITY OF ILLNESS SHIFT TABLE (LAST VALUE VS DAY 0) BY ASSIGNED TREATMENT

Diagnosis: Total

Assigned treatment/Severity shift	Total			Last visit																							
	No	Z	%	Day 7			Day 14			Day 21			Day 28			Day 35			Day 42			Day 49			Day 56		
				No	Z	%	No	Z	%	No	Z	%	No	Z	%	No	Z	%	No	Z	%	No	Z	%	No	Z	%
Imipramine	121	71.2				5	38.5	1	20.0	1	33.3	2	40.0	1	50.0	2	66.7	109	86.5								
	40	23.5	11	84.6	4	30.8	2	40.0	1	33.3	3	60.0	1	50.0	1	33.3	17	13.5									
	9	5.3	2	15.4	4	30.8	2	40.0	1	33.3																	
	170	100.0	13	100.0	13	100.0	5	100.0	3	100.0	5	100.0	2	100.0	3	100.0	3	100.0	126	100.0							
Reboxetine	124	71.3				2	40.0	3	37.5	4	36.4			2	40.0	2	50.0	111	86.7								
	33	19.0	5	55.6	3	60.0	4	50.0	2	18.2	2	50.0	2	40.0	1	25.0	14	10.9									
	17	9.8	4	44.4			1	12.5	5	45.5	2	50.0	1	20.0	1	25.0	3	2.3									
	174	100.0	9	100.0	5	100.0	8	100.0	11	100.0	4	100.0	5	100.0	4	100.0	128	100.0									

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 33

CLINICAL GLOBAL IMPRESSION: SEVERITY OF ILLNESS SHIFT TABLE (LAST VALUE VS DAY 0) BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder

Assigned treatment/Severity shift	Total			Last visit																							
	No	Z	%	Day 7			Day 14			Day 21			Day 28			Day 35			Day 42			Day 49			Day 56		
				No	Z	%	No	Z	%	No	Z	%	No	Z	%	No	Z	%	No	Z	%	No	Z	%	No	Z	%
Imipramine	72	66.1		5	45.5	1	20.0	1	33.3	2	40.0	1	50.0	2	66.7	60	85.7	2	66.7	60	85.7	2	66.7	60	85.7		
	30	27.5	8	80.0	4	36.4	2	40.0	1	33.3	3	60.0	1	50.0	1	33.3	10	14.3	1	33.3	10	14.3	1	33.3	10	14.3	
	7	6.4	2	20.0	2	18.2	2	40.0	1	33.3																	
	109	100.0	10	100.0	11	100.0	5	100.0	3	100.0	5	100.0	2	100.0	3	100.0	70	100.0	3	100.0	70	100.0	3	100.0	70	100.0	
Reboxetine	73	68.2		1	33.3	2	33.3	1	20.0							1	25.0	2	66.7	66	85.7	2	66.7	66	85.7		
	21	19.6	3	50.0	2	66.7	3	50.0	1	20.0	2	66.7	2	50.0	2	50.0	8	10.4	2	50.0	8	10.4	2	50.0	8	10.4	
	13	12.1	3	50.0			1	16.7	3	60.0	1	33.3	1	25.0	1	33.3	3	3.9	1	25.0	3	3.9	1	33.3	3	3.9	
	107	100.0	6	100.0	3	100.0	6	100.0	5	100.0	3	100.0	4	100.0	3	100.0	77	100.0	4	100.0	77	100.0	3	100.0	77	100.0	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 33

CLINICAL GLOBAL IMPRESSION: SEVERITY OF ILLNESS SHIFT TABLE (LAST VALUE VS DAY 0) BY ASSIGNED TREATMENT

Diagnosis: Dysthymia

Assigned treatment/Severity shift	Total			Last visit																							
	No	Z	%	Day 7			Day 14			Day 21			Day 28			Day 35			Day 42			Day 49			Day 56		
				No	Z	%	No	Z	%	No	Z	%	No	Z	%	No	Z	%	No	Z	%	No	Z	%	No	Z	%
Imipramine	DECREASED	49	80.3																								
	NO CHANGE	10	16.4	3	100.0																				49	87.5	
	INCREASED	2	3.3			2	100.0																		7	12.5	
	Total	61	100.0	3	100.0	2	100.0																		56	100.0	
Reboxetine	DECREASED	51	76.1			1	50.0	1	50.0	1	50.0	3	50.0														
	NO CHANGE	12	17.9	2	66.7	1	50.0	1	50.0	1	50.0	1	16.7											1	100.0	6	11.8
	INCREASED	4	6.0	1	33.3							2	33.3														
	Total	67	100.0	3	100.0	2	100.0	2	100.0	2	100.0	6	100.0	1	100.0	1	100.0	1	100.0						1	100.0	51

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 34

CLINICAL GLOBAL IMPRESSION: GLOBAL IMPROVEMENT ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Diagnosis: Total

Assigned treatment/Global improvement	Visit																
	Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	
Imipramine			5	3.2	14	9.7	27	19.4	44	33.1	52	40.3	59	46.5	66	52.4	
		12	7.1	39	24.8	50	34.7	61	43.9	43	32.3	43	33.3	39	30.7	33	26.2
		52	30.6	53	33.8	41	28.5	31	22.3	30	22.6	26	20.2	22	17.3	20	15.9
		88	51.8	47	29.9	33	22.9	15	10.8	9	6.8	6	4.7	6	4.7	6	4.8
		13	7.6	8	5.1	5	3.5	5	3.6	4	3.0	1	0.8			1	0.8
		5	2.9	4	2.5	1	0.7			3	2.3						
			1	0.6													
Total	170	100.0	157	100.0	144	100.0	139	100.0	133	100.0	129	100.0	127	100.0	126	100.0	
Reboxetine		2	1.2	5	3.0	13	8.1	21	13.8	30	21.4	33	24.3	52	39.7	52	40.6
		17	9.8	29	17.6	44	27.5	49	32.2	55	39.3	59	43.4	40	30.5	42	32.8
		42	24.3	66	40.0	54	33.8	49	32.2	36	25.7	28	20.6	24	18.3	18	14.1
		97	56.1	49	29.7	35	21.9	23	15.1	13	9.3	14	10.3	13	9.9	12	9.4
		9	5.2	11	6.7	10	6.3	5	3.3	3	2.1	1	0.7	2	1.5	1	0.8
		4	2.3	5	3.0	4	2.5	3	2.0	2	1.4	1	0.7			3	2.3
	2	1.2					2	1.3	1	0.7							
Total	173	100.0	165	100.0	160	100.0	152	100.0	140	100.0	136	100.0	131	100.0	128	100.0	

3 of 3

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 34

CLINICAL GLOBAL IMPRESSION: GLOBAL IMPROVEMENT ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder

Assigned treatment/Global improvement	Visit																
	Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	
Imipramine	VERY MUCH IMPROVED		2	2.0	2	2.3	13	15.7	23	29.5	28	38.4	34	47.9	38	54.3	
	MUCH IMPROVED	8	7.3	23	23.2	34	38.6	37	44.6	27	34.6	27	37.0	20	28.2	17	24.3
	MINIMALLY IMPROVED	35	32.1	37	37.4	28	31.8	21	25.3	18	23.1	13	17.8	12	16.9	10	14.3
	NO CHANGE	50	45.9	27	27.3	19	21.6	8	9.6	4	5.1	3	4.1	4	5.6	4	5.7
	MINIMALLY HORSE	12	11.0	6	6.1	4	4.5	4	4.8	3	3.8	1	1.4			1	1.4
	MUCH HORSE	4	3.7	3	3.0	1	1.1			3	3.8						
	VERY MUCH HORSE			1	1.0							1	1.4	1	1.4		
Total	109	100.0	99	100.0	88	100.0	83	100.0	78	100.0	75	100.0	71	100.0	70	100.0	
Reboxetine	VERY MUCH IMPROVED	2	1.9	4	4.0	6	6.1	11	12.0	16	18.6	20	23.8	32	40.0	30	39.0
	MUCH IMPROVED	13	12.1	18	17.8	29	29.6	33	35.9	35	40.7	36	42.9	27	33.8	29	37.7
	MINIMALLY IMPROVED	27	25.2	42	41.6	32	32.7	27	29.3	24	27.9	18	21.4	13	16.2	9	11.7
	NO CHANGE	54	50.5	27	26.7	21	21.4	15	16.3	5	5.8	9	10.7	7	8.8	6	7.8
	MINIMALLY HORSE	6	5.6	6	5.9	6	6.1	2	2.2	3	3.5			1	1.2		
	MUCH HORSE	3	2.8	4	4.0	4	4.1	3	3.3	2	2.3	1	1.2			3	3.9
	VERY MUCH HORSE	2	1.9					1	1.1	1	1.2						
Total	107	100.0	101	100.0	98	100.0	92	100.0	86	100.0	84	100.0	80	100.0	77	100.0	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No. : 34

CLINICAL GLOBAL IMPRESSION: GLOBAL IMPROVEMENT ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Diagnosis: Dysthymia

Assigned treatment/Global improvement	Visit																
	Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	
Imipramine	VERY MUCH IMPROVED		3	5.2	12	21.4	14	25.0	21	38.2	24	42.9	25	44.6	28	50.0	
	MUCH IMPROVED		4	6.6	16	27.6	16	28.6	24	42.9	16	28.6	19	33.9	16	28.6	
	MINIMALLY IMPROVED		17	27.9	16	27.6	13	23.2	10	17.9	12	21.8	13	23.2	10	17.9	
	NO CHANGE		38	62.3	20	34.5	14	25.0	7	12.5	5	9.1	3	5.4	2	3.6	
	MINIMALLY WORSE		1	1.6	2	3.4	1	1.8	1	1.8	1	1.8					
Reboxetine	MUCH WORSE		1	1.6	1	1.7											
	Total		61	100.0	58	100.0	56	100.0	56	100.0	55	100.0	56	100.0	56	100.0	
	VERY MUCH IMPROVED		4	6.1	11	17.2	15	24.2	16	26.7	20	37.0	23	44.2	13	25.5	
	MUCH IMPROVED		15	22.7	24	37.5	22	35.5	22	36.7	12	22.2	10	19.2	11	21.6	
	MINIMALLY IMPROVED		43	65.2	22	36.4	14	22.6	8	13.3	8	14.8	5	9.6	6	11.8	
Total	MINIMALLY WORSE		3	4.5	5	7.8	4	6.5	3	5.0			1	1.9	1	2.0	
	MUCH WORSE		1	1.5	1	1.6											
	VERY MUCH WORSE																
Total		66	100.0	64	100.0	62	100.0	60	100.0	54	100.0	52	100.0	51	100.0	51	100.0

345

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 35

CLINICAL GLOBAL IMPRESSION: GLOBAL IMPROVEMENT AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Diagnosis: Total

Assigned treatment/Global improvement	Total			Last visit																	
	No	X	Z	Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
				No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z		
Imipramine	VERY MUCH IMPROVED	67	39.4																		
	MUCH IMPROVED	34	20.0									1	20.0				1	33.3	66	52.4	
	MINIMALLY IMPROVED	28	16.5			5	38.5	1	20.0								1	33.3	33	26.2	
	NO CHANGE	21	12.4	7	53.8	2	15.4	1	20.0	2	66.7	2	40.0	1	50.0	1	50.0		6	4.8	
	MINIMALLY WORSE	13	7.6	4	30.8	3	23.1	3	60.0	1	33.3	1	20.0						1	0.8	
	MUCH WORSE	5	2.9	2	15.4							1	20.0								
	VERY MUCH WORSE	2	1.2			1	7.7											1	33.3		
Total	170	100.0	13	100.0	13	100.0	5	100.0	3	100.0	5	100.0	2	100.0	2	100.0	3	100.0	126	100.0	
Reboxetine	VERY MUCH IMPROVED	53	30.5																		
	MUCH IMPROVED	46	26.4					1	12.5									1	25.0	52	40.6
	MINIMALLY IMPROVED	26	14.9			1	20.0	2	25.0	2	18.2						2	40.0	42	32.8	
	NO CHANGE	26	14.9	4	44.4	3	60.0	2	25.0	3	27.3	2	50.0				2	40.0	18	14.1	
	MINIMALLY WORSE	12	6.9	3	33.3	1	20.0	2	25.0	3	27.3	1	25.0						12	9.4	
	MUCH WORSE	8	4.6	1	11.1			1	12.5	1	9.1	1	25.0	1	20.0			1	25.0	1	0.8
	VERY MUCH WORSE	3	1.7	1	11.1						2	18.2								3	2.3
Total	174	100.0	9	100.0	5	100.0	8	100.0	11	100.0	4	100.0	5	100.0	5	100.0	4	100.0	128	100.0	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOSETINE - PROTOCOL 20124/035
TABLE No. : 35

CLINICAL GLOBAL IMPRESSION: GLOBAL IMPROVEMENT AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder

Assigned treatment/Global improvement	Total			Last visit																	
	No	Z	%	Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
				No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z		
Imipramine	VERY MUCH IMPROVED	39	35.8													1	33.3	38	54.3		
	MUCH IMPROVED	18	16.5									1	20.0					17	24.3		
	MINIMALLY IMPROVED	18	16.5			5	45.5	1	20.0							1	33.3	10	14.3		
	NO CHANGE	16	14.7	4	40.0	2	18.2	1	20.0	2	66.7	2	40.0	1	50.0			4	5.7		
	MINIMALLY WORSE	12	11.0	4	40.0	2	18.2	3	60.0	1	33.3	1	20.0					1	1.4		
	MUCH WORSE	4	3.7	2	20.0	1	9.1					1	20.0								
	VERY MUCH WORSE	2	1.8			1	9.1									1	33.3				
	Total	109	100.0	10	100.0	11	100.0	5	100.0	3	100.0	5	100.0	2	100.0	3	100.0	70	100.0		
Reboxetine	VERY MUCH IMPROVED	31	29.0															1	33.3		
	MUCH IMPROVED	32	29.9					1	16.7						1	25.0	1	33.3	29	37.7	
	MINIMALLY IMPROVED	12	11.2					1	16.7					2	50.0			9	11.7		
	NO CHANGE	16	15.0	3	50.0	2	66.7	2	33.3	2	40.0	1	33.3					6	7.8		
	MINIMALLY WORSE	6	5.6	1	16.7	1	33.3	1	16.7	1	20.0	1	33.3				1	33.3			
	MUCH WORSE	8	7.5	1	16.7			1	16.7	1	20.0	1	33.3	1	25.0			3	3.9		
	VERY MUCH WORSE	2	1.9	1	16.7					1	20.0										
	Total	107	100.0	6	100.0	3	100.0	6	100.0	5	100.0	3	100.0	4	100.0	3	100.0	77	100.0		

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Pharmacia CNS R&D

Reboxetine - Protocol 20124/035

TABLE No. : 36

CGI AT LAST ASSESSMENT: FREQUENCY OF MUCH AND VERY MUCH IMPROVED IN THE TWO TREATMENT GROUPS

Diagnosis	Treatment	Number of patients assessed	Number of patients improved (%)	Between treatment difference (95% C.I.)
Major depressive episodes	Reboxetine	107	63 (58.9%)	6.6% (-6.0 + 19.8)
	Imipramine	109	57 (52.3%)	
Dysthymia	Reboxetine	67	36 (53.7%)	-18.4% (-2.0 + -34.8)
	Imipramine	61	44 (72.1%)	
Total	Reboxetine	174	99 (56.9%)	-2.5% (-12.9 + 7.9)
	Imipramine	170	101 (59.4%)	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 57

CLINICAL GLOBAL IMPRESSION: EFFICACY INDEX ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Diagnosis: Total

Assigned treatment / Efficacy index (*)	Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	
Imipramine	< 1	53	31.2	28	17.8	18	12.5	14	10.1	9	6.8	4	3.1	6	4.7	6	4.8
	1	74	43.5	54	34.4	37	25.7	17	12.2	19	14.3	12	9.3	6	4.7	6	4.8
	1.33 - 1.5	2	1.2	17	10.8	21	14.6	24	17.3	12	9.0	7	5.4	8	6.3	4	3.2
	2	30	17.6	32	20.4	33	22.9	38	27.3	44	33.1	47	36.4	39	30.7	40	31.7
	3	9	5.3	21	13.4	24	16.7	29	20.9	24	18.0	25	19.4	24	18.9	17	13.5
4	2	1.2	5	3.2	11	7.6	17	12.2	25	18.8	34	26.4	44	34.6	53	42.1	
Total	170	100	157	100	144	100	139	100	133	100	129	100	127	100	126	100	
Reboxetine	< 1	42	24.3	27	16.4	20	13.2	9	6.4	10	7.4	7	5.3	6	4.7	6	4.7
	1	88	50.9	72	43.6	57	35.6	30	19.7	29	20.7	18	13.2	18	13.7	17	13.3
	1.33 - 1.5	6	3.5	8	4.8	13	8.1	18	11.8	14	10.0	11	8.1	7	5.3	10	7.8
	2	26	15.0	37	22.4	35	21.9	41	27.0	28	20.0	31	22.8	37	28.2	30	23.4
	3	7	4.0	14	8.5	25	15.6	26	17.1	34	24.3	33	24.3	21	16.0	19	14.8
4	4	2.3	7	4.2	10	6.3	17	11.2	26	18.6	33	24.3	41	31.3	46	35.9	
Total	173	100	165	100	160	100	152	100	140	100	136	100	131	100	128	100	

EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBEXETINE - PROTOCOL 20124/035
TABLE No.: 37

CLINICAL GLOBAL IMPRESSION: EFFICACY INDEX ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder

Assigned treatment / Efficacy index (*)	Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	
Imipramine < 1	33	30.3	19	19.2	12	13.6	9	10.8	6	7.7	2	2.7	4	5.6	4	5.7	
	49	45.0	36	36.4	25	28.4	13	15.7	12	15.4	7	9.6	3	4.2	3	4.3	
	1.33 - 1.5	2	1.8	9	9.1	13	14.8	16	19.3	7	9.0	5	6.8	6	8.5	3	4.3
	2	18	16.5	19	19.2	15	17.0	19	22.9	24	30.8	25	34.2	21	29.6	22	31.4
	3	6	5.5	13	13.1	18	20.5	19	22.9	14	17.9	15	20.5	11	15.5	7	10.0
4	1	0.9	3	3.0	5	5.7	7	8.4	15	19.2	19	26.0	26	36.6	31	44.3	
Total	109	100	99	100	88	100	83	100	78	100	73	100	71	100	70	100	
Reboxetine < 1	25	23.4	17	16.8	11	11.2	14	15.2	7	8.1	8	9.5	6	7.5	5	6.5	
	52	48.6	37	36.6	35	35.7	16	17.4	17	19.8	10	11.9	8	10.0	8	10.4	
	1.33 - 1.5	5	4.7	6	5.9	8	8.2	11	12.0	11	12.8	9	10.7	6	7.5	8	10.4
	2	18	16.8	29	28.7	23	23.5	21	22.8	12	14.0	16	19.0	19	23.7	16	20.8
	3	5	4.7	8	7.9	16	16.3	19	20.7	24	27.9	20	23.8	16	20.0	13	16.9
4	2	1.9	4	4.0	5	5.1	11	12.0	15	17.4	21	25.0	25	31.3	27	35.1	
Total	107	100	101	100	98	100	92	100	86	100	84	100	80	100	77	100	

EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 37

CLINICAL GLOBAL IMPRESSION: EFFICACY INDEX ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Diagnosis: Dysthymia

Assigned treatment / Efficacy index (*)	Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	
Imipramine < 1	20	32.8	9	15.5	6	10.7	5	8.9	3	5.5	2	3.6	2	3.6	2	3.6	
	25	41.0	18	31.0	12	21.4	4	7.1	7	12.7	5	8.9	3	5.4	3	5.4	
	1.33 - 1.5		8	13.8	8	14.3	8	14.3	5	9.1	2	3.6	2	3.6	1	1.8	
	Total	12	19.7	13	22.4	18	32.1	19	33.9	20	36.4	22	39.3	18	32.1	18	32.1
Reboxetine < 1	3	4.9	8	13.8	6	10.7	10	17.9	10	18.2	10	17.9	13	23.2	10	17.9	
	1	1.6	2	3.4	6	10.7	10	17.9	10	18.2	15	26.8	18	32.1	22	39.3	
	Total	61	100	58	100	56	100	56	100	55	100	56	100	56	100	56	100
	17	25.8	10	15.6	9	14.5	6	10.0	2	3.7	2	3.8	1	2.0	1	2.0	
1.33 - 1.5	36	54.5	35	54.7	22	35.5	14	23.3	12	22.2	8	15.4	10	19.6	9	17.6	
	1	1.5	2	3.1	5	8.1	7	11.7	3	5.6	2	3.8	1	2.0	2	3.9	
	8	12.1	8	12.5	12	19.4	20	33.3	16	29.6	15	28.8	18	35.3	14	27.5	
	Total	2	3.0	6	9.4	9	14.5	7	11.7	10	18.5	13	25.0	5	9.8	6	11.8
Total	2	3.0	3	4.7	5	8.1	6	10.0	11	20.4	12	23.1	16	31.4	19	37.3	
	66	100	64	100	62	100	60	100	54	100	52	100	51	100	51	100	

EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No. : 38

CLINICAL GLOBAL IMPRESSION: EFFICACY INDEX AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Diagnosis: Total

Assigned treatment / Efficacy index (*)	total		Last Assessment																	
	No	Z	Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
			No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z		
Imipramine	34	20.00	12	92.31	7	53.85	3	60.00	1	33.33	4	80.00			1	33.33	6	4.76		
1	18	10.59	1	7.69	3	23.08	2	40.00	2	66.67	1	20.00	2	100.0	1	33.33	6	4.76		
1.33 - 1.5	5	2.94													1	33.33	4	3.17		
2	43	25.29			3	23.08											40	31.75		
3	17	10.00															17	13.49		
4	53	31.16															53	42.06		
Total	170	100.0	13	100.0	13	100.0	5	100.0	3	100.0	5	100.0	2	100.0	3	100.0	126	100.0		
Reboxetine	30	17.24	6	66.67	3	60.00	5	62.50	6	54.55	3	75.00	1	20.00			6	4.69		
1	33	18.97	3	33.33	2	40.00	2	25.00	5	45.45	1	25.00	2	40.00	1	25.00	17	13.28		
1.33 - 1.5	11	6.32												1	20.00		10	7.81		
2	31	17.82														1	25.00	30	23.44	
3	21	12.07					1	12.50								1	25.00	19	14.84	
4	48	27.59														1	20.00	46	35.94	
Total	174	100.0	9	100.0	5	100.0	8	100.0	11	100.0	4	100.0	5	100.0	4	100.0	123	100.0		

EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 38

CLINICAL GLOBAL IMPRESSION: EFFICACY INDEX AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder

Assigned treatment / Efficacy index (*)	total		Last Assessment																	
	No	z	Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
			No	z	No	z	No	z	No	z	No	z	No	z	No	z	No	z		
Imipramine																				
< 1	27	24.77	9	90.00	5	45.45	3	60.00	1	33.33	4	80.00			1	33.33	4	5.71		
1	15	13.76	1	10.00	3	27.27	2	40.00	2	66.67	1	20.00	2	100.0	1	33.33	3	4.29		
1.33 - 1.5	4	3.67													1	33.33	3	4.29		
2	25	22.94			3	27.27											22	31.43		
3	7	6.42															7	10.00		
4	31	28.44															31	44.29		
Total	109	100.0	10	100.0	11	100.0	5	100.0	3	100.0	5	100.0	2	100.0	3	100.0	70	100.0		
Reboxetine																				
< 1	23	21.50	5	83.33	3	100.0	3	50.00	4	80.00	2	66.67	1	25.00			5	6.49		
1	16	14.95	1	16.67			2	33.33	1	20.00	1	33.33	2	50.00	1	33.33	8	10.39		
1.33 - 1.5	9	8.41											1	25.00			8	10.39		
2	16	14.95															16	20.78		
3	15	14.02					1	16.67								1	33.33	13	16.88	
4	28	26.17														1	33.33	27	35.06	
Total	107	100.0	6	100.0	3	100.0	6	100.0	5	100.0	3	100.0	4	100.0	3	100.0	77	100.0		

EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 36

CLINICAL GLOBAL IMPRESSION: EFFICACY INDEX AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Diagnosis: Dysthymia

Assigned treatment / Efficacy index (*)	total		Last Assessment																	
	No	%	Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
			No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%		
Imipramine			3	100.0	2	100.0												2	3.57	
	1	3	4.92															3	5.36	
1.33 - 1.5	1	1.64																1	1.79	
2	18	29.51																18	32.14	
3	10	16.39																10	17.86	
4	22	36.07																22	39.29	
Total	61	100.0	3	100.0	2	100.0												56	100.0	
Reboxetine			1	33.33			2	100.0	2	33.33	1	100.0						1	1.96	
1	17	25.37	2	66.67	2	100.0			4	66.67								9	17.65	
1.33 - 1.5	2	2.99																2	3.92	
2	15	22.39																14	27.45	
3	6	8.96																6	11.76	
4	20	29.85																19	37.25	
Total	67	100.0	3	100.0	2	100.0	2	100.0	6	100.0	1	100.0	1	100.0	1	100.0	1	51	100.0	

C2
C2
C2

EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 39

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON TOTAL SCORE ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Diagnosis: Total

	Time table assessment																		
	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	
Assigned treatment																			
	Imipramine	No	168	167	157	144	139	132	129	126									
		Mean	30.02	27.26	22.95	19.31	15.80	13.08	11.02	8.85									
		STD	7.36	8.03	9.38	9.96	9.72	9.84	9.53	8.74									
		Median	30	27	23	18	15	11	9	7									
Min		10	8	0	0	0	0	0	0										
Max	48	54	46	46	37	35	51	48	35										
Reboxetine	No	171	170	164	158	151	138	134	128										
	Mean	29.65	26.68	23.62	21.20	18.62	15.19	13.22	11.73										
	STD	7.44	8.25	8.53	10.00	10.42	10.07	9.43	9.71										
	Median	29	26	23	21	18	14	12	11										
	Min	7	5	3	1	0	0	0	0										
Max	48	48	46	46	42	40	36	38	42										

Median (x): median of differences vs day0
Median (z): median of percent differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 39

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON TOTAL SCORE ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder

Assigned treatment	Time table assessment													
	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56					
Imipramine	No	108	107	99	88	83	77	73	71	70				
	Mean	31.18	28.58	24.03	20.67	16.86	13.71	11.34	9.99	9.13				
	STD	6.82	8.03	8.81	9.27	9.35	9.70	9.85	9.89	8.87				
	Median	31	29	25	20	16	12	9	7	7				
	Min	15	8	2	0	0	0	0	0	0				
	Max	48	54	46	46	37	35	51	48	35				
Reboxetine	No	104	104	100	96	91	84	83	80	77				
	Mean	30.71	27.36	24.19	21.92	19.09	15.99	14.07	12.24	11.94				
	STD	7.66	8.71	8.97	10.45	10.83	10.77	10.13	10.45	11.04				
	Median	31	28	25	21	18	16	14	11	8				
	Min	7	5	3	1	0	0	0	0	0				
	Max	48	45	43	46	42	40	36	38	42				

Median (*): median of differences vs day0
Median (x): median of percent differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 59

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON TOTAL SCORE ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Diagnosis: Dysthymia

Assigned treatment	Time table assessment																			
	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56		
Imipramine	No	60	60	58	56	55	56	56	56	60	60	58	56	55	56	56	56	56	56	
	Mean	27.93	24.90	21.10	17.16	14.23	12.18	10.61	8.50	27.93	24.90	21.10	17.16	14.23	12.18	10.61	9.54	8.50	8.50	
	STD	7.89	7.53	10.09	10.69	10.13	10.05	9.16	8.22	8.64	7.89	7.53	10.09	10.69	10.13	10.05	9.16	8.22	8.64	8.64
	Median	28	26	20	15	12	9	7	6	6	28	26	20	15	12	9	7	6	6	6
	Min	10	8	0	0	0	0	0	0	0	10	8	0	0	0	0	0	0	0	0
Reboxetine	Max	47	46	46	46	37	34	29	33	47	46	46	46	37	34	29	29	29	33	
	No	67	66	64	62	60	54	51	51	67	66	64	62	60	54	51	51	51	51	
	Mean	28.01	25.62	22.72	20.10	17.92	13.94	11.84	11.41	11.41	28.01	25.62	22.72	20.10	17.92	13.94	11.84	12.35	11.41	11.41
	STD	6.81	7.42	7.76	9.23	9.61	8.83	8.09	8.06	8.06	6.81	7.42	7.76	9.23	9.61	8.83	8.09	8.50	8.50	8.06
	Median	28	25	23	20	18	13	11	10	10	28	25	23	20	18	13	11	11	11	10
Min	9	9	6	2	0	0	0	0	0	9	9	6	2	0	0	0	0	0	0	
Max	47	48	46	46	42	37	31	32	31	47	48	46	46	42	37	31	31	32	31	

Median (*): median of differences vs day0
Median (x): median of percent differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOZETINE - PROTOCOL 20124/03S

TABLE No. : 40

HUNTCOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON TOTAL SCORE AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Diagnosis: Total

	Total	Last assessment													
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56						
Assigned treatment															
Imipramine	No	168	11	13	5	3	5	2	3	126					
	Mean	14.02	30.82	29.54	32.40	35.33	26.20	21.00	25.67	8.85					
	STD	12.76	8.34	9.92	9.56	1.53	9.98	1.44	23.59	8.74					
	Median	10	30	30	32	35	29	21	28	6					
	Min	0	15	15	23	34	10	20	1	0					
	Max	48	46	43	46	37	35	22	48	35					
Rebozetine	No	171	7	6	7	12	3	4	4	128					
	Mean	15.51	31.29	26.00	24.71	29.83	32.33	18.00	19.00	11.73					
	STD	11.77	7.23	5.48	9.32	7.48	4.51	13.22	14.74	9.93					
	Median	12	30	25	23	31	32	17	20	10					
	Min	0	22	20	8	18	28	5	0	0					
	Max	45	45	33	37	42	37	33	36	42					

Median (*): median of differences vs day0
Median (Z): median of percent differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 40

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON TOTAL SCORE AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder

Assigned treatment	Total	Last assessment										
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56			
Imipramine	No	108	9	11	5	3	5	2	3	70		
	Mean	16.36	32.67	28.73	32.40	35.33	26.20	21.00	25.67	9.13		
	STD	13.58	7.19	10.61	9.56	1.53	9.98	1.41	23.59	8.87		
	Median	12	30	28	32	35	29	21	28	7		
	Min	0	26	15	23	34	10	20	1	0		
	Max	48	46	43	46	37	35	22	48	35		
Reboxetine	No	104	4	4	5	6	2	3	3	77		
	Mean	16.07	34.00	25.00	25.80	34.00	30.00	22.33	18.67	11.94		
	STD	12.85	8.08	5.94	11.17	5.33	2.83	12.22	18.04	11.04		
	Median	12	32	24	29	35	30	25	20	8		
	Min	0	27	20	8	26	28	9	0	0		
	Max	45	45	33	37	42	32	33	36	42		

Median (x): median of differences vs day0
Median (z): median of percent differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No. : 40

MONTGOMERY ASBERG DEPRESSION RATING SCALE
SUMMARY STATISTICS ON TOTAL SCORE AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Diagnosis: Dysthymia

	Assigned treatment										Last assessment										
	Total	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56		Total	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56		
Imipramine	No	60	2	2																56	
	Mean	9.82	22.50	34.00																	8.50
	STD	9.93	10.61	2.83																	8.64
	Median	6	23	34																	6
	Min	0	15	32																	0
	Max	36	30	36																	33
Reboxetine	No	67	3	2	2	6	1	1	1	1	1	1	1	1	1	1	1	1	1	51	
	Mean	14.64	27.67	28.00	22.00	25.67	37.00	5.00	20.00	11.41											8.06
	STD	9.89	4.93	5.66	1.41	7.28															
	Median	12	30	28	22	26	37	5	20	10											
	Min	0	22	24	21	18	37	5	20	0											
	Max	37	31	32	23	36	37	5	20	31											

Median (*): median of differences vs day0
Median (%): median of percent differences vs day0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 41

GERIATRIC DEPRESSION RATING SCALE: SUMMARY STATISTICS ON TOTAL SCORE ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT
 Diagnosis: Total

	Visit																	
	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56
Imipramine	No	168	167	156	144	138	126	126	125	168	167	156	144	138	126	126	126	125
	Mean	23.37	22.34	19.51	17.50	15.51	13.51	11.29	10.43	23.37	22.34	19.51	17.50	15.51	13.51	11.29	10.43	9.18
	STD	4.52	5.10	7.20	7.82	8.09	8.76	8.06	7.83	4.52	5.10	7.20	7.82	8.09	8.76	8.06	7.83	7.76
	Median	24.00	23.00	20.00	18.50	16.00	13.50	10.50	10.00	24.00	23.00	20.00	18.50	16.00	13.50	10.50	10.00	8.00
	Min	7	8	0	0	0	0	0	0	7	8	0	0	0	0	0	0	0
Reboxetine	Max	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30
	No	172	170	164	159	151	138	134	128	172	170	164	159	151	138	134	130	128
	Mean	23.13	21.92	20.67	19.08	17.11	14.57	12.84	11.38	23.13	21.92	20.67	19.08	17.11	14.57	12.84	12.18	11.38
	STD	4.74	6.02	6.36	7.00	7.76	7.99	7.79	8.06	4.74	6.02	6.36	7.00	7.76	7.99	7.79	8.06	8.13
	Median	24.00	23.00	21.00	19.00	17.00	15.00	13.00	11.50	24.00	23.00	21.00	19.00	17.00	15.00	13.00	11.50	10.00
Min	1	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	
Max	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PEARACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 41

GERIATRIC DEPRESSION RATING SCALE: SUMMARY STATISTICS ON TOTAL SCORE ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder

		Visit											
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56			
Imipramine	No	108	107	98	88	83	77	72	70	69			
	Mean	23.64	22.78	19.83	18.15	16.13	13.84	11.44	10.57	9.32			
	STD	4.24	5.14	6.98	7.34	8.13	8.82	8.40	8.56	8.27			
	Median	24.00	24.00	21.00	19.00	18.00	14.00	11.00	10.00	8.00			
	Min	13	8	3	1	0	0	0	0	0			
Reboxetine	No	30	30	30	30	30	30	30	30	30			
	Mean	23.25	21.41	20.39	18.99	17.11	14.91	12.89	11.95	11.52			
	STD	4.54	6.48	6.72	7.54	8.33	8.75	8.70	8.67	9.01			
	Median	24.00	23.00	21.00	19.00	17.00	16.00	13.00	10.50	9.00			
	Min	10	2	0	0	0	0	0	0	0			
Max	30	30	30	30	30	30	30	30	30	30			

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 41

GERIATRIC DEPRESSION RATING SCALE: SUMMARY STATISTICS ON TOTAL SCORE ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Diagnosis: Dysthymia

	Visit																	
	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56
Imipramine	No	60	60	58	56	55	55	54	56	56	56	56	56	55	55	54	56	56
	Mean	22.88	21.55	18.97	16.48	14.58	13.04	11.09	10.25	9.00	9.00	9.00	9.00	8.03	8.73	7.66	6.88	7.15
	STD	4.98	4.96	7.59	8.47	8.03	8.73	7.66	6.88	7.15	7.15	7.15	7.15	8.03	8.73	7.66	6.88	7.15
	Median	23.00	21.00	19.00	16.50	15.00	12.00	10.00	10.00	8.00	8.00	8.00	8.00	10.00	10.00	10.00	10.00	10.00
	Min	7	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Reboxetine	No	30	30	30	30	30	30	30	29	29	29	29	29	30	30	30	30	29
	Mean	22.96	22.74	21.13	19.21	17.12	14.04	12.76	12.56	11.18	11.18	11.18	11.18	17.12	14.04	12.76	12.56	11.18
	STD	5.07	5.13	5.75	6.48	6.84	6.62	6.12	6.05	6.69	6.69	6.69	6.69	6.84	6.62	6.12	7.05	6.69
	Median	23.00	24.00	21.00	19.00	17.00	14.00	13.00	12.00	11.00	11.00	11.00	11.00	13.00	14.00	13.00	12.00	11.00
	Min	1	1	3	0	1	0	0	0	0	0	0	0	1	0	0	0	0
Max	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 42

GERIATRIC DEPRESSION RATING SCALE: SUMMARY STATISTICS ON TOTAL SCORE AT LAST ASSESSMENT BY ASSIGNED TREATMENT

	Baseline		Last Assessment																
	Day 0	Total	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	
Imipramine	No	168	168	12	12	5	3	5	2	4	125								
	Mean	23.37	12.89	25.00	22.92	24.00	27.00	25.40	23.50	17.25	9.18								
	STD	4.52	9.70	4.92	5.84	4.18	2.65	5.03	2.12	11.90	7.76								
	Median	24.00	10.50	26.50	24.50	25.00	28.00	27.00	23.50	16.50	8.00								
	Min	7	0	14	14	18	24	17	22	7	0								
	Max	30	30	30	30	29	29	30	30	29	30								
Reboxetine	No	172	172	7	6	8	11	4	4	128									
	Mean	23.13	13.95	21.29	23.67	21.25	24.36	25.75	13.25	14.25	11.38								
	STD	4.74	8.87	5.28	3.88	3.49	4.72	5.19	7.68	9.74	8.13								
	Median	24.00	13.00	22.00	23.00	20.50	25.00	28.00	12.50	17.50	10.00								
	Min	1	0	12	20	17	13	18	5	0	0								
	Max	30	30	28	30	27	30	29	23	22	30								

Diagnosis: Total

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 42

GERIATRIC DEPRESSION RATING SCALE: SUMMARY STATISTICS ON TOTAL SCORE AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Diagnosis: Major Depressive Disorder

	Baseline		Last Assessment											
	Day 0	Total	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	Day 70	Day 77	
Imipramine	No	108	10	10	5	3	5	2	4	69				
	Mean	23.64	14.54	26.50	21.80	24.00	27.00	25.40	23.50	17.25	9.32			
	STD	4.24	10.23	3.44	5.77	4.18	2.65	5.03	2.12	11.90	8.27			
	Median	24.00	15.00	27.00	21.00	25.00	28.00	27.00	23.50	16.50	8.00			
	Min	13	0	21	14	18	24	17	22	7	0			
	Max	30	30	30	30	29	29	30	25	29	30			
Reboxetine	No	105	4	4	5	6	3	3	3	77				
	Mean	23.25	14.18	22.50	24.00	22.20	24.83	24.67	14.33	13.00	11.52			
	STD	4.54	9.60	4.51	4.90	3.70	6.15	5.77	9.02	11.53	9.01			
	Median	24.00	13.00	22.50	23.00	21.00	26.00	28.00	15.00	17.00	9.00			
	Min	10	0	17	20	18	13	18	5	0	0			
	Max	30	30	28	30	27	30	28	23	22	30			

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 42

GERIATRIC DEPRESSION RATING SCALE: SUMMARY STATISTICS ON TOTAL SCORE AT LAST ASSESSMENT BY ASSIGNED TREATMENT

Diagnosis: Dysthymia

	Baseline		Last Assessment												
	Day 0	Total	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	Day 70	Day 77	Day 84	
Imipramine	No	60	2	2											56
	Mean	22.88	17.50	28.50											9.00
	STD	4.98	4.95	0.71											7.15
	Median	23.00	17.50	28.50											8.00
	Min	7	0	14	28										0
	Max	30	29	21	29										29
Reboxetine	No	67	3	2	3	5	1	1	1	1	1	1	1	1	51
	Mean	22.96	13.58	19.67	23.00	19.67	23.80	29.00	10.00	18.00	11.18				
	STD	5.07	7.66	6.81	1.41	3.06	2.77				6.69				
	Median	23.00	13.00	22.00	23.00	19.00	23.00	29.00	10.00	18.00	11.00				
	Min	1	0	12	22	17	21	29	10	18	0				
	Max	30	30	25	24	23	28	29	10	18	30				

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 43

ADVERSE EVENTS: FREQUENCY (95% C.I.) OF PATIENTS WHO COMPLAINED OF AT LEAST ONE ADVERSE EVENT DURING THERAPY BY SEX AND ASSIGNED TREATMENT

	Assigned treatment					
	Imipramine			Reboxetine		
	Female	Male	Total	Female	Male	Total
Pt exposed	126	45	171	137	39	176
Pt with adverse events	88	34	122	93	27	120
% on exposed	69.84	75.55	71.34	67.88	69.23	68.18
95% L.L.	61.03	60.46	63.94	59.37	52.43	60.75
95% U.L.	77.69	87.12	77.99	75.60	82.98	74.99
No. of adverse events	247	91	338	249	58	307
Ratio A.E. on Pt with A.E.	2.80	2.67	2.77	2.67	2.14	2.55

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS 88D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 44

ADVERSE EVENTS: FREQUENCY (95% C.I.) OF PATIENTS WHO COMPLAINED OF AT LEAST ONE ADVERSE EVENT DURING THERAPY BY AGE AND ASSIGNED TREATMENT

	Assigned treatment							
	Imipramine				Reboxetine			
	Total	< 70	70 - 79	>= 80	Total	< 70	70 - 79	>= 80
Pt exposed	171	58	65	48	176	68	72	36
Pt with adverse events	122	46	48	28	120	43	50	27
Z on exposed	71.34	79.31	73.84	58.33	68.18	63.23	69.44	75.00
95% L.L.	63.94	66.65	61.46	43.21	60.75	50.67	57.47	57.80
95% U.L.	77.99	88.83	83.97	72.39	74.99	74.61	79.76	87.88
No. of adverse events	338	114	144	80	307	105	139	63
Ratio A.E. on Pt with A.E.	2.77	2.47	3.00	2.85	2.55	2.44	2.78	2.35

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 45

ADVERSE EVENTS: FREQUENCY (95% C.I.) OF PATIENTS WHO COMPLAINED OF AT LEAST ONE ADVERSE EVENT DURING THERAPY BY DSM III CLASSIFICATION AND ASSIGNED TREATMENT

	Assigned treatment									
	Imipramine					Reboxetine				
	Total	296.2	296.3	300.4	Total	296.2	296.3	296.5	300.4	
Pt exposed	171	36	73	62	176	45	65	1	67	
Pt with adverse events	122	30	50	42	120	35	37	0	48	
% on exposed	71.34	83.33	68.49	67.74	68.18	77.77	58.75	0.00	71.64	
95% L.I.	63.94	67.19	56.56	54.66	60.75	62.91	45.62	0.00	59.31	
95% U.I.	77.99	93.63	78.87	79.06	74.99	88.80	70.99	95.00	81.99	
No. of adverse events	338	90	145	103	307	97	96	0	114	
Ratio A.E. on Pt with A.E.	2.77	3.00	2.90	2.45	2.55	2.77	2.59	0	2.37	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT AND SEX

Adverse events/Assigned treatment	Female				Male				Total					
	No of Pt. exp.	% on Pt. with AE	No of AE	Ratio (*): No of AE / % on Pt. with AE	No of Pt. exp.	% on Pt. with AE	No of AE	Ratio (*): No of AE / % on Pt. with AE	No of Pt. exp.	% on Pt. with AE	No of AE	Ratio (*): No of AE / % on Pt. with AE		
Pt exposed	126	100.0			45	100.0			171	100.0				
	137	100.0			39	100.0			176	100.0				
Pt with a.e.	88	69.8	247	2.80	34	75.6	100.0	91	2.67	122	71.3	338	2.77	
	93	67.9	249	2.67	27	69.2	100.0	58	2.14	120	68.2	307	2.55	
MOUTH DRY	28	22.2	31.8	1.07	11	24.4	32.3	13	1.18	39	22.8	43	1.10	
	34	24.8	36.5	1.05	5	12.8	18.5	5	1.00	39	22.2	41	1.05	
CONSTIPATION	24	19.0	27.2	1.25	7	15.6	20.5	12	1.71	31	18.1	25.4	42	1.35
	25	18.2	26.8	1.20	6	15.4	22.2	6	1.00	31	17.6	25.8	36	1.16
NAUSEA	13	10.3	14.7	1.00	4	8.9	11.7	4	1.00	17	9.9	13.9	17	1.00
	13	9.5	13.9	1.00	5	12.8	18.5	5	1.00	18	10.2	15.0	18	1.00
SWEATING INCREASED	13	10.3	14.7	1.07	2	4.4	5.8	2	1.00	15	8.8	12.2	16	1.06
	15	10.9	16.1	1.00	1	2.6	3.7	1	1.00	16	9.1	13.3	16	1.00
DIZZINESS	10	7.9	11.3	1.20	7	15.6	20.5	8	1.14	17	9.9	13.9	20	1.17
	7	5.1	7.5	1.14	4	10.3	14.8	4	1.00	11	6.3	9.1	12	1.09
HEADACHE	7	5.6	7.9	2.05	2	4.4	5.8	2	1.00	9	5.3	7.3	22	2.44
	8	5.8	8.6	1.25	3	7.7	11.1	3	1.00	11	6.3	9.1	13	1.18
INSOMNIA	5	4.0	5.6	1.00						5	2.9	4.0	5	1.00
	9	6.6	9.6	1.33	2	5.1	7.4	3	1.50	11	6.3	9.1	15	1.36
URINARY TRACT INFECTION	10	7.9	11.3	1.00						10	5.8	8.1	10	1.00
	5	3.6	5.3	1.00	1	2.6	3.7	2	2.00	6	3.4	5.0	7	1.16
TREMOR	4	3.2	4.5	1.00	2	4.4	5.8	2	1.00	6	3.5	4.9	6	1.00
	7	5.1	7.5	1.00						7	4.0	5.8	7	1.00

(CONTINUED)

(*): number of adverse events on patients who complained of adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT AND SEX

Adverse events/Assigned treatment	Female				Male				Total			
	No of Pt. exp.	% on Pt. with AE	No of AE	Ratio (x)	No of Pt. exp.	% on Pt. with AE	No of AE	Ratio (x)	No of Pt. exp.	% on Pt. with AE	No of AE	Ratio (x)
VISION ABNORMAL	5	4.0	5.6	1.00	1	2.2	2.9	1.00	6	3.5	4.9	1.00
	5	3.6	5.3	1.00	1	2.6	3.7	1.00	6	3.4	5.0	1.00
SOMNOLENCE	6	4.8	6.8	1.00	1	2.2	2.9	1.00	7	4.1	5.7	1.00
	4	2.9	4.3	1.25					4	2.3	3.3	1.25
MICTURITION DISORDER	1	0.8	1.1	1.00	5	11.1	14.7	1.00	6	3.5	4.9	1.00
	1	0.7	1.0	1.00	4	10.3	14.8	1.00	5	2.8	4.1	1.00
CONFUSION	3	2.4	3.4	1.00	1	2.2	2.9	1.00	4	2.3	3.2	1.00
	5	3.6	5.3	1.00	1	2.6	3.7	1.00	6	3.4	5.0	1.00
ANOREXIA	5	4.0	5.6	1.00					5	2.9	4.0	1.00
	3	2.2	3.2	1.00	1	2.6	3.7	1.00	4	2.3	3.3	1.00
TACHYCARDIA	3	2.4	3.4	1.00	3	6.7	8.8	1.00	6	3.5	4.9	1.00
	1	0.7	1.0	1.00	2	5.1	7.4	1.00	3	1.7	2.5	1.00
ABDOMINAL PAIN	2	1.6	2.2	1.00					2	1.2	1.6	1.00
	7	5.1	7.5	1.00					7	4.0	5.8	1.00
PARESTHESIA	4	3.2	4.5	1.00					4	2.3	3.2	1.00
	2	1.5	2.1	1.00	2	5.1	7.4	1.00	4	2.3	3.3	1.00
AGITATION	4	3.2	4.5	1.00					4	2.3	3.2	1.00
	4	2.9	4.3	1.00					4	2.3	3.3	1.00
FALL	5	4.0	5.6	1.60	1	2.2	2.9	1.00	6	3.5	4.9	1.50
	1	0.7	1.0	1.00	1	2.6	3.7	2.00	2	1.1	1.6	3.00
URINARY RETENTION	2	1.6	2.2	1.00	2	4.4	5.8	1.00	4	2.3	3.2	1.00
	3	2.2	3.2	1.00					3	1.7	2.5	1.00

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT AND SEX

Adverse events/Assigned treatment	Female				Male				Total			
	No of Pt. exp.	% on Pt. with AE	No of AE	Ratio (*): AE	No of Pt. exp.	% on Pt. with AE	No of AE	Ratio (*): AE	No of Pt. exp.	% on Pt. with AE	No of AE	Ratio (*): AE
HYPOTENSION	7	5.6	7.9	1.00	7	1.00	7	1.00	14	4.1	14.6	1.00
FATIGUE	3	2.4	3.4	1.00	3	1.00	3	1.00	6	2.9	6.4	1.00
	2	1.5	2.1	1.00	2	1.00	2	1.00	4	1.1	4.2	1.00
BRONCHITIS	3	2.4	3.4	1.00	3	1.00	3	1.00	6	2.9	6.4	1.00
	1	0.7	1.0	1.00	1	1.00	1	1.00	2	0.6	2.0	1.00
MALaise	2	1.6	2.2	2.00	4	2.00	4	2.50	6	2.3	6.2	2.25
	2	1.5	2.1	1.50	3	1.50	3	1.50	5	1.1	5.6	1.50
DIARRHOEA	3	2.4	3.4	1.00	3	1.00	3	1.00	6	1.8	6.4	1.00
	2	1.5	2.1	1.50	3	1.50	3	1.50	5	1.1	5.6	1.50
HYPOTENSION POSTURAL	1	0.8	1.1	1.00	2	1.00	2	2.00	3	1.8	3.4	1.66
	2	1.5	2.1	1.00	2	1.00	2	1.00	4	1.1	4.2	1.00
ATAXIA	1	0.8	1.1	1.00	1	1.00	1	1.00	2	1.2	2.2	1.00
	1	0.7	1.0	1.00	1	1.00	1	1.00	2	1.1	2.2	1.00
CONJUNCTIVITIS	1	0.8	1.1	1.00	1	1.00	1	1.00	2	1.2	2.2	1.00
	2	1.5	2.1	1.00	2	1.00	2	1.00	4	1.1	4.2	1.00
PNEUMONIA	2	1.6	2.2	1.00	2	1.00	2	1.00	4	1.8	4.2	1.00
	1	0.7	1.0	1.00	1	1.00	1	1.00	2	0.6	2.0	1.00
PAIN	1	0.8	1.1	1.00	1	1.00	1	1.00	2	0.6	2.0	1.00
	3	2.2	3.2	1.33	4	1.33	4	1.33	7	1.7	7.5	1.33
FRACTURE	2	1.6	2.2	1.00	2	1.00	2	1.00	4	1.2	4.2	1.00
	1	0.7	1.0	1.00	1	1.00	1	1.00	2	0.6	2.0	1.00
ARTHRALGIA	1	0.8	1.1	1.00	1	1.00	1	1.00	2	1.2	2.2	1.00

(CONTINUED)

(*): number of adverse events on patients who complained of adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT AND SEX

Adverse events/Assigned treatment	Female				Male				Total			
	No of Pt. exp.	% on exp.	No of AE with AE	Ratio (x)	No of Pt. exp.	% on exp.	No of AE with AE	Ratio (x)	No of Pt. exp.	% on exp.	No of AE with AE	Ratio (x)
ARTHRALGIA	1	0.7	1.0	1.00					1	0.6	0.8	1.00
HYPERTENSION	2	1.6	2.2	1.00					2	1.2	1.6	1.00
PALPITATION	1	0.7	1.0	1.00					1	0.6	0.8	1.00
	1	0.8	1.1	1.00					1	0.6	0.8	1.00
DYSPEPSIA	2	1.5	2.1	1.00					2	1.1	1.6	1.00
DYSPHAGIA	3	2.2	3.2	1.00					3	1.7	2.5	1.00
	1	0.8	1.1	1.00					1	0.6	0.8	1.00
	2	1.5	2.1	1.00					2	1.1	1.6	1.00
HYPOKALAEMIA	1	0.8	1.1	1.00					1	0.6	0.8	1.00
	1	0.7	1.0	1.00					1	0.6	0.8	1.00
WEIGHT DECREASE	1	0.7	1.0	1.00	1	2.6	3.7	1.00	2	1.1	1.6	1.00
	1	0.8	1.1	1.00					1	0.6	0.8	1.00
ANAEMIA	1	0.7	1.0	1.00	1	2.6	3.7	1.00	2	1.1	1.6	1.00
	2	1.6	2.2	1.00	1	2.2	2.9	1.00	3	1.8	2.4	1.00
FEVER	2	1.6	2.2	1.00					2	1.2	1.6	1.00
	1	0.7	1.0	1.00					1	0.6	0.8	1.00
INFLUENZA-LIKE SYMPTOMS					1	2.2	2.9	1.00	1	0.6	0.8	1.00
	2	1.5	2.1	1.00					2	1.1	1.6	1.00
PRURITUS	2	1.6	2.2	1.00					2	1.2	1.6	1.00
DYSKINESIA					2	4.4	5.8	1.00	2	1.2	1.6	1.00
HYPOAESTHESIA	1	0.8	1.1	1.00					1	0.6	0.8	1.00
	1	0.7	1.0	1.00					1	0.6	0.8	1.00
NEURALGIA	2	1.5	2.1	1.00					2	1.1	1.6	1.00

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT AND SEX

Adverse events/Assigned treatment	Female				Male				Total			
	No of Pt. exp.	% on Pt. with AE	No of AE	Ratio (*)	No of Pt. exp.	% on Pt. with AE	No of AE	Ratio (*)	No of Pt. exp.	% on Pt. with AE	No of AE	Ratio (*)
SYNCOPE	1	0.8	1.1	1.00	1	2.2	2.9	1.00	2	1.2	1.6	2
VOMITING	1	0.8	1.1	1.00					1	0.6	0.8	1
					1	2.6	3.7	1.00	1	0.6	0.8	1
ANXIETY	2	1.5	2.1	1.00					2	1.1	1.6	2
IMPOTENCE					1	2.2	2.9	1.00	1	0.6	0.8	1
					1	2.6	3.7	1.00	1	0.6	0.8	1
NERVOUSNESS	1	0.7	1.0	1.00	1	2.6	3.7	1.00	2	1.1	1.6	2
PARANOID REACTION	1	0.8	1.1	1.00					1	0.6	0.8	1
					1	2.6	3.7	1.00	1	0.6	0.8	1
FLATULENCE	1	0.8	1.1	1.00					1	0.6	0.8	1
					1	2.6	3.7	1.00	1	0.6	0.8	1
STOMATITIS	1	0.8	1.1	1.00					1	0.6	0.8	1
					1	2.6	3.7	1.00	1	0.6	0.8	1
GASTRO-INTESTINAL DISORDER NOS	2	1.5	2.1	1.00					2	1.1	1.6	2
HYPERCHOLESTEROLA-EMIA	1	0.8	1.1	1.00					1	0.6	0.8	1
					1	2.6	3.7	1.00	1	0.6	0.8	1
HYPERTRIGLYCERIDA-EMIA	1	0.8	1.1	1.00					1	0.6	0.8	1
					1	2.6	3.7	1.00	1	0.6	0.8	1
FIBRILLATION ATRIAL					1	2.2	2.9	1.00	1	0.6	0.8	1
					1	2.6	3.7	1.00	1	0.6	0.8	1
SINUSITIS	1	0.8	1.1	1.00					1	0.6	0.8	1

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT AND SEX

Adverse events/Assigned treatment	Female				Male				Total			
	No of Pt. exp.	% on exp. with AE	No of AE	Ratio (*)	No of Pt. exp.	% on exp. with AE	No of AE	Ratio (*)	No of Pt. exp.	% on exp. with AE	No of AE	Ratio (*)
SINUSITIS	1	0.7	1.0	1.00					1	0.6	0.8	1.00
RIGORS	2	1.5	2.1	1.00					2	1.1	1.6	1.00
HONITIASIS	2	1.5	2.1	1.00					2	1.1	1.6	1.00
RASH ERYTHEMATOUS	1	0.7	1.0	1.00					1	0.6	0.8	1.00
PILOERECTION	1	0.7	1.0	1.00					1	0.6	0.8	1.00
FRACTURE PATHOLOGICAL	1	0.8	1.1	1.00					1	0.6	0.8	1.00
NYALGIA	1	0.7	1.0	1.00					1	0.6	0.8	1.00
COMA	1	0.8	1.1	1.00					1	0.6	0.8	1.00
CONVULSIONS	1	0.8	1.1	1.00					1	0.6	0.8	1.00
CONVULSIONS GRAND MAL					1	2.6	3.7	1.00	1	0.6	0.8	1.00
COORDINATION ABNORMAL	1	0.8	1.1	1.00					1	0.6	0.8	1.00
HYPERKINESIA	1	0.7	1.0	1.00					1	0.6	0.8	1.00
NEURITIS	1	0.7	1.0	1.00					1	0.6	0.8	1.00
NEUROPATHY	1	0.7	1.0	1.00					1	0.6	0.8	1.00
STUPOR					1	2.2	2.9	1.00	1	0.6	0.8	1.00
VERTIGO	1	0.8	1.1	1.00					1	0.6	0.8	1.00
EYE PAIN	1	0.7	1.0	1.00					1	0.6	0.8	1.00
EAR DISORDER NOS	1	0.7	1.0	1.00					1	0.6	0.8	1.00
TASTE PERVERSION	1	0.8	1.1	1.00					1	0.6	0.8	1.00
APATHY					1	2.2	2.9	1.00	1	0.6	0.8	1.00

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS 8&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT AND SEX

Adverse events/Assigned treatment	Female				Male				Total				
	No of Pt. exp.	Z on exp.	No of Pt. with AE	No of AE	No of Pt. exp.	Z on exp.	No of Pt. with AE	No of AE	No of Pt. exp.	Z on exp.	No of Pt. with AE	No of AE	Ratio (*)
LIBIDO DECREASED	1	0.7	1.0	1	1.00				1	0.6	0.8	1	1.00
PARONYCHIA	1	0.7	1.0	1	1.00				1	0.6	0.8	1	1.00
SLEEP DISORDER	1	0.7	1.0	1	1.00				1	0.6	0.8	1	1.00
SUICIDE ATTEMPT	1	0.8	1.1	1	1.00				1	0.6	0.8	1	1.00
DEPRESSION AGGRAVATED	1	0.7	1.0	1	1.00				1	0.6	0.8	1	1.00
CONCENTRATION IMPAIRED	1	0.7	1.0	1	1.00				1	0.6	0.8	1	1.00
GLOSSITIS						1	2.6	3.7	2	2.00	0.8	2	2.00
HEPATIC FUNCTION ABNORMAL						1	2.2	2.9	1	1.00	0.8	1	1.00
SGPT INCREASED						1	2.2	2.9	1	1.00	0.8	1	1.00
GAMMA-GT INCREASED	1	0.7	1.0	1	1.00				1	0.6	0.8	1	1.00
BUN INCREASED	1	0.7	1.0	1	1.00				1	0.6	0.8	1	1.00
GLOBULINS INCREASED						1	2.2	2.9	1	1.00	0.8	1	1.00
GLYCOURIA	1	0.7	1.0	1	1.00				1	0.6	0.8	1	1.00
HYPOTHYROIDISM	1	0.8	1.1	1	1.00				1	0.6	0.8	1	1.00
MYOCARDIAL INFARCTION						1	2.2	2.9	1	1.00	0.8	1	1.00
BUNDLE BRANCH BLOCK	1	0.8	1.1	1	1.00				1	0.6	0.8	1	1.00
EXTRASYSTOLES						1	2.6	3.7	1	1.00	0.8	1	1.00
CEREBROVASCULAR DISORDER	1	0.8	1.1	1	1.00				1	0.6	0.8	1	1.00

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT AND SEX

Adverse events/Assigned treatment	Female				Male				Total			
	No of Pt. exp.	% on exp. with AE	No of Pt. with AE	Ratio (%)	No of Pt. exp.	% on exp. with AE	No of Pt. with AE	Ratio (%)	No of Pt. exp.	% on exp. with AE	No of Pt. with AE	Ratio (%)
PERIPHERAL ISCHAEMIA	1	0.8	1.1	1.00					1	0.6	0.8	1.00
THROMBOSIS ARTERIAL					1	2.6	3.7	1.00	1	0.6	0.8	1.00
COUGHING	1	0.7	1.0	1.00					1	0.6	0.8	1.00
DYSPNOEA					1	2.2	2.9	1.00	1	0.6	0.8	1.00
PHARYNGITIS					1	2.6	3.7	1.00	1	0.6	0.8	1.00
UPPER RESP TRACT INFECTION	1	0.7	1.0	1.00					1	0.6	0.8	1.00
ASTHMA	1	0.7	1.0	1.00					1	0.6	0.8	1.00
GRANULOCYTOPENIA	1	0.8	1.1	1.00					1	0.6	0.8	1.00
PURPURA	1	0.8	1.1	1.00					1	0.6	0.8	1.00
CYSTITIS	1	0.7	1.0	1.00					1	0.6	0.8	1.00
NOCTURIA	1	0.8	1.1	1.00					1	0.6	0.8	1.00
RENAL FUNCTION ABNORMAL	1	0.7	1.0	1.00					1	0.6	0.8	1.00
PULMONARY CARCINOMA	1	0.7	1.0	1.00					1	0.6	0.8	1.00
OEDEMA PERIPHERAL	1	0.7	1.0	1.00					1	0.6	0.8	1.00
ALLERGIC REACTION					1	2.2	2.9	1.00	1	0.6	0.8	1.00
ASTHENIA					1	2.6	3.7	1.00	1	0.6	0.8	1.00
BACK PAIN	1	0.7	1.0	1.00					1	0.6	0.8	1.00
CHEST PAIN					1	2.2	2.9	1.00	1	0.6	0.8	1.00
CHEST PAIN PRECORDIAL	1	0.8	1.1	1.00					1	0.6	0.8	1.00

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT AND SEX

Adverse events/Assigned treatment	Female				Male				Total			
	No of Pt. exp.	% on exp.	No of Pt. with AE	Ratio No of AE (*)	No of Pt. exp.	% on exp.	No of Pt. with AE	Ratio No of AE (*)	No of Pt. exp.	% on exp.	No of Pt. with AE	Ratio No of AE (*)
ESR INCREASED					1	2.2	2.9	1.00				
MASAL POLYP	1	0.8	1.1	1.00					1	0.6	0.8	1.00
INFECTION	1	0.7	1.0	1.00					1	0.6	0.8	1.00

379

(*) number of adverse events on patients who complained of adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: AUTONOMIC NERVOUS SYSTEM DISORDERS

Adverse events/Assigned treatment	Female				Male				Total			
	No of Pt	% on exp.	No of Pt with AE	Ratio (*): AE	No of Pt	% on exp.	No of Pt with AE	Ratio (*): AE	No of Pt	% on exp.	No of Pt with AE	Ratio (*): AE
MOUTH DRY	28	22.2	31.8	1.07	11	24.4	32.3	1.18	39	22.8	31.9	1.10
	34	24.8	36.5	1.05	5	12.8	18.5	1.00	39	22.2	32.5	1.05
SWEATING INCREASED	13	10.3	14.7	1.07	2	4.4	5.8	1.00	15	8.8	12.2	1.06
	15	10.9	16.1	1.00	1	2.6	3.7	1.00	16	9.1	13.3	1.00

380

(*): number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: BODY AS A WHOLE-GENERAL DISORDERS

Adverse events/Assigned treatment	Female			Male			Total						
	No of Pt exp.	% on exp. with AE	No of Pt Ratio (*)	No of Pt exp.	% on exp. with AE	No of Pt Ratio (*)	No of Pt exp.	% on exp. with AE	No of Pt Ratio (*)				
ASTHENIA / FATIGUE	3	2.4	3	2	4.4	2	1.00	5	2.9	4.0	5	1.00	
	2	1.5	2	1	2.6	1	1.00	3	1.7	2.5	3	1.00	
FALL	5	4.0	8	1	2.2	2.9	1.00	6	3.5	4.9	9	1.50	
	1	0.7	1	1	2.6	3.7	2	2.00	1.1	1.6	3	1.50	
MALAISE	2	1.6	2	2	4.4	5.8	5	2.50	4	2.3	3.2	9	2.25
	2	1.5	2	1	2.2	2.9	3	1.50	2	1.1	1.6	3	1.50
PAIN	1	0.8	1	1	2.2	2.9	1	1.00	1	0.6	0.8	1	1.00
	3	2.2	3	2	4.4	5.8	4	1.33	3	1.7	2.5	4	1.33
FEVER	2	1.6	2	2	4.4	5.8	2	1.00	2	1.2	1.6	2	1.00
	1	0.7	1	1	2.2	2.9	1	1.00	1	0.6	0.8	1	1.00
INFLUENZA-LIKE SYMPTOMS	2	1.5	2	1	2.2	2.9	1	1.00	1	0.6	0.8	1	1.00
	2	1.5	2	1	2.2	2.9	2	1.00	2	1.1	1.6	2	1.00
RIGORS	2	1.5	2	1	2.2	2.9	2	1.00	2	1.1	1.6	2	1.00
ALLERGIC REACTION	2	1.5	2	1	2.2	2.9	1	1.00	1	0.6	0.8	1	1.00
CHEST PAIN	1	0.8	1	1	2.2	2.9	1	1.00	1	0.6	0.8	1	1.00
ESR INCREASED	1	0.8	1	1	2.2	2.9	1	1.00	1	0.6	0.8	1	1.00
NASAL POLYP	1	0.8	1	1	2.2	2.9	1	1.00	1	0.6	0.8	1	1.00

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: CARDIOVASCULAR DISORDERS, GENERAL

Adverse events/Assigned treatment	Female				Male				Total					
	No of Pt	% on exp.	No of Pt with AE	Ratio of No of AE (*)	No of Pt	% on exp.	No of Pt with AE	Ratio of No of AE (*)	No of Pt	% on exp.	No of Pt with AE	Ratio of No of AE (*)		
HYPOTENSION AND RELATED SYMPTOMS	17	13.5	19.3	21	1.23	10	22.2	29.4	13	1.30	27	15.8	34	1.25
TACHYCARDIA	9	6.6	9.6	10	1.11	4	10.3	14.8	4	1.00	13	7.4	14	1.07
HYPERTENSION	3	2.4	3.4	3	1.00	3	6.7	8.8	3	1.00	6	3.5	6	1.00
PALPITATION	1	0.7	1.0	1	1.00	2	5.1	7.4	2	1.00	3	1.7	3	1.00
FIBRILLATION ATRIAL	2	1.6	2.2	2	1.00						2	1.2	2	1.00
AEDEMA	1	0.7	1.0	1	1.00						1	0.6	1	1.00
BUNDLE BRANCH BLOCK	1	0.8	1.1	1	1.00						1	0.6	1	1.00
CARDIAC ISCHEMIA AND RELATED SYMPTOMS	2	1.5	2.1	2	1.00						2	1.1	2	1.00
CEREBROVASCULAR DISORDER	1	0.7	1.0	1	1.00						1	0.6	1	1.00
EXTRASYSTOLES	1	0.8	1.1	1	1.00						1	0.6	1	1.00
MYOCARDIAL INFARCTION	1	0.8	1.1	1	1.00						1	0.6	1	1.00
PERIPHERAL ISCHAEMIA	1	0.8	1.1	1	1.00						1	0.6	1	1.00

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: CARDIOVASCULAR DISORDERS, GENERAL

Adverse events/Assigned treatment	Female			Male			Total						
	No of Pt	% on exp.	No of Pt with AE	No of Pt	% on exp.	No of Pt with AE	No of Pt	% on exp.	No of Pt with AE				
THROMBOSIS ARTERIAL				1	2.6	3.7	1	1.00	1	0.6	0.8	1	1.00
Reboxetine													

33 00 33

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

CC
00
4

Body system: CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO

Adverse events/Assigned treatment	Female				Male				Total			
	No of Pt exp.	% on exp. with AE	No of AE	Ratio No of AE (*)	No of Pt exp.	% on exp. with AE	No of AE	Ratio No of AE (*)	No of Pt exp.	% on exp. with AE	No of AE	Ratio No of AE (*)
HEADACHE / MIGRAINE	7	5.6	7.9	2.85	2	4.4	5.8	1.00	9	5.3	7.3	2.44
	8	5.8	8.6	1.25	3	7.7	11.1	1.00	11	6.3	9.1	1.18
TREMOR	4	3.2	4.5	1.00	2	4.4	5.8	1.00	6	3.5	4.9	1.00
	7	5.1	7.5	1.00					7	4.0	5.8	1.00
CONFUSION	3	2.4	3.4	1.00	1	2.2	2.9	1.00	4	2.3	3.2	1.00
	5	3.6	5.3	1.00	1	2.6	3.7	1.00	6	3.4	5.0	1.00
PARAESTHESIA	4	3.2	4.5	1.00					4	2.3	3.2	1.00
	2	1.5	2.1	1.00	2	5.1	7.4	1.00	4	2.3	3.3	1.00
APAXIA	1	0.8	1.1	1.00	1	2.2	2.9	1.00	2	1.2	1.6	1.00
	1	0.7	1.0	1.00	1	2.6	3.7	1.00	2	1.1	1.6	1.00
DYSKINESIA					2	4.4	5.8	1.00	2	1.2	1.6	1.00
	1	0.8	1.1	1.00					1	0.6	0.8	1.00
HYPOAESTHESIA	1	0.7	1.0	1.00					1	0.6	0.8	1.00
	2	1.5	2.1	1.00					2	1.1	1.6	1.00
NEURALGIA	1	0.8	1.1	1.00					1	0.6	0.8	1.00
	1	0.8	1.1	1.00					1	0.6	0.8	1.00
CONVULSIONS	1	0.8	1.1	1.00					1	0.6	0.8	1.00
					1	2.6	3.7	1.00	1	0.6	0.8	1.00
CONVULSIONS GRAND MAL												
	1	0.8	1.1	1.00					1	0.6	0.8	1.00
COORDINATION ABNORMAL	1	0.8	1.1	1.00					1	0.6	0.8	1.00
	1	0.7	1.0	1.00					1	0.6	0.8	1.00
HYPERKINESIA	1	0.7	1.0	1.00					1	0.6	0.8	1.00
	1	0.7	1.0	1.00					1	0.6	0.8	1.00

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
 BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO

Adverse events/Assigned treatment	Female			Male			Total		
	No of Pt	% on exp.	No of AE with AE	No of Pt	% on exp.	No of AE with AE	No of Pt	% on exp.	No of AE with AE
NEUROPATHY	1	0.7	1.0	1	1.00	1	0.6	0.8	1
STUPOR				1	2.2	2.9	1	0.5	0.8
VERTIGO	1	0.8	1.1	1	1.00	1	0.6	0.8	1

33
 00
 01

(*) number of adverse events on patients who complained of adverse events
 (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: ENDOCRINE DISORDERS

Adverse events/Assigned treatment	Female			Total		
	No of Pt exp.	Z on exp. with AE	No of Pt with AE	Ratio No of Pt with AE (*)	Z on exp. with AE	No of Pt with AE
HYPOTHYROIDISM	1	0.8	1.1	1	0.6	1
				1.00	0.8	1.00

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: GASTRO-INTESTINAL SYSTEM DISORDERS

Adverse events/Assigned treatment	Female				Male				Total						
	No of Pt	% on exp.	% on Pt with AE	Ratio No of AE (*)	No of Pt	% on exp.	% on Pt with AE	Ratio No of AE (*)	No of Pt	% on exp.	% on Pt with AE	Ratio No of AE (*)			
CONSTIPATION	24	19.0	27.2	30	1.25	7	15.6	20.5	12	1.71	31	18.1	25.4	42	1.35
NAUSEA AND RELATED SYMPTOMS	25	18.2	26.8	30	1.20	6	15.4	22.2	6	1.00	31	17.6	25.8	36	1.16
ABDOMINAL PAIN	13	10.3	14.7	14	1.07	4	8.9	11.7	4	1.00	17	9.9	13.9	18	1.05
ANOREXIA	15	10.9	16.1	16	1.06	5	12.8	18.5	6	1.20	20	11.4	16.6	22	1.10
DIARRHOEA	2	1.6	2.2	2	1.00						2	1.2	1.6	2	1.00
DYSPLAGIA	7	5.1	7.5	7	1.00						7	4.0	5.8	7	1.00
FLATULENCE	5	4.0	5.6	5	1.00						5	2.9	4.0	5	1.00
GASTRO-INTESTINAL DISORDER NOS	3	2.2	3.2	3	1.00	1	2.6	3.7	1	1.00	4	2.3	3.3	4	1.00
STOMATITIS	3	2.4	3.4	3	1.00						3	1.8	2.4	3	1.00
GLOSSITIS	2	1.5	2.1	3	1.50						2	1.1	1.6	3	1.50
GASTRO-INTESTINAL DISORDER NOS	2	1.5	2.1	2	1.00						2	1.1	1.6	2	1.00
STOMATITIS	1	0.8	1.1	1	1.00						1	0.6	0.8	1	1.00
GLOSSITIS	1	0.7	1.0	1	1.00						1	0.6	0.8	1	1.00
GASTRO-INTESTINAL DISORDER NOS						1	2.6	3.7	2	2.00	1	0.6	0.8	2	2.00

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: HEARING AND VESTIBULAR DISORDERS

Adverse events/Assigned treatment	Female			Total		
	No of Pt	% on exp.	Ratio No of AE with AE (*)	No of Pt	% on exp.	Ratio No of AE with AE (*)
EAR DISORDER NOS Reboxetine	1	0.7	1.00	1	0.6	1.00

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: HEMATOLOGY DISORDERS

Adverse events/Assigned treatment	Female			Male			Total		
	No of Pt	% on exp.	Ratio No of AE (*)	No of Pt	% on exp.	Ratio No of AE (*)	No of Pt	% on exp.	Ratio No of AE (*)
ANEMIA	2	1.6	1.00	1	2.2	1.00	3	1.8	1.00
GRANULOCYTOPENIA	1	0.8	1.00	1	1.1	1.00	2	0.6	1.00
PURPURA	1	0.8	1.00	1	1.1	1.00	2	0.6	1.00

C3
C6
C9

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: LIVER AND BILIAR SYSTEM DISORDERS

Adverse events/Assigned treatment	Female			Male			Total		
	No of Pt	% on exp.	No of Pt with AE	No of Pt	% on exp.	No of Pt with AE	No of Pt	% on exp.	No of Pt with AE
INCREASED LIVER ENZYMES	1	0.7	1.0	1	2.2	2.9	1	0.6	0.8
HEPATIC FUNCTION ABNORMAL				1	2.2	2.9	1	0.6	0.8
							1	1.00	1
							1	1.00	1
							1	1.00	1

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: METABOLIC AND NUTRITIONAL DISORDERS

Adverse events/Assigned treatment	Female			Male			Total		
	No of Pt exp.	% on exp. with AE	No of Pt with AE	No of Pt exp.	% on exp. with AE	No of Pt with AE	No of Pt exp.	% on exp. with AE	No of Pt with AE
HYPOKALAEMIA	1	0.8	1.1	1	1.00	1	1	1.00	1
	1	0.7	1.0	2	2.00	1	1	1.00	3
WEIGHT DECREASE	1	0.8	1.1	1	1.00	1	1	1.00	1
	1	0.7	1.0	1	1.00	1	2	2.00	2
HYPERCHOLESTEROLAEMIA	1	0.8	1.1	1	1.00	1	1	1.00	1
	1	0.8	1.1	1	1.00	1	1	1.00	1
HYPERTRIGLYCERIDAEMIA	1	0.8	1.1	1	1.00	1	1	1.00	1
	1	0.7	1.0	1	1.00	1	1	1.00	1
BUN INCREASED	1	0.7	1.0	1	1.00	1	1	1.00	1
	1	0.7	1.0	1	1.00	1	1	1.00	1
GLUCOSURIA	1	0.7	1.0	1	1.00	1	1	1.00	1
	1	0.7	1.0	1	1.00	1	1	1.00	1

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: MUSCULO-SKELETAL SYSTEM DISORDERS

Adverse events/Assigned treatment	Female			Male			Total		
	No of Pt	% on exp.	No of Pt with AE	No of Pt	% on exp.	No of Pt with AE	No of Pt	% on exp.	No of Pt with AE
ARTHRALGIA	1	0.8	1.1	1	2.2	2.9	2	1.2	1.6
FRACTURE	1	0.7	1.0				1	0.6	0.8
	2	1.6	2.2				2	1.2	1.6
BACK PAIN	1	0.7	1.0				1	0.6	0.8
	1	0.7	1.0				1	0.6	0.8
FRACTURE PATHOLOGICAL	1	0.8	1.1				1	0.6	0.8
RYALGIA	1	0.7	1.0				1	0.6	0.8

392

(*): number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: NEOPLASM

Adverse events/Assigned treatment	Female			Total		
	No of Pt	% on exp.	Ratio of AE with AE (*)	No of Pt	% on exp.	Ratio of AE with AE (*)
PULMONARY CARCINOMA	1	0.7	1.0	1	0.6	1.00
Reboxetine						
				1	0.6	0.8
						1
						1.00

393

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: PSYCHIATRIC DISORDERS

Adverse events/Assigned treatment	Female				Male				Total			
	No of Pt exp.	% on exp.	No of Pt with AE	Ratio of AE (*)	No of Pt exp.	% on exp.	No of Pt with AE	Ratio of AE (*)	No of Pt exp.	% on exp.	No of Pt with AE	Ratio of AE (*)
INSOMNIA	5	4.0	5.6	1.00					5	2.9	4.0	1.00
	9	6.6	9.6	1.33	2	5.1	7.4	1.50	11	6.3	9.1	1.36
AGITATION / ANXIETY / NERVOUSNESS	4	3.2	4.5	1.00					4	2.3	3.2	1.00
	6	4.4	6.4	1.16	1	2.6	3.7	1.00	7	4.0	5.8	1.14
SOMNOLENCE	6	4.8	6.8	1.00	1	2.2	2.9	1.00	7	4.1	5.7	1.00
	4	2.9	4.3	1.25					4	2.3	3.3	1.25
PARANOID REACTION	1	0.8	1.1	1.00					1	0.6	0.8	1.00
					1	2.6	3.7	1.00	1	0.6	0.8	1.00
APATHY					1	2.2	2.9	1.00	1	0.6	0.8	1.00
CONCENTRATION IMPAIRED	1	0.7	1.0	1.00					1	0.6	0.8	1.00
DEPRESSION AGGRAVATED	1	0.7	1.0	1.00					1	0.6	0.8	1.00
LIBIDO DECREASED	1	0.7	1.0	1.00					1	0.6	0.8	1.00
PAROMIRIA	1	0.7	1.0	1.00					1	0.6	0.8	1.00
SLEEP DISORDER	1	0.7	1.0	1.00					1	0.6	0.8	1.00
SUICIDE ATTEMPT	1	0.8	1.1	1.00					1	0.6	0.8	1.00

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RD

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: REPRODUCTIVE DISORDERS, MALE

Adverse events/Assigned treatment	Male			Total		
	No of Pt	% on exp.	Ratio AE (*)	No of Pt	% on exp.	Ratio AE (*)
Imipramine	1	2.2	1.00	1	0.6	1.00
Reboxetine	1	2.6	1.00	1	0.6	1.00

395

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: RESISTANCE MECHANISM DISORDERS

Adverse events/Assigned treatment	Female			Total		
	No of Pt	% on exp.	Ratio AE (*)	No of Pt	% on exp.	Ratio AE (*)
HONILIASIS	2	1.5	2 1.00	2	1.1	2 1.00
INFECTION	1	0.7	1 1.00	1	0.6	1 1.00

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: RESPIRATORY SYSTEM DISORDERS

Adverse events/Assigned treatment	Female			Male			Total								
	No of Pt exp.	Z on exp. with AE	No of AE	Ratio (%)	No of Pt exp.	Z on exp. with AE	No of AE	Ratio (%)	No of Pt exp.	Z on exp. with AE	No of AE	Ratio (%)			
BRONCHITIS	3	2.4	3.4	3	1.00	2	4.4	5.8	2	1.00	5	2.9	4.0	5	1.00
	1	0.7	1.0	1	1.00						1	0.6	0.8	1	1.00
PNEUMONIA	2	1.6	2.2	2	1.00	1	2.2	2.9	1	1.00	3	1.8	2.4	3	1.00
	1	0.7	1.0	1	1.00						1	0.6	0.8	1	1.00
SINUSITIS	1	0.8	1.1	1	1.00						1	0.6	0.8	1	1.00
	1	0.7	1.0	1	1.00						1	0.6	0.8	1	1.00
ASTHMA	1	0.7	1.0	1	1.00						1	0.6	0.8	1	1.00
	1	0.7	1.0	1	1.00						1	0.6	0.8	1	1.00
COUGHING	1	0.7	1.0	1	1.00						1	0.6	0.8	1	1.00
	1	0.7	1.0	1	1.00						1	0.6	0.8	1	1.00
DYSPNOEA											1	2.2	2.9	1	1.00
						1	2.6	3.7	1	1.00	1	0.6	0.8	1	1.00
PHARYNGITIS											1	2.6	3.7	1	1.00
						1	2.6	3.7	1	1.00	1	0.6	0.8	1	1.00
UPPER RESP TRACT INFECTION	1	0.7	1.0	1	1.00						1	0.6	0.8	1	1.00

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: SKIN AND APPENDAGES DISORDERS

Adverse events/Assigned treatment	Female			Total		
	No of Pt	% on exp.	Ratio of AE with AE (*)	No of Pt	% on exp.	Ratio of AE with AE (*)
PRURITUS	2	1.6	2.2	2	1.2	1.00
ERYTHEMA / RASH	1	0.7	1.0	1	0.6	1.00
PILORECTION	1	0.7	1.0	1	0.6	1.00

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: SPECIAL SENSES OTHER, DISORDERS

Adverse events/Assigned treatment	Female			Total		
	No of Pt	% on exp.	Ratio No of Pt with AE to exp. AE (*)	No of Pt	% on exp.	Ratio No of Pt with AE to exp. AE (*)
TASTE PERVERSION	1	0.8	1.1	1	0.6	1.00
Imipramine	1	0.8	1.1	1	0.6	1.00

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: URINARY SYSTEM DISORDERS

Adverse events/Assigned treatment	Female				Male				Total			
	No of Pt	% on exp.	No of Pt with AE	Ratio No of AE (*)	No of Pt	% on exp.	No of Pt with AE	Ratio No of AE (*)	No of Pt	% on exp.	No of Pt with AE	Ratio No of AE (*)
URINARY HESITANCY / RETENTION	3	2.4	3.4	1.00	7	15.6	20.5	1.00	10	5.8	8.1	1.00
	3	2.2	3.2	1.33	4	10.3	14.8	1.00	7	4.0	5.8	1.14
URINARY TRACT INFECTION	10	7.9	11.3	1.00					10	5.8	8.1	1.00
	5	3.6	5.3	1.00	1	2.6	3.7	2.00	6	3.4	5.0	1.16
CYSTITIS	1	0.7	1.0	1.00					1	0.6	0.8	1.00
NOCTURIA	1	0.8	1.1	1.00					1	0.6	0.8	1.00
RENAL FUNCTION ABNORMAL	1	0.7	1.0	1.00					1	0.6	0.8	1.00

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 47

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND SEX

Body system: VISION DISORDERS

Adverse events/Assigned treatment	Female			Male			Total		
	No of Pt exp.	% on exp. with AE	No of Pt with AE	No of Pt exp.	% on exp. with AE	No of Pt with AE	No of Pt exp.	% on exp. with AE	No of Pt with AE
BLURRED VISION	5	4.0	5.6	1	2.2	2.9	6	3.5	4.9
CONJUNCTIVITIS	5	3.6	5.3	1	2.6	3.7	6	3.4	5.0
	1	0.8	1.1	1	2.2	2.9	2	1.2	1.6
EYE PAIN	2	1.5	2.1				2	1.1	1.6
	1	0.7	1.0				1	0.6	0.8

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No: 68

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND DIAGNOSIS

Body system: AUTONOMIC NERVOUS SYSTEM DISORDERS

Adverse events/Assigned treatment	Major Depressive Disorder				Dysthymia				Total			
	No of Pt	% on exp.	% on Pt with AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	Ratio (*)
MOUTH DRY	25	22.9	31.2	1.08	14	22.6	33.3	1.14	39	22.8	31.9	1.10
	18	16.5	25.0	1.11	21	31.3	43.7	1.00	39	22.2	32.5	1.05
SWEATING INCREASED	8	7.3	10.0	1.00	7	11.3	16.6	1.14	15	8.8	12.2	1.06
	11	10.1	15.2	1.00	5	7.5	10.4	1.00	16	9.1	13.3	1.00

402

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No: 4A

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND DIAGNOSIS

Body system: BODY AS A WHOLE-GENERAL DISORDERS

Adverse events/Assigned treatment	Major Depressive Disorder				Dysthymia				Total			
	No of Pt	% on exp.	% on Pt with AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	Ratio (*)
ASTHENIA / FATIGUE	2	1.8	2.5	1.00	2	1.8	2.5	1.00	4	3.6	5.0	1.00
	2	1.8	2.7	1.00	2	1.8	2.7	1.00	4	3.6	5.4	1.00
FALL	4	3.7	5.0	1.75	2	1.8	2.7	1.00	6	5.5	7.4	1.50
	2	1.8	2.7	1.50					2	1.8	2.7	1.50
MALaise	2	1.8	2.5	2.50	2	1.8	2.7	1.00	4	3.6	5.1	2.25
	2	1.8	2.7	1.50					2	1.8	2.7	1.50
PAIN	1	0.9	1.2	1.00					1	0.9	1.2	1.00
	1	0.9	1.3	1.00	2	1.8	2.7	1.00	3	2.7	3.6	1.33
FEVER	2	1.8	2.5	1.00					2	1.8	2.5	1.00
					1	0.9	1.2	1.00	1	0.9	1.2	1.00
INFLUENZA-LIKE SYMPTOMS	1	0.9	1.2	1.00					1	0.9	1.2	1.00
					2	1.8	2.7	1.00	2	1.8	2.7	1.00
RIGORS	1	0.9	1.3	1.00					1	0.9	1.3	1.00
					2	1.8	2.7	1.00	2	1.8	2.7	1.00
ALLERGIC REACTION	1	0.9	1.2	1.00					1	0.9	1.2	1.00
CHEST PAIN	1	0.9	1.2	1.00					1	0.9	1.2	1.00
ESR INCREASED					1	0.9	1.2	1.00	1	0.9	1.2	1.00
NASAL POLYP					1	0.9	1.2	1.00	1	0.9	1.2	1.00

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No. 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND DIAGNOSIS

404

Body system: CARDIOVASCULAR DISORDERS, GENERAL

Adverse events/Assigned treatment	Major Depressive Disorder					Dysthymia					Total					
	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	
HYPOTENSION AND RELATED SYMPTOMS	Imipramine	22	20.2	27.5	28	1.27	5	8.1	11.9	6	1.20	27	15.8	22.1	34	1.25
	Reboxetine	11	10.1	15.2	12	1.09	2	3.0	4.1	2	1.00	13	7.4	10.8	14	1.07
TACHYCARDIA	Imipramine	5	4.6	6.2	5	1.00	1	1.6	2.3	1	1.00	6	3.5	4.9	6	1.00
	Reboxetine	2	1.8	2.7	2	1.00	1	1.5	2.0	1	1.00	3	1.7	2.5	3	1.00
HYPERTENSION	Imipramine	1	0.9	1.2	1	1.00	1	1.6	2.3	1	1.00	2	1.2	1.6	2	1.00
	Reboxetine	1	0.9	1.3	1	1.00						1	0.6	0.8	1	1.00
PALPITATION	Imipramine	1	0.9	1.2	1	1.00						1	0.6	0.8	1	1.00
	Reboxetine	1	0.9	1.3	1	1.00	1	1.5	2.0	1	1.00	2	1.1	1.6	2	1.00
FIBRILLATION ATRIAL	Imipramine	1	0.9	1.2	1	1.00						1	0.6	0.8	1	1.00
	Reboxetine	1	0.9	1.3	1	1.00						1	0.6	0.8	1	1.00
AEDEMA	Imipramine	1	0.9	1.3	1	1.00						1	0.6	0.8	1	1.00
	Reboxetine	1	0.9	1.2	1	1.00						1	0.6	0.8	1	1.00
BUNDLE BRANCH BLOCK	Imipramine	1	0.9	1.2	1	1.00						1	0.6	0.8	1	1.00
	Reboxetine	1	0.9	1.2	1	1.00						1	0.6	0.8	1	1.00
CARDIAC ISCHEMIA AND RELATED SYMPTOMS	Imipramine	1	0.9	1.2	1	1.00						1	0.6	0.8	1	1.00
	Reboxetine	1	0.9	1.2	1	1.00						1	0.6	0.8	1	1.00
CEREBROVASCULAR DISORDER	Imipramine	1	0.9	1.2	1	1.00						1	0.6	0.8	1	1.00
	Reboxetine	1	0.9	1.3	1	1.00						1	0.6	0.8	1	1.00
EXTRASYSTOLES	Imipramine	1	0.9	1.2	1	1.00						1	0.6	0.8	1	1.00
	Reboxetine	1	0.9	1.2	1	1.00						1	0.6	0.8	1	1.00
MYOCARDIAL INFARCTION	Imipramine	1	0.9	1.2	1	1.00						1	0.6	0.8	1	1.00
	Reboxetine	1	0.9	1.2	1	1.00						1	0.6	0.8	1	1.00
PERIPHERAL ISCHAEMIA	Imipramine	1	0.9	1.2	1	1.00						1	0.6	0.8	1	1.00
	Reboxetine	1	0.9	1.3	1	1.00						1	0.6	0.8	1	1.00
THROMBOSIS ARTERIAL	Imipramine	1	0.9	1.2	1	1.00						1	0.6	0.8	1	1.00
	Reboxetine	1	0.9	1.3	1	1.00						1	0.6	0.8	1	1.00

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20/24/035

TABLE No: 68

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND DIAGNOSIS

Body system: CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO

Adverse events/Assigned treatment	Major Depressive Disorder					Dysthymia					Total				
	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
HEADACHE / MIGRAINE	7	6.4	8.7	20	2.85	2	3.2	4.7	2	1.00	9	5.3	7.3	22	2.44
	8	7.3	11.1	10	1.25	3	4.5	6.2	3	1.00	11	6.3	9.1	13	1.18
TREMOR	5	4.6	6.2	5	1.00	1	1.6	2.3	1	1.00	6	3.5	4.9	6	1.00
	3	2.8	4.1	3	1.00	4	6.0	8.3	4	1.00	7	4.0	5.8	7	1.00
CONFUSION	3	2.8	3.7	3	1.00	1	1.6	2.3	1	1.00	4	2.3	3.2	4	1.00
	3	2.8	4.1	3	1.00	3	4.5	6.2	3	1.00	6	3.4	5.0	6	1.00
PARAESTHESIA	3	2.8	3.7	3	1.00	1	1.6	2.3	1	1.00	4	2.3	3.2	4	1.00
	1	0.9	1.3	1	1.00	3	4.5	6.2	3	1.00	4	2.3	3.3	4	1.00
ATAXIA	1	0.9	1.2	1	1.00	1	1.6	2.3	1	1.00	2	1.2	1.6	2	1.00
						2	3.0	4.1	2	1.00	2	1.1	1.6	2	1.00
DYSKINESIA	2	1.8	2.5	2	1.00						2	1.2	1.6	2	1.00
HYPOAESTHESIA	1	0.9	1.2	1	1.00						1	0.6	0.8	1	1.00
						1	1.5	2.0	1	1.00	1	0.6	0.8	1	1.00
NEURALGIA	1	0.9	1.3	1	1.00	1	1.5	2.0	1	1.00	2	1.1	1.6	2	1.00
COMA	1	0.9	1.2	1	1.00						1	0.6	0.8	1	1.00
CONVULSIONS	1	0.9	1.2	1	1.00						1	0.6	0.8	1	1.00
CONVULSIONS GRAND MAL	1	0.9	1.3	1	1.00						1	0.6	0.8	1	1.00
COORDINATION ABNORMAL	1	0.9	1.2	1	1.00						1	0.6	0.8	1	1.00
HYPERTHESIA						1	1.5	2.0	1	1.00	1	0.6	0.8	1	1.00
NEURITIS						1	1.5	2.0	1	1.00	1	0.6	0.8	1	1.00

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No: 48

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND DIAGNOSIS

Body system: CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO

Adverse events/Assigned treatment	Major Depressive Disorder				Dysthymia				Total			
	No of Pt	Z on exp.	No of Pt with AE	Ratio (**)	No of Pt	Z on exp.	No of Pt with AE	Ratio (**)	No of Pt	Z on exp.	No of Pt with AE	Ratio (**)
NEUROPATHY	1	0.9	1.3	1.00					1	0.6	0.8	1.00
STUPOR	1	0.9	1.2	1.00					1	0.6	0.8	1.00
VERTIGO					1	1.6	2.3	1.00	1	0.6	0.8	1.00

406

(**) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No. 48

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND DIAGNOSIS

Body system: ENDOCRINE DISORDERS

Adverse events/Assigned treatment	Major Depressive Disorder				Total			
	No of Pt exp.	Z on exp. with AE	Pt No of AE	Ratio (*)	No of Pt exp.	Z on exp. with AE	No of AE	Ratio (*)
HYPOTHYROIDISM Imipramine	1	0.9	1.2	1.00	1	0.6	1	1.00

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No: 48

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND DIAGNOSIS

Body system: GASTRO-INTESTINAL SYSTEM DISORDERS

Adverse events/Assigned treatment	Major Depressive Disorder						Dysthymia						Total		
	No of Pt exp.	Z on exp.	X on Pt with AE	No of AE	Ratio (*)	No of Pt	Z on exp.	X on Pt with AE	No of AE	Ratio (*)	No of Pt	Z on exp.	X on Pt with AE	No of AE	Ratio (*)
CONSTIPATION	20	18.3	25.0	29	1.45	11	17.7	26.1	13	1.18	31	18.1	25.4	42	1.35
	22	20.2	30.5	26	1.18	9	13.4	18.7	10	1.11	31	17.6	25.8	36	1.16
NAUSEA AND RELATED SYMPTOMS	8	7.3	10.0	8	1.00	9	14.5	21.4	10	1.11	17	9.9	13.9	18	1.05
	11	10.1	15.2	13	1.18	9	13.4	18.7	9	1.00	20	11.4	16.6	22	1.10
ABDOMINAL PAIN	1	0.9	1.2	1	1.00	1	1.6	2.3	1	1.00	2	1.2	1.6	2	1.00
	4	3.7	5.5	4	1.00	3	4.5	6.2	3	1.00	7	4.0	5.8	7	1.00
ANOREXIA	3	2.8	3.7	3	1.00	2	3.2	4.7	2	1.00	5	2.9	4.0	5	1.00
	3	2.8	4.1	3	1.00	1	1.5	2.0	1	1.00	4	2.3	3.3	4	1.00
DIARRHOEA	2	1.8	2.5	2	1.00	1	1.6	2.3	1	1.00	3	1.8	2.4	3	1.00
	2	1.8	2.7	3	1.50						2	1.1	1.6	3	1.50
DYSPHAGIA	1	0.9	1.2	1	1.00						1	0.6	0.8	1	1.00
	1	0.9	1.3	1	1.00	1	1.5	2.0	1	1.00	2	1.1	1.6	2	1.00
FLATULENCE	1	0.9	1.2	1	1.00						1	0.6	0.8	1	1.00
	1	0.9	1.3	1	1.00						1	0.6	0.8	1	1.00
GASTRO-INTESTINAL DISORDER NOS						2	3.0	4.1	2	1.00	2	1.1	1.6	2	1.00
	1	0.9	1.2	1	1.00						1	0.6	0.8	1	1.00
STOMATITIS						1	1.5	2.0	1	1.00	1	0.6	0.8	1	1.00
	1	0.9	1.3	2	2.00						1	0.6	0.8	2	2.00

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No. 68

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND DIAGNOSIS

Body system: HEARING AND VESTIBULAR DISORDERS

Adverse events/Assigned treatment	Major Depressive Disorder				Total					
	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
EAR DISORDER NOS Reboxetine	1	0.9	1.3	1	1.00	1	0.6	0.6	1	1.00

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No: 48

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND DIAGNOSIS

Body system: HEMATOLOGY DISORDERS

Adverse events/Assigned treatment	Major Depressive Disorder				Dysthymia				Total			
	No of Pt	% on exp.	No of Pt with AE	Ratio (*): AE	No of Pt	% on exp.	No of Pt with AE	Ratio (*): AE	No of Pt	% on exp.	No of Pt with AE	Ratio (*): AE
ANEMIA	3	2.8	3	1.00					3	1.8	3	1.00
GRANULOCYTOPENIA	1	0.9	1	1.00					1	0.6	1	1.00
PURPURA					1	1.6	2.3	1.00	1	0.6	2.3	1.00

410

(*): number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No: 48

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND DIAGNOSIS

Body system: LIVER AND BILIAR SYSTEM DISORDERS

Adverse events/Assigned treatment	Major Depressive Disorder				Dysthymia				Total							
	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (**)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (**)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (**)	
INCREASED LIVER ENZYMES																
Imipramine				1	1.00		1.6	2.3	1	1.00		0.6	0.8	1	1.00	
Reboxetine	1	0.9	1.3	1	1.00						1	0.6	0.8	1	1.00	
HEPATIC FUNCTION ABNORMAL																
Imipramine	1	0.9	1.2	1	1.00						1	0.6	0.8	1	1.00	

411

(**) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No: 48

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND DIAGNOSIS

Body system: METABOLIC AND NUTRITIONAL DISORDERS

Adverse events/Assigned treatment	Major Depressive Disorder				Dysthymia				Total			
	No of Pt exp.	% on exp. with AE	No of Pt AE	Ratio (*)	No of Pt exp.	% on exp. with AE	No of Pt AE	Ratio (*)	No of Pt exp.	% on exp. with AE	No of Pt AE	Ratio (*)
HYPOKALAEMIA	1	0.9	1.2	1.00					1	0.6	0.8	1.00
	1	0.9	1.3	1.00	1	1.5	2.0	2.00	2	1.1	1.6	1.50
WEIGHT DECREASE	1	0.9	1.2	1.00					1	0.6	0.8	1.00
					2	3.0	4.1	1.00	2	1.1	1.6	1.00
HYPERCHOLESTEROLAEMIA	1	0.9	1.2	1.00					1	0.6	0.8	1.00
	1	0.9	1.3	1.00					1	0.6	0.8	1.00
HYPERTRIGLYCERIDAEMIA	1	0.9	1.2	1.00					1	0.6	0.8	1.00
	1	0.9	1.3	1.00					1	0.6	0.8	1.00
BUN INCREASED	1	0.9	1.2	1.00					1	0.6	0.8	1.00
	1	0.9	1.3	1.00					1	0.6	0.8	1.00
GLOBULINS INCREASED	1	0.9	1.2	1.00					1	0.6	0.8	1.00
					1	1.5	2.0	1.00	1	0.6	0.8	1.00
GLYCOSURIA												

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No: 48

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND DIAGNOSIS

Body system: MUSCULO-SKELETAL SYSTEM DISORDERS

Adverse events/Assigned treatment	Major Depressive Disorder				Dysthymia				Total			
	No of Pt	% on exp.	No of Pt with AE	Ratio of AE (*)	No of Pt	% on exp.	No of Pt with AE	Ratio of AE (*)	No of Pt	% on exp.	No of Pt with AE	Ratio of AE (*)
ARTHRALGIA	2	1.8	2.5	2 1.00					2	1.2	1.6	2 1.00
					1	1.5	2.0	1 1.00	1	0.6	0.8	1 1.00
FRACTURE	2	1.8	2.5	2 1.00					2	1.2	1.6	2 1.00
	1	0.9	1.3	1 1.00					1	0.6	0.8	1 1.00
BACK PAIN					1	1.5	2.0	1 1.00	1	0.6	0.8	1 1.00
FRACTURE PATHOLOGICAL					1	1.6	2.3	1 1.00	1	0.6	0.8	1 1.00
NYALGIA	1	0.9	1.3	1 1.00					1	0.6	0.8	1 1.00

413

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No: 48

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND DIAGNOSIS

Body system: NEOPLASM

Adverse events/Assigned treatment	Major Depressive Disorder				Total		
	No of Pt exp.	% on exp. with AE	No of Pt with AE	Ratio No of Pt with AE (*)	No of Pt exp.	% on exp. with AE	No of Pt with AE
PULMONARY CARCINOMA Reboxetine	1	0.9	1.3	1	1	0.6	1
				1.00	1	0.6	1.00

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No: 48

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND DIAGNOSIS

Body system: PSYCHIATRIC DISORDERS

Adverse events/Assigned treatment	Major Depressive Disorder					Dysthymia					Total				
	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*): AE	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*): AE	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*): AE
INSOMNIA	5	4.6	6.2	5	1.00						5	2.9	4.0	5	1.00
	7	6.4	9.7	8	1.14	4	6.0	8.3	7	1.75	11	6.3	9.1	15	1.36
AGITATION / ANXIETY / NERVOUSNESS	3	2.8	3.7	3	1.00	1	1.6	2.3	1	1.00	4	2.3	3.2	4	1.00
	4	3.7	5.5	5	1.25	3	4.5	6.2	3	1.00	7	4.0	5.8	8	1.14
SOMNOLENCE	4	3.7	5.0	4	1.00	3	4.8	7.1	3	1.00	7	4.1	5.7	7	1.00
	4	3.7	5.5	5	1.25						4	2.3	3.3	5	1.25
PARANOID REACTION	1	0.9	1.2	1	1.00						1	0.6	0.8	1	1.00
						1	1.5	2.0	1	1.00	1	0.6	0.8	1	1.00
APATHY						1	1.6	2.3	1	1.00	1	0.6	0.8	1	1.00
						1	1.5	2.0	1	1.00	1	0.6	0.8	1	1.00
CONCENTRATION IMPAIRED															
DEPRESSION AGGRAVATED	1	0.9	1.3	1	1.00						1	0.6	0.8	1	1.00
						1	1.5	2.0	1	1.00	1	0.6	0.8	1	1.00
LIBIDO DECREASED															
PARANITRIA	1	0.9	1.3	1	1.00						1	0.6	0.8	1	1.00
						1	1.5	2.0	1	1.00	1	0.6	0.8	1	1.00
SLEEP DISORDER															
						1	1.6	2.3	1	1.00	1	0.6	0.8	1	1.00
SUICIDE ATTEMPT															
						1	1.6	2.3	1	1.00	1	0.6	0.8	1	1.00

(*): number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No: 48

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND DIAGNOSIS

Body system: REPRODUCTIVE DISORDERS, MALE

Adverse events/Assigned treatment	Major Depressive Disorder			Dysthymia			Total		
	No of Pt	% on exp.	Ratio of AE (*)	No of Pt	% on exp.	Ratio of AE (*)	No of Pt	% on exp.	Ratio of AE (*)
IMPOTENCE									
Imipramine	1	1.6	1	2.3	1	1.00	1	0.6	1
Reboxetine	1	0.9	1	1.3	1	1.00	1	0.6	1

416

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No: 48

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND DIAGNOSIS

Body system: RESISTANCE MECHANISM DISORDERS

Adverse events/Assigned treatment	Major Depressive Disorder				Dysthymia				Total			
	No of Pt	% on exp.	No of Pt with AE	Ratio No of Pt with AE (*)	% on exp.	No of Pt with AE	Ratio No of Pt with AE (*)	% on exp.	No of Pt with AE	Ratio No of Pt with AE (*)	% on exp.	No of Pt with AE
HONNIGS	1	0.9	1.3	1.00	1	1.5	1.00	2	1.1	1.00	2	1.00
INFECTIO	1	0.9	1.3	1.00				1	0.6		1	1.00

417

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No: 48

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND DIAGNOSIS

Body system: RESPIRATORY SYSTEM DISORDERS

Adverse events/Assigned treatment	Major Depressive Disorder				Dysthymia				Total			
	No of Pt	% on exp.	% on Pt with AE	Ratio (*)	No of AE	No of Pt with AE	% on exp.	Ratio (*)	No of AE	No of Pt with AE	% on exp.	Ratio (*)
BRONCHITIS	4	3.7	5.0	1.00	4	1	1.6	1.00	1	5	2.9	1.00
PNEUMONIA	1	0.9	1.3	1.00	1					1	0.6	1.00
	2	1.8	2.5	1.00	2	1	1.6	1.00	1	3	1.8	1.00
SINUSITIS						1	1.5	1.00	1	1	0.6	1.00
						1	1.6	1.00	1	1	0.6	1.00
ASTHMA	1	0.9	1.3	1.00	1					1	0.6	1.00
COUGHING	1	0.9	1.3	1.00	1					1	0.6	1.00
DYSPNOEA	1	0.9	1.2	1.00	1	1	1.5	1.00	1	1	0.6	1.00
PHARYNGITIS	1	0.9	1.3	1.00	1					1	0.6	1.00
UPPER RESP TRACT INFECTION						1	1.5	1.00	1	1	0.6	1.00

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PIARNACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No: 48
 ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
 BY ASSIGNED TREATMENT, BODY SYSTEM AND DIAGNOSIS

Body system: SKIN AND APPENDAGES DISORDERS

Adverse events/Assigned treatment	Major Depressive Disorder				Dysthymia				Total						
	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (*)
PRURITUS	1	0.9	1.2	1	1.00	1	1.6	2.3	1	1.00	2	1.2	1.6	2	1.00
ERYTHEMA / RASH	1	0.9	1.3	1	1.00						1	0.6	0.8	1	1.00
PILORECTION	1	0.9	1.3	1	1.00						1	0.6	0.8	1	1.00

419

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PRARMACIA CNS R3D

REBOXETINE - PROTOCOL 20124/035

TABLE No: 48

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND DIAGNOSIS

Body system: SPECIAL SENSES OTHER, DISORDERS

Adverse events/Assigned treatment	Major Depressive Disorder				Total			
	No of Pt on exp.	% on exp. with AE	No of Pt on exp.	Ratio (%)	No of Pt on exp.	% on exp. with AE	No of Pt on exp.	Ratio (%)
TASTE PERVERSION	1	0.9	1.2	1.00	1	0.6	0.8	1.00

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No: 48

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND DIAGNOSIS

Body system: URINARY SYSTEM DISORDERS

Adverse events/Assigned treatment	Major Depressive Disorder					Dysthymia					Total				
	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (**)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (**)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (**)
URINARY HESITANCY / RETENTION	5	4.6	6.2	5	1.00	5	8.1	11.9	5	1.00	10	5.8	8.1	10	1.00
	6	5.5	8.3	7	1.16	1	1.5	2.0	1	1.00	7	4.0	5.8	8	1.14
URINARY TRACT INFECTION	7	6.4	8.7	7	1.00	3	4.8	7.1	3	1.00	10	5.8	8.1	10	1.00
	5	4.6	6.9	6	1.20	1	1.5	2.0	1	1.00	6	3.4	5.0	7	1.16
CYSTITIS						1	1.5	2.0	1	1.00	1	0.6	0.8	1	1.00
NOCTURIA	1	0.9	1.2	1	1.00						1	0.6	0.8	1	1.00
RENAL FUNCTION ABNORMAL	1	0.9	1.3	1	1.00						1	0.6	0.8	1	1.00

(**) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No: 46

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT, BODY SYSTEM AND DIAGNOSIS

Body system: VISION DISORDERS

Adverse events/Assigned treatment	Major Depressive Disorder				Dysthymia				Total						
	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (%)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (%)	No of Pt	% on exp.	% on Pt with AE	No of AE	Ratio (%)
BLURRED VISION	3	2.8	3.7	3	1.00	3	4.8	7.1	3	1.00	6	3.5	4.9	6	1.00
	4	3.7	5.5	4	1.00	2	3.0	4.1	2	1.00	6	3.4	5.0	6	1.00
CONJUNCTIVITIS	1	0.9	1.2	1	1.00	1	1.6	2.3	1	1.00	2	1.2	1.6	2	1.00
	2	1.8	2.7	2	1.00						2	1.1	1.6	2	1.00
EYE PAIN	1	0.9	1.3	1	1.00						1	0.6	0.8	1	1.00

422

(*) number of adverse events on patients who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 49

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT AND SEX, GROUPED BY BODY SYSTEM

Body system/Assigned treatment	Female				Male				Total						
	No of Pt	% on exp.	No of Pt with AE	Ratio No of AE (*)	No of Pt	% on exp.	No of Pt with AE	Ratio No of AE (*)	No of Pt	% on exp.	No of Pt with AE	Ratio No of AE (*)			
Pt exposed	126	100.0			45	100.0			171	100.0					
	197	100.0			39	100.0			176	100.0					
Pt with a.e.	88	69.8	100.0	2.67	34	75.6	100.0	91	2.67	122	71.3	100.0	338	2.77	
	93	67.9	100.0	2.67	27	69.2	100.0	58	2.14	120	68.2	100.0	307	2.55	
GASTRO-INTESTINAL SYSTEM DISORDERS	41	32.5	46.5	57	1.39	11	24.4	32.3	16	1.45	52	30.4	42.6	73	1.40
	45	32.8	48.3	65	1.44	11	28.2	40.7	15	1.36	56	31.8	46.6	80	1.42
AUTONOMIC NERVOUS SYSTEM DISORDERS	36	28.6	40.9	44	1.22	13	28.9	38.2	15	1.15	49	28.7	40.1	59	1.20
	42	30.7	45.1	51	1.21	6	15.4	22.2	6	1.00	48	27.3	40.0	57	1.18
CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO	21	16.7	23.8	37	1.76	9	20.0	26.4	9	1.00	30	17.5	24.5	46	1.53
	27	19.7	29.0	31	1.14	8	20.5	29.6	8	1.00	35	19.9	29.1	39	1.11
CARDIOVASCULAR DISORDERS, GENERAL	25	19.8	28.4	31	1.24	11	24.4	32.3	18	1.63	36	21.1	29.5	49	1.36
	14	10.2	15.0	15	1.07	8	20.5	29.6	9	1.12	22	12.5	18.3	24	1.09
PSYCHIATRIC DISORDERS	15	11.9	17.0	17	1.13	2	4.4	5.8	2	1.00	17	9.9	13.9	19	1.11
	21	15.3	22.5	29	1.38	3	7.7	11.1	5	1.66	24	13.6	20.0	34	1.41
URINARY SYSTEM DISORDERS	14	11.1	15.9	14	1.00	7	15.6	20.5	7	1.00	21	12.3	17.2	21	1.00
	10	7.3	10.7	11	1.10	5	12.8	18.5	6	1.20	15	8.5	12.5	17	1.13
BODY AS A WHOLE-GENERAL DISORDERS	13	10.3	14.7	19	1.46	7	15.6	20.5	12	1.71	20	11.7	16.3	31	1.55
	10	7.3	10.7	15	1.50	2	5.1	7.4	3	1.50	12	6.8	10.0	18	1.50
VISION DISORDERS	6	4.8	6.8	6	1.00	2	4.4	5.8	2	1.00	8	4.7	6.5	8	1.00
	7	5.1	7.5	8	1.14	1	2.6	3.7	1	1.00	8	4.5	6.6	9	1.12
RESPIRATORY SYSTEM DISORDERS	5	4.0	5.6	6	1.20	2	4.4	5.8	4	2.00	7	4.1	5.7	10	1.42
	5	3.6	5.3	6	1.20	1	2.6	3.7	1	1.00	6	3.4	5.0	7	1.16

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 49

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT AND SEX, GROUPED BY BODY SYSTEM

Body system/Assigned treatment	Female				Male				Total			
	No of Pt	% on exp.	% on Pt with AE	Ratio No of AE (*)	No of Pt	% on exp.	% on Pt with AE	Ratio No of AE (*)	No of Pt	% on exp.	% on Pt with AE	Ratio No of AE (*)
METABOLIC AND NUTRITIONAL DISORDERS	3	2.4	3.4	4 1.33	1	2.2	2.9	1 1.00	4	2.3	3.2	5 1.25
	5	3.6	5.3	6 1.20	3	7.7	11.1	3 1.00	8	4.5	6.6	9 1.12
MUSCULO-SKELETAL SYSTEM DISORDERS	4	3.2	4.5	4 1.00	1	2.2	2.9	1 1.00	5	2.9	4.0	5 1.00
	4	2.9	4.3	4 1.00					4	2.3	3.3	4 1.00
HEMATOLOGY DISORDERS	4	3.2	4.5	4 1.00	1	2.2	2.9	1 1.00	5	2.9	4.0	5 1.00
SKIN AND APPENDAGES DISORDERS	2	1.6	2.2	2 1.00					2	1.2	1.6	2 1.00
LIVER AND BILIAR SYSTEM DISORDERS	2	1.5	2.1	2 1.00					2	1.1	1.6	2 1.00
	1	0.7	1.0	1 1.00	2	4.4	5.8	2 1.00	2	1.2	1.6	2 1.00
RESISTANCE MECHANISM DISORDERS	3	2.2	3.2	3 1.00					3	1.7	2.5	3 1.00
REPRODUCTIVE DISORDERS, MALE					1	2.2	2.9	1 1.00	1	0.6	0.8	1 1.00
ENDOCRINE DISORDERS	1	0.8	1.1	1 1.00	1	2.6	3.7	1 1.00	1	0.6	0.8	1 1.00
HEARING AND VESTIBULAR DISORDERS	1	0.7	1.0	1 1.00					1	0.6	0.8	1 1.00
NEOPLASH	1	0.7	1.0	1 1.00					1	0.6	0.8	1 1.00
SPECIAL SENSES OTHER, Imipramine	1	0.8	1.1	1 1.00					1	0.6	0.8	1 1.00

(*) number of adverse events on patients who complained of adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 50

FREQUENCY OF PATIENTS COMPLAINING OF AT LEAST ONE ADVERSE EVENT

Body system / Adverse events	Major Depressive Disorder		Dysthymia		Adj. odds ratio	
	Reboxetine	Imipramine	Reboxetine	Imipramine	Lower bound	Upper bound
EXPOSED PATIENTS	109	109	67	62		
ANY ADVERSE EVENT	72	80	48	42	0.5450	0.8610
AUTONOMIC NERVOUS SYSTEM DISORDERS	18	25	21	14	0.5770	0.9560
MOUTH DRY						
SWEATING INCREASED	11	8	5	7	0.4970	1.0380
ASTHENIA / FATIGUE	2	2	1	3	0.1380	0.5720
CARDIOVASCULAR DISORDERS, GENERAL	11	22	2	5	0.2120	0.4250
HYPOTENSION AND RELATED SYMPTOMS						
CONFUSION	3	3	3	1	0.4080	1.4720
HEADACHE / MIGRAINE	8	7	3	2	0.4880	1.2130
PARAESTHESIA	1	3	3	1	0.2340	0.9610
TREMOR	3	5	4	1	0.3730	1.1960
CONSTIPATION	22	20	9	11	0.5600	0.9700
GASTRO-INTESTINAL SYSTEM DISORDERS	11	8	9	9	0.5790	1.1510
NAUSEA AND RELATED SYMPTOMS	4	3	3	1	0.5020	1.7350
PSYCHIATRIC DISORDERS	7	5	4	4	0.7770	2.2490
AGITATION / ANXIETY / NERVOUSNESS						
INSOMNIA						
SOMNOLENCE	4	4		3	0.1630	0.5530
URINARY SYSTEM DISORDERS	6	5	1	5	0.2540	0.6720
URINARY RESISTANCY / RETENTION						
URINARY TRACT INFECTION	5	7	1	3	0.2060	0.5740
VISION DISORDERS	4	3	2	3	0.3060	0.9670
BLURRED VISION						

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 51

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

Adverse events	Assigned treatment	Total	Days of treatment																		
			0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56		
			No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	
MOUTH DRY	Imipramine	43	100	31	72.1	3	7.0	1	2.3	1	2.3	2	4.7	3	7.0	2	4.7				
	Reboxetine	41	100	26	63.4	4	9.8	5	12.2	4	9.8	1	2.4	1	2.4						
CONSTIPATION	Imipramine	42	100	15	35.7	8	19.0	6	14.3	3	7.1	4	9.5	2	4.8	2	4.8	2	4.8		
	Reboxetine	36	100	18	50.0	1	2.8	4	11.1	2	5.6	6	16.7	3	8.3	2	5.6				
SWEATING INCREASED	Imipramine	16	100	4	25.0	3	18.8			5	31.3	2	12.5	1	6.3	1	6.3				
	Reboxetine	16	100	6	37.5	3	18.8	3	18.8									1	6.3		
DIZZINESS	Imipramine	20	100	9	45.0	1	5.0	2	10.0	2	10.0	4	20.0			1	5.0	1	5.0		
	Reboxetine	12	100	4	33.3	3	25.0	1	8.3	2	16.7			1	8.3	1	8.3				
NAUSEA	Imipramine	17	100	11	64.7	1	5.9			5	29.4										
	Reboxetine	18	100	9	50.0	6	33.3			3	16.7										
TREMOR	Imipramine	6	100	3	50.0			1	16.7	1	16.7			1	16.7						
	Reboxetine	7	100	1	14.3	2	28.6			1	14.3			3	42.9						
HEADACHE	Imipramine	22	100	1	4.5	3	13.6	5	22.7	3	13.6	3	13.6	3	13.6	2	9.1	2	9.1		
	Reboxetine	13	100	3	23.1	3	23.1	4	30.8	1	7.7	1	7.7			1	7.7				
INSOMNIA	Imipramine	5	100	3	60.0	1	20.0			1	20.0										
	Reboxetine	15	100	5	33.3	1	6.7	3	20.0	2	13.3	2	13.3	2	13.3						
MICTURITION DISORDER	Imipramine	6	100			1	16.7			3	50.0			2	33.3						
	Reboxetine	5	100	2	40.0	1	20.0					1	20.0	1	20.0						
VISION ABNORMAL	Imipramine	6	100	1	16.7	2	33.3	2	33.3	1	16.7										
	Reboxetine	6	100			1	16.7			2	33.3			1	16.7					1	16.7
URINARY TRACT INFECTION	Imipramine	10	100	2	20.0			1	10.0	3	30.0	3	30.0	1	10.0						
	Reboxetine	7	100					3	42.9	1	14.3	1	14.3	1	14.3	1	14.3				

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 51

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

Adverse events	Assigned treatment	Total	Days of treatment																	
			0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56	
			No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%
SOMNOLENCE	Imipramine	7	100	3	42.9	1	14.3	2	28.6											
	Reboxetine	5	100	1	20.0			2	40.0											
ANOREXIA	Imipramine	5	100	1	20.0															
	Reboxetine	4	100	2	50.0			1	25.0	1	25.0									
TACHYCARDIA	Imipramine	6	100	4	66.7															
	Reboxetine	3	100	1	33.3	2	66.7													
FATIGUE	Imipramine	5	100	2	40.0	1	20.0													
	Reboxetine	2	100	1	50.0			1	50.0											
HYPOTENSION	Imipramine	7	100	4	57.1			1	14.3											
	Imipramine	2	100	1	50.0	1	50.0													
ABDOMINAL PAIN	Reboxetine	7	100	5	71.4			1	14.3											
	Imipramine	4	100	2	50.0			2	50.0											
PARAESTHESIA	Reboxetine	4	100	3	75.0	1	25.0													
	Imipramine	9	100	2	22.2					1	11.1	1	11.1	2	22.2	2	22.2	1	11.1	
MALAISE	Reboxetine	3	100			1	33.3	1	33.3											
	Imipramine	4	100	1	25.0	2	50.0			1	25.0									
CONFUSION	Reboxetine	6	100	2	33.3	2	33.3	1	16.7											
	Imipramine	5	100	2	40.0	2	40.0													
HYPOTENSION POSTURAL	Reboxetine	2	100	1	50.0															
	Imipramine	4	100	1	25.0					1	25.0	1	25.0	1	25.0					
AGITATION	Reboxetine	4	100	1	25.0			1	25.0											
	Imipramine	1	100	1	100															

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 51

4-2-00

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

Adverse events	Assigned treatment	Days of treatment																				
		Total		0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56		
		No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	
IMPOTENCE	Reboxetine	1	100			1	100															
	Reboxetine	3	100	1	33.3			2	66.7													
	Imipramine	5	100	1	20.0					2	40.0	1	20.0								1	20.0
BRONCHITIS	Reboxetine	1	100									1	100									
	Imipramine	9	100	2	22.2	1	11.1			2	22.2	3	33.3								1	11.1
	Reboxetine	3	100	1	33.3			1	33.3												1	33.3
RIGORS	Reboxetine	2	100																			
	Imipramine	4	100	4	100																	
	Reboxetine	3	100	1	33.3			1	33.3													
URINARY RETENTION	Imipramine	1	100																			
	Reboxetine	2	100	1	50.0																	
	Imipramine	1	100					1	100													
WEIGHT DECREASE	Reboxetine	2	100	1	50.0																	
	Imipramine	2	100			2	100															
	Reboxetine	2	100																			
CONJUNCTIVITIS	Reboxetine	2	100																			
	Imipramine	2	100																			
	Reboxetine	2	100																			
ANXIETY	Reboxetine	2	100																			
	Imipramine	2	100	1	50.0																	
	Reboxetine	2	100																			
ATAXIA	Reboxetine	2	100																			
	Imipramine	1	100	1	100																	
	Reboxetine	2	100																			
DYSPHAGIA	Imipramine	1	100	1	100																	
	Reboxetine	2	100	1	50.0																	
	Imipramine	1	100	1	100																	
FLATULENCE	Reboxetine	1	100	1	100																	
	Imipramine	1	100	1	100																	
	Reboxetine	1	100	1	100																	
MYOCARDIAL INFARCTION	Imipramine	1	100	1	100																	
	Reboxetine	1	100	1	100																	
	Imipramine	1	100	1	100																	

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 51

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

Adverse events	Assigned treatment	Days of treatment																				
		Total		0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56		
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	
GASTRO-INTESTINAL DISORDER NOS	Reboxetine	2	100	1	50.0																	
	Imipramine	1	100																			
PAIN	Reboxetine	4	100			1	25.0	2	50.0													
	Imipramine	1	100	1	100																	
PALPITATION	Reboxetine	2	100	1	50.0																	
	Imipramine	1	100	1	100																	
CHEST PAIN PRECORDIAL	Reboxetine	1	100																			
	Imipramine	1	100	1	100																	
STOMATITIS	Reboxetine	1	100																			
	Imipramine	1	100			1	100															
DIARRHOEA	Reboxetine	3	100																			
	Imipramine	3	100			1	33.3															
HYPERTENSION	Reboxetine	2	100																			
	Imipramine	2	100	1	50.0	1	50.0															
HYPOKALAEMIA	Reboxetine	1	100																			
	Imipramine	1	100	1	100																	
EAR DISORDER NOS	Reboxetine	3	100																			
	Imipramine	1	100	1	100																	
TASTE PERVERSION	Reboxetine	1	100																			
	Imipramine	1	100	1	100																	
OEDEMA PERIPHERAL	Reboxetine	1	100																			
	Imipramine	1	100																			
HYPERCHOLESTEROLAEMIA	Reboxetine	1	100																			
	Imipramine	1	100																			
PNEUMONIA	Reboxetine	3	100																			
	Imipramine	3	100																			
	Reboxetine	4	100	1	100																	
	Imipramine	4	100																			

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 51

430

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

Adverse events	Assigned treatment	Days of treatment																					
		Total		0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56			
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%		
FRACTURE PATHOLOGICAL	Imipramine	1	100			1	100																
DYSKINESIA	Imipramine	2	100			1	50.0																
RENAL FUNCTION ABNORMAL	Reboxetine	1	100						1	100													
SINUSITIS	Imipramine	1	100																				
	Reboxetine	1	100																		1	100	
ARTHRALGIA	Imipramine	2	100	1	50.0																		
	Reboxetine	1	100																			1	100
MONILIASIS	Reboxetine	2	100					1	50.0														
BUNDLE BRANCH BLOCK	Imipramine	1	100																				
	Reboxetine	1	100																				
LIBIDO DECREASED	Reboxetine	1	100																				
FIBRILLATION ATRIAL	Imipramine	1	100																				
	Reboxetine	1	100																				
FRACTURE	Imipramine	2	100																				
	Reboxetine	1	100	1	100																		
PARANOID REACTION	Imipramine	1	100																				
	Reboxetine	1	100																				
COORDINATION ABNORMAL	Imipramine	1	100																				
	Reboxetine	1	100																				
ANAEMIA	Imipramine	3	100																				
	Reboxetine	1	100																				
CONCENTRATION IMPAIRED	Reboxetine	1	100																				
	Imipramine	2	100	1	50.0																		

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 51

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

Adverse events	Assigned treatment	Total	Days of treatment																	
			0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56	
			No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%
FEVER	Imipramine	2	100					1	50.0											
	Reboxetine	1	100																	
	Reboxetine	1	100																	
CYSTITIS	Imipramine	1	100																	
	Reboxetine	2	100																	
	Reboxetine	2	100																	
INFLUENZA-LIKE SYMPTOMS	Imipramine	1	100																	
	Reboxetine	1	100																	
	Reboxetine	1	100																	
ASTHMA	Imipramine	1	100																	
	Reboxetine	1	100																	
	Reboxetine	1	100																	
HYPOAESTHESIA	Imipramine	1	100																	
	Reboxetine	1	100																	
	Reboxetine	1	100																	
NERVOUSNESS	Imipramine	2	100																	
	Reboxetine	2	100																	
	Reboxetine	2	100																	
GLOSSITIS	Imipramine	2	100																	
	Reboxetine	2	100																	
	Reboxetine	2	100																	
PILORECTION	Imipramine	1	100																	
	Reboxetine	1	100																	
	Reboxetine	1	100																	
BUN INCREASED	Imipramine	1	100																	
	Reboxetine	1	100																	
	Reboxetine	1	100																	
NOCTURIA	Imipramine	1	100																	
	Reboxetine	1	100																	
	Reboxetine	1	100																	
SYNCOPE	Imipramine	2	100																	
	Reboxetine	2	100																	
	Reboxetine	2	100																	
VOMITING	Imipramine	1	100																	
	Reboxetine	1	100																	
	Reboxetine	1	100																	
ALLERGIC REACTION	Imipramine	1	100																	
	Reboxetine	1	100																	
	Reboxetine	1	100																	
EYE PAIN	Imipramine	1	100																	
	Reboxetine	1	100																	
	Reboxetine	1	100																	
PARONYCHIA	Imipramine	1	100																	
	Reboxetine	1	100																	
	Reboxetine	1	100																	
COMA	Imipramine	1	100																	
	Reboxetine	1	100																	
	Reboxetine	1	100																	
CEREBROVASCULAR DISORDER	Imipramine	1	100																	
	Reboxetine	1	100																	
	Reboxetine	1	100																	

431

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 51

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

Adverse events	Assigned treatment	Days of treatment																					
		Total		0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56			
		No	AE %	No	AE %	No	AE %	No	AE %	No	AE %	No	AE %	No	AE %	No	AE %	No	AE %	No	AE %		
NEURALGIA	Reboxetine	2	100			1	50.0																
COUGHING	Reboxetine	1	100			1	100																
ASTHENIA	Reboxetine	1	100			1	100																
DEPRESSION AGGRAVATED	Reboxetine	1	100						1	100													
EXTRASYSTOLES	Reboxetine	1	100									1	100										
HYPOTHYROIDISM	Imipramine	1	100											1	100								
RASH EXTREMATOUS	Reboxetine	1	100													1	100						
UPPER RESP TRACT INFECTION	Reboxetine	1	100															1	100				
SOPT INCREASED	Imipramine	1	100																	1	100		
GRANULOCYTOPENIA	Imipramine	1	100																		1	100	
HYPERTRIGLYCERIDAEMIA	Imipramine	1	100																			1	100
VERTIGO	Reboxetine	1	100																			1	100
SUICIDE ATTEMPT	Imipramine	1	100			1	100																
SLEEP DISORDER	Imipramine	1	100			1	100																
PULMONARY CARCINOMA	Reboxetine	1	100			1	100																
NEUROPATHY	Reboxetine	1	100																				
DYSPNOEA	Reboxetine	1	100																				
STUPOR	Imipramine	1	100																				
PURPURA	Imipramine	1	100																				
NEBRITIS	Reboxetine	1	100																				

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

- PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 51

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

Adverse events	Assigned treatment	Total	Days of treatment																		
			0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56		
			No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	
THROMBOSIS ARTERIAL	Reboxetine	1	100																		
BACK PAIN	Reboxetine	1	100						1	100											
CONVULSIONS	Imipramine	1	100																		
HEPATIC FUNCTION ABNORMAL	Imipramine	1	100																		
GLOBULINS INCREASED	Imipramine	1	100																		
CHEST PAIN	Imipramine	1	100																		
HYPERKINESIA	Reboxetine	1	100																		
APATHY	Imipramine	1	100																		
CONVULSIONS GRAND MAL	Reboxetine	1	100																		
PHARYNGITIS	Reboxetine	1	100																		
INFECTION	Reboxetine	1	100																		
ESR INCREASED	Imipramine	1	100																		
NASAL POLYP	Imipramine	1	100																		
PERIPHERAL ISCHAEMIA	Imipramine	1	100																		
GAMMA-GT INCREASED	Reboxetine	1	100																		
GLYCOSURIA	Reboxetine	1	100																		

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 52

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: AUTONOMIC NERVOUS SYSTEM DISORDERS

Adverse events/Assigned treatment	Total		Days of treatment																	
	No AE	Z	0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56	
			No AE	Z	No AE	Z	No AE	Z	No AE	Z	No AE	Z	No AE	Z	No AE	Z	No AE	Z	No AE	Z
MOUTH DRY	43	100	31	72.1	3	7.0	1	2.3	1	2.3	2	4.7	3	7.0	2	4.7				
	41	100	26	63.4	4	9.8	5	12.2	4	9.8	1	2.4	1	2.4						
SWEATING INCREASED	16	100	4	25.0	3	18.8			5	31.3	2	12.5	1	6.3	1	6.3				
	16	100	6	37.5	3	18.8	3	18.8	3	18.8							1	6.3		

434

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 52
 ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Adverse events/Assigned treatment	Total	Days of treatment																	
		0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56	
		No	AE %	No	AE %	No	AE %	No	AE %	No	AE %	No	AE %	No	AE %	No	AE %	No	AE %
ASTHENIA / FATIGUE	5	100	2	40.0	1	20.0													
	3	100	1	33.3	1	33.3													
MALAISE	9	100	2	22.2			1	11.1	1	11.1	2	22.2	2	22.2	1	11.1			
	3	100			1	33.3													
FALL	9	100	2	22.2	1	11.1			2	22.2	3	33.3							
	3	100	1	33.3															
RIGORS	2	100			2	100													
PAIN	1	100																	
FEVER	4	100			1	25.0	2	50.0			1	25.0							
	2	100	1	50.0			1	50.0											
INFLUENZA-LIKE SYMPTOMS	1	100																	
	2	100	2	100															
ALLERGIC REACTION	1	100																	
	1	100	1	100															
CHEST PAIN	1	100																	
ESR INCREASED	1	100																	
NASAL POLYP	1	100																	

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 52

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: CARDIOVASCULAR DISORDERS, GENERAL

Adverse events/Assigned treatment	Total		Days of treatment																	
			0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56	
			No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%
HYPOTENSION AND RELATED SYMPTOMS	34	100	16	47.1	3	8.8	4	11.8	2	5.9	5	14.7	2	5.9	1	2.9	1	2.9		
	Reboxetine																			
TACHYCARDIA	14	100	5	35.7	3	21.4	1	7.1	2	14.3			2	14.3	1	7.1				
	Imipramine																			
HYDARDIAL INFARCTION	3	100	1	33.3	2	66.7														
	Reboxetine																			
CARDIAC ISCHEMIA AND RELATED SYMPTOMS	1	100	1	100																
	Imipramine																			
PALPITATION	1	100	1	100																
	Reboxetine																			
HYPERTENSION	2	100	1	50.0																
	Imipramine																			
AEDEMA	1	100								1	100									
	Reboxetine																			
BUNDLE BRANCH BLOCK	1	100								1	100									
	Imipramine																			
FIBRILLATION ATRIAL	1	100								1	100									
	Imipramine																			
CEREBROVASCULAR DISORDER	1	100																		
	Reboxetine																			
EXTRASYSTOLES	1	100																		
	Reboxetine																			
THROMBOSIS ARTERIAL	1	100																		
	Reboxetine																			
PERIPHERAL ISCHAEMIA	1	100																		
	Imipramine																			

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 52

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO

Adverse events/Assigned treatment	Total		Days of treatment																	
	No	AE %	0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56	
			No	AE %	No	AE %	No	AE %	No	AE %	No	AE %	No	AE %	No	AE %	No	AE %	No	AE %
TREMR	6	100	3	50.0			1	16.7	1	16.7										
HEADACHE / MIGRAINE	7	100	1	14.3	2	28.6			1	14.3	3	42.9								
	22	100	1	4.5	3	13.6	5	22.7	3	13.6	3	13.6	3	13.6	2	9.1	2	9.1		
	13	100	3	23.1	3	23.1	4	30.8	1	7.7	1	7.7			1	7.7				
PARAESTHESIA	4	100	2	50.0			2	50.0												
	4	100	3	75.0	1	25.0														
CONFUSION	4	100	1	25.0	2	50.0			1	25.0										
	6	100	2	33.3	2	33.3	1	16.7							1	16.7				
ATAXIA	2	100	1	50.0					1	50.0										
	2	100			1	50.0			1	50.0										
DYSKINESIA	2	100			1	50.0	1	50.0												
COORDINATION ABNORMAL	1	100							1	100										
HYPOAESTHESIA	1	100																		
	1	100							1	100										
COMA	1	100			1	100														
NEURALGIA	2	100			1	50.0														
VERTIGO	1	100	1	100																
NEUROPATHY	1	100			1	100														
STUPOR	1	100							1	100										
NEURITIS	1	100							1	100										
CONVULSIONS	1	100																	1	100

(CONTINUED)

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R8D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 52

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO

Adverse events/Assigned treatment	Total		Days of treatment																											
	No AE	%	0-7	8-14	15-21	22-28	29-35	36-42	43-49	50-56	> 56	0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56		
			No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
HYPERKINESIA	1	100					1	100																						
CONVULSIONS GRAND MAL	1	100																												

438

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 52

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: ENDOCRINE DISORDERS

Adverse events/Assigned treatment	Total		Days of treatment																		
	No AE	X	0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56		
			No AE	X	No AE	X	No AE	X	No AE	X	No AE	X	No AE	X	No AE	X	No AE	X	No AE	X	
HYPOTHYROIDISM Imipramine	1	100												1	100						

439

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R3D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 52

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: GASTRO-INTESTINAL SYSTEM DISORDERS

Adverse events/Assigned treatment	Total		Days of treatment																											
	No	%	0-7	8-14	15-21	22-28	29-35	36-42	43-49	50-56	> 56	0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56		
	AE	%	No	AE	%	No	AE	%	No	AE	%	No	AE	%	No	AE	%	No	AE	%	No	AE	%	No	AE	%	No	AE	%	
CONSTIPATION	42	100	15	35.7	8	19.0	6	14.3	3	7.1	4	9.5	2	4.8	2	4.8	2	4.8	2	4.8	2	4.8	2	4.8	2	4.8	2	4.8	2	4.8
	36	100	18	50.0	1	2.8	4	11.1	2	5.6	6	16.7	3	8.3	2	5.6														
NAUSEA AND RELATED SYMPTOMS	18	100	12	66.7	1	5.6			5	27.8																				
	22	100	10	45.5	7	31.8	2	9.1	3	13.6																				
ANOREXIA	5	100			1	20.0			1	20.0																				
	4	100	2	50.0			1	25.0	1	25.0																				
ABDOMINAL PAIN	2	100	1	50.0			1	50.0																						
	7	100	5	71.4			1	14.3																						
DYSPHAGIA	1	100	1	100																										
	2	100	1	50.0																										
FLATULENCE	1	100	1	100																										
	1	100	1	100																										
GASTRO-INTESTINAL DISORDER NOS	2	100	1	50.0			1	50.0																						
	1	100							1	100																				
STOMATITIS	1	100																												
	1	100			1	100																								
DIARRHOEA	3	100																												
	3	100																												
GLOSSITIS	2	100																												
	2	100			2	100																								

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 52

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: HEARING AND VESTIBULAR DISORDERS

Adverse events/Assigned treatment	Days of treatment																					
	Total		0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56			
	No	AE %	No	AE %	No	AE %	No	AE %	No	AE %	No	AE %	No	AE %	No	AE %	No	AE %	No	AE %		
EAR DISORDER NOS	1	100	1	100																		
Reboxetine																						

441

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No. : 52

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: HEMATOLOGY DISORDERS

Adverse events/Assigned treatment	Total	Days of treatment																	
		0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
ANEMIA	3	100				1	33.3												
GRANULOCYTOPENIA	1	100																	
PURPURA	1	100				1	100												

442

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 52

ADVERSE EVENTS: OCCURENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: LIVER AND BILIAR SYSTEM DISORDERS	Adverse events/Assigned treatment	Total	Days of treatment																	
			0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56	
			No	AE %	No	AE %	No	AE %	No	AE %	No	AE %	No	AE %	No	AE %	No	AE %	No	AE %
INCREASED LIVER ENZYMES	Imipramine	1	100																	
	Reboxetine	1	100																	
HEPATIC FUNCTION ABNORMAL	Imipramine	1	100							1	100									

443

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 52

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: METABOLIC AND NUTRITIONAL DISORDERS

Adverse events/Assigned treatment	Total		Days of treatment												
	No	%	0-7	8-14	15-21	22-28	29-35	36-42	43-49	50-56	> 56				
	AE	Z	No	AE	Z	No	AE	Z	No	AE	Z	No	AE	Z	
WEIGHT DECREASE	1	100			1	100									
	2	100	1	50.0											
HYPOKALAEMIA	1	100	1	100											
	3	100			1	33.3							1	33.3	
HYPERCHOLESTEROLAEMIA	1	100												1	100
	1	100				1	100								
BUN INCREASED	1	100				1	100								
HYPERTRIGLYCERIDAEMIA	1	100												1	100
	1	100										1	100		
GLOBULINS INCREASED	1	100													
GLYCOSURIA	1	100												1	100

4 4 4

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 52

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: MUSCULO-SKELETAL SYSTEM DISORDERS

Adverse events/Assigned treatment	Total	Days of treatment																	
		0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56	
		No	AE %	No	AE %	No	AE %	No	AE %	No	AE %	No	AE %	No	AE %	No	AE %	No	AE %
FRACTURE PATHOLOGICAL	1	100																	
ARTHRALGIA	2	100	1	50.0															
	1	100																	
MYALGIA	1	100																	
FRACTURE	2	100					1	100											
	1	100																	
BACK PAIN	1	100					1	100											

445

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 52

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: NEOPLASIA

Adverse events/Assigned treatment	Total		Days of treatment														
	No AE	X	0-7	8-14	15-21	22-28	29-35	36-42	43-49	50-56	> 56						
			No AE	X	No AE	X	No AE	X	No AE	X	No AE	X	No AE	X			
PULMONARY CARCINOMA	1	100	1	100													
Reboxetine																	

446

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 52

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: PSYCHIATRIC DISORDERS

Adverse events/Assigned treatment	Total		Days of treatment																			
			0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56			
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%		
INSOMNIA	5	100	3	60.0	1	20.0			1	20.0												
	15	100	5	33.3	1	6.7	3	20.0	2	13.3	2	13.3	2	13.3								
SOMNOLENCE	7	100	3	42.9	1	14.3	2	28.6			1	14.3										
	5	100	1	20.0			1	20.0	2	40.0											1	20.0
AGITATION / ANXIETY / NERVOUSNESS	4	100	1	25.0					1	25.0	1	25.0	1	25.0								
REBOXETINE	8	100	1	12.5	1	12.5	3	37.5	1	12.5	1	12.5	1	12.5	1	12.5	1	12.5				
REBOXETINE	1	100							1	100												
IMIPRAMINE	1	100									1	100										
REBOXETINE	1	100			1	100																
REBOXETINE	1	100									1	100										
CONCENTRATION IMPAIRED	1	100																				
REBOXETINE	1	100	1	100																		
PARONIRIA	1	100																				
DEPRESSION AGGRAVATED	1	100							1	100												
SUICIDE ATTEMPT	1	100	1	100																		
SLEEP DISORDER	1	100	1	100																		
APATHY	1	100																			1	100

447

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 52

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: REPRODUCTIVE DISORDERS, MALE

Adverse events/Assigned treatment	Total	Days of treatment																	
		0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
IMPOTENCE																			
Imipramine	1	100																	
Reboxetine	1	100	1	100															

448

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 52

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: RESISTANCE MECHANISM DISORDERS

Adverse events/Assigned treatment	Total		Days of treatment												
	No	%	0-7	8-14	15-21	22-28	29-35	36-42	43-49	50-56	> 56				
	AE	Z	No	AE	Z	No	AE	Z	No	AE	Z	No	AE	Z	
MONILIASIS	2	100			1	50.0									
INFECTIO	1	100										1	100		

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 52

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: RESPIRATORY SYSTEM DISORDERS

Adverse events/Assigned treatment	Total	Days of treatment																		
		0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56		
		No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	
BRONCHITIS	5	100	1	20.0					2	40.0										
PNEUMONIA	3	100						1	33.3											
SINUSITIS	1	100	1	100																
ASTHMA	1	100																		
COUGHING	1	100																		
UPPER RESP TRACT INFECTION	1	100																		
DYSPNOEA	1	100																		
PHARYNGITIS	1	100																		

450

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 52

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: SKIN AND APPENDAGES DISORDERS

Adverse events/Assigned treatment	Total	Days of treatment																		
		0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56		
		No AE	Z	No AE	Z	No AE	Z	No AE	Z	No AE	Z	No AE	Z	No AE	Z	No AE	Z	No AE	Z	
PRURITUS	2	100	1	50.0	1	50.0														
PILOBRECTION	1	100					1	100												
ERYTHEMA / RASH	1	100												1	100					

451

(some adverse events are grouped in cluster.)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 52

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: SPECIAL SENSES OTHER, DISORDERS

Adverse events/Assigned treatment	Total		Days of treatment																	
	No AE	%	0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56	
					No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
TASTE PERVERSION	1	100			1	100														

452

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 52

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: URINARY SYSTEM DISORDERS

Adverse events/Assigned treatment	Total	Days of treatment																	
		0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56	
		No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%	No AE	%
URINARY HESITANCY / RETENTION	10	100	4	40.0	1	10.0		3	30.0			2	20.0						
	8	100	3	37.5	2	25.0	1	12.5			1	12.5							
URINARY TRACT INFECTION	10	100	2	20.0			1	10.0	3	30.0	3	30.0	1	10.0					
	7	100					3	42.9	1	14.3	1	14.3	1	14.3					
RENAL FUNCTION ABNORMAL	1	100					1	100											
CYSTITIS	1	100	1	100															
NOCTURIA	1	100																	

453

(some adverse events are grouped in cluster.)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 52

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: VISION DISORDERS

Adverse events/Assigned treatment	Total	Days of treatment																		
		0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56		
		No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	
BLURRED VISION		6	100	1	16.7	2	33.3	2	33.3	1	16.7									
CONJUNCTIVITIS		6	100	1	16.7					2	33.3	1	16.7			1	16.7			
EYE PAIN		2	100	2	100															
		2	100							1	50.0									
		1	100																	

454

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 53

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

Body system	Assigned treatment	Days of treatment																				
		Total		0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56		
		No AE	Z	No AE	Z	No AE	Z	No AE	Z	No AE	Z	No AE	Z	No AE	Z	No AE	Z	No AE	Z	No AE	Z	
GASTRO-INTESTINAL SYSTEM DISORDERS	Imipramine	73	100	30	41.1	11	15.1	6	8.2	11	15.1	4	5.5	5	6.8	2	2.7	4	5.5			
	Reboxetine	80	100	38	47.5	8	10.0	12	15.0	6	7.5	6	7.5	4	5.0	4	5.0	2	2.5			
AUTONOMIC NERVOUS SYSTEM DISORDERS	Imipramine	59	100	35	59.3	6	10.2	1	1.7	6	10.2	4	6.8	4	6.8	3	5.1					
	Reboxetine	57	100	32	56.1	7	12.3	8	14.0	7	12.3	1	1.8	1	1.8			1	1.8			
CARDIOVASCULAR DISORDERS, GENERAL	Imipramine	49	100	24	49.0	5	10.2	4	8.2	4	8.2	5	10.2	3	6.1	2	4.1	1	2.0	1	2.0	
	Reboxetine	24	100	7	29.2	6	25.0	1	4.2	4	16.7	1	4.2	2	8.3	1	4.2	2	8.3			
CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO	Imipramine	46	100	9	19.6	7	15.2	9	19.6	8	17.4	5	10.9	4	8.7	2	4.3	2	4.3			
	Reboxetine	39	100	9	23.1	11	28.2	6	15.4	4	10.3	5	12.8			4	10.3					
PSYCHIATRIC DISORDERS	Imipramine	19	100	8	42.1	2	10.5	2	10.5	2	10.5	3	15.8	1	5.3	1	5.3					
	Reboxetine	34	100	9	26.5	3	8.8	7	20.6	7	20.6	3	8.8	3	8.8	1	2.9	1	2.9			
URINARY SYSTEM DISORDERS	Imipramine	21	100	6	28.6	1	4.8	1	4.8	6	28.6	4	19.0	3	14.3							
	Reboxetine	17	100	4	23.5	2	11.8	1	5.9	4	23.5	2	11.8	2	11.8	1	5.9	1	5.9			
BODY AS A WHOLE-GENERAL DISORDERS	Imipramine	31	100	8	25.8	2	6.5	1	3.2	4	12.9	5	16.1	3	9.7	3	9.7	5	16.1			
	Reboxetine	18	100	4	22.2	5	27.8	5	27.8							1	5.6	2	11.1	1	5.6	
VISION DISORDERS	Imipramine	8	100	1	12.5	4	50.0	2	25.0	1	12.5											
	Reboxetine	9	100	1	11.1	1	11.1			3	33.3	2	22.2	1	11.1			1	11.1			
RESPIRATORY SYSTEM DISORDERS	Imipramine	10	100	1	10.0			1	10.0	3	30.0	1	10.0					2	20.0	2	20.0	
	Reboxetine	7	100	1	14.3	2	28.6											2	28.6			
METABOLIC AND NUTRITIONAL DISORDERS	Imipramine	5	100	1	20.0			1	20.0			1	20.0								2	40.0
	Reboxetine	9	100	1	11.1			1	11.1	2	22.2	2	22.2					1	11.1	2	22.2	

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 53

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

Body system	Assigned treatment	Total No AE	Days of treatment																	
			0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56	
			No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%
MUSCULO-SKELETAL SYSTEM DISORDERS	Imipramine	5	100	1	20.0															
	Reboxetine	4	100	1	25.0				2	50.0										
REPRODUCTIVE DISORDERS, MALE	Imipramine	1	100	1	100															
	Reboxetine	1	100																	
SKIN AND APPENDAGES DISORDERS	Imipramine	2	100	1	50.0															
	Reboxetine	2	100						1	50.0										
HEARING AND VESTIBULAR DISORDERS	Reboxetine	1	100	1	100															
	Imipramine	1	100																	
SPECIAL SENSES OTHER, DISORDERS	Imipramine	1	100																	
	Reboxetine	1	100																	
HEMATOLOGY DISORDERS	Imipramine	5	100						2	40.0										
	Reboxetine	3	100			1	33.3							1	33.3					
RESISTANCE MECHANISM DISORDERS	Imipramine	2	100																	
	Reboxetine	1	100																	
LIVER AND BILIAR SYSTEM DISORDERS	Imipramine	1	100																	
	Reboxetine	1	100																	
ENDOCRINE DISORDERS	Imipramine	1	100																	
	Reboxetine	1	100																	
NEOPLASM	Reboxetine	1	100																	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 54

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Adverse events / severity	Adverse events Number		Dose taken on onset date			Highest dose taken from 3 days before		
	Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose	
All adverse events	Mild	128	103	25		115	13	
	Moderate	124	105	16		109	12	
	Severe	55	53	2		52	3	
	Unknown	3	3			3		
Total	307	264	43		279	28		
MOUTH DRY	Mild	24	22	2		24		
	Moderate	12	11	1		11	1	
	Severe	5	5			5		
	Total	41	38	3		40	1	
CONSTIPATION	Mild	45	12	3		13	2	
	Moderate	14	13	1		13	1	
	Severe	7	6	1		5	2	
	Total	36	31	5		31	5	
HEADACHE	Mild	3	2	1		3		
	Moderate	8	7	1		7	1	
	Severe	2	2			2		
	Total	13	11	2		12	1	
DIZZINESS	Mild	4	4			4		
	Moderate	5	4	1		5		
	Severe	2	2			2		
	Unknown	1	1			1		

(CONTINUED)

(*) all remainder patients
 REBOXETINE - low dose <= 4 mg/day, high dose > 6 mg/day
 IMIPRAMINE - low dose <= 75 mg/day, high dose > 100 mg/day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 54

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Adverse events / severity	Adverse events		Dose taken on onset date			Highest dose taken from 3 days before		
	Number		Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
DIZZINESS	Total	12	11	1		12		
	Mild	11	8	3		11		
	Moderate	3	2	1		3		
	Severe	3	3			3		
	Unknown	1	1			1		
SWEATING INCREASED	Total	18	14	4		18		
	Mild	5	4	1		5		
	Moderate	8	8			8		
	Severe	3	2	1		3		
	Total	16	14	2		16		
URINARY TRACT INFECTION	Mild	5	4	1		4	1	
	Moderate	2	2			2		
	Total	7	6	1		6	1	
	Mild	1	1			1		
	Moderate	2	2			2		
FALL	Total	3	3			3		
	Moderate	2	1	1		1	1	
	Severe	1	1			1		
	Total	3	2	1		2	1	
	Mild	3	2	1		3		
SOMNOLENCE	Moderate	2	1	1		1	1	
	Total	2	1	1		1	1	
	Mild	3	2	1		2	1	
	Moderate	2	1	1		1	1	
	Total	5	3	2		3	2	

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 4 mg/day, high dose > 4 mg/day
IMIPRAMINE - low dose <= 75 mg/day, high dose > 100 mg/day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 54

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Adverse events / severity	Adverse events Number		Dose taken on onset date			Highest dose taken from 3 days before		
	Total	Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
SOMNOLENCE	Total	5	3	2		4	1	
TREMOR	Mild	6	2	4		3	3	
	Moderate	1	1			1		
TACHYCARDIA	Total	7	3	4		4	3	
	Mild	1	1			1		
VISION ABNORMAL	Moderate	1	1			1		
	Severe	1	1			1		
	Total	3	3			3		
	Mild	4	2	2		2	2	
MICTURITION DISORDER	Moderate	2	2			2		
	Total	6	4	2		4	2	
	Mild	5	4	1		3	2	
ANOREXIA	Total	5	4	1		3	2	
	Mild	1	1			1		
	Moderate	2	1	1		2		
	Severe	1	1			1		
HYPOTENSION POSTURAL	Total	4	3	1		4		
	Mild	1	1			1		
	Moderate	1	1			1		
INSOMNIA	Total	2	2			2		
	Mild	2		2		2		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 4 mg/day, high dose > 4 mg/day
IMIPRAMINE - low dose <= 75 mg/day, high dose > 100 mg/day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 54

460

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Adverse events / severity	Adverse events		Dose taken on onset date			Highest dose taken from 3 days before		
	Number		Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
INSOMNIA	Moderate	9	7	2		6	3	
	Severe	4	4			4		
	Total	15	11	4		12	3	
BRONCHITIS	Moderate	1		1			1	
	Total	1		1			1	
FATIGUE	Mild	2	2			2		
	Total	2	2			2		
CONFUSION	Moderate	3	3			3		
	Severe	3	3			3		
	Total	6	6			6		
PARESTHESIA	Mild	4	4			4		
	Total	4	4			4		
AGITATION	Moderate	2	2			2		
	Severe	1	1			1		
	Unknown	1	1			1		
URINARY RETENTION	Moderate	4	4			4		
	Total	2	2			2		
DIARRHOEA	Moderate	1	1			1		
	Total	3	3			3		
DIARRHOEA	Mild	3	2	1		2	1	
	Total	3	2	1		2	1	

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 4 mg/day, high dose > 6 mg/day
IMIPRAMINE - low dose <= 75 mg/day, high dose > 100 mg/day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 54

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Adverse events / severity	Adverse events		Dose taken on onset date			Highest dose taken from 3 days before		
	Number		Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
PNEUMONIA	Mild	1	1			1		
	Total	1	1			1		
ATAXIA	Mild	2	1	1		1		1
	Total	2	1	1		1		1
CONJUNCTIVITIS	Mild	1	1			1		
	Moderate	1	1			1		
	Total	2	2			2		
ABDOMINAL PAIN	Mild	1	1			1		
	Moderate	5	5			5		
	Severe	1	1			1		
	Total	7	7			7		
FEVER	Moderate	1	1			1		
	Total	1	1			1		
	Severe	1	1			1		
FRACTURE	Total	1	1			1		
	Moderate	1	1			1		
	Severe	1	1			1		
ARTHRALGIA	Total	1	1			1		
	Moderate	1	1			1		
	Total	1	1			1		
HYPERTENSION	Moderate	1	1			1		
	Total	1	1			1		
	Moderate	1	1			1		
HYPOAESTHESIA	Moderate	1	1			1		
	Total	1	1			1		
	Moderate	1	1			1		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 4 mg/day, high dose > 4 mg/day
IMIPRAMINE - low dose <= 75 mg/day, high dose > 100 mg/day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 54

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Adverse events / severity	Adverse events			Dose taken on onset date			Highest dose taken from 3 days before			
	Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
VOMITING	Mild	1	1					1		
	Total	1	1					1		
IMPOTENCE	Mild	1	1					1		
	Total	1	1					1		
HYPERCHOLESTEROLAEMIA	Moderate	1	1					1		
	Total	1	1					1		
HYPOALAEMIA	Moderate	1	1						1	
	Severe	2	2					1	1	
Total		3	3					1	2	
		1	1					1		
HYPERTRIGLYCERIDAEMIA	Mild	1	1					1		
	Total	1	1					1		
SINUSITIS	Moderate	1	1					1		
	Total	1	1					1		
INFLUENZA-LIKE SYMPTOMS	Mild	1	1					1		
	Severe	1	1					1		
Total		2	2					2		
		1	1					1		
PALPITATION	Mild	1	1					1		
	Severe	1	1					1		
Total		2	2					2		
		2	2					2		
DYSPRAGIA	Moderate	2	2					2		
	Total	2	2					2		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 4 mg/day, high dose > 4 mg/day
INIPRAMINE - low dose <= 75 mg/day, high dose > 100 mg/day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 54
ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE
BY SEVERITY AND ASSIGNED TREATMENT

47
C3
C3

Assigned treatment: Reboxetine

Adverse events / severity	Adverse events			Dose taken on onset date			Highest dose taken from 3 days before			
	Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
WEIGHT DECREASE	Mild	1		1						1
	Severe	1	1					1		
	Total	2	1	1				1		1
FIBRILLATION ATRIAL	Moderate	1	1					1		
	Total	1	1					1		
	Severe	1	1					1		
PARANOID REACTION	Total	1	1					1		
	Mild	1	1					1		
	Total	1	1					1		
FLATULENCE	Total	1	1					1		
	Moderate	1	1					1		
	Total	1	1					1		
STOMATITIS	Total	1	1					1		
	Mild	2	2					2		
	Moderate	2	2					2		
PAIN	Total	4	4					4		
	Moderate	3	3					3		
	Total	3	3					3		
DYSPEPSIA	Mild	1	1					1		
	Moderate	1								1
	Total	2	1	1				1		1
GLOSSITIS	Mild	1	1					1		
	Severe	1	1					1		
	Total	1	1					1		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 4 mg/day, high dose > 6 mg/day
IMIPRAMINE - low dose <= 75 mg/day, high dose > 100 mg/day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 34

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Adverse events / severity	Adverse events			Dose taken on onset date			Highest dose taken from 3 days before			
	Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
GLOSSITIS	2	2						2		
GASTRO-INTESTINAL DISORDER NOS	1	1						1		
	1	1						1		
RIGORS	2	2						2		
	1	1						1		
	1	1						1		
NERVOUSNESS	2	2						2		
	1	1						1		
	1	1						1		
ANXIETY	2	2						2		
	2	2						2		
MONILIASIS	2	2						2		
	2	2						2		
PILORECTION	1	1						1		
	1	1						1		
NYALGIA	1	1						1		
	1	1						1		
NEURITIS	1	1						1		
	1	1						1		
EYE PAIN	1	1						1		

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 4 mg/day, high dose > 6 mg/day
IMIPRANINE - low dose <= 75 mg/day, high dose > 100 mg/day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 54

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Adverse events / severity	Adverse events			Dose taken on onset date			Highest dose taken from 3 days before			
	Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
EYE PAIN	1	1						1		
LIBIDO DECREASED	1		1					1		
SLEEP DISORDER	1	1						1		
GLYCOSURIA	1	1						1		
COUGHING	1	1						1		
UPPER RESP TRACT INFECTION	1	1						1		
ASTHENIA	1	1						1		
RASH ERYTHEMATOUS	1	1						1		
EAR DISORDER NOS	1	1						1		
PARONYCHIA	1	1						1		
GAMMA-GT INCREASED	1	1						1		
Total	1	1	1	1	1	1	1	1	1	1

(CONTINUED)

(*) all remainder patients
 REBOXETINE - low dose <= 4 mg/day, high dose > 6 mg/day
 IMPRAPHINE - low dose <= 75 mg/day, high dose > 100 mg/day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 54

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

468

Assigned treatment: Reboxetine

Adverse events / severity	Adverse events		Dose taken on onset date			Highest dose taken from 3 days before		
	Number		Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
BUN INCREASED	Moderate	1	1				1	
	Total	1	1				1	
EXTRASYSTOLES	Moderate	1		1				1
	Total	1		1				1
PHARYNGITIS	Moderate	1	1				1	
	Total	1	1				1	
ASTHMA	Moderate	1	1				1	
	Total	1	1				1	
CYSTITIS	Moderate	1	1				1	
	Total	1	1				1	
RENAL FUNCTION ABNORMAL	Moderate	1	1				1	
	Total	1	1				1	
PULMONARY CARCINOMA	Moderate	1	1				1	
	Total	1	1				1	
OEDEMA PERIPHERAL	Moderate	1		1				
	Total	1		1				
BACK PAIN	Moderate	1	1				1	
	Total	1	1				1	
INFECTION	Moderate	1		1				
	Total	1		1				

(CONTINUED)

(*) all remainder patients
 REBOXETINE - low dose <= 4 mg/day, high dose > 6 mg/day
 IMIPRAMINE - low dose <= 75 mg/day, high dose > 100 mg/day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 54

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Adverse events / severity	Adverse events			Dose taken on onset date			Highest dose taken from 3 days before		
	Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose		
CONVULSIONS GRAND MAL	Severe	1	1				1		
	Total	1	1				1		
HYPERKINESIA	Severe	1	1				1		
	Total	1	1				1		
NEUROPATHY	Severe	1	1				1		
	Total	1	1				1		
DEPRESSION AGGRAVATED	Severe	1	1				1		
	Total	1	1				1		
CONCENTRATION IMPAIRED	Severe	1	1				1		
	Total	1	1				1		
THROMBOSIS ARTERIAL	Severe	1	1				1		
	Total	1	1				1		

467

(*) all remainder patients
REBOXETINE - low dose <= 4 mg/day, high dose > 6 mg/day
INIPRAMINE - low dose <= 75 mg/day, high dose > 100 mg/day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 54

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Imipramine

Adverse events / severity	Adverse events		Dose taken on onset date			Highest dose taken from 3 days before		
	Number		Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
All adverse events	Mild	147	114	33		120	27	
	Moderate	119	106	13		105	14	
	Severe	62	59	3		61	1	
	Unknown	10	9	1		8	2	
Total	338	288	50		294	44		
MOUTH DRY	Mild	24	21	3		21	3	
	Moderate	17	17			17		
	Severe	2	2			2		
	Total	43	40	3		40	3	
CONSTIPATION	Mild	18	14	4		14	4	
	Moderate	19	19			19		
	Severe	4	4			4		
	Unknown	1	1			1		
Total	42	38	4		38	4		
HEADACHE	Mild	6	2	4		2	4	
	Moderate	13	7	6		8	5	
	Severe	3	3			3		
	Total	22	12	10		13	9	
DIZZINESS	Mild	12	12			12		
	Moderate	5	4	1		4	1	
	Severe	3	3			3		
	Total	20	19	1		19	1	

(CONTINUED)

(*) all remainder patients
 REBOXETINE - low dose <= 4 mg/day, high dose > 4 mg/day
 IMIPRAMINE - low dose <= 75 mg/day, high dose > 75 mg/day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 54

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO RISE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Imipramine

Adverse events / severity	Adverse events			Dose taken on onset date			Highest dose taken from 3 days before		
	Number	Low dose (%)	High dose	Overdose	Low dose (*)	High dose	Overdose		
DIZZINESS	Total	20	19	1		19	1		
	Mild	11	9	2		11			
	Moderate	5	5			5			
	Severe	1	1			1			
SWEATING INCREASED	Total	17	15	2		17			
	Mild	5	2	3		2	3		
	Moderate	7	6	1		7			
	Severe	4	4			4			
URINARY TRACT INFECTION	Total	16	12	4		13	3		
	Mild	5	5			5			
	Moderate	4	3	1		3	1		
	Unknown	1	1			1			
FALL	Total	10	9	1		9	1		
	Mild	2	2			2			
	Moderate	1	1			1			
	Severe	3	2	1		3			
MALAISE	Total	9	8	1		9			
	Mild	7	3	4		3	4		
	Severe	2	2			2			
	Total	9	5	4		5	4		

(*) all remainder patients
REBOXETINE - low dose <= 4 mg/day, high dose > 6 mg/day
IMIPRAMINE - low dose <= 75 mg/day, high dose > 100 mg/day

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

470

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 54

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Imipramine

Adverse events / severity	Adverse events			Dose taken on onset date			Highest dose taken from 3 days before			
	Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
SOMNOLENCE	Mild	5	5					5		
	Moderate	1	1					1		
	Severe	1	1					1		
	Total	7	7					7		
HYPOTENSION	Moderate	4	3	1				3		1
	Severe	3	3					3		
	Total	7	6	1				6		1
TREMOR	Mild	3	2	1				2		1
	Moderate	3	3					3		
	Total	6	5	1				5		1
TACHYCARDIA	Mild	2	2					2		
	Moderate	4	3	1				3		1
	Total	6	5	1				5		1
VISION ABNORMAL	Mild	4	4					4		
	Moderate	1	1					1		
	Severe	1	1					1		
	Total	6	6					6		
MICTURITION DISORDER	Mild	6	1	5				4		2
	Total	6	1	5				4		2
ANOREXIA	Mild	4	1	3				2		2
	Severe	1	1					1		

(CONTINUED)

(*) all remainder patients
 REBOXETINE - low dose <= 4 mg/day, high dose > 6 mg/day
 IMIPRAMINE - low dose <= 75 mg/day, high dose > 100 mg/day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 54

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Imipramine

Adverse events / severity	Adverse events		Dose taken on onset date			Highest dose taken from 3 days before		
	Number		Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
ANOREXIA	Total	5	2	3		3	2	
	Mild	1	1			1		
	Moderate	2	2			2		
	Severe	2	2			2		
Total	5	5				5		
INSOMNIA	Mild	2	1	1		2		
	Moderate	3	3			3		
	Total	5	4	1		5		
BRONCHITIS	Mild	1	1			1		
	Moderate	3	3			3		
	Unknown	1	1			1		
	Total	5	5			5		
FATIGUE	Mild	1	1			1		
	Moderate	2	1	1		1	1	
	Severe	2	2			2		
	Total	5	4	1		4	1	
CONFUSION	Mild	1	1			1		
	Severe	3	3			3		
	Total	4	4			4		
PARAESTHESIA	Mild	1	1			1		
	Moderate	2	2			2		
	Total	3	3			3		

(CONTINUED)

(*) all remainder patients
 REBOXETINE - low dose <= 4 mg/day, high dose > 6 mg/day
 IMIPRAMINE - low dose <= 75 mg/day, high dose > 100 mg/day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 54

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

472

Assigned treatment: Imipramine

Adverse events / severity	Adverse events		Dose taken on onset date			Highest dose taken from 3 days before		
	Number		Low dose (†)	High dose	Overdose	Low dose (*)	High dose	Overdose
PARAESTHESIA	Severe	1	1			1		
	Total	4	4			4		
AGITATION	Mild	2		2			2	
	Moderate	2						
Total	4		2	2		2	2	
URINARY RETENTION	Moderate	1	1				1	
	Severe	3	3				3	
Total	4		4			4		
DIARRHOEA	Mild	2	2				2	
	Severe	1	1				1	
Total	3		3			3		
ANAEMIA	Mild	1	1				1	
	Moderate	1	1				1	
Severe	1			1			1	
Total	3		2	1		2	3	
PNEUMONIA	Severe	2	2				2	
	Unknown	1	1				1	
Total	3		3			3		
ATAXIA	Mild	1	1				1	
	Severe	1	1				1	
Total	2		2			2		

(CONTINUED)

(*) all remainder patients
 REBOXETINE - low dose <= 4 mg/day, high dose > 6 mg/day
 IMIPRAMINE - low dose <= 75 mg/day, high dose > 100 mg/day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 54

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Imipramine

Adverse events / severity	Adverse events		Dose taken on onset date			Highest dose taken from 3 days before		
	Number		Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
DYSKINESIA	Mild	1	1			1		
	Severe	1	1			1		
	Total	2	2			2		
SYNCOPE	Mild	1	1			1		
	Severe	1	1			1		
	Total	2	2			2		
CONJUNCTIVITIS	Mild	1	1			1		
	Moderate	1	1			1		
	Total	2	2			2		
ABDOMINAL PAIN	Mild	1	1			1		
	Severe	1	1			1		
	Total	2	2			2		
FEVER	Mild	2	2			2		
	Moderate	2	2			2		
	Total	4	4			4		
PRURITUS	Mild	2	2			2		
	Moderate	2	2			2		
	Total	4	4			4		
FRACTURE	Moderate	1	1			1		
	Severe	1	1			1		
	Total	2	2			2		
ARTHRALGIA	Moderate	2	2			2		
	Total	2	2			2		

(CONTINUED)

(*) all remainder patients
 REBOXETINE - low dose <= 4 mg/day, high dose > 6 mg/day
 IMIPRAMINE - low dose <= 75 mg/day, high dose > 100 mg/day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 54
 ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE
 BY SEVERITY AND ASSIGNED TREATMENT

474

Assigned treatment: Imipramine

Adverse events / severity	Adverse events Number	Dose taken on onset date			Highest dose taken from 3 days before		
		Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
HYPERTENSION	Moderate	1			1		
	Severe	1			1		
	Total	2			2		
COORDINATION ABNORMAL	Mild	1			1		
	Total	1			1		
	Mild	1		1			1
HYPOAESTHESIA	Total	1		1			1
	Mild	1					
	Total	1					
VERTIGO	Mild	1			1		
	Total	1			1		
	Mild	1					
VOMITING	Total	1			1		
	Mild	1					
	Total	1					
IMPOTENCE	Mild	1			1		
	Total	1			1		
	Mild	1					
SPT INCREASED	Total	1			1		
	Mild	1					
	Total	1					
HYPERCHOLESTEROLA- EMIA	Mild	1			1		
	Total	1			1		
	Mild	1					
HYPOKALAEMIA	Total	1			1		
	Mild	1					
	Total	1					
HYPERTRIGLYCERIDA- EMIA	Mild	1			1		
	Total	1			1		
	Mild	1					
Total	Total	1			1		
	Mild	1					
	Total	1					

(CONTINUED)

(*) all remainder patients
 REBOXETINE - low dose <= 4 mg/day, high dose > 6 mg/day
 IMIPRAMINE - low dose <= 75 mg/day, high dose > 100 mg/day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No. : 54
 ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE
 BY SEVERITY AND ASSIGNED TREATMENT

475

Assigned treatment: Imipramine

Adverse events / severity	Adverse events		Dose taken on onset date			Highest dose taken from 3 days before		
	Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose	
BUNDLE BRANCH BLOCK	Mild	1			1			
	Total	1			1			
SINUSITIS	Mild	1			1			
	Total	1			1			
NOCTURIA	Mild	1			1			
	Total	1			1			
ALLERGIC REACTION	Mild	1			1			
	Total	1			1			
INFLUENZA-LIKE SYMPTOMS	Mild	1			1			
	Total	1			1			
STUPOR	Moderate	1			1			
	Total	1			1			
PALPITATION	Moderate	1			1			
	Total	1			1			
APATHY	Moderate	1			1			
	Total	1			1			
DYSPRAGIA	Moderate	1			1			
	Total	1			1			
HEPATIC FUNCTION ABNORMAL	Moderate	1			1		1	
	Total	1			1		1	

(CONTINUED)

(*) all remainder patients
 REBOXETINE - low dose <= 4 mg/day, high dose > 6 mg/day
 IMIPRAMINE - low dose <= 75 mg/day, high dose > 100 mg/day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 54

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Imipramine

Adverse events / severity	Adverse events		Dose taken on onset date			Highest dose taken from 3 days before		
	Number		Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
GLOBULINS INCREASED	Moderate	1	1					1
	Total	1	1					1
WEIGHT DECREASE	Moderate	1	1				1	
	Total	1	1				1	
HYPOTHYROIDISM	Moderate	1	1				1	
	Total	1	1				1	
FIBRILLATION ATRIAL	Moderate	1	1				1	
	Total	1	1				1	
GRANULOCYTOPENIA	Moderate	1	1				1	
	Total	1	1				1	
PURPURA	Moderate	1	1				1	
	Total	1	1				1	
CHEST PAIN	Moderate	1			1			1
	Total	1			1			1
FRACTURE PATHOLOGICAL	Severe	1	1				1	
	Total	1	1				1	
COMA	Severe	1	1				1	
	Total	1	1				1	
CONVULSIONS	Severe	1	1				1	
	Total	1	1				1	
TASTE PERVERSION	Severe	1	1				1	
	Total	1	1				1	

(CONTINUED)

(*) all remainder patients
REBOXETINE - low dose <= 4 mg/day, high dose > 6 mg/day
IMIPRAMINE - low dose <= 75 mg/day, high dose > 100 mg/day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R8D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 54

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Imipramine

Adverse events / severity	Adverse events			Dose taken on onset date			Highest dose taken from 3 days before		
	Number	Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose		
TASTE PERVERSION	1	1							
PARANOID REACTION	1	1							
SUICIDE ATTEMPT	1	1							
FLATULENCE	1	1							
MYOCARDIAL INFARCTION	1	1							
CEREBROVASCULAR DISORDER	1	1							
PERIPHERAL ISCHAEMIA	1	1							
DYSPNOEA	1	1							
CHEST PAIN PRECORDIAL	1	1							
ESR INCREASED	1	1							
STOMATITIS	1	1							
Total	1	1							

(CONTINUED)

(*) all remainder patients
 REBOXETINE - low dose <= 4 mg/day, high dose > 6 mg/day
 IMIPRAMINE - low dose <= 75 mg/day, high dose > 100 mg/day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 54

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS ACCORDING TO DOSE TAKEN THE DAY OF ONSET AND THREE DAYS BEFORE BY SEVERITY AND ASSIGNED TREATMENT

Assigned treatment: Imipramine

Adverse events / severity	Adverse events		Dose taken on onset date			Highest dose taken from 3 days before		
	Number		Low dose (*)	High dose	Overdose	Low dose (*)	High dose	Overdose
PAIN	1		1				1	
		Total	1				1	
NASAL POLYP	1		1			1		
		Total	1			1		

478

(*) all remainder patients
 REBOXETINE - low dose <= 4 mg/day, high dose > 6 mg/day
 IMIPRAMINE - low dose <= 75 mg/day, high dose > 100 mg/day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 55

ADVERSE EVENTS: NUMBER OF PATIENTS WHO COMPLAINED OF AT LEAST ONE ADVERSE EVENT BY MAXIMAL SEVERITY LEVEL, SEX, AGE, DSMIII

Assigned treatment / Severity level	Sex						Age						DSM III													
	Total			Female			Male			< 70		70 - 79		>= 80		296.2		296.3		300.4						
	No.	Pt	%	No.	Pt	%	No.	Pt	%	No.	Pt	%	No.	Pt	%	No.	Pt	%	No.	Pt	%	No.	Pt	%		
Imipramine	33	27.0		17	19.3		16	47.1		14	30.4		14	29.2		5	17.9		12	40.0		9	18.0		12	28.6
	51	41.8		40	45.5		11	32.4		22	47.8		22	45.8		7	25.0		9	30.0		23	46.0		19	45.2
	38	31.1		31	35.2		7	20.6		10	21.7		12	25.0		16	57.1		9	30.0		18	36.0		11	26.2
	122	100.0		88	100.0		34	100.0		46	100.0		48	100.0		28	100.0		30	100.0		50	100.0		42	100.0
Reboxetine	42	35.0		33	35.5		9	33.3		22	51.2		13	26.0		7	25.9		8	22.9		15	40.5		19	39.6
	42	35.0		31	33.3		11	40.7		15	34.9		20	40.0		7	25.9		14	40.0		11	29.7		17	35.4
	36	30.0		29	31.2		7	25.9		6	14.0		17	34.0		13	46.1		13	37.1		11	29.7		12	25.0
	120	100.0		93	100.0		27	100.0		43	100.0		50	100.0		27	100.0		35	100.0		37	100.0		48	100.0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R2D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 56

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity	Assigned treatment																		
	Imipramine						Reboxetine												
	Female		Male		Total		Female		Male		Total								
No. Pt.	(*) %	No. Pt.	(*) %	No. Pt.	(*) %	No. Pt.	(*) %	No. Pt.	(*) %	No. Pt.	(*) %								
All adverse events	Mild	17	19.3	16	47.1	47.1	33	27.0	27.0	33	35.5	35.5	9	33.3	33.3	42	35.0	35.0	
	Moderate	40	45.5	45.5	11	32.4	32.4	51	41.8	41.8	31	33.3	33.3	11	40.7	40.7	42	35.0	35.0
	Severe	31	35.2	35.2	7	20.6	20.6	38	31.1	31.1	29	31.2	31.2	7	25.9	25.9	36	30.0	30.0
	Total	88	100	100	34	100	100	122	100	100	93	100	100	27	100	100	120	100	100
MOUTH DRY	Mild	11	39.3	12.5	9	81.8	26.5	20	51.3	16.4	19	55.9	20.4	3	60.0	11.1	22	56.4	18.3
	Moderate	15	53.6	47.0	2	18.2	5.9	17	43.6	13.9	11	32.4	11.8	1	20.0	3.7	12	30.8	10.0
	Severe	2	7.1	2.3				2	5.1	1.6	4	11.8	4.3	1	20.0	3.7	5	12.8	4.2
	Total	28	100	31.8	11	100	32.4	39	100	32.0	34	100	36.6	5	100	18.5	39	100	32.5
CONSTIPATION	Mild	7	29.2	8.0	4	57.1	11.8	11	35.5	9.0	10	40.0	10.8	3	50.0	11.1	13	41.9	10.8
	Moderate	13	54.2	14.8	2	28.6	5.9	15	48.4	12.3	9	36.0	9.7	3	50.0	11.1	12	38.7	10.0
	Severe	3	12.5	3.4	1	14.3	2.9	4	12.9	3.3	6	24.0	6.5				6	19.4	5.0
	Missing	1	4.2	1.1				1	3.2	0.8									
NAUSEA	Total	24	100	27.3	7	100	20.6	31	100	25.4	25	100	26.9	6	100	22.2	31	100	25.8
	Mild	8	61.5	9.1	3	75.0	8.8	11	64.7	9.0	6	46.2	6.5	5	100	18.5	11	61.1	9.2
	Moderate	4	30.8	4.5	1	25.0	2.9	5	29.4	4.1	3	23.1	3.2				3	16.7	2.5
	Severe	1	7.7	1.1				1	5.9	0.8	3	23.1	3.2				3	16.7	2.5
SWEATING INCREASED	Missing										1	7.7	1.1				1	5.6	0.8
	Total	13	100	14.8	4	100	11.8	17	100	13.9	13	100	14.0	5	100	18.5	18	100	15.0
	Mild	3	23.1	3.4	1	50.0	2.9	4	26.7	3.3	5	39.3	5.4				5	31.3	4.2
	Moderate	6	46.2	6.8	1	50.0	2.9	7	46.7	5.7	7	46.7	7.5	1	100	3.7	8	50.0	6.7

(*) % on all patients with adverse events

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 56

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity	Assigned treatment																		
	Imipramine						Reboxetine												
	Female		Male		Total		Female		Male		Total								
No. Pt.	(*) Z	No. Pt.	(*) Z	No. Pt.	(*) Z	No. Pt.	(*) Z	No. Pt.	(*) Z	No. Pt.	(*) Z								
SWEATING INCREASED	Severe	4	30.8	4.5			4	26.7	3.3	3	20.0	3.2			3	18.8	2.5		
	Total	13	100	14.8	2	100	5.9	15	100	12.3	15	100	16.1	1	100	3.7	16	100	13.3
	Mild	5	50.0	5.7	4	57.1	11.8	9	52.9	7.4	2	28.6	2.2	2	50.0	7.4	4	36.4	3.3
DIZZINESS	Moderate	3	30.0	3.4	2	28.6	5.9	5	29.4	4.1	3	42.9	3.2	2	50.0	7.4	5	45.5	4.2
	Severe	2	20.0	2.3	1	14.3	2.9	3	17.6	2.5	2	28.6	2.2				2	18.2	1.7
	Total	10	100	11.4	7	100	20.6	17	100	13.9	7	100	7.5	4	100	14.8	11	100	9.2
HEADACHE	Mild	1	14.3	1.1	1	50.0	2.9	2	22.2	1.6	1	12.5	1.1	1	33.3	3.7	2	18.2	1.7
	Moderate	4	57.1	4.5	1	50.0	2.9	5	55.6	4.1	5	62.5	5.4	2	66.7	7.4	7	63.6	5.8
	Severe	2	28.6	2.3				2	22.2	1.6	2	25.0	2.2				2	18.2	1.7
INSOMNIA	Total	7	100	8.0	2	100	5.9	9	100	7.4	8	100	8.6	3	100	11.1	11	100	9.2
	Mild	2	40.0	2.3				2	40.0	1.6	2	22.2	2.2				2	18.2	1.7
	Moderate	3	60.0	3.4				3	60.0	2.5	4	44.4	4.3	1	50.0	3.7	5	45.5	4.2
URINARY TRACT INFECTION	Severe										3	33.3	3.2	1	50.0	3.7	4	36.4	3.3
	Total	5	100	5.7				5	100	4.1	9	100	9.7	2	100	7.4	11	100	9.2
	Mild	5	50.0	5.7				5	50.0	4.1	5	100	5.4				5	43.3	4.2
TREMOR	Moderate	4	40.0	4.5				4	40.0	3.3				1	100	3.7	1	16.7	0.8
	Missing	1	10.0	1.1				1	10.0	0.8									
	Total	10	100	11.4				10	100	8.2	5	100	5.4	1	100	3.7	6	100	5.0
TREOR	Mild	2	50.0	2.3	1	50.0	2.9	3	50.0	2.5	6	85.7	6.5				6	85.7	5.0
	Moderate	2	50.0	2.3	1	50.0	2.9	3	50.0	2.5	1	14.3	1.1				1	14.3	0.8

(*) Z on all patients with adverse events

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 56

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity	Assigned treatment												
	Imipramine						Reboxetine						
	Female		Male		Total		Female		Male		Total		
No. Pt.	(*) Z	No. Pt.	(*) Z	No. Pt.	(*) Z	No. Pt.	(*) Z	No. Pt.	(*) Z	No. Pt.	(*) Z		
TREMOR	Total	4	100	4.5	2	100	5.9	6	100	4.9	7	100	5.8
	Mild	3	60.0	3.4	1	100	2.9	4	66.7	3.3	3	60.0	3.2
	Moderate	1	20.0	1.1				1	16.7	0.8	2	40.0	2.2
	Severe	1	20.0	1.1				1	16.7	0.8			
SOMNOLENCE	Total	5	100	5.7	1	100	2.9	6	100	4.9	5	100	5.4
	Mild	4	66.7	4.5	1	100	2.9	5	71.4	4.1	2	50.0	2.2
	Moderate	1	16.7	1.1				1	14.3	0.8	2	50.0	2.2
	Severe	1	16.7	1.1				1	14.3	0.8			
MICTURITION DISORDER	Total	6	100	6.8	1	100	2.9	7	100	5.7	4	100	4.3
	Mild	1	100	1.1	5	100	14.7	6	100	4.9	1	100	1.1
	Total	1	100	1.1	5	100	14.7	6	100	4.9	1	100	1.1
	Mild				1	100	2.9	1	25.0	0.8			
CONFUSION	Total												
	Moderate							2	40.0	2.2	1	100	3.7
	Severe	3	100	3.4				3	75.0	2.5	3	60.0	3.2
	Total	3	100	3.4	1	100	2.9	4	100	3.3	5	100	5.4
ANOREXIA	Total	4	80.0	4.5				4	80.0	3.3	1	33.3	1.1
	Mild							1	33.3	1.1			
	Moderate							1	33.3	1.1	1	100	3.7
	Severe	1	20.0	1.1				1	20.0	0.8	1	33.3	1.1
TACHYCARDIA	Total	5	100	5.7				5	100	4.1	3	100	3.2
	Mild	1	33.3	1.1	1	33.3	2.9	2	33.3	1.6			
	Total	1	33.3	1.1	1	33.3	2.9	2	33.3	1.6	1	50.0	3.7
	Mild										1	50.0	3.7

(CONTINUED)

(*) Z on all patients with adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 56

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity	Assigned treatment																				
	Imipramine						Reboxetine														
	Female			Male			Female			Male			Total								
	No. Pt.	x	(*) x	No. Pt.	x	(*) x	No. Pt.	x	(*) x	No. Pt.	x	(*) x	No. Pt.	x	(*) x						
TACHYCARDIA	Moderate	2	66.7	2.3	2	66.7	5.9	4	66.7	3.3	1	100	1.1			1	33.3	0.8			
	Severe															1	33.3	0.8			
	Total	3	100	3.4	3	100	8.8	6	100	4.9	1	100	1.1	2	100	7.4	3	100	2.5		
ABDOMINAL PAIN	Mild	1	50.0	1.1				1	50.0	0.8	1	14.3	1.1			1	14.3	0.8			
	Moderate															5	71.4	4.2			
	Severe	1	50.0	1.1				1	50.0	0.8	1	14.3	1.1			1	14.3	0.8			
Total	2	100	2.3				2	100	1.6	2	100	7.5			7	100	5.8				
PARAESTHESIA	Mild	1	25.0	1.1				1	25.0	0.8	2	100	2.2			2	100	7.4	4	100	3.3
	Moderate	2	50.0	2.3				2	50.0	1.6											
	Severe	1	25.0	1.1				1	25.0	0.8											
Total	4	100	4.5				4	100	3.3	2	100	2.2			2	100	7.4	4	100	3.3	
AGITATION	Mild	2	50.0	2.3				2	50.0	1.6											
	Moderate	2	50.0	2.3				2	50.0	1.6											
	Severe															1	25.0	1.1	2	50.0	1.7
Missing																1	25.0	0.8			
Total	4	100	4.5				4	100	3.3	4	100	4.3			4	100	3.3				
FALL	Mild	1	20.0	1.1				1	16.7	0.8											
	Moderate	1	20.0	1.1				1	16.7	0.8	1	100	1.1			1	100	3.7	2	100	1.7
	Severe	2	40.0	2.3	1	100	2.9	3	50.0	2.5											
Missing	1	20.0	1.1				1	16.7	0.8												

(CONTINUED)

(*) x on all patients with adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 56

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity	Assigned treatment															
	Imipramine						Reboxetine									
	Female		Male		Total		Female		Male		Total					
No. Pt.	(*) Z	No. Pt.	(*) Z	No. Pt.	(*) Z	No. Pt.	(*) Z	No. Pt.	(*) Z	No. Pt.	(*) Z					
FALL	5	100	5.7	1	100	2.9	6	100	4.9	1	100	1.1	2	100	3.7	1.7
URINARY RETENTION	2	100	2.3	1	100	2.9	3	75.0	2.5	1	33.3	1.1	1	33.3	0.8	0.8
HYPOTENSION	4	57.1	4.5				4	100	3.3	3	100	3.2				2.5
FATIGUE	3	42.9	3.4				3	42.9	2.5							
BRONCHITIS	2	66.7	2.3				2	40.0	1.6							
MALAISE	1	50.0	1.1	2	100	5.9	3	60.0	2.5	1	100	1.1				0.8
DIARRHOEA	2	66.7	2.3				2	66.7	1.6							1.7

(CONTINUED)

(*) Z on all patients with adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 56

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity	Assigned treatment											
	Imipramine						Reboxetine					
	Female		Male		Total		Female		Male		Total	
No. Pt.	(*) %	No. Pt.	(*) %	No. Pt.	(*) %	No. Pt.	(*) %	No. Pt.	(*) %	No. Pt.	(*) %	
DIARRHOEA	Severe	1 33.3	1.1			1 33.3	0.8					
	Total	3 100	3.4			3 100	2.5	2 100	2.2			2 100 1.7
HYPOTENSI-ON POSTURAL	Mild							1 50.0	1.1			1 50.0 0.8
	Moderate			1 50.0	2.9	1 33.3	0.8	1 50.0	1.1			1 50.0 0.8
Severe		1 100	1.1	1 50.0	2.9	2 66.7	1.6					
	Total	1 100	1.1	2 100	5.9	3 100	2.5	2 100	2.2			2 100 1.7
ATAXIA	Mild	1 100	1.1			1 50.0	0.8	1 100	1.1	1 100	3.7	2 100 1.7
	Severe			1 100	2.9	1 50.0	0.8					
Total		1 100	1.1	1 100	2.9	2 100	1.6	1 100	1.1	1 100	3.7	2 100 1.7
	Mild	1 100	1.1			1 50.0	0.8	1 50.0	1.1			1 50.0 0.8
Moderate				1 100	2.9	1 50.0	0.8	1 50.0	1.1			1 50.0 0.8
	Total	1 100	1.1	1 100	2.9	2 100	1.6	2 100	2.2			2 100 1.7
PNEUMONIA	Mild							1 100	1.1			1 100 0.8
	Severe	1 50.0	1.1	1 100	2.9	2 66.7	1.6					
Missing		1 50.0	1.1			1 33.3	0.8					
	Total	2 100	2.3	1 100	2.9	3 100	2.5	1 100	1.1			1 100 0.8
PAIN	Mild							1 33.3	1.1			1 33.3 0.8
	Moderate							2 66.7	2.2			2 66.7 1.7
Missing		1 100	1.1			1 100	0.8					
	Total	1 100	1.1			1 100	0.8	3 100	3.2			3 100 2.5

(CONTINUED)

(*) % on all patients with adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 56
NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity	Assigned treatment																	
	Imipramine									Reboxetine								
	Female			Male			Total			Female			Male			Total		
	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z
FRACTURE	Moderate	1	50.0	1.1			1	50.0	0.8									
	Severe	1	50.0	1.1			1	50.0	0.8	1	100	1.1						1
	Total	2	100	2.3			2	100	1.6	1	100	1.1						1
ARTHRALGIA	Moderate	1	100	1.1	1	100	2.9	2	100	1.6	1	100	1.1					
	Total	1	100	1.1	1	100	2.9	2	100	1.6	1	100	1.1					1
	Total	1	100	1.1	1	100	2.9	2	100	1.6	1	100	1.1					1
HYPERTENSION	Moderate	1	50.0	1.1			1	50.0	0.8	1	100	1.1						
	Severe	1	50.0	1.1			1	50.0	0.8									
	Total	2	100	2.3			2	100	1.6	1	100	1.1						1
PALPITATION	Moderate	1	100	1.1			1	100	0.8									
	Severe	1	100	1.1			1	100	0.8									
	Total	2	200	2.3			2	200	1.6	1	100	1.1						1
DYSPEPSIA	Moderate	1	100	1.1			1	100	0.8									
	Severe	1	100	1.1			1	100	0.8	1	150.0	1.1						1
	Total	2	200	2.3			2	200	1.6	2	300	2.2						2
DYSPHAGIA	Moderate	1	100	1.1			1	100	0.8	3	300	3.2						
	Severe	1	100	1.1			1	100	0.8	3	300	3.2						3
	Total	2	200	2.3			2	200	1.6	6	600	6.4						6
HYPOKALAEMIA	Moderate	1	100	1.1			1	100	0.8	2	200	2.2						
	Severe	1	100	1.1			1	100	0.8	2	200	2.2						2
	Total	2	200	2.3			2	200	1.6	4	400	4.4						4
HEIGHT DECREASE	Moderate	1	100	1.1			1	100	0.8									
	Severe	1	100	1.1			1	100	0.8	1	100	1.1	1	100	3.7	2	200	1.7
	Total	2	200	2.3			2	200	1.6	2	200	2.2	3	300	4.8	4	400	3.4

(*) Z on all patients with adverse events

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 56

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity	Assigned treatment														
	Imipramine							Reboxetine							
	Female			Male			Total	Female			Male			Total	
	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z
WEIGHT DECREASE	Moderate	1	100	1.1			1	100	0.8						
	Severe									1	100	1.1			1
	Total	1	100	1.1			1	100	0.8	1	100	1.1	1	100	3.7
ANAEMIA	Mild	1	50.0	1.1			1	33.3	0.8						
	Moderate				1	100	2.9	1	33.3	0.8					
	Severe	1	50.0	1.1			1	33.3	0.8						
Total	2	100	2.3	1	100	2.9	3	100	2.5						
FEVER	Mild	2	100	2.3			2	100	1.6						
	Moderate									1	100	1.1			1
	Total	2	100	2.3			2	100	1.6	1	100	1.1	1	100	0.8
INFLUENZA-LIKE SYMPTOMS	Mild				1	100	2.9	1	100	0.8					
	Severe									1	50.0	1.1			1
	Total				1	100	2.9	1	100	0.8	1	50.0	1.1	1	50.0
PRURITUS	Moderate	2	100	2.3			2	100	1.6						
	Severe	2	100	2.3			2	100	1.6						
	Total	2	100	2.3			2	100	1.6						
DYSKINESIA	Mild				1	50.0	2.9	1	50.0	0.8					
	Severe				1	50.0	2.9	1	50.0	0.8					
	Total				2	100	5.9	2	100	1.6					
HYPOAESTHESIA	Mild	1	100	1.1			1	100	0.8						
	Moderate									1	100	1.1			1
	Total	1	100	1.1			1	100	0.8	1	100	1.1	1	100	0.8

(CONTINUED)

(*) % on all patients with adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 56

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity	Assigned treatment																			
	Imipramine							Reboxetine												
	Female			Male			Total	Female			Male			Total						
	No. Pt.	(*) %	No. Pt.	(*) %	No. Pt.	(*) %	No. Pt.	(*) %	No. Pt.	(*) %	No. Pt.	(*) %	No. Pt.	(*) %						
HYPOAESTHESIA	Total	1	100	1.1			1	100	0.8	1	100	1.1			1	100	0.8			
	Mild						1	50.0	1.1						1	50.0	0.8			
	Moderate						1	50.0	1.1						1	50.0	0.8			
SYNCOPE	Total						2	100	2.2						2	100	1.7			
	Mild						1	100	2.9						1	100	0.8			
	Severe	1	100	1.1			1	50.0	0.8											
VOMITING	Total	1	100	1.1	1	100	2.9	100	1.6											
	Mild	1	100	1.1			1	100	0.8					1	100	3.7	1	100	0.8	
	Severe	1	100	1.1			1	100	0.8					1	100	3.7	1	100	0.8	
ANXIETY	Total						2	100	2.2						2	100	1.7			
	Mild						1	100	2.9						1	100	0.8			
	Severe						1	50.0	0.8					1	100	3.7	1	100	0.8	
IMPOTENCE	Total						1	100	0.8						1	100	0.8			
	Mild						1	100	2.9						1	100	3.7	1	100	0.8
	Severe						1	50.0	0.8					1	100	3.7	1	100	0.8	
NERVOUSNESS	Total						1	100	1.1						1	100	0.8			
	Mild						1	100	1.1						1	100	0.8			
	Severe						1	50.0	0.8					1	100	3.7	2	100	1.7	
PARANOID REACTION	Total	1	100	1.1			1	100	0.8						1	100	0.8			
	Mild						1	100	0.8						1	100	0.8			
	Severe	1	100	1.1			1	100	0.8						1	100	0.8			
FLATULENCE	Total						1	100	1.1						1	100	0.8			
	Mild						1	100	1.1						1	100	0.8			
	Severe	1	100	1.1			1	100	0.8						1	100	0.8			

(CONTINUED)

(*) % on all patients with adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 56

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity	Assigned treatment															
	Imipranine						Reboxetine									
	Female		Male		Total		Female		Male		Total					
No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z		
FLATULENCE	1	100	1.1			1	100	0.8	1	100	1.1			1	100	0.8
STOMATITIS									1	100	1.1			1	100	0.8
Missing	1	100	1.1			1	100	0.8								
Total	1	100	1.1			1	100	0.8	1	100	1.1			1	100	0.8
GASTRO-INTESTINAL DISORDER NOS									1	50.0	1.1			1	50.0	0.8
Mild									1	50.0	1.1			1	50.0	0.8
Moderate									1	50.0	1.1			1	50.0	0.8
Total									2	100	2.2			2	100	1.7
HYPERCHOLESTEROLAEMIA	1	100	1.1			1	100	0.8								
Mild																
Moderate																
Total	1	100	1.1			1	100	0.8						1	100	0.8
HYPERTRIGLYCIDAEMIA	1	100	1.1			1	100	0.8						1	100	0.8
Mild																
Total	1	100	1.1			1	100	0.8						1	100	0.8
FIBRILLATION ATRIAL									1	100	2.9			1	100	0.8
Mild									1	100	2.9			1	100	0.8
Total									1	100	2.9			1	100	0.8
SINUSITIS	1	100	1.1			1	100	0.8								
Mild																
Moderate														1	100	1.1
Total	1	100	1.1			1	100	0.8						1	100	0.8
RIGORS														1	50.0	0.8
Mild														1	50.0	0.8
Severe														1	50.0	0.8
Total									2	100	2.2			2	100	1.7

(CONTINUED)

(*) Z on all patients with adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 56

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity	Assigned treatment																	
	Imipramine									Reboxetine								
	Female			Male			Total			Female			Male			Total		
	No. Pt.	z	(*) %	No. Pt.	z	(*) %	No. Pt.	z	(*) %	No. Pt.	z	(*) %	No. Pt.	z	(*) %	No. Pt.	z	(*) %
NONILIASIS																		
Severe																		
Total																		
RASH																		
ERYTHEMATOUS																		
Total																		
PILORECTIC																		
MILD																		
Total																		
FRACTURE																		
PATHOLOGICAL																		
CAL	1	100	1.1															
Total	1	100	1.1															
MYALGIA																		
Total																		
COMA																		
Severe	1	100	1.1															
Total	1	100	1.1															
CONVULSIONS																		
Severe	1	100	1.1															
Total	1	100	1.1															
CONVULSIONS GRAND MAL																		
Severe																		
Total																		
COORDINATION ABNORMAL																		
MILD	1	100	1.1															
Total	1	100	1.1															
HYPERKINESIA																		
Severe																		
Total																		

(CONTINUED)

(*) % on all patients with adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 56

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity	Assigned treatment																	
	Imipramine						Reboxetine											
	Female			Male			Total			Female			Male			Total		
	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z
NEURITIS	Mild						1	100	1.1									
	Total						1	100	1.1									
	Severe						1	100	1.1									
NEUROPATHY	Total						1	100	1.1									
	Severe						1	100	1.1									
	Total						1	100	1.1									
STUPOR	Moderate						1	100	2.9									
	Total						1	100	2.9									
	Mild	1	100	1.1														
VERTIGO	Total	1	100	1.1			1	100	0.8									
	Mild	1	100	1.1			1	100	0.8									
	Total	1	100	1.1			1	100	0.8									
EYE PAIN	Mild											1	100	1.1				
	Total											1	100	1.1				
	Moderate											1	100	1.1				
EAR DISORDER NOS	Total											1	100	0.8				
	Severe											1	100	0.8				
	Total											1	100	0.8				
TASTE PERVERSION	Severe	1	100	1.1														
	Total	1	100	1.1														
	Moderate																	
APATHY	Total						1	100	2.9									
	Mild											1	100	1.1				
	Total						1	100	2.9									
LIBIDO DECREASED	Total											1	100	1.1				
	Moderate											1	100	1.1				
	Total											1	100	1.1				
PARONERIA	Moderate											1	100	1.1				
	Total											1	100	1.1				
	Mild											1	100	1.1				

(CONTINUED)

(*) Z on all patients with adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 56

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity	Assigned treatment											
	Imipramine						Reboxetine					
	Female		Male		Total		Female		Male		Total	
No. Pt.	(*) Z	No. Pt.	(*) Z	No. Pt.	(*) Z	No. Pt.	(*) Z	No. Pt.	(*) Z	No. Pt.	(*) Z	
SLEEP DISORDER												
Total						1	100 1.1				1 100 0.8	
SUICIDE ATTEMPT	1	100 1.1			1	100 0.8					1 100 0.8	
Total	1	100 1.1			1	100 0.8					1 100 0.8	
DEPRESSION AGGRAVATED												
Total								1	100 1.1		1 100 0.8	
CONCENTRATION IMPAIRED								1	100 1.1		1 100 0.8	
Total								1	100 1.1		1 100 0.8	
GLOSSITIS												
Total										1	100 3.7	
HEPATIC FUNCTION ABNORMAL												
Moderate			1	100 2.9	1	100 0.8						
Total			1	100 2.9	1	100 0.8						
SGPT INCREASED												
Mild			1	100 2.9	1	100 0.8						
Total			1	100 2.9	1	100 0.8						
GAMMA-GT INCREASED												
Moderate								1	100 1.1		1 100 0.8	
Total								1	100 1.1		1 100 0.8	
BUN INCREASED												
Moderate								1	100 1.1		1 100 0.8	
Total								1	100 1.1		1 100 0.8	
GLOBULINS INCREASED												
Moderate			1	100 2.9	1	100 0.8						
Total			1	100 2.9	1	100 0.8						

(CONTINUED)

(*) Z on all patients with adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 REBOXYTINE - PROTOCOL 20124/035
 TABLE No.: 56

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity	Assigned treatment													
	Imipramine							Reboxetine						
	Female			Male				Female			Male			
	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	Total	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	Total
GLYCOSURIA Mild														
Total														
HYPOTHYROID- Moderate	1	100	1.1				1	100	0.8					
IDISM Total	1	100	1.1				1	100	0.8					
MYOCARDIAL Severe				1	100	2.9	1	100	0.8					
INFARCTION Total				1	100	2.9	1	100	0.8					
BUNDLE Mild	1	100	1.1				1	100	0.8					
BRANCHES Total	1	100	1.1				1	100	0.8					
BLOCK Moderate														
OLEES Total														
EXTRASIST- Moderate														
OLEES Total														
CEREBROVA- Severe	1	100	1.1				1	100	0.8					
SCULAR Total	1	100	1.1				1	100	0.8					
DISORDER Severe	1	100	1.1				1	100	0.8					
PERIPHERAL Total	1	100	1.1				1	100	0.8					
ISCHAEMIA Severe	1	100	1.1				1	100	0.8					
THROMBOSIS Total	1	100	1.1				1	100	0.8					
ARTERIAL Severe														
Total														
COUGHING Mild										1	100	1.1		
Total										1	100	1.1		
DYSPNOEA Severe				1	100	2.9	1	100	0.8					
Total				1	100	2.9	1	100	0.8					

(*) Z on all patients with adverse events

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 56

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity	Assigned treatment													
	Inipramine						Reboxetine							
	Female			Male			Female			Male				
	No. Pt.	(*) %	No. Pt.	(*) %	No. Pt.	(*) %	No. Pt.	(*) %	No. Pt.	(*) %	No. Pt.	(*) %		
PHARYNGITIS														
Total														
UPPER RESP TRACT INFECTION														
Total														
ASTHMA														
Total														
GRANULOCYTOPENIA	1	100	1.1				1	100	0.8					
Total	1	100	1.1				1	100	0.8					
PURPURA	1	100	1.1				1	100	0.8					
Total	1	100	1.1				1	100	0.8					
CYSTITIS														
Total														
NOCTURIA	1	100	1.1				1	100	0.8					
Total	1	100	1.1				1	100	0.8					
RENAL FUNCTION ABNORMAL														
Total														
PULMONARY CARCINOMA														
Total														
OEDEMA PERIPHERAL														
Total														

(CONTINUED)

(*) % on all patients with adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 56

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Adverse events / Severity	Assigned treatment														
	Inipramine							Reboxetine							
	Female			Male				Female			Male				
	No. Pt.	Z	(*) %	No. Pt.	Z	(*) %	Total Z	No. Pt.	Z	(*) %	No. Pt.	Z	(*) %	Total Z	(*) %
ALLERGIC REACTION				1	100	2.9	1	100	0.8						
Total				1	100	2.9	1	100	0.8						
ASTHENIA															
Total															
BACK PAIN															
Moderate															
Total															
CHEST PAIN															
Moderate				1	100	2.9	1	100	0.8						
Total				1	100	2.9	1	100	0.8						
CHEST PAIN PRECORDIAL				1	100	1.1									
Total				1	100	1.1									
ESR INCREASED															
Severe				1	100	2.9	1	100	0.8						
Total				1	100	2.9	1	100	0.8						
NASAL POLYP															
Missing				1	100	1.1									
Total				1	100	1.1									
INFECTIO															
Moderate															
Total															

(*) % on all patients with adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 57
NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS, GROUPED BY BODY SYSTEM, BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Body system / Severity	Assigned treatment																		
	Imipramine									Reboxetine									
	Female			Male			Total			Female			Male			Total			
	No.	(*)	z	No.	(*)	z	No.	(*)	z	No.	(*)	z	No.	(*)	z	No.	(*)	z	
All adverse events	Mild	17	19.3	19.3	16	47.1	47.1	33	27.0	27.0	33	35.5	35.5	9	33.3	33.3	42	35.0	35.0
	Moderate	40	45.5	45.5	11	32.4	32.4	51	41.8	41.8	31	33.3	33.3	11	40.7	40.7	42	35.0	35.0
	Severe	31	35.2	35.2	7	20.6	20.6	38	31.1	31.1	29	31.2	31.2	7	25.9	25.9	36	30.0	30.0
	Total	88	100	100	34	100	100	122	100	100	93	100	100	27	100	100	120	100	100
GASTRO-INTESTINAL SYSTEM DISORDERS	Mild	18	43.9	20.5	7	63.6	20.6	25	48.1	20.5	16	35.6	17.2	6	54.5	22.2	22	39.3	18.3
	Moderate	17	41.5	19.3	3	27.3	8.8	20	38.5	16.4	18	40.0	19.4	4	36.4	14.8	22	39.3	18.3
	Severe	5	12.2	5.7	1	9.1	2.9	6	11.5	4.9	11	24.4	11.8	1	9.1	3.7	12	21.4	10.0
	Missing	1	2.4	1.1				1	1.9	0.8									
AUTONOMIC NERVOUS SYSTEM DISORDERS	Total	41	100	46.6	11	100	32.4	52	100	42.6	45	100	48.4	11	100	40.7	56	100	46.7
	Mild	12	33.3	13.6	10	76.9	29.4	22	44.9	18.0	21	50.0	22.6	3	50.0	11.1	24	50.0	20.0
	Moderate	18	50.0	20.5	3	23.1	8.8	21	42.9	17.2	14	33.3	15.1	2	33.3	7.4	16	33.3	13.3
	Severe	6	16.7	6.8				6	12.2	4.9	7	16.7	7.5	1	16.7	3.7	8	16.7	6.7
CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO	Total	36	100	40.9	13	100	38.2	49	100	40.2	42	100	45.2	6	100	22.2	48	100	40.0
	Mild	6	28.6	6.8	4	44.4	11.8	10	33.3	8.2	10	37.0	10.8	4	50.0	14.8	14	40.0	11.7
	Moderate	7	33.3	8.0	3	39.3	8.8	10	33.3	8.2	10	37.0	10.8	3	37.5	11.1	13	37.1	10.8
	Severe	8	38.1	9.1	2	22.2	5.9	10	33.3	8.2	7	25.9	7.5	1	12.5	3.7	8	22.9	6.7
CARDIOVASCULAR DISORDERS, GENERAL	Total	21	100	23.9	9	100	26.5	30	100	24.6	27	100	29.0	8	100	29.6	35	100	29.2
	Mild	7	28.0	8.0	6	54.5	17.6	13	36.1	10.7	4	28.6	4.3	3	37.5	11.1	7	31.8	5.8
	Moderate	8	32.0	9.1	3	27.3	6.8	11	30.6	9.0	7	50.0	7.5	3	37.5	11.1	10	45.5	8.3
	Severe	10	40.0	11.4	2	18.2	5.9	12	33.3	9.8	3	21.4	3.2	2	25.0	7.4	5	22.7	4.2

(*) z on all patients with adverse events

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 57
 NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS, GROUPED BY BODY SYSTEM, BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Body system / Severity	Assigned treatment																		
	Imipramine						Reboxetine												
	Female		Male		Total		Female		Male		Total								
No. Pt.	(*) %	No. Pt.	(*) %	(*) No. Pt.	(*) %	No. Pt.	(*) %	No. Pt.	(*) %	(*) No. Pt.	(*) %								
CARDIOVASCULAR DISORDERS, GENERAL	Total	25	100	28.4	11	100	32.4	36	100	29.5	14	100	29.6	22	100	18.3			
	Mild	8	53.3	9.1	1	50.0	2.9	9	52.9	7.4	6	28.6	6.5	6	25.0	5.0			
	Moderate	4	26.7	4.5	1	50.0	2.9	5	29.4	4.1	6	28.6	6.5	1	33.3	3.7	7	29.2	5.8
	Severe	3	20.0	3.4				3	17.6	2.5	8	38.1	8.6	2	66.7	7.4	10	44.7	8.3
	Missing											1	4.8	1.1			1	4.2	0.8
Total	15	100	17.0	2	100	5.9	17	100	13.9	21	100	22.6	3	100	11.1	24	100	20.0	
URINARY SYSTEM DISORDERS	Total	7	50.0	8.0	5	71.4	14.7	12	57.1	9.8	5	50.0	5.4	4	80.0	14.8	9	60.0	7.5
	Mild	4	28.6	4.5	1	14.3	2.9	5	23.8	4.1	4	40.0	4.3	1	20.0	3.7	5	33.3	4.2
	Moderate	2	14.3	2.3	1	14.3	2.9	3	14.3	2.5	1	10.0	1.1				1	6.7	0.8
	Severe	1	7.1	1.1				1	4.8	0.8									
	Missing																		
Total	14	100	15.9	7	100	20.6	21	100	17.2	10	100	10.8	5	100	18.5	15	100	12.5	
BODY AS A WHOLE-GENERAL DISORDERS	Total	4	30.8	4.5	4	57.1	11.8	8	40.0	6.6	3	30.0	3.2	1	50.0	3.7	4	33.3	3.3
	Mild	3	23.1	3.4	1	14.3	2.9	4	20.0	3.3	4	40.0	4.3	1	50.0	3.7	5	41.7	4.2
	Moderate	4	30.8	4.5	2	28.6	5.9	6	30.0	4.9	3	30.0	3.2				3	25.0	2.5
	Severe	2	15.4	2.3				2	10.0	1.6									
	Missing																		
Total	13	100	14.8	7	100	20.6	20	100	16.4	10	100	10.3	2	100	7.4	12	100	10.0	
VISION DISORDERS	Total	4	66.7	4.5	1	50.0	2.9	5	62.5	4.1	4	57.1	4.3	1	100	3.7	5	62.5	4.2
	Mild	1	16.7	1.1	1	50.0	2.9	2	25.0	1.6	3	42.9	3.2				3	37.5	2.5
	Moderate	1	16.7	1.1				1	12.5	0.8									
	Severe																		
	Missing																		

(*) % on all patients with adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 57

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS, GROUPED BY BODY SYSTEM, BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Body system / Severity	Assigned treatment																		
	Imipramine									Reboxetine									
	Female			Male			Total			Female			Male			Total			
	No. Pt.	z	(*) z	No. Pt.	z	(*) z	No. Pt.	z	(*) z	No. Pt.	z	(*) z	No. Pt.	z	(*) z	No. Pt.	z	(*) z	
VISION DISORDERS	Total	6	100	6.8	2	100	5.9	8	100	6.6	7	100	7.5	1	100	3.7	8	100	6.7
	Mild	2	40.0	2.3				2	33.6	1.6	2	40.0	2.2				2	33.3	1.7
	Moderate	1	20.0	1.1	1	50.0	2.9	2	33.6	1.6	3	60.0	3.2	1	100	3.7	4	66.7	3.3
	Severe	1	20.0	1.1	1	50.0	2.9	2	33.6	1.6									
RESPIRATORY SYSTEM DISORDERS	Total	1	20.0	1.1				1	14.3	0.8									
	Mild	5	100	5.7	2	100	5.9	7	100	5.7	5	100	5.4	1	100	3.7	6	100	5.0
	Moderate	2	66.7	2.3				2	50.0	1.6	2	40.0	2.2	1	33.3	3.7	3	37.5	2.5
	Severe	1	33.3	1.1	1	100	2.9	2	50.0	1.6	1	20.0	1.1	1	33.3	3.7	2	25.0	1.7
METABOLIC AND NUTRITIONAL DISORDERS	Total	3	100	3.4	1	100	2.9	4	100	3.3	5	100	5.4	3	100	11.1	8	100	6.7
	Mild										1	25.0	1.1				1	25.0	0.8
	Moderate	2	50.0	2.3	1	100	2.9	3	60.0	2.5	2	50.0	2.2				2	50.0	1.7
	Severe	2	50.0	2.3				2	40.0	1.6	1	25.0	1.1				1	25.0	0.8
MUSCULO-SKELETAL SYSTEM DISORDERS	Total	4	100	4.5	1	100	2.9	5	100	4.1	4	100	4.3				4	100	3.3
	Mild	1	25.0	1.1				1	20.0	0.8									
	Moderate	2	50.0	2.3	1	100	2.9	3	60.0	2.5									
	Severe	1	25.0	1.1				1	20.0	0.8									
HEMATOLOGY DISORDERS	Total	4	100	4.5	1	100	2.9	5	100	4.1									
	Mild																		
	Moderate	2	50.0	2.3	1	100	2.9	3	60.0	2.5									
	Severe	1	25.0	1.1				1	20.0	0.8									
SKIN AND APPENDAGES DISORDERS	Total	4	100	4.5	1	100	2.9	5	100	4.1									
	Mild																		
	Moderate	2	100	2.3				2	100	1.6									
	Severe																		

(*) z on all patients with adverse events

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No: 58
NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS, GROUPED BY BODY SYSTEM, BY MAXIMAL SEVERITY LEVEL, DIAGNOSIS AND ASSIGNED TREATMENT

Body system / Severity	Assigned treatment																			
	Imipramine						Reboxetine													
	Major Depressive Disorder		Dysthymia		Total		Major Depressive Disorder		Dysthymia		Total									
	No. Pt.	(*) Z	No. Pt.	(*) Z	No. Pt.	(*) Z	No. Pt.	(*) Z	No. Pt.	(*) Z	No. Pt.	(*) Z								
All adverse events	Mild	21	26.2	12	28.6	33	27.0	23	31.9	31.9	49	39.6	42	35.0	35.0					
	Moderate	32	40.0	19	45.2	51	41.8	25	34.7	34.7	47	35.4	42	35.0	35.0					
	Severe	27	33.8	11	26.2	38	31.1	24	33.3	33.3	42	25.0	36	30.0	30.0					
	Total	80	100	42	100	122	100	72	100	100	48	100	120	100	100					
GASTRO-INTESTINAL SYSTEM DISORDERS	Mild	12	40.0	15	0	13	59.1	31.0	25	48.1	20.5	11	31.4	15.3	11	52.4	22.9	22	59.3	18.3
	Moderate	12	40.0	15	0	8	36.4	19.0	20	38.5	16.4	14	40.0	19.4	8	38.1	16.7	22	59.3	18.3
	Severe	5	16.7	6	3	1	4.5	2.4	6	11.5	4.9	10	28.6	13.9	2	9.5	4.2	12	21.4	10.0
	Missing	1	3.3	1	2				1	1.9	0.8									
Total	30	100	37.5	22	100	52.4	52	100	42.6	35	100	48.6	21	100	43.8	56	100	46.7		
AUTONOMIC NERVOUS SYSTEM DISORDERS	Mild	15	50.0	18	8	7	36.8	16.7	22	44.9	18.0	11	44.0	15.3	13	56.5	27.1	24	50.0	20.0
	Moderate	11	36.7	13	8	10	52.6	23.8	21	42.9	17.2	9	36.0	12.5	7	30.4	14.6	16	33.3	13.3
	Severe	4	13.3	5	0	2	10.5	4.8	6	12.2	4.9	5	20.0	6.9	3	13.0	6.3	8	16.7	6.7
	Total	30	100	37.5	19	100	45.2	49	100	40.2	25	100	34.7	23	100	47.9	48	100	40.0	
CENTRAL & PERIPHERAL NERVOUS SYSTEM DISORDERS	Mild	7	30.4	8	8	3	42.9	7.1	10	33.3	8.2	4	23.5	5.6	10	55.6	20.8	14	40.0	11.7
	Moderate	8	34.8	10	0	2	28.6	4.8	10	33.3	8.2	9	52.9	12.5	4	22.2	8.3	13	37.1	10.8
	Severe	8	34.8	10	0	2	28.6	4.8	10	33.3	8.2	4	23.5	5.6	4	22.2	8.3	8	22.9	6.7
	Total	23	100	28.7	7	100	16.7	30	100	24.6	17	100	23.6	18	100	37.5	35	100	29.2	
CARDIOVASCULAR DISORDERS, GENERAL	Mild	10	34.5	12.5	3	42.9	7.1	13	56.1	10.7	5	27.8	6.9	2	50.0	4.2	7	31.8	5.8	
	Moderate	10	34.5	12.5	1	14.3	2.4	11	30.6	9.0	8	44.4	11.1	2	50.0	4.2	10	45.5	8.3	

(CONTINUED)

(*) x on all patients with adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No: 58
 NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS, GROUPED BY BODY SYSTEM, BY MAXIMAL SEVERITY LEVEL, DIAGNOSIS AND ASSIGNED TREATMENT

Body system / Severity	Assigned treatment																			
	Imipramine									Reboxetine										
	Major Depressive Disorder			Dysthymia			Total			Major Depressive Disorder			Dysthymia			Total				
	No.	(*)	Z	No.	(*)	Z	No.	(*)	Z	No.	(*)	Z	No.	(*)	Z	No.	(*)	Z		
VISION DISORDERS	Severe			1	25.0	2.4	1	12.5	0.8											
	Total	4	100	5.0	4	100	9.5	8	100	6.6	6	100	8.3	2	100	4.2	8	100	6.7	
		1	25.0	1.2	1	33.3	2.4	2	28.6	1.6										
RESPIRATORY SYSTEM DISORDERS	Moderate	1	25.0	1.2	1	33.3	2.4	2	28.6	1.6	4	100	5.6							
	Severe	2	50.0	2.5				2	28.6	1.6										
	Missing				1	33.3	2.4	1	14.3	0.8										
METABOLIC AND NUTRITIONAL DISORDERS	Total	4	100	5.0	3	100	7.1	7	100	5.7	4	100	5.6	2	100	4.2	6	100	5.0	
	Mild	2	50.0	2.5				2	50.0	1.6	1	25.0	1.4	2	50.0	4.2	3	75.0	2.5	
	Moderate	2	50.0	2.5				2	50.0	1.6	2	50.0	2.8				2	50.0	1.7	
MUSCULOSKELETAL SYSTEM DISORDERS	Severe										1	25.0	1.4	2	50.0	4.2	3	75.0	2.5	
	Total	4	100	5.0				4	100	3.3	4	100	5.6	4	100	8.3	8	100	6.7	
	Mild										1	25.0	1.4				1	25.0	0.8	
HEMATOLOGY DISORDERS	Moderate	3	75.0	3.8				3	60.0	2.5										
	Severe	1	25.0	1.2	1	100	2.4	2	40.0	1.6	1	50.0	1.4				1	25.0	0.8	
	Total	4	100	5.0	1	100	2.4	5	100	4.1	2	100	2.8	2	100	4.2	4	100	3.3	
HEMATOLOGY DISORDERS	Mild	1	25.0	1.2				1	20.0	0.8										
	Moderate	2	50.0	2.5	1	100	2.4	3	60.0	2.5										
	Severe	1	25.0	1.2				1	20.0	0.8										
Total	4	100	5.0	1	100	2.4	5	100	4.1											

(CONTINUED)

(*) % on all patients with adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No: 58

NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS, GROUPED BY BODY SYSTEM, BY MAXIMAL SEVERITY LEVEL, DIAGNOSIS AND ASSIGNED TREATMENT

Body system / Severity	Assigned treatment											
	Inipramine						Reboxetine					
	Major Depressive Disorder		Dysthymia		Total		Major Depressive Disorder		Dysthymia		Total	
	No. Pt.	(*) Z	No. Pt.	(*) Z	(*) No. Z	(*) No. Z	No. Pt.	(*) Z	No. Pt.	(*) Z	(*) No. Z	(*) No. Z
SKIN AND APPENDAGES DISORDERS	Mild											
	Moderate	1 100	1.2	1 100	2.4	2 100	1.6	1 50.0	1.4		1 50.0	0.8
	Total	1 100	1.2	1 100	2.4	2 100	1.6	1 50.0	1.4		1 50.0	0.8
LIVER AND BILIAR SYSTEM DISORDERS	Mild			1 100	2.4	1 50.0	0.8					
	Moderate	1 100	1.2			1 50.0	0.8	1 100	1.4		1 100	0.8
	Total	1 100	1.2	1 100	2.4	2 100	1.6	1 100	1.4		1 100	0.8
RESISTANCE MECHANISM DISORDERS	Moderate							1 50.0	1.4		1 33.3	0.8
	Severe							1 50.0	1.4	1 100	2.1	1.7
	Total							2 100	2.8	1 100	2.1	2 66.7
REPRODUCTIVE DISORDERS, MALE	Mild			1 100	2.4	1 100	0.8					
	Total			1 100	2.4	1 100	0.8					
	Moderate	1 100	1.2			1 100	0.8					
ENDOCRINE DISORDERS	Moderate	1 100	1.2			1 100	0.8					
	Total	1 100	1.2			1 100	0.8					
	Moderate							1 100	1.4		1 100	0.8
HEARING AND VESTIBULAR DISORDERS	Total							1 100	1.4		1 100	0.8
	Moderate							1 100	1.4		1 100	0.8
	Total							1 100	1.4		1 100	0.8
NEOPLASM	Moderate							1 100	1.4		1 100	0.8
	Total							1 100	1.4		1 100	0.8

(CONTINUED)

(*) Z on all patients with adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 2012A/035
 TABLE No: 58
 NUMBER OF PATIENTS WHO COMPLAINED OF ADVERSE EVENTS, GROUPED BY BODY SYSTEM, BY MAXIMAL SEVERITY LEVEL, DIAGNOSIS AND ASSIGNED TREATMENT

Body system / Severity	Assigned treatment																		
	Imipramine							Reboxetine											
	Major Depressive Disorder			Dysthymia				Total			Major Depressive Disorder			Dysthymia				Total	
	No. Pt.	Z	(*)	No. Pt.	Z	(*)	No. Pt.	Z	(*)	No. Pt.	Z	(*)	No. Pt.	Z	(*)	No. Pt.	Z	(*)	
Severe	1	100	1.2				1	100	0.8										
OTHER, DISORDERS	1	100	1.2				1	100	0.8										

504

(*) Z on all patients with adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 59

ADVERSE EVENTS: DURATION OF EPISODES (*) BY ASSIGNED TREATMENT

Adverse events/Assigned treatment	No of Episodes	Duration of episodes (days)		
		Min	50%	Max
All adverse events	Imipramine	1	8	47
	Reboxetine	1	10	37
MOUTH DRY	Imipramine	43	19	55
	Reboxetine	41	24	44
CONSTIPATION	Imipramine	42	18	47
	Reboxetine	36	17	46
HEADACHE	Imipramine	22	1	11
	Reboxetine	13	4	15
NAUSEA	Imipramine	17	6	19
	Reboxetine	18	8	19
DIZZINESS	Imipramine	20	5	42
	Reboxetine	12	7	36
SWEATING INCREASED	Imipramine	16	14	47
	Reboxetine	16	12	35
INSOMNIA	Imipramine	5	5	10
	Reboxetine	15	2	25
URINARY TRACT INFECTION	Imipramine	10	3	27
	Reboxetine	7	4	12
TREMOR	Imipramine	6	4	21
	Reboxetine	7	14	26
VISION ABNORMAL	Imipramine	6	4	22
	Reboxetine	6	4	22

(CONTINUED)

(*) For those events which were present before treatment but the severity increased during treatment the time when the change was first recorded was taken as onset date
For those events which were still present at the end of the study, the visit date of last report was taken as the end date of the event

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 59

ADVERSE EVENTS: DURATION OF EPISODES (*) BY ASSIGNED TREATMENT

Adverse events/Assigned treatment	No of Episodes	Duration of episodes (days)		
		Min	50%	Max
VISION ABNORMAL	6	4	18	26
SONNOLENCE	7	1	12	50
FALL	5	1	7	31
	9	1	1	2
	3	1	1	1
	9	1	2	4
	3	1	2	30
	6	20	34	48
	5	7	13	55
	4	2	4	6
	6	1	8	18
	5	8	19	37
	4	5	7	25
	6	4	10	27
	3	5	29	46
	2	6	10	13
	7	1	6	34
	4	7	10	25
	4	10	11	17
	4	1	12	30
	4	1	5	6

(CONTINUED)

(*) For those events which were present before treatment but the severity increased during treatment the time when the change was first recorded was taken as onset date
For those events which were still present at the end of the study, the visit date of last report was taken as the end date of the event

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 59

ADVERSE EVENTS: DURATION OF EPISODES (*) BY ASSIGNED TREATMENT

Adverse events/Assigned treatment	No of Episodes	Duration of episodes (days)		
		Min	50%	Max
URINARY RETENTION	4	1	4	5
	3	1	3	5
HYPOTENSION	7	1	19	36
	5	4	6	19
HYPOTENSION POSTURAL	2	9	14	18
	5	2	7	47
FATIGUE	2	20	27	33
	3	1	7	7
DIARRHOEA	3	1	2	3
	5	7	10	13
BRONCHITIS	1	6	6	6
	1	4	4	4
PAIN	4	6	10	17
	2	2	15	27
ATAXIA	2	2	4	5
	2	5	7	8
CONJUNCTIVITIS	2	5	18	31
	1	10	10	10
HYPOKALAEMIA	3	1	8	14
	3	5	7	8
PNEUMONIA	1	9	9	9

(CONTINUED)

(*) For those events which were present before treatment but the severity increased during treatment the time when the change was first recorded was taken as onset date
For those events which were still present at the end of the study, the visit date of last report was taken as the end date of the event

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 59

ADVERSE EVENTS: DURATION OF EPISODES (*) BY ASSIGNED TREATMENT

Adverse events/Assigned treatment	No of Episodes	Duration of episodes (days)		
		Min	50%	Max
FRACTURE	2	2	6	9
		1	1	1
ARTHRALGIA	2	2	6	10
		1	7	7
HYPERTENSION	2	1	8	15
		1	15	15
PALPITATION	1	4	4	4
		2	1	17
DYSPEPSIA	3	2	15	55
		1	22	22
DYSPHAGIA	2	1	11	20
		1	25	25
WEIGHT DECREASE	2	15	15	15
		3	1	4
ANAEMIA	2	2	3	3
		1	2	2
FEVER	1	6	6	6
		2	4	5
PRURITUS	2	2	5	8
		2	2	15
DYSKINESIA	2	2	15	28
		1	5	5
HYPOAESTHESIA	1	5	5	5

(CONTINUED)

(*) For those events which were present before treatment but the severity increased during treatment the time when the change was first recorded was taken as onset date
For those events which were still present at the end of the study, the visit date of last report was taken as the end date of the event

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 59

ADVERSE EVENTS: DURATION OF EPISODES (*) BY ASSIGNED TREATMENT

Adverse events/Assigned treatment	No of Episodes	Duration of episodes (days)			
		Min	50%	90%	Max
HYPOAESTHESIA	1	12	12	12	12
NEURALGIA	2	1	3	4	4
SYNCOPE	2	1	2	2	2
VOMITING	1	3	3	3	3
ANXIETY	1	4	4	4	4
IMPOTENCE	2	11	30	49	49
NERVOUSNESS	1	53	53	53	53
PARANOID REACTION	1	35	35	35	35
FLATULENCE	2	3	9	14	14
GLOSSITIS	1	10	10	10	10
STOMATITIS	1	3	3	3	3
GASTRO-INTESTINAL DISORDER NOS	1	55	55	55	55
HYPERCHOLESTEROLAEMIA	1	2	2	2	2
HYPERTRIGLYCERIDAEMIA	2	4	5	5	5
	1	25	25	25	25
	1	17	17	17	17
	2	25	28	30	30
	1	1	1	1	1
	1	30	30	30	30
	1	1	1	1	1
	1	1	1	1	1

(CONTINUED)

(*) For those events which were present before treatment but the severity increased during treatment the time when the change was first recorded was taken as onset date
For those events which were still present at the end of the study, the visit date of last report was taken as the end date of the event

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 59

ADVERSE EVENTS: DURATION OF EPISODES (*) BY ASSIGNED TREATMENT

Adverse events/Assigned treatment	No of Episodes	Duration of episodes (days)			
		Min	50%	90%	Max
FIBRILLATION ATRIAL	1	26	26	26	26
	1	1	1	1	1
SINUSITIS	1	5	5	5	5
	1	36	36	36	36
RIGORS	2	23	35	46	46
HONNILLIASIS	2	7	14	20	20
RASH ERYTHEMATOUS	1	13	13	13	13
PILORECTION	1	15	15	15	15
FRACTURE PATHOLOGICAL	1	32	32	32	32
NYALGIA	1	32	32	32	32
COMA	1	12	12	12	12
CONVULSIONS	1	1	1	1	1
CONVULSIONS GRAND MAL	1	1	1	1	1
COORDINATION ABNORMAL	1	20	20	20	20
HYPERKINESIA	1	3	3	3	3
NEURITIS	1	7	7	7	7
NEUROFATHY	1	3	3	3	3
STUPOR	1	1	1	1	1
VERTIGO	1	4	4	4	4
EYE PAIN	1	8	8	8	8
EAR DISORDER NOS	1	43	43	43	43

(CONTINUED)

(*) For those events which were present before treatment but the severity increased during treatment the time when the change was first recorded was taken as onset date
For those events which were still present at the end of the study, the visit date of last report was taken as the end date of the event

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 59

ADVERSE EVENTS: DURATION OF EPISODES (*) BY ASSIGNED TREATMENT

Adverse events/Assigned treatment	No of Episodes	Duration of episodes (days)		
		Min	50%	Max
TASTE PERVERSION	1	49	49	49
APATHY	1	6	6	6
LIBIDO DECREASED	1	35	35	35
PARONIRIA	1	8	8	8
SLEEP DISORDER	1	5	5	5
SUICIDE ATTEMPT	1	1	1	1
DEPRESSION AGGRAVATED	1	9	9	9
CONCENTRATION IMPAIRED	1	27	27	27
HEPATIC FUNCTION ABNORMAL	1	1	1	1
SOFT INCREASED	1	3	3	3
GAMMA-GT INCREASED	1	1	1	1
BUN INCREASED	1	15	15	15
GLOBULINS INCREASED	1	1	1	1
GLYCOSURIA	1	17	17	17
HYPOTHYROIDISM	1	9	9	9
MYOCARDIAL INFARCTION	1	66	66	66
BUNDLE BRANCH BLOCK	1	29	29	29
EXTRASYSTOLES	1	8	8	8
CEREBROVASCULAR DISORDER	1	12	12	12
PERIPHERAL ISCHAEMIA	1	1	1	1
THROMBOSIS ARTERIAL	1	2	2	2

(CONTINUED)

(*) For those events which were present before treatment but the severity increased during treatment the time when the change was first recorded was taken as onset date
For those events which were still present at the end of the study, the visit date of last report was taken as the end date of the event

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 59

ADVERSE EVENTS: DURATION OF EPISODES (*) BY ASSIGNED TREATMENT

Adverse events/Assigned treatment	No of Episodes	Duration of episodes (days)			
		Min	50%	90%	Max
COUGHING	1	4	4	4	4
DYSPROEA	1	1	1	1	1
PHARYNGITIS	1	6	6	6	6
UPPER RESP TRACT INFECTION	1	4	4	4	4
ASTHMA	1	9	9	9	9
GRANULOCYTOPENIA	1	8	8	8	8
PURPURA	1	7	7	7	7
CYSTITIS	1	11	11	11	11
NOCTURIA	1	21	21	21	21
RENAL FUNCTION ABNORMAL	1	32	32	32	32
PULMONARY CARCINOMA	1	4	4	4	4
OEDEMA PERIPHERAL	1	49	49	49	49
ALLERGIC REACTION	1	11	11	11	11
ASTHENIA	1	5	5	5	5
BACK PAIN	1	5	5	5	5
CHEST PAIN	1	1	1	1	1
CHEST PAIN PRECORDIAL	1	56	56	56	56
ESR INCREASED	1	1	1	1	1
NASAL POLYP	1	5	5	5	5
INFECTION	1	6	6	6	6

(*) For those events which were present before treatment but the severity increased during treatment the time when the change was first recorded was taken as onset date
For those events which were still present at the end of the study, the visit date of last report was taken as the end date of the event

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 60
ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY SYMPTOMATIC TREATMENT AND ASSIGNED TREATMENT

Adverse events	Assigned treatment											
	Imipramine						Reboxetine					
	Symptomatic treatment						Symptomatic treatment					
	YES		NO		Total		YES		NO		Total	
No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	
No. of pt. with A.E.	40	32.8	82	67.2	122	100.0	46	38.3	74	61.7	120	100.0
No. of adverse events	79	23.4	259	76.6	338	100.0	76	24.8	231	75.2	307	100.0
MOUTH DRY	4	9.3	39	90.7	43	100.0	2	4.9	39	95.1	41	100.0
CONSTIPATION	14	33.3	28	66.7	42	100.0	14	38.9	22	61.1	36	100.0
HEADACHE	11	50.0	11	50.0	22	100.0	2	15.4	11	84.6	13	100.0
NAUSEA	2	11.8	15	88.2	17	100.0	1	5.6	17	94.4	18	100.0
DIZZINESS			20	100.0	20	100.0	1	8.3	11	91.7	12	100.0
SWEATING INCREASED	1	6.3	15	93.8	16	100.0	2	12.5	14	87.5	16	100.0
INSOMNIA	1	20.0	4	80.0	5	100.0	8	53.3	7	46.7	15	100.0
URINARY TRACT INFECTION	7	70.0	3	30.0	10	100.0	6	85.7	1	14.3	7	100.0
TREMOR			6	100.0	6	100.0			7	100.0	7	100.0
VISION ABNORMAL	1	16.7	5	83.3	6	100.0	1	16.7	5	83.3	6	100.0
SOMNOLENCE			7	100.0	7	100.0			5	100.0	5	100.0
FALL	1	11.1	8	88.9	9	100.0			3	100.0	3	100.0
MALaise			9	100.0	9	100.0			3	100.0	3	100.0
HICTURITION DISORDER			6	100.0	6	100.0	1	20.0	4	80.0	5	100.0
CONFUSION	1	25.0	3	75.0	4	100.0	1	16.7	5	83.3	6	100.0
ANOREXIA			5	100.0	5	100.0			4	100.0	4	100.0
TACHYCARDIA	2	33.3	4	66.7	6	100.0			3	100.0	3	100.0
ABDOMINAL PAIN			2	100.0	2	100.0	1	14.3	6	85.7	7	100.0
PARAESTHESIA	1	25.0	3	75.0	4	100.0			4	100.0	4	100.0

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 60

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY SYMPTOMATIC TREATMENT AND ASSIGNED TREATMENT

Adverse events	Assigned treatment											
	Imipramine						Reboxetine					
	Symptomatic treatment						Symptomatic treatment					
	YES		NO		Total		YES		NO		Total	
No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	
AGITATION		4	100.0	4	100.0	2	50.0	2	50.0	4	100.0	
URINARY RETENTION		4	100.0	4	100.0	1	33.3	2	66.7	3	100.0	
HYPOTENSION	4	57.1	3	42.9	7	100.0						
HYPOTENSION POSTURAL												
FATIGUE	1	20.0	4	80.0	5	100.0	1	50.0	1	50.0	2	100.0
DIARRHOEA	1	33.3	2	66.7	3	100.0	2	66.7	1	33.3	3	100.0
BRONCHITIS	3	60.0	2	40.0	5	100.0	1	100.0			1	100.0
PAIN			1	100.0	1	100.0	1	25.0	3	75.0	4	100.0
ATAXIA			2	100.0	2	100.0			2	100.0	2	100.0
CONJUNCTIVITIS	2	100.0			2	100.0	1	50.0	1	50.0	2	100.0
HYPOKALAEMIA	1	100.0			1	100.0	3	100.0			3	100.0
PNEUMONIA	1	33.3	2	66.7	3	100.0	1	100.0			1	100.0
FRACTURE			2	100.0	2	100.0			1	100.0	1	100.0
ARTHRALGIA	2	100.0			2	100.0	1	100.0			1	100.0
HYPERTENSION	2	100.0			2	100.0			1	100.0	1	100.0
PALPITATION			1	100.0	1	100.0			2	100.0	2	100.0
DYSPEPSIA							2	66.7	1	33.3	3	100.0
DYSPHAGIA	1	100.0			1	100.0	2	100.0			2	100.0
HEIGHT DECREASE			1	100.0	1	100.0			2	100.0	2	100.0
ANEMIA	2	66.7	1	33.3	3	100.0						
FEVER	1	50.0	1	50.0	2	100.0			1	100.0	1	100.0

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 60

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY SYMPTOMATIC TREATMENT AND ASSIGNED TREATMENT

Adverse events	Assigned treatment													
	Imipramine							Reboxetine						
	Symptomatic treatment							Symptomatic treatment						
	YES	NO	Z	No.	Z	No.	Total	YES	NO	Z	No.	Z	No.	Total
INFLUENZA-LIKE SYMPTOMS			1	100.0	1	100.0	2				2	100.0	2	100.0
PRURITUS	1		50.0	1	50.0	2								
HYPOAESTHESIA			1	100.0	1	100.0				1	100.0	1	100.0	
NEURALGIA							2	100.0						2
SYNCOPE			2	100.0	2	100.0								
VOMITING			1	100.0	1	100.0				1	100.0	1	100.0	
ANXIETY											2	100.0	2	100.0
NERVOUSNESS											2	100.0	2	100.0
PARANOID REACTION			1	100.0	1	100.0				1	100.0	1	100.0	
FLATULENCE	1		100.0			1	100.0			1	100.0			1
STOMATITIS			1	100.0	1	100.0				1	100.0			1
GASTRO-INTESTINAL DISORDER NOS								2	100.0					2
HYPERCHOLESTEROLAEMIA			1	100.0	1	100.0				1	100.0	1	100.0	
HYPERTRIGLYCERIDAEMIA			1	100.0	1	100.0				1	100.0	1	100.0	
SINUSITIS			1	100.0	1	100.0				1	100.0	1	100.0	
RIGORS											2	100.0	2	100.0
NONILLIASIS								1	50.0		1	50.0	2	100.0
DYSKINESIA	1		50.0	1	50.0	2	100.0							
IMPOTENCE			1	100.0	1	100.0				1	100.0	1	100.0	
GLOSSITIS											2	100.0	2	100.0

(CONTINUED)

CU
1-1
CU

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 60
 ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY SYMPTOMATIC TREATMENT AND ASSIGNED TREATMENT

Adverse events	Assigned treatment											
	Imipramine						Reboxetine					
	Symptomatic treatment						Symptomatic treatment					
	YES	NO	Total		YES	NO	Total		YES	NO	Total	
No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	
FIBRILLATION ATRIAL	1	100.0			1	100.0					1	100.0
RASH ERYTHEMATOUS											1	100.0
PILOERECTOR											1	100.0
FRACTURE PATHOLOGICAL			1	100.0							1	100.0
NVALGIA											1	100.0
COMA			1	100.0								
CONVULSIONS	1	100.0			1	100.0						
COORDINATION ABNORMAL			1	100.0								
HYPERINESIA								1	100.0			1
NEURITIS											1	100.0
NEUROPATHY											1	100.0
VERTIGO			1	100.0								
EYE PAIN											1	100.0
EAR DISORDER NOS								1	100.0			1
TASTE PERVERSION			1	100.0								
LIBIDO DECREASED											1	100.0
PARONIRIA											1	100.0
SLEEP DISORDER											1	100.0
SUICIDE ATTEMPT			1	100.0								
DEPRESSION AGGRAVATED											1	100.0
CONCENTRATION IMPAIRED								1	100.0			1

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 2012A/035
TABLE No.: 60

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY SYMPTOMATIC TREATMENT AND ASSIGNED TREATMENT

Adverse events	Assigned treatment											
	Imipramine						Reboxetine					
	Symptomatic treatment						Symptomatic treatment					
	YES	NO	Z	No.	Z	Total	YES	NO	Z	No.	Z	Total
GAMMA-GT INCREASED												
BUN INCREASED												
GLYCOSURIA												
HYPOTHYROIDISM	1	100.0				1	100.0					
BUNDLE BRANCH BLOCK												
CEREBROVASCULAR DISORDER												
PERIPHERAL ISCHAEMIA	1	100.0				1	100.0					
COUGHING												
UPPER RESP TRACT INFECTION												
ASTHMA												
GRANULOCYTOPENIA												
PURPURA												
CYSTITIS												
NOCTURIA	1	100.0				1	100.0					
RENAL FUNCTION ABNORMAL												
PULMONARY CARCINOMA												
OEDEMA PERIPHERAL												
BACK PAIN												
CHEST PAIN PRECORDIAL	1	100.0				1	100.0					
NASAL POLYP												
INFECTION												

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 60

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY SYMPTOMATIC TREATMENT AND ASSIGNED TREATMENT

Adverse events	Assigned treatment													
	Imigraine						Reboxetine							
	Symptomatic treatment						Symptomatic treatment							
	YES	NO	Total	YES	NO	Total	YES	NO	Total	YES	NO	Total		
No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z			
CONVULSIONS GRAND MAL														
STUPOR			1	100.0	1	100.0						1	100.0	
APATHY			1	100.0	1	100.0								
HEPATIC FUNCTION ABNORMAL			1	100.0	1	100.0								
SQPT INCREASED			1	100.0	1	100.0								
GLOBULINS INCREASED			1	100.0	1	100.0								
MYOCARDIAL INFARCTION			1	100.0	1	100.0								
EXTRASISTOLES														
THROMBOSIS ARTERIAL														
DYSPNOEA	1	100.0			1	100.0								
PHARYNGITIS									1	100.0			1	100.0
ALLERGIC REACTION	1	100.0			1	100.0								
ASTHENIA														
CHEST PAIN	1	100.0			1	100.0							1	100.0
ESR INCREASED			1	100.0	1	100.0								

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 61

ADVERSE EVENTS BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment	Study drug																	
	No change			Dose reduced			Temporarily interrupted			Definitively withdrawn			Missing			Total		
	No.	%	z	No.	%	z	No.	%	z	No.	%	z	No.	%	z	No.	%	z
All adverse events	Imipramine	238	76.4	4	1.2	8	2.4	74	21.9	14	4.1	338	100.0					
	Reboxetine	235	76.5	7	2.3	6	2.0	54	17.6	5	1.6	307	100.0					
MOUTH DRY	Imipramine	37	86.0	1	2.3			5	11.6			43	100.0					
	Reboxetine	38	92.7					3	7.3			41	100.0					
CONSTIPATION	Imipramine	35	83.3					6	14.3	1	2.4	42	100.0					
	Reboxetine	33	91.7	1	2.8			2	5.6			36	100.0					
HYPOTENSION AND RELATED SYMPTOMS	Imipramine	24	70.6	1	2.9	1	2.9	7	20.6	1	2.9	34	100.0					
	Reboxetine	8	57.1	2	14.3			3	21.4	1	7.1	14	100.0					
NAUSEA AND RELATED SYMPTOMS	Imipramine	16	86.9					2	11.1			18	100.0					
	Reboxetine	17	77.3			1	4.5	3	13.6	1	4.5	22	100.0					
HEADACHE / MIGRAINE	Imipramine	21	95.5					1	4.5			22	100.0					
	Reboxetine	10	76.9					3	23.1			13	100.0					
SWEATING INCREASED	Imipramine	11	68.8					5	31.3			16	100.0					
	Reboxetine	10	62.5	1	6.3			5	31.3			16	100.0					
INSOMNIA	Imipramine	3	69.0					2	40.0			5	100.0					
	Reboxetine	13	86.7					2	13.3			15	100.0					
URINARY HESITANCY / RETENTION	Imipramine	2	20.0					8	80.0			10	100.0					
	Reboxetine	5	62.5					3	37.5			8	100.0					
URINARY TRACT INFECTION	Imipramine	8	80.0					1	10.0	1	10.0	10	100.0					
	Reboxetine	7	100.0									7	100.0					
TREMOR	Imipramine	5	83.3					1	16.7			6	100.0					

(CONTINUED)

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 61

ADVERSE EVENTS BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment	Study drug																			
	No change			Dose reduced			Temporarily interrupted			Definitively withdrawn			Missing			Total				
	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%		
TREMOR	2	28.6	14.3	1	14.3														7	100.0
FALL	2	22.2				1	11.1	33.3	3	33.3	3	33.3							9	100.0
MALAISE	2	66.7							1	33.3									3	100.0
	7	77.8							2	22.2									9	100.0
	3	100.0																	3	100.0
AGITATION / ANXIETY / NERVUSNESS	1	25.0							3	75.0									4	100.0
	2	25.0							4	50.0	2	25.0							8	100.0
SOMNOLENCE	4	57.1	14.3	1	14.3				2	28.6									7	100.0
	4	80.0							1	20.0									5	100.0
BLURRED VISION	5	83.3							1	16.7									6	100.0
	4	66.7							2	33.3									6	100.0
CONFUSION	3	75.0							1	25.0									4	100.0
	2	33.3				1	16.7	3	50.0										6	100.0
TACHYCARDIA	5	83.3							1	16.7									6	100.0
	2	66.7	33.3	1	33.3														3	100.0
ABDOMINAL PAIN	1	50.0							1	50.0									2	100.0
	3	42.9	14.3	1	14.3	2	28.6	1	14.3										7	100.0
ANOREXIA	2	40.0							3	60.0									5	100.0
	3	75.0							1	25.0									4	100.0
ASTHENIA / FATIGUE	3	60.0	20.0	1	20.0				1	20.0									5	100.0
	3	100.0																	3	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 61

ADVERSE EVENTS BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment	Study drug																	
	No change			Dose reduced			Temporarily interrupted			Definitively withdrawn			Missing			Total		
	No.	%	%	No.	%	%	No.	%	%	No.	%	%	No.	%	%	No.	%	%
PARAESTHESIA	Imipramine	2	50.0							2	50.0					4	100.0	
	Reboxetine	4	100.0													4	100.0	
DIARRHOEA	Imipramine	3	100.0													3	100.0	
	Reboxetine	3	100.0													3	100.0	
BRONCHITIS	Imipramine	2	40.0			1	20.0								2	40.0		
	Reboxetine	1	100.0												1	100.0		
PAIN	Imipramine													1	100.0			
	Reboxetine	3	75.0						1	25.0					4	100.0		
ATAXIA	Imipramine	1	50.0						1	50.0					2	100.0		
	Reboxetine	2	100.0												2	100.0		
HYPOKALAEMIA	Imipramine					1	100.0								1	100.0		
	Reboxetine	2	66.7						1	33.3					3	100.0		
PNEUMONIA	Imipramine													2	66.7			
	Reboxetine	1	100.0											1	100.0			
CONJUNCTIVITIS	Imipramine	2	100.0												2	100.0		
	Reboxetine	1	50.0			1	50.0								2	100.0		
FEVER	Imipramine	2	100.0												2	100.0		
	Reboxetine	1	100.0												1	100.0		
INFLUENZA-LIKE SYMPTOMS	Imipramine	1	100.0												1	100.0		
	Reboxetine	2	100.0												2	100.0		
HYPERTENSION	Imipramine	1	50.0						1	50.0					2	100.0		
	Reboxetine																	

(CONTINUED)

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 61

ADVERSE EVENTS BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse event/Assigned treatment	Study drug																	
	No change			Dose reduced			Temporarily interrupted			Definitively withdrawn			Missing			Total		
	No.	X	Z	No.	X	Z	No.	X	Z	No.	X	Z	No.	X	Z	No.	X	Z
HYPERTENSION	Reboxetine	1	100.0													1	100.0	
	Imipramine								1	100.0						1	100.0	
PALPITATION	Reboxetine	1	50.0						1	50.0						2	100.0	
	Imipramine	1	100.0													1	100.0	
DYSPHAGIA	Reboxetine	1	50.0						1	50.0						2	100.0	
	Imipramine	1	100.0													1	100.0	
ANEMIA	Reboxetine	1	33.3						1	33.3						3	100.0	
	Imipramine	1	100.0													1	100.0	
WEIGHT DECREASE	Reboxetine	2	100.0													2	100.0	
	Imipramine	2	100.0													2	100.0	
ARTHRALGIA	Reboxetine	1	100.0													1	100.0	
	Imipramine	1	100.0													1	100.0	
FRACTURE	Reboxetine	1	50.0						1	50.0						2	100.0	
	Imipramine	1	100.0													1	100.0	
RIGORS	Reboxetine	2	100.0													2	100.0	
	Imipramine	1	100.0													1	100.0	
FIBRILLATION ATRIAL	Reboxetine	1	50.0						1	50.0						2	100.0	
	Imipramine	1	100.0													1	100.0	
DYSKINESIA	Reboxetine	1	50.0						1	50.0						2	100.0	
	Imipramine	1	100.0													1	100.0	
HYPOAESTHESIA	Reboxetine	2	100.0													2	100.0	
	Imipramine	1	100.0													1	100.0	
NEURALGIA	Reboxetine	1	100.0													1	100.0	
	Imipramine	1	100.0													1	100.0	
FLATULENCE	Reboxetine	1	100.0													1	100.0	
	Imipramine	1	100.0													1	100.0	

(CONTINUED)

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 61
 ADVERSE EVENTS BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

U
 S
 C

Adverse events/Assigned treatment	Study drug													
	No change			Dose reduced			Temporarily interrupted		Definitively withdrawn		Missing		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
GASTRO-INTESTINAL DISORDER NOS	Reboxetine	2	100.0										2	100.0
	Reboxetine	2	100.0										2	100.0
GLOSSITIS	Imipramine										1	100.0	1	100.0
	Reboxetine	1	100.0										1	100.0
INCREASED LIVER ENZYMES	Imipramine	1	100.0										1	100.0
	Reboxetine	1	100.0										1	100.0
HYPERCHOLESTEROLEMIA	Imipramine	1	100.0										1	100.0
	Reboxetine	1	100.0										1	100.0
HYPERTRIGLYCERIDEMIA	Imipramine	1	100.0										1	100.0
	Reboxetine	1	100.0										1	100.0
IMPOTENCE	Imipramine								1	100.0			1	100.0
	Reboxetine	1	100.0										1	100.0
NONILIASIS	Reboxetine	1	100.0										1	100.0
	Reboxetine	1	50.0							1	50.0		2	100.0
SINUSITIS	Imipramine					1	100.0						1	100.0
	Reboxetine	1	100.0										1	100.0
PRURITUS	Imipramine	1	50.0										1	50.0
	Imipramine								1	100.0			1	100.0
PARANOID REACTION	Reboxetine													
	Imipramine	1	100.0										1	100.0
ALLERGIC REACTION	Imipramine	1	100.0										1	100.0
	Imipramine	1	100.0										1	100.0
CHEST PAIN	Imipramine	1	100.0										1	100.0
	Imipramine	1	100.0										1	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 61
ADVERSE EVENTS BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment	Study drug																	
	No change			Dose reduced			Temporarily interrupted			Definitively withdrawn			Missing			Total		
	No.	%	z	No.	%	z	No.	%	z	No.	%	z	No.	%	z	No.	%	z
AEDEMA	1	100.0														1	100.0	
BUNDLE BRANCH BLOCK	1	100.0														1	100.0	
CARDIAC ISCHEMIA AND RELATED SYMPTOMS	1	100.0														1	100.0	
EXTRASYSTOLES	1	100.0														1	100.0	
CONVULSIONS GRAND MAL	1	100.0														1	100.0	
COORDINATION ABNORMAL	1	100.0														1	100.0	
STUPOR	1	100.0														1	100.0	
VERTIGO	1	100.0														1	100.0	
HYPOTHYROIDISM	1	100.0														1	100.0	
EAR DISORDER NOS	1	100.0														1	100.0	
GRANULOCYTOPENIA	1	100.0														1	100.0	
PURPURA	1	100.0														1	100.0	
BUN INCREASED	1	100.0														1	100.0	
GLYCOSURIA	1	100.0														1	100.0	
BACK PAIN	1	100.0														1	100.0	
FRACTURE PATHOLOGICAL	1	100.0														1	100.0	
MYALGIA	1	100.0														1	100.0	
APATHY	1	100.0														1	100.0	
CONCENTRATION IMPAIRED	1	100.0														1	100.0	
PAROSMIA	1	100.0														1	100.0	
SLEEP DISORDER	1	100.0														1	100.0	

(some adverse events are grouped in cluster)

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 61

ADVERSE EVENTS BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment	Study drug																		
	No change			Dose reduced			Temporarily interrupted			Definitively withdrawn			Missing			Total			
	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	
SUICIDE ATTEMPT																			
INFECTION																			
ASTHMA																			
COUGHING																			
DYSPNOEA																			
PHARYNGITIS																			
UPPER RESP TRACT INFECTION																			
ERYTHEMA / RASH																			
PILORECTION																			
TASTE PERVERSION																			
CYSTITIS																			
NOCTURIA																			
RENAL FUNCTION ABNORMAL																			
EYE PAIN																			
NASAL POLYP																			
CEREBROVASCULAR DISORDER																			
PERIPHERAL ISCHAEMIA																			
THROMBOSIS ARTERIAL																			
COMA																			
CONVULSIONS																			
HYPERMESIA																			

(CONTINUED)

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 61

ADVERSE EVENTS BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment	Study drug																	
	No change			Dose reduced			Temporarily interrupted			Definitively withdrawn			Missing			Total		
	No.	%		No.	%		No.	%		No.	%		No.	%		No.	%	
NEURITIS										1	100.0					1	100.0	
NEUROPATHY										1	100.0					1	100.0	
HEPATIC FUNCTION ABNORMAL										1	100.0					1	100.0	
GLOBULINS INCREASED										1	100.0					1	100.0	
PULMONARY CARCINOMA										1	100.0					1	100.0	
DEPRESSION AGGRAVATED										1	100.0					1	100.0	
LIBIDO DECREASED										1	100.0					1	100.0	
MYOCARDIAL INFARCTION														1	100.0	1	100.0	

01
22
0

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 62
 ADVERSE EVENTS: DISAPPEARED AFTER ACTION ON STUDY DRUG AND REAPPEARED ON RESUMING TREATMENT BY ASSIGNED TREATMENT

Adverse events/Assigned treatment	Modified study drug												Temporarily interrupted																
	Disappeared						Reappeared						Disappeared																
	NO		YES		Not applicable		Total		NO		YES		Not applicable		Total		NO		YES		Not applicable		Total						
No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z						
All adverse events	26	38.8	34	50.7	7	10.4	67	100.0	6	100.0														6	100.0				
	17	19.8	57	66.3	12	14.0	86	100.0	2	25.0														6	75.0	8	100.0		
HYPOENSION AND RELATED SYMPTOMS	2	40.0	2	40.0	1	20.0	5	100.0																					
	2	22.2	7	77.8			9	100.0	1	100.0																	1	100.0	
SWEATING INCREASED	3	50.0	3	50.0			6	100.0																					
	1	20.0	4	80.0			5	100.0																					
URINARY HESITANCY / RETENTION	1	33.3	2	66.7			3	100.0																					
			8	100.0			8	100.0																					
MOUTH DRY			3	100.0			3	100.0																					
	1	16.7	5	83.3			6	100.0																					
CONSTIPATION	1	33.3	2	66.7			3	100.0																					
	2	33.3	4	66.7			6	100.0																					
AGITATION / ANXIETY / NERVOUSNESS	2	50.0	2	50.0			4	100.0																					
	1	33.3	2	66.7			3	100.0																					
TREMOR	1	20.0	4	80.0			5	100.0																					
			1	100.0			1	100.0																					
NAUSEA AND RELATED SYMPTOMS			3	75.0	1	25.0	4	100.0	1	100.0																		1	100.0
			2	100.0			2	100.0																					
FALL					1	100.0	1	100.0																					
			2	50.0	2	50.0	4	100.0																				1	100.0

(CONTINUED)
 (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 62

ADVERSE EVENTS: DISAPPEARED AFTER ACTION ON STUDY DRUG AND REAPPEARED ON RESUMING TREATMENT BY ASSIGNED TREATMENT

CT
C2
C3

Adverse events/Assigned treatment	Modified study drug																
	Disappeared						Temporarily interrupted										
	NO		YES		Not applicable		Total		NO		YES		Not applicable		Total		
	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	
CONFUSION	Reboxetine	2	50.0	2	50.0			4	100.0	1	100.0					1	100.0
	Imipramine			1	100.0			1	100.0								
ABDOMINAL PAIN	Reboxetine	1	25.0	3	75.0			4	100.0	2	100.0					2	100.0
	Imipramine			1	100.0			1	100.0								
HEADACHE / MIGRAINE	Reboxetine	1	33.3	2	66.7			3	100.0								
	Imipramine	1	100.0					1	100.0								
ANOREXIA	Reboxetine	1	100.0					1	100.0								
	Imipramine	1	33.3	2	66.7			3	100.0								
INSOMNIA	Reboxetine	2	100.0					2	100.0								
	Imipramine	1	50.0	1	50.0			2	100.0								
SOMNOLENCE	Reboxetine	1	100.0					1	100.0								
	Imipramine			3	100.0			3	100.0								
FRACTURE	Reboxetine					1	100.0	1	100.0								
	Imipramine					2	100.0	2	100.0								
BLURRED VISION	Reboxetine			2	100.0			2	100.0								
	Imipramine			1	100.0			1	100.0								
ASTHENIA / FATIGUE	Imipramine			2	100.0			2	100.0								
	Reboxetine			2	100.0			2	100.0								
PALPITATION	Reboxetine			1	100.0			1	100.0								
	Imipramine			1	100.0			1	100.0								

(CONTINUED)

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 62

ADVERSE EVENTS: DISAPPEARED AFTER ACTION ON STUDY DRUG AND REAPPEARED ON RESUMING TREATMENT BY ASSIGNED TREATMENT

CT
SC
CC

Adverse events/Assigned treatment	Notified study drug											
	Disappeared						Temporarily interrupted					
	NO		YES		Not applicable		NO		YES		Not applicable	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
TACHYCARDIA					1	100.0						
					1	100.0						
PARAESTHESIA					1	50.0						
					1	50.0						
ANEMIA					1	50.0						
					1	50.0						
HYPOKALAEMIA					1	100.0						
					1	100.0						
PARANOID REACTION					1	100.0						
					1	100.0						
NASAL POLYP					1	100.0						
					1	100.0						
PAIN					1	100.0						
					1	100.0						
CEREBROVASCULAR DISORDER					1	100.0						
					1	100.0						
HYPERTENSION					1	100.0						
					1	100.0						
PERIPHERAL ISCHAEMIA					1	100.0						
					1	100.0						
THROMBOSIS ARTERIAL					1	100.0						
					1	100.0						
ATAXIA					1	100.0						
					1	100.0						
COMA					1	100.0						
					1	100.0						
CONVULSIONS					1	100.0						
					1	100.0						
DYSKINESIA					1	100.0						
					1	100.0						
HYPERMESIA					1	100.0						
					1	100.0						

(CONTINUED)

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 62

ADVERSE EVENTS: DISAPPEARED AFTER ACTION ON STUDY DRUG AND REAPPEARED ON RESUMING TREATMENT BY ASSIGNED TREATMENT

CF
CJ
C

Adverse events/Assigned treatment	Modified study drug										Temporarily interrupted					
	Disappeared					Reappeared					Disappeared			Reappeared		
	NO		YES		Not applicable		Total		NO		YES		Not applicable		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
HYPOAESTHESIA	1	100.0					1	100.0								
NEURITIS	1	100.0					1	100.0								
NEUROPATHY	1	100.0					1	100.0								
DYSPHAGIA			1	100.0			1	100.0								
HEPATIC FUNCTION ABNORMAL					1	100.0	1	100.0								
GLOBULINS INCREASED					1	100.0	1	100.0								
PULMONARY CARCINOMA	1	100.0					1	100.0								
DEPRESSION AGGRAVATED									1	100.0						
LIBIDO DECREASED									1	100.0						
IMPOTENCE									1	100.0						
BRONCHITIS														1	100.0	
PNEUMONIA	1	100.0					1	100.0								
SINUSITIS	1	100.0					1	100.0								
PRURITUS									1	100.0						
URINARY TRACT INFECTION									1	100.0						
CONJUNCTIVITIS	1	100.0					1	100.0								

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS RED
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 63

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

C7
C3
1-1

Adverse events/Assigned treatment	Modified study drug												Unchanged study drug or Missing																						
	Recovered with sequelae			Still present			Death			Missing			Total			Recovered with sequelae			Still present			Death			Missing			Total							
	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z
ALL adverse events	Imipramine	62	72.1	2	2.3	18	20.9	3	3.5	1	1.2	86	100	171	67.9	2	0.8	42	16.7	3	1.2	34	13.5	252	100										
	Reboxetine	34	50.7	1	1.5	28	41.8			4	6.0	67	100	163	67.9	2	0.8	48	20.0			27	11.3	240	100										
MOUTH DRY	Imipramine	5	83.3			1	16.7					6	100	25	67.6			10	27.0			2	5.4	37	100										
	Reboxetine	3	100									3	100	24	63.2	1	2.6	10	26.3			3	7.9	38	100										
CONSTIPATION	Imipramine	4	66.7			2	33.3					6	100	25	69.4			5	13.9			6	16.7	36	100										
	Reboxetine	2	66.7							1	33.3	3	100	20	60.6			11	33.3			2	6.1	33	100										
HYPOTENSION AND RELATED SYMPTOMS	Imipramine	7	77.8			2	22.2					9	100	15	60.0			6	24.0			4	16.0	25	100										
	Reboxetine	1	20.0			3	60.0			1	20.0	5	100	3	33.3			2	22.2			4	44.4	9	100										
NAUSEA AND RELATED SYMPTOMS	Imipramine	2	100									2	100	16	100									16	100										
	Reboxetine	2	50.0			2	50.0					4	100	16	88.9							2	11.1	18	100										
HEADACHE / MIGRAINE	Imipramine					1	100					1	100	21	100									21	100										
	Reboxetine	2	66.7			1	33.3					3	100	10	100									10	100										
SWEATING INCREASED	Imipramine	3	60.0			2	40.0					5	100	6	54.5			1	9.1			4	36.4	11	100										
	Reboxetine	3	50.0			3	50.0					6	100	8	80.0			2	20.0					10	100										
INSOMNIA	Imipramine	1	50.0			1	50.0					2	100	3	100									3	100										
	Reboxetine					2	100					2	100	12	92.3							1	7.7	13	100										
URINARY HESITANCY / RETENTION	Imipramine	7	87.5			1	12.5					8	100	1	50.0			1	50.0					2	100										
	Reboxetine	2	66.7			1	33.3					3	100	4	80.0			1	20.0					5	100										
URINARY TRACT INFECTION	Imipramine	1	100									1	100	8	88.9									1	11.1	9	100								
	Reboxetine												7	100											7	100									

(CONTINUED)

(some adverse events are grouped in clusters)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS RED

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 63

51
53
4

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment	Modified study drug										Unchanged study drug or Missing												
	Recovered with sequelae		Still present		Death		Missing		Total		Recovered		Recovered with sequelae		Still present		Death		Missing		Total		
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	
INFLUENZA-LIKE SYMPTOMS	Imipramine																						
	Reboxetine																						
HYPERTENSION	Imipramine			1	100					1	100												
	Reboxetine																						
PALPITATION	Imipramine			1	100					1	100												
	Reboxetine																						
DYSPHAGIA	Imipramine			1	100					1	100												
	Reboxetine																						
ANEMIA	Imipramine	1	100							1	100												
	Reboxetine	1	50.0							2	100												
WEIGHT DECREASE	Imipramine																						
	Reboxetine																						
ARTERIALGIA	Imipramine																						
	Reboxetine																						
FRACTURE	Imipramine	1	50.0							2	100												
	Reboxetine																						
RIGORS	Imipramine																						
	Reboxetine																						
FIBRILLATION ATRIAL	Imipramine																						
	Reboxetine																						
DYSKINESIA	Imipramine	1	100							1	100												
	Imipramine																						

(CONTINUED)

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/095
TABLE No.: 65

C1
C3
C7

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment	Modified study drug										Unchanged study drug or Missing											
	Recovered with sequelae		Still present		Death		Missing		Total		Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
HYPOAESTHESIA					1	100																
NEURALGIA											2	100										
FLATULENCE															1	100						
GASTRO-INTESTINAL DISORDER NOS																						
GLOSSITIS											2	100										
STOMATITIS																						
INCREASED LIVER ENZYMES																						
HYPERCHOLESTEROL-AEMIA																						
HYPERTRIGLYCERID-AEMIA																						
PARANOID REACTION																						
IMPOTENCE																						
MONILLIASIS																						
SINUSITIS																						

(CONTINUED)

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No. : 63

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

UT
W
O

Adverse events/Assigned treatment	Modified study drug										Unchanged study drug or Missing											
	Recovered with sequelae		Still present		Death		Missing		Total		Recovered		Still present		Death		Missing		Total			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%		
SINUSITIS																						
Reboxetine																						
PRURITUS	1	100							1	100											1	100
Imipramine																						
ALLERGIC REACTION																						
Imipramine																						
CHEST PAIN																						
Imipramine																						
ESR INCREASED																						
Imipramine																						
NASAL POLYP																						
Imipramine																						
AEDEMA																						
Reboxetine																						
Imipramine																						
BUNDLE BRANCH BLOCK																						
Imipramine																						
CARDIAC ISCHEMIA AND RELATED SYMPTOMS																						
Imipramine																						
CEREBROVASCULAR DISORDER																						
Imipramine																						
EXTRASYSTOLES																						
Reboxetine																						
MYOCARDIAL INFARCTION																						
Imipramine																						
PERIPHERAL ISCHAEMIA																						
Imipramine																						
THROMBOSIS ARTERIAL																						
Reboxetine																						
Imipramine																						
COMA																						
Imipramine																						
CONVULSIONS	1	100																				
Imipramine																						

(CONTINUED)

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 63

CT
CC
CO

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY
BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Adverse events/Assigned treatment	Modified study drug										Unchanged study drug or Missing										
	Recovered with sequelae		Still present		Death		Missing		Total		Recovered with sequelae		Still present		Death		Missing		Total		
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	
PULMONARY CARCINOMA					1	100															
APATHY																					
CONCENTRATION IMPAIRED																					
DEPRESSION AGGRAVATED					1	100															
LIBIDO DECREASED	1	100																			
PARONYCHIA																					
SLEEP DISORDER																					
SUICIDE ATTEMPT																					
INFECTION																					
ASTHMA																					
COUGHING																					
DYSPNOEA																					
PHARYNGITIS																					
UPPER RESP TRACT INFECTION																					
ERYTHEMA / RASH																					
PHLORECTION																					
TASTE PERVERSION																					
CYSTITIS																					

(CONTINUED)

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 64

5140

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Adverse events	Assigned treatment	Days of treatment																										
		0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56										
		No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)									
Pt exposed		171	100	1.72	158	100	1.66	146	100	1.65	142	100	1.75	138	100	2.02	131	100	1.96	129	100	1.84	127	100	1.83	26	100	1.75
	Imipramine																											
	Reboxetine	176	100	1.53	165	100	1.65	161	100	1.67	153	100	1.75	144	100	1.82	139	100	1.83	133	100	1.62	128	100	1.58	20	100	1.76
	Imipramine	51	18.1	1.00	29	18.4	1.00	26	17.8	1.00	24	16.9	1.00	21	15.2	1.00	19	13.2	1.00	18	12.9	1.00	12	9.0	1.00	11	8.6	1.00
	Reboxetine	26	14.8	1.00	28	17.0	1.00	24	14.9	1.00	25	16.3	1.00	21	15.9	1.00	19	13.2	1.00	18	12.9	1.00	16	12.4	1.00	13	10.2	1.00
	Imipramine	45	8.8	1.00	22	13.9	1.04	26	17.8	1.00	26	18.3	1.00	22	15.9	1.04	18	13.7	1.05	16	12.4	1.00	14	10.5	1.00	11	8.6	1.00
	Reboxetine	17	9.7	1.05	17	10.3	1.00	16	9.9	1.00	16	10.5	1.00	19	13.2	1.05	17	12.2	1.05	14	10.5	1.00	11	8.6	1.00	11	8.6	1.00
	Imipramine	4	2.3	1.00	6	3.8	1.00	5	3.4	1.00	5	3.4	1.00	10	7.0	1.00	11	8.0	1.00	9	6.9	1.00	8	6.2	1.00	7	5.5	1.00
	Reboxetine	6	3.4	1.00	6	3.6	1.00	7	4.3	1.00	8	5.2	1.00	8	5.2	1.00	6	4.2	1.00	5	3.6	1.00	4	3.0	1.00	4	3.1	1.00
	Imipramine	9	5.3	1.00	6	3.8	1.00	6	4.1	1.00	8	5.6	1.00	10	7.2	1.00	10	7.2	1.00	4	3.1	1.00	4	3.1	1.00	4	3.1	1.25
	Reboxetine	4	2.3	1.00	5	3.0	1.00	4	2.5	1.00	4	2.6	1.00	4	2.6	1.00	2	1.4	1.00	3	2.2	1.00	4	3.0	1.00	3	2.3	1.00
	Imipramine	11	6.4	1.00	4	2.5	1.00	2	1.4	1.00	5	3.5	1.00	4	2.9	1.00	2	1.5	1.00									
	Reboxetine	9	5.1	1.00	10	6.1	1.00	4	2.5	1.00	5	3.3	1.00	2	1.4	1.00	2	1.4	1.00	2	1.4	1.00	1	0.8	1.00			
	Imipramine	3	1.8	1.00	3	1.9	1.00	4	2.7	1.00	5	3.5	1.00	3	2.2	1.00	3	2.2	1.00	3	2.3	1.00	2	1.6	1.00	1	0.8	1.00
	Reboxetine	1	0.6	1.00	3	1.8	1.00	3	1.9	1.00	3	1.9	1.00	4	2.6	1.00	5	3.5	1.00	5	3.6	1.00	5	3.8	1.00	5	3.9	1.00
	Imipramine	1	0.6	1.00	4	2.5	1.00	6	4.1	1.00	4	2.8	1.25	3	2.2	1.66	3	2.3	1.66	2	1.66	1.50	2	1.6	1.50	1	0.8	2.00
	Reboxetine	3	1.7	1.00	3	1.8	1.00	5	3.1	1.00	2	1.3	1.00	2	1.3	1.00	2	1.4	1.00	2	1.4	1.00	2	1.5	1.00			
	Imipramine	3	1.8	1.00	2	1.3	1.00	1	0.7	1.00	2	1.4	1.00	2	1.4	1.00	2	1.4	1.00	2	1.5	1.00	1	0.8	1.00	1	0.8	1.00
	Reboxetine	5	2.8	1.00	6	3.6	1.00	6	3.7	1.00	5	3.3	1.00	5	3.5	1.00	5	3.5	1.00	5	3.6	1.00	1	0.8	1.00			
	Imipramine				1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	4	2.8	1.00	4	2.9	1.00	6	4.6	1.00	6	4.7	1.00	6	4.7	1.00
	Reboxetine	2	1.1	1.00	3	1.8	1.00	2	1.2	1.00	1	0.7	1.00	1	0.7	1.00	2	1.4	1.00	3	2.2	1.00	3	2.3	1.00	2	1.6	1.00

(*) number of adverse events on number of patient who complained of adverse events

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 64

51
41

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Adverse events	Assigned treatment	Days of treatment																													
		0-7			8-14			15-21			22-28			29-35			36-42			43-49			50-56			> 56					
		No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)						
VISION ABNORMAL	Imipramine	1	0.6	1.00	3	1.9	1.00	4	2.7	1.00	4	2.7	1.00	4	2.9	1.00	3	2.3	1.00	3	2.3	1.00	3	2.4	1.00	1	3.8	1.00			
	Reboxetine																														
URINARY TRACT INFECTION	Imipramine	2	1.2	1.00	1	0.6	1.00	1	0.7	1.00	3	2.1	1.00	6	4.3	1.00	7	5.3	1.00	5	3.9	1.00	2	1.6	1.00	1	3.8	1.00			
	Reboxetine																														
SONNOLENCE	Imipramine	3	1.8	1.00	3	1.9	1.00	4	2.7	1.00	2	1.4	1.00	3	2.2	1.00	2	1.5	1.00	2	1.6	1.00	2	1.6	1.00	1	3.8	1.00			
	Reboxetine	1	0.6	1.00				1	0.6	1.00	2	1.3	1.00	2	1.4	1.00	2	1.4	1.00	2	1.5	1.00	2	1.6	1.00	2	1.6	1.00			
ANOREXIA	Imipramine				1	0.6	1.00	1	0.7	1.00	2	1.4	1.00	2	1.4	1.00	2	1.4	1.00	4	3.1	1.00	4	3.1	1.00	4	3.1	1.00	1	3.8	1.00
	Reboxetine	2	1.1	1.00	2	1.2	1.00	2	1.2	1.00	2	1.3	1.00	2	1.3	1.00															
TACHYCARDIA	Imipramine	4	2.3	1.00	2	1.3	1.00	2	1.3	1.00	2	1.4	1.00	2	1.4	1.00	2	1.4	1.00	2	1.4	1.00	2	1.4	1.00	1	0.8	1.00			
	Reboxetine	1	0.6	1.00	2	1.2	1.00	2	1.2	1.00	2	1.3	1.00	2	1.3	1.00	2	1.4	1.00	2	1.4	1.00	2	1.4	1.00	1	0.8	1.00			
FATIGUE	Imipramine	2	1.2	1.00	2	1.3	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	2	1.5	1.00	3	2.3	1.00	2	1.6	1.00	1	3.8	1.00
	Reboxetine	1	0.6	1.00	1	0.6	1.00	2	1.2	1.00	2	1.3	1.00	2	1.3	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00			
HYPOTENSION	Imipramine	4	2.3	1.00	3	1.9	1.00	3	2.1	1.00	3	2.1	1.00	3	2.1	1.00	3	2.1	1.00	3	2.3	1.00	3	2.3	1.00	2	1.6	1.00			
	Imipramine	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00															
ABDOMINAL PAIN	Reboxetine	5	2.8	1.00	3	1.8	1.00	2	1.2	1.00	2	1.3	1.00	2	1.4	1.00	2	1.4	1.00	1	0.7	1.00	1	0.7	1.00	2	1.5	1.00			
	Imipramine	2	1.2	1.00	2	1.3	1.00	2	1.4	1.00	2	1.4	1.00	2	1.4	1.00	1	0.7	1.00	1	0.8	1.00									
PARAESTHESIA	Reboxetine	3	1.7	1.00	4	2.4	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00															
	Imipramine	2	1.2	1.00	1	0.6	1.00				1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	2	1.5	1.00	2	1.6	1.00	1	0.8	1.00			
NALTAISE	Reboxetine				1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00			
	Imipramine	1	0.6	1.00	2	1.3	1.00				1	0.7	1.00	1	0.7	1.00															
CONFUSION	Imipramine	1	0.6	1.00	2	1.3	1.00				1	0.7	1.00	1	0.7	1.00															

(*) number of adverse events on number of patient who complained of adverse events

(CONTINUED)

9550089

THIS PAGE IS BLANK.

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

542

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 64

CT
4
3

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Adverse events	Assigned treatment	Days of treatment																							
		0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56							
		No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)						
CONFUSION	Reboxetine	2	1.1	1.00	4	2.4	1.00	3	1.9	1.00	1	0.7	1.00	1	0.8	1.00									
	Imipramine	1	0.6	2.00	3	1.9	1.00	1	0.7	1.00				1	0.8	1.00	1	0.8	1.00						
HYPOTENSION POSTURAL	Reboxetine	1	0.6	1.00	1	0.6	1.00	1	0.6	1.00				1	0.7	1.00	1	0.8	1.00	1	5.0	1.00			
	Imipramine	1	0.6	1.00							1	0.7	1.00	2	1.5	1.00	2	1.6	1.00	2	1.6	1.00			
AGITATION	Reboxetine	1	0.6	1.00				1	0.6	1.00	1	0.7	1.00	1	0.7	1.00									
	Imipramine	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00			
IMPOTENCE	Reboxetine				1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00			
	Imipramine				1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00			
DYSPEPSIA	Reboxetine	1	0.6	1.00	1	0.6	1.00	3	1.9	1.00	2	1.3	1.00	2	1.4	1.00	2	1.5	1.00	2	1.6	1.00	1	5.0	1.00
	Imipramine	1	0.6	1.00	1	0.6	1.00				2	1.4	1.00	3	2.2	1.00	3	2.2	1.00	3	2.2	1.00	1	3.8	1.00
BRONCHITIS	Reboxetine																								
	Imipramine	2	1.2	1.00	1	0.6	1.00				1	0.7	2.00	3	2.2	1.00							1	0.8	1.00
FALL	Reboxetine	1	0.6	1.00				1	0.6	1.00															
	Imipramine				2	1.2	1.00	2	1.2	1.00	2	1.3	1.00	2	1.4	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00
RIGORS	Reboxetine	4	2.3	1.00	1	0.6	1.00																		
	Imipramine	1	0.6	1.00	1	0.6	1.00	2	1.2	1.00	2	1.2	1.00	1	0.7	1.00									
URINARY RETENTION	Reboxetine																								
	Imipramine	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00			
WEIGHT DECREASE	Reboxetine																								
	Imipramine	1	0.6	1.00	1	0.6	1.00	2	1.3	1.00	2	1.4	1.00												
CONJUNCTIVITIS	Reboxetine																								
	Imipramine	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00
ANXIETY	Reboxetine																								
	Imipramine	1	0.6	1.00	1	0.6	1.00	1	0.6	1.00	2	1.3	1.00	2	1.4	1.00	2	1.4	1.00	2	1.4	1.00	1	0.8	1.00

(*) number of adverse events on number of patient who complained of adverse events

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 64

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

57
44

Adverse events	Assigned treatment	Days of treatment																				
		0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56				
		No	Z on	No	Z on	No	Z on	No	Z on	No	Z on	No	Z on	No	Z on	No	Z on	No	Z on			
ATAXIA	Imipramine	1	0.6	1.00																		
	Reboxetine																					
DYSPHAGIA	Imipramine	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00												
	Reboxetine	1	0.6	1.00																		
FLATULENCE	Imipramine	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00	1	5.0	1.00
	Reboxetine	1	0.6	1.00																		
MYOCARDIAL INFARCTION	Imipramine	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00	1	0.8	1.00
	Reboxetine																					
GASTRO-INTESTINAL DISORDER NOS	Imipramine	1	0.6	1.00	1	0.6	1.00	2	1.3	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00			
	Reboxetine																					
PAIN	Imipramine																					
	Reboxetine																					
PALPITATION	Imipramine	1	0.6	1.00	1	0.6	1.00															
	Reboxetine	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00	1	0.8	1.00
CHEST PAIN PRECORDIAL	Imipramine	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00	1	0.8	1.00
	Reboxetine																					
STOMATITIS	Imipramine																					
	Reboxetine																					
DIARRHOEA	Imipramine																					
	Reboxetine																					
HYPERTENSION	Imipramine	1	0.6	1.00	2	1.3	1.00	1	0.7	1.00												

(*) number of adverse events on number of patient who complained of adverse events

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No. : 64

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

CJ
K
C1

Adverse events	Assigned treatment	Days of treatment																							
		0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56							
		No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)						
HYPERTENSION	Reboxetine	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00	1	5.0	1.00			
HYPOKALAEMIA	Imipramine																								
	Reboxetine																								
EAR DISORDER NOS	Reboxetine	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00									
TASTE PERVERSION	Imipramine																								
	Reboxetine																								
OEDEMA PERIPHERAL	Reboxetine	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00	1	0.8	1.00	1	3.8	1.00
HYPERCHOLESTEROLAEMIA	Imipramine																								
	Reboxetine																								
PNEUMONIA	Imipramine																								
	Reboxetine	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00	1	0.8	1.00	1	5.0	1.00
FRACTURE PATHOLOGICAL	Imipramine																								
	Reboxetine																								
DYSKINESIA	Imipramine																								
	Reboxetine																								
RENAL FUNCTION ABNORMAL	Imipramine																								
	Reboxetine																								
SINUSITIS	Imipramine																								
	Reboxetine																								
ARTHRALGIA	Imipramine	1	0.6	1.00	1	0.6	1.00																		
	Reboxetine																								

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 64

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

CT
47

Adverse events	Assigned treatment	Days of treatment																	
		0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56	
		No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)
INFLUENZA-LIKE SYMPTOMS	Reboxetine	2	1.1	1.00			1	0.7	1.00										
ASTHMA	Reboxetine				1	0.6	1.00	1	0.7	1.00									
HYPOAESTHESIA	Imipranine										1	0.7	1.00						
	Reboxetine				1	0.6	1.00	1	0.7	1.00									
	Reboxetine				2	1.2	1.00	1	0.7	1.00									
	Reboxetine				1	0.6	2.00	1	0.7	1.00									
	Reboxetine							1	0.7	1.00	1	0.7	1.00	1	0.7	1.00			
	Reboxetine							1	0.7	1.00	1	0.7	1.00	1	0.7	1.00			
	Imipranine										1	0.7	1.00	1	0.8	1.00			
	Imipranine	1	0.6	1.00							1	0.7	1.00						
	Imipranine	1	0.6	1.00															
	Reboxetine				1	0.6	1.00												
	Imipranine	1	0.6	1.00	1	0.6	1.00												
	Reboxetine	1	0.6	1.00	1	0.6	1.00												
	Imipranine	1	0.6	1.00	1	0.6	1.00												
	Imipranine				1	0.6	1.00	1	0.7	1.00									
	Imipranine				1	0.6	1.00	1	0.7	1.00									
	Reboxetine				1	0.6	1.00												

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 64

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Adverse events	Assigned treatment	Days of treatment																	
		0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56	
		No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)
COUGHING	Reboxetine	1	0.6	1.00	1	0.6	1.00												
ASTHMA	Reboxetine	1	0.6	1.00	1	0.6	1.00												
DEPRESSION AGGRAVATED	Reboxetine				1	0.7	1.00												
EXTRASYSTOLES	Reboxetine							1	0.7	1.00	1	0.7	1.00						
HYPOTHYROIDISM	Imipramine										1	0.8	1.00	1	0.8	1.00			
RASH ERYTHEMATOUS	Reboxetine													1	0.8	1.00	1	0.8	1.00
UPPER RESP TRACT INFECTION	Reboxetine													1	0.8	1.00	1	0.8	1.00
SQRT INCREASED	Imipramine													1	0.8	1.00	1	0.8	1.00
GRANULOCYTOPENIA	Imipramine																1	0.8	1.00
HYPERTRIGLYCERIDAEMIA	Reboxetine																1	0.8	1.00
VERTIGO	Imipramine	1	0.6	1.00															
SUICIDE ATTEMPT	Imipramine	1	0.6	1.00															
SLEEP DISORDER	Reboxetine	1	0.6	1.00															
PULMONARY CARCINOMA	Reboxetine	1	0.6	1.00															

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CHS RED
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 64

51
49

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Adverse events	Assigned treatment	Days of treatment																			
		0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56			
		No. Pt.	% on exp. (*)	No. Pt.	% on exp. (*)	No. Pt.	% on exp. (*)	No. Pt.	% on exp. (*)	No. Pt.	% on exp. (*)	No. Pt.	% on exp. (*)	No. Pt.	% on exp. (*)	No. Pt.	% on exp. (*)	No. Pt.	% on exp. (*)		
NEUROPATHY	Reboxetine	1	0.6	1.00																	
DYSNOEA	Imipramine			1	0.7	1.00															
STUPOR	Imipramine						1	0.7	1.00												
PURPURA	Imipramine						1	0.7	1.00												
NEURITIS	Reboxetine						1	0.7	1.00												
THROMBOSIS ARTERIAL	Reboxetine						1	0.7	1.00												
BACK PAIN	Reboxetine						1	0.7	1.00												
CONVULSIONS	Imipramine									1	0.7	1.00									
HEPATIC FUNCTION ABNORMAL	Imipramine												1	0.7	1.00						
GLOBULINS INCREASED	Imipramine									1	0.7	1.00									
CHEST PAIN	Imipramine									1	0.7	1.00									
HYPERKINESIA	Reboxetine									1	0.7	1.00									
APATHY	Imipramine														1	0.8	1.00				
CONVULSIONS GRAND MAL	Reboxetine														1	0.8	1.00				
PHARYNGITIS	Reboxetine														1	0.8	1.00				
INFECTION	Reboxetine														1	0.8	1.00				
ESR INCREASED	Imipramine																	1	0.8	1.00	

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CHS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 64

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Adverse events	Assigned treatment	Days of treatment																	
		0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56	
		No Pt. exp. (*)	% on Pt. exp. (*)	No Pt. exp. (*)	% on Pt. exp. (*)	No Pt. exp. (*)	% on Pt. exp. (*)	No Pt. exp. (*)	% on Pt. exp. (*)	No Pt. exp. (*)	% on Pt. exp. (*)	No Pt. exp. (*)	% on Pt. exp. (*)	No Pt. exp. (*)	% on Pt. exp. (*)	No Pt. exp. (*)	% on Pt. exp. (*)	No Pt. exp. (*)	% on Pt. exp. (*)
NASAL POLYP	Imipramine																		
PERIPHERAL ISCHAEMIA	Imipramine																		
GAMMA-GT INCREASED	Reboxetine																		
GLYCOSURIA	Reboxetine																		

CT
CT
O

(*) number of adverse events on number of patient who complained of adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMA CIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 65

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: AUTONOMIC NERVOUS SYSTEM DISORDERS

Adverse events/Assigned treatment	Days of treatment																		
	0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56		
	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	
MOUTH DRY	31	18.1	29	18.4	26	17.8	24	16.9	21	15.2	18	13.7	16	12.4	13	10.2	4	15.4	1.00
	26	14.8	28	17.0	24	14.9	25	16.3	19	13.2	18	12.9	12	9.0	11	8.6	5	25.0	1.00
SWEATING INCREASED	4	2.3	6	3.6	5	3.4	10	7.0	11	8.0	9	6.9	8	6.2	7	5.5	1	3.8	1.00
	6	3.4	6	3.6	7	4.3	8	5.2	6	4.2	5	3.6	4	3.0	4	3.1	2	10.0	1.00

CT
CT
1

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 65

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: BODY AS A WHOLE-GENERAL DISORDERS

Adverse events/Assigned treatment	Days of treatment																				
	0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56				
	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)			
ASTHENIA / FATIGUE	2	1.2 1.00	2	1.3 1.00	1	0.7 1.00	1	0.7 1.00	1	0.7 1.00	2	1.5 1.00	3	2.3 1.00	2	1.6 1.00	1	0.8 1.00	1	0.8 1.00	
	1	0.6 1.00	2	1.2 1.00	3	1.9 1.00	2	1.3 1.00	1	0.7 1.00	1	0.7 1.00	1	0.8 1.00	1	0.8 1.00					
MALAISE	2	1.2 1.00	1	0.6 1.00																	
	1	0.6 1.00	1	0.6 1.00	1	0.6 1.00	1	0.7 1.00	1	0.7 1.00	2	1.5 1.00	2	1.6 1.00	1	0.8 1.00					
FALL	2	1.2 1.00	1	0.6 1.00																	
	1	0.6 1.00	1	0.6 1.00					3	2.2 1.00											
RIGORS																					
	2	1.2 1.00	2	1.2 1.00	2	1.2 1.00	2	1.3 1.00	2	1.4 1.00	1	0.7 1.00	1	0.8 1.00	1	0.8 1.00					
PAIN																					
	1	0.6 1.00	1	0.6 1.00	2	1.2 1.00	1	0.7 1.00													
FEVER	1	0.6 1.00			1	0.7 1.00															
INFLUENZA-LIKE SYMPTOMS																					
	2	1.1 1.00																			
ALLERGIC REACTION	1	0.6 1.00	1	0.6 1.00																	
CHEST PAIN																					
ESR INCREASED																					
NASAL POLYP																					

(*) number of adverse events on number of patient who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 65

CT CT
C3
ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM
Body system: CARDIOVASCULAR DISORDERS, GENERAL

Adverse events/Assigned treatment	Days of treatment																																			
	0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56																			
	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)																		
HYPOTENSION AND RELATED SYMPTOMS	Imipramine	15	8.8	1.06	12	7.6	1.00	11	7.7	1.00	11	7.7	1.00	12	8.7	1.00	8	6.1	1.00	7	5.4	1.00	7	5.5	1.14	1	3.8	1.00								
	Reboxetine	5	2.8	1.00	6	3.6	1.00	5	3.1	1.00	4	2.6	1.00	2	1.4	1.00	2	1.4	1.00	4	2.9	1.00	5	3.8	1.00	4	3.1	1.00	2	10.0	1.00					
TACHYCARDIA	Imipramine	4	2.3	1.00	2	1.3	1.00	2	1.4	1.00	2	1.4	1.00	2	1.4	1.00																				
	Reboxetine	1	0.6	1.00	2	1.2	1.00	2	1.3	1.00	2	1.3	1.00	2	1.4	1.00	2	1.4	1.00	2	1.4	1.00	1	0.8	1.00	1	0.8	1.00	1	0.8	1.00					
MYOCARDIAL INFARCTION	Imipramine	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00	1	0.8	1.00	1	0.8	1.00	1	3.8	1.00		
	Imipramine																																			
CARDIAC ISCHEMIA AND RELATED SYMPTOMS	Imipramine	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00	1	0.8	1.00	1	0.8	1.00	1	0.8	1.00		
	Imipramine																																			
PALPITATION	Imipramine	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00		
	Reboxetine	1	0.6	1.00	1	0.6	1.00	1	0.6	1.00	1	0.6	1.00	1	0.6	1.00	1	0.6	1.00	1	0.6	1.00	1	0.6	1.00	1	0.6	1.00	1	0.6	1.00	1	0.6	1.00		
HYPERTENSION	Imipramine	1	0.6	1.00	2	1.3	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00		
	Reboxetine																																			
AEDEMA	Reboxetine																																			
	Reboxetine																																			
BUNDLE BRANCH BLOCK	Imipramine																																			
	Imipramine																																			
FIBRILLATION ATRIAL	Imipramine																																			
	Reboxetine																																			
CEREBROVASCULAR DISORDER	Imipramine																																			
	Reboxetine																																			
EXTRASYSTOLES	Reboxetine																																			
	Reboxetine																																			
THROMBOSIS ARTERIAL	Reboxetine																																			
	Reboxetine																																			

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 65

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: CARDIOVASCULAR DISORDERS, GENERAL

Adverse events/Assigned treatment	Days of treatment																		
	0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56		
	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	
PERIPHERAL ISCHAEMIA																			
Imipramine																			
																		1	3.8
																			1.00

554

(*) number of adverse events on number of patient who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 65
ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

CT
CT
CT
Body system: CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO

Adverse events/Assigned treatment	Days of treatment																							
	0-7	8-14	15-21	22-28	29-35	36-42	43-49	50-56	> 56	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)			
TREMOR	3	1.8	1.00	3	1.9	1.00	4	2.7	1.00	5	3.5	1.00	3	2.2	1.00	3	2.3	1.00	2	1.6	1.00	1	0.8	1.00
HEALACHE / MIGRAINE	1	0.6	1.00	3	1.8	1.00	3	1.9	1.00	4	2.6	1.00	5	3.6	1.00	5	3.6	1.00	5	3.8	1.00	5	3.9	1.00
PARAESTHESIA	3	1.7	1.00	3	1.8	1.00	6	4.1	1.00	4	2.8	1.25	3	2.2	1.66	3	2.3	1.66	2	1.6	1.50	1	0.8	2.00
CONFUSION	2	1.2	1.00	2	1.3	1.00	5	3.1	1.00	2	1.3	1.00	2	1.4	1.00	2	1.4	1.00	2	1.4	1.00	2	1.5	1.00
ATAxia	3	1.7	1.00	4	2.4	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00			
DYSKINESIA	1	0.6	1.00	2	1.3	1.00				1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00
COORDINATION ABNORMAL	2	1.1	1.00	4	2.4	1.00	3	1.9	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00
HYP0AESTHESIA	1	0.6	1.00																					
C0R0A				1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00
NEUR0ALGIA				1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00
VERTIGO	1	0.6	1.00	1	0.6	1.00																		
NEUR0PATHY				1	0.6	1.00																		
STUPOR				1	0.6	1.00																		
NEURITIS				1	0.7	1.00																		

(*) number of adverse events on number of patient who complained of adverse events (some adverse events are grouped in cluster)

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 65

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO

Adverse events/Assigned treatment	Days of treatment																		
	0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56		
	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	
CONVULSIONS Imipramine					1	0.7	1.00												
HYPERKINESIA Reboxetine					1	0.7	1.00												
CONVULSIONS GRAND MAL Reboxetine													1	0.8	1.00				

57
56

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 65

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

CT
CT
CO

Body system: GASTRO-INTESTINAL SYSTEM DISORDERS

Adverse events/Assigned treatment	Days of treatment																														
	0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56														
	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)													
CONSTIPATION	15	8.8	1.00	22	13.9	1.04	26	17.8	1.00	26	18.3	1.00	22	15.9	1.04	18	13.7	1.05	16	12.4	1.00	14	11.0	1.00	5	19.2	1.00				
	17	9.7	1.05	17	10.3	1.00	16	9.9	1.00	16	10.5	1.00	19	13.2	1.05	17	12.2	1.05	14	10.5	1.00	11	8.6	1.00	6	30.0	1.00				
NAUSEA AND RELATED SYMPTOMS	11	6.4	1.09	4	2.5	1.00	2	1.4	1.00	5	3.5	1.00	4	2.9	1.00	2	1.5	1.00													
	10	5.7	1.00	11	6.7	1.09	6	3.7	1.16	7	4.6	1.00	4	2.8	1.00	3	2.2	1.00	2	1.5	1.00	1	0.8	1.00	1	5.0	1.00				
ANOREXIA				1	0.6	1.00	1	0.7	1.00	2	1.4	1.00	2	1.4	1.00	2	1.4	1.00	4	3.1	1.00	4	3.1	1.00	4	3.1	1.00	1	3.8	1.00	
	2	1.1	1.00	2	1.2	1.00	2	1.2	1.00	2	1.3	1.00																			
ABDOMINAL PAIN	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00																			
	5	2.8	1.00	9	1.8	1.00	2	1.2	1.00	2	1.3	1.00	2	1.4	1.00	1	0.7	1.00	2	1.5	1.00										
DYSPHAGIA	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00																			
	1	0.6	1.00																												
FLATULENCE	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00	1	0.8	1.00	1	5.0	1.00	
	1	0.6	1.00																												
GASTRO-INTESTINAL DISORDER NOS																															
	1	0.6	1.00	1	0.6	1.00	2	1.2	1.00	2	1.3	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00	1	0.8	1.00				
STONATITIS													1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00	1	0.8	1.00				
DIARRHOEA																															
GLOSSITIS																															

(*) number of adverse events on number of patient who complained of adverse events
(Some adverse events are grouped in cluster)

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 65

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: HEARING AND VESTIBULAR DISORDERS

Adverse events/Assigned treatment	Days of treatment																																			
	0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56																			
	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)																		
EAR DISORDER NOS	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00	1	0.8	1.00	1	0.8	1.00	1	0.8	1.00	1	0.8	1.00	1	0.8	1.00

CT
CT
CS

9550089.

(*) number of adverse events on number of patient who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBORETTINE - PROTOCOL 20124/035
TABLE No.: 65

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: HEMATOLOGY DISORDERS

Adverse events/Assigned treatment	Days of treatment																					
	0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56					
	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)				
ANEMIA					1	0.7	1.00		2	1.4	1.00					1	0.8	1.00				
GRANULOCYTOPENIA																1	0.8	1.00	1	3.8	1.00	
PURPURA					1	0.7	1.00															

CT 60

(*) number of adverse events on number of patient who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 65

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: METABOLIC AND NUTRITIONAL DISORDERS

Adverse events/Assigned treatment	Days of treatment																		
	0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56		
	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	
WEIGHT DECREASE																			
Imipramine																			
Reboxetine	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00				
HYPOKALAEMIA																			
Imipramine																			
Reboxetine	1	0.6	1.00	1	0.6	1.00													
HYPERCHOLESTEROLAEMIA																			
Imipramine																			
Reboxetine																			
BUN INCREASED																			
Reboxetine																			
HYPERTRIGLYCERIDAEMIA																			
Imipramine																			
Reboxetine																			
GLOBULINS INCREASED																			
Imipramine																			
Reboxetine																			
GLYCOSURIA																			
Reboxetine																			

CT
C
R

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 65

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: MUSCULO-SKELETAL SYSTEM DISORDERS

Adverse events/Assigned treatment	Days of treatment																		
	0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56		
	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	
FRACTURE PATHOLOGICAL																			
	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00				
ARTHRALGIA																			
	1	0.6	1.00	1	0.6	1.00													
NYALGIA																			
							1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00	1
FRACTURE																			
	1	0.6	1.00							1	0.7	1.00	1	0.8	1.00	1	0.8	1.00	
BACK PAIN																			
							1	0.7	1.00										

57
63

(*) number of adverse events on number of patient who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS RED

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 65

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: NEOPLASM

Adverse events/Assigned treatment	Days of treatment																		
	0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56		
	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	
PULMONARY CARCINOMA	1	0.6	1.00																
Reboxetine																			

564

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 65

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: PSYCHIATRIC DISORDERS

Adverse events/Assigned treatment	Days of treatment																									
	0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56									
	No Pt	% exp. (*)	No Pt	% exp. (*)	No Pt	% exp. (*)	No Pt	% exp. (*)	No Pt	% exp. (*)	No Pt	% exp. (*)	No Pt	% exp. (*)	No Pt	% exp. (*)	No Pt	% exp. (*)								
INSOMNIA	3	1.8	1.00	2	1.3	1.00	1	0.7	1.00	2	1.4	1.00	2	1.5	1.00	1	0.8	1.00								
	5	2.8	1.00	6	3.6	1.00	5	3.3	1.00	5	3.6	1.00	5	3.6	1.00	2	1.6	1.00	1	0.8	1.00					
SOMNOLENCE	3	1.8	1.00	3	1.9	1.00	4	2.7	1.00	2	1.4	1.00	3	2.2	1.00	2	1.5	1.00	2	1.6	1.00	1	0.8	1.00		
	1	0.6	1.00				1	0.6	1.00	2	1.3	1.00	2	1.4	1.00	2	1.4	1.00	2	1.5	1.00	2	1.6	1.00		
AGITATION / ANXIETY / NERVOUSNESS	1	0.6	1.00							1	0.7	1.00	2	1.4	1.00	2	1.5	1.00	2	1.6	1.00	2	1.6	1.00		
	1	0.6	1.00	1	0.6	1.00	3	1.9	1.33	3	2.0	1.33	2	1.4	1.00	2	1.4	1.00	3	2.3	1.00	1	0.8	1.00	1	0.8
LIBIDO DECREASED										1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00		
													1	0.7	1.00	1	0.8	1.00	1	0.8	1.00					
PARANOID REACTION																										
				1	0.6	1.00																				
CONCENTRATION IMPAIRED																										
PARONYCHIA	1	0.6	1.00	1	0.6	1.00																				
DEPRESSION AGGRAVATED																										
SUICIDE ATTEMPT	1	0.6	1.00																							
SLEEP DISORDER	1	0.6	1.00																							
APATHY																										

(*) number of adverse events on number of patient who complained of adverse events (some adverse events are grouped in cluster)

57 57 57

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE – PROTOCOL 20124/035
 TABLE No.: 65

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: REPRODUCTIVE DISORDERS, MALE

Adverse events/Assigned treatment	Days of treatment																				
	0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56				
	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)			
IMPOTENCE	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00			
Reboxetine			1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	

66

(*) number of adverse events on number of patient who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS RED

REBOXETINE – PROTOCOL 20124/035
TABLE No.: 65

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: RESPIRATORY SYSTEM DISORDERS

Adverse events/Assigned treatment	Days of treatment																							
	0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56							
	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)						
BRONCHITIS	Imipramine	1	0.6	1.00	1	0.6	1.00	2	1.4	1.00	3	2.2	1.00	2	1.5	1.00	1	0.8	1.00	1	3.8	1.00		
	Reboxetine										1	0.7	1.00											
PNEUMONIA	Imipramine																							
	Reboxetine	1	0.6	1.00	1	0.6	1.00													1	0.8	1.00	2	7.7
SINUSITIS	Imipramine																							
	Reboxetine																							
ASTHMA	Reboxetine																							
	Reboxetine																							
COUGHING	Reboxetine																							
	Reboxetine	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00	1	5.0
UPPER RESP TRACT INFECTION	Reboxetine																							
	Reboxetine																							
DYSPNOEA	Imipramine																							
	Reboxetine																							
PHARYNGITIS	Imipramine																							
	Reboxetine																							

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 65

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: SKIN AND APPENDAGES DISORDERS

Adverse events/Assigned treatment	Days of treatment																		
	0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56		
	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	
PRURITUS	1	0.6	1.00	2	1.3	1.00													
PILOERECTOR																			
ERYTHEMA / RASH							1	0.7	1.00	1	0.7	1.00	1	0.7	1.00				
													1	0.8	1.00	1	0.8	1.00	

51 63

(*) number of adverse events on number of patient who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE – PROTOCOL 20124/035
TABLE No.: 65

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: SPECIAL SENSES OTHER, DISORDERS

Adverse events/Assigned treatment	Days of treatment																				
	0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56				
	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)			
TASTE PERVERSION Imipramine	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00	1	0.8	1.00

570

(*) number of adverse events on number of patient who complained of adverse events
(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 65

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: URINARY SYSTEM DISORDERS

Adverse events/Assigned treatment	Days of treatment																										
	0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56										
	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)	No Pt	% on exp. (*)									
URINARY HESITANCY / RETENTION	4	2.3	1.00	2	1.3	1.00	1	0.7	1.00	4	2.8	1.00	4	2.9	1.00	6	4.6	1.00	6	4.7	1.00	1	3.8	1.00			
	2	1.1	1.50	4	2.4	1.00	4	2.5	1.00	2	1.3	1.00	2	1.4	1.00	3	2.2	1.00	3	2.3	1.00	2	1.6	1.00			
URINARY TRACT INFECTION	2	1.2	1.00	1	0.6	1.00	1	0.7	1.00	3	2.1	1.00	6	4.3	1.00	7	5.3	1.00	5	3.9	1.00	2	1.6	1.00	1	3.8	1.00
										3	2.0	1.00	3	2.1	1.00	3	2.2	1.00	2	1.5	1.00	1	0.8	1.00	1	5.0	1.00
RENAL FUNCTION ABNORMAL																											
										1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00	1	5.0	1.00
CYSTITIS	1	0.6	1.00	1	0.6	1.00	1	0.6	1.00																		
NOCTURIA														1	0.7	1.00	1	0.8	1.00	1	0.8	1.00	1	0.8	1.00		

(*) number of adverse events on number of patient who complained of adverse events (some adverse events are grouped in cluster)

CJ
~
L

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 65

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND BODY SYSTEM

Body system: VISION DISORDERS

Adverse events/Assigned treatment	Days of treatment																								
	0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56								
	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)	No Pt	Z on exp. (*)							
BLURRED VISION	1	0.6	1.00	3	1.9	1.00	4	2.7	1.00	4	2.8	1.00	4	2.9	1.00	3	2.3	1.00	3	2.4	1.00	1	3.8	1.00	
CONJUNCTIVITIS																									
EYE PAIN	1	0.6	1.00	1	0.6	1.00	2	1.4	1.00																

2/2

(*) number of adverse events on number of patient who complained of adverse events (some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 66

573

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

Body system Pt exposed	Days of treatment																		
	0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56		
	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	
Assigned treatment																			
Imipramine	171	100 1.72 158	100 1.66 146	100 1.65 161	100 1.67 153	100 1.75 144	100 1.82 139	100 1.96 129	100 1.84 127	100 1.58 120	100 1.76 116	100 1.83 126	100 1.83 126	100 1.83 126	100 1.83 126	100 1.83 126	100 1.83 126	100 1.83 126	100 1.83 126
Reboxetine	27	15.8 1.11 28	17.7 1.10 30	20.5 1.06 35	24.6 1.08 27	19.6 1.14 26	19.8 1.07 21	16.3 1.09 19	15.0 1.10 16	15.0 1.10 16	15.0 1.10 16	15.0 1.10 16	15.0 1.10 16	15.0 1.10 16	15.0 1.10 16	15.0 1.10 16	15.0 1.10 16	15.0 1.10 16	15.0 1.10 16
Imipramine	33	18.8 1.15 29	17.6 1.20 25	15.5 1.28 25	16.3 1.24 23	16.0 1.21 21	15.1 1.14 20	15.0 1.05 15	11.7 1.00 8	40.0 1.00 8	40.0 1.00 8	40.0 1.00 8	40.0 1.00 8	40.0 1.00 8	40.0 1.00 8	40.0 1.00 8	40.0 1.00 8	40.0 1.00 8	40.0 1.00 8
Reboxetine	34	19.9 1.02 33	20.9 1.06 29	19.9 1.06 29	21.8 1.09 31	21.8 1.09 31	20.3 1.14 25	19.1 1.12 23	17.8 1.04 19	15.0 1.05 15	11.7 1.00 8	40.0 1.00 8	40.0 1.00 8	40.0 1.00 8	40.0 1.00 8	40.0 1.00 8	40.0 1.00 8	40.0 1.00 8	40.0 1.00 8
Imipramine	30	17.0 1.06 33	20.0 1.03 28	17.4 1.10 30	19.6 1.10 23	16.0 1.08 21	15.1 1.09 15	11.3 1.06 14	10.9 1.07 6	30.0 1.06 6	30.0 1.06 6	30.0 1.06 6	30.0 1.06 6	30.0 1.06 6	30.0 1.06 6	30.0 1.06 6	30.0 1.06 6	30.0 1.06 6	30.0 1.06 6
Reboxetine	20	11.7 1.20 17	10.8 1.17 15	10.3 1.06 15	10.6 1.06 15	10.9 1.13 12	9.2 1.00 12	9.3 1.00 12	9.4 1.08 4	15.4 1.00 4	15.4 1.00 4	15.4 1.00 4	15.4 1.00 4	15.4 1.00 4	15.4 1.00 4	15.4 1.00 4	15.4 1.00 4	15.4 1.00 4	15.4 1.00 4
Imipramine	7	4.0 1.00 10	6.1 1.00 8	5.0 1.12 8	6.5 1.00 8	5.6 1.00 8	6.5 1.00 9	6.5 1.00 9	6.3 1.00 8	6.3 1.00 8	6.3 1.00 8	6.3 1.00 8	6.3 1.00 8	6.3 1.00 8	6.3 1.00 8	6.3 1.00 8	6.3 1.00 8	6.3 1.00 8	6.3 1.00 8
Reboxetine	9	5.3 1.00 13	8.2 1.00 15	10.3 1.00 15	10.6 1.13 11	8.0 1.36 9	6.9 1.33 5	3.9 1.40 3	2.4 1.33 2										
Imipramine	9	5.1 1.00 17	10.3 1.00 14	8.7 1.00 14	6.5 1.10 10	6.3 1.00 9	6.3 1.00 7	5.0 1.00 10	7.5 1.00 5	3.9 1.00 5	3.9 1.00 5	3.9 1.00 5	3.9 1.00 5	3.9 1.00 5	3.9 1.00 5	3.9 1.00 5	3.9 1.00 5	3.9 1.00 5	3.9 1.00 5
Reboxetine	7	4.1 1.14 5	3.2 1.00 5	3.4 1.00 5	3.5 1.00 5	3.5 1.00 5	5.8 1.00 7	5.3 1.00 7	5.4 1.00 7	5.4 1.00 7	5.4 1.00 7	5.4 1.00 7	5.4 1.00 7	5.4 1.00 7	5.4 1.00 7	5.4 1.00 7	5.4 1.00 7	5.4 1.00 7	5.4 1.00 7
Imipramine	8	4.5 1.12 9	5.5 1.00 8	5.0 1.37 11	7.2 1.18 11	7.6 1.09 11	7.6 1.09 11	7.9 1.00 8	6.0 1.00 4	3.1 1.25 1	7.7 1.00 2	7.7 1.00 2	7.7 1.00 2	7.7 1.00 2	7.7 1.00 2	7.7 1.00 2	7.7 1.00 2	7.7 1.00 2	7.7 1.00 2
Reboxetine	6	3.5 1.00 3	1.9 1.00 2	1.4 1.00 2	4.9 1.00 7	4.9 1.00 7	4.9 1.00 7	8.0 1.00 14	10.7 1.00 12	9.3 1.00 8	6.3 1.00 4	3.1 1.00 2	10.0 1.00 2	10.0 1.00 2	10.0 1.00 2	10.0 1.00 2	10.0 1.00 2	10.0 1.00 2	10.0 1.00 2
Imipramine	3	1.7 1.33 5	3.0 1.00 5	3.1 1.00 5	3.9 1.00 6	4.2 1.00 7	5.0 1.00 6	4.5 1.00 4	3.1 1.00 6	4.5 1.00 4	3.1 1.00 6	4.5 1.00 4	3.1 1.00 6	4.5 1.00 4	3.1 1.00 6	4.5 1.00 4	3.1 1.00 6	4.5 1.00 4	3.1 1.00 6
Reboxetine	6	3.5 1.33 5	3.2 1.00 2	1.4 1.00 2	2.8 1.25 6	4.3 1.00 4	3.1 1.00 4	3.1 1.00 5	3.9 1.00 6	4.7 1.16 1	3.8 1.00 1	3.8 1.00 1	3.8 1.00 1	3.8 1.00 1	3.8 1.00 1	3.8 1.00 1	3.8 1.00 1	3.8 1.00 1	3.8 1.00 1
Imipramine	4	2.3 1.00 6	3.6 1.00 8	5.0 1.12 5	3.3 1.20 3	2.1 1.33 3	2.1 1.33 3	2.2 1.33 5	3.8 1.20 3	2.3 1.33 1	5.0 1.00 1	5.0 1.00 1	5.0 1.00 1	5.0 1.00 1	5.0 1.00 1	5.0 1.00 1	5.0 1.00 1	5.0 1.00 1	5.0 1.00 1
Reboxetine	1	0.6 1.00 5	3.2 1.00 6	4.1 1.00 4	2.8 1.00 4	2.9 1.00 4	2.9 1.00 3	2.3 1.00 3	2.3 1.00 3	2.4 1.00 3	2.4 1.00 3	2.4 1.00 3	2.4 1.00 3	2.4 1.00 3	2.4 1.00 3	2.4 1.00 3	2.4 1.00 3	2.4 1.00 3	2.4 1.00 3
Imipramine	1	0.6 1.00 2	1.2 1.00 1	0.6 1.00 1	2.0 1.33 4	2.8 1.00 4	2.8 1.00 4	2.9 1.00 4	2.9 1.00 4	3.1 1.00 4	3.1 1.00 4	3.1 1.00 4	3.1 1.00 4	3.1 1.00 4	3.1 1.00 4	3.1 1.00 4	3.1 1.00 4	3.1 1.00 4	3.1 1.00 4
Reboxetine	1	0.6 1.00 2	1.2 1.00 1	0.6 1.00 1	2.0 1.33 4	2.8 1.00 4	2.8 1.00 4	2.9 1.00 4	2.9 1.00 4	3.1 1.00 4	3.1 1.00 4	3.1 1.00 4	3.1 1.00 4	3.1 1.00 4	3.1 1.00 4	3.1 1.00 4	3.1 1.00 4	3.1 1.00 4	3.1 1.00 4

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 66

01
774

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

Body system	Assigned treatment	Days of treatment																										
		0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56										
		No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)									
RESPIRATORY SYSTEM DISORDERS	Imipramine	1	0.6	1.00	1	0.6	1.00	3	2.1	1.00	3	2.2	1.00	2	1.5	1.00	1	0.8	1.00	2	1.6	1.00	2	7.7	1.50			
	Reboxetine	1	0.6	1.00	2	1.2	1.50	2	1.2	1.00	1	0.7	1.00	2	1.4	1.00	1	0.7	1.00	3	2.3	1.00	2	1.6	1.00			
METABOLIC AND NUTRITIONAL DISORDERS	Imipramine	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	2	1.4	1.00	1	0.8	1.00					1	3.8	2.00		
	Reboxetine	1	0.6	1.00	1	0.6	1.00	3	2.0	1.00	3	2.8	1.00	4	2.9	1.00	4	2.9	1.00	2	1.5	1.00	2	1.6	1.00	3	15.0	1.00
MUSCULO-SKELETAL SYSTEM DISORDERS	Imipramine	1	0.6	1.00	2	1.3	1.00	1	0.7	1.00	1	0.7	1.00	2	1.4	1.00	2	1.5	1.00	1	0.8	1.00	2	1.6	1.00			
	Reboxetine	1	0.6	1.00							2	1.3	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	2	1.6	1.00	1	5.0	1.00
REPRODUCTIVE DISORDERS, MALE	Imipramine	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00			
	Reboxetine				1	0.6	1.00	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00			
SKIN AND APPENDAGES DISORDERS	Imipramine	1	0.6	1.00	2	1.3	1.00																					
	Reboxetine							1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00
HEARING AND VESTIBULAR DISORDERS	Reboxetine																											
	Imipramine	1	0.6	1.00	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00			
SPECIAL SENSES OTHER, DISORDERS	Imipramine																											
	Reboxetine	1	0.6	1.00	1	0.6	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00	1	0.8	1.00	2	1.6	1.00
HEMATOLOGY DISORDERS	Imipramine																											
	Reboxetine							2	1.4	1.00	2	1.4	1.00															
RESISTANCE MECHANISM DISORDERS	Imipramine																											
	Reboxetine							1	0.6	1.00																		

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 56

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

Body system	Assigned treatment	Days of treatment																	
		0-7		8-14		15-21		22-28		29-35		36-42		43-49		50-56		> 56	
		No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)
LIVER AND BILIAR SYSTEM DISORDERS	Reboxetine																		
	Imipramine																		
	Reboxetine																		
ENDOCRINE DISORDERS	Imipramine																		
	Reboxetine																		
NEOPLASH	Reboxetine	1	0.6	1.00															

07 01 01

(*) number of adverse events on number of patient who complained of adverse events

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 67

ADVERSE EVENTS BY RELATIONSHIP TO THE EXPERIMENTAL TREATMENT AND ASSIGNED TREATMENT

Adverse events/Assigned treatment	Relationship																								
	Definite			Probable			Possible			Doubtful			None			Unknown			Missing			Total			
	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	
Total adverse events	31	9.2	99	29.3	100	29.6	44	13.0	41	12.1	11	3.3	12	3.6	338	100.0									
MOUTH DRY	10	3.3	87	28.3	110	35.8	56	18.2	28	9.1	12	3.9	4	1.3	307	100.0									
CONSTIPATION	3	7.3	21	51.2	14	34.1	3	7.3							43	100.0									
	2	4.8	13	31.0	19	45.2	6	14.3	1	2.4			1	2.4	42	100.0									
	1	2.8	13	36.1	18	50.0	3	8.3	1	2.8					36	100.0									
HYPOTENSION AND RELATED SYMPTOMS	4	11.8	13	38.2	11	32.4	4	11.8			1	2.9	1	2.9	34	100.0									
	1	7.1	3	21.4	6	42.9	2	14.3			1	7.1	1	7.1	14	100.0									
NAUSEA AND RELATED SYMPTOMS	6	33.3	3	16.7	8	44.4					1	5.6			16	100.0									
	3	13.6	6	27.3	8	36.4	4	18.2					1	4.5	22	100.0									
HEADACHE / MIGRAINE					3	13.6	3	13.6	16	72.7					22	100.0									
			4	30.8	5	38.5	2	15.4	1	7.7	1	7.7			13	100.0									
SWEATING INCREASED			8	50.0	6	37.5	1	6.3			1	6.3			16	100.0									
	1	6.3	7	43.8	6	37.5	1	6.3	1	6.3					16	100.0									
INSOMNIA			2	40.0	3	60.0									5	100.0									
			4	26.7	8	53.3	3	20.0							15	100.0									
URINARY RESISTANCY / RETENTION	1	10.0	7	70.0	2	20.0									10	100.0									
			5	62.5	2	25.0	1	12.5							8	100.0									
URINARY TRACT INFECTION							2	20.0	7	70.0					10	100.0									
							2	20.0	1	14.3	4	57.1			7	100.0									
TREMOR			1	16.7	4	66.7	1	16.7							6	100.0									
			5	71.4	1	14.3	1	14.3							7	100.0									

(CONTINUED)
(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 67

51 77

ADVERSE EVENTS BY RELATIONSHIP TO THE EXPERIMENTAL TREATMENT AND ASSIGNED TREATMENT

Adverse events/Assigned treatment	Relationship																										
	Definite			Probable			Possible			Doubtful			None			Unknown			Missing			Total					
	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%			
FALL	1	11.1	11.1	1	11.1	11.1							1	11.1	2	22.2	3	33.3				9	100.0				
							2	66.7					1	33.3								3	100.0				
MALAISE	1	11.1	77.8	1	11.1																			9	100.0		
							1	33.3	2	66.7															3	100.0	
SOMNOLENCE	2	28.6	14.3	3	42.9	14.3																			7	100.0	
	1	20.0	40.0	1	20.0	20.0																			5	100.0	
BLURRED VISION	1	16.7	33.3	2	33.3	16.7																			6	100.0	
				2	33.3	50.0	1	16.7																		6	100.0
AGITATION / ANXIETY / NERVOUSNESS				3	75.0																					4	100.0
				1	12.5	50.0	2	25.0																		8	100.0
CONFUSION				1	25.0	25.0																				4	100.0
				2	33.3	33.3	1	16.7																		6	100.0
TACHYCARDIA				1	16.7	83.3																				6	100.0
				2	66.7	33.3																				3	100.0
ABDOMINAL PAIN				1	50.0																					2	100.0
				3	42.9	14.3	2	28.6	1	14.3																7	100.0
ANOREXIA				3	60.0																					5	100.0
				1	25.0	50.0																				4	100.0
ASTHENIA / FATIGUE	1	20.0	40.0	1	20.0	20.0																				5	100.0
				1	33.3	33.3	1	33.3																		3	100.0
PARAESTHESIA				1	25.0	25.0	2	50.0																		4	100.0
							3	75.0	1	25.0																4	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 67

ADVERSE EVENTS BY RELATIONSHIP TO THE EXPERIMENTAL TREATMENT AND ASSIGNED TREATMENT

57
3
8

Adverse events/Assigned treatment	Relationship																										
	Definite			Probable			Possible			Doubtful			None			Unknown			Missing			Total					
	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%			
DIARRHOEA	Imipramine																										
	Reboxetine																										
BRONCHITIS	Imipramine																										
	Reboxetine																										
PAIN	Imipramine																										
	Reboxetine																										
ATAXIA	Imipramine	1			50.0																						
	Reboxetine																										
HYPOKALAEMIA	Imipramine																										
	Reboxetine																										
CONJUNCTIVITIS	Imipramine																										
	Reboxetine																										
PNEUMONIA	Imipramine																										
	Reboxetine																										
PALPITATION	Imipramine																										
	Reboxetine																										
HYPERTENSION	Imipramine																										
	Reboxetine																										
DYSPEAGIA	Imipramine																										
	Reboxetine																										
ANEMIA	Imipramine																										
	Reboxetine																										
WEIGHT DECREASE	Imipramine																										
	Reboxetine																										

(CONTINUED)

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 67

ADVERSE EVENTS BY RELATIONSHIP TO THE EXPERIMENTAL TREATMENT AND ASSIGNED TREATMENT

Adverse events/Assigned treatment	Relationship																									
	Definite			Probable			Possible			Doubtful			None			Unknown			Missing			Total				
	No.	%		No.	%		No.	%		No.	%		No.	%		No.	%		No.	%		No.	%			
WEIGHT DECREASE	Reboxetine			1	50.0																			2	100.0	
	Imipramine																								2	100.0
	Reboxetine																								1	100.0
FRACTURE	Imipramine																								2	100.0
	Reboxetine																								1	100.0
	Imipramine																								2	100.0
FEVER	Imipramine																								2	100.0
	Reboxetine																								1	100.0
	Imipramine																								2	100.0
INFLUENZA-LIKE SYMPTOMS	Imipramine																								1	100.0
	Reboxetine																								2	100.0
	Imipramine																								2	100.0
DYSKINESIA	Imipramine																								1	100.0
	Reboxetine																								1	100.0
	Imipramine																								1	100.0
FLATULENCE	Imipramine																								1	100.0
	Reboxetine																								1	100.0
	Imipramine																								1	100.0
PARANOID REACTION	Reboxetine																								1	100.0
	Imipramine																								1	100.0
	Reboxetine																								1	100.0
IMPOTENCE	Imipramine																								1	100.0
	Reboxetine																								1	100.0
	Imipramine																								1	100.0
PRURITUS	Reboxetine																								1	100.0
	Imipramine																								2	100.0
	Reboxetine																								2	100.0
RIGORS	Reboxetine																								2	100.0
	Imipramine																								1	100.0
	Reboxetine																								1	100.0
FIBRILLATION ATRIAL	Imipramine																								1	100.0
	Reboxetine																								1	100.0
	Imipramine																								1	100.0
HYPOAESTHESIA	Reboxetine																								1	100.0
	Imipramine																								1	100.0
	Reboxetine																								1	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 67

CT
CO
C

ADVERSE EVENTS BY RELATIONSHIP TO THE EXPERIMENTAL TREATMENT AND ASSIGNED TREATMENT

Adverse events/Assigned treatment	Relationship																									
	Definite			Probable			Possible			Doubtful			None			Unknown			Missing			Total				
	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%		
GASTRO-INTESTINAL DISORDER NOS	Reboxetine																									
				1		50.0																		2	100.0	
GLOSSITIS	Reboxetine																									
				1		50.0																			2	100.0
INCREASED LIVER ENZYMES	Imipramine																									
				1		100.0																			1	100.0
HYPERTRIGLYCERIDEMIA	Reboxetine																									
				1		100.0																			1	100.0
STOMATITIS	Imipramine																									
				1		100.0																			1	100.0
MONTILIASIS	Reboxetine																									
				1		100.0																			1	100.0
NEURALGIA	Reboxetine																									
				1		50.0																			1	50.0
SINUSITIS	Reboxetine																									
				1		100.0																			1	100.0
HYPERCHOLESTEROLAEMIA	Imipramine																									
				1		100.0																			1	100.0
CONVULSIONS	Reboxetine																									
				1		100.0																			1	100.0
CONVULSIONS GRAND MAL	Imipramine																									
				1		100.0																			1	100.0
LIBIDO DECREASED	Reboxetine																									
				1		100.0																			1	100.0
SLEEP DISORDER	Reboxetine																									
				1		100.0																			1	100.0
TASTE PERVERSION	Imipramine																									
				1		100.0																			1	100.0
CARDIAC ISCHEMIA AND RELATED SYMPTOMS	Imipramine																									
				1		100.0																			1	100.0
MYOCARDIAL INFARCTION	Imipramine																									
				1		100.0																			1	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 67
ADVERSE EVENTS BY RELATIONSHIP TO THE EXPERIMENTAL TREATMENT AND ASSIGNED TREATMENT

CT
CO
CS

Adverse events/Assigned treatment	Relationship																									
	Definite			Probable			Possible			Doubtful			None			Unknown			Missing			Total				
	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%		
CYSTITIS												1	100.0											1	100.0	
CEREBROVASCULAR DISORDER														1	100.0										1	100.0
THROMBOSIS ARTERIAL														1	100.0										1	100.0
COMA														1	100.0										1	100.0
NEUROPATHY														1	100.0										1	100.0
EAR DISORDER NOS														1	100.0										1	100.0
FRACTURE PATHOLOGICAL														1	100.0										1	100.0
PULMONARY CARCINOMA														1	100.0										1	100.0
APATHY														1	100.0										1	100.0
SUICIDE ATTEMPT														1	100.0										1	100.0
ASTHMA														1	100.0										1	100.0
COUGHING														1	100.0										1	100.0
PHARYNGITIS														1	100.0										1	100.0
ESR INCREASED														1	100.0										1	100.0
AEDEMA														1	100.0										1	100.0
EXTRASYSTOLES														1	100.0										1	100.0
HYPERKINESIA														1	100.0										1	100.0
GLYCOSURIA														1	100.0										1	100.0
DEPRESSION AGGRAVATED														1	100.0										1	100.0
DYSPNOEA														1	100.0										1	100.0
UPPER RESP TRACT INFECTION														1	100.0										1	100.0
ERYTHEMA / RASH														1	100.0										1	100.0

(CONTINUED)

(some adverse events are grouped in cluster)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No: 66

ADVERSE EVENTS: NUMBER OF PATIENTS COMPLAINING AT LEAST ONE ADVERSE EVENT WITH DEFINITE OR PROBABLE RELATIONSHIP

	Major Depressive Disorder						Dysthymia						Total					
	Imipramine		Reboxetine		Total		Imipramine		Reboxetine		Total		Imipramine		Reboxetine		Total	
	N	Z	N	Z	N	Z	N	Z	N	Z	N	Z	N	Z	N	Z	N	Z
Patients exposed	109	100.00	109	100.00	62	100.00	67	100.00	171	100.00	176	100.00	171	100.00	176	100.00	176	100.00
Any adverse event	46	42.20	35	32.11	27	43.55	23	34.33	73	42.69	58	32.95	73	42.69	58	32.95	73	42.69
HOUGH DRV	19	17.43	11	10.09	11	17.74	13	19.40	30	17.54	24	13.64	30	17.54	24	13.64	30	17.54
CONSTIPATION	9	8.26	10	9.17	4	6.45	3	4.48	13	7.60	13	7.39	13	7.60	13	7.39	13	7.39
HYPOTENSION AND RELATED SYMPTOMS	13	11.93	4	3.67	2	3.23			15	8.77	4	2.27	15	8.77	4	2.27	15	8.77
SWEATING INCREASED	5	4.59	7	6.42	3	4.84	1	1.49	8	4.68	8	4.55	8	4.68	8	4.55	8	4.55
NAUSEA AND RELATED SYMPTOMS	5	4.59	6	5.50	3	4.84	2	2.99	8	4.68	8	4.55	8	4.68	8	4.55	8	4.55
URINARY HESITANCY / RETENTION	3	2.75	3	2.75	5	8.06	1	1.49	8	4.68	4	2.27	8	4.68	4	2.27	8	4.68
TREMOR			1	0.92	1	1.61	4	5.97	1	0.58	5	2.84	1	0.58	5	2.84	1	0.58
SOMNOLENCE	1	0.92	2	1.83	2	3.23			3	1.75	2	1.14	3	1.75	2	1.14	3	1.75
BLURRED VISION	2	1.83			1	1.61	2	2.99	3	1.75	2	1.14	3	1.75	2	1.14	3	1.75
INSOMNIA	2	1.83	2	1.83			1	1.49	2	1.17	3	1.70	2	1.17	3	1.70	2	1.17
AGITATION / ANXIETY / NERVOUSNESS	2	1.83	1	0.92	1	1.61			3	1.75	1	0.57	3	1.75	1	0.57	3	1.75
ASTHENIA / FATIGUE	2	1.83	1	0.92	1	1.61			3	1.75	1	0.57	3	1.75	1	0.57	3	1.75
ANOREXIA	1	0.92	1	0.92	2	3.23			3	1.75	1	0.57	3	1.75	1	0.57	3	1.75
ABDOMINAL PAIN	1	0.92	2	1.83			1	1.49	1	0.58	3	1.70	1	0.58	3	1.70	1	0.58
HEADACHE / MIGRAINE			3	2.75			1	1.49	4	2.34	4	2.27	4	2.34	4	2.27	4	2.34
MALAISE	2	1.83			2	3.23			4	2.34			4	2.34			4	2.34
CONFUSION	1	0.92	2	1.83					1	0.58	2	1.14	1	0.58	2	1.14	1	0.58
TACHYCARDIA	1	0.92	1	0.92			1	1.49	1	0.58	2	1.14	1	0.58	2	1.14	1	0.58
PALPITATION	1	0.92	1	0.92			1	1.49	1	0.58	2	1.14	1	0.58	2	1.14	1	0.58
PRURITUS	1	0.92			1	1.61			2	1.17			2	1.17			2	1.17
FALL	1	0.92			1	1.61			2	1.17			2	1.17			2	1.17

(CONTINUED)

0184

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No: 68

ADVERSE EVENTS: NUMBER OF PATIENTS COMPLAINING AT LEAST ONE ADVERSE EVENT WITH DEFINITE OR PROBABLE RELATIONSHIP

	Major Depressive Disorder						Dysthymia						Total						
	Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Imipramine		Reboxetine		Total		
	N	Z	N	Z	N	Z	N	Z	N	Z	N	Z	N	Z	N	Z	N	Z	
DYSKINESIA	1	0.92															1	0.58	
IMPOTENCE					1	1.61											1	0.58	
LIBIDO DECREASED							1	1.49									1	0.57	
PARAESTHESIA	1	0.92															1	0.58	
FLATULENCE	1	0.92															1	0.58	
PARANOID REACTION	1	0.92															1	0.58	
SLEEP DISORDER												1	1.49				1	0.57	
TASTE PERVERSION	1	0.92															1	0.58	
CONVULSIONS	1	0.92															1	0.58	
CONVULSIONS GRAND MAL					1	0.92													1
ATAXIA									1	1.61							1	0.58	

51
00
51

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 69

ADVERSE EVENTS(*) PRESENT AT LAST DAY OF TREATMENT AND THEIR RELATIONSHIP TO STUDY MEDICATION
(ONLY PATIENTS WHO WITHDREW FROM THE STUDY FOR ADVERSE EVENTS)

07
00
07

All adverse events	Ass. treatment	Days of Treatment	Ass. treatment	Relationship						Total	
				None	Possible	Probable	Doubtful	Unknown	Definite		Missing
Centre - Patient			Ass. treatment								
5 - 1MD (Female)	Reboxetine	12	Reboxetine	3	14	16	5	2	2		42
	Imipramine		Imipramine	5	11	21	3	1	6		47
	Adverse events		Ass. treatment								
	NEUROPATHY		Reboxetine	1							1
	URINARY RETENTION		Reboxetine		1						1
	CONSTIPATION		Reboxetine		1						1
	MOUTH DRY		Reboxetine		1						1
5 - 10DT (Male)	URINARY RETENTION	5	Imipramine			1					1
5 - 4DT (Male)	INSOMNIA	28	Reboxetine				1				1
	NERVOUSNESS		Reboxetine				1				1
5 - 5DT (Female)	HYPERKINESIA	29	Reboxetine								1
6 - 2HD (Female)	INSOMNIA	7	Imipramine		1				1		1
	DIZZINESS		Imipramine			1					1
	SWEATING INCREASED		Imipramine			1					1
	AGITATION		Imipramine			1					1
8 - 3MD (Female)	COMA	9	Imipramine	1							1
	CEREBROVASCULAR DISORDER		Imipramine	1							1
9 - 6HD (Female)	ABDOMINAL PAIN	3	Imipramine			1					1
	NAUSEA		Imipramine			1					1
9 - 7HD (Female)	DIZZINESS	2	Imipramine			1					1
14 - 1HD (Female)	ABDOMINAL PAIN	27	Reboxetine			1					1

(CONTINUED)

(*) Only adverse events complained on the last day of treatment and still present or resulting in withdrawal

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/03S

TABLE No.: 69

ADVERSE EVENTS (*) PRESENT AT LAST DAY OF TREATMENT AND THEIR RELATIONSHIP TO STUDY MEDICATION
(ONLY PATIENTS WHO WITHDREW FROM THE STUDY FOR ADVERSE EVENTS)

01
00
02

Centre - Patient	Days of Treatment	Adverse events	Ass. treatment	Relationship							Total	
				None	Possible	Probable	Doubtful	Unknown	Definite	Missing		
14 - 1HD (Female)	27	ANXIETY	Reboxetine			1						1
15 - 111HD (Female)	21	URINARY RETENTION	Reboxetine				1					1
15 - 2HD (Female)	10	PARAESTHESIA	Imipramine			1						1
16 - 1DT (Female)	9	NAUSEA	Imipramine		1							1
16 - 3DT (Female)	13	HYPERTENSION	Imipramine				1					1
16 - 3HD (Female)	32	FRACTURE	Imipramine		1							1
		FALL	Imipramine		1							1
17 - 1DT (Female)	20	NERVOUSNESS	Reboxetine		1							1
		CONFUSION	Reboxetine		1							1
20 - 3HD (Female)	7	CONFUSION	Reboxetine				1					1
23 - 6HD (Female)	43	CONSTIPATION	Imipramine		1							1
		ANOREXIA	Imipramine				1					1
		PARANOID REACTION	Imipramine				1					1
		URINARY TRACT INFECTION	Imipramine									1
25 - 1HD (Male)	36	EXTRASYSTOLES	Reboxetine	1								1
30 - 2HD (Female)	3	SWEATING INCREASED	Reboxetine		1				1			1
		HEADACHE	Reboxetine				1					1
30 - 5HD (Female)	6	URINARY RETENTION	Imipramine							1		1
31 - 1HD (Female)	13	FALL	Imipramine				1					1
		HYPOTENSION POSTURAL	Imipramine				1					1

(CONTINUED)

(*) Daily adverse events complained on the last day of treatment and still present or resulting in withdrawal

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035

TABLE No. : 69

ADVERSE EVENTS(*) PRESENT AT LAST DAY OF TREATMENT AND THEIR RELATIONSHIP TO STUDY MEDICATION
(ONLY PATIENTS WHO WITHDREW FROM THE STUDY FOR ADVERSE EVENTS)

CT
CC
CO

Centre - Patient	Days of Treatment	Adverse events	Ass. treatment	Relationship						Total	
				None	Possible	Probable	Doubtful	Unknown	Definite		Missing
31 - 3ND (Male)	3	HYPOTENSION POSTURAL	Imipramine			1					1
		TACHYCARDIA	Imipramine			1					1
		MYOCARDIAL INFARCTION	Imipramine		1						1
32 - 4ND (Female)	20	INSOMNIA	Reboxetine			1					1
		HEADACHE	Reboxetine			1					1
		SOMNOLENCE	Reboxetine			1					1
		MOUTH DRY	Reboxetine			1					1
32 - 5ND (Female)	22	SWEATING INCREASED	Reboxetine			1					1
		ABDOMINAL PAIN	Reboxetine			1					1
		CONSTIPATION	Reboxetine			1					1
		MOUTH DRY	Reboxetine			1					1
		SWEATING INCREASED	Reboxetine			1					1
35 - 4ND (Female)	20	CONSTIPATION	Imipramine			1					1
		CONVULSIONS	Imipramine			1					1
35 - 2ND (Female)	29	SWEATING INCREASED	Reboxetine			1					1
		HYPOAESTHESIA	Reboxetine			1					1
35 - 7DT (Female)	28	NEURITIS	Reboxetine					1			1
		PNEUMONIA	Imipramine	1							1
36 - 12ND (Female)	12	CONFUSION	Imipramine			1					1
		HYPOKALAEMIA	Reboxetine			1					1

(CONTINUED)

(*) Only adverse events complained on the last day of treatment and still present or resulting in withdrawal

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 69

ADVERSE EVENTS(*) PRESENT AT LAST DAY OF TREATMENT AND THEIR RELATIONSHIP TO STUDY MEDICATION
(ONLY PATIENTS WHO WITHDREW FROM THE STUDY FOR ADVERSE EVENTS)

CT
CC
CD

Centre - Patient	Days of Treatment	Adverse events	Ass. treatment	Relationship						Total.	
				None	Possible	Probable	Doubtful	Unknown	Definite		Missing
36 - 13MD (Male)	24	THROMBOSIS ARTERIAL	Reboxetine	1							1
36 - 19MD (Female)	8	DIZZINESS	Reboxetine							1	1
36 - 5DT (Female)	5	NAUSEA	Reboxetine							1	1
36 - 5DT (Female)	5	SUICIDE ATTEMPT	Imipramine	1							1
36 - 7DT (Female)	7	DIZZINESS	Reboxetine		1						1
36 - 7DT (Female)	7	NAUSEA	Reboxetine		1						1
41 - 1MD (Male)	3	HEADACHE	Imipramine		1						1
45 - 2MD (Male)	20	BRONCHITIS	Imipramine						1		1
46 - 4MD (Female)	4	FRACTURE	Reboxetine		1						1
		FALL	Reboxetine		1						1
		CONFUSION	Reboxetine			1					1
		PULMONARY CARCINOMA	Reboxetine	1							1
291 - 1MD (Female)	35	MOUTH DRY	Imipramine							1	1
291 - 3DT (Female)	7	PRURITUS	Imipramine			1					1
293 - 12MD (Male)	42	NICTURITION DISORDER	Reboxetine			1					1
381 - 2MD (Female)	34	PALPITATION	Reboxetine			1					1
381 - 3DT (Female)	19	HEADACHE	Reboxetine		1						1
		PAIN	Reboxetine					1			1
382 - 10MD (Female)	6	DIZZINESS	Imipramine			1					1
		SWEATING INCREASED	Imipramine			1					1

(CONTINUED)

(*) Only adverse events complained on the last day of treatment and still present or resulting in withdrawal

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 69

ADVERSE EVENTS(*) PRESENT AT LAST DAY OF TREATMENT AND THEIR RELATIONSHIP TO STUDY MEDICATION
(ONLY PATIENTS WHO WITHDREW FROM THE STUDY FOR ADVERSE EVENTS)

Centre - Patient	Days of Treatment	Adverse events	Ass. treatment	Relationship						Total	
				None	Possible	Probable	Doubtful	Unknown	Definite		Missing
382 - 10ND (Female)	6	PALPITATION	Imipramine			1					1
		MALaise	Imipramine			1					1
		DIZZINESS	Imipramine						1		1
382 - 7DT (Male)	5	FALL	Imipramine						1		1
		MALaise	Imipramine						1		1
		ATAXIA	Imipramine						1		1
		FATIGUE	Imipramine			1					1
382 - 8ND (Male)	17	SOMNOLENCE	Imipramine			1					1
		DYSKINESIA	Imipramine			1					1
		SYNCOPE	Imipramine			1					1
3802 - 6ND (Female)	21	PARAESTHESIA	Imipramine				1				1

590

(*) Only adverse events complained on the last day of treatment and still present or resulting in withdrawal

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R8D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 70
LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test	Assigned treatment										
	Imipramine					Reboxetine					
	Days of treatment		Days of treatment		Days of treatment		Days of treatment		Days of treatment		
	Screen	1-28	29-56	128	Screen	1-28	29-56	146	Screen	1-28	29-56
HB	Evaluated	145	141	128	146	143	126		143	137	120
	Mean	13.63	13.59	13.57	13.71	13.84	13.85		13.84	13.85	13.85
	STD	1.20	1.31	1.27	1.14	1.14	1.17		1.14	1.14	1.17
	Min	10.03	9.08	9.20	10.84	10.76	10.80		10.76	10.80	10.80
	Max	16.80	16.70	16.60	17.42	17.58	17.10		17.42	17.58	17.10
	Median	13.75	13.80	13.70	13.71	13.80	13.75		13.71	13.80	13.75
	Median diff.		0.00	0.00			0.10			0.10	0.18
P value		0.8664	0.4723			0.0099			0.0099	0.0077	
HT	Evaluated	142	139	125	140	137	120		140	137	120
	Mean	40.14	40.30	40.40	40.45	40.70	40.90		40.45	40.70	40.90
	STD	3.80	3.78	3.69	3.36	3.19	3.85		3.36	3.19	3.85
	Min	28.00	29.13	31.06	32.13	31.00	33.50		32.13	31.00	33.50
	Max	53.50	50.43	52.00	51.00	50.43	58.00		51.00	50.43	58.00
	Median	40.47	40.74	40.80	40.15	40.30	40.53		40.15	40.30	40.53
	Median diff.		0.13	0.60			0.19			0.19	0.83
P value		0.2411	0.1851			0.0396			0.0396	0.0142	
RBC	Evaluated	145	140	127	145	143	125		145	143	125
	Mean	4.48	4.45	4.53	4.50	4.53	4.55		4.50	4.53	4.55
	STD	0.47	0.52	0.44	0.44	0.38	0.42		0.44	0.38	0.42
	Min	2.63	2.56	3.02	2.54	3.21	3.44		2.54	3.21	3.44
	Max	5.59	5.84	5.78	5.96	5.55	6.13		5.96	5.55	6.13

(CONTINUED)

P VALUE: PROBABILITY FROM THE WILCOXON SIGNED RANK TEST

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS RBD
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 70
LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test	Assigned treatment											
	Imipramine						Reboxetine					
	Days of treatment			Days of treatment			Days of treatment			Days of treatment		
	Screen	1-28	29-56	Screen	1-28	29-56	Screen	1-28	29-56	Screen	1-28	29-56
RBC	Median	4.52	4.48	4.54	4.48	4.50	4.48	4.50	4.50	4.48	4.50	4.50
	Median diff.	0.00	0.00	0.00	0.00	0.02	0.00	0.00	0.00	0.00	0.00	0.02
	P value	0.6417	0.7488			0.0525				0.1023	0.0525	
PLATELETS	Evaluated	141	156	123	144	125	144	141	125	141	125	125
	Mean	280.09	280.15	276.67	267.91	284.92	267.91	284.92	282.67	267.91	284.92	282.67
	STD	81.89	85.64	119.60	88.25	99.76	88.25	99.76	97.77	88.25	99.76	97.77
	Min	86.25	-10.00	85.00	45.00	-115.00	45.00	-115.00	12.50	45.00	-115.00	12.50
	Max	549.00	619.00	1260.00	566.67	771.67	566.67	771.67	901.67	566.67	771.67	901.67
	Median	283.33	283.67	256.90	250.00	262.50	250.00	262.50	260.00	250.00	262.50	260.00
	Median diff.		3.15	-4.17		13.57		13.57	12.14		13.57	12.14
	P value		0.4957	0.1767		0.0001		0.0001	0.0031		0.0001	0.0031
ESR 1st h	Evaluated	79	70	68	80	63	80	71	63	80	71	63
	Mean	12.27	22.54	12.28	13.10	16.13	13.10	16.13	15.39	13.10	16.13	15.39
	STD	12.10	63.14	12.57	13.53	17.39	13.53	17.39	16.15	13.53	17.39	16.15
	Min	0.50	0.83	1.05	0.67	0.83	0.67	0.83	0.83	0.67	0.83	0.83
	Max	71.25	525.00	86.00	82.50	111.00	82.50	111.00	88.00	82.50	111.00	88.00
	Median	10.00	10.00	9.00	9.00	10.00	9.00	10.00	10.00	9.00	10.00	10.00
	Median diff.		1.50	0.00		1.00		1.00	0.83		1.00	0.83
	P value		0.0040	0.5966		0.2398		0.2398	0.0512		0.2398	0.0512
ESR 2nd h	Evaluated	58	54	50	51	47	51	47	38	51	47	38
	Mean	24.54	37.22	24.77	26.16	29.05	26.16	29.05	33.03	26.16	29.05	33.03

(CONTINUED)

P VALUE: PROBABILITY FROM THE WILCOXON SIGNED RANK TEST

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE – PROTOCOL 20124/035
TABLE No.: 70

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test	Assigned treatment					
	Imipramine			Reboxetine		
	Days of treatment		Screen	Days of treatment		Screen
ESR 2nd h	17.22	68.61	19.74	23.36	23.91	32.27
STD	6.00	2.22	7.00	-2.22	6.67	6.67
Min	96.00	500.00	100.00	104.76	120.00	148.89
Max	21.00	21.50	18.00	18.95	22.00	21.00
Median		2.50	0.00		1.00	1.17
Median diff.		0.0640	0.1353		0.1832	0.0296
P value						

593

P VALUE: PROBABILITY FROM THE MILDON SIGNED RANK TEST

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RBD
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 70
 LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test	Assigned treatment											
	Imipramine						Reboxetine					
	Days of treatment		29-56		1-28		Days of treatment		29-56		1-28	
MBC	Evaluated	145	141	128	146	143	126	Screen	1-28	29-56	1-28	29-56
	Mean	7.02	7.12	6.74	7.14	7.33	7.45					
	STD	2.06	2.13	1.91	1.84	1.92	2.04					
	Min	2.33	2.94	2.04	3.69	1.94	0.86					
	Max	13.99	15.42	14.66	16.98	13.99	13.56					
	Median	6.88	6.67	6.64	7.00	7.19	7.25					
	Median diff.		0.00	-0.21		0.19	0.24					
P value		0.7938	0.0614		0.3573	0.0130						
MBC: N	Evaluated	139	135	122	139	136	117					
	Mean	62.48	62.63	61.84	61.90	61.71	61.77					
	STD	4.04	4.04	4.46	3.49	3.81	4.04					
	Min	49.67	53.00	50.18	51.00	48.00	47.00					
	Max	74.00	82.50	84.80	72.27	74.90	70.14					
	Median	62.82	62.82	61.74	61.67	62.01	62.18					
	Median diff.		0.00	0.00		-0.24	0.00					
P value		0.8184	0.0586		0.4082	0.8378						
MBC: E	Evaluated	136	132	119	131	127	111					
	Mean	1.72	1.65	1.77	1.67	1.80	1.82					
	STD	0.88	0.94	1.15	0.79	0.96	1.09					
	Min	0.00	-1.00	-1.00	-1.00	0.00	0.00					
	Max	5.67	4.60	7.00	4.00	7.40	10.00					

(CONTINUED)
 P VALUE: PROBABILITY FROM THE MILCOXON SIGNED RANK TEST

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RD
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 70
LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test		Assigned treatment										
		Imipramine					Reboxetine					
		Days of treatment		Days of treatment		Days of treatment		Days of treatment		Days of treatment		
Screen	1-28	29-56	Screen	1-28	29-56	Screen	1-28	29-56	Screen	1-28	29-56	
WBC: E	Median	1.52	1.60	1.68	1.72	1.74	1.80	0.00	0.00	0.00	0.00	0.00
	Median diff.		0.00	0.00								
	P value		0.7467	0.4299				0.2387	0.5923			
	Evaluated	128	125	114	123	121	106					
WBC: B	Mean	0.28	0.35	0.30	0.30	0.32	0.25					
	STD	0.34	0.48	0.36	0.37	0.38	0.37					
	Min	-0.08	-0.08	-0.08	-0.08	-0.08	-0.08					
	Max	1.50	4.00	1.50	2.25	1.50	2.25					
	Median	0.11	0.20	0.15	0.07	0.13	0.00					
	Median diff.		0.00	0.00				0.00	0.00			
	P value		0.1416	0.4948				0.5040	0.2147			
	Evaluated	139	135	122	141	137	118					
WBC: L	Mean	26.96	26.45	27.67	27.06	27.58	27.64					
	STD	4.44	4.24	4.82	4.32	4.67	4.68					
	Min	19.67	11.80	10.80	19.67	18.00	18.33					
	Max	43.80	45.00	45.00	46.33	50.33	47.00					
	Median	26.33	26.20	27.48	27.00	27.14	27.00					
	Median diff.		-0.50	0.00				0.29	0.00			
	P value		0.1336	0.3909				0.1169	0.5778			
	Evaluated	136	132	120	135	134	115					
WBC: M	Mean	5.30	5.34	5.43	5.48	5.44	5.32					

(CONTINUED)

P VALUE: PROBABILITY FROM THE MILDIXON SIGNED RANK TEST

51
52
51

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/035
TABLE No.: 70

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test	Assigned treatment								
	Imipramine				Reboxetine				
	Days of treatment		Days of treatment		Days of treatment		Days of treatment		
MBC: N	Screen	1-28	29-56	Screen	1-28	29-56	Screen	1-28	29-56
STD	1.83	1.78	1.91	1.93	1.62	1.62	1.57	1.62	1.57
Min	1.18	1.00	0.33	1.00	1.90	1.90	0.33	1.90	0.33
Max	12.00	14.00	12.00	15.00	10.87	10.87	9.69	10.87	9.69
Median	5.00	5.09	5.55	5.15	5.17	5.17	5.20	5.17	5.20
Median diff.		0.00	0.00		0.00	0.00		0.00	0.00
P value		0.7466	0.8645		0.5732	0.5732		0.5732	0.4866

9550089

9 9 6

P VALUE: PROBABILITY FROM THE MILCOXON SIGNED RANK TEST

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 70
 LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test	Assigned treatment											
	Imipramine						Reboxetine					
	Days of treatment		29-56		1-28		Days of treatment		29-56		1-28	
	Screen	1-28	29-56	Screen	1-28	29-56	Screen	1-28	29-56	Screen	1-28	29-56
CREATININE	Evaluated	145	142	130	144	141	126					
	Mean	0.91	0.92	0.93	0.90	0.89	0.90					
	STD	0.20	0.21	0.19	0.21	0.22	0.23					
	Min	0.47	0.46	0.46	0.50	0.53	0.44					
	Max	1.54	1.90	1.63	1.70	1.68	2.20					
	Median	0.90	0.90	0.91	0.90	0.85	0.84					
	Median diff.		0.00	0.00		0.00	0.00					
P value		0.3284	0.1568		0.4141	0.6201						
UREA	Evaluated	99	96	85	99	94	83					
	Mean	27.99	28.62	28.45	28.33	29.34	28.67					
	STD	7.42	8.36	7.22	8.43	8.67	7.70					
	Min	13.00	12.83	11.09	8.00	14.60	15.40					
	Max	57.40	59.31	59.00	55.72	61.67	63.67					
	Median	27.00	27.00	27.61	26.00	26.50	27.00					
	Median diff.		-0.25	0.00		0.50	0.50					
P value		0.9644	0.9391		0.1238	0.2127						
BUN	Evaluated	37	36	36	36	35	33					
	Mean	14.85	14.82	14.03	16.13	14.72	14.63					
	STD	4.04	3.11	3.08	4.42	2.80	3.06					
	Min	4.25	6.45	8.10	7.48	11.13	9.75					
	Max	24.60	21.85	21.85	26.25	24.05	21.85					

(CONTINUED)

P VALUE: PROBABILITY FROM THE WILCOXON SIGNED RANK TEST

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 70

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test	Assigned treatment									
	Imipramine					Reboxetine				
	Days of treatment		29-56		14,01		Days of treatment		29-56	
BUN	Screen	1-23	14,70	14,70	14,01	14,70	Screen	1-28	14,15	14,48
	Median		15,14				Median diff.		0,00	-0,66
	Median diff.						P value		0,5903	0,1854
URIC ACID	Evaluated		132	129	118	133	129	116		
	Mean		4,94	4,86	5,04	4,79	4,62	4,73		
	STD		1,27	1,30	1,15	1,57	1,43	1,46		
	Min		0,92	1,13	1,07	0,62	1,13	1,68		
	Max		9,17	8,23	7,93	11,78	9,16	10,72		
	Median		4,87	4,89	4,97	4,60	4,53	4,58		
	Median diff.									
P value										

5 9 8

P VALUE: PROBABILITY FROM THE MILCOXON SIGNED RANK TEST

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RD
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 70
 LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test	Assigned treatment											
	Imipramine						Reboxetine					
	Days of treatment			Days of treatment			Days of treatment			Days of treatment		
	Screen	1-28	29-56	Screen	1-28	29-56	Screen	1-28	29-56	Screen	1-28	29-56
TOT. PROTEINS	Evaluated	143	140	128	144	125	144	142	125	144	142	125
	Mean	7.15	7.19	7.21	7.13	7.24	7.13	7.17	7.24	7.13	7.17	7.24
	STD	0.64	0.65	0.56	0.56	0.56	0.56	0.63	0.56	0.63	0.63	0.56
	Min	4.50	4.88	5.26	4.88	5.45	4.88	5.45	5.45	5.45	5.45	5.45
	Max	8.50	8.66	8.78	8.57	9.06	8.57	9.82	9.06	9.82	9.82	9.06
	Median	7.20	7.20	7.17	7.14	7.26	7.14	7.25	7.26	7.25	7.25	7.26
	Median diff.		0.09	0.04				0.07	0.09		0.07	0.09
P value		0.2242	0.3535				0.1462	0.0231		0.1462	0.0231	
ALBUMINE	Evaluated	137	133	121	135	115	135	133	115	135	133	115
	Mean	4.16	4.13	4.13	4.20	4.22	4.20	4.14	4.22	4.20	4.14	4.22
	STD	0.56	0.63	0.70	0.54	0.65	0.54	0.58	0.65	0.54	0.58	0.65
	Min	2.38	2.26	1.43	2.84	2.08	2.84	2.18	2.08	2.84	2.18	2.08
	Max	6.14	6.59	7.28	6.65	7.79	6.65	7.49	7.79	6.65	7.49	7.79
	Median	4.10	4.05	4.14	4.10	4.10	4.10	4.10	4.10	4.10	4.10	4.10
	Median diff.		0.00	-0.03				-0.01	0.00		-0.01	0.00
P value		0.3219	0.5029				0.0923	0.4038		0.0923	0.4038	
TOT BILIRUBIN	Evaluated	142	138	125	144	125	144	142	125	144	142	125
	Mean	0.56	0.56	0.59	0.60	0.58	0.60	0.58	0.58	0.60	0.58	0.58
	STD	0.18	0.20	0.24	0.21	0.23	0.21	0.20	0.23	0.21	0.20	0.23
	Min	0.00	0.00	0.13	0.20	0.00	0.20	-0.07	0.00	0.20	-0.07	0.00
	Max	1.09	1.45	1.60	1.63	1.56	1.63	1.35	1.56	1.63	1.35	1.56
	P value											

(CONTINUED)
 P VALUE: PROBABILITY FROM THE WILCOXON SIGNED RANK TEST

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE NO.: 70
 LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test	Assigned treatment									
	Imipramine					Reboxetine				
	Days of treatment		29-56		29-56		Days of treatment		29-56	
	Screen	1-23	0.55	0.57	0.57	Screen	1-28	0.56	0.56	0.56
TOX BILIRUBIN	Median		0.00	0.00	0.00		0.00	0.00	0.00	0.00
	Median diff.		0.5610	0.3946			0.4195	0.4672		
	P value									
DIR BILIRUBIN	Evaluated	88	82	73	84	80	69			
	Mean	0.10	0.10	0.11	0.11	0.11	0.11	0.12		
	STD	0.06	0.07	0.07	0.08	0.08	0.10			
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
	Max	0.24	0.25	0.35	0.45	0.40	0.49			
	Median	0.10	0.10	0.10	0.10	0.09	0.10			
	Median diff.		0.00	0.00		0.00	0.00			
	P value		0.9656	0.4458		0.7316	0.4129			

P VALUE: PROBABILITY FROM THE WILCOXON SIGNED RANK TEST

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS RED
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 70
 LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test	Assigned treatment													
	Imipramine						Reboxetine							
	Days of treatment		29-56		1-28		29-56		1-28		29-56			
SCOT	Evaluated	140	137	123	145	143	124	140	137	123	145	143	124	
	Mean	20.47	20.80	21.94	20.55	21.17	20.74	20.47	20.80	21.94	20.55	21.17	20.74	
	STD	5.78	5.78	9.56	5.62	9.93	5.86	5.78	5.78	9.56	5.62	9.93	5.86	
	Min	8.81	9.05	10.19	1.25	7.50	2.00	8.81	9.05	10.19	1.25	7.50	2.00	
	Max	57.33	54.35	108.67	46.52	94.44	53.00	57.33	54.35	108.67	46.52	94.44	53.00	
	Median	20.12	20.29	20.81	20.00	19.70	20.00	20.12	20.29	20.81	20.00	19.70	20.00	
	Median diff.		0.50	0.50		0.00	0.00		0.50	0.50		0.00	0.00	
	P value		0.4182	0.2230		0.9010	0.9095		0.4182	0.2230		0.9010	0.9095	
	SGPT	Evaluated	125	124	113	126	125	109	125	124	113	126	125	109
		Mean	16.96	17.64	18.35	18.41	19.77	18.81	16.96	17.64	18.35	18.41	19.77	18.81
STD		7.83	8.46	8.77	9.79	12.30	8.88	7.83	8.46	8.77	9.79	12.30	8.88	
Min		5.00	4.09	4.09	5.00	5.00	-0.88	5.00	4.09	4.09	5.00	5.00	-0.88	
Max		60.00	64.62	70.00	78.86	112.95	61.67	60.00	64.62	70.00	78.86	112.95	61.67	
Median		15.58	15.79	16.43	16.36	16.87	18.00	15.58	15.79	16.43	16.36	16.87	18.00	
Median diff.			0.63	0.00		0.62	0.63		0.63	0.00		0.62	0.63	
P value			0.3676	0.5915		0.1109	0.0414		0.3676	0.5915		0.1109	0.0414	
GAMMA GT		Evaluated	139	137	119	136	134	116	139	137	119	136	134	116
		Mean	27.89	28.23	29.42	27.74	28.12	27.43	27.89	28.23	29.42	27.74	28.12	27.43
	STD	16.96	16.16	16.59	25.66	20.32	14.96	16.96	16.16	16.59	25.66	20.32	14.96	
	Min	5.87	5.87	10.56	8.00	8.00	8.00	5.87	5.87	10.56	8.00	8.00	8.00	
	Max	140.92	88.00	120.52	269.91	174.86	81.68	140.92	88.00	120.52	269.91	174.86	81.68	
	P value													

(CONTINUED)
 P VALUE: PROBABILITY FROM THE MILDIXON SIGNED RANK TEST

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE NO.: 70
LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test	Assigned treatment											
	Imipramine						Reboxetine					
	Days of treatment		29-56		29-56		Days of treatment		1-28		29-56	
GAMMA CT	Screen	1-28	24.00	24.64	25.78	21.71	21.94	24.00	Screen	1-28	21.94	24.00
	Median											
	Median diff.		0.00	0.00	0.00	0.00	0.00	0.15			0.00	0.15
LDH	P value		0.8221	0.4749				0.1479			0.3453	0.1479
	Evaluated		118	114	104	116	109	97			109	97
	Mean		320.94	312.84	319.63	318.03	323.16	322.35			323.16	322.35
	STD		87.43	73.32	97.31	74.83	108.38	89.10			108.38	89.10
	Min		153.39	156.13	158.87	158.81	196.30	169.83			196.30	169.83
	Max		716.74	622.13	1082.38	594.13	1085.44	819.88			1085.44	819.88
	Median		307.97	302.05	308.44	315.62	305.87	313.95			305.87	313.95
	Median diff.			-3.12	8.05		0.00	7.56			0.00	7.56
	P value		0.4908	0.0929			0.9496	0.3018			0.9496	0.3018
ALK. PROSPH.	Evaluated		140	134	123	141	137	125			137	125
	Mean		113.10	120.63	124.51	114.07	119.97	123.40			119.97	123.40
	STD		34.64	36.72	39.40	34.15	46.84	47.49			46.84	47.49
	Min		38.90	42.50	33.90	40.82	50.09	59.96			50.09	59.96
	Max		268.30	282.71	250.46	221.47	513.88	513.88			513.88	513.88
	Median		110.87	115.57	117.20	108.37	111.63	115.49			111.63	115.49
	Median diff.			5.31	8.15		3.31	4.47			3.31	4.47
	P value		0.0000	0.0000			0.0370	0.0011			0.0370	0.0011

P VALUE: PROBABILITY FROM THE MILDIXON SIGNED RANK TEST

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 70

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test	Assigned treatment											
	Imipramine						Reboxetine					
	Days of treatment			Days of treatment			Days of treatment			Days of treatment		
	Screen	1-28	29-56	Screen	1-28	29-56	Screen	1-28	29-56	Screen	1-28	29-56
GLOBULINS ALPHA 1	Evaluated	115	113	103	114	113	114	113	99	114	113	99
	Mean	0.18	0.20	0.20	0.17	0.18	0.17	0.18	0.18	0.17	0.18	0.18
	STD	0.09	0.13	0.12	0.09	0.09	0.09	0.09	0.10	0.09	0.09	0.10
	Min	-0.04	-0.00	-0.01	-0.05	-0.03	-0.05	-0.03	-0.05	-0.03	-0.03	-0.05
	Max	0.54	0.71	0.70	0.46	0.54	0.46	0.54	0.65	0.46	0.54	0.65
	Median	0.19	0.20	0.19	0.18	0.19	0.18	0.19	0.19	0.19	0.19	0.19
	Median diff.		0.00	0.00		0.01	0.00		0.00		0.01	0.00
P value		0.1524	0.0315		0.0304	0.1238		0.0304	0.1238	0.0304	0.1238	
GLOBULINS ALPHA 2	Evaluated	115	113	103	114	113	114	113	99	114	113	99
	Mean	0.79	0.80	0.80	0.77	0.78	0.77	0.78	0.78	0.77	0.78	0.78
	STD	0.16	0.16	0.17	0.14	0.15	0.14	0.15	0.15	0.14	0.15	0.15
	Min	0.49	0.37	0.48	0.43	0.40	0.43	0.40	0.48	0.43	0.40	0.48
	Max	1.38	1.32	1.49	1.15	1.22	1.15	1.22	1.24	1.15	1.22	1.24
	Median	0.77	0.79	0.77	0.75	0.77	0.75	0.77	0.77	0.75	0.77	0.77
	Median diff.		0.00	0.01		0.01	0.00		0.01		0.01	0.01
P value		0.7899	0.1992		0.1889	0.0659		0.1889	0.0659	0.1889	0.0659	
GLOBULINS BETA	Evaluated	115	113	103	114	113	114	113	99	114	113	99
	Mean	0.95	0.94	0.96	0.95	0.98	0.95	0.98	0.97	0.95	0.98	0.97
	STD	0.15	0.16	0.14	0.17	0.19	0.17	0.19	0.18	0.17	0.19	0.18
	Min	0.56	0.61	0.59	0.62	0.69	0.62	0.69	0.61	0.62	0.69	0.61
	Max	1.41	1.63	1.24	1.58	1.75	1.58	1.75	1.66	1.58	1.75	1.66

(CONTINUED)

P VALUE: PROBABILITY FROM THE WILCOXON SIGNED RANK TEST

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No. : 70

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test	Assigned treatment								
	Imipramine				Reboxetine				
	Days of treatment		Days of treatment		Days of treatment		Days of treatment		
	Screen	1-28	29-56	Screen	1-28	29-56	Screen	1-28	29-56
GLOBULINS BETA	Median	0.94	0.92	0.97	0.92	0.94	0.92	0.94	0.95
	Median diff.		-0.01	0.00		0.02		0.02	0.01
	P value		0.5392	0.3720		0.0853		0.1445	
GLOBULINS GAMMA	Evaluated	115	113	103	114	113	99		
	Mean	1.12	1.14	1.16	1.11	1.15	1.16		
	STD	0.30	0.34	0.34	0.28	0.34	0.30		
	Min	0.40	0.40	0.27	0.42	0.36	0.36		
	Max	2.47	2.74	2.55	1.83	2.32	2.04		
	Median	1.07	1.10	1.13	1.08	1.13	1.16		
	Median diff.		0.00	0.04		0.02	0.06		
	P value		0.5546	0.1408		0.1312	0.0445		

P VALUE: PROBABILITY FROM THE WILCOXON SIGNED RANK TEST

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CHS RD
 REBOXETINE - PROTOCOL 20124/035
 TABLE No. : 70
 LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test	Assigned treatment										
	Imipramine					Reboxetine					
	Days of treatment		Days of treatment		Days of treatment		Days of treatment		Days of treatment		
	Screen	1-28	29-56	124	Screen	1-28	29-56	124	Screen	1-28	29-56
TOT. CHOLEST.	Evaluated	142	138	124	143	138	123	123	143	138	123
	Mean	259.86	262.03	263.47	262.66	262.90	264.81	264.81	262.66	262.90	264.81
	STD	51.91	49.59	47.55	46.15	46.35	45.96	45.96	46.15	46.35	45.96
	Min	138.33	141.45	145.71	148.56	145.23	140.96	140.96	148.56	145.23	140.96
	Max	437.36	403.72	409.63	411.29	472.16	474.48	474.48	411.29	472.16	474.48
	Median	262.76	261.34	265.39	266.95	262.79	268.13	268.13	266.95	262.79	268.13
Median diff.		1.11	1.05			0.00	0.00			0.00	0.00
P value		0.5591	0.6069			0.8424	0.5943			0.8424	0.5943
TRIGLYCERIDES	Evaluated	138	134	121	141	135	121	121	141	135	121
	Mean	146.66	157.11	167.24	146.23	147.21	147.75	147.75	146.23	147.21	147.75
	STD	86.42	113.41	112.13	81.08	75.63	74.84	74.84	81.08	75.63	74.84
	Min	42.88	23.36	55.57	30.68	22.14	56.66	56.66	30.68	22.14	56.66
	Max	611.40	912.50	697.60	621.23	484.52	469.65	469.65	621.23	484.52	469.65
	Median	121.24	120.05	132.01	129.50	126.45	128.89	128.89	129.50	126.45	128.89
Median diff.		-0.34	5.02			1.44	2.87			1.44	2.87
P value		0.9973	0.0049			0.8047	0.4974			0.8047	0.4974
GLUCOSE	Evaluated	136	128	120	143	138	121	121	143	138	121
	Mean	99.77	96.83	97.94	98.01	99.53	101.58	101.58	98.01	99.53	101.58
	STD	28.34	25.91	19.64	27.49	30.89	40.02	40.02	27.49	30.89	40.02
	Min	68.97	67.67	68.41	63.00	50.56	65.23	65.23	63.00	50.56	65.23
	Max	326.20	271.60	211.00	347.81	350.00	357.00	357.00	347.81	350.00	357.00

(CONTINUED)

P VALUE: PROBABILITY FROM THE WILCOXON SIGNED RANK TEST

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No. : 70
 LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test	Assigned treatment											
	Imipramine						Reboxetine					
	Days of treatment			Days of treatment			Days of treatment			Days of treatment		
	Screen	1-28	29-56	Screen	1-28	29-56	Screen	1-28	29-56	Screen	1-28	29-56
NA+	Evaluated	140	137	126	146	143	127					
	Mean	140.88	139.80	140.48	141.10	140.25	140.31					
	STD	3.20	3.59	3.52	3.05	3.21	3.02					
	Min	126.00	126.00	127.00	133.00	132.36	132.88					
	Max	151.56	150.44	151.71	152.67	157.43	151.56					
	Median	141.00	140.17	140.19	141.00	140.17	140.29					
	Median diff.		-1.00	-1.00		-1.00	-0.91					
	P value		0.0005	0.0709		0.0019	0.0021					
CL-	Evaluated	123	122	108	124	121	106					
	Mean	101.85	100.98	101.31	101.81	101.14	101.09					
	STD	2.96	2.79	2.44	2.72	2.89	2.74					
	Min	89.20	88.40	95.60	94.00	91.14	94.80					
	Max	114.47	106.00	112.22	108.40	111.60	112.40					
	Median	102.00	101.20	101.25	102.00	101.20	101.20					
	Median diff.		-0.80	-0.80		-0.50	-0.80					
	P value		0.0003	0.0263		0.0207	0.0109					
K+	Evaluated	140	136	125	146	143	126					
	Mean	4.14	4.24	4.21	4.11	4.20	4.13					
	STD	0.44	0.54	0.48	0.45	0.46	0.45					
	Min	2.88	3.07	3.07	3.04	2.93	2.59					
	Max	5.22	6.17	6.38	6.24	5.63	5.46					

(CONTINUED)

P VALUE: PROBABILITY FROM THE WILCOXON SIGNED RANK TEST

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RD

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 70

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY STATISTICAL ANALYSIS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Laboratory test	Assigned treatment									
	Imipramine					Reboxetine				
	Days of treatment		Days of treatment		Days of treatment		Days of treatment		Days of treatment	
	Screen	1-28	29-56	4.17	4.14	4.14	4.08	4.14	4.14	4.09
K+	Median	4.09	0.00	0.11						
	Median diff.									
	P value	0.0769	0.0256						0.0345	0.9249
Ca++	Evaluated	139	135	124	144	140	124			
	Mean	5.03	5.00	4.97	4.97	5.02	5.00			
	STD	0.30	0.31	0.30	0.29	0.28	0.32			
	Min	4.33	4.30	4.00	3.98	3.96	4.21			
	Max	6.08	6.00	5.50	5.56	5.67	6.47			
	Median	5.04	5.02	4.99	4.98	5.06	5.00			
	Median diff.		-0.03	-0.01		0.05	0.00			
	P value	0.2109	0.1046			0.0163	0.6937			
PO4--	Evaluated	130	126	113	134	130	116			
	Mean	1.19	1.18	1.23	1.18	1.23	1.22			
	STD	0.20	0.16	0.22	0.19	0.18	0.23			
	Min	0.41	0.59	0.73	0.68	0.77	0.77			
	Max	1.94	1.54	2.14	2.10	2.02	2.31			
	Median	1.18	1.20	1.20	1.17	1.22	1.21			
	Median diff.		0.00	0.05		0.05	0.05			
	P value	0.9870	0.0002			0.0000	0.0171			

P VALUE: PROBABILITY FROM THE WILCOXON SIGNED RANK TEST

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No: 71
URINALYSIS: NUMBER AND PERCENTAGE OF PATIENTS ACCORDING TO TIME INTERVAL, BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Reboxetine

	Days of treatment																		
	Screening						1-28 days						29-56 days						
	Female		Male		Total		Female		Male		Total		Female		Male		Total		
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	
SPECIFIC GRAVITY	Abnormal						1	1.1											
	Normal	90	100.0	27	100.0	117	100.0	87	98.9	25	92.6	112	97.4	76	95.0	22	88.0	98	93.3
	Not done									2	7.4	2	1.7	4	5.0	3	12.0	7	6.7
ALBUMIN	Total	90	100.0	27	100.0	117	100.0	88	100.0	27	100.0	115	100.0	80	100.0	25	100.0	105	100.0
	Abnormal	2	1.9			2	1.5	2	1.9	1	3.4	3	2.2						
	Normal	106	98.1	29	100.0	135	98.5	104	98.1	28	96.6	132	97.8	90	94.7	24	88.9	114	93.4
SUGAR	Not done																		
	Total	108	100.0	29	100.0	137	100.0	106	100.0	29	100.0	135	100.0	95	100.0	27	100.0	122	100.0
	Abnormal	2	1.9			2	1.4	3	2.8			3	2.2	5	5.3			5	4.1
RBC	Normal	106	96.1	30	100.0	136	98.6	103	97.2	30	100.0	133	97.8	86	90.5	24	88.9	110	90.2
	Not done													4	4.2	3	11.1	7	5.7
	Total	108	100.0	30	100.0	138	100.0	106	100.0	30	100.0	136	100.0	95	100.0	27	100.0	122	100.0
RBC	Abnormal	2	1.9	1	3.3	3	2.2	1	0.9			1	0.7	1	1.1			1	0.8
	Normal	106	98.1	29	96.7	135	97.8	104	98.1	30	100.0	134	98.5	91	95.8	24	88.9	115	94.3
	Not done							1	0.9			1	0.7	3	3.2	3	11.1	6	4.9
RBC	Total	108	100.0	30	100.0	138	100.0	106	100.0	30	100.0	136	100.0	95	100.0	27	100.0	122	100.0
	Abnormal	43	12.0	3	10.0	16	11.6	9	8.5	1	3.3	10	7.4	7	7.4			7	5.7
	Normal	95	88.0	27	90.0	122	88.4	96	90.6	29	96.7	125	91.9	85	89.5	24	88.9	109	89.3
RBC	Not done							1	0.9			1	0.7	3	3.2	3	11.1	6	4.9
	Total	108	100.0	30	100.0	138	100.0	106	100.0	30	100.0	136	100.0	95	100.0	27	100.0	122	100.0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No: 71

URINALYSIS: NUMBER AND PERCENTAGE OF PATIENTS ACCORDING TO TIME INTERVAL, BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Imipramine

	Days of treatment																		
	Screening						1-28 days						29-56 days						
	Female		Male		Total		Female		Male		Total		Female		Male		Total		
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	
SPECIFIC GRAVITY	Normal	79	100.0	32	100.0	111	100.0	77	98.7	27	84.4	104	94.5	64	92.8	30	96.8	94	94.0
	Not done							1	1.3	5	15.6	6	5.5	5	7.2	1	3.2	6	6.0
	Total	79	100.0	32	100.0	111	100.0	78	100.0	32	100.0	110	100.0	69	100.0	31	100.0	100	100.0
ALBUMIN	Abnormal	2	2.0	1	2.9	3	2.3	3	3.1	1	2.9	4	3.0	1	1.1	1	3.0	2	1.7
	Normal	97	98.0	33	97.1	130	97.7	93	94.9	28	82.4	121	91.7	81	93.1	31	93.9	112	93.3
	Not done							2	2.0	5	14.7	7	5.3	5	5.7	1	3.0	6	5.0
SUGAR	Total	99	100.0	34	100.0	133	100.0	98	100.0	34	100.0	132	100.0	87	100.0	33	100.0	120	100.0
	Abnormal	2	2.0	1	2.9	3	2.2	3	3.0			3	2.3	2	2.3			2	1.7
	Normal	98	98.0	33	97.1	131	97.8	94	94.9	29	85.3	123	92.5	80	92.0	32	97.0	112	93.3
RBC	Not done							2	2.0	5	14.7	7	5.3	5	5.7	1	3.0	6	5.0
	Total	100	100.0	34	100.0	134	100.0	99	100.0	34	100.0	133	100.0	87	100.0	33	100.0	120	100.0
	Abnormal	4	4.1			4	3.0	7	7.2			7	5.3	1	1.2			1	0.8
RBC	Normal	94	95.9	34	100.0	128	97.0	88	90.7	29	85.3	117	89.3	80	93.0	31	93.9	111	93.3
	Not done							2	2.1	5	14.7	7	5.3	5	5.8	2	6.1	7	5.9
	Total	98	100.0	34	100.0	132	100.0	97	100.0	34	100.0	131	100.0	86	100.0	33	100.0	119	100.0
RBC	Abnormal	10	10.4	1	3.0	11	8.5	10	10.5	1	3.0	11	8.6	7	8.2			7	6.0
	Normal	86	89.6	32	97.0	118	91.5	83	87.4	27	81.8	110	85.9	73	85.9	30	96.8	103	88.8
	Not done							2	2.1	5	15.2	7	5.5	5	5.9	1	3.2	6	5.2
Total	96	100.0	33	100.0	129	100.0	95	100.0	33	100.0	128	100.0	85	100.0	31	100.0	116	100.0	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXYTINE - PROTOCOL 20124/035
TABLE No: 72

URINALYSIS: NUMBER AND PERCENTAGE OF PATIENTS AT LAST ASSESSMENT, BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Reboxetine

	Total												Last assessment													
	Female						Male						Female						Male							
	No.		%		Z		No.		%		Z		No.		%		Z		No.		%		Z			
	No.	%	Z	No.	%	Z	No.	%	Z	No.	%	Z	No.	%	Z	No.	%	Z	No.	%	Z	No.	%	Z		
SPECIFIC GRAVITY	Normal	86	95.6	24	88.9	110	94.0	10	100.0	2	100.0	12	100.0	76	95.0	22	88.0	98	93.3							
	Not done	4	4.4	3	11.1	7	6.0							4	5.0	3	12.0	7	6.7							
	Total	90	100.0	27	100.0	117	100.0	10	100.0	2	100.0	12	100.0	80	100.0	25	100.0	105	100.0							
ALBUMIN	Normal	103	95.4	26	89.7	129	94.2	13	100.0	2	100.0	15	100.0	90	94.7	24	88.9	114	93.4							
	Not done	5	4.6	3	10.3	8	5.8							5	5.3	3	11.1	8	6.6							
	Total	108	100.0	29	100.0	137	100.0	13	100.0	2	100.0	15	100.0	95	100.0	27	100.0	122	100.0							
SUGAR	Abnormal	6	5.6			6	4.3	1	7.7			1	6.3	5	5.3			5	4.1							
	Normal	98	90.7	27	90.0	125	90.6	12	92.3	3	100.0	15	93.8	86	90.5	24	88.9	110	90.2							
	Not done	4	3.7	3	10.0	7	5.1							4	4.2	3	11.1	7	5.7							
RBC	Total	108	100.0	30	100.0	138	100.0	13	100.0	3	100.0	16	100.0	95	100.0	27	100.0	122	100.0							
	Abnormal	1	0.9			1	0.7							1	1.1			1	0.8							
	Normal	104	96.3	27	90.0	131	94.9	13	100.0	3	100.0	16	100.0	91	95.8	24	88.9	115	94.3							
WBC	Not done	3	2.8	3	10.0	6	4.3							3	3.2	3	11.1	6	4.9							
	Total	108	100.0	30	100.0	138	100.0	13	100.0	3	100.0	16	100.0	95	100.0	27	100.0	122	100.0							
	Abnormal	8	7.4			8	5.8	1	7.7			1	6.3	7	7.4			7	5.7							
HBC	Normal	97	89.8	27	90.0	124	89.9	12	92.3	3	100.0	15	93.8	85	89.5	24	88.9	109	89.3							
	Not done	3	2.8	3	10.0	6	4.3							3	3.2	3	11.1	6	4.9							
	Total	108	100.0	30	100.0	138	100.0	13	100.0	3	100.0	16	100.0	95	100.0	27	100.0	122	100.0							

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035

TABLE No: 72

URINALYSIS: NUMBER AND PERCENTAGE OF PATIENTS AT LAST ASSESSMENT, BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Imipramine

	Last assessment																			
	Total						1-28 days			29-56 days			Total							
	Female		Male		Total		Female		Male	Total		Female		Male	Total					
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%				
SPECIFIC GRAVITY	Normal	74	93.7	31	96.9	105	94.6	10	100.0	1	100.0	11	100.0	64	92.8	30	96.8	94	94.0	
	Not done	5	6.3	1	3.1	6	5.4							5	7.2	1	3.2	6	6.0	
	Total	79	100.0	32	100.0	111	100.0	10	100.0	1	100.0	11	100.0	69	100.0	31	100.0	100	100.0	
ALBUMIN	Abnormal	2	2.0	1	2.9	3	2.3	1	8.3			1	7.7	1	1.1	1	3.0	2	1.7	
	Normal	92	92.9	32	94.1	124	93.2	11	91.7	1	100.0	12	92.3	81	93.1	31	93.9	112	93.3	
	Not done	5	5.1	1	2.9	6	4.5							5	5.7	1	3.0	6	5.0	
SUGAR	Total	99	100.0	34	100.0	133	100.0	12	100.0	1	100.0	13	100.0	87	100.0	33	100.0	120	100.0	
	Abnormal	3	3.0			3	2.2	1	7.7			1	7.1	2	2.3			2	1.7	
	Normal	92	92.0	33	97.1	125	93.3	12	92.3	1	100.0	13	92.9	80	92.0	32	97.0	112	93.3	
RBC	Not done	5	5.0	1	2.9	6	4.5								5	5.7	1	3.0	6	5.0
	Total	100	100.0	34	100.0	134	100.0	13	100.0	1	100.0	14	100.0	87	100.0	33	100.0	120	100.0	
	Abnormal	1	1.0			1	0.8							1	1.2			1	0.8	
RBC	Normal	92	93.9	32	94.1	124	93.9	12	100.0	1	100.0	13	100.0	80	93.0	31	93.9	111	93.3	
	Not done	5	5.1	2	5.9	7	5.3							5	5.8	2	6.1	7	5.9	
	Total	98	100.0	34	100.0	132	100.0	12	100.0	1	100.0	13	100.0	85	100.0	33	100.0	119	100.0	
RBC	Abnormal	7	7.3			7	5.4							7	8.2			7	6.0	
	Normal	84	87.5	32	97.0	116	89.9	11	100.0	2	100.0	13	100.0	73	85.9	30	96.8	103	88.8	
	Not done	5	5.2	1	3.0	6	4.7							5	5.9	1	3.2	6	5.2	
Total	96	100.0	33	100.0	129	100.0	11	100.0	2	100.0	13	100.0	85	100.0	31	100.0	116	100.0		

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 RESOMETINE - PROTOCOL 20124/035
 TABLE No: 73
 URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABNORMAL OR NORMAL URINALYSIS VALUE AT EACH EVALUATION TIME AS COMPARED TO PRETREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Urinalysis test at baseline	Days of treatment										
	1-28 days					29-56 days					
	Abnormal	Normal	Not done	Total	Total	Abnormal	Normal	Not done	Total	Total	
SPECIFIC GRAVITY	Normal	1	112	2	115				98	7	105
	Total	1	112	2	115				98	7	105
ALBUMIN	Abnormal		2		2					1	1
	Normal	3	130		133				114	7	121
Total	3	132		135				114	8	122	
SUGAR	Abnormal	1	1		2		1				1
	Normal	2	132		134	4	110		7	7	121
Total	3	133		136	5	110		7	7	122	
RBC	Abnormal		3		3		1		2		3
	Normal	1	131	1	133				113	6	119
Total	1	134	1	136	1	115		6	6	122	
WBC	Abnormal	4	11	1	16	2	12		1	1	15
	Normal	6	114		120	5	97		5	5	107
Total	10	125	1	136	7	109		6	6	122	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 REMOXYLINE - PROTOCOL 20124/035
 TABLE No: 73
 URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABNORMAL OR NORMAL URINALYSIS VALUE AT EACH EVALUATION TIME AS COMPARED TO PRETREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

Urinalysis test at baseline	Days of treatment											
	1-28 days						29-56 days					
	Abnormal	Normal	Not done	Total	Abnormal	Total	Abnormal	Normal	Not done	Total	Abnormal	Total
SPECIFIC GRAVITY	Normal		104	6	110			94	6	100		
	Total		104	6	110			94	6	100		
ALBUMIN	Abnormal	1	2		3					2		2
	Normal	3	119	7	129	2	110	6		118		
Total	4	121	7	132	2	112	6		120			
SUGAR	Abnormal	1	2		3					2		2
	Normal	2	121	7	130	2	110	6		118		
Total	3	123	7	133	2	112	6		120			
RBC	Abnormal	1	3		4					2		2
	Normal	6	114	7	127	1	109	7		117		
Total	7	117	7	131	1	111	7		119			
MBC	Abnormal	4	6	1	11	4	4			8		
	Normal	7	104	6	117	3	99	6		108		
Total	11	110	7	128	7	103	6		116			

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXYETINE - PROTOCOL 20124/035

TABLE No: 74

URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABNORMAL OR NORMAL URINALYSIS VALUE AT LAST ASSESSMENT AS COMPARED TO PRETREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Urinalysis test at baseline	Total						Last assessment					
	1-28 days			29-56 days			1-28 days			29-56 days		
	Abnormal	Normal	Total	Not done	Total	Total	Abnormal	Normal	Total	Abnormal	Normal	Total
SPECIFIC GRAVITY	Normal	110	7	117	12	12	98	7	105			
	Total	110	7	117	12	12	98	7	105			
ALBUMIN	Abnormal	1	1	2	1	1		1	1			
	Normal	128	7	135	14	14	114	7	121			
Total	129	8	137	15	15	114	8	122				
SUGAR	Abnormal	2	2	4	1	1		1	1			
	Normal	125	7	132	15	15	110	7	117			
Total	127	9	136	17	17	110	8	118				
BEC	Abnormal	1	2	3	3	3		1	1			
	Normal	129	6	135	16	16	113	6	119			
Total	130	8	138	19	19	113	7	120				
MBC	Abnormal	3	1	4	1	1		2	1			
	Normal	112	5	117	15	15	97	5	102			
Total	115	6	121	16	16	97	7	104				

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No: 74

URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABNORMAL OR NORMAL URINALYSIS VALUE AT LAST ASSESSMENT AS COMPARED TO PRETREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

Urinalysis test at baseline	Total						Last assessment						
	Total			1-28 days			29-56 days			Total			
	Abnormal	Normal	Not done	Abnormal	Normal	Total	Abnormal	Normal	Total	Abnormal	Normal	Not done	Total
SPECIFIC GRAVITY	Normal	105	6	111		11		11	11		94	6	100
	Total	105	6	111		11		11	11		94	6	100
ALBUMIN	Abnormal	1	2	3		1		1	1		2		2
	Normal	2	122	6	130		12	12	12	2	110	6	118
Total	3	124	6	133		1	12	13	13	2	112	6	120
SUGAR	Abnormal	1	2	3		1		1	1		2		2
	Normal	2	123	6	131		13	13	13	2	110	6	118
Total	3	125	6	134		1	13	14	14	2	112	6	120
REC	Abnormal		4	4				2	2		2		2
	Normal	1	120	7	128		11	11	11	1	109	7	117
Total	1	124	7	132		13	13	13	13	1	111	7	119
MBC	Abnormal	4	7	11		3		3	3	4	4		8
	Normal	3	109	6	118		10	10	10	3	99	6	108
Total	7	116	6	129		13	13	13	13	7	103	6	116

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOZETINE - PROTOCOL 20124/035

TABLE No: 75

URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABNORMAL OR NORMAL URINALYSIS VALUE AT EACH EVALUATION TIME AS COMPARED TO PRETREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Rebozetine

Urinalysis test at baseline	Days of treatment							
	1-28 days			29-56 days				
	Absent	Normal	ND	Total	Normal	ND	Total	
SPECIFIC GRAVITY Normal	1	112	2	115	98	7	105	
Total	1	112	2	115	98	7	105	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035

TABLE NO: 75

URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABNORMAL OR NORMAL URINALYSIS VALUE AT EACH EVALUATION TIME AS COMPARED TO PRETREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

Urinalysis test at baseline	Days of treatment					
	1-28 days			29-56 days		
	Normal	ND	Total	Normal	ND	Total
SPECIFIC GRAVITY	104	6	110	94	6	100
Total	104	6	110	94	6	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No: 76

URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABNORMAL OR NORMAL URINALYSIS VALUE AT LAST ASSESSMENT AS COMPARED TO PRETREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Urinalysis test at baseline	Total			Last assessment						
				1-28 days			29-56 days			
	Normal	ND	Total	Normal	Total	ND	Normal	Total	ND	Total
SPECIFIC GRAVITY Normal	110	7	117	12	12		98	7		105
Total	110	7	117	12	12		98	7		105

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No: 76

URINALYSIS: SHIFT TABLE - NUMBER OF PATIENTS WITH ABNORMAL OR NORMAL URINALYSIS VALUE AT LAST ASSESSMENT AS COMPARED TO PRETREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

Urinalysis test at baseline	Total			Last assessment					
				1-28 days			29-56 days		
	Normal	ND	Total	Normal	Total	ND	Normal	Total	ND
SPECIFIC GRAVITY Normal	105	6	111	11	11		94	6	100
Total	105	6	111	11	11		94	6	100

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 77

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY - SHIFF TABLE
NUMBER OF PATIENTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE ACCORDING TO TIME INTERVAL AS COMPARED TO PRE-TREATMENT, BY ASSIGNED TREATMENT

Laboratory test	Assigned treatment																	
	Imipramine									Reboxetine								
	Days of treatment			29-56			1-28			Days of treatment			29-56					
	Low	High	P val	Low	High	P val	Low	High	P val	Low	High	P val	Low	High	P val			
HB	LOW	4		14	7		9	5		7	7		7	7				
	NORMAL	7	112	7	100		8	120	1		3	107	2					
	HIGH					1.080				0.429				0.165				
HT	LOW	21	4		12	10		7	5		4	7						
	NORMAL	6	106	1	9	93		5	118		7	98	3					
	HIGH						1	0.591		1	0.607		1	0.607				
RBC	LOW	23	5		14	8		8	7		5	10						
	NORMAL	7	102		5	97		9	117	1	6	99	4					
	HIGH						2	1	0.260		1	0.595		1	0.247			
PLATELETS	LOW	2	3		4	2		1	3		1	3						
	NORMAL				2	103	5		1	119	5		106	3				
	HIGH						4	3	0.946		4	8	0.574		4	8	0.208	
ESR 1st h	LOW																	
	NORMAL						32	9		32	11		30	10				
	HIGH						9	18	1.000		6	22	0.382		6	17	0.484	
ESR 2nd h	LOW																	
	NORMAL						23	3		19	5		16	3				
	HIGH						6	18	0.508		3	19	0.472		2	16	0.549	

P val : probability from Maxwell's test

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No. : 77

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY - SHIFT TABLE
NUMBER OF PATIENTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE ACCORDING TO TIME INTERVAL AS COMPARED TO PRE-TREATMENT, BY ASSIGNED TREATMENT

Laboratory test	Assigned treatment																							
	Imipramine												Reboxetine											
	Days of treatment						Days of treatment						Days of treatment						Days of treatment					
	1-28		29-56		1-28		29-56		1-28		29-56		1-28		29-56		1-28		29-56		1-28		29-56	
Low	Nor.	High	P val	Low	High	Low	Nor.	High	P val	Low	High	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	
MBC	LOW	6	4		4	4				2	3					3	2							
	NORMAL	4	118	5	107	4				6	124	5				2	111	6						
	HIGH	2	2	0.526	4				0.946	1	2	0.160				2				0.368				
MBC: N	LOW	4	7		5	4				3	4					4	3							
	NORMAL	3	99	10	5	91	5			7	111	3				12	86	4						
	HIGH	8	4	0.402	10	2	0.411			6	2	0.403				4				0.067				
MBC: E	LOW	12	2		9	4				5	4					2	5							
	NORMAL	7	100	2	6	87	5			6	102	4				5	90	4						
	HIGH	7	2	0.062	5	3	0.819			3	3	0.762				1	4			0.912				
MBC: B	LOW	1	1		1	1				1														
	NORMAL	114	6		1	102	6			110	5					1	101	1						
	HIGH	3	0.368		3	0.607				4	1	1.000				3	0.368							
MBC: L	LOW	10	8		10	7				9	9					6	7							
	NORMAL	12	90	2	3	87	3			4	98	7				9	78	8						
	HIGH	8	5	0.111	6	6	0.273			5	5	0.324				4	6	0.453						
MBC: H	LOW	3	6		4	3				4	3					5	2							
	NORMAL	2	100	7	3	84	10			2	97	9				2	81	7						
	HIGH	6	8	0.354	1	8	6	0.903			12	7	0.750			1	12	5	0.387					

P val : probability from Maxwell's test

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RSD

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 77

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY - SHIFT TABLE
NUMBER OF PATIENTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE ACCORDING TO TIME INTERVAL AS COMPARED TO PRE-TREATMENT, BY ASSIGNED TREATMENT

Laboratory test	Assigned treatment																							
	Imipramine												Reboxetine											
	Days of treatment						Days of treatment						Days of treatment						Days of treatment					
	1-28		29-56		1-28		29-56		1-28		29-56		1-28		29-56		1-28		29-56		1-28		29-56	
Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	
CREATININE	1	1			1	1																		
		119	8			109	6							118	4						1	105	5	
		7	6	0.587		4	9	0.497						7	12	0.549					7	8	0.513	
UREA	1	1			1	1																		
	2	73	9		1	66	6					1	65	5								63	3	
		6	5	0.627		6	5	0.607					8	13	0.599						8	7	0.118	
BUN	1	1			1	1																		
	1	26	2			27	2							24	1							20	3	
		3	3	0.905		5	1	0.319					8	2	0.039						8	2	0.227	
URIC ACID	3	3			1	1						4	3									5	2	
	2	102	7		2	92	8					6	97	5							3	87	6	
		8	4	0.875		6	6	0.591				1	4	9	0.446						1	4	8	0.660

P val : probability from Maxwell's test

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 77

LABORATORY TEST: HEMATOLOGY AND BLOOD CHEMISTRY - SHIFT TABLE
NUMBER OF PATIENTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE ACCORDING TO TIME INTERVAL AS COMPARED TO PRE-TREATMENT, BY ASSIGNED TREATMENT

Laboratory test	Assigned treatment																				
	Imipramine									Reboxetine											
	Days of treatment						29-56			1-28			29-56			1-28			29-56		
	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	
TOT. PROTEINS	LOH	6	5		2	7			5	4			1	6							
	NORMAL	7	116	4	3	109	5		7	121	3		2	113	2						
	HIGH	2		0.607	2		0.236		1		7		1		0.403		1		0.311		
ALBUMINE	LOW	4	5		4	4			1	7			1	4							
	NORMAL	11	104	3	11	96			6	109	1		7	90	4						
	HIGH	1	5	0.197	1	5	0.118		4	5	0.391		3	5	0.629						
TOT BILIRUBIN	LOW	2			1	1															
	NORMAL	3	130	3		116	6		2	133	1		2	116	2						
	HIGH			0.202			1	0.030		4	2	0.150		3	2	0.353					
DIR BILIRUBIN	LOW																				
	NORMAL	77	4			68	5			72	2			60	4						
	HIGH	1		0.375			0.069		3	3	1.000		2	3	0.688						

P val : probability from Maxwell's test

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RD

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 77

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY - SHIFF TABLE
NUMBER OF PATIENTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE ACCORDING TO TIME INTERVAL AS COMPARED TO PRE-TREATMENT, BY ASSIGNED TREATMENT

Laboratory test	Assigned treatment																	
	Imipramine									Reboxetine								
	Days of treatment						29-56			1-28			Days of treatment			29-56		
	Low	Nor.	High	P val	Low	High	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	
GLOBULINS ALPHA 1	LOH	10	6		8	7				11	5			12	4			
	NORMAL	6	75	7	3	72	5			5	83	5		3	71	5		
	HIGH	4	5	0.664	2	6	0.236			4	4			1	2	1	0.776	
GLOBULINS ALPHA 2	LOH	3	6		2	7				4	4			2	6			
	NORMAL	6	83	4	3	75	7			2	88	7		5	77	1		
	HIGH	5	6	0.946	2	7	0.112			5	3	0.607		2	6	0.809		
GLOBULINS BETA	LOH	1	3		3	1				3	3			1	2			
	NORMAL	81	11		2	72	9			1	80	9		1	69	9		
	HIGH	1	10	0.603	8	8	0.822			7	13	0.535		6	11	0.627		
GLOBULINS GAMMA	LOH	6	6		5	6				6	6			7	4			
	NORMAL	4	88	5	5	78	5			6	80	7		2	75	3		
	HIGH	2	2	0.430	1	3	0.252			4	4	0.664		3	5	0.717		

P val : probability from Maxwell's test

6 23 51

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 77

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY - SHIFT TABLE
NUMBER OF PATIENTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE ACCORDING TO TIME INTERVAL AS COMPARED TO PRE-TREATMENT, BY ASSIGNED TREATMENT

Laboratory test	Assigned treatment																		
	Imipramine									Reboxetine									
	Days of treatment						1-28			29-56			1-28			29-56			
	Low	Nor.	High	P val	Low	High	P val	Low	High	P val	Low	High	P val	Low	High	P val	Low	High	P val
SCOT	LOW	1			2			1	1										
	NORMAL	126	4		111	6		128	7		1	114	4						
	HIGH	5		0.574	4		0.301	5		1	0.513	4		1	0.607				
SGPT	LOW																		
	NORMAL	1	112	6	1	100	7		111	7		96	5						
	HIGH	3	2	0.368	5		0.513	1	6	0.870	4	2	0.348						
GAMMA GT	LOW	1			1														
	NORMAL	1	109	10	93	12		110	8		96	6							
	HIGH	10	6	0.607	7	6	0.314	3	13	0.227	5	9	1.000						
LDH	LOW	4	1		2	2		2	3		2	2							
	NORMAL	93	5		1	88	2	1	91	5	1	82	5						
	HIGH	7	4	0.513	6	3	0.311	2	5	0.319	2	3	0.445						
ALK. PHOSPH.	LOW	2			1			1	2		3								
	NORMAL	116	7		1	100	13		118	5		105	5						
	HIGH	4	5	0.549	4	4	0.056	4	7	0.368	5	7	0.223						

P val : probability from Maxwell's test

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 77

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY - SHEET TABLE
NUMBER OF PATIENTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE ACCORDING TO TIME INTERVAL AS COMPARED TO PRE-TREATMENT, BY ASSIGNED TREATMENT

Laboratory test	Assigned treatment																			
	Imipramine									Reboxetine										
	Days of treatment									Days of treatment										
	1-28			29-56			1-28			29-56			1-28			29-56				
Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	
TOT. CHOLEST.	2				2					1				1				1		
	2	63	15		2	60	9		1	58	13							50	16	
		10	46	0.607		11	40	0.905		16	49	0.856						12	43	0.456
TRIGLYCERIDES									1											
	1	104	13						98	9								88	11	
		4	12	0.056		3	10	0.004		14	13	0.405						8	13	0.479
GLUCOSE		1							1											
	1	89	7		1	80	10		2	94	12							2	77	16
		18	12	0.089		14	14	0.717		14	13	0.898						15	8	0.890

P val : probability from Maxwell's test

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 77

LABORATORY TEST: HAEMATOLOGY AND BLOOD CHEMISTRY - SHIFT TABLE
NUMBER OF PATIENTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE ACCORDING TO TIME INTERVAL AS COMPARED TO PRE-TREATMENT, BY ASSIGNED TREATMENT

Laboratory test	Assigned treatment																		
	Imipramine									Reboxetine									
	Days of treatment									Days of treatment									
	1-28			29-56			1-28			29-56			1-28			29-56			
Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val	Low	Nor.	High	P val
Na+	LOH	3	3		1	4				5				2	3				
	NORMAL	17	108	2	6	106	4	8	122	2	5	111	2						
	HIGH	4		0.005	3	2	0.762	4	2	0.507		2	2	0.779					
CL-	LOH	2	4		1	3	1			6				1	5				
	NORMAL	10	101		6	93		8	97	2		86	1						
	HIGH	5		0.023	4	0.368		5	2	0.456	1	4	2	0.245					
K+	LOH	2	4		1	4				7				1	7				
	NORMAL	6	116	7	2	113	4	5	124	3		110	2						
	HIGH	1		0.086	1	0.291		3	0.846		2	1	0.449						
Ca++	LOH	1	3			3				6				1	5				
	NORMAL	5	116	3	4	110		3	126	2		106	7						
	HIGH	4		0.725	2	5	0.028	1	0.513		1	1	0.100						
PO4--	LOH	10	6		7	8				10				9	10				
	NORMAL	7	98	1	5	87	2	2	98	7		80	7						
	HIGH	4		0.391	2	2	0.707	3	1	0.031	4	4	0.187						

P val : probability from Maxwell's test

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 78

LABORATORY TEST: NUMBER AND PERCENTAGE OF PATIENTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE

Laboratory test / Assigned treatment	Screen	Days of treatment					
		1-28		29-56			
		No	%	No	%	No	%
HB	Eval.	145	100.0	141	100.0	128	100.0
	down	2	1.4	5	3.5	3	2.3
HT	Eval.	142	100.0	139	100.0	125	100.0
	down	3	2.1	4	2.9	4	3.2
RBC	Eval.	140	100.0	137	100.0	120	100.0
	down	1	0.7				
RBC	Eval.	145	100.0	140	100.0	127	100.0
	down	3	2.1	6	4.3	4	3.1
PLATELETS	Eval.	145	100.0	143	100.0	125	100.0
	down	1	0.7				
PLATELETS	Eval.	141	100.0	136	100.0	123	100.0
	down			1	0.7		
PLATELETS	up	1	0.7	3	2.2	1	0.8
	Eval.	144	100.0	141	100.0	125	100.0
PLATELETS	down			1	0.7		
	up	2	1.4	4	2.8	2	1.6
HBC	Eval.	145	100.0	141	100.0	128	100.0
	down					1	0.8
HBC	up			2	1.4	2	1.6
	Eval.	146	100.0	143	100.0	126	100.0
HBC: N	down					1	0.8
	up	1	0.7				
HBC: N	Eval.	139	100.0	135	100.0	122	100.0

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 78

LABORATORY TEST: NUMBER AND PERCENTAGE OF PATIENTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE

Laboratory test / Assigned treatment	Screen						Days of treatment					
	1-28			29-56			1-28			29-56		
	No	Z	%	No	Z	%	No	Z	%	No	Z	%
MBC: N	Imipramine	down										
		up										
	Reboxetine	Eval.	139	100.0	136	100.0	117	100.0				
		down										
MBC: E		up	1	0.7								
	Imipramine	Eval.	156	100.0	152	100.0	119	100.0				
		up	3	2.2	1	0.8	4	3.4				
	Reboxetine	Eval.	131	100.0	127	100.0	111	100.0				
MBC: B		up										
	Imipramine	Eval.	128	100.0	125	100.0	114	100.0				
		up	2	1.6	6	4.8	4	3.5				
	Reboxetine	Eval.	123	100.0	121	100.0	106	100.0				
MBC: L		up	3	2.4	6	5.0	1	0.9				
	Imipramine	Eval.	139	100.0	135	100.0	122	100.0				
		down	2	1.4	7	5.2	6	4.9				
	Reboxetine	Eval.	141	100.0	137	100.0	118	100.0				
MBC: H		down	6	4.3	4	2.9	2	1.7				
	Imipramine	Eval.	136	100.0	132	100.0	120	100.0				
		up	7	5.1	3	2.3	4	3.3				
	Reboxetine	Eval.	138	100.0	134	100.0	115	100.0				
	up	5	3.6	2	1.5	3	2.6					

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 78

LABORATORY TEST: NUMBER AND PERCENTAGE OF PATIENTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE

Laboratory test / Assigned treatment	Screen	Days of treatment					
		1-28		29-56			
		No	X	No	Z	No	Z
CREATININE	Eval.	145	100.0	142	100.0	130	100.0
	up			1	0.7		
UREA	Eval.	144	100.0	141	100.0	126	100.0
	up					2	1.6
URIC ACID	Eval.	99	100.0	96	100.0	85	100.0
	up	1	1.0	2	2.1	1	1.2
ALBUMINE	Eval.	99	100.0	94	100.0	83	100.0
	up	1	1.0	4	4.3	2	2.4
DIR BILIRUBIN	Eval.	133	100.0	129	100.0	118	100.0
	up	3	2.3	1	0.8		
SGPT	Eval.	133	100.0	129	100.0	116	100.0
	up	4	3.0	2	1.6	2	1.7
SCOT	Eval.	137	100.0	133	100.0	121	100.0
	down					2	1.7
DIR BILIRUBIN	Eval.	84	100.0	80	100.0	69	100.0
	up	1	1.2	1	1.2	2	2.9
SGPT	Eval.	140	100.0	137	100.0	123	100.0
	up	1	0.7	1	0.7	2	1.6
SGPT	Eval.	145	100.0	143	100.0	124	100.0
	up			3	2.1		
SGPT	Eval.	125	100.0	124	100.0	113	100.0
	up	1	0.8	1	0.8	1	0.9
SGPT	Eval.	126	100.0	125	100.0	109	100.0
	up						

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 78

LABORATORY TEST: NUMBER AND PERCENTAGE OF PATIENTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE

Laboratory test / Assigned treatment	Screen						Days of treatment					
	1-28		29-56		1-28		29-56		1-28		29-56	
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z
SGPT	Reboxetine	up	2	1.6	2	1.6	2	1.6	2	1.8	2	1.8
	Imipramine	Eval.	139	100.0	137	100.0	119	100.0	119	100.0	119	100.0
GAMMA GT	Reboxetine	up	1	0.7	4	2.9	2	1.7	2	1.7	2	1.7
	Imipramine	Eval.	136	100.0	134	100.0	116	100.0	116	100.0	116	100.0
LDH	Reboxetine	up	1	0.7	2	1.5	1	0.9	1	0.9	1	0.9
	Imipramine	Eval.	118	100.0	114	100.0	104	100.0	104	100.0	104	100.0
ALK. PHOSPH.	Reboxetine	up	116	100.0	109	100.0	97	100.0	97	100.0	97	100.0
	Imipramine	Eval.	141	100.0	137	100.0	125	100.0	125	100.0	125	100.0
GLOBULINS ALPHA 1	Reboxetine	up	1	0.7	1	0.7	1	0.8	1	0.8	1	0.8
	Imipramine	Eval.	115	100.0	113	100.0	103	100.0	103	100.0	103	100.0
GLOBULINS BETA	Reboxetine	down	6	5.2	6	5.3	5	4.9	5	4.9	5	4.9
	Imipramine	up	3	2.6	6	5.3	7	6.8	7	6.8	7	6.8
GLOBULINS GAMMA	Reboxetine	Eval.	114	100.0	113	100.0	99	100.0	99	100.0	99	100.0
	Imipramine	down	6	5.3	3	2.7	3	3.0	3	3.0	3	3.0
GLOBULINS ALPHA 2	Reboxetine	up	2	1.8	2	1.8	3	3.0	3	3.0	3	3.0
	Imipramine	Eval.	115	100.0	113	100.0	103	100.0	103	100.0	103	100.0
GLOBULINS BETA	Reboxetine	down	1	0.9	1	0.9	3	2.9	3	2.9	3	2.9
	Imipramine	up	1	0.9	1	0.9	3	2.9	3	2.9	3	2.9
GLOBULINS GAMMA	Reboxetine	Eval.	144	100.0	113	100.0	99	100.0	99	100.0	99	100.0
	Imipramine	up	3	2.6	3	2.7	3	3.0	3	3.0	3	3.0
GLOBULINS ALPHA 1	Reboxetine	Eval.	115	100.0	113	100.0	103	100.0	103	100.0	103	100.0
	Imipramine	down	6	5.3	3	2.7	3	3.0	3	3.0	3	3.0

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE NO.: 78

LABORATORY TEST: NUMBER AND PERCENTAGE OF PATIENTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE

Laboratory test / Assigned treatment	Days of treatment									
	Screen			1-28			29-56			
	No	Z	%	No	Z	%	No	Z	%	
GLOBULINS GAMMA	Imipramine	down	1	0.9					1	1.0
		up	1	0.9	2	1.8	2	1.9		
	Reboxetine	Eval.	114	100.0	113	100.0	99	100.0		
		down			1	0.9	3	3.0		
	up			1	0.9					
TOT. CHOLEST.	Imipramine	Eval.	142	100.0	138	100.0	124	100.0		
		up	6	4.2	8	5.8	8	6.5		
	Reboxetine	Eval.	143	100.0	138	100.0	123	100.0		
		up	9	6.3	6	4.3	5	4.1		
TRIGLYCERIDES	Imipramine	Eval.	138	100.0	134	100.0	121	100.0		
		up	7	5.1	10	7.5	10	8.3		
	Reboxetine	Eval.	141	100.0	135	100.0	121	100.0		
		up	7	5.0	7	5.2	11	9.1		
GLUCOSE	Imipramine	Eval.	135	100.0	128	100.0	120	100.0		
		up	11	8.1	6	4.7	5	4.2		
	Reboxetine	Eval.	143	100.0	138	100.0	121	100.0		
		up	5	3.5	9	6.5	8	6.6		
CL-	Imipramine	Eval.	123	100.0	122	100.0	108	100.0		
		down	1	0.8	1	0.8				
	up	1	0.8							
K+	Imipramine	Eval.	140	100.0	136	100.0	125	100.0		
		up			2	1.5	1	0.8		
	Reboxetine	Eval.	145	100.0	143	100.0	126	100.0		

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 76

LABORATORY TEST: NUMBER AND PERCENTAGE OF PATIENTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE

Laboratory test / Assigned treatment	Days of treatment											
	Screen			1-28			29-56					
	No	Z	%	No	Z	%	No	Z	%			
K+	down											
	up	1	0.7									1.6
Ca++	Eval.	144	100.0	140	100.0	124	100.0	124	100.0			100.0
	down	1	0.7									
PO4--	Eval.	130	100.0	126	100.0	113	100.0	113	100.0			100.0
	down	5	3.8	4	3.2	3	2.7	3	2.7			2.7
	up	3	2.3									2.7
	Eval.	134	100.0	130	100.0	116	100.0	116	100.0			100.0
Reboxetine	down	5	3.7	1	0.8	1	0.9	1	0.9			0.9
	up	2	1.5	1	0.8	4	3.4	4	3.4			3.4

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035

TABLE No: 79

BLOOD PRESSURE AND HEART RATE: SUMMARY STATISTICS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Vital signs	LYING														STANDING																					
	Assessment time table														Assessment time table																					
	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56																		
S.B.P.	Evaluated	170	169	162	158	149	138	130	129	125	169	168	161	157	147	130	128	124	170	169	162	158	149	138	130	129	125	169	168	161	157	147	130	128	124	
	Mean	142.5	139.4	138.2	138.1	139.1	138.3	139.0	138.0	138.9	138.4	134.9	134.0	135.0	135.4	135.6	134.6	136.6	142.5	139.4	138.2	138.1	139.1	138.3	139.0	138.0	138.9	138.4	134.9	134.0	135.0	135.4	135.6	134.6	136.6	
	STD	18.7	17.3	17.3	16.2	16.3	16.7	15.8	15.3	13.8	18.1	17.1	17.2	15.6	16.5	17.4	16.2	14.9	18.7	17.3	17.3	16.2	16.3	16.7	15.8	15.3	13.8	18.1	17.1	17.2	15.6	16.5	17.4	16.2	14.9	
	Median	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	135.0	130.0	135.0	135.0	135.0	135.0	136.5	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	135.0	130.0	135.0	135.0	135.0	135.0	136.5	
	Min	105.0	100.0	100.0	105.0	100.0	100.0	100.0	90.0	90.0	100.0	90.0	70.0	100.0	100.0	100.0	80.0	100.0	105.0	100.0	100.0	105.0	100.0	100.0	90.0	90.0	100.0	100.0	100.0	100.0	100.0	100.0	95.0	80.0	100.0	
Max	200.0	200.0	190.0	190.0	190.0	200.0	190.0	175.0	180.0	200.0	192.0	190.0	180.0	180.0	210.0	180.0	180.0	200.0	200.0	190.0	190.0	190.0	200.0	192.0	190.0	180.0	180.0	210.0	180.0	180.0	180.0	180.0	180.0	180.0		
D.B.P.	Evaluated	170	169	162	158	149	138	130	129	125	169	167	161	157	147	136	129	124	170	169	162	158	149	138	130	129	125	169	167	161	157	147	136	129	124	
	Mean	81.5	81.5	81.5	80.9	81.6	81.1	80.8	80.0	81.6	80.5	80.1	81.1	80.0	80.6	80.7	79.5	81.4	81.5	81.5	81.5	80.9	81.6	81.1	80.8	80.0	81.6	80.5	80.1	81.1	80.0	80.6	80.7	79.5	79.3	81.4
	STD	10.4	10.3	10.2	11.1	10.1	10.4	9.7	10.2	8.8	10.9	11.0	10.5	10.4	10.7	10.0	9.6	9.6	10.4	10.3	10.2	11.1	10.1	10.4	9.7	10.2	8.8	10.9	11.0	10.5	10.4	10.7	10.0	9.6	10.1	9.6
	Median	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0
	Min	60.0	60.0	60.0	60.0	60.0	60.0	60.0	55.0	60.0	60.0	50.0	50.0	50.0	50.0	50.0	50.0	50.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0
Max	130.0	120.0	110.0	123.0	120.0	120.0	118.0	110.0	105.0	110.0	126.0	120.0	120.0	120.0	124.0	110.0	112.0	130.0	120.0	110.0	123.0	120.0	120.0	118.0	110.0	105.0	110.0	126.0	120.0	120.0	124.0	110.0	110.0	110.0	112.0	
Heart Rate	Evaluated	169	166	161	156	148	138	132	130	126	166	163	159	154	145	137	131	124	169	166	161	156	148	138	132	130	126	166	163	159	154	145	137	131	124	
	Mean	77.3	79.2	78.9	77.6	78.1	78.3	78.6	78.1	79.0	80.7	82.3	82.2	81.0	81.0	81.5	81.2	82.2	77.3	79.2	78.9	77.6	78.1	78.3	78.6	78.1	79.0	80.7	82.3	82.2	81.0	81.0	81.5	81.9	81.2	82.2
	STD	9.7	10.6	10.7	9.6	10.9	10.0	12.2	9.5	10.7	9.9	10.1	10.9	9.9	11.2	10.3	11.8	10.5	9.7	10.6	10.7	9.6	10.9	10.0	12.2	9.5	10.7	9.9	10.1	10.9	11.2	10.3	11.8	10.2	10.5	10.5
	Median	76.0	77.5	76.0	76.0	79.0	77.0	76.0	78.0	79.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	76.0	77.5	76.0	76.0	79.0	77.0	76.0	78.0	79.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0
	Min	54.0	60.0	56.0	60.0	51.0	58.0	58.0	60.0	52.0	60.0	60.0	60.0	60.0	55.0	58.0	62.0	52.0	54.0	60.0	56.0	60.0	51.0	58.0	58.0	60.0	52.0	60.0	60.0	60.0	60.0	55.0	58.0	62.0	52.0	52.0
Max	110.0	116.0	116.0	112.0	116.0	120.0	120.0	162.0	108.0	102.0	112.0	116.0	120.0	162.0	120.0	120.0	108.0	110.0	116.0	116.0	112.0	116.0	120.0	120.0	162.0	108.0	102.0	112.0	116.0	120.0	120.0	120.0	120.0	116.0	108.0	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBORETTINE - PROTOCOL 20124/035

TABLE No: 79

BLOOD PRESSURE AND HEART RATE: SUMMARY STATISTICS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

Vital signs	LYING																		STANDING																	
	Assessment time table									Assessment time table									Assessment time table									Assessment time table								
	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56
S.B.P.	Evaluated	170	169	156	144	135	129	126	125	170	168	154	143	135	132	129	126	124	170	168	154	143	135	132	129	126	124	170	168	154	143	135	132	129	126	124
	Mean	142.3	139.5	139.0	138.0	138.0	138.8	139.1	137.8	133.9	133.2	135.3	134.5	132.6	134.6	134.1	134.8	134.8	133.9	133.2	135.3	134.5	132.6	134.6	134.1	134.8	134.8	133.9	133.2	135.3	134.5	132.6	134.6	134.1	134.8	134.8
	STD	16.6	18.0	18.4	18.3	18.0	17.3	17.3	18.6	17.4	17.7	17.7	17.9	20.6	17.3	17.0	18.9	17.5	17.4	17.7	17.7	17.9	20.6	17.3	17.0	18.9	17.5	17.4	17.7	17.7	17.9	20.6	17.3	17.0	18.9	17.5
	Median	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0	140.0
	Min	95.0	90.0	100.0	90.0	90.0	95.0	85.0	90.0	90.0	90.0	90.0	90.0	90.0	90.0	90.0	90.0	90.0	90.0	90.0	90.0	90.0	90.0	90.0	90.0	90.0	90.0	90.0	90.0	90.0	90.0	90.0	90.0	90.0	90.0	90.0
Max	200.0	200.0	220.0	200.0	190.0	195.0	200.0	220.0	220.0	220.0	180.0	190.0	180.0	195.0	170.0	180.0	190.0	220.0	220.0	180.0	190.0	180.0	195.0	170.0	180.0	190.0	220.0	220.0	180.0	190.0	180.0	195.0	170.0	180.0	190.0	
D.B.P.	Evaluated	170	169	156	144	135	129	126	125	170	168	154	143	135	132	129	126	124	170	168	154	143	135	132	129	126	124	170	168	154	143	135	132	129	126	124
	Mean	81.4	80.8	81.7	82.5	81.2	81.1	81.0	81.0	81.4	79.6	81.2	81.1	80.8	81.2	80.3	81.0	81.0	81.4	79.6	81.2	81.1	80.8	81.2	80.3	81.0	81.0	81.4	79.6	81.2	81.1	80.8	81.2	80.3	81.0	81.0
	STD	10.1	11.0	10.3	9.2	10.1	9.7	9.7	9.0	9.6	10.7	11.0	10.3	10.8	9.6	10.4	10.3	9.5	9.6	10.7	11.0	10.3	10.8	9.6	10.4	10.3	9.5	9.6	10.7	11.0	10.3	10.8	9.6	10.4	10.3	9.5
	Median	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0
	Min	55.0	50.0	60.0	60.0	50.0	55.0	40.0	50.0	50.0	50.0	50.0	50.0	50.0	50.0	50.0	50.0	50.0	50.0	50.0	50.0	50.0	50.0	50.0	50.0	50.0	50.0	50.0	50.0	50.0	50.0	50.0	50.0	50.0	50.0	50.0
Max	120.0	110.0	120.0	120.0	112.0	120.0	102.0	104.0	108.0	100.0	130.0	120.0	110.0	110.0	118.0	110.0	102.0	108.0	100.0	130.0	120.0	110.0	110.0	118.0	110.0	102.0	108.0	100.0	130.0	120.0	110.0	110.0	118.0	110.0	102.0	
Heart Rate	Evaluated	166	165	154	143	135	128	126	125	166	164	151	142	135	132	128	125	124	166	164	151	142	135	132	128	125	124	166	164	151	142	135	132	128	125	124
	Mean	77.2	78.6	78.5	77.4	78.3	77.9	77.3	77.5	77.4	77.5	77.3	77.5	77.4	77.4	77.5	77.5	77.5	77.4	77.5	77.3	77.5	77.4	77.4	77.5	77.5	77.5	77.4	77.5	77.3	77.5	77.4	77.4	77.5	77.5	77.5
	STD	10.2	10.0	9.1	9.3	10.5	9.4	9.7	8.6	9.5	10.2	9.0	9.5	9.6	9.7	10.2	9.8	9.2	9.5	10.2	9.0	9.5	9.6	9.7	10.2	9.8	9.2	9.5	10.2	9.0	9.5	9.6	9.7	10.2	9.8	9.2
	Median	76.0	78.0	80.0	78.0	78.0	78.0	76.0	77.5	76.0	80.0	82.0	81.0	80.0	80.0	80.0	80.0	80.0	76.0	80.0	82.0	81.0	80.0	80.0	80.0	80.0	80.0	76.0	80.0	82.0	81.0	80.0	80.0	80.0	80.0	80.0
	Min	52.0	60.0	56.0	52.0	58.0	52.0	48.0	56.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0
Max	120.0	120.0	110.0	104.0	120.0	116.0	100.0	100.0	118.0	114.0	120.0	110.0	100.0	116.0	100.0	112.0	104.0	118.0	114.0	120.0	110.0	100.0	116.0	100.0	112.0	104.0	118.0	114.0	120.0	110.0	100.0	116.0	100.0	112.0	104.0	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No: 80

BLOOD PRESSURE AND HEART RATE: SUMMARY STATISTICS ON CHANGES FROM BASELINE OBSERVED DURING TREATMENT ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Vital signs	LYING														STANDING																			
	Assessment time table														Assessment time table																			
	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56										
S.B.P.	Evaluated	169	162	158	149	138	130	129	125	166	161	157	147	137	130	124	169	162	158	149	138	130	129	125	166	161	157	147	137	130	124			
	Mean	-3.1	-3.8	-3.9	-2.7	-3.4	-2.5	-3.8	-2.8	-3.5	-4.1	-3.5	-3.2	-2.2	-2.8	-3.9	-1.8	-3.1	-3.8	-3.9	-2.7	-3.4	-2.5	-3.8	-2.8	-3.5	-4.1	-3.5	-3.2	-2.2	-2.8	-3.9	-1.8	
	STD	15.7	17.5	16.2	16.6	18.4	16.4	17.0	17.0	17.0	14.6	15.2	15.5	17.6	18.4	17.1	15.1	15.7	17.5	16.2	16.6	18.4	16.4	17.0	17.0	14.6	15.2	15.5	17.6	18.4	17.1	16.2	15.1	
	Median	0.0	0.0	-2.0	0.0	-2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.0	0.0	0.0	0.0	0.0	0.0	-2.0	0.0	-2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	Min	-75.0	-50.0	-70.0	-60.0	-60.0	-60.0	-70.0	-60.0	-60.0	-50.0	-60.0	-60.0	-60.0	-50.0	-70.0	-55.0	-75.0	-50.0	-70.0	-60.0	-60.0	-60.0	-70.0	-60.0	-60.0	-60.0	-60.0	-60.0	-50.0	-70.0	-70.0	-55.0	
D.B.P.	Evaluated	50.0	45.0	45.0	50.0	70.0	60.0	30.0	40.0	40.0	35.0	40.0	50.0	80.0	45.0	35.0	50.0	45.0	45.0	50.0	70.0	60.0	30.0	40.0	40.0	35.0	40.0	50.0	80.0	45.0	30.0	35.0		
	Mean	0.1	0.1	-0.7	-0.0	-0.6	-0.5	-1.8	-0.1	-0.3	0.5	-0.9	-0.2	0.3	-0.7	-1.4	0.8	0.1	0.1	-0.7	-0.0	-0.6	-0.5	-1.8	-0.1	-0.3	0.5	-0.9	-0.2	0.3	-0.7	-1.4	0.8	
	STD	10.7	11.6	12.1	11.2	12.2	10.5	11.1	11.1	10.1	10.2	10.9	11.5	11.4	9.9	10.4	10.0	10.7	11.6	12.1	11.2	12.2	10.5	11.1	11.1	10.1	10.2	10.9	11.5	11.4	9.9	10.4	10.0	
	Median	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
	Min	-60.0	-50.0	-50.0	-30.0	-60.0	-30.0	-40.0	-40.0	-40.0	-35.0	-45.0	-30.0	-30.0	-30.0	-30.0	-30.0	-60.0	-50.0	-50.0	-30.0	-60.0	-30.0	-40.0	-40.0	-40.0	-35.0	-45.0	-30.0	-30.0	-30.0	-30.0	-30.0	
Heart Rate	Evaluated	166	161	156	148	138	132	130	126	163	159	154	145	137	131	124	166	161	156	148	138	132	130	126	163	159	154	145	137	131	124			
	Mean	2.0	1.7	0.7	1.1	1.7	1.7	1.1	2.0	1.7	1.4	0.2	0.3	1.2	1.7	0.8	1.9	2.0	1.7	0.7	1.1	1.7	1.7	1.1	2.0	1.7	1.4	0.2	0.3	1.2	1.7	0.8	1.9	
	STD	9.0	9.8	9.5	10.5	9.6	11.8	10.3	10.9	8.8	10.6	10.8	11.1	10.7	11.7	11.5	11.1	9.0	9.8	9.5	10.5	9.6	11.8	10.3	10.9	8.8	10.6	10.8	11.1	10.7	11.7	11.5	11.1	
	Median	0.0	1.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	1.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	
	Min	-20.0	-28.0	-32.0	-30.0	-28.0	-24.0	-24.0	-24.0	-26.0	-24.0	-26.0	-24.0	-24.0	-26.0	-24.0	-25.0	-20.0	-28.0	-32.0	-30.0	-28.0	-24.0	-24.0	-24.0	-26.0	-24.0	-26.0	-24.0	-24.0	-26.0	-24.0	-25.0	
Max	39.0	40.0	28.0	40.0	40.0	82.0	28.0	28.0	32.0	30.0	47.0	30.0	34.0	40.0	70.0	36.0	39.0	40.0	28.0	40.0	40.0	82.0	28.0	28.0	32.0	30.0	47.0	30.0	34.0	40.0	70.0	36.0		

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No. 80
BLOOD PRESSURE AND HEART RATE: SUMMARY STATISTICS ON CHANGES FROM BASELINE OBSERVED DURING TREATMENT
ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Vital signs		LIVING														STANDING																																		
		Assessment time table							Assessment time table							Assessment time table							Assessment time table																											
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56																	
S.B.P.	Evaluated	169	156	144	135	133	129	126	125	168	154	143	135	132	129	126	124	169	156	144	135	133	129	126	125	168	154	143	135	132	129	126	124	169	156	144	135	133	129	126	125	168	154	143	135	132	129	126	124	
	Mean	-2.8	-2.8	-3.8	-4.9	-4.7	-4.0	-4.2	-5.1	-5.3	-4.0	-5.6	-7.4	-5.0	-5.7	-5.3	-5.4	-2.8	-2.8	-3.8	-4.9	-4.7	-4.0	-4.2	-5.1	-5.3	-4.0	-5.6	-7.4	-5.0	-5.7	-5.3	-5.4	-2.8	-2.8	-3.8	-4.9	-4.7	-4.0	-4.2	-5.1	-5.3	-4.0	-5.6	-7.4	-5.0	-5.7	-5.3	-5.4	
	STD	15.3	15.4	16.0	15.3	16.5	16.0	15.9	16.2	15.5	15.2	15.7	17.5	18.8	17.3	17.8	16.9	15.3	15.4	16.0	15.3	16.5	16.0	15.9	16.2	15.5	15.2	15.7	17.5	18.8	17.3	17.8	16.9	15.3	15.4	16.0	15.3	16.5	16.0	15.9	16.2	15.5	15.2	15.7	17.5	18.8	17.3	17.8	16.9	
	Median	0.0	-2.0	0.0	0.0	0.0	-5.0	0.0	0.0	0.0	0.0	-5.0	0.0	0.0	0.0	-5.0	-3.5	0.0	-2.0	0.0	0.0	0.0	-5.0	0.0	0.0	0.0	-5.0	0.0	0.0	0.0	-5.0	-3.5	0.0	-2.0	0.0	0.0	0.0	-5.0	0.0	0.0	0.0	-5.0	0.0	0.0	0.0	-5.0	-3.5			
	Min	-70.0	-45.0	-60.0	-50.0	-70.0	-70.0	-70.0	-70.0	-70.0	-60.0	-60.0	-70.0	-95.0	-95.0	-95.0	-95.0	-70.0	-45.0	-60.0	-50.0	-70.0	-70.0	-70.0	-70.0	-60.0	-60.0	-70.0	-95.0	-95.0	-95.0	-95.0	-95.0	-70.0	-45.0	-60.0	-50.0	-70.0	-70.0	-70.0	-70.0	-60.0	-60.0	-70.0	-95.0	-95.0	-95.0	-95.0	-95.0	
Max	48.0	80.0	60.0	30.0	45.0	30.0	40.0	30.0	30.0	30.0	30.0	40.0	40.0	40.0	40.0	35.0	48.0	80.0	60.0	30.0	45.0	30.0	40.0	30.0	30.0	30.0	30.0	40.0	40.0	40.0	40.0	35.0	48.0	80.0	60.0	30.0	45.0	30.0	40.0	30.0	30.0	30.0	30.0	40.0	40.0	40.0	40.0	35.0		
D.B.P.	Evaluated	169	156	144	135	133	129	126	125	168	154	143	135	132	129	126	124	169	156	144	135	133	129	126	125	168	154	143	135	132	129	126	124	169	156	144	135	133	129	126	125	168	154	143	135	132	129	126	124	
	Mean	-0.5	1.0	1.5	-0.1	-0.2	-0.3	-0.7	-0.2	-1.8	0.1	-0.7	-1.0	-0.3	-1.1	-1.3	-0.8	-0.5	1.0	1.5	-0.1	-0.2	-0.3	-0.7	-0.2	-1.8	0.1	-0.7	-1.0	-0.3	-1.1	-1.3	-0.8	-0.5	1.0	1.5	-0.1	-0.2	-0.3	-0.7	-0.2	-1.8	0.1	-0.7	-1.0	-0.3	-1.1	-1.3	-0.8	
	STD	10.4	9.4	9.8	9.2	10.9	10.4	9.9	9.6	9.8	9.6	9.8	10.1	10.8	10.4	11.3	10.5	10.4	9.4	9.8	9.2	10.9	10.4	9.9	9.6	9.8	9.6	9.8	10.1	10.8	10.4	11.3	10.5	10.4	9.4	9.8	9.2	10.9	10.4	9.9	9.6	9.8	9.6	9.8	10.1	10.8	10.4	11.3	10.5	
	Median	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	Min	-35.0	-30.0	-40.0	-30.0	-36.0	-42.0	-45.0	-45.0	-45.0	-30.0	-30.0	-32.0	-30.0	-35.0	-30.0	-45.0	-35.0	-30.0	-40.0	-30.0	-36.0	-42.0	-45.0	-45.0	-45.0	-30.0	-30.0	-32.0	-30.0	-35.0	-30.0	-45.0	-35.0	-30.0	-40.0	-30.0	-36.0	-42.0	-45.0	-45.0	-45.0	-30.0	-30.0	-32.0	-30.0	-35.0	-30.0	-45.0	
Max	30.0	40.0	35.0	20.0	40.0	40.0	30.0	20.0	30.0	25.0	30.0	30.0	25.0	25.0	30.0	24.0	30.0	40.0	35.0	20.0	40.0	40.0	30.0	20.0	30.0	25.0	30.0	30.0	25.0	25.0	30.0	24.0	30.0	40.0	35.0	20.0	40.0	40.0	30.0	20.0	30.0	25.0	30.0	30.0	25.0	25.0	30.0	24.0		
Heart Rate	Evaluated	165	154	143	135	133	128	126	125	164	151	142	135	132	128	124	165	154	143	135	133	128	126	125	164	151	142	135	132	128	124	165	154	143	135	133	128	126	125	164	151	142	135	132	128	124				
	Mean	1.4	1.6	0.7	1.8	1.5	0.8	1.2	0.8	0.2	1.5	0.5	0.9	1.3	0.3	0.9	0.5	1.4	1.6	0.7	1.8	1.5	0.8	1.2	0.8	0.2	1.5	0.5	0.9	1.3	0.3	0.9	0.5	1.4	1.6	0.7	1.8	1.5	0.8	1.2	0.8	0.2	1.5	0.5	0.9	1.3	0.3	0.9	0.5	
	STD	9.9	10.1	9.2	9.8	9.3	9.0	9.4	9.0	8.3	8.5	9.4	9.6	9.4	10.0	10.2	8.9	9.9	10.1	9.2	9.8	9.3	9.0	9.4	9.0	8.3	8.5	9.4	9.6	9.4	10.0	10.2	8.9	9.9	10.1	9.2	9.8	9.3	9.0	9.4	9.0	8.3	8.5	9.4	9.6	9.4	10.0	10.2	8.9	
	Median	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
	Min	-32.0	-36.0	-24.0	-32.0	-32.0	-32.0	-36.0	-36.0	-28.0	-30.0	-26.0	-34.0	-34.0	-34.0	-34.0	-30.0	-32.0	-36.0	-24.0	-32.0	-32.0	-32.0	-36.0	-36.0	-28.0	-30.0	-26.0	-34.0	-34.0	-34.0	-30.0	-32.0	-36.0	-24.0	-32.0	-32.0	-32.0	-36.0	-36.0	-28.0	-30.0	-26.0	-34.0	-34.0	-34.0	-30.0			
Max	44.0	44.0	30.0	34.0	40.0	22.0	20.0	26.0	26.0	32.0	32.0	28.0	20.0	20.0	32.0	24.0	44.0	44.0	30.0	34.0	40.0	22.0	20.0	26.0	26.0	32.0	32.0	28.0	20.0	20.0	32.0	24.0	44.0	44.0	30.0	34.0	40.0	22.0	20.0	26.0	26.0	32.0	32.0	28.0	20.0	20.0	32.0	24.0		

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 2D124/035
 TABLE No: 81
 BLOOD PRESSURE AND HEART RATE: NUMBER AND PERCENTAGE OF PATIENTS WITH DECREASE OR INCREASE VS BASELINE OF CLINICAL RELEVANCE
 ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

Vital signs	LYING														STANDING													
	Assessment time table														Assessment time table													
	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56				
S.B.P.	Evaluated	No	169	162	158	149	138	130	129	125	168	161	157	147	137	130	128	124										
	Decrease (1)	No	3	10	5	5	6	3	4	5	6	8	7	7	8	2	5	5										
	Z		1.8	6.2	3.2	3.4	4.3	2.3	3.1	4.0	3.6	5.0	4.5	4.8	5.8	1.5	3.9	4.0										
D.B.P.	Increase (2)	No	3	4	3	4	1	3	5	4	4	1	4	4	3	2	2	1										
	Z		1.8	2.5	1.9	2.7	0.7	2.3	3.9	3.2	2.4	0.6	2.5	2.7	2.2	1.5	1.6	0.8										
	Evaluated	No	169	162	158	149	138	130	129	125	167	161	157	147	136	129	128	124										
Both	Decrease (1)	No	2	6	9	3	4	6	5	4	6	4	9	7	6	3	5	5										
	Z		1.2	3.7	5.7	2.0	2.9	4.6	3.9	3.2	3.6	2.5	5.7	4.8	4.4	2.3	3.9	4.0										
	Evaluated	No	11	11	11	6	10	8	9	8	8	12	5	9	9	4	5	5										
Heart rate	Increase (2)	Z	6.5	6.8	7.0	4.0	7.2	6.2	7.0	6.4	4.8	7.5	3.2	6.1	6.6	3.1	3.9	4.0										
	Evaluated	No	169	162	158	149	138	130	129	125	167	161	157	147	136	129	128	124										
	Decrease (1)	No	3	3	2	2	1	1	4	2	1	2	1	1		2	4											
Heart rate	Increase (2)	Z	1.8	1.9	1.3	1.3	0.7	0.8	3.1	1.6	0.6	1.2	0.6	0.7		1.6	3.1											
	Evaluated	No	1	3	4	3	4	2	1	1	1	3	4	3	4	3	2	2										
	Z		0.6	1.9	2.5	2.0	2.9	1.5		0.8	0.6					1.6	3.1											
Heart rate	Decrease (1)	No	166	161	156	148	138	132	130	126	163	159	154	145	137	131	129	124										
	Z		2	3	4	5	4	2	3	4	1	6	8	9	4	2	3	4										
	Evaluated	No	12	15	10	10	12	13	12	14	11	14	8	8	12	13	11	15										
Heart rate	Increase (2)	Z	7.2	9.3	6.4	6.8	8.7	9.8	9.2	11.1	6.7	8.8	5.2	5.5	8.8	9.9	8.5	12.1										

(1) decrease => 20 % of baseline value
 (2) increase => 20 % of baseline value

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 REMOXETINE - PROTOCOL 20124/035
 TABLE No: 81
BLOOD PRESSURE AND HEART RATE: NUMBER AND PERCENTAGE OF PATIENTS WITH DECREASE OR INCREASE VS BASELINE OF CLINICAL RELEVANCE ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

Vital signs		LYING														STANDING																																								
		Assessment time table							Assessment time table							Assessment time table							Assessment time table																																	
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56																							
S.B.P.	Evaluated	No	169	156	144	135	133	129	126	125	168	154	143	135	132	129	126	124	No	169	156	144	135	133	129	126	125	168	154	143	135	132	129	126	124	No	169	156	144	135	133	129	126	125	168	154	143	135	132	129	126	124				
	Decrease (1)	No	2	4	6	8	3	5	4	8	11	7	7	13	8	7	4	4	No	2	4	6	8	3	5	4	8	11	7	7	13	8	7	4	4	No	2	4	6	8	3	5	4	8	11	7	7	13	8	7	4	4				
	Z	1.2	2.6	4.2	5.9	2.3	3.9	3.2	6.4	6.5	6.4	6.5	4.5	4.9	9.6	6.1	5.4	3.2	3.2	Z	1.2	2.6	4.2	5.9	2.3	3.9	3.2	6.4	6.5	6.4	6.5	4.5	4.9	9.6	6.1	5.4	3.2	3.2	Z	1.2	2.6	4.2	5.9	2.3	3.9	3.2	6.4	6.5	6.4	6.5	4.5	4.9	9.6	6.1	5.4	3.2
D.B.P.	Evaluated	No	169	156	144	135	133	129	126	125	168	154	143	135	132	129	126	124	No	169	156	144	135	133	129	126	125	168	154	143	135	132	129	126	124	No	169	156	144	135	133	129	126	125	168	154	143	135	132	129	126	124				
	Decrease (1)	No	8	3	1	2	2	3	2	2	10	7	4	2	2	5	4	2	No	8	3	1	2	2	3	2	2	10	7	4	2	2	5	4	2	No	8	3	1	2	2	3	2	2	10	7	4	2	2	5	4	2				
	Z	4.7	1.9	0.7	1.5	1.5	2.3	1.6	1.6	1.6	6.0	4.5	2.8	1.5	1.5	3.9	3.2	1.6	Z	4.7	1.9	0.7	1.5	1.5	2.3	1.6	1.6	1.6	6.0	4.5	2.8	1.5	1.5	3.9	3.2	1.6	Z	4.7	1.9	0.7	1.5	1.5	2.3	1.6	1.6	1.6	6.0	4.5	2.8	1.5	1.5	3.9	3.2	1.6		
Both	Evaluated	No	169	156	144	135	133	129	126	125	168	154	143	135	132	129	126	124	No	169	156	144	135	133	129	126	125	168	154	143	135	132	129	126	124	No	169	156	144	135	133	129	126	125	168	154	143	135	132	129	126	124				
	Decrease (1)	No	5	1	2	2	5	2	2	1	5	1	5	1	5	6	5	2	4	No	5	1	2	2	5	2	2	1	5	1	5	1	5	6	5	2	4	No	5	1	2	2	5	2	2	1	5	1	5	1	5	6	5	2	4	
	Z	3.0	0.6	1.4	1.5	3.8	1.6	1.6	1.6	0.8	3.0	0.6	3.5	4.4	3.8	1.6	4.8	3.2	Z	3.0	0.6	1.4	1.5	3.8	1.6	1.6	1.6	0.8	3.0	0.6	3.5	4.4	3.8	1.6	4.8	3.2	Z	3.0	0.6	1.4	1.5	3.8	1.6	1.6	1.6	0.8	3.0	0.6	3.5	4.4	3.8	1.6	4.8	3.2		
Heart rate	Evaluated	No	165	154	143	135	133	128	126	125	164	151	142	135	132	128	126	124	No	165	154	143	135	133	128	126	125	164	151	142	135	132	128	126	124	No	165	154	143	135	133	128	126	125	164	151	142	135	132	128	126	124				
	Decrease (1)	No	4	4	5	5	4	4	3	5	5	1	1	5	3	4	5	2	No	4	4	5	5	4	4	3	5	5	1	1	5	3	4	5	2	No	4	4	5	5	4	4	3	5	5	1	1	5	3	4	5	2				
	Z	2.4	2.6	3.5	3.7	3.0	3.1	3.2	2.4	3.0	3.0	0.7	0.7	3.7	2.3	3.1	4.0	1.6	Z	2.4	2.6	3.5	3.7	3.0	3.1	3.2	2.4	3.0	3.0	0.7	0.7	3.7	2.3	3.1	4.0	1.6	Z	2.4	2.6	3.5	3.7	3.0	3.1	3.2	2.4	3.0	3.0	0.7	0.7	3.7	2.3	3.1	4.0	1.6		
Vital signs	Evaluated	No	165	154	143	135	133	128	126	125	164	151	142	135	132	128	126	124	No	165	154	143	135	133	128	126	125	164	151	142	135	132	128	126	124	No	165	154	143	135	133	128	126	125	164	151	142	135	132	128	126	124				
	Decrease (1)	No	4	4	5	5	4	4	3	5	5	1	1	5	3	4	5	2	No	4	4	5	5	4	4	3	5	5	1	1	5	3	4	5	2	No	4	4	5	5	4	4	3	5	5	1	1	5	3	4	5	2				
	Z	2.4	2.6	3.5	3.7	3.0	3.1	3.2	2.4	3.0	3.0	0.7	0.7	3.7	2.3	3.1	4.0	1.6	Z	2.4	2.6	3.5	3.7	3.0	3.1	3.2	2.4	3.0	3.0	0.7	0.7	3.7	2.3	3.1	4.0	1.6	Z	2.4	2.6	3.5	3.7	3.0	3.1	3.2	2.4	3.0	3.0	0.7	0.7	3.7	2.3	3.1	4.0	1.6		
Vital signs	Evaluated	No	165	154	143	135	133	128	126	125	164	151	142	135	132	128	126	124	No	165	154	143	135	133	128	126	125	164	151	142	135	132	128	126	124	No	165	154	143	135	133	128	126	125	164	151	142	135	132	128	126	124				
	Decrease (1)	No	4	4	5	5	4	4	3	5	5	1	1	5	3	4	5	2	No	4	4	5	5	4	4	3	5	5	1	1	5	3	4	5	2	No	4	4	5	5	4	4	3	5	5	1	1	5	3	4	5	2				
	Z	2.4	2.6	3.5	3.7	3.0	3.1	3.2	2.4	3.0	3.0	0.7	0.7	3.7	2.3	3.1	4.0	1.6	Z	2.4	2.6	3.5	3.7	3.0	3.1	3.2	2.4	3.0	3.0	0.7	0.7	3.7	2.3	3.1	4.0	1.6	Z	2.4	2.6	3.5	3.7	3.0	3.1	3.2	2.4	3.0	3.0	0.7	0.7	3.7	2.3	3.1	4.0	1.6		
Vital signs	Evaluated	No	165	154	143	135	133	128	126	125	164	151	142	135	132	128	126	124	No	165	154	143	135	133	128	126	125	164	151	142	135	132	128	126	124	No	165	154	143	135	133	128	126	125	164	151	142	135	132	128	126	124				
	Decrease (1)	No	4	4	5	5	4	4	3	5	5	1	1	5	3	4	5	2	No	4	4	5	5	4	4	3	5	5	1	1	5	3	4	5	2	No	4	4	5	5	4	4	3	5	5	1	1	5	3	4	5	2				
	Z	2.4	2.6	3.5	3.7	3.0	3.1	3.2	2.4	3.0	3.0	0.7	0.7	3.7	2.3	3.1	4.0	1.6	Z	2.4	2.6	3.5	3.7	3.0	3.1	3.2	2.4	3.0	3.0	0.7	0.7	3.7	2.3	3.1	4.0	1.6	Z	2.4	2.6	3.5	3.7	3.0	3.1	3.2	2.4	3.0	3.0	0.7	0.7	3.7	2.3	3.1	4.0	1.6		
Vital signs	Evaluated	No	165	154	143	135	133	128	126	125	164	151	142	135	132	128	126	124	No	165	154	143	135	133	128	126	125	164	151	142	135	132	128	126	124	No	165	154	143	135	133	128	126	125	164	151	142	135	132	128	126	124				
	Decrease (1)	No	4	4	5	5	4	4	3	5	5	1	1	5	3	4	5	2	No	4	4	5	5	4	4	3	5	5	1	1	5	3	4	5	2	No	4	4	5	5	4	4	3	5	5	1	1	5	3	4	5	2				
	Z	2.4	2.6	3.5	3.7	3.0	3.1	3.2	2.4	3.0	3.0	0.7	0.7	3.7	2.3	3.1	4.0	1.6	Z	2.4	2.6	3.5	3.7	3.0	3.1	3.2	2.4	3.0	3.0	0.7	0.7	3.7	2.3	3.1	4.0	1.6	Z	2.4	2.6	3.5	3.7	3.0	3.1	3.2	2.4	3.0	3.0	0.7	0.7	3.7	2.3	3.1	4.0	1.6		
Vital signs	Evaluated	No	165	154	143	135	133	128	126	125	164	151	142	135	132	128	126	124	No	165	154	143	135	133	128	126	125	164	151	142	135	132	128	126	124	No	165	154	143	135	133	128	126	125	164	151	142	135	132	128	126	124				
	Decrease (1)	No	4	4	5	5	4	4	3	5	5	1	1	5	3	4	5	2	No	4	4	5	5	4	4	3	5	5	1	1	5	3	4	5	2	No	4	4	5	5	4	4	3	5	5	1	1	5	3	4	5	2				
	Z	2.4	2.6	3.5	3.7	3.0	3.1	3.2	2.4	3.0	3.0	0.7	0.7	3.7	2.3	3.1	4.0	1.6	Z	2.4	2.6	3.5	3.7	3.0	3.1	3.2	2.4	3.0	3.0	0.7	0.7	3.7	2.3	3.1	4.0	1.6	Z	2.4	2.6	3.5	3.7	3.0	3.1	3.2	2.4	3.0	3.0	0.7	0.7	3.7	2.3	3.1	4.0	1.6		
Vital signs	Evaluated	No	165	154	143	135	133	128	126	125	164	151	142	135	132	128	126	124	No	165	154	143	135	133	128	126	125	164	151	142	135	132	128	126	124	No	165	154	143	135	133	128	126	125	164	151	142	135	132	128	126	124				
	Decrease (1)	No	4	4	5	5	4	4	3	5	5	1	1	5	3	4	5	2	No	4	4	5	5	4	4	3	5	5	1	1	5	3	4	5	2	No	4	4	5	5	4	4	3	5	5	1	1	5	3	4	5	2				
	Z	2.4	2.6																																																					

PHARMACIA CNS-889
553089

REBOXETINE - PROTOCOL 20124/035

TABLE No: 82

BLOOD PRESSURE AND HEART RATE: ABSOLUTE NUMBER OF PATIENTS SHOWING CLINICALLY RELEVANT CHANGES, COMPARED TO BASELINE, ONCE, TWICE OR MORE TIMES DURING THE THERAPY, BY ASSIGNED TREATMENT

Assigned treatment / Vital signs			LYING			STANDING		
			1 time	2 times	3 times or more	1 time	2 times	3 times or more
Imipramine	S.B.P. (1)	Decrease	4	1		10		1
		Increase	7	1		5	1	
	D.B.P. (2)	Decrease	15	3	2	18	6	4
		Increase	5	2	1	8	1	1
	BOTH (1 & 2)	Decrease	3			8		2
		Increase	3			3		
HEART RATE (3)	Increase	10	1	1	6	3	1	
Reboxetine	S.B.P. (1)	Decrease	4			4	3	
		Increase	6	3		6	1	1
	D.B.P. (2)	Decrease	9	6	7	8	3	7
		Increase	9	3	3	7	2	1
	BOTH (1 & 2)	Decrease	1			4		
		Increase	5	1	1	1		1
	HEART RATE (3)	Decrease				1		
		Increase	8	1	6	12	3	4

- (1) decrease => 20 % Vs baseline value and systolic value <= 100 mmHg
 increase => 20 % Vs baseline value and systolic value >= 160 mmHg
 (2) decrease => 20 % Vs baseline value and diastolic value <= 70 mmHg
 increase => 20 % Vs baseline value and diastolic value >= 100 mmHg
 (3) decrease => 20 % Vs baseline value and heart rate value <= 50 beats/min
 increase => 20 % Vs baseline value and heart rate value >= 100 beats/min

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No: 83
BLOOD PRESSURE: NUMBER AND PERCENTAGE OF PATIENTS WITH ORTHOSTATIC HYPOTENSION (*) BEFORE AND DURING THE STUDY ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Assigned treatment / Vital signs	According to time interval													
	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56					
Imipramine	Eval.	170	168	154	163	135	129	126	124					
	No.	2	11	6	7	8	6	5	3					
	\bar{x}	1.2	6.5	3.9	4.9	5.9	4.5	3.9	4.0					
	Mean	37.5	37.3	36.7	40.0	35.6	34.2	31.8	40.0					
	Max.	40.0	60.0	55.0	70.0	50.0	50.0	35.0	50.0					
Reboxetine	Eval.	169	168	161	157	147	129	128	124					
	No.	12	6	8	6	2	2	1	3					
	\bar{x}	7.1	3.6	5.0	3.8	1.4	1.5	0.8	2.3					
	Mean	38.3	44.2	47.5	35.8	35.0	30.0	40.0	31.7					
	Max.	60.0	90.0	90.0	55.0	40.0	30.0	40.0	35.0					

(*) orthostatic hypotension = decrease of systolic blood pressure in standing position => 30 mm Hg as compared to lying position

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 84

BODY WEIGHT: SUMMARY STATISTICS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Reboxetine

Sex		Time interval											
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56			
Female	Evaluated	132	128	123	121	112	107	102	101	98			
	Mean	63.4	63.4	63.4	63.3	63.5	63.5	63.5	63.6	63.8			
	STD	12.1	12.1	12.2	12.2	12.1	12.5	12.5	12.3	12.1			
	Median	61.0	62.5	62.0	62.0	62.5	62.0	62.2	62.0	62.6			
	Min	36.0	35.0	35.0	36.0	36.0	35.0	36.0	35.0	36.0			
	Max	92.0	91.0	91.0	91.5	91.0	92.0	91.5	92.0	91.5			
Male	Evaluated	39	38	38	35	35	30	30	29	27			
	Mean	68.2	68.3	67.8	67.9	67.6	67.7	68.3	68.0	67.5			
	STD	10.3	10.5	10.4	10.9	10.5	10.6	10.6	10.4	10.7			
	Median	66.0	67.0	65.3	65.3	66.8	65.5	66.3	67.5	64.5			
	Min	48.0	47.5	48.0	48.5	47.5	47.5	47.0	48.0	47.5			
	Max	92.5	92.1	92.4	92.2	92.0	91.3	91.8	91.4	91.0			
Total	Evaluated	171	166	161	156	147	137	132	130	125			
	Mean	64.5	64.6	64.5	64.3	64.5	64.4	64.8	64.6	64.6			
	STD	11.9	11.9	11.9	12.0	11.8	12.2	12.2	12.0	11.9			
	Median	63.2	63.9	63.6	63.0	63.2	63.0	63.8	63.5	63.0			
	Min	36.0	35.0	35.0	36.0	36.0	35.0	36.0	35.0	36.0			
	Max	92.5	92.1	92.4	92.2	92.0	92.0	91.8	92.0	91.5			

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 REMOXYLINE - PROTOCOL 20124/035
 TABLE No.: 84

BODY WEIGHT: SUMMARY STATISTICS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Imipramine

Sex		Time interval													
		Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56					
Female	Evaluated	125	124	116	106	102	99	95	93	93					
	Mean	64.6	64.6	64.6	65.4	65.8	66.4	66.4	66.1	66.1					
	STD	11.9	11.8	11.8	11.8	11.7	11.9	11.5	11.5	11.7					
	Median	64.5	64.7	64.4	65.0	66.0	66.4	66.9	66.5	67.0					
	Min	39.3	39.5	40.0	40.5	40.0	40.5	40.0	40.6	40.0					
	Max	104.0	104.0	104.0	104.0	104.0	104.0	104.0	104.0	100.0					
Male	Evaluated	44	43	40	37	33	33	32	33	31					
	Mean	72.4	72.7	72.4	73.5	74.5	73.8	73.6	73.0	74.9					
	STD	12.7	12.4	13.2	12.9	13.0	12.2	12.3	11.4	13.4					
	Median	73.0	73.0	72.9	73.0	75.0	73.0	73.0	73.0	74.0					
	Min	39.0	40.0	38.0	39.0	40.0	42.0	42.0	42.0	42.1					
	Max	113.0	112.0	111.0	110.0	109.0	110.0	110.0	100.0	112.0					
Total	Evaluated	169	167	156	143	135	132	127	126	124					
	Mean	66.7	66.7	66.6	67.5	67.9	68.2	68.2	67.9	68.3					
	STD	12.6	12.4	12.7	12.5	12.6	12.4	12.1	11.8	12.7					
	Median	66.6	67.0	67.0	67.5	68.2	68.8	68.5	68.7	69.0					
	Min	39.0	39.5	38.0	39.0	40.0	40.5	40.0	40.6	40.0					
	Max	113.0	112.0	111.0	110.0	109.0	110.0	110.0	104.0	112.0					

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/035
TABLE No.: BS

BODY HEIGHT: NUMBER AND PERCENTAGE OF PATIENTS WITH VALUES LOWER OR HIGHER (*) THAN PRE-TREATMENT
AT EACH EVALUATION TIME, BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Reboksetine

Sex		Time interval																	
		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56			
		No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z		
Female	Lower	2	1.6	1	0.8	1	0.8	1	0.8	1	0.9	3	2.8	2	2.0	3	3.0	6	6.1
	Same	125	97.7	120	97.6	114	94.2	103	92.0	98	91.6	92	90.2	90	89.1	86	87.8		
	Higher	1	0.8	2	1.6	6	5.0	8	7.1	6	5.6	8	7.8	8	7.9	6	6.1		
	Total	128	100.0	123	100.0	121	100.0	112	100.0	107	100.0	102	100.0	101	100.0	98	100.0		
Male	Lower	1	2.6			1	2.9	3	8.6	1	3.3	2	6.7	3	10.3	4	14.8		
	Same	37	97.4	37	97.4	31	88.6	30	85.7	28	93.3	26	86.7	23	79.3	20	74.1		
	Higher			1	2.6	3	8.6	2	5.7	1	3.3	2	6.7	3	10.3	3	11.1		
	Total	38	100.0	38	100.0	35	100.0	35	100.0	30	100.0	30	100.0	30	100.0	29	100.0	27	100.0
Total	Lower	3	1.8	1	0.6	2	1.3	4	2.7	4	2.9	4	3.0	4	3.0	6	4.6	10	6.0
	Same	162	97.6	157	97.5	145	92.9	133	90.5	126	92.0	118	89.4	113	86.9	106	84.8		
	Higher	1	0.6	3	1.9	9	5.8	10	6.8	7	5.1	10	7.6	11	8.5	9	7.2		
	Total	166	100.0	161	100.0	156	100.0	147	100.0	137	100.0	132	100.0	130	100.0	125	100.0		

(*) LOWER: decrease > 2.5 Kg.
HIGHER: increase > 2.5 Kg.

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 85

BODY HEIGHT: NUMBER AND PERCENTAGE OF PATIENTS WITH VALUES LOWER OR HIGHER (*) THAN PRE-TREATMENT AT EACH EVALUATION TIME, BY ASSIGNED TREATMENT AND SEX

Assigned treatment: Imipramine

Sex		Time interval															
		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56	
		No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%
Female	Lower	1	0.8	2	1.7	4	3.8	3	2.9	4	4.0	4	4.2	5	5.4	7	7.5
	Same	120	96.8	111	95.7	99	93.4	93	91.2	85	85.9	81	85.3	80	86.0	76	81.7
	Higher	3	2.4	3	2.6	3	2.8	6	5.9	10	10.1	10	10.5	8	8.6	10	10.8
	Total	124	100.0	116	100.0	106	100.0	102	100.0	99	100.0	95	100.0	93	100.0	93	100.0
Male	Lower			1	2.5					2	6.1	1	3.1	1	3.0	2	6.5
	Same	43	100.0	37	92.5	36	97.3	32	97.0	29	87.9	29	90.6	30	90.9	28	90.3
	Higher			2	5.0	1	2.7	1	3.0	2	6.1	2	6.3	2	6.1	1	3.2
	Total	43	100.0	40	100.0	37	100.0	33	100.0	33	100.0	32	100.0	33	100.0	31	100.0
Total	Lower	1	0.6	3	1.9	4	2.8	3	2.2	6	4.5	5	3.9	6	4.8	9	7.3
	Same	163	97.6	148	94.9	135	94.4	125	92.6	114	86.4	110	86.6	110	87.3	104	83.9
	Higher	3	1.8	5	3.2	4	2.8	7	5.2	12	9.1	12	9.4	10	7.9	11	8.9
	Total	167	100.0	156	100.0	143	100.0	135	100.0	132	100.0	127	100.0	126	100.0	124	100.0

(*) LOWER: decrease > 2.5 Kg.
HIGHER: increase > 2.5 Kg.

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RSD

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 86

E.C.G.: NUMBER AND PERCENTAGE OF PATIENTS WITH ABNORMAL E.C.G. ACCORDING TO TIME INTERVALS, BY ASSIGNED TREATMENT AND SEX

Assigned treatment/Sex	Female						Male						Total				
	Screening		1-28 days		29-56 days		Screening		1-28 days		29-56 days		Screening		1-28 days	29-56 days	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	
Imipramine	Eval.		108		105		94		34		33		30		142		124
	Normal		77		74		69		23		25		26		100		95
	%		71.30		70.48		73.40		67.65		75.76		86.67		70.42		76.61
Reboxetine	Abnormal		31		31		25		11		8		4		42		29
	%		28.70		29.52		26.60		32.35		24.24		13.33		29.58		23.39
	Eval.		115		110		96		33		33		25		148		121
Reboxetine	Normal		82		78		63		23		21		18		105		81
	%		71.30		70.91		65.63		69.70		63.64		72.00		70.95		66.94
	Abnormal		33		32		33		10		12		7		43		40
%		28.70		29.09		34.38		30.30		36.36		28.00		29.05		33.06	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS R&D

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 87

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH NORMAL OR ABNORMAL E.C.G. VALUE AT EACH EVALUATION TIME AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment/E.C.G. at Baseline		Time interval			
		1-28 days		29-56 days	
		Abnormal	Normal	Abnormal	Normal
Imipramine	No.	29	12	17	15
	%	70.7	29.3	53.1	46.9
	No.	10	87	12	80
	%	10.3	89.7	13.0	87.0
Total	No.	39	99	29	95
	%	28.3	71.7	23.4	76.6
Reboxetine	No.	33	8	26	6
	%	80.5	19.5	81.3	18.8
	No.	11	91	14	75
	%	10.8	89.2	15.7	84.3
Total	No.	44	99	40	81
	%	30.8	69.2	33.1	66.9

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS R&D

REBOXETINE – PROTOCOL 20124/035
TABLE No.: 88

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH NORMAL OR ABNORMAL E.C.G. VALUE AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment/E.C.G. at Baseline	Last assessment						
	Abnormal		Normal		Total		
	No.	Z	No.	Z	No.	Z	
Imipramine	Abnormal	25	59.5	17	40.5	42	100.0
	Normal	12	12.0	88	88.0	100	100.0
	Total	37	26.1	105	79.9	142	100.0
Reboxetine	Abnormal	36	83.7	7	16.3	43	100.0
	Normal	17	16.2	88	83.8	105	100.0
	Total	53	35.8	95	64.2	148	100.0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 89

E.C.G.: NUMBER AND PERCENTAGE OF E.C.G. ABNORMALITIES OBSERVED DURING THE STUDY, BY ASSIGNED TREATMENT

E.C.G. abnormality type	Imipramine						Reboxetine					
	Screening		1-28 days		29-56 days		Screening		1-28 days		29-56 days	
	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z
	142	100.0	138	100.0	124	100.0	148	100.0	143	100.0	121	100.0
Evaluated Pt	3	2.1	2	1.4	3	2.4	3	2.0	2	1.4	3	2.5
A-V BLOCK 1ST DEGREE			1	0.7								
ATR. ECTOPIC BEATS SUPRAVEN. TACHYCARDIA												
ATRIAL ECTOPIC BEATS - COUPLERS	1	0.7										
ATRIAL ECTOPIC BEATS - FREQUENT (> 6/MM)					1	0.8			1	0.7	1	0.8
ATRIAL ECTOPIC BEATS - OCCASIONAL					1	0.8	1	0.7	2	1.4	3	2.5
ATRIAL FIBRILLATION / FLUTTER	4	2.8	5	3.6	4	3.2	2	1.4	2	1.4	1	0.8
BIFASCICULAR BLOCK							1	0.7				
CONDUCTION DISORDER	2	1.4	3	2.2	1	0.8	1	0.7	1	0.7	4	3.3
LEFT ANTERIOR HEMIBLOCK	1	0.7	3	2.2	2	1.6	5	3.4	7	4.9	6	5.0
LEFT AXIAL DEVIATION							1	0.7	1	0.7	1	0.8
LEFT BUNDLE BRANCH BLOCK	4	2.8	2	1.4			1	0.7	2	1.4	1	0.8
LEFT VENTRICULAR HYPERTROPHY	6	4.2	5	3.6	3	2.4	6	4.1	6	4.2	4	3.3
MYOCARDIAL ISCHEMIA	3	2.1	4	2.9	2	1.6	6	4.1	5	3.5	5	4.1
NON SPECIFIC ST-T WAVE CHANGES	1	0.7	4	2.9	2	1.6	3	2.0	1	0.7	3	2.5
OTHER	4	2.8	1	0.7	1	0.8	3	2.0	4	2.8	2	1.7
PREVIOUS MYOCARDIAL INFARCTION	4	2.8	3	2.2	2	1.6	4	2.7	3	2.1	5	4.1
RIGHT BUNDLE BRANCH BLOCK	5	3.5	7	5.1	6	4.8	5	3.4	5	3.5	5	4.1
RIGHT VENTRICULAR HYPERTROPHY									1	0.7		
RIPOLARIZATION DISTURBANCES	3	2.1	3	2.2	1	0.8	1	0.7			1	0.8
SINUS BRADYCARDIA (< 60)	5	3.5	2	1.4	2	1.6	9	6.1	3	2.1	4	3.3
SINUS TACHYCARDIA (> 100)	5	3.5	3	2.2	4	3.2	5	3.4	8	5.6	9	7.4

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 89

E.C.G.: NUMBER AND PERCENTAGE OF E.C.G. ABNORMALITIES OBSERVED DURING THE STUDY, BY ASSIGNED TREATMENT

E.C.G. abnormality type	Inipramine						Reboxetine					
	Screening		1-28 days		29-56 days		Screening		1-28 days		29-56 days	
	No	%	No	%	No	%	No	%	No	%	No	%
VENTRIC. ECTOPIC BEATS-FREQUENT (>6/MI)							1	0.7	1	0.7		
VENTRICULAR ECTOPIC BEATS - OCCASIONAL	4	2.8	1	0.7	5	4.0	3	2.0	5	3.5	3	2.5

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 90

E.C.G.: SHEET TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

	Baseline	Last assessment						Total	
		Absent		Present		Total		Total	
		No	%	No	%	No	%	No	%
E.C.G. Abnormality A-V BLOCK 1ST DEGREE	Baseline								
	Absent	142	97.9	3	2.1	145	100.0		
	Present	2	66.7	1	33.3	3	100.0		
	Total	144	97.3	4	2.7	148	100.0		
ATR. ECTOPIC BEATS SUPRAVEN. TACHICARDIA	Baseline								
	Absent	148	100.0			148	100.0		
	Total	148	100.0			148	100.0		
ATRIAL ECTOPIC BEATS - COMPLETS	Baseline								
	Absent	148	100.0			148	100.0		
	Total	148	100.0			148	100.0		
ATRIAL ECTOPIC BEATS - FREQUENT (> 6/HR)	Baseline								
	Absent	147	99.3	1	0.7	148	100.0		
	Present								
	Total	147	99.3	1	0.7	148	100.0		
ATRIAL ECTOPIC BEATS - OCCASIONAL	Baseline								
	Absent	143	97.3	4	2.7	147	100.0		
	Present	1	100.0			1	100.0		
	Total	144	97.3	4	2.7	148	100.0		
ATRIAL FIBRILLATION / FLUTTER	Baseline								
	Absent	145	99.3	1	0.7	146	100.0		
	Present	1	50.0	1	50.0	2	100.0		
	Total	146	98.6	2	1.4	148	100.0		

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RBD
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 90

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

		Last assessment						Total	
		Absent		Present		Total		Total	
		No	%	No	%	No	%	No	%
E.C.G. Abnormality BIFASCICULAR BLOCK	Baseline								
	Absent	147	100.0					147	100.0
	Present	1	100.0					1	100.0
	Total	148	100.0					148	100.0
CONDUCTION DISORDER	Baseline								
	Absent	143	97.3	4	2.7			147	100.0
	Present	1	100.0					1	100.0
	Total	144	97.3	4	2.7			148	100.0
LEFT ANTERIOR HEMIBLOCK	Baseline								
	Absent	137	95.6	6	4.2			143	100.0
	Present	2	40.0	3	60.0			5	100.0
	Total	139	93.9	9	6.1			148	100.0
LEFT AXIAL DEVIATION	Baseline								
	Absent	147	100.0					147	100.0
	Present			1	100.0			1	100.0
	Total	147	99.3	1	0.7			148	100.0
LEFT BUNDLE BRANCH BLOCK	Baseline								
	Absent	146	99.3	1	0.7			147	100.0
	Present			1	100.0			1	100.0
	Total	146	98.6	2	1.4			148	100.0
LEFT VENTRICULAR HYPERTROPHY	Baseline								
	Absent	141	99.3	1	0.7			142	100.0

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
TABLE No. : 90

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

		Last assessment						Total	
		Absent		Present		Total		Total	
		No	%	No	%	No	%	No	%
E.C.G. Abnormality	Baseline								
	Present			6	100.0			6	100.0
	Total	141	95.3	7	4.7	148	100.0		
MYOCARDIAL ISCHEMIA	Baseline								
	Absent	140	98.6	2	1.4	142	100.0		
	Present	3	50.0	3	50.0	6	100.0		
Total	143	96.6	5	3.4	148	100.0			
NON SPECIFIC ST-T WAVE CHANGES	Baseline								
	Absent	142	97.9	3	2.1	145	100.0		
	Present	2	66.7	1	33.3	3	100.0		
Total	144	97.3	4	2.7	148	100.0			
OTHER	Baseline								
	Absent	144	99.3	1	0.7	145	100.0		
	Present	2	66.7	1	33.3	3	100.0		
Total	146	98.6	2	1.4	148	100.0			
PREVIOUS MYOCARDIAL INFARCTION	Baseline								
	Absent	142	98.6	2	1.4	144	100.0		
	Present	1	25.0	3	75.0	4	100.0		
Total	143	96.6	5	3.4	148	100.0			
RIGHT BUNDLE BRANCH BLOCK	Baseline								
	Absent	142	99.3	1	0.7	143	100.0		
	Present			5	100.0	5	100.0		

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS RED
REBOXETINE - PROTOCOL 20124/035
TABLE No.: 90

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

		Last assessment						Total	
		Absent		Present		Total		No	%
		No	%	No	%	No	%		
E.C.G. Abnormality	Total								
RIGHT BUNDLE BRANCH BLOCK	Baseline	142	95.9	6	4.1	148	100.0		
	Absent	147	99.3	1	0.7	148	100.0		
	Present								
	Total	147	99.3	1	0.7	148	100.0		
RIPOLARIZATION DISTURBANCES	Baseline								
	Absent	146	99.3	1	0.7	147	100.0		
	Present	1	100.0			1	100.0		
	Total	147	99.3	1	0.7	148	100.0		
SINUS BRADYCARDIA (< 60)	Baseline								
	Absent	136	97.8	3	2.2	139	100.0		
	Present	6	66.7	3	33.3	9	100.0		
	Total	142	95.9	6	4.1	148	100.0		
SINUS TACHYCARDIA (> 100)	Baseline								
	Absent	135	94.4	8	5.6	143	100.0		
	Present	2	40.0	3	60.0	5	100.0		
	Total	137	92.6	11	7.4	148	100.0		
VENTRIC. ECTOPIC BEATS-FREQUENT (>6/HR)	Baseline								
	Absent	146	99.3	1	0.7	147	100.0		
	Present	1	100.0			1	100.0		

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 90
 E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT
 AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Reboxetine

E.C.G. Abnormality	Total	Last assessment					
		Absent		Present		Total	
		No	%	No	%	No	%
VENTRIC. ECTOPIC BEATS-FREQUENT (>6/NN)	147	99.3	1	0.7	148	100.0	
VENTRICULAR ECTOPIC BEATS - OCCASIONAL	Baseline	142	97.9	3	2.1	145	100.0
	Absent	2	66.7	1	33.3	3	100.0
	Present	144	97.3	4	2.7	148	100.0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 90

E.C.G.: SHEET TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

		Last assessment						Total				
		Absent		Present		Total		Total				
		No	Z	No	Z	No	Z	No	Z			
E.C.G. Abnormality	Baseline											
	Absent	136	97.8	3	2.2	139	100.0					
	Present	3	100.0			3	100.0					
	Total	139	97.9	3	2.1	142	100.0					
ATR. ECTOPIC BEATS SUPRAVER. TACHICARDIA	Baseline											
	Absent	141	99.3	1	0.7	142	100.0					
	Present											
	Total	141	99.3	1	0.7	142	100.0					
ATRIAL ECTOPIC BEATS - COMPLETS	Baseline											
	Absent	141	100.0			141	100.0					
	Present	1	100.0			1	100.0					
	Total	142	100.0			142	100.0					
ATRIAL ECTOPIC BEATS - FREQUENT (> 6/HH)	Baseline											
	Absent	141	99.3	1	0.7	142	100.0					
	Present											
	Total	141	99.3	1	0.7	142	100.0					
ATRIAL ECTOPIC BEATS - OCCASIONAL	Baseline											
	Absent	141	99.3	1	0.7	142	100.0					
	Present											
	Total	141	99.3	1	0.7	142	100.0					
ATRIAL FIBRILLATION / FLUTTER	Baseline											
	Absent	137	99.3	1	0.7	138	100.0					
	Present											

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 90

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

		Last assessment						Total			
		Absent		Present		Total		Total			
		No	%	No	%	No	%	No	%		
E.C.G. Abnormality	Baseline										
	Present			4	100.0			4	100.0		
	Total	137	96.5	5	3.5	142	100.0				
BIFASCICULAR BLOCK	Baseline										
	Absent	142	100.0					142	100.0		
	Total	142	100.0					142	100.0		
CONDUCTION DISORDER	Baseline										
	Absent	139	99.3	1	0.7	140	100.0				
	Present	2	100.0			2	100.0				
LEFT ANTERIOR HEMIBLOCK	Baseline										
	Absent	140	99.3	1	0.7	141	100.0				
	Present			1	100.0			1	100.0		
LEFT AXIAL DEVIATION	Baseline										
	Absent	140	98.6	2	1.4	142	100.0				
	Total	142	100.0					142	100.0		
LEFT BUNDLE BRANCH BLOCK	Baseline										
	Absent	138	100.0			138	100.0				
	Present	2	50.0	2	50.0	4	100.0				
Total	140	98.6	2	1.4	142	100.0					

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 90

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

		Last assessment						Total	
		Absent		Present		Total		Total	
		No	%	No	%	No	%	No	%
E.C.G. Abnormality	Baseline								
	Absent	135	99.3	1	0.7	136	100.0		
	Present	4	66.7	2	33.3	6	100.0		
	Total	139	97.9	3	2.1	142	100.0		
MYOCARDIAL ISCHEMIA	Baseline								
	Absent	138	99.3	1	0.7	139	100.0		
	Present	1	33.3	2	66.7	3	100.0		
	Total	139	97.9	3	2.1	142	100.0		
NON SPECIFIC ST-T WAVE CHANGES	Baseline								
	Absent	138	97.9	3	2.1	141	100.0		
	Present	1	100.0			1	100.0		
	Total	139	97.9	3	2.1	142	100.0		
OTHER	Baseline								
	Absent	137	99.3	1	0.7	138	100.0		
	Present	4	100.0			4	100.0		
	Total	141	99.3	1	0.7	142	100.0		
PREVIOUS MYOCARDIAL INFARCTION	Baseline								
	Absent	138	100.0			138	100.0		
	Present	1	25.0	3	75.0	4	100.0		
	Total	139	97.9	3	2.1	142	100.0		
RIGHT BUNDLE BRANCH BLOCK	Baseline								
	Absent	134	97.8	3	2.2	137	100.0		

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035

TABLE No.: 90

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

		Last assessment					
		Absent		Present		Total	
		No	%	No	%	No	%
E.C.G. Abnormality RIGHT BUNDLE BRANCH BLOCK	Baseline						
	Present	1	20.0	4	80.0	5	100.0
	Total	135	95.1	7	4.9	142	100.0
RIGHT VENTRICULAR HYPERTROPHY	Baseline						
	Absent	142	100.0			142	100.0
	Total	142	100.0			142	100.0
REPOLARIZATION DISTURBANCES	Baseline						
	Absent	138	99.3	1	0.7	139	100.0
	Present	2	66.7	1	33.3	3	100.0
	Total	140	98.6	2	1.4	142	100.0
SINUS BRADYCARDIA (< 60)	Baseline						
	Absent	136	99.3	1	0.7	137	100.0
	Present	4	80.0	1	20.0	5	100.0
	Total	140	98.6	2	1.4	142	100.0
SINUS TACHYCARDIA (> 100)	Baseline						
	Absent	132	96.4	5	3.6	137	100.0
	Present	5	100.0			5	100.0
	Total	137	96.5	5	3.5	142	100.0
VENTRIC. ECTOPIC BEATS- FREQUENT (>6/HH)	Baseline						
	Absent	142	100.0			142	100.0
	Total	142	100.0			142	100.0

(CONTINUED)

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 TABLE No.: 90

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRE-TREATMENT EVALUATION, BY ASSIGNED TREATMENT

Assigned treatment: Imipramine

	Last assessment					
	Absent		Present		Total	
	No	%	No	%	No	%
E.C.G. Abnormality						
VENTRICULAR ECTOPIC BEATS - OCCASIONAL						
Baseline						
Absent	133	96.4	5	3.6	138	100.0
Present	4	100.0			4	100.0
Total	137	96.5	5	3.5	142	100.0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 91

E.C.G.: NUMBER AND PERCENTAGE OF E.C.G. ABNORMALITIES, BY ABNORMALITY GROUP, OBSERVED DURING THE STUDY BY ASSIGNED TREATMENT

Group of abnormalities	Inipramine						Reboxetine					
	Screening		1-28 days		29-56 days		Screening		1-28 days		29-56 days	
	No	%	No	%	No	%	No	%	No	%	No	%
Evaluated Pt.	142	100.0	138	100.0	124	100.0	148	100.0	143	100.0	121	100.0
Rhythm disorders	17	12.0	11	8.0	12	9.7	20	13.5	22	15.4	19	15.7
Conduction disorders	14	9.9	16	11.6	10	8.1	14	9.5	16	11.2	15	12.4
Ischemic signs	7	4.9	11	8.0	5	4.0	10	6.8	6	4.2	9	7.4
Other disorders	14	9.9	9	6.5	6	4.8	13	8.8	12	8.4	10	8.3

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
TABLE No.: 92

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES, BY ABNORMALITY GROUP, AT LAST ASSESSMENT AS COMPARED TO PRETREATMENT EVALUATION, BY ASSIGNED TREATMENT

E.C.G. Abnormality / Baseline	Last assessment																	
	Imipramine									Reboxetine								
	Absent			Present			Total			Absent			Present			Total		
	No	%	Z	No	%	Z	No	%	Z	No	%	Z	No	%	Z	No	%	Z
Rhythm disorders	Absent	117	93.6	8	6.4	125	100	113	88.3	15	11.7	128	100					
	Present	10	58.8	7	41.2	17	100	8	40.0	12	60.0	20	100					
	Total	127	89.4	15	10.6	142	100	121	81.8	27	18.2	148	100					
Conduction disorders	Absent	123	96.1	5	3.9	128	100	126	94.0	8	6.0	134	100					
	Present	6	42.9	8	57.1	14	100	2	14.3	12	85.7	14	100					
	Total	129	90.8	13	9.2	142	100	128	86.5	20	13.5	148	100					
Ischemic signs	Absent	131	97.0	4	3.0	135	100	132	95.7	6	4.3	138	100					
	Present	3	42.9	4	57.1	7	100	6	60.0	4	40.0	10	100					
	Total	134	94.4	8	5.6	142	100	138	93.2	10	6.8	148	100					
Other disorders	Absent	128	100			128	100	132	97.8	3	2.2	135	100					
	Present	7	50.0	7	50.0	14	100	3	23.1	10	76.9	13	100					
	Total	135	95.1	7	4.9	142	100	135	91.2	13	8.8	148	100					

9550089

Pharmacia

Document 9550089


FIGURES

664

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE – PROTOCOL 20124/035
CUMULATIVE RISK OF DEVELOPING HYPOTENSION AND RELATED SYMPTOMS

Figure No.: 1




Log-Rank Test IMI vs RBX: (1 df) = 6.0165 P = 0.0142

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE – PROTOCOL 20124/035
CUMULATIVE RISK OF DEVELOPING HYPOTENSION AND RELATED SYMPTOMS

Figure No.: 1

DIAGNOSIS: Major Depressive Disorder



090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22


PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/035

CUMULATIVE RISK OF DEVELOPING HYPOTENSION AND RELATED SYMPTOMS

Figure No.: 1

DIAGNOSIS: Dysthymia



667


9550089

Log-Rank Test IMI vs RBX: (1 df) = 1.4752 P = 0.2245

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMAČIA CNS R&D
REBOXETINE – PROTOCOL 20124/035
PERCENTAGE OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT ON EXPOSED ACCORDING TO TIME INTERVAL

Figure No.: 2




090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE – PROTOCOL 20124/035
PERCENTAGE OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT ON EXPOSED ACCORDING TO TIME INTERVAL

Figure No.: 2

Diagnosis: Major Depressive Disorder



9550089


669

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE – PROTOCOL 20124/035
PERCENTAGE OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT ON EXPOSED ACCORDING TO TIME INTERVAL

Figure No.: 2

Diagnosis: Dysthymia



9550089

Pharmacia

Document 9550089

12. APPENDICES

671

9550089

Pharmacia

Document 9550089

12.1 Study Information

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9550089

Pharmacia

Document 9550089

12.1.1 PROTOCOL AND PROTOCOL AMENDMENTS

No protocol amendment valid for all countries was done. Copy of the amendments required by local Ethical Committees (Australia, France and UK) is filed in the Study Master File.

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CLINICAL DEVELOPMENT, CNS

9550089

FARMITALIA CARLO ERBA
R & D, CNS LINE

COMPOUND : Reboxetine
PROTOCOL N° : 20124/035
VERSION : Final, June 15, 1992
PHASE : III
TITLE : Multicenter, multinational double
blind study of the tolerability
and activity of reboxetine vs
imipramine in elderly patients with
depressive disorders
INVESTIGATORS : see enclosure 1
PRODUCT LEADER : Dr. Marek Jarema
Farmitalia Carlo Erba, R & D
Clinical Development, CNS
via Carlo Imbonati 24
20159 Milano
phone: 02/69959081
STUDY MONITOR : see enclosure 13
DATA MANAGEMENT CENTER : Farmitalia Carlo Erba, R & D
via Carlo Imbonati 24
20159 Milano
phone: 02/69952759

This protocol contains strictly confidential information which is not to be communicated or published unless previously authorized by FICE R & D.

20124/035

Date: June 16, 1992

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CLINICAL DEVELOPMENT, CNS

INDEX

1.0 PROTOCOL SUMMARY	Page	1
2.0 INTRODUCTION	"	1
3.0 RATIONALE	"	3
4.0 OBJECTIVE	"	3
5.0 DESIGN	"	3
5.1 Description	"	3
5.2 Number of Subjects	"	3
5.3 Logistics	"	3
6.0 STUDY POPULATION	"	3
6.1 Source of Subjects	"	3
6.2 Inclusion Criteria	"	4
6.3 Exclusion Criteria	"	4
6.4 Identification of Subjects	"	5
7.0 RANDOMIZATION PROCEDURES	"	5
8.0 EXPERIMENTAL TREATMENT	"	5
8.1 Test Preparations	"	5
8.2 Labelling	"	6
8.3 Packaging	"	6
8.4 Drug Supplies Storage	"	6
8.5 Dispensing, Use and Disposal of the Preparations during and at the End of the Study	"	6
9.0 STUDY CONDUCT	"	7
9.1 Pre-treatment Period	"	7
9.2 Treatment Schedule	"	7
9.3 Duration of Treatment	"	7
9.4 Indications for Early Termination of Therapy	"	8
9.5 Dropouts/Replacement of Subjects	"	8
9.6 Concomitant Therapy	"	8
9.7 Indications for opening the code	"	9
9.8 Follow-up	"	9
9.9 Study Timetable	"	9
10.0 EFFICACY ASSESSMENTS	"	9
10.1 Variables to be Measured for Efficacy Assessment	"	9
10.2 Efficacy Definition	"	10
10.3 Criteria for Efficacy Evaluability	"	10

FARMITALIA CARLO ERBA
 ERBAMONT GROUP
 CLINICAL DEVELOPMENT, CNS

11.0 SAFETY ASSESSMENT	"	10
11.1 Variables to be Measured for Safety Assessment	"	10
11.2 Criteria for Safety Evaluability	"	11
12.0 ADVERSE EVENTS	"	11
12.1 Definitions	"	11
12.2 Information to be collected	"	11
12.3 Procedure of Report	"	12
13.0 EVALUATION SCHEDULE	"	13
14.0 STATISTICAL CONSIDERATIONS	"	13
14.1 Sample Size	"	13
14.2 Statistical Analysis	"	13
15.0 ETHICAL ASPECTS	"	14
15.1 Ethical Committee	"	14
15.2 Informed Consent	"	14
16.0 PROTOCOL AMENDMENTS	"	15
17.0 STUDY MONITORING	"	15
18.0 SUPPLY AND INVENTORY	"	15
19.0 ADMINISTRATIVE ASPECTS	"	15
19.1 Insurance Policy	"	15
19.2 Curriculum Vitae	"	16
19.3 Data Collection in the Case Record Form	"	16
19.4 Use of the Information related to the Study	"	16
19.5 Statement of Investigator	"	16
20.0 STUDY REPORT	"	17
20.1 Clinical Study Final Report	"	17
20.2 Publication of Study Results	"	17
21.0 END OF THE STUDY	"	17
22.0 REFERENCES	"	17
23.0 SIGNATURES	"	18
LIST OF ENCLOSURES	"	19
Table 1. EVALUATION SCHEDULE	"	20

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CLINICAL DEVELOPMENT, CNS

1.0 Protocol Summary

The study will be carried out in order to evaluate the tolerability and activity of reboxetine, a new potential antidepressant agent, in elderly depressed patients. After an initial washout period, 300 patients over 65 years suffering from depressive disorders will receive either reboxetine in repeated doses of 4 to 6 mg/day or imipramine 75 to 100 mg/day for the period of 8 weeks. Responders will then enter a follow-up treatment on a long-term basis. The effectiveness will be measured by use of rating scales (HAMD, MADRS, GDS, CGI). Tolerability will be evaluated on the basis of the appearance of newly observed signs/symptoms, vital signs, laboratory tests and ECG.

2.0 Introduction

Reboxetine (FCE 20124 or RS, RS 2-[α -(2-ethoxy-phenoxy) benzyl] morpholine methanesulphonate) is a chemically new compound highly potent in pharmacological and biochemical tests predictive of antidepressant effectiveness: reserpine antagonism, norepinephrine reuptake inhibition, REM sleep latency increase. In addition reboxetine has been found to be able to prevent clonidine effects in rodents after single oral administration, in contrast with what is observed following tricyclic monoamine uptake inhibitors, which were found to be active only upon repeated doses: these results indicate that the compound is able to decrease the sensitivity of α_2 noradrenergic receptors, one of the biochemical correlates of chronic antidepressant treatment, after single oral dose; therefore it may be expected to exert antidepressant effectiveness of faster onset with respect to available antidepressants in patients (1).

In phase I studies healthy volunteers were orally administered single doses of 0.5 - 5 mg of the compound (2,3). After 5 mg orthostatic hypotension, accompanied by tachycardia and by subjective symptomatology consistent with the disturbed circulatory regulation was observed.

In these studies single doses of 1 & 3 mg of the compound showed dose-dependent CNS effects with EEG modifications (decreased power of theta and fast-beta waves in the fronto-central derivate), performance improvement (peg-board test) and growth hormone increase, the latter reportedly sensitive to hypothalamic noradrenergic stimulation by norepinephrine reuptake inhibitors.

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CLINICAL DEVELOPMENT, CNS

9550089

Comparison with the positive control, imipramine 75mg, indicated that reboxetine does not possess the marked sedative activity of imipramine but rather psychostimulating properties. This is based on the evidence that imipramine demonstrates similar EEG modifications in the fronto-central derivative, modifications indicative of sedative activity in the occipito-temporal derivative as well as the deterioration of the Pauli performance test, in the absence of growth hormone modifications. After all treatment standing heart rate increase and salivation decrease was apparent. No other modifications of tolerability parameters were observed.

The pharmacokinetics of the compound were evaluated in the above mentioned studies as well as after administration of 2 mg ¹⁴C-FCE 20124 to 3 healthy volunteers (4). Most of the radioactivity circulating in plasma (73% in terms of AUC) was accounted for by unchanged reboxetine; the average peak levels were observed at 2 hours, with remarkably stable levels 1-6 hours after administration; its plasma half-life was estimated as 13.2 h, slightly lower than that of total radioactivity.

Antidepressant efficacy of reboxetine has been demonstrated in a controlled study in Major Depressive Disorders carried out vs desipramine and placebo. Frequency of response (50% decrease of Hamilton Depression Rating Scale, study end point) was significantly higher in the reboxetine (60%) than in the placebo (35%) group. As to the time course of the response, significant differences vs placebo in the average values of the rating scales applied were observed from day 10-14 of the treatment in the reboxetine group and from day 14-21 in the desipramine group. The overall superiority of reboxetine over desipramine in the administered dose range reached statistical significance for one of the rating scales at the end of treatment, confirming the trend seen in the other scales.

As far as signs/symptoms are concerned, dry mouth and blurred vision were reported less frequently in patients treated with reboxetine than imipramine. On the other hand urinary hesitancy was significantly more frequent in reboxetine group. Noteworthy trends included greater frequency of headache in patients treated with reboxetine, of constipation in both the desipramine and reboxetine group and of tachycardia in desipramine treated patients.

9550089

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CLINICAL DEVELOPMENT, CNS

3.0 Rationale

Phase II results obtained in controlled conditions in adult patients suffering from Major Depressive Disorders indicate that reboxetine is an effective antidepressant agent. A dose-finding study in 12 elderly depressed patients showed overall good tolerability of reboxetine in the dose range of 4 to 8 mg. Only 3 out of 12 patients did not reach the maximum dose of 8 mg because of slight to moderate side effects (report in preparation). The tolerability and activity of the compound in the elderly need now to be tested in controlled conditions vs a reference antidepressant. Since phase II evidence on antidepressant efficacy of the compound is expected to apply also to the elderly, the analysis will focus on the comparative evaluation of the tolerability of two agents. Stratification for the diagnosis of Major Depressive Episode and Dysthymia will be undertaken.

4.0 Objective

The study will be carried out in order to evaluate the tolerability and efficacy of reboxetine in elderly patients suffering from depressive disorders.

5.0 Design

5.1 Description

This Phase III study will be carried out on a multi-center, multinational basis according to a double blind parallel group design, controlled vs imipramine with random allocation of patients to one of the two treatments.

5.2 Number of Subjects Proposed

Each center will recruit enough patients to collect a total sample of 300 patients fulfilling the criteria for entering the study.

5.3 Logistics

The centers participating in the study are listed in enclosure 1.

6.0 Study Population

6.1 Source of Subjects

Depressed patients in acceptable physical conditions hospitalized following the onset of depressive episode

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CLINICAL DEVELOPMENT, CNS

9550089

or attending the out-patients clinics of the participating centers.

6.2 Inclusion Criteria

- Patients aged over 65 years
- Fulfilment of the DSM-III-R criteria for Major Depressive Episode or Dysthymia (enclosure 2)
- Total score of 18 or more in the 21-HAMD (enclosure 3) at screen
- Total score of 22 or more in the MMS (enclosure 4)
- Informed consent (see 15.2, proposed form - enclosure 5)

6.3 Exclusion Criteria

- Resistance to antidepressant treatment (lack of response to at least two courses of previous antidepressants given at full doses for more than 1 month).
- Clinically relevant abnormal findings in the physical examination and/or laboratory tests at admission (see Safety Assessments).
- History of Major Depressive Episodes associated with endocrine disorders: hypo and hyper-thyroidism tested by TSH and T4 in thyroid drug-free conditions at screen and defined as at least 10% abnormal values of the laboratory norms; adrenal insufficiency, etc.
- Past history of any drug hypersensitivity.
- History or presence of gastrointestinal disease likely to cause impairment of gastrointestinal absorption, liver disease (hepatic insufficiency defined as clinically relevant abnormal findings of following tests: hemolytic markers - SGOT and SGPT; cholestasis markers - total bilirubin, gamma-GT, alkaline phosphatase; mesenchymal activations markers - serum protein electrophoresis) or kidney disease (renal insufficiency defined as moderate to medium renal impairment with creatinine clearance not lower than 30 ml.min⁻¹) or other conditions known to interfere with the absorption, distribution, metabolism and excretion of drugs.
- Participation in any clinical study with an investigational compound in the 4 weeks preceding the study

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CLINICAL DEVELOPMENT, CNS

9550089

8.2 Labelling

The experimental treatments will be contained in glass amber bottles labelled with the indication of the N° of subject and the treatment week (enclosure 6).

8.3 Packaging

Eighteen glass amber bottles (nine for the "morning" and nine for the "evening") labelled with the patient's number and the indication day 1-3, day 4 -7, week 2, week 3, week 4 ... week 8 will be prepared for each patient. For the first week two "morning" and two "evening" bottles will be prepared: 1 bottle will contain medication for days 1-3, i.e. 4 tablets (3 tablets + 1 tablet for possible losses), and 1 bottle will contain medication for days 4 -7, i.e. 5 tablets (4 tablets + 1).

Each "morning" and "evening" bottle for the treatment from week 2 to week 8 will contain the medication necessary for 7 days of treatment, i.e. 8 tablets (7 tablets plus 1 tablet for possible losses). In addition for each patient a carton labelled with the patient number and the indication "week 4 - dose 2" to "week 8 - dose 2" will be provided for the possible dosage increase during the treatment period starting from 4th week.

8.4 Drug Supplies Storage

Drug supplies will be stored at room temperature. All drug supplies will be handled under the direct responsibility of the Investigator and held by the hospital pharmacy.

The Study Monitor will check drug storage conditions during monitoring visits. The Investigator will be also responsible for drug accountability and will keep a record of the test compounds received from the Sponsor as well as of the dispensed drug.

8.5 Dispensing, Use and Disposal of the Preparation during and at the End of the Study

Medication will be dispensed to the patient on the occasion of each visit; the Investigator will detach the upper label from each of the weekly bottles and will attach them in the appropriate space in the Case Record Form. Used bottles will be returned to the study Monitor during site visits. All unused medication will be returned to Farmitalia Carlo Erba at the end of the study.

9550089

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CLINICAL DEVELOPMENT, CNS

9.0 Study Conduct

9.1 Pre-treatment Period

Patients will be checked for eligibility according to the inclusion and exclusion criteria. No washout will be needed in drug-free patients. A washout period will be required for patients stopping other medication before entry in the study. This period will last 4 days in the case of previous non-psychotropic medication, 7 days in the case of previous psychotropic medication including reversible MAO inhibitors, 14 days in the case of previous MAOI administration and 3 - 4 weeks in the case of previous fluoxetine therapy. During this period the only permissible psychotropic medication will be sleep inducer p.r.n. A shortacting benzodiazepine (see 9.6), alternatively chloral hydrate or chlormethiazole, as sleep inducer can be used.

Informed consent will be obtained (see 15.2). Eligible patients will be randomized to one of two treatment groups and will then undergo baseline assessments.

Information on patients screened for the study, including those not eligible, will be collected in the Screening Form - enclosure 7.

9.2 Treatment Schedule

Patients will receive 2 capsules of reboxetine or imipramine (one in the morning and one in the evening). Treatment will be taken at least 2 hours before or after meals.

In the case of lack of effect or unsatisfactory response (no change or minimal improvement at the CGI - see assessments) but of good tolerance, after 3 weeks of treatment the dose can be increased up to 6 mg of reboxetine or 100 mg of imipramine. In the case of intolerance the dose will be reduced to the previously well tolerated dosage level.

The daily dose can be reduced by half (only the morning dose will be administered) in the case of emergence of non tolerable signs or symptoms. Interruption of treatment for more than two consecutive days will not be allowed. Such patients will be defined as non compliant with the treatment.

9.3 Duration of Treatment

Treatment will be administered for eight weeks.

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CLINICAL DEVELOPMENT, CNS

9550089

9.4 Indications for Early Termination of Therapy

Termination of test therapy prior to completion of the treatment period may be considered under the following circumstances:

- Patient's request
- Unacceptable toxicity: this is defined as the occurrence of serious and/or unexpected (see Adverse Events) adverse events or the persistence of non tolerable signs or symptoms which are not alleviated by reducing the dose to the lower dosage level
- Lack of efficacy during the treatment: this will apply to patients who after completion of at least 3 weeks of treatment show worsening of the global clinical picture (CGI - Global Improvement, see assessments)
- Switch to mania

If treatment is discontinued the final complete battery of assessments will be carried out.

9.5 Dropouts/Replacement of Subjects

Patients who drop out of the study for any reason during treatment will not be substituted. For those patients who have been selected for the study who drop out at any time, even before the entrance to the treatment period, documentation will be provided.

9.6 Concomitant Therapy

Only drugs considered essential will be allowed. These should be stable for at least one month before admission to the study. Drugs that may interfere with the pharmacokinetics/pharmacodynamics of reboxetine will be stopped for a period at least 5 times their elimination half-life before the study start.

In particular the following drugs should not be used during the trial: neuroleptics, antidepressants, psychostimulants, tranquilizers (with the exception of sleep medication, see below), antiparkinson and anticholinergic agents, sympathomimetic drugs, hormones including L-thyroxine (with the exception of hormonal therapy of the degenerative diseases) and anesthetic agents.

During the course of the study non psychotropic medication which is considered necessary for the

FARMITALIA CARLO ERBA
ERBACONT GROUP
CLINICAL DEVELOPMENT, CNS

9550089

patient's welfare may be administered. The drugs, dosage, reason and frequency of administration will be recorded on the CRF. A shortacting benzodiazepine, alternatively chloral hydrate or chlormethiazole, as a sleep inducer p.r.n. at bed-time will be allowed.

9.7 Indications for opening the code

The Investigator will be given individual sealed envelopes containing the information on each patient's treatment. These latter may be opened only in case of emergency necessitating treatment identification; the Investigator will immediately (within 24 hours) inform the study Monitor (enclosure 13) or FICE Milan (see address on cover page) and will report full description of reasons for opening the code in the CRF (Adverse Event Form).

9.8 Follow-up

A follow-up visit will be carried out for each patient one month after treatment discontinuation in order to monitor possible withdrawal reactions and collect information on possible adverse events.

Patients willing to continue receiving the experimental treatment after completion of the 8 week treatment period, and having demonstrated very good or good improvement (CGI) at the end of the 8th week vs day 0, will be maintained under the experimental treatment on a long-term basis in double-blind conditions up to completion of the 2 months experimental treatment in the last patient of the study. Afterwards patients may continue the treatment in open conditions with reboxetine or imipramine respectively.

9.9 Study Timetable

Foreseen start date:	July 1992
Duration of accrual:	12 months
Foreseen end date:	July 1993

10.0 Efficacy Assessments

10.1 Variables to be Measured for Efficacy Assessment

On days 0, 7, 14, 21, 28, 35, 42, 49 and 56 the following scales will be applied:

- 21-items Hamilton Depression Rating Scale /HAMD/ (7), see enclosure 3
- Montgomery-Asberg Depression Rating Scale /MADRS/ (8), see enclosure 15

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CLINICAL DEVELOPMENT, CNS

9550089

- Geriatric Depression Rating Scale /GDS/ (9), see enclosure 16
- Clinical Global Impression /CGI/ (10), see enclosure 8

All psychiatric evaluations and ratings will be carried out by the same observer for a given patient.

10.2 Efficacy Definition

An improvement of clinical picture scored as "1" (very much improved) or "2" (much improved) on the Clinical Global Impression - Global Improvement vs day 0 will be considered to be a response.

10.3 Criteria for Efficacy Evaluability

Every randomized patient will be included in the analysis.

11.0 Safety Assessment

11.1 Variables to be Measured for Safety Assessment

- Standard medical history: pre-treatment screen
- Standard clinical examination: full physical examination; chest X-ray or pulmonary function test (optional): screen
- Blood pressure and pulse will be measured in the lying position (after 5 minutes lying) and in the standing position (1-2 minutes after standing up) in the morning: at each weekly visit
- ECG: at screen, day 28 and at the end of treatment
- At screen: TSH, T4 and creatinine clearance. Alternatively creatinine clearance can be calculated according to the formula:
$$\frac{(140 - \text{age}) \times \text{body weight (kg)}}{72 \times \text{serum creatinine (mg/ml)}} \quad (\text{male})$$

$$\frac{(140 - \text{age}) \times \text{body weight (kg)}}{85 \times \text{serum creatinine (mg/ml)}} \quad (\text{female})$$
- laboratory tests (full blood count, ESR, serum electrolytes, liver enzymes, blood sugar, BUN, serum creatinine, uric acid, total bilirubin, total serum proteins and electrophoresis, serum cholesterol and triglycerides, urine analysis): at screen, day 28 and at the end of treatment

FARMITALIA CARLO ERBA
ERBAMONT GROUP
MEDICAL DEVELOPMENT, CNS

9550089

-
- Adverse events: a check list will be administered at each visit (see enclosure 9).

11.2 Criteria for Safety Evaluability

Every patient who has received at least one dose of the experimental treatment will be included in the safety evaluation.

12.0 Adverse Events

Patients will be notified of possible adverse events they could experience and instructed to immediately report them to the Investigator.

12.1 Definitions

"Serious": Any event that suggests a significant hazard, contraindication, side effect or precaution, including any one of the following:

- fatal or life-threatening;
- disabling or incapacitating;
- requiring or prolonging hospitalization;
- congenital anomaly;
- cancer;
- overdose.

For a list of examples of "serious" adverse events reported to U.K. CSM, see Br. J. Clin. Pharmacol. 26: 679-688, 1988.

"Unexpected": Any adverse event that is not identified in nature, severity or frequency in the current investigator brochure because it has not been previously reported in association with the given investigational drug or, if previously reported, its frequency has not yet been adequately characterized.

12.2 Information to be collected

The following information should be collected for every adverse event occurring in the study:

- study and patient identification;
- age, sex, race, weight;
- treatment and dose at time of adverse event;
- concomitant drugs;
- date of onset, if known, or clinic visit at which the event was discovered;
- duration of treatment at time of adverse event (or date of treatment start);
- description of the adverse event (verbatim, using the original term used by the Investigator);

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CLINICAL DEVELOPMENT, CNS

9550089

-
- duration of the adverse event;
 - severity (e.g. mild, moderate, severe);
 - action taken (none, change in dose, treatment interrupted or stopped, etc.);
 - outcome (recovered with no residual effect, persistent but no treatment, persistent and being treated, residual effect being treated, residual effect with no treatment, death);
 - dechallenge (did the AE disappear after treatment withdrawal or dose reduction?)
 - rechallenge (did the AE reappear on resuming treatment?)
 - investigator's evaluation of causal relationship between treatment and AE.

The Karch and Lasagna modified criteria (enclosure 11) will serve as guidelines for definition of drug cause-effect relationship.

The same information should be collected for any serious AE occurring within one month of the last dosing or during follow-up. In the case of death on study or within one month after the last dosing, the following additional information is needed:

- cause of death;
- other significant conditions contributing to death, but not related to the causes given above;
- autopsy findings (when applicable)

The same information should be collected if death occurs later but is the final outcome of an event which started within the indicated time frame.

12.3 Procedure of report

Any adverse event, noticed by the Investigator or complained of by the patient, including clinically relevant lab abnormalities, will be recorded in the appropriate section of the CRF, regardless of presumed relationship to study medication.

In addition, any serious (expected or unexpected) adverse event should also be reported separately, as promptly as possible (within 24 hours) to the study monitor and by filling in an Adverse Event Report Form (enclosure 10).

Any fatal or life-threatening event should be reported immediately by the Investigator by phone or fax to the local study monitor. Farmitalia Carlo Erba will notify the regulatory authorities in accordance with statutory requirements.

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CLINICAL DEVELOPMENT, CNS

9550089

13.0 Evaluation Schedule

Is reported in table 1.

14.0 Statistical Considerations

14.1 Sample size

The main aim of the study is to compare the safety of the two compound, reboxetine and imipramine, the former being expected as better tolerated. In order to test this hypothesis the ratio between the number of patients experiencing at least one adverse events, mild through severe, whichever the nature, during the study period out of the total number of randomized patients will be taken as the principal end-point of the study.

Previous studies with imipramine estimated a rate of adverse events, mild to severe, as high as 60%. The rate of events of the same severity under reboxetine is expected to be no higher than 40%.

Additionally, since ethical reasons suggest to stop the trial in this type of population as soon as a conclusion of inferiority of one of the two treatments is reached, one interim analysis according to O'Brian Fleming group sequential method is planned.

Therefore in order to prove with a power of 90% the hypothesis of a better tolerability of reboxetine, according to the above mentioned O'Brian Fleming plan, 67 patients per arm for each of the two sequentially tested groups are required. The procedure will ensure an overall two tailed- α -level of 0.05 and the significance test will be carried out at a level 0.015 at the first stage and 0.042 at the second stage.

14.2 Statistical Analysis

The analysis of the main end-point of the study will be carried out by Mantel-Haenszel test using center as stratification factor. Adverse events will be also described in terms of severity, relationship with the treatments and time of onset. Body system classification of events will be included.

For all the laboratory examination and within each of the two treatments the following analysis will be provided:

- Frequency and percentage of patients whose values are below, within or above the normal range at each

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CLINICAL DEVELOPMENT, CNS

9550089

visit. Either Mc Nemar test or Stuart-Maxwell test will be adopted for testing if the distribution across the categories at baseline differs from the distribution at each visit.

- Frequency and percentage of patients whose values are lower, equal or higher than their baseline values. Two tails sign test will be adopted for testing the hypothesis of equality of the proportion of lower values and higher values against the alternative hypothesis of difference in either the directions. Comparison with baseline and each visit will be provided.
- Means of difference between baseline and each visit assessment will be tested by either two-tails paired t-test or signed-rank test depending on the distribution of the variable. Standardisation across different laboratories ranges will be provided in order to make difference comparable.

Vital signs will be summarised by descriptive statistics, broken down by treatment.

Efficacy variables, as Hamilton total score, Clinical Global Impression score, Efficacy index score, considered as secondary end-points of this study will be submitted to parametric or non parametric explorative analysis, such as analysis of covariance, Wilcoxon test. Ninety-five percent confidence interval of the differences of means of continuous variables after 4 and 8 weeks of treatment will be also provided.

15.0 Ethical Aspects

The study will be carried out according to the Helsinki Declaration (Hong-Kong revisions, enclosure 12).

15.1 Ethical Committee

This study will not be undertaken until approval is obtained from the Ethical Committee of each participating center. It is responsibility of the Investigator to submit the study protocol with its attachments to the Committee.

The Investigator is committed, in compliance with local requirements, to inform the Committee of any emergent problems, serious adverse reactions or protocol amendments.

15.2 Informed Consent

Before entering the study each patient will receive the information about the nature, duration and purpose of

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CLINICAL DEVELOPMENT, CNS

9550089

the study and the action of the compound explained in such a manner that the patient is aware of the potential risks, inconveniences or adverse effects that may occur and can express his/her informed consent to participation.

The consent form (proposed form - enclosure 5) will be signed by the patient or by the next of kin and by the Investigator. In the latter case, the signature of a witness will testify that full information has been given to the patient.

16.0 Protocol Amendments

After the protocol has been signed, no changes will be made without the agreement of both the Investigator and the Sponsor. Any change will be recorded on a written agreement which will be signed and dated by both parties and attached to the original protocol. Where required by local laws regulatory approval will be obtained before implementing any protocol amendment.

17.0 Study Monitoring

The Monitors for the study are listed in enclosure 13. A prestudy visit will be made by the Monitor to the Investigator in order to discuss problems, if any, and the obligations of both the Sponsor and the Investigator. During the trial monitoring visits will be paid to the site by the study Monitor monthly.

The trial may also be monitored by the Sponsor's Quality Assurance Department. During visits the Monitor will assess the progress of the study, review compliance with the study protocol, discuss any problem, check the CRFs for legibility, accuracy and completeness, assess the status of drug storage dispensing and retrieval.

18.0 Supply and Inventory

Test preparations will be supplied by Farmitalia Carlo Erba in the form described in 6.1. Records will be kept by the Investigator as to the disposition of study drug for each patient. A disposition form accounting for all study supplies will be signed by the Investigator (enclosure 17).

19.0 Administrative Aspects

19.1 Insurance Policy

Farmitalia Carlo Erba Company declares to have a group insurance cover (policy N°481.440647.50 - Fondiaria Assicurazioni) which provides indemnity to the

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CLINICAL DEVELOPMENT, CNS

9550089

Investigator, to the co-Investigators and to the subjects participating in the trial (enclosure 14). Where local law requires the investigator will be provided with the complementary police by the Subsidiary.

19.2 Curriculum Vitae

The Investigator will provide the Sponsor with signed copies of his/her and co-Investigators CVs.

19.3 Data Collection in the Case Record Form

All study data will be recorded in the CRF supplied by the Sponsor (Attachment B). A black ink ball point pen should be used for entering the data to ensure the good quality of the reproduced CRFs copies.

Only the Principal Investigator and the duly authorized co-Investigators can make entries in the CRF.

Corrections must be made by crossing out the incorrect entry (which must remain legible) and entering the correction followed by the Investigator's initials and the date of the correction.

During monitoring visits the Monitor will remove the original and one copy of each page, while the Investigator will retain a copy for his files. These copies together with the drug disposition records will be kept by the Investigator for fifteen years after the discontinuation of the investigation.

19.4 Use of the Information related to the Study

All unpublished documentation including the protocol, the CRF and the Investigator's Brochure, given to the Investigator is confidential. These documents cannot be disclosed to a third party without the written consent of FICE R&D. The submission of these documents to the Ethical Committee is expressly permitted.

The Investigator agrees that FICE R&D maintains the right to utilize the results of this study, in their original form and/or in a global report, for submission to the governmental and regulatory authorities of any country.

19.5 Statement of Investigator

The study will be carried out according to Good Clinical Practice (GCP). The Investigator agrees to comply with the GCP procedures by signing the statement (enclosure 18).

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CLINICAL DEVELOPMENT, CNS

9550089

20.0 Study Report

20.1 Clinical Study Final Report

The final Medical Study Report will be written by the Product Leader and will be submitted to the Investigator for approval and signature.

20.2 Publication of Study Results

The results of the study will be published in a common publication, agreed upon between Investigator and FICE R&D.

The Investigator, whilst free to use the data resulting from this study for individual publications (subsequent to the common one), is asked to discuss any paper with Farmitalia Carlo Erba prior to submission; to this purpose a copy of manuscript/abstract has to be provided for FICE R&D Approval Procedure 30 days prior to publication.

21.0 End of the Study

Either the Investigator or FICE R&D could terminate this study at any time for well documented reasons. In this event the other party will be immediately notified.

22.0 References

1. Reboxetine Investigator Brochure, FICE, CNS Line, June 1988
2. /602i - Herrman W.M. et al. (AFB - Berlin)
Safety and tolerance of reboxetine in healthy male volunteers - A single rising dose tolerance study.
June 15, 1984.
3. /603i - Herrman W.M. (AFB - Berlin)
Reboxetine - Quantitative pharmaco EEG and pharmacopsychological study.
January, 1985.
4. /604i - Dubini A. et al.
Disposition and fate of ¹⁴C- reboxetine administered orally to healthy volunteers.
March, 1985.
5. /118i - Strolin Benedetti et al.
A new HPLC method for the determination of FCE 20124 and its metabolite FCE 22930 in human plasma.
September, 1987.

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CLINICAL DEVELOPMENT, CNS

9550089

6. Stark P., Hardison D.
J. Clin. Psychiat. 1985, 46, 3:53-58
7. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol, 1967, 6:278-296
8. Montgomery SA, Asberg M: A new depression rating scale designed to be sensitive to change. Br J Psychiat, 1979, 134:382-389
9. Yesavage JA, Brink TL, Rose TL, Adey M: The geriatric depression rating scale: comparison with other self-report and psychiatric rating scales. In: Crook T, Ferris S, Bartus R (eds.): Assessment in geriatric psychopharmacology. M Powley Ass Inc, New Canaan, 1983:166-167
10. Guy W: Early Clinical Drug Evaluation Unit (ECDEU) assessment manual. US Department of Health, Education and Welfare. Washington DC, 1976:217-222

23.0 Signatures

Investigator _____

Study Monitor _____

Product Leader *M. J. Jansse*

Line Medical Head *Adriano Rubin*

Biostatistician *Anna Petrosione*

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CLINICAL DEVELOPMENT, CNS

9550089

LIST OF ENCLOSURES

1. LIST OF CENTERS
2. DSM-III-R CRITERIA OF MAJOR DEPRESSIVE EPISODE AND DYSTHYMIA
3. HAMILTON DEPRESSION RATING SCALE (HAMD)
4. MINI MENTAL STATE (MMS)
5. CONSENT FORM
6. EXPERIMENTAL TREATMENT LABELLING
7. SCREENING FORM
8. CLINICAL GLOBAL IMPRESSION (CGI)
9. ADVERSE EVENTS CHECK LIST
10. ADVERSE EVENT REPORT FORM
11. KARCH AND LASAGNA MODIFIED CRITERIA
12. DECLARATION OF HELSINKI
13. LIST OF MONITORS
14. INSURANCE POLICY
15. MONTGOMERY-ASBERG DEPRESSION RATING SCALE
16. GERIATRIC DEPRESSION SCALE
17. DRUG ACCOUNTABILITY FORM
18. STATEMENT OF INVESTIGATOR

ATTACHMENT A

PROTOCOL 20124/035: OPERATING PROCEDURES FOR TRAINING ON ASSESSMENT INSTRUMENTS, STUDY MONITORING AND COORDINATION

ATTACHMENT B

CASE RECORD FORM

FARMITALIA CARLO ERBA
 ERBAMONT GROUP
 CLINICAL DEVELOPMENT, CNS

9550089

Table 1

		EVALUATION SCHEDULE									
Period	:	Screen		Treatment							
Day	:	0	7	14	21	28	35	42	49	56	
<u>Assessment</u>											
Medical History	:	X									
Physical Examination	:	X									
ECG	:	X				X				X	
MMS	:	X									
Vital Signs	:	X	X	X	X	X	X	X	X	X	
Laboratory	:	X				X				X	
HAMD	:	X	X	X	X	X	X	X	X	X	
MADRS	:		X	X	X	X	X	X	X	X	
GDS	:		X	X	X	X	X	X	X	X	
CGI	:		X	X	X	X	X	X	X	X	
Adverse Events	:		X	X	X	X	X	X	X	X	

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CLINICAL DEVELOPMENT, CNS

9550089

Enclosure 1

LIST OF PARTICIPATING CENTERS

No.	Country	Principal Investigator (Institution, Address)	Number of patients
1.	Australia	Prof. Edmond Chiu Academic Unit for Psychiatry of Old Age Mont Park Hospital Campus Private Bag N° 1 Rosanna Victoria 3084	10
2.	"	Dr. David Ames Royal Park Psychiatric Hospital Park St, Parkville Victoria 3052	10
3.	"	Prof. John Snowdon Director of Psychogeriatrics The Rozelle Hospital P O Box 1, Rozelle NSW 2039	10
4.	"	Dr. Bob Russell Dpt of Rehabilitation and Geriatrics Royal North Shore Hospital Pacific Highway, St Leonards NSW 2065	10
5.	Belgium	Prof. M. Van Moffaert Universitair Ziekenhuis Gent Psychiatrische Kliniek De Pintelaan 185, 9000 Gent phone (091) 4043390	20
6.	"	Dr. Remi Spiers Dr. J.E. Dewilde Sint Camillus Ziekenhuis Beukenlaan 20 9820 Sint-Denijs-Westrem	20
7.	"	Dr. G. Bollen Dr. Hannes Sancta Maria Ziekenhuis Melverencentrum 11 3800 Sint-Truinden	12
8.	"	Dr. F. Roelandts Universitair Ziekenhuis De Pintelaan 185, 9000 Bruxelles	20

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CLINICAL DEVELOPMENT, CNS

9550089

Enclosure 1 cont'd

9. Brazil	Prof. Costa e Silva Department of Psychiatry University of Rio de Janeiro 22461 Rio de Janeiro Tel: (55-21) 2260112	10
10. "	Prof. M. Versiani Department of Psychiatry Federal University Av. Capacabana 1133, s. 1303 Rio de Janeiro Tel: (55-21) 5213993	40
11. France	Dr. Micas Hopital Lagrave, Place Lange 31052 Toulouse Cedex tel. 61777833	8
12. "	Dr. Jean Pierre Charmes Hopital Jean Rebeyrol Service de Gériatrie Avenue du Buisson 87042 Limoges Cedex tel. 55056123	8
13. "	Dr. Quenet Centre National de Geriatrie 78320 La Verriere tel. 34617942	8
14. "	Dr. Caussannel Service de Neurologie Centre Hospitalier General Route de Tarbes 32011 Auch tel. 62613232	8
15. "	Prof. Philippe Delwailly Centre de Soins Pour Personnes Agées 104 Avenue du Peuple Belge 59037 Lille Cedex tel. 20444598	8
16. "	Dr. Pagot Centre Hospitalier Specialise 56896 Saint-Ave Cedex tel. 97544949	8

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CLINICAL DEVELOPMENT, CNS

9550089

Enclosure 1 cont'd

17.	France	Prof. Bercoff Hopital de Boisguillaume Service de Gériatrie 147 rue du Maréchal Juin 76320 Boisguillaume tel. 35088181	8
18.	"	Dr. Clerc Centre Hospitalier ScECIALISE 7 Chaussee de Villecherel 50170 Pontorson tel. 33607200	8
19.	"	Dr. Serio Giovanni Clinique "La Roseraie" 6 rue Neuve de l'Hopital 02200 Soissons tel.23531404	8
20.	"	Dr. Castiglioni Hopital Sainte Merguerite Service de Psychiatrie 270 Bd Sainte Marguerite 13275 Marseille Cedex tel. 91744000	8
21.	"	Dr. J. Verdeau Pailles Polyclinique Neuro Psychiatrique 11300 Limox tel. 68310061	8
22.	Germany	Dr. H. Berzewski Psychiatr. Ambulanz und Kriseninterventionsstation Freie Universität Berlin Universitätsklinikum Steglitz Hindenburgdamm 30, W-1000 Berlin 45	6
23.	"	Prof.Dr.K. L. Täschner Bürgerhospital der Stadt Stuttgart Psychiatrische Klinik Tunzhofer Strasse 14-16 7000 Stuttgart	6
24.	"	Prof.Dr.F.Reimer Psychiatrisches Landeskrankenhaus 7102 Weinsberg	4

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CLINICAL DEVELOPMENT, CNS

9550089

Enclosure 1 cont'd

25.	Germany	Prof.Dr. H.J.Möller Psychiatrische Universitätsklinik Sigmund-Freud-Str. 25 5300 Bonn (Venusberg) 1	2
26.	"	Dr. Morgner BZKH Dresden-Neustadt Klinik für Neuropsychiatrie Oberloschwitz, Alpenstr. 1 0-8054 Dresden	6
27.	"	Prof.Dr.B.Pflug Universitätsklinik Frankfurt Zentrum für Psychiatrie Heinrich-Hoffmann-Str. 10 6000 Frankfurt 71	4
28.	"	Dr.H.J.Schierle Puisseauxplatz 2 6054 Rodgau	8
29.	"	Prof.Dr.H.Woelk Psychiatrisches Krankenhaus Universität Giessen Licher Strasse 106, 6300 Giessen	24
30.	United Kingdom	Dr S. V. Korgaonkar Weller Wing, Bedford General Hospital Kempston Road, Bedford MK42 9DJ Tel: (44) 234-355122	10
31.	"	Dr. B. Lawlor St James' Hospital Dublin (353) 1537822	6
32.	"	Prof. C. Katona (N° to be confirmed) Princess Alexandra Hospital Harlow (44) 279444455	
3301	"	Dr. L. Luke Luton and Dunstable Hospital Lewsey Road Luton Beds LU4 0DT (44) 0582491122	8

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CLINICAL DEVELOPMENT, CNS

9550089

Enclosure 1 cond't

3302	United Kingdom	Dr. L. Luke Fairfield Hospital Stotfield Road Hitchin, Herts SG5 4AA Tel: (44) 0462 730123	8
34.	Belgium	cancelled	
35.	"	Dr. P. Bourgeois Heilig Hart Ziekenhuis Wilgenstraat 2 8800 Roeselare	8
36.	"	Dr. Ph. Tack Sint Andries Ziekenhuis Neuropsychiatries Krommewalstraat 11 8700 Tielt	8
37.	"	Dr. M Derely Institut SANATIA Rue du Moulin 27-29 1020 Bruxelles	cancelled
381.	United Kingdom	Dr. I. K. I. Ibrahim Farnham Hospital Hale Road, Farnham Surrey, GU9 9QL Tel: (44) 252-726666	10
382.	"	Dr. I. K. I. Ibrahim Frimley Park Hospital Portsmouth Road Camberley, Surrey GU16 5UJ Tel: (44) 276-692777	10
39.	"	Dr. A. Bayer Royal Cardif Infirmary (44) 222492233	8
401.	"	Dr. G. Nanayakkara/Dr. J. Hajioff Hill End Hospital Hill End Lane St Albans, Herts AL4 0RB Tel: (44) 727-855555	8
402.	"	Dr. G. Nanayakkara/Dr. J. Hajioff Hemel Hempstead General Hospital Hillfield Road Hemel Hempstead Hertfordshire HP2 4AD Tel: (44) 442- 213141 ext 2800	8

FARMITALIA CARLO ERBA
ERBANONT GROUP
CLINICAL DEVELOPMENT, CNS

9550089

Enclosure 1 cont'd

- | | | |
|--------------------|--|---|
| 41. United Kingdom | Dr. E. J. Byrne
Withington Hospital
West Didsbury
Manchester, M20 8LR
Tel: (44) 61-447-3317 | 8 |
| 42. " | Dr T. Venkateswarlu
The Directorate of Mental Health
729 The Ridge
St Leonards-on-Sea
East Sussex TN37 7PT
Tel: (44) 424-754889 | 8 |
| 43. Australia | Dr Tom George
Prince Charles Hospital
Brisbane | |
| 44. United Kingdom | Dr T Smout
Pembury Hospital
Tonbridge Wells, Kent TN2 4QJ | |

9550089

Enclosure 2

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2|0|1|2|4|0

Centre No. [][][][]

Pat. Initials [][][]

Visit/cycle S|C|R|E|

Date [][][]
[][][]

DSM-III-R: DIAGNOSTIC CRITERIA FOR THE MAJOR DEPRESSIVE EPISODE

Note: all A, B, C and D must be marked as "present"

Mark "1" if present

A. At least five of the following symptoms have been present during the same two-week period and represent a change from previous functioning; at least one of the symptoms is either 1) depressed mood or 2) loss of interest or pleasure.

- 1) depressed mood most of the day, nearly every day, as indicated by subjective account or observation by others
- 2) markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day (as indicated either by subjective account or observation by others of apathy most of the time)
- 3) significant weight loss or weight gain when not dieting (e.g. more than 5% of body weight in a month), or decrease or increase in appetite nearly every day
- 4) insomnia or hypersomnia nearly every day
- 5) psychomotor agitation or retardation nearly every day (observable by others, not merely subjective feelings of restlessness or being slowed down)
- 6) fatigue or loss of energy nearly every day
- 7) feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) nearly every day (not merely self-reproach or guilt about being sick)
- 8) diminished ability to think or concentrate, or indecisiveness, nearly every day (either by subjective account or as observed by others)
- 9) recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide

"A" present.....

- B. 1) It cannot be established that an organic factor initiated and maintained the disturbance
- 2) The disturbance is not a normal reaction to the death of a loved one

"B" present.....

C. At no time during the disturbance have there been delusions or hallucinations for as long as two weeks in the absence of prominent mood symptoms (i.e., before the mood symptoms developed or after they have remitted)

"C" present.....

D. Not superimposed on Schizophrenia, Schizophreniform Disorder, Delusional Disorder, or Psychotic Disorder NOS.

"D" present.....

703

2-scre

investigator's signature _____

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

FARMITALIA CARLO ERBA
Erbamont Group

Compound ~~REDOXINE~~ Enclosure 2 cont'd Protocol No 210.124.035

Centre No. [][][][] Pat. Initials [][][] Visit/cycle S I C R E E N
Date [][][] [][][] [][][]
D M Y

DSM-III-R: DIAGNOSTIC CRITERIA FOR THE DYSTHYMIA

Note: all A, B, C, D, E, F, and G must be marked as "present" Mark "X" if present

- A. Depressed mood for most of the day, more days than not, as indicated either by subjective account or observation by others, for at least two years. "A" present.....
- B. Presence, while depressed, of at least two of the following:
- 1) poor appetite or overeating
 - 2) insomnia or hypersomnia
 - 3) low energy or fatigue
 - 4) low self-esteem
 - 5) poor concentration or difficulty making decisions
 - 6) feelings of hopelessness
- "B" present.....
- C. During a two-year period of the disturbance, never without the symptoms in A for more that two months at a time. "C" present.....
- D. No evidence of an unequivocal Major Depressive Episode during the first two years of the disturbance. "D" present.....
- E. Has never had a Manic Episode or an unequivocal Hypomanic Episode. "E" present.....
- F. Not superimposed on a chronic psychotic disorder, such as Schizophrenia or Delusional Disorder. "F" present.....
- G. It cannot be established that an organic factor initiated and maintained the disturbance, e.g., prolonged administration of an antihypertensive medication. "G" present.....

3-scre

Investigator's signature _____

9550089

Encl. 3 cont'd

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2|0|1|2|4|0|3|5|

Centre No. [][][][]

Patient No. [][][]

Initials [][][]

Visit/Cycle [D|A|Y|][0]

Date [][][][][][][]
D M Y

8. Retardation (Slowness of thought and speech; impaired ability to concentrate; decreased motor activity)

- [0] Normal speech and thought
 [1] Slight retardation at interview
 [2] Obvious retardation at interview
 [3] Interview difficult
 [4] Complete stupor

9. Agitation

- [0] None [1] Fidgetiness [2] Playing with hands, hair, etc.
 [3] Moving about, can't sit still [4] Hand wringing, nail biting, hair-pulling, biting of lips

10. Anxiety psychic

- [0] No difficulty [1] Subjective tension and irritability
 [2] Worrying about minor matters [3] Apprehensive attitude apparent in face or speech
 [4] Fears expressed without questioning

11. Anxiety somatic

Physiological concomitants of anxiety, such as: Gastro-intestinal (*dry mouth, wind, indigestion, diarrhea, cramps, belching*); Cardio-vascular (*palpitations, headaches*); Respiratory (*hyperventilation, sighing*); Urinary frequency; Sweating

- [0] Absent [1] Mild [2] Moderate
 [3] Severe [4] Incapacitating

12. Somatic symptoms gastrointestinal

- [0] None
 [1] Loss of appetite but eating without staff encouragement. Heavy feelings in abdomen
 [2] Difficulty eating without staff urging. Requests or requires laxatives or medication for bowels or medication for G.I. symptoms

13. Somatic symptoms general

- [0] None
 [1] Heaviness in limbs, back or head. Backaches, headache, muscle aches. Loss of energy and fatigability
 [2] Any clear-cut symptoms rates 2

14. Genital symptoms (Such as: Loss of libido; Menstrual disturbances)

- [0] Absent [1] Mild [2] Severe

15. Hypochondriasis

- [0] Not present [1] Self-absorption (bodily)
 [2] Preoccupation with health [3] Frequent complaints, requests for help, etc.
 [4] Hypochondriacal delusions

3

Investigator's signature _____

706

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9550089

Enclosure 4

FARMITALIA CARLO ERBA

Compound REBOXETINE

Protocol No

Erbamont Group

Patient No

Initials

Visit/Cycle

Centre No:

Investigator name

Monitor's name

Date

MINI-MENTAL STATUS

Necessary materials: pencil, three sheets of drawing paper

Tick for a correct response

- | | |
|--|--------------------------|
| 1. What day of the week is it? | <input type="checkbox"/> |
| 2. What is the date today? | <input type="checkbox"/> |
| 3. What is the month? | <input type="checkbox"/> |
| 4. What is the season? | <input type="checkbox"/> |
| 5. What is the year? | <input type="checkbox"/> |
| <hr/> | |
| 6. Where are we now? | <input type="checkbox"/> |
| 7. What floor are we on | <input type="checkbox"/> |
| 8. In which town are we? | <input type="checkbox"/> |
| 9. In which county/districts are we? | <input type="checkbox"/> |
| 10. In which country are we? | <input type="checkbox"/> |
| 11. Repeat the following words: "Lemon, Key, Balloon" | <input type="checkbox"/> |
| 12. (The examiner should pronounce the words at a rate of | <input type="checkbox"/> |
| 13. one per second. In case of difficulties repeat up to 5 times) | <input type="checkbox"/> |
| <hr/> | |
| 14. | <input type="checkbox"/> |
| 15. Subtract 7 from 100 and make 5 subtractios | <input type="checkbox"/> |
| 16. | <input type="checkbox"/> |
| 17. Each correct subtraction = Tick | <input type="checkbox"/> |
| 18. | <input type="checkbox"/> |
| <hr/> | |
| 19. | <input type="checkbox"/> |
| 20. Can you remember the three words you have just said? | <input type="checkbox"/> |
| 21. | <input type="checkbox"/> |
| <hr/> | |
| 22. What is this? (show a pencil) | <input type="checkbox"/> |
| 23. What is this? (show a watch) | <input type="checkbox"/> |
| 24. Repeat the following "No ifs, ands or buts" | <input type="checkbox"/> |
| <hr/> | |
| 25. Follow a three-stage command. "Take this piece of paper, | <input type="checkbox"/> |
| 26. fold it in half and put it on the floor" | <input type="checkbox"/> |
| 27. (Maximum 3 points) | <input type="checkbox"/> |
| <hr/> | |
| 28. Read and obey what is written on this piece of paper ("Close your eyes") | <input type="checkbox"/> |
| <hr/> | |
| 29. Write a sentence of your choice on this piece of paper. | <input type="checkbox"/> |
| <hr/> | |
| 30. Copy this drawing on a piece of paper | <input type="checkbox"/> |

Total correct _____



Page n _____ Visit n. _____

Signature _____

708

9550089

ENCLOSURE 5

REBOXETINE PROTOCOL 20124/035

Multicenter, multinational double blind study of the tolerability and activity of reboxetine vs imipramine in elderly patients with depressive disorders.

CONSENT FORM

Principal Investigator:

EXPLANATION

Purpose of the study

Reboxetine, a new potential antidepressant agent, has effects in animals which suggest that it may exert therapeutic efficacy of faster onset, in comparison with established antidepressant drugs, in patients suffering from depressive disorders. The trial is proposed in order to learn about the antidepressant effectiveness and the tolerability of the compound in elderly patients.

Plan of the study

After an initial drug free wash out period of 4 to 7 days, patients will receive reboxetine in the daily dose up to 8 mg, or imipramine in the daily dose up to 150 mg for eight weeks. Treatment will be discontinued in case of re-emerge of psychiatric symptomatology or in case of significant side-effects. In addition patients participating in the study can withdraw their consent at any time without prejudice to their continued medical treatment.

During treatment, physical and psychiatric examination will be done on frequent occasions, in order to determine possible side-effects and benefit of treatments. Blood tests, urinalysis, ECG will be undertaken at the entry to the study, after 4 weeks of treatment and at the end of the treatment. Blood pressure and pulse will be taken every week.

Possible discomforts and risks

Antidepressant drugs can cause dry mouth, blurred vision, dizziness, mild difficulty in voiding urine, postural hypotension and electrocardiographic changes.

Reboxetine has been so far administered for 28 days to about 180 patients and was well tolerated up to the dose of 5 mg twice daily. In the dose range of 3-5 mg twice daily clinically relevant improvement of depressive condition was present in the majority of patients; symptoms complained off by patients were mainly mild and transient and included most frequently headache, sweating, lassitude, nasal congestion, constipation and urinary hesitancy. At higher doses orthostatic hypotension, tachycardia, dizziness, blurred vision and nausea were reported.

Patients participating in the study will be carefully monitored to detect early signs of such side-effects.

Possible benefits

Other drugs are available for treatment of depressive disorders but none has been of proven value in all cases. This study will allow the evaluation of the antidepressant activity of reboxetine in comparison with imipramine, a compound of established efficacy.

Alternative treatment

Patients would receive alternative pharmacological therapy with an antidepressant drug chosen on the basis of response during previous episodes, if any. Risks and benefits of receiving treatment with any of the available antidepressant drugs can be explained by the Investigator.

Confidentiality

Participation in the study will be kept confidential to the extent permitted by law.

Problems and questions

Should any problem or question arise with regard to the study, patients can contact the Principal Investigator:

.....
or the other staff members also involved in the study:

.....

9550089

ENCLOSURE 5

In addition any problem or question can be discussed with a member of the Institutional Review Board, the Committee which has evaluated the potential risks and possible benefits of the study.

Payments and policy regarding research-related injuries.

Patients will not be paid for the participation in the study. The Clinical Center will provide short-term medical care for any physical injury resulting from participation in the study. No long-term medical care or financial compensations for such injuries will be provided except as it may be through whatever remedies are normally available under law. Insurance coverage is granted through the Sponsor Company.

PATIENT CONSENT

I have read the explanation about this study and I have been given the opportunity to discuss it and to ask questions. I hereby consent to take part in this study.

Patient's Signature

date

I have explained all the above indicated aspects of the study to the patient, who expressed his/her consent to the participation.

Investigator's Signature

date

Witness' Signature

date

9550089

ENCLOSURE 6

REBOXETINE PROTOCOL 20124/035

EXPERIMENTAL DRUG LABELLING

REBOXETINE PROTOCOL 20124/035
PATIENT N°
WEEK
BATCH N°
EXPIRY.....
DRUG FOR INVESTIGATIONAL USE

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9550089

Enclosure 7



Patent article

Hospital File Out Patient Reg. N°

1111111

Phase III

**Multicenter, multinational
double-blind study
of the activity and
tolerability of reboxetine
vs imipramine
in elderly patients with
depressive disorders**

PROTOCOL 20124/035

SCREENING FORM

Investigator's signature _____

ERBAMONT GROUP

713

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9550089

Encl 7 cont'd

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 20124/03 5

Pat. Initials [][][][]

Visit: **S: C: R: E: E: N**

Date [][][] [][][] [][][]
D M Y

ADMISSION EXAMINATION

CHEST X-RAY taken on [][][] [][][] [][][] normal abnormal
D M Y

If abnormal, detail _____

VITAL SIGNS

- Body temperature (°C) [][][]
- Respiratory rate (breaths/min) [][][]
- 5 min lying arterial blood pressure (mmHg) systolic [][][] diastolic [][][]
- 5 min lying heart rate (beats/min) [][][]
- 2 min standing arterial blood pressure (mmHg) systolic [][][] diastolic [][][]
- 2 min standing heart rate (beats/min) [][][]

MEDICAL HISTORY

- Important previous diseases _____

Investigator's signature _____

Enc1 7 cont'd

FARMITALIA CARLO ERBA
Erbamont Group

9550089
Compound **REBOXETINE**

Protocol No. 20124/03⁵

Pat. Initials

Visit: S C R E E N I

Date
D M Y

ECG

HEART RATE

- Normal
 - Abnormal
- if abnormal check one or more boxes as appropriate:
- 1 Sinus bradycardia (<60)
 - 2 Sinus tachycardia (>100)
 - 3 Sick Sinus Syndrome
 - Atrial ectopic beats:
 - Occasional
 - Frequent (>6/mm)
 - Couplets
 - Supraventricular Tachycardia
 - Ventricular ectopic beats:
 - Occasional
 - Frequent (>6/mm)
 - Polymorphic
 - Couplets
 - Ventricular Tachycardia
 - Atrial fibrillation/flutter
 - A-V Block 1st degree
 - 2nd degree - Mobitz 1
 - Mobitz 2
 - Complete
 - Left ventricular hypertrophy
 - Right ventricular hypertrophy
 - Myocardial ischemia
 - Previous Myocardial infarction
 - Acute Myocardial infarction
 - Right bundle branch block
 - Left bundle branch block
 - Left anterior hemiblock
 - Left posterior hemiblock
 - Bifascicular Block (specify)
 - Trifascicular Block (specify)
 - Other

(specify) _____

716

Investigator's signature _____

9550089

ENCL / CONT'D

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 20124/03⁵

Pat. Initials

Visit: SCREEN

Date
D M Y

CONT' ECG

Please, add here the ORIGINAL TRACING AND MEDICAL REPORT

Investigator's signature _____

717

9550089 Encl 7 cont'd

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 20124/

Pat. Initials _____

Visit: S.C.R.I.E.

Date _____
D M

LABORATORY TESTS

Tests	Value	Clinically Significant abnormality*	Tests	Value	Clinically Significant abnormality*
BLOOD TESTS		<input type="checkbox"/>	BUN		<input type="checkbox"/>
HB		<input type="checkbox"/>	Creatinine		<input type="checkbox"/>
HCT		<input type="checkbox"/>	Uric acid		<input type="checkbox"/>
RBC		<input type="checkbox"/>	Total bilirubin		<input type="checkbox"/>
WBC		<input type="checkbox"/>	Direct bilirubin		<input type="checkbox"/>
Neutrophils		<input type="checkbox"/>	Total protein		<input type="checkbox"/>
Lymphocytes		<input type="checkbox"/>	Blood albumin		<input type="checkbox"/>
Eosinophils		<input type="checkbox"/>	Cholesterol		<input type="checkbox"/>
Monocytes		<input type="checkbox"/>	Triglycerides		<input type="checkbox"/>
Basophils		<input type="checkbox"/>	Globulins α 1		<input type="checkbox"/>
Platelets		<input type="checkbox"/>	α 2		<input type="checkbox"/>
Na ⁺		<input type="checkbox"/>	β		<input type="checkbox"/>
K ⁺		<input type="checkbox"/>	γ		<input type="checkbox"/>
Cl ⁻		<input type="checkbox"/>	CLcr		<input type="checkbox"/>
Ca ⁺⁺		<input type="checkbox"/>	TSH		<input type="checkbox"/>
PO ₄ ⁻⁻⁻		<input type="checkbox"/>	T ₄		<input type="checkbox"/>
SGOT		<input type="checkbox"/>	URINALYSIS	Normal	Abnormal
SGPT		<input type="checkbox"/>	Specific gravity	<input type="checkbox"/>	<input type="checkbox"/>
γ-GT		<input type="checkbox"/>	Albumin	<input type="checkbox"/>	<input type="checkbox"/>
LDH		<input type="checkbox"/>	Sugar	<input type="checkbox"/>	<input type="checkbox"/>
Alkaline phosphatase		<input type="checkbox"/>	RBC	<input type="checkbox"/>	<input type="checkbox"/>
Blood sugar		<input type="checkbox"/>	WBC	<input type="checkbox"/>	<input type="checkbox"/>

* Cross in case of clinically significant abnormality.

Observation: _____

Investigator's signature _____

9550089 Encl. 7 cont'd

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 20124/03

Pat. Initials

Visit: **S C R E E N**

Date
D M Y

PREVIOUS ANTIDEPRESSIVE TREATMENTS

NAME*	EFFICACY (Very poor, Poor, Fair, Good, Very good)	SIDE EFFECTS (if any)
	VP P F G VG	<input type="text"/>
	VP P F G VG	<input type="text"/>
	VP P F G VG	<input type="text"/>
	VP P F G VG	<input type="text"/>
	VP P F G VG	<input type="text"/>

Last treatment taken: name* Last day of treatment
D M Y

Drug free, Wash-Out Period: from to
D M Y D M Y

CONCOMITANT DRUGS (during the drug free, wash-out period)

NAME*	Daily Dose (mg)	Started on (date)			Discontinued on (date)			Reason for the administration
		D	M	Y	D	M	Y	

* Please use trade name

Observations: _____

Investigator's signature _____

9550089 Encl 7 cont'd

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 20124/03 5

Pat. Initials

Visit: S C R E E N

Date
D M Y

ELEGIBILITY OF THE PATIENT

INCLUSION CRITERIA

FOLLOWING QUESTIONS NEED TO BE ANSWERED YES :	YES	NO
- Aged over 65 years?	<input type="checkbox"/>	<input type="checkbox"/>
- Are the DSM-III-R criteria for Major Depressive Episodes or Dysthymia ?	<input type="checkbox"/>	<input type="checkbox"/>
- Total score of 18 or above in the 21-HAMD?	<input type="checkbox"/>	<input type="checkbox"/>
- Total score of 22 or above in the MMS?	<input type="checkbox"/>	<input type="checkbox"/>
- Able and willing (he/she or the next of kin) to give Informed Consent?	<input type="checkbox"/>	<input type="checkbox"/>

EXCLUSION CRITERIA

FOLLOWING QUESTIONS NEED TO BE ANSWERED NO :	<input type="checkbox"/>	<input type="checkbox"/>
- Cyclothymia?	<input type="checkbox"/>	<input type="checkbox"/>
- History of Major Depressive Episodes, associated to Endocrine Disorders?	<input type="checkbox"/>	<input type="checkbox"/>
- History of drug hypersensitivity?	<input type="checkbox"/>	<input type="checkbox"/>
- History of seizures or serious brain injury?	<input type="checkbox"/>	<input type="checkbox"/>
- Evidence of substance use disorder within past 6 months or currently?	<input type="checkbox"/>	<input type="checkbox"/>
- ECT in the previous 6 months?	<input type="checkbox"/>	<input type="checkbox"/>
- Participation in a clinical trial with an investigational compound in the 4 weeks preceding the study?	<input type="checkbox"/>	<input type="checkbox"/>
- Resistance to previous antidepressive treatments?	<input type="checkbox"/>	<input type="checkbox"/>
- Psychotropic treatment during wash-out period?	<input type="checkbox"/>	<input type="checkbox"/>
- High risk of suicide?	<input type="checkbox"/>	<input type="checkbox"/>
- Chronic respiratory insufficiency?	<input type="checkbox"/>	<input type="checkbox"/>
- Current evidence of urinary retention?	<input type="checkbox"/>	<input type="checkbox"/>
- Current evidence of glaucoma?	<input type="checkbox"/>	<input type="checkbox"/>
- Important clinical illness in the 4 weeks preceding the study?	<input type="checkbox"/>	<input type="checkbox"/>
- Clinically significant lab values abnormality?	<input type="checkbox"/>	<input type="checkbox"/>
- Clinically significant physical abnormality?	<input type="checkbox"/>	<input type="checkbox"/>

If yes, please specify: _____

CONCLUSION

Is the patient eligible for this study? yes no

If yes, this patient will receive the following patient number:

Investigator's signature _____

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9550089

Enclosure 8

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2 0 1 2 4 0 3 5

Centre No. _____

Patient No. _____

Initials _____

Visit/cycle W E E K

Date _____
D M Y

CLINICAL GLOBAL IMPRESSION (CGI)

A. SEVERITY OF ILLNESS

Considering your clinical experience with this particular population, how mentally ill is the patient at this time?

- 1 Normal, not at all ill
- 2 Borderline mentally ill
- 3 Mildly ill
- 4 Moderately ill
- 5 Markedly ill
- 6 Severely ill
- 7 Among the most extremely ill patients

B. GLOBAL IMPROVEMENT (rate total improvement whether or not, in your judgement, it is due entirely to drug treatment)

Compared to this condition at admission to the study, how much has he changed?

- 1 Very much improved
- 2 Much improved
- 3 Minimally improved
- 4 No change
- 5 Minimally worse
- 6 Much worse
- 7 Very much worse

C. EFFICACY INDEX (rate this item on the basis of drug effect only)

Activity	Tolerability: side effects			
	None	Do not significantly interfere with patient's functioning	Significantly interfere with patient's functioning	Outweigh therapeutic effect
MARKED Vast improvement, complete or nearly complete remission of all symptoms	1	2	3	4
MODERATE Decided improvement, partial remission of symptoms	5	6	7	8
MINIMAL Slight improvement which does not alter status of care of patient	9	10	11	12
UNCHANGED OR WORSE	13	14	15	16

8

Investigator's signature _____

721

9550089

Enclosure 9

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2 0 1 2 4 0 3 5

Centre No.

Patient No.

Initials

Visit/cycle D A Y

Date
 0 M Y

ADVERSE EVENTS: CHECK-LIST

1. AUTONOMIC

- Dry mouth
- Nasal congestion
- Blurred vision
- Constipation
- Urinary hesitancy
- Urinary retention
- Increased salivation
- Sweating
- Vomiting
- Diarrhoea
- Sexual disturbances
- Nausea

2. BEHAVIORAL TOXICITY

- Confusional reaction
- Excitement/agitation
- Increased motor activity
- Decreased motor activity
- Insomnia
- Drowsiness
- Lassitude

3. CARDIOVASCULAR

- Hypotension
- Dizziness
- Circulatory collapse
- Tachycardia
- Hypertension
- Precordial pain

4. NEUROLOGICAL

- Rigidity
- Tremor
- Akathisia
- Dystonia
- Paresthesias
- Seizures
- Myoclonus
- Muscular pain

5. OTHER

- Skin-rash
- Urticaria
- Decreased appetite
- Headache
- Dyspnea

FARMITALIA CARLO ERBA
Erbamont Group

9550089
Compound **REBOXETINE**

Enclosure 10 Cont'd

Protocol No. 20124/035

Patient No. [] [] []

Visit: D A Y

Date [] [] []
D M Y

4. DECHALLENGE/RECHALLENGE

Did the adverse event disappear after treatment withdrawal or dose reduction?

- 1 no
- 2 yes
- 3 not applicable

Did the adverse event reappear on resuming treatment?

- 1 no
- 2 yes
- 3 not applicable

5. PREDISPOSING OR CONTRIBUTING CONDITIONS

- 1 no
- 2 yes, specify: _____

6. RELATIONSHIP TO STUDY MEDICATION (according to modified Karch and Lasagna criteria, see protocol)

- 1 definite
- 2 probable
- 3 possible
- 4 doubtful
- 5 unknown
- 6 none

7. OUTCOME OF EVENT TO DATE (if patient died, fill in the Death Report Form)

- 1 recovered
- 2 recovered with sequelae
- 3 still present
- 4 death

8. DESCRIPTIVE SUMMARY/OTHER RELEVANT MEDICAL DATA

Investigator's signature _____

724



ADVERSE EVENT REPORT

PATIENT n° _____ Suspect drug _____ <small>Country Program Country</small>																																										
Section I REPORT STATUS <input type="checkbox"/> Initial Report <input type="checkbox"/> Follow-up Rep. n° _____ <input type="checkbox"/> Final Report	SOURCE OF DATA <input type="checkbox"/> Hospital <input type="checkbox"/> Non-Hospital <input type="checkbox"/> Research Protocol <input type="checkbox"/> Literature <input type="checkbox"/> PMS <input type="checkbox"/> Named Pt. Supply <input type="checkbox"/> Spontaneous Report	Event first reported to Company _____ Protocol n° _____ ID of patient in the study _____																																								
PATIENT IDENTIFICATION																																										
Patient's name (initials): _____ Birth Date: _____ Sex: M <input type="checkbox"/> F <input type="checkbox"/> Ethnic group: 1 = European, 2 = Asian, 3 = Negro, 4 = Other (specify) _____ Weight: _____ Height: _____																																										
ADVERSE EVENTS																																										
Section III	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 5%;">Code <small>(use WHO code)</small></th> <th style="width: 55%;">Description</th> <th style="width: 10%;">Onset Date <small>da mo yr</small></th> <th style="width: 5%;">Onset Type</th> <th style="width: 5%;">Seve- rity</th> <th style="width: 5%;">Duration <small>(days)</small></th> <th style="width: 5%;">Relat. ship drug event</th> <th style="width: 5%;">Treat- ment</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">1</td> <td>_____</td> <td>_____</td> <td style="text-align: center;">_____</td> <td style="text-align: center;">_____</td> <td style="text-align: center;">_____</td> <td style="text-align: center;">_____</td> <td style="text-align: center;">_____</td> </tr> <tr> <td style="text-align: center;">2</td> <td>_____</td> <td>_____</td> <td style="text-align: center;">_____</td> <td style="text-align: center;">_____</td> <td style="text-align: center;">_____</td> <td style="text-align: center;">_____</td> <td style="text-align: center;">_____</td> </tr> <tr> <td style="text-align: center;">3</td> <td>_____</td> <td>_____</td> <td style="text-align: center;">_____</td> <td style="text-align: center;">_____</td> <td style="text-align: center;">_____</td> <td style="text-align: center;">_____</td> <td style="text-align: center;">_____</td> </tr> <tr> <td style="text-align: center;">4</td> <td>_____</td> <td>_____</td> <td style="text-align: center;">_____</td> <td style="text-align: center;">_____</td> <td style="text-align: center;">_____</td> <td style="text-align: center;">_____</td> <td style="text-align: center;">_____</td> </tr> </tbody> </table>	Code <small>(use WHO code)</small>	Description	Onset Date <small>da mo yr</small>	Onset Type	Seve- rity	Duration <small>(days)</small>	Relat. ship drug event	Treat- ment	1	_____	_____	_____	_____	_____	_____	_____	2	_____	_____	_____	_____	_____	_____	_____	3	_____	_____	_____	_____	_____	_____	_____	4	_____	_____	_____	_____	_____	_____	_____	Legenda: Onset type: 1 = Gradual 2 = Sudden 3 = Unknown Severity: 1 = Mild 2 = Moderate 3 = Severe 4 = Unknown Relationship: 1 = Drug related 2 = Probably 3 = Possibly 4 = Doubtful 5 = Not known 6 = Not drug related Treatment: 1 = Outpatient required 2 = Hospital required
Code <small>(use WHO code)</small>	Description	Onset Date <small>da mo yr</small>	Onset Type	Seve- rity	Duration <small>(days)</small>	Relat. ship drug event	Treat- ment																																			
1	_____	_____	_____	_____	_____	_____	_____																																			
2	_____	_____	_____	_____	_____	_____	_____																																			
3	_____	_____	_____	_____	_____	_____	_____																																			
4	_____	_____	_____	_____	_____	_____	_____																																			
NOTE: A descriptive summary of adverse event must be typewritten in Section IX																																										
OUTCOME OF EVENT TO DATE																																										
Section IV	<input type="checkbox"/> Alive with sequelae <input type="checkbox"/> Recovered <input type="checkbox"/> Still under treatment for event <input type="checkbox"/> Died (give cause date) _____																																									
Date of death: _____ Cause of death (specify): _____ <small style="text-align: right;">USE WHO CODE!</small>																																										
TESTS/LABORATORY DATA																																										
Section V	<input type="checkbox"/> Blood <input type="checkbox"/> X-ray <input type="checkbox"/> Biopsy <input type="checkbox"/> Other <input type="checkbox"/> Urine <input type="checkbox"/> ECG <input type="checkbox"/> Autopsy 1 = No 2 = Yes (give details in Section VII) 3 = Yes - Results not yet available																																									
SUSPECT DRUG INFORMATION																																										
Section VI	Generic and trade name: _____ <small style="text-align: right;">USE CODE (GEN/TRADE)</small> Indication for use: _____ <small style="text-align: right;">USE WHO CODE!</small> Route of administration: Oral <input type="checkbox"/> I.M. <input type="checkbox"/> I.V. <input type="checkbox"/> Rectal <input type="checkbox"/> Topical <input type="checkbox"/> Other <input type="checkbox"/> _____ <small style="text-align: right;">specify</small> Total daily dose* _____ mg _____ mg/m ² Frequency _____ Therapy days from _____ to _____ Therapy duration (days)** _____ Was the treatment with suspected drug reduced in dosage? <input type="checkbox"/> No <input type="checkbox"/> Yes Was the treatment with suspected drug discontinued? <input type="checkbox"/> No <input type="checkbox"/> Yes Did reaction abate? <input type="checkbox"/> No <input type="checkbox"/> Yes Was drug reintroduced or dose increased? <input type="checkbox"/> No <input type="checkbox"/> Yes Did reaction reappear? <input type="checkbox"/> No <input type="checkbox"/> Yes																																									
* For oncologic drug, this dose refers to total dose/cycle ** For oncologic drug, this refers to the number of cycles administered.																																										

RECENT/CONCOMITANT DRUG AND MEDICAL CONDITIONS						
	Do not write in shaded area	drugs	Total daily dose (mg)	Route	Dates of Administration from to	Indication Use WHO code
1	_____	_____	_____	_____	_____	_____
2	_____	_____	_____	_____	_____	_____
3	_____	_____	_____	_____	_____	_____
4	_____	_____	_____	_____	_____	_____

* For oncologic drug, this dose refers to total dose/cycle
 ** Route: 1 = Oral 2 = I.M. 3 = I.V. 4 = Rectal 5 = Topical 6 = Other (specify) _____

OTHER RELEVANT CONDITIONS (cross and specify)

Section VII

Allergies _____

Previous drug reactions _____

Cardiovascular diseases _____

Endocrine diseases _____

C.N.S. diseases _____

Renal diseases _____

Gastro-intestinal diseases _____

Liver diseases _____

Respiratory diseases _____

Other _____

LABORATORY TEST AND RESULTS					
	Date	Site	Findings*	Diagnosis	Do not write in shaded area
X-RAY	_____	_____	<input type="checkbox"/>	_____	_____
	_____	_____	<input type="checkbox"/>	_____	_____
	_____	_____	<input type="checkbox"/>	_____	_____
ECG	_____	_____	<input type="checkbox"/>	_____	_____
	_____	_____	<input type="checkbox"/>	_____	_____
	_____	_____	<input type="checkbox"/>	_____	_____
Section VIII BIOPSY	_____	_____	<input type="checkbox"/>	_____	_____
	_____	_____	<input type="checkbox"/>	_____	_____
	_____	_____	<input type="checkbox"/>	_____	_____
AUTOPSY	_____	_____	<input type="checkbox"/>	_____	_____
	_____	_____	<input type="checkbox"/>	_____	_____
	_____	_____	<input type="checkbox"/>	_____	_____

*Findings: 1 = Normal 2 = Abnormal (indicate diagnosis)

20124 035 ENCL 10 cont'd

LABORATORY TESTS AND RESULTS		Date	Date	Date
Tests	(Reference Laboratory Value)	Day	Month	Year
HAEMATOLOGY				
Hb	(___ to ___ g/dL)	___	___	___
Haematocrit	(___ to ___ %)	___	___	___
ESR (Westerg)	(___ to ___ mm 1st h.)	___	___	___
RBC	(___ to ___ million μ L)	___	___	___
WBC	(___ to ___ thousand μ L)	___	___	___
Platelets	(___ to ___ thousand μ L)	___	___	___
Other (specify)	_____			
CHEMISTRY				
BUN	(___ to ___ mg/dL)	___	___	___
Creatinine	(< ___ mg/dL)	___	___	___
Creatinine Clearance	(___ to ___ ml/min)	___	___	___
Uric Acid	(___ to ___ mg/dL)	___	___	___
Calcium	(___ to ___ mg/dL)	___	___	___
Plasma Electrolytes				
Na ⁺	(___ to ___ mEq/L)	___	___	___
K ⁺	(___ to ___ mEq/L)	___	___	___
Cl ⁻	(___ to ___ mEq/L)	___	___	___
Total Bilirubin	(___ to ___ mg/dL)	___	___	___
SGOT	(___ to ___ IU/L)	___	___	___
SGPT	(___ to ___ IU/L)	___	___	___
LDH	(___ to ___ IU/L)	___	___	___
CPK	(___ to ___ IU/L)	___	___	___
γ -Glutamyl-transpeptidase	(< ___ mU/ml)	___	___	___
Alkaline phosphatase	(___ to ___ KA units)	___	___	___
Total Proteins	(___ to ___ G/dL)	___	___	___
Albumin	(___ to ___ G/dL)	___	___	___
Globulin	(___ to ___ G/dL)	___	___	___
Glucose	(___ to ___ mg/dL)	___	___	___
Cholesterol	(___ to ___ mg/dL)	___	___	___
Triglycerides	(< ___ mg/dL)	___	___	___
Other (specify)	_____			
URINALYSIS				
Leucocytes	(1 = No 2 = Yes)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Haematuria	(1 = No 2 = Yes)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Albuminuria	(1 = No 2 = Yes)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other (specify)	_____			
OTHER LABORATORY TESTS (specify)				

Section VIII (continued)

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Faraitalia Carlo Erba
Erbaent Group

9550089

ENCLOSURE 11

Corporate Medical Coordination

ADVERSE DRUG REACTION - A CRITICAL REVIEW

CAUSE-EFFECT RELATIONSHIP

P.E.KARCH, L.LASAGNA
(JAMA Dec. 22, 1975-Vol.234)

1. DEFINITE (or CERTAIN)

A reaction that follows a reasonable temporal sequence from administration of the drug or in which the drug level has been established in body fluids or tissues; that follows a known response pattern to the suspected drug; and that is confirmed by improvement on stopping the drug (dechallenge), and reappearance of the reaction on repeated exposure (rechallenge).

2. PROBABLE

A reaction that follows a reasonable temporal sequence from administration of the drug; that follows a known response pattern to the suspected drug; that is confirmed by dechallenge; and that could not be reasonably explained by the known characteristics of the patient's clinical state.

3. POSSIBLE

A reaction that follows a reasonable temporal sequence from administration of the drug; that follows a known response pattern to the suspected drug; but that could have been produced by the patient's clinical state or other modes of therapy administered to the patient.

4. DOUBTFUL

Any reaction that does not meet the criteria above.

5. UNKNOWN

Relationship for which no evaluation can be made.

6. NOT RELATED

A reaction for which sufficient information exists to indicate that the aetiology is unrelated to the study drug.

9550089

Enclosure 12

Appendix 5
Declaration of Helsinki IV (Hong Kong - September 1989)

WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI

Recommendations guiding physicians
in biomedical research involving human subjects

Adopted by the 18th World Medical Assembly,
Helsinki, Finland, June 1964,

and amended by the
29th World Medical Assembly,
Tokyo, Japan, October 1975,
35th World Medical Assembly,
Venice, Italy, October 1983
and the

41st World Medical Assembly
Hong Kong, September 1989

INTRODUCTION

It is the mission of the physician to safeguard the health of the people. His or her knowledge and conscience are dedicated to the fulfillment of this mission.

The Declaration of Geneva of the World Medical Association binds the physician with the words, "The health of my patient will be my first consideration," and the International Code of Medical Ethics declares that, "A physician shall act only in the patient's interest when providing medical care which might have the effect of weakening the physical and mental condition of the patient." The purpose of biomedical research involving human subjects must be to improve diagnostic, therapeutic and prophylactic procedures and the understanding of the aetiology and pathogenesis of disease.

In current medical practice most diagnostic, therapeutic or prophylactic procedures involve hazards. This applies especially to biomedical research.

Medical progress is based on research which ultimately must rest in part on experimentation involving human subjects.

In the field of biomedical research a fundamental distinction must be recognized between medical research in which the aim is essentially diagnostic or therapeutic for a patient, and medical research, the essential object of which is purely scientific and without implying direct diagnostic or therapeutic value to the person subjected to the research.

Special caution must be exercised in the conduct of research which may affect the environment and the welfare of animals used for research must be respected.

Because it is essential that the results of laboratory experiments be applied to human beings to further scientific knowledge and to help suffering humanity, the World Medical Association has prepared the following recommendations as a guide to every physician in biomedical research involving human subjects. They should be kept under review in the future. It must be stressed that the standards as drafted are only a guide to physicians all over the world. Physicians are not relieved from criminal, civil and ethical responsibilities under the laws of their own countries.

I. BASIC PRINCIPLES

1. Biomedical research involving human subjects must conform to generally accepted scientific principles and should be based on adequately performed laboratory and animal experimentation and on a thorough knowledge of the scientific literature.
2. The design and performance of each experimental procedure involving human subjects should be clearly formulated in an experimental protocol which should be transmitted for consideration, comment and guidance to a specially appointed committee independent of the investigator and the sponsor provided that this independent committee is in conformity with the laws and regulations of the country in which the research experiment is performed.
3. Biomedical research involving human subjects should be conducted only by scientifically qualified persons and under the supervision of a clinically competent medical person. The responsibility for the human subject must always rest with a medically qualified person and never rest on the subject of the research, even though the subject has given his or her consent.
4. Biomedical research involving human subjects cannot legitimately be carried out unless the importance of the objective is in proportion to the inherent risk to the subject.
5. Every biomedical research project involving human subjects should be preceded by careful assessment of predictable risks in comparison with foreseeable benefits to the subject or to others. Concern for the interests of the subject must always prevail over the interests of science and society.
6. The right of the research subject to safeguard his or her integrity must always be respected. Every precaution should be taken to respect the privacy of the subject and to minimize the impact of the study on the subject's physical and mental integrity and on the personality of the subject.
7. Physicians should abstain from engaging in research projects involving human subject unless they are satisfied that the hazard involved are believed to be predictable. Physicians should cease any investigation if the hazards are found to outweigh the potential benefits.
8. In publication of the results of his or her research, the physician is obliged to preserve the accuracy of the results. Reports of experimentation not in accordance with the principles laid down in this Declaration should not be accepted for publication.
9. In any research on human beings, each potential subject must be adequately informed of the aims, methods, anticipated benefits and potential hazard of the study and the discomfort it may entail. He or she should be informed that he or she is at liberty to abstain from participation in the study and that he or she is free to withdraw his or her consent to participation at any time. The physician should then obtain the subject's freely-given informed consent, preferably in writing.
10. When obtaining informed consent for the research project the physician should be particularly cautious if the subject is in a dependent relationship to him or her or may consent under duress. In that case the informed consent should be obtained by a physician who is not engaged in the investigation and who is completely independent of this official relationship.
11. In case of legal incompetence, informed consent should be obtained from the legal guardian in accordance with national legislation. Where physical or mental incapacity makes it impossible to obtain informed consent, or when the subject is a minor, permission from the responsible relative replaces that of the subject in accordance with national legislation. Whenever the minor child is in fact able to give a consent, the minor's consent must be obtained in addition to the consent of the minor's legal guardian.
12. The research protocol should always contain a statement of the ethical considerations involved and should indicate that the principles enunciated in the present Declaration are complied with.

9550089

Cont'd Encl. 12

II. MEDICAL RESEARCH COMBINED WITH PROFESSIONAL CARE
(Clinical research)

1. In the treatment of the sick person, the physician must be free to use a new diagnostic and therapeutic measure, if in his or her judgement it offers hope of saving life, reestablishing health or alleviating suffering.
2. The potential benefits, hazards and discomfort of a new method should be weighed against the advantages of the best current diagnostic and therapeutic methods.
3. In any medical study, every patient - including those of a control group, if any - should be assured of the best proven diagnostic and therapeutic method.
4. The refusal of the patient of participate in a study must never interfere with the physician-patient relationship.
5. If the physician considers it essential not to obtain informed consent, the specific reasons for this proposal should be stated in the experimental protocol for transmission to the independent committee (1, 2).
6. The physician can combine medical research with professional care, the objective being the acquisition of new medical knowledge, only to the extent that medical research is justified by its potential diagnostic or therapeutic value for the patient.

III. NON-THERAPEUTIC BIOMEDICAL RESEARCH INVOLVING HUMAN SUBJECTS (Non-clinical biomedical research)

1. In the purely scientific application of medical research carried out on a human being, it is the duty of the physician to remain the protector of the life and health of that person on whom biomedical research is being carried out.
2. The subjects should be volunteers - either healthy persons or patients for whom the experimental design is not related to the patient's illness.
3. The investigator or the investigating team should discontinue the research if in his/her or their judgement it may, if continued, be harmful to the individual.
4. In research on man, the interest of science and society should never take precedence over considerations related to the wellbeing of the subject.

ERRAMONT GROUP
ERRAMONT GROUP
CLINICAL DEVELOPMENT, CNS

9550089

Enclosure 13

LIST OF MONITORS

Country	Monitor (Address)
Australia	Dr. S. Orrman-Rossiter 10 Ferntree Place Private Bag 39, Clayton North, Vic 3168 phone: (61-3) 5589544 fax: (61-3) 5589501
Belgium	Dr. S. Dasseville Av. Herrmann Debrouxlaan 52 1160 Bruxelles phone: (32-2) 6755200 fax: (32-2) 6754646
Brazil	Dr. Alcione Moraes de Souza Rodovia Washington Luiz km 119,293 25085 Duque de Caxias Rio de Janeiro phone: (55-21) 7715220 fax: (55-21) 7720095
France	Dr. M. Bosc 100, Av. Albert 1 ^{er} , B.P.203 92502 Rueil Malmaison Cedex phone: (33-1) 47142200 fax: (33-1) 47496658
Germany	Dr. K. Ludwig Merzhauser Str. 112 Postfach 480 7800 Freiburg in Breisgau phone: (49-761) 4013208 fax: (49-761) 4013199
United Kingdom	Dr. J. Banister Italia House 23 Grosvenor Road St. Alban's, Herts. AL1 3AW phone: (44) 72740290 fax: (44) 72740290



LA FONDIARIA

ASSICURAZIONI S.p.A.

Fondata nel 1872 - Capitale L. 104.878.000.000, versato - Sede in Firenze
V. 0550009
Iscritta al n. 57045 Registro Società del Tribunale di Firenze e al
n. 42383 C.C.I.A.A. di Firenze - Impresa autorizzata all'esercizio delle assicurazioni
(art. 65 R.D.L. 29-4-1923 n. 966) - Codice Fiscale 00432690105 - Partita I.V.A. 04234690487

Agenzia Generale di

Milano 3.1.1992

Enclosure 14

Spett.Le
FARMITALIA CARLO ERBA S.R.L.
Via Iabonati, 24

20159 MILANO

DICHIARAZIONE DECLARATION To whom it may concern

La sottoscritta La Fondiaria Assicurazioni spa - con sede in Firenze - Via
Lorenzo il Magnifico 1 -
The undersigned La Fondiaria Assicurazioni spa with head office in Firenze -
Via Lorenzo il Magnifico 1 -

dichiara a tutti gli effetti che la Spett.le FARMITALIA CARLO ERBA S.R.L.
hereby declares to all intents and purposes that the firma FARMITALIA CARLO ERBA S.R.L.

con sede in Milano - Via Iabonati, 24 e' assicurata contro la
with head office in Milan - Via Iabonati, 24, is insured against

responsabilita' civile verso terzi per danni derivanti dalla sua attivita' (ivi compresa "produzione"
third party liability for damage deriving from their activities (including "production"

e "smercio") e dalle sue proprieta' con polizza n.481.440647.50, scadente il 31.12.1992
and "sales") and its properties, under policy No.481.440647.50, expiring on 31.12.1992

e tacitamente rinnovabile di anno in anno, per il massimale unico di L.
10.000.000.000,=(dieci miliardi) per sinistro
automatically renewable for one year at a time, to cover up to L.10.000.000.000 (ten
thousand million Lire) as a single anyone claim,

nei termini tutti di cui alla polizza stessa.
in all terms concerning the policy itself.

La garanzia e' valida per il mondo intero e prevede, tra l'altro, anche l'estensione della copertura ai seguenti:
This coverage is applicable through out the world, and includes the following:

- danni causati da specialita' medicinali e prodotti medicinali che secondo la
- damage arising from medicinal specialities and products which, according to

comune prassi, prima della loro registrazione sanitaria e della loro
normal practice, before they are officially registered and

immissione in commercio, vengono consegnati a cliniche, ospedali,
put on the market, are giving to clinics, hospitals

case di cura ed esercenti professioni sanitarie per sperimentazioni e
nursing homes and professional health workers for clinical trials and

prove cliniche, nonche' ai danni causati a seguito di somministrazione
tests and damage arising following administration for pharmacological tests

Mod. 1A3889 - 2500002-0/91 - It. Am. - Roma





LA FONDIARIA ASSICURAZIONI S.p.A.

Fondata nel 1872 - Capitale L. 104.878.000.000, versato - Sede in Firenze
Via de' Tornabuoni 1 - Iscritta al n. 57085 Registro Società del Tribunale di Firenze e al
n. 428553 C.C.I.A.A. di Firenze - Impresa autorizzata all'esercizio delle assicurazioni
(art. 65 R.D. L. 29-4-1923 n. 966) - Codice Fiscale 0043260105 - Partita I.V.A. 04234690487

Agenzia Generale di

Encl. 14 cont'd

per ricerche di farmacologia ed esperimenti con farmaci e preparazioni già registrate in Italia
experiments of drugs or preparations already registered in Italy

e/o all'estero, ma con posologie diverse da quelle
and/or in other countries but using dosages different from these

indicate dalle case produttrici e con nuovi farmaci in fase di studio;
indicated by the manufacturer and of new drugs in the study stage;

comprese tutte le attività inerenti e connesse alle sperimentazioni stesse,
including all activities connected with and inherent to tests and trials

quali la tecnica di somministrazione dei farmaci ed il prelievo del
such as the methods of administering drugs and withdrawing

sangue dai soggetti per studio; il tutto con prodotti
blood samples from subjects under study; all with products

sia ad uso umano che non, propri e/o di terzi;
for human use or not, own and/or of the third party.

- connessi a responsabilità civile che possa derivare personalmente
- damage relating to third party liability which may result personally

agli sperimentatori sia nel paese dell'Assicurata che all'estero
to the experimenters both in the country of Insured and/or in other countries

in ragione degli esperimenti effettuati su richiesta e/o per conto dell'Assicurata stessa.
because of the experiments effected at request and/or for account of the Insured.

La presente viene rilasciata a richiesta della Spett.le FARMITALIA CARLO ERBA S.R.L.
This declaration is issued in response to a request by FARMITALIA CARLO ERBA S.R.L.

Relativamente alla presente dichiarazione redatta sia in lingua italiana che in
Relatively to the present declaration drawn up both in Italian language and

lingua inglese, viene convenuto che, in caso di divergenza tra i due testi,
English language, it is agreed that, in case of divergence between the two texts,

prevarrà; ai fini interpretativi, il testo in lingua italiana.
the one in Italian language will prevail for the purpose of interpretation.

In fede

LA FONDIARIA ASSICURAZIONI SPA
S.U. SPANZIOLANTI
G. PEREGO

Mod. 1.838/0 - 26/00012 - 4/91 - T.Us. - Firenze



FARMITALIA CARLO ERBA
Erbamont Group

Enclosure 15
Compound ~~555009~~ **PROXETINE**

Protocol No. 2012403

Centre No. [][][][]

Patient No. [][][]

Initials [][][]

Visit/cycle 0 | A | Y | [][]

Date [][] / [][] / [][]
D M Y

MONTGOMERY ASBERG DEPRESSION RATING SCALE (MADRS)

I. Apparent sadness

Representing despondency, gloom and despair, (more than just ordinary transient low spirits) reflected in speech, facial expression, and posture. Rate by depth and inability to brighten up.

- 0 - No sadness.
- 1 -
- 2 - Looks dispirited but does brighten up without difficulty.
- 3 -
- 4 - Appears sad and unhappy most of the time.
- 5 -
- 6 - Looks miserable all the time. Extremely despondent.

II. Reported sadness

Representing reports of depressed mood, regardless of whether it is reflected in appearance or not. Includes low spirits, despondency or the feeling of being beyond help and without hope.

- Rate according to intensity, duration and the extent to which the mood is reported to be influenced by events.
- 0 - Occasional sadness in keeping with the circumstances.
 - 1 -
 - 2 - Sad or low but brightens up without difficulty.
 - 3 -
 - 4 - Pervasive feelings of sadness or gloominess. The mood is still influenced by external circumstances.
 - 5 -
 - 6 - Continuous or unvarying sadness, misery or despondency.

III. Inner tension

Representing feelings of ill-defined discomfort, edginess, inner turmoil, mental tension mounting to either panic, dread or anguish. Rate according to intensity, frequency, duration and the extent of reassurance called for.

- 0 - Placid. Only fleeting inner tension.
- 1 -
- 2 - Occasional feelings of edginess and ill-defined discomfort.
- 3 -
- 4 - Continuous feelings of inner tension or intermittent panic which the patient can only master with some difficulty.
- 5 -
- 6 - Unrelenting dread or anguish. Overwhelming panic.

IV. Reduced sleep

Representing the experience of reduced duration or depth of sleep compared to the subject's own normal pattern when well.

- 0 - Sleeps as usual.
- 1 -
- 2 - Slight difficulty dropping off to sleep or slightly reduced, light or fitful sleep.
- 3 -
- 4 - Sleep reduced or broken by at least two hours.
- 5 -
- 6 - Less than two or three hours sleep

V. Reduced appetite

Representing the feeling of a loss of appetite compared with when well. Rate by loss of desire for food or the need to be persuaded oneself to eat.

- 0 - Normal or increased appetite.
- 1 -
- 2 - Slightly reduced appetite.
- 3 -
- 4 - No appetite. Food is tasteless.
- 5 -
- 6 - Needs persuasion to eat at all.

Investigator's signature _____

FARMITALIA CARLO ERBA
Erbamont Group

9550089
Compound REBOXETINE

Enclosure 16
Protocol No. 20124/035

Patient No. _____

Visit: D A Y _____

Date _____
D M Y

GDS: GERIATRIC DEPRESSION SCALE

Please ask patient the following questions:

- | | | |
|--|------------------------------|-----------------------------|
| 1. Are you basically satisfied with your life? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 2. Have you dropped many of your activities and interest? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 3. Do you feel that your life is empty? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 4. Do you often get bored? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 5. Are you hopeful about the future? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 6. Are you bothered by thoughts you can't get out of your head? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 7. Are you in good spirits most of the time? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 8. Are you afraid that something bad is going to happen to you? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 9. Do you feel happy most of the time? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 10. Do you often feel helpless? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 11. Do you often get restless and fidgety? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 12. Do you prefer to stay at home, rather than going out and doing new things? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 13. Do you frequently worry about the future? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 14. Do you feel you have more problems with memory than most? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 15. Do you think it is wonderful to be alive now? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 16. Do you often feel downhearted and blue? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 17. Do you feel pretty worthless the way you are now? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 18. Do you worry a lot about the past? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 19. Do you find life very exciting? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 20. Is it hard for you to get started on new project? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 21. Do you feel full of energy? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 22. Do you feel that your situation is hopeless? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 23. Do you think that most people are better off than you are? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 24. Do you frequently get upset over little things? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 25. Do you frequently feel like crying? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 26. Do you have trouble concentrating? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 27. Do you enjoy getting up in the morning? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 28. Do you prefer to avoid social gatherings? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 29. Is it easy for you to make decisions? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |
| 30. Is your mind as clear as it used to be? | YES <input type="checkbox"/> | NO <input type="checkbox"/> |

Total score:

*: Please, score 1 point for each answer marked in white (not shaded) box.

Investigator's signature _____

9550089

Enclosure 17

DRUG ACCOUNTABILITY

Compound: **REBOXETINE**

Protocol N°: **20124/035**

Title: Multicenter, multinational double-blind study of the activity and tolerability of Reboxetine vs Imipramine in elderly patients with Depressive Disorders.

Centre N°/City _____

Investigator: _____

Treatment received: |__|_|_| for patient N°__ to patient N°__ Receipt N°_____

d m y

Bottles per patient received: 16 + 5 (dose 2)

Pat N°	Pat. Init.	Date Start	Weekly treatment given	N° of remaining bottles per pat.	N° of remaining caps. per pat.
			1 2 3 4 5 6 7 8 Dose 2: 4 5 6 7 8	__ + __ (dose 2)	__ + __ (dose 2)
			1 2 3 4 5 6 7 8 Dose 2: 4 5 6 7 8	__ + __ (dose 2)	__ + __ (dose 2)
			1 2 3 4 5 6 7 8 Dose 2: 4 5 6 7 8	__ + __ (dose 2)	__ + __ (dose 2)
			1 2 3 4 5 6 7 8 Dose 2: 4 5 6 7 8	__ + __ (dose 2)	__ + __ (dose 2)
			1 2 3 4 5 6 7 8 Dose 2: 4 5 6 7 8	__ + __ (dose 2)	__ + __ (dose 2)
			1 2 3 4 5 6 7 8 Dose 2: 4 5 6 7 8	__ + __ (dose 2)	__ + __ (dose 2)

N° of total caps. to be returned: _____

N° of total bottles to be returned: _____

Date: _____

Investigator's signature _____

- ♦ The present form, duly filled out, should be kept as record by the investigator, together with his/her copy of CRFs.
- ♦ A photocopy of the present form should be given to the monitor of Farmitalia Carlo Erba together with the unused drug at the end of the study.

**STATEMENT OF INVESTIGATOR FOR REBOXETINE CLINICAL STUDIES
PROTOCOL N° 20124/035**

1. Name and address of investigator:

2. Education, training and experience that qualifies the investigator as an expert in the clinical investigation of the drug for the use under investigation. Attached is the Curriculum Vitae.

3. Name and address of medical school, hospital or other research facility where the clinical investigation will be conducted:

4. Name and address of clinical laboratory facilities to be used in the study. Mark "x" in appropriate box:

 Same as the above mentioned Institution (no other clinical laboratory facilities will be used during the study)

 Other, specify (name and address):

5. Name and address of the Ethical Committee approval that is responsible for approval of the study:

 Same as the above mentioned Institution

 Other, specify:

9550089

Encl. 18 cont'd

Page 2 of 3

6. Names of the co-investigators (e.g. research fellows, residents, associates) who will be assisting the investigator in the conduct of the investigation:

1. _____
2. _____
3. _____
4. _____

7. Commitments

I agree to conduct the study in accordance with the current protocol and will only make changes in the protocol after notifying the sponsor, except when necessary to protect the safety, the rights, or welfare of subjects.

I agree to conduct the study in accordance with Good Clinical Practice (GCP) requirements.

I agree to personally conduct or supervise the described investigation.

I agree to inform patients that the drugs are being used for investigational purposes and I will ensure that the requirements relating to obtaining informed consent are met.

I agree to report to the sponsor adverse experiences that occur in the course of the investigation.

I have read and understand the information in the investigator's brochure, including the potential risks and side effects of the drugs.

I agree to ensure that all associates, colleagues and employees assisting in the conduct of the study are informed about their obligations in meeting the above commitments.

I agree to maintain adequate and accurate records and to make those records available for inspection.

9550089
Bl 18 cont'd

Page 3 of 3

I will not make any changes in the research without Ethical Committee approval, except where necessary to eliminate apparent immediate hazards to human subjects.

I agree to comply with all other requirements regarding the obligations of clinical investigators as per the declaration of Helsinki (and its modifications).

8. Signature of investigator

9. Date _____

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9550089

Attachment A

REBOXETINE PROTOCOL 20124/035: OPERATING PROCEDURES FOR STUDY MONITORING AND COORDINATION.

Aim

The purpose of these procedures is to provide standardization of the study conduct in the different clinical centers and to assure data uniformity and compatibility by appropriate interventions during data gathering.

Study monitoring

During the course of the study monthly monitoring visits will be conducted by Study Monitors from Farmitalia Carlo Erba.

The start-up visit will take place after approval of the protocol by the Institutional Review Board (IRB) or Ethical Committee. On this visit the following documents will be collected:

- copy of the protocol signed by the Principal Investigator;
- CV of Principal Investigator and Co-Investigators;
- the written approval of the study (typed on the Institute's letter head) by the Hospital or University Center Review Board and the IRB members list;
- an IRB approved blank copy of the consent form;
- the list of the laboratory normal values or ranges of the lab. tests.

These documents will be sent to FICE-Milan. On the occasion of this visit the monitor will also check that the CRFs and the drug supply have been delivered to the Clinical Investigator and the accompanying letter, signed by the Clinical Investigator, will be collected. In addition the Monitor will identify the staff members who will be involved in the study conduct and the monitoring visits schedule will be agreed.

9550089

Prot. 20124/035 Cont. Attachment A

The first monitoring visit will be done immediately after the recruitment of the first two, three patients.

The periodic monitoring visits are carried out in order to:

- 1 verify protocol adherence: patient eligibility, times of assessments, completeness of data, drug count;
- 2 verify data consistency looking for inconsistencies or errors in the data recorded on the CRF;
- 3 verify the accuracy of data collection in CRFs against the original clinic or hospital records for:
 - patient's initials and hospital record N°
 - signed informed consent
 - study medication administration and concomitant medications
 - physician notes on adverse events
 - 20% of data for laboratory tests, patient history and vital signs; in case of an error rate > 15% all data need to be monitored;
 - total Hamilton score reported in the hospital record.

Source-verified data can be initialled by the study monitor in the CRF.

- 4 review all adverse events including laboratory abnormalities, occurred since the previous visit. Should the information of a serious, or unexpected adverse event newly emerge, the local study Monitor must immediately (within two working days) inform the Product Leader in Milan;
- 5 evaluate patient recruitment rate and treatment discontinuations;
- 6 verify study medication storage and accountability and collect bottles of completed treatments;
- 7 ensure continued acceptability of the facilities and of the staff.

CRFs will be completed in black ink and corrections, if needed, made only by the Clinical Investigator with a single line throughout; the corrections will be initialled by Clinical Investigator and dated. Each page of each completed CRF will be signed by Clinical Investigator.

9550089

Prot. 20124/035 Cont. Attachment 035

After review for accuracy and completeness, the original and first copy of each page of the CRF will be removed (leaving the second copy with the Investigator). The first copy will be sent to Milan by Special Delivery Service for review and data processing while the original will be retained by the Monitor in the subsidiary until completion of the whole treatment period of the individual patient.

After each monitoring visit the periodic site visit report and the patient's progress report form will be filled in. Copy of them will be sent to FICE Milan.

The study termination visit will be performed upon Investigator's completion of all CRFs of treated patients. During this visit:

- 1 the monitor will check and collect the remaining completed CRFs and will perform a final data review;
- 2 a final check and review of drug accounting, inventorying of remaining drug supplies and arrangement to send them to FICE will be done;
- 3 a time frame for study reporting will be discussed;
- 4 appropriate follow-up of patients under long-term treatment will be assured and monitoring and collection of data from these patients discussed and agreed

The study termination visit form will be filled in and copy of it sent to FICE Milan.

Study coordination

In order to obtain uniformity and standardization in the carrying out of the study a Steering Committee is established. All questions arising during the conduct of the study will be submitted to the Committee for advice and action taking.

In particular the Committee will take care of:

- queries about patients acceptability
- possible need of protocol amendments
- possible need of premature termination of the study
- acceptability of particular cases of protocol violations
- evaluation of clinically relevant adverse events and their scientific and ethical consequences in terms of issues raised or study discontinuation.

9550089

Prot 20124/035 Cont Attachment A

Members of the Committee will be: Prof. T. Ban.

Any problem or issue arising during the conduct of the study will be submitted to the Committee in writing by the Clinical Investigators or by the study Monitors. "Ad hoc" meetings of the Committee will be organized when needed. File note of the meeting with conclusions about action taking will be circulated to Clinical Investigators and study Monitors.

9550089

Pharmacia

Document 9550089

12.1.2 CRF SAMPLE

A complete CRF sample is filed in the Study Master File.

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9550089

Pharmacia

Document 9550089

**12.1.3 ETHICS COMMITTEES OR INVESTIGATIONAL REVIEW BOARDS:
APPROVALS, LIST OF MEMBERS, PATIENT INFORMATION AND
CONSENT FORMS**

Investigational Review Boards and Ethics Committees approvals were obtained according to local regulations and laws: copy of the approval documents and of Ethics Committees, list of members are filed in the Study Master File. The copy of Ethics Committee approval for center 48 (Melbourne-Australia) is not filed in the Study Master File as the original has been lost at the centre.

The proposed consent form is enclosed (Enclosure 5 of Appendix 12.1.1). Copy of forms approved by Ethics Committees and local translations are filed in the Study Master File.

9550089

Pharmacia

Document 9550089

12.1.4 CLINICAL INVESTIGATORS LIST, SIGNATURES AND CURRICULA VITAE

PRINCIPAL INVESTIGATORS AND AFFILIATIONS

- Centre 1: Prof E Chiu *
Henry Pride Geriatric Centre, Nolan Avenue, Kew, Victoria 3101,
Australia
- Centre 2: Dr D Ames
Royal Park Psychiatric Hospital, Private Bag 3, Parkville Victoria 3052,
Australia
- Centre 3: Prof J Snowdon
Dept. of Psychogeriatrics, The Rozelle Hospital, P.O. Box 1, Rozelle
NSW 2039, Australia
- Centre 4: Dr B Russell
Dept. of Rehabilitation and Geriatrics, Royal North Shore Hospital,
Pacific Highway, St. Leonards NSW 2065, Australia
- Centre 5: Prof M Van Moffaert
Universitair Ziekenhuis Gent, Psychiatrische Kliniek, De Pintelaan 185,
9000 Gent, Belgium
- Centre 6: Dr R Spiers
St. Camillus Ziekenhuis, Beukenlaan 20, 9280 St. Denijs-Westrem,
Belgium
- Centre 7: Dr J Bollen
Sancta Maria Psychiatr. Ziekenhuis, Melverencentrum 11, 3800 Sint
Truiden, Belgium
- Centre 8: Dr F Roelandts
Stichting voor de Psychogeriatric, Gentssesteenweg 1050, 1080
Bruxelles, Belgium
- Centre 9: Prof. JA Costa e Silva
Santa Casa Da Misericordia, Rua Santa Luzia 206, 22461 Rio de
Janeiro, Brazil

9550089

Pharmacia

Document 9550089

-
- Centre 10: Prof. M Versiani *
Institute of Psychiatry, Federal University, Rua Visconde de Pirajá
407/805, Ipanema - Rio de Janeiro, Brazil
- Centre 12: Dr JP Charnes
Hôpital Jean Rebeyrol, Service de Gériatrie, Av. du Buisson, 87042
Limoges Cedex, France
- Centre 13: Dr Y Quenet
Centre National de Gériatrie, 78320 La Verrière, France
- Centre 14: Dr J Daumer
CHS Charcot, 56850 Caudan, France
- Centre 15: Prof P Delwailly
Centre de Soins pour Personnes Agées, 23, rue des Bateliers, 59037
Lille Cedex, France
- Centre 16: Dr R Pagot
CHS, 56896 Saint-Ave Cedex, France
- Centre 17: Prof E Bercoff
Hôpital de Bois-Guillaume, Service de Gériatrie, 147, rue du Maréchal
Juin, 76320 Bois-Guillaume, France
- Centre 18: Dr G Clerc
Hôpital de Pontorson, 7, La Chaussée de Villecherol, 50170 Pontorson,
France
- Centre 20: Dr RA Castiglioni
Hôpital Sainte Marguerite, Service de Psychiatrie, 270, bd. Sainte
Marguerite, 13275 Marseille Cedex, France
- Centre 22: Dr H Berzewski
Universitätsklinikum Steglitz, Freie Universität Berlin,
Hindenburgdamm 30, 12203 Berlin, Germany
- Centre 23: Prof KL Täschner
Bürgerhospital, Psychiatrische Klinik, Tunzhofer Str. 14-16, 70191
Stuttgart, Germany
- Centre 25: Prof HJ Möller
Psychiatrische Universitätsklinik, Sigmund Freud Str. 25, 53127 Bonn,
Germany

9550089

Pharmacia

Document 9550089

- Centre 26: Dr J Morgner
Bezirkskrankenhaus, Neuropsych. Klinik Oberloschwitz, Alpenstr. 1,
01326 Dresden, Germany
- Centre 27: Prof B Pflug
Zentrum für Psychiatrie am Klinikum der JW Goethe Universität,
Heinrich Hoffmann Str. 10, 60528 Frankfurt/Main, Germany
- Centre 28: Dr HJ Schierle
Puisseaux Platz 2, 63110 Rodgau, Germany
- Centre 29: Prof H Woelk
Gießen, Germany
(Coordinator for centres from 29/1 to 29/5)
- Centre 29/1: Dr M O'Connolly
Haimendorfstr. 4, 91126 Schwabach, Germany
- Centre 29/2: Dr H Wiswedel
Friedenstr. 12, 90765 Fürth, Germany
- Centre 29/3: Dr G Stumpf
Volkacher Str. 31, 90427 Nürnberg, Germany
- Centre 29/4: Dr K Schröter
Altdorfer Str. 11, 91207 Lauf/Pegnitz, Germany
- Centre 29/5: Dr P Adler
Schnieglingerstr. 36a, 90419 Nürnberg, Germany
- Centre 30: Dr SV Korgaonkar
Bedford Hospital, Kempston Road, Bedford MK45 9DJ, UK
- Centre 31: Dr B Lawlor
St James' Hospital, St James' Street, PO Box 580, Dublin 8, Ireland
- Centre 32: Prof C Katona
Princess Alexandra Hospital, Hamstel Road, Harlow, Essex, CM10
1QX, UK
- Centre
33/01: Dr S Luke
Luton and Dunstable Hospital, Lewsey Road, Luton, Beds, LU4 0DT,
UK

9550089

Pharmacia

Document 9550089

- Centre: Dr S Luke
33/02 Fairfield Hospital, Stotfield Road, Hitchin, Herts, SG5 4AA, UK
- Centre 35: Dr P Bourgeois
Heilig Hart Ziekenhuis, Wilgenstraat 2, 8800 Roeselare, Belgium
- Centre 36: Dr Ph Tack
Sint Andries Ziekenhuis, Neuropsychiatrie, Krommewalstraat 11, 8700 Tielt, Belgium
- Centre 38/1: Dr IKI Ibrahim
Farnham Hospital, Hale Road, Farnham, Surrey, GU9 9QL, UK
- Centre 38/2: Dr IKI Ibrahim
Frimley Park Hospital, Portsmouth Road, Frimley, Camberley, Surrey GU 16 5UJ, UK
- Centre 41: Dr R Bullock
Victoria Hospital, Okus Road, Swindon, Wilts SN1 4HZ, UK
- Centre 42: Dr T Venkat
Conquest Hospital, St Anne's Centre, 729 The Ridge, St. Leonards-on-Sea, East Sussex TN37 7PT, UK
- Centre 43: Dr T George
The Prince Charles Hospital, Chermside, QLD 4032, Australia
- Centre 44: Dr M Smout
Pembury Hospital, Tonbridge Wells, Kent TN2 4 QJ, UK
- Centre 45: Prof Bulpitt
Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
- Centre 46: Dr J Mullin
De La Pole Hospital, Willerby - Hull HU10 6ED, UK
- Centre 48 Prof D O'Connor
Academic Unit of Psychogeriatrics, Heatherton Hospital, Kingston Road, Heatherton, Vic 3202, Australia

Investigators' Signatures and Curricula Vitae are filed in the Study Master File.

* Present address of the Investigator. The address of the study centre is reported in the Synopsis.

9550089

Pharmacia

Document 9550089

12.1.5 CERTIFICATES OF ANALYSIS

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9550089

STABILIMENTO DI NERVIANO
VIA MILANO, 68
20014 NERVIANO (MI)
TELEFONO (0391) 587400
TELEGRAMMI FARMITALIA CARLO ERBA NERVIANO
CASSELLA POSTALE 2
TELEX 310879 MONTEP PER FARMITALIA NERVIANO



DATA June 15th, 1992

VS. RIF.

NS. RIF.

TEL. DIRETTO

CERTIFICATE OF ANALYSIS

REBOXETINE 2 mg capsules

Batch SF 1308

Manufacturing date	: May, 1992
Expiry date	: September, 1994
Appearance	: red-brown, hard-gelatin capsule, snap-fit, size No. 0, containing one 2 mg Reboxetine white, round, convex, 6 mm diameter tablet, marked S.F. on one surface (batch No. SF 1249)
Identification	: positive
Average weight	: mg 100.45
Uniformity of content	: within the limits, according to Eur. Ph. 2nd Ed., section V.5.2.2
Assay	: mg 2.040 of Reboxetine/capsule
Related substances	: 0.82%
Disintegration time	: 10 minutes
Microbial contamination	: total viable aerobic count < 1000 moulds and yeasts < 100 E. Coli and Salmonellae : absent

Approved by

754

: Virginio Busnelli

S.R.L. SEDE LEGALE IN MILANO

GRUPPO ERBAMONT

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9550089

CENTRO RICERCHE
VIA GIOVANNI XXIII 23
20014 NERVIANO
TELEFONO (0331) 587250
TELEGRAMMI FARMITALIA CARLO ERBA NERVIANO
CASELLA POSTALE 2
TELEX 310679 MONTED PFR FARMITALIA NERVIANO



DATA May 4th, 1993

CERTIFICATE OF ANALYSIS No. PC/071

REBOXETINE 2 mg capsules

Batch A06G01

Manufacturing date : March, 1993
Expiry date : September, 1995
Appearance : swedish orange, hard-gelatin capsule,
snap-fit, size 0, containing
one 2 mg Reboxetine white, round,
convex, 6 mm diameter tablet,
marked S.F. on one surface (batch
No. SF 1330)
Identification : positive
Average weight : mg 98.35
Uniformity of content : within the limits, according to Ph.
Eur. 2nd Ed., Section V.5.2.2
Assay : mg 1.988 of Reboxetine/capsule
Related substances : 0.493 %
Disintegration : 9 minutes and 30 seconds
Microbial contamination : total viable aerobic count < 1000
moulds and yeasts < 100
E.coli and Salmonellae : absent
Analysis date : March 17th, 1993
Approved by : Virginio Busnelli *Busnelli*

755

SPL. SECE LEGALE "MILANO"
CAPITALE 200.000.000 L. 5/8/732 12/2007
FARMACIA VALSUGANA S.R.L. 238246

GRUPPO ERBAMONT

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9550089



Data January 24th, 1994

Vs. Rif.

Ns. Rif.

Tel. Diretto

CERTIFICATE OF ANALYSIS No. PC/267

REBOXETINE 4 mg capsules

Batch SF 1264

Manufacturing date : October, 1991
Expiry date : September, 1994
Appearance : red-brown, hard-gelatin capsule, snap-fit, size No. 0, containing two 2 mg Reboxetine white, round, convex, 6 mm diameter tablets, marked S.F. on one surface (batch No. SF 1249)
Identification : positive
Average weight : mg 201.10
Uniformity of content : within the limits, according to Ph. Eur. 2nd Ed., Section V.5.2.2
Assay : mg 3.95 of Reboxetine/capsule
Dissolution : 93.9% of the L.A. after 15 minutes
Disintegration : 6 minutes
Microbial contamination : total viable aerobic count < 1000 moulds and yeasts < 100
E. Coli and Salmonellae : absent

Note : this certificate replaces the previous one edited on May 14th, 1992, vis-a-vis the extension of shelf-life

Approved by : V. Busnelli *Busnelli*

756

Centro Ricerche
Farmitalia Carlo Erba srl
Via Giovanni XXIII, 23
20014 Nerviano (MI) Italy

Telef. (0331) 58.3111 (Centralino)
Casella Postale 2

Sede Legale Milano
Capit. L. 528.732.127.000 I.V.
Trib. Milano R.S. N. 238246
Vol. 6366 - Fasc. 46

C.C.I.A.A. N. 1171077
Cod. Fisc. e Part. IVA
N. 07608290156

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

LA QUALITÀ È IL NOSTRO MODO DI FARMACIA

9550089

CENTRO RICERCHE
VIA GIOVANNI XXIII 23
20014 NERVIANO
TELEFONO (0371) 587230
TELEGRAMMI FARMITALIA CARLO ERBA NERVIANO
CASELLA POSTALE 2
TELEX 310679 MONTE PER FARMITALIA NERVIANO


 FARMITALIA CARLO ERBA

DATA March 24th, 1993

CERTIFICATE OF ANALYSIS No. PC/040

REBOXETINE 4 mg capsules

Batch A06G02

Manufacturing date	: February, 1993
Expiry date	: September, 1995
Appearance	: red-brown, hard-gelatin capsule, snap-fit, size No. 0, containing two 2 mg Reboxetine white, round, convex, 6 mm diameter tablet, marked S.F. on one surface (batch No. SF 1330)
Identification	: positive
Average weight	: mg 194.24
Uniformity of content	: within the limits, according to Eur. Ph. 2nd Ed., section V.5.2.2
Assay	: mg 4.054 of Reboxetine/capsule
Related substances	: 0.65%
Disintegration time	: 6 minutes and 30 seconds
Microbial contamination	: total viable aerobic count < 1000 moulds and yeasts < 100 E. Coli and Salmonellae : absent
Analysis date	: March 1st, 1993
Approved by	: Virginio Busnelli 

757

GRUPPO ERBAMONT
S.P.A. SEDE LEGALE IN MILANO
CAPITALE SOC. L. 503.732.017.000
FARMITALIA CARLO ERBA S.P.A. 20024
VIALE S. PIETRO 18 - 20122 MILANO
TELEFONO (02) 587230 - TELEGRAMMI FARMITALIA CARLO ERBA NERVIANO
TELEX 310679 MONTE PER FARMITALIA NERVIANO

GRUPPO ERBAMONT

9550089

VIA CARLO IMBONATI, 24
20159 MILANO



TELEFONO (02) 69851 (CENTRALINO)
TELEGRAMMI ERBACAR-MILANO
CASELLA POSTALE 10519
C.C. POSTALE 619205
TELEX 330314 ERBA-I.

DATA July 30th, 1992

VS. RIF.

NS. RIF.

TEL. DIRETTO

CERTIFICATE OF ANALYSIS

Imipramine hydrochloride 25 mg capsules

Batch SF 1321

Manufacturing date	: July 1992
Expiry date	: December 1996
Description	: hard-gelatin capsule, swedish orange opaque, size No.0, containing one 25 mg TOFRANIL sugar coated, dark pink orange, tablets (GEIGY, batch No. 192)
Average weight	: mg 75.31
Uniformity of mass	: complies, according to Eur. Ph., 2nd Ed., requirements
Disintegration time	: 12 minutes
Identification	: positive, according to B.P. 1988 monograph texts A, B and C, page 956
Assay	: 25.06 mg/capsule (B.P. 1988 monograph, page 956)
Related substances	: within the limits, according to B.P.1988 monograph, page 956
Microbial contamination	: total viable aerobic count < 1000 moulds and yeasts < 100 E. Coli and Salmonellae : absent

Approved by

758

SRL - SEDE LEGALE IN MILANO
CAPITALE L. 528.732.127.000 IV

GRUPPO ERBAMONT

9550089

VIA CARLO IMBONATI 24
20159 MILANO



TELEFONO (02) 49951 (CENTRALINO)
TELEGRAMMI ERBA-CAH-MILANO
CASELLA POSTALE 10519
C.C. POSTALE 619205
TELE 330314 ERBA-I

DATA March 24th, 1992

VS. RIF.

NS. RIF.

TEL. DIRETTO

CERTIFICATE OF ANALYSIS

Imipramine hydrochloride 50 mg capsules

Batch SF 1265

Manufacturing date : December 1990
Expiry date : December 1995
Description : hard-gelatin capsule, opaque red-brown,
size No.0, containing two 25 mg TOFRANIL
sugar coated, dark pink orange, tablets
(GEIGY, batch No. 178)
Average weight : mg 151.49
Uniformity of mass : complies, according to Eur. Ph., 2nd Ed.,
requirements
Disintegration time : 12 minutes
Identification : positive, according to B.P. 1988
monograph texts A, B and C, page 956
Assay : 48.41 mg/capsule (B.P. 1988 monograph,
page 956)
Related substances : within the limits, according to B.P.1988
monograph, page 956
Microbial contamination : total viable aerobic count < 1000
moulds and yeasts < 100
E. Coli and Salmonellae : absent

Approved by

760

: V. Busnelli *Busnelli*

IRP. REDE LEGALI IN MILANO
PUBBLICITÀ - 4381 22127/001V
PUBBLICITÀ DI MILANO - 4381 22127/001V
PUBBLICITÀ - PASC 36 - C.C.I.A.A. N° 171077
C.C.D. PASC E PART IVA N° 07608290158

GRUPPO ERBAMONT

9550089

VIA CARLO IMBONATI, 24
20159 MILANO



TELEFONO (02) 69951 (CENTRALINO)
TELEGRAMMI ERBACAR MILANO
CASSELLA POSTALE 10519
C.C. POSTALE 610705
TELEX 330314 ERBA-I

September 14th, 1992

DATA

VS. RIF

NS. RIF

TEL DIRETTO

CERTIFICATE OF ANALYSIS

Imipramine hydrochloride 50 mg capsules

Batch SF 1323

Manufacturing date : July, 1992
Expiry date : December, 1996

Description : hard-gelatin capsule, swedish orange opaque,
size No.0, containing two 25 mg TOFRANIL
sugar coated, dark pink orange, tablets
(GEIGY, batch No. 191)

Average weight : mg 151.23

Uniformity of mass : complies, according to Eur. Ph., 2nd Ed.,
requirements

Disintegration time : 12 minutes

Identification : positive, according to B.P. 1988
monograph texts A, B and C, page 956

Assay : 50.32 mg/capsule (B.P. 1988 monograph,
page 956)

Related substances : within the limits, according to B.P.1988
monograph, page 956

Microbial contamination : total viable aerobic count < 1000
moulds and yeasts < 100
E. Coli and Salmonellae : absent

Approved by

: V. Busnelli

761

DR. VENE EDIZIONE 1988
CASSELLA POSTALE 10519
TELEFONO (02) 69951
TELEX 330314 ERBA-I

GRUPPO ERBAMONT

9550089

CENTRO RICERCHE
VIA GIOVANNI XXIII, 23
20014 NERMANO
TELEFONO (0331) 587250
TELEGRAMMI FARMITALIA CARLO ERBA NERMANO
CASSELLA POSTALE 2
TELEX 310679 MONTEP PER FARMITALIA NERMANO



February 9th, 1993
DATA

CERTIFICATE OF ANALYSIS No PC/003

Imipramine hydrochloride 50 mg capsules

Batch SF 1353

Manufacturing date : December, 1992
Expiry date : February, 1997
Description : hard-gelatin capsule, swedish orange opaque,
size No.0, containing two 25 mg TOFRANIL
sugar coated, dark pink orange, tablets
(GEIGY, batch No. 197)
Average weight : mg 150.15
Uniformity of mass : complies, according to Eur. Ph., 2nd Ed.,
requirements
Disintegration time : 13 minutes
Identification : positive, according to B.P. 1988
monograph texts A, B and C, page 956
Assay : 50.06 mg/capsule (B.P. 1988 monograph,
page 956)
Related substances : within the limits, according to B.P.1988
monograph, page 956
Microbial contamination : total viable aerobic count < 1000
moulds and yeasts < 100
E.Coli and Salmonellae : absent
Approved by : V. Busnelli *Busnelli*

762

S.P.A. SEDE LEGALE N. MILANO
CAPITALE SOC. L. 2.287.000.000
ISCRIZIONE REPERTELLA 1979/2

GRUPPO ERBAMONT

090177e1803f200fApproved\Approved On: 12-Nov-2002 22:22

9550089

CENTRO RICERCHE
VIA GIOVANNI XX I 23
20014 NERVIANO
TELEFONO 0331/587250
TELEGRAMMI FARMITALIA CARLO ERBA NERVIANO
CASSELLA POSTALE 2
TELEF. 310879 MONTE PER FARMITALIA NERVIANO

 FARMITALIA CARLO ERBA

DATA September 10th, 1993

CERTIFICATE OF ANALYSIS No. PC/171

Imipramine hydrochloride 50 mg capsules

Batch A27G02

Manufacturing date : July, 1993
Expiry date : April, 1998
Description : hard-gelatin capsule, swedish orange opaque,
size No.0, containing two 25 mg TOFRANIL
sugar coated, dark pink orange, tablets
(GEIGY, batch No. H007)
Average weight : mg 152.04
Uniformity of mass : complies, according to Eur. Ph., 2nd Ed.,
requirements
Disintegration time : 10 minutes
Identification : positive, according to B.P. 1988
monograph texts A, B and C, page 956
Assay : 49.55 mg/capsule (B.P. 1988 monograph,
page 956)
Related substances : within the limits, according to B.P.1988
monograph, page 956
Microbial contamination : total viable aerobic count < 1000
moulds and yeasts < 100
E.coli and Salmonellae : absent
Approved by : V. Busnelli *Busnelli*

763

TELEFONO 0331/587250
TELEGRAMMI FARMITALIA CARLO ERBA NERVIANO
CASSELLA POSTALE 2
TELEF. 310879 MONTE PER FARMITALIA NERVIANO

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9550089

Pharmacia

Document 9550089

12.1.6 AUDIT CERTIFICATE

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

764

9550089

Pharmacia
PPC Italy - GCP-Quality Assurance

R&D/Q.A. AUDIT CERTIFICATE

Product **REBOXETINE**
Protocol N°: **FCE 20124/035** N° GCP: **117**
Study title: **Multicenter, multinational double-blind study of the tolerability and activity of Reboxetine vs Imipramine in elderly patients suffering from Depressive Disorders.**

Type of Audit	Site	Audit date(s)	Reporting date
Draft Protocol	FICE - Milan	27.02-11.03.1992	11.03.1992
Final Protocol	FICE - Milan	25-26.05.1992	26.05.1992
Study Master File	Pharmacia - Milan	20.02-23.03.1995	28.03.1995
Investigator Site and CRO	Centre N° 10 (Brazil)	02-09.05.1995	31.05.1995
Data Listings vs CRFs	Pharmacia - Milan	17-27.11.1995	01.12.1995
Draft Final Report	Pharmacia - Milan	30.01-14.02.1996	16.02.1996
Final Report	Pharmacia - Milan	15-25.03.1996	25.03.1996

Signature of the Head of PPC Italy - GCP-Q.A. Q. Kavan
Date: March 25th, 1996

9550089

Pharmacia

Document 9550089

12.1.7 RANDOMISATION LIST

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

766

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
 REBOXETINE - PROTOCOL 20124/035
 MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
 AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=Australia CENTER=1 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Imipramine
4	Reboxetine
5	Imipramine
6	Reboxetine
7	Imipramine
8	Reboxetine
9	Imipramine
10	Reboxetine
11	Reboxetine
12	Imipramine
13	Reboxetine
14	Imipramine

----- COUNTRY=Australia CENTER=1 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Reboxetine
4	Imipramine
5	Imipramine
6	Imipramine
7	Reboxetine
8	Reboxetine
9	Reboxetine
10	Imipramine
11	Reboxetine
12	Imipramine
13	Reboxetine
14	Reboxetine

----- COUNTRY=Australia CENTER=2 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Reboxetine
4	Imipramine
5	Reboxetine
6	Imipramine
7	Reboxetine
8	Imipramine
9	Reboxetine
10	Imipramine
11	Reboxetine
12	Imipramine
13	Reboxetine
14	Reboxetine

----- COUNTRY=Australia CENTER=2 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Reboxetine
3	Imipramine
4	Imipramine
5	Imipramine
6	Reboxetine
7	Reboxetine
8	Imipramine
9	Imipramine
10	Reboxetine
11	Reboxetine
12	Imipramine
13	Imipramine
14	Imipramine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
 REBOXETINE - PROTOCOL 20124/035
 MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
 AND TOLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=Australia CENTER=3 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Imipramine
4	Reboxetine
5	Imipramine
6	Reboxetine
7	Imipramine
8	Reboxetine
9	Reboxetine
10	Imipramine
11	Imipramine
12	Reboxetine
13	Imipramine
14	Imipramine

----- COUNTRY=Australia CENTER=3 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Imipramine
4	Reboxetine
5	Imipramine
6	Reboxetine
7	Reboxetine
8	Imipramine
9	Reboxetine
10	Reboxetine
11	Imipramine
12	Imipramine
13	Imipramine
14	Reboxetine

----- COUNTRY=Australia CENTER=4 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetine
3	Reboxetine
4	Imipramine
5	Imipramine
6	Reboxetine
7	Imipramine
8	Reboxetine
9	Reboxetine
10	Reboxetine
11	Imipramine
12	Imipramine
13	Reboxetine
14	Reboxetine

----- COUNTRY=Australia CENTER=4 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Reboxetine
4	Imipramine
5	Reboxetine
6	Imipramine
7	Reboxetine
8	Imipramine
9	Reboxetine
10	Imipramine
11	Imipramine
12	Reboxetine
13	Reboxetine
14	Reboxetine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
 REBOXETINE - PROTOCOL 20124/035
 MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
 AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=Australia CENTER=43 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Imipramine
2	Imipramine
3	Reboxetine
4	Reboxetine
5	Reboxetine
6	Imipramine
7	Reboxetine
8	Imipramine
9	Imipramine
10	Reboxetine
11	Reboxetine
12	Imipramine
13	Imipramine
14	Reboxetine
15	Imipramine
16	Reboxetine
17	Reboxetine
18	Imipramine
19	Imipramine
20	Reboxetine
21	Imipramine
22	Imipramine
23	Reboxetine
24	Reboxetine

----- COUNTRY=Australia CENTER=43 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Reboxetine
4	Imipramine
5	Imipramine
6	Reboxetine
7	Reboxetine
8	Imipramine
9	Reboxetine
10	Reboxetine
11	Imipramine
12	Imipramine
13	Imipramine
14	Reboxetine
15	Imipramine
16	Reboxetine
17	Imipramine
18	Imipramine
19	Reboxetine
20	Reboxetine
21	Reboxetine
22	Imipramine
23	Imipramine
24	Reboxetine

----- COUNTRY=Australia CENTER=48 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Imipramine
2	Imipramine
3	Reboxetine
4	Reboxetine
5	Imipramine
6	Reboxetine
7	Reboxetine
8	Imipramine
9	Imipramine
10	Reboxetine
11	Imipramine
12	Reboxetine
13	Imipramine
14	Imipramine
15	Reboxetine
16	Reboxetine
17	Reboxetine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
REBOXETINE - PROTOCOL 20124/035
MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=Australia CENTER=48 STRATA=Major Depres. EP. -----
(continued)

PATIENT	TREATMENT
18	Imipramine
19	Imipramine
20	Reboxetine
21	Imipramine
22	Reboxetine
23	Reboxetine
24	Imipramine

----- COUNTRY=Australia CENTER=48 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Reboxetine
4	Imipramine
5	Reboxetine
6	Imipramine
7	Reboxetine
8	Imipramine
9	Reboxetine
10	Imipramine
11	Reboxetine
12	Imipramine
13	Imipramine
14	Reboxetine
15	Imipramine
16	Reboxetine
17	Imipramine
18	Reboxetine
19	Reboxetine
20	Imipramine
21	Reboxetine
22	Imipramine
23	Reboxetine
24	Imipramine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
 REBOXETINE - PROTOCOL 20124/035
 MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
 AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=Belgium CENTER=5 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Reboxetine
2	Reboxetine
3	Imipramine
4	Imipramine
5	Reboxetine
6	Imipramine
7	Reboxetine
8	Imipramine
9	Reboxetine
10	Imipramine
11	Imipramine
12	Reboxetine
13	Imipramine
14	Imipramine
15	Reboxetine
16	Reboxetine
17	Imipramine
18	Reboxetine
19	Imipramine
20	Reboxetine
21	Reboxetine
22	Imipramine
23	Reboxetine
24	Imipramine

----- COUNTRY=Belgium CENTER=5 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Imipramine
2	Imipramine
3	Reboxetine
4	Reboxetine
5	Reboxetine
6	Reboxetine
7	Imipramine
8	Imipramine
9	Reboxetine
10	Imipramine
11	Reboxetine
12	Imipramine
13	Imipramine
14	Imipramine
15	Reboxetine
16	Reboxetine
17	Reboxetine
18	Reboxetine
19	Imipramine
20	Imipramine
21	Imipramine
22	Reboxetine
23	Imipramine
24	Reboxetine

----- COUNTRY=Belgium CENTER=6 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Reboxetine
4	Imipramine
5	Imipramine
6	Reboxetine
7	Reboxetine
8	Imipramine
9	Reboxetine
10	Reboxetine
11	Imipramine
12	Imipramine
13	Imipramine
14	Reboxetine
15	Imipramine
16	Reboxetine
17	Imipramine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
REBOXETINE - PROTOCOL 20124/035
MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=Belgium CENTER=6 STRATA=Major Depres. Ep. -----
(continued)

PATIENT	TREATMENT
18	Imipramine
19	Reboxetine
20	Reboxetine
21	Imipramine
22	Imipramine
23	Reboxetine
24	Reboxetine

----- COUNTRY=Belgium CENTER=6 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Reboxetine
3	Imipramine
4	Imipramine
5	Reboxetine
6	Imipramine
7	Reboxetine
8	Imipramine
9	Imipramine
10	Reboxetine
11	Imipramine
12	Reboxetine
13	Imipramine
14	Imipramine
15	Reboxetine
16	Reboxetine
17	Imipramine
18	Reboxetine
19	Reboxetine
20	Imipramine
21	Imipramine
22	Reboxetine
23	Reboxetine
24	Imipramine

----- COUNTRY=Belgium CENTER=7 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetine
3	Imipramine
4	Reboxetine
5	Reboxetine
6	Reboxetine
7	Imipramine
8	Imipramine
9	Reboxetine
10	Imipramine
11	Reboxetine
12	Imipramine
13	Imipramine
14	Imipramine
15	Reboxetine
16	Reboxetine
17	Reboxetine
18	Imipramine
19	Reboxetine
20	Imipramine
21	Reboxetine
22	Imipramine
23	Reboxetine
24	Imipramine

----- COUNTRY=Belgium CENTER=7 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Imipramine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
 REBOXETINE - PROTOCOL 20124/035
 MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
 AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=Belgium CENTER=7 STRATA=Dysthymia -----
 (continued)

PATIENT	TREATMENT
4	Reboxetine
5	Reboxetine
6	Imipramine
7	Imipramine
8	Reboxetine
9	Reboxetine
10	Imipramine
11	Imipramine
12	Reboxetine
13	Imipramine
14	Reboxetine
15	Imipramine
16	Reboxetine
17	Imipramine
18	Imipramine
19	Reboxetine
20	Reboxetine
21	Imipramine
22	Reboxetine
23	Reboxetine
24	Imipramine

----- COUNTRY=Belgium CENTER=8 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Reboxetine
2	Reboxetine
3	Imipramine
4	Imipramine
5	Reboxetine
6	Imipramine
7	Reboxetine
8	Imipramine
9	Reboxetine
10	Imipramine
11	Reboxetine
12	Imipramine
13	Reboxetine
14	Imipramine
15	Imipramine
16	Reboxetine
17	Reboxetine
18	Imipramine
19	Imipramine
20	Reboxetine
21	Reboxetine
22	Imipramine
23	Reboxetine
24	Imipramine

----- COUNTRY=Belgium CENTER=8 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Imipramine
2	Imipramine
3	Reboxetine
4	Reboxetine
5	Imipramine
6	Reboxetine
7	Imipramine
8	Reboxetine
9	Reboxetine
10	Imipramine
11	Reboxetine
12	Imipramine
13	Reboxetine
14	Imipramine
15	Imipramine
16	Reboxetine
17	Imipramine
18	Reboxetine
19	Imipramine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
 REBOXETINE - PROTOCOL 20124/035
 MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
 AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=Belgium CENTER=8 STRATA=Dysthymia -----
 (continued)

PATIENT	TREATMENT
20	Reboxetine
21	Imipramine
22	Reboxetine
23	Imipramine
24	Reboxetine

----- COUNTRY=Belgium CENTER=34 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetine
3	Imipramine
4	Reboxetine
5	Imipramine
6	Reboxetine
7	Imipramine
8	Reboxetine
9	Imipramine
10	Reboxetine
11	Reboxetine
12	Imipramine
13	Imipramine
14	Reboxetine
15	Reboxetine
16	Imipramine
17	Imipramine
18	Reboxetine
19	Imipramine
20	Reboxetine
21	Reboxetine
22	Imipramine
23	Imipramine
24	Reboxetine

----- COUNTRY=Belgium CENTER=34 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetine
3	Imipramine
4	Reboxetine
5	Reboxetine
6	Reboxetine
7	Imipramine
8	Imipramine
9	Imipramine
10	Reboxetine
11	Imipramine
12	Reboxetine
13	Imipramine
14	Reboxetine
15	Reboxetine
16	Imipramine
17	Reboxetine
18	Imipramine
19	Reboxetine
20	Imipramine
21	Reboxetine
22	Imipramine
23	Imipramine
24	Reboxetine

----- COUNTRY=Belgium CENTER=35 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Imipramine
4	Reboxetine
5	Reboxetine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
 REBOXETINE - PROTOCOL 20124/035
 MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
 AND TOLLERABILITY OF REBOXETINE VS TMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=Belgium CENTER=35 STRATA=Major Depres. Ep. -----
 (continued)

PATIENT	TREATMENT
6	Reboxetina
7	Imipramine
8	Imipramine
9	Imipramine
10	Reboxetina
11	Reboxetina
12	Imipramine
13	Reboxetina
14	Imipramine
15	Imipramine
16	Reboxetina
17	Imipramine
18	Imipramine
19	Reboxetina
20	Reboxetina
21	Reboxetina
22	Reboxetina
23	Imipramine
24	Imipramine

----- COUNTRY=Belgium CENTER=35 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetina
2	Imipramine
3	Imipramine
4	Reboxetina
5	Imipramine
6	Imipramine
7	Reboxetina
8	Reboxetina
9	Reboxetina
10	Reboxetina
11	Imipramine
12	Imipramine
13	Reboxetina
14	Imipramine
15	Imipramine
16	Reboxetina
17	Reboxetina
18	Imipramine
19	Reboxetina
20	Imipramine
21	Imipramine
22	Reboxetina
23	Reboxetina
24	Imipramine

----- COUNTRY=Belgium CENTER=36 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetina
3	Imipramine
4	Reboxetina
5	Reboxetina
6	Imipramine
7	Reboxetina
8	Imipramine
9	Reboxetina
10	Reboxetina
11	Imipramine
12	Imipramine
13	Reboxetina
14	Imipramine
15	Reboxetina
16	Imipramine
17	Reboxetina
18	Imipramine
19	Reboxetina
20	Imipramine
21	Imipramine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
 REBOXETINE - PROTOCOL 20124/035
 MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
 AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=Belgium CENTER=36 STRATA=Major Depres. Ep. -----
 (continued)

PATIENT	TREATMENT
22	Reboxetine
23	Imipramine
24	Reboxetine

----- COUNTRY=Belgium CENTER=36 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetine
3	Imipramine
4	Reboxetine
5	Imipramine
6	Imipramine
7	Reboxetine
8	Reboxetine
9	Imipramine
10	Reboxetine
11	Reboxetine
12	Imipramine
13	Imipramine
14	Imipramine
15	Reboxetine
16	Reboxetine
17	Reboxetine
18	Imipramine
19	Reboxetine
20	Imipramine
21	Reboxetine
22	Imipramine
23	Reboxetine
24	Imipramine

----- COUNTRY=Belgium CENTER=37 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Imipramine
2	Imipramine
3	Reboxetine
4	Reboxetine
5	Imipramine
6	Imipramine
7	Reboxetine
8	Reboxetine
9	Imipramine
10	Reboxetine
11	Reboxetine
12	Imipramine
13	Reboxetine
14	Reboxetine
15	Imipramine
16	Imipramine
17	Reboxetine
18	Reboxetine
19	Imipramine
20	Imipramine
21	Reboxetine
22	Imipramine
23	Reboxetine
24	Imipramine

----- COUNTRY=Belgium CENTER=37 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetine
3	Reboxetine
4	Imipramine
5	Reboxetine
6	Imipramine
7	Reboxetine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS
REBOXETINE - PROTOCOL 20124/035
MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=Belgium CENTER=37 STRATA=Dysthymia -----
(continued)

PATIENT	TREATMENT
8	Imipramine
9	Reboxetine
10	Imipramine
11	Imipramine
12	Reboxetine
13	Reboxetine
14	Imipramine
15	Imipramine
16	Reboxetine
17	Imipramine
18	Reboxetine
19	Imipramine
20	Reboxetine
21	Reboxetine
22	Imipramine
23	Imipramine
24	Reboxetine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
 REBOXETINE - PROTOCOL 20124/035
 MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
 AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=Brazil CENTER=9 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetine
3	Reboxetine
4	Imipramine
5	Reboxetine
6	Imipramine
7	Imipramine
8	Reboxetine
9	Imipramine
10	Reboxetine
11	Reboxetine
12	Imipramine
13	Imipramine
14	Reboxetine

----- COUNTRY=Brazil CENTER=9 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Imipramine
2	Imipramine
3	Reboxetine
4	Reboxetine
5	Reboxetine
6	Imipramine
7	Imipramine
8	Reboxetine
9	Imipramine
10	Reboxetine
11	Reboxetine
12	Imipramine
13	Reboxetine
14	Imipramine

----- COUNTRY=Brazil CENTER=10 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetine
3	Reboxetine
4	Imipramine
5	Imipramine
6	Reboxetine
7	Imipramine
8	Reboxetine
9	Reboxetine
10	Imipramine
11	Imipramine
12	Reboxetine
13	Reboxetine
14	Imipramine
15	Reboxetine
16	Imipramine
17	Reboxetine
18	Imipramine
19	Imipramine
20	Reboxetine
21	Reboxetine
22	Imipramine
23	Imipramine
24	Reboxetine
25	Reboxetine
26	Imipramine
27	Reboxetine
28	Imipramine
29	Reboxetine
30	Imipramine
31	Imipramine
32	Reboxetine
33	Reboxetine
34	Reboxetine
35	Imipramine
36	Imipramine
37	Imipramine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
REBOXETINE - PROTOCOL 20124/035
MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=Brazil CENTER=10 STRATA=Major Depres. Ep. -----
(continued)

PATIENT	TREATMENT
38	Inipramine
39	Reboxetine
40	Reboxetine

----- COUNTRY=Brazil CENTER=10 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Inipramine
3	Inipramine
4	Reboxetine
5	Reboxetine
6	Reboxetine
7	Inipramine
8	Inipramine
9	Inipramine
10	Reboxetine
11	Inipramine
12	Reboxetine
13	Reboxetine
14	Inipramine
15	Reboxetine
16	Inipramine
17	Reboxetine
18	Inipramine
19	Reboxetine
20	Inipramine
21	Reboxetine
22	Inipramine
23	Reboxetine
24	Inipramine
25	Inipramine
26	Reboxetine
27	Reboxetine
28	Inipramine
29	Inipramine
30	Inipramine
31	Reboxetine
32	Reboxetine
33	Reboxetine
34	Reboxetine
35	Inipramine
36	Inipramine
37	Reboxetine
38	Inipramine
39	Inipramine
40	Reboxetine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
REBOXETINE - PROTOCOL 20124/035
MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=France CENTER=11 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Reboxetine
4	Imipramine
5	Imipramine
6	Reboxetine
7	Reboxetine
8	Imipramine
9	Reboxetine
10	Reboxetine
11	Imipramine
12	Imipramine

----- COUNTRY=France CENTER=11 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Reboxetine
4	Imipramine
5	Reboxetine
6	Reboxetine
7	Imipramine
8	Imipramine
9	Imipramine
10	Reboxetine
11	Imipramine
12	Reboxetine

----- COUNTRY=France CENTER=12 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Imipramine
4	Reboxetine
5	Imipramine
6	Reboxetine
7	Imipramine
8	Reboxetine
9	Reboxetine
10	Reboxetine
11	Imipramine
12	Imipramine

----- COUNTRY=France CENTER=12 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Reboxetine
4	Imipramine
5	Imipramine
6	Imipramine
7	Reboxetine
8	Reboxetine
9	Reboxetine
10	Reboxetine
11	Imipramine
12	Imipramine

----- COUNTRY=France CENTER=13 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Imipramine
4	Reboxetine
5	Imipramine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
REBOXETINE - PROTOCOL 20124/035
MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=France CENTER=13 STRATA=Major Depres. Ep. -----
(continued)

PATIENT	TREATMENT
6	Reboxetine
7	Reboxetine
8	Imipramine
9	Imipramine
10	Imipramine
11	Reboxetine
12	Reboxetine

----- COUNTRY=France CENTER=13 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetine
3	Imipramine
4	Reboxetine
5	Reboxetine
6	Imipramine
7	Imipramine
8	Reboxetine
9	Reboxetine
10	Imipramine
11	Reboxetine
12	Imipramine

----- COUNTRY=France CENTER=14 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Reboxetine
4	Imipramine
5	Reboxetine
6	Imipramine
7	Imipramine
8	Reboxetine
9	Reboxetine
10	Reboxetine
11	Imipramine
12	Imipramine

----- COUNTRY=France CENTER=14 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Imipramine
4	Reboxetine
5	Reboxetine
6	Reboxetine
7	Imipramine
8	Imipramine
9	Imipramine
10	Reboxetine
11	Reboxetine
12	Imipramine

----- COUNTRY=France CENTER=15 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Reboxetine
4	Imipramine
5	Imipramine
6	Imipramine
7	Reboxetine
8	Reboxetine
9	Imipramine

781

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
 REBOXETINE - PROTOCOL 20124/035
 MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
 AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=France CENTER=15 STRATA=Major Depres. Ep. -----
 (continued)

PATIENT	TREATMENT
10	Reboxetine
11	Imipramine
12	Reboxetine

----- COUNTRY=France CENTER=15 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Reboxetine
4	Imipramine
5	Reboxetine
6	Imipramine
7	Reboxetine
8	Imipramine
9	Reboxetine
10	Imipramine
11	Imipramine
12	Reboxetine

----- COUNTRY=France CENTER=16 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Imipramine
4	Reboxetine
5	Reboxetine
6	Imipramine
7	Reboxetine
8	Imipramine
9	Reboxetine
10	Imipramine
11	Imipramine
12	Reboxetine

----- COUNTRY=France CENTER=16 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetine
3	Imipramine
4	Reboxetine
5	Imipramine
6	Reboxetine
7	Reboxetine
8	Imipramine
9	Reboxetine
10	Imipramine
11	Imipramine
12	Reboxetine

----- COUNTRY=France CENTER=17 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Imipramine
4	Reboxetine
5	Imipramine
6	Reboxetine
7	Reboxetine
8	Imipramine
9	Imipramine
10	Reboxetine
11	Reboxetine
12	Imipramine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
 REBOXETINE - PROTOCOL 20124/035
 MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
 AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=France CENTER=17 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Reboxetine
3	Imipramine
4	Imipramine
5	Imipramine
6	Reboxetine
7	Reboxetine
8	Imipramine
9	Imipramine
10	Imipramine
11	Imipramine
12	Reboxetine

----- COUNTRY=France CENTER=18 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Imipramine
2	Imipramine
3	Reboxetine
4	Reboxetine
5	Reboxetine
6	Imipramine
7	Reboxetine
8	Imipramine
9	Reboxetine
10	Imipramine
11	Imipramine
12	Reboxetine

----- COUNTRY=France CENTER=18 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetine
3	Imipramine
4	Reboxetine
5	Imipramine
6	Reboxetine
7	Imipramine
8	Reboxetine
9	Reboxetine
10	Imipramine
11	Imipramine
12	Reboxetine

----- COUNTRY=France CENTER=19 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Imipramine
4	Reboxetine
5	Reboxetine
6	Imipramine
7	Imipramine
8	Reboxetine
9	Imipramine
10	Imipramine
11	Reboxetine
12	Reboxetine

----- COUNTRY=France CENTER=19 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Reboxetine
4	Imipramine
5	Imipramine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
 REBOXETINE - PROTOCOL 20124/035
 MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
 AND TOLERABILITY OF REBOXETINE VS. IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=France CENTER=19 STRATA=Dysthymia -----
 (continued)

PATIENT	TREATMENT
6	Reboxetine
7	Imipramine
8	Reboxetine
9	Reboxetine
10	Reboxetine
11	Imipramine
12	Imipramine

----- COUNTRY=France CENTER=20 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetine
3	Reboxetine
4	Imipramine
5	Imipramine
6	Reboxetine
7	Reboxetine
8	Imipramine
9	Imipramine
10	Reboxetine
11	Reboxetine
12	Imipramine

----- COUNTRY=France CENTER=20 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Reboxetine
4	Imipramine
5	Imipramine
6	Reboxetine
7	Reboxetine
8	Imipramine
9	Reboxetine
10	Imipramine
11	Reboxetine
12	Imipramine

----- COUNTRY=France CENTER=21 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Reboxetine
2	Reboxetine
3	Imipramine
4	Imipramine
5	Imipramine
6	Reboxetine
7	Reboxetine
8	Imipramine
9	Reboxetine
10	Reboxetine
11	Imipramine
12	Imipramine

----- COUNTRY=France CENTER=21 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Reboxetine
4	Imipramine
5	Imipramine
6	Imipramine
7	Reboxetine
8	Reboxetine
9	Reboxetine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
REBOXETINE - PROTOCOL 20124/035
MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=France CENTER=21 STRATA=Dysthymia -----
(continued)

PATIENT	TREATMENT
10	Imipramine
11	Reboxetine
12	Imipramine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
 REBOXETINE - PROTOCOL 20124/035
 MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
 AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=Germany CENTER=22 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Reboxetine
2	Reboxetine
3	Imipramine
4	Imipramine
5	Imipramine
6	Imipramine
7	Reboxetine
8	Reboxetine
9	Imipramine
10	Reboxetine
11	Reboxetine
12	Imipramine

----- COUNTRY=Germany CENTER=22 STRATA=Dyethymia -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetine
3	Reboxetine
4	Imipramine
5	Reboxetine
6	Reboxetine
7	Imipramine
8	Imipramine
9	Reboxetine
10	Imipramine
11	Imipramine
12	Reboxetine

----- COUNTRY=Germany CENTER=23 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Reboxetine
2	Reboxetine
3	Imipramine
4	Imipramine
5	Imipramine
6	Imipramine
7	Reboxetine
8	Reboxetine
9	Imipramine
10	Imipramine
11	Reboxetine
12	Reboxetine

----- COUNTRY=Germany CENTER=23 STRATA=Dyethymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Imipramine
4	Reboxetine
5	Reboxetine
6	Imipramine
7	Reboxetine
8	Imipramine
9	Imipramine
10	Reboxetine
11	Reboxetine
12	Imipramine

----- COUNTRY=Germany CENTER=24 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Imipramine
2	Imipramine
3	Reboxetine
4	Reboxetine
5	Imipramine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
REBOXETINE - PROTOCOL 20124/035
MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=Germany CENTER=24 STRATA=Major Depres. Ep. -----
(continued)

PATIENT	TREATMENT
6	Imipramine
7	Reboxetine
8	Reboxetine
9	Reboxetine
10	Reboxetine
11	Imipramine
12	Imipramine

----- COUNTRY=Germany CENTER=24 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetine
3	Imipramine
4	Reboxetine
5	Reboxetine
6	Imipramine
7	Imipramine
8	Reboxetine
9	Imipramine
10	Reboxetine
11	Imipramine
12	Reboxetine

----- COUNTRY=Germany CENTER=25 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Reboxetine
4	Imipramine
5	Reboxetine
6	Imipramine
7	Reboxetine
8	Imipramine
9	Imipramine
10	Imipramine
11	Reboxetine
12	Reboxetine

----- COUNTRY=Germany CENTER=25 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Reboxetine
3	Imipramine
4	Imipramine
5	Imipramine
6	Reboxetine
7	Reboxetine
8	Imipramine
9	Imipramine
10	Reboxetine
11	Imipramine
12	Reboxetine

----- COUNTRY=Germany CENTER=26 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetine
3	Imipramine
4	Reboxetine
5	Reboxetine
6	Imipramine
7	Reboxetine
8	Imipramine
9	Reboxetine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
 REBOXETINE - PROTOCOL 20124/035
 MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
 AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=Germany CENTER=26 STRATA=Major Depres. Ep. -----
 (continued)

PATIENT	TREATMENT
10	Reboxetine
11	Imipramine
12	Imipramine

----- COUNTRY=Germany CENTER=26 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Reboxetine
3	Imipramine
4	Imipramine
5	Imipramine
6	Imipramine
7	Reboxetine
8	Reboxetine
9	Reboxetine
10	Imipramine
11	Reboxetine
12	Imipramine

----- COUNTRY=Germany CENTER=27 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Imipramine
2	Imipramine
3	Reboxetine
4	Reboxetine
5	Imipramine
6	Imipramine
7	Reboxetine
8	Reboxetine
9	Reboxetine
10	Imipramine
11	Imipramine
12	Reboxetine

----- COUNTRY=Germany CENTER=27 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Imipramine
2	Imipramine
3	Reboxetine
4	Reboxetine
5	Reboxetine
6	Imipramine
7	Reboxetine
8	Imipramine
9	Imipramine
10	Reboxetine
11	Reboxetine
12	Imipramine

----- COUNTRY=Germany CENTER=28 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Reboxetine
4	Imipramine
5	Reboxetine
6	Reboxetine
7	Imipramine
8	Imipramine
9	Reboxetine
10	Imipramine
11	Reboxetine
12	Imipramine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
 REBOXETINE - PROTOCOL 20124/035
 MULTICENTER, MULTINATIONAL, DOUBLE-BLIND STUDY OF THE ACTIVITY
 AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=Germany CENTER=28 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetine
3	Imipramine
4	Reboxetine
5	Imipramine
6	Reboxetine
7	Imipramine
8	Reboxetine
9	Reboxetine
10	Imipramine
11	Reboxetine
12	Imipramine

----- COUNTRY=Germany CENTER=29 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetine
3	Imipramine
4	Reboxetine
5	Imipramine
6	Reboxetine
7	Reboxetine
8	Imipramine
9	Imipramine
10	Reboxetine
11	Imipramine
12	Reboxetine
13	Imipramine
14	Reboxetine
15	Imipramine
16	Reboxetine
17	Reboxetine
18	Reboxetine
19	Imipramine
20	Imipramine
21	Imipramine
22	Imipramine
23	Reboxetine
24	Reboxetine
25	Imipramine
26	Imipramine
27	Reboxetine
28	Reboxetine
29	Reboxetine
30	Imipramine
31	Imipramine
32	Reboxetine
33	Imipramine
34	Imipramine
35	Reboxetine
36	Reboxetine
37	Imipramine
38	Reboxetine
39	Reboxetine
40	Imipramine

----- COUNTRY=Germany CENTER=29 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Reboxetine
3	Imipramine
4	Imipramine
5	Reboxetine
6	Imipramine
7	Imipramine
8	Reboxetine
9	Imipramine
10	Imipramine
11	Reboxetine
12	Reboxetine
13	Reboxetine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
REBOXETINE - PROTOCOL 20124/035
MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=Germany CENTER=29 STRATA=Dysthymia -----
(continued)

PATIENT	TREATMENT
14	Imipramine
15	Imipramine
16	Reboxetine
17	Imipramine
18	Imipramine
19	Reboxetine
20	Reboxetine
21	Reboxetine
22	Imipramine
23	Reboxetine
24	Imipramine
25	Imipramine
26	Reboxetine
27	Reboxetine
28	Imipramine
29	Reboxetine
30	Reboxetine
31	Imipramine
32	Imipramine
33	Imipramine
34	Reboxetine
35	Reboxetine
36	Imipramine
37	Imipramine
38	Reboxetine
39	Imipramine
40	Reboxetine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
 REBOXETINE - PROTOCOL 20124/035
 MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
 AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=U.K. CENTER=30 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetine
3	Imipramine
4	Reboxetine
5	Imipramine
6	Reboxetine
7	Reboxetine
8	Imipramine
9	Reboxetine
10	Imipramine
11	Imipramine
12	Reboxetine
13	Reboxetine
14	Imipramine

----- COUNTRY=U.K. CENTER=30 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetine
3	Imipramine
4	Reboxetine
5	Imipramine
6	Imipramine
7	Reboxetine
8	Reboxetine
9	Reboxetine
10	Imipramine
11	Reboxetine
12	Imipramine
13	Imipramine
14	Reboxetine

----- COUNTRY=U.K. CENTER=31 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetine
3	Imipramine
4	Reboxetine
5	Imipramine
6	Imipramine
7	Reboxetine
8	Reboxetine
9	Imipramine
10	Imipramine
11	Reboxetine
12	Reboxetine
13	Imipramine
14	Reboxetine

----- COUNTRY=U.K. CENTER=31 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Reboxetine
3	Imipramine
4	Imipramine
5	Imipramine
6	Imipramine
7	Reboxetine
8	Reboxetine
9	Reboxetine
10	Imipramine
11	Reboxetine
12	Imipramine
13	Reboxetine
14	Reboxetine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
 REBOXETINE - PROTOCOL 20124/035
 MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
 AND TOLLERABILITY OF REBOXETINE VS INIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=U.K. CENTER=32 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Imipramine
2	Imipramine
3	Reboxetine
4	Reboxetine
5	Reboxetine
6	Imipramine
7	Reboxetine
8	Imipramine
9	Reboxetine
10	Imipramine
11	Imipramine
12	Reboxetine
13	Reboxetine
14	Imipramine
15	Reboxetine
16	Imipramine
17	Reboxetine
18	Imipramine
19	Imipramine
20	Reboxetine
21	Reboxetine
22	Imipramine
23	Reboxetine
24	Imipramine

----- COUNTRY=U.K. CENTER=32 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Reboxetine
4	Imipramine
5	Reboxetine
6	Imipramine
7	Imipramine
8	Reboxetine
9	Imipramine
10	Imipramine
11	Reboxetine
12	Reboxetine
13	Imipramine
14	Reboxetine
15	Reboxetine
16	Imipramine
17	Reboxetine
18	Imipramine
19	Imipramine
20	Reboxetine
21	Reboxetine
22	Imipramine
23	Reboxetine
24	Imipramine

----- COUNTRY=U.K. CENTER=33 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Reboxetine
4	Imipramine
5	Reboxetine
6	Imipramine
7	Imipramine
8	Reboxetine
9	Imipramine
10	Reboxetine
11	Reboxetine
12	Imipramine
13	Imipramine
14	Imipramine
15	Reboxetine
16	Reboxetine
17	Imipramine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
 REBOXETINE - PROTOCOL 20124/035
 MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
 AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=U.K. CENTER=33 STRATA=Major Depres. Ep. -----
 (continued)

PATIENT	TREATMENT
18	Reboxetine
19	Imipramine
20	Reboxetine
21	Reboxetine
22	Reboxetine
23	Imipramine
24	Imipramine

----- COUNTRY=U.K. CENTER=33 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetine
3	Reboxetine
4	Imipramine
5	Imipramine
6	Imipramine
7	Reboxetine
8	Reboxetine
9	Imipramine
10	Reboxetine
11	Imipramine
12	Reboxetine
13	Reboxetine
14	Imipramine
15	Imipramine
16	Reboxetine
17	Imipramine
18	Imipramine
19	Reboxetine
20	Reboxetine
21	Reboxetine
22	Reboxetine
23	Imipramine
24	Imipramine

----- COUNTRY=U.K. CENTER=38 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Reboxetine
2	Reboxetine
3	Imipramine
4	Imipramine
5	Imipramine
6	Reboxetine
7	Reboxetine
8	Imipramine
9	Reboxetine
10	Imipramine
11	Reboxetine
12	Imipramine
13	Imipramine
14	Imipramine
15	Reboxetine
16	Reboxetine
17	Imipramine
18	Reboxetine
19	Reboxetine
20	Imipramine
21	Imipramine
22	Reboxetine
23	Imipramine
24	Reboxetine

----- COUNTRY=U.K. CENTER=38 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Imipramine
2	Imipramine
3	Reboxetine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
 REBOXETINE - PROTOCOL 20124/035
 MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
 AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=U.K. CENTER=38 STRATA=Dysthymia -----
 (continued)

PATIENT	TREATMENT
4	Reboxetine
5	Reboxetine
6	Imipramine
7	Imipramine
8	Reboxetine
9	Reboxetine
10	Imipramine
11	Imipramine
12	Reboxetine
13	Imipramine
14	Reboxetine
15	Imipramine
16	Reboxetine
17	Imipramine
18	Imipramine
19	Reboxetine
20	Reboxetine
21	Reboxetine
22	Imipramine
23	Reboxetine
24	Imipramine

----- COUNTRY=U.K. CENTER=39 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Imipramine
2	Imipramine
3	Reboxetine
4	Reboxetine
5	Imipramine
6	Imipramine
7	Reboxetine
8	Reboxetine
9	Reboxetine
10	Reboxetine
11	Imipramine
12	Imipramine
13	Imipramine
14	Reboxetine
15	Imipramine
16	Reboxetine
17	Imipramine
18	Reboxetine
19	Reboxetine
20	Imipramine
21	Reboxetine
22	Imipramine
23	Reboxetine
24	Imipramine

----- COUNTRY=U.K. CENTER=39 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Imipramine
4	Reboxetine
5	Reboxetine
6	Reboxetine
7	Imipramine
8	Imipramine
9	Imipramine
10	Reboxetine
11	Imipramine
12	Reboxetine
13	Reboxetine
14	Reboxetine
15	Imipramine
16	Imipramine
17	Imipramine
18	Imipramine
19	Reboxetine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
 REBOXETINE - PROTOCOL 20124/035
 MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
 AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=U.K. CENTER=39 STRATA=Dysthymia -----
 (continued)

PATIENT	TREATMENT
20	Reboxetine
21	Imipramine
22	Reboxetine
23	Reboxetine
24	Imipramine

----- COUNTRY=U.K. CENTER=40.1 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Reboxetine
2	Reboxetine
3	Imipramine
4	Imipramine
5	Imipramine
6	Imipramine
7	Reboxetine
8	Reboxetine
9	Reboxetine
10	Reboxetine
11	Imipramine
12	Imipramine
13	Imipramine
14	Reboxetine
15	Imipramine
16	Reboxetine
17	Imipramine
18	Reboxetine
19	Imipramine
20	Reboxetine
21	Reboxetine
22	Imipramine
23	Reboxetine
24	Imipramine

----- COUNTRY=U.K. CENTER=40.1 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Reboxetine
4	Imipramine
5	Imipramine
6	Imipramine
7	Reboxetine
8	Reboxetine
9	Imipramine
10	Imipramine
11	Reboxetine
12	Reboxetine
13	Reboxetine
14	Imipramine
15	Reboxetine
16	Imipramine
17	Imipramine
18	Reboxetine
19	Reboxetine
20	Imipramine
21	Reboxetine
22	Reboxetine
23	Imipramine
24	Imipramine

----- COUNTRY=U.K. CENTER=40.2 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetine
3	Reboxetine
4	Imipramine
5	Imipramine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
 REBOXETINE - PROTOCOL 20124/035
 MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
 AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=U.K. CENTER=40.2 STRATA=Major Depres. Ep. -----
 (continued)

PATIENT	TREATMENT
6	Reboxetine
7	Imipramine
8	Reboxetine
9	Imipramine
10	Imipramine
11	Reboxetine
12	Reboxetine
13	Reboxetine
14	Reboxetine
15	Imipramine
16	Imipramine
17	Reboxetine
18	Imipramine
19	Imipramine
20	Reboxetine
21	Reboxetine
22	Reboxetine
23	Imipramine
24	Imipramine

----- COUNTRY=U.K. CENTER=40.2 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetine
3	Reboxetine
4	Imipramine
5	Imipramine
6	Imipramine
7	Reboxetine
8	Reboxetine
9	Reboxetine
10	Imipramine
11	Imipramine
12	Reboxetine
13	Imipramine
14	Reboxetine
15	Imipramine
16	Reboxetine
17	Reboxetine
18	Imipramine
19	Reboxetine
20	Imipramine
21	Reboxetine
22	Imipramine
23	Imipramine
24	Reboxetine

----- COUNTRY=U.K. CENTER=41 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetine
3	Imipramine
4	Reboxetine
5	Reboxetine
6	Reboxetine
7	Imipramine
8	Imipramine
9	Imipramine
10	Imipramine
11	Reboxetine
12	Reboxetine
13	Reboxetine
14	Imipramine
15	Imipramine
16	Reboxetine
17	Reboxetine
18	Imipramine
19	Imipramine
20	Reboxetine
21	Imipramine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
REBOXETINE - PROTOCOL 20124/035
MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=U.K. CENTER=41 STRATA=Major Depres. Ep. -----
(continued)

PATIENT	TREATMENT
22	Reboxetine
23	Imipramine
24	Reboxetine

----- COUNTRY=U.K. CENTER=41 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Reboxetine
4	Imipramine
5	Reboxetine
6	Reboxetine
7	Imipramine
8	Imipramine
9	Reboxetine
10	Reboxetine
11	Imipramine
12	Imipramine
13	Imipramine
14	Reboxetine
15	Imipramine
16	Reboxetine
17	Imipramine
18	Reboxetine
19	Reboxetine
20	Imipramine
21	Imipramine
22	Reboxetine
23	Reboxetine
24	Imipramine

----- COUNTRY=U.K. CENTER=42 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetine
3	Imipramine
4	Reboxetine
5	Imipramine
6	Reboxetine
7	Imipramine
8	Reboxetine
9	Reboxetine
10	Imipramine
11	Imipramine
12	Reboxetine
13	Imipramine
14	Reboxetine
15	Imipramine
16	Reboxetine
17	Reboxetine
18	Imipramine
19	Imipramine
20	Reboxetine
21	Imipramine
22	Reboxetine
23	Imipramine
24	Reboxetine

----- COUNTRY=U.K. CENTER=42 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetine
3	Imipramine
4	Reboxetine
5	Reboxetine
6	Reboxetine
7	Imipramine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
 REBOXETINE - PROTOCOL 20.24/035
 MULTICENTER, MULTINATIONAL, DOUBLE-BLIND STUDY OF THE ACTIVITY
 AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=U.K. CENTER=42 STRATA=Dysthymia -----
 (continued)

PATIENT	TREATMENT
8	Imipramine
9	Imipramine
10	Reboxetine
11	Imipramine
12	Reboxetine
13	Reboxetine
14	Imipramine
15	Imipramine
16	Reboxetine
17	Imipramine
18	Reboxetine
19	Imipramine
20	Reboxetine
21	Imipramine
22	Reboxetine
23	Reboxetine
24	Imipramine

----- COUNTRY=U.K. CENTER=44 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Reboxetine
2	Reboxetine
3	Imipramine
4	Imipramine
5	Reboxetine
6	Reboxetine
7	Imipramine
8	Imipramine
9	Reboxetine
10	Imipramine
11	Imipramine
12	Reboxetine
13	Imipramine
14	Reboxetine
15	Reboxetine
16	Imipramine
17	Reboxetine
18	Reboxetine
19	Imipramine
20	Imipramine
21	Imipramine
22	Reboxetine
23	Imipramine
24	Reboxetine

----- COUNTRY=U.K. CENTER=44 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Reboxetine
4	Imipramine
5	Imipramine
6	Imipramine
7	Reboxetine
8	Reboxetine
9	Imipramine
10	Imipramine
11	Reboxetine
12	Reboxetine
13	Reboxetine
14	Imipramine
15	Imipramine
16	Reboxetine
17	Reboxetine
18	Imipramine
19	Reboxetine
20	Imipramine
21	Imipramine
22	Reboxetine
23	Reboxetine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
 REBOXETINE - PROTOCOL 20124/035
 MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
 AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=U.K. CENTER=44 STRATA=Dysthymia -----
 (continued)

PATIENT	TREATMENT
24	Imipramine

----- COUNTRY=U.K. CENTER=45 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Reboxetine
4	Imipramine
5	Imipramine
6	Imipramine
7	Reboxetine
8	Reboxetine
9	Reboxetine
10	Imipramine
11	Imipramine
12	Reboxetine
13	Reboxetine
14	Imipramine
15	Reboxetine
16	Imipramine
17	Imipramine
18	Reboxetine
19	Imipramine
20	Reboxetine
21	Reboxetine
22	Imipramine
23	Imipramine
24	Reboxetine

----- COUNTRY=U.K. CENTER=45 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Imipramine
2	Imipramine
3	Reboxetine
4	Reboxetine
5	Reboxetine
6	Imipramine
7	Imipramine
8	Reboxetine
9	Imipramine
10	Imipramine
11	Reboxetine
12	Reboxetine
13	Reboxetine
14	Reboxetine
15	Imipramine
16	Imipramine
17	Imipramine
18	Reboxetine
19	Imipramine
20	Reboxetine
21	Imipramine
22	Reboxetine
23	Imipramine
24	Reboxetine

----- COUNTRY=U.K. CENTER=46 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Imipramine
2	Imipramine
3	Reboxetine
4	Reboxetine
5	Reboxetine
6	Reboxetine
7	Imipramine
8	Imipramine
9	Reboxetine

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

.....
 10 Imipramine
 11 Reboxetine
 12 Imipramine
 13 Reboxetine
 14 Imipramine
 15 Reboxetine
 16 Imipramine
 17 Reboxetine
 18 Imipramine
 19 Reboxetine
 20 Imipramine
 21 Reboxetine
 22 Imipramine
 23 Reboxetine
 24 Reboxetine

----- COUNTRY=U.K. CENTER=46 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Reboxetine
2	Imipramine
3	Reboxetine
4	Imipramine
5	Reboxetine
6	Reboxetine
7	Imipramine
8	Imipramine
9	Imipramine
10	Imipramine
11	Reboxetine
12	Reboxetine
13	Reboxetine
14	Imipramine
15	Reboxetine
16	Reboxetine
17	Imipramine
18	Reboxetine
19	Imipramine
20	Imipramine
21	Reboxetine
22	Imipramine
23	Imipramine
24	Reboxetine

----- COUNTRY=U.K. CENTER=47 STRATA=Major Depres. Ep. -----

PATIENT	TREATMENT
1	Reboxetine
2	Reboxetine
3	Imipramine
4	Imipramine
5	Imipramine
6	Reboxetine
7	Imipramine
8	Reboxetine
9	Reboxetine
10	Reboxetine
11	Imipramine
12	Imipramine
13	Reboxetine
14	Reboxetine
15	Reboxetine
16	Imipramine
17	Imipramine
18	Imipramine
19	Reboxetine

9550089

PHARMACIA THERAPEUTICS, CNS BUSINESS UNIT
REBOXETINE - PROTOCOL 20124/035
MULTICENTER, MULTINATIONAL, DOUBLE BLIND STUDY OF THE ACTIVITY
AND TOLLERABILITY OF REBOXETINE VS IMIPRAMINE IN ELDERLY PATIENTS

RANDOMIZATION LIST

----- COUNTRY=U.K. CENTER=47 STRATA=Dysthymia -----

PATIENT	TREATMENT
1	Imipramine
2	Reboxetine
3	Imipramine
4	Reboxetine
5	Reboxetine
6	Imipramine
7	Reboxetine
8	Imipramine
9	Reboxetine
10	Imipramine
11	Imipramine
12	Reboxetine
13	Reboxetine
14	Imipramine
15	Reboxetine
16	Imipramine
17	Imipramine
18	Reboxetine
19	Imipramine
20	Reboxetine
21	Imipramine
22	Reboxetine
23	Imipramine
24	Reboxetine

9550089

Pharmacia

Document 9550089

12.1.8 LABORATORY REFERENCE VALUES AND CRITERIA USED TO JUDGE
LABORATORY ABNORMALITIES AS CLINICALLY RELEVANT

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS-RED 0550089

REBOXETINE - PROTOCOL 20124/035
APPENDIX No.: 12.1.8

LABORATORY REFERENCE VALUES

Laboratory test	Units	Range values			
		Female		Male	
		Min	Max	Min	Max
HB	g/dl	12.00	16.00	13.50	17.50
HT	%	36.00	46.00	41.00	53.00
RBC	10 ⁶ /mm ³	4.00	5.20	4.50	5.90
PLATELETS	10 ³ /mm ³	150.00	400.00	150.00	400.00
ESR 1st h	mm	0.00	10.00	0.00	10.00
ESR 2nd h	mm	0.00	20.00	0.00	20.00
WBC	10 ³ /mm ³	4.50	11.00	4.50	11.00
WBC: N	%	57.00	67.00	57.00	67.00
WBC: E	%	1.00	3.00	1.00	3.00
WBC: B	%	0.00	0.75	0.00	0.75
WBC: L	%	23.00	33.00	23.00	33.00
WBC: M	%	3.00	7.00	3.00	7.00
CREATININE	mg/dl	0.50	1.10	0.60	1.20
CREATININE CLEARANCE	ml/min	86.00	128.00	97.00	137.00
UREA	mg/dl	15.00	35.00	15.00	35.00
BUN	mg/dl	7.00	18.00	7.00	18.00
URIC ACID	mg/dl	2.60	6.00	3.50	7.20
TOT. PROTEINS	g/dl	6.40	8.30	6.40	8.30
ALBUMINE	g/dl	3.50	5.00	3.50	5.00
TOT BILIRUBIN	mg/dl	0.20	1.00	0.20	1.00
DIR BILIRUBIN	mg/dl	0.00	0.20	0.00	0.20
SGOT	U/l	10.00	30.00	10.00	30.00
SGPT	U/l	5.00	30.00	5.00	30.00
GAMMA GT	U/l	8.00	40.00	9.00	50.00
LDH	U/l	210.00	420.00	210.00	420.00
ALK. PHOSPH.	U/l	56.00	155.00	62.00	176.00
GLOBULINS ALPHA 1	g/dl	0.10	0.30	0.10	0.30
GLOBULINS ALPHA 2	g/dl	0.60	1.00	0.60	1.00
GLOBULINS BETA	g/dl	0.70	1.10	0.70	1.10
GLOBULINS GAMMA	g/dl	0.80	1.60	0.80	1.60
SEDIMENT.	mm/h	0.00	20.00	0.00	15.00
TOT. CHOLEST.	mg/dl	152.00	268.00	158.00	276.00
HDL	mg/dl	35.00	65.00	29.00	60.00
TRIGLYCERIDES	mg/dl	38.00	160.00	49.00	284.00
GLUCOSE	mg/dl	70.00	105.00	70.00	105.00
Na+	mEq/l	136.00	146.00	136.00	146.00
Cl-	mEq/l	98.00	106.00	98.00	106.00
K+	mEq/l	3.50	5.10	3.50	5.10
Ca++	mEq/l	4.50	5.50	4.50	5.50
PO4--	mEq/l	1.00	1.50	1.00	1.50
T4	ug/dl	5.00	12.00	5.00	12.00
TSH	mU/l	2.00	10.00	2.00	10.00

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124/035
APPENDIX No.: 12.1.8

CRITERIA USED TO JUDGE LABORATORY ABNORMALITIES AS CLINICALLY RELEVANT

Laboratory test	Percent variation above or below normal range (*)
HB	- 15
HT	- 15
RBC	- 15
PLATELETS	- 30
HRC	- 30
HRC: N	- 30
HRC: E	- 30
HRC: B	- 30
HRC: L	- 30
HRC: M	- 30
CREATININE	+ 50
UREA	+ 50
BUN	+ 30
URIC ACID	+ 30
TOT. PROTEINS	+ 30
ALBUMINE	+ 30
TOT BILIRUBIN	+ 100
DIR BILIRUBIN	+ 100
SGPT	+ 100
SGOT	+ 100
GAMMA GT	+ 100
LDH	+ 100
ALK. PHOSPH.	+ 100
GLOBULINS ALPHA 1	+ 30
GLOBULINS ALPHA 2	+ 30
GLOBULINS BETA	+ 30
GLOBULINS GAMMA	+ 30
TOT. CHOLEST.	+ 30
HDL	- 20
TRIGLYCERIDES	+ 30
GLUCOSE	+ 30
NA+	- 10
CL-	- 10
K+	- 15
Ca++	- 15
PO4--	- 15
ESR/h	- 15
	not defined

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550089

Pharmacia

Document 9550089

12.1.9 ADVERSE EVENTS GROUPED IN CLUSTERS

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Appendix No.: 12.1.9

ADVERSE EVENTS GROUPED IN CLUSTERS

Body System	Cluster	Adverse event	Treatment	No of AE	No of Pt with AE		
BODY AS A WHOLE-GENERAL DISORDERS	ASTHENIA / FATIGUE	ASTHENIA	Reboxetine	1	1		
		FATIGUE	Imipramine	5	5		
		FATIGUE	Reboxetine	2	2		
CARDIOVASCULAR DISORDERS, GENERAL	AEDEMA CARDIAC ISCHEMIA AND RELATED SYMPTOMS HYPOTENSION AND RELATED SYMPTOMS	OEDEMA PERIPHERAL	Reboxetine	1	1		
		CHEST PAIN PRECORDIAL	Imipramine	1	1		
		DIZZINESS	Imipramine	20	17		
		DIZZINESS	Reboxetine	12	11		
		HYPOTENSION	Imipramine	7	7		
		HYPOTENSION POSTURAL	Imipramine	5	3		
		HYPOTENSION POSTURAL	Reboxetine	2	2		
		SYNCOPE	Imipramine	2	2		
		CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO	HEADACHE / MIGRAINE	HEADACHE	Imipramine	22	9
				HEADACHE	Reboxetine	13	11
GASTRO-INTESTINAL SYSTEM DISORDERS	NAUSEA AND RELATED SYMPTOMS	VOMITING	Imipramine	1	1		
		VOMITING	Reboxetine	1	1		
		DYSPEPSIA	Reboxetine	3	3		
		NAUSEA	Imipramine	17	17		
		NAUSEA	Reboxetine	18	18		
RENATOLOGY DISORDERS	ANAEMIA	ANAEMIA	Imipramine	9	3		
LIVER AND BILIAR SYSTEM DISORDERS	INCREASED LIVER ENZYMES	SGPT INCREASED	Imipramine	1	1		
		GAMMA-GT INCREASED	Reboxetine	1	1		
PSYCHIATRIC DISORDERS	AGITATION / ANXIETY / NERVOUSNESS	AGITATION	Imipramine	4	4		
		AGITATION	Reboxetine	4	4		
		ANXIETY NERVOUSNESS	Reboxetine	2	2		
SKIN AND APPENDAGES DISORDERS	ERYTHEMA / RASH	RASH ERYTHEMATOUS	Reboxetine	1	1		
		URINARY SYSTEM DISORDERS	URINARY RETENTION	Imipramine	4	4	
URINARY RETENTION	Reboxetine		3	3			
MICTURITION DISORDER	Imipramine		6	6			
MICTURITION DISORDER	Reboxetine		5	5			
VISION DISORDERS	BLURRED VISION		Imipramine	6	6		
		VISION ABNORMAL	Reboxetine	6	6		

9550089

Pharmacia

Document 9550089

12.1.10 STATISTICAL ANALYSIS PROGRAMS LISTINGS

```

*
*          PHARMACIA CNS R&D          9550089          ;
*
*          APPENDIX No.: 12.1.10          ;
*
*-----*
*          REBOXETINE          -          PHARMACIA CNS R&D          *
*
*          PGM NAME: LAB003          *
*          CREATED: 07.12.93          *
*          AIM          : Stuart-Maxwell test          *
*
*          BY CORTESI - PANSID MI          *
*-----*

%macro labstat(var= );

*-----*
* creazione di tre archivi;          *
* 1. stat - valore standard + differenza rispetto al basale          *
*          (utilizzato per tavola statistica) e          *
*          shift table (test binominale + % up and down)          *
* 2. maxw - maxwell test (binomiale by piroetta)          *
*-----*

proc sort data = labst;
  by centre patient lab_par day;

data stat(keep = lab_par day lab_ind lab_dif &var
            cod_trt bas nr_paz nvis num_ord)

  shift(keep = lab_par day &var cod_trt num_ord
        lab_bas lab_now k up down same nvis)

  maxw (keep = lab_par day &var cod_trt
        indice k nvis num_ord);

set labst;
by centre patient lab_par day ;
retain bas lab_bas 0;

if first.patient then nr_paz = 1;
else nr_paz = 0;

if first.lab_par then do;
  bas = lab_ind;
  lab_bas = lab_uid;
  lab_dif = .;
end;

else do;
  k = 1;
  lab_now = lab_uid;
  lab_dif = lab_ind - bas;
  up = 0;
  down = 0;
  same = 0;
  if lab_dif > 0 then up = 1;
  else if lab_dif < 0 then down = 1;
  else same = 1;
  output shift;
  indice = (lab_bas-1) * 3 + (lab_now);
  output maxw;
end;
output stat;

*-----*
* tramite la proc univariate si calcolano i parametri statistici *
*-----*

  * proc univariate * ;

proc sort data = stat;
  by &var cod_trt lab_par day;

proc univariate data = stat noprint;
  by &var cod_trt lab_par day;
  var lab_ind lab_dif bas;
  id num_ord;
  output out =stat (drop=x2-x9 y1-y6)
    mean =lab_mean x2 bas_mean
    nmiss =lab_miss x9 y6
    median=lab_medi dif_medi bas_medi
    std =lab_std x3 bas_std
    min =lab_min x4 y1
    max =lab_max x5 y2
    n =lab_frq x6 y3
    probt =x7 t_prob y4

```

```

        probs =x8      s_prob      y5;
                                9550089
*-----*
* preparazione archivio contenente il numero di pz con valori uguali,*
* sopra, sotto rispetto al basale. *
*-----*

proc sort data = shift ;
  by &var cod_trt lab_par day lab_bas lab_now;

proc means data = shift noprint;
  by &var cod_trt lab_par day;
  var up down same;
  id num_ord;
  output out=shifts
         sum=up down same;

                                *-----*
                                * unione dei due archivi *
                                *-----*

data stat ;
merge stat (in=a) shifts(in=b);
  by &var cod_trt lab_par day;
  if a = 1 or b = 1;
  if b=1 then do;
    if up = down then p_value = 1;
    else p_value = 2. * (probbnml(.5,sum(up,down),min(up,down)));
  end;

                                *-----*
                                * il test di significatività : test del segno *
                                * (distribuzione non parametrica) *
                                *-----*

p_test = s_prob;

                                *-----*
                                * test di maxwell (by Nicoletta Pirotta) *
                                *-----*

proc sort data = maxw ;
  by &var cod_trt lab_par day indice;

proc means data = maxw noprint;
  by &var cod_trt lab_par day indice;
  var k;
  id num_ord;
  output out=maxw
         sum=k;

data maxw(keep = &var cod_trt lab_par day p_maxw num_ord);
  set maxw;
  by &var cod_trt lab_par day indice;
  retain a11 a12 a13 a21 a22 a23 a31 a32 a33;
  array _a_ (9) a11 a12 a13 a21 a22 a23 a31 a32 a33;

  if first.day then do i=1 to 9; _a_(i) = 0 ; end;

  _a_(indice)=k;
  if last.day then do;
    n12=(a12+a21)/2;
    n13=(a13+a31)/2;
    n23=(a23+a32)/2;

    d1=a12+a13-a21-a31;
    d2=a21+a23-a12-a32;
    d3=a31+a32-a13-a23;

    d1=d1*d1;
    d2=d2*d2;
    d3=d3*d3;

    numx2=n23*d1+n13*d2+n12*d3;
    denx2=(n12*(n13+n23)+n13*n23)*2;
    if denx2 > 0 then do;
      x2=numx2/denx2;
      p_maxw = 1 - probchi(x2,2);
    end;
  else do;
    if a32 > 0 or a23 > 0 then do;
      if a32 = a23 then p_maxw = 1;
      else do;
        denx2=a32+a23;
        numx2=min(a32,a23);
        p_maxw = 2. * probbnml(0.5,denx2,numx2);
      end;
    end;
  end; * if a32 > 0 ..... ;

```



```
else if a21 > 0 or a12 > 0 then do;
  if a21 = a12 then p_maxw = 1; 9550089
  else do;
    denx2=a21+a12;
    numx2=min(a21,a12);
    p_maxw = 2. * probbnml(0.5,denx2,numx2);
  end;
end; * if a21 > 0 ..... ;
else if a31 > 0 or a13 > 0 then do;
  if a31 = a13 then p_maxw = 1;
  else do;
    denx2=a31+a13;
    numx2=min(a31,a13);
    p_maxw = 2. * probbnml(0.5,denx2,numx2);
  end;
end; * if a31 > 0 ..... ;
else p_maxw = 1; * tutti gli elementi no su diag.;
end; * if denx2 <= 0 ..... ;
output;
end; * if last day ..... ;

proc means data = shift noprint;
  by &var cod_trt lab_par day lab_bas lab_now;
  var k ;
  id num_ord;
  output out=shift
         sum=k;

data maxw (keep = &var cod_trt lab_par day p_maxw maxw_p num_ord
               dw sm up k lab_bas);;
merge shift(in=a) maxw(in=b);
by &var cod_trt lab_par day ;
retain maxw_p;
if first.day then maxw_p = . ;
dw = . ; sm = . ; up = . ;
array now (3) dw sm up;
now(lab_now) = k;
output;
if last.day then do;
  * generazione di tutti i possibili incroci (con valori a zero);
  dw = . ; sm = . ; up = . ; k = . ;
  lab_bas = 1; output;
  lab_bas = 2; output;
  lab_bas = 3;
  maxw_p = p_maxw;
  output;
end;
run;

%mend labstat;
```

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

```
TITLE1 'PHARMACIA - CNS R&D';
TITLE3 'REBOXETINE - PROTOCOL 20124/35';          9550089
TITLE5 'APPENDIX NO. 12.1.10';
FOOTNOTE;
```

```
*****
*- PROGRAM .. : Y00.REBOX035.PGM(CONFHAM)      -*
*- GOAL ..... : CONFIDENCE INTERVAL OF THE    -*
*-              DIFFERENCE BETWEEN TWO MEANS  -*
*- AUTHOR ... : N.O.                          -*
*- REFERENCE  : GILL                          -*
*-                                                  -*
*****;
```

```
*****;
* MC=MEAN (CAMPION)                               ;
* MS=MEAN (STANDARD)                              ;
* NC=NUMBER OF OBSERVATION (CAMPION)              ;
* NS=NUMBER OF OBSERVATION (STANDARD)            ;
* STDC=STANDARD DEVIATION (CAMPION)              ;
* STDS=STANDARD DEVIATION (CAMPION)             ;
*****;
DATA PIPPO;INPUT
  TIT $ MC MS NC NS STDC STDS ;
CARDS;
m.d. 12.27 12.66 105 108 10.4 10.33
dys  11.06 14.45 67 60 9.38 8.48
total 11.80 13.30 172 168 10.01 9.72
;
RUN;
proc format ; value $tit 'm.d.='Major Depressive Episodes'
                  'dys ='Dysthymia'
                  'total'='Total';

DATA PIPPO;SET PIPPO;
dfs=ns-1;dfc=nc-1;df=dfc+dfs;
s2e=(stdc*stdc*dfc+stds*stds*dfs)/df;
tt=abs(tinv(0.025,df));
ERR2=(1/NC+1/NS);
ERR=SQRT(ERR2*S2E);
DIFF=MC-MS;
INF=DIFF-TT*ERR;
SUP=DIFF+TT*ERR;

LABEL DIFF='DIFFERENCE REBOXETINE-IMIPRAMINE'
      INF='LOWER LIMIT' SUP='UPPER LIMIT'
      MC='MEAN REBOXETINE' MS='MEAN IMIPRAMINE';
PROC PRINT LABEL NOOBS;
TITLE9 'DIFFERENCE BETWEEN TREATMENT AND CONFIDENCE INTERVAL 95%';
VAR TIT MC MS DIFF INF SUP s2e;
Format tit $tit.;
RUN;
```

```
*-----* ;
* |          PHARMACIA CNS R&D                      9550089
* |          REBOXETINE - PROTOCOL 20124/035        | ;
* |          APPENDIX 12.1.10                       | ;
* |          CONFIDENCE INTERVAL OF A DIFFERENCE BETWEEN PROPORTIONS| ;
*-----* ;
* REFERENCE ;
* PEACE K.E. BIOPHARMACEUTICAL STATISTICS FOR DRUG DEVELOPMENT,
* MARCEL DEKKER, INC.1988,Pg478
*
* MACROVAR IN INPUT:
* . &TOT      = DATA SET IN INPUT
* . &YC       = SUCCESSES IN THE CAMPION
* . &NC       = FAILURES IN THE CAMPION
* . &YS       = SUCCESSES IN THE STANDARD
* . &NS       = FAILURES IN THE STANDARD
* .....;

%MACRO MCINTPCD;
DATA T;SET &TOT;
NNC=&YC+&NC;
NNS=&YS+&NS;
PC=&YC/NNC;
PS=&YS/NNS;
SED=PS*(1-PS)/NNS+PC*(1-PC)/NNC;
DIF=PC-PS;
LIMINF=DIF-&Z*SQRT(SED);
LIMSUP=DIF+&Z*SQRT(SED);
RUN;
%MEND MCINTPCD ;
*-----* ;
```

9550089

Pharmacia

Document 9550089

12.1.11 SELECTION OF STATISTICAL ANALYSIS OUTPUTS

9550089

**PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035**

Appendix No.: 12.1.11

SELECTION OF STATISTICAL ANALYSIS OUTPUTS

Study end-point: Odds of experiencing at least one adverse event

The following analyses have been carried out on study end-point and on events and cluster of events of particular relevance in terms of frequency:

- Adjusted odds ratio (95% CI) by Mantel-Haenszel method using diagnosis as strata
- Breslow-Day test for homogeneity across strata

The following analyses have been carried out both for the total patient sample, and for each subgroup identified by the stratification factor, i.e. patients with Major Depressive Episode/Disorder and Dysthymia.

Efficacy analyses

HAMD decrease at last assessment

- Tables showing descriptive statistics (n, mean, standard deviation SD)
- Between treatment difference and 95% confidence interval

CGI at last assessment

- Difference between frequency of much and very much improved in the two treatment groups and 95% confidence interval

Analysis of Adverse Events

- Long-rank test on the time to the first occurrence of selected signs-symptoms for the comparisons between the two active treatments.

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
APPENDIX No.: 12.1.11

PATIENTS WHO COMPLAINED AT LEAST ONE ADVERSE EVENT

TABLE 1 OF TRT BY EVENTO
CONTROLLING FOR STRATA=N.D.D.

TRT	EVENTO		Total
	Yes	No	
Frequency Row Pct			
Reboxetine	72 66.06	37 33.94	109
Imipramine	80 73.39	29 26.61	109
Total	152	66	218

TABLE 2 OF TRT BY EVENTO
CONTROLLING FOR STRATA=Dysrhythmia

TRT	EVENTO		Total
	Yes	No	
Frequency Row Pct			
Reboxetine	48 71.64	19 28.36	67
Imipramine	42 67.74	20 32.26	62
Total	90	39	129

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOMEXINE - PROTOCOL 20124/035
APPENDIX No.: 12.1.11

PATIENTS WHO COMPLAINED AT LEAST ONE ADVERSE EVENT

SUMMARY STATISTICS FOR TET BY EVENTO
CONTROLLING FOR STRATA

Cochran-Mantel-Haenszel Statistics (Based on Table Scores)

Statistic	Alternative Hypothesis	DF	Value	Prob
1	Nonzero Correlation	1	0.409	0.522
2	Row Mean Scores Differ	1	0.409	0.522
3	General Association	1	0.409	0.522

Estimates of the Common Relative Risk (Row1/Row2)

Type of Study	Method	Value	95% Confidence Bounds
Case-Control (Odds Ratio)	Mantel-Haenszel	0.861	0.545 1.361
	Logit	0.861	0.544 1.364
Cohort (Col1 Risk)	Mantel-Haenszel	0.956	0.831 1.098
	Logit	0.956	0.831 1.098
Cohort (Col2 Risk)	Mantel-Haenszel	1.110	0.806 1.530
	Logit	1.109	0.804 1.530

The confidence bounds for the M-H estimates are test-based.

Breslow-Day Test for Homogeneity of the Odds Ratios

Chi-Square = 1.215 DF = 1 Prob = 0.270

Total Sample Size = 347

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/035
 APPENDIX No.: 12.1.11
 PATIENTS WHO COMPLAINED AT LEAST ONCE ACITATION / ANXIETY / NERVOUSNESS

TABLE 1 OF TRT BY EVENTO
 CONTROLLING FOR STRATA=H.D.D.

TRT	EVENTO		Total
	Yes	No	
Frequency Row Pct			
Reboxetine	4 3.67	105 96.33	109
Imipramine	3 2.75	106 97.25	109
Total	7	211	218

TABLE 2 OF TRT BY EVENTO
 CONTROLLING FOR STRATA=Dyschymia

TRT	EVENTO		Total
	Yes	No	
Frequency Row Pct			
Reboxetine	3 4.48	64 95.52	67
Imipramine	1 1.61	61 98.39	62
Total	4	125	129

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REMOXETINE - PROTOCOL 20124/035
 APPENDIX No.: 12.4.11

PATIENTS WHO COMPLAINED AT LEAST ONCE AGITATION / ANXIETY / NERVOUSNESS

SUMMARY STATISTICS FOR TRI BY EVENTO
 CONTROLLING FOR STRATA

Cochran-Mantel-Haenszel Statistics (Based on Table Scores)

Statistic	Alternative Hypothesis	DF	Value	Prob
1	Nonzero Correlation	1	0.756	0.385
2	Row Mean Scores Differ	1	0.756	0.385
3	General Association	1	0.756	0.385

Estimates of the Common Relative Risk (Row1/Row2)

Type of Study	Method	Value	95% Confidence Bounds
Case-Control (Odds Ratio)	Mantel-Haenszel	1.733	0.502 5.984
	Logit	1.695	0.477 6.019
Cohort (Col1 Risk)	Mantel-Haenszel	1.704	0.512 5.670
	Logit	1.665	0.486 5.697
Cohort (Col2 Risk)	Mantel-Haenszel	0.983	0.946 1.021
	Logit	0.983	0.946 1.021

The confidence bounds for the M-H estimates are test-based.

Breslow-Day Test for Homogeneity of the Odds Ratios

Chi-Square = 0.294 DF = 1 Prob = 0.588

Total Sample Size = 347

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
APPENDIX No.: 12.1.1.f1

PATIENTS WHO COMPLAINED AT LEAST ONCE ASTHENIA / FATIGUE

TABLE 1 OF TRT BY EVENTO
CONTROLLING FOR STRATA=H.D.D.

TRT	EVENTO		Total
	Yes	No	
Frequency Row Pct			
Reboxetine	2 1.83	107 98.17	109
Imipramine	2 1.83	107 98.17	109
Total	4	214	218

TABLE 2 OF TRT BY EVENTO
CONTROLLING FOR STRATA=Dysrhythmia

TRT	EVENTO		Total
	Yes	No	
Frequency Row Pct			
Reboxetine	1 1.49	66 98.51	67
Imipramine	3 4.84	59 95.16	62
Total	4	125	129

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
APPENDIX No.: 12.1.11

PATIENTS WHO COMPLAINED AT LEAST ONCE ASTHENIA / FATIGUE

SUMMARY STATISTICS FOR TRI BY EVENTO
CONTROLLING FOR STRATA

Cochran-Mantel-Haenszel Statistics (Based on Table Scores)

Statistic	Alternative Hypothesis	DF	Value	Prob
1	Nonzero Correlation	1	0.592	0.442
2	Row Mean Scores Differ	1	0.592	0.442
3	General Association	1	0.592	0.442

Estimates of the Common Relative Risk (Row1/Row2)

Type of Study	Method	Value	95% Confidence Bounds
Case-Control (Odds Ratio)	Mantel-Haenszel	0.572	0.138 2.375
	Logit	0.596	0.133 2.664
Cohort (Col1 Risk)	Mantel-Haenszel	0.579	0.144 2.331
	Logit	0.603	0.139 2.614
Cohort (Col2 Risk)	Mantel-Haenszel	1.013	0.981 1.046
	Logit	1.009	0.977 1.041

The confidence bounds for the M-H estimates are test-based.

Breslow-Day Test for Homogeneity of the Odds Ratios

Chi-Square = 0.636 DF = 1 Prob = 0.425

Total Sample Size = 347

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RSD
 REBOXETINE - PROTOCOL 20124/025
 APPENDIX No.: 12.1.11
 PATIENTS WHO COMPLAINED AT LEAST ONCE BLURRED VISION
 TABLE 1 OF TRT BY EVENTO
 CONTROLLING FOR STRATA=M.D.D.

TRT	EVENTO		Total
	Yes	No	
Frequency			
Row Pct			
Reboxetine	4	105	109
	3.67	96.33	
Imipramine	3	106	109
	2.75	97.25	
Total	7	211	218

TABLE 2 OF TRT BY EVENTO
 CONTROLLING FOR STRATA=Dysrhythmia

TRT	EVENTO		Total
	Yes	No	
Frequency			
Row Pct			
Reboxetine	2	65	67
	2.99	97.01	
Imipramine	3	59	62
	4.84	95.16	
Total	5	124	129

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBORNINE - PROTOCOL 20124/085
APPENDIX No.: 12.1.11

PATIENTS WHO COMPLAINED AT LEAST ONCE BLURRED VISION

SUMMARY STATISTICS FOR TRI BY EVENTO
CONTROLLING FOR STRATA

Cochran-Mantel-Haenszel Statistics (Based on Table Scores)

Statistic	Alternative Hypothesis	DF	Value	Prob
1	Nonzero Correlation	1	0.003	0.955
2	Row Mean Scores Differ	1	0.003	0.955
3	General Association	1	0.003	0.955

Estimates of the Common Relative Risk (Row1/Row2)
95%

Type of Study	Method	Value	Confidence Bounds
Case-Control (Odds Ratio)	Mantel-Haenszel	0.967	0.306 3.055
	Logit	0.970	0.302 3.118
Cohort (Col1 Risk)	Mantel-Haenszel	0.968	0.319 2.942
	Logit	0.970	0.314 2.997
Cohort (Col2 Risk)	Mantel-Haenszel	1.001	0.962 1.042
	Logit	1.000	0.961 1.040

The confidence bounds for the M-H estimates are test-based.

Breslow-Day Test for Homogeneity of the Odds Ratios

Chi-Square = 0.441 DF = 1 Prob = 0.507

Total Sample Size = 347

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 APPENDIX No.: 12.1.11
 PATIENTS WHO COMPLAINED AT LEAST ONCE CONFUSION
 CONTROLLING FOR STRATA=H.D.D.

TABLE 1 OF TRT BY EVENTO
 CONTROLLING FOR STRATA=H.D.D.

TRT	EVENTO		Total
	Yes	No	
Frequency Row Pct			
Reboxetine	3 2.75	106 97.25	109
Imipramine	3 2.75	106 97.25	109
Total	6	212	218

TABLE 2 OF TRT BY EVENTO
 CONTROLLING FOR STRATA=Dystymia

TRT	EVENTO		Total
	Yes	No	
Frequency Row Pct			
Reboxetine	3 4.48	64 95.52	67
Imipramine	1 1.61	61 98.39	62
Total	4	125	129

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PIARMACIA CNS RED

REBOWETINE - PROTOCOL 20124/035
APPENDIX No.: 12.1.11

PATIENTS WHO COMPLAINED AT LEAST ONCE CONFUSION

SUMMARY STATISTICS FOR TEST BY EVENTO
CONTROLLING FOR STRATA

Cochran-Mantel-Haenszel Statistics (Based on Table Scores)

Statistic	Alternative Hypothesis	DF	Value	Prob
1	Nonzero Correlation	1	0.349	0.555
2	Row Mean Scores Differ	1	0.349	0.555
3	General Association	1	0.349	0.555

Estimates of the Common Relative Risk (Row1/Row2)
95%

Type of Study	Method	Value	Confidence Bounds
Case-Control (Odds Ratio)	Mantel-Haenszel	1.472	0.408 5.310
	Logit	1.421	0.378 5.340
Cohort (Col1 Risk)	Mantel-Haenszel	1.457	0.418 5.079
	Logit	1.404	0.387 5.098
Cohort (Col2 Risk)	Mantel-Haenszel	0.989	0.954 1.026
	Logit	0.990	0.955 1.026

The confidence bounds for the M-H estimates are test-based.

Breslow-Day Test for Homogeneity of the Odds Ratios

Chi-Square = 0.555 DF = 1 Prob = 0.456

Total Sample Size = 347

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
APPENDIX No.: 12.1.11

PATIENTS WHO COMPLAINED AT LEAST ONCE CONSTIPATION

TABLE 1 OF TRT BY EVENTO
CONTROLLING FOR STRATA=N.D.D.

TRT	EVENTO		Total
	Yes	No	
Frequency Row Pct			
Reboxetine	22 20.18	87 79.82	109
Imipramine	20 18.35	89 81.65	109
Total	42	176	218

TABLE 2 OF TRT BY EVENTO
CONTROLLING FOR STRATA=Dysdymia

TRT	EVENTO		Total
	Yes	No	
Frequency Row Pct			
Reboxetine	9 13.43	58 86.57	67
Imipramine	11 17.74	51 82.26	62
Total	20	109	129

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/085
APPENDIX No.: 12.1.11

PATIENTS WHO COMPLAINED AT LEAST ONCE CONSTIPATION

SUMMARY STATISTICS FOR TET BY EVENTO
CONTROLLING FOR STRATA

Cochran-Mantel-Haenszel Statistics (Based on Table Scores)

Statistic	Alternative Hypothesis	DF	Value	Prob
1	Nonzero Correlation	1	0.012	0.914
2	Row Mean Scores Differ	1	0.012	0.914
3	General Association	1	0.012	0.914

Estimates of the Common Relative Risk (Row1/Row2)

Type of Study	Method	Value	95% Confidence Bounds
Case-Control (Odds Ratio)	Mantel-Haenszel	0.970	0.560 1.681
	Logit	0.970	0.559 1.684
Cohort (Col1 Risk)	Mantel-Haenszel	0.975	0.621 1.532
	Logit	0.979	0.623 1.539
Cohort (Col2 Risk)	Mantel-Haenszel	1.005	0.911 1.109
	Logit	1.009	0.915 1.113

The confidence bounds for the M-H estimates are test-based.

Breslow-Day Test for Homogeneity of the Odds Ratios

Chi-Square = 0.562 DF = 1 Prob = 0.453

Total Sample Size = 347

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 APPENDIX No.: 12.1.11
 PATIENTS WHO COMPLAINED AT LEAST ONCE HEADACHE / MIGRAINE

TABLE 1 OF TRT BY EVENTO
 CONTROLLING FOR STRATA-H.D.D.

TRT	EVENTO		Total
Frequency Row Pct	Yes	No	Total
Reboxetine	8 7.34	101 92.66	109
Imipramine	7 6.42	102 93.58	109
Total	15	203	218

TABLE 2 OF TRT BY EVENTO
 CONTROLLING FOR STRATA-Dysrhythmia

TRT	EVENTO		Total
Frequency Row Pct	Yes	No	Total
Reboxetine	3 4.48	64 95.52	67
Imipramine	2 3.23	60 96.77	62
Total	5	124	129

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS R&D

REMEXIME - PROTOCOL 20124/035
APPENDIX No.: 12.1.11

PATIENTS WHO COMPLAINED AT LEAST ONCE HEADACHE / MIGRAINE

SUMMARY STATISTICS FOR TRI BY EVENTO
CONTROLLING FOR STRATA

Cochran-Mantel-Haenszel Statistics (Based on Table Scores)

Statistic	Alternative Hypothesis	DF	Value	Prob
1	Nonzero Correlation	1	0.173	0.678
2	Row Mean Scores Differ	1	0.173	0.678
3	General Association	1	0.173	0.678

Estimates of the Common Relative Risk (Row1/Row2)

Type of Study	Method	Value	95% Confidence Bounds
Case-Control (Odds Ratio)	Mantel-Haenszel	1.213	0.488 3.017
	Logit	1.212	0.488 3.014
Cohort (Col1 Risk)	Mantel-Haenszel	1.199	0.510 2.820
	Logit	1.197	0.509 2.814
Cohort (Col2 Risk)	Mantel-Haenszel	0.989	0.939 1.042
	Logit	0.989	0.940 1.039

The confidence bounds for the M-H estimates are test-based.

Breslow-Day Test for Homogeneity of the Odds Ratios

Chi-Square = 0.034 DF = 1 Prob = 0.854

Total Sample Size = 347

0000

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
APPENDIX No.: 12.1.11

PATIENTS WHO COMPLAINED AT LEAST ONCE HYPOTENSION AND RELATED SYMPTOMS

TABLE 1 OF TRT BY EVENTO
CONTROLLING FOR STRATA=M.D.D.

TRT	EVENTO		Total
	Yes	No	
Frequency Row Pct			
Reboxetine	11 10.09	98 89.91	109
Imipramine	22 20.18	87 79.82	109
Total	33	185	218

TABLE 2 OF TRT BY EVENTO
CONTROLLING FOR STRATA=Dysthymia

TRT	EVENTO		Total
	Yes	No	
Frequency Row Pct			
Reboxetine	2 2.99	65 97.01	67
Imipramine	5 8.06	57 91.94	62
Total	7	122	129

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS RED

RENOVEMINE - PROTOCOL 20124/035
APPENDIX No.: 12.1.11

PATIENTS WHO COMPLAINED AT LEAST ONCE HYPOTENSION AND RELATED SYMPTOMS

SUMMARY STATISTICS FOR TRI BY EVENTO
CONTROLLING FOR STRATA

Cochran-Mantel-Haenszel Statistics (Based on Table Scores)

Statistic	Alternative Hypothesis	DF	Value	Prob
1	Nonzero Correlation	1	5.853	0.016
2	Row Mean Scores Differ	1	5.853	0.016
3	General Association	1	5.853	0.016

Estimates of the Common Relative Risk (Row1/Row2)
95%

Type of Study	Method	Value	Confidence Bounds
Case-Control (Odds Ratio)	Mantel-Haenszel	0.425	0.212 0.850
	Logit	0.426	0.210 0.863
Cohort (Col1 Risk)	Mantel-Haenszel	0.475	0.260 0.868
	Logit	0.478	0.257 0.889
Cohort (Col2 Risk)	Mantel-Haenszel	1.098	1.018 1.184
	Logit	1.080	1.009 1.156

The confidence bounds for the M-H estimates are test-based.

Breslow-Day Test for Homogeneity of the Odds Ratios

Chi-Square = 0.062 DF = 1 Prob = 0.803

Total Sample Size = 347

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 APPENDIX No.: 12.1.1.11
 PATIENTS WHO COMPLAINED AT LEAST ONCE INSOMNIA

TABLE 1 OF TRT BY EVENTO
 CONTROLLING FOR STRATA=H.D.D.

TRT	EVENTO		Total
	Yes	No	
Reboxetine	7 6.42	102 93.58	109
Imipramine	5 4.59	104 95.41	109
Total	12	206	218

TABLE 2 OF TRT BY EVENTO
 CONTROLLING FOR STRATA=Dysthymia

TRT	EVENTO		Total
	Yes	No	
Reboxetine	4 5.97	63 94.03	67
Imipramine	0 0.00	62 100.00	62
Total	4	125	129

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXYLINE - PROTOCOL 20124/035
APPENDIX No.: 12.1.11

PATIENTS WHO COMPLAINED AT LEAST ONCE INSOMNIA

SUMMARY STATISTICS FOR TRI BY EVENTO
CONTROLLING FOR STRATA

Cochran-Mantel-Haenszel Statistics (Based on Table Scores)

Statistic	Alternative Hypothesis	DF	Value	Prob
1	Nonzero Correlation	1	2.234	0.135
2	Row Mean Scores Differ	1	2.234	0.135
3	General Association	1	2.234	0.135

Estimates of the Common Relative Risk (Row1/Row2)

Type of Study	Method	Value	Confidence Bounds
Case-Control (Odds Ratio)	Mantel-Haenszel	2.249	0.777 6.511
	Logit *	1.838	0.615 5.494
Cohort (Col1 Risk)	Mantel-Haenszel	2.169	0.786 5.987
	Logit *	1.762	0.622 4.996
Cohort (Col2 Risk)	Mantel-Haenszel	0.965	0.922 1.011
	Logit	0.959	0.918 1.002

The confidence bounds for the M-H estimates are test-based.

* denotes that the logit estimators use a correction of 0.5 in every cell of those tables that contain a zero.

Breslow-Day Test for Homogeneity of the Odds Ratios

Chi-Square = 2.309 DF = 1 Prob = 0.129

Total Sample Size = 347

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
APPENDIX No.: 12.1.11

PATIENTS WHO COMPLAINED AT LEAST ONCE MOUTH DRY

TABLE 1 OF TRT BY EVENTO
CONTROLLING FOR STRATA=M.D.D.

TRT	EVENTO		Total
	Yes	No	
Frequency			
Row Pct			
Reboxetine	18	91	109
	16.51	83.49	
Imipramine	25	84	109
	22.94	77.06	
Total	43	175	218

TABLE 2 OF TRT BY EVENTO
CONTROLLING FOR STRATA=Dysrhythmia

TRT	EVENTO		Total
	Yes	No	
Frequency			
Row Pct			
Reboxetine	21	46	67
	31.34	68.66	
Imipramine	14	48	62
	22.58	77.42	
Total	35	94	129

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBORNETIME - PROTOCOL 20124/035
APPENDIX No.: 12.1.1f1

PATIENTS WHO COMPLAINED AT LEAST ONCE MOUTH DRY

SUMMARY STATISTICS FOR TBT BY EVENTO
CONTROLLING FOR STRATA

Cochran-Mantel-Haenszel Statistics (Based on Table Scores)

Statistic	Alternative Hypothesis	DF	Value	Prob
1	Nonzero Correlation	1	0.030	0.861
2	Row Mean Scores Differ	1	0.030	0.861
3	General Association	1	0.030	0.861

Estimates of the Common Relative Risk (Row1/Row2)

Type of Study	Method	Value	95% Confidence Bounds
Case-Control (Odds Ratio)	Mantel-Haenszel	0.956	0.577 1.583
	Logit	0.955	0.572 1.594
Cohort (Co1 Risk)	Mantel-Haenszel	0.966	0.653 1.429
	Logit	0.979	0.658 1.456
Cohort (Co2 Risk)	Mantel-Haenszel	1.010	0.902 1.131
	Logit	1.024	0.915 1.145

The confidence bounds for the M-H estimates are test-based.

Breslow-Day Test for Homogeneity of the Odds Ratios

Chi-Square = 2.639 DF = 1 Prob = 0.104

Total Sample Size = 347

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
APPENDIX No.: 12.1.11

PATIENTS WHO COMPLAINED AT LEAST ONCE NAUSEA AND RELATED SYMPTOMS

TABLE 1 OF TRT BY EVENTO
CONTROLLING FOR STRATA=D.D.

TRT	EVENTO		Total
	Yes	No	
Frequency Row Pct			
Reboxetine	11 10.09	98 89.91	109
Imipramine	8 7.34	101 92.66	109
Total	19	199	218

TABLE 2 OF TRT BY EVENTO
CONTROLLING FOR STRATA=Dysrhythmia

TRT	EVENTO		Total
	Yes	No	
Frequency Row Pct			
Reboxetine	9 13.43	58 86.57	67
Imipramine	9 14.52	53 85.48	62
Total	18	111	129

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
APPENDIX No.: 12.1.11

PATIENTS WHO COMPLAINED AT LEAST ONCE NAUSEA AND RELATED SYMPTOMS

SUMMARY STATISTICS FOR TET BY EVENTU
CONTROLLING FOR STRATA

Cochran-Mantel-Haenszel Statistics (Based on Table Scores)

Statistic	Alternative Hypothesis	DF	Value	Prob
1	Nonzero Correlation	1	0.161	0.689
2	Row Mean Scores Differ	1	0.161	0.689
3	General Association	1	0.161	0.689

Estimates of the Common Relative Risk (Row1/Row2)
95%

Type of Study	Method	Value	Confidence Bounds
Case-Control (Odds Ratio)	Mantel-Haenszel	1.151	0.579 2.285
	Logit	1.149	0.577 2.287
Cohort (Col1 Risk)	Mantel-Haenszel	1.139	0.616 2.084
	Logit	1.124	0.610 2.071
Cohort (Col2 Risk)	Mantel-Haenszel	0.985	0.916 1.060
	Logit	0.981	0.914 1.053

The confidence bounds for the M-R estimates are test-based.

Breslow-Day Test for Homogeneity of the Odds Ratios

Chi-Square = 0.391 DF = 1 Prob = 0.532

Total Sample Size = 347

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
APPENDIX No.: 12.1.11

PATIENTS WHO COMPLAINED AT LEAST ONCE PARAESTHESIA

TABLE 1 OF TRT BY EVENTO
CONTROLLING FOR STRATA=H.D.D.

TRT	EVENTO		Total
	Yes	No	
Frequency Row Pct			
Reboxetine	1 0.92	108 99.08	109
Imipramine	3 2.75	106 97.25	109
Total	4	214	218

TABLE 2 OF TRT BY EVENTO
CONTROLLING FOR STRATA=Dysrhythmia

TRT	EVENTO		Total
	Yes	No	
Frequency Row Pct			
Reboxetine	3 4.48	64 95.52	67
Imipramine	1 1.61	61 98.39	62
Total	4	125	129

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS RED

REGIMINE - PROTOCOL 20124/035
APPENDIX No.: 12.1.11

PATIENTS WHO COMPLAINED AT LEAST ONCE PARAESTHESIA

SUMMARY STATISTICS FOR TBT BY EVENTO
CONTROLLING FOR STRATA

Cochran-Mantel-Haenszel Statistics (Based on Table Scores)

Statistic	Alternative Hypothesis	DF	Value	Prob
1	Nonzero Correlation	1	0.003	0.956
2	Row Mean Scores Differ	1	0.003	0.956
3	General Association	1	0.003	0.956

Estimates of the Common Relative Risk (Row1/Row2)
95% Confidence Bounds

Type of Study	Method	Value	95% Confidence Bounds
Case-Control (Odds Ratio)	Mantel-Haenszel	0.961	0.234 3.945
	Logit	0.962	0.191 4.839
Cohort (Col1 Risk)	Mantel-Haenszel	0.962	0.240 3.845
	Logit	0.967	0.198 4.720
Cohort (Col2 Risk)	Mantel-Haenszel	1.001	0.969 1.034
	Logit	1.006	0.975 1.038

The confidence bounds for the M-H estimates are test-based.

Breslow-Day Test for Homogeneity of the Odds Ratios

Chi-Square = 1.895 DF = 1 Prob = 0.169

Total Sample Size = 347

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9550089

PHARMACIA CNS R2D
 REBOXETINE - PROTOCOL 20124/085
 APPENDIX No.: 12.1.11
 PATIENTS WHO COMPLAINED AT LEAST ONCE SOMNOLENCE
 CONTROLLING FOR STRATA=H.D.D.

TABLE 1 OF TRT BY EVENTO

TRT	EVENTO	Yes	No	Total
Frequency Row Pct				
Reboxetine		4 3.67	105 96.33	109
Imipramine		4 3.67	105 96.33	109
Total		8	210	218

TABLE 2 OF TRT BY EVENTO

CONTROLLING FOR STRATA=Dysythymia

TRT	EVENTO	Yes	No	Total
Frequency Row Pct				
Reboxetine		0 0.00	67 100.00	67
Imipramine		3 4.84	59 95.16	62
Total		3	126	129

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REDOXETINE - PROTOCOL 20124/035
APPENDIX No.: 12.1.11

PATIENTS WHO COMPLAINED AT LEAST ONCE SOMNOLENCE

SUMMARY STATISTICS FOR TRI BY EVENTO
CONTROLLING FOR STRATA

Cochran-Mantel-Haenszel Statistics (Based on Table Scores)

Statistic	Alternative Hypothesis	DF	Value	Prob
1	Nominal Correlation	1	0.908	0.341
2	Row Mean Scores Differ	1	0.908	0.341
3	General Association	1	0.908	0.341

Estimates of the Common Relative Risk (Row1/Row2)

Type of Study	Method	Value	95% Confidence Bounds
Case-Control (Odds Ratio)	Mantel-Haenszel	0.553	0.163 1.870
	Logit *	0.684	0.191 2.453
Cohort (Col1 Risk)	Mantel-Haenszel	0.562	0.172 1.838
	Logit *	0.701	0.204 2.408
Cohort (Col2 Risk)	Mantel-Haenszel	1.019	0.981 1.058
	Logit	1.023	0.985 1.063

The confidence bounds for the M-H estimates are test-based.

* denotes that the logit estimators use a correction of 0.5 in every cell of those tables that contain a zero.

Breslow-Day Test for Homogeneity of the Odds Ratios

Chi-Square = 2.552 DF = 1 Prob = 0.110

Total Sample Size = 347

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 REBOXETINE – PROTOCOL 20124/055
 APPENDIX No.: 12.1.11

PATIENTS WHO COMPLAINED AT LEAST ONCE SHEATING INCREASED

TABLE 1 OF TRT BY EVENTO
 CONTROLLING FOR STRATA=B.D.D.

TRT	EVENTO		Total
	Yes	No	
Reboxetine	11 10.09	98 89.91	109
Imipramine	8 7.34	101 92.66	109
Total	19	199	218

TABLE 2 OF TRT BY EVENTO
 CONTROLLING FOR STRATA=Dysphymia

TRT	EVENTO		Total
	Yes	No	
Reboxetine	5 7.46	62 92.54	67
Imipramine	7 11.29	55 88.71	62
Total	12	117	129

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOVETINE - PROTOCOL 20124/035
APPENDIX No.: 12.1.11

PATIENTS WHO COMPLAINED AT LEAST ONCE SWEATING INCREASED

SUMMARY STATISTICS FOR TRI BY EVENTU
CONTROLLING FOR STRATA

Cochran-Mantel-Haenszel Statistics (Based on Table Scores)

Statistic	Alternative Hypothesis	DF	Value	Prob
1	Nonzero Correlation	1	0.010	0.920
2	Row Mean Scores Differ	1	0.010	0.920
3	General Association	1	0.010	0.920

Estimates of the Common Relative Risk (Row1/Row2)
95%

Type of Study	Method	Value	Confidence Bounds
Case-Control (Odds Ratio)	Mantel-Haenszel	1.038	0.497 2.168
	Logit	1.040	0.493 2.194
Cohort (Col1 Risk)	Mantel-Haenszel	1.035	0.529 2.027
	Logit	1.035	0.523 2.046
Cohort (Col2 Risk)	Mantel-Haenszel	0.997	0.933 1.065
	Logit	0.995	0.931 1.063

The confidence bounds for the M-H estimates are test-based.

Breslow-Day Test for Homogeneity of the Odds Ratios

Chi-Square = 1.069 DF = 1 Prob = 0.301

Total Sample Size = 347

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RBD
 REBOXETINE - PROTOCOL 20124/035
 APPENDIX No.: 12.1.11
 PATIENTS WHO COMPLAINED AT LEAST ONCE TRENDR

TABLE 1 OF TRT BY EVENTO
 CONTROLLING FOR STRATA=M.D.D.

TRT	EVENTO		Total
	Yes	No	
Frequency Row Pct			
Reboxetine	3 2.75	106 97.25	109
Imipramine	5 4.59	104 95.41	109
Total	8	210	218

TABLE 2 OF TRT BY EVENTO
 CONTROLLING FOR STRATA=Dysthymia

TRT	EVENTO		Total
	Yes	No	
Frequency Row Pct			
Reboxetine	4 5.97	63 94.03	67
Imipramine	1 1.61	61 98.39	62
Total	5	124	129

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS RED

REBOXETINE - PROTOCOL 20124/035
APPENDIX No.: 12.1.11

PATIENTS WHO COMPLAINED AT LEAST ONCE TRENOR

SUMMARY STATISTICS FOR TRI BY EVENTO
CONTROLLING FOR STRATA

Cochran-Mantel-Haenszel Statistics (Based on Table Scores)

Statistic	Alternative Hypothesis	DF	Value	Prob
1	Nonzero Correlation	1	0.052	0.820
2	Row Mean Scores Differ	1	0.052	0.820
3	General Association	1	0.052	0.820

Estimates of the Common Relative Risk (Row1/Row2)
95%

Type of Study	Method	Value	Confidence Bounds
Case-Control (Odds Ratio)	Mantel-Haenszel	1.138	0.373 3.471
	Logit	1.038	0.307 3.508
Cohort (Col1 Risk)	Mantel-Haenszel	1.134	0.385 3.339
	Logit	1.030	0.317 3.350
Cohort (Col2 Risk)	Mantel-Haenszel	0.995	0.955 1.037
	Logit	0.995	0.955 1.037

The confidence bounds for the M-H estimates are test-based.

Breslow-Day Test for Homogeneity of the Odds Ratios

Chi-Square = 2.123 DF = 1 Prob = 0.145

Total Sample Size = 347

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RBD
 REBOXETINE - PROTOCOL 20124/035
 APPENDIX No.: 12.1.11

PATIENTS WHO COMPLAINED AT LEAST ONCE URINARY HESITANCY / RETENTION

TABLE 1 OF TRT BY EVENTO
 CONTROLLING FOR STRATA=H.D.D.

TRT	EVENTO		Total
	Yes	No	
Frequency Row Pct			
Reboxetine	6 5.50	103 94.50	109
Imipramine	5 4.59	104 95.41	109
Total	11	207	218

TABLE 2 OF TRT BY EVENTO
 CONTROLLING FOR STRATA=Dyschymia

TRT	EVENTO		Total
	Yes	No	
Frequency Row Pct			
Reboxetine	1 1.49	66 98.51	67
Imipramine	5 8.06	57 91.94	62
Total	6	123	129

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS R&D

REBEXETINE - PROTOCOL 20124/035
APPENDIX No.: 12.1.11

PATIENTS WHO COMPLAINED AT LEAST ONCE URINARY HESITANCY / RETENTION

SUMMARY STATISTICS FOR TRI BY EVENTO
CONTROLLING FOR STRATA

Cochran-Mantel-Haenszel Statistics (Based on Table Scores)

Statistic	Alternative Hypothesis	DF	Value	Prob
1	Nonzero Correlation	1	0.643	0.423
2	Row Mean Scores Differ	1	0.643	0.423
3	General Association	1	0.643	0.423

Estimates of the Common Relative Risk (Row1/Row2)
95%

Type of Study	Method	Value	Confidence Bounds
Case-Control (Odds Ratio)	Mantel-Haenszel	0.672	0.254 1.777
	Logit	0.761	0.263 2.204
Cohort (Col1 Risk)	Mantel-Haenszel	0.683	0.269 1.735
	Logit	0.781	0.283 2.157
Cohort (Col2 Risk)	Mantel-Haenszel	1.020	0.972 1.070
	Logit	1.020	0.972 1.071

The confidence bounds for the M-H estimates are test-based.

Breslow-Day Test for Homogeneity of the Odds Ratios

Chi-Square = 2.642 DF = 1 Prob = 0.104

Total Sample Size = 347

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/035
 APPENDIX No.: 12.1.11

PATIENTS WHO COMPLAINED AT LEAST ONCE URINARY TRACT INFECTION

TABLE 1 OF TRT BY EVENTO
 CONTROLLING FOR STRATA=H.D.D.

TRT	EVENTO		Total
	Yes	No	
Frequency Row Pct			
Reboxetine	5 4.59	104 95.41	109
Imipramine	7 6.42	102 93.58	109
Total	12	206	218

TABLE 2 OF TRT BY EVENTO
 CONTROLLING FOR STRATA=Dysthymia

TRT	EVENTO		Total
	Yes	No	
Frequency Row Pct			
Reboxetine	1 1.49	66 98.51	67
Imipramine	3 4.84	59 95.16	62
Total	4	125	129

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS R&D

RESUME - PROTOCOL 20124/035
APPENDIX No.: 12.1.11

PATIENTS WHO COMPLAINED AT LEAST ONCE URINARY TRACT INFECTION

SUMMARY STATISTICS FOR TRI BY EVENT
CONTROLLING FOR STRATA

Cochran-Mantel-Haenszel Statistics (Based on Table Scores)

Statistic	Alternative Hypothesis	DF	Value	Prob
1	Nonzero Correlation	1	1.129	0.288
2	Row Mean Scores Differ	1	1.129	0.288
3	General Association	1	1.129	0.288

Estimates of the Common Relative Risk (Row1/Row2)
95%

Type of Study	Method	Value	Confidence Bounds
Case-Control (Odds Ratio)	Mantel-Haenszel	0.574	0.206 1.599
	Logit	0.586	0.205 1.671
Cohort (Col1 Risk)	Mantel-Haenszel	0.589	0.222 1.563
	Logit	0.604	0.222 1.640
Cohort (Col2 Risk)	Mantel-Haenszel	1.025	0.979 1.074
	Logit	1.027	0.982 1.075

The confidence bounds for the M-H estimates are test-based.

Breslow-Day Test for Homogeneity of the Odds Ratios

Chi-Square = 0.435 DF = 1 Prob = 0.509

Total Sample Size = 347

08
14
08

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
APPENDIX 12.1.11

SUMMARY STATISTICS ON TOTAL SCORE HAMILTON DECREASE AT LAST ASSESSMENT WITH RESPECT TO BASELINE VALUE

		TREATMENT	
		Imipramine	Reboxetine
STRATA			
Major Depressive Disorder	N	108	105
	MEAN	12.7	12.3
	SD	10.3	10.4
Dysthymia	N	60	67
	MEAN	14.5	11.1
	SD	8.5	9.4
Total	N	168	172
	MEAN	13.3	11.8
	SD	9.7	10.0

9550089

PHARMACIA - CNS R&D

REBOXETINE - PROTOCOL 20124/35

APPENDIX NO. 12.1.11

DIFFERENCE BETWEEN TREATMENT AND CONFIDENCE INTERVAL 95%					
POPULATION	MEAN REBOXETINE	MEAN IMIPRAMINE	DIFFERENCE REBOXETINE-IMIPRAMINE	LOWER LIMIT	UPPER LIMIT
Major Depressive Episodes	12.27	12.66	-0.39	-3.19014	2.41014
Dysthymia	11.06	14.45	-3.39	-6.54416	-0.23584
Total	11.80	13.30	-1.50	-3.60546	0.60546

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 APPENDIX 12.1.11

CSI AT LAST ASSESSMENT : DIFFERENCE BETWEEN FREQUENCY OF MUCH AND VERY MUCH IMPROVED IN THE TWO TREATMENT GROUPS
 CONSIDERING ALL POPULATION

SUCCESS RATE REBOXETINE	SUCCESS RATE IMIPRAMINE	NUMBER PTS REBOXETINE	NUMBER PTS IMIPRAMINE	STANDARD ERROR DIFFERENCE	SECESS RATE DIFFERENCE	INFERIOR LIMIT	SUPERIOR LIMIT
0.56897	0.59412	174	170	.0028279	-0.025152	-0.12938	0.079077

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R80
 REBOXETINE - PROTOCOL 20124/035
 APPENDIX 12.1.11

CGI AT LAST ASSESSMENT : DIFFERENCE BETWEEN FREQUENCY OF MUCH AND VERY MUCH IMPROVED IN THE TWO TREATMENT GROUPS FOR EACH STRATA

STRATA	SUCCESS RATE REBOXETINE	SUCCESS RATE IMIPRAMINE	NUMBER PYS REBOXETINE	NUMBER PYS IMIPRAMINE	STANDARD ERROR DIFFERENCE	SECCSS RATE DIFFERENCE	INFERIOR LIMIT	SUPERIOR LIMIT
MAJOR DEPRESSIVE EPISODES	0.58879	0.52294	107	109	.0045515	0.06585	-0.06638	0.19808
DYSTHYMIA	0.53731	0.72131	67	61	.0070060	-0.18400	-0.34805	-0.01994

00 01 02

9550089

PHARMACIA CNS R&D
 RESOMETINE - PROTOCOL 20124/035
 APPENDIX No.: 12.1.1.f1
 CUMULATIVE RISK OF DEVELOPING HYPOTENSION AND RELATED SYMPTOMS

The LIFEVEST Procedure
 Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	xCensored
IMI	171	27	144	84.2105
RBX	176	13	163	92.6136
Total	347	40	307	88.4726

Testing Homogeneity of Survival Curves over Strata
 Time Variable: DAY

Rank Statistics

COD_TRT	Log-Rank	Milcoxon
IMI	7.7315	2383.0
RBX	-7.7315	-2383.0

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	9.93542	-9.93542
RBX	-9.93542	9.93542

Covariance Matrix for the Milcoxon Statistics

COD_TRT	IMI	RBX
IMI	937918	-937918
RBX	-937918	937918

Test of Equality over Strata

Test	Chi-Square	DF	Pr >
Log-Rank	6.0165	1	0.0142
Milcoxon	6.0546	1	0.0139
-2Log(LR)	6.4288	1	0.0112

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R8D

REBOMETINE - PROTOCOL 20124/035
APPENDIX No.: 12.1.11

CUMULATIVE RISK OF DEVELOPING HYPOTENSION AND RELATED SYMPTOMS

DIAGNOSIS: Major Depressive Disorder

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	ZCensored
IMI	109	22	87	79.8165
RBX	109	11	98	89.9083
Total	218	33	185	84.8624

Testing Homogeneity of Survival Curves over Strata
Time Variable: DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	6.1099	1199.0
RBX	-6.1099	-1199.0

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	8.17440	-8.17440
RBX	-8.17440	8.17440

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	290229	-290229
RBX	-290229	290229

Test of Equality over Strata

Test	Chi-Square	DF	Pr >
Log-Rank	4.5668	1	0.0326
Wilcoxon	4.9533	1	0.0260
-2Log(LR)	5.2399	1	0.0221

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

RESOMETINE - PROTOCOL 20124/035
APPENDIX No.: 12.1.11

CUMULATIVE RISK OF DEVELOPING HYPOTENSION AND RELATED SYMPTOMS

DIAGNOSIS: Dysthymia

The LIFTEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	ZCensored
IMI	62	5	57	91.9355
RBX	67	2	65	97.0149
Total	129	7	122	94.5736

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	1.6054	178.00
RBX	-1.6054	-178.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	1.74720	-1.74720
RBX	-1.74720	1.74720

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	24576.0	-24576.0
RBX	-24576.0	24576.0

Test of Equality over Strata

Test	Chi-Square	DF	Pr >
Log-Rank	1.4752	1	0.2245
Wilcoxon	1.2892	1	0.2562
-2Log(LR)	1.4924	1	0.2218

00
01
02

9550089

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 RESCRIPTINE - PROTOCOL 2012A/035
 APPENDIX No.: 12.1.11
 CUMULATIVE RISK OF DEVELOPING AGITATION / ANXIETY / NERVOUSNESS

The LIFETEST Procedure
 Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	174	4	167	97.6608
RBX	176	7	169	96.0227
Total	347	11	336	96.8300

Testing Homogeneity of Survival Curves over Strata
 Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	-1.3645	-416.00
RBX	1.3645	416.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	2.74799	-2.74799
RBX	-2.74799	2.74799

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	242539	-242539
RBX	-242539	242539

Test of Equality over Strata

Test	Chi-Square	DF	Pr >
Log-Rank	0.6775	1	0.4104
Wilcoxon	0.7135	1	0.3983
-2Log(LR)	0.7043	1	0.4014

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9550089

PHARMACIA CNS RD
 REMOXETINE - PROTOCOL 20124/035
 APPENDIX No.: 12.1.11

CUMULATIVE RISK OF DEVELOPING ASTHENIA / FATIGUE

The LIFETEST Procedure
 Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	XCensored
IMI	171	5	166	97.0760
RBX	176	3	173	98.2955
Total	347	8	339	97.6945

Testing Homogeneity of Survival Curves over Strata
 Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	1.0907	304.00
RBX	-1.0907	-304.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	1.99412	-1.99412
RBX	-1.99412	1.99412

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	190810	-190810
RBX	-190810	190810

Test of Equality over Strata

Test	Chi-Square	DF	Pr >
Log-Rank	0.5966	1	0.4399
Wilcoxon	0.4843	1	0.4865
-2Log(LR)	0.6065	1	0.4361

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9550089

PHARMACIA CNS RBX
 REDUXINE - PROTOCOL 20124/055
 APPENDIX No.: 12.1.11

CUMULATIVE RISK OF DEVELOPING BLURRED VISION

The LIFETEST Procedure
 Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	XCensored
IMI	171	6	165	96.4912
RBX	176	6	170	96.5909
Total	347	12	335	96.5418

Testing Homogeneity of Survival Curves over Strata
 Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	0.20720	162.00
RBX	-0.20720	-162.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	2.99392	-2.99392
RBX	-2.99392	2.99392

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	260475	-260475
RBX	-260475	260475

Test of Equality over Strata

Test	Chi-Square	DF	Pr >
Log-Rank	0.0143	1	0.9047
Wilcoxon	0.1088	1	0.7509
-2Log(LR)	0.0094	1	0.9229

CR

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBUNEXTINE - PROTOCOL 20124/055
APPENDIX No.: 12.1.11

CUMULATIVE RISK OF DEVELOPING CONFUSION

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	X Censored
IMI	171	4	167	97.6608
RBX	176	6	170	96.5909
Total	347	10	337	97.1182

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	-0.89611	-278.00
RBX	0.89611	278.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	2.49550	-2.49550
RBX	-2.49550	2.49550

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	247205	-247205
RBX	-247205	247205

Test of Equality over Strata

Test	Chi-Square	DF	Pr >
Log-Rank	0.3218	1	0.5705
Wilcoxon	0.3126	1	0.5761
-2Log(LR)	0.3158	1	0.5741

PHARMACIA CNS R2D
 RESOMETINE - PROTOCOL 20124/035
 APPENDIX No.: 12.1.11

CUMULATIVE RISK OF DEVELOPING CONSTIPATION

The LIFEYEST Procedure
 Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	171	31	140	81.8713
RBX	176	31	145	82.3864
Total	347	62	285	82.1526

Testing Homogeneity of Survival Curves over Strata
 Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	0.91371	391.00
RBX	-0.91371	-391.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	15.2665	-15.2665
RBX	-15.2665	15.2665

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	1345635	-1345635
RBX	-1345635	1345635

Test of Equality over Strata

Test	Chi-Square	DF	Pr >
Log-Rank	0.0547	1	0.8151
Wilcoxon	0.1156	1	0.7361
-2Log(LR)	0.0777	1	0.7804

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS R&D

REBORELINE - PROTOCOL 20124/035
APPENDIX No.: 12.1.1f

CUMULATIVE RISK OF DEVELOPING HEADACHE / MIGRAINE

The LIFEESTY Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	XCensored
IMI	171	9	162	94.7368
RBX	176	11	165	93.7500
Total	347	20	327	94.2363

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Milcoxon
IMI	-0.74626	-258.00
RBX	0.74626	258.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	4.98618	-4.98618
RBX	-4.98618	4.98618

Covariance Matrix for the Milcoxon Statistics

COD_TRT	IMI	RBX
IMI	472614	-472614
RBX	-472614	472614

Test of Equality over Strata

Test	Chi-Square	DF	Pr >
Log-Rank	0.1117	1	0.7382
Milcoxon	0.1408	1	0.7074
-2Log(LR)	0.1231	1	0.7257

PHARMACIA CNS RED
 REMOXETINE - PROTOCOL 20124/055
 APPENDIX No.: 12.1.11
 CUMULATIVE RISK OF DEVELOPING INSOMNIA

The LIFETEST Procedure
 Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	XCensored
IMI	171	5	166	97.0760
RBX	176	11	165	93.7500
Total	347	16	331	95.3890

Testing Homogeneity of Survival Curves over Strata
 Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	-2.8881	-895.00
RBX	2.8881	895.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	3.98460	-3.98460
RBX	-3.98460	3.98460

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	404094	-404094
RBX	-404094	404094

Test of Equality over Strata

Test	Chi-Square	DF	Pr >
Log-Rank	2.0934	1	0.1479
Wilcoxon	1.9623	1	0.1592
-2Log(LR)	2.2353	1	0.1349

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RBD

REBOXETINE - PROTOCOL 20124/035
APPENDIX No.: 12.1.11

CUMULATIVE RISK OF DEVELOPING MOUTH DRY

The LIFEEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	%Censored
IMI	174	39	132	77.1930
RBX	176	39	137	77.8409
Total	347	78	269	77.5216

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Milcoxon
IMI	1.2176	568.00
RBX	-1.2176	-568.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	18.8424	-18.8424
RBX	-18.8424	18.8424

Covariance Matrix for the Milcoxon Statistics

COD_TRT	IMI	RBX
IMI	1718970	-1718970
RBX	-1718970	1718970

Test of Equality over Strata

Test	Chi-Square	DF	Pr >
Log-Rank	0.0787	1	0.7791
Milcoxon	0.1877	1	0.6649
-2Log(LR)	0.1652	1	0.6844

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 REBOXETINE – PROTOCOL 20124/035
 APPENDIX No.: 12.1.11
 CUMULATIVE RISK OF DEVELOPING NAUSEA AND RELATED SYMPTOMS

The LIFEYEST Procedure
 Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	X Censored
IMI	171	17	154	90.0585
RBX	176	20	156	88.6364
Total	347	37	310	89.3372

Testing Homogeneity of Survival Curves over Strata
 Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Milcoxon
IMI	-1.1296	-344.00
RBX	1.1296	344.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	9.05682	-9.05682
RBX	-9.05682	9.05682

Covariance Matrix for the Milcoxon Statistics

COD_TRT	IMI	RBX
IMI	910532	-910532
RBX	-910532	910532

Test of Equality over Strata

Test	Chi-Square	DF	Pr >
Log-Rank	0.1409	1	0.7074
Milcoxon	0.1083	1	0.7421
-2Log(LR)	0.1722	1	0.6782

9550089

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 APPENDIX No.: 12.1.11

CUMULATIVE RISK OF DEVELOPING PARANESTHESIA

The LIFETEST Procedure
 Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	Zensored
IMI	171	4	167	97.6608
RBX	176	4	172	97.7273
Total	347	8	339	97.6945

Testing Homogeneity of Survival Curves over Strata
 Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	0.08302	-7.0000
RBX	-0.08302	7.0000

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	1.99010	-1.99010
RBX	-1.99010	1.99010

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	217907	-217907
RBX	-217907	217907

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	0.0035	1	0.9531
Wilcoxon	0.0002	1	0.9880
-2Log(LR)	0.0018	1	0.9659

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RBX

REBOXETINE - PROTOCOL 20124/035
APPENDIX No.: 12.1.11

CUMULATIVE RISK OF DEVELOPING SOMNOLENCE

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	XCensored
IMI	171	7	164	95.9064
RBX	176	4	172	97.7273
Total	347	11	336	96.8300

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	1.6565	572.00
RBX	-1.6565	-572.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	2.74357	-2.74357
RBX	-2.74357	2.74357

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	261224	-261224
RBX	-261224	261224

Test of Equality over Strata

Test	Chi-Square	DF	Pr >
Log-Rank	1.0002	1	0.3173
Wilcoxon	1.2525	1	0.2631
-2Log(LR)	1.0229	1	0.3118

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 RESOMETINE - PROTOCOL 20124/035
 APPENDIX No.: 12.1.11

CUMULATIVE RISK OF DEVELOPING SWEATING INCREASED

The LIFETEST Procedure
 Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	XCensored
IMI	174	15	156	91.2281
RBX	176	16	160	90.9091
Total	347	31	316	91.0663

Testing Homogeneity of Survival Curves over Strata
 Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	-0.20820	-185.00
RBX	0.20820	185.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	7.72256	-7.72256
RBX	-7.72256	7.72256

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	706065	-706065
RBX	-706065	706065

Test of Equality over Strata

Test	Chi-Square	DF	Pr >
Log-Rank	0.0056	1	0.9403
Wilcoxon	0.0485	1	0.8257
-2Log(LR)	0.0043	1	0.9476

9550089

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
APPENDIX No.: 12.1.11

CUMULATIVE RISK OF DEVELOPING TREMOR

The LIFETEST Procedure
Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	XCensored
IMI	171	6	165	96.4912
RBX	176	7	169	96.0227
Total	347	13	334	96.2536

Testing Homogeneity of Survival Curves over Strata
Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	-0.34221	-56.000
RBX	0.34221	56.000

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	3.24605	-3.24605
RBX	-3.24605	3.24605

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	300126	-300126
RBX	-300126	300126

Test of Equality over Strata

Test	Chi-Square	DF	Pr >
Log-Rank	0.0361	1	0.8494
Wilcoxon	0.0104	1	0.9186
-2Log(LR)	0.0422	1	0.8371

PHARMACIA CNS RBD
 REBOXETINE - PROTOCOL 20124/035
 APPENDIX No.: 12.1.11
 CUMULATIVE RISK OF DEVELOPING URINARY HESITANCY / RETENTION

The LIFETIME Procedure
 Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	XCensored
IMI	171	10	161	94.4520
RBX	176	7	169	96.0227
Total	347	17	330	95.1009

Testing Homogeneity of Survival Curves over Strata
 Time Variable DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	1.6776	500.00
RBX	-1.6776	-500.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	4.23700	-4.23700
RBX	-4.23700	4.23700

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	400304	-400304
RBX	-400304	400304

Test of Equality over Strata

Test	Chi-Square	DF	Pr >
Log-Rank	0.6642	1	0.4151
Wilcoxon	0.6245	1	0.4294
-2Log(LR)	0.6997	1	0.4029

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 RENOXYTINE - PROTOCOL 20124/035
 APPENDIX No.: 12.1.11
 CUMULATIVE RISK OF DEVELOPING URINARY TRACT INFECTION

The LIFETEST Procedure
 Summary of the Number of Censored and Uncensored Values

COD_TRT	Total	Failed	Censored	XCensored
IMI	171	10	161	94.1520
RBX	176	6	170	96.5909
Total	347	16	331	95.3890

Testing Homogeneity of Survival Curves over Strata
 Time Variable: DAY

Rank Statistics

COD_TRT	Log-Rank	Wilcoxon
IMI	2.2439	714.00
RBX	-2.2439	-714.00

Covariance Matrix for the Log-Rank Statistics

COD_TRT	IMI	RBX
IMI	3.98495	-3.98495
RBX	-3.98495	3.98495

Covariance Matrix for the Wilcoxon Statistics

COD_TRT	IMI	RBX
IMI	320816	-320816
RBX	-320816	320816

Test of Equality over Strata

Test	Chi-Square	DF	Pr >
Log-Rank	1.2635	1	0.2610
Wilcoxon	1.5891	1	0.2075
-2Log(LR)	1.2642	1	0.2609


9550089

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

CUMULATIVE RISK OF DEVELOPING AGITATION / ANXIETY / NERVOUSNESS


APPENDIX No.: 12.1.11



128

9550089

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
CUMULATIVE RISK OF DEVELOPING ASTHENIA / FATIGUE
APPENDIX No.: 12.1.11



872


9550089

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

CUMULATIVE RISK OF DEVELOPING BLURRED VISION

APPENDIX No.: 12.1.11



Log-Rank Test IMI vs RBX: (1 df) = 0.0143 P = 0.9047

873


9550089

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

CUMULATIVE RISK OF DEVELOPING CONFUSION

APPENDIX No.: 12.1.11



874

9550089

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
CUMULATIVE RISK OF DEVELOPING CONSTIPATION
APPENDIX No.: 12.1.11



875


9550089

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

CUMULATIVE RISK OF DEVELOPING HEADACHE / MIGRAINE

APPENDIX No.: 12.1.11




Log-Rank Test IMI vs RBX: (1 df) = 0.1117 P = 0.7382

876

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
CUMULATIVE RISK OF DEVELOPING INSOMNIA
APPENDIX No.: 12.1.11

9550089




Log-Rank Test IMI vs RBX: (1 df) = 2.0934 P = 0.1479

877

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
CUMULATIVE RISK OF DEVELOPING MOUTH DRY
APPENDIX No.: 12.1.11

9550089



Log-Rank Test IMI vs RBX: (1 df) = 0.0787 P = 0.7791

--- Imipramine
— Reboxetine

878


9550089

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

CUMULATIVE RISK OF DEVELOPING NAUSEA AND RELATED SYMPTOMS


APPENDIX No.: 12.1.11



879

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
CUMULATIVE RISK OF DEVELOPING PARESTHESIA
APPENDIX No.: 12.1.11


9550089



088

9550089

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
CUMULATIVE RISK OF DEVELOPING SOMNOLENCE
APPENDIX No.: 12.1.11



881

9550089

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/095
CUMULATIVE RISK OF DEVELOPING SWEATING INCREASED
APPENDIX No.: 12.1.11




Log-Rank Test IMI vs RBX: (1 df) = 0.0056 P = 0.9403

22
88
88

9550089

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
CUMULATIVE RISK OF DEVELOPING TREMOR
APPENDIX No.: 12.1.11




9550089

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

CUMULATIVE RISK OF DEVELOPING URINARY HESITANCY / RETENTION

APPENDIX No.: 12.1.11



Log-Rank Test IMI vs RBX: (1 df) = 0.6642 P = 0.4151

488


9550089

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

CUMULATIVE RISK OF DEVELOPING URINARY TRACT INFECTION

APPENDIX No.: 12.1.11



Log-Rank Test IMI vs RBX: (1 df) = 1.2635 P = 0.2610

12
00
00

9550089

Pharmacia

Document 9550089

12.1.12 ECG CODES

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS-BSD
REBOXETINE - PROTOCOL 20124035

APPENDIX No.: 12.1.12

ECG CODES

0 Normal

1 Rhythm disorders

- 10 Sinus bradycardia (<60)
- 20 Sinus tachycardia (>100)
- 30 Sick Sinus Syndrome
- 40
 - Atrial ectopic beats:
 - 41 - Occasional
 - 42 - Frequent (>6/mm)
 - 43 - Couplets
 - 44 - Supraventricular Tachycardia
- 50
 - Ventricular ectopic beats:
 - 51 - Occasional
 - 52 - Frequent (>6/mm)
 - 53 - Polymorphic
 - 54 - Couplets
 - 55 - Ventricular Tachycardia
- 60
 - Atrial fibrillation/flutter
- 105
 - Vagotonia
- 108
 - Atrial-ventricular dissociation

2 Conduction disorders

- 70
 - A-V Block
 - 71 - 1st degree
 - 72 - 2nd degree - Mobitz 1
 - 73 - Complete - Mobitz 2
- 85
 - Right bundle branch block
- 86
 - Left bundle branch block
- 87
 - Left anterior hemiblock
- 88
 - Left posterior hemiblock
- 89
 - Bifascicular Block (specify)
- 90
 - Trifascicular Block (specify)
- 91
 - Conduction disorders
- 103
 - Left axial deviation
- 106
 - Right incomplete bundle branch block

3 Ischemic signs

- 102
 - Repolarization disturbances
- 107
 - Non specific ST-T changes
- 82
 - Myocardial ischemia
- 84
 - Acute Myocardial infarction

4 Other

- 80
 - Left ventricular hypertrophy
- 81
 - Right ventricular hypertrophy
- 83
 - Previous Myocardial infarction
- 93
 - Other (specify) _____
- 104
 - Right axial deviation

887

9550089

Pharmacia

Document 9550089

12.2 Patient Information

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9550089

Pharmacia

Document 9550089

12.2.1 SERIOUS ADVERSE EVENTS - CASE HISTORIES

Narratives of serious adverse events reported on reboxetine treatment and case summaries of serious adverse events reported on reference treatment.

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9550089

Pharmacia

Document 9550089

Narrative of Event No. BE 0047 Protocol No. 20124/ 035 Patient No. 1

Center: Gent (Belgium)

Investigator: Van Moffaert

Adverse event: meningioma (operated) (date of the event: 12 November 1992)

Patient's history: the patient was a 83 year old female and was suffering from a Major Depressive Episode for 3 months when she entered the Study 20124/035 on 23 October 1992. She had had the onset of depressive disorder at the age of 83 years.

The patient had undergone an hysterectomy. She had been suffering from paresis in both legs since 25 April 1992 and hypertension. She was on treatment with bisoprolol fumarate and temazepam.

Baseline ECG and chest X-ray were normal.

Experimental period: the patient entered the 20124/035 study on 23 October 1992 and received the experimental treatment as follows:

Treatment		Days	Dose (mg/day)	Remarks
From	To			
30 October 1992	9 November 1992	11	4	
10 November 1992	10 November 1992	1	2	

On 9 November 1992 the patient developed an urinary retention and on 10 November 1992 there was a neurological worsening of her paresis resulting in an almost complete paralysis of both legs. A Neutron Magnetic Resonance (NMR) test was performed and a mass in the brain was detected. The experimental treatment was definitively discontinued.

On 14 November 1992 the patient was operated to remove this mass. The biopsy was performed and it was found to be a psammomatous meningioma. After the surgery she remained in the hospital till 14 January 1993 for full recovery.

During the study the patient had received the experimental treatment for 12 days and she had received a cumulative amount of 46 mg of reboxetine.

Comments: the Investigator judged the adverse event as not drug related.

9550089

Pharmacia

Document 9550089

Narrative of Event No.GB 0308 Protocol No. 20124/ 035 Patient No. 4

Center: Hull (United Kingdom)

Investigator: Mullin

Adverse event: acute confusional state and fall (date of the event: 11 December 1993)

Patient's history: the patient was a 78 year old female and was suffering from a Major Depressive Episode for 3 months when she entered the Study 20124/035 on 3 December 1993. She had had the onset of depressive disorder at the age of 74 years.

The patient been suffering from angina pectoris, severe scoliosis of dorsal spine and arthritis of both hips. She was on treatment with glyceryl trinitrate.

Baseline ECG was normal.

Experimental period: the patient entered Study 20124/035 on 3 December 1993 and received the experimental treatment as follows:

Treatment		Days	Dose (mg/day)	Remarks
From	To			
8 December 1993	10 December 1993	3	4	
11 December 1993	11 December 1993	1	2	

On 11 December 1993 the patient complained of acute confusional state and during the same day she fell reporting the fracture of some ribs. On chest X-ray a suspicious mass, probably cancer of bronchus, was detected. The experimental treatment was definitively discontinued.

At the moment of the event the patient had been under the experimental treatment for 4 days and she had received a cumulative amount of 14 mg of reboxetine, while being treated with 2 mg of the compound.

Comments: the Investigator judged the adverse event as possibly drug related.

9550089

Pharmacia

Document 9550089

CASE SUMMARY OF EVENT	AU 0098
PROTOCOL No.	20124/035
PT. No.	3 MD Centre 1
SEX	F
AGE AT ENTRY	65
EXPERIMENTAL TREATMENT	Imipramine
DAILY DOSE	75
TREATMENT PERIOD	3 June 1993 - 28 July 1993
AFTER DAYS	28
ADE (DATE OF THE EVENT)	Right Bundle Branch Block And A-V Block 1st Degree (30 June 1993)
DISCONTINUED	No
COURSE	Under Treatment
RELEVANT HISTORY	Rheumatic Fever
RELEVANT BASELINE CONDIT.	Major Depressive Disorder, Hypertension
PREVIOUS ANTIDEPRESSIVE TREATMENTS	Dothiepin
RELEVANT EVENTS	No
CONCOMITANT MEDICATIONS	Propranolol, Temazepam, Oxazepam

TREATMENT PERIOD			DAILY DOSE	CUMULATIVE DOSE
from	to	total days	(mg)	(mg)
03/06/93	05/06/93	3	50	150
06/06/93	08/06/93	3	75	225
09/06/93	09/06/93	1	50	50
10/06/93	15/06/93	6	75	450
16/06/93	16/06/93	1	25	25
17/06/93	28/07/93	42	75	3150
		56		4050
till	30/06/93	28	75	1950

9550089

Pharmacia

Document 9550089

CASE SUMMARY OF EVENT	AU 0078
PROTOCOL No.	20124/035
PT. No.	1 MD Centre 4
SEX	M
AGE AT ENTRY	74
EXPERIMENTAL TREATMENT	Imipramine
DAILY DOSE	0
TREATMENT PERIOD	25 November 1992 - 28 December 1992
AFTER DAYS	35
ADE (DATE OF THE EVENT)	Atrial Fibrillation (5 January 1993)
DISCONTINUED	Yes
COURSE	Under Treatment
RELEVANT HISTORY	Carcinoma of Colon
RELEVANT BASELINE CONDIT.	Major Depressive Disorder, Gout, A-V Block First Degree
PREVIOUS ANTIDEPRESSIVE TREATMENTS	Doxepin
RELEVANT EVENTS	Sinus Tachycardia
CONCOMITANT MEDICATIONS	Allopurinol, Temazepam

TREATMENT PERIOD			DAILY DOSE	CUMULATIVE DOSE
from	to	total days	(mg)	(mg)
25/11/92	28/11/92	4	50	200
29/11/92	15/12/92	17	75	1275
16/12/92	22/12/92	7	100	700
23/12/92	23/12/92	1	50	50
24/12/92	28/12/92	5	100	500
29/12/92	29/12/92	1	0	0
		35		2725

9550089

Pharmacia

Document 9550089

CASE SUMMARY OF EVENT	BE 0046
PROTOCOL No.	20124/035
PT. No.	3 MD Centre 8
SEX	F
AGE AT ENTRY	72
EXPERIMENTAL TREATMENT	Imipramine
DAILY DOSE	0
TREATMENT PERIOD	2 October 1992 - 10 October 1992
AFTER DAYS	9
ADE (DATE OF THE EVENT)	Death (Apoplexy) (21 October 1992)
DISCONTINUED	
COURSE	
RELEVANT HISTORY	Lung Cancer (operated on 24 July 1992)
RELEVANT BASELINE CONDIT.	Major Depressive Disorder, Cardiovascular Failure
PREVIOUS ANTIDEPRESSIVE TREATMENTS	No
RELEVANT EVENTS	Cerebrovascular Accident Probably Due to Cerebral Emboly, Deep Coma
CONCOMITANT MEDICATIONS	Captopril, Nifedipine

TREATMENT PERIOD			DAILY DOSE	CUMULATIVE DOSE
from	to	total days	(mg)	(mg)
02/10/92	04/10/92	3	50	150
05/10/92	09/10/92	5	75	375
10/10/92	10/10/92	1	25	25
		9		550

9550089

Pharmacia

Document 9550089

CASE SUMMARY OF EVENT	FR
PROTOCOL No.	20124/035
PT. No.	2 MD Centre 13
SEX	F
AGE AT ENTRY	94
EXPERIMENTAL TREATMENT	Imipramine
DAILY DOSE	25
TREATMENT PERIOD	11 December 1993 - 4 February 1994
AFTER DAYS	1
ADE (DATE OF THE EVENT)	Sudden Faint (11 December 1993) Syncope
DISCONTINUED	No
COURSE	Recovered
RELEVANT HISTORY	Several Fractures of the Femur (Operated)
RELEVANT BASELINE CONDIT.	Major Depressive Disorder, Hypertension
PREVIOUS ANTIDEPRESSIVE TREATMENTS	No
RELEVANT EVENTS	Bronchitis, Hypokalemia
CONCOMITANT MEDICATIONS	Nitrendipine, Lorazepam

TREATMENT PERIOD			DAILY DOSE	CUMULATIVE DOSE
from	to	total days	(mg)	(mg)
11/12/93	11/12/93	1	25	25
12/12/93	12/12/93	1	0	0
13/12/93	13/12/93	1	25	25
14/12/93	14/01/94	32	75	2400
15/01/94	31/01/94	17	100	1700
01/02/94	01/02/94	1	0	0
02/02/94	03/02/94	2	100	200
04/02/94	04/02/94	1	50	50
		56		4400
till	11/12/93	1	25	25

9550089

Pharmacia

Document 9550089

CASE SUMMARY OF EVENT	FR 0270
PROTOCOL No.	20124/035
PT. No.	2 MD Centre 13
SEX	F
AGE AT ENTRY	94
EXPERIMENTAL TREATMENT	Imipramine
DAILY DOSE	100
TREATMENT PERIOD	11 December 1993 - 4 February 1994
AFTER DAYS	52
ADE (DATE OF THE EVENT)	Fracture of the Neck of the Femur (Operated) (31 January 1994)
DISCONTINUED	Yes
COURSE	Not Recovered
RELEVANT HISTORY	Several Fractures Of The Femur (Operated)
RELEVANT BASELINE CONDIT.	Major Depressive Disorder, Hypertension
PREVIOUS ANTIDEPRESSIVE TREATMENTS	No
RELEVANT EVENTS	Bronchitis, Hypokalemia, Sudden Faint, Hypotension, Myocardial Ischemia
CONCOMITANT MEDICATIONS	Nitrendipine, Lorazepam, Amoxicillin, Potassium Chloride, Lormetazepam

TREATMENT PERIOD			DAILY DOSE	CUMULATIVE DOSE
from	to	total days	(mg)	(mg)
11/12/93	11/12/93	1	25	25
12/12/93	12/12/93	1	0	0
13/12/93	13/12/93	1	25	25
14/12/93	14/01/94	32	75	2400
15/01/94	31/01/94	17	100	1700
01/02/94	01/02/94	1	0	0
02/02/94	03/02/94	2	100	200
04/02/94	04/02/94	1	50	50
		56		4400
till	31/01/94	52	100	4150

9550089

Pharmacia

Document 9550089

CASE SUMMARY OF EVENT	FR 0196
PROTOCOL No.	20124/035
PT. No.	3 MD Centre 16
SEX	F
AGE AT ENTRY	68
EXPERIMENTAL TREATMENT	Imipramine
DAILY DOSE	25
TREATMENT PERIOD	9 May 1993 - 9 June 1993
AFTER DAYS	32
ADE (DATE OF THE EVENT)	Fall and Fracture of the Knee (Operated) (9 June 1993)
DISCONTINUED	Yes
COURSE	Under Treatment
RELEVANT HISTORY	See Baseline Conditions
RELEVANT BASELINE CONDIT.	Major Depressive Disorder
PREVIOUS ANTIDEPRESSIVE TREATMENTS	No
RELEVANT EVENTS	No
CONCOMITANT MEDICATIONS	Temazepam

TREATMENT PERIOD			DAILY DOSE	CUMULATIVE DOSE
from	to	total days	(mg)	(mg)
09/05/93	11/05/93	3	50	150
12/05/93	08/06/93	28	75	2100
09/06/93	09/06/93	1	25	25
		32		2275

9550089

Pharmacia

Document 9550089

CASE SUMMARY OF EVENT	GB
PROTOCOL No.	20124/035
PT. No.	5 MD Centre 30
SEX	F
AGE AT ENTRY	75
EXPERIMENTAL TREATMENT	Imipramine
DAILY DOSE	25
TREATMENT PERIOD	18 December 1993 - 24 December 1993
AFTER DAYS	6
ADE (DATE OF THE EVENT)	Difficulty in Passing Urine (23 December 1993)
DISCONTINUED	Yes
COURSE	Recovered
RELEVANT HISTORY	Cerebrovascular Accident
RELEVANT BASELINE CONDIT.	Major Depressive Disorder
PREVIOUS ANTIDEPRESSIVE TREATMENTS	No
RELEVANT EVENTS	No
CONCOMITANT MEDICATIONS	None

TREATMENT PERIOD			DAILY DOSE	CUMULATIVE DOSE
from	to	total days	(mg)	(mg)
18/12/93	20/12/93	3	50	150
21/12/93	22/12/93	2	75	150
23/12/93	23/12/93	1	25	25
24/12/93	24/12/93	1	0	0
		7		325
till	23/12/93	6	25	325

9550089

Pharmacia

Document 9550089

CASE SUMMARY OF EVENT	GB 0242
PROTOCOL No.	20124/035
PT. No.	3 MD Centre 31
SEX	M
AGE AT ENTRY	84
EXPERIMENTAL TREATMENT	Imipramine
DAILY DOSE	50
TREATMENT PERIOD	14 December 1992 -16 December 1992
AFTER DAYS	1
ADE (DATE OF THE EVENT)	Postural Hypotension (14 December 1992)
DISCONTINUED	Yes
COURSE	Rec. With Seq.
RELEVANT HISTORY	See Baseline Conditions
RELEVANT BASELINE CONDIT.	Major Depressive Disorder, Mild Postural Hypotension, Diabetes Mellitus, Chronic Obstructive Airways Disease (COAD), Ankle Oedema
PREVIOUS ANTIDEPRESSIVE TREATMENTS	Trazodone, Fluoxetine
RELEVANT EVENTS	Worsening Of Postural Hypotension
CONCOMITANT MEDICATIONS	Gliclazide, Furosemide/Amloride

TREATMENT PERIOD			DAILY DOSE	CUMULATIVE DOSE
from	to	total days	(mg)	(mg)
14/12/92	16/12/92	3	50	150
till	14/12/92	1	50	50

9550089

Pharmacia

Document 9550089

CASE SUMMARY OF EVENT	BE 0052
PROTOCOL No.	20124/035
PT. No.	2 MD Centre 35
SEX	F
AGE AT ENTRY	72
EXPERIMENTAL TREATMENT	Imipramine
DAILY DOSE	0
TREATMENT PERIOD	3 March 1993 - 30 March 1993
AFTER DAYS	29
ADE (DATE OF THE EVENT)	Epileptic Attack (31 March 1993)
DISCONTINUED	Yes
COURSE	Recovered
RELEVANT HISTORY	See Baseline Conditions
RELEVANT BASELINE CONDIT.	Major Depressive Disorder, Hyperthyroidism, Atrial Fibrillation, Repolarisation Disturbances
PREVIOUS ANTIDEPRESSIVE TREATMENTS	Mianserin
RELEVANT EVENTS	No
CONCOMITANT MEDICATIONS	Digitoxin, Verapamil, Clotiapine, Domperidone, Nitrofurantoin

TREATMENT PERIOD			DAILY DOSE	CUMULATIVE DOSE
from	to	total days	(mg)	(mg)
03/03/93	05/03/93	3	50	150
06/03/93	29/03/93	24	75	1800
30/03/93	30/03/93	1	25	25
31/03/93	31/03/93	1	0	0
		29		1975

9550089

Pharmacia

Document 9550089

CASE SUMMARY OF EVENT	BE 0050
PROTOCOL No.	20124/035
PT. No.	1 MD Centre 36
SEX	M
AGE AT ENTRY	83
EXPERIMENTAL TREATMENT	Imipramine
DAILY DOSE	0
TREATMENT PERIOD	16 January 1993 - 8 March 1993
AFTER DAYS	52
ADE (DATE OF THE EVENT)	Death (Pulmonary Oedema) (14 March 1993)
DISCONTINUED	
COURSE	
RELEVANT HISTORY	Transient Ischemic Attack (Tia)
RELEVANT BASELINE CONDIT.	Major Depressive Disorder, Chronic Obstructive Pulmonary Disease (COPD), Hypertension, Carcinoma of Prostate, Right Bundle Branch Block
PREVIOUS ANTIDEPRESSIVE TREATMENTS	No
RELEVANT EVENTS	Bronchial Infection, Pneumococcus Pneumonia, Cardiovascular Decompensation, Paroxysmal Asystolia (Pace-Maker), Pulmonary Insufficiency
CONCOMITANT MEDICATIONS	Zopiclone, Theophylline, Nifedipine, Goserelin, Acetylsalicylic Acid, Acetylcysteine, Ipratropium Bromide, Salbutamol, Amoxicillin

TREATMENT PERIOD			DAILY DOSE	CUMULATIVE DOSE
from	to	total days	(mg)	(mg)
16/01/93	18/01/93	3	50	150
19/01/93	07/03/93	48	75	3600
08/03/93	08/03/93	1	25	25
		52		3775

9550089

Pharmacia

Document 9550089

CASE SUMMARY OF EVENT	BE 0053
PROTOCOL No.	20124/035
PT. No.	5 DT Center 36
SEX	F
AGE AT ENTRY	65
EXPERIMENTAL TREATMENT	Imipramine
DAILY DOSE	0
TREATMENT PERIOD	3 April 1993 - 7 April 1993
AFTER DAYS	5
ADE (DATE OF THE EVENT)	Suicide (8 April 1993)
DISCONTINUED	
COURSE	
RELEVANT HISTORY	See Baseline Conditions
RELEVANT BASELINE CONDIT.	Dysthymia, Hypertension, Diabetes Mellitus and Polyneuropathy, Esophagitis, Urinary Tract Infection, Osteoporosis, Pain in Limbs
PREVIOUS ANTIDEPRESSIVE TREATMENTS	Clomipramine, Dosulepin
RELEVANT EVENTS	No
CONCOMITANT MEDICATIONS	Gliquidone, Omeprazole, Nitrofurantoin, Calcium, Carbamazepine

TREATMENT PERIOD			DAILY DOSE	CUMULATIVE DOSE
from	to	total days	(mg)	(mg)
03/04/93	05/04/93	3	50	150
06/04/93	07/04/93	2	75	150
		5		300

9550089

Pharmacia

Document 9550089

CASE SUMMARY OF EVENT	DD 0329
PROTOCOL No.	20124/035
PT. No.	25 DT Centre 291
SEX	F
AGE AT ENTRY	80
EXPERIMENTAL TREATMENT	Imipramine
DAILY DOSE	75
TREATMENT PERIOD	4 November 1993 - 30 December 1993
AFTER DAYS	12
ADE (DATE OF THE EVENT)	Fracture of the Neck of the Femur (15 November 1993)
DISCONTINUED	No
COURSE	Rec. With Seq.
RELEVANT HISTORY	See Baseline Conditions
RELEVANT BASELINE CONDIT.	Dysthymia, Coronary Heart Disease, Arrhythmia, Right Bundle Branch Block, Hyperuricemia
PREVIOUS ANTIDEPRESSIVE TREATMENTS	No
RELEVANT EVENTS	Osteoporosis
CONCOMITANT MEDICATIONS	Acetylsalicylic Acid, Digitoxin, Isosorbide Mononitrate, Propafenone Hydrochloride, Allopurinol

TREATMENT PERIOD			DAILY DOSE	CUMULATIVE DOSE
from	to	total days	(mg)	(mg)
04/11/93	06/11/93	3	50	150
07/11/93	30/12/93	54	75	4050
		57		4200
till	15/11/93	12	75	825

9550089

Pharmacia

Document 9550089

CASE SUMMARY OF EVENT	GB 0410
PROTOCOL No.	20124/035
PT. No.	8 MD Centre 382
SEX	M
AGE AT ENTRY	83
EXPERIMENTAL TREATMENT	Imipramine
DAILY DOSE	75
TREATMENT PERIOD	26 January 1994 -11 February 1994
AFTER DAYS	17
ADE (DATE OF THE EVENT)	Drowsy and Jerky Movements in Legs (11 February 1994)
DISCONTINUED	Yes
COURSE	Recovered
RELEVANT HISTORY	See Baseline Conditions
RELEVANT BASELINE CONDIT.	Major Depressive Disorder, Heart Failure, Osteomalacia, Colitis, Ecg: Atrial Ectopic Beats, Ventricular Ectopic Beats, Atrial Fibrillation/Flutter, Left Ventricular Hypertrophy, Myocardial Ischemia
PREVIOUS ANTIDEPRESSIVE TREATMENTS	No
RELEVANT EVENTS	Drowsiness, Collapse
CONCOMITANT MEDICATIONS	Acetylsalicylic Acid, Digoxin, Furosemide, Lisinopril, Calcium Glubionate, Mesalazine

TREATMENT PERIOD			DAILY DOSE	CUMULATIVE DOSE
from	to	total days	(mg)	(mg)
26/01/94	26/01/94	1	25	25
27/01/94	28/01/94	2	50	100
29/01/94	06/02/94	9	75	675
07/02/94	09/02/94	3	0	0
10/02/94	11/02/94	2	75	150
		17		950

9550089

Pharmacia

Document 9550089

CASE SUMMARY OF EVENT	GB
PROTOCOL No.	20124/035
PT. No.	7 MD Centre 3302
SEX	F
AGE AT ENTRY	93
EXPERIMENTAL TREATMENT	Imipramine
DAILY DOSE	0
TREATMENT PERIOD	13 November 1993 - 8 January 1994
AFTER DAYS	57
ADE (DATE OF THE EVENT)	Death (bronchopneumonia) (20 January 1994)
DISCONTINUED	
COURSE	
RELEVANT HISTORY	See Baseline Conditions
RELEVANT BASELINE CONDIT.	Major Depressive Disorder, Heart Failure, Dyspepsia
PREVIOUS ANTIDEPRESSIVE TREATMENTS	Fluoxetine
RELEVANT EVENTS	Bronchitis
CONCOMITANT MEDICATIONS	Furosemide, Domperidone, Temazepam, Cephalexin

TREATMENT PERIOD			DAILY DOSE	CUMULATIVE DOSE
from	to	total days	(mg)	(mg)
13/11/93	15/11/93	3	50	150
16/11/93	27/11/93	12	75	900
28/11/93	28/11/93	1	25	25
29/11/93	29/11/93	1	50	50
30/11/93	07/12/93	8	75	600
08/12/93	08/12/93	1	25	25
09/12/93	07/01/94	30	75	2250
08/01/94	08/01/94	1	25	25
		57		4025

9550089

Pharmacia

Document 9550089

12.2.2 INDIVIDUAL DATA LISTINGS

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Diagnosis	Patient	Treatment	Initials	In-out patient	Hospital date	Sex	Age (years)	Weight (kg)	Height (cm)	Race	DSM-III-R (*)	Mini-mental state exam. (total score)		
1	M.D.D.	1ND	Reboxetine	OND	IN	29/10/92	Female	76	59.0	159.0	Caucasian	296.3	26.0		
		1DT	Reboxetine	LJM	IN	16/11/93	Male	78	52.0	168.0	Caucasian	296.3	27.0		
		2ND	Imipramine	ADM	OUT	01/11/92	Male	65	72.0	172.0	Caucasian	296.3	27.0		
		2DT	Imipramine	AM	OUT	01/11/92	Male	73	75.0	182.0	Caucasian	296.3	27.0		
		3ND	Imipramine	PHM	IN	25/05/93	Female	65	75.0	160.0	Caucasian	296.3	28.0		
		3DT	Reboxetine	CM	IN	05/12/93	Male	68	60.0	170.0	Caucasian	296.3	29.0		
		4ND	Reboxetine	LH	IN	11/10/93	Female	76	48.0	155.0	Caucasian	296.3	28.0		
		4DT	Imipramine	JN	IN	27/01/94	Male	74	64.0	168.0	Caucasian	296.3	30.0		
		2	M.D.D.	1ND	Reboxetine	AH	IN	31/12/92	Male	71	79.0	157.0	Caucasian	296.2	22.0
		3	M.D.D.	1ND	Reboxetine	EN	IN	23/04/93	Female	71	57.0	156.0	Caucasian	296.3	27.0
		4	M.D.D.	1ND	Imipramine	FC	IN	03/11/92	Male	74	75.0	167.0	Caucasian	296.2	30.0
		5	Dysthymia	1DT	Imipramine	VKM	OUT	14/12/92	Female	68	80.0	161.0	Caucasian	300.4	26.0
2DT	Imipramine			VER	IN	14/12/92	Female	90	42.0	159.0	Caucasian	300.4	22.0		
3DT	Reboxetine			BRG	OUT	01/11/92	Male	74	63.0	176.0	Caucasian	300.4	29.0		
4DT	Reboxetine			DSR	OUT	01/11/92	Male	81	64.0	163.0	Caucasian	300.4	26.0		
5DT	Reboxetine			VFD	OUT	05/12/93	Female	66	85.0	161.0	Caucasian	300.4	27.0		
6DT	Reboxetine			SCH	OUT	05/12/93	Female	70	52.0	161.0	Caucasian	300.4	28.0		
7DT	Imipramine			BEJ	OUT	05/12/93	Female	65	68.0	162.0	Caucasian	300.4	30.0		
8DT	Imipramine			HEV	OUT	05/12/93	Female	66	75.0	155.0	Caucasian	300.4	30.0		
9DT	Reboxetine			NAU	IN	30/04/93	Female	77	44.0	152.0	Caucasian	300.4	28.0		
10DT	Imipramine			VAD	IN	25/04/93	Male	74	75.0	176.0	Caucasian	300.4	30.0		
11DT	Reboxetine			EVE	IN	03/05/93	Female	78	50.0	153.0	Caucasian	300.4	28.0		
12DT	Imipramine			ALL	OUT	03/05/93	Female	80	74.0	157.0	Caucasian	300.4	27.0		
6	M.D.D.	1ND	Reboxetine	VBR	IN	12/10/92	Female	83	65.0	162.0	Caucasian	296.2	24.0		
		2ND	Reboxetine	CRI	IN	12/11/92	Male	78	85.0	178.0	Caucasian	296.3	25.0		
		3ND	Imipramine	VDE	OUT	12/11/92	Female	71	90.0	173.0	Caucasian	296.3	26.0		
		4ND	Imipramine	VDM	OUT	12/11/92	Male	80	70.0	174.0	Caucasian	296.2	30.0		
		5ND	Reboxetine	VA	OUT	17/07/93	Male	66	64.0	171.0	Caucasian	296.3	24.0		
		6ND	Reboxetine	VSD	IN	17/07/93	Male	69	61.0	172.0	Caucasian	296.2	25.0		
		7ND	Reboxetine	LS	OUT	17/07/93	Male	85	81.0	173.0	Caucasian	296.2	27.0		
		8ND	Imipramine	KAD	IN	24/10/93	Female	68	83.7	162.0	Caucasian	296.3	22.0		
		9ND	Reboxetine	DHC	OUT	24/10/93	Female	68	69.0	165.0	Caucasian	296.3	28.0		
		10ND	Imipramine	VER	OUT	25/11/93	Female	71	55.0	151.0	Caucasian	296.3	30.0		
		11ND	Imipramine	VHM	IN	25/11/93	Female	68	65.2	153.0	Caucasian	296.3	24.0		
		12ND	Reboxetine	JG	OUT	25/11/93	Female	66	79.0	166.0	Caucasian	296.3	30.0		

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

907

9550089

2

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Diagnosis	Patient	Treatment	Initials	In-out patient	Hospital date	Age (years)	Sex	Height (kg)	Height (cm)	Race	DSM-III-R (*)	Mini-mental state exam. (total score)	
6	Dysthymia	1DT	Reboxetine	GM	IN	07/10/92	72	Female	64.0	158.0	Caucasian	300.4	26.0	
		2DT	Reboxetine	COO	IN	17/01/93	68	Female	71.0	167.0	Caucasian	300.4	28.0	
		3DT	Imipramine	NJ	IN	02/03/93	65	Female	64.5	160.0	Caucasian	300.4	24.0	
		4DT	Imipramine	KJ	IN	28/04/93	69	Female	70.0	146.0	Caucasian	300.4	27.0	
		5DT	Reboxetine	BM	IN	07/06/93	68	Female	81.5	172.0	Caucasian	300.4	27.0	
	M.D.D.	1MD	Reboxetine	VM	IN	08/11/92	70	Female	64.0	168.0	Caucasian	296.3	27.0	
		2MD	Imipramine	PC	IN	05/11/92	70	Female	81.0	178.0	Caucasian	296.3	28.0	
		3MD	Reboxetine	UM	IN	27/11/92	68	Female	63.0	160.0	Caucasian	296.3	29.0	
		4MD	Imipramine	BUY	IN	08/12/92	71	Female	66.0	162.0	Caucasian	296.3	27.0	
		5MD	Imipramine	VHK	IN	06/11/92	71	Female	58.5	164.0	Caucasian	296.3	22.0	
		6MD	Reboxetine	DTA	IN	23/04/93	77	Female	57.0	160.0	Caucasian	296.3	24.0	
		7MD	Reboxetine	OJ	OUT		70	Female	55.0	162.0	Caucasian	296.3	29.0	
		8MD	Imipramine	SK	IN	18/11/93	74	Female	73.0	188.0	Caucasian	296.3	24.0	
		M.D.D.	1MD	Imipramine	VHR	IN	04/01/93	66	Male	66.0	175.0	Caucasian	296.3	29.0
			3MD	Imipramine	GC	IN	10/04/93	67	Female	63.0	162.0	Caucasian	296.3	22.0
4MD	Reboxetine		ZBL	IN	06/04/93	74	Female	55.0	161.0	Caucasian	296.3	30.0		
3&2MD	Reboxetine		GMJ	IN	12/02/93	67	Female	59.0	168.0	Caucasian	296.3	25.0		
Dysthymia	1DT		Imipramine	VR	IN	12/12/86	83	Female	65.0	161.0	Caucasian	300.4	23.0	
	2DT	Imipramine	PJ	IN	30/09/84	89	Female	62.0	155.0	Caucasian	300.4	28.0		
	3DT	Reboxetine	GO	IN	20/04/86	78	Female	53.0	150.0	Caucasian	300.4	27.0		
	4DT	Reboxetine	DSM	IN	24/03/90	72	Female	59.0	155.0	Caucasian	300.4	28.0		
	701DT	Reboxetine	PR	IN	13/08/92	74	Female	87.0	165.0	Caucasian	300.4	26.0		
	702DT	Imipramine	MA	IN	01/02/90	83	Female	58.0	177.0	Caucasian	300.4	24.0		
	703DT	Imipramine	D	IN	29/07/92	79	Male	90.0	178.0	Caucasian	300.4	23.0		
	704DT	Reboxetine	VHG	IN	23/07/87	67	Female	79.5	165.0	Caucasian	300.4	30.0		
	M.D.D.	1MD	Reboxetine	JM	IN	18/02/92	68	Female	58.0	160.0	Caucasian	296.3	25.0	
		2MD	Reboxetine	JC	IN	23/10/91	69	Female	92.0	172.0	Caucasian	296.2	30.0	
3MD		Imipramine	OG	IN	17/08/92	72	Female	52.0	160.0	Caucasian	296.3	26.0		
4MD		Imipramine	GF	IN	01/11/91	70	Male	56.0	162.0	Caucasian	296.3	29.0		
701MD		Imipramine	RR	IN	21/02/92	70	Male	56.0	168.0	Caucasian	296.3	26.0		
702MD	Reboxetine	VEF	IN	09/09/92	70	Male	48.0	165.0	Caucasian	296.3	23.0			
703MD	Imipramine	VSJ	IN	17/07/92	71	Female	76.0	175.0	Caucasian	296.3	30.0			
704MD	Reboxetine	J	IN	27/10/92	76	Female	57.0	158.0	Caucasian	296.2	27.0			

908

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

9550089

3

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 1,0

PATIENT IDENTIFICATION

Centre	Diagnosis	Patient	Treatment	Initials	In-out patient	status	Age	Weight	Height	Race	DSM-III-R	Mini-mental	
					patient	date	(years)	(kg)	(cm)		(*)	state exam.	
												(Total score)	
9	Dysthymia	1DT	Imipramine	ET	OUT		67	58.0	156.0	Caucasian	300.4	30.0	
		2DT	Imipramine	MD	OUT		72	92.0	165.0	Caucasian	300.4	30.0	
		3DT	Reboxetine	LP	OUT		65	55.0	152.0	Caucasian	300.4	30.0	
			8DT	Reboxetine	AF	OUT		65	89.0	168.0	Caucasian	300.4	30.0
			1HD	Imipramine	OS	OUT		71	72.0	165.0	Caucasian	296.3	27.0
			2HD	Reboxetine	GB	OUT		66	56.0	154.0	Caucasian	296.3	25.0
			4HD	Imipramine	MD	OUT		65	82.0	156.0	Caucasian	296.3	30.0
			5HD	Reboxetine	ES	OUT		70	65.0	165.0	Caucasian	296.3	30.0
			6HD	Imipramine	EM	OUT		65	51.0	164.0	Caucasian	296.3	30.0
			7HD	Imipramine	LC	OUT		69	56.0	155.0	Caucasian	296.3	30.0
			10DT	Reboxetine	MS	OUT		71	60.0	162.0	Caucasian	300.4	30.0
			2DT	Imipramine	JPC	OUT		70	72.0	168.0	Caucasian	300.4	29.0
10	Dysthymia	3DT	Imipramine	CB	OUT		74	80.0	171.0	Caucasian	300.4	30.0	
		4DT	Reboxetine	AC	OUT		68	70.0	163.0	Caucasian	300.4	30.0	
		5DT	Reboxetine	SR	OUT		67	58.0	165.0	Caucasian	300.4	30.0	
		6DT	Reboxetine	AG	OUT		71	68.0	166.0	Caucasian	300.4	27.0	
		7DT	Imipramine	MP	OUT		73	80.0	172.0	Caucasian	300.4	30.0	
		8DT	Imipramine	AH	OUT		73	60.0	150.0	Caucasian	300.4	28.0	
		9DT	Imipramine	PS	OUT		72	62.0	165.0	Caucasian	300.4	29.0	
		10DT	Reboxetine	MP	OUT		67	70.0	161.0	Caucasian	300.4	30.0	
		11DT	Imipramine	MA	OUT		67	57.0	157.0	Caucasian	300.4	30.0	
		12DT	Reboxetine	BM	OUT		68	73.0	166.0	Caucasian	300.4	30.0	
		13DT	Reboxetine	LG	OUT		70	63.0	161.0	Caucasian	300.4	27.0	
		14DT	Imipramine	CS	OUT		69	60.0	167.0	Caucasian	300.4	30.0	
16DT	Imipramine	MV	OUT		70	74.0	166.0	Caucasian	300.4	30.0			
19DT	Reboxetine	AA	OUT		69	62.0	165.0	Caucasian	300.4	29.0			
	M.D.D.	1HD	Imipramine	IS	OUT		67	68.0	162.0	Caucasian	296.2	26.0	
		2HD	Reboxetine	DP	OUT		64	81.0	171.0	Caucasian	296.2	28.0	
		3HD	Reboxetine	ES	OUT		70	76.0	168.0	Black	296.2	26.0	
		4HD	Imipramine	ER	OUT		72	67.0	165.0	Caucasian	296.2	26.0	
		5HD	Imipramine	PL	OUT		73	85.0	170.0	Black	296.2	29.0	
		6HD	Reboxetine	WG	OUT		70	65.0	165.0	Caucasian	296.2	27.0	
		7HD	Imipramine	PD	OUT		69	80.0	178.0	Caucasian	296.2	30.0	
		8HD	Reboxetine	RP	OUT		68	50.0	172.0	Caucasian	296.2	30.0	
		9HD	Reboxetine	IS	OUT		70	68.0	170.0	Caucasian	296.2	29.0	
		10HD	Imipramine	EC	OUT		72	65.0	160.0	Caucasian	296.2	29.0	
		11HD	Imipramine	SC	OUT		72	60.0	160.0	Caucasian	296.2	29.0	
		12HD	Reboxetine	PS	OUT		67	58.0	172.0	Caucasian	296.2	28.0	
15HD	Reboxetine	CS	OUT		74	80.0	174.0	Caucasian	296.2	30.0			

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
300.4=Dysthymia

909

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Diagnosis	Patient	Treatment	Initials	In-out patient	Hospital date	Sex	Age (years)	Weight (kg)	Height (cm)	Race	DSM-III-R (*)	Mini-mental state exam. (total score)
10	M.D.D.	17HD	Reboxetine	SG	OUT		Female	73	58.0	162.0	Caucasian	296.2	27.0
		18HD	Imipramine	YN	OUT		Female	66	74.0	172.0	Caucasian	296.2	29.0
		20HD	Reboxetine	MP	OUT		Female	71	71.0	160.0	Caucasian	296.2	29.0
12	Dysthymia	1DT	Reboxetine	AR	IN	17/04/92	Female	85	51.0	155.0	Caucasian	300.4	23.0
		1MD	Reboxetine	BO	IN	08/08/91	Female	84	48.0	158.0	Caucasian	296.3	22.0
13	Dysthymia	1DT	Imipramine	RH	IN	10/09/93	Female	82	50.0	163.0	Caucasian	300.4	30.0
		2DT	Reboxetine	DL	OUT		Female	76	50.0	155.0	Caucasian	300.4	23.0
		3DT	Imipramine	HR	IN	22/10/93	Female	79	58.0	160.0	Caucasian	300.4	29.0
		4DT	Reboxetine	BR	OUT		Female	69	50.0	153.0	Caucasian	300.4	24.0
14	M.D.D.	1MD	Reboxetine	CT	IN	03/02/93	Female	80	36.0	150.0	Caucasian	296.2	30.0
		2MD	Imipramine	MA	IN	10/12/93	Female	94	48.0	160.0	Caucasian	296.2	23.0
		3MD	Imipramine	FR	IN	28/01/94	Male	79	77.0	184.0	Caucasian	296.3	28.0
15	Dysthymia	1DT	Reboxetine	BA	IN	17/07/92	Female	86	68.0	157.0	Caucasian	300.4	29.0
		2DT	Imipramine	DV	IN	26/01/92	Female	89	83.0	170.0	Caucasian	300.4	24.0
16	Dysthymia	1MD	Reboxetine	BLA	IN	11/02/91	Female	77	61.0	160.0	Caucasian	296.3	29.0
		2MD	Imipramine	LG	IN	09/10/90	Female	84	65.2	160.0	Caucasian	296.3	22.0
		3MD	Reboxetine	CH	IN	03/02/93	Female	83	44.0	150.0	Caucasian	296.2	23.0
		4MD	Imipramine	PH	IN	18/06/93	Female	86	75.0	165.0	Caucasian	296.2	26.0
		11MD	Reboxetine	CAS	IN	01/10/93	Female	65	61.0	163.0	Caucasian	296.3	24.0
		112MD	Imipramine	BJ	IN	12/10/93	Female	84	76.0	158.0	Caucasian	296.2	27.0
		3DT	Imipramine	CD	IN	21/07/93	Female	75	70.0	161.0	Caucasian	300.4	24.0
16	Dysthymia	1DT	Imipramine	GAI	IN	04/02/93	Female	74	60.0	151.0	Caucasian	300.4	26.0
		2DT	Reboxetine	FRA	IN	22/04/93	Male	71	58.5	168.0	Caucasian	300.4	23.0
		3DT	Imipramine	CO	IN	21/07/93	Female	75	70.0	161.0	Caucasian	300.4	24.0
16	M.D.D.	1MD	Reboxetine	SE	IN	23/01/93	Female	85	50.0	151.0	Caucasian	296.2	22.0
		2MD	Imipramine	MAR	IN	07/04/93	Male	72	61.0	173.0	Caucasian	296.2	22.0
		3MD	Imipramine	NIN	IN	04/05/93	Female	68	50.0	159.0	Caucasian	296.3	22.0

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Diagnosis	Patient	Treatment	Initials	In-out patient	Hospital date	Sex	Age (years)	Height (kg)	Height (cm)	Race	DSM-III-R (*)	Mini-mental state exam. (total score)
16	M.D.D.	4MD	Reboxetine	DE	IN	12/04/94	Female	75	57.0	160.0	Caucasian	296.3	25.0
17	Dysthymia	1DT	Reboxetine	CHA	OUT		Female	81	54.0	158.0	Caucasian	300.4	26.0
		2DT	Reboxetine	YS	OUT		Female	76	58.0	163.0	Caucasian	300.4	28.0
		3DT	Imipramine	GAU	OUT		Male	79	77.0	183.0	Caucasian	300.4	29.0
		4DT	Imipramine	DJ	OUT		Female	81	56.0	172.0	Caucasian	300.4	25.0
		211DT	Reboxetine	DEL	OUT		Female	83	66.0	164.0	Caucasian	300.4	26.0
18	M.D.D.	1MD	Reboxetine	PE	OUT		Female	71	45.5	160.0	Caucasian	296.3	25.0
		2MD	Imipramine	PON	OUT		Female	87	56.0	156.0	Caucasian	296.3	24.0
		3MD	Imipramine	CA	IN	19/10/93	Female	74	45.0	150.0	Caucasian	296.3	26.0
		4MD	Reboxetine	VG	OUT		Female	65	50.0	160.0	Caucasian	296.2	30.0
		211MD	Reboxetine	LEF	OUT		Female	70	52.0	155.0	Caucasian	296.3	25.0
18	Dysthymia	1DT	Imipramine	BER	IN	30/07/93	Female	80	39.0	150.0	Caucasian	300.4	27.0
		2DT	Reboxetine	LAP	IN	02/11/93	Female	71	55.0	156.0	Caucasian	300.4	27.0
18	M.D.D.	1MD	Imipramine	LAR	IN	17/05/93	Female	81	64.0	155.0	Caucasian	296.3	25.0
		2MD	Reboxetine	CAZ	IN	22/05/93	Female	68	47.0	153.0	Caucasian	296.3	29.0
		3MD	Reboxetine	TIJ	IN	26/07/93	Female	82	68.0	155.0	Caucasian	296.3	23.0
		4MD	Reboxetine	FEV	IN	24/09/93	Female	79	52.0	169.0	Caucasian	296.3	23.0
20	M.D.D.	3MD	Reboxetine	MA	OUT		Female	80	53.0	162.0	Caucasian	296.2	30.0
22	M.D.D.	1MD	Reboxetine	RFR	IN	21/06/93	Female	81	47.0	157.0	Caucasian	296.3	30.0
23	M.D.D.	1MD	Reboxetine	ET	IN	19/01/93	Female	71	58.9	160.0	Caucasian	296.2	30.0
		2MD	Reboxetine	BG	IN	15/12/92	Female	69	63.0	160.0	Caucasian	296.3	29.0
		3MD	Imipramine	SB	IN	12/03/93	Female	80	49.0	158.0	Caucasian	296.3	28.0
		4MD	Imipramine	AG	IN	15/03/93	Female	80	74.0	160.0	Caucasian	296.3	30.0
		5MD	Imipramine	IK	IN	13/04/93	Female	69	64.0	160.0	Caucasian	296.3	30.0
		6MD	Imipramine	AS	IN	28/06/93	Female	72	61.0	151.0	Caucasian	296.3	30.0
25	M.D.D.	1MD	Reboxetine	BG	IN	27/08/93	Male	68	60.8	174.0	Caucasian	296.2	28.0
		2MD	Imipramine	SD	IN	19/11/93	Female	67	57.6	158.0	Caucasian	296.3	28.0

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
300.4=Dysthymia

9550089

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Diagnosis	Patient	Treatment	Initials	In-out patient	Hospital date	Sex	Age (years)	Weight (kg)	Height (cm)	Race	DSK-III-R (*)	Mini-mental state exam. (total score)
26	Dysthymia	1DT	Reboxetine	LL	IN	04/06/93	Female	68	48.0	161.0	Caucasian	300.4	29.0
	H.D.D.	1HD	Imipramine	JR	IN	23/04/93	Female	69	88.0	169.0	Caucasian	296.3	30.0
27	H.D.D.	1HD	Imipramine	KB	IN	29/01/93	Male	79	60.5	176.0	Caucasian	296.3	30.0
28	Dysthymia	1DT	Imipramine	MP	OUT		Female	91	44.0	160.0	Caucasian	300.4	25.0
		2DT	Reboxetine	FC	OUT		Male	82	68.0	167.0	Caucasian	300.4	27.0
		3DT	Imipramine	LM	OUT		Male	69	75.0	176.0	Caucasian	300.4	27.0
	H.D.D.	1HD	Reboxetine	EH	OUT		Female	70	86.5	156.0	Caucasian	296.3	23.0
		2HD	Imipramine	MS	OUT		Female	86	71.0	160.0	Caucasian	296.3	22.0
		3HD	Reboxetine	HC	OUT		Female	66	85.0	158.0	Caucasian	296.3	27.0
		4HD	Imipramine	BS	OUT		Male	87	78.0	173.0	Caucasian	296.3	25.0
		5HD	Reboxetine	JH	OUT		Female	66	75.0	165.0	Caucasian	296.3	24.0
	H.D.D.	1HD	Imipramine	ED	IN	08/04/93	Female	87	45.4	166.0	Caucasian	296.3	29.0
		2HD	Reboxetine	GH	OUT		Female	74	73.0	162.0	Caucasian	296.3	26.0
		3HD	Imipramine	EM	OUT		Female	86	54.0	143.0	Caucasian	296.2	27.0
		4HD	Reboxetine	JP	IN	24/10/93	Female	78	66.6	164.0	Caucasian	296.3	28.0
		5HD	Imipramine	BR	IN	26/11/93	Female	75	69.0	156.0	Caucasian	296.3	30.0
31	Dysthymia	1DT	Reboxetine	AH	OUT		Female	77	66.0	146.0	Caucasian	300.4	27.0
	H.D.D.	1HD	Imipramine	SOC	OUT		Female	76	41.0	142.0	Caucasian	296.2	30.0
		2HD	Reboxetine	NJ	OUT		Female	79	46.1	138.0	Caucasian	296.2	23.0
		3HD	Imipramine	HF	OUT		Male	84	68.0	172.0	Caucasian	296.3	24.0
32	H.D.D.	1HD	Imipramine	MB	OUT		Female	66	75.0	152.0	Caucasian	296.3	28.0
		2HD	Imipramine	IH	OUT		Female	70	75.0	165.0	Caucasian	296.2	29.0
		3HD	Reboxetine	SM	OUT		Female	67	58.0	150.0	Caucasian	296.2	29.0
		4HD	Reboxetine	MP	OUT		Female	68	57.0	160.0	Caucasian	296.3	28.0
		5HD	Reboxetine	NEB	OUT		Female	78	50.0	163.0	Caucasian	296.3	29.0
		6HD	Imipramine	EEF	OUT		Male	81	99.0	180.0	Caucasian	296.3	28.0
35	Dysthymia	1DT	Reboxetine	DA	IN	16/01/93	Female	69	72.0	154.0	Caucasian	300.4	26.0

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

42
1-1
30

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Diagnosis	Patient	Treatment	Initials	Patient status		Age (years)	Weight (kg)	Height (cm)	Race	DSM-III-R (*)	Mini-mental state exam. (total score)	
					In-out	Hospital date							
35	Dysethymia	2DT	Imipramine	SH	IN	01/03/93	Female	67	155.0	Caucasian	300.4	30.0	
		3DT	Imipramine	LA	IN	29/03/93	Male	74	178.0	Caucasian	300.4	29.0	
		4DT	Reboxetine	MS	IN	19/04/93	Female	65	90.0	156.0	Caucasian	300.4	25.0
		5DT	Imipramine	LE	IN	26/08/93	Female	77	62.0	150.0	Caucasian	300.4	25.0
		6DT	Imipramine	CL	OUT		Female	69	91.0	160.0	Caucasian	300.4	25.0
		7DT	Reboxetine	DM	IN	15/10/93	Female	78	67.5	159.0	Caucasian	300.4	26.0
		8DT	Reboxetine	VH	IN	28/12/93	Female	72	38.0	152.0	Caucasian	300.4	30.0
		M.D.D.	1HD	Reboxetine	VP	IN	25/01/93	Female	71	57.0	165.0	Caucasian	296.3
	2HD		Imipramine	RY	IN	02/02/93	Female	72	62.0	170.0	Caucasian	296.3	24.0
	3HD		Imipramine	CL	IN	26/03/93	Female	66	69.0	162.0	Caucasian	296.2	23.0
	4HD		Reboxetine	PH	IN	31/03/93	Male	90	54.5	157.0	Caucasian	296.2	26.0
	5HD		Reboxetine	VA	IN	01/07/93	Male	70	60.5	155.0	Caucasian	296.2	29.0
	6HD		Reboxetine	BD	IN	17/01/94	Female	69	91.0	162.0	Caucasian	296.3	30.0
	7HD		Imipramine	SL	IN	12/11/93	Female	74	82.0	160.0	Caucasian	296.3	26.0
	8HD		Imipramine	PH	IN	30/01/94	Female	74	58.0	160.0	Caucasian	296.3	22.0
	36	Dysethymia	1DT	Imipramine	DZ	IN	01/02/93	Female	78	78.4	162.0	Caucasian	300.4
2DT			Reboxetine	DCG	OUT		Female	66	72.0	163.0	Caucasian	300.4	29.0
3DT			Imipramine	LM	IN	16/02/93	Female	80	57.5	160.0	Caucasian	300.4	26.0
4DT			Reboxetine	BA	OUT		Female	74	59.5	155.0	Caucasian	300.4	27.0
5DT			Imipramine	DC	IN	11/03/93	Female	65	80.0	162.0	Caucasian	300.4	28.0
6DT			Imipramine	BJ	OUT		Female	72	62.0	160.0	Caucasian	300.4	29.0
7DT			Reboxetine	HG	OUT		Female	75	59.0	174.0	Caucasian	300.4	30.0
8DT			Reboxetine	TR	IN	04/05/93	Female	80	55.7	160.0	Caucasian	300.4	28.0
9DT		Imipramine	VA	OUT		Female	65	66.0	172.0	Caucasian	300.4	30.0	
10DT		Reboxetine	JR	IN	17/10/93	Male	79	75.0	173.0	Caucasian	300.4	23.0	
11DT		Reboxetine	VC	IN	28/10/93	Male	78	65.0	162.0	Caucasian	300.4	23.0	
12DT		Imipramine	NC	IN	11/12/93	Female	61	45.0	152.0	Caucasian	300.4	26.0	
M.D.D.		1HD	Imipramine	LA	IN	08/01/93	Male	83	64.9	170.0	Caucasian	296.2	25.0
		2HD	Reboxetine	DG	IN	27/01/93	Female	65	76.0	164.0	Caucasian	296.2	26.0
		3HD	Imipramine	PY	IN	05/01/93	Female	84	45.0	160.0	Caucasian	296.2	22.0
		4HD	Reboxetine	YMJ	IN	02/03/93	Female	79	63.0	170.0	Caucasian	296.3	25.0
	5HD	Reboxetine	DA	IN	20/04/93	Female	79	78.0	160.0	Caucasian	296.3	30.0	
	6HD	Imipramine	VH	IN	07/04/93	Female	65	74.3	162.0	Caucasian	296.2	23.0	
	7HD	Reboxetine	SH	OUT		Female	81	50.0	154.0	Caucasian	296.2	24.0	
	8HD	Imipramine	WM	IN	12/04/93	Female	67	104.0	149.0	Caucasian	296.2	29.0	
9HD	Reboxetine	VG	IN	12/06/93	Male	82	68.0	170.0	Caucasian	296.2	23.0		
10ND	Reboxetine	MA	IN	03/06/93	Male	77	66.0	168.0	Caucasian	296.3	25.0		
11ND	Imipramine	AM	OUT		Female	61	52.0	152.0	Caucasian	296.3	27.0		
12ND	Imipramine	CH	OUT		Female	78	53.7	165.0	Caucasian	296.2	24.0		

(*) DIAGNOSIS: 296.2-Major Depressive Disorder, First Episode
296.3-Major Depressive Disorder, Multiple Episode
300.4-Dysethymia

9550089

9550089

8

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Diagnosis	Patient	Treatment	Initials	Patient status		Age (years)	Weight (kg)	Height (cm)	Race	DSM-III-R (*)	Mini-mental state exam. (total score)		
					In-out	Hospital date								
36	M.D.D.	13ND	Reboxetine	PF	IN	11/08/93	76	53.0	180.0	Caucasian	296.2	25.0		
		14ND	Imipramine	CJ	IN	02/11/93	70	71.0	170.0	Caucasian	296.3	29.0		
		15ND	Reboxetine	DMA	IN	05/10/93	73	60.5	154.0	Caucasian	296.5	30.0		
		16ND	Imipramine	BJ	OUT		72	71.0	164.0	Caucasian	296.3	28.0		
		17ND	Reboxetine	VH	OUT		80	54.0	160.0	Caucasian	296.2	30.0		
		18ND	Imipramine	BH	OUT		78	69.0	166.0	Caucasian	296.3	27.0		
		19ND	Reboxetine	A2	OUT		81	55.0	165.0	Caucasian	296.2	30.0		
		20ND	Imipramine	CR	IN	23/01/94	70	74.0	166.0	Caucasian	296.3	22.0		
		37	M.D.D.	3ND	Reboxetine	BLJ	IN	09/03/93	81	59.0	160.0	Caucasian	296.3	29.0
		41	M.D.D.	1ND	Imipramine	DF	OUT		69	74.0	166.0	Caucasian	296.2	28.0
2ND	Reboxetine			BE	IN	18/02/94	68	57.0	170.0	Caucasian	296.2	30.0		
3ND	Imipramine			FG	OUT		85	73.0	178.0	Caucasian	296.3	27.0		
4ND	Reboxetine			JM	OUT		74	77.0	159.0	Caucasian	296.3	30.0		
5ND	Reboxetine			GH	OUT		69	72.0	164.0	Caucasian	296.3	30.0		
42	Dysthymia			1DT 2DT	Imipramine Reboxetine	MP DG	OUT OUT		79 68	166.4 174.5	Caucasian Caucasian	300.4 300.4	28.0 30.0	
43	M.D.D.	1ND	Imipramine	JS	IN	04/10/93	73	71.8	165.1	Caucasian	296.3	30.0		
		2ND	Reboxetine	KS	IN	14/09/93	79	52.0	153.0	Caucasian	296.3	27.0		
		3ND	Imipramine	JP	OUT		82	87.2	168.0	Caucasian	296.3	27.0		
		4DT	Reboxetine	EB	IN	18/02/93	77	60.6	152.0	Caucasian	296.2	26.0		
44	Dysthymia	1DT	Imipramine	AJ	IN	07/05/93	77	59.6	155.0	Caucasian	296.3	30.0		
		2DT	Imipramine	CH	OUT		72	94.6	175.0	Caucasian	296.2	29.0		
		3DT	Reboxetine	FH	OUT		79	80.0	155.0	Caucasian	296.3	27.0		
		4DT	Imipramine	MR	IN	07/12/93	70	55.6	153.0	Caucasian	296.3	27.0		
		5ND	Imipramine	MS	IN	27/12/93	74	65.0	160.0	Caucasian	296.3	29.0		
		6ND	Reboxetine	FS	IN	27/07/93	76	61.7	163.0	Caucasian	300.4	29.0		
44	M.D.D.	1ND	Reboxetine	D	IN	07/07/93	76	71.0	162.0	Caucasian	296.3	27.0		
		2ND	Reboxetine	DG	IN	13/09/93	73	73.9	164.0	Caucasian	296.3	28.0		
		3ND	Imipramine	JH	IN	04/10/93	73	64.2	155.0	Caucasian	296.3	27.0		
		4ND	Imipramine	JO	OUT		81	65.3	162.9	Caucasian	296.3	27.0		

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

9550089

9

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Diagnosis	Patient	Treatment	Initials	Patient status		Age (years)	Weight (kg)	Height (cm)	Race	DSM-III-R (*)	Mini-mental state exam. (total score)	
					In-out patient	Hospital date							
45	Dysthymia	1DT	Imipramine	JN	OUT	Female	79	56.5	160.0	Caucasian	300.4	28.0	
		1HD	Reboxetine	RL	IN	09/11/93	Male	76	78.0	178.0	Caucasian	296.2	30.0
		2HD	Imipramine	PM	OUT	Male	77	55.0	173.0	Caucasian	296.3	22.0	
		1HD	Imipramine	KT	OUT	Male	69	113.0	183.0	Caucasian	296.2	30.0	
46	H.D.D.	3HD	Imipramine	AJ	IN	13/10/93	Female	72	54.0	163.0	Caucasian	296.3	29.0
		3HD	Reboxetine	IM	OUT	Female	73	60.2	182.0	Caucasian	296.3	30.0	
		4HD	Reboxetine	EMT	OUT	Female	78	45.3	150.0	Caucasian	296.3	27.0	
		1DT	Reboxetine	VN	IN	16/06/93	Female	74	41.7	148.0	Caucasian	296.2	28.0
2DT	Imipramine	VA	IN	25/06/93	Female	65	75.6	156.0	Caucasian	296.3	27.0		
291	Dysthymia	1DT	Reboxetine	MK	OUT	Female	81	80.0	166.0	Caucasian	300.4	25.0	
		2DT	Reboxetine	SS	OUT	Female	73	80.0	162.0	Caucasian	300.4	29.0	
		3DT	Imipramine	BG	OUT	Female	73	74.0	164.0	Caucasian	300.4	26.0	
		4DT	Imipramine	MH	OUT	Male	87	58.0	178.0	Caucasian	300.4	26.0	
		25DT	Imipramine	ED	OUT	Female	80	64.0	162.0	Caucasian	300.4	24.0	
		26DT	Reboxetine	GO	OUT	Female	81	56.0	156.0	Caucasian	300.4	28.0	
		27DT	Reboxetine	SA	OUT	Female	88	67.0	162.0	Caucasian	300.4	23.0	
		28DT	Imipramine	SB	OUT	Female	73	71.0	163.0	Caucasian	300.4	24.0	
292	H.D.D.	1HD	Imipramine	SE	OUT	Female	80	51.0	160.0	Caucasian	296.3	23.0	
		2HD	Reboxetine	HB	OUT	Female	68	62.0	163.0	Caucasian	296.3	23.0	
		3HD	Imipramine	SA	OUT	Male	67	88.0	170.0	Caucasian	296.3	23.0	
		4HD	Reboxetine	DH	OUT	Male	68	79.0	174.0	Caucasian	296.3	27.0	
292	Dysthymia	5DT	Reboxetine	MF	OUT	Male	79	81.3	175.0	Caucasian	300.4	23.0	
		6DT	Imipramine	MG	OUT	Female	69	79.3	169.0	Caucasian	300.4	23.0	
		7DT	Imipramine	NM	OUT	Male	68	72.3	168.0	Caucasian	300.4	26.0	
		8DT	Reboxetine	MB	OUT	Female	73	72.8	168.0	Caucasian	300.4	29.0	
		21DT	Reboxetine	KS	OUT	Female	78	67.2	163.0	Caucasian	300.4	24.0	
		22DT	Imipramine	EK	OUT	Female	61	66.5	169.0	Caucasian	300.4	25.0	
		23DT	Reboxetine	MH	OUT	Male	69	74.6	171.0	Caucasian	300.4	27.0	
		24DT	Imipramine	AE	OUT	Female	65	66.2	167.0	Caucasian	300.4	24.0	

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

9550089

10

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Diagnosis	Patient	Treatment	Initials	Patient status		Age (years)	Weight (kg)	Height (cm)	Race	DSM-III-R (*)	Mini-mental state exam. (total score)	
					In-out	Hospital date							
292	M.D.D.	5MD	Imipramine	LS	Female	73	64.3	171.0	Caucasian	296.2	25.0		
		6MD	Reboxetine	KL	Female	71	70.3	168.0	Caucasian	296.2	23.0		
		7MD	Reboxetine	WK	Male	82	69.7	166.0	Caucasian	296.2	22.0		
		8MD	Imipramine	BH	Male	68	62.5	171.0	Caucasian	296.2	22.0		
		21MD	Imipramine	PK	Female	72	66.8	165.0	Caucasian	296.3	23.0		
		22MD	Imipramine	AW	Female	67	60.3	162.0	Caucasian	296.2	23.0		
		23MD	Reboxetine	GL	Female	75	72.8	161.0	Caucasian	296.2	25.0		
		24MD	Reboxetine	KB	Male	75	92.8	179.0	Caucasian	296.2	24.0		
		293	Dysthymia	9DT	Imipramine	MR	Female	67	71.0	167.0	Caucasian	300.4	27.0
				10DT	Imipramine	RK	Female	64	72.0	170.0	Caucasian	300.4	25.0
				11DT	Reboxetine	ER	Female	68	74.0	170.0	Caucasian	300.4	24.0
				12DT	Reboxetine	VN	Female	69	73.0	178.0	Caucasian	300.4	21.0
294	M.D.D.			9MD	Imipramine	MS	Female	80	69.0	167.0	Caucasian	296.3	24.0
				10MD	Reboxetine	SV	Female	65	74.0	168.0	Caucasian	296.3	23.0
294	Dysthymia	11MD	Imipramine	MD	Male	65	72.0	169.0	Caucasian	296.3	24.0		
		12MD	Reboxetine	MH	Male	56	81.0	180.0	Caucasian	296.3	24.0		
		13DT	Reboxetine	TH	Female	68	48.0	150.0	Caucasian	300.4	22.0		
		14DT	Imipramine	KH	Female	73	71.0	158.0	Caucasian	300.4	24.0		
		15DT	Imipramine	VG	Female	75	70.0	158.0	Caucasian	300.4	24.0		
		16DT	Reboxetine	RM	Female	81	82.0	168.0	Caucasian	300.4	24.0		
		29DT	Reboxetine	RA	Female	80	58.0	158.0	Caucasian	300.4	23.0		
		30DT	Reboxetine	FF	Female	79	67.0	164.0	Caucasian	300.4	24.0		
		31DT	Imipramine	SK	Female	80	73.8	164.0	Caucasian	300.4	24.0		
		32DT	Imipramine	SD	Male	73	79.4	168.0	Caucasian	300.4	24.0		
		295	M.D.D.	13MD	Imipramine	SM	Female	80	56.0	150.0	Caucasian	296.3	23.0
				14MD	Reboxetine	BG	Female	82	50.0	155.0	Caucasian	296.2	22.0
15MD	Imipramine			BF	Female	82	67.0	167.0	Caucasian	296.2	23.0		
16MD	Reboxetine			MM	Female	65	66.0	168.0	Caucasian	296.3	24.0		
25MD	Imipramine			RE	Female	71	73.0	163.0	Caucasian	296.2	25.0		
26MD	Imipramine			BB	Female	75	58.0	166.0	Caucasian	296.2	25.0		
27MD	Reboxetine			RK	Female	67	84.0	164.0	Caucasian	296.2	24.0		
28MD	Reboxetine			RE	Female	76	56.0	150.0	Caucasian	296.2	25.0		
17DT	Imipramine			SZ	Male	65	75.0	165.0	Caucasian	300.4	27.0		
18DT	Imipramine			AS	Female	71	62.0	165.0	Caucasian	300.4	26.0		
19DT	Reboxetine			ES	Female	69	74.0	168.0	Caucasian	300.4	27.0		

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.4=Major Depressive Disorder, Bipolar
300.4=Dysthymia

916

9550089

11

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Diagnosis	Patient	Treatment	Initials	Patient status		Age (years)	Weight (kg)	Height (cm)	Race	DSK-III-R (#)	Mini-mental state exam. (total score)
					In-out patient	Hospital date						
295	Dysthymia	20DT	Reboxetine	BM	OUT	Female	66	80.0	168.0	Caucasian	300.4	26.0
	M.D.D.	17ND 18ND 19ND 20ND	Reboxetine Reboxetine Imipramine Imipramine	MS KJ PR PF	OUT OUT OUT OUT	Female Female Male Female	64 73 66 82	64.0 60.0 78.0 75.0	159.0 158.0 177.0 164.0	Caucasian Caucasian Caucasian Caucasian	296.3 296.3 296.3 296.3	28.0 28.0 28.0 26.0
381	Dysthymia	3DI	Reboxetine	YN	OUT	Female	77	50.0	156.0	Caucasian	300.4	30.0
	M.D.D.	1MD 2MD 4MD	Reboxetine Reboxetine Imipramine	ST DR EN	OUT IN OUT	Male Female Female	86 67 88	63.3 44.2 59.0	168.0 163.0 156.0	Caucasian Caucasian Caucasian	296.2 296.2 296.2	30.0 27.0 27.0
382	Dysthymia	5DI 6DI 7DI 8DI 9DI	Reboxetine Imipramine Imipramine Reboxetine Reboxetine	RS ET MAT MS HM	IN OUT OUT IN IN	Male Female Male Female Female	63 79 82 86 78	65.9 63.5 89.2 56.3 165.0	173.0 158.0 195.0 160.0 165.0	Caucasian Caucasian Caucasian Caucasian Caucasian	300.4 300.4 300.4 300.4 300.4	26.0 30.0 30.0 24.0 26.0
917	M.D.D.	5MD 6MD 7MD 8MD 9MD 10MD	Imipramine Reboxetine Reboxetine Imipramine Reboxetine Imipramine	JS MP MR AL FT MS	IN OUT OUT IN OUT OUT	Female Female Female Male Female Female	74 74 88 83 86 85	47.7 63.2 52.0 57.0 58.4 48.5	152.0 154.0 185.0 185.0 159.0	Caucasian Caucasian Caucasian Caucasian Caucasian Caucasian	296.3 296.2 296.3 296.2 296.2 296.2	30.0 29.0 23.0 18.0 23.0 30.0
3301	M.D.D.	1MD 2MD 3MD	Reboxetine Imipramine Reboxetine	EGS CD FM	IN IN IN	Female Male Female	76 85 71	62.0 39.0 65.0	158.0 143.0 175.0	Caucasian Caucasian Caucasian	296.3 296.3 296.3	30.0 27.0 29.0
3302	M.D.D.	5MD 6MD 7MD	Reboxetine Imipramine Imipramine	AL EMF AT	IN IN OUT	Female Female Female	84 73 93	69.6 44.9 52.5	170.0 140.0 146.0	Caucasian Caucasian Caucasian	296.3 296.3 296.2	25.0 30.0 23.0

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R80
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 2.0

HISTORY OF THE MENTAL DISORDER AND PRESENT EPISODE

Centre	Patient	Unknown	History of mental disorder		Duration at the time		Present episode		External stress
			Age of onset	No. of episodes last episode	of admission	of admission	Best characterized	Onset was	
1	1HD		68	1	3 months	6 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	1DT		68	2	4 weeks	6 months	Similar prev. cond.	Insidious (>= 3 months)	Absent
	2HD		64	1	12 months	12 months	Similar prev. cond.	Insidious (>= 3 months)	Absent
	2DT		68	1	2 months	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	3HD		45	40	4 weeks	6 months	Similar prev. cond.	Insidious (>= 3 months)	Absent
	3DT		64	1	6 weeks	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	4HD		62	1	4 months	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	4DT		22	20	1 month	1 month	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	2	1HD		71		5 months	First occurrence	Acute (< 2 weeks)	Definitely present
	3	1HD		29	5	10 months	3 weeks	Similar prev. cond.	Acute (< 2 weeks)
4	1HD		74		6 weeks	First occurrence	Subacute (>= 2 weeks)	Definitely present	
5	1HD		83	0		3 months	Chronic condition	Insidious (>= 3 months)	Probably present
	1DT		66	0		2 years	Chronic condition	Insidious (>= 3 months)	Definitely present
	2HD		76	1	2 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	2DT		88	0		2 years	First occurrence	Insidious (>= 3 months)	Absent
	3HD		63	3	3 months	2 years	Similar prev. cond.	Acute (< 2 weeks)	Probably present
	3DT		79	3	2 years	2 weeks	Chronic condition	Acute (< 2 weeks)	Probably present
	4HD		52	0		7 months	First occurrence	Insidious (>= 3 months)	Probably present
	4DT		52	3	16 weeks	2 years	Similar prev. cond.	Insidious (>= 3 months)	Absent
	5HD		64	1	2 months	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	5DT		42	4	1 year	2 years	Similar prev. cond.	Insidious (>= 3 months)	Definitely present
	6HD		65	0		1 month	First occurrence	Subacute (>= 2 weeks)	Absent
	6DT		68	1	1 year	2 years and 6 months	Chronic condition	Insidious (>= 3 months)	Absent
	7HD		84	0		6 weeks	First occurrence	Subacute (>= 2 weeks)	Absent
	7DT		63	0		2 years	First occurrence	Insidious (>= 3 months)	Probably present
	8HD		48	5	3 months	6 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	8DT		63	0		3 years	Chronic condition	Insidious (>= 3 months)	Probably present
	9HD	Yes	65	1	6 months	5 weeks	Chronic condition	Insidious (>= 3 months)	Probably present
	9DT		65	2	3 months	5 weeks	Chronic condition	Insidious (>= 3 months)	Absent
10HD		60	2	6 weeks	3 years	Chronic condition	Subacute (>= 2 weeks)	Definitely present	
11HD	Yes	63	0	1 year	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present	
11DT		61	3	18 weeks	2 years	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present	
12HD		78	0		2 years	Chronic condition	Insidious (>= 3 months)	Probably present	
6	1HD		36	3	6 months and 3 weeks	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	1DT		66	10	5 months	2 months	Chronic condition	Insidious (>= 3 months)	Absent
	2HD		50	0		3 weeks	Similar prev. cond.	Acute (< 2 weeks)	Absent
	2DT		64	0	4 years	4 years	First occurrence	Insidious (>= 3 months)	Probably present
	3HD		30	3	5 months	2 months	Similar prev. cond.	Acute (< 2 weeks)	Absent

9550089

9550089

2

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REMONETINE - PROTOCOL 20124/035
 Listing No.: 2.0

HISTORY OF THE MENTAL DISORDER AND PRESENT EPISODE

Centre	Patient	Unknown	History of mental disorder		Duration at the time of admission		Present episode		External stress
			Age at onset	No. of episodes	Last onset	Duration	Best characterized	Onset was	
6	3DT		50	6	3 years	2 months	Chronic condition	Subacute (>= 2 weeks)	Definitely present
	4RD		47	2	1 month and 3 weeks	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	4DT		40			4 months	Chronic condition	Insidious (>= 3 months)	Absent
	5RD		50	20	weeks	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	5DT		25			8 weeks	Chronic condition	Subacute (>= 2 weeks)	Absent
	6RD		66	5	3 months	5 months	Similar prev. cond.	Insidious (>= 3 months)	Absent
	7RD		40	12	7 months	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	8RD		30	10	3 months	3 months	Similar prev. cond.	Acute (< 2 weeks)	Absent
7	1RD	9	53		13 years	1 year	Chronic condition	Insidious (>= 3 months)	Probably present
	3RD	9	46	6	3 months	1 month	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	4RD		55	4	3 months	5 months	Different prev. cond.	Acute (< 2 weeks)	Probably present
	342RD		63	2	6 months	3 months	Chronic condition	Insidious (>= 3 months)	Absent
8	1RD	Yes	65	3	months	3 weeks	Chronic condition	Insidious (>= 3 months)	Absent
	2RD	Yes	68			3 years	Chronic condition	Insidious (>= 3 months)	Absent
	3RD	Yes	35	1		1 year	First occurrence	Insidious (>= 3 months)	Probably present
	4RD	Yes				3 months	Chronic condition	Insidious (>= 3 months)	Probably present
	4DT	Yes				2 months	Chronic condition	Insidious (>= 3 months)	Absent
	761RD	Yes	50	10	4 months	3 years	Similar prev. cond.	Insidious (>= 3 months)	Absent
	762RD	Yes				40 years	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	762DT	Yes				3 months	Chronic condition	Insidious (>= 3 months)	Absent
	763RD	Yes	55	1	2 years	2 years	Chronic condition	Insidious (>= 3 months)	Probably present
	703DT	Yes				10 months	Chronic condition	Insidious (>= 3 months)	Absent
	704RD	Yes				1 year	Chronic condition	Insidious (>= 3 months)	Probably present
	704DT	Yes				9 months	First occurrence	Insidious (>= 3 months)	Probably present
						3 years	Similar prev. cond.	Insidious (>= 3 months)	Absent
9	1RD		51	1	6 months	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	31		31	10	3 years	3 years	Chronic condition	Subacute (>= 2 weeks)	Absent
	2RD		49	2	4 months	4 months	Similar prev. cond.	Acute (< 2 weeks)	Probably present
	3DT		28	12	3 years	2 years	Chronic condition	Subacute (>= 2 weeks)	Absent
	4RD		20	2	years	2 years	Chronic condition	Insidious (>= 3 months)	Absent
	5RD		24	3	8 months	4 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	6RD		30	6	2 months	4 months	Similar prev. cond.	Insidious (>= 3 months)	Absent
	7RD		30	2	1 year	4 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	62		62	2	4 months	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	8DT		40	6	4 years	3 years	Chronic condition	Acute (< 2 weeks)	Absent
10	1RD		67	0		3 months	First occurrence	Subacute (>= 2 weeks)	Absent
	1DT		68	0		3 years	First occurrence	Subacute (>= 2 weeks)	Absent
	2RD		64	0		4 months	First occurrence	Subacute (>= 2 weeks)	Absent
	2DT		66	0		4 years	First occurrence	Subacute (>= 2 weeks)	Absent

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No.: 2.0

HISTORY OF THE MENTAL DISORDER AND PRESENT EPISODE

Centre	Patient	Unknown	History of mental disorder		Duration at the time of admission	Present episode		External stress
			Age of onset	No. of episodes last episode		Best characterized	Onset was	
10	3HD		70	0	5 months	First occurrence	Subacute (>= 2 weeks)	Absent
	3DT		70	0	4 years	First occurrence	Subacute (>= 2 weeks)	Absent
	4HD		71	0	5 months	First occurrence	Acute (< 2 weeks)	Absent
	4DT		66	0	2 years	First occurrence	Subacute (>= 2 weeks)	Absent
	5HD		73	0	4 months	First occurrence	Subacute (>= 2 weeks)	Absent
	5DT		65	0	2 years	First occurrence	Subacute (>= 2 weeks)	Absent
	6HD		69	0	6 months	First occurrence	Subacute (>= 2 weeks)	Absent
	6DT		67	0	4 years	First occurrence	Insidious (>= 3 months)	Absent
	7HD		69	0	4 months	First occurrence	Acute (< 2 weeks)	Absent
	7DT		70	0	3 years	First occurrence	Insidious (>= 3 months)	Absent
	8HD		68	0	3 months	First occurrence	Acute (< 2 weeks)	Absent
	8DT		70	0	3 years	First occurrence	Subacute (>= 2 weeks)	Absent
	9HD		70	0	6 months	First occurrence	Subacute (>= 2 weeks)	Absent
	9DT		68	0	4 years	First occurrence	Subacute (>= 2 weeks)	Absent
	10HD		72	0	2 months	First occurrence	Acute (< 2 weeks)	Absent
	10DT		65	0	2 years	First occurrence	Subacute (>= 2 weeks)	Absent
	13HD		72	0	5 months	First occurrence	Subacute (>= 2 weeks)	Absent
	13DT		65	0	2 years	First occurrence	Subacute (>= 2 weeks)	Absent
	12HD		67	0	3 months	First occurrence	Acute (< 2 weeks)	Absent
	12DT		65	0	3 years	First occurrence	Subacute (>= 2 weeks)	Absent
14DT		68	0	2 years	First occurrence	Acute (< 2 weeks)	Absent	
15HD		74	0	3 months	First occurrence	Subacute (>= 2 weeks)	Absent	
16DT		68	0	2 years	First occurrence	Subacute (>= 2 weeks)	Absent	
17HD		73	0	5 months	First occurrence	Acute (< 2 weeks)	Absent	
18HD		66	0	4 months	First occurrence	Acute (< 2 weeks)	Absent	
19DT		66	0	3 years	First occurrence	Subacute (>= 2 weeks)	Absent	
20HD		71	0	6 months	First occurrence	Acute (< 2 weeks)	Absent	
12	1HD	Yes			5 months	Chronic condition	Insidious (>= 3 months)	Definitely present
	1DT	Yes			2 months	Chronic condition	Subacute (>= 2 weeks)	Probably present
13	1HD	Yes			3 months	First occurrence	Acute (< 2 weeks)	Definitely present
	1DT		78	0	4 years	Chronic condition	Insidious (>= 3 months)	Probably present
	2HD		94	0	3 weeks	First occurrence	Subacute (>= 2 weeks)	Absent
	2DT		60	2 years	5 months	Chronic condition	Insidious (>= 3 months)	Absent
	3HD		77	2 months	3 weeks	Chronic condition	Subacute (>= 2 weeks)	Absent
	3DT		76	2	3 years	Chronic condition	Insidious (>= 3 months)	Absent
4DT		85		4 years	Similar prev. cond.	Insidious (>= 3 months)	Absent	
14	1HD		63	6 months	2 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	1DT							
15	1HD	Yes			5 months and 3 months	Chronic condition	Insidious (>= 3 months)	Absent
	1DT	Yes	81	6 months	3 months	Chronic condition	Subacute (>= 2 weeks)	Probably present
	2HD	Yes			2 years and 3 months	Chronic condition	Subacute (>= 3 months)	Probably present

920

9550089

4

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBEXETINE - PROTOCOL 20124/035

Listing No.: 2.0

HISTORY OF THE MENTAL DISORDER AND PRESENT EPISODE

Centre	Patient	History of mental disorder		Duration at the time		Present episode		External stress
		Age of onset	No. of episodes last episode	of admission	of admission	Best characterized	Onset was	
15	3HD		0	3 weeks	First occurrence	Subacute (>= 2 weeks)	Probably present	
	4HD	Yes	1	3 weeks	First occurrence	Subacute (>= 2 weeks)	Probably present	
	11HD		1	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present	
	112HD	Yes	2	2 months	First occurrence	Subacute (>= 2 weeks)	Probably present	
16	1HD		0	6 weeks	First occurrence	Subacute (>= 2 weeks)	Absent	
	1DT		1	2 years	Chronic condition	Subacute (>= 2 weeks)	Absent	
	2HD		0	3 weeks	First occurrence	Subacute (>= 2 weeks)	Definitely present	
	2DT		0	1 month	First occurrence	Subacute (>= 2 weeks)	Definitely present	
	3HD		3	3 years	Chronic condition	Insidious (>= 3 months)	Absent	
	3DT		3	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent	
	4HD		1	1 month	Chronic condition	Subacute (>= 2 weeks)	Absent	
	4DT		1	3 months and 3 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent	
17	1HD		1	2 months	Similar prev. cond.	Insidious (>= 3 months)	Definitely present	
	1DT		1	2 months	Chronic condition	Insidious (>= 3 months)	Absent	
	2HD	Yes	1	4 years	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present	
	2DT	Yes	2	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present	
	3HD	Yes	1	2 years and 4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent	
	3DT		1	6 months	Similar prev. cond.	Insidious (>= 3 months)	Probably present	
	4HD		2	2 years	Chronic condition	Insidious (>= 3 months)	Absent	
	4DT		2	1 month	First occurrence	Subacute (>= 2 weeks)	Definitely present	
	21HD		2	8 months	Chronic condition	Subacute (>= 2 weeks)	Definitely present	
	21HD		3	2 months	Different prev. cond.	Subacute (>= 2 weeks)	Probably present	
18	1HD		1	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent	
	1DT	Yes	2	8 weeks	Chronic condition	Insidious (>= 3 months)	Probably present	
	2HD		2	1 year	Similar prev. cond.	Subacute (>= 2 weeks)	Absent	
	2DT		3	2 months	Chronic condition	Subacute (>= 2 weeks)	Absent	
	4HD		2	26 months	Chronic condition	Insidious (>= 3 months)	Absent	
20	3HD		1	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present	
	4HD		1	1 year	Chronic condition	Insidious (>= 3 months)	Definitely present	
22	3HD		0	1 year	First occurrence	Insidious (>= 3 months)	Probably present	
	1HD		0	8 weeks	Chronic condition	Subacute (>= 2 weeks)	Absent	
23	1HD		10	5 months	First occurrence	Insidious (>= 3 months)	Definitely present	
	2HD		1	1 month	Similar prev. cond.	Subacute (>= 2 weeks)	Absent	
	3HD		4	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present	
	4HD		5	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present	
	5HD		3	2 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present	
	6HD		3	2 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present	
25	1HD		0	1 year and 6 months	First occurrence	Subacute (>= 2 weeks)	Probably present	

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

5

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 2.0

HISTORY OF THE MENTAL DISORDER AND PRESENT EPISODE

Centro	Patient	Unknown	History of mental disorder		Duration at the time		Best characterized	Present episode		External stress
			Age of onset	No. of episodes	Duration of last episode	at admission		Onset was	Onset was	
25	2ND		48	2	5 weeks	3 months	Similar prev. cond.	Insidious (>= 3 months)	Insidious (>= 3 months)	Probably present
26	1ND		56	5	4 weeks	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent	Absent
	1DT		62	0		2 years	Chronic condition	Insidious (>= 3 months)	Probably present	Probably present
27	1ND		78	1	3 months	6 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent	Absent
	1ND		66	3	6 months	6 weeks	Chronic condition	Subacute (>= 2 weeks)	Absent	Absent
28	1DT		81	0	3 years	2 years	Chronic condition	Insidious (>= 3 months)	Absent	Absent
	2ND		56	10	2 years	6 months	Chronic condition	Insidious (>= 3 months)	Absent	Absent
29	2DT		78	0		4 months	Chronic condition	Subacute (>= 2 weeks)	Absent	Absent
	3ND		62	2	4 months	6 weeks	Chronic condition	Insidious (>= 3 months)	Absent	Absent
30	3DT		64	1	2 years and 6 months	3 years	Similar prev. cond.	Acute (< 2 weeks)	Absent	Absent
	4ND		72	3	6 months	4 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent	Absent
31	5ND		61	1	12 months	8 weeks	Similar prev. cond.	Acute (< 2 weeks)	Absent	Absent
	1ND		52	2	4 months	4 months	Similar prev. cond.	Acute (< 2 weeks)	Absent	Absent
32	2ND		39	1	9 months	6 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present	Probably present
	3ND	Yes	45	1	3 months	18 months	First occurrence	Insidious (>= 3 months)	Absent	Absent
33	4ND		23	1	3 months	2 months	Similar prev. cond.	Acute (< 2 weeks)	Definitely present	Definitely present
	5ND		23	1	3 weeks	1 year	Similar prev. cond.	Insidious (>= 3 months)	Absent	Absent
34	1ND		18	4	5 months	9 months	Different prev. cond.	Insidious (>= 3 months)	Absent	Absent
	2ND	Yes	78	0		6 months	Chronic condition	Insidious (>= 3 months)	Absent	Absent
35	3ND		76	2	6 months	1 year	Similar prev. cond.	Insidious (>= 3 months)	Absent	Absent
	1ND		63	1	6 weeks	8 weeks	Chronic condition	Subacute (>= 2 weeks)	Absent	Absent
36	2ND		70	0		7 months	First occurrence	Insidious (>= 3 months)	Definitely present	Definitely present
	3ND		47	3	months	5 months	Chronic condition	Insidious (>= 3 months)	Absent	Absent
37	4ND		58	1	1 year	3 years	Chronic condition	Insidious (>= 3 months)	Probably present	Probably present
	5ND		70	2	3 years	2 years and 6 months	Chronic condition	Insidious (>= 3 months)	Definitely present	Definitely present
38	6ND		69	2	3 years	2 years and 6 months	Chronic condition	Insidious (>= 3 months)	Definitely present	Definitely present
	1ND		35	2	3 months	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent	Absent
39	1DT		63	4	10 months	3 months	Chronic condition	Subacute (>= 2 weeks)	Absent	Absent
	2ND		68	4		6 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent	Absent
40	2DT		58	1	6 months	2 months	Chronic condition	Subacute (>= 2 weeks)	Probably present	Probably present
	3ND		66	0		2 months	First occurrence	Insidious (>= 3 months)	Absent	Absent
41	3ND		72	0		6 months	Chronic condition	Insidious (>= 3 months)	Probably present	Probably present
	4ND		90	0		2 months	Chronic condition	Subacute (>= 2 weeks)	Absent	Absent
42	4DT		60	0		6 years	First occurrence	Insidious (>= 3 months)	Probably present	Probably present
	5ND		70	0		8 months	Chronic condition	Insidious (>= 3 months)	Absent	Absent
43	5ND		70	0		8 months	First occurrence	Insidious (>= 3 months)	Probably present	Probably present
	1ND		35	2	3 months	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent	Absent
44	1DT		63	4	10 months	3 months	Chronic condition	Subacute (>= 2 weeks)	Absent	Absent
	2ND		68	4		6 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent	Absent
45	2DT		58	1	6 months	2 months	Chronic condition	Subacute (>= 2 weeks)	Probably present	Probably present
	3ND		66	0		2 months	First occurrence	Insidious (>= 3 months)	Absent	Absent
46	3ND		72	0		6 months	Chronic condition	Insidious (>= 3 months)	Probably present	Probably present
	4ND		90	0		2 months	Chronic condition	Subacute (>= 2 weeks)	Absent	Absent
47	4DT		60	0		6 years	First occurrence	Insidious (>= 3 months)	Probably present	Probably present
	5ND		70	0		8 months	Chronic condition	Insidious (>= 3 months)	Absent	Absent

9550089

9550089

6

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035

Listing No.: 2.0

HISTORY OF THE MENTAL DISORDER AND PRESENT EPISODE

Centre	Patient	Unknown	Age of onset	No episodes	Duration of last episode	Duration at the time of admission	Best characterized	Present episode	Onset was	External stress
35	5DT		70	2	6 months	4 months	Chronic condition	Insidious (>= 3 months)	Insidious (>= 3 months)	Definitely present
	6ND		64	1	5 months	3 months	Similar prev. cond.	Insidious (>= 3 months)	Insidious (>= 3 months)	Probably present
	6DT		30	2	10 months	3 years	Similar prev. cond.	Insidious (>= 3 months)	Insidious (>= 3 months)	Absent
	7ND		49	2	4 months	2 months	Similar prev. cond.	Insidious (>= 3 months)	Insidious (>= 3 months)	Definitely present
	7DT	Yes				3 months	Chronic condition	Insidious (>= 3 months)	Insidious (>= 3 months)	Absent
	8ND		57	2	3 months	4 months	Similar prev. cond.	Insidious (>= 3 months)	Insidious (>= 3 months)	Absent
	8DT		71	1	3 months	7 months	Chronic condition	Insidious (>= 3 months)	Insidious (>= 3 months)	Absent
	36	1ND		63	0		2 weeks	First occurrence	Subacute (>= 2 weeks)	Subacute (>= 2 weeks)
1DT			76	0		2 years	First occurrence	Insidious (>= 3 months)	Insidious (>= 3 months)	Probably present
2ND			65	0		3 months	First occurrence	Insidious (>= 3 months)	Insidious (>= 3 months)	Absent
2DT			62	0		4 years	First occurrence	Insidious (>= 3 months)	Insidious (>= 3 months)	Definitely present
3ND			84	0		2 months	First occurrence	Insidious (>= 3 months)	Insidious (>= 3 months)	Absent
3DT			77	0		3 years	First occurrence	Insidious (>= 3 months)	Insidious (>= 3 months)	Probably present
4ND			72	1	2 months	5 months	Different prev. cond.	Insidious (>= 3 months)	Insidious (>= 3 months)	Definitely present
4DT			72	0		2 years	First occurrence	Subacute (>= 2 weeks)	Subacute (>= 2 weeks)	Probably present
5ND			60	2	3 months	4 years	Similar prev. cond.	Insidious (>= 3 months)	Insidious (>= 3 months)	Probably present
5DT			61	0		5 months	First occurrence	Insidious (>= 3 months)	Insidious (>= 3 months)	Probably present
6ND			65	0		3 years	First occurrence	Insidious (>= 3 months)	Insidious (>= 3 months)	Probably present
6DT			69	0		1 month	First occurrence	Insidious (>= 3 months)	Insidious (>= 3 months)	Probably present
7ND			81	0		6 years	First occurrence	Insidious (>= 3 months)	Insidious (>= 3 months)	Probably present
7DT			65	0		3 weeks	Different prev. cond.	Subacute (>= 2 weeks)	Subacute (>= 2 weeks)	Absent
8DT			77	0		2 years and 6 months	First occurrence	Insidious (>= 3 months)	Insidious (>= 3 months)	Absent
9ND			82	0		2 months	First occurrence	Subacute (>= 2 weeks)	Subacute (>= 2 weeks)	Absent
9DT			62	0		3 years	First occurrence	Insidious (>= 3 months)	Insidious (>= 3 months)	Absent
10ND			75	1	3 months	3 months	Similar prev. cond.	Insidious (>= 3 months)	Insidious (>= 3 months)	Absent
10DT			69	2	2 years	2 years	Similar prev. cond.	Insidious (>= 3 months)	Insidious (>= 3 months)	Absent
11ND			80	1	4 months	1 month	Similar prev. cond.	Insidious (>= 3 months)	Insidious (>= 3 months)	Absent
11DT		74	3	2 months	2 years	Different prev. cond.	Subacute (>= 2 weeks)	Subacute (>= 2 weeks)	Probably present	
12ND		78	0		2 months	First occurrence	Insidious (>= 3 months)	Insidious (>= 3 months)	Absent	
12DT		78	0		3 years	First occurrence	Insidious (>= 3 months)	Insidious (>= 3 months)	Absent	
13ND		76	0		1 month	First occurrence	Subacute (>= 2 weeks)	Subacute (>= 2 weeks)	Absent	
14ND		57	2	2 months	2 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Subacute (>= 2 weeks)	Probably present	
15ND		40	2	1 month	2 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Subacute (>= 2 weeks)	Probably present	
16ND		71	1	2 months	3 months	Similar prev. cond.	Insidious (>= 3 months)	Insidious (>= 3 months)	Probably present	
17ND		80	0		4 weeks	First occurrence	Subacute (>= 2 weeks)	Subacute (>= 2 weeks)	Absent	
18ND		78	1	6 weeks	3 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Subacute (>= 2 weeks)	Absent	
19ND		81	0		2 months	First occurrence	Subacute (>= 2 weeks)	Subacute (>= 2 weeks)	Probably present	
20ND		61	3	1 month	3 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Subacute (>= 2 weeks)	Probably present	
37	3ND		35	1	3 months	3 months	Different prev. cond.	Insidious (>= 3 months)	Insidious (>= 3 months)	Absent
	41	1ND		69	0		4 months	First occurrence	Subacute (>= 2 weeks)	Absent
2ND			66	0		3 weeks	Subacute (>= 2 weeks)	Subacute (>= 2 weeks)	Absent	
3ND			84	1	8 months and 1 day	6 weeks and 3 days	Similar prev. cond.	Subacute (>= 2 weeks)	Absent	
4ND			59	3	3 months and 1 week	3 weeks and 3 days	Chronic condition	Subacute (>= 2 weeks)	Probably present	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

7

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No.: 2.0

HISTORY OF THE MENTAL DISORDER AND PRESENT EPISODE

Centre	Patient	Unknown	History of mental disorder		Duration at the time		Best characterized	Present episode		External stress
			Age of onset	No. of episodes last episode	of admission	of admission		Onset was	Onset was	
41	5ND		67	1	14 months	18 days	Similar prev. cond.	Acute (< 2 weeks)	Acute (< 2 weeks)	Probably present
42	1ND		40	2	6 months	9 months	Similar prev. cond.	Insidious (>= 3 months)	Insidious (>= 3 months)	Absent
	1DT		38	8	1 year and 9 months	3 years and 7 months	Similar prev. cond.	Insidious (>= 3 months)	Insidious (>= 3 months)	Probably present
	2ND		38	4	3 years and 4 months	3 years and 8 months	Similar prev. cond.	Insidious (>= 3 months)	Insidious (>= 3 months)	Definitely present
	2DT		56	2	8 months	2 years and 2 weeks	Chronic condition	Insidious (>= 3 months)	Insidious (>= 3 months)	Probably present
	3ND		68	4	9 months and 2 weeks	5 months and 2 weeks	Similar prev. cond.	Insidious (>= 3 months)	Insidious (>= 3 months)	Absent
43	1DT		77	0	3 months	8 weeks	First occurrence	Subacute (>= 2 weeks)	Subacute (>= 2 weeks)	Definitely present
	2DT		71	1	3 months	2 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Subacute (>= 2 weeks)	Probably present
	3DT		72	10	weeks	10 weeks	First occurrence	Acute (< 2 weeks)	Acute (< 2 weeks)	Absent
	4DT		63	2	1 year	5 months	Similar prev. cond.	Subacute (>= 2 weeks)	Subacute (>= 2 weeks)	Absent
	5ND		50	1	6 months	2 months	Similar prev. cond.	Acute (< 2 weeks)	Acute (< 2 weeks)	Probably present
	6ND		69	2	7 months	3 months	Similar prev. cond.	Subacute (>= 2 weeks)	Subacute (>= 2 weeks)	Absent
44	1ND		50	2	10 weeks	14 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Subacute (>= 2 weeks)	Absent
	1DT		56	4	weeks	3 years	Chronic condition	Subacute (>= 2 weeks)	Subacute (>= 2 weeks)	Absent
	2ND		37	6	3 months	5 months	Chronic condition	Insidious (>= 3 months)	Insidious (>= 3 months)	Absent
	3ND		52	10	3 months	7 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Subacute (>= 2 weeks)	Absent
	4ND		45	8	2 months	2 years	Similar prev. cond.	Insidious (>= 3 months)	Insidious (>= 3 months)	Definitely present
	1ND	Yes	77	1	4 weeks	3 weeks	First occurrence	Subacute (>= 2 weeks)	Subacute (>= 2 weeks)	Probably present
45	1DT	Yes				2 years	First occurrence	Insidious (>= 3 months)	Insidious (>= 3 months)	Absent
	2ND	Yes				3 weeks	Chronic condition	Subacute (>= 2 weeks)	Subacute (>= 2 weeks)	Absent
46	1ND		68	0	14 months	14 months	First occurrence	Insidious (>= 3 months)	Insidious (>= 3 months)	Probably present
	2ND		68	1	6 months	2 months	Similar prev. cond.	Insidious (>= 3 months)	Insidious (>= 3 months)	Absent
	3ND		28	6	4 months	6 months	Similar prev. cond.	Insidious (>= 3 months)	Insidious (>= 3 months)	Probably present
	4ND		74	1	6 months	3 months	Similar prev. cond.	Insidious (>= 3 months)	Insidious (>= 3 months)	Absent
48	1DT		73	0	4 months	4 months	First occurrence	Insidious (>= 3 months)	Insidious (>= 3 months)	Definitely present
	2DT		65	1	2 months	3 months	Similar prev. cond.	Insidious (>= 3 months)	Insidious (>= 3 months)	Definitely present
291	1ND		45	3	2 years	6 weeks	Chronic condition	Subacute (>= 2 weeks)	Subacute (>= 2 weeks)	Absent
	1DT		71	12	8 months	2 years	Chronic condition	Subacute (>= 2 weeks)	Subacute (>= 2 weeks)	Absent
	2ND		66	1	4 months	2 years	Similar prev. cond.	Subacute (>= 2 weeks)	Subacute (>= 2 weeks)	Absent
	2DT		58	2	years	12 months	Chronic condition	Subacute (>= 2 weeks)	Subacute (>= 2 weeks)	Absent
	3ND		63	1	6 months	8 weeks	Similar prev. cond.	Insidious (>= 3 months)	Insidious (>= 3 months)	Absent
	3DT		63	5	3 months	6 months	Chronic condition	Insidious (>= 3 months)	Insidious (>= 3 months)	Absent
	4ND	Yes	58	1	6 months	2 years	Chronic condition	Insidious (>= 3 months)	Insidious (>= 3 months)	Absent
	4DT		81	1	6 months	2 years	Chronic condition	Insidious (>= 3 months)	Insidious (>= 3 months)	Absent
	25DT		78	0		2 years	Chronic condition	Insidious (>= 3 months)	Insidious (>= 3 months)	Absent
	26DT		79	0		2 years	Chronic condition	Insidious (>= 3 months)	Insidious (>= 3 months)	Absent

9550089

8

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS 8&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 2.0

HISTORY OF THE MENTAL DISORDER AND PRESENT EPISODE

Contro	Patient	Unknown	History of mental disorder		Duration at the time of admission	Best characterized	Present episode		External stress
			Age of onset	No. of episodes last episode			Onset was	Onset was	
291	27DT		80	2	2 years	Chronic condition	Subacute (>= 2 weeks)	Absent	
	28DT		65	2	2 years	Chronic condition	Insidious (>= 3 months)	Absent	
	5ND		73	0	6 weeks	First occurrence	Subacute (>= 2 weeks)	Definitely present	
	5DT		76	3	3 years	First occurrence	Insidious (>= 3 months)	Probably present	
	6ND		71	7	7 weeks	First occurrence	Subacute (>= 2 weeks)	Definitely present	
	6DT		66	3	3 years	First occurrence	Insidious (>= 3 months)	Definitely present	
	7ND		81	7	7 weeks	First occurrence	Subacute (>= 2 weeks)	Probably present	
	7DT		64	4	4 years	First occurrence	Insidious (>= 3 months)	Definitely present	
	8ND		67	6	6 weeks	First occurrence	Subacute (>= 2 weeks)	Absent	
	8DT		70	3	3 years	First occurrence	Insidious (>= 3 months)	Definitely present	
292	21ND		67	1	4 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent	
	21DT		75	0	4 years	First occurrence	Insidious (>= 3 months)	Definitely present	
	22ND		67	0	6 weeks	First occurrence	Subacute (>= 2 weeks)	Definitely present	
	22DT		74	0	3 years	First occurrence	Insidious (>= 3 months)	Absent	
	23ND		75	0	6 weeks	First occurrence	Subacute (>= 2 weeks)	Probably present	
	23DT		67	0	20 months	Chronic condition	Insidious (>= 3 months)	Probably present	
	24ND	Yes			30 months	Chronic condition	Subacute (>= 2 weeks)	Definitely present	
	24DT		65	3	3 years	Chronic condition	Insidious (>= 3 months)	Definitely present	
	9ND		75	3	3 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent	
	9DT		60	4	4 months	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present	
293	10ND		60	3	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent	
	10DT		58	3	1 year	Similar prev. cond.	Subacute (>= 2 weeks)	Absent	
	11ND		58	4	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Absent	
	11DT		59	3	1 year	Similar prev. cond.	Subacute (>= 2 weeks)	Absent	
	12ND		47	4	1 year	Similar prev. cond.	Subacute (>= 2 weeks)	Absent	
	12DT		58	5	2 years and 6 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent	
	13ND		78	1	1 month	Similar prev. cond.	Insidious (>= 3 months)	Absent	
	13DT		58	3	2 years and 6 months	Similar prev. cond.	Insidious (>= 3 months)	Definitely present	
	14ND	Yes			6 weeks	First occurrence	Subacute (>= 2 weeks)	Definitely present	
	14DT		71	2	2 years and 6 months	Chronic condition	Insidious (>= 3 months)	Probably present	
294	15ND		81	2	2 months and 2 weeks	Chronic condition	Subacute (>= 2 weeks)	Definitely present	
	15DT		72	3	3 years	Chronic condition	Insidious (>= 3 months)	Absent	
	16ND		61	1	6 months	Chronic condition	Subacute (>= 2 weeks)	Definitely present	
	16DT		76	2	2 months and 2 weeks	Chronic condition	Insidious (>= 3 months)	Absent	
	25ND		71	0	3 years and 4 months	Chronic condition	Insidious (>= 3 months)	Probably present	
	26ND		75	0	3 months and 3 weeks	First occurrence	Insidious (>= 3 months)	Absent	
	27ND		66	4	4 months	First occurrence	Insidious (>= 3 months)	Probably present	
	27DT		76	2	2 years and 2 months	Similar prev. cond.	Insidious (>= 3 months)	Definitely present	
	28ND		77	0	2 years and 4 months	Chronic condition	Insidious (>= 3 months)	Absent	
	28DT		77	0	2 years and 4 months	Chronic condition	Insidious (>= 3 months)	Definitely present	
31DT		78	0	2 years	Chronic condition	Insidious (>= 3 months)	Absent		
32DT		71	0	2 years	Chronic condition	Insidious (>= 3 months)	Absent		

9 23 31

PHARMACIA CNS RED
 RECONQUETE - FORTOCEL, 20124/035
 Listing No. 1. 2.0

HISTORY OF THE NEURAL DISORDER AND PRESENT EPISODE

Centre	Patient	History of neural disorder		Duration at the time of admission	Present episode		External stress
		Age of onset	No. of episodes		Best characterized	Quart was	
235	170D	Unknown	47	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Probably present
	170T	Unknown	60	3, 16 months	Chronic condition	Insidious (>= 3 months)	Definitely present
	180D	Unknown	53	4 weeks	Similar prev. cond.	Subacute (>= 2 weeks)	Definitely present
	180T	Unknown	60	4, 4 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	190D	Unknown	60	1 month	Chronic condition	Insidious (>= 3 months)	Absent
	190T	Unknown	55	10, 6 months	Chronic condition	Insidious (>= 3 months)	Probably present
	280D	Unknown	60	10, 4 months	Chronic condition	Insidious (>= 3 months)	Absent
280T	280D	Unknown	10	4 weeks	Similar prev. cond.	Insidious (>= 3 months)	Definitely present
	280T	Unknown	58	7, 6 months	Similar prev. cond.	Insidious (>= 3 months)	Definitely present
381	10D	Unknown	86	2 weeks	First occurrence	Subacute (>= 2 weeks)	Definitely present
	20D	Unknown	67	0	First occurrence	Insidious (>= 3 months)	Definitely present
	30T	Unknown	20	0	Chronic condition	Insidious (>= 3 months)	Definitely present
	40D	Yes	58	0	First occurrence	Insidious (>= 3 months)	Definitely present
382	50D	Unknown	73	1 year	Similar prev. cond.	Insidious (>= 3 months)	Absent
	50T	Yes	74	48 years	Chronic condition	Subacute (>= 2 weeks)	Probably present
	60D	Unknown	77	12 weeks	Diffuse prev. cond.	Subacute (>= 2 weeks)	Probably present
	60T	Unknown	76	2 weeks and 6 months	First occurrence	Insidious (>= 3 months)	Probably present
	70D	Unknown	86	6 months	Chronic condition	Insidious (>= 3 months)	Probably present
	70T	Unknown	80	0	Chronic condition	Insidious (>= 3 months)	Absent
	80D	Yes	80	3 months	First occurrence	Insidious (>= 3 months)	Absent
	80T	Yes	80	5 years	Chronic condition	Insidious (>= 3 months)	Absent
	90D	Yes	85	3 months	Chronic condition	Insidious (>= 3 months)	Probably present
	100D	Yes	85	4 months	First occurrence	Insidious (>= 3 months)	Definitely present
3301	10D	Unknown	63	4 months	Similar prev. cond.	Subacute (>= 2 weeks)	Absent
	20D	Unknown	65	2 months	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	30D	Unknown	69	1, 4 months	Similar prev. cond.	Insidious (>= 3 months)	Probably present
3302	50D	Unknown	51	2, 6 weeks	Similar prev. cond.	Insidious (>= 3 months)	Absent
	60D	Unknown	51	2, 3 months	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	60D	Unknown	51	2, 3 months	Similar prev. cond.	Insidious (>= 3 months)	Probably present
	70D	Unknown	93	1 week	First occurrence	Subacute (>= 2 weeks)	Probably present

9550089

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

1

PHARMACIA CNS R2D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 3.0

- A. At least five of the following symptoms have been present during the same two-week period and represent a change from previous functioning: at least one of the symptoms is either 1) depressed mood or 2) loss of interest or pleasure.
- 1) depressed mood most of the day, nearly every day, as indicated by subjective account or observation by others
 - 2) markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day (as indicated either by subjective account or observation by others of apathy most of the time)
 - 3) significant weight loss or weight gain when not dieting (e.g. more than 5% of body weight in a month), or decrease or increase in appetite nearly every day
 - 4) insomnia or hypersomnia nearly every day
 - 5) psychomotor agitation or retardation nearly every day (observable by others, not merely subjective feelings of restlessness or being slowed down)
 - 6) fatigue or loss of energy nearly every day
 - 7) feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) nearly every day (not merely self-reproach or guilt about being sick)
 - 8) diminished ability to think or concentrate, or indecisiveness, nearly every day (either by subjective account or as observed by others)
 - 9) recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide
- B. 1) it cannot be established that an organic factor initiated and maintained the disturbance
2) the disturbance is not a normal reaction to the death of a loved one
- C. At no time during the disturbance have there been delusions or hallucinations for as long as two weeks in the absence of prominent mood symptoms (i.e., before the mood symptoms developed or after they have remitted)
- D. Not superimposed on Schizophrenia, Schizophreniform, Disorder, Delusional Disorder, or Psychotic Disorder NOS.

9 13 1

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

2

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 3.0

DMS-III-R: DIAGNOSTIC CRITERIA FOR MAJOR DEPRESSIVE EPISODE

Centro	Patient	Sex	Age	DSM-III-R	A - Items									B - Items		C - Present		D - Present	
					1)	2)	3)	4)	5)	6)	7)	8)	9)	1)	2)	Present	Present	Present	Present
8	2ND	Female	69	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	3ND	Female	72	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	4ND	Male	70	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	701ND	Male	70	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	702ND	Male	70	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	703ND	Female	71	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
704ND	Female	76	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	
9	1ND	Female	71	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2ND	Female	66	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	4ND	Female	65	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	5ND	Female	70	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	7ND	Female	69	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
10	1ND	Female	67	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2ND	Male	64	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	3ND	Male	70	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	4ND	Female	72	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	5ND	Female	73	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	6ND	Male	70	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	7ND	Male	69	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	8ND	Male	68	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	9ND	Female	70	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	10ND	Female	72	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
12	1ND	Female	84	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2ND	Female	80	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	3ND	Female	94	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	4ND	Male	79	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	5ND	Female	81	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	6ND	Female	81	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
15	1ND	Female	77	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2ND	Female	84	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	3ND	Female	83	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	4ND	Female	86	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X

929

9550089

3

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 3.0
DMS-III-R: DIAGNOSTIC CRITERIA FOR MAJOR DEPRESSIVE EPISODE

Centre	Patient	Sex	Age	DSM-III-R	A - Items									B - Items		C		D	
					Present	1)	2)	3)	4)	5)	6)	7)	8)	9)	Present	1)	2)	Present	Present
15	11ND	Female	65	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	112ND	Female	84	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
16	1ND	Female	85	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2ND	Male	72	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	3ND	Female	68	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	4ND	Female	75	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
17	1ND	Female	71	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2ND	Female	87	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	3ND	Female	74	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	4ND	Female	65	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	211ND	Female	70	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
18	1ND	Female	81	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2ND	Female	68	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	3ND	Female	82	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	4ND	Female	73	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
20	3ND	Female	80	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
22	1ND	Female	81	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
23	1ND	Female	71	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2ND	Female	69	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	3ND	Female	80	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	4ND	Female	80	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	5ND	Female	69	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	6ND	Female	72	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
25	1ND	Male	68	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2ND	Female	67	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
26	1ND	Female	69	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
27	1ND	Male	79	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
28	1ND	Female	70	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2ND	Female	86	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	3ND	Female	66	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X

9550089

4

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 3.0

DMS-III-R: DIAGNOSTIC CRITERIA FOR MAJOR DEPRESSIVE EPISODE

Centre	Patient	Sex	Age	DSM-III-R	A - Items									B - Items		C		D					
					Present	1)	2)	3)	4)	5)	6)	7)	8)	9)	Present	1)	2)	Present	1)	2)	Present	1)	2)
28	4HD	Male	87	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	
	5HD	Female	66	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
30	1HD	Female	87	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2HD	Female	74	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	3HD	Female	86	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	4HD	Female	78	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	5HD	Female	75	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
31	1HD	Female	76	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2HD	Female	79	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
32	3HD	Male	84	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	4HD	Female	66	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
35	1HD	Female	71	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2HD	Female	72	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	3HD	Female	66	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	4HD	Male	90	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	5HD	Male	70	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
36	6HD	Female	69	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	7HD	Female	74	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	8HD	Female	74	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	9HD	Male	83	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	10HD	Male	65	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	11HD	Female	84	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	12HD	Female	79	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	13HD	Female	65	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	14HD	Female	81	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	15HD	Female	67	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	16HD	Male	82	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	17HD	Male	77	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	18HD	Female	81	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	19HD	Female	78	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	20HD	Male	76	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	21HD	Male	70	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
22HD	Female	73	296.5	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	
23HD	Female	72	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	

931

9550089

5

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 3.0

DMS-III-R: DIAGNOSTIC CRITERIA FOR MAJOR DEPRESSIVE EPISODE

Centre	Patient	Sex	Age	DSM-III-R	A Items									B Items		C		D	
					Present	1)	2)	3)	4)	5)	6)	7)	8)	9)	Present	1)	2)	Present	Present
36	17HD	Female	80	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	18HD	Female	78	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	20HD	Female	70	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
37	3HD	Female	81	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	41	Male	69	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
42	2HD	Male	68	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	3HD	Male	85	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	4HD	Male	74	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	5HD	Male	69	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
43	1HD	Female	73	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2HD	Female	79	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
44	1DT	Female	77	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2DT	Female	77	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	3DT	Male	72	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	4DT	Female	79	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	5HD	Female	70	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	6HD	Female	74	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
45	1HD	Female	76	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2HD	Female	73	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
46	1HD	Male	69	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2HD	Female	72	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	3HD	Female	73	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	4HD	Female	78	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
48	1DT	Female	74	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2DT	Female	65	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
291	1HD	Female	80	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X

932

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 3.0
 DMS-III-R: DIAGNOSTIC CRITERIA FOR MAJOR DEPRESSIVE EPISODE

Centre	Patient	Sex	Age	DSM-III-R	A - Items									B - Items		C		D	
					Present	1)	2)	3)	4)	5)	6)	7)	8)	9)	Present	1)	2)	Present	Present
3501	1HD	Female	76	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2HD	Male	85	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	3HD	Female	71	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
3502	5HD	Female	84	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	6HD	Female	73	296.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	7HD	Female	93	296.2	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

1

PHARMACIA CNS RSD

REBOXETINE - PROTOCOL 20124/035
Listing No.: 3.1

- A. Depressed mood for most of the day, more days than not, as indicated either by subjective account or observation by others, for at least two years.
- B. Presence, while depressed, of at least two of the following:
 - 1) poor appetite or overeating
 - 2) insomnia or hypersomnia
 - 3) low energy or fatigue
 - 4) low self-esteem
 - 5) poor concentration or difficulty making decisions
 - 6) feeling of hopelessness
- C. During a two-year period of the disturbance, never without the symptoms in A for more than two months at a time.
- D. No evidence of an unequivocal Major Depressive Episode during the first two years of the disturbance.
- E. Has never had a Manic Episode or an unequivocal Hypomanic Episode.
- F. Not superimposed on a chronic psychotic disorder, such as Schizophrenia or Delusional Disorder.
- G. It cannot be established that an organic factor initiated and maintained the disturbance, e.g., prolonged administration of an antihypertensive medication.

935

9550089

3

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 3.1

DSM-III-R: DIAGNOSTIC CRITERIA FOR DYSTHYMIA

Centre	Patient	Sex	Age	DSM-III-R	A						B								
					Pre	son	t	1	2	3	4	5	6	Present	Present	Present	Present		
10	15DT	Female	70	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	14DT	Female	69	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	16DT	Male	70	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
12	19DT	Male	69	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	1DT	Female	85	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	1DT	Female	82	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
13	2DT	Female	76	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	3DT	Female	79	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	4DT	Female	89	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
15	1DT	Female	86	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2DT	Female	89	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
16	1DT	Female	74	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2DT	Male	71	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	3DT	Female	75	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
17	1DT	Female	81	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2DT	Female	76	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	3DT	Male	79	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	211DT	Female	83	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
18	1DT	Female	80	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2DT	Female	71	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
26	1DT	Female	68	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
28	1DT	Female	91	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	3DT	Male	69	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
31	1DT	Female	77	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
35	1DT	Female	69	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	3DT	Male	74	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X

937

9550089

4

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REMOXTINE - PROTOCOL 20124/035
 Listing No.: 3.1
 DHS-III-R: DIAGNOSTIC CRITERIA FOR DYSTHIMIA

Centro	Patient	Sex	Age	DSM-III-R	t	B						C		D		E		F		G	
						A ₁	A ₂	A ₃	A ₄	A ₅	A ₆	Present	Present	Present	Present	Present	Present	Present	Present	Present	Present
35	4DT	Female	65	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	5DT	Female	77	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	6DT	Female	69	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	8DT	Female	78	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
36	1DT	Female	78	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2DT	Female	66	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	3DT	Female	80	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	4DT	Female	74	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	5DT	Female	65	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	6DT	Female	72	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	7DT	Female	75	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	8DT	Female	80	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	9DT	Female	65	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	10DT	Male	79	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	11DT	Male	78	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	12DT	Female	81	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
42	1DT	Female	79	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2DT	Male	68	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
44	1DT	Female	76	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	1DT	Female	79	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
291	1DT	Female	81	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	2DT	Female	73	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	3DT	Female	73	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	4DT	Male	87	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	25DT	Female	80	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	26DT	Female	81	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	27DT	Female	88	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	28DT	Female	73	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
292	5DT	Male	79	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	6DT	Female	69	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	7DT	Male	68	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	8DT	Female	73	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	21DT	Female	79	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	23DT	Female	81	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
24DT	Male	69	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	
24DT	Female	68	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	

9550089

5

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 3.1
 DNS-III-R: DIAGNOSTIC CRITERIA FOR DYSTONIA

Centre	Patient	Sex	Age	DSM-III-R	t	B						C		D		E		F		G	
						Pre	Pro	sen	sun	1)	2)	3)	4)	5)	6)	Present	Present	Present	Present	Present	Present
293	90T	Female	67	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	100T	Female	66	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	110T	Female	68	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	120T	Female	69	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
294	130T	Female	68	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	140T	Female	73	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	150T	Female	75	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	160T	Female	81	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	290T	Female	80	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	300T	Female	79	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	310T	Female	80	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
320T	Male	73	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	
295	170T	Male	65	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	180T	Female	71	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	190T	Female	69	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
381	30T	Female	77	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
382	50T	Male	63	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	60T	Female	79	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	70T	Male	82	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	80T	Female	86	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	90T	Female	78	300.4	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X

939

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 4
 MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS
 Centre Patient Sex Age Medical history / Admission examination

1	1ND	Female	76	HYPERTENSION NOS ALLERGIC RHINITIS NOS SLEEP DISTURBANCES HEADACHE
	1DT	Male	78	ONS-SUSP CARDIOVASC DIS EATING DISORDERS NEC/NOS ECTROPION DIAPHRAGMATIC HERNIA DIVERTICULA SM INTESTINE CHOLELITH N AC CHOLECIST ESOPHAGITIS ARTROPATHY NOS ANOREXIA NERVOSA UNUSUAL LOSS OF WEIGHT NAUSEA AND VOMITING
	2ND	Male	65	SLEEP DISTURBANCES
	2DT	Male	73	SLEEP DISTURBANCES TOX EFF NONMED SUBST NEC
	3ND	Female	65	OBESITY RHEUM FEV N/O HRT INVOLV HYPERTENSION NOS ACUTE TONSILLITIS SLEEP DISTURBANCES
	3DT	Male	68	HYPERTENSION NOS SLEEP DISTURBANCES
	4ND	Female	76	LIPOMA ANEMIA NOS SPECIAL SYMPTOM NEC/NOS DIVERTICULA OF COLON SLEEP DISTURBANCES
	4DT	Male	74	ONS-SUSP CARDIOVASC DIS LEFT BB BLOCK NEC
2	1ND	Male	71	ANXIETY STATES ALCOHOL DEPENDENCE SYNDR HYPERTENSION NOS CONSTIPATION HEADACHE

9550089

2

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 4

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre Patient Sex Age Medical History / Admission examination

3	1MD	Female	71	HYPERTENSION NOS CHRONIC BRONCHITIS NOS SLEEP DISTURBANCES COUGH
4	1MD	Male	74	MALIGNANT NEO COLON NOS GOUT NOS SLEEP DISTURBANCES
5	1MD	Female	83	OTHER GU NEOPLASM NOS PARALYSLA NOS HYPERTENSION NOS CONSTIPATION SLEEP DISTURBANCES
	1DT	Female	68	REN NEO GI TRACT NEC/NOS STOMACH ULCER NOS DIAPHRAGMATIC HERNIA CONSTIPATION CHOLELITHIASIS NOS PROLAPSE OF VAGINAL WALL UTERINE PROLAPSE ABN INVOLUN MOVEMENT NEC CONCUSSION
	2ND	Male	78	INTESTINAL BYPASS STATUS OTH MALIGN NEO GI/PERITON MALIGN NEOPL PROSTATE DIGESTIVE NEOPLASM NOS ACUTE MYOCARDIAL INFARCT CARDIAC DYSRHYTHIA NOS STOMACH ULCER NOS APPENDICITIS NOS FEMORAL HERNIA CONSTIPATION SYNCOPE AND COLLAPSE SLEEP DISTURBANCES NAUSEA AND VOMITING
	2DT	Female	90	ORB-SUSP CARDIOVASC DIS
	3DT	Male	74	HYPERTENSION NOS CEREBROVASC DISEASE NOS

941

9550089

3

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Centre	Patient	Sex	Age	Medical history / Admission examination
5	4MD	Male	80	URINOSTOMY STATUS NEC MALIGN NEOPL KIDNEY OSTEOARTHRITIS NOS SPONDYLOSIS NOS SLEEP DISTURBANCES
	4DT	Male	81	OBES-SUSP CARDIOVASC DIS HYPERTENSION NOS CHG ISCHERIC HRT DIS NOS CARDIAC DYSRHYTHMIA NOS TRANSIENT CEREB ISCHERIA
	5DT	Female	66	EXTREMITY DIS NEC/NOS RHEUMATOID ARTHRITIS URIN TRACT INFECTION NOS
	6MD	Female	69	HEART DISEASE NOS
	6DT	Female	70	IRRITABLE COLON SLEEP DISTURBANCES
	7DT	Female	65	CEREBROVASC DISEASE NOS APPENDICITIS NOS
	8MD	Female	68	HYPERTENSION NOS SLEEP DISTURBANCES
	8DT	Female	66	OTHER GU NEOPLASM NOS CALCULUS OF KIDNEY FEMALE CLIMACTERIC STATE OSTEOARTHRITIS NOS
	9DT	Female	77	OBES-SUSP CARDIOVASC DIS HYPERTENSION NOS FX UPPER HUMERUS-CLOSED FX NECK OF FEMUR NOS-CL
	11DT	Female	70	FACIAL NERVE DIS NOS CHOLELITHIAS NOS SLEEP DISTURBANCES
	12MD	Female	66	CARDIAC DYSRHYTHMIA NEC

942

9550089

4

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D	
REBOXETINE - PROTOCOL 20124/035	
Listing No.: 4	
MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS	
Centre	Patient Sex Age Medical history / Admission examination
5	12DT Male 80 OBS-SUSP CARDIOVASC DIS GOUT NOS HYPERTENSION NOS
6	1ND Female 70 SLEEP DISTURBANCES
	1DT Female 72 SLEEP DISTURBANCES
	2ND Female 70 ASN BLOOD CHEMISTRY NEC SLEEP DISTURBANCES
	3ND Female 68 DIABETES MELLITUS UNCOMP CHOLELITHIASIS NOS SLEEP DISTURBANCES
	3DT Female 65 HYPERTENSION NOS DIZZINESS AND GIDDINESS SLEEP DISTURBANCES PALPITATIONS
	4ND Female 71 SLEEP DISTURBANCES
	4DT Female 69 URIN TRACT INFECTION NOS DIZZINESS AND GIDDINESS SLEEP DISTURBANCES
	5ND Female 71 PERIPH VASCULAR DIS NOS SLEEP DISTURBANCES
	5DT Female 68 HYPERLIPIDEMIA NEC/NOS HYPERTENSION NOS TRANSIENT CEREB ISCHEMIA SLEEP DISTURBANCES
	6ND Female 77 CER LYMPHOCYT THYROIDIT PERNICIOUS ANEMIA SLEEP DISTURBANCES EDEMA

943

9550089

5

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 4

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre Patient Sex Age Medical History / Admission examination

6	7ND	Female	70	HYPERTENSION NOS SLEEP DISTURBANCES
	8ND	Female	74	HYPERTENSION NOS SLEEP DISTURBANCES
7	1ND	Male	66	SPECIAL SYMPTOM NEC/NOS CONSTIPATION SLEEP DISTURBANCES
	3ND	Female	67	MIGRAINE NOS PAINFUL ORGANSIM NOS STOMACH ULCER NOS GASTRITIS/RODENTITIS NOS SLEEP DISTURBANCES
	4ND	Female	74	DIABETES MELLITUS UNCOMP CARDIAC DYSRHYTHIA NOS SLEEP DISTURBANCES
	34-2ND	Female	67	SLEEP DISTURBANCES
8	1ND	Female	68	INTESTINAL BYPASS STATUS ESOPHAGITIS
	1DT	Female	83	HEART DISEASE NOS CONSTIPATION GENERAL OSTEOARTROSIS SLEEP DISTURBANCES
	2ND	Female	69	ANGINA PECTORIS HEART DISEASE NOS VARICOSE VEIN OF LEG NOS GENERAL OSTEOARTROSIS
	2DT	Female	89	CIRCULATORY DISEASE NOS
	3ND	Female	72	MAL NEO BRONCH/LUNG NOS OTH AC ISCHEMIC HRT DIS CONGESTIVE HEART FAILURE

944

9550089

6

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REMOXTIME - PROTOCOL 20124/035
 Listing No.: 4
 MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre	Patient	Sex	Age	Medical history / Admission examination
8	3DT	Female	78	PARALYSIS AGITANS HYPERTENSIVE HRT DIS NOS OLD MYOCARDIAL INFARCT
	4DT	Female	72	OLD MYOCARDIAL INFARCT ESOPHAGITIS SLEEP DISTURBANCES EDEMA
	701ND	Male	70	ABN INVOLIN MOVEMENT NEC REACTIVE CONFUSION SLEEP DISTURBANCES
	701DT	Female	74	DIABETES MELLITUS UNCOMP OBESITY NEUROPATHY IN DIABETES SLEEP DISTURBANCES
	702ND	Male	70	URINGSITOMY STATUS NEC HYPERPLASIA OF PROSTATE SLEEP DISTURBANCES
	702DT	Female	88	GLAUCOMA NOS
	703ND	Female	71	HYPOTENSION NOS SLEEP DISTURBANCES
	703DT	Male	79	ESOPHAGITIS DIAPHRAGMATIC HERNIA
	704ND	Female	76	HYPERTENSION NOS ACUTE MYOCARDIAL INFARCT CHR ISCHERIC HRT DIS NOS
	704DT	Female	67	DIABETES MELLITUS UNCOMP DIZZINESS AND GIDDINESS
9	2ND	Female	66	ANOREXIA

9550089

7

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D	
REBOXETINE - PROTOCOL 20124/035	
Listing No.: 4	
MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS	
Centre	Patient Sex Age Medical history / Admission examination
9	6ND Female 65 SLEEP DISTURBANCES
12	1ND Female 84 OBS-SUSP CARDIOVASC DIS ANXIETY STATES PARALYSIS ACITANS SLEEP DISTURBANCES ABDOMINAL PAIN TRANSCEVRY FX FEMUR-CLOSE
13	1DT Female 85 OBS-SUSP CARDIOVASC DIS DIABETES MELLITUS UNCOMP PARALYSIS ACITANS SLEEP DISTURBANCES TRANSCEVRY FX FEMUR-CLOSE
13	1ND Female 80 IDIO PERIPH NEURPHY NOS
13	1DT Female 82 HYPERTENSION NOS ARTEROPATHY NOS CARPAL FRACTURE FX NECK OF FEMUR NOS-CL
2ND	Female 94 HYPERTENSION NOS CONSTIPATION SLEEP DISTURBANCES FX FEMUR SHAFT/NOS-CLOSE
2DT	Female 76 ANXIETY STATES GIANT CELL ARTERITIS HEPATITIS NOS PURE HYPERCHOLESTEROLEM PAIN IN JOINT CERVICAL DISC DISPLACMNT
3ND	Male 79 ANXIETY STATES HYPERTENSION NOS CONSTIPATION SLEEP DISTURBANCES
3DT	Female 79 ANXIETY STATES HYPERTENSION NOS ASCUD VERTEBRAL ART OCCLUSION TRANSIENT CEREB ISCHEMIA

9550089

8

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Centre	Patient	Sex	Age	Medical history / Admission examination
13	3DT	Female	79	CONSTIPATION DIZZINESS AND GIDDINESS
	4DT	Female	89	HYPERTENSION NOS CEREBROVASC DISEASE NOS CONSTIPATION SLEEP DISTURBANCES
14	1MD	Female	81	BENIGN NEO CORPUS UTERI CONGEN HIP DISLOCATION
15	1MD	Female	77	SPINAL CORD DISEASE NOS STOMACH ULCER NOS PRURITIC DISORDER NOS OSTEOPOROSIS NOS SLEEP DISTURBANCES MALAISE AND FATIGUE
	1DT	Female	86	GOITER NOS HYPOTHYROIDISM NOS HYPOHYPEREMIA PARAPLEGIA NOS HYPERTENSION NOS CHR ISCHEMIC HRT DIS NOS ARTERIAL DISEASE NOS
	2MD	Female	84	HEMIPLEGIA NOS HYPERTENSION NOS ANGINA PECTORIS CHR ISCHEMIC HRT DIS NOS CVA CHOLELITHIASIS NOS SLEEP DISTURBANCES
	2DT	Female	89	ORS-SUSP CARDIOVASC DIS ANXIETY STATES HEMIPLEGIA NOS HYPERTENSION NOS HEPOTENSIO NOS HEPOTENSIO NOS CIRCULATORY DISEASE NOS BACKACHE NOS
	3MD	Female	83	CARDIAC PACEMAKER STATUS HYPERTENSION NOS ANGINA PECTORIS CHR ISCHEMIC HRT DIS NOS

9550089

9

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 4
 MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS
 Centre Patient Sex Age Medical history / Admission examination

15	3ND	Female	83	SLEEP DISTURBANCES TRAUMATIC BRAIN HEM NEC
	4ND	Female	86	BENIGN NEO UTERUS NOS BEN NEO CEREBR MENINGES ANEMIA NOS HYPERTENSION NOS CIRCULATORY DISEASE NOS
	11ND	Female	65	SUICIDE/SELF-INJURY NOS MUSC-SKT CARDIOVASC DIS LUMBAR SLEEP DISTURBANCES FX LUMBAR VERTEBRA-CLOSE FX LOWER RADIUS/ULNA-CL
	112ND	Female	84	ARTHRITIS STATUS DEGENERATION OF MACULA HYPERTENSION NOS CEREBROVASC DISEASE NOS GENERAL OSTEDARTHROSIS BACK DISORDER NOS OSTEOMYELITIS NOS SLEEP DISTURBANCES
16	1ND	Female	85	HYPERTENSION NOS URIN TRACT INFECTION NOS SLEEP DISTURBANCES
	1DT	Female	74	MALIG NEO SKIN TRUNK CONSTIPATION
	2ND	Male	72	HEART DISEASE NOS STOMACH FUNCTION DIS NEC CONSTIPATION SLEEP DISTURBANCES
	2DT	Male	71	CHRONIC HYPOTENSION SALIVARY SECRETION DIS CONSTIPATION SLEEP DISTURBANCES
	3ND	Female	68	SLEEP DISTURBANCES

PERMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 4

MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre	Patient	Sex	Age	Medical history / Admission examination
16	30T	Female	75	HYPERTENSION NOS CONSTIPATION SLEEP DISTURBANCES
	4HD	Female	75	PARALYSIS ACETANS HYPERTENSION NOS RECTAL PROLAPSE PROLAPSE OF VAGINAL MALL FEMALE GENITAL DIS NOS SLEEP DISTURBANCES
17	1HD	Female	71	SLEEP DISTURBANCES
	2HD	Female	87	INTESTINAL BYPASS STATUS DIGESTIVE NEOPLASM NOS
	3HD	Female	74	SLEEP DISTURBANCES
	4HD	Female	65	SLEEP DISTURBANCES
	4DT	Female	81	ENTERITIS OF INFECT ORIG IRRITABLE COLON
	21HD	Female	83	HEART DISEASE NOS
18	1HD	Female	81	SLEEP DISTURBANCES
	1DT	Female	80	URIN TRACT INFECTION NOS SLEEP DISTURBANCES
	2HD	Female	68	SLEEP DISTURBANCES
	2DT	Female	71	HYPERTENSION NOS SLEEP DISTURBANCES
	3HD	Female	82	HYPERTENSION NOS DIZZINESS AND CLIMBERS SLEEP DISTURBANCES

9550089

9550089

11

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS B&D		REBOXETINE - PROTOCOL 20124/035		Listing No.: 4		MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS	
Centre	Patient	Sex	Age	Medical history / Admission examination			
18	4ND	Female	79	SLEEP DISTURRANCES			
22	1ND	Female	81	SLEEP DISTURRANCES			
23	1ND	Female	71	NERVOUSNESS			
2ND	Female	69	OBS-SUSP CARDIOVASC DIS FEMALE CLIMACTERIC STATE SLEEP DISTURRANCES SKIN SENSATION DISTURB TOXIC EFFECT METALS NEC				
3ND	Female	80	CONGESTIVE HEART FAILURE CONSTIPATION SLEEP DISTURRANCES				
4ND	Female	80	BORDERLINE GLAUCOMA OPEN-ANGLE GLAUCOMA				
5ND	Female	69	HYPOTHYROIDISM NOS HYPOTHYROIDISM NOS CONSTIPATION NAUSEA AND VOMITING				
6ND	Female	72	PURE HYPERCHOLESTEROLEM CHR ISCHEMIC HRT DIS NEC CHR ISCHEMIC HRT DIS NOS SOLITARY CYST OF BREAST SLEEP DISTURRANCES NERVOUSNESS				
25	1ND	Male	68	PURE HYPERCHOLESTEROLEM MONOCLON PARAPROTEINEMIA TOBACCO USE DISORDER HYPERTENSION NOS ATHEROSCLEROSIS NOS STRUCTURE OF ARTERY ABN BLOOD CHEMISTRY NEC			
2ND	Female	67	OPEN-ANGLE GLAUCOMA CARDIAC DYSRHYTHMIA NEC SLEEP DISTURRANCES NERVOUSNESS				

9550089

12

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 4
 MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre Patient Sex Age Medical History / Admission examination

26	1ND	Female	69	SLEEP DISTURBANCES
	1DT	Female	68	STOMACH ULCER NOS ATROPHIC GASTRITIS ESOPHAGEAL ANOMALY NEC
27	1MD	Male	79	CORONARY ATHEROSCLEROSIS HYPERPLASIA OF PROSTATE SLEEP DISTURBANCES
28	1MD	Female	70	OBESITY OSTEOARTHRITIS NOS
	2ND	Female	86	SENILE CATARACT OSTEOARTHRITIS NOS
	2DT	Male	82	ACUTIC ANEURYSM NOS CHRONIC LIVER DIS NEC
	3MD	Female	66	HYPERLIPIDEMIA NEC/NOS OBESITY PSYCHOGEN CARDIOVASC DIS
	3DT	Male	69	INTRACRANIAL HEMORR NOS
	5MD	Female	66	THYROTOXICOSIS NOS HYPERLIPIDEMIA NEC/NOS
30	1ND	Female	87	MULTIPLE MYELOMA ATRIAL FIBRILL/FLUTTER PREMATURE BEATS SLEEP DISTURBANCES
	2ND	Female	74	UTERINE LEIOMYOMA CONGESTIVE HEART FAILURE CHOLELITH W CHOLELCHS NEC
	4ND	Female	78	PULMONARY TB NOS HYPERTENSION NOS SLEEP DISTURBANCES

251

9550089

13

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PEARMACTA CNS RED		REBOXETINE - PROTOCOL 20124/035		
MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS		Listing No.: 4		
Centre	Patient	Sex	Age	Medical history / Admission examination
30	5ND	Female	75	CVA
31	1ND	Female	76	PULMONARY TB NOS OLD MYOCARDIAL INFARCT EFFUSION OF JOINT SLEEP DISTURBANCES
	1DT	Female	77	BREAST NEOPLASM NOS HYPERTENSION NOS
	2ND	Female	79	OLD MYOCARDIAL INFARCT LEFT HEART FAILURE CHRONIC STIMULUS NOS SLEEP DISTURBANCES
	3ND	Male	84	DIABETES MELLITUS UNCOMP ORTHOSTATIC HYPOTENSION EDEMA
32	1ND	Female	66	MALIGNANT NEOPLASM NOS HYPERTENSION NOS DIVERTICULA OF COLON OSTEOARTHRITIS NOS SLEEP DISTURBANCES
	2ND	Female	70	HYPERTENSION NOS
	3ND	Female	67	HYPERTENSION NOS SLEEP DISTURBANCES
	4ND	Female	68	ANXIETY STATES FEMALE CLIMACTERIC STATE SLEEP DISTURBANCES
	5ND	Female	78	EYE REPLACEMENT NEC RETINAL VASC OCCLUSION PROPHYLACTIC ONE EYE SLEEP DISTURBANCES
	6ND	Male	61	VENOUS THROMBOSIS NOS OSTEITIS DEFORMANS NOS

952

9550089

14

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 4
 MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS
 Centre Patient Sex Age Medical history / Admission examination

35	1ND	Female	71	OTHER GU NEOPLASM NOS ADHESIVE CAPSULIT SHOULDER SLEEP DISTURBANCES PALPITATIONS
	1DT	Female	69	BEN NEO CEREBR MENINGES URIN TRACT INFECTION NOS OTHER GU NEOPLASM NOS THYROTOXICOSIS NOS ANGINA PECTORIS SALIVARY SECRETION DIS ESOPHAGITIS DIAPHRAGMATIC HERNIA COLELITHIASIS NOS URIN TRACT INFECTION NOS SLEEP DISTURBANCES PALPITATIONS
	2ND	Female	72	THYROTOXICOSIS NOS ATRIAL FIBRILL/FLUTTER SLEEP DISTURBANCES ANOREXIA
	2DT	Female	67	DIAPHRAGMATIC HERNIA PURE HYPERCHOLESTEROLEM SLEEP DISTURBANCES
	3ND	Female	66	DIABETES MELLITUS UNCOMP HYPERTENSION NOS ATRIAL FIBRILL/FLUTTER CEREBRAL ATHEROSCLEROSIS RENAL DYSFUNCTION NOS SLEEP DISTURBANCES
	3DT	Male	74	IDIO PERIPH NEURPTBY NOS CATARACT NOS HYPERTENSION NOS CEREBR ARTERY OCCLUS NOS KERATODERMA, ACQUIRED SLEEP DISTURBANCES PALPITATIONS
	4ND	Male	90	ANEMIA NOS CONSTIPATION CHOLELITH W CHOLECYSTIS NEC

953

9550089

15

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 4
 MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre Patient Sex Age Medical history / Admission examination

35	4ND	Male	90	RENAL URETERAL DIS NOS URIN TRACT INFECTION NOS PROSTATIC DISORDER NOS RENAL URETERAL DIS NOS SPERMATOCELE CYSTIC KIDNEY DISEASE ABN BLOOD CHEMISTRY NEC
	4DT	Female	65	COLOSTOMY STATUS INTESTINAL BYPASS STATUS MALIGNANT NEOPL RECTUM SLEEP DISTURBANCES TACHICARDIA NOS
	5ND	Male	70	OTHER GU NEOPLASM NOS ACUTE MYOCARDIAL INFARCT ANGINA PECTORIS STOMACH FUNCTION DIS NEC DIVERSTICULA OF COLON CONSTIPATION CHOLELITHIASIS NOS SLEEP DISTURBANCES
	5DT	Female	77	DIABETES MELLITUS UNCOMP KERATITIS NOS HYPERTENSION NOS ANGINA PECTORIS ASCVD GASTRODUODENAL DIS NOS INGUINAL HERNIA NOS RENAL SCLEROSIS NOS SLEEP DISTURBANCES
	6ND	Female	69	OBS-SUSP CARDIOVASC DIS UTERINE LEIOMYOMA CATARACT NOS CEREBROVASC DISEASE NOS AC APPEND W PERITONITIS DIAPHRAGMATIC HERNIA DISC DISPLACEMENT NOS SLEEP DISTURBANCES
	6DT	Female	69	GOITER NOS DIABETES MELLITUS UNCOMP HYPERLIPIDEMIA NEC/NOS HYPERLIPIDEMIA NEC/NOS HYPERTENSION NOS CEREBROVASC DISEASE NOS

954

9550089

16

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R6D	
REMOXYLINE - PROTOCOL 20124/035	
Listing No.: 4	
MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS	
Centre	Patient Sex Age Medical history / Admission examination
35	60T Female 69 MONOARTHRITIS NOS SLEEP DISTURBANCES
	74D Female 74 MALIGNANT NEOPLASIA OF SKIN NOS MALIGNANT NEOPLASIA OF UTERUS BENIGN NEOPLASIA OF UTERUS VENOUS THROMBOSIS NOS MALIGNANT NEOPLASIA OF UTERUS SLEEP DISTURBANCES
	70T Female 78 THYROTOXICOSIS NOS ANXIETY DISORDER ATRIAL FIBRILLATION DIABETES MELLITUS UNCOMPLICATED GENERAL OSTEOARTHRITIS SLEEP DISTURBANCES
	80D Female 74 IRON DEFICIENCY ANEMIA CONSTIPATION PAIN IN LIMB SLEEP DISTURBANCES FX HUMERUS SHAFT/NOS-CL
36	10D Male 83 OBS-SUSP CARDIOVASCULAR DISEASE MALIGNANT NEOPLASIA OF PROSTATE HYPERTENSION NOS TRANSIENT CEREBRAL ISCHEMIA CHRONIC AIRWAY OBSTRUCTION SLEEP DISTURBANCES
	10T Female 78 INFLAMMATORY NEUROPATHY NOS SLEEP DISTURBANCES
	20D Female 65 HYPERTENSION NOS LUMBAGO SLEEP DISTURBANCES
	20T Female 66 HYPERTENSION NOS ESOPHAGITIS INGUINAL HERNIA NOS
	30D Female 84 UTERINE STENOSIS NOS BENIGN NEOPLASIA OF BREAST HYPERTENSION NOS CONGESTIVE HEART FAILURE

39
37
37

9550089

17

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Centre	Patient	Sex	Age	Medical history / Admission examination
36	3ND	Female	84	STOMACH FUNCTION DIS NEC RENAL - URETERAL DIS NOS OSTEOARTHRISIS NOS SLEEP DISTURBANCES
	3DT	Female	80	PURE HYPERCHOLESTEROLEM HYPERTENSION NOS CIRCULATORY DISEASE NOS DUODENAL ULCER NOS SLEEP DISTURBANCES
	4ND	Female	79	ESOPHAGITIS SLEEP DISTURBANCES GENERAL SYMPTOMS NEC
	4DT	Female	74	HYPERTENSION NOS TRANSIENT CEREB ISCHEMIA DIZZINESS AND GIDDINESS SLEEP DISTURBANCES
	5ND	Female	79	OBES-SUSP CARDIOVASC DIS TOXIC DIFFUSE GOITER HYPERTENSION NOS CVA SLEEP DISTURBANCES
	5DT	Female	65	DIABETES MELLITUS UNCOMP NEUROPATHY IN DIABETES HYPERTENSION NOS ESOPHAGITIS URIN TRACT INFECTION NOS OLD FB IN SOFT TISSUE OSTEOPOROSIS
	6ND	Female	65	OBES-SUSP CARDIOVASC DIS CVA OSTEOARTHRISIS NOS SLEEP DISTURBANCES
	6DT	Female	72	DEGEN/VASCULAR DIS EAR HYPERTENSION NOS CEREBROVASC DISEASE NOS SLEEP DISTURBANCES
	7ND	Female	81	CANDIDAL VULVOVAGINITIS

956

9550089

16

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Centre	Patient	Sex	Age	Medical history / Admission examination
36	7HD	Female	81	DIABETES MELLITUS UNCOMP ESOPHAGITIS
	7DT	Female	75	DIABETES MELLITUS UNCOMP HYPERTENSION NOS OSTEOPOROSIS SLEEP DISTURBANCES
	8HD	Female	67	SLEEP DISTURBANCES DYSPNEA/RESPIRATORY ABN
	8DT	Female	80	OBS-SUSP CARDIOVASC DIS SPONDYLOSIS NOS OSTEOPOROSIS SLEEP DISTURBANCES NERVOUSNESS
	9HD	Male	82	OBS-SUSP CARDIOVASC DIS HYPERTENSION NOS CEREBROVASC DISEASE NOS OBSTRUCT CHR BRONCHITIS CHR AIRWAY OBSTRUCT NEC URINATION ABNORM NEC
	9DT	Female	65	MIGRAINE NOS HYPERTENSION NOS POLYP OF NASAL CAVITY CHRONIC SINUSITIS NOS ESOPHAGITIS SLEEP DISTURBANCES
	10HD	Male	77	PURE HYPERCHOLESTEROLEM ATRIAL FIBRILL/FLUTTER CEREBROVASC DISEASE NOS PERIPH VASCULAR DIS NOS HYPOTENSION NOS URIN TRACT INFECTION NOS HYPERPLASIA OF PROSTATE SLEEP DISTURBANCES
	10DT	Male	79	HYPERPLASIA OF PROSTATE SLEEP DISTURBANCES
	11HD	Female	81	SLEEP DISTURBANCES HEADACHE

9550089

9550089

19

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/035
 Listing No.: 4
 MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre Patient Sex Age Medical history / Admission examination

36	11DT	Male	78	HX-MAJOR CARDIOVASC SURG OBS-SUSP CARDIOVASC DIS OTH AC ISCHEMIC HRT DIS OLD MYOCARDIAL INFARCT DISC DISPLACEMENT NOS BACKACHE NOS SLEEP DISTURBANCES
	12ND	Female	78	ATRIAL FIBRILL/FLUTTER DUODENAL ULCER NOS SPINAL STENOSIS NEC OSTEOPOROSIS SLEEP DISTURBANCES
	12DT	Female	81	HYPERTENSION NOS HEART DISEASE NOS OSTEOPOROSIS
	13ND	Male	76	OBS-SUSP CARDIOVASC DIS OTHER GU NEOPLASM NOS CVA SLEEP DISTURBANCES
	14ND	Male	70	IRON DEFICIENCY ANEMIAS GASTRITIS/DUODENITIS NOS SLEEP DISTURBANCES
	15ND	Female	73	HYPERTENSION NOS SLEEP DISTURBANCES
	16ND	Female	72	HYPERTR OESTR CARDIOMYOP ATRIAL FIBRILL/FLUTTER
	17ND	Female	80	HYPERTENSION NOS AORTIC VALVE DISORDER HEART DISEASE NOS CIRCULATORY DISEASE NOS CHR AIRWAY OBSTRUCT REC SLEEP DISTURBANCES ABR BLOOD CHEMISTRY NEC
	18ND	Female	78	DIABETES MELLITUS UNCOMP HYPERTENSION NOS

9
 01
 00

9550089

20

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 4
 MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre	Patient	Sex	Age	Medical history / Admission examination
36	18ND	Female	78	DIZZINESS AND GIDDINESS SLEEP DISTURBANCES
	19ND	Female	81	GASTRITIS/DUODENITIS NOS SLEEP DISTURBANCES
	20ND	Female	70	CONDUCT DISTURBANCE NOS HEMIPLEGIA NOS HYPERTENSION NOS HEART DISEASE NOS INTRACEREBRAL HEMORRHAGE ABSCESS OF LUNG HEPATITIS NOS SLEEP DISTURBANCES
37	3ND	Female	81	HEPATITIS NOS UREN TRACT INFECTION NOS SLEEP DISTURBANCES
41	2ND	Male	68	DUODENAL ULCER NOS
	4ND	Male	74	STOMACH ULCER NOS
	5ND	Male	69	HYPERPLASIA OF PROSTATE
42	1ND	Female	73	SLEEP DISTURBANCES
	1DT	Female	79	UNCERT BEHAV NEO UTERUS OLD MYOCARDIAL INFARCT CONSTIPATION SYMPTOMS IN BREAST LUMBAGO SLEEP DISTURBANCES
	2ND	Female	79	ASTHMA NOS OTR MUSCUL SYMPT LIMB SLEEP DISTURBANCES
	3ND	Male	82	IRON DEFICIENCY ANEMIAS DYSPLASIA OF COLON SLEEP DISTURBANCES

9550089

9550089

21

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Centre	Patient	Sex	Age	Medical history / Admission examination
43	1DT	Female	77	BACKACHE NOS OSTEOPOROSIS FX DORSAL VERTEBRA-CLOSE
	2DT	Female	77	GLAUCOMA NOS URIN TRACT INFECTION NOS SLEEP DISTURBANCES
	3DT	Male	72	BENIGN NEOPLASIA LG BOWEL HYPERPLASIA OF PROSTATE SLEEP DISTURBANCES
	4DT	Female	79	MALIGNANT NEO COLON NOS CATARACT NOS HEARING LOSS HYPERTENSION NOS HEART FAILURE NOS BRONCHITIS NOS DIAPHRAGMATIC HERNIA ARTHROPATHY NOS SLEEP DISTURBANCES
44	5ND	Female	70	MALIGN NEOPL BREAST NOS SLEEP DISTURBANCES
	6ND	Female	74	HYPOTHYROIDISM NOS CHR ISCHEMIC CRT DIS NOS URIN TRACT INFECTION NOS PEPTIC ULCER NOS PROLAPSE OF VAGINAL WALL SLEEP DISTURBANCES
	1ND	Female	76	MALIGN NEOPL BREAST NOS CONSTIPATION SLEEP DISTURBANCES
	1DT	Female	76	INTESTINAL BYPASS STATUS MALIGNANT NEO COLON NOS NEUROLOGIC DISORDER NOS STOMACH ULCER NOS SLEEP DISTURBANCES
2ND	Female	73	HYPERTENSION NOS ASTHMA NOS DIAPHRAGMATIC HERNIA	

960

9550089

22

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 4
 MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre	Patient	Sex	Age	Medical history / Admission examination
44	2ND	Female	73	URIN TRACT INFECTION NOS URIN TRACT INFECTION NOS SLEEP DISTURBANCES
	3ND	Female	73	UTERINE LEIOMYOMA NEUROTIC DISORDER NOS BARBITURATE DEPENDENCE HYPERTENSION NOS VENOUS THROMBOSIS NOS DUODENAL ULCER NOS DIAPHRAGMATIC HERNIA CONSTIPATION TEN CENTRAL SYMPTOMS NOS HEADACHE
	4ND	Male	81	OPS-SUSP CARDIOVASC DIS MALARIA NOS LEPTOSPIROSIS NOS MALIGNANT NEOPLASIA NOS INGUINAL HERNIA NOS HYPERPLASIA OF PROSTATE MALIGNANT NEOPLASIA NOS SLEEP DISTURBANCES
45	1ND	Male	76	CHOLECYSTITIS NEC
	1DT	Female	79	SYNDROME RAYNAUD ASTHMA NOS PEPTIC ULCER NOS OSTEOMYELITIS NOS OSTEOPOROSIS EDEMA
	2ND	Male	77	PULMONARY TB NOS HYPERTENSION NOS STOMACH ULCER NOS CIRRHOSIS OF LIVER NOS
46	1ND	Male	69	CORONARY ATHEROSCLEROSIS SLEEP DISTURBANCES
	3ND	Female	73	HEARING LOSS NOS THROMPHLEBITIS CHOLELITHIASIS NOS

961

9550089

23

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Centre	Patient	Sex	Age	Medical history / Admission examination
	PHARMACIA CNS RED			
	REBOXETINE - PROTOCOL 20124/035 Listing No.: 4			
	MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS			
Centre	Patient	Sex	Age	Medical history / Admission examination
46	4HD	Female	78	ANGINA PECTORIS ARTHROPATHY NOS SCOLIOSIS
48	1DT	Female	74	ANXIETY STATES APPENDICITIS NOS ENTHESOPATHY NOS OTH MUSCLE/LIGAMENT DIS CONVULSIONS FB RESPIRATORY TREE NOS
	2DT	Female	65	OTHER OJ NEOPLASM NOS CAPRAL TUNNEL SYNDROME HYPERTENSION NOS APPENDICITIS NOS SEM CRANIAL SYMPTOMS NOS SLEEP DISTURBANCES
291	1MD	Female	80	CHOLELITH N AC CHOLECYST CHOLELITHIASIS NOS
	1DT	Female	81	SIMPLE GOITER SIMPLE GOITER HYPERTENSION NOS DUODENAL ULCER NOS GASTRITIS/DUODENITIS NOS
	2HD	Female	68	UTERINE LEIOMYOMA HYPERTENSION NOS CHOLELITHIASIS NOS
	2DT	Female	73	HYPERLIPIDEMIA NEC/NOS SENILE CATARACT HYPERTENSION NOS
	3DT	Female	73	PURE HYPERCHOLESTEROLEM HYPERTENSION NOS CHR ISCHERIC HRT DIS NEC
	4HD	Male	68	PULMONARY TB NOS BRONCHITIS NOS
	4DT	Male	87	DIABETES MELLITUS UNCOMP CEREBROVASC DISEASE NOS

962

9550089

24

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS R&D
 REBOMETHE - PROTOCOL 20124/035
 Listing No.: 4
 MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre Patient Sex Age Medical history / Admission examination

291	25DT	Female	80	CHR ISCHEMIC HRT DIS NEC RT BUNDLE BRANCH BLOCK CARDIAC DYSRHYTHIA NOS DIVERTICULA OF COLON ABN BLOOD CHEMISTRY NEC
	26DT	Female	81	PURE HYPERCHOLESTEROLEM PROZOAL ENCEPHALITIS HYPERTENSION NOS
	27DT	Female	88	CEREBROVASC DISEASE NOS
	28DT	Female	73	DIABETES MELLITUS UNCOMP HYPERLIPIDEMIA NEC/NOS SVEINGOMVELIA HYPERTENSION NOS ARTROPATHY NOS ANOMALIES OF SPINE TRAUM SUBARACHNOID HEM BRAIN INJURY NEC
292	5MD	Female	73	HYPERLIPIDEMIA NEC/NOS HYPOTENSION NOS ABN BLOOD CHEMISTRY NEC
	5DT	Male	79	HYPERLIPIDEMIA NEC/NOS CHR ISCHEMIC HRT DIS NEC HYPERPLASIA OF PROSTATE ABN BLOOD CHEMISTRY NEC
	6MD	Female	71	HYPERLIPIDEMIA NEC/NOS CORONARY ATHEROSCLEROSIS CHR ISCHEMIC HRT DIS NEC THROMBOLEPTIS LEG NOS COMPRESSION OF VEIN ABN BLOOD CHEMISTRY NEC
	6DT	Female	69	HYPERLIPIDEMIA NEC/NOS
	7MD	Male	82	CORONARY ATHEROSCLEROSIS CHR ISCHEMIC HRT DIS NEC HYPOTENSION NOS ABN BLOOD CHEMISTRY NEC

9550089

25

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS B&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 4
 MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre Patient Sex Age Medical History / Admission examination

292	7DT	Male	66	HYPERTENSION NOS CIRCUMSCRIBE SCLERODERMA
	8MD	Male	68	DIABETES MELLITUS UNCOMP HYPERLIPIDEMIA NEC/NOS HYPERTENSION NOS HYPERPLASIA OF PROSTATE ABN BLOOD CHEMISTRY NEC
	8DT	Female	73	CORONARY ATHEROSCLEROSIS
	21MD	Female	72	HYPERTENSION NOS CHOLELITH W CHOLECYS NEC
	21DT	Female	79	HYPERTENSION NOS CORONARY ATHEROSCLEROSIS CHOLELITH W CHOLECYS NEC
	22DT	Female	81	HYPERTENSION NOS CIRCULATORY DISEASE NOS
	23MD	Female	75	HYPOTENSION NOS ABN BLOOD CHEMISTRY NEC
	23DT	Male	69	ACUTE MYOCARDIAL INFARCT CHR ISCHEMIC HRT DIS NEC ABN BLOOD CHEMISTRY NEC
	24MD	Male	75	JOINT REPLACEMENT NEC HYPERTENSION NOS CORONARY ATHEROSCLEROSIS HYPERPLASIA OF PROSTATE
293	9MD	Female	80	CHR ISCHEMIC HRT DIS NEC
	9DT	Female	67	VARICOSE VEIN OF LEG NOS BRONCHITIS NOS CHOLELITHIASIS NOS
	10MD	Female	65	DUODENAL ULCER NOS

9550089

26

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Centre	Patient	Sex	Age	Medical history / Admission examination
293	10DT	Female	66	GOUT NOS ARTHRITIS NOS
	11ND	Male	65	OSTEOARTHRITIS NOS RHEUMATISM NOS
	11DT	Female	68	OTHER GU NEOPLASM NOS DIABETES MELLITUS UNCOMP
	12ND	Male	56	GOUT NOS
294	13ND	Female	80	STRICTURE OF ARTERY URIN TRACT INFECTION NOS DIZZINESS AND GIDDINESS
	13DT	Female	68	STRICTURE OF ARTERY OSTEOARTHRITIS NOS DISC DISPLACEMENT NOS OSTEOPOROSIS
	14ND	Female	82	STRICTURE OF ARTERY SPONDYLOSIS NOS RHEUMATISM NOS OSTEOPOROSIS
	14DT	Female	73	METABOLISM DISORDER NOS CONGESTIVE HEART FAILURE STRICTURE OF ARTERY OSTEOARTHRITIS NOS SPONDYLOSIS NOS ENTHESOPATHY NOS OSTEOPOROSIS
	15ND	Female	82	CEREBROVASC DISEASE NOS STRICTURE OF ARTERY RHEUMATISM NOS RHEUMATISM NOS SLEEP DISTURBANCES MALAISE AND FATIGUE
	15DT	Female	75	METABOLISM DISORDER NOS CEREBROVASC DISEASE NOS

965

9550089

27

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 4
 MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre Patient Sex Age Medical history / Admission examination

294	15DI	Female	75	STRUCTURE OF ARTERY MONOARTHRITIS NOS SPONDYLOSIS NOS SHOULDER REGION DIS NEC OSTEOCHONDROPATHY NOS DIZZINESS AND GIDDINESS
	16ND	Female	65	MIGRAINE NOS CIRCULATORY DISEASE NOS OSTEOARTHRITIS NOS RHEUMATISM NOS
	16DI	Female	81	ATHEROSCLEROSIS NOS STRUCTURE OF ARTERY SPONDYLOSIS NOS RHEUMATISM NOS
	25ND	Female	71	HYPERTENSION NOS CIRCULATORY DISEASE NOS SPONDYLOSIS NOS
	26ND	Female	75	HYPERTENSION NOS POLYARTHRITIS NOS MONOARTHRITIS NOS SPONDYLOSIS NOS OSTEOPOROSIS
	27ND	Female	67	HYPERLIPIDEMIA NEC/NOS OBESITY CEREBROVASC DISEASE NOS STRUCTURE OF ARTERY SPONDYLOSIS NOS
	28ND	Female	76	CEREBROVASC DISEASE NOS OSTEOARTHRITIS NOS SPONDYLOSIS NOS OSTEOCHONDROPATHY NOS
	29DI	Female	80	CHR ISCHEMIC HRT DIS NEC STRUCTURE OF ARTERY OSTEOCHONDROPATHY NOS OSTEOPOROSIS
	30DI	Female	79	HYPERTENSION NOS CHR ISCHEMIC HRT DIS NEC

9550089

28

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 4
 MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre Patient Sex Age Medical history / Admission examination

294	30DT	Female	79	MONOARTHRITIS NOS
	31DT	Female	80	HYPERTENSION NOS CEREBROVASC DISEASE NOS STRICTURE OF ARTERY GENERAL OSTEOARTHRITIS DIZZINESS AND GIDDINESS NERVOUSNESS
	32DT	Male	73	DIABETES MELLITUS UNCOMP HYPERLIPIDEMIA NEC/NOS METABOLIC DISORDER NOS CEREBROVASC DISEASE NOS STRICTURE OF ARTERY GENERAL OSTEOARTHRITIS SPONDYLOSIS NOS
295	17HD	Female	64	MALIGN NEOPL BREAST NOS HYPERTENSION NOS
	17DT	Male	65	CARDIAC DYSRHYTHMIA NOS HEART DISEASE NOS
	18HD	Female	73	NONTOX NODUL GOITER NOS PURE HYPERCHOLESTEROLEM HYPERTENSION NOS ABN BLOOD CHEMISTRY NEC
	18DT	Female	71	PURE HYPERCHOLESTEROLEM IRRITABLE COLON CHOLECYSTITIS NEC
	19HD	Male	66	HYPERLIPIDEMIA NEC/NOS OLD MYOCARDIAL INFARCT HYPERPLASIA OF PROSTATE
	19DT	Female	69	HYPERTENSION NOS OBSTRUCT CHR BRONCHITIS
	20HD	Female	82	HYPERTENSION NOS OSTEOPOROSIS
	20DT	Female	66	JOINT REPLACEMENT NEC

967

9550089

29

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D	
REBOXETINE - PROTOCOL 20124/035	
Listing No.: 4	
MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS	
Centre	Patient Sex Age Medical history / Admission examination
295	20DT Female 66 HYPERTENSION NOS
381	1ND Male 86 JOINT REPLACEMENT NEC CONGESTIVE HEART FAILURE TRANSIENT CEREB ISCHEMIA CONSTIPATION URIN TRACT INFECTION NOS HYPERPLASIA OF PROSTATE OSTEODARTHROSIS NOS
	2ND Female 67 CONGESTIVE HEART FAILURE CVA ANOMALIES OF SPINE
	3DT Female 77 ALCOHOL DEPENDENCE SYNDR ORTHOSTATIC HYPOTENSION ARTHRITIS NOS SLEEP DISTURBANCES MALAISE AND FATIGUE
	4ND Female 88 HYPERTENSION NOS ANGINA PECTORIS CHR ISCHEMIC HRT DIS NOS
382	5ND Female 74 LUNG DISEASE NEC ANXIETY STATES ANGINA PECTORIS LUNG DISEASE NEC CONSTIPATION NAUSEA AND VOMITING
	5DT Male 63 ALCOHOL DEPENDENCE SYNDR
	6ND Female 74 HYPERTENSION NOS CONSTIPATION SPONDYLOSIS NOS
	6DT Female 79 DIABETES MELLITUS UNCOMP ANGINA PECTORIS HEPATIC ENCEPHALOPATHY HEPATIC FAILURE NOS TRANSIENT CEREB ISCHEMIA OSTEODARTHROSIS NOS ARTHRITIS NOS

9550089

30

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Centre	Patient	Sex	Age	Medical history / Admission examination
382	6DT	Female	79	FREQ URINATION/POLYURIA
	7ND	Female	88	ANXIETY STATES HEMIPLEGIA NOS TRANSIENT CEREB ISCHEMIA DIVERGICULA OF COLON GENERAL SYMPTOMS NEC INCONTINENCE OF URINE ABNORMAL REFLEX
	7DT	Male	82	CVA HYPERPLASIA OF PROSTATE
	8ND	Male	83	ENTERITIS OF INFECT ORIG OSTROMALACIA NOS HEARING LOSS NOS CEREBROVASC HTD DIS NOS CYSTIC FIBROSIS/FLUTTER CONGESTIVE HEART FAILURE
	8DT	Female	86	FALL NEC NOS URIN TRACT INFECTION NOS OSTEOARTHRISIS NOS ARTHRITIS NOS SLEEP DISTURBANCES ABNORMAL REFLEX
	9ND	Female	86	IRON DEFICIENCY ANEMIAS CONGESTIVE HEART FAILURE
	9DT	Female	78	DIARRHEA OF INFECT ORIG THRUSH HEART FAILURE NOS URIN TRACT INFECTION NOS PAIN IN LIMB ABDOMINAL PAIN
	10ND	Female	85	HYPERTENSION NOS STOMACH FUNCTION DIS NEC OSTEOARTHRISIS NOS SLEEP DISTURBANCES HEADACHE
3301	1ND	Female	76	CARDIOGEGALY ANEMIA NOS

969

9550089

31

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 4
MEDICAL HISTORY AND ADMISSION EXAMINATION FINDINGS

Centre	Patient	Sex	Age	Medical history / Admission examination
3301	1HD	Female	76	CONSTIPATION SLEEP DISTURBANCES ELEVATED SEDIMENT RATE
	2HD	Male	85	DIAPHRAGMATIC HERNIA CONSTIPATION SLEEP DISTURBANCES
	3HD	Female	71	ASTHMA NOS SLEEP DISTURBANCES
3302	5HD	Female	84	HYPOTOLEMIA ATROPY NOS SLEEP DISTURBANCES
	6HD	Female	73	CONSTIPATION SLEEP DISTURBANCES
	7HD	Female	93	HEART FAILURE NOS STOMACH FUNCTION DIS NEC SLEEP DISTURBANCES

970

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 5.0
 CHEST X-RAY

Centre	Patient	Sex	Assessment	Date	Chest X-Ray - Pulmonary Function - Abnormality
1	1ND	Female	Screen	02/11/92	Normal
	1DT	Male	Screen	18/11/93	Normal
	2ND	Male	Screen	16/11/92	Normal
	2DT	Male	Screen	08/12/93	Abnormal CAPILLARY DIS NEC/NOS EMPHYSEMA
	3ND	Female	Screen	31/05/93	Normal
	3DT	Male	Screen	16/12/93	Abnormal POSTINFAM PULM FIBROSIS ABN FINDINGS-LUNG FIELD CONG ANOM OF AORTA NEC
	4ND	Female	Screen	19/10/93	Normal
	4DT	Male	Screen	31/01/94	Normal
2	1ND	Male	Screen	07/01/93	Normal
3	1ND	Female	Screen	27/04/93	Abnormal CARDIOMEGALY EMPHYSEMA LUNG DISEASE NEC
4	1ND	Male	Screen	23/11/92	Normal
5	1ND	Female	Screen	19/10/92	Normal
	1DT	Female	Screen	13/10/92	Normal
	2ND	Male	Screen	16/11/92	Normal
	2DT	Female	Screen	29/12/92	Normal
	3ND	Female	Screen		Not done

9550089

2

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Assessment	Date	Chest X-Ray - Pulmonary Function Value	Abnormality
5	3DT	Male	Screen	18/03/93	Abnormal	ANOMALIES OF SPINE CHR AIRWAY OBSTRUCT NEC
	4MD	Male	Screen	11/92	Normal	
	4PT	Male	Screen		Not done	
	5ND	Male	Screen	28/07/93	Abnormal	CHR AIRWAY OBSTRUCT NEC
	5NT	Female	Screen		Not done	
	6ND	Male	Screen	26/07/93	Normal	
	6DT	Female	Screen		Not done	
	7ND	Male	Screen		Not done	
	7DT	Female	Screen		Not done	
	8ND	Female	Screen		Not done	
	8DT	Female	Screen		Not done	
	9ND	Female	Screen		Not done	
	9DT	Female	Screen	30/04/93	Normal	
	10ND	Female	Screen		Not done	
	10DT	Male	Screen		Not done	
	11ND	Female	Screen	29/11/93	Normal	

972

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

3

PHARMACIA CNS R&D
 RESOMETINE - PROTOCOL 20124/035
 Listing No.: 5.0
 CHEST X-RAY

Centre	Patient	Sex	Assessment	Date	Chest X-Ray - Value	Pulmonary Function - Abnormality	
5	11DT	Female	Screen	05/05/93	Abnormal	PLEURAL EFFUSION NOS	
	12MD	Female	Screen		Not done		
	12DT	Male	Screen		Not done		
	1MD	Female	Screen		Not done		
	1DT	Female	Screen		Not done		
	2MD	Female	Screen		Not done		
	2DT	Female	Screen		Not done		
	3MD	Female	Screen	03/92	Normal		
	3DT	Female	Screen	05/04/93	Normal		
	4MD	Female	Screen		Not done		
6	4DT	Female	Screen		Not done		
	5MD	Female	Screen		Not done		
	5DT	Female	Screen		Not done		
	6MD	Female	Screen		Not done		
	7MD	Female	Screen		Not done		
	8MD	Female	Screen		Not done		
	7	1MD	Male	Screen	10/04/92	Normal	

9550089

973

9550089

4

090177e1803f200f\Approved\On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Assessment	Chest X-Ray - Pulmonary Function		
				Date	Value	
7	3ND	Female	Screen	19/04/93	Abnormal	CHR AIRWAY OBSTRUCT NEC
	4ND	Female	Screen	21/04/93	Abnormal	EMPHYSEMA SHOULDER REGION DIS NEC CHR AIRWAY OBSTRUCT NEC
8	342ND	Female	Screen		Not done	
	1ND	Female	Screen	18/02/92	Abnormal	POSTINFLAM PULM FIBROSIS
	1DT	Female	Screen	07/04/92	Normal	
	2ND	Female	Screen	10/08/92	Normal	
	2DT	Female	Screen	10/12/92	Normal	
	3ND	Female	Screen	06/08/92	Abnormal	ABN FINDINGS-LUNG FIELD HX-MAJOR ORGAN SURG NEC
	3DT	Female	Screen	15/06/92	Abnormal	AORTIC ATHEROSCLEROSIS
	4ND	Male	Screen	22/04/92	Abnormal	POSTINFLAM PULM FIBROSIS
	4DT	Female	Screen	15/06/92	Normal	
	701ND	Male	Screen	07/09/92	Abnormal	POSTINFLAM PULM FIBROSIS
701DT	Female	Screen	07/09/92	Normal		
702ND	Male	Screen	27/05/92	Abnormal	LUNG DISEASE NEC	
702DT	Female	Screen	21/04/92	Normal		
703ND	Female	Screen	26/03/92	Normal		

974

9550089

5

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 RESOXETINE - PROTOCOL 20124/035
 Listing No.: 5.0
 CHEST X-RAY

Centre	Patient	Sex	Assessment	Date	Chest X-Ray - Value	Pulmonary Function - Abnormality
8	703DT	Male	Screen	26/01/93	Normal	
	704MD	Female	Screen	29/10/92	Normal	
	704DT	Female	Screen	24/09/92	Normal	
9	1MD	Female	Screen		Not done	
	1DT	Female	Screen		Not done	
	2MD	Female	Screen		Not done	
	2DT	Female	Screen		Not done	
	3DT	Female	Screen		Not done	
	4MD	Female	Screen		Not done	
	5MD	Female	Screen		Not done	
	6MD	Female	Screen		Not done	
10	7MD	Female	Screen		Not done	
	8DT	Female	Screen		Not done	
	1MD	Female	Screen	28/04/93	Normal	
	1DT	Female	Screen	21/09/93	Normal	
	2MD	Male	Screen	10/08/93	Normal	
	2DT	Male	Screen	24/08/93	Normal	

975

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

6

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 5.0
 CHEST X-RAY

Centre	Patient	Sex	Assessment	Date	Chest X-Ray - Pulmonary Function Value	Abnormality
10	3MD	Male	Screen	28/07/93	Normal	
	3DT	Male	Screen	21/09/93	Normal	
	4MD	Female	Screen	14/09/93	Normal	
	4DT	Female	Screen	24/07/93	Normal	
	5MD	Female	Screen	09/09/93	Normal	
	5DT	Female	Screen	06/07/93	Normal	
	6MD	Male	Screen	23/09/93	Normal	
	6DT	Male	Screen	27/07/93	Normal	
	7MD	Male	Screen	01/10/93	Normal	
	7DT	Female	Screen	22/08/93	Normal	
	8MD	Male	Screen	10/09/93	Normal	
	8DT	Female	Screen	10/08/93	Normal	
	9MD	Female	Screen	25/08/93	Normal	
	9DT	Male	Screen	03/10/93	Normal	
	10MD	Female	Screen	10/10/93	Normal	
	10DT	Female	Screen	21/09/93	Normal	
	11MD	Female	Screen	14/09/93	Normal	

9550089

976

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

7

9550089

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Assessment	Date	Chest X-Ray - Value	Pulmonary Function Abnormality
10	11DT	Female	Screen	10/10/93	Normal	
	12ND	Male	Screen	20/09/93	Normal	
	12DT	Female	Screen	30/10/93	Normal	
	13DT	Female	Screen	02/10/93	Normal	
	14DT	Female	Screen	06/10/93	Normal	
	15ND	Female	Screen	08/10/93	Normal	
	16DT	Male	Screen	14/10/93	Normal	
	17ND	Female	Screen	09/10/93	Normal	
	18ND	Female	Screen	08/09/93	Normal	
	19DT	Male	Screen	30/08/93	Normal	
	20ND	Female	Screen	10/10/93	Normal	
12	1ND	Female	Screen		Not done	
	1DT	Female	Screen	18/05/93	Normal	
13	1ND	Female	Screen	04/03/93	Normal	
	1DT	Female	Screen	08/09/93	Normal	
	2ND	Female	Screen	13/12/93	Normal	
	2DT	Female	Screen	16/10/93	Normal	

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

8

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 5.0
 CHEST X-RAY

Centre	Patient	Sex	Assessment Date	Chest X-Ray - Value	Pulmonary Function - Abnormality
13	3MD	Male	Screen 31/01/94	Normal	
	3DT	Female	Screen 25/10/93	Normal	
	4DT	Female	Screen 27/01/94	Normal	
14	1MD	Female	Screen 23/03/94	Normal	
15	1MD	Female	Screen 23/02/93	Abnormal	CARDIOMEGALY PLEURISY W/O EFFUS OR TB
	1DT	Female	Screen 08/06/93	Abnormal	CARDIOMEGALY
	2MD	Female	Screen 02/03/93	Abnormal	AORTIC ATHEROSCLEROSIS CARDIOMEGALY
	2DT	Female	Screen 09/02/94	Abnormal	CARDIOMEGALY
	3MD	Female	Screen 04/05/93	Normal	
	4MD	Female	Screen 12/07/93	Abnormal	AORTIC ATHEROSCLEROSIS CARDIOMEGALY
16	111MD	Female	Screen 23/08/93	Normal	
	112MD	Female	Screen 25/11/93	Abnormal	CARDIOMEGALY
	1MD	Female	Screen 26/01/93	Normal	
	1DT	Female	Screen 08/02/93	Abnormal	ABN FINDINGS-LUNG FIELD
	2MD	Male	Screen 08/04/93	Normal	
	2DT	Male	Screen 30/04/93	Abnormal	ABN FINDINGS-LUNG FIELD

9550089

9550089

9

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RRD
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Assessment	Chest X-Ray - Pulmonary Function	
				Date	Value / Abnormality
16	3MD	Female	Screen	06/05/93	Normal
	3DT	Female	Screen	23/07/93	Normal
	4MD	Female	Screen	19/04/94	Abnormal POSTINFILAN PULM FIBROSIS
	1MD	Female	Screen	06/01/93	Normal
	1DT	Female	Screen	30/03/93	Normal
	2MD	Female	Screen	13/04/93	Normal
	2DT	Female	Screen	09/06/93	Normal
	3MD	Female	Screen	19/10/93	Normal
	3DT	Male	Screen	12/10/93	Normal
	4MD	Female	Screen	11/01/94	Normal
18	4DT	Female	Screen	24/05/93	Normal
	21MD	Female	Screen	10/05/94	Normal
	21DT	Female	Screen	14/02/94	Normal
	1MD	Female	Screen		Not done
	1DT	Female	Screen		Not done
	2MD	Female	Screen		Not done
	2DT	Female	Screen		Not done

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

10

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 5.0
 CHEST X-RAY

Centre	Patient	Sex	Assessment	Date	Chest X-Ray - Pulmonary Function Value	Abnormality
18	3ND	Female	Screen		Not done	
	4ND	Female	Screen		Not done	
20	3ND	Female	Screen		Not done	
22	1ND	Female	Screen	23/06/93	Normal	
23	1ND	Female	Screen	21/01/93	Normal	
	2ND	Female	Screen	16/12/92	Normal	
	3ND	Female	Screen	18/03/93	Normal	
	4ND	Female	Screen	22/03/93	Normal	
	5ND	Female	Screen	20/04/93	Normal	
	6ND	Female	Screen	05/07/93	Abnormal	ATHEROSCLEROSIS NOS ABN FINDINGS-LUNG FIELD
25	1ND	Male	Screen	02/09/93	Normal	
	2ND	Female	Screen	23/11/93	Abnormal	AORTIC ANEURYSM NOS CONG ANOM OF AORTA NEC
26	1ND	Female	Screen	26/04/93	Normal	
	1DT	Female	Screen		Not done	
27	1ND	Male	Screen	09/02/93	Normal	
28	1ND	Female	Screen	13/04/93	Normal	
	1DT	Female	Screen	13/04/93	Normal	

980

9550089

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 5.0
 CHEST X-RAY

Centre	Patient	Sex	Assessment	Date	Chest X-Ray - Pulmonary Function Value	Abnormality
28	2ND	Female	Screen	20/04/93	Normal	
	2DT	Male	Screen	20/04/93	Normal	
	3ND	Female	Screen	20/04/93	Normal	
	3DT	Male	Screen	03/05/93	Normal	
	4ND	Male	Screen	26/04/93	Normal	
	5ND	Female	Screen	10/05/93	Normal	
30	1ND	Female	Screen	20/04/93	Normal	
	2ND	Female	Screen	09/07/93	Normal	
	3ND	Female	Screen	25/10/93	Normal	
	4ND	Female	Screen	25/10/93	Normal	
	5ND	Female	Screen	27/11/93	Normal	
	1ND	Female	Screen	18/08/92	Abnormal	ABN FINDINGS-LUNG FIELD
31	1DT	Female	Screen	15/09/92	Abnormal	CARDIOMEGALY
	2ND	Female	Screen	24/11/92	Normal	
	3ND	Male	Screen	01/12/92	Abnormal	PNEUMONIA, ORGANISM NOS
	1ND	Female	Screen	19/03/93	Normal	
	2ND	Female	Screen	07/04/93	Normal	

PHARMACIA CNS R&D
 REDOXETINE - PROTOCOL 20124/035
 Listing No.: 5.0
 CHEST X-RAY

Centre	Patient	Sex	Assessment Date	Value	Pulmonary Function Abnormality
32	3MD	Female	Screen 15/04/93	Normal	
	4MD	Female	Screen 30/09/93	Normal	
	5MD	Female	Screen 22/10/93	Abnormal	ABN FINDINGS-LUNG FIELD
	6MD	Male	Screen 02/11/93	Abnormal	CARDIOMEGALY
35	1MD	Female	Screen 25/01/93	Normal	
	1DT	Female	Screen 17/02/93	Normal	
	2MD	Female	Screen 25/02/93	Normal	
	2DT	Female	Screen 02/03/93	Normal	
	3MD	Female	Screen 29/03/93	Abnormal	CARDIOMEGALY
	3DT	Male	Screen 29/03/93	Abnormal	POSTINFLAM PULM FIBROSIS
	4MD	Male	Screen 01/04/93	Normal	
	4DT	Female	Screen 20/04/93	Normal	
	5MD	Male	Screen 02/07/93	Normal	
	5DT	Female	Screen 27/08/93	Abnormal	PLEURISY W/O EFFUS OR TB
	6MD	Female	Screen 17/01/94	Normal	
	6DT	Female	Screen	Not done	
	7MD	Female	Screen 15/11/93	Normal	

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

13

PHARMACIA CNS R&D
 REBONETINE - PROTOCOL 20124/035
 Listing No.: 5.0
 CHEST X-RAY

Centre	Patient	Sex	Assessment	Date	Chest X-Ray - Pulmonary Function Value	Abnormality
35	7DT	Female	Screen	15/10/93	Normal	
	8MD	Female	Screen	01/02/94	Normal	
	8DT	Female	Screen	29/12/93	Normal	
36	1MD	Male	Screen	14/01/93	Abnormal	TUBERCULOUS PLEURISY TB BRONCHIECTASIS
	1DT	Female	Screen	29/01/93	Abnormal	BRONCHITIS NOS CARDIOMEGALY
	2MD	Female	Screen	27/01/93	Normal	
	2DT	Female	Screen	18/02/93	Normal	
	3MD	Female	Screen	01/02/93	Abnormal	ABN FINDINGS-LUNG FIELD
	3DT	Female	Screen	16/02/93	Normal	
	4MD	Female	Screen	03/03/93	Normal	
	4DT	Female	Screen	15/02/93	Normal	
	5MD	Female	Screen	20/04/93	Abnormal	TOXIC DIFFUSE GOITER
	5DT	Female	Screen	11/03/93	Normal	
	6MD	Female	Screen	07/04/93	Normal	
	6DT	Female	Screen	02/04/93	Normal	
	7MD	Female	Screen	14/05/93	Normal	

9550089

983

9550089

14

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PIARNACIA CNS R8D

REBRETINE - PROTOCOL 20124/035
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Assessment	Date	Chest X-Ray - Pulmonary Function Value	Abnormality
96	7DT	Female	Screen	15/04/93	Abnormal	LUNG DISEASE NEC
	8MD	Female	Screen	12/05/93	Normal	
	8DT	Female	Screen	05/05/93	Normal	
	9MD	Male	Screen	14/06/93	Normal	
	9DT	Female	Screen	23/06/93	Normal	
	10MD	Male	Screen	03/06/93	Abnormal	SILICA PNEUMOCOIN NEC
	10DT	Male	Screen	20/10/93	Abnormal	BRONCHITIS NOS
	11MD	Female	Screen	06/07/93	Normal	
	11DT	Male	Screen	04/11/93	Normal	
	12MD	Female	Screen	08/09/93	Abnormal	PULM CONGEST/HYPOSTASIS
	12DT	Female	Screen	13/12/93	Normal	
	13MD	Male	Screen	17/08/93	Abnormal	ENPHYSEMA CHR AIRWAY OBSTRUCT NEC
	14MD	Male	Screen	02/11/93	Normal	
	15MD	Female	Screen	28/07/93	Normal	
	16MD	Female	Screen	02/11/93	Abnormal	CARDIOMEGALY
	17MD	Female	Screen	09/11/93	Normal	

9
8
4

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

15

PHARMACIA CNS RD
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 5.0
 CHEST X-RAY

9550089

Centre	Patient	Sex	Assessment	Date	Chest X-Ray - Value	Pulmonary Function - Abnormality
36	18ND	Female	Screen	11/01/94	Normal	
	19ND	Female	Screen	04/01/94	Normal	
	20ND	Female	Screen	24/01/94	Normal	
37	3ND	Female	Screen	16/03/93	Normal	
41	1ND	Male	Screen	15/02/94	Normal	
	2ND	Male	Screen	18/02/94	Normal	
	3ND	Male	Screen	16/02/94	Normal	
	4ND	Male	Screen	24/02/94	Normal	
	5ND	Male	Screen	17/02/94	Normal	
42	1ND	Female	Screen	21/10/93	Normal	
	10T	Female	Screen	15/11/93	Normal	
	2ND	Female	Screen	21/10/93	Abnormal	CARDIOMEGALY
	20T	Male	Screen	22/11/93	Normal	
	3ND	Male	Screen	15/11/93	Normal	
43	10T	Female	Screen	19/02/93	Abnormal	KYPHOSIS
	20T	Female	Screen	10/05/93	Normal	
	30T	Male	Screen	15/09/93	Normal	

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/03S
 Listing No.: 5.0
 CHEST X-RAY

Centre	Patient	Sex	Assessment	Date	Value	Pulmonary Function Abnormality
43	4DT	Female	Screen	22/09/93	Normal	
	5ND	Female	Screen	10/12/93	Normal	
	6ND	Female	Screen	14/02/94	Abnormal	SCOLIOSIS PLEURISY W/O EFFUS OR TB PULMONARY TB NOS ABN FINDINGS-LUNG FIELD
44	1ND	Female	Screen	31/08/93	Abnormal	CARDIOMEGALY
	1DT	Female	Screen	11/05/93	Normal	
	2ND	Female	Screen	14/09/93	Normal	
	3ND	Female	Screen	11/10/93	Normal	
	4ND	Male	Screen	26/01/94	Normal	
45	1ND	Male	Screen	09/11/93	Normal	
	1DT	Female	Screen	08/07/93	Normal	
	2ND	Male	Screen	17/11/93	Abnormal	PLEURISY W/O EFFUS OR TB EMPHYSEMA
46	1ND	Male	Screen	21/09/93	Normal	
	2ND	Female	Screen	13/10/93	Normal	
	3ND	Female	Screen	25/11/94	Normal	
	4ND	Female	Screen	03/12/93	Normal	
48	1DT	Female	Screen	12/06/93	Normal	

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

17

9550089

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Assessment	Date	Chest X-Ray - Pulmonary Function Value	Abnormality
48	2DT	Female	Screen			Not done
291	1HD	Female	Screen	19/03/93		Normal
	1DT	Female	Screen	21/04/93		Normal
	2HD	Female	Screen	06/03/93		Normal
	2DT	Female	Screen	06/04/93		Normal
	3HD	Male	Screen	20/04/93		Normal
	3DT	Female	Screen	10/05/93		Normal
	4HD	Male	Screen	04/09/92		Normal
	4DT	Male	Screen	04/05/93		Normal
	25DT	Female	Screen	03/11/93		Normal
	26DT	Female	Screen	08/06/93		Normal
	27DT	Female	Screen	03/11/93		Normal
	28DT	Female	Screen	18/11/93		Normal
292	5HD	Female	Screen	19/02/93		Normal
	5DT	Male	Screen	25/02/93		Normal
	6HD	Female	Screen	02/03/93		Normal
	6DT	Female	Screen	10/03/93		Normal

987

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

18

9550089

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/03S
 Listing No.: 5.0
 CHEST X-RAY

Centre	Patient	Sex	Assessment	Date	Chest X-Ray - Pulmonary Function Abnormality
292	7ND	Male	Screen	30/03/93	Normal
	7DT	Male	Screen	11/03/93	Normal
	8ND	Male	Screen	01/04/93	Normal
	8DT	Female	Screen	22/03/92	Normal
	21ND	Female	Screen	30/04/93	Normal
	21DT	Female	Screen	30/04/93	Normal
	22ND	Female	Screen	05/05/93	Normal
	22DT	Female	Screen	30/04/93	Normal
	23ND	Female	Screen	10/05/93	Normal
	23DT	Male	Screen	03/05/93	Normal
	24ND	Male	Screen	02/04/93	Normal
	24DT	Female	Screen	21/05/93	Normal
293	9ND	Female	Screen	12/02/93	Normal
	9DT	Female	Screen	19/05/93	Normal
	10ND	Female	Screen	16/03/93	Normal
	10DT	Female	Screen	15/07/93	Normal
	11ND	Male	Screen	08/07/93	Normal

988

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9550089

PHARMACIA CNS 28D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 5.0
 CHEST X-RAY

Centre	Patient	Sex	Assessment	Date	Value	Pulmonary Function Abnormality
293	11DT	Female	Screen	12/11/93	Normal	
	12ND	Male	Screen	08/09/93	Normal	
	12DT	Female	Screen	10/12/93	Normal	
294	13ND	Female	Screen	15/02/93	Abnormal	EMPHYSEMA
	13DT	Female	Screen	13/01/93	Normal	
	14ND	Female	Screen	06/07/92	Normal	
	14DT	Female	Screen	24/06/92	Normal	
	15ND	Female	Screen	12/05/92	Normal	
	15DT	Female	Screen	30/01/92	Normal	
	16ND	Female	Screen	07/04/92	Normal	
	16DT	Female	Screen	26/01/93	Normal	
	25ND	Female	Screen	26/05/93	Normal	
	26ND	Female	Screen	17/05/93	Normal	
	27ND	Female	Screen	18/02/92	Normal	
	28ND	Female	Screen	15/06/93	Normal	
	29DT	Female	Screen	25/08/93	Normal	
	30DT	Female	Screen	14/07/92	Normal	

9550089

20

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBONETINE - PROTOCOL 20124/035
Listing No.: 5.0

CHEST X-RAY

Centre	Patient	Sex	Assessment	Date	Value	Pulmonary Function Abnormality
294	31DT	Female	Screen	07/04/92	Normal	
	32DT	Male	Screen	23/11/92	Normal	
295	17HD	Female	Screen	22/02/93	Normal	
	17DT	Male	Screen	23/04/93	Normal	
	18HD	Female	Screen	20/04/93	Normal	
	18DT	Female	Screen	27/04/93	Normal	
	19HD	Male	Screen	13/05/93	Normal	
	19DT	Female	Screen	07/05/93	Abnormal	OBSTRUCT CHR BRONCHITIS
	20HD	Female	Screen	13/05/93	Normal	
	20DT	Female	Screen	10/05/93	Normal	
381	1HD	Male	Screen	12/10/93	Normal	
	2HD	Female	Screen	30/01/94	Abnormal	CARDIOGEGALY LEFT HEART FAILURE
	3DT	Female	Screen	08/02/94	Normal	
	4HD	Female	Screen	25/02/94	Normal	
382	5HD	Female	Screen	12/11/94	Abnormal	SCOLIOSIS
	5DT	Male	Screen	13/10/93	Normal	

990

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

21

9550089

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/03S
 Listing No.: 5.0
 CHEST X-RAY

Centre	Patient	Sex	Assessment Date	Chest X-Ray - Pulmonary Function Value	Abnormality
382	6ND	Female	Screen 30/09/93	Normal	
	6DT	Female	Screen 22/10/93	Normal	
	7ND	Female	Screen 17/12/93	Normal	
	7DT	Male	Screen 22/10/93	Normal	
	8ND	Male	Screen 12/01/94	Abnormal	CARDIOMEGALY CONGESTIVE HEART FAILURE
	8DT	Female	Screen 20/12/93	Normal	
	9ND	Female	Screen 11/02/94	Abnormal	CARDIOMEGALY
	9DT	Female	Screen 06/02/92	Normal	
	10ND	Female	Screen 11/02/94	Normal	
	1ND	Female	Screen 17/09/92	Abnormal	CARDIOMEGALY
3301	2ND	Male	Screen 06/01/93	Normal	
	3ND	Female	Screen 12/01/93	Normal	
3302	5ND	Female	Screen 05/11/92	Normal	
	6ND	Female	Screen 24/06/93	Normal	
	7ND	Female	Screen 11/11/93	Normal	

991

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No.: 6

PREVIOUS ANTIDEPRESSIVE TREATMENT

Centre	Patient	Sex	Age	Name	Previous antidepressive treatment	Efficacy	Side effects	Last taken	Last day of treat.
1	1ND	Female	76	AMITRIPTYLINE	Good	Y	xxx	28/10/92	
	1DT	Male	78	PROTHIADEN	Poor		xxx	15/11/93	
	2DT	Male	73	TRYPTANOL MOCLOBEMIDE	Poor Poor		xxx	02/12/93	
	3ND	Female	65	PROTHIADEN	Poor	Y	xxx	26/05/93	
	3DT	Male	68	TRYPTANOL	Poor		xxx	04/12/93	
	4ND	Female	76	PROZAC	Very poor	Y	xxx	20/09/93	
	4DT	Male	74	DOXEPIN PROTHIADEN	Poor Poor		xxx	26/01/94	
	2	1ND	Male	74	DOTHIEPIN	Fair	Y	xxx	07/01/93
	3	1ND	Female	71	DOXEPIN			xxx	23/04/93
	4	1ND	Male	74	DOXEPIN	Fair		xxx	16/11/92
5	1DT	Female	68	TEAZOLAN	Very poor	Y			
	2ND	Male	78	LERIVON PROZAC	Poor Poor		xxx	20/10/92	
	3DT	Male	74	PROTHIADEN			xxx	91	
	4DT	Male	81	DOSULEPIN MOCLOBEMIDE FLANSEIN CLOMIPRAMINE	Poor Fair Good Good		xxx	20/12/92	
	5DT	Female	66	AMITRIPTYLINE DOSULEPIN MAPROTILINE	Poor Good Fair		xxx	09/02/93	

9550089

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 6
 PREVIOUS ANTIDEPRESSIVE TREATMENT

Centre	Patient	Sex	Age	Name	Previous antidepressive treatment		Last day of treat.
					Efficacy	Side effects taken	
5	6ND	Male	69	MIANSERIN	Fair	xxx	29/07/93
	6DT	Female	70	CIPRAMIL SINEQUAN PROZAC	Very poor Very poor Poor	xxx	12/92
	7ND	Male	85	ANITRIPTYLINE	Fair	xxx	03/10/93
	7DT	Female	65	PROZAC PROTHLADEN ANAFRANIL	Fair Poor Poor	xxx	20/01/93
	8ND	Female	68	PROTHLADEN TEPITZOL REDOMEX	Fair Fair Fair	xxx	24/10/93
	8DT	Female	66	LERIVON	Poor		
	10ND	Female	71	TRAZODONE	Fair	xxx	31/10/93
	11ND	Female	68	MIANSERIN DOSULEPIN	Fair Fair	xxx	25/11/93
	11DT	Female	70	REDOMEX	Good		
	12ND	Female	66	CLONIPRAMINE	Fair	y	20/12/93
6	1ND	Female	70	NIAMID NOVERIL SINEQUAN	Very good Good Good	xxx	85
	1DT	Female	72	MAPROTYLINE DOSULEPIN	Fair Good	xxx	07/10/92
	2ND	Female	70	DOSULEPIN	Very good	xxx	25/10/92

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 6
PREVIOUS ANTIDEPRESSIVE TREATMENT

Centre	Patient	Sex	Age	Name	Previous antidepressive treatment			Last day of treat.
					Efficacy	Side effects	Last taken	
6	2DT	Female	68	PROZAC ANAFRANIL PROTHIADEN	Fair Poor Poor	Y	***	15/01/93
	3MD	Female	68	AMITRIPTYLINE AMITRIPTYLINE	Good Poor	Y Y	*** ***	16/11/92
	3DT	Female	65	TEAZOLAN CIPRANIL LERIVON	Fair Fair Very poor		***	30/03/93
	4MD	Female	71	PROZAC	Good		***	10/10/92
	4DT	Female	69	FLUOXETINE	Poor		***	05/04/93
	5MD	Female	71	LERIVON SERTRALINE HYDROCHLORIDE TEAZOLAN	Poor Poor Fair	Y Y	***	18/03/93
	5DT	Female	68	PROZAC ANAFRANIL	Very poor Fair		***	13/09/93
	6MD	Female	77	PROTHIADEN NOVERIL	Fair Fair		***	05/04/93
	7MD	Female	70	DOSULEPIN AMITRIPTYLINE FLUOXETINE MAPROTILINE	Poor Good Good Fair		***	01/10/93
	8MD	Female	74	NOVERIL CIPRANIL ANAFRANIL REDONEX	Very poor Very poor Very poor Very poor		***	27/10/93
7	1MD	Male	66	PROZAC TUFRANIL	Fair Fair		***	04/01/93
	3MD	Female	67	REDONEX TRYPTIZOL	Poor Good		***	88

494

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No. : 6

PREVIOUS ANTIDEPRESSIVE TREATMENT

Centre	Patient	Sex	Age	Name	Previous antidepressive treatment	Efficacy	Side effects	Last taken	Last day of treat.
7	3ND	Female	67	ANAFRANIL ALIVAL	Good				
	4ND	Female	74	ANAFRANIL	Good				
	342ND	Female	67	CIPRANIL	Poor		xxx	16/02/93	
	1ND	Female	68	LERIVON	Very poor		xxx	05/12/91	
8	1DT	Female	83	REDONEX	Poor		xxx	01/08/92	
	3DT	Female	78	TRAZOLAN	Very poor		xxx	21/09/92	
	4ND	Male	70	ANAFRANIL	Very poor		xxx	20/09/92	
	701ND	Male	70	PROTHIADEN	Poor		xxx	01/10/92	
9	703DT	Male	79	PROTHIADEN	Very poor		xxx	24/01/93	
	704DT	Female	67	PROTHIADEN	Poor		xxx	25/01/93	
	6ND	Female	65	MAPROTYLINE	Poor		xxx	10/10/93	
	2DT	Male	70	MAPROTYLINE	Poor	Y	xxx	09/09/93	
10	3ND	Male	70	AMITRIPTYLINE	Poor	Y	xxx	09/09/93	
	6ND	Male	70	FLUOXETINE	Poor	Y	xxx	22/08/93	
	1ND	Female	84	STABLON	Poor		xxx	30/03/93	
	1DT	Female	85	ANAFRANIL	Fair		xxx	27/04/93	
13	1ND	Female	80	STABLON	Poor		xxx	17/03/93	

45
55
51

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 6
 PREVIOUS ANTIDEPRESSIVE TREATMENT

Centre	Patient	Sex	Age	Name	Previous antidepressive treatment	Efficacy	Side effects	Last taken	Last day of treat.
13	2DT	Female	76	ANAFRANIL	Poor	xxx	xxx	25/09/93	
	3MD	Male	79	ATHYMIL	Good				
15	1MD	Female	77	ATHYMIL SURVECTOR	Fair Fair	xxx	xxx	04/92	
	2MD	Female	84	SURVECTOR ATHYMIL	Very poor Fair	xxx	xxx	17/12/90	
	2DT	Female	89	SURVECTOR	Fair	xxx	xxx	06/04/93	
	4MD	Female	86	ANAFRANIL	Very poor	xxx	xxx	08/07/93	
	111MD	Female	65	STABLON	Very poor	xxx	xxx	01/10/93	
16	1MD	Female	85	VIVALAN	Very poor	xxx	xxx	22/01/93	
	1DT	Female	74	TRAZOLAN	Poor	xxx	xxx	10/02/93	
	2DT	Male	71	ANAFRANIL	Poor	xxx	xxx	22/04/93	
	3DT	Female	75	STABLON	Very poor	xxx	xxx	21/07/93	
	4MD	Female	75	PROZAC	Fair	xxx	xxx	92	
17	1MD	Female	71	LAROXYL	Poor	xxx	xxx	08/03/93	
	2DT	Female	76	STABLON	Very poor	xxx	Y	07/06/93	
	4MD	Female	65	PROZAC	Poor	xxx	xxx	16/12/93	
	4DT	Female	81	ATHYMIL SURVECTOR	Poor Poor	xxx	Y	20/12/93	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 6
PREVIOUS ANTIDEPRESSIVE TREATMENT

Centre	Patient	Sex	Age	Name	Previous antidepressive treatment	Efficacy	Side effects	Last taken	Last day of treat.
18	2HD	Female	68	LAROXYL		Good		xxx	02/05/93
	2DT	Female	71	ANAFRANIL LAROXYL		Good		xxx	18/10/93
	3HD	Female	82	LUDIOMIL LAROXYL FARMETINE		Good Good		xxx	01/08/93
	4HD	Female	79	VIVALAN		Poor		xxx	
22	1HD	Female	81	DOXEPIN AMITRIPTYLINE		Fair Good		xxx	22/06/93
23	1HD	Female	71	AFONAL LUDIOMIL ANAFRANIL SAROTEN STANGYL		Poor Poor Poor Poor Poor		xxx	25/01/93
	2HD	Female	69	AFONAL LUDIOMIL SAROTEN		Fair Good Very good	Y Y	xxx	28/01/93
	3HD	Female	80	FLUOXETINE SAROTEN		Poor Poor	Y Y	xxx	01/03/93
	4HD	Female	80	SAROTEN AMITRIPTYLINE		Poor Poor	Y Y	xxx	24/05/93
	5HD	Female	69	AMITRIPTYLINE		Poor	Y	xxx	30/04/93
	6HD	Female	72	ANAFRANIL		Good	Y	xxx	28/06/93
25	2HD	Female	67	MIANSERIN		Poor		xxx	18/11/93
26	1HD	Female	69	LAROXYL		Fair		xxx	22/04/93

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 6
PREVIOUS ANTIDEPRESSIVE TREATMENT

Centre	Patient	Sex	Age	Name	Previous antidepressive treatment	Efficacy	Side effects	Last taken	Last day of treat.
27	1ND	Male	79	TOLMIN STANGYL		Good Very poor		xxx	29/01/93
28	1ND	Female	70	LUDIOMIL ANAFRANIL - SLOW RELEASE		Poor Poor		xxx xxx	30/03/93
	2ND	Female	86	LUDIOMIL		Poor		xxx	04/04/93
30	3ND	Female	66	SAROTEN RETARD NORTRIPTYLINE		Poor Poor		xxx xxx	04/04/93
	1ND	Female	87	PROTHIADEN		Poor		xxx	09/04/93
	4ND	Female	78	PROTHIADEN		Poor		xxx	26/10/93
31	1ND	Female	76	ALLEGRON		Poor		xxx	15/09/92
	1DT	Female	77	PROTHIADEN SURMONTIL		Good Good		xxx	90
	2ND	Female	79	PROTHIADEN		Very poor	Y	xxx	08/08/92
	3ND	Male	84	HOLIPAXIN PROZAC		Very poor Very poor		xxx	01/12/92
32	1ND	Female	66	LOFEPRAMINE AMITRIPTYLINE CLONIPRAMINE		Poor Good Fair		xxx	09/03/93
	3ND	Female	67	CLONIPRAMINE		Fair		xxx	06/04/93
	4ND	Female	68	DOTHIPIPI		Poor		xxx	09/92
	5ND	Female	78	MIANSERIN		Fair		xxx	23/09/93

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 6

PREVIOUS ANTIDEPRESSIVE TREATMENT

Centre	Patient	Sex	Age	Name	Previous antidepressive treatment			Last day of treat.
					Efficacy	Side effects	Last taken	
32	6ND	Male	81	PAROXETINE LOFEPRAMINE	Fair Fair	xxx	02/09/93	
	1ND	Female	71	PROZAC SINERGAN	Poor Poor	xxx	21/01/93	
35	2ND	Female	72	TRAZOLAN LERIVON	Poor Poor	xxx	22/02/93	
	2DT	Female	67	ANAFRANIL VIVALAN REDONEX	Poor Poor Poor	xxx	20/02/93	
4ND	4ND	Male	90	LERIVON TRAZOLAN	Poor Poor	xxx	08/04/93	
	5ND	Male	70	VIVALAN	Poor	xxx	30/06/93	
5DT	5DT	Female	77	LERIVON CIPRAMIL	Good Good	xxx	25/08/93	
	6ND	Female	69	SERTRALINE	Very poor			
6DT	6DT	Female	69	LERIVON SERTRALINE	Poor Poor	Y	11/10/93	
	7ND	Female	74	LERIVON VENLAFAXINE CIPRAMIL	Poor Very good Poor	xxx	30/11/93	
7DT	7DT	Female	78	TRAZOLAN	Poor	xxx		
	8DT	Female	72	TRAZOLAN SERTRALINE	Very poor Poor	xxx	28/12/93	
36	3ND	Female	84	LERIVON	Very poor	xxx	20/01/93	
	4ND	Female	79	PROTHIADEN	Poor	xxx	01/03/93	

999

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/03S
 Listing No.: 6
 PREVIOUS ANTIDEPRESSIVE TREATMENT

Centre	Patient	Sex	Age	Name	Previous antidepressive treatment	Efficacy	Side effects	Last taken	Last day of treat.
36	4DT	Female	74	PROTHIADEN	Poor	xxx		03/03/93	
	5ND	Female	79	NIANID	Fair	xxx		27/09/89	
	5DT	Female	65	PROTHIADEN ANAFRANIL	Poor Very poor	xxx	Y	25/03/93	
	7DT	Female	75	ANAFRANIL	Poor	xxx		20/04/93	
	9DT	Female	65	TOFRANIL	Fair	xxx		12/92	
	10ND	Male	77	MIANSERIN	Good	xxx		12/90	
	10DT	Male	79	REDONEX	Fair	xxx		92	
	11ND	Female	81	TYMELYT	Good	xxx		31/03/92	
	11DT	Male	78	LERIVON	Fair	xxx		11/91	
	12ND	Female	78	REDONEX	Very poor	xxx		15/09/93	
	12DT	Female	81	IMIPRAMINE	Very poor	xxx		14/12/93	
	13ND	Male	76	ANAFRANIL	Fair	xxx		07/09/93	
	15ND	Female	73	ANAFRANIL	Good	xxx		30/08/93	
	16ND	Female	72	ANAFRANIL - SLOW RELEASE	Poor	xxx		01/11/93	
	18ND	Female	78	PROZAC	Fair	xxx		18/06/93	
	20ND	Female	70	ANAFRANIL	Good	xxx		01/09/91	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 PAROXETINE - PROTOCOL 20124/035
 Listing No.: 6
 PREVIOUS ANTI-DEPRESSIVE TREATMENT

Centre	Patient	Sex	Age	Name	Previous anti-depressive treatment			Last day of treat.
					Efficacy	Side effects	Last taken	
37	3ND	Female	81	TRAZOLAN				
41	1ND	Male	69	DOTHIEPIN	Fair		xxx	08/02/94
3ND	3ND	Male	85	LOFEPRAMINE PROTHIADEN	Good Fair		xxx	14/02/94
4ND	4ND	Male	74	PAROXETINE LOFEPRAMINE AMITRIPTYLINE	Fair Good Good		xxx	10/02/94
5ND	5ND	Male	69	FLUNOXAMINE MIANSERIN PAROXETINE AMITRIPTYLINE	Fair Good Poor Good	Y Y	xxx	18/02/94
42	1ND	Female	73	AMITRIPTYLINE	Fair		xxx	07/85
1DT	1DT	Female	79	PAROXETINE PROTHIADEN LOFEPRAMINE	Poor Poor Poor	Y Y Y	xxx	26/04/93
2ND	2ND	Female	79	PROZAC MOLIPAXIN PROTHIADEN	Very poor Poor Poor	Y Y Y	xxx	02/06/93
2DT	2DT	Male	68	MOLIPAXIN AMITRIPTYLINE	Poor Very poor	Y Y	xxx	06/07/93
3ND	3ND	Male	82	ANAFRANIL LITHIUM CARBONATE LOFEPRAMINE	Poor Fair Poor	Y Y Y	xxx	31/08/93
43	2DT	Female	77	NORTRIPTYLINE	Fair	Y	xxx	07/05/93
4DT	4DT	Female	79	NORTRIPTYLINE	Good	Y	xxx	90
6ND	6ND	Female	74	FLUOXETINE	Poor	Y	xxx	27/01/94

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RD

REBOXETINE - PROTOCOL 20124/035

Listing No. 6

PREVIOUS ANTIDEPRESSIVE TREATMENT

Centre	Patient	Sex	Age	Name	Previous antidepressive treatment	Efficacy	Side effects	Last taken	Last day of treat.
44	1ND	Female	76	AMITRIPTYLINE	Fair			xxx	25/08/93
				CLOMIPRAMINE	Poor	Y			
				LOFEPRAMINE	Fair				
				AMOXAPINE	Good				
	1DT	Female	76	SERTRALINE	Fair			xxx	
				NOCLOREXIDE	Fair				
				AMOXAPINE	Very poor	Y			25/07/93
				LOFEPRAMINE	Fair				
	2ND	Female	73	SERTRALINE	Good			xxx	
				AMOXAPINE	Poor	Y			
				TRIFAZOL	Good				12/09/93
				AMITRIPTYLINE	Fair				
	3ND	Female	73	TRIMIPRAMINE	Good	Y			
				IMIPRAMINE	Good	Y			
				AMOXAPINE	Poor				
				FLUOXETINE	Fair				07/10/93
	4ND	Male	81	LITHIUM	Fair	Y		xxx	
				IMIPRAMINE	Fair				
				PAROXETINE	Poor				
				IMIPRAMINE	Poor				
	2ND	Male	77	SERTRALINE	Fair			xxx	
				AMOXAPINE	Poor				
				NORTRIPTYLINE	Good				12/10/93
				LITHIUM	Fair				
45	2ND	Male	77	GABANIL	Fair			xxx	01/12/92
46	1ND	Male	69	LOFEPRAMINE	Poor			xxx	17/09/93
48	1DT	Female	74	PROTHIADEN	Poor			xxx	01/10/93
	1DT	Female	74	TOFRANIL	Poor			xxx	
				PROTHIADEN	Poor				
				TOLYON	Poor				15/06/93

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No.: 6

PREVIOUS ANTIDEPRESSIVE TREATMENT

Centre	Patient	Sex	Age	Name	Previous antidepressive treatment	Efficacy	Side effects	Last taken	Last day of treat.
48	2DT	Female	65	PROTHIADEN		Poor	Y	***	17/06/93
291	2DT	Female	73	SINQUAN		Fair		***	26/03/93
	4MD	Male	68	SAROTEN		Poor		***	88
	28DT	Female	73	ANAFRANIL		Poor		***	30/08/93
292	21MD	Female	72	EQUILIBRIN		Fair		***	28/10/87
	23DT	Male	69	STANGYL		Fair		***	09/92
293	9MD	Female	80	INSTIDOM EQUILIBRIN		Fair Good		***	01/92
	9DT	Female	67	FLUOXETINE INSIDON		Poor Fair		***	30/10/92
	10MD	Female	65	FEVARIN APONAL		Poor Fair		***	18/12/92
	10DT	Female	66	FLUOXETINE STANGYL		Fair Fair		***	18/06/92
	11MD	Male	65	MIANSERIN INSIDON EQUILIBRIN		Fair Fair Poor		***	09/12/92
	11DT	Female	68	EQUILIBRIN INSIDON		Fair Fair		***	17/11/92
	12MD	Male	56	APONAL SINQUAN FLUOXAMINE MALEATE		Poor Fair Poor		***	10/11/92
	12DT	Female	69	FLUOXETINE		Poor		***	16/12/90

1003

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listings No. 6

PREVIOUS ANTIDEPRESSIVE TREATMENT

Centre	Patient	Sex	Age	Name	Previous antidepressive treatment	Efficacy	Side effects	Last taken	Last day of treat.
293	12DT	Female	69	APONAL	Poor				
295	17MD	Female	64	VIVALAN LUDIONIL	Good Fair		***	29/10/90	
18MD	73	Female		EQUILIBRIN	Poor				
18DT	71	Female		INSIDON	Fair		***	08/02/93	
19MD	66	Male		SINQUAN	Poor				
19DT	69	Female		HAPROTILINE HYDROCHLORIDE LUDIONIL EQUILIBRIN TOLVIN	Fair Good Good Fair	Y	***	22/01/93	
20MD	82	Female		LUDIONIL TOLVIN	Fair Good		***	05/10/92	
20DT	66	Female		LUDIONIL TOLVIN	Fair Fair		***	26/11/92	
381	3DT	Female	77	PAROMETINE	Poor	Y	***	10/01/94	
3301	1MD	Female	76	PROTHIADEN	Poor		***	07/88	
3302	3MD	Female	71	LOFEPRAMINE	Very poor		***	07/01/93	
	5MD	Female	84	PROZAC GAMANIL	Poor Good		***	23/10/92	
6MD	73	Female		PROTHIADEN	Fair	Y	***	18/06/93	
7MD	93	Female		PROZAC	Very poor		***	10/93	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RD

REBOXETINE - PROTOCOL 20124/035
 Listing No.: 6.1
 DRUG FREE - WASH-OUT PERIOD

Centre	Patient	Last day of previous treatment	Wash out period		Days	Treatment	
			From (*)	To (a)		Start date	Randomized
1	1HD	28/10/92	29/10/92	04/11/92	8	05/11/92	Reboxetine
	1DT	15/11/93	16/11/93	25/11/93	10	26/11/93	Reboxetine
	2HD			16/11/92		17/11/92	Imipramine
	2DT	02/12/93	03/12/93	08/12/93	6	09/12/93	Imipramine
	3HD	26/05/93	27/05/93	02/06/93	7	03/06/93	Imipramine
	3DT	04/12/93	05/12/93	09/12/93	5	10/12/93	Reboxetine
	4HD	20/09/93	21/09/93	18/10/93	29	19/10/93	Reboxetine
	4DT	26/01/94	27/01/94	31/01/94	6	01/02/94	Imipramine
	1HD	07/01/93	08/01/93	14/01/93	7	15/01/93	Reboxetine
	1HD	23/04/93	24/04/93	04/05/93	12	05/05/93	Reboxetine
4	1HD	16/11/92	17/11/92	24/11/92	8	25/11/92	Imipramine
	1HD			29/10/92	7	30/10/92	Reboxetine
5	1DT			14/10/92	28	11/11/92	Imipramine
	2HD	20/10/92	16/11/92	23/11/92	8	24/11/92	Reboxetine
2DT				14/12/92	9	23/12/92	Imipramine
	3HD			16/03/93		17/03/93	Imipramine
3DT				02/01/91	816	27/03/93	Reboxetine

(*) if missing date = last day of previous treatment + 1 day
 (a) same as start treatment date - 1 day

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 6.1
DRUG FREE - WASH-OUT PERIOD

Centre	Patient	Last day of previous treatment	From (*)	To (B)	Days	Start date	Treatment Randomized
5	4MD	18/11/92	23/11/92	24/11/92	6	24/11/92	Imipramine
	4DT	20/12/92	21/12/92	02/02/93	45	03/02/93	Reboxetine
	5MD		20/07/93	03/08/93	15	04/08/93	Reboxetine
	5DT	09/02/93	10/02/93	16/02/93	8	17/02/93	Reboxetine
	6MD	29/07/93	30/07/93	04/08/93	7	05/08/93	Imipramine
	6DT	12/92	02/12/92	26/02/93	86	27/02/93	Reboxetine
	7MD	03/10/93	04/10/93	26/10/93	24	27/10/93	Reboxetine
	7DT	20/01/93	21/01/93	12/03/93	51	13/03/93	Imipramine
	8MD	24/10/93	25/10/93	10/11/93	18	11/11/93	Imipramine
	8DT		04/05/93	04/05/93		05/05/93	Imipramine
	9MD		15/11/93	15/11/93		16/11/93	Reboxetine
	9DT		01/05/93	01/05/93		02/05/93	Reboxetine
	10MD	31/10/93	01/11/93	24/11/93	25	25/11/93	Imipramine
	10DT		05/05/93	05/05/93		06/05/93	Imipramine
	11MD	25/11/93	26/11/93	01/12/93	7	02/12/93	Imipramine
	11DT		10/05/93	10/05/93		11/05/93	Reboxetine

* Wash out period date = last day of previous treatment + 1 day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
 Listing No. : 6, 4
 DRUG FREE - WASH-OUT PERIOD

Centre	Patient	Last day of previous treatment	Wash out period		Days	Treatment	
			From (*)	To (a)		Start date	Randomized
5	12HD	20/12/93	21/12/93	05/01/94	17	06/01/94	Reboxetine
	12DT			20/05/93		21/05/93	Imipramine
	1HD	85	02/01/85	12/11/92	2873	13/11/92	Reboxetine
	1DT	07/10/92	08/10/92	20/10/92	14	21/10/92	Reboxetine
	2HD	25/10/92	26/10/92	10/11/92	17	11/11/92	Imipramine
	2DT	15/01/93	16/01/93	20/01/93	5	21/01/93	Reboxetine
	3HD	16/11/92	17/11/92	02/12/92	17	03/12/92	Reboxetine
	3DT	30/03/93	31/03/93	07/04/93	8	08/04/93	Imipramine
	4HD	10/10/92	08/12/92	14/12/92	7	15/12/92	Imipramine
	4DT	05/04/93	06/04/93	04/05/93	30	05/05/93	Imipramine
6	5HD	18/03/93	19/03/93	02/04/93	15	03/04/93	Imipramine
	5DT	13/09/93	14/09/93	19/11/93	68	20/11/93	Reboxetine
	6HD	05/04/93	06/04/93	28/04/93	23	29/04/93	Reboxetine
	7HD	01/10/93	02/10/93	19/10/93	19	20/10/93	Reboxetine
	8HD	27/10/93	28/10/93	22/11/93	27	23/11/93	Imipramine
	1HD	04/01/93	05/01/93	08/01/93	5	09/01/93	Imipramine

(*) if missing date = last day of previous treatment + 1 day
 (a) same as start treatment date - 1 day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Centre	Patient	Last day of previous treatment	Wash out period		Days	Treatment	
			From (*)	To (a)		Start date	Randomized
7	3HD	88	16/04/93	22/04/93	7	23/04/93	Imipramine
	4HD		16/04/93	23/04/93	8	24/04/93	Reboxetine
	342HD	16/02/93	17/02/93	22/02/93	6	23/02/93	Reboxetine
	1HD	05/12/91	06/12/91	29/09/92	299	30/09/92	Reboxetine
8	1DT	01/08/92	02/08/92	27/09/92	57	28/09/92	Imipramine
	2HD		23/09/92	29/09/92	7	30/09/92	Reboxetine
	2DT		29/09/92	29/09/92		30/09/92	Imipramine
	3SD		01/10/92	01/10/92		02/10/92	Imipramine
	3DT	21/09/92	22/09/92	01/10/92	10	02/10/92	Reboxetine
	4HD	20/09/92	21/09/92	01/10/92	11	02/10/92	Imipramine
	4DT		01/10/92	01/10/92		02/10/92	Reboxetine
	701HD	01/10/92	02/10/92	08/10/92	7	09/10/92	Imipramine
	701DT		08/10/92	08/10/92		09/10/92	Reboxetine
	702HD		15/10/92	15/10/92		16/10/92	Reboxetine
702DT		08/10/92	08/10/92		09/10/92	Imipramine	
703HD		08/02/93	08/02/93		09/02/93	Imipramine	

(*) if missing date = last day of previous treatment + 1 day
(a) same as start treatment date - 1 day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 6.1
 DRUG FREE - WASH-OUT PERIOD

Centre	Patient	Last day of previous treatment	Wash out period		Days	Treatment	
			From (*)	To (a)		Start date	Randomized
8	703DT	24/01/93	25/01/93	08/02/93	15	09/02/93	Imipramine
	704HD			08/02/93		09/02/93	Reboxetine
	704DT	25/01/93	26/01/93	08/02/93	14	09/02/93	Reboxetine
9	1HD			27/09/93		28/09/93	Imipramine
	1DT			14/12/93		15/12/93	Imipramine
	2HD			30/09/93		01/10/93	Reboxetine
	2DT			21/12/93		22/12/93	Imipramine
	3DT			12/10/93		13/10/93	Reboxetine
	4HD			12/10/93		13/10/93	Imipramine
	5HD			25/10/93		26/10/93	Reboxetine
10	6HD	10/10/93	11/10/93	02/11/93	23	03/11/93	Imipramine
	7HD			09/11/93		10/11/93	Imipramine
	8DT			15/11/93		16/11/93	Reboxetine
	1HD		24/09/93	01/10/93	8	02/10/93	Imipramine
	1DT		23/11/93	30/11/93	8	01/12/93	Reboxetine
2HD		24/09/93	01/10/93	8	02/10/93	Reboxetine	

(*) if missing date = last day of previous treatment + 1 day
 (a) same as start treatment date - 1 day

1009

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Centre	Patient	Last day of previous treatment	Wash out period		Days	Treatment	
			From (*)	To (a)		Start date	Randomized
10	2DI	09/09/93	23/11/93	30/11/93	8	01/12/93	Imipramine
	3ND	09/09/93	24/09/93	01/10/93	8	02/10/93	Reboxetine
	3DI		24/11/93	01/12/93	8	02/12/93	Imipramine
	4ND		28/09/93	05/10/93	8	06/10/93	Imipramine
	4DI		24/11/93	01/12/93	8	02/12/93	Reboxetine
	5ND		29/09/93	05/10/93	7	06/10/93	Imipramine
	5DI		26/11/93	03/12/93	8	04/12/93	Reboxetine
	6ND	22/08/93	01/10/93	08/10/93	8	09/10/93	Reboxetine
	6DI		26/11/93	03/12/93	8	04/12/93	Reboxetine
	7ND		01/10/93	08/10/93	8	09/10/93	Imipramine
7DI		26/11/93	03/12/93	8	04/12/93	Imipramine	
8ND		08/10/93	15/10/93	8	16/10/93	Reboxetine	
8DI		26/11/93	03/12/93	8	04/12/93	Imipramine	
9ND		12/11/93	19/11/93	8	20/11/93	Reboxetine	
9DI		30/11/93	07/12/93	8	08/12/93	Imipramine	
10ND		15/10/93	22/10/93	8	23/10/93	Imipramine	

(*) if missing date = Last day of previous treatment + 1 day
(a) same as start treatment date - 1 day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No: 6.4

DRUG FREE - WASH-OUT PERIOD

Centre	Patient	Last day of previous treatment	Wash out period		Days	Treatment		
			From (*)	To (3)		Start date	Randomized	
10	10DT		30/11/93	07/12/93	8	08/12/93	Reboxetine	
	11HD		15/10/93	22/10/93	8	23/10/93	Imipramine	
	11DT		30/11/93	07/12/93	8	08/12/93	Imipramine	
	12HD		19/10/93	26/10/93	8	27/10/93	Reboxetine	
	12DT		30/11/93	07/12/93	8	08/12/93	Reboxetine	
	13DT		19/10/93	26/10/93	8	27/10/93	Reboxetine	
	14DT		22/10/93	29/10/93	8	30/10/93	Imipramine	
	15HD		22/10/93	29/10/93	8	30/10/93	Reboxetine	
	16DT		22/10/93	29/10/93	8	30/10/93	Imipramine	
	17HD		29/10/93	05/11/93	8	06/11/93	Reboxetine	
	18HD		29/10/93	05/11/93	8	06/11/93	Imipramine	
	19DT		29/10/93	05/11/93	8	06/11/93	Reboxetine	
	12	20HD		29/10/93	05/11/93	8	06/11/93	Reboxetine
		1HD	30/03/93	31/03/93	27/04/93	28	28/04/93	Reboxetine
	13	1DT	27/04/93	28/04/93	19/05/93	23	20/05/93	Reboxetine
1HD		17/03/93	18/03/93	07/04/93	22	08/04/93	Reboxetine	

(*) if missing date = last day of previous treatment + 1 day
 (3) same as start treatment date - 1 day

1011

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No. : 6.1

DRUG FREE - WASH-OUT PERIOD

Centre	Patient	Last day of previous treatment	Wash out period		Days	Treatment	
			From (*)	To (a)		Start date	Randomized
13	1DT			22/09/93		23/09/93	Imipramine
	2ND			10/12/93		11/12/93	Imipramine
	2DT	25/09/93	26/09/93	21/10/93	27	22/10/93	Reboxetine
	3ND		93	02/02/94	398	03/02/94	Imipramine
	3DT			08/11/93		09/11/93	Imipramine
	4DT			02/02/94		03/02/94	Reboxetine
	1ND		31/03/94	05/04/94	6	06/04/94	Reboxetine
	1ND	04/92	02/04/92	28/02/93	334	01/03/93	Reboxetine
	1DT			25/07/93		26/07/93	Reboxetine
	2ND		17/12/90	18/12/90	23/03/93	827	24/03/93
14	2DT	06/04/93	07/04/93	21/02/94	322	22/02/94	Imipramine
	3ND			05/05/93		06/05/93	Reboxetine
	4ND	08/07/93	09/07/93	14/07/93	6	15/07/93	Imipramine
	11ND	01/10/93	02/10/93	07/10/93	6	08/10/93	Reboxetine
	112ND			28/11/93		29/11/93	Imipramine
	1ND	22/01/93	11/02/93	17/02/93	7	18/02/93	Reboxetine

(*) if missing date = last day of previous treatment + 1 day
(a) same as start treatment date - 1 day

1012

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9550089

PHARMACIA CMS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 6.1
DRUG FREE - WASH-OUT PERIOD

Centre	Patient	Last day of previous treatment	Wash out period		Days	Treatment	
			From (*)	To (B)		Start date	Randomized
16	10T	10/02/93	11/02/93	17/02/93	7	18/02/93	Imipramine
	2ND		07/04/93	14/04/93	8	15/04/93	Imipramine
	20T	22/04/93	23/04/93	03/05/93	11	04/05/93	Reboxetine
	3ND		04/05/93	08/05/93	5	09/05/93	Imipramine
	30T	21/07/93	22/07/93	28/07/93	7	29/07/93	Imipramine
	4ND	92	02/01/92	18/04/94	839	19/04/94	Reboxetine
	1ND	08/03/93	09/03/93	30/03/93	22	31/03/93	Reboxetine
	10T			27/04/93		28/04/93	Reboxetine
	2ND			20/04/93		21/04/93	Imipramine
	20T	07/06/93	08/06/93	06/07/93	30	07/07/93	Reboxetine
17	3ND			05/11/93		06/11/93	Imipramine
	30T			18/10/93		19/10/93	Imipramine
	4ND	16/12/93	17/12/93	11/01/94	27	12/01/94	Reboxetine
	40T	20/12/93	21/12/93	18/01/94	30	19/01/94	Imipramine
	211ND			18/05/94		19/05/94	Reboxetine
	2110T			04/04/94		05/04/94	Reboxetine

(*) if missing date = last day of previous treatment + 1 day
(B) same as start treatment date - 1 day

1013

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No. - 6.1

DRUG FREE - WASH-OUT PERIOD

Centre	Patient	Last day of previous treatment	Wash out period		Days	Treatment	
			From (*)	To (g)		Start date	Randomized
18	1MD		18/05/93	26/05/93	9	27/05/93	Imipramine
	1DT		03/08/93	11/08/93	9	12/08/93	Imipramine
	2MD	02/05/93	22/05/93	29/05/93	8	30/05/93	Imipramine
	2DT	18/10/93	04/11/93	08/11/93	5	09/11/93	Reboxetine
	3ND	01/08/93	02/08/93	13/08/93	13	14/08/93	Reboxetine
	4ND		28/09/93	02/10/93	5	03/10/93	Reboxetine
	3ND		08/07/93	08/07/93		09/07/93	Reboxetine
	1ND	22/06/93	23/06/93	24/06/93	2	25/06/93	Reboxetine
	1ND	25/01/93	26/01/93	29/01/93	5	30/01/93	Reboxetine
	2ND	28/01/93	29/01/93	01/02/93	5	02/02/93	Reboxetine
25	3ND	01/03/93	19/03/93	22/03/93	4	23/03/93	Imipramine
	4ND	24/03/93	25/03/93	30/03/93	6	31/03/93	Imipramine
	5ND	30/04/93	01/05/93	04/05/93	4	05/05/93	Imipramine
	6ND	28/06/93	29/06/93	05/07/93	7	06/07/93	Imipramine
	1ND		26/08/93	26/08/93		27/08/93	Reboxetine
	2ND	18/11/93	19/11/93	25/11/93	7	26/11/93	Imipramine

(*) if missing date = last day of previous treatment + 1 day
 (g) same as start treatment date - 1 day

1014

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 6.1
DRUG FREE - WASH-OUT PERIOD

Centre	Patient	Last day of previous treatment	Wash out period		Days	Treatment Randomized
			From (*)	To (B)		
26	1ND	22/04/93	23/04/93	26/04/93	5	27/04/93 Imipramine
	1DT		25/06/93	28/06/93	4	29/06/93 Reboxetine
	1ND	29/01/93	30/01/93	01/02/93	3	02/02/93 Imipramine
	1ND	30/03/93	31/03/93	19/04/93	21	20/04/93 Reboxetine
	1DT			21/04/93		22/04/93 Imipramine
27	2ND	04/04/93	05/04/93	25/04/93	22	26/04/93 Imipramine
	2DT			26/04/93		27/04/93 Reboxetine
	3ND	04/04/93	05/04/93	26/04/93	23	27/04/93 Reboxetine
30	3DT			10/05/93		11/05/93 Imipramine
	4ND			03/05/93		04/05/93 Imipramine
	5ND			24/05/93		25/05/93 Reboxetine
	1ND	09/04/93	10/04/93	20/04/93	12	21/04/93 Imipramine
	2ND			15/07/93		16/07/93 Reboxetine
4ND	3ND			07/11/93		08/11/93 Imipramine
	4ND	26/10/93	27/10/93	01/11/93	7	02/11/93 Reboxetine
	5ND			17/12/93		18/12/93 Imipramine

(*) if missing date = last day of previous treatment + 1 day
(B) same as start treatment date - 1 day

1015

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D									
REBOXETINE - PROTOCOL 20124/035									
Listing No. 6.1									
DRUG FREE - WASH-OUT PERIOD									
Centre	Patient	Last day of previous treatment	Wash out period		Days	Treatment			
			From (*)	To (a)		Start date	Randomized		
31	1ND	15/09/92	16/09/92	22/09/92	8	23/09/92	Imipramine		
	1DT	90	02/01/90	22/09/92	996	23/09/92	Reboxetine		
	2ND	08/08/92	09/08/92	01/12/92	115	02/12/92	Reboxetine		
	3ND	01/12/92	02/12/92	13/12/92	13	14/12/92	Imipramine		
	32	1ND	09/03/93	10/03/93	24/03/93	16	25/03/93	Imipramine	
		2ND		02/04/93	14/04/93	13	15/04/93	Imipramine	
		3ND	06/04/93	07/04/93	21/04/93	16	22/04/93	Reboxetine	
		4ND	09/92	08/09/93	06/10/93	29	07/10/93	Reboxetine	
		5ND	23/09/93	27/10/93	03/11/93	8	04/11/93	Reboxetine	
		6ND	02/09/93	09/09/93	16/11/93	69	17/11/93	Imipramine	
35	1ND	21/01/93	22/01/93	25/01/93	4	26/01/93	Reboxetine		
	1DT		20/02/93	02/03/93	11	03/03/93	Reboxetine		
	2ND	22/02/93	23/02/93	02/03/93	8	03/03/93	Imipramine		
	2DT	20/02/93	21/02/93	02/03/93	10	03/03/93	Imipramine		
	3ND		26/03/93	29/03/93	4	30/03/93	Imipramine		
	3DT			10/92	30/03/93	181	31/03/93	Imipramine	

(*) if missing data = last day of previous treatment + 1 day
(a) same as start treatment date - 1 day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 6.1
 DRUG FREE - WASH-OUT PERIOD

Centre	Patient	Last day of previous treatment	Wash out period		Days	Start date	Treatment Randomized
			From (*)	To (B)			
35	4HD	08/04/93	09/04/93	19/04/93	11	20/04/93	Reboxetine
	4DT		19/04/93	26/04/93	8	27/04/93	Reboxetine
	5XD	30/06/93	01/07/93	08/07/93	9	09/07/93	Reboxetine
	5DT	25/08/93	26/08/93	01/09/93	7	02/09/93	Imipramine
	6HD		17/01/94	20/01/94	4	21/01/94	Reboxetine
	6DT	11/10/93	12/10/93	19/10/93	8	20/10/93	Imipramine
	7HD	30/11/93	01/12/93	09/12/93	9	10/12/93	Imipramine
	7DT		15/10/93	19/10/93	5	20/10/93	Reboxetine
	8HD		25/01/94	31/01/94	7	01/02/94	Imipramine
	8DT	28/12/93	04/01/94	10/01/94	7	11/01/94	Reboxetine
36	1HD		08/01/93	15/01/93	8	16/01/93	Imipramine
	1DT		29/01/93	02/02/93	5	03/02/93	Imipramine
	2HD		27/01/93	02/02/93	7	03/02/93	Reboxetine
	2DT			24/02/93		25/02/93	Reboxetine
	3HD	20/01/93	29/01/93	05/02/93	8	06/02/93	Imipramine
			25/02/93	01/03/93	5	02/03/93	Imipramine
	3DT						

(*) if missing date = last day of previous treatment + 1 day
 (B) same as start treatment date - 1 day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124-035
 Listing No.: 6
 DRUG FREE - WASH-OUT PERIOD

Centre	Patient	Last day of previous treatment	Wash out period		Days	Treatment	
			From (*)	To (#)		Start date	Randomized
36	4ND	01/03/93	02/03/93	08/03/93	7	09/03/93	Reboxetine
	4DT	03/03/93	04/03/93	11/03/93	8	12/03/93	Reboxetine
	5ND	27/09/89	19/04/93	25/04/93	5	24/04/93	Reboxetine
	5DT	25/03/93	26/03/93	02/04/93	9	03/04/93	Imipramine
	6ND		22/04/93	30/04/93	9	01/05/93	Imipramine
	6DT		31/03/93	09/04/93	10	10/04/93	Imipramine
	7ND		05/05/93	12/05/93	8	13/05/93	Reboxetine
	7DT	20/04/93	21/04/93	30/04/93	11	01/05/93	Reboxetine
	8ND		17/05/93	25/05/93	9	26/05/93	Imipramine
	8DT		08/05/93	14/05/93	7	15/05/93	Reboxetine
	9ND		11/06/93	15/06/93	5	16/06/93	Reboxetine
	9DT	12/92	24/06/93	28/06/93	5	29/06/93	Imipramine
	10ND	12/90	12/06/93	21/06/93	10	22/06/93	Reboxetine
	10DT	92	19/10/93	25/10/93	7	26/10/93	Reboxetine
	11ND	31/03/92	04/07/93	08/07/93	5	09/07/93	Imipramine
	11DT	11/91	02/11/93	09/11/93	8	10/11/93	Reboxetine

(*) if missing date = last day of previous treatment + 1 day
 (#) same as start treatment date - 1 day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 6.1
DRUG FREE - WASH-OUT PERIOD

Centre	Patient	Last day of previous treatment	Wash out period		Days	Treatment	
			From (*)	To (S)		Start date	Randomized
36	12ND	15/09/93	16/09/93	23/09/93	9	24/09/93	Imipramine
	12DT	14/12/93	15/12/93	21/12/93	8	22/12/93	Imipramine
	13ND	07/09/93	13/09/93	20/09/93	8	21/09/93	Reboxetine
	14ND		25/10/93	02/11/93	9	03/11/93	Imipramine
	15ND	30/08/93	15/10/93	22/10/93	8	23/10/93	Reboxetine
	16ND	01/11/93	02/11/93	08/11/93	8	09/11/93	Imipramine
	17ND		02/11/93	09/11/93	8	10/11/93	Reboxetine
	18ND	18/06/93	06/11/93	12/01/94	68	13/01/94	Imipramine
	19ND		07/01/94	14/01/94	8	15/01/94	Reboxetine
	20ND	01/09/91	23/01/94	31/01/94	9	01/02/94	Imipramine
37	3ND		11/03/93	17/03/93	7	18/03/93	Reboxetine
	1ND	08/02/94	09/02/94	21/02/94	14	22/02/94	Imipramine
	2ND		22/02/94	22/02/94		23/02/94	Reboxetine
	3ND	14/02/94	15/02/94	24/02/94	11	25/02/94	Imipramine
	4ND	10/02/94	21/02/94	27/02/94	7	28/02/94	Reboxetine
5ND	18/02/94	19/02/94	02/03/94	13	03/03/94	Reboxetine	

(*) if missing date = last day of previous treatment + 1 day
(S) same as start treatment date - 1 day

1019

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D									
REBOXETINE - PROTOCOL 20124/035									
Listing No.: 6.1									
DRUG FREE - WASH-OUT PERIOD									
Centre	Patient	Last day of previous treatment	Wash out period		Days	Treatment		Start date	Randomized
			From (*)	To (a)		Start date	Randomized		
42	1HD	07/85	04/10/93	25/10/93	22	26/10/93	Imipramine		
	1DT	26/04/93	12/10/93	24/11/93	44	25/11/93	Imipramine		
	2HD	02/06/93	15/06/93	25/10/93	133	26/10/93	Reboxetine		
	2DT	06/07/93	01/11/93	08/12/93	38	09/12/93	Reboxetine		
	3HD	31/08/93	28/09/93	24/11/93	58	25/11/93	Imipramine		
	1DT			18/02/93			19/02/93	Reboxetine	
43	2DT	07/05/93	08/05/93	10/05/93	4	11/05/93	Imipramine		
	3DT			14/09/93		15/09/93	Imipramine		
	4DT	90	02/01/90	22/09/93	1361	23/09/93	Reboxetine		
	5HD			09/12/93		10/12/93	Imipramine		
	6HD		27/01/94	28/01/94	20	16/02/94	Imipramine		
	1HD		26/08/93	27/08/93	8	03/09/93	Reboxetine		
44	1DT		27/07/93	30/07/93	4	31/07/93	Reboxetine		
	2HD		12/09/93	13/09/93	7	20/09/93	Reboxetine		
	3HD		07/10/93	08/10/93	7	14/10/93	Imipramine		
	4HD		12/10/93	13/10/93	11	31/01/94	Imipramine		

(*) if missing date = last day of previous treatment + 1 day
 (a) same as start treatment date - 1 day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 6.1
DRUG FREE - WASH-OUT PERIOD

Centre	Patient	Last day of previous treatment	Wash out period		Days	Treatment	
			From (*)	To (a)		Start date	Randomized
45	1MD			24/11/93		25/11/93	Reboxetine
	1DT			11/08/93		12/08/93	Imipramine
	2MD	01/12/92	02/12/92	06/12/93	371	07/12/93	Imipramine
	1MD	17/09/93	18/09/93	27/09/93	11	28/09/93	Imipramine
46	2MD	01/10/93	02/10/93	18/10/93	18	19/10/93	Imipramine
	3MD		07/11/93	01/12/93	25	02/12/93	Reboxetine
	4MD		24/11/93	07/12/93	14	08/12/93	Reboxetine
	1DT	15/06/93	16/06/93	23/06/93	8	24/06/93	Reboxetine
291	2DT	17/06/93	18/06/93	27/06/93	10	28/06/93	Imipramine
	1MD			21/03/93		22/03/93	Imipramine
	1DT			21/04/93		22/04/93	Reboxetine
	2MD			19/04/93		20/04/93	Reboxetine
48	2DT	26/03/93	27/03/93	21/04/93	26	22/04/93	Reboxetine
	3MD			18/04/93		19/04/93	Imipramine
	3DT			13/05/93		14/05/93	Imipramine
	4MD	88	02/01/88	02/05/93	1949	03/05/93	Reboxetine

(*) if missing date = last day of previous treatment + 1 day
(a) same as start treatment date - 1 day

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9550089

Centre	Patient	Last day of previous treatment	Wash out period		Days	Treatment		
			From (*)	To (9)		Start date	Randomized	
291	4DT			04/05/93		05/05/93	Imipramine	
	25DT			03/11/93		04/11/93	Imipramine	
	26DT			05/06/93		09/06/93	Reboxetine	
	27DT			03/11/93		04/11/93	Reboxetine	
	28DT	30/08/93	31/08/93	17/11/93	79	18/11/93	Imipramine	
	292	5ND			17/02/93		03/03/93	Imipramine
		5DT			22/02/93		05/03/93	Reboxetine
		6ND			19/02/93		03/03/93	Reboxetine
		6DT			05/03/93		15/03/93	Imipramine
		7ND			30/03/93		20/04/93	Reboxetine
7DT				08/03/93		18/03/93	Imipramine	
8ND				01/04/93		22/04/93	Imipramine	
8DT				22/03/93		08/04/93	Reboxetine	
21ND			28/10/87	30/04/93		07/05/93	Imipramine	
21DT				30/04/93		03/05/93	Reboxetine	
22ND			05/05/93		19/05/93	Imipramine		

(*) if missing date = last day of previous treatment + 1 day
 (9) same as start treatment date - 1 day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
 Listing No.: 6.1
 DRUG FREE - WASH-OUT PERIOD

Centre	Patient	Last day of previous treatment	Wash out period		Days	Treatment	
			From (*)	To (3)		Start date	Randomized
292	22DT		16/04/93	04/05/93	19	05/05/93	Imipramine
	23HD		10/05/93	26/05/93	17	27/05/93	Reboxetine
	23DT	09/92	03/05/93	13/05/93	11	14/05/93	Reboxetine
	24HD		28/05/93	04/06/93	8	05/06/93	Reboxetine
	24DT		21/05/93	01/06/93	12	02/06/93	Imipramine
	9HD	01/92	02/01/92	17/02/93	414	18/02/93	Imipramine
	9DT	30/10/92	31/10/92	25/05/93	207	26/05/93	Imipramine
	10HD	18/12/92	19/12/92	22/03/93	94	23/03/93	Reboxetine
	10DT	18/06/92	19/06/92	19/07/93	396	20/07/93	Imipramine
	11HD	09/12/92	10/12/92	11/07/93	214	12/07/93	Imipramine
294	11DT	17/11/92	18/11/92	17/11/93	365	18/11/93	Reboxetine
	12HD	10/11/92	11/11/92	15/09/93	309	16/09/93	Reboxetine
	12DT	16/12/90	17/12/90	12/12/93	1092	13/12/93	Reboxetine
	13HD			14/02/93		15/02/93	Imipramine
	13DT		10/01/93	07/03/93	57	08/03/93	Reboxetine
	14HD			14/02/93		15/02/93	Reboxetine

(*) if missing date = last day of previous treatment + 1 day
 (3) same as start treatment date - 1 day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No : 6.1

DRUG FREE - WASH-OUT PERIOD

Centre	Patient	Last day of previous treatment	Wash out period		Days	Treatment	
			From (*)	To (a)		Start date	Randomized
294	14DT		09/02/93	07/03/93	27	08/03/93	Imipramine
	15ND			21/02/93		22/02/93	Imipramine
	15DT		12/90	08/03/93	829	09/03/93	Imipramine
	16ND			22/02/93		23/02/93	Reboxetine
	16DT			08/03/93		09/03/93	Reboxetine
	25ND			13/06/93		14/06/93	Imipramine
	26ND			13/06/93		14/06/93	Imipramine
	27ND			14/06/93		15/06/93	Reboxetine
	28ND			14/06/93		15/06/93	Reboxetine
	29DT		27/05/93	13/06/93	18	14/06/93	Reboxetine
295	30DT			13/06/93		14/06/93	Reboxetine
	31DT			20/06/93		21/06/93	Imipramine
	32DT			20/06/93		21/06/93	Imipramine
	17ND		23/10/90	20/04/93	905	21/04/93	Reboxetine
	17DT		05/91	26/04/93	727	27/04/93	Imipramine
	18ND		07/89	22/04/93	1392	23/04/93	Reboxetine

(*) if missing date = last day of previous treatment + 1 day
(a) same as start treatment date - 1 day

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 6.1
DRUG FREE - WASH-OUT PERIOD

Centre	Patient	Last day of previous treatment	Wash out period		Days	Treatment		
			From (*)	To (3)		Start date	Randomized	
295	18DT	08/02/93	09/02/93	28/04/93	79	29/04/93	Imipramine	
	19MD		29/10/92	13/05/93	197	14/05/93	Imipramine	
	19DT	22/01/93	23/01/93	09/05/93	107	10/05/93	Reboxetine	
	20MD	05/10/92	06/10/92	13/05/93	220	14/05/93	Imipramine	
	20DT	26/11/92	27/11/92	11/05/93	166	12/05/93	Reboxetine	
	381	1MD		09/12/93	09/12/93		10/12/93	Reboxetine
		2MD		01/02/94	01/02/94		02/02/94	Reboxetine
		3DT	10/01/94	11/01/94	07/02/94	29	08/02/94	Reboxetine
		4MD		28/02/94	28/02/94		01/03/94	Imipramine
	382	5MD		14/11/93	14/11/93		15/11/93	Imipramine
5DT			20/10/93	20/10/93		21/10/93	Reboxetine	
6MD			11/11/93	11/11/93		12/11/93	Reboxetine	
6DT			21/10/93	21/10/93		22/10/93	Imipramine	
7MD			19/12/93	19/12/93		20/12/93	Reboxetine	
7DT			21/10/93	21/10/93		22/10/93	Imipramine	
8MD				25/01/94	25/01/94		26/01/94	Imipramine

(*) if missing date = last day of previous treatment + 1 day
(3) same as start treatment date - 1 day

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9550089

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
 Listing No.: 6.1
 DRUG FREE - WASH-OUT PERIOD

Centre	Patient	Last day of previous treatment	Wash out period		Days	Treatment	
			From (*)	To (‡)		Start date	Randomized
382	8DT			21/12/93		22/12/93	Reboxetine
	9ND			10/02/94		11/02/94	Reboxetine
	9DT			07/02/94		08/02/94	Reboxetine
	10ND			10/02/94		11/02/94	Imipramine
3301	1ND	07/88	02/07/88	23/09/92	1546	24/09/92	Reboxetine
	2ND			11/01/93		12/01/93	Imipramine
3302	3ND	07/01/93	08/01/93	15/01/93	9	16/01/93	Reboxetine
	5ND	23/10/92	24/10/92	06/11/92	15	07/11/92	Reboxetine
	6ND	18/06/93	19/06/93	25/06/93	8	26/06/93	Imipramine
	7ND	10/93	25/10/93	12/11/93	19	13/11/93	Imipramine

1026

(*) if missing date = last day of previous treatment + 1 day
 (‡) same as start treatment date - 1 day

PHARMACIA CNS 899
 930089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA

Centre: 1

	Patient							
	1DT	1MD	2DT	2MD	3DT	3MD	4DT	4MD
	Male	Fem.	Male	Male	Male	Fem.	Male	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED								
Aged over 65 years	YES	YES	YES	YES	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 18 or above in the HAMD	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED								
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO	NO	NO	NO	NO

PHARMACIA CNS 39089

REBOXETINE - PROTOCOL 20124/035

Listing No.: 7

INCLUSION / EXCLUSION CRITERIA

Centre: 2

	Pati-ent
	IND
	Male
FOLLOWING QUESTIONS NEED TO BE ANSWERED	
Aged over 65 years	YES
Normal body weight/height ratio	YES
Are the DSM-III-R criteria for MDE or Dy	YES
Total score of 18 or above in the HAMD	YES
Total score of 22 or above in the MMS	YES
Able and willing () to give informed c..	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED	
History of Major D.E., associ. to endoc.	NO
History of drug hypersensitivity	NO
History of seizures or serious brain in.	NO
Evidence of substance use disorder	NO
ECT in the previous 6 months	NO
Participation in a clinical trial with .	NO
Resistance to previous antidep. treat.	NO
High risk of suicide	NO
Clinically significant lab values abnor.	NO
Clinically significant physical abnorma.	NO

PHARMACIA ~~CMS-298~~ 553089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA
 Centre: 3

	Pati- ent
	MND
	Føn.
FOLLOWING QUESTIONS NEED TO BE ANSWERED	
Aged over 65 years	YES
Normal body weight/height ratio	YES
Are the DSM-III-R criteria for MDE or Dy	YES
Total score of 18 or above in the HAM-D	YES
Total score of 22 or above in the MMS	YES
Able and willing () to give informed c..	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED	
History of Major D.E., associ. to endoc.	NO
History of drug hypersensitivity	NO
History of seizures or serious brain in.	NO
Evidence of substance use disorder	NO
ECT in the previous 6 months	NO
Participation in a clinical trial with .	NO
Resistance to previous antidep. treat.	NO
High risk of suicide	NO
Clinically significant lab values abnor.	NO
Clinically significant physical abnorma.	NO

PHARMACIA ~~CNS 580~~ 9550089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA

Centre: 4

	Patient
	1HD
	Male
FOLLOWING QUESTIONS NEED TO BE ANSWERED	
Aged over 65 years	YES
Normal body weight/height ratio	YES
Are the DSM-III-R criteria for MDE or Dy	YES
Total score of 18 or above in the HAM-D	YES
Total score of 22 or above in the MMS	YES
Able and willing () to give informed c..	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED	
History of Major D.E., associ. to endoc.	NO
History of drug hypersensitivity	NO
History of seizures or serious brain in.	NO
Evidence of substance use disorder	NO
ECT in the previous 6 months	NO
Participation in a clinical trial with .	NO
Resistance to previous antidep. treat.	NO
High risk of suicide	NO
Clinically significant lab values abnor.	NO
Clinically significant physical abnorma.	NO

PHARMACIA C9554089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA
 Centre: 5

	Patient													
	1DT	1MD	10DT	10MD	11DT	11MD	12DT	12MD	2DT	2MD	3DT	3MD	4DT	
	Fem.	Fem.	Male	Fem.	Fem.	Fem.	Male	Fem.	Fem.	Male	Male	Fem.	Male	
FOLLOWING QUESTIONS NEED TO BE ANSWERED														
Aged over 65 years	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
Total score of 18 or above in the HAM-D	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
Able and willing () to give informed c..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
FOLLOWING QUESTIONS NEED TO BE ANSWERED														
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
Participation in a clinical trial with .	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
High risk of suicide	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
Clinically significant physical abnorma.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	

(CONTINUED)

PHARMACIA 09550089
 REBONETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA

Centre: 5

	Patient										
	4MD	5DT	5MD	6DT	6MD	7DT	7MD	8DT	8MD	9DT	9MD
	Male	Fem.	Male	Fem.	Male	Fem.	Male	Fem.	Male	Fem.	
FOLLOWING QUESTIONS NEED TO BE ANSWERED											
Aged over 65 years	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 18 or above in the HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED											
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO

PHARMACIA 953089

REBOXETINE - PROTOCOL 20124/035

Listing No.: 7

INCLUSION / EXCLUSION CRITERIA

Centre: 6

	Patient													
	1DT	1MD	2DT	2MD	3DT	3MD	4DT	4MD	5DT	5MD	6MD	7MD	8MD	
	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	
FOLLOWING QUESTIONS NEED TO BE ANSWERED														
Aged over 65 years	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
Total score of 18 or above in the HAM-D	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
Able and willing () to give informed c..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
FOLLOWING QUESTIONS NEED TO BE ANSWERED														
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
Participation in a clinical trial with .	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
High risk of suicide	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
Clinically significant physical abnorma.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	

PHARMACIA CNS 55089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA

Centre: 7

	Patient			
	1MD	3MD	3&2MD	4MD
	Male	Fem.	Fem.	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED				
Aged over 65 years	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES
Total score of 18 or above in the HAMD	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED				
History of Major D.E., associ. to endoc.	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO

PHARMACIA CJS 840
 9550089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA

Centre: 8

	Patient												
	1DT	1ND	2DT	2ND	3DT	3ND	4DT	4ND	701DT	701ND	702DT	702ND	703DT
	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Male	Fem.	Male	Fem.	Male	Male
FOLLOWING QUESTIONS NEED TO BE ANSWERED													
Aged over 65 years	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Are the DSM-III-R criteria for NDE or Dy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 18 or above in the HAM-D	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED													
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO

(CONTINUED)

PHARMACIA ~~2540~~89
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA

Centre: 8

	Patient		
	703MD	704DT	704MD
	Fem.	Fem.	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED			
Aged over 65 years	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES
Total score of 18 or above in the HAMD	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED			
History of Major D.E., associ. to endoc.	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO
High risk of suicide	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO

PHARMACIA 953089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 7
INCLUSION / EXCLUSION CRITERIA

Centre: 9

	Patient									
	1DT	1MD	2DT	2MD	3DT	4MD	5MD	6MD	7MD	8DT
	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED										
Aged over 65 years	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 18 or above in the HAM-D	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED										
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO

PHARMACIA 0953089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA
 Centre: 10

	Patient													
	1DT	1MD	10DT	10MD	11DT	11MD	12DT	12MD	13DT	14DT	15MD	16DT	17MD	
	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Male	Fem.	Fem.	Fem.	Male	Fem.	
FOLLOWING QUESTIONS NEED TO BE ANSWERED														
Aged over 65 years	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
Total score of 18 or above in the HAM-D	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
Able and willing () to give informed c..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
FOLLOWING QUESTIONS NEED TO BE ANSWERED														
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
Participation in a clinical trial with .	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
High risk of suicide	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
Clinically significant physical abnorma.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	

(CONTINUED)

PHARMACIA 09550089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA

Centre: 10

	Patient												
	18MD	19DT	2DT	2MD	20ND	3DT	3MD	4DT	4MD	5DT	5MD	6DT	6MD
	Fem.	Male	Male	Male	Fem.	Male	Male	Fem.	Fem.	Fem.	Fem.	Male	Male
FOLLOWING QUESTIONS NEED TO BE ANSWERED													
Aged over 65 years	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 18 or above in the HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED													
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Participation in a clinical trial with ,	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO

(CONTINUED)

PHARMACIA C~~95590~~89
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA

Centre: 10

	Patient					
	7DT	7ND	8DT	8ND	9DT	9ND
	Fem.	Male	Fem.	Male	Male	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED						
Aged over 65 years	YES	YES	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES	YES
Total score of 18 or above in the HAMD	YES	YES	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES	YES
Able and willing () to give informed c.,	YES	YES	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED						
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO	NO	NO

PHARMACIA C9559089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA

Centre: 12

	Patient	
	10T	1ND
	Fem.	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED		
Aged over 65 years	YES	YES
Normal body weight/height ratio	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES
Total score of 18 or above in the HAMD	YES	YES
Total score of 22 or above in the MMS	YES	YES
Able and willing () to give informed c..	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED		
History of Major D.E., associ. to endoc.	NO	NO
History of drug hypersensitivity	NO	NO
History of seizures or serious brain in.	NO	NO
Evidence of substance use disorder	NO	NO
ECT in the previous 6 months	NO	NO
Participation in a clinical trial with .	NO	NO
Resistance to previous antidep. treat.	NO	NO
High risk of suicide	NO	NO
Clinically significant lab values abnor.	NO	NO
Clinically significant physical abnorma.	NO	NO

PHARMACIA CME-~~549~~ 9550089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA

Centre: 13

	Patient						
	1DT	1ND	2DT	2ND	3DT	3ND	4DT
	Fem.	Fem.	Fem.	Fem.	Fem.	Male	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED							
Aged over 65 years	YES	YES	YES	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES	YES	YES
Total score of 18 or above in the HAMD	YES	YES	YES	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED							
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO	NO	NO	NO

PHARMACIA CUS 890
 953089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA

Centre: 14

	Pati-ent
	M
	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED	
Aged over 65 years	YES
Normal body weight/height ratio	YES
Are the DSM-III-R criteria for MDE or Dy	YES
Total score of 18 or above in the HAMD	YES
Total score of 22 or above in the MMS	YES
Able and willing () to give informed c..	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED	
History of Major D.E., associ. to endoc.	NO
History of drug hypersensitivity	NO
History of seizures or serious brain in.	NO
Evidence of substance use disorder	NO
ECT in the previous 6 months	NO
Participation in a clinical trial with .	NO
Resistance to previous antidep. treat.	NO
High risk of suicide	NO
Clinically significant lab values abnor.	NO
Clinically significant physical abnorma.	NO

PHARMACIA CUS 200
553089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 7
INCLUSION / EXCLUSION CRITERIA

Centre: 15

	Patient							
	1DT	1ND	111ND	112ND	2DT	2ND	3ND	4ND
	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED								
Aged over 65 years	YES	YES	YES	YES	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 18 or above in the HAMD	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 22 or above in the MNS	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED								
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO	NO	NO	NO	NO

PHARMACIA CNS-228
 9530089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA

Centre: 16

	Patient						
	1DT	1MD	2DT	2MD	3DT	3MD	4MD
	Fem.	Fem.	Male	Male	Fem.	Fem.	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED							
Aged over 65 years	YES	YES	YES	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES	YES	YES
Total score of 18 or above in the HAM-D	YES	YES	YES	YES	YES	YES	YES
Total score of 22 or above in the MNS	YES	YES	YES	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED							
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO	NO	NO	NO

PHARMACIA ~~0550089~~

REBOXETINE - PROTOCOL 20124/035
Listing No.: 7
INCLUSION / EXCLUSION CRITERIA

Centre: 17

	Patient									
	1DT	1MD	2DT	2MD	211DT	211MD	3DT	3MD	4DT	4MD
	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Male	Fem.	Fem.	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED										
Aged over 65 years	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 18 or above in the HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED										
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO

PHARMACIA CUS 890
 9550089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA

Centre: 18

	Patient					
	1DT	1MD	2DT	2MD	3MD	4MD
	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED						
Aged over 65 years	YES	YES	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES	YES
Total score of 18 or above in the HAM-D	YES	YES	YES	YES	YES	YES
Total score of 22 or above in the NMS	YES	YES	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED						
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO	NO	NO

PHARMACIA ~~0558089~~
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA
 Centre: 20

	Pati- ent
	3ND
	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED	
Aged over 65 years	YES
Normal body weight/height ratio	YES
Are the DSM-III-R criteria for MDE or Dy	YES
Total score of 18 or above in the HAM-D	YES
Total score of 22 or above in the NMS	YES
Able and willing () to give informed c..	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED	
History of Major D.E., associ. to endoc.	NO
History of drug hypersensitivity	NO
History of seizures or serious brain in.	NO
Evidence of substance use disorder	NO
ECT in the previous 6 months	NO
Participation in a clinical trial with .	NO
Resistance to previous antidep. treat.	NO
High risk of suicide	NO
Clinically significant lab values abnor.	NO
Clinically significant physical abnorma.	NO

PHARMACIA ~~CS 54089~~
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA
 Centre: 22

	Pati- ent
	MD
	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED	
Aged over 65 years	YES
Normal body weight/height ratio	YES
Are the DSM-III-R criteria for MDE or Dy	YES
Total score of 18 or above in the HAM-D	YES
Total score of 22 or above in the MMS	YES
Able and willing () to give informed c..	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED	
History of Major D.E., associ. to endoc.	NO
History of drug hypersensitivity	NO
History of seizures or serious brain in.	NO
Evidence of substance use disorder	NO
ECT in the previous 6 months	NO
Participation in a clinical trial with .	NO
Resistance to previous antidep. treat.	NO
High risk of suicide	NO
Clinically significant lab values abnor.	NO
Clinically significant physical abnorma.	NO

PHARMACIA 0550089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA

Centre: 23

	Patient					
	1ND	2ND	3ND	4ND	5ND	6ND
	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED						
Aged over 65 years	YES	YES	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES	YES
Total score of 18 or above in the HAMD	YES	YES	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED						
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO	NO	NO

PHARMACIA CNS 3590089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA
 Centre: 25

	Patient	
	1ND	2ND
	Male	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED		
Aged over 65 years	YES	YES
Normal body weight/height ratio	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES
Total score of 15 or above in the HAMD	YES	YES
Total score of 22 or above in the MMS	YES	YES
Able and willing () to give informed c..	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED		
History of Major D.E., associ. to endoc.	NO	NO
History of drug hypersensitivity	NO	NO
History of seizures or serious brain in.	NO	NO
Evidence of substance use disorder	NO	NO
ECT in the previous 6 months	NO	NO
Participation in a clinical trial with .	NO	NO
Resistance to previous antidep. treat.	NO	NO
High risk of suicide	NO	NO
Clinically significant lab values abnor.	NO	NO
Clinically significant physical abnorma.	NO	NO

PHARMACIA ~~CM-298~~
3530089
REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
INCLUSION / EXCLUSION CRITERIA

Centre: 26

	Patient	
	1DT	1MD
	Fem.	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED		
Aged over 65 years	YES	YES
Normal body weight/height ratio	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES
Total score of 18 or above in the HAM-D	YES	YES
Total score of 22 or above in the MMS	YES	YES
Able and willing () to give informed c..	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED		
History of Major D.E., associ. to endoc.	NO	NO
History of drug hypersensitivity	NO	NO
History of seizures or serious brain in.	NO	NO
Evidence of substance use disorder	NO	NO
ECT in the previous 6 months	NO	NO
Participation in a clinical trial with .	NO	NO
Resistance to previous antidep. treat.	NO	NO
High risk of suicide	NO	NO
Clinically significant lab values abnor.	NO	NO
Clinically significant physical abnorma.	NO	NO

PHARMACIA C~~9550~~89
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA
 Centre: 27

	Pati-ent
	IND
	Male
FOLLOWING QUESTIONS NEED TO BE ANSWERED	
Aged over 65 years	YES
Normal body weight/height ratio	YES
Are the DSM-III-R criteria for MDE or Dy	YES
Total score of 18 or above in the HAMD	YES
Total score of 22 or above in the MMS	YES
Able and willing () to give informed c..	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED	
History of Major D.E., associ. to endoc.	NO
History of drug hypersensitivity	NO
History of seizures or serious brain in.	NO
Evidence of substance use disorder	NO
ECT in the previous 6 months	NO
Participation in a clinical trial with .	NO
Resistance to previous antidep. treat.	NO
High risk of suicide	NO
Clinically significant lab values abnor.	NO
Clinically significant physical abnorma.	NO

PHARMACIA ~~CNS 540~~ 54089

REBOXETINE - PROTOCOL 20124/035

Listing No.: 7.

INCLUSION / EXCLUSION CRITERIA

Centre: 28

	Patient							
	1DT	1MD	2DT	2MD	3DT	3MD	4MD	5MD
	Fem.	Fem.	Male	Fem.	Male	Fem.	Male	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED								
Aged over 65 years	YES	YES	YES	YES	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 16 or above in the HAND	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED								
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO	NO	NO	NO	NO

PHARMACIA 0556089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA
 Centre: 30

	Patient				
	1MD	2MD	3MD	4MD	5MD
	Fem.	Fem.	Fem.	Fem.	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED					
Aged over 65 years	YES	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES
Total score of 18 or above in the HAMD	YES	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED					
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO	NO

PHARMACIA ~~0530089~~

REBOXETINE - PROTOCOL 20124/035

Listing No.: 7

INCLUSION / EXCLUSION CRITERIA

Centre: 31

	Patient			
	1DT	1MD	2ND	3ND
	Fem.	Fem.	Fem.	Male
FOLLOWING QUESTIONS NEED TO BE ANSWERED				
Aged over 65 years	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES
Total score of 16 or above in the HAMD	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED				
History of Major D.E., associ. to endoc.	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO
Participation in a clinical trial with ,	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO

PHARMACIA 959089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA

Centre: 32

	Patient					
	1MD	2MD	3MD	4MD	5MD	6MD
	Fem.	Fem.	Fem.	Fem.	Fem.	Male
FOLLOWING QUESTIONS NEED TO BE ANSWERED						
Aged over 65 years	YES	YES	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES	YES
Total score of 18 or above in the HAMD	YES	YES	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED						
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO	NO	NO

PHARMACIA 9558089

REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA

Centre: 35

	Patient													
	1DT	1ND	2DT	2ND	3DT	3ND	4DT	4ND	5DT	5ND	6DT	6ND	7DT	
	Fem.	Fem.	Fem.	Fem.	Male	Fem.	Fem.	Male	Fem.	Male	Fem.	Fem.	Fem.	
FOLLOWING QUESTIONS NEED TO BE ANSWERED														
Aged over 65 years	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
Total score of 18 or above in the HAM-D	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
Able and willing () to give informed c..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
FOLLOWING QUESTIONS NEED TO BE ANSWERED														
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
Participation in a clinical trial with .	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
High risk of suicide	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO	NO	YES	NO	NO	NO	NO	NO	
Clinically significant physical abnorma.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	

(CONTINUED)

PHARMACIA ~~0530089~~

REBOXETINE - PROTOCOL 20124/035
Listing No.: 7
INCLUSION / EXCLUSION CRITERIA

Centre: 35

	Patient		
	7MD	8DT	8MD
	Fem.	Fem.	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED			
Aged over 65 years	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES
Total score of 18 or above in the HAM-D	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED			
History of Major D.E., associ. to endoc.	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO
High risk of suicide	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO
Clinically significant physical abnormal.	YES	NO	NO

4

PHARMACIA ~~05540~~89
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA
 Centre: 36

	Patient													
	1DT	1ND	10DT	10ND	11DT	11ND	12DT	12ND	13ND	14ND	15ND	16ND	17ND	
	Fem.	Male	Male	Male	Male	Fem.	Fem.	Fem.	Male	Male	Fem.	Fem.	Fem.	
FOLLOWING QUESTIONS NEED TO BE ANSWERED														
Aged over 65 years	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
Total score of 18 or above in the HAM-D	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
Able and willing () to give informed c..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
FOLLOWING QUESTIONS NEED TO BE ANSWERED														
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
Participation in a clinical trial with .	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
High risk of suicide	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	
Clinically significant physical abnorma.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	

(CONTINUED)

PHARMACIA CJS 870
 955089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA

Centre: 36

	Patient												
	18MD	19MD	2DT	2ND	20MD	3DT	3MD	4DT	4MD	5DT	5MD	6DT	6MD
	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED													
Aged over 65 years	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 18 or above in the HAM-D	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED													
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO

(CONTINUED)

PHARMACIA ~~055089~~
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA

Centre: 36

	Patient					
	7DT	7MD	8DT	8MD	9DT	9MD
	Fem.	Fem.	Fem.	Fem.	Fem.	Male
FOLLOWING QUESTIONS NEED TO BE ANSWERED						
Aged over 65 years	YES	YES	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES	YES
Total score of 18 or above in the HAM-D	YES	YES	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED						
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO	NO	NO

PHARMACIA ~~09540089~~
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA
 Centre: 37

	Pati- ent
	3ND
	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED	
Aged over 65 years	YES
Normal body weight/height ratio	YES
Are the DSM-III-R criteria for MDE or Dy	YES
Total score of 18 or above in the HAMD	YES
Total score of 22 or above in the MMS	YES
Able and willing () to give informed c..	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED	
History of Major D.E., associ. to endoc.	NO
History of drug hypersensitivity	NO
History of seizures or serious brain in.	NO
Evidence of substance use disorder	NO
ECT in the previous 6 months	NO
Participation in a clinical trial with .	NO
Resistance to previous antidep. treat.	NO
High risk of suicide	NO
Clinically significant lab values abnor.	NO
Clinically significant physical abnorma.	NO

PHARMACIA 9950089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA

Centre: 41

	Patient				
	1MD	2MD	3MD	4MD	5MD
	Male	Male	Male	Male	Male
FOLLOWING QUESTIONS NEED TO BE ANSWERED					
Aged over 65 years	YES	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES
Total score of 16 or above in the HAMD	YES	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED					
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO	NO

PHARMACIA QMS 89
 9530089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA

Centre: 42

	Patient				
	1DT	1MD	2DT	2MD	3MD
	Fem.	Fem.	Male	Fem.	Male
FOLLOWING QUESTIONS NEED TO BE ANSWERED					
Aged over 65 years	YES	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES
Total score of 18 or above in the HAMD	YES	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED					
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO	NO

PHARMACIA CNS 549
 955089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA

Centre: 43

	Patient					
	1DT	2DT	3DT	4DT	5DT	6MD
	Fem.	Fem.	Male	Fem.	Fem.	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED						
Aged over 65 years	YES	YES	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES	YES
Total score of 18 or above in the HAM-D	YES	YES	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED						
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO	NO	NO

PHARMACIA 0950089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA

Centre: 44

	Patient				
	1DT	1ND	2ND	3ND	4ND
	Fem.	Fem.	Fem.	Fem.	Male
FOLLOWING QUESTIONS NEED TO BE ANSWERED					
Aged over 65 years	YES	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES
Total score of 18 or above in the HAMD	YES	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED					
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO	NO

PHARMACIA ~~45-008~~ **95089**

REBOXETINE - PROTOCOL 20124/035

Listing No.: 7

INCLUSION / EXCLUSION CRITERIA

Centre: 45

	Patient		
	1DT	1MD	2MD
	Fem.	Male	Male
FOLLOWING QUESTIONS NEED TO BE ANSWERED			
Aged over 65 years	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES
Total score of 18 or above in the HAM-D	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED			
History of Major D.E., associ. to endoc.	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO
High risk of suicide	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO

PHARMACIA ~~955089~~

REBOXETINE - PROTOCOL 20124/035
Listing No.: 7
INCLUSION / EXCLUSION CRITERIA

Centre: 46

	Patient			
	1MD	2MD	3MD	4MD
	Male	Fem.	Fem.	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED				
Aged over 65 years	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES
Total score of 18 or above in the HAMD	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED				
History of Major D.E., associ. to endoc.	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO

PHARMACIA ~~55-0089~~
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA
 Centre: 48

	Patient	
	1DT	2DT
	Fem.	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED		
Aged over 65 years	YES	YES
Normal body weight/height ratio	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES
Total score of 18 or above in the HAMD	YES	YES
Total score of 22 or above in the MMS	YES	YES
Able and willing () to give informed c..	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSHERED		
History of Major D.E., associ. to endoc.	NO	NO
History of drug hypersensitivity	NO	NO
History of seizures or serious brain in.	NO	NO
Evidence of substance use disorder	NO	NO
ECT in the previous 6 months	NO	NO
Participation in a clinical trial with .	NO	NO
Resistance to previous antidep. treat.	NO	NO
High risk of suicide	NO	NO
Clinically significant lab values abnor.	NO	NO
Clinically significant physical abnorma.	NO	NO

PHARMACIA 0550089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA
 Centre: 291

	Patient											
	1DT	1ND	2DT	2ND	25DT	26DT	27DT	28DT	3DT	3MD	4DT	4MD
	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Male	Male	Male
FOLLOWING QUESTIONS NEED TO BE ANSWERED												
Aged over 65 years	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 18 or above in the HAND	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED												
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO

PHARMACIA ~~958089~~
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA
 Centre: 292

	Patient												
	21DT	21MD	22DT	22MD	23DT	23MD	24DT	24MD	5DT	5MD	6DT	6MD	7DT
	Fem.	Fem.	Fem.	Fem.	Male	Fem.	Fem.	Male	Male	Fem.	Fem.	Fem.	Male
FOLLOWING QUESTIONS NEED TO BE ANSWERED													
Aged over 65 years	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 18 or above in the HAM-D	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED													
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO

(CONTINUED)

PHARMACIA ~~015-418~~
 9350089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA
 Centre: 292

	Patient		
	7MD	8DT	8MD
	Male	Fem.	Male
FOLLOWING QUESTIONS NEED TO BE ANSWERED			
Aged over 65 years	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES
Total score of 18 or above in the HAM-D	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED			
History of Major D.E., associ. to endoc.	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO
High risk of suicide	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO

PHARMACIA ~~95500~~ 89

REBOXETINE - PROTOCOL 20124/035

Listing No.: 7

INCLUSION / EXCLUSION CRITERIA

Centre: 293

	Patient							
	10DT	10MD	11DT	11MD	12DT	12MD	9DT	9MD
	Fem.	Fem.	Fem.	Male	Fem.	Male	Fem.	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED								
Aged over 65 years	YES	YES	YES	YES	YES	NO	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 18 or above in the HAMD	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED								
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO	NO	NO	NO	NO

PHARMACIA 955089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA
 Centre: 294

	Patient												
	13DT	13MD	14DT	14MD	15DT	15MD	16DT	16MD	25MD	26MD	27MD	28MD	29DT
	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED													
Aged over 65 years	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 18 or above in the HAND	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED													
History of Major D.E., associ. to endoc.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO

(CONTINUED)

PHARMACIA ~~05-1089~~
05-1089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 7
INCLUSION / EXCLUSION CRITERIA

Centre: 294

	Patient		
	30DT	31DT	32DT
	Fem.	Fem.	Male
FOLLOWING QUESTIONS NEED TO BE ANSWERED			
Aged over 65 years	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES
Total score of 18 or above in the HAM-D	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED			
History of Major D.E., associ. to endoc.	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO
High risk of suicide	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO

PHARMACIA ~~95-0089~~
 95-0089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA
 Centre: 295

	Patient							
	17DT	17MD	18DT	18MD	19DT	19MD	20DT	20MD
	Male	Fem.	Fem.	Fem.	Fem.	Male	Fem.	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED								
Aged over 65 years	YES	YES	YES	YES	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 18 or above in the HAND	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED								
History of Major D.E., associ. to endec.	NO	NO	NO	NO	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO	NO	NO	NO	NO

PHARMACIA ~~SWS-PP8~~
 9550089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA

Centre: 381

	Patient			
	1MD	2MD	3DT	4MD
	Male	Fem.	Fem.	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED				
Aged over 65 years	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES
Total score of 18 or above in the HAMD	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED				
History of Major D.E., associ. to endoc.	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO	NO

PHARMACIA ~~0550089~~

REBOXETINE - PROTOCOL 20124/035

Listing No.: 7

INCLUSION / EXCLUSION CRITERIA

Centre: 382

	Patient										
	10MD	5DT	5MD	6DT	6MD	7DT	7MD	8DT	8MD	9DT	9MD
	Fem.	Male	Fem.	Fem.	Fem.	Male	Fem.	Fem.	Male	Fem.	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED											
Aged over 65 years	YES	NO	YES	YES	YES	YES	YES	YES	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 18 or above in the HAMD	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
Able and willing () to give informed c.,	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED											
History of Major D.E., associ. to endec.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
High risk of suicide	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	YES	NO	NO	NO	NO	NO	NO	NO	NO

PHARMACIA 05549
 953089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA
 Centre: 3301

	Patient		
	1ND	2ND	3ND
	Fem.	Male	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED			
Aged over 65 years	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES
Total score of 18 or above in the HAM-D	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED			
History of Major D.E., associ. to endoc.	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO
High risk of suicide	NO	NO	NO
Clinically significant lab values abnor.	YES	NO	NO
Clinically significant physical abnorma.	NO	NO	NO

PHARMACIA GW 849
 9530089
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 7
 INCLUSION / EXCLUSION CRITERIA
 Centre: 3302

	Patient		
	5MD	6MD	7MD
	Fem.	Fem.	Fem.
FOLLOWING QUESTIONS NEED TO BE ANSWERED			
Aged over 65 years	YES	YES	YES
Normal body weight/height ratio	YES	YES	YES
Are the DSM-III-R criteria for MDE or Dy	YES	YES	YES
Total score of 18 or above in the HAM-D	YES	YES	YES
Total score of 22 or above in the MMS	YES	YES	YES
Able and willing () to give informed c..	YES	YES	YES
FOLLOWING QUESTIONS NEED TO BE ANSWERED			
History of Major D.E., associ. to endoc.	NO	NO	NO
History of drug hypersensitivity	NO	NO	NO
History of seizures or serious brain in.	NO	NO	NO
Evidence of substance use disorder	NO	NO	NO
ECT in the previous 6 months	NO	NO	NO
Participation in a clinical trial with .	NO	NO	NO
Resistance to previous antidep. treat.	NO	NO	NO
High risk of suicide	NO	NO	NO
Clinically significant lab values abnor.	NO	NO	NO
Clinically significant physical abnorma.	NO	NO	NO

9550089

1

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
1	1ND	Female	Reboxetine		ANTISTINE	02/12/92	Day 28	17/12/92	Day 49
					ROGADON	29/10/92	Screen	30/12/92(*)	Day 56
					PANAMAX	29/10/92	Screen	09/12/92	Day 42
	1DT	Male	Reboxetine		BETAMIN	10/04/93	Screen	15/11/93	Screen
					CATOVIT	30/11/93	Day 7	22/12/93	Day 28
					NOTILIUM	05/02/93	Screen	11/12/93	Day 21
	1082				PEPCIDIN	05/02/93	Screen	14/12/93	Day 21
					SOLPRIN	10/04/93	Screen	09/12/93	Day 14
	2ND	Male	Imipramine		ANTISTINE	18/11/92	Day 7	28/11/92	Day 14
					KENACORB	23/11/92	Day 14	28/11/92	Day 14
					ROBIPNOL	01/11/92	Screen	11/01/93(*)	Day 56
	2DT	Male	Imipramine		TEMAZEPAM	02/12/93(\$)	Screen	03/12/93	Screen
	3ND	Female	Imipramine		AGAROL	22/06/93	Day 21	02/07/93	Day 35
					INDERAL	01/01/73	Screen	28/07/93(*)	Day 56
					NU-LAX	04/06/93	Day 7	22/06/93	Day 21
					SENNA	07/06/93	Day 7	22/06/93	Day 21

(\$) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (X) - end date missing = visit date during treatment
 (3) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

2

9550089

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit					
1	3ND	Female	Imipramine		SENA	02/07/93	Day 35	28/07/93(*)	Day 56					
					SEREPAX	01/01/73	Screen	28/07/93(*)	Day 56					
					TEMAZEPAM	25/05/93	Screen	01/06/93	Screen					
					DUPHALAC	10/12/93	Day 7	23/12/93	Day 14					
					HINIPRES	08/12/93	Screen	03/02/94(*)	Day 56					
					NITRAZEPAM	24/12/93	Day 21	28/12/93	Day 21					
					NU-LAX	24/12/93	Day 21	03/02/94(*)	Day 56					
					TEMAZEPAM	08/12/93 28/12/93	Screen Day 35	24/12/93 03/02/94(*)	Day 21 Day 56					
					BACTROBAN	10/12/93	Day 56	13/12/93(*)	Day 56					
					CLONAZEPAM	11/10/93	Screen	11/10/93	Day 7					
2	4DT	Male	Imipramine		FERRO-GRADUMET	01/07/93	Screen	12/11/93	Day 28					
					LOSEC	10/06/93	Screen	13/12/93(*)	Day 56					
					TEMAZEPAM	11/10/93	Screen	11/10/93	Day 7					
					ASPIRINE	01/12/93	Screen	24/02/94(*)	Day 28					
					ATENOLOL	04/02/93	Day 21	08/02/93(*)	Day 28					
					3	4MD	Female	Reboxetine		BACTROBAN	10/12/93	Day 56	13/12/93(*)	Day 56
										CLONAZEPAM	11/10/93	Screen	11/10/93	Day 7
										FERRO-GRADUMET	01/07/93	Screen	12/11/93	Day 28
										LOSEC	10/06/93	Screen	13/12/93(*)	Day 56
										TEMAZEPAM	11/10/93	Screen	11/10/93	Day 7
ASPIRINE	01/12/93	Screen	24/02/94(*)	Day 28										
ATENOLOL	04/02/93	Day 21	08/02/93(*)	Day 28										
BACTROBAN	10/12/93	Day 56	13/12/93(*)	Day 56										
CLONAZEPAM	11/10/93	Screen	11/10/93	Day 7										
FERRO-GRADUMET	01/07/93	Screen	12/11/93	Day 28										

(*) - start date missing = screening date - 1
(*) - end date missing = last dose taken date if last visit
(*) - end date missing = visit date during treatment
(*) - only for concomitant drug reported at screen visit

PHARMACIA CNS RED
 REBOSATINE - PROTOCOL 20124-035
 Listing No.: 8.0
 CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	Start report visit	End date	Last report visit
2	1084	Male	Rebozatine		CAPTOPRIL	12/01/99	Screen	08/02/99(*)	Day 28
					COLONYL	12/01/99	Screen	08/02/99(*)	Day 28
					INDAPAMINE	12/01/99	Screen	08/02/99(*)	Day 28
					LORAZEPAM	12/01/99	Screen	08/02/99(*)	Day 28
					PARACETAMOL	12/01/99	Screen	08/02/99(*)	Day 28
					SENA	12/01/99	Screen	08/02/99(*)	Day 28
					TEMASEFAN	28/01/99	Day 14	08/02/99(*)	Day 28
					ERYTHROMYCIN	06/05/99	Day 7	07/05/99	Day 7
					IFECAC	30/04/99 18/05/99	Screen Day 14	04/05/99 19/05/99	Screen Day 14
					MYLANTA	07/05/99	Day 7	07/05/99	Day 7
3	1084	Female	Rebozatine		TEMASEFAN	23/04/99 07/06/99	Screen Day 35	04/05/99 22/06/99(*)	Screen Day 49
					TETRAZOLINA	29/04/99	Screen	04/05/99	Screen
					TOLU TINCTURE	30/04/99 18/05/99	Screen Day 14	04/05/99 19/05/99	Screen Day 14
					ZESTRIL	27/02/99	Screen	22/06/99(*)	Day 49
					ALLOPURINOL	19/11/98(*)	Screen	29/12/98(*)	Day 35

(*) - start date missing = screening date - 1
 (**) - end date missing = last dose taken date if last visit missing
 (**) - end date missing = last date during treatment
 (**) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

4

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 2012A/035
 Listing No.: 8.0
 CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
4	1M	Male	Imipramine		TEMAZEPAM	24/11/92	Screen	29/12/92(*)	Day 35
5	1M	Female	Reboxetine		DUPHALAC	91	Screen	10/11/92(*)	Day 14
					EUBYPNOS	23/10/92	Screen	10/11/92(*)	Day 14
					ISOTEN	91	Screen	10/11/92(*)	Day 14
	1F	Female	Imipramine		ACTIFED	14/12/92	Day 35	19/12/92	Day 35
					DUPHALAC	03/08/92	Screen	06/01/93(*)	Day 56
					DUSPATALIN	27/04/92 30/11/92	Screen Day 21	24/11/92 07/12/92	Day 14 Day 28
					LAXOBERON	14/11/92	Day 7	15/11/92	Day 7
					VIBRATAB	14/12/92	Day 35	23/12/92	Day 35
2M		Male	Reboxetine		CORDARONE	90	Screen	18/01/93(*)	Day 56
					DUSPATALIN	05/12/92	Day 14	18/01/93(*)	Day 56
					EUBYPNOS	15/11/92	Screen	18/01/93(*)	Day 56
					LANDXIN	90	Screen	18/01/93(*)	Day 56
					LAXOBERON	14/11/92(\$)	Screen	04/12/92	Day 14
					PRIMPERAN	14/11/92(\$)	Screen	29/11/92	Day 7

1085

9550089

(\$) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (x) - end date missing = visit date during treatment
 (a) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

5

9550089

PERMANENT CHS MRB
 HEMORRHOID - PROCTOL 28/06/93
 Listing No.: B.0
 CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Completed in protocol	Concomitant drug	Start date	Next report visit	End date	Next report visit				
5	287	Female	Enipenolone		ASPIRIN	15/01/93	Day 28	15/02/93(1)	Day 56				
					CLEMAR	15/01/93	Day 28	15/02/93(1)	Day 56				
					IBUPROFEN	15/01/93	Day 28	15/01/98	Day 82				
					PARACETAMOL	14/12/92	Screen	15/01/93	Day 28				
					LEONORIN	04/01/93	Day 21	04/01/93	Day 21				
					OL-METINE	91	Screen	11/05/93(1)	Day 56				
					REURACTINE	85	Screen	21/05/93(1)	Day 56				
					ORONIN	88	Screen	21/05/93(1)	Day 56				
					ACETYSALICYLIC ACID	80	Screen	15/01/98(1)	Day 56				
					IBUPROFEN	15/01/92	Screen	15/01/93(1)	Day 56				
6	307	Male	Enipenolone		REURACTINE	88	Screen	15/01/93(1)	Day 56				
					PERISARTINE	88	Screen	15/01/93(1)	Day 56				
					ACETICACID	87	Screen	02/05/93(1)	Day 28				
					IBUPROFEN	87	Screen	02/05/93(1)	Day 28				
					LAURICIN	87	Screen	02/05/93(1)	Day 28				
					407	Male	Enipenolone		ASPIRIN	87	Screen	02/05/93(1)	Day 28
									IBUPROFEN	87	Screen	02/05/93(1)	Day 28
									PERISARTINE	87	Screen	02/05/93(1)	Day 28
									ACETICACID	87	Screen	02/05/93(1)	Day 28
									IBUPROFEN	87	Screen	02/05/93(1)	Day 28
LAURICIN	87	Screen	02/05/93(1)	Day 28									
ASPIRIN	87	Screen	02/05/93(1)	Day 28									
IBUPROFEN	87	Screen	02/05/93(1)	Day 28									
PERISARTINE	87	Screen	02/05/93(1)	Day 28									
ACETICACID	87	Screen	02/05/93(1)	Day 28									

(1) - start date missing = screening date - 1
 (2) - end date missing = last date taken date if last visit
 (3) - only for concomitant drugs reported in screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

6

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 8.0
 CONCOMITANT DRUGS

Contre	Patient	Sex	Treatment	Complets as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
5	5DT	Female	Reboxetine		SINEMET	17/03/93	Day 28	17/03/93(*)	Day 28
	6ND	Male	Imipramine		DIGOXIN	08/92	Screen	18/08/93(*)	Day 14
	6DT	Female	Reboxetine		EUHPNOS	19/02/93	Screen	23/04/93(*)	Day 56
	7DT	Female	Imipramine		NOOTROPIL	24/04/93	Day 56	23/04/93(*)	Day 56
	8ND	Female	Imipramine		STOFILAN	90	Screen	07/05/93(*)	Day 56
	8DT	Female	Imipramine		LORAMET	25/10/93	Screen	05/01/94(*)	Day 56
	9DT	Female	Reboxetine		FRUMASINE	17/11/93	Day 7	05/01/94(*)	Day 56
	11ND	Female	Imipramine		TENORMIN	88	Screen	05/01/94(*)	Day 56
					PREMARIN	87	Screen	29/06/93(*)	Day 56
					ACENTERINE	93	Screen	25/06/93(*)	Day 56
					DUPHALAC	17/05/93	Day 21	25/05/93	Day 28
					FRAXIPARINE	30/04/93	Screen	25/06/93(*)	Day 56
					MODURETIC	93	Screen	25/06/93(*)	Day 56
					CORTISONE	15/12/93	Day 14	22/12/93	Day 21
					DUPHALAC	10/12/93	Day 7	29/12/93(2)	Day 28

1087

9550089

(*) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (2) - end date missing = visit date during treatment
 (3) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

7

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
5	11ND	Female	Imipramine		IMOVANE	05/12/93	Day 7	29/12/93(*)	Day 28
					OXITETRACYCLIN	15/12/93	Day 14	22/12/93	Day 21
	11DI	Female	Reboxetine		EUKYPRUS	04/05/93	Screen	07/06/93(*)	Day 28
					PRIMPERAN	14/05/93	Day 7	07/06/93(*)	Day 28
	12DI	Male	Imipramine		ASPIRINE	85	Screen	15/07/93(*)	Day 56
6					ISOPTIN	85	Screen	15/07/93(*)	Day 56
	1ND	Female	Reboxetine		LAXOBERON	09/06/93	Day 21	16/06/93	Day 28
					ZYLORIC	86	Screen	15/07/93(*)	Day 56
	1DI	Female	Reboxetine		LORAMET	08/11/92	Screen	07/01/93(*)	Day 56
	2ND	Female	Reboxetine		LORMETAZEPAM	13/08/92	Screen	16/12/92(*)	Day 56
3ND					TENAZEPAM	01/07/92	Screen	17/11/92(*)	Day 7
					LORAMET	03/92	Screen	27/01/93(*)	Day 56
					MINIDIAB	03/92	Screen	27/01/93(*)	Day 56
3DI					HYDERGINE	04/03/93(\$)	Screen	02/06/93(*)	Day 56
					INDERAL	04/03/93(\$)	Screen	02/06/93(*)	Day 56

9550089

1088

(\$) - start date missing = screening date - 1
(*) - end date missing = last dose taken date if last visit
(X) - end date missing = visit date during treatment
(@) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

6

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
6	3DT	Female	Imipramine		MONURETIC	04/03/93(\$)	Screen	02/06/93(*)	Day 56
					PRIMPERAN	21/04/93	Day 14	02/06/93(*)	Day 56
					TEMAZEPAM	04/03/93(\$)	Screen	02/06/93(*)	Day 56
	4WD	Female	Imipramine		LOBANET	08/12/92	Screen	18/01/93(*)	Day 35
	4DT	Female	Imipramine		LOBANET	90	Screen	29/06/93(*)	Day 56
					PRUNASINE	21/05/93	Day 21	29/06/93(*)	Day 56
					SIBELIUX	90	Screen	28/04/93	Screen
					STUGERON	90	Screen	29/06/93(*)	Day 56
					ZOROXIN	07/05/93	Day 7	17/05/93	Day 14
					EFFORTIL	14/05/93	Day 42	28/05/93(*)	Day 56
					HYDERGINE	29/03/93(\$)	Screen	28/05/93(*)	Day 56
					PRIMPERAN	29/04/93	Day 28	28/05/93(*)	Day 56
					TEMAZEPAM	92	Screen	28/05/93(*)	Day 56
					ZOROXIN	07/04/93	Day 7	16/04/93	Day 14
					ACETYSALICYLIC ACID	07/06/93	Screen	14/01/94(*)	Day 56

1089

9550089

(\$) - start date missing = screening date - 1
(*) - end date missing = last dose taken date if last visit
(x) - end date missing = visit date during treatment
(a) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 8.0
 CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
6	5DT	Female	Reboxetine		AHLIODIPINE	07/06/93	Screen	14/01/94(*)	Day 56
					LORANET	07/06/93	Screen	14/01/94(*)	Day 56
					ZOCOR	92	Screen	14/01/94(*)	Day 56
					DYTEMZIDE	02/11/92	Screen	01/06/93(*)	Day 35
					LORNETAZEPAN	22/04/93(§)	Screen	01/06/93(*)	Day 35
					MAXI-B 5000	11/92	Screen	01/06/93(*)	Day 35
					NOVOTHYRAL	88	Screen	01/06/93(*)	Day 35
					LORNETAZEPAN	83	Screen	14/12/93(*)	Day 56
					QUINAPRIL	90	Screen	14/12/93(*)	Day 56
					CORGARD	90	Screen	17/01/94(*)	Day 56
7	4HD	Male	Imipramine		LORANET	88	Screen	17/01/94(*)	Day 56
					CHLORAL HYDRATE	09/01/93	Day 7	05/03/93(x)	Day 56
					PIMOZIDE	05/01/93(§) 13/02/93	Screen Day 42	08/01/93 05/03/93(x)	Screen Day 56
					TAMARINE	06/01/93	Screen	05/03/93(x)	Day 56
					TIAPRIDE	05/01/93(§)	Screen	08/01/93	Screen

9550089

1090

(§) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (x) - end date missing = visit date during treatment
 (9) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

10

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
7	1MD	Male	Imipramine		ZOLPIDEM	05/01/93(§)	Screen	08/01/93	Screen
	3MD	Female	Imipramine		CLOTTAPINE	01/05/93 04/05/93	Day 14 Day 14	01/05/93 04/05/93	Day 14 Day 14
					GAVISCON	30/04/93	Day 14	17/06/93(*)	Day 56
					LACTULOSE	26/04/93	Day 7	17/06/93(*)	Day 56
					LONARID N	18/05/93 20/05/93	Day 28 Day 28	18/05/93 20/05/93	Day 28 Day 28
					LORANET	84	Screen	17/06/93(*)	Day 56
					MAALOX	91	Screen	04/05/93	Day 14
					MOTILIUM	24/05/93	Day 35	17/06/93(*)	Day 56
					PANADOL	13/05/93 18/05/93 20/05/93 23/05/93 29/05/93 06/06/93	Day 21 Day 28 Day 28 Day 35 Day 42 Day 49	13/05/93 18/05/93 20/05/93 26/05/93 01/06/93 09/06/93	Day 21 Day 28 Day 28 Day 35 Day 42 Day 49
					TAGCEL	91	Screen	17/06/93(*)	Day 56
					CHLORAL HYDRATE	16/04/93	Screen	29/05/93(*)	Day 42
					DIAGONIL	65	Screen	29/05/93(*)	Day 42
					ISOPTIN	90	Screen	29/05/93(*)	Day 42

9550089

1091

(§) - start date missing = screening date - 1
(*) - end date missing = last dose taken date if last visit
(Z) - end date missing = visit date during treatment
(3) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

11

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 8.0
 CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
7	342ND	Female	Reboxetine		LORAMET	92	Screen	17/02/93	Screen
					URFADYN	20/03/93	Day 28	29/03/93	Day 35
8	1ND	Female	Reboxetine		ZANTAC	08/92	Screen	24/11/92(*)	Day 56
	1DT	Female	Imipramine		BISACODYL	20/09/92(\$) 17/10/92	Screen Day 21	12/10/92(Z) 22/11/92(*)	Day 14 Day 56
					DOCUSATE SODIUM	20/09/92(\$) 17/10/92	Screen Day 21	12/10/92(Z) 22/11/92(*)	Day 14 Day 56
					LANOXIN	20/09/92(\$)	Screen	22/11/92(*)	Day 56
					LORAMET	91	Screen	22/11/92(*)	Day 56
	2ND	Female	Reboxetine		CAPOTEN	23/10/91	Screen	24/11/92(*)	Day 56
					LASIX	23/10/91	Screen	24/11/92(*)	Day 56
					NITROGLYCERIN	23/10/91	Screen	24/11/92(*)	Day 56
					TINSET	18/09/92	Screen	24/11/92(*)	Day 56
	2DT	Female	Imipramine		COMPLAMIN	90	Screen	24/11/92(*)	Day 56
	3ND	Female	Imipramine		ADALAT	89	Screen	10/10/92(*)	Day 14
					CAPOTEN	29/07/92	Screen	10/10/92(*)	Day 14

9550089

1092

(\$) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (Z) - end date missing = visit date during treatment
 (*) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

12

9550089

PREHACIA CNS RBD
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
8	30F	Female	Reboxetine		ADALAT - SLOW RELEASE	90	Screen	26/11/92(*)	Day 56
	40F	Female	Reboxetine		CANRENOL	91	Screen	26/11/92(*)	Day 56
					STILNOX	91	Screen	26/11/92(*)	Day 56
					TAGAMET	18/09/92	Screen	26/11/92(*)	Day 56
	701MD	Male	Imipramine		ALCOHOL	04/11/92	Day 28	04/11/92	Day 28
					HALDOL	10/08/92	Screen	02/10/92	Screen
					ROHIPNOL	10/08/92	Screen	03/12/92(*)	Day 56
	7010F	Female	Reboxetine		ASPEGIC	23/10/92	Day 14	24/10/92	Day 21
					INSULIN	28/09/92(§)	Screen	03/12/92(*)	Day 56
					TENESTA	13/08/92	Screen	03/12/92(*)	Day 56
	702MD	Male	Reboxetine		LENDORMIN	09/09/92	Screen	10/12/92(*)	Day 56
					ZOROXIN	04/09/92	Screen	09/10/92	Screen
	7020F	Female	Imipramine		TIMOPTOL	90	Screen	03/12/92(*)	Day 56
	703MD	Female	Imipramine		CORTISONE	12/92	Screen	05/04/93(*)	Day 56
					LORAMET	12/92	Screen	05/04/93(*)	Day 56
	7030F	Male	Imipramine		ZANTAC	11/92	Screen	05/04/93(*)	Day 56

(§) - start date missing = screening date - 1
(*) - end date missing = last dose taken date if last visit
(x) - end date missing = visit date during treatment
(a) - only for concomitant drug reported at screen visit

1093

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

13

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 8.0
 CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit					
8	704MD	Female	Reboxetine		AHLUDIPINE	25/01/93(\$)	Screen	05/04/93(*)	Day 56					
					LASIX	25/01/93(\$)	Screen	05/04/93(*)	Day 56					
					TENORMIN	25/01/93(\$)	Screen	05/04/93(*)	Day 56					
					BETASERC	92	Screen	05/04/93(*)	Day 56					
					DIAMICRON	90	Screen	05/04/93(*)	Day 56					
					BROMAZEPAM	11/08/93	Screen	10/10/93	Screen					
					ALPIDEM	11/01/92	Screen	22/06/93(*)	Day 56					
					ASPIRINE	30/12/91	Screen	22/06/93(*)	Day 56					
					DMSYPATALIN	11/12/92	Screen	22/06/93(*)	Day 56					
					MODOPAR	06/03/93	Screen	22/06/93(*)	Day 56					
9	6HD	Female	Reboxetine		TEMESTA	83	Screen	22/06/93(*)	Day 56					
					ASPIRINE	02/92	Screen	14/07/93(*)	Day 56					
					CALCIUM PHOSPHATE	02/92	Screen	14/07/93(*)	Day 56					
					DEDROGYL	02/92	Screen	14/07/93(*)	Day 56					
					FURADANTINE	30/06/93	Day 49	07/07/93	Day 49					
					12	1MD	Female	Reboxetine						

9550089

1094

(\$) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (x) - end date missing = visit date during treatment
 (a) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

14

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 8.0
 CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
12	10T	Female	Reboxetine		MODOPAR	02/92	Screen	14/07/93(*)	Day 56
					STILNOX	02/92	Screen	14/07/93(*)	Day 56
13	10D	Female	Reboxetine		STILNOX	08/04/93	Day 7	02/06/93(*)	Day 56
					SULFARLEM	27/05/93	Day 56	02/06/93(*)	Day 56
					SURGAM	22/04/93	Day 21	28/04/93	Day 21
					VITAMIN B1	26/03/93(\$)	Screen	02/06/93(*)	Day 56
					VITAMIN B6	26/03/93(\$)	Screen	02/06/93(*)	Day 56
					FONZYLANE	16/09/93(\$)	Screen	17/11/93(*)	Day 56
					SECTRAL	16/09/93(\$)	Screen	17/11/93(*)	Day 56
					TENSTATEN	16/09/93(\$)	Screen	17/11/93(*)	Day 56
					ATARAX	03/02/94	Day 56	07/02/94	Day 56
					AUGMENTIN	11/12/93	Day 7	23/12/93	Day 14
					DIFFU K	11/12/93	Day 7	20/12/93	Day 14
					DOLIPRANE	01/02/94	Day 56	04/02/94(*)	Day 56
					DUPHALAC	25/11/93(\$)	Screen	04/02/94(*)	Day 56

9550089

10937

(\$) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (X) - end date missing = visit date during treatment
 (a) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

15

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 8.0
 CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
13	2ND	Female	Imipramine		FELDENE	01/02/94	Day 56	04/02/94(*)	Day 56
					FENTANYL	01/02/94	Day 56	01/02/94	Day 56
					FORENE	01/02/94	Day 56	01/02/94	Day 56
					FRAXIPARINE	03/02/94	Day 56	04/02/94(*)	Day 56
					FUMAFER	01/02/94	Day 56	04/02/94(*)	Day 56
					HEPT-A-NYL	03/02/94	Day 56	04/02/94(*)	Day 56
					HYPROVEL	01/02/94	Day 56	01/02/94	Day 56
					NIDREL	93	Screen	06/01/94	Day 28
					NOCTAMID	18/12/93	Day 14	04/02/94(*)	Day 56
					PERIACETINE	03/02/94	Day 56	04/02/94(*)	Day 56
					PIPRAH	01/02/94	Day 56	04/02/94(*)	Day 56
					RISORDAN	01/02/94	Day 56	04/02/94(*)	Day 56
					TEMESTA	93	Screen	11/12/93	Day 14
					TRACIUM	01/02/94	Day 56	01/02/94	Day 56
					CORTANCYL	92	Screen	17/12/93(*)	Day 56

9550089

1096

(*) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (X) - end date missing = visit date during treatment
 (Z) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

16

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
13	2DT	Female	Reboxetine		DIFFU X	22/11/93	Day 35	02/12/93	Day 42
					DOLIPRANE	92	Screen	17/12/93(*)	Day 56
					DUPHALAC	27/11/93	Day 42	17/12/93(*)	Day 56
					TEMESTA	22/10/93	Screen	17/12/93(*)	Day 56
	3MD	Male	Imipramine		DUPHALAC	93	Screen	31/03/94(*)	Day 56
					IMOYANE	93	Screen	31/03/94(*)	Day 56
					LISANXIA	93	Screen	31/03/94(*)	Day 56
					NATISPRAY	07/03/94	Day 35	07/03/94	Day 35
					SERHTON	14/02/94	Day 14	31/03/94(*)	Day 56
	3DT	Female	Imipramine		DUPHALAC	93	Screen	04/01/94(*)	Day 56
					LEXONIL	93	Screen	04/01/94(*)	Day 56
					NIDREL	93	Screen	04/01/94(*)	Day 56
					SULFARLEM	25/11/93	Day 21	04/01/94(*)	Day 56
	4DT	Female	Reboxetine		ANLODIPINE	93	Screen	31/03/94(*)	Day 56
					DUPHALAC	93	Screen	31/03/94(*)	Day 56

9550089

1097

(*) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (Z) - end date missing = visit date during treatment
 (S) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0
CONCOMITANT DRUGS

9550089

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
13	4DT	Female	Reboxetine		NOCTAMID	93	Screen	31/03/94(*)	Day 56
					PEPDINE	03/03/94	Day 28	31/03/94(*)	Day 56
					POLYSILANE	20/02/94	Day 21	06/03/94	Day 35
					SERNION	93	Screen	31/03/94(*)	Day 56
					VASTAREL	93	Screen	31/03/94(*)	Day 56
					SULFARLEM	13/04/94	Day 7	02/05/94(*)	Day 28
					ALVITYL	22/02/93(\$)	Screen	25/04/93(*)	Day 56
					ATARAX	22/02/93(\$)	Screen	25/04/93(*)	Day 56
					STILNOX	22/02/93(\$)	Screen	25/04/93(*)	Day 56
					DIFFU K	07/92	Screen	19/09/93(*)	Day 56
1098	1DT	Female	Reboxetine		LASILIX	07/92	Screen	19/09/93(*)	Day 56
					THYROXIN	18/07/93(\$)	Screen	19/09/93(*)	Day 56
					TORONTAL	07/92	Screen	19/09/93(*)	Day 56
					RISORDAN	01/03/93(\$)	Screen	02/04/93(*)	Day 14
					STILNOX	01/03/93(\$)	Screen	02/04/93(*)	Day 14

(\$) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (X) - end date missing = visit date during treatment
 (a) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

18

PHARMACIA CNS RSD
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 8.0
 CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
15	2HD	Female	Imipramine		TRANDATE	01/03/93(\$)	Screen	02/04/93(*)	Day 14
	2DT	Female	Imipramine		ADALATE	06/02/94(\$)	Screen	18/04/94(*)	Day 56
					ASPERGIC	06/02/94(\$)	Screen	18/04/94(*)	Day 56
					DEXTROPROXIFEN	06/02/94(\$)	Screen	18/04/94(*)	Day 56
					LOPRIL	06/02/94(\$)	Screen	18/04/94(*)	Day 56
					NITRIDERM TTS	06/02/94(\$)	Screen	18/04/94(*)	Day 56
					OXYCARDIN	06/02/94(\$)	Screen	18/04/94(*)	Day 56
					PARACETAMOL	06/02/94(\$)	Screen	18/04/94(*)	Day 56
					XANAX	11/93	Screen	18/04/94(*)	Day 56
					CORVASAL	90	Screen	30/06/93(*)	Day 56
					NITRIDERM TTS	90	Screen	30/06/93(*)	Day 56
					STILNOX	01/93	Screen	30/06/93(*)	Day 56
					TRANDATE	02/05/93(\$)	Screen	30/06/93(*)	Day 56
					CATAPRESSAN	11/07/93(\$)	Screen	08/09/93(*)	Day 56
					ESBERIVEN	06/93	Screen	08/09/93(*)	Day 56

9550089

1099

(\$) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (Z) - end date missing = visit date during treatment
 (S) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS 88D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
15	4HD	Female	Imipramine		FUMAFER	06/93	Screen	08/09/93(*)	Day 56
					LEDERFOLIN	06/93	Screen	08/09/93(*)	Day 56
					SULFARLEH	29/07/93	Day 14	19/08/93	Day 35
					ANTALVIC	01/10/93	Screen	28/10/93(*)	Day 21
					LOVENOX	01/10/93	Screen	28/10/93(*)	Day 21
					ROHPNOL	04/10/93(§)	Screen	28/10/93(*)	Day 21
					DOLIPRANE	02/11/93	Screen	23/01/94(*)	Day 56
					ECAZIDE	21/11/93(§)	Screen	23/01/94(*)	Day 56
					SERHION	21/10/93	Screen	23/01/94(*)	Day 56
					STILNOX	09/93	Screen	23/01/94(*)	Day 56
16	1HD	Female	Reboxetine		ADALATE	22/01/93	Screen	14/04/93(*)	Day 56
					NORHISON	11/02/93	Screen	14/04/93(*)	Day 56
					DUPHALAC	08/02/93	Screen	26/02/93(*)	Day 14
					MICROLAX	08/02/93	Screen	26/02/93(*)	Day 14
1100					NORHISON	11/02/93	Day 7	27/02/93	Day 14

(§) - start date missing = screening date - 1
(*) - end date missing = last dose taken date if last visit
(?) - end date missing = visit date during treatment
(@) - only for concomitant drug reported at screen visit

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

20

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 8.0
 CONCOMITANT DRUGS

9550089

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
16	2MD	Male	Imipramine		DUPHALAC	03/93	Screen	09/06/93(*)	Day 56
					DUSPATALIN	03/93	Screen	09/06/93(*)	Day 56
					INOVANE	07/04/93	Screen	10/04/93	Screen
					NORMISON	10/04/93	Screen	09/06/93(*)	Day 56
					RYTHMODAN	92	Screen	09/06/93(*)	Day 56
					SULFARLEN	25/05/93	Day 42	09/06/93(*)	Day 56
2DT		Male	Reboxetine		HEPT-A-NYL	29/04/93	Screen	28/06/93(*)	Day 56
					NORMISON	22/04/93	Screen	28/06/93(*)	Day 56
					SULFARLEN	28/04/93	Screen	28/06/93	Day 56
3MD		Female	Imipramine		NORMISON	04/05/93	Screen	09/06/93(*)	Day 35
3DT		Female	Imipramine		ADALATE	22/07/93	Screen	10/08/93(*)	Day 14
					ALDACTAZINE	89	Screen	10/08/93(*)	Day 14
					DUPHALAC	21/07/93	Screen	10/08/93(*)	Day 14
					NORMISON	22/07/93	Screen	10/08/93	Day 14
					TILDIEN	89	Screen	10/08/93(*)	Day 14

1101

(*) - start date missing = screening date - 1
 (**) - end date missing = last dose taken date if last visit
 (Z) - end date missing = visit date during treatment
 (S) - only for concomitant drug reported at screen visit

9550089

21

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: B.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
16	4ND	Female	Reboxetine		MODOPAR	91	Screen	13/06/94(*)	Day 56
					NORMISON	12/04/94	Screen	13/06/94(*)	Day 56
					SERC	91	Screen	13/06/94(*)	Day 56
					TRASICOR	91	Screen	13/06/94(*)	Day 56
17	1ND	Female	Reboxetine		STILNOX	09/03/93	Screen	25/05/93(*)	Day 56
	3ND	Female	Imipramine		MOVANE	25/10/93	Screen	19/11/93(*)	Day 14
	4ND	Female	Reboxetine		TELDAE	16/11/93	Day 14	19/11/93(*)	Day 14
	4DT	Female	Imipramine		NORMISON	11/01/94	Screen	09/03/94(*)	Day 56
					DUSPAYALIN	15/09/90	Screen	15/03/94(*)	Day 56
					RECTOPANBILINE	20/01/92	Screen	15/03/94(*)	Day 56
	211DT	Female	Reboxetine		CORDARONE	01/10/90	Screen	30/05/94(*)	Day 56
					LASILIX	01/10/90	Screen	30/05/94(*)	Day 56
18	1ND	Female	Imipramine		CHLORAL HYDRATE	18/05/93	Screen	21/07/93	Day 56
	1DT	Female	Imipramine		BACTRIM FORTE	16/08/93	Day 7	26/08/93	Day 21
					NITROFURANTOIN	14/09/93	Day 35	25/09/93	Day 49

(*) - start date missing = screening date - 1
(*) - end date missing = last dose taken date if last visit
(2) - end date missing = visit date during treatment
(3) - only for concomitant drug reported at screen visit

1102

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
18	1DT	Female	Imipramine		NORMISON	03/08/93	Screen	06/10/93(*)	Day 56
	2HD	Female	Imipramine		CHLORAL HYDRATE	22/05/93 28/06/93	Screen Day 28	12/06/93 26/06/93	Day 14 Day 28
	2DT	Female	Reboxetine		NORMISON	04/11/93	Day 7	06/12/93	Day 28
	3MD	Female	Reboxetine		QUINAPRIL 91		Screen	06/12/93(*)	Day 28
					ALDACTONE	07/90	Screen	01/10/93(*)	Day 49
					CHLORAL HYDRATE	06/08/93	Screen	01/10/93(*)	Day 49
					VASTAREL	01/88	Screen	01/10/93(*)	Day 49
	4HD	Female	Reboxetine		NORMISON	28/09/93	Screen	27/11/93(*)	Day 56
22	1HD	Female	Reboxetine		NOCTAMID	21/06/93	Screen	30/06/93(*)	Day 7
23	1HD	Female	Reboxetine		CHLORALDURAT	29/01/93	Screen	29/01/93	Screen
					METOCLOPRAMIDE	01/02/93	Day 7	01/02/93	Day 7
	2HD	Female	Reboxetine		ASPIRINE	24/01/93	Screen	21/03/93	Day 49
					CANVLOFIN	22/03/93	Day 49	29/03/93(*)	Day 56
					CHLORAL HYDRATE	01/02/93	Screen	29/03/93	Day 56
					CIPROHEPTADINE	05/02/93	Day 7	01/03/93	Day 28

9550089

1103

(S) - start date missing = screening date - 1
(*) - end date missing = last dose taken date if last visit
(X) - end date missing = visit date during treatment
(Z) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

23

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
23	2ND	Female	Reboxetine		DISTRANEURIN	01/02/93	Day 21	01/03/93	Day 28
					POLYBION	05/02/93	Day 7	22/02/93	Day 21
					PRESOMEN	20/01/93	Screen	15/03/93	Day 42
	3ND	Female	Imipramine		CHLORALDURAT	19/03/93	Screen	17/05/93(*)	Day 56
					DIGOXIN	19/03/93	Screen	22/03/93	Screen
					DISTRANEURIN	20/03/93	Screen	21/03/93	Screen
						23/03/93	Day 7	24/03/93	Day 7
						11/04/93	Day 21	12/04/93	Day 21
					EUGALAC	18/03/93	Screen	17/05/93(*)	Day 56
					ISOKET RETARD	22/03/93	Day 7	17/05/93(*)	Day 56
					LAXOBERAL	24/03/93	Day 7	25/03/93	Day 7
						29/03/93	Day 7	30/03/93	Day 14
						02/04/93	Day 14	03/04/93	Day 14
						05/04/93	Day 14	06/04/93	Day 21
						13/04/93	Day 28	14/04/93	Day 28
					LEFAX	11/04/93	Day 21	24/04/93	Day 35
					LOPIRIN COR	17/03/93	Screen	17/05/93(*)	Day 56
					SAB SIMPLEX	24/03/93	Day 7	26/03/93	Day 7
						30/03/93	Day 14	17/05/93(*)	Day 56
	4ND	Female	Imipramine		BETAMANN	02/04/93	Day 7	25/05/93(*)	Day 56

1104

(*) - start date missing = screening date - 1
(*) - end date missing = last dose taken date if last visit
(*) - end date missing = visit date during treatment
(*) - only for concomitant drug reported at screen visit

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

24

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
23	4ND	Female	Imipramine		CHLORALDURAT	19/04/93	Day 49	14/05/93	Day 49
					PILOCARPINE	15/03/93	Screen	25/05/93(*)	Day 56
					SULFAMETHOXAZOLE	30/04/93	Day 49	14/05/93	Day 49
					AGIOLAX	10/05/93	Day 7	13/05/93(*)	Day 14
					CHLORALDURAT	08/05/93	Day 7	13/05/93(*)	Day 14
	6ND	Female	Imipramine		EUGALAC	21/04/93	Screen	05/05/93	Screen
					MAALOX	02/04/93	Screen	03/04/93	Screen
					SENNA	06/05/93	Day 7	08/05/93	Day 7
					THYROXIN	29/04/93	Screen	13/05/93(*)	Day 14
					CHLORALDURAT	02/07/93	Screen	05/07/93	Screen
6ND	Female	Imipramine		CHLORALDURAT	10/07/93	Day 7	11/07/93	Day 7	
				DISTRAMOURIN	22/07/93	Day 21	17/08/93(*)	Day 49	
				DISTRAMOURIN	02/07/93	Screen	05/07/93	Screen	
				DISTRAMOURIN	11/07/93	Day 7	11/07/93	Day 7	
				ISOSORBIDE MONONITRATE	01/07/93	Screen	17/08/93(*)	Day 49	
				LAXOBERAL	12/07/93	Day 7	12/07/93	Day 7	
				LAXOBERAL	16/07/93	Day 14	17/07/93	Day 14	
				LAXOBERAL	26/07/93	Day 21	26/07/93	Day 21	
				LAXOBERAL	30/07/93	Day 28	31/07/93	Day 28	
				LAXOBERAL	30/07/93	Day 28	31/07/93	Day 28	

9550089

1105

(§) - start date missing = screening date - 1
(*) - end date missing = last dose taken date if last visit
(X) - end date missing = visit date during treatment
(3) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PIRAMAX CRS RBD
 REMOXTINE - PROTOCOL 2014/055
 Listing No.: 0.0
 CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Completed as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
23	6HD	Female	Isiprasine		THYROXIN	10/08/93	Day 42	17/08/93(*)	Day 49
25	1HD	Male	Robaxetine		CHLORALDRAT	24/08/93	Day 7	14/09/93	Day 21
					OMANED	01/01/90	Screen	01/10/93(*)	Day 35
					SIMVASTATIN	01/01/90	Screen	01/10/93(*)	Day 35
					TEMAZEPAN	15/09/93	Day 21	22/09/93	Day 28
					TENTAL	01/01/90	Screen	01/10/93(*)	Day 35
					VERATIDE	01/01/91	Screen	21/09/93	Day 28
					ZILOLIC	16/09/93	Day 21	01/10/93(*)	Day 35
					ALPRAZOLAN	19/11/93	Screen	22/11/93	Screen
					CHLORALDRAT	19/11/93	Screen	09/12/93	Day 14
					CHLORPHOTHIXENE	29/11/93	Day 7	29/11/93	Day 7
					OMAZEPAN	22/11/93	Screen	20/01/94(*)	Day 56
					TAVOR	04/12/93	Day 21	20/01/94(*)	Day 56
					ZOPICLONE	10/12/93	Day 21	20/01/94(*)	Day 56
26	1HD	Female	Isiprasine		CHLORAL DRATE	23/04/93	Screen	21/05/93(*)	Day 56

9550089

1106

(*) - start date missing = screening date - 1
 (**) - end date missing = last date taken date if last visit
 (**) - end date missing = visit date during treatment
 (**) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

26

PHARMACIA CIS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 8.0
 CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
26	1DT	Female	Reboxetine		PASPERTIN	13/07/93	Day 21	11/08/93(*)	Day 49
27	1MD	Male	Imipramine		DALMADORM	30/01/93	Screen	08/02/93(*)	Day 7
30	1MD	Female	Imipramine		DIGOXIN	12/04/93(\$)	Screen	17/06/93(*)	Day 56
					TEMAZEPAM	12/04/93(\$)	Screen	17/06/93(*)	Day 56
	2MD	Female	Reboxetine		DIGOXIN	11/07/93(\$)	Screen	18/07/93(*)	Day 7
	4MD	Female	Reboxetine		ATENLOLOL	28/10/93(\$)	Screen	30/12/93(*)	Day 56
31	1MD	Female	Imipramine		TEMAZEPAM	24/10/93	Screen	30/12/93(*)	Day 56
					FRÜHLIL	01/92	Screen	15/09/92	Screen
					NORMISON	26/08/92	Screen	05/10/92(*)	Day 14
					PARACETAMOL	28/09/92	Day 7	05/10/92	Day 14
					VOLTAROL	05/10/92	Day 14	05/10/92(*)	Day 14
	1DT	Female	Reboxetine		CENTYL K	25/09/92	Day 7	28/10/92(*)	Day 35
					DUPHALAC	25/09/92	Day 7	23/10/92	Day 35
					NORMISON	09/10/92	Day 21	28/10/92(*)	Day 35
					SENERGOT	09/10/92	Day 21	28/10/92(*)	Day 35

9550089

1107

(*) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (X) - end date missing = visit date during treatment
 (\$) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

27

9550089

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 6.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
31	2ND	Female	Reboxetine		ASPIRINE	90	Screen	29/01/93(*)	Day 56
					CERUMOL	07/12/92	Day 7	18/01/93	Day 42
					CHLORONYCETIN	20/01/93	Day 49	03/02/93	Day 56
					FRUMIL	90	Screen	29/01/93(*)	Day 56
					LIQUIFILM TEARS	06/01/93	Day 35	20/01/93	Day 49
					NORMISON	09/92	Screen	22/01/93	Day 49
					DIAMICRON	05/02/92	Screen	16/12/92(*)	Day 7
					FRUMIL	10/02/92	Screen	16/12/92(*)	Day 7
					DANTRON	28/04/93	Day 42	19/05/93(*)	Day 56
					DIHYDROCODEINE BITARTRATE	90	Screen	19/05/93(*)	Day 56
32	1ND	Female	Imipramine		DOCUSATE	28/04/93	Day 42	19/05/93(*)	Day 56
					MODURETIC	78	Screen	19/05/93(*)	Day 56
					PARACETANOL	90	Screen	19/05/93(*)	Day 56
					PROPRANOLOL	78	Screen	19/05/93(*)	Day 56
					TEMAZEPAM	90	Screen	19/05/93(*)	Day 56

(*) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (X) - end date missing = visit date during treatment
 (Q) - only for concomitant drug reported at screen visit

1108

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

28

9550089

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
32	2ND	Female	Imipramine		LORAZEPAM	10/92	Screen	02/04/93	Screen
					MODURET	88	Screen	09/06/93(*)	Day 56
	3ND	Female	Reboxetine		FLOXAPEN	03/06/93	Day 49	10/06/93	Day 49
					HONUCOR	12/92	Screen	16/06/93(*)	Day 56
					MAVIDREX	12/92	Screen	16/06/93(*)	Day 56
					TEHAZEPAM	87	Screen	16/06/93(*)	Day 56
	4ND	Female	Reboxetine		PREPAP-C	82	Screen	26/10/93(*)	Day 21
					TEHAZEPAM	88	Screen	26/10/93(*)	Day 21
					THIORIDAZINE	07/93	Screen	22/09/93	Screen
	5ND	Female	Reboxetine		TEHAZEPAM	27/10/93	Screen	25/11/93(*)	Day 28
	6ND	Male	Imipramine		AMOXICILLIN	23/12/93	Day 49	29/12/93	Day 49
	1ND	Female	Reboxetine		BETHANECHOL CHLORIDE	29/01/93	Day 7	08/02/93	Day 14
					CHLORAL HYDRATE	28/01/93	Day 7	14/02/93(*)	Day 21
					DEPRONAL	25/01/93 08/02/93	Screen Day 14	02/02/93 08/02/93	Day 14 Day 14
					DUPHALAC	28/01/93	Day 7	14/02/93(*)	Day 21

1109

(*) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (X) - end date missing = visit date during treatment
 (3) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

29

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
35	1ND	Female	Reboxetine		INDERAL - SLOW RELEASE	25/01/93	Screen	14/02/93(*)	Day 21
					TEMESTA	25/01/93	Screen	14/02/93(*)	Day 21
	1DT	Female	Reboxetine		AUGHENTIN	19/04/93	Day 49	25/04/93	Day 49
					BACTRIN	16/03/93	Day 14	22/03/93	Day 21
					CHLORAL HYDRATE	03/03/93	Day 7	07/03/93	Day 7
					CORYTON	92	Screen	27/04/93(*)	Day 56
					DUPHALAC	05/04/93	Day 35	27/04/93(*)	Day 56
					FURADANTINE	01/03/93	Screen	06/03/93	Day 7
					INDERAL	92	Screen	27/04/93(*)	Day 56
					LAXOBERON	09/04/93	Day 35	27/04/93(*)	Day 56
					LORANET	01/93 08/03/93	Screen Day 7	02/03/93 27/04/93(*)	Screen Day 56
					SULFARLEN	92	Screen	27/04/93(*)	Day 56
					XYLOCAINE	29/03/93	Day 28	27/04/93(*)	Day 56
					ZANTAC	92	Screen	27/04/93(*)	Day 56
	2ND	Female	Imipramine		BACTRIN	22/03/93	Day 21	23/03/93	Day 21

1110

9550089

(§) - start date missing = screening date - 1
(*) - end date missing = last dose taken date if last visit
(2) - end date missing = visit date during treatment
(3) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

30

PHARMACIA CNS R&D
 RESOXETINE - PROTOCOL 20124/035
 Listing No.: 8.0
 CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
35	2HD	Female	Imipramine		DIGITALINE	86	Screen	31/03/93(*)	Day 35
					EFFORTIL	30/03/93	Day 28	31/03/93(*)	Day 35
					ETUHINE	92	Screen	31/03/93(*)	Day 35
					FURADANTIN	23/03/93	Day 21	28/03/93	Day 28
					ISOPTIN	90	Screen	31/03/93(*)	Day 35
					MOTILIUM	90	Screen	31/03/93(*)	Day 35
					VALIUM	31/03/93	Day 35	31/03/93	Day 35
	2DT	Female	Imipramine		LORHETAZEPAM	01/93	Screen	27/04/93(*)	Day 56
	3HD	Female	Imipramine		CHLORAL HYDRATE	01/04/93	Screen	05/04/93(*)	Day 7
					DIAMICRON	92	Screen	05/04/93(*)	Day 7
					KREDEX	92	Screen	05/04/93(*)	Day 7
					LANDXIN	92	Screen	05/04/93	Day 7
					LORAMET	26/03/93	Screen	31/03/93	Screen
					MARCOURAR	92	Screen	05/04/93(*)	Day 7
					MAXI-B 5000	27/03/93	Screen	01/04/93	Day 7

9550089

(*) - start date missing = screening date - 1
 (**) - end date missing = last dose taken date if last visit
 (Z) - end date missing = visit date during treatment
 (S) - only for concomitant drug reported at screen visit

11111

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

31

PEARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
35	3ND	Female	Imipramine		ZOROXIN	01/04/93	Day 7	05/04/93	Day 7
	3DT	Male	Imipramine		ASPIRINE	10/92	Screen	26/05/93(*)	Day 56
					SELECTOL	90	Screen	26/05/93(*)	Day 56
					TEMESTA	90	Screen	26/05/93(*)	Day 56
	4ND	Male	Reboxetine		DUPHALAC	15/04/93(§)	Screen	10/05/93	Day 28
					FURADANTINE	08/06/93 07/06/93	Screen Day 49	15/06/93 13/06/93	Screen Day 56
					MODURETIC	15/04/93(§)	Screen	14/06/93(*)	Day 56
					PRONASINE	11/05/93	Day 28	14/06/93(*)	Day 56
					ZOROXIN	22/05/93	Day 35	28/05/93	Day 35
					ZYLORIC	15/04/93(§)	Screen	14/06/93(*)	Day 56
	4DT	Female	Reboxetine		CHLORAL HYDRATE	30/04/93	Day 7	29/05/93	Day 35
					LENDORMIN	29/05/93	Day 35	21/06/93(*)	Day 56
					SECTRAL	21/04/93(§)	Screen	21/06/93(*)	Day 56
					TEMESTA	21/04/93(§)	Screen	21/06/93(*)	Day 56
	5ND	Male	Reboxetine		CEDOCARD	92	Screen	02/09/93(*)	Day 56

1112

9550089

(§) - start date missing = screening date - 1
(*) - end date missing = last dose taken date if last visit
(z) - end date missing = visit date during treatment
(a) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

32

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
35	5ND	Male	Reboxetine		DUPHALAC	92	Screen	02/09/93(*)	Day 56
					LORANET	02/07/93	Screen	02/09/93(*)	Day 56
					PRIMPERAN	92	Screen	02/09/93(*)	Day 56
	5DT	Female	Imipramine		CARVEDILOL	31/08/93(§)	Screen	27/10/93(*)	Day 56
					DUPHALAC	28/09/93	Day 28	27/10/93(*)	Day 56
					MOTILIUM	27/08/93	Screen	27/10/93(*)	Day 56
					NITROGLICERINA	31/08/93(§)	Screen	27/10/93(*)	Day 56
					NOCTAMID	31/08/93(§)	Screen	27/10/93(*)	Day 56
					SULFARLEM	28/09/93	Day 28	27/10/93(*)	Day 56
					TEARS NATURALE	31/08/93(§)	Screen	27/10/93(*)	Day 56
					ASPIRINA	18/01/94(§)	Screen	02/03/94(*)	Day 42
					DUPHALAC	19/02/94	Day 35	02/03/94(*)	Day 42
					HYDERGINE	18/01/94(§)	Screen	02/03/94(*)	Day 42
					INDOCID RETARD	18/01/94(§)	Screen	02/03/94(*)	Day 42
	6ND	Female	Reboxetine		LORANET	18/01/94	Screen	28/01/94	Day 14

9550089

1113

(§) - start date missing = screening date - 1
(*) - end date missing = last dose taken date if last visit
(X) - end date missing = visit date during treatment
(3) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

33

9550089

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
35	6ND	Female	Reboxetine		ROHIPNOL	25/01/94	Day 14	02/03/94(*)	Day 42
					STAURODORIN	25/01/94	Day 7	28/01/94	Day 14
					TEMESTA	25/01/94	Day 14	02/03/94(*)	Day 42
	6DT	Female	Imipramine		EUGLUCON	11/10/93(\$)	Screen	14/12/93(*)	Day 56
					HYDREGINA	11/10/93(\$)	Screen	14/12/93(*)	Day 56
					LIPANTHYL	11/10/93(\$)	Screen	14/12/93(*)	Day 56
					LORANET	12/10/93	Screen	17/10/93	Screen
					TEMESTA	18/10/93	Screen	14/12/93(*)	Day 56
					TENORMIN	11/10/93(\$)	Screen	14/12/93(*)	Day 56
					EFFORTIL	17/12/93	Day 14	18/12/93	Day 14
	7ND	Female	Imipramine		FERRO-GRADUNET	17/12/93	Day 14	17/01/94(*)	Day 42
					LORANET	89	Screen	17/01/94(*)	Day 42
					OMNIBIONTA	15/11/93	Screen	17/01/94(*)	Day 42
	7DT	Female	Reboxetine		DOGMATIL	06/11/93	Day 21	16/11/93(*)	Day 28
					INDERAL - SLOW RELEASE	14/10/93(\$)	Screen	16/11/93(*)	Day 28

(\$) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (X) - end date missing = visit date during treatment
 (3) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

34

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
35	7DT	Female	Reboxetine		LANITOP	14/10/93(§)	Screen	16/11/93(*)	Day 28
					LORANET	15/10/93	Screen	16/11/93(*)	Day 28
					TENESTA	15/10/93	Screen	16/11/93(*)	Day 28
					VOLTAREN	14/10/93(§)	Screen	16/11/93(*)	Day 28
	8ND	Female	Imipramine		BETAXOLOL	21/02/94	Day 21	21/03/94(*)	Day 49
					CHLORAL HYDRATE	21/02/94	Day 21	21/03/94(*)	Day 49
					DITROPAN	02/03/94	Day 35	21/03/94(*)	Day 49
					DUFALAC	10/01/94	Screen	21/03/94(*)	Day 49
					FERROGRANUMET	11/02/94	Day 14	14/03/94	Day 42
					LOESFERRON	10/01/94	Screen	06/02/94	Day 7
					LORANET	10/01/94	Screen	21/03/94(*)	Day 49
					PERDOLAN	10/01/94	Screen	31/01/94	Screen
	8DT	Female	Reboxetine		LAXOBERON	31/01/94	Day 21	07/03/94(*)	Day 56
					LORANET	21/01/94	Day 14	07/03/94(*)	Day 56
36	1ND	Male	Imipramine		ADALAT	92	Screen	22/02/93	Day 42

9550089

1115

(§) - start date missing = screening date - 1
(*) - end date missing = last dose taken date if last visit
(X) - end date missing = visit date during treatment
(@) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

35

9550089

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
36	1MD	Male	Imipramine		ASPIRINA INFANTIL	22/12/92	Screen	08/03/93(*)	Day 56
					ATROVENT	11/02/93	Day 28	08/03/93(*)	Day 56
					AUGMENTIN	14/02/93	Day 35	23/02/93	Day 42
					CLAVUCID	12/02/93	Day 28	14/02/93	Day 35
					DINDERGOT	28/02/93	Day 49	08/03/93(*)	Day 56
					IHOVANE	92	Screen	08/03/93(*)	Day 56
					LISONUCIL	05/02/93	Day 21	08/03/93(*)	Day 56
					THEOLAIR	92	Screen	08/03/93(*)	Day 56
					TRANKENE	10/02/93	Day 28	14/02/93	Day 35
					VENTOLIN	11/02/93	Day 28	08/03/93(*)	Day 56
					ZOLADEX	28/01/93	Day 14	08/03/93(*)	Day 56
1DT		Female	Imipramine		LEXOTAN	92	Screen	30/03/93(*)	Day 56
					VIONEURIN-6 FORTE	92	Screen	30/03/93(*)	Day 56
2MD		Female	Reboxetine		BEFACT	27/01/93	Screen	30/03/93(*)	Day 56
					LORANET	27/01/93	Screen	16/03/93	Day 42

(*) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (2) - end date missing = visit date during treatment
 (3) - only for concomitant drug reported at screen visit

1116

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

36

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
36	2ND	Female	Reboxetine		RENITEC	92	Screen	30/03/93(*)	Day 56
					ROHYPNOL	16/03/93	Day 42	30/03/93(*)	Day 56
					SERENASE	09/03/93	Day 35	16/03/93	Day 42
	2DT	Female	Reboxetine		AACIFEMINE	03/03/93	Day 7	22/04/93(*)	Day 56
					EMCONCOR	92	Screen	22/04/93(*)	Day 56
					NOCTAHID	14/03/93	Day 21	22/04/93(*)	Day 56
					OMEPRAZOLE	92	Screen	22/04/93(*)	Day 56
	3ND	Female	Imipramine		ALVITYL	01/93	Screen	02/04/93(*)	Day 56
					CHLORHEXIDINE GLUCONATE	05/03/93	Day 28	29/03/93	Day 56
					DEPRONAL	19/02/93	Day 14	05/03/93	Day 28
					ESTULIC	92	Screen	02/04/93(*)	Day 56
					ISRADIPINE	92	Screen	02/04/93(*)	Day 56
					LANOXIN	92	Screen	02/04/93(*)	Day 56
					LEXOTAN	92	Screen	16/02/93	Day 14
					LORAMET	10/02/93	Day 7	02/04/93(*)	Day 56

9550089

1117

(\$) - start date missing = screening date - 1
(*) - end date missing = last dose taken date if last visit
(x) - end date missing = visit date during treatment
(a) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

37

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 8.0
 CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
36	3ND	Female	Imipramine		NEOGENYL	15/02/93	Day 14	02/04/93(*)	Day 56
					PRINPERAN	01/93	Screen	02/04/93(*)	Day 56
					TENORETIC	92	Screen	02/03/93	Day 28
					VALTRAN	09/03/93	Day 35	02/04/93(*)	Day 56
					ZOROXIN	08/03/93	Day 35	15/03/93	Day 42
	3DT	Female	Imipramine		CAPRENOL	92	Screen	27/04/93(*)	Day 56
					CEBUR	92	Screen	27/04/93(*)	Day 56
					CHLORAL HYDRATE	01/93	Screen	12/03/93	Day 14
					DAFLON	92	Screen	27/04/93(*)	Day 56
					DORHONCT	12/03/93	Day 14	27/04/93(*)	Day 56
					LOSEC	25/02/93	Screen	27/04/93(*)	Day 56
					BEFACT	02/03/93	Screen	01/05/93(*)	Day 56
	4ND	Female	Reboxetine		FLURAZEPAN	08/04/93	Day 35	01/05/93(*)	Day 56
					LOSEC	03/03/93	Screen	01/05/93(*)	Day 56
					NADEX	05/03/93	Screen	01/05/93(*)	Day 56

9550089

1118

(§) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (x) - end date missing = visit date during treatment
 (a) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

38

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 8.0
 CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
36	4ND	Female	Reboxetine		PRIMPERAN	03/03/93	Screen	01/05/93(*)	Day 56
					SERENASE	02/93	Screen	08/04/93	Day 28
	4DT	Female	Reboxetine		HYDROGINE	93	Screen	06/05/93(*)	Day 56
					ROBUPNOL	93	Screen	06/05/93(*)	Day 56
	5ND	Female	Reboxetine		ASPIRINA INFANTIL	91	Screen	18/06/93(*)	Day 56
					DOBONDOCT	30/04/93	Day 7	18/06/93(*)	Day 56
					HYDROGINE	91	Screen	18/06/93(*)	Day 56
					LORANET	04/93	Screen	30/04/93	Day 7
					PRAZINE	91	Screen	18/06/93(*)	Day 56
					RYDENE	91	Screen	18/06/93(*)	Day 56
					STRUMAZOL	91	Screen	18/06/93(*)	Day 56
	5DT	Female	Imipramine		CALCIUM	92	Screen	07/04/93(*)	Day 7
					FURADANTINE MC	93	Screen	07/04/93(*)	Day 7
					GLURENORM	92	Screen	07/04/93(*)	Day 7
					LOSEC	03/93	Screen	07/04/93(*)	Day 7

9550089

1119

(S) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (X) - end date missing = visit date during treatment
 (B) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

39

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
36	5DT	Female	Inipramine		TEGRETOL	93	Screen	07/04/93(*)	Day 7
	6HD	Female	Inipramine		ASPIRINA INFANTIL	07/04/93	Screen	25/06/93(*)	Day 56
					INOYANE	07/04/93	Screen	31/05/93	Day 35
					MOOTROPIL	07/04/93	Screen	25/06/93(*)	Day 56
					PERSANTIN	07/04/93	Screen	25/06/93(*)	Day 56
					PRAKILENE	07/04/93	Screen	25/06/93(*)	Day 56
					SELO-ZOK	15/06/93	Day 49	25/06/93(*)	Day 56
					VOLTAREN	20/04/93	Screen	25/06/93(*)	Day 56
	6DT	Female	Inipramine		CATAPRESAN	30/03/93(§)	Screen	04/06/93(*)	Day 56
					HALCION	30/03/93(§)	Screen	04/06/93(*)	Day 56
					PRAKILENE	30/03/93(§)	Screen	04/06/93(*)	Day 56
					TENORIN	30/03/93(§)	Screen	04/06/93(*)	Day 56
	7HD	Female	Reboxetine		AACIFENINE	30/04/93	Screen	25/05/93	Day 14
					CISAPRIDE MONOHYDRATE	13/04/93	Screen	07/07/93(*)	Day 56
					DAKTARIN GINECOLOGICO	30/04/93	Screen	12/05/93	Screen

1120

(§) - start date missing = screening date - 1
(*) - end date missing = last dose taken date if last visit
(**) - end date missing = visit date during treatment
(§) - only for concomitant drug reported at screen visit

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

40

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
36	7ND	Female	Reboxetine		ENGLUCON	02/05/93(*)	Screen	07/07/93(*)	Day 56
					GLUCOPHAGE FORTE	02/05/93(*)	Screen	07/07/93(*)	Day 56
					GYNO-DARTARIN	25/05/93	Day 14	07/07/93(*)	Day 56
					IMODIUM	27/06/93 06/07/93	Day 49 Day 56	27/06/93 07/07/93	Day 49 Day 56
					LOSEC	13/04/93	Screen	07/07/93(*)	Day 56
					PEFLACINE	30/04/93	Screen	12/05/93	Screen
					PRIMPERAN	13/04/93	Screen	07/07/93(*)	Day 56
					TARIVID	15/06/93	Day 35	22/06/93	Day 42
					CALCIUM-SANDOZ	91	Screen	07/05/93(*)	Day 7
					CITRULLINE MALATE	91	Screen	07/05/93(*)	Day 7
					STAURODORM	20/04/93	Screen	07/05/93(*)	Day 7
					XANAX	92	Screen	07/05/93(*)	Day 7
					NOCTAMID	07/05/93	Screen	20/07/93(*)	Day 56
					SEDURAL	07/05/93	Screen	20/07/93(*)	Day 56
					ASPIRINA INFANTIL	04/05/93	Screen	16/07/93(*)	Day 63

9550089

1121

(*) - start date missing = screening date - 1
(*) - end date missing = last dose taken date if last visit
(x) - end date missing = visit date during treatment
(3) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

41

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: B.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
36	SDT	Female	Reboxetine		CALCIUK-SANDOZ	09/05/93	Screen	16/07/93(*)	Day 63
					DEPRONAL	18/06/93	Day 35	16/07/93(*)	Day 63
					DUPHALAC	02/06/93	Day 21	16/07/93(*)	Day 63
					LORAMET	04/05/93	Screen	19/05/93	Day 7
					PERSANTINE	04/05/93	Screen	16/07/93(*)	Day 63
					STAUBODORH	20/05/93	Day 7	16/07/93(*)	Day 63
					XANAX	04/05/93	Screen	17/05/93	Day 14
9HD		Male	Reboxetine		ASPIRINA INFANTIL	92	Screen	10/08/93(*)	Day 56
					ATROVENT	11/06/93	Screen	10/08/93(*)	Day 56
					AUGMENTIN	11/06/93	Screen	11/07/93	Day 28
					BEROTEC	11/06/93	Screen	10/08/93(*)	Day 56
					BETHANECHOL CHLORIDE	06/93	Screen	10/08/93(*)	Day 56
					HYDERGINE	06/93	Screen	18/06/93	Day 7
					LASIX	11/06/93	Screen	26/06/93	Day 14
					MODURETIC	11/06/93	Screen	26/06/93	Day 14

9550089

1122

(§) - start date missing = screening data - 1
(*) - end date missing = last dose taken date if last visit
(X) - end date missing = visit date during treatment
(a) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

42

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
36	9MD	Male	Reboxetine		NOOTROPIL	11/06/93	Screen	18/06/93	Day 7
					PEFLACINE	19/07/93	Day 35	28/07/93	Day 49
					TAGAMET	06/93	Screen	10/08/93(*)	Day 56
					TREDLAIR	11/06/93	Screen	10/08/93(*)	Day 56
	90T	Female	Imipramine		ESTRADERM	20/07/93	Day 28	19/08/93(*)	Day 56
					INDERAL - SLOW RELEASE	01/07/92	Screen	19/08/93(*)	Day 56
					LORANET	07/92	Screen	19/08/93(*)	Day 56
					RENITEC	91	Screen	19/08/93(*)	Day 56
					TAGAMET	92	Screen	19/08/93(*)	Day 56
					ZOROXIN	03/08/93	Day 42	05/08/93	Day 42
					BURONIL	05/06/93	Screen	21/06/93	Screen
					DICETEL	08/06/93(§)	Day 49	09/08/93	Day 49
					DIHYDROGUT	05/08/93	Day 49	16/08/93(*)	Day 56
					EFFORTIL PLUS	05/06/93	Screen	16/08/93(*)	Day 56
					HYDERGINE	08/06/93	Screen	16/08/93(*)	Day 56

9550089

1123

(§) - start date missing = screening date - 1
(*) - end date missing = last dose taken date if last visit
(Z) - end date missing = visit date during treatment
(3) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

43

9550089

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: B.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
36	10ND	Male	Reboxetine		LANOXIN	05/06/93	Screen	16/08/93(*)	Day 56
					LIPANTHYL	05/06/93	Screen	16/08/93(*)	Day 56
					LOFTYL	05/06/93	Screen	16/08/93(*)	Day 56
					NEOGENYL	02/07/93	Day 14	16/08/93(*)	Day 56
					NOCTAMID	21/06/93	Screen	16/08/93(*)	Day 56
					HELLICOPRIN	15/06/93	Screen	16/08/93(*)	Day 56
112	10DT	Male	Reboxetine		IMOVANE	17/10/93	Screen	20/12/93(*)	Day 56
112	11ND	Female	Imipramine		SEDURAL	05/07/93	Screen	02/09/93(*)	Day 56
					TEMESTA	93	Screen	02/09/93(*)	Day 56
					ASPIRINA INFANTIL	25/10/93 23/11/93	Screen Day 14	19/11/93 19/12/93(*)	Day 14 Day 42
					DEXPRONAL	29/10/93(\$) 23/11/93	Screen Day 14	19/11/93 19/12/93(*)	Day 14 Day 42
					DORNINOCT	16/11/93 23/11/93	Day 7 Day 14	19/11/93 19/12/93(*)	Day 14 Day 42
					EMCONCOR	88 23/11/93	Screen Day 14	19/11/93 19/12/93(*)	Day 14 Day 42
					HALDOL	22/11/93	Day 14	19/12/93(*)	Day 42

(\$) - start date missing = screening date - 1
(*) - end date missing = last dose taken date if last visit
(Z) - end date missing = visit date during treatment
(a) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

44

PHARMACIA CNS R&D
 REBOXYTINE - PROTOCOL 20124/035
 Listing No.: 8.0
 CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
36	11DT	Male	Reboxetine		NOCTAMID	02/11/93	Screen	16/11/93	Day 7
					NOZINAN	17/11/93	Day 14	17/11/93	Day 14
					PHENERGAN	22/11/93	Day 14	24/11/93	Day 14
					PRAXILENE	28/10/93 23/11/93	Screen Day 14	19/11/93 19/12/93(*)	Day 14 Day 42
					SEDINAL	17/11/93 23/11/93	Day 14 Day 14	19/11/93 19/12/93(*)	Day 14 Day 42
					TREMBLEX	24/11/93	Day 21	19/12/93(*)	Day 42
					LANOXIN	03/09/93	Screen	05/10/93(*)	Day 14
					LOSEC	03/09/93	Screen	05/10/93(*)	Day 14
					PHENERGAN	92	Screen	05/10/93(*)	Day 14
					RYTHMONORM	08/09/93	Screen	05/10/93(*)	Day 14
					TEHESTA	92	Screen	05/10/93(*)	Day 14
					APTINE	93	Screen	15/02/94(*)	Day 56
					CALCIUM	93	Screen	15/02/94(*)	Day 56
					LANITOP	93	Screen	15/02/94(*)	Day 56

9550089

(*) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (X) - end date missing = visit date during treatment
 (a) - only for concomitant drug reported at screen visit

9550089

45

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: B.0

CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as Protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
36	13ND	Male	Reboxetine		CATAPRESSAN	11/10/93	Day 21	14/10/93(*)	Day 28
					DISPREIL	02/11/92	Screen	14/10/93(*)	Day 28
					KALUMFLORID	08/10/93	Day 21	14/10/93(*)	Day 28
					LORANET	08/93	Screen	14/10/93(*)	Day 28
					PERSANTINE	02/11/92	Screen	14/10/93(*)	Day 28
					PLENDIL	11/10/93	Day 21	14/10/93(*)	Day 28
14ND	Male		Imipramine		NOCTAMID	02/11/93	Screen	28/12/93(*)	Day 56
15ND	Female		Reboxetine		LORANET	05/10/93	Screen	09/11/93(*)	Day 21
16ND	Female		Imipramine		SELO-20K	92	Screen	03/01/94(*)	Day 56
17ND	Female		Reboxetine		ALDACTAZINE	93	Screen	11/11/93(*)	Day 7
					HYDERGINE	93	Screen	11/11/93(*)	Day 7
					LEXOTAN	92	Screen	11/11/93(*)	Day 7
					NOVODIGAL	93	Screen	11/11/93(*)	Day 7
					THEOLAIR	93	Screen	11/11/93(*)	Day 7
					VELMAMITOL	93	Screen	11/11/93(*)	Day 7
					ZILORIC	93	Screen	11/11/93(*)	Day 7

(*) - start date missing = screening date - 1
 (x) - end date missing = last dose taken date if last visit
 (2) - end date missing = visit date during treatment
 (3) - only for concomitant drug reported at screen visit

1126

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

46

9550089

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 8.0
 CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
36	18ND	Female	Imipramine		DIAMICRON	90	Screen	09/03/94(*)	Day 56
					HYDERGINE	30/08/93	Screen	09/03/94(*)	Day 56
					ISRADIPINE	24/05/93	Screen	09/03/94(*)	Day 56
					LORANET	01/93	Screen	09/03/94(*)	Day 56
	19ND	Female	Reboxetine		CLOZAN	12/93	Screen	22/01/94(*)	Day 14
					MOTILIUM	28/12/93	Screen	22/01/94(*)	Day 14
					MILANTA-II	28/12/93	Screen	22/01/94(*)	Day 14
	20ND	Female	Imipramine		DISPRIL	02/05/90	Screen	28/03/94(*)	Day 56
					DYFENZIDE	90	Screen	28/03/94(*)	Day 56
					NEOGENYL	28/01/94	Screen	28/03/94(*)	Day 56
					NOCTAMID	30/01/94	Screen	28/03/94(*)	Day 56
					TEGRETOL	10/03/90	Screen	28/03/94(*)	Day 56
37	3ND	Female	Reboxetine		HALCION	10/03/93	Screen	24/03/93(*)	Day 7
					ZORONIN	16/03/93	Screen	25/03/93	Day 7
41	2ND	Male	Reboxetine		ZANTAC	07/78	Screen	19/04/94(*)	Day 56

(*) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (2) - end date missing = visit date during treatment
 (3) - only for concomitant drug reported at screen visit

1127

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9550089

PHARMACIA CES RMB
 REMOXTINE - PROTOCOL 20124/035
 Listing No.: 8.0
 CONCOMITANT DRUGS

Concomitant	Patient	Sex	Treatment	Complete in protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
42	1ND	Female	Imipramine		CELODRAL HYDRATE	08/10/93	Screen	20/12/93(*)	Day 56
	1DT	Female	Imipramine		CELODRAL HYDRATE	27/10/93	Screen	19/01/94(*)	Day 56
	2ND	Female	Reboxetine		LACTULOSE	27/10/93	Screen	19/01/94(*)	Day 56
		Female	Reboxetine		CELODRAL HYDRATE	15/09/93	Screen	20/12/93(*)	Day 56
					RUTINE SULFATE	10/03/93	Screen	20/12/93(*)	Day 56
	112	Male	Imipramine		VENTOLIN	05/01/93	Screen	20/12/93(*)	Day 56
	113	Male	Imipramine		CELODRAL HYDRATE	19/10/93	Screen	19/01/94(*)	Day 56
	114	Female	Reboxetine		FERRUSULFAT	10/06/89	Screen	19/01/94(*)	Day 56
	43	Female	Reboxetine		DUPHALAC	28/02/93	Day 14	02/04/93(*)	Day 42
					ENDINE	19/02/93	Screen	03/03/93	Day 14
					MICROLAX	27/02/93	Day 14	27/02/93	Day 14
						13/03/93	Day 28	14/03/93	Day 28
					PARACETANOL	18/02/93	Screen	19/02/93	Screen
	2DT	Female	Imipramine		SEDURON	25/02/93	Day 7	25/02/93	Day 7
					PILOCARPINE	90	Screen	01/06/93(*)	Day 21
					TEMAZEPAM	05/93	Screen	01/06/93(*)	Day 21

(*) - start date missing = screening date - 1
 (**) - end date missing = last date taken date if last visit
 (**) - end date missing = last date during treatment
 (**) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

48

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 2012A/035
Listing No.: 8.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
43	2DF	Female	Imipramine		TIMOLOL	90	Screen	01/06/93(*)	Day 21
	3DF	Male	Imipramine		ASPIRINE	04/11/93	Day 56	04/11/93	Day 56
					BISACODYL	22/09/93	Day 14	30/09/93	Day 21
					DOCUSATE	30/09/93	Day 21	30/09/93	Day 21
					PETHIDINE	01/10/93	Day 21	01/10/93	Day 21
					SENOKOT	01/10/93	Day 21	15/10/93	Day 35
						24/10/93	Day 42	25/10/93	Day 42
						02/11/93	Day 49	02/11/93	Day 49
						05/11/93	Day 56	05/11/93	Day 56
					TEMAZEPAM	15/09/93	Screen	25/09/93	Day 14
4DT		Female	Reboxetine		AGAROL	01/11/93	Day 42	18/11/93(*)	Day 56
					DIGOXIN	88	Screen	18/11/93(*)	Day 56
					RANIPRIL	06/93	Screen	18/11/93(*)	Day 56
					TEMAZEPAM	08/93	Screen	18/11/93(*)	Day 56
5ND		Female	Imipramine		DIAZEPAM	10/12/93	Day 7	30/12/93	Day 21
					OXLAZEPAM	31/12/93	Day 28	12/01/94(*)	Day 35
					TAMOXIFEN	01/93	Screen	12/01/94(*)	Day 35

1129

(*) - start date missing = screening date - 1
(*) - end date missing = last dose taken date if last visit
(*) - end date missing = visit date during treatment
(*) - only for concomitant drug reported at screen visit

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

49

PHARMACIA CNS R&D
 ROBEXETINE - PROTOCOL 20124/035
 Listing No.: B.0
 CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
43	5ND	Female	Imipramine		TEMAZEPAM	06/12/93	Screen	12/01/94(*)	Day 35
					URAL	08/12/93	Screen	23/12/93	Day 14
					CARDIZEM	06/93	Screen	14/04/94(*)	Day 56
					ISOSORBIDE	06/93	Screen	14/04/94(*)	Day 56
					LOMOTIL	08/04/94	Day 56	08/04/94	Day 56
					MODURETIC	06/93	Screen	14/04/94(*)	Day 56
					OROXINE	92	Screen	14/04/94(*)	Day 56
					TEMAZEPAM	27/12/93	Screen	14/04/94(*)	Day 56
					ZANTAC	92	Screen	14/04/94(*)	Day 56
					CO-DANTHRAMER	31/07/93	Screen	30/09/93	Day 21
					FYBOCEL	16/09/93	Day 14	28/10/93(*)	Day 56
					PARACETAMOL	12/09/93	Day 14	28/10/93(*)	Day 56
					PROPANLOL	16/10/93	Day 49	21/10/93(X)	Day 49
44	1ND	Female	Robexetine		TAMOXIFEN	03/91	Screen	28/10/93(*)	Day 56
					TEMAZEPAM	07/07/93	Screen	28/10/93(*)	Day 56

9550089

1130

(*) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (X) - end date missing = visit date during treatment
 (S) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

50

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 8.0
 CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
44	1DT	Female	Reboxetine		TEMAZEPAN	27/03/93	Screen	24/09/93(*)	Day 56
					THIORIDAZINE	27/03/93	Screen	30/07/93	Screen
	2ND	Female	Reboxetine		CINETIDINE	16/09/93	Screen	06/10/93	Day 14
					CO-DANTHRAMER	14/10/93	Day 28	15/11/93(*)	Day 56
					GAVISCON	27/09/93	Day 7	11/11/93	Day 56
					HEMINEVREIN	14/10/93	Day 28	15/11/93(*)	Day 56
					ISOSORBIDE MONONITRATE	06/10/93	Day 21	08/10/93	Day 21
					NUCAINE	11/11/93	Day 56	15/11/93(*)	Day 56
					DFLOXACIN	17/09/93	Screen	22/09/93	Screen
					ONEPRAZOLE	06/10/93	Day 21	15/11/93(*)	Day 56
					PARACETANOL	24/09/93 06/10/93	Day 7 Day 21	24/09/93 01/11/93	Day 7 Day 42
					TEMAZEPAN	13/09/93 01/11/93	Screen Day 42	27/10/93 15/11/93(*)	Day 35 Day 56
	3ND	Female	Imipramine		AMPICILLIN	07/12/93	Day 56	12/12/93	Day 56
					BISACODYL	11/10/93	Screen	09/12/93(*)	Day 56

1131

9550089

(\$) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (X) - end date missing = visit date during treatment
 (a) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

51

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: B.0
 CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
44	3ND	Female	Imipramine		CLONAZEPAN	86	Screen	09/12/93(*)	Day 56
					DEXTROPROXYPHENE HYDROC	11/10/93	Screen	09/12/93(*)	Day 56
					PARACETANOL	11/10/93	Screen	09/12/93(*)	Day 56
					TEMAZEPAN	86	Screen	09/12/93(*)	Day 56
	4ND	Male	Imipramine		ASPIRINE	90	Screen	28/03/94(*)	Day 56
					BUCLIZINE HYDROCHLORIDE	18/03/94	Day 49	18/03/94	Day 49
					CISPLATIN	18/03/94	Day 49	18/03/94	Day 49
					FOLINIC ACID	18/03/94	Day 49	20/03/94	Day 49
					LACTULOSE	18/03/94	Day 49	20/03/94	Day 49
					METHOTREXATE	18/03/94	Day 49	18/03/94	Day 49
					MYSTATIN	18/03/94	Day 49	28/03/94(*)	Day 56
					TEMAZEPAN	27/05/92	Screen	28/03/94(*)	Day 56
45	1ND	Male	Reboxetine		SENOKOT	02/12/93	Day 14	04/12/93	Day 14
	1DT	Female	Imipramine		ASILONE	18/08/93	Day 7	19/08/93	Day 7
					FRUHEL	01/04/93	Screen	06/10/93(*)	Day 56
					ONEPRAZOLE	25/08/93	Day 14	06/10/93(*)	Day 56

9550089

1132

(\$) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (x) - end date missing = visit date during treatment
 (a) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

52

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: B.0
 CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as Protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
45	2ND	Male	Imipramine		CAPTURIL	12/11/93	Screen	21/12/93(2)	Day 14
46	1ND	Male	Imipramine		ATENOLOL	01/07/90	Screen	23/11/93(*)	Day 56
48	4ND	Female	Reboxetine		YENAZEPAN	01/08/93	Screen	10/10/93	Day 14
	1DT	Female	Reboxetine		TRINITRIN	01/01/88	Screen	11/12/93(*)	Day 7
					ALPRIM	12/06/93	Screen	21/06/93	Screen
					DIAZEPAN	12/06/93	Day 7	28/06/93	Screen
					DILANTIN	12/06/93	Screen	29/06/93	Day 7
	2DT	Female	Imipramine		FRANVCETIN	05/07/93	Day 7	12/07/93	Day 14
					FYBOGEL	28/06/93	Day 7	05/08/93	Day 42
					MULTIYIT	05/07/93	Day 14	05/08/93	Day 42
					NORMISON	26/06/93	Screen	04/08/93	Day 42
291	1DT	Female	Reboxetine		EUTHYROX	20/07/92	Screen	16/06/93(*)	Day 56
					NIFEDIPINE	02/91	Screen	16/06/93(*)	Day 56
	2ND	Female	Reboxetine		PRES	27/02/93	Screen	14/06/93(*)	Day 56
	2DT	Female	Reboxetine		QUINAPRIL	08/10/92	Screen	16/06/93(*)	Day 56

9550089

1133

(*) - start date missing = screening date - 1
 (**) - end date missing = last dose taken date if last visit
 (2) - end date missing = visit date during treatment
 (3) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

53

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: B.0
 CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
291	3DT	Female	Imipramine		BEZAFIBRATE	24/03/93	Screen	20/05/93(*)	Day 7
					CILAZAPRIL	24/03/93	Screen	20/05/93(*)	Day 7
	4ND	Male	Reboxetine		ISOSORBIDE MONONITRATE	01/04/93	Screen	20/05/93(*)	Day 7
	4DT	Male	Imipramine		BRONUC	09/92	Screen	28/06/93(*)	Day 56
					GINKGO TREE LEAVES EXTRAC 90	90	Screen	29/06/93(*)	Day 56
					GLIBENCLAMIDE 83	83	Screen	29/06/93(*)	Day 56
1134	25DT	Female	Imipramine		ALLOPURINOL	02/11/93(\$)	Screen	30/12/93(*)	Day 56
					ASPIRINE	02/11/93(\$)	Screen	30/12/93(*)	Day 56
					DIGIMERCK	02/11/93(\$)	Screen	30/12/93(*)	Day 56
					ISOSORBIDE MONONITRATE	02/11/93(\$)	Screen	30/12/93(*)	Day 56
					RYTHONORM	02/11/93(\$)	Screen	30/12/93(*)	Day 56
	26DT	Female	Reboxetine		LOPIRIN	05/91	Screen	03/08/93(*)	Day 56
	27DT	Female	Reboxetine		GINKGO TREE LEAVES EXTRAC 90	90	Screen	30/12/93(*)	Day 56
	28DT	Female	Imipramine		BEZAFIBRATE	90	Screen	17/01/94(*)	Day 56
					EUGLUCON 85	85	Screen	17/01/94(*)	Day 56

9550089

(\$) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (2) - end date missing = visit date during treatment
 (3) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

54

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 8.0
 CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
291	28DT	Female	Imipramine		NIFEDIPINE	90	Screen	17/01/94(*)	Day 56
292	5HD	Female	Imipramine		ALLO. COMP. - RATIOPHARM	04/02/93	Screen	27/04/93(*)	Day 56
					NOVADRAL RETARD	18/02/91	Screen	20/04/93	Day 49
					SINVASTATIN	28/02/91	Screen	27/04/93(*)	Day 56
	5DT	Male	Reboxetine		DURANITRAT	18/02/93	Screen	29/04/93(*)	Day 56
					EPIDROPAL	07/84	Screen	29/04/93(*)	Day 56
1133	6HD	Female	Reboxetine		DIGIHERCK	17/07/90	Screen	28/04/93(*)	Day 56
31					FENOFIBRATE	14/12/92	Screen	28/04/93(*)	Day 56
					ISOMET RETARD	12/11/92	Screen	28/04/93(*)	Day 56
					VENOSTASIN	01/04/82	Screen	28/04/93(*)	Day 56
6DT		Female	Imipramine		ZOCOR	25/04/91	Screen	10/05/93(*)	Day 56
7HD		Male	Reboxetine		ALLO. COMP. - RATIOPHARM	07/88	Screen	15/06/93(*)	Day 56
					DURANITRAT	13/01/93	Screen	15/06/93(*)	Day 56
7DT		Male	Imipramine		INFLANERAN	31/03/93	Day 14	04/04/93	Day 21
					NEPRAL	08/07/92	Screen	13/05/93(*)	Day 56

9550089

(\$) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (x) - end date missing = visit date during treatment
 (a) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

55

9550089

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
292	8MD	Male	Imipramine		BAZOTON	01/83	Screen	17/06/93(*)	Day 56
					EPIDROPAL	08/79	Screen	17/06/93(*)	Day 56
					EUGLUCON	05/90	Screen	17/06/93(*)	Day 56
					NEPHRAL	11/92	Screen	17/06/93(*)	Day 56
	8DT	Female	Reboxetine		NEPHRAL	12/07/91	Screen	03/06/93(*)	Day 56
					PIROXICAM	20/04/93	Day 14	20/04/93	Day 14
11	21MD	Female	Imipramine		NEPHRAL	27/03/91	Screen	02/07/93(*)	Day 56
13	21DT	Female	Reboxetine		DIGOTAB	21/01/80	Screen	28/06/93(*)	Day 56
6					NEOTRI	22/04/93	Screen	28/06/93(*)	Day 56
	22DT	Female	Imipramine		NEPHRAL	25/04/93	Screen	29/06/93(*)	Day 56
	23MD	Female	Reboxetine		CODIPRONT	25/06/93	Day 35	30/06/93	Day 35
					DORSCRIPPIN	25/06/93	Day 35	30/06/93	Day 35
					EPIDROPAL	08/03/88	Screen	21/07/93(*)	Day 56
					FELDEN	10/07/93	Day 49	13/07/93	Day 49
					RHEFLUIN	22/04/93	Screen	21/07/93(*)	Day 56

(*) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (X) - end date missing = visit date during treatment
 (S) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9550089

56

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 8.0
 CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
292	23DT	Male	Reboxetine		ASPIRINE	29/10/90	Screen	08/07/93(*)	Day 56
					DURANITRAT	09/02/93	Screen	08/07/93(*)	Day 56
					EPIDROPAL	28/02/90	Screen	08/07/93(*)	Day 56
	24ND	Male	Reboxetine		BAZOTON	86	Screen	30/07/93(*)	Day 56
					DIGOTAB	25/06/92	Screen	30/07/93(*)	Day 56
					FOSINOPRIL	30/04/93	Screen	30/07/93(*)	Day 56
1137					PHENOXETHYLPENICILLIN C	17/07/93	Day 49	22/07/93	Day 49
	9ND	Female	Imipramine		ISOKET	87	Screen	14/04/93(*)	Day 56
	9DT	Female	Imipramine		CHOLAGOGON NATTERMANN	02/04/89	Screen	20/07/93(*)	Day 56
					FLUTIMUCIL	02/03/90	Screen	20/07/93(*)	Day 56
	10DT	Female	Imipramine		LINDIGOA DEPOT	01/01/89	Screen	20/07/93(*)	Day 56
					RANTUDIL	88	Screen	13/09/93(*)	Day 56
					REMED	88	Screen	13/09/93(*)	Day 56
	11ND	Male	Imipramine		ALIVORAN	06/91	Screen	05/09/93(*)	Day 56
	11DT	Female	Reboxetine		EUGLUCON	06/87	Screen	01/12/93(*)	Day 14

(*) - start date missing = screening date - 1
 (**) - end date missing = last dose taken date if last visit
 (X) - end date missing = visit date during treatment
 (S) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

57

9550089

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
293	12ND	Male	Reboxetine		ZYLORIC	06/89	Screen	27/10/93(*)	Day 42
294	13ND	Female	Imipramine		GODANED	20/10/89	Screen	12/04/93(*)	Day 56
	13DT	Female	Reboxetine		GODANED	01/08/90	Screen	03/05/93(*)	Day 56
	14ND	Female	Reboxetine		MUSKEL TRANCPAL	24/07/92	Screen	12/04/93(*)	Day 56
	14DT	Female	Imipramine		FRUBIASE CALCIUM FORTE	09/01/91	Screen	03/05/93(*)	Day 56
					GINKGO TREE LEAVES EXTRAC	21/07/92	Screen	03/05/93(*)	Day 56
11					SEDALIPID	04/06/91	Screen	03/05/93(*)	Day 56
13					ASPIRINE	28/08/92	Screen	19/04/93(*)	Day 56
3					RHEUKON	10/09/91	Screen	19/04/93(*)	Day 56
8					VETREN	10/01/91	Screen	19/04/93(*)	Day 56
	15DT	Female	Imipramine		ACETYSALICYLIC ACID	08/02/91	Screen	03/05/93(*)	Day 56
					ALLOPURINOL	18/04/90	Screen	03/05/93(*)	Day 56
					GINKGO TREE LEAVES EXTRAC	02/09/91	Screen	03/05/93(*)	Day 56
	16ND	Female	Reboxetine		ASS-RATIOPHARM	05/04/91	Screen	19/04/93(*)	Day 56
					MAGNESIUM VERLA DRAGEES	13/02/89	Screen	19/04/93(*)	Day 56

(*) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (2) - end date missing = visit date during treatment
 (3) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

58

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
294	16DT	Female	Reboxetine		GODANED	11/09/91	Screen	03/05/93(*)	Day 56
	25MD	Female	Imipramine		TEBONIN	18/02/91	Screen	03/05/93(*)	Day 56
	26MD	Female	Imipramine		GODANED	25/01/89	Screen	08/08/93(*)	Day 56
	27MD	Female	Reboxetine		DURAVOLTEN	12/08/90	Screen	08/08/93(*)	Day 56
	28MD	Female	Reboxetine		GODANED	20/06/85	Screen	02/08/93(*)	Day 56
	29DT	Female	Reboxetine		ACETYLSALICYLIC ACID	25/10/89	Screen	09/08/93(*)	Day 56
11	11	Female	Reboxetine		PIDILAY	14/05/93	Screen	08/08/93(*)	Day 56
11	11	Female	Reboxetine		ARELIX	10/08/91	Screen	08/08/93(*)	Day 56
11	11	Female	Reboxetine		DICLOFENAC	08/06/91	Screen	08/08/93(*)	Day 56
	31DT	Female	Imipramine		NIVADIL	20/10/92	Screen	08/08/93(*)	Day 56
	32DT	Male	Imipramine		KYTTA-SEDATIVUM	22/04/91	Screen	15/08/93(*)	Day 56
					VERTIGOHEEL	17/10/92	Screen	15/08/93(*)	Day 56
					ALLOPURINOL	22/07/90	Screen	15/08/93(*)	Day 56
					GODANED	30/10/91	Screen	15/08/93(*)	Day 56
					KYTTA-SEDATIVUM	20/06/93(\$)	Screen	15/08/93(*)	Day 56

9550089

(\$) - start date missing = screening date - 1
(*) - end date missing = last dose taken date if last visit
(X) - end date missing = visit date during treatment
(?) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

59

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 8.0
 CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First visit report	End date	Last visit report
295	17MD	Female	Reboxetine		BELNIF	09/01/90	Screen	19/04/93	Screen
					DIUTENSAT	21/03/91	Screen	15/06/93(*)	Day 56
					TAMOXIFEN	09/87	Screen	15/06/93(*)	Day 56
	17DT	Male	Imipramine		DIGITOXIN 'DIDIER'	21/05/91	Screen	23/06/93(*)	Day 56
					PROCURUM	28/01/93	Screen	23/06/93(*)	Day 56
	18MD	Female	Reboxetine		METOPROLOL TARTRATE	21/01/93	Screen	17/06/93(*)	Day 56
	19MD	Male	Imipramine		ISMO	04/85	Screen	08/07/93(*)	Day 56
	19DT	Female	Reboxetine		EUSPIRAX	02/09/85	Screen	04/07/93(*)	Day 56
					LOPIRIN	23/10/90	Screen	04/07/93(*)	Day 56
	20MD	Female	Imipramine		BRISERIN HITE	11/04/88	Screen	08/07/93(*)	Day 56
	20DT	Female	Reboxetine		ACCUPRO	20/11/90	Screen	06/07/93(*)	Day 56
	1MD	Male	Reboxetine		AMOXIL	05/12/93	Screen	15/12/93	Day 7
					ASPIRINE	04/11/93	Screen	03/02/94(*)	Day 56
					ENALAPRIL	12/04/91	Screen	03/02/94(*)	Day 56
					LACTULOSE	04/11/93	Screen	03/02/94(*)	Day 56

9550089

1140

(*) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (2) - end date missing = visit date during treatment
 (3) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

60

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 5.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
381	1ND	Male	Reboxetine		PANADOL	25/11/93	Screen	03/02/94(*)	Day 56
	2ND	Female	Reboxetine		FRUMIL	30/01/94	Screen	07/03/94(*)	Day 35
					LACTULOSE	16/02/94	Day 14	07/03/94(*)	Day 35
					MYSTATIN	16/02/94	Day 14	07/03/94(*)	Day 35
					SENNA	07/02/94	Day 7	07/03/94(*)	Day 35
	3DF	Female	Reboxetine		DISTALGESIC	15/12/89	Screen	26/02/94(*)	Day 21
1141					TEMAZEPAM	91	Screen	07/02/94	Screen
					VITAMIN B-COMPLEX FORTE	10/04/86	Screen	26/02/94(*)	Day 21
					VITAMIN B12	22/02/94	Day 14	26/02/94(*)	Day 21
	4ND	Female	Imipramine		ASPIRINE	12/09/89	Screen	14/03/94(*)	Day 14
					BURINEX	12/09/89	Screen	14/03/94(*)	Day 14
					DILTIAZEM	02/07/92	Screen	14/03/94(*)	Day 14
					ENALAPRIL	01/04/91	Screen	14/03/94(*)	Day 14
					NITRAZEPAM	14/03/94	Day 14	14/03/94(*)	Day 14
382	5ND	Female	Imipramine		CEPHRADINE	05/11/93	Screen	12/11/93	Screen

(*) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (2) - end date missing = visit date during treatment
 (3) - only for concomitant drug reported at screen visit

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

61

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
382	5ND	Female	Imipramine		DIAZEPAM	08/11/93	Screen	12/11/93	Screen
					ISOSORBIDE MONONITRATE	04/11/93	Screen	12/01/94(*)	Day 56
					LACTULOSE	10/11/93	Screen	12/01/94(*)	Day 56
					MAXOLON	04/11/93	Screen	12/11/93	Screen
	5DT	Male	Reboxetine		SANDO X	23/10/93	Day 7	26/10/93	Day 7
					THIAMINE	23/10/93	Day 7	05/11/93(Z)	Day 14
					MODURETIC	27/09/93	Screen	07/01/94(*)	Day 56
					MET	15/11/93	Day 7	17/12/93(Z)	Day 35
						31/12/93	Day 49	07/01/94(*)	Day 56
					NEFOPAM	03/07/92	Screen	07/01/94(*)	Day 56
					ASPIRINE	12/10/90	Screen	17/12/93(*)	Day 56
					BURINEX K	12/10/90	Screen	17/12/93(*)	Day 56
					DIGOXIN	90	Screen	17/12/93(*)	Day 56
					DILTIAZEM	90	Screen	17/12/93(*)	Day 56
					ENALAPRIL	12/10/90	Screen	17/12/93(*)	Day 56
					ERYTHROMYCIN	16/12/93	Day 56	17/12/93(*)	Day 56

9550089

1142

(*) - start date missing = screening date - 1
(*) - end date missing = last dose taken date if last visit
(Z) - end date missing = visit date during treatment
(*) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

62

PHARMACIA CNS RD
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 8.0
 CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
342	6DT	Female	Imipramine		FUCIDIN	16/12/93	Day 56	17/12/93(*)	Day 56
					PRO-BANTHINE	12/10/90	Screen	17/12/93(*)	Day 56
					VOLTAROL	90	Screen	17/12/93(*)	Day 56
	7ND	Female	Reboxetine		ASPIRINE	30/10/93	Screen	07/02/94(*)	Day 56
					LORAZEPAM	28/08/92	Screen	17/12/93	Screen
					PARACETAMOL	28/08/92	Screen	07/02/94(*)	Day 56
11					VOLTAROL	10/10/93	Screen	07/02/94(*)	Day 56
14					ASPIRINE	10/01/94	Screen	11/02/94(*)	Day 21
23	8ND	Male	Imipramine		DIGOXIN	85	Screen	11/02/94(*)	Day 21
					FRUSEMIDE	10/01/94	Screen	11/02/94(*)	Day 21
					LISINAPRIL	10/01/94	Screen	11/02/94(*)	Day 21
					MESALAZINE	22/01/94	Screen	11/02/94(*)	Day 21
					SANDOCAL	10/01/94	Screen	11/02/94(*)	Day 21
	8DT	Female	Reboxetine		AMOXIL	15/12/93	Screen	27/12/93	Day 14
					DIPHENHYDRAMINE	17/12/93	Screen	09/02/94	Day 49

9550089

(*) - start date missing = screening date - 1
 (x) - end date missing = last dose taken date if last visit
 (Z) - end date missing = visit date during treatment
 (a) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

63

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 8.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
382	8DT	Female	Reboxetine		DISTALGESIC	09/02/94	Day 56	15/02/94(*)	Day 56
					NSI	16/02/94	Day 56	15/02/94(*)	Day 56
					NISTATIN	09/02/94	Day 49	15/02/94(*)	Day 56
					PARACETANOL	17/12/93	Screen	09/02/94	Day 49
					TEMAZEPAN	82	Screen	15/02/94(*)	Day 56
					TRIMETHOPRIM	26/12/93	Day 7	04/01/94	Day 14
1	9MD	Female	Reboxetine		FERROGRAD C	12/03/94	Day 35	18/03/94(2)	Day 35
1					FRUHLI	90	Screen	08/04/94(*)	Day 56
1					CEPHALOSPORIN C	14/02/94	Day 14	22/02/94	Day 14
1					CODEINE PHOSPHATE	06/02/94	Screen	09/03/94(*)	Day 35
					FRUSEMIDE	28/01/94	Screen	09/03/94(*)	Day 35
					FYBOGEL	06/02/94	Screen	09/03/94(*)	Day 35
					LINCTUS CODEINE	19/02/94	Day 21	22/02/94	Day 21
					MEBEVERINE	06/02/94	Screen	09/03/94(*)	Day 35
					NISTATIN	06/02/94	Screen	10/02/94	Screen

9550089

(§) - start date missing = screening date - 1
(*) - end date missing = last dose taken date if last visit
(x) - end date missing = visit date during treatment
(a) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

64

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: B.0
CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
382	90T	Female	Reboxetine		TEMAZEPAN	28/02/94	Day 28	09/03/94(*)	Day 35
	10ND	Female	Imipramine		BENDROFLUAZIDE	01/07/85	Screen	16/02/94(*)	Day 7
					DEHYDROCODEINE	17/06/93	Screen	16/02/94(*)	Day 7
					LOSEC	02/06/93	Screen	16/02/94(*)	Day 7
					NITRAZEPAN	03/02/79	Screen	11/02/94	Screen
3301	1ND	Female	Reboxetine		LACTULOSE	17/09/92	Screen	24/09/92(*)	Day 7
	2ND	Male	Imipramine		TEMAZEPAN	17/09/92	Screen	24/09/92(*)	Day 7
					LACTULOSE	31/12/92	Screen	09/03/93(*)	Day 56
					RANITIDINE	11/92	Screen	09/03/93(*)	Day 56
	3ND	Female	Reboxetine		TEMAZEPAN	31/12/92	Screen	09/03/93(*)	Day 56
					RECOTIDE	09/01/93	Screen	18/02/93(*)	Day 35
					PARACETANOL	30/01/93	Day 14	05/02/93	Day 14
					SALBUTAMOL	09/01/93 06/02/93	Screen Day 21	28/01/93 18/02/93(*)	Day 14 Day 35
					TEMAZEPAN	09/01/93	Screen	05/02/93	Day 21
3302	5ND	Female	Reboxetine		DEXTRORSE INJECTION	24/11/92	Day 21	30/11/92	Day 21

9550089

(S) - start date missing = screening date - 1
(*) - end date missing = last dose taken date if last visit
(X) - end date missing = visit date during treatment
(a) - only for concomitant drug reported at screen visit

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

65

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 8.0
 CONCOMITANT DRUGS

Centre	Patient	Sex	Treatment	Complete as protocol	Concomitant drug	Start date	First report visit	End date	Last report visit
3302	5ND	Female	Reboxetine		SALINA	14/11/92 24/11/92	Day 14 Day 21	16/11/92 30/11/92	Day 14 Day 21
					TEMAZEPAM	07/92	Screen	17/11/92	Day 14
					VOLTAROL - SLOW RELEASE	06/92	Screen	27/11/92(*)	Day 21
6ND	Female	Imipramine		FYBOGEL	23/06/93	Screen	16/07/93(*)	Day 21	
				TEMAZEPAM	23/06/93	Screen	16/07/93(*)	Day 21	
7ND	Female	Imipramine		CERBALEXIN	12/01/94	Day 56	08/01/94(*)	Day 56	
				FRUSEMIDE	03/11/93	Screen	11/01/94	Day 56	
				MOTILIUM	25/10/93	Screen	12/11/93	Screen	
					TEMAZEPAM	09/11/93(\$)	Screen	08/01/94(*)	Day 56

9550089

1146

(\$) - start date missing = screening date - 1
 (*) - end date missing = last dose taken date if last visit
 (x) - end date missing = visit date during treatment
 (a) - only for concomitant drug reported at screen visit

9550089

1

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D													
REBOXETINE - PROTOCOL 20124/035													
Listing No.: 9.0													
EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE													
Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)
1	1HD	Reboxetine	05/11/92	30/12/92	56	4	4	100.0	100.0		2	2	
					56								
1DI		Reboxetine	26/11/93	20/01/94	56	4	4	100.0	100.0		2	2	
					56								
2HD		Imipramine	17/11/92	19/11/92	3	50	50	100.0	100.0		25	25	
			20/11/92	07/12/92	18	75	75	100.0	100.0		25	50	
			08/12/92	11/01/93	35	100	100	100.0	100.0		50	50	
					56								
2DI		Imipramine	09/12/93	11/12/93	3	50	50	100.0	100.0		25	25	
			12/12/93	22/12/93	11	75	75	100.0	100.0		25	50	
					14								
3HD		Imipramine	03/06/93	05/06/93	3	50	50	100.0	100.0		25	25	
			06/06/93	08/06/93	3	75	75	100.0	100.0		25	50	
			09/06/93	09/06/93	1	75	50	66.7	95.2	1m	25	50	
			10/06/93	15/06/93	6	75	75	100.0	97.4		25	50	
			16/06/93	16/06/93	1	75	25	33.3	92.9	1e	25	50	
			17/06/93	28/07/93	42	75	75	100.0	98.2		25	50	
					56								
3DI		Reboxetine	10/12/93	30/12/93	21	4	4	100.0	100.0		2	2	
			31/12/93	01/01/94	2	6	6	100.0	100.0		4	2	
			02/01/94	02/01/94	1	6	0.0	0.0	95.8	4m	4	2	
			03/01/94	03/02/94	32	6	6	100.0	98.2		4	2	
					56								
4HD		Reboxetine	19/10/93	23/10/93	5	4	4	100.0	100.0		2	2	
			24/10/93	24/10/93	1	4	2	50.0	91.7	4e	2	2	
			25/10/93	08/11/93	15	4	4	100.0	97.6		2	2	
			09/11/93	13/12/93	35	6	6	100.0	99.1		4	2	
					56								
4DI		Imipramine	01/02/94	03/02/94	3	50	50	100.0	100.0		25	25	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 9=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
 m = morning, e = evening

1147

9550089

2

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED													
REBOXETINE - PROTOCOL 20124/095													
Listing No.: 9.0													
EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE													
Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	Compl. day	Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)
1	4DT	Imipramine	04/02/94	24/02/94	21	75	75	100.0	100.0		25	50	
					24								
2	1HD	Reboxetine	15/01/93	05/02/93	22	4	4	100.0	100.0		2	2	
			06/02/93	07/02/93	2	4	4	100.0	100.0		4	4	
			08/02/93	08/02/93	1	4	4	100.0	100.0	6e	4	4	
					25								
3	1HD	Reboxetine	05/05/93	25/05/93	21	4	4	100.0	100.0		2	2	
			28/05/93	21/06/93	27	6	6	100.0	100.0		4	4	
			22/06/93	22/06/93	1	6	4	100.0	100.0	6e	4	4	
					49								
4	1HD	Imipramine	25/11/92	27/11/92	3	50	50	100.0	100.0		25	25	
			28/11/92	28/11/92	1	75	50	66.7	91.7		25	25	
			29/11/92	15/12/92	17	75	75	100.0	98.4		25	50	
			16/12/92	22/12/92	7	100	100	100.0	98.8		50	50	
			23/12/92	23/12/92	1	100	50	100.0	98.9	5e	50	50	
			24/12/92	28/12/92	5	100	100	100.0	99.0		50	50	
			29/12/92	29/12/92	1	100	50.0	50.0	97.6	1m 6a			
					35								
5	1HD	Reboxetine	30/10/92	09/11/92	11	4	4	100.0	100.0		2	2	
			10/11/92	10/11/92	1	4	2	100.0	100.0	6e	2	2	
					12								
1DT		Imipramine	11/11/92	11/11/92	1	50	25	100.0	100.0			25	
			12/11/92	13/11/92	2	50	50	100.0	100.0	9m	25	25	
			14/11/92	06/01/93	54	75	75	100.0	100.0		25	50	
					57								
2HD		Reboxetine	24/11/92	29/12/92	36	4	4	100.0	100.0		2	2	
			30/12/92	30/12/92	1	4	4	100.0	100.0		2	4	
			31/12/92	18/01/93	19	4	4	100.0	100.0		2	2	
					56								

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
 m = morning, e = evening

1148

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)		
5	2DT	Imipramine	23/12/92	25/12/92	3	50	50	100.0	100.0		25	25			
			26/12/92	05/01/93	11	75	75	100.0	100.0		25	50			
			06/01/93	07/01/93	2	75	75	100.0	100.0	3m 3e	25	50			
			08/01/93	14/02/93	58	75	75	100.0	100.0						
			54												
3MD	Imipramine	17/03/93	19/03/93	3	50	50	100.0	100.0			25	25			
		20/03/93	11/05/93	53	75	75	100.0	100.0		25	50				
			56												
3DT	Reboxetine	27/03/93	21/05/93	56	4	4	100.0	100.0			2	2			
		56													
4MD	Imipramine	24/11/92	26/11/92	3	50	50	100.0	100.0			25	25			
		27/11/92	18/01/93	53	75	75	100.0	100.0		25	50				
		56													
4DT	Reboxetine	03/02/93	02/03/93	28	4	4	100.0	100.0			2	2			
		28													
5MD	Reboxetine	04/08/93	11/08/93	8	4	4	100.0	100.0			2	2			
		12/08/93	12/08/93	1	4	2	50.0	94.4	4e	2					
		13/08/93	13/08/93	1	4	0.0	0.0	85.0	4m 4e	2					
		14/08/93	15/08/93	2	4	2	50.0	79.2	4m	2					
			12												
5DT	Reboxetine	17/02/93	17/03/93	29	4	4	100.0	100.0			2	2			
		29													
6MD	Imipramine	05/08/93	07/08/93	3	50	50	100.0	100.0			25	25			
		08/08/93	18/08/93	11	75	75	100.0	100.0		25	50				
			14												
6DT	Reboxetine	27/02/93	01/03/93	3	4	4	100.0	100.0			2	2			
		02/03/93	03/03/93	2	4	4	100.0	100.0	3m 3e	2					

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

9550089

4

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
5	6DT	Reboxetine	04/03/93	23/04/93	51	4	4	100.0	100.0		2	2	
					56								
7HD	Reboxetine	27/10/93	16/11/93	21	4	4	100.0	100.0			2	2	
				21									
7DT	Imipramine	13/03/93	15/03/93	3	50	50	100.0	100.0			25	25	
				53	75	75	100.0	100.0			25	50	
8HD	Imipramine	11/11/93	13/11/93	3	50	50	100.0	100.0			25	25	
				53	75	75	100.0	100.0			25	50	
8DT	Imipramine	05/05/93	07/05/93	3	50	50	100.0	100.0			25	25	
				53	75	75	100.0	100.0			25	50	
9HD	Reboxetine	16/11/93	10/01/94	56	4	4	100.0	100.0			2	2	
				56									
9DT	Reboxetine	02/05/93	25/06/93	55	4	4	100.0	100.0			2	2	
				55									
10HD	Imipramine	25/11/93	27/11/93	3	50	50	100.0	100.0			25	25	
				11	75	75	100.0	100.0			25	50	
10DT	Imipramine	06/05/93	08/05/93	3	50	50	100.0	100.0			25	25	
				1	75	75	100.0	100.0			25	50	
				1	25	25	100.0	100.0			3e		
				1	75	75	100.0	100.0			3m 3e		
				1	75	75	100.0	100.0			3m 6e		
				14									

1150

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
 m = morning, e = evening

9550089

5

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REMOXYLINE - PROTOCOL 20124/035
 Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (x)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)
5	11ND	Imipramine	02/12/93	04/12/93	3	50	50	100.0	100.0		25	25	
			05/12/93	05/01/94	32	75	75	100.0	100.0		25	50	
					35								
11DT	Reboxetine	11/05/93	07/06/93	28	4	4	100.0	100.0		2	2		
				28									
12ND	Reboxetine	06/01/94	03/03/94	57	4	4	100.0	100.0		2	2		
				57									
12DT	Imipramine	21/05/93	23/05/93	3	50	50	100.0	100.0			25	25	
		24/05/93	28/05/93	5	75	75	100.0	100.0			25	50	
		29/05/93	29/05/93	1	75	50	66.7	96.3	1m		25	50	
		30/05/93	15/07/93	47	75	75	100.0	99.4			25	50	
				56									
1ND	Reboxetine	13/11/92	07/01/93	56	4	4	100.0	100.0		2	2		
				56									
1DT	Reboxetine	21/10/92	16/12/92	57	4	4	100.0	100.0		2	2		
				57									
2ND	Imipramine	11/11/92	13/11/92	3	50	50	100.0	100.0			25	25	
		14/11/92	16/11/92	3	75	75	100.0	100.0			25	50	
		17/11/92	17/11/92	1	75	25	100.0	100.0	6o		25	25	
2DT	Reboxetine	21/01/93	27/01/93	7	4	4	100.0	100.0		2	2		
				7									
3ND	Reboxetine	03/12/92	27/01/93	56	4	4	100.0	100.0		2	2		
				56									

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 9=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
 m = morning, e = evening

1154

9550089

6

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	Compl. day	X cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)
6	3DI	Imipramine	08/04/93	10/04/93	3	50	50	100.0	100.0		25	25	
			11/04/93	28/04/93	18	75	75	100.0	100.0		25	50	
			29/04/93	02/06/93	35	100	100	100.0	100.0		50	50	
					56								
4ND	Imipramine	15/12/92	15/12/92	1	50	25	100.0	100.0		9m	25	25	
		16/12/92	17/12/92	2	50	50	100.0	100.0		25	25		
		18/12/92	18/01/93	32	75	75	100.0	100.0		25	50		
					35								
4DT	Imipramine	05/05/93	07/05/93	3	50	50	100.0	100.0			25	25	
		08/05/93	29/06/93	53	75	75	100.0	100.0			25	50	
					56								
5ND	Imipramine	03/04/93	05/04/93	3	50	50	100.0	100.0			25	25	
		06/04/93	30/04/93	25	75	75	100.0	100.0			25	50	
		01/05/93	28/05/93	28	100	100	100.0	100.0			50	50	
					56								
5DT	Reboxetine	20/11/93	24/11/93	5	4	4	100.0	100.0			2	2	
		25/11/93	25/11/93	1	4	2	50.0	91.7		1m	2	2	
					56								
6ND	Reboxetine	29/04/93	19/05/93	21	4	4	100.0	100.0			2	2	
		20/05/93	31/05/93	12	6	6	100.0	100.0			4	2	
		01/06/93	01/06/93	1	6	4	100.0	100.0		6e	4	4	
					34								
7ND	Reboxetine	20/10/93	09/11/93	21	4	4	100.0	100.0			2	2	
		10/11/93	14/12/93	35	6	6	100.0	100.0			4	2	
					56								

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
 (xx) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
 m = morning, e = evening

9550089

7

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS 88D													
REBOXETINE - PROTOCOL 20124/035													
Listing No.: 9.0													
EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE													
Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	Compl. day	X cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)
6	8ND	Imipramine	23/11/93	25/11/93	3	50	50	100.0	100.0		25	25	
			26/11/93	17/01/94	53	75	75	100.0	100.0		25	50	
			56										
7	1ND	Imipramine	09/01/93	11/01/93	3	50	50	100.0	100.0		25	25	
			12/01/93	13/03/93	61	75	75	100.0	100.0		25	50	
			64										
3ND		Imipramine	23/04/93	25/04/93	3	50	50	100.0	100.0		25	25	
			26/04/93	20/05/93	25	75	75	100.0	100.0		25	50	
			21/05/93	17/06/93	28	100	100	100.0	100.0		50	50	
			56										
4ND		Reboxetine	24/04/93	16/05/93	21	4	4	100.0	100.0		2	2	
			13/05/93	28/05/93	14	6	4	100.0	100.0		4	2	
			23/05/93	23/05/93	1	6	4	100.0	100.0	6e	4	4	
			36										
342ND		Reboxetine	23/02/93	11/03/93	17	4	4	100.0	100.0		2	2	
			12/03/93	12/03/93	1	4	4	0.0	94.4	1m 1e	2	2	
			13/03/93	15/03/93	3	4	4	100.0	95.2		2	2	
			16/03/93	19/04/93	35	6	6	100.0	98.2		4	2	
			56										
8	1ND	Reboxetine	30/09/92	27/10/92	28	4	4	100.0	100.0		2	2	
			28/10/92	30/10/92	3	6	6	100.0	100.0		4	2	
			31/10/92	31/10/92	1	6	6	0.0	96.9	1m 1e	4	2	
			01/11/92	24/11/92	24	6	6	100.0	98.2		4	2	
			56										
1DT		Imipramine	26/09/92	30/09/92	3	50	50	100.0	100.0		25	25	
			01/10/92	22/11/92	53	75	75	100.0	100.0		25	50	
			56										
2ND		Reboxetine	30/09/92	24/11/92	56	4	4	100.0	100.0		2	2	

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 10=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
 m = morning, e = evening

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

8

PHARMACIA CNS RED													
REBOXETINE - PROTOCOL 20124/035													
Listing No.: 9.0													
EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE													
Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (ng)	Daily dose (ng)	Compl. day	X cumulat.	Reason (x)	Morning dose (ng)	Evening dose (ng)	Overdose (xx)
8	2DT	Imipramine	30/09/92	02/10/92	3	50	50	100.0	100.0		25	25	
			03/10/92	27/10/92	25	75	100.0	100.0		25	50		
			28/10/92	24/11/92	28	100	100.0	100.0		50	50		
56													
3HD	Imipramine	02/10/92	04/10/92	3	50	50	100.0	100.0			25	25	
		05/10/92	09/10/92	5	75	100.0	100.0			25	50		
		10/10/92	10/10/92	1	75	25	100.0	100.0	3e		25	25	
		9											
56													
4HD	Imipramine	02/10/92	04/10/92	3	50	50	100.0	100.0			25	25	
		05/10/92	17/10/92	13	75	75	100.0	100.0			25	50	
		18/10/92	18/10/92	1	75	0.0	94.1	10m 10a			25	50	
		19/10/92	20/10/92	2	75	100.0	94.7	10m 10a			25	50	
		21/10/92	21/10/92	1	75	0.0	90.0	10m 10a			25	50	
		22/10/92	27/10/92	6	75	100.0	92.3				25	50	
26													
4DT	Reboxetine	02/10/92	26/11/92	56	4	4	100.0	100.0			2	2	
		56											
701MD	Imipramine	09/10/92	11/10/92	3	50	50	100.0	100.0			25	25	
		12/10/92	13/11/92	33	75	100.0	100.0			25	50		
		14/11/92	14/11/92	1	75	50	66.7	99.1	1n		25	50	
		15/11/92	03/12/92	19	75	75	100.0	99.4			25	50	
		56											
701DT	Reboxetine	09/10/92	29/10/92	21	4	4	100.0	100.0			2	2	
		30/10/92	03/12/92	35	6	6	100.0	100.0			4	2	

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
 (xx) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
 a = morning, e = evening

9550089

9

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)				
8	702ND	Reboxetine	16/10/92	12/11/92	28	4	4	100.0	100.0		2	2					
				13/11/92	4	6	100.0	100.0		4	2						
				17/11/92	1	6	33.3	98.0	1m	4	2						
				18/11/92	23	6	100.0	98.8		4	2						
				56													
				702DT	Imipramine	09/10/92	11/10/92	3	50	50	100.0	100.0			25	25	
							12/10/92	53	75	100.0	100.0		25	50			
				56													
				703ND	Imipramine	09/02/93	11/02/93	3	50	50	100.0	100.0			25	25	
							12/02/93	6	75	100.0	100.0		25	50			
18/02/93	1	75	25				33.3	93.3	1e	25	25						
19/02/93	17	75	100.0				97.5		25	50							
08/03/93	1	75	25				33.3	95.2	1e	25	25						
09/03/93	8	75	100.0				96.3		25	50							
17/03/93	1	75	0.0				93.7	1m 1e	25	25							
18/03/93	19	75	100.0				95.8		25	50							
56																	
703DT	Imipramine	09/02/93	11/02/93				3	50	50	100.0	100.0			25	25		
			12/02/93	53	75	100.0	100.0		25	50							
56																	
704ND	Reboxetine	09/02/93	07/03/93	27	4	4	100.0	100.0			2	2					
			08/03/93	1	4	2	50.0	98.2	1e	2	2						
			09/03/93	8	4	100.0	98.6		2	2							
			17/03/93	1	4	0.0	95.9	1m 1e	2	2							
			18/03/93	1	4	100.0	96.1		2	2							
			19/03/93	1	4	0.0	93.6	1m 1e	2	2							
			20/03/93	17	4	100.0	95.5		2	2							
			56														
			704DT	Reboxetine	09/02/93	05/04/93	56	4	4	100.0	100.0			2	2		

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 9=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
M = morning, E = evening

1155

PHARMACIA CES BHD
REBOXETINE - PROTOCOL 20126/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	Comp. day	Comp. cumulat.	Reason (%)	Morning dose (mg)	Evening dose (mg)	Overshoot (%)
9	10D	Imipramine	28/09/93	28/09/93	1	50	25	100.0	100.0	5a	25	25	
			29/09/93	30/09/93	2	50	50	100.0	100.0		25	50	
			30/09/93	01/10/93	3	50	75	100.0	100.0		25	50	
			23/11/93	23/11/93	1	75	25	100.0	100.0	9a	25		
				57									
10T	Imipramine	15/12/93	17/12/93	3	50	50	100.0	100.0		25	25		
		18/12/93	08/02/94	53	75	75	100.0	100.0		25	50		
				56									
20D	Reboxetine	01/10/93	25/11/93	56	4	4	100.0	100.0		2	2		
				56									
30T	Imipramine	22/12/93	24/12/93	3	50	50	100.0	100.0		25	25		
		25/12/93	15/02/94	53	75	75	100.0	100.0		25	50		
				58									
30T	Reboxetine	12/10/93	25/11/93	64	4	4	100.0	100.0		2	2		
		26/11/93	24/11/93	4	4	4	100.0	100.0	3a, 3a	2	2		
				11	4	4	100.0	100.0		2	2		
				56									
40D	Imipramine	13/10/93	15/10/93	3	50	50	100.0	100.0		25	25		
		16/10/93	07/12/93	53	75	75	100.0	100.0		25	50		
				56									
50D	Reboxetine	24/10/93	20/12/93	56	4	4	100.0	100.0		2	2		
		21/12/93	21/12/93	1	4	2	100.0	100.0	5a	2			
				57									
60D	Imipramine	03/11/93	04/11/93	2	50	50	100.0	100.0		25	25		
		05/11/93	05/11/93	1	50	25	100.0	100.0	6a	25	25		

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=stact/and treatment in morning or evening, 9=reason unknown, 10=high dose, 11=low dose, 12=high dose, 13=high dose, 14=high dose, 15=high dose, 16=high dose, 17=high dose, 18=high dose, 19=high dose, 20=high dose, 21=high dose, 22=high dose, 23=high dose, 24=high dose, 25=high dose, 26=high dose, 27=high dose, 28=high dose, 29=high dose, 30=high dose, 31=high dose, 32=high dose, 33=high dose, 34=high dose, 35=high dose, 36=high dose, 37=high dose, 38=high dose, 39=high dose, 40=high dose, 41=high dose, 42=high dose, 43=high dose, 44=high dose, 45=high dose, 46=high dose, 47=high dose, 48=high dose, 49=high dose, 50=high dose, 51=high dose, 52=high dose, 53=high dose, 54=high dose, 55=high dose, 56=high dose, 57=high dose, 58=high dose, 59=high dose, 60=high dose, 61=high dose, 62=high dose, 63=high dose, 64=high dose, 65=high dose, 66=high dose, 67=high dose, 68=high dose, 69=high dose, 70=high dose, 71=high dose, 72=high dose, 73=high dose, 74=high dose, 75=high dose, 76=high dose, 77=high dose, 78=high dose, 79=high dose, 80=high dose, 81=high dose, 82=high dose, 83=high dose, 84=high dose, 85=high dose, 86=high dose, 87=high dose, 88=high dose, 89=high dose, 90=high dose, 91=high dose, 92=high dose, 93=high dose, 94=high dose, 95=high dose, 96=high dose, 97=high dose, 98=high dose, 99=high dose, 100=high dose.

(**): 1=high daily dose in one administration, 2=low daily dose in one administration, 3=high daily dose in one administration, 4=low daily dose in one administration, 5=high daily dose in one administration, 6=low daily dose in one administration, 7=high daily dose in one administration, 8=low daily dose in one administration, 9=high daily dose in one administration, 10=low daily dose in one administration, 11=high daily dose in one administration, 12=low daily dose in one administration, 13=high daily dose in one administration, 14=low daily dose in one administration, 15=high daily dose in one administration, 16=low daily dose in one administration, 17=high daily dose in one administration, 18=low daily dose in one administration, 19=high daily dose in one administration, 20=low daily dose in one administration, 21=high daily dose in one administration, 22=low daily dose in one administration, 23=high daily dose in one administration, 24=low daily dose in one administration, 25=high daily dose in one administration, 26=low daily dose in one administration, 27=high daily dose in one administration, 28=low daily dose in one administration, 29=high daily dose in one administration, 30=low daily dose in one administration, 31=high daily dose in one administration, 32=low daily dose in one administration, 33=high daily dose in one administration, 34=low daily dose in one administration, 35=high daily dose in one administration, 36=low daily dose in one administration, 37=high daily dose in one administration, 38=low daily dose in one administration, 39=high daily dose in one administration, 40=low daily dose in one administration, 41=high daily dose in one administration, 42=low daily dose in one administration, 43=high daily dose in one administration, 44=low daily dose in one administration, 45=high daily dose in one administration, 46=low daily dose in one administration, 47=high daily dose in one administration, 48=low daily dose in one administration, 49=high daily dose in one administration, 50=low daily dose in one administration, 51=high daily dose in one administration, 52=low daily dose in one administration, 53=high daily dose in one administration, 54=low daily dose in one administration, 55=high daily dose in one administration, 56=low daily dose in one administration, 57=high daily dose in one administration, 58=low daily dose in one administration, 59=high daily dose in one administration, 60=low daily dose in one administration, 61=high daily dose in one administration, 62=low daily dose in one administration, 63=high daily dose in one administration, 64=low daily dose in one administration, 65=high daily dose in one administration, 66=low daily dose in one administration, 67=high daily dose in one administration, 68=low daily dose in one administration, 69=high daily dose in one administration, 70=low daily dose in one administration, 71=high daily dose in one administration, 72=low daily dose in one administration, 73=high daily dose in one administration, 74=low daily dose in one administration, 75=high daily dose in one administration, 76=low daily dose in one administration, 77=high daily dose in one administration, 78=low daily dose in one administration, 79=high daily dose in one administration, 80=low daily dose in one administration, 81=high daily dose in one administration, 82=low daily dose in one administration, 83=high daily dose in one administration, 84=low daily dose in one administration, 85=high daily dose in one administration, 86=low daily dose in one administration, 87=high daily dose in one administration, 88=low daily dose in one administration, 89=high daily dose in one administration, 90=low daily dose in one administration, 91=high daily dose in one administration, 92=low daily dose in one administration, 93=high daily dose in one administration, 94=low daily dose in one administration, 95=high daily dose in one administration, 96=low daily dose in one administration, 97=high daily dose in one administration, 98=low daily dose in one administration, 99=high daily dose in one administration, 100=low daily dose in one administration.

m = morning, e = evening

9550089

11

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	Compl. day	Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)
9	7MD	Imipramine	10/11/93	10/11/93	1	50	50	100.0	100.0		25	25	
			11/11/93	11/11/93	1	50	25	100.0	100.0	60	25		
8DT	Reboxetine		16/11/93	10/01/94	56	4	4	100.0	100.0		2	2	
					56								
10	1MD	Imipramine	02/10/93	04/10/93	3	50	50	100.0	100.0		25	25	
			05/10/93	22/10/93	18	75	75	100.0	100.0		25	50	
			23/10/93	26/11/93	35	100	100	100.0	100.0		50	50	
10T	Reboxetine		01/12/93	21/12/93	21	4	4	100.0	100.0		2	2	
			22/12/93	25/01/94	35	6	6	100.0	100.0		4	2	
2MD	Reboxetine		02/10/93	26/11/93	56	4	4	100.0	100.0		2	2	
					56								
2DT	Imipramine		01/12/93	03/12/93	3	50	50	100.0	100.0		25	25	
			04/12/93	21/12/93	18	75	75	100.0	100.0		25	50	
			22/12/93	25/01/94	35	100	100	100.0	100.0		50	50	
3MD	Reboxetine		02/10/93	22/10/93	21	4	4	100.0	100.0		2	2	
			23/10/93	26/11/93	35	6	6	100.0	100.0		4	2	
3DT	Imipramine		02/12/93	04/12/93	3	50	50	100.0	100.0		25	25	
			25/12/93	22/12/93	18	75	75	100.0	100.0		25	50	
			23/12/93	26/01/94	35	100	100	100.0	100.0		50	50	

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(xx) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
M = morning, E = evening

9550089

12

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (ng)	Baily dose (ng)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (ng)	Evening dose (ng)	Overdose (**)
10	4HD	Imipramine	06/10/93	08/10/93	56	50	50	100.0	100.0		25	25	
			09/10/93	26/10/93	18	75	75	100.0	100.0		25	50	
			27/10/93	30/11/93	35	100	100	100.0	100.0		50	50	
4DF	Reboxetine	02/12/93	22/12/93	21	4	4	100.0	100.0	100.0		2	2	
		23/12/93	26/01/94	35	6	6	100.0	100.0		4	2		
		56											
5HD	Imipramine	06/10/93	08/10/93	3	50	50	100.0	100.0	100.0		25	25	
		09/10/93	26/10/93	18	75	75	100.0	100.0		25	50		
		27/10/93	30/11/93	35	100	100	100.0	100.0		50	50		
5DF	Reboxetine	04/12/93	23/12/93	20	4	4	100.0	100.0	100.0		2	2	
		24/12/93	28/01/94	36	6	6	100.0	100.0		4	2		
		56											
6HD	Reboxetine	09/10/93	29/10/93	21	4	4	100.0	100.0	100.0		2	2	
		30/10/93	03/12/93	35	6	6	100.0	100.0		4	2		
		56											
6DT	Reboxetine	04/12/93	23/12/93	20	4	4	100.0	100.0	100.0		2	2	
		24/12/93	28/01/94	36	6	6	100.0	100.0		4	2		
		56											
7HD	Imipramine	09/10/93	11/10/93	3	50	50	100.0	100.0	100.0		25	25	
		12/10/93	29/10/93	18	75	75	100.0	100.0		25	50		
		30/10/93	03/12/93	35	100	100	100.0	100.0		50	50		
7DT	Imipramine	04/12/93	06/12/93	3	50	50	100.0	100.0	100.0		25	25	
		07/12/93	23/12/93	17	75	75	100.0	100.0		25	50		
		56											

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
 m = morning, e = evening

9550089

13

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (ng)	Daily dose (ng)	Compl. day	Compl. cumulat.	Reason (*)	Morning dose (ng)	Evening dose (ng)	Overdose (**)
10	7DT	Imipramine	24/12/93	28/01/94	36	400	100	100.0	100.0		50	50	
					56								
	8ND	Reboxetine	16/10/93	05/11/93	21	4	4	100.0	100.0		2	2	
			06/11/93	10/12/93	35	6	6	100.0	100.0		4	4	
					56								
	8DT	Imipramine	04/12/93	06/12/93	3	50	50	100.0	100.0		25	25	
			07/12/93	28/01/94	55	75	75	100.0	100.0		25	50	
					56								
	9ND	Reboxetine	20/11/93	10/12/93	21	4	4	100.0	100.0		2	2	
			11/12/93	14/01/94	35	6	6	100.0	100.0		4	4	
					56								
	9DT	Imipramine	08/12/93	10/12/93	3	50	50	100.0	100.0		25	25	
			11/12/93	28/12/93	18	75	75	100.0	100.0		25	50	
			29/12/93	01/02/94	35	100	100	100.0	100.0		50	50	
					56								
	10ND	Imipramine	23/10/93	25/10/93	3	50	50	100.0	100.0		25	25	
			26/10/93	12/11/93	18	75	75	100.0	100.0		25	50	
			13/11/93	17/12/93	35	100	100	100.0	100.0		50	50	
					56								
	10DT	Reboxetine	08/12/93	28/12/93	21	4	4	100.0	100.0		2	2	
			29/12/93	01/02/94	35	6	6	100.0	100.0		4	4	
					56								
	11ND	Imipramine	23/10/93	25/10/93	3	50	50	100.0	100.0		25	25	
			26/10/93	12/11/93	18	75	75	100.0	100.0		25	50	
			13/11/93	17/12/93	35	100	100	100.0	100.0		50	50	
					56								
	11DT	Imipramine	08/12/93	10/12/93	3	50	50	100.0	100.0		25	25	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

9550089

14

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (ng)	Daily dose (ng)	Compl. day	X cumulat.	Reason (*)	Morning dose (ng)	Evening dose (ng)	Overdose (xx)
10	11DT	Imipramine	11/12/93	01/02/94	53	75	75	100.0	100.0		25	50	
					56								
12ND		Reboxetine	27/10/93	16/11/93	21	4	4	100.0	100.0		2	2	
			17/11/93	21/12/93	35	6	6	100.0	100.0		4	2	
					56								
12DT		Reboxetine	08/12/93	28/12/93	21	4	4	100.0	100.0		2	2	
			29/12/93	01/02/94	35	6	6	100.0	100.0		4	2	
					56								
13DT		Reboxetine	27/10/93	16/11/93	21	4	4	100.0	100.0		2	2	
			17/11/93	21/12/93	35	6	6	100.0	100.0		4	2	
					56								
14DT		Imipramine	30/10/93	01/11/93	3	50	50	100.0	100.0		25	25	
			02/11/93	19/11/93	18	75	75	100.0	100.0		25	50	
			20/11/93	23/12/93	34	100	100	100.0	100.0		50	50	
					55								
15ND		Reboxetine	30/10/93	19/11/93	21	4	4	100.0	100.0		2	2	
			20/11/93	23/12/93	34	6	6	100.0	100.0		4	2	
					55								
16DT		Imipramine	30/10/93	01/11/93	3	50	50	100.0	100.0		25	25	
			02/11/93	19/11/93	18	75	75	100.0	100.0		25	50	
			20/11/93	23/12/93	34	100	100	100.0	100.0		50	50	
					55								
17ND		Reboxetine	06/11/93	26/11/93	21	4	4	100.0	100.0		2	2	
			27/11/93	30/12/93	34	6	6	100.0	100.0		4	2	
					55								
18ND		Imipramine	06/11/93	08/11/93	3	50	50	100.0	100.0		25	25	
			09/11/93	26/11/93	18	75	75	100.0	100.0		25	50	

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 9=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
n = morning, e = evening

1160

9550089

15

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (%)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)
10	18ND	Imipramine	27/11/93	30/12/93	34	100	100	100.0	100.0		50	50	
					55								
19DI	Reboxetine	06/11/93	26/11/93	21	4	4	100.0	100.0			2	2	
			27/11/93	30/12/93	34	6	6	100.0	100.0		4	4	
					55								
20ND	Reboxetine	06/11/93	26/11/93	21	4	4	100.0	100.0			2	2	
			27/11/93	30/12/93	34	6	6	100.0	100.0		4	4	
					55								
12	1ND	Reboxetine	28/04/93	22/06/93	56	4	4	100.0	100.0		2	2	
					56								
1DI	Reboxetine	20/05/93	14/07/93	56	4	4	100.0	100.0			2	2	
					56								
13	1ND	Reboxetine	08/04/93	10/04/93	3	4	2	100.0	100.0	5e	2	2	
			11/04/93	02/06/93	53	4	4	100.0	100.0		2	2	
					56								
1DI	Imipramine	23/09/93	25/09/93	3	50	25	100.0	100.0		5e	25	25	
			26/09/93	29/09/93	4	75	25	100.0	100.0	5e	25	25	
			30/09/93	17/11/93	49	75	75	100.0	100.0		25	50	
					56								
2HD	Imipramine	11/12/93	11/12/93	1	50	25	100.0	100.0		5e	25	25	
			12/12/93	12/12/93	1	50	100.0	100.0		3m 3e	25	25	
			13/12/93	13/12/93	1	50	25	100.0	100.0	5e	25	25	
			14/12/93	07/01/94	25	75	100.0	100.0			50	50	
			08/01/94	31/01/94	24	100	100.0	100.0			50	50	
			01/02/94	01/02/94	1	100	100.0	100.0		5m 5e	50	50	
			02/02/94	03/02/94	2	100	100.0	100.0			50	50	
			04/02/94	04/02/94	1	100	50	100.0	100.0	9e	50	50	

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
m = morning, e = evening

1161

9550089

16

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (ng)	Daily dose (ng)	Compl. day	% compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)									
13	2DT	Reboxetine	22/10/93	22/10/93	1	4	2	100.0	100.0	9m		2	2									
			23/10/93	10/11/93	19	4	4	100.0	100.0			2	2									
			11/11/93	11/11/93	1	4	2	50.0	97.6	1m		2	2									
			12/11/93	12/11/93	1	4	4	100.0	97.7			2	2									
			13/11/93	16/12/93	34	6	6	100.0	99.1	9e		4	2									
			17/12/93	17/12/93	1	6	4	100.0	99.1			4										
			57																			
			3DT	3MD	Imipramine	03/02/94	03/02/94	1	50	25	100.0	100.0	9m		25	25						
						04/02/94	03/02/94	2	50	50	100.0	100.0			25	25						
						06/02/94	03/03/94	29	75	75	100.0	100.0			50	50						
04/03/94	30/03/94	27				100	100	100.0	100.0			50	50									
31/03/94	31/03/94	1				100	50	100.0	100.0	9e		50										
57																						
4DT	4DT	Reboxetine				05/02/94	03/02/94	1	4	2	100.0	100.0	9m		2	2						
						04/02/94	03/03/94	28	4	4	100.0	100.0			2	2						
						04/03/94	30/03/94	27	6	6	100.0	100.0			4	2						
						31/03/94	31/03/94	1	6	4	100.0	100.0	9e		4							
			57																			
			14	1MD	Reboxetine	06/04/94	02/05/94	27	4	4	100.0	100.0			2	2						
						27																
						15	1MD	Reboxetine	01/03/93	25/04/93	56	4	4	100.0	100.0			2	2			
									56													
									1DT	Reboxetine	26/07/93	19/09/93	56	4	4	100.0	100.0			2	2	

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 9=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
 m = morning, e = evening

1162

PHARMACIA CNS RAD
REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0.

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	Compl. day	Compl. cumulat.	Reason (%)	Morning dose (mg)	Evening dose (mg)	Overdose (%)				
15	210	Imipramine	24/03/93	26/03/93	3	50	50	100.0	100.0		25	25					
					7	75	100.0	100.0		25	50						
					10												
					207	Imipramine	22/02/94	24/02/94	3	50	50	100.0	100.0		25	25	
									5	75	100.0	100.0		25	50		
	300	Reboxetine	06/05/93	20/06/93	4	4	4	100.0	100.0			2	2				
					1	4	2	50.0	98.9	10	2	2					
					9	4	4	100.0	99.1		2	2					
					56												
					400	Imipramine	15/07/93	17/07/93	3	50	50	100.0	100.0		25	25	
5	75	100.0	100.0						25	50							
56																	
11100	Reboxetine	08/10/93	15/10/93	8					4	4	100.0	100.0			2	2	
				1					4	2	50.0	94.4	10	2	2		
				12	4	4	100.0	97.6		2	2						
				21													
				11200	Imipramine	29/11/93	01/12/93	3	50	50	100.0	100.0		25	25		
5	75	100.0	100.0						25	50							
56																	
110	Reboxetine	18/02/93	14/04/93					5	4	4	100.0	100.0		2	2		
								56									
				107	Imipramine	19/02/93	20/02/93	3	50	50	100.0	100.0		25	25		
								5	75	100.0	100.0		25	50			
								1	75	25	100.0	108.0	60	25	50		
56																	
56																	

9550089

(*) =forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 9=because unknown, 10=high dose, 11=low dose, 12=double high dose, 13=double low dose, 14=high daily dose in one administration, 15=low daily dose in one administration, m = morning, e = evening

9550089

18

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (%)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)		
16	2HD	Imipramine	15/04/93	17/04/93	3	50	50	100.0	100.0		25	25			
			18/04/93	09/06/93	53	75	75	100.0	100.0		25	50			
			56												
			04/05/93	28/06/93	56	4	4	100.0	100.0		2	2			
			56												
	3HD	Imipramine	09/05/93	11/05/93	3	50	50	100.0	100.0			25	25		
			12/05/93	08/06/93	28	75	75	100.0	100.0	6e	25	50			
			09/06/93	09/06/93	1	75	25	100.0	100.0		25				
			32												
			29/07/93	31/07/93	3	50	50	100.0	100.0		25	25			
3DT	Imipramine	01/08/93	04/08/93	4	75	75	100.0	100.0			25	25			
		05/08/93	10/08/93	6	75	25	100.0	100.0	3e	25	50				
		13													
		19/04/94	13/06/94	56	4	4	100.0	100.0		2	2				
		56													
17	1HD	Reboxetine	31/03/93	06/04/93	7	4	4	100.0	100.0		2	2			
			07/04/93	07/04/93	1	4	6	100.0	100.0		2	4			
			08/04/93	12/04/93	5	4	4	100.0	100.0		2	2			
			13/04/93	13/04/93	1	4	2	50.0	96.4	1e	2	2			
			14/04/93	19/04/93	6	4	4	100.0	97.5		2	2			
			20/04/93	20/04/93	1	4	4	100.0	97.6		4	2			
			21/04/93	04/05/93	14	4	4	100.0	98.6		2	2			
			05/05/93	09/05/93	5	6	6	100.0	98.8		4	2			
			10/05/93	10/05/93	1	6	2	33.3	97.2	1n	4	2			
			11/05/93	21/05/93	11	6	6	100.0	97.8		4	2			
22/05/93	22/05/93	1	6	8	100.0	97.8		4	4						
23/05/93	25/05/93	3	6	6	100.0	97.9		4	2						
56															

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 9=adverse event, 10=adverse event
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
n = morning, e = evening

9550089

19

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	Compl. day	% Compl. cumulat.	Reason (%)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
17	1DT	Reboxetine	28/04/93	16/05/93	19	4	4	100.0	100.0		2	2	
			17/05/93	17/05/93	1	4	2	100.0	100.0	6a	2	2	
					20								
	2ND	Imipramine	21/04/93	23/04/93	3	50	50	100.0	100.0		25	25	
			24/04/93	15/06/93	53	75	75	100.0	100.0		25	50	
					56								
	2DT	Reboxetine	07/07/93	31/08/93	56	4	4	100.0	100.0		2	2	
					56								
	3ND	Imipramine	06/11/93	08/11/93	3	50	50	100.0	100.0		25	25	
			09/11/93	19/11/93	11	75	75	100.0	100.0		25	50	
					14								
	3DT	Imipramine	19/10/93	21/10/93	3	50	50	100.0	100.0		25	25	
			22/10/93	13/12/93	53	75	75	100.0	100.0		25	50	
					56								
4ND	Reboxetine	12/01/94	09/03/94	57	4	4	100.0	100.0		2	2		
				57									
4DT	Imipramine	19/01/94	21/01/94	3	50	50	100.0	100.0		25	25		
		22/01/94	15/03/94	53	75	75	100.0	100.0		25	50		
				56									
21ND	Reboxetine	19/05/94	13/07/94	56	4	4	100.0	100.0		2	2		
				56									
21DT	Reboxetine	05/04/94	30/05/94	56	4	4	100.0	100.0		2	2		
				56									
18	Imipramine	27/05/93	29/05/93	3	50	50	100.0	100.0		25	25		
		30/05/93	21/07/93	53	75	75	100.0	100.0		25	50		
				56									

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=Start/end treatment in morning or evening, 10=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
 m = morning, e = evening

9550089

20

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)
18	1DT	Imipramine	12/08/93	14/08/93	3	50	50	100.0	100.0		25	25	
			15/08/93	06/10/93	53	75	75	100.0	100.0		25	50	
			56										
2HD	Imipramine	30/05/93	01/06/93	3	50	50	100.0	100.0			25	25	
		02/06/93	19/06/93	18	75	75	100.0	100.0			25	50	
		20/06/93	26/06/93	7	100	100	100.0	100.0			50	50	
28													
2DT	Reboxetine	09/11/93	29/11/93	21	4	4	100.0	100.0			2	2	
		30/11/93	06/12/93	7	6	6	100.0	100.0			4	4	
28													
3ND	Reboxetine	14/08/93	03/09/93	21	4	4	100.0	100.0			2	2	
		04/09/93	01/10/93	28	6	6	100.0	100.0			4	4	
49													
4ND	Reboxetine	03/10/93	23/10/93	21	4	4	100.0	100.0			2	2	
		24/10/93	27/11/93	35	6	6	100.0	100.0			4	4	
56													
20	3ND	Reboxetine	09/07/93	15/07/93	7	4	4	100.0	100.0		2	2	
7													
22	1HD	Reboxetine	25/06/93	29/06/93	5	4	4	100.0	100.0		2	2	
			30/06/93	30/06/93	1	4	2	100.0	100.0	6a	2	2	
6													
23	1HD	Reboxetine	30/01/93	31/01/93	2	4	4	100.0	100.0		2	2	
			01/02/93	01/02/93	1	4	6	100.0	100.0		4	4	
			02/02/93	26/03/93	53	4	4	100.0	100.0		2	2	(B - n)

1166

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 6a=reason unknown
(xx) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
n = morning, e = evening

9550089

21

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (ng)	Daily dose (ng)	Compl. day	X cumulat.	Reason (x)	Morning dose (ng)	Evening dose (ng)	Overdose (xx)		
23	2HD	Reboxetine	02/02/93	14/02/93	13	4	4	100.0	100.0		2	2			
			15/02/93	15/02/93	1	4	2	50.0	96.4	10e	2	2			
			16/02/93	29/03/93	42	4	4	100.0	99.1		2	2			
			56												
			23/03/93	25/03/93	3	50	50	100.0	100.0		25	25			
			26/03/93	17/05/93	53	75	75	100.0	100.0		25	50			
	4HD	Imipramine	31/03/93	02/04/93	3	50	50	100.0	100.0			25	25		
			03/04/93	25/05/93	53	75	75	100.0	100.0		25	50			
			56												
			05/05/93	07/05/93	3	50	50	100.0	100.0		25	25			
			08/05/93	12/05/93	5	75	75	100.0	100.0		25	50			
			13/05/93	13/05/93	1	75	25	100.0	100.0	6e	25	25			
6HD	Imipramine	06/07/93	08/07/93	3	50	50	100.0	100.0			25	25			
		09/07/93	17/08/93	40	75	75	100.0	100.0		25	50				
		43													
		27/08/93	27/08/93	1	4	2	100.0	100.0		9m	2	2			
		28/08/93	16/09/93	20	4	4	100.0	100.0		2	2				
		17/09/93	01/10/93	15	6	6	100.0	100.0		4	2				
2HD	Imipramine	26/11/93	28/11/93	3	50	50	100.0	100.0			25	25			
		29/11/93	16/12/93	18	75	75	100.0	100.0		25	50				
		17/12/93	26/12/93	10	100	100	100.0	100.0		50	50				
		27/12/93	27/12/93	1	100	50	50.0	98.4	1m	50	50				
		28/12/93	20/01/94	24	100	100	100.0	99.1		50	50				
		36													

(*) 1=forget to take, 2=lost medication, 3=subverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 9=reason unknown, 10=reason unknown
(xx) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
n = morning, e = evening

1167

9550089

22

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)																						
26	1ND	Imipramine	27/04/93	29/04/93	3	50	50	100.0	100.0		25	25																							
														30/04/93	21/06/93	53	75	100.0	100.0	25	50														
														56																					
														29/06/93	11/08/93	44	4	100.0	100.0	2	2														
														44																					
27	1ND	Imipramine	02/02/93	04/02/93	3	50	50	100.0	100.0		25	25																							
														05/02/93	08/02/93	4	75	100.0	100.0	25	50														
														7																					
														20/04/93	24/04/93	5	4	100.0	100.0	2	2														
														56																					
28	1ND	Reboxetine	25/04/93	25/04/93	1	4	2	50.0	91.7	1a	2	2																							
														26/04/93	30/05/93	35	4	100.0	98.8	2	2														
														31/05/93	31/05/93	1	4	6	100.0	98.8	2	4													
														01/06/93	14/06/93	14	4	100.0	99.1	2	2														
														56																					
														1A	1D	Imipramine	22/04/93	24/04/93	3	50	50	100.0	100.0		25	25									
																												25/04/93	25/05/93	31	75	100.0	100.0	25	50
																												26/05/93	26/05/93	1	75	0.0	97.1	1m	1a
																												27/05/93	16/06/93	21	75	100.0	98.2	25	50
																												56							
2ND	1ND	Imipramine	26/04/93	28/04/93	3	50	50	100.0	100.0		25	25																							
														29/04/93	21/06/93	54	75	100.0	100.0	25	50														
														57																					
														27/04/93	21/06/93	56	4	100.0	100.0	2	2														
														56																					
3ND	2DF	Reboxetine	27/04/93	21/06/93	56	4	4	100.0	100.0		2	2																							
														27/04/93	21/06/93	56	4	100.0	100.0	2	2														
														56																					
														27/04/93	21/06/93	56	4	100.0	100.0	2	2														
														56																					

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 9=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
n = morning, e = evening

9550089

23

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/055
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)
28	SDF	Imipramine	11/05/93	13/05/93	3	50	50	100.0	100.0		25	25	
			14/05/93	04/07/93	52	75	75	100.0	100.0		25	50	
			05/07/93	05/07/93	1	75	150	100.0	100.0		50	100	(B - m) (B - e)
4ND	Imipramine	04/05/93	06/05/93	3	50	50	100.0	100.0			25	25	
		07/05/93	09/05/93	3	75	75	100.0	100.0		25	50		
		10/05/93	10/05/93	1	75	150	100.0	100.0		50	100	(B - m) (B - e)	
		11/05/93	10/06/93	31	75	75	100.0	100.0		25	50		
		08/06/93	07/06/93	28	75	25	33.3	88.9	4e	25	50		
		15/06/93	14/06/93	7	75	75	100.0	90.3		25	50		
		21/06/93	20/06/93	6	75	100	100.0	90.5		25	50	(B - m)	
22/06/93	28/06/93	7	75	75	100.0	91.7		25	50				
5ND	Reboxetine	25/05/93	29/05/93	5	4	4	100.0	100.0			2	2	
		30/05/93	30/05/93	1	4	2	50.0	91.7	1e	2	2		
		31/05/93	19/07/93	50	4	4	100.0	99.1		2	2		
30	1BD	Imipramine	21/04/93	23/04/93	3	50	50	100.0	100.0		25	25	
			24/04/93	16/06/93	54	75	75	100.0	100.0		25	50	
			17/06/93	17/06/93	1	75	25	100.0	100.0	9e	25	25	
2ND	Reboxetine	16/07/93	17/07/93	2	4	4	100.0	100.0		2	2		
		18/07/93	18/07/93	1	4	2	100.0	100.0	6e	2	2		
3ND	Imipramine	08/11/93	08/11/93	1	50	25	100.0	100.0		9m	25	25	
		09/11/93	10/11/93	2	50	50	100.0	100.0		25	25		
		11/11/93	29/11/93	49	75	75	100.0	100.0		25	50		
		30/11/93	03/01/94	35	100	100	100.0	100.0		50	50		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
 m = morning, e = evening

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)						
30	4ND	Reboxetine	02/11/93	30/12/93	57	4	4	100.0	100.0		2	2							
					59	4	4	100.0	100.0		2	2							
					59	50	50	100.0	100.0		25	25							
					3	75	75	100.0	100.0	3e	25	50							
					2	75	25	100.0	100.0	3m 6e	25	25							
	31	1ND	Imipramine	23/09/92	25/09/92	7	50	50	100.0	100.0		25	25						
						3	75	75	100.0	100.0		25	50						
						1	75	75	100.0	100.0	3m 3e	25	25						
						7	75	75	100.0	100.0		25	50						
						1	75	25	100.0	100.0	6e	25	25						
						13	1DT	Reboxetine	23/09/92	23/09/92	1	4	2	100.0	100.0	3e	2	2	
											1	4	4	100.0	100.0		2	2	(E - e)
											1	4	4	100.0	100.0		2	2	
8	4	2	50.0	95.8	1e						2	2							
6	4	4	100.0	97.2							2	2	(K - e)						
36	2ND	Reboxetine	02/12/92	03/12/92	2	4	4	100.0	100.0		2	2							
					1	4	4	100.0	100.0		2	2	(E - e)						
					16	4	4	100.0	100.0		2	2							
					1	4	2	100.0	100.0	3e	2	2							
					39	4	4	100.0	100.0		2	2							

1170

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=season unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

9550089

25

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
31	3MD	Imipramine	14/12/92	16/12/92	3	50	50	100.0	100.0		25	25	
					3								
					3								
32	1MD	Imipramine	25/03/93	27/03/93	3	50	50	100.0	100.0		25	25	
					52	75	100.0	100.0		25	50		
					1	75	100.0	100.0	9e	25			
					56								
2MD	Imipramine	15/04/93	17/04/93	3	50	50	100.0	100.0			25	25	
				3	75	100.0	100.0		25	50			
				9	75	100.0	100.0	3e	25				
				41	75	100.0	100.0	5e	25				
				56									
3MD	Reboxetine	22/04/93	12/05/93	21	4	4	100.0	100.0			2	2	
				13	6	10	100.0	100.0		4	2		
				1	6	10	100.0	100.0	9e	8	2	yes	
				6	6	6	100.0	100.0		4	2		
				1	6	4	66.7	99.2	10e	4	2		
				13	6	6	100.0	99.4		4	2		
				1	6	4	100.0	99.4	9e	4	4		
				56									
				16	4	4	100.0	100.0		2	2		
				4	4	2	100.0	100.0	5m				
5MD	Reboxetine	04/11/93	10/11/93	7	4	4	100.0	100.0			2	2	
				14	4	2	100.0	100.0	3e	2			
				1	4	2	100.0	100.0	6e	2			
6MD	Imipramine	17/11/93	19/11/93	3	50	50	100.0	100.0		25	25		
				26	75	100.0	100.0		25	50			
				22									

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=adverse event
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration, 8=low daily dose in one administration, 9=evening, 10=evening

1171

9550089

26

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)
32	6HD	Imipramine	16/12/93	11/01/94	27	100	100	100.0	100.0		50	50	
			12/01/94	12/01/94	1	100	50	100.0	100.0	9e			
57													
35	1HD	Reboxetine	26/01/93	14/02/93	20	4	4	100.0	100.0		2	2	
			15/02/93	15/02/93	1	4		100.0	100.0	3m 6e			
21													
1DT		Reboxetine	03/03/93	27/04/93	56	4	4	100.0	100.0		2	2	
			56										
2HD	Imipramine	03/03/93	05/03/93	3	50	50	100.0	100.0			25	25	
		06/03/93	20/03/93	24	75	75	100.0	100.0			25	50	
		20/03/93	30/03/93	11	75	25	100.0	100.0	3e		25		
		31/03/93	31/03/93	1	75		100.0	100.0	3m 6e				
29													
2DT	Imipramine	03/03/93	05/03/93	3	50	50	100.0	100.0			25	25	
		06/03/93	21/03/93	16	75	75	100.0	100.0			25	50	
		22/03/93	22/03/93	1	75	25	33.3	96.7	10e		25		
		23/03/93	27/04/93	36	75	75	100.0	98.8			25	50	
56													
3HD	Imipramine	30/03/93	01/04/93	3	50	50	100.0	100.0			25	25	
		02/04/93	05/04/93	4	75	75	100.0	100.0			25	50	
7													
3DT	Imipramine	31/03/93	02/04/93	3	50	50	100.0	100.0			25	25	
		03/04/93	26/05/93	54	75	75	100.0	100.0			25	50	
57													
4HD	Reboxetine	20/04/93	04/05/93	15	4	4	100.0	100.0			2	2	
		05/05/93	06/05/93	2	4	2	100.0	100.0	3m		2	2	
		07/05/93	12/05/93	6	4	4	100.0	100.0			2	2	
		13/05/93	13/05/93	1	4	2	100.0	100.0	3e		2		
32													

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 9=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
n = morning, e = evening

9550089

27

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	Compl. day	% compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)								
35	4DT	Reboxetine	27/04/93	23/05/93	27	4	4	100.0	100.0		2	2	(3 - m) (3 - o)								
														24/05/93	25/05/93	2	4	100.0	100.0	6	4
														26/05/93	31/05/93	6	4	100.0	100.0	4	2
														01/06/93	21/06/93	21	6	100.0	100.0	4	2
																56					
5HD	Reboxetine	09/07/93	02/09/93	56	4	4	100.0	100.0			2	2									
																56					
5DT	Imipramine	02/09/93	04/09/93	3	50	50	100.0	100.0			25	25									
														05/09/93	27/10/93	53	75	100.0	100.0	25	50
6HD	Reboxetine	21/01/94	01/03/94	40	4	4	100.0	100.0		6e	2	2									
														02/03/94	02/03/94	1	4	2	100.0	100.0	2
6DT	Imipramine	20/10/93	22/10/93	3	50	50	100.0	100.0			25	25									
														23/10/93	14/12/93	53	75	100.0	100.0	25	50
7HD	Imipramine	10/12/93	12/12/93	3	50	50	100.0	100.0			25	25									
														13/12/93	17/01/94	36	75	100.0	100.0	25	50
7DT	Reboxetine	20/10/93	16/11/93	28	4	4	100.0	100.0			2	2									
																39					
8HD	Imipramine	01/02/94	03/02/94	3	50	50	100.0	100.0			25	25									
														04/02/94	19/03/94	44	75	100.0	100.0	25	50
														20/03/94	20/03/94	1	75	33.3	98.6	4e	25
														21/03/94	21/03/94	1	75	100.0	98.6	25	50
																28					

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
a = morning, e = evening

1173

9550089

28

PARAMETER THE NEW
 REMEDIATION - PROPOSED STRATEGIES
 Linking No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Center	Publ. no.	Treatment	From date	To date	Week (Wk)	Dose prescribed (mg)	Daily dose (mg)	Compl. (%)	Compl. (%)	Mean (%)	Morning dose (mg)	Evening dose (mg)	Dose/day (mg)
35	887	Reboxetine	11/8/79	8/7/82/84	25	4	4	100.0	100.0		2	2	
36	100	Trifluoperazine	16/4/75	18/1/73	3	50	50	100.0	100.0		25	25	
			8/8/87/85	08/03/83	4	25	25	100.0	100.0	60	25	25	
					52								
107	Impromidine	03/02/73	05/02/73	3	50	50	100.0	100.0		25	25	50	
			04/02/73	30/03/73	25	75	75	100.0	100.0		25	50	
210	Reboxetine	03/02/93	05/02/93	3	4	4	100.0	100.0		2	2		
			07/02/93	07/02/93	1	4	4	100.0	100.0	20	2	2	
			08/02/93	20/03/93	9	4	4	100.0	100.0	100	2	2	
			20/02/93	21/02/93	26								
217	Reboxetine	20/02/93	15/03/93	1	4	4	100.0	100.0		2	2		
			17/02/93	17/02/93	1	4	4	100.0	100.0	10	2	2	
			07/02/93	01/04/93	1	4	4	100.0	100.0	10	2	2	
			02/04/93	07/04/93	4	4	4	100.0	100.0	10	2	2	
			05/04/93	21/04/93	4	4	4	100.0	100.0	10	2	2	
			05/04/93	21/04/93	4	4	4	100.0	100.0	10	2	2	
300	Trifluoperazine	15/02/73	03/02/73	3	50	50	100.0	100.0		25	25	50	
			25/02/73	25/02/73	25	75	75	100.0	100.0		25	50	
			25/02/73	01/04/73	18								
307	Impromidine	05/02/73	07/02/73	3	50	50	100.0	100.0		25	25	50	

(*) Percent to take into medication? (b) Average number of days taken in morning or evening.
 (c) Increase in compliance. (d) Low dose + high dose. (e) Multiple high dose, multiple low dose.
 (f) High daily dose in one administration, low daily dose in one administration.
 n = number; s = evening

(18 - 8)

9550089

29

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	Compl. day	X cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
36	30F	Imipramine	05/03/93	19/04/93	46	75	75	100.0	100.0		25	50	(B - e)
			20/04/93	20/04/93	1	75	125	100.0	100.0		25	100	
			21/04/93	27/04/93	7	75	75	100.0	100.0		25	50	
57													
4ND	Reboxetine	09/03/93	05/04/93	28	4	4	100.0	100.0	100.0		2	2	
		06/04/93	01/05/93	26	6	6	100.0	100.0	100.0		4	2	
54													
4DT	Reboxetine	12/03/93	06/05/93	56	4	4	100.0	100.0	100.0		2	2	
56													
5ND	Reboxetine	24/04/93	18/06/93	56	4	4	100.0	100.0	100.0		2	2	
56													
5DT	Imipramine	03/04/93	05/04/93	3	50	50	100.0	100.0	100.0		25	25	
		06/04/93	07/04/93	2	75	75	100.0	100.0	100.0		25	50	
5													
6ND	Imipramine	01/05/93	03/05/93	3	50	50	100.0	100.0	100.0		25	25	
		04/05/93	25/06/93	53	75	75	100.0	100.0	100.0		25	50	
56													
6DT	Imipramine	10/04/93	12/04/93	3	50	50	100.0	100.0	100.0		25	25	
		13/04/93	04/06/93	53	75	75	100.0	100.0	100.0		25	50	
56													
7ND	Reboxetine	13/05/93	21/06/93	40	4	4	100.0	100.0	100.0		2	2	(D - e)
		22/06/93	22/06/93	1	4	4	100.0	100.0	100.0	1m	4	4	
		23/06/93	07/07/93	15	4	4	100.0	100.0	100.0		2	2	
56													
7DT	Reboxetine	01/05/93	02/05/93	2	4	4	100.0	100.0	100.0		2	2	(B - m)
		03/05/93	03/05/93	1	4	2	50.0	83.3	10e		2	2	
		04/05/93	04/05/93	1	4	6	100.0	87.5			4	2	

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=Start/end treatment in morning or evening, 10=reason unknown

(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration, m = morning, e = evening

9550089

30

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)	
36	7DT	Reboxetine	05/05/93	07/05/93	3	4	4	100.0	92.9		2	2		
			26/05/93	26/05/93	1	50	150	100.0	100.0			50	100	(B - m) (B - e)
			27/05/93	28/05/93	2	50	150	100.0	100.0			25	25	
			29/05/93	29/05/93	1	75	150	100.0	100.0			50	100	(B - m) (B - e)
			30/05/93	31/05/93	2	75	150	100.0	100.0			25	50	
			01/06/93	03/06/93	3	75	150	100.0	100.0			25	50	
			04/06/93	04/06/93	1	75	75	66.7	66.7	1m		25	25	
			05/06/93	06/06/93	2	75	75	66.7	66.7			25	50	
			07/06/93	07/06/93	1	75	25	33.3	33.3	1e		25	25	
			08/06/93	20/07/93	43	75	75	100.0	96.2			25	50	
8DT	Reboxetine	15/05/93	17/05/93	3	4	4	100.0	100.0			2	2		
		18/05/93	24/05/93	7	4	4	0.0	30.0	4m 4e					
		25/05/93	16/07/93	53	4	4	100.0	88.9			2	2		
		16/06/93	10/08/93	56	4	4	100.0	100.0			2	2		
		29/06/93	01/07/93	3	50	50	100.0	100.0			25	25		
9DT	Imipramine	02/07/93	11/07/93	10	75	75	100.0	100.0			25	50		
		12/07/93	12/07/93	1	75	50	66.7	97.6	1m		25	50		
		13/07/93	18/08/93	37	75	75	100.0	99.3			25	50		
		19/08/93	19/08/93	1	75	25	100.0	99.4	3e		25	25		
		20/08/93	23/08/93	4	75	100.0	99.4	99.4	3m 3e		25	25		
		22/06/93	09/07/93	18	4	4	100.0	100.0			2	2		
10MD	Reboxetine	10/07/93	10/07/93	1	4	2	50.0	97.4	1m		2	2		
		11/07/93	11/07/93	1	4	2	50.0	95.0	1e		2	2		
		12/07/93	14/07/93	3	4	4	100.0	95.7			2	2		
		13/07/93	13/07/93	1	4	2	50.0	93.8	1e		2	2		
		14/07/93	18/07/93	5	4	4	100.0	92.0			2	2		
		17/07/93	18/08/93	31	4	4	100.0	96.4			2	2		

1176

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=stop treatment in morning or evening, 9=season unknown, 10=reason unknown
(xx) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

9550089

31

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	X Compl. day	X cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)	
36	10DT	Reboxetine	26/10/93	19/12/93	56	4	4	100.0	100.0		2	2		
			20/12/93	20/12/93	1	4	2	50.0	99.1	1e	2	2		
			56											
11ND	Imipramine	09/07/93	11/07/93	3	50	50	100.0	100.0			25	25		
		12/07/93	02/09/93	53	75	75	100.0	100.0			25	50		
		56												
11DT	Reboxetine	10/11/93	19/11/93	10	4	4	100.0	100.0			2	2		
		20/11/93	20/11/93	1	4	2	100.0	100.0			2	2		
		21/11/93	21/11/93	1	4	2	100.0	100.0			3e	2		
		22/11/93	22/11/93	1	4	2	100.0	100.0			3m 3e	2	2	
		23/11/93	18/12/93	26	4	4	100.0	100.0			2	2		
		19/12/93	19/12/93	1	4	2	100.0	100.0			6e	2	2	
		40												
12ND	Imipramine	26/09/93	26/09/93	3	50	50	100.0	100.0			25	25		
		27/09/93	05/10/93	9	75	75	100.0	100.0			25	50		
12														
12DT	Imipramine	22/12/93	24/12/93	3	50	50	100.0	180.0			25	25		
		25/12/93	15/02/94	53	75	75	100.0	100.0			25	50		
56														
13HD	Reboxetine	21/09/93	06/10/93	16	4	4	100.0	100.0			2	2		
		07/10/93	07/10/93	1	4	2	50.0	97.1	1e		2	2		
		08/10/93	09/10/93	2	4	4	100.0	97.4			2	2		
		10/10/93	10/10/93	1	4	2	50.0	95.0	1e		2	2		
		11/10/93	14/10/93	4	4	4	100.0	95.8			2	2		
24														
14ND	Imipramine	03/11/93	05/11/93	3	50	50	100.0	100.0			25	25		
		06/11/93	07/11/93	2	75	75	100.0	100.0			25	50		
		08/11/93	08/11/93	1	75	50	66.7	94.4	1m		25	50		

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 9=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
m = morning, e = evening

1177

9550089

32

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/055
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)	
36	14MD	Imipramine	09/11/93	28/12/93	50	75	75	100.0	99.4		25	50		
					56									
	15MD	Reboxetine	23/10/93	08/11/93	17	4	4	100.0	100.0		2	2		
					1	4	2	100.0	100.0	6a	2			
	16MD	Imipramine	09/11/93	11/11/93	3	50	50	100.0	100.0			25	25	
					48	75	75	100.0	100.0		25	50		
					35	100	100	100.0	100.0		50	50		
					56									
					2	4	4	100.0	100.0		2	2		
	17MD	Reboxetine	10/11/93	11/11/93	2	4	4	100.0	100.0					
					2									
					3	50	50	100.0	100.0		25	25		
18MD	Imipramine	13/01/94	15/01/94	3	50	50	100.0	100.0			25	25		
				53	75	75	100.0	100.0		25	50			
				56										
19MD	Reboxetine	15/01/94	22/01/94	8	4	4	100.0	100.0		2	2			
				8										
20MD	Imipramine	01/02/94	03/02/94	3	50	50	100.0	100.0			25	25		
				53	75	75	100.0	100.0		25	50			
				56										
37	Reboxetine	18/03/93	19/03/93	2	4	4	100.0	100.0			2	2		
				1	4	2	50.0	83.3	4e	2	2			
				4	4	4	100.0	92.9		2	2			
				7										
41	Imipramine	22/02/94	22/02/94	1	50	25	100.0	100.0		9m		25		
				1	50	50	100.0	100.0		25	25			
				1	50	25	100.0	100.0	6e	25	25			

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 9=reason unknown
 (**) 1=low, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
 a = morning, e = evening

9550089

33

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (ng)	Daily dose (ng)	Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (ng)	Evening dose (ng)	Overdose (**)			
41	2HD	Reboxetine	23/02/94	19/04/94	3	4	4	100.0	100.0		2	2				
					56											
					56											
					3	50	50	100.0	100.0		25	25				
					53	75	75	100.0	100.0		25	50				
42	1HD	Imipramine	26/10/93	28/10/93	3	50	50	100.0	100.0		25	25				
					53	75	75	100.0	100.0		25	50				
					56											
					3	50	50	100.0	100.0		25	25				
					53	75	75	100.0	100.0		25	50				
	1DT	Imipramine	25/11/93	27/11/93	3	50	50	100.0	100.0		25	25				
					53	75	75	100.0	100.0		25	50				
					56											
					22	4	4	100.0	100.0		2	2				
					1	4	2	100.0	100.0		2	2				
	2HD	Reboxetine	26/10/93	16/11/93	22	4	4	100.0	100.0		2	2				
					1	4	2	100.0	100.0		2	2				
					6	4	4	100.0	100.0		3m	3m				
					1	4	2	100.0	100.0		3m	3m				
					26	4	4	100.0	100.0		2	2				
	2DT	Reboxetine	09/12/93	09/12/93	1	4	4	100.0	100.0		2	2				
					1	4	2	100.0	100.0	6e	2	2				
					2											

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=stop/end treatment in morning or evening, 10=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
 n = morning, e = evening

9550089

34

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	Compl. day	X cumulat.	Reasons (*)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)		
42	3ND	Imipramine	25/11/93	27/11/93	3	50	50	100.0	100.0		25	25			
			28/11/93	15/12/93	18	75	75	100.0	100.0		25	50			
			16/12/93	12/01/94	28	100	100	100.0	100.0		50	50			
			13/01/94	19/01/94	7	75	75	100.0	100.0		25	50			
			56												
43	4DT	Reboxetine	19/02/93	19/02/93	1	4	2	100.0	100.0	9m			2		
			20/02/93	01/04/93	41	4	4	100.0	100.0		2		2		
			02/04/93	02/04/93	1	4	2	100.0	100.0	6e					
			43												
2DT	Imipramine	11/05/93	11/05/93	1	50	25	100.0	100.0	9m		25	25			
		12/05/93	13/05/93	2	50	50	100.0	100.0		25	25				
		14/05/93	14/05/93	1	75	50	66.7	91.7		25	25				
		15/05/93	31/05/93	17	75	75	100.0	98.4		25	50				
		01/06/93	01/06/93	1	75	25	100.0	98.5	6e		25				
			22												
3DT	Imipramine	15/09/93	15/09/93	1	50	25	100.0	100.0	9m		25	25			
		16/09/93	17/09/93	2	50	50	100.0	100.0		25	25				
		18/09/93	30/09/93	13	75	75	100.0	100.0		25	50				
		01/10/93	01/10/93	1	75	50	100.0	100.0	5m		50				
		02/10/93	10/11/93	40	75	75	100.0	100.0		25	50				
			57												
4DT	Reboxetine	23/09/93	23/09/93	1	4	2	100.0	100.0	9m				2		
		24/09/93	15/10/93	22	4	4	100.0	100.0			2	2			
		16/10/93	16/10/93	1	4	2	50.0	97.9	1e		2	2			
		17/10/93	21/10/93	5	4	4	100.0	98.3			2	2			
		22/10/93	22/10/93	1	4	2	50.0	96.7	1e		2	2			
		23/10/93	06/11/93	15	4	4	100.0	97.8			2	2			
		07/11/93	07/11/93	1	4	2	50.0	96.7	1m		2	2			
		08/11/93	17/11/93	10	4	4	100.0	97.3			2	2			
		18/11/93	18/11/93	1	4	2	100.0	97.4	9e						
					57										
5DT	Imipramine	10/12/93	10/12/93	1	50	25	100.0	100.0	9m				25		
		11/12/93	12/12/93	2	50	50	100.0	100.0		25		25			

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 9=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
m = morning, e = evening

1180

9550089

35

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	Compl. day	Compl. cumulat.	Reason (x)	Morning dose (mg)	Evening dose (mg)	Overdose (**)			
43	5ND	Imipramine	13/12/93	11/01/94	30	75	75	100.0	100.0	6e	25	50				
			12/01/94	12/01/94	1	75	25	100.0	100.0		25					
	6ND	Imipramine	16/02/94	18/02/94	3	50	50	100.0	100.0			25	25			
			19/02/94	15/03/94	26	75	75	100.0	100.0		25	50	50			
			17/03/94	17/03/94	1	75	123	100.0	100.0	9m	25	100	100	yes		
			18/03/94	14/04/94	28	75	75	100.0	100.0		25	50	50			
			58													
			44	1ND	Reboxetine	03/09/93	28/10/93	56	4	4	100.0	100.0		2	2	
						56										
			10F	Reboxetine	31/07/93	24/09/93	56	4	4	100.0	100.0			2	2	
56																
2ND	Reboxetine	20/09/93	20/09/93	1	4	2	100.0	100.0				2	2			
		21/09/93	25/10/93	35	4	4	100.0	100.0			2	2				
		26/10/93	31/10/93	6	6	6	100.0	100.0			4	2				
		01/11/93	01/11/93	1	4	6	100.0	100.0			4	2				
		02/11/93	14/11/93	13	4	4	100.0	100.0			2	2				
		15/11/93	15/11/93	1	4	2	100.0	100.0			9e	2	2			
		57														
		3ND	Imipramine	14/10/93	14/10/93	1	50	25	100.0	100.0			25	25		
				15/10/93	16/10/93	2	50	50	100.0	100.0		9m	25	25		
				17/10/93	08/12/93	53	75	75	100.0	100.0		9e	25	50		
09/12/93	09/12/93			1	75	25	100.0	100.0			25					
4ND	Imipramine	31/01/94	31/01/94	1	50	25	100.0	100.0				25	25			
		01/02/94	01/02/94	2	50	50	100.0	100.0			25	25				
		03/02/94	12/02/94	11	75	75	100.0	100.0			25	50				
		14/02/94	14/02/94	1	75	23	33.3	95.6	10e		25	50				
		15/02/94	09/03/94	23	75	23	100.0	98.2			25	50				
		10/03/94	10/03/94	1	75	23	33.3	95.5	1e		25	25				
		11/03/94	28/03/94	18	75	75	100.0	97.7			25	50				
		57														

(*) 1=ferrot to take, 2=last medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=Start/end treatment in morning or evening, 10=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double, low dose, 6=high daily dose in one administration, 9=low daily dose in one administration
 m = morning, e = evening

1181

9550089

36

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)
45	1HD	Reboxetine	25/11/93	25/11/93	1	4	2	100.0	100.0	9m	2	2	
			26/11/93	01/01/94	37	4	4	100.0	100.0		2	2	
			02/01/94	02/01/94	1	4	2	50.0	98.7	1e	2	2	
			03/01/94	19/01/94	17	4	4	100.0	99.1	9e	2	2	
			20/01/94	20/01/94	1	4	2	100.0	99.1		2		
46	1DT	Imipramine	12/08/93	16/08/93	3	50	50	100.0	100.0		25	25	
			15/08/93	06/10/93	52	75	75	100.0	100.0		25	50	
					56								
46	2HD	Imipramine	07/12/93	09/12/93	3	50	50	100.0	100.0		25	25	
			10/12/93	15/12/93	6	75	75	100.0	100.0		25	50	
			16/12/93	16/12/93	1	25	25	33.3	93.3	10a	25	25	
			17/12/93	20/12/93	4	75	0.0	0.0	66.7	10m 10e	25	50	
			21/12/93	26/12/93	6	75	75	100.0	76.7		25	50	
					20								
46	1HD	Imipramine	28/09/93	28/09/93	1	50	25	100.0	100.0	9m	25	25	
			29/09/93	30/09/93	2	50	50	100.0	100.0		25	25	
			01/10/93	22/11/93	53	75	75	100.0	100.0	9e	25	50	
			23/11/93	23/11/93	1	75	25	100.0	100.0		25	25	
2HD	2HD	Imipramine	19/10/93	19/10/93	1	50	50	100.0	100.0		25	25	
			20/10/93	20/10/93	1	50	100.0	100.0	3m 3e	25	25		
			21/10/93	21/10/93	1	50	50	100.0	100.0		25	25	
			22/10/93	07/11/93	17	75	75	100.0	100.0	6e	25	50	
			08/11/93	08/11/93	1	75	25	100.0	100.0		25	25	
		57											
3HD	3HD	Reboxetine	02/12/93	02/12/93	1	4	2	100.0	100.0	9m	2	2	
			03/12/93	26/01/94	55	4	4	100.0	100.0	9e	2	2	
			27/01/94	27/01/94	1	4	2	100.0	100.0		2	2	

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
m = morning, e = evening

9550089

37

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)
46	4ND	Reboxetine	08/12/93	10/12/93	3	4	4	100.0	100.0	6e	2	2	
			11/12/93	11/12/93	1	4	2	100.0	100.0		2		
					4								
48	1DT	Reboxetine	24/06/93	24/06/93	1	4	2	100.0	100.0	6e	2		
					1								
1183	2DT	Imipramine	28/06/93	30/06/93	3	50	50	100.0	100.0		25	25	
			01/07/93	03/07/93	3	75	75	100.0	100.0		25	50	
			04/07/93	04/07/93	1	75	50	66.7	95.2	1m		50	
			05/07/93	18/07/93	14	75	75	100.0	98.4		25	50	
			19/07/93	03/08/93	16	100	100	100.0	99.1		50	50	
			04/08/93	04/08/93	1	100	50	100.0	99.1	6e		50	
				38									
291	1ND	Imipramine	22/03/93	24/03/93	3	50	50	100.0	100.0		25	25	
			25/03/93	17/04/93	24	75	75	100.0	100.0		25	50	
			18/04/93	18/04/93	1	75	25	33.3	97.6	10e	25		
			19/04/93	25/04/93	7	75	50	100.0	98.1	3m		50	
				35									
1DT	Reboxetine	22/04/93	24/04/93	3	4	4	100.0	100.0			2	2	
		25/04/93	27/04/93	3	4	4	100.0	100.0			2	2	
		28/04/93	28/04/93	1	4	2	50.0	92.9	4e		2	2	
		29/04/93	16/06/93	49	4	4	100.0	99.1			2	2	
				56								(M - e)	
2ND	Reboxetine	20/04/93	14/06/93	56	4	4	100.0	100.0			2	2	
				56									
2DT	Reboxetine	22/04/93	16/05/93	25	4	4	100.0	100.0			2	2	
		17/05/93	17/05/93	1	4	2	50.0	96.1	4e		2	2	
		18/05/93	24/05/93	7	4	4	100.0	96.5			2	2	
		25/05/93	26/05/93	2	4	4	0.0	92.9	10m 10e		2	2	

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 9=reason unknown
(xx) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration, 8=high daily dose in one administration, 9=low daily dose in one administration, 10=high daily dose in one administration, 11=low daily dose in one administration, 12=high daily dose in one administration, 13=low daily dose in one administration, 14=high daily dose in one administration, 15=low daily dose in one administration, 16=high daily dose in one administration, 17=low daily dose in one administration, 18=high daily dose in one administration, 19=low daily dose in one administration, 20=high daily dose in one administration, 21=low daily dose in one administration, 22=high daily dose in one administration, 23=low daily dose in one administration, 24=high daily dose in one administration, 25=low daily dose in one administration, 26=high daily dose in one administration, 27=low daily dose in one administration, 28=high daily dose in one administration, 29=low daily dose in one administration, 30=high daily dose in one administration, 31=low daily dose in one administration, 32=high daily dose in one administration, 33=low daily dose in one administration, 34=high daily dose in one administration, 35=low daily dose in one administration, 36=high daily dose in one administration, 37=low daily dose in one administration, 38=high daily dose in one administration, 39=low daily dose in one administration, 40=high daily dose in one administration, 41=low daily dose in one administration, 42=high daily dose in one administration, 43=low daily dose in one administration, 44=high daily dose in one administration, 45=low daily dose in one administration, 46=high daily dose in one administration, 47=low daily dose in one administration, 48=high daily dose in one administration, 49=low daily dose in one administration, 50=high daily dose in one administration, 51=low daily dose in one administration, 52=high daily dose in one administration, 53=low daily dose in one administration, 54=high daily dose in one administration, 55=low daily dose in one administration, 56=high daily dose in one administration, 57=low daily dose in one administration, 58=high daily dose in one administration, 59=low daily dose in one administration, 60=high daily dose in one administration, 61=low daily dose in one administration, 62=high daily dose in one administration, 63=low daily dose in one administration, 64=high daily dose in one administration, 65=low daily dose in one administration, 66=high daily dose in one administration, 67=low daily dose in one administration, 68=high daily dose in one administration, 69=low daily dose in one administration, 70=high daily dose in one administration, 71=low daily dose in one administration, 72=high daily dose in one administration, 73=low daily dose in one administration, 74=high daily dose in one administration, 75=low daily dose in one administration, 76=high daily dose in one administration, 77=low daily dose in one administration, 78=high daily dose in one administration, 79=low daily dose in one administration, 80=high daily dose in one administration, 81=low daily dose in one administration, 82=high daily dose in one administration, 83=low daily dose in one administration, 84=high daily dose in one administration, 85=low daily dose in one administration, 86=high daily dose in one administration, 87=low daily dose in one administration, 88=high daily dose in one administration, 89=low daily dose in one administration, 90=high daily dose in one administration, 91=low daily dose in one administration, 92=high daily dose in one administration, 93=low daily dose in one administration, 94=high daily dose in one administration, 95=low daily dose in one administration, 96=high daily dose in one administration, 97=low daily dose in one administration, 98=high daily dose in one administration, 99=low daily dose in one administration, 100=high daily dose in one administration

FELMUCIA CMS RED
REBOUTYNE - PROTOCOL 20124/055
Listing No.: 5.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	Z Compl. day	X Compl. cumulat.	Reason (%)	Morning dose (mg)	Evening dose (mg)	Overdose (mg)
291	291	Rebouxetine	27/05/93	16/06/93	21	4	4	100.0	95.5		2	2	
			19/06/93	01/06/93	8	50	50	100.0	100.0		25	25	
		Imipramine	22/06/93	07/05/93	16	75	75	100.0	100.0		25	50	
			08/05/93	08/05/93	1	75	100	100.0	100.0		50	50	(B - m)
			09/05/93	20/05/93	12	75	75	100.0	100.0		25	50	
			21/05/93	08/05/93	1	100	100	100.0	100.0		25	50	
			22/05/93	23/05/93	1	75	75	100.0	100.0		25	50	
			23/05/93	23/05/93	1	75	125	100.0	100.0		25	100	
			24/05/93	13/06/93	21	75	75	100.0	100.0		25	50	
					56								
307		Imipramine	14/05/93	16/05/93	3	50	50	100.0	100.0		25	25	
			17/05/93	20/05/93	4	75	75	100.0	100.0		25	50	
					7								
400		Rebouxetine	03/05/93	31/05/93	29	4	4	100.0	100.0		2	2	
			01/06/93	28/06/93	28	4	4	100.0	100.0		4	2	
					57								
407		Imipramine	05/05/93	07/05/93	3	50	50	100.0	100.0		25	25	
			08/05/93	07/06/93	31	75	75	100.0	100.0		25	50	
			09/06/93	09/06/93	1	75	75	100.0	100.0	4*	25	50	
			20/06/93	20/06/93	1	75	25	100.0	98.6		25	50	
			21/06/93	29/06/93	9	75	75	100.0	97.2	1*	25	50	
					56				97.6		25	90	
2507		Imipramine	04/11/93	06/11/93	3	50	50	100.0	100.0		25	25	
			07/11/93	30/11/93	24	75	75	100.0	100.0		25	50	
					57								
2607		Rebouxetine	09/06/93	03/08/93	56	4	4	100.0	100.0		2	2	
					56								

9550089

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=adverse, 8=start/end treatment in morning or evening, 9=reason unknown, 10=below dose + high dose, 11=admissible high dose, 12=admissible low dose, 13=high daily dose in one administration, 14=low daily dose in one administration, m = morning, e = evening

9550089

39

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PEARACIA CNS RED																
REBOXETINE - PROTOCOL 20124/035																
Listing No.: 9.0																
EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE																
Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	Compl. day	X cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)			
291	27DT	Reboxetine	04/11/93	30/12/93	57	4	4	100.0	100.0		2	2				
					57											
28DT		Imipramine	18/11/93	20/11/93	3	50	50	100.0	100.0		25	25				
			21/11/93	17/01/94	58	75	75	100.0	100.0		25	50				
292	SMD	Imipramine	03/03/93	05/03/93	3	50	50	100.0	100.0			25	25			
			06/03/93	20/03/93	15	75	75	100.0	100.0			25	50			
			21/03/93	21/03/93	1	75	75	100.0	100.0	1m			50	50		
			24/03/93	26/03/93	2	75	75	100.0	100.0				50	50		
			26/03/93	26/03/93	1	100	100	100.0	100.0				50	50		
			25/03/93	25/03/93	1	100	100	100.0	100.0			1e	50	50		
			26/03/93	05/04/93	11	100	100	100.0	100.0				50	50		
			06/04/93	06/04/93	1	100	100	100.0	100.0			1e	50	50		
			07/04/93	15/04/93	9	100	100	100.0	100.0				50	50		
			16/04/93	16/04/93	1	100	100	100.0	100.0			1e	50	50		
			17/04/93	27/04/93	11	100	100	100.0	100.0				50	50		
								56								
			5DT		Reboxetine	06/03/93	14/03/93	9	4	4	100.0	100.0		2	2	
15/03/93	15/03/93	1				4	2	50.0	50.0		2	2				
16/03/93	26/03/93	11				4	4	100.0	100.0	1e			2	2		
27/03/93	27/03/93	1				6	6	100.0	100.0				4	4		
28/03/93	28/03/93	1				6	4	66.7	96.4			1e	4	4		
29/03/93	18/04/93	21				6	6	100.0	100.0				4	4		
19/04/93	19/04/93	1				6	4	66.7	97.4			1e	4	4		
20/04/93	29/04/93	10				6	6	100.0	100.0				4	4		
								55								
6MD		Reboxetine				04/03/93	05/03/93	2	4	4	100.0	100.0		2	2	
			06/03/93	06/03/93	1	4	2	50.0	83.3	1e			2	2		
			07/03/93	28/03/93	22	4	4	100.0	98.0				2	2		
			29/03/93	29/03/93	1	4	2	50.0	96.2	1m			2	2		
			30/03/93	10/04/93	12	4	4	100.0	97.4				2	2		
			11/04/93	11/04/93	1	4	2	50.0	96.2	1m			2	2		
			12/04/93	22/04/93	11	4	4	100.0	97.0				2	2		
			23/04/93	23/04/93	1	4	2	50.0	96.1	1e			2	2		
			24/04/93	28/04/93	5	4	4	100.0	96.4				2	2		

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 9=change by patient, 10=change by physician

(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration, 8=high daily dose in one administration, 9=low daily dose in one administration, 10=high daily dose in one administration

m = morning, e = evening

9550089

40

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	Compl. day	X cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)			
292	6DT	Imipramine	16/03/93	18/03/93	3	50	50	100.0	100.0		25	25				
			19/03/93	23/03/93	5	75	75	100.0	100.0		25	50				
			24/03/93	24/03/93	1	75	25	33.3	92.6	1e	25	25				
			25/03/93	05/04/93	12	75	75	100.0	96.8		25	50				
			06/04/93	06/05/93	31	100	100	100.0	96.7	1e	50	50				
			07/05/93	07/05/93	1	100	50	50.0	97.8		50	50				
			08/05/93	10/05/93	3	100	100	100.0	97.9		50	50				
			56													
			7ND	Reboxetine	21/04/93	22/05/93	32	4	4	100.0	100.0		2	2		
					23/05/93	23/05/93	1	4	2	50.0	98.5	1m	2	2		
					24/05/93	15/06/93	23	4	4	100.0	99.1		2	2		
					56											
7DT	Imipramine	19/03/93	21/03/93	3	50	50	100.0	100.0			25	25				
		22/03/93	27/03/93	6	75	75	100.0	100.0		25	50					
		28/03/93	28/03/93	1	75	50	66.7	96.7	1m	25	50					
		29/03/93	12/04/93	15	75	75	100.0	98.7		25	50					
		13/04/93	13/04/93	1	75	50	66.7	97.4	1m	25	50					
		14/04/93	17/04/93	4	75	75	100.0	97.8		25	50					
		18/04/93	18/04/93	1	75	25	33.3	95.7	1e	25	25					
		19/04/93	13/05/93	25	75	75	100.0	97.6		25	50					
		56														
		8ND	Imipramine	23/04/93	25/04/93	3	50	50	100.0	100.0			25	25		
				26/04/93	13/05/93	18	75	75	100.0	100.0		25	50			
				14/05/93	17/06/93	35	100	100	100.0	100.0		50	50			
8DT	Reboxetine	09/04/93	09/04/93	1	4	4	100.0	100.0			2	2				
		10/04/93	10/04/93	1	4	2	50.0	75.0	1e	2	2					
		11/04/93	29/04/93	19	4	4	100.0	97.6		2	2					
		30/04/93	03/06/93	35	6	6	100.0	99.1		4	2					
56																

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 9=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
a = morning, e = evening

1186

9550089

41

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)		
292	21ND	Imipramine	08/05/93	10/05/93	3	50	50	100.0	100.0		25	25			
			11/05/93	18/05/93	8	75	75	100.0	100.0		25	50			
			19/05/93	19/05/93	1	25	25	33.3	94.4	1a	25	25			
			20/05/93	19/06/93	31	75	75	100.0	98.4		25	50			
			20/06/93	20/06/93	1	75	50	66.7	97.7	1m	25	50			
			21/06/93	02/07/93	12	75	75	100.0	98.2		25	50			
			56												
21DT	Reboxetine	04/05/93	13/05/93	10	4	4	100.0	100.0			2	2			
		14/05/93	14/05/93	1	4	2	50.0	95.5	1e	2	2				
		15/05/93	29/05/93	15	4	2	50.0	92.1		2	2				
		30/05/93	30/05/93	1	4	2	50.0	98.3	1m	2	2				
		31/05/93	24/06/93	25	4	4	100.0	98.1		2	2				
			25/06/93	25/06/93	1	4	2	50.0	97.2	1e	2	2			
			26/06/93	28/06/93	3	4	4	100.0	97.3		2	2			
			56												
22ND	Imipramine	20/05/93	22/05/93	3	50	50	100.0	100.0			25	25			
		23/05/93	04/06/93	13	75	75	100.0	100.0		25	50				
		05/06/93	05/06/93	1	75	25	33.3	96.1	1e	25	25				
		06/06/93	09/06/93	4	75	75	100.0	96.8		25	50				
		10/06/93	14/07/93	35	100	100	100.0	98.8		50	50				
			56												
22DT	Imipramine	05/05/93	07/05/93	3	50	50	100.0	100.0			25	25			
		08/05/93	19/05/93	12	75	75	100.0	100.0		25	50				
		20/05/93	20/05/93	1	75	50	66.7	97.9	1m	25	50				
		21/05/93	25/05/93	5	75	75	100.0	98.4		25	50				
		26/05/93	02/06/93	8	100	100	100.0	98.9		50	50				
			03/06/93	03/06/93	1	100	50	50.0	97.2	1e	50	50			
			04/06/93	29/06/93	26	100	100	100.0	98.5		50	50			
			56												
23ND	Reboxetine	27/05/93	12/06/93	17	4	4	100.0	100.0			2	2			
		13/06/93	13/06/93	1	4	2	50.0	97.2	1e	2	2				
		14/06/93	16/06/93	3	4	4	100.0	97.6		2	2				
		17/06/93	15/07/93	29	6	6	100.0	99.0		4	4				
		16/07/93	16/07/93	1	6	2	33.3	97.7	1m	4	4				
			17/07/93	21/07/93	5	6	6	100.0	97.9		4	4			

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration, 8=high daily dose in one administration, 9=low daily dose in one administration, 10=reason unknown

9550089

42

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	Compl. day	Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
292	23DT	Reboxetine	14/05/93	18/05/93	5	4	4	100.0	100.0		2	2	
			19/05/93	19/05/93	1	4	2	50.0	91.7	1e	2	2	
			20/05/93	28/05/93	9	4	4	100.0	96.7		2	2	
			29/05/93	29/05/93	1	4	2	50.0	93.8	1e	2	2	
			30/05/93	27/06/93	29	4	4	100.0	97.8		2	2	
			28/06/93	28/06/93	1	4	2	50.0	96.7	1m	2	2	
			29/06/93	08/07/93	10	4	4	100.0	97.3		2	2	
			05/06/93	10/07/93	36	4	4	100.0	100.0		2	2	
			11/07/93	11/07/93	1	4	2	50.0	98.6	1e	2	2	
			12/07/93	30/07/93	19	4	4	100.0	99.1		2	2	
293	24DT	Imipramine	02/06/93	04/06/93	3	50	50	100.0	100.0		25	25	
			05/06/93	10/06/93	6	75	75	100.0	100.0		25	50	
			11/06/93	11/06/93	1	75	50	66.7	96.7	1m	25	50	
			12/06/93	22/06/93	11	75	75	100.0	98.4		25	50	
			23/06/93	07/07/93	15	100	100	100.0	99.1		50	50	
			08/07/93	08/07/93	1	100	50	50.0	97.7	1e	50	50	
			09/07/93	27/07/93	19	100	100	100.0	98.5		50	50	
			18/02/93	20/02/93	3	50	50	100.0	100.0		25	25	
			21/02/93	10/04/93	49	75	75	100.0	100.0		25	50	
			11/04/93	11/04/93	1	75	0.0	96.1		1m	25	50	
12/04/93	14/04/93	3	75	75	100.0	96.2		25	50				
293	9DT	Imipramine	26/05/93	28/05/93	3	50	50	100.0	100.0		25	25	
			29/05/93	02/06/93	5	75	75	100.0	100.0		25	50	
			03/06/93	03/06/93	1	75	0.0	88.9		1m	25	50	
			14/06/93	10/06/93	7	75	75	100.0	93.8		25	50	
			15/06/93	14/06/93	1	75	0.0	88.2		1m	25	50	
			12/06/93	25/06/93	14	75	75	100.0	93.5		25	50	
			26/06/93	26/06/93	1	75	50	66.7	92.7	1m	25	50	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 9=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
 m = morning, e = evening

1188

9550089

43

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (x)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)			
293	9DT	Imipramine	27/06/93	01/07/93	5	75	75	100.0	93.7	1m 1e	25	50				
			02/07/93	02/07/93	1	75	75	0.0	91.2							
			03/07/93	10/07/93	8	75	75	100.0	92.8			25	50			
			11/07/93	11/07/93	1	75	50	66.7	92.2	1m						
			12/07/93	14/07/93	3	75	75	100.0	92.7			25	50			
			15/07/93	15/07/93	1	75	50	66.7	92.2	1m						
			16/07/93	16/07/93	1	75	0.0	0.0	90.4	1m 1e						
			17/07/93	20/07/93	4	75	75	100.0	91.1			25	50			
			56													
			10MD	Reboxetine	23/03/93	10/04/93	19	4	4	100.0	100.0			2	2	
11/04/93	11/04/93	1			4	2	50.0	97.5	1m							
12/04/93	17/04/93	6			4	4	100.0	98.1			2	2				
18/04/93	08/08/93	17			4	2	50.0	97.7	1e							
05/08/93	05/08/93	1			4	4	100.0	95.6			2	2				
07/08/93	13/08/93	7			4	2	50.0	95.2	1m							
14/08/93	14/08/93	1			4	4	100.0	93.8	1m 1e							
15/08/93	17/05/93	3			4	4	100.0	93.8			2	2				
56																
10DT	Imipramine	20/07/93			22/07/93	3	50	50	100.0	100.0			25	25		
		23/07/93	06/08/93	15	75	75	100.0	100.0			25	50				
		07/08/93	07/08/93	1	75	75	0.0	94.7	1m 1e							
		08/08/93	09/08/93	2	75	75	100.0	95.2			25	50				
		10/08/93	11/08/93	2	100	100	100.0	95.7			50	50				
		12/08/93	12/08/93	1	100	50	50.0	93.8	1e							
		13/08/93	25/08/93	13	100	50	50.0	92.0	1m							
		14/08/93	26/08/93	12	100	100	100.0	94.6			50	50				
		26/08/93	31/08/93	5	100	100	100.0	93.0	1m 1e							
		01/09/93	01/09/93	1	100	50	50.0	92.0	1m							
02/09/93	07/09/93	6	100	100	100.0	93.0			50	50						
08/09/93	08/09/93	1	100	50	50.0	92.2	1m									
09/09/93	09/09/93	1	100	100	100.0	92.3			50	50						
10/09/93	10/09/93	1	100	50	50.0	91.5	1e									
11/09/93	13/09/93	3	100	100	100.0	92.0			50	50						

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 8=low daily dose in one administration
m = morning, e = evening

9550089

44

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)			
293	11ND	Imipramine	12/07/93	14/07/93	3	50	50	100.0	100.0		25	25				
			15/07/93	04/08/93	21	75	75	100.0	100.0		25	50				
			05/08/93	05/08/93	1	75	50	66.7	98.7	1m	25	50				
			06/08/93	12/08/93	7	75	75	100.0	99.0	1e	25	50				
			13/08/93	13/08/93	1	75	25	33.3	97.0	1e	25	50				
			14/08/93	19/08/93	6	75	75	100.0	97.4	1m	25	50				
			20/08/93	20/08/93	1	75	50	66.7	96.7	1m	25	50				
			21/08/93	31/08/93	11	75	75	100.0	97.4	1m	25	50				
			01/09/93	01/09/93	1	75	50	66.7	96.8	1m	25	50				
			02/09/93	02/09/93	1	75	25	33.3	95.6	1e	25	50				
			03/09/93	03/09/93	3	75	75	100.0	95.6		25	50				
								56								
			11DT	Reboxetine	18/11/93	27/11/93	10	4	4	100.0	100.0	100.0		2	2	
					28/11/93	28/11/93	1	4	0	0.0	90.9	1m	2	2		
29/11/93	01/12/93	3			4	4	100.0	92.9	1m 1e	2	2					
					14											
16/09/93	08/10/93	23			4	4	100.0	100.0		2	2					
09/10/93	09/10/93	1			4	2	50.0	97.9	1e	2	2					
1190	Reboxetine	10/10/93	10/10/93	1	4	2	50.0	96.0	1m	2	2					
		11/10/93	13/10/93	3	4	4	100.0	96.4	1m	2	2					
		14/10/93	21/10/93	8	6	6	100.0	97.2	1e	4	4					
		22/10/93	22/10/93	1	6	4	66.7	96.4	1e	4	4					
		23/10/93	23/10/93	1	6	2	33.3	94.7	1m	4	4					
		24/10/93	27/10/93	4	6	6	100.0	95.2		4	4					
							42									
		12DT	Reboxetine	13/12/93	05/01/94	24	4	4	100.0	100.0		2	2			
				06/01/94	06/01/94	1	4	2	50.0	98.0	1e	2	2			
				07/01/94	17/01/94	11	4	4	100.0	98.6	1m	2	2			
18/01/94	18/01/94			1	4	2	50.0	97.3	1m	2	2					
19/01/94	24/01/94			6	4	4	100.0	97.7	1m	2	2					
25/01/94	25/01/94			1	4	2	50.0	96.6	1m	2	2					
26/01/94	06/02/94			12	4	4	100.0	97.3		2	2					
					56											
294	Imipramine	15/02/93	17/02/93	3	50	50	100.0	100.0		25	25					
		18/02/93	18/02/93	1	75	75	100.0	100.0		25	50					

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 9=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration, 8=high daily dose in one administration, 9=low daily dose in one administration
m = morning, e = evening

9550089

45

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (ng)	Daily dose (ng)	Compl. day	Compl. cumulat.	Reason (*)	Morning dose (ng)	Evening dose (ng)	Overdose (xx)
294	13HD	Imipramine	19/02/93	21/02/93	3	75	25	33.3	71.4	1e	25		
			22/02/93	12/04/93	50	75	75	100.0	96.5		25	50	
	13DT	Reboxetine	08/03/93	28/03/93	21	4	4	100.0	100.0		2	2	
			29/03/93	03/05/93	36	6	6	100.0	100.0		4	2	
	14HD	Reboxetine	15/02/93	12/04/93	57	4	4	100.0	100.0		2	2	
					57								
	14DT	Imipramine	08/03/93	10/03/93	3	50	50	100.0	100.0		25	25	
			11/03/93	28/03/93	18	75	75	100.0	100.0		25	50	
	15HD	Imipramine	22/02/93	24/02/93	3	50	50	100.0	100.0		25	25	
			25/02/93	19/04/93	54	75	75	100.0	100.0		25	50	
	15DT	Imipramine	09/03/93	11/03/93	3	50	50	100.0	100.0		25	25	
			12/03/93	29/03/93	18	75	75	100.0	100.0		25	50	
	16HD	Reboxetine	23/02/93	15/03/93	21	4	4	100.0	100.0		2	2	
			16/03/93	19/04/93	35	6	6	100.0	100.0		4	2	
	16DT	Reboxetine	09/03/93	29/03/93	21	4	4	100.0	100.0		2	2	
			30/03/93	03/05/93	35	6	6	100.0	100.0		4	2	
	25HD	Imipramine	14/06/93	16/06/93	3	50	50	100.0	100.0		25	25	
			17/06/93	08/08/93	53	75	75	100.0	100.0		25	50	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 9=reason unknown
(xx) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
n = morning, e = evening

1191

9550089

46

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (ng)	Daily dose (ng)	% Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (ng)	Evening dose (ng)	Overdose (**)
294	26MD	Imipramine	14/06/93	16/06/93	3	50	50	100.0	100.0		25	25	
			17/06/93	08/08/93	53	75	75	100.0	100.0		25	50	
	27HD	Reboxetine	15/06/93	02/08/93	49	4	4	100.0	100.0		2	2	
			03/08/93	10/08/93	8	4	4	0.0	86.0				
	28HD	Reboxetine	15/06/93	09/08/93	56	4	4	100.0	100.0		2	2	
					56								
	29DT	Reboxetine	14/06/93	04/07/93	21	4	4	100.0	100.0		2	2	
			05/07/93	08/08/93	35	6	6	100.0	100.0		4	2	
	30DT	Reboxetine	14/06/93	04/07/93	21	4	4	100.0	100.0		2	2	
			05/07/93	08/08/93	35	6	6	100.0	100.0		4	2	
	31DT	Imipramine	21/06/93	23/06/93	3	50	50	100.0	100.0		25	25	
			24/06/93	18/07/93	25	75	75	100.0	100.0		25	50	
	32DT	Imipramine	19/07/93	15/08/93	28	100	100	100.0	100.0		50	50	
					56								
295	17HD	Reboxetine	21/06/93	23/06/93	3	50	50	100.0	100.0		25	25	
			24/06/93	11/07/93	18	75	75	100.0	100.0		25	50	
			12/07/93	15/08/93	35	100	100	100.0	100.0		50	50	
					56								
			21/04/93	15/06/93	56	4	4	100.0	100.0		2	2	
					56								

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 8=low daily dose in one administration
m = morning, e = evening

9550089

47

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Baily dose (mg)	Compl. day	x cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (xx)
295	17DT	Imipramine	27/04/93	29/04/93	3	50	50	100.0	100.0		25	25	(M - e)
			30/04/93	30/04/93	1	75	50	66.7	91.7		25	25	
			01/05/93	23/06/93	54	75	75	100.0	99.4		25	50	
56													
18ND	Reboxetine	23/04/93	17/06/93	56	4	4	100.0	100.0			2	2	
		56											
18DT	Imipramine	29/04/93	01/05/93	3	50	50	100.0	100.0			25	25	
		02/05/93	23/06/93	55	75	75	100.0	100.0			25	50	
56													
19ND	Imipramine	14/05/93	16/05/93	3	50	50	100.0	100.0			25	25	
		17/05/93	08/07/93	53	75	75	100.0	100.0			25	50	
56													
19DT	Reboxetine	10/05/93	04/07/93	56	4	4	100.0	100.0			2	2	
		56											
20ND	Imipramine	14/05/93	16/05/93	3	50	50	100.0	100.0			25	25	
		17/05/93	08/07/93	53	75	75	100.0	100.0			25	50	
56													
20DT	Reboxetine	12/05/93	06/07/93	56	4	4	100.0	100.0			2	2	
		56											
381	Reboxetine	10/12/93	22/12/93	13	4	4	100.0	100.0			2	2	
		23/12/93	23/12/93	1	4	4	100.0	100.0		9m 9e	2	2	
		24/12/93	05/01/94	13	4	4	100.0	100.0		9m 9e	2	2	
		06/01/94	06/01/94	1	4	4	100.0	100.0		9m 9e	2	2	
		07/01/94	03/02/94	28	4	4	100.0	100.0			2	2	
		56											
2ND	Reboxetine	02/02/94	05/03/94	33	4	4	100.0	100.0			2	2	
		07/03/94	07/03/94	1	4	2	100.0	100.0		6e	2	2	

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 9=adverse event, 10=adverse event
(xx) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
m = morning, e = evening

1193

9550089

48

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)					
381	3DT	Reboxetine	08/02/94	26/02/94	34	4	4	100.0	100.0		2	2						
					19													
					4ND	Imipramine	01/03/94	03/03/94	3	50	50	100.0	100.0		25	25		
							04/03/94	14/03/94	11	75	75	100.0	100.0		25	50		
					382	5ND	Imipramine	15/11/93	15/11/93	1	50	25	100.0	100.0	9m		25	
										2	50	50	100.0	100.0		25	25	
										3	75	50	66.7	66.7		25	25	
										4	75	50	66.7	66.7		25	25	
										5	75	75	100.0	91.7		50	50	(M - a)
										6	75	75	100.0	91.7		50	50	(E - m)
										7	75	75	100.0	92.6		50	50	(M - a)
										8	75	100	100.0	93.3		50	50	(E - m)
										9	75	75	100.0	98.0	5m	25	50	
										10	75	75	100.0	98.9		25	50	
5DT	Reboxetine	21/10/93	04/11/93	15	4	4	100.0	100.0		2	2							
		05/11/93	12/11/93	8	4	0.0	0.0	65.2										
6ND	Reboxetine	12/11/93	12/11/93	12/11/93	1	4	2	100.0	100.0			2						
					2	4	4	100.0	100.0	9m	2	2						
					3	6	6	100.0	100.0		4	4						
					4	6	4	100.0	100.0	9e	4	4						
					5	6	6	100.0	100.0									
6DT	Imipramine	22/10/93	24/10/93	3	50	50	100.0	100.0		25	25							
		25/10/93	17/12/93	54	75	75	100.0	100.0		25	50							
7ND	Reboxetine	20/12/93	07/02/94	50	4	4	100.0	100.0		2	2							
					57													

(*) 1=forgotten to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 9m=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 9=low daily dose in one administration
m = morning, e = evening

9550089

49

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (mg)	Daily dose (mg)	Compl. day	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)	Overdose (**)
382	7DT	Imipramine	22/10/93	24/10/93	50	50	100.0	100.0			25	25	
					3	75	100.0	100.0			23	50	
					1	75	100.0	100.0	6e		25		
					5	50	100.0	100.0	9m		25	25	
					2	75	100.0	100.0			25	50	
8ND	Imipramine	26/01/94	26/01/94	50	25	100.0	100.0				25		
				1	50	100.0	100.0			25	25		
				2	75	100.0	100.0			25	50		
				2	75	100.0	100.0	5m	5e	25	50		
				2	75	100.0	100.0			25	50		
8DT	Reboxetine	22/12/93	22/12/93	17	4	100.0	100.0				2	2	
				1	4	100.0	100.0			2	2		
				4	4	100.0	100.0	3m		2	2		
				2	4	100.0	100.0			2	2		
				49	4	100.0	100.0			2	2		
9ND	Reboxetine	11/02/94	08/04/94	56	4	100.0	100.0				2	2	
				57	4	100.0	100.0			2	2		
				57	4	100.0	100.0			2	2		
				1	4	100.0	100.0	9m		2	2		
				20	4	100.0	100.0			2	2		
9DT	Reboxetine	08/02/94	08/02/94	57	4	100.0	100.0				2	2	
				20	4	100.0	100.0			2	2		
				1	4	100.0	100.0	4m		2	2		
				7	4	100.0	100.0	4m	4e	2	2		
				1	4	100.0	100.0			2	2		
10ND	Imipramine	11/02/94	11/02/94	30	50	100.0	100.0				25	25	
				1	50	100.0	100.0			25	50		
				2	75	100.0	100.0	6e		25	50		
				1	75	100.0	100.0			25	50		
				6	25	100.0	100.0			25	50		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 9=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
m = morning, e = evening

11951

9550089

51

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RSD

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY DOSE AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Dose prescribed (ng)	Daily dose (ng)	% Compl. day	% Compl. cumulat.	Reason (#)	Morning dose (ng)	Evening dose (ng)	Overdose (**)
3302	7HD	Imipramine	08/01/94	08/01/94	1	75	25	100.0	98.8	9a	25		
									57				

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 8=low daily dose in one administration
a = morning, e = evening

1197

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

1

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	Compl. day	% Compl. cumulat.	Morning Cps	Evening Cps	Reason (%)	Overdose (**)
1	1ND	Reboxetine	05/11/92	30/12/92	56	2	2	100.0	100.0	1	1		
					56								
	1DT	Reboxetine	26/11/93	20/01/94	56	2	2	100.0	100.0	1	1		
					56								
	2ND	Imipramine	17/11/92	11/01/93	56	2	2	100.0	100.0	1	1		
					56								
	2DT	Imipramine	09/12/93	22/12/93	14	2	2	100.0	100.0	1	1		
					14								
	3ND	Imipramine	03/06/93	08/06/93	6	2	2	100.0	100.0	1	1		
					6	2	1	50.0	92.9	1	1	1m	
					6	2	2	100.0	96.2	1	1		
					6	2	1	50.0	92.3	1	1	1e	
					6	2	2	100.0	96.2	1	1		
					6	2	2	100.0	96.2	1	1		
3DT	Reboxetine	10/12/93	01/01/94	23	2	2	100.0	100.0	1	1			
				1	2	0	0.0	95.8	1	1	4m 4e		
				32	2	2	100.0	96.2	1	1			
				56									
				5	2	2	100.0	100.0	1	1			
				1	2	1	50.0	91.7	1	1	4e		
4ND	Reboxetine	19/10/93	23/10/93	5	2	2	100.0	100.0	1	1			
				1	2	2	100.0	99.1	1	1			
4DT	Imipramine	01/02/94	24/02/94	24	2	2	100.0	100.0	1	1			
				24									
2	1ND	Reboxetine	15/01/93	07/02/93	24	2	2	100.0	100.0	1	1		
					1	2	1	50.0	98.0	1	1	6e	

1198

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. Cps	X Cumpl. day	Z Cumpl. cumulat.	Morning Cps	Evening Cps	Reasons (*)	Overdose (**)
3	1ND	Reboxetine	05/05/93	21/06/93	48	2	2	100.0	100.0	1	1		
			22/06/93	22/06/93	1	2	1	50.0	99.0	1		6e	
			49										
4	1ND	Imipramine	25/11/92	22/12/92	28	2	2	100.0	100.0	1	1		
			23/12/92	23/12/92	1	2	1	100.0	100.0	1		5e	
			24/12/92	28/12/92	5	2	2	100.0	100.0	1		1m	
			29/12/92	29/12/92	1	2	0.0	0.0	97.1			6e	
35													
5	1ND	Reboxetine	30/10/92	09/11/92	11	2	2	100.0	100.0	1	1		
			10/11/92	10/11/92	1	2	1	50.0	95.8	1		6e	
12													
1DT	Imipramine	11/11/92	11/11/92	1	2	1	100.0	100.0	0	1	1	9m	
		12/11/92	06/01/93	56	2	2	100.0	100.0	1	1			
57													
2ND	Reboxetine	24/11/92	29/12/92	36	2	2	100.0	100.0	1	1			
		30/12/92	30/12/92	1	2	3	50.0	98.6	1	2			(B - e)
		31/12/92	18/01/93	19	2	2	100.0	99.1	1	1			
56													
2DT	Imipramine	23/12/92	05/01/93	14	2	2	100.0	100.0	1	1			
		06/01/93	07/01/93	2	2	2	100.0	100.0	1	1			
		08/01/93	14/02/93	38	2	2	100.0	100.0	1	1			3m 3e
54													
3ND	Imipramine	17/03/93	11/05/93	56	2	2	100.0	100.0	1	1			
		56											
3DT	Reboxetine	27/03/93	21/05/93	56	2	2	100.0	100.0	1	1			
		56											

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

1199

9550089

3

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PEARLACIA CNS R8D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. Cps	Z Cumpl. day	Z Cumulat. compliat. Cps	Morning Cps	Evening Cps	Reason (*)	Overdose (**)
5	4ND	Imipramine	24/11/92	18/01/93	56	2	2	100.0	100.0	1	1		
					56	2	2	100.0	100.0	1	1		
	4DT	Reboxetine	03/02/93	02/03/93	28	2	2	100.0	100.0	1	1		
					28	2	2	100.0	100.0	1	1		
					8	2	2	100.0	100.0	1	1		
					1	2	1	50.0	94.4	1	1	4e	
	5ND	Reboxetine	04/08/93	11/08/93	8	2	2	100.0	100.0	1	1		
					1	2	1	50.0	94.4	1	1	4e	
					1	2	2	100.0	85.0			4m	4e
					2	2	1	50.0	79.2	1	1	4m	4e
	5DT	Reboxetine	17/02/93	17/03/93	12	2	2	100.0	100.0	1	1		
					29	2	2	100.0	100.0	1	1		
6ND	Imipramine	05/08/93	18/08/93	14	2	2	100.0	100.0	1	1			
				14	2	2	100.0	100.0	1	1			
6DT	Reboxetine	27/02/93	01/03/93	3	2	2	100.0	100.0	1	1			
				2	2	2	100.0	100.0			3m	3e	
				51	2	2	100.0	100.0	1	1			
				56	2	2	100.0	100.0	1	1			
7ND	Reboxetine	27/10/93	16/11/93	21	2	2	100.0	100.0	1	1			
				21	2	2	100.0	100.0	1	1			
7DT	Imipramine	13/03/93	07/05/93	56	2	2	100.0	100.0	1	1			
				56	2	2	100.0	100.0	1	1			
8ND	Imipramine	11/11/93	05/01/94	56	2	2	100.0	100.0	1	1			
				56	2	2	100.0	100.0	1	1			

1200

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
 m = morning, e = evening

9550089

4

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. Cps	Z Cumul. compl. day	Morning Cps	Evening Cps	Reason (*)	Overdose (**)	
5	8DT	Imipramine	05/05/93	29/06/93	56	2	2	100.0	1	1			
9ND	Reboxetine	16/11/93	10/01/94	56	2	2	100.0	100.0	1	1			
9DT	Reboxetine	02/05/93	25/06/93	55	2	2	100.0	100.0	1	1			
10ND	Imipramine	25/11/93	08/12/93	14	2	2	100.0	100.0	1	1			
10DT	Imipramine	06/05/93	09/05/93	4	2	2	100.0	100.0	1	1	3a 3b 3c 3d 3e 3f 3g 3h 3i 3j 3k 3l 3m 3n 3o 3p 3q 3r 3s 3t 3u 3v 3w 3x 3y 3z		
11ND	Imipramine	02/12/93	05/01/94	35	2	2	100.0	100.0	1	1			
11DT	Reboxetine	11/05/93	07/06/93	28	2	2	100.0	100.0	1	1			
12ND	Reboxetine	06/01/94	03/03/94	57	2	2	100.0	100.0	1	1			
12DT	Imipramine	21/05/93	28/05/93	8	2	2	100.0	100.0	1	1			

1201

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/03S
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	Compl. day	Compl. cumulat.	Morning Cps	Evening Cps	Reason (%)	Overdose (**)
6	1HD	Reboxetine	19/11/92	07/01/93	56	2	2	100.0	100.0	1	1		
1DT	Reboxetine	21/10/92	16/12/92	57	2	2	100.0	100.0	1	1			
2ND	Imipramine	11/11/92	16/11/92	6	2	2	100.0	100.0	1	1		6e	
2DT	Reboxetine	21/01/93	27/01/93	7	2	2	100.0	100.0	1	1			
3ND	Reboxetine	09/12/92	27/01/93	56	2	2	100.0	100.0	1	1			
3DT	Imipramine	08/04/93	02/06/93	56	2	2	100.0	100.0	1	1			
4ND	Imipramine	15/12/92	15/12/92	1	2	1	100.0	100.0	0	0	1	9m	
4DT	Imipramine	05/05/93	29/06/93	56	2	2	100.0	100.0	1	1			
5ND	Imipramine	03/04/93	28/05/93	56	2	2	100.0	100.0	1	1			
5DT	Reboxetine	20/11/93	24/11/93	5	2	2	100.0	100.0	1	1			

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

9550089

6

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. Cps	Z Cumul. compl. day	Morning Cps	Evening Cps	Reason (%)	Dropdose (%)																												
6	5DF	Reboxetine	26/11/93	14/01/94	50	2	2	100.0	99.1	1	1																													
													56																											
													6ND	Reboxetine	29/04/93	31/05/93	33	2	2	100.0	100.0	1	1	6e																
																										01/06/93	01/06/93	1	2	1	50.0	98.5	1							
																										34														
																										7HD	Reboxetine	20/10/93	14/12/93	56	2	2	100.0	100.0	1	1				
	56																																							
	8ND	Imipramine	23/11/93	17/01/94	56	2	2	100.0	100.0	1	1																													
													56																											
													7	1HD	Imipramine	09/01/93	13/03/93	64	2	2	100.0	100.0	1	1																
																										3HD	Imipramine	23/04/93	17/06/93	56	2	2	100.0	100.0	1	1				
56																																								
4HD	Reboxetine	24/04/93	28/05/93	35	2	2	100.0	100.0	1	1	6e																													
																																							29/05/93	
													36																											
													342HD	Reboxetine	23/02/93	11/03/93	17	2	2	100.0	100.0	1	1	1m	1e															
																										12/03/93	12/03/93	1	2	0	0	94.4								
																										13/03/93	19/04/93	38	2	2	100.0	98.2	1	1						
56																																								
8	1ND	Reboxetine	30/09/92	30/10/92	31	2	2	100.0	100.0	1	1	1m														1e														
																											31/10/92	31/10/92	1	2	0	0	96.9							
													01/11/92	24/11/92	24	2	2	100.0	98.2	1	1																			
													56																											
													1DT	Imipramine	28/09/92	22/11/92	56	2	2	100.0	100.0	1	1																	
																											56													

1203

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

7

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	Compl. day	X	Z	Morning Cps	Evening Cps	Reason (*)	Overdose (**)
8	2HD	Reboxetine	30/09/92	24/11/92	56	2	2	100.0	100.0	1	1	1		
2DT	Imipramine	30/09/92	24/11/92	56	2	2	100.0	100.0	1	1	1	1		
3HD	Imipramine	02/10/92	09/10/92	8	2	2	100.0	100.0	1	1	1	1	3e	
3DT	Reboxetine	02/10/92	26/11/92	56	2	2	100.0	100.0	1	1	1	1		
4HD	Imipramine	02/10/92	17/10/92	16	2	2	100.0	100.0	1	1	1	1	10m 10e	
4DT	Reboxetine	02/10/92	26/11/92	56	2	2	100.0	100.0	1	1	1	1		
701HD	Imipramine	09/10/92	13/11/92	36	2	2	100.0	100.0	1	1	1	1	1m	
701DT	Reboxetine	09/10/92	03/12/92	56	2	2	100.0	100.0	1	1	1	1		
702HD	Reboxetine	16/10/92	16/11/92	32	2	2	100.0	100.0	1	1	1	1		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) f=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

1204

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

8

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. Cps	% Compl. day	% Cumulat.	Morning Cps	Evening Cps	Reason (%)	Overdose (%)		
8	702ND	Reboxetine	17/11/92	17/11/92	1	2	1	50.0	98.5		1	1m			
			18/11/92	18/11/92	23	2	2	100.0	99.1	1	1				
			56												
			09/10/92	03/12/92	56	2	2	100.0	100.0		1	1			
			56												
			09/02/93	17/02/93	9	2	2	100.0	100.0		1	1			
	703ND	Imipramine	18/02/93	18/02/93	1	2	1	50.0	95.0		1	1a			
			19/02/93	07/03/93	17	2	2	100.0	98.1	1	1				
			08/03/93	08/03/93	1	2	1	50.0	96.4		1	1a			
			09/03/93	16/03/93	8	2	2	100.0	97.2	1	1	1m 1a			
			17/03/93	17/03/93	1	2	0.0	94.6		1	1				
			18/03/93	05/04/93	19	2	2	100.0	96.4		1	1			
56															
703DT	Imipramine	09/02/93	05/04/93	56	2	2	100.0	100.0		1	1				
56															
704ND	Reboxetine	09/02/93	07/03/93	27	2	2	100.0	100.0		1	1				
		08/03/93	08/03/93	1	2	1	50.0	98.2		1	1a				
		09/03/93	16/03/93	8	2	2	100.0	98.6	1	1					
		17/03/93	17/03/93	1	2	0.0	95.9		1	1	1m 1a				
		18/03/93	18/03/93	1	2	2	100.0	96.1	1	1					
		19/03/93	19/03/93	1	2	0.0	93.6		1	1	1m 1a				
56															
704DT	Reboxetine	09/02/93	05/04/93	56	2	2	100.0	100.0		1	1				
56															
9	1ND	Imipramine	28/09/93	28/09/93	1	2	1	100.0	100.0		0	1	9m		
			29/09/93	22/11/93	55	2	2	100.0	100.0		1	1			
			23/11/93	23/11/93	1	2	1	100.0	100.0		1	0	9a		
57															

1205

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
 m = morning, e = evening

9550089

9

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS B&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Evening Cps	Reason (*)	Overdose (**)	
9	1DT	Imipramine	15/12/93	08/02/94	56	2	2	100.0	100.0	1	1			
					56									
	2HD	Reboxetine	01/10/93	25/11/93	56	2	2	100.0	100.0	1	1			
					56									
	2DT	Imipramine	22/12/93	15/02/94	56	2	2	100.0	100.0	1	1			
					56									
	3DT	Reboxetine	13/10/93	25/11/93	44	2	2	100.0	100.0	1	1			
					26/11/93	26/11/93	1	2	100.0	100.0				
					27/11/93	07/12/93	11	2	100.0	100.0	1	1		3m 3o
					56									
4HD	Imipramine	13/10/93	07/12/93	56	2	2	100.0	100.0	1	1				
				56										
5HD	Reboxetine	26/10/93	20/12/93	56	2	2	100.0	100.0	1	1				
				21/12/93	21/12/93	1	2	100.0	100.0	1	0		9e	
6HD	Imipramine	03/11/93	04/11/93	2	2	2	100.0	100.0	1	1				
				05/11/93	05/11/93	1	2	50.0	83.3	1			6e	
7HD	Imipramine	10/11/93	10/11/93	1	2	2	100.0	100.0	1	1				
				11/11/93	11/11/93	1	2	50.0	75.0	1			6e	
8DT	Reboxetine	16/11/93	10/01/94	56	2	2	100.0	100.0	1	1				
				56										
10	1HD	Imipramine	02/10/93	26/11/93	56	2	2	100.0	100.0	1	1			
					56									

1206

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
n = morning, o = evening

9550089

10

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps. prescribed	Daily Compl. Cps	% day	Cumulative Compl. Cps	% cumulat.	Morning Cps	Evening Cps	Reason (%)	Overdose (xx)
10	10T	Reboxetine	01/12/93	25/01/94	56	2	2	100.0	100.0	100.0	1	1		
					56									
20	20D	Reboxetine	02/10/93	26/11/93	56	2	2	100.0	100.0	100.0	1	1		
					56									
20	20T	Imipramine	01/12/93	25/01/94	56	2	2	100.0	100.0	100.0	1	1		
					56									
30	30D	Reboxetine	02/10/93	26/11/93	56	2	2	100.0	100.0	100.0	1	1		
					56									
30	30T	Imipramine	02/12/93	26/01/94	56	2	2	100.0	100.0	100.0	1	1		
					56									
40	40D	Imipramine	06/10/93	30/11/93	56	2	2	100.0	100.0	100.0	1	1		
					56									
40	40T	Reboxetine	02/12/93	26/01/94	56	2	2	100.0	100.0	100.0	1	1		
					56									
50	50D	Imipramine	06/10/93	30/11/93	56	2	2	100.0	100.0	100.0	1	1		
					56									
50	50T	Reboxetine	04/12/93	28/01/94	56	2	2	100.0	100.0	100.0	1	1		
					56									
60	60D	Reboxetine	09/10/93	03/12/93	56	2	2	100.0	100.0	100.0	1	1		
					56									

1207

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
 n = morning, e = evening

9550089

11

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R3D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. Cps	% day	% cumulat.	Morning Cps	Evening Cps	Reason (*)	Overdose (xx)
10	6DT	Reboxetine	04/12/93	28/01/94	56	2	2	100.0	100.0	1	1		
					56								
	7MD	Imipramine	09/10/93	03/12/93	56	2	2	100.0	100.0	1	1		
					56								
	7DT	Imipramine	04/12/93	28/01/94	56	2	2	100.0	100.0	1	1		
					56								
	8ND	Reboxetine	16/10/93	10/12/93	56	2	2	100.0	100.0	1	1		
					56								
	8DT	Imipramine	04/12/93	28/01/94	56	2	2	100.0	100.0	1	1		
					56								
	9ND	Reboxetine	20/11/93	14/01/94	56	2	2	100.0	100.0	1	1		
					56								
	9DT	Imipramine	08/12/93	01/02/94	56	2	2	100.0	100.0	1	1		
					56								
	10ND	Imipramine	23/10/93	17/12/93	56	2	2	100.0	100.0	1	1		
					56								
	10DT	Reboxetine	08/12/93	01/02/94	56	2	2	100.0	100.0	1	1		
					56								
	11ND	Imipramine	23/10/93	17/12/93	56	2	2	100.0	100.0	1	1		
					56								
	11DT	Imipramine	08/12/93	01/02/94	56	2	2	100.0	100.0	1	1		

1208

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

12

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. Cps	% Compl. day	% Cumulat.	Morning Cps	Evening Cps	Reason (*)	Overdose (xx)
10	12HD	Reboxetine	27/10/93	21/12/93	56	2	2	100.0	100.0	1	1		
					56								
	12DT	Reboxetine	08/12/93	01/02/94	56	2	2	100.0	100.0	1	1		
					56								
	13DT	Reboxetine	27/10/93	21/12/93	56	2	2	100.0	100.0	1	1		
					56								
	14DT	Imipramine	30/10/93	23/12/93	55	2	2	100.0	100.0	1	1		
					55								
	15HD	Reboxetine	30/10/93	29/12/93	55	2	2	100.0	100.0	1	1		
					55								
	16DT	Imipramine	30/10/93	23/12/93	55	2	2	100.0	100.0	1	1		
					55								
	17HD	Reboxetine	06/11/93	30/12/93	55	2	2	100.0	100.0	1	1		
					55								
	18HD	Imipramine	06/11/93	30/12/93	55	2	2	100.0	100.0	1	1		
					55								
	19DT	Reboxetine	06/11/93	30/12/93	55	2	2	100.0	100.0	1	1		
					55								
	20HD	Reboxetine	06/11/93	30/12/93	55	2	2	100.0	100.0	1	1		
					55								

1209

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

9550089

13

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PEARLACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 9.0
 EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	Z Compl. day	Z Compl. cumulat.	Morning Cps	Evening Cps	Reason (*)	Overdose (**)
12	1ND	Reboxetine	28/04/93	22/06/93	56	2	2	100.0	100.0	1	1		
					56								
					56								
13	1DT	Reboxetine	20/05/93	14/07/93	56	2	2	100.0	100.0	1	1		
					56								
					56								
13	1ND	Reboxetine	08/04/93	10/04/93	3	2	1	100.0	100.0	1	1	5e	
					53	2	2	100.0	100.0	1	1		
					56								
13	1DT	Imipramine	23/09/93	29/09/93	7	2	1	100.0	100.0	1	1	5e	
					49	2	2	100.0	100.0	1	1		
					56								
2ND	2ND	Imipramine	11/12/93	11/12/93	1	2	1	100.0	100.0	1	1	5a	
					1	2	1	100.0	100.0	1	1	3m, 3e	
					1	2	1	100.0	100.0	1	1	5e	
2ND	2ND	Imipramine	13/12/93	13/12/93	1	2	2	100.0	100.0	1	1		
					49	2	2	100.0	100.0	1	1		
					1	2	2	100.0	100.0	1	1		
2ND	2ND	Imipramine	01/02/94	01/02/94	1	2	2	100.0	100.0	1	1	5m, 5e	
					2	2	2	100.0	100.0	1	1		
					1	2	1	100.0	100.0	1	0	9e	
2ND	2ND	Reboxetine	22/10/93	22/10/93	56	2	1	100.0	100.0	0	1		
					1	2	1	100.0	100.0	0	1	9m	
					19	2	2	100.0	100.0	1	1		
3ND	3ND	Imipramine	03/02/94	03/02/94	55	2	1	100.0	100.0	0	1	9m	
					55	2	2	100.0	100.0	1	1		
					57	2	1	100.0	100.0	1	0	9e	

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
 m = morning, e = evening

1210

9550089

14

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. Cps	Z Compl. day	Z Compl. cumulat.	Morning Cps	Evening Cps	Reason (%)	Overdose (%)				
13	3DT	Imipramine	12/11/93 04/01/94	03/01/94 04/01/94	53 1	2 2	2 1	100.0 100.0	100.0 100.0	1 1	1 0	9a					
														57			
14	4DT	Reboxetine	03/02/94 04/02/94 31/03/94	03/02/94 30/03/94 31/03/94	1 55 1	2 2 2	1 2 1	100.0 100.0 100.0	100.0 100.0 100.0	0 1 1	1 1 0	9m 9e					
														57			
15	1HD	Reboxetine	06/04/94	02/05/94	27 27	2 2	2 2	100.0 100.0	100.0 100.0	1 1	1 1						
														56			
16	1DT	Reboxetine	26/07/93	19/09/93	56 56	2 2	2 2	100.0 100.0	100.0 100.0	1 1	1 1						
														56			
17	2HD	Imipramine	24/03/93	02/04/93	10 10	2 2	2 2	100.0 100.0	100.0 100.0	1 1	1 1						
														56			
18	2DT	Imipramine	22/02/94	18/04/94	56 56	2 2	2 2	100.0 100.0	100.0 100.0	1 1	1 1						
														56			
19	3HD	Reboxetine	06/05/93 21/06/93 22/06/93	20/06/93 21/06/93 30/06/93	46 1 9	2 2 2	2 1 2	100.0 50.0 100.0	100.0 98.9 99.1	1 1 1	1 1 1	1e					
														56			
20	4HD	Imipramine	15/07/93	08/09/93	56 56	2 2	2 2	100.0 100.0	100.0 100.0	1 1	1 1						
														56			
21	11HD	Reboxetine	08/10/93 16/10/93	15/10/93 16/10/93	8 1	2 2	2 1	100.0 50.0	100.0 94.4	1 1	1 1	1a					
														56			

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

9550089

15

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. Cps	X Cumpl. day	X Cumulat.	Morning Cps	Evening Cps	Reason (*)	Overdose (**)	
15	111ND	Reboxetine	17/10/93	28/10/93	12	2	2	100.0	97.6	1	1			
					21									
	112ND	Imipramine	29/11/93	23/01/94	56	2	2	100.0	100.0	1	1			
					56									
	16	1ND	Reboxetine	18/02/93	14/04/93	56	2	2	100.0	100.0	1	1		
						56								
	1DT	Imipramine	18/02/93	25/02/93	8	2	2	100.0	100.0	1	1			
					1	2	1	50.0	94.4	1	1	6e		
	2HD	2DT	Imipramine	15/04/93	09/06/93	56	2	2	100.0	100.0	1	1		
						56								
3HD	3DT	Imipramine	09/05/93	08/06/93	31	2	2	100.0	100.0	1	1			
					1	2	1	50.0	98.4	1	1	6e		
4HD	4DT	Reboxetine	19/04/94	13/06/94	56	2	2	100.0	100.0	1	1			
					56									
17	1ND	Reboxetine	31/03/93	06/04/93	7	2	2	100.0	100.0	1	1			
					1	2	3	50.0	93.8	1	2			
					5	2	2	100.0	96.2	1	1			
					1	2	1	50.0	92.9	1	1			
					13									

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
 m = morning, e = evening

1212

9550089

16

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RSD

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. Cps	X Compl. day	X Cumulat. compl.	Morning Cps	Evening Cps	Reason (*)	Overdose (**)				
17	1ND	Reboxetine	14/04/93	19/04/93	6	2	2	100.0	95.0	1	1		(B - m)				
			20/04/93	20/04/93	1	2	3	50.0	92.9	2	1						
			21/04/93	09/05/93	19	2	2	100.0	96.3	1	1						
			10/05/93	10/05/93	1	2	1	50.0	95.1	1	1	1m					
			11/05/93	21/05/93	11	2	2	100.0	96.2	1	1						
			22/05/93	22/05/93	1	2	3	50.0	95.3	1	2						
			23/05/93	25/05/93	3	2	2	100.0	95.5	1	1						
								56									
			18	1DT	Reboxetine	28/04/93	16/05/93	19	2	2	100.0	100.0		1	1		6e
						17/05/93	17/05/93	1	2	1	50.0	97.5		1			
19	2ND	Imipramine	21/04/93	15/06/93	56	2	2	100.0	100.0	1	1						
								56									
20	2DT	Reboxetine	07/07/93	31/08/93	56	2	2	100.0	100.0	1	1						
								56									
21	3ND	Imipramine	06/11/93	19/11/93	14	2	2	100.0	100.0	1	1						
								14									
22	3DT	Imipramine	19/10/93	13/12/93	56	2	2	100.0	100.0	1	1						
								56									
23	4ND	Reboxetine	12/01/94	09/03/94	57	2	2	100.0	100.0	1	1						
								57									
24	4DT	Imipramine	19/01/94	15/03/94	56	2	2	100.0	100.0	1	1						
								56									
25	211ND	Reboxetine	19/05/94	13/07/94	56	2	2	100.0	100.0	1	1						
								56									

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, B=double low dose, C=high daily dose in one administration, B=low daily dose in one administration
 n = morning, e = evening

9550089

17

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. Cps	Z	X	Morning Cps	Evening Cps	Reason (*)	Overdose (**)
17	21DDT	Reboxetine	05/04/94	30/05/94	56	2	2	100.0	100.0	1	1		
					56								
18	1HD	Imipramine	27/05/93	21/07/93	56	2	2	100.0	100.0	1	1		
					56								
	1DT	Imipramine	12/08/93	06/10/93	56	2	2	100.0	100.0	1	1		
					56								
	2ND	Imipramine	30/05/93	26/06/93	28	2	2	100.0	100.0	1	1		
					28								
	2DT	Reboxetine	09/11/93	06/12/93	28	2	2	100.0	100.0	1	1		
					28								
	3ND	Reboxetine	14/08/93	01/10/93	49	2	2	100.0	100.0	1	1		
					49								
	4ND	Reboxetine	03/10/93	27/11/93	56	2	2	100.0	100.0	1	1		
					56								
20	3ND	Reboxetine	09/07/93	15/07/93	7	2	2	100.0	100.0	1	1		
					7								
22	1HD	Reboxetine	25/06/93	29/06/93	5	2	2	100.0	100.0	1	1		
			30/06/93	30/06/93	1	2	1	50.0	91.7	1	1	6e	
					6								
23	1HD	Reboxetine	30/01/93	31/01/93	2	2	2	100.0	100.0	1	1		
			01/02/93	01/02/93	1	2	3	50.0	83.3	2	1		
			02/02/93	26/03/93	53	2	2	100.0	99.1	1	1		
					56								(B - m)

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
 m = morning, e = evening

9550089

18

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. Cps	% day	Cumul. compl. Cps	%	Morning Cps	Evening Cps	Reason (*)	Overdose (**)			
23	2ND	Reboxetine	02/02/93	14/02/93	13	2	2	100.0	100.0		1	1					
			15/02/93	15/02/93	1	2	1	50.0	96.4	1	10e						
			16/02/93	29/03/93	42	2	2	100.0	99.1	1							
56																	
3ND	Imipramine	Imipramine	23/03/93	17/05/93	56	2	2	100.0	100.0		1	1					
			56														
			31/03/93	25/05/93	56	2	2	100.0	100.0	1	1						
56																	
5ND	Imipramine	Imipramine	05/05/93	12/05/93	8	2	2	100.0	100.0		1	1					
			13/05/93	13/05/93	1	2	1	50.0	94.4	1	6e						
			9														
6ND	Imipramine	Imipramine	06/07/93	17/08/93	43	2	2	100.0	100.0		1	1					
			43														
			27/08/93	27/08/93	1	2	1	100.0	100.0	0	9m						
25	1ND	Reboxetine	28/08/93	01/10/93	35	2	2	100.0	100.0		1	1					
			36														
			26/11/93	26/12/93	31	2	2	100.0	100.0	1	1						
2ND	Imipramine	Imipramine	27/12/93	27/12/93	1	2	1	50.0	98.4		1	1					
			28/12/93	20/01/94	24	2	2	100.0	99.1	1	1m						
			56														
26	1ND	Imipramine	27/04/93	21/06/93	56	2	2	100.0	100.0		1	1					
			56														
			29/06/93	11/08/93	44	2	2	100.0	100.0	1	1						
44																	
27	1ND	Imipramine	02/02/93	08/02/93	7	2	2	100.0	100.0		1	1					
			7														
			44														

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

9550089

19

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. Cps	X Z Cumulat. compl. Cps	Morning Cps	Evening Cps	Reason (*)	Overdose (**)																			
28	1MD	Reboxetine	20/04/93	24/04/93	7	2	2	100.0	1	1																					
													25/04/93	25/04/93	1	2	1	50.0	91.7	1	1e										
													26/04/93	30/05/93	35	2	2	100.0	98.8	1											
													31/05/93	31/05/93	1	2	3	50.0	97.6	1	(B - e)										
													01/06/93	14/06/93	14	2	2	100.0	98.2	1											
															56																
													10T	Imipramine	22/04/93	25/05/93	34	2	2	100.0	100.0	1	1	1m	1e						
																										26/05/93	26/05/93	1	2	0.0	97.1
																										27/05/93	16/06/93	21	2	2	100.0
															56																
2HD	Imipramine	26/04/93	21/06/93	57	2	2	100.0	100.0	1	1																					
															57																
2DT	Reboxetine	27/04/93	21/06/93	56	2	2	100.0	100.0	1	1																					
															56																
3MD	Reboxetine	27/04/93	21/06/93	56	2	2	100.0	100.0	1	1																					
															56																
3DT	Imipramine	11/05/93	04/07/93	55	2	2	100.0	100.0	1	1		(B - m) (B - e)																			
													05/07/93	05/07/93	1	2	4	0.0	98.2	2	2										
				56																											
4MD	Imipramine	04/05/93	09/05/93	6	2	2	100.0	100.0	1	1		(B - m) (B - e)																			
													10/05/93	10/05/93	1	2	4	0.0	85.7	2	2										
													11/05/93	07/06/93	28	2	2	100.0	97.1	1	1	4e									
													08/06/93	14/06/93	7	2	1	50.0	89.3	1											
													15/06/93	20/06/93	6	2	2	100.0	90.6	1	1										
													21/06/93	21/06/93	1	2	3	50.0	89.8	2	1	(B - m)									
22/06/93	28/06/93	7	2	2	100.0	91.1	1	1																							

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/stop treatment in morning or evening, 10=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
 m = morning, e = evening

9550089

20

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. %	Cumulative Compl. %	Morning Cps	Evening Cps	Reason (*)	Overdose (xx)
28	5HD	Reboxetine	25/05/93	29/05/93	5	2	100.0	100.0	1	1		
			30/05/93	30/05/93	1	2	50.0	91.7	1		1e	
			31/05/93	19/07/93	50	2	100.0	99.1	1	1		
30	1HD	Imipramine	21/04/93	16/06/93	57	2	100.0	100.0	1	1		
			17/06/93	17/06/93	1	2	100.0	100.0	1	0	9a	
			16/07/93	17/07/93	2	2	100.0	100.0	1	1		
2HD	Reboxetine	16/07/93	17/07/93	2	2	100.0	100.0	1	1			
		18/07/93	18/07/93	1	2	50.0	83.3	1		6a		
				3	2	100.0	100.0	0	1	9m		
3HD	Imipramine	08/11/93	08/11/93	1	2	100.0	100.0	0	1			
		09/11/93	03/01/94	56	2	100.0	100.0	1	1			
				57	2	100.0	100.0	1	1			
4HD	Reboxetine	02/11/93	30/12/93	59	2	100.0	100.0	1	1			
				59	2	100.0	100.0	1	1			
				5	2	100.0	100.0	1	1			
5HD	Imipramine	18/12/93	22/12/93	5	2	100.0	100.0	1	1			
		23/12/93	23/12/93	1	2	100.0	100.0	1		3e		
		24/12/93	24/12/93	1	2	50.0	92.9	1		3m 6a		
31	1HD	Imipramine	23/09/92	26/09/92	4	2	100.0	100.0	1	1		
			27/09/92	27/09/92	1	2	100.0	100.0	1		3m 3e	
			28/09/92	04/10/92	7	2	100.0	100.0	1	1		
1DT	Reboxetine	05/10/92	05/10/92	1	2	50.0	96.2	1		6a		
				13	2	100.0	100.0	1	1			
		23/09/92	23/09/92	1	2	100.0	100.0	1		3e		

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

1217

9550089

21

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. day	% Compl. cumulat.	Morning Cps	Evening Cps	Reason (*)	Overdose (xx)			
31	1DT	Reboxetine	04/10/92	04/10/92	1	2	1	50.0	1	1	1e				
			05/10/92	21/10/92	17	2	2	100.0	98.3	1	1				
			22/10/92	22/10/92	1	2	1	100.0	98.3	1	0	9e			
			23/10/92	27/10/92	5	2	2	100.0	98.6	1	1				
			28/10/92	28/10/92	1	2	1	50.0	97.2	1	1	6e			
			36												
			02/12/92	20/12/92	19	2	2	100.0	100.0	1	1				
			21/12/92	21/12/92	1	2	1	100.0	100.0	1	1			3e	
			22/12/92	29/01/93	39	2	2	100.0	100.0	1	1				
			59												
32	1ND	Imipramine	14/12/92	16/12/92	3	2	2	100.0	100.0	1	1				
			3												
			25/03/93	18/05/93	55	2	2	100.0	100.0	1	1				
56															
32	2ND	Imipramine	15/04/93	20/04/93	6	2	2	100.0	100.0	1	1				
			21/04/93	29/04/93	9	2	1	100.0	100.0	1	1	3e			
			30/04/93	09/06/93	41	2	1	100.0	100.0	1	1	5e			
			56												
			22/04/93	25/05/93	34	2	2	100.0	100.0	1	1				
33	3ND	Reboxetine	26/05/93	26/05/93	1	2	3	0.0	97.1	2	1	9e			
			27/05/93	01/06/93	6	2	2	100.0	97.6	1	1				
			02/06/93	02/06/93	1	2	1	50.0	96.4	1	1	10e			
			03/06/93	15/06/93	13	2	2	100.0	97.3	1	1				
			16/06/93	16/06/93	1	2	1	100.0	97.3	1	0	9e			
			56												
			07/10/93	22/10/93	16	2	2	100.0	100.0	1	1				
4ND	Reboxetine	23/10/93	26/10/93	4	2	1	100.0	100.0	1	1	5m				
		20													

1218

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
 (xx) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
 m = morning, e = evening

9550089

22

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. day	Cumpl. cumulat.	Morning Cps	Evening Cps	Reason (*)	Overdose (**)	
32	SMD	Reboxetine	04/11/93	10/11/93	7	2	2	100.0	1	1			
			11/11/93	24/11/93	14	2	1	100.0	100.0	1		3e	
			25/11/93	25/11/93	1	2	1	50.0	97.7	1		6e	
					22								
35	1MD	Reboxetine	17/11/93	11/01/94	56	2	2	100.0	1	1			
			12/01/94	12/01/94	1	2	1	100.0	100.0	1	0	9e	
					57								
					20	2	100.0	100.0	1	1			
					15/02/93	15/02/93	1	50.0	97.6		3m	6e	
					21								
1DT		Reboxetine	03/03/93	27/04/93	56	2	2	100.0	100.0	1	1		
					56								
					27	2	2	100.0	100.0	1	1		
2MD		Imipramine	30/03/93	30/03/93	1	2	1	100.0	100.0	1			
			31/03/93	31/03/93	1	2	1	50.0	98.3	1		3e	6e
					29								
2DT		Imipramine	03/03/93	21/03/93	19	2	2	100.0	100.0	1	1		
			22/03/93	22/03/93	1	2	1	50.0	97.5	1		10e	
			23/03/93	27/04/93	36	2	2	100.0	99.1	1	1		
					56								
3MD		Imipramine	30/03/93	05/04/93	7	2	2	100.0	100.0	1	1		
					7								
					57	2	2	100.0	100.0	1	1		
4MD		Reboxetine	20/04/93	04/05/93	15	2	2	100.0	100.0	1	1		
			05/05/93	06/05/93	2	2	1	100.0	100.0	1		3m	
			07/05/93	12/05/93	6	2	2	100.0	100.0	1	1		

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
n = morning, e = evening

9550089

23

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. Cps	Z Cumul. compl. day	Z Cumul. compl. Cps	Morning Cps	Evening Cps	Reason (x)	Overdose (xx)
35	4HD	Reboxetine	13/05/93	13/05/93	1	2	1	100.0	100.0	1	1	3e	
			14/05/93	14/06/93	32	2	2	100.0	100.0	1	1		
					56								
4DT	Reboxetine	27/04/93	23/05/93	27	2	2	100.0	100.0	1	1			
		24/05/93	25/05/93	2	2	4	100.0	100.0	2	2			
		25/05/93	21/06/93	27	2	2	100.0	100.0	1	1			
		56										(3 - m) (3 - e)	
5ND	Reboxetine	09/07/93	02/09/93	56	2	2	100.0	100.0	1	1			
		56											
5DT	Imipramine	02/09/93	27/10/93	56	2	2	100.0	100.0	1	1			
		56											
6ND	Reboxetine	21/01/94	01/03/94	40	2	2	100.0	100.0	1	1		6e	
		02/03/94	02/03/94	1	2	1	50.0	98.8	1	1			
		41											
6DT	Imipramine	20/10/93	14/12/93	56	2	2	100.0	100.0	1	1			
		56											
7ND	Imipramine	10/12/93	17/01/94	39	2	2	100.0	100.0	1	1			
		39											
7DT	Reboxetine	20/10/93	16/11/93	28	2	2	100.0	100.0	1	1			
		28											
8ND	Imipramine	01/02/94	19/03/94	47	2	2	100.0	100.0	1	1			
		20/03/94	20/03/94	1	2	1	50.0	99.0	1	1		4e	
		21/03/94	21/03/94	1	2	2	100.0	99.0	1	1			
		49											
8DT	Reboxetine	11/01/94	07/03/94	56	2	2	100.0	100.0	1	1			

(x) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(xx) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

1220

9550089

24

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PIARRACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. Cps	Z Cumpl. day	Z Cumpl. cumulat.	Morning Cps	Evening Cps	Reason (*)	Overdose (**)
36	1MD	Imipramine	16/01/93	07/03/93	56	2	2	100.0	100.0	1	1		
			08/03/93	08/03/93	1	2	1	50.0	99.0	1		6e	
1DT	Imipramine		03/02/93	30/03/93	56	2	2	100.0	100.0	1	1		
			03/02/93	05/02/93	56	2	2	100.0	100.0	1	1		
2HD	Reboxetine		06/02/93	06/02/93	3	2	2	100.0	100.0	1	1		
			07/02/93	07/02/93	1	2	1	50.0	87.5	1	1	2m	
			08/02/93	29/03/93	50	2	2	100.0	98.2	1	1	2e	
			30/03/93	30/03/93	1	2	1	50.0	97.3	1	1	10m	
			25/02/93	16/03/93	56	2	2	100.0	100.0	1	1		
2DT	Reboxetine		17/03/93	17/03/93	20	2	2	100.0	100.0	1	1		
			18/03/93	31/03/93	14	2	2	100.0	98.6	1	1	1m	
3HD	Imipramine		01/04/93	01/04/93	1	2	2	100.0	100.0	1	1		
			02/04/93	07/04/93	6	2	2	100.0	97.6	1	1	1e	
			08/04/93	08/04/93	1	2	3	50.0	96.5	2	2		
			09/04/93	22/04/93	14	2	2	100.0	97.4	1	1		(B - m)
			06/02/93	02/04/93	56	2	2	100.0	100.0	1	1		
3DT	Imipramine		02/03/93	19/04/93	49	2	2	100.0	100.0	1	1		
			20/04/93	20/04/93	1	2	3	50.0	99.0	1	2		
4HD	Reboxetine		21/04/93	27/04/93	7	2	2	100.0	99.1	1	1		
			09/03/93	01/05/93	54	2	2	100.0	100.0	1	1		

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
m = morning, e = evening

1221

9550089

25

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	Z Compl. day	Z Compl. cumulat.	Morning Cps	Evening Cps	Reason (*)	Overdose (**)
36	4DT	Reboxetine	12/03/93	06/05/93	54	2	2	100.0	100.0	1	1		
					56	2	2	100.0	100.0	1	1		
5MD	Reboxetine	24/04/93	18/06/93	56	2	2	100.0	100.0	100.0	1	1		
				56	2	2	100.0	100.0	100.0	100.0	1	1	
5DT	Imipramine	03/04/93	07/04/93	5	2	2	100.0	100.0	100.0	1	1		
				5	2	2	100.0	100.0	100.0	100.0	1	1	
6MD	Imipramine	01/05/93	25/06/93	56	2	2	100.0	100.0	100.0	1	1		
				56	2	2	100.0	100.0	100.0	100.0	1	1	
6DT	Imipramine	10/04/93	04/06/93	56	2	2	100.0	100.0	100.0	1	1		
				56	2	2	100.0	100.0	100.0	100.0	1	1	
7MD	Reboxetine	13/05/93	21/06/93	40	2	2	100.0	100.0	100.0	1	1		
				1	2	2	0.0	97.6	1	2	1m	(D - e)	
				15	2	2	100.0	98.2	1	1			
7DT	Reboxetine	01/05/93	02/05/93	2	2	2	100.0	100.0	100.0	1	1		
				1	2	1	50.0	83.3	1	1	10e	(B - m)	
				1	2	3	50.0	75.0	2	1			
8MD	Imipramine	26/05/93	26/05/93	56	2	2	100.0	100.0	100.0	1	1		
				1	2	4	0.0	0.0	2	2	(B - m) (B - e)		
				2	2	2	100.0	66.7	1	1	(B - m) (B - e)		
				1	2	4	0.0	50.0	2	2			
				5	2	2	100.0	77.8	1	1			
				1	2	1	50.0	75.0	1	1	1m		
				2	2	2	100.0	78.2	1	1			
1	2	1	50.0	76.9	1	1e							

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, C=high daily dose in one administration, D=low daily dose in one administration, m = morning, e = evening

9550089

26

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. Cps	% Compl. day	% Cumulat.	Morning Cps	Evening Cps	Reason (*)	Overdose (**)	
36	8ND	Imipramine	08/06/93	20/07/93	43	2	2	100.0	94.6	1	1			
					56									
80T	Reboxetine	15/05/93	17/05/93	24/05/93	3	2	2	100.0	100.0	1	1			
					7	2	2	100.0	30.0			4m	4e	
					53	2	2	100.0	88.9	1	1			
					63									
9ND	Reboxetine	16/06/93	10/08/93	56	2	2	100.0	100.0	1	1				
				56										
90T	Imipramine	29/06/93	11/07/93	12/07/93	13	2	2	100.0	100.0	1	1			
					1	2	1	50.0	95.4			1m		
					37	2	2	100.0	99.0	1	1			
					1	2	1	100.0	99.0			3e		
					4	2	2	100.0	99.1			3m	3e	
					56									
10ND	Reboxetine	22/06/93	09/07/93	10/07/93	18	2	2	100.0	100.0	1	1			
					1	2	1	50.0	97.4			1m		
					1	2	1	50.0	95.0			1e		
					3	2	2	100.0	95.7	1	1			
					1	2	1	50.0	93.8			1e		
					31	2	2	100.0	92.0	1	1			1m
10NT	Reboxetine	26/10/93	19/12/93	20/12/93	55	2	2	100.0	100.0	1	1			
					1	2	1	50.0	99.1	1	1		1e	
11ND	Imipramine	09/07/93	02/09/93	56	2	2	100.0	100.0	1	1				
				56										
11DT	Reboxetine	10/11/93	19/11/93	20/11/93	10	2	2	100.0	100.0	1	1			
					1	2	1	100.0	100.0	1	1		3e	

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
 n = morning, e = evening

9550089

27

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. Cps	Z Cumul. compliat. Cps	Morning Cps	Evening Cps	Reason (*)	Overdose (**)	
36	11DT	Reboxetine	21/11/93	21/11/93	1	2	1	100.0	100.0	1		3m	
			22/11/93	22/11/93	1	2	2	100.0	100.0	1	1	3m 3e	
			23/11/93	19/12/93	26	2	2	100.0	100.0	1	1		6e
			19/12/93	19/12/93	1	2	1	50.0	98.8	1			
					40								
12ND		Imipramine	24/09/93	05/10/93	12	2	2	100.0	100.0	1			
					12								
12DT		Imipramine	22/12/93	15/02/94	56	2	2	100.0	100.0	1			
					56								
13ND	Reboxetine	21/09/93	06/10/93	16	2	2	100.0	100.0	1	1			
		07/10/93	07/10/93	1	2	1	50.0	97.1	1	1	1e		
		08/10/93	09/10/93	2	2	2	100.0	97.4	1	1			
		10/10/93	10/10/93	1	2	1	50.0	95.0	1	1	1e		
		11/10/93	14/10/93	4	2	2	100.0	95.8	1	1			
					24								
14ND	Imipramine	03/11/93	07/11/93	5	2	2	100.0	100.0	1	1			
		08/11/93	08/11/93	1	2	1	50.0	94.7	1	1	1m		
		09/11/93	28/12/93	50	2	2	100.0	99.1	1	1			
					56								
15ND		Reboxetine	23/10/93	08/11/93	17	2	2	100.0	100.0	1			
			09/11/93	09/11/93	1	2	1	50.0	97.2	1		6e	
					18								
16ND		Imipramine	09/11/93	03/01/94	56	2	2	100.0	100.0	1			
					56								
17ND		Reboxetine	10/11/93	11/11/93	2	2	2	100.0	100.0	1			
					2								
18ND		Imipramine	13/01/94	09/03/94	56	2	2	100.0	100.0	1			

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
n = morning, e = evening

1224

9550089

23

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. Cps	% Compl. day	Cumulat. Cps	% Compl. cumulat.	Morning Cps	Evening Cps	Reason (#)	Overdose (**)	
36	19ND	Reboxetine	15/01/94	22/01/94	8	2	2	100.0	100.0	100.0	1	1			
					8										
					56	2	2	100.0	100.0	1	1				
37	3ND	Reboxetine	18/03/93	19/03/93	2	2	2	100.0	100.0	100.0	1	1			
					1	2	1	50.0	83.3	1	1	4a			
					4	2	2	100.0	92.9	1	1				
					7										
41	1ND	Imipramine	22/02/94	22/02/94	1	2	1	100.0	100.0	100.0	0	1	9m		
					1	2	2	100.0	100.0	1	1				
					3	2	1	50.0	83.3	1	1	6a			
122	2ND	Reboxetine	23/02/94	19/04/94	56	2	2	100.0	100.0	100.0	1	1			
					56										
25	3ND	Imipramine	25/02/94	21/04/94	56	2	2	100.0	100.0	100.0	1	1			
					56										
51	4ND	Reboxetine	28/02/94	24/04/94	56	2	2	100.0	100.0	100.0	1	1			
					56										
42	5ND	Reboxetine	03/03/94	27/04/94	56	2	2	100.0	100.0	100.0	1	1			
					56										
42	1ND	Imipramine	26/10/93	20/12/93	56	2	2	100.0	100.0	100.0	1	1			
					56										

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 9=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
 n = morning, e = evening

9550089

29

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	Z Compl. day	Z Compl. cumulat.	Morning Cps	Evening Cps	Reason (*)	Overdose (**)																					
42	1DT	Imipramine	25/11/93	19/01/94	56	2	2	100.0	100.0	1	1																							
														56																				
														2ND	Reboxetine	26/10/93	16/11/93	22	2	2	100.0	100.0	1	1	3e 3m 3o 3m									
																											17/11/93	17/11/93	1	1	100.0	100.0	1	1
																											18/11/93	23/11/93	6	2	100.0	100.0	1	1
24/11/93	24/11/93	1	2	100.0	100.0	1	1																											
25/11/93	20/12/93	26	2	100.0	100.0	1	1																											
2DT	Reboxetine	09/12/93	09/12/93	1	2	2	100.0	100.0	1	1	1	6e																						
														10/12/93	10/12/93	1	2	50.0	75.0	1	1													
														3ND	Imipramine	25/11/93	19/01/94	56	2	2	100.0	100.0	1	1										
																											2							
																											56							
43	1DT	Reboxetine	19/02/93	19/02/93	1	2	1	100.0	100.0	0	1	9m																						
														20/02/93	01/04/93	41	2	100.0	100.0	1	1													
														02/04/93	02/04/93	1	2	50.0	98.8	1	1													
														2DT	Imipramine	11/05/93	11/05/93	1	2	1	100.0	100.0	0	1	9m									
																											12/05/93	31/05/93	20	2	100.0	100.0	1	1
01/06/93	01/06/93	1	2	50.0	97.7	1	1																											
3DT	Imipramine	15/09/93	15/09/93	1	2	1	100.0	100.0	0	1	1	9m																						
														16/09/93	30/09/93	15	2	100.0	100.0	1	1													
														01/10/93	01/10/93	1	2	100.0	100.0	1	1													
														02/10/93	10/11/93	40	2	100.0	100.0	1	1													
														57																				
4DT	Reboxetine	23/09/93	23/09/93	1	2	1	100.0	100.0	0	1	1	9m																						
														24/09/93	15/10/93	22	2	100.0	100.0	1	1													
														16/10/93	16/10/93	1	2	50.0	97.9	1	1													
														1e																				
															57																			

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
n = morning, o = evening

9550089

30

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. day	Z Cumpl. cumulat.	Morning Cps	Evening Cps	Reason (x)	Overdose (xx)			
43	40F	Reboxetine	17/10/93	21/10/93	5	2	2	100.0	98.3	1	1				
			22/10/93	22/10/93	1	2	1	50.0	-96.7	1		1e			
			23/10/93	06/11/93	15	2	2	100.0	97.8	1	1				
			07/11/93	07/11/93	1	2	1	50.0	96.7	1		1m			
			08/11/93	17/11/93	10	2	2	100.0	97.3	1	1				
			18/11/93	18/11/93	1	2	1	100.0	97.4	1	0		9e		
								57							
								57							
								57							
								57							
44	50D	Isipramine	10/12/93	10/12/93	1	2	1	100.0	100.0	0	1	9m			
			11/12/93	11/01/94	32	2	2	100.0	100.0	1	1				
			12/01/94	12/01/94	1	2	1	50.0	98.5	1		6e			
								34							
								34							
								34							
								34							
								34							
								34							
								34							
44	60D	Isipramine	16/02/94	16/03/94	29	2	2	100.0	100.0	1	1				
			17/03/94	17/03/94	1	2	3	0.0	96.7	1	2	9m	yes		
			18/03/94	14/04/94	28	2	2	100.0	95.3	1	1				
								58							
								58							
								58							
								58							
								58							
								58							
								58							
44	10D	Reboxetine	03/09/93	28/10/93	56	2	2	100.0	100.0	1	1				
								56							
								56							
								56							
								56							
								56							
								56							
								56							
								56							
								56							
44	10T	Reboxetine	31/07/93	24/09/93	56	2	2	100.0	100.0	1	1				
								56							
								56							
								56							
								56							
								56							
								56							
								56							
								56							
								56							
44	20D	Reboxetine	20/09/93	20/09/93	1	2	1	100.0	100.0	0	1	9m			
			21/09/93	14/11/93	55	2	2	100.0	100.0	1	1				
			15/11/93	15/11/93	1	2	1	100.0	100.0	1	0		9e		
								57							
								57							
								57							
								57							
								57							
								57							
								57							
44	30D	Isipramine	14/10/93	14/10/93	1	2	1	100.0	100.0	0	1	9m			
			15/10/93	08/12/93	55	2	2	100.0	100.0	1	1				
			09/12/93	09/12/93	1	2	1	100.0	100.0	1	0		9e		
								57							
								57							
								57							
								57							
								57							
								57							
								57							
44	40D	Isipramine	31/01/94	31/01/94	1	2	1	100.0	100.0	0	1	9m			
			01/02/94	13/02/94	13	2	2	100.0	100.0	1	1				

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
 m = morning, e = evening

9550089

31

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	Compl. day	Cumulat. compliat.	Morning Cps	Evening Cps	Reason (#)	Overdose (xx)		
44	4ND	Imipramine	14/02/94	14/02/94	1	2	1	50.0	96.7	1	1	10a			
			15/02/94	09/03/94	23	2	2	100.0	98.7	1	1				
			10/03/94	10/03/94	1	2	1	50.0	97.4	1	1	1e			
45	1ND	Reboxetine	11/03/94	28/03/94	18	2	2	100.0	98.2	1	1				
			57												
			25/11/93	25/11/93	1	2	1	100.0	100.0	0	1	1	9m		
46	1ND	Imipramine	02/11/94	01/01/94	37	2	2	100.0	100.0	1	1				
			02/11/94	02/01/94	1	2	1	50.0	98.7	1	1	1e			
			03/01/94	19/01/94	17	2	2	100.0	99.1	1	1				
			20/01/94	20/01/94	1	2	1	100.0	99.1	1	0		9e		
			57												
46	1ND	Imipramine	12/08/93	06/10/93	56	2	2	100.0	100.0	1	1				
			56												
			07/12/93	15/12/93	9	2	2	100.0	100.0	1	1				
46	2ND	Imipramine	16/12/93	16/12/93	1	2	1	50.0	95.0	1	1	10a			
			17/12/93	20/12/93	4	2	0	0.0	67.9	1	1	10m 10b			
			21/12/93	26/12/93	6	2	2	100.0	77.5	1	1				
			20												
46	1ND	Imipramine	28/09/93	28/09/93	1	2	1	100.0	100.0	0	1	9m			
			29/09/93	22/11/93	55	2	2	100.0	100.0	1	1				
			23/11/93	23/11/93	1	2	1	100.0	100.0	1	0		9e		
46	2ND	Imipramine	19/10/93	19/10/93	1	2	2	100.0	100.0	1	1				
			20/10/93	20/10/93	1	2	2	100.0	100.0	1	1	3m 3e			
			21/10/93	07/11/93	18	2	2	100.0	100.0	1	1				
46	3ND	Reboxetine	08/11/93	08/11/93	1	2	1	50.0	97.6	1	1	6e			
			21												
			02/12/93	02/12/93	1	2	1	100.0	100.0	0	1	9m			
46	3ND	Reboxetine	03/12/93	26/01/94	55	2	2	100.0	100.0	1	1				
			27/01/94	27/01/94	1	2	1	100.0	100.0	1	0		9e		
			21												

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 9=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
 m = morning, e = evening

9550089

32

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RSD
REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. Cps	X Compl. day	Z Compl. cumulat.	Morning Cps	Evening Cps	Reason (*)	Overdose (**)
					57								
46	4MD	Reboxetine	08/12/93	10/12/93	3	2	2	100.0	100.0	1	1		
			11/12/93	11/12/93	1	2	1	50.0	87.5	1		6e	
					4								
48	1DT	Reboxetine	24/06/93	24/06/93	1	2	1	50.0	50.0	1		6e	
					1								
2DT		Imipramine	28/06/93	03/07/93	6	2	2	100.0	100.0	1	1		
			04/07/93	04/07/93	1	2	1	50.0	92.9	1		1m	
			05/07/93	03/08/93	30	2	2	100.0	98.6	1	1		
			04/08/93	04/08/93	1	2	1	50.0	97.4	1		6e	
					38								
291	1MD	Imipramine	22/03/93	17/04/93	27	2	2	100.0	100.0	1	1		
			18/04/93	18/04/93	1	2	1	50.0	98.2	1		10e	
			19/04/93	25/04/93	7	2	1	100.0	98.6		1	3n	
					35								
1229	1DT	Reboxetine	22/04/93	27/04/93	6	2	2	100.0	100.0	1	1		
			28/04/93	28/04/93	1	2	1	50.0	92.9	1		4e	
			29/04/93	16/06/93	49	2	2	100.0	99.1	1	1		
					56								
2MD		Reboxetine	20/04/93	14/06/93	56	2	2	100.0	100.0	1	1		
					56								
2DT		Reboxetine	22/04/93	16/05/93	25	2	2	100.0	100.0	1	1		
			17/05/93	17/05/93	1	2	1	50.0	98.1	1		4e	
			18/05/93	24/05/93	7	2	2	100.0	98.5	1	1		
			25/05/93	26/05/93	2	2	2	0.0	92.9			10m 10e	
			27/05/93	16/06/93	21	2	2	100.0	95.5	1	1		
					56								

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/ond treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

9550089

33

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Z Daily Cps	Z Cumpl. day	Z Cumpl. cumulat.	Morning Cps	Evening Cps	Reason (*)	Overdose (**)		
291	3ND	Imipramine	15/04/93	07/05/93	19	2	2	100.0	100.0	1	1				
			08/05/93	08/05/93	1	2	3	50.0	97.5	2	1		(B - m)		
			09/05/93	20/05/93	12	2	2	100.0	98.4	1	1				
			21/05/93	21/05/93	1	2	3	50.0	97.0	2	1		(B - m)		
			22/05/93	22/05/93	1	2	2	100.0	97.1	1	1				
			23/05/93	23/05/93	1	2	3	50.0	95.7	1	2		(B - e)		
			24/05/93	13/06/93	21	2	2	100.0	97.3	1	1				
								56							
			30T	Imipramine	14/05/93	20/05/93	7	2	2	100.0	100.0	1	1		
										7					
4ND	Reboxetine	03/05/93	28/06/93	57	2	2	100.0	100.0	1	1					
							57								
4DT	Imipramine	05/05/93	07/06/93	34	2	2	100.0	100.0	1	1					
		08/05/93	08/06/93	1	2	1	50.0	98.6	1	1		1e			
		09/05/93	19/06/93	11	2	2	100.0	98.9	1	1					
		20/06/93	20/06/93	1	2	1	50.0	97.9	1	1		1e			
		21/06/93	23/06/93	9	2	2	100.0	98.2	1	1					
							56								
25DT	Imipramine	04/11/93	30/12/93	57	2	2	100.0	100.0	1	1					
							57								
26DT	Reboxetine	09/06/93	03/08/93	56	2	2	100.0	100.0	1	1					
							56								
27DT	Reboxetine	04/11/93	30/12/93	57	2	2	100.0	100.0	1	1					
							57								
28DT	Imipramine	18/11/93	17/01/94	61	2	2	100.0	100.0	1	1					
							61								
292	5ND	Imipramine	03/03/93	20/03/93	18	2	2	100.0	100.0	1	1				
								61							

1230

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

9550089

34

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R3D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	Compl. day	Compl. cumulat.	Morning Cps	Evening Cps	Reason (*)	Overdose (**)			
292	5HD	Imipramine	21/03/93	21/03/93	1	2	1	50.0	97.4	1	1	1m				
			22/03/93	24/03/93	3	2	2	100.0	97.7	1	1					
			25/03/93	25/03/93	1	2	1	50.0	95.7	1	1	1e				
			26/03/93	05/04/93	11	2	2	100.0	97.1	1	1					
			06/04/93	06/04/93	1	2	1	50.0	95.7	1	1	1e				
			07/04/93	15/04/93	9	2	2	100.0	96.6	1	1					
			16/04/93	16/04/93	1	2	1	50.0	95.6	1	1	1e				
			17/04/93	27/04/93	11	2	2	100.0	96.4	1	1					
								56								
			50T	Reboxetine	06/03/93	14/03/93	9	2	2	100.0	100.0	100.0	1	1	1e	
15/03/93	15/03/93	1			2	1	50.0	95.0	1	1						
16/03/93	27/03/93	12			2	2	100.0	97.7	1	1						
28/03/93	28/03/93	1			2	1	50.0	95.7	1	1	1e					
29/03/93	18/04/93	21			2	2	100.0	97.7	1	1						
19/04/93	19/04/93	1			2	1	50.0	96.7	1	1	1e					
20/04/93	29/04/93	10			2	2	100.0	97.3	1	1						
					55											
60D	Reboxetine	04/03/93			05/03/93	2	2	2	100.0	100.0	100.0	1	1	1e		
		06/03/93			06/03/93	1	2	1	50.0	83.3	1	1				
		07/03/93	28/03/93	22	2	2	100.0	98.0	1	1						
		29/03/93	29/03/93	1	2	1	50.0	96.2	1	1	1m					
		30/03/93	10/04/93	12	2	2	100.0	97.4	1	1						
		11/04/93	11/04/93	1	2	1	50.0	96.2	1	1	1m					
		12/04/93	22/04/93	11	2	2	100.0	97.0	1	1						
		23/04/93	23/04/93	1	2	1	50.0	96.1	1	1	1e					
		24/04/93	28/04/93	5	2	2	100.0	96.4	1	1						
							56									
60T	Imipramine	16/03/93	23/03/93	8	2	2	100.0	100.0	100.0	1	1	1e				
		24/03/93	24/03/93	1	2	1	50.0	94.4	1	1						
		25/03/93	06/05/93	43	2	2	100.0	99.0	1	1						
		07/05/93	07/05/93	1	2	1	50.0	98.1	1	1	1e					
		08/05/93	10/05/93	3	2	2	100.0	98.2	1	1						
					56											
70D	Reboxetine	21/04/93	22/05/93	32	2	2	100.0	100.0	100.0	1	1	1m				
		23/05/93	23/05/93	1	2	1	50.0	98.5	1	1						

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

1231

9550089

35

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. Cps	Compl. day	Z	Compl. cumulat.	Morning Cps	Evening Cps	Reason (*)	Overdose (**)
292	7ND	Reboxetine	24/05/93	15/06/93	23	2	2	100.0	99.1	1	1	1		
			56											
7DT	Imipramine	19/03/93	27/03/93	9	2	2	100.0	100.0		1	1	1		
		28/03/93	28/03/93	1	2	1	50.0	95.0		1m				
		29/03/93	12/04/93	15	2	2	100.0	98.0		1m				
		13/04/93	13/04/93	1	2	1	50.0	96.2		1e				
		14/04/93	17/04/93	4	2	2	100.0	96.7		1e				
		18/04/93	18/04/93	1	2	1	50.0	95.2						
25			19/04/93	13/05/93	25	2	2	100.0	97.3	1	1	1		
			56											
8ND	Imipramine	23/04/93	17/06/93	56	2	2	100.0	100.0		1	1	1		
		56												
8DT	Reboxetine	09/04/93	09/04/93	1	2	2	100.0	100.0		1	1	1		
		10/04/93	10/04/93	1	2	1	50.0	75.0		1e				
		11/04/93	03/06/93	54	2	2	100.0	99.1						
		56												
21ND	Imipramine	08/05/93	18/05/93	11	2	2	100.0	100.0		1	1	1		
		19/05/93	19/05/93	1	2	1	50.0	95.8		1e				
		20/05/93	19/06/93	31	2	2	100.0	98.8		1m				
		20/06/93	20/06/93	1	2	1	50.0	97.7		1m				
		21/06/93	02/07/93	12	2	2	100.0	98.2						
		56												
21DT	Reboxetine	04/05/93	13/05/93	10	2	2	100.0	100.0		1	1	1		
		14/05/93	14/05/93	1	2	1	50.0	95.5		1e				
		15/05/93	29/05/93	15	2	2	100.0	98.1		1m				
		30/05/93	30/05/93	1	2	1	50.0	96.3		1m				
		31/05/93	24/06/93	25	2	2	100.0	98.1		1e				
		25/06/93	25/06/93	1	2	1	50.0	97.2		1e				
		26/06/93	28/06/93	3	2	2	100.0	97.3						
		56												
22ND	Imipramine	20/05/93	04/06/93	16	2	2	100.0	100.0		1	1	1		

1232

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
n = morning, e = evening

9550089

37

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	Compl. day	Compl. cumulat.	Morning Cps	Evening Cps	Reason (*)	Overdose (**)			
293	9ND	Imipramine	18/02/93	10/04/93	56	2	2	100.0	100.0	1	1	1m 1e				
				11/04/93	1	2	0.0	98.1								
				12/04/93	3	2	100.0	98.2	1	1						
				56												
				26/05/93	8	2	100.0	100.0	1	1						
				03/06/93	1	2	0.0	88.9							1m 1e	
				04/06/93	7	2	100.0	93.8	1	1						
				11/06/93	1	2	0.0	88.2							1m 1e	
				12/06/93	14	2	100.0	93.5	1	1						
				26/06/93	1	2	50.0	92.2							1m	
9DT	Imipramine	26/05/93	01/07/93	56	2	2	100.0	93.2	1	1						
			02/07/93	1	2	0.0	90.8									
			03/07/93	6	2	100.0	92.4	1	1							
			11/07/93	1	2	50.0	91.5							1m		
			12/07/93	3	2	100.0	92.0	1	1							
			15/07/93	1	2	50.0	91.2							1m		
			16/07/93	1	2	0.0	89.4							1m 1e		
			17/07/93	4	2	100.0	90.2	1	1							
			56													
			23/03/93	19	2	100.0	100.0	1	1							
10MD	Reboxetine	11/04/93	10/04/93	1	2	1	50.0	97.5	1	1						
			11/04/93	6	2	100.0	98.1	1	1							
			12/04/93	1	2	50.0	96.3							1e		
			18/04/93	17	2	100.0	97.7	1	1							
			19/04/93	1	2	0.0	95.6							1m 1e		
			06/05/93	6	2	100.0	96.1	1	1							
			07/05/93	1	2	50.0	95.2									
			13/05/93	1	2	0.0	93.4							1m		
			14/05/93	3	2	100.0	93.8	1	1							
			56													
10DT	Imipramine	20/07/93	04/08/93	18	2	2	100.0	100.0	1	1						
			07/08/93	4	2	0.0	94.7									
			08/08/93	4	2	100.0	95.7	1	1							
			12/08/93	1	2	50.0	93.8	1	1							

1234

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
 n = morning, e = evening

9550089

38

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. %	Cumul. %	Morning Cps	Evening Cps	Reason (x)	Overdose (xx)			
293	10DT	Inipramine	13/08/93	13/08/93	1	2	1	50.0	92.0	1	1	1m			
			14/08/93	25/08/93	12	2	2	100.0	94.6	1	1				
			26/08/93	26/08/93	1	2	2	0.0	92.1			1m	1e		
			27/08/93	31/08/93	5	2	2	100.0	93.0	1	1				
			01/09/93	01/09/93	1	2	1	50.0	92.0			1m			
			02/09/93	07/09/93	6	2	2	100.0	93.0	1	1				
			08/09/93	08/09/93	1	2	1	50.0	92.2			1m			
			09/09/93	09/09/93	1	2	2	100.0	92.3	1	1				
			16/09/93	10/09/93	1	2	1	50.0	91.5			1e			
			11/09/93	13/09/93	3	2	2	100.0	92.0	1	1				
								56							
			118D	Inipramine	12/07/93	04/08/93	24	2	2	100.0	100.0	1	1		
					05/08/93	05/08/93	24	2	1	50.0	98.0			1m	
					06/08/93	12/08/93	7	2	2	100.0	98.4	1	1		
13/08/93	13/08/93	1			2	1	50.0	97.0			1e				
14/08/93	19/08/93	6			2	2	100.0	97.4	1	1					
20/08/93	20/08/93	1			2	1	50.0	96.3			1m				
21/08/93	31/08/93	11			2	2	100.0	97.1	1	1					
01/09/93	01/09/93	1			2	1	50.0	96.2			1m				
02/09/93	02/09/93	1			2	1	50.0	95.3			1e				
03/09/93	05/09/93	3			2	2	100.0	95.5	1	1					
					56										
11DT	Reboxetine	18/11/93			27/11/93	10	2	2	100.0	100.0	1	1			
		28/11/93			28/11/93	1	2	2	0.0	90.9			1m	1e	
		29/11/93			01/12/93	3	2	2	100.0	92.9	1	1			
					14										
128D	Reboxetine	16/09/93	08/10/93	23	2	2	100.0	100.0	1	1					
		09/10/93	09/10/93	1	2	1	50.0	97.9			1e				
		10/10/93	10/10/93	1	2	1	50.0	96.0			1m				
		11/10/93	21/10/93	11	2	2	100.0	97.2	1	1					
		22/10/93	22/10/93	1	2	1	50.0	95.9			1e				
		23/10/93	23/10/93	1	2	1	50.0	94.7			1m				
		24/10/93	27/10/93	4	2	2	100.0	95.2	1	1					
							42								
		12DT	Reboxetine	13/12/93	05/01/94	24	2	2	100.0	100.0	1	1			

1235

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
 m = morning, e = evening

9550089

39

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. Cps	% Compl. day	Morning Cps	Evening Cps	Reason (*)	Overdose (**)			
293	12DT	Reboxetine	06/01/94	06/01/94	1	2	1	50.0	98.0	1	1e				
			07/01/94	17/01/94	11	2	2	100.0	98.6	1	1				
			18/01/94	18/01/94	1	2	1	50.0	97.3	1	1	1m			
			19/01/94	24/01/94	6	2	2	100.0	97.7	1	1	1m			
			25/01/94	25/01/94	1	2	1	50.0	96.6	1	1				
			26/01/94	06/02/94	12	2	2	100.0	97.3	1	1				
					56										
			294	13ND	Imipramine	15/02/93	18/02/93	4	2	2	100.0	100.0	1	1	
						19/02/93	21/02/93	3	2	1	50.0	78.6	1	1	1e
						22/02/93	12/04/93	50	2	2	100.0	97.4	1	1	
								57							
			13DT	Reboxetine	08/03/93	03/05/93	57	2	2	100.0	100.0	1	1		
		57													
14ND	Reboxetine	15/02/93	12/04/93	57	2	2	100.0	100.0	1	1					
				57											
14DT	Imipramine	08/03/93	03/05/93	57	2	2	100.0	100.0	1	1					
				57											
15ND	Imipramine	22/02/93	19/04/93	57	2	2	100.0	100.0	1	1					
				57											
15DT	Imipramine	09/03/93	03/05/93	56	2	2	100.0	100.0	1	1					
				56											
16ND	Reboxetine	23/02/93	19/04/93	56	2	2	100.0	100.0	1	1					
				56											
16DT	Reboxetine	09/03/93	03/05/93	56	2	2	100.0	100.0	1	1					
				56											

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

9550089

40

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Evening Cps	Reason (*)	Overdose (**)
294	25ND	Imipramine	14/06/93	08/08/93	56	2	2	100.0	100.0	1	1		
					56								
	26ND	Imipramine	14/06/93	08/08/93	56	2	2	100.0	100.0	1	1		
					56								
	27ND	Reboxetine	15/06/93	02/08/93	49	2	2	100.0	100.0	1	1		
					8	2	0.0	86.0					
					57								
	28ND	Reboxetine	15/06/93	09/08/93	56	2	2	100.0	100.0	1	1		
					56								
	29DT	Reboxetine	14/06/93	08/08/93	56	2	2	100.0	100.0	1	1		
56													
30DT	Reboxetine	14/06/93	08/08/93	56	2	2	100.0	100.0	1	1			
				56									
31DT	Imipramine	21/06/93	15/08/93	56	2	2	100.0	100.0	1	1			
				56									
32DT	Imipramine	21/06/93	15/08/93	56	2	2	100.0	100.0	1	1			
				56									
295	17ND	Reboxetine	21/04/93	15/06/93	56	2	2	100.0	100.0	1	1		
					56								
	17DT	Imipramine	27/04/93	23/06/93	58	2	2	100.0	100.0	1	1		
					58								
	18ND	Reboxetine	23/04/93	17/06/93	56	2	2	100.0	100.0	1	1		
					56								

1237

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

9550089

41

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Evening Cps	Reason (*)	Overdose (**)				
295	18DT	Imipramine	29/04/93	23/06/93	56	2	2	100.0	100.0	1	1						
19ND	Imipramine	14/05/93	08/07/93	56	2	2	100.0	100.0	100.0	1	1						
19DT	Reboxetine	10/05/93	04/07/93	56	2	2	100.0	100.0	100.0	1	1						
20ND	Imipramine	14/05/93	08/07/93	56	2	2	100.0	100.0	100.0	1	1						
20DT	Reboxetine	12/05/93	06/07/93	56	2	2	100.0	100.0	100.0	1	1						
381	1ND	Reboxetine	10/12/93	22/12/93	13	2	2	100.0	100.0	1	1						
381	2ND	Reboxetine	02/02/94	06/03/94	33	2	2	100.0	100.0	1	1						
381	3DT	Reboxetine	08/02/94	26/02/94	19	2	2	100.0	100.0	1	1						
4ND	Imipramine	01/03/94	14/03/94	14	2	2	100.0	100.0	100.0	1	1						

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, A=double high dose, B=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
m = morning, e = evening

9550089

42

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. Cps	% Compl. day	% Compl. cumulat.	Morning Cps	Evening Cps	Reason (#)	Overdose (xx)
382	SMD	Imipramine	15/11/93	15/11/93	14	2	1	100.0	100.0	0	1	9m	
			16/11/93	18/12/93	33	2	2	100.0	100.0	1	1		
			19/12/93	19/12/93	1	2	100.0	100.0					5m 5e
			20/12/93	12/01/94	24	2	2	100.0	100.0	1	1		
5DT	Reboxetine	21/10/93	04/11/93	15	2	2	100.0	100.0	1	1			
		05/11/93	12/11/93	8	2	0.0	65.2						
6ND	Reboxetine	12/11/93	12/11/93	23	2	1	100.0	100.0	0	1	9m		
		13/11/93	06/01/94	55	2	2	100.0	100.0	1	1			
		07/01/94	07/01/94	1	2	1	100.0	100.0	1	0	9e		
				57									
6DT	Imipramine	22/10/93	17/12/93	57	2	2	100.0	100.0	1	1			
				57									
7RD	Reboxetine	20/12/93	07/02/94	50	2	2	100.0	100.0	1	1			
				50									
7DT	Imipramine	22/10/93	25/10/93	4	2	2	100.0	100.0	1	1			
		26/10/93	26/10/93	1	2	1	50.0	90.0	1	1	6e		
8MD	Imipramine	26/01/94	26/01/94	5	2	1	100.0	100.0	0	1	9m		
		27/01/94	06/02/94	11	2	2	100.0	100.0	1	1			
		07/02/94	09/02/94	3	2	100.0	100.0					5m 5e	
		10/02/94	11/02/94	2	2	2	100.0	100.0	1	1			
8DT	Reboxetine	22/12/93	22/12/93	17	1	1	100.0	100.0	0	1	9m		
		23/12/93	26/12/93	4	2	2	100.0	100.0	1	1			

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, C=high daily dose in one administration, D=low daily dose in one administration
 n = morning, o = evening

9550089

43

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Cps	Compl. day	Compl. cumulat.	Morning Cps	Evening Cps	Reason (*)	Overdose (**)		
382	8DT	Reboxetine	27/12/93	28/12/93	2	2	1	100.0	100.0	1	1	3m			
			29/12/93	15/02/94	49	2	2	100.0	100.0	1	1				
			56												
			11/02/94	08/04/94	57	2	2	100.0	100.0	1	1				
			57												
			08/02/94	08/02/94	1	2	1	100.0	100.0	0	0	1	1	9m	
			09/02/94	28/02/94	20	2	2	100.0	100.0	1	1	1	1		
			01/03/94	01/03/94	1	2	1	50.0	97.7	0	0	1	1	4m	
			02/03/94	08/03/94	7	2	2	0.0	74.1	0	0	1	1	4m	4a
			09/03/94	09/03/94	1	2	2	100.0	75.0	1	1	1	1		
30															
1240	10ND	Imipramine	11/02/94	11/02/94	1	2	1	100.0	100.0	0	0	9m			
			12/02/94	15/02/94	4	2	2	100.0	100.0	1	1	1	6e		
			16/02/94	16/02/94	1	2	1	50.0	91.7	1	1	1			
			6												
3301	1ND	Reboxetine	24/09/92	24/09/92	1	2	1	50.0	50.0	1	1	6e			
			1												
2ND	Imipramine	12/01/93	29/01/93	18	2	2	100.0	100.0	1	1	1	4m	4a		
		30/01/93	30/01/93	1	2	0	0.0	94.7	0	0	1	1			
		31/01/93	09/03/93	38	2	2	100.0	98.2	1	1	1	1			
		57													
		16/01/93	08/02/93	24	2	2	100.0	100.0	1	1	1	1			
		09/02/93	09/02/93	1	2	1	50.0	98.0	0	0	1	1	4m		
3ND	Reboxetine	10/02/93	11/02/93	2	2	2	100.0	98.1	1	1	1	4m			
		12/02/93	12/02/93	1	2	1	50.0	96.4	1	1	1	4m			
		13/02/93	18/02/93	6	2	2	100.0	97.1	1	1	1	1			
		34													
3302	5ND	Reboxetine	07/11/92	09/11/92	3	2	2	100.0	100.0	1	1				
			10/11/92	13/11/92	4	2	3	50.0	71.4	2	1	1		(B - m)	

(*) 1=forget to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 9=start/end treatment in morning or evening, 10=reason unknown
(**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, C=high daily dose in one administration, B=low daily dose in one administration
m = morning, e = evening

9550089

44

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 9.0

EXPERIMENTAL TREATMENT: DAILY AND CUMULATIVE COMPLIANCE

Centre	Patient	Treatment	From date	To date	Treat. days	Cps prescribed	Daily Compl. Cps	% Compl. day	% Compl. cumul.	Morning Cps	Evening Cps	Reason (*)	Overdose (**)	
3302	5HD	Reboxetine	14/11/92	21/11/92	8	2	2	100.0	86.7	1	1			
			22/11/92	22/11/92	1	2	0	100.0	87.5	0	0	9m 9e		
			23/11/92	26/11/92	4	2	2	100.0	90.0	1	1			
			27/11/92	27/11/92	1	2	1	50.0	88.1	1	1	6e		
					21									
	6HD	Imipramine	26/06/93	11/07/93	16	2	2	100.0	100.0	1	1			
			12/07/93	12/07/93	1	2	0	0.0	94.1	1	1	4m 4e		
			13/07/93	15/07/93	3	2	2	100.0	95.0	1	1			
			16/07/93	16/07/93	1	2	1	50.0	92.9	1	1	6e		
					21									
7HD	Imipramine	13/11/93	27/11/93	15	2	2	100.0	100.0	1	1				
		28/11/93	28/11/93	1	2	1	100.0	100.0	1	0	9e			
		29/11/93	29/11/93	1	2	1	100.0	100.0	0	1	9m			
		30/11/93	07/12/93	8	2	2	100.0	100.0	1	1				
		08/12/93	08/12/93	1	2	1	50.0	98.1	1	1	1e			
		09/12/93	07/01/94	30	2	2	100.0	99.1	1	1				
		08/01/94	08/01/94	1	2	1	100.0	99.1	1	0	9e			
				57										

1241

(*) 1=forgot to take, 2=lost medication, 3=adverse event, 4=change by patient, 5=change by physician, 6=drop out, 7=overdose, 8=start/end treatment in morning or evening, 9=reason unknown
 (**) 1=low dose, 2=high dose, 3=low dose + high dose, 4=double high dose, 5=double low dose, 6=high daily dose in one administration, 7=low daily dose in one administration
 m = morning, e = evening

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

1

PHARMACIA CMS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 10.0
 ASSIGNED vs RANDOMIZED TREATMENT

Centre	Diagnosis	Treatment	Given	Start treat. date	Patient	Randomized	Error	
					Patient	Treatment	(*)	
1	Major Depressive Disorder	Reboxetine		05/11/92	1ND	1	Reboxetine	
		Imipramine		17/11/92	2ND	2	Imipramine	
		Imipramine		03/06/93	3ND	3	Imipramine	
		Reboxetine		19/10/93	4ND	4	Reboxetine	*
		Imipramine		26/11/93	1DT	5	Imipramine	*
		Reboxetine		09/12/93	2DT	6	Reboxetine	*
		Imipramine		10/12/93	3DT	7	Imipramine	*
		Reboxetine		01/02/94	4DT	8	Reboxetine	*
		Imipramine						
		Reboxetine		15/01/93	1ND	1	Reboxetine	
		Reboxetine		05/05/93	1ND	1	Reboxetine	
		2	Major Depressive Disorder	Imipramine		25/11/92	1ND	1
Imipramine				11/11/92	1DT	1	Imipramine	
Imipramine				23/12/92	2DT	2	Imipramine	
Reboxetine				03/02/93	4DT	3	Reboxetine	
Reboxetine				17/02/93	5DT	4	Reboxetine	
Imipramine				13/03/93	7DT	5	Reboxetine	*
Reboxetine				27/03/93	3DT	6	Imipramine	*
Reboxetine				02/05/93	9DT	7	Imipramine	*
Imipramine				05/05/93	8DT	8	Reboxetine	*
Imipramine				06/05/93	10DT	9	Reboxetine	*
Reboxetine				11/05/93	11DT	10	Imipramine	*
Imipramine				21/05/93	12DT	11	Imipramine	*
3	Major Depressive Disorder	Reboxetine		30/10/92	1ND	1	Reboxetine	
		Reboxetine		24/11/92	2ND	2	Reboxetine	
		Imipramine		24/11/92	4ND	3	Imipramine	
		Imipramine		17/03/93	3ND	4	Imipramine	
		Reboxetine		04/08/93	5ND	5	Reboxetine	
		Imipramine		05/08/93	6ND	6	Imipramine	
		Reboxetine		27/10/93	7ND	7	Reboxetine	
		Imipramine		11/11/93	8ND	8	Imipramine	
		Reboxetine		16/11/93	9ND	9	Reboxetine	
		Imipramine		25/11/93	10ND	10	Imipramine	
		Imipramine		02/12/93	11ND	11	Imipramine	
		Reboxetine		06/01/94	12ND	12	Reboxetine	
4	Major Depressive Disorder	Reboxetine		21/10/92	1DT	1	Reboxetine	
		Reboxetine		21/01/93	2DT	2	Reboxetine	

(*) Assigned treatment different from randomized

1242

9550089

2

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 10.0
 ASSIGNED vs RANDOMIZED TREATMENT

Centre	Diagnosis	Treatment	Start treat. date	Patient	Randomized Treatment	Error (#)
6	Dysthymia	Imipramine	08/04/93	3DT	Imipramine	
		Imipramine	05/05/93	4DT	Imipramine	
		Reboxetine	20/11/93	5DT	Reboxetine	
7	Major Depressive Disorder	Imipramine	11/11/92	2HD	Reboxetine	*
		Reboxetine	13/11/92	1HD	Imipramine	*
		Reboxetine	03/12/92	3HD	Reboxetine	
		Imipramine	15/12/92	4HD	Imipramine	
		Imipramine	03/04/93	5HD	Imipramine	
		Reboxetine	29/04/93	6HD	Reboxetine	
		Reboxetine	20/10/93	7HD	Reboxetine	
		Imipramine	23/11/93	8HD	Imipramine	
8	Major Depressive Disorder	Imipramine	09/01/93	1HD	Imipramine	
		Reboxetine	23/02/93	342HD	Reboxetine	
		Imipramine	23/04/93	3HD	Imipramine	
		Reboxetine	24/04/93	4HD	Reboxetine	
9	Dysthymia	Imipramine	28/09/92	1DT	Imipramine	
		Imipramine	30/09/92	2DT	Imipramine	
		Reboxetine	02/10/92	3DT	Reboxetine	
		Reboxetine	02/10/92	4DT	Reboxetine	
		Reboxetine	09/10/92	701DT	Imipramine	*
		Imipramine	09/10/92	702DT	Reboxetine	*
		Imipramine	09/02/93	703DT	Imipramine	
		Reboxetine	09/02/93	704DT	Reboxetine	
9	Major Depressive Disorder	Reboxetine	30/09/92	1HD	Reboxetine	
		Reboxetine	30/09/92	2HD	Reboxetine	
		Imipramine	02/10/92	3HD	Imipramine	
		Imipramine	02/10/92	4HD	Imipramine	
		Reboxetine	16/10/92	701HD	Reboxetine	*
9	Dysthymia	Reboxetine	13/10/93	3DT	Imipramine	*
		Reboxetine	16/11/93	6DT	Imipramine	*
		Imipramine	15/12/93	1DT	Reboxetine	*
		Imipramine	22/12/93	2DT	Reboxetine	*
9	Major Depressive Disorder	Imipramine	28/09/93	1HD	Imipramine	
		Reboxetine	01/10/93	2HD	Reboxetine	

(*): Assigned treatment different from randomized

1243

9550089

3

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 10.0
ASSIGNED vs RANDOMIZED TREATMENT

Centre	Diagnosis	Treatment	Given		Randomized		Error (%)
			Start treat. date	Patient	Patient	Treatment	
9	Major Depressive Disorder	Imipramine	13/10/93	44D	3	Reboxetine	*
		Reboxetine	26/10/93	54D	4	Imipramine	*
		Imipramine	03/11/93	64D	5	Reboxetine	*
		Imipramine	10/11/93	74D	6	Imipramine	
10	Dysthymia	Reboxetine	27/10/93	130T	1	Reboxetine	
		Imipramine	30/10/93	140T	2	Imipramine	
		Imipramine	30/10/93	160T	3	Imipramine	
		Reboxetine	06/11/93	190T	4	Reboxetine	
		Reboxetine	01/12/93	10T	5	Reboxetine	*
		Imipramine	01/12/93	20T	6	Reboxetine	
		Imipramine	02/12/93	30T	7	Imipramine	*
		Reboxetine	02/12/93	40T	8	Imipramine	*
		Reboxetine	04/12/93	50T	9	Imipramine	*
		Reboxetine	04/12/93	60T	10	Reboxetine	
		Imipramine	04/12/93	70T	11	Imipramine	*
		Imipramine	04/12/93	80T	12	Reboxetine	*
		Imipramine	08/12/93	90T	13	Reboxetine	*
		Reboxetine	08/12/93	100T	14	Imipramine	*
		Imipramine	08/12/93	110T	15	Reboxetine	*
		Reboxetine	08/12/93	120T	16	Imipramine	*
12	Major Depressive Disorder	Imipramine	02/10/93	14D	1	Imipramine	
		Reboxetine	02/10/93	24D	2	Reboxetine	
		Reboxetine	02/10/93	34D	3	Reboxetine	
		Imipramine	06/10/93	44D	4	Imipramine	
		Reboxetine	06/10/93	54D	5	Imipramine	
		Reboxetine	09/10/93	64D	6	Reboxetine	
		Imipramine	09/10/93	74D	7	Imipramine	
		Reboxetine	16/10/93	84D	8	Reboxetine	*
		Imipramine	23/10/93	104D	9	Reboxetine	
		Imipramine	23/10/93	114D	10	Imipramine	*
		Reboxetine	27/10/93	124D	11	Imipramine	*
		Reboxetine	30/10/93	134D	12	Reboxetine	
		Reboxetine	06/11/93	174D	13	Reboxetine	
		Imipramine	06/11/93	184D	14	Imipramine	
		Reboxetine	06/11/93	204D	15	Reboxetine	
		Reboxetine	20/11/93	94D	16	Imipramine	*
13	Dysthymia	Reboxetine	20/05/93	10T	1	Reboxetine	
		Reboxetine	28/04/93	14D	1	Reboxetine	
13	Dysthymia	Imipramine	23/09/93	10T	1	Imipramine	

(*): Assigned treatment different from randomized

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 10.0
 ASSIGNED vs RANDOMIZED TREATMENT

Centre	Diagnosis	Given			Randomized			Error (*)
		Treatment	Start treat. date	Patient	Patient	Treatment	Error	
13	Dysthymia	Reboxetine	22/10/93	2DT	2	Reboxetine		
		Imipramine	09/11/93	3DT	3	Imipramine		
		Reboxetine	03/02/94	4DT	4	Reboxetine		
13	Major Depressive Disorder	Reboxetine	08/04/93	1ND	1	Reboxetine		
		Imipramine	11/12/93	2ND	2	Imipramine		
		Imipramine	03/02/94	3ND	3	Imipramine		
14	Major Depressive Disorder	Reboxetine	06/04/94	1ND	1	Reboxetine		
15	Dysthymia	Reboxetine	26/07/93	1DT	1	Reboxetine		
		Imipramine	22/02/94	2DT	2	Imipramine		
15	Major Depressive Disorder	Reboxetine	01/03/93	1ND	1	Reboxetine		
		Imipramine	24/02/93	2ND	2	Imipramine		
		Reboxetine	06/05/93	3ND	3	Reboxetine		
		Imipramine	15/07/93	4ND	4	Imipramine		
		Reboxetine	08/10/93	11ND	5	Imipramine	*	
		Imipramine	29/11/93	112ND	6	Imipramine		
16	Dysthymia	Imipramine	18/02/93	1DT	1	Imipramine		
		Reboxetine	04/05/93	2DT	2	Reboxetine		
		Imipramine	29/07/93	3DT	3	Imipramine		
16	Major Depressive Disorder	Reboxetine	18/02/93	1ND	1	Reboxetine		
		Imipramine	15/04/93	2ND	2	Imipramine		
		Imipramine	09/05/93	3ND	3	Imipramine		
		Reboxetine	19/04/94	4ND	4	Reboxetine		
17	Dysthymia	Reboxetine	28/04/93	1DT	1	Reboxetine		
		Reboxetine	07/07/93	2DT	2	Reboxetine		
		Imipramine	19/10/93	3DT	3	Imipramine		
		Imipramine	19/01/94	4DT	4	Imipramine		
		Reboxetine	05/04/94	21DT	5	Imipramine	*	
17	Major Depressive Disorder	Reboxetine	31/03/93	1ND	1	Reboxetine		
		Imipramine	21/04/93	2ND	2	Imipramine		
		Imipramine	06/11/93	3ND	3	Imipramine		
		Reboxetine	12/01/94	4ND	4	Reboxetine		
17	Major Depressive Disorder	Reboxetine	19/05/94	211ND	5	Imipramine	*	

(*) Assigned treatment different from randomized

1245

9550089

5

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 10.0
 ASSIGNED vs RANDOMIZED TREATMENT

Centre	Diagnosis	Treatment	Given Start treat. date	Patient	Randomized Patient	Treatment	Error (*)
18	Dysthymia	Imipramine	12/08/93	1DT	1	Imipramine	
		Reboxetine	09/11/93	2DT	2	Reboxetine	
19	Major Depressive Disorder	Imipramine	27/05/93	1MD	1	Imipramine	
		Imipramine	30/05/93	2MD	2	Imipramine	
		Reboxetine	14/08/93	3MD	3	Reboxetine	
		Reboxetine	03/10/93	4MD	4	Reboxetine	
20	Major Depressive Disorder	Reboxetine	09/07/93	3MD	1	Imipramine	*
22	Major Depressive Disorder	Reboxetine	25/06/93	1MD	1	Reboxetine	
23	Major Depressive Disorder	Reboxetine	30/04/93	1MD	1	Reboxetine	
		Reboxetine	02/02/93	2MD	2	Reboxetine	
		Imipramine	23/03/93	3MD	3	Imipramine	
		Imipramine	31/03/93	4MD	4	Imipramine	
		Imipramine	05/05/93	5MD	5	Imipramine	
		Imipramine	06/07/93	6MD	6	Imipramine	
25	Major Depressive Disorder	Reboxetine	27/08/93	1MD	1	Reboxetine	
		Imipramine	26/11/93	2MD	2	Imipramine	
26	Dysthymia	Reboxetine	29/06/93	1DT	1	Reboxetine	
27	Major Depressive Disorder	Imipramine	27/04/93	1MD	1	Imipramine	
		Imipramine	02/02/93	1MD	1	Imipramine	
28	Dysthymia	Imipramine	22/04/93	1DT	1	Imipramine	
		Reboxetine	27/04/93	2DT	2	Reboxetine	
		Imipramine	11/05/93	3DT	3	Imipramine	
29	Major Depressive Disorder	Reboxetine	20/04/93	1MD	1	Reboxetine	
		Imipramine	26/04/93	2MD	2	Imipramine	
		Reboxetine	27/04/93	3MD	3	Reboxetine	
		Imipramine	04/05/93	4MD	4	Imipramine	
		Reboxetine	25/05/93	5MD	5	Reboxetine	

(*) Assigned treatment different from randomized

12
46

9550089

6

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 10.0
ASSIGNED vs RANDOMIZED TREATMENT

Centre	Diagnosis	Treatment	Start treat. date	Patient	Randomized Patient Treatment	Error (*)
29	Dysthymia	Reboxetine	06/03/93	5DT	Reboxetine	
		Reboxetine	08/03/93	13DT	Reboxetine	
		Imipramine	08/03/93	14DT	Imipramine	
		Imipramine	09/03/93	15DT	Imipramine	
		Reboxetine	09/03/93	16DT	Reboxetine	
		Imipramine	16/03/93	6DT	Imipramine	
		Imipramine	19/03/93	7DT	Imipramine	
		Reboxetine	09/04/93	8DT	Reboxetine	*
		Reboxetine	22/04/93	1DT	Reboxetine	*
		Reboxetine	22/04/93	2DT	Reboxetine	*
		Imipramine	27/04/93	17DT	Imipramine	*
		Reboxetine	29/04/93	18DT	Reboxetine	*
		Reboxetine	04/05/93	24DT	Reboxetine	
		Imipramine	05/05/93	4DT	Imipramine	
		Imipramine	05/05/93	22DT	Imipramine	
		Reboxetine	10/05/93	19DT	Reboxetine	*
		Imipramine	12/05/93	20DT	Imipramine	
		Imipramine	14/05/93	3DT	Imipramine	
		Reboxetine	14/05/93	23DT	Reboxetine	*
		Imipramine	26/05/93	9DT	Imipramine	*
		Reboxetine	02/06/93	24DT	Reboxetine	*
		Reboxetine	09/06/93	26DT	Reboxetine	*
		Reboxetine	14/06/93	29DT	Reboxetine	*
		Reboxetine	14/06/93	30DT	Reboxetine	*
		Imipramine	21/06/93	31DT	Imipramine	*
		Imipramine	21/06/93	32DT	Imipramine	*
		Imipramine	20/07/93	10DT	Imipramine	*
		Reboxetine	04/11/93	25DT	Reboxetine	*
		Reboxetine	18/11/93	27DT	Reboxetine	*
		Imipramine	18/11/93	11DT	Imipramine	*
		Reboxetine	18/11/93	28DT	Reboxetine	*
		Reboxetine	13/12/93	12DT	Reboxetine	*
Major Depressive Disorder	Imipramine	15/02/93	13ND	Imipramine		
	Reboxetine	15/02/93	14ND	Reboxetine		
	Imipramine	18/02/93	9ND	Imipramine	*	
	Reboxetine	22/02/93	15ND	Reboxetine	*	
	Imipramine	03/03/93	16ND	Imipramine	*	
	Reboxetine	03/03/93	5ND	Reboxetine	*	
	Reboxetine	04/03/93	6ND	Reboxetine	*	
	Imipramine	22/03/93	1ND	Imipramine	*	
	Reboxetine	23/03/93	10ND	Reboxetine	*	
	Imipramine	19/04/93	3ND	Imipramine	*	
	Reboxetine	20/04/93	2ND	Reboxetine	*	
	Reboxetine	21/04/93	7ND	Reboxetine	*	
	Reboxetine	21/04/93	17ND	Reboxetine	*	

(*) Assigned treatment different from randomized

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

7

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 10.0
 ASSIGNED vs RANDOMIZED TREATMENT

Centre	Diagnosis	Given		Randomized		Error (*)			
		Treatment	Start treat. date	Patient	Patient				
29	Major Depressive Disorder	Imipramine	23/04/93	8ND	14	Reboxetine	*		
		Reboxetine	23/04/93	16ND	15	Imipramine	*		
		Reboxetine	03/05/93	4ND	16	Reboxetine	*		
		Imipramine	08/05/93	21ND	17	Reboxetine	*		
		Imipramine	14/05/93	19ND	18	Reboxetine	*		
		Imipramine	14/05/93	20ND	19	Imipramine	*		
		Reboxetine	20/05/93	22ND	20	Imipramine	*		
		Reboxetine	27/05/93	23ND	21	Imipramine	*		
		Reboxetine	05/06/93	26ND	22	Imipramine	*		
		Imipramine	14/06/93	25ND	23	Reboxetine	*		
		Imipramine	14/06/93	26ND	24	Reboxetine	*		
		Reboxetine	27ND	27ND	25	Imipramine	*		
		Reboxetine	15/06/93	28ND	26	Imipramine	*		
		Imipramine	12/07/93	11ND	27	Reboxetine	*		
		Reboxetine	16/09/93	12ND	28	Reboxetine	*		
		30	Major Depressive Disorder	Imipramine	21/04/93	1ND	1	Imipramine	*
				Reboxetine	16/07/93	2ND	2	Reboxetine	*
				Reboxetine	02/11/93	4ND	3	Imipramine	*
Imipramine	08/11/93			3ND	4	Reboxetine	*		
Imipramine	18/12/93			5ND	5	Imipramine	*		
31	Dysthymia	Reboxetine	23/09/92	1DT	1	Reboxetine			
Major Depressive Disorder	Imipramine	23/09/92	1ND	1	Imipramine				
	Reboxetine	02/12/92	2ND	2	Reboxetine				
	Imipramine	14/12/92	3ND	3	Imipramine				
32	Major Depressive Disorder	Imipramine	25/05/93	1ND	1	Imipramine			
		Imipramine	15/04/93	2ND	2	Imipramine			
		Reboxetine	22/04/93	3ND	3	Reboxetine			
		Reboxetine	07/10/93	4ND	4	Reboxetine			
		Reboxetine	04/11/93	5ND	5	Reboxetine			
		Imipramine	17/11/93	6ND	6	Imipramine			
35	Dysthymia	Reboxetine	03/03/93	1DT	1	Reboxetine			
		Imipramine	03/03/93	2DT	2	Imipramine			
		Imipramine	31/03/93	3DT	3	Imipramine			
		Reboxetine	27/04/93	4DT	4	Reboxetine			
		Imipramine	02/09/93	5DT	5	Imipramine			
		Imipramine	20/10/93	6DT	6	Imipramine			
		Reboxetine	20/10/93	7DT	7	Reboxetine			
		Reboxetine	11/01/94	8DT	8	Reboxetine			

(*) Assigned treatment different from randomized

9550089

1248

9550089

8

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 10.0
 ASSIGNED vs RANDOMIZED TREATMENT

Centre	Diagnosis	Treatment	Given	Start treat. date	Patient	Randomized	Error
					Patient	Treatment	(*)
35	Major Depressive Disorder	Reboxetine		26/01/93	4HD	Reboxetine	
		Imipramine		03/03/93	2HD	Imipramine	
		Imipramine		30/03/93	3HD	Imipramine	
		Reboxetine		20/04/93	4HD	Reboxetine	
		Reboxetine		09/07/93	5HD	Reboxetine	*
		Imipramine		10/12/93	7HD	Reboxetine	*
		Reboxetine		21/01/94	6HD	Imipramine	
		Imipramine		01/02/94	8HD	Imipramine	
36	Dysthymia	Imipramine		03/02/93	4DT	Imipramine	
		Reboxetine		25/02/93	2DT	Reboxetine	
		Imipramine		02/03/93	3DT	Imipramine	
		Reboxetine		12/03/93	4DT	Reboxetine	
		Imipramine		03/04/93	5DT	Imipramine	
		Imipramine		10/04/93	6DT	Reboxetine	
		Reboxetine		01/05/93	7DT	Imipramine	
		Reboxetine		15/05/93	8DT	Reboxetine	
		Imipramine		23/06/93	9DT	Imipramine	
		Reboxetine		26/10/93	10DT	Reboxetine	
		Reboxetine		10/11/93	11DT	Reboxetine	
		Imipramine		22/12/93	12DT	Imipramine	
37	Major Depressive Disorder	Imipramine		16/01/93	1HD	Imipramine	
		Reboxetine		03/02/93	2HD	Reboxetine	
		Imipramine		06/02/93	3HD	Imipramine	
		Reboxetine		09/03/93	4HD	Reboxetine	
		Imipramine		24/04/93	5HD	Reboxetine	
		Reboxetine		01/05/93	6HD	Imipramine	
		Imipramine		13/05/93	7HD	Reboxetine	
		Reboxetine		26/05/93	8HD	Imipramine	
		Reboxetine		16/06/93	9HD	Reboxetine	
		Imipramine		22/06/93	10HD	Reboxetine	
		Reboxetine		09/07/93	11HD	Imipramine	*
		Imipramine		21/09/93	13HD	Imipramine	*
		Reboxetine		24/09/93	12HD	Reboxetine	*
		Imipramine		23/10/93	14HD	Imipramine	*
		Imipramine		03/11/93	16HD	Reboxetine	*
		Reboxetine		09/11/93	14HD	Imipramine	
		Imipramine		10/11/93	17HD	Reboxetine	
		Reboxetine		13/01/94	18HD	Imipramine	
		Reboxetine		15/01/94	19HD	Reboxetine	
		Imipramine		01/02/94	20HD	Imipramine	
				3HD	Imipramine	*	

(*) Assigned treatment different from randomized

1249

9550089

9

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 10.0
ASSIGNED vs RANDOMIZED TREATMENT

Centre	Diagnosis	Treatment	Given Start treat. date	Patient	Randomized Patient	Treatment	Error (*)
41	Major Depressive Disorder	Imipramine	22/02/94	1MD	1	Imipramine	
		Reboxetine	23/02/94	2MD	2	Reboxetine	
		Imipramine	25/02/94	3MD	3	Imipramine	
		Reboxetine	28/02/94	4MD	4	Reboxetine	
		Reboxetine	03/03/94	5MD	5	Reboxetine	
42	Dysthymia	Imipramine	25/11/93	1DT	1	Imipramine	
		Reboxetine	09/12/93	2DT	2	Reboxetine	
43	Major Depressive Disorder	Imipramine	26/10/93	1MD	1	Imipramine	
		Reboxetine	26/10/93	2MD	2	Reboxetine	
		Imipramine	25/11/93	3MD	3	Imipramine	
44	Major Depressive Disorder	Reboxetine	19/02/93	1DT	1	Imipramine	*
		Imipramine	11/05/93	2DT	2	Imipramine	*
		Imipramine	15/09/93	3DT	3	Reboxetine	*
		Reboxetine	23/09/93	4DT	4	Reboxetine	*
		Imipramine	10/12/93	5MD	5	Reboxetine	*
		Imipramine	16/02/94	6MD	6	Imipramine	
45	Dysthymia	Reboxetine	31/07/93	1DT	1	Reboxetine	
		Reboxetine	03/09/93	1MD	1	Reboxetine	
46	Major Depressive Disorder	Reboxetine	20/09/93	2MD	2	Reboxetine	
		Imipramine	14/10/93	3MD	3	Imipramine	
		Imipramine	31/01/94	4MD	4	Imipramine	
		Imipramine	12/08/93	1DT	1	Imipramine	
47	Major Depressive Disorder	Reboxetine	25/11/93	1MD	1	Reboxetine	
		Imipramine	07/12/93	2MD	2	Imipramine	
48	Major Depressive Disorder	Imipramine	28/09/93	1MD	1	Imipramine	
		Imipramine	19/10/93	2MD	2	Imipramine	
		Reboxetine	02/12/93	3MD	3	Reboxetine	
		Reboxetine	06/12/93	4MD	4	Reboxetine	
49	Major Depressive Disorder	Reboxetine	24/06/93	1DT	1	Imipramine	*
		Reboxetine					

(*) Assigned treatment different from randomized

1250

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

10

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 10.0
 ASSIGNED vs RANDOMIZED TREATMENT

Centre	Diagnosis	Treatment	Given Start treat. date	Patient	Randomized Patient	Treatment	Error (*)
48	Major Depressive Disorder	Imipramine	28/06/93	2DT	2	Imipramine	
381	Dysthymia	Reboxetine	08/02/94	3DT	1	Imipramine	*
	Major Depressive Disorder	Reboxetine	18/12/93	1ND	1	Reboxetine	
		Reboxetine	02/02/94	2ND	2	Reboxetine	
		Imipramine	01/03/94	4ND	3	Imipramine	
382	Dysthymia	Reboxetine	21/10/93	5DT	5	Reboxetine	
		Imipramine	22/10/93	6DT	6	Imipramine	
		Imipramine	22/10/93	7DT	7	Imipramine	
		Reboxetine	22/12/93	8DT	8	Reboxetine	
		Reboxetine	08/02/94	9DT	9	Reboxetine	
3301	Major Depressive Disorder	Reboxetine	12/11/93	6ND	5	Imipramine	*
		Imipramine	15/11/93	5ND	6	Reboxetine	*
		Reboxetine	20/12/93	7ND	7	Reboxetine	
		Reboxetine	26/01/94	8ND	8	Imipramine	
		Reboxetine	11/02/94	9ND	9	Reboxetine	
3302	Major Depressive Disorder	Imipramine	11/02/94	10ND	10	Imipramine	
		Reboxetine	24/09/92	1ND	1	Reboxetine	
		Imipramine	12/01/93	2ND	2	Imipramine	
		Reboxetine	15/01/93	3ND	3	Reboxetine	
		Reboxetine	07/11/92	5ND	5	Reboxetine	
		Imipramine	26/06/93	6ND	6	Imipramine	
		Imipramine	13/11/93	7ND	7	Imipramine	

1251

9550089

(*) Assigned treatment different from randomized

9550089

1

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXYTINE - PROTOCOL 20124/035
 LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose as protocol	Complete as protocol	Reason	Decision to discontinue	Drug compliance	
1	1ND	Female	Day 56	30/12/92	YES			As prescribed	
	1DT	Male	Day 56	20/01/94	YES			As prescribed	
	2ND	Male	Day 56	11/01/93	YES			As prescribed	
	2DT	Male	Day 14	22/12/93	NO	Deterioration	Physician	As prescribed	
	3ND	Female	Day 56	28/07/93	YES			As prescribed	
	3DT	Male	Day 56	03/02/94	YES			As prescribed	
	4ND	Female	Day 56	13/12/93	YES			As prescribed	
	4DT	Male	Day 28	24/02/94	NO	Deterioration	Physician	As prescribed	
	5	1ND	Male	Day 28	08/02/93	NO	Deterioration	Physician	As prescribed
	3	1ND	Female	Day 49	22/06/93	NO	Deterioration	Physician	As prescribed
4	1ND	Male	Day 35	29/12/92	NO	Deterioration	Physician	As prescribed	
	1ND	Female	Day 14	10/11/92	NO	Adverse event	Physician	As prescribed	
	1DT	Female	Day 56	06/01/93	YES			As prescribed	
5	2ND	Male	Day 56	18/01/93	YES			As prescribed	
	2DT	Female	Day 56	14/02/93	YES			As prescribed	
	3ND	Female	Day 56	11/05/93	YES			As prescribed	
3DT	Male	Day 56	21/05/93	YES			As prescribed		

1252

9550089

2

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 BEROXETINE - PROTOCOL 20124/035
 LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
5	4ND	Male	Day 56	18/01/93	YES			As prescribed
	4DT	Male	Day 28	02/03/93	NO	Adverse event	Patient	Unknown
	5ND	Male	Day 14	15/08/93	NO	Patient uncooperative	Patient	Confirmed irregularities
	5DT	Female	Day 28	17/03/93	NO	Adverse event	Physician	As prescribed
	6ND	Male	Day 14	18/08/93	NO	Patient uncooperative	Patient	As prescribed
	6DT	Female	Day 56	23/04/93	YES			As prescribed
	7ND	Male	Day 21	16/11/93	NO	Patient uncooperative	Patient	As prescribed
	7DT	Female	Day 56	07/05/93	YES			As prescribed
	8ND	Female	Day 56	05/01/94	YES			As prescribed
	8DT	Female	Day 56	29/06/93	YES			As prescribed
	9ND	Female	Day 56	10/01/94	YES			As prescribed
	9DT	Female	Day 56	25/06/93	YES			As prescribed
	10ND	Female	Day 14	08/12/93	NO	Lost to follow up	Patient	As prescribed
	10DT	Male	Day 7	10/05/93	NO	Adverse event	Physician	As prescribed
	11ND	Female	Day 35	05/01/94	NO	Patient uncooperative	Patient	As prescribed
	11DT	Female	Day 28	07/06/93	NO	Lost to follow up	Patient	As prescribed
	12ND	Female	Day 56	03/03/94	YES			As prescribed

12
 27
 33

9550089

3

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R8D
REBOXETINE - PROTOCOL 20124/035
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
5	12DT	Male	Day 56	15/07/93	YES			As prescribed
6	1MD	Female	Day 56	07/01/93	YES			As prescribed
	1DT	Female	Day 56	16/12/92	YES			As prescribed
	2MD	Female	Day 7	17/11/92	NO	Adverse event Deterioration	Physician	As prescribed
	2DT	Female	Day 7	27/01/93	NO	Protocol violation	Physician	As prescribed
	3MD	Female	Day 56	27/01/93	YES			As prescribed
	3DT	Female	Day 56	02/06/93	YES			As prescribed
	4MD	Female	Day 35	18/01/93	NO	Deterioration	Patient	As prescribed
	4DT	Female	Day 56	29/06/93	YES			As prescribed
	5MD	Female	Day 56	28/05/93	YES			As prescribed
	5DT	Female	Day 56	14/01/94	YES			As prescribed
	6MD	Female	Day 35	01/06/93	NO	Deterioration	Physician	As prescribed
	7MD	Female	Day 56	14/12/93	YES			As prescribed
	8MD	Female	Day 56	17/01/94	YES			As prescribed
7	1MD	Male	Day 63	13/03/93	YES			As prescribed
	3MD	Female	Day 56	17/06/93	YES			As prescribed
	4MD	Female	Day 42	29/05/93	NO	Deterioration	Physician	As prescribed

1254

9550089

4

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 LISTING No.: 11.0
 REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
7	342HD	Female	Day 56	19/04/93	YES			As prescribed
8	1HD	Female	Day 56	24/11/92	YES			As prescribed
	1DT	Female	Day 56	22/11/92	YES			As prescribed
	2HD	Female	Day 56	24/11/92	YES			As prescribed
	2DT	Female	Day 56	24/11/92	YES			As prescribed
	3HD	Female	Day 14	10/10/92	NO	Adverse event		As prescribed
	3DT	Female	Day 56	26/11/92	YES			As prescribed
	4HD	Male	Day 28	27/10/92	NO	Other	Others	As prescribed
	4DT	Female	Day 56	26/11/92	YES			As prescribed
	701HD	Male	Day 56	03/12/92	YES			As prescribed
	701DT	Female	Day 56	03/12/92	YES			As prescribed
	702HD	Male	Day 56	10/12/92	YES			As prescribed
	702DT	Female	Day 56	03/12/92	YES			As prescribed
	703HD	Female	Day 56	05/04/93	YES			As prescribed
	703DT	Male	Day 56	05/04/93	YES			As prescribed
	704HD	Female	Day 56	05/04/93	YES			As prescribed
	704DT	Female	Day 56	05/04/93	YES			As prescribed

9550089

5

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS 88D
 ZERONETINE - PROTOCOL 20124/035
 LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose as protocol	Complete as protocol	Reason	Decision to discontinue	Drug compliance
9	1HD	Female	Day 56	23/11/93	YES			As prescribed
	1DT	Female	Day 56	08/02/94	YES			As prescribed
	2HD	Female	Day 56	25/11/93	YES			As prescribed
	2DT	Female	Day 56	15/02/94	YES			As prescribed
	3DT	Female	Day 56	07/12/93	YES			As prescribed
	4HD	Female	Day 56	07/12/93	YES			As prescribed
	5HD	Female	Day 56	21/12/93	YES			As prescribed
	6HD	Female	Day 7	05/11/93	NO	Adverse event	Patient	As prescribed
	7HD	Female	Day 7	11/11/93	NO	Adverse event	Patient	As prescribed
	8DT	Female	Day 56	10/01/94	YES			As prescribed
	1HD	Female	Day 56	26/11/93	YES			As prescribed
	1DT	Female	Day 56	25/01/94	YES			As prescribed
	2HD	Male	Day 56	26/11/93	YES			As prescribed
	2DT	Male	Day 56	25/01/94	YES			As prescribed
10	3HD	Male	Day 56	26/11/93	YES			As prescribed
	3DT	Male	Day 56	26/01/94	YES			As prescribed
	4HD	Female	Day 56	30/11/93	YES			As prescribed

1256

9550089

6

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose as protocol	Complete as protocol	Reason	Decision to discontinue	Drug compliance
10	4DT	Female	Day 56	26/01/94	YES			As prescribed
	5ND	Female	Day 56	30/11/93	YES			As prescribed
	5DT	Female	Day 56	28/01/94	YES			As prescribed
	6ND	Male	Day 56	03/12/93	YES			As prescribed
	6DT	Male	Day 56	28/01/94	YES			As prescribed
	7ND	Male	Day 56	03/12/93	YES			As prescribed
	7DT	Female	Day 56	28/01/94	YES			As prescribed
	8ND	Male	Day 56	10/12/93	YES			As prescribed
	8DT	Female	Day 56	28/01/94	YES			As prescribed
	9ND	Female	Day 56	14/01/94	YES			As prescribed
	9DT	Male	Day 56	01/02/94	YES			As prescribed
	10ND	Female	Day 56	17/12/93	YES			As prescribed
	10DT	Female	Day 56	01/02/94	YES			As prescribed
	11ND	Female	Day 56	17/12/93	YES			As prescribed
	11DT	Female	Day 56	01/02/94	YES			As prescribed
	12ND	Male	Day 56	21/12/93	YES			As prescribed
	12DT	Female	Day 56	01/02/94	YES			As prescribed

1257

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REMOXYLINE - PROTOCOL 20124/035
 LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance	
10	13DT	Female	Day 56	21/12/93	YES			As prescribed	
	14DT	Female	Day 56	23/12/93	YES			As prescribed	
	15MD	Female	Day 56	23/12/93	YES			As prescribed	
	16DT	Male	Day 56	23/12/93	YES			As prescribed	
	17MD	Female	Day 56	30/12/93	YES			As prescribed	
	18ND	Female	Day 56	30/12/93	YES			As prescribed	
	19DT	Male	Day 56	30/12/93	YES			As prescribed	
	20ND	Female	Day 56	30/12/93	YES			As prescribed	
	12	1MD	Female	Day 56	22/06/93	YES			As prescribed
		1DT	Female	Day 56	14/07/93	YES			As prescribed
1MD		Female	Day 56	02/06/93	YES			As prescribed	
1DT		Female	Day 56	17/11/93	YES			As prescribed	
13	2MD	Female	Day 56	04/02/94	YES			As prescribed	
	2DT	Female	Day 56	17/12/93	YES			As prescribed	
	3MD	Male	Day 56	31/03/94	YES			As prescribed	
	3DT	Female	Day 56	04/01/94	YES			As prescribed	
	4DT	Female	Day 56	31/03/94	YES			Confirmed irregularities	

9550089

3

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RD
REBONETINE - PROTOCOL 20124/035
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
14	1HD	Female	Day 28	02/05/94	NO	Adverse event	Physician	As prescribed
15	1HD	Female	Day 56	25/04/93	YES			As prescribed
	1DT	Female	Day 56	19/09/93	YES			As prescribed
	2HD	Female	Day 14	02/04/93	NO	Adverse event	Patient	As prescribed
	2DT	Female	Day 56	18/04/94	YES			As prescribed
	3ND	Female	Day 56	30/06/93	YES			As prescribed
	4HD	Female	Day 56	08/09/93	YES			As prescribed
	11HD	Female	Day 21	28/10/93	NO	Adverse event	Physician	As prescribed
	112HD	Female	Day 56	23/01/94	YES			As prescribed
16	1HD	Female	Day 56	14/04/93	YES			As prescribed
	1DT	Female	Day 14	26/02/93	NO	Adverse event Deterioration	Physician Patient	As prescribed
	2HD	Male	Day 56	09/06/93	YES			As prescribed
	2DT	Male	Day 56	28/06/93	YES			As prescribed
	3HD	Female	Day 35	09/06/93	NO	Intercurrent medical problem	Physician	As prescribed
	3DT	Female	Day 14	10/08/93	NO	Adverse event	Physician	As prescribed
	4HD	Female	Day 56	13/06/94	YES			As prescribed

1259

9550089

9

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PEARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 LISTING No.: 11.0
 REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose as protocol	Complete as protocol	Reason	Decision to discontinue	Drug compliance
17	1MD	Female	Day 56	25/05/93	YES			As prescribed
	1DT	Female	Day 21	17/05/93	NO	Adverse event	Physician	As prescribed
	2MD	Female	Day 56	15/06/93	YES			As prescribed
	2DT	Female	Day 56	31/08/93	YES			As prescribed
	3MD	Female	Day 14	19/11/93	NO	Deterioration	Patient	As prescribed
	3DT	Male	Day 56	13/12/93	YES			As prescribed
	4MD	Female	Day 56	09/03/94	YES			As prescribed
	4DT	Female	Day 56	15/03/94	YES			As prescribed
	21MD	Female	Day 56	13/07/94	YES			As prescribed
	21DT	Female	Day 56	30/05/94	YES			As prescribed
18	1MD	Female	Day 56	21/07/93	YES			As prescribed
	1DT	Female	Day 56	06/10/93	YES			As prescribed
	2MD	Female	Day 28	26/06/93	NO	Deterioration	Physician	As prescribed
	2DT	Female	Day 28	06/12/93	NO	Deterioration	Others	As prescribed
	3MD	Female	Day 49	01/10/93	NO	Patient uncooperative	Patient	As prescribed
	4MD	Female	Day 56	27/11/93	YES			As prescribed
	3MD	Female	Day 7	15/07/93	NO	Adverse event	Physician	As prescribed

1260

9550089

10

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/035
 LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose as protocol	Complete as protocol	Reason	Decision to discontinue	Drug compliance
22	1ND	Female	Day 7	30/06/93	NO	Deterioration	Physician Patient	As prescribed
23	1ND	Female	Day 56	26/03/93	YES			As prescribed
	2ND	Female	Day 56	29/03/93	YES			As prescribed
	3ND	Female	Day 56	17/05/93	YES			As prescribed
	4ND	Female	Day 56	25/05/93	YES			As prescribed
	5ND	Female	Day 14	13/05/93	NO	Protocol violation	Physician	As prescribed
	6ND	Female	Day 49	17/08/93	NO	Intercurrent medical problem Deterioration	Physician	As prescribed
25	1ND	Male	Day 35	01/10/93	NO	Adverse event Deterioration	Physician	As prescribed
	2ND	Female	Day 56	20/01/94	YES			As prescribed
26	1ND	Female	Day 56	21/06/93	YES			Suspected irregularities
	1DT	Female	Day 49	11/08/93	NO	Patient uncooperative	Patient	Suspected irregularities
27	1ND	Male	Day 7	08/02/93	NO	Deterioration	Physician	As prescribed
	1ND	Female	Day 56	14/06/93	YES			As prescribed
28	1DT	Female	Day 56	16/06/93	YES			As prescribed
	2ND	Female	Day 56	21/06/93	YES			As prescribed
	2DT	Male	Day 56	21/06/93	YES			As prescribed

1261

9550089

11

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Completes as protocol	Reason	Decision to discontinue	Drug compliance
28	3ND	Female	Day 56	21/06/93	YES			As prescribed
	3DT	Male	Day 56	05/07/93	YES			As prescribed
	4ND	Male	Day 56	28/06/93	YES			Confirmed irregularities
	5ND	Female	Day 56	19/07/93	YES			As prescribed
	1ND	Female	Day 56	17/06/93	YES			As prescribed
30	2ND	Female	Day 7	18/07/93	NO	Adverse event	Patient	As prescribed
	3ND	Female	Day 56	03/01/94	YES			As prescribed
	4ND	Female	Day 56	30/12/93	YES			As prescribed
	5ND	Female	Day 7	23/12/93	NO	Adverse event	Physician	As prescribed
	1ND	Female	Day 14	05/10/92	NO	Adverse event	Physician	As prescribed
31	1DT	Female	Day 35	28/10/92	NO	Deterioration	Physician	As prescribed
	2ND	Female	Day 56	29/01/93	YES			As prescribed
	3ND	Male	Day 7	16/12/92	NO	Adverse event	Physician	As prescribed
	1ND	Female	Day 56	19/05/93	YES			As prescribed
	2ND	Female	Day 56	09/06/93	YES			As prescribed
32	3ND	Female	Day 56	16/06/93	YES			As prescribed
	4ND	Female	Day 21	26/10/93	NO	Adverse event Deterioration	Physician Patient	As prescribed

1262

9550089

12

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 RESOXETINE - PROTOCOL 20124/035
 LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
32	5HD	Female	Day 28	25/11/93	NO	Adverse event Deterioration	Physician Patient	As prescribed
	6HD	Male	Day 56	12/01/94	YES			As prescribed
35	1HD	Female	Day 21	14/02/93	NO	Adverse event Protocol violation	Patient	As prescribed
	1DT	Female	Day 56	27/04/93	YES			As prescribed
	2HD	Female	Day 35	31/03/93	NO	Adverse event	Physician	As prescribed
	2DT	Female	Day 56	27/04/93	YES			As prescribed
	3HD	Female	Day 7	05/04/93	NO	Adverse event	Physician	As prescribed
	3DT	Male	Day 56	26/05/93	YES			As prescribed
	4HD	Male	Day 56	14/06/93	YES			As prescribed
	4DT	Female	Day 56	21/06/93	YES			As prescribed
	5HD	Male	Day 56	02/09/93	YES			As prescribed
	5DT	Female	Day 56	27/10/93	YES			As prescribed
	6HD	Female	Day 42	02/03/94	NO	Patient uncooperative	Patient	As prescribed
	6DT	Female	Day 56	14/12/93	YES			As prescribed
	7HD	Female	Day 42	17/01/94	NO	Protocol violation Intercurrent medical problem Deterioration	Physician	As prescribed

1263

9550089

13

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBONETINE - PROTOCOL 20124/035
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Adverse event	Decision to discontinue	Drug compliance
35	7DT	Female	Day 28	16/11/93	NO	Adverse event Patient uncooperative	Patient	As prescribed	
	8ND	Female	Day 49	21/03/94	NO	Patient uncooperative Other	Physician Patient	As prescribed	
	8DT	Female	Day 56	07/03/94	YES			As prescribed	
36	1ND	Male	Day 56	08/03/93	NO	Adverse event	Physician	As prescribed	
	1DT	Female	Day 56	30/03/93	YES			As prescribed	
	2ND	Female	Day 56	30/03/93	YES			As prescribed	
	2DT	Female	Day 56	22/04/93	YES			As prescribed	
	3ND	Female	Day 56	02/04/93	YES			As prescribed	
	3DT	Female	Day 56	27/04/93	YES			As prescribed	
	4ND	Female	Day 56	01/05/93	NO	Patient uncooperative	Patient	As prescribed	
	4DT	Female	Day 56	06/05/93	YES			As prescribed	
	5ND	Female	Day 56	18/06/93	YES			As prescribed	
	5DT	Female	Day 7	07/04/93	NO	Death		As prescribed	
	6ND	Female	Day 56	25/06/93	YES			As prescribed	
	6DT	Female	Day 56	04/06/93	YES			As prescribed	
	7ND	Female	Day 56	07/07/93	YES			As prescribed	
	7DT	Female	Day 7	07/05/93	NO	Adverse event	Patient	As prescribed	

1264

9550089

14

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 LISTING No.: 11.0
 REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
36	8ND	Female	Day 56	20/07/93	YES			As prescribed
	8DT	Female	Day 63	16/07/93	YES			As prescribed
	9ND	Male	Day 56	10/08/93	YES			As prescribed
	9DT	Female	Day 56	19/08/93	YES			As prescribed
	10ND	Male	Day 56	16/08/93	YES			As prescribed
	10DT	Male	Day 56	20/12/93	YES			As prescribed
	11ND	Female	Day 56	02/09/93	YES			As prescribed
	11DT	Male	Day 42	19/12/93	NO	Patient uncooperative	Patient	As prescribed
	12ND	Female	Day 14	05/10/93	NO	Adverse event	Physician	As prescribed
	12DT	Female	Day 56	15/02/94	YES			As prescribed
	13ND	Male	Day 28	14/10/93	NO	Adverse event	Physician	As prescribed
	14ND	Male	Day 56	28/12/93	YES			As prescribed
	15ND	Female	Day 21	09/11/93	NO	Lost to follow up Patient uncooperative	Patient	As prescribed
	16ND	Female	Day 56	03/01/94	YES			As prescribed
	17ND	Female	Day 7	11/11/93	NO	Patient uncooperative	Patient	As prescribed
	18ND	Female	Day 56	09/03/94	YES			As prescribed

1265

9550089

15

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS 8&D
REBOXETINE - PROTOCOL 20124/035
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
36	19HD	Female	Day 14	22/01/94	NO	Adverse event	Patient	As prescribed
	20HD	Female	Day 56	28/03/94	YES			As prescribed
37	3HD	Female	Day 7	24/03/93	NO	Patient uncooperative	Patient	Suspected irregularities
41	1HD	Male	Day 7	24/02/94	NO	Adverse event Deterioration	Patient	As prescribed
	2HD	Male	Day 56	19/04/94	YES			As prescribed
	3HD	Male	Day 56	21/04/94	YES			As prescribed
	4HD	Male	Day 56	24/04/94	YES			As prescribed
	5HD	Male	Day 56	27/04/94	YES			As prescribed
42	1HD	Female	Day 56	20/12/93	YES			As prescribed
	1DT	Female	Day 56	19/01/94	YES			As prescribed
	2HD	Female	Day 56	20/12/93	YES			As prescribed
	2DT	Male	Day 7	10/12/93	NO	Adverse event	Patient	As prescribed
	3HD	Male	Day 56	19/01/94	YES			As prescribed
43	1DT	Female	Day 42	02/04/93	NO	Deterioration Other	Patient	As prescribed
	2DT	Female	Day 21	01/06/93	NO	Deterioration	Physician	As prescribed
	3DT	Male	Day 56	10/11/93	YES			As prescribed
	4DT	Female	Day 56	18/11/93	YES			As prescribed

1266

9550089

16

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/035
 LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
43	5ND	Female	Day 35	12/01/94	NO	Deterioration	Physician	As prescribed
	6ND	Female	Day 56	14/04/94	YES			As prescribed
44	1ND	Female	Day 56	28/10/93	YES			As prescribed
	1DT	Female	Day 56	24/09/93	YES			As prescribed
	2ND	Female	Day 56	15/11/93	YES			As prescribed
	3ND	Female	Day 56	09/12/93	YES			As prescribed
	4ND	Male	Day 56	28/03/94	YES			As prescribed
45	1ND	Male	Day 56	20/01/94	YES			As prescribed
	1DT	Female	Day 56	06/10/93	YES			As prescribed
	2ND	Male	Day 21	26/12/93	NO	Intercurrent medical problem Patient uncooperative	Physician	Confirmed irregularities
46	1ND	Male	Day 56	23/11/93	YES			As prescribed
	2ND	Female	Day 21	08/11/93	NO	Adverse event	Physician Patient	As prescribed
	3ND	Female	Day 56	27/01/94	YES			As prescribed
	4ND	Female	Day 7	11/12/93	NO	Adverse event	Physician	As prescribed
48	1DT	Female	Day 7	24/06/93	NO	Patient uncooperative	Patient	Suspected irregularities
	2DT	Female	Day 42	04/08/93	NO	Deterioration	Physician	As prescribed

1267

9550089

17

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose as protocol	Complete as protocol	Adverse event	Reason	Decision to discontinue	Drug compliance	
291	1ND	Female	Day 35	25/04/93	NO			Patient	As prescribed	
	1DT	Female	Day 56	16/06/93	YES				Suspected irregularities	
	2ND	Female	Day 56	14/06/93	YES				As prescribed	
	2DT	Female	Day 56	16/06/93	YES				As prescribed	
	3ND	Male	Day 56	13/06/93	YES				As prescribed	
	3DT	Female	Day 7	20/05/93	NO	Adverse event		Patient	As prescribed	
	4ND	Male	Day 56	28/06/93	YES				As prescribed	
	4DT	Male	Day 56	29/06/93	YES				As prescribed	
	5DT	Female	Day 56	30/12/93	YES				As prescribed	
	6DT	Female	Day 56	03/08/93	YES				As prescribed	
	7DT	Female	Day 56	30/12/93	YES				As prescribed	
	8DT	Female	Day 56	17/01/94	YES				As prescribed	
	292	5ND	Female	Day 56	27/04/93	YES				Confirmed irregularities
		5DT	Male	Day 56	29/04/93	YES				Confirmed irregularities
6ND		Female	Day 56	28/04/93	YES				Confirmed irregularities	
6DT		Female	Day 56	10/05/93	YES				Confirmed irregularities	
7ND		Male	Day 56	15/06/93	YES				As prescribed	

1268

9550089

13

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBDXETINE - PROTOCOL 20124/035
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
292	70T	Male	Day 56	13/05/93	YES			Confirmed irregularities
	80D	Male	Day 56	17/06/93	YES			As prescribed
	80T	Female	Day 56	03/06/93	YES			As prescribed
	210D	Female	Day 56	02/07/93	YES			As prescribed
	210T	Female	Day 56	28/06/93	YES			As prescribed
	220D	Female	Day 56	14/07/93	YES			As prescribed
	220T	Female	Day 56	23/06/93	YES			As prescribed
	230D	Female	Day 56	21/07/93	YES			As prescribed
	230T	Male	Day 56	08/07/93	YES			As prescribed
	240D	Male	Day 56	30/07/93	YES			As prescribed
	240T	Female	Day 56	27/07/93	YES			As prescribed
293	90D	Female	Day 56	14/04/93	YES			Suspected irregularities
	90T	Female	Day 56	20/07/93	YES			As prescribed
	100D	Female	Day 56	17/05/93	YES			Suspected irregularities
	100T	Female	Day 56	13/09/93	YES			Confirmed irregularities
	110D	Male	Day 56	05/09/93	YES			Confirmed irregularities
	110T	Female	Day 14	01/12/93	NO	Patient uncooperative	Patient	As prescribed

1269

9550089

19

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Adverse event	Decision to discontinue	Drug compliance
293	12ND	Male	Day 42	27/10/93	NO			Patient	As prescribed
	12DT	Female	Day 56	06/02/94	YES				Confirmed irregularities
294	13ND	Female	Day 56	12/04/93	YES				As prescribed
	13DT	Female	Day 56	03/05/93	YES				As prescribed
	14ND	Female	Day 56	12/04/93	YES				As prescribed
	14DT	Female	Day 56	03/05/93	YES				As prescribed
	15ND	Female	Day 56	19/04/93	YES				As prescribed
	15DT	Female	Day 56	03/05/93	YES				As prescribed
	16ND	Female	Day 56	19/04/93	YES				As prescribed
	16DT	Female	Day 56	03/05/93	YES				As prescribed
	25ND	Female	Day 56	08/08/93	YES				As prescribed
	26ND	Female	Day 56	08/08/93	YES				As prescribed
	27ND	Female	Day 56	02/08/93	NO	Lost to follow up		Patient	As prescribed
	28ND	Female	Day 56	09/08/93	YES				As prescribed
	29DT	Female	Day 56	08/08/93	YES				As prescribed
	30DT	Female	Day 56	08/08/93	YES				As prescribed
	31DT	Female	Day 56	15/08/93	YES				As prescribed

1270

9550089

20

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/03S
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
294	32DT	Male	Day 56	15/08/93	YES			As prescribed
295	17MD	Female	Day 56	15/06/93	YES			As prescribed
	17DT	Male	Day 56	23/06/93	YES			As prescribed
	18MD	Female	Day 56	17/06/93	YES			As prescribed
	18DT	Female	Day 56	23/06/93	YES			As prescribed
	19MD	Male	Day 56	08/07/93	YES			As prescribed
	19DT	Female	Day 56	04/07/93	YES			As prescribed
	20MD	Female	Day 56	08/07/93	YES			As prescribed
	20DT	Female	Day 56	06/07/93	YES			As prescribed
381	1MD	Male	Day 56	03/02/94	YES			As prescribed
	2MD	Female	Day 35	07/03/94	NO	Adverse event	Physician	As prescribed
	3DT	Female	Day 21	26/02/94	NO	Adverse event	Physician	As prescribed
	4MD	Female	Day 14	14/03/94	NO	Adverse event Protocol violation	Physician	As prescribed
382	5MD	Female	Day 56	12/01/94	YES			Confirmed irregularities
	5DT	Male	Day 21	12/11/93	NO	Lost to follow up	Patient	Unknown
	6MD	Female	Day 56	07/01/94	YES			As prescribed

1271

9550089

21

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
LISTING No.: 11.0

REASONS FOR DISCONTINUATION OF THE TREATMENT

Centre	Patient	Sex	Last visit	Date of last dose	Complete as protocol	Reason	Decision to discontinue	Drug compliance
382	6DT	Female	Day 56	17/12/93	YES			As prescribed
	7ND	Female	Day 56	07/02/94	YES			As prescribed
	7DT	Male	Day 7	26/10/93	NO	Adverse event	Physician	As prescribed
	8ND	Male	Day 21	11/02/94	NO	Adverse event	Physician	As prescribed
	8DT	Female	Day 56	15/02/94	YES			As prescribed
	9ND	Female	Day 56	08/04/94	YES			As prescribed
	9DT	Female	Day 35	09/03/94	NO	Adverse event Protocol violation Lost to follow up Patient uncooperative	Patient	Suspected irregularities
	10ND	Female	Day 7	16/02/94	NO	Adverse event	Physician	As prescribed
3301	1ND	Female	Day 7	24/09/92	NO	Intercurrent medical problem	Physician	As prescribed
	2ND	Male	Day 56	09/03/93	YES			As prescribed
	3ND	Female	Day 35	18/02/93	NO	Deterioration	Physician	As prescribed
3302	5ND	Female	Day 21	27/11/92	NO	Deterioration	Physician	As prescribed
	6ND	Female	Day 21	16/07/93	NO	Adverse event	Patient	As prescribed
	7ND	Female	Day 56	08/01/94	YES			As prescribed

1272

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

2

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day
1	2MD	Imipramine	Male		2	2	2	1	1	2	0	0	2	0	1
				05. INSOMNIA MIDDLE	2	2	1	1	2	0	0	0	0	0	0
				06. INSOMNIA LATE	2	2	2	1	1	2	0	0	0	0	0
				07. WORK AND ACTIVITIES	3	3	2	1	0	0	0	0	1	1	1
				08. RETARDATION	0	0	0	1	2	0	0	0	1	0	0
				09. AGITATION	1	1	0	0	1	0	0	0	0	0	0
				10. ANXIETY PSYCHIC	0	0	0	0	0	0	0	0	0	0	0
				11. ANXIETY SOMATIC	0	0	0	0	0	0	0	0	0	0	0
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	0	0	0	0	0
				13. SOMATIC GENERAL	1	1	1	1	0	0	0	0	0	0	0
				14. GENITAL SYMPTOMS	1	1	0	0	0	0	0	0	0	0	0
				15. HYPOCHONDRIASIS	1	1	0	0	0	0	0	0	0	0	0
				16. LOSS OF WEIGHT	1	1	0	0	0	0	0	0	0	0	0
				17. INSIGHT	1	1	1	1	2	1	0	0	1	1	1
				18. DIURNAL VARIATION	1	1	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	1	1	0	0	0	0	0	0	0	0	0
				20. PARANOID	1	1	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	25	25	13	20	9	1	10	5	10	5	5
2DT	Imipramine	Male			3	3	4	4	4	3	4	3	4	3	4
				01. DEPRESSED MOOD	1	1	0	0	0	0	0	0	0	0	0
				02. GUILT	2	2	2	2	2	2	2	2	2	2	2
				03. SUICIDE	2	2	2	2	2	2	2	2	2	2	2
				04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2
				05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2
				06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2
				07. WORK AND ACTIVITIES	1	1	1	2	1	2	1	2	1	2	1
				08. RETARDATION	3	3	2	2	3	2	3	2	3	2	3
				09. AGITATION	4	4	4	3	3	3	3	3	3	3	3
				10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2
				11. ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1
				13. SOMATIC GENERAL	0	0	0	0	0	0	0	0	0	0	0
				14. GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2
				15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0	0	0	0
				22. Total score	31	31	33	31	31	31	33	31	31	31	31
3MD	Imipramine	Female			3	2	2	2	0	0	0	0	0	0	0
				01. DEPRESSED MOOD	1	1	0	0	0	0	0	0	0	0	0
				02. GUILT	0	0	0	0	0	0	0	0	0	0	0
				03. SUICIDE	2	2	0	0	0	0	0	0	0	0	0
				04. INSOMNIA EARLY	1	1	0	0	0	0	0	0	0	0	0
				05. INSOMNIA MIDDLE	2	2	0	0	0	0	0	0	0	0	0
				06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2
				07. WORK AND ACTIVITIES	3	2	1	0	0	0	0	0	0	0	0
				08. RETARDATION	3	2	1	0	0	0	0	0	0	0	0
				09. AGITATION	0	0	1	1	0	0	0	0	0	0	0

1274

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

3

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63
1	3ND	Imipramine	Female	HAMILTON DEPRESSION RATING SCALE		1	2	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
						3	2	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
						2	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
						0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
						1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
						0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
						1	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
						0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
						0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
						0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
						0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
						0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
						20	23	13	6	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0
3DT	Reboxetine	Male				3	3	3	4	3	3	1	2	3	1	2	3	1	0	0	0	0	0	0
						0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
						0	0	0	2	2	2	2	2	2	1	0	0	0	0	0	0	0	0	0
						2	2	2	2	2	2	2	2	2	1	0	0	0	0	0	0	0	0	0
						2	2	2	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1
						3	3	3	3	3	3	1	3	2	1	0	0	0	0	0	0	0	0	0
						2	2	2	1	1	1	2	0	0	0	0	0	0	0	0	0	0	0	0
						1	1	1	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1
						3	3	3	1	3	3	1	2	1	0	2	1	0	2	1	0	0	0	0
						2	2	2	1	1	1	1	0	2	1	0	2	1	0	2	1	0	0	0
						0	0	0	1	1	1	1	1	0	2	0	2	0	2	0	0	0	0	0
						1	1	1	0	1	1	1	1	1	0	2	2	0	2	0	0	0	0	0
						2	2	2	2	2	2	3	3	1	2	2	2	2	2	2	2	2	2	2
						2	2	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
						0	0	0	1	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0
						0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
						0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
						27	27	24	32	26	12	20	20	7	3									
4ND	Reboxetine	Female				3	3	3	3	3	3	3	2	2	1	1	1	1	1	1	1	1	1	1
						2	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1
						2	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1
						2	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1
						2	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1
						3	3	3	2	2	2	2	2	2	0	0	0	0	0	0	0	0	0	0
						2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
						2	2	2	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1
						3	3	3	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1
						2	2	2	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1
						2	2	2	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1
						1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1

1275

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

4

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient Treatment	Sex	HAMILTON DEPRESSION RATING SCALE																			
			Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63									
1	4WD	Female	13. SOMATIC GENERAL	1	1	0	0	0	0	0	0	1	1	0	0	1	1					
			14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
			15. HYPOCHONDRIASIS	3	3	2	2	0	0	2	0	1	1	1	0	0	0	0				
			16. LOSS OF WEIGHT	2	2	1	2	0	0	1	0	0	0	0	0	0	0	0	0			
			17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
			18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
			19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
			20. PARANOID	2	2	2	2	0	1	2	2	0	0	0	0	0	1	1	0			
			21. OBSESSIONAL/COMPULSIVE	0	0	0	1	0	1	0	1	1	0	1	1	0	1	1	1			
			22. Total score	35	35	34	26	33	24	18	13	12	7									
			4DT	Imipramine	Male	01. DEPRESSED MOOD	4	4	3	2	0	3	4									
						02. GUILT	3	3	2	0	0	2										
						03. SUICIDE	1	1	0	0	1											
						04. INSOMNIA EARLY	2	2	1	1	1	2										
						05. INSOMNIA MIDDLE	2	2	1	0	2											
						06. INSOMNIA LATE	2	2	2	1	2											
						07. WORK AND ACTIVITIES	3	3	2	2	2											
						08. RETARDATION	2	2	1	1	1	2										
						09. AGITATION	0	0	0	1	1	2										
						10. ANXIETY PSYCHIC	3	3	1	1	1	3										
						11. ANXIETY SOMATIC	2	2	0	1	3											
						12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	0										
13. SOMATIC GENERAL	1	1				1	1	0	0													
14. GENITAL SYMPTOMS	0	0				0	0	0	2													
15. HYPOCHONDRIASIS	2	2				0	0	0	0													
16. LOSS OF WEIGHT	0	0				0	0	0	0													
17. INSIGHT	0	0				0	0	0	0													
18. DIURNAL VARIATION	0	0				0	0	0	0													
19. DEPERSONALIZATION	1	1				0	0	1	0													
20. PARANOID	0	0				0	0	0	0													
21. OBSESSIONAL/COMPULSIVE	1	1				1	1	0	0													
22. Total score	30	30				18	14	29														
2	1MD	Male	01. DEPRESSED MOOD	4	4	3	2	1	3													
			02. GUILT	0	0	0	0	0	0													
			03. SUICIDE	2	2	1	1	1														
			04. INSOMNIA EARLY	2	2	0	0	0	1													
			05. INSOMNIA MIDDLE	2	2	2	2	2														
			06. INSOMNIA LATE	0	0	1	0	1	2													
			07. WORK AND ACTIVITIES	3	3	4	3	3														
			08. RETARDATION	0	0	0	0	0	1													
			09. AGITATION	1	1	1	0	0	1													
			10. ANXIETY PSYCHIC	1	1	1	1	1	2													
			11. ANXIETY SOMATIC	2	2	2	1	1	2													
			12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1													
			13. SOMATIC GENERAL	2	2	2	2	2	2													
			14. GENITAL SYMPTOMS	0	0	0	0	0	0													
			15. HYPOCHONDRIASIS	1	1	1	1	1	1													
			16. LOSS OF WEIGHT	2	2	1	1	1	2													

1276

9550089

5

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient Treatment	Sex	Hamilton depression rating scale	Screen Day	0	7	14	21	28	35	42	49	56	Day 63						
2	1ND	Reboxetine	Male	17.INSIGHT	1	1	0	1	1	0	0	0	0	0						
				18.DIURNAL VARIATION	0	0	0	0	2	2										
				19.DEPERSONALIZATION	1	0	0	0	0	0	0	0	0	0	0	0				
				20.PARANOID	1	0	0	0	0	0	0	0	0	0	0	0				
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0				
				22.Total score	26	26	17	18	20	27										
				3	1ND	Reboxetine	Female	01.DEPRESSED MOOD	3	3	4	3	3	3	3	3	3	3		
								02.GUILTY	0	0	0	0	0	0	0	0	0	0	0	
								03.SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2
								04.INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2
								05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2
								06.INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2
								07.WORK AND ACTIVITIES	4	2	4	3	3	3	2	2	2	2	2	2
								08.RETARDATION	1	2	2	1	2	1	1	1	1	1	1	1
								09.AGITATION	0	0	0	0	0	0	0	0	0	0	0	0
								10.ANKIETY PSYCHIC	3	0	0	0	0	0	0	0	0	0	0	0
								11.ANKIETY SOMATIC	0	0	0	0	0	0	0	0	0	0	0	0
								12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1
								13.SOMATIC GENERAL	0	2	2	2	2	2	2	2	2	2	2	2
								14.GENERAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0
								15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0
								16.LOSS OF WEIGHT	0	1	0	0	0	0	0	0	0	0	0	0
17.INSIGHT	0	0	0					0	0	0	0	0	0	0	0	0				
18.DIURNAL VARIATION	0	0	0					0	0	0	0	0	0	0	0	0				
19.DEPERSONALIZATION	0	0	0					0	0	0	0	0	0	0	0	0				
20.PARANOID	0	0	0					0	0	0	0	0	0	0	0	0				
21.OBSESSIONAL/COMPULSIVE	0	0	0					0	0	0	0	0	0	0	0	0				
22.Total score	20	18	23					17	18	18	12	11	17							
4	1ND	Imipramine	Male	01.DEPRESSED MOOD	1	1	1	1	1	1	1	1	1	2						
				02.GUILTY	2	2	2	2	2	2	2	2	2	2	2					
				03.SUICIDE	1	1	1	1	1	1	1	1	1	1	1					
				04.INSOMNIA EARLY	2	2	1	0	0	1	1	1	1	1	1					
				05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0					
				06.INSOMNIA LATE	1	1	2	2	2	2	2	2	2	2	2					
				07.WORK AND ACTIVITIES	2	3	3	3	3	3	3	3	3	3	3					
				08.RETARDATION	1	1	1	1	1	1	1	1	1	1	1					
				09.AGITATION	1	1	1	1	1	1	1	1	1	1	1					
				10.ANKIETY PSYCHIC	3	3	3	3	3	3	3	3	3	3	3					
				11.ANKIETY SOMATIC	0	0	0	0	0	0	0	0	0	0	0					
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1					
				13.SOMATIC GENERAL	0	0	0	0	0	0	0	0	0	0	0					
				14.GENERAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0					
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0					
				16.LOSS OF WEIGHT	2	2	2	2	2	2	2	2	2	2	2					
				17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0					
				18.DIURNAL VARIATION	2	2	2	2	2	2	2	2	2	2	2					
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0					
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0					

1237

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

6

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63						
4	1ND	Imipramine	Male	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
			22.Total score	19	20	21	17	15	13	19																				
5	1ND	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	2																						
				02.GUILT	0	0	0	0																						
				03.SUICIDE	1	1	1	1																						
				04.INSOMNIA EARLY	1	1	1	1																						
				05.INSOMNIA MIDDLE	1	1	1	1																						
				06.INSOMNIA LATE	0	0	0	0																						
				07.WORK AND ACTIVITIES	3	3	3	3																						
				08.RETARDATION	2	2	2	2																						
				09.AGITATION	2	2	2	2																						
				10.ANXIETY PSYCHIC	1	1	1	1																						
				11.ANXIETY SOMATIC	1	1	1	1																						
				12.SOMATIC GASTROINTESTINAL	1	1	1	1																						
				13.SOMATIC GENERAL	0	0	0	0																						
				14.CENTRAL SYMPTOMS	2	2	2	2																						
				15.HYPOCHONDRIASIS	0	0	0	0																						
				16.LOSS OF WEIGHT	0	0	0	0																						
				17.INSIGHT	1	1	1	1																						
				18.DIURNAL VARIATION	0	0	0	0																						
				19.DEPERSONALIZATION	0	0	0	0																						
				20.PARANOID	2	2	2	2																						
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0																						
				22.Total score	22	24	21	27																						
10T	Imipramine	Female	01.DEPRESSED MOOD	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
			02.GUILT	2	2	2	2																							
			03.SUICIDE	2	2	2	2																							
			04.INSOMNIA EARLY	2	2	2	2																							
			05.INSOMNIA MIDDLE	2	2	2	2																							
			06.INSOMNIA LATE	1	1	1	1																							
			07.WORK AND ACTIVITIES	1	1	1	1																							
			08.RETARDATION	1	1	1	1																							
			09.AGITATION	2	2	2	2																							
			10.ANXIETY PSYCHIC	4	4	4	4																							
			11.ANXIETY SOMATIC	4	4	4	4																							
			12.SOMATIC GASTROINTESTINAL	2	2	2	2																							
			13.SOMATIC GENERAL	1	1	1	1																							
			14.CENTRAL SYMPTOMS	0	0	0	0																							
			15.HYPOCHONDRIASIS	3	3	3	3																							
			16.LOSS OF WEIGHT	0	0	0	0																							
			17.INSIGHT	1	1	1	1																							
			18.DIURNAL VARIATION	1	1	1	1																							
			19.DEPERSONALIZATION	0	0	0	0																							
			20.PARANOID	1	1	1	1																							
			21.OBSESSIONAL/COMPULSIVE	0	0	0	0																							
			22.Total score	32	31	31	25																							

1278

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

7

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient Treatment	Sex	Hamilton depression rating scale	HAMILTON DEPRESSION RATING SCALE																						
				Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63													
5	2ND	Male	01. DEPRESSED MOOD	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
			02. GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			04. INSOMNIA EARLY	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			05. INSOMNIA MIDDLE	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			06. INSOMNIA LATE	2	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
			08. RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			09. AGITATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			10. ANXIETY PSYCHIC	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
			11. ANXIETY SOMATIC	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
			12. SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			15. HYPOCHONDRIASIS	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
			16. LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			22. Total score			23	25	20	19	17	14	13	14	23	14	23	27									
2DT	Imipramine	Female	01. DEPRESSED MOOD	3	3	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2		
			02. GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			03. SUICIDE	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			04. INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			05. INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			06. INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
			08. RETARDATION	3	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			09. AGITATION	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
			10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			11. ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			13. SOMATIC GENERAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			14. GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			15. HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			16. LOSS OF WEIGHT	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			17. INSIGHT	2	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			20. PARANOID	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			22. Total score			26	26	18	17	17	14	13	14	23	21	23										
3ND	Imipramine	Female	01. DEPRESSED MOOD	3	3	3	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0		
			02. GUILT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
			03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	

1279

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

10

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day							
5	SMD	Reboxetine	Male	13. SOMATIC GENERAL	1	2	1	1	1													
				14. GENITAL SYMPTOMS	2	2	0	2														
				15. HYPOCHONDRIASIS	1	1	1	2	4													
				16. LOSS OF WEIGHT	0	0	0	0	0													
				17. INSIGHT	2	1	2	2														
				18. DIURNAL VARIATION	0	0	0	0	0													
				19. DEPERSONALIZATION	2	1	1	1	1													
				20. PARANOID	2	1	1	1	1													
				21. OBSESSIONAL/COMPULSIVE	0	1	1	1	2													
				22. Total score	29	29	27	27														
				5DT	Reboxetine	Female	01. DEPRESSED MOOD	3	3	1	1	3	4	4						4		
							02. GUILT	1	1	4	3	0	4								4	
							03. SUICIDE	1	2	1	0	2	4									4
							04. INSOMNIA EARLY	1	1	2	2	2	4									4
							05. INSOMNIA MIDDLE	0	0	1	1	1	2									4
							06. INSOMNIA LATE	0	0	1	1	1	1									2
							07. NOOK AND ACTIVITIES	5	3	3	1	1	1	1	1	2						2
							08. RETARDATION	1	1	2	1	1	1	3	4							4
							09. AGITATION	1	1	2	1	1	1	1	0	0						0
							10. ANXIETY PSYCHIC	2	1	2	1	1	1	1	1	1	1	1	1	1	1	4
							11. ANXIETY SOMATIC	1	1	2	1	2	2	2	2	2	2	2	2	2	2	4
							12. SOMATIC GASTROINTESTINAL	1	1	2	2	2	2	2	2	2	2	2	2	2	2	4
13. SOMATIC GENERAL	2	2	1				2	2	2	2	2	2	2	2	2	2	2	4				
14. GENITAL SYMPTOMS	1	1	1				1	1	1	1	1	1	1	1	1	1	1	4				
15. HYPOCHONDRIASIS	2	3	1				1	1	1	1	1	1	1	1	1	1	1	4				
16. LOSS OF WEIGHT	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0				
17. INSIGHT	2	2	1				2	2	2	2	2	2	2	2	2	2	2	4				
18. DIURNAL VARIATION	1	1	0				1	0	0	0	0	0	0	0	0	0	0	0				
19. DEPERSONALIZATION	1	0	1				0	0	0	0	0	0	0	0	0	0	0	1				
20. PARANOID	0	0	0				0	0	0	0	0	0	0	0	0	0	0	1				
21. OBSESSIONAL/COMPULSIVE	0	0	0				0	0	0	0	0	0	0	0	0	0	0	1				
22. Total score	26	25	28				28	24	27	27	27	27	27	27	27	27	27	43				
6HD	Imipramine	Male	01. DEPRESSED MOOD	3	4	2	2	2														
			02. GUILT	0	0	0	0	0														
			03. SUICIDE	0	0	0	0	0														
			04. INSOMNIA EARLY	1	1	1	1	2														
			05. INSOMNIA MIDDLE	1	1	1	1	1														
			06. INSOMNIA LATE	2	1	1	1	1														
			07. NOOK AND ACTIVITIES	2	4	2	2	2														
			08. RETARDATION	2	4	0	1	1														
			09. AGITATION	2	1	2	2	1														
			10. ANXIETY PSYCHIC	2	2	1	2	2														
			11. ANXIETY SOMATIC	3	1	1	1	1														
			12. SOMATIC GASTROINTESTINAL	2	0	0	0	0														
			13. SOMATIC GENERAL	2	1	1	1	1														
			14. GENITAL SYMPTOMS	1	0	1	1	1														
			15. HYPOCHONDRIASIS	1	0	1	1	1														
			16. LOSS OF WEIGHT	3	2	2	2	2														

1282

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

11

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63					
5	6ND	Imipramine	Male	17.INSIGHT	2	2	1	1											
				18. DIURNAL VARIATION	0	0	0	0											
				19. DEPERSONALIZATION	1	0	0	0											
				20. PARANOID	1	0	0	0											
				21. OBSESSIONAL/COMPULSIVE	1	1	1	1											
				22.Total score	31	25	17	21											
				6DT	Reboxetine	Female	01. DEPRESSED MOOD	3	3	1	1	0	1	0	0	0	0	0	
							02. GUILT	3	3	2	2	0	0	0	0	0	0	0	0
							03. SUICIDE	2	1	2	1	0	0	0	0	0	0	0	0
							04. INSOMNIA EARLY	2	2	1	2	1	1	2	1	2	1	2	2
							05. INSOMNIA MIDDLE	2	2	1	2	1	2	1	2	2	1	2	1
							06. INSOMNIA LATE	0	1	0	1	0	0	0	0	0	0	0	0
							07. WORK AND ACTIVITIES	2	3	2	1	0	0	0	0	0	0	0	0
							08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0
							09. AGITATION	3	4	3	3	2	3	1	2	1	2	1	2
							10. ANXIETY PSYCHIC	4	4	3	3	2	1	1	1	1	1	1	1
							11. ANXIETY SOMATIC	4	4	3	3	2	1	1	1	1	1	1	1
							12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	1	1	1	1	1	1
							13. SOMATIC GENERAL	0	0	0	0	0	0	0	2	0	0	0	0
							14. GENITAL SYMPTOMS	3	4	3	3	2	0	1	0	1	0	1	1
							15. HYPOCHONDRIASIS	2	1	0	0	0	0	0	0	0	0	0	0
							16. LOSS OF WEIGHT	0	0	1	1	0	0	0	0	0	0	0	0
17. INSIGHT	1	1	1				1	1	1	1	1	1	1	1	1				
18. DIURNAL VARIATION	1	1	1				1	0	1	0	0	0	0	0	0				
19. DEPERSONALIZATION	0	1	1				1	0	1	0	0	0	0	0	0				
20. PARANOID	0	1	1				1	0	0	0	0	0	0	0	0				
21. OBSESSIONAL/COMPULSIVE	2	2	2				1	1	1	1	1	1	1	1	1				
22.Total score	38	41	29				26	15	18	10	8	11	12						
7ND	Reboxetine	Male	01. DEPRESSED MOOD	3	3	3	3	3											
			02. GUILT	2	3	3	3	1	0	0									
			03. SUICIDE	0	1	1	1	0	0										
			04. INSOMNIA EARLY	2	2	2	2	2	0										
			05. INSOMNIA MIDDLE	2	2	2	2	2	1										
			06. INSOMNIA LATE	2	2	1	2	1	1										
			07. WORK AND ACTIVITIES	4	4	2	0	4	1										
			08. RETARDATION	0	0	2	1	4	0										
			09. AGITATION	2	2	2	2	0	1										
			10. ANXIETY PSYCHIC	1	1	2	1	2	1										
			11. ANXIETY SOMATIC	3	2	1	1	1	3										
			12. SOMATIC GASTROINTESTINAL	2	1	2	1	0	0										
			13. SOMATIC GENERAL	4	1	2	1	1	1										
			14. GENITAL SYMPTOMS	2	1	1	1	2	2										
			15. HYPOCHONDRIASIS	3	1	1	1	0	0										
			16. LOSS OF WEIGHT	0	0	0	0	1	1										
			17. INSIGHT	0	1	1	1	1	1										
			18. DIURNAL VARIATION	0	0	0	0	0	0										
			19. DEPERSONALIZATION	0	1	1	1	1	1										
			20. PARANOID	0	1	1	1	1	1										
			21. OBSESSIONAL/COMPULSIVE	2	2	2	1	1	1										
			22.Total score	38	41	29	26	15	18	10	8	11	12						

1283

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

12

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient Treatment	Sex	Hamilton depression rating scale	Screen Day	0	7	14	21	28	35	42	49	56	Day 63	
5	7ND	Reboxetine	Male	2	1	1	1	1							
		22.Total score		32	31	27	33	18							
5	7DT	Imipramine	Female	3	3	2	1	1	0	0	0	0	0	0	
			01. DEPRESSED MOOD												
			02. GUILT	2	2	1	1	1	0	0	0	0	0	0	0
			03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0
			04. INSOMNIA EARLY	2	2	1	1	1	0	0	0	0	0	0	0
			05. INSOMNIA MIDDLE	1	1	1	1	1	0	0	0	0	0	0	0
			06. INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0
			07. WORK AND ACTIVITIES	2	2	2	1	1	0	0	0	0	0	0	0
			08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0
			09. AGITATION	2	2	1	1	0	0	0	0	0	0	0	0
			10. ANXIETY PSYCHIC	3	3	2	2	1	1	1	1	1	1	1	1
			11. ANXIETY SOMATIC	1	1	1	1	0	0	0	0	0	0	0	0
			12. SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	0	0	0	0	0	0
			13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1
			14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0
			15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0
			16. LOSS OF WEIGHT	2	2	0	0	0	0	0	0	0	0	0	0
			17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0
			18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0
			19. DEPERSONALIZATION	2	2	1	1	1	1	0	0	0	0	0	0
			20. PARANOID	2	2	1	1	1	0	0	0	0	0	0	0
			21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0
22.Total score		26	26	17	14	9	6	7	5	4	3	4	3		
5	8ND	Imipramine	Female	3	3	4	3	2	2	1	0	0	0	1	
			01. DEPRESSED MOOD												
			02. GUILT	2	2	2	2	1	0	0	0	0	0	0	0
			03. SUICIDE	0	0	1	1	1	0	0	0	0	0	0	0
			04. INSOMNIA EARLY	1	1	0	2	0	0	0	0	0	0	0	0
			05. INSOMNIA MIDDLE	0	0	1	2	0	1	1	0	0	0	0	0
			06. INSOMNIA LATE	2	2	1	1	2	1	1	0	0	0	0	0
			07. WORK AND ACTIVITIES	4	4	4	3	2	3	2	2	1	1	1	1
			08. RETARDATION	3	3	2	2	2	1	0	0	0	0	0	0
			09. AGITATION	1	1	1	1	1	0	0	0	0	0	0	0
			10. ANXIETY PSYCHIC	1	1	2	2	1	1	1	1	1	1	1	1
			11. ANXIETY SOMATIC	0	0	1	1	1	1	1	1	1	1	1	1
			12. SOMATIC GASTROINTESTINAL	2	2	1	2	1	2	0	0	0	0	0	0
			13. SOMATIC GENERAL	2	2	2	2	1	1	1	1	1	1	1	1
			14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0
			15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0
			16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0
			17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0
			18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0
			19. DEPERSONALIZATION	1	1	0	0	0	0	0	0	0	0	0	0
			20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0
			21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0
22.Total score		22	25	25	27	22	17	10	8	5	7	5	7		

1284

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

14

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63
5	90T	Reboxetine	Female	05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
				06.INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	3	2	3	2	3	2	3	2	3	2	3	2	3	2	3	2	3
				08.RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				09.AGITATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				17.INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				20.PARANOID	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22.Total score	19	20	15	13	10	5	2	3	2	2	3	2	2	3	2	2	2	2	2	3
10ND		Imipramine	Female	01.DEPRESSED MOOD	4	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				02.GUILT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				03.SUICIDE	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	0	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				08.RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				09.AGITATION	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				16.LOSS OF WEIGHT	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				17.INSIGHT	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				18.DIURNAL VARIATION	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20.PARANOID	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				22.Total score	29	30	27	20	20	27	20	20	20	20	20	20	20	20	20	20	20	20	20	20
10DT		Imipramine	Male	01.DEPRESSED MOOD	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				02.GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				08.RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

1286

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

15

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day						
5	10DT	Imipramine	Male	09. AGITATION	3	3	2														
				10. ANXIETY PSYCHIC	1	1	1														
				11. ANXIETY SOMATIC	2	2	2														
				12. SOMATIC GASTROINTESTINAL	1	1	1														
				13. SOMATIC GENERAL	2	2	2														
				14. GENITAL SYMPTOMS	1	1	2														
				15. HYPOCHONDRIASIS	0	0	0														
				16. LOSS OF WEIGHT	0	0	0														
				17. INSIGHT	1	1	1														
				18. DIURNAL VARIATION	1	1	1														
				19. DEPERSONALIZATION	0	0	0														
				20. PARANOID	1	1	1														
				21. OBSESSIONAL/COMPULSIVE	0	0	0														
				22. Total score	19	19	19														
				11ND	Imipramine	Female	01. DEPRESSED MOOD	2	2	2	2	4	3	3	3	3	3	3	3		
							02. GUILT	1	1	0	0	1	1	1	1	1	1	1	1	1	
							03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0
							04. INSOMNIA EARLY	1	1	1	1	1	1	0	0	0	0	0	0	0	0
							05. INSOMNIA MIDDLE	1	1	1	1	1	1	0	0	0	0	0	0	0	0
							06. INSOMNIA LATE	1	2	2	2	2	2	2	2	2	2	2	2	2	2
							07. WORK AND ACTIVITIES	2	1	1	1	4	4	4	4	4	4	4	4	4	4
							08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2
09. AGITATION	2	2	2				2	2	2	2	2	2	2	2	2	2	2				
10. ANXIETY PSYCHIC	1	0	0				0	0	0	0	0	0	0	0	0	0	0				
11. ANXIETY SOMATIC	1	0	0				0	0	0	0	0	0	0	0	0	0	0				
12. SOMATIC GASTROINTESTINAL	2	2	2				2	2	2	2	2	2	2	2	2	2	2				
13. SOMATIC GENERAL	1	1	1				1	1	1	0	0	0	0	0	0	0	0				
14. GENITAL SYMPTOMS	2	2	2				2	2	2	2	2	2	2	2	2	2	2				
15. HYPOCHONDRIASIS	1	1	1				1	1	1	1	1	1	1	1	1	1	1				
16. LOSS OF WEIGHT	1	1	1				1	1	1	2	0	0	0	0	0	0	0				
17. INSIGHT	2	2	2				2	2	2	2	2	2	2	2	2	2	2				
18. DIURNAL VARIATION	1	1	1				1	1	1	0	0	0	0	0	0	0	0				
19. DEPERSONALIZATION	0	0	0				0	0	0	0	0	0	0	0	0	0	0				
20. PARANOID	0	0	0				0	0	0	0	0	0	0	0	0	0	0				
21. OBSESSIONAL/COMPULSIVE	0	0	0				0	0	0	0	0	0	0	0	0	0	0				
22. Total score	29	21	20				27	22	22	22	22	22	22	22	22	22	22	22			
11DT	Reboxetine	Female	01. DEPRESSED MOOD	3	3	3	1	1	1	1	1	1	1	1	1						
			02. GUILT	2	2	2	2	2	2	2	2	2	2	2	2	2					
			03. SUICIDE	1	1	1	0	0	0	0	0	0	0	0	0	0					
			04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2					
			05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1					
			06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1					
			07. WORK AND ACTIVITIES	3	3	3	2	2	2	2	2	2	2	2	2	2					
			08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0					
			09. AGITATION	3	3	3	3	3	3	3	3	3	3	3	3	3					
			10. ANXIETY PSYCHIC	3	3	3	2	2	2	2	2	2	2	2	2	2					
			11. ANXIETY SOMATIC	3	3	3	3	3	3	3	3	3	3	3	3	3					
			12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1					

1287

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

16

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
5	14DT	Reboxetine	Female		2	2	2	2	2	2	2	2	2	2
				13. SOMATIC GENERAL	0	0	0	0	0	0	0	0	0	0
				14. GENITAL SYMPTOMS	4	4	3	3	3	3	3	3	3	3
				15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0
				16. LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	2	2	2	2	2	2	2	2	2	2
				20. PARANOID	2	2	2	2	2	2	2	2	2	2
				21. OBSESSIONAL/COMPULSIVE	35	35	29	28	25	25	25	25	25	25
				22. Total score										
12ND	Reboxetine	Female			3	2	1	1	2	3	2	2	2	2
				01. DEPRESSED MOOD	2	1	1	0	0	2	1	1	0	0
				02. GUILT	0	1	0	0	0	0	0	0	0	0
				03. SUICIDE	2	1	0	1	1	2	2	2	1	1
				04. INSOMNIA EARLY	0	1	0	1	1	0	0	0	0	0
				05. INSOMNIA MIDDLE	0	1	2	1	1	0	0	0	1	1
				06. INSOMNIA LATE	0	0	1	0	0	0	0	1	2	1
				07. WORK AND ACTIVITIES	1	3	2	1	1	1	3	1	0	0
				08. RETARDATION	2	1	1	1	1	1	1	0	0	0
				09. AGITATION	1	2	1	1	1	1	1	1	1	0
				10. ANXIETY PSYCHIC	2	2	2	1	1	1	1	1	1	0
				11. ANXIETY SOMATIC	2	2	1	1	1	1	1	1	1	0
				12. SOMATIC GASTROINTESTINAL	2	2	2	2	1	2	1	1	1	0
				13. SOMATIC GENERAL	2	2	2	2	1	0	1	0	2	1
				14. GENITAL SYMPTOMS	1	1	1	0	0	1	1	2	1	1
				15. HYPOCHONDRIASIS	2	1	2	1	1	0	2	2	2	1
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0
				17. INSIGHT	2	2	1	2	1	1	0	0	0	1
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	0	0	0	0	1	0	0	1	1	0
				20. PARANOID	0	1	1	1	0	0	1	1	1	1
				21. OBSESSIONAL/COMPULSIVE	0	0	1	1	0	0	1	1	0	1
				22. Total score	24	26	25	18	13	8	19	21	19	16
12DT	Imipramine	Male			1	1	1	0	0	0	0	0	0	0
				01. DEPRESSED MOOD	2	2	2	2	2	2	1	1	1	0
				02. GUILT	0	0	0	0	0	0	0	0	0	0
				03. SUICIDE	1	1	1	1	1	1	1	1	1	0
				04. INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0
				05. INSOMNIA MIDDLE	2	2	2	1	1	1	1	0	0	0
				06. INSOMNIA LATE	2	2	2	1	1	1	1	0	0	0
				07. WORK AND ACTIVITIES	1	1	1	1	1	1	1	1	1	1
				08. RETARDATION	2	3	1	1	1	1	1	1	1	0
				09. AGITATION	3	3	1	1	1	1	1	0	0	0
				10. ANXIETY PSYCHIC	1	1	1	1	1	1	1	1	1	0
				11. ANXIETY SOMATIC	0	0	0	0	0	0	0	0	0	0
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	0
				13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	0
				14. GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	1
				15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0
				16. LOSS OF WEIGHT	2	2	2	2	2	2	2	2	2	1
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	2	2	2	2	2	2	2	2	2	1
				22. Total score	0	0	0	0	0	0	0	0	0	0

1288

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63								
5	12DT	Inipramine	Male	17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0							
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
				20.PARANOID	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
				21.OBSESSIONAL/COMPULSIVE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
				22.Total score	23	24	20	14	14	14	14	11	7	6	3																	
				6	14ND	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
								02.GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
								03.SUICIDE	2	2	2	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
								04.INSOMNIA EARLY	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
05.INSOMNIA MIDDLE	2	2	2					2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
06.INSOMNIA LATE	2	2	2					2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
07.WORK AND ACTIVITIES	4	4	4					4	4	4	4	3	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
08.RETARDATION	3	3	2					2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
09.AGITATION	0	0	0					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
10.ANXIETY PSYCHIC	0	0	0					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
11.ANXIETY SOMATIC	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0								
12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2								
13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1								
14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0								
15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0								
16.LOSS OF WEIGHT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2								
17.INSIGHT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2								
18.DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1								
19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0								
20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0								
21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0								
22.Total score	25	25	22	19	13	13	10	8	7																							
10T	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2							
			02.GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0						
			03.SUICIDE	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
			04.INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
			05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
			06.INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
			07.WORK AND ACTIVITIES	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
			08.RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
			09.AGITATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
			10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1								
12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1								
13.SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2								
14.GENITAL SYMPTOMS	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2								
15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0								
16.LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1								
17.INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1								
18.DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0								
19.DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1								
20.PARANOID	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1								

1289

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

18

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
6	1DT	Reboxetine	Female	21. OBSESSIONAL/COMPULSIVE	1	1	1	1	1	0	0	0	0	0	0		
		22. Total score	26	26	24	17	11	42	9	6	9	9					
2ND	Imipramine	Female	01. DEPRESSED MOOD	4	4	4	4	4	4	4	4	4	4	4	4		
			02. GUILT	1	2	2	2	2	2	2	2	2	2	2	2	2	
			03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			04. INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3
			08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			09. AGITATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			14. GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			15. HYPOCHONDRIASIS	1	2	2	2	2	2	2	2	2	2	2	2	2	2
			16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			19. DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			22. Total score	27	29	35	27	29	35	27	29	35	27	29	35	27	29
2DT	Reboxetine	Female	01. DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2	2	2		
			02. GUILT	1	1	1	1	1	1	1	1	1	1	1	1	1	
			03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			04. INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			06. INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3
			08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			09. AGITATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			10. ANXIETY PSYCHIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			11. ANXIETY SOMATIC	2	1	1	1	1	1	1	1	1	1	1	1	1	1
			12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			14. GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			16. LOSS OF WEIGHT	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			18. DIURNAL VARIATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			22. Total score	25	23	22	25	23	22	25	23	22	25	23	22	25	23

1290

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

19

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day
6	3ND	Reboxetine	Female	HAMILTON DEPRESSION RATING SCALE											
				01. DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3
				02. GUILT	2	2	2	2	2	2	2	2	2	2	2
				03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1
				04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2
				05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1
				06. INSOMNIA LATE	1	1	2	2	2	2	2	2	2	2	2
				07. WORK AND ACTIVITIES	3	4	3	3	3	3	2	2	2	2	2
				08. RETARDATION	1	1	1	0	0	0	0	0	0	0	0
				09. AGITATION	2	2	2	2	2	2	2	2	2	2	2
				10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2
				11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1
				13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2
				14. GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2
				15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2
				16. LOSS OF WEIGHT	2	1	2	0	0	0	0	0	0	0	0
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1
				19. DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1
				22. Total score	32	33	34	29	29	23	31	20	27	20	27
				01. DEPRESSED MOOD	4	4	3	4	3	2	3	3	3	3	3
				02. GUILT	0	0	0	0	0	0	0	0	0	0	0
				03. SUICIDE	2	2	1	2	1	1	1	1	1	1	0
				04. INSOMNIA EARLY	2	2	1	2	2	2	2	2	2	2	2
				05. INSOMNIA MIDDLE	1	1	1	1	0	0	2	1	1	1	1
				06. INSOMNIA LATE	1	1	0	1	1	1	1	0	0	0	0
				07. WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2
				08. RETARDATION	2	2	2	2	2	1	1	1	1	1	1
				09. AGITATION	0	0	0	1	1	0	0	0	0	0	0
				10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2
				11. ANXIETY SOMATIC	1	1	1	2	2	1	0	2	2	2	2
				12. SOMATIC GASTROINTESTINAL	0	0	0	1	1	0	0	0	0	0	0
				13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2
				14. GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2
				15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	1	1	1	1	1	1	1	1	1	1	1
				21. OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1
				22. Total score	25	25	20	26	22	10	21	20	21	20	19
				01. DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2	2
				02. GUILT	0	0	0	0	0	0	0	0	0	0	0
				03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1
				04. INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1

1291

4ND

Imipramine Female

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

21

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63							
6	SMD	Imipramine	Female	HAMILTON DEPRESSION RATING SCALE																											
				09. AGITATION	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
				10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				11. ANXIETY SOMATIC	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
				13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				14. GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				16. LOSS OF WEIGHT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				19. DEPERSONALIZATION	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
				20. PARANOID	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				22. Total score	28	26	24	23	24	23	24	22	21	22	21	22	22	21	22	21	22	21	22	22	21	22	22	21	27		
				50Y	Reboxetine	Female	HAMILTON DEPRESSION RATING SCALE																								
							01. DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
							02. GUILT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
							03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
							04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
							05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
							06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
07. WORK AND ACTIVITIES	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
08. RETARDATION	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
09. AGITATION	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
10. ANXIETY PSYCHIC	1	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
11. ANXIETY SOMATIC	1	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
12. SOMATIC GASTROINTESTINAL	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
13. SOMATIC GENERAL	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
14. GENITAL SYMPTOMS	1	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
15. HYPOCHONDRIASIS	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
16. LOSS OF WEIGHT	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
17. INSIGHT	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
18. DIURNAL VARIATION	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
19. DEPERSONALIZATION	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
20. PARANOID	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
21. OBSESSIONAL/COMPULSIVE	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
22. Total score	20	20	20	16	13	16	13	11	11	10	9	8	8	8	8	8	8	8	8	8	8	8	8	8							
6HD	Reboxetine	Female	HAMILTON DEPRESSION RATING SCALE																												
			01. DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3					
			02. GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
			03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
			04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
			05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
			06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
			07. WORK AND ACTIVITIES	4	3	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
			08. RETARDATION	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
			09. AGITATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
			10. ANXIETY PSYCHIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
			11. ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1							

1293

9550089

22

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63					
6	6ND	Reboxetine	Female	13. SOMATIC GENERAL	2	1	1	1	1	1	1	1	1	1					
				14. GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2				
				15. HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1	1			
				16. LOSS OF WEIGHT	2	1	0	2	0	1	1	1	1	1	1	1			
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0			
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0			
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0			
				20. PARANOID	1	1	0	0	0	0	0	0	0	0	0	0			
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0			
				22. Total score	25	20	13	15	16	21									
				7ND	Reboxetine	Female	01. DEPRESSED MOOD	3	3	3	3	3	3	3	3	2	2	1	
							02. GUILT	1	1	1	1	1	1	1	1	1	1	1	0
							03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0
							04. INSOMNIA EARLY	1	2	2	2	2	1	1	1	1	1	1	1
							05. INSOMNIA MIDDLE	2	1	1	1	1	2	1	1	1	1	1	1
							06. INSOMNIA LATE	2	2	1	1	1	1	1	1	1	1	1	1
							07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	2	2	2	1	1
							08. RETARDATION	1	1	1	1	1	0	0	0	0	0	0	0
							09. AGITATION	2	2	2	2	2	2	2	2	2	2	1	1
							10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	1
							11. ANXIETY SOMATIC	1	2	2	1	1	1	1	1	1	1	1	1
							12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1
13. SOMATIC GENERAL	2	2	2				2	2	2	2	2	2	2	2	1				
14. GENITAL SYMPTOMS	2	2	2				2	2	2	2	2	2	2	2	1				
15. HYPOCHONDRIASIS	1	1	1				1	1	1	1	1	1	1	1	1				
16. LOSS OF WEIGHT	2	0	0				0	0	0	0	0	0	0	0	0				
17. INSIGHT	0	0	0				0	0	0	0	0	0	0	0	0				
18. DIURNAL VARIATION	0	0	0				0	0	0	0	0	0	0	0	0				
19. DEPERSONALIZATION	1	1	1				1	1	1	1	1	1	1	1	1				
20. PARANOID	0	0	0				0	0	0	0	0	0	0	0	0				
21. OBSESSIONAL/COMPULSIVE	0	0	0				0	0	0	0	0	0	0	0	0				
22. Total score	27	26	26				24	25	24	20	17	12	11						
8ND	Imipramine	Female	01. DEPRESSED MOOD	4	4	4	4	3	3	3	2	1	1	1					
			02. GUILT	1	1	1	0	0	0	0	0	0	0	0					
			03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0					
			04. INSOMNIA EARLY	2	2	2	2	2	1	1	1	1	1	1					
			05. INSOMNIA MIDDLE	2	2	1	2	1	1	1	1	1	1	1					
			06. INSOMNIA LATE	2	2	2	2	1	1	1	1	1	1	1					
			07. WORK AND ACTIVITIES	3	3	3	3	2	1	1	1	1	1	1					
			08. RETARDATION	2	2	2	2	1	1	1	1	1	1	1					
			09. AGITATION	1	2	1	1	1	2	2	1	1	1	1					
			10. ANXIETY PSYCHIC	2	2	2	2	1	1	1	1	1	1	1					
			11. ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1					
			12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1					
			13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	1					
			14. GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	1					
			15. HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1					
			16. LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1					

1294

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

23

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 2012A/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63										
6	8WD	Imipramine	Female	17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0									
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1						
				19. DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
				22. Total score	28	29	29	25	19	18	15	15	10	8																				
				7	1MD	Imipramine	Male	01. DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
								02. GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
								03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
								04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
								05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
								06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
								07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
								08. RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
								09. AGITATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
								10. ANXIETY PSYCHIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
								11. ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
								12. SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
								13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
								14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
								15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
								16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
17. INSIGHT	1	1	1					1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
18. DIURNAL VARIATION	0	0	0					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
19. DEPERSONALIZATION	0	0	0					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
20. PARANOID	1	1	1					1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
22. Total score	21	23	17					5	5	7	6	4	4	4																				
3ND	Imipramine	Female	01. DEPRESSED MOOD					2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3					
			02. GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0							
			03. SUICIDE	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1						
			04. INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0						
			05. INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0						
			06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2						
			07. WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2						
			08. RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1						
			09. AGITATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0						
			10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2						
			11. ANXIETY SOMATIC	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0						
			12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1						
			13. SOMATIC GENERAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0						
			14. GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2						
			15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0						
			16. LOSS OF WEIGHT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2						
			17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0						
			18. DIURNAL VARIATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2						
			19. DEPERSONALIZATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2						
			20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0						

1295

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

24

PEARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63
7	34D	Imipramine	Female	21. OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	0	1	1	1	1	1	1	1	1	0	0	0	0
				22. Total score	19	20	26	24	16	18	9	10	6	6										
4HD	Reboxetine	Female	01. DEPRESSED MOOD	2	2	3	3	4	3	3	3	3	3											
				02. GUILT	0	0	0	0	0	0	0	0	0	0										
				03. SUICIDE	0	0	0	0	0	0	0	0	0	0										
				04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2										
				05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2										
				06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2										
				07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3										
				08. RETARDATION	0	0	1	1	1	1	1	1	1	1										
				09. AGITATION	0	1	1	2	2	2	2	2	2	2										
				10. ANXIETY PSYCHIC	2	2	3	2	2	2	2	2	2	2										
				11. ANXIETY SOMATIC	3	2	2	1	2	2	2	2	2	2										
				12. SOMATIC GASTROINTESTINAL	2	1	2	2	2	2	2	2	2	2										
				13. SOMATIC GENERAL	2	2	2	1	2	2	2	2	2	2										
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0										
				15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2										
				16. LOSS OF WEIGHT	2	2	1	0	0	0	0	0	0	0										
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0										
				18. DIURNAL VARIATION	1	1	2	2	2	2	2	2	2	2										
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0										
				20. PARANOID	0	0	0	0	0	0	0	0	0	0										
				21. OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1										
				22. Total score	26	25	29	26	28	28	27	27	27	26										
342HD	Reboxetine	Female	01. DEPRESSED MOOD	4	3	3	3	1	3	3	3	3	3											
				02. GUILT	0	0	1	0	0	0	0	0	0	0										
				03. SUICIDE	2	0	0	0	0	0	0	0	0	0										
				04. INSOMNIA EARLY	0	2	1	2	1	2	2	2	2	2										
				05. INSOMNIA MIDDLE	0	2	1	0	0	0	0	0	0	0										
				06. INSOMNIA LATE	1	0	1	1	1	1	1	1	1	1										
				07. WORK AND ACTIVITIES	4	4	4	4	4	4	4	4	4	4										
				08. RETARDATION	3	3	3	2	3	2	2	2	2	2										
				09. AGITATION	2	4	4	4	4	4	4	4	4	4										
				10. ANXIETY PSYCHIC	3	3	2	2	1	2	2	2	2	2										
				11. ANXIETY SOMATIC	1	1	1	0	0	0	0	0	0	0										
				12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2										
				13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2										
				14. GENITAL SYMPTOMS	2	2	0	2	0	0	0	0	0	0										
				15. HYPOCHONDRIASIS	2	2	1	0	0	0	0	0	0	0										
				16. LOSS OF WEIGHT	2	2	1	0	1	2	1	1	1	1										
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0										
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0										
				19. DEPERSONALIZATION	2	2	1	1	1	2	0	1	0	1										
				20. PARANOID	1	0	0	0	0	1	0	0	0	0										
				21. OBSESSIONAL/COMPULSIVE	0	1	1	1	1	0	1	0	1	0										
				22. Total score	33	36	30	27	28	27	29	27	26	24										

1296

9550089

25

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day				
8	1ND	Reboxetine	Female	01.DEPRESSED MOOD	4	4	4	4	4	4	4	2	2	4	4				
				02.GUILT	4	4	4	3	3	3	0	0	0	0	0	0	0		
				03.SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	0	0	0	0	0
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	0	0	0	0	0
				06.INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				08.RETARDATION	2	2	2	2	2	2	2	2	2	2	3	1	1	1	1
				09.AGITATION	2	2	2	2	2	2	2	2	2	2	3	1	1	1	1
				10.ANXIETY PSYCHIC	3	3	3	3	3	3	3	3	3	3	2	0	0	0	0
				11.ANXIETY SOMATIC	3	3	3	3	3	3	3	3	3	3	2	0	0	0	0
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				16.LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				20.PARANOID	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				21.OBSESSIONAL/COMPULSIVE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				22.Total score	37	37	37	27	28	27	26	19	8	9	26	0	0	0	0
10T	Imipramine	Female	01.DEPRESSED MOOD	2	2	2	4	2	1	1	1	0	0	0	0				
			02.GUILT	4	4	4	0	0	0	0	0	0	0	0	0	0			
			03.SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			04.INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
			05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			06.INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
			07.WORK AND ACTIVITIES	3	3	3	4	4	4	3	2	3	0	0	0	0	0		
			08.RETARDATION	3	3	3	1	1	1	1	1	1	0	0	0	0	0		
			09.AGITATION	0	0	0	1	1	1	1	1	1	0	0	0	0	0		
			10.ANXIETY PSYCHIC	4	4	4	3	3	3	0	1	1	0	0	0	0	0		
			11.ANXIETY SOMATIC	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			12.SOMATIC GASTROINTESTINAL	2	1	1	1	1	1	1	1	1	0	0	0	0	0		
			13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	0	0	0	0	0		
			14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
			16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			18.DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			20.PARANOID	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
			21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			22.Total score	24	25	18	8	12	10	1	3	3	2	0	0	0	0		
2ND	Reboxetine	Female	01.DEPRESSED MOOD	2	2	2	1	1	1	1	0	0	0	0	0				
			02.GUILT	1	1	1	0	0	0	0	0	0	0	0	0				
			03.SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0				
			04.INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1				

1297

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

26

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63						
8	2ND	Reboxetine	Female	05.INSOMNIA MIDDLE	0	0	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0					
				06.INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				07.WORK AND ACTIVITIES	4	4	4	4	3	3	3	3	3	3	3	3	1	1	1	1	1	1	1	1	1	1	1	1		
				08.RETARDATION	2	2	2	3	3	3	3	3	3	3	3	3	0	0	0	0	0	0	0	0	0	0	0	0		
				09.AGITATION	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
				10.ANXIETY PSYCHIC	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				11.ANXIETY SOMATIC	2	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				12.SOMATIC GASTROINTESTINAL	2	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
				14.GENITAL SYMPTOMS	2	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
				16.LOSS OF WEIGHT	3	3	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				17.INSIGHT	0	0	0	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				19.DEPERSONALIZATION	2	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				20.PARANOID	2	2	2	2	2	2	2	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1		
				21.OBSESSIONAL/COMPULSIVE	2	2	2	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0		
				22.Total score				28	28	20	19	18	17	16	15	14	13	7	7	3	3	4	4	4	4	4	4	4		
				20T	Imipramine	Female	01.DEPRESSED MOOD	3	3	4	4	4	4	4	4	4	4	2	2	2	1	1	1	1	1	1	1	1	1	
							02.CUILT	3	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
							03.SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2	0	0	0	0	0	0	0	0	0	0	0
							04.INSOMNIA EARLY	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
05.INSOMNIA MIDDLE	2	2	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
06.INSOMNIA LATE	1	1	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
07.WORK AND ACTIVITIES	2	2	2				3	2	2	2	2	2	2	2	2	2	2	2	1	1	1	1	1	1	1	1				
08.RETARDATION	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
09.AGITATION	0	0	0				2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
10.ANXIETY PSYCHIC	4	4	4				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
11.ANXIETY SOMATIC	3	3	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
12.SOMATIC GASTROINTESTINAL	1	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
13.SOMATIC GENERAL	1	1	1				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
14.GENITAL SYMPTOMS	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
15.HYPOCHONDRIASIS	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
16.LOSS OF WEIGHT	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
17.INSIGHT	0	0	0				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
18.DIURNAL VARIATION	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
19.DEPERSONALIZATION	2	2	0				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
20.PARANOID	2	2	2				2	2	2	2	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1				
21.OBSESSIONAL/COMPULSIVE	1	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
22.Total score							30	29	19	16	15	14	13	12	11	11	7	7	3	3	4	4	4	4	4	4	4			
3MD	Imipramine	Female	01.DEPRESSED MOOD	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4						
			02.CUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
			03.SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
			04.INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
			05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
			06.INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
			07.WORK AND ACTIVITIES	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4					
			08.RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					

1298

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

27

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63	
8	3MD	Imipramine	Female		2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				09. AGITATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				10. ANXIETY PSYCHIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				11. ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				13. SOMATIC GENERAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				16. LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				22. Total score	19	19	19	18	18	18	18	18	18	18	18	18	18	18	18	18	18	18	18	18	18
3DI	Reboxetine		Female		4	4	4	3	3	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				01. DEPRESSED MOOD	3	3	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				02. GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				04. INSOMNIA EARLY	0	0	0	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				05. INSOMNIA MIDDLE	0	0	0	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				06. INSOMNIA LATE	0	0	0	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				07. WORK AND ACTIVITIES	4	4	4	4	4	3	1	3	0	0	0	0	0	0	0	0	0	0	0	0	0
				08. RETARDATION	3	3	3	3	3	4	3	1	2	1	1	1	1	1	1	1	1	1	1	1	1
				09. AGITATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				10. ANXIETY PSYCHIC	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				11. ANXIETY SOMATIC	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				13. SOMATIC GENERAL	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				16. LOSS OF WEIGHT	2	2	2	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17. INSIGHT	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	23	23	23	25	13	13	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
4MD	Imipramine		Male		4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
				01. DEPRESSED MOOD	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				02. GUILT	2	2	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				03. SUICIDE	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				04. INSOMNIA EARLY	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				05. INSOMNIA MIDDLE	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				06. INSOMNIA LATE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
				07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				08. RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				09. AGITATION	1	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				11. ANXIETY SOMATIC	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1299

9550089

28

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63						
8	4WD	Imipramine	Male	13.SOMATIC GENERAL	1	1	1	1	1	2	2	2	2	1	1	2	1	1	1	1	1	1	1	2	2					
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				15.HYPOCHONDRIASIS	3	3	3	3	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4		
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				17.INSIGHT	1	1	1	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				19.DEPERSONALIZATION	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
				22.Total score	33	35	37	40	41	41	41	41	41	41	41	41	41	41	41	41	41	41	41	41	41	41	41	41		
				40T	Reboxetine	Female	01.DEPRESSED MOOD	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	
							02.GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
							03.SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
04.INSOMNIA EARLY	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
05.INSOMNIA MIDDLE	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
06.INSOMNIA LATE	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
07.WORK AND ACTIVITIES	4	4	4				4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4				
08.RETARDATION	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
09.AGITATION	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
10.ANxiety PSYCHIC	4	4	4				4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4			
11.ANxiety SOMATIC	1	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
12.SOMATIC GASTROINTESTINAL	1	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
13.SOMATIC GENERAL	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0							
15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2							
16.LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1							
17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0							
18.DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0							
19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0							
20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0							
21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1							
22.Total score	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20							
701HD	Imipramine	Male	01.DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3						
			02.GUILT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
			03.SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
			04.INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
			05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
			06.INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
			07.WORK AND ACTIVITIES	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4					
			08.RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
			09.AGITATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
			10.ANxiety PSYCHIC	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
			11.ANxiety SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
			12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
			13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0								
15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0								
16.LOSS OF WEIGHT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2								

1300

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

30

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63	
8	702HD	Reboxetine	Male	21	21	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
				22..total score																				16	
	702DT	Imipramine	Female	3	2	3	2	2	1	1	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0
				01-DEPRESSED MOOD																					0
				02-GUILT																					1
				03-SUICIDE																					0
				04-INSOMNIA EARLY																					0
				05-INSOMNIA MIDDLE																					0
				06-INSOMNIA LATE																					0
				07-WORK AND ACTIVITIES																					0
				08-RETARDATION																					0
				09-AGITATION																					0
				10-ANXIETY PSYCHIC																					0
				11-ANXIETY SOMATIC																					0
				12-SOMATIC GASTROINTESTINAL																					0
				13-SOMATIC GENERAL																					0
				14-GENERAL SYMPTOMS																					0
				15-HYPOCHONDRIASIS																					0
				16-LOSS OF WEIGHT																					0
				17-INSIGHT																					0
				18-DIURNAL VARIATION																					0
				19-DEPERSONALIZATION																					0
				20-PARANOID																					0
				21-OBSESSIONAL/COMPULSIVE																					0
				22..total score																					1
				01-DEPRESSED MOOD																					2
				02-GUILT																					0
				03-SUICIDE																					0
				04-INSOMNIA EARLY																					1
				05-INSOMNIA MIDDLE																					1
				06-INSOMNIA LATE																					1
				07-WORK AND ACTIVITIES																					2
				08-RETARDATION																					2
				09-AGITATION																					1
				10-ANXIETY PSYCHIC																					0
				11-ANXIETY SOMATIC																					2
				12-SOMATIC GASTROINTESTINAL																					2
				13-SOMATIC GENERAL																					1
				14-GENERAL SYMPTOMS																					1
				15-HYPOCHONDRIASIS																					0
				16-LOSS OF WEIGHT																					0
				17-INSIGHT																					0
				18-DIURNAL VARIATION																					0
				19-DEPERSONALIZATION																					0
				20-PARANOID																					0
				21-OBSESSIONAL/COMPULSIVE																					0
				22..total score																					15
				01-DEPRESSED MOOD																					2
				02-GUILT																					0
				03-SUICIDE																					0
				04-INSOMNIA EARLY																					1
				05-INSOMNIA MIDDLE																					1
				06-INSOMNIA LATE																					1
				07-WORK AND ACTIVITIES																					2
				08-RETARDATION																					2
				09-AGITATION																					1
				10-ANXIETY PSYCHIC																					0
				11-ANXIETY SOMATIC																					2
				12-SOMATIC GASTROINTESTINAL																					2
				13-SOMATIC GENERAL																					1
				14-GENERAL SYMPTOMS																					1
				15-HYPOCHONDRIASIS																					0
				16-LOSS OF WEIGHT																					0
				17-INSIGHT																					0
				18-DIURNAL VARIATION																					0
				19-DEPERSONALIZATION																					0
				20-PARANOID																					0
				21-OBSESSIONAL/COMPULSIVE																					0
				22..total score																					14
				01-DEPRESSED MOOD																					2
				02-GUILT																					0
				03-SUICIDE																					0
				04-INSOMNIA EARLY																					1
				05-INSOMNIA MIDDLE																					1
				06-INSOMNIA LATE																					1
				07-WORK AND ACTIVITIES																					2
				08-RETARDATION																					2
				09-AGITATION																					1
				10-ANXIETY PSYCHIC																					0
				11-ANXIETY SOMATIC																					

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

31

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day		
8	703DT Imipramine	Male	HAMILTON DEPRESSION RATING SCALE													
			01. DEPRESSED MOOD	3	3	3	3	3	2	2	2	2	2	2	0	
			02. GUILT	0	1	1	1	1	1	1	1	1	1	1	1	1
			03. SUICIDE	3	1	1	1	1	1	1	0	0	0	0	0	0
			04. INSOMNIA EARLY	0	1	2	1	1	1	0	0	0	0	0	0	0
			05. INSOMNIA MIDDLE	2	2	2	1	1	1	0	0	0	0	0	0	0
			06. INSOMNIA LATE	1	0	1	1	1	1	0	0	0	0	0	0	0
			07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3
			08. RETARDATION	2	1	1	1	1	1	1	1	1	1	1	1	1
			09. AGITATION	0	1	1	1	1	1	0	0	0	0	0	0	0
			10. ANXIETY PSYCHIC	1	2	2	2	2	2	1	1	1	1	1	1	1
			11. ANXIETY SOMATIC	0	1	1	1	1	1	0	0	0	0	0	0	0
			12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1
			13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1
			14. GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2	2	2
			15. HYPOCHONDRIASIS	3	3	3	3	3	3	3	3	3	3	3	3	3
			16. LOSS OF WEIGHT	0	2	2	2	2	2	2	2	2	2	2	2	2
			17. INSIGHT	2	2	2	2	2	2	2	2	2	2	2	2	2
			18. DIURNAL VARIATION	2	2	2	2	2	2	2	2	2	2	2	2	2
			19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0
			20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0
			21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0
22. Total score	26	29	29	26	26	26	12	11	12	11	12	11	8			
704MD	Reboxetine	Female	HAMILTON DEPRESSION RATING SCALE													
			01. DEPRESSED MOOD	3	3	3	3	3	2	2	2	2	2	2	0	
			02. GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0
			03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0
			04. INSOMNIA EARLY	2	2	2	1	1	1	2	2	2	2	2	2	1
			05. INSOMNIA MIDDLE	0	2	2	2	2	2	2	2	2	2	2	2	1
			06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	1
			07. WORK AND ACTIVITIES	3	3	3	3	3	3	2	2	2	2	2	2	1
			08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0
			09. AGITATION	1	1	1	1	1	1	1	1	1	1	1	1	1
			10. ANXIETY PSYCHIC	1	1	1	1	1	1	1	1	1	1	1	1	1
			11. ANXIETY SOMATIC	3	3	3	3	3	3	2	2	2	2	2	2	0
			12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1
			13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1
			14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0
			15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2
			16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0
			17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1
			18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0
			19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0
			20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0
			21. OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1	1	1
22. Total score	21	22	22	16	8	8	5	7	3	5	7	3	5			
704DT	Reboxetine	Female	01. DEPRESSED MOOD	2	3	2	2	2	2	1	1	1	2	2		
			02. GUILT	4	4	4	4	4	1	1	0	0	0	0		
			03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0		
			04. INSOMNIA EARLY	2	2	2	2	2	2	2	1	1	1	1		

1303

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

32

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63
8	704DT	Female	Reboxetine	Hamilton depression rating scale	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				05. INSOMNIA MIDDLE	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				06. INSOMNIA LATE	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				07. WORK AND ACTIVITIES	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				08. RETARDATION	0	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				09. AGITATION	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				11. ANXIETY SOMATIC	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				12. SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				16. LOSS OF WEIGHT	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				17. INSIGHT	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	25	28	25	25	25	25	27	16	10	9	12	13							
9	1ND	Female	Imipramine	Hamilton depression rating scale	3	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				01. DEPRESSED MOOD	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				02. GUILT	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				03. SUICIDE	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				04. INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				07. WORK AND ACTIVITIES	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				08. RETARDATION	3	3	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				09. AGITATION	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				10. ANXIETY PSYCHIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				11. ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				13. SOMATIC GENERAL	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				15. HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				16. LOSS OF WEIGHT	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17. INSIGHT	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	28	28	9	11	11	11	11	11	10	10	7	4							
				01. DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				02. GUILT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				04. INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				07. WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2

1304

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

33

PHARMACIA CMS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day					
9	1DT	Imipramine	Female	09. AGITATION	2	2	2	0	0	0	0	0	0	0	0					
				10. ANXIETY PSYCHIC	3	3	3	2	0	1	0	0	0	0	0	0				
				11. ANXIETY SOMATIC	2	2	2	1	0	1	0	0	0	0	0	0	0			
				12. SOMATIC GASTROINTESTINAL	1	1	1	0	0	0	0	0	0	0	0	0	0			
				13. SOMATIC GENERAL	2	2	2	1	1	0	1	0	0	0	0	0	0			
				14. GENITAL SYMPTOMS	1	1	1	1	1	0	0	0	0	0	0	0	0			
				15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0			
				16. LOSS OF WEIGHT	2	2	2	0	0	0	0	0	0	0	0	0	0			
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0			
				18. DIURNAL VARIATION	1	1	1	1	1	0	0	0	0	0	0	0	0			
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0			
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0			
				21. OBSESSIVE/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0			
				22. Total score	21	20	16	11	1	3	0	1	0	0	0	0	0	0		
				2ND	Reboxetine	Female	01. DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3	1	
							02. GUILT	0	0	0	0	1	0	0	0	0	0	0	0	0
							03. SUICIDE	2	2	2	1	1	1	1	1	1	1	1	1	0
							04. INSOMNIA EARLY	2	2	2	1	1	1	1	1	1	1	1	1	0
							05. INSOMNIA MIDDLE	2	2	2	1	1	1	1	1	1	1	1	1	0
							06. INSOMNIA LATE	3	3	3	3	3	3	3	3	3	3	3	3	1
							07. WORK AND ACTIVITIES	0	1	1	2	2	2	2	2	2	2	2	2	1
							08. RETARDATION	3	3	3	2	2	3	1	2	0	0	0	0	0
09. AGITATION	3	3	3				2	2	3	1	2	0	0	0	0	0				
10. ANXIETY PSYCHIC	3	3	3				3	3	2	2	2	2	2	2	2	1				
11. ANXIETY SOMATIC	2	2	2				2	1	1	1	1	1	1	1	1	0				
12. SOMATIC GASTROINTESTINAL	1	1	1				2	1	1	1	1	1	1	1	1	0				
13. SOMATIC GENERAL	2	2	2				2	2	2	2	2	2	2	2	2	1				
14. GENITAL SYMPTOMS	2	2	2				2	2	2	2	2	2	2	2	2	1				
15. HYPOCHONDRIASIS	0	0	0				0	0	0	0	0	0	0	0	0	0				
16. LOSS OF WEIGHT	2	2	2				2	1	0	0	0	0	0	0	0	0				
17. INSIGHT	0	0	0				0	0	0	0	0	0	0	0	0	0				
18. DIURNAL VARIATION	1	1	1				1	1	0	0	0	0	0	0	0	0				
19. DEPERSONALIZATION	0	0	0				0	0	0	0	0	0	0	0	0	0				
20. PARANOID	0	0	0				0	0	0	0	0	0	0	0	0	0				
21. OBSESSIVE/COMPULSIVE	0	0	0				0	0	0	0	0	0	0	0	0	0				
22. Total score	29	29	28				21	25	19	23	17	17	17	17	17	7				
2DT	Imipramine	Female	01. DEPRESSED MOOD	3	3	3	2	0	0	0	0	0	0	0	0					
			02. GUILT	1	1	1	0	0	0	0	0	0	0	0	0					
			03. SUICIDE	4	4	4	0	0	0	0	0	0	0	0	0					
			04. INSOMNIA EARLY	4	4	4	0	0	0	0	0	0	0	0	0					
			05. INSOMNIA MIDDLE	4	4	4	0	0	0	0	0	0	0	0	0					
			06. INSOMNIA LATE	0	1	1	0	0	0	0	0	0	0	0	0					
			07. WORK AND ACTIVITIES	3	3	3	2	0	0	0	0	0	0	0	0					
			08. RETARDATION	2	2	2	1	0	0	0	0	0	0	0	0					
			09. AGITATION	2	2	2	1	0	0	0	0	0	0	0	0					
			10. ANXIETY PSYCHIC	3	3	3	2	1	1	0	0	0	0	0	0					
			11. ANXIETY SOMATIC	2	2	2	2	1	1	0	0	0	0	0	0					
			12. SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0	0	0	0	0					

1305

9550089

34

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centro	Patient Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day
9	2DT	Imipramine	Female	13.SOMATIC GENERAL	1	1	2	1	0	1	1	0	0	0
				14.GENITAL SYMPTOMS	2	2	1	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0
				22.Total score	23	23	17	5	3	1	2	2	0	0
3DT	Reboxetine	Female	01.DEPRESSED MOOD	3	2	2	2	0	1	1	1	0	0	0
			02.GUILT	0	0	1	0	0	0	0	0	0	0	0
			03.SUICIDE	1	1	0	0	1	0	0	0	0	0	0
			04.INSOMNIA EARLY	0	0	0	1	1	1	1	0	0	0	0
			05.INSOMNIA MIDDLE	0	0	0	0	1	1	1	1	0	0	0
			06.INSOMNIA LATE	0	0	0	1	1	1	1	1	0	0	0
			07.WORK AND ACTIVITIES	3	2	2	2	0	0	0	1	0	0	0
			08.RETARDATION	1	1	0	0	0	0	0	0	0	0	0
			09.AGITATION	1	2	1	2	0	0	0	0	0	0	0
			10.ANXIETY PSYCHIC	2	3	3	2	0	1	1	0	1	1	1
			11.ANXIETY SOMATIC	1	1	2	2	0	0	0	0	0	0	0
			12.SOMATIC GASTROINTESTINAL	1	0	0	0	0	0	0	0	0	0	0
			13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	0	0
			14.GENITAL SYMPTOMS	2	2	2	2	1	1	1	1	0	0	0
			15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0
			16.LOSS OF WEIGHT	1	0	0	0	0	0	0	0	0	0	0
			17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0
			18.DIURNAL VARIATION	2	1	1	1	0	0	0	1	0	0	0
			19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0
			20.PARANOID	0	0	0	0	0	0	0	0	0	0	0
			21.OBSESSIONAL/COMPULSIVE	1	0	0	0	0	0	0	0	0	0	0
			22.Total score	21	17	16	16	5	6	6	7	2	1	1
4TD	Imipramine	Female	01.DEPRESSED MOOD	3	3	2	1	1	1	1	0	0	0	0
			02.GUILT	1	1	0	0	0	0	0	0	0	0	0
			03.SUICIDE	2	1	0	0	0	0	0	0	0	0	0
			04.INSOMNIA EARLY	0	0	1	0	0	0	0	0	0	0	0
			05.INSOMNIA MIDDLE	0	0	1	0	1	0	0	0	0	0	0
			06.INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0
			07.WORK AND ACTIVITIES	3	3	3	2	1	0	0	0	0	0	0
			08.RETARDATION	3	0	1	1	0	0	0	0	0	0	0
			09.AGITATION	1	2	1	0	0	0	0	0	0	0	0
			10.ANXIETY PSYCHIC	2	2	2	1	2	3	2	0	0	0	0
			11.ANXIETY SOMATIC	2	1	0	1	1	0	0	0	0	0	0
			12.SOMATIC GASTROINTESTINAL	2	1	0	1	0	0	0	0	0	0	0
			13.SOMATIC GENERAL	1	2	2	2	2	1	1	1	0	0	0
			14.GENITAL SYMPTOMS	2	2	2	2	2	1	1	1	0	0	0
			15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0
			16.LOSS OF WEIGHT	1	0	0	0	0	0	0	0	0	0	0
			17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0
			18.DIURNAL VARIATION	2	1	1	1	0	0	0	1	0	0	0
			19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0
			20.PARANOID	0	0	0	0	0	0	0	0	0	0	0
			21.OBSESSIONAL/COMPULSIVE	1	0	0	0	0	0	0	0	0	0	0
			22.Total score	21	17	16	16	5	6	6	7	2	1	1

1306

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

35

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day						
9	4ND	Imipramine	Female	17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0						
				18.DIURNAL VARIATION	2	2	1	1	1	1	1	1	0	0	0	0					
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				22.Total score	23	19	14	11	9	7	6	6	0	0	0	0	0	0			
				5ND	Reboxetine	Female	01.DEPRESSED MOOD	3	3	3	3	2	2	2	2	2	2	2	1		
							02.GUILT	1	2	2	2	2	2	2	2	2	2	2	2	1	
							03.SUICIDE	2	1	1	1	1	1	1	1	1	1	1	1	1	0
							04.INSOMNIA EARLY	0	2	1	1	1	1	1	1	1	1	1	1	1	0
							05.INSOMNIA MIDDLE	0	1	1	1	1	1	1	1	1	1	1	1	1	0
							06.INSOMNIA LATE	0	1	1	1	1	1	1	1	1	1	1	1	1	0
							07.WORK AND ACTIVITIES	3	2	2	2	2	2	2	2	2	2	2	2	2	1
							08.RETARDATION	3	3	3	3	3	3	3	3	3	3	3	3	3	3
							09.AGITATION	1	3	3	3	3	3	3	3	3	3	3	3	3	3
							10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	1
							11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1
							12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1
							13.SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2
							14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0
							15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0
							16.LOSS OF WEIGHT	0	1	1	1	1	1	1	1	1	1	1	1	1	1
17.INSIGHT	0	1	1				1	1	1	1	1	1	1	1	1	1	1				
18.DIURNAL VARIATION	2	1	1				1	1	1	1	1	1	1	1	1	1	1				
19.DEPERSONALIZATION	0	0	0				0	0	0	0	0	0	0	0	0	0	0				
20.PARANOID	0	0	0				0	0	0	0	0	0	0	0	0	0	0				
21.OBSESSIONAL/COMPULSIVE	0	0	0				0	0	0	0	0	0	0	0	0	0	0				
22.Total score	23	28	28				21	20	19	17	17	17	17	17	17	12	12	4			
6ND	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3	3						
			02.GUILT	1	1	1	1	1	1	1	1	1	1	1	1	1					
			03.SUICIDE	2	1	1	1	1	1	1	1	1	1	1	1	1					
			04.INSOMNIA EARLY	0	1	1	1	1	1	1	1	1	1	1	1	1					
			05.INSOMNIA MIDDLE	0	1	1	1	1	1	1	1	1	1	1	1	1					
			06.INSOMNIA LATE	1	2	2	2	2	2	2	2	2	2	2	2	2					
			07.WORK AND ACTIVITIES	3	2	2	2	2	2	2	2	2	2	2	2	2					
			08.RETARDATION	2	1	1	1	1	1	1	1	1	1	1	1	1					
			09.AGITATION	2	2	2	2	2	2	2	2	2	2	2	2	2					
			10.ANXIETY PSYCHIC	3	2	2	2	2	2	2	2	2	2	2	2	2					
			11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2					
			12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1					
			13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1					
			14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2	2	2					
			15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0					
			16.LOSS OF WEIGHT	1	0	0	0	0	0	0	0	0	0	0	0	0					
			17.INSIGHT	1	0	0	0	0	0	0	0	0	0	0	0	0					
			18.DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0					
			19.DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1					
			20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0					
			21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0					
			22.Total score	23	28	28	21	20	19	17	17	17	17	17	17	12	12	4			

1307

9550089

36

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63	
9	6ND	Imipramine	Female	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22.Total score	25	21	23																		
7ND		Imipramine	Female	01.DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				02.GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				03.SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				06.INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				08.RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				09.AGITATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				11.ANXIETY SOMATIC	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22.Total score	22	20	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21
8DT		Reboxetine	Female	01.DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				02.GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				03.SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				08.RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				09.AGITATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22.Total score	20	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22

1308

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

37

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63	
10	1MD	Imipramine	Female		3	4	0	0	3	3	2	2	1	1	0	0	0	0	0	0	0	0	0	0	0
				01. DEPRESSED MOOD	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				02. GUILT	2	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				03. SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				04. INSOMNIA EARLY	2	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				05. INSOMNIA MIDDLE	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				06. INSOMNIA LATE	3	3	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				07. WORK AND ACTIVITIES	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				09. AGITATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				10. ANXIETY PSYCHIC	3	3	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				11. ANXIETY SOMATIC	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				14. GENITAL SYMPTOMS	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				15. HYPOCHONDRIASIS	1	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17. INSIGHT	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	28	28	23	18	13	10	7	5	6	6	6	6	6	6	6	6	6	6	6	6	5
10T		Reboxetine	Female		3	4	0	0	3	3	2	2	1	1	0	0	0	0	0	0	0	0	0	0	0
				01. DEPRESSED MOOD	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				02. GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				04. INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				05. INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				06. INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				07. WORK AND ACTIVITIES	3	3	3	3	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				09. AGITATION	3	3	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				10. ANXIETY PSYCHIC	3	3	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				11. ANXIETY SOMATIC	3	3	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				13. SOMATIC GENERAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				14. GENITAL SYMPTOMS	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	2	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				22. Total score	21	21	20	16	14	10	9	6	6	6	6	6	6	6	6	6	6	6	6	6	5
2MD		Reboxetine	Male		4	4	4	4	3	3	2	2	1	1	0	0	0	0	0	0	0	0	0	0	0
				01. DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				02. GUILT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				03. SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				04. INSOMNIA EARLY	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1309

9550089

9550089

38

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient Treatment	Sex	Hamilton depression rating scale	Screen Day	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
10	ZND	Reboxetine	Male	2	1	1	1	1	2	2	1	1	0	0
				2	2	1	1	1	0	0	1	0	0	0
				4	4	3	3	3	2	2	2	1	1	1
				0	0	0	0	0	0	0	0	0	0	0
				2	1	2	2	2	2	1	1	1	1	1
				2	3	3	2	2	2	1	1	0	0	1
				2	2	2	2	2	2	0	0	0	0	2
				1	1	1	1	1	1	1	1	1	1	1
				0	2	0	0	0	0	0	0	0	0	0
				0	0	0	0	0	0	0	0	0	0	0
				1	1	1	1	1	1	1	1	1	1	1
				1	1	1	1	1	1	1	1	1	1	1
				0	0	0	0	0	0	0	0	0	0	0
				1	1	1	1	1	1	1	1	1	1	1
				0	0	0	0	0	0	0	0	0	0	0
				1	1	1	1	1	1	1	1	1	1	1
				30	33	29	23	19	13	9	13	8	8	9
20T	Imipramine	Male		3	3	3	1	0	0	0	1	0	0	0
				1	1	1	1	0	0	0	0	0	0	0
				0	0	0	0	0	0	0	0	0	0	0
				0	0	0	0	0	0	0	0	0	0	0
				0	0	0	0	0	0	0	0	0	0	0
				3	3	2	1	0	0	0	1	0	0	0
				0	0	0	0	0	0	0	0	0	0	0
				0	0	0	0	0	0	0	0	0	0	0
				3	3	3	2	2	2	1	1	1	1	2
				3	3	3	2	2	2	1	2	3	3	2
				0	0	0	0	0	0	0	0	0	0	0
				2	2	2	2	0	0	0	0	0	0	0
				1	1	1	1	1	1	1	1	1	1	1
				0	0	0	0	0	0	0	0	0	0	0
				1	1	2	1	1	2	1	1	1	2	1
				1	1	0	0	0	0	0	0	0	0	0
				0	0	0	0	0	0	0	0	0	0	0
				1	2	2	1	1	1	0	0	0	0	0
				0	0	0	0	0	0	0	0	0	0	0
				1	0	1	1	1	1	1	1	1	1	1
				21	21	20	14	8	7	6	11	6	8	8
30D	Reboxetine	Male		3	4	4	4	4	3	2	2	1	1	1
				0	0	0	1	1	1	0	0	0	0	0
				2	2	2	1	1	1	1	0	0	0	0
				1	1	1	1	2	1	1	1	2	2	2
				1	2	1	1	1	1	1	1	0	0	0
				2	2	2	2	1	1	1	0	0	0	0
				4	4	4	3	4	3	3	2	2	2	1
				0	0	0	0	0	0	0	0	0	0	0

1310

9550089

40

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63	
10	4ND	Imipramine	Female	13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				14. GENITAL SYMPTOMS	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				15. HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				16. LOSS OF WEIGHT	1	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				21. OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				22. Total score	29	29	28	22	18	16	13	12	7	8											
40T	Reboxetine	Female	01. DEPRESSED MOOD	2	3	4	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			02. GUILT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			04. INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			05. INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			06. INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			07. WORK AND ACTIVITIES	3	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			09. AGITATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			10. ANXIETY PSYCHIC	4	3	3	2	3	2	3	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1
			11. ANXIETY SOMATIC	4	3	3	2	3	2	3	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1
			12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			14. GENITAL SYMPTOMS	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			16. LOSS OF WEIGHT	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			17. INSIGHT	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			19. DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			22. Total score	19	21	20	15	15	9	5	5	8	7												
5ND	Imipramine	Female	01. DEPRESSED MOOD	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
			02. GUILT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			03. SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			05. INSOMNIA MIDDLE	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			07. WORK AND ACTIVITIES	3	4	3	3	4	3	4	3	4	3	4	3	4	3	4	3	4	3	4	3	4	3
			08. RETARDATION	2	1	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			09. AGITATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			10. ANXIETY PSYCHIC	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
			11. ANXIETY SOMATIC	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
			12. SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			14. GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			15. HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			16. LOSS OF WEIGHT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			18. DIURNAL VARIATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			19. DEPERSONALIZATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			20. PARANOID	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			21. OBSESSIONAL/COMPULSIVE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			22. Total score	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

1312

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

41

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day
10	SMD	Imipramine	Female		0	0	0	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	2	1	1	2	1	1	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0
				22.Total score	29	30	29	28	27	24	18	11	8	7	
501	Reboxetine		Female		2	3	3	3	3	3	4	3	3	3	3
				-02.GUILT	1	1	2	2	1	2	2	2	2	2	2
				03.SUICIDE	0	0	0	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0
				06.INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	3	4	3	4	3	4	3	4
				08.RETARDATION	0	0	0	0	0	0	0	0	0	0	0
				09.AGITATION	0	0	0	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	3	3	3	3	4	3	3	3	3	3	3
				11.ANXIETY SOMATIC	4	3	2	3	3	3	3	3	3	3	3
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	2	2	2	2	2	1	1	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	2	2	2	2	2	1	1	2	1	1	1
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	1	1	1	0	0	0	0	0	0	0
				22.Total score	19	20	20	20	21	19	23	20	20	20	19
6ND	Reboxetine		Male		4	4	4	4	4	4	4	4	4	4	4
				01.DEPRESSED MOOD	0	0	0	0	0	0	0	0	0	0	0
				02.GUILT	0	0	0	0	0	0	0	0	0	0	0
				03.SUICIDE	0	0	0	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	1	1	1	1	2	2	2	2
				05.INSOMNIA MIDDLE	1	2	1	2	1	1	2	1	2	1	2
				06.INSOMNIA LATE	1	2	1	1	1	0	0	0	1	0	0
				07.WORK AND ACTIVITIES	4	4	4	4	4	3	4	3	4	4	4
				08.RETARDATION	0	0	0	0	0	0	0	0	0	0	0
				09.AGITATION	3	3	3	3	3	3	3	3	3	3	3
				10.ANXIETY PSYCHIC	3	3	3	3	3	4	4	3	3	3	3
				11.ANXIETY SOMATIC	2	2	2	2	3	2	4	3	2	3	3
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	2	2	0	0	2	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	2	1	0	1	3	1	1	0	0

1313

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

43

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 12.0

Centre	Patient Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63			
70	7DT	Imipramine	Female	Hamilton depression rating scale	2	3	3	3	3	3	3	3	2	2	1	0	0	0	0	0	0	0	0	0		
				01. DEPRESSED MOOD	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				02. GUILT	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	
				03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				04. INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				05. INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				06. INSOMNIA LATE	2	3	2	3	2	3	2	2	2	2	1	0	0	0	0	0	0	0	0	0	0	
				07. WORK AND ACTIVITIES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				09. AGITATION	3	3	2	3	2	3	2	2	2	2	1	2	2	1	2	2	1	2	2	2	2	1
				10. ANXIETY PSYCHIC	3	3	2	3	2	3	2	2	2	2	1	2	2	1	2	2	1	2	2	2	2	1
				11. ANXIETY SOMATIC	3	2	3	2	3	2	3	2	2	2	1	2	2	1	2	2	1	2	2	2	2	1
				12. SOMATIC GASTROINTESTINAL	6	6	5	6	5	6	5	5	5	5	4	4	4	4	4	4	4	4	4	4	4	3
				13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				15. HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	1	2	1	2	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	2	2	2	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				22. Total score	19	21	20	22	19	15	11	8	7	7	7	7	7	7	7	7	7	7	7	7	7	
80D	80D	Reboxetine	Male	Hamilton depression rating scale	3	4	4	4	4	4	4	4	2	2	1	0	0	0	0	0	0	0	0	0	0	
				01. DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
				02. GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				04. INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
				06. INSOMNIA LATE	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
				07. WORK AND ACTIVITIES	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				09. AGITATION	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
				10. ANXIETY PSYCHIC	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
				11. ANXIETY SOMATIC	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
				12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
				13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				14. GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
				15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				19. DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				20. PARANOID	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				21. OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				22. Total score	29	30	24	20	15	10	11	9	8	8	8	8	8	8	8	8	8	8	8	8	8	
80D	80D	Imipramine	Female	Hamilton depression rating scale	3	2	2	2	2	2	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	
				01. DEPRESSED MOOD	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				02. GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				04. INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

1315

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

45

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63	
10	90T	Imipramine	Male	HAMILTON DEPRESSION RATING SCALE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				09. AGITATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				10. ANXIETY PSYCHIC	4	4	2	2	2	2	3	3	3	2	2	2	2	2	2	2	2	2	2	3	3
				11. ANXIETY SOMATIC	2	2	3	3	3	3	3	3	3	2	2	2	2	2	2	2	2	2	2	2	2
				12. SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				14. GENITAL SYMPTOMS	2	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1
				15. HYPOCHONDRIASIS	1	1	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	2	2	2	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSSIONAL/COMPULSIVE	2	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				22. Total score	22	22	21	21	21	21	23	23	21	21	20	20	22	22	20	20	22	22	20	20	20
10ND		Imipramine	Female		3	3	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				01. DEPRESSED MOOD	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				02. GUILT	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				03. SUICIDE	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				04. INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				06. INSOMNIA LATE	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				07. WORK AND ACTIVITIES	3	4	3	3	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				09. AGITATION	3	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				10. ANXIETY PSYCHIC	3	3	3	3	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				11. ANXIETY SOMATIC	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				14. GENITAL SYMPTOMS	3	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	32	32	29	24	24	18	17	17	17	8	7	10	8	7	10	8	7	10	8	8	
10DT		Reboxetine	Female		3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
				01. DEPRESSED MOOD	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				02. GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				05. INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				06. INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				07. WORK AND ACTIVITIES	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				09. AGITATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				10. ANXIETY PSYCHIC	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				11. ANXIETY SOMATIC	3	3	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2

1317

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

46

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63		
10	10DT	Reboxetine	Female	13. SOMATIC GENERAL	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				15. HYPOCHONDRIASIS	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				16. LOSS OF WEIGHT	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	20	21	15	11	6	9	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6
11	11MD	Imipramine	Female	01. DEPRESSED MOOD	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	
				02. GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				04. INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				05. INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				06. INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				07. WORK AND ACTIVITIES	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
				08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				09. AGITATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				10. ANXIETY PSYCHIC	4	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				11. ANXIETY SOMATIC	3	4	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				14. GENITAL SYMPTOMS	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				20. PARANOID	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	30	28	28	26	22	22	17	11	6	6	6	6	6	6	6	6	6	6	6	6	6	6
11	11DT	Imipramine	Female	01. DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
				02. GUILT	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				04. INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				05. INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				06. INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				07. WORK AND ACTIVITIES	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				09. AGITATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				10. ANXIETY PSYCHIC	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				11. ANXIETY SOMATIC	4	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				13. SOMATIC GENERAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				16. LOSS OF WEIGHT	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				20. PARANOID	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2

1318

9550089

47

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/03S
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
10	11DT	Imipramine	Female	17-INSIGHT	1	1	0	0	0	0	0	0	0	0
				18-DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0
				19-DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0
				20-PARANOID	0	0	0	0	0	0	0	0	0	0
				21-OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0
				22.Total score	21	20	15	9	6	4	5	4	5	3
12ND		Reboxetine	Male	01-DEPRESSED MOOD	3	3	4	3	4	4	4	3	4	3
				02-GUILT	2	2	2	1	2	1	2	2	1	2
				03-SUICIDE	0	0	0	0	0	0	0	0	0	0
				04-INSOMNIA EARLY	2	2	2	2	1	2	2	2	1	2
				05-INSOMNIA MIDDLE	1	1	1	1	2	1	2	1	1	1
				06-INSOMNIA LATE	1	2	1	2	1	1	1	1	1	1
				07-WORK AND ACTIVITIES	4	4	4	4	4	4	4	4	4	4
				08-RETARDATION	2	2	3	2	1	2	2	2	2	2
				09-AGITATION	0	0	0	0	0	0	0	0	0	0
				10-ANXIETY PSYCHIC	2	3	3	3	3	4	3	2	3	3
				11-ANXIETY SOMATIC	3	3	3	3	3	4	3	2	3	3
				12-SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2
				13-SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2
				14-GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1
				15-HYPOCHONDRIASIS	2	1	2	3	2	2	3	2	1	1
				16-LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0
				17-INSIGHT	0	0	0	0	0	0	0	0	0	0
				18-DIURNAL VARIATION	1	1	2	1	1	2	2	1	1	1
				19-DEPERSONALIZATION	0	0	2	0	0	0	1	0	0	0
				20-PARANOID	0	0	0	0	0	0	0	0	0	0
				21-OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0
				22.Total score	26	27	32	29	27	28	33	27	25	27
12DT		Reboxetine	Female	01-DEPRESSED MOOD	2	3	3	3	1	1	0	0	0	0
				02-GUILT	2	2	1	1	1	1	0	0	0	0
				03-SUICIDE	0	0	0	0	0	0	0	0	0	0
				04-INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0
				05-INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0
				06-INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0
				07-WORK AND ACTIVITIES	0	0	0	0	0	0	0	0	0	0
				08-RETARDATION	0	0	0	0	0	0	0	0	0	0
				09-AGITATION	0	0	0	0	0	0	0	0	0	0
				10-ANXIETY PSYCHIC	0	0	0	0	0	0	0	0	0	0
				11-ANXIETY SOMATIC	4	4	3	1	2	1	1	1	2	1
				12-SOMATIC GASTROINTESTINAL	2	2	2	1	0	0	0	0	0	0
				13-SOMATIC GENERAL	2	2	2	1	0	0	0	0	0	0
				14-GENITAL SYMPTOMS	2	2	2	1	1	1	1	1	1	1
				15-HYPOCHONDRIASIS	3	2	1	2	1	1	2	2	2	2
				16-LOSS OF WEIGHT	2	0	0	0	0	2	0	0	0	2
				17-INSIGHT	0	0	0	0	0	0	0	0	0	0
				18-DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0
				19-DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0
				20-PARANOID	0	0	0	0	0	0	0	0	0	0

1319

9550089

48

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day
10	12DT	Reboxetine	Female	21.OBSESSIONAL/COMPULSIVE 22.Total score	0 20	0 20	0 16	0 10	0 9	0 10	0 5	0 5	0 8	0 5	0 9
13DT	Reboxetine	Female	01.DEPRESSED MOOD 02.GUILT 03.SUICIDE 04.INSOMNIA EARLY 05.INSOMNIA MIDDLE 06.INSOMNIA LATE 07.WORK AND ACTIVITIES 08.RETARDATION 09.AGITATION 10.ANXIETY PSYCHIC 11.ANXIETY SOMATIC 12.SOMATIC GASTROINTESTINAL 13.SOMATIC GENERAL 14.GENITAL SYMPTOMS 15.HYPOCHONDRIASIS 16.LOSS OF HEIGHT 17.INSIGHT 18.DIURNAL VARIATION 19.DEPERSONALIZATION 20.PARANOID 21.OBSESSIONAL/COMPULSIVE 22.Total score	3 1 0 0 0 0 3 0 0 3 3 0 2 2 3 0 0 0 1 2 1 1 23	3 1 0 0 0 0 3 0 0 3 3 0 2 2 3 0 0 0 1 2 1 1 23	3 1 0 0 0 0 3 2 0 0 3 2 2 3 0 0 0 1 2 1 1 23	2 1 0 0 0 0 2 1 0 0 2 1 1 0 0 0 0 2 1 1 1 23	1 1 0 0 0 0 2 1 0 0 2 1 1 0 0 0 0 2 1 1 1 23	2 1 0 0 0 0 2 1 0 0 2 1 1 0 0 0 0 2 1 1 1 23	2 1 0 0 0 0 2 1 0 0 2 1 1 0 0 0 0 2 1 1 1 23	2 1 0 0 0 0 2 1 0 0 2 1 1 0 0 0 0 2 1 1 1 23	2 1 0 0 0 0 2 1 0 0 2 1 1 0 0 0 0 2 1 1 1 23	2 1 0 0 0 0 2 1 0 0 2 1 1 0 0 0 0 2 1 1 1 23	2 1 0 0 0 0 2 1 0 0 2 1 1 0 0 0 0 2 1 1 1 23	
14DT	Imipramine	Female	01.DEPRESSED MOOD 02.GUILT 03.SUICIDE 04.INSOMNIA EARLY 05.INSOMNIA MIDDLE 06.INSOMNIA LATE 07.WORK AND ACTIVITIES 08.RETARDATION 09.AGITATION 10.ANXIETY PSYCHIC 11.ANXIETY SOMATIC 12.SOMATIC GASTROINTESTINAL 13.SOMATIC GENERAL 14.GENITAL SYMPTOMS 15.HYPOCHONDRIASIS 16.LOSS OF HEIGHT 17.INSIGHT 18.DIURNAL VARIATION 19.DEPERSONALIZATION 20.PARANOID 21.OBSESSIONAL/COMPULSIVE 22.Total score	3 1 0 0 0 0 3 0 0 3 3 0 2 2 3 0 0 0 1 2 1 1 23	3 1 0 0 0 0 3 0 0 3 3 0 2 2 3 0 0 0 1 2 1 1 23	3 1 0 0 0 0 3 0 0 3 3 0 2 2 3 0 0 0 1 2 1 1 23	2 1 0 0 0 0 2 1 0 0 2 1 1 0 0 0 0 2 1 1 1 23	2 1 0 0 0 0 2 1 0 0 2 1 1 0 0 0 0 2 1 1 1 23	2 1 0 0 0 0 2 1 0 0 2 1 1 0 0 0 0 2 1 1 1 23	2 1 0 0 0 0 2 1 0 0 2 1 1 0 0 0 0 2 1 1 1 23	2 1 0 0 0 0 2 1 0 0 2 1 1 0 0 0 0 2 1 1 1 23	2 1 0 0 0 0 2 1 0 0 2 1 1 0 0 0 0 2 1 1 1 23	2 1 0 0 0 0 2 1 0 0 2 1 1 0 0 0 0 2 1 1 1 23	2 1 0 0 0 0 2 1 0 0 2 1 1 0 0 0 0 2 1 1 1 23	2 1 0 0 0 0 2 1 0 0 2 1 1 0 0 0 0 2 1 1 1 23

1320

9550089

49

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
10	15ND	Reboxetine	Female	01. DEPRESSED MOOD	3	3	2	1	0	0	0	0	0	0		
				02. GUILT	0	0	0	0	0	0	0	0	0	0	0	
				03. SUICIDE	2	2	1	0	0	0	0	0	0	0	0	0
				04. INSOMNIA EARLY	2	2	1	0	0	0	0	0	0	0	0	0
				05. INSOMNIA MIDDLE	2	2	0	0	0	0	0	0	0	0	0	0
				06. INSOMNIA LATE	2	2	0	0	0	0	0	0	0	0	0	0
				07. WORK AND ACTIVITIES	4	4	3	1	1	1	1	1	1	1	1	1
				08. RETARDATION	2	3	2	1	1	1	1	1	1	1	1	1
				09. AGITATION	0	0	0	0	0	0	0	0	0	0	0	0
				10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2
				11. ANXIETY SOMATIC	2	3	3	1	1	1	1	1	1	1	1	1
				12. SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0	0	0	0	0
				13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2
				14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1
				15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	2	2	1	2	1	1	1	1	1	1	1	1
				19. DEPERSONALIZATION	1	1	2	1	1	1	1	1	1	1	1	1
				20. PARANOID	1	1	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	28	30	29	16	12	7	8	6	7	8	7	6
16DT	16DT	Imipramine	Male	01. DEPRESSED MOOD	3	3	2	1	0	0	0	0	0	0		
				02. GUILT	1	1	1	0	0	0	0	0	0	0	0	
				03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	
				04. INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0	
				05. INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0	
				06. INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	
				07. WORK AND ACTIVITIES	3	3	2	2	1	0	0	0	0	0	0	0
				08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0
				09. AGITATION	0	0	0	0	0	0	0	0	0	0	0	0
				10. ANXIETY PSYCHIC	1	2	2	2	2	2	2	2	2	2	2	2
				11. ANXIETY SOMATIC	3	3	2	1	2	1	0	0	0	0	0	0
				12. SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0	0	0	0	0
				13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2
				14. GENITAL SYMPTOMS	2	2	1	1	1	1	1	1	1	1	1	1
				15. HYPOCHONDRIASIS	2	2	1	0	0	0	0	0	0	0	0	0
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0
				17. INSIGHT	1	1	1	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	1	2	2	1	1	1	1	1	1	1	1	1
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	19	19	18	11	7	4	5	6	5	6	5	6
17ND	17ND	Reboxetine	Female	01. DEPRESSED MOOD	3	3	2	1	0	0	0	0	0	0		
				02. GUILT	0	0	0	0	0	0	0	0	0	0		
				03. SUICIDE	0	0	0	0	0	0	0	0	0	0		
				04. INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0		

1324

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

51

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63							
10	19DT	Reboxetine	Male	09. ACTIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0						
				10. ANXIETY PSYCHIC	2	2	3	4	2	3	2	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
				11. ANXIETY SOMATIC	3	3	3	2	2	3	2	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				12. SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				14. GENITAL SYMPTOMS	1	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1			
				15. HYPOCHONDRIASIS	2	2	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1			
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				17. INSIGHT	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				19. DEPERSONALIZATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				21. OBSSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
				22. Total score	20	22	23	20	21	20	21	20	15	15	17	16	16	16	16	16	16	16	16	16	16	16	16	16	16		
				20ND	Reboxetine	Female	01. DEPRESSED MOOD	3	3	3	4	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
							02. GUILT	2	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
							03. SUICIDE	2	1	2	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
							04. INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
							05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
							06. INSOMNIA LATE	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
							07. WORK AND ACTIVITIES	3	3	3	4	3	4	3	4	3	4	3	4	3	4	3	4	3	4	3	4	3	4	3	4
							08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
09. AGITATION	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
10. ANXIETY PSYCHIC	2	2	2				3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
11. ANXIETY SOMATIC	2	2	2				3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
12. SOMATIC GASTROINTESTINAL	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
13. SOMATIC GENERAL	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
14. GENITAL SYMPTOMS	1	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
15. HYPOCHONDRIASIS	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
16. LOSS OF WEIGHT	1	0	2				0	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
17. INSIGHT	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
18. DIURNAL VARIATION	1	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
19. DEPERSONALIZATION	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
20. PARANOID	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
21. OBSSIONAL/COMPULSIVE	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
22. Total score	28	31	32				31	27	23	23	23	23	23	24	30	30	30	30	30	30	30	30	30	30	30	30	30	30			
12	1ND	Reboxetine	Female	04. DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3						
				02. GUILT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
				03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				05. INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				06. INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				07. WORK AND ACTIVITIES	3	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				09. AGITATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			

1323

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

53

PHARMACIA CNS 8&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day						
13	1ND	Reboxetine	Female	17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0					
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				22.Total score	28	28	25	19	12	11	9	7	7	7	7	7	7	6			
				1ND	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	4	3	2	1	1	1	0	0	0	0	
							02.GUILT	2	2	3	2	2	1	0	0	0	0	0	0	0	0
							03.SUICIDE	1	1	1	2	1	1	0	0	0	0	0	0	0	0
							04.INSOMNIA EARLY	1	1	1	1	1	1	0	0	0	0	0	0	0	0
							05.INSOMNIA MIDDLE	1	1	1	1	1	0	0	0	0	0	0	0	0	0
							06.INSOMNIA LATE	1	1	1	2	1	1	0	0	0	0	0	0	0	0
							07.WORK AND ACTIVITIES	2	2	2	3	3	3	1	1	0	0	1	0	1	0
08.RETARDATION	1	1	1				1	1	1	0	0	0	0	0	0	0	0				
09.AGITATION	0	0	0				0	0	0	0	0	0	0	0	0	0	0				
10.ANXIETY PSYCHIC	3	3	3				3	2	2	0	0	0	0	0	0	0	0				
11.ANXIETY SOMATIC	2	2	2				1	1	1	1	1	1	1	0	0	0	0				
12.SOMATIC GASTROINTESTINAL	1	1	1				1	1	1	0	0	0	0	0	0	0	0				
13.SOMATIC GENERAL	1	1	1				1	1	1	0	0	0	0	0	0	0	0				
14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0							
15.HYPOCHONDRIASIS	2	2	2	2	2	2	0	0	0	0	0	0	0	0							
16.LOSS OF WEIGHT	1	1	1	0	0	0	1	1	0	0	0	0	0	0							
17.INSIGHT	0	0	0	0	0	0	1	1	0	0	0	0	0	0							
18.DIURNAL VARIATION	1	1	1	1	1	0	0	0	0	0	0	0	0	0							
19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0							
20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0							
21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0							
22.Total score	23	23	23	26	19	17	3	4	2	2	4	2	4	2							
2ND	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	4	3	3	3	3	3	2	1	1						
			02.GUILT	2	2	2	3	2	2	2	2	2	1	1	1						
			03.SUICIDE	1	1	1	3	2	2	2	2	2	1	0	0						
			04.INSOMNIA EARLY	0	0	0	2	1	0	0	1	1	1	1	1						
			05.INSOMNIA MIDDLE	0	0	0	1	1	0	0	1	1	1	1	1						
			06.INSOMNIA LATE	2	1	1	1	1	0	0	1	0	0	0	0						
			07.WORK AND ACTIVITIES	4	4	4	4	3	4	4	4	4	2	3	4						
			08.RETARDATION	1	1	1	1	1	0	0	0	0	0	0	0						
			09.AGITATION	1	1	1	1	0	0	0	0	0	0	0	0						
			10.ANXIETY PSYCHIC	1	1	1	2	1	1	1	1	1	1	1	1						
			11.ANXIETY SOMATIC	0	0	0	0	0	0	0	0	0	0	0	0						
			12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2						
			13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1						
14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0									
15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0									
16.LOSS OF WEIGHT	2	2	2	0	0	2	0	0	1	1	1	1									
17.INSIGHT	0	0	0	1	0	1	0	1	1	1	1	1									
18.DIURNAL VARIATION	2	2	2	2	2	1	2	1	0	0	0	0									
19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0									
20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0									

13 25

9550089

54

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63
13	ZND	Imipramine	Female	21-OBSessional/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22.Total score	22	30	26	21	19	21	17	17	12	11	12									
	ZDT	Reboxetine	Female	01-DEPRESSED MOOD	3	3	3	3	3	3	2	2	2	2	2	2	2	2	2	2	3	3	2	2
				02.GUILT	3	3	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	0	0
				03.SUICIDE	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	1	2	1	2	1	0	1	0	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	1	1	2	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	1	1	1	1	0	0	1	1	1	1	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	3	3	2	3	2	3	2	1	2	3	2	3	2	3	2	3	2	2
				08.RETARDATION	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
				09.AGITATION	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
				10.ANKIETY PSYCHIC	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				11.ANKIETY SOMATIC	3	3	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21.OBSessional/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22.Total score	26	25	22	17	17	19	11	12	15	10										
	SND	Imipramine	Male	01-DEPRESSED MOOD	4	4	3	2	2	2	2	2	2	2	2	2	2	2	2	2	1	1	1	2
				02.GUILT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1	1	1	1
				03.SUICIDE	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				04.INSOMNIA EARLY	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				06.INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	4	4	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				08.RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				09.AGITATION	3	3	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				10.ANKIETY PSYCHIC	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				11.ANKIETY SOMATIC	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21.OBSessional/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22.Total score	28	27	20	15	16	16	12	9	12	10										

1326

9550089

55

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient Treatment	Sex	Hamilton depression rating scale																								
			Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63														
13	3DT	Isipramine	Female	01. DEPRESSED MOOD	4	4	3	3	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0				
				02. GUILT	3	3	3	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				03. SUICIDE	2	2	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				04. INSOMNIA EARLY	2	2	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				05. INSOMNIA MIDDLE	2	2	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				06. INSOMNIA LATE	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				07. WORK AND ACTIVITIES	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				08. RETARDATION	3	3	3	3	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				09. AGITATION	3	3	3	3	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				10. ANXIETY PSYCHIC	3	3	3	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				11. ANXIETY SOMATIC	3	3	3	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				12. SOMATIC GASTROINTESTINAL	3	3	3	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				13. SOMATIC GENERAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				19. DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSSSSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	26	26	23	21	11	6	5	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
				14	4DT	Reboxetine	Female	01. DEPRESSED MOOD	2	2	2	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1
02. GUILT	2	2	2					1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
03. SUICIDE	0	0	0					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
04. INSOMNIA EARLY	0	0	0					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
05. INSOMNIA MIDDLE	0	0	0					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
06. INSOMNIA LATE	0	0	0					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
07. WORK AND ACTIVITIES	0	0	0					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
08. RETARDATION	1	1	1					1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
09. AGITATION	0	0	0					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
10. ANXIETY PSYCHIC	1	1	1					1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
11. ANXIETY SOMATIC	1	1	1					1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
12. SOMATIC GASTROINTESTINAL	1	1	1					1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
13. SOMATIC GENERAL	1	1	1					1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
14. GENITAL SYMPTOMS	2	2	2					2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
15. HYPOCHONDRIASIS	0	0	0					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
16. LOSS OF WEIGHT	0	0	0					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
17. INSIGHT	0	0	0					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
18. DIURNAL VARIATION	1	1	1					1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
19. DEPERSONALIZATION	2	2	2					2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
20. PARANOID	1	1	1					1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
21. OBSSSSIONAL/COMPULSIVE	0	0	0					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
22. Total score	18	21	14					11	12	12	7	6	4	4	4	4	4	4	4	4	4	4	4	4	4	4	
14	1ND	Reboxetine	Female					01. DEPRESSED MOOD	4	4	4	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				02. GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				03. SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
				04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		

1327

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

56

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63	
14	1ND	Reboxetine	Female	05.INSOMNIA MIDDLE	1	0	1	1	0	0	0	0	0	1											
				06.INSOMNIA LATE	1	1	1	1	0	0	0	0	0	1											
				07.WORK AND ACTIVITIES	4	3	1	1	1	1	1	1	4												
				08.RETARDATION	2	2	1	1	1	0	1	1	4												
				09.AGIATION	0	0	0	0	1	0	2	0	2												
				10.ANXIETY PSYCHIC	4	5	2	2	2	1	3	3													
				11.ANXIETY SOMATIC	3	3	2	1	2	2	3	3													
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1												
				13.SOMATIC GENERAL	0	0	0	0	0	0	0	0	0												
				14.GENITAL SYMPTOMS	3	3	1	1	1	1	3	3													
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0												
				16.LOSS OF HEIGHT	0	0	0	0	0	0	0	0	0												
				17.INSIGHT	1	1	1	1	1	1	0	0	0												
				18.DIURNAL VARIATION	2	2	0	1	1	0	0	0	0												
				19.DEPERSONALIZATION	1	1	0	0	0	0	0	0	0												
				20.PARANOID	1	0	0	0	0	0	0	0	0												
				21.OBSESSIONAL/COMPULSIVE	1	2	0	1	0	1	0	0	0												
				22.Total score	34	31	15	13	8	26															
15	1ND	Reboxetine	Female	01 DEPRESSED MOOD	3	0	1	1	1	1	0	1	1	1	0	0	1	1	2	0	1	2	0	1	1
				02.GUILT	0	0	0	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				03.SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	3	2	3	2	3	2	3	1	2	3	3	3	3	3	3	3	3	3	3	3	3
				08.RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				09.AGIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				16.LOSS OF HEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	2	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22.Total score	29	29	23	18	17	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11
1DT		Reboxetine	Female	01 DEPRESSED MOOD	3	3	3	3	2	2	3	2	3	2	2	2	1	1	1	1	1	1	1	1	1
				02.GUILT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				03.SUICIDE	0	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				06.INSOMNIA LATE	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				08.RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1328

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

58

PHARMACIA CMS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	HAMILTON DEPRESSION RATING SCALE												
				Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
15	ZDT	Imipramine	Female	2	2	1	1	1	1	1	1	1	1	1		
				0	0	0	0	0	0	0	0	0	0	0		
				3	1	1	1	1	1	1	1	1	1	1		
				0	0	0	0	0	0	0	0	0	0	0		
				1	1	1	1	1	1	1	1	1	1	1		
				1	1	1	1	1	1	1	1	1	1	1		
				0	0	0	0	0	0	0	0	0	0	0		
				1	1	1	1	1	1	1	1	1	1	1		
				1	1	1	1	1	1	1	1	1	1	1		
				29	29	21	16	15	14	14	10	11	7			
				2	2	3	2	1	1	1	0	0	0	0		
				4	1	2	2	1	0	1	0	0	0	0		
				1	1	1	3	6	0	0	0	0	0	0		
				0	0	0	0	0	0	0	0	0	0	0		
				0	0	1	1	1	0	0	0	0	0	0		
				4	3	2	3	1	2	1	1	1	1	1		
				2	2	1	1	1	0	1	0	1	0	0		
				1	1	1	2	1	1	1	1	1	1	1		
				3	1	2	2	1	0	0	0	0	0	0		
				2	2	2	2	2	2	2	2	2	1	1		
				1	1	0	1	0	0	0	0	0	0	0		
				0	0	0	0	0	0	0	0	0	0	0		
				2	1	2	2	0	1	1	1	0	0	0		
				1	1	1	1	1	0	0	0	0	0	0		
				2	1	1	1	1	1	1	1	1	1	1		
				1	1	1	1	1	0	0	0	0	0	0		
				2	1	1	1	1	1	1	1	1	1	1		
				1	1	0	1	1	1	1	1	1	1	1		
				1	1	1	1	1	1	1	1	1	1	1		
				26	21	21	23	11	8	9	8	8	4			
				3	2	2	1	1	1	1	0	0	0	0		
				4	1	1	1	1	1	0	0	0	0	0		
				1	1	1	0	0	0	0	0	0	0	0		
				2	2	2	1	1	1	1	1	1	1	1		
				0	0	0	1	1	1	1	1	1	1	1		
				0	0	0	1	1	0	1	1	0	0	0		
				3	3	3	2	1	1	1	2	1	1	1		
				1	0	1	1	1	0	0	0	0	0	0		
				3	4	1	1	1	1	1	1	0	0	0		
				3	2	2	1	2	1	1	1	1	0	0		
				1	2	2	2	2	1	1	1	1	1	1		
				1	1	1	1	0	0	0	0	0	0	0		
				2	2	1	1	1	0	1	1	1	0	0		
				0	0	0	0	0	0	0	0	0	0	0		
				3	3	2	2	1	1	1	1	1	0	0		
				0	0	0	0	0	0	0	0	0	0	0		

1330

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

59

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63								
15	4HD	Imipramine	Female	17. INSIGHT	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0							
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
				19. DEPERSONALIZATION	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
				20. PARANOID	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
				21. OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
				22.Total score	31	27	24	20	16	11	13	12	7	5																		
				11	1ND	Reboxetine	Female	01. DEPRESSED MOOD	4	4	3	3	3	2	2																	
								02. GUILT	2	2	1	1	1	1																		
								03. SUICIDE	2	2	2	2	2	2																		
								04. INSOMNIA EARLY	2	2	2	2	2	2																		
								05. INSOMNIA MIDDLE	2	2	2	2	2	2																		
								06. INSOMNIA LATE	2	2	2	2	2	2																		
07. WKB AND ACTIVITIES	4	4	3					3	3	3																						
08. RETARDATION	3	3	3					3	3	3																						
09. AGITATION	0	0	0					0	0	0																						
10. ANXIETY PSYCHIC	3	3	1					1	1	1																						
11. ANXIETY SOMATIC	2	1	1					1	1	1																						
12. SOMATIC GASTROINTESTINAL	1	1	1					1	1	1																						
13. SOMATIC GENERAL	2	1	1					1	1	1																						
14. GENITAL STYPTORS	0	0	0					0	0	0																						
15. HYPOCHONDRIASIS	2	1	1					1	1	2	2																					
16. LOSS OF WEIGHT	0	0	0					0	0	0																						
17. INSIGHT	2	2	2					2	2	1	1																					
18. DIURNAL VARIATION	0	0	0					0	0	0																						
19. DEPERSONALIZATION	2	1	2					1	2	1	1																					
20. PARANOID	1	1	1					1	1	1	1																					
21. OBSESSIONAL/COMPULSIVE	1	1	1					1	1	1	1																					
22.Total score	37	31	27					25	22																							
11	12ND	Imipramine	Female	01. DEPRESSED MOOD	3	3	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0							
				02. GUILT	2	1	2	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
				03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
				04. INSOMNIA EARLY	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
				05. INSOMNIA MIDDLE	2	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
				06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
				07. WKB AND ACTIVITIES	3	3	2	2	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1				
				08. RETARDATION	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
				09. AGITATION	1	1	1	1	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0				
				10. ANXIETY PSYCHIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
				11. ANXIETY SOMATIC	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
				13. SOMATIC GENERAL	1	2	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
				14. GENITAL STYPTORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
				15. HYPOCHONDRIASIS	3	3	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
				19. DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
				20. PARANOID	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				

1331

9550089

61

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	7	14	21	28	35	42	49	56	Day 63			
16	2ND	Imipramine	Male	01. DEPRESSED MOOD	3	3	2	1	1	1	1	1	1	1	1			
				02. GUILT	2	2	1	1	1	1	1	1	1	1	1	1		
				03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				04. INSOMNIA EARLY	2	1	1	1	1	1	1	1	1	1	1	1	1	1
				05. INSOMNIA MIDDLE	2	1	1	1	1	1	1	1	1	1	1	1	1	1
				06. INSOMNIA LATE	2	2	2	1	0	0	0	0	0	0	0	0	0	0
				07. WORK AND ACTIVITIES	4	4	3	2	2	2	1	1	1	1	1	1	1	1
				08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				09. AGITATION	2	3	3	2	2	2	1	1	1	1	1	1	1	1
				10. ANXIETY PSYCHIC	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				11. ANXIETY SOMATIC	2	2	2	1	1	1	1	1	1	1	1	1	1	1
				12. SOMATIC GASTROINTESTINAL	2	2	2	1	1	1	1	1	1	1	1	1	1	1
				13. SOMATIC GENERAL	2	2	2	1	1	1	1	1	1	1	1	1	1	1
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				16. LOSS OF WEIGHT	2	0	0	0	0	0	0	0	0	0	0	0	0	0
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score				26	25	20	13	9	10	8	5	5	5	5
20T		Reboxetine	Male	01. DEPRESSED MOOD	3	3	3	2	2	0	0	0	0	0	0			
				02. GUILT	1	1	2	3	2	1	1	1	1	1	1	1		
				03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	
				04. INSOMNIA EARLY	2	1	2	1	1	1	1	1	1	1	1	1	1	
				05. INSOMNIA MIDDLE	2	2	1	1	1	1	1	1	1	1	1	1	1	
				06. INSOMNIA LATE	2	2	1	1	1	1	1	1	1	1	1	1	1	
				07. WORK AND ACTIVITIES	4	4	4	4	4	4	3	2	1	1	1	1	1	
				08. RETARDATION	2	1	1	1	1	1	1	1	1	1	1	1	1	
				09. AGITATION	1	1	1	1	1	1	1	1	1	1	1	1	1	
				10. ANXIETY PSYCHIC	2	3	2	2	2	1	1	1	1	1	1	1	1	
				11. ANXIETY SOMATIC	2	2	2	2	2	1	1	1	1	1	1	1	1	
				12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	1	1	1	1	1	1	1	1	
				13. SOMATIC GENERAL	0	0	0	0	0	0	0	0	0	0	0	0	0	
				14. GENITAL SYMPTOMS	1	1	0	0	0	0	0	0	0	0	0	0	0	
				15. HYPOCHONDRIASIS	2	0	0	0	0	0	0	0	0	0	0	0	0	
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	
				21. OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1	1	1	
				22. Total score				27	26	24	17	13	6	6	4	4	5	3
3ND		Imipramine	Female	01. DEPRESSED MOOD	3	3	3	3	2	2	1	1	1	1	1			
				02. GUILT	1	1	1	1	1	1	1	1	1	1	1			
				03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0			
				04. INSOMNIA EARLY	2	1	1	1	1	1	1	1	1	1	1			

1333

9550089

62

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day
16	3WD	Imipramine	Female	HAMILTON DEPRESSION RATING SCALE		1	1	0	1	0	0	0	0	0	0
				05.INSOMNIA MIDDLE		1	1	0	1	0	0	0	0	0	0
				06.INSOMNIA LATE		1	2	1	1	1	1	1	1	1	0
				07.WORK AND ACTIVITIES		4	4	4	4	3	2	2	2	4	4
				08.RETARDATION		3	3	3	2	2	2	2	2	2	2
				09.AGITATION		0	0	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC		2	2	2	1	1	1	1	1	1	1
				11.ANXIETY SOMATIC		1	2	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL		2	2	2	2	2	2	2	2	2	1
				13.SOMATIC GENERAL		2	2	2	2	2	2	2	2	2	1
				14.GENITAL SYMPTOMS		0	0	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS		0	0	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT		1	0	0	0	0	0	0	0	0	0
				17.INSIGHT		0	0	0	0	2	1	3	1	3	0
				18.DIURNAL VARIATION		0	0	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION		0	0	0	0	0	0	0	0	0	0
				20.PARANOID		0	0	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE		0	0	0	0	0	0	0	0	0	0
				22.Total score		23	23	20	19	17	15	16	16	16	16
30T		Imipramine	Female			2	2	2	2	3					
				01.DEPRESSED MOOD		2	2	2	2	3					
				02.GUILT		0	0	0	0	1					
				03.SUICIDE		0	0	0	0	2					
				04.INSOMNIA EARLY		2	1	1	2	2					
				05.INSOMNIA MIDDLE		1	1	0	2	2					
				06.INSOMNIA LATE		2	2	1	2	2					
				07.WORK AND ACTIVITIES		4	4	4	4	4					
				08.RETARDATION		1	1	1	1	1					
				09.AGITATION		0	0	1	1	1					
				10.ANXIETY PSYCHIC		2	2	1	3	3					
				11.ANXIETY SOMATIC		3	2	2	4	4					
				12.SOMATIC GASTROINTESTINAL		2	2	1	2	2					
				13.SOMATIC GENERAL		2	1	1	2	2					
				14.GENITAL SYMPTOMS		0	0	0	0	0					
				15.HYPOCHONDRIASIS		3	3	2	2	2					
				16.LOSS OF WEIGHT		2	0	0	2	2					
				17.INSIGHT		0	0	0	0	0					
				18.DIURNAL VARIATION		1	0	0	0	0					
				19.DEPERSONALIZATION		0	0	0	0	0					
				20.PARANOID		0	0	0	0	0					
				21.OBSESSIONAL/COMPULSIVE		1	1	1	1	1					
				22.Total score		28	22	18	18	34					
4WD		Reboxetine	Female			3	3	2	2	1	1	1	1	1	1
				01.DEPRESSED MOOD		3	3	2	2	1	1	1	1	1	1
				02.GUILT		1	2	2	1	1	0	0	0	0	0
				03.SUICIDE		1	0	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY		2	2	2	2	1	1	1	1	1	1
				05.INSOMNIA MIDDLE		1	2	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE		2	2	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES		4	4	3	3	3	2	2	2	2	2
				08.RETARDATION		2	2	2	2	2	2	2	2	2	2
				09.AGITATION		0	0	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC		2	2	2	2	2	2	2	2	2	2
				11.ANXIETY SOMATIC		3	3	3	3	3	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL		2	2	2	2	2	2	2	2	2	2
				13.SOMATIC GENERAL		0	0	0	0	0	0	0	0	0	0
				14.GENITAL SYMPTOMS		0	0	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS		3	3	3	3	3	2	2	2	2	2
				16.LOSS OF WEIGHT		2	0	0	2	2	2	2	2	2	2
				17.INSIGHT		0	0	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION		1	0	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION		0	0	0	0	0	0	0	0	0	0
				20.PARANOID		0	0	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE		1	1	1	1	1	1	1	1	1	1
				22.Total score		28	22	18	18	34					

1334

9550089

64

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63									
17	4DT	Reboxetine	Female	13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1								
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0						
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
				16.LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
				17.INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
				20.PARANOID	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
				22.Total score	21	21	21	21	21	21	21	21	21	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20				
				2ND	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3			
							02.GUILT	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
							03.SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
							04.INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
							05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
							06.INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
							07.WORK AND ACTIVITIES	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
							08.RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
							09.AGITATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
							10.ANXIETY PSYCHIC	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
							11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
							12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
13.SOMATIC GENERAL	1	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
14.GENITAL SYMPTOMS	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
15.HYPOCHONDRIASIS	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
16.LOSS OF WEIGHT	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
17.INSIGHT	1	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
18.DIURNAL VARIATION	1	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
19.DEPERSONALIZATION	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
20.PARANOID	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
21.OBSESSIONAL/COMPULSIVE	1	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
22.Total score	27	27	27				27	27	27	27	25	24	24	24	24	24	23	23	23	23	23	23	22	22	22	22	18	18					
2DT	Reboxetine	Female	01.DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2							
			02.GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0						
			03.SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
			04.INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
			05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
			06.INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
			07.WORK AND ACTIVITIES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
			08.RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
			09.AGITATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
			10.ANXIETY PSYCHIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
			11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
			12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
			13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
			14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
			15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
			16.LOSS OF WEIGHT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					

1336

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

65

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63				
17	20T	Reboxetine	Female	HAMILTON DEPRESSION RATING SCALE	1	1	1	1	1	1	1	1	1	1				
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1		
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1		
				19. DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1		
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0		
				21. OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1	1		
				22. Total score	20	20	18	18	18	17	17	15	15	15	15	15		
				3ND	Imipramine	Female	HAMILTON DEPRESSION RATING SCALE	3	3	3	3	3	3	3	3	3	3	3
							01. DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3
							02. GUILT	1	1	1	1	1	1	1	1	1	1	1
03. SUICIDE	1	1	1				1	1	1	1	1	1	1	1				
04. INSOMNIA EARLY	2	2	2				2	2	2	2	2	2	2	2				
05. INSOMNIA MIDDLE	2	2	2				2	2	2	2	2	2	2	2				
06. INSOMNIA LATE	2	2	2				2	2	2	2	2	2	2	2				
07. WORK AND ACTIVITIES	3	3	3				3	3	3	3	3	3	3	3				
08. RETARDATION	2	2	2				2	2	2	2	2	2	2	2				
09. AGITATION	2	2	2				2	2	2	2	2	2	2	2				
10. ANXIETY PSYCHIC	3	3	3	3	3	3	3	3	3	3	3							
11. ANXIETY SOMATIC	3	3	3	3	3	3	3	3	3	3	3							
12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2							
13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2							
14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1							
15. HYPOCHONDRIASIS	3	3	3	3	3	3	3	3	3	3	3							
16. LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1							
17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0							
18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0							
19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0							
20. PARANOID	0	0	0	0	0	0	0	0	0	0	0							
21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0							
22. Total score	33	35	32	32	32	32	32	32	32	32	32	32						
30T	Imipramine	Male	HAMILTON DEPRESSION RATING SCALE	2	2	2	2	2	2	2	2	2	2	2				
			01. DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2	2				
			02. GUILT	3	3	3	3	3	3	3	3	3	3	3				
			03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0				
			04. INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1				
			05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1				
			06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1				
			07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3				
			08. RETARDATION	1	1	1	1	1	1	1	1	1	1	1				
			09. AGITATION	3	3	3	3	3	3	3	3	3	3	3				
10. ANXIETY PSYCHIC	3	3	3	3	3	3	3	3	3	3	3							
11. ANXIETY SOMATIC	3	3	3	3	3	3	3	3	3	3	3							
12. SOMATIC GASTROINTESTINAL	4	4	4	4	4	4	4	4	4	4	4							
13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2							
14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1							
15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0							
16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0							
17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1							
18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1							
19. DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1							
20. PARANOID	1	1	1	1	1	1	1	1	1	1	1							

1337

9550089

66

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 ROBEXETINE - PROTOCOL 20124/035
 Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
17	30T	Imipramine	Male	21. OBSESSIONAL/COMPULSIVE 22. Total score	32	2	2	2	2	2	1	1	1	1
4ND		Roboxetine	Female	01. DEPRESSED MOOD 02. GUILT 03. SUICIDE 04. INSOMNIA EARLY 05. INSOMNIA MIDDLE 06. INSOMNIA LATE 07. WORK AND ACTIVITIES 08. RETARDATION 09. AGITATION 10. ANXIETY PSYCHIC 11. ANXIETY SOMATIC 12. SOMATIC GASTROINTESTINAL 13. SOMATIC GENERAL 14. GENITAL SYMPTOMS 15. HYPOCHONDRIASIS 16. LOSS OF WEIGHT 17. INSIGHT 18. DIURNAL VARIATION 19. DEPERSONALIZATION 20. PARANOID 21. OBSESSIONAL/COMPULSIVE 22. Total score	2	2	2	2	2	2	2	2	2	2
40T		Imipramine	Female	01. DEPRESSED MOOD 02. GUILT 03. SUICIDE 04. INSOMNIA EARLY 05. INSOMNIA MIDDLE 06. INSOMNIA LATE 07. WORK AND ACTIVITIES 08. RETARDATION 09. AGITATION 10. ANXIETY PSYCHIC 11. ANXIETY SOMATIC 12. SOMATIC GASTROINTESTINAL 13. SOMATIC GENERAL 14. GENITAL SYMPTOMS 15. HYPOCHONDRIASIS 16. LOSS OF WEIGHT 17. INSIGHT 18. DIURNAL VARIATION 19. DEPERSONALIZATION 20. PARANOID 21. OBSESSIONAL/COMPULSIVE 22. Total score	2	2	2	2	2	2	2	2	2	2

1338

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

68

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 12.0

Centre	Patient Treatment	Sex	Hamilton depression rating scale	Screen Day	0	7	14	21	28	35	42	49	56	Day 63					
18	1MD	Imipramine	Female	05. INSOMNIA MIDDLE	1	2	1	1	0	1	0	0	0	0					
				06. INSOMNIA LATE	1	2	1	1	0	1	1	1	0	0	0				
				07. WORK AND ACTIVITIES	3	3	2	2	2	2	1	1	1	1	1	2			
				08. RETARDATION	2	2	2	1	2	2	1	1	1	1	1	1			
				09. AGITATION	2	2	1	1	1	2	0	1	1	1	1	1			
				10. ANXIETY PSYCHIC	3	3	2	1	2	1	1	1	1	1	1	1			
				11. ANXIETY SOMATIC	2	2	1	2	1	1	1	1	1	1	1	1			
				12. SOMATIC GASTROINTESTINAL	2	2	1	1	1	1	0	0	0	0	0	0			
				13. SOMATIC GENERAL	2	2	1	1	1	1	1	1	1	1	1	1			
				14. GENITAL SYMPTOMS	2	2	0	0	0	0	0	0	0	0	0	0			
				15. HYPOCHONDRIASIS	2	2	2	2	2	1	1	1	1	1	1	1			
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0			
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0			
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0			
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0			
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0			
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0			
				22. Total score	27	28	23	19	16	19	11	11	9	9	12	0	0		
				10T	10T	Imipramine	Female	01. DEPRESSED MOOD	2	2	2	2	1	1	0	0	0	0	
								02. GUILT	2	2	2	3	1	1	0	0	0	0	0
								03. SUICIDE	1	1	0	1	0	0	0	0	0	0	0
								04. INSOMNIA EARLY	2	2	1	1	1	1	0	0	0	0	0
05. INSOMNIA MIDDLE	1	2	1					1	0	0	0	0	0	0	0				
06. INSOMNIA LATE	2	2	1					1	1	0	0	0	0	0	0				
07. WORK AND ACTIVITIES	3	3	2					2	1	2	2	1	1	1	1	1			
08. RETARDATION	2	2	2					2	1	1	1	0	0	0	0	0			
09. AGITATION	1	1	1					2	1	1	1	1	1	1	1	1			
10. ANXIETY PSYCHIC	3	3	2					2	2	2	1	1	1	1	1	1			
11. ANXIETY SOMATIC	2	2	2					2	2	2	1	1	1	1	1	1			
12. SOMATIC GASTROINTESTINAL	1	1	1					1	1	1	0	0	0	0	0	0			
13. SOMATIC GENERAL	0	0	0					0	0	0	0	0	0	0	0	0			
14. GENITAL SYMPTOMS	2	2	2					2	2	2	1	1	1	1	1	1			
15. HYPOCHONDRIASIS	0	0	0					0	0	0	0	0	0	0	0	0			
16. LOSS OF WEIGHT	0	0	0					0	0	0	0	0	0	0	0	0			
17. INSIGHT	0	0	0					0	0	0	0	0	0	0	0	0			
18. DIURNAL VARIATION	0	0	0					0	0	0	0	0	0	0	0	0			
19. DEPERSONALIZATION	0	0	0					0	0	0	0	0	0	0	0	0			
20. PARANOID	0	0	0					0	0	0	0	0	0	0	0	0			
21. OBSESSIONAL/COMPULSIVE	0	0	0					0	0	0	0	0	0	0	0	0			
22. Total score	25	25	19					23	15	11	6	3	0	0	0	0	0		
2MD	2MD	Imipramine	Female	01. DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2					
				02. GUILT	2	2	2	2	2	2	2	2	2	2					
				03. SUICIDE	2	2	2	2	2	2	2	2	2	2					
				04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2					
				05. INSOMNIA MIDDLE	2	2	1	1	2	1	2	1	2	1					
				06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2					
07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3									
08. RETARDATION	2	2	2	2	2	2	2	2	2	2									

1340

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

69

PHARMACIA CNS R2D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
18	2MD	Imipramine	Female			1	2	2	2	2	2	2	2	2	2
				09. AGITATION											
				10. ANXIETY PSYCHIC											
				11. ANXIETY SOMATIC											
				12. SOMATIC GASTROINTESTINAL											
				13. SOMATIC GENERAL											
				14. GENITAL SYMPTOMS											
				15. HYPOCHONDRIASIS											
				16. LOSS OF WEIGHT											
				17. INSIGHT											
				18. DIURNAL VARIATION											
				19. DEPERSONALIZATION											
				20. PARANOID											
				21. OBSSIONAL/COMPULSIVE											
				22. Total score		29	29	28	32	27					
2DT		Reboxetine	Female			3	3	2	3	3	3	2	2	2	2
				01. DEPRESSED MOOD											
				02. GUILT											
				03. SUICIDE											
				04. INSOMNIA EARLY											
				05. INSOMNIA MIDDLE											
				06. INSOMNIA LATE											
				07. MOOK AND ACTIVITIES											
				08. RETARDATION											
				09. AGITATION											
				10. ANXIETY PSYCHIC											
				11. ANXIETY SOMATIC											
				12. SOMATIC GASTROINTESTINAL											
				13. SOMATIC GENERAL											
				14. GENITAL SYMPTOMS											
				15. HYPOCHONDRIASIS											
				16. LOSS OF WEIGHT											
				17. INSIGHT											
				18. DIURNAL VARIATION											
				19. DEPERSONALIZATION											
				20. PARANOID											
				21. OBSSIONAL/COMPULSIVE											
				22. Total score		31	27	31	27	24					
3MD		Reboxetine	Female			2	2	3	3	2	1	2	2	2	1
				01. DEPRESSED MOOD											
				02. GUILT											
				03. SUICIDE											
				04. INSOMNIA EARLY											
				05. INSOMNIA MIDDLE											
				06. INSOMNIA LATE											
				07. MOOK AND ACTIVITIES											
				08. RETARDATION											
				09. AGITATION											
				10. ANXIETY PSYCHIC											
				11. ANXIETY SOMATIC											
				12. SOMATIC GASTROINTESTINAL											

1341

9550089

70

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
18	3MD	Reboxetine	Female	1	1	1	1	1	0	1	1	1	1	1
				13. SOMATIC GENERAL	0	0	0	0	0	0	0	0	0	0
				14. GENITAL SYMPTOMS	3	3	3	2	2	2	2	2	2	1
				15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0
				22. Total score	29	27	26	26	26	16	11	16	17	17
4MD	Reboxetine	Female	01. DEPRESSED MOOD	4	3	3	3	3	2	1	0	0	0	0
			02. GUILT	3	3	3	3	3	2	1	0	0	1	1
			03. SUICIDE	2	2	2	2	2	1	0	0	0	0	0
			04. INSOMNIA EARLY	2	2	2	2	2	1	0	1	0	0	0
			05. INSOMNIA MIDDLE	1	1	1	1	1	0	0	0	0	0	0
			06. INSOMNIA LATE	1	1	1	1	1	0	0	0	0	0	0
			07. WORK AND ACTIVITIES	2	2	2	2	2	2	1	1	1	1	1
			08. RETARDATION	4	4	4	4	3	2	2	1	1	1	1
			09. AGITATION	3	3	3	3	3	2	1	0	0	0	0
			10. ANXIETY PSYCHIC	0	0	0	0	0	0	0	0	0	0	0
			11. ANXIETY SOMATIC	3	2	2	2	2	2	1	1	1	1	1
			12. SOMATIC GASTROINTESTINAL	3	3	3	3	2	2	1	1	1	1	1
			13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1
			14. GENITAL SYMPTOMS	2	1	1	1	1	1	1	1	1	1	1
			15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0
			16. LOSS OF WEIGHT	2	2	2	2	2	1	0	1	1	1	1
			17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0
			18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0
			19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0
			20. PARANOID	0	0	0	0	0	0	0	0	0	0	0
			21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0
			22. Total score	32	29	29	29	29	14	8	5	4	4	5
20	3MD	Reboxetine	Female	01. DEPRESSED MOOD	3	3	3	3	2	1	0	0	0	0
			02. GUILT	2	2	2	2	2	1	0	0	0	0	0
			03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0
			04. INSOMNIA EARLY	1	1	1	1	1	0	0	0	0	0	0
			05. INSOMNIA MIDDLE	1	1	1	1	1	0	0	0	0	0	0
			06. INSOMNIA LATE	1	1	1	1	1	0	0	0	0	0	0
			07. WORK AND ACTIVITIES	3	3	3	3	3	2	1	1	1	1	1
			08. RETARDATION	2	2	2	2	2	1	0	0	0	0	0
			09. AGITATION	2	2	2	2	2	1	0	0	0	0	0
			10. ANXIETY PSYCHIC	0	0	0	0	0	0	0	0	0	0	0
			11. ANXIETY SOMATIC	2	2	2	2	2	1	1	1	1	1	1
			12. SOMATIC GASTROINTESTINAL	3	3	3	3	3	2	1	1	1	1	1
			13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1
			14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1
			15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0
			16. LOSS OF WEIGHT	2	2	2	2	2	1	0	0	0	0	0

1342

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

71

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63			
20	3ND	Reboxetine	Female	17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0			
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0		
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	
				22. Total score	22	22	24											
22	1ND	Reboxetine	Female	01. DEPRESSED MOOD	3	3	3	4	4	4	4	4	4	4	4			
				02. GUILT	0	0	0	0	0	0	0	0	0	0	0	0		
				03. SUICIDE	1	1	1	3	3	3	3	3	3	3	3	3	3	
				04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	
				05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	
				06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	
				07. WORK AND ACTIVITIES	3	3	3	4	4	4	4	4	4	4	4	4	4	
				08. RETARDATION	2	1	1	1	1	1	1	1	1	1	1	1	1	
				09. AGITATION	1	3	4	4	4	4	4	4	4	4	4	4	4	
				10. ANXIETY PSYCHIC	1	3	3	3	3	3	3	3	3	3	3	3	3	
				11. ANXIETY SOMATIC	3	3	3	3	3	3	3	3	3	3	3	3	3	
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	
				13. SOMATIC GENERAL	2	1	1	2	2	2	2	2	2	2	2	2	2	
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	
				15. HYPOCHONDRIASIS	3	2	2	2	2	2	2	2	2	2	2	2	2	
				16. LOSS OF WEIGHT	2	2	2	2	2	2	2	2	2	2	2	2	2	
				17. INSIGHT	0	0	0	1	1	1	1	1	1	1	1	1	1	
				18. DIURNAL VARIATION	2	2	2	2	2	2	2	2	2	2	2	2	2	
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	
								21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0
								22. Total score	32	33	42							
23	1ND	Reboxetine	Female	01. DEPRESSED MOOD	3	3	3	4	4	4	4	4	4	4				
				02. GUILT	1	1	1	1	1	1	1	1	1	1	1			
				03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1		
				04. INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0	0		
				05. INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0	0		
				06. INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0		
				07. WORK AND ACTIVITIES	3	4	4	4	4	4	4	4	4	4	4	4		
				08. RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1		
				09. AGITATION	2	3	3	3	3	3	3	3	3	3	3	3		
				10. ANXIETY PSYCHIC	4	4	4	4	4	4	4	4	4	4	4	4		
				11. ANXIETY SOMATIC	1	2	2	2	2	2	2	2	2	2	2	2		
				12. SOMATIC GASTROINTESTINAL	0	1	1	1	1	1	1	1	1	1	1	1		
				13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2		
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0		
				15. HYPOCHONDRIASIS	2	3	3	3	3	3	3	3	3	3	3	3		
				16. LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1	1		
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0		
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0		
				19. DEPERSONALIZATION	2	3	3	3	3	3	3	3	3	3	3	3		
								20. PARANOID	1	0	0	0	0	0	0	0	0	

1343

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

72

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63			
23	1ND	Reboxetine	Female	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				22.Total score	24	30	22	21	8	8	8	8	10	7	4	5											
2ND	Reboxetine	Female	01.DEPRESSED MOOD	3	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
			02.GUILT	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			03.SUICIDE	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			04.INSOMNIA EARLY	0	0	2	1	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			05.INSOMNIA MIDDLE	1	2	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			06.INSOMNIA LATE	3	3	2	1	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			07.WORK AND ACTIVITIES	1	1	1	0	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			08.RETARDATION	1	1	1	0	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			09.AGITATION	1	1	1	1	1	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			10.ANXIETY PSYCHIC	1	1	1	1	1	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			11.ANXIETY SOMATIC	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			13.SOMATIC GENERAL	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			14.GENITAL SYMPTOMS	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			15.HYPOCHONDRIASIS	1	3	1	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			16.LOSS OF WEIGHT	1	1	0	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			18.DIURNAL VARIATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			19.DEPERSONALIZATION	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			22.Total score	23	26	19	13	10	10	10	6	5	3	7													
3ND	Imipramine	Female	01.DEPRESSED MOOD	4	4	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
			02.GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			03.SUICIDE	1	1	1	2	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			04.INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			05.INSOMNIA MIDDLE	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			06.INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			07.WORK AND ACTIVITIES	3	3	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			08.RETARDATION	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			09.AGITATION	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			10.ANXIETY PSYCHIC	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			11.ANXIETY SOMATIC	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			12.SOMATIC GASTROINTESTINAL	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			14.GENITAL SYMPTOMS	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			15.HYPOCHONDRIASIS	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			16.LOSS OF WEIGHT	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			18.DIURNAL VARIATION	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			19.DEPERSONALIZATION	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			22.Total score	23	23	19	18	15	13	8	10	9	8														

1344

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

73

PHARMACIA CNS R&D
REBONETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day
23	4WD	Imipramine	Female	HAMILTON DEPRESSION RATING SCALE										
				Hamilton depression rating scale										
				01. DEPRESSED MOOD	4	4	2	3	1	3	1	0	0	0
				02. GUILT	0	0	0	0	1	0	0	0	0	0
				03. SUICIDE	1	1	1	0	1	0	0	0	0	0
				04. INSOMNIA EARLY	1	1	0	0	1	0	0	0	0	0
				05. INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0
				06. INSOMNIA LATE	1	1	0	1	0	0	0	0	0	0
				07. WORK AND ACTIVITIES	2	2	2	1	1	1	1	0	0	0
				08. RETARDATION	2	2	1	1	1	1	1	1	1	1
				09. AGITATION	2	2	0	0	0	0	0	0	0	0
				10. ANXIETY PSYCHIC	1	1	0	0	0	0	0	0	0	0
				11. ANXIETY SOMATIC	3	3	0	2	0	1	1	1	1	1
				12. SOMATIC GASTROINTESTINAL	1	1	0	0	0	0	0	0	0	0
				13. SOMATIC GENERAL	1	1	0	0	0	0	0	0	0	0
				14. GENITAL SYMPTOMS	1	1	0	0	0	0	0	0	0	0
				15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0
				16. LOSS OF WEIGHT	1	1	1	1	1	1	1	0	0	0
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	1	1	1	0	1	0	0	0	0	0
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0
				22. Total score	22	22	8	12	9	13	5	2	2	1
5MD		Imipramine	Female	HAMILTON DEPRESSION RATING SCALE										
				01. DEPRESSED MOOD	3	3	3	3	3	3	4	4	4	4
				02. GUILT	2	2	0	1	1	1	1	1	1	1
				03. SUICIDE	1	1	1	1	1	1	1	1	1	1
				04. INSOMNIA EARLY	1	1	0	0	0	0	0	0	0	0
				05. INSOMNIA MIDDLE	1	1	0	0	0	0	0	0	0	0
				06. INSOMNIA LATE	2	2	1	1	1	1	1	1	1	1
				07. WORK AND ACTIVITIES	3	3	2	2	2	2	2	2	2	2
				08. RETARDATION	2	2	1	1	1	1	1	1	1	1
				09. AGITATION	1	1	1	1	1	1	1	1	1	1
				10. ANXIETY PSYCHIC	3	3	2	2	2	2	2	2	2	2
				11. ANXIETY SOMATIC	0	0	0	0	0	0	0	0	0	0
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1
				13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1
				14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1
				15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2
				16. LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1
				19. DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1
				20. PARANOID	1	1	1	1	1	1	1	1	1	1
				21. OBSESSIONAL/COMPULSIVE	1	1	0	0	0	0	0	0	0	0
				22. Total score	28	29	27	28	28	27	28	27	28	28
6MD		Imipramine	Female	HAMILTON DEPRESSION RATING SCALE										
				01. DEPRESSED MOOD	3	4	3	2	2	4	4	4	4	4
				02. GUILT	1	2	1	1	1	1	3	3	3	3
				03. SUICIDE	1	1	1	0	1	0	0	1	1	1
				04. INSOMNIA EARLY	1	1	1	1	1	0	1	1	1	1

1345

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

74

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 2012A/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63						
23	6ND	Imipramine	Female	05. INSOMNIA MIDDLE	1	1	1	0	0	2	1	2	1	1	1						
				06. INSOMNIA LATE	2	1	1	1	1	1	1	1	1	1	1	1					
				07. WORK AND ACTIVITIES	4	4	4	4	4	4	4	4	4	4	4	4	4	4			
				08. RETARDATION	2	3	2	1	2	2	2	2	2	2	3	3	3	3			
				09. AGITATION	2	3	2	1	1	1	1	1	1	2	2	2	2	2			
				10. ANXIETY PSYCHIC	3	3	2	2	2	3	3	3	3	3	2	2	2	2			
				11. ANXIETY SOMATIC	2	3	3	3	3	3	3	3	3	3	2	2	2	2			
				12. SOMATIC GASTROINTESTINAL	1	2	1	1	1	1	1	1	1	1	2	2	2	2			
				13. SOMATIC GENERAL	1	2	0	0	2	2	2	2	2	2	2	2	2	2			
				14. GENITAL SYMPTOMS	2	1	1	1	1	1	1	1	1	1	2	2	2	2			
				15. HYPOCHONDRIASIS	1	2	1	1	1	1	1	1	1	1	4	4	4	4			
				16. LOSS OF WEIGHT	0	2	2	1	1	1	1	1	1	1	4	4	4	4			
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				18. DIURNAL VARIATION	2	1	1	0	1	1	2	1	2	1	1	1	1	1			
				19. DEPERSONALIZATION	0	1	0	0	1	0	0	0	0	0	0	0	0	0			
				20. PARAMOIID	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				21. OBSESSIONAL/COMPULSIVE	1	0	0	1	0	0	0	0	0	0	0	0	0	0			
				22. Total score				30	35	26	20	25	27	31	43	42	42	42			
				25	1ND	Reboxetine	Male	01. DEPRESSED MOOD	4	4	4	4	4	4	4	4	4	4	4		
								02. GUILT	2	2	1	1	1	1	1	1	1	1	1	1	
								03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1	1
								04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2
05. INSOMNIA MIDDLE	2	2	2					2	2	2	2	2	2	2	2	2	2				
06. INSOMNIA LATE	2	2	2					2	2	2	2	2	2	2	2	2	2				
07. WORK AND ACTIVITIES	4	4	4					4	4	4	4	4	4	4	4	4	4				
08. RETARDATION	2	2	2					2	2	2	2	2	2	2	2	2	2				
09. AGITATION	2	2	2					2	2	2	2	2	2	2	2	2	2				
10. ANXIETY PSYCHIC	3	3	3					3	3	3	3	3	3	3	3	3	3				
11. ANXIETY SOMATIC	3	3	3					3	3	3	3	3	3	3	3	3	3				
12. SOMATIC GASTROINTESTINAL	2	2	2					2	2	2	2	2	2	2	2	2	2				
13. SOMATIC GENERAL	2	2	2					2	2	2	2	2	2	2	2	2	2				
14. GENITAL SYMPTOMS	4	4	4					4	4	4	4	4	4	4	4	4	4				
15. HYPOCHONDRIASIS	4	4	4					4	4	4	4	4	4	4	4	4	4				
16. LOSS OF WEIGHT	2	2	2					2	2	2	2	2	2	2	2	2	2				
17. INSIGHT	1	1	1					1	1	1	1	1	1	1	1	1	1				
18. DIURNAL VARIATION	0	0	0					0	0	0	0	0	0	0	0	0	0				
19. DEPERSONALIZATION	3	3	3					3	3	3	3	3	3	3	3	3	3				
20. PARAMOIID	1	1	1					1	1	1	1	1	1	1	1	1	1				
21. OBSESSIONAL/COMPULSIVE	0	0	0					0	0	0	0	0	0	0	0	0	0				
22. Total score								43	43	39	41	41	41	37	40	40	40	40			
2ND	Imipramine	Female	01. DEPRESSED MOOD	2	4	4	1	2	2	2	3	2	2	2	2						
			02. GUILT	3	5	3	2	2	1	1	1	0	0	0	0						
			03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0						
			04. INSOMNIA EARLY	2	2	1	0	0	0	0	0	0	0	0	0						
			05. INSOMNIA MIDDLE	2	2	2	0	0	0	0	0	0	0	0	0						
			06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2						
			07. WORK AND ACTIVITIES	3	3	4	3	2	2	2	2	2	2	2	2						
			08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2						

1346

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

75

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day						
25	2ND	Imipramine	Female	HAMILTON DEPRESSION RATING SCALE																
				09. AGITATION	2	2	2	1	1	2	2	2	2	2	2	2				
				10. ANXIETY PSYCHIC	0	0	1	2	1	1	1	1	3	1	1	1	1			
				11. ANXIETY SOMATIC	1	1	2	1	2	2	0	0	0	1	1	1	1			
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1			
				13. SOMATIC GENERAL	1	1	2	0	0	0	0	0	0	0	0	0	0			
				14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1	1			
				15. HYPOCHONDRIASIS	0	1	1	1	1	1	1	1	1	1	0	1	1			
				16. LOSS OF WEIGHT	1	1	2	0	0	1	0	1	0	0	0	0	0			
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0			
				18. DIURNAL VARIATION	1	1	0	2	1	1	1	1	1	1	1	1	1			
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0			
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0			
				21. OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1	1	1			
				22. Total score	25	28	31	19	18	18	16	19	16	14	14	14	14			
				26	1ND	Imipramine	Female	HAMILTON DEPRESSION RATING SCALE												
								01. DEPRESSED MOOD	3	3	2	1	1	1	1	1	2	2	2	2
								02. GUILT	2	2	2	1	1	1	1	1	0	0	0	0
								03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0
								04. INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1
								05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1
								06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1
07. WORK AND ACTIVITIES	2	2	2					2	2	2	2	2	2	2	2	2				
08. RETARDATION	1	2	1					1	1	1	1	1	0	0	0	0				
09. AGITATION	2	2	2					2	2	2	2	2	2	2	2	2				
10. ANXIETY PSYCHIC	3	3	2					2	2	2	2	2	2	2	2	2				
11. ANXIETY SOMATIC	1	2	2					2	2	2	2	2	2	2	2	2				
12. SOMATIC GASTROINTESTINAL	1	2	2					2	2	2	2	2	2	2	2	2				
13. SOMATIC GENERAL	1	1	1					1	1	1	1	1	1	1	1	1				
14. GENITAL SYMPTOMS	2	2	2					2	2	2	2	2	2	2	2	2				
15. HYPOCHONDRIASIS	0	0	0					0	0	0	0	0	0	0	0	0				
16. LOSS OF WEIGHT	2	2	2					2	2	2	2	2	2	2	2	2				
17. INSIGHT	0	0	0					0	0	0	0	0	0	0	0	0				
18. DIURNAL VARIATION	2	2	2					2	2	2	2	2	2	2	2	2				
19. DEPERSONALIZATION	0	0	0					0	0	0	0	0	0	0	0	0				
20. PARANOID	0	0	0					0	0	0	0	0	0	0	0	0				
21. OBSESSIONAL/COMPULSIVE	0	0	0					0	0	0	0	0	0	0	0	0				
22. Total score	25	28	23	21	16	15	16	16	16	16	16	16	16							
10T	Reboxetine	Female	HAMILTON DEPRESSION RATING SCALE																	
			01. DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2	2						
			02. GUILT	1	1	1	1	1	1	1	1	1	1	1						
			03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0						
			04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2						
			05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2						
			06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2						
			07. WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2						
			08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2						
			09. AGITATION	2	2	2	2	2	2	2	2	2	2	2						
			10. ANXIETY PSYCHIC	1	1	1	1	1	1	1	1	1	1	1						
			11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2						
12. SOMATIC GASTROINTESTINAL	3	3	3	3	3	3	3	3	3	3	3									

1347

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

76

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63					
26	1DT	Reboxetine	Female	13. SOMATIC GENERAL	1	2	2	2	2	2	2	2	2	2	2					
				14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1				
				15. HYPOCHONDRIASIS	3	2	3	3	3	2	2	2	2	2	2	2	2			
				16. LOSS OF WEIGHT	0	0	0	0	0	1	1	1	1	1	1	1	1			
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1			
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1			
				19. DEPERSONALIZATION	1	1	1	1	1	0	0	0	0	0	0	0	0			
				20. PARANOID	1	0	0	0	0	0	0	0	0	0	0	0	0			
				21. OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1	1	1			
				22. Total score	31	29	30	30	31	27	27	27	27	27	27	27	27			
				27	1MD	Imipramine	Male	01. DEPRESSED MOOD	4	4	4	4	4	4	4	4	4	4	4	
								02. GUILT	2	2	2	2	2	2	2	2	2	2	2	2
								03. SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2
								04. INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1
								05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2
								06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2
								07. WORK AND ACTIVITIES	4	4	4	4	4	4	4	4	4	4	4	4
								08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2
								09. AGITATION	0	0	0	0	0	0	0	0	0	0	0	0
								10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2
								11. ANXIETY SOMATIC	0	0	0	0	0	0	0	0	0	0	0	0
								12. SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0	0	0	0	0
13. SOMATIC GENERAL	1	1	1					1	1	1	1	1	1	1	1	1				
14. GENITAL SYMPTOMS	2	2	2					2	2	2	2	2	2	2	2	2				
15. HYPOCHONDRIASIS	0	0	0					0	0	0	0	0	0	0	0	0				
16. LOSS OF WEIGHT	2	2	2					2	2	2	2	2	2	2	2	2				
17. INSIGHT	2	2	2					2	2	2	2	2	2	2	2	2				
18. DIURNAL VARIATION	0	0	0					0	0	0	0	0	0	0	0	0				
19. DEPERSONALIZATION	3	3	3					3	3	3	3	3	3	3	3	3				
20. PARANOID	0	0	0					0	0	0	0	0	0	0	0	0				
21. OBSESSIONAL/COMPULSIVE	0	0	0					0	0	0	0	0	0	0	0	0				
22. Total score	35	35	38					38	38	38	38	38	38	38	38	38	38			
28	1MD	Reboxetine	Female	01. DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3					
				02. GUILT	2	2	2	2	2	2	2	2	2	2	2					
				03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1					
				04. INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1					
				05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1					
				06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1					
				07. WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2					
				08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2					
				09. AGITATION	2	2	2	2	2	2	2	2	2	2	2					
				10. ANXIETY PSYCHIC	0	0	0	0	0	0	0	0	0	0	0					
				11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2					
				12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2					
				13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1					
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0					
				15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2					
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0					

1348

9550089

77

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63						
28	1ND	Reboxetine	Female	17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0						
				18.DIURNAL VARIATION	2	2	2	2	2	2	2	2	2	2	2	2	2				
				19.DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				22.Total score	25	25	25	22	15	15	15	10	8	8	8	8	8	8			
				1DT	Imipramine	Female	01.DEPRESSED MOOD	2	1	1	1	1	1	1	1	1	1	1	1	1	
							02.GUILT	1	1	0	0	0	0	0	0	0	0	0	0	0	0
							03.SUICIDE	0	0	1	1	1	1	1	1	1	1	1	1	1	1
							04.INSOMNIA EARLY	1	0	0	0	0	0	0	0	0	0	0	0	0	0
05.INSOMNIA MIDDLE	1	1	1				1	1	1	1	1	1	1	1	1	1	1				
06.INSOMNIA LATE	1	1	1				1	1	1	1	1	1	1	1	1	1	1				
07.WORK AND ACTIVITIES	2	2	2				2	2	2	2	2	2	2	2	2	2	2				
08.RETARDATION	3	2	2				2	2	2	2	2	2	2	2	2	2	2				
09.AGITATION	1	1	1				1	1	1	1	1	1	1	1	1	1	1				
10.ANXIETY PSYCHIC	2	2	2				2	2	2	2	2	2	2	2	2	2	2				
11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1							
12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0							
13.SOMATIC GENERAL	1	0	0	0	0	0	0	0	0	0	0	0	0	0							
14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0							
15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2							
16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0							
17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0							
18.DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1							
19.DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1							
20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0							
21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0							
22.Total score	20	16	16	16	16	13	9	9	9	9	9	9	9	9							
28	1ND	Imipramine	Female	01.DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2	2	2					
				02.GUILT	2	2	2	2	2	2	2	2	2	2	2	2	2				
				03.SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1	1				
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1	1				
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1				
				06.INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1				
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2	2	2				
				08.RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2				
				09.AGITATION	1	1	1	1	1	1	1	1	1	1	1	1	1				
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	1	1	1	1	1	1	1				
11.ANXIETY SOMATIC	0	0	0	0	0	0	0	0	0	0	0	0	0								
12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0	0	0	0	0	0								
13.SOMATIC GENERAL	0	0	0	0	0	0	0	0	0	0	0	0	0								
14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0								
15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2								
16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0								
17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0								
18.DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1								
19.DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1								
20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0								
21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0								
22.Total score	20	16	16	16	16	13	9	9	9	9	9	9	9								

1349

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

76

PHARMACIA CNS RRD
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63			
Z8	ZMD	Imipramine	Female	21. OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
			22. Total score	19	19	15	15	15	14	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	9
Z8	ZDT	Reboxetine	Male	01. DEPRESSED MOOD	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			02. GUILT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Z8	ZDT	Reboxetine	Male	03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			04. INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Z8	ZDT	Reboxetine	Male	05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Z8	ZDT	Reboxetine	Male	07. WORK AND ACTIVITIES	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			08. RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Z8	ZDT	Reboxetine	Male	09. AGITATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
Z8	ZDT	Reboxetine	Male	11. ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Z8	ZDT	Reboxetine	Male	13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Z8	ZDT	Reboxetine	Male	15. HYPOCHONDRIASIS	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Z8	ZDT	Reboxetine	Male	17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Z8	ZDT	Reboxetine	Male	19. DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Z8	ZDT	Reboxetine	Male	21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			22. Total score	19	20	20	16	16	13	12	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9
Z8	ZMD	Reboxetine	Female	01. DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
			02. GUILT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
Z8	ZMD	Reboxetine	Female	03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			04. INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Z8	ZMD	Reboxetine	Female	05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Z8	ZMD	Reboxetine	Female	07. WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			08. RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Z8	ZMD	Reboxetine	Female	09. AGITATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
Z8	ZMD	Reboxetine	Female	11. ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Z8	ZMD	Reboxetine	Female	13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Z8	ZMD	Reboxetine	Female	15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Z8	ZMD	Reboxetine	Female	17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Z8	ZMD	Reboxetine	Female	19. DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Z8	ZMD	Reboxetine	Female	21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			22. Total score	23	23	18	18	13	11	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10

1350

9550089

79

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
28	3DT	Imipramine	Male	Hamilton depression rating scale	2	2	1	1	0	0	0	0	0	0		
				01..DEPRESSED MOOD	1	1	1	1	1	1	1	1	1	1	1	
				02..GUILT	0	0	0	0	0	0	0	0	0	0	0	0
				03..SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2
				04..INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2
				05..INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2
				06..INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2
				07..WORK AND ACTIVITIES	1	1	1	1	1	1	1	1	1	1	1	1
				08..RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1
				09..AGITATION	1	1	1	1	1	1	1	1	1	1	1	1
				10..ANXIETY PSYCHIC	1	1	1	1	1	1	1	1	1	1	1	1
				11..ANXIETY SOMATIC	0	0	0	0	0	0	0	0	0	0	0	0
				12..SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0	0	0	0	0
				13..SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1
				14..CENTRAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2	2
				15..HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0
				16..LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1	1
				17..INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0
				18..DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1
				19..DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0
				20..PARANOID	0	0	0	0	0	0	0	0	0	0	0	0
				21..OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0
22..Total score	20	20	20	16	10	10	10	10	10	10	9	7	7			
4HD	Imipramine	Male	Hamilton depression rating scale	2	2	2	2	2	1	1	1	1	0			
			01..DEPRESSED MOOD	1	1	1	1	1	1	1	1	1	1	1		
			02..GUILT	0	0	0	0	0	0	0	0	0	0	0		
			03..SUICIDE	1	1	1	1	1	1	1	1	1	1	1		
			04..INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1		
			05..INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1		
			06..INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1		
			07..WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2		
			08..RETARDATION	3	3	3	3	2	1	1	1	1	1	1		
			09..AGITATION	1	1	1	1	1	1	1	1	1	1	1		
			10..ANXIETY PSYCHIC	2	2	2	2	2	1	0	1	0	0	0		
			11..ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1		
			12..SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0	0	0	0		
			13..SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1		
			14..CENTRAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0		
			15..HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2		
			16..LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0		
			17..INSIGHT	0	0	0	0	0	0	0	0	0	0	0		
			18..DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1		
			19..DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1		
			20..PARANOID	0	0	0	0	0	0	0	0	0	0	0		
			21..OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0		
22..Total score	20	21	21	21	17	11	13	12	9	6	6					
5HD	Reboxetine	Female	Hamilton depression rating scale	2	2	2	2	2	1	1	1	1	0			
			01..DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2			
			02..GUILT	2	2	2	2	2	2	2	2	2	2			
			03..SUICIDE	0	0	0	0	0	0	0	0	0	0			
04..INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2					

1351

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

83

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	HAMILTON DEPRESSION RATING SCALE																									
					Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63															
31	1MD	Imipramine	Female	17. INSIGHT	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0							
				18. DIURNAL VARIATION	1	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
				19. DEPERSONALIZATION	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
				22. Total score	26	16	13	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14			
				1DT	Reboxetine	Female	01. DEPRESSED MOOD	2	3	1	1	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4			
							02. GUILT	1	0	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
							03. SUICIDE	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
							04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
							05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
							06. INSOMNIA LATE	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
							07. WORK AND ACTIVITIES	3	2	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
							08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
							09. AGITATION	1	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
							10. ANXIETY PSYCHIC	3	3	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
							11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
							12. SOMATIC GASTROINTESTINAL	2	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
							13. SOMATIC GENERAL	2	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
							14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
							15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
							16. LOSS OF WEIGHT	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
17. INSIGHT	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
18. DIURNAL VARIATION	1	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
19. DEPERSONALIZATION	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
20. PARANOID	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
21. OBSESSIONAL/COMPULSIVE	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
22. Total score	21	21	19				27	29	29	29	29	29	29	29	29	29	29	29	29	29	29	29	29	29	29	29				
2ND	Reboxetine	Female	01. DEPRESSED MOOD	3	4	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2							
			02. GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0						
			03. SUICIDE	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
			04. INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
			05. INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
			06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
			07. WORK AND ACTIVITIES	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
			08. RETARDATION	0	1	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
			09. AGITATION	2	3	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
			10. ANXIETY PSYCHIC	1	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
			11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
			12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
			13. SOMATIC GENERAL	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
			14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
			15. HYPOCHONDRIASIS	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
			16. LOSS OF WEIGHT	2	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
			17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
			18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
			19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
			20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					

1355

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

84

PIARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63	
31	2ND	Reboxetine	Female	21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			22. Total score	23	30	23	14	16	12	10	8	8	15												
3ND	3ND	Imipramine	Male	01. DEPRESSED MOOD	4	4																			
			02. GUILT	0	0																				
				03. SUICIDE	2	2																			
				04. INSOMNIA EARLY	2	2																			
				05. INSOMNIA MIDDLE	1	1																			
				06. INSOMNIA LATE	2	2																			
				07. WORK AND ACTIVITIES	4	4																			
				08. RETARDATION	2	2																			
				09. AGITATION	0	0																			
				10. ANXIETY PSYCHIC	2	2																			
				11. ANXIETY SOMATIC	0	0																			
				12. SOMATIC GASTROINTESTINAL	2	2																			
				13. SOMATIC GENERAL	2	2																			
				14. GENITAL SYMPTOMS	0	0																			
				15. HYPOCHONDRIASIS	4	4																			
				16. LOSS OF WEIGHT	1	1																			
				17. INSIGHT	0	0																			
				18. DIURNAL VARIATION	0	0																			
				19. DEPERSONALIZATION	0	0																			
				20. PARANOID	0	0																			
				21. OBSESSIONAL/COMPULSIVE	1	1																			
				22. Total score	29	34																			
32	1ND	Imipramine	Female	01. DEPRESSED MOOD	3	3																			
			02. GUILT	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				03. SUICIDE	1	1																			
				04. INSOMNIA EARLY	2	2																			
				05. INSOMNIA MIDDLE	2	2																			
				06. INSOMNIA LATE	1	1																			
				07. WORK AND ACTIVITIES	2	2																			
				08. RETARDATION	1	1																			
				09. AGITATION	0	0																			
				10. ANXIETY PSYCHIC	1	1																			
				11. ANXIETY SOMATIC	2	2																			
				12. SOMATIC GASTROINTESTINAL	1	1																			
				13. SOMATIC GENERAL	2	2																			
				14. GENITAL SYMPTOMS	0	0																			
				15. HYPOCHONDRIASIS	3	3																			
				16. LOSS OF WEIGHT	0	0																			
				17. INSIGHT	0	0																			
				18. DIURNAL VARIATION	0	0																			
				19. DEPERSONALIZATION	2	1																			
				20. PARANOID	0	0																			
				21. OBSESSIONAL/COMPULSIVE	0	0																			
				22. Total score	22	24																			

1356

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

85

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
32	2ND	Imipranine	Female	01..DEPRESSED MOOD	3	3	0	0	0	0	0	0	0	0		
				02..GUILT	1	0	0	0	0	0	0	0	0	0	0	
				03..SUICIDE	1	1	0	0	0	0	0	0	0	0	0	0
				04..INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0	0
				05..INSOMNIA MIDDLE	0	2	0	0	0	0	0	0	0	0	0	0
				06..INSOMNIA LATE	0	0	1	0	0	0	0	0	0	0	0	0
				07..WORK AND ACTIVITIES	2	1	2	0	1	1	1	1	1	1	0	0
				08..RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0
				09..AGITATION	1	0	0	0	0	0	0	0	0	0	0	0
				10..ANXIETY PSYCHIC	3	2	0	1	1	1	1	1	1	1	0	0
				11..ANXIETY SOMATIC	2	2	0	2	2	1	1	1	1	1	1	0
				12..SOMATIC GASTROINTESTINAL	0	0	2	2	2	1	1	1	1	1	1	0
				13..SOMATIC GENERAL	2	2	2	2	2	1	1	1	1	1	1	1
				14..GENITAL SYMPTOMS	2	2	2	2	2	1	1	1	1	1	1	1
				15..HYPOCHONDRIASIS	2	2	2	2	2	1	1	1	1	1	1	1
				16..LOSS OF WEIGHT	0	0	2	0	0	0	0	0	0	0	0	0
				17..INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0
				18..DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0
				19..DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0
				20..PARANOID	0	0	0	0	0	0	0	0	0	0	0	0
				21..OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0
				22..Total score	19	17	17	6	7	5	6	6	5	4	4	2
3ND	Reboxetine	Female	01..DEPRESSED MOOD	3	3	3	3	3	3	2	1	2	2			
			02..GUILT	0	1	1	1	1	1	1	1	1	1	1		
			03..SUICIDE	2	2	2	2	2	2	2	2	2	2	2		
			04..INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2		
			05..INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2		
			06..INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2		
			07..WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2		
			08..RETARDATION	0	0	0	0	0	0	0	0	0	0	0		
			09..AGITATION	0	0	0	0	0	0	0	0	0	0	0		
			10..ANXIETY PSYCHIC	1	3	2	2	2	2	2	2	2	2	2		
			11..ANXIETY SOMATIC	1	2	1	1	1	1	1	1	1	1	1		
			12..SOMATIC GASTROINTESTINAL	1	2	1	1	1	1	1	1	1	1	1		
			13..SOMATIC GENERAL	1	2	2	2	2	2	2	2	2	2	2		
			14..GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0		
			15..HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0		
			16..LOSS OF WEIGHT	1	0	0	0	0	0	0	0	0	0	0		
			17..INSIGHT	0	0	0	0	0	0	0	0	0	0	0		
			18..DIURNAL VARIATION	2	2	2	2	2	2	2	2	2	2	2		
			19..DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0		
			20..PARANOID	0	0	0	0	0	0	0	0	0	0	0		
			21..OBSESSIONAL/COMPULSIVE	2	2	2	2	2	2	2	2	2	2	2		
			22..Total score	22	27	24	23	25	25	23	16	17	12	17		
4ND	Reboxetine	Female	01..DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3			
			02..GUILT	2	1	1	1	1	1	1	1	1	1			
			03..SUICIDE	2	1	0	1	0	1	2	1	2	0			
			04..INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2			

13
C
3

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

86

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 2012A/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day
52	4MD	Reboxetine	Female	HAMILTON DEPRESSION RATING SCALE		0	2	2	1	1					
				05. INSOMNIA MIDDLE		0	2	2	1	1					
				06. INSOMNIA LATE		2	2	2	1	2					
				07. WORK AND ACTIVITIES		2	2	2	2	2					
				08. RETARDATION		0	0	0	0	0					
				09. AGITATION		0	0	0	0	0					
				10. ANXIETY PSYCHIC		1	2	2	2	2					
				11. ANXIETY SOMATIC		1	2	1	0	2					
				12. SOMATIC GASTROINTESTINAL		0	0	1	0	0					
				13. SOMATIC GENERAL		2	2	2	2	2					
				14. GENITAL SYMPTOMS		0	0	0	0	0					
				15. HYPOCHONDRIASIS		0	0	0	0	0					
				16. LOSS OF WEIGHT		0	0	0	0	0					
				17. INSIGHT		0	0	0	0	0					
				18. DIURNAL VARIATION		1	2	1	1	1					
				19. DEPERSONALIZATION		2	2	1	1	0					
				20. PARANOID		0	0	0	0	0					
				21. OBSESSIONAL/COMPULSIVE		0	0	0	0	0					
				22. Total score		20	23	20	15	17					
5ND		Reboxetine	Female			2	2	3	3	3					
				01. DEPRESSED MOOD		2	2	3	3	3					
				02. GUILT		0	0	0	0	0					
				03. SUICIDE		0	0	1	0	1					
				04. INSOMNIA EARLY		0	0	0	0	0					
				05. INSOMNIA MIDDLE		1	1	0	0	0					
				06. INSOMNIA LATE		2	2	1	0	0					
				07. WORK AND ACTIVITIES		2	2	2	2	2					
				08. RETARDATION		0	0	0	0	0					
				09. AGITATION		1	2	1	1	1					
				10. ANXIETY PSYCHIC		3	3	2	2	1					
				11. ANXIETY SOMATIC		1	1	1	1	1					
				12. SOMATIC GASTROINTESTINAL		1	0	1	1	0					
				13. SOMATIC GENERAL		0	0	1	1	0					
				14. GENITAL SYMPTOMS		0	0	0	0	0					
				15. HYPOCHONDRIASIS		0	0	1	1	1					
				16. LOSS OF WEIGHT		2	1	0	0	0					
				17. INSIGHT		0	0	0	0	0					
				18. DIURNAL VARIATION		1	1	1	1	1					
				19. DEPERSONALIZATION		0	0	0	0	0					
				20. PARANOID		0	0	0	0	0					
				21. OBSESSIONAL/COMPULSIVE		0	0	0	0	0					
				22. Total score		19	18	16	14	13					
6ND		Imipramine	Male			5	3	3	3	2					
				01. DEPRESSED MOOD		5	3	3	3	2					
				02. GUILT		0	0	0	0	0					
				03. SUICIDE		2	2	2	2	2					
				04. INSOMNIA EARLY		0	0	0	0	0					
				05. INSOMNIA MIDDLE		1	1	1	1	1					
				06. INSOMNIA LATE		0	0	0	0	0					
				07. WORK AND ACTIVITIES		2	2	2	2	2					
				08. RETARDATION		0	0	0	0	0					

13:58

9550089

88

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/035
 Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day
35	1DT	Reboxetine	Female	1	1	1	1	1	1	1	1	1	1	1
			13.SOMATIC GENERAL	1	0	0	0	0	0	0	0	0	0	0
			14.GENITAL SYMPTOMS	3	3	3	3	3	3	3	3	3	3	3
			15.HYPOCHONDRIASIS	1	1	0	0	0	1	0	1	0	1	1
			16.LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1
			17.INSIGHT	0	0	1	1	1	0	0	0	0	0	0
			18.DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0
			19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0
			20.PARANOID	1	1	1	1	1	1	1	1	1	1	1
			21.OBSESSIONAL/COMPULSIVE	21	22	19	18	16	19	16	16	17	19	19
			22.Total score											
2ND		Imipramine	Female	4	2	2	4	3	4	3	3	3	3	3
			01.DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2	2
			02.GUILT	2	2	1	1	1	1	1	1	1	1	1
			03.SUICIDE	2	2	2	2	2	2	2	2	2	2	2
			04.INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1
			05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1
			06.INSOMNIA LATE	4	4	4	4	4	4	4	4	4	4	4
			07.WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3
			08.RETARDATION	1	1	1	1	1	1	1	1	1	1	1
			09.AGITATION	1	1	1	1	1	1	1	1	1	1	1
			10.ANKIETY PSYCHIC	1	1	1	1	1	1	1	1	1	1	1
			11.ANKIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2
			12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2
			13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1
			14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2
			15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1
			16.LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1
			17.INSIGHT	1	1	1	1	1	1	1	1	1	1	1
			18.DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0
			19.DEPERSONALIZATION	2	2	2	2	2	2	2	2	2	2	2
			20.PARANOID	0	0	0	0	0	0	0	0	0	0	0
			21.OBSESSIONAL/COMPULSIVE	33	32	29	32	28	33	33	33	33	33	33
			22.Total score											
2DT		Imipramine	Female	3	3	2	0	0	0	0	0	0	0	0
			01.DEPRESSED MOOD	0	0	0	0	0	0	0	0	0	0	0
			02.GUILT	0	0	0	0	0	0	0	0	0	0	0
			03.SUICIDE	2	2	1	0	0	0	0	0	0	0	0
			04.INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0
			05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1
			06.INSOMNIA LATE	3	3	2	0	0	0	0	0	0	0	0
			07.WORK AND ACTIVITIES	1	1	1	1	1	1	1	1	1	1	1
			08.RETARDATION	1	1	1	1	1	1	1	1	1	1	1
			09.AGITATION	2	2	2	2	2	2	2	2	2	2	2
			10.ANKIETY PSYCHIC	1	1	1	1	1	1	1	1	1	1	1
			11.ANKIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2
			12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2
			13.SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2
			14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0
			15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0
			16.LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1
			17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0
			18.DIURNAL VARIATION	2	2	2	2	2	2	2	2	2	2	2
			19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0
			20.PARANOID	0	0	0	0	0	0	0	0	0	0	0
			21.OBSESSIONAL/COMPULSIVE	33	32	29	32	28	33	33	33	33	33	33
			22.Total score											

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

89

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63	
35	2DT	Imipramine	Female	17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22.Total score	20	20	10	10	0	0	0	0	0	1	2	2	2	2	2	0	0	0	0	0	0
3MD		Imipramine	Female	01. DEPRESSED MOOD	3	3	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
				02. GUILT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				06. INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				07. WORK AND ACTIVITIES	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
				08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				09. AGITATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				10. ANXIETY PSYCHIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				16. LOSS OF WEIGHT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22.Total score	27	27	27	36	36	36	36	36	36	36	36	36	36	36	36	36	36	36	36	36	36
3BT		Imipramine	Male	01. DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				02. GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				08. RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				09. AGITATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				11. ANXIETY SOMATIC	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				16. LOSS OF WEIGHT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

1361

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

90

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
35	30T	Imipramine	Male	21. OBSESSIONAL/COMPULSIVE 22. Total score	1 23	1 23	0 7	0 6	0 2	0 3	0 1	0 0	0 13	0 6	0 6
40D	Reboxetine	Male	01. DEPRESSED MOOD 02. GUILT 03. SUICIDE 04. INSOMNIA EARLY 05. INSOMNIA MIDDLE 06. INSOMNIA LATE 07. WORK AND ACTIVITIES 08. RETARDATION 09. AGITATION 10. ANXIETY PSYCHIC 11. ANXIETY SOMATIC 12. SOMATIC GASTROINTESTINAL 13. SOMATIC GENERAL 14. GENITAL SYMPTOMS 15. HYPOCHONDRIASIS 16. LOSS OF WEIGHT 17. INSIGHT 18. DIURNAL VARIATION 19. DEPERSONALIZATION 20. PARANOID 21. OBSESSIONAL/COMPULSIVE 22. Total score	3 0 1 2 1 1 3 1 0 2 1 2 0 3 1 0 0 0 1 1 2 0 0 0 0 1 24	3 0 1 2 1 1 3 1 0 2 1 2 0 2 1 0 0 0 1 1 2 0 0 0 0 1 24	3 0 1 2 1 1 3 1 0 2 1 2 0 3 1 0 0 0 1 1 2 0 0 0 0 1 24	3 0 1 2 1 1 3 1 0 2 1 2 0 3 1 0 0 0 1 1 2 0 0 0 0 1 24	2 0 0 1 1 1 3 1 0 2 1 2 0 3 1 0 0 0 1 1 2 0 0 0 0 1 24	2 0 0 1 1 1 3 1 0 2 1 2 0 3 1 0 0 0 1 1 2 0 0 0 0 1 24	2 0 0 1 1 1 3 1 0 2 1 2 0 3 1 0 0 0 1 1 2 0 0 0 0 1 24	2 0 0 1 1 1 3 1 0 2 1 2 0 3 1 0 0 0 1 1 2 0 0 0 0 1 24	2 0 0 1 1 1 3 1 0 2 1 2 0 3 1 0 0 0 1 1 2 0 0 0 0 1 24	2 0 0 1 1 1 3 1 0 2 1 2 0 3 1 0 0 0 1 1 2 0 0 0 0 1 24	2 0 0 1 1 1 3 1 0 2 1 2 0 3 1 0 0 0 1 1 2 0 0 0 0 1 24	
40T	Reboxetine	Female	01. DEPRESSED MOOD 02. GUILT 03. SUICIDE 04. INSOMNIA EARLY 05. INSOMNIA MIDDLE 06. INSOMNIA LATE 07. WORK AND ACTIVITIES 08. RETARDATION 09. AGITATION 10. ANXIETY PSYCHIC 11. ANXIETY SOMATIC 12. SOMATIC GASTROINTESTINAL 13. SOMATIC GENERAL 14. GENITAL SYMPTOMS 15. HYPOCHONDRIASIS 16. LOSS OF WEIGHT 17. INSIGHT 18. DIURNAL VARIATION 19. DEPERSONALIZATION 20. PARANOID 21. OBSESSIONAL/COMPULSIVE 22. Total score	3 1 2 2 1 1 3 1 0 2 1 2 0 3 1 0 0 0 1 1 2 0 0 0 0 1 24	2 1 1 2 1 1 3 1 0 2 1 2 0 3 1 0 0 0 1 1 2 0 0 0 0 1 24	2 1 1 2 1 1 3 1 0 2 1 2 0 3 1 0 0 0 1 1 2 0 0 0 0 1 24	2 1 1 2 1 1 3 1 0 2 1 2 0 3 1 0 0 0 1 1 2 0 0 0 0 1 24	2 1 1 2 1 1 3 1 0 2 1 2 0 3 1 0 0 0 1 1 2 0 0 0 0 1 24	2 1 1 2 1 1 3 1 0 2 1 2 0 3 1 0 0 0 1 1 2 0 0 0 0 1 24	2 1 1 2 1 1 3 1 0 2 1 2 0 3 1 0 0 0 1 1 2 0 0 0 0 1 24	2 1 1 2 1 1 3 1 0 2 1 2 0 3 1 0 0 0 1 1 2 0 0 0 0 1 24	2 1 1 2 1 1 3 1 0 2 1 2 0 3 1 0 0 0 1 1 2 0 0 0 0 1 24	2 1 1 2 1 1 3 1 0 2 1 2 0 3 1 0 0 0 1 1 2 0 0 0 0 1 24	2 1 1 2 1 1 3 1 0 2 1 2 0 3 1 0 0 0 1 1 2 0 0 0 0 1 24	2 1 1 2 1 1 3 1 0 2 1 2 0 3 1 0 0 0 1 1 2 0 0 0 0 1 24

1362

9550089

91

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient Treatment	Sex	Hamilton depression rating scale	Screening Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day		
35	SMD	Male	01. DEPRESSED MOOD	4	4	1	1	1	1	1	1	1	1	1		
			02. GUILT	0	0	0	0	0	0	0	0	0	0	0	0	
			03. SUICIDE	2	1	0	0	0	0	0	2	1	1	2	1	0
			04. INSOMNIA EARLY	1	2	0	2	2	2	2	2	1	1	1	1	2
			05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	0
			06. INSOMNIA LATE	2	1	1	1	1	1	1	1	1	1	1	1	1
			07. WORK AND ACTIVITIES	3	2	1	2	1	2	1	1	1	2	1	1	1
			08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0
			09. AGITATION	0	0	0	0	0	0	0	0	0	0	0	0	0
			10. ANXIETY PSYCHIC	3	3	0	1	1	1	1	0	0	0	0	0	0
			11. ANXIETY SOMATIC	2	2	0	0	0	0	0	0	0	0	0	0	0
			12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	0	1	1	1	1	1	1
			13. SOMATIC GENERAL	1	2	2	2	2	2	2	2	2	2	2	2	2
			14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0
			15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2
			16. LOSS OF HEIGHT	2	0	0	0	0	0	0	0	0	0	0	0	0
			17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1
			18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0
			19. DEPERSONALIZATION	1	1	0	0	0	0	0	0	0	0	0	0	0
			20. PARANOID	1	1	0	0	0	0	0	0	0	0	0	0	0
			21. OBSESSIONAL/COMPULSIVE	2	2	1	1	1	1	1	1	1	1	1	1	1
			22. Total score			28	25	11	17	15	17	17	13	14	11	11
5DT	Imipramine	Female	01. DEPRESSED MOOD	3	3	1	0	0	0	0	0	0	0	1		
			02. GUILT	1	1	0	0	0	0	0	0	0	0	0	0	
			03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	
			04. INSOMNIA EARLY	1	1	1	1	1	1	1	1	0	1	1	1	
			05. INSOMNIA MIDDLE	1	1	0	0	0	0	0	0	0	0	0	0	
			06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	
			07. WORK AND ACTIVITIES	2	2	1	1	1	1	1	1	1	1	1	1	
			08. RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	
			09. AGITATION	0	0	0	0	0	0	0	0	0	0	0	0	
			10. ANXIETY PSYCHIC	2	2	1	1	1	1	1	1	1	1	1	1	
			11. ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	
			12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	
			13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	
			14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	
			15. HYPOCHONDRIASIS	1	1	0	0	0	0	0	0	0	0	0	0	
			16. LOSS OF HEIGHT	3	3	1	1	1	1	1	1	1	1	1	1	
			17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	
			18. DIURNAL VARIATION	2	2	0	0	0	0	0	0	0	0	0	0	
			19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	
			20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	
			21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	
			22. Total score			22	22	11	5	5	7	6	6	7	7	14
6ND	Reboxetine	Female	01. DEPRESSED MOOD	1	1	1	1	1	2	2	2	2	2	2		
			02. GUILT	0	0	0	0	0	0	0	0	0	0	0		
			03. SUICIDE	2	2	0	0	0	0	0	0	0	0	0		
			04. INSOMNIA EARLY	0	0	2	2	1	2	1	2	1	2	1	2	

1363

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

93

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63	
35	7HD	Imipramine	Female	09. AGITATION	2	2	1	1	1	1	1	1	1	1	1	1	1	2							
				10. ANXIETY PSYCHIC	3	3	1	1	0	1	1	1	1	1	1	2	3								
				11. ANXIETY SOMATIC	3	3	2	1	1	1	1	1	1	1	2	2									
				12. SOMATIC GASTROINTESTINAL	2	2	1	1	1	1	1	1	1	0	0	1									
				13. SOMATIC GENERAL	2	2	1	1	1	1	1	1	1	1	1	1									
				14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	0	1	1									
				15. HYPOCHONDRIASIS	3	3	2	2	1	1	1	1	1	1	2	2									
				16. LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1	1									
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1									
				18. DIURNAL VARIATION	2	2	1	1	1	1	1	1	1	1	1										
				19. DEPERSONALIZATION	1	1	0	0	0	0	0	0	0	0	0	0									
				20. PARANOID	1	1	0	0	0	0	0	0	0	0	0	0									
				21. OBSSSSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0									
				22. Total score	39	39	22	20	15	13	20	24													
7DT	Reboxetine	Female	01. DEPRESSED MOOD	3	3	3	2	1	1	2															
			02. GUILT	1	1	1	1	1	1	1															
			03. SUICIDE	2	2	2	2	2	2	2															
			04. INSOMNIA EARLY	2	2	2	1	1	1	2															
			05. INSOMNIA MIDDLE	2	2	2	1	1	1	1															
			06. INSOMNIA LATE	1	1	1	1	1	1	1															
			07. WORK AND ACTIVITIES	2	2	2	3	2	3	2															
			08. RETARDATION	1	1	1	1	1	1	1															
			09. AGITATION	2	2	2	3	2	2	2															
			10. ANXIETY PSYCHIC	3	3	3	4	4	4	2															
			11. ANXIETY SOMATIC	3	3	3	3	2	2	2															
			12. SOMATIC GASTROINTESTINAL	1	1	1	1	2	2	1															
			13. SOMATIC GENERAL	0	0	0	0	0	0	0															
			14. GENITAL SYMPTOMS	3	3	3	3	1	2	2															
			15. HYPOCHONDRIASIS	1	1	1	2	1	2	1															
			16. LOSS OF WEIGHT	1	1	1	1	1	1	1															
			17. INSIGHT	1	1	1	1	1	1	1															
			18. DIURNAL VARIATION	2	2	2	2	1	1	1															
			19. DEPERSONALIZATION	1	1	1	1	1	1	1															
			20. PARANOID	0	0	0	1	1	1	1															
			21. OBSSSSIONAL/COMPULSIVE	0	0	0	1	1	1	1															
			22. Total score	32	36	38	29	25	25	27															
8ND	Imipramine	Female	01. DEPRESSED MOOD	2	2	2	2	1	1	1															
			02. GUILT	0	0	0	0	0	0	0															
			03. SUICIDE	2	2	2	1	1	1	1															
			04. INSOMNIA EARLY	2	2	2	2	1	1	1															
			05. INSOMNIA MIDDLE	1	1	1	2	1	1	1															
			06. INSOMNIA LATE	1	1	1	1	1	1	1															
			07. WORK AND ACTIVITIES	1	1	1	1	1	1	1															
			08. RETARDATION	2	2	2	1	2	1	1															
			09. AGITATION	3	3	3	2	1	1	1															
			10. ANXIETY PSYCHIC	2	2	2	2	1	1	1															
			11. ANXIETY SOMATIC	2	2	2	2	2	2	1															
			12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1															

1365

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

94

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/03S
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63					
35	SMD	Imipramine	Female	HAMILTON DEPRESSION RATING SCALE																
				13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1				
				14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1	1			
				15. HYPOCHONDRIASIS	3	3	3	3	3	3	3	3	3	3	3	3	3			
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0			
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1			
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1			
				19. DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1			
				20. PARANOID	1	1	1	1	1	1	1	1	1	1	1	1	1			
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0			
				22. Total score	29	29	30	25	23	18	19	21	21	21	21	21	21			
				36	IND	Imipramine	Male	HAMILTON DEPRESSION RATING SCALE												
								01. DEPRESSED MOOD	3	3	3	3	2	2	2	2	2	2	2	2
								02. GUILT	2	2	2	2	2	2	2	2	2	2	2	2
								03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0
								04. INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0	0
								05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2
								06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1
								07. WORK AND ACTIVITIES	3	3	3	3	2	2	2	2	2	2	2	2
								08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2
								09. ACITATION	2	2	2	2	2	2	2	2	2	2	2	2
								10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2
11. ANXIETY SOMATIC	1	1	1					1	1	1	1	1	1	1	1	1				
12. SOMATIC GASTROINTESTINAL	1	1	1					1	1	1	1	1	1	1	1	1				
13. SOMATIC GENERAL	0	0	0					0	0	0	0	0	0	0	0	0				
14. GENITAL SYMPTOMS	0	0	0					0	0	0	0	0	0	0	0	0				
15. HYPOCHONDRIASIS	1	1	1					1	1	1	1	1	1	1	1	1				
16. LOSS OF WEIGHT	1	1	1					1	1	1	1	1	1	1	1	1				
17. INSIGHT	1	1	1					1	1	1	1	1	1	1	1	1				
18. DIURNAL VARIATION	1	1	1					1	1	1	1	1	1	1	1	1				
19. DEPERSONALIZATION	0	0	0					0	0	0	0	0	0	0	0	0				
20. PARANOID	0	0	0					0	0	0	0	0	0	0	0	0				
21. OBSESSIONAL/COMPULSIVE	1	1	1					1	1	1	1	1	1	1	1	1				
22. Total score	26	26	25	24	18	17	14	13	15	15	13	15								
36	IND	Imipramine	Male	HAMILTON DEPRESSION RATING SCALE																
				01. DEPRESSED MOOD	4	4	4	4	4	4	4	4	4	4	4					
				02. GUILT	2	2	2	2	2	2	2	2	2	2	2					
				03. SUICIDE	2	2	2	2	2	2	2	2	2	2	2					
				04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2					
				05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1					
				06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2					
				07. WORK AND ACTIVITIES	4	4	4	4	3	3	3	3	3	3	3					
				08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0					
				09. ACITATION	0	0	0	0	0	0	0	0	0	0	0					
				10. ANXIETY PSYCHIC	1	1	1	1	1	1	1	1	1	1	1					
				11. ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1					
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1					
				13. SOMATIC GENERAL	0	0	0	0	0	0	0	0	0	0	0					
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0					
				15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2					
16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0									

1366

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

95

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63			
36	1ND	Imipramine	Male	HAMILTON DEPRESSION RATING SCALE																							
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				22. Total score	23	23	19	7	7	7	5	4	4	4	4	4	4	4	4	4	4	4	4	4	4	6	
1DT	Imipramine	Female	HAMILTON DEPRESSION RATING SCALE																								
			01. DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				02. GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				06. INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				07. WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				09. AGITATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				11. ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				16. LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	20	20	18	7	7	7	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
2ND	Reboxetine	Female	HAMILTON DEPRESSION RATING SCALE																								
			01. DEPRESSED MOOD	4	4	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				02. GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				06. INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				07. WORK AND ACTIVITIES	3	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				09. AGITATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				10. ANXIETY PSYCHIC	3	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				14. GENITAL SYMPTOMS	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				15. HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				16. LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

1367

9550089

96

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63	
36	2MD	Reboxetine	Female	21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	27	26	17	14	16	20	21	15	15	15	15	15	15	15	15	15	15	15	15	15	15
	2DT	Reboxetine	Female	01. DEPRESSED MOOD	3	3	2	2	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				02. GUILTY	2	2	2	2	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				03. SUICIDE	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				04. INSOMNIA EARLY	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				06. INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				07. WORK AND ACTIVITIES	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				09. AGITATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				10. ANXIETY PSYCHIC	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				11. ANXIETY SOMATIC	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				13. SOMATIC GENERAL	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				15. HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				18. DIURNAL VARIATION	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	21	21	14	14	10	8	10	8	1	1	1	1	1	1	1	1	1	1	1	1	1
3MD	Imigranin	Female		01. DEPRESSED MOOD	4	4	4	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				02. GUILTY	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				04. INSOMNIA EARLY	2	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				05. INSOMNIA MIDDLE	2	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				06. INSOMNIA LATE	2	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				08. RETARDATION	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				09. AGITATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				10. ANXIETY PSYCHIC	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				11. ANXIETY SOMATIC	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				15. HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				18. DIURNAL VARIATION	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	29	29	25	15	17	17	17	16	16	16	16	16	16	16	16	16	16	16	16	16	16

1368

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

97

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen	Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63					
36	3DT	Imipramine	Female	HAMILTON DEPRESSION RATING SCALE																										
				01. DEPRESSED MOOD	3	3	3	2	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				02. GUILT	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				04. INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				05. INSOMNIA MIDDLE	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				06. INSOMNIA LATE	2	2	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				07. WORK AND ACTIVITIES	3	3	3	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				09. AGITATION	2	2	2	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				10. ANXIETY PSYCHIC	2	2	2	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				11. ANXIETY SOMATIC	2	2	2	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				12. SOMATIC GASTROINTESTINAL	2	2	2	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				13. SOMATIC GENERAL	2	2	2	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				15. HYPOCHONDRIASIS	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
				16. LOSS OF WEIGHT	2	2	2	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
22. Total score	27	27	27	21	8	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
4ND	Reboxetine	Female	HAMILTON DEPRESSION RATING SCALE																											
			01. DEPRESSED MOOD	3	3	3	3	3	3	2	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
			02. GUILT	3	3	3	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
			03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
			04. INSOMNIA EARLY	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
			05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
			06. INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
			08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
			09. AGITATION	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
			10. ANXIETY PSYCHIC	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
			11. ANXIETY SOMATIC	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
			12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
			13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
			14. GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
			15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
			16. LOSS OF WEIGHT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
			17. INSIGHT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
			18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			20. PARANOID	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
			21. OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
22. Total score	37	37	37	35	32	25	21	19	19	19	19	19	19	19	19	19	19	19	19	19	19	19	19	19	19					
4DT	Reboxetine	Female	01. DEPRESSED MOOD	3	3	2	2	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
			02. GUILT	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
			03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
			04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			

1369

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

99

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
36	5DT	Imipramine	Female	HAMILTON DEPRESSION RATING SCALE		3	3	3	3	3	3	3	3	3	3
				09. AGITATION											
				10. ANXIETY PSYCHIC											
				11. ANXIETY SOMATIC											
				12. SOMATIC GASTROINTESTINAL											
				13. SOMATIC GENERAL											
				14. DENTAL SYMPTOMS											
				15. HYPOCHONDRIASIS											
				16. LOSS OF WEIGHT											
				17. INSIGHT											
				18. DIURNAL VARIATION											
				19. DEPERSONALIZATION											
				20. PARANOID											
				21. OBSESSIONAL/COMPULSIVE											
				22. Total score		39	39	39	39	39	39	39	39	39	39
6MD		Imipramine	Female	HAMILTON DEPRESSION RATING SCALE		2	2	2	2	2	2	2	2	2	2
				01. DEPRESSED MOOD											
				02. GUILT											
				03. SUICIDE											
				04. INSOMNIA EARLY											
				05. INSOMNIA MIDDLE											
				06. INSOMNIA LATE											
				07. WORK AND ACTIVITIES											
				08. RETARDATION											
				09. AGITATION											
				10. ANXIETY PSYCHIC											
				11. ANXIETY SOMATIC											
				12. SOMATIC GASTROINTESTINAL											
				13. SOMATIC GENERAL											
				14. DENTAL SYMPTOMS											
				15. HYPOCHONDRIASIS											
				16. LOSS OF WEIGHT											
				17. INSIGHT											
				18. DIURNAL VARIATION											
				19. DEPERSONALIZATION											
				20. PARANOID											
				21. OBSESSIONAL/COMPULSIVE											
				22. Total score		21	21	21	21	21	21	21	21	21	21
6DT		Imipramine	Female	HAMILTON DEPRESSION RATING SCALE		3	3	3	3	3	3	3	3	3	3
				01. DEPRESSED MOOD											
				02. GUILT											
				03. SUICIDE											
				04. INSOMNIA EARLY											
				05. INSOMNIA MIDDLE											
				06. INSOMNIA LATE											
				07. WORK AND ACTIVITIES											
				08. RETARDATION											
				09. AGITATION											
				10. ANXIETY PSYCHIC											
				11. ANXIETY SOMATIC											
				12. SOMATIC GASTROINTESTINAL											

1371

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

100

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day						
36	6DT	Imipramine	Female	13. SOMATIC GENERAL	2	2	2	1	1	1	1	1	1	1	1						
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0				
				15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				16. LOSS OF WEIGHT	2	2	2	1	1	1	1	1	1	1	1	1	1	1			
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				22. Total score	21	21	19	16	11	10	9	6	6	6	6	6	6	6			
				7MD	Reboxetine	Female	01. DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2	2	2		
							02. GUILT	1	1	1	1	1	1	1	1	1	1	1	1	1	
							03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0
							04. INSOMNIA EARLY	2	2	2	1	1	1	1	1	1	1	1	1	1	1
							05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1
							06. INSOMNIA LATE	2	1	1	1	1	1	1	1	1	1	1	1	1	1
							07. WORK AND ACTIVITIES	3	3	3	3	3	2	2	2	2	2	2	2	2	2
							08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2
							09. AGITATION	1	2	2	2	2	2	2	2	2	2	2	2	2	2
							10. ANXIETY PSYCHIC	0	0	0	0	0	0	0	0	0	0	0	0	0	0
							11. ANXIETY SOMATIC	0	0	0	0	0	0	0	0	0	0	0	0	0	0
							12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2
13. SOMATIC GENERAL	2	2	2				2	2	2	2	2	2	2	2	2	2	2				
14. GENITAL SYMPTOMS	1	0	0				0	0	0	0	0	0	0	0	0	0	0				
15. HYPOCHONDRIASIS	2	2	2				2	2	2	2	2	2	2	2	2	2	2				
16. LOSS OF WEIGHT	2	2	2				2	2	2	2	2	2	2	2	2	2	2				
17. INSIGHT	1	1	1				1	1	1	1	1	1	1	1	1	1	1				
18. DIURNAL VARIATION	2	2	2				2	2	2	2	2	2	2	2	2	2	2				
19. DEPERSONALIZATION	0	0	0				0	0	0	0	0	0	0	0	0	0	0				
20. PARANOID	0	0	0				0	0	0	0	0	0	0	0	0	0	0				
21. OBSESSIONAL/COMPULSIVE	0	0	0				0	0	0	0	0	0	0	0	0	0	0				
22. Total score	26	26	21				21	19	19	19	19	19	19	19	19	19	19				
7DT	Reboxetine	Female	01. DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2	2	2						
			02. GUILT	1	1	1	1	1	1	1	1	1	1	1	1	1					
			03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1	1					
			04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2					
			05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2					
			06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2					
			07. WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2	2	2					
			08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0					
			09. AGITATION	2	2	2	2	2	2	2	2	2	2	2	2	2					
			10. ANXIETY PSYCHIC	3	3	3	3	3	3	3	3	3	3	3	3	3					
			11. ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1					
			12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1					
			13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2					
			14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0					
			15. HYPOCHONDRIASIS	3	3	3	3	3	3	3	3	3	3	3	3	3					
			16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0					

1372

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

101

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 2012A/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63	
36	7DT	Reboxetine	Female	17.INSIGHT	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22.Total score	25	25	29																		
8ND		Imipramine	Female	01.DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				02.GUILT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				03.SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				06.INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				08.RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				09.AGITATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22.Total score	24	24	20	20	12	8	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
8DT		Reboxetine	Female	01.DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				02.GUILT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				08.RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				09.AGITATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				16.LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				17.INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

1373

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

102

PHARMACIA CNS 8&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63
36	80T	Reboxetine	Female	21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	24	24	23	13	13	7	7	12	15	14	14									
36	90D	Reboxetine	Male	01. DEPRESSED MOOD	2	2	4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				02. GUILT	1	1	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				03. SUICIDE	4	4	3	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				04. INSOMNIA EARLY	2	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				05. INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				06. INSOMNIA LATE	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				07. WORK AND ACTIVITIES	4	4	4	4	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				08. RETARDATION	2	2	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				09. AGITATION	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				10. ANXIETY PSYCHIC	1	1	3	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				11. ANXIETY SOMATIC	2	2	3	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				13. SOMATIC GENERAL	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				15. HYPOCHONDRIASIS	1	1	1	3	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				16. LOSS OF WEIGHT	1	1	1	1	0	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				17. INSTINCT	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				18. DIURNAL VARIATION	1	1	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	2	2	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	27	27	38	25	10	7	9	7	7	7	7	7	7	7	7	7	7	7	7	7
36	90T	Imipramine	Female	01. DEPRESSED MOOD	3	3	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				02. GUILT	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				04. INSOMNIA EARLY	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				05. INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				06. INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				07. WORK AND ACTIVITIES	2	2	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				08. RETARDATION	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				09. AGITATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				15. HYPOCHONDRIASIS	3	3	3	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17. INSTINCT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	21	21	19	14	10	8	10	8	10	7	7	7	7	7	7	7	7	7	7	7

1374

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

103

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day		
36	10ND	Reboxetine	Male	01. DEPRESSED MOOD	3	3	1	1	1	0	0	0	0	0	0		
				02. GUILT	0	0	0	0	0	0	0	0	0	0	0	0	
				03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0
				04. INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1	1
				05. INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0	0	0
				06. INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0	0
				07. WORK AND ACTIVITIES	3	3	1	0	0	0	0	0	0	0	0	0	0
				08. RETARDATION	2	2	1	0	0	0	0	0	0	0	0	0	0
				09. AGITATION	3	3	1	0	0	0	0	0	0	0	0	0	0
				10. ANXIETY PSYCHIC	2	2	1	0	0	0	0	0	0	0	0	0	0
				11. ANXIETY SOMATIC	3	3	1	1	1	1	1	1	1	1	1	1	1
				12. SOMATIC GASTROINTESTINAL	2	2	1	0	0	0	0	0	0	0	0	0	0
				13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1
				14. GENITAL SYMPTOMS	3	3	1	0	0	0	0	0	0	0	0	0	0
				15. HYPOCHONDRIASIS	2	2	0	0	0	0	0	0	0	0	0	0	0
				16. LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score				23	28	13	6	6	5	5	5	5	5
10DT	Reboxetine	Male	01. DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2	2			
			02. GUILT	1	1	1	1	1	1	1	1	1	1	1	1		
			03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0		
			04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2		
			05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2		
			06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2		
			07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3		
			08. RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1		
			09. AGITATION	2	2	2	2	2	2	2	2	2	2	2	2		
			10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2		
			11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2		
			12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2		
			13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2		
			14. GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2	2		
			15. HYPOCHONDRIASIS	3	3	3	3	3	3	3	3	3	3	3	3		
			16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0		
			17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0		
			18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1		
			19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0		
			20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0		
			21. OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1	1		
			22. Total score				30	30	32	30	28	28	26	29	33		
11ND	Imipramine	Female	01. DEPRESSED MOOD	4	4	4	4	4	4	4	4	4	4				
			02. GUILT	2	2	2	2	2	2	2	2	2	2				
			03. SUICIDE	1	1	1	1	1	1	1	1	1	1				
			04. INSOMNIA EARLY	1	1	1	1	1	1	1	1	1					

1375

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

10/4

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63						
36	11ND	Imipramine	Female	05..INSOMNIA MIDDLE	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0					
				06..INSOMNIA LATE	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				07..WORK AND ACTIVITIES	3	3	3	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0		
				08..RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0		
				09..AGITATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				10..ANXIETY PSYCHIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0		
				11..ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0		
				12..SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0		
				13..SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0	0	0	0	0	0		
				14..GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				15..HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
				16..LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0		
				17..INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				18..DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0		
				19..DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				20..PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				21..OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				22..Total score				25	23	23	21	11	8	8	4	4	3	2	2	2	2	2	2	2	2	2	2	1		
				11DF	Reboxetine	Male	01..DEPRESSED MOOD	3	3	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	1	1	1	1		
							02..GUILT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	
							03..SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0
							04..INSOMNIA EARLY	1	1	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
05..INSOMNIA MIDDLE	1	1	1				1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
06..INSOMNIA LATE	1	1	1				1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
07..WORK AND ACTIVITIES	3	3	3				3	3	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
08..RETARDATION	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
09..AGITATION	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
10..ANXIETY PSYCHIC	3	3	3				3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3			
11..ANXIETY SOMATIC	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
12..SOMATIC GASTROINTESTINAL	1	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
13..SOMATIC GENERAL	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
14..GENITAL SYMPTOMS	3	3	3				3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3			
15..HYPOCHONDRIASIS	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
16..LOSS OF WEIGHT	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
17..INSIGHT	1	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
18..DIURNAL VARIATION	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
19..DEPERSONALIZATION	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
20..PARANOID	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
21..OBSESSIONAL/COMPULSIVE	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
22..Total score							25	25	25	28	25	22	25	18	11	11	11	11	11	11	11	11	11	11	11	11	11			
12ND	Imipramine	Female	01..DEPRESSED MOOD	3	3	3	3	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0						
			02..GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
			03..SUICIDE	2	2	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
			04..INSOMNIA EARLY	1	1	1	1	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
			05..INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
			06..INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
			07..WORK AND ACTIVITIES	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4				
			08..RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				

1376

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

106

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day
36	13MD	Reboxetine	Male		1	1	1	2	2	2	2	2	2	2	2
				13. SOMATIC GENERAL	1	1	1	2	2	2	2	2	2	2	2
				14. CERITAL SYMPTOMS	0	0	0	1	1	1	1	1	1	1	1
				15. HYPOCHONDRIASIS	2	2	2	1	1	1	1	1	1	1	1
				16. LOSS OF WEIGHT	2	2	2	1	2	2	2	2	2	2	2
				17. INSIGHT	1	1	1	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	1	1	1	0	0	0	0	0	0	0	0
				20. PARANOIA	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIVE/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1
				22. Total score	19	19	19	26	26	26	26	26	26	26	26
14MD		Imipramine	Male		2	2	2	1	1	0	0	0	0	0	0
				01. DEPRESSED MOOD	2	2	2	1	1	0	0	0	0	0	0
				02. GUILT	1	1	1	0	0	0	0	0	0	0	0
				03. SUICIDE	2	2	2	0	0	0	0	0	0	0	0
				04. INSOMNIA EARLY	1	1	1	1	1	0	0	0	0	0	0
				05. INSOMNIA MIDDLE	2	2	2	1	1	1	1	1	1	1	1
				06. INSOMNIA LATE	2	2	2	1	1	1	1	1	1	1	1
				07. WORK AND ACTIVITIES	2	2	2	1	1	1	1	1	1	1	1
				08. RETARDATION	2	2	2	1	1	1	1	1	1	1	1
				09. AGITATION	2	2	2	1	1	1	1	1	1	1	1
				10. ANXIETY PSYCHIC	0	0	0	0	0	0	0	0	0	0	0
				11. ANXIETY SOMATIC	1	1	1	0	0	0	0	0	0	0	0
				12. SOMATIC GASTROINTESTINAL	2	2	2	1	1	1	1	1	1	1	1
				13. SOMATIC GENERAL	1	1	1	1	1	0	0	0	0	0	0
				14. CERITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0
				15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0
				16. LOSS OF WEIGHT	1	1	1	0	0	0	0	0	0	0	0
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOIA	1	1	1	1	1	1	1	1	1	1	1
				21. OBSESSIVE/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	20	20	15	8	6	4	2	2	2	2	2
15MD		Reboxetine	Female		1	1	1	1	1	1	1	1	1	1	1
				01. DEPRESSED MOOD	1	1	1	1	1	1	1	1	1	1	1
				02. GUILT	1	1	1	1	1	1	1	1	1	1	1
				03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0
				04. INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1
				05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1
				06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1
				07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3
				08. RETARDATION	1	1	1	1	1	1	1	1	1	1	1
				09. AGITATION	1	1	1	1	1	1	1	1	1	1	1
				10. ANXIETY PSYCHIC	1	1	1	1	1	1	1	1	1	1	1
				11. ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1
				13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1
				14. CERITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1
				15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2
				16. LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1

1378

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

107

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63				
36	15HD	Reboxetine	Female	17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20		
16HD	Imigranin	Female	01. DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
			02. GUILT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
			03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			04. INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
			06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
			07. WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
			08. RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			09. AGITATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			10. ANXIETY PSYCHIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			11. ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			12. SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
			16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
							21. Total score	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21
			17HD	Reboxetine	Female	01. DEPRESSED MOOD	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
02. GUILT	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
03. SUICIDE	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
04. INSOMNIA EARLY	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
05. INSOMNIA MIDDLE	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
06. INSOMNIA LATE	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
07. WORK AND ACTIVITIES	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
08. RETARDATION	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
09. AGITATION	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
10. ANXIETY PSYCHIC	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
11. ANXIETY SOMATIC	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
12. SOMATIC GASTROINTESTINAL	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
13. SOMATIC GENERAL	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
14. GENITAL SYMPTOMS	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
15. HYPOCHONDRIASIS	3	3				3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
16. LOSS OF WEIGHT	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
17. INSIGHT	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
18. DIURNAL VARIATION	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
19. DEPERSONALIZATION	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
20. PARANOID	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
							21. Total score	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21

1379

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

106

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63
36	17MD	Reboxetine	Female	21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	24	24	24	24																
18MD		Imipramine	Female	01. DEPRESSED MOOD	3	3	3	3	2	2	2	2	2	0	0	0	0	0	0	0	0	0	0	0
				02. GUILT	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
				03. SUICIDE	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
				04. INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
				05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
				06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
				07. WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	0	0	0	0	0	0	0	0	0	0	0
				08. RETARDATION	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				09. AGITATION	2	2	2	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				10. ANXIETY PSYCHIC	2	2	2	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				11. ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
				13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
				14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
				15. HYPOCHONDRIASIS	2	2	2	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				16. LOSS OF WEIGHT	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17. INSIGHT	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	24	24	24	20	15	15	15	15	2	2	2	2	2	2	2	2	2	2	2	2
19MD		Reboxetine	Female	01. DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	0	0	0	0	0	0	0	0	0	0	0
				02. GUILT	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
				03. SUICIDE	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
				04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	0	0	0	0	0	0	0	0	0	0	0
				05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
				06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
				07. WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	0	0	0	0	0	0	0	0	0	0	0
				08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				09. AGITATION	2	2	2	2	2	2	2	2	2	0	0	0	0	0	0	0	0	0	0	0
				10. ANXIETY PSYCHIC	3	3	3	3	3	3	3	3	3	0	0	0	0	0	0	0	0	0	0	0
				11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	0	0	0	0	0	0	0	0	0	0	0
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
				13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
				14. GENITAL SYMPTOMS	3	3	3	3	3	3	3	3	3	0	0	0	0	0	0	0	0	0	0	0
				15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	25	25	25	25	25	25	25	25	25	0	0	0	0	0	0	0	0	0	0	0

1380

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

110

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63	
41	1ND	Imipramine	Male	HAMILTON DEPRESSION RATING SCALE	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63	
				05.INSOMNIA MIDDLE	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				08.RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				09.AGIATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				10.ANxiety PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				11.ANxiety SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22.Total score	22	24	24	27	27	27	27	27	27	27	27	27	27	27	27	27	27	27	27	27	27
				01.DEPRESSED MOOD	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				02.GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				03.SUICIDE	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1
				07.WORK AND ACTIVITIES	2	3	2	3	2	3	2	3	2	3	2	3	2	3	2	3	2	3	2	3	2
				08.RETARDATION	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				09.AGIATION	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				10.ANxiety PSYCHIC	3	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				11.ANxiety SOMATIC	4	3	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				14.GENITAL SYMPTOMS	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	2	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17.INSIGHT	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22.Total score	29	18	15	5	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				01.DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				02.GUILT	3	3	2	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				03.SUICIDE	3	3	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				07.WORK AND ACTIVITIES	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				08.RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2

1382

2ND Roboxetine Male

3ND Imipramine Male

9550089

111

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63					
41	3MD	Imipramine	Male	Hamilton depression rating scale	3	4	2	1	2	2	2	2	2	2					
				09. ACITATION	3	1	1	1	1	1	1	1	1	1	1	2			
				10. ANXIETY PSYCHIC	3	1	1	1	1	1	1	1	1	1	1	1	2		
				11. ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	0		
				12. SOMATIC GASTROINTESTINAL	0	0	0	1	1	1	1	1	1	1	1	1	0		
				13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2		
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0		
				15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0		
				16. LOSS OF WEIGHT	2	2	2	2	2	2	2	2	2	2	2	2	2		
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0		
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1		
				19. DEPERSONALIZATION	3	2	0	0	0	0	0	0	0	0	0	0	0		
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0		
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0		
				22. Total score	31	29	21	26	19	20	20	19	20	19	18	18	18		
				4MD	Reboxetine	Male	Hamilton depression rating scale	1	2	2	1	1	1	1	1	1	1	1	
							01. DEPRESSED MOOD	1	1	2	1	1	1	1	1	1	1	1	1
							02. GUILT	1	1	1	1	1	1	1	1	1	1	1	1
							03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1
							04. INSOMNIA EARLY	2	2	2	1	1	1	1	1	1	1	1	1
							05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1
							06. INSOMNIA LATE	1	2	1	1	1	1	1	1	1	1	1	1
07. WORK AND ACTIVITIES	2	2	2				2	2	2	2	2	2	2	2	2				
08. RETARDATION	1	1	1				1	1	1	1	1	1	1	1	1				
09. ACITATION	1	1	1				1	1	1	1	1	1	1	1	1				
10. ANXIETY PSYCHIC	2	2	1				1	1	1	1	1	1	1	1	1				
11. ANXIETY SOMATIC	2	2	1				1	1	1	1	1	1	1	1	1				
12. SOMATIC GASTROINTESTINAL	1	1	1				1	1	1	1	1	1	1	1	1				
13. SOMATIC GENERAL	2	2	1				1	1	1	1	1	1	1	1	1				
14. GENITAL SYMPTOMS	1	1	0				0	0	0	0	0	0	0	0	0				
15. HYPOCHONDRIASIS	1	1	1				1	1	1	1	1	1	1	1	1				
16. LOSS OF WEIGHT	1	1	1				1	1	1	1	1	1	1	1	1				
17. INSIGHT	0	0	0				0	0	0	0	0	0	0	0	0				
18. DIURNAL VARIATION	0	0	0				0	0	0	0	0	0	0	0	0				
19. DEPERSONALIZATION	2	2	1				1	1	1	1	1	1	1	1	1				
20. PARANOID	0	0	0				0	0	0	0	0	0	0	0	0				
21. OBSESSIONAL/COMPULSIVE	0	0	0				0	0	0	0	0	0	0	0	0				
22. Total score	24	25	21	16	12	8	8	10	8	10	10	10	8						
5MD	Reboxetine	Male	Hamilton depression rating scale	1	1	1	1	1	1	1	1	1	1	1					
			01. DEPRESSED MOOD	1	1	1	1	1	1	1	1	1	1	1					
			02. GUILT	2	1	1	1	1	1	1	1	1	1	1					
			03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1					
			04. INSOMNIA EARLY	2	2	0	0	0	0	0	0	0	0	0					
			05. INSOMNIA MIDDLE	1	2	1	1	1	1	1	1	1	1	1					
			06. INSOMNIA LATE	2	2	1	1	1	1	1	1	1	1	1					
			07. WORK AND ACTIVITIES	1	1	1	1	1	1	1	1	1	1	1					
			08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0					
			09. ACITATION	1	1	1	1	1	1	1	1	1	1	1					
			10. ANXIETY PSYCHIC	1	1	0	0	0	0	0	0	0	0	0					
			11. ANXIETY SOMATIC	2	2	2	1	1	1	1	1	1	1	1					

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

112

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
41	SMD	Reboxetine	Male	HAMILTON DEPRESSION RATING SCALE										
				Hamilton depression rating scale	0	7	14	21	28	35	42	49	56	63
				13. SOMATIC GENERAL	2	2	2	1	2	2	2	2	2	2
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0
				15. HYPOCHONDRIASIS	0	0	1	1	1	1	1	1	0	0
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	1	1	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	1	1	1	0	0	0	0	0	0	0
				22. Total score	20	21	16	10	8	8	8	7	7	7
42	1HD	Imipramine	Female	HAMILTON DEPRESSION RATING SCALE										
				Hamilton depression rating scale	0	7	14	21	28	35	42	49	56	63
				01. DEPRESSED MOOD	2	2	2	1	2	1	1	1	0	0
				02. GUILT	2	2	1	1	1	0	1	0	0	0
				03. SUICIDE	1	1	1	0	0	0	0	0	0	0
				04. INSOMNIA EARLY	2	2	1	0	1	0	0	0	0	0
				05. INSOMNIA MIDDLE	2	2	1	0	0	0	0	0	0	0
				06. INSOMNIA LATE	2	2	1	0	0	0	0	0	0	0
				07. WORK AND ACTIVITIES	3	3	2	2	2	1	0	0	0	0
				08. RETARDATION	1	1	0	0	0	0	0	0	0	0
				09. AGITATION	0	0	0	0	0	0	0	0	0	0
				10. ANXIETY PSYCHIC	2	2	2	2	2	2	1	0	0	0
				11. ANXIETY SOMATIC	2	2	1	1	1	1	1	0	0	0
				12. SOMATIC GASTROINTESTINAL	1	2	1	1	1	1	0	0	0	0
				13. SOMATIC GENERAL	1	2	1	1	1	1	0	0	0	0
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0
				15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2
				16. LOSS OF WEIGHT	2	2	1	0	0	0	0	0	0	0
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	1	1	1	1	1	0	0	0	0	0
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0
				22. Total score	26	29	22	12	13	6	4	1	4	0
10X		Imipramine	Female	HAMILTON DEPRESSION RATING SCALE										
				Hamilton depression rating scale	0	7	14	21	28	35	42	49	56	63
				01. DEPRESSED MOOD	4	4	2	2	3	2	3	3	3	3
				02. GUILT	2	1	2	1	2	2	1	1	1	1
				03. SUICIDE	1	1	2	1	1	0	1	0	0	2
				04. INSOMNIA EARLY	1	2	2	2	2	2	2	2	2	2
				05. INSOMNIA MIDDLE	2	2	2	1	2	2	2	2	2	2
				06. INSOMNIA LATE	2	2	2	2	1	2	2	2	2	2
				07. WORK AND ACTIVITIES	3	3	3	2	2	2	2	2	2	2
				08. RETARDATION	0	0	1	1	1	0	0	0	0	0
				09. AGITATION	3	4	2	0	0	0	0	0	0	0
				10. ANXIETY PSYCHIC	3	3	2	2	2	2	2	2	2	2
				11. ANXIETY SOMATIC	2	2	2	2	1	1	1	1	1	1
				12. SOMATIC GASTROINTESTINAL	2	2	1	1	1	1	1	1	0	0
				13. SOMATIC GENERAL	1	1	1	2	1	1	1	1	1	1
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0
				15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2
				16. LOSS OF WEIGHT	2	2	2	2	2	2	2	2	2	2

1384

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

113

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63	
42	10T	Imipramine	Female	17.INSIGHT	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				20.PARANOID	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22.Total score	35	33	29	25	19	16	22	19	17	19	19	19	17	19	17	19	17	19	17	19	19
20D		Reboxetine	Female	01.DEPRESSED MOOD	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				02.GUILT	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				03.SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				04.INSOMNIA EARLY	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				08.RETARDATION	2	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				09.AGITATION	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				19.DEPERSONALIZATION	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22.Total score	29	29	19	16	15	16	6	4	10	5	5	5	5	5	5	5	5	5	5	5	5
20T		Reboxetine	Male	01.DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				02.GUILT	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				03.SUICIDE	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				05.INSOMNIA MIDDLE	0	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				08.RETARDATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				09.AGITATION	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

13 08 01

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

114

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63	
42	2DT	Reboxetine	Male	21-OBSessional/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22-Total score	19	19	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20
	3ND	Imipramine	Male	01-DEPRESSED MOOD	2	2	2	4	3	3	3	2	3	3	3	3	3	2	2	2	2	2	2	2	1
				02-GUILTY	1	1	1	1	2	1	2	1	2	1	2	1	2	1	0	1	0	1	1	1	0
				03-SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0
				04-INSOMNIA EARLY	1	1	2	2	2	2	2	0	0	0	0	0	0	0	1	1	0	0	0	0	0
				05-INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				06-INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				07-WORK AND ACTIVITIES	2	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				08-RETARDATION	0	0	1	0	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				09-AGITATION	2	2	2	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				10-ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				11-ANXIETY SOMATIC	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				12-SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				13-SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				14-GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				15-HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				16-LOSS OF WEIGHT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				17-INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18-DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19-DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20-PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21-OBSessional/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22-Total score	23	25	25	26	26	26	26	20	15	19	15	14	14	14	14	14	14	14	14	14	8
43	1DT	Reboxetine	Female	01-DEPRESSED MOOD	3	3	3	3	3	3	3	2	3	2	3	2	2	2	2	2	2	2	2	2	2
				02-GUILTY	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				03-SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				04-INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				05-INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				06-INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				07-WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				08-RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				09-AGITATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				10-ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				11-ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				12-SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				13-SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				14-GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				15-HYPOCHONDRIASIS	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				16-LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17-INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				18-DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19-DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20-PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21-OBSessional/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				22-Total score	26	26	26	24	23	23	24	23	24	21	24	21	24	21	24	21	24	21	24	21	24

1386

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

117

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day						
43	6ND	Imipramine	Female	09. AGITATION	2	2	1	1	1	1	1	1	1	1	1						
				10. ANXIETY PSYCHIC	2	2	1	2	2	2	2	2	2	2	2	3					
				11. ANXIETY SOMATIC	1	1	0	1	1	1	1	1	1	1	1	1	1	1			
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	0	0	0	0	0	0	0	0	0			
				13. SOMATIC GENERAL	2	2	1	1	1	1	1	1	1	1	1	1	1	0			
				14. GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				15. HYPOCHONDRIASIS	2	2	0	0	0	0	0	0	0	0	0	0	0	0			
				16. LOSS OF WEIGHT	1	1	1	0	0	0	0	0	0	0	0	0	0	0			
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				18. DIURNAL VARIATION	1	1	1	0	1	1	0	0	0	0	0	0	0	0			
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				21. OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
				22. Total score	29	29	22	19	15	12	13	13	11	11	11	11	11	11			
				44	1ND	Reboxetine	Female	01. DEPRESSED MOOD	3	3	2	3	3	2	0	2	2	2	2		
								02. GUILT	1	1	0	0	0	0	0	0	0	0	0	0	
								03. SUICIDE	1	1	0	0	1	0	0	0	0	0	0	0	0
								04. INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0	0	0
								05. INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0	0	0
								06. INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0	0
								07. WORK AND ACTIVITIES	2	2	2	1	0	2	2	2	2	2	2	2	2
								08. RETARDATION	2	2	1	1	1	0	1	1	1	1	1	1	1
09. AGITATION	0	0	0					0	0	0	0	0	0	0	0	0	0				
10. ANXIETY PSYCHIC	4	4	1					1	2	0	1	0	0	0	0	0	0				
11. ANXIETY SOMATIC	3	3	2					2	2	1	1	1	1	1	1	1	1				
12. SOMATIC GASTROINTESTINAL	2	2	1					1	1	1	1	1	1	1	1	1	1				
13. SOMATIC GENERAL	1	1	1					1	1	1	1	1	1	1	1	1	1				
14. GENITAL SYMPTOMS	0	0	0					0	0	0	0	0	0	0	0	0	0				
15. HYPOCHONDRIASIS	0	0	0					0	0	0	0	0	0	0	0	0	0				
16. LOSS OF WEIGHT	1	1	1					0	0	0	0	0	0	0	0	0	0				
17. INSIGHT	0	0	0					0	0	0	0	0	0	0	0	0	0				
18. DIURNAL VARIATION	2	2	1					1	1	1	1	1	1	1	1	1	1				
19. DEPERSONALIZATION	0	0	0					0	0	0	0	0	0	0	0	0	0				
20. PARANOID	0	0	0					0	0	0	0	0	0	0	0	0	0				
21. OBSESSIONAL/COMPULSIVE	0	0	0					0	0	0	0	0	0	0	0	0	0				
22. Total score	23	23	14					13	14	12	11	12	11	12	11	12	11	11			
10F	Reboxetine	Female	01. DEPRESSED MOOD	4	4	3	1	2	2	2	2	2	2	2	1						
			02. GUILT	2	2	0	0	1	1	1	1	1	1	1	1						
			03. SUICIDE	2	2	3	0	1	1	1	1	1	1	1	1						
			04. INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0	0						
			05. INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0	0						
			06. INSOMNIA LATE	2	2	1	0	0	1	0	0	0	0	0	0						
			07. WORK AND ACTIVITIES	2	2	1	0	1	1	1	1	1	1	1	1						
			08. RETARDATION	2	2	3	0	2	2	2	2	2	2	2	2						
			09. AGITATION	1	1	1	0	1	0	0	0	0	0	0	0						
			10. ANXIETY PSYCHIC	2	2	2	1	2	1	1	1	1	1	1	1						
			11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2						
			12. SOMATIC GASTROINTESTINAL	2	2	2	1	1	1	1	1	1	1	1	1						

1389

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

119

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63						
44	3MD	Inigramine	Female	17.INSIGHT	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
				18.DIURNAL VARIATION	1	1	1	1	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				20.PARANOID	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
				22.Total score	22	22	12	11	11	6	6	6	6	13	6	6	13	6	6	6	6	6	6	8	8	8				
44	4MD	Inigramine	Male	01.DEPRESSED MOOD	3	3	3	3	0	0	0	0	0	2	3	3	3	2	3	2	3	2	2	2	2					
				02.GUILT	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0		
				03.SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	0	0	0	0	0	0	0	0	0	0	
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				05.INSOMNIA MIDDLE	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				06.INSOMNIA LATE	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				07.WORK AND ACTIVITIES	3	3	3	3	2	2	2	2	1	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
				08.RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				09.AGITATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				10.ANKIETY PSYCHIC	1	1	1	1	1	1	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				11.ANKIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				13.SOMATIC GENERAL	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				14.CENTRAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				16.LOSS OF WEIGHT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
				17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
				22.Total score	18	19	18	18	11	11	10	10	11	11	18	19	11	11	11	11	11	11	11	13	13	13				
45	1MD	Reboxetine	Male	01.DEPRESSED MOOD	3	3	3	3	1	1	2	2	3	3	3	3	3	3	3	3	3	3	3	3	3					
				02.GUILT	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				03.SUICIDE	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
				08.RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				09.AGITATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				10.ANKIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
				11.ANKIETY SOMATIC	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				14.CENTRAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				16.LOSS OF WEIGHT	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				17.INSIGHT	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				18.DIURNAL VARIATION	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				20.PARANOID	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

1391

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

120

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day
45	1MD	Reboxetine	Male	21	25	24	0	0	0	0	0	0	0	0	0
				22.Total score											
10Y		Imipramine	Female	3	3	3	3	3	3	3	3	1	1	1	0
				01.DEPRESSED MOOD											
				02.GUILT	2	2	1	1	1	1	1	1	1	1	0
				03.SUICIDE	1	0	0	0	1	1	1	0	0	0	0
				04.INSOMNIA EARLY	2	2	1	2	1	1	0	1	1	1	1
				05.INSOMNIA MIDDLE	1	0	1	1	1	0	0	1	1	1	1
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	2	3	3	2	2	2	2	1	1	1	0
				08.RETARDATION	1	0	0	0	1	0	0	0	0	0	0
				09.AGITATION	1	2	2	2	2	1	1	1	1	1	0
				10.ANKIETY PSYCHIC	3	1	2	2	1	1	1	1	1	1	0
				11.ANKIETY SOMATIC	1	2	2	2	1	1	1	1	1	1	0
				12.SOMATIC GASTROINTESTINAL	0	0	0	1	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	0
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	0	0	0	0	0	0
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	1	1	1	1	0
				18.DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0
				22.Total score	22	22	22	22	22	19	17	15	12	12	5
2ND		Imipramine	Male	3	3	3	3	3	3	3	3	3	3	3	3
				01.DEPRESSED MOOD											
				02.GUILT	0	2	2	2	2	2	2	2	2	2	1
				03.SUICIDE	2	2	2	2	2	2	2	2	2	2	2
				04.INSOMNIA EARLY	0	2	2	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2
				06.INSOMNIA LATE	0	2	2	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2
				08.RETARDATION	0	0	1	1	1	1	1	1	1	1	1
				09.AGITATION	0	1	1	1	1	1	1	1	1	1	1
				10.ANKIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	3
				11.ANKIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0	0	0	0
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0
				16.LOSS OF WEIGHT	2	2	2	2	2	2	2	2	2	2	2
				17.INSIGHT	0	1	1	1	1	1	1	1	1	1	1
				18.DIURNAL VARIATION	0	2	2	2	2	2	2	2	2	2	2
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0
				20.PARANOID	1	0	0	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0
				22.Total score	19	27	27	27	27	27	27	27	27	27	24

1392

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

121

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	7	14	21	28	35	42	49	56	Day 63			
46	1ND	Imipramine	Male	01. DEPRESSED MOOD	3	3	1	1	1	1	0	0	0	0	0			
				02. GUILT	2	2	1	1	1	0	0	0	0	0	0	0		
				03. SUICIDE	1	0	0	0	0	0	0	0	0	0	0	0	0	0
				04. INSOMNIA EARLY	2	2	1	1	0	0	0	0	0	0	0	0	0	0
				05. INSOMNIA MIDDLE	1	2	1	1	0	0	1	0	0	0	0	0	0	0
				06. INSOMNIA LATE	2	2	0	1	1	0	0	0	0	0	0	0	0	0
				07. WORK AND ACTIVITIES	1	2	1	0	1	0	0	0	0	0	0	0	0	0
				08. RETARDATION	0	2	1	0	0	0	0	0	0	0	0	0	0	0
				09. AGITATION	2	1	0	0	1	1	0	0	0	0	0	0	0	0
				10. ANXIETY PSYCHIC	2	2	1	1	1	1	0	0	0	0	0	0	0	0
				11. ANXIETY SOMATIC	2	1	1	1	0	1	0	0	0	0	0	0	0	0
				12. SOMATIC GASTROINTESTINAL	1	1	0	0	0	1	0	0	0	0	0	0	0	0
				13. SOMATIC GENERAL	1	1	1	1	0	1	0	0	0	0	0	0	0	0
				14. GENITAL SYMPTOMS	2	2	1	2	1	1	1	1	1	1	1	1	1	1
				15. HYPOCHONDRIASIS	1	0	0	0	1	0	1	0	0	0	0	0	0	0
				16. LOSS OF WEIGHT	2	0	0	0	1	0	1	0	0	0	0	0	0	0
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	1	1	0	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score				26	24	11	11	7	7	11	1	1	1	1
2ND	Imipramine	Female	01. DEPRESSED MOOD	3	2	2	2	2	1	1	0	0	0	0	0			
			02. GUILT	2	2	2	2	1	1	1	1	1	1	1	1	1		
			03. SUICIDE	1	1	0	0	0	0	0	0	0	0	0	0	0	0	
			04. INSOMNIA EARLY	2	2	1	2	1	2	1	2	1	2	1	2	1	2	
			05. INSOMNIA MIDDLE	1	2	0	2	0	2	0	2	0	2	0	2	0	2	
			06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
			07. WORK AND ACTIVITIES	3	3	3	3	3	2	2	2	2	2	2	2	2	2	
			08. RETARDATION	1	2	2	2	2	2	2	2	2	2	2	2	2	2	
			09. AGITATION	3	2	1	1	1	1	1	1	1	1	1	1	1	1	
			10. ANXIETY PSYCHIC	3	2	1	1	1	1	1	1	1	1	1	1	1	1	
			11. ANXIETY SOMATIC	2	1	2	1	2	0	1	0	0	0	0	0	0	0	
			12. SOMATIC GASTROINTESTINAL	1	2	1	2	1	1	1	1	1	1	1	1	1	1	
			13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
			14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			15. HYPOCHONDRIASIS	2	1	1	1	1	0	0	0	0	0	0	0	0	0	
			16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			18. DIURNAL VARIATION	2	2	0	1	0	1	0	0	0	0	0	0	0	0	
			19. DEPERSONALIZATION	1	0	0	0	0	0	0	0	0	0	0	0	0	0	
			20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			22. Total score				33	30	24	21	16	16	16	1	1	1	1	1
3ND	Reboxetine	Female	01. DEPRESSED MOOD	2	2	2	2	2	1	1	1	1	1	0	1			
			02. GUILT	2	2	2	2	1	1	2	1	1	1	0	0			
			03. SUICIDE	1	0	0	0	0	0	0	0	0	0	0	0	0		
			04. INSOMNIA EARLY	2	2	2	2	2	2	2	1	0	0	1	2	0		

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

123

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen	Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63
48	10T	Reboxetine	Female				2	1	2																
				09. ACITATION			1	1	2																
				10. ANXIETY PSYCHIC			1	1	2																
				11. ANXIETY SOMATIC			1	1	2																
				12. SOMATIC GASTROINTESTINAL			2	1	1																
				13. SOMATIC GENERAL			2	2	2																
				14. GENITAL SYMPTOMS			0	0	0																
				15. HYPOCHONDRIASIS			2	2	3																
				16. LOSS OF WEIGHT			2	2	2																
				17. INSIGHT			0	0	0																
				18. DIURNAL VARIATION			1	1	1																
				19. DEPERSONALIZATION			2	2	2																
				20. PARANOID			0	0	0																
				21. OBSESSIONAL/COMPULSIVE			0	0	0																
				22. Total score			29	27	30																
20T		Imipramine	Female				3	3	2				2	2	1	1	1	1	1	1					
				01. DEPRESSED MOOD			3	3	2				2	2	1	1	1	1	1	1	1				
				02. GUILT			2	1	1				1	1	1	1	1	1	1	1	1				
				03. SUICIDE			1	1	1				0	0	0	0	0	0	0	0	0				
				04. INSOMNIA EARLY			2	2	2				2	2	2	2	2	2	2	2	2				
				05. INSOMNIA MIDDLE			2	2	2				2	2	2	2	2	2	2	2	2				
				06. INSOMNIA LATE			2	1	2				2	2	1	1	1	1	1	1	1				
				07. WORK AND ACTIVITIES			3	3	3				2	2	2	2	2	2	2	2	2				
				08. RETARDATION			1	1	1				1	1	1	1	1	1	1	1	1				
				09. ACITATION			2	1	0				1	1	1	1	1	1	1	1	1				
				10. ANXIETY PSYCHIC			1	2	2				1	1	1	1	1	1	1	1	1				
				11. ANXIETY SOMATIC			2	2	2				2	2	2	2	2	2	2	2	2				
				12. SOMATIC GASTROINTESTINAL			1	1	1				1	1	1	1	1	1	1	1	1				
				13. SOMATIC GENERAL			0	1	1				1	1	1	1	1	1	1	1	1				
				14. GENITAL SYMPTOMS			0	0	0				0	0	0	0	0	0	0	0	0				
				15. HYPOCHONDRIASIS			1	2	2				2	2	2	2	2	2	2	2	2				
				16. LOSS OF WEIGHT			2	2	1				1	1	1	1	1	1	1	1	1				
				17. INSIGHT			1	1	1				1	1	1	1	1	1	1	1	1				
				18. DIURNAL VARIATION			1	1	1				1	1	1	1	1	1	1	1	1				
				19. DEPERSONALIZATION			0	0	1				0	0	0	0	0	0	0	0	0				
				20. PARANOID			0	0	0				0	0	0	0	0	0	0	0	0				
				21. OBSESSIONAL/COMPULSIVE			0	0	0				0	0	0	0	0	0	0	0	0				
				22. Total score			27	28	27				23	21	16	14	14	16	16	16	16				
291	10D	Imipramine	Female				4	4	2				2	2	2	2	2	2	2	2					
				01. DEPRESSED MOOD			4	4	2				2	2	2	2	2	2	2	2	2				
				02. GUILT			3	3	2				2	2	2	2	2	2	2	2	2				
				03. SUICIDE			2	2	1				1	1	1	1	1	1	1	1	1				
				04. INSOMNIA EARLY			2	2	2				2	2	2	2	2	2	2	2	2				
				05. INSOMNIA MIDDLE			1	1	1				1	1	1	1	1	1	1	1	1				
				06. INSOMNIA LATE			2	2	2				2	2	2	2	2	2	2	2	2				
				07. WORK AND ACTIVITIES			3	3	3				3	3	3	3	3	3	3	3	3				
				08. RETARDATION			1	1	1				1	1	1	1	1	1	1	1	1				
				09. ACITATION			3	3	2				2	2	2	2	2	2	2	2	2				
				10. ANXIETY PSYCHIC			3	3	2				2	2	2	2	2	2	2	2	2				
				11. ANXIETY SOMATIC			3	3	3				3	3	3	3	3	3	3	3	3				
				12. SOMATIC GASTROINTESTINAL			1	1	1				1	1	1	1	1	1	1	1	1				

9550089

124

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACTA CNS R&D
REBOXETINE - PROTOCOL 2012A/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63				
291	1ND	Imipramine	Female	13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1				
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0			
				15.HYPOCHONDRIASIS	3	3	2	2	2	2	2	2	2	2	2	2	2	2	
				16.LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				22.Total score	34	34	27	27	25	25	24	24	24	24	24	24	24	24	
				1DT	Reboxetine	Female	01.DEPRESSED MOOD	3	3	2	2	2	2	2	2	2	2	2	2
							02.GUILT	2	2	2	2	2	2	2	2	2	2	2	2
							03.SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2
							04.INSOMNIA EARLY	0	0	1	0	0	0	0	0	0	0	0	0
							05.INSOMNIA MIDDLE	0	0	1	0	0	0	0	0	0	0	0	0
							06.INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0
							07.WORK AND ACTIVITIES	2	3	3	3	2	2	2	2	2	2	2	2
							08.RETARDATION	2	2	1	1	1	1	1	1	1	1	1	1
							09.AGITATION	0	0	0	0	0	0	0	0	0	0	0	0
							10.ANXIETY PSYCHIC	3	3	2	2	2	2	2	2	2	2	2	2
							11.ANXIETY SOMATIC	1	1	0	0	0	0	0	0	0	0	0	0
							12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1
13.SOMATIC GENERAL	2	2	2				2	2	2	2	2	2	2	2	2				
14.GENITAL SYMPTOMS	1	1	0				0	0	0	0	0	0	0	0	0				
15.HYPOCHONDRIASIS	3	3	2				2	2	2	2	2	2	2	2	2				
16.LOSS OF WEIGHT	0	0	0				0	0	0	0	0	0	0	0	0				
17.INSIGHT	1	1	1				1	1	1	1	1	1	1	1	1				
18.DIURNAL VARIATION	0	0	0				0	0	0	0	0	0	0	0	0				
19.DEPERSONALIZATION	0	0	0				0	0	0	0	0	0	0	0	0				
20.PARANOID	0	0	0				0	0	0	0	0	0	0	0	0				
21.OBSESSIONAL/COMPULSIVE	0	0	0				0	0	0	0	0	0	0	0	0				
22.Total score	24	24	20				18	17	14	13	12	12	12	12	12				
2HD	Reboxetine	Female	01.DEPRESSED MOOD	4	4	3	3	3	3	4	4	4	4	4					
			02.GUILT	2	2	2	2	2	2	2	2	2	2	2					
			03.SUICIDE	2	2	2	2	2	2	2	2	2	2	2					
			04.INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2					
			05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2					
			06.INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2					
			07.WORK AND ACTIVITIES	1	1	1	1	1	1	1	1	1	1	1					
			08.RETARDATION	3	3	3	3	3	3	3	3	3	3	3					
			09.AGITATION	2	2	2	2	2	2	2	2	2	2	2					
			10.ANXIETY PSYCHIC	0	0	0	0	0	0	0	0	0	0	0					
			11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2					
			12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2					
			13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1					
			14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1					
			15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1					
			16.LOSS OF WEIGHT	2	2	2	2	2	2	2	2	2	2	2					

1396

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

125

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63				
291	2ND	Reboxetine	Female	17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	30	30	27	27	27	27	27	27	27	31	31	31	31	31	31	31	31	31	31	31	31	31		
20T	Reboxetine	Female	01. DEPRESSED MOOD	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4			
			02. GUILT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
			03. SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
			04. INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			05. INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			06. INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
			08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
			09. AGITATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			10. ANXIETY PSYCHIC	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
			11. ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			12. SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
			14. CENTRAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			15. HYPOCHONDRIASIS	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
			16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
							22. Total score	25	25	28	28	28	28	28	28	28	23	22	21	19	19	19	19	19	19	19	19	19
3ND	Imipramine	Male	01. DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3			
			02. GUILT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
			03. SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
			04. INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
			05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
			06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
			07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
			08. RETARDATION	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
			09. AGITATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			10. ANXIETY PSYCHIC	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
			11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
			12. SOMATIC GASTROINTESTINAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
			14. CENTRAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			15. HYPOCHONDRIASIS	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
			16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
			18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		

1397

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

126

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63			
291	3WD	Imipramine	Male	21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			Female	22.Total score	26	26	12	10	8	8	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	
3DT	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
			02.GUILT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
			03.SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			04.INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			06.INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			07.WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
			08.RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			09.AGIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			10.ANKIETY PSYCHIC	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
			11.ANKIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			14.GEMITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			15.HYPOCHONDRIASIS	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
			16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			17.INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			18.DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			22.Total score	26	26	26	26	26	12	10	8	8	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
4WD	Reboxetine	Male	01.DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
			02.GUILT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
			03.SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
			04.INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
			06.INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
			07.WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
			08.RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			09.AGIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			10.ANKIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			11.ANKIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			14.GEMITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
			16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			18.DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			22.Total score	24	24	24	24	24	12	10	8	8	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4

1398

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

127

PEARNACTA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day			
291	4DT	Imipramine	Male	HAMILTON DEPRESSION RATING SCALE														
				01. DEPRESSED MOOD	4	4	3	2	2	2	2	2	2	2	2	2	2	
				02. GUILT	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				03. SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				04. INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				05. INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				06. INSOMNIA LATE	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				07. WORK AND ACTIVITIES	4	4	4	4	4	4	4	4	4	4	4	4	4	4
				08. RETARDATION	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				09. AGITATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				10. ANXIETY PSYCHIC	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				11. ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				15. HYPOCHONDRIASIS	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				16. LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOIA	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0
22. Total score	26	26	25	23	23	23	23	23	23	23	23	23	23	23	23			
25DT	Imipramine	Female	HAMILTON DEPRESSION RATING SCALE															
			01. DEPRESSED MOOD	5	3	2	2	2	2	2	2	2	2	2	2	2		
			02. GUILT	2	2	2	2	2	2	2	2	2	2	2	2	2		
			03. SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2	2		
			04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2		
			05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2		
			06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1		
			07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3		
			08. RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1		
			09. AGITATION	1	1	1	1	1	1	1	1	1	1	1	1	1		
			10. ANXIETY PSYCHIC	3	3	3	3	3	3	3	3	3	3	3	3	3		
			11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2		
			12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2		
			13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2		
14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0					
15. HYPOCHONDRIASIS	3	3	3	3	3	3	3	3	3	3	3	3	3					
16. LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1					
17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1					
18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1					
19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0					
20. PARANOIA	0	0	0	0	0	0	0	0	0	0	0	0	0					
21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0					
22. Total score	32	32	29	29	29	29	29	29	29	29	29	29	29	29				
26DT	Reboxetine	Female	HAMILTON DEPRESSION RATING SCALE															
			01. DEPRESSED MOOD	3	3	3	2	2	2	2	2	2	2	2	2			
			02. GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0		
			03. SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2	2		
04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2					

1399

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

128

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
291	26DT	Reboxetine	Female		2	2	2	2	2	2	2	2	2	2	2
				05. INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0
				06. INSOMNIA LATE	3	3	3	3	3	3	3	3	3	3	3
				07. WORK AND ACTIVITIES	0	0	0	0	0	0	0	0	0	0	0
				08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0
				09. AGITATION	2	2	2	2	2	2	2	2	2	2	2
				10. ANXIETY PSYCHIC	1	1	1	1	1	1	1	1	1	1	1
				11. ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1
				13. SOMATIC GENERAL	0	0	0	0	0	0	0	0	0	0	0
				14. GENITAL SYMPTOMS	3	3	3	3	3	3	3	3	3	3	3
				15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2
				16. LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	24	24	22	20	15	15	15	17	17	17	17
				01. DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3
				02. GUILT	2	2	2	2	2	2	2	2	2	2	2
				03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1
				04. INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1
				05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2
				06. INSOMNIA LATE	3	3	3	3	3	3	3	3	3	3	3
				07. WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2
				08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0
				09. AGITATION	2	2	2	2	2	2	2	2	2	2	2
				10. ANXIETY PSYCHIC	1	1	1	1	1	1	1	1	1	1	1
				11. ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1
				13. SOMATIC GENERAL	0	0	0	0	0	0	0	0	0	0	0
				14. GENITAL SYMPTOMS	3	3	3	3	3	3	3	3	3	3	3
				15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0
				16. LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	26	26	26	24	21	23	20	19	17	17	17
27DT	27DT	Reboxetine	Female		4	4	3	3	2	2	2	2	2	2	2
				01. DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3
				02. GUILT	2	2	2	2	2	2	2	2	2	2	2
				03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1
				04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2
				05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2
				06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2
				07. WORK AND ACTIVITIES	1	1	1	1	1	1	1	1	1	1	1
				08. RETARDATION	0	0	0	0	0	0	0	0	0	0	0
				09. AGITATION	1	1	1	1	1	1	1	1	1	1	1
				10. ANXIETY PSYCHIC	1	1	1	1	1	1	1	1	1	1	1
				11. ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1
				13. SOMATIC GENERAL	0	0	0	0	0	0	0	0	0	0	0
				14. GENITAL SYMPTOMS	3	3	3	3	3	3	3	3	3	3	3
				15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0
				16. LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	26	26	26	24	21	23	20	19	17	17	17
28DT	28DT	Imipramine	Female		4	4	3	3	2	2	2	2	2	2	2
				01. DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3
				02. GUILT	2	2	2	2	2	2	2	2	2	2	2
				03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1
				04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2
				05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2
				06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2
				07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3
				08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2

1400

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

129

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day					
291	28DT	Imipramine	Female	09. AGITATION	0	0	0	0	0	0	0	0	0	0	0					
				10. ANXIETY PSYCHIC	3	3	3	2	1	1	1	1	1	1	1	1				
				11. ANXIETY SOMATIC	2	2	2	2	1	1	1	1	1	1	1	1	1			
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1			
				13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1			
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0			
				15. HYPOCHONDRIASIS	3	3	3	3	2	2	2	2	2	2	2	2	2			
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0			
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1			
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0			
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0			
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0			
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0			
				22. Total score	31	31	27	20	17	16	16	16	16	16	16	16	16	16		
				292	5ND	Imipramine	Female	01. DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2	2	
								02. GUILT	1	1	1	1	1	1	1	1	1	1	1	1
								03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0
								04. INSOMNIA EARLY	2	1	1	1	1	1	1	1	1	1	1	1
								05. INSOMNIA MIDDLE	1	2	1	1	1	1	1	1	1	1	1	1
								06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1
								07. WAKE AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2	2
								08. RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1
09. AGITATION	2	1	1					1	1	1	1	1	1	1	1	1				
10. ANXIETY PSYCHIC	3	3	2					2	2	2	2	2	2	2	2	2				
11. ANXIETY SOMATIC	2	2	2					2	2	2	2	2	2	2	2	2				
12. SOMATIC GASTROINTESTINAL	1	1	1					1	1	1	1	1	1	1	1	1				
13. SOMATIC GENERAL	1	1	1					1	1	1	1	1	1	1	1	1				
14. GENITAL SYMPTOMS	0	0	0					0	0	0	0	0	0	0	0	0				
15. HYPOCHONDRIASIS	2	2	2					2	2	2	2	2	2	2	2	2				
16. LOSS OF WEIGHT	0	0	0					0	0	0	0	0	0	0	0	0				
17. INSIGHT	0	0	0					0	0	0	0	0	0	0	0	0				
18. DIURNAL VARIATION	2	2	2					2	2	2	2	2	2	2	2	2				
19. DEPERSONALIZATION	0	0	0					0	0	0	0	0	0	0	0	0				
20. PARANOID	0	0	0					0	0	0	0	0	0	0	0	0				
21. OBSESSIONAL/COMPULSIVE	0	0	0					0	0	0	0	0	0	0	0	0				
22. Total score	23	23	22					20	22	18	15	14	15	13	13	13	13			
5DT	Reboxetine	Male	01. DEPRESSED MOOD	3	3	2	2	2	2	2	2	2	2	2	2					
			02. GUILT	2	2	2	2	2	2	2	2	2	2	2						
			03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0						
			04. INSOMNIA EARLY	1	2	2	2	2	2	2	2	2	2	2						
			05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2						
			06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2						
			07. WAKE AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2						
			08. RETARDATION	1	1	2	2	2	2	2	2	2	2	2						
			09. AGITATION	2	2	2	2	2	2	2	2	2	2	2						
			10. ANXIETY PSYCHIC	3	3	2	2	2	2	2	2	2	2	2						
			11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2						
			12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1						

1401

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

130

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63							
292	SDT	Reboxetine	Male	13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2						
				14. GENTAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
				15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				16. LOSS OF WEIGHT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				22. Total score	29	28	25	25	24	20	19	18	15	13	12	13	13	15	13	13	12	13	12	13	12	13	13	13			
				6HD	Reboxetine	Female	01. DEPRESSED MOOD	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
							02. GUILT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
							03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
							04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
							05. INSOMNIA MIDDLE	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
							06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
							07. WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
							08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
							09. AGITATION	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1
							10. ANXIETY PSYCHIC	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
							11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
							12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
13. SOMATIC GENERAL	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
14. GENTAL SYMPTOMS	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
15. HYPOCHONDRIASIS	1	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
16. LOSS OF WEIGHT	1	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
17. INSIGHT	1	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
18. DIURNAL VARIATION	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
19. DEPERSONALIZATION	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
20. PARANOID	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
21. OBSESSIONAL/COMPULSIVE	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
22. Total score	26	26	25				22	19	15	13	13	12	13	12	13	12	13	12	13	12	13	12	13	12	13	13	13				
6DT	Imipramine	Female	01. DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2						
			02. GUILT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
			03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
			04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
			05. INSOMNIA MIDDLE	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
			06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
			07. WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
			08. RETARDATION	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
			09. AGITATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
			10. ANXIETY PSYCHIC	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
			11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
			12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
			13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
			14. GENTAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
			15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
			16. LOSS OF WEIGHT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					

1402

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

131

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63							
292	6DT	Imipramine	Female	17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0						
				18. DIURNAL VARIATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				22. Total score	27	28	28	26	24	19	19	19	16	16	14																
				7ND	Reboxetine	Male	01. DEPRESSED MOOD	3	3	3	3	3	3	3	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1		
							02. GUILT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
							03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
							04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
05. INSOMNIA MIDDLE	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
06. INSOMNIA LATE	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
07. WORK AND ACTIVITIES	3	3	3				3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3			
08. RETARDATION	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
09. AGITATION	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
10. ANXIETY PSYCHIC	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
11. ANXIETY SOMATIC	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
12. SOMATIC GASTROINTESTINAL	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
13. SOMATIC GENERAL	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
14. GENITAL SYMPTOMS	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
15. HYPOCHONDRIASIS	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
16. LOSS OF WEIGHT	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
17. INSIGHT	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
18. DIURNAL VARIATION	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
19. DEPERSONALIZATION	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
20. PARANOID	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
21. OBSESSIONAL/COMPULSIVE	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
22. Total score	29	29	29				27	22	18	17	17	15	14																		
7DT	Imipramine	Male	01. DEPRESSED MOOD	3	3	3	3	3	3	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1						
			02. GUILT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
			03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
			04. INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
			05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
			06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
			07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3				
			08. RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
			09. AGITATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
			10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2							
12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1							
13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2							
14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0							
15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2							
16. LOSS OF WEIGHT	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0							
17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0							
18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1							
19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0							
20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0							

1403

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

132

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day		
292	70T	Imipramine	Male	21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0		
				22. Total score	26	27	21	17	14	16	17	15	13				
8ND		Imipramine	Male	01. DEPRESSED MOOD	2	3	3	2	2	2	2	1	1	1	1		
				02. GUILT	2	1	1	1	1	1	1	1	1	1	1	1	
				03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1	1
				04. INSOMNIA EARLY	2	2	2	2	2	1	1	1	1	1	1	1	1
				05. INSOMNIA MIDDLE	2	1	1	2	1	1	1	1	1	1	1	1	1
				06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2
				07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3
				08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2
				09. AGITATION	1	2	2	2	2	2	2	2	2	2	2	2	2
				10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2
				11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2
				12. SOMATIC GASTROINTESTINAL	2	1	2	2	1	1	1	1	1	1	1	1	1
				13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2
				14. GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2	2	2
				15. HYPOCHONDRIASIS	0	1	1	1	1	1	1	1	1	1	1	1	1
				16. LOSS OF WEIGHT	1	2	2	2	2	2	2	2	2	2	2	2	2
				17. INSIGHT	2	2	2	2	2	2	2	2	2	2	2	2	2
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1
				20. PARANOIA	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	29	30	30	29	26	24	21	17	15	13			
8DT		Reboxetine	Female	01. DEPRESSED MOOD	3	3	3	2	2	1	1	1	1	1			
				02. GUILT	3	3	2	1	1	1	1	1	1	1	1		
				03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1	
				04. INSOMNIA EARLY	2	2	2	2	1	1	1	1	1	1	1	1	
				05. INSOMNIA MIDDLE	2	1	1	1	2	1	1	1	1	1	1	1	
				06. INSOMNIA LATE	2	2	2	2	1	1	1	1	1	1	1	1	
				07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	
				08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	
				09. AGITATION	2	2	2	2	2	2	2	2	2	2	2	2	
				10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	
				11. ANXIETY SOMATIC	3	2	2	2	2	2	2	2	2	2	2	2	
				12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	
				13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	
				14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1	
				15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	
				16. LOSS OF WEIGHT	1	0	0	0	0	0	0	0	0	0	0	0	
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	
				20. PARANOIA	0	0	0	0	0	0	0	0	0	0	0	0	
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	
				22. Total score	34	31	29	23	24	19	18	16	16	14			

1404

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

133

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
292	21ND	Imipramine	Female	3	3	2	2	1	1	1	1	1	1
			01. DEPRESSED MOOD	2	2	2	2	1	1	1	1	1	1
			02. GUILT	1	1	0	0	0	0	0	0	0	0
			03. SUICIDE	2	2	1	1	1	1	1	1	1	1
			04. INSOMNIA EARLY	2	2	1	1	1	1	1	1	1	1
			05. INSOMNIA MIDDLE	2	2	1	1	1	1	1	1	1	1
			06. INSOMNIA LATE	2	2	2	2	1	1	1	1	1	1
			07. WORK AND ACTIVITIES	3	3	3	3	2	2	2	2	2	2
			08. RETARDATION	2	2	2	2	1	1	1	1	1	1
			09. AGITATION	2	2	2	2	1	1	1	1	1	1
			10. ANXIETY PSYCHIC	2	2	2	2	1	1	1	1	1	1
			11. ANXIETY SOMATIC	3	3	2	2	1	1	1	1	1	1
			12. SOMATIC GASTROINTESTINAL	2	2	2	2	1	1	1	1	1	1
			13. SOMATIC GENERAL	2	2	2	2	1	1	1	1	1	1
			14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1
			15. HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1
			16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0
			17. INSIGHT	0	0	0	0	0	0	0	0	0	0
			18. DIURNAL VARIATION	2	2	1	1	1	1	1	1	1	1
			19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0
			20. PARANOID	0	0	0	0	0	0	0	0	0	0
			21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0
			22. Total score	30	32	30	24	19	16	14	10	10	10
21DT	Reboxetine	Female	01. DEPRESSED MOOD	3	3	3	2	2	1	1	1	1	0
			02. GUILT	2	2	1	1	1	1	0	0	0	0
			03. SUICIDE	1	1	0	0	0	0	0	0	0	0
			04. INSOMNIA EARLY	2	2	2	2	1	1	1	1	1	1
			05. INSOMNIA MIDDLE	2	2	1	1	1	1	1	1	1	1
			06. INSOMNIA LATE	2	2	1	2	1	1	1	1	1	1
			07. WORK AND ACTIVITIES	3	3	3	3	2	2	2	2	2	2
			08. RETARDATION	2	2	2	2	1	1	1	1	1	1
			09. AGITATION	0	1	1	1	1	1	0	0	0	0
			10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	1	1	1
			11. ANXIETY SOMATIC	2	2	2	2	2	2	2	1	1	1
			12. SOMATIC GASTROINTESTINAL	1	1	2	2	1	1	1	1	1	1
			13. SOMATIC GENERAL	2	2	2	2	1	1	1	1	1	1
			14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1
			15. HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1
			16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0
			17. INSIGHT	0	0	0	0	0	0	0	0	0	0
			18. DIURNAL VARIATION	2	2	1	1	1	1	1	1	1	1
			19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0
			20. PARANOID	0	0	0	0	0	0	0	0	0	0
			21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0
			22. Total score	28	29	24	21	17	16	12	11	8	8
22ND	Imipramine	Female	01. DEPRESSED MOOD	2	3	3	3	2	2	2	2	2	2
			02. GUILT	2	2	2	2	2	2	2	1	1	1
			03. SUICIDE	0	0	0	0	0	0	0	0	0	0
			04. INSOMNIA EARLY	2	2	2	2	1	1	1	1	1	1

1405

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

134

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/095
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63				
292	22HD	Imipramine	Female	Hamilton depression rating scale	2	2	2	1	1	1	1	1	1	1				
				05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2			
				06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2		
				07. WORK AND ACTIVITIES	4	4	3	3	3	3	3	3	3	3	3	3		
				08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2		
				09. ABILITY	0	1	2	2	1	1	1	1	1	1	1	2		
				10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2		
				11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2		
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1		
				13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1		
				14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1		
				15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0		
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0		
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1		
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1		
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0		
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0		
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0		
				22.Total score	26	29	28	26	25	24	24	23	22	22	24	21	21	
				22DT	Imipramine	Female	Hamilton depression rating scale	2	3	3	3	3	2	2	2	2	2	
							01. DEPRESSED MOOD	1	1	1	1	1	1	1	1	1	1	1
							02. GUILT	1	1	1	1	1	1	1	1	1	1	1
03. SUICIDE	2	2	2				2	2	2	2	2	2	2	2				
04. INSOMNIA EARLY	2	2	2				2	2	2	2	2	2	2	2				
05. INSOMNIA MIDDLE	2	2	2				2	2	2	2	2	2	2	2				
06. INSOMNIA LATE	2	2	2				2	2	2	2	2	2	2	2				
07. WORK AND ACTIVITIES	3	3	3				3	3	3	3	3	3	3	3				
08. RETARDATION	2	2	2				2	2	2	2	2	2	2	2				
09. ABILITY	2	2	2				2	2	2	2	2	2	2	2				
10. ANXIETY PSYCHIC	1	1	1				1	1	1	1	1	1	1	1				
11. ANXIETY SOMATIC	2	2	2				2	2	2	2	2	2	2	2				
12. SOMATIC GASTROINTESTINAL	1	1	1				1	1	1	1	1	1	1	1				
13. SOMATIC GENERAL	2	2	2				2	2	2	2	2	2	2	2				
14. GENITAL SYMPTOMS	0	0	0				0	0	0	0	0	0	0	0				
15. HYPOCHONDRIASIS	0	0	0				0	0	0	0	0	0	0	0				
16. LOSS OF WEIGHT	0	0	0				0	0	0	0	0	0	0	0				
17. INSIGHT	0	1	0				0	0	0	0	0	0	0	0				
18. DIURNAL VARIATION	2	2	2				2	2	2	2	2	2	2	2				
19. DEPERSONALIZATION	0	0	0				0	0	0	0	0	0	0	0				
20. PARANOID	0	0	0				0	0	0	0	0	0	0	0				
21. OBSESSIONAL/COMPULSIVE	0	0	0				0	0	0	0	0	0	0	0				
22.Total score	25	29	28	27	27	24	21	19	19	21	21	21						
23HD	Reboxetine	Female	Hamilton depression rating scale	2	2	2	2	2	1	1	1	1	1					
			01. DEPRESSED MOOD	1	1	1	1	1	1	1	1	1	1					
			02. GUILT	0	0	0	0	0	0	0	0	0	0					
			03. SUICIDE	2	2	2	2	2	2	2	2	2	2					
			04. INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1					
			05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2						
			06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2						
			07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3						
08. RETARDATION	2	2	2	2	2	2	2	2	2									

1406

9550089

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

135

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63									
292	23ND	Reboxetine	Female	09. AGITATION	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0								
				10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
				11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
				13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
				14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
				15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				22. Total score	27	27	27	26	23	21	15	14	13	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12			
				23DT	Reboxetine	Male	01. DEPRESSED MOOD	3	3	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1			
							02. GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
							03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
							04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
							05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
							06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
							07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
							08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
09. AGITATION	1	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
10. ANXIETY PSYCHIC	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
11. ANXIETY SOMATIC	1	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
12. SOMATIC GASTROINTESTINAL	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
13. SOMATIC GENERAL	1	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
14. GENITAL SYMPTOMS	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
15. HYPOCHONDRIASIS	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
16. LOSS OF WEIGHT	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
17. INSIGHT	1	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
18. DIURNAL VARIATION	1	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
19. DEPERSONALIZATION	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
20. PARANOID	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
21. OBSESSIONAL/COMPULSIVE	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
22. Total score	26	26	26				27	23	18	15	13	11	10	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9				
24ND	Reboxetine	Male	01. DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2							
			02. GUILT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1						
			03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
			04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
			05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
			06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
			07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3					
			08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
			09. AGITATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
			10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
			11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
			12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					

1407

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

136

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day
292	24MD	Reboxetine	Male		1	1	2	2	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	2	2	2	2	2	2	2
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0
				22.Total score	30	29	29	27	20	18	13	11	10	11	11
240T		Imipramine	Female		2	2	2	2	3	2	2	2	2	2	2
				01.DEPRESSED MOOD	2	2	2	2	3	2	2	2	2	2	2
				02.GUILT	1	1	1	1	1	1	1	1	1	1	1
				03.SUICIDE	1	1	1	1	1	1	1	1	1	1	1
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3
				08.RETARDATION	2	2	2	2	2	2	2	2	2	2	2
				09.AGITATION	1	1	1	1	1	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1
				15.HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0
				22.Total score	27	28	26	24	26	24	24	20	18	18	18
293	9MD	Imipramine	Female		3	3	3	3	3	2	2	2	2	2	2
				01.DEPRESSED MOOD	3	3	3	3	3	2	2	2	2	2	2
				02.GUILT	1	1	1	1	1	1	1	1	1	1	1
				03.SUICIDE	0	0	0	0	0	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3
				08.RETARDATION	2	2	2	2	2	2	2	2	2	2	2
				09.AGITATION	1	1	1	1	1	1	1	1	1	1	1
				10.ANXIETY PSYCHIC	1	1	1	1	1	1	1	1	1	1	1
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1
				16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0

1408

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

137

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63		
293	9ND	Imipramine	Female		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				22. Total score	22	22	22	21	21	18	18	18	18	17	15	12										
9DT	Imipramine	Female			2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
				01. DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
				02. GUILT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
				03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				04. INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				07. WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
				08. RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				09. AGITATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				10. ANXIETY PSYCHIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				11. ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				15. HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				16. LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				17. INSIGHT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				24. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				22. Total score	20	20	20	21	20	18	16	14	12	10	10											
10ND	Reboxetine	Female			3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
				01. DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
				02. GUILT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
				03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
				05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
				07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
				08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
				09. AGITATION	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
				10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
				11. ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				15. HYPOCHONDRIASIS	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

1409

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

140

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63	
293	12DT	Reboxetine	Female	05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				07. WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				08. RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				09. AGITATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				16. LOSS OF WEIGHT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				19. DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	24	24	24	23	23	23	21	19	16	14	14	14	14	14	14	14	14	14	14	14	14
294	13ND	Imipramine	Female	01. DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				02. GUILT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				15. HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				20. PARANOID	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				21. OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				22. Total score	32	32	30	26	26	21	11	9	7	7	7	7	7	7	7	7	7	7	7	7	7
13DT		Reboxetine	Female	01. DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				02. GUILT	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				03. SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				04. INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2

1412

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

141

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day
294	13DT	Female	09. AGITATION	2	2	2	2	2	2	2	2	2	2	2
			10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2
			11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2
			12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2
			13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2
			14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1
			15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2
			16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0
			17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1
			18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0
			19. DEPERSONALIZATION	2	2	2	2	2	2	2	2	2	2	2
			20. PARANOID	1	1	1	1	1	1	1	1	1	1	1
			21. OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1
			22. Total score	35	35	35	35	35	26	35	35	35	35	35
140D	Reboxetine	Female	01. DEPRESSED MOOD	2	2	2	2	2	1	1	1	0	0	0
			02. GUILT	3	3	3	3	3	2	1	1	0	0	0
			03. SUICIDE	2	2	2	2	2	2	2	1	0	0	0
			04. INSOMNIA EARLY	1	1	1	1	1	1	1	1	1	0	0
			05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	1	1	0	0
			06. INSOMNIA LATE	2	2	2	2	2	2	2	1	1	0	0
			07. WORK AND ACTIVITIES	3	3	3	3	3	2	1	1	0	0	0
			08. RETARDATION	1	1	1	1	1	0	0	0	0	0	0
			09. AGITATION	2	2	2	2	2	1	1	1	0	0	0
			10. ANXIETY PSYCHIC	2	2	2	2	2	1	1	1	0	0	0
			11. ANXIETY SOMATIC	2	2	2	2	2	2	2	1	0	0	0
			12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	1	1	1	0	0	0
			13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	0	0	0
			14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	0	0	0	0
			15. HYPOCHONDRIASIS	1	1	1	1	1	1	1	0	0	0	0
			16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0
			17. INSIGHT	1	1	1	1	1	1	1	1	0	0	0
			18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0
			19. DEPERSONALIZATION	2	2	2	2	2	2	2	1	0	0	0
			20. PARANOID	1	1	1	1	1	1	1	1	0	0	0
			21. OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	0	0	0
			22. Total score	32	32	32	33	26	16	9	7	2	0	0
140T	Imipramine	Female	01. DEPRESSED MOOD	3	3	3	3	3	3	3	3	2	2	2
			02. GUILT	3	3	3	3	3	3	3	2	2	1	1
			03. SUICIDE	2	2	2	2	2	2	2	2	2	1	1
			04. INSOMNIA EARLY	1	1	1	1	1	1	1	2	2	1	1
			05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	1	1	1
			06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	0	0
			07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	2	1	1
			08. RETARDATION	1	1	1	1	1	1	1	1	1	0	0
			09. AGITATION	2	2	2	2	2	2	2	2	2	1	1
			10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	1	1
			11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	1	1
			12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	1	1

1413

9550089

142

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63		
294	14DT	Imipramine	Female		2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1	
				13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1	
				14. GENERAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1	
				15. HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1
				20. PARANOID	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				21. OBSESSIONAL/COMPULSIVE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1
				22. Total score	34	34	34	34	34	34	34	34	34	34	34	34	34	31	31	31	25	25	25	25	15	
15HD		Imipramine	Female		2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0	
				01. DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0
				02. GUILT	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	0
				03. SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0
				04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0
				05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0
				06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0
				07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	0
				08. RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0
				09. AGITATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0
				10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0
				11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0
				12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0
				13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0
				14. GENERAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0
				15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0
				20. PARANOID	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0
				21. OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0
				22. Total score	34	34	34	34	34	34	34	34	34	34	13	13	0	0	0	0	0	0	0	0	0	0
15DT		Imipramine	Female		3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	1	
				01. DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	1
				02. GUILT	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	1
				03. SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1
				04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1
				05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1
				06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0
				07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	0
				08. RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0
				09. AGITATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0
				10. ANXIETY PSYCHIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				11. ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1
				13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0
				14. GENERAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0
				15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

1414

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

143

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day							
294	15DT	Inipramine	Female	17.INSIGHT	1	1	1	1	1	1	1	1	1	1	1	0						
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
				19. DEPERSONALIZATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1			
				20. PARANOID	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0			
				21. OBSESSIONAL/COMPULSIVE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1			
				22. Total score	33	33	33	33	33	33	33	33	33	33	33	26	18	11				
				16MD	Reboxetine	Female	01. DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2	2	2	0		
							02. GUILT	2	2	2	2	2	2	2	2	2	2	2	2	2	0	
							03. SUICIDE	3	3	3	3	3	3	3	3	3	3	3	3	3	3	0
							04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0
							05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0
							06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0
							07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	0
							08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0
							09. AGITATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0
							10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0
							11. ANXIETY SOMATIC	3	3	3	3	3	3	3	3	3	3	3	3	3	3	0
							12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0
							13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0
							14. GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0
							15. HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0
							16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
17. INSIGHT	1	1	1				1	1	1	1	1	1	1	1	1	1	1	0				
18. DIURNAL VARIATION	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0				
19. DEPERSONALIZATION	2	2	2				2	2	2	2	2	2	2	2	2	2	2	0				
20. PARANOID	1	1	1				1	1	1	1	1	1	1	1	1	1	1	0				
21. OBSESSIONAL/COMPULSIVE	1	1	1				1	1	1	1	1	1	1	1	1	1	1	0				
22. Total score	35	35	35				35	35	35	35	35	35	35	15	6	0	0	0				
16DT	Reboxetine	Female	01. DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3	3	0						
			02. GUILT	3	3	3	3	3	3	3	3	3	3	3	3	3	0					
			03. SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0				
			04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0				
			05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0				
			06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0				
			07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	0				
			08. RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0				
			09. AGITATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0				
			10. ANXIETY PSYCHIC	3	3	3	3	3	3	3	3	3	3	3	3	3	3	0				
			11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0				
			12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0				
			13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0				
			14. GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0				
			15. HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0				
			16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
			17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0				
			18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
			19. DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0				
			20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
			21. OBSESSIONAL/COMPULSIVE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	0				
			22. Total score	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0				

1415

9550089

144

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63		
294	160T	Reboxetine	Female	21.OBSESSIONAL/COMPULSIVE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
		22.Total score		34	34	34	34	34	34	34	34	34	34	34	34	34	34	34	34	34	34	34	34	34	34	34
294	25ND	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
		02.GUILT	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
294	25ND	Imipramine	Female	03.SUICIDE	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
		04.INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
294	25ND	Imipramine	Female	05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		06.INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
294	25ND	Imipramine	Female	07.WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
		08.RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
294	25ND	Imipramine	Female	09.AGITATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
		10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
294	25ND	Imipramine	Female	11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
		12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
294	25ND	Imipramine	Female	13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
294	25ND	Imipramine	Female	15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		16.LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
294	25ND	Imipramine	Female	17.INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		18.DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
294	25ND	Imipramine	Female	19.DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
294	25ND	Imipramine	Female	21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		22.Total score	34	34	34	34	34	34	34	34	34	34	34	34	34	34	34	34	34	34	34	34	34	34	34	34
294	25ND	Imipramine	Female	01.DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
		02.GUILT	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
294	25ND	Imipramine	Female	03.SUICIDE	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
		04.INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
294	25ND	Imipramine	Female	05.INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		06.INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
294	25ND	Imipramine	Female	07.WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
		08.RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
294	25ND	Imipramine	Female	09.AGITATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
		10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
294	25ND	Imipramine	Female	11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
294	25ND	Imipramine	Female	13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
294	25ND	Imipramine	Female	15.HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		16.LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
294	25ND	Imipramine	Female	17.INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		18.DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
294	25ND	Imipramine	Female	19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		20.PARANOID	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
294	25ND	Imipramine	Female	21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		22.Total score	33	33	33	33	33	33	33	33	33	33	33	33	33	33	33	33	33	33	33	33	33	33	33	33

1416

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

145

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63	
294	277D	Reboxetine	Female	01. DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				02. GUILT	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				03. SUICIDE	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				08. RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				09. AGITATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				14. GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				15. HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				16. LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				19. DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				22. Total score	35	35	34	34	32	32	32	29	29	29	29	29	29	29	29	29	29	29	29	29	29
28ND		Reboxetine	Female	01. DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				02. GUILT	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				03. SUICIDE	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				08. RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				09. AGITATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				16. LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				22. Total score	33	33	33	26	26	26	15	15	15	15	15	15	15	15	15	15	15	15	15	15	15
29DT		Reboxetine	Female	01. DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				02. GUILT	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				03. SUICIDE	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2

1417

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

146

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day						
294	29DT	Reboxetine	Female	05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1						
				06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2					
				07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3			
				08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				09. AGITATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				10. ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				14. GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				15. HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
				19. DEPERSONALIZATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				21. OBSESSIONAL/COMPULSIVE	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				22. Total score	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38		
				30DT	30DT	Reboxetine	Female	01. DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3		
								02. GUILT	3	3	3	3	3	3	3	3	3	3	3	3	
								03. SUICIDE	3	3	3	3	3	3	3	3	3	3	3	3	3
								04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2
05. INSOMNIA MIDDLE	1	1	1					1	1	1	1	1	1	1	1	1	1				
06. INSOMNIA LATE	1	1	1					1	1	1	1	1	1	1	1	1	1				
07. WORK AND ACTIVITIES	3	3	3					3	3	3	3	3	3	3	3	3	3				
08. RETARDATION	1	1	1					1	1	1	1	1	1	1	1	1	1				
09. AGITATION	2	2	2					2	2	2	2	2	2	2	2	2	2				
10. ANXIETY PSYCHIC	2	2	2					2	2	2	2	2	2	2	2	2	2				
11. ANXIETY SOMATIC	2	2	2					2	2	2	2	2	2	2	2	2	2				
12. SOMATIC GASTROINTESTINAL	1	1	1					1	1	1	1	1	1	1	1	1	1				
13. SOMATIC GENERAL	2	2	2					2	2	2	2	2	2	2	2	2	2				
14. GENITAL SYMPTOMS	0	0	0					0	0	0	0	0	0	0	0	0	0				
15. HYPOCHONDRIASIS	0	0	0					0	0	0	0	0	0	0	0	0	0				
16. LOSS OF WEIGHT	1	1	1					1	1	1	1	1	1	1	1	1	1				
17. INSIGHT	1	1	1					1	1	1	1	1	1	1	1	1	1				
18. DIURNAL VARIATION	1	1	1					1	1	1	1	1	1	1	1	1	1				
19. DEPERSONALIZATION	2	2	2					2	2	2	2	2	2	2	2	2	2				
20. PARANOID	0	0	0					0	0	0	0	0	0	0	0	0	0				
21. OBSESSIONAL/COMPULSIVE	1	1	1					1	1	1	1	1	1	1	1	1	1				
22. Total score	33	33	33					33	33	33	33	33	33	33	33	33	33	33			
31DT	31DT	Inipramine	Female	01. DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3						
				02. GUILT	3	3	3	3	3	3	3	3	3	3	3						
				03. SUICIDE	3	3	3	3	3	3	3	3	3	3	3						
				04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2						
				05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2						
				06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1						
				07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3						
				08. RETARDATION	1	1	1	1	1	1	1	1	1	1	1						

1418

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

147

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 2012/4/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63						
294	34DT	Imipramine	Female	09. AGITATION	2	2	2	2	2	1	1	1	1	1						
				10. ANXIETY PSYCHIC	2	2	2	2	1	1	1	1	1	1	1					
				11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2				
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1				
				13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1				
				14. GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2	2				
				15. HYPOCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0				
				16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0				
				17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1			
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1			
				19. DEPERSONALIZATION	2	2	2	2	2	2	2	2	2	2	2	2	2			
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0			
				21. OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1	1	1			
				22. Total score	33	33	33	33	33	33	33	29	20	20	20	20	20			
				32DT	Imipramine	Male	01. DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	2	1		
							02. GUILT	3	3	3	3	3	3	3	3	3	2	1	1	
							03. SUICIDE	2	2	2	2	2	2	2	2	2	2	1	1	
							04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	1	1	
							05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	1	1	
							06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	0	
							07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	2	1	0
							08. RETARDATION	1	1	1	1	1	1	1	1	1	1	1	0	0
09. AGITATION	2	2	2				2	2	2	2	2	2	2	1	1	1				
10. ANXIETY PSYCHIC	1	1	1				1	1	1	1	1	1	1	1	1	1				
11. ANXIETY SOMATIC	2	2	2				2	2	2	2	2	2	2	2	2	2				
12. SOMATIC GASTROINTESTINAL	1	1	1				1	1	1	1	1	1	1	1	1	0				
13. SOMATIC GENERAL	1	1	1				1	1	1	1	1	1	1	1	1	1				
14. GENITAL SYMPTOMS	2	2	2				2	2	2	2	2	2	2	2	2	1				
15. HYPOCHONDRIASIS	1	1	1				1	1	1	1	1	1	1	1	1	1				
16. LOSS OF WEIGHT	0	0	0				0	0	0	0	0	0	0	0	0	0				
17. INSIGHT	1	1	1				1	1	1	1	1	1	1	1	1	0				
18. DIURNAL VARIATION	0	0	0				0	0	0	0	0	0	0	0	0	0				
19. DEPERSONALIZATION	2	2	2				2	2	2	2	2	2	2	2	2	1				
20. PARANOID	1	1	1				1	1	1	1	1	1	1	1	1	0				
21. OBSESSIONAL/COMPULSIVE	2	2	2				2	2	2	2	2	2	2	2	2	1				
22. Total score	33	33	33				33	33	33	32	33	33	33	26	18	10				
295	17ND	Reboxetine	Female	01. DEPRESSED MOOD	2	2	2	2	1	1	1	1	1	1						
				02. GUILT	1	1	0	0	0	0	0	0	0	0	0					
				03. SUICIDE	1	1	0	0	0	0	0	0	0	0	0					
				04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2					
				05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2					
				06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1					
				07. WORK AND ACTIVITIES	2	2	1	1	1	1	1	1	1	1	1	1				
				08. RETARDATION	1	1	1	1	1	1	1	1	1	1	1	1				
				09. AGITATION	2	2	2	2	1	1	1	1	1	1	1	1				
				10. ANXIETY PSYCHIC	2	2	2	2	1	1	1	1	1	1	1	1				
				11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2				

1419

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

149

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63						
295	18ND	Reboxetine	Female	17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0						
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0				
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				22. Total score	23	23	22	18	18	22	23	20	21								
				180T	Imipramine	Female	01. DEPRESSED MOOD	2	2	2	2	2	2	2	1	1	1	1	1		
							02. GUILT	2	2	2	2	2	1	1	1	1	0	0	0	0	
							03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0
							04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2
05. INSOMNIA MIDDLE	2	2	2				2	2	2	2	2	2	2	2	2	2	2				
06. INSOMNIA LATE	1	1	1				1	1	1	1	1	1	1	1	1	1	1				
07. WORK AND ACTIVITIES	2	2	2				2	2	2	2	2	2	2	2	2	2	2				
08. RETARDATION	1	1	1				1	1	1	1	1	1	1	1	1	1	1				
09. AGITATION	2	2	2				2	2	2	2	2	2	2	2	2	2	2				
10. ANXIETY PSYCHIC	3	3	3				3	3	2	2	2	2	2	2	2	2	2				
19ND	Imipramine	Male	11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2					
			12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1					
			13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1					
			14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
			15. HYPOCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
			16. LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
			17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
			18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
			19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
			20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0							
22. Total score	24	24	24	24	24	21	19	14	14												
19ND	Imipramine	Male	01. DEPRESSED MOOD	3	3	3	3	3	3	3	3	2	2	2	2						
			02. GUILT	1	1	1	1	1	1	1	1	1	1	1	1	1					
			03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1	1					
			04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2					
			05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1	1	1					
			06. INSOMNIA LATE	1	1	1	1	1	1	1	1	1	1	1	1	1					
			07. WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2	2	2					
			08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2					
			09. AGITATION	2	2	2	2	2	2	2	2	2	2	2	2	2					
			10. ANXIETY PSYCHIC	3	3	3	3	3	3	3	3	3	3	3	3	3					
11. ANXIETY SOMATIC	3	3	3	3	3	3	3	3	3	3	3	3	3								
12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1								
13. SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2								
14. GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1	1								
15. HYPOCHONDRIASIS	3	3	3	3	3	3	3	3	3	3	3	3	3								
16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0								
17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1								
18. DIURNAL VARIATION	2	2	2	2	2	2	2	2	2	2	2	2	2								
19. DEPERSONALIZATION	2	2	2	2	2	2	2	2	2	2	2	2	2								
20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0								

1421

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

150

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day						
295	198D	Imipramine	Male	Hamilton depression rating scale																
				1	1	1	1	1	1	1	1	1	1	1	1					
					33	33	33	33	33	33	33	33	33	33	30	30	31			
					21. OBSESSIONAL/COMPULSIVE															
					22. Total score															
				198T	Reboxetine	Female	Hamilton depression rating scale													
							3	3	3	3	2	2	2	2	2	2	2	3	3	
								01. DEPRESSED MOOD												
								02. GUILT												
								03. SUICIDE												
								04. INSOMNIA EARLY												
								05. INSOMNIA MIDDLE												
								06. INSOMNIA LATE												
								07. WORK AND ACTIVITIES												
								08. RETARDATION												
								09. AGITATION												
								10. ANXIETY PSYCHIC												
								11. ANXIETY SOMATIC												
								12. SOMATIC GASTROINTESTINAL												
								13. SOMATIC GENERAL												
								14. GENITAL SYMPTOMS												
								15. HYPOCHONDRIASIS												
	16. LOSS OF WEIGHT																			
	17. INSIGHT																			
	18. DIURNAL VARIATION																			
	19. DEPERSONALIZATION																			
	20. PARANOID																			
	21. OBSESSIONAL/COMPULSIVE																			
	22. Total score																			
208D	Imipramine	Female	Hamilton depression rating scale																	
			3	3	3	3	3	3	3	3	3	3	3	3	3					
				01. DEPRESSED MOOD																
				02. GUILT																
				03. SUICIDE																
				04. INSOMNIA EARLY																
				05. INSOMNIA MIDDLE																
				06. INSOMNIA LATE																
				07. WORK AND ACTIVITIES																
				08. RETARDATION																
				09. AGITATION																
				10. ANXIETY PSYCHIC																
				11. ANXIETY SOMATIC																
				12. SOMATIC GASTROINTESTINAL																
				13. SOMATIC GENERAL																
				14. GENITAL SYMPTOMS																
				15. HYPOCHONDRIASIS																
				16. LOSS OF WEIGHT																
				17. INSIGHT																
				18. DIURNAL VARIATION																
				19. DEPERSONALIZATION																
				20. PARANOID																
	21. OBSESSIONAL/COMPULSIVE																			
	22. Total score																			

1422

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

153

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63						
381	4WD	Imipramine	Female	09. AGITATION	2	2	3	2													
				10. ANXIETY PSYCHIC	1	1	3	1													
				11. ANXIETY SOMATIC	1	1	3	1													
				12. SOMATIC GASTROINTESTINAL	2	2	2	1													
				13. SOMATIC GENERAL	1	1	1	0													
				14. GENITAL SYMPTOMS	0	0	0	0													
				15. HYPOCHONDRIASIS	2	2	3	1													
				16. LOSS OF WEIGHT	0	0	0	0													
				17. INSIGHT	1	1	1	2													
				18. DIURNAL VARIATION	1	1	1	1													
				19. DEPERSONALIZATION	2	2	0	0													
				20. PARANOID	0	0	0	0													
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0													
				22. Total score	26	26	31	17													
				382	5ND	Imipramine	Female	01. DEPRESSED MOOD	3	4	2	2	1	1	1	0	0	1	1		
								02. GUILT	3	2	3	2	0	1	1	0	3	1	0	1	
								03. SUICIDE	2	2	1	1	1	1	0	1	0	1	0	1	0
								04. INSOMNIA EARLY	1	2	2	2	1	1	0	0	0	0	0	0	0
								05. INSOMNIA MIDDLE	1	2	2	2	1	1	0	0	0	0	0	0	0
								06. INSOMNIA LATE	1	2	2	2	1	1	0	0	0	0	0	0	0
								07. WORK AND ACTIVITIES	2	2	2	2	1	1	1	1	1	1	1	3	1
								08. RETARDATION	3	2	2	2	1	1	1	1	0	1	0	1	1
09. AGITATION	3	4	1					1	1	1	2	0	3	1	2	2	2				
10. ANXIETY PSYCHIC	4	4	4					4	0	4	3	1	3	1	4	1	4				
11. ANXIETY SOMATIC	4	4	4					4	0	4	3	1	2	1	3	1	3				
12. SOMATIC GASTROINTESTINAL	2	2	1					1	1	1	1	1	1	1	2	2	2				
13. SOMATIC GENERAL	0	0	0					0	0	0	0	0	0	0	0	0	0				
14. GENITAL SYMPTOMS	2	2	1					1	1	1	1	1	1	1	1	2	2				
15. HYPOCHONDRIASIS	3	3	3					3	3	3	3	3	3	3	2	3	3				
16. LOSS OF WEIGHT	3	3	0					2	0	2	0	2	3	3	2	3	2				
17. INSIGHT	1	1	1					1	1	1	0	0	0	1	1	1	0				
18. DIURNAL VARIATION	2	2	1					1	1	1	1	1	1	1	0	0	1				
19. DEPERSONALIZATION	2	4	1					1	1	1	1	1	1	1	0	0	0				
20. PARANOID	0	0	0					0	0	0	0	0	0	0	0	0	0				
21. OBSESSIONAL/COMPULSIVE	2	2	1					1	1	1	0	1	0	0	0	0	0				
22. Total score	44	48	34					30	19	17	20	12	30	17	17	20	12	30			
5DT	Reboxetine	Male	01. DEPRESSED MOOD	4	3	1	3														
			02. GUILT	3	3	3	3														
			03. SUICIDE	2	2	2	0														
			04. INSOMNIA EARLY	0	2	2	1														
			05. INSOMNIA MIDDLE	0	2	2	1														
			06. INSOMNIA LATE	0	2	2	1														
			07. WORK AND ACTIVITIES	3	4	0	1														
			08. RETARDATION	1	2	2	2														
			09. AGITATION	0	4	2	1														
			10. ANXIETY PSYCHIC	0	4	2	2														
			11. ANXIETY SOMATIC	0	3	3	2														
			12. SOMATIC GASTROINTESTINAL	2	1	1	1														

1425

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

154

PEARMACTA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63		
382	5DT	Reboxetine	Male	13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				15. HYPOCHONDRIASIS	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				16. LOSS OF WEIGHT	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17. INSIGHT	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				19. DEPERSONALIZATION	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSSIONAL/COMPULSIVE	0	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	19	45	25	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21
6HD	Reboxetine	Female	01. DEPRESSED MOOD	4	3	3	2	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	
			02. GUILT	3	2	2	2	1	3	1	3	1	3	1	3	1	3	1	3	1	3	1	3	1	3	1
			03. SUICIDE	2	2	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2
			04. INSOMNIA EARLY	2	2	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			05. INSOMNIA MIDDLE	2	2	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			06. INSOMNIA LATE	2	2	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			07. WORK AND ACTIVITIES	3	3	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			08. RETARDATION	2	2	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			09. AGITATION	3	3	3	2	4	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			10. ANXIETY PSYCHIC	4	3	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			11. ANXIETY SOMATIC	3	4	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			12. SOMATIC GASTROINTESTINAL	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			13. SOMATIC GENERAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			14. GENITAL SYMPTOMS	3	3	3	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
			15. HYPOCHONDRIASIS	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			16. LOSS OF WEIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			17. INSIGHT	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			18. DIURNAL VARIATION	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			19. DEPERSONALIZATION	3	2	2	1	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			21. OBSSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			22. Total score	43	39	39	24	35	30	28	27	29	24	21	21	21	21	21	21	21	21	21	21	21	21	21
6DT	Imipramine	Female	01. DEPRESSED MOOD	3	2	2	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
			02. GUILT	3	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			03. SUICIDE	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			04. INSOMNIA EARLY	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			05. INSOMNIA MIDDLE	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			06. INSOMNIA LATE	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			07. WORK AND ACTIVITIES	3	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			08. RETARDATION	2	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			09. AGITATION	3	2	2	1	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			10. ANXIETY PSYCHIC	3	3	3	0	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			11. ANXIETY SOMATIC	0	2	2	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			12. SOMATIC GASTROINTESTINAL	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			13. SOMATIC GENERAL	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
			16. LOSS OF WEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

1426

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

155

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63								
382	60T	Imipramine	Female	17. INSIGHT	1	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0							
				18. DIURNAL VARIATION	2	2	0	2	2	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
				19. DEPERSONALIZATION	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
				20. PARANOID	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
				21. OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
				22. Total score	34	18	21	27	13	12	10	5	9	5	9	7																
				7ND		Reboxetine	Female	01. DEPRESSED MOOD	1	1	1	1	0	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
								02. GUILT	2	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
								03. SUICIDE	1	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
								04. INSOMNIA EARLY	2	2	1	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
05. INSOMNIA MIDDLE	2	2	1					1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
06. INSOMNIA LATE	2	2	1					1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
07. WORK AND ACTIVITIES	2	2	2					2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
08. RETARDATION	1	1	1					1	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0				
09. AGITATION	1	1	1					1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
10. ANXIETY PSYCHIC	2	2	1					1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
11. ANXIETY SOMATIC	1	1	1					1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
12. SOMATIC GASTROINTESTINAL	2	2	1					1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
13. SOMATIC GENERAL	1	1	2					1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
14. GENITAL SYMPTOMS	0	0	0					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
15. HYPOCHONDRIASIS	2	2	2					2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
16. LOSS OF WEIGHT	2	2	3					0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
17. INSIGHT	1	1	1					1	2	1	0	0	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
18. DIURNAL VARIATION	1	1	1					1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
19. DEPERSONALIZATION	0	0	0					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
20. PARANOID	0	0	0					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
21. OBSESSIONAL/COMPULSIVE	0	0	0					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
22. Total score	26	26	22					22	16	15	12	9	8	6	6	4																
7DT		Imipramine	Male	01. DEPRESSED MOOD	1	1	1	1	0	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1								
				02. GUILT	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
				03. SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
				04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
				05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
				06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
				07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3				
				08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
				09. AGITATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
				10. ANXIETY PSYCHIC	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3				
				11. ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
				12. SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
				13. SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
				15. HYPOCHONDRIASIS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
				16. LOSS OF WEIGHT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
				17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
				18. DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				

1427

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

156

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day
382	7DT	Imipramine	Male	21.OBSESSIONAL/COMPULSIVE	1	1									
				22.Total score	29	29									
8ND		Imipramine	Male	01.DEPRESSED MOOD	3	1	3	3							
				02.GUILT	3	2	1	0							
				03.SUICIDE	1	1	2	2							
				04.INSOMNIA EARLY	1	0	0	0							
				05.INSOMNIA MIDDLE	1	0	0	0							
				06.INSOMNIA LATE	1	0	0	0							
				07.WORK AND ACTIVITIES	2	3	3	3							
				08.RETARDATION	2	2	2	3							
				09.AGITATION	2	0	2	0							
				10.ANXIETY PSYCHIC	1	2	2	2							
				11.ANXIETY SOMATIC	2	1	1	1							
				12.SOMATIC GASTROINTESTINAL	1	1	1	2							
				13.SOMATIC GENERAL	1	2	2	2							
				14.GENITAL SYMPTOMS	0	0	0	0							
				15.HYPOCHONDRIASIS	1	2	4	0							
				16.LOSS OF WEIGHT	3	3	0	0							
				17.INSIGHT	0	1	1	1							
				18.DIURNAL VARIATION	1	1	1	1							
				19.DEPERSONALIZATION	0	0	0	0							
				20.PARANOID	0	0	0	0							
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0							
				22.Total score	26	22	25	20							
8DT		Reboxetine	Female	01.DEPRESSED MOOD	1	1	2	1	1	1	1	1	1	2	2
				02.GUILT	0	0	3	2	1	1	1	0	1	0	0
				03.SUICIDE	1	1	0	1	1	0	0	0	0	0	0
				04.INSOMNIA EARLY	2	2	2	1	1	1	0	0	0	0	0
				05.INSOMNIA MIDDLE	2	2	2	1	1	1	0	0	0	0	0
				06.INSOMNIA LATE	2	2	2	1	1	0	0	0	0	0	0
				07.WORK AND ACTIVITIES	4	4	4	3	2	1	1	2	2	1	1
				08.RETARDATION	2	2	1	2	2	1	1	1	2	1	2
				09.AGITATION	2	2	1	2	2	1	0	2	1	1	2
				10.ANXIETY PSYCHIC	4	4	0	1	1	0	1	1	1	1	1
				11.ANXIETY SOMATIC	3	3	2	1	2	0	0	1	1	2	1
				12.SOMATIC GASTROINTESTINAL	2	2	2	1	1	0	0	0	2	1	1
				13.SOMATIC GENERAL	1	1	2	2	1	0	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0
				15.HYPOCHONDRIASIS	3	3	2	2	0	0	0	0	0	2	2
				16.LOSS OF WEIGHT	3	3	0	2	0	0	0	0	0	0	0
				17.INSIGHT	1	1	1	1	1	1	2	2	0	0	0
				18.DIURNAL VARIATION	2	2	1	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	2	2	1	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	0	0	0	0	0	0	0	0
				22.Total score	38	38	29	25	19	9	8	9	9	19	0

1428

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

157

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day				
382	9ND	Reboxetine	Female	01. DEPRESSED MOOD	2	3	0	0	1	1	0	0	0	0	0	0			
				02. GUILT	1	1	0	0	1	0	0	0	0	0	0	0	0	0	
				03. SUICIDE	2	2	0	0	1	1	1	1	1	1	1	1	1	1	1
				04. INSOMNIA EARLY	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1
				05. INSOMNIA MIDDLE	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1
				06. INSOMNIA LATE	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1
				07. WORK AND ACTIVITIES	3	3	1	1	1	1	1	1	1	1	1	1	1	1	1
				08. RETARDATION	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1
				09. AGITATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				10. ANXIETY PSYCHIC	3	3	1	1	1	1	1	1	1	1	1	1	1	1	1
				11. ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				12. SOMATIC GASTROINTESTINAL	2	2	0	0	1	0	0	0	0	0	0	0	0	0	0
				13. SOMATIC GENERAL	2	2	0	0	1	0	0	0	0	0	0	0	0	0	0
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				15. HYPOCHONDRIASIS	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0
				16. LOSS OF WEIGHT	2	2	0	0	2	2	2	2	2	2	2	2	2	2	2
				17. INSIGHT	0	0	0	0	2	2	2	2	2	2	2	2	2	2	2
				18. DIURNAL VARIATION	2	2	1	1	0	0	0	0	0	0	0	0	0	0	0
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	30	31	12	12	11	5	3	4	2	4	2	2	2	2	4
9DT	Reboxetine	Female	01. DEPRESSED MOOD	3	3	3	3	2	1	2	2	2	2	2	2	2			
			02. GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			03. SUICIDE	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
			05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
			06. INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
			07. WORK AND ACTIVITIES	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
			08. RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
			09. AGITATION	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
			10. ANXIETY PSYCHIC	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			11. ANXIETY SOMATIC	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
			12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
13. SOMATIC GENERAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
14. GENITAL SYMPTOMS	3	3	3	3	3	3	3	3	3	3	3	3	3	3					
15. HYPOCHONDRIASIS	3	3	3	3	3	3	3	3	3	3	3	3	3	3					
16. LOSS OF WEIGHT	3	3	3	3	3	3	3	3	3	3	3	3	3	3					
17. INSIGHT	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
18. DIURNAL VARIATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
19. DEPERSONALIZATION	3	3	3	3	3	3	3	3	3	3	3	3	3	3					
20. PARANOID	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
21. OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
22. Total score	38	41	40	16	22	32	32	32	32	32	32	32	32	32	32				
10ND	Imipramine	Female	01. DEPRESSED MOOD	2	2	2	2	2	2	2	2	2	2	2	2	2			
			02. GUILT	1	1	1	1	1	1	1	1	1	1	1	1	1			
			03. SUICIDE	1	1	1	1	1	1	1	1	1	1	1	1	1			
			04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2			

1429

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

158

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63
362	10ND	Imipramine	Female	HAMILTON DEPRESSION RATING SCALE	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				08.RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				09.AGITATION	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				10.ANXIETY PSYCHIC	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				11.ANXIETY SOMATIC	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				13.SOMATIC GENERAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				14.GENITAL SYMPTOMS	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				15.HYPCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				16.LOSS OF HEIGHT	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				17.INSIGHT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				18.DIURNAL VARIATION	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				19.DEPERSONALIZATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22.Total score	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
					37	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38
3301	1ND	Reboxetine	Female	HAMILTON DEPRESSION RATING SCALE	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63
				01.DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				02.GUILT	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				03.SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				04.INSOMNIA EARLY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				05.INSOMNIA MIDDLE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				08.RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				09.AGITATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				10.ANXIETY PSYCHIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				11.ANXIETY SOMATIC	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				12.SOMATIC GASTROINTESTINAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				13.SOMATIC GENERAL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				14.GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				15.HYPCHONDRIASIS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				16.LOSS OF HEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21.OBSESSIONAL/COMPULSIVE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				22.Total score	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
					27	27	27	27	27	27	27	27	27	27	27	27	27	27	27	27	27	27	27	27
2ND		Imipramine	Male	HAMILTON DEPRESSION RATING SCALE	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63
				01.DEPRESSED MOOD	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				02.GUILT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				03.SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				04.INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				05.INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				06.INSOMNIA LATE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				07.WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				08.RETARDATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				09.AGITATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				10.ANXIETY PSYCHIC	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
				11.ANXIETY SOMATIC	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				12.SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				13.SOMATIC GENERAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				14.GENITAL SYMPTOMS	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
				15.HYPCHONDRIASIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				16.LOSS OF HEIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				17.INSIGHT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18.DIURNAL VARIATION	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
				19.DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				20.PARANOID	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				21.OB																				

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

159

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	HAMILTON DEPRESSION RATING SCALE																			
				Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63									
3301	2ND	Imipramine	Male	09. AGITATION	3	3	2	2	1	1	0	0	0	0	0	0	0						
				10. ANXIETY PSYCHIC	4	4	3	2	2	1	1	1	1	1	1	1							
				11. ANXIETY SOMATIC	1	1	1	2	2	2	2	2	2	2	2	2	2	2	2				
				12. SOMATIC GASTROINTESTINAL	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2				
				13. SOMATIC GENERAL	1	1	1	2	2	2	2	2	2	2	2	2	2	2	2				
				14. GENITAL SYMPTOMS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				15. HYPOCHONDRIASIS	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				16. LOSS OF WEIGHT	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
				17. INSIGHT	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				18. DIURNAL VARIATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				19. DEPERSONALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				20. PARANOID	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
				21. OBSESSIONAL/COMPULSIVE	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
				22. Total score	35	36	29	28	23	20	15	11	10	9									
				3ND	Reboxetine	Female	01. DEPRESSED MOOD	2	3	4	4	4	4	4	4	4	4	4	4	4	4		
							02. GUILT	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
							03. SUICIDE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
							04. INSOMNIA EARLY	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2
							05. INSOMNIA MIDDLE	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
							06. INSOMNIA LATE	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2
							07. WORK AND ACTIVITIES	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
							08. RESTRACTION	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1
09. ACTIVATION	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0				
10. ANXIETY PSYCHIC	4	4	4				4	4	4	4	4	4	4	4	4	4	4	4	4				
11. ANXIETY SOMATIC	3	3	3				3	3	3	3	3	3	3	3	3	3	3	3	3				
12. SOMATIC GASTROINTESTINAL	3	3	3				3	3	3	3	3	3	3	3	3	3	3	3	3				
13. SOMATIC GENERAL	1	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1				
14. GENITAL SYMPTOMS	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2				
15. HYPOCHONDRIASIS	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0				
16. LOSS OF WEIGHT	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2				
17. INSIGHT	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0				
18. DIURNAL VARIATION	2	2	2				2	2	2	2	2	2	2	2	2	2	2	2	2				
19. DEPERSONALIZATION	1	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1				
20. PARANOID	0	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0				
21. OBSESSIONAL/COMPULSIVE	1	1	1				1	1	1	1	1	1	1	1	1	1	1	1	1				
22. Total score	32	36	37				37	39	44														
3302	5ND	Reboxetine	Female	01. DEPRESSED MOOD	3	2	2	2	2	2	2	2	2	2	2	2							
				02. GUILT	2	1	1	1	1	1	1	1	1	1	1								
				03. SUICIDE	2	2	2	2	2	2	2	2	2	2	2								
				04. INSOMNIA EARLY	2	2	2	2	2	2	2	2	2	2	2								
				05. INSOMNIA MIDDLE	1	1	1	1	1	1	1	1	1	1	1								
				06. INSOMNIA LATE	1	1	2	2	2	2	2	2	2	2	2								
				07. WORK AND ACTIVITIES	1	2	1	1	1	1	1	1	1	1	1								
				08. RESTRACTION	3	2	3	3	3	3	3	3	3	3	3								
				09. ACTIVATION	0	1	1	1	1	1	1	1	1	1	1								
				10. ANXIETY PSYCHIC	0	1	1	1	1	1	1	1	1	1	1								
				11. ANXIETY SOMATIC	1	2	2	2	2	2	2	2	2	2	2								
				12. SOMATIC GASTROINTESTINAL	1	1	2	2	2	2	2	2	2	2	2								

1431

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

160

PHARMACIA CNS 23D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.0

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
3302	5MD	Reboxetine	Female	13. SOMATIC GENERAL 14. GENITAL SYMPTOMS 15. HYPOCHONDRIASIS 16. LOSS OF WEIGHT 17. INSIGHT 18. DIURNAL VARIATION 19. DEPERSONALIZATION 20. PARANOID 21. OBSESSIONAL/COMPULSIVE 22. Total score	1	1	1	0	0	0	0	0	0	0	1
6MD	Imipramine	Female	01. DEPRESSED MOOD 02. GUILT 03. SUICIDE 04. INSOMNIA EARLY 05. INSOMNIA MIDDLE 06. INSOMNIA LATE 07. WORK AND ACTIVITIES 08. RETARDATION 09. AGITATION 10. ANXIETY PSYCHIC 11. ANXIETY SOMATIC 12. SOMATIC GASTROINTESTINAL 13. SOMATIC GENERAL 14. GENITAL SYMPTOMS 15. HYPOCHONDRIASIS 16. LOSS OF WEIGHT 17. INSIGHT 18. DIURNAL VARIATION 19. DEPERSONALIZATION 20. PARANOID 21. OBSESSIONAL/COMPULSIVE 22. Total score	3	3	3	2	2	2	2	2	2	2	2	2
7MD	Imipramine	Female	01. DEPRESSED MOOD 02. GUILT 03. SUICIDE 04. INSOMNIA EARLY 05. INSOMNIA MIDDLE 06. INSOMNIA LATE 07. WORK AND ACTIVITIES 08. RETARDATION 09. AGITATION 10. ANXIETY PSYCHIC 11. ANXIETY SOMATIC 12. SOMATIC GASTROINTESTINAL 13. SOMATIC GENERAL 14. GENITAL SYMPTOMS 15. HYPOCHONDRIASIS 16. LOSS OF WEIGHT	3	3	3	3	3	2	2	2	2	2	2	2

1432

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

161

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 12.0

HAMILTON DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
3302	7MD	Imipramine	Female	17. INSIGHT	0	0	0	0	0	0	0	0	0	0	0
				18. DIURNAL VARIATION	2	2	2	2	2	2	2	2	2	2	2
				19. DEPERSONALIZATION	1	1	1	1	1	1	1	1	1	1	1
				20. PARANOID	0	0	0	0	0	0	0	0	0	0	0
				21. OBSESSIONAL/COMPULSIVE	0	0	0	0	0	0	0	0	0	0	0
				22. Total score	22	22	20	16	15	11	12	12	14	11	

1433

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
1	1ND	Reboxetine	Female	1. ANXIETY/SOMATIZATION	0.83	0.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				2. WEIGHT	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3. COGNITIVE DISTURBANCE	0.67	0.50	0.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				4. DIURNAL VARIATION	2.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5. RETARDATION	1.25	1.25	0.00	0.25	0.00	0.00	0.00	0.00	0.00	0.25	0.00
				6. SLEEP DISTURBANCE	0.67	1.67	0.67	1.67	1.00	0.33	0.00	0.33	0.00	0.33	0.00
				7. Total score	5.42	6.08	0.83	1.92	1.00	0.33	0.00	0.33	0.00	0.58	0.00
				10T	Reboxetine	Male	1. ANXIETY/SOMATIZATION	0.83	1.33	1.17	0.33	0.00	0.33	0.00	0.33
2. WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
3. COGNITIVE DISTURBANCE	0.67	0.50	0.17	0.17	0.00	0.17	0.00	0.00	0.00	0.00	0.00				
4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
5. RETARDATION	2.00	1.75	1.25	0.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
6. SLEEP DISTURBANCE	2.00	2.00	0.67	0.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
7. Total score	7.50	5.58	3.25	1.67	0.00	0.50	0.33	0.00	0.33	0.00	0.33	0.00			
2ND	1434	Imipramine	Male	1. ANXIETY/SOMATIZATION	0.67	0.67	0.33	1.67	0.17	0.00	0.00	0.33	0.33		
				2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3. COGNITIVE DISTURBANCE	0.67	0.67	0.00	0.33	0.33	0.00	0.00	0.00	0.50	0.00	
				4. DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				5. RETARDATION	2.50	2.50	1.50	1.50	0.75	0.25	0.00	0.75	0.50	0.00	
				6. SLEEP DISTURBANCE	2.00	2.00	1.67	1.67	1.00	0.67	0.00	0.67	0.33	0.00	
				7. Total score	6.83	6.83	3.50	4.17	2.25	0.25	0.00	2.25	1.17	0.00	
				2DT	Imipramine	Male	1. ANXIETY/SOMATIZATION	1.67	1.67	1.67	1.17	0.00	0.00	0.00	0.00
2. WEIGHT	2.00	2.00	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00					
3. COGNITIVE DISTURBANCE	1.17	1.17	0.83	1.00	0.00	0.00	0.00	0.00	0.00	0.00					
4. DIURNAL VARIATION	0.00	0.00	1.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00					
5. RETARDATION	1.50	1.50	2.25	2.00	0.00	0.00	0.00	0.00	0.00	0.00					
6. SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00					
7. Total score	8.33	8.33	9.75	10.17	0.00	0.00	0.00	0.00	0.00	0.00					
3ND	1	Imipramine	Female	1. ANXIETY/SOMATIZATION	1.17	1.17	0.83	0.17	0.00	0.33	0.00	0.00	0.00		
				2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3. COGNITIVE DISTURBANCE	0.33	0.67	0.17	0.17	0.00	0.00	0.00	0.00	0.00	0.00	
				4. DIURNAL VARIATION	0.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				5. RETARDATION	1.50	1.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				6. SLEEP DISTURBANCE	1.67	1.67	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				7. Total score	4.67	6.00	3.67	2.33	0.00	0.33	0.00	0.00	0.00	0.00	
				3DT	Reboxetine	Male	1. ANXIETY/SOMATIZATION	1.50	1.50	1.00	1.67	0.50	1.17	1.17	0.50
2. WEIGHT	2.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00					
3. COGNITIVE DISTURBANCE	0.17	0.17	0.67	1.00	0.17	0.00	0.33	0.00	0.33	0.00					
4. DIURNAL VARIATION	0.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00					
5. RETARDATION	2.25	2.25	1.75	2.25	2.00	1.75	2.00	1.75	2.00	0.75					
6. SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	1.67	2.00	1.67	2.00	1.67	0.33					
7. Total score	7.92	7.92	6.42	7.92	5.83	3.17	4.92	4.50	1.58	0.67					

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

2

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 2012/4/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63			
1	4HD	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.33	0.83	1.00	1.33	0.67	0.67	0.67	0.83	0.33			
				2.WEIGHT	2.00	2.00	1.00	2.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	1.50	1.50	1.83	1.00	2.00	0.83	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.33
				4.DIURNAL VARIATION	0.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	1.50	2.25	1.50	1.25	1.50	1.25	1.50	1.00	1.00	0.50	0.75
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	0.33	0.00
				7.Total score	9.17	9.17	8.17	8.33	7.25	4.83	4.75	2.83	2.33	1.42				
2	1HD	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	0.50	0.67	1.00	1.50	1.67	1.17	1.17	1.50	1.67			
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.67	0.17	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				4.DIURNAL VARIATION	0.00	0.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.50	1.50	2.75	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				6.SLEEP DISTURBANCE	2.00	2.00	1.33	0.67	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				7.Total score	6.75	6.75	5.00	4.00	6.75	6.75	6.75	6.75	6.75	6.75	6.75	6.75	6.75	6.75
3	1HD	Reboxetine	Female	1.ANXIETY/SOMATIZATION	0.67	0.67	0.67	0.67	0.50	0.83	0.67	0.67	0.67	0.67	0.67			
				2.WEIGHT	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.50	0.00	0.17	0.00	0.17	0.00	0.00	0.17	0.00	0.00	0.00	
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				5.RETARDATION	1.75	2.00	1.50	1.25	1.00	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.75	
				6.SLEEP DISTURBANCE	1.33	1.67	1.00	1.00	1.00	1.33	1.00	1.00	1.33	1.00	1.00	1.00	1.33	
				7.Total score	7.25	5.83	3.67	5.58	5.83	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	
4	1HD	Imipramine	Male	1.ANXIETY/SOMATIZATION	0.67	0.67	0.67	0.67	0.00	0.33	0.67	0.67	0.67	0.67	0.67			
				2.WEIGHT	2.00	2.00	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.83	0.83	0.33	0.33	0.50	0.50	0.50	0.50	0.50		
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00		
				5.RETARDATION	1.00	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25		
				6.SLEEP DISTURBANCE	1.00	1.00	1.33	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
				7.Total score	7.33	7.58	7.52	7.08	5.08	4.50	5.83	5.83	5.83	5.83	5.83	5.83		
5	1HD	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.17	1.50	1.17	2.17										
				2.WEIGHT	0.00	0.00	0.00	0.00										
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.83										
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00										
				5.RETARDATION	2.00	2.00	2.00	1.75										

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

3

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
5	1MD	Reboxetine	Female	6.SLEEP DISTURBANCE	0.67	0.67	0.67	0.67								
				7.Total score	4.67	5.00	4.62	5.42								
10	1DT	Imipramine	Female	1.ANXIETY/SOMATIZATION	2.50	2.50	2.17	2.00	1.33	1.33	1.17	0.67	0.67	0.67		
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	1.17	1.17	1.17	0.83	0.83	0.33	0.33	0.33	0.17	0.00	0.00	
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	
				5.RETARDATION	1.00	0.75	0.75	0.50	0.50	0.50	0.50	0.50	0.25	0.00	0.00	
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.33	1.00	0.33	0.33	0.33	0.33	0.33	0.33	0.33
				7.Total score	7.33	7.08	7.08	5.83	5.33	3.50	2.50	1.92	1.60	1.00	1.00	1.00
20	2MD	Reboxetine	Male	1.ANXIETY/SOMATIZATION	2.17	2.50	2.00	1.83	1.67	1.33	1.17	1.33	1.50	1.83		
				2.WEIGHT	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	0.00	0.00	0.00	0.17	0.00	0.00	0.00	0.00	0.00	1.00	1.33	
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				5.RETARDATION	1.25	1.25	1.00	1.25	1.25	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				6.SLEEP DISTURBANCE	1.33	1.67	1.00	0.67	0.67	0.67	0.67	0.67	0.67	1.33	1.33	1.33
				7.Total score	5.75	5.42	4.25	3.92	3.58	3.00	2.83	3.00	4.83	5.50	5.50	5.50
30	3DT	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.33	1.00	1.00	1.00	1.00	1.33	1.33	1.33		
				2.WEIGHT	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.67	0.67	0.67	0.67	0.67	0.67	1.00	1.00	1.00	
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				5.RETARDATION	2.25	2.25	1.00	1.25	1.25	1.25	1.25	1.25	1.50	1.25	1.50	1.50
				6.SLEEP DISTURBANCE	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.67	0.67	0.67	0.67
				7.Total score	6.08	6.08	4.33	4.25	4.25	4.25	4.25	4.83	5.42	4.92	5.50	5.50
40	4DT	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	1.33	1.33	0.33	0.33	0.33	0.33	0.33	0.33		
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	1.00	1.00	0.83	0.83	0.33	0.33	0.33	0.33	0.17	0.00	0.00	
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				5.RETARDATION	1.75	1.75	1.50	1.25	0.75	0.75	0.75	0.75	0.50	0.25	0.25	
				6.SLEEP DISTURBANCE	1.00	1.00	1.67	0.67	0.33	0.33	0.33	0.33	0.33	0.33	0.33	
				7.Total score	5.25	5.25	5.33	4.08	2.75	2.75	1.75	1.75	1.33	0.92	0.92	
50	5DT	Reboxetine	Male	1.ANXIETY/SOMATIZATION	2.00	1.83	1.00	0.83	0.17	0.33	0.33	0.33	0.17	0.17		
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	0.67	0.50	0.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				5.RETARDATION	1.75	1.75	1.00	0.75	0.25	0.00	0.00	0.00	0.00	0.00	0.00	
				6.SLEEP DISTURBANCE	1.67	1.67	1.00	0.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				7.Total score	8.08	7.75	4.17	2.25	0.42	0.33	0.33	0.33	0.33	0.33	0.17	0.17
60	6DT	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.83	1.83	1.67	1.50	1.50	1.33	1.33	1.33	1.17			
				2.WEIGHT	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	0.17	0.17	0.33	0.17	0.17	0.17	0.17	0.17	0.33	0.17		

9550089

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

5

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
5	7ND	Reboxetine	Male	2.WEIGHT	0.00	0.00	0.00	1.00	1.00						
				3.COGNITIVE DISTURBANCE	1.17	1.50	1.50	0.67	0.50						
				4.DIURNAL VARIATION	0.00	0.00	0.00	2.00	0.00						
				5.RETARDATION	2.25	2.00	1.25	3.25	1.50						
				6.SLEEP DISTURBANCE	2.00	2.00	1.67	2.00	0.67						
				7.Total score	7.08	6.83	5.75	10.08	4.67						
7DI	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	0.83	0.67	0.50	0.33	0.67	0.17	0.17	0.17	0.17	
			2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			3.COGNITIVE DISTURBANCE	1.33	1.33	0.83	0.83	0.50	0.50	0.50	0.00	0.00	0.00	0.00	
			4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	
			5.RETARDATION	1.25	1.25	1.00	0.50	0.25	0.25	0.25	0.00	0.00	0.00	0.00	
			6.SLEEP DISTURBANCE	1.00	1.00	0.67	0.33	0.33	0.00	0.00	0.00	0.00	0.00	0.00	
			7.Total score	8.58	8.58	4.33	3.67	2.58	2.42	1.17	0.92	0.67	0.50	0.50	
8ND	Imipramine	Female	1.ANXIETY/SOMATIZATION	0.83	1.33	1.50	1.50	0.83	1.00	0.33	0.67	0.17	0.17	0.33	
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	0.00	0.00	0.00	
			3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.83	0.67	0.67	0.67	0.00	0.00	0.00	0.00	
			4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			5.RETARDATION	2.50	2.50	2.00	2.00	2.00	2.00	1.25	1.00	0.75	1.25	1.25	
			6.SLEEP DISTURBANCE	1.00	1.00	0.67	1.67	1.33	0.67	0.67	0.00	0.33	0.00	0.33	
			7.Total score	5.00	5.50	5.33	6.00	5.83	4.67	3.25	1.67	1.25	1.58	1.25	
14C3	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.83	1.83	1.83	1.67	1.33	1.50	0.83	1.00		
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	0.83	0.83	0.67	0.50	0.50	0.50	0.50	0.50	0.50	0.50		
			4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			5.RETARDATION	1.25	1.25	1.25	1.00	0.75	0.75	0.50	0.50	0.50	0.50		
			6.SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			7.Total score	5.75	5.75	5.75	5.33	5.08	4.92	4.33	4.50	3.58	3.50		
9ND	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.50	1.00	1.33	0.83	1.17	1.17	0.83	0.50	0.33		
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.50	0.50	0.67	0.50	0.50	0.33	0.00		
			4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			5.RETARDATION	2.00	1.75	2.00	1.50	1.50	2.00	1.75	1.50	1.50	1.00		
			6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.33	1.33	1.33	1.00	1.00	1.00	1.00		
			7.Total score	6.67	6.58	6.33	6.00	5.17	6.17	5.75	5.08	4.33	2.33		
9DI	Reboxetine	Female	1.ANXIETY/SOMATIZATION	0.83	1.00	0.83	0.83	0.33	0.17	0.00	0.00	0.00	0.00		
			2.WEIGHT	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	0.67	0.67	0.33	0.33	0.17	0.17	0.17	0.00	0.00	0.00		
			4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			5.RETARDATION	2.00	2.00	1.50	1.25	1.50	0.25	0.25	0.50	0.50	0.50		
			6.SLEEP DISTURBANCE	0.33	0.33	0.33	0.33	0.33	0.00	0.33	0.00	0.33	0.00		
			7.Total score	4.83	5.00	4.00	2.75	2.33	1.92	0.42	0.83	0.50	0.67		

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

7

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
5	12DT	Imipramine	Male	6.SLEEP DISTURBANCE	1.00	1.00	0.67	0.67	0.67	0.67	0.33	0.33	0.33	0.00	
				7.Total score	5.58	5.75	5.08	2.83	2.83	2.25	1.42	1.25	0.67		
6	14D	Reboxetine	Female	1.ANXIETY/SOMATIZATION	0.83	0.83	0.67	0.50	0.50	0.33	0.17	0.17	0.17	0.00	
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.17	0.00	0.00	0.00	0.00	0.00	0.17	0.17
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.50	2.50	2.25	1.50	1.50	1.25	1.00	0.75	0.67	0.67	0.67
				6.SLEEP DISTURBANCE	1.67	1.67	1.33	1.00	1.00	0.67	0.67	0.67	0.67	0.67	0.67
				7.Total score	8.33	8.33	6.08	5.42	4.00	3.25	2.83	2.75	2.58		
1D1	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.50	0.83	0.50	0.67	0.67	0.33	0.50	0.50		
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	0.83	1.00	0.83	0.67	0.33	0.33	0.17	0.33	0.17	0.33		
			4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			5.RETARDATION	2.00	1.75	1.75	1.25	1.00	1.00	0.50	0.50	0.50	0.50		
			6.SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	0.67	0.33	0.33	0.33	0.33	0.67		
			7.Total score	5.50	5.42	5.08	3.75	2.50	2.67	1.83	1.33	2.00	2.08		
2D1	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.50	2.00									
			2.WEIGHT	0.00	0.00	0.00									
			3.COGNITIVE DISTURBANCE	0.83	1.00	1.17									
			4.DIURNAL VARIATION	0.00	0.00	0.00									
			5.RETARDATION	2.25	2.25	2.50									
			6.SLEEP DISTURBANCE	1.67	1.67	2.00									
			7.Total score	6.08	6.42	7.67									
3D1	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.17									
			2.WEIGHT	2.00	0.00	0.00									
			3.COGNITIVE DISTURBANCE	0.17	0.17	0.17									
			4.DIURNAL VARIATION	2.00	2.00	2.00									
			5.RETARDATION	2.25	2.25	2.25									
			6.SLEEP DISTURBANCE	1.00	1.00	1.00									
			7.Total score	8.75	6.75	6.58									
5	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.50	1.00	1.00	1.00	1.17	1.50	1.67		
			2.WEIGHT	2.00	1.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	1.17	1.17	1.17	1.00	1.00	0.83	0.50	1.17	1.00	1.00		
			4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			5.RETARDATION	2.25	2.50	2.25	2.00	2.00	2.00	1.75	1.75	1.75	1.75		
			6.SLEEP DISTURBANCE	1.33	1.67	2.00	1.67	1.33	1.00	1.00	1.33	1.00	1.33		
			7.Total score	9.25	8.83	9.92	7.17	7.17	5.17	4.58	4.42	5.75	5.75		
3D1	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	1.00	1.33	1.17	0.33	0.83	1.17	1.00	1.00		
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			3.COGNITIVE DISTURBANCE	0.50	0.50	0.33	0.50	0.17	0.33	0.33	0.33	0.17			

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

8

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
6	3DT	Imipramine	Female	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	1.00	1.00	1.00	1.00
				2.50	2.50	2.25	2.50	2.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00
				1.33	1.33	0.67	1.33	1.00	0.67	1.67	1.00	1.00	1.00	1.00	1.00
				6.50	6.50	5.25	6.67	5.67	3.17	4.83	5.50	5.33	5.17		
4MD	Imipramine	Female	1.17	1.17	1.50	1.50	1.50	1.50	1.50	1.50	1.50				
			2.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			0.17	0.17	0.17	0.33	0.33	0.33	0.33	0.50					
			1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00					
4DT	Imipramine	Female	1.50	1.33	1.17	1.17	0.83	0.67	0.67	0.67	0.67	0.83	0.50	0.50	0.50
			0.00	0.00	0.00	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
			0.50	0.67	0.67	0.33	0.17	0.17	0.00	0.00	0.00	0.00	0.00	0.17	0.00
			0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
4F	Imipramine	Female	2.25	2.00	2.00	2.00	2.00	1.83	1.75	1.75	1.75	0.75	0.75	0.50	0.50
			0.67	1.00	0.67	0.67	0.67	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33
			4.92	5.00	4.50	5.83	2.42	1.92	1.75	1.92	1.50	1.33	2.00	1.33	
			1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17
5MD	Imipramine	Female	1.17	1.17	1.17	1.17	1.17	1.33	1.33	1.33	1.00	1.17	1.17	1.17	1.33
			2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
			0.50	0.83	0.50	0.50	0.50	0.33	0.50	0.50	0.50	0.50	0.50	0.50	0.50
			0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5DT	Reboxetine	Female	0.83	0.83	1.00	1.00	0.83	0.67	0.67	0.67	0.67	0.50	0.33	0.33	0.33
			0.00	0.00	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
			0.50	0.67	0.50	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17
			0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
6MD	Reboxetine	Female	1.75	1.75	1.75	1.50	1.50	1.25	1.00	1.00	1.00	1.00	1.00	1.00	1.00
			1.67	1.33	1.67	1.33	1.00	0.67	0.67	0.67	0.67	0.67	0.67	0.67	
			4.75	4.58	6.92	3.83	3.08	2.50	2.50	2.50	2.50	2.50	2.50	2.50	
			1.00	0.83	0.67	0.67	0.67	0.83	1.00						
7MD	Reboxetine	Female	0.33	0.33	0.00	0.00	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17
			0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			2.75	2.25	1.75	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	
			1.33	1.00	0.67	0.67	1.33	1.67	1.33	1.67	1.33	1.67	1.33	1.67	

9550089

9

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

Centre	Patient Treatment	Sex	Hamilton depression rating scale	HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE													
				Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63				
6	7MD	Female	2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
			3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.83	0.67	0.83	0.67	0.50	0.17	0.17	0.17	0.17	0.00	0.00
			4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
			5.RETARDATION	2.25	2.25	2.25	2.00	2.00	2.00	1.75	1.50	1.00	0.75	1.00	1.00	1.00	1.00
			6.SLEEP DISTURBANCE	1.67	1.67	1.33	1.33	1.33	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
			7.Total score	7.75	5.92	5.75	5.42	5.50	5.33	4.42	3.83	2.89	2.58	2.89	2.89	2.89	2.89
			1.ANXIETY/SOMATIZATION	1.17	1.17	1.50	1.17	0.67	0.83	0.83	0.83	0.67	0.50	0.50	0.50	0.50	0.33
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
7	1MD 1442	Male	1.ANXIETY/SOMATIZATION	1.00	1.00	1.17	0.50	0.50	0.50	0.50	0.67	0.50	0.50	0.17	0.17		
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	0.50	0.50	0.67	0.33	0.33	0.33	0.33	0.33	0.17	0.17	0.17	0.17		
			4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			5.RETARDATION	1.75	1.75	1.50	0.80	0.80	0.80	0.80	0.80	0.80	0.80	0.80	0.80		
			6.SLEEP DISTURBANCE	1.67	1.67	0.00	0.00	0.00	0.33	0.33	0.33	0.00	0.67	0.67	0.67		
			7.Total score	4.92	6.92	3.33	0.83	0.83	1.33	1.17	0.67	1.00	1.00	1.00	1.00		
			1.ANXIETY/SOMATIZATION	1.00	1.00	1.17	0.50	0.50	0.50	0.50	0.67	0.50	0.50	0.50	0.50		
3MD	Imipramine	Female	1.ANXIETY/SOMATIZATION	0.50	0.50	1.67	1.50	1.33	1.33	1.50	0.67	0.83	0.83	0.83			
			2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			3.COGNITIVE DISTURBANCE	0.50	0.33	0.50	0.50	0.17	0.33	0.17	0.33	0.17	0.00	0.00			
			4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00			
			5.RETARDATION	1.75	2.25	2.25	2.00	1.50	1.00	1.00	1.00	1.00	1.00	1.00			
			6.SLEEP DISTURBANCE	0.67	0.67	0.67	0.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			7.Total score	7.42	7.75	7.08	6.67	4.00	5.83	1.83	2.00	1.08	1.08	1.08			
			1.ANXIETY/SOMATIZATION	1.83	1.50	1.83	1.33	1.67	1.67	1.67	1.67	1.67	1.67	1.67			
4MD	Reboxetine	Female	1.ANXIETY/SOMATIZATION	2.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
			2.WEIGHT	0.17	0.33	0.33	0.50	0.50	0.50	0.50	0.50	0.50	0.50				
			3.COGNITIVE DISTURBANCE	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00				
			4.DIURNAL VARIATION	1.25	1.25	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75				
			5.RETARDATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00				
			6.SLEEP DISTURBANCE	8.25	8.08	8.92	7.58	7.92	7.92	7.92	7.92	7.92	7.92				
			7.Total score	16.67	16.67	16.67	16.67	16.67	16.67	16.67	16.67	16.67	16.67				
			1.ANXIETY/SOMATIZATION	1.67	1.83	1.17	1.50	1.17	1.00	1.17	1.00	1.17	1.00	0.83			
34-2MD	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.83	1.17	1.50	1.17	1.00	1.17	1.00	1.17	1.00				
			2.WEIGHT	2.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
			3.COGNITIVE DISTURBANCE	1.17	1.17	1.00	1.00	1.17	1.17	1.17	1.17	1.17	1.17				
			4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
			5.RETARDATION	3.25	3.00	3.00	2.25	3.00	2.75	2.75	2.75	2.75	2.50				
			6.SLEEP DISTURBANCE	0.33	1.33	1.00	1.00	0.67	1.00	1.33	1.00	1.00	1.00				
			7.Total score	8.42	9.33	7.33	5.75	6.00	5.92	6.42	7.58	5.67	5.35				
			1.ANXIETY/SOMATIZATION	1.67	1.83	1.17	1.50	1.17	1.00	1.17	1.00	1.17	1.00				

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

10

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day		
8	1ND	Reboxetine	Female	Hamilton depression rating scale	2.00	2.00	1.67	1.33	1.17	1.17	1.17	0.33	0.50	1.17		
				1.ANXIETY/SOMATIZATION	2.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	2.00	1.83	0.83	0.83	0.83	0.17	0.00	0.00	0.00	0.00	0.17	0.67
				4.DIURNAL VARIATION	1.00	2.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.75	1.75	1.75	2.00	2.00	1.75	1.50	2.75	1.50	1.25	2.50	2.50
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	2.00	2.00	2.00	0.00	0.00	0.00	0.00	0.00	1.67
7.Total score	9.08	9.92	6.58	7.17	7.00	6.75	4.08	1.83	1.92	6.00	1.92	6.00				
10T	Imipramine	Female	Hamilton depression rating scale	1.50	1.17	1.17	0.17	0.83	0.67	0.00	0.33	0.33	0.33	0.33		
			1.ANXIETY/SOMATIZATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			2.WEIGHT	0.83	1.17	0.17	0.00	0.33	0.17	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	0.00	0.00	0.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00		
			4.DIURNAL VARIATION	2.00	2.25	2.25	1.50	1.00	1.25	0.00	0.00	0.00	0.00	0.00		
			5.RETARDATION	0.67	0.67	0.33	0.00	0.00	0.00	0.00	0.33	0.33	0.33	0.00		
			6.SLEEP DISTURBANCE	5.00	5.25	3.92	2.67	3.17	2.08	0.33	0.67	0.67	0.67	0.67		
7.Total score	1.17	1.17	0.50	0.50	0.50	0.33	0.33	0.33	0.33	0.33	0.33					
2ND	Reboxetine	Female	Hamilton depression rating scale	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17			
			1.ANXIETY/SOMATIZATION	3.00	3.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			2.WEIGHT	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17		
			3.COGNITIVE DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			4.DIURNAL VARIATION	2.50	2.50	2.00	1.75	1.75	1.75	1.50	0.50	0.00	0.00	0.00		
			5.RETARDATION	0.33	0.33	0.67	0.67	0.67	0.67	0.33	0.00	0.00	0.00	0.00		
			6.SLEEP DISTURBANCE	8.17	8.17	4.33	4.08	3.92	1.50	0.50	0.67	0.67	0.67	0.67		
7.Total score	1.50	1.50	0.67	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50					
2DT	Imipramine	Female	Hamilton depression rating scale	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67			
			1.ANXIETY/SOMATIZATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			2.WEIGHT	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83			
			3.COGNITIVE DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			4.DIURNAL VARIATION	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.25			
			5.RETARDATION	0.40	0.40	0.40	0.40	0.40	0.40	0.40	0.40	0.40	0.40			
			6.SLEEP DISTURBANCE	4.75	4.75	3.75	3.17	2.17	2.17	2.17	2.17	2.17	2.17			
7.Total score	0.83	0.83	0.33	0.17	0.00	0.33	0.33	0.33	0.33	0.33						
3ND	Imipramine	Female	Hamilton depression rating scale	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00			
			1.ANXIETY/SOMATIZATION	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83			
			2.WEIGHT	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83			
			3.COGNITIVE DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			4.DIURNAL VARIATION	2.75	2.75	2.50	1.50	0.25	1.50	0.00	0.00	0.00	0.00			
			5.RETARDATION	2.75	2.75	2.50	1.50	0.25	1.50	0.00	0.00	0.00	0.00			
			6.SLEEP DISTURBANCE	2.75	2.75	2.50	1.50	0.25	1.50	0.00	0.00	0.00	0.00			
7.Total score	0.83	0.83	0.33	0.17	0.00	0.33	0.33	0.33	0.33	0.33						
3DT	Reboxetine	Female	Hamilton depression rating scale	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00			
			1.ANXIETY/SOMATIZATION	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83			
			2.WEIGHT	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83			
			3.COGNITIVE DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			4.DIURNAL VARIATION	2.75	2.75	2.50	1.50	0.25	1.50	0.00	0.00	0.00	0.00			
			5.RETARDATION	2.75	2.75	2.50	1.50	0.25	1.50	0.00	0.00	0.00	0.00			
			6.SLEEP DISTURBANCE	2.75	2.75	2.50	1.50	0.25	1.50	0.00	0.00	0.00	0.00			
7.Total score	0.83	0.83	0.33	0.17	0.00	0.33	0.33	0.33	0.33	0.33						

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
8	30F	Reboxetine	Female	6.SLEEP DISTURBANCE	0.00	0.00	2.00	1.00	0.00	0.33	0.33	0.00	0.00	0.00
				7.Total score	6.42	6.42	7.67	3.17	1.42	2.17	0.83	0.83	0.33	0.33
4M	4M	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.83	1.83	1.83	2.67	2.67					
				2.WEIGHT	0.00	0.00	1.00	0.00	0.00					
4M	4M	Imipramine	Male	3.COGNITIVE DISTURBANCE	1.17	1.50	1.33	2.00	2.17					
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00					
4M	4M	Imipramine	Male	5.RETARDATION	2.75	2.75	2.75	2.25	2.25					
				6.SLEEP DISTURBANCE	1.33	1.33	2.00	1.00	1.00					
4M	4M	Imipramine	Male	7.Total score	7.08	7.42	8.32	7.92	8.08					
				1.ANXIETY/SOMATIZATION	1.17	1.17	0.33	0.33	0.33	0.00	0.33	0.33	0.33	0.33
4M	4M	Imipramine	Male	2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.17	0.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
4M	4M	Imipramine	Male	4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	1.00	1.00	1.00	0.25	0.50	0.25	0.25	0.25
4M	4M	Imipramine	Male	6.SLEEP DISTURBANCE	0.67	0.67	0.67	0.33	0.67	0.00	0.00	0.00	0.00	0.67
				7.Total score	6.00	6.00	2.00	1.67	2.00	0.25	0.83	0.58	0.58	0.58
70M	70M	Imipramine	Male	1.ANXIETY/SOMATIZATION	0.50	0.50	1.00	0.67	0.67	0.33	0.33	0.33	0.00	0.33
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
70M	70M	Imipramine	Male	3.COGNITIVE DISTURBANCE	1.17	1.33	1.33	0.17	0.17	0.17	0.17	0.00	0.00	0.33
				4.DIURNAL VARIATION	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
70M	70M	Imipramine	Male	5.RETARDATION	2.00	2.00	2.25	0.50	0.50	0.00	0.00	0.00	0.00	0.00
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	0.00	0.33	2.00	0.00	0.00	0.00	0.00
70M	70M	Imipramine	Male	7.Total score	7.00	7.17	6.92	1.33	2.25	2.50	0.50	0.33	0.00	0.67
				1.ANXIETY/SOMATIZATION	0.67	0.67	0.67	0.83	0.00	0.00	0.00	0.00	0.00	0.00
70M	70M	Imipramine	Male	2.WEIGHT	0.00	2.00	0.00	0.00	0.00	2.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.17	0.33	0.00	0.17	0.00	0.17	0.00	0.00
70M	70M	Imipramine	Male	4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.50	2.00	1.50	1.25	1.25	1.25	0.50	1.00
70M	70M	Imipramine	Male	6.SLEEP DISTURBANCE	0.67	0.67	0.00	0.00	0.33	0.00	0.33	0.00	1.00	0.67
				7.Total score	4.25	6.25	2.33	3.17	1.83	3.42	1.58	0.50	2.17	2.08
70M	70M	Imipramine	Male	1.ANXIETY/SOMATIZATION	0.83	0.83	0.67	0.50	0.33	0.33	0.33	0.50	0.17	0.33
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
70M	70M	Imipramine	Male	3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.67	0.50	0.33	0.33	0.33	0.33	0.67
				4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
70M	70M	Imipramine	Male	5.RETARDATION	2.50	2.50	2.25	1.25	1.25	1.50	1.50	1.50	1.50	1.75
				6.SLEEP DISTURBANCE	0.00	0.00	0.00	0.00	0.67	0.00	0.33	0.00	0.33	0.00
70M	70M	Imipramine	Male	7.Total score	6.83	6.83	4.42	3.08	2.56	2.50	2.67	3.33	3.00	3.75
				1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	0.00	0.93	0.33	0.33	0.33	0.00	0.50
70M	70M	Imipramine	Male	2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.17	0.17	0.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS BRD
REBOXETINE - PROTOCOL 2012A-835
Listing No. 3 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Combo Patient Treatment	Sex	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	Day 63				
8	702DT	Imipramine	Female	Hamilton depression rating scale												
				4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				5. COGNITIVE DISTURBANCE	2.50	2.25	1.50	1.50	0.75	1.25	0.50	0.50	0.50	0.00	0.00	
				6. SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				7. Total score	6.67	6.42	3.67	3.67	1.88	1.58	0.83	0.83	0.50	1.00	0.17	
				1. ANXIETY/SOMATIZATION	1.83	2.00	2.00	2.00	2.00	1.75	1.75	1.75	1.75	1.75	1.75	1.00
				2. WEIGHT	0.33	0.17	0.17	0.17	0.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00
3. COGNITIVE DISTURBANCE	1.00	2.00	2.00	2.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00				
4. DIURNAL VARIATION	1.50	1.75	1.75	2.00	2.25	1.00	1.25	1.25	1.25	1.25	1.25	1.25				
5. RETARDATION	2.00	2.00	2.00	2.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00				
6. SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00				
7. Total score	6.67	7.52	7.52	7.52	7.52	4.17	3.08	3.08	3.08	3.08	4.23					
9	703DT	Imipramine	Male	Hamilton depression rating scale												
				4. DIURNAL VARIATION	1.33	1.67	1.67	1.50	1.50	0.67	0.50	0.50	0.50	0.50		
				5. COGNITIVE DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				6. SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	
				7. Total score	2.50	2.25	2.25	2.25	2.25	1.50	1.50	1.50	1.50	1.50	1.00	
				1. ANXIETY/SOMATIZATION	1.00	1.00	1.67	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	
				2. WEIGHT	7.33	5.42	6.08	7.25	7.25	3.33	3.17	3.17	3.17	3.17	1.67	
3. COGNITIVE DISTURBANCE	1.50	1.50	1.50	1.33	0.33	0.33	0.00	0.00	0.00	0.00	0.00					
4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00					
5. RETARDATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00					
6. SLEEP DISTURBANCE	1.75	1.75	1.75	1.25	1.00	0.00	0.00	0.25	0.25	0.25	0.25					
7. Total score	1.33	2.00	2.00	1.00	0.67	2.00	1.33	1.33	0.67	0.67	0.67					
10	704DT	Reboxetine	Female	Hamilton depression rating scale												
				4. DIURNAL VARIATION	1.67	1.50	1.50	1.50	1.50	0.67	0.50	0.50	0.50	0.50		
				5. COGNITIVE DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				6. SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				7. Total score	4.75	5.25	5.25	5.58	5.08	2.33	1.58	1.58	2.08	0.92	1.25	
				1. ANXIETY/SOMATIZATION	1.67	1.50	1.50	1.50	1.50	0.67	0.50	0.50	0.50	0.50	0.50	
				2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
3. COGNITIVE DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00					
4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00					
5. RETARDATION	1.00	1.50	1.00	1.00	1.00	0.00	0.25	0.25	0.25	0.25	0.25					
6. SLEEP DISTURBANCE	1.33	2.00	2.00	2.00	2.00	2.00	1.67	1.67	1.67	1.67	1.67					
7. Total score	5.17	6.17	5.50	5.50	7.50	4.75	2.58	2.58	2.42	3.17	3.42					
11	705DT	Imipramine	Female	Hamilton depression rating scale												
				4. DIURNAL VARIATION	1.00	1.00	0.33	0.50	0.50	0.50	0.67	0.50	0.67	0.33		
				5. COGNITIVE DISTURBANCE	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				6. SLEEP DISTURBANCE	1.00	1.00	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17		
				7. Total score	2.50	2.50	0.75	1.25	1.25	1.25	1.25	1.25	1.25	0.50		
				1. ANXIETY/SOMATIZATION	1.33	1.33	1.33	0.67	0.67	1.00	1.00	1.00	1.00	1.00		
				2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
3. COGNITIVE DISTURBANCE	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
4. DIURNAL VARIATION	1.00	1.00	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17						
5. RETARDATION	2.50	2.50	0.75	1.25	1.25	1.25	1.25	1.25	1.25	0.50						
6. SLEEP DISTURBANCE	1.33	1.33	1.33	0.67	0.67	1.00	1.00	1.00	1.00	1.00						
7. Total score	7.83	7.83	4.42	2.58	2.58	2.58	2.33	2.33	2.33	1.33						
12	707DT	Imipramine	Female	Hamilton depression rating scale												
				4. DIURNAL VARIATION	1.33	1.33	1.00	0.67	0.00	0.50	0.00	0.47	0.00	0.00		
				5. COGNITIVE DISTURBANCE	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				6. SLEEP DISTURBANCE	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				7. Total score	3.33	3.33	1.00	0.67	0.00	0.50	0.00	0.47	0.00	0.00		
				1. ANXIETY/SOMATIZATION	1.33	1.33	1.00	0.67	0.00	0.50	0.00	0.47	0.00	0.00		
				2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
3. COGNITIVE DISTURBANCE	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
4. DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
5. RETARDATION	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
6. SLEEP DISTURBANCE	1.33	1.33	1.33	0.67	0.67	1.00	1.00	1.00	1.00	1.00						
7. Total score	7.83	7.83	4.42	2.58	2.58	2.58	2.33	2.33	2.33	1.33						

9550089

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day	
9	1D1	Imipramine	Female	2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.25	1.25	1.25	1.50	0.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				6.SLEEP DISTURBANCE	0.33	0.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				7.Total score	6.58	4.92	3.92	3.17	2.25	0.50	0.00	0.00	0.00	0.00	0.00	0.00
				2HD	Reboxetine	Female	1.ANKIETY/SOMATIZATION	1.17	1.17	1.33	0.67	0.83	0.67	1.00	0.83	0.83
			2.WEIGHT	2.00	2.00	2.00	1.00	0.00	0.00	1.00	1.00	1.00	1.00	0.00		
			3.COGNITIVE DISTURBANCE	0.83	0.67	0.67	0.50	0.83	0.33	0.50	0.17	0.17	0.00	0.00		
			4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	2.00	1.00	1.00	1.00	1.00	1.00	0.00		
			5.RETARDATION	2.00	2.25	2.25	2.50	2.50	2.50	2.50	2.25	2.25	2.25	1.25		
			6.SLEEP DISTURBANCE	2.00	2.00	1.33	1.00	1.00	0.67	0.67	0.00	0.00	0.00	0.00		
			7.Total score	9.00	9.08	8.58	5.67	7.17	5.17	6.67	5.25	5.25	5.25	1.58		
2DI	Imipramine	Female	1.ANKIETY/SOMATIZATION	1.00	1.00	1.00	0.67	0.50	0.17	0.33	0.33	0.33	0.00	0.00		
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	0.67	0.67	0.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			5.RETARDATION	2.50	2.50	1.75	0.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			6.SLEEP DISTURBANCE	0.67	0.67	0.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			7.Total score	5.83	5.83	4.42	0.92	0.50	0.17	0.33	0.33	0.00	0.00			
3DI	Reboxetine	Female	1.ANKIETY/SOMATIZATION	1.00	0.83	1.00	0.83	0.17	0.17	0.17	0.17	0.00	0.33	0.17		
			2.WEIGHT	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	0.50	0.50	0.33	0.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			4.DIURNAL VARIATION	2.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			5.RETARDATION	2.25	1.75	1.50	1.50	0.25	0.50	0.75	0.00	0.00	0.00	0.00		
			6.SLEEP DISTURBANCE	0.00	0.33	0.33	0.67	1.00	1.00	1.00	1.00	1.00	0.00	0.00		
			7.Total score	6.75	4.42	4.17	4.33	1.42	1.67	2.75	2.75	0.33	0.17			
4MD	Imipramine	Female	1.ANKIETY/SOMATIZATION	1.00	0.83	0.33	0.67	0.50	0.67	0.50	0.50	0.00	0.00	0.00		
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			3.COGNITIVE DISTURBANCE	0.67	0.67	0.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00			
			5.RETARDATION	2.75	2.00	2.00	1.50	1.00	0.50	0.00	0.00	0.00	0.00			
			6.SLEEP DISTURBANCE	0.00	0.00	0.67	0.00	0.33	0.00	0.00	0.00	0.00	0.00			
			7.Total score	6.42	5.50	4.17	3.17	2.83	2.17	2.00	0.00	0.00	0.00			
5MD	Reboxetine	Female	1.ANKIETY/SOMATIZATION	1.00	1.00	0.83	0.83	0.83	0.83	0.83	0.67	0.67	0.67	0.17		
			2.WEIGHT	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00		
			3.COGNITIVE DISTURBANCE	0.67	1.00	0.67	0.67	0.67	0.50	0.50	0.33	0.17	0.00			
			4.DIURNAL VARIATION	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00		
			5.RETARDATION	2.75	2.50	1.75	1.50	1.75	1.50	1.50	1.50	1.25	0.50			
			6.SLEEP DISTURBANCE	0.00	1.33	1.00	1.00	1.00	0.67	0.67	0.67	0.00	0.00			
			7.Total score	6.42	7.83	6.25	6.00	6.25	5.67	5.33	5.33	3.25	0.83			

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

14

PHARMACIA CMS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 42.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
9	6HD	Imipramine	Female	1. ANXIETY/SOMATIZATION	1.17	0.83	1.00									
				2. WEIGHT	1.00	0.00	0.00									
				3. COGNITIVE DISTURBANCE	0.83	0.50	0.67									
				4. DIURNAL VARIATION	1.00	1.00	1.00									
				5. RETARDATION	2.50	2.00	2.00									
				6. SLEEP DISTURBANCE	0.33	1.33	1.33									
				7. Total score	6.83	5.67	6.00									
7HD	Imipramine	Female	1. ANXIETY/SOMATIZATION	1.33	1.17	1.17										
			2. WEIGHT	2.00	0.00	0.00										
			3. COGNITIVE DISTURBANCE	0.50	0.50	0.50										
			4. DIURNAL VARIATION	1.00	1.00	1.00										
			5. RETARDATION	2.00	2.25	2.00										
			6. SLEEP DISTURBANCE	0.00	0.00	0.67										
			7. Total score	6.83	4.92	5.55										
8DT	Reboxetine	Female	1. ANXIETY/SOMATIZATION	1.00	1.17	1.17	1.00	0.83	1.00	0.83	1.00	0.83	0.83	0.67		
			2. WEIGHT	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			3. COGNITIVE DISTURBANCE	0.33	0.50	0.50	0.50	0.50	0.50	0.67	0.50	0.33	0.50	0.00	0.00	
			4. DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
			5. RETARDATION	1.75	1.75	2.00	2.00	2.00	2.25	1.75	1.25	1.75	1.25	1.60	1.00	
			6. SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	0.67	0.33	0.33	0.33	0.33	0.00	0.33	0.00	
			7. Total score	6.08	6.42	5.67	5.50	5.00	5.25	4.25	3.75	2.83	3.00	3.00	2.83	
10	1HD	Imipramine	Female	1. ANXIETY/SOMATIZATION	1.50	1.50	1.33	0.83	0.50	0.33	0.33	0.33	0.33	0.67		
				2. WEIGHT	1.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3. COGNITIVE DISTURBANCE	0.50	0.33	0.50	0.00	0.17	0.17	0.17	0.33	0.17	0.33	0.17	0.00
				4. DIURNAL VARIATION	1.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5. RETARDATION	2.25	2.25	2.00	2.00	1.50	1.00	0.50	0.50	0.50	0.25	0.75	0.75
				6. SLEEP DISTURBANCE	1.67	1.33	1.00	1.33	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67
				7. Total score	7.92	9.42	5.83	5.17	3.83	3.17	1.67	1.83	1.42	2.08	1.42	2.08
10	1DT	Reboxetine	Female	1. ANXIETY/SOMATIZATION	1.83	1.67	1.50	1.17	1.00	0.83	0.67	0.50	0.67	0.67		
				2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3. COGNITIVE DISTURBANCE	0.67	0.67	0.83	0.50	0.67	0.17	0.00	0.00	0.00	0.00	0.17	
				4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				5. RETARDATION	1.50	1.75	1.50	1.50	1.00	0.25	0.00	0.00	0.00	0.00	0.00	
				6. SLEEP DISTURBANCE	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	0.57	0.00	
				7. Total score	4.00	4.08	3.83	3.17	2.67	2.25	3.67	1.50	1.33	0.83	0.83	
10	2HD	Reboxetine	Male	1. ANXIETY/SOMATIZATION	1.33	1.33	1.50	1.33	1.17	0.83	0.33	0.67	0.50	0.67		
				2. WEIGHT	0.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3. COGNITIVE DISTURBANCE	1.00	1.00	1.00	0.67	0.33	0.17	0.17	0.33	0.17	0.17	0.17	
				4. DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				5. RETARDATION	2.50	2.75	2.50	1.75	1.50	1.00	0.75	1.00	0.75	1.00	0.50	

1447

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

15

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Screen Day	0	7	14	21	28	35	42	49	56	Day 63			
10	2HD	Reboxetine	Male	Hamilton depression rating scale	1.67	1.67	1.00	1.00	1.00	1.00	1.00	1.00	0.67	0.67			
				7.Total score	7.50	9.75	7.00	5.75	5.00	3.00	2.25	3.00	1.83	2.00			
10	2DT	Imipramine	Male	6.SLEEP DISTURBANCE	1.83	1.83	1.67	1.33	0.83	0.83	0.67	1.17	0.83	1.00	1.00		
				7.Total score	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				1.ANXIETY/SOMATIZATION	0.50	0.50	0.67	0.50	0.33	0.17	0.17	0.00	0.00	0.00	0.00	0.00	0.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.75	1.75	1.50	0.75	0.25	0.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				6.SLEEP DISTURBANCE	4.08	4.08	3.83	2.58	1.42	1.25	1.08	2.08	1.08	1.42	1.08	1.08	1.42
7.Total score	1.67	1.67	1.67	1.50	1.33	1.33	1.17	1.00	0.83	0.67	1.00	0.83	0.67				
10	3HD	Reboxetine	Male	1.ANXIETY/SOMATIZATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				2.WEIGHT	0.83	0.83	0.83	0.83	0.83	0.50	0.33	0.50	0.17	0.33	0.33	0.33	
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	1.00	2.00	1.00	2.00	1.00	1.00	1.00	1.00	1.00	
				4.DIURNAL VARIATION	2.25	2.50	2.50	2.25	2.50	1.75	1.50	1.25	1.50	1.00	0.75	1.00	
				5.RETARDATION	1.33	1.67	1.33	1.33	1.33	1.00	0.67	0.67	0.67	0.67	0.67	0.67	
				6.SLEEP DISTURBANCE	8.08	7.67	9.33	7.92	8.17	7.58	6.00	4.42	2.67	3.42	2.67	3.42	
				7.Total score	1.67	1.67	1.67	1.50	1.33	1.33	1.17	1.00	0.83	0.67	1.00	0.83	0.67
				7.Total score	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
10	3DT	Imipramine	Male	1.ANXIETY/SOMATIZATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				2.WEIGHT	0.50	0.50	0.33	0.33	0.17	0.50	0.00	0.17	0.50	0.00	0.17	0.00	
				3.COGNITIVE DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				4.DIURNAL VARIATION	1.50	1.75	2.25	1.50	1.00	0.75	0.25	0.25	0.25	0.25	0.25	0.25	
				5.RETARDATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				6.SLEEP DISTURBANCE	3.67	3.92	4.08	3.00	2.33	2.25	1.25	1.25	1.08	2.92	1.08	2.92	
				7.Total score	1.67	1.67	1.67	1.50	1.17	1.17	1.00	0.83	0.67	0.67	0.67	0.67	
				7.Total score	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
10	4HD	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00		
				2.WEIGHT	0.83	0.83	0.67	0.50	0.17	0.17	0.00	0.17	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	1.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
				4.DIURNAL VARIATION	3.00	3.00	2.50	1.50	1.25	1.00	0.75	0.25	0.25	0.25	0.25		
				5.RETARDATION	0.00	0.00	0.00	0.00	1.33	1.33	1.33	1.33	1.33	1.33	1.33		
				6.SLEEP DISTURBANCE	7.50	7.50	8.83	6.50	4.92	4.50	4.00	3.75	1.92	1.92	1.92		
				7.Total score	1.67	1.67	1.67	1.50	1.17	1.17	1.00	0.83	0.67	0.67	0.67		
				7.Total score	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
10	4DT	Reboxetine	Female	1.ANXIETY/SOMATIZATION	0.50	0.50	0.50	0.50	0.33	0.33	0.00	0.00	0.00	0.00			
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				4.DIURNAL VARIATION	1.50	1.75	2.25	1.25	1.25	1.00	0.50	0.50	0.25	0.50	0.50		
				5.RETARDATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				6.SLEEP DISTURBANCE	3.67	4.08	4.00	2.92	1.83	1.00	0.92	1.50	1.50	1.50	1.50		
				7.Total score	1.67	1.50	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67		
				7.Total score	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
10	5HD	Imipramine	Female	1.ANXIETY/SOMATIZATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
				2.WEIGHT	0.50	0.67	0.50	0.67	0.67	0.33	0.00	0.17	0.00	0.00			
				3.COGNITIVE DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			

1448

9550089

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

16

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
10	5MD	Imipramine	Female	Hamilton depression rating scale	1.00	2.00	1.00	1.00	2.00	1.00	1.00	0.00	0.00	0.00	0.00
				4. DIURNAL VARIATION	2.50	2.50	2.00	2.00	1.75	1.25	0.50	0.50	0.50	0.50	
				7. Total score	1.67	1.67	1.67	1.00	0.67	0.33	0.00	0.33	0.00	0.33	0.00
5DT	Reboxetine	Female	Hamilton depression rating scale	1.83	1.67	1.50	1.67	1.83	1.50	1.83	1.50	1.33	1.33	1.50	1.50
			1. ANXIETY/SOMATIZATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
			7. Total score	3.58	3.83	3.83	4.08	3.75	4.58	3.92	4.00	3.75	4.00	3.75	
6MD	Reboxetine	Male	Hamilton depression rating scale	1.83	1.67	1.83	1.50	2.17	2.17	2.00	1.83	1.83	1.83	1.50	
			1. ANXIETY/SOMATIZATION	0.50	0.50	0.83	0.67	0.50	0.67	1.00	0.83	0.67	0.50	0.50	
			7. Total score	2.25	2.25	2.25	2.43	2.00	2.25	2.00	2.25	2.00	2.25	2.25	
6DT	Reboxetine	Male	Hamilton depression rating scale	1.33	1.50	1.00	1.00	0.83	0.67	0.50	0.50	0.50	0.50	0.50	
			1. ANXIETY/SOMATIZATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			7. Total score	3.67	4.08	3.17	2.33	2.25	1.17	3.00	3.17	2.75	1.00		
7MD	Imipramine	Male	Hamilton depression rating scale	2.17	2.00	1.33	1.17	1.17	0.83	0.50	0.83	0.50	0.50	0.50	
			1. ANXIETY/SOMATIZATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			7. Total score	8.00	7.00	6.50	5.08	4.67	3.75	1.92	2.00	1.83	1.67		
7DT	Imipramine	Female	Hamilton depression rating scale	1.67	1.50	1.67	1.83	1.67	1.17	0.67	1.00	1.00	0.83	0.83	
			1. ANXIETY/SOMATIZATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			7. Total score	3.58	4.08	3.83	4.25	3.67	2.92	3.75	1.42	1.25	1.25		
8MD	Reboxetine	Male	Hamilton depression rating scale	1.83	2.00	1.67	1.17	0.83	1.00	0.83	0.67	0.50	0.50	0.50	
			1. ANXIETY/SOMATIZATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			7. Total score	3.58	4.08	3.83	4.25	3.67	2.92	3.75	1.42	1.25	1.25		

1449

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day			
10	8MD	Reboxetine	Male	Hamilton depression rating scale	1.00	0.00	0.00	0.00	0.00	0.00	2.00	0.00	0.00	0.00	0.00			
				2.WEIGHT	0.67	0.67	0.33	0.50	0.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				4.DIURNAL VARIATION	2.00	2.25	2.00	1.50	1.00	1.00	1.00	1.00	1.00	0.50	0.50	0.50	0.50	0.75
				5.RETARDATION	1.33	1.33	1.00	1.00	1.00	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.33
				6.SLEEP DISTURBANCE	7.83	7.25	6.00	5.17	4.00	2.17	4.00	2.00	1.83	1.83	1.75	1.75	1.75	1.75
				7.Total score	4.25	4.33	3.83	2.75	1.33	1.08	1.67	0.92	1.33	0.92	1.33	0.92	1.33	0.92
8DY	Imipramine	Female	Hamilton depression rating scale	1.83	2.00	1.67	1.17	0.67	0.50	1.00	0.50	0.50	0.83	0.83	0.50			
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	0.67	0.83	0.67	0.33	0.17	0.33	0.17	0.17	0.00	0.00	0.00	0.00	0.17		
			4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			5.RETARDATION	1.75	1.50	1.50	1.25	0.50	0.25	0.50	0.25	0.50	0.25	0.50	0.25	0.50		
			6.SLEEP DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			7.Total score	4.25	4.33	3.83	2.75	1.33	1.08	1.67	0.92	1.33	0.92	1.33	0.92	1.33	0.92	
9ND	Reboxetine	Female	Hamilton depression rating scale	1.83	1.83	1.67	1.33	1.33	1.33	1.00	0.67	0.67	0.67	0.67	0.50			
			2.WEIGHT	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	1.00	1.17	0.83	0.50	0.67	0.17	0.00	0.00	0.00	0.00	0.00	0.00	0.17		
			4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			5.RETARDATION	2.00	2.00	1.75	1.50	1.50	1.00	1.00	0.50	0.50	0.50	0.25	0.25	0.25		
			6.SLEEP DISTURBANCE	1.00	1.33	1.33	1.00	1.00	0.67	1.00	0.67	1.00	0.67	1.00	0.67	1.00		
			7.Total score	6.83	6.33	5.58	4.33	4.50	2.83	2.17	1.83	1.92	1.83	1.92	1.58	1.58		
9DT	Imipramine	Male	Hamilton depression rating scale	1.50	1.50	1.50	1.50	1.83	1.67	1.33	1.67	1.67	1.67	1.50				
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			3.COGNITIVE DISTURBANCE	1.00	0.83	1.00	0.83	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67			
			4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			5.RETARDATION	1.75	2.00	1.50	1.75	2.00	1.75	2.00	1.50	1.50	1.75	1.75	1.75			
			6.SLEEP DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			7.Total score	4.25	4.33	4.00	4.08	4.50	4.08	4.00	3.83	4.25	3.92	4.25	3.92			
10ND	Imipramine	Female	Hamilton depression rating scale	2.00	2.00	2.00	1.50	1.17	1.00	0.83	0.83	0.67	0.67	0.67				
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
			3.COGNITIVE DISTURBANCE	1.17	1.00	0.83	0.83	0.50	0.50	0.50	0.50	0.50	0.50	0.50				
			4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00				
			5.RETARDATION	1.75	2.00	1.75	1.50	1.00	0.25	0.25	0.25	0.25	0.25	0.25				
			6.SLEEP DISTURBANCE	1.67	1.67	1.33	1.00	1.00	1.00	0.67	0.67	0.67	0.67	0.67				
			7.Total score	7.58	7.67	6.92	5.83	4.67	4.50	1.75	1.58	2.25	1.83	2.25				
10DT	Reboxetine	Female	Hamilton depression rating scale	1.50	1.83	1.50	1.00	0.83	0.83	0.67	0.67	0.67	0.67					
			2.WEIGHT	2.00	0.00	0.00	0.00	0.00	2.00	0.00	0.00	0.00	0.00	0.00				
			3.COGNITIVE DISTURBANCE	0.00	0.17	0.17	0.33	0.00	0.17	0.00	0.17	0.17	0.17	0.17				
			4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
			5.RETARDATION	1.25	1.50	1.25	0.75	0.25	0.50	0.50	0.50	0.50	0.25	0.25				
			6.SLEEP DISTURBANCE	1.33	1.00	0.00	0.00	0.00	0.00	0.33	0.00	0.33	0.00	0.00				
			7.Total score	6.08	4.50	2.92	2.08	1.08	3.25	1.17	1.25	1.25	1.25	0.92				

1450

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

18

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Screen Day	0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63			
10	11ND	Imipramine	Female	Hamilton depression rating scale	2.33	2.17	2.00	1.67	1.33	1.00	0.67	0.67	0.67	0.67			
				1-ANXIETY/SOMATIZATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
				2-WEIGHT	0.33	0.17	0.00	0.17	0.00	0.17	0.00	0.17	0.00	0.17	0.00	0.17	0.17
				3-COGNITIVE DISTURBANCE	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				4-DIURNAL VARIATION	2.75	3.00	3.00	2.75	2.50	2.50	1.75	1.25	1.75	1.25	1.75	1.25	1.25
				5-RETARDATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				7-Total score	8.42	7.33	9.00	6.92	5.33	7.42	4.75	3.42	1.08	1.08	1.08	1.08	1.08
11DF	Imipramine	Female	Hamilton depression rating scale	2.00	1.67	1.50	0.67	0.33	0.17	0.50	0.50	0.50	0.50	0.33			
			1-ANXIETY/SOMATIZATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00		
			2-WEIGHT	0.17	0.33	0.17	0.33	0.17	0.17	0.00	0.00	0.00	0.00	0.00	0.00		
			3-COGNITIVE DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			4-DIURNAL VARIATION	1.50	1.50	1.25	0.75	0.75	0.50	0.50	0.25	0.50	0.25	0.50	0.25		
			5-RETARDATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			7-Total score	5.67	5.50	2.92	1.75	1.25	0.83	1.00	0.75	1.00	0.75	1.00	0.58		
12ND	Reboxetine	Male	Hamilton depression rating scale	1.50	1.50	0.67	2.00	1.67	1.67	2.00	1.67	1.50	1.50	1.50			
			1-ANXIETY/SOMATIZATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			2-WEIGHT	0.33	0.33	0.67	0.17	0.33	0.17	0.33	0.17	0.33	0.17	0.33	0.17		
			3-COGNITIVE DISTURBANCE	1.00	1.00	2.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00		
			4-DIURNAL VARIATION	2.50	2.50	3.00	2.50	2.25	2.75	2.75	2.75	2.75	2.50	2.50	2.50		
			5-RETARDATION	1.33	1.67	1.33	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67		
			7-Total score	6.67	7.00	8.67	7.33	6.92	7.92	8.92	8.92	8.92	8.92	8.92	8.92		
12DF	Reboxetine	Female	Hamilton depression rating scale	2.00	1.83	1.50	0.83	0.67	0.67	0.67	0.67	1.00	0.83				
			1-ANXIETY/SOMATIZATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00			
			2-WEIGHT	0.33	0.67	0.33	0.17	0.33	0.33	0.33	0.33	0.33	0.33	0.33			
			3-COGNITIVE DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			4-DIURNAL VARIATION	1.00	1.25	1.25	1.00	0.75	0.50	0.25	0.25	0.25	0.25	0.25			
			5-RETARDATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			7-Total score	5.33	3.75	3.08	2.00	1.75	3.50	0.92	1.50	3.25	1.50	3.25			
13DF	Reboxetine	Female	Hamilton depression rating scale	1.83	1.67	1.83	1.17	0.33	0.50	0.50	0.67	0.67	0.67				
			1-ANXIETY/SOMATIZATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			2-WEIGHT	0.67	0.83	0.83	0.67	0.50	0.00	0.00	0.00	0.00	0.17	0.00			
			3-COGNITIVE DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			4-DIURNAL VARIATION	2.00	2.00	2.00	1.50	0.75	0.50	0.25	0.25	0.25	0.25	0.25			
			5-RETARDATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			7-Total score	4.50	4.50	4.67	3.33	1.58	1.00	2.75	2.92	1.08	0.92	1.08			
14DF	Imipramine	Female	Hamilton depression rating scale	1.67	1.83	1.67	1.17	0.83	0.50	0.50	0.33	0.33	0.33				
			1-ANXIETY/SOMATIZATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
			2-WEIGHT	0.50	0.33	0.50	0.33	0.17	0.00	0.17	0.00	0.17	0.00				
			3-COGNITIVE DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
			5-RETARDATION	1.75	2.00	2.00	1.25	1.00	1.25	1.00	0.25	0.25	0.25				

1451

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

19

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63				
10	140T	Imipramine	Female	6.SLEEP DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
				7.Total score	3.92	4.17	4.17	2.75	2.00	0.75	0.92	3.08	3.08	0.00	0.75			
				15ND	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.00	1.33	1.33	0.83	0.83	0.67	0.67	0.50	0.50	0.67	
							2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
							3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.33	0.17	0.00	0.17	0.00	0.17	0.00	0.17
							4.DIURNAL VARIATION	2.00	2.00	2.00	1.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
							5.RETARDATION	2.50	2.75	2.50	1.75	1.00	0.75	0.50	0.75	0.50	0.50	0.75
6.SLEEP DISTURBANCE	2.00	1.67	1.67				0.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
7.Total score	8.17	8.42	8.17	4.25	4.00	1.42	1.58	1.17	3.00	1.58								
16DT	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	1.33	0.83	0.67	0.67	0.33	0.33	0.83	0.50					
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00					
			3.COGNITIVE DISTURBANCE	0.50	0.50	0.83	0.33	0.17	0.33	0.17	0.00	0.17	0.00					
			4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00					
			5.RETARDATION	1.75	1.75	1.25	1.00	0.50	0.25	0.25	0.50	0.25	0.25					
			6.SLEEP DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00					
			7.Total score	3.75	3.75	3.42	2.17	1.33	1.25	0.75	1.00	1.08	0.92					
17ND	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.83	1.83	1.50	1.33	1.00	0.67	0.67	0.33	0.67	0.50					
			2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00					
			3.COGNITIVE DISTURBANCE	0.33	0.17	0.50	0.17	0.33	0.17	0.33	0.17	0.17	0.17					
			4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00					
			5.RETARDATION	2.50	2.75	2.25	2.00	1.25	0.25	0.25	0.75	0.25	0.25					
			6.SLEEP DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	1.33	1.33	0.67	0.00					
			7.Total score	8.67	8.75	6.25	5.50	3.58	2.42	2.25	1.92	1.08	0.92					
18ND	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.33	1.50	1.33	1.00	0.83	0.83	0.17	0.33	0.50					
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00					
			3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	1.00	0.67	0.67	0.33	0.33	0.33	0.33					
			4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00					
			5.RETARDATION	1.75	2.00	2.25	2.00	2.00	1.25	0.75	0.50	0.50	0.25					
			6.SLEEP DISTURBANCE	1.67	1.67	1.00	1.33	0.67	0.67	0.33	0.33	0.33	0.67					
			7.Total score	7.75	7.83	5.58	5.67	7.50	3.58	2.58	1.33	1.50	1.75					
19DT	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.50	1.50	1.67	1.83	1.17	1.83	1.17	1.17	1.50	1.17					
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00					
			3.COGNITIVE DISTURBANCE	0.67	0.83	0.83	0.33	0.83	0.33	0.50	0.50	0.50	0.50					
			4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00					
			5.RETARDATION	1.75	2.00	2.00	1.75	2.25	1.75	1.25	1.25	1.25	1.00					
			6.SLEEP DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00					
			7.Total score	3.92	4.33	4.50	3.92	4.25	3.92	2.92	2.92	3.25	4.67					
20ND	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.50	1.50	1.67	1.33	1.33	1.33	1.17	1.17	1.33					
			2.WEIGHT	1.00	0.00	2.00	0.00	2.00	0.00	0.00	0.00	0.00	2.00					
			3.COGNITIVE DISTURBANCE	1.17	1.33	1.00	1.33	0.67	1.00	0.83	0.67	1.33						

9550089

1452

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

21

PHARMACIA CNS RSD

REBOXETINE - PROTOCOL 2012/4/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63			
13	20T	Reboxetine	Female	2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.67	0.50	0.50	0.50	0.17	0.17	0.17	0.17	0.17	0.00	
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00
				5.RETARDATION	1.75	1.75	1.75	1.50	1.75	1.50	1.75	1.50	1.75	1.00	1.50	1.00	1.00
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.00	0.67	1.00	0.67	1.00	0.67	1.00	0.67	1.00	0.67
				7.Total score	5.58	5.42	4.92	3.83	3.75	5.00	3.25	3.50	4.33	2.33			
3MD	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.33	1.00	0.83	0.67	0.67	0.67	0.67	0.33	0.50	0.50	0.50			
			2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	1.33	1.50	1.00	0.67	0.67	0.67	0.33	0.33	0.33	0.50	0.33	0.33		
			4.DIURNAL VARIATION	2.00	2.00	0.00	0.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00		
			5.RETARDATION	2.00	2.00	1.50	1.00	1.00	0.50	0.50	0.50	0.50	0.50	0.75	0.75		
			6.SLEEP DISTURBANCE	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	1.00	0.33	0.33		
			7.Total score	7.33	5.50	4.17	3.17	5.00	4.17	2.83	3.50	2.92					
3DT	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	1.00	0.67	0.67	0.50	0.50	0.33	0.33	0.33	0.33			
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	1.33	1.33	1.17	0.83	0.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.90	0.90	0.90	0.25	0.25	0.25	0.25	0.25		
			5.RETARDATION	1.75	1.75	1.50	1.25	0.75	0.50	0.50	0.50	0.50	0.50	0.50	0.50		
			6.SLEEP DISTURBANCE	1.33	1.33	1.00	0.67	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33		
			7.Total score	6.42	6.42	5.67	5.25	3.08	1.33	1.08	0.92	0.92					
4DT	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	0.50	0.67	0.67	0.67	0.50	0.33	0.33	0.33	0.33			
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	0.83	1.00	0.83	0.33	0.33	0.33	0.17	0.17	0.00	0.00	0.00	0.00		
			4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			5.RETARDATION	1.50	1.50	1.25	0.75	1.00	1.00	0.50	0.50	0.50	0.25	1.00	1.00		
			6.SLEEP DISTURBANCE	0.00	0.67	0.33	0.67	0.67	0.67	0.67	0.33	0.33	0.33	0.33	0.67		
			7.Total score	4.33	5.17	2.92	2.42	2.67	2.67	1.50	1.33	0.92	2.00				
14	1ND	Reboxetine	Female	1.ANXIETY/SOMATIZATION	2.17	2.00	1.33	1.17	0.83	1.83							
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.00	0.33	0.00	0.67							
				4.DIURNAL VARIATION	2.00	2.00	0.00	1.00	1.00	0.00							
				5.RETARDATION	2.50	2.25	1.00	0.75	2.00	2.00							
				6.SLEEP DISTURBANCE	1.33	1.00	1.00	0.00	0.00	1.00							
				7.Total score	8.83	8.08	3.33	3.25	2.33	5.50							
15	1ND	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.83	2.00	1.50	1.17	0.83	0.67	0.83	1.17	0.67	0.83			
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.50	0.33	0.33	0.33	0.33	0.33	0.67	0.17	0.33		
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				5.RETARDATION	1.75	1.50	1.25	1.00	1.00	0.25	1.50	1.50	0.75	1.50	1.50		
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.67	2.00	1.00	2.00	2.00	2.00	2.00	2.00		
				7.Total score	6.42	6.33	5.25	4.17	4.17	2.50	2.42	4.58	4.33	4.17			

1454

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 42.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
15	1D1	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.17	1.50	1.00	0.83	1.33	0.83	0.67	0.67	0.33	0.17		
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.83	1.00	0.67	0.83	0.67	0.67	0.33	0.33	0.17	0.17	0.17	0.17
				4.DIURNAL VARIATION	0.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.25	1.50	1.25	1.25	1.00	1.00	0.75	0.50	0.50	0.50	0.50	0.50
				6.SLEEP DISTURBANCE	1.33	2.00	2.00	2.00	2.00	1.67	1.00	1.00	0.67	0.67	0.67	0.67
				7.Total score	4.58	8.00	4.92	4.92	5.25	4.17	3.00	2.75	1.67	1.50		
2ND	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.33	1.33	1.00									
			2.WEIGHT	2.00	0.00	0.00	0.00									
			3.COGNITIVE DISTURBANCE	1.17	1.17	1.17	0.83									
			4.DIURNAL VARIATION	0.00	0.00	0.00	0.00									
			5.RETARDATION	1.50	1.50	1.50	0.50									
			6.SLEEP DISTURBANCE	0.33	0.67	0.00	0.00									
			7.Total score	6.17	4.67	4.00	2.33									
2DT	Imipramine	Female	1.ANXIETY/SOMATIZATION	2.00	1.83	1.00	1.00	0.83	0.83	1.00	0.50	0.67	0.67	0.50		
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	0.83	0.83	0.67	0.50	0.50	0.50	0.50	0.50	0.33	0.17	0.00		
			4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	0.75	0.75	0.75	0.75	0.50		
			5.RETARDATION	1.75	1.75	1.50	1.00	1.00	0.75	0.75	0.67	0.67	0.67	0.67		
			6.SLEEP DISTURBANCE	1.33	1.67	1.33	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67		
			7.Total score	6.92	7.08	5.50	4.17	4.00	3.75	2.92	2.25	3.25	1.67			
3MD	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.17	1.33	1.50	0.50	0.67	0.67	0.67	0.67	0.67	0.17		
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	1.33	1.17	1.00	1.17	0.67	0.17	0.33	0.50	0.33	0.33	0.33		
			4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			5.RETARDATION	2.00	1.75	1.50	1.50	0.75	0.75	0.75	0.75	0.75	0.75	0.75		
			6.SLEEP DISTURBANCE	0.00	0.00	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33		
			7.Total score	5.00	4.08	4.17	4.50	2.25	1.58	1.75	1.42	1.50	0.75			
4MD	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.83	1.83	1.50	1.33	1.00	0.50	0.83	0.67	0.67	0.50	0.17		
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	1.83	1.50	1.00	0.83	0.67	0.67	0.50	0.50	0.50	0.17	0.17		
			4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			5.RETARDATION	1.75	1.25	1.50	1.00	0.75	0.50	0.50	0.50	0.50	0.25	0.25		
			6.SLEEP DISTURBANCE	0.67	0.67	1.00	1.00	1.00	0.67	1.00	1.00	0.67	0.67	0.67		
			7.Total score	6.08	5.25	5.00	4.17	3.42	2.33	2.83	2.67	1.56	1.25			
11MD	Reboxetine	Female	1.ANXIETY/SOMATIZATION	2.00	1.50	1.17	1.17	1.00								
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00								
			3.COGNITIVE DISTURBANCE	1.33	0.83	0.83	0.67	0.67								
			4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00								
			5.RETARDATION	2.75	2.75	2.25	2.25	2.00								

1455

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

23

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63				
15	111ND	Reboxetine	Female	6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00				
				7.Total score	8.08	7.08	6.25	5.83	5.17									
				112ND	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.17	0.67	0.50	0.83	0.50	0.33	0.50	0.17	
							2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
							3.COGNITIVE DISTURBANCE	1.17	1.00	0.67	0.67	0.17	0.33	0.17	0.33	0.00	0.00	0.00
							4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
							5.RETARDATION	1.75	1.75	1.25	1.00	0.50	0.75	0.50	0.75	0.50	0.25	0.50
6.SLEEP DISTURBANCE	1.67	1.33	1.00	1.33	0.67	1.00	0.67	0.67	0.67	0.67	0.67	0.67						
7.Total score	6.08	5.58	4.08	3.67	1.83	2.92	1.83	2.08	1.83	2.08	1.67	1.08						
16	1ND	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	0.67	0.50	0.50	0.50	0.33	0.17	0.33	0.17				
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	0.00	0.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
				5.RETARDATION	2.25	2.50	1.75	1.50	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75		
				6.SLEEP DISTURBANCE	1.67	1.33	1.00	0.67	0.67	0.33	0.33	0.33	0.33	0.33	0.00	0.33		
				7.Total score	5.08	5.17	3.42	2.67	1.92	1.58	1.42	1.25	1.08	1.25	1.08	1.42		
17	1DT	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.00	1.33	1.50	1.83	1.83									
				2.WEIGHT	1.00	0.00	0.00	1.00	1.00									
				3.COGNITIVE DISTURBANCE	0.67	0.33	0.33	0.50	0.50									
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00									
				5.RETARDATION	2.25	2.25	2.00	2.25	2.25									
				6.SLEEP DISTURBANCE	2.00	1.67	2.00	2.00	2.00									
				7.Total score	6.92	5.58	5.83	7.58										
18	2ND	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	1.00	0.67	0.50	0.50	0.33	0.17	0.33	0.33				
				2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	0.33	0.50	0.33	0.17	0.17	0.17	0.17	0.17	0.00	0.00	0.17			
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
				5.RETARDATION	2.25	2.50	2.00	1.25	1.00	1.00	0.75	0.75	0.50	0.50	0.50			
				6.SLEEP DISTURBANCE	1.67	1.33	1.00	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33			
				7.Total score	7.58	5.67	4.67	3.08	2.00	2.33	2.58	1.25	1.17	1.17	1.33			
19	2DI	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.17	1.50	1.17	0.67	0.50	0.17	0.33	0.17	0.17	0.00				
				2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	0.50	0.67	0.83	0.50	0.17	0.17	0.17	0.17	0.17	0.17	0.17			
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
				5.RETARDATION	2.25	2.00	2.00	1.75	1.50	0.75	0.75	0.75	0.50	0.50	0.25			
				6.SLEEP DISTURBANCE	2.00	1.67	1.00	1.33	1.00	0.33	0.33	0.33	0.33	0.33	0.33			
				7.Total score	7.92	5.83	5.33	3.92	3.17	1.42	1.33	0.83	1.17	0.83	1.17			
20	3ND	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.33	1.17	0.83	1.00	0.67	1.00	0.67	0.67					
				2.WEIGHT	1.00	0.00	0.00	1.00	2.00	2.00	1.00	3.00	3.00					
				3.COGNITIVE DISTURBANCE	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.00	0.17					

1456

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

24

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
16	3MD	Imipramine	Female	4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				5. RETARDATION	2.50	2.50	2.50	1.75	1.50	1.75	1.50	1.75	1.50	1.75	1.50
				6. SLEEP DISTURBANCE	1.33	1.33	1.00	0.67	0.67	0.67	0.67	0.33	0.33	0.33	0.33
				7. Total score	6.17	5.33	4.50	5.25	5.42	4.17	5.92				
3DT	Imipramine	Female	1. ANXIETY/SOMATIZATION	2.00	1.67	1.17	2.17								
			2. WEIGHT	2.00	0.00	0.00	2.00								
			3. COGNITIVE DISTURBANCE	0.17	0.17	0.33	0.83								
			4. DIURNAL VARIATION	1.00	0.00	0.00	0.00								
4MD	Reboxetine	Female	5. RETARDATION	1.75	1.75	1.75	2.00								
			6. SLEEP DISTURBANCE	1.67	1.33	0.67	2.00								
			7. Total score	8.58	4.92	3.92	9.00								
			1. ANXIETY/SOMATIZATION	1.83	2.00	1.83	1.67	1.17	1.17	1.17	1.17	1.33	1.00	1.33	1.00
4MD	Reboxetine	Female	2. WEIGHT	1.00	0.00	0.00	0.00								
			3. COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.17	0.17	0.00	0.00	0.00	0.00	0.00	0.00	
			4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			5. RETARDATION	2.25	2.50	2.00	1.75	1.50	1.00	0.75	0.75	0.75	0.75	0.75	0.75
4MD	Reboxetine	Female	6. SLEEP DISTURBANCE	1.67	2.00	1.67	1.33	1.00	0.33	0.00	0.33	0.00	0.33	0.67	
			7. Total score	7.08	6.83	5.83	4.92	3.83	2.50	2.08	2.08	2.08	2.08	2.25	
			1. ANXIETY/SOMATIZATION	2.33	2.33	2.33	2.33	2.17	2.17	2.17	2.17	2.17	2.17	2.17	2.17
			2. WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
17	1MD	Reboxetine	Female	3. COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.67	0.67	0.67	0.67	0.67	0.67	0.67	
				4. DIURNAL VARIATION	0.00	0.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00
				5. RETARDATION	2.25	2.25	2.25	1.75	1.75	1.75	1.75	1.75	1.75	1.50	1.50
				6. SLEEP DISTURBANCE	1.67	1.67	1.33	1.67	1.33	2.00	2.00	2.00	2.00	2.00	2.00
17	1MD	Reboxetine	Female	7. Total score	9.08	9.08	7.75	7.42	5.92	6.58	8.58	9.33	7.33	7.33	
				1. ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.33	1.33						
				2. WEIGHT	1.00	1.00	1.00	1.00	1.00						
				3. COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.67						
17	1DT	Reboxetine	Female	4. DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
				5. RETARDATION	1.75	1.75	1.50	1.50							
				6. SLEEP DISTURBANCE	0.00	0.00	0.00	0.00	0.00						
				7. Total score	5.75	5.75	5.75	5.50	5.50						
2MD	Imipramine	Female	1. ANXIETY/SOMATIZATION	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67		
			2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3. COGNITIVE DISTURBANCE	0.83	0.83	0.67	0.50	0.50	0.33	0.33	0.33	0.33	0.33		
			4. DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
2MD	Imipramine	Female	5. RETARDATION	1.50	1.50	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25		
			6. SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67		
			7. Total score	6.67	6.67	6.25	6.08	6.08	5.92	5.92	5.92	5.92	5.67	4.08	
			1. ANXIETY/SOMATIZATION	1.33	1.33	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.00	1.00	

1457

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

25

PHARMACIA CNS B&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 6	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63			
17	20T	Reboxetine	Female	2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				5.RETARDATION	1.50	1.50	1.25	1.25	1.25	1.00	1.00	1.00	0.75	0.75	0.75	0.75	
				6.SLEEP DISTURBANCE	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67
				7.Total score	5.00	5.00	4.58	4.58	4.58	4.33	4.33	4.33	3.92	3.92	3.92	3.92	
				1.ANXIETY/SOMATIZATION	2.17	2.33	2.00	2.17									
				2.WEIGHT	1.00	2.00	0.00	0.00									
30D	Imipramine	Female	1.ANXIETY/SOMATIZATION	2.17	2.17	2.00	1.83	1.83	1.67	1.33	1.33	1.17	1.17	1.17			
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	1.67	1.67	1.33	1.17	1.17	1.00	1.00	1.00	0.83	0.83	0.83	0.83		
			4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			5.RETARDATION	1.50	1.50	1.50	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	
			6.SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.67	0.67	1.00	1.00		
			7.Total score	6.33	6.33	5.83	5.25	5.25	4.58	3.75	3.75	3.75	3.75	3.75	3.75		
			1.ANXIETY/SOMATIZATION	2.17	2.17	2.00	1.83	1.83	1.67	1.67	1.67	1.33	1.33	1.17	1.17	1.17	
40D	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.17	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.50			
			2.WEIGHT	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.33	0.33	0.33	0.33		
			4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			5.RETARDATION	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25		
			6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.33	1.33	1.33	1.33		
			7.Total score	5.75	5.75	5.58	5.08	5.08	4.92	4.92	4.92	4.58	4.58	4.58	4.58		
			1.ANXIETY/SOMATIZATION	1.33	1.33	1.17	1.17	1.17	1.00	0.83	0.83	0.83	0.83	0.83	0.83	0.83	
210D	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.50	1.50	1.50	1.50	1.47	1.47	1.47	1.47	1.47			
			2.WEIGHT	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			3.COGNITIVE DISTURBANCE	1.67	1.67	1.33	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17		
			4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			5.RETARDATION	1.75	1.75	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.25	1.25	1.25		
			6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67		
			7.Total score	8.75	8.75	8.00	7.17	7.17	7.17	7.17	7.17	6.83	6.83	6.42	6.25		
			1.ANXIETY/SOMATIZATION	1.67	1.67	1.50	1.50	1.50	1.50	1.50	1.47	1.47	1.47	1.47	1.47		

1458

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

26

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
17	2110T	Female	1. ANXIETY/SOMATIZATION	1.17	1.17	1.17	1.17	1.00	1.00	1.00	1.00	1.00	1.00	
			2. WEIGHT	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
			3. COGNITIVE DISTURBANCE	1.17	1.17	1.17	1.17	1.00	1.00	1.00	1.00	1.00	1.00	1.00
			4. DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
			5. RETARDATION	2.25	2.25	2.00	1.75	1.50	1.25	1.25	1.25	1.25	1.25	1.25
			6. SLEEP DISTURBANCE	0.67	0.67	0.67	0.67	1.00	1.00	1.00	1.00	1.00	1.00	1.00
			7. Total score	7.25	7.25	6.83	6.75	6.50	6.25	6.25	6.25	6.25	6.25	6.25
18	11D	Female	1. ANXIETY/SOMATIZATION	1.83	1.83	1.00	1.33	1.00	0.67	0.50	0.67	0.67	0.83	
			2. WEIGHT	0.00	0.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
			3. COGNITIVE DISTURBANCE	0.67	0.50	0.83	0.33	0.50	0.67	0.17	0.33	0.17	0.33	0.33
			4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
			5. RETARDATION	2.25	2.25	1.75	1.25	1.25	1.25	0.75	0.75	0.75	1.00	1.00
			6. SLEEP DISTURBANCE	1.00	1.67	1.00	1.00	0.33	1.00	0.67	0.67	0.33	0.33	0.33
			7. Total score	5.75	6.25	6.58	4.92	4.92	4.92	3.25	3.25	1.92	1.92	2.50
1459	10T	Female	1. ANXIETY/SOMATIZATION	1.50	1.33	1.17	1.33	1.33	0.67	0.50	0.17	0.00	0.00	
			2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
			3. COGNITIVE DISTURBANCE	0.67	0.67	0.50	1.00	0.33	0.33	0.60	0.60	0.00	0.00	0.00
			4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
			5. RETARDATION	1.75	1.75	1.50	1.50	0.75	1.00	0.75	0.50	0.50	0.00	0.00
			6. SLEEP DISTURBANCE	1.67	2.00	1.00	1.00	0.67	0.33	0.00	0.00	0.00	0.00	0.00
			7. Total score	5.58	5.75	4.17	4.83	3.08	2.33	1.25	0.67	0.00	0.00	0.00
2ND	11D	Female	1. ANXIETY/SOMATIZATION	1.83	1.83	1.83	1.67	1.83	1.67	1.83	1.67	1.67	1.67	
			2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
			3. COGNITIVE DISTURBANCE	0.83	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
			4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
			5. RETARDATION	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75
			6. SLEEP DISTURBANCE	2.00	1.67	1.67	1.67	2.00	1.33	1.33	1.33	1.33	1.33	1.33
			7. Total score	6.42	6.25	6.25	6.08	8.58	5.75	5.75	5.75	5.75	5.75	5.75
2DI	2110T	Female	1. ANXIETY/SOMATIZATION	1.83	1.83	1.83	1.83	1.50	1.50	1.50	1.50	1.50	1.50	
			2. WEIGHT	0.00	0.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
			3. COGNITIVE DISTURBANCE	0.83	0.67	1.17	1.00	1.00	1.00	0.83	0.83	0.83	0.83	0.83
			4. DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
			5. RETARDATION	2.25	2.00	1.75	2.25	2.00	2.00	1.75	1.75	1.75	1.75	1.75
			6. SLEEP DISTURBANCE	1.67	1.00	1.33	1.33	1.00	1.00	1.00	1.00	1.00	1.00	1.00
			7. Total score	7.58	6.50	8.08	7.42	6.50	5.08	5.08	5.08	5.08	5.08	5.08
3ND	2110T	Female	1. ANXIETY/SOMATIZATION	1.83	1.67	1.33	1.50	1.50	1.17	1.17	1.17	1.17	1.00	
			2. WEIGHT	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
			3. COGNITIVE DISTURBANCE	0.67	0.67	1.00	0.67	0.67	0.67	0.33	0.17	0.17	0.17	0.50
			4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
			5. RETARDATION	2.00	2.00	2.25	2.25	2.25	2.25	2.50	1.25	0.75	1.50	1.50

9550089

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

27

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20324/035
 Listing No.: 12.1

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
18	3ND	Reboxetine	Female	6.SLEEP DISTURBANCE	2.00	1.67	1.67	1.33	1.00	0.67	0.00	0.67	0.67	0.67
				7.Total score	6.50	6.00	6.25	5.75	5.67	3.42	2.08	3.50	3.67	
4ND	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.83	1.50	1.67	1.50	1.67	0.67	0.50	0.50	0.50	0.50	0.33
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
			3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	1.00	1.00	0.50	0.17	0.00	0.00	0.00	0.17
			4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
			5.RETARDATION	2.75	2.50	2.50	2.25	2.00	1.50	0.75	0.25	0.25	0.25	0.50
			6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	0.33	0.33	0.33	0.33	0.00	0.00
			7.Total score	7.08	6.50	6.67	6.42	6.33	3.00	1.75	1.08	0.75	1.00	
20	3ND	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				6.SLEEP DISTURBANCE	1.00	1.00	1.33	1.00	1.00	1.33	1.00	1.00	1.33	1.00
				7.Total score	4.83	4.83	6.17	4.83	4.83	6.17				
22	1ND	Reboxetine	Female	1.ANXIETY/SOMATIZATION	2.00	1.83	2.17	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	0.33	0.83	1.67	0.33	0.83	1.67	0.33	0.83	1.67	
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
				5.RETARDATION	2.00	1.75	2.25	2.00	1.75	2.25	2.00	1.75	2.25	
				6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
				7.Total score	10.33	10.42	12.08							
23	1ND	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	2.00	1.33	1.17	0.33	0.50	0.33	0.17	0.00	0.00
				2.WEIGHT	1.00	1.00	0.00	0.00	1.00	1.00	0.00	1.00	1.00	1.00
				3.COGNITIVE DISTURBANCE	1.17	1.50	0.50	0.83	0.17	0.67	0.17	0.67	0.17	0.00
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.75	2.00	2.25	1.75	1.00	0.75	1.00	1.00	0.75	1.00
				6.SLEEP DISTURBANCE	0.00	0.00	0.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				7.Total score	5.42	6.50	5.42	5.75	2.50	2.42	2.00	2.33	1.75	2.00
2ND	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	0.83	0.67	0.67	0.00	0.17	0.00	0.00	0.00	
			2.WEIGHT	1.00	1.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	
			3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.17	0.00	0.00	0.17	0.00	0.00	0.17	
			4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
			5.RETARDATION	1.75	2.00	1.50	0.75	0.50	1.00	0.50	0.25	0.00	0.50	
			6.SLEEP DISTURBANCE	1.00	1.67	1.00	1.00	0.67	1.00	0.40	0.67	0.33	1.00	
			7.Total score	7.42	8.33	5.83	4.58	3.83	5.00	2.83	2.92	2.33	2.67	
3ND	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.00	0.83	1.00	0.83	0.33	0.67	0.67	0.50	
			2.WEIGHT	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			3.COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.50	0.17	0.17	0.17	0.17	0.17		

1460

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

28

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 2012A/035
Listing No.: 12.1

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
23	3ND	Imipramine	Female	HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE	1.00	1.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	
				4. DIURNAL VARIATION	2.25	2.25	1.50	1.25	1.00	0.50	0.50	0.50	0.75	0.50	1.00
				7. Total score	6.42	6.42	6.50	6.25	5.50	5.17	3.33	2.92	2.67	2.50	
4ND	Imipramine	Female	1. ANXIETY/SOMATIZATION	1.00	1.00	0.00	0.83	0.00	0.17	0.67	0.33	0.17	0.00		
			2. WEIGHT	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00		
			3. COGNITIVE DISTURBANCE	0.50	0.50	0.17	0.00	0.33	0.33	0.50	0.00	0.00	0.00		
5ND	Imipramine	Female	4. DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			5. RETARDATION	2.25	2.25	1.25	1.25	1.00	0.75	1.25	0.50	0.25	0.25		
			7. Total score	6.42	6.42	3.42	3.42	3.67	3.58	2.75	1.83	0.42	0.25		
6ND	Imipramine	Female	1. ANXIETY/SOMATIZATION	1.17	1.17	1.67	1.83								
			2. WEIGHT	1.00	1.00	1.00	1.00								
			3. COGNITIVE DISTURBANCE	1.00	1.17	0.83	1.00								
25	1ND	Reboxetine	Male	4. DIURNAL VARIATION	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00		
				5. RETARDATION	2.25	2.25	2.00	2.00							
				7. Total score	7.75	7.92	7.83	6.50							
26	1ND	Imipramine	Female	1. ANXIETY/SOMATIZATION	1.33	2.00	1.33	1.17	1.67	1.67	2.00	1.83	2.33		
				2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				3. COGNITIVE DISTURBANCE	0.83	1.17	0.67	0.50	0.50	0.17	0.67	1.83	1.83		
25	1ND	Reboxetine	Male	4. DIURNAL VARIATION	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
				5. RETARDATION	2.75	3.00	2.50	2.00	2.50	2.50	3.00	3.25	3.25		
				7. Total score	1.33	1.00	1.00	0.67	0.33	1.33	1.00	1.00	1.00		
25	1ND	Reboxetine	Male	1. ANXIETY/SOMATIZATION	8.25	8.17	6.50	4.33	6.00	7.67	7.33	12.25	9.42		
				2. WEIGHT	2.50	2.00	2.33	2.50	2.50	2.33	2.50				
				3. COGNITIVE DISTURBANCE	2.00	2.00	0.00	0.00	0.00	0.00	0.00				
25	1ND	Reboxetine	Male	4. DIURNAL VARIATION	1.67	1.67	1.50	1.33	1.33	1.33	1.50				
				5. RETARDATION	2.50	2.50	2.25	2.25	2.50	2.50					
				7. Total score	10.67	10.67	9.08	10.25	10.33	7.92	8.50				
25	1ND	Reboxetine	Male	1. ANXIETY/SOMATIZATION	0.50	0.67	1.17	0.83	0.83	0.83	0.50	0.67	0.67		
				2. WEIGHT	1.00	1.00	2.00	0.00	0.00	1.00	0.00	0.00	0.00		
				3. COGNITIVE DISTURBANCE	1.00	1.00	0.83	0.67	0.67	0.67	0.67	0.67	0.50		
25	1ND	Reboxetine	Male	4. DIURNAL VARIATION	1.00	1.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00		
				5. RETARDATION	2.00	2.50	1.50	1.50	1.25	1.75	1.25	1.00	1.00		
				7. Total score	2.00	2.00	1.50	1.50	0.67	0.67	0.67	0.67	0.67		
25	1ND	Reboxetine	Male	1. ANXIETY/SOMATIZATION	7.50	8.17	8.58	5.67	4.67	5.42	4.92	5.08	3.83		
				2. WEIGHT	1.50	1.83	1.67	1.50	1.00	0.83	1.00				
				3. COGNITIVE DISTURBANCE	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		

1461

9550089

29

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

Centre	Patient	Treatment	Sex	HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE													
				Hamilton depression rating scale													
				Screen	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63			
26	1M	Imipramine	Female	2.WEIGHT	0.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.50	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	
				4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				5.RETARDATION	1.75	2.00	1.50	1.25	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				7.Total score	6.92	7.50	5.67	6.08	4.33	4.17	4.50	4.50	4.50	4.50	4.50	4.50	
				1.ANKIETY/SOMATIZATION	2.00	1.83	2.00	2.00	2.00	1.83	1.83	1.83	1.83	1.83	1.83	1.83	
2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00					
3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83					
4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00					
5.RETARDATION	1.75	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50					
6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00					
7.Total score	7.58	7.17	7.33	7.33	8.33	7.67	7.67	7.67	7.67	7.67	7.67	7.67					
27	1M	Imipramine	Male	1.ANKIETY/SOMATIZATION	1.83	1.83	2.33										
				2.WEIGHT	2.00	2.00	1.00										
				3.COGNITIVE DISTURBANCE	1.17	1.17	1.33										
				4.DIURNAL VARIATION	0.00	0.00	0.00										
				5.RETARDATION	2.50	2.50	2.50										
				6.SLEEP DISTURBANCE	1.67	1.67	1.67										
				7.Total score	9.17	9.17	8.83										
1.ANKIETY/SOMATIZATION	1.00	1.00	1.00	1.00	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50					
2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00					
3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	0.83	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67					
4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00					
5.RETARDATION	1.75	1.75	1.75	1.25	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75					
6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00					
7.Total score	7.68	7.08	7.08	6.42	4.92	4.92	4.92	4.92	4.92	4.92	4.92	4.92					
28	1M	Reboxetine	Female	1.ANKIETY/SOMATIZATION	1.00	0.83	0.83	0.83	0.83	0.50	0.50	0.50	0.50	0.50			
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	0.83	0.67	0.67	0.67	0.67	0.67	0.67	0.67		
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00		
				5.RETARDATION	1.75	1.75	1.75	1.25	0.75	0.75	0.75	0.75	0.75	0.75	0.75		
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
				7.Total score	7.68	7.08	7.08	6.42	4.92	4.92	4.92	4.92	4.92	4.92	4.92		
1.ANKIETY/SOMATIZATION	1.00	0.83	0.83	0.83	0.83	0.50	0.50	0.50	0.50	0.50	0.50	0.50					
2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00					
3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50					
4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00					
5.RETARDATION	1.75	1.25	1.25	1.25	1.00	0.75	0.75	0.75	0.75	0.75	0.75	0.75					
6.SLEEP DISTURBANCE	1.00	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67					
7.Total score	5.25	4.25	4.25	4.25	3.67	2.92	2.92	2.92	2.92	2.92	2.92	2.92					
29	2M	Imipramine	Female	1.ANKIETY/SOMATIZATION	0.50	0.50	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33			
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	1.17	1.17	1.00	1.00	1.00	0.83	0.67	0.67	0.67	0.67	0.67		
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
				5.RETARDATION	1.25	1.25	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75		
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
				7.Total score	4.92	4.92	4.08	4.08	4.08	3.92	2.50	2.50	2.50	2.50	2.50		

1462

9550089

30

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63					
28	ZDI	Reboxetine	Male	1. ANXIETY/SOMATIZATION	1.17	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00				
				2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				3. COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.50	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17	
				4. DIURNAL VARIATION	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				5. RETARDATION	1.25	1.00	1.00	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25	
				6. SLEEP DISTURBANCE	1.00	1.00	1.00	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67
				7. Total score	4.08	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	3.50	3.50	3.33	3.33	3.33	3.33	3.33	3.33	3.33	3.33	3.33	3.33	
30	SMD	Reboxetine	Female	1. ANXIETY/SOMATIZATION	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67			
				2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				3. COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	
				4. DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				5. RETARDATION	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	
				6. SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				7. Total score	5.75	5.75	5.75	5.75	5.75	5.75	5.75	5.75	5.75	5.75	5.75	5.75	5.75	3.92	3.92	3.92	3.92	3.92	3.92	3.92	3.92	3.92	3.92	3.92	
30	3DI	Imipramine	Male	1. ANXIETY/SOMATIZATION	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67			
				2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				3. COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	
				4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				5. RETARDATION	1.50	1.50	1.50	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	
				6. SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
				7. Total score	4.83	4.83	4.83	4.83	4.83	4.83	4.83	4.83	4.83	4.83	4.83	4.83	4.83	2.17	2.17	2.17	2.17	2.17	2.17	2.17	2.17	2.17	2.17	2.17	
30	4MD	Imipramine	Male	1. ANXIETY/SOMATIZATION	1.00	1.00	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.00	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50			
				2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				3. COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	
				4. DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				5. RETARDATION	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	
				6. SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				7. Total score	5.25	6.25	6.25	5.42	5.42	5.42	5.42	5.42	5.42	5.42	5.42	5.42	4.50	3.25	3.25	3.50	3.50	3.50	3.50	3.50	3.50	3.50	3.50	3.50	
30	SMD	Reboxetine	Female	1. ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83			
				2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				3. COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	
				4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				5. RETARDATION	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	
				6. SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
				7. Total score	5.50	5.50	5.50	5.50	5.50	5.50	5.50	5.50	5.50	5.50	5.50	5.50	5.50	2.67	1.42	1.42	1.42	1.42	1.42	1.42	1.42	1.42	1.42	1.42	
30	1MD	Imipramine	Female	1. ANXIETY/SOMATIZATION	1.83	2.00	2.00	1.67	1.67	1.67	1.67	1.67	1.67	1.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67			
				2. WEIGHT	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00		
				3. COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	
				4. DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
				5. RETARDATION	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	
				6. SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
				7. Total score	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	

1463

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

31

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre Patient Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63			
30	1ND	Imipramine Female	6.SLEEP DISTURBANCE	0.67	0.67	0.33	0.33	0.00	0.00	0.00	0.00	0.00	0.00		
			7.Total score	8.58	8.75	6.08	3.83	1.42	0.42	0.25	0.00	2.00	0.00		
			2ND	Reboxetine Female	1.ANXIETY/SOMATIZATION	1.67	1.83								
					2.WEIGHT	2.00	2.00								
					3.COGNITIVE DISTURBANCE	1.33	1.33								
					4.DIURNAL VARIATION	2.00	2.00								
					5.RETARDATION	1.00	1.00								
6.SLEEP DISTURBANCE	0.67	0.67													
7.Total score	8.67	8.83													
3ND	Imipramine Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	0.83	1.00	0.50	0.50	0.33	0.50	0.50			
		2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
		3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.50	0.50	0.50	0.17	0.00	0.00	0.00			
		4.DIURNAL VARIATION	1.00	2.00	1.00	1.00	1.00	1.00	2.00	1.00	1.00	1.00			
		5.RETARDATION	1.50	1.50	1.75	1.50	1.50	1.00	0.75	0.50	0.50	0.50			
		6.SLEEP DISTURBANCE	1.00	1.00	1.00	0.67	1.00	0.33	0.00	0.33	0.00	0.33			
		7.Total score	6.50	7.50	5.75	4.50	5.00	3.33	3.42	2.17	0.17	2.33			
4ND	Reboxetine Female	1.ANXIETY/SOMATIZATION	1.00	0.83	0.83	0.33	0.00	0.00	0.00	0.17	0.00	0.17			
		2.WEIGHT	2.00	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
		3.COGNITIVE DISTURBANCE	0.17	0.33	0.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
		4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00			
		5.RETARDATION	1.50	1.75	1.50	0.75	0.25	0.50	0.25	0.00	0.00	0.00			
		6.SLEEP DISTURBANCE	0.67	0.67	0.67	0.00	0.67	0.00	0.00	0.00	0.00	0.00			
		7.Total score	7.33	7.58	6.67	2.08	1.92	0.50	0.25	0.17	0.00	0.17			
5ND	Imipramine Female	1.ANXIETY/SOMATIZATION	2.17	2.50	1.17										
		2.WEIGHT	1.00	1.00	0.00										
		3.COGNITIVE DISTURBANCE	0.67	0.67	0.33										
		4.DIURNAL VARIATION	2.00	2.00	2.00										
		5.RETARDATION	2.50	2.50	1.50										
		6.SLEEP DISTURBANCE	1.67	2.00	1.67										
		7.Total score	10.00	10.67	6.67										
31	1ND	Imipramine Female	1.ANXIETY/SOMATIZATION	1.17	0.83	0.67	0.83								
			2.WEIGHT	1.00	2.00	0.00	1.00								
			3.COGNITIVE DISTURBANCE	1.00	0.67	0.50	0.00								
			4.DIURNAL VARIATION	1.00	0.00	0.00	1.00								
			5.RETARDATION	2.25	1.00	1.00	1.25								
			6.SLEEP DISTURBANCE	0.67	0.33	0.67	0.67								
			7.Total score	7.08	4.83	2.83	4.75								
1DT	Reboxetine Female	1.ANXIETY/SOMATIZATION	1.33	1.50	1.00	1.50	1.50	1.33	1.33	1.33	1.33	1.33			
		2.WEIGHT	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
		3.COGNITIVE DISTURBANCE	0.67	0.50	0.67	0.83	1.33	0.67	0.83	1.33	0.67	0.83			

9550089

1464

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

32

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
31	10F	Reboxetine	Female	4. DIURNAL VARIATION	1.00	1.00	2.00	1.00	0.00	1.00	0.33	0.33	1.00		
				5. RETARDATION	1.25	1.25	1.75	1.75	2.00	1.75	1.75				
				7. Total score	1.00	1.00	1.33	1.33	1.33	1.00	1.00				
2ND	Reboxetine	Female	1. ANXIETY/SOMATIZATION	1.17	1.67	1.50	0.83	1.17	1.00	0.50	0.33	0.33	1.00		
			2. WEIGHT	2.00	2.00	1.00	0.00	0.00	0.00	0.00	1.00	0.00	1.00		
			3. COGNITIVE DISTURBANCE	0.67	1.17	0.50	0.33	0.17	0.00	0.00	0.00	0.00	0.00	0.00	
3ND	Imipramine	Male	4. DIURNAL VARIATION	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00		
			5. RETARDATION	1.50	2.00	1.75	1.00	1.25	1.00	0.50	0.00	1.00	1.00		
			7. Total score	1.33	0.67	0.67	0.67	0.67	0.33	0.67	0.67	1.00	1.00	1.00	
3ND	Imipramine	Male	1. ANXIETY/SOMATIZATION	1.67	2.17										
			2. WEIGHT	1.00	2.00										
			3. COGNITIVE DISTURBANCE	0.50	0.67										
3ND	Imipramine	Female	4. DIURNAL VARIATION	0.00	0.00										
			5. RETARDATION	2.50	2.50										
			7. Total score	1.67	1.67										
3ND	Imipramine	Female	1. ANXIETY/SOMATIZATION	1.50	1.67	1.50	0.83	0.83	0.67	0.50	0.33	0.67	0.50		
			2. WEIGHT	0.00	0.00	2.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	
			3. COGNITIVE DISTURBANCE	0.33	0.33	0.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
2ND	Imipramine	Female	4. DIURNAL VARIATION	2.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00		
			5. RETARDATION	1.00	1.25	1.00	0.50	0.50	0.25	0.00	0.00	0.00	0.00	0.00	
			7. Total score	1.67	2.00	2.00	1.67	2.00	2.00	1.67	1.00	1.00	1.00	1.00	
2ND	Imipramine	Female	1. ANXIETY/SOMATIZATION	1.50	1.33	1.00	0.67	0.83	0.50	0.67	0.17	0.50	0.17		
			2. WEIGHT	0.00	0.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			3. COGNITIVE DISTURBANCE	0.50	0.17	0.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
3ND	Reboxetine	Female	4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			5. RETARDATION	1.75	1.50	1.75	0.50	0.50	0.50	0.50	0.50	0.50	0.00	0.25	
			7. Total score	3.75	3.67	5.25	1.17	1.33	1.00	1.17	2.67	0.67	0.67	0.42	
3ND	Reboxetine	Female	1. ANXIETY/SOMATIZATION	0.67	1.50	1.00	0.83	1.17	1.00	0.67	0.67	0.50	0.83		
			2. WEIGHT	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			3. COGNITIVE DISTURBANCE	0.67	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.50	0.67	
4ND	Reboxetine	Female	4. DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00		
			5. RETARDATION	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.00	0.75	1.00	
			7. Total score	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.33	1.33	1.80	
4ND	Reboxetine	Female	1. ANXIETY/SOMATIZATION	0.67	1.00	1.00	0.67	1.00	0.67	0.67	0.67	0.50	0.83		
			2. WEIGHT	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			3. COGNITIVE DISTURBANCE	0.67	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.50	0.67	

1465

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

33

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
32	4MD	Reboxetine	Female	2.WEIGHT	0.00	0.60	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	1.00	0.67	0.33	0.50	0.33	0.50	0.33	0.50	0.33	0.50	0.33	0.50
				4.DIURNAL VARIATION	1.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25
				6.SLEEP DISTURBANCE	1.33	2.00	2.00	0.67	1.00	1.33	2.00	2.00	0.67	1.00	1.33	2.00
				7.Total score	5.25	6.92	5.58	4.08	4.58	5.25	6.92	5.58	4.08	4.58	5.25	6.92
				1.ANXIETY/SOMATIZATION	1.33	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17
2.WEIGHT	2.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
3.COGNITIVE DISTURBANCE	0.17	0.33	0.33	0.17	0.33	0.17	0.33	0.17	0.33	0.17	0.33	0.17				
4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00				
5.RETARDATION	1.00	1.00	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25				
6.SLEEP DISTURBANCE	1.00	1.00	0.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
7.Total score	6.50	5.50	4.08	3.58	3.42	3.50	4.17	4.58	3.58	3.42	3.50	4.17				
35	1MD	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.33	1.17	1.17	1.17	1.17	1.17	1.17			
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67		
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				5.RETARDATION	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25		
				6.SLEEP DISTURBANCE	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33		
				7.Total score	3.75	3.75	3.58	3.42	4.17	4.58	3.75	3.75	3.58	3.42	4.17	
1.ANXIETY/SOMATIZATION	1.33	1.00	1.17	0.83	1.83	1.33	1.00	1.17	0.83	1.83						
2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00							
3.COGNITIVE DISTURBANCE	0.50	0.50	0.17	0.00	0.17	0.50	0.50	0.17	0.00	0.17						
4.DIURNAL VARIATION	0.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00	1.00	0.00						
5.RETARDATION	2.50	2.50	2.25	2.00	2.50	2.50	2.50	2.25	2.00	2.50						
6.SLEEP DISTURBANCE	1.67	1.67	0.00	0.00	1.00	1.67	1.67	0.00	0.00	1.00						
7.Total score	8.00	7.67	3.58	3.83	5.50	8.00	7.67	3.58	3.83	5.50						
101	10T	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.50	1.33	1.50	1.67	1.67	1.67	1.67			
				2.WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	0.83	1.00	0.50	0.50	0.33	0.33	0.50	0.33	0.33			
				4.DIURNAL VARIATION	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00			
				5.RETARDATION	0.75	0.75	0.75	0.75	0.50	0.75	0.50	0.75	0.50			
				6.SLEEP DISTURBANCE	0.67	0.67	1.00	1.00	0.67	1.00	0.67	1.00	0.67			
				7.Total score	4.92	5.08	4.75	4.58	4.00	4.75	3.17	3.92	3.42	4.50		
201	2MD	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.67	1.33	1.67	1.33	1.67				
				2.WEIGHT	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
				3.COGNITIVE DISTURBANCE	1.17	1.17	0.83	0.83	1.00	1.17	0.83	1.00				
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
				5.RETARDATION	3.25	3.25	3.00	3.25	3.00	3.00	3.00	3.00				
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33				
				7.Total score	8.08	7.08	6.50	7.08	6.00	6.00	6.00	6.00				

1466

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

34

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day	
35	ZDT	Imipramine	Female	1. ANXIETY/SOMATIZATION	1.33	1.33	0.33	0.00	0.00	0.00	0.33	0.33	0.00	0.00	0.00	
				2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3. COGNITIVE DISTURBANCE	0.33	0.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				4. DIURNAL VARIATION	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5. RETARDATION	1.75	1.75	1.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				6. SLEEP DISTURBANCE	1.00	1.00	0.67	0.00	0.00	0.33	0.00	0.00	0.00	0.00	0.00	0.00
				7. Total score	4.42	4.42	3.25	0.00	0.00	0.33	0.33	0.00	0.33	0.33	0.00	0.00
				3ND	Imipramine	Female	1.33	1.33	2.00							
3DT	Imipramine	Male	1. ANXIETY/SOMATIZATION	1.17	1.17	0.67	0.67	0.33	0.33	0.50	0.17	0.00	0.00	1.17	0.83	
			2. WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			3. COGNITIVE DISTURBANCE	0.67	0.67	1.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			5. RETARDATION	2.50	2.50	3.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			6. SLEEP DISTURBANCE	1.00	1.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			7. Total score	7.50	7.50	8.42	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			3DT	Imipramine	Male	1.17	1.17	0.67	0.67	0.33	0.33	0.50	0.17	0.00	0.00	1.17
4ND	Reboxetine	Male	1. ANXIETY/SOMATIZATION	1.67	1.67	1.50	1.50	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.50	
			2. WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			3. COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.17	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	
			4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			5. RETARDATION	1.75	1.75	1.50	1.50	1.50	1.25	1.50	1.50	1.50	1.50	1.50	1.50	
			6. SLEEP DISTURBANCE	1.33	1.33	1.67	1.33	1.67	1.33	1.00	1.33	1.00	1.33	1.00	1.33	
			7. Total score	6.08	6.08	5.00	4.50	5.17	4.58	4.50	4.83	4.50	4.83	4.50	4.67	
			4ND	Reboxetine	Male	1.67	1.67	1.50	1.50	1.67	1.67	1.67	1.67	1.67	1.67	1.50
4DT	Reboxetine	Female	1. ANXIETY/SOMATIZATION	1.50	1.50	1.33	1.33	1.33	1.33	1.17	1.17	1.17	1.00	1.17	0.67	
			2. WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			3. COGNITIVE DISTURBANCE	0.67	0.50	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.17	0.00	
			4. DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	
			5. RETARDATION	2.25	1.75	1.75	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.00	0.75	
			6. SLEEP DISTURBANCE	1.33	1.33	1.00	1.33	1.33	1.00	1.00	1.00	1.00	1.00	1.00	0.67	
			7. Total score	8.75	8.08	7.42	5.50	5.50	5.00	5.00	4.17	2.92	1.83	1.83	1.83	
			4DT	Reboxetine	Female	1.50	1.50	1.33	1.33	1.33	1.33	1.17	1.17	1.17	1.00	1.17
5ND	Reboxetine	Male	1. ANXIETY/SOMATIZATION	1.67	1.83	1.00	1.17	1.00	1.00	1.00	0.83	0.67	0.67	0.67		
			2. WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3. COGNITIVE DISTURBANCE	0.83	0.67	0.17	0.33	0.50	0.83	0.50	0.67	0.33	0.17	0.33		
			4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			5. RETARDATION	1.75	1.50	0.50	1.00	1.00	0.50	0.50	0.50	0.75	0.50	0.50		

9550089

1467

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
35	SMD	Reboxetine	Male	6. SLEEP DISTURBANCE	1.33	1.33	0.67	1.33	1.33	1.33	1.00	1.00	1.00	1.00
				7. Total score	7.58	5.33	2.33	3.89	3.33	3.67	2.83	3.08	2.50	2.33
50T	Imipramine	Female	1. ANXIETY/SOMATIZATION	1.17	1.17	0.83	0.50	0.50	0.50	0.83	0.67	0.50	1.50	
			2. WEIGHT	3.00	3.00	1.00	0.00	0.00	1.00	0.00	1.00	1.00	0.00	
6MD	Reboxetine	Female	3. COGNITIVE DISTURBANCE	0.17	0.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			4. DIURNAL VARIATION	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
1468	Imipramine	Female	5. RETARDATION	1.50	1.50	0.75	0.25	0.50	0.25	0.25	0.25	0.25	0.50	
			6. SLEEP DISTURBANCE	1.00	1.00	0.67	0.33	0.33	0.33	0.00	0.33	0.67	0.33	
60T	Imipramine	Female	7. Total score	8.83	8.83	3.25	1.08	1.08	2.33	1.08	2.25	2.42	2.67	
			1. ANXIETY/SOMATIZATION	1.50	1.50	0.83	1.00	0.83	1.00	1.00	1.00	1.00	1.00	
70T	Reboxetine	Female	2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			3. COGNITIVE DISTURBANCE	0.33	0.33	0.17	0.17	0.17	0.17	0.00	0.00	0.67	0.00	
80T	Imipramine	Female	4. DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
			5. RETARDATION	1.25	1.25	0.75	0.75	0.75	1.00	1.00	1.00	1.25	1.00	
60T	Imipramine	Female	6. SLEEP DISTURBANCE	1.33	1.33	1.33	1.67	1.67	1.33	1.67	2.00	1.67	2.00	
			7. Total score	5.42	5.42	4.08	4.58	4.42	4.50	4.67	6.92	6.92	6.92	
70T	Reboxetine	Female	1. ANXIETY/SOMATIZATION	0.67	1.33	1.00	0.67	0.67	0.67	0.67	0.00	0.00	0.00	
			2. WEIGHT	1.00	1.00	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	
70T	Imipramine	Female	3. COGNITIVE DISTURBANCE	0.67	1.00	0.83	0.33	0.33	0.33	0.17	0.17	0.17	0.00	
			4. DIURNAL VARIATION	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
70T	Reboxetine	Female	5. RETARDATION	2.25	2.75	2.00	0.75	0.75	0.75	0.75	0.25	0.25	0.00	
			6. SLEEP DISTURBANCE	1.67	2.00	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	
70T	Imipramine	Female	7. Total score	8.25	9.08	5.17	2.08	1.42	2.58	0.42	2.58	0.42	2.25	
			1. ANXIETY/SOMATIZATION	2.33	2.33	1.33	1.17	0.83	0.83	0.83	1.33	1.67	1.67	
70T	Reboxetine	Female	2. WEIGHT	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
			3. COGNITIVE DISTURBANCE	1.17	1.17	0.33	0.33	0.17	0.17	0.17	0.17	0.17	0.33	
70T	Imipramine	Female	4. DIURNAL VARIATION	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
			5. RETARDATION	2.50	2.50	1.75	1.75	1.25	1.25	1.75	1.75	1.75	1.75	
70T	Reboxetine	Female	6. SLEEP DISTURBANCE	1.67	1.67	1.00	0.67	0.67	0.67	0.67	0.67	1.00	1.00	
			7. Total score	10.67	10.67	6.42	5.92	4.92	4.42	5.92	4.42	5.92	6.75	
80T	Imipramine	Female	1. ANXIETY/SOMATIZATION	2.00	2.17	2.33	2.17	1.67	1.67	1.67	1.67	1.50	1.50	
			2. WEIGHT	1.00	2.00	1.33	1.50	0.83	0.67	0.83	0.67	0.83	0.83	
80T	Reboxetine	Female	3. COGNITIVE DISTURBANCE	1.00	1.33	1.50	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
			4. DIURNAL VARIATION	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
80T	Imipramine	Female	5. RETARDATION	1.50	1.50	1.75	1.25	1.25	1.00	1.00	1.25	1.25	1.25	
			6. SLEEP DISTURBANCE	1.67	1.67	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	
80T	Reboxetine	Female	7. Total score	9.17	10.67	10.92	7.58	7.67	8.25	7.67	8.25	8.25	8.25	
			1. ANXIETY/SOMATIZATION	1.83	1.83	1.50	1.67	1.67	1.67	1.67	1.33	1.33	1.33	
80T	Imipramine	Female	2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			3. COGNITIVE DISTURBANCE	1.17	1.17	1.33	0.83	0.83	0.83	0.83	1.00	1.00	1.00	

9550089

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

36

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
35	8HD	Imipramine	Female	4. DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				5. RETARDATION	1.50	1.50	1.50	1.00	0.75	1.00	1.00	1.00		
				6. SLEEP DISTURBANCE	1.33	1.33	2.00	1.00	0.67	1.00	1.00	1.00		
				7. Total score	6.83	6.83	7.33	6.00	5.50	3.58	3.75	4.39	4.33	
8DT	Reboxetine	Female	1. ANXIETY/SOMATIZATION	1.00	1.00	1.00	1.17	1.17	1.33	1.00	1.00	1.00	1.50	0.67
			2. WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	1.00	1.00	0.00	0.00	0.00
			3. COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.83	0.67	0.50	0.33	0.33	0.33	0.50	1.00
				4. DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				5. RETARDATION	2.00	2.00	1.75	1.25	1.00	0.75	1.00	0.75	1.00	
				6. SLEEP DISTURBANCE	1.67	1.67	1.33	1.00	0.00	0.00	0.00	0.00	0.00	
				7. Total score	7.50	7.50	5.92	6.08	4.75	4.00	4.25	4.08	3.58	3.50
36	1ND	Imipramine	Male	1. ANXIETY/SOMATIZATION	0.83	0.83	0.67	0.17	0.00	0.00	0.00	0.00	0.00	0.00
				2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.00
				3. COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.17	0.00	0.00	0.00	0.00	0.00	0.00
				4. DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00		
				5. RETARDATION	2.00	2.00	2.00	1.00	1.00	0.75	0.75	0.75	0.75	
				6. SLEEP DISTURBANCE	1.67	1.67	0.67	0.00	0.33	0.33	0.33	0.33	0.33	
				7. Total score	6.17	6.17	5.00	2.83	2.50	1.33	1.08	1.08	3.08	
1DT	Imipramine	Female	1. ANXIETY/SOMATIZATION	1.33	1.33	1.17	0.33	0.17	0.33	0.33	0.33	0.33	0.33	0.33
			2. WEIGHT	1.00	1.00	1.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
			3. COGNITIVE DISTURBANCE	0.17	0.17	0.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				4. DIURNAL VARIATION	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00		
				5. RETARDATION	1.50	1.50	1.50	0.75	0.25	0.25	0.25	0.25	0.25	
				6. SLEEP DISTURBANCE	1.00	1.00	0.67	0.00	0.33	0.33	0.33	0.33	0.33	
				7. Total score	6.00	6.00	5.50	3.08	0.42	0.92	0.92	0.92	0.92	
2ND	Reboxetine	Female	1. ANXIETY/SOMATIZATION	1.83	1.83	1.17	1.17	1.17	1.67	1.67	1.67	1.17	1.17	1.17
			2. WEIGHT	1.00	1.00	1.00	0.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00
			3. COGNITIVE DISTURBANCE	0.00	0.00	0.17	0.17	0.17	0.33	0.33	0.17	0.17	0.17	0.17
				4. DIURNAL VARIATION	1.00	1.00	1.00	0.00	0.00	0.00	1.00	1.00		
				5. RETARDATION	2.50	2.25	1.00	1.00	1.50	0.67	0.67	1.00	1.00	
				6. SLEEP DISTURBANCE	1.33	1.33	1.00	0.67	0.50	0.50	0.50	1.00	1.00	
				7. Total score	7.67	7.42	5.33	3.00	5.00	4.17	5.17	4.08	4.08	
2DT	Reboxetine	Female	1. ANXIETY/SOMATIZATION	1.50	1.50	1.00	1.00	0.83	0.50	0.00	0.00	0.00	0.00	0.00
			2. WEIGHT	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
			3. COGNITIVE DISTURBANCE	0.50	0.50	0.33	0.33	0.17	0.00	0.00	0.00	0.00	0.00	0.00
				4. DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00		
				5. RETARDATION	1.25	1.25	0.75	0.50	0.50	0.00	0.00	0.00		
				6. SLEEP DISTURBANCE	1.00	1.00	0.67	0.67	0.67	0.33	0.33	0.33	0.33	
				7. Total score	5.25	5.25	3.75	2.17	1.83	0.33	0.33	0.33	0.33	
3ND	Imipramine	Female	1. ANXIETY/SOMATIZATION	1.67	1.67	1.50	1.33	1.50	1.50	1.50	1.50	1.50	1.50	1.50

1469

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

38

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
36	6ND	Imipramine	Female	1. ANXIETY/SOMATIZATION	1.67	1.67	1.33	0.83	0.83	0.83	0.33	0.33	0.33	0.33		
				2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3. COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				4. DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5. RETARDATION	1.00	1.00	1.00	0.25	0.25	0.25	0.00	0.00	0.00	0.00	0.00	0.00
				6. SLEEP DISTURBANCE	1.00	1.00	1.00	0.33	0.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				7. Total score	5.17	5.17	4.83	2.58	1.42	1.42	0.33	0.33	0.33	0.33	0.33	0.33
6DT	Imipramine	Female	1. ANXIETY/SOMATIZATION	1.00	1.00	1.00	0.83	0.83	0.83	0.83	0.67	0.67	0.67	0.67		
			2. WEIGHT	2.00	2.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			3. COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.33	0.17	0.17	0.00	0.00	0.00	0.00	0.00	0.00	
			4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			5. RETARDATION	2.25	2.25	2.00	1.50	0.75	0.75	0.50	0.50	0.25	0.25	0.25	0.25	
			6. SLEEP DISTURBANCE	0.67	0.67	0.67	0.67	0.67	0.33	0.33	0.33	0.33	0.33	0.33	0.33	
			7. Total score	6.25	6.25	5.00	4.33	2.42	2.08	1.83	1.25	1.25	1.25	1.25	1.25	
7ND	Reboxetine	Female	1. ANXIETY/SOMATIZATION	1.17	1.17	1.00	1.00	1.00	1.00	0.17	0.17	0.17	0.17	0.17		
			2. WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			3. COGNITIVE DISTURBANCE	0.33	0.50	0.50	0.50	0.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			4. DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	
			5. RETARDATION	2.00	1.75	1.75	1.75	1.25	1.25	0.00	0.00	0.00	0.00	0.00	0.00	
			6. SLEEP DISTURBANCE	1.67	1.67	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	
			7. Total score	9.17	9.08	6.25	6.25	5.75	5.75	0.17	0.17	0.17	0.17	0.17	0.17	
7DT	Reboxetine	Female	1. ANXIETY/SOMATIZATION	1.83	1.83	2.17										
			2. WEIGHT	0.00	0.00	0.00										
			3. COGNITIVE DISTURBANCE	0.67	0.67	0.83										
			4. DIURNAL VARIATION	0.00	0.00	0.00										
			5. RETARDATION	1.00	1.00	1.25										
			6. SLEEP DISTURBANCE	2.00	2.00	2.00										
			7. Total score	5.50	5.50	6.25										
8ND	Imipramine	Female	1. ANXIETY/SOMATIZATION	1.33	1.33	1.17	0.83	0.50	0.33	0.33	0.00	0.00	0.00	0.00		
			2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3. COGNITIVE DISTURBANCE	0.67	0.67	0.33	0.17	0.17	0.00	0.00	0.00	0.00	0.00	0.00		
			4. DIURNAL VARIATION	2.00	2.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			5. RETARDATION	2.25	2.25	2.00	0.75	0.50	0.50	0.00	0.00	0.00	0.00	0.00		
			6. SLEEP DISTURBANCE	0.33	0.33	0.33	0.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			7. Total score	6.58	6.58	5.83	4.08	2.42	0.83	0.83	0.83	0.83	0.83	0.83		
8DT	Reboxetine	Female	1. ANXIETY/SOMATIZATION	1.67	1.67	1.67	1.33	1.33	1.33	0.83	0.83	1.17	1.17	1.17		
			2. WEIGHT	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3. COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.17	0.17	0.00	0.00	0.00	0.00	0.00	0.00		
			4. DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			5. RETARDATION	1.50	1.50	1.50	1.50	1.00	1.00	1.00	1.00	1.00	1.00	1.00		

1471

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

39

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
36	86T	Female	6.SLEEP DISTURBANCE	1.00	1.00	1.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	
			7.Total score	6.67	6.67	5.67	2.50	2.50	1.33	2.67	3.25	3.08	3.08	
			1.ANXIETY/SOMATIZATION	1.17	1.17	2.33	1.83	0.50	0.50	0.50	0.50	0.50	0.50	0.50
			2.WEIGHT	1.00	1.00	1.00	0.00	2.00	0.00	2.00	0.00	1.00	1.00	0.00
			3.COGNITIVE DISTURBANCE	1.33	1.33	1.17	0.83	0.00	0.00	0.00	0.00	0.00	0.00	0.00
			4.DIURNAL VARIATION	1.00	1.00	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
			5.RETARDATION	2.00	2.00	2.75	1.75	1.25	1.00	1.00	1.00	0.75	0.75	0.75
6.SLEEP DISTURBANCE	0.67	0.67	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
7.Total score	7.17	7.17	10.25	6.42	3.75	1.50	3.50	2.25	2.25	2.25	2.25			
90D	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.67	1.67	1.50	1.50	1.17	1.17	1.00	1.00	1.00	1.00	
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			3.COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.17	0.17	0.17	0.17	0.17	0.17	0.17	
			4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	
			5.RETARDATION	1.75	1.75	1.50	0.75	0.00	0.00	0.00	0.00	0.00	0.00	
			6.SLEEP DISTURBANCE	0.33	0.33	0.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			7.Total score	5.08	5.08	4.67	3.42	1.67	1.33	3.33	1.17	1.17	1.17	
100D	Reboxetine	Male	1.ANXIETY/SOMATIZATION	2.00	2.00	1.00	0.67	0.67	0.67	0.67	0.67	0.67	0.67	
			2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			3.COGNITIVE DISTURBANCE	0.50	0.50	0.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			4.DIURNAL VARIATION	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			5.RETARDATION	2.25	2.25	1.00	0.25	0.25	0.00	0.00	0.00	0.00	0.00	
			6.SLEEP DISTURBANCE	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	
			7.Total score	8.08	8.08	3.50	1.25	1.00	1.00	1.00	1.00	1.00	1.00	
100T	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.83	1.83	1.83	1.83	1.83	1.83	1.67	1.67	2.00	2.33	
			2.WEIGHT	0.00	0.00	0.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	
			3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.67	0.50	0.50	0.50	0.50	0.67	
			4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	
			5.RETARDATION	2.00	2.00	2.00	2.00	2.00	1.75	1.75	1.50	1.50	1.75	
			6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
			7.Total score	7.50	7.50	7.50	9.50	7.50	7.08	7.08	6.67	7.25	8.75	
110D	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	1.00	0.67	0.67	0.33	0.17	0.17	0.17	0.00	
			2.WEIGHT	1.60	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.17	0.00	0.00	0.00	0.00	0.00	0.00	
			4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	
			5.RETARDATION	2.00	2.00	2.00	1.00	0.75	0.25	0.25	0.25	0.00	0.00	
			6.SLEEP DISTURBANCE	1.33	1.33	1.00	0.33	0.33	0.33	0.33	0.33	0.33	0.33	
			7.Total score	6.83	6.83	5.50	3.17	1.75	0.92	0.75	0.50	0.50	0.33	
110T	Reboxetine	Male	1.ANXIETY/SOMATIZATION	2.00	2.00	2.00	1.33	1.00	0.83	0.67	0.67	0.67		
			2.WEIGHT	0.00	0.00	0.00	1.00	1.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67		

1472

9550089

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

40

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
36	11DT	Reboxetine	Male	Hamilton depression rating scale	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				4. DIURNAL VARIATION	1.50	1.50	1.25	1.25	0.75	0.25	0.25	0.25	0.25	0.25	0.25
				5. RETARDATION	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				6. SLEEP DISTURBANCE	5.17	5.17	6.17	6.42	5.92	4.25	2.92	2.92	2.92	2.92	2.92
				7. Total score	1.00	1.00	0.83	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				1. ANXIETY/SOMATIZATION	0.50	0.50	0.33	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67
				3. COGNITIVE DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
12HD	Imipramine	Female	Hamilton depression rating scale	1.50	1.50	1.50	1.50	1.50	1.17	1.00	0.67	0.67	0.67		
			4. DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			5. RETARDATION	1.50	1.50	1.50	1.25	1.25	0.25	0.25	0.25	0.25	0.25		
			6. SLEEP DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			7. Total score	5.67	5.67	4.67	4.42	4.08	2.42	1.08	1.08	1.08			
			1. ANXIETY/SOMATIZATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			3. COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67			
13HD	Reboxetine	Male	Hamilton depression rating scale	1.00	1.00	0.83	1.00	1.00	1.00	2.00	2.00	2.00	2.00		
			4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			5. RETARDATION	1.50	1.50	2.00	3.00	3.00	3.00	3.00	3.00	3.00			
			6. SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00			
			7. Total score	5.83	5.83	5.17	7.50	7.50	7.50	7.50	7.50				
			1. ANXIETY/SOMATIZATION	2.00	2.00	1.00	2.00	2.00	2.00	2.00	2.00				
			3. COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.50	0.50	0.50	0.50					
14HD	Imipramine	Male	Hamilton depression rating scale	0.67	0.67	0.67	0.33	0.17	0.17	0.00	0.00	0.00	0.00		
			4. DIURNAL VARIATION	0.67	0.67	0.67	0.17	0.17	0.17	0.17	0.17	0.17			
			5. RETARDATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			6. SLEEP DISTURBANCE	1.50	1.50	1.00	0.50	0.25	0.00	0.00	0.00				
			7. Total score	5.50	5.50	3.33	2.00	1.58	1.00	0.50	0.50				
			1. ANXIETY/SOMATIZATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00				
			3. COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67				
15HD	Reboxetine	Female	Hamilton depression rating scale	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17			
			4. DIURNAL VARIATION	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33				
			5. RETARDATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00				
			6. SLEEP DISTURBANCE	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50				
			7. Total score	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00				
			1. ANXIETY/SOMATIZATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00				
			3. COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33				
16HD	Imipramine	Female	Hamilton depression rating scale	1.00	1.00	1.00	1.00	1.00	0.83	0.67	0.67	0.67			
			4. DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00				
			5. RETARDATION	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50				
			6. SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00				
			7. Total score	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00				
			1. ANXIETY/SOMATIZATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00				
			3. COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33				

1473

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

41

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
36	16ND	Imipramine	Female	2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.67	0.50	0.33	0.33	0.33	0.33	0.33
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	1.50	1.50	1.50	1.50	1.25	0.75	0.75	0.75	0.75	0.75	0.75
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33
				7.Total score	5.50	5.50	5.50	4.50	3.58	2.75	2.75	2.75	2.75	2.75	2.75
				1.ANXIETY/SOMATIZATION	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67
17ND	Reboxetine	Female	2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67		
			4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			5.RETARDATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67		
			7.Total score	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00		
			1.ANXIETY/SOMATIZATION	1.33	1.33	1.17	0.83	0.33	0.00	0.00	0.00	0.00	0.00		
18ND	Imipramine	Female	2.WEIGHT	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			3.COGNITIVE DISTURBANCE	0.67	0.67	0.50	0.33	0.33	0.00	0.00	0.00	0.00			
			4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00			
			5.RETARDATION	1.75	1.75	1.50	1.00	1.00	0.00	0.00	0.00	0.00			
			6.SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00			
			7.Total score	6.75	6.75	5.17	4.17	4.17	0.33	0.00	0.00	0.00			
			1.ANXIETY/SOMATIZATION	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67			
19ND	Reboxetine	Female	2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67			
			4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00				
			5.RETARDATION	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50				
			6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33				
			7.Total score	6.17	6.17	6.17	6.17	6.17	6.17	6.17	6.17				
			1.ANXIETY/SOMATIZATION	1.83	1.83	1.83	1.67	1.67	1.67	1.67	1.67				
20ND	Imipramine	Female	2.WEIGHT	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00			
			3.COGNITIVE DISTURBANCE	1.33	1.33	1.33	1.00	0.83	0.50	0.50	0.50				
			4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00				
			5.RETARDATION	1.50	1.50	1.50	1.50	1.25	1.00	1.00	1.00				
			6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33				
			7.Total score	8.00	8.00	8.00	7.50	6.50	6.08	6.50	5.50				
			1.ANXIETY/SOMATIZATION	1.00	0.83	0.83	0.83	0.83	0.83	0.83	0.83				
37	Reboxetine	Female	2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83				
			4.DIURNAL VARIATION	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25				
			5.RETARDATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00				
			6.SLEEP DISTURBANCE	5.08	5.08	5.08	5.08	5.08	5.08	5.08	5.08				
			7.Total score	10.16	10.16	10.16	10.16	10.16	10.16	10.16	10.16				
			1.ANXIETY/SOMATIZATION	1.00	0.83	0.83	0.83	0.83	0.83	0.83	0.83				

1474

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

42

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

9550089

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
41	1ND	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.33	1.50	1.83									
				2.WEIGHT	1.00	2.00	2.00									
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50									
				4.DIURNAL VARIATION	1.00	1.00	1.00									
				5.RETARDATION	1.00	1.00	1.50									
				6.SLEEP DISTURBANCE	1.67	1.67	1.33									
				7.Total score	6.50	7.67	8.17									
2ND	Reboxetine	Male	1.ANXIETY/SOMATIZATION	2.17	1.17	0.83	0.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			3.COGNITIVE DISTURBANCE	1.00	0.33	0.33	0.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			4.DIURNAL VARIATION	2.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			5.RETARDATION	1.00	1.25	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			6.SLEEP DISTURBANCE	1.33	1.00	1.00	0.67	0.67	0.33	0.33	0.33	0.33	0.33	0.33	0.33	
			7.Total score	7.50	4.75	4.17	1.17	0.67	0.33	0.33	0.33	0.33	0.33	0.33	0.33	
3ND	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.00	0.67	0.67	1.33	1.17	1.17	1.00	0.83	0.67	0.67	0.67		
			2.WEIGHT	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
			3.COGNITIVE DISTURBANCE	2.00	2.00	1.00	1.00	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	
			4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
			5.RETARDATION	2.00	2.00	1.50	1.75	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	
			6.SLEEP DISTURBANCE	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	
			7.Total score	8.67	8.33	6.83	7.75	4.75	5.75	5.75	5.75	5.75	5.75	5.75	5.75	
4ND	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	0.83	0.83	0.50	0.17	0.33	0.33	0.33	0.33	0.33		
			2.WEIGHT	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			3.COGNITIVE DISTURBANCE	1.00	1.00	0.50	0.17	0.00	0.17	0.00	0.17	0.17	0.17	0.17		
			4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			5.RETARDATION	1.25	1.25	1.25	1.00	1.00	0.75	0.50	0.75	0.75	0.75	0.75		
			6.SLEEP DISTURBANCE	1.33	1.67	1.33	1.00	1.00	1.00	0.67	1.00	0.67	1.00	0.67		
			7.Total score	5.92	6.25	5.42	4.33	3.67	2.92	2.67	3.25	3.25	3.25	3.25		
5ND	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	1.33	0.83	0.50	0.67	0.67	0.67	0.67	0.50	0.50		
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	0.83	0.83	0.50	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17		
			4.DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			5.RETARDATION	0.50	0.50	0.50	0.50	0.25	0.25	0.25	0.25	0.25	0.25	0.25		
			6.SLEEP DISTURBANCE	1.67	2.00	1.00	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67		
			7.Total score	5.17	5.50	3.53	2.17	1.83	1.75	1.75	1.75	1.75	1.75	1.58		
42	1ND	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.53	1.50	1.17	0.83	0.67	0.67	0.50	0.00	0.33	0.00		
				2.WEIGHT	2.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	0.50	0.83	0.50	0.17	0.17	0.00	0.17	0.00	0.17	0.00	0.00	
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				5.RETARDATION	1.50	1.50	1.50	0.75	1.00	0.25	0.00	0.25	0.00	0.25	0.25	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

43

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63			
42	1ND	Imipramine	Female	6.SLEEP DISTURBANCE	2.00	2.00	1.33	0.67	1.00	0.33	0.00	0.00	0.33	0.00			
				7.Total score	8.33	8.83	6.50	3.42	3.83	1.25	0.67	0.25	0.92	0.00			
42	1DT	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.83	1.67	1.33	1.50	1.17	1.00	1.17	1.17	1.17	0.50	1.00		
				2.WEIGHT	2.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	
				3.COGNITIVE DISTURBANCE	1.50	1.17	1.17	0.50	0.50	0.33	0.33	0.33	0.33	0.33	0.50	1.00	1.00
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	1.75	1.75	1.50	1.50	1.50	1.25	1.25	1.25	1.25	1.25	1.50	1.25	1.25
				6.SLEEP DISTURBANCE	1.67	2.00	2.00	2.00	2.00	1.33	1.33	1.33	1.33	1.33	1.33	0.67	0.33
				7.Total score	9.75	9.58	8.00	6.50	4.83	4.33	5.58	5.08	4.83	4.83	5.08	4.83	5.25
43	1DT	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.50	1.00	0.83	0.83	0.33	0.33	0.50	0.50	0.50			
				2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	0.50	0.83	0.33	0.47	0.33	0.17	0.00	0.17	0.00	0.00	0.00		
				4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00		
				5.RETARDATION	2.00	1.25	1.50	1.25	1.00	0.50	0.50	1.00	0.25	0.25	0.25		
				6.SLEEP DISTURBANCE	2.00	2.00	1.33	1.33	1.00	0.33	0.33	0.33	0.67	0.33	0.33		
				7.Total score	9.83	9.58	5.17	4.56	4.17	1.33	0.92	2.33	1.08	1.08			
44	02DT	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	1.17	1.17	1.17	1.33	0.67	1.17	1.00	0.67			
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	0.83	0.17	0.33	0.33	0.33	0.17	0.33	0.33	0.33	0.17	0.17	0.00	
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				5.RETARDATION	1.00	1.25	1.25	1.25	1.25	1.00	1.25	1.25	1.25	1.25	1.25	1.25	
				6.SLEEP DISTURBANCE	0.67	1.67	1.67	1.67	1.67	1.00	0.33	0.33	0.67	0.33	0.33	0.33	
				7.Total score	4.67	5.25	5.42	5.42	5.42	4.17	1.33	0.92	2.33	1.08	1.08		
45	3ND	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.17	1.17	1.33	1.17	1.33	0.67	1.17	1.00	1.00	0.67			
				2.WEIGHT	2.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.33	0.33	0.33	0.33	0.33	0.33	0.33		
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
				5.RETARDATION	1.00	1.50	1.75	2.00	1.50	1.50	1.50	1.50	1.50	1.25	1.00	0.50	
				6.SLEEP DISTURBANCE	1.67	2.00	2.00	2.00	2.00	0.67	1.00	0.67	1.00	0.67	0.67	0.33	
				7.Total score	7.50	7.33	6.75	6.83	5.17	4.17	5.00	4.08	3.83	3.83	2.50		
46	1DT	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.50	1.33	1.33	1.50	1.33	1.83	1.83				
				2.WEIGHT	0.00	0.00	0.00	0.00	2.00	0.00	0.00	0.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.33	0.17	0.33	0.33	0.33	0.33	0.33	0.33			
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
				5.RETARDATION	1.75	1.75	2.00	2.25	1.75	2.50	2.00	2.00	2.00	2.00			
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.33	1.00	1.00	1.00	1.00	1.00			
				7.Total score	5.75	5.75	5.50	5.42	6.75	5.33	4.67	5.33	4.67	5.17			
47	2DT	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	1.33	1.17	1.17	1.17	1.17	1.17					
				2.WEIGHT	2.00	2.00	0.00	0.00	2.00	0.00	0.00	2.00					
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.50	0.67	0.50	0.67					

9550089

44

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PEARLACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
43	20T	Imipramine	Female	1.00	1.00	1.00	1.00	0.00								
				1.75	1.75	1.50	2.25									
				1.33	1.33	1.33	1.67									
				7.92	7.92	6.08	5.50	7.75								
				7.92	7.92	6.08	5.50	7.75								
				1.00	1.00	1.00	1.00	0.00								
				1.75	1.75	1.50	2.25									
	30T	Imipramine	Male	2.00	2.00	1.67	1.83	0.83	0.17	0.33	0.33	0.33	0.17	0.33		
				2.00	2.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				0.83	0.83	1.00	0.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				2.00	2.00	2.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				2.00	2.00	2.00	1.50	0.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				1.67	1.67	1.67	1.67	0.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				10.50	10.50	9.33	8.67	3.00	0.17	0.83	1.00	0.17	0.83	1.00	0.17	0.33
44	20T	Imipramine	Female	1.17	1.17	1.17	1.17	1.17	1.00	1.00	0.83	0.83	0.83			
				2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				0.33	0.33	0.33	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.00	
				1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				2.25	2.25	2.25	2.00	1.25	1.25	1.25	1.25	1.00	1.00	1.00	1.00	
				1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.00	1.00	1.00	1.00	
				8.08	8.08	6.08	5.67	4.42	3.58	3.75	3.00	3.00	3.00	3.00	2.83	
	30T	Imipramine	Female	1.83	1.83	1.50	1.33	1.33	1.33	1.50						
				2.00	2.00	1.00	0.00	0.00	0.00	0.00	2.00					
				1.00	1.00	0.83	1.00	1.00	1.00	1.00	0.83					
				1.00	1.00	2.00	2.00	2.00	2.00	2.00	1.00					
				2.50	2.50	2.50	2.25	2.25	2.25	2.25	2.50					
				1.67	1.67	1.67	1.33	1.67	1.33	1.67	1.67					
				10.00	10.00	9.50	7.92	8.25	7.92	7.92	9.50					
45	20T	Imipramine	Female	1.33	1.33	0.83	0.83	0.83	0.67	0.67	0.67	0.67	0.67			
				1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				1.00	1.00	0.83	0.67	0.33	0.33	0.33	0.17	0.33	0.17	0.33		
				1.00	1.00	0.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				2.25	2.25	2.25	1.50	1.25	1.09	1.25	1.09	0.75	1.00	0.75	1.00	
				1.33	1.33	1.00	1.00	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.33	
				7.92	7.92	4.92	5.00	4.08	2.67	2.92	3.00	2.42	2.33	2.42	2.33	
	30T	Imipramine	Female	1.17	1.17	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83		
				1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				1.00	1.00	0.33	0.33	0.67	0.17	0.33	0.17	0.33	0.17	0.33		
				2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	
				1.25	1.25	0.75	1.00	1.00	0.00	0.50	0.25	0.75	0.75	0.75	1.00	
				0.67	0.67	0.67	0.33	1.00	0.67	0.67	0.67	0.67	0.67	0.67	0.67	
				7.08	7.08	4.58	3.50	3.50	4.17	3.08	3.42	2.42	2.42	2.42	6.00	
46	20T	Imipramine	Female	1.50	1.50	1.50	1.50	0.67	0.67	0.83	0.83	0.83	0.17			
				1.50	1.50	1.50	1.50	0.67	0.67	0.67	0.67	0.67	0.67	0.67		
				1.50	1.50	1.50	1.50	0.67	0.67	0.67	0.67	0.67	0.67	0.67		
				1.50	1.50	1.50	1.50	0.67	0.67	0.67	0.67	0.67	0.67	0.67		
				1.50	1.50	1.50	1.50	0.67	0.67	0.67	0.67	0.67	0.67	0.67		
				1.50	1.50	1.50	1.50	0.67	0.67	0.67	0.67	0.67	0.67	0.67		
				1.50	1.50	1.50	1.50	0.67	0.67	0.67	0.67	0.67	0.67	0.67		
	30T	Imipramine	Female	1.50	1.50	1.50	1.50	0.67	0.67	0.83	0.83	0.83	0.83	0.17		
				1.50	1.50	1.50	1.50	0.67	0.67	0.67	0.67	0.67	0.67	0.67		
				1.50	1.50	1.50	1.50	0.67	0.67	0.67	0.67	0.67	0.67	0.67		
				1.50	1.50	1.50	1.50	0.67	0.67	0.67	0.67	0.67	0.67	0.67		
				1.50	1.50	1.50	1.50	0.67	0.67	0.67	0.67	0.67	0.67	0.67		
				1.50	1.50	1.50	1.50	0.67	0.67	0.67	0.67	0.67	0.67	0.67		
				1.50	1.50	1.50	1.50	0.67	0.67	0.67	0.67	0.67	0.67	0.67		

1477

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

45

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day			
44	10T	Reboxetine	Female	Hamilton depression rating scale	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
				2.WEIGHT	1.17	1.17	1.17	0.33	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.00	
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				4.DIURNAL VARIATION	1.75	1.75	1.75	1.25	1.25	1.00	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.50
				5.RETARDATION	0.67	0.67	0.33	0.00	0.33	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.33
				6.SLEEP DISTURBANCE	8.08	8.08	5.75	2.25	3.92	3.17	3.42	3.42	3.42	3.42	3.42	3.42	3.42	2.17
				7.Total score	0.83	0.83	0.83	1.50	0.83	1.33	1.33	1.17	0.83	1.00	0.83	1.00	0.83	0.83
				1.ANXIETY/SOMATIZATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				2.WEIGHT	0.83	0.83	0.33	0.33	0.17	0.17	0.33	0.17	0.33	0.17	0.33	0.17	0.33	0.17
				3.COGNITIVE DISTURBANCE	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
4.DIURNAL VARIATION	1.75	1.75	1.75	1.25	1.25	1.00	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.50				
5.RETARDATION	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67				
6.SLEEP DISTURBANCE	6.08	6.08	3.58	5.25	3.58	4.42	4.83	4.83	4.83	4.83	4.83	4.83	4.83	1.50				
7.Total score	1.83	1.83	0.83	0.83	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.67				
3ND	Imipramine	Female	Hamilton depression rating scale	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			2.WEIGHT	0.50	0.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			4.DIURNAL VARIATION	1.75	1.75	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			5.RETARDATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			6.SLEEP DISTURBANCE	5.08	5.08	3.50	3.83	4.17	1.42	1.42	1.42	1.42	1.42	1.42	1.42	1.42		
			7.Total score	1.00	0.83	0.67	1.00	1.17	0.50	0.83	0.83	0.83	0.50	0.83	0.50	0.83		
			1.ANXIETY/SOMATIZATION	2.00	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			2.WEIGHT	0.00	0.17	0.17	0.00	0.00	0.17	0.67	0.33	0.00	0.33	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
4.DIURNAL VARIATION	2.25	2.25	2.25	1.00	0.75	1.50	2.00	2.25	1.50	2.00	2.25	1.50	1.75					
5.RETARDATION	0.33	0.67	0.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00					
6.SLEEP DISTURBANCE	5.58	5.92	5.75	3.00	1.92	3.17	4.50	4.50	4.50	4.50	4.50	4.50	4.50					
7.Total score	1.00	0.83	0.83	0.83	0.50	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67					
45	10D	Reboxetine	Male	Hamilton depression rating scale	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
				2.WEIGHT	0.50	0.83	0.67	0.17	0.33	0.67	0.67	0.67	0.67	0.67	0.67	0.67		
				3.COGNITIVE DISTURBANCE	0.00	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				4.DIURNAL VARIATION	1.25	1.75	1.75	1.00	1.00	1.25	1.00	1.25	1.00	1.25	1.00	1.25		
				5.RETARDATION	2.00	2.00	2.00	2.00	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67		
				6.SLEEP DISTURBANCE	5.75	7.42	7.25	4.75	3.83	5.25	5.25	5.25	5.25	5.25	5.25	5.25		
				7.Total score	1.00	0.83	0.83	0.83	0.50	0.67	0.67	0.67	0.67	0.67	0.67	0.67		
				1.ANXIETY/SOMATIZATION	1.00	0.00	0.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				2.WEIGHT	0.50	0.83	0.67	0.17	0.33	0.67	0.67	0.67	0.67	0.67	0.67	0.67		
				3.COGNITIVE DISTURBANCE	0.00	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
4.DIURNAL VARIATION	1.25	1.75	1.75	1.00	1.00	1.25	1.00	1.25	1.00	1.25	1.00	1.25						
5.RETARDATION	2.00	2.00	2.00	2.00	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67						
6.SLEEP DISTURBANCE	5.75	7.42	7.25	4.75	3.83	5.25	5.25	5.25	5.25	5.25	5.25	5.25						
7.Total score	1.17	1.00	1.17	1.17	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67						
10T	Imipramine	Female	Hamilton depression rating scale	0.67	0.67	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50					
			2.WEIGHT	0.00	0.67	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50				
			3.COGNITIVE DISTURBANCE	0.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00				
			4.DIURNAL VARIATION	1.50	1.50	1.50	1.25	1.50	1.25	1.50	1.25	1.50	1.25	1.50				
			5.RETARDATION	1.67	1.33	1.33	1.67	1.33	1.67	1.33	1.67	1.33	1.67	1.33				
			6.SLEEP DISTURBANCE	5.00	6.50	6.50	6.58	5.17	4.58	4.08	3.67	3.67	3.67	3.67				
			7.Total score	1.17	1.00	1.17	1.17	0.67	0.67	0.67	0.67	0.67	0.67	0.67				
			1.ANXIETY/SOMATIZATION	0.67	0.67	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50				
			2.WEIGHT	0.00	0.67	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50				
			3.COGNITIVE DISTURBANCE	0.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00				
4.DIURNAL VARIATION	1.50	1.50	1.50	1.25	1.50	1.25	1.50	1.25	1.50	1.25	1.50							
5.RETARDATION	1.67	1.33	1.33	1.67	1.33	1.67	1.33	1.67	1.33	1.67	1.33							
6.SLEEP DISTURBANCE	5.00	6.50	6.50	6.58	5.17	4.58	4.08	3.67	3.67	3.67	3.67							
7.Total score	1.17	1.00	1.17	1.17	0.67	0.67	0.67	0.67	0.67	0.67	0.67							

1478

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

46

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day		
45	2ND	Imipramine	Male	1. ANXIETY/SOMATIZATION	0.83	1.00	1.17										
				2. WEIGHT	2.00	2.00	2.00										
				3. COGNITIVE DISTURBANCE	0.50	0.83	0.50										
				4. DIURNAL VARIATION	2.00	2.00	2.00										
				5. RETARDATION	1.25	1.50	1.25										
				6. SLEEP DISTURBANCE	0.67	2.00	1.67										
				7. Total score	7.25	9.33	8.58										
46	1ND	Imipramine	Male	1. ANXIETY/SOMATIZATION	1.17	0.83	0.50	0.67	0.17	0.83	0.00	0.00	0.00	0.00	0.00		
				2. WEIGHT	2.00	0.00	1.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3. COGNITIVE DISTURBANCE	0.83	0.50	0.17	0.17	0.33	0.17	0.00	0.00	0.00	0.00	0.00	0.00	
				4. DIURNAL VARIATION	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				5. RETARDATION	1.50	2.25	1.00	1.00	0.50	0.75	0.25	0.25	0.25	0.25	0.25	0.25	
				6. SLEEP DISTURBANCE	1.67	2.00	0.67	0.67	0.33	0.33	0.00	0.00	0.00	0.00	0.00	0.00	
				7. Total score	8.17	6.58	3.33	2.50	2.33	3.08	0.25	0.25	0.25	0.25	0.25	0.25	
47	2ND	Imipramine	Female	1. ANXIETY/SOMATIZATION	1.33	1.17	1.33	0.83	1.00								
				2. WEIGHT	2.00	1.00	1.00	0.00	0.00								
				3. COGNITIVE DISTURBANCE	1.17	0.83	0.50	0.33	0.50								
				4. DIURNAL VARIATION	2.00	2.00	0.00	1.00	0.00								
				5. RETARDATION	2.25	2.25	2.00	2.00	1.50								
				6. SLEEP DISTURBANCE	1.67	2.00	1.00	1.67	1.00								
				7. Total score	10.42	9.25	6.08	5.83	4.00								
48	3ND	Reboxetine	Female	1. ANXIETY/SOMATIZATION	1.00	1.33	1.50	1.00	0.33	1.33	1.17	0.83	0.17	0.67			
				2. WEIGHT	2.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00		
				3. COGNITIVE DISTURBANCE	0.67	0.50	0.67	0.50	0.17	0.50	0.33	0.17	0.17	0.17	0.17		
				4. DIURNAL VARIATION	1.00	1.00	0.00	1.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00		
				5. RETARDATION	1.75	2.00	1.50	1.75	1.00	1.75	1.00	1.25	1.00	0.50	0.75		
				6. SLEEP DISTURBANCE	1.33	1.33	2.00	1.33	1.00	0.67	0.67	0.67	0.67	0.67	0.67		
				7. Total score	7.75	6.17	5.67	5.58	2.50	6.25	4.42	2.67	1.50	1.50	1.58		
49	4ND	Reboxetine	Female	1. ANXIETY/SOMATIZATION	1.50	1.00											
				2. WEIGHT	2.00	1.00											
				3. COGNITIVE DISTURBANCE	0.50	0.67											
				4. DIURNAL VARIATION	1.00	1.00											
				5. RETARDATION	1.75	2.00											
				6. SLEEP DISTURBANCE	1.33	2.00											
				7. Total score	8.08	7.67											
48	10T	Reboxetine	Female	1. ANXIETY/SOMATIZATION	1.33	1.33	1.67										
				2. WEIGHT	2.00	2.00	2.00										
				3. COGNITIVE DISTURBANCE	1.17	0.67	0.83										
				4. DIURNAL VARIATION	1.00	1.00	1.00										
				5. RETARDATION	1.75	1.75	1.75										

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

47

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
48	1DT	Reboxetine	Female	6.SLEEP DISTURBANCE	1.33	1.67	1.67	1.33	0.83	0.67	1.17			
				7.Total score	8.58	8.42	8.92							
	2DT	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.00	1.67	1.67	1.33	0.83	0.67	1.17			
				2.WEIGHT	2.00	2.00	1.00	1.00	2.00	2.00	2.00			
				3.COGNITIVE DISTURBANCE	0.83	0.50	0.50	0.33	0.33	0.33	0.33			
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00	0.00			
				5.RETARDATION	1.75	1.75	1.50	1.25	1.25	0.75	0.50	0.25		
				6.SLEEP DISTURBANCE	2.00	1.67	2.00	1.67	1.33	1.33	1.33			
				7.Total score	8.58	8.58	7.67	6.75	5.25	4.83	5.08			
				291	1ND	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.83	1.83	1.50	1.50	1.50	
2.WEIGHT	1.00	1.00	1.00					1.00	0.00	0.00				
				3.COGNITIVE DISTURBANCE	1.33	1.33	0.83	0.67	0.67					
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00				
				5.RETARDATION	2.00	2.00	1.50	1.50	1.50					
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.33	1.33					
				7.Total score	8.83	8.83	7.50	7.00	6.00					
				1480	1DT	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.63	1.83	1.33	1.33	1.17	1.00
2.WEIGHT	0.00	0.00	0.00					0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.67	0.33	0.33	0.33	0.33	
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.25	2.25	1.50	1.50	1.25	1.25	1.00	1.00	1.00	
				6.SLEEP DISTURBANCE	0.00	0.00	0.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				7.Total score	4.75	4.75	4.17	3.50	2.75	2.58	2.33	2.33	2.33	
				2ND	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.33	1.50	1.50	1.50
2.WEIGHT	2.00	2.00	0.00				0.00	1.00	1.00	1.00	1.00	1.00	1.00	
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.83	0.83	0.83	0.83		
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	
				5.RETARDATION	2.50	2.50	2.25	2.25	2.50	2.50	2.50	2.50		
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	
				7.Total score	9.17	9.17	6.92	6.92	7.83	7.83	7.83	7.83		
				2DT	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.67	1.50	1.50	1.33	1.00
2.WEIGHT	0.00	0.00	0.00				0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.83	0.50	0.50	0.50	0.50		
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				5.RETARDATION	2.50	2.50	2.50	2.00	1.75	1.75	1.75	1.75		
				6.SLEEP DISTURBANCE	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				7.Total score	5.00	5.00	6.00	6.00	4.75	4.58	4.25	4.25		
				3ND	Imipramine	Male	1.ANXIETY/SOMATIZATION	1.67	1.67	0.67	0.50	0.50	0.17	0.17
2.WEIGHT	0.00	0.00	0.00				0.00	0.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.33	0.17	0.17	0.17	0.17	0.17		

9550089

9550089

48

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 42.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
291	3ND	Imipramine	Male	4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				5. RETARDATION	2.25	2.25	1.50	1.00	1.00	1.00	0.50	0.50	0.50	0.50	0.50
				6. SLEEP DISTURBANCE	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				7. Total score	5.58	5.58	2.50	2.17	1.67	1.67	0.83	0.83	0.83		
30T		Imipramine	Female	1. ANXIETY/SOMATIZATION	1.67	1.67	1.67								
				2. WEIGHT	0.00	0.00	0.00								
				3. COGNITIVE DISTURBANCE	0.67	0.67	0.67								
				4. DIURNAL VARIATION	0.00	0.00	0.00								
				5. RETARDATION	1.75	1.75	1.75								
				6. SLEEP DISTURBANCE	1.67	1.67	1.67								
				7. Total score	5.75	5.75	5.75								
4ND		Reboxetine	Male	1. ANXIETY/SOMATIZATION	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17	
				2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3. COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67
				4. DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5. RETARDATION	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75
				6. SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67
				7. Total score	6.25	6.25	6.25	6.25	6.25	6.25	6.25	6.25	6.25	6.25	6.25
14041		Imipramine	Male	1. ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	
				2. WEIGHT	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				3. COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67
				4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5. RETARDATION	2.75	2.75	2.50	2.00	2.00	1.75	1.50	1.50	1.50	1.50	1.50
				6. SLEEP DISTURBANCE	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33
				7. Total score	6.25	6.25	6.00	5.50	5.50	5.50	5.50	5.50	5.50	5.50	5.50
25DT		Imipramine	Female	1. ANXIETY/SOMATIZATION	2.17	2.17	2.00	2.00	2.00	1.83	1.83	1.83	1.83	1.83	
				2. WEIGHT	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				3. COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83
				4. DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5. RETARDATION	1.75	1.75	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25
				6. SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67
				7. Total score	8.42	8.42	7.75	7.75	7.75	7.75	7.75	7.75	7.75	7.75	7.75
26DT		Reboxetine	Female	1. ANXIETY/SOMATIZATION	1.67	1.67	1.67	1.50	0.83	0.83	0.83	0.83	1.33	1.33	
				2. WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3. COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.33	0.17	0.17	0.17	0.17	0.17	0.17	
				4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				5. RETARDATION	1.50	1.50	1.50	1.25	1.25	1.25	1.25	1.25	1.25	1.25	
				6. SLEEP DISTURBANCE	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	
				7. Total score	6.83	6.83	4.83	4.42	3.58	3.58	3.58	3.58	3.58	3.58	
27DT		Reboxetine	Female	1. ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.17	1.33	1.17	1.00	1.00	1.00		

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

49

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
291	27DF	Reboxetine	Female	2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.50	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.00	2.00	2.00	1.50	1.50	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25
				6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33
				7.Total score	6.50	6.50	6.50	6.00	5.83	5.08	4.92	4.58	4.58	4.58	4.58	4.58	4.58
				1.ANXIETY/SOMATIZATION	1.83	1.83	1.83	1.50	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17
2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.50	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33				
4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
5.RETARDATION	2.25	2.25	2.00	1.75	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50				
6.SLEEP DISTURBANCE	2.00	2.00	1.00	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33				
7.Total score	6.92	6.92	5.67	4.08	3.33	3.33	3.33	3.33	3.33	3.33	3.33	3.33	3.33				
292	5ND	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.67	1.50	1.33	1.33	1.33	1.00	1.00	1.00	1.00	0.83		
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50		
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00		
				5.RETARDATION	1.25	1.25	1.25	1.25	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
				6.SLEEP DISTURBANCE	1.33	1.33	1.00	0.67	1.33	0.67	1.00	1.00	1.00	1.00	1.00		
				7.Total score	6.58	6.58	6.25	5.75	6.42	5.33	4.00	3.83	4.08	3.58	3.58		
1.ANXIETY/SOMATIZATION	1.83	1.67	1.50	1.50	1.67	1.50	1.00	0.83	0.83	0.83	0.83						
2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.50	0.33	0.33	0.50	0.50	0.50	0.50	0.50						
4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00						
5.RETARDATION	1.50	1.50	1.50	1.50	1.50	1.25	1.25	1.25	1.25	1.25	1.25						
6.SLEEP DISTURBANCE	1.67	1.67	1.67	2.00	1.67	1.33	1.33	1.33	1.33	1.33	1.33						
7.Total score	8.67	8.50	6.33	6.50	6.17	5.17	5.08	4.92	4.08	3.42	3.42						
600	27DF	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.50	1.50	1.17	1.17	0.83	0.67	0.67	0.67	0.67			
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
				3.COGNITIVE DISTURBANCE	0.33	0.50	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33			
				4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00			
				5.RETARDATION	1.75	1.50	1.50	1.50	1.00	0.75	0.50	0.50	0.75	0.75			
				6.SLEEP DISTURBANCE	1.67	2.00	2.00	1.67	1.33	1.00	0.67	1.00	1.00	1.00			
				7.Total score	7.42	7.50	7.33	6.67	5.83	4.17	3.67	3.75	3.50	3.75			
1.ANXIETY/SOMATIZATION	1.67	1.50	1.67	1.67	1.50	1.17	1.00	0.67	0.83	0.67							
2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00							
3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.50	0.50	0.33	0.33	0.33	0.33	0.33							
4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00							
5.RETARDATION	1.50	1.75	1.50	1.50	1.25	1.25	1.25	1.25	1.25	1.25							
6.SLEEP DISTURBANCE	1.67	2.00	2.00	1.67	1.33	1.00	0.67	1.33	1.00	0.67							
7.Total score	7.50	7.92	7.83	7.33	6.83	5.08	5.25	4.58	4.42	3.92							

1482

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

50

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
292	7ND	Reboxetine	Male	1. ANXIETY/SOMATIZATION	1.50	1.67	1.50	1.33	1.17	1.00	1.17	1.00	1.17	1.00		
				2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				3. COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.33	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17
				4. DIURNAL VARIATION	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5. RETARDATION	2.25	2.25	2.25	2.00	1.50	1.25	1.25	1.25	1.25	1.25	1.25	1.25
				6. SLEEP DISTURBANCE	2.00	1.67	2.00	1.67	1.00	1.33	1.00	1.00	1.00	1.00	1.00	1.00
				7. Total score	8.25	8.08	8.25	7.67	5.83	4.75	4.58	4.17	3.92			
				70T	Imipramine	Male	1. ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.17	0.83	0.83	1.00	1.17	1.00
2. WEIGHT	1.00	0.00	0.00				0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
3. COGNITIVE DISTURBANCE	0.67	0.83	0.50				0.33	0.17	0.17	0.17	0.17	0.17	0.17	0.17		
4. DIURNAL VARIATION	1.00	1.00	1.00				1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
5. RETARDATION	1.75	1.75	2.00				1.50	1.25	1.25	1.25	1.25	1.25	1.25	1.25		
6. SLEEP DISTURBANCE	1.33	1.67	1.67				1.33	1.00	0.67	1.00	1.00	1.00	1.00	1.00		
7. Total score	7.25	6.75	6.67				5.50	4.67	3.92	4.42	4.58	4.17	3.67			
8ND	Imipramine	Male	1. ANXIETY/SOMATIZATION				1.50	1.50	1.67	1.50	1.17	1.00	1.00	1.00	0.83	0.67
			2. WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3. COGNITIVE DISTURBANCE	0.67	0.67	0.83	0.83	0.83	0.50	0.50	0.50	0.50	0.50	0.33		
			4. DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			5. RETARDATION	1.75	2.25	2.25	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00		
			6. SLEEP DISTURBANCE	2.00	1.67	1.67	2.00	1.67	1.33	1.67	1.33	1.33	1.33	1.00		
			7. Total score	8.92	9.08	7.42	7.33	6.67	6.17	5.67	4.67	4.33	3.83			
			8DT	Reboxetine	Female	1. ANXIETY/SOMATIZATION	1.83	1.67	1.50	1.33	1.33	1.17	1.00	1.00	1.00	0.83
2. WEIGHT	1.00	0.00				0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
3. COGNITIVE DISTURBANCE	1.00	1.00				0.83	0.50	0.67	0.50	0.33	0.17	0.17	0.17	0.17		
4. DIURNAL VARIATION	2.25	2.25				2.25	1.75	1.75	1.25	1.25	1.25	1.25	1.25	1.25		
5. RETARDATION	2.00	1.67				1.67	1.33	1.00	1.33	1.00	1.00	1.00	1.00	1.00		
6. SLEEP DISTURBANCE	2.00	1.67				1.67	2.00	1.67	1.33	1.67	1.33	1.33	1.33	1.00		
7. Total score	9.08	7.58				7.25	5.92	6.08	4.92	4.42	4.42	4.42	4.00			
21ND	Imipramine	Female				1. ANXIETY/SOMATIZATION	1.50	1.67	1.50	1.33	1.00	0.83	1.00	0.83	1.00	0.67
			2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3. COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.50	0.33	0.33	0.17	0.17	0.17	0.17	0.00		
			4. DIURNAL VARIATION	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			5. RETARDATION	2.25	2.25	2.25	2.00	1.75	1.25	1.25	1.25	1.25	1.25	1.25		
			6. SLEEP DISTURBANCE	1.67	2.00	1.67	1.33	1.00	1.00	1.00	1.00	1.00	0.67	0.33		
			7. Total score	8.25	8.75	8.25	6.17	5.08	4.42	4.42	3.92	2.25	2.08			
			21DT	Reboxetine	Female	1. ANXIETY/SOMATIZATION	1.33	1.50	1.33	1.33	1.17	1.00	1.00	0.83	0.83	0.83
2. WEIGHT	0.00	0.00				0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
3. COGNITIVE DISTURBANCE	0.50	0.67				0.33	0.33	0.17	0.17	0.00	0.00	0.00	0.00			
4. DIURNAL VARIATION	2.00	2.00				2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00			
5. RETARDATION	2.25	2.25				2.25	2.25	1.75	1.50	1.25	0.75	0.75	0.50			

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
292	21DT	Reboxetine	Female	6.SLEEP DISTURBANCE	2.00	1.67	1.33	1.33	1.00	1.00	1.00	0.67	0.67	0.67	
				7.Total score	8.08	8.08	7.92	6.25	5.58	4.67	4.42	3.58	3.25	2.67	
22ND	Imipramine	Female	1.ANKIETY/SOMATIZATION	1.17	1.33	1.17	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			3.COGNITIVE DISTURBANCE	0.33	0.50	0.67	0.50	0.50	0.33	0.33	0.50	0.33	0.33	0.50	0.50
			4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
			5.RETARDATION	2.25	2.50	2.25	2.25	2.25	2.00	2.00	2.00	2.00	2.00	2.00	2.00
			6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.67	1.67	1.33	1.67	1.67	1.67	1.67	1.33	1.67
			7.Total score	7.75	8.33	8.08	7.58	7.42	7.00	7.17	7.00	6.67	6.67	7.17	
22DT	Imipramine	Female	1.ANKIETY/SOMATIZATION	1.00	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.17	1.17	1.33	
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.50	0.50	0.33	0.00	0.00	0.00	0.00	0.00	
			4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
			5.RETARDATION	1.75	2.25	2.25	2.00	2.00	1.75	1.75	1.75	1.50	1.50	1.50	
			6.SLEEP DISTURBANCE	2.00	2.00	1.67	1.67	2.00	1.67	1.33	1.00	1.33	1.00	1.33	
			7.Total score	7.42	8.25	7.92	7.75	7.83	7.08	6.42	5.92	6.00	6.50		
23ND 14 84	Reboxetine	Female	1.ANKIETY/SOMATIZATION	1.33	1.50	1.33	1.33	1.17	0.83	0.83	0.67	0.67	0.67		
			2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	0.50	0.50	0.67	0.33	0.33	0.33	0.17	0.17	0.17	0.00		
			4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			5.RETARDATION	2.00	2.00	2.25	1.75	1.75	1.00	1.00	1.00	1.00	1.00		
			6.SLEEP DISTURBANCE	1.67	2.00	1.67	1.67	1.33	1.00	1.00	1.00	0.67	1.00		
			7.Total score	8.50	7.00	6.75	6.08	5.58	4.17	4.00	3.83	3.50	3.67		
23DT	Reboxetine	Male	1.ANKIETY/SOMATIZATION	1.33	1.17	1.33	1.33	0.83	0.67	0.67	0.67	0.67	0.67		
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	0.33	0.50	0.67	0.33	0.33	0.33	0.17	0.00	0.00	0.00		
			4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			5.RETARDATION	2.25	2.25	2.00	1.75	1.50	1.00	0.75	0.75	0.75	0.75		
			6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.67	1.33	1.00	1.00	1.00	0.67	0.33		
			7.Total score	6.92	6.92	7.00	6.08	5.00	4.33	3.63	3.42	3.08	2.75		
24ND	Reboxetine	Male	1.ANKIETY/SOMATIZATION	1.50	1.50	1.67	1.67	1.47	1.17	0.83	0.83	0.83	0.67		
			2.WEIGHT	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.50	0.33	0.33	0.17	0.00	0.00	0.00		
			4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00		
			5.RETARDATION	2.00	2.00	2.00	2.00	1.50	1.50	1.00	1.00	1.00	1.00		
			6.SLEEP DISTURBANCE	1.67	2.00	1.67	1.33	1.00	0.67	0.67	0.33	0.33	0.67		
			7.Total score	9.83	8.17	8.00	7.50	6.00	4.67	3.67	3.17	3.00	3.33		
24DT	Imipramine	Female	1.ANKIETY/SOMATIZATION	1.50	1.50	1.33	1.33	1.33	1.33	1.50	1.17	1.00	1.00		
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			3.COGNITIVE DISTURBANCE	0.50	0.67	0.50	0.50	0.50	0.33	0.33	0.33	0.17	0.00		

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

52

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
292	24DT	Imipramine	Female	Hamilton depression rating scale	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
				4. DIURNAL VARIATION	2.00	2.00	1.75	2.25	2.00	2.00	2.00	2.00	2.00	1.75	1.75	
				6. SLEEP DISTURBANCE	2.00	2.00	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67
				7. Total score	7.00	7.17	6.83	6.25	6.75	6.33	6.17	5.33	5.08	5.08	5.08	5.08
293	9ND	Imipramine	Female	1. ANXIETY/SOMATIZATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.83		
				2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3. COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33
				4. DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5. RETARDATION	2.00	2.00	2.00	1.75	1.25	1.25	1.00	0.75	0.50	0.50	0.50	0.50
				6. SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.33	1.33	1.33	1.00	0.67	0.67	0.67	0.67
				7. Total score	6.00	6.00	6.00	5.75	5.75	4.92	4.67	4.08	3.33	3.33	3.33	3.33
9DT	Imipramine	Female	1. ANXIETY/SOMATIZATION	1.17	1.17	1.17	1.17	1.00	0.83	0.50	0.50	0.33	0.33	0.33		
			2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3. COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.50	0.50	0.50	0.50		
			4. DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			5. RETARDATION	1.25	1.25	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			6. SLEEP DISTURBANCE	1.00	1.00	1.33	1.33	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			7. Total score	5.08	5.08	5.42	5.17	4.67	3.50	3.25	2.67	2.25	2.25	2.25		
10ND	Reboxetine	Female	1. ANXIETY/SOMATIZATION	1.17	1.33	1.33	1.33	1.33	1.33	0.83	0.67	0.67	0.67	0.50		
			2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3. COGNITIVE DISTURBANCE	0.83	0.67	0.67	0.67	0.67	0.50	0.50	0.50	0.33	0.33	0.17		
			4. DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			5. RETARDATION	2.00	2.00	2.00	2.00	2.00	1.50	1.25	1.00	0.75	0.75	0.75		
			6. SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.33	1.00	1.00		
			7. Total score	6.67	6.67	6.67	6.67	6.00	5.25	5.08	4.33	3.42	3.42	3.42		
10DT	Imipramine	Female	1. ANXIETY/SOMATIZATION	1.00	1.00	1.17	1.17	1.17	1.00	1.00	1.00	1.00	1.00	0.83		
			2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3. COGNITIVE DISTURBANCE	0.33	0.33	0.33	0.50	0.50	0.50	0.50	0.50	0.33	0.33	0.33		
			4. DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			5. RETARDATION	2.00	2.00	2.00	2.00	1.75	1.50	1.50	1.00	0.75	0.50	0.50		
			6. SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.00	1.00	0.67		
			7. Total score	6.00	6.00	6.17	6.33	6.08	5.67	5.00	4.50	4.08	3.33	3.33		
11ND	Imipramine	Male	1. ANXIETY/SOMATIZATION	1.17	1.17	1.17	1.17	1.17	1.00	0.67	0.67	0.67	0.67	0.67		
			2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3. COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.50	0.33	0.33	0.33	0.33	0.33	0.33		
			4. DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			5. RETARDATION	2.00	2.00	2.00	2.00	1.75	1.25	1.25	1.00	0.67	0.67	0.67		
			6. SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.33	1.00	0.67		
			7. Total score	6.50	6.50	6.50	6.50	6.08	5.08	4.25	3.42	2.42	2.42	2.42		
11DT	Reboxetine	Female	1. ANXIETY/SOMATIZATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00			

1485

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

53

PHARMACIA CNS R&D

REBONETINE - PROTOCOL 20124/035
Listing No.: 12.1

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
293	14DT	Reboxetine	Female	2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				5.RETARDATION	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.25
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67
				7.Total score	6.42	6.42	6.42	6.42	6.42	6.42	6.42	6.42	6.42	6.42	6.42	6.42
				12ND	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.33	1.33	1.33	1.17	0.83	0.83
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.83	0.67	0.67	0.33	0.33	0.33	0.33			
			4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00			
			5.RETARDATION	2.00	2.00	2.00	2.00	1.75	1.50	1.25	1.00	1.00	1.00			
			6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00	1.33	1.00	1.00	1.00			
			7.Total score	7.17	7.17	7.17	6.75	6.50	5.08	4.17	4.17	4.17	4.17			
1486	12DT	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.33	1.33	1.33	1.17	1.00	1.00	1.00	1.00		
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	0.50	0.50	0.50	0.50	0.33	0.33	0.33	0.33	0.33	0.33	0.33	
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				5.RETARDATION	1.50	1.50	1.50	1.50	1.25	1.00	1.00	1.00	1.00	1.00	1.00	
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67
				7.Total score	6.17	6.17	6.00	6.00	5.58	5.17	4.33	3.83	3.83	3.83	3.83	3.83
294	13MD	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.33	1.33	1.17	0.67	0.50	0.50	0.50	0.50		
				2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	1.50	1.50	1.33	1.33	1.00	0.67	0.50	0.33	0.33	0.33	0.33	
				4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				5.RETARDATION	2.25	2.25	2.25	1.50	1.25	0.50	0.50	0.25	0.00	0.00	0.00	
				6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.33	1.00	0.33	0.33	0.33	0.33	0.33	0.33	
				7.Total score	6.92	6.92	6.58	5.50	4.42	2.17	1.83	1.42	0.33	0.33	0.33	
13DT	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.83	1.83	1.83	1.83	1.83	1.17	1.83	1.83	1.83	1.83			
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	1.83	1.83	1.83	1.83	1.50	1.83	1.83	1.83	1.83	1.83	1.83		
			4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			5.RETARDATION	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.25		
			6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.33	1.00	1.33	1.33	1.33	1.33	1.33	1.33		
			7.Total score	7.25	7.25	7.25	7.25	5.42	7.25	7.25	7.25	7.25	7.25	7.25		
148D	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.50	1.17	0.83	0.33	0.00	0.00	0.00			
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			3.COGNITIVE DISTURBANCE	1.83	1.83	2.00	1.50	0.83	0.33	0.33	0.33	0.33	0.33			
			4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
			5.RETARDATION	1.75	1.75	1.75	1.25	0.50	0.50	0.50	0.50	0.50	0.50			
			6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67			
			7.Total score	6.75	6.75	6.75	6.92	5.58	3.50	2.17	1.83	0.67	0.67			

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

54

PHARMACIA CNS R&D
 ROBEXETINE - PROTOCOL 20124/035
 Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
294	14PT	Imipramine	Female	1. ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.50	1.50	1.33	1.33	1.17	0.67			
				2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3. COGNITIVE DISTURBANCE	2.00	2.00	2.00	2.00	2.00	1.67	1.67	1.67	1.67	1.33	0.83	
				4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				5. RETARDATION	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.25	1.75	1.00	
				6. SLEEP DISTURBANCE	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.00	0.67	
				7. Total score	7.08	7.08	7.08	7.08	7.08	6.58	6.58	6.58	6.58	5.25	3.17	
15ND	15DT	Imipramine	Female	1. ANXIETY/SOMATIZATION	1.67	1.67	1.67	1.67	1.67	0.50	0.00	0.00	0.00	0.00		
				2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3. COGNITIVE DISTURBANCE	1.83	1.83	1.83	1.83	1.83	0.67	0.00	0.00	0.00	0.00	0.00	
				4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				5. RETARDATION	2.00	2.00	2.00	2.00	2.00	0.75	0.00	0.00	0.00	0.00	0.00	
				6. SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.00	0.00	0.00	0.00	0.00	0.00	
				7. Total score	7.17	7.17	7.17	7.17	2.92	0.00	0.00	0.00	0.00	0.00	0.00	
16ND	16DT	Roboxetine	Female	1. ANXIETY/SOMATIZATION	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.00	0.33		
				2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	
				3. COGNITIVE DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.83	0.83	
				4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				5. RETARDATION	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.00	1.00	
				6. SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.00	0.67	
				7. Total score	7.08	7.08	7.08	7.08	7.08	7.08	7.08	7.08	7.08	5.50	3.83	
16ND	16DT	Roboxetine	Female	1. ANXIETY/SOMATIZATION	1.67	1.67	1.67	1.67	1.67	0.33	0.00	0.00	0.00	0.00		
				2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3. COGNITIVE DISTURBANCE	1.83	1.83	1.83	1.83	1.83	0.83	0.17	0.00	0.00	0.00	0.00	
				4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				5. RETARDATION	2.25	2.25	2.25	2.25	2.25	1.00	0.50	0.00	0.00	0.00	0.00	
				6. SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.33	1.00	0.00	0.00	0.00	0.00	
				7. Total score	7.42	7.42	7.42	7.42	3.50	1.67	0.00	0.00	0.00	0.00	0.00	
16ND	16DT	Roboxetine	Female	1. ANXIETY/SOMATIZATION	1.50	1.50	1.50	1.50	1.50	0.33	0.33	0.33	0.33	0.00		
				2. WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3. COGNITIVE DISTURBANCE	2.00	2.00	2.00	2.00	2.00	0.50	0.50	0.50	0.50	0.33	0.00	
				4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				5. RETARDATION	2.25	2.25	2.25	2.25	2.25	1.00	0.25	0.00	0.00	0.00	0.00	
				6. SLEEP DISTURBANCE	1.33	1.33	1.33	1.33	1.33	1.00	0.33	0.00	0.00	0.00	0.00	
				7. Total score	7.08	7.08	7.08	7.08	2.83	2.83	1.25	0.00	0.00	0.00	0.00	
25ND	25DT	Imipramine	Female	1. ANXIETY/SOMATIZATION	1.33	1.33	1.33	0.83	0.83	0.33	0.00	0.00	0.00			
				2. WEIGHT	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				3. COGNITIVE DISTURBANCE	1.67	1.67	1.50	1.17	0.83	0.17	0.00	0.00	0.00	0.00		
				4. DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00		
				5. RETARDATION	2.25	2.25	2.25	1.75	1.00	0.50	0.00	0.00	0.00	0.00		

9550089

1487

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

55

PHARMACTA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Screening Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day
294	25ND	Imipramine	Female	Hamilton depression rating scale	1.67	1.67	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00
				6.SLEEP DISTURBANCE	8.92	8.92	6.08	5.75	4.67	2.00	0.00	0.00	0.00	0.00
				7.Total score										
26ND		Imipramine	Female	1.17	1.17	0.83	0.83	0.83	0.83	0.00	0.00	0.00	0.00	0.00
				1.ANXIETY/SOMATIZATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				2.WEIGHT	1.67	1.67	1.50	1.17	0.67	0.00	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	2.50	2.50	2.25	1.75	1.50	0.75	0.00	0.00	0.00	0.00
				5.RETARDATION	1.67	1.67	1.33	1.33	1.00	0.00	0.00	0.00	0.00	0.00
				6.SLEEP DISTURBANCE	8.00	8.00	7.58	5.25	4.83	3.25	0.00	0.00	0.00	0.00
				7.Total score										
27ND		Reboxetine	Female	1.33	1.33	1.00	1.17	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				1.ANXIETY/SOMATIZATION	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				2.WEIGHT	1.67	1.67	1.83	1.67	1.67	1.67	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	2.25	2.25	2.25	2.25	2.25	0.50	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	1.83	1.53	1.25	1.00	0.00	0.00	0.00	0.00
				6.SLEEP DISTURBANCE	9.25	9.25	8.92	8.42	6.92	5.50	0.00	0.00	0.00	0.00
				7.Total score										
28ND		Reboxetine	Female	1.33	1.33	1.17	1.00	0.93	0.90	0.00	0.00	0.00	0.00	0.00
				1.ANXIETY/SOMATIZATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				2.WEIGHT	1.67	1.67	1.83	1.50	0.83	0.50	0.00	0.00	0.00	0.00
				3.COGNITIVE DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	2.25	2.25	2.00	1.25	0.50	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	2.00	2.00	2.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
				6.SLEEP DISTURBANCE	7.25	7.25	5.50	3.42	1.00	0.00	0.00	0.00	0.00	0.00
				7.Total score										
29DT		Reboxetine	Female	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.00	1.00	0.83	0.83
				1.ANXIETY/SOMATIZATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				2.WEIGHT	2.00	2.00	2.00	2.00	2.00	2.00	1.50	1.50	0.67	0.67
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00
				4.DIURNAL VARIATION	2.50	2.50	2.50	2.50	2.50	2.50	2.00	2.00	1.25	1.25
				5.RETARDATION	1.67	1.67	1.67	1.67	1.67	1.33	1.33	1.33	1.00	1.00
				6.SLEEP DISTURBANCE	8.83	8.83	8.83	8.83	8.83	6.83	6.83	6.83	3.75	3.75
				7.Total score										
30DT		Reboxetine	Female	1.17	1.17	1.17	1.17	1.17	1.00	0.83	0.83	0.83	0.83	0.83
				1.ANXIETY/SOMATIZATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				2.WEIGHT	1.83	1.83	1.83	1.83	1.83	1.67	1.17	1.17	1.17	1.17
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	1.00	1.00	0.60	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	2.25	2.25	2.25	2.25	2.25	1.25	1.25	1.25	1.25	1.25
				5.RETARDATION	1.67	1.67	1.67	1.67	1.67	1.00	1.00	1.00	1.00	1.00
				6.SLEEP DISTURBANCE	7.92	7.92	7.92	7.92	6.92	4.25	4.25	4.25	4.25	4.25
				7.Total score										
31DT		Imipramine	Female	1.17	1.17	1.17	1.17	1.17	1.00	0.83	0.83	0.83	0.83	0.83
				1.ANXIETY/SOMATIZATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				2.WEIGHT	1.83	1.83	1.83	1.83	1.67	1.17	1.17	1.17	1.17	1.17
				3.COGNITIVE DISTURBANCE										

1488

9550089

9550089

57

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient Treatment	Sex	Hamilton depression rating scale	Screen Day	0 Day	7 Day	14 Day	21 Day	28 Day	35 Day	42 Day	49 Day	56 Day	63 Day		
295	19HD	Male	2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.17	
			4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
			5.RETARDATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
			6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.67
			7.Total score	8.50	8.50	8.50	8.50	8.50	8.50	8.50	8.50	8.50	8.50	8.50	8.50	8.25
			1.ANXIETY/SOMATIZATION	1.33	1.33	1.33	1.33	1.17	1.33	1.17	1.33	1.50	1.50	1.50	1.50	1.50
2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83	0.83		
4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00		
5.RETARDATION	1.75	1.75	1.75	1.75	1.75	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	2.00		
6.SLEEP DISTURBANCE	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.67	1.33		
7.Total score	7.58	7.58	7.58	7.58	7.17	7.58	7.17	7.58	7.17	7.58	7.17	7.58	7.17	7.67		
20HD	19DT	Female	1.ANXIETY/SOMATIZATION	1.17	1.17	1.33	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			3.COGNITIVE DISTURBANCE	0.83	0.83	0.83	0.67	0.67	0.67	0.67	0.67	0.50	0.50	0.50	0.50	0.50
			4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
			5.RETARDATION	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.50	1.50	1.50	1.50	1.50
			6.SLEEP DISTURBANCE	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33	1.33
			7.Total score	6.08	6.08	6.25	6.25	6.25	6.00	6.25	6.00	5.83	5.83	5.83	5.83	5.83
20DT	19DT	Female	1.ANXIETY/SOMATIZATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.17	
			2.WEIGHT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			3.COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.50	0.50	0.50	0.50	0.50
			4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
			5.RETARDATION	1.50	1.50	1.50	1.25	1.25	1.25	1.25	1.25	1.00	1.00	1.00	1.00	0.75
			6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.33
			7.Total score	5.17	5.17	5.17	4.92	4.92	4.58	4.58	4.17	3.50	3.50	3.17	2.42	2.42
381	1HD	Male	1.ANXIETY/SOMATIZATION	1.17	1.50	1.67	1.50	1.67	1.00	1.00	0.67	1.00	0.67	1.00	0.83	
			2.WEIGHT	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
			3.COGNITIVE DISTURBANCE	0.67	0.83	0.67	0.50	0.33	0.33	0.33	0.50	0.50	0.50	0.50	0.50	
			4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
			5.RETARDATION	1.25	0.75	1.00	0.75	0.75	0.75	0.75	0.75	0.50	0.50	0.50	0.50	
			6.SLEEP DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
			7.Total score	8.08	9.08	9.33	5.75	5.75	5.75	5.75	6.33	6.00	6.33	6.00	1.92	2.08
2HD	19DT	Female	1.ANXIETY/SOMATIZATION	2.33	1.83	1.50	1.17	0.83	0.50	0.50	1.50	1.50	1.50	1.50		
			2.WEIGHT	3.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	1.00	0.17	0.67	0.50	0.33	0.33	0.33	0.33	0.00	0.00	0.00	0.00	
			4.DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			5.RETARDATION	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.25	1.00	1.00	1.00	1.00	
			6.SLEEP DISTURBANCE	1.00	1.00	1.00	1.67	1.67	1.67	1.67	1.67	1.00	1.00	1.00	1.00	
			7.Total score	8.58	5.25	6.08	4.83	2.92	1.50	4.83	2.92	1.50	4.83	2.92	1.50	

1490

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

58

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
381	SDT	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.67	1.67	1.00	1.50	1.50							
				2.WEIGHT	0.00	0.00	0.00	0.00	3.00							
				3.COGNITIVE DISTURBANCE	1.00	1.17	0.33	0.33	0.83							
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00	2.00							
				5.RETARDATION	1.50	1.25	1.00	1.25	2.00							
				6.SLEEP DISTURBANCE	1.00	1.00	1.00	2.00	1.00							
				7.Total score	6.17	6.08	4.33	6.08	10.33							
4ND	5MD	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.33	2.17	1.00								
				2.WEIGHT	0.00	0.00	0.00	0.00								
				3.COGNITIVE DISTURBANCE	1.00	1.00	1.50	0.67								
				4.DIURNAL VARIATION	1.00	1.00	1.00	1.00								
				5.RETARDATION	1.25	1.25	1.25	1.00								
				6.SLEEP DISTURBANCE	2.00	2.00	1.00	0.67								
				7.Total score	6.58	6.58	6.92	4.33								
382	5MD	Imipramine	Female	1.ANXIETY/SOMATIZATION	2.67	2.50	2.33	1.67	1.50	0.83	1.67	1.33	2.50	1.50		
				2.WEIGHT	3.00	3.00	0.00	2.00	0.00	0.00	3.00	0.00	2.00	3.00	2.00	
				3.COGNITIVE DISTURBANCE	2.00	2.33	1.17	1.00	0.50	0.83	0.00	1.17	0.83	0.00	1.17	0.50
				4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	1.00	0.00	0.00	1.00	0.00	1.00	1.00	1.00
				5.RETARDATION	2.00	2.00	1.50	1.25	0.75	0.75	0.25	1.00	0.25	1.00	0.75	1.00
				6.SLEEP DISTURBANCE	1.00	2.00	2.00	2.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
				7.Total score	12.67	13.83	8.00	8.92	4.75	4.42	5.25	4.58	8.67	5.58		
5DT	Reboxetine	Male	1.ANXIETY/SOMATIZATION	1.00	2.00	1.17	1.17									
			2.WEIGHT	0.00	3.00	0.00	0.00									
			3.COGNITIVE DISTURBANCE	0.83	2.50	1.33	0.67									
			4.DIURNAL VARIATION	0.00	0.00	1.00	1.00									
			5.RETARDATION	2.00	2.25	0.75	1.50									
			6.SLEEP DISTURBANCE	0.00	2.00	2.00	1.00									
			7.Total score	3.83	11.75	6.25	5.33									
6MD	Reboxetine	Female	1.ANXIETY/SOMATIZATION	2.50	2.17	1.50	1.50	1.83	2.33	1.67	1.83	1.83	2.00			
			2.WEIGHT	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00		
			3.COGNITIVE DISTURBANCE	2.00	1.83	1.17	2.00	0.67	0.67	0.83	1.00	0.83	0.83	0.50		
			4.DIURNAL VARIATION	0.00	1.00	1.00	1.00	2.00	1.00	1.00	2.00	1.00	1.00	1.00		
			5.RETARDATION	2.25	2.00	1.00	1.75	1.50	1.50	1.25	1.50	1.25	1.50	1.00		
			6.SLEEP DISTURBANCE	2.00	2.00	1.00	2.00	1.00	2.00	2.00	1.00	2.00	2.00	2.00	0.00	
			7.Total score	9.75	9.00	5.67	8.25	8.25	6.50	7.50	7.08	5.17	5.17	5.50		
6DT	Imipramine	Female	1.ANXIETY/SOMATIZATION	1.33	1.50	1.50	1.17	0.83	0.67	0.67	0.50	0.50	0.67			
			2.WEIGHT	0.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	1.67	0.50	0.83	0.83	0.33	0.33	0.17	0.17	0.17	0.17	0.17		
			4.DIURNAL VARIATION	2.00	2.00	0.00	2.00	2.00	1.00	1.00	1.00	0.00	0.00	1.00		
			5.RETARDATION	2.00	0.75	1.25	1.50	0.75	0.50	0.75	0.25	0.75	0.25	0.75		

1491

9550089

9550089

59

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
382	60F	Imipramine	Female	Hamilton depression rating scale	2.00	0.33	0.67	2.00	0.33	1.00	0.00	0.00	0.35	0.00
				6.SLEEP DISTURBANCE	9.00	5.08	4.25	8.50	4.25	3.50	2.75	0.52	3.58	2.08
				7.Total score	1.50	1.50	1.33	1.00	1.17	0.83	0.50	1.00	0.83	0.50
7MD	Reboxetine	Female	1.ANXIETY/SOMATIZATION	2.00	2.00	3.00	0.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
			2.WEIGHT	0.67	0.67	0.50	0.67	0.33	0.33	0.17	0.00	0.00	0.00	
			3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	0.00	1.00	1.00	0.00	0.00	0.00	0.00	
			4.DIURNAL VARIATION	1.00	1.00	1.00	0.75	1.00	0.75	0.25	0.25	0.25	0.25	
			5.RETARDATION	2.00	2.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	
			6.SLEEP DISTURBANCE	8.17	8.17	7.83	3.42	4.50	3.92	2.58	1.42	1.08	0.75	
			7.Total score	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	
7DT	Imipramine	Male	1.ANXIETY/SOMATIZATION	0.83	0.83	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
			2.WEIGHT	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
			3.COGNITIVE DISTURBANCE	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	
			4.DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
			5.RETARDATION	8.83	8.83	8.83	8.83	8.83	8.83	8.83	8.83	8.83	8.83	
			6.SLEEP DISTURBANCE	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
			7.Total score	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
80D	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.00	1.50	1.63	1.33	1.33	1.00	0.33	0.67	0.50	1.67	1.00
			2.WEIGHT	3.00	3.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
			3.COGNITIVE DISTURBANCE	1.00	0.50	0.83	0.33	0.67	0.33	0.17	0.33	0.33	0.33	
			4.DIURNAL VARIATION	1.00	1.00	1.00	0.83	0.67	0.33	0.17	0.33	0.33	0.33	
			5.RETARDATION	1.75	1.50	2.00	2.25	1.00	1.00	1.00	1.00	1.00	1.00	
			6.SLEEP DISTURBANCE	1.00	0.00	0.00	0.00	1.25	1.50	0.75	0.50	1.00	1.00	
			7.Total score	8.75	7.50	5.67	4.92	1.00	0.33	0.00	0.00	0.00	0.33	
90D	Reboxetine	Female	1.ANXIETY/SOMATIZATION	2.33	2.33	1.50	1.33	1.00	0.33	0.67	0.50	1.67	1.00	
			2.WEIGHT	3.00	3.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			3.COGNITIVE DISTURBANCE	1.00	1.00	1.00	0.83	0.67	0.33	0.17	0.33	0.33	0.33	
			4.DIURNAL VARIATION	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
			5.RETARDATION	1.75	1.75	1.75	1.50	1.25	1.50	0.75	0.50	1.00	1.00	
			6.SLEEP DISTURBANCE	2.00	2.00	2.00	1.00	1.00	0.33	0.00	0.00	0.00	0.33	
			7.Total score	12.08	12.08	7.25	7.67	4.92	2.75	2.33	1.83	4.50	3.67	
90D	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.50	1.50	0.83	1.00	0.67	0.33	0.33	0.33	0.33	0.33	
			2.WEIGHT	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			3.COGNITIVE DISTURBANCE	0.67	0.67	0.33	0.17	0.33	0.00	0.00	0.00	0.00	0.00	
			4.DIURNAL VARIATION	2.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			5.RETARDATION	1.75	2.00	0.50	0.50	0.50	0.50	0.00	0.00	0.25	0.25	
			6.SLEEP DISTURBANCE	2.00	2.00	0.67	1.00	1.00	0.33	0.33	0.33	0.00	0.33	
			7.Total score	9.52	10.17	3.53	2.67	2.50	1.17	0.87	0.92	0.33	0.92	
90T	Reboxetine	Female	1.ANXIETY/SOMATIZATION	1.83	2.33	2.33	1.17	1.00	1.50	1.50	1.50	1.50	1.50	
			2.WEIGHT	3.00	3.00	2.00	0.00	2.00	0.00	0.00	0.00	0.00		
			3.COGNITIVE DISTURBANCE	1.33	1.33	1.33	0.33	0.17	1.67	1.67	1.67	1.67		

1432

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

60

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 12.1

HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
382	90T	Reboxetine	Female	4. DIURNAL VARIATION	2.00	2.00	2.00	0.00	1.00	2.00					
				5. RETARDATION	2.00	2.00	2.00	1.25	1.50	1.50					
				6. SLEEP DISTURBANCE	2.00	2.00	2.00	0.67	2.00	1.67					
				7. Total score	12.17	12.67	11.67	3.42	7.67	8.33					
10ND	Imipramine	Female	1. ANXIETY/SOMATIZATION	2.50	2.50	1.17									
			2. WEIGHT	2.00	2.00	0.00									
			3. COGNITIVE DISTURBANCE	1.00	1.17	0.83									
				4. DIURNAL VARIATION	2.00	2.00	1.00								
				5. RETARDATION	1.50	1.50	1.75								
				6. SLEEP DISTURBANCE	2.00	2.00	2.00								
				7. Total score	11.00	11.17	6.75								
3301	1ND	Reboxetine	Female	1. ANXIETY/SOMATIZATION	1.00	1.00									
				2. WEIGHT	0.00	0.00									
				3. COGNITIVE DISTURBANCE	1.50	1.17									
				4. DIURNAL VARIATION	2.00	2.00									
				5. RETARDATION	2.00	2.00									
				6. SLEEP DISTURBANCE	0.67	0.67									
				7. Total score	7.17	6.83									
2ND	Imipramine	Male	1. ANXIETY/SOMATIZATION	2.00	2.00	1.50	1.67	1.50	1.33	1.00	0.83	0.67	0.67	0.67	
			2. WEIGHT	2.00	2.00	2.00	2.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			3. COGNITIVE DISTURBANCE	1.17	1.33	1.00	1.00	0.83	0.83	0.50	0.50	0.33	0.33	0.33	
				4. DIURNAL VARIATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				5. RETARDATION	2.00	2.00	1.75	1.25	1.00	1.00	1.00	0.50	0.50		
				6. SLEEP DISTURBANCE	2.00	2.00	1.67	1.67	1.33	1.00	0.67	0.67	0.33		
				7. Total score	9.17	9.33	7.92	7.58	4.92	4.17	3.17	2.33	2.17		
3ND	Reboxetine	Female	1. ANXIETY/SOMATIZATION	1.67	2.00	1.83	2.00	2.00	2.00	2.50					
			2. WEIGHT	2.00	2.00	2.00	0.00	0.00	0.00	0.00	1.00				
			3. COGNITIVE DISTURBANCE	1.83	1.83	1.83	2.00	1.83	2.17						
				4. DIURNAL VARIATION	2.00	2.00	2.00	2.00	2.00	2.00	2.00				
				5. RETARDATION	0.50	1.00	1.25	2.00	1.75						
				6. SLEEP DISTURBANCE	1.67	1.67	2.00	2.00	2.00	2.00					
				7. Total score	9.67	10.50	10.92	9.25	9.83	11.42					
3302	Reboxetine	Female	1. ANXIETY/SOMATIZATION	0.83	1.17	1.17	1.17								
			2. WEIGHT	1.00	2.00	2.00	2.00								
			3. COGNITIVE DISTURBANCE	0.67	0.67	0.67	0.67								
				4. DIURNAL VARIATION	0.00	1.00	2.00	2.00							
				5. RETARDATION	1.75	1.25	1.75	2.25							
				6. SLEEP DISTURBANCE	1.33	1.67	1.33	1.33							
				7. Total score	5.58	7.75	8.92	9.42							
6ND	Imipramine	Female	1. ANXIETY/SOMATIZATION	1.17	1.17	1.00	1.17	1.00	1.17	1.50					

1493

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

61

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 42.1

Centre	Patient	Treatment	Sex	Hamilton depression rating scale	Screen Day	0	Day	7	Day	14	Day	21	Day	28	Day	35	Day	42	Day	49	Day	56	Day	63				
3302	6MD	Imipramine	Female	HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE	Screen Day	2.00	2.00	0.00	0.00	0.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
				2.WEIGHT	0.67	0.67	0.33	0.17	0.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				3.COGNITIVE DISTURBANCE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				4.DIURNAL VARIATION	1.25	1.25	1.25	0.75	1.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				5.RETARDATION	1.67	1.67	1.00	1.00	1.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				6.SLEEP DISTURBANCE	6.75	6.75	3.58	3.08	6.75	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				7.Total score	0.83	0.83	0.67	0.67	0.83	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
7MD	7MD	Imipramine	Female	HAMILTON DEPRESSION RATING SCALE: FACTOR AND TOTAL SCORE	Screen Day	0.83	0.83	0.67	0.67	0.67	0.83	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67		
				1.ANKIETY/SOMATIZATION	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				2.WEIGHT	1.00	1.17	1.00	0.67	1.00	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50
				3.COGNITIVE DISTURBANCE	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				4.DIURNAL VARIATION	1.75	1.50	1.50	1.00	1.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75
				5.RETARDATION	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67
				6.SLEEP DISTURBANCE	6.25	6.17	5.83	5.00	6.25	4.75	4.75	4.75	4.75	4.75	4.75	4.75	4.75	4.75	4.75	4.75	4.75	4.75	4.75	4.75	4.75	4.75	4.75	4.75
7.Total score	0.83	0.83	0.67	0.67	0.83	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67				

1494

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

1

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63			
1	1ND	Reboxetine	Female	01.REPORTED SADNESS	2	0	0	0	0	0	0	0	1	0	0		
				02.INNER TENSION	2	0	0	1	0	0	0	0	0	0	1	0	
				03.APPARENT SADNESS	2	0	0	0	0	0	0	0	0	0	0	0	0
				04.SUICIDAL THOUGHTS	4	3	4	4	0	0	0	0	1	0	0	0	0
				05.INERTIA	1	0	0	0	0	0	0	0	0	0	0	0	0
				06.INABILITY TO FEEL	2	1	0	0	0	0	0	0	0	0	0	0	0
				07.PESSIMISTIC THOUGHTS	2	1	0	0	0	0	0	0	0	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	1	0	0	0	0	0	0	0	0	0	0	0	0
				09.REDUCED SLEEP	2	0	0	0	0	0	0	0	0	0	0	0	0
				10.REDUCED APPETITE	1	0	0	0	0	0	0	0	0	0	0	0	0
				11.Total score	19	5	5	5	0	0	1	0	0	0	0	4	0
1495	1DT	Reboxetine	Male	01.REPORTED SADNESS	3	1	1	1	0	0	0	0	0	0	0		
				02.INNER TENSION	3	2	1	0	0	0	0	0	0	0	0	0	
				03.APPARENT SADNESS	2	3	1	0	0	2	1	0	0	0	1	0	
				04.SUICIDAL THOUGHTS	3	2	2	0	0	0	0	0	0	0	0	0	0
				05.INERTIA	4	4	2	0	0	0	0	0	0	0	0	0	0
				06.INABILITY TO FEEL	4	3	2	1	0	0	0	0	0	0	0	0	0
				07.PESSIMISTIC THOUGHTS	4	3	1	0	0	0	0	0	0	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	0	0	0	0	0	0	0	0	0	0	0
				09.REDUCED SLEEP	3	0	0	0	0	0	0	0	0	0	0	0	0
				10.REDUCED APPETITE	1	0	0	0	0	0	0	0	0	0	0	0	0
				11.Total score	29	20	10	1	2	1	0	0	0	0	0	2	0
2ND	Imipramine	Male	01.REPORTED SADNESS	4	4	4	4	2	1	1	0	2	2	2	0		
			02.INNER TENSION	4	3	2	2	0	0	0	0	0	0	0	0	0	
			03.APPARENT SADNESS	2	0	2	0	0	0	0	0	0	0	0	0	0	
			04.SUICIDAL THOUGHTS	4	4	5	4	0	0	2	2	2	2	2	2	0	
			05.INERTIA	2	0	0	0	0	0	0	0	0	0	0	0	0	
			06.INABILITY TO FEEL	4	3	1	0	0	1	0	0	0	0	0	0	0	
			07.PESSIMISTIC THOUGHTS	4	2	2	0	0	0	2	1	1	1	1	1	1	
			08.CONCENTRATIONS DIFFICULTIES	2	0	2	1	1	1	1	1	1	1	1	1	1	
			09.REDUCED SLEEP	2	0	1	1	0	0	2	1	0	0	2	0	0	
			10.REDUCED APPETITE	3	0	1	0	0	0	1	0	0	0	1	0	0	
			11.Total score	33	18	20	10	3	1	0	0	0	0	10	9	0	
2DT	Imipramine	Male	01.REPORTED SADNESS	4	6	6	6	6	4	6	6	6	6	6	6		
			02.INNER TENSION	4	6	6	6	6	6	6	6	6	6	6	6		
			03.APPARENT SADNESS	3	3	3	4	4	4	4	4	4	4	4	4		
			04.SUICIDAL THOUGHTS	4	6	6	6	6	6	6	6	6	6	6	6		
			05.INERTIA	4	4	4	4	4	4	4	4	4	4	4	4		
			06.INABILITY TO FEEL	2	2	2	2	2	2	2	2	2	2	2	2		
			07.PESSIMISTIC THOUGHTS	4	4	4	4	4	4	4	4	4	4	4	4		
			08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2	2	2	2	2	2		
			09.REDUCED SLEEP	4	4	4	4	4	4	4	4	4	4	4	4		
			10.REDUCED APPETITE	4	4	4	4	4	4	4	4	4	4	4	4		
			11.Total score	35	42	42	39	35	35	42	42	39	35	42	42	39	

9550089

2

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63			
1	3ND	Imipramine	Female	01.REPORTED SADNESS	4	2	0	0	0	0	0	0	0	0	0		
				02.INNER TENSION	3	2	1	0	0	0	0	0	0	0	0	0	0
				03.APPARENT SADNESS	5	3	2	0	2	0	0	0	0	0	0	0	0
				04.SUICIDAL THOUGHTS	6	3	4	0	0	0	0	0	0	0	0	0	0
				05.INERTIA	3	3	3	0	0	0	0	0	0	0	0	0	0
				06.INABILITY TO FEEL	4	3	0	0	0	0	0	0	0	0	0	0	0
				07.PESSIMISTIC THOUGHTS	2	2	0	0	0	0	0	0	0	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	3	2	0	0	0	0	0	0	0	0	0	0	0
				09.REDUCED SLEEP	0	2	0	0	0	0	0	0	0	0	0	0	0
				10.REDUCED APPETITE	0	1	0	0	0	0	0	0	0	0	0	0	0
				11.Total score	30	23	7	0	2	0	0	0	0	0	0	0	0
3OT	Reboxetine	Male	01.REPORTED SADNESS	4	4	5	4	4	1	2	2	2	1	0	0		
			02.INNER TENSION	6	4	4	4	4	2	2	2	2	2	1	0	0	
			03.APPARENT SADNESS	5	3	3	3	2	2	2	2	2	2	1	1	1	
			04.SUICIDAL THOUGHTS	5	5	4	4	4	4	5	4	5	4	4	1	1	
			05.INERTIA	4	3	3	3	3	1	3	3	3	3	0	0	0	
			06.INABILITY TO FEEL	1	1	2	0	0	0	3	2	2	2	1	0	0	
			07.PESSIMISTIC THOUGHTS	2	2	3	3	2	2	2	2	2	2	2	1	0	
			08.CONCENTRATIONS DIFFICULTIES	4	4	4	4	4	3	2	2	2	2	2	0	0	
			09.REDUCED SLEEP	2	2	2	2	2	2	2	2	2	2	2	0	0	
			10.REDUCED APPETITE	0	0	2	2	0	0	0	0	0	0	0	0	0	
			11.Total score	33	28	32	27	17	21	20	5	2	2	1	1	1	
4ND	Reboxetine	Female	01.REPORTED SADNESS	6	4	4	6	6	4	2	2	2	1	1	1		
			02.INNER TENSION	6	4	4	4	6	3	2	2	2	2	2	1	1	
			03.APPARENT SADNESS	2	4	3	3	3	3	2	2	2	2	2	0	0	
			04.SUICIDAL THOUGHTS	6	4	4	4	5	3	3	3	3	3	2	0	0	
			05.INERTIA	4	4	4	3	5	3	3	3	3	2	1	0	0	
			06.INABILITY TO FEEL	4	4	4	4	4	3	3	3	3	2	1	1	1	
			07.PESSIMISTIC THOUGHTS	4	5	2	4	4	2	1	1	1	1	1	1	1	
			08.CONCENTRATIONS DIFFICULTIES	4	4	4	4	4	2	1	1	1	1	1	1	1	
			09.REDUCED SLEEP	4	4	3	5	4	3	2	2	2	2	2	0	0	
			10.REDUCED APPETITE	4	4	3	4	4	2	1	1	1	1	1	0	0	
			11.Total score	43	40	34	46	30	24	17	13	6	6	6	6	6	
4DT	Imipramine	Male	01.REPORTED SADNESS	3	2	3	3	6	3	3	3	3	3	3	3		
			02.INNER TENSION	3	2	3	3	6	3	3	3	3	3	3	3		
			03.APPARENT SADNESS	3	2	3	4	4	2	4	4	4	4	4	4		
			04.SUICIDAL THOUGHTS	4	4	4	2	4	2	4	4	4	4	4	4		
			05.INERTIA	2	2	3	0	5	2	3	2	2	2	2	2		
			06.INABILITY TO FEEL	2	2	2	3	5	2	3	2	2	2	2	2		
			07.PESSIMISTIC THOUGHTS	3	3	3	3	4	3	3	3	3	3	3	3		
			08.CONCENTRATIONS DIFFICULTIES	3	3	3	3	4	3	3	3	3	3	3	3		
			09.REDUCED SLEEP	3	3	3	3	3	3	3	3	3	3	3	3		
			10.REDUCED APPETITE	0	0	0	1	1	0	0	0	0	0	0	0		

1496

9550089

3

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
1	401	Imipramine	Male	11.Total score	26	23	27	37						
2	100	Reboxetine	Male	01.REPORTED SADNESS	5	4	4	3	5					
				02.INNER TENSION	4	4	3	3	5					
				03.APPARENT SADNESS	4	3	2	4	3					
				04.SUICIDAL THOUGHTS	4	2	2	2	4					
				05.INERTIA	4	2	2	2	2					
				06.INABILITY TO FEEL	2	1	2	3	3					
				07.PESSIMISTIC THOUGHTS	4	4	3	3	4					
				08.CONCENTRATIONS DIFFICULTIES	3	2	3	3	4					
				09.REDUCED SLEEP	1	1	1	1	2					
				10.REDUCED APPETITE	3	2	1	2	4					
				11.Total score	34	26	22	27	36					
3	100	Reboxetine	Female	01.REPORTED SADNESS	5	6	3	4	4	4	4	5	6	
				02.INNER TENSION	5	6	5	4	5	5	4	4	6	
				03.APPARENT SADNESS	2	0	0	0	0	0	0	0	0	
				04.SUICIDAL THOUGHTS	4	6	4	5	6	2	0	4	4	
				05.INERTIA	3	4	2	3	4	3	3	4	4	
				06.INABILITY TO FEEL	3	6	4	4	5	4	3	5	4	
				07.PESSIMISTIC THOUGHTS	5	5	4	4	4	4	4	1	4	
				08.CONCENTRATIONS DIFFICULTIES	4	5	3	5	3	4	2	5	4	
				09.REDUCED SLEEP	1	1	0	0	0	0	0	0	0	
				10.REDUCED APPETITE	3	4	0	1	0	0	0	0	3	
				11.Total score	35	43	25	30	31	26	17	36		
4	100	Imipramine	Male	01.REPORTED SADNESS	4	4	4	5	5	6				
				02.INNER TENSION	4	4	3	4	4	4	4	4	4	
				03.APPARENT SADNESS	3	2	1	1	2	3				
				04.SUICIDAL THOUGHTS	4	4	4	4	3	3				
				05.INERTIA	3	2	2	3	2	2				
				06.INABILITY TO FEEL	2	2	2	2	3	4				
				07.PESSIMISTIC THOUGHTS	4	4	4	4	4	4				
				08.CONCENTRATIONS DIFFICULTIES	2	2	3	3	2	4				
				09.REDUCED SLEEP	3	4	4	4	4	4				
				10.REDUCED APPETITE	2	2	1	1	1	1				
				11.Total score	31	30	28	31	30	35				
5	100	Reboxetine	Female	01.REPORTED SADNESS	3	3	3	3	3					
				02.INNER TENSION	3	3	3	3	3					
				03.APPARENT SADNESS	2	2	2	2	2					
				04.SUICIDAL THOUGHTS	2	2	2	2	2					
				05.INERTIA	1	1	1	1	1					
				06.INABILITY TO FEEL	2	2	2	2	2					
				07.PESSIMISTIC THOUGHTS	2	2	2	2	2					
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2					
				09.REDUCED SLEEP	2	2	2	2	2					

1497

9550089

4

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63					
5	1MD	Reboxetine	Female	10. REDUCED APPETITE	1	1	1	1	1	0	0	0	0	0					
				11. Total score	20	20	21	21	21	21	21	21	21	21	21	21			
				1DT	Imipramine	Female	01. REPORTED SADNESS	2	2	1	1	1	0	0	0	0	0	0	
							02. INNER TENSION	1	1	0	0	0	0	0	0	0	0	0	0
							03. APPARENT SADNESS	3	3	2	2	2	1	1	1	1	1	1	1
							04. SUICIDAL THOUGHTS	3	3	2	2	2	1	1	1	1	1	1	1
							05. INERTIA	0	0	0	0	0	0	0	0	0	0	0	0
							06. INABILITY TO FEEL	2	2	2	2	2	1	1	1	1	1	1	1
							07. PESSIMISTIC THOUGHTS	2	2	2	2	2	1	1	1	1	1	1	1
							08. CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	1	1	1	1	1	1
							09. REDUCED SLEEP	2	2	2	2	2	1	1	1	1	1	1	1
10. REDUCED SLEEP	1	1	1				1	1	1	1	1	1	1	1	1				
11. Total score	17	17	13				11	5	4	3	3	3	3	3	3	3			
2ND	Reboxetine	Male	01. REPORTED SADNESS	1	2	4	2	2	1	3	1	1	3	4					
			02. INNER TENSION	0	1	2	2	2	1	2	1	2	1	2	2				
			03. APPARENT SADNESS	0	1	3	1	0	1	1	1	1	1	2	3				
			04. SUICIDAL THOUGHTS	3	2	2	2	2	2	1	1	1	1	3	3				
			05. INERTIA	0	0	0	0	0	0	0	0	0	0	0	0				
			06. INABILITY TO FEEL	0	0	0	0	0	0	0	0	0	0	0	1				
			07. PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1	1	1	1	1	1				
			08. CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	1	1	1	1	1	2				
			09. REDUCED SLEEP	1	1	1	1	1	1	1	1	1	1	1	2				
			10. REDUCED SLEEP	0	0	1	1	1	1	1	1	1	1	1	2				
			11. Total score	7	9	15	8	7	10	6	15	19	15	15	19				
2DT	Imipramine	Female	01. REPORTED SADNESS	5	1	1	1	1	1	2	2	2	3	2					
			02. INNER TENSION	5	2	2	2	2	2	2	2	2	2	3	2				
			03. APPARENT SADNESS	3	3	3	3	3	3	3	3	3	3	3	2				
			04. SUICIDAL THOUGHTS	2	2	2	2	2	2	2	2	2	2	2	2				
			05. INERTIA	2	2	2	2	2	2	2	2	2	2	2	2				
			06. INABILITY TO FEEL	4	2	2	2	2	2	2	2	2	2	2	2				
			07. PESSIMISTIC THOUGHTS	3	3	3	3	3	3	3	3	3	3	3	3				
			08. CONCENTRATIONS DIFFICULTIES	3	3	2	2	2	2	2	2	2	2	2	2				
			09. REDUCED SLEEP	3	2	2	2	2	2	2	2	2	2	2	2				
			10. REDUCED SLEEP	3	1	1	1	1	1	1	1	1	1	1	1				
			11. Total score	33	21	21	21	22	24	22	22	22	22	22	20				
3ND	Imipramine	Female	01. REPORTED SADNESS	4	2	2	2	1	1	1	0	0	0	0					
			02. INNER TENSION	3	2	2	2	1	1	1	1	0	0	0					
			03. APPARENT SADNESS	2	2	2	2	1	1	1	1	1	1	1					
			04. SUICIDAL THOUGHTS	2	2	2	2	1	1	1	1	1	1	1					
			05. INERTIA	1	1	0	0	0	0	0	0	0	0	0					
			06. INABILITY TO FEEL	1	1	1	1	1	1	1	1	1	1	1					
			07. PESSIMISTIC THOUGHTS	1	2	2	2	1	1	1	1	1	1	1					
			08. CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	0	0	0	0	0	0					

1498

9550089

5

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CHS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
5	3M	Imipramine	Female	09. REDUCED SLEEP	1	1	1	1	1	1	1	0	0	0		
				10. REDUCED APPETITE	1	0	0	0	0	0	0	0	0	0	0	
				11. Total score	18	15	13	7	6	6	5	3	3	3	3	
	3F	Reboxetine	Male	01. REPORTED SADNESS	4	2	1	1	1	0	0	0	0	0	0	
				02. INNER TENSION	3	2	1	1	0	0	0	0	0	0	0	
				03. APPARENT SADNESS	1	1	1	0	0	0	0	0	0	0	0	
				04. SUICIDAL THOUGHTS	3	2	1	0	0	0	0	0	0	0	0	
				05. INERTIA	1	1	0	0	0	0	0	0	0	0	0	
				06. INABILITY TO FEEL	1	1	1	0	0	0	0	0	0	0	0	0
				07. PESSIMISTIC THOUGHTS	3	2	1	0	0	0	0	0	0	0	0	0
				08. CONCENTRATIONS DIFFICULTIES	1	1	0	0	0	0	0	0	0	0	0	0
09. REDUCED SLEEP				1	1	0	0	0	0	0	0	0	0	0	0	
10. REDUCED APPETITE				1	1	0	0	0	0	0	0	0	0	0	0	
11. Total score				19	14	6	2	0	0	0	0	0	0	0	0	
4M	Imipramine	Male	01. REPORTED SADNESS	3	3	2	2	1	1	1	2	2	2	1		
			02. INNER TENSION	2	2	2	2	2	2	1	1	1	1	1		
			03. APPARENT SADNESS	3	3	2	2	2	2	2	2	2	2	2		
			04. SUICIDAL THOUGHTS	3	3	2	2	2	2	2	2	2	2	2		
			05. INERTIA	4	3	3	3	2	1	1	1	1	1	0		
			06. INABILITY TO FEEL	3	3	3	2	2	2	2	2	2	2	2		
			07. PESSIMISTIC THOUGHTS	3	3	3	3	3	3	3	3	3	3	2	2	
			08. CONCENTRATIONS DIFFICULTIES	0	0	0	0	0	0	0	0	0	0	1	1	
			09. REDUCED SLEEP	3	3	3	3	2	2	2	2	2	2	2	1	
			10. REDUCED APPETITE	1	1	0	0	0	0	0	0	0	0	0	0	
			11. Total score	25	24	19	16	15	15	15	15	15	15	15	12	
4F	Reboxetine	Male	01. REPORTED SADNESS	2	2	3	3	3	3	3	3	3	3	3		
			02. INNER TENSION	2	2	2	2	2	2	2	2	2	2	2		
			03. APPARENT SADNESS	2	2	2	2	2	2	2	2	2	2	2		
			04. SUICIDAL THOUGHTS	1	1	1	1	1	1	1	1	1	1	1		
			05. INERTIA	1	0	1	1	1	1	1	1	1	1	1		
			06. INABILITY TO FEEL	3	1	1	1	1	1	1	1	1	1	1		
			07. PESSIMISTIC THOUGHTS	0	0	1	1	1	1	1	1	1	1	1		
			08. CONCENTRATIONS DIFFICULTIES	0	0	1	1	1	1	1	1	1	1	1		
			09. REDUCED SLEEP	1	0	1	1	1	1	1	1	1	1	1		
			10. REDUCED APPETITE	0	0	1	1	1	1	1	1	1	1	1		
			11. Total score	12	9	17	20	18	18	18	18	18	18	18	18	
5M	Reboxetine	Male	01. REPORTED SADNESS	5	4	2	2	2	2	2	2	2	2			
			02. INNER TENSION	3	3	2	5	3	3	3	3	3	3			
			03. APPARENT SADNESS	4	4	4	3	2	2	2	2	2	2			
			04. SUICIDAL THOUGHTS	3	2	2	2	2	2	2	2	2	2			
			05. INERTIA	1	0	0	0	0	0	0	0	0	0			
			06. INABILITY TO FEEL	3	1	1	2	1	1	1	1	1	1			
			07. PESSIMISTIC THOUGHTS	5	1	1	1	1	1	1	1	1	1			

1499

9550089

6

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RBD
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63			
5	5MD	Reboxetine	Male	08.CONCENTRATIONS DIFFICULTIES		4	1										
				09.REDUCED SLEEP	5	2											
				10.REDUCED APPETITE	0	2											
				11.Total score	31	22	20										
				5DT	Reboxetine	Female	01.REPORTED SADNESS	1	1	2	4	6					
							02.INNER TENSION	4	1	4	4	6					
							03.APPARENT SADNESS	2	2	4	2	6					
							04.SUICIDAL THOUGHTS	1	3	2	1	6					
							05.INERTIA	0	1	0	0	0					
							06.INABILITY TO FEEL	4	1	4	3	2					
							07.PESSIMISTIC THOUGHTS	4	1	4	1	2					
08.CONCENTRATIONS DIFFICULTIES	4	1	2				1	2									
09.REDUCED SLEEP	2	2	2				2	2									
10.REDUCED APPETITE	2	2	1				0	4									
11.Total score	24	15	25				18	36									
6MD	Imipramine	Male	01.REPORTED SADNESS	5	2	3											
			02.INNER TENSION	3	3	2											
			03.APPARENT SADNESS	4	1	3											
			04.SUICIDAL THOUGHTS	2	3	4											
			05.INERTIA	1	0	0											
			06.INABILITY TO FEEL	3	3	3											
			07.PESSIMISTIC THOUGHTS	5	2	3											
			08.CONCENTRATIONS DIFFICULTIES	3	3	2											
			09.REDUCED SLEEP	3	1	1											
			10.REDUCED APPETITE	1	1	1											
			11.Total score	30	19	22											
6DT	Reboxetine	Female	01.REPORTED SADNESS	4	3	2	0	0	0	0	0	0	0				
			02.INNER TENSION	4	3	1	0	0	0	0	0	0	0				
			03.APPARENT SADNESS	4	3	3	1	2	2	1	2	1	2				
			04.SUICIDAL THOUGHTS	4	3	3	2	3	3	2	3	3	3				
			05.INERTIA	4	2	1	0	0	0	0	0	0	0				
			06.INABILITY TO FEEL	3	2	3	4	4	4	4	4	4	4				
			07.PESSIMISTIC THOUGHTS	4	3	2	1	0	0	1	1	1	1				
			08.CONCENTRATIONS DIFFICULTIES	4	3	1	0	0	0	0	0	0	0				
			09.REDUCED SLEEP	4	3	1	0	0	0	0	0	0	1				
			10.REDUCED APPETITE	2	1	0	0	0	0	0	0	0	0				
			11.Total score	37	26	18	8	9	8	10	8	10	11				
7MD	Reboxetine	Male	01.REPORTED SADNESS	3	1	1	1	2									
			02.INNER TENSION	3	1	1	1	1									
			03.APPARENT SADNESS	3	3	1	1	1									
			04.SUICIDAL THOUGHTS	2	4	2	4	1									
			05.INERTIA	1	1	3	0	0									
			06.INABILITY TO FEEL	3	4	3	0	0									

1500

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

7

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 73.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63				
5	7HD	Reboxetine	Male	07.PESSIMISTIC THOUGHTS	1	1	3	1									
				08.CONCENTRATIONS DIFFICULTIES	3	1	1	1									
				09.REDUCED SLEEP	3	3	0	0									
				10.REDUCED APPETITE	1	1	1	1									
				11.Total score	23	20	16	8									
				7DT	Imipramine	Female	01.REPORTED SADNESS	5	3	2	2	2	1	0	1	0	0
							02.INNER TENSION	4	3	2	2	1	0	0	0	0	0
							03.APPARENT SADNESS	4	4	5	3	1	1	2	1	0	0
							04.SUICIDAL THOUGHTS	3	3	2	2	0	0	0	0	0	0
							05.INERTIA	4	3	1	0	0	0	0	0	0	0
							06.INABILITY TO FEEL	1	1	1	1	1	0	1	0	0	0
07.PESSIMISTIC THOUGHTS	3	3	2				2	1	2	0	0	0	0				
08.CONCENTRATIONS DIFFICULTIES	3	2	2				1	1	2	1	0	0	0				
09.REDUCED SLEEP	3	3	2				1	1	1	0	0	0	0				
10.REDUCED APPETITE	1	1	0				0	0	0	0	0	0	0				
11.Total score	31	26	17				14	9	7	4	4	2	0	0			
8ND	Imipramine	Female	01.REPORTED SADNESS	5	5	5	3	3	2	2	1	0	2				
			02.INNER TENSION	4	5	4	3	2	2	1	0	0	2				
			03.APPARENT SADNESS	2	3	3	2	2	0	2	0	0	0				
			04.SUICIDAL THOUGHTS	1	1	4	3	2	2	1	2	0	0				
			05.INERTIA	3	2	3	2	4	0	0	0	0	1				
			06.INABILITY TO FEEL	1	2	3	3	2	3	1	1	2	2				
			07.PESSIMISTIC THOUGHTS	4	4	4	3	2	3	2	2	1	3				
			08.CONCENTRATIONS DIFFICULTIES	2	1	2	3	2	2	1	1	0	0				
			09.REDUCED SLEEP	2	3	3	2	1	1	0	0	0	0				
			10.REDUCED APPETITE	1	1	1	1	0	0	0	0	0	0				
			11.Total score	25	27	32	25	20	15	10	7	12	7				
8DT	Imipramine	Female	01.REPORTED SADNESS	4	4	3	3	2	2	1	1	0	0				
			02.INNER TENSION	4	4	3	3	3	2	2	1	1	0				
			03.APPARENT SADNESS	3	3	5	2	2	2	2	1	1	0				
			04.SUICIDAL THOUGHTS	3	3	3	3	3	3	3	3	3	3				
			05.INERTIA	0	0	0	0	0	0	0	0	0	0				
			06.INABILITY TO FEEL	2	2	2	2	2	2	2	2	2	2				
			07.PESSIMISTIC THOUGHTS	2	2	2	1	1	1	1	1	1	1				
			08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	1	1	1	1				
			09.REDUCED SLEEP	2	2	1	1	1	1	1	1	1	1				
			10.REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0				
			11.Total score	22	22	19	17	16	14	13	11	8	8				
9ND	Reboxetine	Female	01.REPORTED SADNESS	6	4	3	3	4	4	4	3	1	1				
			02.INNER TENSION	5	4	3	3	4	4	3	3	2	2				
			03.APPARENT SADNESS	4	3	3	3	3	3	3	2	2	2				
			04.SUICIDAL THOUGHTS	5	4	4	5	4	4	3	3	3	3				
			05.INERTIA	2	4	4	4	2	2	1	1	1	1				

9550089

1501

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

8

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
5	9ND	Reboxetine	Female	06.INABILITY TO FEEL	4	4	3	3	4	4	3	1	2		
				07.PESSIMISTIC THOUGHTS	5	4	4	4	5	3	3	2			
				08.CONCENTRATIONS DIFFICULTIES	3	2	2	2	3	3	2	1			
				09.REDUCED SLEEP	2	1	1	1	1	1	0	0			
				10.REDUCED APPETITE	2	0	0	0	0	0	0	0			
				11.Total score	38	30	27	26	30	28	24	18	14		
				01.REPORTED SADNESS	2	2	2	2	1	1	1	0			
				02.INNER TENSION	3	3	2	2	0	0	0	1			
				03.APPARENT SADNESS	1	1	1	1	0	0	0	0			
				04.SUICIDAL THOUGHTS	2	2	2	2	0	0	0	0			
				05.INERTIA	3	3	2	2	0	0	0	0			
06.INABILITY TO FEEL	2	2	2	2	1	1	1	0							
07.PESSIMISTIC THOUGHTS	4	3	3	3	1	0	1	0							
08.CONCENTRATIONS DIFFICULTIES	3	3	2	2	0	0	0	0							
09.REDUCED SLEEP	3	2	2	2	0	0	0	0							
10.REDUCED APPETITE	2	1	1	1	0	0	0	0							
11.Total score	25	22	19	17	3	3	2	3	3						
1502	10ND	Imipramine	Female	01.REPORTED SADNESS	5	5	1								
				02.INNER TENSION	5	4	2	2							
				03.APPARENT SADNESS	4	3	2	2							
				04.SUICIDAL THOUGHTS	4	4	2	2							
				05.INERTIA	4	4	2	2							
				06.INABILITY TO FEEL	3	3	2	2							
				07.PESSIMISTIC THOUGHTS	3	3	2	2							
				08.CONCENTRATIONS DIFFICULTIES	4	3	3	3							
				09.REDUCED SLEEP	3	3	3	3							
				10.REDUCED APPETITE	0	0	0	0							
				11.Total score	35	32	16								
10DT	Imipramine	Male	01.REPORTED SADNESS	1	1										
			02.INNER TENSION	2	2										
			03.APPARENT SADNESS	2	2										
			04.SUICIDAL THOUGHTS	2	2										
			05.INERTIA	1	1										
			06.INABILITY TO FEEL	2	2										
			07.PESSIMISTIC THOUGHTS	2	2										
			08.CONCENTRATIONS DIFFICULTIES	2	2										
			09.REDUCED SLEEP	1	1										
			10.REDUCED APPETITE	0	0										
			11.Total score	15	15										
11ND	Imipramine	Female	01.REPORTED SADNESS	3	3	5	5	5	5						
			02.INNER TENSION	3	3	2	2	4	3	3					
			03.APPARENT SADNESS	2	2	4	3	2	2	4					
			04.SUICIDAL THOUGHTS	3	3	4	4	3	3	4					

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9

PHARMACIA CNS RSD
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63				
5	11ND	Imipramine	Female	05.INERTIA	5	5	5	4	4	4								
				06.INABILITY TO FEEL	2	2	2	3	3									
				07.PESSIMISTIC THOUGHTS	2	2	5	4	4									
				08.CONCENTRATIONS DIFFICULTIES	2	2	4	4	4									
				09.REDUCED SLEEP	0	0	2	2	2									
				10.REDUCED APPETITE	0	0	1	0	0									
				11.Total score	22	22	38	34	34									
				11DT	Reboxetine	Female	01.REPORTED SADNESS	2	1	1	1	1	1					
							02.INNER TENSION	4	3	2	2	2						
							03.APPARENT SADNESS	3	3	3	3	3						
							04.SUICIDAL THOUGHTS	0	2	3	3	3						
05.INERTIA	2	2	2				2	2										
06.INABILITY TO FEEL	3	3	2				2	2										
07.PESSIMISTIC THOUGHTS	0	0	0				0	0										
08.CONCENTRATIONS DIFFICULTIES	2	2	2				2	2										
09.REDUCED SLEEP	1	0	2				2	2										
10.REDUCED APPETITE	20	19	18				18	18										
11.Total score																		
1503	12MD	Reboxetine	Female	01.REPORTED SADNESS	4	3	4	2	2	2	2	2	1	1				
				02.INNER TENSION	4	4	3	4	2	1	1	1	1	1	1			
				03.APPARENT SADNESS	4	4	3	5	1	1	2	2	2	2	1			
				04.SUICIDAL THOUGHTS	1	1	1	0	0	1	2	2	2	2	1			
				05.INERTIA	1	1	1	1	0	0	0	0	0	0	1			
				06.INABILITY TO FEEL	4	4	3	2	1	1	2	1	1	1	1			
				07.PESSIMISTIC THOUGHTS	4	4	3	1	1	1	1	1	1	1	1			
				08.CONCENTRATIONS DIFFICULTIES	4	3	1	2	1	1	3	1	2	1	0			
				09.REDUCED SLEEP	3	3	1	1	1	1	3	1	1	0	1			
				10.REDUCED APPETITE	0	0	1	1	0	1	0	1	0	1	0			
				11.Total score	29	24	22	11	9	15	15	12	8					
12DT	Imipramine	Male	01.REPORTED SADNESS	0	0	0	0	0	0	0	0	0	0	0				
			02.INNER TENSION	2	1	1	0	0	0	0	0	0	0	0				
			03.APPARENT SADNESS	4	2	2	2	2	1	1	1	1	1	1				
			04.SUICIDAL THOUGHTS	4	4	3	3	2	1	1	1	1	0	0				
			05.INERTIA	0	0	0	0	0	0	0	0	0	0	0				
			06.INABILITY TO FEEL	3	3	2	2	2	1	1	1	1	1	1				
			07.PESSIMISTIC THOUGHTS	1	1	0	0	0	0	0	0	0	0	0				
			08.CONCENTRATIONS DIFFICULTIES	0	0	0	0	0	0	0	0	0	0	0				
			09.REDUCED SLEEP	3	3	3	2	2	1	1	1	1	1	0				
			10.REDUCED APPETITE	17	14	12	9	8	4	4	4	4	3					
			11.Total score															
6	1ND	Reboxetine	Female	01.REPORTED SADNESS	5	5	4	3	3	3	2	2	2					
				02.INNER TENSION	5	5	5	3	3	3	2	2	2					
				03.APPARENT SADNESS	2	2	2	1	1	1	1	1	1					

9550089

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

10

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63				
6	1M	Reboxetine	Female	04.SUICIDAL THOUGHTS	4	4	3	2	2	1	1	1	1	1				
				05.INERTIA	3	3	3	3	3	0	0	0	0	0				
				06.INABILITY TO FEEL	4	4	3	2	2	2	1	1	1	1				
				07.PESSIMISTIC THOUGHTS	5	4	4	3	3	2	2	1	1	1				
				08.CONCENTRATIONS DIFFICULTIES	4	4	4	4	4	4	4	4	3	2	2			
				09.REDUCED SLEEP	4	4	4	4	3	3	3	2	2	2	2			
				10.REDUCED APPETITE	2	2	1	0	0	0	0	0	0	0	0	0		
				11.Total score	38	37	33	24	22	18	15	12	11	11	11	11		
				10T	Reboxetine	Female	01.REPORTED SADNESS	3	3	2	2	2	1	1	0	0	0	1
							02.INNER TENSION	3	3	2	2	2	1	1	1	1	1	1
							03.APPARENT SADNESS	3	3	2	2	2	2	2	2	2	2	2
04.SUICIDAL THOUGHTS	3	3	2				2	2	2	2	2	2	2	2				
05.INERTIA	3	2	2				1	1	1	1	1	0	0	0				
06.INABILITY TO FEEL	2	2	2				1	1	1	1	1	1	1	1				
07.PESSIMISTIC THOUGHTS	3	3	2				1	1	1	1	1	1	1	1				
08.CONCENTRATIONS DIFFICULTIES	3	3	2				1	1	1	1	1	0	1	1				
09.REDUCED SLEEP	1	1	1				1	1	1	1	1	1	1	1				
10.REDUCED APPETITE	1	1	1				0	0	0	0	0	0	0	0				
11.Total score	25	24	18				13	12	9	7	8	10	10					
2M	Imipramine	Female	01.REPORTED SADNESS	5	5	5	5	5	5	5	5	5	5	5				
			02.INNER TENSION	5	5	4	4	4	4	4	4	4	4	4				
			03.APPARENT SADNESS	3	3	3	3	3	3	3	3	3	3	3				
			04.SUICIDAL THOUGHTS	4	4	4	4	4	4	4	4	4	4	4				
			05.INERTIA	3	3	3	3	3	3	3	3	3	3	3				
			06.INABILITY TO FEEL	2	2	2	2	2	2	2	2	2	2	2				
			07.PESSIMISTIC THOUGHTS	4	4	4	4	4	4	4	4	4	4	4				
			08.CONCENTRATIONS DIFFICULTIES	4	4	4	4	4	4	4	4	4	4	4				
			09.REDUCED SLEEP	2	2	2	2	2	2	2	2	2	2	2				
			10.REDUCED APPETITE	1	1	1	1	1	1	1	1	1	1	1				
			11.Total score	33	40	33	40	33	40	33	40	33	40					
20T	Reboxetine	Female	01.REPORTED SADNESS	4	4	4	4	4	4	4	4	4	4					
			02.INNER TENSION	4	4	4	4	4	4	4	4	4	4					
			03.APPARENT SADNESS	2	2	2	2	2	2	2	2	2	2					
			04.SUICIDAL THOUGHTS	3	3	3	3	3	3	3	3	3	3					
			05.INERTIA	2	2	2	2	2	2	2	2	2	2					
			06.INABILITY TO FEEL	3	3	3	3	3	3	3	3	3	3					
			07.PESSIMISTIC THOUGHTS	4	4	4	4	4	4	4	4	4	4					
			08.CONCENTRATIONS DIFFICULTIES	4	4	4	4	4	4	4	4	4	4					
			09.REDUCED SLEEP	4	4	4	4	4	4	4	4	4	4					
			10.REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0					
			11.Total score	30	30	30	30	30	30	30	30	30	30					
3M	Reboxetine	Female	01.REPORTED SADNESS	5	5	5	5	5	5	5	5	5	5					
			02.INNER TENSION	5	5	5	5	5	5	5	5	5	5					

1504

9550089

11

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63			
6	3ND	Reboxetine	Female	Montgomery Asberg Depression Rating Scale												
				03.APPARENT SADNESS	3	3	3	3	2	2	2	2	3	3	4	
				04.SUICIDAL THOUGHTS	4	4	4	4	3	2	2	2	3	3	3	3
				05.INERTIA	4	4	3	3	2	2	2	2	2	3	2	2
				06.INABILITY TO FEEL	2	2	2	2	1	1	1	1	2	2	2	2
				07.PESSIMISTIC THOUGHTS	5	4	4	4	3	2	2	2	3	3	3	3
				08.CONCENTRATIONS DIFFICULTIES	4	3	3	3	2	2	2	2	2	2	2	3
				09.REDUCED SLEEP	2	2	2	2	2	2	2	2	2	2	2	2
				10.REDUCED APPETITE	1	1	1	1	1	1	1	1	1	1	1	1
				11.Total score	35	33	32	31	23	20	20	26	26	27	27	27
				3DT	Imipramine	Female	Montgomery Asberg Depression Rating Scale									
01.REPORTED SADNESS	5	4	5				4	3	4	4	4	4	4	4		
02.INNER TENSION	5	5	4				4	3	3	3	3	4	4	4		
03.APPARENT SADNESS	4	4	4				4	2	3	2	2	2	2	2		
04.SUICIDAL THOUGHTS	3	2	3				2	2	4	4	4	4	4	4		
05.INERTIA	0	0	3				1	0	1	0	0	0	0	0		
06.INABILITY TO FEEL	4	4	4				4	3	4	4	4	4	4	4		
07.PESSIMISTIC THOUGHTS	4	3	4				4	1	2	1	1	1	1	1		
08.CONCENTRATIONS DIFFICULTIES	5	5	4				3	3	3	4	4	4	4	4		
09.REDUCED SLEEP	0	0	0				0	0	0	1	1	1	1	1		
10.REDUCED APPETITE	3	2	2				1	2	2	2	2	2	2	2		
11.Total score	33	29	34	24	18	29	26	26	26	26	26					
4ND	Imipramine	Female	Montgomery Asberg Depression Rating Scale													
			01.REPORTED SADNESS	3	3	3	3	3	3	3	3	3	3			
			02.INNER TENSION	4	4	4	4	4	4	4	4	4	4			
			03.APPARENT SADNESS	1	2	3	3	3	3	3	4	4	4			
			04.SUICIDAL THOUGHTS	3	3	3	2	2	2	2	2	2	2			
			05.INERTIA	3	3	3	3	2	0	0	0	0	0			
			06.INABILITY TO FEEL	2	2	2	2	2	2	2	2	2	2			
			07.PESSIMISTIC THOUGHTS	3	3	3	3	3	3	3	4	5	5			
			08.CONCENTRATIONS DIFFICULTIES	4	4	4	4	4	4	4	4	4	4			
			09.REDUCED SLEEP	5	5	5	5	4	4	4	5	5	5			
			10.REDUCED APPETITE	1	1	0	0	0	0	0	0	0	0			
11.Total score	29	30	30	29	26	29	29	29	29	29						
4DT	Imipramine	Female	Montgomery Asberg Depression Rating Scale													
			01.REPORTED SADNESS	4	4	4	3	2	2	2	2	0	0			
			02.INNER TENSION	4	4	4	3	2	2	2	2	2	1	1		
			03.APPARENT SADNESS	3	2	2	2	2	1	1	1	1	1			
			04.SUICIDAL THOUGHTS	2	2	2	2	2	2	2	2	2	2			
			05.INERTIA	0	0	0	0	0	0	0	0	0	0			
			06.INABILITY TO FEEL	3	3	2	1	1	0	0	0	0	0			
			07.PESSIMISTIC THOUGHTS	3	3	3	2	1	1	1	1	1	1			
			08.CONCENTRATIONS DIFFICULTIES	3	3	2	1	0	0	0	0	0	0			
			09.REDUCED SLEEP	1	2	2	2	0	0	0	0	0	0			
			10.REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0			
11.Total score	23	23	20	14	10	8	7	5	5							
5ND	Imipramine	Female	Montgomery Asberg Depression Rating Scale													
			01.REPORTED SADNESS	5	4	4	4	4	4	4	4	4	4			

1505

9550089

12

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63			
6	5ND	Imipramine	Female	02. INNER TENSION	5	5	4	4	4	4	4	4	4	4			
				03. APPARENT SADNESS	4	4	4	4	3	4	4	4	4	4	4		
				04. SUICIDAL THOUGHTS	4	4	4	4	4	4	4	4	4	4	4	4	
				05. INERTIA	4	3	3	3	3	3	4	4	1	1	1	4	
				06. INABILITY TO FEEL	5	4	4	4	5	4	4	4	4	4	4	4	
				07. PESSIMISTIC THOUGHTS	4	3	3	3	3	3	2	2	2	3	3	3	
				08. CONCENTRATIONS DIFFICULTIES	5	5	4	4	4	4	4	4	4	4	4	4	
				09. REDUCED SLEEP	1	1	1	1	2	1	1	1	1	1	1	1	
				10. REDUCED APPETITE	3	1	2	1	2	1	2	2	2	2	2	2	
				11. Total score	40	34	33	33	33	33	32	30	31	31	31	31	35
				5DT	Reboxetine	Female	01. REPORTED SADNESS	3	3	3	3	2	2	2	1	1	1
02. INNER TENSION	3	3	3				3	3	2	2	2	2	1	1			
03. APPARENT SADNESS	3	3	2				2	2	2	2	2	2	2	2			
04. SUICIDAL THOUGHTS	3	4	3				2	2	2	2	2	2	2	2			
05. INERTIA	0	0	0				0	0	0	0	0	0	0	0			
06. INABILITY TO FEEL	2	2	1				2	1	2	1	2	1	2	1			
07. PESSIMISTIC THOUGHTS	3	3	2				2	2	2	2	2	2	2	2			
08. CONCENTRATIONS DIFFICULTIES	3	3	2				2	2	2	2	2	2	2	2			
09. REDUCED SLEEP	2	1	0				0	0	0	0	0	0	0	0			
10. REDUCED APPETITE	1	1	0				0	0	0	0	0	0	0	0			
11. Total score	23	23	16				15	12	14	11	7	7					
6ND	Reboxetine	Female	01. REPORTED SADNESS	3	3	3	3	3	4	4	3	2	2				
			02. INNER TENSION	3	3	3	3	3	3	3	3	3	3				
			03. APPARENT SADNESS	2	2	2	2	2	2	2	2	2	2				
			04. SUICIDAL THOUGHTS	2	2	2	2	2	2	2	2	2	2				
			05. INERTIA	1	0	1	1	1	1	1	1	1	1				
			06. INABILITY TO FEEL	3	1	1	1	2	2	2	2	2	2				
			07. PESSIMISTIC THOUGHTS	1	2	2	2	2	2	2	2	2	2				
			08. CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2	2	2	2				
			09. REDUCED SLEEP	1	1	1	1	1	1	1	1	1	1				
			10. REDUCED APPETITE	1	1	1	1	0	0	0	0	0					
			11. Total score	19	17	17	21	31	31								
7ND	Reboxetine	Female	01. REPORTED SADNESS	4	4	4	4	4	4	3	3	2	2				
			02. INNER TENSION	5	4	4	4	4	4	4	4	4	4				
			03. APPARENT SADNESS	3	3	4	3	3	3	2	2	2	2				
			04. SUICIDAL THOUGHTS	4	4	4	4	4	4	4	4	4	4				
			05. INERTIA	4	4	4	4	3	2	2	2	2	2				
			06. INABILITY TO FEEL	2	2	2	2	3	3	2	2	2	2				
			07. PESSIMISTIC THOUGHTS	4	4	3	3	3	3	2	2	2	2				
			08. CONCENTRATIONS DIFFICULTIES	4	3	4	4	4	4	4	4	4	4				
			09. REDUCED SLEEP	2	1	2	2	2	2	2	2	2	2				
			10. REDUCED APPETITE	1	1	1	1	1	1	1	1	1	1				
			11. Total score	33	30	32	31	30	29	22	16	13					

1506

9550089

13

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
6	8ND	Imipramine	Female	01.REPORTED SADNESS	5	5	4	3	3	2	1	1	1	1	
				02.INNER TENSION	6	5	4	3	2	2	2	2	2	2	2
				03.APPARENT SADNESS	3	3	3	2	2	2	2	2	2	2	2
				04.SUICIDAL THOUGHTS	4	4	4	3	2	2	2	2	2	2	2
				05.INERTIA	3	3	3	1	1	1	0	0	0	0	0
				06.INABILITY TO FEEL	3	3	3	2	2	2	1	1	1	1	1
				07.PESSIMISTIC THOUGHTS	5	5	3	2	2	2	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	4	4	3	2	2	1	1	1	1	1	1
				09.REDUCED SLEEP	2	1	1	0	0	0	0	0	0	0	0
				10.REDUCED APPETITE	0	1	1	0	0	0	0	0	0	0	0
				11.Total score	35	34	29	18	16	14	10	8	9		
7	1ND	Imipramine	Male	01.REPORTED SADNESS	3	3	1	1	0	0	0	0	0	0	
				02.INNER TENSION	4	4	3	2	1	1	0	0	0	0	
				03.APPARENT SADNESS	4	4	4	3	2	3	2	2	2	2	
				04.SUICIDAL THOUGHTS	3	2	0	1	1	1	0	0	0	0	
				05.INERTIA	0	0	0	1	1	0	0	1	1	1	
				06.INABILITY TO FEEL	3	3	1	1	0	0	0	0	0	0	
				07.PESSIMISTIC THOUGHTS	1	1	1	0	0	0	0	0	0	0	
				08.CONCENTRATIONS DIFFICULTIES	4	4	1	1	0	0	0	0	0	0	
				09.REDUCED SLEEP	4	4	3	1	1	1	0	0	0	0	
				10.REDUCED APPETITE	3	3	1	1	0	1	0	0	0	0	
				11.Total score	29	26	12	11	5	7	2	5	5		
3ND	Imipramine	Female	01.REPORTED SADNESS	5	5	5	2	2	2	0	0	0	0		
			02.INNER TENSION	4	4	4	4	3	1	1	0	0	0		
			03.APPARENT SADNESS	3	3	3	2	2	0	1	1	1	1		
			04.SUICIDAL THOUGHTS	5	5	5	2	1	1	1	0	0	0		
			05.INERTIA	2	2	2	1	4	0	0	0	0	0		
			06.INABILITY TO FEEL	3	4	3	3	3	2	2	1	1	1		
			07.PESSIMISTIC THOUGHTS	4	4	4	4	2	2	1	0	0	0		
			08.CONCENTRATIONS DIFFICULTIES	4	5	4	3	2	1	1	1	1	1		
			09.REDUCED SLEEP	2	2	2	2	2	1	1	0	0	0		
			10.REDUCED APPETITE	2	2	2	2	2	1	1	0	0	0		
			11.Total score	36	36	34	23	23	9	9	2	2			
4ND	Reboxetine	Female	01.REPORTED SADNESS	2	4	4	4	4	4	4	4	4	4		
			02.INNER TENSION	4	4	4	4	5	5	5	5	5			
			03.APPARENT SADNESS	3	4	4	4	4	4	4	4	4			
			04.SUICIDAL THOUGHTS	3	5	5	5	5	5	5	5				
			05.INERTIA	2	4	4	4	4	4	4	4				
			06.INABILITY TO FEEL	3	3	3	3	3	3	3	3				
			07.PESSIMISTIC THOUGHTS	1	3	3	3	4	4	4	4				
			08.CONCENTRATIONS DIFFICULTIES	4	4	4	4	4	4	4	4				
			09.REDUCED SLEEP	2	3	3	3	3	3	3	3				
			10.REDUCED APPETITE	1	1	1	1	1	1	1	1				
			11.Total score	25	35	35	37	37	32	32	37	37			

1507

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

14

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
7	342ND	Reboxetine	Female	01.REPORTED SADNESS	4	4	3	3	3	3	3	3	4	
				02.INNER TENSION	2	2	2	0	1	2	2	2	2	2
				03.APPARENT SADNESS	4	5	5	2	5	4	4	4	5	4
				04.SUICIDAL THOUGHTS	4	3	4	4	3	3	3	3	3	3
				05.INERTIA	6	6	6	6	4	6	6	6	4	5
				06.INABILITY TO FEEL	4	4	4	4	4	4	3	4	4	4
				07.PESSIMISTIC THOUGHTS	5	6	5	4	5	4	4	4	4	4
				08.CONCENTRATIONS DIFFICULTIES	4	4	4	5	4	4	4	4	4	4
				09.REDUCED SLEEP	2	4	0	4	2	2	3	2	2	2
				10.REDUCED APPETITE	1	0	0	0	1	2	2	2	2	2
				11.Total score	36	36	33	30	32	34	34	35	35	35
8	1ND	Reboxetine	Female	01.REPORTED SADNESS	6	6	6	6	6	6	4	2	6	
				02.INNER TENSION	6	6	6	6	6	4	2	2	6	
				03.APPARENT SADNESS	6	4	4	4	4	4	2	2	4	
				04.SUICIDAL THOUGHTS	4	4	2	2	2	0	0	0	4	
				05.INERTIA	4	4	2	2	2	6	0	0	4	
				06.INABILITY TO FEEL	4	4	4	4	4	4	2	2	4	
				07.PESSIMISTIC THOUGHTS	6	4	2	2	2	6	2	2	6	
				08.CONCENTRATIONS DIFFICULTIES	6	4	4	4	4	4	0	2	2	
				09.REDUCED SLEEP	4	4	4	4	4	4	4	4	6	
				10.REDUCED APPETITE	2	0	0	0	0	0	0	0	0	
				11.Total score	48	38	34	34	34	40	14	14	42	
10T	Imipramine	Female	01.REPORTED SADNESS	6	2	2	2	0	2	0	0	0		
			02.INNER TENSION	6	6	2	0	2	0	0	0	0		
			03.APPARENT SADNESS	3	2	0	2	0	0	0	0	0		
			04.SUICIDAL THOUGHTS	6	2	0	0	0	4	2	0	0		
			05.INERTIA	6	6	0	0	0	0	0	0	0		
			06.INABILITY TO FEEL	4	2	2	2	2	0	2	0	0		
			07.PESSIMISTIC THOUGHTS	6	6	4	2	4	2	0	0	0		
			08.CONCENTRATIONS DIFFICULTIES	4	2	0	2	0	0	0	0	0		
			09.REDUCED SLEEP	6	2	2	2	0	0	0	0	0		
			10.REDUCED APPETITE	0	0	0	0	0	0	0	0	0		
			11.Total score	47	30	12	12	8	10	2	2	0		
2ND	Reboxetine	Female	01.REPORTED SADNESS	4	0	0	0	0	0	0	0	0		
			02.INNER TENSION	4	0	0	2	0	0	0	0	0		
			03.APPARENT SADNESS	2	2	2	0	2	0	0	0	0		
			04.SUICIDAL THOUGHTS	4	2	2	0	2	0	0	0	0		
			05.INERTIA	0	0	0	0	0	0	0	0	0		
			06.INABILITY TO FEEL	0	2	0	0	2	0	0	0	0		
			07.PESSIMISTIC THOUGHTS	2	4	2	2	0	0	0	0	0		
			08.CONCENTRATIONS DIFFICULTIES	4	4	0	0	0	0	0	0	0		
			09.REDUCED SLEEP	2	2	0	2	0	0	0	0	0		
			10.REDUCED APPETITE	0	0	0	2	0	0	0	0	0		

1508

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

15

PHARMACIA CNS RSD
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
8	2MD	Reboxetine	Female	22	16	8	8	6	0	0	0	0	0
				11.Total score									
	2DT	Imipramine	Female	2	4	4	4	2	0	0	0	0	0
				01.REPORTED SADNESS									
				02.INNER TENSION									
				03.APPARENT SADNESS									
				04.SUICIDAL THOUGHTS									
				05.INERTIA									
				06.INABILITY TO FEEL									
				07.PESSIMISTIC THOUGHTS									
				08.CONCENTRATIONS DIFFICULTIES									
				09.REDUCED SLEEP									
				10.REDUCED APPETITE									
				16	24	14	14	12	2	2	0	0	0
				11.Total score									
	3MD	Imipramine	Female	2	4	4	4	2	0	0	0	0	0
				01.REPORTED SADNESS									
				02.INNER TENSION									
				03.APPARENT SADNESS									
				04.SUICIDAL THOUGHTS									
				05.INERTIA									
				06.INABILITY TO FEEL									
				07.PESSIMISTIC THOUGHTS									
				08.CONCENTRATIONS DIFFICULTIES									
				09.REDUCED SLEEP									
				10.REDUCED APPETITE									
				24	26	24	26	24	26	24	26	24	26
				11.Total score									
	3DT	Reboxetine	Female	6	6	0	0	0	0	0	0	0	0
				01.REPORTED SADNESS									
				02.INNER TENSION									
				03.APPARENT SADNESS									
				04.SUICIDAL THOUGHTS									
				05.INERTIA									
				06.INABILITY TO FEEL									
				07.PESSIMISTIC THOUGHTS									
				08.CONCENTRATIONS DIFFICULTIES									
				09.REDUCED SLEEP									
				10.REDUCED APPETITE									
				40	48	10	4	10	2	2	0	0	0
				11.Total score									
	4MD	Imipramine	Male	6	6	6	6	6	6	6	6	6	6
				01.REPORTED SADNESS									
				02.INNER TENSION									
				03.APPARENT SADNESS									
				04.SUICIDAL THOUGHTS									
				05.INERTIA									
				06.INABILITY TO FEEL									
				07.PESSIMISTIC THOUGHTS									
				08.CONCENTRATIONS DIFFICULTIES									
				09.REDUCED SLEEP									

1509

9550089

16

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
8	4ND	Imipramine	Male	10. REDUCED APPETITE 11. Total score	4 48	4 54	4 46	4 46						
	4DT	Reboxetine	Female	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS 05. INERTIA 06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS 08. CONCENTRATIONS DIFFICULTIES 09. REDUCED SLEEP 10. REDUCED APPETITE 11. Total score	2 4 4 4 4 6 2 2 0 30	2 4 0 4 0 2 0 2 2 12	2 2 2 4 0 4 0 4 4 22	0 2 0 0 0 0 0 0 0 2	0 2 0 0 0 0 0 0 0 2	2 4 0 0 0 0 0 0 0 6	0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0	0 4 0 2 0 0 2 2 0 14	2 4 2 0 0 0 2 2 0 14
	701ND	Imipramine	Male	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS 05. INERTIA 06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS 08. CONCENTRATIONS DIFFICULTIES 09. REDUCED SLEEP 10. REDUCED APPETITE 11. Total score	6 6 2 4 4 4 6 4 6 4 46	6 6 2 4 4 2 0 2 2 44	0 0 0 2 2 0 0 0 0 2	0 0 0 2 2 0 2 0 2 8	0 0 0 6 0 2 0 0 0 8	0 0 0 0 0 0 0 0 0 2	0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 2	0 0 2 0 0 0 0 0 0 2
	701DT	Reboxetine	Female	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS 05. INERTIA 06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS 08. CONCENTRATIONS DIFFICULTIES 09. REDUCED SLEEP 10. REDUCED APPETITE 11. Total score	4 4 2 2 2 2 6 2 2 4 24	2 2 2 2 0 0 4 0 2 4 14	6 6 0 0 2 2 0 0 2 20	4 4 0 2 2 0 2 2 2 18	2 4 2 0 0 4 0 0 0 16	4 4 2 0 2 0 2 2 2 20	2 2 0 0 0 0 0 0 0 6	4 4 0 0 0 0 0 0 0 14	4 4 0 0 0 0 0 0 0 12	4 4 0 0 0 0 0 0 0 12
	702ND	Reboxetine	Male	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS 05. INERTIA 06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS 08. CONCENTRATIONS DIFFICULTIES	4 4 2 2 2 2 6 2	4 4 2 0 2 2 4 0	4 4 2 2 0 2 4 0	4 4 4 0 0 2 2 2	4 4 4 0 0 2 2 2	4 4 2 0 0 0 2 2	4 4 2 0 0 2 2 2	4 4 2 0 0 2 2 2	4 4 2 0 0 2 2 2	4 4 2 0 0 2 2 2

1510

9550089

17

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
8	702HD	Reboxetine	Male	09. REDUCED SLEEP 10. REDUCED APPETITE 11. Total score	2 0 26	2 0 18	2 4 28	2 0 24	2 0 24	2 0 22	2 0 28	2 0 22	2 0 28	2 0 28
	702DT	Imipramine	Female	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS 05. INERTIA 06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS 08. CONCENTRATIONS DIFFICULTIES 09. REDUCED SLEEP 10. REDUCED APPETITE 11. Total score	4 4 2 2 4 4 5 2 4 2 34	2 0 2 2 2 4 1 2 0 17	0 0 0 0 2 4 4 0 0 10	0 0 0 0 4 4 4 0 0 8	0 0 0 0 4 4 4 0 0 6	0 0 0 0 2 2 2 0 0 4	0 0 0 0 0 2 2 0 0 4	0 0 0 0 0 2 2 0 0 4	0 0 0 0 0 2 2 0 0 4	1 0 0 0 0 0 0 0 0 4
	703HD	Imipramine	Female	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS 05. INERTIA 06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS 08. CONCENTRATIONS DIFFICULTIES 09. REDUCED SLEEP 10. REDUCED APPETITE 11. Total score	4 4 2 4 0 4 4 0 4 0 22	4 4 2 4 0 4 4 0 4 0 22	4 6 2 2 0 6 4 0 4 0 28	6 6 2 4 0 6 2 0 4 0 34	6 2 2 4 0 4 6 0 4 0 12	2 2 0 2 0 2 2 0 2 0 10	2 2 0 2 0 2 2 0 2 0 8	2 2 0 2 0 2 2 0 2 0 10	2 2 0 2 0 2 2 0 2 0 8	2 2 0 2 0 2 2 0 2 0 16
	703DT	Imipramine	Male	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS 05. INERTIA 06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS 08. CONCENTRATIONS DIFFICULTIES 09. REDUCED SLEEP 10. REDUCED APPETITE 11. Total score	4 1 2 2 0 4 6 0 2 0 25	4 2 2 2 0 4 6 0 2 0 26	4 2 2 2 0 6 6 0 2 0 26	4 2 2 2 0 6 6 0 2 0 26	4 0 0 0 0 4 4 0 2 0 10	4 0 0 0 0 4 4 0 2 0 10	4 0 0 0 0 4 4 0 2 0 10	4 0 0 0 0 4 4 0 2 0 10	4 0 0 0 0 4 4 0 2 0 10	8 0 0 0 0 0 0 0 0 0 8
	704HD	Reboxetine	Female	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS 05. INERTIA 06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS	2 2 4 0 0 6	2 2 6 0 0 4	2 2 2 0 0 4	2 0 2 2 0 2	2 0 2 4 0 2	2 0 2 2 0 2	2 0 2 4 0 2	2 0 2 4 0 2	2 0 2 4 0 2	0 0 0 1 0 0 0

1511

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

18

9550089

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63			
8	704MD	Reboxetine	Female	08. CONCENTRATIONS DIFFICULTIES	2	2	2	0	0	0	0	0	0	0		
				09. REDUCED SLEEP	4	4	2	0	0	0	0	0	0	0	0	
				10. REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0	0	
				11. Total score	22	22	16	6	6	6	8	8	2	2	1	
				01. REPORTED SADNESS	4	4	4	4	2	0	0	0	0	2	2	2
				02. INNER TENSION	2	2	2	2	2	0	0	0	0	2	2	2
				03. APPARENT SADNESS	2	2	2	2	2	2	2	2	2	2	2	2
				04. SUICIDAL THOUGHTS	4	6	6	6	4	4	2	2	2	2	2	2
				05. INERTIA	0	0	0	0	0	0	0	0	0	0	0	0
				06. INABILITY TO FEEL	4	4	4	4	2	2	2	2	2	2	2	2
				07. PESSIMISTIC THOUGHTS	4	4	4	4	2	2	2	2	2	2	2	2
9	1ND	Imipramine	Female	08. CONCENTRATIONS DIFFICULTIES	0	0	0	0	0	0	0	0	0	0		
				09. REDUCED SLEEP	2	2	2	2	2	0	0	0	0	0	0	
				10. REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0	0	
				11. Total score	22	24	24	24	16	8	6	6	14	14	12	
				01. REPORTED SADNESS	4	1	1	2	2	0	0	0	0	0	0	0
				02. INNER TENSION	4	1	1	2	2	0	0	0	0	0	0	0
				03. APPARENT SADNESS	2	1	1	3	3	3	3	3	2	2	1	1
				04. SUICIDAL THOUGHTS	3	3	2	2	2	3	3	3	3	3	0	0
				05. INERTIA	2	0	0	0	0	0	0	0	0	0	0	0
				06. INABILITY TO FEEL	3	1	1	1	1	1	1	1	1	1	1	1
				07. PESSIMISTIC THOUGHTS	3	1	1	2	2	2	2	2	2	2	2	1
10	1DT	Imipramine	Female	08. CONCENTRATIONS DIFFICULTIES	3	0	1	1	1	0	0	0	0	0		
				09. REDUCED SLEEP	3	0	1	1	1	0	0	0	0	0	0	
				10. REDUCED APPETITE	2	0	0	0	0	0	0	0	0	0	0	
				11. Total score	29	8	10	14	13	9	9	9	5	5	3	
				01. REPORTED SADNESS	4	4	3	0	0	0	0	0	0	0	0	0
				02. INNER TENSION	4	4	3	0	0	0	0	0	0	0	0	0
				03. APPARENT SADNESS	4	4	3	0	0	0	0	0	0	0	0	0
				04. SUICIDAL THOUGHTS	2	0	0	0	0	0	0	0	0	0	0	0
				05. INERTIA	3	0	0	0	0	0	0	0	0	0	0	0
				06. INABILITY TO FEEL	3	3	0	0	0	0	0	0	0	0	0	0
				07. PESSIMISTIC THOUGHTS	3	3	3	3	0	1	0	0	0	0	0	0
11	2ND	Reboxetine	Female	08. CONCENTRATIONS DIFFICULTIES	3	3	0	0	0	0	0	0	0	0		
				09. REDUCED SLEEP	2	3	0	0	0	0	0	0	0	0	0	
				10. REDUCED APPETITE	2	2	0	0	0	0	0	0	0	0	0	
				11. Total score	30	26	13	3	2	1	0	0	0	0	0	
				01. REPORTED SADNESS	5	5	4	4	4	4	4	4	4	4	2	2
				02. INNER TENSION	5	5	4	4	4	4	4	4	4	4	2	2
				03. APPARENT SADNESS	5	4	4	4	3	3	2	3	0	0	0	0
				04. SUICIDAL THOUGHTS	4	4	3	3	2	3	2	3	0	0	0	0
				05. INERTIA	4	3	3	3	4	4	4	4	4	4	4	4
				06. INABILITY TO FEEL	5	5	3	3	3	3	3	3	3	3	3	3

1512

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

19

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63					
9	2ND	Reboxetine	Female	07.PESSIMISTIC THOUGHTS	5	4	3	4	3	3	4	4	2						
				08.CONCENTRATIONS DIFFICULTIES	5	4	3	4	3	3	4	2							
				09.REDUCED SLEEP	4	4	3	4	2	3	4	2							
				10.REDUCED APPETITE	2	2	2	1	2	2	2	2							
				11.Total score	44	38	33	36	30	33	33	20							
				2DT	Imipramine	Female	01.REPORTED SADNESS	5	3	0	0	0	0	0	0	0	0	0	
							02.INNER TENSION	5	3	0	0	0	0	0	0	0	0	0	0
							03.APPARENT SADNESS	5	4	2	2	0	2	1	0	0	0	0	0
							04.SUICIDAL THOUGHTS	3	2	0	0	0	0	0	0	0	0	0	0
							05.INERTIA	0	0	0	0	0	0	0	0	0	0	0	0
							06.INABILITY TO FEEL	4	3	2	0	0	0	0	0	0	0	0	0
07.PESSIMISTIC THOUGHTS	4	3	0				0	0	0	0	0	0	0	0	0				
08.CONCENTRATIONS DIFFICULTIES	4	3	0				0	0	0	0	0	0	0	0	0				
09.REDUCED SLEEP	4	2	0				0	0	0	0	0	0	0	0	0				
10.REDUCED APPETITE	2	0	0				0	0	0	0	0	0	0	0	0				
11.Total score	36	23	4				2	0	2	1	0	0	0	0	0				
3DT	Reboxetine	Female	01.REPORTED SADNESS	3	3	2	0	0	1	1	2	0	0	0					
			02.INNER TENSION	3	3	2	0	1	1	2	0	0	0	0					
			03.APPARENT SADNESS	3	3	4	0	2	2	0	2	2	2	0	0				
			04.SUICIDAL THOUGHTS	3	3	3	3	2	2	3	0	0	0	0	0				
			05.INERTIA	1	1	2	0	0	0	0	0	0	0	0	0				
			06.INABILITY TO FEEL	0	0	1	0	1	1	0	0	0	0	0	0				
			07.PESSIMISTIC THOUGHTS	3	3	3	0	0	0	2	0	0	0	0	0				
			08.CONCENTRATIONS DIFFICULTIES	3	3	3	0	0	0	1	0	0	0	0	0				
			09.REDUCED SLEEP	3	3	3	0	0	0	1	0	0	0	0	0				
			10.REDUCED APPETITE	1	1	1	0	0	0	0	0	0	0	0	0				
			11.Total score	23	23	24	3	7	7	11	2	2	2	2	2				
4ND	Imipramine	Female	01.REPORTED SADNESS	4	3	2	1	1	2	2	0	0	0	0					
			02.INNER TENSION	4	3	2	0	2	2	0	0	0	0	0					
			03.APPARENT SADNESS	4	3	1	3	4	3	0	0	0	0	0					
			04.SUICIDAL THOUGHTS	0	0	0	2	0	0	0	0	0	0	0					
			05.INERTIA	0	0	0	0	0	0	0	0	0	0	0					
			06.INABILITY TO FEEL	2	1	0	0	0	0	0	0	0	0	0					
			07.PESSIMISTIC THOUGHTS	3	3	3	1	3	3	0	0	0	0	0	0				
			08.CONCENTRATIONS DIFFICULTIES	3	2	2	0	1	1	0	0	0	0	0	0				
			09.REDUCED SLEEP	3	1	2	0	2	1	0	0	0	0	0	0				
			10.REDUCED APPETITE	2	0	0	0	0	0	0	0	0	0	0	0				
			11.Total score	25	19	12	7	14	12	0	0	0	0	0	0				
5ND	Reboxetine	Female	01.REPORTED SADNESS	4	4	3	4	4	3	3	3	3	2	2					
			02.INNER TENSION	4	4	3	4	3	3	3	3	2	2	2					
			03.APPARENT SADNESS	2	3	3	3	3	2	2	2	2	0	0					
			04.SUICIDAL THOUGHTS	3	3	3	3	3	2	2	2	0	0	0					
			05.INERTIA	2	3	3	3	3	3	2	1	1	0	0					

9550089

1513

9550089

20

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: Y3.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63					
9	5ND	Reboxetine	Female	Montgomery Asberg Depression Rating Scale														
				06.INABILITY TO FEEL	3	2	2	2	2	2	2	2	2	1	1			
				07.PESSIMISTIC THOUGHTS	3	4	4	4	3	3	3	3	2	1	1	0		
				08.CONCENTRATIONS DIFFICULTIES	3	4	4	4	3	3	3	3	2	1	1	0		
				09.REDUCED SLEEP	3	3	3	3	3	3	2	2	2	1	0	0		
				10.REDUCED APPETITE	2	2	2	2	2	1	0	1	1	0	0	0		
				11.Total score	29	32	30	32	27	24	20	13	7					
				6ND	Imipramine	Female	01.REPORTED SADNESS	4	4									
							02.INNER TENSION	4	4									
							03.APPARENT SADNESS	3	3									
							04.SUICIDAL THOUGHTS	3	3									
05.ENERGIA	2	3																
06.INABILITY TO FEEL	3	3																
07.PESSIMISTIC THOUGHTS	4	4																
08.CONCENTRATIONS DIFFICULTIES	3	3																
09.REDUCED SLEEP	3	3																
10.REDUCED APPETITE	2	2																
11.Total score	31	33																
7ND	Imipramine	Female	01.REPORTED SADNESS	4	4													
			02.INNER TENSION	4	4													
			03.APPARENT SADNESS	4	4													
			04.SUICIDAL THOUGHTS	0	2													
			05.ENERGIA	3	3													
			06.INABILITY TO FEEL	2	2													
			07.PESSIMISTIC THOUGHTS	3	3													
			08.CONCENTRATIONS DIFFICULTIES	3	3													
			09.REDUCED SLEEP	2	2													
			10.REDUCED APPETITE	2	2													
			11.Total score	27	29													
8DT	Reboxetine	Female	01.REPORTED SADNESS	4	4	4	4	4	3	2	2	2	2					
			02.INNER TENSION	4	4	4	4	3	3	3	3	3	3	3				
			03.APPARENT SADNESS	4	4	4	3	3	2	1	0	1	0	1				
			04.SUICIDAL THOUGHTS	1	3	3	3	4	3	0	2	0	0	0				
			05.ENERGIA	3	3	3	3	3	3	3	3	3	3	3				
			06.INABILITY TO FEEL	3	3	3	3	3	3	2	1	2	1	2				
			07.PESSIMISTIC THOUGHTS	3	3	3	3	3	3	3	3	2	1	0	1			
			08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2	2	0	0	0	0			
			09.REDUCED SLEEP	2	2	2	2	2	2	2	2	0	0	0	0			
			10.REDUCED APPETITE	2	2	2	2	2	2	2	2	1	1	1	1			
			11.Total score	29	31	31	30	32	24	17	16	15						
10	1ND	Imipramine	Female	01.REPORTED SADNESS	5	5	2	2	1	0	0	0	0					
				02.INNER TENSION	6	4	2	1	2	0	0	0	0	0				
				03.APPARENT SADNESS	4	4	2	1	2	2	2	2	2	2				
				04.SUICIDAL THOUGHTS	4	4	3	2	2	2	3	2	2	2				

1514

9550089

21

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63				
10	4ND	Imipramine	Female	05.INERTIA	3	3	2	1	0	0	0	0	0	0				
				06.INABILITY TO FEEL	4	4	2	2	2	1	1	1	0	0	0	1		
				07.PESSIMISTIC THOUGHTS	5	3	3	1	2	0	0	0	0	0	0	2		
				08.CONCENTRATIONS DIFFICULTIES	4	4	4	1	1	0	0	0	0	0	0	0		
				09.REDUCED SLEEP	2	2	1	0	2	0	0	0	0	0	0	0		
				10.REDUCED APPETITE	3	2	0	0	0	0	0	0	0	0	0	0		
				11.Total score	40	35	21	11	14	5	6	4	7					
				10D	Reboxetine	Female	01.REPORTED SADNESS	5	4	3	2	2	0	0	0	0	0	0
							02.INNER TENSION	5	3	3	2	2	0	0	0	0	0	0
							03.APPARENT SADNESS	4	4	2	2	2	2	2	2	2	2	2
							04.SUICIDAL THOUGHTS	0	0	0	0	3	3	1	0	0	0	0
05.INERTIA	0	0	0				0	2	2	1	0	0	0	0				
06.INABILITY TO FEEL	1	1	1				1	1	0	0	0	0	0	0				
07.PESSIMISTIC THOUGHTS	3	3	3				2	1	0	0	0	0	0	0				
08.CONCENTRATIONS DIFFICULTIES	3	3	2				2	1	0	0	0	0	0	0				
09.REDUCED SLEEP	3	4	2				1	0	0	0	0	0	0	0				
10.REDUCED APPETITE	0	0	0				0	0	0	0	0	0	0	0				
11.Total score	24	22	16				12	9	8	6	3	3						
20D	Reboxetine	Male	01.REPORTED SADNESS	5	5	3	2	2	1	0	0	0	0	0				
			02.INNER TENSION	5	6	3	2	1	0	0	0	0	0	0				
			03.APPARENT SADNESS	4	3	2	2	2	1	2	1	2	1	2				
			04.SUICIDAL THOUGHTS	4	3	3	3	2	2	2	2	2	2	2				
			05.INERTIA	3	3	3	2	0	0	0	0	0	0	0				
			06.INABILITY TO FEEL	4	3	2	2	1	1	1	1	1	1	1				
			07.PESSIMISTIC THOUGHTS	3	4	2	1	2	0	2	2	2	2	2				
			08.CONCENTRATIONS DIFFICULTIES	6	4	3	1	1	0	2	0	1	0	1				
			09.REDUCED SLEEP	2	2	2	1	0	0	0	0	0	0	0				
			10.REDUCED APPETITE	3	3	2	2	0	0	0	0	0	0	0				
			11.Total score	39	36	25	16	10	4	11	6	8						
20D	Imipramine	Male	01.REPORTED SADNESS	3	3	1	0	0	0	0	0	0	0	0				
			02.INNER TENSION	4	3	3	0	0	0	2	0	0	0	0				
			03.APPARENT SADNESS	5	4	4	2	3	2	3	3	3	3	3				
			04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0	0	0	0	0				
			05.INERTIA	0	0	0	0	0	0	0	0	0	0	0				
			06.INABILITY TO FEEL	2	2	3	2	2	1	2	1	1	1	1				
			07.PESSIMISTIC THOUGHTS	5	3	3	0	0	0	2	0	0	0	0				
			08.CONCENTRATIONS DIFFICULTIES	4	4	2	0	0	2	0	0	0	0	0				
			09.REDUCED SLEEP	3	2	2	0	0	0	0	0	0	0	0				
			10.REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0	0				
			11.Total score	26	21	18	4	5	3	11	4	4						
30D	Reboxetine	Male	01.REPORTED SADNESS	5	5	5	6	4	2	2	2	1	0					
			02.INNER TENSION	6	6	5	5	4	3	2	1	2	2					
			03.APPARENT SADNESS	4	3	4	3	3	2	2	2	2	2					

1515

9550089

22

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63				
10	3HD	Reboxetine	Male	04.SUICIDAL THOUGHTS	5	4	3	3	3	3	2	2	2	2				
				05.INERTIA	4	4	4	4	4	2	0	0	0	0	0	0		
				06.INABILITY TO FEEL	2	4	3	4	2	2	1	1	2	2	2	2		
				07.PESSIMISTIC THOUGHTS	5	5	3	4	3	4	2	2	2	2	2	2		
				08.CONCENTRATIONS DIFFICULTIES	4	5	4	4	3	4	2	2	4	2	2	2		
				09.REDUCED SLEEP	0	0	1	2	2	0	0	0	0	0	0	0		
				10.REDUCED APPETITE	4	3	2	2	2	0	0	0	0	0	0	0		
				11.Total score	39	39	34	37	30	23	14	11	12					
				30T	Imipramine	Male	01.REPORTED SADNESS	4	5	2	1	1	1	0	0	0	0	0
							02.INNER TENSION	5	4	4	2	3	0	0	0	0	0	0
							03.APARENT SADNESS	5	4	3	3	2	2	2	2	3	3	3
04.SUICIDAL THOUGHTS	0	0	0				0	0	0	0	0	0	0	0				
05.INERTIA	0	0	0				0	0	0	0	0	0	0	0				
06.INABILITY TO FEEL	2	2	2				2	1	1	0	0	0	0	0				
07.PESSIMISTIC THOUGHTS	5	5	4				3	2	0	0	0	0	0	0				
08.CONCENTRATIONS DIFFICULTIES	4	4	3				2	2	0	0	0	0	0	0				
09.REDUCED SLEEP	2	2	2				2	2	0	0	0	0	0	0				
10.REDUCED APPETITE	0	0	0				0	0	0	0	0	0	0	0				
11.Total score	27	27	20				15	13	3	2	4	4						
4HD	Imipramine	Female	01.REPORTED SADNESS	6	6	3	2	2	2	2	0	0	0	0				
			02.INNER TENSION	6	5	3	3	2	2	2	2	2	2	2				
			03.APARENT SADNESS	4	4	3	3	2	2	2	2	2	2	2				
			04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0	0	0	0	0				
			05.INERTIA	2	2	2	2	2	2	2	2	2	2	2				
			06.INABILITY TO FEEL	3	2	2	2	2	1	1	1	0	0	0				
			07.PESSIMISTIC THOUGHTS	4	4	3	2	2	2	2	2	2	2	2				
			08.CONCENTRATIONS DIFFICULTIES	3	4	3	2	2	1	1	1	0	0	0				
			09.REDUCED SLEEP	2	2	2	2	2	1	2	0	0	0	0				
			10.REDUCED APPETITE	4	2	2	0	0	0	0	0	0	0	0				
			11.Total score	34	31	24	17	15	13	12	6	4						
4DT	Reboxetine	Female	01.REPORTED SADNESS	5	5	3	3	3	2	0	0	0	0	0				
			02.INNER TENSION	5	5	4	3	2	2	0	0	0	0	0				
			03.APARENT SADNESS	5	5	3	3	2	2	3	2	3	2	3				
			04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0	0	0	0	0				
			05.INERTIA	0	0	0	0	0	0	0	0	0	0	0				
			06.INABILITY TO FEEL	3	3	3	2	2	2	2	1	1	1	1				
			07.PESSIMISTIC THOUGHTS	4	4	4	3	3	2	0	2	2	2	2				
			08.CONCENTRATIONS DIFFICULTIES	3	3	3	3	2	2	0	1	2	0	0				
			09.REDUCED SLEEP	4	3	2	2	2	0	0	0	0	0	0				
			10.REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0	0				
			11.Total score	29	29	22	19	15	8	5	6	8						
5HD	Imipramine	Female	01.REPORTED SADNESS	5	5	6	5	3	3	3	0	0	0	0				
			02.INNER TENSION	6	5	5	4	4	3	0	0	0	0	0				

1516

9550089

23

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63			
10	5ND	Imipramine	Female	Montgomery Asberg Depression Rating Scale												
				03. APPARENT SADNESS	4	5	4	5	3	3	3	2	2	2	2	
				04. SUICIDAL THOUGHTS	5	5	5	3	3	1	1	1	1	0	1	1
				05. INERTIA	0	0	0	0	4	4	4	4	4	4	4	4
				06. INABILITY TO FEEL	4	4	3	3	3	2	2	2	2	2	2	1
				07. PESSIMISTIC THOUGHTS	5	4	3	3	3	2	2	2	0	0	0	0
				08. CONCENTRATIONS DIFFICULTIES	4	4	4	3	2	2	2	0	0	0	0	0
				09. REDUCED SLEEP	3	3	3	2	2	0	0	0	0	0	0	0
				10. REDUCED APPETITE	3	3	3	3	1	0	0	0	0	0	0	0
				11. Total score	39	39	36	31	28	20	9	8	8	8	8	8
				5DT	Reboxetine	Female	Montgomery Asberg Depression Rating Scale									
01. REPORTED SADNESS	4	4	3				4	4	5	3	3	3	3	4	4	
02. INNER TENSION	5	5	4				5	4	4	4	4	4	4	4	4	
03. APPARENT SADNESS	5	4	4				5	4	5	4	5	4	4	4	4	
04. SUICIDAL THOUGHTS	0	0	0				0	0	0	0	0	0	0	0	0	
05. INERTIA	0	0	0				0	0	0	0	0	0	0	0	0	
06. INABILITY TO FEEL	3	3	2				2	3	3	3	3	3	3	3	3	
07. PESSIMISTIC THOUGHTS	4	4	4				4	4	4	4	4	4	4	4	4	
08. CONCENTRATIONS DIFFICULTIES	3	3	3				3	3	3	3	3	3	3	3	3	
09. REDUCED SLEEP	3	3	2				2	3	4	3	3	3	3	3	3	
10. REDUCED APPETITE	0	0	0				0	0	0	0	0	0	0	0	0	
11. Total score	27	26	23	24	26	33	25	25	25	25	25	25				
6ND	Reboxetine	Male	Montgomery Asberg Depression Rating Scale													
			01. REPORTED SADNESS	6	6	6	5	5	5	5	5	5	5	5	5	
			02. INNER TENSION	6	6	5	6	5	6	6	6	6	6	6	6	
			03. APPARENT SADNESS	4	4	4	4	4	4	4	4	4	4	4	4	
			04. SUICIDAL THOUGHTS	5	4	3	3	3	3	3	3	3	3	3	3	
			05. INERTIA	4	4	4	4	4	4	4	4	4	4	4	4	
			06. INABILITY TO FEEL	5	4	3	3	2	3	3	3	3	3	3	2	
			07. PESSIMISTIC THOUGHTS	4	3	4	4	3	3	4	4	4	4	4	3	
			08. CONCENTRATIONS DIFFICULTIES	4	3	3	3	3	3	4	4	4	4	4	3	
			09. REDUCED SLEEP	0	0	0	0	0	2	0	2	0	0	0	0	
			10. REDUCED APPETITE	0	0	0	0	0	0	0	2	0	0	0	0	
11. Total score	38	34	31	34	28	35	36	31	31	31	28	28				
6DT	Reboxetine	Male	Montgomery Asberg Depression Rating Scale													
			01. REPORTED SADNESS	4	4	1	2	0	0	0	0	0	0	0	0	
			02. INNER TENSION	4	4	3	3	0	0	0	0	0	0	0	0	
			03. APPARENT SADNESS	5	4	3	3	1	2	1	2	1	2	2	2	
			04. SUICIDAL THOUGHTS	0	0	0	0	0	0	0	0	0	0	0	0	
			05. INERTIA	0	0	0	0	0	0	0	0	0	0	0	0	
			06. INABILITY TO FEEL	3	2	2	2	1	2	1	2	2	1	2	1	
			07. PESSIMISTIC THOUGHTS	4	2	2	3	2	2	2	2	0	0	0	0	
			08. CONCENTRATIONS DIFFICULTIES	4	2	2	2	0	0	0	0	0	0	0	0	
			09. REDUCED SLEEP	3	3	2	2	2	0	0	0	0	0	0	0	
			10. REDUCED APPETITE	2	2	2	2	0	0	0	0	0	0	0	0	
11. Total score	29	23	15	19	4	6	4	4	4	4	4	3				
7ND	Imipramine	Male	Montgomery Asberg Depression Rating Scale													
			01. REPORTED SADNESS	4	5	3	2	2	0	0	0	0	0	0	0	

1517

9550089

24

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
10	7ND	Imipramine	Male	02.INNER TENSION	6	5	2	3	2	0	0	0	0	0		
				03.APPARENT SADNESS	4	3	3	3	2	2	2	2	2	1	2	
				04.SUICIDAL THOUGHTS	4	3	2	3	2	2	1	1	1	1	1	
				05.INERTIA	0	0	0	0	0	0	0	0	0	0	0	
				06.INABILITY TO FEEL	4	2	3	2	1	1	1	1	0	0	0	
				07.PESSIMISTIC THOUGHTS	5	4	3	2	3	1	0	0	0	0	0	
				08.CONCENTRATIONS DIFFICULTIES	4	3	4	3	3	0	0	0	0	0	0	
				09.REDUCED SLEEP	0	0	0	0	0	0	0	0	0	0	0	
				10.REDUCED APPETITE	2	2	0	0	0	0	0	0	0	0	0	
				11.Total score	35	28	20	18	15	6	5	3	4			
				15	7DT	Imipramine	Female	01.REPORTED SADNESS	4	4	5	4	2	1	0	0
02.INNER TENSION	4	5	5					5	3	2	0	0	0	0		
03.APPARENT SADNESS	4	4	5					4	3	2	2	1	2	2		
04.SUICIDAL THOUGHTS	0	0	0					0	0	0	0	0	0	0		
05.INERTIA	0	0	0					0	0	0	2	1	2	2		
06.INABILITY TO FEEL	2	2	3					3	2	2	2	2	2	1		
07.PESSIMISTIC THOUGHTS	3	4	4					3	3	2	0	0	0	0		
08.CONCENTRATIONS DIFFICULTIES	2	3	3					2	2	2	0	0	0	0		
09.REDUCED SLEEP	0	0	0					0	0	0	0	0	0	0		
10.REDUCED APPETITE	2	2	2					2	2	0	0	0	0	0		
11.Total score	21	24	27					23	17	11	6	4	5			
18	8ND	Reboxetine	Male	01.REPORTED SADNESS	5	6	2	0	0	0	0	0	0	0		
				02.INNER TENSION	6	5	5	3	0	0	0	0	0	0		
				03.APPARENT SADNESS	5	4	3	3	2	2	1	2	1	1		
				04.SUICIDAL THOUGHTS	4	2	2	2	2	2	2	2	1	1		
				05.INERTIA	2	2	0	0	4	3	0	0	0	0		
				06.INABILITY TO FEEL	3	3	2	2	1	1	2	2	2	2		
				07.PESSIMISTIC THOUGHTS	4	3	3	2	0	0	0	0	0	0		
				08.CONCENTRATIONS DIFFICULTIES	4	3	2	2	0	0	0	0	0	0		
				09.REDUCED SLEEP	3	3	3	1	0	0	0	0	0	0		
				10.REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0		
				11.Total score	36	31	22	15	9	8	7	6	4			
8DT	Imipramine	Female	01.REPORTED SADNESS	3	2	1	0	0	0	0	0	0	0			
			02.INNER TENSION	4	4	3	0	0	0	0	0	0	0			
			03.APPARENT SADNESS	5	4	2	2	1	3	2	2	2	2			
			04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0	0	0	0			
			05.INERTIA	0	0	0	0	0	0	0	0	0	0			
			06.INABILITY TO FEEL	3	2	1	1	0	1	1	1	1	1			
			07.PESSIMISTIC THOUGHTS	4	4	2	2	0	1	0	1	0	0			
			08.CONCENTRATIONS DIFFICULTIES	3	3	2	1	0	1	0	1	0	0			
			09.REDUCED SLEEP	3	3	0	0	0	0	0	0	0	0			
			10.REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0			
			11.Total score	25	22	11	6	1	6	3	5	3				

9550089

25

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
10	9ND	Reboxetine	Female	01.REPORTED SADNESS	6	4	3	3	2	0	0	0	0	0	
				02.INNER TENSION	6	5	4	4	2	0	0	0	0	0	0
				03.APPARENT SADNESS	5	4	3	3	2	2	2	2	2	2	2
				04.SUICIDAL THOUGHTS	4	3	2	3	0	0	0	0	0	0	0
				05.INERTIA	3	3	3	0	0	0	0	0	0	0	0
				06.INABILITY TO FEEL	3	3	3	2	1	1	1	0	0	0	0
				07.PESSIMISTIC THOUGHTS	5	5	4	4	3	1	1	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	4	4	3	4	3	2	1	0	0	0	0
				09.REDUCED SLEEP	3	3	2	2	2	0	0	0	0	0	0
				10.REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0	0
				11.Total score	39	34	24	25	17	8	7	4	3		
15	9DT	Imipramine	Male	01.REPORTED SADNESS	4	3	4	4	4	4	3	3	2	4	
				02.INNER TENSION	4	5	5	6	4	4	4	4	3	5	5
				03.APPARENT SADNESS	5	4	4	4	4	3	4	3	4	3	4
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0	0	0	0	0
				05.INERTIA	0	0	0	0	0	0	0	0	0	0	0
				06.INABILITY TO FEEL	2	2	1	2	3	2	2	2	2	2	2
				07.PESSIMISTIC THOUGHTS	5	3	4	4	4	3	4	4	3	4	4
				08.CONCENTRATIONS DIFFICULTIES	3	3	2	4	3	3	2	3	3	4	4
				09.REDUCED SLEEP	4	4	3	3	4	4	3	3	3	4	4
				10.REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0	0
				11.Total score	27	24	23	28	26	23	22	20	26		
19	10ND	Imipramine	Female	01.REPORTED SADNESS	4	5	1	0	0	0	0	0	0	0	
				02.INNER TENSION	5	5	3	2	2	2	2	0	0	0	0
				03.APPARENT SADNESS	4	4	3	2	3	2	2	2	2	2	2
				04.SUICIDAL THOUGHTS	5	4	3	2	2	2	2	2	2	2	2
				05.INERTIA	4	4	3	2	0	0	0	0	0	0	0
				06.INABILITY TO FEEL	3	2	2	1	2	2	2	1	1	1	1
				07.PESSIMISTIC THOUGHTS	5	4	4	2	1	2	0	2	0	1	1
				08.CONCENTRATIONS DIFFICULTIES	4	3	2	1	2	2	0	0	0	0	0
				09.REDUCED SLEEP	4	3	2	2	1	2	0	0	0	0	0
				10.REDUCED APPETITE	3	3	2	2	2	0	0	0	0	0	0
				11.Total score	41	37	25	15	15	12	7	7	6		
19	10DT	Reboxetine	Female	01.REPORTED SADNESS	4	4	0	0	0	0	0	0	0	0	
				02.INNER TENSION	5	5	2	0	0	0	0	0	0	0	0
				03.APPARENT SADNESS	5	3	2	2	2	1	2	3	2	2	2
				04.SUICIDAL THOUGHTS	3	0	0	0	0	0	1	0	0	0	0
				05.INERTIA	4	4	1	1	1	0	0	0	0	0	0
				06.INABILITY TO FEEL	3	2	1	0	1	1	1	0	1	0	1
				07.PESSIMISTIC THOUGHTS	2	2	2	0	0	1	0	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	0	0	1	0	0	0	0	0
				09.REDUCED SLEEP	0	0	0	0	0	0	0	0	0	0	0
				10.REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0	0
				11.Total score	28	22	10	3	4	4	4	4	3		

9550089

26

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
10	11HD	Imipramine	Female	01.REPORTED SADNESS	5	6	6	6	2	1	0	0	0		
				02.INNER TENSION	6	6	5	6	3	2	0	0	0	0	
				03.APPARENT SADNESS	5	5	4	4	3	2	2	2	2	2	
				04.SUICIDAL THOUGHTS	0	0	0	0	4	4	3	0	0	0	0
				05.INERTIA	4	4	3	3	2	0	0	0	0	0	0
				06.INABILITY TO FEEL	3	4	3	3	2	1	0	0	0	0	0
				07.PESSIMISTIC THOUGHTS	4	5	4	4	3	3	1	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	4	4	4	4	3	2	1	0	0	0	0
				09.REDUCED SLEEP	0	0	0	0	0	0	0	0	0	0	0
				10.REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0	0
				11.Total score	31	34	29	30	21	16	9	2	2	2	2
11	11DT	Imipramine	Female	01.REPORTED SADNESS	4	3	0	0	0	0	0	0	0		
				02.INNER TENSION	4	5	2	2	0	0	0	0	0	0	
				03.APPARENT SADNESS	5	4	2	2	2	2	2	2	2	1	
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0	0	0	0	0
				05.INERTIA	3	3	2	0	0	0	0	0	0	0	0
				06.INABILITY TO FEEL	2	1	1	1	1	1	1	1	1	1	1
				07.PESSIMISTIC THOUGHTS	2	2	1	1	0	2	0	1	0	1	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	0	1	0	1	0	0	0
				09.REDUCED SLEEP	3	2	1	1	0	0	0	0	0	0	0
				10.REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0	0
				11.Total score	25	22	10	8	3	6	3	5	2	2	2
12	12HD	Reboxetine	Male	01.REPORTED SADNESS	4	6	4	4	5	6	4	6	4		
				02.INNER TENSION	5	6	4	4	6	6	5	6	6	5	
				03.APPARENT SADNESS	5	5	6	4	4	4	4	4	4	4	
				04.SUICIDAL THOUGHTS	5	4	5	5	4	5	4	4	3	5	
				05.INERTIA	0	0	0	0	0	0	0	0	0	0	0
				06.INABILITY TO FEEL	4	3	4	4	3	5	3	4	4	4	
				07.PESSIMISTIC THOUGHTS	5	4	5	4	5	5	4	5	4	5	
				08.CONCENTRATIONS DIFFICULTIES	4	4	4	4	5	4	5	5	4	4	
				09.REDUCED SLEEP	3	3	2	3	2	4	3	2	3	2	
				10.REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0	
				11.Total score	35	35	34	33	33	40	32	35	35	35	
12	12DT	Reboxetine	Female	01.REPORTED SADNESS	4	3	3	2	2	0	0	0	0		
				02.INNER TENSION	4	4	5	3	3	0	0	0	0	0	
				03.APPARENT SADNESS	5	4	2	3	3	3	2	4	3	3	
				04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0	0	0	0	
				05.INERTIA	4	4	2	0	0	0	0	0	0	0	
				06.INABILITY TO FEEL	2	2	2	2	2	1	0	1	0	0	
				07.PESSIMISTIC THOUGHTS	0	0	0	0	0	0	0	0	0	0	
				08.CONCENTRATIONS DIFFICULTIES	3	3	0	0	0	0	0	0	0	0	
				09.REDUCED SLEEP	4	3	2	2	2	0	0	0	0	0	
				10.REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0	

1520

9550089

27

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
10	12DT	Female	11.Total score	26	23	16	12	11	4	2	5	3	
		Female	01.REPORTED SADNESS	4	4	1	1	0	0	0	0	0	
		Female	02.INNER TENSION	4	4	3	2	0	0	0	0	0	
			03.APPARENT SADNESS	4	3	2	2	2	2	2	2	3	
			04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0	0	0	
			05.INERTIA	2	3	2	2	2	1	2	1	1	
			06.INABILITY TO FEEL	2	4	4	0	2	0	0	0	0	
			07.PESSIMISTIC THOUGHTS	3	3	2	2	0	0	0	0	0	
			08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	0	0	0	0	0	
			09.REDUCED SLEEP	0	2	2	1	0	0	0	0	0	
			10.REDUCED APPETITE	0	0	0	0	0	0	0	0	0	
			11.Total score	21	23	16	10	6	3	4	3	4	
		Female	01.REPORTED SADNESS	4	4	2	2	0	0	0	0	0	
		Female	02.INNER TENSION	5	5	3	2	0	0	0	0	0	
			03.APPARENT SADNESS	4	4	3	2	2	2	2	2	2	
			04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0	0	0	
			05.INERTIA	0	0	0	0	0	0	3	3	2	
			06.INABILITY TO FEEL	2	2	2	1	1	2	2	1	1	
			07.PESSIMISTIC THOUGHTS	4	4	2	2	0	0	0	0	0	
			08.CONCENTRATIONS DIFFICULTIES	3	4	2	1	0	0	0	0	0	
			09.REDUCED SLEEP	3	3	3	3	0	0	0	0	0	
			10.REDUCED APPETITE	0	0	0	0	0	0	0	0	0	
			11.Total score	25	26	17	10	3	4	7	6	5	
15	15MD	Female	11.Total score	4	4	2	0	0	0	0	0	0	
		Female	01.REPORTED SADNESS	4	4	3	2	0	0	0	0	0	
		Female	02.INNER TENSION	3	5	2	2	2	1	2	2	2	
			03.APPARENT SADNESS	4	4	2	0	0	0	0	0	0	
			04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0	0	0	
			05.INERTIA	2	4	2	3	1	1	2	1	1	
			06.INABILITY TO FEEL	5	5	2	4	1	1	1	0	1	
			07.PESSIMISTIC THOUGHTS	5	4	2	2	0	1	0	0	0	
			08.CONCENTRATIONS DIFFICULTIES	0	0	0	0	0	0	0	0	0	
			09.REDUCED SLEEP	4	3	0	0	0	0	0	0	0	
			10.REDUCED APPETITE	3	3	0	0	0	0	0	0	0	
			11.Total score	31	34	15	13	4	4	5	3	4	
16	16DT	Male	11.Total score	4	1	0	0	0	0	0	0	0	
		Male	01.REPORTED SADNESS	5	3	2	2	0	0	0	0	0	
			02.INNER TENSION	4	2	2	2	3	0	2	3	2	
			03.APPARENT SADNESS	0	0	0	0	0	0	0	0	0	
			04.SUICIDAL THOUGHTS	0	0	0	0	1	1	0	0	0	
			05.INERTIA	3	4	2	2	2	2	0	0	0	
			06.INABILITY TO FEEL	4	4	2	2	0	0	2	0	0	
			07.PESSIMISTIC THOUGHTS	2	3	2	2	0	0	0	0	0	
			08.CONCENTRATIONS DIFFICULTIES	2	3	2	0	0	0	0	0	0	
			09.REDUCED SLEEP	3	3	0	0	0	0	0	0	0	

1521

9550089

28

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
10	16DT	Imipramine	Male	10. REDUCED APPETITE 11. Total score	0 24	0 20	0 10	0 4	0 6	0 3	0 4	0 3	0 2	
	17MD	Reboxetine	Female	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS 05. INERTIA 06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS 08. CONCENTRATIONS DIFFICULTIES 09. REDUCED SLEEP 10. REDUCED APPETITE 11. Total score	4 5 4 0 4 3 5 0 0 30	3 4 4 0 2 2 4 3 0 22	2 3 3 0 2 4 3 0 0 19	1 2 2 0 1 2 2 0 0 10	0 2 3 0 0 0 0 0 0 5	0 0 3 0 0 1 0 0 0 7	0 0 1 1 0 0 0 0 0 3	0 0 2 0 0 0 0 0 0 2	0 0 2 0 0 0 0 0 0 2	
	18MD	Imipramine	Female	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS 05. INERTIA 06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS 08. CONCENTRATIONS DIFFICULTIES 09. REDUCED SLEEP 10. REDUCED APPETITE 11. Total score	4 5 4 4 5 5 4 3 3 43	5 6 4 2 4 4 5 3 3 40	5 6 3 3 4 3 3 3 4 38	6 6 4 4 4 3 4 4 2 40	2 3 3 0 2 2 2 2 2 22	1 2 3 2 0 2 2 2 0 14	0 0 2 1 0 1 1 1 0 5	0 0 2 2 0 1 1 1 0 2	0 0 2 2 0 1 1 1 0 6	
	19DT	Reboxetine	Male	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS 05. INERTIA 06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS 08. CONCENTRATIONS DIFFICULTIES 09. REDUCED SLEEP 10. REDUCED APPETITE 11. Total score	5 4 4 0 0 3 4 3 3 28	4 5 5 0 0 2 3 3 4 24	5 5 5 0 0 3 2 3 4 27	6 6 4 0 0 2 3 3 2 26	4 5 4 0 0 3 3 2 2 25	2 3 3 0 0 2 2 3 2 18	3 4 3 0 0 2 3 3 2 18	3 4 3 0 0 2 3 3 2 20	3 4 3 0 0 2 4 4 2 25	
	20MD	Reboxetine	Female	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS 05. INERTIA 06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS 08. CONCENTRATIONS DIFFICULTIES	5 5 5 5 4 4 5 4 4	5 6 4 3 3 3 5 5 4	6 5 4 3 3 3 5 5 4	6 6 4 3 3 3 5 5 4	4 5 4 3 3 4 3 3 4	4 5 3 3 3 4 4 4 4	4 4 3 3 3 4 4 4 4	6 5 4 4 4 2 2 2 4	4 5 4 4 4 3 4 4 4	

15222

9550089

29

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63			
10	20ND	Reboxetine	Female	09. REDUCED SLEEP	3	2	3	2	2	3	3	3	3	3			
				10. REDUCED APPETITE	4	4	4	2	2	2	2	2	2	2	2		
				11. Total score	43	40	41	40	33	37	31	38	40	40	40		
				12	1ND	Reboxetine	Female	01. REPORTED SADNESS	4	3	3	2	2	2	2	0	0
								02. INNER TENSION	4	3	3	2	2	2	2	2	2
								03. APPARENT SADNESS	2	1	2	2	2	2	3	3	3
								04. SUICIDAL THOUGHTS	2	2	2	2	2	2	1	1	1
								05. INERTIA	2	2	1	1	1	1	1	1	1
								06. INABILITY TO FEEL	2	2	2	2	2	2	2	2	2
								07. PESSIMISTIC THOUGHTS	5	4	3	3	3	3	3	3	3
				08. CONCENTRATIONS DIFFICULTIES	3	3	3	2	2	2	2	2	2				
09. REDUCED SLEEP	3	2	3	3	3	3	3	3	3								
10. REDUCED APPETITE	1	1	1	1	1	1	1	1	1								
11. Total score	28	23	23	20	20	20	21	18	18								
11	1DT	Reboxetine	Female	01. REPORTED SADNESS	3	2	2	2	2	2	2	2	2				
				02. INNER TENSION	4	3	3	3	3	3	3	3	4				
				03. APPARENT SADNESS	4	3	3	3	2	2	2	2	2				
				04. SUICIDAL THOUGHTS	2	1	1	2	2	2	1	1	1				
				05. INERTIA	1	0	0	0	1	1	1	1	1				
				06. INABILITY TO FEEL	1	2	2	2	2	2	1	1	1				
				07. PESSIMISTIC THOUGHTS	4	4	3	3	3	3	3	3	3				
				08. CONCENTRATIONS DIFFICULTIES	3	2	2	2	2	2	2	2	2				
				09. REDUCED SLEEP	3	2	2	1	1	2	2	2	2				
				10. REDUCED APPETITE	4	4	3	3	3	2	2	2	2				
				11. Total score	29	23	21	21	21	20	19	20	22				
12	1ND	Reboxetine	Female	01. REPORTED SADNESS	4	4	3	2	1	1	0	1	1				
				02. INNER TENSION	3	3	3	2	1	1	0	1	1				
				03. APPARENT SADNESS	3	3	3	0	1	1	0	0	0				
				04. SUICIDAL THOUGHTS	3	3	3	0	1	0	0	0	0				
				05. INERTIA	4	4	4	3	3	2	2	2	2				
				06. INABILITY TO FEEL	2	2	2	0	1	0	0	0	0				
				07. PESSIMISTIC THOUGHTS	4	4	3	3	1	0	0	0	0				
				08. CONCENTRATIONS DIFFICULTIES	2	2	2	2	1	1	0	0	0				
				09. REDUCED SLEEP	4	4	3	2	2	2	1	1	1				
				10. REDUCED APPETITE	0	0	0	0	0	0	0	0	0				
				11. Total score	29	29	25	16	12	12	4	7	6				
13	1ND	Reboxetine	Female	01. REPORTED SADNESS	4	4	3	2	1	1	0	1	1				
				02. INNER TENSION	3	3	3	2	1	1	0	1	1				
				03. APPARENT SADNESS	3	3	3	0	1	1	0	0	0				
				04. SUICIDAL THOUGHTS	3	3	3	0	1	0	0	0	0				
				05. INERTIA	4	4	4	3	3	2	2	2	2				
				06. INABILITY TO FEEL	2	2	2	0	1	0	0	0	0				
				07. PESSIMISTIC THOUGHTS	4	4	3	3	1	0	0	0	0				
				08. CONCENTRATIONS DIFFICULTIES	2	2	2	2	1	1	0	0	0				
				09. REDUCED SLEEP	4	4	3	2	2	2	1	1	1				
				10. REDUCED APPETITE	0	0	0	0	0	0	0	0	0				
				11. Total score	29	29	25	16	12	12	4	7	6				
14	1DT	Imipramine	Female	01. REPORTED SADNESS	4	4	3	2	0	0	0	0	0				
				02. INNER TENSION	3	3	3	2	1	1	0	0	0				
				03. APPARENT SADNESS	2	2	2	2	0	0	0	0	0				
				04. SUICIDAL THOUGHTS	2	2	1	1	0	0	0	0	0				
				05. INERTIA	1	1	3	2	0	0	0	0	0				
				06. INABILITY TO FEEL	2	2	3	2	1	1	0	1	0				
				07. PESSIMISTIC THOUGHTS	3	3	2	2	0	0	0	0	0				

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63				
13	1DT	Female	Montgomery Asberg Depression Rating Scale													
			08.CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	0	0	0	0	0	0		
			09.REDUCED SLEEP	1	1	2	2	0	0	0	0	0	0	0		
			10.REDUCED APPETITE	1	1	0	0	0	0	0	0	0	0	0		
			11.Total score	20	19	20	16	2	4	0	0	0	1	0		
			2ND	Female	Montgomery Asberg Depression Rating Scale											
					01.REPORTED SADNESS	5	5	3	4	4	4	4	2	2	1	1
					02.INNER TENSION	4	4	3	4	4	3	2	2	1	1	1
					03.APPARENT SADNESS	3	2	1	1	1	1	1	0	0	0	0
					04.SUICIDAL THOUGHTS	4	3	2	0	0	4	2	2	2	1	1
					05.INERTIA	5	6	3	5	6	5	3	3	3	3	3
					06.INABILITY TO FEEL	4	2	2	3	3	1	2	2	2	2	2
					07.PESSIMISTIC THOUGHTS	5	6	3	3	3	5	4	2	2	1	1
08.CONCENTRATIONS DIFFICULTIES	4	4			3	3	2	3	2	2	2	1	1			
09.REDUCED SLEEP	3	4			2	2	2	1	1	1	0	0	0			
10.REDUCED APPETITE	2	4			1	2	2	0	1	0	0	0	0			
11.Total score	39	40			23	27	27	27	16	12	12	10	10			
2DT	Female	Montgomery Asberg Depression Rating Scale														
		01.REPORTED SADNESS	5	5	3	3	2	2	1	1	4	2	2			
		02.INNER TENSION	4	4	3	3	2	2	1	1	3	2	2			
		03.APPARENT SADNESS	4	4	3	2	2	1	1	1	2	1	1			
		04.SUICIDAL THOUGHTS	4	4	3	2	2	1	1	1	2	1	1			
		05.INERTIA	4	4	3	3	2	2	2	2	3	1	1			
		06.INABILITY TO FEEL	0	0	3	2	2	1	1	1	2	2	2			
		07.PESSIMISTIC THOUGHTS	4	4	2	2	2	1	1	1	1	1	1			
		08.CONCENTRATIONS DIFFICULTIES	4	3	3	3	1	1	1	1	2	1	1			
		09.REDUCED SLEEP	3	3	3	2	1	1	1	1	1	1	1			
		10.REDUCED APPETITE	2	1	1	1	0	0	0	0	0	0	0			
		11.Total score	34	32	27	23	16	10	10	20	20	12	12			
		3ND	Male	Montgomery Asberg Depression Rating Scale												
01.REPORTED SADNESS	3			2	2	3	3	2	2	1	1	2	2			
02.INNER TENSION	3			2	2	2	2	2	1	1	2	2	2			
03.APPARENT SADNESS	3			2	1	2	2	1	1	1	0	2	2			
04.SUICIDAL THOUGHTS	1			2	3	2	2	2	2	1	2	1	2			
05.INERTIA	1			1	0	1	1	1	1	0	0	0	0			
06.INABILITY TO FEEL	2			2	2	2	2	2	2	1	1	1	1			
07.PESSIMISTIC THOUGHTS	2			2	1	1	1	1	1	1	1	1	1			
08.CONCENTRATIONS DIFFICULTIES	2			2	1	1	1	1	1	1	1	1	1			
09.REDUCED SLEEP	2			2	2	2	2	2	1	1	1	1	1			
10.REDUCED APPETITE	1			1	1	1	1	1	1	1	1	1	1			
11.Total score	20			18	15	17	17	14	9	9	9	9	12			
3DT	Female			Montgomery Asberg Depression Rating Scale												
		01.REPORTED SADNESS	4	4	3	2	1	0	0	0	0	0	0			
		02.INNER TENSION	4	3	3	1	0	0	0	0	0	0	0			
		03.APPARENT SADNESS	3	3	2	1	0	0	0	0	0	0	0			
		04.SUICIDAL THOUGHTS	4	3	2	1	1	1	1	1	1	1	1			
		05.INERTIA	1	2	3	2	2	2	0	0	0	0	0			
06.INABILITY TO FEEL	3	3	2	2	2	2	1	1	1	0	0					

9550089

1524

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

32

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
15	40T	Reboxetine	Female	2	2	2	2	1	1	1	1	1	1
				3	2	2	3	2	3	2	1	1	1
				4	2	2	4	2	1	1	1	0	0
				4	3	3	4	3	1	2	0	0	1
				1	1	1	1	1	0	0	0	0	0
				33	25	24	30	21	13	13	9	8	8
				11.Total score									
2ND		Imipramine	Female	3	3	1							
				3	3	1							
				3	2	2							
				1	0	0							
				4	3	3							
				3	3	2							
				2	4	2							
				3	2	2							
				2	2	1							
				2	2	1							
				26	24	16							
				11.Total score									
20T		Imipramine	Female	3	3	2	2	1	2	1	1	1	1
				3	2	2	2	1	1	2	1	1	1
				3	3	2	2	2	1	1	2	1	1
				4	3	2	3	3	2	3	2	2	2
				1	1	1	0	0	1	0	0	0	1
				2	2	2	2	1	1	1	1	2	2
				4	4	3	3	3	2	2	2	1	1
				3	2	3	1	2	2	2	1	1	1
				3	2	3	1	2	1	1	1	0	0
				1	1	1	1	1	1	1	1	1	1
				25	22	20	16	15	15	14	14	14	14
				11.Total score									
3ND		Reboxetine	Female	3	2	3	1	1	0	1	0	0	0
				4	2	2	1	1	0	1	0	0	0
				3	2	3	1	0	1	1	0	0	0
				0	2	2	2	0	0	0	0	0	0
				6	4	4	4	4	4	4	4	4	3
				4	4	3	2	2	3	2	2	1	1
				3	3	3	1	1	2	1	1	1	1
				3	2	2	0	1	1	0	1	0	0
				3	2	2	2	1	1	1	0	0	0
				2	1	1	1	1	0	0	0	0	0
				31	24	25	15	12	12	11	9	5	5
				11.Total score									
4ND		Imipramine	Female	3	3	3	1	1	1	1	1	0	0
				2	3	3	1	1	1	1	0	0	0
				2	2	2	2	2	2	2	1	1	1
				3	3	4	3	3	3	3	2	2	2
				11.Total score									

9550089

9550089

33

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63			
15	4ND	Imipramine	Female	05. INERTIA	3	2	3	0	0	0	1	0	0			
				06. INABILITY TO FEEL	3	3	3	3	2	2	1	1				
				07. PESSIMISTIC THOUGHTS	3	4	3	2	3	2	1	1				
				08. CONCENTRATIONS DIFFICULTIES	3	3	3	3	2	2	1	0				
				09. REDUCED SLEEP	4	4	2	2	2	1	0	0				
				10. REDUCED APPETITE	2	2	1	1	1	0	0	0				
				11. Total score	28	29	27	18	16	14	6	5				
				111ND	Reboxetine	Female	01. REPORTED SADNESS	5	4	4	3	4	4	4	4	4
							02. INNER TENSION	5	4	4	4	2	2	4	4	
							03. APPARENT SADNESS	5	2	2	2	4	4	4	4	
							04. SUICIDAL THOUGHTS	5	5	4	4	2	2	4	4	
05. INERTIA	4	5	3				2	2	2	4	4					
06. INABILITY TO FEEL	4	5	3				2	4	4	4	4					
07. PESSIMISTIC THOUGHTS	4	5	3				4	4	4	4	4					
08. CONCENTRATIONS DIFFICULTIES	5	4	4				4	2	2	2	2					
09. REDUCED SLEEP	2	2	2				2	2	2	2	2					
10. REDUCED APPETITE	4	2	2				2	2	2	2	2					
11. Total score	41	36	30				29	29	29	29						
1112ND	Imipramine	Female	01. REPORTED SADNESS	3	3	2	2	1	2	1	1	1				
			02. INNER TENSION	3	2	2	2	2	1	1	0					
			03. APPARENT SADNESS	3	3	1	1	2	1	2	1					
			04. SUICIDAL THOUGHTS	4	4	2	2	2	2	2	2					
			05. INERTIA	3	3	0	0	0	0	0	0					
			06. INABILITY TO FEEL	3	2	1	1	2	1	1	0					
			07. PESSIMISTIC THOUGHTS	4	4	2	2	2	3	3	2					
			08. CONCENTRATIONS DIFFICULTIES	2	3	2	2	2	1	1	1					
			09. REDUCED SLEEP	3	2	2	2	1	1	1	0					
			10. REDUCED APPETITE	1	1	1	1	1	1	0	0					
			11. Total score	29	27	15	13	16	12	11	8					
16	1ND	Reboxetine	Female	01. REPORTED SADNESS	4	2	1	1	1	1	0	0	0			
				02. INNER TENSION	4	2	2	1	1	1	1	1				
				03. APPARENT SADNESS	3	2	2	1	1	1	1	1				
				04. SUICIDAL THOUGHTS	4	3	2	2	1	1	0	1				
				05. INERTIA	4	2	2	1	0	0	1	1				
				06. INABILITY TO FEEL	3	2	2	1	1	1	1	1				
				07. PESSIMISTIC THOUGHTS	4	3	3	2	1	0	0	1				
				08. CONCENTRATIONS DIFFICULTIES	3	2	1	1	1	0	0	0				
				09. REDUCED SLEEP	2	2	2	1	1	1	1	1				
				10. REDUCED APPETITE	0	0	0	0	0	0	0	0				
				11. Total score	31	20	17	11	7	5	6	7				
1DT	Imipramine	Female	01. REPORTED SADNESS	4	4	4	4	4	4	4	4	4				
			02. INNER TENSION	4	3	3	5	3	3	5	3					
			03. APPARENT SADNESS	3	3	3	3	3	3	3	3					

15 15 27

9550089

34

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63				
16	1BT	Imipramine	Female	04.SUICIDAL THOUGHTS	4	4	5											
				05.INERTIA	4	3	2											
				06.INABILITY TO FEEL	3	2	2											
				07.PESSIMISTIC THOUGHTS	4	4	4											
				08.CONCENTRATIONS DIFFICULTIES	2	2	2											
				09.REDUCED SLEEP	2	2	3											
				10.REDUCED APPETITE	1	1	1											
				11.Total score	31	28	36											
				2ND	Imipramine	Male	01.REPORTED SADNESS	4	2	1	0	1	1	1	1	0	0	0
							02.INNER TENSION	4	2	2	1	1	1	1	1	1	0	0
							03.APPARENT SADNESS	3	2	1	1	1	1	1	1	1	1	1
04.SUICIDAL THOUGHTS	4	3	2				1	1	1	1	1	1	1	1				
05.INERTIA	4	2	2				1	1	0	0	0	0	0	0				
06.INABILITY TO FEEL	4	4	3				2	1	1	1	1	1	1	1				
07.PESSIMISTIC THOUGHTS	4	3	2				1	1	1	1	1	1	1	1				
08.CONCENTRATIONS DIFFICULTIES	2	2	1				1	1	0	0	0	0	0	0				
09.REDUCED SLEEP	3	3	2				1	1	1	1	1	1	1	1				
10.REDUCED APPETITE	1	1	2				0	0	0	0	0	0	0	0				
11.Total score	33	25	18				9	9	7	6	5							
2DT	Reboxetine	Male	01.REPORTED SADNESS	2	2	1	1	1	0	0	0	0	0	0				
			02.INNER TENSION	3	3	2	1	1	1	1	1	1	0	0				
			03.APPARENT SADNESS	3	2	2	1	1	1	1	1	1	1	0				
			04.SUICIDAL THOUGHTS	3	3	2	2	1	1	1	1	1	1	1				
			05.INERTIA	4	3	2	1	1	0	0	0	0	0	0				
			06.INABILITY TO FEEL	4	4	3	2	1	1	1	1	1	1	1				
			07.PESSIMISTIC THOUGHTS	4	4	3	3	1	1	1	1	1	1	1				
			08.CONCENTRATIONS DIFFICULTIES	2	2	1	1	0	0	0	0	0	0	0				
			09.REDUCED SLEEP	3	3	2	2	2	2	2	2	2	2	2				
			10.REDUCED APPETITE	1	1	0	0	0	0	0	0	0	0	0				
			11.Total score	29	27	18	14	4	4	4	4	4	4	4	2			
3ND	Imipramine	Female	01.REPORTED SADNESS	3	3	3	2	2	1	1	1	1	1	1				
			02.INNER TENSION	4	3	2	2	2	2	2	2	2	2	2				
			03.APPARENT SADNESS	3	3	2	2	2	2	2	2	2	2	2				
			04.SUICIDAL THOUGHTS	3	2	2	2	2	2	2	2	2	2	2				
			05.INERTIA	4	3	3	3	3	3	3	3	3	3	3				
			06.INABILITY TO FEEL	4	4	4	3	3	2	2	2	2	2	2				
			07.PESSIMISTIC THOUGHTS	4	4	4	3	2	2	2	2	2	2	2				
			08.CONCENTRATIONS DIFFICULTIES	3	3	2	1	1	1	1	1	1	1	1				
			09.REDUCED SLEEP	2	2	2	2	2	2	2	2	2	2	2				
			10.REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0	0				
			11.Total score	30	27	22	19	16	10									
3DT	Imipramine	Female	01.REPORTED SADNESS	3	2	3												
			02.INNER TENSION	3	3	3												

1528

9550089

35

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63				
16	3DT	Imipramine	Female	03.-APPARENT SADNESS	3	2	4											
				04.-SUICIDAL THOUGHTS	3	3	4											
				05.-INERTIA	3	3	4											
				06.-INABILITY TO FEEL	3	3	3											
				07.-PESSIMISTIC THOUGHTS	3	2	4											
				08.-CONCENTRATIONS DIFFICULTIES	2	2	2											
				09.-REDUCED SLEEP	2	2	3											
				10.-REDUCED APPETITE	1	1	2											
				11.-Total score	26	22	32											
				17	1MD	Reboxetine	Female	01.-REPORTED SADNESS	3	3	2	1	1	0	0	0	0	0
								02.-INNER TENSION	4	3	2	2	2	1	1	1	1	
03.-APPARENT SADNESS	3	3	3					2	2	2	1	1	1					
04.-SUICIDAL THOUGHTS	4	3	3					3	3	2	1	1	1					
05.-INERTIA	4	3	3					3	2	1	1	1	1					
06.-INABILITY TO FEEL	4	3	2					2	2	2	2	2	2					
07.-PESSIMISTIC THOUGHTS	4	3	3					2	2	2	2	2	2					
08.-CONCENTRATIONS DIFFICULTIES	2	2	1					1	1	1	0	0	0					
09.-REDUCED SLEEP	3	2	2					2	1	1	1	0	0					
10.-REDUCED APPETITE	1	1	1					0	0	0	0	0	0					
11.-Total score	32	26	21					16	12	10	7	7	9					
17	1MD	Reboxetine	Female	01.-REPORTED SADNESS	4	3	3	3	3	4	4	3	3	3				
				02.-INNER TENSION	4	3	3	3	4	4	4	4	3	3				
				03.-APPARENT SADNESS	4	4	4	4	4	4	4	4	3	3				
				04.-SUICIDAL THOUGHTS	4	4	5	4	4	4	4	4	4	4				
				05.-INERTIA	4	4	4	4	4	4	4	4	4	4				
				06.-INABILITY TO FEEL	5	5	5	5	5	4	4	4	3	3				
				07.-PESSIMISTIC THOUGHTS	4	4	4	4	4	4	4	4	3	3				
				08.-CONCENTRATIONS DIFFICULTIES	4	4	4	4	4	4	4	3	3	3				
				09.-REDUCED SLEEP	2	2	2	2	2	2	2	2	2	2				
				10.-REDUCED APPETITE	2	2	2	2	1	2	2	2	2	2				
				11.-Total score	37	35	36	35	36	33	34	31	30					
18	1DT	Reboxetine	Female	01.-REPORTED SADNESS	2	2	2	2	2	2	2	2	2	2				
				02.-INNER TENSION	2	2	2	2	2	2	2	2	2					
				03.-APPARENT SADNESS	4	3	3	3	3	3	3	3	3					
				04.-SUICIDAL THOUGHTS	0	0	0	0	0	0	0	0	0					
				05.-INERTIA	0	0	0	0	0	0	0	0	0					
				06.-INABILITY TO FEEL	4	4	4	4	4	4	4	4	4					
				07.-PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2	2	2					
				08.-CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2	2	2					
				09.-REDUCED SLEEP	2	2	2	2	2	2	2	2	2					
				10.-REDUCED APPETITE	2	2	2	2	2	2	2	2	2					
				11.-Total score	22	21	21	21	21	21	21	21	21					
2MD	1MD	Imipramine	Female	01.-REPORTED SADNESS	4	4	4	4	4	2	2	2	2	2				

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

36

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63			
17	2ND	Imipramine	Female	02.INNER TENSION	2	2	2	2	2	2	2	1	1			
				03.APPARENT SADNESS	4	4	4	4	2	2	2	2	2	1		
				04.SUICIDAL THOUGHTS	2	2	2	2	2	2	2	2	2	2		
				05.INERTIA	2	2	2	2	2	2	2	2	2	2		
				06.INABILITY TO FEEL	2	2	2	2	2	2	2	2	2	2		
				07.PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2	2	2	1	2	
				08.CONCENTRATIONS DIFFICULTIES	4	4	4	4	2	2	2	2	2	2	2	
				09.REDUCED SLEEP	2	2	2	2	2	2	2	2	2	2	2	
				10.REDUCED APPETITE	2	2	2	2	2	2	2	2	2	2	2	
				11.Total score	28	26	26	24	22	20	20	20	19	19	17	17
				20	Reboxetine	Female	01.REPORTED SADNESS	4	4	4	2	2	2	2	2	2
02.INNER TENSION	2	2	2				2	2	2	2	2	2	2			
03.APPARENT SADNESS	2	2	2				2	2	2	2	2	2	2			
04.SUICIDAL THOUGHTS	2	2	2				2	0	0	0	0	0	0			
05.INERTIA	2	2	2				2	2	2	2	2	2	2			
06.INABILITY TO FEEL	2	2	2				2	2	2	2	2	2	2			
07.PESSIMISTIC THOUGHTS	0	0	0				0	0	0	0	0	0	0			
08.CONCENTRATIONS DIFFICULTIES	2	2	2				2	2	2	2	2	2	2			
09.REDUCED SLEEP	0	0	0				0	0	0	0	0	0	0			
10.REDUCED APPETITE	2	2	2				2	2	2	2	2	2	2			
11.Total score	18	18	18				16	14	14	14	14	14	14			
30	Imipramine	Female	01.REPORTED SADNESS	5	5	5	5	5	5	5	5	5	5			
			02.INNER TENSION	4	4	4	4	4	4	4	4	4	4			
			03.APPARENT SADNESS	4	4	4	4	4	4	4	4	4	4			
			04.SUICIDAL THOUGHTS	6	6	6	6	6	6	6	6	6	6			
			05.INERTIA	4	4	4	4	4	4	4	4	4	4			
			06.INABILITY TO FEEL	4	4	4	4	4	4	4	4	4	4			
			07.PESSIMISTIC THOUGHTS	6	5	5	5	5	5	5	5	5	5			
			08.CONCENTRATIONS DIFFICULTIES	5	5	5	5	5	5	5	5	5	5			
			09.REDUCED SLEEP	3	3	3	3	3	3	3	3	3	3			
			10.REDUCED APPETITE	3	1	2	2	2	2	2	2	2	2			
			11.Total score	44	43	43	43	43	43	43	43	43	43			
30	Imipramine	Male	01.REPORTED SADNESS	4	4	4	4	4	4	4	4	4	4			
			02.INNER TENSION	4	4	4	4	4	4	4	4	4	4			
			03.APPARENT SADNESS	4	4	4	4	4	4	4	4	4	4			
			04.SUICIDAL THOUGHTS	4	4	4	4	4	4	4	4	4	4			
			05.INERTIA	2	2	2	2	2	2	2	2	2	2			
			06.INABILITY TO FEEL	6	4	4	4	4	4	4	4	4	4			
			07.PESSIMISTIC THOUGHTS	4	4	4	4	4	4	4	4	4	4			
			08.CONCENTRATIONS DIFFICULTIES	4	4	4	4	4	4	4	4	4	4			
			09.REDUCED SLEEP	4	4	4	4	4	4	4	4	4	4			
			10.REDUCED APPETITE	4	4	4	4	4	4	4	4	4	4			
			11.Total score	40	38	38	36	34	34	34	34	34	34			

9550089

37

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
17	4MD	Reboxetine	Female	01. REPORTED SADNESS	4	4	2	2	2	2	2	2	2	2	
				02. INNER TENSION	4	4	4	4	2	2	2	2	2	2	2
				03. APPARENT SADNESS	4	2	2	2	2	2	2	2	2	2	2
				04. SUICIDAL THOUGHTS	4	4	4	4	4	2	2	2	2	2	2
				05. INERTIA	4	4	4	4	2	2	2	2	2	2	2
				06. INABILITY TO FEEL	2	2	2	2	2	2	2	2	2	2	2
				07. PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2	2	2	2	2
				08. CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2	2	2	2	2
				09. REDUCED SLEEP	4	4	4	4	2	2	2	2	2	2	2
				10. REDUCED APPETITE	2	2	2	2	2	2	2	2	2	2	2
				11. Total score	32	30	28	24	22	20	20	20	20	20	20
40T	Imipramine	Female	01. REPORTED SADNESS	4	4	4	4	4	2	2	2	2	2		
			02. INNER TENSION	4	4	4	4	4	4	4	4	4	4	2	
			03. APPARENT SADNESS	4	4	4	4	4	4	4	4	4	4	2	
			04. SUICIDAL THOUGHTS	4	4	4	4	4	4	4	4	4	4	2	
			05. INERTIA	2	2	2	2	2	2	2	2	2	2	2	
			06. INABILITY TO FEEL	4	4	4	4	4	4	4	4	4	4	4	
			07. PESSIMISTIC THOUGHTS	4	4	4	4	4	4	4	4	4	4	4	
			08. CONCENTRATIONS DIFFICULTIES	4	4	4	4	4	4	4	4	4	4	4	
			09. REDUCED SLEEP	2	2	2	2	2	2	2	2	2	2	2	
			10. REDUCED APPETITE	2	2	2	2	2	2	2	2	2	2	2	
			11. Total score	34	34	32	28	26	24	24	22	22	22	22	
211MD	Reboxetine	Female	01. REPORTED SADNESS	2	2	2	2	2	2	2	2	2	2		
			02. INNER TENSION	2	2	2	2	2	2	2	2	2	2		
			03. APPARENT SADNESS	2	2	2	2	2	2	2	2	2	2		
			04. SUICIDAL THOUGHTS	2	2	2	2	2	2	2	2	2	2		
			05. INERTIA	2	2	2	2	2	2	2	2	2	2		
			06. INABILITY TO FEEL	2	2	2	2	2	2	2	2	2	2		
			07. PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2	2	2	2		
			08. CONCENTRATIONS DIFFICULTIES	4	4	4	4	4	4	4	4	4	4		
			09. REDUCED SLEEP	2	2	2	2	2	2	2	2	2	2		
			10. REDUCED APPETITE	2	2	2	2	2	2	2	2	2	2		
			11. Total score	22	22	19	18	15	16	15	14	15	14	15	
211DT	Reboxetine	Female	01. REPORTED SADNESS	2	2	2	2	2	2	2	2	2	2		
			02. INNER TENSION	4	4	4	4	4	4	4	4	4	4		
			03. APPARENT SADNESS	2	2	2	2	2	2	2	2	2	2		
			04. SUICIDAL THOUGHTS	2	2	2	2	2	2	2	2	2	2		
			05. INERTIA	4	4	4	4	4	4	4	4	4	4		
			06. INABILITY TO FEEL	2	2	2	2	2	2	2	2	2	2		
			07. PESSIMISTIC THOUGHTS	4	4	4	4	4	4	4	4	4	4		
			08. CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2	2	2	2		
			09. REDUCED SLEEP	2	2	2	2	2	2	2	2	2	2		
			10. REDUCED APPETITE	4	4	4	4	4	4	4	4	4	4		
			11. Total score	28	28	26	26	26	24	20	20	20	20		

1531

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

39

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
18	2DT	Reboxetine	Female	28	31	29	28	31					
				11.Total score									
	3MD	Reboxetine	Female	4	4	4	5	3	2	2	2		
				01.REPORTED SADNESS									
				02.INNER TENSION									
				03.APPARENT SADNESS									
				04.SUICIDAL THOUGHTS									
				05.INERTIA									
				06.INABILITY TO FEEL									
				07.PESSIMISTIC THOUGHTS									
				08.CONCENTRATIONS DIFFICULTIES									
				09.REDUCED SLEEP									
				10.REDUCED APPETITE									
				36	40	37	42	23	16	19	20		
				11.Total score									
	4MD	Reboxetine	Female	5	5	5	5	2	1	1	1	1	1
				01.REPORTED SADNESS									
				02.INNER TENSION									
				03.APPARENT SADNESS									
				04.SUICIDAL THOUGHTS									
				05.INERTIA									
				06.INABILITY TO FEEL									
				07.PESSIMISTIC THOUGHTS									
				08.CONCENTRATIONS DIFFICULTIES									
				09.REDUCED SLEEP									
				10.REDUCED APPETITE									
				43	43	41	38	16	7	7	6		
				11.Total score									
	20	3MD	Reboxetine	Female	3	3	2						
				01.REPORTED SADNESS									
				02.INNER TENSION									
				03.APPARENT SADNESS									
				04.SUICIDAL THOUGHTS									
				05.INERTIA									
				06.INABILITY TO FEEL									
				07.PESSIMISTIC THOUGHTS									
				08.CONCENTRATIONS DIFFICULTIES									
				09.REDUCED SLEEP									
				10.REDUCED APPETITE									
				18	27								
				11.Total score									
	22	1MD	Reboxetine	Female	4	6							
				01.REPORTED SADNESS									
				02.INNER TENSION									
				03.APPARENT SADNESS									
				04.SUICIDAL THOUGHTS									
				05.INERTIA									
				06.INABILITY TO FEEL									
				07.PESSIMISTIC THOUGHTS									
				08.CONCENTRATIONS DIFFICULTIES									
				09.REDUCED SLEEP									
				4	6								
				11.Total score									

15
33

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

40

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63			
22	1ND	Reboxetine	Female	10. REDUCED APPETITE	2	5											
				11. Total score	36	45											
				01. REPORTED SADNESS	6	5	4	4	2	2	3	3	3	3	3	2	
				02. INNER TENSION	6	4	4	4	4	4	4	4	4	4	4	4	3
				03. APPARENT SADNESS	5	2	2	2	2	2	3	3	3	3	3	3	1
				04. SUICIDAL THOUGHTS	1	1	0	0	0	0	0	0	0	0	0	0	0
				05. INERTIA	1	1	2	2	2	2	2	2	2	2	2	2	2
				06. INABILITY TO FEEL	4	3	4	4	4	4	4	4	4	4	4	4	4
				07. PESSIMISTIC THOUGHTS	5	2	5	5	2	2	1	1	1	1	1	1	1
				08. CONCENTRATIONS DIFFICULTIES	6	2	2	2	2	2	2	2	2	2	2	2	2
				09. REDUCED SLEEP	4	2	2	2	2	2	2	2	2	2	2	2	2
10. REDUCED SLEEP	4	2	2	2	2	2	2	2	2	2	2	2	2				
11. Total score	42	23	27	18	18	12	17	11	8								
23	1ND	Reboxetine	Female	10. REDUCED APPETITE													
				11. Total score													
				01. REPORTED SADNESS													
				02. INNER TENSION													
				03. APPARENT SADNESS													
				04. SUICIDAL THOUGHTS													
				05. INERTIA													
				06. INABILITY TO FEEL													
				07. PESSIMISTIC THOUGHTS													
				08. CONCENTRATIONS DIFFICULTIES													
				09. REDUCED SLEEP													
10. REDUCED SLEEP																	
11. Total score																	
24	2ND	Reboxetine	Female	10. REDUCED APPETITE	3	2	0	1	2	2	1	0	0	0			
				11. Total score	3	2	2	2	1	1	1	0	0	0	0		
				01. REPORTED SADNESS	4	2	2	2	1	1	1	0	0	0	0		
				02. INNER TENSION	3	3	2	2	1	1	2	2	2	2	2	4	
				03. APPARENT SADNESS	5	4	4	4	2	2	0	0	0	0	0	0	
				04. SUICIDAL THOUGHTS	4	4	2	2	2	2	2	2	2	2	2	2	
				05. INERTIA	4	3	2	2	2	2	2	2	2	2	2	2	
				06. INABILITY TO FEEL	4	4	2	2	1	1	0	0	0	0	0	0	
				07. PESSIMISTIC THOUGHTS	4	4	2	2	2	2	2	2	2	2	2	2	
				08. CONCENTRATIONS DIFFICULTIES	3	3	2	2	2	2	2	2	2	2	2	2	
				09. REDUCED SLEEP	2	2	2	2	2	2	2	2	2	2	2	2	
10. REDUCED SLEEP	4	2	2	2	2	2	2	2	2	2	2	2					
11. Total score	36	29	19	19	12	8	5	5	4								
25	3ND	Imipramine	Female	10. REDUCED APPETITE	5	4	3	2	2	1	1	1	2	2			
				11. Total score	5	3	3	3	2	1	2	1	1	1	1		
				01. REPORTED SADNESS	2	2	2	2	2	2	2	2	2	2	2		
				02. INNER TENSION	2	2	2	2	2	2	2	2	2	2	2		
				03. APPARENT SADNESS	2	2	2	2	2	2	2	2	2	2	2		
				04. SUICIDAL THOUGHTS	1	2	2	2	2	2	2	2	2	2	2		
				05. INERTIA	1	2	2	2	2	2	2	2	2	2	2		
				06. INABILITY TO FEEL	3	3	1	3	0	0	0	0	0	0	0		
				07. PESSIMISTIC THOUGHTS	4	3	2	2	2	2	2	2	2	2	2		
				08. CONCENTRATIONS DIFFICULTIES	4	4	3	2	2	2	2	2	2	2	2		
				09. REDUCED SLEEP	1	1	1	1	2	2	2	2	2	2	2		
10. REDUCED SLEEP	3	2	2	2	2	2	2	2	2	2	2						
11. Total score	30	27	21	22	17	12	14	13	11								
26	4ND	Imipramine	Female	10. REDUCED APPETITE	3	1	2	1	2	3	1	1	0	0			
				11. Total score	3	1	2	2	1	3	1	0	0	0			
				01. REPORTED SADNESS	3	1	2	1	2	1	1	0	0	0			
				02. INNER TENSION	3	1	2	2	1	1	1	0	0	0			
				03. APPARENT SADNESS	3	1	2	3	1	1	1	0	0	0			
				04. SUICIDAL THOUGHTS	3	1	2	2	2	2	0	0	0				
				05. INERTIA	3	1	1	0	0	0	0	0	0				
				06. INABILITY TO FEEL	3	2	2	2	1	3	2	1	2				
				07. PESSIMISTIC THOUGHTS	2	1	1	1	2	1	1	1	1				
				08. CONCENTRATIONS DIFFICULTIES	3	1	2	1	2	1	0	0	0				
				09. REDUCED SLEEP	2	1	2	1	2	1	1	1	1				
10. REDUCED SLEEP	3	1	2	1	2	1	1	0	0								
11. Total score	3	1	2	1	2	1	1	0	0								

9550089

1534

9550089

41

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63			
23	4ND	Imipramine	Female	09. REDUCED SLEEP	3	1	1	2	3	1	1	1	1	1			
				10. REDUCED APPETITE	2	0	1	2	1	0	1	0	0	0	0		
				11. Total score	28	10	16	16	14	15	8	5	4	4	4		
				5ND	Imipramine	Female	01. REPORTED SADNESS	3	3	4	4	4	4	4	4	4	4
							02. INNER TENSION	4	4	4	4	4	4	4	4	4	4
							03. APPARENT SADNESS	3	3	3	3	3	3	3	3	3	3
							04. SUICIDAL THOUGHTS	3	3	3	3	3	3	3	3	3	3
							05. INERTIA	2	2	2	2	2	2	2	2	2	2
							06. INABILITY TO FEEL	2	2	2	2	2	2	2	2	2	2
							07. PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2	2	2	2
							08. CONCENTRATIONS DIFFICULTIES	3	3	4	3	4	3	3	3	3	3
09. REDUCED SLEEP	4	3	4				3	3	3	3	3	3	3				
10. REDUCED APPETITE	3	2	1				2	2	1	2	2	1	2				
11. Total score	29	28	30				31	30	31	31	31	31	31	31			
6ND	Imipramine	Female	01. REPORTED SADNESS	6	5	4	4	4	4	5	6	6	6				
			02. INNER TENSION	5	5	4	4	4	4	4	4	4	4				
			03. APPARENT SADNESS	4	4	3	2	4	3	4	3	4	4				
			04. SUICIDAL THOUGHTS	2	3	3	2	3	2	4	3	4	3				
			05. INERTIA	3	4	4	4	4	4	4	4	4	4				
			06. INABILITY TO FEEL	5	6	4	5	6	5	6	5	6	5				
			07. PESSIMISTIC THOUGHTS	5	4	4	4	4	5	5	5	5	5				
			08. CONCENTRATIONS DIFFICULTIES	4	5	4	4	4	4	4	4	4	4				
			09. REDUCED SLEEP	4	2	2	2	1	1	1	1	1	1				
			10. REDUCED APPETITE	1	1	1	1	1	1	1	1	1	1				
			11. Total score	39	39	33	31	36	34	51	48	48	48				
25	1ND	Reboxetine	Male	01. REPORTED SADNESS	6	6	6	6	6	6	6	6	6				
				02. INNER TENSION	6	6	6	6	6	6	6	6	6				
				03. APPARENT SADNESS	5	5	5	5	5	5	5	5	5				
				04. SUICIDAL THOUGHTS	6	6	6	6	6	6	6	6	6				
				05. INERTIA	5	5	5	5	5	5	5	5	5				
				06. INABILITY TO FEEL	3	3	3	3	3	3	3	3	3				
				07. PESSIMISTIC THOUGHTS	3	3	3	3	3	3	3	3	3				
				08. CONCENTRATIONS DIFFICULTIES	4	4	4	4	4	4	4	4	4				
				09. REDUCED SLEEP	3	3	3	3	3	3	3	3	3				
				10. REDUCED APPETITE	2	2	2	2	2	2	2	2	2				
				11. Total score	43	43	44	49	44	46	46	46	46				
2ND	Imipramine	Female	01. REPORTED SADNESS	5	5	3	4	4	4	3	3	3	4				
			02. INNER TENSION	5	5	4	4	4	4	4	4	4	4				
			03. APPARENT SADNESS	4	4	3	3	4	3	3	3	3	4				
			04. SUICIDAL THOUGHTS	5	4	4	4	4	4	4	4	4	4				
			05. INERTIA	3	4	4	4	4	4	4	4	4	3				
			06. INABILITY TO FEEL	4	4	4	4	4	4	4	4	4	3				
			07. PESSIMISTIC THOUGHTS	3	4	4	3	3	3	3	3	3	3				

1538

9550089

42

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
25	2ND	Imipramine	Female	08. CONCENTRATIONS DIFFICULTIES	4	4	4	4	3	2	2	2	2		
				09. REDUCED SLEEP	4	4	4	3	2	2	3	3	2	2	
				10. REDUCED APPETITE	1	1	1	1	1	1	1	1	1	1	1
				11. Total score	38	39	34	33	29	30	27	28	29	29	29
26	1ND	Imipramine	Female	01. REPORTED SADNESS	3	2	1	1	1	1	2	2	2		
				02. INNER TENSION	2	2	1	1	1	2	2	2	2	2	
				03. APPARENT SADNESS	3	3	2	2	1	2	2	2	2	2	
				04. SUICIDAL THOUGHTS	2	2	2	2	1	1	1	1	1	1	
				05. INERTIA	3	2	2	0	0	1	1	1	1	1	
				06. INABILITY TO FEEL	4	3	3	3	2	3	3	3	3	3	3
				07. PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2	2	2	2	2
				08. CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	2	2	2	2	2	2
				09. REDUCED SLEEP	2	2	2	1	1	1	1	1	2	2	2
				10. REDUCED APPETITE	1	0	0	0	0	0	0	0	0	0	0
				11. Total score	24	20	17	13	10	17	17	17	17	17	17
27	1ND	Imipramine	Male	01. REPORTED SADNESS	6	6	6	6	6	6	6	6	6		
				02. INNER TENSION	2	2	2	2	2	2	2	2	2	2	
				03. APPARENT SADNESS	3	3	3	3	3	3	3	3	3	3	
				04. SUICIDAL THOUGHTS	3	3	3	3	3	3	3	3	3	3	
				05. INERTIA	3	3	3	3	3	3	3	3	3	3	
				06. INABILITY TO FEEL	3	3	3	3	3	3	3	3	3	3	
				07. PESSIMISTIC THOUGHTS	3	3	3	3	3	3	3	3	3	3	
				08. CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2	2	2	2	
				09. REDUCED SLEEP	2	2	2	2	2	2	2	2	2	2	
				10. REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0	
				11. Total score	23	24	24	22	20	20	20	20	20	20	
28	1ND	Reboxetine	Female	01. REPORTED SADNESS	3	3	2	1	1	1	0	0	0		
				02. INNER TENSION	1	2	1	0	0	0	0	0	0		
				03. APPARENT SADNESS	1	1	1	1	1	1	1	1	1		
				04. SUICIDAL THOUGHTS	0	0	0	0	0	0	0	0	0		
				05. INERTIA	0	0	0	0	0	0	0	0	0		
				06. INABILITY TO FEEL	0	0	0	0	0	0	0	0	0		
				07. PESSIMISTIC THOUGHTS	4	4	4	4	4	4	4	4	4		
				08. CONCENTRATIONS DIFFICULTIES	4	4	4	4	4	4	4	4	4		
				09. REDUCED SLEEP	3	3	3	3	3	3	3	3	3		
				10. REDUCED APPETITE	5	5	5	5	5	5	5	5	5		
				11. Total score	43	46	43	43	43	43	43	43	43		

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63				
28	1M0	Reboxetine	Female	07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	0	0	0				
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	1	1	1	1					
				09.REDUCED SLEEP	2	2	2	2	2	1	1	1					
				10.REDUCED APPETITE	0	0	0	0	0	0	0	0					
				11.Total score	11	12	10	6	6	6	3	3	3				
				10T	Imipramine	Female	01.REPORTED SADNESS	1	1	1	1	1	0	1	1	1	1
							02.INNER TENSION	2	1	1	1	1	0	1	1	1	1
							03.APPARENT SADNESS	2	2	2	2	1	1	0	0	0	0
							04.SUICIDAL THOUGHTS	2	2	2	2	1	1	1	1	1	1
							05.INERTIA	0	0	0	0	0	0	0	0	0	0
							06.INABILITY TO FEEL	2	2	2	2	2	1	1	1	1	1
07.PESSIMISTIC THOUGHTS	2	2	2				2	2	1	1	1	1	1				
08.CONCENTRATIONS DIFFICULTIES	1	1	1				1	1	0	0	0	0	0				
09.REDUCED SLEEP	1	1	1				1	1	1	1	1	1	1				
10.REDUCED APPETITE	0	0	0				0	0	0	0	0	0	0				
11.Total score	13	12	12				12	9	5	5	6	6	6				
2ND	Imipramine	Female	01.REPORTED SADNESS	3	2	2	2	1	0	0	0	0	0				
			02.INNER TENSION	3	2	2	2	1	1	1	1	1	1				
			03.APPARENT SADNESS	2	1	1	1	0	0	0	0	0	0				
			04.SUICIDAL THOUGHTS	1	1	1	1	0	0	0	0	0	0				
			05.INERTIA	0	0	0	0	0	0	0	0	0	0				
			06.INABILITY TO FEEL	0	0	0	0	0	0	0	0	0	0				
			07.PESSIMISTIC THOUGHTS	2	2	2	2	1	1	1	1	1	1				
			08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	1	1	1	1	1				
			09.REDUCED SLEEP	2	2	2	2	2	1	1	1	1	1				
			10.REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0				
			11.Total score	15	18	12	12	5	4	4	4	4	4				
2DT	Reboxetine	Male	01.REPORTED SADNESS	1	1	0	0	0	0	0	0	0	0				
			02.INNER TENSION	1	1	0	0	0	0	0	0	0	0				
			03.APPARENT SADNESS	3	3	2	2	1	1	0	0	0	0				
			04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0	0	0	0				
			05.INERTIA	0	0	0	0	0	0	0	0	0	0				
			06.INABILITY TO FEEL	1	2	1	1	0	0	0	0	0	0				
			07.PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1	1	1	1				
			08.CONCENTRATIONS DIFFICULTIES	0	0	0	0	0	0	0	0	0	0				
			09.REDUCED SLEEP	1	1	1	1	1	1	0	0	0	0				
			10.REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0				
			11.Total score	9	10	6	6	4	3	2	2	2	2				
3ND	Reboxetine	Female	01.REPORTED SADNESS	3	3	3	3	2	1	0	0	0	0				
			02.INNER TENSION	3	3	3	3	1	0	0	0	0	0				
			03.APPARENT SADNESS	1	1	1	1	0	0	0	0	0	0				
			04.SUICIDAL THOUGHTS	1	1	1	1	1	1	1	1	1	1				
			05.INERTIA	0	0	0	0	0	0	0	0	0	0				

9550089

1537

9550089

44

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RSD
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63					
28	3ND	Reboxetine	Female	06. INABILITY TO FEEL	0	0	0	0	0	0	0	0	0	0					
				07. PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1	1	1	1	1	1			
				08. CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2	2	2	2	2	2			
				09. REDUCED SLEEP	1	1	1	1	1	1	1	1	1	1	1	1			
				10. REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0	0	0			
				11. Total score	12	12	12	12	8	3	2	2	2	2	2	2			
				30T	Imipramine	Male	01. REPORTED SADNESS	2	2	1	0	0	0	0	0	0	0	0	
							02. INNER TENSION	1	1	0	0	0	0	0	0	0	0	0	
							03. APPARENT SADNESS	1	1	1	0	0	0	0	0	0	0	0	
							04. SUICIDAL THOUGHTS	1	1	1	1	1	1	1	1	1	1	1	1
							05. INERTIA	0	0	0	0	0	0	0	0	0	0	0	0
06. INABILITY TO FEEL	2	2	2				2	2	2	2	2	2	2	2	2				
07. PESSIMISTIC THOUGHTS	2	2	2				2	2	2	2	2	2	2	2	2				
08. CONCENTRATIONS DIFFICULTIES	1	1	1				1	1	1	1	1	1	1	1	1				
09. REDUCED SLEEP	0	0	0				0	0	0	0	0	0	0	0	0				
10. REDUCED APPETITE	0	0	0				0	0	0	0	0	0	0	0	0				
11. Total score	10	10	8				6	6	6	6	6	6	6	6	6				
4ND	Imipramine	Male	01. REPORTED SADNESS	3	3	3	2	2	1	1	1	1	0	0					
			02. INNER TENSION	3	3	3	2	1	1	1	1	1	1	0					
			03. APPARENT SADNESS	2	2	2	2	1	1	0	0	0	0	0					
			04. SUICIDAL THOUGHTS	2	2	2	1	0	0	0	0	0	0	0					
			05. INERTIA	0	0	0	0	0	0	0	0	0	0	0					
			06. INABILITY TO FEEL	1	1	1	1	1	1	1	1	1	1	1	1				
			07. PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1	1	1	1	1	1				
			08. CONCENTRATIONS DIFFICULTIES	1	1	1	1	1	1	1	1	1	1	1	1				
			09. REDUCED SLEEP	2	2	2	2	1	1	1	1	1	1	1	1				
			10. REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0	0	0				
			11. Total score	15	15	15	10	6	5	4	4	4	4	4	4				
5ND	Reboxetine	Female	01. REPORTED SADNESS	2	2	2	2	1	1	1	1	1	0	0					
			02. INNER TENSION	2	2	2	2	1	1	1	1	1	1	0					
			03. APPARENT SADNESS	1	1	1	1	0	0	0	0	0	0	0					
			04. SUICIDAL THOUGHTS	1	1	1	1	1	1	1	1	1	1	1					
			05. INERTIA	2	1	1	0	0	0	0	0	0	0	0					
			06. INABILITY TO FEEL	1	1	1	1	1	1	1	1	1	1	1					
			07. PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1	1	1	1	1					
			08. CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2	2	2	2	2					
			09. REDUCED SLEEP	2	1	1	1	1	1	1	1	1	1	1					
			10. REDUCED APPETITE	0	1	1	1	1	1	1	1	1	1	1					
			11. Total score	13	13	13	10	8	8	7	7	7	7	7					
30	1ND	Imipramine	Female	01. REPORTED SADNESS	5	5	3	1	1	0	0	0	0						
				02. INNER TENSION	6	4	3	2	1	0	0	0							
				03. APPARENT SADNESS	5	4	3	2	1	1	1	0							
				04. SUICIDAL THOUGHTS	4	2	2	1	1	0	0	0							

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

45

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
30	1ND	Imipramine	Female	05. INERTIA	3	2	2	1	0	0	0	0	0	0		
				06. INABILITY TO FEEL	4	4	3	2	1	0	0	0	0	0	0	
				07. PESSIMISTIC THOUGHTS	4	4	3	2	1	0	1	1	1	0	0	
				08. CONCENTRATIONS DIFFICULTIES	4	4	3	2	1	0	0	0	0	0	0	
				09. REDUCED SLEEP	3	2	1	2	0	0	0	0	0	0	0	
				10. REDUCED APPETITE	1	0	0	0	0	0	0	0	0	0	0	
				11. Total score	39	31	23	15	7	2	1	1	1	1	1	1
				01. REPORTED SADNESS	5											
				02. INNER TENSION	4											
				03. APPARENT SADNESS	4											
				04. SUICIDAL THOUGHTS	3											
2ND	Reboxetine	Female	05. INERTIA	2												
			06. INABILITY TO FEEL	2												
			07. PESSIMISTIC THOUGHTS	4												
			08. CONCENTRATIONS DIFFICULTIES	3												
			09. REDUCED SLEEP	3												
			10. REDUCED APPETITE	2												
			11. Total score	35												
			01. REPORTED SADNESS	5												
			02. INNER TENSION	4												
			03. APPARENT SADNESS	4												
			04. SUICIDAL THOUGHTS	3												
3ND	Imipramine	Female	05. INERTIA	3	3	3	3	3	1	1	1	1	1			
			06. INABILITY TO FEEL	3	3	3	3	2	2	1	1	1	1			
			07. PESSIMISTIC THOUGHTS	4	4	3	3	2	2	1	1	1	1			
			08. CONCENTRATIONS DIFFICULTIES	4	4	3	3	2	2	1	1	1	1			
			09. REDUCED SLEEP	3	3	2	2	2	1	1	1	1	1			
			10. REDUCED APPETITE	2	2	2	2	2	1	1	1	1	1			
			11. Total score	33	33	28	31	17	7	9	5	5	5	5		
			01. REPORTED SADNESS	5												
			02. INNER TENSION	4												
			03. APPARENT SADNESS	4												
			04. SUICIDAL THOUGHTS	3												
4ND	Reboxetine	Female	05. INERTIA	5	5	1	0	0	1	1	0	0	0			
			06. INABILITY TO FEEL	1	2	0	0	0	0	0	0	0	0			
			07. PESSIMISTIC THOUGHTS	3	3	0	4	1	1	0	0	0	0			
			08. CONCENTRATIONS DIFFICULTIES	3	3	1	2	2	2	0	0	0	0			
			09. REDUCED SLEEP	5	5	0	3	1	2	0	0	0	0			
			10. REDUCED APPETITE	3	3	0	0	0	0	0	0	0	0			
			11. Total score	33	38	3	17	9	4	4	4	4	4	4		
			01. REPORTED SADNESS	6												
			02. INNER TENSION	4												
			03. APPARENT SADNESS	4												
			04. SUICIDAL THOUGHTS	3												
5ND	Imipramine	Female	05. INERTIA	6	4											
			06. INABILITY TO FEEL	4	3											
			07. PESSIMISTIC THOUGHTS	4	3											
			08. CONCENTRATIONS DIFFICULTIES	4	3											
			09. REDUCED SLEEP	4	3											
			10. REDUCED APPETITE	4	3											
			11. Total score	44	33											
			01. REPORTED SADNESS	6												
			02. INNER TENSION	4												
			03. APPARENT SADNESS	4												
			04. SUICIDAL THOUGHTS	3												

9550089

1539

9550089

47

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63			
31	3MD	Imipramine	Male	03. APPARENT SADNESS	4												
				04. SUICIDAL THOUGHTS	6												
				05. INERTIA	5												
				06. INABILITY TO FEEL	4												
				07. PESSIMISTIC THOUGHTS	5												
				08. CONCENTRATIONS DIFFICULTIES	0												
				09. REDUCED SLEEP	4												
				10. REDUCED APPETITE	4												
				11. Total score	44												
				01. REPORTED SADNESS	4	3	2	1	0	0	0	0	0	0	0	0	0
				02. INNER TENSION	4	3	2	2	1	1	0	0	0	0	0	0	0
03. APPARENT SADNESS	3	2	2	1	1	0	0	0	0	0	0	0	0				
04. SUICIDAL THOUGHTS	5	4	3	4	4	4	4	4	4	4	4	4	2				
05. INERTIA	3	3	2	3	0	3	0	2	2	2	2	2	2				
06. INABILITY TO FEEL	3	2	1	2	0	0	0	0	0	0	0	0	1				
07. PESSIMISTIC THOUGHTS	2	2	1	2	1	0	0	0	0	0	0	0	0				
08. CONCENTRATIONS DIFFICULTIES	2	2	1	1	0	0	0	0	0	0	0	0	0				
09. REDUCED SLEEP	2	1	0	1	0	0	0	0	0	0	0	0	0				
10. REDUCED APPETITE	2	1	0	1	0	0	0	0	0	0	0	0	0				
11. Total score	30	23	14	18	6	7	4	4	4	4	4	4	5				
32	1MD	Imipramine	Female	01. REPORTED SADNESS	3	4	0	1	0	0	0	0	0	0			
				02. INNER TENSION	3	4	0	1	0	0	0	0	0	0	0		
				03. APPARENT SADNESS	3	0	2	1	0	3	0	0	0	0	0		
				04. SUICIDAL THOUGHTS	3	0	1	0	0	1	0	0	0	0	0		
				05. INERTIA	0	3	0	2	2	2	2	2	2	2	2		
				06. INABILITY TO FEEL	3	2	2	0	0	2	0	2	2	2	2		
				07. PESSIMISTIC THOUGHTS	3	2	2	1	1	1	1	1	1	1	1	1	
				08. CONCENTRATIONS DIFFICULTIES	1	3	1	0	0	1	0	0	0	0	0	0	
				09. REDUCED SLEEP	2	1	0	1	0	1	0	0	0	0	0	0	
				10. REDUCED APPETITE	2	1	0	1	0	0	0	0	0	0	0	0	
				11. Total score	22	21	7	7	3	9	4	4	4	4	4	4	
33	2MD	Imipramine	Female	01. REPORTED SADNESS	3	4	0	1	0	0	0	0	0	0			
				02. INNER TENSION	3	4	0	1	0	0	0	0	0	0	0		
				03. APPARENT SADNESS	3	0	2	1	0	3	0	0	0	0	0		
				04. SUICIDAL THOUGHTS	3	0	1	0	0	1	0	0	0	0	0		
				05. INERTIA	0	3	0	2	2	2	2	2	2	2	2		
				06. INABILITY TO FEEL	3	2	2	0	0	2	0	2	2	2	2		
				07. PESSIMISTIC THOUGHTS	3	2	2	1	1	1	1	1	1	1	1	1	
				08. CONCENTRATIONS DIFFICULTIES	1	3	1	0	0	1	0	0	0	0	0		
				09. REDUCED SLEEP	2	1	0	1	0	1	0	0	0	0	0		
				10. REDUCED APPETITE	2	1	0	1	0	0	0	0	0	0	0		
				11. Total score	22	21	7	7	3	9	4	4	4	4	4	4	
34	3MD	Reboxetine	Female	01. REPORTED SADNESS	4	4	4	4	4	3	3	3	3	4			
				02. INNER TENSION	4	4	4	4	4	4	4	4	3	3	4		
				03. APPARENT SADNESS	4	3	3	3	3	3	2	2	2	2	3		
				04. SUICIDAL THOUGHTS	4	4	5	4	4	4	3	3	3	3	3		
				05. INERTIA	3	3	3	3	3	2	2	2	2	2	2		
				06. INABILITY TO FEEL	4	4	4	3	3	3	3	3	3	3	3		
				07. PESSIMISTIC THOUGHTS	3	2	2	3	3	3	2	2	2	2	2		
				08. CONCENTRATIONS DIFFICULTIES	3	3	3	3	3	3	3	3	3	3	3		
				09. REDUCED SLEEP	2	2	2	2	2	2	2	2	2	2	2		
				10. REDUCED APPETITE	3	3	3	3	3	3	2	2	2	2	2		
				11. Total score	34	32	33	32	31	26	22	22	22	23	23	28	
35	4MD	Reboxetine	Female	01. REPORTED SADNESS	4	4	3	4	4	3	3	3	4				
				02. INNER TENSION	4	4	4	4	4	4	4	4	4	4			
				03. APPARENT SADNESS	4	3	3	3	3	3	2	2	2	2			
				04. SUICIDAL THOUGHTS	4	4	5	4	4	4	3	3	3	3			
				05. INERTIA	3	3	3	3	3	2	2	2	2	2			
				06. INABILITY TO FEEL	4	4	4	3	3	3	3	3	3	3			
				07. PESSIMISTIC THOUGHTS	3	2	2	3	3	3	2	2	2	2			
				08. CONCENTRATIONS DIFFICULTIES	3	3	3	3	3	3	3	3	3	3			
				09. REDUCED SLEEP	2	2	2	2	2	2	2	2	2	2			
				10. REDUCED APPETITE	3	3	3	3	3	3	2	2	2	2			
				11. Total score	34	32	33	32	31	26	22	22	23	23	28		

1541

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

48

9550089

PHARMACIA CNS RSD

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
32	4MD	Reboxetine	Female	02. INNER TENSION	4	4	3	4					
				03. APPARENT SADNESS	3	3	3	4					
				04. SUICIDAL THOUGHTS	4	4	4	4					
				05. INERTIA	0	2	0	1					
				06. INABILITY TO FEEL	3	3	3	4					
				07. PESSIMISTIC THOUGHTS	4	4	3	4					
				08. CONCENTRATIONS DIFFICULTIES	3	3	3	4					
				09. REDUCED SLEEP	2	2	2	2					
				10. REDUCED APPETITE	2	1	2	2					
				11. Total score	29	29	25	32					
				5ND	Reboxetine	Female	01. REPORTED SADNESS	3	4	3	3	4	
02. INNER TENSION	3	3	3				3						
03. APPARENT SADNESS	4	3	3				3						
04. SUICIDAL THOUGHTS	3	3	1				1						
05. INERTIA	4	3	2				2						
06. INABILITY TO FEEL	3	3	2				2						
07. PESSIMISTIC THOUGHTS	3	2	3				3						
08. CONCENTRATIONS DIFFICULTIES	2	3	2				2						
09. REDUCED SLEEP	1	1	0				0						
10. REDUCED APPETITE	1	2	1				2						
11. Total score	27	27	20				21	26					
6ND	Imipramine	Male	01. REPORTED SADNESS	4	4	4	4	4			4	4	4
			02. INNER TENSION	4	4	4	4	4			4	4	4
			03. APPARENT SADNESS	4	4	4	4	4			4	4	4
			04. SUICIDAL THOUGHTS	2	1	2	2	2			2	2	2
			05. INERTIA	1	0	0	0	0			0	0	0
			06. INABILITY TO FEEL	3	3	4	3	4			3	3	3
			07. PESSIMISTIC THOUGHTS	2	4	4	4	4			4	4	4
			08. CONCENTRATIONS DIFFICULTIES	2	2	2	2	3			2	2	2
			09. REDUCED SLEEP	0	1	1	1	1			1	1	0
			10. REDUCED APPETITE	3	3	2	2	3			2	2	3
			11. Total score	23	26	27	25	29	26			26	26
35	1ND	Reboxetine	Female	01. REPORTED SADNESS	5	5	4	5					
				02. INNER TENSION	6	5	5	5					
				03. APPARENT SADNESS	3	4	3	3					
				04. SUICIDAL THOUGHTS	4	0	0	0					
				05. INERTIA	5	4	3	3					
				06. INABILITY TO FEEL	5	4	4	4					
				07. PESSIMISTIC THOUGHTS	4	4	3	5					
				08. CONCENTRATIONS DIFFICULTIES	4	4	4	4					
				09. REDUCED SLEEP	5	5	4	4					
				10. REDUCED APPETITE	3	1	1	3					
				11. Total score	44	36	31	37					

15/2

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

50

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63			
35	30T	Imipramine	Male	Montgomery Asberg Depression Rating Scale												
				01.REPORTED SADNESS	2	1	0	0	0	0	0	0	0	1	1	0
				02.INNER TENSION	3	1	0	0	0	0	0	0	0	0	1	1
				03.APPARENT SADNESS	2	0	1	1	1	0	0	0	0	3	3	1
				04.SUICIDAL THOUGHTS	3	1	0	0	0	0	0	0	0	2	2	1
				05.INERTIA	2	0	0	0	0	0	0	0	0	0	2	1
				06.INABILITY TO FEEL	3	1	0	0	0	0	0	0	0	0	1	0
				07.PESSIMISTIC THOUGHTS	3	1	0	0	0	0	0	0	0	0	1	0
				08.CONCENTRATIONS DIFFICULTIES	2	1	0	0	0	0	0	0	0	0	0	0
				09.REDUCED SLEEP	1	1	1	0	1	0	0	0	0	0	1	1
				10.REDUCED APPETITE	1	1	1	0	0	0	0	0	0	0	1	1
11.Total score	22	8	2	2	1	2	0	0	0	0	12	6				
4HD	Reboxetine	Male	Montgomery Asberg Depression Rating Scale													
			01.REPORTED SADNESS	4	4	4	4	3	3	3	3	3	3	3	3	
			02.INNER TENSION	4	4	4	4	2	2	2	2	2	2	2	2	
			03.APPARENT SADNESS	3	1	2	2	2	2	2	2	2	2	2	2	
			04.SUICIDAL THOUGHTS	4	4	3	3	3	3	3	3	3	3	3	2	
			05.INERTIA	3	2	2	2	2	2	2	2	2	2	2	2	
			06.INABILITY TO FEEL	2	1	0	0	0	0	0	0	0	0	0	0	
			07.PESSIMISTIC THOUGHTS	3	2	4	2	3	3	3	3	3	3	3	2	
			08.CONCENTRATIONS DIFFICULTIES	3	3	4	3	3	3	3	3	3	3	2	2	
			09.REDUCED SLEEP	2	3	4	2	3	2	2	2	2	2	2	2	
			10.REDUCED APPETITE	2	1	1	1	1	1	1	1	1	1	0	0	
11.Total score	28	25	23	20	23	21	21	21	22	21	21	18				
4UT	Reboxetine	Female	Montgomery Asberg Depression Rating Scale													
			01.REPORTED SADNESS	3	2	2	2	2	2	2	2	2	1	1	1	
			02.INNER TENSION	3	3	2	2	2	2	2	2	2	2	2	2	
			03.APPARENT SADNESS	3	3	3	3	3	3	3	3	3	3	3	3	
			04.SUICIDAL THOUGHTS	3	3	2	2	2	2	2	2	2	2	1	1	
			05.INERTIA	3	2	2	2	2	2	2	2	2	1	1	0	
			06.INABILITY TO FEEL	3	2	2	2	2	2	2	2	2	1	1	1	
			07.PESSIMISTIC THOUGHTS	4	3	2	2	2	2	2	2	2	2	2	2	
			08.CONCENTRATIONS DIFFICULTIES	4	3	2	2	2	2	2	2	2	1	1	0	
			09.REDUCED SLEEP	2	2	2	2	2	2	2	2	2	1	1	0	
			10.REDUCED APPETITE	4	2	2	1	1	1	1	1	1	1	1	1	
11.Total score	32	25	21	20	18	19	17	14	14	12	12	12				
5ND	Reboxetine	Male	Montgomery Asberg Depression Rating Scale													
			01.REPORTED SADNESS	5	1	2	2	2	2	2	2	2	2	2	1	
			02.INNER TENSION	5	1	3	4	4	4	4	4	4	3	2	2	
			03.APPARENT SADNESS	4	1	2	3	3	3	3	3	3	2	2	1	
			04.SUICIDAL THOUGHTS	3	2	3	3	3	3	3	3	3	2	2	3	
			05.INERTIA	3	2	2	1	2	2	2	2	2	1	0	0	
			06.INABILITY TO FEEL	1	0	1	0	0	0	0	0	0	0	1	0	
			07.PESSIMISTIC THOUGHTS	2	1	1	2	2	2	2	2	2	2	2	2	
			08.CONCENTRATIONS DIFFICULTIES	4	1	1	2	2	2	2	2	2	2	2	2	
			09.REDUCED SLEEP	4	2	2	3	3	3	3	3	3	2	2	1	
			10.REDUCED APPETITE	2	1	2	2	1	0	2	2	2	1	1	1	

1544

9550089

51

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
35	5HD	Reboxetine	Male	33	12	19	20	23	22	18	14	12	
			11.Total score										
	5DT	Imipramine	Female	3	1	0	0	1	1	0	0	1	
			01.REPORTED SADNESS										
			02.INNER TENSION										
			03.APPARENT SADNESS										
			04.SUICIDAL THOUGHTS										
			05.INERTIA										
			06.INABILITY TO FEEL										
			07.PESSIMISTIC THOUGHTS										
			08.CONCENTRATIONS DIFFICULTIES										
			09.REDUCED SLEEP										
			10.REDUCED APPETITE										
			11.Total score	21	11	4	4	5	4	6	4	13	
	6HD	Reboxetine	Female	1	1	2	1	2	2	2			
			01.REPORTED SADNESS										
			02.INNER TENSION										
			03.APPARENT SADNESS										
			04.SUICIDAL THOUGHTS										
			05.INERTIA										
			06.INABILITY TO FEEL										
			07.PESSIMISTIC THOUGHTS										
			08.CONCENTRATIONS DIFFICULTIES										
			09.REDUCED SLEEP										
			10.REDUCED APPETITE										
			11.Total score	22	13	13	18	17	17	25			
	6DT	Imipramine	Female	5	3	1	1	1	1	1	0	0	
			01.REPORTED SADNESS										
			02.INNER TENSION										
			03.APPARENT SADNESS										
			04.SUICIDAL THOUGHTS										
			05.INERTIA										
			06.INABILITY TO FEEL										
			07.PESSIMISTIC THOUGHTS										
			08.CONCENTRATIONS DIFFICULTIES										
			09.REDUCED SLEEP										
			10.REDUCED APPETITE										
			11.Total score	39	26	14	11	11	6	5	1	0	
	7HD	Imipramine	Female	5	3	2	1	2	2	2			
			01.REPORTED SADNESS										
			02.INNER TENSION										
			03.APPARENT SADNESS										
			04.SUICIDAL THOUGHTS										
			05.INERTIA										
			06.INABILITY TO FEEL										
			07.PESSIMISTIC THOUGHTS										
			08.CONCENTRATIONS DIFFICULTIES										
			09.REDUCED SLEEP										
			10.REDUCED APPETITE										
			11.Total score	39	26	14	11	11	6	5	1	0	

1545

9550089

52

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
35	74D	Imipramine	Female	10. REDUCED APPETITE 11. Total score	1 38	0 22	0 19	0 13	0 12	0 16	0 20			
	70T	Reboxetine	Female	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS 05. INERTIA 06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS 08. CONCENTRATIONS DIFFICULTIES 09. REDUCED SLEEP 10. REDUCED APPETITE 11. Total score	5 4 6 3 3 3 4 3 2 36	5 4 4 3 3 2 5 3 2 36	3 2 3 3 2 3 3 4 4 26	3 3 3 3 2 2 3 3 1 27	2 3 4 3 1 2 3 3 3 23					
	84D	Imipramine	Female	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS 05. INERTIA 06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS 08. CONCENTRATIONS DIFFICULTIES 09. REDUCED SLEEP 10. REDUCED APPETITE 11. Total score	4 4 3 4 2 4 3 4 3 35	4 4 3 4 2 4 3 2 4 35	3 4 3 3 2 3 2 4 3 30	2 3 3 3 2 2 3 3 2 25	2 3 3 3 2 2 2 3 3 25	2 3 3 3 2 2 2 3 3 25	3 4 3 2 2 2 2 4 3 28	3 4 3 2 2 2 2 4 3 28		
1546	80T	Reboxetine	Female	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS 05. INERTIA 06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS 08. CONCENTRATIONS DIFFICULTIES 09. REDUCED SLEEP 10. REDUCED APPETITE 11. Total score	3 2 3 4 2 4 3 3 2 26	3 2 4 3 2 4 3 3 2 27	3 2 4 3 2 4 3 3 2 26	2 2 2 1 1 2 2 2 2 16	1 2 2 0 1 2 2 2 3 15	1 1 2 0 1 2 2 2 2 12	2 2 2 0 1 2 2 2 1 13	2 2 2 0 1 2 2 3 2 14	2 2 2 0 1 2 2 2 2 15	
	14D	Imipramine	Male	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS 05. INERTIA 06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS 08. CONCENTRATIONS DIFFICULTIES	5 4 2 4 2 1 4 3	4 3 2 3 2 1 3 3	2 2 1 0 1 1 1 1	1 0 0 1 0 1 1 0	1 0 0 1 0 1 1 0	1 0 0 1 1 1 1 0	1 0 0 0 1 1 1 0	1 0 0 0 1 1 1 0	0 0 0 0 1 1 1 0	0 0 0 0 1 1 1 0

9550089

53

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63				
36	1HD	Imipramine	Male	09. REDUCED SLEEP	4	2	1	0	0	0	0	0	0				
				10. REDUCED APPETITE	6	3	1	1	1	1	1	1	1	0			
				11. Total score	35	26	11	6	5	5	5	1					
				1DT	Imipramine	Female	01. REPORTED SADNESS	4	4	3	2	0	0	0	0	0	0
							02. INNER TENSION	4	3	2	1	1	1	1	1	1	1
							03. APPARENT SADNESS	3	3	2	1	0	0	0	0	0	0
							04. SUICIDAL THOUGHTS	2	2	1	1	2	1	1	1	1	1
							05. INERTIA	3	2	1	1	0	0	0	0	0	0
							06. INABILITY TO FEEL	2	2	1	1	0	0	0	0	0	0
							07. PESSIMISTIC THOUGHTS	4	4	3	2	1	1	1	1	1	1
							08. CONCENTRATIONS DIFFICULTIES	4	4	3	2	0	0	0	0	0	0
09. REDUCED SLEEP	2	2	1				0	0	0	0	0	0	0				
10. REDUCED APPETITE	1	1	1				0	0	0	0	0	0	0				
11. Total score	29	27	18				11	4	3	3	3	3	3	3			
2HD	Reboxetine	Female	01. REPORTED SADNESS	5	3	3	3	5	5	3	3	3	3				
			02. INNER TENSION	4	3	3	2	4	4	3	3	3	3				
			03. APPARENT SADNESS	2	2	2	2	2	2	2	2	2	2				
			04. SUICIDAL THOUGHTS	4	2	2	2	2	2	2	2	2	2				
			05. INERTIA	2	2	2	2	2	2	2	2	2	2				
			06. INABILITY TO FEEL	4	1	1	1	1	1	1	1	1	1				
			07. PESSIMISTIC THOUGHTS	3	3	3	3	3	3	3	2	2	2				
			08. CONCENTRATIONS DIFFICULTIES	4	3	3	3	3	3	2	2	2	2				
			09. REDUCED SLEEP	1	3	2	2	2	2	1	1	1	1				
			10. REDUCED APPETITE	1	1	1	1	3	2	1	1	1	1				
			11. Total score	30	23	22	21	28	27	20	20	20	20				
2DT	Reboxetine	Female	01. REPORTED SADNESS	3	2	2	1	1	1	0	0	0	0				
			02. INNER TENSION	3	2	2	1	1	1	0	0	0	0				
			03. APPARENT SADNESS	2	1	1	1	1	0	0	0	0	0				
			04. SUICIDAL THOUGHTS	3	3	3	3	2	1	1	1	1	1				
			05. INERTIA	0	0	0	0	0	0	0	0	0	0				
			06. INABILITY TO FEEL	3	3	3	3	2	1	1	1	1	1				
			07. PESSIMISTIC THOUGHTS	4	3	3	3	2	0	0	0	0	0				
			08. CONCENTRATIONS DIFFICULTIES	4	3	3	3	2	0	0	0	0	0				
			09. REDUCED SLEEP	2	2	2	2	2	0	0	0	0	0				
			10. REDUCED APPETITE	1	1	1	1	1	0	0	0	0	0				
			11. Total score	25	20	20	17	14	3	2	2	2	2				
3HD	Imipramine	Female	01. REPORTED SADNESS	5	5	3	4	4	4	4	4	4	4				
			02. INNER TENSION	4	4	3	3	3	3	3	3	3	3				
			03. APPARENT SADNESS	4	4	2	2	2	2	2	2	2	2				
			04. SUICIDAL THOUGHTS	3	3	1	1	1	1	1	1	1	1				
			05. INERTIA	4	4	4	4	4	4	4	4	4	4				
			06. INABILITY TO FEEL	4	3	3	3	3	3	3	3	3	3				
			07. PESSIMISTIC THOUGHTS	5	4	4	4	4	4	4	4	4	4				

1547

9550089

54

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63				
36	3ND	Imipramine	Female	08. CONCENTRATIONS DIFFICULTIES	4	4	3	3	3	3	3	3	3	3				
				09. REDUCED SLEEP	2	2	2	2	2	2	2	2	2	2	2			
				10. REDUCED APPETITE	3	3	2	2	2	1	1	1	1	1	1	1		
				11. Total score	38	36	27	28	28	26	26	26	26	26	26	26		
				3DT	Imipramine	Female	01. REPORTED SADNESS	4	3	1	0	0	0	0	0	0	0	0
							02. INNER TENSION	4	3	1	0	0	0	0	0	0	0	0
							03. APPARENT SADNESS	4	2	1	1	1	0	0	0	0	0	0
							04. SUICIDAL THOUGHTS	3	2	1	1	1	1	1	1	1	1	1
							05. INERTIA	3	1	0	0	0	0	0	0	0	0	0
							06. INABILITY TO FEEL	2	2	2	2	2	0	0	0	0	0	0
							07. PESSIMISTIC THOUGHTS	2	2	2	1	2	0	0	0	0	0	0
08. CONCENTRATIONS DIFFICULTIES	2	2	1				0	1	0	0	0	0	0	0				
09. REDUCED SLEEP	3	2	1				1	0	0	0	0	0	0	0				
10. REDUCED APPETITE	1	1	0				0	0	0	0	0	0	0	0				
11. Total score	26	20	10				6	8	1	1	1	1	1	0	0			
4ND	Reboxetine	Female	01. REPORTED SADNESS	4	4	3	2	2	3	3	3	3	3	5				
			02. INNER TENSION	4	4	4	4	3	3	3	3	3	3	3				
			03. APPARENT SADNESS	4	4	4	4	3	3	2	2	2	2	3				
			04. SUICIDAL THOUGHTS	3	3	2	2	2	2	2	2	2	2	2				
			05. INERTIA	5	5	5	4	4	4	4	4	3	2	2				
			06. INABILITY TO FEEL	2	2	2	2	2	2	2	2	2	1	1				
			07. PESSIMISTIC THOUGHTS	3	3	3	3	3	3	3	3	2	2	2				
			08. CONCENTRATIONS DIFFICULTIES	4	4	4	4	4	4	4	4	4	4	4				
			09. REDUCED SLEEP	3	3	3	3	3	3	3	3	3	3	3				
			10. REDUCED APPETITE	1	1	1	1	1	1	1	1	0	0	0				
			11. Total score	33	33	31	27	29	23	20	20	20	20	20	35			
4DT	Reboxetine	Female	01. REPORTED SADNESS	4	3	3	2	2	1	0	0	0	0					
			02. INNER TENSION	4	3	3	2	1	1	1	1	1	1					
			03. APPARENT SADNESS	4	4	4	4	2	2	2	2	2	2					
			04. SUICIDAL THOUGHTS	3	3	3	3	3	2	2	2	2	2					
			05. INERTIA	0	0	0	0	0	0	0	0	0	0					
			06. INABILITY TO FEEL	2	2	2	1	1	1	1	1	1	1					
			07. PESSIMISTIC THOUGHTS	3	2	2	1	1	1	1	1	1	1					
			08. CONCENTRATIONS DIFFICULTIES	3	3	3	2	1	1	1	1	1	1					
			09. REDUCED SLEEP	2	2	2	2	1	0	0	0	0	0					
			10. REDUCED APPETITE	2	1	1	1	1	0	0	0	0						
			11. Total score	27	23	23	15	12	9	8	8	8	8					
5ND	Reboxetine	Female	01. REPORTED SADNESS	4	2	2	1	1	1	0	0	0	0					
			02. INNER TENSION	4	2	2	1	1	1	1	0	0						
			03. APPARENT SADNESS	3	2	1	1	1	0	0	0							
			04. SUICIDAL THOUGHTS	3	3	2	2	2	1	1	0							
			05. INERTIA	1	1	1	1	1	1	1	0							
			06. INABILITY TO FEEL	2	2	2	2	2	2	2	2							

1548

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

55

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
36	5ND	Reboxetine	Female	07.PESSIMISTIC THOUGHTS 08.CONCENTRATIONS DIFFICULTIES 09.REDUCED SLEEP 10.REDUCED APPETITE 11.Total score	2 3 3 0 25	1 2 1 0 16	1 2 1 0 14	1 2 1 0 11	1 1 1 0 11	1 1 0 0 7	1 1 0 0 7	1 1 0 0 7	1 0 0 0 2	1 0 0 0 2
5DT	5DT	Imipramine	Female	01.REPORTED SADNESS 02.INNER TENSION 03.APPARENT SADNESS 04.SUICIDAL THOUGHTS 05.INERTIA 06.INABILITY TO FEEL 07.PESSIMISTIC THOUGHTS 08.CONCENTRATIONS DIFFICULTIES 09.REDUCED SLEEP 10.REDUCED APPETITE 11.Total score	5 4 4 4 2 2 2 3 3 1 30									
6ND	6ND	Imipramine	Female	01.REPORTED SADNESS 02.INNER TENSION 03.APPARENT SADNESS 04.SUICIDAL THOUGHTS 05.INERTIA 06.INABILITY TO FEEL 07.PESSIMISTIC THOUGHTS 08.CONCENTRATIONS DIFFICULTIES 09.REDUCED SLEEP 10.REDUCED APPETITE 11.Total score	2 2 2 2 2 4 2 2 1 22	2 2 1 2 2 4 2 2 1 20	1 1 1 1 0 3 2 1 1 12	1 1 0 1 0 2 2 1 1 9	1 1 0 1 0 2 2 1 1 9	0 0 0 0 0 2 1 0 0 2	0 0 0 0 0 2 1 0 0 2	0 0 0 0 0 2 1 0 0 2	0 0 0 0 0 2 1 0 0 2	0 0 0 0 0 2 1 0 0 2
6DT	6DT	Imipramine	Female	01.REPORTED SADNESS 02.INNER TENSION 03.APPARENT SADNESS 04.SUICIDAL THOUGHTS 05.INERTIA 06.INABILITY TO FEEL 07.PESSIMISTIC THOUGHTS 08.CONCENTRATIONS DIFFICULTIES 09.REDUCED SLEEP 10.REDUCED APPETITE 11.Total score	5 4 4 2 0 4 4 2 2 26	5 4 1 2 0 4 4 2 2 26	3 3 2 2 0 4 3 2 0 21	2 2 1 2 0 3 2 2 2 17	2 1 1 2 0 3 2 2 1 13	2 1 1 2 0 2 2 1 1 11	1 0 1 1 0 2 1 1 1 8	1 0 1 1 0 2 1 1 1 6	1 0 1 1 0 2 1 0 1 6	1 0 1 1 0 2 1 0 1 6
7ND	7ND	Reboxetine	Female	01.REPORTED SADNESS 02.INNER TENSION 03.APPARENT SADNESS 04.SUICIDAL THOUGHTS 05.INERTIA	3 3 4 4 4	2 3 1 3 4	2 3 1 3 3	2 2 1 3 3	2 2 1 3 3	0 0 0 0 4	0 0 0 0 4	0 0 0 0 4	0 0 0 0 4	0 0 0 0 4

9550089

1549

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

56

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63					
36	7ND	Reboxetine	Female	06. INABILITY TO FEEL	3	3	3	2	0	0	0	0	0					
				07. PESSIMISTIC THOUGHTS	5	4	4	3	1	1	1	0	0					
				08. CONCENTRATIONS DIFFICULTIES	2	2	2	2	0	0	0	0	0					
				09. REDUCED SLEEP	3	3	3	3	0	0	0	0	0					
				10. REDUCED APPETITE	0	0	0	0	0	0	0	0	0					
				11. Total score	28	25	24	21	1	1	1	1	1					
				7DT	Reboxetine	Female	01. REPORTED SADNESS	2	3									
							02. INNER TENSION	3	4									
							03. APPARENT SADNESS	4	4									
							04. SUICIDAL THOUGHTS	4	4									
							05. INERTIA	1	4									
06. INABILITY TO FEEL	2	2																
07. PESSIMISTIC THOUGHTS	4	4																
08. CONCENTRATIONS DIFFICULTIES	3	4																
09. REDUCED SLEEP	1	2																
10. REDUCED APPETITE	0	0																
11. Total score	24	31																
8ND	Imipramine	Female	01. REPORTED SADNESS	5	4	2	1	0	0	0	0	0	0					
			02. INNER TENSION	4	3	2	1	1	0	0	0	0	0	0				
			03. APPARENT SADNESS	3	3	2	0	0	0	0	0	0	0	0				
			04. SUICIDAL THOUGHTS	3	3	1	1	0	0	0	0	0	0	0				
			05. INERTIA	1	1	1	0	1	0	0	0	0	0	0				
			06. INABILITY TO FEEL	3	3	2	1	1	1	0	0	0	0	0				
			07. PESSIMISTIC THOUGHTS	5	3	2	2	1	1	0	0	0	0	0				
			08. CONCENTRATIONS DIFFICULTIES	5	5	3	0	0	0	0	0	0	0	0				
			09. REDUCED SLEEP	2	2	1	1	1	1	0	0	0	0	0				
			10. REDUCED APPETITE	3	2	0	0	0	0	0	0	0	0	0				
			11. Total score	34	29	16	7	5	5	0	0	0	0	0	0			
8DT	Reboxetine	Female	01. REPORTED SADNESS	2	2	2	1	1	1	1	1	1	1					
			02. INNER TENSION	3	3	2	1	1	1	1	1	1	1	1				
			03. APPARENT SADNESS	3	3	3	2	2	1	1	1	1	1	1				
			04. SUICIDAL THOUGHTS	4	4	4	4	4	4	4	4	4	4	4				
			05. INERTIA	2	2	2	2	2	2	2	2	2	2	2				
			06. INABILITY TO FEEL	2	2	2	2	2	2	2	2	2	2	2				
			07. PESSIMISTIC THOUGHTS	1	1	1	1	1	1	1	1	1	1	1	1			
			08. CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	0	0	0	0	0	0				
			09. REDUCED SLEEP	2	2	2	1	1	0	0	0	0	0	0				
			10. REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0	0				
			11. Total score	21	20	20	12	12	8	9	11	11	11	11	11			
9ND	Reboxetine	Male	01. REPORTED SADNESS	3	5	3	1	1	1	1	1	1	1					
			02. INNER TENSION	3	5	3	0	0	0	0	0	0	0					
			03. APPARENT SADNESS	1	2	2	0	0	0	0	0	0	0					
			04. SUICIDAL THOUGHTS	2	2	0	0	0	0	0	0	0	0					

9550089

1550

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

57

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/095
Listing No.: 15.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63				
36	9ND	Reboxetine	Male	05.INERTIA	1	2	1	0	0	0	0	0	0	0				
				06.INABILITY TO FEEL	3	5	3	2	1	1	1	1	1	1	1			
				07.PESSIMISTIC THOUGHTS	5	6	3	0	0	0	0	0	0	0	0			
				08.CONCENTRATIONS DIFFICULTIES	3	4	3	0	0	0	0	0	0	0	0			
				09.REDUCED SLEEP	2	3	2	0	0	0	0	0	0	0	0			
				10.REDUCED APPETITE	4	5	2	0	0	0	0	0	0	0	0			
				11.Total score	27	39	22	3	2	2	2	2	2	2	2	2		
				9UT	Imipramine	Female	01.REPORTED SADNESS	3	3	2	0	0	0	0	0	0	0	0
							02.INNER TENSION	4	3	1	0	0	0	0	0	0	0	0
							03.APPARENT SADNESS	3	3	2	2	2	1	1	1	1	1	1
							04.SUICIDAL THOUGHTS	1	1	0	0	0	0	0	0	0	0	0
05.INERTIA	2	1	1				1	1	1	1	1	1	1	1				
06.INABILITY TO FEEL	3	3	2				1	0	0	0	0	0	0	0				
07.PESSIMISTIC THOUGHTS	5	4	2				1	0	0	0	0	0	0	0				
08.CONCENTRATIONS DIFFICULTIES	3	3	2				1	0	0	0	0	0	0	0				
09.REDUCED SLEEP	2	2	1				0	0	0	0	0	0	0	0				
10.REDUCED APPETITE	0	0	0				0	0	0	0	0	0	0	0				
11.Total score	26	23	13				6	3	3	2	2	2	2	2	3			
10ND	Reboxetine	Male	01.REPORTED SADNESS	3	2	1	1	1	0	0	0	0	0	0				
			02.INNER TENSION	4	2	0	0	0	0	0	0	0	0	0				
			03.APPARENT SADNESS	4	2	1	1	1	1	1	1	1	1	1				
			04.SUICIDAL THOUGHTS	2	2	1	1	1	1	1	1	1	1	1				
			05.INERTIA	4	4	1	1	1	1	1	1	1	1	1				
			06.INABILITY TO FEEL	3	2	1	1	1	1	1	1	1	1	1				
			07.PESSIMISTIC THOUGHTS	3	2	1	1	0	0	0	0	0	0	0				
			08.CONCENTRATIONS DIFFICULTIES	3	2	1	1	0	0	0	0	0	0	0				
			09.REDUCED SLEEP	2	0	0	0	0	0	0	0	0	0	0				
			10.REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0	0				
			11.Total score	28	18	7	7	4	4	4	4	4	4	4	4			
10DT	Reboxetine	Male	01.REPORTED SADNESS	4	4	4	4	4	3	3	3	3	3	3				
			02.INNER TENSION	4	4	4	4	4	3	3	3	3	3	3				
			03.APPARENT SADNESS	3	3	3	3	2	2	2	2	2	2	2				
			04.SUICIDAL THOUGHTS	4	4	4	4	4	4	4	4	4	4	4				
			05.INERTIA	4	4	4	4	4	4	4	4	4	4	4				
			06.INABILITY TO FEEL	2	2	2	2	2	2	2	2	2	2	2				
			07.PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2	2	2	2	2				
			08.CONCENTRATIONS DIFFICULTIES	3	3	3	3	2	2	2	2	2	2	2				
			09.REDUCED SLEEP	3	3	3	3	3	3	3	3	3	3	3				
			10.REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0	0				
			11.Total score	29	29	29	29	25	25	25	24	24	24	24	27			
11ND	Imipramine	Female	01.REPORTED SADNESS	5	5	3	2	1	0	0	0	0	0	0				
			02.INNER TENSION	4	4	3	2	1	0	0	0	0	0	0				
			03.APPARENT SADNESS	2	2	2	1	0	0	0	0	0	0	0				

1551

9550089

58

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RBD

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63				
36	11ND	Imipramine	Female	04.SUICIDAL THOUGHTS	4	4	1	1	1	1	1	1	1	1				
				05.INERTIA	4	3	2	2	1	1	1	0	0	0	0			
				06.INABILITY TO FEEL	2	2	2	2	1	1	1	1	1	1	1	1		
				07.PESSIMISTIC THOUGHTS	4	4	3	2	0	0	0	0	0	0	0	0		
				08.CONCENTRATIONS DIFFICULTIES	3	3	2	1	0	0	0	0	0	0	0	0		
				09.REDUCED SLEEP	1	1	0	0	0	0	0	0	0	0	0	0		
				10.REDUCED APPETITE	1	1	0	0	0	0	0	0	0	0	0	0		
				11.Total score	30	29	19	13	5	3	5	2	2	2	2	2	2	
				11DT	Reboxetine	Male	01.REPORTED SADNESS	4	4	3	2	2	1	1	1	1	1	1
							02.INNER TENSION	4	4	2	2	1	0	0	0	0	0	0
							03.APPARENT SADNESS	4	4	2	2	2	2	2	2	2	2	2
04.SUICIDAL THOUGHTS	3	3	2				2	2	2	2	2	2	2	2				
05.INERTIA	2	2	2				2	1	1	1	1	1	1	1				
06.INABILITY TO FEEL	2	2	2				2	2	2	2	2	2	2	2				
07.PESSIMISTIC THOUGHTS	2	2	2				2	1	0	0	0	0	0	0	0			
08.CONCENTRATIONS DIFFICULTIES	3	3	2				2	1	1	1	1	1	1	1				
09.REDUCED SLEEP	3	3	2				2	1	1	1	1	1	1	1				
10.REDUCED APPETITE	1	1	1				1	1	1	1	1	1	1	1				
11.Total score	28	28	20				17	12	5	5	5	5	5	5	5			
12ND	Imipramine	Female	01.REPORTED SADNESS	3	3	6	6	6	6	6	6	6	6	6				
			02.INNER TENSION	4	4	4	4	4	4	4	4	4	4	4				
			03.APPARENT SADNESS	1	1	4	4	4	4	4	4	4	4	4				
			04.SUICIDAL THOUGHTS	3	2	6	6	6	6	6	6	6	6	6				
			05.INERTIA	3	2	6	6	6	6	6	6	6	6	6				
			06.INABILITY TO FEEL	1	4	6	6	6	6	6	6	6	6	6				
			07.PESSIMISTIC THOUGHTS	5	4	6	6	6	6	6	6	6	6	6				
			08.CONCENTRATIONS DIFFICULTIES	2	3	6	6	6	6	6	6	6	6	6				
			09.REDUCED SLEEP	2	4	6	6	6	6	6	6	6	6	6				
			10.REDUCED APPETITE	2	1	0	0	0	0	0	0	0	0	0				
			11.Total score	26	28	40	40	40	40	40	40	40	40	40	40			
12DT	Imipramine	Female	01.REPORTED SADNESS	2	2	2	2	2	2	2	2	2	2	2				
			02.INNER TENSION	2	2	2	1	1	1	1	1	1	1	1				
			03.APPARENT SADNESS	2	2	2	2	2	2	2	2	2	2	2				
			04.SUICIDAL THOUGHTS	0	0	0	0	0	0	0	0	0	0	0				
			05.INERTIA	2	2	2	2	2	2	2	2	2	2	2				
			06.INABILITY TO FEEL	2	2	2	2	2	2	2	2	2	2	2				
			07.PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2	2	2	2	2				
			08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2	2	2	2	2				
			09.REDUCED SLEEP	0	0	0	0	0	0	0	0	0	0	0				
			10.REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0	0				
			11.Total score	14	14	14	12	9	4	4	4	4	4	4	4			
13ND	Reboxetine	Male	01.REPORTED SADNESS	2	4	6	6	6	6	6	6	6	6					
			02.INNER TENSION	2	3	4	4	4	4	4	4	4	4					

15:52

9550089

60

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/03S
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
36	17HD	Reboxetine	Female	02.INNER TENSION	2	2								
				03.APPARENT SADNESS	3	3								
				04.SUICIDAL THOUGHTS	3	3								
				05.INERTIA	2	2								
				06.INABILITY TO FEEL	2	2								
				07.PESSIMISTIC THOUGHTS	5	5								
				08.CONCENTRATIONS DIFFICULTIES	4	4								
				09.REDUCED SLEEP	2	2								
				10.REDUCED APPETITE	4	4								
				11.Total score	29	29								
18ND		Imipramine	Female	01.REPORTED SADNESS	4	4	2	2	0	0	0	0	0	0
				02.INNER TENSION	3	2	1	1	0	0	0	0	0	0
				03.APPARENT SADNESS	3	2	1	1	0	0	0	0	0	0
				04.SUICIDAL THOUGHTS	2	2	2	2	0	0	0	0	0	0
				05.INERTIA	3	3	2	2	0	0	0	0	0	0
				06.INABILITY TO FEEL	2	2	2	2	1	0	0	0	0	0
				07.PESSIMISTIC THOUGHTS	4	3	2	2	1	0	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	3	3	2	2	0	0	0	0	0	0
				09.REDUCED SLEEP	2	2	2	2	0	0	0	0	0	0
				10.REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0
				11.Total score	26	23	16	16	3	0	0	0	0	0
19ND		Reboxetine	Female	01.REPORTED SADNESS	4	4	4	4						
				02.INNER TENSION	3	3	3	3						
				03.APPARENT SADNESS	4	4	4	4						
				04.SUICIDAL THOUGHTS	2	2	2	2						
				05.INERTIA	2	2	2	2						
				06.INABILITY TO FEEL	1	1	1	1						
				07.PESSIMISTIC THOUGHTS	2	2	2	2						
				08.CONCENTRATIONS DIFFICULTIES	4	4	4	4						
				09.REDUCED SLEEP	2	2	2	2						
				10.REDUCED APPETITE	2	2	2	2						
				11.Total score	26	26	26	26						
20ND		Imipramine	Female	01.REPORTED SADNESS	5	5	4	4	3	2	2	2	2	2
				02.INNER TENSION	4	4	4	4	3	2	2	2	2	2
				03.APPARENT SADNESS	4	4	4	4	3	3	3	3	3	3
				04.SUICIDAL THOUGHTS	4	4	4	4	4	4	4	4	4	4
				05.INERTIA	3	3	3	3	3	3	3	3	3	3
				06.INABILITY TO FEEL	4	4	4	4	4	4	4	4	4	4
				07.PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2	2	2	2
				08.CONCENTRATIONS DIFFICULTIES	3	3	3	3	3	3	3	3	3	3
				09.REDUCED SLEEP	3	3	3	3	3	3	3	3	3	3
				10.REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0
				11.Total score	32	32	30	30	28	25	25	25	25	25

1554

9550089

61

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
37	3MD	Reboxetine	Female	01.REPORTED SADNESS	4										
				02.INNER TENSION	4										
				03.APPARENT SADNESS	4										
				04.SUICIDAL THOUGHTS	4										
				05.INERTIA	0										
				06.INABILITY TO FEEL	2										
				07.PESSIMISTIC THOUGHTS	0										
				08.CONCENTRATIONS DIFFICULTIES	2										
				09.REDUCED SLEEP	2										
				10.REDUCED APPETITE	2										
				11.Total score	24										
41	1MD	Imipramine	Male	01.REPORTED SADNESS	1	1									
				02.INNER TENSION	2	2									
				03.APPARENT SADNESS	4	4									
				04.SUICIDAL THOUGHTS	3	4									
				05.INERTIA	3	3									
				06.INABILITY TO FEEL	3	3									
				07.PESSIMISTIC THOUGHTS	2	3									
				08.CONCENTRATIONS DIFFICULTIES	3	3									
				09.REDUCED SLEEP	1	2									
				10.REDUCED APPETITE	1	1									
				11.Total score	23	26									
15	2HD	Reboxetine	Male	01.REPORTED SADNESS	2	2	0	0	0	0	0	0	0	0	
				02.INNER TENSION	2	2	0	0	0	0	0	0	0	0	
				03.APPARENT SADNESS	4	2	1	0	0	0	0	0	0	0	
				04.SUICIDAL THOUGHTS	4	2	1	2	1	1	1	1	1	1	
				05.INERTIA	1	0	0	0	0	0	0	0	0	0	
				06.INABILITY TO FEEL	4	2	0	0	0	0	0	0	0	0	
				07.PESSIMISTIC THOUGHTS	3	1	1	0	0	0	0	0	0	0	
				08.CONCENTRATIONS DIFFICULTIES	2	2	0	0	0	0	0	0	0	0	
				09.REDUCED SLEEP	1	0	0	0	0	0	0	0	0	0	
				10.REDUCED APPETITE	1	1	0	0	0	0	0	0	0	0	
				11.Total score	24	14	3	2	1	1	1	1	1	1	
57	3MD	Imipramine	Male	01.REPORTED SADNESS	5	4	3	2	2	2	2	2	2	2	
				02.INNER TENSION	4	3	4	3	3	3	3	3	3	3	
				03.APPARENT SADNESS	3	3	3	3	3	3	3	3	3	3	
				04.SUICIDAL THOUGHTS	1	2	2	2	2	2	2	2	2	2	
				05.INERTIA	1	1	2	2	2	2	2	2	2	2	
				06.INABILITY TO FEEL	2	2	2	2	2	2	2	2	2	2	
				07.PESSIMISTIC THOUGHTS	2	2	3	3	3	3	3	3	3	3	
				08.CONCENTRATIONS DIFFICULTIES	4	3	4	3	3	3	3	3	3	3	
				09.REDUCED SLEEP	4	3	3	3	2	2	2	2	2	2	
				10.REDUCED APPETITE	4	2	2	2	2	2	2	2	2	2	
				11.Total score	30	26	28	24	24	24	24	24	24	24	

9550089

62

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
41	4ND	Reboxetine	Male	01.REPORTED SADNESS	4	3	2	2	2	2	2	2	2	2		
				02.INNER TENSION	3	3	3	2	2	2	2	2	2	2	2	2
				03.APPARENT SADNESS	3	4	3	3	2	2	2	2	2	2	2	2
				04.SUICIDAL THOUGHTS	6	4	3	3	3	2	2	2	2	2	2	2
				05.INERTIA	2	2	2	1	1	0	0	0	0	0	0	0
				06.INABILITY TO FEEL	2	2	1	1	1	1	1	1	1	1	1	1
				07.PESSIMISTIC THOUGHTS	3	2	1	1	1	1	1	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	1	1	1	1	1	1	1	1
				09.REDUCED SLEEP	2	2	1	1	1	1	1	1	1	1	1	1
				10.REDUCED APPETITE	2	2	1	0	0	0	0	0	0	0	0	0
				11.Total score	29	23	18	15	13	12	12	12	12	12	12	12
5ND	5ND	Reboxetine	Male	01.REPORTED SADNESS	3	2	1	1	1	1	1	1	1	1		
				02.INNER TENSION	3	3	2	2	1	1	1	1	1	1	1	
				03.APPARENT SADNESS	3	3	2	2	2	2	2	2	2	2	2	
				04.SUICIDAL THOUGHTS	3	4	3	2	2	2	2	2	2	2	2	
				05.INERTIA	2	1	1	1	0	0	0	0	0	0	0	
				06.INABILITY TO FEEL	2	2	1	1	1	0	0	0	0	0	0	
				07.PESSIMISTIC THOUGHTS	2	2	1	1	1	1	1	1	1	1	1	
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	1	1	1	1	1	1	1	
				09.REDUCED SLEEP	2	2	2	1	1	1	1	1	1	1	1	
				10.REDUCED APPETITE	1	0	0	0	0	0	0	0	0	0	0	
				11.Total score	23	20	14	11	8	6	5	5	5	5	5	5
42	1ND	Imipramine	Female	01.REPORTED SADNESS	4	4	2	2	2	0	0	0	0	0		
				02.INNER TENSION	4	4	2	2	2	0	0	0	0	0	0	
				03.APPARENT SADNESS	4	4	2	2	2	0	0	0	0	0	0	
				04.SUICIDAL THOUGHTS	4	4	0	2	2	1	1	2	1	1	2	
				05.INERTIA	4	2	0	2	0	0	0	0	0	0	0	
				06.INABILITY TO FEEL	4	2	2	0	0	0	0	0	0	0	0	
				07.PESSIMISTIC THOUGHTS	4	2	2	2	0	0	0	0	0	0	0	
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	0	0	0	0	0	0	0	0	
				09.REDUCED SLEEP	2	2	0	0	0	0	0	0	0	0	0	
				10.REDUCED APPETITE	2	2	0	0	0	0	0	0	0	0	0	
				11.Total score	30	26	14	10	2	1	1	2	0	0	0	0
4DT	1DT	Imipramine	Female	01.REPORTED SADNESS	4	4	2	2	2	4	4	4	4	4		
				02.INNER TENSION	4	4	2	2	2	4	4	4	4	4	4	
				03.APPARENT SADNESS	4	4	4	4	4	4	4	4	4	4	4	
				04.SUICIDAL THOUGHTS	4	4	4	2	2	2	2	2	2	2	2	
				05.INERTIA	4	4	4	0	0	0	0	0	0	0	0	
				06.INABILITY TO FEEL	4	4	4	3	2	2	2	2	2	2	2	
				07.PESSIMISTIC THOUGHTS	4	4	4	2	2	2	2	2	2	2	2	
				08.CONCENTRATIONS DIFFICULTIES	4	4	2	2	2	2	2	2	2	2	2	
				09.REDUCED SLEEP	2	2	2	2	2	2	2	2	2	2	2	
				10.REDUCED APPETITE	2	2	2	2	2	2	2	2	2	2	2	

15/06

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

63

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
42	1DT	Imipramine	Female	Montgomery Asberg Depression Rating Scale											
				11.Total score	36	36	27	16	16	24	26	18	20		
	2ND	Reboxetine	Female	01.REPORTED SADNESS	4	2	2	2	2	2	2	2	0	2	
				02.INNER TENSION	4	2	2	2	2	0	2	2	2	0	
				03.APPARENT SADNESS	4	4	4	4	2	2	0	0	2	2	0
				04.SUICIDAL THOUGHTS	4	2	4	2	2	0	0	0	0	0	2
				05.INERTIA	2	1	2	2	2	0	0	0	0	0	0
				06.INABILITY TO FEEL	4	2	2	2	2	0	0	2	2	2	0
				07.PESSIMISTIC THOUGHTS	4	2	2	2	2	0	0	0	0	0	0
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	0	0	2	2	2	0
				09.REDUCED SLEEP	2	1	0	0	0	0	2	2	2	0	0
10.REDUCED APPETITE				2	2	0	0	0	0	0	0	2	0	0	
11.Total score	32	20	18	16	16	24	26	18	20	4					
2DT	Reboxetine	Male	01.REPORTED SADNESS	2	2										
			02.INNER TENSION	2	2										
			03.APPARENT SADNESS	2	2										
			04.SUICIDAL THOUGHTS	4	4										
			05.INERTIA	2	2										
			06.INABILITY TO FEEL	2	2										
			07.PESSIMISTIC THOUGHTS	2	2										
			08.CONCENTRATIONS DIFFICULTIES	2	2										
			09.REDUCED SLEEP	2	2										
			10.REDUCED APPETITE	2	2										
			11.Total score	22	22										
3ND	Imipramine	Male	01.REPORTED SADNESS	4	4	4	4	2	2	2	2	2	0		
			02.INNER TENSION	4	4	4	4	2	2	2	2	2	2		
			03.APPARENT SADNESS	4	4	4	4	2	2	4	2	2	2		
			04.SUICIDAL THOUGHTS	4	4	4	4	2	2	2	4	2	2		
			05.INERTIA	2	2	2	2	0	0	0	0	0	0		
			06.INABILITY TO FEEL	2	4	4	4	2	2	2	2	4	2		
			07.PESSIMISTIC THOUGHTS	2	4	4	4	2	2	2	2	2	0		
			08.CONCENTRATIONS DIFFICULTIES	2	4	2	2	2	2	2	2	2	0		
			09.REDUCED SLEEP	2	2	2	2	2	2	2	2	2	0		
			10.REDUCED APPETITE	2	2	2	2	2	2	2	2	2	0		
			11.Total score	28	34	32	26	16	20	20	18	6			
43	1DT	Reboxetine	Female	01.REPORTED SADNESS	5	4	4	4	5	4	4	4	4		
				02.INNER TENSION	5	5	5	4	5	4	5	4	4		
				03.APPARENT SADNESS	2	3	2	2	2	2	3	3	3		
				04.SUICIDAL THOUGHTS	5	5	5	4	4	4	4	4	4		
				05.INERTIA	2	3	3	3	3	3	3	3	3		
				06.INABILITY TO FEEL	4	4	3	3	3	3	3	3	3		
				07.PESSIMISTIC THOUGHTS	4	4	4	4	4	4	4	4	4		
				08.CONCENTRATIONS DIFFICULTIES	4	4	3	3	2	2	2	2	2		
				09.REDUCED SLEEP	2	3	3	2	2	2	2	2	2		

1557

9550089

64

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
43	1DT	Reboxetine	Female	1	1	1	1	1	2	2	2		
				34	34	32	29	31	30	33			
				10. REDUCED APPETITE									
				11. Total score									
2DT	Imipramine	Female		4	4	4	5						
				5	4	3	3	5					
				3	3	3	3						
				4	4	4	4						
				3	3	2	3						
				4	4	3	2						
				4	4	3	4						
				2	2	2	2						
				4	4	3	3						
				2	2	2	2						
				33	31	26	32						
3DT	Imipramine	Male		5	5	4	4	0	0	0	0	0	0
				5	4	4	4	1	0	0	0	0	0
				4	3	3	2	0	1	2	0	0	0
				4	3	3	2	0	0	1	0	0	0
				3	3	3	3	1	0	0	0	0	0
				3	3	3	3	1	0	0	0	0	0
				4	4	4	4	0	0	0	0	0	0
				4	4	2	2	0	0	0	0	0	0
				2	2	2	2	0	1	0	0	0	0
				2	1	1	1	0	0	0	0	0	0
				36	32	28	13	0	2	3	0	0	0
4DT	Reboxetine	Female		4	3	3	3	3	2	2	2	2	2
				4	4	4	4	2	2	2	2	1	1
				2	2	2	2	3	2	2	2	2	2
				3	4	4	3	3	3	2	2	1	1
				2	2	2	2	2	2	2	1	1	1
				3	3	3	3	2	2	2	2	2	1
				4	3	3	3	2	2	2	1	1	1
				4	4	3	2	2	2	1	1	1	1
				2	2	2	2	2	2	1	0	0	0
				2	1	1	1	0	0	0	0	0	0
				30	28	26	24	21	19	15	15	12	
5ND	Imipramine	Female		5	5	5	5	5	6				
				5	5	5	5	5	5				
				4	4	3	3	3	3				
				4	4	3	3	4	3				
				3	3	2	2	3	2				
				4	4	4	4	3	3				
				5	3	3	3	4	4				
				5	3	3	3	3	3				
				4	4	4	4	3	3				

1558

9550089

65

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63						
43	5ND	Imipramine	Female	09. REDUCED SLEEP	2	2	2	2	2	2	2	2	2	2						
				10. REDUCED APPETITE	2	2	2	2	2	2	2	2	2	2	2					
				11. Total score	38	36	32	30	34	33										
				6ND	Imipramine	Female	01. REPORTED SADNESS	4	5	3	2	2	2	1	2	1	2	2		
							02. INNER TENSION	5	5	3	3	2	2	2	2	2	2	2		
							03. APPARENT SADNESS	4	3	2	2	3	2	1	2	1	2	3	3	
							04. SUICIDAL THOUGHTS	4	2	3	2	2	2	2	2	2	2	2	2	
							05. INERTIA	3	3	2	2	2	0	0	0	0	0	0	1	
							06. INABILITY TO FEEL	3	2	3	1	1	0	1	1	0	1	1	1	1
							07. PESSIMISTIC THOUGHTS	4	3	2	2	2	2	2	2	2	2	1	1	1
							08. CONCENTRATIONS DIFFICULTIES	3	4	3	2	2	2	2	1	2	2	1	2	2
09. REDUCED SLEEP	2	2	2				2	2	2	2	2	2	2	0	0	1				
10. REDUCED APPETITE	1	1	1				1	1	0	0	0	0	0	0	0	0				
11. Total score	33	30	24				18	16	13	10	15									
44	1ND	Reboxetine	Female	01. REPORTED SADNESS	3	1	1	2	1	0	1	1	0	1	1					
				02. INNER TENSION	4	1	3	3	2	1	2	1	2	1	1	1				
				03. APPARENT SADNESS	4	2	3	3	3	2	3	3	2	3	3	4				
				04. SUICIDAL THOUGHTS	4	4	2	1	4	4	3	0	4	3	0	4				
				05. INERTIA	3	3	3	2	2	2	2	0	2	0	2	2				
				06. INABILITY TO FEEL	3	2	1	2	2	0	0	0	0	0	0	1				
				07. PESSIMISTIC THOUGHTS	3	1	1	2	1	1	1	1	1	1	1	2	2			
				08. CONCENTRATIONS DIFFICULTIES	2	1	1	2	1	1	1	1	1	1	1	1	1			
				09. REDUCED SLEEP	1	1	0	0	0	2	0	2	0	0	0	1	1			
				10. REDUCED APPETITE	2	1	1	1	1	0	1	0	1	1	0	0	1			
				11. Total score	29	17	16	18	16	14	6	19								
1DT	Reboxetine	Female	01. REPORTED SADNESS	5	4	1	2	2	2	1	2	1	1	1						
			02. INNER TENSION	4	4	1	3	2	2	2	2	2	2	1	1					
			03. APPARENT SADNESS	3	3	2	3	2	3	1	3	3	1	1	1					
			04. SUICIDAL THOUGHTS	4	2	0	4	4	4	3	4	4	3	2	3					
			05. INERTIA	5	3	2	3	3	3	3	3	3	2	2	2					
			06. INABILITY TO FEEL	3	2	2	2	2	2	2	1	2	2	1	1					
			07. PESSIMISTIC THOUGHTS	3	4	2	2	2	1	1	1	1	1	1	1					
			08. CONCENTRATIONS DIFFICULTIES	4	4	1	2	2	2	2	2	2	2	1	1					
			09. REDUCED SLEEP	4	4	0	1	2	1	1	1	1	1	0	0					
			10. REDUCED APPETITE	4	4	0	2	2	2	2	2	2	2	1	0					
			11. Total score	39	33	11	24	21	20	11	21									
2ND	Reboxetine	Female	01. REPORTED SADNESS	4	2	3	1	4	3	3	3	3	2	2						
			02. INNER TENSION	4	1	3	2	3	3	3	3	3	3	1	1					
			03. APPARENT SADNESS	3	2	3	2	3	2	3	2	3	2	3	2					
			04. SUICIDAL THOUGHTS	4	4	4	4	4	4	4	4	4	4	0	0					
			05. INERTIA	3	3	3	2	2	3	1	3	3	1	3	2					
			06. INABILITY TO FEEL	3	0	3	0	3	0	0	1	0	0	1	0					
			07. PESSIMISTIC THOUGHTS	4	4	1	4	2	2	2	3	2	2	2	2					

9550089

66

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63					
44	2ND	Reboxetine	Female	08. CONCENTRATIONS DIFFICULTIES	3	1	3	2	2	2	1	2	1	0					
				09. REDUCED SLEEP	2	0	1	0	0	0	0	0	0	0	0	0			
				10. REDUCED APPETITE	0	1	1	0	1	0	1	0	1	0	0	0			
				11. Total score	30	15	28	15	22	21	17	16	11	11	11	11			
				3ND	Imipramine	Female	01. REPORTED SADNESS	3	2	4	4	3	1	2	2	0	0	0	
							02. INNER TENSION	4	2	4	2	0	1	1	1	0	0	0	
							03. APPARENT SADNESS	2	1	0	0	0	0	1	0	0	0	0	
							04. SUICIDAL THOUGHTS	1	2	0	4	4	2	4	4	4	5	4	5
							05. INERTIA	3	3	4	4	4	3	5	3	3	3	3	3
							06. INABILITY TO FEEL	1	0	4	2	0	0	0	0	0	0	0	0
							07. PESSIMISTIC THOUGHTS	4	2	4	4	3	1	2	1	1	1	1	1
08. CONCENTRATIONS DIFFICULTIES	4	2	2				2	2	1	2	1	2	2	1	2				
09. REDUCED SLEEP	0	0	0				0	0	0	0	0	0	0	0	0				
10. REDUCED APPETITE	3	0	0				0	0	0	0	0	0	0	0	0				
11. Total score	24	14	22				20	11	11	13	12	9	9	9	9				
4ND	1560	Imipramine	Male	01. REPORTED SADNESS	3	4	3	3	4	4	4	2	2	3					
				02. INNER TENSION	4	3	0	0	2	3	4	2	2	4	2				
				03. APPARENT SADNESS	2	1	3	2	2	3	2	2	2	2	2				
				04. SUICIDAL THOUGHTS	3	3	2	0	0	0	0	0	0	0	0				
				05. INERTIA	3	3	3	3	2	3	3	2	2	2	2				
				06. INABILITY TO FEEL	4	4	4	3	3	4	4	4	4	4	4				
				07. PESSIMISTIC THOUGHTS	4	3	2	2	3	3	4	3	4	3	4				
				08. CONCENTRATIONS DIFFICULTIES	3	2	1	2	3	3	4	3	3	2	3				
				09. REDUCED SLEEP	1	1	2	1	2	2	2	2	2	0	1				
				10. REDUCED APPETITE	1	1	0	0	0	3	2	2	2	1	1				
				11. Total score	28	25	20	15	19	29	28	16	24	24	24				
45	1ND	Reboxetine	Male	01. REPORTED SADNESS	6	5	2	3	4	4	2	1	1	1					
				02. INNER TENSION	4	4	4	4	4	4	2	1	1	1					
				03. APPARENT SADNESS	3	3	2	2	3	2	1	0	0	0					
				04. SUICIDAL THOUGHTS	5	5	4	4	2	2	2	2	1	0					
				05. INERTIA	0	0	0	0	0	0	0	0	0	0					
				06. INABILITY TO FEEL	3	3	0	0	3	2	0	0	0	0					
				07. PESSIMISTIC THOUGHTS	4	4	0	1	3	1	0	0	0	0					
				08. CONCENTRATIONS DIFFICULTIES	3	3	2	2	2	1	0	0	0	0					
				09. REDUCED SLEEP	3	3	4	3	2	0	0	0	0	0					
				10. REDUCED APPETITE	4	3	2	2	2	0	0	0	0						
				11. Total score	35	33	20	21	25	11	4	3	3						
4ND	1ND	Imipramine	Female	01. REPORTED SADNESS	4	4	4	3	3	2	2	2	0						
				02. INNER TENSION	3	4	3	4	4	2	2	2	0						
				03. APPARENT SADNESS	3	3	3	2	2	2	0	1	0						
				04. SUICIDAL THOUGHTS	5	5	5	5	3	3	4	4	4						
				05. INERTIA	0	0	1	1	0	0	0	0	0						
				06. INABILITY TO FEEL	3	4	4	4	3	3	2	3	2						

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
45	1DI	Imipramine	Female	07.PESSIMISTIC THOUGHTS	2	3	4	3	3	2	2	2	0		
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2	0			
				09.REDUCED SLEEP	2	2	2	2	1	1	1	1			
				10.REDUCED APPETITE	1	1	1	1	1	1	1	0			
				11.Total score	25	28	29	27	22	18	16	18	7		
				01.REPORTED SADNESS	4		4								
				02.INNER TENSION	4		3								
				03.APPARENT SADNESS	5		3								
				04.SUICIDAL THOUGHTS	4		4								
				05.INERTIA	3		3								
				06.INABILITY TO FEEL	3		3								
46	1HD	Imipramine	Male	07.PESSIMISTIC THOUGHTS	3	2	2	2	1	1	1	1	0		
				08.CONCENTRATIONS DIFFICULTIES	3	2	2	2	2	2	2	0			
				09.REDUCED SLEEP	3	2	2	2	2	2	2	0			
				10.REDUCED APPETITE	3	2	2	2	2	2	2	0			
				11.Total score	33	27	27	27	10	10	10	0			
				01.REPORTED SADNESS	4	2	2	1	1	1	0	0			
				02.INNER TENSION	4	2	1	0	0	0	0	0			
				03.APPARENT SADNESS	3	2	2	2	2	0	0	0			
				04.SUICIDAL THOUGHTS	5	2	3	2	2	0	0	0			
				05.INERTIA	1	0	0	0	0	0	0	0			
				06.INABILITY TO FEEL	2	2	2	2	1	1	0	0			
07.PESSIMISTIC THOUGHTS	2	1	2	1	1	1	0	0							
08.CONCENTRATIONS DIFFICULTIES	3	2	2	1	2	0	0	0							
09.REDUCED SLEEP	2	1	1	0	0	0	0	0							
10.REDUCED APPETITE	1	0	0	0	0	0	0	0							
11.Total score	27	14	15	7	10	0	0	0							
2ND	Imipramine	Female	01.REPORTED SADNESS	4	4	3	3	3	2	2	0	0			
			02.INNER TENSION	4	4	4	4	2	2	1	0				
			03.APPARENT SADNESS	5	3	2	3	3	3	2	2				
			04.SUICIDAL THOUGHTS	5	3	5	4	4	4	4	2				
			05.INERTIA	4	3	1	0	0	0	0	0				
			06.INABILITY TO FEEL	3	2	2	2	2	2	2	2				
			07.PESSIMISTIC THOUGHTS	4	4	4	4	4	4	4	4				
			08.CONCENTRATIONS DIFFICULTIES	3	3	2	3	2	3	2	2				
			09.REDUCED SLEEP	3	2	2	2	2	2	2	2				
			10.REDUCED APPETITE	2	1	1	1	1	1	1	1				
			11.Total score	35	29	26	24	24	24	24	24				
3ND	Reboxetine	Female	01.REPORTED SADNESS	3	3	3	2	2	2	2	0	0			
			02.INNER TENSION	3	3	2	2	3	2	1	0				
			03.APPARENT SADNESS	3	4	3	2	3	3	2	2				
			04.SUICIDAL THOUGHTS	4	6	3	3	3	2	2	0				
			05.INERTIA	2	4	0	0	2	1	0	0				

9550089

9550089

68

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
46	3ND	Reboxetine	Female	06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS 08. CONCENTRATIONS DIFFICULTIES 09. REDUCED SLEEP 10. REDUCED APPETITE 11. Total score	2 4 2 3 0 26	3 3 4 2 1 34	2 3 2 2 0 20	1 2 1 1 0 14	1 3 1 2 0 22	1 2 3 2 0 17	2 2 1 2 0 14	0 1 1 0 0 6	1 1 1 0 0 7	
4ND		Reboxetine	Female	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS 05. INERTIA 06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS 08. CONCENTRATIONS DIFFICULTIES 09. REDUCED SLEEP 10. REDUCED APPETITE 11. Total score	4 3 4 4 4 4 4 3 3 1 36									
48	1DT	Reboxetine	Female	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS 05. INERTIA 06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS 08. CONCENTRATIONS DIFFICULTIES 09. REDUCED SLEEP 10. REDUCED APPETITE 11. Total score	4 3 3 4 4 4 2 4 2 2 31	4 5 4 4 4 3 3 4 2 2 35								
2DT		Imipramine	Female	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS 05. INERTIA 06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS 08. CONCENTRATIONS DIFFICULTIES 09. REDUCED SLEEP 10. REDUCED APPETITE 11. Total score	4 4 3 4 4 3 4 4 3 2 35	3 3 3 3 3 3 3 3 3 2 31	2 2 3 3 3 3 3 3 2 2 26	3 3 2 3 3 3 3 3 2 2 26	2 2 2 2 3 2 2 2 2 1 19	1 2 2 3 3 2 2 2 2 1 19	2 2 2 3 3 2 2 2 3 1 22			
291	1ND	Imipramine	Female	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS	5 4 4 3	3 3 3 2	3 3 3 2	3 3 2 2	3 3 2 2	3 3 2 2	3 3 2 2	2 2 2 2	2 2 2 2	

1562

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

70

9550089

PHARMACIA CMS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
291	3ND	Imipramine	Male	04.SUICIDAL THOUGHTS	1	1	1	0	0	0	0	0	0	0
				05.INERTIA	1	1	1	0	0	0	0	0	0	0
				06.INABILITY TO FEEL	3	2	2	2	2	1	1	1	1	1
				07.PESSIMISTIC THOUGHTS	3	2	2	2	2	1	1	1	1	1
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	1	1	1	1	1	1	1
				09.REDUCED SLEEP	3	2	2	2	2	1	1	1	1	1
				10.REDUCED APPETITE	2	2	2	2	2	1	1	0	0	0
				11.Total score	22	17	15	13	13	8	8	7	7	7
30T	Imipramine	Female	01.REPORTED SADNESS	3	3									
			02.INNER TENSION	4	4									
			03.APPARENT SADNESS	3	3									
			04.SUICIDAL THOUGHTS	4	4									
			05.INERTIA	1	1									
			06.INABILITY TO FEEL	3	3									
			07.PESSIMISTIC THOUGHTS	3	3									
			08.CONCENTRATIONS DIFFICULTIES	3	3									
			09.REDUCED SLEEP	3	3									
			10.REDUCED APPETITE	3	3									
			11.Total score	30	30									
4ND	Reboxetine	Male	01.REPORTED SADNESS	3	3	3	3	3	3	3	3	3	3	3
			02.INNER TENSION	4	4	4	4	4	4	4	4	4	4	4
			03.APPARENT SADNESS	3	3	3	3	3	3	3	3	3	3	3
			04.SUICIDAL THOUGHTS	4	4	4	4	4	4	4	4	4	4	4
			05.INERTIA	1	1	1	1	1	1	1	1	1	1	1
			06.INABILITY TO FEEL	3	3	3	3	3	3	3	3	3	3	3
			07.PESSIMISTIC THOUGHTS	4	4	4	4	4	4	4	4	4	4	4
			08.CONCENTRATIONS DIFFICULTIES	3	3	3	3	3	3	3	3	3	3	3
			09.REDUCED SLEEP	4	4	4	4	4	4	4	4	4	4	4
			10.REDUCED APPETITE	2	2	2	2	2	2	2	2	2	2	2
			11.Total score	31	31	31	31	31	31	31	31	31	31	31
4DT	Imipramine	Male	01.REPORTED SADNESS	5	4	3	3	3	2	2	2	2	2	2
			02.INNER TENSION	4	4	4	4	4	4	4	4	4	4	4
			03.APPARENT SADNESS	3	3	3	3	3	2	2	2	2	2	2
			04.SUICIDAL THOUGHTS	2	2	2	2	2	0	0	0	0	0	0
			05.INERTIA	2	2	2	2	2	1	1	1	1	1	1
			06.INABILITY TO FEEL	4	4	4	4	4	4	4	4	4	4	4
			07.PESSIMISTIC THOUGHTS	5	5	5	5	5	4	4	4	4	4	4
			08.CONCENTRATIONS DIFFICULTIES	4	4	4	4	4	4	4	4	4	4	4
			09.REDUCED SLEEP	4	4	4	4	4	4	4	4	4	4	4
			10.REDUCED APPETITE	3	3	3	3	3	2	2	2	2	2	2
			11.Total score	36	35	34	32	32	22	22	22	22	22	22
25DT	Imipramine	Female	01.REPORTED SADNESS	4	3	3	3	3	2	2	1	1	1	1
			02.INNER TENSION	3	3	3	3	3	3	2	1	1	1	1

1564

9550089

71

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXYTINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63				
291	25DT	Imipramine	Female	Montgomery Asberg Depression Rating Scale													
				03.APPARENT SADNESS	2	2	2	2	2	2	2	2	2	1	1	1	
				04.SUICIDAL THOUGHTS	4	3	3	3	3	3	3	2	2	1	1	1	
				05.INERTIA	3	3	3	3	3	3	3	2	2	1	1	1	
				06.INABILITY TO FEEL	3	3	3	3	3	3	3	2	2	1	1	1	
				07.PESSIMISTIC THOUGHTS	4	3	3	3	3	3	3	2	2	1	1	1	
				08.CONCENTRATIONS DIFFICULTIES	3	3	3	3	3	3	3	2	2	1	1	1	
				09.REDUCED SLEEP	3	3	3	3	3	3	3	2	2	1	1	1	
				10.REDUCED APPETITE	4	3	3	3	3	3	3	2	1	1	1	1	
				11.Total score	34	29	29	29	29	29	29	26	19	10	10	10	10
				26DT	Reboxetine	Female	Montgomery Asberg Depression Rating Scale										
01.REPORTED SADNESS	3	3	2				2	2	2	2	2	2	2	2	2		
02.INNER TENSION	2	2	2				2	2	2	2	2	2	2	2	2		
03.APPARENT SADNESS	2	2	2				2	2	2	2	2	2	2	2	2		
04.SUICIDAL THOUGHTS	4	4	4				4	4	4	4	4	4	4	4	4		
05.INERTIA	4	3	2				2	2	2	2	2	2	2	2	2		
06.INABILITY TO FEEL	3	3	3				3	3	3	3	3	3	3	3	3		
07.PESSIMISTIC THOUGHTS	3	3	3				3	3	3	3	3	3	3	3	3		
08.CONCENTRATIONS DIFFICULTIES	3	3	3				3	3	3	3	3	3	3	3	3		
09.REDUCED SLEEP	3	3	3				3	3	3	3	3	3	3	3	3		
10.REDUCED APPETITE	3	3	3				3	3	3	3	3	3	3	3	3		
11.Total score	31	30	27	25	25	25	25	25	25	24	24	24	24				
27DT	Reboxetine	Female	Montgomery Asberg Depression Rating Scale														
			01.REPORTED SADNESS	3	3	2	2	2	2	2	2	2	1	1	1		
			02.INNER TENSION	3	3	2	2	2	2	2	2	2	2	2	2		
			03.APPARENT SADNESS	2	2	2	1	2	2	2	2	2	2	2	2		
			04.SUICIDAL THOUGHTS	3	3	3	2	2	2	2	2	2	1	1	1		
			05.INERTIA	3	3	2	0	2	2	2	2	2	1	1	1		
			06.INABILITY TO FEEL	4	4	4	3	3	3	3	2	2	2	2	2		
			07.PESSIMISTIC THOUGHTS	4	4	3	2	2	2	2	2	2	2	2	2		
			08.CONCENTRATIONS DIFFICULTIES	3	3	3	2	3	3	3	3	3	2	2	2		
			09.REDUCED SLEEP	4	4	4	2	3	3	3	3	3	2	2	2		
			10.REDUCED APPETITE	4	4	3	2	3	3	3	3	3	2	2	2		
11.Total score	33	33	28	17	25	25	25	25	20	16	16	14	14				
28DT	Imipramine	Female	Montgomery Asberg Depression Rating Scale														
			01.REPORTED SADNESS	4	3	3	2	2	2	2	2	2	2	2	2		
			02.INNER TENSION	4	4	3	2	2	2	2	2	2	2	2	2		
			03.APPARENT SADNESS	5	3	2	2	2	2	2	2	2	1	1	2		
			04.SUICIDAL THOUGHTS	3	2	2	2	2	2	2	2	2	2	2	2		
			05.INERTIA	4	4	3	3	3	3	3	3	3	3	2	2		
			06.INABILITY TO FEEL	4	3	2	2	2	2	2	2	2	2	2	2		
			07.PESSIMISTIC THOUGHTS	4	3	2	2	2	2	2	2	2	2	2	2		
			08.CONCENTRATIONS DIFFICULTIES	4	3	2	2	2	2	2	2	2	2	2	2		
			09.REDUCED SLEEP	5	4	3	2	2	2	2	2	2	2	2	2		
			10.REDUCED APPETITE	3	3	2	2	2	2	2	2	2	2	2	2		
11.Total score	40	32	24	21	21	21	21	21	20	19	19	20	20				
292	5ND	Imipramine	Female	Montgomery Asberg Depression Rating Scale													
				01.REPORTED SADNESS	2	2	2	2	2	2	2	2	2	1	1	1	

9550089

72

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20424/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
292	5ND	Imipramine	Female	02. INNER TENSION	2	2	2	2	2	1	1	1	1		
				03. APPARENT SADNESS	3	3	2	2	2	2	2	2	1	2	
				04. SUICIDAL THOUGHTS	3	3	2	2	2	2	2	2	1	1	
				05. INERTIA	3	3	2	2	2	2	2	2	1	1	
				06. INABILITY TO FEEL	3	3	2	2	2	2	2	2	1	1	
				07. PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2	2	2	2	
				08. CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2	2	2	1	
				09. REDUCED SLEEP	2	2	2	2	2	2	2	2	1	1	
				10. REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0	
				11. Total score	21	20	18	17	14	10	10	11			
				50T	Reboxetine	Male	01. REPORTED SADNESS	4	3	3	2	2	2	2	1
02. INNER TENSION	3	3	3				3	2	2	2	2	2	1		
03. APPARENT SADNESS	4	4	3				3	2	2	2	2	2	1		
04. SUICIDAL THOUGHTS	3	3	3				2	2	2	2	2	2	1		
05. INERTIA	3	3	3				3	2	2	2	2	2	1		
06. INABILITY TO FEEL	3	3	3				3	2	2	2	2	2	1		
07. PESSIMISTIC THOUGHTS	3	3	3				3	2	2	2	2	2	2		
08. CONCENTRATIONS DIFFICULTIES	3	3	3				3	2	2	2	2	2	2		
09. REDUCED SLEEP	3	3	3				3	2	2	2	2	2	2		
10. REDUCED APPETITE	0	0	1				0	0	0	0	0	0	0		
11. Total score	29	28	27				24	18	17	14	10				
6ND	Reboxetine	Female	01. REPORTED SADNESS	3	2	2	1	1	1	1	1	1	1		
			02. INNER TENSION	3	3	2	2	2	2	2	2	1	1		
			03. APPARENT SADNESS	3	2	2	2	2	2	2	2	2	1		
			04. SUICIDAL THOUGHTS	3	3	2	2	2	2	2	2	2	1		
			05. INERTIA	2	2	1	1	1	1	1	1	1	1		
			06. INABILITY TO FEEL	3	2	2	2	2	2	2	2	2	1		
			07. PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2	2	2	2		
			08. CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2	2	2	2		
			09. REDUCED SLEEP	2	2	2	2	2	2	2	2	2	2		
			10. REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0		
			11. Total score	23	20	16	13	10	11	12	11	10			
60T	Imipramine	Female	01. REPORTED SADNESS	4	4	3	3	2	2	2	2	2	1		
			02. INNER TENSION	3	3	3	3	2	2	2	2	2	2		
			03. APPARENT SADNESS	3	3	3	3	2	2	2	2	2	1		
			04. SUICIDAL THOUGHTS	4	4	3	3	2	2	2	2	2	1		
			05. INERTIA	3	3	3	3	2	2	2	2	2	1		
			06. INABILITY TO FEEL	4	4	4	4	3	3	3	3	3	2		
			07. PESSIMISTIC THOUGHTS	3	3	3	3	2	2	2	2	2	2		
			08. CONCENTRATIONS DIFFICULTIES	4	4	4	4	3	3	3	3	3	2		
			09. REDUCED SLEEP	4	4	4	4	3	3	3	3	3	2		
			10. REDUCED APPETITE	1	2	2	2	2	2	2	2	1	1		
			11. Total score	33	34	33	30	22	19	15	15	12			

1566

9550089

73

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RBD
REBOXETINE - PROTOCOL 2012/4/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63			
292	7ND	Reboxetine	Male	Montgomery Asberg Depression Rating Scale												
				01. REPORTED SADNESS	4	4	3	2	1	1	1	1	1	1	1	
				02. INNER TENSION	3	4	4	2	2	2	2	2	2	2	2	1
				03. APPARENT SADNESS	3	3	3	3	2	2	2	2	2	2	2	1
				04. SUICIDAL THOUGHTS	3	3	3	3	2	2	2	2	2	2	2	1
				05. INERTIA	3	3	3	3	2	2	2	2	2	2	2	1
				06. INABILITY TO FEEL	4	4	3	3	3	2	2	2	2	2	2	2
				07. PESSIMISTIC THOUGHTS	3	3	3	3	2	2	2	2	2	2	2	1
				08. CONCENTRATIONS DIFFICULTIES	4	4	4	4	2	2	2	2	2	2	2	1
				09. REDUCED SLEEP	4	4	3	3	2	2	2	2	2	2	2	1
				10. REDUCED APPETITE	1	1	1	0	0	0	0	0	0	0	0	0
11. Total score	32	33	30	24	18	17	15	14	13	12	10	10				
7DT	Imipramine	Male	Montgomery Asberg Depression Rating Scale													
			01. REPORTED SADNESS	4	4	3	2	2	2	2	2	2	2	2	1	
			02. INNER TENSION	5	3	3	2	2	2	2	2	2	2	2	2	
			03. APPARENT SADNESS	4	3	2	2	2	2	2	2	2	2	2	1	
			04. SUICIDAL THOUGHTS	3	3	2	2	1	1	1	1	1	1	1	1	
			05. INERTIA	3	3	3	2	2	1	1	1	1	1	1	1	
			06. INABILITY TO FEEL	4	4	3	2	2	2	2	2	2	2	2	1	
			07. PESSIMISTIC THOUGHTS	3	3	3	2	2	1	1	1	1	1	1	1	
			08. CONCENTRATIONS DIFFICULTIES	3	3	3	3	2	2	2	2	2	2	2	1	
			09. REDUCED SLEEP	4	4	3	3	2	2	2	2	2	2	2	1	
			10. REDUCED APPETITE	1	1	1	0	0	0	0	0	0	0	0	0	
11. Total score	32	31	24	19	16	15	14	13	10	10	10					
8ND	Imipramine	Male	Montgomery Asberg Depression Rating Scale													
			01. REPORTED SADNESS	4	4	3	3	3	3	3	3	3	3	3	1	
			02. INNER TENSION	4	4	4	4	4	4	4	4	4	4	4	1	
			03. APPARENT SADNESS	3	4	3	3	3	3	3	3	3	3	3	1	
			04. SUICIDAL THOUGHTS	3	3	3	4	3	3	3	3	3	3	3	1	
			05. INERTIA	4	4	4	4	4	4	4	4	4	4	4	2	
			06. INABILITY TO FEEL	3	4	4	4	4	4	4	4	4	4	4	2	
			07. PESSIMISTIC THOUGHTS	3	3	3	3	3	3	3	3	3	3	3	1	
			08. CONCENTRATIONS DIFFICULTIES	3	3	3	3	3	3	3	3	3	3	3	1	
			09. REDUCED SLEEP	4	4	3	3	3	3	3	3	3	3	3	2	
			10. REDUCED APPETITE	1	1	1	1	0	0	0	0	0	0	0	0	
11. Total score	32	34	31	34	31	28	18	12	10	10	10					
8DT	Reboxetine	Female	Montgomery Asberg Depression Rating Scale													
			01. REPORTED SADNESS	4	4	3	2	2	2	2	2	2	2	2	1	
			02. INNER TENSION	4	3	3	3	2	2	2	2	2	2	2	1	
			03. APPARENT SADNESS	3	3	2	2	2	2	2	2	2	2	2	1	
			04. SUICIDAL THOUGHTS	3	3	2	2	1	1	1	1	1	1	1	1	
			05. INERTIA	3	3	2	2	2	2	2	2	2	2	2	1	
			06. INABILITY TO FEEL	4	3	3	3	3	3	3	3	3	3	3	2	
			07. PESSIMISTIC THOUGHTS	3	3	3	3	2	2	2	2	2	2	2	1	
			08. CONCENTRATIONS DIFFICULTIES	3	3	3	3	2	2	2	2	2	2	2	1	
			09. REDUCED SLEEP	4	4	3	3	2	2	2	2	2	2	2	1	
			10. REDUCED APPETITE	1	1	1	0	0	0	0	0	0	0	0	0	
11. Total score	32	30	23	23	18	15	13	13	10	10	10					

1567

7

9550089

75

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 19.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
292	22DT	Imipramine	Female	33	33	32	33	30	28	25	25	27	
				Montgomery Asberg Depression Rating Scale									
				11.Total score									
	23ND	Reboxetine	Female	4	4	3	3	2	1	1	1	0	
				01.REPORTED SADNESS									
				02.INNER TENSION									
				03.APPARENT SADNESS									
				04.SUICIDAL THOUGHTS									
				05.INERTIA									
				06.INABILITY TO FEEL									
				07.PESSIMISTIC THOUGHTS									
				08.CONCENTRATIONS DIFFICULTIES									
				09.REDUCED SLEEP									
				10.REDUCED APPETITE									
				33	34	31	28	22	16	14	12	11	
				11.Total score									
	23DT	Reboxetine	Male	4	4	3	2	2	2	1	1	0	
				01.REPORTED SADNESS									
				02.INNER TENSION									
				03.APPARENT SADNESS									
				04.SUICIDAL THOUGHTS									
				05.INERTIA									
				06.INABILITY TO FEEL									
				07.PESSIMISTIC THOUGHTS									
				08.CONCENTRATIONS DIFFICULTIES									
				09.REDUCED SLEEP									
				10.REDUCED APPETITE									
				32	31	27	22	19	16	12	10	8	
				11.Total score									
	24ND	Reboxetine	Male	4	4	4	3	2	2	1	1	0	
				01.REPORTED SADNESS									
				02.INNER TENSION									
				03.APPARENT SADNESS									
				04.SUICIDAL THOUGHTS									
				05.INERTIA									
				06.INABILITY TO FEEL									
				07.PESSIMISTIC THOUGHTS									
				08.CONCENTRATIONS DIFFICULTIES									
				09.REDUCED SLEEP									
				10.REDUCED APPETITE									
				33	32	31	26	23	19	16	12	9	
				11.Total score									
	24DT	Imipramine	Female	4	4	3	3	3	3	3	2	2	
				01.REPORTED SADNESS									
				02.INNER TENSION									
				03.APPARENT SADNESS									
				04.SUICIDAL THOUGHTS									
				05.INERTIA									
				06.INABILITY TO FEEL									
				07.PESSIMISTIC THOUGHTS									
				08.CONCENTRATIONS DIFFICULTIES									
				09.REDUCED SLEEP									
				4	4	3	3	3	3	3	2	2	
				11.Total score									

9550089

76

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
292	240F	Imipramine	Female	32	31	29	0	0	0	0	0	0	0
				Montgomery Asberg Depression Rating Scale									
				10. REDUCED APPETITE									
				11. Total score									
293	9ND	Imipramine	Female	4	4	4	4	2	2	2	1	1	1
				01. REPORTED SADNESS									
				02. INNER TENSION									
				03. APPARENT SADNESS									
				04. SUICIDAL THOUGHTS									
				05. INERTIA									
				06. INABILITY TO FEEL									
				07. PESSIMISTIC THOUGHTS									
				08. CONCENTRATIONS DIFFICULTIES									
				09. REDUCED SLEEP									
				10. REDUCED APPETITE									
				11. Total score									
90T		Imipramine	Female	3	3	2	1	1	1	0	0	0	0
				01. REPORTED SADNESS									
				02. INNER TENSION									
				03. APPARENT SADNESS									
				04. SUICIDAL THOUGHTS									
				05. INERTIA									
				06. INABILITY TO FEEL									
				07. PESSIMISTIC THOUGHTS									
				08. CONCENTRATIONS DIFFICULTIES									
				09. REDUCED SLEEP									
				10. REDUCED APPETITE									
				11. Total score									
10ND		Reboxetine	Female	3	3	3	3	2	2	2	1	1	1
				01. REPORTED SADNESS									
				02. INNER TENSION									
				03. APPARENT SADNESS									
				04. SUICIDAL THOUGHTS									
				05. INERTIA									
				06. INABILITY TO FEEL									
				07. PESSIMISTIC THOUGHTS									
				08. CONCENTRATIONS DIFFICULTIES									
				09. REDUCED SLEEP									
				10. REDUCED APPETITE									
				11. Total score									
10DT		Imipramine	Female	2	2	2	2	1	1	1	0	0	0
				01. REPORTED SADNESS									
				02. INNER TENSION									
				03. APPARENT SADNESS									
				04. SUICIDAL THOUGHTS									
				05. INERTIA									
				06. INABILITY TO FEEL									
				07. PESSIMISTIC THOUGHTS									
				08. CONCENTRATIONS DIFFICULTIES									

1570

9550089

77

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
293	10DT	Imipramine	Female	09. REDUCED SLEEP	1	1	1	1	1	1	1	1	1	
				10. REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0
				11. Total score	14	14	15	15	12	10	9	8	7	7
				01. REPORTED SADNESS	2	2	2	2	1	1	0	0	0	0
				02. INNER TENSION	3	3	3	3	2	1	1	1	1	1
				03. APPARENT SADNESS	3	3	3	3	2	1	1	1	1	1
				04. SUICIDAL THOUGHTS	3	3	3	3	2	1	1	1	1	1
				05. INERTIA	1	1	1	1	1	1	1	1	1	1
				06. INABILITY TO FEEL	2	2	2	2	1	1	1	1	1	1
				07. PESSIMISTIC THOUGHTS	3	3	3	3	2	1	1	0	0	0
				08. CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	1	1	1	1
09. REDUCED SLEEP	2	2	2	2	2	2	1	1	1	1				
10. REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0				
11. Total score	21	21	21	19	13	10	8	7	7					
11DT	Reboxetine	Female	01. REPORTED SADNESS	4	4	4	4	4	4	4	4	4	4	
			02. INNER TENSION	4	4	4	4	4	4	4	4	4	4	
			03. APPARENT SADNESS	3	3	3	3	3	3	3	3	3	3	
			04. SUICIDAL THOUGHTS	3	2	2	2	2	2	2	2	2	2	
			05. INERTIA	1	1	1	1	1	1	1	1	1	1	
			06. INABILITY TO FEEL	3	3	3	3	3	3	3	3	3	3	
			07. PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2	2	2	2	
			08. CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2	2	2	2	
			09. REDUCED SLEEP	3	3	3	3	3	3	3	3	3	3	
			10. REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0	
			11. Total score	25	24	24	24	24	24	24	24	24		
12ND	Reboxetine	Male	01. REPORTED SADNESS	4	4	3	2	2	1	1	1	1	1	
			02. INNER TENSION	3	3	3	2	2	2	2	2	2	2	
			03. APPARENT SADNESS	2	2	2	2	2	2	2	2	2	2	
			04. SUICIDAL THOUGHTS	3	3	3	3	3	3	3	3	3	3	
			05. INERTIA	1	1	1	1	1	1	1	1	1	1	
			06. INABILITY TO FEEL	3	3	3	3	3	3	3	3	3	3	
			07. PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2	2	2	2	
			08. CONCENTRATIONS DIFFICULTIES	3	3	3	3	3	3	3	3	3	3	
			09. REDUCED SLEEP	3	3	3	3	3	3	3	3	3	3	
			10. REDUCED APPETITE	0	0	0	0	0	0	0	0	0	0	
			11. Total score	24	24	23	20	20	14	9	9	9		
12DT	Reboxetine	Female	01. REPORTED SADNESS	3	3	3	2	2	1	1	1	1	1	
			02. INNER TENSION	3	3	3	3	2	1	1	1	1	1	
			03. APPARENT SADNESS	3	3	3	2	1	1	1	1	1	1	
			04. SUICIDAL THOUGHTS	4	3	3	2	2	2	1	1	1	0	
			05. INERTIA	1	1	1	1	1	1	1	1	1	1	
			06. INABILITY TO FEEL	3	3	3	2	2	2	2	2	2	2	
			07. PESSIMISTIC THOUGHTS	3	3	3	3	2	2	2	2	2	2	

9550089

78

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RBD

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
293	12DT	Reboxetine	Female	2	2	2	2	1	1	1	1	1	1
				3	3	3	3	2	2	2	2	2	1
				0	0	0	0	0	0	0	0	0	0
				25	24	23	20	15	12	11	10	8	8
294	13ND	Imipramine	Female	4	4	3	2	1	1	1	0	0	0
				3	3	2	2	1	1	1	0	0	0
				4	4	4	2	1	1	1	0	0	0
				4	4	4	2	1	1	0	0	0	0
				2	2	2	2	2	1	0	0	0	0
				2	2	2	2	1	1	1	0	0	0
				4	3	2	2	1	1	0	0	0	0
				3	3	3	2	1	1	0	0	0	0
				3	3	3	2	1	1	0	0	0	0
				3	3	3	2	1	1	0	0	0	0
				32	30	27	20	12	10	5	0	0	0
13DT		Reboxetine	Female	4	4	4	4	3	4	4	4	4	4
				4	4	4	4	2	4	4	4	4	4
				4	4	4	4	3	4	4	4	4	4
				4	4	4	4	2	4	4	4	4	4
				2	2	2	2	2	2	2	2	2	2
				3	3	3	3	3	3	3	3	3	3
				2	2	2	2	1	2	2	2	2	2
				3	3	3	3	1	3	3	3	3	3
				2	2	2	2	2	2	2	2	2	2
				31	31	31	31	21	31	31	31	31	31
14ND		Reboxetine	Female	4	4	4	4	2	1	1	1	0	0
				4	4	4	3	1	1	1	1	0	0
				3	3	3	2	2	1	1	0	0	0
				4	4	4	2	1	1	0	0	0	0
				4	4	4	2	1	1	0	0	0	0
				3	3	3	2	1	1	0	0	0	0
				3	3	3	2	1	1	0	0	0	0
				4	4	4	3	2	1	0	0	0	0
				4	4	4	3	2	1	0	0	0	0
				4	4	4	3	2	1	0	0	0	0
				4	4	4	3	2	1	0	0	0	0
				36	34	32	22	14	10	5	3	0	0
14DT		Imipramine	Female	4	4	4	4	4	3	3	2	1	1
				4	4	4	4	4	3	3	2	1	1
				3	3	3	3	3	3	3	2	1	1
				3	3	3	3	3	3	3	2	1	1
				3	3	3	3	3	3	3	2	1	1
				4	4	4	4	4	4	4	3	2	1

9550089

79

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63				
294	14DT	Imipramine	Female	Montgomery Asberg Depression Rating Scale	4	4	4	4	4	3	3	2	0				
				07.PESSIMISTIC THOUGHTS	3	3	3	3	3	3	3	2	1	0			
				08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2	2	2	0			
				09.REDUCED SLEEP	2	2	2	2	2	2	2	2	2	1			
				10.REDUCED APPETITE	32	32	32	32	32	28	28	28	20	8			
				11.Total score													
				15ND	Imipramine	Female	01.REPORTED SADNESS	4	4	4	4	2	0	0	0	0	0
							02.INNER TENSION	4	4	4	3	3	0	0	0	0	0
							03.APPARENT SADNESS	3	3	3	3	3	0	0	0	0	0
							04.SUICIDAL THOUGHTS	4	4	3	3	3	0	0	0	0	0
							05.INERTIA	4	4	4	3	3	0	0	0	0	0
06.INABILITY TO FEEL	4	4	3				3	2	0	0	0	0	0				
07.PESSIMISTIC THOUGHTS	4	3	3				3	2	0	0	0	0	0				
08.CONCENTRATIONS DIFFICULTIES	2	3	3				3	3	0	0	0	0	0				
09.REDUCED SLEEP	2	3	3				3	3	0	0	0	0	0				
10.REDUCED APPETITE	2	2	2				2	1	0	0	0	0	0				
11.Total score	32	33	32				30	23	0	0	0	0	0				
15DT	Imipramine	Female	01.REPORTED SADNESS	4	4	4	4	4	4	4	3	1	1				
			02.INNER TENSION	4	4	4	4	4	4	4	3	2	1				
			03.APPARENT SADNESS	4	4	4	4	4	4	4	2	2	1				
			04.SUICIDAL THOUGHTS	3	3	3	3	3	3	3	2	1	0				
			05.INERTIA	3	3	3	3	3	3	3	2	1	0				
			06.INABILITY TO FEEL	4	4	4	4	4	4	4	4	2	1				
			07.PESSIMISTIC THOUGHTS	3	3	3	3	3	3	3	2	1	0				
			08.CONCENTRATIONS DIFFICULTIES	4	4	4	4	4	4	4	4	2	1				
			09.REDUCED SLEEP	3	3	3	3	3	3	3	2	1	0				
			10.REDUCED APPETITE	2	2	2	2	2	2	2	2	1	0				
			11.Total score	34	34	34	34	34	34	22	13	4	4				
16ND	Reboxetine	Female	01.REPORTED SADNESS	4	4	4	4	2	1	0	0	0	0				
			02.INNER TENSION	3	3	3	3	2	1	0	0	0	0				
			03.APPARENT SADNESS	4	4	4	4	4	0	0	0	0	0				
			04.SUICIDAL THOUGHTS	4	4	4	4	2	0	0	0	0	0				
			05.INERTIA	3	3	3	3	2	0	0	0	0	0				
			06.INABILITY TO FEEL	4	4	4	4	1	0	0	0	0	0				
			07.PESSIMISTIC THOUGHTS	3	3	3	3	1	0	0	0	0	0				
			08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	1	0	0	0	0	0				
			09.REDUCED SLEEP	2	2	2	2	1	0	0	0	0	0				
			10.REDUCED APPETITE	3	3	3	3	1	0	0	0	0	0				
			11.Total score	32	32	32	34	15	2	0	0	0	0				
16DT	Reboxetine	Female	01.REPORTED SADNESS	4	4	4	4	4	2	2	1	0					
			02.INNER TENSION	4	4	4	4	4	4	2	2	1					
			03.APPARENT SADNESS	4	4	4	4	4	4	1	1	0					
			04.SUICIDAL THOUGHTS	5	5	5	5	5	1	1	0	0					
			05.INERTIA	3	3	3	3	3	1	1	0	0					

11 07 23

PHARMACIA CNS RBD
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
294	16DT	Reboxetine	Female	06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS 08. CONCENTRATIONS DIFFICULTIES 09. REDUCED SLEEP 10. REDUCED APPETITE 11. Total score	4 3 4 2 2 35	4 3 4 2 2 35	4 3 4 2 2 35	4 3 4 2 2 35	4 3 4 2 2 35	1 1 1 1 1 11	1 1 1 0 0 10	1 1 1 0 0 5	0 0 0 0 0 0	0 0 0 0 0 0
25ND		Imipramine	Female	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS 05. INERTIA 06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS 08. CONCENTRATIONS DIFFICULTIES 09. REDUCED SLEEP 10. REDUCED APPETITE 11. Total score	5 5 5 5 5 4 4 3 2 42	5 5 4 4 4 4 4 3 2 42	5 5 4 4 4 4 4 3 2 37	5 5 4 4 4 4 4 3 2 22	5 5 4 4 4 4 4 3 2 17	1 1 1 1 1 0 0 0 0 5	0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0
26ND		Imipramine	Female	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS 05. INERTIA 06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS 08. CONCENTRATIONS DIFFICULTIES 09. REDUCED SLEEP 10. REDUCED APPETITE 11. Total score	4 4 4 5 4 4 4 4 4 3 40	4 4 4 4 4 4 4 3 2 37	4 4 4 3 3 4 3 2 2 26	4 4 4 3 3 4 3 2 2 19	4 4 4 3 3 4 3 2 2 15	0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0
27ND		Reboxetine	Female	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS 05. INERTIA 06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS 08. CONCENTRATIONS DIFFICULTIES 09. REDUCED SLEEP 10. REDUCED APPETITE 11. Total score	5 5 4 5 5 5 5 4 4 3 46	5 5 5 4 5 5 5 4 3 3 44	5 5 5 5 5 5 4 3 3 43	5 5 5 4 5 5 5 4 3 3 39	5 5 4 4 4 4 4 3 3 37	0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0
28ND		Reboxetine	Female	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS	5 5 5 5	5 5 5 5	4 4 4 3	4 4 4 2	4 4 4 1	0 0 0 1	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0

1574

9550089

81

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
294	28ND	Reboxetine	Female	05. INERTIA	4	4	3	2	1	0	0	0	0	0
				06. INABILITY TO FEEL	4	4	3	2	1	0	0	0	0	0
				07. PESSIMISTIC THOUGHTS	4	5	3	2	1	0	0	0	0	0
				08. CONCENTRATIONS DIFFICULTIES	4	5	3	2	0	0	0	0	0	0
				09. REDUCED SLEEP	4	4	2	1	0	0	0	0	0	0
				10. REDUCED APPETITE	2	2	2	1	0	0	0	0	0	0
				11. Total score	42	44	31	19	7	0	0	0	0	0
294	29DT	Reboxetine	Female	01. REPORTED SADNESS	4	4	4	4	4	3	3	3	3	2
				02. INNER TENSION	4	4	4	4	4	3	3	3	3	2
				03. APPARENT SADNESS	5	5	5	5	5	5	5	5	5	2
				04. SUICIDAL THOUGHTS	5	5	5	5	5	2	2	2	2	1
				05. INERTIA	4	4	4	4	4	3	3	3	3	2
				06. INABILITY TO FEEL	4	4	4	4	4	3	3	3	3	2
				07. PESSIMISTIC THOUGHTS	4	4	4	4	4	3	3	3	3	1
				08. CONCENTRATIONS DIFFICULTIES	4	4	4	4	4	2	2	2	2	1
				09. REDUCED SLEEP	4	4	4	4	4	2	2	2	2	1
				10. REDUCED APPETITE	4	4	4	4	4	2	2	2	2	1
				11. Total score	42	42	42	42	42	26	26	26	26	15
300	30DT	Reboxetine	Female	01. REPORTED SADNESS	5	5	5	5	4	2	2	2	2	2
				02. INNER TENSION	5	5	5	5	4	2	2	2	2	2
				03. APPARENT SADNESS	5	5	5	5	4	2	2	2	2	2
				04. SUICIDAL THOUGHTS	5	5	5	5	4	2	2	2	2	2
				05. INERTIA	4	4	4	4	4	2	2	2	2	2
				06. INABILITY TO FEEL	5	5	5	5	4	2	2	2	2	2
				07. PESSIMISTIC THOUGHTS	4	4	4	4	3	2	2	2	2	2
				08. CONCENTRATIONS DIFFICULTIES	4	4	4	4	4	2	2	2	2	2
				09. REDUCED SLEEP	5	5	5	5	4	2	2	2	2	2
				10. REDUCED APPETITE	4	4	4	4	4	2	2	2	2	2
				11. Total score	46	46	46	46	37	20	20	20	20	20
310	31DT	Imipramine	Female	01. REPORTED SADNESS	5	5	5	5	4	2	2	2	2	2
				02. INNER TENSION	5	5	5	5	4	2	2	2	2	2
				03. APPARENT SADNESS	5	5	5	5	4	2	2	2	2	2
				04. SUICIDAL THOUGHTS	5	5	5	5	4	2	2	2	2	2
				05. INERTIA	4	4	4	4	4	2	2	2	2	2
				06. INABILITY TO FEEL	5	5	5	5	4	2	2	2	2	2
				07. PESSIMISTIC THOUGHTS	4	4	4	4	3	2	2	2	2	2
				08. CONCENTRATIONS DIFFICULTIES	4	4	4	4	4	2	2	2	2	2
				09. REDUCED SLEEP	5	5	5	5	4	2	2	2	2	2
				10. REDUCED APPETITE	4	4	4	4	4	2	2	2	2	2
				11. Total score	46	46	46	46	37	20	20	20	20	20
320	32DT	Imipramine	Male	01. REPORTED SADNESS	4	4	4	4	4	4	3	1	1	1
				02. INNER TENSION	4	4	4	4	4	4	3	2	2	1
				03. APPARENT SADNESS	4	4	4	4	4	4	4	2	2	1

15 7 51

9550089

63

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63				
295	18DT	Imipramine	Female	03. APPARENT SADNESS	3	3	3	3	3	3	3	2	2	2				
				04. SUICIDAL THOUGHTS	4	4	4	4	4	4	3	3	3	2	2			
				05. INERTIA	3	3	3	3	3	3	3	3	3	2	1	1		
				06. INABILITY TO FEEL	3	3	3	3	3	3	3	3	3	2	2	2		
				07. PESSIMISTIC THOUGHTS	2	2	2	2	2	2	2	2	2	2	2	2		
				08. CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2	2	2	2	1	1		
				09. REDUCED SLEEP	2	2	2	2	2	2	2	2	2	1	1	1		
				10. REDUCED APPETITE	2	2	2	2	2	2	2	2	2	2	1	1		
				11. Total score	28	28	28	28	27	24	21	16	16					
				19MD	1577	Imipramine	Male	01. REPORTED SADNESS	4	4	4	4	4	4	4	3	3	3
								02. INNER TENSION	4	4	4	4	4	4	4	4	4	4
03. APPARENT SADNESS	4	4	4					4	4	4	4	4	4	3	3			
04. SUICIDAL THOUGHTS	4	4	4					4	4	4	4	4	4	4	4			
05. INERTIA	2	2	2					2	2	2	2	2	2	2	2			
06. INABILITY TO FEEL	3	3	3					3	3	3	3	3	3	3	3			
07. PESSIMISTIC THOUGHTS	2	2	2					2	2	2	2	2	2	2	2			
08. CONCENTRATIONS DIFFICULTIES	3	3	3					3	3	3	3	3	3	2	2			
09. REDUCED SLEEP	4	4	4					4	4	4	4	4	4	4	3			
10. REDUCED APPETITE	2	2	2					2	2	2	2	2	2	2	2			
11. Total score	32	32	32					32	34	34	32	30	31					
19DT		Reboxetine	Female	01. REPORTED SADNESS	4	4	4	4	4	4	3	3	4	3				
				02. INNER TENSION	3	3	3	3	3	3	3	3	3	4	3			
				03. APPARENT SADNESS	3	3	3	3	3	3	3	3	3	4	3			
				04. SUICIDAL THOUGHTS	4	4	4	4	4	4	4	4	4	3	3			
				05. INERTIA	0	0	0	0	0	0	0	0	0	0	0			
				06. INABILITY TO FEEL	4	4	4	4	4	4	4	4	4	4	4			
				07. PESSIMISTIC THOUGHTS	4	4	4	4	4	4	4	4	4	4	4			
				08. CONCENTRATIONS DIFFICULTIES	4	4	4	4	4	4	4	4	4	4	3			
				09. REDUCED SLEEP	2	2	2	2	2	2	2	2	2	2	2			
				10. REDUCED APPETITE	2	2	2	2	2	2	2	2	2	2	2			
				11. Total score	30	30	30	29	29	29	31	32	28					
20MD		Imipramine	Female	01. REPORTED SADNESS	3	3	3	3	3	3	3	3	2	3				
				02. INNER TENSION	3	3	3	3	3	3	3	3	3	3	3			
				03. APPARENT SADNESS	4	4	4	4	4	4	4	4	4	3	3			
				04. SUICIDAL THOUGHTS	2	2	2	2	2	2	2	2	2	2	2			
				05. INERTIA	3	3	3	3	3	3	3	3	3	2	2			
				06. INABILITY TO FEEL	3	3	3	3	3	3	3	3	3	2	2			
				07. PESSIMISTIC THOUGHTS	4	4	4	4	4	4	4	4	4	3	3			
				08. CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2	2	2	2	2			
				09. REDUCED SLEEP	2	2	2	2	2	2	2	2	2	2	2			
				10. REDUCED APPETITE	29	29	28	28	26	26	26	24	25					
				11. Total score	2	2	2	2	2	2	2	1	1					
20DT		Reboxetine	Female	01. REPORTED SADNESS	2	2	2	2	2	2	1	1	1	1				

9550089

85

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
381	4MD	Imipramine	Female	Montgomery Asberg Depression Rating Scale											
				01.REPORTED SADNESS	2	2	2	2	2	2	2	2	2	2	2
				02.INNER TENSION	2	2	2	2	2	2	2	2	2	2	2
				03.APPARENT SADNESS	3	4	1	1	1	1	1	1	1	1	1
				04.SUICIDAL THOUGHTS	4	2	2	2	2	2	2	2	2	2	2
				05.INERTIA	2	2	1	1	1	1	1	1	1	1	1
				06.INABILITY TO FEEL	3	4	0	0	0	0	0	0	0	0	0
				07.PESSIMISTIC THOUGHTS	3	4	2	2	2	2	2	2	2	2	2
				08.CONCENTRATIONS DIFFICULTIES	4	4	2	2	2	2	2	2	2	2	2
				09.REDUCED SLEEP	2	2	1	1	1	1	1	1	1	1	1
				10.REDUCED APPETITE	2	2	2	2	2	2	2	2	2	2	2
11.Total score	27	28	15	15	15	15	15	15	15	15	15	15			
382	5MD	Imipramine	Female	Montgomery Asberg Depression Rating Scale											
				01.REPORTED SADNESS	6	6	2	2	2	2	2	2	2	2	2
				02.INNER TENSION	6	4	4	2	2	2	2	2	2	2	2
				03.APPARENT SADNESS	2	4	2	2	2	2	2	2	2	2	2
				04.SUICIDAL THOUGHTS	6	6	4	2	2	2	2	2	2	2	2
				05.INERTIA	4	2	2	2	2	2	2	2	2	2	2
				06.INABILITY TO FEEL	2	4	4	2	2	2	2	2	2	2	2
				07.PESSIMISTIC THOUGHTS	6	4	2	2	2	2	2	2	2	2	2
				08.CONCENTRATIONS DIFFICULTIES	4	4	2	2	2	2	2	2	2	2	2
				09.REDUCED SLEEP	4	4	2	2	2	2	2	2	2	2	2
				10.REDUCED APPETITE	4	2	2	2	2	2	2	2	2	2	2
11.Total score	44	40	28	20	20	20	20	20	20	20	20	16			
5DT	Reboxetine	Male	Montgomery Asberg Depression Rating Scale												
			01.REPORTED SADNESS	6	6	4	4	4	4	4	4	4	4	4	
			02.INNER TENSION	6	6	4	4	4	4	4	4	4	4	4	
			03.APPARENT SADNESS	4	4	0	0	0	0	0	0	0	0	0	
			04.SUICIDAL THOUGHTS	4	4	2	2	2	2	2	2	2	2	2	
			05.INERTIA	4	4	0	0	0	0	0	0	0	0	0	
			06.INABILITY TO FEEL	4	4	0	0	0	0	0	0	0	0	0	
			07.PESSIMISTIC THOUGHTS	4	4	2	2	2	2	2	2	2	2	2	
			08.CONCENTRATIONS DIFFICULTIES	5	4	2	2	2	2	2	2	2	2	2	
			09.REDUCED SLEEP	6	4	4	4	4	4	4	4	4	4	4	
			10.REDUCED APPETITE	4	4	0	0	0	0	0	0	0	0	0	
11.Total score	47	28	32	32	32	32	32	32	32	32	32				
6MD	Reboxetine	Female	Montgomery Asberg Depression Rating Scale												
			01.REPORTED SADNESS	6	4	6	6	6	6	6	6	6	6	6	
			02.INNER TENSION	4	3	6	4	4	4	4	4	4	4	4	
			03.APPARENT SADNESS	4	3	4	4	4	4	4	4	4	4	4	
			04.SUICIDAL THOUGHTS	6	2	4	4	4	4	4	4	4	4	4	
			05.INERTIA	4	4	4	4	4	4	4	4	4	4	4	
			06.INABILITY TO FEEL	4	2	4	4	4	4	4	4	4	4	4	
			07.PESSIMISTIC THOUGHTS	4	2	4	4	4	4	4	4	4	4	4	
			08.CONCENTRATIONS DIFFICULTIES	2	2	2	2	2	2	2	2	2	2	2	
			09.REDUCED SLEEP	3	2	4	4	4	4	4	4	4	4	4	
			10.REDUCED APPETITE	2	2	2	2	2	2	2	2	2	2	2	
11.Total score	39	26	40	40	40	40	40	40	40	40	40				

1579

9550089

86

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
362	6DT	Imipramine	Female	01.REPORTED SADNESS	4	2	4	2	1	1	1	2	0		
				02.INNER TENSION	2	2	3	2	2	0	2	0			
				03.APPARENT SADNESS	4	2	4	2	1	0	1	1			
				04.SUICIDAL THOUGHTS	4	2	6	0	2	0	1	0			
				05.INERTIA	6	2	2	0	2	0	0	0			
				06.INABILITY TO FEEL	2	4	2	0	2	1	1	1			
				07.PESSIMISTIC THOUGHTS	4	4	4	0	1	2	1	1			
				08.CONCENTRATIONS DIFFICULTIES	4	2	2	1	0	1	0	0			
				09.REDUCED SLEEP	4	2	2	0	0	1	0	1			
				10.REDUCED APPETITE	2	2	2	0	2	0	0	0			
				11.Total score	38	24	32	7	13	8	9	4			
7ND	Reboxetine	Female	01.REPORTED SADNESS	4	2	0	1	1	1	0	0	0	0		
			02.INNER TENSION	4	2	2	1	1	1	0	0				
			03.APPARENT SADNESS	2	2	0	2	1	2	1	2				
			04.SUICIDAL THOUGHTS	4	3	2	0	0	0	0	0				
			05.INERTIA	4	3	0	2	0	2	0	0				
			06.INABILITY TO FEEL	2	2	4	1	0	1	0	0				
			07.PESSIMISTIC THOUGHTS	6	2	0	1	0	0	0	0				
			08.CONCENTRATIONS DIFFICULTIES	4	2	0	1	0	1	0	0				
			09.REDUCED SLEEP	4	2	2	1	0	1	0	0				
			10.REDUCED APPETITE	2	0	0	0	0	0	0	0				
			11.Total score	36	20	10	10	3	8	3	1				
7DT	Imipramine	Male	01.REPORTED SADNESS	4											
			02.INNER TENSION	4											
			03.APPARENT SADNESS	2											
			04.SUICIDAL THOUGHTS	4											
			05.INERTIA	4											
			06.INABILITY TO FEEL	4											
			07.PESSIMISTIC THOUGHTS	4											
			08.CONCENTRATIONS DIFFICULTIES	2											
			09.REDUCED SLEEP	4											
			10.REDUCED APPETITE	4											
			11.Total score	38											
8ND	Imipramine	Male	01.REPORTED SADNESS	4	4	6									
			02.INNER TENSION	4	4	4									
			03.APPARENT SADNESS	3	3	4									
			04.SUICIDAL THOUGHTS	0	0	0									
			05.INERTIA	4	4	4									
			06.INABILITY TO FEEL	6	6	6									
			07.PESSIMISTIC THOUGHTS	4	4	4									
			08.CONCENTRATIONS DIFFICULTIES	4	4	4									
			09.REDUCED SLEEP	4	4	4									
			10.REDUCED APPETITE	2	2	2									

1580

9550089

87

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
382	8HD	Imipramine	Male	11.Total score	35	35	40							
	8BT	Reboxetine	Female	01.REPORTED SADNESS	4	0	2	2	0	1	0	4	1	
				02.INNER TENSION	4	0	2	2	1	1	2	4	2	
				03.APPARENT SADNESS	4	0	2	2	0	0	2	4	1	
				04.SUICIDAL THOUGHTS	5	4	2	2	2	0	0	0	0	
				05.INERTIA	6	2	4	2	0	0	0	2	0	
				06.INABILITY TO FEEL	2	2	1	1	1	0	2	4	2	
				07.PESSIMISTIC THOUGHTS	3	2	2	2	1	1	0	2	1	
				08.CONCENTRATIONS DIFFICULTIES	4	4	4	2	1	1	0	2	1	
				09.REDUCED SLEEP	2	2	2	2	1	0	2	2	0	
				10.REDUCED APPETITE	0	0	0	2	0	0	0	0	0	
				11.Total score	36	16	22	18	7	4	8	24	8	
	9HD	Reboxetine	Female	01.REPORTED SADNESS	4	2	2	2	2	0	1	1	1	
				02.INNER TENSION	4	2	2	2	1	0	1	0	0	
				03.APPARENT SADNESS	4	2	1	2	0	0	2	0	0	
				04.SUICIDAL THOUGHTS	4	2	2	2	2	1	1	0	0	
				05.INERTIA	4	0	2	0	0	0	0	0	0	
				06.INABILITY TO FEEL	4	2	2	0	1	2	2	0	1	
				07.PESSIMISTIC THOUGHTS	4	1	2	1	0	0	1	0	0	
				08.CONCENTRATIONS DIFFICULTIES	4	0	2	2	0	0	1	0	0	
				09.REDUCED SLEEP	2	2	1	1	1	0	0	0	0	
				10.REDUCED APPETITE	2	0	0	1	1	0	0	0	0	
				11.Total score	36	13	16	13	7	3	9	1	4	
	9DT	Reboxetine	Female	01.REPORTED SADNESS	4	4	1	2	2					
				02.INNER TENSION	4	4	1	2	2					
				03.APPARENT SADNESS	2	2	1	2	2					
				04.SUICIDAL THOUGHTS	6	6	2	6	6					
				05.INERTIA	2	4	0	0	0					
				06.INABILITY TO FEEL	2	2	1	2	2					
				07.PESSIMISTIC THOUGHTS	2	2	2	2	2					
				08.CONCENTRATIONS DIFFICULTIES	4	4	2	2	4					
				09.REDUCED SLEEP	4	4	2	2	4					
				10.REDUCED APPETITE	2	2	0	2	2					
				11.Total score	32	34	42	24	28					
	10HD	Imipramine	Female	01.REPORTED SADNESS	4	2								
				02.INNER TENSION	4	2								
				03.APPARENT SADNESS	4	2								
				04.SUICIDAL THOUGHTS	4	6								
				05.INERTIA	4	4								
				06.INABILITY TO FEEL	4	4								
				07.PESSIMISTIC THOUGHTS	4	2								
				08.CONCENTRATIONS DIFFICULTIES	4	2								
				09.REDUCED SLEEP	4	3								

1581

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

88

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 13.0

MONTGOMERY ASBERG DEPRESSION RATING SCALE

Centre	Patient	Treatment	Sex	Montgomery Asberg Depression Rating Scale	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
382	10ND	Inipramine	Female	10. REDUCED APPETITE 11. Total score	2 38	1 26								
3301	1ND	Reboxetine	Female	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS 05. INERTIA 06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS 08. CONCENTRATIONS DIFFICULTIES 09. REDUCED SLEEP 10. REDUCED APPETITE 11. Total score	3 3 2 3 2 3 3 2 2 25									
2ND		Inipramine	Male	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS 05. INERTIA 06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS 08. CONCENTRATIONS DIFFICULTIES 09. REDUCED SLEEP 10. REDUCED APPETITE 11. Total score	4 3 2 4 3 4 4 3 2 30	4 3 2 4 3 2 2 2 2 26	4 3 2 3 2 2 2 2 2 23	4 3 2 2 2 2 2 2 1 19	3 3 2 1 2 1 1 2 2 17	3 3 1 1 1 1 1 1 1 15	2 2 1 1 1 2 2 1 1 14	2 2 1 1 1 2 2 1 1 14	2 2 1 1 1 2 2 1 1 15	1 2 2 1 1 2 2 1 1 15
3ND		Reboxetine	Female	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS 05. INERTIA 06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS 08. CONCENTRATIONS DIFFICULTIES 09. REDUCED SLEEP 10. REDUCED APPETITE 11. Total score	3 4 3 3 2 2 2 2 2 27	3 4 3 3 2 2 2 2 2 28	3 4 3 3 2 2 2 2 2 31	3 4 4 4 3 2 2 2 2 31	3 4 4 4 3 3 3 4 3 17	3 4 4 4 3 3 3 4 3 15	3 4 4 4 3 3 3 4 3 14	3 4 4 4 3 3 3 4 3 14	3 4 4 4 3 3 3 4 3 15	4 4 4 4 3 3 3 4 3 35
3302	5ND	Reboxetine	Female	01. REPORTED SADNESS 02. INNER TENSION 03. APPARENT SADNESS 04. SUICIDAL THOUGHTS 05. INERTIA 06. INABILITY TO FEEL 07. PESSIMISTIC THOUGHTS 08. CONCENTRATIONS DIFFICULTIES	3 3 2 3 3 3 3 2	3 3 2 3 3 3 3 2	3 3 2 3 3 3 3 2	3 3 2 3 3 3 3 2	3 3 2 3 3 3 3 2	3 3 2 3 3 3 3 2	3 3 2 3 3 3 3 2	3 3 2 3 3 3 3 2	3 3 2 3 3 3 3 2	3 3 2 3 3 3 3 2

9550089

15 08 2

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Geriatric Depression Scale

01. Are you basically satisfied with your life?
02. Have you dropped many of your activities and interest?
03. Do you feel that your life is empty?
04. Do you often get bored?
05. Are you hopeful about the future?
06. Are you bothered by thoughts you can't get out of your head?
07. Are you in good spirits most of the time?
08. Are you afraid that something bad is going to happen to you?
09. Do you feel happy most of the time?
10. Do you often feel helpless?
11. Do you often get restless and fidgety?
12. Do you prefer to stay at home than going out and doing new things?
13. Do you frequently worry about the future?
14. Do you feel you have more problems with memory than most?
15. Do you think it is wonderful to be alive now?
16. Do you often feel downhearted and blue?
17. Do you feel pretty worthless the way you are now?
18. Do you worry a lot about the past?
19. Do you find life very exciting?
20. Is it hard for you to get started on new projects?
21. Do you feel full of energy?
22. Do you feel that your situation is hopeless?
23. Do you think that most people are better off than you are?
24. Do you frequently get upset over little things?
25. Do you frequently feel like crying?
26. Do you have trouble concentrating?
27. Do you enjoy getting up in the morning?
28. Do you prefer to avoid social gatherings?
29. Is it easy for you to make decisions?
30. Is your mind as clear as it used to be?

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

1

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	_Day0_		_Day7_		_Day14_		_Day21_		_Day28_		_Day35_		_Day42_		_Day49_		_Day56_		_Day63_	
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
1	10D	Reboxetine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		01.Are you () satisfied with your life	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		02.Have you dropped many of your act..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		03.Do you feel that your life is empty	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		04.Do you often get bored	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		07.Are you in good spirits most of ...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		08.Are you afraid that something bad..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		09.Do you feel happy most of the time	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		10.Do you often feel helpless	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		11.Do you often get restless and f.....	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		12.Do you prefer to stay at home,....	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		13.Do you frequently worry about the..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		15.Do you think it is wonderful to be..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		16.Do you often feel downhearted	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		17.Do you feel pretty worthless the ...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		18.Do you worry a lot about the past ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		19.Do you find life very exciting	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		20.Is it hard for you to get started..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		21.Do you feel full of energy	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		23.Do you think that most people are..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		24.Do you frequently get upset over...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		25.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		26.Do you have trouble concentrating	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		27.Do you enjoy getting up in the mor..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		28.Do you prefer to avoid social gat..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		29.Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		30.Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		31.Total score	11	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10T	Reboxetine	01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		02.Have you dropped many of your act..	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		03.Do you feel that your life is empty	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		04.Do you often get bored	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		06.Are you bothered by thoughts you ...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		09.Do you feel happy most of the time	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		10.Do you often feel helpless	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		11.Do you often get restless and f.....	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		12.Do you prefer to stay at home,....	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		13.Do you frequently worry about the..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		14.Do you feel you have more problems.	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		15.Do you think it is wonderful to be..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		16.Do you often feel downhearted	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		17.Do you feel pretty worthless the ...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		18.Do you worry a lot about the past ..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

15885

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

3

PHARMACIA CNS R&D
 REMOETINE - PROTOCOL 20124/035
 Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient	Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
				Y	N	Y	N	Y	N	Y	N	Y	N
1	ZDF	Imipramine	04. Do you often get bored	0	1	1	1						
			05. Are you hopeful about the future	0	0	1	1						
			06. Are you bothered by thoughts you ...	0	0	1	1						
			07. Are you in good spirits most of ...	1	1	0	1						
			08. Are you afraid that something bad...	1	0	1	1						
			09. Do you feel happy most of the time	1	1	1	1						
			10. Do you often feel helpless	1	1	1	1						
			11. Do you often get restless and f....	1	1	1	1						
			12. Do you prefer to stay at home, ...	1	1	1	1						
			13. Do you frequently worry about the...	0	1	1	1						
			14. Do you feel you have more problems.	0	1	1	1						
			15. Do you think it is wonderful to be.	0	1	1	1						
			16. Do you often feel downhearted	1	1	1	1						
			17. Do you feel pretty worthless the ...	1	1	1	1						
			18. Do you worry a lot about the past	1	1	1	1						
			19. Do you find life very exciting	1	1	1	1						
			20. Is it hard for you to get started...	1	1	1	1						
			21. Do you feel full of energy	1	1	1	1						
			22. Do you feel that your situation ...	1	1	1	1						
			23. Do you think that most people are...	1	1	1	1						
			24. Do you frequently get upset over...	1	1	1	1						
			25. Do you frequently feel like crying	0	1	1	1						
			26. Do you have trouble concentrating	0	1	1	1						
			27. Do you enjoy getting up in the mor.	1	1	1	1						
			28. Do you prefer to avoid social gat...	1	1	1	1						
			29. Is it easy for you to make decision	1	1	1	1						
			30. Is your mind as clear as it used ...	0	1	1	1						
			31..Total score	19	0	26	29						
3ND		Imipramine	01. Are you () satisfied with your life	1	0	0	0						
			02. Have you dropped many of your act...	1	1	0	0						
			03. Do you feel that your life is empty	1	1	0	0						
			04. Do you often get bored	0	0	1	0						
			05. Are you hopeful about the future	0	0	0	0						
			06. Are you bothered by thoughts you ...	1	0	0	0						
			07. Are you in good spirits most of ...	1	0	0	0						
			08. Are you afraid that something bad...	0	0	0	0						
			09. Do you feel happy most of the time	1	1	0	0						
			10. Do you often feel helpless	1	1	0	0						
			11. Do you often get restless and f....	1	1	0	0						
			12. Do you prefer to stay at home, ...	0	0	1	0						
			13. Do you frequently worry about the...	1	0	0	0						
			14. Do you feel you have more problems.	0	0	0	0						
			15. Do you think it is wonderful to be.	0	0	0	0						
			16. Do you often feel downhearted	1	1	0	0						
			17. Do you feel pretty worthless the ...	1	1	0	0						
			18. Do you worry a lot about the past	0	1	0	0						
			19. Do you find life very exciting	1	1	1	1						
			20. Is it hard for you to get started...	0	1	0	0						
			21. Do you feel full of energy	1	0	0	0						

1587

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

4

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
1	3ND Imipramine	0	1	0	0	0	0	0	0	0	0
	22.Do you feel that your situation ...	1	0	0	0	0	0	0	0	0	0
	23.Do you think that most people are...	1	0	0	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	1	0	0	0	1	0	0	0	0	0
	25.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	0	0	0	0	0	0	0	0	0	0
	28.Do you prefer to avoid social gat...	0	0	0	0	0	0	0	0	0	0
	29.Is it easy for you to make decision	0	1	0	0	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	1	1	0	0	1	0	0	0	0	0
	31.Total score	18	15	3	1	1	0	0	0	0	0
3NT	Reboxetine	1	0	1	1	0	0	0	0	0	0
	01.Are you () satisfied with your life	1	1	1	1	0	1	0	0	0	0
	02.Have you dropped many of your act...	1	1	1	1	0	1	0	0	0	0
	03.Do you feel that your life is empty	1	1	1	1	1	0	0	0	0	0
	04.Do you often get bored	1	0	0	1	1	0	0	0	0	0
	05.Are you hopeful about the future	0	0	1	1	1	0	0	0	0	0
	06.Are you bothered by thoughts you ...	1	1	1	1	1	1	0	0	0	0
	07.Are you in good spirits most of ...	1	1	1	1	0	1	1	0	0	0
	08.Are you afraid that something bad...	1	1	1	1	1	1	1	0	0	0
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	0	0	0
	10.Do you often feel helpless	1	0	0	1	0	0	0	0	0	0
	11.Do you often get restless and f....	1	0	0	1	0	1	0	0	0	0
	12.Do you prefer to stay at home, ...	1	1	1	1	0	1	1	0	0	0
	13.Do you frequently worry about the...	1	1	1	1	1	1	1	0	0	0
	14.Do you feel you have more problems.	1	1	1	1	0	0	0	0	0	0
	15.Do you think it is wonderful to be.	0	0	0	0	0	0	0	0	0	0
	16.Do you often feel downhearted	1	1	1	1	0	0	0	0	0	0
	17.Do you feel pretty worthless the ..	1	1	1	1	0	0	0	0	0	0
	18.Do you worry a lot about the past	1	1	0	1	0	1	0	0	0	0
	19.Do you find life very exciting	1	0	0	1	1	1	1	0	0	0
	20.Is it hard for you to get started..	0	0	1	1	0	0	1	0	0	0
	21.Do you feel full of energy	1	1	1	1	1	1	1	0	0	0
	22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0
	23.Do you think that most people are...	0	0	0	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	0	0	0	0	0	0	0	0	0	0
	28.Do you prefer to avoid social gat...	1	1	1	1	1	1	0	0	0	0
	29.Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	0	1	0	1	0	1	0	0	0	0
	31.Total score	19	17	25	22	12	14	13	1	0	0
4ND	Reboxetine	1	1	1	1	1	1	0	0	0	0
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	0	0	0
	02.Have you dropped many of your act...	1	1	1	1	1	1	1	0	0	0
	03.Do you feel that your life is empty	0	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	0	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	0	0	0
	06.Are you bothered by thoughts you ...	1	1	1	1	1	1	1	1	1	1

1508

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

5

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63					
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N		
1	4ND	Reboxetine	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
			08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
			09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
			10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			12.Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			14.Do you feel you have more problems.	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			23.Do you think that most people are..	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			24.Do you frequently get upset over...	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			31.Total score			26	29	28	25	30	30	28	28	17	16	11										
			40T	Inipramine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
					02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
					03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
					04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
					05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
					06.Are you bothered by thoughts you ..	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
07.Are you in good spirits most of ...	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
08.Are you afraid that something bad..	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
09.Do you feel happy most of the time	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
10.Do you often feel helpless	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
11.Do you often get restless and f....	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
12.Do you prefer to stay at home,	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
13.Do you frequently worry about the..	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
14.Do you feel you have more problems.	0	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
15.Do you think it is wonderful to be.	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
16.Do you often feel downhearted	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
17.Do you feel pretty worthless the ..	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
18.Do you worry a lot about the past	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
19.Do you find life very exciting	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
20.Is it hard for you to get started..	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
21.Do you feel full of energy	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
22.Do you feel that your situation ...	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
23.Do you think that most people are..	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
24.Do you frequently get upset over...	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		

11 00 09

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

6

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	_Day0_		_Day7_		_Day14_		_Day21_		_Day28_		_Day35_		_Day42_		_Day49_		_Day56_		_Day63_	
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
1	4PI	Imipramine	1	1	1	1	1	0	1	0	1	1	0	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	1	1	0	1	0	1	1	0	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social get..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		31.Total score	26	24	24	25	25	26	26	26	27	27	27	27	27	27	27	27	27	27	27	27
2	4HD	Reboxetine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social get..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		31.Total score	27	22	22	26	26	28	28	28	27	27	27	27	27	27	27	27	27	27	27	27
3	4HD	Reboxetine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1590

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

7

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63					
			Y	Y	Y	Y	Y	Y	Y	Y	Y	Y					
3	1MD	Reboxetine	10. Do you often feel helpless	1	1	1	1	1	1	1	1	1	1				
			11. Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1			
			12. Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1	1			
			13. Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1			
			14. Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1			
			15. Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1	1			
			16. Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1			
			17. Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1			
			18. Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1			
			19. Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1			
			20. Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1			
			21. Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1			
			22. Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1			
			23. Do you think that most people are...	1	1	1	1	1	1	1	1	1	1	1			
			24. Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1			
			25. Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1			
			26. Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1			
			27. Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1			
			28. Do you prefer to avoid social gat...	1	1	1	1	1	1	1	1	1	1	1			
			29. Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1			
			30. Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1			
			31. Total score			24	25	15	22	19	17	5	22				
			4	1MD	Imipramine	01. Are you () satisfied with your life	1	1	1	1	1	1	1	1	1		
						02. Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	
						03. Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1
						04. Do you often get bored	1	1	1	1	1	1	1	1	1	1	1
						05. Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0	0
						06. Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1
						07. Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1
						08. Are you afraid that something had..	0	0	0	0	0	0	0	0	0	0	0
						09. Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1
10. Do you often feel helpless	1	1				1	1	1	1	1	1	1	1	1			
11. Do you often get restless and f....	1	1				1	1	1	1	1	1	1	1	1			
12. Do you prefer to stay at home,	1	1				1	1	1	1	1	1	1	1	1			
13. Do you frequently worry about the..	1	1				1	1	1	1	1	1	1	1	1			
14. Do you feel you have more problems.	1	1				1	1	1	1	1	1	1	1	1			
15. Do you think it is wonderful to be..	1	1				1	1	1	1	1	1	1	1	1			
16. Do you often feel downhearted	1	1				1	1	1	1	1	1	1	1	1			
17. Do you feel pretty worthless the ...	1	1				1	1	1	1	1	1	1	1	1			
18. Do you worry a lot about the past	1	1				1	1	1	1	1	1	1	1	1			
19. Do you find life very exciting	1	1				1	1	1	1	1	1	1	1	1			
20. Is it hard for you to get started..	1	1				1	1	1	1	1	1	1	1	1			
21. Do you feel full of energy	0	1				1	1	1	1	1	1	1	1	1			
22. Do you feel that your situation ...	0	1				1	1	1	1	1	1	1	1	1			
23. Do you think that most people are...	0	1				1	1	1	1	1	1	1	1	1			
24. Do you frequently get upset over...	0	1				1	1	1	1	1	1	1	1	1			
25. Do you frequently feel like crying	0	1				1	1	1	1	1	1	1	1	1			
26. Do you have trouble concentrating	0	1				1	1	1	1	1	1	1	1	1			
27. Do you enjoy getting up in the mor..	1	1				1	1	1	1	1	1	1	1	1			

15 91

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

8

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
4	1ND Imipramine	1	1	1	1	1	1	1	1	1	1
	28. Do you prefer to avoid social gat..										
	29. Is it easy for you to make decision										
	30. Is your mind as clear as it used ..										
	31. Total score	22	24	23	22	27	28				
5	1ND Reboxetine	1	1	1	1	1	1	1	1	1	1
	01. Are you () satisfied with your life										
	02. Have you dropped many of your act..										
	03. Do you feel that your life is empty										
	04. Do you often get bored										
	05. Are you hopeful about the future										
	06. Are you bothered by thoughts you ..										
	07. Are you in good spirits most of ..										
	08. Are you afraid that something bad..										
	09. Do you feel happy most of the time										
	10. Do you often feel helpless										
	11. Do you often get restless and f....										
	12. Do you prefer to stay at home,										
	13. Do you frequently worry about the..										
	14. Do you feel you have more problems.										
	15. Do you think it is wonderful to be..										
	16. Do you often feel downhearted										
	17. Do you feel pretty worthless the ..										
	18. Do you worry a lot about the past ..										
	19. Do you find life very exciting										
	20. Is it hard for you to get started..										
	21. Do you feel full of energy										
	22. Do you feel that your situation ...										
	23. Do you think that most people are..										
	24. Do you frequently get upset over...										
	25. Do you frequently feel like crying										
	26. Do you have trouble concentrating										
	27. Do you enjoy getting up in the mor..										
	28. Do you prefer to avoid social gat..										
	29. Is it easy for you to make decision										
	30. Is your mind as clear as it used ..										
	31. Total score	29	29	30							
10T	1ND Imipramine	1	1	1	1	1	1	1	1	1	1
	01. Are you () satisfied with your life										
	02. Have you dropped many of your act..										
	03. Do you feel that your life is empty										
	04. Do you often get bored										
	05. Are you hopeful about the future										
	06. Are you bothered by thoughts you ..										
	07. Are you in good spirits most of ...										
	08. Are you afraid that something bad..										
	09. Do you feel happy most of the time										
	10. Do you often feel helpless										
	11. Do you often get restless and f....										
	12. Do you prefer to stay at home,										

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient	Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
				Y	N	Y	N	Y	N	Y	N	Y	N
5	10T	Imipramine	13.Do you frequently worry about the...	1	1	1	1	1	1	0	0	0	0
			14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
			15.Do you think it is wonderful to be.	1	1	1	1	1	1	0	0	0	0
			16.Do you often feel downhearted	1	1	1	1	1	1	0	0	0	0
			17.Do you feel pretty worthless the ..	1	1	1	0	0	0	0	0	0	0
			18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
			19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
			20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
			21.Do you feel full of energy	1	1	1	1	1	1	1	0	0	0
			22.Do you feel that your situation ...	1	1	1	1	0	0	0	0	0	0
			23.Do you think that most people are...	1	1	1	1	0	0	1	1	1	0
			24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	0
			25.Do you frequently feel like crying	1	1	1	1	0	0	0	0	0	0
			26.Do you have trouble concentrating	1	1	1	1	1	1	0	0	0	0
			27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	0
			28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
			29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
			30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
			31.Total score	30	30	29	28	23	23	15	15	15	13
2ND		Reboxetine	01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0
			02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
			03.Do you feel that your life is empty	0	0	0	0	0	0	0	0	0	0
			04.Do you often get bored	0	0	0	0	0	0	0	0	0	0
			05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
			06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0
			07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
			08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
			09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
			10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
			11.Do you often get restless and f....	0	0	0	0	0	0	0	0	0	0
			12.Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1
			13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
			14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0
			15.Do you think it is wonderful to be.	0	0	0	0	0	0	0	0	0	0
			16.Do you often feel downhearted	0	0	0	0	0	0	0	0	0	0
			17.Do you feel pretty worthless the ...	0	0	0	0	0	0	0	0	0	0
			18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0
			19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
			20.Is it hard for you to get started...	1	1	1	1	1	1	1	1	1	1
			21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
			22.Do you feel that your situation ...	1	1	1	1	0	0	0	0	0	0
			23.Do you think that most people are...	1	1	1	1	0	0	0	0	0	0
			24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0
			25.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0
			26.Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0
			27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
			28.Do you prefer to avoid social gat...	0	0	0	0	0	0	0	0	0	0
			29.Is it easy for you to make decision ..	0	0	0	0	0	0	0	0	0	0
			30.Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0	0

9550089

15 50 3

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

10

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
5	2ND Reboxetine	17	17	22	16	16	18	19	22	22	
	31.Total score										
	01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	0	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	0	0	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	0	0	0	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	0	0	0	0	0
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be.	1	1	0	0	0	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	0	0	1	1	1	1	1
	17.Do you worry a lot about the past ...	1	1	1	1	1	1	1	1	1	1
	18.Do you find life very exciting	1	1	0	0	0	0	0	0	0	0
	19.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21.Do you feel that your situation ...	1	1	0	0	0	1	1	1	1	1
	22.Do you think that most people are...	0	0	0	0	0	1	1	1	1	1
	23.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0
	24.Do you frequently feel like crying	1	1	0	0	0	0	0	0	0	0
	25.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
	26.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1
	27.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
	28.Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0
	29.Is your mind as clear as it used ..	1	1	0	0	0	1	1	1	1	1
	30.Total score	23	24	18	18	18	23	23	23	23	23
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	0	0	0	0	0
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1

1 1 1 1 1 1 1 1 1 1 1 1

3ND

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63	
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
5	3ND																				
	Imipramine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the morn.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social get...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	31.Total score	26	26	26	26	26	26	26	19	18	17	17	17	17	17	17	17	17	17	17	17
50F	Reboxetine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	02.Have you dropped many of your act..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	03.Do you feel that your life is empty	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	04.Do you often get bored	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	11.Do you often get restless and f....	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	12.Do you prefer to stay at home,	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	13.Do you frequently worry about the..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	22.Do you think that your situation ...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	23.Do you think that most people are..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the morn.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social get...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	29.Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	31.Total score	9	9	9	9	6	6	5	5	3	3	3	3	3	3	3	3	3	3	3	3

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

12

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
S 4ND Imipramine	01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	0	0	0	0	0	0
	05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	1	1	1	0	0	0	0	0	0
	10.Do you often feel helpless	1	1	1	1	0	0	0	0	0	0
	11.Do you often get restless and f....	1	1	1	1	0	0	0	0	0	0
	12.Do you prefer to stay at home, ...	1	1	1	1	0	0	0	0	0	0
	13.Do you frequently worry about the...	1	1	1	1	0	0	0	0	0	0
	14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be.	1	1	1	1	0	0	0	0	0	0
	16.Do you often feel downhearted	1	1	1	1	0	0	0	0	0	0
	17.Do you feel pretty worthless the ...	1	1	1	1	0	0	0	0	0	0
	18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	1	1	1	1	0	0	0	0	0	0
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	0	0	0	0	0	0
	22.Do you feel that your situation ...	1	1	1	1	0	0	0	0	0	0
	23.Do you think that most people are..	1	1	1	1	0	0	0	0	0	0
	24.Do you frequently get upset over...	1	1	1	1	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	1	1	1	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	1	1	1	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	0	0	0	0	0	0	0	0	0	0
	28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	1	1	1	1	0	0	0	0	0	0
	31.Total score		17	17	11	11	9	9	1	1	0
4DT Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	0	0	0	0	0	0
	05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	0	0	0	0	0	0
	10.Do you often feel helpless	1	1	1	1	0	0	0	0	0	0
	11.Do you often get restless and f....	1	1	1	1	0	0	0	0	0	0
	12.Do you prefer to stay at home, ...	1	1	1	1	0	0	0	0	0	0
	13.Do you frequently worry about the...	1	1	1	1	0	0	0	0	0	0
	14.Do you feel you have more problems.	1	1	1	1	0	0	0	0	0	0
	15.Do you think it is wonderful to be.	1	1	1	1	0	0	0	0	0	0
	16.Do you often feel downhearted	1	1	1	1	0	0	0	0	0	0
	17.Do you worry a lot about the past	1	1	1	1	0	0	0	0	0	0
	18.Do you find life very exciting	1	1	1	1	0	0	0	0	0	0

1596

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

13

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63		
			Y	N	Y	N	Y	N	Y	N	Y	N		
5	4PT	Reboxetine	19.Do you find life very exciting	1	1	0	0	0	0	0	0	0	0	
			20.Is it hard for you to get started..	0	1	1	1	1	1	1	1	1	1	1
			21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1
			22.Do you think that your situation ...	0	0	1	1	1	1	1	1	1	1	1
			23.Do you think that most people are...	0	1	1	1	1	1	1	1	1	1	1
			24.Do you frequently get upset over...	1	0	1	1	1	1	1	1	1	1	1
			25.Do you frequently feel like crying	1	0	1	1	1	1	1	1	1	1	1
			26.Do you have trouble concentrating	1	0	1	1	1	1	1	1	1	1	1
			27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1	1
			28.Do you prefer to avoid social get..	1	1	1	1	1	1	1	1	1	1	1
			29.Is it easy for you to make decision	0	1	0	1	1	1	1	1	1	1	1
30.Is your mind as clear as it used ..	1	0	1	1	1	1	1	1	1	1	1			
31.Total score			23	22	26	26	26	26	26	26	26	26		
5ND	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	
		05.Are you hopeful about the future	0	1	1	1	1	1	1	1	1	1	1	
		06.Are you bothered by thoughts you ...	1	0	1	1	1	1	1	1	1	1	1	
		07.Are you in good spirits most of ...	1	0	1	1	1	1	1	1	1	1	1	
		08.Are you afraid that something bad..	0	1	1	1	1	1	1	1	1	1	1	
		09.Do you feel happy most of the time	0	1	1	1	1	1	1	1	1	1	1	
		10.Do you often feel helpless	0	1	1	1	1	1	1	1	1	1	1	
		11.Do you often get restless and f....	0	1	1	1	1	1	1	1	1	1	1	
12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1			
13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1			
14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1			
15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1	1			
16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1			
17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1			
18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1			
19.Do you find life very exciting	0	1	1	1	1	1	1	1	1	1	1			
20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1			
21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1			
22.Do you feel that your situation ...	0	1	1	1	1	1	1	1	1	1	1			
23.Do you think that most people are...	0	1	1	1	1	1	1	1	1	1	1			
24.Do you frequently get upset over...	0	1	1	1	1	1	1	1	1	1	1			
25.Do you frequently feel like crying	0	1	1	1	1	1	1	1	1	1	1			
26.Do you have trouble concentrating	0	1	1	1	1	1	1	1	1	1	1			
27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1	1			
28.Do you prefer to avoid social get..	1	1	1	1	1	1	1	1	1	1	1			
29.Is it easy for you to make decision	0	1	1	1	1	1	1	1	1	1	1			
30.Is your mind as clear as it used ..	1	0	1	1	1	1	1	1	1	1	1			
31.Total score			19	25	20	20	20	20	20	20	20	20		
5DT	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1		
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1		
		03.Do you feel that your life is empty	0	1	1	1	1	1	1	1	1	1		

1597

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

14

PHARMACIA CMS R&D

REBOMETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63	
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
5	5DT																				
	Rebometine																				
	04.Do you often get bored	1	1	1	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10.Do you often feel helpless	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	0	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	0	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	0	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	0	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be.	1	1	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	0	0	0	0	1	1	1	0	0	1	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are...	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	0	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	1	0	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	1	0	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor.	1	1	1	1	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	0	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ...	0	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	31.Total score	20	20	20	19	20	19	20	20	20	20	20	20	20	20	20	20	20	20	20	20
6ND	Imipramine																				
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	0	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	04.Do you often get bored	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1598

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

15

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
5	6ND	Imipramine	0	0	0	0	0	0	0	0	0	0
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31.Total score	23	22	22	19						
6ND	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	0	0	0	0	0	0	0	0	0	0
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0
		07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31.Total score	22	19	15	14	15	6	6	6	6	6
7ND	Reboxetine	01.Are you () satisfied with your life	0	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	0	0	0	0	0	0	0	0	0	0
		05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1

1599

9550089

17

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
5	7DT Imipramine	0	0	0	0	0	0	0	0	0	0
	25. Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0
	26. Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0
	27. Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
	28. Do you prefer to avoid social gat..	1	0	0	1	1	1	1	0	1	0
	29. Is it easy for you to make decision	1	0	0	1	1	1	1	0	1	0
	30. Is your mind as clear as it used ..	0	23	0	21	0	11	0	7	0	7
	31. Total score										
8ND	Imipramine	0	1	1	1	0	0	0	0	0	0
	01. Are you () satisfied with your life	1	1	1	1	0	0	0	0	0	0
	02. Have you dropped many of your act..	1	1	1	1	0	0	1	0	0	0
	03. Do you feel that your life is empty	1	1	1	1	0	0	0	0	0	0
	04. Do you often get bored	0	1	1	0	0	0	0	0	0	0
	05. Are you hopeful about the future	1	1	0	0	0	0	0	0	0	0
	06. Are you bothered by thoughts you ..	0	1	1	1	1	0	0	0	0	1
	07. Are you in good spirits most of ...	1	1	1	1	0	0	0	0	0	0
	08. Are you afraid that something bad..	1	1	1	1	0	0	0	0	0	0
	09. Do you feel happy most of the time	1	1	1	1	0	0	0	0	0	0
	10. Do you often feel helpless	1	1	1	1	0	0	0	0	0	0
	11. Do you often get restless and f.....	1	0	1	1	0	0	0	0	0	0
	12. Do you prefer to stay at home,	1	1	1	1	0	1	0	1	0	1
	13. Do you frequently worry about the..	1	1	1	1	0	1	0	1	0	1
	14. Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0
	15. Do you think it is wonderful to be..	0	0	1	1	1	1	0	0	0	0
	16. Do you often feel downhearted	1	1	1	1	0	0	0	0	0	0
	17. Do you feel pretty worthless the ..	0	0	0	0	0	0	0	0	0	0
	18. Do you worry a lot about the past	0	0	0	1	0	0	0	0	0	0
	19. Do you find life very exciting	0	0	1	1	0	0	0	0	0	0
	20. Is it hard for you to get started..	1	1	1	1	0	1	1	0	0	1
	21. Do you feel full of energy	1	1	1	1	1	1	0	0	0	1
	22. Do you feel that your situation ...	0	1	1	0	0	0	0	0	0	0
	23. Do you think that most people are..	0	1	1	0	0	0	0	0	0	0
	24. Do you frequently get upset over...	0	1	0	0	0	0	0	0	0	0
	25. Do you frequently feel like crying	1	0	1	0	0	0	0	0	0	0
	26. Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0
	27. Do you enjoy getting up in the mor.	0	0	1	0	0	0	0	0	0	0
	28. Do you prefer to avoid social gat..	0	0	1	1	1	1	1	1	1	1
	29. Is it easy for you to make decision	0	0	0	0	1	0	0	0	0	0
	30. Is your mind as clear as it used ..	0	13	0	25	1	0	8	0	0	7
	31. Total score										
8DT	Imipramine	0	0	0	0	0	0	0	0	0	0
	01. Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02. Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03. Do you feel that your life is empty	0	1	1	0	0	0	0	0	0	0
	04. Do you often get bored	1	1	1	1	0	0	0	0	0	0
	05. Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
	06. Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
	07. Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
	08. Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0
	09. Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1

1601

9550089

18

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 15.0
 GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
5	SDT Imipramine	1	1	1	1	1	0	1	1	1	1
	10. Do you often feel helpless	1	1	1	1	1	0	1	1	1	1
	11. Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
	12. Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1
	13. Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
	14. Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	15. Do you think it is wonderful to be.	1	1	1	1	0	1	1	1	1	1
	16. Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17. Do you feel pretty worthless the ..	1	0	1	1	1	1	1	0	0	0
	18. Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
	19. Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20. Is it hard for you to get started...	1	1	1	1	1	1	0	0	0	0
	21. Do you feel full of energy	1	1	1	1	1	1	0	0	0	0
	22. Do you feel that your situation ...	1	1	1	1	1	1	0	0	0	0
	23. Do you think that most people are...	1	1	1	1	1	1	0	0	0	0
	24. Do you frequently get upset over...	1	1	1	1	1	1	0	0	0	0
	25. Do you frequently feel like crying	1	1	1	1	0	0	1	0	1	0
	26. Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0
	27. Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
	28. Do you prefer to avoid social gat...	1	1	1	1	1	1	1	1	1	1
	29. Is it easy for you to make decision	0	1	1	1	0	1	0	1	0	1
	30. Is your mind as clear as it used ..	24	24	24	23	20	21	15	15	15	15
	31. Total score										
9ND	Reboxetine	1	1	1	0	0	0	0	0	0	0
	01. Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02. Have you dropped many of your act..	1	1	1	1	1	0	0	0	0	0
	03. Do you feel that your life is empty	1	1	1	1	0	0	0	0	0	0
	04. Do you often get bored	1	0	0	0	0	0	0	0	0	0
	05. Are you hopeful about the future	1	0	0	0	0	0	0	0	0	0
	06. Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
	07. Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
	08. Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
	09. Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10. Do you often feel helpless	1	1	1	1	1	0	1	0	0	0
	11. Do you often get restless and f.....	1	1	1	1	1	0	1	0	0	0
	12. Do you prefer to stay at home,	1	1	1	0	1	1	1	1	1	1
	13. Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
	14. Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	15. Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
	16. Do you often feel downhearted	1	0	1	1	1	1	1	1	1	1
	17. Do you feel pretty worthless the	1	0	0	0	0	0	0	0	0	0
	18. Do you worry a lot about the past	1	0	0	0	0	0	0	0	0	0
	19. Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20. Is it hard for you to get started...	1	1	1	1	1	1	1	1	1	1
	21. Do you feel full of energy	0	1	1	1	1	1	1	1	1	1
	22. Do you feel that your situation ...	0	1	1	1	1	1	1	1	1	1
	23. Do you think that most people are...	0	1	1	1	1	1	1	1	1	1
	24. Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
	25. Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
	26. Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
	27. Do you enjoy getting up in the mar.	1	1	1	1	1	1	1	1	1	1

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

19

PHARMACIA CNS R8D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient	Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63		
				Y	N	Y	N	Y	N	Y	N	Y	N		
5	9ND	Reboxetine	28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1		
			29.Is it easy for you to make decision	1	1	0	0	1	0	1	0	1	0	1	
			30.Is your mind as clear as it used ..	1	0	0	0	0	0	0	0	0	0	0	7
			31.Total score	27	23	19	19	19	18	18	17	10	10	7	
9DT	Reboxetine	01.Are you () satisfied with your life	0	0	0	0	1	1	1	0	0	0	0		
		02.Have you dropped many of your act..	1	1	1	1	1	0	0	0	0	0	0		
		03.Do you feel that your life is empty	1	1	0	0	0	0	0	0	0	0	0		
		04.Do you often get bored	0	1	0	0	0	0	0	0	0	0	0		
		05.Are you hopeful about the future	1	1	1	1	1	0	0	0	1	1	1		
		06.Are you bothered by thoughts you ..	1	1	1	1	1	0	0	0	0	0	0		
		07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0	0		
		08.Are you afraid that something bad..	1	1	1	1	1	0	0	0	0	0	0		
		09.Do you feel happy most of the time	1	1	1	1	1	0	0	0	0	0	0		
		10.Do you often feel helpless	1	1	1	1	1	0	0	0	0	0	0		
		11.Do you often get restless and f.....	0	0	0	0	0	0	0	0	0	0	0		
		12.Do you prefer to stay at home, ...	1	1	1	1	1	0	0	0	0	0	0		
		13.Do you frequently worry about the...	0	0	0	0	0	0	0	0	0	0	0		
		14.Do you feel you have more problems.	1	1	0	0	0	0	0	0	0	0	0		
		15.Do you think it is wonderful to be.	1	1	1	1	1	0	0	0	0	0	0		
		16.Do you often feel downhearted	1	1	1	1	1	0	0	0	0	0	0		
		17.Do you feel pretty worthless the ..	1	1	1	1	1	0	0	0	0	0	0		
		18.Do you carry a lot about the past	0	0	0	0	0	0	0	0	0	0	0		
		19.Do you find life very exciting	1	1	1	1	1	0	0	0	0	0	0		
		20.Is it hard for you to get started..	1	1	1	1	1	0	0	0	0	0	0		
		21.Do you feel full of energy	0	0	0	0	0	0	0	0	0	0	0		
		22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0	0		
		23.Do you think that most people are...	0	0	0	0	0	0	0	0	0	0	0		
		24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0	0		
		25.Do you frequently feel like crying	1	1	1	1	1	0	0	0	0	0	0		
		26.Do you have trouble concentrating	1	1	1	1	1	0	0	0	0	0	0		
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	0	0	0	0	0	0		
		28.Do you prefer to avoid social gat..	1	1	1	1	1	0	0	0	0	0	0		
		29.Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0	0		
		30.Is your mind as clear as it used ..	1	1	1	1	1	0	0	0	0	0	0		
		31.Total score	20	20	18	18	18	18	18	18	18	18	18	18	
10ND	Imipramine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1		
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1		
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1		
		04.Do you often get bored	0	0	0	0	0	0	0	0	0	0	0		
		05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0	0		
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1		
		07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0	0		
		08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0	0		
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1		
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1		
		11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1		
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1		

1603

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

20

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient	Treatment	Geriatric Depression Scale	_Day0_	_Day7_	_Day14_	_Day21_	_Day28_	_Day35_	_Day42_	_Day49_	_Day56_	_Day63_
				Y	N	Y	N	Y	N	Y	N	Y	N
5	10MD	Imipramine	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
			14.Do you feel you have more problems.	1	0	1	0	1	0	1	0	1	0
			15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
			16.Do you often feel downhearted	0	0	0	0	0	0	0	0	0	0
			17.Do you feel pretty worthless the ..	1	0	0	1	0	1	0	1	0	0
			18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0
			19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
			20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
			21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
			22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
			23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
			24.Do you frequently get upset over...	1	0	1	0	1	0	1	0	1	0
			25.Do you frequently feel like crying	1	0	1	0	1	0	1	0	1	0
			26.Do you have trouble concentrating	1	0	1	0	1	0	1	0	1	0
			27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
			28.Do you prefer to avoid social get..	1	1	1	1	1	1	1	1	1	1
			29.Is it easy for you to make decision	0	1	0	1	0	1	0	1	0	1
			30.Is your mind as clear as it used ..	0	1	0	1	0	1	0	1	0	1
			31.Total score	0	21	0	19	0	23	0	21	0	23
			01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
			02.Have you dropped many of your act..	1	0	1	0	1	0	1	0	1	0
			03.Do you feel that your life is empty	0	0	0	0	0	0	0	0	0	0
			04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
			05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
			06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0
			07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
			08.Are you afraid that something had..	1	1	1	1	1	1	1	1	1	1
			09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
			10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
			11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
			12.Do you prefer to stay at home, ...	1	0	1	0	1	0	1	0	1	0
			13.Do you frequently worry about the..	1	0	1	0	1	0	1	0	1	0
			14.Do you feel you have more problems.	1	0	1	0	1	0	1	0	1	0
			15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
			16.Do you often feel downhearted	1	0	1	0	1	0	1	0	1	0
			17.Do you feel pretty worthless the ..	1	0	1	0	1	0	1	0	1	0
			18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
			19.Do you find life very exciting	0	0	0	0	0	0	0	0	0	0
			20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
			21.Do you feel full of energy	0	0	0	0	0	0	0	0	0	0
			22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
			23.Do you think that most people are...	1	0	1	0	1	0	1	0	1	0
			24.Do you frequently get upset over...	1	0	1	0	1	0	1	0	1	0
			25.Do you frequently feel like crying	1	0	1	0	1	0	1	0	1	0
			26.Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0
			27.Do you enjoy getting up in the mor.	0	0	0	0	0	0	0	0	0	0
			28.Do you prefer to avoid social get..	0	0	0	0	0	0	0	0	0	0
			29.Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0
			30.Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0	0

1604

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

21

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
5	100T Imipramine	14	14	14	14	14	14	14	14	14	14
	31.Total score	14	14	14	14	14	14	14	14	14	14
11MD	Imipramine	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	0	0	0	0	0	0	0	0	0	0
	04.Do you often get bored	0	0	0	0	0	0	0	0	0	0
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home.	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the...	0	0	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	24.Do you feel full of energy	0	0	0	0	0	0	0	0	0	0
	22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0
	23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat..	0	0	0	0	0	0	0	0	0	0
	29.Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0	0
	31.Total score	17	18	22	24	24	24	24	24	24	24
11DI	Reboxetine	0	0	0	0	0	0	0	0	0	0
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ...	0	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad...	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the...	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1

1605

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient	Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63	
				Y	N	Y	N	Y	N	Y	N	Y	N	
5	11DT	Reboxetine	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	
			17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1
			18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1
			19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1
			20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1
			21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1
			22.Do you feel that your situation ...	1	1	0	1	1	1	1	1	1	1	1
			23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1	1
			24.Do you frequently get upset over...	1	1	0	0	0	0	0	0	0	0	0
			25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1
			26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1
			27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1
			28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1
			29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1
30.Is your mind as clear as it used ..	0	26	0	25	21	0	21	0	21	0	21	0		
			31.Total score											
12MD	Reboxetine	Reboxetine	01.Are you () satisfied with your life	1	0	0	0	0	1	1	1	0	1	
			02.Have you dropped many of your act..	1	0	0	0	0	1	1	1	0	1	
			03.Do you feel that your life is empty	1	0	0	0	0	0	1	1	1	1	
			04.Do you often get bored	1	0	0	0	0	0	1	1	1	1	
			05.Are you hopeful about the future	1	0	0	0	0	0	0	0	0	0	0
			06.Are you bothered by thoughts you ...	0	0	0	0	0	1	1	1	1	1	1
			07.Are you in good spirits most of ...	1	0	0	0	0	0	0	1	0	0	1
			08.Are you afraid that something bad..	1	0	0	0	0	0	0	0	0	0	0
			09.Do you feel happy most of the time	1	0	0	0	0	0	0	0	0	0	0
			10.Do you often feel helpless	0	0	0	0	0	0	0	0	0	0	0
			11.Do you often get restless and f....	0	0	0	0	0	0	0	0	0	0	0
			12.Do you prefer to stay at home, ...	0	0	0	0	0	0	0	0	0	0	0
			13.Do you frequently worry about the..	0	0	0	0	0	0	0	0	0	0	0
			14.Do you feel you have more problems.	1	0	0	0	0	0	0	0	0	0	0
15.Do you think it is wonderful to be.	1	0	0	0	0	0	0	0	0	0	0			
16.Do you often feel downhearted	0	0	0	0	0	0	0	0	0	0	0			
17.Do you feel pretty worthless the ..	0	0	0	0	0	0	0	0	0	0	0			
18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0	0			
19.Do you find life very exciting	0	0	0	0	0	0	0	0	0	0	0			
20.Is it hard for you to get started..	0	0	0	0	0	0	0	0	0	0	0			
21.Do you feel full of energy	0	0	0	0	0	0	0	0	0	0	0			
22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0	0			
23.Do you think that most people are..	0	0	0	0	0	0	0	0	0	0	0			
24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0	0			
25.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0	0			
26.Do you have trouble concentrating	1	1	0	0	0	0	0	0	0	0	0			
27.Do you enjoy getting up in the mr.	0	0	0	0	0	0	0	0	0	0	0			
28.Do you prefer to avoid social gat..	1	0	0	0	0	0	0	0	0	0	0			
29.Is it easy for you to make decision	1	0	0	0	0	0	0	0	0	0	0			
30.Is your mind as clear as it used ..	1	0	0	0	0	0	0	0	0	0	0			
			31.Total score	14	3	3	2	2	21	22	18	19		

1606

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

23

PIARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63		
			Y	N	Y	N	Y	N	Y	N	Y	N		
5	12DT	Imipramine	Geriatric Depression Scale											
			01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0	0
			02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1
			03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1
			04.Do you often get bored	0	1	0	0	0	0	0	0	0	0	0
			05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1
			06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1
			07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1
			08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1
			09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1
			10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1
			11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1
			12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1
			13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1
			14.Do you feel you have more problems.	0	1	0	0	0	0	0	0	0	0	0
			15.Do you think it is wonderful to be..	0	0	0	0	0	0	0	0	0	0	0
			16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1
			17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1	1
			18.Do you worry a lot about the past ..	1	1	1	1	1	1	1	1	1	1	1
			19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1
			20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1
			21.Do you feel full of energy	0	0	0	0	0	0	0	0	0	0	0
			22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0	0
			23.Do you think that most people are..	0	0	0	0	0	0	0	0	0	0	0
			24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0	0
			25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1
			26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1
			27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1	1
			28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1
			29.Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0	0
			30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1
31.Total score			23	20	13	13	13	10	10	10	9	9		
6	18D	Reboxetine	Geriatric Depression Scale											
			01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1
			02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1
			03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1
			04.Do you often get bored	0	1	0	0	0	0	0	0	0	0	0
			05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1
			06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0	0
			07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1
			08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1
			09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1
			10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1
			11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1
			12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1
			13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1
			14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0	0
			15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1	1
			16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1
			17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1	1
18.Do you worry a lot about the past ..	0	0	0	0	0	0	0	0	0	0	0			

1607

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

24

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	_Day0_		_Day7_		_Day14_		_Day21_		_Day28_		_Day35_		_Day42_		_Day49_		_Day56_		_Day63_					
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N				
6	4HD	Reboxetine	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
			20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
			21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
			22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
			23.Do you think that most people are...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			25.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
			27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
			28.Do you prefer to avoid social get..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
			29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
			30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
			31.Total score			22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	
			10T	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
					02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
					03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
					04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
					05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
					06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
					07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
					08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
					09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
					10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
					11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
					12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
					13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
					14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
					15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
					16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
					17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
					18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
19.Do you find life very exciting	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
20.Is it hard for you to get started..	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
21.Do you feel full of energy	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
22.Do you feel that your situation ...	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
23.Do you think that most people are...	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
24.Do you frequently get upset over...	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
25.Do you frequently feel like crying	0	0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
26.Do you have trouble concentrating	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
27.Do you enjoy getting up in the mor.	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
28.Do you prefer to avoid social get..	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
29.Is it easy for you to make decision	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
30.Is your mind as clear as it used ..	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
31.Total score					27	28	28	25	25	19	21	21	12	12	9	12	16	16	16	16	16	16	16	16		
2MD	Imipramine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			

1608

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

25

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63	
		Y	N	Y	N	Y	N	Y	N	Y	N	
2ND Imipramine	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	
	06.Are you bothered by thoughts you ..	0	1	1	1	1	1	1	1	1	1	
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	
	15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1	
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	
	17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1	
	18.Do you worry a lot about the past	0	1	1	1	1	1	1	1	1	1	
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	
	23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1	
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	
	27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1	
	28.Do you prefer to avoid social gat...	1	1	1	1	1	1	1	1	1	1	
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	
	31.Total score		28	30								
	2DT Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
04.Do you often get bored		0	1	1	1	1	1	1	1	1	1	
05.Are you hopeful about the future		1	1	1	1	1	1	1	1	1	1	
06.Are you bothered by thoughts you ..		1	1	1	1	1	1	1	1	1	1	
07.Are you in good spirits most of ...		1	1	1	1	1	1	1	1	1	1	
08.Are you afraid that something bad..		0	1	1	1	1	1	1	1	1	1	
09.Do you feel happy most of the time		1	1	1	1	1	1	1	1	1	1	
10.Do you often feel helpless		1	1	1	1	1	1	1	1	1	1	
11.Do you often get restless and f....		0	1	1	1	1	1	1	1	1	1	
12.Do you prefer to stay at home,		1	1	1	1	1	1	1	1	1	1	
13.Do you frequently worry about the..		1	1	1	1	1	1	1	1	1	1	
14.Do you feel you have more problems.		1	1	1	1	1	1	1	1	1	1	
15.Do you think it is wonderful to be..		1	1	1	1	1	1	1	1	1	1	
16.Do you often feel downhearted		1	1	1	1	1	1	1	1	1	1	
17.Do you feel pretty worthless the ...		1	1	1	1	1	1	1	1	1	1	
18.Do you worry a lot about the past		0	1	1	1	1	1	1	1	1	1	
19.Do you find life very exciting		1	1	1	1	1	1	1	1	1	1	
20.Is it hard for you to get started..		1	1	1	1	1	1	1	1	1	1	
21.Do you feel full of energy		1	1	1	1	1	1	1	1	1	1	

1609

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

26

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0 Y N	Day7 Y N	Day14 Y N	Day21 Y N	Day28 Y N	Day35 Y N	Day42 Y N	Day49 Y N	Day56 Y N	Day63 Y N	
6 ZDT Reboxetine	22.Do you feel that your situation ...	0	0									
	23.Do you think that most people are..	0	0									
	24.Do you frequently get upset over...	0	0									
	25.Do you frequently feel like crying	0	0									
	26.Do you have trouble concentrating	1	1									
	27.Do you enjoy getting up in the mor..	1	1									
	28.Do you prefer to avoid social gat..	1	1									
	29.Is it easy for you to make decision	1	1									
	30.Is your mind as clear as it used ..	1	1									
	31.Total score		22	22								
	3MD Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
02.Have you dropped many of your act..		1	1	1	1	1	1	1	1	1	1	
03.Do you feel that your life is empty		1	1	1	1	1	1	1	1	1	1	
04.Do you often get bored		1	1	1	1	1	1	1	1	1	1	
05.Are you hopeless about the future		1	1	1	1	1	0	0	0	0	0	
06.Are you bothered by thoughts you ...		1	1	1	1	1	1	1	1	1	1	
07.Are you in good spirits most of ...		1	1	1	1	1	1	1	1	1	1	
08.Are you afraid that something bad...		1	1	0	0	0	0	0	0	0	0	
09.Do you feel happy most of the time		1	1	1	1	1	1	1	1	1	1	
10.Do you often feel helpless		1	1	1	1	1	1	1	1	1	1	
11.Do you often get restless and f....		1	1	1	1	1	1	1	1	1	1	
12.Do you prefer to stay at home,....		1	1	1	1	1	1	1	1	1	1	
13.Do you frequently worry about the..		1	1	1	1	1	1	1	1	1	1	
14.Do you feel you have more problems.		1	1	1	1	1	1	1	1	1	1	
15.Do you think it is wonderful to be..		1	1	1	1	1	1	1	1	1	1	
16.Do you often feel downhearted		1	1	1	1	1	1	1	1	1	1	
17.Do you feel pretty worthless the ..		1	1	1	1	1	1	1	1	1	1	
18.Do you worry a lot about the past		1	1	1	1	1	1	1	1	1	1	
19.Do you find life very exciting		1	1	1	1	1	1	1	1	1	1	
20.Is it hard for you to get started..		1	1	1	1	1	1	1	1	1	1	
21.Do you feel full of energy		1	1	1	1	1	1	1	1	1	1	
22.Do you feel that your situation ...		1	1	1	1	1	1	0	0	0	0	
23.Do you think that most people are..		1	1	1	1	1	1	1	1	1	1	
24.Do you frequently get upset over...		1	1	1	1	1	1	1	1	1	1	
25.Do you frequently feel like crying		1	1	1	1	1	1	1	1	1	1	
26.Do you have trouble concentrating		1	1	1	1	1	1	1	1	1	1	
27.Do you enjoy getting up in the mor..		1	1	1	1	1	1	1	1	1	1	
28.Do you prefer to avoid social gat..		1	1	1	1	1	1	1	1	1	1	
29.Is it easy for you to make decision		1	1	1	1	1	1	1	1	1	1	
30.Is your mind as clear as it used ..		1	1	1	1	1	1	1	1	1	1	
31.Total score			30	29	29	29	29	26	27	29	29	29
3DT Imipramine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	
	05.Are you hopeless about the future	1	1	1	0	0	0	0	0	0	0	
	06.Are you bothered by thoughts you ...	1	1	1	1	1	1	1	1	1	1	

1610

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

27

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20126/035
 Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63		
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y
6	3DI	Imipramine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		07. Are you in good spirits most of ...																					
		08. Are you afraid that something bad...																					
		09. Do you feel happy most of the time																					
		10. Do you often feel helpless																					
		11. Do you often get restless and f....																					
		12. Do you prefer to stay at home, ...																					
		13. Do you frequently worry about the...																					
		14. Do you feel you have more problems.																					
		15. Do you think it is wonderful to be.																					
		16. Do you often feel downhearted																					
		17. Do you feel pretty worthless the ...																					
		18. Do you worry a lot about the past																					
		19. Do you find life very exciting																					
		20. Is it hard for you to get started...																					
		21. Do you feel full of energy																					
		22. Do you think that most people are...																					
		23. Do you frequently get upset over...																					
		24. Do you frequently feel like crying																					
		25. Do you have trouble concentrating																					
		26. Do you enjoy getting up in the mor.																					
		27. Do you prefer to avoid social gat...																					
		28. Do you prefer to avoid social gat...																					
		29. Is it easy for you to make decision																					
		30. Is your mind as clear as it used ...																					
		31. Total score	30		28	29	25	25	22	25	25	25	25	25	25	25	25	25	25	25	25	25	25
4HD	Imipramine	01. Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		02. Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		03. Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		04. Do you often get bored	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		05. Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		06. Are you bothered by thoughts you ...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		07. Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		08. Are you afraid that something bad...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		09. Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		10. Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		11. Do you often get restless and f.....	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		12. Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		13. Do you frequently worry about the...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		14. Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		15. Do you think it is wonderful to be...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		16. Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		17. Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		18. Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		19. Do you find life very exciting	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		20. Is it hard for you to get started...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		21. Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		22. Do you think that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		23. Do you think that most people are...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		24. Do you frequently get upset over...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

1611

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

28

PHARMACIA CNS RBD

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
6	4MD	Imipramine	1	0	1	1	0	0	0	0	0	0
		25. Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
		26. Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27. Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
		28. Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
		29. Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30. Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31. Total score	23	23	23	23	22	25	25	25	25	25
6	4PT	Imipramine	1	1	1	1	1	0	0	0	0	0
		01. Are you () satisfied with your life	1	1	1	1	1	0	0	0	0	0
		02. Have you dropped many of your act..	1	1	1	1	0	0	0	0	0	0
		03. Do you feel that your life is empty	1	1	1	1	0	0	0	0	0	0
		04. Do you often get bored	1	1	1	1	0	0	0	0	0	0
		05. Are you hopeful about the future	1	1	1	1	0	0	0	0	0	0
		06. Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
		07. Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
		08. Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09. Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
		10. Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
		11. Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1
		12. Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
		13. Do you frequently worry about the..	1	1	1	1	1	0	1	0	1	1
		14. Do you feel you have more problems.	1	1	1	1	1	0	0	0	0	0
		15. Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
		16. Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		17. Do you feel pretty worthless the ..	1	1	1	1	0	0	0	0	0	0
		18. Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
		19. Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20. Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21. Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22. Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		23. Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
		24. Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		25. Do you frequently feel like crying	1	1	1	1	1	0	0	0	0	0
		26. Do you have trouble concentrating	1	1	1	1	1	0	0	0	0	0
		27. Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
		28. Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
		29. Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30. Is your mind as clear as it used ..	1	1	1	1	0	1	0	0	0	0
		31. Total score	28	27	27	23	17	15	8	6	0	7
6	5MD	Imipramine	1	1	1	1	1	1	1	1	1	1
		01. Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02. Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03. Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04. Do you often get bored	1	1	1	1	1	1	1	1	1	1
		05. Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
		06. Are you bothered by thoughts you ..	0	0	1	1	1	1	1	1	1	1
		07. Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
		08. Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09. Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1

1612

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

29

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
6	5HD Imipramine	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
	28.Is it easy for you to avoid social get...	1	1	1	1	1	1	1	1	1	1
	29.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
	30.	28	29	30	30	30	30	30	30	30	30
	31.Total score										
5DT	Reboxetine	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	0	0	0	0	0	0	0	0	0	0
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1

1613

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

30

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63	
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
6	5DT Reboxetine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	31.Total score	27	25	19	19	18	18	13	15	13	15	13	15	13	9	9	0	0	7	7	7
6WD	Reboxetine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	31.Total score	0	18	20	20	14	14	21	30	21	30	21	30	21	13	13	0	0	7	7	7
7HD	Reboxetine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	05.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	06.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1614

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

31

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient	Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
				Y	N	Y	N	Y	N	Y	N	Y	N
6	7ND	Reboxetine	13. Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	0
			14. Do you feel you have more problems.	0	1	1	1	1	1	1	1	1	1
			15. Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	0
			16. Do you often feel downhearted	1	1	1	1	1	1	1	1	1	0
			17. Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	0
			18. Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	0
			19. Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
			20. Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
			21. Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
			22. Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
			23. Do you think that most people are..	1	1	1	1	1	1	1	1	1	0
			24. Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
			25. Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
			26. Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
			27. Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	0
			28. Do you prefer to avoid social get..	1	1	1	1	1	1	1	1	1	1
			29. Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
			30. Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
			31. Total score	27	28	26	28	28	26	25	21	16	
8ND		Imipramine	01. Are you () satisfied with your life	1	1	1	1	1	0	0	0	0	0
			02. Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	0
			03. Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	0
			04. Do you often get bored	1	1	1	1	1	1	1	1	1	0
			05. Are you bothered about the future	1	1	1	1	1	1	1	1	1	0
			06. Are you often full of thoughts you ..	0	0	0	0	0	0	0	0	0	0
			07. Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	0
			08. Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0
			09. Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	0
			10. Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
			11. Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
			12. Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
			13. Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	0
			14. Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	0
			15. Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	0
			16. Do you often feel downhearted	1	1	1	1	1	1	1	1	1	0
			17. Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	0
			18. Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	0
			19. Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
			20. Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
			21. Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
			22. Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
			23. Do you think that most people are..	1	1	1	1	1	1	1	1	1	0
			24. Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	0
			25. Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	0
			26. Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	0
			27. Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1
			28. Do you prefer to avoid social get..	1	1	1	1	1	1	1	1	1	1
			29. Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
			30. Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	0

16151

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

32

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0 Y N	Day7 Y N	Day14 Y N	Day21 Y N	Day28 Y N	Day35 Y N	Day42 Y N	Day49 Y N	Day56 Y N	Day63 Y N	
6 BMD	31.Total score	0	0	0	0	0	0	0	0	0	0	
7 1MD	Imipramine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
		08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,....	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0
		15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		17.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
		18.Do you find life very exciting	0	0	0	0	0	0	0	0	0	0
		19.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		20.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		21.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		22.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
		23.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
		25.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		26.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
		27.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
		28.Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0
		29.Is your mind as clear as it used ...	0	0	0	0	0	0	0	0	0	0
		30.Is your mind as clear as it used ...	0	0	0	0	0	0	0	0	0	0
		31.Total score		22	21	21	21	21	21	21	21	21
8MD	Imipramine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
		06.Are you bothered by thoughts you ...	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,....	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1

1616

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

33

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No.: 45.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
7	3HD	Imipramine	1	1	1	1	1	0	0	0	0	0
		16.Do you often feel downhearted	1	1	1	1	1	0	0	0	0	0
		17.Do you feel pretty worthless the ..	1	1	1	1	1	0	0	0	0	0
		18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0
		19.Do you find life very exciting	1	1	1	1	1	1	0	0	0	0
		20.Is it hard for you to get started..	1	1	1	1	1	1	0	0	0	0
		21.Do you feel full of energy	1	1	1	1	1	1	1	0	0	0
		22.Do you feel that your situation ...	1	1	1	1	1	1	0	0	0	0
		23.Do you think that most people are...	1	1	1	1	1	1	0	0	0	0
		24.Do you frequently get upset over...	1	1	1	1	1	1	0	0	0	0
		25.Do you frequently feel like crying	1	1	1	1	1	1	0	0	0	0
		26.Do you have trouble concentrating	1	1	1	1	1	1	0	0	0	0
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	0	0	0	0
		28.Do you prefer to avoid social get...	0	1	1	1	1	0	0	0	0	0
		29.Is it easy for you to make a decision	1	1	1	1	1	1	0	0	0	0
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	0	0	0	0
		31.Total score	27	28	26	28	28	16	12	12	0	0
4HD	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	0	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	0	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	0	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	0	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	0	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	0	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	0	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	0	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	0	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	0	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are...	0	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	0	0	0	0	0	0	0	0	0
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social get...	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make a decision	0	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31.Total score	19	28	27	29	29	29	28	28	28	28

1617

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

34

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
7	342HD	Reboxetine	1	1	1	1	1	1	1	1	1	1
		01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	0	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	0	0	1	0	0	1	1	0	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	0	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	0	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the...	1	0	0	1	0	1	1	0	1	1
		14.Do you feel you have more problems.	0	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be...	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	0	1	0	1	1	1	1	1	1	1
		17.Do you worry a lot about the past	0	1	0	0	1	1	1	1	1	1
		18.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	0	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	0	1	1	1	1	1	1	1	1
		23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	0	0	0	1	0	1	0
		25.Do you frequently feel like crying	1	1	1	0	1	0	1	1	0	0
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor..	1	1	0	0	1	1	1	1	1	1
		28.Do you prefer to avoid social get..	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31.Total score	26	25	21	26	25	26	29	25	27	27
8	1HD	Reboxetine	0	1	1	1	1	1	0	0	1	1
		01.Are you () satisfied with your life	0	1	1	1	1	1	0	0	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	0	1	1	1
		04.Do you often get bored	0	1	1	1	1	1	0	1	1	1
		05.Are you hopeful about the future	0	1	1	1	1	1	0	0	1	1
		06.Are you bothered by thoughts you ...	1	1	1	1	1	1	0	0	1	1
		07.Are you in good spirits most of ...	0	1	1	1	1	1	0	0	1	1
		08.Are you afraid that something bad..	0	1	1	1	1	1	0	0	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f.....	1	0	1	1	1	1	1	0	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	0	1	1
		13.Do you frequently worry about the...	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be...	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		17.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
		18.Do you find life very exciting	1	0	1	0	1	1	1	0	1	1

1618

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

35

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	_Day0_		_Day7_		_Day14_		_Day21_		_Day28_		_Day35_		_Day42_		_Day49_		_Day56_		_Day63_			
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N		
8	4ND	Reboxetine	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	1	1	1	
			20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	1	1	1
			21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	1	1	1
			22.Do you feel that your situation ...	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0
			24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0
			26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0
			27.Do you enjoy getting up in the mor.	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			28.Do you prefer to avoid social get...	0	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0
			29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0
30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0			
31.Total score	23	25	25	25	25	25	26	27	26	27	26	27	26	26	11	8	8	8	8	30	30			
10T	Imipramine	01.Are you () satisfied with your life	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		02.Have you dropped many of your act..	1	1	1	0	1	1	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	
		03.Do you feel that your life is empty	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		04.Do you often get bored	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		05.Are you hopeful about the future	1	1	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	
		06.Are you bothered by thoughts you ..	1	1	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	
		10.Do you often feel helpless	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		11.Do you often get restless and f....	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
12.Do you prefer to stay at home,	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
13.Do you frequently worry about the ..	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0			
15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0			
16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0			
17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0			
18.Do you worry a lot about the past	0	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0			
19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0			
20.Is it hard for you to get started..	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
21.Do you feel full of energy	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
22.Do you feel that your situation ...	1	0	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0			
23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0			
24.Do you frequently get upset over...	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
25.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
26.Do you have trouble concentrating	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
27.Do you enjoy getting up in the morn.	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
28.Do you prefer to avoid social get...	0	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0			
29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0			
30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0			
31.Total score	25	20	15	15	15	15	15	10	10	10	7	7	7	7	3	1	1	1	1	1	1			
2ND	Reboxetine	01.Are you () satisfied with your life	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		02.Have you dropped many of your act..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		03.Do you feel that your life is empty	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		

1619

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

36

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient	Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
				Y	N	Y	N	Y	N	Y	N	Y	N
8	2ND	Reboxetine	04. Do you often get bored	0	0	0	0	0	0	0	0	0	0
			05. Are you bothered by thoughts you ...	0	0	1	1	0	0	0	0	0	0
			06. Are you in good spirits most of ...	0	0	0	0	0	0	1	1	0	0
			07. Are you afraid that something bad ...	0	0	0	0	0	0	0	0	0	0
			08. Are you feel happy most of the time	1	1	1	1	1	0	0	0	0	0
			09. Do you often feel helpless	1	1	0	0	0	0	0	0	0	0
			10. Do you often get restless and f....	1	1	1	1	1	0	0	0	0	0
			11. Do you prefer to stay at home,	0	0	1	1	0	0	0	0	0	0
			12. Do you frequently worry about the..	0	0	1	1	0	0	0	0	0	0
			13. Do you feel you have more problems.	1	1	1	1	0	0	0	0	0	0
			14. Do you think it is wonderful to be..	1	1	1	1	1	0	0	0	0	0
			15. Do you often feel downhearted	1	1	0	0	0	0	0	0	0	0
			16. Do you feel pretty worthless the ..	1	1	0	0	0	0	0	0	0	0
			17. Do you worry a lot about the past	0	0	0	0	0	0	1	0	0	0
			18. Do you find life very exciting	0	0	0	0	0	0	0	0	0	0
			19. Is it hard for you to get started..	1	1	0	0	0	0	0	0	0	0
			20. Do you feel full of energy	1	1	0	0	0	0	0	0	0	0
			21. Do you feel that your situation ...	1	1	0	0	0	0	0	0	0	0
			22. Do you think that most people are...	1	1	0	0	0	0	0	0	0	0
			23. Do you frequently get upset over...	1	1	0	0	0	0	0	0	0	0
			24. Do you frequently feel like crying	1	1	0	0	0	0	0	0	0	0
			25. Do you have trouble concentrating	1	1	0	0	0	0	0	0	0	0
			26. Do you enjoy getting up in the mor.	1	1	0	0	0	0	0	0	0	0
			27. Do you prefer to avoid social gat...	1	1	0	0	0	0	0	0	0	0
			28. Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0
			29. Is your mind as clear as it used ..	1	1	0	0	0	0	0	0	0	0
			30. Total score	14	8	9	8	6	2	6	4	2	2
8	2ND	Reboxetine	04. Do you often get bored	0	0	0	0	0	0	0	0	0	0
			05. Are you bothered by thoughts you ...	0	0	1	1	0	0	0	0	0	0
			06. Are you in good spirits most of ...	0	0	0	0	0	0	1	1	0	0
			07. Are you afraid that something bad ...	0	0	0	0	0	0	0	0	0	0
			08. Are you feel happy most of the time	1	1	1	1	1	0	0	0	0	0
			09. Do you often feel helpless	1	1	0	0	0	0	0	0	0	0
			10. Do you often get restless and f....	1	1	1	1	1	0	0	0	0	0
			11. Do you prefer to stay at home,	0	0	1	1	0	0	0	0	0	0
			12. Do you frequently worry about the..	0	0	1	1	0	0	0	0	0	0
			13. Do you feel you have more problems.	1	1	1	1	0	0	0	0	0	0
			14. Do you think it is wonderful to be..	1	1	1	1	1	0	0	0	0	0
			15. Do you often feel downhearted	1	1	0	0	0	0	0	0	0	0
			16. Do you feel pretty worthless the ..	1	1	0	0	0	0	0	0	0	0
			17. Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0
			18. Do you find life very exciting	0	0	0	0	0	0	0	0	0	0
			19. Is it hard for you to get started..	1	1	0	0	0	0	0	0	0	0
			20. Do you feel full of energy	1	1	0	0	0	0	0	0	0	0
			21. Do you feel that your situation ...	1	1	0	0	0	0	0	0	0	0
			22. Do you think that most people are...	1	1	0	0	0	0	0	0	0	0
			23. Do you frequently get upset over...	1	1	0	0	0	0	0	0	0	0
			24. Do you frequently feel like crying	1	1	0	0	0	0	0	0	0	0
			25. Do you have trouble concentrating	1	1	0	0	0	0	0	0	0	0
			26. Do you enjoy getting up in the mor.	1	1	0	0	0	0	0	0	0	0
			27. Do you prefer to avoid social gat...	1	1	0	0	0	0	0	0	0	0
			28. Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0
			29. Is your mind as clear as it used ..	1	1	0	0	0	0	0	0	0	0
			30. Total score	14	8	9	8	6	2	6	4	2	2
8	2ND	Reboxetine	01. Are you () satisfied with your life	0	0	1	1	1	0	0	0	0	0
			02. Have you dropped many of your act..	1	1	1	1	1	0	0	0	0	0
			03. Do you feel that your life is empty	1	1	1	1	1	0	0	0	0	0
			04. Do you often get bored	0	0	1	1	1	0	0	0	0	0
			05. Are you hopeful about the future	1	1	0	0	0	0	0	0	0	0
			06. Are you bothered by thoughts you ...	0	0	0	0	0	0	0	0	0	0
			07. Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
			08. Are you afraid that something bad ...	0	0	0	0	0	0	0	0	0	0
			09. Do you feel happy most of the time	1	1	1	1	1	0	0	0	0	0
			10. Do you often feel helpless	1	1	0	0	0	0	0	0	0	0
			11. Do you often get restless and f....	1	1	1	1	1	0	0	0	0	0
			12. Do you prefer to stay at home,	0	0	1	1	0	0	0	0	0	0
			13. Do you frequently worry about the..	0	0	1	1	0	0	0	0	0	0
			14. Do you feel you have more problems.	1	1	1	1	0	0	0	0	0	0
			15. Do you think it is wonderful to be..	1	1	1	1	1	0	0	0	0	0
			16. Do you often feel downhearted	1	1	0	0	0	0	0	0	0	0
			17. Do you feel pretty worthless the ..	0	0	0	0	0	0	0	0	0	0
			18. Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0
			19. Do you find life very exciting	1	1	0	0	0	0	0	0	0	0
			20. Is it hard for you to get started..	1	1	0	0	0	0	0	0	0	0
			21. Do you feel full of energy	1	1	1	1	1	0	0	0	0	0

1620

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

37

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63		
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y
8	2DT	Imipramine	0	1	0	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		22.Do you feel that your situation ...																					
		23.Do you think that most people are..	1	0	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		24.Do you frequently get upset over...	0	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		25.Do you frequently feel like crying	0	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		26.Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
		27.Do you enjoy getting up in the mor.	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		28.Do you prefer to avoid social gat..	1	0	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0
		29.Is it easy for you to make decision	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		30.Is your mind as clear as it used ..	0	12	19	17	17	17	20	20	20	20	2	0	0	1	0	0	0	0	0	0	0
		31.Total score																					
8	3BD	Imipramine	0	1	0	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		01.Are you () satisfied with your life	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		02.Have you dropped many of your act..	1	0	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		05.Are you hopeful about the future	0	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		06.Are you bothered by thoughts you ..	0	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		07.Are you in good spirits most of ...	1	0	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		08.Are you afraid that something bad..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		10.Do you often feel helpless	1	0	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		11.Do you often get restless and f....	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		12.Do you prefer to stay at home,	1	0	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		13.Do you frequently worry about the..	1	0	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		14.Do you feel you have more problems.	1	0	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		16.Do you often feel downhearted	1	0	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		17.Do you feel pretty worthless the ..	1	0	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		18.Do you worry a lot about the past	1	0	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		20.Is it hard for you to get started..	1	0	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		22.Do you feel that your situation ...	1	0	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		23.Do you think that most people are..	1	0	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		24.Do you frequently get upset over...	1	0	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		25.Do you frequently feel like crying	1	0	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		26.Do you have trouble concentrating	1	0	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		28.Do you prefer to avoid social gat..	0	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		31.Total score	23		23																		
8	3DT	Reboxetine	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
		05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

1621

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

38

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient	Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
				Y	N	Y	N	Y	N	Y	N	Y	N
8	3DT	Reboxetine	07. Are you in good spirits most of the time	1	1	0	0	0	0	0	0	0	0
			08. Are you afraid that something bad will happen	1	1	0	0	0	0	0	0	0	0
			09. Do you often feel restless	1	1	1	1	0	0	0	0	0	0
			10. Do you often feel helpless	1	1	1	1	0	0	0	0	0	0
			11. Do you often get bored	1	1	1	1	0	0	0	0	0	0
			12. Do you prefer to stay at home	1	1	1	1	0	0	0	0	0	0
			13. Do you frequently worry about the future	1	1	0	0	0	0	0	0	0	0
			14. Do you think it is wonderful to be able to do things	1	1	0	0	0	0	0	0	0	0
			15. Do you often feel downhearted	1	1	1	1	0	0	0	0	0	0
			16. Do you feel pretty worthless	1	1	1	1	0	0	0	0	0	0
			17. Do you worry a lot about the past	1	1	0	0	0	0	0	0	0	0
			18. Do you find life very exciting	0	0	0	0	0	0	0	0	0	0
			19. Is it hard for you to get started	1	1	1	1	0	0	0	0	0	0
			20. Do you feel full of energy	1	1	0	0	0	0	0	0	0	0
			21. Do you feel that your situation is not what you want	1	1	0	0	0	0	0	0	0	0
			22. Do you think that most people are better off than you are	1	1	0	0	0	0	0	0	0	0
			23. Do you frequently get upset	1	1	0	0	0	0	0	0	0	0
			24. Do you frequently feel like crying	1	1	0	0	0	0	0	0	0	0
			25. Do you have trouble concentrating	1	1	0	0	0	0	0	0	0	0
			26. Do you enjoy getting up in the morning	0	0	0	0	0	0	0	0	0	0
			27. Do you prefer to avoid social gatherings	1	1	0	0	0	0	0	0	0	0
			28. Do you prefer to avoid social gatherings	1	1	0	0	0	0	0	0	0	0
			29. Is it easy for you to make decisions	1	1	0	0	0	0	0	0	0	0
			30. Is your mind as clear as it used to be	1	1	0	0	0	0	0	0	0	0
			31. Total score	22	24	14	8	9	4	3	0	0	0
4MD		Imipramine	01. Are you satisfied with your life	1	1	1	1	1	1	1	1	1	1
			02. Have you dropped many of your activities	1	1	1	1	1	1	1	1	1	1
			03. Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
			04. Do you often get bored	1	1	1	1	1	1	1	1	1	1
			05. Are you hopeless about the future	1	1	1	1	1	1	1	1	1	1
			06. Are you bothered by thoughts of death	1	1	1	1	1	1	1	1	1	1
			07. Are you in good spirits most of the time	1	1	1	1	1	1	1	1	1	1
			08. Are you afraid that something bad will happen	1	1	1	1	1	1	1	1	1	1
			09. Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
			10. Do you often get restless and fidgety	1	1	1	1	1	1	1	1	1	1
			11. Do you prefer to stay at home	1	1	1	1	1	1	1	1	1	1
			12. Do you frequently worry about the future	1	1	1	1	1	1	1	1	1	1
			13. Do you feel you have more problems than you can handle	1	1	1	1	1	1	1	1	1	1
			14. Do you think it is wonderful to be able to do things	1	1	1	1	1	1	1	1	1	1
			15. Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
			16. Do you feel pretty worthless	1	1	1	1	1	1	1	1	1	1
			17. Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
			18. Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
			19. Do you think it is wonderful to be able to do things	1	1	1	1	1	1	1	1	1	1
			20. Is it hard for you to get started	1	1	1	1	1	1	1	1	1	1
			21. Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
			22. Do you feel that your situation is not what you want	1	1	1	1	1	1	1	1	1	1
			23. Do you think that most people are better off than you are	1	1	1	1	1	1	1	1	1	1
			24. Do you frequently get upset	1	1	1	1	1	1	1	1	1	1

1622

9550089

39

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0 Y N	Day7 Y N	Day14 Y N	Day21 Y N	Day28 Y N	Day35 Y N	Day42 Y N	Day49 Y N	Day56 Y N	Day63 Y N
8	4ND	Imipramine	1	0	1	1	1	0	0	1	1	0
		25.Do you frequently feel like crying	1	0	1	1	1	0	0	1	1	0
		26.Do you have trouble concentrating	1	1	0	0	0	0	0	0	0	0
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	0	0	0	0	0
		28.Do you prefer to avoid social gat..	1	1	1	1	1	0	0	0	0	0
		29.Is it easy for you to make decision	1	1	1	1	1	0	0	0	0	0
		30.Is your mind as clear as it used ..	0	25	29	28	29					
		31.Total score										
4PT	Reboxetine	01.Are you () satisfied with your life	1	0	1	1	1	1	0	0	1	1
		02.Have you dropped many of your act..	1	0	1	1	1	0	0	0	0	0
		03.Do you feel that your life is empty	1	1	1	1	1	0	0	0	1	0
		04.Do you often get bored	1	0	0	0	0	0	0	0	0	0
		05.Are you hopeful about the future	1	0	0	0	0	0	0	0	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	0	0	0	0	0
		07.Are you in good spirits most of ...	1	1	1	1	1	1	0	0	0	0
		08.Are you afraid that something bad..	1	1	1	1	1	0	0	0	0	1
		09.Do you feel happy most of the time	1	0	0	0	0	0	0	0	0	0
		10.Do you often feel helpless	1	0	0	0	0	0	0	0	0	0
		11.Do you often get restless and f.....	1	0	0	0	0	0	0	0	0	0
		12.Do you prefer to stay at home,	1	1	0	0	0	0	0	0	0	0
		13.Do you frequently worry about the..	1	0	0	0	0	0	0	0	0	0
		14.Do you feel you have more problems.	1	1	1	1	1	0	0	0	0	0
		15.Do you think it is wonderful to be..	1	1	1	1	1	0	0	0	0	0
		16.Do you often feel downhearted	1	1	1	1	1	0	0	0	0	0
		17.Do you feel pretty worthless the ..	1	1	1	1	1	0	0	0	0	0
		18.Do you worry a lot about the past	1	1	1	1	1	0	0	0	0	0
		19.Do you find life very exciting	1	1	1	1	1	0	0	0	0	0
		20.Is it hard for you to get started..	1	1	1	1	1	0	0	0	0	0
		21.Do you feel full of energy	1	0	0	0	0	0	0	0	0	0
		22.Do you feel that your situation ...	1	0	0	0	0	0	0	0	0	0
		23.Do you think that most people are..	1	0	0	0	0	0	0	0	0	0
		24.Do you frequently get upset over...	1	0	0	0	0	0	0	0	0	0
		25.Do you frequently feel like crying	0	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0
		27.Do you enjoy getting up in the mor.	1	1	0	0	0	0	0	0	0	0
		28.Do you prefer to avoid social gat..	0	0	0	0	0	0	0	0	0	0
		29.Is it easy for you to make decision	0	1	0	0	0	0	0	0	0	0
		30.Is your mind as clear as it used ...	22	18	17	16	9	9	5	2	0	14
		31.Total score										
701ND	Imipramine	01.Are you () satisfied with your life	1	1	1	0	0	0	0	0	0	0
		02.Have you dropped many of your act..	1	1	1	1	0	0	0	0	0	0
		03.Do you feel that your life is empty	1	1	1	1	1	0	0	0	0	0
		04.Do you often get bored	1	1	1	0	1	0	0	0	0	0
		05.Are you hopeful about the future	1	1	0	0	0	0	0	0	0	0
		06.Are you bothered by thoughts you ..	1	1	1	1	1	0	0	0	0	0
		07.Are you in good spirits most of ...	1	1	1	0	0	0	0	0	0	0
		08.Are you afraid that something bad..	1	1	1	1	1	0	0	0	0	0
		09.Do you feel happy most of the time	1	1	1	0	1	0	0	0	0	0

16 N:

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

40

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	_Day0_		_Day7_		_Day14_		_Day21_		_Day28_		_Day35_		_Day42_		_Day49_		_Day56_		_Day63_	
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
8	701HD	Imipramine	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		10.Do you often feel helpless	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		11.Do you often get restless and f....	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		12.Do you prefer to stay at home, ...	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		13.Do you frequently worry about the..	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		14.Do you feel you have more problems.	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		15.Do you think it is wonderful to be.	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		16.Do you often feel downhearted	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		17.Do you feel pretty worthless the ..	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		18.Do you worry a lot about the past	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		19.Do you find life very exciting	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		20.Is it hard for you to get started...	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		21.Do you feel full of energy	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		22.Do you feel that your situation ...	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		23.Do you think that most people are...	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		24.Do you frequently get upset over...	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		25.Do you frequently feel like crying	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		26.Do you have trouble concentrating	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		27.Do you enjoy getting up in the mor.	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		28.Is it easy for you to make decision	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		29.Is your mind as clear as it used ..	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		31.Total score	29	23	29	23	9	10	9	10	9	9	10	9	10	9	10	9	10	9	10	9
701DT	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1624

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

43

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Ceriatric Depression Scale	Day0 Y N	Day7 Y N	Day14 Y N	Day21 Y N	Day28 Y N	Day35 Y N	Day42 Y N	Day49 Y N	Day56 Y N	Day63 Y N
8	703MD	Inipramine	31.Total score	17	17	30	30	12	14	14	12	18
	703DF	Inipramine	01.Are you () satisfied with your life..	1	1	0	0	1	0	0	1	1
			02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1
			03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1
			04.Do you often get bored	0	0	0	0	0	0	0	0	0
			05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0
			06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0
			07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0
			08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0
			09.Do you feel happy most of the time	0	0	0	0	0	0	0	0	0
			10.Do you often feel helpless	0	0	0	0	0	0	0	0	0
			11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1
			12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1
			13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1
			14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0
			15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1
			16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1
			17.Do you worry a lot about the past ...	1	1	1	1	1	1	1	1	1
			18.Do you find life very exciting	0	0	0	0	0	0	0	0	0
			20.Is it hard for you to get started..	0	0	0	0	0	0	0	0	0
			21.Do you feel full of energy	1	1	1	1	1	1	1	1	1
			22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1
			23.Do you think that most people are...	1	1	1	1	1	1	1	1	1
			24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1
			25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1
			26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1
			27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1
			28.Do you prefer to avoid social gat..	0	0	0	0	0	0	0	0	0
			29.Is it easy for you to make decision	0	0	0	0	0	0	0	0	0
			30.Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0
			31.Total score	16	21	19	18	16	16	16	16	11
	704MD	Reboxetine	01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0
			02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1
			03.Do you feel that your life is empty	0	0	0	0	0	0	0	0	0
			04.Do you often get bored	0	0	0	0	0	0	0	0	0
			05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1
			06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0
			07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0
			08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0
			09.Do you feel happy most of the time	0	0	0	0	0	0	0	0	0
			10.Do you often feel helpless	1	1	1	1	1	1	1	1	1
			11.Do you often get restless and f.....	0	0	0	0	0	0	0	0	0
			12.Do you prefer to stay at home,	0	0	0	0	0	0	0	0	0
			13.Do you frequently worry about the..	0	0	0	0	0	0	0	0	0
			14.Do you think it is wonderful to be.	0	0	0	0	0	0	0	0	0
			15.Do you often feel downhearted	1	1	1	1	1	1	1	1	1

1627

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

44

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63			
			Y	N	Y	N	Y	N	Y	N	Y	N			
8	704HD	Reboxetine	16.Do you often feel demotivated	1	1	1	0	0	0	0	0	0			
			17.Do you feel pretty worthless the ..	1	0	1	0	0	0	0	0	0	0		
			18.Do you worry a lot about the past	1	0	0	0	0	0	0	0	0	0		
			19.Do you find life very exciting	1	1	0	0	0	0	0	0	0	0		
			20.Is it hard for you to get started..	0	0	0	1	0	0	0	0	0	0		
			21.Do you feel full of energy	1	1	1	1	0	0	0	0	0	0		
			22.Do you feel that your situation ...	1	1	0	0	0	0	0	0	0	0		
			23.Do you think that most people are...	1	0	0	0	0	0	0	0	0	0		
			24.Do you frequently get upset over...	1	0	1	0	0	0	0	0	0	0		
			25.Do you frequently feel like crying	0	0	1	0	0	0	0	0	0	0		
			26.Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0		
			27.Do you enjoy getting up in the mor.	0	0	0	0	0	0	0	0	0	0		
			28.Do you prefer to avoid social get..	0	0	0	0	0	0	0	0	0	0		
			29.Is it easy for you to make decision	0	0	1	0	0	0	0	0	0	0		
			30.Is your mind as clear as it used ..	0	13	14	11	5	0	0	1	3	0	0	
					31.Total score										
			704DT	Reboxetine	01.Are you () satisfied with your life	0	1	1	1	0	1	1	1	1	1
					02.Have you dropped many of your act	1	0	1	1	0	0	1	0	1	1
					03.Do you feel that your life is empty	1	0	1	0	0	0	1	0	1	0
					04.Do you often get bored	1	1	1	1	1	1	1	1	0	0
					05.Are you hopeful about the future	1	1	1	1	1	1	1	1	0	0
					06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
					07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
					08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
					09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
					10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
					11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
					12.Do you prefer to stay at home,	1	0	0	1	1	1	1	1	1	1
					13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
					14.Do you feel you have more problems.	0	0	0	1	1	1	1	1	1	1
					15.Do you think it is wonderful to be..	0	1	1	1	1	1	1	1	1	1
16.Do you often feel demotivated	1	1			1	1	1	1	1	1	1	1			
17.Do you feel pretty worthless the ..	1	1			1	1	1	1	1	1	1	1			
18.Do you worry a lot about the past	1	1			1	1	1	1	1	1	1	1			
19.Is it hard for you to get started..	1	1			1	1	1	1	1	1	1	1			
20.Do you feel full of energy	1	1			1	1	1	1	1	1	1	1			
21.Do you feel that your situation ...	1	1			1	1	1	1	1	1	1	1			
22.Do you think that most people are...	1	1			1	1	1	1	1	1	1	1			
23.Do you frequently get upset over...	1	0			1	0	0	0	0	0	0	0			
24.Do you frequently feel like crying	1	0			1	1	1	1	1	1	1	1			
25.Do you have trouble concentrating	0	0			1	1	1	1	1	1	1	1			
26.Do you enjoy getting up in the mr.	0	0			0	0	0	0	0	0	0	0			
27.Do you prefer to avoid social get...	1	1			1	1	1	1	1	1	1	1			
28.Is it easy for you to make decision	1	0			1	1	1	1	1	1	1	1			
29.Is your mind as clear as it used ..	20	0			24	26	26	19	10	10	10	15	13		
		31.Total score													

1628

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

45

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63	
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
9	1MD Imipramine	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	01.Are you () satisfied with your life	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	02.Have you dropped many of your act..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	03.Do you feel that your life is empty	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	04.Do you often get bored	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10.Do you often feel helpless	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	11.Do you often get restless and f....	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	12.Do you prefer to stay at home,	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	13.Do you frequently worry about the..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	16.Do you often feel downhearted	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	17.Do you feel pretty worthless the ...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	18.Do you worry a lot about the past	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20.Is it hard for you to get started..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	21.Do you feel full of energy	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	22.Do you feel that your situation ...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	23.Do you think that most people are...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	28.Do you prefer to avoid social gat..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	29.Is it easy for you to make decision	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	31.Total score	23	0	10	10	10	10	10	10	11	11	11	11	11	11	11	11	11	11	11	11
10T	1MD Imipramine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1629

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

46

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
9	1DF	Imipramine	1	1	1	1	0	0	0	0	0	0
		19.Do you find life very exciting	1	1	1	1	0	0	0	0	0	0
		20.Is it hard for you to get started..	1	1	1	1	0	0	0	0	0	0
		21.Do you feel full of energy	1	1	1	1	0	0	0	0	0	0
		22.Do you think that your situation ...	1	1	1	1	0	0	0	0	0	0
		23.Do you think that most people are...	1	1	1	1	0	0	0	0	0	0
		24.Do you frequently get upset over...	1	1	1	1	0	0	0	0	0	0
		25.Do you frequently feel like crying	1	1	1	1	0	0	0	0	0	0
		26.Do you have trouble concentrating	1	1	1	1	0	0	0	0	0	0
		27.Do you enjoy getting up in the morn.	1	1	1	1	0	0	0	0	0	0
		28.Do you prefer to avoid social gat...	1	1	1	1	0	0	0	0	0	0
		29.Is it easy for you to make decision	1	1	1	1	0	0	0	0	0	0
		30.Is your mind as clear as it used ..	1	1	1	1	0	0	0	0	0	0
		31.Total score	28	25	12	2	0	0	0	0	0	0
2ND	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helplessness	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the morn.	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat...	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31.Total score	29	30	30	30	29	29	28	28	14	14
2DF	Imipramine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1

1630

9550089

48

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63	
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
9	3DT Reboxetine	1	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	22.Do you feel that your situation ...																				
	23.Do you think that most people are ...																				
	24.Do you frequently get upset over ...																				
	25.Do you frequently feel like crying																				
	26.Do you have trouble concentrating																				
	27.Do you enjoy getting up in the mor.																				
	28.Do you prefer to avoid social gat..																				
	29.Is it easy for you to make decision																				
	30.Is your mind as clear as it used ..																				
	31.Total score	17	30	21	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4MD	Imipramine	1	1	1	1	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0
	01.Are you () satisfied with your life																				
	02.Have you dropped many of your act..																				
	03.Do you feel that your life is empty																				
	04.Do you often get bored																				
	05.Are you bothered about the future																				
	06.Are you hopeful about the future																				
	07.Are you in good spirits most of ...																				
	08.Are you afraid that something bad..																				
	09.Do you feel happy most of the time																				
	10.Do you often feel helpless																				
	11.Do you often get restless and f....																				
	12.Do you prefer to stay at home, ...																				
	13.Do you frequently worry about the..																				
	14.Do you feel you have more problems.																				
	15.Do you think it is wonderful to be.																				
	16.Do you often feel downhearted																				
	17.Do you feel pretty worthless the ..																				
	18.Do you worry a lot about the past																				
	19.Do you find life very exciting																				
	20.Is it hard for you to get started..																				
	21.Do you feel full of energy																				
	22.Do you feel that your situation ...																				
	23.Do you think that most people are..																				
	24.Do you frequently get upset over...																				
	25.Do you frequently feel like crying																				
	26.Do you have trouble concentrating																				
	27.Do you enjoy getting up in the mor.																				
	28.Do you prefer to avoid social gat..																				
	29.Is it easy for you to make decision																				
	30.Is your mind as clear as it used ..																				
	31.Total score	30	26	17	11	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21
5MD	Reboxetine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life																				
	02.Have you dropped many of your act..																				
	03.Do you feel that your life is empty																				
	04.Do you often get bored																				
	05.Are you hopeful about the future																				
	06.Are you bothered by thoughts you ..																				

1632

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

49

PHARMACIA CNS R&D
 REBoxetine - PROTOCOL 20124/035
 Listing No.: 15.0
 GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	SMD	Geriatric Depression Scale	_Day0_		_Day7_		_Day14_		_Day21_		_Day28_		_Day35_		_Day42_		_Day49_		_Day56_		_Day63_		
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	
9		07.Are you in good spirits most of ...	1		1		1		1		1		1		1		1		1		0		0
		08.Are you afraid that something bad..	1		1		1		1		1		1		1		1		1		0		0
		09.Do you feel happy most of the time	1		1		1		1		1		1		1		1		1		0		0
		10.Do you often feel helpless	1		0		1		1		1		1		1		1		1		0		0
		11.Do you often get restless and f....	1		1		1		1		1		1		1		1		1		0		0
		12.Do you prefer to stay at home, ...	1		1		1		1		1		1		1		1		1		0		0
		13.Do you frequently worry about the..	1		1		1		1		1		1		1		1		1		0		0
		14.Do you feel you have more problems.	0		1		1		1		1		1		1		1		1		0		0
		15.Do you think it is wonderful to be.	1		1		1		1		1		1		1		1		1		0		0
		16.Do you often feel downhearted	1		1		1		1		1		1		1		1		1		0		0
		17.Do you often feel worthless the ...	1		1		1		1		1		1		1		1		1		0		0
		18.Do you worry a lot about the past	1		1		1		1		1		1		1		1		1		0		0
		19.Do you find life very exciting	0		1		1		1		1		1		1		1		1		0		0
		20.Is it hard for you to get started..	0		1		1		1		1		1		1		1		1		0		0
		21.Do you feel full of energy	1		1		1		1		1		1		1		1		1		0		0
		22.Do you feel that your situation ...	1		0		1		1		1		1		1		1		1		0		0
		23.Do you think that most people are...	1		0		1		1		1		1		1		1		1		0		0
		24.Do you frequently get upset over...	1		1		1		1		1		1		1		1		1		0		0
		25.Do you frequently feel like crying	1		0		1		1		1		1		1		1		1		0		0
		26.Do you have trouble concentrating	1		1		1		1		1		1		1		1		1		0		0
		27.Do you enjoy getting up in the mor.	0		1		1		1		1		1		1		1		1		0		0
		28.Do you prefer to avoid social gat...	1		1		1		1		1		1		1		1		1		0		0
		29.Is it easy for you to make decision	1		1		1		1		1		1		1		1		1		0		0
		30.Is your mind as clear as it used ..	1		0		1		1		1		1		1		1		1		0		0
		31.Total score	22		23		25		25		25		24		24		20		18		7		7
6HD		01.Are you () satisfied with your life	1		1		1		1		1		1		1		1		1		0		0
		02.Have you dropped many of your act..	1		1		1		1		1		1		1		1		1		0		0
		03.Do you feel that your life is empty	1		1		1		1		1		1		1		1		1		0		0
		04.Do you often get bored	1		1		1		1		1		1		1		1		1		0		0
		05.Are you hopeful about the future	1		1		1		1		1		1		1		1		1		0		0
		06.Are you bothered by thoughts you ...	1		1		1		1		1		1		1		1		1		0		0
		07.Are you in good spirits most of ...	1		1		1		1		1		1		1		1		1		0		0
		08.Are you afraid that something bad..	1		1		1		1		1		1		1		1		1		0		0
		09.Do you feel happy most of the time	1		1		1		1		1		1		1		1		1		0		0
		10.Do you often feel helpless	1		1		1		1		1		1		1		1		1		0		0
		11.Do you often get restless and f....	1		1		1		1		1		1		1		1		1		0		0
		12.Do you prefer to stay at home,	1		1		1		1		1		1		1		1		1		0		0
		13.Do you frequently worry about the..	1		1		1		1		1		1		1		1		1		0		0
		14.Do you feel you have more problems.	1		1		1		1		1		1		1		1		1		0		0
		15.Do you think it is wonderful to be.	1		1		1		1		1		1		1		1		1		0		0
		16.Do you often feel downhearted	1		1		1		1		1		1		1		1		1		0		0
		17.Do you often feel worthless the ...	1		1		1		1		1		1		1		1		1		0		0
		18.Do you worry a lot about the past	1		1		1		1		1		1		1		1		1		0		0
		19.Do you find life very exciting	1		1		1		1		1		1		1		1		1		0		0
		20.Is it hard for you to get started..	1		1		1		1		1		1		1		1		1		0		0
		21.Do you feel full of energy	1		1		1		1		1		1		1		1		1		0		0
		22.Do you feel that your situation ...	1		1		1		1		1		1		1		1		1		0		0
		23.Do you think that most people are...	1		1		1		1		1		1		1		1		1		0		0
		24.Do you frequently get upset over...	1		1		1		1		1		1		1		1		1		0		0

1633

9550089

50

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
9	6ND	Imipramine	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31.Total score	30	30	30	30	30	30	30	30	30	30
7ND	Imipramine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be.	0	0	0	0	0	0	0	0	0	0
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31.Total score	24	24	24	24	24	24	24	24	24	24
8DT	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1

1634

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

52

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	_Day0_		_Day7_		_Day14_		_Day21_		_Day28_		_Day35_		_Day42_		_Day49_		_Day56_		_Day63_	
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
10	1ND	Imipramine	1	1	1	1	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0
		28.Do you prefer to avoid social gat..																				
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		31.Total score	27	25	22	19	16	11	11	10	7											
10T	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		13.Do you frequently worry about the..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		31.Total score	24	25	20	23	9	10	11	9	7											
2ND	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1636

9550089

53

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63	
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
10	2ND																				
	Reboxetine	1	1	1	0	1	0	1	0	0	0	1	0	0	0	0	0	0	1	0	0
	13.Do you frequently worry about the..	1	1	1	0	1	0	1	0	0	0	1	0	0	0	0	0	0	1	0	0
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	0	1	1	1	1	0	1	0	0	0	0	0	0	0	0	0	0	1	0	1
	22.Do you feel that your situation ...	0	1	1	1	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	23.Do you think that most people are...	0	1	1	1	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	1	1	1	0	1	1	1	0	1	1	0	0	0	1	0	1	0	1	0	0
	25.Do you frequently feel like crying	1	1	1	0	1	1	1	0	1	1	0	0	0	1	0	1	0	1	0	0
	26.Do you have trouble concentrating	1	1	1	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	28.Do you prefer to avoid social gat...	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	29.Is it easy for you to make decision	1	1	1	1	1	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	31.Total score	27	24	24	19	19	14	14	10	5	8	7	9	9	7	7	7	7	9	9	9
20	ZDT																				
	Imipramine	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0
	01.Are you () satisfied with your life	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0
	02.Have you dropped many of your act..	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	03.Do you feel that your life is empty	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	04.Do you often get bored	0	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	10.Do you often feel helpless	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	11.Do you often get restless and f....	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	12.Do you prefer to stay at home,	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	13.Do you frequently worry about the..	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be.	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	16.Do you often feel downhearted	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	17.Do you feel pretty worthless the ...	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	18.Do you worry a lot about the past	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	20.Is it hard for you to get started..	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	21.Do you feel full of energy	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	22.Do you feel that your situation ...	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	23.Do you think that most people are...	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	28.Do you prefer to avoid social gat...	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	29.Is it easy for you to make decision	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	31.Total score	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

1637

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

54

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0 Y N I	Day7 Y N I	Day14 Y N I	Day21 Y N I	Day28 Y N I	Day35 Y N I	Day42 Y N I	Day49 Y N I	Day56 Y N I	Day63 Y N I
10	2DT Imipramine	1	1	1	1	1	1	1	1	1	1
	31.Total score	22	13	9	7	8	6	6	8	8	8
3ND	Reboxetine	1	1	1	1	1	1	1	1	0	0
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	0	0
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	0	1
	03.Do you feel that your life is empty	1	1	1	0	1	1	0	1	1	1
	04.Do you often get bored	1	1	1	1	1	0	0	0	0	0
	05.Are you hopeful about the future	0	0	1	1	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	0	0	0	0
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,.....	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the...	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted.....	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
	31.Total score	27	25	28	25	23	17	13	12	10	10
30T	Imipramine	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	0	0
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	0	0
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	0	0
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	0	0	0	1	1	0	0	1	1	0
	06.Are you bothered by thoughts you ..	1	1	1	1	1	0	0	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	0	0	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	0	0	1	1	1	0	0	1	1	0
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,.....	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the...	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted.....	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
	31.Total score	27	25	28	25	23	17	13	12	10	10

9550089

55

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
10	30T	Inipramine	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31.Total score	21	17	19	17	14	11	12	11	10	10
40D	Inipramine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act.	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat...	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31.Total score	28	24	21	15	19	8	12	9	7	7

1639

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

56

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63			
			Y	N	Y	N	Y	N	Y	N	Y	N			
10	4DT	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	0	0		
			02.Have you dropped many of your act..	1	1	1	1	1	0	1	0	1	1	1	
			03.Do you feel that your life is empty	1	1	1	1	1	1	0	1	0	1	1	
			04.Do you often get bored	0	1	0	0	0	0	0	1	0	0	0	
			05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	0	
			06.Are you bothered by thoughts you ..	1	1	1	1	1	1	0	0	1	1	0	
			07.Are you in good spirits most of ...	1	1	1	1	1	1	0	0	1	1	1	
			08.Are you afraid that something bad..	1	1	1	1	1	1	0	0	1	1	1	
			09.Do you feel happy most of the time	1	1	1	1	1	1	0	0	0	0	0	
			10.Do you often feel helpless	1	1	1	1	1	1	1	1	0	1	1	
			11.Do you often get restless and f....	1	1	1	1	1	1	0	1	0	1	1	
			12.Do you prefer to stay at home,	0	1	0	0	0	0	1	1	1	0	1	
			13.Do you frequently worry about the..	1	0	0	0	0	0	0	0	1	0	0	
			14.Do you feel you have more problems.	1	1	0	0	0	0	0	0	0	0	0	
			15.Do you think it is wonderful to be..	1	1	1	1	1	1	0	0	0	1	1	
			16.Do you often feel downhearted	1	1	1	1	1	1	0	0	0	1	1	
			17.Do you feel pretty worthless the ...	1	1	1	1	1	1	0	0	0	1	1	
			18.Do you worry a lot about the past ..	1	1	0	0	0	0	0	1	1	0	0	
			19.Do you find life very exciting	1	1	0	0	0	0	0	0	0	0	0	
			20.Is it hard for you to get started..	1	1	1	1	1	1	0	0	0	1	0	
			21.Do you feel full of energy	1	1	0	0	0	0	0	0	0	0	0	
			22.Do you feel that your situation ...	1	1	0	1	1	1	1	1	0	0	1	
			23.Do you think that most people are..	1	0	1	1	1	1	1	1	0	1	1	
			24.Do you frequently get upset over...	1	0	1	1	1	1	0	1	0	1	1	
			25.Do you frequently feel like crying	1	1	1	1	1	1	0	1	0	1	0	
			26.Do you have trouble concentrating	1	1	1	1	1	1	0	0	1	0	0	
			27.Do you enjoy getting up in the mor..	0	0	0	0	0	0	0	0	0	0	0	
			28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	
			29.Is it easy for you to make decision ..	1	1	1	1	1	1	1	1	1	1	1	
			30.Is your mind as clear as it used ..	0	24	1	0	0	0	1	1	1	0	0	1
					31.Total score		22	16	11	15	13	16	15	0	15
5MD	Imipramine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	0	0		
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1		
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	0	0	1	1		
		04.Do you often get bored	1	1	1	1	1	1	1	0	0	0	0		
		05.Are you hopeful about the future	1	1	1	1	1	1	0	0	0	0	0		
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	0	0	0	0	0		
		07.Are you in good spirits most of ...	1	1	1	1	1	1	0	0	1	1	0		
		08.Are you afraid that something bad..	1	1	1	1	1	1	0	0	0	1	0		
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	0	0	1	0		
		10.Do you often feel helpless	1	1	1	1	1	1	1	0	0	0	0		
		11.Do you often get restless and f....	1	1	1	1	1	1	0	0	0	0	0		
		12.Do you prefer to stay at home,	1	1	1	1	1	1	0	1	0	0	0		
		13.Do you frequently worry about the..	1	0	0	0	0	0	0	1	0	1	0		
		14.Do you feel you have more problems.	1	1	1	1	1	1	0	0	0	0	0		
		15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	0	0	0		
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	0	0	0		
		17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	0	0	0		
		18.Do you worry a lot about the past ..	1	0	1	1	1	1	1	1	0	0	0		

1640

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

57

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	_Day0_		_Day7_		_Day14_		_Day21_		_Day28_		_Day35_		_Day42_		_Day49_		_Day56_		_Day63_		
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	
10	5ND	Imipramine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		19. Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		20. Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		21. Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		22. Do you think that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		23. Do you think that most people are..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		24. Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		25. Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		26. Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		27. Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		28. Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		29. Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		30. Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		31. Total score	28	25	23	22	20	18	18	9	7	7	7	7	7	7	7	7	7	7	7	7	
50T	Reboxetine	01. Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		02. Have you dropped many of your act..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		03. Do you feel that your life is empty	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		04. Do you often get bored	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		05. Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		06. Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		07. Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		08. Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		09. Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		10. Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		11. Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		12. Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		13. Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		14. Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		15. Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		16. Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		17. Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		18. Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		19. Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		20. Is it hard for you to get started..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		21. Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		22. Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		23. Do you think that most people are..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		24. Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		25. Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		26. Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		27. Do you enjoy getting up in the mor.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		28. Do you prefer to avoid social gat..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		29. Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		30. Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		31. Total score	0	15	20	18	17	19	18	17	19	18	17	21	17	18	17	17	17	17	17	17	21
6ND	Reboxetine	01. Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		02. Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		03. Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	

1641

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

58

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
10	6MD										
	Reboxetine	1	1	1	1	1	1	1	1	1	1
	04. Do you often get bored	1	0	1	0	0	1	1	1	1	1
	05. Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06. Are you bothered by thoughts you ...	1	1	1	1	1	1	1	1	1	1
	07. Are you in good spirits most of ...	1	0	1	1	1	1	1	1	1	0
	08. Are you afraid that something bad...	1	1	1	1	1	1	1	1	1	1
	09. Do you feel happy most of the time	0	1	1	1	0	1	1	1	1	1
	10. Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11. Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1
	12. Do you prefer to stay at home,	0	0	0	0	0	1	0	1	0	0
	13. Do you frequently worry about the...	1	1	1	1	1	1	1	1	1	1
	14. Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	15. Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
	16. Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17. Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1
	18. Do you enjoy a lot about the past	1	1	1	1	1	1	1	1	1	1
	19. Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20. Is it hard for you to get started...	1	1	1	1	1	1	1	1	1	1
	21. Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
	22. Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
	23. Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
	24. Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
	25. Do you frequently feel like crying	0	1	0	0	0	0	0	0	0	0
	26. Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
	27. Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
	28. Do you prefer to avoid social gat...	1	1	1	1	1	1	1	1	1	1
	29. Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	30. Is your mind as clear as it used ...	0	1	1	1	1	1	1	1	1	1
	31. Total score	26	26	25	23	24	28	26	25	25	24
6DT	Reboxetine										
	01. Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02. Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03. Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
	04. Do you often get bored	0	0	1	0	0	1	0	1	0	1
	05. Are you hopeful about the future	0	0	1	0	0	0	0	0	0	0
	06. Are you bothered by thoughts you ...	1	1	1	1	1	1	1	1	1	1
	07. Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
	08. Are you afraid that something bad...	1	1	1	1	1	1	1	1	1	1
	09. Do you feel happy most of the time	0	0	0	0	0	0	0	0	0	0
	10. Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11. Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1
	12. Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
	13. Do you frequently worry about the...	1	1	1	1	1	1	1	1	1	1
	14. Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0
	15. Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
	16. Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17. Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1
	18. Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
	19. Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20. Is it hard for you to get started...	1	1	1	1	1	1	1	1	1	1
	21. Do you feel full of energy	1	1	1	1	1	1	1	1	1	1

1642

9550089

59

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 45.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
10	6DT Reboxetine	1	1	0	1	0	1	1	0	1	1
	22.Do you feel that your situation ...	1	1	0	1	0	1	1	0	1	1
	23.Do you think that most people are...	1	0	1	1	0	1	0	1	0	0
	24.Do you frequently get upset over...	1	0	1	1	1	0	0	1	0	0
	25.Do you frequently feel like crying	1	0	1	1	0	1	0	0	1	0
	26.Do you have trouble concentrating	1	1	0	0	0	0	0	0	0	1
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	0	0	0	0	1
	28.Do you prefer to avoid social gat..	1	1	1	1	1	0	0	0	0	1
	29.Is it easy for you to make decision	1	1	1	1	0	0	1	0	0	0
	30.Is your mind as clear as it used ..	1	1	0	0	0	0	0	0	0	0
	31.Total score	23	22	17	18	13	15	13	11	12	12
7MD	Imipramine	1	0	0	1	0	1	0	0	0	0
	01.Are you () satisfied with your life	1	1	1	1	0	1	0	0	0	0
	02.Have you dropped many of your act..	1	1	1	1	0	1	1	0	0	0
	03.Do you feel that your life is empty	1	1	0	1	0	1	1	0	1	0
	04.Do you often get bored	1	0	0	1	1	0	1	0	0	0
	05.Are you hopeful about the future	1	1	1	1	1	0	0	0	0	0
	06.Are you bothered by thoughts you ..	1	1	1	1	1	0	0	0	0	0
	07.Are you in good spirits most of ...	1	1	1	1	1	0	0	0	0	0
	08.Are you afraid that something bad..	1	1	1	1	1	0	0	0	0	0
	09.Do you feel happy most of the time	1	1	0	0	1	0	0	0	0	0
	10.Do you often feel helpless	1	1	1	1	1	0	0	0	0	0
	11.Do you often get restless and f....	1	1	1	1	1	0	0	0	0	0
	12.Do you prefer to stay at home, ...	1	1	1	1	1	0	0	0	0	0
	13.Do you frequently worry about the..	1	0	1	1	0	1	0	1	1	0
	14.Do you feel you have more problems.	1	0	1	1	0	1	0	0	0	0
	15.Do you think it is wonderful to be.	1	1	1	1	1	0	0	0	0	0
	16.Do you often feel downhearted	1	1	1	1	1	0	0	0	0	0
	17.Do you feel pretty worthless the ..	1	1	1	1	0	0	0	0	0	0
	18.Do you worry a lot about the past	1	1	1	1	0	0	0	0	0	0
	19.Do you find life very exciting	1	1	1	1	1	0	0	0	0	0
	20.Is it hard for you to get started..	1	1	1	1	0	0	0	0	0	0
	21.Do you feel full of energy	1	1	1	1	1	0	0	0	0	0
	22.Do you feel that your situation ...	1	0	1	0	0	0	0	0	0	0
	23.Do you think that most people are...	1	1	1	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	1	1	1	1	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	1	1	1	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	1	1	1	0	0	0	0	0	0
	27.Do you enjoy getting up in the morn.	1	1	1	1	0	0	0	0	0	0
	28.Do you prefer to avoid social gat...	1	1	1	1	0	0	0	0	0	0
	29.Is it easy for you to make decision	1	1	1	0	1	0	0	0	0	0
	30.Is your mind as clear as it used ..	1	0	1	0	1	0	0	0	0	0
	31.Total score	28	22	22	18	18	9	8	10	6	6
7DT	Imipramine	1	1	1	1	1	1	1	0	0	0
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	0	0	0
	02.Have you dropped many of your act..	1	1	1	1	1	1	0	1	0	0
	03.Do you feel that your life is empty	1	1	0	1	0	0	1	1	1	0
	04.Do you often get bored	0	1	0	1	0	0	0	0	0	1
	05.Are you hopeful about the future	0	1	1	1	1	1	0	0	0	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	0	1	1

1643

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

60

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63		
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y
10	7DI	Imipramine	1	1	1	1	1	1	1	1	0	0	0	0	1	1	0	0	0	0	0	0	0
		07.Are you in good spirits most of ...																					
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	0	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be.	1	1	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over....	1	1	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		31.Total score	21	21	21	20	20	25	16	16	12	12	13	10	10	10	10	10	10	10	10	10	10
8SD	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	0	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		14.Do you feel you have more problems.	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1644

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

61

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63	
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
10	Reboxetine	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	25.Do you frequently feel like crying	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	26.Do you have trouble concentrating	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	31.Total score	27	22	23	18	23	18	23	18	23	18	23	18	23	18	23	18	23	18	23	18
80T	Inipramine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	31.Total score	18	16	14	8	14	8	14	8	14	8	14	8	14	8	14	8	14	8	14	8
90D	Reboxetine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1645

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

62

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
10	9ND										
	Reboxetine										
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home, ...	1	0	0	0	0	0	0	0	0	0
	13.Do you frequently worry about the..	0	0	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset ever...	1	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	0	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gnt.	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	0	1	1	1	1	1	1	1	1	1
	31.Total score	0	22	20	16	17	16	14	9	8	8
9DT	Imipramine										
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	0	0	0	0	0	0	0	0	0
	04.Do you often get bored	0	0	0	0	0	0	0	0	0	0
	05.Are you bothered about the future	1	1	1	1	1	1	1	1	1	1
	06.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
	07.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0
	08.Do you feel happy most of the time	0	0	0	0	0	0	0	0	0	0
	09.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	10.Do you often get restless and f....	1	0	0	0	0	0	0	0	0	0
	11.Do you prefer to stay at home, ...	1	0	0	0	0	0	0	0	0	0
	12.Do you frequently worry about the..	1	0	0	0	0	0	0	0	0	0
	13.Do you feel you have more problems.	1	0	0	0	0	0	0	0	0	0
	14.Do you think it is wonderful to be.	0	1	1	1	1	1	1	1	1	1
	15.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	16.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
	17.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
	18.Do you find life very exciting	0	0	0	0	0	0	0	0	0	0
	19.Is it hard for you to get started..	1	0	0	0	0	0	0	0	0	0
	20.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
	21.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
	22.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
	23.Do you frequently get upset ever...	1	0	0	0	0	0	0	0	0	0
	24.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0
	25.Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0
	26.Do you enjoy getting up in the mor.	0	0	0	0	0	0	0	0	0	0
	27.Do you prefer to avoid social gnt.	0	0	0	0	0	0	0	0	0	0
	28.Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0
	29.Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0	0
	30.Total score	0	0	0	0	0	0	0	0	0	0

1646

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

63

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63	
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
10	9DT Imipramine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat..																				
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	0	0	17	20	20	20	21	21	21	21	21	21	21	21	21	21	21	21
	31.Total score	16	19	19	17	20	20	20	20	20	20	20	20	21	21	21	21	21	21	21	19
10ND	Imipramine	1	1	0	0	1	1	0	0	1	0	1	0	0	0	0	0	0	0	0	0
	01.Are you () satisfied with your life																				
	02.Have you dropped many of your act..	1	1	0	0	1	0	1	0	1	0	1	0	0	1	0	1	0	0	0	0
	03.Do you feel that your life is empty	1	1	0	1	1	0	1	0	1	0	1	0	1	0	1	0	1	0	0	0
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits act of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	0	1	0	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	0	1	0	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	0	1	0	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor..	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	31.Total score	25	25	22	22	19	19	12	8	9	9	10	6	6	6	6	6	6	6	6	6
10DT	Reboxetine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life																				
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1647

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

64

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
10	10DT	Reboxetine	1	1	0	0	1	0	0	0	0	1
		13.Do you frequently worry about the...	1	1	0	0	1	0	0	0	0	0
		14.Do you feel you have more problems.	1	1	0	0	0	0	0	0	0	0
		15.Do you think it is wonderful to be.	1	1	1	1	1	0	0	1	1	0
		16.Do you often feel downhearted	1	1	1	1	1	0	0	1	1	0
		17.Do you feel pretty worthless the ..	0	0	0	0	0	0	0	0	0	0
		18.Do you worry a lot about the past	1	1	0	0	1	0	0	1	0	0
		19.Do you find life very exciting	1	1	0	0	0	0	1	0	0	0
		20.Is it hard for you to get started..	1	1	0	0	0	0	1	0	0	1
		21.Do you feel full of energy	1	1	0	0	1	1	0	0	0	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	0	0	0	1
		23.Do you think that most people are...	1	1	0	0	0	0	0	0	0	0
		24.Do you frequently get upset over...	1	0	0	0	0	0	0	0	0	0
		25.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0
		26.Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0
		27.Do you enjoy getting up in the morn.	1	1	1	1	1	0	0	0	0	0
		28.Do you prefer to avoid social get...	1	1	1	1	1	0	0	0	0	0
		29.Is it easy for you to make decision	1	1	0	0	1	0	0	0	0	1
		30.Is your mind as clear as it used ..	1	1	0	0	1	0	0	0	0	1
		31.Total score	21	22	13	9	20	13	13	11	11	13
11	11ND	Imipramine	1	1	1	0	1	1	0	0	0	0
		01.Are you () satisfied with your life	1	1	1	0	1	1	0	0	0	0
		02.Have you dropped many of your act...	1	1	1	1	1	1	0	0	0	1
		03.Do you feel that your life is empty	1	1	0	0	0	0	0	0	0	0
		04.Do you often get bored	0	0	0	0	0	0	1	0	0	0
		05.Are you hopeful about the future	0	0	0	0	0	0	1	0	0	0
		06.Are you bothered by thoughts you ..	1	0	0	0	1	1	1	0	0	0
		07.Are you in good spirits most of ...	1	0	0	0	0	0	0	0	0	0
		08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0
		09.Do you feel happy most of the time	1	0	0	0	0	0	0	0	0	0
		10.Do you often feel helpless	1	0	0	0	0	0	0	0	0	0
		11.Do you often get restless and f....	1	0	0	0	0	0	0	0	0	0
		12.Do you prefer to stay at home,	1	0	0	0	0	0	0	0	0	0
		13.Do you frequently worry about the..	0	0	0	0	0	0	0	0	0	0
		14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0
		15.Do you think it is wonderful to be.	1	1	1	1	1	0	0	0	0	0
		16.Do you often feel downhearted	1	1	1	1	1	0	0	0	0	0
		17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	0	0	0
		18.Do you worry a lot about the past	1	1	1	1	1	1	0	0	0	0
		19.Do you find life very exciting	1	1	0	0	0	0	0	0	0	0
		20.Is it hard for you to get started..	1	1	0	0	0	0	0	0	0	0
		21.Do you feel full of energy	1	1	0	0	1	1	1	0	0	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	0	0	0
		23.Do you think that most people are...	1	1	1	1	1	1	1	0	0	0
		24.Do you frequently get upset over...	1	1	1	1	1	0	0	0	0	0
		25.Do you frequently feel like crying	1	1	1	1	1	0	0	0	0	0
		26.Do you have trouble concentrating	1	1	1	1	0	0	0	0	0	0
		27.Do you enjoy getting up in the morn.	1	1	0	0	0	0	0	0	0	0
		28.Do you prefer to avoid social get...	1	1	0	0	1	1	1	0	0	0
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	0	0	0
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	0	0	0	0

1648

PEARMACTIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
10	11ND Inipramine	31.Total score	25	21	20	25	20	17	18	6	7
	11NDT Inipramine	01.Are you () satisfied with your life	1	1	1	0	0	0	0	0	0
		02.Have you dropped many of your act..	1	1	1	1	1	1	0	0	0
		03.Do you feel that your life is empty	0	0	0	0	0	0	0	0	0
		04.Do you often get bored	0	0	0	0	0	0	0	0	0
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	0	0	0	0	0	0	0	0	0
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	0	0	0	0	0	0	0	0	0
		14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0
		15.Do you think it is wonderful to be.	0	0	0	0	0	0	0	0	0
		16.Do you often feel downhearted	0	0	0	0	0	0	0	0	0
		17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are..	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social get...	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1
		31.Total score	20	22	18	11	12	10	8	8	8
12ND	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	0	0	0	0	0	0	0	0	0
		14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

66

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
10	12HD	Reboxetine	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ..	1	1	0	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	0	1	1	1	1	1	1	0	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	0	1	1	0	1	0	1	0	0	0
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31.Total score	25	26	24	26	24	29	24	23	24	24
12DT	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	0	0	1	0	1	1	1	1
		03.Do you feel that your life is empty	1	0	0	1	0	1	0	0	0	0
		04.Do you often get bored	0	0	1	1	0	0	0	0	0	0
		05.Are you hopeful about the future	1	0	1	1	1	0	0	0	0	0
		06.Are you bothered by thoughts you ..	1	0	0	1	1	0	0	0	0	0
		07.Are you in good spirits most of ...	1	1	0	0	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	0	0	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	0	0	1	0	0	0	0
		10.Do you often feel helpless	1	1	1	0	1	1	0	0	0	0
		11.Do you often get restless and f....	0	1	0	0	1	0	1	0	1	0
		12.Do you prefer to stay at home,	0	0	1	1	1	0	1	0	1	1
		13.Do you frequently worry about the..	0	0	0	1	1	0	0	0	1	0
		14.Do you feel you have more problems.	0	0	1	1	1	0	0	0	0	0
		15.Do you think it is wonderful to be.	0	1	1	0	1	1	0	1	0	0
		16.Do you often feel downhearted	0	1	1	0	1	1	1	1	1	1
		17.Do you feel pretty worthless the ..	0	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	0	0	0	1	1	1	0	1	0	0
		19.Do you find life very exciting	1	1	0	1	0	0	0	1	1	1
		20.Is it hard for you to get started..	0	1	1	0	1	0	0	0	0	0
		21.Do you feel full of energy	0	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	0	1	0	1	0	0	0	0	0
		26.Do you have trouble concentrating	0	0	0	1	0	0	0	0	0	0
		27.Do you enjoy getting up in the mor..	0	0	0	1	0	0	0	0	0	0
		28.Do you prefer to avoid social gat..	0	0	0	1	0	0	0	1	1	1
		29.Is it easy for you to make decision	0	0	1	1	0	0	1	1	1	1
		30.Is your mind as clear as it used ..	0	1	0	0	0	0	0	1	0	0
		31.Total score	13	16	15	17	15	14	10	11	10	10

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

67

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
10	13DT Reboxetine	1	1	1	1	0	0	0	0	0	0
	01.Are you () satisfied with your life	1	1	1	1	0	0	0	0	0	0
	02.Have you dropped many of your act..	1	1	1	1	0	0	0	0	0	0
	03.Do you feel that your life is empty	1	1	1	1	0	0	0	0	0	0
	04.Do you often get bored	1	1	1	1	0	0	0	0	0	0
	05.Are you hopeful about the future	1	1	1	1	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	1	1	1	0	0	0	0	0	0
	08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	1	1	1	0	0	0	0	0	0
	10.Do you often feel helpless	0	0	0	0	0	0	0	0	0	0
	11.Do you often get restless and f.....	0	0	0	0	0	0	0	0	0	0
	12.Do you prefer to stay at home,	1	1	1	1	0	0	0	0	0	0
	13.Do you frequently worry about the...	0	0	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be.	1	1	1	1	0	0	0	0	0	0
	16.Do you often feel downhearted	1	1	1	1	0	0	0	0	0	0
	17.Do you feel pretty worthless the ...	1	1	1	1	0	0	0	0	0	0
	18.Do you worry a lot about the past	1	1	1	1	0	0	0	0	0	0
	19.Do you find life very exciting	1	1	1	1	0	0	0	0	0	0
	20.Is it hard for you to get started..	1	1	1	1	0	0	0	0	0	0
	21.Do you feel full of energy	1	1	1	1	0	0	0	0	0	0
	22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0
	23.Do you think that most people are...	0	0	0	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	1	1	1	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	1	1	1	1	0	0	0	0	0	0
	28.Do you prefer to avoid social gat..	1	1	1	1	0	0	0	0	0	0
	29.Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0	0
	31.Total score	19	19	15	12	8	11	8	9	7	7
14DT	Imipramine	1	1	1	1	1	0	0	0	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	0	0	0	1	1
	02.Have you dropped many of your act..	1	1	1	1	0	0	0	0	0	0
	03.Do you feel that your life is empty	1	1	1	1	0	0	0	0	0	0
	04.Do you often get bored	1	1	1	1	0	0	0	0	0	0
	05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	1	1	1	1	0	0	0	0	0	0
	07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	1	1	1	0	0	0	0	0	0
	09.Do you feel happy most of the time	0	0	0	0	0	0	0	0	0	0
	10.Do you often feel helpless	0	0	0	0	0	0	0	0	0	0
	11.Do you often get restless and f.....	1	1	1	1	0	0	0	0	0	0
	12.Do you prefer to stay at home,	1	1	1	1	0	0	0	0	0	0
	13.Do you frequently worry about the...	1	1	1	1	0	0	0	0	0	0
	14.Do you feel you have more problems.	1	1	1	1	0	0	0	0	0	0
	15.Do you think it is wonderful to be.	1	1	1	1	0	0	0	0	0	0
	16.Do you often feel downhearted	1	1	1	1	0	0	0	0	0	0
	17.Do you feel pretty worthless the ...	1	1	1	1	0	0	0	0	0	0
	18.Do you worry a lot about the past	1	1	1	1	0	0	0	0	0	0

1651

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

68

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
10	14DT Imipramine	1	1	1	1	1	0	0	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	0	0	0	0	0
	20.Is it hard for you to get started..	1	1	1	1	0	0	0	0	0	0
	21.Do you feel full of energy	1	1	1	1	0	0	0	0	0	0
	22.Do you think that your situation ...	1	1	0	0	0	0	0	0	0	0
	23.Do you think that most people are..	1	1	1	1	0	0	0	0	0	0
	24.Do you frequently get upset over...	0	1	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	0	1	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	0	1	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	0	1	0	0	0	0	0	0	0	0
	28.Do you prefer to avoid social gat..	1	1	1	1	1	0	0	0	0	0
	29.Is it easy for you to make decision	1	1	0	0	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0	0
	31.Total score	22	22	19	16	9	8	10	6	5	
15SD	Reboxetine	1	1	1	1	1	0	0	0	0	0
	01.Are you () satisfied with your life	1	1	1	1	1	0	0	0	0	0
	02.Have you dropped many of your act..	1	1	0	0	0	0	0	0	0	0
	03.Do you feel that your life is empty	1	1	0	0	0	0	0	0	0	0
	04.Do you often get bored	0	1	0	0	0	0	0	0	0	0
	05.Are you hopeful about the future	0	1	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	1	1	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	1	1	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	1	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	1	1	0	0	0	0	0	0	0
	10.Do you often feel helpless	1	1	1	0	0	0	0	0	0	0
	11.Do you often get restless and f....	1	1	1	0	0	0	0	0	0	0
	12.Do you prefer to stay at home, ...	1	1	0	0	0	0	0	0	0	0
	13.Do you frequently worry about the..	1	1	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	1	1	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be.	1	1	1	0	0	0	0	0	0	0
	16.Do you often feel downhearted	1	1	1	0	0	0	0	0	0	0
	17.Do you feel pretty worthless the ..	1	1	1	0	0	0	0	0	0	0
	18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	1	1	1	1	0	0	0	0	0	0
	20.Is it hard for you to get started..	1	1	1	0	0	0	0	0	0	0
	21.Do you feel full of energy	1	1	1	0	0	0	0	0	0	0
	22.Do you feel that your situation ...	1	1	1	0	0	0	0	0	0	0
	23.Do you think that most people are...	1	1	0	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	1	1	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	1	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	1	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	1	1	1	0	0	0	0	0	0	0
	28.Do you prefer to avoid social gat...	1	1	1	0	0	0	0	0	0	0
	29.Is it easy for you to make decision	1	1	0	0	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	1	1	0	0	0	0	0	0	0	0
	31.Total score	28	27	18	11	8	7	6	6	7	
16DT	Imipramine	1	1	0	0	0	0	0	0	0	0
	01.Are you () satisfied with your life	1	1	0	0	0	0	0	0	0	0
	02.Have you dropped many of your act..	1	0	0	0	0	0	0	0	0	0
	03.Do you feel that your life is empty	1	0	0	0	0	0	0	0	0	0

16 DT

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

69

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	_Day0_		_Day7_		_Day14_		_Day21_		_Day28_		_Day35_		_Day42_		_Day49_		_Day56_		_Day63_	
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
10	16DT Imipramine	1	0	0	1	0	1	1	1	1	0	0	0	0	0	0	1	0	0	0	0
	04.Do you often get bored																				
	05.Are you bothered about the future																				
	06.Are you bothered by thoughts you ..																				
	07.Are you in good spirits most of ...																				
	08.Are you afraid that something bad..																				
	09.Do you feel happy most of the time																				
	10.Do you often feel helpless																				
	11.Do you often get restless and f....																				
	12.Do you prefer to stay at home,																				
	13.Do you frequently worry about the..																				
	14.Do you feel you have more problems.																				
	15.Do you think it is wonderful to be..																				
	16.Do you often feel downhearted																				
	17.Do you worry a lot about the past																				
	18.Do you find life very exciting																				
	19.Do you feel full of energy																				
	20.Is it hard for you to get started..																				
	21.Do you feel that your situation ...																				
	22.Do you think that most people are...																				
	23.Do you frequently get upset over...																				
	24.Do you frequently feel like crying																				
	25.Do you have trouble concentrating																				
	26.Do you enjoy getting up in the mor..																				
	27.Do you prefer to avoid social gat..																				
	28.Is it easy for you to make decision																				
	29.Is your mind as clear as it used ..																				
	31.Total score	18	0	17	12	0	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0
17HD	Reboxetine	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
	01.Are you () satisfied with your life																				
	02.Have you dropped many of your act..																				
	03.Do you feel that your life is empty																				
	04.Do you often get bored																				
	05.Are you bothered about the future																				
	06.Are you bothered by thoughts you ..																				
	07.Are you in good spirits most of ...																				
	08.Are you afraid that something bad..																				
	09.Do you feel happy most of the time																				
	10.Do you often feel helpless																				
	11.Do you often get restless and f....																				
	12.Do you prefer to stay at home,																				
	13.Do you frequently worry about the..																				
	14.Do you feel you have more problems.																				
	15.Do you think it is wonderful to be..																				
	16.Do you often feel downhearted																				
	17.Do you worry a lot about the past																				
	18.Do you find life very exciting																				
	19.Do you feel full of energy																				
	20.Is it hard for you to get started..																				
	21.Do you feel that your situation ...																				

1653

9550089

70

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient	Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63	
				Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
10	17ND	Reboxetine	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			27.Do you enjoy getting up in the mor.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			31.Total score	27	21	21	15	15	10	10	8	8	6	6	6	7	7	0	0	0	0	9	9
18ND		Imipramine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			05.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			06.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			07.Are you afraid that something bad...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			08.Are you often feel helpless	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			09.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			10.Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			11.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			12.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			13.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			14.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			15.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			16.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			17.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			18.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			19.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			20.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			21.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			22.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			23.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			24.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			25.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			26.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			27.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			31.Total score	26	25	24	24	19	19	15	15	10	10	10	11	11	0	0	0	0	11	11	11
19DT		Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			05.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			06.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			07.Are you afraid that something bad...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			08.Are you often feel helpless	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			09.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			10.Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			11.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			12.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			13.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			14.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			15.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			16.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			17.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			18.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			19.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			20.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			21.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			22.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			23.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			24.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			25.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			26.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			27.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			31.Total score	26	25	24	24	19	19	15	15	10	10	10									

9550089

72

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 45.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63	
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
10	20ND Reboxetine	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat..	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	29.Is it easy for you to make decision	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	31.Total score	27	24	24	25	21	23	23	19	19	22	17	20	21	22	19	22	23	23	23	23
12	1ND Reboxetine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act.	1	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1
	03.Do you feel that your life is empty	1	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be.	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	29.Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	31.Total score	0	22	21	20	19	19	19	20	20	21	20	22	21	22	22	22	22	22	22	22
10F	Reboxetine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1656

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

73

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	_Day0_		_Day7_		_Day14_		_Day21_		_Day28_		_Day35_		_Day42_		_Day49_		_Day56_		_Day63_	
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
12	10T	Reboxetine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		31.Total score	0	22	0	22	0	21	0	11	0	17	20	20	20	20	20	20	20	20	20	22
13	10D	Reboxetine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		25.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		26.Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1657

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

74

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63		
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y
13	1ND	Reboxetine	0	1	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		28.Do you prefer to avoid social gat..																					
		29.Is it easy for you to make decision	1	0	1	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		30.Is your mind as clear as it used ..	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		31.Total score	23	23	23	21	21	17	19	14	10	10	10	10	9								
14	1DT	Imipramine	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		01.Are you () satisfied with your life																					
		02.Have you dropped many of your act..	1	1	1	1	1	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
		03.Do you feel that your life is empty	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		04.Do you often get bored	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		05.Are you hopeful about the future	1	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		06.Are you bothered by thoughts you ..	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		07.Are you in good spirits most of ..	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		08.Are you afraid that something bad..	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		10.Do you often feel helpless	1	0	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		11.Do you often get restless and f.....	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		12.Do you prefer to stay at home,	1	1	1	1	1	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		14.Do you feel you have more problems.	0	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		16.Do you often feel downhearted	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		19.Do you find life very exciting	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		21.Do you feel full of energy	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		23.Do you think that most people are..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		25.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		28.Do you prefer to avoid social gat..	0	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		31.Total score	22	21	21	25	22	22	9	8	10	11	11	4									
2ND		Imipramine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		01.Are you () satisfied with your life																					
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

16
57
68

PEARNAZIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient	Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63		
				Y	N	Y	N	Y	N	Y	N	Y	N		
13	2ND	Imipramine	13.Do you frequently worry about the..	0	1	0	1	0	0	0	0	0	1	1	
			14.Do you feel you have more problems.	1	1	1	1	0	1	1	1	0	1	1	1
			15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	0	1	1	1
			16.Do you often feel downhearted	1	1	1	1	1	1	1	1	0	1	1	1
			17.Do you feel pretty worthless the ..	1	1	0	1	1	1	1	1	1	1	0	0
			18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	0	1	1	1
			19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1
			20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1
			21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1
			22.Do you feel that your situation ...	1	1	0	1	1	1	1	0	0	0	0	0
			23.Do you think that most people are..	1	0	1	0	0	1	0	0	0	0	0	0
24.Do you frequently get upset over...	1	1	1	1	0	1	0	0	0	0	0	0			
25.Do you frequently feel like crying	1	0	1	1	1	1	1	0	0	0	0	0			
26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1			
27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	0	0			
28.Is it easy for you to avoid social get..	1	1	1	1	1	1	1	1	1	1	0	0			
29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1			
30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1			
			26	28	22	24	25	25	11	16	16	16	16		
28F	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	0	0	
		02.Have you dropped many of your act...	1	1	1	1	1	1	1	1	1	1	1	1	
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	0	1	1	0	
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	0	
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	0	1	1	0	
		06.Are you bothered by thoughts you ..	1	1	0	1	1	1	1	1	0	0	1	0	
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	0	0	1	0	
		08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0	0	0	
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	0	0	
		11.Do you often get restless and f....	1	1	1	1	0	0	0	0	0	0	0	0	
12.Do you prefer to stay at home,	1	1	1	1	0	0	0	0	0	1	1	0			
13.Do you frequently worry about the..	1	0	1	0	1	0	0	0	0	0	0	0			
14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	0	1	1	0			
15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	0			
16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	0			
17.Do you feel pretty worthless the ..	1	1	1	1	0	0	0	0	0	0	0	0			
18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1			
19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1			
20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1			
21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1			
22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1			
23.Do you think that most people are...	1	1	1	1	0	0	0	0	0	0	0	0			
24.Do you frequently get upset over...	1	0	1	0	0	0	0	0	0	0	0	0			
25.Do you frequently feel like crying	1	0	1	0	1	0	0	0	0	0	0	0			
26.Do you have trouble concentrating	1	1	0	1	1	1	1	1	0	1	1	1			
27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1			
28.Is it easy for you to avoid social get..	1	1	1	1	0	1	1	1	0	0	0	0			
29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1			
30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1			

9550089

76

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
13	2DT Reboxetine	1	1	1	1	1	1	1	1	1	1
	31.Total score	27	26	23	23	18	14	14	21	11	11
3ND	Imipramine	1	1	1	1	1	1	0	0	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	0	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	0	1	1	1	0	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad...	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	0	1	1	1	1	0	1	0	0
	11.Do you often get restless and f....	1	0	1	0	0	1	0	0	1	0
	12.Do you prefer to stay at home,....	1	0	1	1	1	1	0	0	0	0
	13.Do you frequently worry about the...	1	1	0	0	0	0	1	0	0	0
	14.Do you think it is wonderful to be...	1	1	1	1	1	1	1	1	1	1
	15.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	16.Do you feel pretty worthless the ...	1	0	0	0	0	0	0	0	0	0
	17.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
	18.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	19.Is it hard for you to get started..	1	1	0	1	1	1	1	1	1	1
	20.Do you feel full of energy	1	0	0	0	0	0	0	0	0	0
	21.Do you feel that your situation ...	1	0	0	0	0	0	0	0	0	0
	22.Do you think that most people are...	1	0	0	0	0	0	0	0	0	0
	23.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently feel like crying	1	1	0	0	0	0	0	0	0	0
	25.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
	26.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1
	27.Do you prefer to avoid social gat...	1	1	1	1	1	1	1	1	1	1
	28.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	29.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
	31.Total score	29	22	19	20	23	20	20	18	18	18
3DT	Imipramine	1	1	1	1	0	0	0	0	0	0
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	0	0	0	0	0	0
	05.Are you hopeful about the future	1	1	1	1	0	0	0	0	0	0
	06.Are you bothered by thoughts you ...	1	1	1	1	0	0	0	0	0	0
	07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad...	0	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,....	1	1	1	1	0	0	0	0	0	0
	13.Do you frequently worry about the...	1	1	1	1	0	0	0	0	0	0
	14.Do you think it is wonderful to be...	1	0	0	0	0	0	0	0	0	0
	15.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1

1660

9550089

77

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/055

Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63	
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
13	3DT Imipramine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social get...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	31.Total score	28	28	28	28	23	23	15	15	15	15	8	8	7	7	7	7	7	7	7	5
4DT	Reboxetine	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	01.Are you () satisfied with your life	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	02.Have you dropped many of your act..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	03.Do you feel that your life is empty	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	04.Do you often get bored	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	12.Do you prefer to stay at home,	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	13.Do you frequently worry about the..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be.	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	22.Do you feel that your situation ...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	23.Do you think that most people are...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor.	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social get...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	31.Total score	22	24	17	17	19	19	19	19	17	17	15	15	12	12	12	12	12	12	12	17

1661

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

78

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
14 1ND Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	0	0	0	1	0	0	0	0
	03.Do you feel that your life is empty	1	0	0	0	1	0	0	0	0	0
	04.Do you often get bored	1	0	0	0	1	0	0	0	0	0
	05.Are you hopeful about the future	1	0	0	0	0	0	1	0	0	0
	06.Are you bothered by thoughts you ..	1	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	1	1	1	0	0	1	0	0	0
	08.Are you afraid that something bad..	1	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	0	0	0	0	0	0	0	0	0
	11.Do you often get restless and f....	1	0	0	0	0	0	0	0	0	0
	12.Do you prefer to stay at home,	1	0	0	0	0	0	0	0	0	0
	13.Do you frequently worry about the..	1	0	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	0	0	0	0	0	0	0	0	0
	17.Do you feel pretty worthless the ...	1	0	0	0	0	0	0	0	0	0
	18.Do you worry a lot about the past ..	1	0	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	0	0	0	0	0	0	0	0	0
	23.Do you think that most people are...	1	0	0	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	1	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor..	1	0	0	0	0	0	0	0	0	0
	28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
	31.Total score		25	14	13	11	25				
15 1ND Reboxetine	01.Are you () satisfied with your life	0	0	0	0	0	0	1	1	0	0
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	0	0	0	0	0	0	0	0	0	0
	10.Do you often feel helpless	1	0	0	0	0	0	0	0	0	0
	11.Do you often get restless and f....	0	0	0	0	0	0	0	0	0	0
	12.Do you prefer to stay at home,	0	0	0	0	0	0	0	0	0	0
	13.Do you frequently worry about the..	0	0	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be..	1	0	0	0	0	0	0	0	0	0
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past ..	1	1	1	1	1	1	1	1	1	1

1662

9550089

79

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
15	1HD Reboxetine	1	1	1	1	1	1	1	1	1	1
	19. Do you find life very exciting										
	20. Is it hard for you to get started..										
	21. Do you feel full of energy										
	22. Do you feel that your situation ...										
	23. Do you think that most people are ...										
	24. Do you frequently get upset over ...										
	25. Do you frequently feel like crying										
	26. Do you have trouble concentrating										
	27. Do you enjoy getting up in the mor.										
	28. Do you prefer to avoid social gat..										
	29. Is it easy for you to make decision										
	30. Is your mind as clear as it used ..										
	31. Total score	17	0	17	0	16	14	17	16	0	16
10T	Reboxetine	1	0	0	0	0	0	0	0	0	0
	01. Are you () satisfied with your life										
	02. Have you dropped many of your act..										
	03. Do you feel that your life is empty										
	04. Do you often get bored										
	05. Are you hopeful about the future										
	06. Are you bothered by thoughts you ..										
	07. Are you in good spirits most of ...										
	08. Are you afraid that something bad..										
	09. Do you feel happy most of the time										
	10. Do you often feel helpless										
	11. Do you often get restless and f....										
	12. Do you prefer to stay at home, ...										
	13. Do you frequently worry about the..										
	14. Do you feel you have more problems.										
	15. Do you think it is wonderful to be..										
	16. Do you often feel downhearted										
	17. Do you feel pretty worthless the ..										
	18. Do you worry a lot about the past										
	19. Do you find life very exciting										
	20. Is it hard for you to get started..										
	21. Do you feel full of energy										
	22. Do you feel that your situation ...										
	23. Do you think that most people are ...										
	24. Do you frequently get upset over ...										
	25. Do you frequently feel like crying										
	26. Do you have trouble concentrating										
	27. Do you enjoy getting up in the mor.										
	28. Do you prefer to avoid social gat..										
	29. Is it easy for you to make decision										
	30. Is your mind as clear as it used ..										
	31. Total score	20	0	20	0	19	16	11	8	0	7
2HD	Imipramine	1	1	1	1	1	1	1	1	1	1
	01. Are you () satisfied with your life										
	02. Have you dropped many of your act..										
	03. Do you feel that your life is empty										

1663

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

80

PHARMACIA CNS R&D
 REBOMETLINE - PROTOCOL 20124/035
 Listing No.: 45.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
15	2MD										
	Imipramine										
	04. Do you often get bored	1	1	1	1						
	05. Are you hopeful about the future	0	0	0	0						
	06. Are you bothered by thoughts you ...	1	1	0	0						
	07. Are you in good spirits most of ...	0	0	0	0						
	08. Are you afraid that something bad...	1	1	1	1						
	09. Do you often feel happy most of the time	0	0	0	0						
	10. Do you often feel helpless	0	0	0	0						
	11. Do you often get restless and f....	1	1	1	1						
	12. Do you prefer to stay at home, ...	0	0	0	0						
	13. Do you frequently worry about the...	0	0	0	0						
	14. Do you feel you have more problems.	1	1	1	1						
	15. Do you think it is wonderful to be...	1	1	1	1						
	16. Do you often feel downhearted	1	1	1	1						
	17. Do you feel pretty worthless the...	1	1	1	1						
	18. Do you worry a lot about the past	1	1	1	1						
	19. Do you find life very exciting	1	1	1	1						
	20. Is it hard for you to get started...	1	1	1	1						
	21. Do you feel full of energy	1	1	1	1						
	22. Do you feel that your situation ...	1	1	1	1						
	23. Do you think that most people are...	0	0	0	0						
	24. Do you frequently get upset aver...	1	1	1	1						
	25. Do you frequently feel like crying	1	1	1	1						
	26. Do you have trouble concentrating	1	1	1	1						
	27. Do you enjoy getting up in the mor.	1	1	1	1						
	28. Do you prefer to avoid social gat...	0	0	0	0						
	29. Is it easy for you to make decision	1	1	1	1						
	30. Is your mind as clear as it used ..	0	0	0	0						
	31. Total score	0	21	0	21	0	16				
20f	2MD										
	Imipramine										
	01. Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0
	02. Have you dropped many of your act..	1	1	1	1	0	1	0	1	0	1
	03. Do you feel that your life is empty	1	1	1	1	0	0	0	0	0	0
	04. Do you often get bored	0	0	0	0	0	0	0	0	0	0
	05. Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06. Are you bothered by thoughts you ...	1	1	0	0	0	0	0	0	0	0
	07. Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
	08. Are you afraid that something bad...	1	1	1	1	1	1	1	1	1	1
	09. Do you often feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10. Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11. Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
	12. Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1
	13. Do you frequently worry about the...	1	1	1	1	1	1	1	1	1	1
	14. Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	15. Do you think it is wonderful to be...	1	1	1	1	1	1	1	1	1	1
	16. Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17. Do you feel pretty worthless the...	1	1	1	1	1	1	1	1	1	1
	18. Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
	19. Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20. Is it hard for you to get started...	1	1	1	1	1	1	1	1	1	1
	21. Do you feel full of energy	1	1	1	1	1	1	1	1	1	1

1664

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

81

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
15	20T	Imipramine	1	0	1	0	0	0	0	0	0	1
		22.Do you feel that your situation ...										
		23.Do you think that most people are...										
		24.Do you frequently get upset over...										
		25.Do you frequently feel like crying										
		26.Do you have trouble concentrating										
		27.Do you enjoy getting up in the mor.										
		28.Do you prefer to avoid social get..										
		29.Is it easy for you to make decision										
		30.Is your mind as clear as it used ..										
		31.Total score	0	20	0	18	15	0	12	11	0	11
3MD	Reboxetine	01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeless about the future	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
		08.Are you afraid that something bad...	0	0	0	0	0	0	0	0	0	0
		09.Do you feel happy most of the time	0	0	0	0	0	0	0	0	0	0
		10.Do you often feel helpless	0	0	0	0	0	0	0	0	0	0
		11.Do you often get restless and f.....	0	0	0	0	0	0	0	0	0	0
		12.Do you prefer to stay at home,....	1	0	1	0	1	0	1	0	1	0
		13.Do you frequently worry about the..	1	0	1	0	1	0	1	0	1	0
		14.Do you feel you have more problems.	1	0	1	0	1	0	1	0	1	0
		15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		17.Do you worry a lot about the past ..	1	1	1	1	1	1	1	1	1	1
		18.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	0	1	0	1	0	1	0	1	0
		22.Do you feel that your situation ...	1	0	1	0	1	0	1	0	1	0
		23.Do you think that most people are...	1	0	1	0	1	0	1	0	1	0
		24.Do you frequently get upset over...	1	0	1	0	1	0	1	0	1	0
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social get..	0	0	0	0	0	0	0	0	0	0
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	0	0	0	0	0	0	0	0	0
		31.Total score	23	0	18	12	11	9	7	9	0	5
4MD	Imipramine	01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeless about the future	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1

1665

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

32

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
15	4ND Imipramine	0	1	1	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	1	1	1	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	1	1	1	0	0	1	1	1	0
	09.Do you feel happy most of the time	0	1	0	0	0	0	0	0	0	0
	10.Do you often feel helpless	1	1	1	1	0	0	0	0	0	0
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	0
	12.Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	0
	13.Do you frequently worry about the..	0	1	0	0	1	0	1	0	0	0
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	0
	17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	0
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	0
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social get...	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
	31.Total score	22	0	22	18	19	16	16	14	10	8
111ND	Reboxetine	0	0	0	0	0	0	0	0	0	0
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	0	0	0	0	0	0	0	0	0	0
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1

1666

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

83

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63	
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
15	111HD Reboxetine	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	25.Do you frequently feel like crying	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	26.Do you have trouble concentrating	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	27.Do you enjoy getting up in the mor.	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	28.Do you prefer to avoid social gat..	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	29.Is it easy for you to make decision	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	30.Is your mind as clear as it used ..	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	31.Total score	23	20	20	21	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20
15	112HD Imipramine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	31.Total score	21	18	12	12	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9
16	1HD Reboxetine	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	01.Are you () satisfied with your life	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

1667

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

84

PHARMACIA CNS RD
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63	
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
16	4MD Reboxetine	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1
	10. Do you often feel helpless																				
	11. Do you often get restless and f....	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	12. Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	13. Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	14. Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	15. Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	16. Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	17. Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	18. Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	19. Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20. Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21. Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	22. Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	23. Do you think that most people are..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	24. Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	25. Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	26. Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	27. Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	28. Do you prefer to avoid social gat...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	29. Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	30. Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	31. Total score	25	22	25	21	19	15	12	7	9											
4DI	Imipramine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	01. Are you () satisfied with your life																				
	02. Have you dropped many of your act..	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	03. Do you feel that your life is empty	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	04. Do you often get bored	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	05. Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	06. Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	07. Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	08. Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	09. Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10. Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	11. Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	12. Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	13. Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	14. Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	15. Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	16. Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	17. Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	18. Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	19. Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20. Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21. Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	22. Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	23. Do you think that most people are..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	24. Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	25. Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	26. Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	27. Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1668

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

85

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
16	1DT Imipramine	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat..										
	29.Is it easy for you to make decision										
	30.Is your mind as clear as it used ..										
	31.Total score	25	26	29							
2HD	Imipramine	1	1	1	0	0	1	1	0	0	0
	01.Are you () satisfied with your life										
	02.Have you dropped many of your act..										
	03.Do you feel that your life is empty										
	04.Do you often get bored										
	05.Are you hopeful about the future										
	06.Are you bothered by thoughts you ..										
	07.Are you in good spirits most of ...										
	08.Are you afraid that something bad..										
	09.Do you feel happy most of the time										
	10.Do you often feel helpless										
	11.Do you often get restless and f.....										
	12.Do you prefer to stay at home,....										
	13.Do you frequently worry about the..										
	14.Do you feel you have more problems.										
	15.Do you think it is wonderful to be..										
	16.Do you often feel demotiated										
	17.Do you worry a lot about the past										
	18.Do you find life very exciting										
	19.Do you find life very exciting										
	20.Is it hard for you to get started..										
	21.Do you feel full of energy										
	22.Do you feel that your situation ...										
	23.Do you think that most people are..										
	24.Do you frequently get upset over...										
	25.Do you frequently feel like crying										
	26.Do you have trouble concentrating										
	27.Do you enjoy getting up in the mor..										
	28.Do you prefer to avoid social gat..										
	29.Is it easy for you to make decision										
	30.Is your mind as clear as it used ..										
	31.Total score	23	20	14	9	11	11	11	10	9	9
2DT	Reboxetine	1	1	1	1	1	0	0	0	0	0
	01.Are you () satisfied with your life										
	02.Have you dropped many of your act..										
	03.Do you feel that your life is empty										
	04.Do you often get bored										
	05.Are you hopeful about the future										
	06.Are you bothered by thoughts you ..										
	07.Are you in good spirits most of ...										
	08.Are you afraid that something bad..										
	09.Do you feel happy most of the time										
	10.Do you often feel helpless										
	11.Do you often get restless and f.....										
	12.Do you prefer to stay at home,....										

16 69

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

86

PHARMACIA CNS R&D
 REBONETINE - PROTOCOL 20124/035
 Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63		
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y
16	2DT	Rebonetine	1	1	1	1	1	1	0	1	0	1	0	1	0	1	0	0	0	0	1	0	0
		13.Do you frequently worry about the...	1	1	1	1	1	1	0	1	0	1	0	1	0	1	0	0	0	0	1	0	0
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	0	1	0	0	0	0	0	0	0	0	0	0	0
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0
		17.Do you feel pretty worthless the ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	0	1	0	1	1	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		23.Do you think that most people are...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		24.Do you frequently get upset over...	1	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		25.Do you frequently feel like crying	1	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		26.Do you have trouble concentrating	1	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		28.Do you prefer to avoid social gat...	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		29.Is it easy for you to make a decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		31.Total score	23	23	22	22	18	18	11	11	8	8	6	6	6	6	6	6	6	6	6	6	6
3ND		Imipramine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		11.Do you often get restless and f....	1	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		12.Do you prefer to stay at home,	1	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		13.Do you frequently worry about the...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		23.Do you think that most people are...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		24.Do you frequently get upset over...	1	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		25.Do you frequently feel like crying	1	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		26.Do you have trouble concentrating	1	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make a decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1670

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

87

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
16	3HD	Inipramine	31.Total score	23	24	21	18	20	17			
	3DT	Inipramine	01.Are you () satisfied with your life	1	1	1	1					
			02.Have you dropped many of your act..	1	0	1	1					
			03.Do you feel that your life is empty	1	0	1	1					
			04.Do you often get bored	1	0	1	1					
			05.Are you hopeful about the future	1	1	1	1					
			06.Are you bothered by thoughts you ..	1	1	1	1					
			07.Are you in good spirits most of ...	1	1	1	1					
			08.Are you afraid that something bad..	1	1	1	1					
			09.Do you feel happy most of the time	1	1	1	1					
			10.Do you often feel helpless	0	1	1	1					
			11.Do you often get restless and f.....	1	0	1	0					
			12.Do you prefer to stay at home,	1	1	1	1					
			13.Do you frequently worry about the...	1	1	1	1					
			14.Do you feel you have more problems.	1	1	1	1					
			15.Do you think it is wonderful to be.	1	1	1	1					
			16.Do you often feel downhearted	1	1	1	1					
			17.Do you feel pretty worthless the ...	1	1	1	1					
			18.Do you worry a lot about the past ...	0	1	1	1					
			19.Do you find life very exciting	1	1	1	1					
			20.Is it hard for you to get started..	1	1	1	1					
			21.Do you feel full of energy	1	1	1	1					
			22.Do you feel that your situation ...	1	0	1	1					
			23.Do you think that most people are...	0	0	1	1					
			24.Do you frequently get upset over...	0	0	1	1					
			25.Do you frequently feel like crying	0	0	0	0					
			26.Do you have trouble concentrating	1	1	1	1					
			27.Do you enjoy getting up in the mor.	1	1	1	1					
			28.Do you prefer to avoid social gat..	0	0	1	1					
			29.Is it easy for you to make decision	1	1	1	1					
			30.Is your mind as clear as it used ..	1	1	1	1					
			31.Total score	23	22	28	28					
4HD	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	0	1	0	0	0
		02.Have you dropped many of your act..	1	1	1	1	1	1	0	0	0	1
		03.Do you feel that your life is empty	1	1	0	0	0	0	0	0	0	0
		04.Do you often get bored	1	0	0	0	0	0	0	0	0	0
		05.Are you hopeful about the future	1	1	1	1	1	0	0	0	0	1
		06.Are you bothered by thoughts you ..	1	0	0	0	0	0	0	0	0	0
		07.Are you in good spirits most of ...	1	1	1	1	1	1	0	0	0	0
		08.Are you afraid that something bad..	1	1	1	1	1	0	0	0	0	0
		09.Do you feel happy most of the time	1	1	1	1	1	1	0	0	0	0
		10.Do you often feel helpless	1	1	1	1	1	0	0	0	0	0
		11.Do you often get restless and f.....	1	1	0	0	0	0	0	0	0	0
		12.Do you prefer to stay at home,	1	1	0	0	0	0	0	0	0	0
		13.Do you frequently worry about the...	1	1	1	1	1	0	0	0	0	0
		14.Do you feel you have more problems.	1	1	1	1	1	0	0	0	0	0
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	0	1	0	1

1671

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

28

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
16	4ND	Reboxetine	0	1	0	1	0	0	0	0	0	0
		16.Do you often feel downhearted										
		17.Do you worry a lot about the past	1	0	0	0	0	0	0	0	0	0
		18.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		19.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		20.Do you feel full of energy	0	0	0	0	0	0	0	0	0	0
		21.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0
		22.Do you think that most people are...	0	0	0	0	0	0	0	0	0	0
		23.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0
		24.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0
		25.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		26.Do you enjoy getting up in the mor.	0	0	0	0	0	0	0	0	0	0
		27.Do you prefer to avoid social get..	0	0	0	0	0	0	0	0	0	0
		28.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		29.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31.Total score	22	20	17	15	12	10	6	7	7	7
17	1ND	Reboxetine	1	1	1	1	1	1	1	1	1	1
		01.Are you () satisfied with your life										
		02.Have you dropped any of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you often get bored	1	1	1	1	1	1	1	1	1	1
		04.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
		05.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
		06.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		07.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
		08.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
		09.Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1
		10.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
		11.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
		12.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
		13.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		14.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
		15.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		16.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		17.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		18.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
		19.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		20.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
		21.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		22.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
		23.Do you prefer to avoid social get..	1	1	1	1	1	1	1	1	1	1
		24.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		25.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31.Total score	29	30	29	30	30	30	30	30	30	30

1672

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

89

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	_Day0_		_Day7_		_Day14_		_Day21_		_Day28_		_Day35_		_Day42_		_Day49_		_Day56_		_Day63_	
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
17	40T	Reboxetine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		01.Are you () satisfied with your life	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
		02.Have you dropped many of your act..	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
		03.Do you feel that your life is empty	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		11.Do you often get restless and f.....	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
		17.Do you feel pretty worthless the ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		23.Do you think that most people are...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		25.Do you frequently feel like crying	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		28.Do you prefer to avoid social gat..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		31.Total score	19	19	19	19	20	20	19	19	19	19	19	19	19	19	19	19	19	19	19	19
2HD		Imipramine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		01.Are you () satisfied with your life	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
		02.Have you dropped many of your act..	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
		03.Do you feel that your life is empty	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ..	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
		18.Do you worry a lot about the past	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0

1673

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

90

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient	Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63		
				Y	N	Y	N	Y	N	Y	N	Y	N		
17	2ND	Imipramine	19.Do you find life very exciting 20.Is it hard for you to get started.. 21.Do you feel full of energy 22.Do you feel that your situation ... 23.Do you think that most people are.. 24.Do you frequently get upset over... 25.Do you frequently feel like crying 26.Do you have trouble concentrating 27.Do you enjoy getting up in the mor.. 28.Do you prefer to avoid social gat.. 29.Is it easy for you to make decision 30.Is your mind as clear as it used .. 31.Total score	1	1	1	1	1	1	1	1	1	1		
				0	0	0	0	0	0	0	0	0	0		
				1	1	1	1	1	1	1	1	1	1		
				0	0	0	0	0	0	0	0	0	0		
				1	1	1	1	1	1	1	1	1	1		
				0	0	0	0	0	0	0	0	0	0		
				1	1	1	1	1	1	1	1	1	1		
				0	0	0	0	0	0	0	0	0	0		
				1	1	1	1	1	1	1	1	1	1		
				1	1	1	1	1	1	1	1	1	1		
				1	1	1	1	1	1	1	1	1	1		
				1	1	1	1	1	1	1	1	1	1		
				18	18	18	18	18	18	19	18	19	19		
ZDT		Reboxetine	01.Are you () satisfied with your life 02.Have you dropped many of your act.. 03.Do you feel that your life is empty 04.Do you often get bored 05.Are you hopeful about the future 06.Are you bothered by thoughts you .. 07.Are you in good spirits most of ... 08.Are you afraid that something bad.. 09.Do you feel happy most of the time 10.Do you often feel helpless 11.Do you often get restless and f.... 12.Do you prefer to stay at home, ... 13.Do you frequently worry about the.. 14.Do you feel you have more problems. 15.Do you think it is wonderful to be.. 16.Do you often feel downhearted 17.Do you feel pretty worthless the .. 18.Do you worry a lot about the past 19.Do you find life very exciting 20.Is it hard for you to get started.. 21.Do you feel full of energy 22.Do you feel that your situation ... 23.Do you think that most people are.. 24.Do you frequently get upset over... 25.Do you frequently feel like crying 26.Do you have trouble concentrating 27.Do you enjoy getting up in the mor.. 28.Do you prefer to avoid social gat.. 29.Is it easy for you to make decision 30.Is your mind as clear as it used .. 31.Total score	0	0	0	0	0	0	0	0	0	0	0	0
				1	1	1	1	1	1	1	1	1	1		
				1	1	1	1	1	1	1	1	1	1		
				0	0	0	0	0	0	0	0	0	0		
				1	1	1	1	1	1	1	1	1	1		
				0	0	0	0	0	0	0	0	0	0		
				1	1	1	1	1	1	1	1	1	1		
				0	0	0	0	0	0	0	0	0	0		
				1	1	1	1	1	1	1	1	1	1		
				1	1	1	1	1	1	1	1	1	1		
				1	1	1	1	1	1	1	1	1	1		
				1	1	1	1	1	1	1	1	1	1		
				18	18	18	18	16	16	16	15	16	14		
3ND		Imipramine	01.Are you () satisfied with your life 02.Have you dropped many of your act.. 03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1		
				1	1	1	1	1	1	1	1	1	1		

1674

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

91

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/035
 Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63		
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y
17	3ND	Imipramine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		31.Total score	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30
30T	Imipramine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		09.Do you feel happy most of the time	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		15.Do you think it is wonderful to be.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1675

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

92

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0 Y N	Day7 Y N	Day14 Y N	Day21 Y N	Day28 Y N	Day35 Y N	Day42 Y N	Day49 Y N	Day56 Y N	Day63 Y N
17	3DT Imipramine	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gnt..	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
	31.Total score	22	20	19	19	18	18	18	9	9	9
4ND	Reboxetine	1	1	1	1	1	1	0	0	0	0
	01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0
	02.Have you dropped many of your act..	0	0	0	0	0	0	0	0	0	0
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ..	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	0	0	0	0	0	0	0	0	0	0
	10.Do you often feel helpless	0	0	0	0	0	0	0	0	0	0
	11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	0	0	0	0	0	0	0	0	0	0
	14.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
	15.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	16.Do you feel pretty worthless the ..	0	0	0	0	0	0	0	0	0	0
	17.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0
	18.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	19.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	20.Do you feel full of energy	0	0	0	0	0	0	0	0	0	0
	21.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
	22.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
	23.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
	25.Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0
	26.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
	27.Do you prefer to avoid social gnt..	1	1	1	1	1	1	1	1	1	1
	28.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	29.Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0	0
	31.Total score	17	17	14	12	11	11	11	10	9	9
4DT	Imipramine	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	0	0	0	0	0	0	0	0	0	0
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1

1676

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

94

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	_Day0_		_Day7_		_Day14_		_Day21_		_Day28_		_Day35_		_Day42_		_Day49_		_Day56_		_Day63_	
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
17	211HD Reboxetine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	31.Total score	20	19	19	17	17	18	18	16	16	14	13	13	13	13	13	13	13	13	13	13
211DT	Reboxetine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	16.Do you often feel downhearted	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	17.Do you feel pretty worthless the ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	31.Total score	19	17	17	15	15	15	14	14	12	10	9	8	8	8	8	8	8	8	8	8
18	1MD Imipramine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1678

9550089

95

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
18	18D	Inipramine	1	1	1	1	1	0	0	0	0	0
		10.Do you often feel helpless	1	1	1	1	1	0	0	0	0	0
		11.Do you often get restless and f....	1	1	1	1	1	0	0	0	0	0
		12.Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	0	0	0	0	0
		17.Do you feel pretty worthless the ..	1	1	1	1	1	0	0	0	0	0
		18.Do you worry a lot about the past	1	1	1	1	1	0	0	0	0	0
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are..	1	1	1	1	1	0	0	0	0	0
		24.Do you frequently get upset over...	1	1	1	1	1	0	0	0	0	0
		25.Do you frequently feel like crying	1	1	1	1	1	0	0	0	0	0
		26.Do you have trouble concentrating	1	1	1	1	1	0	0	0	0	0
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social get...	1	1	1	1	1	0	0	0	0	0
		29.Is it easy for you to make decision	1	1	1	1	1	0	0	0	0	0
		30.Is your mind as clear as it used ..	1	1	1	1	1	0	0	0	0	0
		31.Total score	30	30	17	13	13	7	7	7	7	8
18F	18F	Inipramine	1	1	1	1	1	1	1	1	1	1
		01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1

1679

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

96

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	_Day0_		_Day7_		_Day14_		_Day21_		_Day28_		_Day35_		_Day42_		_Day49_		_Day56_		_Day63_		
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	
1B 10F Imipramine	28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	31.Total score	29	22	23	23	15	15	15	15	12	12	12	12	12	12	12	12	12	12	12	12	12
2HD Imipramine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home.....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	17.Do you worry a lot about the past ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	18.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		31.Total score	29	30	29	29	29	29	29	29	29	29	29	29	29	29	29	29	29	29	29	29
2DT Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1680

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

97

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
1B	20f	Reboxetine	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the...	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the morn.	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social get...	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31.Total score	30	30	30	28	25					
3MD	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	0	0	0	0	0
		02.Have you dropped many of your act...	1	1	1	1	1	0	0	0	0	0
		03.Do you feel that your life is empty	1	1	1	1	1	0	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	0	0	0	0	0
		06.Are you bothered by thoughts you ..	1	1	1	1	1	0	0	0	0	0
		07.Are you in good spirits most of ...	1	1	1	1	1	0	0	0	0	0
		08.Are you afraid that something bad..	1	1	1	1	1	0	0	0	0	0
		09.Do you feel happy most of the time	1	1	1	1	1	0	0	0	0	0
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f....	1	1	1	1	1	0	0	0	0	0
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	0	0	0	0
		17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	1	1	1	1	1	0	0	0	0	0
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started...	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	0	0	0	0	0
		23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	1	1	0	0	0	0	0
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the morn.	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social get...	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1

1681

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

98

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0 Y N	Day7 Y N	Day14 Y N	Day21 Y N	Day28 Y N	Day35 Y N	Day42 Y N	Day49 Y N	Day56 Y N	Day63 Y N
18	3ND										
	Reboxetine										
	31.Total score	30	30	30	30	21	17	17	17	17	17
4ND	Reboxetine	1	1	1	1	0	0	0	0	0	0
	01.Are you () satisfied with your life	1	1	1	1	0	0	0	0	0	0
	02.Have you dropped many of your act..	1	1	1	1	0	0	0	0	0	0
	03.Do you feel that your life is empty	1	1	1	1	0	0	0	0	0	0
	04.Do you often get bored	1	1	1	1	0	0	0	0	0	0
	05.Are you hopeful about the future	1	1	1	1	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	1	1	1	1	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	1	1	1	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	1	1	1	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	1	1	1	0	0	0	0	0	0
	10.Do you often feel helpless	1	1	1	1	0	0	0	0	0	0
	11.Do you often get restless and f....	1	1	1	1	0	0	0	0	0	0
	12.Do you prefer to stay at home,	1	1	1	1	0	0	0	0	0	0
	13.Do you frequently worry about the..	1	1	1	1	0	0	0	0	0	0
	14.Do you feel you have more problems.	1	1	1	1	0	0	0	0	0	0
	15.Do you think it is wonderful to be.	1	1	1	1	0	0	0	0	0	0
	16.Do you often feel downhearted	1	1	1	1	0	0	0	0	0	0
	17.Do you feel pretty worthless the...	1	1	1	1	0	0	0	0	0	0
	18.Do you worry a lot about the past	1	1	1	1	0	0	0	0	0	0
	19.Do you find life very exciting	1	1	1	1	0	0	0	0	0	0
	20.Is it hard for you to get started..	1	1	1	1	0	0	0	0	0	0
	21.Do you feel full of energy	1	1	1	1	0	0	0	0	0	0
	22.Do you feel that your situation ...	1	1	1	1	0	0	0	0	0	0
	23.Do you think that most people are..	1	1	1	1	0	0	0	0	0	0
	24.Do you frequently get upset over...	1	1	1	1	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	1	1	1	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	1	1	1	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	1	1	1	1	0	0	0	0	0	0
	28.Do you prefer to avoid social gat..	1	1	1	1	0	0	0	0	0	0
	29.Is it easy for you to make decisioa	1	1	1	1	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	1	1	1	1	0	0	0	0	0	0
	31.Total score	30	30	30	30	13	0	0	0	0	0
20	3ND										
	Reboxetine										
	01.Are you () satisfied with your life	1	1	1	1	0	0	0	0	0	0
	02.Have you dropped many of your act..	0	0	0	0	0	0	0	0	0	0
	03.Do you feel that your life is empty	0	0	0	0	0	0	0	0	0	0
	04.Do you often get bored	0	1	1	1	0	0	0	0	0	0
	05.Are you hopeful about the future	1	1	1	1	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	1	1	1	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	1	1	1	0	0	0	0	0	0
	10.Do you often feel helpless	1	1	1	1	0	0	0	0	0	0
	11.Do you often get restless and f....	1	1	1	1	0	0	0	0	0	0
	12.Do you prefer to stay at home,	1	1	1	1	0	0	0	0	0	0
	13.Do you frequently worry about the..	1	1	1	1	0	0	0	0	0	0
	14.Do you feel you have more problems.	1	1	1	1	0	0	0	0	0	0
	15.Do you think it is wonderful to be.	1	1	1	1	0	0	0	0	0	0

16
08
22

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

99

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	_Day0_	_Day7_	_Day14_	_Day21_	_Day28_	_Day35_	_Day42_	_Day49_	_Day56_	_Day63_
			Y	N	Y	N	Y	N	Y	N	Y	N
20	3ND	Reboxetine										
		16.Do you often feel downhearted	1	0	1							
		17.Do you feel pretty worthless the ..	1	1	0							
		18.Do you worry a lot about the past	1	1	1							
		19.Do you find life very exciting	1	1	1							
		20.Is it hard for you to get started..	1	0	0							
		21.Do you feel full of energy	1	0	1							
		22.Do you feel that your situation ...	0	1	0							
		23.Do you think that most people are...	1	0	0							
		24.Do you frequently get upset over...	1	1	1							
		25.Do you frequently feel like crying	1	1	1							
		26.Do you have trouble concentrating	1	1	1							
		27.Do you enjoy getting up in the mor.	1	1	1							
		28.Do you prefer to avoid social get..	0	0	0							
		29.Is it easy for you to make decision	1	1	1							
		30.Is your mind as clear as it used ..	0	1	1							
		31.Total score	0	19	17							
22	1ND	Reboxetine										
		01.Are you () satisfied with your life	0	1	1							
		02.Have you dropped many of your act..	1	1	1							
		03.Do you feel that your life is empty	1	1	1							
		04.Do you often get bored	1	1	1							
		05.Are you worried about the future	1	1	1							
		06.Are you bothered by thoughts you ..	0	1	1							
		07.Are you in good spirits most of ...	1	1	1							
		08.Are you afraid that something bad..	1	1	1							
		09.Do you feel happy most of the time	1	1	1							
		10.Do you often feel helpless	1	1	1							
		11.Do you often get restless and f....	1	1	1							
		12.Do you prefer to stay at home,	1	1	1							
		13.Do you frequently worry about the..	1	1	1							
		14.Do you feel you have more problems.	0	1	1							
		15.Do you think it is wonderful to be.	1	0	1							
		16.Do you often feel downhearted	0	1	1							
		17.Do you feel pretty worthless the ..	1	0	1							
		18.Do you worry a lot about the past	1	0	1							
		19.Do you find life very exciting	1	1	1							
		20.Is it hard for you to get started..	1	1	1							
		21.Do you feel full of energy	1	1	1							
		22.Do you feel that your situation ...	1	1	1							
		23.Do you think that most people are...	1	0	1							
		24.Do you frequently get upset over...	0	1	0							
		25.Do you frequently feel like crying	1	0	1							
		26.Do you have trouble concentrating	1	1	1							
		27.Do you enjoy getting up in the mor.	0	1	1							
		28.Do you prefer to avoid social get..	0	1	1							
		29.Is it easy for you to make decision	1	1	1							
		30.Is your mind as clear as it used ..	1	1	1							
		31.Total score	22	28	28							

16
80
63

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

100

PEARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63		
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	
23 1HD Reboxetine	01.Are you () satisfied with your life	1		1		1		1		1		1		1		1		1		1		
	02.Have you dropped many of your act..	1		1		1		1		1		1		1		1		1		1		
	03.Do you feel that your life is empty	1		1		1		1		1		1		1		1		1		1		
	04.Do you often get bored	1		1		1		1		1		1		1		1		1		1		
	05.Are you hopeful about the future	1		1		1		1		1		1		1		1		1		1		
	06.Are you bothered by thoughts you ..	1		1		1		1		1		1		1		1		1		1		
	07.Are you in good spirits most of ...	1		1		1		1		1		1		1		1		1		1		
	08.Are you afraid that something bad..	1		1		1		1		1		1		1		1		1		1		
	09.Do you feel happy most of the time	1		1		1		1		1		1		1		1		1		1		
	10.Do you often feel helpless	1		1		1		1		1		1		1		1		1		1		
	11.Do you often get restless and f.....	1		1		1		1		1		1		1		1		1		1		
	12.Do you prefer to stay at home,	1		1		1		1		1		1		1		1		1		1		
	13.Do you frequently worry about the...	1		1		1		1		1		1		1		1		1		1		
	14.Do you feel you have more Problems.	1		1		1		1		1		1		1		1		1		1		
	15.Do you think it is wonderful to be.	1		1		1		1		1		1		1		1		1		1		
	16.Do you often feel downhearted	1		1		1		1		1		1		1		1		1		1		
	17.Do you feel pretty worthless the ..	1		1		1		1		1		1		1		1		1		1		
	18.Do you find life very exciting	1		1		1		1		1		1		1		1		1		1		
	19.Is it hard for you to get started..	1		1		1		1		1		1		1		1		1		1		
	20.Do you feel full of energy	1		1		1		1		1		1		1		1		1		1		
	21.Do you feel that your situation ...	1		1		1		1		1		1		1		1		1		1		
	22.Do you think that most people are..	1		1		1		1		1		1		1		1		1		1		
	23.Do you frequently get upset over...	1		1		1		1		1		1		1		1		1		1		
	24.Do you frequently feel like crying	1		1		1		1		1		1		1		1		1		1		
	25.Do you have trouble concentrating	1		1		1		1		1		1		1		1		1		1		
	26.Do you enjoy getting up in the mor.	1		1		1		1		1		1		1		1		1		1		
	27.Do you prefer to avoid social gat..	1		1		1		1		1		1		1		1		1		1		
	28.Is it easy for you to make decision	1		1		1		1		1		1		1		1		1		1		
	29.Is your mind as clear as it used ..	1		1		1		1		1		1		1		1		1		1		
	30.Total score			28		28		26		23		21		19		14		14		11		11
	2HD Reboxetine	01.Are you () satisfied with your life	1		1		1		1		1		1		1		1		1		1	
02.Have you dropped many of your act..		1		1		1		1		1		1		1		1		1		1		
03.Do you feel that your life is empty		1		1		1		1		1		1		1		1		1		1		
04.Do you often get bored		1		1		1		1		1		1		1		1		1		1		
05.Are you hopeful about the future		1		1		1		1		1		1		1		1		1		1		
06.Are you bothered by thoughts you ...		1		1		1		1		1		1		1		1		1		1		
07.Are you in good spirits most of ...		1		1		1		1		1		1		1		1		1		1		
08.Are you afraid that something bad..		1		1		1		1		1		1		1		1		1		1		
09.Do you feel happy most of the time		1		1		1		1		1		1		1		1		1		1		
10.Do you often feel helpless		1		1		1		1		1		1		1		1		1		1		
11.Do you often get restless and f.....		1		1		1		1		1		1		1		1		1		1		
12.Do you prefer to stay at home,		1		1		1		1		1		1		1		1		1		1		
13.Do you frequently worry about tha...		1		1		1		1		1		1		1		1		1		1		
14.Do you feel you have more Problems.		1		1		1		1		1		1		1		1		1		1		
15.Do you think it is wonderful to be.		1		1		1		1		1		1		1		1		1		1		
16.Do you often feel downhearted		1		1		1		1		1		1		1		1		1		1		
17.Do you feel pretty worthless the ..		1		1		1		1		1		1		1		1		1		1		
18.Do you worry a lot about the past		1		1		1		1		1		1		1		1		1		1		

1684

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

101

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	_Day0_	_Day7_	_Day14_	_Day21_	_Day28_	_Day35_	_Day42_	_Day49_	_Day56_	_Day63_		
			Y	N	Y	N	Y	N	Y	N	Y	N		
23	ZND	Reboxetine	19.Do you find life very exciting	0	1	1	1	1	1	0	0	1	0	
			20.Is it hard for you to get started..	1	1	1	1	0	0	0	0	0	0	0
			21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1
			22.Do you feel that your situation ...	1	0	0	0	0	0	0	0	0	0	0
			23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1	1
			24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1
			25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1
			26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1
			27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1
			28.Do you prefer to avoid social gat..	0	1	1	1	1	1	1	1	1	1	1
			29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1
30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1			
31.Total score	27	26	20	20	20	12	10	3	6	4				
3ND	Imipramine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1		
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1		
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1		
		04.Do you often get bored	0	0	0	0	0	0	0	0	0	0		
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1		
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1		
		07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0		
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1		
		09.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1		
		10.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1		
		11.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1		
12.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1				
13.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1				
14.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1				
15.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1				
16.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1				
17.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0				
18.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1				
19.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1				
20.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1				
21.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1				
22.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1				
23.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1				
24.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1				
25.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1				
26.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1				
27.Do you prefer to avoid social gat..	0	1	1	1	1	1	1	1	1	1				
28.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1				
29.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1				
30.Total score	22	24	20	19	14	16	17	13	12					
4ND	Imipramine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1		
		02.Have you dropped many of your act..	1	0	1	1	1	1	1	1	1	1		
		03.Do you feel that your life is empty	1	0	1	1	1	1	1	1	1	1		

16
00
51

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

102

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0
GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	_Day0_		_Day7_		_Day14_		_Day21_		_Day28_		_Day35_		_Day42_		_Day49_		_Day56_		_Day63_	
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
23	4ND Imipramine	1	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0
	04. Do you often get bored	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	05. Are you hopeful about the future	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	06. Are you bothered by thoughts you ...	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	07. Are you in good spirits most of ...	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	08. Are you afraid that something bad...	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	09. Do you feel happy most of the time	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	10. Do you often feel helpless	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	11. Do you often get restless and f....	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	12. Do you prefer to stay at home,	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	13. Do you frequently worry about the...	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	14. Do you feel you have more problems.	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	15. Do you think it is wonderful to be...	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	16. Do you often feel downhearted	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	17. Do you feel pretty worthless the ...	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	18. Do you worry a lot about the past	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	19. Do you find life very exciting	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	20. Is it hard for you to get started...	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	21. Do you feel full of energy	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	22. Do you feel that your situation ...	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	23. Do you think that most people are...	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	24. Do you frequently get upset over...	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	25. Do you frequently feel like crying	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	26. Do you frequently feel like crying	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	27. Do you have trouble concentrating	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	28. Do you enjoy getting up in the mor.	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	29. Do you prefer to avoid social gat...	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	30. Is it easy for you to make decision	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	31. Total score	20	14	15	16	15	14	13	13	14	15	14	14	13	13	14	15	14	14	13	13
5ND	Imipramine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	01. Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	02. Have you dropped many of your act...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	03. Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	04. Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	05. Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	06. Are you bothered by thoughts you ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	07. Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	08. Are you afraid that something bad...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	09. Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10. Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	11. Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	12. Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	13. Do you frequently worry about the...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	14. Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	15. Do you think it is wonderful to be...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	16. Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	17. Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	18. Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	19. Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20. Is it hard for you to get started...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21. Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1686

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

103

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
23	SND Imipramine	1	1	1	1	0	0	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	0	0	1	1	1	1
	23.Do you think that most people are...	1	1	1	1	0	0	1	1	1	1
	24.Do you frequently get upset over...	1	0	1	1	0	0	1	1	1	1
	25.Do you frequently feel like crying	1	0	1	1	0	0	1	1	1	1
	26.Do you have trouble concentrating	1	0	1	1	0	0	1	1	1	1
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social get..	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	0	24	1	1	1	1	1	1	1	1
	31.Total score	24	24	26	26	23	22	29	29	29	29
6ND	Imipramine	1	1	1	0	0	0	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	0	0	0	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeless about the future	1	1	1	0	0	0	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	0	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	0	1	1	1	1
	15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ..	1	0	0	0	0	0	0	0	0	0
	18.Do you worry a lot about the past	1	0	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	0	1	1	1	1	1	1	1	1
	23.Do you think that most people are...	1	1	1	0	0	0	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	1	1	0	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social get..	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
	31.Total score	29	27	26	21	23	22	29	29	29	29
25	1ND Reboxetine	0	0	0	0	1	1	1	1	1	1
	01.Are you () satisfied with your life	0	0	0	0	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeless about the future	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1

1687

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

104

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0 Y N	Day7 Y N	Day14 Y N	Day21 Y N	Day28 Y N	Day35 Y N	Day42 Y N	Day49 Y N	Day56 Y N	Day63 Y N
25	4ND Reboxetine	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	0	0	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	0	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	1	0	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor.	1	0	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social get...	1	0	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
	31.Total score	26	23	27	27	26	28	28	28	28	28
2ND	Imipramine	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	0	1	0	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	0	1	0	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	0	1	0	0	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	0	1	1	1	1	1	0
	13.Do you frequently worry about the..	1	1	0	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	0	0	1	0	0	0	0	0	0	0
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1

1688

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

105

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient	Treatment	Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63					
				Y	N	Y	N	Y	N	Y	N	Y	N					
25	2ND	Inipramine	25.Do you frequently feel like crying	1	0	1	0	1	0	1	0	1	0					
			26.Do you have trouble concentrating	1	1	1	0	1	0	1	0	1	0	1				
			27.Do you enjoy getting up in the mor.	1	1	0	0	1	0	0	0	0	0	0				
			28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1			
			29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1			
			30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1			
			31.Total score	26	27	20	21	22	23	23	23	21	21	24	24			
			26	1MD	Inipramine	01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0		
						02.Have you dropped many of your act..	0	0	0	0	0	0	0	0	0	0	0	
						03.Do you feel that your life is empty	0	0	0	0	0	0	0	0	0	0	0	
						04.Do you often get bored	0	0	0	0	0	0	0	0	0	0	0	
						05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1
						06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1
07.Are you in good spirits most of ...	1	1				1	1	1	1	1	1	1	1	1	1			
08.Are you afraid that something bad...	1	1				1	1	1	1	1	1	1	1	1	1			
09.Do you feel happy most of the time	1	1				1	1	1	1	1	1	1	1	1	1			
10.Do you often feel helpless	1	1				1	1	1	1	1	1	1	1	1	1			
11.Do you often get restless and f.....	1	1				1	1	1	1	1	1	1	1	1	1			
12.Do you prefer to stay at home,...	1	1				1	1	1	1	1	1	1	1	1	1			
13.Do you frequently worry about the..	1	1				1	1	1	1	1	1	1	1	1	1			
14.Do you feel you have more problems.	1	1				1	1	1	1	1	1	1	1	1	1			
15.Do you think it is wonderful to be.	1	1				1	1	1	1	1	1	1	1	1	1			
16.Do you often feel downhearted	1	1				1	1	1	1	1	1	1	1	1	1			
17.Do you feel pretty worthless the ..	1	1				1	1	1	1	1	1	1	1	1	1			
18.Do you worry a lot about the past	1	1				1	1	1	1	1	1	1	1	1	1			
19.Do you find life very exciting	1	1				1	1	1	1	1	1	1	1	1	1			
20.Is it hard for you to get started..	1	1				1	1	1	1	1	1	1	1	1	1			
21.Do you feel full of energy	1	1				1	1	1	1	1	1	1	1	1	1			
22.Do you feel that your situation ...	0	0				0	0	0	0	0	0	0	0	0	0			
23.Do you think that most people are..	0	0				0	0	0	0	0	0	0	0	0	0			
24.Do you frequently get upset over...	0	0				0	0	0	0	0	0	0	0	0	0			
25.Do you frequently feel like crying	0	0				0	0	0	0	0	0	0	0	0	0			
26.Do you have trouble concentrating	0	0				0	0	0	0	0	0	0	0	0	0			
27.Do you enjoy getting up in the mor.	0	0				0	0	0	0	0	0	0	0	0	0			
28.Do you prefer to avoid social gat..	1	1				1	1	1	1	1	1	1	1	1	1			
29.Is it easy for you to make decision	1	1				1	1	1	1	1	1	1	1	1	1			
30.Is your mind as clear as it used ..	0	0				0	0	0	0	0	0	0	0	0	0			
31.Total score	16	35				16	10	10	11	11	11	17	17	17	17			
27	1DT	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1					
			02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1				
			03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1				
			04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1				
			05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1				
			06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1				
			07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1				
			08.Are you afraid that something bad...	1	1	1	1	1	1	1	1	1	1	1				
			09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1				

1689

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

106

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
26	10T	Reboxetine	1	1	1	1	0	0	0	0	0	0
		10.Do you often feel helpless	1	1	1	1	0	0	0	0	0	0
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	0	0	0	0	0	0
		15.Do you think it is wonderful to be..	1	1	1	1	0	0	0	0	0	0
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ..	1	1	1	1	0	0	0	0	0	0
		18.Do you worry a lot about the past	1	1	1	1	0	0	0	0	0	0
		19.Do you find life very exciting	0	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	0	0	0	0	0	0	0	0	0
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0
		27.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		28.Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0	0
		31.Total score	24	24	23	24	19	19	19	19	19	18
27	10D	Imipramine	1	1	1	1	1	1	1	1	1	1
		01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	0	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1

1690

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

107

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0
GERIATRIC DEPRESSION SCALE

Centre	Patient	Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63		
				Y	N	Y	N	Y	N	Y	N	Y	N		
27	1MD	Imipramine	28.Do you prefer to avoid social gat..	1	1										
			29.Is it easy for you to make decision	1	1										
			30.Is your mind as clear as it used ..	1	1										
			31.Total score	27	29										
28	1MD	Reboxetine	01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0		
			02.Have you dropped many of your act..	0	0	0	0	0	0	0	0	0	0	0	
			03.Do you feel that your life is empty	0	0	0	0	0	0	0	0	0	0	0	
			04.Do you often get bored	0	0	0	0	0	0	0	0	0	0	0	
			05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1
			06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0	0	0
			07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0	0	0
			08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0	0	0
			09.Do you feel happy most of the time	0	0	0	0	0	0	0	0	0	0	0	0
			10.Do you often feel helpless	0	0	0	0	0	0	0	0	0	0	0	0
			11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1	1
			12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1
			13.Do you frequently worry about the...	1	1	1	1	1	1	1	1	1	1	1	1
			14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0	0	0
			15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1
			16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1
			17.Do you feel pretty worthless the ...	0	0	0	0	0	0	0	0	0	0	0	0
			18.Do you worry a lot about the past ..	0	0	0	0	0	0	0	0	0	0	0	0
			19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1
			20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1
			21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1
			22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0	0	0
			23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1	1	1
			24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0	0	0
			25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1
			26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1
			27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1
			28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1
			29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1
			30.Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0	0	0	0
						31.Total score	15	16	15	17	16	18	18	17	17
10T	Imipramine	01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0	0		
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1		
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1		
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1		
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1		
		06.Are you bothered by thoughts you ...	0	0	0	0	0	0	0	0	0	0	0		
		07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0	0		
		08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0	0		
		09.Do you feel happy most of the time	0	0	0	0	0	0	0	0	0	0	0		
		10.Do you often feel helpless	0	0	0	0	0	0	0	0	0	0	0		
		11.Do you often get restless and f.....	0	0	0	0	0	0	0	0	0	0	0		
		12.Do you prefer to stay at home,	0	0	0	0	0	0	0	0	0	0	0		

1691

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

109

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient	Treatment	Geriatric Depression Scale	Day0 Y N	Day7 Y N	Day14 Y N	Day21 Y N	Day28 Y N	Day35 Y N	Day42 Y N	Day49 Y N	Day56 Y N	Day63 Y N
28	2ND	Imipramine	31.Total score	15	15	10	20	16	14	16	20	15	15
	2DT	Reboxetine	01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0
			02.Have you dropped many of your act..	0	0	0	0	0	0	0	0	0	0
			03.Do you feel that your life is empty	0	0	0	0	0	0	0	0	0	0
			04.Do you often get bored	0	0	0	0	0	0	0	0	0	0
			05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
			06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0
			07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
			08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0
			09.Do you feel happy most of the time	0	0	0	0	0	0	0	0	0	0
			10.Do you often feel helpless	0	0	0	0	0	0	0	0	0	0
			11.Do you often get restless and f....	0	0	0	0	0	0	0	0	0	0
			12.Do you prefer to stay at home,	0	0	0	0	0	1	0	1	0	1
			13.Do you frequently worry about the..	0	0	0	0	0	0	0	0	0	0
			14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0
			15.Do you think it is wonderful to be.	0	0	0	0	0	0	0	0	0	0
			16.Do you often feel downhearted	0	0	0	0	0	0	0	0	0	0
			17.Do you feel pretty worthless the....	0	0	0	0	0	0	0	0	0	0
			18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0
			19.Do you find life very exciting	0	0	1	1	1	0	0	1	0	0
			20.Is it hard for you to get started..	0	0	0	0	0	0	0	0	0	1
			21.Do you feel full of energy	0	0	0	0	0	0	0	0	0	1
			22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	1
			23.Do you think that most people are..	0	0	1	0	1	0	0	1	0	0
			24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0
			25.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0
			26.Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0
			27.Do you enjoy getting up in the mor.	1	0	0	0	0	0	0	0	0	1
			28.Do you prefer to avoid social get..	0	0	1	1	1	1	1	1	1	1
			29.Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0
			30.Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0	0
			31.Total score	0	1	0	3	0	2	0	4	0	6
3ND		Reboxetine	01.Are you () satisfied with your life	0	0	1	0	0	0	0	1	0	0
			02.Have you dropped many of your act..	0	0	1	0	1	0	1	1	0	1
			03.Do you feel that your life is empty	0	0	0	0	0	0	0	0	0	0
			04.Do you often get bored	0	0	0	0	0	0	0	0	0	0
			05.Are you hopeful about the future	1	1	0	0	0	1	1	0	0	1
			06.Are you bothered by thoughts you ..	1	1	0	0	0	1	1	0	0	1
			07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
			08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0
			09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
			10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
			11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
			12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
			13.Do you frequently worry about the..	1	1	0	1	1	1	1	1	1	1
			14.Do you feel you have more problems.	1	1	0	1	1	1	1	1	1	1
			15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1

1693

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

110

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63	
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
28	3RD Reboxetine	1	0	1	1	1	0	1	1	1	0	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted																				
	17.Do you feel pretty worthless the ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	18.Do you worry a lot about the past	1	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started...	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	31.Total score	21	21	21	18	18	18	18	18	19	19	18	18	19	20	20	20	20	20	20	20
30T	Imipramine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	01.Are you () satisfied with your life																				
	02.Have you dropped many of your act..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	03.Do you feel that your life is empty	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	04.Do you often get bored	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10.Do you often feel helpless	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	11.Do you often get restless and f....	1	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	13.Do you frequently worry about the..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be.	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	16.Do you often feel downhearted	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	17.Do you feel pretty worthless the ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	23.Do you think that most people are..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	31.Total score	13	11	11	10	10	8	8	8	8	8	5	5	8	8	8	8	8	8	8	8

1694

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

111

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
	Y	N	Y	N	Y	N	Y	N	Y	N
28 4HD Imipramine	0	0	1	1	0	0	0	1	0	0
01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0
02.Have you dropped many of your act..	0	0	0	0	0	0	0	0	0	0
03.Do you feel that your life is empty	0	0	0	0	0	0	0	0	0	0
04.Do you often get bored	0	0	0	0	0	0	0	0	0	0
05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1
12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
15.Do you think it is wonderful to be..	0	0	0	0	0	0	0	0	0	0
16.Do you often feel downhearted	0	0	0	0	0	0	0	0	0	0
17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1
18.Do you worry a lot about the past ..	0	0	0	0	0	0	0	0	0	0
19.Do you find life very exciting	0	0	0	0	0	0	0	0	0	0
20.Is it hard for you to get started..	0	0	0	0	0	0	0	0	0	0
21.Do you feel full of energy	0	0	0	0	0	0	0	0	0	0
22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0
23.Do you think that most people are...	0	0	0	0	0	0	0	0	0	0
24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
25.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0
26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
27.Do you enjoy getting up in the mor..	0	0	0	0	0	0	0	0	0	0
28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
29.Is it easy for you to make decision ..	1	1	1	1	1	1	1	1	1	1
30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
31.Total score	13	21	21	18	18	17	16	22	1	18
5HD Reboxetine	0	0	0	0	0	0	0	0	0	0
01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
02.Have you dropped many of your act..	0	0	0	0	0	0	0	0	0	0
03.Do you feel that your life is empty	0	0	0	0	0	0	0	0	0	0
04.Do you often get bored	0	0	0	0	0	0	0	0	0	0
05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
09.Do you feel happy most of the time	0	0	0	0	0	0	0	0	0	0
10.Do you often feel helpless	0	0	0	0	0	0	0	0	0	0
11.Do you often get restless and f.....	0	0	0	0	0	0	0	0	0	0
12.Do you prefer to stay at home,	0	0	0	0	0	0	0	0	0	0
13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
15.Do you think it is wonderful to be..	0	0	0	0	0	0	0	0	0	0
16.Do you often feel downhearted	0	0	0	0	0	0	0	0	0	0
17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1
18.Do you worry a lot about the past ..	1	1	1	1	1	1	1	1	1	1

1695

9550089

112

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63	
			Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	
			N	N	N	N	N	N	N	N	N	N	
28	5ND	Reboxetine	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	
			20.Is it hard for you to get started..	0	0	0	0	0	0	0	0	0	0
			21.Do you feel full of energy	1	0	0	0	0	0	0	0	0	0
			22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0
			23.Do you think that most people are..	1	0	0	0	0	0	0	0	0	0
			24.Do you frequently get upset over...	0	1	0	0	0	0	0	0	0	0
			25.Do you frequently feel like crying	0	1	1	1	1	1	1	1	1	1
			26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
			27.Do you enjoy getting up in the mor.	1	0	0	0	0	0	0	0	0	0
			28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
			29.Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0
30.Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0	0			
31.Total score	13	0	13	0	13	16	18	18	13	14			
30	1ND	Imipramine	01.Are you () satisfied with your life	1	1	1	1	0	0	0	0	0	
			02.Have you dropped many of your act..	1	1	1	1	0	0	0	0	0	
			03.Do you feel that your life is empty	1	1	1	0	0	0	0	0	0	
			04.Do you often get bored	1	1	1	0	0	0	0	0	0	
			05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	
			06.Are you bothered by thoughts you ..	1	1	1	1	0	0	0	0	0	
			07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	
			08.Are you afraid that something bad..	1	1	0	0	0	0	0	0	0	
			09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	
			10.Do you often feel helpless	1	1	1	1	0	0	0	0	0	
			11.Do you often get restless and f....	1	1	1	1	0	0	0	0	0	
12.Do you prefer to stay at home, ...	1	1	1	0	0	0	0	0	0				
13.Do you frequently worry about the..	1	1	0	0	0	0	0	0	0				
14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0				
15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1				
16.Do you often feel downhearted	1	1	1	0	0	0	0	0	0				
17.Do you feel pretty worthless the ..	1	1	0	0	0	0	0	0	0				
18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0				
19.Do you find life very exciting	1	1	1	1	1	1	1	1	1				
20.Is it hard for you to get started..	1	1	1	1	0	0	0	0	0				
21.Do you feel full of energy	1	1	1	1	1	1	1	1	1				
22.Do you feel that your situation ...	1	0	0	0	0	0	0	0	0				
23.Do you think that most people are..	1	0	0	0	0	0	0	0	0				
24.Do you frequently get upset ever...	1	0	0	0	0	0	0	0	0				
25.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0				
26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1				
27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1				
28.Do you prefer to avoid social gat..	0	0	0	0	0	0	0	0	0				
29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1				
30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1				
31.Total score	24	23	21	16	7	6	6	8					
30	2ND	Reboxetine	01.Are you () satisfied with your life	1									
			02.Have you dropped many of your act..	1									
			03.Do you feel that your life is empty	0									

1696

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

113

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63			
			Y	N	Y	N	Y	N	Y	N	Y	N			
30	2ND	Reboxetine	04. Do you often get bored	1	1										
			05. Are you hopeful about the future	1	1										
			06. Are you bothered by thoughts you ...	1	1										
			07. Are you in good spirits most of ...	1	1										
			08. Are you afraid that something bad...	1	1										
			09. Do you feel happy most of the time	1	1										
			10. Do you often feel helpless	0	0										
			11. Do you often get restless and f....	1	0										
			12. Do you prefer to stay at home,	1	0										
			13. Do you frequently worry about the..	1	0										
			14. Do you feel you have more problems.	1	0										
			15. Do you think it is wonderful to be.	0	0										
			16. Do you often feel downhearted	1	0										
			17. Do you feel pretty worthless the ..	1	0										
			18. Do you worry a lot about the past	1	0										
			19. Do you find life very exciting	1	1										
			20. Is it hard for you to get started..	1	1										
			21. Do you feel full of energy	1	1										
			22. Do you feel that your situation ...	0	0										
			23. Do you think that most people are...	1	0										
			24. Do you frequently get upset over...	1	0										
			25. Do you frequently feel like crying	1	0										
			26. Do you have trouble concentrating	1	1										
			27. Do you enjoy getting up in the mor.	1	1										
			28. Do you prefer to avoid social gat...	0	0										
			29. Is it easy for you to make decision	0	0										
			30. Is your mind as clear as it used ..	1	1										
			31. Total score			21									
			3ND	Imipramine	01. Are you () satisfied with your life	1	1	1	1	1	0	0	0	0	0
					02. Have you dropped many of your act..	1	1	1	1	1	1	0	0	0	0
					03. Do you feel that your life is empty	1	1	1	1	1	1	0	0	0	0
04. Do you often get bored	0	0			0	0	0	0	0	0	0	0			
05. Are you hopeful about the future	1	1			1	1	1	1	0	0	0	0			
06. Are you bothered by thoughts you ...	1	1			1	1	1	1	0	0	0	0			
07. Are you in good spirits most of ...	1	1			1	1	1	1	0	0	0	0			
08. Are you afraid that something bad...	1	1			1	1	1	1	0	0	0	0			
09. Do you feel happy most of the time	1	1			1	1	1	1	0	0	0	0			
10. Do you often feel helpless	1	1			1	1	1	1	0	0	0	0			
11. Do you often get restless and f....	1	1			1	1	1	1	0	0	0	0			
12. Do you prefer to stay at home,	1	1			1	1	1	1	0	0	0	0			
13. Do you frequently worry about the..	1	1			1	1	1	1	0	0	0	0			
14. Do you feel you have more problems.	1	1			1	1	1	1	0	0	0	0			
15. Do you think it is wonderful to be.	1	1			1	1	1	1	0	0	0	0			
16. Do you often feel downhearted	1	1			1	1	1	1	0	0	0	0			
17. Do you feel pretty worthless the ...	1	1			1	1	1	1	0	0	0	0			
18. Do you worry a lot about the past	1	1			1	1	1	1	0	0	0	0			
19. Do you find life very exciting	1	1			1	1	1	1	1	1	1	1			
20. Is it hard for you to get started..	1	1			1	1	1	1	1	1	1	1			
21. Do you feel full of energy	1	1			1	1	1	1	1	1	1	1			

1697

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

114

PIARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
30	3MD Imipramine	1	1	1	1	1	1	0	0	0	0
	22.Do you feel that your situation ...	1	1	1	1	1	1	0	0	0	0
	23.Do you think that most people are...	1	1	1	1	0	1	1	0	0	0
	24.Do you frequently get upset over...	1	1	1	1	0	0	1	1	0	1
	25.Do you frequently feel like crying	0	1	1	1	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	1	0	1	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	0	0	0	0	0	1	1	0	0	0
	28.Do you prefer to avoid social gat...	1	1	0	1	1	0	1	0	0	0
	29.Is it easy for you to make decision	1	1	1	1	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	1	1	0	0	0	0	1	0	0	0
	31.Total score	24	25	17	23	10	10	10	5	0	5
4MD	Reboxetine	1	1	0	1	0	0	0	0	0	0
	01.Are you () satisfied with your life	1	1	0	1	0	0	0	0	0	0
	02.Have you dropped many of your act...	1	1	0	1	0	0	0	0	0	0
	03.Do you feel that your life is empty	1	1	0	1	0	0	0	0	0	0
	04.Do you often get bored	0	0	0	0	0	0	0	0	0	0
	05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	1	1	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	1	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad...	1	1	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	0	1	0	1	0	0	0	0	0	0
	10.Do you often feel helpless	0	0	0	0	0	0	0	0	0	0
	11.Do you often get restless and f.....	1	0	0	0	0	0	0	0	0	0
	12.Do you prefer to stay at home,	1	0	0	0	0	0	0	0	0	0
	13.Do you frequently worry about the..	1	0	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	1	1	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be.	1	1	0	0	0	0	0	0	0	0
	16.Do you often feel downhearted	1	1	0	0	0	0	0	0	0	0
	17.Do you feel pretty worthless the ..	1	1	0	0	0	0	0	0	0	0
	18.Do you worry a lot about the past	0	1	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	1	1	0	1	1	1	0	0	0	0
	20.Is it hard for you to get started..	1	1	0	1	1	1	0	0	0	0
	21.Do you feel full of energy	1	1	0	1	1	1	0	0	0	0
	22.Do you feel that your situation ...	1	1	0	0	0	0	0	0	0	0
	23.Do you think that most people are...	1	1	0	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	1	0	0	0	1	1	0	0	0
	27.Do you enjoy getting up in the mor.	0	1	0	0	1	0	0	0	0	0
	28.Do you prefer to avoid social gat...	1	1	0	0	1	0	0	0	0	0
	29.Is it easy for you to make decision	1	1	0	0	1	0	0	0	0	0
	30.Is your mind as clear as it used ..	1	1	0	0	1	1	0	0	0	0
	31.Total score	23	24	0	18	6	6	1	0	0	0
5MD	Imipramine	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act...	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1

1698

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

115

PHARMACIA CNS R2D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient	Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
				Y	N	Y	N	Y	N	Y	N	Y	N
30	5ND	Imipramine	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
			08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
			09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
			10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
			11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
			12.Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1
			13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
			14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
			15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
			16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
			17.Do you feel pretty worthless the ..	0	0	0	0	0	0	0	0	0	0
			18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0
			19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
			20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
			21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
			22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
			23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
			24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
			25.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0
			26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
			27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
			28.Do you prefer to avoid social get...	1	1	1	1	1	1	1	1	1	1
			29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
			30.Is your mind as clear as it used ...	1	1	1	1	1	1	1	1	1	1
			31.Total score	27	27	27	27	27	27	27	27	27	27
31	1ND	Imipramine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
			02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
			03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
			04.Do you often get bored	0	0	0	0	0	0	0	0	0	0
			05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
			06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
			07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
			08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
			09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
			10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
			11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
			12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
			13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
			14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
			15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
			16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
			17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1
			18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0
			19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
			20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
			21.Do you feel full of energy	0	0	0	0	0	0	0	0	0	0
			22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
			23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
			24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1

1699

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

116

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
31	1MD	Imipramine	1	1	0	0						
		25. Do you frequently feel like crying	1	1	0	0						
		26. Do you have trouble concentrating	1	1	0	0						
		27. Do you enjoy getting up in the mor.	1	0	1	1						
		28. Do you prefer to avoid social gat..	1	1	0	0						
		29. Is it easy for you to make decision	1	1	0	0						
		30. Is your mind as clear as it used ..	1	1	1	1						
		31. Total score	24	18	16							
10F	Reboxetine	01. Are you () satisfied with your life	1	1	1	1	1	1				
		02. Have you dropped many of your act..	1	1	1	1	1	1				
		03. Do you feel that your life is empty	1	1	1	1	1	1				
		04. Do you often get bored	1	0	0	1	0	1				
		05. Are you hopeful about the future	1	1	1	1	1	1				
		06. Are you bothered by thoughts you ..	1	0	1	1	1	1				
		07. Are you in good spirits most of ...	0	1	0	0	1	1				
		08. Are you afraid that something bad..	1	1	1	1	1	1				
		09. Do you feel happy most of the time	1	0	1	1	1	1				
		10. Do you often feel helpless	1	1	1	1	1	1				
		11. Do you often get restless and f.....	1	1	1	1	1	1				
		12. Do you prefer to stay at home,....	1	1	1	1	1	1				
		13. Do you frequently worry about this..	1	1	1	1	1	1				
		14. Do you feel you have more problems.	0	0	0	1	0	1				
		15. Do you think it is wonderful to be..	1	1	1	1	1	1				
		16. Do you often feel downhearted	1	1	1	1	1	1				
		17. Do you feel pretty worthless tho ...	0	0	0	0	0	0				
		18. Do you find life very exciting	1	1	1	1	1	1				
		19. Is it hard for you to get started..	1	1	1	1	1	1				
		20. Do you feel full of energy	1	1	1	1	1	1				
		21. Do you feel that your situation ...	1	1	1	1	1	1				
		22. Do you think that most people are..	1	1	1	1	1	1				
		23. Do you frequently get upset over...	1	1	1	1	1	1				
		24. Do you frequently feel like crying	0	1	1	1	1	1				
		25. Do you have trouble concentrating	1	1	0	1	1	1				
		26. Do you enjoy getting up in the mor.	1	1	1	1	1	1				
		27. Do you prefer to avoid social gat..	1	1	1	1	1	1				
		28. Is it easy for you to make decision	1	1	1	1	1	1				
		29. Is your mind as clear as it used ..	1	1	1	1	1	1				
		30. Is your mind as clear as it used ..	1	1	1	1	1	1				
		31. Total score	25	24	26	28	25	29				
2MD	Reboxetine	01. Are you () satisfied with your life	0	1	1	1	1	1	0	0	0	1
		02. Have you dropped many of your act..	1	1	0	0	0	0	0	0	1	0
		03. Do you feel that your life is empty	1	1	1	1	1	1	0	0	1	0
		04. Do you often get bored	1	1	1	1	1	1	1	0	1	0
		05. Are you hopeful about the future	1	1	1	1	1	1	1	0	0	0
		06. Are you bothered by thoughts you ...	1	1	0	0	0	0	0	0	0	0
		07. Are you in good spirits most of ...	0	1	1	1	1	1	0	0	0	0
		08. Are you afraid that something bad..	0	1	1	1	1	1	0	0	0	0
		09. Do you feel happy most of the time	1	1	1	1	1	1	0	0	0	0

1700

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

117

PELARNACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
31	2HD Reboxetine	1	0	0	1	0	0	0	0	0	0
	10.Do you often feel helpless	1	0	0	1	0	0	0	0	0	0
	11.Do you often get restless and f....	1	1	1	0	1	0	0	0	0	0
	12.Do you prefer to stay at home, ...	1	0	1	1	1	0	0	1	0	0
	13.Do you frequently worry about the..	1	1	0	1	1	0	0	0	1	0
	14.Do you feel you have more problems.	1	0	1	1	1	1	0	0	0	1
	15.Do you think it is wonderful to be.	1	0	1	1	0	1	0	0	0	0
	16.Do you often feel downhearted	1	1	1	1	1	1	0	0	0	1
	17.Do you feel pretty worthless the ..	1	0	1	0	1	0	0	0	0	0
	18.Do you worry a lot about the past	1	1	0	1	0	0	0	0	0	0
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	0	0	0	0
	21.Do you feel full of energy	1	1	1	1	1	1	1	0	0	0
	22.Do you feel that your situation ...	1	0	1	1	0	0	0	0	0	0
	23.Do you think that most people are...	1	1	1	1	1	1	1	0	0	0
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	0	0	0
	25.Do you frequently feel like crying	1	1	1	1	0	1	0	0	0	0
	26.Do you have trouble concentrating	1	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	0	0	0	0
	28.Do you prefer to avoid social gat...	1	1	1	1	1	1	1	0	0	0
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
	31.Total score	26	24	21	24	16	18	8	3	11	11
3HD	Imipramine	1	0	0	0	0	0	0	0	0	0
	01.Are you () satisfied with your life	1	0	0	0	0	0	0	0	0	0
	02.Have you dropped many of your act..	1	0	0	0	0	0	0	0	0	0
	03.Do you feel that your life is empty	1	0	0	0	0	0	0	0	0	0
	04.Do you often get bored	1	0	0	0	0	0	0	0	0	0
	05.Are you hopeful about the future	1	0	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	1	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something had..	1	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	0	0	0	0	0	0	0	0	0
	10.Do you often feel helpless	1	0	0	0	0	0	0	0	0	0
	11.Do you often get restless and f....	1	0	0	0	0	0	0	0	0	0
	12.Do you prefer to stay at home,	1	0	0	0	0	0	0	0	0	0
	13.Do you frequently worry about the..	1	0	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	1	0	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be.	1	0	0	0	0	0	0	0	0	0
	16.Do you often feel downhearted	1	0	0	0	0	0	0	0	0	0
	17.Do you feel pretty worthless the ...	1	0	0	0	0	0	0	0	0	0
	18.Do you worry a lot about the past	1	0	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	1	0	0	0	0	0	0	0	0	0
	20.Is it hard for you to get started..	1	0	0	0	0	0	0	0	0	0
	21.Do you feel full of energy	1	0	0	0	0	0	0	0	0	0
	22.Do you feel that your situation ...	1	0	0	0	0	0	0	0	0	0
	23.Do you think that most people are...	1	0	0	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	1	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	1	0	0	0	0	0	0	0	0	0

1701

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

118

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
31	3ND	Inipramine	28. Do you prefer to avoid social gat..	1	0	0	0	0	0	0	0	0
			29. Is it easy for you to make decision	1	0	0	0	0	0	0	0	0
			30. Is your mind as clear as it used ..	0	25	0	0	0	0	0	0	0
31. Total score												
32	1ND	Inipramine	01. Are you () satisfied with your life	0	0	0	0	0	0	0	0	0
			02. Have you dropped many of your act..	1	0	0	0	0	0	0	0	0
			03. Do you feel that your life is empty	1	0	0	0	0	0	0	0	0
			04. Do you often get bored	0	0	1	0	0	0	0	0	0
			05. Are you hopeful about the future	0	0	0	0	0	0	0	0	0
			06. Are you bothered by thoughts you ..	1	0	0	0	0	0	0	0	0
			07. Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0
			08. Are you afraid that something bad..	0	0	0	0	0	0	0	0	0
			09. Do you feel happy most of the time	1	1	0	0	0	0	0	0	0
			10. Do you often feel helpless	1	1	0	0	0	0	0	0	0
			11. Do you often get restless and f....	0	1	1	0	0	0	0	0	0
			12. Do you prefer to stay at home,	1	1	1	0	1	0	0	0	0
			13. Do you frequently worry about the ..	1	1	1	0	0	0	0	0	0
			14. Do you feel you have more problems.	0	0	0	0	0	0	0	0	0
			15. Do you think it is wonderful to be..	1	1	0	0	0	0	0	0	0
			16. Do you often feel demotivated.....	1	1	1	0	0	0	0	0	0
			17. Do you feel pretty worthless the ..	1	1	0	0	0	0	0	0	0
			18. Do you worry a lot about the past	0	0	0	0	0	0	0	0	0
			19. Do you find life very exciting	1	1	1	1	1	1	1	1	1
			20. Is it hard for you to get started..	1	1	1	1	1	1	1	1	1
			21. Do you feel full of energy	1	1	1	1	1	1	1	1	1
			22. Do you feel that your situation ...	1	0	0	0	0	0	0	0	0
			23. Do you think that most people are..	1	0	0	0	0	0	0	0	0
			24. Do you frequently get upset over...	1	1	1	0	0	0	0	0	0
			25. Do you frequently feel like crying	1	1	1	0	0	0	0	0	0
			26. Do you have trouble concentrating	1	1	0	0	0	0	0	0	0
			27. Do you enjoy getting up in the mor..	1	1	1	0	0	0	0	0	0
			28. Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1
			29. Is it easy for you to make decision	0	0	0	0	0	0	0	0	0
			30. Is your mind as clear as it used ..	1	0	0	0	0	0	0	0	0
			31. Total score			19	17	10	5	4	3	1
2ND	Inipramine	01. Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0
		02. Have you dropped many of your act..	1	0	0	0	0	0	0	0	0	0
		03. Do you feel that your life is empty	1	0	0	0	0	0	0	0	0	0
		04. Do you often get bored	0	0	0	0	0	0	0	0	0	0
		05. Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
		06. Are you bothered by thoughts you ..	1	0	0	0	0	0	0	0	0	0
		07. Are you in good spirits most of ...	1	0	0	0	0	0	0	0	0	0
		08. Are you afraid that something bad..	1	0	0	0	0	0	0	0	0	0
		09. Do you feel happy most of the time	1	1	0	0	0	0	0	0	0	0
		10. Do you often feel helpless	1	1	0	0	0	0	0	0	0	0
		11. Do you often get restless and f....	1	0	0	0	0	0	0	0	0	0
		12. Do you prefer to stay at home,	1	0	1	0	0	0	0	0	0	0

1702

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

119

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	_Day0_		_Day7_		_Day14_		_Day21_		_Day28_		_Day35_		_Day42_		_Day49_		_Day56_		_Day63_	
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
32	2ND Imipramine	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	13.Do you frequently worry about the...	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be.	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	16.Do you often feel downhearted	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	17.Do you feel pretty worthless the ..	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	23.Do you think that most people are...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	28.Do you prefer to avoid social get...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	29.Is it easy for you to make decision	0	1	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	30.Is your mind as clear as it used to	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	31.Total score	17	14	14	6	4	4	2	2	2	2	2	2	2	2	2	2	2	2	2	2
3ND	Reboxetine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	0	1	0	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	17.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	18.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are...	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social get...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	0	1	1	0	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used to	0	1	0	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	31.Total score	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

9550089

1703

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

120

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
32	3MD Reboxetine	26	28	26	28	28	26	28	26	28	28
	31.Total score	1	1	1	1	1	1	1	1	1	1
4MD	Reboxetine	1	0	1	0	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
	31.Total score	28	26	25	24	27	24	27	24	27	27
5MD	Reboxetine	0	1	0	0	0	0	0	0	0	0
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ...	0	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1

1704

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

121

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
32 5ND Reboxetine	16.Do you often feel downhearted	0	1	1	1	0	0				
	17.Do you feel pretty worthless the ..	1	0	1	1	0	1				
	18.Do you worry a lot about the past	0	0	0	0	0	0				
	19.Do you find life very exciting	1	1	1	1	1	1				
	20.Is it hard for you to get started..	0	0	0	0	0	0				
	21.Do you feel full of energy	1	1	1	1	0	0				
	22.Do you feel that your situation ...	1	0	1	1	0	0				
	23.Do you think that most people are...	1	0	1	1	0	0				
	24.Do you frequently get upset over...	1	0	1	1	0	0				
	25.Do you frequently feel like crying	1	0	1	1	0	0				
	26.Do you have trouble concentrating	1	0	1	1	0	0				
27.Do you enjoy getting up in the mor.	0	0	0	1	0	0					
28.Do you prefer to avoid social get...	0	0	0	0	0	0					
29.Is it easy for you to make decision	0	1	0	0	0	0					
30.Is your mind as clear as it used ..	1	0	1	1	0	0					
31.Total score		18	19	14	13	13					
6ND Imipramine	01.Are you () satisfied with your life	1	1	1	1	1	1		1	1	1
	02.Have you dropped many of your act.	1	1	1	1	1	1		1	1	1
	03.Do you feel that your life is empty	1	0	1	1	1	1		1	1	1
	04.Do you often get bored	1	0	0	0	0	0		0	0	0
	05.Are you hopeless about the future	1	1	1	1	1	1		1	1	1
	06.Are you bothered by thoughts you ...	1	1	1	1	1	1		1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1		1	1	1
	08.Are you afraid that something bad...	1	1	1	1	1	1		1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1		1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1		1	1	1
	11.Do you often get restless and f.....	1	0	0	0	0	0		0	0	0
12.Do you prefer to stay at home,	1	1	1	1	1	1		1	1	1	
13.Do you frequently worry about the..	1	1	1	1	1	1		1	1	1	
14.Do you feel you have more problems.	1	1	0	1	1	1		1	1	1	
15.Do you think it is wonderful to be.	1	1	1	1	1	1		1	1	1	
16.Do you often feel downhearted	1	1	1	1	1	1		1	1	1	
17.Do you feel pretty worthless the ..	1	0	0	0	0	0		0	0	0	
18.Do you worry a lot about the past	1	1	1	1	1	1		1	1	1	
19.Is it hard for you to get started..	1	1	1	1	1	1		1	1	1	
20.Do you feel full of energy	1	1	1	1	1	1		1	1	1	
21.Do you feel that your situation ...	1	1	1	1	1	1		1	1	1	
22.Do you think that most people are...	1	1	1	1	1	1		1	1	1	
23.Do you frequently get upset over...	1	1	1	1	1	1		1	1	1	
24.Do you frequently feel like crying	1	1	1	1	1	1		1	1	1	
25.Do you have trouble concentrating	1	1	1	1	1	1		1	1	1	
26.Do you enjoy getting up in the mor.	0	1	1	1	1	1		1	1	1	
27.Do you prefer to avoid social get...	1	1	1	1	1	1		1	1	1	
28.Do you prefer to avoid social get...	1	1	1	1	1	1		1	1	1	
29.Is it easy for you to make decision	1	1	0	0	0	0		1	1	0	
30.Is your mind as clear as it used ..	1	1	1	1	1	1		1	1	1	
31.Total score		26	26	24	25	24		26	26	26	

1705

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

122

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y N	Y N	Y N	Y N	Y N	Y N	Y N	Y N	Y N	Y N
35	Reboxetine	0	0	0	0	0	0	0	0	0	0
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
	31.Total score	27	25	23	25	23	25	23	25	23	25
101	Reboxetine	0	0	0	0	0	0	0	0	0	0
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ...	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	0	0	0	0	0	0	0	0	0	0
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1

1706

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

123

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63		
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y
35	1DT	Reboxetine	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	1	1	1	1	1	1
		21.Do you feel full of energy	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		22.Do you think that your situation ...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		23.Do you think that most people are..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		24.Do you frequently get upset over...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		25.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		26.Do you have trouble concentrating	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		31.Total score	21	17	16	14	18	13	12	13	12	12	13	12	12	12	12	12	12	12	12	12	12
2ND		Imipramine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		31.Total score	27	26	27	24	28	27	24	24	24	28	27	24	24	24	24	24	24	24	24	24	24
2DF		Imipramine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1707

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

124

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/055
 Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63	
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
35	2DY Imipramine	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	04.Do you often get bored	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	05.Are you hopeful about the future	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10.Do you often feel helpless	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	11.Do you often get restless and f....	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	12.Do you prefer to stay at home,	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	13.Do you frequently worry about the..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	16.Do you often feel downhearted	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	17.Do you feel pretty worthless the...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	18.Do you worry a lot about the past ..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20.Is it hard for you to get started..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	21.Do you feel full of energy	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	22.Do you feel that your situation ...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	23.Do you think that most people are..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	28.Do you prefer to avoid social get...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	29.Is it easy for you to make decision	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	31.Total score	23	0	15	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3MD	Imipramine	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	03.Do you feel that your life is empty	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	04.Do you often get bored	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	05.Are you hopeful about the future	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	10.Do you often feel helpless	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	11.Do you often get restless and f....	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	12.Do you prefer to stay at home,	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	13.Do you frequently worry about the..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	16.Do you often feel downhearted	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	17.Do you feel pretty worthless the...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	18.Do you worry a lot about the past ..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20.Is it hard for you to get started..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	21.Do you feel full of energy	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

1708

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

125

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
35	3ND Imipramine	0	1	0	0	0	0	0	0	0	0
	22.Do you feel that your situation ...	1	0	1	0	0	0	0	0	0	0
	23.Do you think that most people are...	1	0	1	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	1	0	1	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	0	1	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	0	1	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	1	0	1	0	0	0	0	0	0	0
	28.Do you prefer to avoid social gat..	1	0	1	0	0	0	0	0	0	0
	29.Is it easy for you to make decision	1	0	1	0	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	1	0	1	0	0	0	0	0	0	0
	31.Total score	23	10	2	0	1	0	0	12	0	5
30I	Imipramine	0	0	0	0	0	0	0	0	0	0
	01.Are you () satisfied with your life	1	0	0	0	0	0	0	0	0	0
	02.Have you dropped many of your act..	1	0	0	0	0	0	0	0	0	0
	03.Do you feel that your life is empty	1	0	0	0	0	0	0	0	0	0
	04.Do you often get bored	0	0	0	0	0	0	0	0	0	0
	05.Are you hopeful about the future	1	0	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	1	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	0	0	0	0	0	0	0	0	0
	10.Do you often feel helpless	1	0	0	0	0	0	0	0	0	0
	11.Do you often get restless and f.....	1	0	0	0	0	0	0	0	0	0
	12.Do you prefer to stay at home,	1	0	0	0	0	0	0	0	0	0
	13.Do you frequently worry about the..	1	0	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	1	0	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be..	0	0	0	0	0	0	0	0	0	0
	16.Do you often feel downhearted	1	0	0	0	0	0	0	0	0	0
	17.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0
	18.Do you find life very exciting	1	0	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	1	0	0	0	0	0	0	0	0	0
	20.Is it hard for you to get started..	1	0	0	0	0	0	0	0	0	0
	21.Do you feel full of energy	1	0	0	0	0	0	0	0	0	0
	22.Do you feel that your situation ...	1	0	0	0	0	0	0	0	0	0
	23.Do you think that most people are...	1	0	0	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	1	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	1	0	0	0	0	0	0	0	0	0
	28.Do you prefer to avoid social gat..	1	0	0	0	0	0	0	0	0	0
	29.Is it easy for you to make decision	1	0	0	0	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0	0
	31.Total score	20	10	2	0	1	0	0	12	0	5
4ND	Reboxetine	0	0	0	0	0	0	0	0	0	0
	01.Are you () satisfied with your life	1	0	0	0	0	0	0	0	0	0
	02.Have you dropped many of your act..	1	0	0	0	0	0	0	0	0	0
	03.Do you feel that your life is empty	1	0	0	0	0	0	0	0	0	0
	04.Do you often get bored	1	0	0	0	0	0	0	0	0	0
	05.Are you hopeful about the future	1	0	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	1	0	0	0	0	0	0	0	0	0

1709

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

126

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20324/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
35	4MB	Reboxetine	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	0	1	1	1	0	0	0	0	0
		11.Do you often get restless and f....	1	0	1	1	1	0	0	1	0	0
		12.Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		17.Do you often feel worthless the ...	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past ...	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	0	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0
		26.Do you have trouble concentrating	1	0	0	0	0	0	0	0	0	0
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat...	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision ..	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	0	0	0	0	0	0	0	0	0
		31.Total score	24	21	21	19	21	16	16	17	15	15
4DT	4DT	Reboxetine	0	0	0	0	0	0	0	0	0	0
		01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		17.Do you often feel worthless the ...	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past ...	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1

1710

9550089

127

PEARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
35	4DT	Reboxetine	1	0	1	0	0	0	0	0	0	0
		25.Do you frequently feel like crying	1	1	1	0	0	0	0	0	0	0
		26.Do you have trouble concentrating	1	1	1	0	0	0	0	0	0	0
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	0	0	0	0	0	0	0	0
		31.Total score	24	26	21	20	23	20	17	13	0	11
5ND		Reboxetine	0	0	0	0	0	0	0	0	0	0
		01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,....	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
		14.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1
		15.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		16.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1
		17.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
		18.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31.Total score	22	8	17	18	20	16	17	13	0	12
5NT		Imipramine	0	0	0	0	0	0	0	0	0	0
		01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1

1711

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

128

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
35	5DT	Imipramine	1	0	0	0	0	0	1	0	0	0
		10. Do you often feel helpless										
		11. Do you often get restless and f....										
		12. Do you prefer to stay at home, ...		1	0	0	0	0	0	0	0	0
		13. Do you frequently worry about the..		1	0	1	0	0	0	0	0	0
		14. Do you feel you have more problems.		1	0	1	0	1	0	0	0	0
		15. Do you think it is wonderful to be.		1	0	0	0	0	0	0	0	0
		16. Do you often feel downhearted		1	0	0	0	0	0	0	0	0
		17. Do you feel pretty worthless the ..		0	0	0	0	0	0	0	0	0
		18. Do you worry a lot about the past		1	1	1	1	1	1	1	0	0
		19. Do you find life very exciting		1	1	1	1	1	1	1	1	1
		20. Is it hard for you to get started...		1	1	1	1	1	1	1	1	1
		21. Do you feel full of energy		1	0	0	0	0	0	0	0	0
		22. Do you feel that your situation ...		1	0	0	0	0	0	0	0	0
		23. Do you think that most people are...		1	0	0	0	0	0	0	0	0
		24. Do you frequently get upset over...		1	0	0	0	0	0	0	0	0
		25. Do you frequently feel like crying		1	0	0	0	0	0	0	0	0
		26. Do you have trouble concentrating		1	1	0	0	1	0	0	1	0
		27. Do you enjoy getting up in the mor.		1	0	0	0	0	0	0	0	0
		28. Do you prefer to avoid social gat...		0	0	0	0	0	0	0	0	0
		29. Is it easy for you to make decision		0	0	1	1	1	0	0	0	0
		30. Is your mind as clear as it used ..		0	0	0	0	0	1	0	0	0
		31. Total score	22	0	11	6	5	6	5	8	4	4
6ND	Reboxetine	01. Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0
		02. Have you dropped many of your act..	1	1	0	0	1	1	1	1	1	1
		03. Do you feel that your life is empty	1	1	0	0	1	1	1	1	1	1
		04. Do you often get bored	1	1	0	0	1	1	1	1	1	1
		05. Are you hopeful about the future	0	0	0	1	1	1	0	0	0	0
		06. Are you bothered by thoughts you ..	1	0	0	0	1	1	1	1	1	1
		07. Are you in good spirits most of ...	1	0	0	1	1	1	1	1	1	1
		08. Are you afraid that something bad..	1	0	0	1	1	1	1	1	1	1
		09. Do you feel happy most of the time	1	1	0	1	1	1	1	1	1	1
		10. Do you often feel helpless	1	0	0	0	0	0	0	0	0	0
		11. Do you often get restless and f....	0	0	0	0	0	0	0	0	0	0
		12. Do you prefer to stay at home,	1	0	0	1	1	1	1	1	1	1
		13. Do you frequently worry about the..	1	0	0	1	1	1	1	1	1	1
		14. Do you feel you have more problems.	1	0	0	1	1	1	1	1	1	1
		15. Do you think it is wonderful to be.	1	0	0	1	1	1	1	1	1	1
		16. Do you often feel downhearted	1	0	0	1	1	1	1	1	1	1
		17. Do you feel pretty worthless the ...	1	0	0	1	1	1	1	1	1	1
		18. Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
		19. Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20. Is it hard for you to get started...	1	1	1	1	1	1	1	1	1	1
		21. Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22. Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0
		23. Do you think that most people are...	1	0	0	0	0	0	0	0	0	0
		24. Do you frequently get upset over...	1	0	0	0	0	0	0	0	0	0
		25. Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0
		26. Do you have trouble concentrating	1	1	0	1	1	1	1	1	1	1
		27. Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1

1712

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

129

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient	Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
				Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
				N	N	N	N	N	N	N	N	N	N
35	68D	Reboxetine	28.Do you prefer to avoid social gat..	0	0	1	0	1	0	0	0	0	0
			29.Is it easy for you to make decision	1	1	0	1	0	1	0	1	1	1
			30.Is your mind as clear as it used ..	1	1	0	1	0	1	1	1	1	1
			31.Total score	22	12	17	22	25	19	23	23	23	23
68F		Imipramine	01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0
			02.Have you dropped many of your act..	1	1	1	0	0	0	0	0	0	0
			03.Do you feel that your life is empty	1	1	0	0	0	0	0	0	0	0
			04.Do you often get bored	0	0	0	0	0	0	0	0	0	0
			05.Are you hopeful about the future	1	1	0	0	0	0	0	0	0	0
			06.Are you bothered by thoughts you ..	1	1	1	1	1	1	0	0	0	0
			07.Are you in good spirits most of ...	1	1	1	0	0	0	0	0	0	0
			08.Are you afraid that something bad..	1	1	0	1	0	0	0	0	0	0
			09.Do you feel happy most of the time	1	1	1	0	0	0	0	0	0	0
			10.Do you often feel helpless	1	0	0	0	0	0	0	0	0	0
			11.Do you often get restless and f....	1	0	0	0	0	0	0	0	0	0
			12.Do you prefer to stay at home,	1	1	0	1	0	1	0	0	0	0
			13.Do you frequently worry about the..	1	1	0	0	0	0	0	0	0	0
			14.Do you feel you have more problems.	1	1	1	0	0	0	0	0	0	0
			15.Do you think it is wonderful to be.	1	1	1	1	1	0	0	0	0	0
			16.Do you often feel dumberhearted	1	1	0	0	0	0	0	0	0	0
			17.Do you feel pretty worthless the...	0	0	0	0	0	0	0	0	0	0
			18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0
			19.Do you find life very exciting	1	1	0	1	1	0	0	0	0	0
			20.Is it hard for you to get started..	1	1	1	1	1	0	0	0	0	0
			21.Do you feel full of energy	1	1	1	1	1	0	0	0	0	0
			22.Do you feel that your situation ...	1	0	0	1	0	0	0	0	0	0
			23.Do you think that most people are...	1	1	1	1	0	0	0	0	0	0
			24.Do you frequently get upset over...	0	1	1	0	1	0	0	0	0	0
			25.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0
			26.Do you have trouble concentrating	1	1	1	0	0	0	0	0	0	0
			27.Do you enjoy getting up in the mor.	1	1	0	0	0	0	0	0	0	0
			28.Do you prefer to avoid social gat..	1	0	0	0	0	0	0	0	0	0
			29.Is it easy for you to make decision	1	1	0	1	1	0	0	0	0	0
			30.Is your mind as clear as it used ..	1	1	1	0	1	0	0	0	0	0
			31.Total score	24	20	13	9	10	2	0	0	0	0
78D		Imipramine	01.Are you () satisfied with your life	1	0	0	0	0	0	0	0	0	0
			02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
			03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
			04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
			05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
			06.Are you bothered by thoughts you ...	1	0	1	0	0	1	1	1	1	1
			07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
			08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
			09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
			10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
			11.Do you often get restless and f....	1	1	0	0	0	0	0	0	0	0
			12.Do you prefer to stay at home,	1	1	1	0	0	0	0	0	0	0

1713

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

131

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
35	7DT	Reboxetine	Y N	Y N	Y N	Y N	Y N	Y N	Y N	Y N	Y N	Y N
		31.Total score	30	30	30	23	22					
	8ND	Imipramine	1	1	1	1	0	0	0	0	0	0
		01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	0	0	1	1	1	1	1
		08.Are you afraid that something bad...	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,....	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	0	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31.Total score	30	30	30	27	27	28	26	26	26	26
	8DT	Reboxetine	1	1	1	1	1	1	1	1	1	1
		01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act	1	1	1	1	1	0	0	0	0	0
		03.Do you feel that your life is empty	1	1	1	1	1	1	0	0	0	0
		04.Do you often get bored	1	1	1	1	1	1	0	0	0	0
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	0	0	0	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1

1715

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

132

PHARMACIA CMS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63		
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y
35	RDT	Reboxetine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0
		16.Do you often feel downhearted																					
		17.Do you feel pretty worthless the ..																					
		18.Do you worry a lot about the past																					
		19.Do you find life very exciting																					
		20.Is it hard for you to get started..																					
		21.Do you feel full of energy																					
		22.Do you feel that your situation ...																					
		23.Do you think that most people are..																					
		24.Do you frequently get upset over...																					
		25.Do you frequently feel like crying																					
		26.Do you have trouble concentrating																					
		27.Do you enjoy getting up in the mor..																					
		28.Do you prefer to avoid social gat..																					
		29.Is it easy for you to make decision																					
		30.Is your mind as clear as it used ..																					
		31.Total score	30		28		29		21		20		18		22		23		19				
36	4ND	Inipramine	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		01.Are you () satisfied with your life																					
		02.Have you dropped many of your act..																					
		03.Do you feel that your life is empty																					
		04.Do you often get bored																					
		05.Are you hopeful about the future																					
		06.Are you bothered by thoughts you ..																					
		07.Are you in good spirits most of ...																					
		08.Are you afraid that something bad..																					
		09.Do you feel happy most of the time																					
		10.Do you often feel helpless																					
		11.Do you often get restless and f.....																					
		12.Do you prefer to stay at home,																					
		13.Do you frequently worry about the..																					
		14.Do you feel you have more problems.																					
		15.Do you think it is wonderful to be..																					
		16.Do you often feel downhearted																					
		17.Do you feel pretty worthless the ...																					
		18.Do you worry a lot about the past																					
		19.Do you find life very exciting																					
		20.Is it hard for you to get started..																					
		21.Do you feel full of energy																					
		22.Do you feel that your situation ...																					
		23.Do you think that most people are...																					
		24.Do you frequently get upset over...																					
		25.Do you frequently feel like crying																					
		26.Do you have trouble concentrating																					
		27.Do you enjoy getting up in the mor..																					
		28.Do you prefer to avoid social gat..																					
		29.Is it easy for you to make decision																					
		30.Is your mind as clear as it used ..																					
		31.Total score	21		18		9		8		8		8		8		8		7				

1716

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

133

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
36	1DT Imipramine	1	1	1	0	0	0	0	0	0	0
	01.Are you () satisfied with your life	1	1	1	0	0	0	0	0	0	0
	02.Have you dropped many of your act..	1	1	1	0	0	0	0	0	0	0
	03.Do you feel that your life is empty	1	1	1	0	0	0	0	0	0	0
	04.Do you often get bored	0	0	0	0	0	0	0	0	0	0
	05.Are you hopeful about the future	1	1	1	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	1	1	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	1	1	0	0	0	0	0	0	0
	10.Do you often feel helpless	1	1	1	0	0	0	0	0	0	0
	11.Do you often get restless and f....	1	1	1	0	0	0	0	0	0	0
	12.Do you prefer to stay at home,	1	1	1	0	0	0	0	0	0	0
	13.Do you frequently worry about the..	1	1	1	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	1	1	1	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be..	1	1	1	0	0	0	0	0	0	0
	16.Do you often feel downhearted	0	0	0	0	0	0	0	0	0	0
	17.Do you feel pretty worthless the ...	0	0	0	0	0	0	0	0	0	0
	18.Do you worry a lot about the past ...	0	0	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	1	1	1	0	0	0	0	0	0	0
	20.Is it hard for you to get started..	1	1	1	0	0	0	0	0	0	0
	21.Do you feel full of energy	1	1	1	0	0	0	0	0	0	0
	22.Do you feel that your situation ...	1	1	1	0	0	0	0	0	0	0
	23.Do you think that most people are...	1	1	1	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	1	1	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor..	1	1	1	0	0	0	0	0	0	0
	28.Do you prefer to avoid social get..	1	1	1	0	0	0	0	0	0	0
	29.Is it easy for you to make decision	1	1	1	0	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	1	1	1	0	0	0	0	0	0	0
	31.Total score	20	20	18	12	8	8	4	4	4	4
2HD	Reboxetine	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	0	0	0	0	0	0	0
	03.Do you feel that your life is empty	1	1	1	0	0	0	0	0	0	0
	04.Do you often get bored	1	1	1	0	0	0	0	0	0	0
	05.Are you hopeful about the future	1	1	1	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	1	1	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	1	1	0	0	0	0	0	0	0
	10.Do you often feel helpless	1	1	1	0	0	0	0	0	0	0
	11.Do you often get restless and f....	1	1	1	0	0	0	0	0	0	0
	12.Do you prefer to stay at home,	1	1	1	0	0	0	0	0	0	0
	13.Do you frequently worry about the..	1	1	1	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be..	1	1	1	0	0	0	0	0	0	0
	16.Do you often feel downhearted	1	1	1	0	0	0	0	0	0	0
	17.Do you feel pretty worthless the ...	1	1	1	0	0	0	0	0	0	0
	18.Do you worry a lot about the past ...	1	1	1	0	0	0	0	0	0	0

1717

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

134

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
36	2ND Reboxetine	1	1	1	1	1	1	1	1	1	1
	19. Do you find life very exciting	1	0	0	1	1	1	1	1	1	1
	20. Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21. Do you feel full of energy	1	0	0	0	0	0	0	0	0	0
	22. Do you think that your situation ...	0	0	0	0	0	0	0	0	0	0
	23. Do you think that most people are..	0	0	0	0	0	0	0	0	0	0
	24. Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0
	25. Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0
	26. Do you have trouble concentrating	1	0	0	0	0	0	0	0	0	0
	27. Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
	28. Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
	29. Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	30. Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
	31. Total score	22	14	15	15	25	25	14	14	0	14
20F	Reboxetine	1	1	1	1	0	0	0	0	0	0
	01. Are you () satisfied with your life	1	0	0	0	0	0	0	0	0	0
	02. Have you dropped many of your act..	0	0	0	0	0	0	0	0	0	0
	03. Do you feel that your life is empty	0	0	0	0	0	0	0	0	0	0
	04. Do you often get bored	0	0	0	0	0	0	0	0	0	0
	05. Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06. Are you bothered by thoughts you ...	0	0	0	0	0	0	0	0	0	0
	07. Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
	08. Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
	09. Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10. Do you often feel helpless	1	0	0	0	0	0	0	0	0	0
	11. Do you often get restless and f....	1	0	0	0	0	0	0	0	0	0
	12. Do you prefer to stay at home,	1	0	0	0	0	0	0	0	0	0
	13. Do you frequently worry about the..	1	0	0	0	0	0	0	0	0	0
	14. Do you feel you have more problems.	1	0	0	0	0	0	0	0	0	0
	15. Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
	16. Do you often feel downhearted	1	0	0	0	0	0	0	0	0	0
	17. Do you feel pretty worthless the ..	1	0	0	0	0	0	0	0	0	0
	18. Do you worry a lot about the past	1	0	0	0	0	0	0	0	0	0
	19. Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20. Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21. Do you feel full of energy	1	0	0	0	0	0	0	0	0	0
	22. Do you feel that your situation ...	1	0	0	0	0	0	0	0	0	0
	23. Do you think that most people are..	1	0	0	0	0	0	0	0	0	0
	24. Do you frequently get upset over...	1	0	0	0	0	0	0	0	0	0
	25. Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0
	26. Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
	27. Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
	28. Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
	29. Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	30. Is your mind as clear as it used ..	1	0	0	0	0	0	0	0	0	0
	31. Total score	21	18	18	15	12	0	0	0	0	0
30D	Imipramine	1	1	1	1	1	1	1	1	1	1
	01. Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02. Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03. Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1

1718

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

135

PIARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y N	Y N	Y N	Y N	Y N	Y N	Y N	Y N	Y N	Y N
36	3ND Imipramine	1	1	1	1	1	1	1	1	1	1
	04. Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05. Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06. Are you bothered by thoughts you ...	1	1	1	1	1	1	1	1	1	1
	07. Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
	08. Are you afraid that something bad...	1	1	1	1	1	1	1	1	1	1
	09. Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10. Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11. Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
	12. Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
	13. Do you frequently worry about the...	1	1	1	1	1	1	1	1	1	1
	14. Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	15. Do you think it is wonderful to be...	1	1	1	1	1	1	1	1	1	1
	16. Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17. Do you feel pretty worthless the....	0	0	0	0	0	0	0	0	0	0
	18. Do you worry a lot about the past...	0	0	0	0	0	0	0	0	0	0
	19. Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20. Is it hard for you to get started...	1	1	1	1	1	1	1	1	1	1
	21. Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
	22. Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
	23. Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
	24. Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
	25. Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
	26. Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
	27. Do you enjoy getting up in the mor...	1	1	1	1	1	1	1	1	1	1
	28. Do you prefer to avoid social gat...	0	0	0	0	0	0	0	0	0	0
	29. Is it easy for you to make decision...	0	0	0	0	0	0	0	0	0	0
	30. Is your mind as clear as it used ...	0	0	0	0	0	0	0	0	0	0
	31. Total score	24	25	24	26	22	22	22	22	22	22
30T	Imipramine	1	1	1	0	0	0	0	0	0	0
	01. Are you () satisfied with your life	1	1	1	0	0	0	0	0	0	0
	02. Have you dropped many of your act...	1	1	1	0	0	0	0	0	0	0
	03. Do you feel that your life is empty	1	1	1	0	0	0	0	0	0	0
	04. Do you often get bored	1	1	1	0	0	0	0	0	0	0
	05. Are you hopeful about the future	1	1	1	0	0	0	0	0	0	0
	06. Are you bothered by thoughts you ...	1	1	1	0	0	0	0	0	0	0
	07. Are you in good spirits most of ...	1	1	1	0	0	0	0	0	0	0
	08. Are you afraid that something bad...	1	1	1	0	0	0	0	0	0	0
	09. Do you feel happy most of the time	1	1	1	0	0	0	0	0	0	0
	10. Do you often feel helpless	1	1	1	0	0	0	0	0	0	0
	11. Do you often get restless and f....	1	1	1	0	0	0	0	0	0	0
	12. Do you prefer to stay at home,	1	1	1	0	0	0	0	0	0	0
	13. Do you frequently worry about the...	1	1	1	0	0	0	0	0	0	0
	14. Do you feel you have more problems.	1	1	1	0	0	0	0	0	0	0
	15. Do you think it is wonderful to be...	1	1	1	0	0	0	0	0	0	0
	16. Do you often feel downhearted	1	1	1	0	0	0	0	0	0	0
	17. Do you feel pretty worthless the....	1	1	1	0	0	0	0	0	0	0
	18. Do you worry a lot about the past...	1	1	1	0	0	0	0	0	0	0
	19. Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20. Is it hard for you to get started...	1	1	1	1	1	1	1	1	1	1
	21. Do you feel full of energy	1	1	1	1	1	1	1	1	1	1

1719

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

136

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	_Day0_		_Day7_		_Day14_		_Day21_		_Day28_		_Day35_		_Day42_		_Day49_		_Day56_		_Day63_	
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
36	3DT Imipramine	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	22.Do you feel that your situation ...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	23.Do you think that most people are..	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	28.Do you prefer to avoid social gst..	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	29.Is it easy for you to make decision	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	31.Total score	23	20	8	8	4	8	8	4	8	8	8	8	8	8	8	8	8	8	8	8
4HD	Reboxetine	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	03.Do you feel that your life is empty	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	05.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	06.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	23.Do you think that most people are..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gst...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	31.Total score	23	23	23	23	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	25
4DT	Reboxetine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	03.Do you feel that your life is empty	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	04.Do you often get bored	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1720

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

137

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63			
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
36	4DT	Reboxetine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1			
1	1	1	1																					

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

138

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
36	5ND Reboxetine	1	0	1	1	1	1	1	0	0	0
	25.Do you frequently feel like crying										
	26.Do you have trouble concentrating										
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	0	0	0	0	0
	28.Do you prefer to avoid social gat..	0	0	0	0	0	0	0	0	0	0
	29.Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0	0
	31.Total score	15	0	13	10	8	6	6	5	5	5
5DI	Imipramine	1	0	0	0	0	0	0	0	0	0
	01.Are you () satisfied with your life										
	02.Have you dropped many of your act..	0	0	0	0	0	0	0	0	0	0
	03.Do you feel that your life is empty	0	0	0	0	0	0	0	0	0	0
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,....	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	0	0	0	0	0	0	0	0	0	0
	17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat..	0	0	0	0	0	0	0	0	0	0
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0	0
	31.Total score	0	20	0	0	0	0	0	0	0	0
6ND	Imipramine	0	0	0	0	0	0	0	0	0	0
	01.Are you () satisfied with your life										
	02.Have you dropped many of your act	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	0	0	0	0	0	0	0	0	0	0
	04.Do you often get bored	0	0	0	0	0	0	0	0	0	0
	05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1

1722

9550089

140

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
36	6DT Imipramine	0	0	0	0	0	0	0	0	0	0
	28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	20	20	17	10	9	9	7	6	6	6
	31.Total score										
7MD	Reboxetine	0	0	0	0	0	0	0	0	0	0
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	0	0	0	0	0	0	0	0	0	0
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
	09.Do you often feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
	13.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
	14.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
	15.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	16.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
	17.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	18.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
	19.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	0	0	0	0	0	0	0	0	0	0
	28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	25	23	23	21	21	21	21	21	21	21
	31.Total score										
7DT	Reboxetine	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	0	0	0	0	0	0	0	0	0	0
	03.Do you feel that your life is empty	0	0	0	0	0	0	0	0	0	0
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0
	09.Do you often feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	0	0	0	0	0	0	0	0	0	0
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1

1724

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

144

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
36	7DT	Reboxetine	1	0	1	1	0	0	0	0	0	0
		13.Do you frequently worry about the..	1	0	1	1	0	0	0	0	0	0
		14.Do you feel you have more problems.	1	0	1	1	0	0	0	0	0	0
		15.Do you think it is wonderful to be.	1	1	1	1	0	0	0	0	0	0
		16.Do you often feel downhearted	1	0	1	1	0	0	0	0	0	0
		17.Do you feel pretty worthless the ..	1	0	1	1	0	0	0	0	0	0
		18.Do you worry a lot about the past	1	1	1	1	0	0	0	0	0	0
		19.Do you find life very exciting	1	1	1	1	0	0	0	0	0	0
		20.Is it hard for you to get started..	1	1	1	1	0	0	0	0	0	0
		21.Do you feel full of energy	1	0	1	1	0	0	0	0	0	0
		22.Do you feel that your situation ...	1	0	1	1	0	0	0	0	0	0
		23.Do you think that most people are..	1	1	1	1	0	0	0	0	0	0
		24.Do you frequently get upset over...	1	0	1	1	0	0	0	0	0	0
		25.Do you frequently feel like crying	1	0	1	1	0	0	0	0	0	0
		26.Do you have trouble concentrating	1	1	1	1	0	0	0	0	0	0
		27.Do you enjoy getting up in the mor.	1	1	1	1	0	0	0	0	0	0
		28.Do you prefer to avoid social gat..	1	1	1	1	0	0	0	0	0	0
		29.Is it easy for you to make decision	1	1	1	1	0	0	0	0	0	0
		30.Is your mind as clear as it used ..	1	1	1	1	0	0	0	0	0	0
		31.Total score	22	25								
8ND	Imipramine	04.Are you () satisfied with your life	1	1	0	0	0	0	0	0	0	0
		02.Have you dropped many of your act..	1	0	0	0	0	0	0	0	0	0
		03.Do you feel that your life is empty	1	0	0	0	0	0	0	0	0	0
		04.Do you often get bored	1	1	0	1	1	0	0	0	0	0
		05.Are you hopeful about the future	1	0	0	1	1	0	0	0	0	0
		06.Are you bothered by thoughts you ..	1	1	1	1	0	0	0	0	0	0
		07.Are you in good spirits most of ...	0	0	0	1	1	0	0	0	0	0
		08.Are you afraid that something bad..	0	0	0	1	1	0	0	0	0	0
		09.Do you feel happy most of the time	1	1	1	0	0	0	0	0	0	0
		10.Do you often feel helpless	1	1	0	0	0	0	0	0	0	0
		11.Do you often get restless and f....	1	1	1	0	0	0	0	0	0	0
		12.Do you prefer to stay at home, ...	1	1	1	0	0	0	0	0	0	0
		13.Do you frequently worry about the..	1	1	0	1	1	0	0	0	0	0
		14.Do you feel you have more problems.	0	0	1	0	0	0	0	0	0	0
		15.Do you think it is wonderful to be.	1	1	1	1	0	0	0	0	0	0
		16.Do you often feel downhearted	1	1	1	1	0	0	0	0	0	0
		17.Do you feel pretty worthless the ..	1	0	0	0	0	0	0	0	0	0
		18.Do you worry a lot about the past	1	0	0	0	0	0	0	0	0	0
		19.Do you find life very exciting	1	1	1	1	1	1	0	0	0	0
		20.Is it hard for you to get started..	1	1	1	1	0	0	0	0	0	0
		21.Do you feel full of energy	1	0	0	0	0	0	0	0	0	0
		22.Do you feel that your situation ...	1	0	1	0	0	0	0	0	0	0
		23.Do you think that most people are..	1	0	0	0	0	0	0	0	0	0
		24.Do you frequently get upset over...	1	0	0	0	0	0	0	0	0	0
		25.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0
		26.Do you have trouble concentrating	1	1	1	0	0	1	0	0	0	0
		27.Do you enjoy getting up in the mor.	1	1	1	0	0	0	0	0	0	0
		28.Do you prefer to avoid social gat..	1	1	1	0	0	0	0	0	0	0
		29.Is it easy for you to make decision	1	1	1	0	0	0	0	0	0	0
		30.Is your mind as clear as it used ..	1	1	0	0	0	0	0	0	0	0

1725

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

142

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63	
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
36	8HD Imipramine																				
	31.Total score																				
	8DT Reboxetine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	01.Are you () satisfied with your life																				
	02.Have you dropped many of your act..																				
	03.Do you feel that your life is empty																				
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..																				
	07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	14.Do you think it is wonderful to be..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	15.Do you often feel downhearted	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	16.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	17.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	18.Do you find life very exciting	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	19.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	22.Do you think that most people are..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	23.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	24.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	25.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	26.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	27.Do you prefer to avoid social get..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	28.Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	29.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	30.Total score	16	16	16	16	16	16	16	16	16	16	16	16	16	16	16	16	16	16	16	16
	8ND Reboxetine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	01.Are you () satisfied with your life																				
	02.Have you dropped many of your act..																				
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..																				
	07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1726

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

143

PHARMACIA CNS RD

REBOXETINE - PROTOCOL 20124/035
Listing No.: 45.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
36	9MD Reboxetine	1	1	1	1	1	0	0	0	0	0
	16. Do you often feel downhearted	1	1	1	1	1	0	0	0	0	0
	17. Do you feel pretty worthless the ..	1	0	1	1	0	0	0	0	0	0
	18. Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
	19. Do you find life very exciting	1	1	1	1	0	0	0	0	0	0
	20. Is it hard for you to get started...	1	1	1	1	1	1	1	1	1	1
	21. Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
	22. Do you feel that your situation ...	1	1	0	0	0	0	0	0	0	0
	23. Do you think that most people are...	1	1	1	0	0	0	0	0	0	0
	24. Do you frequently get upset over...	1	0	1	0	0	0	0	0	0	0
	25. Do you frequently feel like crying	1	1	1	1	0	0	0	0	0	0
	26. Do you have trouble concentrating	1	1	1	1	1	0	0	0	0	0
	27. Do you enjoy getting up in the mor.	1	1	1	1	0	0	0	0	0	0
	28. Do you prefer to avoid social gat..	1	1	1	1	0	0	0	0	0	0
	29. Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	30. Is your mind as clear as it used ..	1	1	1	1	0	0	0	0	0	0
	31. Total score	25	28	26	17	11	6	5	5	0	5
9DT	Imipramine	1	1	0	0	0	0	0	0	0	0
	01. Are you () satisfied with your life	1	0	0	0	0	0	0	0	0	0
	02. Have you dropped many of your act..	1	0	0	0	0	0	0	0	0	0
	03. Do you feel that your life is empty	1	1	0	0	0	0	0	0	0	0
	04. Do you often get bored	1	1	0	0	0	0	0	0	0	0
	05. Are you hopeful about the future	1	1	1	0	0	0	0	0	0	0
	06. Are you bothered by thoughts you ..	1	0	0	0	0	0	0	0	0	0
	07. Are you in good spirits most of ...	0	0	1	0	0	0	0	0	0	0
	08. Are you afraid that something bad...	0	0	0	0	0	0	0	0	0	0
	09. Do you feel happy most of the time	1	1	1	0	0	0	0	0	0	0
	10. Do you often feel helpless	1	1	1	0	0	0	0	0	0	0
	11. Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
	12. Do you prefer to stay at home,	1	0	0	0	0	0	0	0	0	0
	13. Do you frequently worry about the..	0	0	0	0	0	0	0	0	0	0
	14. Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0
	15. Do you think it is wonderful to be.	1	1	0	0	0	0	0	0	0	0
	16. Do you often feel downhearted	1	1	0	0	0	0	0	0	0	0
	17. Do you feel pretty worthless the ..	1	0	0	0	0	0	0	0	0	0
	18. Do you worry a lot about the past	1	1	0	0	0	0	0	0	0	0
	19. Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20. Is it hard for you to get started...	1	1	1	0	0	0	0	0	0	0
	21. Do you feel full of energy	1	1	1	0	0	0	0	0	0	0
	22. Do you feel that your situation ...	1	0	0	0	0	0	0	0	0	0
	23. Do you think that most people are...	1	0	1	0	0	0	0	0	0	0
	24. Do you frequently get upset over...	1	1	0	0	0	0	0	0	0	0
	25. Do you frequently feel like crying	1	1	0	0	0	0	0	0	0	0
	26. Do you have trouble concentrating	1	1	0	0	0	0	0	0	0	0
	27. Do you enjoy getting up in the mor.	1	1	0	0	0	0	0	0	0	0
	28. Do you prefer to avoid social gat..	1	0	0	0	0	0	0	0	0	0
	29. Is it easy for you to make decision	1	1	0	0	0	0	0	0	0	0
	30. Is your mind as clear as it used ..	1	1	0	0	0	0	0	0	0	0
	31. Total score	23	22	9	2	2	0	2	0	2	2

1727

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

144

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
36	10MD Reboxetine	0	0	0	0	0	0	0	0	0	0
	01.Are you () satisfied with your life	1	0	0	0	0	0	0	0	0	0
	02.Have you dropped many of your act..	1	0	0	0	0	0	0	0	0	0
	03.Do you feel that your life is empty	1	0	1	0	0	0	0	0	0	0
	04.Do you often get bored	1	1	0	0	0	0	0	0	0	0
	05.Are you hopeful about the future	1	1	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	1	1	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	1	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	1	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	0	0	0	0	0	0	0	0	0
	10.Do you often feel helpless	1	0	0	0	0	0	0	0	0	0
	11.Do you often get restless and f.....	1	0	0	0	0	0	0	0	0	0
	12.Do you prefer to stay at home	1	0	0	0	0	0	0	0	0	0
	13.Do you frequently worry about the...	1	0	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	1	1	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be..	1	0	0	0	0	0	0	0	0	0
	16.Do you often feel downhearted	1	0	0	0	0	0	0	0	0	0
	17.Do you feel pretty worthless the ..	1	0	0	0	0	0	0	0	0	0
	18.Do you worry a lot about the past	1	0	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	1	1	0	0	0	0	0	0	0	0
	20.Is it hard for you to get started..	1	1	0	0	0	0	0	0	0	0
	21.Do you feel full of energy	1	0	0	0	0	0	0	0	0	0
	22.Do you feel that your situation ...	1	0	0	0	0	0	0	0	0	0
	23.Do you think that most people are..	1	0	0	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	1	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor..	1	0	0	0	0	0	0	0	0	0
	28.Do you prefer to avoid social gat..	0	0	0	0	0	0	0	0	0	0
	29.Is it easy for you to make decision	0	1	0	0	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	0	1	0	0	0	0	0	0	0	0
	31.Total score	23	7	5	2	2	2	2	2	2	2
10DT	Reboxetine	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	0	0	0	0	0	0	0	0	0
	03.Do you feel that your life is empty	1	0	0	0	0	0	0	0	0	0
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ...	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1

1728

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

145

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
36	10DT Reboxetine	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting										
	20.Is it hard for you to get started..										
	21.Do you feel full of energy										
	22.Do you feel that your situation ...										
	23.Do you think that most people are..										
	24.Do you frequently get upset over...										
	25.Do you frequently feel like crying										
	26.Do you have trouble concentrating										
	27.Do you enjoy getting up in the mor.										
	28.Do you prefer to avoid social gat..										
	29.Is it easy for you to make decision										
	30.Is your mind as clear as it used ..										
	31.Total score	26	26	26	26	23	23	21	22	25	25
11MD	11MD Imipramine	1	1	1	1	0	0	0	0	0	0
	01.Are you () satisfied with your life										
	02.Have you dropped many of your act..										
	03.Do you feel that your life is empty										
	04.Do you often get bored										
	05.Are you hopeful about the future										
	06.Are you bothered by thoughts you ..										
	07.Are you in good spirits most of ...										
	08.Are you afraid that something bad..										
	09.Do you feel happy most of the time										
	10.Do you often feel helpless										
	11.Do you often get restless and f....										
	12.Do you prefer to stay at home, ...										
	13.Do you frequently worry about the..										
	14.Do you feel you have more problems.										
	15.Do you think it is wonderful to be.										
	16.Do you often feel downhearted										
	17.Do you feel pretty worthless the ..										
	18.Do you worry a lot about the past										
	19.Do you find life very exciting										
	20.Is it hard for you to get started..										
	21.Do you feel full of energy										
	22.Do you feel that your situation ...										
	23.Do you think that most people are..										
	24.Do you frequently get upset over...										
	25.Do you frequently feel like crying										
	26.Do you have trouble concentrating										
	27.Do you enjoy getting up in the mor.										
	28.Do you prefer to avoid social gat..										
	29.Is it easy for you to make decision										
	30.Is your mind as clear as it used ..										
	31.Total score	26	26	16	14	6	4	4	4	0	4
11DT	11DT Reboxetine	1	1	1	1	1	0	0	0	0	0
	01.Are you () satisfied with your life										
	02.Have you dropped many of your act..										
	03.Do you feel that your life is empty										

1729

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

146

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	_Day0_		_Day7_		_Day14_		_Day21_		_Day28_		_Day35_		_Day42_		_Day49_		_Day56_		_Day63_	
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
36	11DT Reboxetine	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	04.Do you often get bored																				
	05.Are you hopeful about the future																				
	06.Are you bothered by thoughts you ..																				
	07.Are you in good spirits most of ...																				
	08.Are you afraid that something bad..																				
	09.Do you feel happy most of the time																				
	10.Do you often feel helpless																				
	11.Do you often get restless and f.....																				
	12.Do you prefer to stay at home,																				
	13.Do you frequently worry about the..																				
	14.Do you feel you have more problems.																				
	15.Do you think it is wonderful to be..																				
	16.Do you often feel downhearted																				
	17.Do you feel pretty worthless the																				
	18.Do you worry a lot about the past ..																				
	19.Do you find life very exciting																				
	20.Is it hard for you to get started..																				
	21.Do you feel full of energy																				
	22.Do you feel that your situation ...																				
	23.Do you think that most people are..																				
	24.Do you frequently get upset over...																				
	25.Do you frequently feel like crying																				
	26.Do you have trouble concentrating																				
	27.Do you enjoy getting up in the mor..																				
	28.Do you prefer to avoid social gat..																				
	29.Is it easy for you to make decision																				
	30.Is your mind as clear as it used ..																				
	31.Total Score	0	24	0	24	19	17	17	11	10	10	0	0	0	0	0	0	0	0	0	0
12HD	Imipramine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	01.Are you () satisfied with your life																				
	02.Have you dropped many of your act..																				
	03.Do you feel that your life is empty																				
	04.Do you often get bored																				
	05.Are you hopeful about the future																				
	06.Are you bothered by thoughts you ..																				
	07.Are you in good spirits most of ...																				
	08.Are you afraid that something bad..																				
	09.Do you feel happy most of the time																				
	10.Do you often feel helpless																				
	11.Do you prefer to stay at home,																				
	12.Do you often get restless and f.....																				
	13.Do you frequently worry about the..																				
	14.Do you feel you have more problems.																				
	15.Do you think it is wonderful to be..																				
	16.Do you often feel downhearted																				
	17.Do you feel pretty worthless the ..																				
	18.Do you worry a lot about the past ..																				
	19.Do you find life very exciting																				
	20.Is it hard for you to get started..																				
	21.Do you feel full of energy																				

1730

9550089

147

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
36	12MD	Imigranin	1	1	1	1	0	0	0	0	0	0
		22.Do you feel that your situation ...	1	1	1	1	0	0	0	0	0	0
		23.Do you think that most people are...	1	1	1	1	0	0	0	0	0	0
		24.Do you frequently get upset over...	1	1	0	0	0	0	0	0	0	0
		25.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0
		26.Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0
		27.Do you enjoy getting up in the mor.	0	0	0	0	0	0	0	0	0	0
		28.Do you prefer to avoid social gat..	1	1	1	1	0	0	0	0	0	0
		29.Is it easy for you to make decision	1	1	1	1	0	0	0	0	0	0
		30.Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0	0
		31.Total score	0	23	0	22						
12DT		Imigranin	1	1	1	1	0	0	0	0	0	0
		01.Are you () satisfied with your life	1	1	1	1	0	0	0	0	0	0
		02.Have you dropped many of your act..	1	0	0	0	1	0	1	0	1	0
		03.Do you feel that your life is empty	1	1	1	0	1	0	0	0	0	0
		04..Do you often get bored	1	1	1	0	0	0	0	0	0	0
		05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
		06.Are you bothered by thoughts you ..	1	1	1	1	0	0	0	0	0	0
		07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
		08.Are you afraid that something bad..	1	1	1	1	0	0	0	0	0	0
		09.Do you feel happy most of the time	1	1	1	1	0	0	0	0	0	0
		10.Do you often feel helpless	0	0	0	0	0	0	0	0	0	0
		11.Do you often get restless and f....	0	0	0	0	0	0	0	0	0	0
		12.Do you prefer to stay at home, ...	0	0	0	0	0	0	0	0	0	0
		13.Do you frequently worry about the..	0	0	0	0	0	0	0	0	0	0
		14.Do you feel you have more problems.	1	0	0	0	0	0	0	0	0	0
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	0	0	0	0	0	0	0	0	0	0
		17.Do you feel pretty worthless the ..	0	0	0	0	0	0	0	0	0	0
		18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	0	0	0	0	0	0	0	0	0	0
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are...	1	1	1	1	0	0	0	0	0	0
		24.Do you frequently get upset over...	1	1	1	1	0	0	0	0	0	0
		25.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31.Total score	19	19	19	16	15	10	8	8	8	8
13MD		Reboxetine	0	0	0	0	0	0	0	0	0	0
		01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04..Do you often get bored	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0

1731

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

148

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
36	13MD Reboxetine	07.Are you in good spirits most of ...	0	0	0	1	1	1				
		08.Do you feel happy most of the time	0	0	0	1	1	1				
		10.Do you often feel helpless	0	0	0	1	1	1				
		11.Do you often get restless and f....	1	0	0	0	0	0				
		12.Do you prefer to stay at home,	0	0	0	1	1	1				
		13.Do you frequently worry about the..	0	0	0	1	1	1				
		14.Do you feel you have more problems.	0	0	0	1	1	1				
		15.Do you think it is wonderful to be.	0	0	0	1	1	1				
		16.Do you often feel downhearted	0	0	0	1	1	1				
		17.Do you feel pretty worthless the ...	0	0	0	1	1	1				
		18.Do you worry a lot about the past	0	0	0	1	1	1				
		19.Do you find life very exciting	1	1	1	1	1	1				
		20.Is it hard for you to get started..	1	1	1	1	1	1				
		21.Do you feel full of energy	1	1	1	1	1	1				
		22.Do you feel that your situation ...	0	0	0	1	1	1				
		23.Do you think that most people are...	0	0	0	1	1	1				
		24.Do you frequently get upset over...	0	0	0	0	0	0				
		25.Do you frequently feel like crying	1	0	0	0	0	0				
		26.Do you have trouble concentrating	1	0	0	0	0	0				
		27.Do you enjoy getting up in the mor.	0	0	0	1	1	1				
		28.Do you prefer to avoid social gat...	0	0	0	1	1	1				
		29.Is it easy for you to make decision	0	1	0	1	1	1				
		30.Is your mind as clear as it used ..	0	1	0	1	1	1				
		31.Total score	0	10	0	10	25	25				
14MD	Imipramine	01.Are you () satisfied with your life	0	0	0	0	0	0				
		02.Have you dropped many of your act..	1	1	1	1	1	1				
		03.Do you feel that your life is empty	1	1	1	1	1	1				
		04.Do you often get bored	1	1	1	1	1	1				
		05.Are you hopeful about the future	1	0	0	0	0	0				
		06.Are you bothered by thoughts you ...	0	0	0	0	0	0				
		07.Are you in good spirits most of ...	0	0	0	0	0	0				
		08.Are you afraid that something bad..	0	0	0	0	0	0				
		09.Do you feel happy most of the time	1	1	1	1	1	1				
		10.Do you often feel helpless	1	0	0	0	0	0				
		11.Do you often get restless and f....	1	1	1	1	1	1				
		12.Do you prefer to stay at home,	1	1	1	1	1	1				
		13.Do you frequently worry about the..	1	1	1	1	1	1				
		14.Do you feel you have more problems.	1	1	1	1	1	1				
		15.Do you think it is wonderful to be.	0	0	0	0	0	0				
		16.Do you often feel downhearted	1	0	0	0	0	0				
		17.Do you feel pretty worthless the ...	1	0	0	0	0	0				
		18.Do you worry a lot about the past	1	0	0	0	0	0				
		19.Do you find life very exciting	1	1	1	1	1	1				
		20.Is it hard for you to get started..	1	1	1	1	1	1				
		21.Do you feel full of energy	1	0	0	0	0	0				
		22.Do you feel that your situation ...	1	0	0	0	0	0				
		23.Do you think that most people are...	1	0	0	0	0	0				
		24.Do you frequently get upset over...	1	0	0	0	0	0				

1732

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

149

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
36	14MD	Imipramine	1	1	1	0	0	0	0	0	0	0
		25. Do you frequently feel like crying	1	1	1	0	0	0	0	0	0	0
		26. Do you have trouble concentrating	1	1	1	0	0	0	0	0	0	0
		27. Do you enjoy getting up in the mor.	1	1	0	0	0	0	0	0	0	0
		28. Do you prefer to avoid social gat..	0	0	0	0	0	0	0	0	0	0
		29. Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0
		30. Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0	0
		31. Total score	20	13	7	3	2	1	1	0	1	1
15ND	Reboxetine	01. Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0
		02. Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03. Do you feel that your life is empty	1	0	1	0	1	0	1	0	1	0
		04. Do you often get bored	0	0	0	0	0	0	0	0	0	0
		05. Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
		06. Are you bothered by thoughts you ..	3	1	1	1	1	1	1	1	1	1
		07. Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
		08. Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09. Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
		10. Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
		11. Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
		12. Do you prefer to stay at home, ...	1	0	0	0	0	0	0	0	0	0
		13. Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
		14. Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
		15. Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
		16. Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		17. Do you feel pretty worthless the ..	0	0	0	0	0	0	0	0	0	0
		18. Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0
		19. Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20. Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21. Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22. Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0
		23. Do you think that most people are..	0	0	0	0	0	0	0	0	0	0
		24. Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0
		25. Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0
		26. Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27. Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
		28. Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
		29. Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30. Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31. Total score	18	18	18	18	18	18	18	18	18	18
16ND	Imipramine	01. Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02. Have you dropped many of your act..	0	0	0	0	0	0	0	0	0	0
		03. Do you feel that your life is empty	0	0	0	0	0	0	0	0	0	0
		04. Do you often get bored	1	1	1	1	1	1	1	1	1	1
		05. Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
		06. Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0
		07. Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
		08. Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0
		09. Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1

1733

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

150

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63	
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
36	16HD Imipramine	1	0	1	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0
	10.Do you often feel helpless																				
	11.Do you often get restless and f....																				
	12.Do you prefer to stay at home,																				
	13.Do you frequently worry about the..																				
	14.Do you feel you have more problems.																				
	15.Do you think it is wonderful to be.																				
	16.Do you often feel downhearted																				
	17.Do you feel pretty worthless the ..																				
	18.Do you worry a lot about the past																				
	19.Do you find life very exciting																				
	20.Is it hard for you to get started..																				
	21.Do you feel full of energy																				
	22.Do you feel that your situation ...																				
	23.Do you think that most people are...																				
	24.Do you frequently get upset over...																				
	25.Do you have trouble concentrating																				
	26.Do you enjoy getting up in the mor..																				
	27.Do you prefer to avoid social get...																				
	28.Is it easy for you to make decision																				
	29.Is your mind as clear as it used ..																				
	31.Total score	18	0	18	0	18	0	18	0	18	0	15	0	10	0	10	0	10	0	10	0
17HD	Reboxetine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life																				
	02.Have you dropped many of your act..																				
	03.Do you feel that your life is empty																				
	04.Do you often get bored																				
	05.Are you hopeful about the future																				
	06.Are you bothered by thoughts you ..																				
	07.Are you in good spirits most of ...																				
	08.Are you afraid that something bad..																				
	09.Do you feel happy most of the time																				
	10.Do you often feel helpless																				
	11.Do you often get restless and f....																				
	12.Do you prefer to stay at home,																				
	13.Do you frequently worry about the..																				
	14.Do you feel you have more problems.																				
	15.Do you think it is wonderful to be.																				
	16.Do you often feel downhearted																				
	17.Do you feel pretty worthless the ...																				
	18.Do you worry a lot about the past																				
	19.Do you find life very exciting																				
	20.Is it hard for you to get started..																				
	21.Do you feel full of energy																				
	22.Do you feel that your situation ...																				
	23.Do you think that most people are...																				
	24.Do you frequently get upset over...																				
	25.Do you frequently feel like crying																				
	26.Do you have trouble concentrating																				
	27.Do you enjoy getting up in the mor..																				

1734

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

151

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	_Day0_	_Day7_	_Day14_	_Day21_	_Day28_	_Day35_	_Day42_	_Day49_	_Day56_	_Day63_
		Y	N	Y	N	Y	N	Y	N	Y	N
36	17ND Reboxetine	1	1	1	1	0	0	0	0	0	0
	28.Do you prefer to avoid social gat..	1	1	1	1	0	0	0	0	0	0
	29.Is it easy for you to make decision	1	1	1	1	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0	0
	31.Total score	22	22	22	22						
18ND	Imipramine	1	1	1	1	1	0	0	0	0	0
	01.Are you () satisfied with your life	1	1	1	1	1	0	0	0	0	0
	02.Have you dropped many of your act..	1	1	1	1	0	0	0	0	0	0
	03.Do you feel that your life is empty	1	1	1	1	0	0	0	0	0	0
	04.Do you often get bored	1	1	1	1	0	0	0	0	0	0
	05.Are you hopeful about the future	1	1	1	1	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	1	1	1	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	1	1	1	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	1	1	1	0	0	0	0	0	0
	10.Do you often feel helpless	1	1	1	1	0	0	0	0	0	0
	11.Do you often get restless and f.....	1	1	1	1	0	0	0	0	0	0
	12.Do you prefer to stay at home,.....	1	1	1	1	0	0	0	0	0	0
	13.Do you frequently worry about thi...	0	0	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be...	0	0	0	0	0	0	0	0	0	0
	16.Do you often feel demotiated	1	1	1	1	0	0	0	0	0	0
	17.Do you feel pretty worthless the ...	0	0	0	0	0	0	0	0	0	0
	18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	1	1	1	1	1	0	0	0	0	0
	20.Is it hard for you to get started..	1	1	1	1	0	0	0	0	0	0
	21.Do you feel full of energy	1	1	1	1	0	0	0	0	0	0
	22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0
	23.Do you think that most people are...	1	1	1	1	0	0	0	0	0	0
	24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	1	1	1	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor..	1	1	1	1	0	0	0	0	0	0
	28.Do you prefer to avoid social gat..	1	1	1	1	0	0	0	0	0	0
	29.Is it easy for you to make decision	1	1	1	1	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	1	1	1	1	0	0	0	0	0	0
	31.Total score	22	20	14	14	1	0	0	0	0	0
19ND	Reboxetine	1	1	1	1	1	0	0	0	0	0
	01.Are you () satisfied with your life	1	1	1	1	1	0	0	0	0	0
	02.Have you dropped many of your act..	0	0	0	0	0	0	0	0	0	0
	03.Do you feel that your life is empty	0	0	0	0	0	0	0	0	0	0
	04.Do you often get bored	0	0	0	0	0	0	0	0	0	0
	05.Are you hopeful about the future	1	1	1	1	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	1	1	1	1	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	1	1	1	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	1	1	1	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	1	1	1	0	0	0	0	0	0
	10.Do you often feel helpless	0	0	0	0	0	0	0	0	0	0
	11.Do you often get restless and f.....	1	1	1	1	0	0	0	0	0	0
	12.Do you prefer to stay at home,.....	1	1	1	1	0	0	0	0	0	0

17 3 51

9550089

152

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
36	19ND Reboxetine	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	0	0	0	0	0	0	0	0	0	0
	21.Do you feel full of energy	0	0	0	0	0	0	0	0	0	0
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0	0
	31.Total score	20	20	20	20	20	20	20	20	20	20
20MD	Imipramine	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	0	0	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ..	0	0	0	0	0	0	0	0	0	0
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
	31.Total score	1	1	1	1	1	1	1	1	1	1

1736

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

153

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	_Day0_	_Day7_	_Day14_	_Day21_	_Day28_	_Day35_	_Day42_	_Day49_	_Day56_	_Day63_
			Y N	Y N	Y N	Y N	Y N	Y N	Y N	Y N	Y N	Y N
36	20MD	Imipramine	26	26	26	26	26	25	25	25	25	25
		31.Total score										
37	3MD	Reboxetine	1	1	1	1	1	1	1	1	1	1
		01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	0	0	0	0	0	0	0	0	0	0
		13.Do you frequently worry about the...	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel dehearted	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the...	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past ..	0	0	0	0	0	0	0	0	0	0
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor..	0	0	0	0	0	0	0	0	0	0
		28.Do you prefer to avoid social gat..	0	0	0	0	0	0	0	0	0	0
		29.Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31.Total score	20	20	20	20	20	20	20	20	20	20
41	1MD	Imipramine	0	0	0	0	0	0	0	0	0	0
		01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the...	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be..	0	0	0	0	0	0	0	0	0	0

1737

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

154

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
41	1HD										
	Indipramine										
	16.Do you often feel downhearted	1	0								
	17.Do you feel pretty worthless the ..	1	1								
	18.Do you worry a lot about the past	0	1								
	19.Do you find life very exciting	1	1								
	20.Is it hard for you to get started..	0	1								
	21.Do you feel full of energy	0	1								
	22.Do you feel that your situation ...	0	0								
	23.Do you think that most people are...	0	1								
	24.Do you frequently get upset over...	1	0								
	25.Do you have trouble concentrating	1	1								
	26.Do you enjoy getting up in the mor.	1	0								
	27.Do you prefer to avoid social get...	1	1								
	28.Is it easy for you to make decision	0	0								
	29.Is your mind as clear as it used ..	1	1								
	31.Total score	19	21								
2HD	Reboxetine										
	01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0
	02.Have you dropped many of your act..	1	1	0	0	0	0	0	0	0	0
	03.Do you feel that your life is empty	1	0	1	0	1	0	0	0	0	0
	04.Do you often get bored	0	0	0	1	0	0	0	0	0	0
	05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	1	1	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	0	0	0	0	0	0	0	0	0	0
	10.Do you often feel helpless	0	0	0	0	0	0	0	0	0	0
	11.Do you often get restless and f.....	1	1	0	0	0	0	0	0	0	0
	12.Do you prefer to stay at home,	1	0	0	0	0	0	0	0	0	0
	13.Do you frequently worry about the..	0	0	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be..	1	0	0	0	0	0	0	0	0	0
	16.Do you often feel downhearted	0	0	0	0	0	0	0	0	0	0
	17.Do you feel pretty worthless the ..	0	0	0	0	0	0	0	0	0	0
	18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	1	1	1	0	0	0	0	0	0	0
	20.Is it hard for you to get started..	1	1	0	0	0	0	0	0	0	0
	21.Do you feel full of energy	1	1	0	0	0	0	0	0	0	0
	22.Do you feel that your situation ...	1	1	0	0	0	0	0	0	0	0
	23.Do you think that most people are...	0	0	0	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	1	0	0	0	0	0	0	0	0	0
	25.Do you have trouble concentrating	1	0	0	0	0	0	0	0	0	0
	26.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
	27.Do you prefer to avoid social get...	1	0	0	0	0	0	0	0	0	0
	28.Is it easy for you to make decision	1	0	0	0	0	0	0	0	0	0
	29.Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0	0
	31.Total score	16	7	3	3	3	2	2	2	2	2

1738

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

155

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63		
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	
41 3WD Imipramine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	05.Are you hopeful about the future	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	17.Do you worry a lot about the past ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	18.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat..	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	31.Total score		24		20		23		19		21		21		21		22		21		21	
	4ND Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
02.Have you dropped many of your act..		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
03.Do you feel that your life is empty		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
04.Do you often get bored		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
05.Are you hopeful about the future		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
06.Are you bothered by thoughts you ..		0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	
07.Are you in good spirits most of ...		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
08.Are you afraid that something bad..		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
09.Do you feel happy most of the time		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
10.Do you often feel helpless		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
11.Do you often get restless and f....		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
12.Do you prefer to stay at home,		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
13.Do you frequently worry about the..		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
14.Do you feel you have more problems.		0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	
15.Do you think it is wonderful to be.		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
16.Do you often feel downhearted		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
17.Do you worry a lot about the past ..		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
18.Do you find life very exciting		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	

1739

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

156

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient	Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63				
				Y	N	Y	N	Y	N	Y	N	Y	N				
41	4MD	Reboxetine	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1				
			20.Is it hard for you to get started..	1	0	0	0	0	0	0	0	0	0	0	0		
			21.Do you feel full of energy	1	1	1	1	1	1	0	0	0	0	0	0		
			22.Do you think that your situation ...	1	1	0	1	1	0	0	0	0	0	0	0		
			23.Do you think that most people are...	1	0	0	0	0	0	0	0	0	0	0	0		
			24.Do you frequently get upset over...	1	1	1	1	0	1	0	0	0	0	0	0		
			25.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0	0	0		
			26.Do you have trouble concentrating	1	1	1	1	1	1	0	0	0	0	0	0		
			27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	0	0	0	0	0	0		
			28.Do you prefer to avoid social get..	0	0	0	0	0	0	0	0	0	0	0	0		
			29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1		
			30.Is your mind as clear as it used ..	1	1	0	1	0	1	0	1	0	0	0	0		
			31.Total score			24	23	18	0	19	17	13	13	11	11		
			5MD	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	
					02.Have you dropped many of your act..	1	1	1	1	0	0	0	0	0	0	0	
					03.Do you feel that your life is empty	1	1	1	0	0	0	0	0	0	0	0	
					04.Do you often get bored	0	0	0	0	0	0	0	0	0	0	0	
					05.Are you hopeless about the future	0	0	0	1	1	0	0	0	0	0	0	
					06.Are you bothered by thoughts you ..	1	1	1	1	0	0	0	0	0	0	0	
					07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0	0	
					08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1
					09.Do you feel happy most of the time	1	0	0	0	0	0	0	0	0	0	0	
					10.Do you often feel helpless	1	0	0	0	0	0	0	0	0	0	0	
					11.Do you often get restless and f....	1	0	0	0	0	0	0	0	0	0	0	
					12.Do you prefer to stay at home, ...	1	0	0	0	1	0	0	0	0	0	0	
					13.Do you frequently worry about the..	0	0	0	0	0	0	0	0	0	0	0	
					14.Do you feel you have more problems.	1	1	1	1	1	0	0	0	0	0	0	
					15.Do you think it is wonderful to be..	0	0	0	0	0	0	0	0	0	0	0	
					16.Do you often feel downhearted	0	0	0	0	1	1	1	1	1	1	1	
					17.Do you feel pretty worthless the ..	0	0	0	0	0	0	0	0	0	0	0	
					18.Do you worry a lot about the past	1	0	0	0	0	0	0	0	0	0	0	
19.Do you find life very exciting	1	1			1	1	1	1	1	1	1	1	1				
20.Is it hard for you to get started..	1	0			0	0	0	0	0	0	0	0	0				
21.Do you feel full of energy	1	0			0	0	1	1	1	1	1	1	1				
22.Do you think that your situation ...	1	0			0	0	0	0	0	0	0	0	0				
23.Do you think that most people are..	1	0			0	0	0	0	0	0	0	0	0				
24.Do you frequently get upset over...	1	0			0	0	0	0	0	0	0	0	0				
25.Do you frequently feel like crying	0	0			0	0	0	0	0	0	0	0	0				
26.Do you have trouble concentrating	0	0			0	0	0	0	0	0	0	0	0				
27.Do you enjoy getting up in the mor.	1	1			1	1	1	1	1	1	1	1	1				
28.Do you prefer to avoid social get..	0	0			0	0	0	0	0	0	0	0	0				
29.Is it easy for you to make decision	0	0			0	0	0	0	0	0	0	0	0				
30.Is your mind as clear as it used ...	0	0			0	0	0	0	0	0	0	0	0				
31.Total score					16	10	9	0	11	10	7	6	6	5			
42	1MD	Imipramine	01.Are you () satisfied with your life	1	1	0	0	0	0	0	0	0	0				
			02.Have you dropped many of your act..	1	1	1	1	0	0	0	0	0	0				
			03.Do you feel that your life is empty	1	1	0	1	0	0	0	0	0	0				

1740

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

157

PHARMACIA CNS R&D

REBONETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63		
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y
42	IND	Imipramine	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		04.Do you often get bored	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		31.Total score	25	25	25	25	12	7	7	5	3	3	3	3	2	2	3	3	3	3	3	3	3
42	IND	Imipramine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,.....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1741

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

158

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day65		
			Y	N	Y	N	Y	N	Y	N	Y	N		
42	1DT	Imipramine	22.Do you feel that your situation ...	1	1	0	0	0	0	0	0	0	0	
			23.Do you think that most people are...	1	1	1	1	0	0	0	0	0	0	0
			24.Do you frequently get upset over...	1	1	1	1	1	1	0	0	1	0	0
			25.Do you frequently feel like crying	1	1	1	1	1	1	0	1	1	0	0
			26.Do you have trouble concentrating	1	1	0	1	0	0	0	1	1	1	0
			27.Do you enjoy getting up in the mor.	1	1	0	0	1	1	0	1	1	0	0
			28.Do you prefer to avoid social get..	1	1	0	0	0	0	1	1	0	0	0
			29.Is it easy for you to make decision	1	1	1	0	1	1	1	1	0	0	1
			30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	0	0	0	1
			31.Total score	30	30	26	24	18	25	21	19	20		
			2HD	Reboxetine	01.Are you () satisfied with your life	1	1	0	0	0	0	0	0	0
02.Have you dropped many of your act..	1	1			1	1	0	0	0	1	0	0	0	
03.Do you feel that your life is empty	1	1			1	1	0	0	0	1	0	0	0	
04.Do you often get bored	1	1			1	1	0	0	0	0	0	0	0	
05.Are you hopeless about the future	0	0			0	0	0	0	0	0	0	0	0	
06.Are you bothered by thoughts you ..	1	1			0	0	0	0	0	0	0	0	0	
07.Are you in good spirits most of ...	1	1			1	1	0	0	0	0	0	0	0	
08.Are you afraid that something bad..	1	1			1	1	0	0	0	0	0	0	0	
09.Do you feel happy most of the time	1	1			1	1	0	0	0	0	0	0	0	
10.Do you often feel helpless	1	1			1	1	0	0	0	0	0	0	0	
11.Do you often get restless and f.....	1	1			1	1	0	0	0	0	0	0	0	
12.Do you prefer to stay at home.....	1	1			1	1	0	0	0	0	0	0	0	
13.Do you frequently worry about the..	1	1			0	1	0	0	0	0	0	0	0	
14.Do you feel you have more problems.	1	1			0	1	0	0	0	0	0	0	0	
15.Do you think it is wonderful to be..	0	0			0	0	0	0	0	0	0	0	0	
16.Do you often feel demotivated	1	1			1	1	0	0	0	0	0	0	0	
17.Do you feel pretty worthless the ...	1	1			1	1	0	0	0	0	0	0	0	
18.Do you worry a lot about the past	1	1			1	1	0	0	0	0	0	0	0	
19.Do you find life very exciting	1	1			1	1	0	0	0	0	0	0	0	
20.Is it hard for you to get started..	1	1			1	1	1	1	1	0	0	1	1	
21.Do you feel full of energy	1	1			1	1	1	1	1	0	0	1	1	
22.Do you feel that your situation ...	1	1			0	0	0	0	0	0	0	0	0	
23.Do you think that most people are..	1	1			0	0	0	0	0	0	0	0	0	
24.Do you frequently get upset over...	1	1			0	0	0	0	0	0	0	0	0	
25.Do you frequently feel like crying	1	1			0	0	0	0	0	0	0	0	0	
26.Do you have trouble concentrating	1	1			0	0	0	0	0	0	0	0	0	
27.Do you enjoy getting up in the mor.	1	1			1	1	1	1	0	0	0	0	0	
28.Do you prefer to avoid social get..	1	1			1	1	1	1	0	0	0	0	0	
29.Is it easy for you to make decision	1	1			1	1	1	1	1	0	0	0	0	
30.Is your mind as clear as it used ..	1	1			1	1	1	1	0	0	0	0	0	
31.Total score	26	23			21	19	4	3	5	3	5	3	5	
2DT	Reboxetine	01.Are you () satisfied with your life	1	0										
		02.Have you dropped many of your act..	1	1										
		03.Do you feel that your life is empty	1	0										
		04.Do you often get bored	1	1										
		05.Are you hopeless about the future	1	0										
		06.Are you bothered by thoughts you ..	1	0										

1742

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

159

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
42	2DT Reboxetine	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	0	0	0	0	0	0	0	0	0
	10.Do you often feel helpless	1	0	0	0	0	0	0	0	0	0
	11.Do you often get restless and f....	1	0	0	0	0	0	0	0	0	0
	12.Do you prefer to stay at home,	1	0	0	0	0	0	0	0	0	0
	13.Do you frequently worry about the..	1	0	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	1	0	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be.	0	0	0	0	0	0	0	0	0	0
	16.Do you often feel downhearted	0	0	0	0	0	0	0	0	0	0
	17.Do you feel pretty worthless the ...	0	0	0	0	0	0	0	0	0	0
	18.Do you worry a lot about the past ..	1	0	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	0	0	0	0	0	0	0	0	0	0
	22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0
	23.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0
	24.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0
	25.Do you have trouble concentrating	1	0	0	0	0	0	0	0	0	0
	26.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
	27.Do you prefer to avoid social gat..	0	0	0	0	0	0	0	0	0	0
	28.Do you prefer to make decision	1	1	1	1	1	1	1	1	1	1
	29.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
	31.Total score	19	12	12	12	12	12	12	12	12	12
3HD	Imipramine	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	0	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	0	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	0	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	0	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	0	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be.	0	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past ..	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	0	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	0	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are..	0	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	0	1	1	1	1	1	1	1	1	1

1743

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

160

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
42	38D	Imipramine	1	0	1	1	1	1	0	1	0	0
		25.Do you frequently feel like crying	1	0	1	1	1	1	0	1	0	0
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	0
		27.Do you enjoy getting up in the mor.	1	1	1	1	0	1	1	1	1	0
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	0
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	0
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	0	1	1	0
		31.Total score	21	29	30	25	24	24	16	19	16	3
43	10T	Reboxetine	1	1	1	1	1	1	1	1	1	1
		01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	0	0	0	0	0	0	0	0	0
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	0	0	0	0	0	0	0	0	0
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	0	0	0	0	0	0	0	0	0
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ..	1	0	0	0	0	0	0	0	0	0
		18.Do you worry a lot about the past	1	0	0	0	0	0	0	0	0	0
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	0	0	0	0	0	0	0	0	0
		25.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0
		26.Do you have trouble concentrating	1	0	0	0	0	0	0	0	0	0
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	0	0	0	0	0	0	0	0	0
		31.Total score	25	18	18	12	14	16	15	16	15	15
43	20T	Imipramine	0	0	0	0	0	0	0	0	0	0
		01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	0	0	0	0	0	0	0	0	0	0
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1

1744

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

161

PHARMACIA CNS R&D
 RESOXETINE - PROTOCOL 20124/035
 Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
43	20T	Imipramine	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	0	1	0	1	0	1	0	1	0
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0
		15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	0	0	0	1	1	1	1	1	1
		17.Do you feel pretty worthless the ..	1	0	0	0	1	1	1	1	1	1
		18.Do you worry a lot about the past ..	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	0	0	0	0	1	1	1	1	1	1
		23.Do you think that most people are...	0	0	0	0	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat...	1	0	0	0	0	0	0	0	0	0
		29.Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0
		30.Is your mind as clear as it used ..	1	0	0	0	0	0	0	0	0	0
		31.Total score	24	17	14	22						
43	20T	Imipramine	1	1	1	1	1	1	1	1	1	1
		01.Are you () satisfied with your life	1	0	1	1	0	0	0	0	0	0
		02.Have you dropped many of your act..	1	0	1	1	0	0	0	0	0	0
		03.Do you feel that your life is empty	1	0	1	1	0	0	0	0	0	0
		04.Do you often get bored	1	1	1	1	0	0	0	0	0	0
		05.Are you hopeful about the future	1	1	1	1	0	0	0	0	0	0
		06.Are you bothered by thoughts you ..	1	1	1	1	0	0	0	0	0	0
		07.Are you in good spirits most of ...	1	1	1	1	0	0	0	0	0	0
		08.Are you afraid that something bad..	1	1	1	1	0	0	0	0	0	0
		09.Do you feel happy most of the time	1	1	1	1	0	0	0	0	0	0
		10.Do you often feel helpless	1	1	1	1	0	0	0	0	0	0
		11.Do you often get restless and f....	1	1	1	1	0	0	0	0	0	0
		12.Do you prefer to stay at home,	1	1	1	1	0	0	0	0	0	0
		13.Do you frequently worry about the..	1	1	1	1	0	0	0	0	0	0
		14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0
		15.Do you think it is wonderful to be..	1	1	1	1	0	0	0	0	0	0
		16.Do you often feel downhearted	1	0	0	0	0	0	0	0	0	0
		17.Do you feel pretty worthless the	1	0	0	0	0	0	0	0	0	0
		18.Do you worry a lot about the past ..	1	1	1	1	0	0	0	0	0	0
		19.Do you find life very exciting	1	1	1	1	0	0	0	0	0	0
		20.Is it hard for you to get started..	1	1	1	1	0	0	0	0	0	0
		21.Do you feel full of energy	1	1	1	1	0	0	0	0	0	0
		22.Do you feel that your situation ...	1	1	1	1	0	0	0	0	0	0
		23.Do you think that most people are...	1	1	1	1	0	0	0	0	0	0
		24.Do you frequently get upset over...	1	1	1	1	0	0	0	0	0	0
		25.Do you frequently feel like crying	1	1	1	1	0	0	0	0	0	0
		26.Do you have trouble concentrating	1	1	1	1	0	0	0	0	0	0
		27.Do you enjoy getting up in the mor..	1	1	1	1	0	0	0	0	0	0

1745

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

162

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	_Day0_		_Day7_		_Day14_		_Day21_		_Day28_		_Day35_		_Day42_		_Day49_		_Day56_		_Day63_			
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N		
43	Imipramine	28.Do you prefer to avoid social gat..	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		29.Is it easy for you to make decision	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		31.Total score	24	21	21	21	14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
40T	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		07.Are you in good spirits most of ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
50D	Imipramine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		04.Do you often get bored	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1746

PHARMACIA CNS R6D

REBOMENTINE - PROTOCOL 20124-035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
43	SMD	Imipramine	1	0	1	0	1	1	1	1	1	1
		13.Do you frequently worry about the...	1	0	1	0	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	0	1	1	1	1	1
		15.Do you think it is wonderful to be.	1	1	1	1	0	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ..	1	0	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social get...	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31.Total score	26	26	27	27	26	27	26	27	26	27
6ND	Imipramine	01.Are you () satisfied with your life	1	1	1	0	0	0	0	0	0	0
		02.Have you dropped many of your act..	1	1	1	0	0	0	0	0	0	0
		03.Do you feel that your life is empty	1	1	1	0	0	0	0	0	0	0
		04.Do you often get bored	0	0	0	0	0	0	0	0	0	0
		05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	0	0	0	0	0	0	0
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	0	0	0	0	0	0	0
		10.Do you often feel helpless	1	1	1	0	0	0	0	0	0	0
		11.Do you often get restless and f....	1	1	1	0	0	0	0	0	0	0
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	0	0	0	0	0	0	0
		17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0
		23.Do you think that most people are...	0	0	0	0	0	0	0	0	0	0
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	0	0	0	0	0	0	0
		26.Do you have trouble concentrating	1	1	1	0	0	0	0	0	0	0
		27.Do you enjoy getting up in the mor.	1	1	1	0	0	0	0	0	0	0
		28.Do you prefer to avoid social get...	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0	0

1747

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

165

PRAXINACIA CNS RSD

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63		
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	
44 10F Reboxetine	16. Do you often feel downhearted	1	1	1	1	0	0	1	1	1	1	1	1	0	0	0	0	0	0	0	0	
	17. Do you feel pretty worthless the ..	1	1	1	1	0	0	1	1	1	1	1	1	0	0	0	0	0	0	0	0	
	18. Do you worry a lot about the past	1	1	1	1	0	0	1	1	1	1	1	1	0	0	0	0	0	0	0	0	
	19. Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20. Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21. Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	22. Do you feel that your situation ...	1	1	1	1	0	0	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0
	23. Do you think that most people are...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	24. Do you frequently get upset over...	0	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	25. Do you frequently feel like crying	1	1	1	1	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	26. Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	27. Do you enjoy getting up in the mor.	0	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	28. Do you prefer to avoid social get..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	29. Is it easy for you to make decision	0	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	30. Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	31. Total score		26	30	30	19	25	21	19	10	11	11	11	11	11	11	11	11	11	11	11	11
	2ND Reboxetine	01. Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		02. Have you dropped many of your act..	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		03. Do you feel that your life is empty	1	1	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		04. Do you often get bored	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		05. Are you huperrull about the future	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		06. Are you bothered by thoughts you ...	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		07. Are you in good spiriks most of ...	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		08. Are you afraid that something bad..	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		09. Do you feel happy most of the time	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		10. Do you often feel helpless	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		11. Do you often get restless and f....	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		12. Do you prefer to stay at home,	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		13. Do you frequently worry about the..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		14. Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		15. Do you think it is wonderful to be.	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
16. Do you often feel downhearted		1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
17. Do you feel pretty worthless the ..		1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
18. Do you worry a lot about the past		1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
19. Do you find life very exciting		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
20. Is it hard for you to get started..		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
21. Do you feel full of energy		1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
22. Do you feel that your situation ...		1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
23. Do you think that most people are...		1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
24. Do you frequently get upset over...		1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
25. Do you frequently feel like crying		1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
26. Do you have trouble concentrating		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
27. Do you enjoy getting up in the mor.		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
28. Do you prefer to avoid social get..		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
29. Is it easy for you to make decision		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
30. Is your mind as clear as it used ..		1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
31. Total score			20	10	14	14	12	11	11	14	11	11	11	11	11	11	11	11	11	11	11	9

1749

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

166

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63				
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	
44	3ND	Imipramine	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0		
			01.Are you () satisfied with your life	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	
			02.Have you dropped many of your act..	1	1	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	1	1	1
			03.Do you feel that your life is empty	1	1	1	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	1	1
			04.Do you often get bored	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			05.Are you hopeful about the future	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			06.Are you bothered by thoughts you ..	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			07.Are you in good spirits most of ...	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			10.Do you often feel helpless	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			11.Do you often get restless and f.....	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			12.Do you prefer to stay at home,	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			13.Do you frequently worry about the..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			17.Do you feel pretty worthless the ..	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			18.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			19.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			21.Do you feel full of energy	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			22.Do you feel that your situation ...	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			23.Do you think that most people are...	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			24.Do you frequently get upset over...	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			25.Do you frequently feel like crying	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			26.Do you have trouble concentrating	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			28.Do you prefer to avoid social get..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			29.Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			30.Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
31.Total score			21	15	15	19	19	17	10	20	19	15	15	15	15	15	15	15	15	15	15	15			
4ND	4ND	Imipramine	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			01.Are you () satisfied with your life	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			03.Do you feel that your life is empty	1	1	1	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	1	
			04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			06.Are you bothered by thoughts you ..	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			09.Do you feel happy most of the time	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			10.Do you often feel helpless	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			11.Do you often get restless and f.....	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
			16.Do you often feel downhearted	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
			17.Do you feel pretty worthless the ..	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				

1750

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

167

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient	Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63		
				Y	N	Y	N	Y	N	Y	N	Y	N		
44	4MD	Imipramine	19. Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	
			20. Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1
			21. Do you feel full of energy	0	0	0	0	0	0	0	0	0	0	0	0
			22. Do you think that your situation ...	1	0	0	0	0	0	0	0	0	0	0	0
			23. Do you think that most people are..	0	0	0	0	0	0	0	0	0	0	0	0
			24. Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0	0	0
			25. Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0	0	0
			26. Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0	0	0
			27. Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1
			28. Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1
			29. Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1
30. Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1			
31. Total score			21	19	12	10	22	21	20	17	17	17			
45	1MD	Reboxetine	01. Are you () satisfied with your life	1	0	1	0	0	0	0	0	0	0	0	
			02. Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	0
			03. Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1
			04. Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1
			05. Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1
			06. Are you bothered by thoughts you ..	1	0	0	0	0	0	0	0	0	0	0	0
			07. Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1
			08. Are you afraid that something bad..	1	0	0	0	0	0	0	0	0	0	0	0
			09. Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1
			10. Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1
			11. Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1
12. Do you prefer to stay at home,	1	0	0	0	0	0	0	0	0	0	0	0			
13. Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1			
14. Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1			
15. Do you think it is wonderful to be.	1	0	0	0	0	0	0	0	0	0	0	0			
16. Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1			
17. Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1	1			
18. Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1			
19. Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1			
20. Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1			
21. Do you feel full of energy	0	0	0	0	0	0	0	0	0	0	0	0			
22. Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0	0	0			
23. Do you think that most people are..	1	1	1	1	1	1	1	1	1	1	1	1			
24. Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1			
25. Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1			
26. Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1			
27. Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1			
28. Do you prefer to avoid social gat...	1	1	1	1	1	1	1	1	1	1	1	1			
29. Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0	0	0			
30. Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1			
31. Total score			27	21	18	17	20	21	16	13	11	11			
1DT	1MD	Imipramine	01. Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0		
			02. Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	
			03. Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	

1701

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

168

FRARMACIA CMS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
45	10T Imipramine	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	0	0	0	0	0	0	0	0	0	0
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started...	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social get...	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
	31.Total score	15	15	15	15	15	15	15	15	15	15
2ND	Imipramine	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started...	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1

1752

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

169

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centro Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
45	2ND Imipramine	0	1	1	1	1	0	0	0	0	0
	22.Do you feel that your situation ...	0	1	1	1	1	0	0	0	0	0
	23.Do you think that most people are..	0	1	1	1	1	0	0	0	0	0
	24.Do you frequently get upset over...	1	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	1	0	0	0	0	0	0	0	0	0
	28.Do you prefer to avoid social gat..	1	0	0	0	0	0	0	0	0	0
	29.Is it easy for you to make decision	1	0	0	0	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	1	0	0	0	0	0	0	0	0	0
	31.Total score	24	15	6	5	6	3	0	0	0	3
46	1ND Imipramine	1	1	1	1	1	0	0	0	0	0
	01.Are you () satisfied with your life	1	1	1	1	1	0	0	0	0	0
	02.Have you dropped many of your act..	1	0	0	0	0	0	0	0	0	0
	03.Do you feel that your life is empty	1	0	0	0	0	0	0	0	0	0
	04.Do you often get bored	1	0	0	0	0	0	0	0	0	0
	05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	0	1	1	0	0	0	0	0	0	0
	10.Do you often feel helpless	0	1	1	0	0	0	0	0	0	0
	11.Do you often get restless and f.....	0	1	1	0	0	0	0	0	0	0
	12.Do you prefer to stay at home,	0	0	0	0	0	0	0	0	0	0
	13.Do you frequently worry about the..	0	1	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	0	0	0	0	1	0	0	0	0	0
	15.Do you think it is wonderful to be..	0	0	0	0	0	0	0	0	0	0
	16.Do you often feel downhearted	0	1	0	0	0	0	0	0	0	0
	17.Do you feel pretty worthless the ..	0	1	0	0	0	0	0	0	0	0
	18.Do you worry a lot about the past	0	1	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	0	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	0	1	1	0	0	0	0	0	0	0
	21.Do you feel full of energy	1	1	1	0	0	0	0	0	0	0
	22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0
	23.Do you think that most people are..	0	0	0	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	0	1	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	0	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat..	0	0	0	0	0	0	0	0	0	0
	29.Is it easy for you to make decision	0	1	0	0	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	0	1	0	0	0	0	0	0	0	0
	31.Total score	14	15	6	5	6	3	0	0	0	3
2ND Imipramine	01.Are you () satisfied with your life	1	1	1	1	1	0	0	0	0	0
	02.Have you dropped many of your act..	1	0	0	0	0	0	0	0	0	0
	03.Do you feel that your life is empty	1	0	0	0	0	0	0	0	0	0
	04.Do you often get bored	1	0	0	0	0	0	0	0	0	0
	05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	0	1	1	0	0	0	0	0	0	0
	10.Do you often feel helpless	0	1	1	0	0	0	0	0	0	0
	11.Do you often get restless and f.....	0	1	1	0	0	0	0	0	0	0
	12.Do you prefer to stay at home,	0	0	0	0	0	0	0	0	0	0
	13.Do you frequently worry about the..	0	1	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	0	0	0	0	1	0	0	0	0	0
	15.Do you think it is wonderful to be..	0	0	0	0	0	0	0	0	0	0
	16.Do you often feel downhearted	0	1	0	0	0	0	0	0	0	0
	17.Do you feel pretty worthless the ..	0	1	0	0	0	0	0	0	0	0
	18.Do you worry a lot about the past	0	1	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	0	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	0	1	1	0	0	0	0	0	0	0
	21.Do you feel full of energy	1	1	1	0	0	0	0	0	0	0
	22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0
	23.Do you think that most people are..	0	0	0	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	0	1	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	0	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat..	0	0	0	0	0	0	0	0	0	0
	29.Is it easy for you to make decision	0	1	0	0	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	0	1	0	0	0	0	0	0	0	0
	31.Total score	14	15	6	5	6	3	0	0	0	3

1753

9550089

170

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
46	2ND Imipramine	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	0	0	1	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	0	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	0	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past ..	1	0	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	0	1	0	1	0	1	0	1	0
	23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat...	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision ..	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	0	0	0	0	0	0	0	0
	31.Total score	27	23	24	24	25	25	25	25	25	25
3ND	Reboxetine	1	1	0	0	0	1	0	0	0	0
	01.Are you () satisfied with your life	1	1	0	0	0	1	0	0	0	0
	02.Have you dropped many of your act..	0	1	0	0	1	0	0	0	0	0
	03.Do you feel that your life is empty	0	1	0	0	0	0	0	0	0	0
	04.Do you often get bored	1	0	0	0	0	0	0	0	0	0
	05.Are you hopeless about the future	0	0	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	1	1	1	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	1	1	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the...	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	0	1	1	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past ..	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are...	0	1	0	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1

1754

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

171

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63		
			Y	N	Y	N	Y	N	Y	N	Y	N		
46	3MD	25.Do you frequently feel like crying	1	1	0	0	0	0	0	0	0	0		
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	0	
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	0	
		28.Do you prefer to avoid social get..	1	1	1	1	1	1	1	1	1	1	0	
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	0	
		30.Is your mind as clear as it used ..	0	1	0	0	0	0	0	0	0	0	0	
		31.Total score		24	27	18	10	16	14	12	4	4	4	4
		48	10T	01.Are you () satisfied with your life	1									
				02.Have you dropped many of your act..	0									
				03.Do you feel that your life is empty	1									
				04.Do you often get bored	0									
				05.Are you hopeful about the future	1									
				06.Are you bothered by thoughts you ..	0									
07.Are you in good spirits most of ..	1													
08.Are you afraid that something bad..	1													
09.Do you feel happy most of the time	1													
10.Do you often feel helpless	1													
11.Do you often get restless and f....	1													
12.Do you prefer to stay at home,	1													
13.Do you frequently worry about the..	1													
14.Do you feel you have more problems.	1													
15.Do you think it is wonderful to be..	1													
16.Do you often feel downhearted	1													
17.Do you feel pretty worthless the ..	1													
18.Do you worry a lot about the past	1													
19.Do you find life very exciting	1													
20.Is it hard for you to get started..	1													
21.Do you feel full of energy	1													
22.Do you feel that your situation ...	1													
23.Do you think that most people are..	1													
24.Do you frequently get upset over...	1													
25.Do you frequently feel like crying	1													
26.Do you have trouble concentrating	1													
27.Do you enjoy getting up in the mor.	1													
28.Do you prefer to avoid social get..	1													
29.Is it easy for you to make decision	1													
30.Is your mind as clear as it used ..	0													
31.Total score												26		
48	10T	01.Are you () satisfied with your life	1											
		02.Have you dropped many of your act..	1											
		03.Do you feel that your life is empty	1											
		04.Do you often get bored	1											
		05.Are you hopeful about the future	1											
		06.Are you bothered by thoughts you ..	0											
		07.Are you in good spirits most of ..	1											
		08.Are you afraid that something bad..	0											
		09.Do you feel happy most of the time	1											

17 55 51

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

172

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20126/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
48	1DT	Reboxetine	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	0	0	0	0	0	0	0	0	0	0
		14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0
		25.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0
		26.Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0
		27.Do you prefer to avoid social gat...	1	1	1	1	1	1	1	1	1	1
		28.Do you enjoy getting up in the mor...	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	0	0	0	0	0	0	0	0	0	0
		31.Total score	19	23								
2DT		Imipramine	1	1	1	1	1	1	1	1	1	1
		01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	0	0	0	0	0	0	0	0	0	0
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	0	0	0	0	0	0	0	0	0	0
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor...	1	1	1	1	1	1	1	1	1	1

1756

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

173

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
48 2DT Imipramine	28. Do you prefer to avoid social gat...	1	1	1	1	1	1	1	1	1	1
	29. Is it easy for you to make decision	1	1	1	1	0	0	1	1	1	1
	30. Is your mind as clear as it used ..	1	1	1	1	0	22	21	22	21	22
	31. Total score	24	25	25	23	23	21	21	22	21	22
291 1MD Imipramine	01. Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02. Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03. Do you feel that your life is empty	1	1	0	1	1	1	1	1	1	1
	04. Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05. Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06. Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
	07. Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
	08. Are you afraid that something bad..	1	1	1	1	0	1	1	1	1	1
	09. Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10. Do you often feel helpless	1	0	1	1	1	1	1	1	1	1
	11. Do you often get restless and f.....	1	0	1	1	1	1	1	1	1	1
	12. Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
	13. Do you frequently worry about the...	1	1	1	1	1	1	1	1	1	1
	14. Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	15. Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1
	16. Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17. Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
	18. Do you worry a lot about the past	0	0	0	0	0	1	1	1	1	1
	19. Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20. Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21. Do you feel full of energy	1	1	0	1	1	1	1	1	1	1
	22. Do you feel that your situation ...	1	1	0	1	1	1	1	1	1	1
	23. Do you think that most people are..	1	1	0	1	1	1	1	1	1	1
	24. Do you frequently get upset over...	0	0	0	0	1	1	1	1	1	1
	25. Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
	26. Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
	27. Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1
	28. Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
	29. Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	30. Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31. Total score	28	24	26	27	30	30	27	27	30
1DT Reboxetine	01. Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0
	02. Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03. Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
	04. Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05. Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06. Are you bothered by thoughts you ...	1	1	1	1	1	1	1	1	1	1
	07. Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
	08. Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0
	09. Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10. Do you often feel helpless	1	0	0	0	0	0	0	0	0	0
	11. Do you often get restless and f.....	1	0	1	0	1	0	1	0	1	0
	12. Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1

1757

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

179

PHARMACIA CHS 28D
 REMOXETINE - IMPROCK 20124/035
 Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Center Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63	
		Y	N	Y	N	Y	N	Y	N	Y	N	
291 40F Roxoxetine	13. Do you frequently worry about the future?	1	0	1	0	1	0	1	0	1	0	
	14. Do you think it is wonderful to be old?	1	0	1	0	1	0	1	0	1	0	
	15. Do you often feel demoralized?	1	0	1	0	1	0	1	0	1	0	
	16. Do you often feel worthless?	1	0	1	0	1	0	1	0	1	0	
	17. Do you feel pretty worthless the most of the time?	1	0	1	0	1	0	1	0	1	0	
	18. Do you worry a lot about the past?	1	0	1	0	1	0	1	0	1	0	
	19. Do you often feel lonely?	1	0	1	0	1	0	1	0	1	0	
	20. Is it hard for you to get started?	1	0	1	0	1	0	1	0	1	0	
	21. Do you feel full of energy?	0	1	0	1	0	1	0	1	0	1	
	22. Do you feel that your situation is better than most people are?	0	1	0	1	0	1	0	1	0	1	
	23. Do you think that most people are better off than you are?	0	1	0	1	0	1	0	1	0	1	
	24. Do you frequently feel like crying?	1	0	1	0	1	0	1	0	1	0	
	25. Do you have trouble concentrating?	1	0	1	0	1	0	1	0	1	0	
	26. Do you enjoy getting up in the morn.	1	0	1	0	1	0	1	0	1	0	
	27. Do you prefer to avoid social get-togethers?	1	0	1	0	1	0	1	0	1	0	
	28. Do you prefer to avoid social get-togethers?	1	0	1	0	1	0	1	0	1	0	
	29. Is your mind as clear as it used to be?	1	0	1	0	1	0	1	0	1	0	
	31. Total score		21	20	20	20	19	19	14	15	14	14
	30D Roxoxetine	01. Are you satisfied with your life?	1	1	1	1	1	1	1	1	1	1
		02. Have you dropped many of your activities?	1	1	1	1	1	1	1	1	1	1
		03. Do you feel that your life is empty?	1	1	1	1	1	1	1	1	1	1
		04. Do you often get bored?	1	1	1	1	1	1	1	1	1	1
		05. Do you often think about the future?	1	1	1	1	1	1	1	1	1	1
		06. Are you bothered by thoughts you have?	1	1	1	1	1	1	1	1	1	1
		07. Are you in good spirits most of the time?	1	1	1	1	1	1	1	1	1	1
		08. Are you afraid that something bad will happen to you?	1	1	1	1	1	1	1	1	1	1
		09. Do you feel happy most of the time?	1	1	1	1	1	1	1	1	1	1
		10. Do you often get restless and fidgety?	1	1	1	1	1	1	1	1	1	1
		11. Do you often get worried about the future?	1	1	1	1	1	1	1	1	1	1
		12. Do you prefer to stay at home, rather than go out?	1	1	1	1	1	1	1	1	1	1
		13. Do you frequently worry about the future?	1	1	1	1	1	1	1	1	1	1
14. Do you think it has more problems than you can handle?		1	1	1	1	1	1	1	1	1	1	
15. Do you often feel downhearted and hopeless?		1	1	1	1	1	1	1	1	1	1	
16. Do you often feel worthless?		1	1	1	1	1	1	1	1	1	1	
17. Do you feel pretty worthless the most of the time?		1	1	1	1	1	1	1	1	1	1	
18. Do you worry a lot about the past?		1	1	1	1	1	1	1	1	1	1	
19. Do you often feel lonely?		1	1	1	1	1	1	1	1	1	1	
20. Is it hard for you to get started?		1	1	1	1	1	1	1	1	1	1	
21. Do you feel full of energy?		1	1	1	1	1	1	1	1	1	1	
22. Do you feel that your situation is better than most people are?		1	1	1	1	1	1	1	1	1	1	
23. Do you think that most people are better off than you are?		1	1	1	1	1	1	1	1	1	1	
24. Do you frequently feel like crying?		1	1	1	1	1	1	1	1	1	1	
25. Do you have trouble concentrating?		1	1	1	1	1	1	1	1	1	1	
26. Do you enjoy getting up in the morning?		1	1	1	1	1	1	1	1	1	1	
27. Do you prefer to avoid social get-togethers?		1	1	1	1	1	1	1	1	1	1	
28. Do you prefer to avoid social get-togethers?		1	1	1	1	1	1	1	1	1	1	
29. Is your mind as clear as it used to be?		1	1	1	1	1	1	1	1	1	1	
30. Is your mind as clear as it used to be?		1	1	1	1	1	1	1	1	1	1	

9550089

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

175

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 15.0
 GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0 Y N	Day7 Y N	Day14 Y N	Day21 Y N	Day28 Y N	Day35 Y N	Day42 Y N	Day49 Y N	Day56 Y N	Day63 Y N	
291	2ND Reboxetine	31.Total score	30	29	29	29	29	30	30	30	30	30	
2DT	Reboxetine	01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0	
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	0	0	0	0	0	0	0	0	0	0	0
		11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ...	0	0	0	0	0	0	0	0	0	0	0
		18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0	0
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0	0
		23.Do you think that most people are..	0	0	0	0	0	0	0	0	0	0	0
		24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0	0
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1
		31.Total score			21	22	23	23	22	21	21	21	21
3ND	Imipramine	01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0	
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	
		05.Are you hopeful about the future	1	0	0	0	0	0	0	0	0	0	
		06.Are you bothered by thoughts you ...	1	1	1	1	1	1	1	1	1	1	
		07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0	
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	
		11.Do you often get restless and f.....	1	0	0	0	0	0	0	0	0	0	
		12.Do you prefer to stay at home,	1	0	0	0	0	0	0	0	0	0	
		13.Do you frequently worry about the..	0	0	0	0	0	0	0	0	0	0	
		14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0	
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	

1759

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

176

PHARMACIA CNS RD

REBOMETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	_Day0_		_Day7_		_Day14_		_Day21_		_Day28_		_Day35_		_Day42_		_Day49_		_Day56_		_Day63_	
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
291	3HD Imipramine	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	21.Do you feel full of energy	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	23.Do you think that most people are...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social get...	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	31.Total score	21	19	19	19	19	19	19	19	19	19	5	5	5	5	5	5	5	5	5	5
30T	Imipramine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	02.Have you dropped many of your act..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	03.Do you feel that your life is empty	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	13.Do you frequently worry about the..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	17.Do you feel pretty worthless the ...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	21.Do you feel full of energy	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat...	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	31.Total score	21	19	19	19	19	19	19	19	19	19	5	5	5	5	5	5	5	5	5	5

1760

9550089

177

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	_Day0_		_Day7_		_Day14_		_Day21_		_Day28_		_Day35_		_Day42_		_Day49_		_Day56_		_Day63_	
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
291	4HD	Reboxetine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		01.Are you () satisfied with your life	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
		02.Have you dropped many of your act..	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
		03.Do you feel that your life is empty	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		17.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		18.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		19.Is it hard for you to get started...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		20.Do you feel full of energy	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
		21.Do you feel that your situation ...	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
		22.Do you think that most people are...	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
		23.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		25.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		26.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		27.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		28.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		29.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		30.Total score	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25
40T		Imipramine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		05.Are you hopeful about the future	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		06.Are you bothered by thoughts you ..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		07.Are you in good spirits most of ...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		08.Are you afraid that something bad..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		09.Do you feel happy most of the time	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		10.Do you often feel helpless	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		11.Do you often get restless and f.....	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		12.Do you prefer to stay at home	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		13.Do you frequently worry about the...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		14.Do you feel you have more problems.	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		15.Do you think it is wonderful to be..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		16.Do you often feel downhearted	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		17.Do you worry a lot about the past	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		18.Do you find life very exciting	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		19.Is it hard for you to get started...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		20.Do you feel full of energy	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		21.Do you feel that your situation ...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		22.Do you think that most people are...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		23.Do you frequently get upset over...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		24.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		25.Do you have trouble concentrating	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		26.Do you enjoy getting up in the mor..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		27.Do you prefer to avoid social gat..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		28.Is it easy for you to make decision	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		29.Is your mind as clear as it used ..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		30.Total score	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25

1761

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

178

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 45.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
291	40T	Imipramine	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22.Do you think that your situation ...	0	0	0	0	0	0	0	0	0	0
		23.Do you think that most people are...	0	0	0	0	0	0	0	0	0	0
		24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31.Total score	22	21	21	20	15	15	15	15	15	15
25DT	Imipramine	01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0
		02.Have you dropped many of your act	1	0	0	0	0	0	0	0	0	0
		03.Do you feel that your life is empty	0	0	0	0	0	0	0	0	0	0
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
		06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	0	0	0	0	0	0	0	0	0	0
		14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	0	0	0	0	0	0	0	0	0	0
		22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0
		23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	0	0	0	0	0	0	0	0	0	0
		28.Do you prefer to avoid social est..	0	0	0	0	0	0	0	0	0	0
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31.Total score	20	20	26	26	23	19	6	6	6	6
26DT	Reboxetine	01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0
		02.Have you dropped many of your act..	1	0	1	0	1	0	0	0	0	0
		03.Do you feel that your life is empty	0	0	0	0	0	0	0	0	0	0

1762

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

179

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	_Day0_		_Day7_		_Day14_		_Day21_		_Day28_		_Day35_		_Day42_		_Day49_		_Day56_		_Day63_	
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
291	260T	Reboxetine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel hopeless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the....	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		18.Do you cry a lot about the past	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social get..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		31.Total score	20	20	19	19	19	19	19	19	19	19	19	19	19	18	18	18	18	18	18	18
270T	Reboxetine	01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel hopeless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1763

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

180

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
251	27DT	Reboxetine	0	0	0	0	0	0	0	0	0	0
		22.Do you feel that your situation ...										
		23.Do you think that most people are..										
		24.Do you frequently get upset over...										
		25.Do you frequently feel like crying	1	0	1	0	1	0	0	0	0	0
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	0	0	0	0	0	0	0	0	0	0
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	19	19	18	18	16	13	13	12	12	12
		31.Total score										
252	28DT	Imipramine	1	1	1	0	0	0	0	0	0	0
		01.Are you () satisfied with your life										
		02.Have you dropped many of your act..	1	1	1	0	1	0	1	0	1	0
		03.Do you feel that your life is empty	1	0	0	0	0	0	0	0	0	0
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	0	0	0	0	0	0	0	0	0	0
		06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f....	0	0	0	0	0	0	0	0	0	0
		12.Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0
		19.Do you find life very exciting	1	1	1	0	0	0	0	1	1	1
		20.Is it hard for you to get started..	1	1	1	0	0	0	1	1	1	0
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	0	0	0	0	0	0	0
		23.Do you think that most people are..	0	0	0	0	0	0	0	0	0	0
		24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31.Total score	24	23	22	22	22	15	15	16	16	16
292	SMD	Imipramine	1	1	1	1	1	1	1	0	0	0
		01.Are you () satisfied with your life										
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	0	1	1	1	1	0	0	0	0	0
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	0	0	1	1	0	0	0

1764

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

181

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	_Day0_		_Day7_		_Day14_		_Day21_		_Day28_		_Day35_		_Day42_		_Day49_		_Day56_		_Day63_	
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
292	5HD Imipramine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1
	15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	22.Do you think that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1
	25.Do you frequently feel like crying	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	31.Total score	25	27	26	26	26	26	26	26	26	26	23	23	17	17	16	16	16	16	16	16
50F	Reboxetine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	22.Do you think that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1765

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

182

PIARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	_Day0_	_Day7_	_Day14_	_Day21_	_Day28_	_Day35_	_Day42_	_Day49_	_Day56_	_Day63_
			Y	N	Y	N	Y	N	Y	N	Y	N
292	5DT	Reboxetine	1	1	1	1	1	0	0	0	0	0
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	0	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social get..	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31.Total score	25	25	27	26	25	23	17	17	13	13
6ND		Reboxetine	1	1	1	1	0	0	0	0	0	0
		01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	0	0	0	0	0	0	0
		05.Are you hopeful about the future	0	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	0	1	1	1	1	1	1	1	1
		11.Do you often get restless and f.....	1	0	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	0	0	1	0	1	0	1
		15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	0	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ..	0	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	0	1	0	0	0	0	0	0	0
		23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	0	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	0	0	0	0	0
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social get..	1	1	1	1	0	0	0	0	0	0
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31.Total score	25	27	26	22	21	21	16	17	16	16
6DT		Imipramine	1	1	1	1	1	1	0	1	1	1
		01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	0	0	0	0	0	0	0	0	0
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ...	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	0	0	0	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1

1766

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

183

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	_Day0_		_Day7_		_Day14_		_Day21_		_Day28_		_Day35_		_Day42_		_Day49_		_Day56_		_Day63_		
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	
292 6DT Imipramine	10.Do you often feel helpless	1		1		1		1		1		1		1		1		1		1		
	11.Do you often get restless and f....	1		1		1		1		1		1		1		1		1		1		
	12.Do you prefer to stay at home, ...	1		1		1		1		1		1		1		1		1		1		
	13.Do you frequently worry about the..	1		1		1		1		1		1		1		1		1		1		
	14.Do you feel you have more problems.	0		0		0		0		0		0		0		0		0		0		
	15.Do you think it is wonderful to be.	1		1		1		1		1		1		1		1		1		1		
	16.Do you often feel downhearted	1		1		1		1		1		1		1		1		1		1		
	17.Do you feel pretty worthless the ..	1		1		1		1		1		1		1		1		1		1		
	18.Do you worry a lot about the past	1		1		1		1		1		1		1		1		1		1		
	19.Do you find life very exciting	1		1		1		1		1		1		1		1		1		1		
	20.Is it hard for you to get started..	1		1		1		1		1		1		1		1		1		1		
	21.Do you feel full of energy	1		1		1		1		1		1		1		1		1		1		
	22.Do you feel that your situation ...	1		1		1		1		1		1		1		1		1		1		
	23.Do you think that most people are..	1		1		1		1		1		1		1		1		1		1		
	24.Do you frequently get upset over...	1		1		1		1		1		1		1		1		1		1		
	25.Do you frequently feel like crying	1		1		1		1		1		1		1		1		1		1		
	26.Do you have trouble concentrating	1		1		1		1		1		1		1		1		1		1		
	27.Do you enjoy getting up in the mor.	1		1		1		1		1		1		1		1		1		1		
	28.Do you prefer to avoid social get..	1		1		1		1		1		1		1		1		1		1		
	29.Is it easy for you to make decision	1		1		1		1		1		1		1		1		1		1		
	30.Is your mind as clear as it used ..	1		1		1		1		1		1		1		1		1		1		
	31.Total score		28		27		27		27		22		23		18		18		13		13	
	7ND Reboxetine	01.Are you () satisfied with your life	1		1		1		1		1		1		1		1		1		1	
		02.Have you dropped many of your act..	1		1		1		1		1		1		1		1		1		1	
		03.Do you feel that your life is empty	1		1		1		1		1		1		1		1		1		1	
		04.Do you often get bored	1		1		1		1		1		1		1		1		1		1	
		05.Are you hopeful about the future	1		1		1		1		1		1		1		1		1		1	
		06.Are you bothered by thoughts you ..	1		1		1		1		1		1		1		1		1		1	
		07.Are you in good spirits most of ...	1		1		1		1		1		1		1		1		1		1	
		08.Are you afraid that something bad..	1		1		1		1		1		1		1		1		1		1	
		09.Do you feel happy most of the time	1		1		1		1		1		1		1		1		1		1	
10.Do you often feel helpless		1		1		1		1		1		1		1		1		1		1		
11.Do you often get restless and f....		1		1		1		1		1		1		1		1		1		1		
12.Do you prefer to stay at home, ...		1		1		1		1		1		1		1		1		1		1		
13.Do you frequently worry about the..		1		1		1		1		1		1		1		1		1		1		
14.Do you feel you have more problems.		0		0		0		0		0		0		0		0		0		0		
15.Do you think it is wonderful to be.		1		1		1		1		1		1		1		1		1		1		
16.Do you often feel downhearted		1		1		1		1		1		1		1		1		1		1		
17.Do you feel pretty worthless the ..		1		1		1		1		1		1		1		1		1		1		
18.Do you worry a lot about the past		1		1		1		1		1		1		1		1		1		1		
19.Do you find life very exciting		1		1		1		1		1		1		1		1		1		1		
20.Is it hard for you to get started..		1		1		1		1		1		1		1		1		1		1		
21.Do you feel full of energy		1		1		1		1		1		1		1		1		1		1		
22.Do you feel that your situation ...		1		1		1		1		1		1		1		1		1		1		
23.Do you think that most people are..		1		1		1		1		1		1		1		1		1		1		
24.Do you frequently get upset over...		1		1		1		1		1		1		1		1		1		1		
25.Do you frequently feel like crying		1		1		1		1		1		1		1		1		1		1		
26.Do you have trouble concentrating		1		1		1		1		1		1		1		1		1		1		
27.Do you enjoy getting up in the mor.		1		1		1		1		1		1		1		1		1		1		

1767

9550089

184

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
292	7ND Reboxetine	1	1	1	1	1	1	0	0	0	0
	28.Do you prefer to avoid social gat..	1	1	1	1	1	1	0	0	0	0
	29.Is it easy for you to make decision	1	1	1	1	1	1	0	0	0	0
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	0	1
	31.Total score	27	26	25	20	15	15	13	14	10	12
70I	Imipramine	1	1	1	1	0	0	0	0	0	0
	01.Are you () satisfied with your life	1	1	1	1	0	0	0	0	0	0
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits act y ..	1	1	1	1	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	0	0	0	0	0	0
	10.Do you often feel helpless	1	1	1	1	0	0	0	0	0	0
	11.Do you often get restless and f....	1	1	1	1	0	0	0	0	0	0
	12.Do you prefer to stay at home,	1	1	1	1	0	0	0	0	0	0
	13.Do you frequently worry about the..	1	1	1	1	0	0	0	0	0	0
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	0	0	0	0	0	0
	17.Do you feel pretty worthless the ..	1	1	1	1	0	0	0	0	0	0
	18.Do you worry a lot about the past	1	1	1	1	0	0	0	0	0	0
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	0	0	0	0	0	0
	23.Do you think that most people are..	1	1	1	1	0	0	0	0	0	0
	24.Do you frequently get upset over...	1	1	1	1	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	1	1	1	0	0	0	0	0	0
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat..	1	1	1	1	0	0	0	0	0	0
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
	31.Total score	26	23	20	16	14	16	16	15	14	14
8ND	Imipramine	1	1	1	1	1	1	1	0	0	0
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	0	0	0
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	0	0	0
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	0	0	0	0	0	0

1768

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

186

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		Day 63		
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y
292	8DT	Reboxetine	31.Total score	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21MD	Imipramine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			05.Are you hopeful about the future	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			12.Do you prefer to stay at home,.....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			13.Do you frequently worry about the..	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			15.Do you think it is wonderful to hb.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			16.Do you often feel dehearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			26.Do you have trouble concentrating	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			31.Total score	26	25	24	24	24	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21
	21DT	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			05.Are you hopeful about the future	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			08.Are you afraid that something bad..	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			15.Do you think it is wonderful to hb.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			16.Do you often feel dehearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			26.Do you have trouble concentrating	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			31.Total score	26	25	24	24	24	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21

1770

9550089

187

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
292	21DT	Reboxetine	1	0	1	1	0	0	0	0	0	0
		16.Do you often feel downhearted	1	0	1	1	0	0	0	0	0	0
		17.Do you feel pretty worthless the ..	1	0	0	0	0	0	0	0	0	0
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are..	1	0	1	0	0	0	0	0	0	0
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31.Total score	26	24	24	20	14	10	12	10	7	7
22ND		Imipramine	1	1	1	1	1	1	1	1	1	1
		01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	0	0	0	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	0	0	0	0	0	0	0	0	0
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	0	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	0	0	1	0	0	0	0	0	0
		15.Do you think it is wonderful to be..	1	0	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	0	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are...	1	0	1	0	0	0	0	0	0	0
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31.Total score	26	24	23	23	24	23	22	24	24	24

1771

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

188

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	_Day0_		_Day7_		_Day14_		_Day21_		_Day28_		_Day35_		_Day42_		_Day49_		_Day56_		_Day63_	
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
292	22DT Imipramine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	17.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	18.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	19.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social get...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	31.Total score	26	27	25	24	23	23	23	21	21	21	21	21	21	21	21	21	21	21	21	22
23MD	Reboxetine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	17.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	18.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1772

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

189

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 15.0
 GERIATRIC DEPRESSION SCALE

Centre	Patient	Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63	
				Y	N	Y	N	Y	N	Y	N	Y	N	
292	23MD	Reboxetine	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	
			20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1
			21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1
			22.Do you think that your situation ...	1	1	1	1	1	1	1	1	1	1	1
			23.Do you think that most people are..	0	1	0	0	0	0	0	0	0	0	0
			24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1
			25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1
			26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1
			27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1
			28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1
			29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1
30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1			
31.Total score	26	27	25	23	21	12	11	11	11	11	11	8		
230T	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	0	
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	0	
		03.Do you often get bored	1	1	0	0	0	0	1	0	0	0	0	
		04.Do you often get bored	1	1	0	0	0	0	1	0	0	0	0	
		05.Are you bothered by thoughts you ...	1	1	1	1	1	1	1	1	1	1	1	
		06.Are you hopefull about the future	1	1	1	1	1	1	1	1	1	1	1	
		07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0	0	
		08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0	0	
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	
		11.Do you often get restless and f.....	1	1	0	1	0	0	0	0	0	0	0	
12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1			
13.Do you frequently worry about the..	0	0	0	0	0	0	0	0	0	0	0			
14.Do you feel you have more problems,	1	1	1	1	1	1	1	1	1	1	1			
15.Do you think it is wonderful to be,	1	1	1	1	1	1	1	1	1	1	1			
16.Do you often feel downhearted	0	0	0	0	0	0	0	0	0	0	0			
17.Do you feel pretty worthless the ..	0	0	0	0	0	0	0	0	0	0	0			
18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0	0			
19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1			
20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1			
21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1			
22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1			
23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1	1			
24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1			
25.Do you frequently feel like crying	0	1	0	0	0	0	0	0	0	0	0			
26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1			
27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1			
28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1			
29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1			
30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1			
31.Total score	25	24	19	17	13	10	11	10	10	11	10	6		
24MD	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	0	
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	0	
		03.Do you often get bored	1	1	1	1	1	1	1	1	1	1	0	

1773

9550089

198

PARACETAMOL CHS RED
 REBOXITINE - PROTOCOL 20194/025
 Listing No.: 1510

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63							
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N				
292	24ND	Reboxitine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1				
			04.Do you often get bored	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
			05.Are you hopeful about the future	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			06.Are you in good spirits most of the time	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			07.Are you in good spirits most of the time	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			08.Are you afraid that something bad will happen	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			09.Do you often feel happy most of the time	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			10.Do you often feel helpless	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			11.Do you often feel lonely	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			12.Do you prefer to stay at home, rather than go out	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			13.Do you frequently worry about the future	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			14.Do you feel you have more problems than you can handle	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			15.Do you think it is wonderful to be able to do things you used to do	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			16.Do you feel that you are not as energetic as you used to be	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			17.Do you feel pretty worthless these days	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			18.Do you worry a lot about the past	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			19.Do you find life very exciting	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			20.Is it hard for you to get started on things you want to do	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			21.Do you find life very exciting	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			22.Do you feel that your situation is not what you want	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			23.Do you think that most people are better off than you are	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			24.Do you frequently get upset over things	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			25.Do you frequently get upset over things	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			26.Do you have trouble concentrating	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			27.Do you enjoy getting up in the morning	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			28.Do you prefer to avoid social gatherings	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			29.Is it easy for you to make decisions	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			30.Do you feel that you are not as clear as you used to be	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			31.Total score			25	25	24	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17		
			2407	Enipramine	Enipramine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
						04.Do you often get bored	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
						05.Are you hopeful about the future	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
						06.Are you in good spirits most of the time	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
						07.Are you in good spirits most of the time	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
08.Are you afraid that something bad will happen	1	0				1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
09.Do you often feel happy most of the time	1	0				1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
10.Do you often feel helpless	1	0				1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
11.Do you often feel lonely	1	0				1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
12.Do you prefer to stay at home, rather than go out	1	0				1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
13.Do you frequently worry about the future	1	0				1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
14.Do you feel you have more problems than you can handle	1	0				1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
15.Do you think it is wonderful to be able to do things you used to do	1	0				1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
16.Do you feel that you are not as energetic as you used to be	1	0				1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
17.Do you feel pretty worthless these days	1	0				1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
18.Do you worry a lot about the past	1	0				1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
19.Do you find life very exciting	1	0				1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
20.Is it hard for you to get started on things you want to do	1	0				1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
21.Do you feel that your situation is not what you want	1	0				1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
22.Do you think that most people are better off than you are	1	0				1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
23.Do you frequently get upset over things	1	0				1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
24.Do you frequently get upset over things	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0						
25.Do you have trouble concentrating	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0						
26.Do you enjoy getting up in the morning	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0						
27.Do you prefer to avoid social gatherings	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0						
28.Do you find life very exciting	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0						
29.Is it easy for you to make decisions	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0						
30.Do you feel that you are not as clear as you used to be	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0						
31.Total score			25	25	24	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17					

1774

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

191

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/035
 Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	_Day0_		_Day7_		_Day14_		_Day21_		_Day28_		_Day35_		_Day42_		_Day49_		_Day56_		_Day63_	
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
292	240T	Imipramine	1	0	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...																				
		23.Do you think that most people are..																				
		24.Do you frequently get upset over...																				
		25.Do you frequently feel like crying																				
		26.Do you have trouble concentrating																				
		27.Do you enjoy getting up in the mor.																				
		28.Do you prefer to avoid social get..																				
		29.Is it easy for you to make decision																				
		30.Is your mind as clear as it used ..																				
		31.Total score	26		24		24	24	24	24	25	25	26	26	22	22	18	18	18	18	18	18
293	9ND	Imipramine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		01.Are you () satisfied with your life																				
		02.Have you dropped many of your act..																				
		03.Do you feel that your life is empty																				
		04.Do you often get bored																				
		05.Are you bothered by thoughts you ..																				
		06.Are you in good spirits most of ...																				
		07.Are you afraid that something bad..																				
		08.Are you feel happy most of the time																				
		09.Do you often feel helpless																				
		10.Do you often get restless and f.....																				
		11.Do you prefer to stay at home,																				
		12.Do you frequently worry about the..																				
		13.Do you feel you have more problems.																				
		14.Do you think it is wonderful to be..																				
		15.Do you often feel downhearted																				
		16.Do you worry a lot about the past																				
		17.Do you find life very exciting																				
		18.Is it hard for you to get started..																				
		19.Do you feel full of energy																				
		20.Do you think that most people are...																				
		21.Do you frequently get upset over...																				
		22.Do you frequently feel like crying																				
		23.Do you have trouble concentrating																				
		24.Do you enjoy getting up in the m.																				
		25.Do you prefer to avoid social get...																				
		26.Is it easy for you to make decision																				
		27.Is your mind as clear as it used ..																				
		31.Total score	27		26		27	27	27	27	25	25	23	23	23	11	11	7	7	7	7	7
9DT	Imipramine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..																				
		03.Do you feel that your life is empty																				
		04.Do you often get bored																				
		05.Are you bothered by thoughts you ..																				

1775

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

192

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 45.0

GERIATRIC DEPRESSION SCALE

Centre	Patient	Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
				Y	N	Y	N	Y	N	Y	N	Y	N
293	9DT	Inipramine	07.Are you in good spirits most of ...	1	1	1	0	0	0	0	0	0	0
			08.Are you afraid that something bad..	1	1	1	1	0	0	0	0	0	0
			09.Do you feel happy most of the time	1	1	1	1	0	0	0	0	0	0
			10.Do you often feel helpless	1	1	1	1	0	0	0	0	0	0
			11.Do you often get restless and f....	1	1	1	1	0	0	0	0	0	0
			12.Do you prefer to stay at home, ...	1	1	1	1	0	0	0	0	0	0
			13.Do you frequently worry about the..	1	1	1	1	0	0	0	0	0	0
			14.Do you feel you have more problems.	1	1	1	1	0	0	0	0	0	0
			15.Do you think it is wonderful to be.	1	1	1	1	0	0	0	0	0	0
			16.Do you often feel downhearted	1	1	1	1	0	0	0	0	0	0
			17.Do you feel pretty worthless the ..	1	1	1	1	0	0	0	0	0	0
			18.Do you worry a lot about the past	1	1	1	1	0	0	0	0	0	0
			19.Do you find life very exciting	1	1	1	1	0	0	0	0	0	0
			20.Is it hard for you to get started..	1	1	1	1	0	0	0	0	0	0
			21.Do you feel full of energy	1	1	1	1	0	0	0	0	0	0
			22.Do you think that most people are...	1	1	1	1	0	0	0	0	0	0
			23.Do you frequently get upset over...	1	1	1	1	0	0	0	0	0	0
			24.Do you frequently feel like crying	1	1	1	1	0	0	0	0	0	0
			25.Do you have trouble concentrating	1	1	1	1	0	0	0	0	0	0
			26.Do you enjoy getting up in the mor.	1	1	1	1	0	0	0	0	0	0
			27.Do you prefer to avoid social get...	1	1	1	1	0	0	0	0	0	0
			28.Is it easy for you to make decision	1	1	1	1	0	0	0	0	0	0
			29.Is your mind as clear as it used ..	1	1	1	1	0	0	0	0	0	0
			31.Total score	26	26	24	12	6	4	2	3	3	3
10MD		Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	0	0
			02.Have you dropped many of your act..	1	1	1	1	1	1	1	0	0	0
			03.Do you feel that your life is empty	1	1	1	1	1	1	1	0	0	0
			04.Do you often get bored	1	1	1	1	1	1	1	0	0	0
			05.Are you hopeful about the future	1	1	1	1	0	0	0	0	0	0
			06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	0	0	0
			07.Are you in good spirits most of ...	1	1	1	1	1	1	1	0	0	0
			08.Are you afraid that something bad..	1	1	1	1	1	1	1	0	0	0
			09.Do you feel happy most of the time	1	1	1	1	1	1	1	0	0	0
			10.Do you often feel restless and f....	1	1	1	1	1	1	1	0	0	0
			11.Do you prefer to stay at home,	1	1	1	1	1	1	1	0	0	0
			12.Do you frequently worry about the..	1	1	1	1	1	1	1	0	0	0
			13.Do you feel you have more problems.	1	1	1	1	1	1	1	0	0	0
			14.Do you think it is wonderful to be.	1	1	1	1	1	1	1	0	0	0
			15.Do you often feel downhearted	1	1	1	1	1	1	1	0	0	0
			16.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	0	0	0
			17.Do you worry a lot about the past	1	1	1	1	1	1	1	0	0	0
			18.Do you find life very exciting	1	1	1	1	1	1	1	0	0	0
			20.Is it hard for you to get started..	1	1	1	1	1	1	1	0	0	0
			21.Do you feel full of energy	1	1	1	1	1	1	1	0	0	0
			22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0
			23.Do you think that most people are...	1	1	1	1	1	1	1	0	0	0
			24.Do you frequently get upset over...	1	1	1	1	1	1	1	0	0	0

1776

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

193

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63				
			Y	N	Y	N	Y	N	Y	N	Y	N				
293	10ND	Reboxetine	25. Do you frequently feel like crying	1	1	1	1	0	0	0	0	0	0			
			26. Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1		
			27. Do you enjoy getting up in the mor.	1	1	1	1	1	1	0	0	0	0	0		
			28. Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1		
			29. Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1		
			30. Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1		
			31. Total score	27	27	27	27	27	27	22	14	7	5			
			10DT	10DT	Imipramine	01. Are you () satisfied with your life	1	1	1	1	0	0	0	0	0	0
						02. Have you dropped many of your act..	1	1	1	1	0	0	0	0	0	0
						03. Do you feel that your life is empty	1	1	1	1	1	1	0	0	0	0
						04. Do you often get bored	1	1	1	1	1	1	0	0	0	0
						05. Are you hopeful about the future	1	1	1	1	1	1	1	0	0	0
						06. Are you bothered by thoughts you ..	1	1	1	1	1	1	1	0	0	0
07. Are you in good spirits most of ...	1	1				1	1	1	1	1	0	0	0			
08. Are you afraid that something bad..	0	0				0	0	0	0	0	0	0	0			
09. Do you feel happy most of the time	0	0				0	0	0	0	0	0	0	0			
10. Do you often feel helpless	1	1				1	1	1	1	0	0	0	0			
11. Do you often get restless and f....	1	1				1	1	1	1	0	0	0	0			
12. Do you prefer to stay at home,....	1	1				1	1	1	1	1	0	0	0			
13. Do you frequently worry about the..	1	1				1	1	1	1	1	0	0	0			
14. Do you feel you have more problems.	1	1	1	1	1	1	1	0	0	0						
15. Do you think it is wonderful to be..	1	1	1	1	0	0	0	0	0	0						
16. Do you worry a lot about the past ..	1	1	1	1	1	1	0	0	0	0						
17. Do you feel pretty worthless the ..	1	1	1	1	1	1	1	0	0	0						
18. Do you worry a lot about the past	1	1	1	1	1	1	1	0	0	0						
19. Do you find life very exciting	0	0	0	0	0	0	0	0	0	0						
20. Is it hard for you to get started..	1	1	1	1	1	1	1	0	0	0						
21. Do you feel full of energy	1	1	1	1	1	1	1	1	1	1						
22. Do you feel that your situation ...	1	1	1	1	1	1	1	0	0	0						
23. Do you think that most people are..	1	1	1	1	1	1	1	1	1	1						
24. Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1						
25. Do you frequently feel like crying	1	1	1	1	1	1	0	0	0	0						
26. Do you have trouble concentrating	0	0	0	0	0	0	0	0	0	0						
27. Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1						
28. Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1						
29. Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1						
30. Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1						
31. Total score	27	27	26	23	16	9	3	1								
11ND	11ND	Imipramine	01. Are you () satisfied with your life	1	1	1	1	0	0	0	0	0				
			02. Have you dropped many of your act	1	1	1	1	0	0	0	0	0				
			03. Do you feel that your life is empty	1	1	1	1	0	0	0	0	0				
			04. Do you often get bored	1	1	1	1	0	0	0	0	0				
			05. Are you hopeful about the future	1	1	1	1	1	1	1	0	0				
			06. Are you bothered by thoughts you ..	1	1	1	1	1	1	0	0	0				
			07. Are you in good spirits most of ...	1	1	1	1	0	0	0	0	0				
			08. Are you afraid that something bad..	1	1	1	1	0	0	0	0	0				
			09. Do you feel happy most of the time	1	1	1	1	1	1	1	1	1				

1777

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

194

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 45.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day 0		Day 7		Day 14		Day 21		Day 28		Day 35		Day 42		Day 49		Day 56		Day 63	
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
293	11HD	Imipramine	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
		10.Do you often feel helpless	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
		11.Do you often get restless and f....	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
		12.Do you prefer to stay at home, ...	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
		13.Do you frequently worry about the..	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
		14.Do you feel you have more problems.	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		31.Total score	27	27	27	27	25	25	21	21	14	14	8	8	4	4	2	2	0	0	0	2
11DT	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1778

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

195

PHARMACIA CNS R8D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
293	11DT Reboxetine	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
	31.Total score	26	24	22							
12HD	Reboxetine	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,....	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
	31.Total score	30	30	27	17	16	10	5			
12DI	Reboxetine	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ...	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1

1779

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

196

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient	Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
				Y	N	Y	N	Y	N	Y	N	Y	N
293	12DT	Reboxetine	13. Do you frequently worry about the...	0	0	0	0	0	0	0	0	0	0
			14. Do you feel you have more problems.	1	1	0	0	0	0	0	0	0	0
			15. Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	0	0
			16. Do you often feel downhearted	1	1	1	1	1	1	1	0	0	0
			17. Do you feel pretty worthless the ...	1	1	1	0	0	0	0	0	0	0
			18. Do you worry a lot about the past	1	1	1	1	1	1	1	0	0	0
			19. Do you find life very exciting	1	1	1	1	1	1	1	0	0	0
			20. Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
			21. Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
			22. Do you feel that your situation ...	1	1	1	1	1	0	0	0	0	0
			23. Do you think that most people are..	1	1	1	0	0	0	0	0	0	0
			24. Do you frequently get upset over...	1	1	1	0	0	0	0	0	0	0
			25. Do you frequently feel like crying	1	1	1	1	0	0	0	0	0	0
			26. Do you have trouble concentrating	1	1	1	1	0	0	0	0	0	0
			27. Do you enjoy getting up in the mor..	1	1	1	1	0	0	0	0	0	0
			28. Do you prefer to avoid social get..	1	1	1	1	1	1	1	0	0	0
			29. Is it easy for you to make decision	1	1	1	1	1	1	1	0	0	0
			30. Is your mind as clear as it used ..	1	1	1	1	1	1	0	1	0	1
			31. Total score	28	28	25	22	17	11	9	8	5	5
294	13MD	Imipramine	01. Are you () satisfied with your life	1	1	1	1	1	0	0	0	0	0
			02. Have you dropped many of your act..	1	1	1	1	1	0	0	0	0	0
			03. Do you feel that your life is empty	1	1	1	1	1	0	0	0	0	0
			04. Do you often get bored	1	1	1	1	1	0	0	0	0	0
			05. Are you bothered by thoughts you ..	1	1	1	1	0	1	0	0	0	0
			06. Are you in good spirits most of ...	1	1	0	0	1	1	0	0	0	0
			07. Are you afraid that something bad..	1	1	0	1	1	1	0	0	0	0
			08. Do you feel happy most of the time	1	1	1	1	1	1	1	0	0	0
			09. Do you often feel helpless	1	1	0	0	1	1	1	0	0	0
			10. Do you often get restless and f....	1	1	0	0	1	0	0	0	0	0
			11. Do you prefer to stay at home, ...	1	1	0	0	1	0	0	0	0	0
			12. Do you frequently worry about the..	0	0	1	1	0	0	0	0	0	0
			13. Do you feel you have more problems.	1	1	1	0	1	0	0	0	0	0
			14. Do you think it is wonderful to be.	1	1	1	0	1	1	0	0	0	0
			15. Do you often feel downhearted	1	1	1	1	1	1	0	0	0	0
			16. Do you feel pretty worthless the ...	1	1	1	0	1	1	0	0	0	0
			17. Do you worry a lot about the past	1	1	0	0	1	1	0	0	0	0
			18. Do you find life very exciting	0	0	0	0	1	1	0	0	0	0
			19. Do you feel full of energy	1	1	1	1	0	0	0	0	0	0
			20. Is it hard for you to get started..	1	1	1	1	1	0	0	0	0	0
			21. Do you feel that your situation ...	0	0	0	0	1	0	0	0	0	0
			22. Do you think that most people are..	0	0	1	1	0	0	0	0	0	0
			23. Do you frequently get upset over...	1	1	1	1	0	0	0	0	0	0
			24. Do you frequently feel like crying	0	1	1	1	0	0	0	0	0	0
			25. Do you have trouble concentrating	1	1	1	1	1	0	0	0	0	0
			26. Do you enjoy getting up in the mor..	1	1	0	0	0	0	0	0	0	0
			27. Do you prefer to avoid social get..	0	0	0	1	1	0	0	0	0	0
			28. Is it easy for you to make decision	1	1	1	1	1	1	0	0	0	0
			29. Is your mind as clear as it used ..	1	1	1	1	1	0	0	0	0	0
			30. Is your mind as clear as it used ..	1	1	1	1	1	0	0	0	0	0

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

197

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63	
		Y N	Y N	Y N	Y N	Y N	Y N	Y N	Y N	Y N	Y N	
294	13MB Imipramine	30	30	30	30	18	19	23	11	2	0	0
	31.Total score	1	1	1	1	1	1	1	1	1	1	1
13DT	Reboxetine	1	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad...	1	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the...	1	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1	1
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1
	23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	1
	25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1
	26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	1
	28.Do you prefer to avoid social get..	1	1	1	1	1	1	1	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1
	30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1
	31.Total score	30	30	30	30	18	30	30	30	30	30	30
14MD	Reboxetine	1	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1
	04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad...	1	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1
	11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1	1
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1
	13.Do you frequently worry about the...	1	1	1	1	1	1	1	1	1	1	1
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1
	15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1

1781

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

198

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
294	14MD	Reboxetine	0	1	1	1	1	0	0	0	0	0
		16.Do you often feel downhearted	0	1	1	1	1	0	0	0	0	0
		17.Do you feel pretty worthless the ..	0	1	0	1	1	0	0	0	0	0
		18.Do you worry a lot about the past	1	1	0	1	1	1	0	0	0	0
		19.Do you find life very exciting	0	1	1	0	1	0	0	0	0	0
		20.Is it hard for you to get started..	0	0	0	1	1	0	0	0	0	0
		21.Do you feel full of energy	0	0	0	1	0	0	0	0	0	0
		22.Do you feel that your situation ...	1	0	0	1	1	0	0	0	0	0
		23.Do you think that most people are..	1	0	1	1	1	0	0	0	0	0
		24.Do you frequently get upset over...	1	1	1	1	0	0	0	0	0	0
		25.Do you frequently feel like crying	1	1	1	1	0	0	0	0	0	0
		26.Do you have trouble concentrating	0	0	0	1	1	0	0	0	0	0
		27.Do you enjoy getting up in the mor.	0	0	0	1	1	0	0	0	0	0
		28.Do you prefer to avoid social gat..	1	1	1	1	1	0	0	0	0	0
		29.Is it easy for you to make decision	1	1	1	0	1	1	0	0	0	0
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	0	0	0	0
		31.Total score	23	23	23	22	25	9	0	0	0	0
14MD	Imipramine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	0	0
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	0	0
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	0	0
		04.Do you often get bored	1	1	1	1	1	1	1	1	0	0
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	0	0
		06.Are you bothered by thoughts you ...	1	1	1	1	1	1	1	1	0	0
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	0	0
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	0	0
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
		11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home, ...	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	0	0
		14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	0	0
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	0	0
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	0	0
		17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	0	0
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	0	0
		19.Do you find life very exciting	1	1	1	1	1	1	1	1	0	0
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	0	0
		21.Do you feel full of energy	1	1	1	1	1	1	1	1	0	0
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	0	0
		23.Do you think that most people are..	1	1	1	1	1	1	1	1	0	0
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	0	0
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	0	0
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	0	0
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	0	0
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	0	0
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	0	0
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	0	0
		31.Total score	30	30	30	30	30	30	30	15	9	9

1782

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

199

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
294 15HD Imipramine	01.Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0
	02.Have you dropped many of your act..	0	0	0	0	0	0	0	0	0	0
	03.Do you feel that your life is empty	0	0	0	0	0	0	0	0	0	0
	04.Do you often get bored	0	0	0	0	0	0	0	0	0	0
	05.Are you hopeful about the future	0	0	1	1	1	1	0	0	0	0
	06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	1	1	1	1	1	0	0	0	0
	08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	1	1	1	1	1	0	0	0	0
	10.Do you often feel helpless	0	0	0	0	0	0	0	0	0	0
	11.Do you often get restless and f....	0	0	0	0	0	0	0	0	0	0
	12.Do you prefer to stay at home,	0	0	0	0	0	0	0	0	0	0
	13.Do you frequently worry about the..	0	0	0	0	0	0	0	0	0	0
	14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0
	15.Do you think it is wonderful to be.	0	1	1	1	1	0	0	0	0	0
	16.Do you often feel dejected	1	1	1	1	1	0	0	0	0	0
	17.Do you feel pretty worthless the ...	1	0	0	0	0	0	0	0	0	0
	18.Do you worry a lot about the past	1	0	0	0	0	0	0	0	0	0
	19.Do you find life very exciting	0	1	1	1	1	0	0	0	0	0
	20.Is it hard for you to get started..	1	0	0	0	0	0	0	0	0	0
	21.Do you feel full of energy	1	0	0	0	0	0	0	0	0	0
	22.Do you feel that your situation ...	1	0	0	0	0	0	0	0	0	0
	23.Do you think that most people are...	1	0	0	0	0	0	0	0	0	0
	24.Do you frequently get upset over...	1	0	0	0	0	0	0	0	0	0
	25.Do you frequently feel like crying	1	1	1	1	1	0	0	0	0	0
	26.Do you have trouble concentrating	1	1	1	1	1	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	0	0	0	0	0
	28.Do you prefer to avoid social gat..	0	0	0	0	0	0	0	0	0	0
	29.Is it easy for you to make decision	1	0	0	0	0	0	0	0	0	0
	30.Is your mind as clear as it used ..	1	0	0	0	0	0	0	0	0	0
	31.Total score		14	8	8	10	12	0	0	0	0
15DI Imipramine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	0	0
	02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	0	0
	03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	0	0
	04.Do you often get bored	1	1	1	1	1	1	1	1	0	0
	05.Are you hopeful about the future	1	1	1	1	1	1	1	1	0	0
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	0	0
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	0	0
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	0	0
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	0	0
	10.Do you often feel helpless	1	1	1	1	1	1	1	1	0	0
	11.Do you often get restless and f....	1	1	1	1	1	1	1	1	0	0
	12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	0	0
	13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	0	0
	14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	0	0
	15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	0
	16.Do you often feel dejected	1	1	1	1	1	1	1	1	1	0
	17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	0
	18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	0

1783

9550089

200

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Centre	Patient	Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63	
				Y	N	Y	N	Y	N	Y	N	Y	N	
294	15DT	Imipramine	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	0	
			20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	0
			21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	0
			22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	0
			23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1	0
			24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1	0
			25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	0
			26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	0
			27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1	0
			28.Do you prefer to avoid social get..	1	1	1	1	1	1	1	1	1	1	0
			29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	0
30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	0			
			31.Total score	30	30	30	30	30	30	30	14	10	0	
16HD	Reboxetine		01.Are you () satisfied with your life	1	1	1	1	1	1	0	0	0	0	
			02.Have you dropped many of your act..	1	1	1	1	1	1	1	0	0	0	0
			03.Do you often get bored	1	1	1	1	1	1	1	0	0	0	0
			04.Do you often get bored	1	1	1	1	1	1	1	0	0	0	0
			05.Are you hopeful about the future	1	1	1	1	1	1	1	0	0	0	0
			06.Are you bothered by thoughts you ...	1	1	1	1	1	1	1	0	0	0	0
			07.Are you in good spirits most of ...	1	1	1	1	1	1	1	0	0	0	0
			08.Are you afraid that something bad..	1	1	1	1	1	1	1	0	0	0	0
			09.Do you feel happy most of the time	1	1	1	1	1	1	1	0	0	0	0
			10.Do you often feel helpless	1	1	1	1	1	1	1	0	0	0	0
			11.Do you often get restless and f....	1	1	1	1	1	1	1	0	0	0	0
12.Do you prefer to stay at home,	1	1	1	1	1	1	1	0	0	0	0			
13.Do you frequently worry about the..	1	1	1	1	1	1	1	0	0	0	0			
14.Do you feel you have more problems.	1	1	1	1	1	1	1	0	0	0	0			
15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	0	0	0	0			
16.Do you often feel downhearted	1	1	1	1	1	1	1	0	0	0	0			
17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	0	0	0	0			
18.Do you worry a lot about the past	1	1	1	1	1	1	1	0	0	0	0			
19.Do you find life very exciting	0	1	1	1	1	1	1	0	0	0	0			
20.Is it hard for you to get started..	0	1	1	1	1	1	1	0	0	0	0			
21.Do you feel full of energy	0	1	1	1	1	1	1	0	0	0	0			
22.Do you feel that your situation ...	1	1	1	1	1	1	1	0	0	0	0			
23.Do you think that most people are...	1	1	1	1	1	1	1	0	0	0	0			
24.Do you frequently get upset over...	1	1	1	1	1	1	1	0	0	0	0			
25.Do you frequently feel like crying	1	1	1	1	1	1	1	0	0	0	0			
26.Do you have trouble concentrating	1	1	1	1	1	1	1	0	0	0	0			
27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	0	0	0	0			
28.Do you prefer to avoid social get..	1	1	1	1	1	1	1	0	0	0	0			
29.Is it easy for you to make decision	1	1	1	1	1	1	1	0	0	0	0			
30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	0	0	0	0			
			31.Total score	28	30	30	30	15	1	0	0	0		
16DT	Reboxetine		01.Are you () satisfied with your life	1	1	1	1	1	1	0	0	0	0	
			02.Have you dropped many of your act..	1	1	1	1	1	1	1	0	0	0	
			03.Do you feel that your life is empty	1	1	1	1	1	1	1	0	0	0	

1784

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

201

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
294	16WT	Reboxetine	1	1	1	1	1	0	0	0	0	0
		04. Do you often get bored	1	1	1	1	1	0	0	0	0	0
		05. Are you bothered about the future	1	1	1	1	1	0	0	0	0	0
		06. Are you bothered by thoughts you ...	1	1	1	1	1	0	0	0	0	0
		07. Are you in good spirits most of ...	1	1	1	1	1	0	0	0	0	0
		08. Are you afraid that something bad..	1	1	1	1	1	1	1	0	0	0
		09. Do you feel happy most of the time	1	1	1	1	1	0	0	0	0	0
		10. Do you often feel helpless	1	1	1	1	1	1	1	0	0	0
		11. Do you often get restless and f....	1	1	1	1	1	1	1	0	0	0
		12. Do you prefer to stay at home,	1	1	1	1	1	0	0	0	0	0
		13. Do you frequently worry about the..	1	1	1	1	1	0	0	0	0	0
		14. Do you feel you have more problems.	1	1	1	1	1	0	0	0	0	0
		15. Do you think it is wonderful to be..	1	1	1	1	1	0	0	0	0	0
		16. Do you often feel downhearted	1	1	1	1	1	1	1	0	0	0
		17. Do you feel pretty worthless the ...	1	1	1	1	1	0	0	0	0	0
		18. Do you worry a lot about the past ..	1	1	1	1	1	0	0	0	0	0
		19. Do you find life very exciting	1	1	1	1	1	0	0	0	0	0
		20. Is it hard for you to get started..	1	1	1	1	1	0	0	0	0	0
		21. Do you feel full of energy	1	1	1	1	1	1	1	0	0	0
		22. Do you feel that your situation ...	1	1	1	1	1	1	1	0	0	0
		23. Do you think that most people are...	1	1	1	1	1	1	1	0	0	0
		24. Do you frequently get upset over...	1	1	1	1	1	0	0	0	0	0
		25. Do you frequently feel like crying	1	1	1	1	1	0	0	0	0	0
		26. Do you have trouble concentrating	1	1	1	1	1	0	0	0	0	0
		27. Do you enjoy getting up in the mor..	1	1	1	1	1	0	0	0	0	0
		28. Do you prefer to avoid social gat...	1	1	1	1	1	0	0	0	0	0
		29. Is it easy for you to make decision	1	1	1	1	1	0	0	0	0	0
		30. Is your mind as clear as it used ..	1	1	1	1	1	0	0	0	0	0
		31. Total score	30	30	30	30	30	8	8	0	0	0
25ND		Imipramine	1	1	1	1	0	0	0	0	0	0
		01. Are you () satisfied with your life	1	1	1	1	0	0	0	0	0	0
		02. Have you dropped many of your act..	1	1	1	1	0	0	0	0	0	0
		03. Do you feel that your life is empty	1	1	1	1	0	0	0	0	0	0
		04. Do you often get bored	1	1	1	1	0	0	0	0	0	0
		05. Are you hopeful about the future	1	1	1	1	1	0	0	0	0	0
		06. Are you bothered by thoughts you ...	1	1	1	1	1	0	0	0	0	0
		07. Are you in good spirits most of ...	1	1	1	1	1	0	0	0	0	0
		08. Are you afraid that something bad..	1	1	1	1	1	0	0	0	0	0
		09. Do you feel happy most of the time	1	1	1	1	1	0	0	0	0	0
		10. Do you often feel helpless	1	1	1	1	1	0	0	0	0	0
		11. Do you often get restless and f....	1	1	1	1	0	0	0	0	0	0
		12. Do you prefer to stay at home,	1	1	1	1	0	0	0	0	0	0
		13. Do you frequently worry about the..	1	1	1	1	0	0	0	0	0	0
		14. Do you feel you have more problems.	1	1	1	1	0	0	0	0	0	0
		15. Do you think it is wonderful to be..	1	1	1	1	0	0	0	0	0	0
		16. Do you often feel downhearted	1	1	1	1	0	0	0	0	0	0
		17. Do you feel pretty worthless the ...	1	1	1	1	0	0	0	0	0	0
		18. Do you worry a lot about the past ..	1	1	1	1	0	0	0	0	0	0
		19. Do you find life very exciting	1	1	1	1	0	0	0	0	0	0
		20. Is it hard for you to get started..	1	1	1	1	1	0	0	0	0	0
		21. Do you feel full of energy	1	1	1	1	1	0	0	0	0	0

1785

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

202

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63		
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y
294	25HD	Imipramine	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		22.Do you feel that your situation ...	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		23.Do you think that most people are...	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		24.Do you frequently get upset over...	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		25.Do you frequently feel like crying	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		26.Do you have trouble concentrating	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		29.Is it easy for you to make decision	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		30.Is your mind as clear as it used ..	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		31.Total score	30	30	30	22	11	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
26HD	Imipramine	01.Are you () satisfied with your life	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		02.Have you dropped many of your act..	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		03.Do you feel that your life is empty	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		04.Do you often get bored	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		05.Are you hopeful about the future	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		07.Are you in good spirits most of ...	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		08.Are you afraid that something bad..	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		09.Do you feel happy most of the time	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		10.Do you often feel helpless	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		11.Do you often get restless and f....	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		12.Do you prefer to stay at home, ...	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		13.Do you frequently worry about the..	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		14.Do you feel you have more problems.	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		15.Do you think it is wonderful to be..	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		16.Do you often feel downhearted	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		17.Do you feel pretty worthless the ..	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		19.Do you find life very exciting	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		20.Is it hard for you to get started..	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		21.Do you feel full of energy	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		22.Do you feel that your situation ...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		23.Do you think that most people are...	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		24.Do you frequently get upset over...	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		25.Do you frequently feel like crying	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		26.Do you have trouble concentrating	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		27.Do you enjoy getting up in the mor.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		29.Is it easy for you to make decision	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		30.Is your mind as clear as it used ..	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		31.Total score	25	27	27	21	15	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
27HD	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		02.Have you dropped many of your act..	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		03.Do you feel that your life is empty	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		04.Do you often get bored	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		05.Are you hopeful about the future	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

1786

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

203

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63		
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	
294 27HD Reboxetine	07. Are you in good spirits most of ...	1		1		1		1		1		1		0		0		0		0		
	08. Are you afraid that something bad...	1		1		1		1		1		1		0		0		0		0		
	09. Do you feel happy most of the time	1		1		1		1		1		1		0		0		0		0		
	10. Do you often feel helpless	1		1		1		1		1		1		0		0		0		0		
	11. Do you often get restless and f....	1		1		1		1		1		1		0		0		0		0		
	12. Do you prefer to stay at home, ...	1		1		1		1		1		1		0		0		0		0		
	13. Do you frequently worry about the..	1		1		1		1		1		1		0		0		0		0		
	14. Do you feel you have more problems.	1		1		1		1		1		1		0		0		0		0		
	15. Do you think it is wonderful to be.	1		1		1		1		1		1		0		0		0		0		
	16. Do you often feel downhearted	1		1		1		1		1		1		0		0		0		0		
	17. Do you feel pretty worthless the ...	1		1		1		1		1		1		0		0		0		0		
	18. Do you worry a lot about the past	1		1		1		1		1		1		0		0		0		0		
	19. Do you find life very exciting	1		1		1		1		1		1		0		0		0		0		
	20. Is it hard for you to get started...	1		1		1		1		1		1		0		0		0		0		
	21. Do you feel full of energy	1		1		1		1		1		1		0		0		0		0		
	22. Do you feel that your situation ...	1		1		1		1		1		1		0		0		0		0		
	23. Do you think that most people are...	1		1		1		1		1		1		0		0		0		0		
	24. Do you frequently get upset over...	1		1		1		1		1		1		0		0		0		0		
	25. Do you frequently feel like crying	1		1		1		1		1		1		0		0		0		0		
	26. Do you have trouble concentrating	1		1		1		1		1		1		0		0		0		0		
	27. Do you enjoy getting up in the mor.	1		1		1		1		1		1		0		0		0		0		
	28. Do you prefer to avoid social gat...	1		1		1		1		1		1		0		0		0		0		
	29. Is it easy for you to make decision	1		1		1		1		1		1		0		0		0		0		
	30. Is your mind as clear as it used ...	1		1		1		1		1		1		0		0		0		0		
	31. Total score			30		27		24		20		16		0		0		0		0		0
	22HD Reboxetine	01. Are you () satisfied with your life	1		1		1		1		1		1		0		0		0		0	
		02. Have you dropped many of your act...	1		1		1		1		1		1		0		0		0		0	
		03. Do you feel that your life is empty	1		1		1		1		1		1		0		0		0		0	
		04. Do you often get bored	1		1		1		1		1		1		0		0		0		0	
		05. Are you hopeful about the future	1		1		1		1		1		1		0		0		0		0	
		06. Are you bothered by thoughts you ..	1		1		1		1		1		1		0		0		0		0	
07. Are you in good spirits most of ...		1		1		1		1		1		1		0		0		0		0		
08. Are you afraid that something bad...		1		1		1		1		1		1		0		0		0		0		
09. Do you feel happy most of the time		1		1		1		1		1		1		0		0		0		0		
10. Do you often feel helpless		1		1		1		1		1		1		0		0		0		0		
11. Do you often get restless and f....		1		1		1		1		1		1		0		0		0		0		
12. Do you prefer to stay at home, ...		1		1		1		1		1		1		0		0		0		0		
13. Do you frequently worry about the..		1		1		1		1		1		1		0		0		0		0		
14. Do you feel you have more problems.		1		1		1		1		1		1		0		0		0		0		
15. Do you think it is wonderful to be.		1		1		1		1		1		1		0		0		0		0		
16. Do you often feel downhearted		1		1		1		1		1		1		0		0		0		0		
17. Do you feel pretty worthless the ...		1		1		1		1		1		1		0		0		0		0		
18. Do you worry a lot about the past		1		1		1		1		1		1		0		0		0		0		
19. Do you find life very exciting		0		1		1		1		1		1		0		0		0		0		
20. Is it hard for you to get started...		1		1		1		1		1		1		0		0		0		0		
21. Do you feel full of energy		1		1		1		1		1		1		0		0		0		0		
22. Do you feel that your situation ...		1		1		1		1		1		1		0		0		0		0		
23. Do you think that most people are...		1		1		1		1		1		1		0		0		0		0		
24. Do you frequently get upset over...		1		1		1		1		1		1		0		0		0		0		

1787

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

205

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
294	30DT Reboxetine	1	1	1	1	1	0	0	0	0	0
	10.Do you often feel helpless	1	1	1	1	1	0	0	0	0	0
	11.Do you often get restless and f....	1	1	1	1	1	0	0	0	0	0
	12.Do you prefer to stay at home, ...	1	1	1	1	1	0	0	0	0	0
	13.Do you frequently worry about the..	1	1	1	1	1	0	1	0	0	0
	14.Do you feel you have more problems.	1	1	1	1	1	0	0	0	0	0
	15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ..	1	1	1	1	1	1	0	1	1	1
	18.Do you worry a lot about the past	1	1	1	1	1	1	0	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	0	1	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	1	0	0	0	0	0
	23.Do you think that most people are..	1	1	1	1	1	0	0	0	0	0
	24.Do you frequently get upset over...	1	1	1	1	1	0	0	0	0	0
	25.Do you frequently feel like crying	1	1	1	1	1	0	0	0	0	0
	26.Do you have trouble concentrating	1	1	1	1	1	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	0	0	0	0	0
	28.Do you prefer to avoid social get..	1	1	1	1	1	0	1	1	1	1
	29.Is it easy for you to make decision	1	1	1	1	1	0	1	0	0	0
	30.Is your mind as clear as it used ..	1	1	1	1	1	0	1	0	0	0
	31.Total score	30	30	30	30	30	14	14	14	14	14
30DT	Inipramine	1	1	1	1	1	1	0	0	0	0
	01.Are you () satisfied with your life	1	1	1	1	1	1	0	0	0	0
	02.Have you dropped many of your act..	1	1	1	1	1	1	0	0	0	0
	03.Do you feel that your life is empty	1	1	1	1	1	1	0	0	0	0
	04.Do you often get bored	1	1	1	1	1	1	0	0	0	0
	05.Are you hopeful about the future	1	1	1	1	1	1	0	1	1	1
	06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
	07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
	08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
	09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
	10.Do you often feel helpless	1	1	1	1	1	0	0	0	0	0
	11.Do you often get restless and f....	1	1	1	1	1	0	0	0	0	0
	12.Do you prefer to stay at home,	1	1	1	1	1	0	0	0	0	0
	13.Do you frequently worry about the..	1	1	1	1	1	0	0	0	0	0
	14.Do you feel you have more problems.	1	1	1	1	1	0	0	0	0	0
	15.Do you think it is wonderful to be.	1	1	1	1	1	0	1	0	0	0
	16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
	17.Do you feel pretty worthless the ..	1	1	1	1	1	1	0	1	1	1
	18.Do you worry a lot about the past	1	1	1	1	1	1	0	1	1	1
	19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
	20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
	21.Do you feel full of energy	1	1	1	1	1	0	0	0	0	0
	22.Do you feel that your situation ...	1	1	1	1	1	0	0	0	0	0
	23.Do you think that most people are..	1	1	1	1	1	0	0	0	0	0
	24.Do you frequently get upset over...	1	1	1	1	1	0	0	0	0	0
	25.Do you frequently feel like crying	1	1	1	1	1	0	0	0	0	0
	26.Do you have trouble concentrating	1	1	1	1	1	0	0	0	0	0
	27.Do you enjoy getting up in the mor.	1	1	1	1	1	0	0	0	0	0

1789

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

206

PHARMACIA CNS RRD
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
294	31DT	Imipramine	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat...										
		29.Is it easy for you to make decision										
		30.Is your mind as clear as it used ..										
		31.Total score	30	30	30	30	30	14	14	14	0	15
32DT	Imipramine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	0	0
		02.Have you dropped many of your act..										
		03.Do you feel that your life is empty										
		04.Do you often get bored										
		05.Are you hopeful about the future										
		06.Are you bothered by thoughts you ..										
		07.Are you in good spirits most of ...										
		08.Are you afraid that something bad..										
		09.Do you feel happy most of the time										
		10.Do you often feel helpless										
		11.Do you often get restless and f.....										
		12.Do you prefer to stay at home,										
		13.Do you frequently worry about the...										
		14.Do you feel you have some problems.										
		15.Do you think it is wonderful to be.										
		16.Do you often feel dazed/dazed.....										
		17.Do you feel pretty worthless the ..										
		18.Do you carry a lot about the past										
		19.Do you find life very exciting										
		20.Is it hard for you to get started..										
		21.Do you feel full of energy										
		22.Do you feel that your situation ...										
		23.Do you think that most people are..										
		24.Do you frequently get upset over...										
		25.Do you frequently feel like crying										
		26.Do you have trouble concentrating										
		27.Do you enjoy getting up in the mor..										
		28.Do you prefer to avoid social gat...										
		29.Is it easy for you to make decision										
		30.Is your mind as clear as it used ..										
		31.Total score	30	30	30	30	30	30	14	10	0	0
295	17ND	Reboxetine	1	1	1	1	1	1	1	1	1	1
		01.Are you () satisfied with your life										
		02.Have you dropped many of your act..										
		03.Do you feel that your life is empty										
		04.Do you often get bored										
		05.Are you hopeful about the future										
		06.Are you bothered by thoughts you ..										
		07.Are you in good spirits most of ...										
		08.Are you afraid that something bad..										
		09.Do you feel happy most of the time										
		10.Do you often feel helpless										
		11.Do you often get restless and f.....										
		12.Do you prefer to stay at home,										

1790

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

207

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient	Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63	
				Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
295	17ND	Reboxetine	13. Do you frequently worry about the..	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			14. Do you feel you have more problems.	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			15. Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			16. Do you often feel downhearted	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			17. Do you feel pretty worthless the ..	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			18. Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			19. Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			20. Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			21. Do you feel full of energy	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			22. Do you feel that your situation ...	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			23. Do you think that most people are..	1	1	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			24. Do you frequently get upset over...	1	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			25. Do you frequently feel like crying	1	1	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			26. Do you have trouble concentrating	1	1	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			27. Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			28. Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			29. Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			30. Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			31..Total score	25	20	22	18	14	15	7	8	1	5	1	1	1	1	1	1	1	1	1	1
17DT		Imipramine	01. Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			02. Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			03. Do you feel that your life is empty	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			04. Do you often get bored	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			05. Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			06. Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			07. Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			08. Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			09. Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			10. Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			11. Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			12. Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			13. Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			14. Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			15. Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			16. Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			17. Do you feel pretty worthless the ..	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			18. Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			19. Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			20. Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			21. Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			22. Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			23. Do you think that most people are..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			24. Do you frequently get upset over...	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			25. Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			26. Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			27. Do you enjoy getting up in the mor..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			28. Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			29. Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			30. Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
			31..Total score	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1791

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

208

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient	Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
295	17DT	Imipramine	31.Total score	Y	N	Y	N	Y	N	Y	N	Y	N
			01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
			02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
			03.Do you feel that your life is empty	0	0	0	0	0	0	0	0	0	0
			04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
			05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
			06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0
			07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
			08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0
			09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
			10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
			11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1
			12.Do you prefer to stay at home,....	1	1	1	1	1	1	1	1	1	1
			13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
			14.Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0
			15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
			16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
			17.Do you feel pretty worthless the	1	1	1	1	1	1	1	1	1	1
			18.Do you worry a lot about the past	0	0	0	0	0	0	0	0	0	0
			19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
			20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
			21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
			22.Do you think that your situation ...	0	0	0	0	0	0	0	0	0	0
			23.Do you think that most people are...	1	1	1	1	1	1	1	1	1	1
			24.Do you frequently get upset over...	0	0	0	0	0	0	0	0	0	0
			25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
			26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
			27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
			28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
			29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
			30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
			31.Total score	22	23	22	23	27	29	30	27	28	28
			01.Are you () satisfied with your life	1	1	1	1	1	1	0	0	0	0
			02.Have you dropped many of your act..	1	1	1	1	1	1	0	0	0	0
			03.Do you feel that your life is empty	1	1	1	1	1	0	0	0	0	0
			04.Do you often get bored	1	1	1	1	1	0	0	0	0	0
			05.Are you hopeful about the future	1	0	1	1	1	0	0	0	1	1
			06.Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0
			07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
			08.Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0
			09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
			10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
			11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1
			12.Do you prefer to stay at home,....	1	1	1	1	1	1	1	1	1	1
			13.Do you frequently worry about the..	0	0	1	1	1	1	1	0	1	0
			14.Do you feel you have more problems.	0	1	0	1	0	0	0	0	0	0
			15.Do you think it is wonderful to be.	1	0	1	1	1	1	1	1	1	0

1792

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

209

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63	
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
295	180T Imipramine	1	0	0	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0
	16.Do you often feel downhearted																				
	17.Do you feel pretty worthless the ..																				
	18.Do you worry a lot about the past																				
	19.Do you find life very exciting																				
	20.Is it hard for you to get started..																				
	21.Do you feel full of energy																				
	22.Do you feel that your situation ...																				
	23.Do you think that most people are...																				
	24.Do you frequently get upset over...																				
	25.Do you frequently feel like crying																				
	26.Do you have trouble concentrating																				
	27.Do you enjoy setting up in the mor.																				
	28.Do you prefer to avoid social gat...																				
	29.Is it easy for you to make decision																				
	30.Is your mind as clear as it used ..																				
	31.Total score	24	17	23	23	23	23	23	22	22	19	15	15	14	14	12					
19MD	Imipramine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life																				
	02.Have you dropped many of your act..																				
	03.Do you feel that your life is empty																				
	04.Do you often get bored																				
	05.Are you hopeful about the future																				
	06.Are you bothered by thoughts you ..																				
	07.Are you in good spirits most of ...																				
	08.Are you afraid that something bad..																				
	09.Do you feel happy most of the time																				
	10.Do you often feel helpless																				
	11.Do you often get restless and f....																				
	12.Do you prefer to stay at home, ...																				
	13.Do you frequently worry about the..																				
	14.Do you feel you have more problems.																				
	15.Do you think it is wonderful to be.																				
	16.Do you often feel downhearted																				
	17.Do you feel pretty worthless the ..																				
	18.Do you worry a lot about the past																				
	19.Do you find life very exciting																				
	20.Is it hard for you to get started..																				
	21.Do you feel full of energy																				
	22.Do you feel that your situation ...																				
	23.Do you think that most people are...																				
	24.Do you frequently get upset over...																				
	25.Do you frequently feel like crying																				
	26.Do you have trouble concentrating																				
	27.Do you enjoy setting up in the mor.																				
	28.Do you prefer to avoid social gat...																				
	29.Is it easy for you to make decision																				
	30.Is your mind as clear as it used ..																				
	31.Total score	29	30	30	30	30	30	30	25	25	25	24	24	24	24	26					

1793

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

210

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient	Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63		
				Y	N	Y	N	Y	N	Y	N	Y	N		
295	19DT	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1		
			02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	
			03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	
			04.Do you often get bored	1	1	1	1	0	1	1	1	1	1	0	1
			05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	1
			06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1	1	1
			07.Are you in good spirits most of ...	1	1	0	0	1	1	1	1	1	1	1	0
			08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	1
			09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1
			10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	1
			11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	1
			12.Do you prefer to stay at home,	1	1	1	1	0	1	1	1	1	1	1	0
			13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1	1	1
			14.Do you feel you have more problems.	1	1	0	0	1	1	1	1	1	1	1	0
			15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1	1	1
			16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	1
			17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1	1	1
			18.Do you worry a lot about the past ..	1	1	0	0	1	1	1	1	1	1	1	0
			19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1	1	1
			20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1	1	1
			21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1	1	1
			22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1	1	1
			23.Do you think that most people are...	1	0	1	1	1	1	1	1	1	1	1	1
			24.Do you frequently get upset over...	1	1	0	1	1	1	1	1	1	1	1	1
			25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1	1	1
			26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1	1	1
			27.Do you enjoy getting up in the mor..	0	0	1	1	1	1	1	1	1	1	1	1
			28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	0	1	1	1
			29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1	1	1
			30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1	1	1
			31.Total score			28	25	27	27	26	25	23	27	29	25
20ND		Imipramine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1		
			02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1	1	
			03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1	
			04.Do you often get bored	1	1	1	1	1	1	1	1	1	1	1	
			05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1	1	
			06.Are you bothered by thoughts you ...	1	1	1	1	1	1	1	1	1	1	1	
			07.Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0	0	
			08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1	1	
			09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	
			10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1	1	
			11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1	1	
			12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1	1	
			13.Do you frequently worry about the..	0	1	1	1	1	1	1	1	1	1	1	
			14.Do you feel you have more problems.	1	1	1	1	1	1	1	1	1	1	1	
			15.Do you think it is wonderful to be..	1	1	1	1	1	1	1	1	1	1	1	
			16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1	1	
			17.Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1	1	
			18.Do you worry a lot about the past ..	1	1	1	1	1	1	1	1	1	1	1	

1794

9550089

212

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63				
			Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	
361	1ND	04. Do you often get bored	1	1	1	1	0	0	1	1	1	1	0	1	0	0	0	1	0	0	0	0	0		
		05. Are you hopeful about the future	1	1	1	1	0	0	1	1	1	1	0	1	0	0	0	0	0	0	0	0	0		
		06. Are you bothered by thoughts you ...	1	1	1	1	0	0	1	1	1	1	0	1	0	0	0	0	0	0	0	0	0		
		07. Are you in good spirits most of ...	1	1	1	1	1	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		08. Are you afraid that something bad ...	1	1	1	1	1	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		09. Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	
		10. Do you often feel helpless	1	1	1	1	1	1	0	1	1	1	1	0	1	0	0	0	0	0	0	0	0	0	
		11. Do you often get restless and f....	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		12. Do you prefer to stay at home, ...	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		13. Do you frequently worry about the..	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		14. Do you feel you have more problems.	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		15. Do you think it is wonderful to be.	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		16. Do you often feel downhearted	1	1	1	1	1	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		17. Do you worry a lot about the past	1	1	1	1	1	1	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	
		18. Do you find life very exciting	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		19. Do you find it hard for you to get started..	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		20. Is it hard for you to get started..	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		21. Do you feel full of energy	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		22. Do you feel that your situation ...	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		23. Do you think that most people are...	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		24. Do you frequently get upset over...	1	1	1	1	1	1	0	1	1	1	1	0	1	0	0	0	0	0	0	0	0	0	
		25. Do you frequently feel like crying	1	1	1	1	1	1	0	1	1	1	1	0	1	0	0	0	0	0	0	0	0	0	
		26. Do you have trouble concentrating	1	1	1	1	1	1	0	1	1	1	1	0	1	0	0	0	0	0	0	0	0	0	
		27. Do you enjoy getting up in the mor.	1	1	1	1	1	1	0	1	1	1	1	0	1	0	0	0	0	0	0	0	0	0	
		28. Do you prefer to avoid social get...	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		29. Is it easy for you to make decision	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		30. Is your mind as clear as it used ..	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		31. Total score			27	23	19	14	14	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	
		2ND	Reboxetine	01. Are you () satisfied with your life	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				02. Have you dropped many of your act..	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				03. Do you feel that your life is empty	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
04. Do you often get bored	1			1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
05. Are you hopeful about the future	1			1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
06. Are you bothered by thoughts you ...	1			1	1	1	1	1	0	1	1	1	1	0	1	0	0	0	0	0	0	0	0		
07. Are you in good spirits most of ...	1			1	1	1	1	1	0	1	1	1	1	0	1	0	0	0	0	0	0	0	0		
08. Are you afraid that something bad...	1			1	1	1	1	1	0	1	1	1	1	0	1	0	0	0	0	0	0	0	0		
09. Do you feel happy most of the time	1			1	1	1	1	1	0	1	1	1	1	0	1	0	0	0	0	0	0	0	0		
10. Do you often feel helpless	1			1	1	1	1	1	0	1	1	1	1	0	1	0	0	0	0	0	0	0	0		
11. Do you often get restless and f....	1			1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
12. Do you prefer to stay at home, ...	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
13. Do you frequently worry about the..	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
14. Do you feel you have more problems.	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
15. Do you think it is wonderful to be.	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
16. Do you often feel downhearted	1	1	1	1	1	1	0	1	1	1	1	0	1	0	0	0	0	0	0	0	0				
17. Do you worry a lot about the past	1	1	1	1	1	1	0	1	1	1	1	0	1	0	0	0	0	0	0	0	0				
18. Do you find life very exciting	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
19. Do you find it hard for you to get started..	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
20. Is it hard for you to get started..	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
21. Do you feel full of energy	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				

1796

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

213

PHARMACIA CMS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
381	2MD Reboxetine	1	0	1	0	1	0	1	0	1	0
	22. Do you feel that your situation ...										
	23. Do you think that most people are...										
	24. Do you frequently get upset over...										
	25. Do you frequently feel like crying										
	26. Do you have trouble concentrating										
	27. Do you enjoy getting up in the mor.										
	28. Do you prefer to avoid social gat..										
	29. Is it easy for you to make decision										
	30. Is your mind as clear as it used ..										
	31. Total score	0	24	0	15	20	11	0	11	0	18
381	3DT Reboxetine	1	1	1	1	1	1	1	1	1	1
	01. Are you () satisfied with your life										
	02. Have you dropped many of your act..										
	03. Do you feel that your life is empty										
	04. Do you often get bored										
	05. Are you bothered by thoughts you ..										
	06. Are you in good spirits most of ...										
	07. Are you afraid that something bad..										
	08. Do you feel happy most of the time										
	09. Do you often feel helpless										
	10. Do you often get restless and f....										
	11. Do you prefer to stay at home, ...										
	12. Do you frequently worry about the..										
	13. Do you feel you have more problems.										
	14. Do you think it is wonderful to be.										
	15. Do you often feel downhearted										
	16. Do you feel pretty worthless the ..										
	17. Do you worry a lot about the past										
	18. Do you find life very exciting										
	19. Is it hard for you to get started..										
	20. Do you feel full of energy										
	21. Do you think that your situation ...										
	22. Do you think that most people are...										
	23. Do you frequently get upset over...										
	24. Do you frequently feel like crying										
	25. Do you have trouble concentrating										
	26. Do you enjoy getting up in the m.										
	27. Do you prefer to avoid social get...										
	28. Is it easy for you to make decision										
	29. Is your mind as clear as it used ..										
	31. Total score	23	0	15	20	11	0	29	0	23	23
4MD	Imipramine	1	0	0	0	0	0	0	0	0	0
	01. Are you () satisfied with your life										
	02. Have you dropped many of your act..										
	03. Do you feel that your life is empty										
	04. Do you often get bored										
	05. Are you hopeful about the future										
	06. Are you bothered by thoughts you ..										

1797

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

214

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63						
			Y	N	Y	N	Y	N	Y	N	Y	N						
351	4ND	Imipramine	07.Are you in good spirits most of ...										1	1	0			
			08.Are you afraid that something bad..										0	0	0			
			09.Do you feel happy most of the time										1	1	1			
			10.Do you often feel helpless										1	0	0			
			11.Do you often get restless and f....										1	0	1			
			12.Do you prefer to stay at home,										1	1	0			
			13.Do you frequently worry about the..										0	0	0			
			14.Do you feel you have more problems.										0	1	1			
			15.Do you think it is wonderful to be.										1	1	1			
			16.Do you often feel downhearted										1	0	0			
			17.Do you feel pretty worthless the ..										1	0	0			
			18.Do you worry a lot about the past										1	1	0			
			19.Do you find life very exciting										0	1	1			
			20.Is it hard for you to get started..										1	1	1			
			21.Do you feel full of energy										0	1	1			
			22.Do you feel that your situation ...										0	1	1			
			23.Do you think that most people are...										1	1	1			
			24.Do you frequently get upset over...										1	1	1			
			25.Do you frequently feel like crying										1	0	1			
			26.Do you have trouble concentrating										1	1	0			
			27.Do you enjoy getting up in the m...										1	0	0			
			28.Do you prefer to avoid social get...										0	0	0			
			29.Is it easy for you to make decision										1	0	0			
			30.Is your mind as clear as it used ..										0	1	0			
			31.Total score										0	19	21			
													14					
			352	5ND	Imipramine	01.Are you () satisfied with your life										1	1	1
						02.Have you dropped many of your act..										1	1	1
						03.Do you feel that your life is empty										1	1	1
						04.Do you often get bored										1	1	1
						05.Are you hopeful about the future										1	1	1
06.Are you bothered by thoughts you ..										1	1	1						
07.Are you in good spirits most of ...										1	1	1						
08.Are you afraid that something bad..										1	1	1						
09.Do you feel happy most of the time										1	1	1						
10.Do you often feel helpless										1	1	1						
11.Do you often get restless and f....										1	1	1						
12.Do you prefer to stay at home,										1	1	1						
13.Do you frequently worry about the..										1	1	1						
14.Do you feel you have more problems.										0	1	1						
15.Do you think it is wonderful to be.										1	1	1						
16.Do you often feel downhearted										1	1	1						
17.Do you feel pretty worthless the ...										1	1	1						
18.Do you worry a lot about the past										1	1	1						
19.Do you find life very exciting										1	1	1						
20.Is it hard for you to get started..										1	1	1						
21.Do you feel full of energy										1	1	1						
22.Do you feel that your situation ...										1	1	1						
23.Do you think that most people are...										1	1	1						
24.Do you frequently get upset over...										1	1	1						

1798

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

215

PHARMACIA CNS RD

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
382	5HD	Imipramine	1	1	1	1	0	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	1	0	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	0
		28.Do you prefer to avoid social gat..	1	1	1	1	1	0	0	0	0	1
		29.Is it easy for you to make decision	1	1	1	1	0	1	0	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	0	0	1	0	1
		31.Total score	28	30	30	19	20	21	13	21	14	14
5DT	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	0	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	0	1	1	1	1	1	1	1
		05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ..	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	0	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
		10.Do you often feel helpless	1	1	0	1	1	1	1	1	1	1
		11.Do you often get restless and f.....	1	1	1	1	1	1	1	1	1	1
		12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
		13.Do you frequently worry about the..	1	1	0	1	1	1	1	1	1	1
		14.Do you feel you have more problems.	1	1	0	1	1	1	1	1	1	1
		15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
		16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
		17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
		18.Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
		19.Do you find life very exciting	1	1	0	1	1	1	1	1	1	1
		20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
		21.Do you feel full of energy	1	1	0	1	1	1	1	1	1	1
		22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
		23.Do you think that most people are..	1	1	1	1	1	1	1	1	1	1
		24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
		25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
		26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
		27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
		28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
		29.Is it easy for you to make decision	1	1	1	1	1	1	1	1	1	1
		30.Is your mind as clear as it used ..	1	1	1	1	1	1	1	1	1	1
		31.Total score	27	27	24	24	24	24	24	24	24	24
6HD	Reboxetine	01.Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
		02.Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1
		03.Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
		04.Do you often get bored	1	1	1	1	1	1	1	1	1	1
		05.Are you hopeful about the future	0	1	1	1	1	1	1	1	1	1
		06.Are you bothered by thoughts you ...	1	1	1	1	1	1	1	1	1	1
		07.Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
		08.Are you afraid that something bad..	1	1	1	1	1	1	1	1	1	1
		09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	0

1769

PHARMACIA CNS RED
 REMOXYNE - PROTOMOL 20124/035
 Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
	Y	N	Y	N	Y	N	Y	N	Y	N
382 600 Reboxetine	1	1	1	1	1	1	1	1	1	1
10 Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
11 Do you often get restless and f...	1	1	1	1	1	1	1	1	1	1
12 Do you prefer to stay at home...	1	1	1	1	1	1	1	1	1	1
13 Do you frequently worry about th...	0	0	1	1	1	1	1	1	1	1
14 Do you feel you have more probl...	1	0	1	1	1	1	1	1	1	1
15 Do you think you would prefer to b...	1	1	1	1	1	1	1	1	1	1
16 Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
17 Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1
18 Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
19 Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
20 Do you feel that you've just started...	1	1	1	1	1	1	1	1	1	1
21 Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
22 Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
23 Do you think that most people are...	1	0	1	1	1	1	1	1	1	1
24 Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
25 Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
26 Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
27 Do you enjoy getting up in the mor...	1	0	1	1	1	1	1	1	1	1
28 Do you prefer to avoid social get...	1	1	1	1	1	1	1	1	1	1
29 Do you find it hard for you to make decision	1	1	1	1	1	1	1	1	1	1
30 Do you find it hard for you to make decision	1	1	1	1	1	1	1	1	1	1
31 Total score	27	25	29	30	26	20	23	23	20	20
600 Imipramin	1	1	1	1	1	1	1	1	1	1
01 Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1
02 Have you dropped many of your act...	1	1	1	1	1	1	1	1	1	1
03 Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1
04 Do you often get bored	1	1	1	1	1	1	1	1	1	1
05 Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
06 Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
07 Are you in good spirits most of ...	1	1	1	1	1	1	1	1	1	1
08 Are you afraid that something bad...	1	0	0	0	1	0	0	0	0	0
09 Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
10 Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
11 Do you often feel downhearted f...	1	1	1	1	1	1	1	1	1	1
12 Do you prefer to stay at home...	1	1	1	1	1	1	1	1	1	1
13 Do you frequently worry about th...	1	1	1	1	1	1	1	1	1	1
14 Do you feel you have more probl...	1	1	1	1	1	1	1	1	1	1
15 Do you think you would prefer to b...	1	1	1	1	1	1	1	1	1	1
16 Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
17 Do you feel pretty worthless the ...	1	1	1	1	1	1	1	1	1	1
18 Do you worry a lot about the past	1	1	1	1	1	1	1	1	1	1
19 Do you find life very exciting	0	1	1	1	1	1	1	1	1	1
20 Do you feel that you've just started...	0	1	1	1	1	1	1	1	1	1
21 Do you feel full of energy	0	1	1	1	1	1	1	1	1	1
22 Do you feel that your situation ...	0	1	1	1	1	1	1	1	1	1
23 Do you think that most people are...	0	1	1	1	1	1	1	1	1	1
24 Do you frequently get upset over...	0	1	1	1	1	1	1	1	1	1
25 Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
26 Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
27 Do you enjoy getting up in the mor...	1	1	1	1	1	1	1	1	1	1

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

217

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
382	Imipramine	28. Do you prefer to avoid social gat..	1	0	0	0	0	0	0	0	0	0
		29. Is it easy for you to make decision	0	1	0	1	1	0	1	1	0	0
		30. Is your mind as clear as it used ..	1	1	1	1	1	1	0	1	1	0
		31. Total score	22	23	19	21	12	14	13	13	13	7
7HD	Reboxetine	01. Are you () satisfied with your life	1	1	1	1	0	0	0	0	0	0
		02. Have you dropped many of your act..	1	1	1	1	1	1	0	0	0	0
		03. Do you feel that your life is empty	0	1	1	1	1	1	0	0	0	0
		04. Do you often get bored	1	1	0	1	0	1	0	1	0	0
		05. Are you hopeful about the future	1	1	0	1	1	0	0	0	0	0
		06. Are you bothered by thoughts you ..	1	1	0	1	0	1	0	0	0	1
		07. Are you in good spirits most of ...	1	1	1	1	1	1	1	0	0	0
		08. Are you afraid that something bad..	1	0	0	0	0	0	0	0	0	0
		09. Do you feel happy most of the time	1	1	0	0	1	1	0	0	0	0
		10. Do you often feel helpless	1	1	1	0	1	1	0	1	0	0
		11. Do you often get restless and f.....	0	1	0	0	0	0	0	0	0	0
		12. Do you prefer to stay at home, ...	0	0	0	1	0	0	0	0	0	0
		13. Do you frequently worry about the...	1	0	0	1	0	0	0	0	0	0
		14. Do you feel you have more problems.	1	0	0	1	0	0	0	0	0	1
		15. Do you think it is wonderful to be.	0	0	0	0	0	0	0	0	0	0
		16. Do you often feel downhearted.....	1	1	0	0	1	1	1	1	0	0
		17. Do you feel pretty worthless the ..	1	1	0	1	1	1	1	0	0	0
		18. Do you carry a lot about the past	1	1	1	1	1	1	0	1	0	0
		19. Do you find life very exciting	0	1	1	0	1	0	0	1	0	0
		20. Is it hard for you to get started..	0	0	0	1	1	1	1	0	0	0
		21. Do you feel full of energy	1	1	1	1	1	1	1	1	0	1
		22. Do you feel that your situation ...	1	1	1	1	1	1	1	0	0	0
		23. Do you think that most people are...	1	0	0	0	0	0	0	0	0	0
		24. Do you frequently get upset over...	1	0	1	0	0	0	0	0	0	0
		25. Do you frequently feel like crying	1	1	0	1	0	0	1	0	1	1
		26. Do you have trouble concentrating	0	0	1	0	1	0	0	0	0	0
		27. Do you enjoy getting up in the mor.	1	1	0	1	0	0	0	0	0	0
		28. Do you prefer to avoid social gat..	1	1	0	1	1	0	0	0	0	0
		29. Is it easy for you to make decision	1	1	1	1	1	1	0	0	0	0
		30. Is your mind as clear as it used ..	1	1	1	1	0	0	0	0	0	0
		31. Total score	23	21	15	18	12	8	4	4	4	4
7DT	Imipramine	01. Are you () satisfied with your life	1									
		02. Have you dropped many of your act..	1									
		03. Do you feel that your life is empty	1									
		04. Do you often get bored	1									
		05. Are you hopeful about the future	1									
		06. Are you bothered by thoughts you ..	0									
		07. Are you in good spirits most of ...	1									
		08. Are you afraid that something bad..	0									
		09. Do you feel happy most of the time	1									
		10. Do you often feel helpless	1									
		11. Do you often get restless and f.....	0									
		12. Do you prefer to stay at home,	1									

1801

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

218

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
			Y	N	Y	N	Y	N	Y	N	Y	N
382	7BT	Imipramine	1	0	1	0	1	0	1	0	1	0
		13.Do you frequently worry about the...	1	0	1	0	1	0	1	0	1	0
		14.Do you feel you have more problems.	1	0	1	0	1	0	1	0	1	0
		15.Do you think it is wonderful to be.	0	1	0	1	0	1	0	1	0	1
		16.Do you often feel downhearted	1	0	1	0	1	0	1	0	1	0
		17.Do you feel pretty worthless the ..	1	0	1	0	1	0	1	0	1	0
		18.Do you worry a lot about the past	0	1	0	1	0	1	0	1	0	1
		19.Do you find life very exciting	1	0	1	0	1	0	1	0	1	0
		20.Is it hard for you to get started..	0	1	0	1	0	1	0	1	0	1
		21.Do you feel full of energy	1	0	1	0	1	0	1	0	1	0
		22.Do you feel that your situation ...	1	0	1	0	1	0	1	0	1	0
		23.Do you think that most people are...	1	0	1	0	1	0	1	0	1	0
		24.Do you frequently get upset over...	1	0	1	0	1	0	1	0	1	0
		25.Do you frequently feel like crying	1	0	1	0	1	0	1	0	1	0
		26.Do you have trouble concentrating	1	0	1	0	1	0	1	0	1	0
		27.Do you enjoy getting up in the mor.	1	0	1	0	1	0	1	0	1	0
		28.Do you prefer to avoid social get...	0	1	0	1	0	1	0	1	0	1
		29.Is it easy for you to make decision	0	1	0	1	0	1	0	1	0	1
		30.Is your mind as clear as it used ..	1	0	1	0	1	0	1	0	1	0
		31.Total score	20									
8ND		Imipramine	0	1	0	1	0	1	0	1	0	1
		01.Are you () satisfied with your life	0	1	0	1	0	1	0	1	0	1
		02.Have you dropped many of your act...	0	1	0	1	0	1	0	1	0	1
		03.Do you feel that your life is empty	0	1	0	1	0	1	0	1	0	1
		04.Do you often get bored	0	1	0	1	0	1	0	1	0	1
		05.Are you hopeful about the future	0	1	0	1	0	1	0	1	0	1
		06.Are you bothered by thoughts you ..	0	1	0	1	0	1	0	1	0	1
		07.Are you in good spirits most of ...	0	1	0	1	0	1	0	1	0	1
		08.Are you afraid that something bad..	0	1	0	1	0	1	0	1	0	1
		09.Do you feel happy most of the time	1	0	1	0	1	0	1	0	1	0
		10.Do you often feel helpless	1	0	1	0	1	0	1	0	1	0
		11.Do you often get restless and f....	1	0	1	0	1	0	1	0	1	0
		12.Do you prefer to stay at home,	1	0	1	0	1	0	1	0	1	0
		13.Do you frequently worry about the..	1	0	1	0	1	0	1	0	1	0
		14.Do you feel you have more problems.	1	0	1	0	1	0	1	0	1	0
		15.Do you think it is wonderful to be.	0	1	0	1	0	1	0	1	0	1
		16.Do you often feel downhearted	0	1	0	1	0	1	0	1	0	1
		17.Do you feel pretty worthless the ..	0	1	0	1	0	1	0	1	0	1
		18.Do you worry a lot about the past	0	1	0	1	0	1	0	1	0	1
		19.Do you find life very exciting	1	0	1	0	1	0	1	0	1	0
		20.Is it hard for you to get started...	0	1	0	1	0	1	0	1	0	1
		21.Do you feel full of energy	1	0	1	0	1	0	1	0	1	0
		22.Do you feel that your situation ...	1	0	1	0	1	0	1	0	1	0
		23.Do you think that most people are...	1	0	1	0	1	0	1	0	1	0
		24.Do you frequently get upset over...	1	0	1	0	1	0	1	0	1	0
		25.Do you frequently feel like crying	1	0	1	0	1	0	1	0	1	0
		26.Do you have trouble concentrating	1	0	1	0	1	0	1	0	1	0
		27.Do you enjoy getting up in the mor.	1	0	1	0	1	0	1	0	1	0
		28.Do you prefer to avoid social gat...	1	0	1	0	1	0	1	0	1	0
		29.Is it easy for you to make decision	1	0	1	0	1	0	1	0	1	0
		30.Is your mind as clear as it used ..	0	1	0	1	0	1	0	1	0	1

18002

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

219

PEARMACTA CNS RED

REBOXETINE - PROTODOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
382	8ND Inipramine	14	24	26							
	31.Total score										
8DT	Reboxetine	1	0	1	1	0	0	1	1	0	0
	01.Are you () satisfied with your life	1	0	1	1	0	0	1	1	0	0
	02.Have you dropped many of your act..	1	1	1	1	0	0	0	0	0	0
	03.Do you feel that your life is empty	1	1	1	1	0	0	0	0	0	0
	04.Do you often get bored	0	1	1	1	0	0	0	1	0	0
	05.Are you hopeful about the future	1	0	1	0	0	1	0	1	1	0
	06.Are you bothered by thoughts you ..	1	0	1	0	0	1	0	1	1	0
	07.Are you in good spirits most of ...	1	1	1	1	0	0	0	1	1	0
	08.Are you afraid that something bad..	1	1	1	1	0	0	0	1	1	0
	09.Do you feel happy most of the time	1	1	1	1	0	0	0	1	1	1
	10.Do you often feel helpless	1	1	1	1	0	0	0	1	1	1
	11.Do you often get restless and f.....	1	1	1	1	0	0	0	1	1	0
	12.Do you prefer to stay at home,....	1	1	1	1	0	0	0	1	0	0
	13.Do you frequently worry about the..	1	1	1	1	0	0	0	1	0	0
	14.Do you feel you have more problems.	1	1	1	1	0	0	0	1	0	0
	15.Do you think it is wonderful to be.	1	1	1	1	0	0	0	1	0	0
	16.Do you often feel downhearted	1	1	1	1	0	0	0	1	0	0
	17.Do you feel pretty worthless the ...	1	1	1	1	0	0	0	1	0	0
	18.Do you worry a lot about the past ...	1	1	1	1	0	0	0	1	0	0
	19.Do you find life very exciting	0	1	1	1	0	0	0	1	0	0
	20.Is it hard for you to get started..	1	1	1	1	0	0	0	1	1	1
	21.Do you feel full of energy	1	1	1	1	0	0	0	1	1	1
	22.Do you feel that your situation ...	1	1	1	1	0	0	0	1	1	1
	23.Do you think that most people are...	1	1	1	1	0	0	0	1	1	1
	24.Do you frequently get upset over...	1	1	1	1	0	0	0	1	1	0
	25.Do you frequently feel like crying	1	1	1	1	0	0	0	1	1	1
	26.Do you have trouble concentrating	1	1	1	1	0	0	0	1	1	0
	27.Do you enjoy getting up in the mor.	1	1	1	1	0	0	0	1	1	0
	28.Do you prefer to avoid social gat..	1	1	1	1	0	0	0	1	1	0
	29.Is it easy for you to make decision	1	1	1	1	0	0	0	1	1	0
	30.Is your mind as clear as it used ..	1	1	1	1	0	0	0	1	1	0
	31.Total score	24	21	19	19	8	7	6	25	8	8
9ND	Reboxetine	1	1	1	1	0	0	0	0	0	0
	01.Are you () satisfied with your life	1	1	1	1	0	0	0	0	0	0
	02.Have you dropped many of your act..	1	1	1	1	0	0	0	0	0	0
	03.Do you feel that your life is empty	1	1	1	1	0	0	0	0	0	0
	04.Do you often get bored	1	1	1	1	0	0	1	0	0	0
	05.Are you hopeful about the future	1	0	0	1	0	0	0	0	0	0
	06.Are you bothered by thoughts you ..	1	0	0	1	0	0	0	0	0	0
	07.Are you in good spirits most of ...	1	0	0	1	0	0	0	0	0	0
	08.Are you afraid that something bad..	1	0	0	1	0	0	0	0	0	0
	09.Do you feel happy most of the time	1	0	0	1	0	0	0	0	0	0
	10.Do you often feel helpless	1	0	0	1	0	0	0	0	0	0
	11.Do you often get restless and f.....	1	0	0	1	0	0	0	0	0	0
	12.Do you prefer to stay at home,....	0	1	1	0	0	0	0	0	0	0
	13.Do you frequently worry about the..	0	1	0	0	1	0	0	0	0	0
	14.Do you feel you have more problems.	0	1	0	0	0	1	0	0	0	0
	15.Do you think it is wonderful to be.	1	0	0	0	0	0	0	0	0	0

1803

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

220

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient	Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
				Y	N	Y	N	Y	N	Y	N	Y	N
382	9WD	Reboxetine	16.Do you often feel downhearted	1	1	0	0	0	0	0	0	0	0
			17.Do you feel pretty worthless the ..	1	0	1	0	0	0	0	0	0	0
			18.Do you worry a lot about the past	1	0	1	0	0	0	0	0	0	0
			19.Do you find life very exciting	1	0	0	1	0	0	1	0	0	0
			20.Is it hard for you to get started..	1	1	0	1	1	0	0	0	0	0
			21.Do you feel full of energy	0	0	0	1	0	0	0	0	0	0
			22.Do you feel that your situation ...	1	0	0	0	0	0	0	0	0	0
			23.Do you think that most people are..	1	0	0	0	0	0	0	0	0	0
			24.Do you frequently get upset over...	1	0	1	1	1	0	0	1	0	0
			25.Do you frequently feel like crying	1	0	0	0	0	0	0	0	0	0
			26.Do you have trouble concentrating	1	0	0	0	0	0	0	0	0	0
			27.Do you enjoy getting up in the mor.	1	1	0	0	0	0	0	0	0	0
			28.Do you prefer to avoid social gat..	0	1	0	0	0	0	0	0	0	0
			29.Is it easy for you to make decision	0	1	1	0	0	0	0	0	0	0
			30.Is your mind as clear as it used ..	1	0	10	9	3	1	0	0	0	1
			31.Total score	24	8	10	9	3	1	4	2	0	1
9DT		Reboxetine	01.Are you () satisfied with your life	1	1	0	1	1	1	1	1	1	1
			02.Have you dropped many of your act..	1	1	0	1	1	1	1	1	1	1
			03.Do you feel that your life is empty	1	1	0	1	1	1	1	1	1	1
			04.Do you often get bored	1	1	0	1	1	1	1	1	1	1
			05.Are you hopeful about the future	1	1	1	1	1	1	1	1	1	1
			06.Are you bothered by thoughts you ..	1	1	0	1	1	1	1	1	1	1
			07.Are you in good spirits most of ...	1	1	0	1	1	1	1	1	1	1
			08.Are you afraid that something bad..	1	1	0	1	1	1	1	1	1	1
			09.Do you feel happy most of the time	1	1	1	1	1	1	1	1	1	1
			10.Do you often feel helpless	1	1	1	1	1	1	1	1	1	1
			11.Do you often get restless and f....	1	1	1	1	1	1	1	1	1	1
			12.Do you prefer to stay at home,	1	1	0	1	0	1	0	1	0	0
			13.Do you frequently worry about the..	1	1	1	1	1	1	1	1	1	1
			14.Do you feel you have more problems.	0	0	0	1	1	0	1	0	1	1
			15.Do you think it is wonderful to be.	1	1	1	1	1	1	1	1	1	1
			16.Do you often feel downhearted	1	1	1	1	1	1	1	1	1	1
			17.Do you feel pretty worthless the ..	1	1	1	1	1	1	1	1	1	1
			18.Do you worry a lot about the past	1	1	0	1	1	0	1	1	1	1
			19.Do you find life very exciting	1	1	1	1	1	1	1	1	1	1
			20.Is it hard for you to get started..	1	1	1	1	1	1	1	1	1	1
			21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
			22.Do you feel that your situation ...	1	1	1	1	1	1	1	1	1	1
			23.Do you think that most people are..	1	1	0	1	1	0	1	0	1	0
			24.Do you frequently get upset over...	1	1	1	1	1	1	1	1	1	1
			25.Do you frequently feel like crying	1	1	1	1	1	1	1	1	1	1
			26.Do you have trouble concentrating	1	1	1	1	1	1	1	1	1	1
			27.Do you enjoy getting up in the mor.	1	1	0	0	0	0	0	0	0	0
			28.Do you prefer to avoid social gat..	0	0	0	0	0	0	0	0	0	0
			29.Is it easy for you to make decision	1	1	0	0	0	0	0	0	0	0
			30.Is your mind as clear as it used ..	1	1	0	0	0	0	0	0	0	0
			31.Total score	26	28	12	24	8	23	23	23	23	23

1804

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

221

PHARMACIA CNS R&D

REBOZETINE - PRODUKOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0		Day7		Day14		Day21		Day28		Day35		Day42		Day49		Day56		Day63	
		Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N
392	10ND Imipramine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life																				
	02.Have you dropped many of your act..																				
	03.Do you feel that your life is empty																				
	04.Do you often get bored																				
	05.Are you hopeful about the future																				
	06.Are you bothered by thoughts you ..																				
	07.Are you in good spirits most of ...																				
	08.Are you afraid that something bad..																				
	09.Do you feel happy most of the time																				
	10.Do you often feel helpless																				
	11.Do you often get restless and f.....																				
	12.Do you prefer to stay at home,....																				
	13.Do you frequently worry about the..																				
	14.Do you think it is wonderful to be..																				
	15.Do you often feel downhearted																				
	16.Do you worry a lot about the past																				
	17.Do you find life very exciting																				
	18.Do you feel full of energy																				
	19.Do you feel that your situation ...																				
	20.Do you think that most people are..																				
	21.Do you frequently get upset over...																				
	22.Do you frequently feel like crying																				
	23.Do you have trouble concentrating																				
	24.Do you enjoy getting up in the mor..																				
	25.Do you prefer to avoid social get..																				
	26.Is it easy for you to make decision																				
	27.Is your mind as clear as it used ..																				
	31.Total score	23	26																		
3301	1ND Rebozetine	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	01.Are you () satisfied with your life																				
	02.Have you dropped many of your act..																				
	03.Do you feel that your life is empty																				
	04.Do you often get bored																				
	05.Are you hopeful about the future																				
	06.Are you bothered by thoughts you ..																				
	07.Are you in good spirits most of ...																				
	08.Are you afraid that something bad..																				
	09.Do you feel happy most of the time																				
	10.Do you often feel helpless																				
	11.Do you often get restless and f.....																				
	12.Do you prefer to stay at home,....																				
	13.Do you frequently worry about the..																				
	14.Do you think it is wonderful to be..																				
	15.Do you often feel downhearted to be..																				
	16.Do you worry a lot about the past																				
	17.Do you find life very exciting																				
	18.Do you feel full of energy																				
	19.Do you feel that your situation ...																				
	20.Do you think that most people are..																				
	21.Do you frequently get upset over...																				
	22.Do you frequently feel like crying																				
	23.Do you have trouble concentrating																				
	24.Do you enjoy getting up in the mor..																				
	25.Do you prefer to avoid social get..																				
	26.Is it easy for you to make decision																				
	27.Is your mind as clear as it used ..																				

1805

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

222

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient	Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63				
				Y	N	Y	N	Y	N	Y	N	Y	N				
3301	4ND	Reboxetine	19. Do you find life very exciting	1													
			20. Is it hard for you to get started..	0													
			21. Do you feel full of energy	1													
			22. Do you think that your situation ...	0													
			23. Do you think that most people are..	1													
			24. Do you frequently get upset over...	1													
			25. Do you frequently feel like crying	1													
			26. Do you have trouble concentrating	1													
			27. Do you enjoy getting up in the mor.	0													
			28. Do you prefer to avoid social gat..	0													
			29. Is it easy for you to make decision	1													
			30. Is your mind as clear as it used ..	1													
			31. Total score			17											
			2ND	4ND	Inipramine	01. Are you () satisfied with your life	1	1	1	1	1	1	1	1	1	1	
						02. Have you dropped many of your act.	1	1	1	1	1	1	1	1	1	1	1
						03. Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1	1
						04. Do you often get bored	1	1	1	1	1	1	1	1	1	1	1
05. Are you hopeful about the future	1	1				1	1	1	1	1	1	1	1	1	1		
06. Are you bothered by thoughts you ..	1	1				1	1	1	1	1	1	1	1	1	1		
07. Are you in good spirits most of ...	1	1				1	1	1	1	1	1	1	1	1	1		
08. Are you afraid that something bad..	1	1				1	1	1	1	1	1	1	1	1	1		
09. Do you feel happy most of the time	1	1				1	1	1	1	1	1	1	1	1	1		
10. Do you often feel helpless	1	1				1	1	1	1	1	1	1	1	1	1		
11. Do you often get restless and f....	1	1				1	1	1	1	1	1	1	1	1	1		
12. Do you prefer to stay at home, ...	1	1				1	1	1	1	1	1	1	1	1	1		
13. Do you frequently worry about the..	1	1				1	1	1	1	1	1	1	1	1	1		
14. Do you feel you have more problems.	0	0				0	0	0	0	0	0	0	0	0	0		
15. Do you think it is wonderful to be..	1	1				1	1	1	1	1	1	1	1	1	1		
16. Do you often feel downhearted	1	1				1	1	1	1	1	1	1	1	1	1		
17. Do you feel pretty worthless the ...	1	1				1	1	1	1	1	1	1	1	1	1		
18. Do you worry a lot about the past	0	0				0	0	0	0	0	0	0	0	0	0		
19. Do you find life very exciting	1	1				1	1	1	1	1	1	1	1	1	1		
20. Is it hard for you to get started..	1	1				1	1	1	1	1	1	1	1	1	1		
21. Do you feel full of energy	1	1				1	1	1	1	1	1	1	1	1	1		
22. Do you feel that your situation ...	1	1				1	1	1	1	1	1	1	1	1	1		
23. Do you think that most people are..	1	1				1	1	1	1	1	1	1	1	1	1		
24. Do you frequently get upset over...	1	1				1	1	1	1	1	1	1	1	1	1		
25. Do you frequently feel like crying	0	0				0	0	0	0	0	0	0	0	0	0		
26. Do you have trouble concentrating	1	1				1	1	1	1	1	1	1	1	1	1		
27. Do you enjoy getting up in the mor.	1	1				1	1	1	1	1	1	1	1	1	1		
28. Do you prefer to avoid social gat..	1	1				1	1	1	1	1	1	1	1	1	1		
29. Is it easy for you to make decision	1	1				1	1	1	1	1	1	1	1	1	1		
30. Is your mind as clear as it used ..	1	1				1	1	1	1	1	1	1	1	1	1		
31. Total score						27	24	25	21	21	21	13	10	10	10	10	
3ND	4ND	Reboxetine	01. Are you () satisfied with your life	1	0	1	1	1	1	1	1	1	1				
			02. Have you dropped many of your act..	1	1	1	1	1	1	1	1	1	1				
			03. Do you feel that your life is empty	1	1	1	1	1	1	1	1	1	1				

1806

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

223

PHARMACIA CNS R&D

REBOXETINE - PROTUCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
3301 3MD Reboxetine	04. Do you often get bored	0	1	1	1	1					
	05. Are you hopeful about the future	0	0	1	0	1					
	06. Are you bothered by thoughts you ..	1	1	1	1	1					
	07. Are you in good spirits most of ...	1	1	1	1	1					
	08. Are you afraid that something bad..	1	1	1	1	1					
	09. Do you feel happy most of the time	1	1	1	1	1					
	10. Do you often feel helpless	1	1	1	1	1					
	11. Do you often get restless and f....	1	1	1	1	1					
	12. Do you prefer to stay at home,	1	0	1	0	1					
	13. Do you frequently worry about the..	1	1	1	1	1					
	14. Do you feel you have more problems.	1	1	1	1	1					
	15. Do you think it is wonderful to be..	1	1	1	1	1					
	16. Do you often feel downhearted	1	1	1	1	1					
	17. Do you feel pretty worthless the ..	0	1	1	0	1					
	18. Do you worry a lot about the past	1	1	1	1	1					
	19. Do you find life very exciting	1	1	1	1	1					
	20. Is it hard for you to get started...	0	1	1	1	1					
	21. Do you feel full of energy	1	1	1	1	1					
	22. Do you feel that your situation ...	1	1	1	1	1					
	23. Do you think that most people are...	1	1	1	1	1					
	24. Do you frequently get upset over...	1	1	1	1	1					
	25. Do you frequently feel like crying	1	0	1	1	1					
	26. Do you have trouble concentrating	1	0	1	1	1					
	27. Do you enjoy getting up in the mor.	1	1	1	1	1					
	28. Do you prefer to avoid social get...	0	0	0	0	0					
	29. Is it easy for you to make decision	1	0	0	0	0					
	30. Is your mind as clear as it used ..	1	1	1	1	1					
	31. Total score	21	22	26	24	24					29
3302 5MD Reboxetine	01. Are you () satisfied with your life	1	1	1	1	1					
	02. Have you dropped many of your act..	1	1	1	1	1					
	03. Do you feel that your life is empty	1	1	1	1	1					
	04. Do you often get bored	1	1	1	1	1					
	05. Are you hopeful about the future	1	1	1	1	1					
	06. Are you bothered by thoughts you ..	0	0	0	0	0					
	07. Are you in good spirits most of ...	1	1	1	1	1					
	08. Are you afraid that something bad..	1	1	1	1	1					
	09. Do you feel happy most of the time	1	1	1	1	1					
	10. Do you often feel helpless	1	1	1	1	1					
	11. Do you often get restless and f....	1	1	1	1	1					
	12. Do you prefer to stay at home,	1	0	1	0	1					
	13. Do you frequently worry about the..	1	1	1	1	1					
	14. Do you feel you have more problems.	1	1	1	1	1					
	15. Do you think it is wonderful to be..	1	1	1	1	1					
	16. Do you often feel downhearted	1	1	1	1	1					
	17. Do you feel pretty worthless the ...	1	1	1	1	1					
	18. Do you worry a lot about the past	1	1	1	1	1					
	19. Do you find life very exciting	1	1	1	1	1					
	20. Is it hard for you to get started...	1	1	1	1	1					
	21. Do you feel full of energy	1	1	1	1	1					

1807

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

224

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre Patient Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
		Y	N	Y	N	Y	N	Y	N	Y	N
3302 5ND	Reboxetine	1	0	1	0	1	0	1	0	1	0
	22. Do you feel that your situation ...	1	0	1	0	1	0	1	0	1	0
	23. Do you think that most people are ...	1	0	1	0	1	0	1	0	1	0
	24. Do you frequently get upset over ...	1	0	1	0	1	0	1	0	1	0
	25. Do you frequently feel like crying	1	0	1	0	1	0	1	0	1	0
	26. Do you have trouble concentrating	1	0	1	0	1	0	1	0	1	0
	27. Do you enjoy getting up in the mor.	1	0	1	0	1	0	1	0	1	0
	28. Do you prefer to avoid social gat..	1	0	1	0	1	0	1	0	1	0
	29. Is it easy for you to make decision	1	0	1	0	1	0	1	0	1	0
	30. Is your mind as clear as it used ..	1	0	1	0	1	0	1	0	1	0
	31. Total score	25	26	26	26	26	26	26	26	26	26
6ND	Imipramine	0	0	0	0	0	0	0	0	0	0
	01. Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0
	02. Have you dropped many of your act..	1	1	0	0	1	0	1	0	1	0
	03. Do you feel that your life is empty	1	0	0	0	1	0	1	0	1	0
	04. Do you often get bored	1	0	0	0	1	0	1	0	1	0
	05. Are you hopeless about the future	0	0	0	0	0	0	0	0	0	0
	06. Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0
	07. Are you in good spirits most of ...	0	0	0	0	0	0	0	0	0	0
	08. Are you afraid that something bad..	0	0	0	0	0	0	0	0	0	0
	09. Do you feel happy most of the time	1	0	0	0	1	0	1	0	1	0
	10. Do you often feel helpless	1	0	0	0	1	0	1	0	1	0
	11. Do you often get restless and f....	1	0	0	0	1	0	1	0	1	0
	12. Do you prefer to stay at home, ...	1	0	0	0	1	0	1	0	1	0
	13. Do you frequently worry about the..	0	0	0	0	0	0	0	0	0	0
	14. Do you feel you have more problems.	0	0	0	0	0	0	0	0	0	0
	15. Do you think it is wonderful to be.	1	0	0	0	1	0	1	0	1	0
	16. Do you often feel downhearted	1	0	0	0	1	0	1	0	1	0
	17. Do you feel pretty worthless the ..	1	0	0	0	1	0	1	0	1	0
	18. Do you worry a lot about the past	1	0	0	0	1	0	1	0	1	0
	19. Do you find life very exciting	1	0	0	0	1	0	1	0	1	0
	20. Is it hard for you to get started..	1	0	0	0	1	0	1	0	1	0
	21. Do you feel full of energy	1	0	0	0	1	0	1	0	1	0
	22. Do you feel that your situation ...	1	0	0	0	1	0	1	0	1	0
	23. Do you think that most people are...	1	0	0	0	1	0	1	0	1	0
	24. Do you frequently get upset over...	1	0	0	0	1	0	1	0	1	0
	25. Do you frequently feel like crying	1	0	0	0	1	0	1	0	1	0
	26. Do you have trouble concentrating	1	0	0	0	1	0	1	0	1	0
	27. Do you enjoy getting up in the mor.	1	0	0	0	1	0	1	0	1	0
	28. Do you prefer to avoid social gat..	1	0	0	0	1	0	1	0	1	0
	29. Is it easy for you to make decision	1	0	0	0	1	0	1	0	1	0
	30. Is your mind as clear as it used ..	1	0	0	0	1	0	1	0	1	0
	31. Total score	23	11	8	8	18	18	18	18	18	18
7ND	Imipramine	0	0	0	0	0	0	0	0	0	0
	01. Are you () satisfied with your life	0	0	0	0	0	0	0	0	0	0
	02. Have you dropped many of your act..	1	1	0	1	1	0	1	0	1	0
	03. Do you feel that your life is empty	1	0	0	1	0	1	0	1	0	1
	04. Do you often get bored	0	0	0	0	0	0	0	0	0	0
	05. Are you hopeful about the future	1	1	0	0	0	0	0	0	0	0
	06. Are you bothered by thoughts you ..	0	0	0	0	0	0	0	0	0	0

18008

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

225

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 15.0

GERIATRIC DEPRESSION SCALE

Centre	Patient	Treatment	Geriatric Depression Scale	Day0	Day7	Day14	Day21	Day28	Day35	Day42	Day49	Day56	Day63
				Y	N	Y	N	Y	N	Y	N	Y	N
3302	7ND	Imipramine	07.Are you in good spirits most of ...	1	1	1	1	0	0	0	1	1	1
			08.Are you afraid that something bad..	1	1	0	0	0	0	0	0	0	0
			09.Do you feel happy most of the time	1	1	0	0	0	0	0	1	1	1
			10.Do you often feel helpless	1	0	0	0	0	0	0	0	0	0
			11.Do you often get restless and f.....	1	0	0	0	0	0	1	0	0	0
			12.Do you prefer to stay at home,	1	1	1	1	1	1	1	1	1	1
			13.Do you frequently worry about the..	1	0	0	0	0	0	0	0	0	0
			14.Do you feel you have more problems.	1	0	0	0	0	0	0	0	0	0
			15.Do you think it is wonderful to be.	1	1	1	1	0	0	0	0	0	0
			16.Do you often feel downhearted	1	1	1	1	0	0	0	0	0	0
			17.Do you feel pretty worthless the ..	1	0	0	0	0	0	0	0	0	0
			18.Do you worry a lot about the past	1	0	0	0	0	0	0	0	0	0
			19.Do you find life very exciting	1	1	1	1	1	1	1	1	0	0
			20.Is it hard for you to get started..	1	1	0	1	1	1	1	1	1	1
			21.Do you feel full of energy	1	1	1	1	1	1	1	1	1	1
			22.Do you think that your situation ...	1	0	0	0	0	0	0	0	0	0
			23.Do you think that most people are...	1	0	1	0	0	0	0	0	1	0
			24.Do you frequently get upset over...	1	0	1	1	0	0	0	1	1	0
			25.Do you frequently feel like crying	1	1	0	1	1	1	1	1	1	0
			26.Do you have trouble concentrating	1	1	0	0	0	1	1	1	0	0
			27.Do you enjoy getting up in the mor.	1	1	1	1	1	1	1	1	1	1
			28.Do you prefer to avoid social gat..	1	1	1	1	1	1	1	1	1	1
			29.Is it easy for you to make decision	1	0	1	1	1	1	1	1	1	1
			30.Is your mind as clear as it used ..	1	0	1	1	1	1	1	1	1	1
			31.Total score	23	16	18	18	13	13	14	16	13	13

1809

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

1

PHARMACIA CMS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
1	1ND	Reboxetine	Female	Severity of illness	3.00	1.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Global improvement		1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
	1DT	Reboxetine	Male	Severity of illness	4.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Global improvement		2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Efficacy index (*)		5.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
	2ND	Imipramine	Male	Severity of illness	6.00	4.00	4.00	3.00	1.00	4.00	4.00	4.00	4.00	4.00	
				Global improvement		3.00	3.00	2.00	1.00	6.00	6.00	2.00	2.00	3.00	
				Efficacy index (*)		9.00	9.00	5.00	5.00	13.00	13.00	5.00	5.00	6.00	
	2DT	Imipramine	Male	Severity of illness	4.00	5.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	
				Global improvement		6.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
				Efficacy index (*)		13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	
	3ND	Imipramine	Female	Severity of illness	4.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Global improvement		3.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Efficacy index (*)		10.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
	3DT	Reboxetine	Male	Severity of illness	4.00	4.00	5.00	4.00	3.00	4.00	4.00	2.00	2.00	2.00	
				Global improvement		3.00	5.00	4.00	4.00	2.00	2.00	2.00	2.00	2.00	
				Efficacy index (*)		9.00	13.00	13.00	13.00	5.00	5.00	5.00	5.00	5.00	
	4ND	Reboxetine	Female	Severity of illness	6.00	6.00	4.00	6.00	5.00	4.00	3.00	3.00	3.00	2.00	
				Global improvement		4.00	3.00	3.00	6.00	3.00	3.00	3.00	3.00	2.00	
				Efficacy index (*)		13.00	9.00	14.00	14.00	9.00	9.00	5.00	5.00	5.00	
	4DT	Imipramine	Male	Severity of illness	4.00	4.00	5.00	6.00	5.00	4.00	3.00	3.00	3.00	3.00	
				Global improvement		3.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
				Efficacy index (*)		2.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

1810

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

2

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
2	1HD	Reboxetine	Male	Severity of illness	5.00	4.00	4.00	4.00	4.00						
				Global improvement		3.00	3.00	3.00	4.00						
				Efficacy index		11.00	9.00	9.00	14.00						
				Efficacy index (*)		0.67	2.00	2.00	0.50						
3	1HD	Reboxetine	Female	Severity of illness	5.00	6.00	4.00	5.00	5.00	5.00	4.00	6.00			
				Global improvement		4.00	3.00	4.00	4.00	3.00	3.00	5.00			
				Efficacy index		13.00	9.00	13.00	13.00	9.00	9.00	13.00			
				Efficacy index (*)		1.00	2.00	1.00	1.00	2.00	2.00	1.00			
4	1HD	Imipramine	Male	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00					
				Global improvement		5.00	4.00	5.00	5.00	6.00					
				Efficacy index		14.00	14.00	14.00	14.00	14.00					
				Efficacy index (*)		0.50	0.50	0.50	0.50	0.50					
5	1HD	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00						
				Global improvement		4.00	5.00	5.00							
				Efficacy index		14.00	13.00	13.00							
				Efficacy index (*)		0.50	0.50	0.50	0.50						
18	1DT	Imipramine	Female	Severity of illness	6.00	6.00	5.00	5.00	4.00	4.00	3.00	2.00	2.00	2.00	
				Global improvement		4.00	3.00	3.00	3.00	2.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		14.00	9.00	10.00	10.00	6.00	6.00	6.00	2.00	2.00	2.00
				Efficacy index (*)		0.50	2.00	1.00	1.50	1.50	1.50	2.00	4.00		
11	2HD	Reboxetine	Male	Severity of illness	3.00	3.00	3.00	3.00	3.00	3.00	3.00	4.00	4.00	4.00	
				Global improvement		3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index		9.00	9.00	9.00	9.00	5.00	5.00	9.00	9.00	9.00	9.00
				Efficacy index (*)		2.00	2.00	2.00	3.00	3.00	3.00	2.00	2.00		
11	2DT	Imipramine	Female	Severity of illness	5.00	4.00	4.00	4.00	4.00	4.00	4.00	5.00	5.00	5.00	
				Global improvement		2.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index		5.00	6.00	5.00	5.00	10.00	10.00	10.00	10.00	10.00	10.00
				Efficacy index (*)		3.00	1.50	3.00	3.00	1.00	1.00	1.00	1.00		
3HD	1HD	Imipramine	Female	Severity of illness	5.00	5.00	4.00	4.00	3.00	3.00	3.00	2.00	2.00	2.00	
				Global improvement		4.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	9.00	9.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		1.00	2.00	3.00	3.00	3.00	3.00	4.00	4.00		

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
 GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
 EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

3

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

Centre	Patient	Treatment	Sex	C.G.I.	CLINICAL GLOBAL IMPRESSION										
					Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
5	3DT	Reboxetine	Male	Severity of illness	5.00	3.00	3.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00
				Global improvement	3.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)	5.00	5.00	3.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
4MD	Imipramine	Male	Severity of illness	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
			Global improvement	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
			Efficacy index (*)	14.00	14.00	14.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	
4DT	Reboxetine	Male	Severity of illness	4.00	4.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00		
			Global improvement	3.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00		
			Efficacy index (*)	9.00	13.00	13.00	14.00	15.00	15.00	15.00	15.00	15.00	15.00		
5MD	Reboxetine	Male	Severity of illness	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00		
			Global improvement	3.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00		
			Efficacy index (*)	2.00	2.00	0.50	14.00	14.00	14.00	14.00	14.00	14.00	14.00		
5DT	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00		
			Global improvement	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00		
			Efficacy index (*)	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00		
6MD	Imipramine	Male	Severity of illness	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00		
			Global improvement	3.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00		
			Efficacy index (*)	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
6DT	Reboxetine	Female	Severity of illness	6.00	5.00	5.00	4.00	4.00	4.00	4.00	3.00	3.00	3.00		
			Global improvement	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00		
			Efficacy index (*)	10.00	10.00	10.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00		
7MD	Reboxetine	Male	Severity of illness	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00		
			Global improvement	4.00	4.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00		
			Efficacy index (*)	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00		

1812

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

4

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.S.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
5	70F	Imipramine	Female	Severity of illness	6.00	5.00	4.00	4.00	3.00	3.00	3.00	2.00	2.00	2.00	
				Global improvement		3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		10.00	6.00	6.00	6.00	6.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		1.00	1.50	1.50	1.50	4.00	4.00	4.00	4.00	4.00	
8ND	Imipramine	Female	Severity of illness	6.00	6.00	6.00	5.00	5.00	3.00	2.00	2.00	2.00	2.00	2.00	
			Global improvement		4.00	4.00	3.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	
			Efficacy index		14.00	14.00	9.00	5.00	5.00	5.00	5.00	5.00	5.00	1.00	1.00
				Efficacy index (*)		0.50	0.50	2.00	3.00	3.00	3.00	4.00	4.00	4.00	
8DF	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	4.00	4.00	3.00	3.00	3.00	
			Global improvement		4.00	4.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00
			Efficacy index		14.00	14.00	14.00	14.00	14.00	10.00	10.00	10.00	10.00	6.00	6.00
				Efficacy index (*)		0.50	0.50	0.50	0.50	1.00	1.00	1.50	1.50	1.50	
9ND	Reboxetine	Female	Severity of illness	6.00	5.00	5.00	5.00	4.00	4.00	4.00	4.00	3.00	3.00	3.00	
			Global improvement		3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00
			Efficacy index		10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	6.00	6.00	6.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	1.00	1.50	1.50	1.50	1.50	
9DF	Reboxetine	Female	Severity of illness	4.00	3.00	3.00	3.00	3.00	2.00	2.00	1.00	1.00	1.00	1.00	
			Global improvement		3.00	3.00	3.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00	
			Efficacy index		10.00	10.00	10.00	10.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00
				Efficacy index (*)		1.00	1.00	1.00	2.00	4.00	4.00	4.00	4.00		
10ND	Imipramine	Female	Severity of illness	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	3.00	3.00	3.00	
			Global improvement		4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	
			Efficacy index		13.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	6.00	6.00	
				Efficacy index (*)		1.00	2.00	2.00	2.00	1.00	1.50	1.50	1.50		
10DF	Imipramine	Male	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
			Global improvement		4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
			Efficacy index		16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	
				Efficacy index (*)		0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25		
11ND	Imipramine	Female	Severity of illness	5.00	5.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	
			Global improvement		4.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
			Efficacy index		14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	
				Efficacy index (*)		0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50		

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

1813

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

5

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
5	11DT	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
				Global improvement	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index	14.00	14.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
				Efficacy index (*)	0.50	0.50	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
	12MD	Reboxetine	Female	Severity of illness	5.00	5.00	4.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00	
				Global improvement	4.00	3.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index	14.00	10.00	6.00	6.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)	0.50	1.00	1.50	1.50	2.00	2.00	2.00	2.00	2.00		
	12DT	Imipramine	Male	Severity of illness	4.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	
				Global improvement	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index	9.00	9.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00
				Efficacy index (*)	2.00	2.00	1.50	1.50	1.50	1.50	1.50	1.50	4.00		
6	1MD	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	4.00	4.00	3.00	3.00	3.00	
				Global improvement	4.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index	13.00	9.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)	1.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00		
	1DT	Reboxetine	Female	Severity of illness	5.00	5.00	4.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	
				Global improvement	4.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index	14.00	10.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00
				Efficacy index (*)	0.50	1.00	1.50	1.50	1.50	1.50	4.00	4.00	4.00		
2MD	Imipramine	Female	Severity of illness	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	
			Global improvement	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
			Efficacy index	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	
				Efficacy index (*)	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25			
	2DT	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
				Global improvement	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00
				Efficacy index (*)	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00			
3MD	Reboxetine	Female	Severity of illness	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	
			Global improvement	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
			Efficacy index	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	
				Efficacy index (*)	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50			

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

1814

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

6

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
6	30T	Imipramine	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
				Global improvement	3.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index	9.00	14.00	10.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00
				Efficacy index (*)	2.00	0.50	1.00	1.00	3.00	2.00	2.00	2.60	2.00	2.00	
4MD	4MD	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
				Global improvement	5.00	5.00	4.00	3.00	5.00	5.00	5.00	5.00	5.00	5.00	
				Efficacy index	13.00	14.00	14.00	14.00	10.00	14.00	14.00	14.00	14.00	14.00	14.00
				Efficacy index (*)	1.00	0.50	0.50	0.50	1.00	0.50	0.50	0.50	0.50		
4DT	4DT	Imipramine	Female	Severity of illness	4.00	4.00	4.00	3.00	2.00	2.00	2.00	2.00	1.00	1.00	
				Global improvement	4.00	3.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Efficacy index	13.00	9.00	6.00	6.00	2.00	2.00	2.00	2.00	2.00	2.00	
				Efficacy index (*)	1.00	2.00	1.50	1.50	2.00	2.00	2.00	2.00	2.00		
5MD	5MD	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	4.00	4.00	4.00	4.00	4.00	5.00	
				Global improvement	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
				Efficacy index	9.00	9.00	9.00	9.00	10.00	10.00	10.00	10.00	10.00	10.00	
				Efficacy index (*)	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	0.50		
5DT	5DT	Reboxetine	Female	Severity of illness	4.00	4.00	3.00	3.00	3.00	3.00	2.00	1.00	1.00	1.00	
				Global improvement	4.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00		
				Efficacy index	13.00	5.00	5.00	5.00	1.00	5.00	1.00	1.00	1.00		
				Efficacy index (*)	1.00	3.00	3.00	3.00	4.00	3.00	4.00	4.00	4.00		
6MD	6MD	Reboxetine	Female	Severity of illness	4.00	3.00	3.00	4.00	5.00	5.00	5.00	5.00	5.00	5.00	
				Global improvement	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00		
				Efficacy index	9.00	9.00	9.00	9.00	13.00	13.00	13.00	13.00	13.00		
				Efficacy index (*)	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00		
7MD	7MD	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	4.00	4.00	3.00	3.00	3.00	
				Global improvement	4.00	4.00	4.00	4.00	4.00	3.00	3.00	2.00	2.00		
				Efficacy index	13.00	13.00	13.00	13.00	14.00	10.00	10.00	6.00	6.00		
				Efficacy index (*)	1.00	1.00	1.00	1.00	0.50	1.00	1.50	1.50	2.00		
8MD	8MD	Imipramine	Female	Severity of illness	6.00	6.00	6.00	4.00	4.00	3.00	2.00	2.00	2.00	1.00	
				Global improvement	4.00	3.00	2.00	2.00	2.00	1.00	1.00	1.00			
				Efficacy index	13.00	9.00	5.00	5.00	5.00	3.00	3.00	3.00	3.00		
				Efficacy index (*)	1.00	2.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00		

1815

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
7	1M	Imipramine	Male	Severity of illness	5.00	5.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00		
				Global improvement		3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
				Efficacy index		10.00	7.00	3.00	3.00	3.00	3.00	3.00	2.00	1.00	1.00	4.00
	3M	Imipramine	Female	Severity of illness	6.00	6.00	6.00	4.00	4.00	4.00	2.00	2.00	2.00	2.00	2.00	
				Global improvement		5.00	4.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Efficacy index		14.00	14.00	6.00	6.00	6.00	2.00	2.00	2.00	2.00	2.00	2.00
	4M	Reboxetine	Female	Severity of illness	5.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	
				Global improvement		6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	
				Efficacy index		14.00	14.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00
	8	1M	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
					Global improvement		4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
					Efficacy index		13.00	13.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00
2M		Reboxetine	Female	Severity of illness	6.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	
				Global improvement		7.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
				Efficacy index		13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	
10F		Imipramine	Female	Severity of illness	5.00	5.00	3.00	3.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	
				Global improvement		4.00	2.00	4.00	4.00	2.00	2.00	2.00	2.00	2.00	2.00	
				Efficacy index		13.00	1.00	14.00	1.00	1.00	5.00	5.00	1.00	1.00	1.00	
2M		Reboxetine	Female	Severity of illness	3.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	1.00	
				Global improvement		3.00	3.00	3.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00	
				Efficacy index		9.00	13.00	9.00	9.00	5.00	1.00	1.00	1.00	1.00	1.00	
20F	Imipramine	Female	Severity of illness	3.00	5.00	5.00	5.00	5.00	5.00	2.00	2.00	2.00	1.00	1.00		
			Global improvement		6.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00		
			Efficacy index		13.00	13.00	13.00	13.00	9.00	5.00	5.00	5.00	5.00	5.00		

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9550089

8

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
8	SMD	Imipramine	Female	Severity of illness	5.00	5.00									
				Global improvement		4.00									
				Efficacy index		13.00									
				Efficacy index (*)	1.00										
	30T	Reboxetine	Female	Severity of illness	6.00	6.00	3.00	3.00	2.00	2.00	2.00	1.00	1.00	1.00	
				Global improvement		6.00	2.00	1.00	2.00	2.00	2.00	1.00	1.00	1.00	
				Efficacy index		13.00	5.00	1.00	5.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)	1.00	3.00	4.00	3.00	4.00	4.00	4.00	4.00	4.00		
	4MD	Imipramine	Male	Severity of illness	7.00	6.00	7.00	7.00	2.00	2.00	2.00	1.00	1.00	1.00	
				Global improvement		4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
				Efficacy index		13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00
				Efficacy index (*)	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
	4DT	Reboxetine	Female	Severity of illness	4.00	3.00	3.00	2.00	2.00	2.00	2.00	1.00	1.00	3.00	
				Global improvement		2.00	1.00	1.00	1.00	2.00	2.00	2.00	1.00	1.00	4.00
				Efficacy index		1.00	1.00	1.00	1.00	5.00	5.00	1.00	1.00	1.00	13.00
				Efficacy index (*)	4.00	4.00	4.00	4.00	3.00	3.00	4.00	4.00	1.00		
	701MD	Imipramine	Male	Severity of illness	6.00	6.00	3.00	2.00	2.00	1.00	1.00	1.00	1.00	2.00	
				Global improvement		3.00	1.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	
				Efficacy index		9.00	1.00	5.00	6.00	1.00	1.00	1.00	1.00	1.00	
				Efficacy index (*)	2.00	4.00	3.00	3.00	1.50	4.00	4.00	4.00	4.00		
	701DT	Reboxetine	Female	Severity of illness	5.00	4.00	5.00	4.00	4.00	5.00	2.00	3.00	3.00	3.00	
				Global improvement		3.00	6.00	3.00	3.00	5.00	4.00	4.00	3.00	4.00	4.00
				Efficacy index		9.00	14.00	10.00	13.00	13.00	13.00	5.00	13.00	13.00	13.00
				Efficacy index (*)	2.00	0.50	1.00	1.00	1.00	1.00	3.00	1.00	1.00		
	702MD	Reboxetine	Male	Severity of illness	5.00	4.00	5.00	5.00	4.00	4.00	4.00	4.00	4.00	5.00	
				Global improvement		3.00	6.00	5.00	4.00	4.00	3.00	4.00	4.00	4.00	6.00
				Efficacy index		14.00	14.00	14.00	14.00	10.00	14.00	14.00	14.00	14.00	14.00
				Efficacy index (*)	0.50	0.50	0.50	0.50	0.50	1.00	0.50	0.50	0.50		
	702DT	Imipramine	Female	Severity of illness	3.00	3.00	3.00	2.00	1.00	2.00	2.00	2.00	2.00	2.00	
				Global improvement		3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
				Efficacy index		5.00	5.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
				Efficacy index (*)	2.00	2.00	2.00	3.00	4.00	4.00	4.00	4.00			

1817

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
 GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
 EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

9

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

		PHARMACIA CNS R&D													
		REBOXETINE - PROTOCOL 20124/035													
		Listing No.: 16.0													
		CLINICAL GLOBAL IMPRESSION													
Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
8	703ND	Imipramine	Female	Severity of illness	4.00	4.00	6.00	6.00	3.00	2.00	2.00	2.00	2.00	3.00	
				Global improvement	4.00	4.00	6.00	6.00	3.00	2.00	2.00	2.00	2.00	2.00	3.00
				Efficacy index	13.00	15.00	14.00	14.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)	1.00	0.33	0.50	0.50	4.00	4.00	4.00	4.00	3.00		
703DT	Imipramine	Male	Severity of illness	4.00	4.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	
			Global improvement	5.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
			Efficacy index	13.00	9.00	9.00	9.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	2.00
				Efficacy index (*)	1.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00	2.00		
704ND	Reboxetine	Female	Severity of illness	3.00	3.00	3.00	1.00	1.00	1.00	1.00	2.00	1.00	1.00	1.00	
			Global improvement	4.00	4.00	2.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	
			Efficacy index	14.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)	0.50	2.00	2.00	2.00	2.00	2.00	1.50	2.00	2.00		
704DT	Reboxetine	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	3.00	2.00	2.00	2.00	3.00	2.00	
			Global improvement	4.00	4.00	5.00	4.00	4.00	2.00	2.00	2.00	2.00	2.00	2.00	
			Efficacy index	14.00	14.00	14.00	14.00	6.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)	0.50	0.50	0.50	0.50	1.50	4.00	3.00	2.00	4.00		
9	1ND	Imipramine	Female	Severity of illness	4.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	
				Global improvement	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00
				Efficacy index	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	1.00
				Efficacy index (*)	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	4.00		
1DT	Imipramine	Female	Severity of illness	4.00	4.00	3.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
			Global improvement	3.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
			Efficacy index	10.00	5.00	5.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Efficacy index (*)	1.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00	4.00		
2ND	Reboxetine	Female	Severity of illness	6.00	6.00	5.00	5.00	5.00	5.00	5.00	4.00	4.00	4.00	3.00	
			Global improvement	4.00	3.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
			Efficacy index	13.00	9.00	13.00	13.00	9.00	10.00	10.00	10.00	10.00	10.00	10.00	5.00
				Efficacy index (*)	1.00	2.00	2.00	1.00	2.00	1.00	3.00	3.00	3.00		
2DT	Imipramine	Female	Severity of illness	4.00	4.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
			Global improvement	3.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
			Efficacy index	9.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Efficacy index (*)	2.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00		

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
 GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
 EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

10

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
9	3DT	Reboxetine	Female	Severity of illness	4.00	4.00	4.00	1.00	1.00	1.00	2.00	1.00	1.00	1.00		
				Global improvement		4.00	3.00	1.00	1.00	1.00	2.00	1.00	1.00	1.00	1.00	
				Efficacy index		13.00	10.00	2.00	2.00	2.00	5.00	2.00	2.00	2.00	2.00	4.00
	4MD	Imipramine	Female	Severity of illness	4.00	3.00	3.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	
				Global improvement		2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	
				Efficacy index		6.00	6.00	5.00	5.00	5.00	1.00	1.00	1.00	1.00	1.00	4.00
	5MD	Reboxetine	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00	3.00	3.00	3.00	1.00	
				Global improvement		4.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	1.00	1.00
				Efficacy index		13.00	9.00	9.00	9.00	9.00	5.00	5.00	5.00	3.00	3.00	3.00
6MD	Imipramine	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00	3.00	3.00	3.00	1.00		
			Global improvement		4.00	4.00	4.00	4.00	4.00	2.00	2.00	2.00	2.00	1.00	1.00	
			Efficacy index		14.00	14.00	14.00	14.00	14.00	9.00	9.00	9.00	5.00	5.00	1.00	1.00
7MD	Imipramine	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	3.00		
			Global improvement		5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
			Efficacy index		14.00	14.00	14.00	14.00	14.00	13.00	13.00	9.00	9.00	5.00	5.00	5.00
8DT	Reboxetine	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00		
			Global improvement		4.00	4.00	4.00	4.00	4.00	4.00	3.00	3.00	2.00	2.00	2.00	
			Efficacy index		13.00	13.00	13.00	13.00	13.00	13.00	9.00	9.00	5.00	5.00	5.00	
9MD	Imipramine	Female	Severity of illness	5.00	4.00	3.00	3.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00		
			Global improvement		3.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00		
			Efficacy index		10.00	6.00	6.00	6.00	6.00	2.00	2.00	2.00	2.00	2.00	2.00	
10DT	Reboxetine	Female	Severity of illness	5.00	5.00	4.00	3.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00		
			Global improvement		4.00	3.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00		
			Efficacy index		14.00	10.00	6.00	6.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	

1819

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

11

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
10	20D	Reboxetine	Male	Severity of illness	6.00	6.00	4.00	3.00	2.00	1.00	2.00	1.00	1.00	1.00	
				Global improvement	4.00	3.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index	14.00	10.00	6.00	6.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)	0.50	1.00	1.50	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
	20F	Imipramine	Male	Severity of illness	5.00	5.00	3.00	1.00	1.00	1.00	2.00	1.00	1.00	1.00	
				Global improvement	4.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index	13.00	6.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)	1.00	1.50	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
	30D	Reboxetine	Male	Severity of illness	6.00	6.00	6.00	6.00	4.00	3.00	3.00	2.00	2.00	2.00	
				Global improvement	4.00	4.00	4.00	4.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index	13.00	13.00	13.00	10.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00
				Efficacy index (*)	1.00	1.00	1.00	1.00	1.00	1.50	1.50	2.00	2.00	4.00	
	30F	Imipramine	Male	Severity of illness	5.00	5.00	3.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	
				Global improvement	4.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index	14.00	6.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)	0.50	1.50	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
	40D	Imipramine	Female	Severity of illness	5.00	5.00	4.00	3.00	3.00	2.00	2.00	1.00	1.00	1.00	
				Global improvement	4.00	3.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index	14.00	10.00	6.00	6.00	6.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)	0.50	1.00	1.50	1.50	1.50	2.00	2.00	2.00	2.00	2.00	
	40F	Reboxetine	Female	Severity of illness	5.00	5.00	4.00	4.00	2.00	1.00	1.00	1.00	1.00	1.00	
				Global improvement	4.00	3.00	3.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index	14.00	10.00	10.00	10.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)	0.50	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	
	50D	Imipramine	Female	Severity of illness	6.00	6.00	6.00	6.00	4.00	3.00	3.00	1.00	1.00	1.00	
				Global improvement	4.00	4.00	4.00	4.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index	13.00	13.00	13.00	16.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00
				Efficacy index (*)	1.00	1.00	1.00	1.00	1.00	1.50	1.50	2.00	2.00	2.00	
	50F	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
				Global improvement	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Efficacy index	13.00	13.00	13.00	13.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00
				Efficacy index (*)	1.00	1.00	1.00	1.00	0.50	0.50	0.50	0.50	0.50		

1820

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3= mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

12

PHARMACIA CMS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
10	6HD	Reboxetine	Male	Severity of illness	6.00	6.00	5.00	6.00	6.00	6.00	6.00	6.00	6.00	5.00		
				Global improvement	4.00	3.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	3.00
				Efficacy index	13.00	10.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00
				Efficacy index (*)	1.00	1.00	0.50	0.50	0.50	0.50	0.50	0.50	2.00			
	6DT	Reboxetine	Male	Severity of illness	5.00	4.00	3.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00		
				Global improvement	3.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Efficacy index	10.00	6.00	5.00	5.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)	1.00	1.50	3.00	3.00	2.00	2.00	2.00	2.00	2.00			
	7HD	Imipramine	Male	Severity of illness	6.00	4.00	3.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00		
				Global improvement	3.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Efficacy index	10.00	6.00	6.00	6.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)	1.00	1.50	1.50	1.50	2.00	2.00	2.00	2.00	2.00			
	7DT	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	3.00	2.00	1.00	1.00	1.00	1.00		
				Global improvement	4.00	4.00	4.00	4.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	
				Efficacy index	14.00	14.00	14.00	14.00	6.00	6.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)	0.50	0.50	0.50	0.50	1.50	2.00	2.00	2.00	2.00			
	8HD	Reboxetine	Male	Severity of illness	6.00	4.00	3.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00		
				Global improvement	3.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Efficacy index	10.00	5.00	5.00	5.00	3.00	3.00	1.00	1.00	1.00	1.00	1.00	
				Efficacy index (*)	1.00	3.00	3.00	3.00	1.33	1.33	4.00	4.00	2.00			
	8DT	Imipramine	Female	Severity of illness	5.00	5.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
				Global improvement	4.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Efficacy index	15.00	7.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00
				Efficacy index (*)	0.33	1.00	1.00	1.33	1.33	1.33	2.00	2.00	2.00			
	9HD	Reboxetine	Female	Severity of illness	6.00	5.00	4.00	4.00	2.00	1.00	1.00	1.00	1.00	1.00		
				Global improvement	3.00	3.00	3.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Efficacy index	10.00	10.00	10.00	10.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00			
	9DT	Imipramine	Male	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00		
				Global improvement	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
				Efficacy index	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00
				Efficacy index (*)	1.00	1.00	1.00	1.00	0.50	0.50	0.50	0.50	0.50			

1821

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

13

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
10	10HD	Imipramine	Female	Severity of illness	6.00	6.00	4.00	3.00	3.00	1.00	1.00	1.00	1.00	1.00	
				Global improvement	4.00	4.00	3.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index	14.00	10.00	6.00	6.00	6.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)	0.50	1.00	1.50	1.50	2.00	2.00	2.00	2.00	2.00	2.00	
	10DT	Reboxetine	Female	Severity of illness	5.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Global improvement	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index	6.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)	1.50	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
	11HD	Imipramine	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	3.00	2.00	1.00	1.00	1.00	1.00
				Global improvement	4.00	4.00	4.00	3.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index	13.00	13.00	9.00	10.00	10.00	6.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index (*)	1.00	1.00	1.00	2.00	1.00	1.50	2.00	4.00	4.00	4.00	
	11DT	Imipramine	Female	Severity of illness	5.00	4.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Global improvement	3.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index	11.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)	0.67	1.33	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
	12HD	Reboxetine	Male	Severity of illness	5.00	6.00	5.00	5.00	5.00	5.00	6.00	5.00	5.00	5.00	5.00
				Global improvement	5.00	4.00	4.00	4.00	4.00	5.00	4.00	4.00	4.00	4.00	4.00
				Efficacy index	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00
				Efficacy index (*)	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
	12DT	Reboxetine	Female	Severity of illness	5.00	4.00	3.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00
				Global improvement	3.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index	10.00	6.00	6.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)	1.00	1.50	1.50	4.00	4.00	2.00	2.00	2.00	2.00		
	13DT	Reboxetine	Female	Severity of illness	5.00	5.00	4.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00
				Global improvement	4.00	3.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index	14.00	10.00	10.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)	0.50	1.00	1.00	2.00	2.00	2.00	2.00	4.00	4.00		
	14DT	Imipramine	Female	Severity of illness	5.00	5.00	3.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00
				Global improvement	4.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index	14.00	6.00	6.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)	0.50	1.50	1.50	2.00	2.00	2.00	2.00	2.00	2.00		

10022

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

14

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
10	15MD	Reboxetine	Female	Severity of illness	6.00	6.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Global improvement		4.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index		14.00	6.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		0.50	1.50	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
	16DT	Imipramine	Male	Severity of illness	5.00	5.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Global improvement		4.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index		13.00	5.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		1.00	3.00	4.00	2.00	2.00	2.00	2.00	2.00	2.00	
	17MD	Reboxetine	Female	Severity of illness	5.00	4.00	3.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Global improvement		3.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index		10.00	6.00	6.00	6.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		1.00	1.50	1.50	2.00	2.00	2.00	2.00	2.00	2.00	
	18MD	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	3.00	2.00	2.00	2.00	2.00	2.00	
				Global improvement		4.00	4.00	4.00	4.00	2.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index		14.00	14.00	14.00	14.00	6.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		0.50	0.50	0.50	1.50	2.00	2.00	2.00	2.00	2.00	
	19DT	Reboxetine	Male	Severity of illness	5.00	5.00	5.00	5.00	5.00	4.00	4.00	4.00	4.00	4.00	
				Global improvement		4.00	4.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index		14.00	14.00	14.00	14.00	14.00	10.00	10.00	10.00	10.00	10.00
				Efficacy index (*)		0.50	0.50	0.50	0.50	1.00	1.00	1.00	1.00		
	20MD	Reboxetine	Female	Severity of illness	6.00	6.00	6.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	
				Global improvement		4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index		13.00	13.00	13.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00
				Efficacy index (*)		1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00		
12	1MD	Reboxetine	Female	Severity of illness	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
				Global improvement		2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00		
	1DT	Reboxetine	Female	Severity of illness	6.00	5.00	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	
				Global improvement		4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index		13.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00
				Efficacy index (*)		1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00		

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=initially improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

15

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RD
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
13	1MD	Reboxetine	Female	Severity of illness	5.00	5.00	3.00	4.00	4.00	3.00	1.00	1.00	1.00	1.00	
				Global improvement		4.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	10.00	6.00	6.00	5.00	5.00	5.00	5.00	5.00	5.00
	1DT	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00
				Global improvement		4.00	3.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index		13.00	13.00	9.00	2.00	2.00	4.00	4.00	4.00	4.00	4.00
	2MD	Imipramine	Female	Severity of illness	6.00	6.00	5.00	5.00	5.00	5.00	5.00	4.00	3.00	3.00	3.00
				Global improvement		5.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		15.00	10.00	9.00	14.00	10.00	6.00	6.00	6.00	6.00	8.00
2DT	Reboxetine	Female	Severity of illness	6.00	6.00	5.00	5.00	5.00	4.00	3.00	3.00	4.00	4.00	3.00	
			Global improvement		4.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	
			Efficacy index		13.00	9.00	10.00	10.00	10.00	6.00	6.00	6.00	6.00	6.00	
3MD	Imipramine	Male	Severity of illness	5.00	4.00	4.00	4.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	
			Global improvement		3.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
			Efficacy index		9.00	5.00	9.00	9.00	10.00	5.00	9.00	10.00	5.00	9.00	
3DT	Imipramine	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	2.00	1.00	1.00	1.00	1.00	1.00	
			Global improvement		4.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
			Efficacy index		14.00	10.00	10.00	6.00	6.00	2.00	2.00	2.00	2.00	2.00	
4DT	Reboxetine	Female	Severity of illness	4.00	4.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	3.00	
			Global improvement		3.00	2.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	
			Efficacy index		9.00	5.00	10.00	10.00	10.00	10.00	5.00	5.00	1.00	5.00	
14	1MD	Reboxetine	Female	Severity of illness	5.00	4.00	3.00	3.00	3.00	3.00	1.00	1.00	1.00	1.00	
				Global improvement		2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
				Efficacy index		2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	

1824

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

16

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63			
15	1ND	Reboxetine	Female	Severity of illness	5.00	4.00	4.00	4.00	3.00	3.00	4.00	4.00	4.00				
				Global improvement		3.00	3.00	3.00	2.00	2.00	3.00	3.00	3.00	3.00			
				Efficacy index		9.00	9.00	9.00	5.00	5.00	9.00	9.00	9.00	9.00	9.00		
				Efficacy index (*)		2.00	2.00	2.00	3.00	3.00	2.00	2.00	2.00				
	1DT	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	4.00	3.00	2.00	2.00	2.00			
				Global improvement		4.00	5.00	5.00	3.00	3.00	2.00	2.00	2.00	1.00	1.00		
				Efficacy index		13.00	13.00	13.00	9.00	9.00	5.00	5.00	1.00	1.00	4.00	4.00	
				Efficacy index (*)		1.00	1.00	1.00	2.00	2.00	3.00	4.00	4.00				
	2ND	Imipramine	Female	Severity of illness	5.00	5.00	4.00	4.00	4.00	4.00	3.00	3.00	2.00	2.00			
				Global improvement		4.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00		
				Efficacy index		14.00	12.00	12.00	9.00	9.00	5.00	5.00	5.00	5.00	5.00	4.00	
				Efficacy index (*)		0.50	0.50	0.50	3.00	3.00	3.00	3.00	3.00				
	2DT	Imipramine	Female	Severity of illness	5.00	5.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	2.00			
				Global improvement		3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00		
				Efficacy index		9.00	9.00	9.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	4.00	
				Efficacy index (*)		2.00	2.00	2.00	3.00	3.00	3.00	3.00	4.00				
	3ND	Reboxetine	Female	Severity of illness	5.00	5.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	1.00			
				Global improvement		3.00	3.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00		
				Efficacy index		10.00	10.00	5.00	5.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Efficacy index (*)		1.00	1.00	3.00	4.00	4.00	4.00	4.00	4.00				
	4ND	Imipramine	Female	Severity of illness	6.00	5.00	4.00	4.00	4.00	3.00	2.00	2.00	2.00	2.00			
				Global improvement		3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00		
				Efficacy index		9.00	6.00	6.00	6.00	6.00	2.00	2.00	1.00	1.00	1.00	1.00	
				Efficacy index (*)		2.00	1.50	1.50	1.50	2.00	2.00	4.00	4.00				
11	11ND	Reboxetine	Female	Severity of illness	7.00	7.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	2.00			
				Global improvement		4.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	
				Efficacy index		13.00	9.00	12.00	12.00	12.00	12.00	6.00	6.00	2.00	2.00	1.00	1.00
				Efficacy index (*)		1.00	2.00	0.50	0.50	4.00	4.00	4.00	4.00				
11	112ND	Imipramine	Female	Severity of illness	5.00	5.00	5.00	4.00	3.00	3.00	2.00	2.00	2.00	2.00			
				Global improvement		4.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
				Efficacy index		13.00	9.00	3.00	3.00	5.00	5.00	5.00	5.00	5.00	5.00	1.00	1.00
				Efficacy index (*)		1.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	4.00	4.00		

1825

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill, 8=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20424/035
Listing No.: 16.0

Centre	Patient	Treatment	Sex	C.G.I.	CLINICAL GLOBAL IMPRESSION											
					Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
16	1ND	Reboxetine	Female	Severity of illness	5.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
				Global improvement	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
1DT	Imipramine	Female	Severity of illness	5.00	5.00	6.00										
			Global improvement	4.00	4.00	6.00										
			Efficacy index	14.00	15.00											
2ND	Imipramine	Male	Severity of illness	5.00	5.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
			Global improvement	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00		
			Efficacy index	9.00	5.00	5.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00		
2DT	Reboxetine	Male	Severity of illness	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
			Global improvement	4.00	3.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
			Efficacy index	14.00	10.00	10.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00		
3ND	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00		
			Global improvement	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00		
			Efficacy index	13.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00		
3DT	Imipramine	Female	Severity of illness	5.00	5.00	6.00										
			Global improvement	3.00	3.00	5.00										
			Efficacy index	10.00	15.00											
4ND	Reboxetine	Female	Severity of illness	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00		
			Global improvement	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00		
			Efficacy index	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00		
17	1ND	Reboxetine	Female	Severity of illness	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00		
				Global improvement	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00		
				Efficacy index	13.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00		

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

1826

9550089

18

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
17	1DT	Reboxetine	Female	Severity of illness	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00		
				Global improvement	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index	14.00	10.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00
				Efficacy index (*)	0.50	0.50	1.00	0.50	0.50	0.50	0.50	0.50	0.50	0.50		
2MD	2MD	Imipramine	Female	Severity of illness	6.00	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
				Global improvement	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index	5.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)	3.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00		
2DT	2DT	Reboxetine	Female	Severity of illness	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
				Global improvement	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00		
3MD	3MD	Imipramine	Female	Severity of illness	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	
				Global improvement	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00
				Efficacy index	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00
				Efficacy index (*)	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33		
3DT	3DT	Imipramine	Male	Severity of illness	6.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
				Global improvement	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index	9.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00		
4MD	4MD	Reboxetine	Female	Severity of illness	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	
				Global improvement	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index	9.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00		
4DT	4DT	Imipramine	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
				Global improvement	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Efficacy index	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00
				Efficacy index (*)	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00			
21MD	21MD	Reboxetine	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
				Global improvement	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index	9.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00		

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

19

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
17	211DT	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
				Global improvement	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index (*)	13.00	13.00	10.00	10.00	10.00	10.00	9.00	9.00	9.00	9.00	9.00
18	1MD	Imipramine	Female	Severity of illness	5.00	4.00	4.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	
				Global improvement	4.00	4.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)	13.00	5.00	5.00	5.00	5.00	1.00	1.00	1.00	1.00	1.00	4.00
18	1DT	Imipramine	Female	Severity of illness	6.00	5.00	5.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	
				Global improvement	3.00	3.00	3.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)	10.00	10.00	10.00	6.00	6.00	6.00	2.00	2.00	2.00	2.00	2.00
18	2ND	Imipramine	Female	Severity of illness	6.00	6.00	6.00	5.00	6.00	6.00	6.00	6.00	6.00	6.00	
				Global improvement	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Efficacy index (*)	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00
18	2DT	Reboxetine	Female	Severity of illness	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	
				Global improvement	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Efficacy index (*)	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00
18	3MD	Reboxetine	Female	Severity of illness	5.00	6.00	6.00	6.00	4.00	3.00	3.00	4.00	4.00	4.00	
				Global improvement	4.00	4.00	4.00	4.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)	13.00	13.00	13.00	13.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
18	4MD	Reboxetine	Female	Severity of illness	6.00	6.00	6.00	6.00	3.00	3.00	3.00	3.00	3.00	3.00	
				Global improvement	4.00	4.00	4.00	4.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)	13.00	13.00	13.00	13.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
20	3MD	Reboxetine	Female	Severity of illness	3.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
				Global improvement	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Efficacy index (*)	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

21

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
25	2HD	Imipramine	Female	Severity of illness	5.00	6.00	5.00	5.00	5.00	5.00	5.00	5.00	4.00		
				Global improvement		5.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index		14.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	9.00	5.00
26	4HD	Imipramine	Female	Efficacy index (*)		0.50	1.00	1.00	1.00	1.00	2.00	3.00	2.00		
				Severity of illness	4.00	3.00	4.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	4.00
				Global improvement		3.00	3.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00
27	4DT	Reboxetine	Female	Efficacy index (*)		2.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00		
				Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		4.00	4.00	3.00	3.00	3.00	3.00	4.00	4.00	4.00	3.00
28	4HD	Reboxetine	Female	Efficacy index (*)		13.00	13.00	9.00	9.00	13.00	13.00	13.00	9.00		
				Severity of illness	6.00	6.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Global improvement		5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
29	3HD	Imipramine	Male	Efficacy index (*)		15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00		
				Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Global improvement		4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
30	4HD	Reboxetine	Female	Efficacy index (*)		1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00		
				Severity of illness	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
31	4DT	Imipramine	Female	Efficacy index (*)		1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00		
				Severity of illness	5.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
				Global improvement		3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
32	2HD	Imipramine	Female	Efficacy index (*)		2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00		
				Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Global improvement		3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
33	2DT	Reboxetine	Male	Efficacy index (*)		2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00		
				Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global improvement		4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
34	3HD	Imipramine	Male	Efficacy index (*)		13.00	13.00	5.00	5.00	13.00	13.00	13.00	5.00		
				Severity of illness	4.00	5.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
				Global improvement		4.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=slightly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
28	3MD	Reboxetine	Female	Severity of illness	6.00	6.00	5.00	4.00	3.00	2.00	2.00	2.00	2.00	2.00		
				Global improvement		4.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	
				Efficacy index		13.00	9.00	9.00	9.00	9.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		1.00	2.00	2.00	2.00	4.00	4.00	4.00	4.00	4.00		
	3DT	Imipramine	Male	Severity of illness	5.00	5.00	3.00	3.00	2.00	2.00	3.00	2.00	2.00	2.00	2.00	
				Global improvement		4.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	9.00	9.00	9.00	1.00	5.00	5.00	5.00	1.00	1.00	1.00
				Efficacy index (*)		1.00	2.00	2.00	4.00	3.00	3.00	4.00	4.00	4.00		
	4MD	Imipramine	Male	Severity of illness	5.00	6.00	6.00	6.00	4.00	4.00	3.00	3.00	3.00	3.00	2.00	
				Global improvement		4.00	4.00	4.00	4.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	13.00	13.00	13.00	5.00	5.00	5.00	5.00	5.00	5.00	1.00
				Efficacy index (*)		1.00	1.00	1.00	3.00	3.00	3.00	3.00	3.00	4.00		
	5MD	Reboxetine	Female	Severity of illness	5.00	4.00	5.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	
				Global improvement		4.00	4.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	13.00	5.00	5.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		1.00	1.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00		
30	1MD	Imipramine	Female	Severity of illness	5.00	5.00	4.00	3.00	2.00	1.00	1.00	1.00	2.00	2.00	2.00	
				Global improvement		4.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index		13.00	13.00	5.00	5.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		1.00	2.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00		
	2MD	Reboxetine	Female	Severity of illness	5.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	
				Global improvement		15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00
				Efficacy index (*)		0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33
	3MD	Imipramine	Female	Severity of illness	4.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	
				Global improvement		3.00	4.00	4.00	4.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		5.00	13.00	13.00	13.00	5.00	5.00	5.00	5.00	5.00	5.00	1.00
				Efficacy index (*)		3.00	1.00	1.00	3.00	3.00	3.00	3.00	3.00	4.00		
	4MD	Reboxetine	Female	Severity of illness	5.00	5.00	1.00	3.00	2.00	3.00	2.00	2.00	2.00	1.00	1.00	
				Global improvement		3.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00
				Efficacy index		9.00	2.00	7.00	2.00	6.00	2.00	6.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		2.00	2.00	1.00	2.00	1.50	2.00	2.00	2.00	2.00		

1831

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

23

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
30	5ND	Imipramine	Female	Severity of illness	5.00	5.00									
				Global improvement	4.00	4.00									
				Efficacy index	12.00	0.50									
31	1ND	Imipramine	Female	Severity of illness	5.00	4.00	4.00	4.00	5.00	5.00					
				Global improvement	3.00	3.00									
				Efficacy index	10.00	12.00									
1DT	Reboxetine	Female	Severity of illness	4.00	4.00	5.00	5.00	5.00	5.00	5.00					
			Global improvement	4.00	4.00	5.00	5.00	3.00	4.00						
			Efficacy index	14.00	14.00	14.00	14.00	10.00	14.00						
1A 00 CJ N	2ND	Reboxetine	Female	Severity of illness	5.00	5.00	4.00	4.00	3.00	4.00	2.00	1.00	1.00	3.00	
				Global improvement	4.00	3.00	3.00	3.00	2.00	3.00	2.00	1.00	1.00	2.00	
				Efficacy index	13.00	9.00	10.00	10.00	6.00	10.00	2.00	2.00	2.00	2.00	2.00
3ND	Imipramine	Male	Severity of illness	6.00	6.00										
			Global improvement	4.00	4.00										
			Efficacy index	16.00	0.25										
32	1ND	Imipramine	Female	Severity of illness	5.00	5.00	4.00	4.00	3.00	1.00	1.00	1.00	1.00	1.00	
				Global improvement	4.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	
				Efficacy index	14.00	6.00	7.00	6.00	6.00	2.00	2.00	2.00	2.00	2.00	
2ND	Imipramine	Female	Severity of illness	4.00	4.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
			Global improvement	5.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00		
			Efficacy index	15.00	6.00	6.00	6.00	2.00	2.00	2.00	2.00	2.00	2.00		
3ND	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	
			Global improvement	4.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00		
			Efficacy index	13.00	13.00	13.00	13.00	10.00	10.00	10.00	10.00	10.00	10.00		

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
 GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
 EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

24

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
32	4ND	Reboxetine	Female	Severity of illness	4.00	4.00	4.00	4.00							
				Global improvement		4.00	3.00	4.00							
				Efficacy index		14.00	10.00	16.00							
				Efficacy index (*)		0.50	1.00	0.25							
5ND	Reboxetine	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00						
			Global improvement		5.00	3.00	3.00	4.00							
			Efficacy index		15.00	10.00	10.00	16.00							
				Efficacy index (*)		0.33	1.00	1.00	0.25						
6ND	Imipramine	Male	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
			Global improvement		4.00	4.00	4.00	4.00							
			Efficacy index		13.00	13.00	13.00	14.00							
				Efficacy index (*)		1.00	1.00	1.00	0.50						
35	1ND	Reboxetine	Female	Severity of illness	5.00	5.00	4.00	6.00							
				Global improvement		4.00	3.00	5.00							
				Efficacy index		14.00	11.00	15.00							
				Efficacy index (*)		0.50	0.67	0.33							
10F	Reboxetine	Female	Severity of illness	3.00	3.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
			Global improvement		4.00	3.00	3.00	3.00							
			Efficacy index		14.00	10.00	9.00	10.00							
				Efficacy index (*)		0.50	1.00	2.00	1.00	1.00	1.00	1.00	1.00		
2ND	Imipramine	Female	Severity of illness	7.00	6.00	7.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	
			Global improvement		3.00	5.00	4.00	5.00							
			Efficacy index		10.00	15.00	15.00	15.00							
				Efficacy index (*)		1.00	0.33	0.33	0.33						
20F	Imipramine	Female	Severity of illness	3.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
			Global improvement		2.00	1.00	1.00	1.00							
			Efficacy index		1.00	2.00	2.00	2.00							
				Efficacy index (*)		4.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00		
3ND	Imipramine	Female	Severity of illness	4.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	
			Global improvement		6.00	6.00	6.00	6.00							
			Efficacy index		16.00	16.00	16.00	16.00							
				Efficacy index (*)		0.25									

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

25

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RD
REBOXETINE - PROTOCOL 20124-035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
35	3DT	Imipramine	Male	Severity of illness	4.00	2.00	2.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	
				Global improvement		2.00	2.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00
				Efficacy index		5.00	2.00	1.00	2.00	2.00	4.00	4.00	4.00	1.50	2.00
				Efficacy index (*)		3.00	2.00	4.00	4.00	4.00	4.00	1.50	2.00		
4ND	Reboxetine	Male	Male	Severity of illness	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
				Global improvement		4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index		13.00	14.00	7.00	11.00	10.00	10.00	10.00	11.00	11.00	11.00
				Efficacy index (*)		1.00	0.50	1.00	0.67	1.00	1.00	0.67	0.67		
4DT	Reboxetine	Female	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	3.00	3.00	3.00	2.00	
				Global improvement		4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00
				Efficacy index		14.00	10.00	10.00	10.00	9.00	10.00	10.00	10.00	9.00	5.00
				Efficacy index (*)		0.50	1.00	1.00	2.00	1.00	1.00	2.00	3.00		
5ND	Reboxetine	Male	Male	Severity of illness	5.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	
				Global improvement		2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00
				Efficacy index		6.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	9.00
				Efficacy index (*)		1.50	1.00	1.00	1.00	1.00	1.00	2.00	3.00		
5DT	Imipramine	Female	Female	Severity of illness	4.00	3.00	2.00	2.00	2.00	1.00	2.00	2.00	2.00	2.00	
				Global improvement		2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		5.00	5.00	6.00	6.00	6.00	6.00	6.00	5.00	5.00	5.00
				Efficacy index (*)		3.00	3.00	1.50	1.50	1.50	3.00	3.00	3.00		
6ND	Reboxetine	Female	Female	Severity of illness	3.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
				Global improvement		2.00	3.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Efficacy index		6.00	6.00	10.00	10.00	15.00	11.00	11.00	11.00	11.00	11.00
				Efficacy index (*)		1.50	1.50	1.00	0.33	0.67	0.67	0.67	0.67		
6DT	Imipramine	Female	Female	Severity of illness	5.00	4.00	3.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	
				Global improvement		3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
				Efficacy index		9.00	5.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Efficacy index (*)		2.00	3.00	4.00	4.00	4.00	4.00	4.00			
7ND	Imipramine	Female	Female	Severity of illness	6.00	4.00	4.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00	
				Global improvement		3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
				Efficacy index		11.00	10.00	6.00	6.00	6.00	13.00	13.00	13.00	13.00	
				Efficacy index (*)		0.67	1.00	1.50	1.50	1.00	1.00	1.00			

1834

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

26

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0
CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
35	7DT	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	4.00	3.00						
				Global improvement	4.00	3.00	3.00	3.00	3.00						
				Efficacy index	13.00	9.00	11.00	10.00	10.00						
				Efficacy index (*)	1.00	2.00	0.67	1.00							
8ND	Imipramine	Female	Severity of illness	5.00	5.00	4.00	3.00	3.00	3.00	3.00	4.00	4.00	3.00	3.00	
			Global improvement	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
			Efficacy index	14.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
				Efficacy index (*)	0.50	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
8DT	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	3.00	2.00	2.00	3.00	3.00	3.00	
			Global improvement	4.00	4.00	4.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	
			Efficacy index	14.00	14.00	14.00	10.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	10.00
				Efficacy index (*)	0.50	0.50	1.00	1.00	1.50	1.50	1.00	1.00	1.00	1.00	
36	1ND	Imipramine	Male	Severity of illness	5.00	5.00	3.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00
				Global improvement	3.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index	9.00	5.00	8.00	8.00	8.00	2.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index (*)	2.00	3.00	1.50	1.50	2.00	2.00	2.00	2.00	1.33	1.33	
183	1DT	Imipramine	Female	Severity of illness	4.00	4.00	4.00	3.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00
				Global improvement	4.00	3.00	3.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index	13.00	6.00	2.00	2.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)	1.00	1.50	2.00	2.00	4.00	2.00	2.00	4.00	4.00		
2ND	Reboxetine	Female	Severity of illness	5.00	3.00	3.00	3.00	3.00	4.00	4.00	3.00	3.00	3.00	3.00	
			Global improvement	2.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
			Efficacy index	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	
				Efficacy index (*)	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50		
2DT	Reboxetine	Female	Severity of illness	4.00	4.00	4.00	3.00	3.00	3.00	1.00	1.00	1.00	1.00	1.00	
			Global improvement	3.00	3.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	
			Efficacy index	10.00	10.00	6.00	6.00	6.00	2.00	2.00	2.00	2.00	2.00	2.00	
				Efficacy index (*)	1.00	1.00	1.00	1.50	2.00	2.00	2.00	2.00	2.00		
3ND	Imipramine	Female	Severity of illness	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
			Global improvement	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
			Efficacy index	13.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	
				Efficacy index (*)	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00		

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

27

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
36	SDT	Imipramine	Female	Severity of illness	4.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Global improvement		3.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index		9.00	5.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		2.00	3.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
4ND	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	6.00	
			Global improvement		4.00	4.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	6.00	
			Efficacy index		13.00	13.00	9.00	9.00	9.00	5.00	5.00	5.00	5.00	13.00	
				Efficacy index (*)		1.00	1.00	2.00	2.00	3.00	3.00	3.00	1.00		
4DT	Reboxetine	Female	Severity of illness	4.00	4.00	4.00	3.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00	
			Global improvement		3.00	3.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	
			Efficacy index		9.00	9.00	5.00	5.00	1.00	1.00	1.00	1.00	2.00	2.00	
				Efficacy index (*)		2.00	2.00	3.00	4.00	4.00	4.00	2.00	2.00		
5MD	Reboxetine	Female	Severity of illness	4.00	3.00	3.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	
			Global improvement		2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	
			Efficacy index		5.00	5.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Efficacy index (*)		3.00	3.00	4.00	4.00	4.00	4.00	4.00	4.00		
5DT	Imipramine	Female	Severity of illness	5.00	4.00	4.00	3.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	
			Global improvement		2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	
			Efficacy index		3.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
				Efficacy index (*)		3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00		
6MD	Imipramine	Female	Severity of illness	3.00	3.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	
			Global improvement		3.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	
			Efficacy index		9.00	5.00	5.00	5.00	5.00	1.00	1.00	1.00	1.00	1.00	
				Efficacy index (*)		2.00	3.00	3.00	3.00	4.00	4.00	4.00	4.00		
6DT	Imipramine	Female	Severity of illness	4.00	4.00	3.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	
			Global improvement		4.00	3.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	
			Efficacy index		13.00	9.00	5.00	5.00	5.00	1.00	1.00	1.00	1.00	1.00	
				Efficacy index (*)		1.00	2.00	3.00	3.00	4.00	4.00	4.00	4.00		
7ND	Reboxetine	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	1.00	1.00	1.00	1.00	1.00	1.00	
			Global improvement		3.00	3.00	3.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00	
			Efficacy index		3.00	3.00	3.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Efficacy index (*)		2.00	2.00	2.00	4.00	4.00	4.00	4.00	4.00		

1836

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

29

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
36	11DT	Reboxetine	Male	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	2.00	2.00			
				Global improvement		5.00	3.00	3.00	3.00	2.00	2.00				
				Efficacy index		13.00	10.00	9.00	9.00	1.00	1.00				
				Efficacy index (*)		1.00	1.00	2.00	2.00	4.00	4.00				
	12MD	Imipramine	Female	Severity of illness	4.00	4.00	6.00								
				Global improvement		4.00	7.00								
				Efficacy index		13.00	16.00								
				Efficacy index (*)		1.00	0.25								
	12DT	Imipramine	Female	Severity of illness	3.00	4.00	3.00	3.00	3.00	2.00	1.00	1.00	1.00	1.00	
				Global improvement		4.00	4.00	3.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index		13.00	13.00	9.00	9.00	5.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		1.00	1.00	2.00	2.00	3.00	4.00	4.00	4.00		
	13MD	Reboxetine	Male	Severity of illness	3.00	3.00	5.00	5.00	6.00	7.00					
				Global improvement		4.00	6.00	6.00	7.00						
				Efficacy index		13.00	13.00	14.00	16.00						
				Efficacy index (*)		1.00	1.00	0.50	0.25						
	14MD	Imipramine	Male	Severity of illness	3.00	3.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Global improvement		2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index		1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00		
	15MD	Reboxetine	Female	Severity of illness	3.00	3.00	3.00	3.00							
				Global improvement		4.00	4.00	4.00							
				Efficacy index		13.00	13.00	13.00							
				Efficacy index (*)		1.00	1.00	1.00							
	16MD	Imipramine	Female	Severity of illness	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
				Global improvement		4.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index		13.00	13.00	13.00	9.00	5.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		1.00	1.00	1.00	2.00	3.00	3.00	3.00	3.00		
	17MD	Reboxetine	Female	Severity of illness	3.00	3.00									
				Global improvement		4.00									
				Efficacy index		16.00									
				Efficacy index (*)		0.25									

1838

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

30

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
36	18MD	Imipramine	Female	Severity of illness	3.00	3.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Global improvement	3.00	3.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index	10.00	6.00	6.00	6.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)	1.00	1.00	1.50	1.50	2.00	2.00	2.00	2.00	2.00	2.00	
19MD	Reboxetine	Female	Severity of illness	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
			Global improvement	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
			Efficacy index	13.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00
				Efficacy index (*)	1.00	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25	
20MD	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	
			Global improvement	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
			Efficacy index	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00
				Efficacy index (*)	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00		
37	3MD	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
				Global improvement	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
				Efficacy index	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00
				Efficacy index (*)	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50		
41	1MD	Imipramine	Male	Severity of illness	5.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	
				Global improvement	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	
				Efficacy index	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00
				Efficacy index (*)	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50		
2MD	Reboxetine	Male	Severity of illness	5.00	4.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	
			Global improvement	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
			Efficacy index	5.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Efficacy index (*)	3.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00		
3MD	Imipramine	Male	Severity of illness	6.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
			Global improvement	3.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
			Efficacy index	9.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	
				Efficacy index (*)	2.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00		
4MD	Reboxetine	Male	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
			Global improvement	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
			Efficacy index	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	
				Efficacy index (*)	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00		

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
 GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
 EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

31

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
41	5ND	Reboxetine	Male	Severity of illness	5.00	5.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	
				Global improvement	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index	10.00	10.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00
42	1ND	Imipramine	Female	Efficacy index (*)	1.00	1.00	1.00	1.50	1.50	1.50	1.50	1.50	1.50	1.50	
				Severity of illness	4.00	4.00	3.00	3.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00
				Global improvement	3.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
43	1DT	Reboxetine	Female	Efficacy index (*)	2.00	3.00	3.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00	
				Severity of illness	4.00	4.00	4.00	3.00	3.00	4.00	4.00	3.00	3.00	3.00	3.00
				Global improvement	4.00	3.00	3.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00
44	2ND	Reboxetine	Female	Efficacy index (*)	4.00	4.00	10.00	6.00	6.00	10.00	10.00	10.00	10.00	10.00	
				Severity of illness	4.00	4.00	3.00	3.00	3.00	4.00	4.00	3.00	3.00	3.00	3.00
				Global improvement	13.00	10.00	6.00	6.00	6.00	10.00	10.00	10.00	10.00	10.00	10.00
45	2DT	Reboxetine	Male	Efficacy index (*)	1.00	1.00	1.50	1.50	1.50	1.00	1.00	1.00	1.00	1.00	
				Severity of illness	4.00	4.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Global improvement	9.00	9.00	10.00	10.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00
46	3ND	Imipramine	Male	Efficacy index (*)	2.00	3.00	3.00	1.00	1.50	1.50	2.00	2.00	2.00	2.00	
				Severity of illness	3.00	3.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
				Global improvement	4.00	4.00	4.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
47	1DT	Reboxetine	Female	Efficacy index (*)	1.00	1.00	1.00	2.00	2.00	1.00	1.00	1.00	1.50	1.50	
				Severity of illness	5.00	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global improvement	4.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
48	2DT	Imipramine	Female	Efficacy index (*)	4.00	4.00	14.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	
				Severity of illness	4.00	4.00	4.00	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global improvement	4.00	3.00	3.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3= mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

32

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
43	30T	Imipramine	Male	Severity of illness	5.00	5.00	4.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Global improvement	3.00	3.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index	10.00	10.00	10.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
40T	Reboxetine	Female	Severity of illness	4.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	
			Global improvement	4.00	4.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
			Efficacy index	14.00	14.00	10.00	10.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00
50T	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
			Global improvement	4.00	4.00	3.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
			Efficacy index	14.00	14.00	10.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00
60T	Imipramine	Female	Severity of illness	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
			Global improvement	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
			Efficacy index	10.00	10.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00
44	10T	Reboxetine	Female	Severity of illness	4.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	
				Global improvement	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index	1.00	1.00	1.00	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50
44	20T	Reboxetine	Female	Severity of illness	4.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	
				Global improvement	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
40T	Reboxetine	Female	Severity of illness	4.00	4.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	
			Global improvement	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
			Efficacy index	9.00	9.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
20T	Reboxetine	Female	Severity of illness	4.00	3.00	4.00	4.00	3.00	4.00	4.00	4.00	4.00	4.00	2.00	
			Global improvement	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	1.00
			Efficacy index	6.00	11.00	7.00	7.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00
30T	Imipramine	Female	Severity of illness	4.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	
			Global improvement	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
			Efficacy index	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

33

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
44	4ND	Imipramine	Male	Severity of illness	5.00	5.00	4.00	3.00	4.00	5.00	5.00	4.00	4.00		
				Global improvement	4.00	4.00	3.00	3.00	5.00	5.00	5.00	5.00	5.00	4.00	4.00
				Efficacy index	13.00	9.00	9.00	9.00	13.00	13.00	13.00	13.00	13.00	9.00	13.00
				Efficacy index (*)	1.00	2.00	2.00	2.00	1.00	1.00	2.00	2.00	1.00		
45	1ND	Reboxetine	Male	Severity of illness	5.00	4.00	3.00	3.00	4.00	4.00	2.00	1.00	1.00	1.00	
				Global improvement	4.00	4.00	2.00	2.00	3.00	3.00	2.00	2.00	2.00	1.00	1.00
				Efficacy index	14.00	6.00	6.00	5.00	9.00	5.00	5.00	5.00	5.00	1.00	1.00
				Efficacy index (*)	0.50	1.50	3.00	3.00	2.00	3.00	4.00	4.00	4.00		
1842	1DT	Imipramine	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	3.00	2.00	2.00	2.00	2.00	
				Global improvement	4.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00
				Efficacy index	14.00	14.00	14.00	11.00	11.00	11.00	11.00	11.00	11.00	7.00	7.00
				Efficacy index (*)	0.50	0.50	0.50	0.67	0.67	0.67	1.00	1.00	1.00	1.00	
46	2ND	Imipramine	Male	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
				Global improvement	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00
				Efficacy index	13.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	7.00	7.00
				Efficacy index (*)	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
46	4ND	Imipramine	Male	Severity of illness	5.00	3.00	2.00	2.00	3.00	1.00	1.00	1.00	1.00	1.00	
				Global improvement	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index	5.00	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Efficacy index (*)	3.00	3.00	3.00	4.00	2.00	2.00	4.00	4.00	4.00	4.00	
2ND	2ND	Imipramine	Female	Severity of illness	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
				Global improvement	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index	10.00	10.00	10.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00
				Efficacy index (*)	1.00	1.00	1.00	0.67	0.67	0.67	0.67	0.67	0.67		
3ND	3ND	Reboxetine	Female	Severity of illness	5.00	5.00	4.00	3.00	4.00	3.00	2.00	1.00	1.00	2.00	
				Global improvement	5.00	5.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index	15.00	10.00	10.00	5.00	9.00	5.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)	0.33	1.00	3.00	3.00	2.00	3.00	4.00	4.00	4.00		
4ND	4ND	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
				Global improvement	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00		

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3= mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

34

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
48	10F	Reboxetine	Female	Severity of illness	4.00	4.00									
				Global improvement											
				Efficacy index	14.00	0.50									
	20F	Imipramine	Female	Severity of illness	4.00	4.00	4.00	4.00	3.00	3.00	4.00				
				Global improvement											
				Efficacy index	10.00	1.00	10.00	10.00	6.00	6.00	10.00	1.00			
291	10D	Imipramine	Female	Severity of illness	5.00	4.00	4.00	4.00	4.00	4.00					
				Global improvement											
				Efficacy index	10.00	1.00	10.00	10.00	15.00	15.00	0.33				
	10F	Reboxetine	Female	Severity of illness	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
				Global improvement											
				Efficacy index	1.00	1.00	2.00	2.00	2.00	3.00	3.00	4.00	4.00		
	20D	Reboxetine	Female	Severity of illness	5.00	4.00	4.00	4.00	5.00	5.00	5.00	5.00	5.00	5.00	
				Global improvement											
				Efficacy index	10.00	1.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00
	20F	Reboxetine	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	
				Global improvement											
				Efficacy index	0.50	0.50	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00
	30D	Imipramine	Male	Severity of illness	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
				Global improvement											
				Efficacy index	9.00	2.00	9.00	9.00	5.00	5.00	1.00	1.00	1.00	1.00	1.00
	30F	Imipramine	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
				Global improvement											
				Efficacy index	15.00	0.33									

10043

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=wildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=minimally improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

35

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
291	4ND	Reboxetine	Male	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
				Global improvement	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Efficacy index	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00
				Efficacy index (*)	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00		
4DT	Imipramine	Male	Severity of illness	5.00	5.00	5.00	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	
			Global improvement	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	
			Efficacy index	13.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	5.00
				Efficacy index (*)	1.00	2.00	2.00	2.00	3.00	2.00	2.00	2.00	3.00		
25DT	Imipramine	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	3.00	3.00	2.00	2.00	2.00	2.00	
			Global improvement	3.00	4.00	4.00	4.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00	
			Efficacy index	9.00	13.00	13.00	13.00	9.00	5.00	1.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)	2.00	1.00	1.00	1.00	2.00	3.00	4.00	4.00	4.00		
26DT	Reboxetine	Female	Severity of illness	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
			Global improvement	3.00	3.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
			Efficacy index	9.00	9.00	9.00	9.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00
				Efficacy index (*)	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00		
27DT	Reboxetine	Female	Severity of illness	4.00	4.00	4.00	3.00	3.00	4.00	4.00	3.00	3.00	3.00	3.00	
			Global improvement	4.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
			Efficacy index	13.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	
				Efficacy index (*)	1.00	2.00	2.00	3.00	2.00	2.00	4.00	4.00	4.00		
28DT	Imipramine	Female	Severity of illness	5.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
			Global improvement	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
			Efficacy index	9.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
				Efficacy index (*)	2.00	3.00	3.00	3.00	4.00	3.00	3.00	3.00	3.00		
292	5ND	Imipramine	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
				Global improvement	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Efficacy index	14.00	14.00	14.00	13.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00
				Efficacy index (*)	0.50	0.50	0.50	1.00	2.00	3.00	3.00	3.00			
5DT	Reboxetine	Male	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
			Global improvement	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
			Efficacy index	13.00	14.00	14.00	13.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	
				Efficacy index (*)	1.00	0.50	0.50	1.00	2.00	2.00	3.00	3.00			

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

36

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
292	66D	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00		
				Global improvement		4.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
				Efficacy index		13.00	9.00	9.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		1.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00		
	6DT	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	4.00	4.00	4.00	4.00	4.00	3.00	3.00	
				Global improvement		4.00	4.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		14.00	13.00	9.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		0.50	1.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00		
	76D	Reboxetine	Male	Severity of illness	5.00	5.00	5.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
				Global improvement		4.00	4.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		14.00	14.00	9.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		0.50	0.50	2.00	3.00	3.00	3.00	3.00	3.00	3.00		
1845	7DT	Imipramine	Male	Severity of illness	5.00	5.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	
				Global improvement		4.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00
				Efficacy index		14.00	14.00	9.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		0.50	3.00	3.00	3.00	3.00	3.00	3.00	3.00	4.00		
	86D	Imipramine	Male	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	4.00	3.00	3.00	2.00	2.00	
				Global improvement		4.00	4.00	4.00	4.00	3.00	3.00	3.00	2.00	2.00	1.00	1.00
				Efficacy index		14.00	13.00	13.00	13.00	9.00	9.00	9.00	9.00	5.00	5.00	5.00
				Efficacy index (*)		0.50	1.00	1.00	2.00	2.00	2.00	2.00	2.00	4.00		
	8DT	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	
				Global improvement		4.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	9.00	9.00	6.00	6.00	5.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		1.00	2.00	2.00	1.50	3.00	3.00	3.00	3.00	3.00		
	21ND	Imipramine	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	3.00	3.00	3.00	2.00	2.00	2.00	
				Global improvement		4.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00
				Efficacy index		14.00	9.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		0.50	2.00	3.00	3.00	3.00	3.00	4.00	4.00	4.00		
	21DT	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	3.00	3.00	3.00	2.00	2.00	2.00	
				Global improvement		4.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00
				Efficacy index		14.00	10.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		0.50	1.00	3.00	3.00	3.00	3.00	4.00	4.00	4.00		

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
 GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=mainly improved, 4=no change, 5=mainly worse, 6=much worse, 7=very much worse
 EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

37

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
292	22HD	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
				Global improvement		4.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index		14.00	14.00	13.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00
				Efficacy index (*)		0.50	0.50	1.00	2.00	2.00	2.00	2.00	2.00	2.00	
293	22DT	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	4.00	4.00	4.00	4.00	
				Global improvement		4.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index		14.00	13.00	13.00	9.00	9.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		0.50	1.00	1.00	2.00	2.00	3.00	3.00	2.00	2.00	
294	23HD	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	4.00	3.00	3.00	3.00	3.00	2.00	
				Global improvement		4.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		14.00	9.00	9.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		0.50	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	
295	23DT	Reboxetine	Male	Severity of illness	5.00	5.00	4.00	4.00	3.00	3.00	2.00	2.00	2.00	2.00	
				Global improvement		4.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		14.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		0.50	3.00	3.00	3.00	3.00	4.00	4.00	4.00	4.00	
296	24HD	Reboxetine	Male	Severity of illness	5.00	5.00	5.00	4.00	3.00	3.00	2.00	2.00	2.00	2.00	
				Global improvement		4.00	4.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00
				Efficacy index		13.00	14.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		1.00	0.50	3.00	3.00	3.00	4.00	4.00	4.00	4.00	
297	24DT	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	4.00	4.00	4.00	
				Global improvement		4.00	4.00	4.00	4.00	4.00	4.00	4.00	3.00	3.00	3.00
				Efficacy index		14.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	9.00	9.00
				Efficacy index (*)		0.50	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	
298	9HD	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
				Global improvement		4.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00
				Efficacy index		13.00	13.00	13.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00
				Efficacy index (*)		1.00	1.00	1.00	2.00	2.00	2.00	3.00	3.00	3.00	
299	9DT	Imipramine	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
				Global improvement		4.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00
				Efficacy index (*)		1.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
 GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
 EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

38

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
293	10ND	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
				Global improvement		4.00	4.00	4.00	3.00	3.00	2.00	2.00	2.00	2.00	
				Efficacy index		13.00	13.00	13.00	9.00	9.00	5.00	5.00	5.00	5.00	3.00
				Efficacy index (*)		1.00	1.00	1.00	2.00	2.00	3.00	3.00	3.00	3.00	
10DT	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
			Global improvement		4.00	4.00	4.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	
			Efficacy index		13.00	13.00	13.00	9.00	9.00	5.00	5.00	5.00	5.00	5.00	3.00
				Efficacy index (*)		1.00	1.00	1.00	2.00	2.00	3.00	3.00	3.00	3.00	
11ND	Imipramine	Male	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
			Global improvement		4.00	4.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	
			Efficacy index		13.00	13.00	9.00	9.00	5.00	5.00	5.00	5.00	5.00	5.00	3.00
				Efficacy index (*)		1.00	1.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	
11DT	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
			Global improvement		4.00	4.00	4.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	
			Efficacy index		13.00	13.00	13.00	9.00	9.00	5.00	5.00	5.00	5.00	5.00	3.00
				Efficacy index (*)		1.00	1.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	
12ND	Reboxetine	Male	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
			Global improvement		4.00	4.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	
			Efficacy index		13.00	13.00	9.00	9.00	5.00	5.00	5.00	5.00	5.00	5.00	3.00
				Efficacy index (*)		1.00	1.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	
12DT	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
			Global improvement		4.00	4.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	
			Efficacy index		13.00	13.00	9.00	9.00	5.00	5.00	5.00	5.00	5.00	5.00	3.00
				Efficacy index (*)		1.00	1.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	
294	13ND	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
				Global improvement		4.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00
				Efficacy index		13.00	9.00	9.00	5.00	5.00	5.00	5.00	5.00	5.00	1.00
				Efficacy index (*)		1.00	2.00	2.00	3.00	3.00	3.00	4.00	4.00	4.00	
13DT	Reboxetine	Female	Severity of illness	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	
			Global improvement		4.00	4.00	4.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00	
			Efficacy index		13.00	13.00	13.00	9.00	9.00	13.00	13.00	13.00	13.00	13.00	13.00
				Efficacy index (*)		1.00	1.00	1.00	2.00	2.00	1.00	1.00	1.00	1.00	

10047

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

39

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63
294	14MD	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	4.00	4.00	3.00	1.00	1.00	
				Global improvement		4.00	3.00	3.00	2.00	3.00	2.00	2.00	1.00	
				Efficacy index		13.00	9.00	10.00	5.00	6.00	2.00	1.00	4.00	
				Efficacy index (*)		1.00	2.00	1.00	3.00	1.50	2.00	4.00	4.00	
	14DT	Imipramine	Female	Severity of illness	6.00	6.00	6.00	6.00	6.00	6.00	6.00	5.00	4.00	
				Global improvement		4.00	4.00	4.00	4.00	4.00	4.00	3.00	2.00	
				Efficacy index		13.00	13.00	13.00	13.00	13.00	9.00	5.00	5.00	
				Efficacy index (*)		1.00	1.00	1.00	1.00	1.00	1.00	2.00	3.00	
	15ND	Imipramine	Female	Severity of illness	4.00	5.00	5.00	5.00	5.00	3.00	1.00	1.00	1.00	
				Global improvement		4.00	4.00	3.00	3.00	1.00	1.00	1.00	1.00	
				Efficacy index		13.00	13.00	9.00	9.00	1.00	1.00	1.00	1.00	4.00
				Efficacy index (*)		1.00	1.00	2.00	2.00	4.00	4.00	4.00	4.00	
	15DT	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	4.00	4.00	2.00	
				Global improvement		4.00	4.00	4.00	4.00	4.00	3.00	2.00	1.00	
				Efficacy index		13.00	13.00	13.00	13.00	13.00	9.00	5.00	1.00	4.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	1.00	2.00	3.00	4.00	
	16ND	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	4.00	4.00	1.00	
				Global improvement		4.00	4.00	4.00	4.00	4.00	3.00	2.00	1.00	
				Efficacy index		13.00	13.00	13.00	13.00	13.00	9.00	5.00	1.00	4.00
				Efficacy index (*)		1.00	1.00	1.00	2.00	3.00	4.00	4.00	4.00	
	16DT	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	4.00	4.00	2.00	1.00	
				Global improvement		4.00	4.00	4.00	4.00	2.00	2.00	1.00	1.00	
				Efficacy index		13.00	13.00	13.00	13.00	13.00	9.00	5.00	1.00	1.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	3.00	4.00	4.00	4.00	
	25ND	Imipramine	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	1.00	
				Global improvement		4.00	3.00	3.00	2.00	2.00	1.00	1.00	1.00	
				Efficacy index		13.00	9.00	10.00	5.00	1.00	1.00	1.00	1.00	4.00
				Efficacy index (*)		1.00	2.00	1.00	3.00	4.00	4.00	4.00	4.00	
	26ND	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	4.00	1.00	1.00	1.00	1.00	
				Global improvement		4.00	3.00	2.00	2.00	1.00	1.00	1.00	1.00	
				Efficacy index		13.00	9.00	5.00	5.00	1.00	1.00	1.00	1.00	1.00
				Efficacy index (*)		1.00	2.00	3.00	4.00	4.00	4.00	4.00	4.00	

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=initially improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

40

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
294	27HD	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	1.00	1.00	1.00			
				Global improvement		4.00	4.00	4.00	4.00	4.00	1.00	1.00	1.00	1.00		
				Efficacy index		13.00	13.00	13.00	13.00	13.00	1.00	1.00	1.00	4.00	4.00	
				Efficacy index (*)		1.00	1.00	1.00	1.00	4.00	4.00	4.00	4.00			
28HD	28HD	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	4.00	3.00	1.00	1.00	1.00			
				Global improvement		4.00	3.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00		
				Efficacy index		13.00	9.00	5.00	5.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Efficacy index (*)		1.00	2.00	3.00	4.00	4.00	4.00	4.00	4.00			
29DT	29DT	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00			
				Global improvement		4.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	4.00	
				Efficacy index		13.00	13.00	14.00	14.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
				Efficacy index (*)		1.00	1.00	0.50	0.50	1.00	1.00	1.00	1.00			
30DT	30DT	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00			
				Global improvement		4.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	
				Efficacy index		13.00	13.00	13.00	13.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00
				Efficacy index (*)		1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00			
31DT	31DT	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00			
				Global improvement		4.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	
				Efficacy index		13.00	13.00	13.00	13.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00
				Efficacy index (*)		1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00			
32DT	32DT	Imipramine	Male	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	4.00	4.00	4.00			
				Global improvement		4.00	4.00	4.00	4.00	4.00	4.00	4.00	3.00	3.00	3.00	
				Efficacy index		13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	9.00	5.00	5.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	1.00	2.00	2.00	3.00			
295	17HD	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	4.00	4.00	4.00	3.00	3.00	3.00			
				Global improvement		6.00	6.00	6.00	6.00	6.00	5.00	5.00	1.00	1.00	1.00	
				Efficacy index		1.50	1.50	1.50	1.50	1.50	3.00	3.00	3.00	4.00	4.00	4.00
				Efficacy index (*)		1.50	1.50	1.50	1.50	3.00	3.00	3.00	3.00			
17DT	17DT	Imipramine	Male	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00			
				Global improvement		4.00	4.00	5.00	5.00	5.00	5.00	4.00	4.00	4.00	4.00	
				Efficacy index		14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00
				Efficacy index (*)		0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50			

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
 GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
 EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

41

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
295	18ND	Reboxetine	Female	Severity of illness	5.00	5.00	4.00	4.00	5.00	5.00	5.00	5.00	5.00	5.00		
				Global improvement		3.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	5.00
				Efficacy index		10.00	9.00	9.00	14.00	14.00	14.00	14.00	14.00	14.00	13.00	13.00
				Efficacy index (*)		1.00	2.00	2.00	0.50	0.50	0.50	1.00	1.00	1.00		
18DT	18DT	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	4.00	4.00	3.00	3.00	3.00	3.00	
				Global improvement		4.00	4.00	4.00	4.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		14.00	14.00	14.00	14.00	9.00	9.00	9.00	9.00	5.00	5.00	5.00
				Efficacy index (*)		0.50	0.50	0.50	0.50	2.00	2.00	3.00	3.00	3.00		
19ND	19ND	Imipramine	Male	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
				Global improvement		4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Efficacy index		14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00
				Efficacy index (*)		0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50		
19DT	19DT	Reboxetine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
				Global improvement		4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Efficacy index		13.00	14.00	14.00	14.00	14.00	13.00	13.00	13.00	13.00	13.00	13.00
				Efficacy index (*)		1.00	0.50	0.50	0.50	1.00	1.00	1.00	1.00	2.00		
20ND	20ND	Imipramine	Female	Severity of illness	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	
				Global improvement		4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Efficacy index		14.00	14.00	14.00	14.00	14.00	13.00	13.00	13.00	13.00	13.00	13.00
				Efficacy index (*)		0.50	0.50	0.50	0.50	1.00	1.00	1.00	1.00	1.00		
20DT	20DT	Reboxetine	Female	Severity of illness	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
				Global improvement		4.00	4.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		13.00	13.00	9.00	9.00	9.00	5.00	5.00	5.00	5.00	5.00	5.00
				Efficacy index (*)		1.00	1.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00		
381	1ND	Reboxetine	Male	Severity of illness	4.00	3.00	3.00	2.00	3.00	2.00	2.00	2.00	1.00	1.00	1.00	
				Global improvement		3.00	3.00	2.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		10.00	10.00	6.00	10.00	10.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index (*)		1.00	1.00	1.50	1.00	2.00	2.00	2.00	2.00	2.00		
2ND	2ND	Reboxetine	Female	Severity of illness	4.00	4.00	3.00	3.00	2.00	4.00	4.00	4.00	4.00	4.00	4.00	
				Global improvement		4.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Efficacy index		14.00	11.00	10.00	10.00	6.00	16.00	16.00	16.00	16.00	16.00	16.00
				Efficacy index (*)		0.50	0.67	1.00	1.50	0.25	0.25	0.25	0.25	0.25		

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

42

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

		CLINICAL GLOBAL IMPRESSION													
Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63	
381	301	Reboxetine	Female	Severity of illness	4.00	2.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	
				Global improvement	4.00	2.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
				Efficacy index	4.00	5.00	15.00	15.00	10.00	10.00	14.00	14.00	10.00	10.00	10.00
382	400	Imipramine	Female	Efficacy index (*)		3.00	0.33	0.33							
				Severity of illness	4.00	4.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00
				Global improvement	4.00	4.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00
382	500	Imipramine	Female	Efficacy index (*)		13.00	9.00	2.00							
				Severity of illness	4.00	5.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
				Global improvement	4.00	5.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
108	501	Reboxetine	Male	Efficacy index (*)		13.00	13.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	
				Severity of illness	4.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				Global improvement	4.00	4.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00
108	501	Reboxetine	Female	Efficacy index (*)		2.00	1.00								
				Severity of illness	4.00	3.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global improvement	4.00	3.00	6.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
601	601	Imipramine	Female	Efficacy index (*)		10.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	11.00	
				Severity of illness	4.00	1.00	0.50	0.50	0.50	0.50	1.00	1.00	0.50	1.00	0.67
				Global improvement	4.00	3.00	5.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00
700	700	Reboxetine	Female	Efficacy index (*)		0.50	0.50	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
				Severity of illness	3.00	3.00	4.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Global improvement	3.00	4.00	4.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
700	700	Imipramine	Male	Efficacy index (*)		14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	
				Severity of illness	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Global improvement	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
701	701	Imipramine	Male	Efficacy index (*)		2.00	2.00	1.00	1.50	1.50	2.00	2.00	2.00	2.00	
				Severity of illness	4.00	4.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				Global improvement	4.00	4.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

43

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.0

CLINICAL GLOBAL IMPRESSION

Centre	Patient	Treatment	Sex	C.G.I.	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63		
382	8ND	Imipramine	Male	Severity of illness	5.00	4.00	5.00									
				Global improvement		4.00	5.00									
				Efficacy index		13.00	13.00									
				Efficacy index (*)		1.00	1.00									
	8PT	Reboxetine	Female	Severity of illness	4.00	3.00	4.00	3.00	2.00	1.00	2.00	3.00	2.00	2.00		
				Global improvement		3.00	4.00	3.00	2.00	2.00	5.00	3.00	5.00	3.00	3.00	
				Efficacy index		9.00	13.00	10.00	5.00	2.00	14.00	6.00	13.00	6.00	6.00	
				Efficacy index (*)		2.00	1.00	1.00	3.00	2.00	0.50	1.00	1.50			
	9ND	Reboxetine	Female	Severity of illness	5.00	3.00	2.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00		
				Global improvement		2.00	2.00	5.00	2.00	1.00	1.00	1.00	1.00	1.00	2.00	
				Efficacy index		2.00	2.00	13.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	5.00
				Efficacy index (*)		2.00	2.00	1.00	4.00	4.00	4.00	4.00	3.00			
	9PT	Reboxetine	Female	Severity of illness	4.00	4.00	2.00	3.00	4.00							
				Global improvement		4.00	3.00	4.00	4.00	5.00	2.00	1.00	1.00	2.00	2.00	
				Efficacy index		13.00	10.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00			
	10ND	Imipramine	Female	Severity of illness	5.00	5.00										
				Global improvement		5.00										
				Efficacy index		16.00										
				Efficacy index (*)		0.25										
3301	1ND	Reboxetine	Female	Severity of illness	4.00	4.00										
				Global improvement		4.00										
				Efficacy index		13.00										
				Efficacy index (*)		1.00										
	2ND	Imipramine	Male	Severity of illness	6.00	5.00	5.00	4.00	4.00	3.00	3.00	2.00	2.00	2.00		
				Global improvement		3.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	
				Efficacy index		10.00	10.00	10.00	9.00	9.00	5.00	5.00	5.00	5.00	5.00	
				Efficacy index (*)		1.00	1.00	1.00	2.00	2.00	3.00	3.00	3.00			
	3ND	Reboxetine	Female	Severity of illness	4.00	4.00	4.00	4.00	5.00	5.00						
				Global improvement		4.00	5.00	5.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	
				Efficacy index		13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00
				Efficacy index (*)		1.00	1.00	1.00	1.00	0.25						

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

44

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124-035
Listing No.: 16.0

Centre	Patient	Treatment	Sex	C.G.I.	CLINICAL GLOBAL IMPRESSION													
					Day 0	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	Day 56	Day 63				
SS02	5ND	Reboxetine	Female	Severity of illness	4.00	4.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
				Global Improvement		5.00	5.00	6.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Efficacy Index		13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00
	6ND	Imipramine	Female	Efficacy Index (*)		1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
				Severity of illness	4.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global Improvement		2.00	2.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
	7ND	Imipramine	Female	Efficacy Index (*)		3.00	3.00	3.00	0.50	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
				Severity of illness	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global Improvement		3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
				Efficacy Index (*)		9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	
				Severity of illness	2.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
				Global Improvement		2.00	2.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
				Efficacy Index (*)		2.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
				Severity of illness	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global Improvement		3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
				Efficacy Index (*)		2.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	
				Severity of illness	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
				Global Improvement		3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00

1853

SEVERITY OF ILLNESS: 1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=extremely ill
GLOBAL IMPROVEMENT: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse
EFFICACY INDEX (*): computed from the vector activity by the vector side effects

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA DMS RED
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 17.9

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	End date	Last report visit	Save city	Hist ory	Rei ship	Rel ation	Stud Symp	Dis app.	Re app.	Out come			
1	1ND	Reboxetine	05/11/92	30/12/92		MICTURITION DISORDER	Detail	29/10/92(D)	0		0	1								NO		
							Summary	29/10/92(D)				0	1								NO	
2ND		Imipramine	17/11/92	11/01/93		ALLERGIC REACTION	Detail	18/11/92	7	20/11/92	1	3	4	1	YES	3	3	3	3	3	3	
							Summary	18/11/92	20/11/92		14	1	3	4	1	YES	3	3	3	3	1	YES
						CONSTIPATION	Detail	15/11/92(D)	0			2										NO
							Summary	15/11/92(D)				0	2									NO
						DIZZINESS	Detail	25/11/92	56	11/01/93(+)	56	1	2	3	1	2	3	3	3	3	3	YES
							Summary	25/11/92			56	1	2	3	1	2	3	3	3	3	3	YES
						MOUTH DRY	Detail	25/11/92	56	11/01/93(+)	56	1	2	3	1	3	3	3	3	3	3	YES
							Summary	25/11/92			56	1	2	3	1	3	3	3	3	3	3	YES
3ND		Imipramine	05/06/93	26/07/93		ANDREXIA	Detail	26/05/93(D)	0			2										NO
							Summary	26/05/93(D)				0	2									NO
						BUNDLE BRANCH BLOCK	Detail	30/06/93	56	20/07/93(+)	56	1	2	4	1	2	3	3	3	3	3	YES
							Summary	30/06/93			56	1	2	4	1	2	3	3	3	3	3	YES
						CONSTIPATION	Detail	02/06/93(D)	0			1										NO
							Summary	02/06/93(D)				1	1	4	1	YES	3	3	3	3	3	NO
						DIZZINESS	Detail	26/05/93(D)	0			1										NO
							Summary	26/05/93(D)				0	1									NO

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=ongoing, 2=discontinued, 3=withdrawn, 4=terminated
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 1=no, 2=yes
 (+) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (0) first report visit date used (screen data - 1 day used for A.E. reported at day0), (1) onset date A.E.

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBORETINE - PROTOCOL 20124/055
Listine No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report visit	Save rity	Hist ary	Re Stud	Dis app.	Re came (c)					
														visit	drug	trac	Mosp	app.
1	SMD	Isipramline	03/06/93	28/07/93 DYSPLACIA	Detail	26/05/93(C)	0		1					NO				
					Summary	26/05/93(C)		0	1									
					Detail	26/05/93(C)	0		2								NO	
					Summary	26/05/93(C)		0	2									
					Detail	02/06/93(1)	0		1									
					Summary	02/06/93	7	14 16/06/93	1	1	4	1	3	3	3	3	3	
					Detail	02/06/93	15/06/93	14	1	1	4	1	3	3	3	3	3	1
					Summary	02/06/93		14	1	1	4	1	3	3	3	3	3	1
					Detail	26/05/93(C)	0		2									NO
					Summary	26/05/93(C)		0	2									
					Detail	26/05/93(C)	0		1									NO
					Summary	26/05/93(C)		0	1									
30T	Reboretine	18/12/93	03/02/94 CONSTIPATION	Detail	07/12/93(C)	0			1					NO				
				Summary	07/12/93(C)		0	1										
				Detail	17/10/93(C)	0		2								NO		
				Summary	17/10/93(C)		0	2										
				Detail	17/10/93(C)	0		3									NO	
				Summary	17/10/93(C)		0	3										
				Detail	17/10/93(C)	0		1									NO	
				Summary	17/10/93(C)		0	1										
				Detail	17/10/93(C)	0		2									NO	
				Summary	17/10/93(C)		0	2										
				Detail	17/10/93(C)	0		3										

1835

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Kaapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 1=no, 2=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (C) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

3

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report visit	Save rity	Hist ory	Rel ship	Stu dy	Sym ptom	Dis app.	Re sult	Dut y
1	4ND	Reboxetine	19/10/93	13/12/93	CONSTIPATION	Summary	17/10/93(D)		0	3							NO
					FATIGUE	Detail	17/10/93(D)	0		3							NO
						Summary	17/10/93(D)		0	3							NO
					HYPOKINESIA	Detail	17/10/93(D)	0		3							NO
						Summary	17/10/93(D)		0	3							NO
					INSOMNIA	Detail	17/10/93(D)	0		3							NO
						Summary	17/10/93(D)		0	3							NO
					MOUTH DRY	Detail	17/10/93(D)	0		2							NO
						Summary	17/10/93(D)		0	2							NO
					SWEATING-INCREASED	Detail	17/10/93(D)	0		2							NO
						Summary	17/10/93(D)		0	2							NO
					TREMOR	Detail	17/10/93(D)	0		2							NO
						Summary	17/10/93(D)		0	2							NO
2	1ND	Reboxetine	15/01/95	05/02/95	ANOREXIA	Detail	05/01/95(D)	0		2							NO
						Summary	05/01/95(D)		0	2							NO
					CONSTIPATION	Detail	06/01/95(D)	0		1							NO
						Summary	06/01/95(D)		0	1							NO
					DIZZINESS	Detail	06/01/95(D)	0		1							NO
						Summary	06/01/95(D)		0	1							NO
						Detail	06/02/95	28	11/02/95(*)	28	2	1	5	3	2	1	5
						Summary	06/02/95		11/02/95(*)	28	2	1	5	3	2	1	5

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=stop. Inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=free. With seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date
 onset data missing: (D) first report visit date used (screen date - 1 day used for A.E. reported at day0), (I) onset date A.E.

1856

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

4

PHARMACIA CNS RED

REBOXATINE - PROTOCOL 20124/955
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Last report visit	Saves rity	Hist ory	Rep ort	Stu dy	Symp tom	Dis app.	Re Out							
																	Sev	Dis app.	Re Out				
2	IND	Reboxatine	15/01/93	08/02/93	DYSPNOEA	Detail	06/01/93(D)	0		1							NO						
						Summary	06/01/93(D)	0	0	1													
						Detail	06/01/93(D)	0		2												NO	
						Summary	06/01/93(D)	0	0	2													
						Detail	06/01/93(D)	0		1												NO	
						Summary	06/01/93(D)	0	0	1													
						Detail	06/01/93(D)	0		1												NO	
						Summary	06/01/93(D)	0	0	1													
						Detail	06/01/93(D)	0		1												NO	
						Summary	06/01/93(D)	0	0	1													
						Detail	06/01/93(D)	0		1												NO	
						Summary	06/01/93(D)	0	0	1													
3	IND	Reboxatine	05/05/93	22/04/93	ANOREXIA	Detail	22/04/93(D)	0		2							NO						
						Summary	22/04/93(D)	0	0	2													
						Detail	22/04/93(D)	0		1												NO	
						Summary	22/04/93(D)	0	0	1													
						Detail	22/04/93(D)	0		3												NO	
						Summary	22/04/93(D)	0	0	3													
						Detail	06/05/93	07/05/93	1	3	6	1	YES	3	3	3	1						

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=none change, 2=dose reduced, 3=def. withdrawal, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (R) adverse event still present; end date = visit date
 onset date missing: (S) first report visit date used (screen date - 1 day used for A-E, reported at day0), (1) onset date A-E.

1857

9550089

5

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA DNS RED
 REBOXETINE - PROTOCOL 2012/035
 Listing No.: 17.3

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Last report visit	Save rity	Hlet ary	Rel ship	Std drug	Sym tra	Dis app.	Re app.	Out
3	IND	Reboxetine	05/06/93	22/06/93	FLATULENCE	Summary	06/05/93		07/05/93								
						Detail	22/06/93(D)	0		1							
						Summary	22/06/93(D)	0		1							
						Detail	22/06/93(D)	0		3							
						Summary	22/06/93(D)	0		3							
						Detail	22/06/93(D)	0		1							
						Summary	22/06/93(D)	0		1							
4	IND	Imipramine	25/11/92	29/12/92	ANEMIA	Detail	29/12/92	35	29/12/92(*)	35	2	2	3	3	3	3	3
						Summary	29/12/92	35	29/12/92(*)	35	2	2	3	3	3	3	3
						Detail	19/11/92(D)	0		1							
						Summary	19/11/92(D)	0		1							
						Detail	26/12/92	35	26/12/92	35	2	2	3	3	3	3	3
						Summary	26/12/92	35	26/12/92	35	2	2	3	3	3	3	3
						Detail	19/11/92(D)	0		2							
						Summary	19/11/92(D)	0		2							
						Detail	05/01/93	99	30/01/93(*)	99	2	4	4	4	4	4	4
						Summary	05/01/93	99	30/01/93(*)	99	2	4	4	4	4	4	4
						Detail	29/12/92	35	29/12/92(*)	35	2	2	3	3	3	3	3
						Summary	29/12/92	35	29/12/92(*)	35	2	2	3	3	3	3	3
						Detail	29/12/92	35	29/12/92(*)	35	2	2	3	3	3	3	3
						Summary	29/12/92	35	29/12/92(*)	35	2	2	3	3	3	3	3

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe.
 Study drug: 1= no change, 2= dose reduced, 3= def. withdrawn, 4= stop. inter.
 Hospital: 1= required, 2= not req., 3= not appl. -- Outcome: 1= recovered, 2= free. with seq., 3= still present, 4= death
 Disapp./reapp.: 1= no, 2= yes, 3= not appl. -- Relationship: 1= definite, 2= probable, 3= possible, 4= doubtful, 5= unknown, 6= none
 Symptomatic treatment: 0= no, 1= yes
 (C) adverse event used for statistical analysis
 (I) adverse event still present: end date = visit date
 (M) onset data missing: (D) first report visit date used (screen data - 1 day used for A.E. reported at day0), (I) onset date A.E.

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RSD

REBOMETINE - PROTOCOL 20124/025
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	End date	Last report visit	Save rity	Hist ory	Rel ship	Stud app.	Symm	Dis app.	Re come	Out come (c)
4	140	Isipramine	25/11/92	29/12/92	INSONMIA	Detail	19/11/92(0)	0	2	19/11/92(0)	0	2	NO						
						Summary	19/11/92(0)	0	2	19/11/92(0)	0	2	NO						
						NAUSEA	Detail	19/11/92(0)	0	1	19/11/92(0)	0	1	NO					
							Summary	19/11/92(0)	0	1	19/11/92(0)	0	1	NO					
						SWEATING INCREASED	Detail	19/11/92(0)	0	1	19/11/92(0)	0	1	NO					
							Summary	19/11/92(0)	0	1	19/11/92(0)	0	1	NO					
							Detail	17/12/92	28	2	4	1	3	3	3	3	3	3	3
							Summary	17/12/92	35	2	2	3	1	3	3	3	3	3	3
							Summary	17/12/92	29/12/92(*)	35	2	2	3	1	3	3	3	3	3
						TACHYCARDIA	Detail	22/12/92	28	2	2	5	1	3	3	3	3	3	3
							Summary	22/12/92	35	2	2	3	1	3	3	3	3	3	3
							Summary	22/12/92(*)	35	2	2	3	1	3	3	3	3	3	3
						TREMOR	Detail	29/11/92	7	2	2	3	1	3	3	3	3	3	3
								14	2	2	3	1	3	3	3	3	3	3	3
								21	2	2	3	1	3	3	3	3	3	3	3
								28	2	2	3	1	3	3	3	3	3	3	3
							Summary	29/11/92	28	2	2	3	1	3	3	3	3	3	3
							Summary	19/12/92	28	2	2	3	1	3	3	3	3	3	3
							Summary	19/12/92	28	2	2	3	1	3	3	3	3	3	3
5	140	Reboxetine	30/10/92	10/11/92	CONSTIPATION	Detail	22/10/92(0)	0	1	22/10/92(0)	0	1	NO						
						Summary	22/10/92(0)	0	1	22/10/92(0)	0	1	NO						
							Detail	02/11/92	7	2	1	3	1	YES	3	3	3	3	3
							Summary	02/11/92	14	2	1	3	1	YES	3	3	3	3	3
							Summary	02/11/92	12/11/92(*)	14	2	1	3	1	YES	3	3	3	3
						FATIGUE	Detail	22/10/92(0)	0	2	22/10/92(0)	0	2	NO					
							Summary	22/10/92(0)	0	2	22/10/92(0)	0	2	NO					
						HYPOKINESIA	Detail	22/10/92(0)	0	3	22/10/92(0)	0	3	NO					

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe, 4= life threatening
 Study drug: 1= no change, 2= dose reduced, 3= def. withdrawn, 4= temp. inter.
 Hospital: 1= required, 2= not req., 3= not appl. -- Outcomes: 1= recovered, 2= res. with seq., 3= still present, 4= death
 Disapp./Resp.: 1= no, 2= yes, 3= not appl. -- Relationship: 1= definite, 2= probable, 3= possible, 4= doubtful, 5= unknown, 6= none
 Symptomatic treatment: 0= no, 1= yes
 (*) adverse event used for statistical analysis
 (c) adverse event still present; end date = visit date
 (e) onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

9550089

7

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA DNS RBD
 REMOXTINE - PROTOCOL 20124/035
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	End date	Last report visit	Svs	Hist	Rel	Stud	Syme	Dis app.	Re app.	Out		
																				ory	ship
5	IND	Reboxetine	36/10/92	10/11/92	HYPOKINESIA	Summary	22/10/92(0)				0	3								NO	
						INSOMNIA	Detail	22/10/92(0)	0			2									NO
							Summary	22/10/92(0)			0	2									
						MOUTH DRY	Detail	22/10/92(0)	0			1									NO
							Summary	22/10/92(0)	7		0	1									3
							Detail	05/11/92	14		2	1									3
							Summary	05/11/92	14		2	1									3
							Summary	05/11/92	14		2	1									3
						NEUROPATHY	Detail	10/11/92	14		3	1									3
							Summary	10/11/92	14		3	1									3
							Summary	10/11/92	14		3	1									3
						PARAESTHESIA	Detail	22/10/92(0)	0			3									NO
							Summary	22/10/92(0)			0	3									
						URINARY RETENTION	Detail	09/11/92	14		13/11/92	3	2								1
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3	2								3
							Summary	09/11/92	13/11/92		14	3									

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS READ

REBOMETINE - PROTOCOL 20124/955
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last										
									report	Save	Hist	Rel	Stud	Symp	Dis	Re	Out	come	(C)
									visit	rity	ary	ship	drug	tree	Hosp	app.	app.	come	(C)
5	1DT	Imipramine	11/11/92	06/01/93	HEADACHE	Detail	27/11/92	21			2	1	5	1	3	3	3	3	3
						Summary	28/12/92	49			2	1	3	1	3	3	3	3	1
					INSOMNIA	Detail	05/11/92(D)	0			1								NO
						Summary	05/11/92(D)	0			0	1							NO
					MOUTH DRY	Detail	13/11/92	7			2	2	3	1	2	3	3	3	1
						Summary	17/11/92	7			2	2	3	1	2	3	3	3	1
						Detail	11/12/92	35			1	2	3	1	3	3	3	3	1
						Summary	11/12/92	35			1	2	3	1	3	3	3	3	1
					HYALGIA	Detail	06/11/92(D)	0			2								NO
						Summary	05/11/92(D)	0			0	2							NO
					SWEATING INCREASED	Detail	12/12/92	35			2	2	3	1	3	3	3	3	1
						Summary	12/12/92	35			2	2	3	1	3	3	3	3	1
					TREMOR	Detail	08/11/92(D)	0			3								NO
						Summary	06/11/92(D)	0			0	3							NO
20D	Rebometine	24/11/92	18/01/93	INSOMNIA	Detail	14/11/92(D)	0				1								NO
						Summary	14/11/92(D)	0			0	1							NO
20T	Imipramine	23/12/92	14/02/93	ANDREXIA	Detail	15/12/92(D)	0				1								NO
						Summary	15/12/92(D)	0			0	1							NO
					CONFUSION	Detail	04/01/93	14			3	2	6	1	5	5	5	3	1
						Summary	04/01/93	14			5	2	6	1	5	5	5	3	1

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=fatal
 Study drug: 1=as change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (a) adverse event still present: end date = visit date
 onset date missing: (3) first report visit date used (screen date - 1 day used for A-E, reported at day0), (1) onset date A-E.

1861

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS RED
REBOXTIME - PROTOCOL 20124/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Visit End date	Last report		Re	Dis	Re	Out						
											visit r/cy	ary shp										
5	201	Imipramine	28/12/92	16/02/93	INSOMNIA	Detail	15/12/92(D)	0		1												
						Summary	15/12/92(D)	0	0	1												
						Detail	15/12/92(D)	0		2												
						Summary	15/12/92(D)	0	0	2												
						Detail	15/01/93	28	15/01/93(*)	28					YES							
						Summary	15/01/93	28	15/01/93(*)	28					YES							
						Detail	21/01/93	35			1	3	1	3	3	3	3	3	3	3	3	3
						Summary	21/01/93	35			1	3	1	3	3	3	3	3	3	3	3	3
						Detail	21/01/93	49			1	3	1	3	3	3	3	3	3	3	3	3
						Summary	21/01/93	56	15/02/93	15/02/93	56	1	3	1	3	3	3	3	3	3	3	3
300	Imipramine	17/03/93	11/05/93	AGITATION	Detail	15/12/92(D)	0		2													
					Summary	15/12/92(D)	0	0	2													
					Detail	24/01/93	35															
					Summary	24/01/93	56	16/02/93(*)	56													
					Detail	08/03/93(C)	8			1												
					Summary	08/03/93(C)	8	0	1													
					Detail	08/03/93(D)	0		1													
					Summary	08/03/93(D)	0	0	1													
					Detail	08/03/93(D)	0		2													
					Summary	08/03/93(D)	0	0	2													

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe, 4= life threatening, 5= death
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (D) adverse event still present; end date = visit date
 (E) onset date missing; (D) first report visit date used (screen date = 1 day used for A.E. reported at day 0). (C) onset date A.E.

1862

9550089

10

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RAD

REBORELINE - PROTOCOL 20124/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment		Type record	Onset date	Visit No	End date	Last report visit	Save rity	Hist ary	Rea drug	Stud app.	Sym app.	Dis app.	Re Out	
		Start date	End date													
S	AMD	Imipramine	17/05/93	11/05/93	TREMOR			08/05/93(0)	0	1					NO	
					Summary	08/05/93(0)	0	1								
SDT	Reboreline		27/02/93	21/05/93	ASTHMA			17/02/93(0)	0	1					NO	
					Summary	17/02/93(0)	0	1								
					FATIGUE			17/02/93(0)	0	1					NO	
								Summary	17/02/93(0)	0	1					
					INSOMNIA			17/05/93(0)	0	1					NO	
								Summary	17/05/93(0)	0	1					
					TACHYCARDIA			17/03/93(0)	0	1					NO	
								Summary	17/03/93(0)	0	1					
AMD	Imipramine		24/11/92	18/01/93	CONSTIPATION			17/11/92(0)	0	1					NO	
								Summary	17/11/92(0)	0	1					
					HYPERKINESIA			17/11/92(0)	0	2					NO	
								Summary	17/11/92(0)	0	2					
					INSOMNIA			17/11/92(0)	0	1					NO	
								Summary	17/11/92(0)	0	1					
					MOUTH DRY			24/11/92	7	1	2	3	1	1	3	3
								Summary	24/11/92	14	1	2	3	1	3	3
					TREMOR			17/11/92(0)	0	1					NO	
								Summary	17/11/92(0)	0	1					

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdraw, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing! (0) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1863

9550089

11

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/955
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	End date	Last visit	Saves rity	Hist ory	Rel drug	Stud app.	Samp treat	Dls hosp	Re app.	Dut same (c)					
																			report	visit	rel	stud	symp
5	401	Reboxetine	05/02/93	02/03/93	CONSTIPATION	Detail	27/01/93(G)	0			2								NO				
						Summary	27/01/93(G)			0	2												
						Detail	17/02/93	21			2	2	4	1	3	3	3	3	3	3	3	3	3
						Summary	17/02/93	26	02/03/93(*)	26	3	2	4	3	3	1	3	3	3	3	3	3	3
					INSOMNIA	Detail	27/01/93(G)	9			2												
						Summary	27/01/93(G)	26	02/03/93(*)	26	2	1	2	1	3	3	3	3	3	3	3	3	
						Detail	17/02/93	21			2	1	2	1	3	3	3	3	3	3	3	3	3
						Summary	17/02/93	26	02/03/93(*)	26	2	1	2	3	3	1	3	3	3	3	3	3	3
					MOUTH DRY	Detail	27/01/93(G)	9			2												
						Summary	27/01/93(G)	26	02/03/93(*)	26	2	1	2	1	3	3	3	3	3	3	3	3	
						Detail	17/02/93	21			2	1	2	1	3	3	3	3	3	3	3	3	3
						Summary	17/02/93	26	02/03/93(*)	26	2	1	2	3	3	1	3	3	3	3	3	3	3
					NERVOUSNESS	Detail	17/02/93	21			2	2	4	1	3	3	3	3	3	3			
						Summary	17/02/93	26	02/03/93(*)	26	3	2	4	3	3	1	3	3	3	3	3		
						Detail	27/01/93(G)	0			3												
						Summary	27/01/93(G)	26	02/03/93(*)	26	0	3											
					PAROSMIA	Detail	12/08/93	14	13/08/93	14	2	2	4	4	3	2	1	1	1	1			
						Summary	12/08/93	14	13/08/93	14	2	2	4	4	3	2	1	1	1	1	1	1	
						Detail	17/02/93	26	19/02/93(*)	26	3	1	5	3	YES	1	1	3	3	3	3	3	
						Summary	17/02/93	26	19/02/93(*)	26	3	1	5	3	YES	1	1	3	3	3	3	3	
					CONCENTRATION IMPAIRED	Detail	28/02/93	7	05/03/93	7	3	1	3	4	3	2	1	1	1	1			
						Summary	28/02/93	7	05/03/93	7	3	1	3	4	3	2	1	1	1	1	1	1	
						Detail	26/03/93	55			2	2	3	1	3	3	3	3	3	3	3	3	
						Summary	26/03/93	49			3	2	3	1	3	3	3	3	3	3	3	3	

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=none change, 2=dose reduced, 3=def. withdrawal, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=Recovered, 2=free. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (G) first report visit date used (screen date - 1 day used for A.E. reported at day0), (I) onset date A.E.

1864

9550089

12

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

RESOMETINE - PROTOCOL 20124/085
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

S	SPT	Centre Patient Drug	Treatment		Type record	Onset date	Visit No	End date	Last report	Save rity	Hist ery	Rel ship	Stu drug	Sym tra	Dis app.	Re app.	Out coma		
			Start date	End date															
5		Raboxetine	27/02/93	23/04/93	CONCENTRATION IMPAIRED	28/03/93	56	23/04/93(e)	56	3	2	3	1	YES	3	3	3	3	
					Summary	28/03/93				56	3	2	3	1	YES	3	3	3	3
					Detail	18/02/93(O)	0			0	2								
					Summary	18/02/93(O)				0	2								
					CONSTITUTION														
					DIARRHEA														
					FATIGUE														
					INSOMNIA														
					MOUTH DRY														
					RIGORS														
					SOMNOLENCE														
					SWEATING INCREASED														

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl.
Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
Symptomatic treatment: 0=no, 1=yes
(0) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
onset date missing: (O) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1865

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

13

PHARMACIA DNS R&D
 REDOMETINE - PROTOCOL 20124/035
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Visit End date	Last report visit	Sweat	Hist	Raz	Stud	Sypm	traa	Hosp	BPP	Dis app.	Re come (c)	Out		
																							Detail	Summary
5	60T	Reboxetine		27/02/93	28/06/93	SWEATING INCREASED	Detail	09/05/93	21			3	2	3	1					3	3	3	3	
							Summary	09/05/93			28	5	2	3	1						3	3	3	3
70T	Imipramine			13/05/93	07/05/93	AGITATION	Detail	06/05/93(0)	0			0	2											NO
							Summary	06/05/93(0)			0	2												
						ANOREXIA	Detail	06/05/93(0)	0	2	0	2												NO
						DIZZINESS	Detail	06/05/93(0)	0	1	0	1												NO
						INSOMNIA	Detail	06/05/93(0)	0	1	0	1												NO
						MOUTH DRY	Detail	13/05/93	7	14	21	28	1	2	2	1	3	3	3	3	3	3	3	3
						VERTIGO	Detail	15/05/93	7	18/05/93	18/05/93	7	1	1	3	1	3	3	3	3	3	3	3	1
80D	Imipramine			11/11/93	05/01/94	ANOREXIA	Detail	06/11/93(0)	0			0	1											NO
							Summary	06/11/93(0)			0	1												
						CONSTIPATION	Detail	06/11/93(0)	9	14	21	28	1	2	1	5	1	VES	3	3	3	3	3	3

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (d) adverse event still present; end date = visit date
 onset date missing; (0) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1866

9550089

15

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient ID	Drug	Treatment		Type record	Onset date	Visit End No date	Last report visit	Sev	Hist	Rai	Stud	Symp	Dis	Re	Det			
			Start date	End date															
5	9ND	Reboxetine	16/11/93	10/01/96	MVALGIA	Detail	10/12/93	55	1	2	3	1	3	3	3	3			
			42	1	2	3	1	3	3	3	3	3	3	3	3	3	3		
			49	1	2	3	1	3	3	3	3	3	3	3	3	3	3	3	
			56	1	2	3	1	3	3	3	3	3	3	3	3	3	3	3	3
			Summary	10/01/96(*)	56	1	2	3	1	3	3	3	3	3	3	3	3	3	3
			Detail	27/11/93	14	1	2	3	1	3	3	3	3	3	3	3	3	3	3
			21	1	2	3	1	3	3	3	3	3	3	3	3	3	3	3	3
			28	19/12/93	35	19/12/93	35	1	2	3	1	3	3	3	3	3	3	3	3
			Summary	27/11/93	35	1	2	3	1	3	3	3	3	3	3	3	3	3	3
			Detail	29/04/93(C)	8	1	1	3	1	3	3	3	3	3	3	3	3	3	3
14	11/05/93	21	1	1	3	1	YES	3	3	3	3	3	3	3	3	3			
25/05/93	28	25/05/93	28	1	1	3	1	YES	3	3	3	3	3	3	3	3			
Summary	29/04/93(C)	28	1	1	3	1	YES	3	3	3	3	3	3	3	3	3			
7	82/05/93	14	1	2	2	1	3	3	3	3	3	3	3	3	3	3			
21	25/05/93	28	25/05/93	28	1	2	2	1	2	3	1	2	3	3	3	3			
Summary	02/05/93	28	1	2	2	1	2	3	3	3	3	3	3	3	3	3			
8	05/05/93(C)	0	05/05/93(C)	0	2	2	0	0	0	0	0	0	0	0	0	0			
Summary	05/05/93(C)	0	0	2	2	0	0	0	0	0	0	0	0	0	0	0			
11ND	11ND	Imipramine	10/05/93	10/05/93	INSOMNIA	Detail	10/05/93	7	12/05/93	3	2	2	3	3	3	3			
			12/05/93	7	12/05/93	7	3	2	2	3	3	3	3	3	3				
			Summary	10/05/93	7	3	2	2	3	3	3	3	3	3	3				
			Detail	15/12/93	21	22/12/93	21	1	2	6	1	YES	3	3	3	3			
Summary	15/12/93	21	22/12/93	21	1	2	6	1	YES	3	3	3	3						
26/11/93(C)	0	26/11/93(C)	0	1	1	1	1	1	1	1	1	1	1	1	1				
Summary	26/11/93(C)	0	1	1	1	1	1	1	1	1	1	1	1	1	1				

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe, -- History: 1= present before, 2= not observe bef., 3= unknown
 Study drug: 1= no change, 2= dose reduced, 3= def. withdrawn, 4= temp. inter.
 Hospital: 1= required, 2= not req., 3= not appl. -- Outcome: 1= recovered, 2= res. with seq., 3= still present, 4= death
 Disapp./Reapp.: 1= no, 2= yes, 3= not appl. -- Relationship: 1= definite, 2= probable, 3= possible, 4= doubtful, 5= unknown, 6= none
 Symptomatic treatment: 0= no, 1= yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (C) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1868

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

16

PHARMACIA CNS RED
REBOSETINE - PROTOCOL 20124/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	End date	Last report visit	Save rity	Hist ory	Rel ship	Stud drug	Simp app.	Dis app.	Re app.	Out come (c)			
																				02/12/95	05/01/94	05/05/93
5	11MD	Imipramine	02/12/95	05/01/94	05/05/93	CONSTIPATION	Detail	08/12/93	7	08/12/93	08/12/93	7	1	1	3	1	YES	3	3	3	1	
							Summary	08/12/93	7	08/12/93	08/12/93	7	1	1	3	1	YES	3	3	3	1	
							Detail	10/12/93	14	10/12/93	10/12/93	14	2	1	3	1	YES	3	3	3	3	
							Summary	10/12/93	26	10/12/93	10/12/93	26	2	1	3	1	YES	3	3	3	3	
								29/12/93(*)	26	29/12/93	29/12/93	26	2	1	3	1	YES	3	3	3	3	
11DT	Rebosetine	11/05/93	07/06/93	07/06/93	07/06/93	AGITATION	Detail	03/05/93	0	03/05/93	03/05/93	0	1								NO	
							Summary	03/05/93	0	03/05/93	03/05/93	0	1									NO
						ANOREXIA	Detail	14/05/93	7	14/05/93	14/05/93	7	1	3	1	3	1	3	3	3	3	
								14	14	14/05/93	14/05/93	7	1	3	4	1	3	3	3	3	3	
								21	21	14/05/93	14/05/93	7	1	3	4	1	3	3	3	3	3	
								28	28	14/05/93	14/05/93	7	1	3	4	1	3	3	3	3	3	
							Summary	14/05/93	26	14/05/93	14/05/93	26	1	3	3	1	3	3	3	3	3	
								07/06/93(*)	26	07/06/93	07/06/93	26	1	3	3	1	3	3	3	3	3	
						CONSTIPATION	Detail	02/05/93	0	02/05/93	02/05/93	0	2									NO
							Summary	02/05/93	0	02/05/93	02/05/93	0	2									NO
						GASTRO-INTESTINAL DISORDE	Detail	14/05/93	7	14/05/93	14/05/93	7	1	2	3	1	YES	2	3	3	3	
								26	26	14/05/93	14/05/93	7	1	2	3	1	YES	2	3	3	3	
							Summary	14/05/93	26	14/05/93	14/05/93	26	1	2	3	1	YES	2	3	3	3	
								07/06/93(*)	26	07/06/93	07/06/93	26	1	2	3	1	YES	2	3	3	3	
						INSOMNIA	Detail	03/05/93	0	03/05/93	03/05/93	0	2									NO
							Summary	03/05/93	0	03/05/93	03/05/93	0	2									NO
						MOUTH DRY	Detail	14/05/93	26	14/05/93	14/05/93	26	1	3	4	1	3	3	3	3	3	
							Summary	14/05/93	26	14/05/93	14/05/93	26	1	3	4	1	3	3	3	3	3	
12ND	Rebosetine	05/01/94	03/05/94	03/05/94	03/05/94	CONSTIPATION	Detail	20/12/93	0	20/12/93	20/12/93	0	1								NO	
							Summary	20/12/93	0	20/12/93	20/12/93	0	1									NO
						DIZZINESS	Detail	20/12/93	0	20/12/93	20/12/93	0	1									NO
							Summary	20/12/93	0	20/12/93	20/12/93	0	1									NO

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

9550089

1869

PHARMACIA CMS RED
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type	Onset date	Visit End	No data	Last		Dis	Re	Out																																													
											report	visit																																																
											visit	freq	freq	freq	freq	freq	freq																																											
											visit	freq	freq	freq	freq	freq	freq																																											
5	12ND	Reboxetine	05/01/94	05/02/94	SWEATING INCREASED	Detail	10/01/94	7			1	2	2	1	3	3	3																																											
											1	2	2	1	3	3	3																																											
											21	2	1	3	3	3	3																																											
											35	10/02/94	1	2	1	2	3	3																																										
											10/02/94	1	2	1	2	3	3																																											
											Summary	10/01/94	35	1	2	2	1	2	3	3	1	YES																																						
											12DT	Imipramine	21/05/93	15/07/93	AGITATION	Detail	17/05/93(0)	0				2	2																																					
																						Summary	17/05/93(0)	0	2							NO																												
																						12DT	Imipramine	21/05/93	15/07/93	AGITATION	Detail	17/05/93(0)	0				2	2																										
																																	Summary	17/05/93(0)	0	2							NO																	
6	1ND	Reboxetine	13/11/92	07/01/93	ANOREXIA	Detail	07/11/92(0)	0																									2	2																										
																																	Summary	07/11/92(0)	0	2							NO																	
																																	6	1ND	Reboxetine	13/11/92	07/01/93	ANOREXIA	Detail	07/11/92(0)	0			2	2															
																																												Summary	07/11/92(0)	0	2							NO						
																																												6	1ND	Reboxetine	13/11/92	07/01/93	ANOREXIA	Detail	07/11/92(0)	0			1	1				
																																																							Summary	07/11/92(0)	0	1		
											6	1ND	Reboxetine	13/11/92	07/01/93	ANOREXIA	Detail	07/11/92(0)	0																																				3	3				
																																																							Summary	07/11/92(0)	0	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with set., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date
 onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/935
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record date	Onset date	Visit No	Last report visit	Save rity	Hist ary	Rel drug	Stud app.	Svmp	Dis app.	Re app.	Out come (C)					
																		report visit	Save rity	Hist ary	Rel drug	Stud app.
6	1MD	Reboxetine	13/11/92	07/01/93	HYPOKINESIA	Detail	07/11/92(D)	0		0	2							NO				
						Summary	07/11/92(D)															
						Detail	07/11/92(D)	0		2												NO
						Summary	07/11/92(D)															
						Detail	07/11/92(D)	0		1												NO
						Summary	07/11/92(D)															
1D1	Reboxetine	21/10/92	16/12/92	MOUTH DRY	Detail	23/10/92	7				1	2	2	1				3				
					Summary	23/10/92																
					Detail	23/10/92	14		1	2	2	1								3		
					Summary	23/10/92																
					Detail	23/10/92	21		1	2	2	1								3		
					Summary	23/10/92																
2MD	Insipiramine	11/11/92	17/11/92	URINARY TRACT INFECTION	Detail	15/01/93	58	15/01/93	58	15/01/93	1	2	4	1	YES	3	3	3	1			
					Summary	15/01/93																
					Detail	15/01/93	28		15/11/92	28		1	2	2	1					3		
					Summary	15/01/93																
					Detail	15/01/93	28		15/11/92	28		1	2	2	1					3		
					Summary	15/01/93																
2MD	Insipiramine	11/11/92	17/11/92	ABITATION	Detail	18/11/92	7	17/11/92(*)	7	17/11/92(*)	2	2	2	3	3	1	3	3				
					Summary	18/11/92																
					Detail	18/11/92	7		1	2	2	3							3			
					Summary	18/11/92																
					Detail	18/11/92	7		2	2	3								3			
					Summary	18/11/92																
2MD	Insipiramine	11/11/92	17/11/92	DIZZINESS	Detail	18/11/92	7	17/11/92(*)	7	17/11/92(*)	1	2	2	3	3	1	3	3				
					Summary	18/11/92																
					Detail	18/11/92	7		2	2	3								3			
					Summary	18/11/92																
					Detail	18/11/92	7		2	2	3								3			
					Summary	18/11/92																
2MD	Insipiramine	11/11/92	17/11/92	INSOMNIA	Detail	18/11/92	7	17/11/92(*)	7	17/11/92(*)	2	2	3	3	3	1	3	3				
					Summary	18/11/92																
					Detail	18/11/92	7		2	2	3								3			
					Summary	18/11/92																
					Detail	18/11/92	7		2	2	3								3			
					Summary	18/11/92																
2MD	Insipiramine	11/11/92	17/11/92	SWEATING INCREASED	Detail	18/11/92	7	17/11/92(*)	7	17/11/92(*)	2	2	2	3	3	1	3	3				
					Summary	18/11/92																
					Detail	18/11/92	7		2	2	3								3			
					Summary	18/11/92																
					Detail	18/11/92	7		2	2	3								3			
					Summary	18/11/92																

Severity: 1=unknown, 2=mild, 3=moderate, 4=severe, 5=critical, 6=life threatening, 7=death
 Study drug: 1=not used, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=free with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (d) adverse event still present; end date = visit date
 onset date missing: (2) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

9550089

19

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RD
 REBOXETINE - PROTOCOL 28124/93S
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient ID	Drug	Treatment		Adverse event	Type	Onset date	Visit End No date	Last report visit	Sae Hist	Rel	Stud	Symp	Dis	Re	Out										
			Start date	End date																						
6	Z07	Reboxetine	21/01/93	27/01/93	ANOREXIA	Detail	17/01/93(0)	0	0	2							NO									
						Summary	17/01/93(0)		0	2																
						Detail	17/01/93(0)	0	1													NO				
						Summary	17/01/93(0)		0	1																
						Detail	17/01/93(0)	0	3														NO			
						Summary	17/01/93(0)		0	3																
						Detail	17/01/93(0)	0	2															NO		
						Summary	17/01/93(0)		0	2																
						Detail	17/01/93(0)	0	2																NO	
						Summary	17/01/93(0)		0	2																
						Detail	26/11/92(0)	0	2																NO	
						Summary	26/11/92(0)		0	2																
500	Reboxetine	05/12/92	27/01/93	AGITATION	Detail	05/12/92	7	1	2	2	1							2	3	3	3					
					Summary	05/12/92		7	1	2	2	1														
					Detail	05/12/92	14	1	2	2	1															
					Summary	05/12/92	21	1	2	2	1															
					Detail	05/12/92	20	1	2	2	1															
					Summary	05/12/92	35	1	2	2	1															
					Detail	05/12/92	42	1	2	2	1															
					Summary	05/12/92	69	1	2	2	1															
					Detail	26/11/92(0)	0	3																		
					Summary	26/11/92(0)		0	3																	
					Detail	26/11/92(0)	0	2																		
					Summary	26/11/92(0)		0	2																	

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 5=unknown
 Study drug: 1=na change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (s) adverse event still present; end date = visit date
 onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1872

PHARMACIA CNS RED
 REBOXTINE - PROTOCOL 20124/035
 Listing No.: 17.9

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Last report visit	Save rity	Mist ory	Rel ship	Re Stud	Symp	Dis app.	Re app.	Dut	C	
																			Visit No
6	SMD	Reboxetine	03/12/92	27/01/93	MOUTH DRY	Detail	04/12/92	7		1	2	2	1	2	3	3	3		
							14		1	2	2	1	2	3	3	3			
							21		1	2	2	1	2	3	3	3			
							28		1	2	2	1	2	3	3	3			
							35		1	2	2	1	2	3	3	3			
							42		1	2	2	1	2	3	3	3			
							49		1	2	2	1	2	3	3	3			
							56		1	2	2	1	2	3	3	3			
						Summary	04/12/92	27/01/93(*)	56	1	2	2	1	2	3	3	3		
						307	Imipramine	08/04/93	02/06/93	CONSTIPATION	Detail	04/05/93(D)	0		0	1			
					Summary	04/05/93(D)			0	1									NO
					Detail	04/05/93(D)	0		0	1									NO
					Summary	04/05/93(D)			0	1									NO
					Detail	04/05/93(D)	0		0	1									NO
					Summary	04/05/93(D)			0	1									NO
					Detail	04/05/93(D)	0		0	1									NO
					Summary	04/05/93(D)			0	1									NO
					Detail	04/03/93(D)	0		0	1									NO
					Summary	04/03/93(D)			0	1									NO
					Detail	04/03/93(D)	0		0	1									NO
					Summary	04/03/93(D)			0	1									NO
					Detail	04/03/93(D)	0		0	1									NO
					Summary	04/03/93(D)			0	1									NO
					Detail	16/04/93	14		1	2	3	1	2	3	3	3			3
					Summary	16/04/93	24/06/93	21	1	2	3	1	2	3	3	3			3

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe,
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date
 onset date missing: (D) first report visit date used (screen data - 1 day used for A.E. reported at day0), (I) onset date A.E.

9550089

21

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA DNS RBD
REBOVETINE - PROTOCOL 20124/935
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Last report visit	Save rity	Hist ary	Re Stud	Symp	Dis	Re	Out		
																	06/05/93(0)	07/12/92(0)
6	30T	Imipramine	08/04/93	02/06/93	SWEATING INCREASED	Detail	06/05/93(0)	0	1	0	1						NO	
						Summary	06/05/93(0)	0	0	1								
49D	Imipramine	15/12/92	16/01/93	ANOREXIA	Detail	07/12/92(0)	0	2	2	0	2						NO	
					Summary	07/12/92(0)	0	0	2									
					CONSTIPATION	Detail	07/12/92(0)	0	1	0	1						NO	
						Summary	07/12/92(0)	0	0	1								
					DIZZINESS	Detail	22/12/92	14	2	2	3	1	3	3	3	3	3	3
						Summary	22/12/92	14	2	2	3	1	3	3	3	3	3	3
					FATIGUE	Detail	07/12/92(0)	0	3	0	3							NO
						Summary	07/12/92(0)	0	0	3								
					HYPOKINESIA	Detail	07/12/92(0)	0	2	0	2							NO
						Summary	07/12/92(0)	0	0	2								
					INSOMNIA	Detail	07/12/92(0)	0	2	0	2							NO
						Summary	07/12/92(0)	0	0	2								
					MOUTH DRY	Detail	07/12/92(0)	0	1	0	1							NO
						Summary	07/12/92(0)	0	0	1								
					TREMOR	Detail	31/12/92	21	2	2	3	1	3	3	3	3	3	3
						Summary	31/12/92	21	2	2	3	1	3	3	3	3	3	3

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 5=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 5=not appl. -- Outcome: 1=recovered, 2=rec. with ser., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 5=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (A) adverse event still present; end date = visit date
 onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1874

9550089

22

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA DNS RED

REDOXETINE - PROTOCOL 20124/935
Listing No.: 17-B

ADVERSE EVENTS: DETAIL AND SUMMARY

Contra Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Last report visit	Re rity	Hist ary	Rel ship	Drug	Stud	Symp	Dis app.	Re case	Dut					
																		Detail	Summary	Detail	Summary	Detail
6	4DT	Imipramine	05/05/93	29/06/93	CONSTIPATION	21	21	2	2	2	2	2	2	1	YES	2	2	3				
						20	20	1	2	2	2	1	YES	2	2	2	3	3				
						35	35	1	2	2	2	1	YES	2	2	2	3	3				
						42	42	1	2	2	2	1	YES	2	2	2	3	3				
						49	49	1	2	2	2	1	YES	2	2	2	3	3				
						56	56	1	2	2	2	1	YES	2	2	2	3	3				
					Summary	20/05/93	38/06/93(*)	56	2	2	2	2	1	YES	2	2	3	3				
5HD	Imipramine	03/06/93	28/05/93	ANOREXIA	0	0	2	2	0	2								NO				
							Summary	29/05/93(D)	0	2											NO	
							Detail	29/05/93(D)	0	1												NO
							Summary	29/05/93(D)	0	1												NO
							Detail	29/05/93(D)	0	2												NO
							Summary	29/05/93(D)	0	2												NO
				CONSTIPATION	0	0	1	1	0	1									NO			
							Summary	29/03/93(D)	0	2											NO	
							Detail	29/03/93(D)	0	1												NO
							Summary	29/03/93(D)	0	1												NO
							Detail	29/03/93(D)	0	2												NO
							Summary	29/03/93(D)	0	2												NO
				DIZZINESS	0	0	1	1	0	1									NO			
							Summary	29/03/93(D)	0	1											NO	
							Detail	29/03/93(D)	0	1												NO
							Summary	29/03/93(D)	0	1												NO
							Detail	29/03/93(D)	0	2												NO
							Summary	29/03/93(D)	0	2												NO
				FATIGUE	0	0	1	1	0	1									NO			
							Summary	29/03/93(D)	0	2											NO	
							Detail	29/03/93(D)	0	2												NO
							Summary	29/03/93(D)	0	2												NO
							Detail	29/03/93(D)	0	2												NO
							Summary	29/03/93(D)	0	2												NO
				HEADACHE	0	0	1	1	0	1									NO			
							Summary	29/03/93(D)	0	1											NO	
							Detail	29/03/93(D)	0	1												NO
							Summary	29/03/93(D)	0	1												NO
							Detail	29/03/93(D)	0	2												NO
							Summary	29/03/93(D)	0	2												NO

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe,
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present; end date = visit date
onset date missing: (D) first report visit; data used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1875

9550089

24

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REMOVETINE - PROTOCOL 2024/935
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report visit	Save rity	Hist ory	Rel ship	Stud drug	Samp app.	Dis app.	Re app.	Dut app.	Come (c)	
																			7
7	3ND	Imipramin	23/04/93	17/06/93	CONSTIPATION	Detail	25/04/93	7	27/04/93	7	2	1	2	1	2	1	2	1	NO
						Summary	14/04/93(9)		27/04/93		7	2	1	2	1	2	1	2	1
					HEADACHE	Detail	04/05/93	14	04/05/93	14	3	1	6	1	2	3	3	1	YES
						Summary	04/05/93		04/05/93		14	3	1	6	1	2	3	3	1
						Detail	13/05/93	21	13/05/93	21	3	1	6	1	2	3	3	1	YES
						Summary	13/05/93		13/05/93		21	3	1	6	1	2	3	3	1
						Detail	18/05/93	26	18/05/93	26	2	1	6	1	2	3	3	1	YES
						Summary	18/05/93		18/05/93		26	2	1	6	1	2	3	3	1
						Detail	20/05/93	28	20/05/93	28	2	1	6	1	2	3	3	1	YES
						Summary	20/05/93		20/05/93		28	2	1	6	1	2	3	3	1
						Detail	23/05/93	35	23/05/93	35	2	1	6	1	2	3	3	1	YES
						Summary	23/05/93		23/05/93		35	2	1	6	1	2	3	3	1
						Detail	25/05/93	35	25/05/93	35	2	1	6	1	2	3	3	1	YES
						Summary	25/05/93		25/05/93		35	2	1	6	1	2	3	3	1
						Detail	26/05/93	35	26/05/93	35	2	1	6	1	2	3	3	1	YES
						Summary	26/05/93		26/05/93		35	2	1	6	1	2	3	3	1
						Detail	27/05/93	42	27/05/93	42	2	1	6	1	2	3	3	1	YES
						Summary	27/05/93		27/05/93		42	2	1	6	1	2	3	3	1
						Detail	29/05/93	42	29/05/93	42	2	1	6	1	2	3	3	1	YES
						Summary	29/05/93		29/05/93		42	2	1	6	1	2	3	3	1
						Detail	30/05/93	42	30/05/93	42	2	1	6	1	2	3	3	1	YES
						Summary	30/05/93		30/05/93		42	2	1	6	1	2	3	3	1
						Detail	01/06/93	42	01/06/93	42	2	1	6	1	2	3	3	1	YES
						Summary	01/06/93		01/06/93		42	2	1	6	1	2	3	3	1
						Detail	06/06/93	49	06/06/93	49	1	1	6	1	2	3	3	1	YES
						Summary	06/06/93		06/06/93		49	1	1	6	1	2	3	3	1
						Detail	09/06/93	49	09/06/93	49	1	1	6	1	2	3	3	1	YES
						Summary	09/06/93		09/06/93		49	1	1	6	1	2	3	3	1
						Detail	13/06/93	56	13/06/93	56	1	1	6	1	2	3	3	1	YES
						Summary	13/06/93		13/06/93		56	1	1	6	1	2	3	3	1
						Detail	15/06/93	56	15/06/93	56	1	1	6	1	2	3	3	1	YES
						Summary	15/06/93		15/06/93		56	1	1	6	1	2	3	3	1
4ND	Remoxetine		24/04/93	29/05/93	ABSTATION	Detail	14/04/93(9)	0		0	2							NO	
						Summary	14/04/93(9)				0	2							NO
						Detail	14/04/93(9)	0		0	1								NO
						Summary	14/04/93(9)				0	1							NO

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcomes: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (d) adverse event still present; end date = visit date
 onset date missing: (9) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1879

9550089

27

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REMOETINE - PROTOCOL 20124/055
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report visit	Save rity	Hist ory ship	Rel drug	Stud app.	Symp. app.	Dis Hosp	Re app.	Out come (C)							
																		report	visit	rel	stud	symp	dis	re
7	4ND	Reboetine	26/06/93	29/05/93	ANOREXIA	Detail	14/06/93(D)	0	1	0	1							NO						
						Summary	14/06/93(D)		0	1														
						Detail	14/06/93(D)	0	2															
						Summary	26/06/93	7	1	1	4	1	3	3	3	3								
						Detail	14/07/93	14	1	4	1	4	1	3	3	3								
						Summary	14/06/93(D)	07/05/93	14	2	1	4	1	3	3	3								NO
						Detail	26/06/93	7	1	1	4	1	3	3	3	3								
						Summary	26/06/93	04/05/93	14	1	1	4	1	3	3	3								
						Detail	14/06/93(D)	0	2															
						Summary	14/06/93(D)		0	2														
						Detail	14/04/93(D)	0	1															
						Summary	14/04/93(D)		0	1														
362ND	Reboetine	23/02/93	19/06/93	ABITATION	Detail	14/06/93(D)	0	1	0	1								NO						
					Summary	14/06/93(D)		0	1															
					Detail	14/06/93(D)	0	2																
					Summary	14/06/93(D)		0	2															
					Detail	14/04/93(D)	0	1																
					Summary	14/04/93(D)		0	1															
					Detail	14/04/93(D)	0	1																
					Summary	14/04/93(D)		0	1															
					Detail	15/02/93(D)	0	1																
					Summary	15/02/93(D)		0	1															
					Detail	15/02/93(D)	0	3																
					Summary	15/02/93(D)		0	3															
Detail	15/02/93(D)	0	2																					
Summary	15/02/93(D)		0	2																				

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observed before, 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (D) first report visit date used (screen date - 1 day used for A.E. reported at day0), (I) onset date A.E.

1880

9550089

28

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS READ

REBOXETINE - PROTOCOL 20124/955
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No data	Last report visit	Save rity	Hist ory	Rel ation	Stud y	Symp tom	Dis app.	Re Out
7	362ND	Reboxetine	25/02/93	19/04/93	CONFUSION	Detail	15/02/93(0)	0		0	1						NO
						Summary	15/02/93(0)	0		0	1						NO
					DIZZINESS	Detail	15/02/93(0)	0		0	2						NO
						Summary	15/02/93(0)	0		0	2						NO
					FATIGUE	Detail	15/02/93(0)	0		0	5						NO
						Summary	15/02/93(0)	0		0	5						NO
					HYPOKINESIA	Detail	15/02/93(0)	0		0	2						NO
						Summary	15/02/93(0)	0		0	2						NO
					HYPOTENSION	Detail	15/02/93(0)	0		0	1						NO
						Summary	15/02/93(0)	0		0	1						NO
					INSOMNIA	Detail	15/02/93(0)	0		0	2						NO
						Summary	15/02/93(0)	0		0	2						NO
					MOUTH DRY	Detail	15/02/93(0)	0		0	1						NO
						Summary	15/02/93(0)	0		0	1						NO
					URINARY TRACT INFECTION	Detail	20/03/93	28	23/03/93	28	1	1	6	1	1	1	YES
						Summary	20/03/93	28	23/03/93	28	1	1	6	1	1	1	YES
8	1MD	Reboxetine	30/09/92	24/11/92	ANOREXIA	Detail	22/09/92(0)	0		0	1						NO
						Summary	22/09/92(0)	0		0	1						NO
					CONFUSION	Detail	22/09/92(0)	0		0	1						NO
						Summary	22/09/92(0)	0		0	1						NO
					FATIGUE	Detail	22/09/92(0)	0		0	3						NO

Severities: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawal, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcomes: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationships: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
onset date missing: (0) first report visit date used (scored data - 1 day used for A.E. reported at day0), (1) onset date A.E.

1881

9550089

29

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA OES R&D
 REBOXETINE - PROTOCOL 20124/455
 Listing No.: 17.6

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report visit	Save rity	Hist ary	Re Stud drug	Symp tres	Dis app.	Re app.	Out						
																		Disapp.	Reapp.	Out			
6	1MD	Reboxetine	30/09/92	24/11/92	FATIGUE	Summary	22/09/92(G)		0	3								NO					
						Detail	22/09/92(G)	0	1													NO	
						Summary	22/09/92(G)		0	1													NO
						Detail	22/09/92(G)	0	1														NO
						Summary	22/09/92(G)		0	1													NO
						Detail	20/09/92(G)	0	1														NO
						Summary	20/09/92(G)		0	1													NO
						Detail	20/09/92(G)	0	3														NO
						Summary	20/09/92(G)		0	5													NO
						Detail	20/09/92(G)	0	1														NO
2MD	Reboxetine	30/09/92	24/11/92	MOTILATION	Summary	22/09/92(G)		0	2									NO					
					Detail	22/09/92(G)	0	2												NO			
					Summary	22/09/92(G)		0	2												NO		
					Detail	20/09/92(G)	0	2													NO		
					Summary	20/09/92(G)		0	2												NO		
					Detail	20/09/92(G)	0	2													NO		
					Summary	20/09/92(G)		0	2												NO		
					Detail	20/09/92(G)	0	2													NO		
					Summary	20/09/92(G)		0	2													NO	
					Detail	20/09/92(G)	0	2														NO	

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (N) adverse event still present; and data = visit date
 onset date missing: (G) first report visit date used (screen date - 1 day used for A.E. reported at day0), (I) onset date A.E.

1882

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

30

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Last report visit	Recovery	Rel. to drug	Study Sympt	Disapp.	Recovery	Outcome		
																date	date
0	2ND	Reboxetine	38/09/92	24/11/92	CONFUSION	Detail	22/09/92(0)	0	2	0	2					NO	
						Summary	22/09/92(0)	0	2								
						Detail	22/09/92(0)	0	1								
						Summary	22/09/92(0)	0	1								
2DT	Imipramine	38/09/92	24/11/92	FATIGUE	Detail	22/09/92(0)	0	1								NO	
					Summary	22/09/92(0)	0	1									
					Detail	22/09/92(0)	0	1									
					Summary	22/09/92(0)	0	1									
3RD	Imipramine	02/10/92	10/10/92	ANOREXIA	Detail	22/09/92(0)	0	1								NO	
					Summary	22/09/92(0)	0	1									
					Detail	24/09/92(0)	0	2									
					Summary	24/09/92(0)	0	2									
					CEREBROVASCULAR DISORDER	Detail	10/10/92	14	2	6	3	3	3	3	3	4	
						Summary	10/10/92	14	2	6	3	3	3	3	3	4	
						Detail	10/10/92	14	2	6	3	3	3	3	3	4	
						Summary	10/10/92	14	2	6	3	3	3	3	3	4	
					DYSPOEA	Detail	24/09/92(0)	0	2								NO
						Summary	24/09/92(0)	0	2								
						Detail	24/09/92(0)	0	2								
						Summary	24/09/92(0)	0	2								
3DT	Reboxetine	02/10/92	26/11/92	AGITATION	Detail	21/09/92(0)	0	3	3	2	1	5	1	5	5	3	
					Summary	02/10/92	7	2	1	5	1	5	5	3			
					Detail	02/10/92	14	2	1	5	1	5	5	3			
					Summary	02/10/92	14	2	1	5	1	5	5	3			

1883

9550089

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day), (1) onset date A.E.

9550089

31

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA OUS RED
REBOMETINE - PROTOCOL 20124/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report visit	Sev	Hst	Rel	Stad	Syme	Dis app.	Re app.	Out	Some (c)						
																			21/09/92	23/10/92	21/09/92	21/09/92	21/09/92	23/10/92
6	307	Rebometine	02/10/92	26/11/92	ABIATION	Detail	02/10/92	21/09/92	21/09/92	21	3	1	5	1	2	3	3	1						
						Summary	21/09/92	23/10/92	21	3	1	5	1	2	3	3	1							
						Detail	21/09/92	0	0	2														
						Summary	21/09/92	0	0	2														
						Detail	21/09/92	0	0	3														
						Summary	21/09/92	0	0	3														
						Detail	21/09/92	0	0	1														
						Summary	21/09/92	0	0	1														
						Detail	21/09/92	0	0	2														
						Summary	21/09/92	0	0	2														
						Detail	21/09/92	0	0	3														
						Summary	21/09/92	0	0	3														
400	Imipramine	02/10/92	27/10/92	AGITATION	Detail	02/10/92	14/10/92	16/10/92	14	3	1	6	1	3	3	3	1							
					Summary	02/10/92	16/10/92	14	3	1	6	1	3	3	3	1								
					Detail	24/09/92	0	0	2															
					Summary	24/09/92	0	0	2															
					Detail	24/09/92	0	0	5															
					Summary	24/09/92	0	0	5															
					Detail	24/09/92	0	0	1															
					Summary	24/09/92	0	0	1															
					Detail	24/09/92	0	0	1															
					Summary	24/09/92	0	0	1															
					Detail	24/09/92	0	0	1															
					Summary	24/09/92	0	0	1															

Severity: 9=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdraw, 4=stop. Inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 1=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present; end date = visit date
onset data missing: (D) first report visit date used (screen date - 1 day used for A.E. reported at day0), (I) onset date A.E.

1884

9550089

32

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS READ

REBOXETINE - PROTOCOL 2012/955
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Last report visit	Save rity	Hist dry	Rel ship	Stud app.	Svmp trea	Dis hosp	Re app.	Out coms (c)
0	40T	Reboxetine	02/10/92	26/11/92	CONFUSION	Detail	24/09/92(D)	0	0	1							NO
						Summary	24/09/92(D)			0	1						
					FATIGUE	Detail	24/09/92(D)	0	0	1							NO
						Summary	24/09/92(D)			0	1						
					HYPOTENSION	Detail	24/09/92(D)	0	0	1							NO
						Summary	24/09/92(D)			0	1						
					INSOMNIA	Detail	24/09/92(D)	0	0	2							NO
						Summary	24/09/92(D)			0	2						
703MD	Imipramine	09/10/92	05/12/92	AGITATION	Detail	01/10/92(G)	0	0	1								NO
						Summary	01/10/92(G)			0	1						
					CONFUSION	Detail	01/10/92(G)	0	0	1							NO
						Summary	01/10/92(G)			0	1						
					STUPOR	Detail	04/11/92	25	04/11/92	2	3	3	1	2	3	3	1
						Summary	04/11/92		04/11/92	25	2	3	3	1	2	3	3
					TREMOR	Detail	01/10/92(D)	0	0	2							NO
						Summary	01/10/92(D)			0	2						
701DT	Reboxetine	09/10/92	05/12/92	HENDICHE	Detail	25/10/92	14			2	5	5	1	YES	1	3	3
						Summary	25/10/92		25/10/92	21	2	5	5	1	YES	1	3
702MD	Reboxetine	16/10/92	10/12/92	FATIGUE	Detail	08/10/92(G)	0	0	2								NO
						Summary	08/10/92(G)			0	2						

Severity: 1=unknown, 1=ild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdraw, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
onset date missing: (G) first report visit date used (screen date - 1 day used for A.E. reported at day0), (L) onset date A.E.

1885

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

33

PHARMACIA CNS MSD
 REDDMETINE - PROTOCOL 20124/935
 Listing No.: 17-0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	End date	Last report	Save rity	Hist ory	Rel ship	Stud trea	Syp area	Dis app.	Re app.	Det come		
																			16/10/92	18/12/92
B	702ND	Raboxetine	HYPERCHOLESTEROLAEMIA																	
			Detail	12/11/92	28	56	11/12/92(*)	56	2	1	5	1	3	3	3	3	3	3	3	
			Summary	12/11/92	28	56	11/12/92(*)	56	2	1	5	1	3	3	3	3	3	3	3	3
			HYPERTENSIA																	
			Detail	08/10/92(CD)	0	0	0	0	2											
			Summary	08/10/92(CD)	0	0	0	0	2											
			HYPOTENSION																	
			Detail	08/10/92(CD)	0	0	0	0	1											
			Summary	08/10/92(CD)	0	0	0	0	1											
			MOUTH DRY																	
			Detail	16/10/92	21	28	56	11/12/92(*)	56	5	3	3	1	2	3	3	3	3	3	
			Summary	16/10/92	21	28	56	11/12/92(*)	56	5	3	3	1	2	3	3	3	3	3	3
703MD	Imipramine	09/02/93	HEADACHE																	
			Detail	20/02/93	14	21	02/03/93	21	2	1	5	1	3	3	3	3	3	3	3	
			Summary	20/02/93	14	21	02/03/93	21	2	1	5	1	3	3	3	3	3	3	3	3
703DT	Imipramine	09/02/93	APATHY																	
			Detail	24/03/93	49	29/03/93	49	2	1	6	1	3	3	3	3	3	3	3	3	
			Summary	24/03/93	49	29/03/93	49	2	1	6	1	3	3	3	3	3	3	3	3	3
			ESR INCREASED																	
			Detail	05/04/93	56	05/04/93	56	3	2	5	1	3	3	3	3	3	3	3	3	
			Summary	05/04/93	56	05/04/93	56	3	2	5	1	3	3	3	3	3	3	3	3	3
704MD	Raboxetine	09/02/93	INSOMNIA																	
			Detail	10/02/93	7	14	20/02/93	7	3	1	3	1	2	3	3	3	3	3		
			Summary	10/02/93	7	14	20/02/93	7	3	1	3	1	2	3	3	3	3	3	3	
			MOUTH DRY																	
			Detail	10/02/93	7	14	21	26/02/93	7	3	2	2	1	2	3	3	3	3		
			Summary	10/02/93	7	14	21	26/02/93	7	3	2	2	1	2	3	3	3	3	3	

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=stop, inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (d) adverse event still present: end date = visit date
 onset date missing: (CD) first report visit date used (screen date - 1 day used for A-E, reported at day0), (1) onset date A-E.

9550089

1886

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

34

PHARMACIA CNS R02
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 17.9

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Types record	Onset date	Visit No	Visit End date	Last report visit	Save	Hist	Rel	Stud	Symp	Dis	Re	Out				
																			orig	ship	drug	tra
B	764HD	Reboxetine	09/02/93	05/04/93	RENAL FUNCTION ABNORMAL	Detail	06/03/93	28			1	2	5	1		2	3	3	3			
						Summary	06/03/93	56	06/06/93(e)	56	2	2	5	1		2	3	3	3	3	3	3
						Detail	14/02/93	7		1	2	2	1		3	3	3	3				
764DT	Reboxetine	09/02/93	05/06/93	MOUTH DRY	Detail	14/02/93	14			1	2	2	1		2	3	3	3	3			
					Summary	14/02/93	21		1	2	3	1		3	3	3						
					Detail	14/02/93	28		2	2	2	1		2	3	3	1		2	3	3	1
9	IMD	Imipramine	26/09/93	23/11/93	ANOREXIA	Detail	26/09/93(g)	0			2								NO			
						Summary	26/09/93(g)	0		0	2											
						Detail	20/09/93(g)	0		0	2											
LDT	IMD	Imipramine	15/12/93	08/02/94	FATIGUE	Detail	07/12/93(g)	0			0	2							NO			
						Summary	07/12/93(g)	0		0	2											
						Detail	20/09/93(g)	0		0	1											
LDT	IMD	Imipramine	15/12/93	08/02/94	TACHYCARDIA	Detail	20/09/93(g)	0			0	1							NO			
						Summary	20/09/93(g)	0		0	1											
						Detail	07/12/93(g)	0		0	2											
LDT	IMD	Imipramine	15/12/93	08/02/94	HEADACHE	Detail	07/12/93(g)	0			0	2							NO			
						Summary	07/12/93(g)	0		0	2											
						Detail	07/12/93(g)	0		0	1											
LDT	IMD	Imipramine	15/12/93	08/02/94	INSOMNIA	Detail	07/12/93(g)	0			0	1							NO			
						Summary	07/12/93(g)	0		0	1											
						Detail	16/12/93	7	21/12/93	7	2	2	3	1		3	3	3	1			
LDT	IMD	Imipramine	15/12/93	08/02/94	SOMNOLENCE	Detail	16/12/93	7	21/12/93	7	2	2	3	1		3	3	3	1			
						Summary	16/12/93	7	21/12/93	7	2	2	3	1		3	3	3	1			
						Detail	16/12/93	7	21/12/93	7	2	2	3	1		3	3	3	1			

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=discontinued, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (e) adverse event still present; end date = visit date
 (g) onset date missing; (g) first report visit date used (increase date - 1 day used for A.E. reported at day0); (i) onset date A.E.

9550089

1887

9550089

35

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA DNS R&D

REBOXETINE - PROTOCOL 20124/935
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	End date	Last report visit	Save rity	Hist ory	Rel. to study	Sympt. treat	Dis. app.	Re. case	Out							
																			Adverse event	Onset date	Visit No	End date	Last report visit	Save rity	Hist ory
3	2ND	Reboxetine	01/10/93 - 25/11/93	25/11/93	25/11/93	AGITATION	Detail	25/09/93(C)	0			0	2						NO						
							Summary	25/09/93(C)				0	2												
							Detail	25/09/93(C)	0			0	5											NO	
							Summary	25/09/93(C)				0	5												
							Detail	23/09/93(C)	0			2	2	1	4	1	3	3	3	1					
							Summary	31/10/93 - 04/11/93	04/11/93	35	2	1	4	1	3	3	3	3	1						
							Detail	25/09/93(C)	0			0	2												
							Summary	25/09/93(C)				0	2												
							Detail	25/09/93(C)	0			0	2												
							Summary	25/09/93(C)				0	2												
							Detail	25/09/93(C)	0			0	5												
							Summary	25/09/93(C)				0	5												
Detail	25/09/93(C)	0			0	3																			
Summary	25/09/93(C)				0	3																			
Detail	25/09/93(C)	0			0	1																			
Summary	25/09/93(C)				0	1																			
Detail	25/09/93(C)	0			0	2																			
Summary	25/09/93(C)				0	2																			
Detail	25/09/93(C)	0			0	2																			
Summary	25/09/93(C)				0	2																			
Detail	25/09/93(C)	0			0	2																			
Summary	25/09/93(C)				0	2																			
Detail	25/09/93(C)	0			0	1																			
Summary	25/09/93(C)				0	1																			

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe, 4= life threatening, 5= death
 Study drug: 1= no change, 2= dose reduced, 3= dose withheld, 4= temp. inter.
 Hospital: 1= required, 2= not req., 3= not appl.
 Disapp./Reapp.: 1= no, 2= yes, 3= not appl.
 Symptomatic treatment: 1= no, 2= yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date
 onset date missing: (Q) first report visit date used (screen date - 1 day used for A.E. reported at day0), (L) onset date A.E.

1888

9550089

38

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS RED
REBOXTINE - PROTOCOL 2016/035
Listing No.: 17.9

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report		Dis app.	Re come (C)			
									Save	hist					
9	2M2	Reboxetine	01/11/93	25/11/93	VISION ABNORMAL	Detail	25/09/93(C)	0	2	0	2	NO			
						Summary	23/09/93(C)	0	2						
						Detail	14/12/93(C)	0	2			NO			
						Summary	14/12/93(C)	0	2						
						Detail	14/12/93(C)	0	2			NO			
						Summary	14/12/93(C)	0	2						
30T	Reboxetine	15/10/93	07/12/93	ABDOMINAL PAIN	Detail	24/11/93	49	27/11/93	2	2	2	1	1		
					Summary	24/11/93	49	27/11/93	2	2	2	4	1	2	1
					Detail	04/10/93(C)	0	2			NO				
					Summary	04/10/93(C)	0	2							
					Detail	04/10/93(C)	0	2			NO				
					Summary	04/10/93(C)	0	2							

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl.
Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(M) adverse event still present; end date = visit date
onset date missing: (D) first report visit date used (onset date - 1 day used for A.E. reported at day0), (I) onset date A.E.

1889

9550089

37

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA DNS RED

REBOXETINE - PROTOCOL 20124/93S
Listing No.: 17.9

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Last report visit	Save rity	Hist any	Re stud	Symp drug	Dis Hosp	Re app.	Du come					
																	Adverse event	Adverse event	Adverse event	Adverse event	Adverse event
3	Reboxetine	13/10/93	07/12/93	INSONNIA	Detail	04/10/93(C)	0			2							NO				
					Summary	04/10/93(C)		0	2												
					Detail	04/10/93(C)	0														NO
					Summary	04/10/93(C)		0	3												NO
					Detail	20/10/93	14														NO
					Summary	20/10/93	21														NO
					Detail	28/03/11/93	28														NO
					Summary	28/03/11/93	28														NO
					Detail	06/10/93(C)	0														NO
					Summary	06/10/93(C)		0	3												NO
4	Imipramine	13/10/93	07/12/93	AGITATION	Detail	06/10/93(C)	0										NO				
					Summary	06/10/93(C)		0	2											NO	
					Detail	04/10/93(C)	0														NO
					Summary	04/10/93(C)		0	2												NO
					Detail	04/10/93(C)	0														NO
					Summary	04/10/93(C)		0	2												NO
					Detail	04/10/93(C)	0														NO
					Summary	04/10/93(C)		0	2												NO
					Detail	13/10/93	7														NO
					Summary	13/10/93	14														NO
5	Reboxetine	26/10/93	21/12/93	AMBLYOPIA	Detail	04/10/93(C)	0										NO				
					Summary	04/10/93(C)		0	3											NO	
					Detail	10/10/93(C)	0														NO
					Summary	10/10/93(C)		0	2												NO
					Detail	10/10/93(C)	0														NO
					Summary	10/10/93(C)		0	2												NO
					Detail	10/10/93(C)	0														NO
					Summary	10/10/93(C)		0	2												NO
					Detail	10/10/93(C)	0														NO
					Summary	10/10/93(C)		0	2												NO

Severity: 0=unknown, 1= Mild, 2= moderate, 3= severe, -- History: 1= present before, 2= not observed before, 5= unknown
 Study drug: 1= no change, 2= dose reduced, 3= dose withdrawn, 4= temporary, 5= permanent
 Hospital: 1= required, 2= not required, 3= not applicable -- Outcome: 1= recovered, 2= free with set, 3= still present, 4= death
 Disapp./Resp.: 1= no, 2= yes, 3= not applicable -- Relationship: 1= definite, 2= probable, 3= possible, 4= doubtful, 5= unknown, 6= none
 Symptomatic treatment: 0= no, 1= yes
 (C) adverse event used for statistical analysis
 (F) adverse event still present; end date = visit date
 onset date missing: (C) first report visit date used (screen date - 1 day used for A.E. reported at day 0), (F) onset date A.E.

1890

9550089

38

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/935
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient ID#	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	End date	Last report visit	Save city	Hist app.	Rel Tra	Stud drug	Sym app.	Dis app.	Re app.	Dut app.	Come (C)		
																					Detail	Summary
9	SND	Reboxetina	24/10/93	21/12/93	INSOMNIA	Detail	18/10/93(2)	0				2									NO	
						Summary	18/10/93(2)	0			0	2										
					TACHYCARDIA	Detail	18/10/93(2)	0				1										NO
						Summary	18/10/93(2)	0			0	1										
6ND	Inspramone	05/11/93	05/11/93	05/11/93	ABDOMINAL PAIN	Detail	05/11/93	7	08/11/93			3	2	2	3	2	2	2	3	1		
						Summary	05/11/93	08/11/93	7	3	2	2	5	2	2	3	1	YES				
					ANDREXIA	Detail	26/10/93(2)	0				2										NO
						Summary	26/10/93(2)	0			0	2										
					CONSTIPATION	Detail	26/10/93(2)	0				2										NO
						Summary	26/10/93(2)	0			0	2										
					DIZZINESS	Detail	26/10/93(2)	0				2										NO
						Summary	26/10/93(2)	0			0	2										
					FATIGUE	Detail	26/10/93(2)	0				2										NO
						Summary	26/10/93(2)	0			0	2										
					HEADACHE	Detail	26/10/93(2)	0				2										NO
						Summary	26/10/93(2)	0			0	2										
					INSOMNIA	Detail	26/10/93(2)	0				2										NO
						Summary	26/10/93(2)	0			0	2										
					LIBIDO DECREASED	Detail	26/10/93(2)	0				3										NO
						Summary	26/10/93(2)	0			0	3										
					MOUTH DRY	Detail	26/10/93(2)	0				2										

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=none change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (M) adverse event still present; end date = visit date
 (D) onset date missing; (2) first report visit date used (screen date - 1 day used for A.E. reported at day0); (1) onset date A.E.

1891

9550089

39

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOMETINE - PROTOCOL 20124/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Last report visit	Save rftly	Hist ory	Rel ship	Rea Hosp	Stud app.	Symp app.	Dis app.	Re some	Dut some					
																			Summary	Detail	Summary	Detail	Summary
9	64D	Imipramine	05/11/93	05/11/93	MOUTH DRY	Summary	26/10/93(3)	0	2	0	2								NO				
						Detail	05/11/93	7	05/11/93														
						Summary	05/11/93	05/11/93	7	3	2	2	3	2	2	3	2	2	3	1			
						Detail	26/10/93(3)	0	2														
						Summary	26/10/93(3)	0	2														
						Detail	26/10/93(3)	0	2														
						Summary	26/10/93(3)	0	2														
						Detail	26/10/93(3)	0	2														
						Summary	26/10/93(3)	0	2														
						Detail	26/10/93(3)	0	2														
						Summary	26/10/93(3)	0	2														
						79D	Imipramine	10/11/93	11/11/93	ANDREXIA	Summary	02/11/93(3)	0	2	0	2							
Detail	11/11/93	7	12/11/93																				
Summary	11/11/93	12/11/93	7	3	2						2	3	2	2	3	2	2	1					
Detail	02/11/93(3)	0	2																				
Summary	02/11/93(3)	0	2																				
Detail	02/11/93(3)	0	2																				
Summary	02/11/93(3)	0	2																				
Detail	02/11/93(3)	0	2																				
Summary	02/11/93(3)	0	2																				
Detail	02/11/93(3)	0	2																				
Summary	02/11/93(3)	0	2																				

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=cured, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (3) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

43

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/955
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment		Type record	Onset date	Visit No	End date	Last report visit	Save rity	Hist ary	Rel ship	Stud drug	Samp tree	Dis app.	Re come	Out come (c)									
			Start date	End date																						
9	7MD	Imipramine	10/11/93	11/11/93	LIBIDO DECREASED	Detail	02/11/93(2)	0		0	3						NO									
						Summary	02/11/93(2)			0	3															
						Detail	02/11/93(2)	0		1												NO				
						Summary	02/11/93(2)			0	1															
						Detail	02/11/93(2)	0		2												NO				
						Summary	02/11/93(2)			0	2															
						Detail	02/11/93(2)	0		1												NO				
						Summary	02/11/93(2)			0	1															
						Detail	02/11/93(2)	0		1													NO			
						Summary	02/11/93(2)			0	1															
						Detail	02/11/93(2)	0		1													NO			
						Summary	02/11/93(2)			0	1															
8DT	Reboxetine	16/11/93	10/01/94	AGITATION	Detail	06/11/93(2)	0			0	1						NO									
					Summary	06/11/93(2)			0	1																
					Detail	06/11/93(2)	0		1												NO					
					Summary	06/11/93(2)			0	1																
					Detail	06/11/93(2)	0		2												NO					
					Summary	06/11/93(2)			0	2																
					Detail	06/11/93(2)	0		1												NO					
					Summary	06/11/93(2)			0	1																
					Detail	06/11/93(2)	0		2													NO				
					Summary	06/11/93(2)			0	2																
					Detail	06/11/93(2)	0		2													NO				
					Summary	06/11/93(2)			0	2																
9	7MD	Imipramine	10/11/93	11/11/93	LIBIDO DECREASED	Detail	02/11/93(2)	0		0	3						NO									
						Summary	02/11/93(2)			0	3															
						Detail	02/11/93(2)	0		1												NO				
						Summary	02/11/93(2)			0	1															
						Detail	02/11/93(2)	0		2												NO				
						Summary	02/11/93(2)			0	2															
						Detail	02/11/93(2)	0		1												NO				
						Summary	02/11/93(2)			0	1															
						Detail	02/11/93(2)	0		1													NO			
						Summary	02/11/93(2)			0	1															
						Detail	02/11/93(2)	0		2													NO			
						Summary	02/11/93(2)			0	2															
9	8DT	Reboxetine	16/11/93	10/01/94	AGITATION	Detail	06/11/93(2)	0			0						NO									
						Summary	06/11/93(2)			0	1															
						Detail	06/11/93(2)	0		1												NO				
						Summary	06/11/93(2)			0	1															
						Detail	06/11/93(2)	0		2													NO			
						Summary	06/11/93(2)			0	2															
						Detail	06/11/93(2)	0		1													NO			
						Summary	06/11/93(2)			0	1															
						Detail	06/11/93(2)	0		2													NO			
						Summary	06/11/93(2)			0	2															
						Detail	06/11/93(2)	0		2														NO		
						Summary	06/11/93(2)			0	2															
9	8DT	Reboxetine	16/11/93	10/01/94	AGITATION	Detail	06/11/93(2)	0			0						NO									
						Summary	06/11/93(2)			0	1															
						Detail	06/11/93(2)	0		1													NO			
						Summary	06/11/93(2)			0	1															
						Detail	06/11/93(2)	0		2														NO		
						Summary	06/11/93(2)			0	2															
						Detail	06/11/93(2)	0		1														NO		
						Summary	06/11/93(2)			0	1															
						Detail	06/11/93(2)	0		2															NO	
						Summary	06/11/93(2)			0	2															
						Detail	06/11/93(2)	0		2															NO	
						Summary	06/11/93(2)			0	2															
9	8DT	Reboxetine	16/11/93	10/01/94	AGITATION	Detail	06/11/93(2)	0			0						NO									
						Summary	06/11/93(2)			0	1															
						Detail	06/11/93(2)	0		1														NO		
						Summary	06/11/93(2)			0	1															
						Detail	06/11/93(2)	0		2															NO	
						Summary	06/11/93(2)			0	2															
						Detail	06/11/93(2)	0		1															NO	
						Summary	06/11/93(2)			0	1															
						Detail	06/11/93(2)	0		2																NO
						Summary	06/11/93(2)			0	2															
						Detail	06/11/93(2)	0		2																NO
						Summary	06/11/93(2)			0	2															

Severity: 1=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawal, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 1=no, 2=yes
 (c) adverse event used for statistical analysis
 (d) adverse event still present: end date = visit date
 onset date missing: (2) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1893

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/935
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Last report visit	Save rity	Hist ony	Rel ship	Stud drug	Sympt treat	Dis hosp	Re app.	Out come (c)						
																			Detail	Summary	Detail	Summary	Detail	Summary
18	1DT	Reboxetine	01/12/93	25/01/94	FATIGUE	Detail	22/11/93(0)	0	1										NO					
						Summary	22/11/93(0)	0	1															
						Detail	22/11/93(0)	0	1															NO
						Summary	22/11/93(0)	0	1															
						Detail	22/12/93	28	15/01/94	1	2	3	1	2	3	1	2	3	1	2	3	3	1	YES
						Summary	22/12/93	15/01/94	28	1	2	3	1	2	3	1	2	3	1	2	3	3	1	YES
						Detail	01/12/93	7	05/01/94	1	2	3	1	2	3	1	2	3	1	2	3	3	1	YES
						Summary	01/12/93	05/01/94	7	1	2	3	1	2	3	1	2	3	1	2	3	3	1	YES
						Detail	22/12/93	28	15/01/94	1	2	3	1	2	3	1	2	3	1	2	3	3	1	YES
						Summary	22/12/93	15/01/94	28	1	2	3	1	2	3	1	2	3	1	2	3	3	1	YES
2ND	Reboxetine	02/10/93	26/11/93	ANDREXIA	Detail	23/09/93(0)	0	1											NO					
					Summary	23/09/93(0)	0	1																
					Detail	03/10/93	7	26/11/93	1	2	2	1	2	2	1	2	3	1	2	3	3	1	YES	
					Summary	03/10/93	26/11/93	7	1	2	2	1	2	2	1	2	3	1	2	3	3	1	YES	
					Detail	23/09/93(0)	0	1															NO	
					Summary	23/09/93(0)	0	1																
					Detail	23/09/93(0)	0	1																NO
					Summary	23/09/93(0)	0	1																
					Detail	25/09/93(0)	0	2																NO
					Summary	25/09/93(0)	0	2																
Detail	23/09/93(0)	0	1																	NO				
Summary	23/09/93(0)	0	1																					

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (d) adverse event still present; end date = visit date
 onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

PHARMACIA CMS R&D
 REBOXETINE - PROTOCOL 20124/935
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report visit visit rity	Save Hist ony ship drug	Rel Stud app. app. come (c)	Dis app. app. come (c)	Re app. app. come (c)	Dut app. app. come (c)
10	2MD	Reboxetine	02/10/93	26/11/93	MICTURITION DISORDER	Detail	05/10/93	7 26/11/93	7	1 2 2 1	2 3 3 1	2 3 3 1	2 3 3 1	1
						Summary	05/10/93	26/11/93	7	1 2 2 1	2 3 3 1	2 3 3 1	2 3 3 1	1
						Detail	10/12/93	16 18/01/94	14	1 2 3 1	2 3 3 1	2 3 3 1	2 3 3 1	1
						Summary	10/12/93	18/01/94	14	1 2 3 1	2 3 3 1	2 3 3 1	2 3 3 1	1
20T	Imipramine	01/12/93	25/01/94	CONSTIPATION	Detail	10/12/93	16 18/01/94	14	1 2 3 1	2 3 3 1	2 3 3 1	2 3 3 1	1	
					Summary	10/12/93	18/01/94	14	1 2 3 1	2 3 3 1	2 3 3 1	2 3 3 1	1	
					Detail	22/11/93(0)	0	1	1	1	1	1	NO	
					Summary	22/11/93(0)	0	1	1	1	1	1	NO	
30D	Reboxetine	02/10/93	26/11/93	HEADACHE	Detail	22/11/93(0)	0	1	1	1	1	1	NO	
					Summary	22/11/93(0)	0	1	1	1	1	1	NO	
					Detail	06/01/94	42 25/01/94	42	1 2 2 3	2 2 3 1	2 2 3 1	2 2 3 1	1	
					Summary	06/01/94	25/01/94	42	1 2 2 3	2 2 3 1	2 2 3 1	2 2 3 1	1	
30T	Imipramine	02/10/93	26/01/94	CONSTIPATION	Detail	23/10/93	26 15/11/93	26	1 2 3 1	2 3 3 1	2 3 3 1	2 3 3 1	1	
					Summary	23/10/93	15/11/93	26	1 2 3 1	2 3 3 1	2 3 3 1	2 3 3 1	1	
					Detail	23/09/93(0)	0	2	2	2	2	2	NO	
					Summary	23/09/93(0)	0	2	2	2	2	2	NO	
30T	Imipramine	02/10/93	26/01/94	CONSTIPATION	Detail	23/09/93(0)	0	2	2	2	2	2	NO	
					Summary	23/09/93(0)	0	2	2	2	2	2	NO	
					Detail	05/12/93	7 07/01/94	7	1 2 3 1	2 3 3 1	2 3 3 1	2 3 3 1	1	
					Summary	05/12/93	07/01/94	7	1 2 3 1	2 3 3 1	2 3 3 1	2 3 3 1	1	
30T	Imipramine	02/10/93	26/01/94	FATIGUE	Detail	23/11/93(0)	0	2	2	2	2	2	NO	
					Summary	23/11/93(0)	0	2	2	2	2	2	2	NO

Severity: 1=unknown, 2=mild, 3=moderate, 4=severe, 5=critical
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawal, 4=attemp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (0) adverse event still present; end date = visit date
 onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

PHARMACIA CNS RBD

REBOXETINE - PROTOCOL 20124/935
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Center	Patient	Drug	Treatment		Adverse event	Type record	Onset date	Visit No	End date	Last report visit	Save rity	Hist 0ry	Stud ship	Svmp trns	Dis app.	Re app.	Out com (C)				
			Start date	End date																	
10	3DT	Isipramine	02/12/93	24/01/94	HEADACHE	Detail	23/11/93(D)	0		0	1							NO			
						Summary	23/11/93(D)														
						Detail	05/12/93	7	28/01/94	1	2	2	3	2	2	3	2	2	3	1	YES
						Summary	05/12/93	7	28/01/94	1	2	2	3	2	2	3	2	2	3	1	YES
						Detail	07/01/94	42	26/01/94	1	2	2	3	2	2	3	2	2	3	1	YES
						Summary	07/01/94	42	26/01/94	1	2	2	3	2	2	3	2	2	3	1	YES
						Detail	27/09/93(E)	0		1											NO
						Summary	27/09/93(E)	0		1											
						Detail	06/10/93	7	30/11/93	1	2	2	3	2	2	3	2	2	3	1	YES
						Summary	06/10/93	7	30/11/93	1	2	2	3	2	2	3	2	2	3	1	YES
4ND	Isipramine	INSOMNIA	14	30/11/93		Detail	13/10/93	14	30/11/93	14	1	2	2	3	2	2	3	1			
						Summary	13/10/93	14	30/11/93	14	1	2	2	3	2	2	3	1	YES		
						Detail	27/09/93(E)	0		1											
						Summary	27/09/93(E)	0		1											
						Detail	06/10/93	7	30/11/93	1	2	2	3	2	2	3	2	2	3	1	YES
						Summary	06/10/93	7	30/11/93	1	2	2	3	2	2	3	2	2	3	1	YES
						Detail	13/10/93	14	30/11/93	14	1	2	2	3	2	2	3	2	2	3	1
						Summary	13/10/93	14	30/11/93	14	1	2	2	3	2	2	3	2	2	3	1
						Detail	27/09/93(E)	0		1											
						Summary	27/09/93(E)	0		1											
4DT	Reboxetine	SWEATING INCREASED	02/12/93	26/01/94	CONSTIPATION	Detail	23/11/93(D)	0		0	1							NO			
						Summary	23/11/93(D)														
						Detail	30/10/93	28	30/11/93	1	2	2	3	2	2	3	2	2	3	1	
						Summary	30/10/93	28	30/11/93	1	2	2	3	2	2	3	2	2	3	1	YES
						Detail	23/11/93(D)	0		1											
						Summary	23/11/93(D)	0		1											
						Detail	23/11/93(D)	0		1											
						Summary	23/11/93(D)	0		1											
						Detail	23/11/93(D)	0		1											
						Summary	23/11/93(D)	0		1											

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=fatal
 Study drug: 1=not changed, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital required: 1=not req., 2=not appl., 3=not req., 4=not appl.
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl., 4=not appl.
 Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (D) adverse event still present; end date = visit date
 (E) onset date missing; (D) first report visit date used if screen date - 1 day used for A.E. reported at day0; (I) onset date A.E.

PHARMACIA DAS RED
REBOXETINE - PROTOCOL 20124/935
Listing No.: 17.9

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment		Type record	Onset date	Visit End No date	Last report visit	Sev	Hist	Rel	Stud	Symp	Dis	Re	Out				
			Start date	End date																
10	40T	Reboxetine	02/12/93	26/01/94	LIBIDO DECREASED	Detail	25/11/93(C)	0	1								NO			
			Summary	25/11/93(C)		0	1													
			02/12/93	26/01/94	MOUTH DRY	Detail	02/12/93	7/26/01/94		1	2	3				2	2	3	1	
			Summary	02/12/93	26/01/94	7	1	2	3							2	2	3	1	YES
			02/12/93	26/01/94	TREMOR	Detail	25/12/93	26/26/01/94		1	2	3				2	2	3	1	
			Summary	25/12/93	26/01/94	26	1	2	3							2	2	3	1	YES
			06/10/93	30/11/93	VISION ABNORMAL	Detail	10/01/94	42/26/01/94		1	2	3				2	2	3	1	
			Summary	10/01/94	26/01/94	42	1	2	3							2	2	3	1	YES
			06/10/93	30/11/93	ANDROMEDIA	Detail	28/10/93	26/30/11/93		1	2	3				2	2	3	1	
			Summary	28/10/93	30/11/93	26	1	2	3							2	2	3	1	YES
50D	Imipramine	FATIGUE	26/09/93(C)			Detail	26/09/93(C)	0	1								NO			
			Summary	26/09/93(C)		0	1													
			20/09/93(C)			Detail	20/09/93(C)	0	1										NO	
			Summary	20/09/93(C)		0	1													
			20/09/93(C)			Detail	20/09/93(C)	0	2										NO	
			Summary	20/09/93(C)		0	2													
			26/09/93(C)			Detail	26/09/93(C)	0	1										NO	
			Summary	26/09/93(C)		0	1													
			06/12/93	26/01/94	CONSTIPATION	Detail	25/11/93(C)	0	1										NO	
			Summary	25/11/93(C)		0	1													

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=ongoing, 2=discontinued, 3=withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req, 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq, 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (D) first report visit date used (screen data - 1 day used for A.E. reported at day0), (I) onset date A.E.

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

46

PHARMACIA DNS RED
 REBOXETINE - PROTOCOL 28124/93S
 Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report visit	Sev	Hist	Rel	Stad	Sypm	Dis	Re	Out						
																		ory	ship	drug	trns	Hasp	app.
10	SDT	Reboxetine	84/12/93	28/01/94	FATIGUE	Detail	25/11/93(D)	0	2									NO					
						Summary	25/11/93(D)		0	2													
						Detail	25/12/93	28/01/94		1	2	3										1	
						Summary	25/12/93	28/01/94		20	1	2	3									3	1 YES
						Detail	02/01/94	35/01/94		1	2	3										1	
						Summary	02/01/94	35/01/94		35	1	2	3									3	1 YES
						Detail	05/01/94	35/01/94		1	2	3										1	
						Summary	05/01/94	35/01/94		35	1	2	3									3	1 YES
						Detail	05/01/94	35/01/94		1	2	3										1	
						Summary	05/01/94	35/01/94		35	1	2	3									3	1 YES
6ND	Reboxetine	09/10/93	03/12/93	ANOREXIA	Detail	30/09/93(D)	0		1									NO					
					Summary	30/09/93(D)		0	1														
					Detail	30/09/93(D)		0	1												NO		
					Summary	30/09/93(D)		0	1														
					Detail	30/09/93(D)		0	1												NO		
					Summary	30/09/93(D)		0	1														
					Detail	30/09/93(D)		0	1												NO		
					Summary	30/09/93(D)		0	1														
					Detail	18/10/93	14/21/11/93		1	1	3	1									3	1	
					Summary	18/10/93	21/11/93		14	1	1	3	1								3	1 YES	
					INSOMNIA	Detail	30/09/93(D)	0		2								NO					
						Summary	30/09/93(D)		0	2													
						Detail	30/09/93(D)		0	1												NO	
						Summary	30/09/93(D)		0	1													
						Detail	30/09/93(D)		0	1												NO	
						Summary	30/09/93(D)		0	1													
						Detail	30/09/93(D)		0	1												NO	
						Summary	30/09/93(D)		0	1													
						Detail	30/09/93(D)		0	1												NO	
						Summary	30/09/93(D)		0	1													

Severity: 1=unknown, 2=mild, 3=moderate, 4=severe, 5=critical
 Study drug: 1=as change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=unknown, 5=none
 Symptomatic treatment: 1=no, 2=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date
 onset date missing: (2) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

9550089

1899

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

47

PHARMACIA CNS RD
 REBOXETINE - PROTOCOL 2014/935
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment		Type	Onset date	Visit End No date	Last report visit	Save rity	Hist ory	Rel ship	Stud drug	Syp	Dis Resp	Re app.	Out come (C)				
			Start date	End date																
18	80T	Reboxetine	86/12/93	28/01/94	FATIGUE	25/11/93(D)	0	1	0	1							NO			
			Summary																	
			LIBIDO DECREASED																	
			Summary																	
			HICUTITION DISORDER																	
			Summary																	
			MOUTH DRY																	
			Summary																	
			NAUSEA																	
			Summary																	
7MB	Imipramine	09/10/93	09/12/93	CONSTIPATION	09/10/93	7	26/11/93	1	2	3	1						NO			
					Summary															
					HYPERKINESIA															
					Summary															
					INSOMNIA															
					Summary															
					WEIGHT DECREASE															
					Summary															
					PARAMETHESIA															
					Summary															

9550089

1900

Severity: 0=unknown, 1=ild, 2=oderate, 3=evere, 4=ritical
 Study drug: 1=no change, 2=dose reduced, 3=def, 4=temp, 5=withdwn, 6=not used
 Hospital: 1=required, 2=not req, 3=not appl, 4=not used
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl, 4=not used
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (2) first report visit date used (screen data = 1 day used for A.E. reported at day0), (1) onset date A.E.

9550089

46

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS PBD

REBOXETINE - PROTOCOL 20124/935
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	End No date	Last report date	Save rity	Hist ory	Rea shlp	Stud drug	Symp treat	Dis Hosp	Re app.	Re come	Out (C)							
																				report date	visit No	save rity	hist ory	rea shlp	stud drug	symp treat
16	7ND	Imipramine	09/10/93	05/12/93	LIBIDO DECREASED	Detail	30/09/93(2)	0			1									NO						
						Summary	30/09/93(2)		0	1																
						Detail	01/11/93	28	03/12/93		1	2	2	3	2	2	3	1								
						Summary	01/11/93	28	03/12/93		1	2	2	3	2	2	3	1								
						Detail	09/10/93	7	20/10/93		1	2	3	1	2	3	3	1								
						Summary	09/10/93	7	20/10/93		1	2	3	1	2	3	3	1								
7DT	Imipramine	04/12/93	25/01/94	ANOREXIA	Detail	10/01/94	42	25/01/94			1	2	2	3	2	2	2	3	1							
					Summary	10/01/94	42	25/01/94		1	2	2	3	2	2	3	1									
					Detail	25/11/93(2)	0			1																
					Summary	25/11/93(2)	0			1																
					Detail	25/11/93(2)	0			1																
					Summary	25/11/93(2)	0			1																
6MD	Reboxetine	16/10/93	10/12/93	ANOREXIA	Detail	04/12/93	7	20/12/93			1	2	3	1	2	3	3	1								
					Summary	04/12/93	7	20/12/93		1	2	3	1	2	3	1										
					Detail	04/12/93	7	20/12/93		1	2	3	1	2	3	1										
					Summary	04/12/93	7	20/12/93		1	2	3	1	2	3	1										
					Detail	06/11/93	28	10/11/93		2	2	3	1	2	3	3	1									
					Summary	06/11/93	28	10/11/93		2	2	3	1	2	3	3	1									
6MD	Reboxetine	16/10/93	10/12/93	CONSTIPATION	Detail	30/11/93	49	10/12/93			1	2	3	2	2	2	3	1								
					Summary	30/11/93	49	10/12/93		1	2	3	2	2	3	1										

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl.
Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present; end date = visit date
onset date missing: (2) first report visit date used (screen date - 1 day used for A.E., reported at day); (1) onset date A.E.

1901

9550089

50

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA DNS RD

REBOMETINE - PROTOCOL 20124/935
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	End date	Last report	Save	Hist	Rel	Rat	Stud	Symp	Dis	Re	Out	app.		come (c)								
																					resp	dry		ship	drug	tra	Hosp	app.	come (c)		
10	BDT	Imipramine	86/12/93	28/01/94	FATIGUE	Summary	25/11/93(0)		0	1														NO							
						Detail	25/11/93(0)	0	1																				NO		
						Summary	25/11/93(0)		0	1																					NO
						Detail	06/12/93	7	10/01/94	2	2	3	1	2	3	1	2	3	1	2	3	1	2	3	1	2	3	1	1		
						Summary	06/12/93	10/01/94	7	2	2	3	1	2	3	1	2	3	1	2	3	1	2	3	1	2	3	1	1	YES	
						Detail	11/01/94	42	28/01/94	1	2	2	5	2	2	5	2	2	5	2	2	5	2	2	5	2	2	5	1	YES	
						Summary	11/01/94	28/01/94	42	1	2	2	5	2	2	5	2	2	5	2	2	5	2	2	5	2	2	5	1	YES	
						Detail	06/12/93	7	11/12/93	1	1	2	5	1	2	5	1	2	5	1	2	5	1	2	5	1	2	5	1	YES	
						Summary	06/12/93	11/12/93	7	1	2	5	1	2	5	1	2	5	1	2	5	1	2	5	1	2	5	1	1	YES	
						Summary	06/12/93	11/12/93	7	1	2	5	1	2	5	1	2	5	1	2	5	1	2	5	1	2	5	1	1	YES	
9HD	Reboxetine	29/11/93	14/01/94	ANOREXIA	Detail	11/11/93(0)	0	1																	NO						
					Summary	11/11/93(0)		0	1																				NO		
					Detail	11/12/93	26	05/01/94	1	2	3	1	2	3	1	2	3	1	2	3	1	2	3	1	2	3	1	1	YES		
					Summary	11/12/93	05/01/94	26	1	2	3	1	2	3	1	2	3	1	2	3	1	2	3	1	2	3	1	1	YES		
					Detail	11/11/93(0)	0	2																						NO	
					Summary	11/11/93(0)		0	2																						NO
					Detail	02/01/94	69	06/01/94	2	2	4	1	2	4	1	2	4	1	2	4	1	2	4	1	2	4	1	1	YES		
					Summary	02/01/94	06/01/94	69	2	2	4	1	2	4	1	2	4	1	2	4	1	2	4	1	2	4	1	1	YES		
					Detail	11/11/93(0)	0	1																							NO
					Summary	11/11/93(0)		0	1																						NO
10	BDT	Imipramine	86/12/93	28/01/94	FATIGUE	Detail	11/11/93(0)	0	2																NO						
						Summary	11/11/93(0)		0	2																				NO	
10	BDT	Imipramine	86/12/93	28/01/94	FATIGUE	Detail	02/01/94	69	06/01/94	2	2	4	1	2	4	1	2	4	1	2	4	1	2	4	1	1	YES				
						Summary	02/01/94	06/01/94	69	2	2	4	1	2	4	1	2	4	1	2	4	1	2	4	1	2	4	1	1	YES	
10	BDT	Imipramine	86/12/93	28/01/94	FATIGUE	Detail	11/11/93(0)	0	1																	NO					
						Summary	11/11/93(0)		0	1																					NO
10	BDT	Imipramine	86/12/93	28/01/94	FATIGUE	Detail	11/11/93(0)	0	2																	NO					
						Summary	11/11/93(0)		0	2																					NO
10	BDT	Imipramine	86/12/93	28/01/94	FATIGUE	Detail	11/11/93(0)	0	2																	NO					
						Summary	11/11/93(0)		0	2																					NO
10	BDT	Imipramine	86/12/93	28/01/94	FATIGUE	Detail	11/11/93(0)	0	2																	NO					
						Summary	11/11/93(0)		0	2																					NO

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
Study drug: 1=no change, 2=dose reduced, 3=dose, 4=withdrawn, 5=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present; end date = visit date
onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1903

9550089

51

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/935
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment		Adverse event	Type record	Onset date	Visit End No date	Last report visit	Hist rity	Rel ship	Rai drug	Stud app.	Symp. app.	Dis app.	Re come (c)																						
			Start date	End date																																		
10	9ND	Reboxetine	28/11/95	14/01/94	LIBIDO DECREASED	Detail	11/11/95(2)	0	0	1						NO																						
						Summary	11/11/95(2)			0	1																											
						Detail	20/11/95	7	20/12/93		1	2	3	1			2	3	3	1																		
						Summary	20/11/95		20/12/93		7	1	2	3	1		2	3	5	1	YES																	
						Detail	20/11/95	7	30/11/93		1	2	3	1			2	3	5	1																		
						Summary	20/11/95		30/11/93		7	1	2	3	1		2	3	5	1	YES																	
						Detail	11/12/95	20	14/01/94		1	2	2	3			2	2	5	1																		
						Summary	11/12/95		14/01/94		20	1	2	3			2	2	5	1	YES																	
						Detail	11/11/95(2)	0			1										NO																	
						Summary	11/11/95(2)				0	1																										
9DT	Imipramine	06/12/93	01/02/94	CONSTIPATION	Detail	29/11/93(2)	0		1							NO																						
								Summary	29/11/93(2)			0	1																									
								Detail	29/11/93(2)	0			1								NO																	
								Summary	29/11/93(2)				0	1																								
								Detail	29/11/93(2)	0			1									NO																
								Summary	29/11/93(2)				0	1																								
								Detail	29/11/93(2)	0			1									NO																
								Summary	29/11/93(2)				0	1																								
								Detail	29/11/93(2)	0			2										NO															
								Summary	29/11/93(2)				0	2																								

Severity: 1=unknown, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (d) adverse event still present; end date = visit date
 (e) onset date missing; (2) first report visit date used (screen date - 1 day used for A.E. reported at day); (1) onset date A.E.

1904

9550089

52

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA DNS RED
REBOMETINE - PROTOCOL 28124/955
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	End date	Last report visit	save	Hist	Rel	Stud	Symp	Dis	Re	Dut				
10	90T	Imipramine	08/12/93	01/02/94	TREMOR	Summary	29/11/93(2)		0	1										NO			
	10ND	Imipramine	25/10/93	17/12/93	ANOREXIA	Detail	14/10/93(2)	0	1												NO		
						Summary	14/10/93(2)		0	1													
					FATIGUE	Detail	14/10/93(2)	0	1													NO	
						Summary	14/10/93(2)		0	1													
					HYPERKINESIA	Detail	14/10/93(2)	0	1													NO	
						Summary	14/10/93(2)		0	1													
					LIBIDO DECREASED	Detail	14/10/93(2)	0	1													NO	
						Summary	14/10/93(2)		0	1													
					MOUTH DRY	Detail	25/10/93	7	17/12/93													1	
						Summary	25/10/93	7	17/12/93													2 2 3 1	
					NAUSEA	Detail	13/11/93	28	01/12/93													1	
						Summary	13/11/93	28	01/12/93													2 3 5 1	
					SWEATING INCREASED	Detail	01/11/93	14	17/12/93													1	
						Summary	01/11/93	14	17/12/93													2 2 3 1	
	10DT	Reboxetine	08/12/93	01/02/94	ANOREXIA	Detail	29/11/93(2)	0	1													NO	
						Summary	29/11/93(2)		0	1													
					CONSTIPATION	Detail	25/12/93	21	15/01/94													1	
						Summary	25/12/93	21	15/01/94													2 3 3 1	
					FATIGUE	Detail	29/11/93(2)	0	1														NO
						Summary	29/11/93(2)		0	1													

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (M) adverse event still present; end date = visit date
 onset date missing: (2) first report visit date used (green date - 1 day used for A.E. reported at 0900), (1) onset date A.E.

1905

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

53

9550089

PHARMACIA CNS RED
 REBOXETINE - PROCTODOL 20124/035
 Listing No.: 17.9

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment Start date	End date	Adverse event	Type record	Onset date	Visit No	End date	Last report visit	Save rfty	Hist ary	Re ship	Stu ship	Symp tree	Die app.	Re app.	Dut coes (c)								
10	100T	Reboxetine	06/12/93	01/02/94	INSOMNIA	Detail	29/11/93(0)	0		1								NO							
						Summary	29/11/93(0)		0	1															
						Detail	29/11/93(0)	0		1													NO		
						Summary	29/11/93(0)		0	1															
						Detail	06/12/93	7/20/01/94		1	2	3	1										1		
						Summary	06/12/93	20/01/94		7	1	2	3	1										1 YES	
						Detail	05/01/94	35/01/02/94		1	2	2	3											1	
						Summary	05/01/94	01/02/94		35	1	2	2	3										1 YES	
						Detail	14/10/93(0)	0		2															NO
						Summary	14/10/93(0)		0	2															
110D	110D	Imipramine	25/10/93	17/12/93	ANDREXIA	Detail	14/10/93(0)	0		2									NO						
						Summary	14/10/93(0)		0	2															
						Detail	14/10/93(0)	0		2														NO	
						Summary	14/10/93(0)		0	2															
						Detail	14/10/93(0)	0		1															NO
						Summary	14/10/93(0)		0	1															
						Detail	13/11/93	28/03/12/93		1	2	3	1											1	
						Summary	13/11/93	03/12/93		28	1	2	3	1										1 YES	
						Detail	14/10/93(0)	0		1															NO
						Summary	14/10/93(0)		0	1															
110T	110T	Imipramine	06/12/93	01/02/94	ANDREXIA	Detail	29/11/93(0)	0		2									NO						
						Summary	29/11/93(0)		0	2															

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawal, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Respp: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1906

9550089

54

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOMETINE - PROCTOOL 2016/935
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient ID	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	End date	Last report visit	Sav	Hist	Rel	Stud	Syp	Drug	Trea	Hosp	Dis	Re	Duc	Coma (C)									
																								report	visit	rity	ory	ship	drug	tra	hosp	app.
L0	LJDT	Imipramine	08/12/93 - 01/02/94	08/12/93	01/02/94	CONSTIPATION	Detail	08/12/93	7	18/12/93	7	18/12/93	2	2	3	1	2	3	3	1	2	3	3	1								
							Summary	08/12/93	7	18/12/93	7	2	2	3	1	2	3	3	1	2	3	3	1	2	3	3	1	2	3	1		
							Detail	19/12/93	14	01/02/94	14	1	2	2	3	2	2	3	1	2	3	1	2	3	1	2	3	1	2	3	1	
							Summary	19/12/93	14	01/02/94	14	1	2	2	3	2	2	3	1	2	3	1	2	3	1	2	3	1	2	3	1	
							Detail	29/11/93(C)	0	29/11/93(C)	0	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
							Summary	29/11/93(C)	0	29/11/93(C)	0	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
							Detail	29/11/93(C)	0	29/11/93(C)	0	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
							Summary	29/11/93(C)	0	29/11/93(C)	0	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
							Detail	29/12/93	28	05/01/94	28	1	2	3	1	3	3	3	1	2	3	1	3	3	1	3	3	3	1	2	3	1
							Summary	29/12/93	28	05/01/94	28	1	2	3	1	3	3	3	1	2	3	1	3	3	1	3	3	3	1	2	3	1
L240	Reboxetine	27/10/93 - 21/12/93	27/10/93	21/12/93	CONSTIPATION	Detail	08/12/93	7	11/12/93	7	11/12/93	7	1	2	3	1	2	3	3	1	2	3	3	1								
						Summary	08/12/93	7	11/12/93	7	1	2	3	1	2	3	3	1	2	3	3	1	2	3	3	1	2	3	1			
						Detail	08/12/93	7	01/02/94	7	1	2	3	1	2	3	1	2	3	1	2	3	1	2	3	1	2	3	1			
						Summary	08/12/93	7	01/02/94	7	1	2	3	1	2	3	1	2	3	1	2	3	1	2	3	1	2	3	1	2		
						Detail	10/10/93(C)	0	10/10/93(C)	0	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
						Summary	10/10/93(C)	0	10/10/93(C)	0	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
						Detail	10/10/93(C)	0	10/10/93(C)	0	2	2	2	2	0	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
						Summary	10/10/93(C)	0	10/10/93(C)	0	2	2	2	2	0	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
						Detail	10/10/93(C)	0	10/10/93(C)	0	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
						Summary	10/10/93(C)	0	10/10/93(C)	0	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
L240	Reboxetine	27/10/93 - 21/12/93	27/10/93	21/12/93	CONSTIPATION	Detail	08/12/93	7	11/12/93	7	11/12/93	7	1	2	3	1	2	3	3	1	2	3	3	1								
						Summary	08/12/93	7	11/12/93	7	1	2	3	1	2	3	3	1	2	3	3	1	2	3	3	1	2	3	1			
						Detail	08/12/93	7	01/02/94	7	1	2	3	1	2	3	1	2	3	1	2	3	1	2	3	1	2	3	1			
						Summary	08/12/93	7	01/02/94	7	1	2	3	1	2	3	1	2	3	1	2	3	1	2	3	1	2	3	1	2		
						Detail	10/10/93(C)	0	10/10/93(C)	0	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
						Summary	10/10/93(C)	0	10/10/93(C)	0	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
						Detail	10/10/93(C)	0	10/10/93(C)	0	2	2	2	2	0	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
						Summary	10/10/93(C)	0	10/10/93(C)	0	2	2	2	2	0	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
						Detail	10/10/93(C)	0	10/10/93(C)	0	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
						Summary	10/10/93(C)	0	10/10/93(C)	0	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
L240	Reboxetine	27/10/93 - 21/12/93	27/10/93	21/12/93	CONSTIPATION	Detail	08/12/93	7	11/12/93	7	11/12/93	7	1	2	3	1	2	3	3	1	2	3	3	1								
						Summary	08/12/93	7	11/12/93	7	1	2	3	1	2	3	3	1	2	3	3	1	2	3	3	1	2	3	1			
						Detail	08/12/93	7	01/02/94	7	1	2	3	1	2	3	1	2	3	1	2	3	1	2	3	1	2	3	1			
						Summary	08/12/93	7	01/02/94	7	1	2	3	1	2	3	1	2	3	1	2	3	1	2	3	1	2	3	1	2		
						Detail	10/10/93(C)	0	10/10/93(C)	0	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
						Summary	10/10/93(C)	0	10/10/93(C)	0	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
						Detail	10/10/93(C)	0	10/10/93(C)	0	2	2	2	2	0	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
						Summary	10/10/93(C)	0	10/10/93(C)	0	2	2	2	2	0	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
						Detail	10/10/93(C)	0	10/10/93(C)	0	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
						Summary	10/10/93(C)	0	10/10/93(C)	0	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
L240	Reboxetine	27/10/93 - 21/12/93	27/10/93	21/12/93	CONSTIPATION	Detail	08/12/93	7	11/12/93	7	11/12/93	7	1	2	3	1	2	3	3	1	2	3	3	1								
						Summary	08/12/93	7	11/12/93	7	1	2	3	1	2	3	3	1	2	3	3	1	2	3	3	1	2	3	1			
						Detail	08/12/93	7	01/02/94	7	1	2	3	1	2	3	1	2	3	1	2	3	1	2	3	1	2	3	1			
						Summary	08/12/93	7	01/02/94	7	1	2	3	1	2	3	1	2	3	1	2	3	1	2	3	1	2	3	1	2		
						Detail	10/10/93(C)	0	10/10/93(C)	0	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
						Summary	10/10/93(C)	0	10/10/93(C)	0	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
						Detail	10/10/93(C)	0	10/10/93(C)	0	2	2	2	2	0	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
						Summary	10/10/93(C)	0	10/10/93(C)	0	2	2	2	2	0	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
						Detail	10/10/93(C)	0	10/10/93(C)	0	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
						Summary	10/10/93(C)	0	10/10/93(C)	0	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		

1907

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=def. withdraw, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (C) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

9550089

55

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/R35
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	End date	Last report visit	Save	Hist	Rel	Stud	Symp	Dis app.	Re come	Dut		
10	12ND	Reboxetine	27/10/95	21/12/95	INSONNIA	Summary	16/10/95(0)		0	2										NO	
					LIBIDO DECREASED	Detail	16/10/95(0)	0	1												NO
						Summary	16/10/95(0)		0	1											NO
12DT		Reboxetine	06/12/93	01/02/94	ANDREXIA	Detail	29/11/93(0)	0	2												NO
						Summary	29/11/93(0)		0	2											NO
					LIBIDO DECREASED	Detail	29/11/93(0)	0	2												NO
						Summary	29/11/93(0)		0	2											NO
					NAUSEA	Detail	06/12/93	7 16/12/95	1	2	3	1									2 3 3 1
						Summary	06/12/93	16/12/95	7	1	2	3	1								2 3 3 1
					TREMOR	Detail	06/01/94	35 01/02/94	1	2	2	3	1								2 2 3 1
						Summary	06/01/94	01/02/94	35	1	2	2	3	1							2 2 3 1
13DT		Reboxetine	27/10/93	21/12/93	CONSTIPATION	Detail	27/10/93	7 05/12/93	1	2	3	1									2 3 3 1
						Summary	27/10/93	05/12/93	7	1	2	3	1								2 3 3 1
					FATIGUE	Detail	16/10/93(0)	0	1												NO
						Summary	16/10/93(0)		0	1											NO
					LIBIDO DECREASED	Detail	16/10/93(0)	0	2												NO
						Summary	16/10/93(0)		0	2											NO
					MOUTH DRY	Detail	27/10/93	7 05/12/93	1	2	3	1									2 3 3 1
						Summary	27/10/93	05/12/93	7	1	2	3	1								2 3 3 1
					NAUSEA	Detail	17/11/93	26 05/12/95	1	2	3	1									2 3 3 1
						Summary	17/11/93	05/12/95	26	1	2	3	1								2 3 3 1

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (*) adverse event used for statistical analysis
 (**) adverse event still present: end date = visit date
 onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1908

9550089

56

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 REMOXTINE - PROTOCOL 20124/935
 Listing No.: 17.9

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Visit End date	Last report visit	Save rity	Hist ary	Rai ship	Stud drug	Sym tras	Dis app.	Re app.	Dut app.	Sev. (c)							
																				report visit	save rity	hist ary	rai ship	stud drug	sym tras	dis app.
10	1401	Imipramine	30/10/93	25/12/93	AGITATION	Detail	05/12/93	42	23/12/93		42	1	2	2	3	2	2	3	1							
						Summary	05/12/93		23/12/93		42	1	2	2	3	2	2	3	1	YES						
						Detail	05/12/93	42	23/12/93		42	1	2	2	1	2	3	3	1							
						Summary	05/12/93		23/12/93		42	1	2	2	1	2	3	3	1	YES						
						Detail	21/10/93(2)	0			0	2														
						Summary	21/10/93(2)				0	2													NO	
						Detail	21/10/93(2)	0			0	2														
						Summary	21/10/93(2)				0	2														NO
						Detail	30/10/93	7	01/12/93		7	1	2	3	1	2	3	3	1	2	3	3	1			
						Summary	30/10/93		01/12/93		7	1	2	3	1	2	3	3	1	2	3	3	1	YES		
1500	Roxoxetac	30/10/93	25/12/93	CONSTIPATION	Detail	30/10/93	7	07/12/93		7	1	2	3	1	2	3	3	1								
					Summary	30/10/93		07/12/93		7	1	2	3	1	2	3	3	1	YES							
					Detail	18/12/93	56	20/12/93		56	1	2	4	1	2	3	3	1	2	3	3	1				
					Summary	18/12/93		20/12/93		56	1	2	4	1	2	3	3	1	2	3	3	1	YES			
					Detail	21/10/93(2)	0			0	2															
					Summary	21/10/93(2)				0	2														NO	
					Detail	21/10/93(2)	0			0	1															
					Summary	21/10/93(2)				0	1															NO
					Detail	21/10/93(2)	0			0	1															
					Summary	21/10/93(2)				0	1															NO

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=as change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date
 onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1909

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

57

PHARMACIA CNS RBD

REBOXETINE - PROTOCOL 20124/935
Listing No.: 17.9

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Visit End No date	Last report	Save rity	Hist ory	Rel ation	Stud y	Svmp	Dis	Re	Dut						
																			visit	ity	or	ship	drug	trea
18	Reboxetine	30/10/93	25/12/93	INSONNIA	Detail	21/10/93(2)	0	2																
					Summary	21/10/93(2)	0	2																
					Detail	21/10/93(2)	0	1																
					Summary	21/10/93(2)	0	1																
					Detail	20/11/93	28	20/12/93	1	2	3	1	2	3	1	2	3	1	2	3	3	1		
					Summary	20/11/93	20/12/93	28	1	2	3	1	2	3	1	2	3	1	2	3	3	1		
					Detail	21/10/93(2)	0	1																
					Summary	21/10/93(2)	0	1																
					Detail	21/10/93(2)	0	1																
					Summary	21/10/93(2)	0	1																
					Detail	21/10/93(2)	0	1																
					Summary	21/10/93(2)	0	1																
18D	Isipramine	30/10/93	25/12/93	CONSTIPATION	Detail	21/10/93(2)	0	1																
					Summary	21/10/93(2)	0	1																
					Detail	21/10/93(2)	0	1																
					Summary	21/10/93(2)	0	1																
					Detail	21/10/93(2)	0	1																
					Summary	21/10/93(2)	0	1																
					Detail	21/10/93(2)	0	1																
					Summary	21/10/93(2)	0	1																
					Detail	21/10/93(2)	0	1																
					Summary	21/10/93(2)	0	1																
					Detail	21/10/93(2)	0	1																
					Summary	21/10/93(2)	0	1																
17D	Reboxetine	06/11/93	30/12/93	CONSTIPATION	Detail	15/12/93	42	25/12/93	1	2	3	1	2	3	1	2	3	5	1					
					Summary	15/12/93	42	25/12/93	1	2	3	1	2	3	1	2	3	5	1					
					Detail	15/12/93	42	25/12/93	1	2	3	1	2	3	1	2	3	5	1					
					Summary	15/12/93	42	25/12/93	1	2	3	1	2	3	1	2	3	5	1					
					Detail	15/12/93	42	25/12/93	1	2	3	1	2	3	1	2	3	5	1					
					Summary	15/12/93	42	25/12/93	1	2	3	1	2	3	1	2	3	5	1					
					Detail	15/12/93	42	25/12/93	1	2	3	1	2	3	1	2	3	5	1					
					Summary	15/12/93	42	25/12/93	1	2	3	1	2	3	1	2	3	5	1					
					Detail	15/12/93	42	25/12/93	1	2	3	1	2	3	1	2	3	5	1					
					Summary	15/12/93	42	25/12/93	1	2	3	1	2	3	1	2	3	5	1					
					Detail	15/12/93	42	25/12/93	1	2	3	1	2	3	1	2	3	5	1					
					Summary	15/12/93	42	25/12/93	1	2	3	1	2	3	1	2	3	5	1					

Severita: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
 Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (2) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

9550089

1910

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

58

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/935
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment		Adverse event	Type record	Onset date	Visit End No date	Last report visit	Sev	Hist	Rel	Stud	Symp	Dis app.	Re app.	Dut			
			Start date	End date																
10	1740	Reboxetine	06/11/93	30/12/93	FATIGUE	Detail	28/10/93(C)	0	0	2							NO			
			Summary	28/10/93(C)		0	2													
						HYPERKINESIA	Detail	28/10/93(C)	0	0	1								NO	
							Summary	28/10/93(C)	0	1										
						INSOMNIA	Detail	27/11/93	28 15/12/93	1 2 3 1	2 3 1								1	
							Summary	27/11/93	15/12/93	28 1 2 3 1	2 3 1									
						LIBIDO DECREASED	Detail	28/10/93(C)	0	0	2									NO
							Summary	28/10/93(C)	0	2										
						MOUTH DRY	Detail	06/11/93	7 20/11/93	1 2 3 1	2 3 1									1
							Summary	06/11/93	20/11/93	7 1 2 3 1	2 3 1									
1840	Impramine	06/11/93	30/12/93	AGITATION	Detail	01/12/93	28 30/12/93	1 2 2 3	2 2 3 1										1	
					Summary	01/12/93	30/12/93	28 1 2 2 3	2 2 3 1											
					ANOREXIA	Detail	28/10/93(C)	0	0	2										NO
						Summary	28/10/93(C)	0	2											
					CONSTIPATION	Detail	08/11/93	7 30/12/93	1 2 2 3	2 2 3 1									1	
						Summary	08/11/93	30/12/93	7 1 2 2 3	2 2 3 1										
					FATIGUE	Detail	28/10/93(C)	0	0	2										NO
						Summary	28/10/93(C)	0	2											
					INSOMNIA	Detail	28/10/93(C)	0	0	2										NO
						Summary	28/10/93(C)	0	2											

Severity: 1=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observed before, 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=prob. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
onset date missing: (C) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

9550089

1911

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

59

PHARMACIA CNS RED
 REBONETINE - PROTOCOL 20124/935
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report visit	Re	Stu	Somp	Dis	Re	Out				
																visit	city	dry	shp
18	LOND	Isoprasine	06/11/93	30/12/93	LIBIDO DECREASED	Detail	26/10/93(C)	0	1	0	1					NO			
						Summary	26/10/93(C)		0	1									
						Detail	06/11/93	7	30/12/93	1	2	3	2	2	3	1			
						Summary	06/11/93	7	30/12/93	1	2	3	2	2	3	1	YES		
						Detail	06/11/93	14	20/12/93	1	2	3	2	2	3	3	1		
						Summary	15/11/93	14	20/12/93	1	2	3	2	2	3	3	1	YES	
19T	Rebonetine	06/11/93	30/12/93	CONSTIPATION	Detail	26/10/93(C)	0	1	0	1					NO				
					Summary	26/10/93(C)		0	1										
					Detail	06/11/93	7	30/12/93	1	2	3	2	2	3	1				
					Summary	06/11/93	7	30/12/93	1	2	3	2	2	3	1	YES			
					Detail	06/11/93	14	20/12/93	1	2	3	2	2	3	3	1			
					Summary	15/11/93	14	20/12/93	1	2	3	2	2	3	3	1	YES		
20D	Rebonetine	06/11/93	30/12/93	FATIGUE	Detail	26/10/93(C)	0	2	0	2					NO				
					Summary	26/10/93(C)		0	2										
					Detail	06/11/93	7	15/12/93	1	2	3	2	2	3	1				
					Summary	06/11/93	7	15/12/93	1	2	3	2	2	3	1	YES			
					Detail	06/11/93	14	20/12/93	1	2	3	2	2	3	3	1			
					Summary	06/11/93	14	20/12/93	1	2	3	2	2	3	3	1	YES		
20D	Rebonetine	06/11/93	30/12/93	ANOREXIA	Detail	26/10/93(C)	0	2	0	2					NO				
					Summary	26/10/93(C)		0	2										
					Detail	06/11/93	7	15/12/93	1	2	3	2	2	3	1				
					Summary	06/11/93	7	15/12/93	1	2	3	2	2	3	1	YES			
					Detail	06/11/93	14	20/12/93	1	2	3	2	2	3	3	1			
					Summary	06/11/93	14	20/12/93	1	2	3	2	2	3	3	1	YES		
20D	Rebonetine	06/11/93	30/12/93	FATIGUE	Detail	26/10/93(C)	0	2	0	2					NO				
					Summary	26/10/93(C)		0	2										
					Detail	06/11/93	7	15/12/93	1	2	3	2	2	3	1				
					Summary	06/11/93	7	15/12/93	1	2	3	2	2	3	1	YES			
					Detail	06/11/93	14	20/12/93	1	2	3	2	2	3	3	1			
					Summary	06/11/93	14	20/12/93	1	2	3	2	2	3	3	1	YES		
20D	Rebonetine	06/11/93	30/12/93	HYPERKINESIA	Detail	26/10/93(C)	0	1	0	1					NO				
					Summary	26/10/93(C)		0	1										
					Detail	06/11/93	7	15/12/93	1	2	3	2	2	3	1				
					Summary	06/11/93	7	15/12/93	1	2	3	2	2	3	1	YES			
					Detail	06/11/93	14	20/12/93	1	2	3	2	2	3	3	1			
					Summary	06/11/93	14	20/12/93	1	2	3	2	2	3	3	1	YES		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawal, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Respp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (M) adverse event still present; end date = visit date
 onset date missing: (2) first report visit date used (screen date - 1 day used for A.E. reported at day0), (3) onset date A.E.

1912

9550089

9550089

10

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RBD
REBOXETINE - PROTOCOL 20124/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Dentra Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report visit	Save r1CY	Hist ory ship	Rel. Stud Sym	Dis app.	Re Out				
														report	visit	rel	stud
10	20HD	Reboxetine	06/11/93	30/12/93	INSOMNIA	Detail	26/10/93(2)	0	2					NO			
						Summary	26/10/93(2)	0	2								
						Detail	26/10/93(2)	0	1								
						Summary	26/10/93(2)	0	1								
12	1MD	Reboxetine	20/04/93	22/06/93	CONSTIPATION	Detail	17/04/93(2)	0	1					NO			
						Summary	17/04/93(2)	0	1								
						Detail	17/04/93(2)	0	1								
						Summary	17/04/93(2)	0	1								
13	1DT	Reboxetine	20/05/93	14/07/93	URINARY TRACT INFECTION	Detail	30/06/93	49	07/07/93	49	1	2	6	1	YES		
						Summary	30/06/93	49	07/07/93	49	1	2	6	1	YES		
						Detail	26/03/93(2)	0	2								
						Summary	26/03/93(2)	0	2								
13	1MD	Reboxetine	02/04/93	02/04/93	FATIGUE	Detail	26/03/93(2)	0	2					NO			
						Summary	26/03/93(2)	0	2								
						Detail	25/04/93	21	1	2	3	1	3	3	3	3	
						Summary	25/04/93	55	2	2	1	3	3	3	3	3	
13	1MD	Reboxetine	02/04/93	02/04/93	MOUTH DRY	Detail	25/04/93	21	1	2	3	1	3	3			
						Summary	25/04/93	55	2	2	1	3	3	3	3		
						Detail	25/04/93	42	1	2	3	1	3	3	3		
						Summary	25/04/93	56	1	2	3	1	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=tem. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date a visit date
 onset date missing: (D) first report visit date used (screen date - 1 day used for A.E. reported at day0), (I) onset date A.E.

1913

9550089

61

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA OAS RED
REBOXETINE - PROTOCOL 20124/935
Listing No.: 17.9

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient ID	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report visit	Save	Hist	R1	Stud	Symp	Dis	Re	Out								
																			city	dry	ship	drug	trns	Hosp	app.	app.
13	140	Reboxetine	02/04/93	02/04/93		SWEATING INCREASED	Detail	16/04/93	14	2	2	3	1	YES	3	3	3	3	3							
							Summary	16/04/93	56	2	2	3	1	YES	3	3	3	3	3	3	3	3	3			
							Detail	26/05/93	56	2	2	3	1	YES	3	3	3	3	3	3	3	3	3	3		
							Summary	26/05/93	56	2	2	3	1	YES	3	3	3	3	3	3	3	3	3	3		
							Detail	16/09/93(D)	9	1																
							Summary	16/09/93(D)	0	1																
							Detail	20/10/93	26	20/10/93	26	20/10/93	26	20/10/93	26	20/10/93	26	20/10/93	26	20/10/93	26	20/10/93	26	20/10/93	26	20/10/93
							Summary	20/10/93	28	20/10/93	28	20/10/93	28	20/10/93	28	20/10/93	28	20/10/93	28	20/10/93	28	20/10/93	28	20/10/93	28	20/10/93
							Detail	16/09/93(D)	0	1																
							Summary	16/09/93(D)	0	1																
200	101	Isipramine	11/12/93	06/02/94		ANOREXIA	Detail	01/02/94	56	06/02/94(M)	56	1	2	4	4	YES	3	1	3	3						
							Summary	01/02/94	56	06/02/94(M)	56	1	2	4	4	YES	3	1	3	3	3	3				
							Detail	25/11/93(D)	0	3																
							Summary	25/11/93(D)	0	3																
							Detail	11/12/93	7	14	25/12/93	14	2	4	4	YES	3	1	3	3	3	3	3	3	3	
							Summary	11/12/93	14	25/12/93	14	2	4	4	YES	3	1	3	3	3	3	3	3	3	3	
							Detail	25/11/93(D)	0	1																
							Summary	25/11/93(D)	0	1																
							Detail	25/11/93(D)	0	1																
							Summary	25/11/93(D)	0	1																

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawal, 4=temp. later.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (M) adverse event still present; end date = visit date
 onset date missing: (D) first report visit date used (screen date - 1 day used for A.E. reported at day), (1) onset date A.E.

1914

9550089

62

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RBD
REBNETINE - PROTOCOL 20124/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	End date	Adverse event	Type rec'd	Onset date	Visit End No date	Last report visit visit rty	Save ary ship	Hist drug	Rel traa	Stud Hosp	Sump app.	Dis	Re	Dut		
13	290	Imipramine	11/12/93	04/02/94	FALL	Detail Summary	31/01/94 31/01/94	56 56	31/01/94 31/01/94	56 56	3 3	2 2	5 5	4 4	1 1	3 3	3 3	2 2	
					FATIGUE	Detail Summary	25/11/93(0) 25/11/93(0)	0 0		0 0	3 3							NO	
					FRACTURE	Detail Summary	31/01/94 31/01/94	56 56	01/02/94 01/02/94	56 56	3 3	2 2	5 5	4 4	1 1	3 3	3 3	2 2	
					HYPOKALAEMIA	Detail Summary	11/12/93 11/12/93	7 14	20/12/93 20/12/93	14 14	1 1	2 2	6 6	4 4	YES YES	3 3	1 1	3 3	3 3
					HYPOKINESIA	Detail Summary	25/11/93(0) 25/11/93(0)	0 0		0 0	3 3								NO
					HYPERTENSION	Detail Summary	31/12/93 31/12/93	28 56	04/02/94(1) 04/02/94(1)	56 56	2 2	2 2	3 3	1 1	3 3	3 3	3 3	3 3	3 3
					INSOMNIA	Detail Summary	25/11/93(0) 25/11/93(0)	0 0		0 0	2 2								NO
					PAIN	Detail Summary	01/02/94 01/02/94	56 56	04/02/94(1) 04/02/94(1)	56 56									YES
					PERIPHERAL ISCHAEMIA	Detail Summary	07/02/94 07/02/94	99 99	07/02/94(1) 07/02/94(1)	99 99	3 3	2 2	4 4	3 3	YES YES	5 5	1 1	3 3	3 3
					SWOON	Detail Summary	11/12/93 11/12/93	7 7	11/12/93 11/12/93	7 7	3 3	2 2	4 4	4 4	5 5	2 2	1 1	1 1	1 1

Severity: 1=unknown, 2=mild, 3=moderate, 4=severe, 5=critical
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=prob. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present; end date = visit date
onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1915

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

63

PHARMACIA CNS RD
REBOXETINE - PROTOCOL 20126/935
Listing No.: 17.9

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End	Least report visit	Save rity	Mist ory	Rel ship	Stud app.	Symp	Dis app.	Re app.	Out come (c)						
																			No data	28	1	2	4	1
13	2DT	Reboxetine	22/10/93	17/12/93	ATAXIA	Detail	18/11/93	28	19/11/93	1	2	4	1	3	3	1	1	YES						
						Summary	18/11/93	28	1	2	4	1	3	3	3	1	YES							
						Detail	12/11/93	21	2	1	4	1	YES	3	3	3	3	3	3	3	3	3	3	
						Summary	12/11/93	28	1	4	1	YES	3	3	3	3	3	3	3	3	3	3	3	
						Detail	24/11/93	35	2	1	3	1	YES	3	3	3	3	3	3	3	3	3	3	
						Summary	24/11/93	56	2	1	3	1	YES	3	3	3	3	3	3	3	3	3	3	
						Detail	12/10/93(2)	0	0	1														
						Summary	12/10/93(2)	0	0	1														
						Detail	12/10/93(2)	0	0	1														
						Summary	12/10/93(2)	0	0	1														
						Detail	12/10/93(2)	0	0	1														
						Summary	12/10/93(2)	0	0	1														
Detail	19/11/93	28	3	2	5	1	YES	3	3	3	3	3	3	3	3	3	3	3						
Summary	19/11/93	42	2	4	1	YES	3	3	3	3	3	3	3	3	3	3	3	3						
Detail	12/12/93	42	3	2	4	1	YES	3	3	3	3	3	3	3	3	3	3	3						
Summary	12/12/93	56	2	2	4	1	YES	3	3	3	3	3	3	3	3	3	3	3						
Detail	12/10/93(2)	0	0	1																				
Summary	12/10/93(2)	0	0	1																				
Detail	12/10/93(2)	0	0	1																				
Summary	12/10/93(2)	0	0	1																				
Detail	12/10/93(2)	0	0	1																				
Summary	12/10/93(2)	0	0	1																				
Detail	12/10/93(2)	0	0	1																				
Summary	12/10/93(2)	0	0	1																				

Severities: 0=unknown, 1=mild, 2=moderate, 3=severe.
Study drug: 1=none change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present; end date = visit date
onset date missing: (2) first report visit data used (screen data - 1 day used for A.E. reported at day0), (1) onset date A.E.

1916

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

54

PHARMACIA CNS RBD
 REMOXTINE - PROTOCOL 20124/935
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No data	Last report visit	Sev	Hist	Rel	Stu	Sym	Dis	Re	Dut	Some (c)			
																				dry	ship	drug
13	ZDT	Rabovatine	22/10/95	17/12/93	MOUTH DRY		Detail	15/11/93	28	2	1	3	1	3	1	3	3	3	3	3		
								42	1	1	3	1	3	3	3	3	3	3	3	3	3	3
							Summary	13/11/93	56	17/12/93(*)	56	2	1	3	1	3	3	3	3	3	3	3
3MD	Imipramine	05/02/94	31/05/94	CHEST PAIN		Detail	08/11/93	21	06/11/93	21	1	2	4	1	3	3	3	3	3	1		
						Summary	06/11/93	21	06/11/93	21	1	2	4	1	3	3	3	3	3	3	1	
						Detail	07/03/94	35	07/03/94	35	2	2	4	1	YES	5	3	3	3	3	1	
Summary	07/03/94	35	07/03/94	35	2	2	4	1	YES	5	3	3	3	3	1							
3DT	Imipramine	09/11/93	04/01/94	CONSTIPATION		Detail	27/01/94(Q)	0			0	2								NO		
						Summary	27/01/94(Q)	0			0	2										NO
						Detail	27/01/94(Q)	0			0	2										
Summary	27/01/94(Q)	0			0	2												NO				
3DT	Imipramine	09/11/93	04/01/94	CONSTIPATION		Detail	07/11/93(Q)	0			0	1								NO		
						Summary	07/11/93(Q)	7			0	1										NO
						Detail	11/11/93	21			2	1	3	1	YES	3	3	3	3	3	3	3
Summary	11/11/93	35			2	1	4	1	YES	3	3	3	3	3	3	3	3	3				
Detail	11/11/93	42			1	1	4	1	YES	3	3	3	3	3	3	3	3	3				
Summary	11/11/93	49			2	1	4	1	YES	3	3	3	3	3	3	3	3	3				
Detail	11/11/93	56	06/01/94(*)	56	2	1	3	1	YES	3	3	3	3	3	3	3	3	3				
Summary	11/11/93	56	06/01/94(*)	56	2	1	3	1	YES	3	3	3	3	3	3	3	3	3				
3DT						Detail	07/11/93(Q)	0			1									NO		
						Summary	07/11/93(Q)	0		0	1											
3DT						Detail	07/11/93(Q)	0			1									NO		
						Summary	07/11/93(Q)	0		0	1											

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe, 4= life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (M) adverse event still present; end date = visit date
 onset date missing: (Q) first report visit date used (screen date - 1 day used for A.E. reported at day0), (U) onset date A.E.

1917

9550089

65

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS RED

REBOXATINE - PROCTOOL 20/02/95
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	End date	Last report visit	Save rity	Hist ory	Rep	Stud	Symp	Dis Hosp	Re app.	Out came (c)							
13	SDT	Imipramine	09/11/93	06/01/94	HYPOKINESIA	Detail	07/11/93(D)	0				1								NO						
						Summary	07/11/93(D)	0			0	1														
						Detail	14/11/93	7			3	2	3	1	YES	3	3	3	3	3	3	3	3	3	3	
						Summary	14/11/93	7			3	2	3	1	YES	3	3	3	3	3	3	3	3	3	3	
						Detail	14/11/93	27/11/93	14	3	2	3	1	YES	3	3	3	3	3	3	3	3	3	3	3	
						Summary	14/11/93	27/11/93	14	3	2	3	1	YES	3	3	3	3	3	3	3	3	3	3	3	
						Detail	07/11/93(D)	0			1															
						Summary	07/11/93(D)	0			1															
						Detail	07/11/93(D)	0			1															
						Summary	07/11/93(D)	0			1															
40T	Reboxatine	03/12/94	31/03/94	CONSTIPATION	Detail	05/12/93	28	06/12/93	1	2	5	1	3	3	3	3	3	3	3	3	1					
					Summary	05/12/93	28	06/12/93	20	1	2	5	1	3	3	3	3	3	3	3	3	3				
					Detail	12/12/93	35			2	2	3	1	3	3	3	3	3	3	3	3	3	3			
					Summary	12/12/93	35			2	2	3	1	3	3	3	3	3	3	3	3	3	3			
					Detail	12/12/93	42	15/12/93	42	2	2	3	1	3	3	3	3	3	3	3	3	3	3			
					Summary	12/12/93	42	15/12/93	42	2	2	3	1	3	3	3	3	3	3	3	3	3	3			
					Detail	26/11/93	21	30/12/93	21	2	2	3	1	3	3	3	3	3	3	3	3	3	3			
					Summary	26/11/93	21	30/12/93	21	2	2	3	1	3	3	3	3	3	3	3	3	3	3			
					Detail	26/01/94(D)	0			2																
					Summary	26/01/94(D)	0			2																
40T	Reboxatine	03/12/94	31/03/94	CONSTIPATION	Detail	20/02/94	21	06/03/94	2	2	5	1	YES	2	3	3	3	3	3							
					Summary	20/02/94	21	06/03/94	2	2	5	1	YES	2	3	3	3	3	3	3	3					
40T	Reboxatine	03/12/94	31/03/94	CONSTIPATION	Detail	20/02/94	35	06/03/94	55	2	2	4	1	YES	2	3	3	3	3							
					Summary	20/02/94	35	06/03/94	55	2	2	4	1	YES	2	3	3	3	3	3	3					

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe, 4= life threatening, 5= death
 Study drug: 1= no change, 2= dose reduced, 3= def. withdrawn, 4= temp. inter.
 Hospital: 1= required, 2= not req., 3= not appl. -- Outcome: 1= recovered, 2= free, with seq., 3= still present, 4= death
 Disapp./Reapp.: 1= no, 2= yes, 3= not appl. -- Relationship: 1= definite, 2= probable, 3= possible, 4= doubtful, 5= unknown, 6= none
 Symptomatic treatment: 0= no, 1= yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (D) first report visit date used (screen date - 1 day used for A.E. reported at day), (I) onset date A.E.

1918

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

14

PHARMACIA CMS RBD

REBOXETINE - PROTOCOL 20124/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Visit End date	Last report visit	Save rity	Hist only	Rel ship	Re Stud	Symp	Dis Hosp	Re app.	Se come	Out come (C)		
																				Detail	Summary
13	40T	Reboxetine	03/02/94	31/05/94	FATIGUE	Detail	26/01/94(C)	0			0	2								NO	
						Summary	26/01/94(C)														
14	1MD	Reboxetine	05/04/94	02/05/94	ABDOMINAL PAIN	Detail	07/04/94	7			2	1	2	1	2	1	2	3	3	3	3
						Summary	07/04/94	28			2	1	2	3	2	1	3	2	1	3	1
					MOUTH DRY	Detail	26/01/94(C)	0			0	1									NO
						Summary	26/01/94(C)														
					ANOREXIA	Detail	30/02/94(C)	0			0	2									NO
						Summary	30/02/94(C)														
					ANXIETY	Detail	30/04/94	28	10/05/94		26	3	2	2	3	3	2	3	1	3	1
						Summary	30/04/94	10/05/94		26	3	2	2	3	3	2	3	1	3	1	3
					CONSTIPATION	Detail	07/04/94	7	10/04/94		2	1	2	1	2	1	2	3	3	3	1
						Summary	07/04/94	10/04/94		7	2	1	2	1	2	3	3	1	3	3	3
					FATIGUE	Detail	11/04/94	14			2	1	6	1	3	3	3	3	3	3	3
						Summary	11/04/94	28		28	2	1	6	1	3	3	3	3	3	3	3
					DYSPOEIA	Detail	30/03/94(C)	0			0	2									NO
						Summary	30/03/94(C)														
					FATIGUE	Detail	30/03/94(C)	0			0	3									NO
						Summary	30/03/94(C)														
					HYPERTONIA	Detail	30/03/94(C)	0			0	2									NO
						Summary	30/03/94(C)														

Severity: 0=Unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (C) first report visit date used (screen date - 1 day used for A.E. reported at day0), (I) onset date A.E.

1919

9550089

67

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 2014/085
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	End date	Last report visit	Savv	Hist	Rel	Stud	Symp	Dis app.	Re app.	Out come (c)								
																			visit rity	dry	ship	drug	tra	hosp	app.	come (c)
14	IMD	Reboxetine	06/06/94	02/05/94	NYDOKINESIA	Detail	30/03/94(C)	0			0	2							NO							
						Summary	30/03/94(C)				0	2														
						Detail	30/03/94(C)	0				3												NO		
						Summary	30/03/94(C)				0	3														
						Detail	30/03/94(C)	0				2												NO		
						Summary	30/03/94(C)				0	2														
						Detail	07/06/94	7	14/06/94	7	14/06/94	5	1	2	1	YES	2	3	3	1				NO		
						Summary	07/06/94	14/06/94	7	5	1	2	1	YES	2	3	3	1	YES							
						Detail	30/03/94(C)	0				2													NO	
						Summary	30/03/94(C)				0	2														
15	IMD	Reboxetine	01/02/93	25/06/93	ANOREXIA	Detail	22/02/93(C)	0			0	2								NO						
						Summary	22/02/93(C)				0	2														
						Detail	22/02/93(C)	0				2												NO		
						Summary	22/02/93(C)				0	2														
						Detail	22/02/93(C)	0				2													NO	
						Summary	22/02/93(C)				0	2														
						Detail	22/02/93(C)	0				3													NO	
						Summary	22/02/93(C)				0	3														
						Detail	22/02/93(C)	0				3														NO
						Summary	22/02/93(C)				0	3														

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawal, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rel. with seq., 3=still present, 4=death
Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(e) adverse event still present: end date = visit date
onset date missing: (C) first report visit date used (screen date - 1 day used for A.E. reported at day0), (I) onset date A.E.

1920

9550089

68

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RPD
 ROBAXETINE - PROTOCOL 20124/935
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report			Dis app.	Re app.	Dut some (c)	
									city	time	Sym				
15	1MD	Robaxetine	01/02/93	25/06/93	MOUTH DRY	Detail	22/02/93(C)	0	1						
						Summary	22/02/93(C)	0	1						
1DT	Robaxetine	26/07/93	19/09/93	MICTURITION DISORDER	Detail	16/07/93(C)	0	2							
					Summary	16/07/93(C)	0	2							
2MD	Imipramine	24/02/93	02/06/93	ANDREXIA	Detail	01/02/93(C)	0	2							
					Summary	01/02/93(C)	0	2							
				HYPERTENSION	Detail	01/02/93(C)	0	2							
					Summary	01/02/93(C)	0	2							
				RYALGIA	Detail	01/02/93(C)	0	2							
					Summary	01/02/93(C)	0	2							
				PARAESTHESIA	Detail	01/02/93(C)	0	2							
					Summary	01/02/93(C)	0	2							
					Detail	26/03/93	14	06/06/93	3	1	2	3	2	2	3
					Summary	26/03/93	14	06/06/93	3	1	2	3	2	2	3
				SOMNOLENCE	Detail	28/03/93	7	16/06/93(+)	1	2	3	1	2	3	3
					Summary	28/03/93	16	16/06/93(+)	14	1	2	3	1	2	3
2DT	Imipramine	22/02/94	18/06/94	DYSPNOEA	Detail	04/02/94(C)	0	1							
					Summary	04/02/94(C)	0	1							
				FATIGUE	Detail	04/02/94(C)	0	2							
					Summary	04/02/94(C)	0	2							

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=none change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=free with seq., 3=still present, 4=death
 Disapp./Resp.: 1=yes, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (W) adverse event still present; end date = visit date
 onset date missing: (Q) first report visit date used (screen date - 1 day used for A.E. reported at day), (I) onset date A.E.

1921

9550089

69

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RBD

REBOUTINE - PROTOCOL 20124/055
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment		Adverse event	Type record	Onset date	Visit No	End date	Last report visit	Saves rity	Hist ory	Rel ship	Stud drug	Svmp trea	Dis Hosp app.	Re app.	Dut come (C)			
			Start date	End date																	
15	20T	Imipramine	22/02/94	18/04/94	HYPERTENSION	Detail	06/02/94(0)	0		0	1								NO		
						Summary	06/02/94(0)			0	1										
						Detail	06/02/94(0)	0			1										NO
						Summary	06/02/94(0)			0	1								NO		
3ND	Rebouxetine	06/05/93	30/06/93	AGITATION	Detail	02/05/93(0)	0		1										NO		
						Summary	02/05/93(0)			0	1										NO
						Detail	18/05/93	7		2	2	3	1		2	3	3	3	3	3	3
					Summary	18/05/93			14	2	2	3	1		2	3	3	3	YES		
4ND	Imipramine	15/07/95	08/09/95	HYPERKINESIA	Detail	11/07/95(0)	0		3										NO		
						Summary	11/07/95(0)			0	3										NO
						Detail	11/07/95(0)	0		1											
					Summary	11/07/95(0)			0	1									NO		
					Detail	26/07/93	14		2	1	5	1	YES	2	3	3	3	3	NO		
					Summary	26/07/93			21	2	1	2	1	YES	2	3	3	3	NO		
					Detail	15/08/93	28		2	1	2	1	YES	2	3	3	3	3	NO		
					Summary	15/08/93			35	2	1	2	1	YES	2	3	3	3	NO		
					Detail	15/08/93	35		2	1	2	1	YES	2	3	3	3	3	NO		
					Summary	15/08/93			35	2	1	2	1	YES	2	3	3	3	NO		
11ND	Rebouxetine	06/10/93	26/10/93	INSOMNIA	Detail	06/10/93(0)	0		2										NO		
						Summary	06/10/93(0)			0	2										NO
						Detail	06/10/93(0)	0		1											
					Summary	06/10/93(0)			0	1									NO		
					Detail	06/10/93(0)	0		1										NO		
					Summary	06/10/93(0)			0	1									NO		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl., 4=not present, 5=death
Disapp./Reapp.: 1=yes, 2=yes, 3=not appl., 4=not present, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present; end date = visit date
onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1922

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

70

PHARMACIA CHE RBD
 REBOXTINE - PROTOCOL 20124/935
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report visit	Saw rity	Hist ery	Rel. Stud	Sympt drug	Disapp	Re Hosp	Out app.	Case (c)
15	11MD	Reboxetine	08/10/93	28/10/93	URINARY RETENTION	Detail	27/10/93	21	29/10/93(*)	2	3	4	1	3	3	3	3
						Summary	27/10/93										
11MD	Imipramine		29/11/93	29/01/94	DIZZINESS	Detail	21/11/93(O)	0		0	1						
						Summary	21/11/93(O)										
16	1MD	Reboxetine	18/02/93	16/06/93	ANOREXIA	Detail	18/02/93(O)	0		0	2						
						Summary	18/02/93(O)										
					FATIGUE	Detail	18/02/93(O)	0		0	2						
						Summary	18/02/93(O)										
					HYPERTENSION	Detail	18/02/93(O)	0		0	1						
						Summary	18/02/93(O)										
					HYPOKINESIA	Detail	18/02/93(O)	0		0	2						
						Summary	18/02/93(O)										
					INSOMNIA	Detail	18/02/93(O)	0		0	2						
						Summary	18/02/93(O)										
1DT	Imipramine		18/02/93	26/02/93	ANOREXIA	Detail	18/02/93(O)	0		0	2						
						Summary	18/02/93(O)										
					CONSTIPATION	Detail	16/02/93(O)	0		0	2						
						Summary	16/02/93(O)										

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=frec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date a visit date
 onset date missing: (O) first report visit date used (screen date - 1 day used for A.E. reported at day0), (I) onset date A.E.

9550089

1923

9550089

71

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 REMOETINE - PROTOCOL 20124/035
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Types record	Onset date	Visit No	Visit End date	Last report visit	Sav	Hist	Rel	Stu	Sym	Dis app.	Re app.	Dut	Case (C)					
																				report	visit	ry	ity	ry
16	IDT	Imipramine	10/02/93	26/02/93	FATIGUE	Detail	10/02/93(2)	0			0	2								NO				
						Summary	10/02/93(2)			0	2													
						Detail	10/02/93(2)	0			2													NO
						Summary	10/02/93(2)			0	2													
						Detail	10/02/93(2)	0			2													NO
						Summary	10/02/93(2)			0	2													
						Detail	19/02/93	7			2	2	5	1										3
						Summary	19/02/93	14	03/03/93		2	2	5	3										3
						Detail	19/02/93	14	03/03/93		2	2	5	5										3
						Summary	19/02/93	14	03/03/93		2	2	5	5										3
2ND	Imipramine	15/06/93	09/06/93	ANOREXIA	Detail	06/06/93(2)	0				0	2								NO				
					Summary	06/06/93(2)			0	2														
					Detail	06/06/93(2)	0			1												NO		
					Summary	06/06/93(2)			0	1														
					Detail	06/06/93(2)	0			2													NO	
					Summary	06/06/93(2)			0	2														
					Detail	18/05/93	28			1	2	4	1										3	
					Summary	18/05/93	35	20/05/93		1	2	4	1										3	
					Detail	18/05/93	28	20/05/93		1	2	4	1										3	
					Summary	18/05/93	35	20/05/93		1	2	4	1										3	
					INSOMNIA	Detail	15/06/93(2)	0			2									NO				
						Summary	15/06/93(2)			0	2													
						Detail	24/05/93	42			1	2	3	1	YES								3	
						Summary	24/05/93	42			1	2	3	1	YES									3

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe,
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 Symptom: 0=not used for statistical analysis
 (*) adverse event still present; end date = visit date
 (**) onset date missing; (C) first report visit date used (screen date - 1 day used for A.E. reported at day0), (I) onset date A.E.

1924

9550089

72

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBONETINE - PROTOCOL 20124/935
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment		Adverse event	Type record	Onset date	Visit No	End date	Last report visit	Re	Stud	Sypm	Dis app.	Re Out				
			Start date	End date															
16	2ND	Imipramine	15/04/93	09/06/93	MOUTH DRY	Detail	24/05/93	49		1	2	3	1	YES	3	3	3		
			Summary	24/05/93	56	09/06/93(*)	56	1	2	3	1	YES	3	3	3	3	3	3	
20T	Reboxetine	04/05/93	28/06/93	28/06/93	ANOREXIA	Detail	22/04/93(D)	0		3								NO	
			Summary	22/04/93(D)	0	0	3												
					CONSTIPATION	Detail	22/04/93(D)	0		1									NO
						Summary	22/04/93(D)	0	1										
					FATIGUE	Detail	22/04/93(D)	0		2									NO
						Summary	22/04/93(D)	0	2										
					HYPOKINESIA	Detail	22/04/93(D)	0		1									NO
						Summary	22/04/93(D)	0	1										
					HYPOTENSION	Detail	22/04/93(D)	0		1									NO
						Summary	22/04/93(D)	0	1										
					INSOMNIA	Detail	22/04/93(D)	0		2									NO
						Summary	22/04/93(D)	0	2										
					MOUTH DRY	Detail	22/04/93(D)	0		2									NO
						Summary	04/06/93	35	04/06/93	42	1	1	3	1	YES	3	3	3	3
					NAUSEA	Detail	09/05/93	7		1	2	5	1						5
						Summary	09/05/93	14	14/05/93	14	1	2	5	1					

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawal, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=free. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 1=no, 1=yes
(*) adverse event used for statistical analysis
(+) adverse event still present; end date = visit date
onset date missing: (D) first report visit date used (screen date - 1 day used for A.E. reported at day0), (I) onset date A.E.

1925

9550089

73

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA DNS R6D

REBOCETINE - PROTOCOL 20124/935
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Visit End	Last report visit	Save rity	Mist	Rel	Stud	Symp	Dis	Re	Out								
16	3ND	Imipramine	09/05/93	09/06/93	CONSTIPATION	Detail	03/05/93(D)	0			1								NO							
						Summary	03/05/93(D)			0	1															
						Detail	09/06/93	35	09/06/93																	
						Summary	09/06/93		09/06/93							35	3	2	3	3	1	3	3	1	3	3
						Detail	03/05/93(D)	0																		
						Summary	03/05/93(D)									0	2									
						Detail	09/06/93	35	17/06/93																	
						Summary	09/06/93		17/06/93																	
						Detail	03/05/93(D)	0																		
						Summary	03/05/93(D)																			
						Detail	09/06/93	35	17/06/93																	
						Summary	09/06/93		17/06/93																	
30T	Imipramine	29/07/93	10/08/93	ANOREXIA	Detail	03/05/93(D)	0																			
					Summary	03/05/93(D)																				
					Detail	03/05/93(D)	0																			
					Summary	03/05/93(D)																				
					Detail	03/05/93(D)	0																			
					Summary	03/05/93(D)																				
					Detail	03/05/93(D)	0																			
					Summary	03/05/93(D)																				
					Detail	24/05/93	14																			
					Summary	24/05/93		17/06/93																		
					Detail	29/07/93(D)	0																			
					Summary	29/07/93(D)																				
30T	Imipramine	29/07/93	10/08/93	FATIGUE	Detail	26/07/93(D)	0																			
					Summary	26/07/93(D)																				

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawal, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Resp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date
 onset date missing: (2) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

75

9550089

PHARMACIA CNS RED
REBOXTINE - PROTOCOL 20124/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment		Adverse event	Type	Onset date	Visit End	Last report visit	Save	Hist	Rel	Stud	Syp	Dis	Re	Dut	
			Start date	End date														
17	JMD	Reboxetine	31/03/93	25/05/93	DYSPNOEA	Detail	22/03/93(2)	0	0	1							NO	
					Summary	22/03/93(2)	0	0	1									
					FATIGUE	Detail	22/03/93(2)	0	0	3								NO
						Summary	22/03/93(2)	0	0	3								
					HEADACHE	Detail	22/03/93(2)	0	0	2								NO
						Summary	22/03/93(2)	0	0	2								
					HYPERKINESIA	Detail	22/03/93(2)	0	0	2								NO
						Summary	22/03/93(2)	0	0	2								
					INSOMNIA	Detail	22/03/93(2)	0	0	2								NO
						Summary	22/03/93(2)	0	0	2								
					LIBIDO DECREASED	Detail	22/03/93(2)	0	0	3								NO
						Summary	22/03/93(2)	0	0	3								
					MOUTH DRY	Detail	22/03/93(2)	0	0	3								NO
						Summary	22/03/93(2)	0	0	3								
					NYALGIA	Detail	22/03/93(2)	0	0	2								NO
						Summary	22/03/93(2)	0	0	2								
					ODERMA PERIPHERAL	Detail	07/04/93	14	14	2	2	5	1	2	5	5	3	
						Summary	07/04/93	56	56	2	2	5	1	2	5	5	3	
					PARAESTHESIA	Detail	22/03/93(2)	0	0	2								YES
						Summary	22/03/93(2)	0	0	2								

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=temp. severe, 5=permanent severe, 6=death
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (*) adverse event used for statistical analysis
 (†) adverse event still present; end date = visit date
 onset date missing: (2) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1928

9550089

77

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Last report visit	Save rity	Hist any	Rel ship	Stud drug	Symp trea	Dis app.	Re app.	Dut come				
17	10T	Reboxetine	28/04/93	17/05/93		NERVOUSNESS	Summary	16/05/93		16/05/93(*)	21	2	2	3	3	2	1	3	3	YES		
	20D	Isipramine	21/06/93	15/06/93		CONSTIPATION	Detail Summary	12/06/93(D) 12/06/93(D)	0		0	2	2								NO	
						DIZZINESS	Detail Summary	12/06/93(D) 12/06/93(D)	0		0	1	1									NO
						INSOMNIA	Detail Summary	12/06/93(D) 12/06/93(D)	0		0	2	2									NO
						MOUTH DRY	Detail Summary	12/06/93(D) 12/06/93(D)	0		0	2	2									NO
	20T	Reboxetine	07/07/93	31/05/93		CONSTIPATION	Detail Summary	03/07/93(D) 03/07/93(D)	0		0	2	2									NO
						DIZZINESS	Detail Summary	05/07/93(D) 05/07/93(D)	0		0	1	1									NO
						FATIGUE	Detail Summary	05/07/93(D) 05/07/93(D)	0		0	1	1									NO
	30D	Isipramine	06/11/93	19/11/93		ANKERELA	Detail Summary	24/10/93(D) 24/10/93(D)	0		0	3	3									NO
						CONSTIPATION	Detail Summary	24/10/93(D) 24/10/93(D)	0		0	3	3									NO
						FATIGUE	Detail Summary	24/10/93(D) 24/10/93(D)	0		0	3	3									NO

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe, 4= life threatening
Study drug: 1=no change, 2=dose reduced, 3=def. withdraw, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present; end date = visit date
onset date missing: (D) first report visit date used (screen date - 1 day used for A.E. reported at day0), (I) onset date A.E.

1930

9550089

78

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA DNS R&D
 REBOMETINE - PROTOCOL 20124/035
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Patient ID	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	End date	Last report		Dis app.	Re case (C)				
										visit rity	trng traa						
17	Imipramine	06/11/93	19/11/93		HEADACHE	Detail	24/10/93(C)	0			3			NO			
						Summary	24/10/93(C)			0	3						
						Detail	24/10/93(C)	0			3						NO
						Summary	24/10/93(C)			0	3						
						Detail	24/10/93(C)	0			3						NO
						Summary	24/10/93(C)			0	3						
						Detail	24/10/93(C)	0			3						NO
						Summary	24/10/93(C)			0	3						
						Detail	24/10/93(C)	0			3						NO
						Summary	24/10/93(C)			0	3						
						Detail	24/10/93(C)	0			3						NO
						Summary	24/10/93(C)			0	3						
307	Imipramine	19/10/93	13/12/93		ANOREXIA	Detail	17/10/93(C)	0			1			NO			
						Summary	17/10/93(C)			0	1						
						Detail	17/10/93(C)	0			1						NO
						Summary	17/10/93(C)			0	1						
						Detail	17/10/93(C)	0			1						NO
						Summary	17/10/93(C)			0	1						
						Detail	17/10/93(C)	0			1						NO
						Summary	17/10/93(C)			0	1						
						Detail	17/10/93(C)	0			1						NO
						Summary	17/10/93(C)			0	1						
						Detail	17/10/93(C)	0			1						NO
						Summary	17/10/93(C)			0	1						

Severely: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=stop, 4=withdrawn, 5=other
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Resp.: 1=no, 2=yes, 3=not appl.
 Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=sneak
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (D) adverse event still present; end date = visit date
 onset date missing: (0) first report visit date used (1=onset date at day0), (1) onset date A.E.

1931

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

28

PHARMACIA CNS 580

REBOXETINE - PROTOCOL 20124/036
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report visit	Save rity	Hist ery	Rea ship	Stud drug	Symp tree	Dis Hosp	Re app.	Ra	Out	Dis	Re	Out						
																						report	visit	save	hist	rea	stud
17	21MD	Reboxetine	19/05/94	13/07/94	CONFUSION	Detail	09/05/94(0)	0		0	1											NO					
						Summary	09/05/94(0)			0	1																
					CONSTIPATION	Detail	09/05/94(0)	0		0	2												NO				
						Summary	09/05/94(0)			0	2																
21	IDT	Reboxetine	05/04/94	30/05/94	AGITATION	Detail	27/02/94(0)	0		0	2												NO				
						Summary	27/02/94(0)			0	2																
					CONFUSION	Detail	27/02/94(0)	0		0	1												NO				
						Summary	27/02/94(0)			0	1																
						Detail	23/04/94	21		21	3	1	3	1	YES	2	3	3	3	3	3	3	3				
						Summary	23/04/94			21	3	1	3	1	YES	2	3	3	3	3	3	3	3	3	3	3	3
						Detail	05/05/94	35		35	3	1	3	1	YES	2	3	3	3	3	3	3	3				
						Summary	05/05/94			35	3	1	3	1	YES	2	3	3	3	3	3	3	3	3	3	3	3
18	IDT	Imipramine	12/08/93	06/10/93	SWEATING INCREASED	Detail	10/08/93	7		7	2	2	3	1		3	3	3	3	3	3	3					
						Summary	10/08/93			7	2	2	3	1		3	3	3	3	3	3	3	3	3	3		
						Detail	10/08/93	56		56	2	2	3	1		3	3	3	3	3	3	3	3				
						Summary	10/08/93			56	2	2	3	1		3	3	3	3	3	3	3	3	3	3	3	
					URINARY TRACT INFECTION	Detail	06/08/93	7		7	2	2	6	1	YES	3	3	3	3	3	3	3	3				
						Summary	06/08/93			7	2	2	6	1	YES	3	3	3	3	3	3	3	3	3	3	3	
						Detail	21/08/93	21		21	2	2	6	1	YES	3	3	3	3	3	3	3	3				
						Summary	21/08/93			21	2	2	6	1	YES	3	3	3	3	3	3	3	3	3	3	3	
						Detail	25/09/93	35		35	2	2	6	1	YES	3	3	3	3	3	3	3	3				
						Summary	25/09/93			35	2	2	6	1	YES	3	3	3	3	3	3	3	3	3	3	3	
SMD	Reboxetine		14/08/93	01/10/93	DIZZINESS	Detail	05/08/93(0)	0		0	1												NO				
						Summary	05/08/93(0)			0	1																
					INSOMNIA	Detail	05/08/93(0)	0		0	2												NO				
						Summary	05/08/93(0)			0	2																

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe, 4= severe, 5= severe
 Study drug: 1= no change, 2= dose reduced, 3= def. withdrawn, 4= temp. inter.
 Hospital: 1= required, 2= not req., 3= not appl. -- Outcome: 1= recovered, 2= rec. with seq., 3= still present, 4= death
 Disapp./Resp.: 1= no, 2= yes, 3= not appl. -- Relationship: 1= definite, 2= probable, 3= possible, 4= doubtful, 5= unknown, 6= none
 Symptomatic treatment: 1= no, 2= yes
 (C) adverse event used for statistical analysis
 (P) adverse event still present: end date = visit date
 onset date missing: (a) first report visit date used (screen date - 1 day used for A.E. reported at day), (1) onset date A.E.

1933

9550089

61

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS READ

REBOXETINE - PROTOCOL 20126/935
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	End date	Last report visit	Save	Hist	Rel	Stud	Sweep	Dis	Re	Dut	Adverse event			
																			visit	rate		
20	SND	Rebooxetine	09/07/93	15/07/93	CONFUSION	Detail	16/07/93	7	17/07/93	7	2	2	2	2	3	2	2	3	1			
						Summary	16/07/93	7	17/07/93	7	2	2	2	2	2	3	2	2	3	2	2	3
22	IMD	Rebooxetine	25/06/93	30/06/93	AGITATION	Detail	23/06/93(G)	0			3											
						Summary	23/06/93(G)	0		0	3											
					ANDREXIA	Detail	23/06/93(G)	0			2											
						Summary	23/06/93(G)	0		0	2											
					INSOMNIA	Detail	23/06/93(G)	0			3											
						Summary	23/06/93(G)	0		0	3											
					SWEATING INCREASED	Detail	27/06/93	7			1	2	3	3	3	3	1	3	3			
						Summary	27/06/93	7	30/06/93(*)	7	1	2	3	3	3	3	3	3	3	1	3	3
23	IMD	Rebooxetine	30/01/93	26/03/93	AGITATION	Detail	27/01/93(G)	0			1											
						Summary	27/01/93(G)	0		0	1											
					CONSTIPATION	Detail	27/01/93(G)	0			1											
						Summary	27/01/93(G)	0		0	1											
					FATIGUE	Detail	27/01/93(G)	0			2											
						Summary	27/01/93(G)	0		0	2											
					HYPERKINESIA	Detail	27/01/93(G)	0			1											
						Summary	27/01/93(G)	0		0	1											
					HYPOKINESIA	Detail	27/01/93(G)	0			2											
						Summary	27/01/93(G)	0		0	2											

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 5=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=cure, with seq., 3=still present, 4=death
Disapp./Reapp.: 1=yes, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present; end date = visit date
(*) onset date missing: (C) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1934

9550089

82

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RD
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report visit	Save rity	Hist ory	Hist ryp	Stud Symm	Dis Hosp	Re app.	Out some (c)	
25	1ND	Reboxetine	30/01/93	26/03/93	MOUTH DRY	Detail	27/01/93(0)	0		0	2						NO	
						Summary	27/01/93(0)			0	2							
					NAUSEA	Detail	01/02/93	7 01/02/93			2	2	2	1	YES	5	3	1
						Summary	01/02/93	01/02/93		7	2	2	2	1	YES	5	5	1
					SOMNOLENCE	Detail	27/01/93(0)	0			1							NO
						Summary	27/01/93(0)			0	1							
					VISION ABNORMAL	Detail	27/01/93(0)	0			2							NO
						Summary	27/01/93(0)			0	2							
					2ND Reboxetine	02/02/93	29/03/93	AMBLYOPIA	Detail	27/01/93(0)	0							NO
						Summary	27/01/93(0)			0	3							
					FATIGUE	Detail	27/01/93(0)	0			1							NO
						Summary	27/01/93(0)			0	1							
					INSOMNIA	Detail	27/01/93(0)	0			3							NO
						Summary	27/01/93(0)			0	3							
					LIBIDO DECREASED	Detail	27/01/93(0)	0			1							NO
						Summary	27/01/93(0)			0	1							
					MOUTH DRY	Detail	27/01/93(0)	0			1							NO
						Summary	27/01/93(0)			0	1							
					SOMNOLENCE	Detail	27/01/93(0)	0			1							NO
						Summary	27/01/93(0)			0	1							

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=none change, 2=dose reduced, 3=def. withdrawn, 4=stop. Inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (d) adverse event still present: end date = visit date
 (e) onset date missing: (0) first report visit date used (screen data - 1 day used for A.E. reported at day), (1) onset date A.E.

1935

9550089

84

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOCETINE - PROTOCOL 20124/935
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment		Type	Onset date	Visit End No date	Last report		Dis	Re	Out						
			Start date	End date				visit	date									
23	4ND	Imipramine	31/03/93	25/05/93	MOUTH DRY	24/05/93	49	12/05/93	1	1	4	1	3	3	3	1		
			26/05/93	26/05/93		Summary	26/05/93	49	12/05/93	3	1	2	1	3	3	3	1	
						Summary												
5ND	Imipramine	13/05/93	05/05/93	13/05/93	CONSTIPATION	25/04/93(D)	0		1								NO	
			25/04/93(D)	25/04/93(D)		Summary	25/04/93(D)	0		0	1							NO
			07/05/93	07/05/93		Detail	07/05/93	7		2	1	1	1					3
6ND	Tetramine	17/08/93	06/07/93	17/08/93	AGITATION	01/07/93(D)	0		3								NO	
			01/07/93(D)	01/07/93(D)		Summary	01/07/93(D)	0		0	3							NO
			15/07/93	15/07/93		Detail	15/07/93	14		3	2	4	1					3
6ND	Tetramine	17/08/93	06/07/93	17/08/93	AGITATION	01/07/93(D)	0		3								NO	
			01/07/93(D)	01/07/93(D)		Summary	01/07/93(D)	0		0	3							NO
			15/07/93	15/07/93		Detail	15/07/93	14		3	2	4	1					3
6ND	Tetramine	17/08/93	06/07/93	17/08/93	AGITATION	01/07/93(D)	0		3								NO	
			01/07/93(D)	01/07/93(D)		Summary	01/07/93(D)	0		0	3							NO
			15/07/93	15/07/93		Detail	15/07/93	14		3	2	4	1					3
6ND	Tetramine	17/08/93	06/07/93	17/08/93	AGITATION	01/07/93(D)	0		3								NO	
			01/07/93(D)	01/07/93(D)		Summary	01/07/93(D)	0		0	3							NO
			15/07/93	15/07/93		Detail	15/07/93	14		3	2	4	1					3
6ND	Tetramine	17/08/93	06/07/93	17/08/93	AGITATION	01/07/93(D)	0		3								NO	
			01/07/93(D)	01/07/93(D)		Summary	01/07/93(D)	0		0	3							NO
			15/07/93	15/07/93		Detail	15/07/93	14		3	2	4	1					3
6ND	Tetramine	17/08/93	06/07/93	17/08/93	AGITATION	01/07/93(D)	0		3								NO	
			01/07/93(D)	01/07/93(D)		Summary	01/07/93(D)	0		0	3							NO
			15/07/93	15/07/93		Detail	15/07/93	14		3	2	4	1					3
6ND	Tetramine	17/08/93	06/07/93	17/08/93	AGITATION	01/07/93(D)	0		3								NO	
			01/07/93(D)	01/07/93(D)		Summary	01/07/93(D)	0		0	3							NO
			15/07/93	15/07/93		Detail	15/07/93	14		3	2	4	1					3
6ND	Tetramine	17/08/93	06/07/93	17/08/93	AGITATION	01/07/93(D)	0		3								NO	
			01/07/93(D)	01/07/93(D)		Summary	01/07/93(D)	0		0	3							NO
			15/07/93	15/07/93		Detail	15/07/93	14		3	2	4	1					3
6ND	Tetramine	17/08/93	06/07/93	17/08/93	AGITATION	01/07/93(D)	0		3								NO	
			01/07/93(D)	01/07/93(D)		Summary	01/07/93(D)	0		0	3							NO
			15/07/93	15/07/93		Detail	15/07/93	14		3	2	4	1					3
6ND	Tetramine	17/08/93	06/07/93	17/08/93	AGITATION	01/07/93(D)	0		3								NO	
			01/07/93(D)	01/07/93(D)		Summary	01/07/93(D)	0		0	3							NO
			15/07/93	15/07/93		Detail	15/07/93	14		3	2	4	1					3
6ND	Tetramine	17/08/93	06/07/93	17/08/93	AGITATION	01/07/93(D)	0		3								NO	
			01/07/93(D)	01/07/93(D)		Summary	01/07/93(D)	0		0	3							NO
			15/07/93	15/07/93		Detail	15/07/93	14		3	2	4	1					3
6ND	Tetramine	17/08/93	06/07/93	17/08/93	AGITATION	01/07/93(D)	0		3								NO	
			01/07/93(D)	01/07/93(D)		Summary	01/07/93(D)	0		0	3							NO
			15/07/93	15/07/93		Detail	15/07/93	14		3	2	4	1					3
6ND	Tetramine	17/08/93	06/07/93	17/08/93	AGITATION	01/07/93(D)	0		3								NO	
			01/07/93(D)	01/07/93(D)		Summary	01/07/93(D)	0		0	3							NO
			15/07/93	15/07/93		Detail	15/07/93	14		3	2	4	1					3
6ND	Tetramine	17/08/93	06/07/93	17/08/93	AGITATION	01/07/93(D)	0		3								NO	
			01/07/93(D)	01/07/93(D)		Summary	01/07/93(D)	0		0	3							NO
			15/07/93	15/07/93		Detail	15/07/93	14		3	2	4	1					3
6ND	Tetramine	17/08/93	06/07/93	17/08/93	AGITATION	01/07/93(D)	0		3								NO	
			01/07/93(D)	01/07/93(D)		Summary	01/07/93(D)	0		0	3							NO
			15/07/93	15/07/93		Detail	15/07/93	14		3	2	4	1					3
6ND	Tetramine	17/08/93	06/07/93	17/08/93	AGITATION	01/07/93(D)	0		3								NO	
			01/07/93(D)	01/07/93(D)		Summary	01/07/93(D)	0		0	3							NO
			15/07/93	15/07/93		Detail	15/07/93	14		3	2	4	1					3
6ND	Tetramine	17/08/93	06/07/93	17/08/93	AGITATION	01/07/93(D)	0		3								NO	
			01/07/93(D)	01/07/93(D)		Summary	01/07/93(D)	0		0	3							NO
			15/07/93	15/07/93		Detail	15/07/93	14		3	2	4	1					3
6ND	Tetramine	17/08/93	06/07/93	17/08/93	AGITATION	01/07/93(D)	0		3								NO	
			01/07/93(D)	01/07/93(D)		Summary	01/07/93(D)	0		0	3							NO
			15/07/93	15/07/93		Detail	15/07/93	14		3	2	4	1					3
6ND	Tetramine	17/08/93	06/07/93	17/08/93	AGITATION	01/07/93(D)	0		3								NO	
			01/07/93(D)	01/07/93(D)		Summary	01/07/93(D)	0		0	3							NO
			15/07/93	15/07/93		Detail	15/07/93	14		3	2	4	1					3
6ND	Tetramine	17/08/93	06/07/93	17/08/93	AGITATION	01/07/93(D)	0		3								NO	
			01/07/93(D)	01/07/93(D)		Summary	01/07/93(D)	0		0	3							NO
			15/07/93	15/07/93		Detail	15/07/93	14		3	2	4	1					3
6ND	Tetramine	17/08/93	06/07/93	17/08/93	AGITATION	01/07/93(D)	0		3								NO	
			01/07/93(D)	01/07/93(D)		Summary	01/07/93(D)	0		0	3							NO
			15/07/93	15/07/93		Detail	15/07/93	14		3	2	4	1					3
6ND	Tetramine	17/08/93	06/07/93	17/08/93	AGITATION	01/07/93(D)	0		3								NO	
			01/07/93(D)	01/07/93(D)		Summary	01/07/93(D)	0		0	3							NO
			15/07/93	15/07/93		Detail	15/07/93	14		3	2	4	1					3
6ND	Tetramine	17/08/93	06/07/93	17/08/93	AGITATION	01/07/93(D)	0		3								NO	
			01/07/93(D)	01/07/93(D)		Summary	01/07/93(D)	0		0	3							NO
			15/07/93	15/07/93		Detail	15/07/93	14		3	2	4	1					3
6ND	Tetramine	17/08/93	06/07/93	17/08/93	AGITATION	01/07/93(D)	0		3								NO	
			01/07/93(D)	01/07/93(D)		Summary	01/07/93(D)	0		0	3							NO
			15/07/93	15/07/93		Detail	15/07/93	14		3	2	4	1					3
6ND	Tetramine	17/08/93	06/07/93	17/08/93	AGITATION	01/07/93(D)	0		3								NO	
			01/07/93(D)	01/07/93(D)		Summary	01/07/93(D)	0		0	3							NO
			15/07/93	15/07/93		Detail	15/07/93	14		3	2	4	1					3
6ND	Tetramine	17/08/93	06/07/93	17/08/93	AGITATION	01/07/93(D)	0		3								NO	
			01/07/93(D)	01/07/93(D)		Summary	01/07/93(D)	0		0	3							NO
			15/07/93	15/07/93		Detail	15/07/93	14		3	2	4	1					3
6ND	Tetramine	17/08/93	06/07/93	17/08/93	AGITATION	01/07/93(D)	0		3								NO	
			01/07/93(D)	01/07/93(D)		Summary												

9550089

85

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOMETINE - PROTOCOL 20124/93S
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No data	Last report visit	Save rity	Hist ory	Rel ship	Rea Hosp	Stud app.	Comp app.	Dis app.	Re Out
23	8ND	Imipramine	06/07/93	17/08/93	DIARRHOEA	Summary	01/07/93(G)		0	1							NO
					DIZZINESS	Detail	01/07/93(G)	0	2								3
						Summary	15/07/93	14	2	2	4	1	3	3	3	3	3
						Summary	01/07/93(G)	18/08/93(*)	49	2	2	4	3	3	1	3	3
					HEADACHE	Detail	01/07/93(G)	9	2								1
						Summary	01/07/93(G)	07/07/93	7	2	1	3	1	3	3	3	1
					HYPOKINESIA	Detail	01/07/93(G)	0	0	1							NO
						Summary	01/07/93(G)		0	1							NO
					HYPOTHYROIDISM	Detail	10/08/93	42	2	2	4	1	YES	5	5	3	3
						Summary	10/08/93	49	49	2	2	4	1	YES	5	5	3
					MOUTH DRY	Detail	01/07/93(G)	0	2								NO
						Summary	01/07/93(G)	18/08/93(*)	49	2	1	3	3	1	3	3	3
					PARAESTHESIA	Detail	01/07/93(G)	0	0	1							NO
						Summary	01/07/93(G)		0	1							NO
					PARANOID REACTION	Detail	09/08/93	35	2	2	2	1	3	3	3	3	3
						Summary	09/08/93	42	42	3	2	2	1	3	3	3	3
						Summary	09/08/93	18/08/93(*)	49	3	2	2	3	5	1	3	3
					SWEATING INCREASED	Detail	01/07/93(G)	0	5								1
						Summary	01/07/93(G)	7	7	10/07/93	5	1	6	1	3	3	3

Severity: 1=unknown, 1= mild, 2= moderate, 3= severe, -- History: 1= present before, 2= not observe bef., 3= unknown
Study drug: 1= no change, 2= dose reduced, 3= def. withdrawn, 4= temp. inter.
Hospital: 1= required, 2= not req., 3= not appl. -- Outcome: 1= recovered, 2= frag. with sed., 3= still present, 4= death
Disapp./Respa.: 1= no, 2= yes, 3= not appl. -- Relationship: 1= definite, 2= probable, 3= possible, 4= doubtful, 5= unknown, 6= none
Symptomatic treatment: 0= no, 1= yes
(C) adverse event used for statistical analysis
(*) adverse event still present; end date = visit date
onset date missing: (G) first report visit date used (screen date - 1 day used for A.E. reported at day0), (I) onset date A.E.

1938

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

86

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit end date	Last report visit	Save rity	Hist ory	Rel ship	Rea ction	Sym ptom	Disa	Re	Dut	Dut	
																				17/08/93
23	6ND	Imipramine		06/07/93	17/08/93	SWEATING INCREASED	Summary	01/07/93(3)	14	10/07/93	7	3	1	6	1	3	3	3	1	NO
				15/07/93			Detail		21		3	1	6	1		3	3	3		
				26					26		3	1	4	1		3	3	3		
				49			Summary	15/07/93	49	18/08/93(*)	49	3	1	3	1	3	3	3		YES
				7			Detail	12/07/93	7		2	2	3	1		3	3	3		
				14			Summary	12/07/93	14	18/07/93	14	2	2	3	1	3	3	3		YES
				26			Detail	02/08/93	26		1	3	6	1		3	3	3		
				49			Summary	02/08/93	49	18/08/93	49	1	3	6	1	3	3	3		YES
				0			Detail	26/08/93(3)	0		0	3								
				26			Summary	26/08/93(3)	26	26/08/93(3)	26	0	3							NO
				0			Detail	24/08/93(3)	0		0	3								
				26			Summary	24/08/93(3)	26	24/08/93(3)	26	0	3							NO
				26			Detail	24/09/93	26		2	2	5	1		3	3	3		
				35			Summary	24/09/93	35	01/10/93(*)	35	2	2	5	1	3	3	3		YES
				0			Detail	26/08/93(3)	0		0	3								
				26			Summary	26/08/93(3)	26	26/08/93(3)	26	0	3							NO
				0			Detail	26/08/93(3)	0		0	3								
				26			Summary	26/08/93(3)	26	26/08/93(3)	26	0	3							NO
				0			Detail	26/08/93(3)	0		0	2								
				26			Summary	26/08/93(3)	26	26/08/93(3)	26	0	2							NO
				0			Detail	26/08/93(3)	0		0	3								
				26			Summary	26/08/93(3)	26	26/08/93(3)	26	0	3							NO

Severity: 1=unknown, 2=mild, 3=moderate, 4=severe, 5=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawal, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (3) first report visit date used (screen date - 1 day used for A-E, reported at day0), (1) onset date A-E.

9550089

1939

9550089

87

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS 88D

REBOVETINE - PROTOCOL 20126/955
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	End date	Last report visit	Save rity	Hist ury	Mist ery	Rel ation	Stud y	Sump	Dis app.	Re come	Dut come (c)	
																				27/08/93
25	IND	Rebovetine	27/08/93	01/10/93	NAUSEA	Detail	26/08/93(D)	0			0	2								NO
						Summary	26/08/93(S)				0	2								
					VOMITING	Detail	26/08/93(D)	0			0	2								NO
						Summary	26/08/93(S)				0	2								
28D	Imipramine		26/11/93	26/01/94	AGITATION	Detail	21/11/93(D)	0			0	2								NO
						Summary	21/11/93(S)				0	2								
					ANOREXIA	Detail	21/11/93(D)	0			0	2								NO
						Summary	21/11/93(S)				0	2								
					CONSTIPATION	Detail	21/11/93(D)	0			0	1								NO
						Summary	21/11/93(S)				0	1								
					INSOMNIA	Detail	21/11/93(D)	0			0	3								NO
						Summary	21/11/93(S)				0	3								
					MOUTH DRY	Detail	30/11/93	7			2	2	3	1						3
						Summary	30/11/93			7	2	2	1							
					SWEATING INCREASED	Detail	27/11/93	7			2	2	2	1						3
						Summary	27/11/93			7	2	2	1							
						Detail	27/11/93	14			2	2	1							3
						Summary	27/11/93			14	2	2	1							
						Detail	27/11/93	21			2	2	1							3
						Summary	27/11/93			21	2	2	1							
						Detail	27/11/93	29			2	2	1							3
						Summary	27/11/93			29	2	2	1							
						Detail	27/11/93	35			2	2	1							1
						Summary	27/11/93			35	2	2	1							

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl., 4=not present, 5=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (d) adverse event still present: end date = visit date
 onset date missing: (D) first report visit date used (screen date - 1 day used for A.E. reported at day0), (I) onset date A.E.

1940

9550089

88

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/93S
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No data	Last report visit	Save rity	Hst ory	Rel only	Stud drug	Symp trea	Dis app.	Re hosp.	Out app.	Cone (c)		
																				Detail	Summary
25	2ND	Imipramine	26/11/93	20/01/94	TACHYCARDIA	Detail	21/11/93(C)	0		0	1									NO	
						Summary	21/11/93(C)	0		0	1										NO
26	1MD	Imipramine	27/06/93	21/06/93	INSOMNIA	Detail	22/06/93(C)	0		0	2										NO
						Summary	22/06/93(C)	0		0	2										NO
	1DT	Reboxetine	25/06/93	11/08/93	GASTRO-INTESTINAL DISORDER	Detail	13/07/93	21		49	2	1	0	1	YES	3	3	3	3	3	3
						Summary	13/07/93	49	11/08/93(+)	49	2	1	0	1	YES	3	3	3	3	3	3
27	1MD	Imipramine	02/02/93	08/02/93	CONSTIPATION	Detail	31/01/93(C)	0		0	1										NO
						Summary	31/01/93(C)	0		0	1										NO
						Detail	31/01/93(C)	0		0	1										NO
						Summary	31/01/93(C)	0		0	1										NO
						FATIGUE	Detail	31/01/93(C)	0		0	1									NO
						Summary	31/01/93(C)	0		0	1										NO
						HYPOKINESIA	Detail	31/01/93(C)	0		0	2									NO
						Summary	31/01/93(C)	0		0	2										NO
						INSOMNIA	Detail	31/01/93(C)	0		0	1									NO
						Summary	31/01/93(C)	0		0	1										NO
						URINARY RETENTION	Detail	05/02/93	7	05/02/93	7	2	2	2	3	2	2	2	2	2	3
						Summary	05/02/93	7	05/02/93	7	2	2	2	3	2	2	2	2	2	3	1
28	2DT	Reboxetine	27/06/93	21/06/93	GAMMA-GT INCREASED	Detail	19/06/93(C)	0		0	1										NO
						Summary	19/06/93(C)	0		0	1										NO
30	1MD	Imipramine	21/06/93	17/06/93	ABSTINITION	Detail	12/06/93(C)	0		0	2										NO
						Summary	12/06/93(C)	0		0	2										NO

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=fatal
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (D) adverse event still present; end date = visit date
 onset date missing: (D) first report visit date used (screen date - 1 day used for A.E. reported at day0), (U) onset date A.E.

1941

9550089

89

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBORELINE - PROTOCOL 20124/935
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report visit	Save	Hist	Rel	Stud	Somp	Dis	Re	Dut	come (C)								
																			Detail	Summary	Detail	Summary	Detail	Summary	Detail	Summary
30	IMD	Isiprasoline	21/06/93	17/06/93	ANDREXIA	Detail	12/04/93(D)	0	0	1	1								NO							
						Summary	12/04/93(D)	0	0	1	1															
						Detail	12/04/93(D)	0	0	2	2												NO			
						Summary	12/04/93(D)	0	0	2	2															
						Detail	12/04/93(D)	0	0	5	5													NO		
						Summary	12/04/93(D)	0	0	5	5															
						Detail	12/04/93(D)	0	0	1	1													NO		
						Summary	12/04/93(D)	0	0	1	1															
						Detail	12/04/93(D)	0	0	1	1														NO	
						Summary	12/04/93(D)	0	0	1	1															
						Detail	12/04/93(D)	0	0	1	1														NO	
						Summary	12/04/93(D)	0	0	1	1															
2ND	Reboresline		16/07/93	16/07/93	AGITATION	Detail	11/07/93(D)	0	0	2	2									NO						
						Summary	11/07/93(D)	0	0	2	2															
						Detail	11/07/93(D)	0	0	2	2													NO		
						Summary	11/07/93(D)	0	0	2	2															
						Detail	11/07/93(D)	0	0	2	2														NO	
						Summary	11/07/93(D)	0	0	2	2															
						Detail	11/07/93(D)	0	0	2	2														NO	
						Summary	11/07/93(D)	0	0	2	2															
						Detail	11/07/93(D)	0	0	2	2															NO
						Summary	11/07/93(D)	0	0	2	2															
						Detail	11/07/93(D)	0	0	2	2															NO
						Summary	11/07/93(D)	0	0	2	2															

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawal, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl.
Disapp./Reapp.: 1=yes, 2=yes, 3=not appl.
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present; end date = visit date
onset date missing: (D) first report visit date used (screen date - 1 day used for A.E. reported at day0), (I) onset date A.E.

9550089

91

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit end No date	Last report visit	Sev	Hst	Rel	Stud	Symp	Dis	Re	Dut	ADVERSE EVENTS: DETAIL AND SUMMARY						
																		visit rty	ory shp					
30	2ND	Reboxetine	16/07/93	16/07/93	SWEATING INCREASED	Detail	11/07/93(C)	0	1															
						Summary	11/07/93(C)	0	1															
						Detail	17/07/93	7	19/07/93	2	1	3	3	2	2	3	1							
						Summary	17/07/93	7	19/07/93	2	1	3	3	2	2	3	1							
30	2ND	Reboxetine	16/07/93	16/07/93	TACHYCARDIA	Detail	11/07/93(C)	0	1															
						Summary	11/07/93(C)	0	1															
						Detail	11/07/93(C)	0																
						Summary	11/07/93(C)	0																
30	2ND	Reboxetine	16/07/93	16/07/93	VISION ABNORMAL	Detail	11/07/93(C)	0	1															
						Summary	11/07/93(C)	0	1															
						Detail	24/10/93(C)	0																
						Summary	24/10/93(C)	0																
30	2ND	Reboxetine	16/07/93	16/07/93	FATIGUE	Detail	24/10/93(C)	0	3															
						Summary	24/10/93(C)	0	3															
						Detail	24/10/93(C)	0																
						Summary	24/10/93(C)	0																
30	2ND	Reboxetine	16/07/93	16/07/93	HEADACHE	Detail	24/10/93(C)	0	3															
						Summary	24/10/93(C)	0	3															
						Detail	24/10/93(C)	0																
						Summary	24/10/93(C)	0																
30	2ND	Reboxetine	16/07/93	16/07/93	INSOMNIA	Detail	24/10/93(C)	0	2															
						Summary	24/10/93(C)	0	2															
						Detail	28/10/93(C)	0																
						Summary	28/10/93(C)	0																
400	2ND	Reboxetine	02/11/93	30/12/93	ANOREXIA	Detail	05/11/93	14	3	1	3	1	3	1	3	3	3							
						Summary	05/11/93	14	3	1	3	1	3	1	3	3								
						Detail	21	56	30/12/93	3	1	2	1	3	3	3	1							
						Summary	21	56	30/12/93	3	1	2	1	3	3	3	1							

Severity: 1=unknown, 2=mild, 3=moderate, 4=severe, 5=critical
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=free, with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (3) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1944

9550089

92

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R0D
 REMONETINE - PROTOCOL 20124/935
 Listing No.: 17.6

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report visit	Save Hist	Rea	Stu	Syme	Dis	Re	Case	Com							
																		visit	dry	ship	drug	tree	Hosp	app.
30	4ND	Remonetine	02/11/93	30/12/93	FATIGUE	Detail	28/10/93(2)	0	0	1								NO						
						Summary	28/10/93(2)																	
						Detail	28/10/93(2)	0	0	1													NO	
						Summary	28/10/93(2)																	
						Detail	28/10/93(2)	0	0	1													NO	
						Summary	28/10/93(2)																	
						Detail	28/10/93(2)	0	0	1													NO	
						Summary	28/10/93(2)																	
						Detail	28/10/93(2)	0	0	1														NO
						Summary	28/10/93(2)																	
						Detail	28/10/93(2)	0	0	1														NO
						Summary	28/10/93(2)																	
5ND	Imipramine	18/12/93	25/12/93	AGITATION	Detail	11/11/93	14	24/11/93	14	1	2	4	1	2	3	3	1							
					Summary	11/11/93		24/11/93																
					Detail	11/11/93	21	25/11/93(4)	21	1	2	1	1	2	3	3	3	3	3	3	3	NO		
					Summary	11/11/93		25/11/93(4)																
					Detail	28/10/93(2)	0	0	1													NO		
					Summary	28/10/93(2)																		
					Detail	09/12/93(2)	0	0	2													NO		
					Summary	09/12/93(2)																		
					Detail	09/12/93(2)	0	0	3														NO	
					Summary	09/12/93(2)																		
					Detail	09/12/93(2)	0	0	3														NO	
					Summary	09/12/93(2)																		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe,
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (!) adverse event still present; end date = visit date
 onset date missing: (2) first report visit date used (screen date - 1 day used for A.E. reported at day0), (!) onset date A.E.

1945

9550089

93

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA DNS RED
REBDETINE - PROTOCOL 20124/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Start date	End date	Adverse event	Type record	Onset date	Visit end No data	Last report visit	Sav e	Hist	Rel	Stud	Sym	Dis app.	Re come (c)	Dut						
																	report	visit	city	dry	ship	drug
30	SND Imipramine	18/12/93	23/12/93	INSOMNIA	Detail	09/12/93(G)	0	0	3								NO					
					Summary	09/12/93(G)	0	0	3													
					Detail	09/12/93(G)	0	0	3												NO	
					Summary	09/12/93(G)	0	0	3													
					Detail	20/12/93	7	5	2	1	5	5	2	3	2	1	5	5	2	3	5	
					Summary	20/12/93	7	5	2	1	5	5	2	3	2	1	5	5	2	3	5	
31	IMD Imipramine	28/09/92	05/10/92	ANOREXIA	Detail	17/09/92(G)	0	0	1									NO				
					Summary	17/09/92(G)	0	0	1													
					Detail	26/09/92	14	05/10/92	2	2	3	1	YES	2	3	3	1	YES	2	3	3	
					Summary	26/09/92	14	05/10/92	2	2	3	1	YES	2	3	3	1	YES	2	3	3	
					Detail	26/09/92	7	28/09/92	2	2	5	1	2	3	3	1	2	3	3	1	YES	
					Summary	26/09/92	7	28/09/92	2	2	5	1	2	3	3	1	2	3	3	1	YES	
				ARTHRALGIA	Detail	26/09/92	14	05/10/92	2	2	3	1	YES	2	3	3	1	YES				
					Summary	26/09/92	14	05/10/92	2	2	3	1	YES	2	3	3	1	YES	2	3	3	
					Detail	26/09/92	7	28/09/92	2	2	5	1	2	3	3	1	2	3	3	1	YES	
					Summary	26/09/92	7	28/09/92	2	2	5	1	2	3	3	1	2	3	3	1	YES	
					Detail	26/09/92	7	26/09/92	2	2	5	1	2	3	3	2	3	3	2	YES		
					Summary	26/09/92	7	26/09/92	2	2	5	1	2	3	3	2	3	3	2	YES		
				DIZZINESS	Detail	05/10/92	14	05/10/92	1	2	3	YES	2	2	3	1	YES	2	3	1		
					Summary	05/10/92	14	05/10/92	1	2	3	YES	2	2	3	1	YES	2	2	3	1	
					Detail	05/10/92	14	05/10/92	1	2	2	3	YES	2	2	3	1	YES	2	2	3	1
					Summary	05/10/92	14	05/10/92	1	2	2	3	YES	2	2	3	1	YES	2	2	3	1
					Detail	05/10/92	14	05/10/92	1	2	2	3	YES	2	2	3	1	YES	2	2	3	1
					Summary	05/10/92	14	05/10/92	1	2	2	3	YES	2	2	3	1	YES	2	2	3	1
				HYPERTENSION POSTURAL	Detail	05/10/92	14	05/10/92	3	2	2	3	2	2	3	1	YES	2	2	3		
					Summary	05/10/92	14	05/10/92	3	2	2	3	2	2	3	1	YES	2	2	3	1	
					Detail	17/09/92(G)	0	0	1													NO
					Summary	17/09/92(G)	0	0	1													
					Detail	26/09/92	7	05/10/92	2	2	2	1	2	2	3	1	2	2	3	1	YES	
					Summary	26/09/92	7	05/10/92	2	2	2	1	2	2	3	1	2	2	3	1	YES	

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdraw, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Respp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date
 onset date missing: (G) first report visit date used (screen date - 1 day used for A.E. reported at day0), (I) onset date A.E.

9550089

97

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOMETINE - PROTOCOL 20124/955
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Last report visit	Save rity	Mist ory	Rel ship	Stud drug	Symp treat	Dis app.	Re app.	Out come (c)	
																		17/12/92
31	3MD	Imipramine	14/12/92	16/12/92	TACHYCARDIA	Detail	17/12/92	99	12/01/93	99	2	2	3	YES	2	1	3	1
						Summary	17/12/92		12/01/93									
32	1MD	Imipramine	25/05/93	19/05/93	ANOREXIA	Detail	14/05/93(10)	0	28	15/06/93	2	1	6	1	2	5	5	1
						Summary	14/05/93(10)	28	15/06/93	28	2	1	6	1	2	5	5	1
					CONSTIPATION	Detail	14/05/93(10)	0	2		2							
						Summary	14/05/93(10)	7		0	2							
						Detail	25/05/93	42		3	1	3	1	YES	2	3	3	3
							49			2	1	3	1	YES	2	3	3	3
							56											
						Summary	25/05/93	56	19/05/93(4)	56	3	1	3	1	YES	2	3	3
					HEADACHE	Detail	14/03/93(10)	0		1								
						Summary	14/03/93(10)	0		0	1							
					INSOMNIA	Detail	14/03/93(10)	0		3								
						Summary	14/03/93(10)	0		0	3							
					SWEATING INCREASED	Detail	14/03/93(10)	0		2								
						Summary	14/03/93(10)	35	22/04/93	35	2	1	6	1	2	3	3	1
					TASTE PERVERSION	Detail	01/04/93	14		2	2	2	1		3	3	3	3
							21			3	2	2	1		2	5	5	5
							42			2	2	2	1		2	5	5	5
							56											
						Summary	01/04/93	56	19/05/93(4)	56	3	2	2	1	2	5	5	5
2ND	Imipramine	15/04/93	09/06/93	ABITATION	Detail	14/05/93	35	14/05/93		2	1	4	1	2	3	3	1	
					Summary	14/05/93	35	14/05/93		35	2	1	4	1	2	3	3	1

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=free. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
onset date missing: (1) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1950

9550089

96

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA ONS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report visit	Solve rity	Hist ary ship	Rei drug	Stud app.	Symm	Dis Hosp	Re app.	Dut come	C								
																				Report	Visit	Dis	Re	Dut			
S2	2ND	Imipramine	15/04/93	09/06/93		CONSTIPATION	Detail	01/04/93(2)	0		1																
							Summary	01/04/93(2)	7	0	1																
							Detail	15/04/93	7		2	1	3	1													
								26			1	1	3	1													
								42	20/05/93		1	1	3	1													
							Summary	15/04/93	20/05/93	42	2	1	3	1													
							Detail	19/04/93	7		3	2	1	2													
							Summary	19/04/93	25/04/93	14	3	2	1	2													
							Detail	01/04/93(2)	0		1																
							Summary	01/04/93(2)	0		1																
S3	2ND	Reboxetine	22/04/93	16/06/93		FATIGUE	Detail	15/04/93	7		2	2	1	1													
							Summary	15/04/93	56	2	2	1	1														
							Detail	19/04/93	7		3	2	1	2													
							Summary	19/04/93	25/04/93	14	3	2	1	2													
							Detail	05/04/93(2)	0		2																
							Summary	05/04/93(2)	0		2																
							Detail	05/04/93(2)	0		1																
							Summary	05/04/93(2)	0		1																
							Detail	05/04/93(2)	0		1																
							Summary	05/04/93(2)	0		1																

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=none change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Ramp: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1951

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

99

9550089

PHARMACIA CNS RBD
 REBOETINE - PROTOCOL 20124/935
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Visit End date	Last report visit	Sae	Hist	R1	Stud	Symp	Dis	R#	Out	Hosp			app.	come (c)								
																			1	2	3										
32	RBD	Reboetine	22/06/95	16/06/95	INFECTION	Detail	05/06/95	49	05/06/95	49	2	1	4	1	YES	3	3	3	1												
						Summary	05/06/95		49	2	1	4	1	YES	3	3	3	3	1												
						Detail	05/06/95(3)		0		3																				
						Summary	05/06/95(3)		0		3																				
						Detail	05/06/95(2)		0		1																				
						Summary	05/06/95(2)		0		1																				
						Detail	05/06/95(3)		35		2																				
						Summary	05/06/95(3)		35		2																				
						Detail	05/06/95(2)		56		2																				
						Summary	05/06/95(2)		56		2																				
4ND	RBD	Reboetine	07/10/95	26/10/95	ANOREXIA	Detail	08/10/95	7			2	2	2	1	3	3	3	3													
						Summary	08/10/95		14	15/10/95		2	2	2	1	3	3	3	1												
						Detail	08/10/95		14		2																				
						Summary	08/10/95		14		2																				
						Detail	02/09/95(2)		0		2																				
						Summary	02/09/95(2)		0		2																				
						Detail	09/10/95		7		2																				
						Summary	09/10/95		7		2																				
						Detail	02/09/95(2)		14		14																				
						Summary	02/09/95(2)		14		14																				
					FATIGUE	Detail	02/09/95(2)		0		2																				
						Summary	02/09/95(2)		0		2																				
						Detail	21/10/95		21		2																				
						Summary	21/10/95		21		2																				
						Detail	02/09/95(2)		0		2																				
						Summary	02/09/95(2)		0		2																				
						Detail	07/10/95		14		3																				
						Summary	07/10/95		14		3																				
						Detail	07/10/95		21		3																				
						Summary	07/10/95		21		3																				

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawal, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset data missing: (2) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

9550089

100

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA ORS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 17.9

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	End date	Adverse event	Type record	Onset date	Visit End Mo date	Last report visit	Save rfty	Hist ary	Rel ship	Stud Symp	Dis app.	Re come (C)		
32	4ND	Reboxetine	07/10/93	26/10/93	SOMNOLENCE	Detail	07/10/93	7	10/10/93	1	2	1	1	2	3	3	
						Summary	07/10/93	7	1	2	1	1	2	3	3	1	3
						Detail	21/10/93	21	2	1	2	3	3	1	3	3	3
						Summary	21/10/93	21	2	1	2	3	3	1	3	3	3
5ND	Reboxetine	06/11/93	26/11/93	ABDOMINAL PAIN	Detail	06/11/93	7	10/10/93	2	2	2	1	3	3	3	3	
					Summary	06/11/93	14	1	2	2	2	3	1	3	3		
					Detail	17/11/93	14	2	2	2	2	3	1	3	3		
					Summary	17/11/93	14	2	2	2	2	3	1	3	3		
				CONSTIPATION	Detail	02/11/93	8	01/12/93	1	1	1	1	3	3	3	3	
					Summary	02/11/93	14	1	1	2	2	3	1	3	3		
					Detail	02/11/93	14	1	1	2	2	3	1	3	3		
					Summary	02/11/93	28	2	1	2	2	3	1	3	3		
				DIZZINESS	Detail	02/11/93	8	01/12/93	1	1	1	1	3	3	3	3	
					Summary	02/11/93	14	1	1	2	2	3	1	3	3		
					Detail	02/11/93	14	1	1	2	2	3	1	3	3		
					Summary	02/11/93	28	2	1	2	2	3	1	3	3		
				MOUTH DRY	Detail	05/11/93	7	10/11/93	2	2	2	1	3	3	3	3	
					Summary	05/11/93	14	1	1	2	2	3	1	3	3		
					Detail	05/11/93	14	1	1	2	2	3	1	3	3		
					Summary	05/11/93	28	2	1	2	2	3	1	3	3		
				SWEATING INCREASED	Detail	06/11/93	7	17/11/93	2	2	2	1	3	3	3	3	
					Summary	06/11/93	14	2	2	2	2	3	1	3	3		
					Detail	06/11/93	14	2	2	2	2	3	1	3	3		
					Summary	06/11/93	28	2	2	2	2	3	1	3	3		
				TREMOR	Detail	11/11/93	14	01/12/93	2	2	2	3	2	2	1	3	3
					Summary	11/11/93	28	2	2	2	2	3	2	2	1	3	
					Detail	05/10/93	0	2	2	2	2	2	1	3	3		
					Summary	05/10/93	0	2	2	2	2	2	1	3	3		

Severities: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present; end date = visit date
onset date missing: (D) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1953

PHARMACIA DNS RED
 REMOETINE - PROTOCOL 28124/935
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Visit End No date	Last report visit	Seve rity	Hist ory	Rel ationship	Stud y	Drug	tree	Hosp	Dis app.	Re app.	Re come	Out come (c)	
																						17/11/93
32	6ND	Imipramine	17/11/93	12/01/94	CONSTIPATION	Detail	09/12/93	26		3	1	3	1	2	3	3	3	3	3	3	3	3
						Summary	09/12/93	56	12/01/94(*)	56	3	1	3	1	2	3	3	3	3	3	3	3
					FATIGUE	Detail	05/10/93(G)	0		0	2											NO
						Summary	05/10/93(G)	0		0	2											NO
					MOUTH DRY	Detail	05/10/93(G)	0		0	2											NO
						Summary	05/10/93(G)	0		0	2											NO
35	1MD	Remoxetine	26/01/93	14/02/93	ANOREXIA	Detail	26/01/93(G)	0		0	2											NO
						Summary	26/01/93(G)	0		0	2											NO
					CONSTIPATION	Detail	26/01/93	7		2	2	2	2	1	YES	3	3	3	3	3	3	3
						Summary	26/01/93	14		1	2	2	2	1	YES	3	3	3	3	3	3	3
						Detail	15/02/93	21	15/02/93	21	2	2	2	2	3	YES	2	2	2	2	2	2
						Summary	15/02/93	21	15/02/93	21	2	2	2	2	3	YES	2	2	2	2	2	2
					HYPOTENSION POSTURAL	Detail	01/02/93	14		2	2	2	2	1	YES	3	3	3	3	3	3	3
						Summary	01/02/93	21	09/02/93	21	2	2	2	1	YES	3	3	3	3	3	3	3
					INSOMNIA	Detail	26/01/93(G)	0		0	2											NO
						Summary	26/01/93(G)	0		0	2											NO
					MICTURITION DISORDER	Detail	27/01/93	7		1	2	2	2	1	YES	3	3	3	3	3	3	3
						Summary	27/01/93	14	08/02/93	14	1	2	2	1	YES	3	3	3	3	3	3	3
					MOUTH DRY	Detail	15/02/93	21	15/02/93	21	2	2	2	2	3	YES	2	2	2	2	2	2
						Summary	15/02/93	21	15/02/93	21	2	2	2	2	3	YES	2	2	2	2	2	2

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe, 4= life threatening, 5= death
 Study drug: 1= no change, 2= dose reduced, 3= def. withdrawn, 4= temp. inter.
 Hospital: 1= required, 2= not req., 3= not appl. -- Outcome: 1= recovered, 2= free with seq., 3= still present, 4= death
 Disapp./Reapp.: 1= no, 2= yes, 3= not appl. -- Relationship: 1= definite, 2= probable, 3= possible, 4= doubtful, 5= unknown, 6= none
 Symptomatic treatment: 0= no, 1= yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (G) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

9550089

102

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CHE RBD
REBOXETINE - PROTOCOL 20124/93S
Listing No.: 17.6

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report visit	Save rity	Hist ary	Re ship	Re Stud	Symp	Dis app.	Re some							
35	1M0	Reboxetine		24/01/93	14/02/93	SWEATING INCREASED	Detail	04/02/93	14	2	2	2	1	3	3	3	3	3						
							Summary	04/02/93	21	2	2	2	3	2	3	1	1	1	1	1				
							Detail	26/01/93	7	26/01/93	7	2	2	2	1	YES	3	3	5	1	1	1	1	
							Summary	26/01/93	7	26/01/93	7	2	2	2	1	YES	3	3	5	1	1	1	1	
1D1	Reboxetine			02/05/93	27/06/93	ABDOMINAL PAIN	Detail	04/05/93	7	04/05/93	7	1	1	4	1	3	3	3	1					
							Summary	04/05/93	7	04/05/93	7	1	1	4	1	3	3	5	1	1	1			
							Detail	01/05/93(d)	0	01/05/93(d)	0	2	2	2	2	2	2	2	2	2	2	2	2	2
							Summary	01/05/93(d)	0	01/05/93(d)	0	2	2	2	2	2	2	2	2	2	2	2	2	2
						ANOREXIA	Detail	01/05/93(d)	0	01/05/93(d)	0	1	1	1	1	1	1	1	1					
							Summary	01/05/93(d)	0	01/05/93(d)	0	1	1	1	1	1	1	1	1	1	1	1		
							Detail	01/05/93(d)	0	01/05/93(d)	0	1	1	1	1	1	1	1	1	1	1	1	1	
							Summary	01/05/93(d)	0	01/05/93(d)	0	1	1	1	1	1	1	1	1	1	1	1	1	
						CHEST PAIN PRECORDIAL	Detail	01/05/93(d)	0	01/05/93(d)	0	1	1	1	1	1	1	1						
							Summary	01/05/93(d)	0	01/05/93(d)	0	1	1	1	1	1	1	1	1	1				
							Detail	19/06/93	49	19/06/93	49	2	3	5	1	3	3	3	1	1				
							Summary	19/06/93	49	19/06/93	49	2	3	5	1	3	3	3	1	1				
						CONFUSION	Detail	02/06/93	28	02/06/93	28	2	3	3	1	3	3	3	3					
							Summary	02/06/93	35	02/06/93	35	2	3	3	1	YES	3	3	3	3				
							Detail	02/06/93	35	02/06/93	35	2	3	3	1	YES	3	3	3	3				
							Summary	02/06/93	35	02/06/93	35	2	3	3	1	YES	3	3	3	3				
						CONSTIPATION	Detail	19/06/93	49	19/06/93	49	2	3	4	1	3	3	3	1					
							Summary	19/06/93	49	19/06/93	49	2	3	4	1	3	3	3	1					
							Detail	01/05/93(d)	0	01/05/93(d)	0	1	1	1	1	1	1	1	1	1				
							Summary	01/05/93(d)	0	01/05/93(d)	0	1	1	1	1	1	1	1	1					
						INSOMNIA	Detail	01/03/93(d)	0	01/03/93(d)	0	1	1	1	1	1	1	1						
							Summary	01/03/93(d)	0	01/03/93(d)	0	1	1	1	1	1	1	1	1					
							Detail	01/03/93(d)	0	01/03/93(d)	0	1	1	1	1	1	1	1	1					
							Summary	01/03/93(d)	0	01/03/93(d)	0	1	1	1	1	1	1	1	1					

Severity: 1=unknown, 2=mild, 3=moderate, 4=severe, 5=critical
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawal, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date
 onset date missing: (D) first report visit date used (screen date - 1 day used for A.E. reported at day), (I) onset date A.E.

1955

PHARMACIA DNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Start date	End date	Treatment	Adverse event	Type record	Onset date	Visit No	Visit End No date	Last report visit	Reve Hist	Rel	Stud	Symp	Dis	Re	Dut	Hosp	app.	come (c)	NO	
																							Summary
35	10T	Reboxetine	03/05/93	27/05/93	INSONNIA	Summary	01/03/93(d)		0	1													
					MOUTH DRY	Detail	01/03/93(d)	0															
						Summary	10/03/93	14	1	1	1	1	1	1	1	1	1	1	1	1	1	1	NO
						Summary	03/05/93(d)	10/03/93	14	1	1	1	1	1	1	1	1	1	1	1	1	1	NO
					STOMATITIS	Detail	20/03/93	20	1	4	1	1	1	1	1	1	1	1	1	1	1	1	3
						Summary	20/03/93	35	2	1	4	1	1	1	1	1	1	1	1	1	1	1	3
						Summary	20/03/93	35	2	1	4	1	1	1	1	1	1	1	1	1	1	1	3
					UPPER RESP TRACT INFECTION	Detail	19/04/93	49	22/06/93	22/06/93	49	1	2	5	1	1	1	1	1	1	1	1	3
						Summary	19/04/93	22/06/93	49	1	2	5	1	1	1	1	1	1	1	1	1	1	3
						Summary	01/03/93	7	86/03/93	86/03/93	7	2	3	4	1	1	1	1	1	1	1	1	NO
						Summary	01/03/93	86/03/93	7	2	3	4	1	1	1	1	1	1	1	1	1	1	NO
200		Imipramine	03/03/93	31/03/93	CONSTIPATION	Detail	29/03/93	21	23/03/93	23/03/93	21	2	1	3	1	1	1	1	1	1	1	3	
						Summary	29/03/93	23/03/93	21	2	1	3	1	1	1	1	1	1	1	1	1	1	3
						Detail	31/03/93	35	31/03/93	31/03/93	35	2	1	3	1	1	1	1	1	1	1	1	3
						Summary	31/03/93	31/03/93	35	2	1	3	1	1	1	1	1	1	1	1	1	1	3
					CONVULSIONS	Detail	31/03/93	35	31/03/93	31/03/93	35	3	2	2	3	1	1	1	1	1	1	1	3
						Summary	31/03/93	31/03/93	35	3	2	2	3	1	1	1	1	1	1	1	1	1	3
					FEVER	Detail	21/02/93	21	22/02/93	22/02/93	21	1	2	6	1	1	1	1	1	1	1	1	3
						Summary	21/02/93	22/02/93	21	1	2	6	1	1	1	1	1	1	1	1	1	1	3
					HYPOKINESIA	Detail	01/03/93(d)	0															
						Summary	01/03/93(d)	0															
						Detail	03/03/93	7															
						Summary	03/03/93	14															

Severity: 1=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdraw, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 1=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
onset date missing: (a) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

9550089

104

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type	Onset date	Visit No	Last report visit	Sev	Hist	Rel	Stud	Symp	Dis	Re	Dut		
				date	date		record	date		visit										
35	290	Imipramine	03/02/93	31/03/93		HYPOPTENSION	Detail	03/03/93	21	26	2	2	2	1	2	3	3	3	3	
							Summary	03/03/93	25/03/93	26	3	2	2	2	2	3	2	3	1	YES
						TREMOR	Detail	01/03/93(2)	0		1									
							Summary	01/03/93(2)	7		0	1	1	3	1	3	3	3	3	NO
							Detail	06/03/93	14		2	1	3	1	1	3	3	3	3	
								21		2	1	3	1	1	3	3	3	3		
								26		2	1	3	1	1	3	3	3	3		
							Summary	06/03/93	30/03/93(4)	28	2	1	3	1	3	3	3	3	3	YES
207		Imipramine	05/02/93	27/06/93		URINARY TRACT INFECTION	Detail	21/03/93	21	23/03/93	1	6	1	6	1	5	5	5	1	YES
							Summary	21/03/93	23/03/93	21	1	6	1	6	1	5	5	5	1	YES
						ABDOMINAL PAIN	Detail	15/03/93	14		1	1	4	1	1	2	3	3	3	
								21		1	1	4	1	1	4	2	3	3	3	
								26		2	1	4	1	1	4	2	3	3	1	
							Summary	15/03/93	25/03/93	26	1	1	4	1	1	2	3	3	1	YES
						INSOMNIA	Detail	01/03/93(2)	0		1									
							Summary	01/03/93(2)	0		0	1								NO
						SWEATING INCREASED	Detail	30/03/93	35		3	2	3	1	2	3	3	3	3	
								42		13/04/93	2	2	3	1	2	3	3	1		
							Summary	30/03/93	13/04/93	42	3	2	3	1	2	3	3	1	YES	
390		Imipramine	30/03/93	05/06/93		AGITATION	Detail	26/03/93(2)	0		1									
							Summary	26/03/93(2)	0		0	1								NO
						CONFUSION	Detail	31/01/93	7		2	2	2	1	3	3	3	1		
							Summary	31/01/93	01/06/93	7	2	2	1	3	3	3	1	NO		
							Detail	05/04/93	7		3	2	3	1	3	3	3	1		
							Summary	05/04/93	06/06/93	7	3	2	3	1	3	3	3	1	YES	

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe, -- History: 1= present before, 2= not observe bef., 3= unknown
 Study drug: 1= no change, 2= dose reduced, 3= def. withdrawn, 4= temp. inter.
 Hospital: 1= required, 2= not req., 3= not appl. -- Outcome: 1= recovered, 2= rec. with seq., 3= still present, 4= death
 Disapp./Reapp.: 1= no, 2= yes, 3= not appl. -- Relationship: 1= definite, 2= probable, 3= possible, 4= doubtful, 5= unknown, 6= none
 Symptomatic treatment: 0= no, 1= yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date
 onset date missing: (2) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1957

9550089

106

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA DNS RD

REBOXETINE - PROTOCOL 20124/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Last report visit	Save	Hist	Rel	Stud	Simp	Die	Re	Out	NO	
																			data
35	4ND	Reboxetine	20/06/93	14/06/93	HYPERKINESIA	Summary	15/06/93(0)	0	2										
					TACHYCARDIA	Detail	30/06/93	14											
								21											
								26											
								35											
								56											
						Summary	30/06/93	14/06/93	56	3	2	2	2	2	2	2	2	2	2
								28											
								35											
								42											
								49											
								56											
								13/06/93											
								26											
								35											
								42											
								49											
								56											
								13/06/93											
								26											
								35											
								42											
								49											
								56											
								13/06/93											
								26											
								35											
								42											
								49											
								56											
								13/06/93											
								26											
								35											
								42											
								49											
								56											
								13/06/93											
								26											
								35											
								42											
								49											
								56											
								13/06/93											
								26											
								35											
								42											
								49											
								56											
								13/06/93											
								26											
								35											
								42											
								49											
								56											
								13/06/93											
								26											
								35											
								42											
								49											
								56											
								13/06/93											
								26											
								35											
								42											
								49											
								56											
								13/06/93											
								26											
								35											
								42											
								49											
								56											
								13/06/93											
								26											
								35											
								42											
								49											
								56											
								13/06/93											
								26											
								35											
								42											
								49											
								56											
								13/06/93											
								26											
								35											
								42											
								49											
								56											
								13/06/93											
								26											
								35											
								42											
								49											
								56											
								13/06/93											
								26											
								35											
								42											
								49											
								56											
								13/06/93											
								26											
								35											
								42											
								49											
								56											
								13/06/93											

9550089

107

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CAS RED
REBOXETINE - PROTOCOL 28124/935
Listing No.: 17.8

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report visit	Savv	Hist rity	Rel dry	Stud tra	Sym app.	Dis app.	Re come	Det				
																		report	visit	dry	tra
35	SMD	Reboxetine	09/07/93	02/09/95	INSOMNIA	Detail	16/07/93	14	2	1	3	1	YES	3	3	3	3				
						Summary	16/07/93	21	2	1	3	1	YES	3	3	3	1				
						Detail	15/08/93	62	2	1	4	1	YES	3	3	3	1				
						Summary	15/08/93	17/08/93	42	2	1	4	1	YES	3	3	3	1			
						Detail	17/07/93	14	1	2	3	1	3	3	3	3	3				
						Summary	17/07/93	26/07/93	21	1	2	3	1	3	3	3	1				
	SOT	Imipramine	02/09/93	27/10/93	ANOREXIA	Detail	31/08/93(2)	0	2	0	2										
						Summary	31/08/93(2)	0	2												
						Detail	29/09/93	21	1	1	3	1	YES	3	3	3	3				
						Summary	29/09/93	01/10/93	35	1	1	3	1	YES	3	3	3	1			
						Detail	31/08/93(2)	0	2												
						Summary	31/08/93(2)	0	2												
35	SMD	Reboxetine	09/07/93	02/09/95	INSOMNIA	Detail	16/07/93	14	2	1	3	1	YES	3	3	3	3				
						Summary	16/07/93	21	2	1	3	1	YES	3	3	3	1				
						Detail	15/08/93	62	2	1	4	1	YES	3	3	3	1				
						Summary	15/08/93	17/08/93	42	2	1	4	1	YES	3	3	3	1			
						Detail	17/07/93	14	1	2	3	1	3	3	3	3	3				
						Summary	17/07/93	26/07/93	21	1	2	3	1	3	3	3	1				
35	SMD	Reboxetine	09/07/93	02/09/95	INSOMNIA	Detail	16/07/93	14	2	1	3	1	YES	3	3	3	3				
						Summary	16/07/93	21	2	1	3	1	YES	3	3	3	1				
						Detail	15/08/93	62	2	1	4	1	YES	3	3	3	1				
						Summary	15/08/93	17/08/93	42	2	1	4	1	YES	3	3	3	1			
						Detail	17/07/93	14	1	2	3	1	3	3	3	3	3				
						Summary	17/07/93	26/07/93	21	1	2	3	1	3	3	3	1				
35	SMD	Reboxetine	09/07/93	02/09/95	INSOMNIA	Detail	16/07/93	14	2	1	3	1	YES	3	3	3	3				
						Summary	16/07/93	21	2	1	3	1	YES	3	3	3	1				
						Detail	15/08/93	62	2	1	4	1	YES	3	3	3	1				
						Summary	15/08/93	17/08/93	42	2	1	4	1	YES	3	3	3	1			
						Detail	17/07/93	14	1	2	3	1	3	3	3	3	3				
						Summary	17/07/93	26/07/93	21	1	2	3	1	3	3	3	1				
35	SMD	Reboxetine	09/07/93	02/09/95	INSOMNIA	Detail	16/07/93	14	2	1	3	1	YES	3	3	3	3				
						Summary	16/07/93	21	2	1	3	1	YES	3	3	3	1				
						Detail	15/08/93	62	2	1	4	1	YES	3	3	3	1				
						Summary	15/08/93	17/08/93	42	2	1	4	1	YES	3	3	3	1			
						Detail	17/07/93	14	1	2	3	1	3	3	3	3	3				
						Summary	17/07/93	26/07/93	21	1	2	3	1	3	3	3	1				
35	SMD	Reboxetine	09/07/93	02/09/95	INSOMNIA	Detail	16/07/93	14	2	1	3	1	YES	3	3	3	3				
						Summary	16/07/93	21	2	1	3	1	YES	3	3	3	1				
						Detail	15/08/93	62	2	1	4	1	YES	3	3	3	1				
						Summary	15/08/93	17/08/93	42	2	1	4	1	YES	3	3	3	1			
						Detail	17/07/93	14	1	2	3	1	3	3	3	3	3				
						Summary	17/07/93	26/07/93	21	1	2	3	1	3	3	3	1				
35	SMD	Reboxetine	09/07/93	02/09/95	INSOMNIA	Detail	16/07/93	14	2	1	3	1	YES	3	3	3	3				
						Summary	16/07/93	21	2	1	3	1	YES	3	3	3	1				
						Detail	15/08/93	62	2	1	4	1	YES	3	3	3	1				
						Summary	15/08/93	17/08/93	42	2	1	4	1	YES	3	3	3	1			
						Detail	17/07/93	14	1	2	3	1	3	3	3	3	3				
						Summary	17/07/93	26/07/93	21	1	2	3	1	3	3	3	1				
35	SMD	Reboxetine	09/07/93	02/09/95	INSOMNIA	Detail	16/07/93	14	2	1	3	1	YES	3	3	3	3				
						Summary	16/07/93	21	2	1	3	1	YES	3	3	3	1				
						Detail	15/08/93	62	2	1	4	1	YES	3	3	3	1				
						Summary	15/08/93	17/08/93	42	2	1	4	1	YES	3	3	3	1			
						Detail	17/07/93	14	1	2	3	1	3	3	3	3	3				
						Summary	17/07/93	26/07/93	21	1	2	3	1	3	3	3	1				
35	SMD	Reboxetine	09/07/93	02/09/95	INSOMNIA	Detail	16/07/93	14	2	1	3	1	YES	3	3	3	3				
						Summary	16/07/93	21	2	1	3	1	YES	3	3	3	1				
						Detail	15/08/93	62	2	1	4	1	YES	3	3	3	1				
						Summary	15/08/93	17/08/93	42	2	1	4	1	YES	3	3	3	1			
						Detail	17/07/93	14	1	2	3	1	3	3	3	3	3				
						Summary	17/07/93	26/07/93	21	1	2	3	1	3	3	3	1				
35	SMD	Reboxetine	09/07/93	02/09/95	INSOMNIA	Detail	16/07/93	14	2	1	3	1	YES	3	3	3	3				
						Summary	16/07/93	21	2	1	3	1	YES	3	3	3	1				
						Detail	15/08/93	62	2	1	4	1	YES	3	3	3	1				
						Summary	15/08/93	17/08/93	42	2	1	4	1	YES	3	3	3	1			
						Detail	17/07/93	14	1	2	3	1	3	3	3	3	3				
						Summary	17/07/93	26/07/93	21	1	2	3	1	3	3	3	1				
35	SMD	Reboxetine	09/07/93	02/09/95	INSOMNIA	Detail	16/07/93	14	2	1	3	1	YES	3	3	3	3				
						Summary	16/07/93	21	2	1	3	1	YES	3	3	3	1				
						Detail	15/08/93	62	2	1	4	1	YES	3	3	3	1				
						Summary	15/08/93	17/08/93	42	2	1	4	1	YES	3	3	3	1			
						Detail	17/07/93	14	1	2	3	1	3	3	3	3	3				
						Summary	17/07/93	26/07/93	21	1	2	3	1	3	3	3	1				
35	SMD	Reboxetine	09/07/93	02/09/95	INSOMNIA	Detail	16/07/93	14	2	1	3	1	YES	3	3	3	3				
						Summary	16/07/93	21	2	1	3	1	YES	3	3	3	1				
						Detail	15/08/93	62	2	1	4	1	YES	3	3	3	1				
						Summary	15/08/93	17/08/93	42	2	1	4	1	YES	3	3	3	1			
						Detail	17/07/93	14	1	2	3	1	3	3	3	3	3				
						Summary	17/07/93	26/07/93	21	1	2	3	1	3	3	3	1				
35	SMD	Reboxetine	09/07/93	02/09/95	INSOMNIA	Detail	16/07/93	14	2	1	3	1	YES	3	3	3	3				
						Summary	16/07/93	21	2	1	3	1	YES	3	3	3	1				
						Detail	15/08/93	62	2	1	4	1	YES	3	3	3	1				
						Summary	15/08/93	17/08/93	42	2	1	4	1	YES	3	3	3	1			
						Detail	17/07/93	14	1	2	3	1	3	3	3	3	3				
						Summary	17/07/93	26/07/93	21	1	2	3	1	3	3	3	1				
35	SMD	Reboxetine	09/07/93	02/09/95	INSOMNIA	Detail	16/07/93	14	2	1	3	1	YES	3	3	3	3				
						Summary	16/07/93	21	2	1	3	1	YES	3	3	3	1				
						Detail	15/08/93	62	2	1	4	1	YES	3	3	3	1				
						Summary	15/08/93	17/08/93	42	2	1	4	1	YES	3	3	3	1			
						Detail	17/07/93	14	1	2	3	1	3	3	3	3	3				
						Summary	17/07/93	26/07/93	21	1	2	3	1	3	3	3	1				
35	SMD	Reboxetine	09/07/93	02/09/95	INSOMNIA	Detail	16/07/93	14	2	1	3	1	YES	3	3	3	3				
						Summary	16/07/93	21	2	1	3	1	YES	3	3	3	1				
						Detail	15/08/93	62	2	1	4	1	YES	3	3	3	1				
						Summary	15/08/93	17/08/93	42	2	1	4	1	YES	3	3	3	1			
						Detail	17/07/93	14	1	2	3	1	3	3	3	3	3				
						Summary	17/07/93	26/07/93	21	1	2	3	1	3	3	3	1				
35	SMD	Reboxetine	09/07/93	02/09/95	INSOMNIA	Detail	16/07/93	14	2	1	3	1	YES	3	3	3	3				
						Summary	16/07/93	21	2	1	3	1	YES	3	3	3	1				
						Detail	15/08/93	62	2	1	4	1	YES	3	3	3	1				
						Summary	15/08/93	17/08/93	42	2	1	4	1	YES	3	3	3	1			
						Detail	17/07/93	14	1	2	3	1	3	3	3	3	3				
						Summary	1														

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

110

PHARMACIA CNS MSD

REBOMETINE - PROTOCOL 20124/935
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Rebooxetine	Start date	End date	Adverse event	Type record	Onset date	Visit No	Last report visit	Save rity	Hist ary	Re Stud drug	Symp trea	Dis Hosp app.	Re app.	Dis come (c)					
																	Treatment Start date	Treatment End date	Visit End No date	Last report visit	
35	707	Rebooxetine	20/10/93	16/11/93	NEURITIS	Summary	10/11/93		16/11/93(4)	20	1	2	4	3	3	1	3	3	YES		
					SWEATING INCREASED	Detail	16/10/93(2)	0		2										NO	
						Summary	16/10/93(2)	21		3	3	3	3	1	YES	3	3	3	3	3	
						Detail	05/11/93	20		2	3	3	3	3	3	1	3	3	3	3	
						Summary	05/11/93	14/11/93(4)	20	5	3	3	3	3	YES	3	1	3	3	3	
08D	08D	Imipramine	01/02/94	21/03/94	ANOREXIA	Detail	30/01/94(2)	0		1										NO	
						Summary	30/01/94(2)	0	1	0	1										NO
					CONFUSION	Detail	30/01/94(2)	0		2											NO
						Summary	30/01/94(2)	0	2	0	2										NO
					CONSTIPATION	Detail	30/01/94(2)	0		1											NO
						Summary	30/01/94(2)	14		0	1	3	1	3	1	YES	3	3	3	3	
						Detail	10/02/94	21		1	1	3	1	3	1	YES	3	3	3	3	
						Summary	10/02/94	28		2	1	3	1	3	1	YES	3	3	3	3	
						Detail		35		2	1	3	1	3	1	YES	3	3	3	3	
						Summary		42		2	1	3	1	3	1	YES	3	3	3	3	
						Detail	10/02/94	49		2	1	3	1	3	1	YES	3	3	3	3	
						Summary	10/02/94	21/02/94(4)	49	2	1	3	1	3	1	YES	3	3	3	3	
					HEADACHE	Detail	30/01/94(2)	0		1											NO
						Summary	30/01/94(2)	0	1	0	1										NO
					HYPOKINESIA	Detail	30/01/94(2)	0		1											NO
						Summary	30/01/94(2)	0	1	0	1										NO
					INSOMNIA	Detail	30/01/94(2)	0		2											NO
						Summary	30/01/94(2)	0	2	0	2										NO

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=none change, 2=dose reduced, 3=def. withdrawal, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=free. with seq., 3=still present, 4=death
 Disapp./healp: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 symptomatic treatment: 1=yes, 1=yes
 (C) adverse event used for statistical analysis
 (M) adverse event still present; end date = visit date
 onset date missing: (a) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1963

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

111

PHARMACIA CNS RD

REBOXETINE - PROTOCOL 20124/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Visit End date	List report visit	Save	Hist	Rel	Stud	Bymp	Dis app.	Re come (c)	Out														
																				ship	tr	tra	hoop	app.	app.	come (c)							
35	BND	Indipramine	01/02/94	21/03/94	MOUTH DRY		Detail	30/01/94(0)	0			1																					
							Summary	30/01/94(0)	0			0																					
							Detail	05/02/94	7			2	1	3	1																		
							Detail	16			2	1	3	1																			
							Detail	21			2	1	3	1																			
							Detail	28			1	1	3	1																			
							Detail	35			1	1	3	1																			
							Detail	42			1	1	3	1																			
							Detail	49			1	1	3	1																			
							Summary	05/02/94	21/03/94(*)	49	2	1	3	1																			
		NOCTURIA					Detail	01/03/94	35																								
							Detail	42			1	2	3	1																			
							Detail	49			1	2	3	1																			
							Summary	01/03/94	21/03/94(*)	49	1	2	3	1																			
							Detail	30/01/94(0)	0																								
							Summary	30/01/94(0)	0																								
							Detail	21/02/94	21			24/02/94	21	24/02/94	21	24/02/94	21	24/02/94	21	24/02/94	21	24/02/94	21	24/02/94	21	24/02/94	21	24/02/94	21	24/02/94	21	24/02/94	
							Summary	21/02/94	24/02/94	21	24/02/94	21	24/02/94	21	24/02/94	21	24/02/94	21	24/02/94	21	24/02/94	21	24/02/94	21	24/02/94	21	24/02/94	21	24/02/94	21	24/02/94	21	24/02/94
							Detail	09/01/94(0)	0																								
							Summary	09/01/94(0)	0																								
8DT	Reboxetine	11/01/94	07/05/94	ANOREXIA			Detail	30/01/94(0)	0																								
							Summary	30/01/94(0)	0																								
							Detail	30/01/94	21			2	2	3	1																		
							Detail	28			2	2	3	1																			
							Detail	35			2	2	3	1																			
							Detail	42			2	2	3	1																			
							Detail	49			2	2	3	1																			
							Detail	56			2	2	3	1																			
							Summary	30/01/94	07/05/94(*)	56	2	2	3	1																			
									CONSTIPATION					Detail	30/01/94	21																	
Detail	28			2	2	3								1																			
Detail	35			2	2	3								1																			
Detail	42			2	2	3								1																			
Detail	49			2	2	3								1																			
Detail	56			2	2	3								1																			
Summary	30/01/94	07/05/94(*)	56	2	2	3								1																			
Detail	09/01/94(0)	0																															
Summary	09/01/94(0)	0																															

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe,
Study drug: 1=na change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=search
Disapp./Naapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(*) onset date missing: (0) first report visit date used (screen data = 1 day used for A.E. reported at day0), (1) onset date A.E.

9550089

1964

9550089

112

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RBD
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment		Type record	Onset date	Visit No	Visit End date	Last report visit	Sve	Hist	Rel	Stud	Sym	Dis	Re	Out				
			Start date	End date																	
35	BDT	Reboxetine	11/01/94	07/05/94	INSONNIA	Detail	09/01/94(3)	0	2	1	3	3	1	YES	3	3	3	1			
			20/01/94	14	23/01/94	Summary	09/01/94(3)	23/01/94	14	2	3	3	1	YES	3	3	3	1	NO		
			12/01/94	7		Detail	12/01/94	7	1	2	2	1	3	3	3	3	3	3	3		
			12/01/94	14	20/01/94	Summary	12/01/94	20/01/94	14	1	2	2	1	3	3	3	3	3	1		
			12/01/94	14	20/01/94	Summary	12/01/94	20/01/94	14	1	2	2	1	3	3	3	3	3	1	YES	
			14/01/95(2)	0		Detail	14/01/95(2)	0	2												
			14/01/95(2)	0		Summary	14/01/95(2)	0	2												NO
			11/02/95	26		Detail	11/02/95	26	2	2	6	1	YES	3	3	3	3	3	3	3	
			23/02/95	42	23/02/95	Summary	11/02/95	23/02/95	42	2	6	1	YES	3	3	3	3	3	3	1	YES
			09/02/95	26		Detail	09/02/95	26	1	2	5	1	YES	3	3	3	3	3	3	3	
09/02/95	35	14/02/95	Summary	09/02/95	14/02/95	35	1	2	5	1	YES	3	3	3	3	3	1	YES			
14/01/95(3)	0		Detail	14/01/95(3)	0	1															
14/01/95(3)	0		Summary	14/01/95(3)	0	1													NO		
14/01/95(3)	0		Detail	14/01/95(3)	0	2															
05/02/95	21	05/02/95	Summary	14/01/95(3)	0	2													NO		
05/02/95	21	05/02/95	Summary	05/02/95	05/02/95	21	3	1	5	1	YES	2	3	3	3	3	1	YES			
14/01/95(2)	0		Detail	14/01/95(2)	0	1															
14/01/95(2)	0		Summary	14/01/95(2)	0	1													NO		
29/01/95	14	03/02/95	Detail	29/01/95	14	03/02/95	1	2	1	3	3	3	3	3	3	3	1				

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe,
 Study drug: 1=none change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (N) adverse event still present; end date = visit date
 onset date missing: (3) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date N.E.

1965

9550089

113

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
RESOMETINE - PROTOCOL 20124/055
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	End date	Last report visit	Save city	Hist ory	Rel ship	Rat drug	Stud app.	Samp app.	Dis app.	Re app.	Dut app.		
																					16/01/93	08/03/93
36	1MD	Imipramine		16/01/93	08/03/93	HYPOTENSION POSTURAL	Summary	29/01/93	42	05/02/93	14	1	2	2	1	3	3	3	3	3	1 YES	
							Detail	22/02/93	56												3 3 3	
							Summary	22/02/93		12/03/93(*)	56	2	2	2	1	3	3	3	3	3	3	YES
							Detail	14/01/93(O)	0													NO
							Summary	14/01/93(O)														NO
							Detail	08/05/93	56	14/05/93												NO
							Summary	08/05/93		14/05/93	56	3	2	6	3	3	1	3	4	4	4	YES
107	Imipramine			03/02/93	31/03/93	AMOKEXIA	Detail	28/01/93(O)	0													NO
							Summary	28/01/93(O)														NO
							Detail	28/01/93(O)	0													NO
							Summary	28/01/93(O)														NO
							Detail	28/01/93(O)	0													NO
							Summary	28/01/93(O)														NO
							Detail	28/01/93(O)	0													NO
							Summary	28/01/93(O)														NO
							Detail	28/01/93(O)	0													NO
							Summary	28/01/93(O)														NO
							Detail	04/03/93	35	42	10/03/93											NO
							Summary	04/03/93		10/03/93	42	2	2	1	1	2	3	3	3	3	3	3
							Detail	28/01/93(O)	0													NO
							Summary	28/01/93(O)														NO

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe.
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawal, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
onset date missing: (O) first report visit date used (screen data - 1 day used for A.E. reported at day0), (1) onset date A.E.

1966

9550089

114

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RAD
REBOXETINE - PROTOCOL 20124/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment		Adverse event	Onset date	Visit End No data	Last report		Rel	Stud	Symp	Dis	Re	Out										
			Start date	End date				visit	save																
36	101	Imipramine	03/02/93	31/03/93	MOUTH DRY	13/02/93	14	1	2	2	1	2	3	3	3										
						21	20/02/93	1	2	3	1	2	3	3	1										
						20/02/93	21	1	2	2	1	2	3	3	1	YES									
						Summary																			
						38D	Reboxetine	03/02/93	50/03/93	ANOREXIA	26/01/93(0)	0	2	0	2						NO				
											26/01/93(0)	0	2								NO				
											26/01/93(0)	0	1										NO		
											26/01/93(0)	0	1											NO	
											Summary														
																FATIGUE	26/01/93(0)	0	2	0	2				
26/01/93(0)	0	2																					NO		
26/01/93(0)	0	1																						NO	
26/01/93(0)	0	1																						NO	
Summary																									
					HEADACHE	26/01/93(0)	0	2	0	2											NO				
						26/01/93(0)	0	2																NO	
						26/01/93(0)	0	2																	NO
						26/01/93(0)	0	2																	NO
						Summary																			
											HYPOKINESIA	26/01/93(0)	0	2	0	2					NO				
												26/01/93(0)	0	2										NO	
												26/01/93(0)	0	2											NO
												26/01/93(0)	0	2											NO
												Summary													
					INSOMNIA							26/01/93(0)	0	2	0	2					NO				
												26/01/93(0)	0	2										NO	
												26/01/93(0)	0	2											NO
												26/01/93(0)	0	2											NO
												Summary													
											NAUSEA	26/01/93(0)	0	1	0	1					NO				
												26/01/93(0)	0	1										NO	
												26/01/93(0)	0	1											NO
												26/01/93(0)	0	1											NO
												Summary													
					TREMOR							07/02/93	7	1	2	2	1	3	3	3	3				
												28	1	2	1	3	3	3	3	3					
												58	1	2	1	3	3	3	3	3					
												30/03/93(0)	56	1	2	1	3	3	3	3					
												30/03/93(0)	56	1	2	1	3	3	3	3					
						Summary																			

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=dose, 4=withdrawn, 5=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (M) adverse event still present: end date = visit date
 onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1967

9550089

115

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RSD

REBOXETINE - PROTOCOL 20124/935
Listing No.: 17.9

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	ZID	Treatment Start date	End date	Adverse event	Type record	Onset date	Visit End No data	Last report visit	Save rity	Hist ory	Mist ory	Re al drug	Stud drug	Somp app.	Dis app.	Re app.	Out come (c)									
																			17/02/93(D)	17/02/93(D)	17/02/93(D)	17/02/93(D)	17/02/93(D)	17/02/93(D)	17/02/93(D)	17/02/93(D)	17/02/93(D)
36	Reboxetine	201	25/02/93	22/04/93	AGITATION	Detail	17/02/93(D)	0	1	1	1	1	1	1	1	1	1	1	NO								
						Summary	17/02/93(D)	0	0	1	1	1	1	1	1	1	1	1	1	1	1	NO					
						Detail	27/02/93	7	1	2	1	1	1	1	1	1	1	1	1	1	1	1	3	3	3	3	
						Summary	16/03/93	14	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	3	3	3	1
						Detail	27/02/93	14	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	3	3	3	1
						Summary	19/03/93	21	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	3	3	3	5
						Detail	14/03/93	21	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	3	3	3	5
						Summary	14/03/93	56	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	3	3	3	5
						Detail	14/03/93	56	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	3	3	3	5
						Summary	22/06/93(*)	56	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	3	3	3	5
						Summary	17/02/93(D)	0	0	2	2	2	2	2	2	2	2	2	2	2	2	2	2	NO			
						36D	Imipramine	06/02/93	02/04/93	AGITATION	Detail	31/01/93(D)	0	1	1	1	1	1	1	1	1	1	1	1	NO		
Summary	31/01/93(D)	0	0	1	1						1	1	1	1	1	1	1	1	1	1	NO						

Severity: #unknown, 1=ild, 2=oderate, 3=evere, 4=ritical, 5=deadly
Study drug: 1=ne change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcomes: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
onset date missing: (D) first report visit date used (screen date - 1 day used for A.E. reported at day), (I) onset date A.E.

9550089

117

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA DNS RED

REBOXETINE - PROTOCOL 2016/935
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type	Onset date	Visit End	Last report visit	Sev	Hist	Rel	Stud	Symp	Dis	Re	Out				
							record		No data													
36	3DT	Imipramine	02/05/93	27/04/93	HEADACHE	Summary	24/02/93(2)			0	2								NO			
					INSOMNIA	Detail	26/02/93(2)	0		1										NO		
						Summary	24/02/93(2)			0	1									NO		
4ND	Reboxetine	09/02/93	01/05/93	CONSTIPATION	Detail	01/05/93(2)				1										NO		
						Summary	01/05/93(2)			0	1									NO		
					FATIGUE	Detail	01/05/93(2)	0		1										NO		
						Summary	01/05/93(2)			0	1									NO		
4DT	Reboxetine	12/02/93	06/05/93	CONSTIPATION	Detail	25/04/93	49			2	2	2	1	1	2	3	3	3	3	3		
						Summary	25/04/93	56	06/05/93(*)	56	2	2	2	1	2	5	5	5	5	5	YES	
					DIZZINESS	Detail	05/05/93(2)	0		2											NO	
						Summary	05/05/93(2)			0	2										NO	
					INSOMNIA	Detail	05/05/93(2)	0		1											NO	
						Summary	05/05/93(2)			0	1										NO	
5DT	Imipramine	03/04/93	07/04/93	AGITATION	Detail	24/03/93(2)				2											NO	
						Summary	24/03/93(2)			0	2											NO
					CONSTIPATION	Detail	24/03/93(2)	0		2												NO
						Summary	24/03/93(2)			0	2											NO
					MOUTH DRY	Detail	24/03/93(2)	0		1												NO
						Summary	24/03/93(2)			0	1											NO
					PARAESTHESIA	Detail	24/03/93(2)	0		1												NO

Severity: 0=unknown, 1=ild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(*) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
(*) adverse event still present: end date = visit date
onset date missing: (2) first report visit date used (screen data - 1 day used for A.E. reported at day0), (1) onset date A.E.

1970

9550089

116

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS RED

REBOXETINE - PROTOCOL 20124/935
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment		Type record	Onset date	Visit No	End date	Last report date	Save	Hist	Rel	Stud	Sym	Dis	Re	Out		
		Start date	End date															
36	50T	Impramine	03/06/93	07/06/93	PARAMETHESIA	Summary	24/05/93(12)		0	1						NO		
						Detail	08/06/93	7	08/06/93	3	2	6	1			3	3	4
						Summary	08/06/93	08/06/93	7	3	2	6	1			3	3	4
6ND	Impramine	01/05/93	25/06/93	TACHYCARDIA	Detail	15/06/93	49		2	2	3	1	YES	2	3	3		
					Summary	15/06/93	56	25/06/93(1*)	56	2	2	3	1	YES	2	3	3	
					Detail	30/05/93(12)	0		0	1								
6DT	Impramine	10/06/93	04/06/93	PARAMETHESIA	Detail	30/05/93(12)	0		0	1						NO		
					Summary	30/05/93(12)	0		0	1								
					Detail	27/06/93	49	27/06/93	1	2	6	1	YES	3	3	3	1	
7ND	Reboxetine	13/05/93	07/07/93	DIARRHOEA	Summary	27/06/93	49		49	1	2	6	1	YES	3	3	1	
					Detail	06/07/93	56	07/07/93	1	2	6	1	YES	3	3	3	1	
					Summary	06/07/93	56	07/07/93	56	1	2	6	1	YES	3	3	3	
7DT	Reboxetine	01/05/93	07/05/93	DIZZINESS	Detail	15/06/93	35	22/06/93	1	2	6	1	YES	2	3	3	1	
					Summary	15/06/93	35	22/06/93	35	1	2	6	1	YES	2	3	3	
					Detail	01/05/93	7	07/05/93(1*)	7	2	2	3	3	3	3	3		
8ND	Impramine	26/05/93	20/07/93	DYSMPHREA	Detail	06/05/93(12)	0		0	1						NO		
					Summary	06/05/93(12)	0		0	1								
					Detail	01/05/93	7	07/05/93(1*)	7	3	2	3	3	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe,
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=na, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present; end date = visit date
(**) onset date missing; (12) first report visit date used (screen data - 1 day used for A.E. reported at day0), (1) onset date A.E.

1971

9550089

119

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RBD
REBOXETINE - PROTOCOL 20124/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Start date	End date	Treatment	Adverse event	Type record	Onset date	Visit End No date	Last report visit	Save rity	Hist ory	Rai ship	Stud drug	Symp tres	Dis app.	Re app.	Out app.	Sev (c)							
																				1	2	3	4	5	6	7
36	BMD	Imipramine	26/05/93	20/07/93		DYSSTONIA	Detail	04/06/93(C)	0	1	0	1								NO						
							Summary	04/06/93(C)																		
							Detail	04/06/93(C)	0	2	0	2													NO	
80T	Reboxetine	15/05/93	15/07/93		CONSTIPATION	Detail	01/06/93	21	1	2	3	1	5	3	3	3	3	3	3							
						Summary	01/06/93	63	1	2	2	1	5	3	3	3	3	3	3	3	3	3	3	YES		
						Summary	16/07/93(*)	63	1	2	2	1	5	3	3	3	3	3	3	3	3	3	3	YES		
90D	Reboxetine	16/06/93	18/08/93		CONVULSIONS GRAND MAL	Detail	29/07/93	49	3	2	2	1	3	3	3	3	3	3	3	1						
						Summary	29/07/93	49	3	2	2	1	3	3	3	3	3	3	3	3	3	3	1	YES		
						Detail	10/06/93	56	2	2	3	1	3	3	3	3	3	3	3	3	3	3	3	YES		
90T	Imipramine	29/06/93	19/08/93		CONSTIPATION	Detail	08/07/93	14	1	2	2	1	3	3	3	3	3	3	3	3						
						Summary	08/07/93	56	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	YES		
						Summary	23/08/93(*)	56	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	YES		
						FATIGUE	Detail	22/06/93(C)	0	2	0	2									NO					
							Summary	22/06/93(C)																		
							Detail	19/08/93	56	23/08/93	56	1	4	1	1	4	1	1	1	1	1	1	1	1	YES	
						NAUSEA	Detail	22/06/93(C)	0	1	0	1										NO				
							Summary	22/06/93(C)																		
							Detail	19/08/93	56	23/08/93	56	1	6	4	1	6	4	1	1	1	1	1	1	1	1	1
						SINUSITIS	Detail	19/08/93	56	23/08/93	56	1	6	4	1	6	4	1	1	1	1	1	1			
							Summary	19/08/93	56	23/08/93	56	1	6	4	1	6	4	1	1	1	1	1	1	1	1	1
							Summary	22/06/93(C)	0	1	0	1														

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Respp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c): adverse event used for statistical analysis
 (*): adverse event still present; end date = visit date
 onset date missing: (C) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1972

9550089

131

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CIS RD
 REMOXTINE - PROTOCOL 20124/935
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report visit visit rity ary ship drug tree Hosp app. some (c)	Sev	Hist	Rel	Stud	Symp	Dis	Re	Out	
56	11ND	Imipramine	09/07/93	02/09/93	HEADACHE	Detail Summary	04/07/93(2) 04/07/93(2)	0	0	2								NO
11DT	Reboxetine	10/11/93	19/12/93		PARANOID REACTION	Detail Summary	20/11/93 20/11/93	14	3	2	4	4	4	YES	3	2	1	1
12ND	Imipramine	20/09/93	05/10/93		CONFUSION	Detail Summary	02/10/93 09/10/93	14	3	2	2	3	3	2	3	2	3	1
13ND	Reboxetine	21/09/93	14/10/93		ANOREXIA	Detail Summary	16/09/93(2) 16/09/93(2)	0	0	1								NO
					FATIGUE	Detail Summary	16/09/93(2) 16/09/93(2)	0	0	3								NO
					HYPERTENSION	Detail Summary	16/09/93(2) 16/09/93(2)	0	0	1								NO
					HYPOKALEMIA	Detail Summary	07/10/93 07/10/93	21	3	2	3	1	YES	3	3	3	3	3
					THROMBOSIS ARTERIAL	Detail Summary	13/10/93 13/10/93	28	2	2	4	3	YES	3	1	3	3	3
14ND	Imipramine	05/11/93	26/12/93		DIZZINESS	Detail Summary	01/12/93 01/12/93	55	42	1	2	1	3	3	3	3	3	1
17ND	Reboxetine	10/11/93	11/11/93		FATIGUE	Detail Summary	04/11/93(2) 04/11/93(2)	0	0	2								NO

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe, 4= life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawal, 4=other
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Reappr.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (2) first report visit date used (screen date = 1 day used for A.E. reported at day0), (1) onset date A.E.

1974

9550089

122

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	End date	Last report visit	Save rfty	Hist ary	Rel ship	Stud drug	Symp brea	Dis app.	Re app.	Dut come											
																				Dis	Re	Dut								
36	17ND	Reboxetine	10/11/93	11/11/93		HEADACHE	Detail	04/11/93(0)	0			0	2								NO									
							Summary	04/11/93(0)				0	2																	
							Detail	04/11/93(0)	0			0	1													NO				
							Summary	04/11/93(0)				0	1																	
							Detail	04/11/93(0)	0			0	1													NO				
							Summary	04/11/93(0)				0	1																	
							Detail	10/11/93	7	13/11/93	3	1	2	3												2	2	3	1	
							Summary	10/11/93		13/11/93		7	3	1	2	3										2	2	3	1	
							Detail	15/01/94	09/03/94	09/03/94	DIZZINESS	7	1	2	2	1											3	3	3	5
							Summary	15/01/94		09/03/94		56	1	2	2	1										3	3	3	5	
19ND	Reboxetine	15/01/94	22/01/94			HEADACHE	Detail	10/01/94(0)	0			0	1								NO									
							Summary	10/01/94(0)				0	1																	
							Detail	22/01/94	14			3	2	1	3										2	2	3	3		
							Summary	22/01/94		24/01/94		14	3	2	1	3									2	2	3	3		
19ND	Reboxetine	15/01/94	22/01/94			HYPERKINESIA	Detail	13/01/94(0)	0			0	2								NO									
							Summary	13/01/94(0)				0	2																	
19ND	Reboxetine	15/01/94	22/01/94			NAUSEA	Detail	22/01/94	14			3	2	1	3						2	2	3	3						
							Summary	22/01/94		24/01/94		14	3	2	1	3								2	2	3	3			
37	3ND	Reboxetine	10/05/93	24/05/93		AGITATION	Detail	10/05/93(0)	0			0	2								NO									
							Summary	10/05/93(0)				0	2																	

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
Study drug: 1=no change, 2=dose reduced, 3=dose increased, 4=withdrawn, 5=not used
Hospital: 1=required, 2=not req., 3=not appl.
Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
Symptomatic treatment: 0=no, 1=yes
(*) adverse event used for statistical analysis
(†) adverse event still present; end date = visit date
onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1975

9550089

123

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 17.9

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient ID#	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report visit	Sav Hist	R1	R2	R3	R4	R5	R6	R7	R8	R9	R10	R11	R12	R13	R14	R15	R16	R17	R18	R19	R20	R21	R22	R23	R24	R25	R26	R27	R28	R29	R30	R31	R32	R33	R34	R35	R36	R37	R38	R39	R40	R41	R42	R43	R44	R45	R46	R47	R48	R49	R50	R51	R52	R53	R54	R55	R56	R57	R58	R59	R60	R61	R62	R63	R64	R65	R66	R67	R68	R69	R70	R71	R72	R73	R74	R75	R76	R77	R78	R79	R80	R81	R82	R83	R84	R85	R86	R87	R88	R89	R90	R91	R92	R93	R94	R95	R96	R97	R98	R99	R100	R101	R102	R103	R104	R105	R106	R107	R108	R109	R110	R111	R112	R113	R114	R115	R116	R117	R118	R119	R120	R121	R122	R123	R124	R125	R126	R127	R128	R129	R130	R131	R132	R133	R134	R135	R136	R137	R138	R139	R140	R141	R142	R143	R144	R145	R146	R147	R148	R149	R150	R151	R152	R153	R154	R155	R156	R157	R158	R159	R160	R161	R162	R163	R164	R165	R166	R167	R168	R169	R170	R171	R172	R173	R174	R175	R176	R177	R178	R179	R180	R181	R182	R183	R184	R185	R186	R187	R188	R189	R190	R191	R192	R193	R194	R195	R196	R197	R198	R199	R200	R201	R202	R203	R204	R205	R206	R207	R208	R209	R210	R211	R212	R213	R214	R215	R216	R217	R218	R219	R220	R221	R222	R223	R224	R225	R226	R227	R228	R229	R230	R231	R232	R233	R234	R235	R236	R237	R238	R239	R240	R241	R242	R243	R244	R245	R246	R247	R248	R249	R250	R251	R252	R253	R254	R255	R256	R257	R258	R259	R260	R261	R262	R263	R264	R265	R266	R267	R268	R269	R270	R271	R272	R273	R274	R275	R276	R277	R278	R279	R280	R281	R282	R283	R284	R285	R286	R287	R288	R289	R290	R291	R292	R293	R294	R295	R296	R297	R298	R299	R300	R301	R302	R303	R304	R305	R306	R307	R308	R309	R310	R311	R312	R313	R314	R315	R316	R317	R318	R319	R320	R321	R322	R323	R324	R325	R326	R327	R328	R329	R330	R331	R332	R333	R334	R335	R336	R337	R338	R339	R340	R341	R342	R343	R344	R345	R346	R347	R348	R349	R350	R351	R352	R353	R354	R355	R356	R357	R358	R359	R360	R361	R362	R363	R364	R365	R366	R367	R368	R369	R370	R371	R372	R373	R374	R375	R376	R377	R378	R379	R380	R381	R382	R383	R384	R385	R386	R387	R388	R389	R390	R391	R392	R393	R394	R395	R396	R397	R398	R399	R400	R401	R402	R403	R404	R405	R406	R407	R408	R409	R410	R411	R412	R413	R414	R415	R416	R417	R418	R419	R420	R421	R422	R423	R424	R425	R426	R427	R428	R429	R430	R431	R432	R433	R434	R435	R436	R437	R438	R439	R440	R441	R442	R443	R444	R445	R446	R447	R448	R449	R450	R451	R452	R453	R454	R455	R456	R457	R458	R459	R460	R461	R462	R463	R464	R465	R466	R467	R468	R469	R470	R471	R472	R473	R474	R475	R476	R477	R478	R479	R480	R481	R482	R483	R484	R485	R486	R487	R488	R489	R490	R491	R492	R493	R494	R495	R496	R497	R498	R499	R500	R501	R502	R503	R504	R505	R506	R507	R508	R509	R510	R511	R512	R513	R514	R515	R516	R517	R518	R519	R520	R521	R522	R523	R524	R525	R526	R527	R528	R529	R530	R531	R532	R533	R534	R535	R536	R537	R538	R539	R540	R541	R542	R543	R544	R545	R546	R547	R548	R549	R550	R551	R552	R553	R554	R555	R556	R557	R558	R559	R560	R561	R562	R563	R564	R565	R566	R567	R568	R569	R570	R571	R572	R573	R574	R575	R576	R577	R578	R579	R580	R581	R582	R583	R584	R585	R586	R587	R588	R589	R590	R591	R592	R593	R594	R595	R596	R597	R598	R599	R600	R601	R602	R603	R604	R605	R606	R607	R608	R609	R610	R611	R612	R613	R614	R615	R616	R617	R618	R619	R620	R621	R622	R623	R624	R625	R626	R627	R628	R629	R630	R631	R632	R633	R634	R635	R636	R637	R638	R639	R640	R641	R642	R643	R644	R645	R646	R647	R648	R649	R650	R651	R652	R653	R654	R655	R656	R657	R658	R659	R660	R661	R662	R663	R664	R665	R666	R667	R668	R669	R670	R671	R672	R673	R674	R675	R676	R677	R678	R679	R680	R681	R682	R683	R684	R685	R686	R687	R688	R689	R690	R691	R692	R693	R694	R695	R696	R697	R698	R699	R700	R701	R702	R703	R704	R705	R706	R707	R708	R709	R710	R711	R712	R713	R714	R715	R716	R717	R718	R719	R720	R721	R722	R723	R724	R725	R726	R727	R728	R729	R730	R731	R732	R733	R734	R735	R736	R737	R738	R739	R740	R741	R742	R743	R744	R745	R746	R747	R748	R749	R750	R751	R752	R753	R754	R755	R756	R757	R758	R759	R760	R761	R762	R763	R764	R765	R766	R767	R768	R769	R770	R771	R772	R773	R774	R775	R776	R777	R778	R779	R780	R781	R782	R783	R784	R785	R786	R787	R788	R789	R790	R791	R792	R793	R794	R795	R796	R797	R798	R799	R800	R801	R802	R803	R804	R805	R806	R807	R808	R809	R810	R811	R812	R813	R814	R815	R816	R817	R818	R819	R820	R821	R822	R823	R824	R825	R826	R827	R828	R829	R830	R831	R832	R833	R834	R835	R836	R837	R838	R839	R840	R841	R842	R843	R844	R845	R846	R847	R848	R849	R850	R851	R852	R853	R854	R855	R856	R857	R858	R859	R860	R861	R862	R863	R864	R865	R866	R867	R868	R869	R870	R871	R872	R873	R874	R875	R876	R877	R878	R879	R880	R881	R882	R883	R884	R885	R886	R887	R888	R889	R890	R891	R892	R893	R894	R895	R896	R897	R898	R899	R900	R901	R902	R903	R904	R905	R906	R907	R908	R909	R910	R911	R912	R913	R914	R915	R916	R917	R918	R919	R920	R921	R9
--------	-------------	-----------	------------	----------	---------------	-------------	------------	-------------------	-------------------	----------	----	----	----	----	----	----	----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	----

9550089

124

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RBD
 REDONETINE - PROTOCOL 20124/035
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Start date	End date	Adverse event	Type record	Onset date	Visit No	End No date	Last report visit	Sev	Hist	Rel	Stud	Symp	Dis app.	Re app.	Dut		
41	1ND	Imipramine	22/02/94	24/02/94	TREMOR	Detail	14/02/94(3)	0		0	1								NO	
						Summary	14/02/94(3)			0	1									
3ND	Reboxetine		25/02/94	19/04/94	AGITATION	Detail	17/02/94(3)	0		0	2									NO
						Summary	17/02/94(3)			0	2									
					FATIGUE	Detail	17/02/94(3)	0		0	1									NO
						Summary	17/02/94(3)			0	1									
					HEADACHE	Detail	17/02/94(3)	0		0	1									NO
						Summary	17/02/94(3)			0	1									
					INSOMNIA	Detail	17/02/94(3)	0		0	1									NO
						Summary	17/02/94(3)			0	1									
					MOUTH DRY	Detail	17/02/94(3)	0		0	2									NO
						Summary	17/02/94(3)			0	2									
					RHINITIS	Detail	17/02/94(3)	0		0	1									NO
						Summary	17/02/94(3)			0	1									
					SWEATING INCREASED	Detail	17/02/94(3)	0		0	2									NO
						Summary	17/02/94(3)			0	2									
					TREMOR	Detail	17/02/94(3)	0		0	1									NO
						Summary	17/02/94(3)			0	1									
3ND	Imipramine		25/02/94	21/04/94	AGITATION	Detail	15/02/94(3)	0		0	1								NO	
						Summary	15/02/94(3)			0	1									

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq, 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date
 onset date missing: (3) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1977

9550089

126

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 REBOMETINE - PROTOCOL 20124/035
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type	Onset date	Visit	End date	Last report visit	Sev	Hist	Rel	Stud	Symp	Dis app.	Re app.	Out			
									No	No												
41	SND	Reboxetine	05/05/94	27/04/94		HEADACHE	Summary	17/02/94(2)			0	1								NO		
							Detail	17/02/94(2)	0		1	1	3	1	3	1	2	3	3	3		
							Detail	07/03/94	7		1	1	3	1	3	1	2	3	3	3		
									14		1	1	3	1	3	1	2	3	3	3		
									21		1	1	2	1	2	1	3	3	3	3		
									28		1	1	2	1	2	1	3	3	3	3		
									35		1	1	2	1	2	1	3	3	3	3		
									42		1	1	2	1	2	1	3	3	3	3		
									49		1	1	2	1	2	1	3	3	3	3		
									56		1	1	2	1	2	1	3	3	3	3		
							Summary	17/02/94(2)	56		1	1	2	1	2	1	2	3	3	3	NO	
							Detail	26/03/94	28		2	2	3	1	3	1	2	3	3	3		
									35		2	2	3	1	3	1	3	3	3	3		
									42		2	2	3	1	3	1	3	3	3	3		
									49		2	2	2	1	3	1	3	3	3	3		
									55		2	2	2	1	3	1	3	3	3	3		
							Summary	26/03/94	55		2	2	2	1	2	2	2	3	3	3	YES	
							Detail	11/10/93(2)	0		0	1									NO	
							Summary	11/10/93(2)	0		0	1										NO
							Detail	11/10/93(2)	0		0	1										NO
							Summary	11/10/93(2)	0		0	1										NO
							Detail	04/10/93(1)	0		1	1	4	1	4	1	2	3	3	3		
									7		1	1	4	1	4	1	2	3	3	3		
									14		1	1	4	1	4	1	2	3	3	3		
									21		1	1	4	1	4	1	2	3	3	3		
									28		1	1	1	1	2	1	2	3	3	3		
									35		1	1	4	1	4	1	2	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=ongoing, 2=discontinued, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=na, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date
 onset date missing: (2) first report visit date used screen date - 1 day used for A.E. reported at (2000), (1) onset date A.E.

1979

9550089

127

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOMETINE - PROTOCOL 20124/035
Listing No.: 17.9

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No data	Last report visit	Sev	Hist ary	Rel ship	Rep drug	Stud Sym	Dis app.	Re app.	Dut some (c)	
																		report
42	10T	Imipramine	25/11/93	15/01/94	CONSTIPATION	Detail	06/10/93	42	49	12/01/94	1	1	4	1	2	3	3	3
						Summary	06/10/93	49	12/01/94	1	1	4	1	2	3	3	1	NO
						Detail	16/01/94	56	17/01/94	1	1	4	1	2	3	3	1	YES
						Summary	16/01/94	56	17/01/94	1	1	4	1	2	3	3	1	YES
					DIZZINESS	Detail	01/11/93(0)	0			1							NO
						Summary	01/11/93(0)	0			1							NO
					MALaise	Detail	02/01/94	42	02/01/94	1	2	3	1	2	3	3	1	YES
						Summary	02/01/94	42	02/01/94	1	2	3	1	2	3	3	1	YES
						Detail	09/01/94	49	11/01/94	1	2	2	1	2	3	3	1	YES
						Summary	09/01/94	49	11/01/94	1	2	2	1	2	3	3	1	YES
						Detail	17/01/94	56	18/01/94	1	1	2	1	2	3	3	1	YES
						Summary	17/01/94	56	18/01/94	1	1	2	1	2	3	3	1	YES
					MOUTH DRY	Detail	01/11/93(0)	0			1							NO
						Summary	01/11/93(0)	0			1							NO
					NAUSEA	Detail	01/11/93(0)	0			1							NO
						Summary	01/11/93(0)	0			1							NO
					SALIVA INCREASED	Detail	01/11/93(0)	0			1							NO
						Summary	25/11/93	7			1		4	1	2	3	3	3
						Detail	25/11/93	14			1		4	1	2	3	3	3
						Summary	25/11/93	21			1		4	1	2	3	3	3
						Detail	28				1		4	1	2	3	3	3
						Summary	28				1		4	1	2	3	3	3
						Summary	01/11/93(0)	56	19/01/94(0)	56	1	1	4	1	2	3	3	NO
					TREMOR	Detail	11/08/93(1)	0			1							NO
						Summary	11/08/93	7			1		4	1	2	3	3	3
						Detail	14				1		4	1	2	3	3	3
						Summary	21				1		4	1	2	3	3	3
						Detail	28				1		4	1	2	3	3	3
						Summary	28				1		4	1	2	3	3	3

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present; end date = visit date
onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1980

9550089

126

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA DNS R&D
REBOWETINE - PROTOCOL 20124/955
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report visit	Save rity	Hist ory	Rel ory	Stud drug	Simp	Dis app.	Re app.	Out come						
																			Dis app.	Re app.	Out come			
42	1DT	Indipramine	19/01/94	19/01/94	19/01/94	TREMOR	Detail	11/08/93	35	1	1	4	1	2	3	3	3	3	3					
							Summary	11/08/93	56	1	1	4	1	2	3	3	3	3	3	3	3	3	3	3
							Detail	01/11/93(0)	0	1	1	4	1	2	3	3	3	1	NO					
							Summary	27/12/93	35	1	2	4	1	2	3	3	3	1	NO					
							Detail	01/11/93(0)	0	1	2	4	1	2	3	3	3	1	NO					
							Summary	27/12/93	35	1	2	4	1	2	3	3	3	1	NO					
							Detail	17/11/93	28	1	2	4	4	2	1	1	1	1	YES					
							Summary	17/11/93	26	1	2	4	4	2	1	1	1	1	YES					
							Detail	25/10/93(1)	0	1	1	4	1	2	3	3	3	3	3					
							Summary	25/10/93	14	1	1	4	1	2	3	3	3	3	3					
2ND	Reboxetine	26/10/95	29/12/95	29/12/95	CONJUNCTIVITIS	Detail	17/11/93	28	1	2	4	4	2	1	1	1	1	1	1	1				
						Summary	17/11/93	26	1	2	4	4	2	1	1	1	1	1	1	1	1	1		
						Detail	25/10/93(1)	0	1	1	4	1	2	3	3	3	3	3						
						Summary	25/10/93	14	1	1	4	1	2	3	3	3	3	3						
						Detail	08/11/95(*)	14	1	1	4	1	2	3	3	3	3	3						
						Summary	27/11/95	35	1	1	4	1	2	3	3	3	3	3						
						Detail	01/12/95	42	1	1	4	1	2	3	3	3	3	3						
						Summary	02/12/95	42	1	1	4	1	2	3	3	3	3	3						
						Detail	11/10/93(0)	0	1	1	4	1	2	3	3	3	3	3						
						Summary	11/10/93(0)	0	0	1	1	4	1	2	3	3	3	3						
						MOUTH DRY	Detail	25/10/93(1)	0	1	1	4	1	2	3	3	3	3	3	3				
							Summary	25/10/93	14	1	1	4	1	2	3	3	3	3	3					
							Detail	19/11/95	21	1	1	2	1	2	3	3	3	1	NO					
							Summary	19/11/95	21	1	1	2	1	2	3	3	3	1	NO					
							Detail	20/11/95	26	1	1	2	1	2	3	3	3	1	YES					
							Summary	20/11/95	26	1	1	2	1	2	3	3	3	1	YES					
							Detail	25/11/95	35	1	1	4	1	2	3	3	3	1	YES					
							Summary	25/11/95	35	1	1	4	1	2	3	3	3	1	YES					
							Detail	01/12/95	42	1	1	4	1	2	3	3	3	1	YES					
							Summary	01/12/95	42	1	1	4	1	2	3	3	3	1	YES					

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1981

9550089

129

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/935
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient ID#	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Visit End No data	Last report			Dis app.	Re app.	Dut come (c)			
										city	dry	ship						
42	2ND	Reboxetine	26/10/93	20/12/93	VISION ABNORMAL	Detail	18/11/93	28	21/11/93	28	1	2	4	1	2	5	3	1
						Summary	18/11/93			28	1	2	4	1	2	5	3	1
201	Reboxetine	09/12/93	18/12/93	AGITATION	Detail	06/12/93	7	09/12/93		7	1	2	4	1	2	3	3	1
					Summary	09/12/93			7	1	2	4	1	2	3	3	1	NO
		CONSTIPATION			Detail	21/11/93(0)	0			0	1							NO
					Summary	21/11/93(0)			0	1								
		HYPERKINESIA			Detail	21/11/93(0)	0			0	1							NO
					Summary	21/11/93(0)			0	1								
		INSOMNIA			Detail	06/12/93(1)	0			2	2							
					Summary	06/12/93			7	2	2	4	1	2	3	3	1	NO
		MOUTH DRY			Detail	21/11/93(0)	0			1	1							NO
					Summary	21/11/93(0)			0	1								
		NAUSEA			Detail	21/11/93(0)	0			1	1							NO
					Summary	21/11/93(0)			0	1								
		SWEATING INCREASED			Detail	21/11/93(0)	0			1	1							NO
					Summary	21/11/93(0)			0	1								
3ND	Imipramine	25/11/93	19/01/94	CONSTIPATION	Detail	06/09/93(1)	0			1	1	1	4	1	2	5	3	3
					Summary	06/09/93			7	1	1	4	1	2	5	3	1	NO
					Detail	19/12/93	28	21/12/93		28	1	1	4	1	2	5	3	1
					Summary	19/12/93			28	1	1	4	1	2	5	3	1	YES
					Detail	26/12/93	55	28/12/93		55	1	1	4	1	2	5	3	1
					Summary	26/12/93			35	1	1	4	1	2	5	3	1	YES
					Detail	29/12/93	42	31/01/94		42	1	1	2	1	2	3	3	1
					Summary	29/12/93			42	1	1	2	1	2	3	3	1	NO

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=fatal
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date
 onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1982

9550089

130

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA DNS RED

REBOMETINE - PROTOCOL 20124/935
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Start date	End date	Treatment	Adverse event	Type record	Onset date	Visit No	End date	Last report visit	Save rity	Hist ary	Rel ony	Stud drug	Symp trea	Dis app.	Re app.	Dut come (c)		
																				1	2
42	3ND	Imipramine	25/11/93	13/01/94		CONSTIPATION	Summary	29/12/93	0	05/01/94	42	1	1	2	1		2	3	3	1	YES
			07/01/94		Detail		09/01/94	49	09/01/94		49	1	1	2	1		2	3	3	1	YES
			07/01/94		Summary		09/01/94	49	09/01/94		49	1	1	2	1		2	3	3	1	YES
			15/01/94		Detail		15/01/94	56	16/01/94		56	1	1	2	1		2	3	3	1	YES
			15/01/94		Summary		16/01/94	56	16/01/94		56	1	1	2	1		2	3	3	1	YES
					Detail	DIZZINESS	04/11/93(1)	0			1	1	1	4	1		2	3	3	3	NO
					Summary		04/11/93	7	01/12/93(4)		7	1	1	4	1		2	3	3	3	NO
					Detail		20/12/93	26	21/12/93		26	1	2	2	1		2	3	3	1	YES
					Summary		20/12/93	26	21/12/93		26	1	2	2	1		2	3	3	1	YES
					Detail		28/12/93	35	29/12/93		35	1	2	2	1		2	3	3	1	YES
					Summary		28/12/93	35	29/12/93		35	1	2	2	1		2	3	3	1	YES
					Detail		30/12/93	42	31/12/93		42	1	2	2	1		2	3	3	1	YES
					Summary		30/12/93	42	31/12/93		42	1	2	2	1		2	3	3	1	YES
					Detail		10/01/94	49	11/01/94		49	1	2	2	1		2	3	3	1	YES
					Summary		10/01/94	49	11/01/94		49	1	2	2	1		2	3	3	1	YES
					Detail	MOUTH DRY	06/09/93(1)	0			1	1	1	4	1		2	3	3	3	NO
					Summary		06/09/93	7	01/12/93(4)		7	1	1	4	1		2	3	3	3	NO
					Detail		27/12/93	35	29/12/93		35	1	1	4	1		2	3	3	1	YES
					Summary		27/12/93	35	29/12/93		35	1	1	4	1		2	3	3	1	YES
					Detail		30/12/93	42	31/12/93		42	1	1	2	1		2	3	3	1	YES
					Summary		30/12/93	42	31/12/93		42	1	1	2	1		2	3	3	1	YES
					Detail		10/01/94	49	11/01/94		49	1	1	2	1		2	3	3	1	YES
					Summary		10/01/94	49	11/01/94		49	1	1	2	1		2	3	3	1	YES
					Detail	TREMBOR	01/01/94	42	06/01/94		42	1	2	4	1		2	3	3	1	YES
					Summary		01/01/94	42	06/01/94		42	1	2	4	1		2	3	3	1	YES
43	1BT	Reboxetine	19/02/93	02/06/93		ABDOMINAL PAIN	Detail	06/03/93	21		2	2	6	1		3	3	3	3	3	3
								26			2	2	6	1		3	3	3	3	3	3
								55			2	2	6	1		3	3	3	3	3	3
								42			2	2	6	1		3	3	3	3	3	3

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawal, 4=temp. inter., 5=permanent withdrawal
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(a) adverse event still present; end date = visit date
onset date missing: (3) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1983

9550089

134

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient ID#	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End	No date	Last report	Svcs	Mist	Rai	Stud	Symp	Dis	Re	Out	
																				visit rity
43	40T	Reboxetine	23/09/93	18/11/93	AUREXIA	Detail	22/09/93(2)	0			1	1	1	6	1	3	3	3	3	
						Summary	22/09/93(2)	49	86/11/93	86/11/93	49	1	1	6	1	3	3	3	1	NO
						Detail	22/09/93(3)	0			1									
						Summary	22/09/93(3)	7			0	1	2	1	2	1	3	3	3	3
						Detail	27/09/93	56	16/11/93(*)	16/11/93(*)	56	2	1	2	1	YES	3	3	3	3
						Summary	27/09/93	56	16/11/93(*)	16/11/93(*)	56	2	1	2	1	YES	3	3	3	3
						Detail	27/09/93	7			1	2	2	1	1	3	3	3	3	
						Summary	27/09/93	28	16/10/93	16/10/93	28	1	2	2	1	3	3	3	1	YES
						Detail	22/09/93(3)	0			0	2								
						Summary	22/09/93(3)	0			0	2								NO
						Detail	01/10/93	14			1	2	2	1	1	3	3	3	3	
						Summary	01/10/93	21	10/10/93	10/10/93	21	1	2	2	1	3	3	3	1	YES
						Detail	09/10/93	21			1	2	2	1	1	3	3	3	3	
						Summary	09/10/93	49	86/11/93	86/11/93	49	1	2	2	1	3	3	3	1	YES
						Detail	22/09/93(2)	0			1									
						Summary	22/09/93(2)	56	16/11/93(*)	16/11/93(*)	56	1	1	6	1	3	3	3	3	

Severity: 3=unknown, 1= mild, 2=moderate, 3=severe, 4=life threatening
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawal, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=free, with seq., 3=still present, 4=death
Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4= doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=na, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
onset date missing: (2) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1987

9550089

135

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOCETINE - PROTOCOL 20124/025
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report visit	Sae	Hst	Rst	Stud	Drug	Tras	Hosp	Dis app.	Re app.	Dut	Sae (C)																
																					1	2	3	4	5	6	7	8	9	10	11	12				
43	SMD	Imipramine	10/12/93	12/01/94	CONSTIPATION	Detail	12/12/93	7	1	2	2	1	3	3	3	3	3	3	3	3	3	3														
								14	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3											
								21	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3									
								28	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3								
								35	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3							
								Summary	12/01/94(*)	35	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3							
								68	SMD	Imipramine	16/02/94	14/04/94	CONSTIPATION	Detail	26/12/93	7	1	2	2	1	3	3	3	3	3	3	3	3	3	3						
																14	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3				
																21	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
																28	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
																35	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
																Summary	12/01/94(*)	35	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3
68	SMD	Imipramine	16/02/94	14/04/94	CONSTIPATION	Detail	26/12/93	7	1	2	2	1	3	3	3	3	3	3	3	3	3	3														
								14	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3											
								21	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3									
								28	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3								
								35	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3							
								Summary	12/01/94(*)	35	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3							
								68	SMD	Imipramine	16/02/94	14/04/94	CONSTIPATION	Detail	26/12/93	7	1	2	2	1	3	3	3	3	3	3	3	3	3							
																14	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3				
																21	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
																28	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
																35	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
																Summary	12/01/94(*)	35	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3
68	SMD	Imipramine	16/02/94	14/04/94	CONSTIPATION	Detail	26/12/93	7	1	2	2	1	3	3	3	3	3	3	3	3	3															
								14	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3											
								21	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3									
								28	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3								
								35	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3							
								Summary	12/01/94(*)	35	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3							
								68	SMD	Imipramine	16/02/94	14/04/94	CONSTIPATION	Detail	26/12/93	7	1	2	2	1	3	3	3	3	3	3	3	3	3							
																14	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3				
																21	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
																28	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
																35	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
																Summary	12/01/94(*)	35	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3
68	SMD	Imipramine	16/02/94	14/04/94	CONSTIPATION	Detail	26/12/93	7	1	2	2	1	3	3	3	3	3	3	3	3	3															
								14	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3											
								21	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3									
								28	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3								
								35	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3							
								Summary	12/01/94(*)	35	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3							
								68	SMD	Imipramine	16/02/94	14/04/94	CONSTIPATION	Detail	26/12/93	7	1	2	2	1	3	3	3	3	3	3	3	3	3							
																14	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3			
																21	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
																28	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
																35	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
																Summary	12/01/94(*)	35	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3
68	SMD	Imipramine	16/02/94	14/04/94	CONSTIPATION	Detail	26/12/93	7	1	2	2	1	3	3	3	3	3	3	3	3	3															
								14	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3											
								21	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3									
								28	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3								
								35	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3							
								Summary	12/01/94(*)	35	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3							
								68	SMD	Imipramine	16/02/94	14/04/94	CONSTIPATION	Detail	26/12/93	7	1	2	2	1	3	3	3	3	3	3	3	3	3							
																14	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3			
																21	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
																28	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
																35	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
																Summary	12/01/94(*)	35	1	2	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
Study drug: 1=ongoing, 2=discontinued, 3=withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date
onset date missing: (0) first report visit date used (screen date - 1 day used for A-E, reported at day), (1) onset date A-E.

1988

9550089

136

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 17.9

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment		Type record	Onset date	Visit End No date	Last report visit	Save Hist	Rel	Stud	Samp	Dis	Re	Out							
		Start date	End date																		
43	6ND Imipramine	16/02/94	14/04/94	DIARRHOEA	06/04/94	06/04/94	54	14/04/94(*)	54	1	2	4	1	YES	3	3	3	3			
		Summary																			
		Detail		06/03/94		DIZZINESS	06/03/94		21		1	2	2	1		3	3	3	3	3	
		Summary																			
		Detail		18/04/94			18/04/94		56		1	2	2	1		3	3	3	3	3	
		Summary																			
		Detail		26/02/94		MICTURITION DISORDER	26/02/94		14		1	1	3	1		3	3	3	3	3	
		Summary																			
		Detail		28/02/94		MOUTH DRY	28/02/94		7		2	2	2	1		3	3	3	3	3	
		Summary																			
44	1MD Reboxetine	03/01/93	28/10/93	AGITATION	16/10/93	16/10/93	49	21/10/93(*)	49					YES							
		Summary																			
		Detail		01/09/93		ANDREXIA	01/09/93		0		1										
		Summary																			
		Detail		01/09/93		CONSTIPATION	01/09/93		0		2					YES	3	3	3	3	3
		Summary																			
		Detail		02/09/93		HEADACHE	02/09/93		14		2	2	4	1		YES	3	3	3	3	3
		Summary																			

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=cure, 3=with seql., 4=still present, 5=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (M) adverse event still present; end date a visit date
 onset date missing: (D) first report visit date used (screen data - 1 day used for A.E. reported at day), (I) onset date A.E.

9550089

137

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient ID#	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No data	Last report visit	Saves	Hist	Rel	Stud	Dysp	Dis Hosp	Re app.	Dut app.	Coma (C)									
																				visit	city	drug	trns	reas	app.	com	(C)	
44	LND	Reboxetine	28/10/93	28/10/93	28/10/93	HYPERTRIGLYCERIDEMIA	Detail	28/10/93	56	28/10/93(*)	1	2	3	1	3	3	3	3	3	3								
							Summary				56	1	2	3	1	3	3	3	3	3	3	3	3	3				
							Detail	01/09/93(C)	0																			
							Summary	01/09/93(C)	0																			
							Detail	01/09/93(C)	0																			
							Summary	01/09/93(C)	0																			
							Detail	01/09/93(C)	0																			
							Summary	01/09/93(C)	0																			
							Detail	01/09/93(C)	0																			
							Summary	01/09/93(C)	0																			
137	Reboxetine	31/07/93	26/09/93	31/07/93	26/09/93	SWEATING INCREASED	Detail	29/07/93(C)	0																			
							Summary	29/07/93(C)	0																			
							Detail	21/07/93	7																			
							Summary	21/07/93	14	11/08/93	1	2	4	1	3	3	3	3	3	3	3	3	3	3	3			
							Detail	29/07/93(C)	0																			
							Summary	29/07/93(C)	0																			
							Detail	21/07/93	7																			
							Summary	21/07/93	14	11/08/93	1	2	4	1	3	3	3	3	3	3	3	3	3	3	3			
							Detail	29/07/93(C)	0																			
							Summary	29/07/93(C)	0																			
						DIARRHOEA	Detail	06/10/93	56	22/10/93	1	2	5	1	3	3	3	3	3									
							Summary	06/10/93	56	22/10/93	1	2	5	1	3	3	3	3	3	3	3	3						
							Detail	29/07/93(C)	0																			
							Summary	29/07/93(C)	0																			
							Detail	29/07/93(C)	0																			
							Summary	29/07/93(C)	0																			
							Detail	29/07/93(C)	0																			
							Summary	29/07/93(C)	0																			
							Detail	29/07/93(C)	0																			
							Summary	29/07/93(C)	0																			
						GLYCOSURIA	Detail	06/10/93	56	22/10/93	1	2	5	1	3	3	3	3	3									
							Summary	06/10/93	56	22/10/93	1	2	5	1	3	3	3	3	3	3	3	3						
							Detail	29/07/93(C)	0																			
							Summary	29/07/93(C)	0																			
							Detail	29/07/93(C)	0																			
							Summary	29/07/93(C)	0																			
							Detail	29/07/93(C)	0																			
							Summary	29/07/93(C)	0																			
							Detail	29/07/93(C)	0																			
							Summary	29/07/93(C)	0																			

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe,
 Study drug: 1=none change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (O) first report visit date used (screen date - 1 day used for A.E. reported at day0), (I) onset date A.E.

1990

9550089

136

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS READ

REBOXETINE - PROTOCOL 20126/935
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment		Type	Onset	Visit	Last	Dis	Re	Out													
			Start	End								Adverse event	End	report	Save	Hist	Rel	Stud	Symp					
			date	date	record	date	No	date	visit	city	only	drug	trta	Hosp	app.	case	(C)							
64	1DT	Reboxetine	31/07/93	26/09/93	RHINITIS					1								NO						
						Detail	29/07/93(C)	0			0	1												
						Summary	29/07/93(C)																	
2HD	Reboxetine	15/11/93	20/09/93	15/11/93	ABDOMINAL PAIN																			
									Detail	22/09/93	7													
									Summary	22/09/93														
					SWEATING INCREASED																			
									Detail	21/07/93(1)	0													
									Summary	21/07/93	7													
					ANOREXIA																			
									Detail	16/09/93(C)	0													
									Summary	16/09/93(C)														
					CONSTIPATION																			
									Detail	16/09/93(C)	0													
									Summary	16/09/93(C)														
					DIZZINESS																			
									Detail	16/09/93(C)	0													
									Summary	16/09/93(C)														
					DYSPEPSIA																			
									Detail	22/09/93	14													
									Summary	22/09/93	21													
					SOMNOLENCY INCREASED																			
									Detail	15/11/93	56													
									Summary	15/11/93	56													

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe,
Study drug: 1=no change, 2=dose reduced, 3=def. Withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present; end date = visit date
onset date missing: (C) first report visit date used (screen data - 1 day used for A.E. reported at day0), (1) onset date A.E.

1991

9550089

139

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RD
REBOXETINE - PROTOCOL 20124/935
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Last report visit	Save rity	Hist ory	Rel ship	Stad app.	Sym trta	Dis Hosp	Re app.	Out some						
																		date	date	date	date	date	date
44	2ND	Reboxetine	20/09/93	15/11/93	HEADACHE	Detail	24/09/93	7	24/09/93	2	2	4	1	3	3	3	3	1					
						Summary	24/09/93	7	24/09/93	2	2	4	1	3	3	3	3	3	3	1	YES		
						Detail	05/10/93	21	06/10/93	2	2	6	1	YES	3	3	3	3	3	3	1	YES	
						Summary	05/10/93	21	06/10/93	2	2	6	1	YES	3	3	3	3	3	3	1	YES	
						Detail	16/09/93(3)	0		1													NO
						Summary	16/09/93(3)	0		1													NO
						Detail	27/09/93(8)	14	04/10/93(4)	14													YES
						Summary	27/09/93(8)	14	04/10/93(4)	14													YES
						Detail	16/09/93(3)	0		1													NO
						Summary	16/09/93(3)	0		1													NO
3ND	Imipramine	14/10/93	09/12/93	ANOREXIA	Detail	11/11/93(3)	0											NO					
					Summary	11/11/93(3)	0													NO			
					Detail	16/09/93(3)	0														NO		
					Summary	16/09/93(3)	0														NO		
					Detail	11/11/93(3)	0														NO		
					Summary	11/11/93(3)	0														NO		
					Detail	11/11/93(3)	0														NO		
					Summary	11/11/93(3)	0														NO		
					Detail	08/12/93	56	09/12/93(4)	56	1	2	1	2									YES	
					Summary	08/12/93	56	09/12/93(4)	56	1	2	1	2									YES	
					MOUTH DRY	Detail	25/11/93	49											3				
						Summary	25/11/93	49														3	

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe.
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (3) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1992

9550089

142

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/055
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Start date	End date	Adverse event	Type record	Onset date	Visit No	Visit End date	Last report visit	Save rity	Hist ary	Re ship	Stud drug	Sym tras	Dis app.	Re app.	Dut come	C						
																				Summary	Detail	Summary	Detail	Summary	Detail
45	1DT	Imipramine	12/05/95	06/10/95	MOUTH DRY	Detail	07/07/95(C)	0			0	1			1	2	3	3	3	NO					
						Summary	07/07/95(C)																		
						Detail	15/08/95	7																	
						Summary	15/08/95	14																	
						Detail	21	2	1	2	1	2	1	2	1	2	1	2	1	2	3	3	3	3	
						Summary	21	2	1	2	1	2	1	2	1	2	1	2	1	2	3	3	3	3	
						Detail	28	2	1	2	1	2	1	2	1	2	1	2	1	2	3	3	3	3	
						Summary	28	2	1	2	1	2	1	2	1	2	1	2	1	2	3	3	3	3	
						Detail	42	2	1	2	1	2	1	2	1	2	1	2	1	2	3	3	3	3	
						Summary	42	2	1	2	1	2	1	2	1	2	1	2	1	2	3	3	3	3	
Detail	49	2	1	2	1	2	1	2	1	2	1	2	1	2	3	3	3	3							
Summary	49	2	1	2	1	2	1	2	1	2	1	2	1	2	3	3	3	3							
Detail	55	2	1	2	1	2	1	2	1	2	1	2	1	2	3	3	3	3							
Summary	55	2	1	2	1	2	1	2	1	2	1	2	1	2	3	3	3	3							
Detail	06/09/95	28	14/09/95	28	14/09/95	28	14/09/95	28	14/09/95	28	2	2	4	1	2	3	3	1							
Summary	06/09/95	28	14/09/95	28	14/09/95	28	14/09/95	28	14/09/95	28	2	2	4	1	2	3	3	1							
Detail	23/11/95(C)	6									0	2													
Summary	23/11/95(C)	6									0	2													
Detail	29/12/95	99									99	2	3	5	2	3	3	3							
Summary	29/12/95	99									99	2	3	5	2	3	3	3							
Detail	28/11/95(C)	0									0	1													
Summary	28/11/95(C)	0									0	1													
Detail	25/11/95(C)	0									0	2													
Summary	25/11/95(C)	0									0	2													
Detail	25/11/95(C)	0									0	1													
Summary	25/11/95(C)	0									0	1													
Detail	25/11/95(C)	0									0	3													
Summary	25/11/95(C)	0									0	3													

Severity: B=unknown, I=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=one change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: B=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present end date = visit date
(**) onset date missing: (3) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1995

PHARMACIA CNS RED
 REMOETINE - PROTOCOL 20124/035
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type	Onset date	Visit No	Last report visit	Save rfty	Hist ary	Rep app.	Dis app.	Re app.	Dut coma	Sym	Hesp	Trea	Drug	Dose	C											
																						Detail	Summary	Detail	Summary	Detail	Summary	Detail	Summary	Detail	Summary	Detail
46	IMD	Imipramine	28/09/93	28/11/93	CONSTIPATION	Detail	28/09/93(0)	0															NO									
						Summary	28/09/93(0)	0	2	2																						
						Detail	20/09/93(0)	0																								
						Summary	20/09/93(0)	0	2	2																						
						Detail	26/09/93(0)	0																								
						Summary	26/09/93(0)	0	3	3																						
						Detail	20/09/93(0)	0																								
						Summary	20/09/93(0)	0	2	2																						
						Detail	20/10/93	25	29/10/93																							
						Summary	20/10/93	25	29/10/93																							
						Detail	20/09/93(0)	0																								
						Summary	20/09/93(0)	0	2	2																						
2ND	Imipramine	19/10/93	08/11/93	AGITATION	Detail	12/10/93(0)	0																									
					Summary	12/10/93(0)	0	3	3																							
					Detail	12/10/93(0)	0																									
					Summary	12/10/93(0)	0	3	3																							
					Detail	12/10/93(0)	0																									
					Summary	12/10/93(0)	0	3	3																							
					Detail	12/10/93(0)	0																									
					Summary	12/10/93(0)	0	2	2																							
					Detail	12/10/93(0)	9																									
					Summary	12/10/93(0)	9	14	14																							

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe.
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date
 onset date missing: (0) first report visit date used (screen data - 1 day used for A.E. reported at day0), (1) onset date A.E.

9550089

144

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/055
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No data	Least report visit	Save Hist	Rat	Stud	Symp	Dis app.	Re app.	Out come (c)
46	2ND Imipramine					Detail	19/10/95									
						Summary	12/10/95(D)									
					HEADACHE	Detail	12/10/95(D)	0		1						NO
						Summary	12/10/95(D)			0	1					
					HYPERKINESIA	Detail	12/10/95(D)	0		2						NO
						Summary	12/10/95(D)			0	2					
					INSOMNIA	Detail	12/10/95(D)	0		3						NO
						Summary	12/10/95(D)			0	3					
					LIBIDO DECREASED	Detail	12/10/95(D)	0		3						NO
						Summary	12/10/95(D)			0	3					
					MOUTH DRY	Detail	12/10/95(D)	0		2						NO
						Summary	12/10/95(D)			0	2					
5ND	Reboxetine		02/12/95	27/01/96	AGITATION	Detail	26/11/95(D)	0		1						NO
						Summary	26/11/95(D)			0	1					
					ANOREXIA	Detail	26/11/95(D)	0		2						NO
						Summary	26/11/95(D)			0	2					
					CONSTIPATION	Detail	26/11/95(D)	0		1						NO
						Summary	26/11/95(D)			0	1					
					FATIGUE	Detail	26/11/95(D)	0		2						NO
						Summary	26/11/95(D)			0	2					
					INSOMNIA	Detail	26/11/95(D)	0		2						

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=Present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present; end date = visit date
onset date missing: (D) first report visit date used (screen date - 1 day used for A.E. reported at day0), (I) onset date A.E.

1997

PHARMACIA DNS RED
 REBOXETINE - PROTOCOL 20124/935
 Listing No.: 17.9

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Visit End date	Last report visit	Sev	Hist ary	Rel ship	Rai	Stud Sym	Dis app.	Re app.	Dut same (c)					
																		report visit	Sev	Hist ary	Rel ship	Rai
46	Riboxetine	02/12/93	27/01/94	[INSOMNIA]	Summary	26/11/93(D)	7	0	2	0	2	1	2	1	2	3	3	NO				
					Detail	05/12/93	14	3	1	2	1	2	3	3	3	1	2	3	3	1	NO	
					Summary	05/12/93	15	3	1	2	1	2	3	3	3	1	2	3	3	1	YES	
					Detail	26/11/93(D)	0	0	2													NO
					Summary	26/11/93(D)	0	0	2													NO
					Detail	26/11/93(D)	0	0	2													NO
					Summary	26/11/93(D)	0	0	2													NO
					Detail	02/12/93(D)	0	0	1													NO
					Summary	02/12/93(D)	0	0	1													NO
					Detail	02/12/93(D)	0	0	2													
40D	Riboxetine	09/12/93	11/12/93	[ABSTATION]	Summary	02/12/93(D)	7	0	1	0	1	1	2	1	1	3	3	NO				
					Detail	11/12/93	99	23	1	2	3	1	1	3	3	1	1	3	3	1	NO	
					Summary	11/12/93	23	1	2	3	1	1	3	3	1	1	3	3	1	3	YES	
					Detail	11/12/93	7	1	3	3	1	3	3	1	3	3	1	3	3	2	YES	
					Summary	11/12/93	11	1	3	3	1	3	3	1	3	3	1	3	3	2	YES	
					Detail	02/12/93(D)	0	0	2													NO
					Summary	02/12/93(D)	0	0	2													NO
					Detail	02/12/93(D)	0	0	1													NO
					Summary	02/12/93(D)	0	0	1													NO
					Detail	11/12/93	7	0	1													NO
				[CONFUSION]	Summary	02/12/93(D)	7	0	1	0	1	1	2	1	1	3	3	NO				
					Detail	11/12/93	99	23	1	2	3	1	1	3	3	1	1	3	3	1	NO	
					Summary	11/12/93	23	1	2	3	1	1	3	3	1	1	3	3	1	3	YES	
					Detail	11/12/93	7	1	3	3	1	3	3	1	3	3	1	3	3	2	YES	
					Summary	11/12/93	11	1	3	3	1	3	3	1	3	3	1	3	3	2	YES	
					Detail	02/12/93(D)	0	0	2													NO
					Summary	02/12/93(D)	0	0	2													NO
					Detail	11/12/93	7	0	1													NO
					Summary	11/12/93	11	1	3	3	1	3	3	1	3	3	1	3	3	2	YES	
					Detail	11/12/93	7	0	1													NO
				[FATIGUE]	Summary	02/12/93(D)	7	0	1	0	1	1	2	1	1	3	3	NO				
					Detail	11/12/93	99	23	1	2	3	1	1	3	3	1	1	3	3	1	NO	
					Summary	11/12/93	23	1	2	3	1	1	3	3	1	1	3	3	1	3	YES	
					Detail	11/12/93	7	1	3	3	1	3	3	1	3	3	1	3	3	2	YES	
					Summary	11/12/93	11	1	3	3	1	3	3	1	3	3	1	3	3	2	YES	
					Detail	02/12/93(D)	0	0	2													NO
					Summary	02/12/93(D)	0	0	2													NO
					Detail	11/12/93	7	0	1													NO
					Summary	11/12/93	11	1	3	3	1	3	3	1	3	3	1	3	3	2	YES	
					Detail	11/12/93	7	0	1													NO
				[FRACTURE]	Summary	11/12/93	7	0	1	0	1	1	2	1	1	3	3	NO				
					Detail	11/12/93	99	23	1	2	3	1	1	3	3	1	1	3	3	1	NO	
					Summary	11/12/93	23	1	2	3	1	1	3	3	1	1	3	3	1	3	YES	
					Detail	11/12/93	7	1	3	3	1	3	3	1	3	3	1	3	3	2	YES	
					Summary	11/12/93	11	1	3	3	1	3	3	1	3	3	1	3	3	2	YES	
					Detail	02/12/93(D)	0	0	2													NO
					Summary	02/12/93(D)	0	0	2													NO
					Detail	11/12/93	7	0	1													NO
					Summary	11/12/93	11	1	3	3	1	3	3	1	3	3	1	3	3	2	YES	
					Detail	11/12/93	7	0	1													NO

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (D) first report visit date used (screen date - 1 day used for A.E. reported at day0), (I) onset date A.E.

9550089

146

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report visit	Save rity	Hist ary	Re ship	Stud drug	Symm app.	Dis app.	Re Out	
																		1
46	490	Reboxetine	05/12/93	11/12/93	INSOMNIA	Detail	02/12/93(0)	0		0	3							NO
						Summary	02/12/93(0)	0		0	3							NO
						MOUTH DRY	Detail	02/12/93(0)	0		1							NO
							Summary	02/12/93(0)	0		1							NO
						PULMONARY CARCINOMA	Detail	05/12/93(0)	7	11/12/93(0)	7	2	3	6	3	1	3	3
							Summary	05/12/93(0)	7	11/12/93(0)	7	2	3	6	3	1	3	3
46	101	Reboxetine	24/06/93	24/06/93	AGITATION	Detail	24/06/93	7	24/06/93	7	3	2	4	3	YES	3	2	3
						Summary	24/06/93	7	24/06/93	7	3	2	4	3	YES	3	2	3
						ANOREXIA	Detail	15/06/93(0)	0		2							NO
							Summary	15/06/93(0)	0		2							NO
						DYSPEPSIA	Detail	24/06/93	7	24/06/93	7	2	2	4	3	YES	3	2
							Summary	24/06/93	7	24/06/93	7	2	2	4	3	YES	3	2
						FATIGUE	Detail	15/06/93(0)	0		1							NO
							Summary	15/06/93(0)	0		1							NO
						INSOMNIA	Detail	15/06/93(0)	0		2							NO
							Summary	15/06/93(0)	0		2							NO
						MYALGIA	Detail	15/06/93(0)	0		2							NO
							Summary	15/06/93(0)	0		2							NO
201		Imipramine	26/06/93	06/06/93	ANOREXIA	Detail	24/06/93(0)	0		2								NO
						Summary	24/06/93(0)	0		2								NO
						CONSTIPATION	Detail	24/06/93(0)	0		2							NO

Severity: 1=unknown, 1= mild, 2= moderate, 3= severe, 4= life threatening, 5= fatal
 Study drug: 1= no change, 2= dose reduced, 3= dose increased, 4= stopped, 5= unknown
 Hospital: 1= required, 2= not req., 3= not appl., 4= not reported
 Disapp./Respp.: 1= no, 2= yes, 3= not appl., 4= not reported
 Symptomatic treatment: 0= no, 1= yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

1999

9550089

147

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RD
REBOCETINE - PROTOCOL 20126/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Start date	End date	Adverse event	Type record	Onset date	Visit No	Visit End date	Last report visit	Sav	Hist rity	Rel ship	Rea drug	Stu	Sym	Dis Hosp	Re app.	Dut app.	Dis come	Re come	Dut come	NO	
																								Summary
46	2DT	Imipramine	25/06/93	04/08/93	CONSTIPATION	Summary	24/06/93(2)			0	2													
					DYSPHAGIA	Detail	28/06/93	7																
								14																
								21																
						Summary	28/06/93	28	19/07/93															
								13/07/93																
					FATIGUE	Detail	24/06/93(0)	0																
								28																
								35																
								42																
						Summary	24/06/93(0)		05/08/93(4)															
								42																
					HYPRAESTHESIA	Detail	01/08/93	42																
						Summary	01/08/93		05/08/93(4)															
								42																
					INSOMNIA	Detail	24/06/93(0)	0																
						Summary	24/06/93(0)																	
								0																
					MOUTH DRY	Detail	24/06/93(0)	0																
								14																
								21																
								28																
								35																
								42																
						Summary	24/06/93(0)		05/08/93(4)															
								42																
					PARAESTHESIA	Detail	12/07/93	28																
								35																
								42																
						Summary	12/07/93		05/08/93(4)															
								42																

Severity: 1=unknown, 2=mild, 3=moderate, 4=severe, 5=critical
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=cure, with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day), (1) onset date A.E.

2000

9550089

149

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBONETINE - PROTOCOL 20124/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	End date	Last report visit	Save rity	Hist ory	Rel ship	Stud drug	Symm app.	Dis Hosp	Re app.	Out come (c)				
																			1	2	3	4
291	30T	Imipramine	14/05/93	28/05/93	PRURITUS	Detail	15/05/93	7	22/05/93		2	2	2	3		2	2	3	1			
			Summary	15/05/93		7	2	2	2	3		2	2	3	1		2	2	3	1		
250T	Imipramine	04/11/93	30/12/93	FRACTURE PATHOLOGICAL	Detail	15/11/93	14				3	2	6	1		1	3	3	3			
					Summary	15/11/93		42	16/12/93		6	1		1	3	3	3		1	3	3	1
					Summary	15/11/93		42	16/12/93		6	1		1	3	3	3	1		1	3	3
250T	Imipramine	16/11/93	17/01/94	INSOMNIA	Detail	17/11/93(9)	0				3											
					Summary	17/11/93(9)		0	3													
292	54D	Imipramine	03/03/93	27/04/93	MOUTH DRY	Detail	03/03/93	7			1	2	1	1		3	3	3	3			
			Summary	03/03/93		14	11/03/93		1	2	1	1	3	3	3	1		3	3	3	1	
50T	Reboxetine	06/03/93	29/04/93	HEADACHE	Detail	03/03/93	7				1	2	1	1		3	3	3	1			
					Summary	03/03/93		7	06/03/93		1	2	1	1	3	3	3	1		3	3	3
50T	Reboxetine	06/03/93	29/04/93	HEADACHE	Detail	14/03/93	14				2	2	2	1		3	3	3	1			
					Summary	14/03/93		14	16/03/93		14	2	2	2	1	3	3	3	1		3	3
60T	Imipramine	16/02/93	16/05/93	MOUTH DRY	Detail	13/03/93	14				1	2	1	1		3	3	3	1			
					Summary	13/03/93		14	18/03/93		14	1	2	1	1	3	3	3	1		3	3
70D	Reboxetine	21/04/93	15/06/93	HEADACHE	Detail	16/02/93	7				1	2	1	1		3	3	3	1			
					Summary	16/02/93		7	22/03/93		7	1	2	1	1	3	3	3	1		3	3
70D	Reboxetine	21/04/93	15/06/93	HEADACHE	Detail	29/04/93	14				2	2	2	1		3	3	3	1			
					Summary	29/04/93		14	03/05/93		14	2	2	2	1	3	3	3	1		3	3

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=temp. inter. -- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day), (1) onset date A.E.

2002

9550089

152

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS PBD

REBOXETINE - PROTOCOL 20124/935
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment		Type	Onset date	Visit No	Visit End date	Last		Dis	Re	Out							
			Start date	End date					report visit	Sev rity										
292	24ND	Reboxetine	05/06/93	30/07/93	PHARYNGITIS	17/07/93	49	22/07/93	2	2	6	1	YES	2	3	3	1			
			Summary		17/07/93	49	2	2	6	1	YES	2	3	3	1	YES				
240T	Imipramine	02/06/93	27/07/93	NAUSEA	02/06/93	7	07/06/93	2	1	1	1	3	3	3	3	1	YES			
			Summary		02/06/93	7	2	1	1	1	3	3	3	1	YES					
293	12ND	Reboxetine	16/09/93	27/10/93	MICTURITION DISORDER	22/10/93	42	28/10/93	1	2	2	3	2	1	3	3	3			
			Summary		22/10/93	42	1	2	2	3	2	1	3	3	3					
294	13ND	Imipramine	16/02/93	12/04/93	ANOREXIA	16/02/93	0	16/02/93	1	1	1	1	1	1	1	1	1	NO		
			Summary		16/02/93	0	1	1	1	1	1	1	1	1	1	1	1	1	NO	
10ND	Reboxetine	15/02/93	12/04/93	ANOREXIA	07/03/93	21	08/03/93	3	3	6	1	3	3	3	3	3	3	1		
			Summary		07/03/93	21	3	3	6	1	3	3	3	3	3	3	3	3	1	
			14/02/93	ANOREXIA	14/02/93	0	2	2	2	2	2	2	2	2	2	2	2	2	2	NO
			Summary		14/02/93	0	2	2	2	2	2	2	2	2	2	2	2	2	2	2
19ND	Imipramine	22/02/93	19/04/93	ANOREXIA	05/05/93	21	07/05/93	1	3	3	1	3	3	3	3	3	3	1		
			Summary		05/05/93	21	1	3	3	1	3	3	3	3	3	3	3	3	1	
			20/05/93	HEADACHE	20/05/93	35	1	2	3	1	2	3	3	3	3	3	3	3	3	
			Summary		20/05/93	35	1	2	3	1	2	3	3	3	3	3	3	3	3	3
28ND	Imipramine	14/06/93	08/08/93	HEADACHE	28/03/93	42	25/03/93	1	2	3	1	2	3	3	3	3	3	1		
			Summary		28/03/93	42	1	2	3	1	2	3	3	3	3	3	3	3	1	
			21/02/93	ANOREXIA	21/02/93	0	1	1	1	1	1	1	1	1	1	1	1	1	1	NO
			Summary		21/02/93	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1
28ND	Imipramine	14/06/93	08/08/93	HEADACHE	04/07/93	21	05/07/93	2	2	3	1	2	3	3	3	3	3	1		
			Summary		04/07/93	21	2	2	3	1	2	3	3	3	3	3	3	3	1	

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe, 4= life threatening, 5= fatal
 Study drug: 1= no change, 2= dose reduced, 3= def. withdrawn, 4= temp. inter.
 Hospital: 1= required, 2= not req., 3= not appl. -- Outcome: 1= recovered, 2= free, 3= with seq., 4= still present, 5= death
 Disapp./Resp.: 1= no, 2= yes, 3= not appl. -- Relationship: 1= definite, 2= probable, 3= possible, 4= doubtful, 5= unknown, 6= none
 Symptomatic treatment: 0= no, 1= yes
 (C) adverse event used for statistical analysis
 (H) adverse event still present; end date = visit date
 onset date missing: (D) first report visit date used (screen date - 1 day used for A.E. reported at day0), (I) onset date A.E.

2005

9550089

155

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RBD

REBOXETINE - PROTOCOL 20124/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment		Type	Onset date	Visit No	Visit End No date	Last report	Save	Hist	Re	Stud	Svmp	Dis	Re	Out	
			Start date	End date														
361	1M0	Reboxetine	10/12/95	05/02/96	DIIZZINESS	56	05/02/96(*)	56	1	1	3	1	3	3	3	3	3	NO
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															
			Detail															
			Summary															

9550089

156

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient ID#	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	End date	Last report visit	Save	Hist	Rel	Stud Symp	Dis	Re	Out	ADVERSE EVENTS: DETAIL AND SUMMARY									
																			visit	code (C)								
381	2ND	Reboxetine	02/02/94	07/05/94	CONSTIPATION	Summary	31/01/94(C)	7	0	2	3	1	3	1	3	1	YES	2	3	3	NO							
						Detail	02/02/94	21	3	1	3	1	3	1	3	1	3	1	3	1	YES	3	3	3	3			
						Summary	02/02/94	35	3	1	3	1	3	1	3	1	3	1	3	1	YES	2	3	3	3	YES		
						Detail	16/02/94	14	3	2	4	1	3	2	4	1	3	2	4	1	YES	2	3	3	2	YES		
						Summary	16/02/94	22	3	2	4	1	3	2	4	1	3	2	4	1	YES	2	3	3	2	YES		
						Detail	06/02/94	7	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	3		
						Summary	06/02/94	35	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	3	YES	
						Detail	05/02/94	7	1	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	3	3	
						Summary	05/02/94	35	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	3	3	3
						Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	3	3	NO
Summary	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	3	3	NO						
307	Reboxetine	08/02/94	26/02/94	AGITATION	Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	3	3	3	3	3	NO						
					Summary	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
					Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
307	Reboxetine	08/02/94	26/02/94	AGITATION	Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	3	3	3	3	3	NO						
					Summary	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
					Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
307	Reboxetine	08/02/94	26/02/94	AGITATION	Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	3	3	3	3	3	NO						
					Summary	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
					Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
307	Reboxetine	08/02/94	26/02/94	AGITATION	Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	3	3	3	3	NO							
					Summary	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
					Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
307	Reboxetine	08/02/94	26/02/94	AGITATION	Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	3	3	3	3	NO							
					Summary	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
					Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
307	Reboxetine	08/02/94	26/02/94	AGITATION	Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	3	3	3	3	NO							
					Summary	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
					Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
307	Reboxetine	08/02/94	26/02/94	AGITATION	Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	3	3	3	3	NO							
					Summary	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
					Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
307	Reboxetine	08/02/94	26/02/94	AGITATION	Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	3	3	3	3	NO							
					Summary	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
					Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
307	Reboxetine	08/02/94	26/02/94	AGITATION	Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	3	3	3	3	NO							
					Summary	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
					Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
307	Reboxetine	08/02/94	26/02/94	AGITATION	Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	3	3	3	3	NO							
					Summary	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
					Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
307	Reboxetine	08/02/94	26/02/94	AGITATION	Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	3	3	3	3	NO							
					Summary	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
					Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
307	Reboxetine	08/02/94	26/02/94	AGITATION	Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	3	3	3	3	NO							
					Summary	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
					Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
307	Reboxetine	08/02/94	26/02/94	AGITATION	Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	3	3	3	3	NO							
					Summary	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
					Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
307	Reboxetine	08/02/94	26/02/94	AGITATION	Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	3	3	3	3	NO							
					Summary	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
					Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
307	Reboxetine	08/02/94	26/02/94	AGITATION	Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	3	3	3	3	NO							
					Summary	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
					Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
307	Reboxetine	08/02/94	26/02/94	AGITATION	Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	3	3	3	3	NO							
					Summary	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
					Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
307	Reboxetine	08/02/94	26/02/94	AGITATION	Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	3	3	3	3	NO							
					Summary	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
					Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
307	Reboxetine	08/02/94	26/02/94	AGITATION	Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	3	3	3	3	NO							
					Summary	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
					Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3	3	3	3	NO			
307	Reboxetine	08/02/94	26/02/94	AGITATION	Detail	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	3	3	3	3	NO							
					Summary	07/02/94(C)	0	2	2	3	1	3	2	3	1	3	2	3	1	3	3							

PHARMACIA CNS RBD
 REBOXATINE - PROTOCOL 20124/035
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient ID	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Last report visit	Sera	Hst	Rai	Stud	Symp	Dis app.	Re app.	Dut	Come (C)	
																				08/02/94
361	301	Reboxatine		08/02/94	25/02/94	FLUSHING	Summary	07/02/94(0)	0	2										
						HEADACHE	Detail	02/02/94(0)	0	2										
							Summary	02/02/94(0)	0	2										
							Detail	15/02/94	14	3	2	3	1	3	3	3	3	3	3	NO
							Summary	15/02/94	21	3	2	3	3	3	2	3	1	3	3	1
							Detail	01/03/94	01/03/94	21	3	2	3	3	3	2	3	3	3	1 YES
							Summary	07/02/94(0)	0	2										
						HYPERENSION POSTURAL	Detail	07/02/94(0)	0	2										
							Summary	07/02/94(0)	0	2										
						INFLUENZA-LIKE SYMPTOMS	Detail	09/02/94	7	14/02/94	3	4	1	2	3	3	1			
							Summary	09/02/94	14/02/94	7	3	4	1	2	3	3	1			
						INSOMNIA	Detail	07/02/94(0)	0	3										
							Summary	07/02/94(0)	0	3										
						MOUTH DRY	Detail	16/02/94	14	20/02/94	3	2	3	1	2	3	3	2		
							Summary	16/02/94	20/02/94	14	3	2	3	1	2	3	3	2		
						MYALGIA	Detail	07/02/94(0)	0	2										
							Summary	07/02/94(0)	0	2										
						PAIN	Detail	23/02/94	21	28/02/94	2	2	4	3	2	2	3	1		
							Summary	23/02/94	28/02/94	21	2	2	4	3	2	2	3	1		
						SCOTOMA	Detail	07/02/94(0)	0	2										
							Summary	07/02/94(0)	0	2										
						SWEATING INCREASED	Detail	07/02/94(0)	0	2										
							Summary	07/02/94(0)	0	2										

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawal, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=freq. with seq., 3=still present, 4=death
 Disapp./Ramp: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date a visit date
 onset date missing: (0) first report visit date used (screen data - 1 day used for A.E. reported at day0), (1) onset date A.E.

9550089

150

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA DAS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 17.9

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Visit End date	Last report visit	Save rcty	Hist ary	Rel drug	Stud treat	Syme app.	Dis	Re	Out					
																			Sev	Re	Out		
381	30T	Reboxetine	85/02/94	26/02/94	TREMOR	Detail	07/02/94(2)	0			0	2							NO				
						Summary	07/02/94(2)																
						Detail	07/02/94(2)	0			2												
						Summary	07/02/94(2)	21	21/02/94	18/02/94	2	2	4	1	2	4	1	2	3	3	1		
48D	Imipramine	01/03/94	14/03/94	DIARRHOEA	Detail	24/02/94(2)	0				1								NO				
					Summary	24/02/94(2)																	
					Detail	24/02/94(2)	0			1													
					Summary	24/02/94(2)	21	21/02/94	18/02/94	2	2	4	1	2	4	1	2	3	3	1			
382	58D	Imipramine	15/11/93	12/01/94	ANOREXIA	Detail	05/01/94	56	12/01/94		56	1	2	4	1	2	3	3	1	YES			
						Summary	05/01/94																
						Detail	10/12/93	42			1	2	3	1	3	3	3	3	3	3	3	3	3
						Summary	10/12/93	49	05/01/94(*)	49	1	2	3	1	3	3	3	3	3	3	3	3	3
					CONSTIPATION	Detail	10/11/93(2)	0			2												
						Summary	20/12/93																
						Detail	10/11/93(2)	42	23/12/93	23/12/93	1	1	4	1	2	3	1	2	3	3	1		
						Summary	20/12/93	49	23/12/93	23/12/93	42	2	1	4	1	2	3	3	3	3	1		
					COORDINATION ABNORMAL	Detail	10/12/93	42	29/12/93		42	1	2	3	1	3	3	3	1	YES			
						Summary	10/12/93	29/12/93	29/12/93	42	1	2	3	1	3	3	3	3	3	1			

Severity: 0=unknown, 1=ild, 2=moderate, 3=severe, 4=life threatening
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./sepp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
[C] adverse event used for statistical analysis
[*] adverse event still present: end date = visit date
onset date missing: (2) first report visit date used (screen date - 1 day used for A.E. reported at day0); (1) onset date A.E.

2011

9550089

159

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RSD

REBOXETINE - PROTOCOL 20124/155
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Start date	End date	Treatment	Adverse event	Type record	Onset date	Visit No	End No date	Last report visit	Saves	Hist	Rel	Stud	Sypm	Dis	Re	Out						
																				city	dry	ship	drug	area	Mosp
382	SND	Indipramine	15/11/93	12/01/94		DIARRHOEA	Detail	23/12/93	42	29/12/93	1	2	4	1	2	3	3	1							
							Summary	23/12/93	42	29/12/93	1	2	4	1	2	3	3	1							
							Detail	06/12/93	21	06/12/93	1	2	4	1	2	4	3	1							
							Summary	06/12/93	21	06/12/93	1	2	4	1	2	3	3	1							
							Detail	13/12/93	28	16/12/93	1	2	4	1	2	4	3	1							
							Summary	13/12/93	28	16/12/93	1	2	4	1	2	3	3	1							
							Detail	06/12/93	21	06/12/93	1	2	4	1	2	4	3	1							
							Summary	06/12/93	21	06/12/93	1	2	4	1	2	3	3	1							
							Detail	10/12/93	42	10/12/93	1	2	4	1	2	4	3	1							
							Summary	10/12/93	42	10/12/93	1	2	4	1	2	3	3	1							
							Detail	13/12/93	28	13/12/93	1	2	4	1	2	4	3	1							
							Summary	13/12/93	28	13/12/93	1	2	4	1	2	3	3	1							
5DT	Reboxetine		21/10/93	12/11/93		ASTHENIA	Detail	01/11/93	14	01/11/93	1	2	5	1	2	3	3								
							Summary	01/11/93	14	01/11/93	1	2	5	1	2	3	3								
							Detail	10/11/93(0)	0	10/11/93(0)	0	2													
							Summary	10/11/93(0)	0	10/11/93(0)	0	2													
							Detail	10/11/93(0)	0	10/11/93(0)	0	2													
							Summary	10/11/93(0)	0	10/11/93(0)	0	2													
							Detail	10/11/93(0)	0	10/11/93(0)	0	2													
							Summary	10/11/93(0)	0	10/11/93(0)	0	2													
							Detail	10/11/93(0)	0	10/11/93(0)	0	2													
							Summary	10/11/93(0)	0	10/11/93(0)	0	2													
							Detail	10/11/93(0)	0	10/11/93(0)	0	2													
							Summary	10/11/93(0)	0	10/11/93(0)	0	2													

2012

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=none change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

9550089

140

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/055
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	End date	Last report	Sav rity	Hist only	Rea only	Stud only	Sweep	Dis hosp	Re app.	Dut app.	Come (c)		
																					visit	only
362	50T	Reboxetine	21/10/95	12/11/95	ASTHENIA	Summary	01/11/95	05/11/95(4)	14	1	2	3	1	2	3	1	2	3	3	3	YES	
					ATAXIA	Detail	01/11/95	14		1	2	3	1	2	3	1	2	3	3	3	3	
						Summary	01/11/95	05/11/95(4)	14	1	2	3	1	2	3	1	2	3	3	3	3	YES
					DIZZINESS	Detail	01/11/95	14		1	2	3	1	2	3	1	2	3	3	3	3	
						Summary	01/11/95	05/11/95(4)	14	1	2	3	1	2	3	1	2	3	3	3	3	YES
					DYSPOEIA	Detail	19/10/95(0)	0		1												NO
						Summary	19/10/95(0)	0	1													NO
					FATIGUE	Detail	19/10/95(0)	0		1												NO
						Summary	01/11/95	14		1	2	3	1	2	3	1	2	3	3	3	3	NO
						Summary	19/10/95(0)	05/11/95(4)	14	1	2	3	1	2	3	1	2	3	3	3	3	NO
					HEADACHE	Detail	19/10/95(0)	0		1												NO
						Summary	19/10/95(0)	0	1													NO
					HYPERKINESIA	Detail	19/10/95(0)	0		1												NO
						Summary	19/10/95(0)	0	1													NO
					INSOMNIA	Detail	19/10/95(0)	0		1												NO
						Summary	19/10/95(0)	0	1													NO
					SWEATING INCREASED	Detail	19/10/95(0)	0		1												NO
						Summary	19/10/95(0)	0	1													NO
					TREMOR	Detail	19/10/95(0)	0		2												NO
						Summary	19/10/95(0)	0	2													NO
69D	Reboxetine	12/11/95	07/01/96	AGITATION	Detail	26/11/95	21/03/12/95		2	1	3			2	3	3	1					

Severicy: 0=unknown, 1=mild, 2=moderate, 3=severe,
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=free. with seq., 3=skill present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present; end date = visit date
(*) onset date missing: (0) first report visit date used (screen date = 1 day use for A.E. reported at day0), (1) onset date A.E.

2013

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

101

9550089

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 17.9

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre Patient Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Visit End No date	Last report visit	Save city	Hst Sym	Rel drug	Stud app.	Dis app.	Re app.	Out come (c)	
																	12/11/95
382	6HD	Reboxetine	12/11/95	07/01/96	ARBITRATION	Summary	28/11/93	05/12/93	21	2	1	3	2	3	3	1 YES	
				ANXIETY	Detail	20/11/93	14			3	1	3	1	2	3	3	
					Summary	20/11/93	56	07/01/94(*)	56	3	1	3	1	2	3	3	YES
				BACK PAIN	Detail	11/01/95	56	14/01/94	3	1	4	1	YES	3	3	3	1
					Summary	11/01/95	14/01/94	56	3	1	4	1	YES	3	3	3	1 NO
				CONSTIPATION	Detail	10/12/93	35	17/12/93	3	1	3	1	3	3	3	3	1
					Summary	10/12/93	17/12/93	35	3	1	3	1	3	3	3	3	1 YES
					Detail	15/12/93	56		3	1	3	1	3	3	3	3	3
					Summary	15/12/93	07/01/94(*)	56	3	1	3	1	3	3	3	3	3 YES
				DIZZINESS	Detail	11/11/93(*)	0			1							NO
					Summary	11/11/93(*)	0		0					3	3	3	3
					Detail	02/12/93	28		3	2	3	1	3	3	3	3	3
					Summary	02/12/93	35		3	2	3	1	3	3	3	3	3
					Detail	07/01/94	56	07/01/94	56	3	2	3	1	3	3	3	3
					Summary	07/01/94	07/01/94	56	3	2	3	1	3	3	3	3	3 YES
				FATIGUE	Detail	26/11/93	21	30/12/93	1	1	3	4	1	2	3	3	1
					Summary	26/11/93	30/12/93	21	1	3	4	1	2	3	3	3	1 YES
				HEADACHE	Detail	11/11/93(*)	0			2				3	3	3	1
					Summary	11/11/93(*)	0		1	1	3	1	3	3	3	3	1 NO
					Detail	11/11/93(*)	0			2				3	3	3	1
					Summary	11/11/93(*)	0		1	1	3	1	3	3	3	3	1 NO
					Detail	05/12/93	21	05/12/93	2	1	3	1	3	2	3	3	1
					Summary	05/12/93	35	16/12/93	2	1	3	1	3	2	3	3	1
					Detail	16/12/93	35	16/12/93	2	2	3	1	3	3	3	3	1
					Summary	16/12/93	35	16/12/93	35	2	3	1	3	3	3	3	1 YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe.
 Study drug: 1=as change, 2=once reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=free, 3=with seq., 4=still present, 5=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (*) adverse event used for statistical analysis
 (c) adverse event still present; end date = visit date
 onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day), (1) onset date A.E.

2014

9550089

152

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CIS RBD
 REMOETINE - PROTOCOL 20124/035
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report visit	Sev	Hist	Rel	Stud	Sym	Dis	Re	Dut							
302	4ND	Rabovatine	12/11/93	07/01/94	MALAISE	Detail	02/12/93	42		3	2	3	1	3	3	3	3	3	3						
						Summary	02/12/93	49	31/12/93(*)	49	3	2	3	1	3	3	3	3	3	3	3	3	3		
						Detail	06/01/94	56	06/01/94		2	2	4	1	3	3	3	1	3	3	3	3	3	1	
						Summary	06/01/94	56	06/01/94		2	2	4	1	3	3	3	1	3	3	3	3	3	1	
						Detail	11/11/93(*)	0			1														
						Summary	11/11/93(*)	0			1														
						Detail	11/11/93(*)	0			3														
						Summary	11/11/93(*)	0			3														
						Detail	12/11/93	7	19/11/93		1	2	5	1	3	3	3	1	3	3	3	3	3	1	
						Summary	12/11/93	7	19/11/93		1	2	5	1	3	3	3	1	3	3	3	3	3	1	
60T	Imopramine	22/10/93	17/12/93	CHEST PAIN PRECORDIAL	Detail	20/11/93	14	25/11/93		1	1	4	1	3	3	3	3	3	1						
					Summary	20/11/93	14	25/11/93		1	1	4	1	3	3	3	3	3	3	3	1				
60T	Imopramine	22/10/93	17/12/93	CHEST PAIN PRECORDIAL	Detail	06/01/94	56	06/01/94		2	2	4	1	3	3	3	3	3	1						
					Summary	06/01/94	56	06/01/94		2	2	4	1	3	3	3	3	3	3	3	1				
60T	Imopramine	22/10/93	17/12/93	CHEST PAIN PRECORDIAL	Detail	11/11/93(*)	0			1															
					Summary	11/11/93(*)	0			1															
60T	Imopramine	22/10/93	17/12/93	CHEST PAIN PRECORDIAL	Detail	01/01/94	56	01/01/94		3	2	3	1	3	3	3	3	3	1						
					Summary	01/01/94	56	01/01/94		3	2	3	1	3	3	3	3	3	3	3	1				
60T	Imopramine	22/10/93	17/12/93	CHEST PAIN PRECORDIAL	Detail	21/10/93	0			1															
					Summary	21/10/93	0			1															
60T	Imopramine	22/10/93	17/12/93	CHEST PAIN PRECORDIAL	Detail	07/12/93	49	10/12/93(*)		1	2	5	1	2	3	3	3	3	3						
					Summary	07/12/93	49	10/12/93(*)		1	2	5	1	2	3	3	3	3	3	3	3				

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe,
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=free. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (*) adverse event used for statistical analysis
 (c) adverse event still present: end date = visit date
 onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day), (1) onset date A.E.

2015

9550089

163

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 RESNETINE - PROTOCOL 20124/035
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Visit End No data	Last report visit	Save	Hist	Rel	Stud	Sym	Dis	Re	Out
302	6DT	Imipramine	22/10/93	17/12/93	DIZZINESS	Detail	12/12/93	56	1	2	4	1	3	3	3	3	3	3	3
						Summary	12/12/93	56	1	2	4	1	3	3	3	3	3	3	3
						FATIGUE	Detail	01/11/93	14	2	3	1	3	3	3	3	3	3	3
							Detail	01/11/93	42	1	3	1	2	3	3	3	3	3	3
							Summary	01/11/93	56	2	3	1	2	3	3	3	3	3	3
						HEADACHE	Detail	21/10/93	0	1									
							Summary	21/10/93	0	1									
						INSOMNIA	Detail	21/10/93	0	1									
							Summary	21/10/93	0	1									
						MOUTH DRY	Detail	21/10/93	0	1									
							Summary	21/10/93	0	1									
						NYALGIA	Detail	21/10/93	0	1									
							Summary	21/10/93	0	1									
						SOMNOLENCE	Detail	29/10/93	7	1	2	2	1	3	3	3	3	3	3
							Summary	29/10/93	56	1	2	2	1	3	3	3	3	3	3
						SWEATING INCREASED	Detail	01/11/93	14	3	2	3	1	3	3	3	3	3	3
							Detail	01/11/93	21	3	2	2	1	3	3	3	3	3	3
							Detail	01/11/93	28	1	3	1	2	3	3	3	3	3	3
							Detail	01/11/93	56	1	2	3	1	2	3	3	3	3	3
							Summary	01/11/93	56	3	2	2	1	2	3	3	3	3	3
						VISION ABNORMAL	Detail	01/11/93	14	2	1	3	1	2	3	3	3	3	3
							Detail	01/11/93	21	3	1	3	1	2	3	3	3	3	3

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (3) first report visit date used (screen data - 1 day used for A.E. reported at day0), (1) onset date A.E.

2016

9550089

144

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS R&D

REBOXETINE - PROTOCOL 20124/935
Listing No.: 17.9

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	Visit End date	List report	Save	Hist	Rel	Stud	Symp	Dis	Re	Dut	Hop	App.	App.	Come	C						
																									visit rity	ery	shlp	dwg	tres	app.
362	60T	Imipramine	22/10/93	17/12/93	VISION ABNORMAL		Detail	01/11/93	28			1	3	1	2	3	3	3												
							Summary																							
							Detail	01/11/93	28			1	3	1	2	3	3													
							Summary																							
7ND	Reboxetine	20/12/93	07/02/94	DIZZINESS			Detail	30/12/93	14			14																		
							Summary																							
							Detail	30/12/93	14			1	2	4	1	3	3	3												
							Summary																							
7DT	Imipramine	22/10/93	26/10/93	AMBLYOPIA			Detail	21/10/93	0			2																		
							Summary																							
							Detail	26/10/93	7			5	2	1	3	2	2	3												
							Summary																							

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=fatal
Study drug: 1=as change, 2=dose reduced, 3=def. withdraw, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=free, 3=with seq., 4=still present, 5=death
Disapp./Maapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present; end date = visit date
onset date missing: (D) first report visit date used (screen date - 1 day used for A.E. reported at day0), (L) onset date A.E.

2017

9550089

115

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA DAS RED

REBOCETINE - PROTOCOL 20124/035
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient ID#	Drug	Treatment		Type record	Onset date	Visit End No data	Last report visit	Save Hist	Rel Ship	Stud Sym	Dis app.	Re app.	Dut						
			Start date	End date																
362	7DT	Imipramine	22/10/93	26/10/93	CONSTIPATION	Detail	21/10/93(0)	0	2						NO					
						Summary	21/10/93(0)		0	2										
						Detail	26/10/93	7	29/10/93(4)	7	3	2	1	3	2	2	3	1		
						Summary	26/10/93		29/10/93(4)		7	3	2	1	3	2	2	3	1	
						Detail	26/10/93	7	27/10/93	7	3	2	1	3	2	2	2	3	1	
						Summary	26/10/93		27/10/93		7	3	2	1	3	2	2	2	3	1
						Detail	21/10/93(0)	0			1									
						Summary	21/10/93(0)				1									
						Detail	26/10/93	7	27/10/93	7	3	2	2	3	2	2	2	3	1	
						Summary	26/10/93		27/10/93		7	3	2	2	3	2	2	3	1	
						Detail	21/10/93(0)	0			2									
						Summary	21/10/93(0)				2									
8ND	Imipramine		11/02/94	11/02/94	CONFUSION	Detail	23/01/94(0)	0	3						NO					
						Summary	23/01/94(0)		0	3										
						Detail	23/01/94(0)	0			2									
						Summary	23/01/94(0)				2									
						Detail	11/02/94	21	12/02/94	1	2	3	3	1	2	3	1			

2018

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=fatal
Study drug: 1=no change, 2=dose reduced, 3=dose increased, 4=withdrawn, 5=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl.
Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
Symptomatic treatment: 0=no, 1=yes
(*) adverse event used for statistical analysis
(**) adverse event still present; end date = visit date
onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day), (1) onset date A.E.

9550089

167

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 REDOXETINE - PROTOCOL 20124/935
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient ID	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report visit	Save rity	Hist any drug	Rea Hosp	Stud app.	Symp app.	Dis app.	Re come	Out							
																			Detail	Summary	Detail	Summary	Detail	Summary	Detail
302	JDT	Reboxetine	22/12/93	15/02/94	HEADACHE	Detail	21/12/93(O)	0	2	0	2								NO						
						Summary	21/12/93(O)	0	2																
						Detail	21/12/93(O)	0	3															NO	
						Summary	21/12/93(O)	0	3																
						Detail	01/02/94	42	20/02/94	3														YES	
						Summary	01/02/94	42	20/02/94	3															
						Detail	21/12/93(O)	0	3															NO	
						Summary	21/12/93(O)	0	3																
						Detail	05/01/94	21	18/01/94	1	4	1													3
						Summary	05/01/94	21	18/01/94	1	4	1													3
						Detail	31/01/94	42	15/01/94	2	1	3	1	YES											3
						Summary	31/01/94	56	16/02/94(*)	56	2	1	3	1	YES										3
9ND	Reboxetine	11/02/94	08/04/94	ANOREXIA	Detail	09/02/94	49	09/02/94(*)	49	1	2	2	1						3						
					Summary	09/02/94	49	09/02/94(*)	49	1	2	2	1								3				
					Detail	10/02/94(O)	0	3															NO		
					Summary	10/02/94(O)	0	3																	
					Detail	16/02/94	7	20/02/94	1	2	3	1											3		
					Summary	16/02/94	20/02/94	7	1	2	3	1											3		
					Detail	10/02/94(O)	0	2																NO	
					Summary	10/02/94(O)	0	2																	

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe,
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (*) adverse event used for statistical analysis
 (C) adverse event still present; end date = visit date
 (**) onset date missin; (O) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

2020

9550089

166

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/935
Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit No	End date	Last report visit	Save	Hist	Rel	Stud	Symp	Dis app.	Re app.	Out				
																				visit	rity	ory	ship
362	9MD	Reboxetine	11/02/94	08/04/94	INSOMNIA	Detail		10/02/94(1)	0			0	2							NO			
						Summary		10/02/94(1)															
					MOUTH DRY	Detail		16/02/94	7	23/02/94		3	2	3	1					3	3	1	
						Summary		16/02/94		23/02/94													
9DT		Reboxetine	08/02/94	01/03/94	COUGHING	Detail		19/02/94	21	22/02/94		1	2	6	1	YES				3	3	3	1
						Summary		19/02/94		22/02/94													
					CYSTITIS	Detail		12/02/94	7	22/02/94		2	2	4	1	YES				3	3	3	1
						Summary		12/02/94		22/02/94													
					DIARRHOEA	Detail		05/02/94(1)	0			0	3										
						Summary		05/02/94(1)															
					FATIGUE	Detail		05/02/94(1)	0			0	2										
						Summary		05/02/94(1)															
					INFLUENZA-LIKE SYMPTOMS	Detail		09/02/94	7	12/02/94		1	2	4	1					3	3	3	1
						Summary		09/02/94		12/02/94													
					INSOMNIA	Detail		24/12/93(1)	0			3											
						Summary		24/12/93		14													
					MOUTH DRY	Detail		05/02/94(1)	0			0	2										
						Summary		05/02/94(1)															
					NYALGIA	Detail		05/02/94(1)	0			0	2										
						Summary		05/02/94(1)															

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=fatal
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=free. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (1) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

2021

9550089

169

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA DAS RED
 REDOMETINE - PROTOCOL 2014/035
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment		Type	Onset	Visit	Last	Dis	Re	Out																					
			Start	End								report	Save	Hist	Rel	Stud	Symp															
		Adverse event		record	date	No	date	visit	rity	ory	ship	drug	tra	Hesp	app.	ame	(c)															
362	9DT	Reboxetine	05/02/94	09/03/94	PNEUMONIA	13/02/94	7	21/02/94	1	6	1	YES	3	3	3	1																
			Summary		13/02/94	21/02/94	7	1	6	1	YES	3	3	3	1	YES																
			10MD	Imipramine	11/02/94	16/02/94	AGITATION	10/02/94(0)	0		3									NO												
					Summary		10/02/94(0)		0	3											NO											
							CONSTIPATION	10/02/94(0)	10/02/94(0)	0	2		2									NO										
								Summary		10/02/94(0)		0	2											NO								
										DIZZINESS	16/02/94	19/02/94	16/02/94	7	19/02/94	3	2	2	3	1	2	3	3	5								
											Summary		16/02/94	19/02/94	7	3	2	2	3	1	2	3	5	YES								
													DYSPNOEA	10/02/94(0)	10/02/94(0)	0	2		2									NO				
														Summary		10/02/94(0)		0	2											NO		
																FATIGUE	10/02/94(0)	10/02/94(0)	0	2		2									NO	
																	Summary		10/02/94(0)		0	2										
		HEADACHE															10/02/94(0)	10/02/94(0)	0	3		3									NO	
																	Summary		10/02/94(0)		0	3										
																	HYPERKINESIA	10/02/94(0)	10/02/94(0)	0	3		3									NO
																		Summary		10/02/94(0)		0	3									
							INSOMNIA											10/02/94(0)	10/02/94(0)	0	2		2									NO
																		Summary		10/02/94(0)		0	2									
										MALaise								16/02/94	19/02/94	16/02/94	7	19/02/94	3	2	2	3	1	2	3	1		
																		Summary		16/02/94	19/02/94	7	3	2	2	3	1	2	3	1	YES	

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=stem. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

2022

9550089

178

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA DNS RBD
 REDOMETINE - PROTOCOL 20124/055
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment		Type record	Onset date	Visit No	End date	Last report visit	Save	Hist	Re	Stud	Sym	Dis	Re	Out																										
			Start date	End date																																							
302	190	Isipramine	11/02/94	16/02/94	MOUTH DRY	Detail	10/02/94(0)	0	0	2								NO																									
						Summary	10/02/94(0)			0	2																																
								Detail	10/02/94(0)	0	0	2									NO																						
								Summary	10/02/94(0)			0	2																														
								Detail	10/02/94(0)	0	0	2										NO																					
								Summary	10/02/94(0)			0	2																														
								Detail	10/02/94(0)	0	0	2										NO																					
								Summary	10/02/94(0)			0	2																														
								Detail	15/02/94	7	18/02/94(*)	7	2	2	2	2	2	2	2	2	2	3	3																				
								Summary	15/02/94			7	2	2	2	2	2	2	2	2	2	3	3																				
								Detail	18/02/94(0)	0	0	2											NO																				
								Summary	18/02/94(0)			0	2																														
501	190	Rebaratine	26/09/92	26/09/92	CONSTIPATION	Detail	15/09/92(0)	0	0	2									NO																								
						Summary	15/09/92(0)			0	2																																
								Detail	15/09/92(0)	0	0	1									NO																						
								Summary	15/09/92(0)			0	1																														
								Detail	15/09/92(0)	0	0	1										NO																					
								Summary	15/09/92(0)			0	1																														
								Detail	01/01/93	0	0	2										NO																					
								Summary	01/01/93			2																															
								Detail	10/02/94(0)	0	0	2											NO																				
								Summary	10/02/94(0)			0	2																														
								Detail	10/02/94(0)	0	0	2											NO																				
								Summary	10/02/94(0)			0	2																														
280	Isipramine																																										

2023

Severity: 0=unknown, 1=ild, 2=moderate, 3=severe,
 Study drug: 1=ne change, 2=dose reduced, 3=def. withdrawn, 4=tem. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (*) adverse event used for statistical analysis
 (**) adverse event still present; end date = visit date
 onset date missing: (0) first report visit date used (screen data - 1 day used for A.E. reported at day0), (1) onset date A.E.

9550089

171

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CIS R&D
 REMOXTINE - PROTOCOL 20124/835
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment	Start date	End date	Adverse event	Type record	Onset date	Visit End No date	Last report visit	Hist ary ship	Rel Stud Sym	Dis Hosp	Re app.	Sev. (c)					
																Summary	Detail	Summary	Detail	Summary
3301	2ND	Imipramine	09/03/93	09/03/93	CONSTIPATION	Summary	01/01/93(2)	0	2							NO				
						Detail	01/01/93(2)	0	1								NO			
						Summary	01/01/93(2)	0	1									NO		
						Detail	15/01/93	7	1	2	1	1	3	3	3	3	3	3	3	3
3ND	Remoxetine	16/02/93	16/02/93	ASTHMA	Summary	29/01/93	21	06/02/93	21	2	1	6	1	3	3	1	YES			
					Detail	29/01/93	06/02/93	21	2	1	6	1	3	3	3	3	3	3		
					Summary	29/01/93	06/02/93	21	2	1	6	1	3	3	3	3	3	3		
					Detail	06/01/93(2)	0	2												NO
3ND	Remoxetine	11/02/93	11/02/93	DEPRESSION AGGRAVATED	Summary	11/02/93	35	19/02/93(*)	35	3	3	3	3	3	3	3	YES			
					Detail	11/02/93	19/02/93(*)	35	3	3	3	3	3	3	3	3	3			
					Summary	11/02/93	19/02/93(*)	35	3	3	3	3	3	3	3	3	3			
					Detail	06/01/93(2)	0	2												NO
3ND	Remoxetine	08/01/93	08/01/93	PAIN	Summary	08/01/93(2)	0	2									NO			
					Detail	08/01/93(2)	0	2											NO	
					Summary	08/01/93(2)	0	2												NO
					Detail	29/10/92(2)	3	2												NO
3ND	Remoxetine	27/11/92	27/11/92	ANDREXIA	Summary	25/11/92	21	27/11/92(*)	21	3	1	6	3	3	1	3	YES			
					Detail	25/11/92	27/11/92(*)	21	3	1	6	3	3	3	3	3	3			
					Summary	25/11/92	27/11/92(*)	21	3	1	6	3	3	3	3	3	3			
					Detail	29/10/92(2)	3	2												NO
3ND	Remoxetine	27/11/92	27/11/92	ANDREXIA	Summary	29/10/92(2)	3	2									NO			
					Detail	29/10/92(2)	3	2											NO	
					Summary	29/10/92(2)	3	2											NO	
					Detail	29/10/92(2)	3	2												NO

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date
 onset date missing: (2) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

2024

9550089

172

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment		Type record	Onset date	Visit No	End date	Last report visit	Swp	Re Out	Dis app.	Re app.	Swp	Sympt				
			Start date	End date															
3492	59D	Reboxetine	07/11/92	27/11/92	MOUTH DRY	25/10/92(D)	0		0	2						NO			
			Summary																
			URINARY RETENTION																
			Detail 25/10/92(D) 0 2																
			Summary 25/10/92(D) 0 2																
			Detail 22/06/93(D) 0 2																
69D	Imipramine	16/07/93	16/07/93	HEADACHE	22/06/93(D)	0			0	2						NO			
					Summary														
					MOUTH DRY														
					Detail 22/06/93(D) 0 2														
					Summary 22/06/93(D) 0 2														
					Detail 11/07/93 21														
79D	Imipramine	13/11/93	08/01/94	BRONCHITIS	11/07/93	21		17/07/93(P)	21	2	4	3	5	1	3	3			
					Summary														
					TACHYCARDIA														
					Detail 22/06/93(D) 0 2														
					Summary 22/06/93(D) 0 2														
					Detail 12/01/94 99														
79D	Imipramine	13/11/93	08/01/94	BRONCHITIS	12/01/94	99		20/01/94	99	2	6	1	3	3	4				
					Summary														
					CONSTIPATION														
					Detail 09/11/93(D) 0 2														
					Summary 09/11/93(D) 0 2														
					Detail 09/11/93(D) 0 2														
79D	Imipramine	13/11/93	08/01/94	BRONCHITIS	09/11/93(D)	0			0	2						NO			
					Summary														
					FATIGUE														
					Detail 09/11/93(D) 0 2														
					Summary 09/11/93(D) 0 2														
					Detail 06/01/94 56														
79D	Imipramine	13/11/93	08/01/94	BRONCHITIS	06/01/94	56		13/01/94(P)	56	2	4	1	3	3	3				
					Summary														
					BRADYCARDIA														
					Detail 06/01/94 56														
					Summary 06/01/94 56														
					Detail 06/01/94 56														

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=stop, 4=withdrawn, 5=interim
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (P) adverse event still present; end date = visit date
 onset date missing: (D) first report visit date used (screen date - 1 day used for A.E. reported at day0), (I) onset date A.E.

2025

9550089

173

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA OCS R&D
 REMOETINE - PROTOCOL 20124/935
 Listing No.: 17.0

ADVERSE EVENTS: DETAIL AND SUMMARY

Centre	Patient	Drug	Treatment		Type	Onset	Visit	End	Last	Dis	Re	Out
			Start	End								
			date	date	record	date	No	date	visit	re	Out	come (c)
3302	7ND	Imipramine	13/11/93	08/01/94	PNEUMONIA	Details	15/01/94	99	20/01/94	3	3	4
					Summary	15/01/94		20/01/94	99	3		4 YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe.
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawal, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present; end date a visit date
 onset date missing: (0) first report visit date used (screen date - 1 day used for A.E. reported at day0), (1) onset date A.E.

2026

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS 590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 1 Patient: 1MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			30/10/92		02/12/92		30/12/92	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	115-165 (G/L)	01/01/92	137.00		138.00		142.00	
HT	0.37-0.47 (L/L)	01/01/92	0.41		0.41		0.42	
RBC	3.6-5.4 (10 ¹² /L)	01/01/92	4.50		4.50		4.60	
WBC	4-11 (10 ⁹ /L)	01/01/92	7.30		6.70		6.00	
WBC: N	2-7.5 (10 ⁹ /L)	01/01/92	3.80		4.20		3.20	
WBC: L	1-3.5 (10 ⁹ /L)	01/01/92	3.00		2.10		2.40	
WBC: E	0-0.4 (10 ⁹ /L)	01/01/92	0.07		0.07		0.18	
WBC: M	0-0.8 (10 ⁹ /L)	01/01/92	0.40		0.30		0.20	
WBC: B	0-0.1 (10 ⁹ /L)	01/01/92	0.00		0.00		0.00	
PLATELETS	150-400 (10 ⁹ /L)	01/01/92	235.00		276.00		228.00	
NA+	133-146 (MMOL/L)	01/01/92	142.00		139.00		140.00	
K+	3.5-5.2 (MMOL/L)	01/01/92	4.30		5.10		5.30 >	
Ca++	2.1-2.7 (MMOL/L)	01/01/92	2.30		2.40		2.30	
PO4--	0.8-1.5 (MMOL/L)	01/01/92	1.10		1.30		1.20	
SGOT	9-32 (U/L)	01/01/92	18.00		21.00		21.00	
SGPT	0-45 (U/L)	01/01/92	16.00		16.00		16.00	
GAMMA GT	7-32 (U/L)	01/01/92	11.00		13.00		11.00	
ALK. PHOSPH.	45-130 (U/L)	01/01/92	58.00		67.00		75.00	
GLUCOSE	3.3-7.8 (MMOL/L)	01/01/92	5.10		5.70		4.90	
UREA	2.5-7 (MMOL/L)	01/01/92	7.00		6.40		5.60	
CREATININE	0.04-0.14 (MMOL/L)	01/01/92	0.09		0.09		0.09	
CREATININE CLEARANCE	90-150 (ML/MIN)	01/01/92	71.70					
URIC ACID	0.12-0.37 (MMOL/L)	01/01/92			0.32		0.29	
TOT BILIRUBIN	3-20 (UMOL/L)	01/01/92	11.00		4.00		5.00	
TOT. PROTEINS	63-83 (G/L)	01/01/92	73.00		73.00		75.00	
ALBUMINE	35-50 (G/L)	01/01/92	43.00		41.00		42.00	
TOT. CHOLEST.	0-5.5 (MMOL/L)	01/01/92	4.60		5.10		5.00	
TRIGLYCERIDES	0.2-2.2 (MMOL/L)	01/01/92	1.70		3.40 >>		2.10	
TSH	0.2-5 (MU/L)	01/01/92	1.10					
T4	14-38 (PMOL/L)	01/01/92	28.00					

2027

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CN9590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 1 Patient: 2ND Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			04/11/92		14/12/92		11/01/93	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	130-180 (G/L)	01/01/92	151.00		164.00		157.00	
HT	0.4-0.54 (L/L)	01/01/92	0.44		0.49		0.47	
RBC	4.6-6.2 (10 ¹² /L)	01/01/92	4.40	<	5.10		4.90	
WBC	4-11 (10 ⁹ /L)	01/01/92	8.40		9.20		9.20	
WBC: N	2-7.5 (10 ⁹ /L)	01/01/92	5.50		5.10		4.90	
WBC: L	1-3.5 (10 ⁹ /L)	01/01/92	2.40		2.90		3.20	
WBC: E	0-0.4 (10 ⁹ /L)	01/01/92	0.08		0.18		0.46 >	
WBC: M	0-0.8 (10 ⁹ /L)	01/01/92	0.30		1.00	>	0.60	
WBC: B	0-0.1 (10 ⁹ /L)	01/01/92	0.17	>>	0.00		0.00	
PLATELETS	150-400 (10 ⁹ /L)	01/01/92	273.00		290.00		300.00	
NA+	133-146 (MMOL/L)	01/01/92	142.00		138.00		138.00	
K+	3.5-5.2 (MMOL/L)	01/01/92	4.30		4.80		4.50	
Ca++	2.1-2.7 (MMOL/L)	01/01/92	2.30		2.30		2.20	
PO4--	0.8-1.5 (MMOL/L)	01/01/92	0.90		1.10		1.10	
SGOT	11-50 (U/L)	01/01/92	25.00		20.00		20.00	
SGPT	0-45 (U/L)	01/01/92	22.00		16.00		20.00	
GAMMA GT	11-50 (U/L)	01/01/92	72.00	>	30.00		26.00	
ALK. PHOSPH.	45-130 (U/L)	01/01/92	89.00		127.00		134.00 >	
GLUCOSE	3.3-7.8 (MMOL/L)	01/01/92	5.00		4.40		4.10	
UREA	2.5-7 (MMOL/L)	01/01/92	3.90		4.90		4.60	
CREATININE	0.04-0.14 (MMOL/L)	01/01/92	0.08		0.09		0.12	
CREATININE CLEARANCE	90-150 (ML/MIN)	01/01/92	82.90					
URIC ACID	0.15-0.41 (MMOL/L)	01/01/92	0.39		0.42 >		0.42 >	
TOT BILIRUBIN	3-20 (UMOL/L)	01/01/92	9.00		5.00		6.00	
TOT. PROTEINS	63-83 (G/L)	01/01/92	70.00		77.00		75.00	
ALBUMINE	35-50 (G/L)	01/01/92	38.00		42.00		40.00	
TOT. CHOLEST.	0-5.5 (MMOL/L)	01/01/92	3.90		6.80 >		6.60 >	
TRIGLYCERIDES	0.3-2.2 (MMOL/L)	01/01/92	1.80		2.70 >		2.30 >	
TSH	0.2-5 (MU/L)	01/01/92	1.40					
T4	14-38 (PMOL/L)	01/01/92	24.00					

2028

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C 580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 1 Patient: 3MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			26/05/93		30/06/93		28/07/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	115-165 (G/L)	01/01/92	139.00		144.00		145.00	
HT	0.37-0.47 (L/L)	01/01/92	0.42		0.42		0.43	
RBC	3.6-5.4 (10 ¹² /L)	01/01/92	4.70		4.80		4.90	
WBC	4-11 (10 ⁹ /L)	01/01/92	6.40		7.70		7.60	
WBC: N	2-7.5 (10 ⁹ /L)	01/01/92	3.90		5.40		4.20	
WBC: L	1-3.5 (10 ⁹ /L)	01/01/92	2.00		1.70		2.30	
WBC: E	0-0.4 (10 ⁹ /L)	01/01/92			0.42	>	0.53 >>	
WBC: M	0-0.8 (10 ⁹ /L)	01/01/92			0.20		0.30	
WBC: B	0-0.1 (10 ⁹ /L)	01/01/92			0.00		0.23 >>	
PLATELETS	150-400 (10 ⁹ /L)	01/01/92			343.00		363.00	
NA+	133-146 (MMOL/L)	01/01/92	140.00		141.00		142.00	
K+	3.5-5.2 (MMOL/L)	01/01/92	4.30		4.10		4.60	
Ca ⁺⁺	2.1-2.7 (MMOL/L)	01/01/92	2.20		2.10		2.20	
PO4 ⁻⁻	0.8-1.5 (MMOL/L)	01/01/92	1.10		1.00		1.20	
SGOT	9-32 (U/L)	01/01/92	14.00		20.00		35.00 >	
SGPT	0-45 (U/L)	01/01/92	16.00		23.00		61.00 >	
GAMMA GT	7-32 (U/L)	01/01/92	13.00		16.00		30.00	
ALK. PHOSPH.	45-130 (U/L)	01/01/92	93.00		118.00		138.00 >	
GLUCOSE	3.3-7.8 (MMOL/L)	01/01/92	6.30		5.70		6.10	
UREA	2.5-7 (MMOL/L)	01/01/92	5.60				6.00	
CREATININE	0.04-0.14 (MMOL/L)	01/01/92	0.10		0.09		0.09	
CREATININE CLEARANCE	90-150 (ML/MIN)	01/01/92	66.20					
URIC ACID	0.12-0.37 (MMOL/L)	01/01/92	0.11	<	0.33		0.38 >	
TOT. BILIRUBIN	3-20 (UMOL/L)	01/01/92	7.00		6.00		6.00	
TOT. PROTEINS	63-83 (G/L)	01/01/92	73.00		75.00		75.00	
ALBUMINE	35-50 (G/L)	01/01/92	43.00		42.00		47.00	
TOT. CHOLEST.	0-5.5 (MMOL/L)	01/01/92	4.90		5.70	>	6.30 >	
TRIGLYCERIDES	0.2-2.2 (MMOL/L)	01/01/92	1.20		1.30		2.20	
TSH	0.2-5 (MU/L)	01/01/92	2.50					
T4	14-38 (PMOL/L)	01/01/92	18.00					

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

2029

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN 530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 1 Patient: 4ND Treatment: Reboxetine Sex: Female

			Visit number / Laboratory data							
			Screen		Day 21		Day 56		Day 28	
			18/10/93		05/11/93		13/12/93		17/11/93	
			value	(φ)	value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date								
HB	115-165 (G/L)	01/01/92	128.00		128.00		140.00			
HT	0.37-0.47 (L/L)	01/01/92	0.38		0.39		0.41			
RBC	3.6-5.4 (10 ¹² /L)	01/01/92	4.60		4.60		4.90			
WBC	4-11 (10 ⁹ /L)	01/01/92	5.10		5.40		5.90			
WBC: N	2-7.5 (10 ⁹ /L)	01/01/92	3.60		3.70		3.50			
WBC: L	1-3.5 (10 ⁹ /L)	01/01/92	1.20		1.40		2.00			
WBC: E	0-0.4 (10 ⁹ /L)	01/01/92	0.03		0.05		0.00			
WBC: M	0-0.8 (10 ⁹ /L)	01/01/92	0.20		0.20		0.40			
WBC: B	0-0.1 (10 ⁹ /L)	01/01/92	0.00		0.00		0.00			
PLATELETS	150-400 (10 ⁹ /L)	01/01/92	317.00		333.00		420.00 >			
NA+	133-146 (MMOL/L)	01/01/92	137.00				139.00		135.00	
K+	3.5-5.2 (MMOL/L)	01/01/92	4.00				4.20		4.30	
Ca++	2.1-2.7 (MMOL/L)	01/01/92	2.30				2.20		2.20	
PO4--	0.8-1.5 (MMOL/L)	01/01/92	1.20				1.10		1.20	
SGOT	9-32 (U/L)	01/01/92	17.00				19.00		12.00	
SGPT	0-45 (U/L)	01/01/92	15.00							
GAMMA GT	7-32 (U/L)	01/01/92	8.00				9.00		10.00	
ALK. PHOSPH.	45-130 (U/L)	01/01/92	106.00				124.00		110.00	
GLUCOSE	3.3-7.8 (MMOL/L)	01/01/92					4.60		4.10	
UREA	2.5-7 (MMOL/L)	01/01/92	7.40 >				5.00		6.50	
CREATININE	0.04-0.14 (MMOL/L)	01/01/92	0.09				0.07		0.08	
CREATININE CLEARANCE			71.80							
URIC ACID	0.12-0.37 (MMOL/L)	01/01/92	0.21				0.17		0.19	
TOT BILIRUBIN	3-20 (UMOL/L)	01/01/92	6.00				10.00		8.00	
TOT. PROTEINS	63-83 (G/L)	01/01/92	70.00				80.00		71.00	
ALBUMINE	35-50 (G/L)	01/01/92	40.00				45.00		41.00	
TOT. CHOLEST.	0-5.5 (MMOL/L)	01/01/92	5.80 >				6.30 >		6.40 >	
TRIGLYCERIDES	0.2-2.2 (MMOL/L)	01/01/92	1.90				1.90		1.90	
TSH	0.2-5 (MU/L)	01/01/92	1.90							
T4	14-38 (PMOL/L)	01/01/92	20.00							

2030

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C0560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 1 Patient: 1DT Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			19/11/93		23/12/93		20/01/94	
			value	(e)	value	(e)	value	(e)
Laboratory test	Range value	Range date						
HB	130-180 (G/L)	01/01/92	140.00		147.00		139.00	
HT	0.4-0.54 (L/L)	01/01/92	0.42		0.44		0.43	
RBC	4.6-6.2 (10 ¹² /L)	01/01/92	4.20	<	4.40	<	4.20	
WBC	4-11 (10 ⁹ /L)	01/01/92	5.20		5.30		6.50	
WBC: N	2-7.5 (10 ⁹ /L)	01/01/92	3.50		3.90		4.70	
WBC: L	1-3.5 (10 ⁹ /L)	01/01/92	1.50		1.00		1.40	
WBC: E	0-0.4 (10 ⁹ /L)	01/01/92			0.11		0.07	
WBC: M	0-0.8 (10 ⁹ /L)	01/01/92			0.30		0.30	
WBC: B	0-0.1 (10 ⁹ /L)	01/01/92			0.00		0.07	
PLATELETS	150-400 (10 ⁹ /L)	01/01/92	211.00		235.00		219.00	
NA+	133-146 (MMOL/L)	01/01/92	140.00		141.00		138.00	
K+	3.5-5.2 (MMOL/L)	01/01/92	4.50		3.90		4.20	
Ca++	2.1-2.7 (MMOL/L)	01/01/92	2.10		2.20		2.20	
PO4--	0.8-1.5 (MMOL/L)	01/01/92	1.00		1.00		1.00	
SGOT	11-50 (U/L)	01/01/92	17.00		15.00		14.00	
SGPT	0-45 (U/L)	01/01/92			7.00			
GAMMA GT	11-50 (U/L)	01/01/92	16.00		20.00		20.00	
ALK. PHOSPH.	45-130 (U/L)	01/01/92	109.00		112.00		110.00	
GLUCOSE	3.9-7.8 (MMOL/L)	01/01/92	5.20		9.20	>	5.70	
UREA	2.5-7 (MMOL/L)	01/01/92	4.80		4.80		5.00	
CREATININE	0.04-0.14 (MMOL/L)	01/01/92	0.10		0.10		0.09	
CREATININE CLEARANCE	90-150 (ML/MIN)	01/01/92						
URIC ACID	0.15-0.41 (MMOL/L)	01/01/92	147.70					
TOT BILIRUBIN	0.15-0.41 (MMOL/L)	01/01/92	0.21		0.20		0.17	
TOT. PROTEINS	3-20 (UMOL/L)	01/01/92	9.00		9.00		5.00	
ALBUMINE	63-83 (G/L)	01/01/92	72.00		77.00		70.00	
TOT. CHOLEST.	35-50 (G/L)	01/01/92	44.00		47.00		41.00	
TRIGLYCERIDES	0-5.5 (MMOL/L)	01/01/92	6.80	>	6.90	>	6.70	
TSH	0.3-2.2 (MMOL/L)	01/01/92	1.00		1.10		1.20	
T4	0.2-5 (MU/L)	01/01/92	0.80					
	14-38 (PMOL/L)	01/01/92	15.00					

2031

(e) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C8580089

REROXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 1 Patient: 2DT Treatment: Imipramine Sex: Male

			Visit number / Laboratory data
			Screen
			06/12/93
			value (c)
Laboratory test	Range value	Range date	
HB	130-180 (G/L)	01/01/92	172.00
HT	0.4-0.54 (L/L)	01/01/92	0.50
RBC	4.6-6.2 (10 ¹² /L)	01/01/92	5.60
WBC	4-11 (10 ⁹ /L)	01/01/92	6.90
WBC: N	2-7.5 (10 ⁹ /L)	01/01/92	4.70
WBC: L	1-3.5 (10 ⁹ /L)	01/01/92	1.70
WBC: E	0-0.4 (10 ⁹ /L)	01/01/92	0.07
WBC: M	0-0.8 (10 ⁹ /L)	01/01/92	0.40
WBC: B	0-0.1 (10 ⁹ /L)	01/01/92	0.00
PLATELETS	150-400 (10 ⁹ /L)	01/01/92	193.00
NA+	133-146 (MMOL/L)	01/01/92	141.00
K+	3.5-5.2 (MMOL/L)	01/01/92	4.40
Ca++	2.1-2.7 (MMOL/L)	01/01/92	2.20
PO4--	0.8-1.5 (MMOL/L)	01/01/92	1.00
SGOT	11-50 (U/L)	01/01/92	24.00
GAMMA GT	11-50 (U/L)	01/01/92	19.00
ALK. PHOSPH.	45-130 (U/L)	01/01/92	140.00 >
GLUCOSE	3.3-7.8 (MMOL/L)	01/01/92	7.30
UREA	2.5-7 (MMOL/L)	01/01/92	7.30 >
CREATININE	0.04-0.14 (MMOL/L)	01/01/92	0.09
CREATININE CLEARANCE	90-150 (ML/MIN)	01/01/92	77.55
URIC ACID	0.15-0.41 (MMOL/L)	01/01/92	0.16
TOT BILIRUBIN	3-20 (UMOL/L)	01/01/92	8.00
TOT. PROTEINS	63-83 (G/L)	01/01/92	74.00
ALBUMINE	35-50 (G/L)	01/01/92	46.00
TOT. CHOLEST.	0-5.5 (MMOL/L)	01/01/92	3.90
TRIGLYCERIDES	0.3-2.2 (MMOL/L)	01/01/92	1.20
TSH	0.2-5 (MU/L)	01/01/92	1.70
T4	14-38 (PMOL/L)	01/01/92	22.00

2032

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C0550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 1 Patient: 3DT Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			08/12/93		07/01/94		03/02/94	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	130-180 (G/L)	01/01/92	167.00		127.00 <	144.00		
HT	0.4-0.54 (L/L)	01/01/92	0.50		0.38 <	0.44		
RBC	4.6-6.2 (10 ¹² /L)	01/01/92	5.90		4.30 <	5.00		
WBC	4-11 (10 ⁹ /L)	01/01/92	8.20		6.90	5.70		
WBC: N	2-7.5 (10 ⁹ /L)	01/01/92	6.50		4.90	3.40		
WBC: L	1-3.5 (10 ⁹ /L)	01/01/92	1.30		1.10	1.60		
WBC: E	0-0.4 (10 ⁹ /L)	01/01/92				0.23		
WBC: M	0-0.8 (10 ⁹ /L)	01/01/92				0.50		
WBC: B	0-0.1 (10 ⁹ /L)	01/01/92				0.00		
PLATELETS	150-400 (10 ⁹ /L)	01/01/92	361.00		316.00	295.00		
NA+	133-146 (MMOL/L)	01/01/92	140.00		140.00	140.00		
K+	3.5-5.2 (MMOL/L)	01/01/92	4.30		4.30	4.30		
Ca++	2.1-2.7 (MMOL/L)	01/01/92	2.30		2.20	2.20		
PO4--	0.8-1.5 (MMOL/L)	01/01/92	1.00		1.10	1.10		
SGOT	11-50 (U/L)	01/01/92	19.00		11.00	11.00		
GAMMA GT	11-50 (U/L)	01/01/92	16.00		13.00	13.00		
ALK. PHOSPH.	45-130 (U/L)	01/01/92	132.00 >		112.00	112.00		
GLUCOSE	3.3-7.8 (MMOL/L)	01/01/92	7.30		7.50	7.50		
UREA	2.5-7 (MMOL/L)	01/01/92	3.70		5.50	5.50		
CREATININE	0.04-0.14 (MMOL/L)	01/01/92	0.09		0.08	0.08		
CREATININE CLEARANCE	90-150 (ML/MIN)	01/01/92	88.40					
URIC ACID	0.15-0.41 (MMOL/L)	01/01/92			0.23	0.23		
TOT. BILIRUBIN	3-20 (UMOL/L)	01/01/92	11.00		11.00	11.00		
TOT. PROTEINS	63-83 (G/L)	01/01/92	76.00		66.00	66.00		
ALBUMINE	35-50 (G/L)	01/01/92	47.00		40.00	40.00		
TOT. CHOLEST.	0-5.5 (MMOL/L)	01/01/92	5.10		4.80	5.10		
TRIGLYCERIDES	0.3-2.2 (MMOL/L)	01/01/92	1.70		1.70	1.80		
TSH	0.2-5 (MU/L)	01/01/92	1.30					
T4	14-38 (PMOL/L)	01/01/92	24.00					

2033

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C9590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 1 Patient: 40T Treatment: Imipramine Sex: Male

			Visit number / Laboratory date			
			Screen		Day 28	
			31/01/94		24/02/94	
			value	(€)	value	(€)
Laboratory test	Range value	Range date				
HB	130-180 (G/L)	01/01/92	130.00		130.00	
HT	0.4-0.54 (L/L)	01/01/92	0.39	<	0.39	<
RBC	4.6-6.2 (10 ¹² /L)	01/01/92	4.30	<	4.30	<
MBC	4-11 (10 ⁹ /L)	01/01/92	6.70		6.70	
MBC: N	2-7.5 (10 ⁹ /L)	01/01/92	5.20		5.20	
MBC: L	1-3.5 (10 ⁹ /L)	01/01/92	1.20		1.20	
PLATELETS	150-400 (10 ⁹ /L)	01/01/92	308.00		335.00	
NA+	133-146 (MMOL/L)	01/01/92	135.00		131.00	<
K+	3.5-5.2 (MMOL/L)	01/01/92	4.30		4.70	
Ca++	2.1-2.7 (MMOL/L)	01/01/92	2.00	<	2.10	
PO4--	0.8-1.5 (MMOL/L)	01/01/92	1.00		0.90	
SGOT	11-50 (U/L)	01/01/92	13.00		21.00	
GAMMA GT	11-50 (U/L)	01/01/92	21.00			
LDH	90-180 (U/L)	01/01/92			174.00	
ALK. PHOSPH.	45-130 (U/L)	01/01/92	81.00			
UREA	2.5-7 (MMOL/L)	01/01/92	8.10	>	6.60	
CREATININE	0.04-0.14 (MMOL/L)	01/01/92	0.12		0.12	
CREATININE CLEARANCE			83.20			
URIC ACID	0.15-0.41 (MMOL/L)	01/01/92	0.31			
TOT BILIRUBIN	3-20 (UMOL/L)	01/01/92	4.00			
TOT. PROTEINS	63-83 (G/L)	01/01/92	70.00			
ALBUMINE	35-50 (G/L)	01/01/92	43.00			
TOT. CHOLEST.	0-5.5 (MMOL/L)	01/01/92	5.40			
TRIGLYCERIDES	0.3-2.2 (MMOL/L)	01/01/92	1.20			
TSH	0.2-5 (MU/L)	01/01/92	2.30			
T4	14-38 (PMOL/L)	01/01/92	19.00			

2034

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN 580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 2 Patient: 1MD Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date			
			Screen		Day 28	
			11/01/93		12/02/93	
			value	(€)	value	(€)
Laboratory test	Range value	Range date				
HB	130-180 (G/L)	01/01/92	179.00		181.00	>
HT	0.4-0.54 (L/L)	01/01/92	0.50		0.51	
RBC	4.6-6.2 (10 ¹² /L)	01/01/92	5.30		5.40	
NBC	4-11 (10 ⁹ /L)	01/01/92	8.20		10.00	
NBC: N	2-7.5 (10 ⁹ /L)	01/01/92	5.10		5.80	
NBC: L	1-3.5 (10 ⁹ /L)	01/01/92	2.10		3.30	
NBC: E	0-0.4 (10 ⁹ /L)	01/01/92	0.00		0.00	
NBC: M	0-0.8 (10 ⁹ /L)	01/01/92	1.10	>>	0.90	>
NBC: B	0-0.1 (10 ⁹ /L)	01/01/92	0.00		0.00	
PLATELETS	150-400 (10 ⁹ /L)	01/01/92	251.00		268.00	
NA+	133-146 (MMOL/L)	01/01/92	135.00		134.00	
K+	3.5-5.2 (MMOL/L)	01/01/92	4.40		3.40	<
Ca++	2.1-2.7 (MMOL/L)	01/01/92	2.30		2.40	
PO4--	0.8-1.5 (MMOL/L)	01/01/92	1.20		1.40	
SGOT	11-50 (U/L)	01/01/92	29.00		25.00	
SGPT	0-45 (U/L)	01/01/92	29.00		35.00	
GAMMA GT	11-50 (U/L)	01/01/92	93.00	>	93.00	>
ALK. PHOSPH.	45-130 (U/L)	01/01/92	53.00		66.00	
GLUCOSE	3.3-7.8 (MMOL/L)	01/01/92	5.30		5.20	
UREA	2.5-7 (MMOL/L)	01/01/92	5.80		6.70	
CREATININE	0.04-0.14 (MMOL/L)	01/01/92	0.08		0.09	
CREATININE CLEARANCE	90-150 (ML/MIN)	01/01/92	82.90			
URIC ACID	0.15-0.41 (MMOL/L)	01/01/92	0.27		0.32	
TOT BILIRUBIN	3-20 (UMOL/L)	01/01/92	19.00		13.00	
TOT. PROTEINS	63-83 (G/L)	01/01/92	82.00		87.00	>
ALBUMINE	35-50 (G/L)	01/01/92	41.00		43.00	
TOT. CHOLEST.	0-5.5 (MMOL/L)	01/01/92	5.20		4.80	
TRIGLYCERIDES	0.3-2.2 (MMOL/L)	01/01/92	1.90		2.30	>
TSH	0.2-5 (MU/L)	01/01/92	2.70			
T4	14-38 (PMOL/L)	01/01/92	26.00			

2035

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C959089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 3 Patient: 1ND Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 49	
			27/04/93		03/06/93		23/06/93	
			value	(ø)	value	(ø)	value	(ø)
Laboratory test	Range value	Range date						
HB	115-165 (G/L)	01/01/90	127.00		131.00		136.00	
HT	0.37-0.47 (L/L)	01/01/90	0.39		0.39		0.41	
RBC	3.8-5.8 (10 ¹² /L)	01/01/90	4.53		4.80		5.02	
WBC	4-11 (10 ⁹ /L)	01/01/90	4.60		3.80 <		5.70	
WBC: N	2-7.5 (10 ⁹ /L)	01/01/90	2.62		1.82 <		3.31	
WBC: L	1.5-4 (10 ⁹ /L)	01/01/90	1.52		1.41 <		1.77	
WBC: E	0.04-0.4 (10 ⁹ /L)	01/01/90	0.18		0.11		0.17	
WBC: M	0.2-0.8 (10 ⁹ /L)	01/01/90	0.23		0.34		0.46	
WBC: B	0-0.1 (10 ⁹ /L)	01/01/90	0.05		0.04		0.06	
PLATELETS	150-500 (10 ⁹ /L)	01/01/90	224.00		221.00		257.00	
NA+	134-145 (MMOL/L)	01/01/90	138.00		130.00 <		132.00 <	
K+	3.7-4.9 (MMOL/L)	01/01/90	4.50		5.00 >		4.30	
CL-	100-107 (MMOL/L)	01/01/90	100.00		94.00 <		98.00 <	
Ca++	2.24-2.65 (MMOL/L)	01/01/90	2.56		2.58		2.55	
PO4--	0.6-1.3 (MMOL/L)	01/01/90	1.18		1.31 >		1.21	
SGOT	5-55 (U/L)	01/01/90	17.00		21.00		21.00	
SGPT	5-55 (U/L)	01/01/90	11.00		19.00		14.00	
GAMMA GT	0-40 (U/L)	01/01/90	14.00		8.00		11.00	
ALK. PHOSPH.	0-145 (U/L)	01/01/90	111.00		108.00		110.00	
GLUCOSE	3.6-6.6 (MMOL/L)	01/01/90	5.90		5.80		7.80 >	
UREA	3-8 (MMOL/L)	01/01/90	5.80		2.90 <		3.10	
CREATININE	55-120 (UMOL/L)	01/01/90	88.00		72.00		91.00	
URIC ACID	0.18-0.38 (MMOL/L)	01/01/90	0.19		0.12 <		0.13 <	
TOT. BILIRUBIN	0-18 (UMOL/L)	01/01/90	6.00		9.00		9.00	
TOT. PROTEINS	61-84 (G/L)	01/01/90	66.00		65.00		70.00	
ALBUMINE	40-52 (G/L)	01/01/90	46.00		45.00		47.00	
TOT. CHOLEST.	0-5.2 (MMOL/L)	01/01/90	5.50 >		5.20		5.40 >	
TRIGLYCERIDES	0-2 (MMOL/L)	01/01/90	0.50		0.50		0.80	
TSH	0.5-4 (MU/L)	01/01/90	0.31					
T4	8-16 (PMOL/L)	01/01/90	13.90					
ESR/SEDIMENT. RATE 1st h	0-7 (MM)	01/01/90	12.00					

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

(ø) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C0560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 4 Patient: 1ND Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 35	
			20/11/92		22/12/92		29/12/92	
			value	(⊕)	value	(⊕)	value	(⊕)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	01/01/90	14.70		14.00		12.20 <	
HT	42-52 (%)	01/01/90	42.30		41.20 <		36.20 <	
RBC	4.5-6.5 (10 ⁶ /UL)	01/01/90	4.36 <		4.26 <		3.75 <<	
WBC	4-11 (10 ³ /UL)	01/01/90	4.50		4.60		6.30	
WBC: N	2-7.5 (10 ³ /UL)	01/01/90	3.20		3.00		4.34	
WBC: L	1.5-4 (10 ³ /UL)	01/01/90	0.80 <<		1.10 <		1.03 <<	
WBC: E	0-0.4 (10 ³ /UL)	01/01/90	0.03		0.06		0.16	
WBC: M	0.2-0.8 (10 ³ /UL)	01/01/90	0.50		0.50		0.76	
WBC: B	0-0.1 (10 ³ /UL)	01/01/90	0.01		0.01		0.01	
PLATELETS	150-450 (10 ³ /UL)	01/01/90	171.00		186.00		164.00	
NA+	133-145 (MMOL/L)	01/01/90	141.00		138.00		137.00	
K+	3.5-5 (MMOL/L)	01/01/90	4.90		4.40		4.20	
CL-	99-108 (MMOL/L)	01/01/90	107.00		107.00		103.00	
Ca ⁺⁺	2.05-2.55 (MMOL/L)	01/01/90	2.21		2.17		2.06	
PO4 ⁻⁻	0.8-1.55 (MMOL/L)	01/01/90	0.78 <		1.14		1.28	
SGOT	5-40 (U/L)	01/01/90	16.00		15.00		85.00 >>	
SGPT	5-40 (U/L)	01/01/90	12.00		11.00		96.00 >>	
GAMMA GT	5-65 (U/L)	01/01/90	14.00		14.00		75.00 >	
LDH	100-190 (U/L)	01/01/90	204.00 >		175.00		240.00 >	
ALK. PHOSPH.	20-95 (U/L)	01/01/90	59.00		61.00		137.00 >	
GLUCOSE	3.5-8 (MMOL/L)	01/01/90	6.00		5.00		6.00	
UREA	2-7 (MMOL/L)	01/01/90	6.20		4.40		7.10 >	
CREATININE	0.05-0.11 (MMOL/L)	01/01/90	0.12 >		0.11		0.12 >	
CREATININE CLEARANCE	1-1.8 (ML/SEC)	01/01/90	0.80					
URIC ACID	0.21-0.45 (MMOL/L)	01/01/90	0.28		0.25		0.24	
TOT BILIRUBIN	5-17 (MMOL/L)	01/01/90	14.00		13.00		18.00 >	
DIR BILIRUBIN	0-8 (MMOL/L)	01/01/90	7.00		7.00		10.00 >	
TOT. PROTEINS	60-80 (G/L)	01/01/90	63.00		62.00		60.00	
ALBUMINE	40-55 (G/L)	01/01/90	45.00		43.00		39.00 <	
TOT. CHOLEST.	0-5.5 (MMOL/L)	01/01/90	5.06		4.39		3.59	
TRIGLYCERIDES	0.6-2 (MMOL/L)	01/01/90	1.42		1.38		0.90	
GLOBULINS ALPHA 1	1.5-3 (G/L)	01/01/90	2.48		1.89		4.54 >>	
GLOBULINS ALPHA 2	3.5-6.9 (G/L)	01/01/90	4.62		4.13		8.99 >>	
GLOBULINS BETA	6-11.6 (G/L)	01/01/90	7.10		6.08		9.23	
GLOBULINS GAMMA	6.6-14.1 (G/L)	01/01/90	8.58		7.49		9.56	
TSH	0.3-2.5 (UU/ML)	01/01/90	0.70					
T4	60-144 (NMOL/L)	01/01/90	111.00					

2037

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CN 580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 5 Patient: 1MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	
			23/10/92	
			value	(c)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	01/10/92	14.60	
HT	36-46 (%)	01/10/92	43.30	
RBC	4.2-5.4 (10 ⁶ /MM ³)	01/10/92	4.53	
WBC	4.5-11 (10 ³ /MM ³)	01/10/92	15.10	>>
WBC: N	40-74 (%)	01/10/92	33.10	<
WBC: L	19-48 (%)	01/10/92	61.10	>
WBC: E	0-7 (%)	01/10/92	0.91	
WBC: M	3.5-9 (%)	01/10/92	4.92	
WBC: B	0-1.5 (%)	01/10/92	0.01	
PLATELETS	130-400 (10 ³ /MM ³)	01/10/92	171.00	
NA+	135-145 (MMOL/L)	01/10/92	142.00	
K+	3.6-4.8 (MMOL/L)	01/10/92	3.57	<
CL-	98-108 (MMOL/L)	01/10/92	102.00	
Ca ⁺⁺	8.5-10.5 (MG/DL)	01/10/92	9.41	
PO ₄ ⁻⁻	2.7-4.5 (MG/DL)	01/10/92	3.05	
SGOT	0-31 (U/L)	01/10/92	11.00	
SGPT	0-31 (U/L)	01/10/92	21.00	
GAMMA GT	7-32 (U/L)	01/10/92	26.00	
LDH	230-460 (U/L)	01/10/92	407.00	
ALK. PHOSPH.	42-98 (U/L)	01/10/92	79.00	
GLUCOSE	0.6-1 (G/L)	01/10/92	1.46	>>
UREA	0.18-0.43 (G/L)	01/10/92	0.31	
CREATININE	0.7-1.3 (MG/DL)	01/10/92	0.88	
CREATININE CLEARANCE	90-139 (ML/MIN)	01/10/92	49.53	
URIC ACID	2.4-5.7 (MG/DL)	01/10/92	4.10	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/10/92	0.83	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/10/92	0.28	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/10/92	6.70	
ALBUMINE	52-68 (%)	01/10/92	57.00	
TOT. CHOLEST.	155-280 (MG/DL)	01/10/92	199.00	
TRIGLYCERIDES	60-241 (MG/DL)	01/10/92	135.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/10/92	3.10	
GLOBULINS ALPHA 2	6.2-11 (%)	01/10/92	11.00	
GLOBULINS BETA	10.5-15 (%)	01/10/92	13.50	
GLOBULINS GAMMA	12-21 (%)	01/10/92	15.40	
TSH	0.1-5 (UU/ML)	01/10/92	0.45	
T4	4.5-13 (UG/DL)	01/10/92	6.80	
ESR/SEDIMENT. RATE 1st h	3-12 (MM)	01/10/92	4.00	
ESR/SEDIMENT. RATE 2nd h	8-24 (MM)	01/10/92	9.00	

2038

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C9580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 5 Patient: 2ND Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			16/11/92		21/12/92		18/01/93	
			value	(e)	value	(e)	value	(e)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	01/10/92	13.40	<	14.80		16.00	
HT	41-53 (%)	01/10/92	40.00	<	41.50		46.30	
RBC	4.7-6.1 (10 ⁶ /MM ³)	01/10/92	4.11	<	4.37	<	4.92	
WBC	4.5-11 (10 ³ /MM ³)	01/10/92	6.76		8.15		10.60	
WBC: N	40-74 (%)	01/10/92	64.50		63.70		60.80	
WBC: L	19-48 (%)	01/10/92	24.50		23.60		24.10	
WBC: E	0-7 (%)	01/10/92	1.38		0.91		0.82	
WBC: M	3.5-9 (%)	01/10/92	9.13	>	11.10	>	12.70 >>	
WBC: B	0-1.5 (%)	01/10/92	0.52		0.70		1.64 >	
PLATELETS	130-400 (10 ³ /MM ³)	01/10/92	236.00		299.00		345.00	
NA+	135-145 (MMOL/L)	01/10/92	147.00	>	140.00			
K+	3.6-4.8 (MMOL/L)	01/10/92	3.81		4.09			
CL-	98-108 (MMOL/L)	01/10/92	107.00		96.00	<		
Ca++	8.5-10.5 (MG/DL)	01/10/92	9.31		9.33			
PO4--	2.7-4.5 (MG/DL)	01/10/92	2.96		3.10			
SGOT	0-37 (U/L)	01/10/92	18.00		25.00			
SGPT	0-40 (U/L)	01/10/92	19.00		31.00			
GAMMA GT	11-49 (U/L)	01/10/92	53.00	>	38.00			
LDH	230-460 (U/L)	01/10/92	364.00		382.00			
ALK. PHOSPH.	53-128 (U/L)	01/10/92	84.00		90.00			
GLUCOSE	0.6-1 (G/L)	01/10/92	1.13	>	1.44	>>		
UREA	0.18-0.43 (G/L)	01/10/92	0.51	>	0.49	>		
CREATININE	0.7-1.3 (MG/DL)	01/10/92	1.45	>	1.45	>		
CREATININE CLEARANCE	80-125 (ML/MIN)	01/10/92	48.45					
URIC ACID	3.4-7.3 (MG/DL)	01/10/92	7.30		8.70	>		
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/10/92	0.29		0.55			
DIR BILIRUBIN	0-0.36 (MG/DL)	01/10/92	0.08		0.09			
TOT. PROTEINS	6.7-7.9 (G/DL)	01/10/92	6.50	<	7.30			
ALBUMINE	52-68 (%)	01/10/92	58.10		53.80			
TOT. CHOLEST.	155-280 (MG/DL)	01/10/92	288.00	>	284.00	>		
TRIGLYCERIDES	60-241 (MG/DL)	01/10/92	443.00	>>	308.00	>>		
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/10/92	3.50		2.30	<		
GLOBULINS ALPHA 2	6.2-11 (%)	01/10/92	10.20		10.30			
GLOBULINS BETA	10.5-15 (%)	01/10/92	15.30	>	18.30	>		
GLOBULINS GAMMA	12-21 (%)	01/10/92	12.90		15.30			
TSH	0.1-5 (UU/ML)	01/10/92	0.92					
T4	4.5-13 (UG/DL)	01/10/92	6.80					
ESR/SEDIMENT. RATE	0-7 (MM)	01/10/92						
1st h			13.00		26.00			
ESR/SEDIMENT. RATE	4-15 (MM)	01/10/92						
2nd h			26.00		47.00			

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

(e) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS 930089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 5 Patient: 3MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			09/03/93		13/04/93		11/05/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/10/92	14.50		13.80		14.00	
HT	36-46 (X)	01/10/92	42.00		41.00		44.00	
RBC	4.2-5.4 (10 ⁶ /MM3)	01/10/92	4.90		4.93		4.96	
WBC	4.5-11 (10 ³ /MM3)	01/10/92	9.90		9.70		9.00	
WBC: N	40-74 (X)	01/10/92	66.00		64.20		60.00	
WBC: L	19-48 (X)	01/10/92	32.00		22.20		24.00	
WBC: E	0-7 (X)	01/10/92	1.00		2.20		4.00	
WBC: M	3.5-9 (X)	01/10/92	1.00	<	8.20		>	
WBC: B	0-1.5 (X)	01/10/92	0.00		0.00		1.00	
PLATELETS	130-400 (10 ³ /MM3)	01/10/92	272.00		282.00		292.00	
NA+	135-145 (MMOL/L)	01/10/92	142.00		142.00		141.00	
K+	3.6-4.8 (MMOL/L)	01/10/92	3.80		4.10		4.00	
CL-	98-108 (MMOL/L)	01/10/92	98.00		98.00		97.00	
Ca++	8.5-10.5 (MG/DL)	01/10/92	9.30		10.40		10.00	
PO4--	2.7-4.5 (MG/DL)	01/10/92	3.80		4.00		4.10	
SGOT	0-31 (U/L)	01/10/92	11.00		7.00		9.00	
SGPT	0-31 (U/L)	01/10/92	16.00		8.00		11.00	
GAMMA GT	7-32 (U/L)	01/10/92	19.00		13.00		14.00	
LDH	230-460 (U/L)	01/10/92	168.00	<	171.00	<	174.00	
ALK. PHOSPH.	42-98 (U/L)	01/10/92	159.00	>	154.00	>	152.00	
GLUCOSE	0.6-1 (G/L)	01/10/92	1.07	>	1.10	>	0.96	
UREA	0.18-0.43 (G/L)	01/10/92	0.29		0.46	>		
CREATININE	0.7-1.3 (MG/DL)	01/10/92	0.82		0.97		0.97	
CREATININE CLEARANCE	90-139 (ML/MIN)	01/10/92	89.09					
URIC ACID	2.4-5.7 (MG/DL)	01/10/92	6.30	>	7.30	>	7.00	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/10/92	0.79		0.82		0.80	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/10/92	0.12		0.13		0.14	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/10/92	7.90		8.10	>	8.20	
ALBUMINE	52-68 (X)	01/10/92	60.50		60.30		60.20	
TOT. CHOLEST.	155-280 (MG/DL)	01/10/92	234.00		259.00		266.00	
TRIGLYCERIDES	60-241 (MG/DL)	01/10/92	174.00		199.00		179.00	
GLOBULINS ALPHA 1	2.5-4.8 (X)	01/10/92	3.20		9.12	>>	3.02	
GLOBULINS ALPHA 2	6.2-11 (X)	01/10/92	10.80		10.20		10.02	
GLOBULINS BETA	10.5-15 (X)	01/10/92	12.10		12.20		12.20	
GLOBULINS GAMMA	12-21 (X)	01/10/92	10.40	<	10.60	<	10.40	
TSH	0.1-5 (UU/ML)	01/10/92	5.00					
T4	4.5-13 (UG/DL)	01/10/92	8.00					

2040

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C8560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 5 Patient: 4MD Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			18/11/92		21/12/92		18/01/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	01/10/92	12.20	<	13.40	<	14.38	
HT	41-53 (%)	01/10/92	37.40	<	39.90	<	42.91	
RBC	4.7-6.1 (10 ⁶ /MM ³)	01/10/92	4.29	<	4.58	<	4.92	
HBC	4.5-11 (10 ³ /MM ³)	01/10/92	8.36		8.74		7.83	
HBC: N	40-74 (%)	01/10/92	77.40	>	76.00	>	72.51	
HBC: L	19-48 (%)	01/10/92	10.10	<<	9.75	<<	10.82	
HBC: E	0-7 (%)	01/10/92	1.97		2.75		2.81	
HBC: M	3.5-9 (%)	01/10/92	9.42	>	10.30	>	12.25	
HBC: B	0-1.5 (%)	01/10/92	1.07		1.17		1.61	
PLATELETS	130-400 (10 ³ /MM ³)	01/10/92	347.00		293.00		291.40	
NA+	135-145 (MMOL/L)	01/10/92	140.00		144.00		143.00	
K+	3.6-4.8 (MMOL/L)	01/10/92	4.70		5.19	>	5.76	
CL-	98-108 (MMOL/L)	01/10/92	102.00		103.00		103.00	
Ca++	8.5-10.5 (MG/DL)	01/10/92	9.06		9.15		10.20	
PO4--	2.7-4.5 (MG/DL)	01/10/92	3.42		2.68	<		
SGOT	0-37 (U/L)	01/10/92	18.00		19.00		20.00	
SGPT	0-40 (U/L)	01/10/92	8.00		11.00		12.00	
GAMMA GT	11-49 (U/L)	01/10/92	13.00				35.00	
LDH	230-460 (U/L)	01/10/92	329.00		280.00		306.00	
ALK. PHOSPH.	53-128 (U/L)	01/10/92			98.00		110.00	
GLUCOSE	0.6-1 (G/L)	01/10/92	1.03	>	0.86		0.86	
UREA	0.18-0.43 (G/L)	01/10/92	0.42		0.44	>	0.51	
CREATININE	0.7-1.3 (MG/DL)	01/10/92	1.50	>	1.61	>	1.73	
CREATININE CLEARANCE	80-125 (ML/MIN)	01/10/92	51.85					
URIC ACID	3.4-7.3 (MG/DL)	01/10/92	6.10		6.90		6.70	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/10/92	0.26		0.28		0.28	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/10/92	0.02		0.06		0.06	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/10/92	6.60	<	6.60	<	7.00	
ALBUMINE	52-68 (%)	01/10/92			53.30		54.70	
TOT. CHOLEST.	155-280 (MG/DL)	01/10/92	212.00		223.00		256.00	
TRIGLYCERIDES	60-241 (MG/DL)	01/10/92	102.00		96.00		133.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/10/92	4.30		3.60		2.90	
GLOBULINS ALPHA 2	6.2-11 (%)	01/10/92	13.00	>	13.00	>	12.70	
GLOBULINS BETA	10.5-15 (%)	01/10/92	15.50	>	14.40		15.20	
GLOBULINS GAMMA	12-21 (%)	01/10/92	15.30		15.70		14.40	
TSH	0.1-5 (UU/ML)	01/10/92	0.92					
T4	4.5-13 (UG/DL)	01/10/92	6.80					

2041

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CN580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 5 Patient: SMD Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date
			Screen
			28/07/93
			value (c)
Laboratory test	Range value	Range date	
HB	14-18 (G/DL)	01/10/92	14.60
HT	41-53 (X)	01/10/92	41.20
RBC	4.7-6.1 (10 ⁶ /MM ³)	01/10/92	5.04
WBC	4.5-11 (10 ³ /MM ³)	01/10/92	6.92
WBC: N	40-74 (X)	01/10/92	63.40
WBC: L	19-48 (X)	01/10/92	23.90
WBC: E	0-7 (X)	01/10/92	1.50
WBC: M	3.5-9 (X)	01/10/92	10.80 >
WBC: B	0-1.5 (X)	01/10/92	0.50
PLATELETS	130-400 (10 ³ /MM ³)	01/10/92	330.00
NA+	135-145 (MMOL/L)	01/10/92	140.00
K+	3.6-4.8 (MMOL/L)	01/10/92	4.54
CL-	98-108 (MMOL/L)	01/10/92	102.00
Ca++	8.5-10.5 (MG/DL)	01/10/92	9.70
PO4--	2.7-4.5 (MG/DL)	01/10/92	3.99
SGOT	0-37 (U/L)	01/10/92	15.00
SGPT	0-40 (U/L)	01/10/92	18.00
GAMMA GT	11-49 (U/L)	01/10/92	31.00
LDH	230-460 (U/L)	01/10/92	331.00
ALK. PHOSPH.	53-128 (U/L)	01/10/92	98.00
GLUCOSE	0.6-1 (G/L)	01/10/92	0.81
UREA	0.18-0.43 (G/L)	01/10/92	0.39
CREATININE	0.7-1.3 (MG/DL)	01/10/92	1.07
CREATININE CLEARANCE			50.99
URIC ACID	3.4-7.3 (MG/DL)	01/10/92	4.10
TOT. CHOLEST.	155-280 (MG/DL)	01/10/92	123.00 <
TRIGLYCERIDES	60-241 (MG/DL)	01/10/92	83.00
TSH	0.1-5 (UU/ML)	01/10/92	0.43
T4	4.5-13 (UG/DL)	01/10/92	13.00
ESR/SEDIMENT. RATE 1st h	0-7 (MM)	01/10/92	20.00
ESR/SEDIMENT. RATE 2nd h	4-15 (MM)	01/10/92	36.00

2042

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 5 Patient: 6MD Treatment: Imipramine Sex: Male

			Visit number / Laboratory date
			Screen
			29/07/93
			value (†)
Laboratory test	Range value	Range date	
HB	14-18 (G/DL)	01/10/92	15.30
HT	41-53 (%)	01/10/92	43.70
RBC	4.7-6.1 (10 ⁶ /MM ³)	01/10/92	4.74
WBC	4.5-11 (10 ³ /MM ³)	01/10/92	6.52
WBC: N	40-74 (%)	01/10/92	77.69 >
WBC: L	19-48 (%)	01/10/92	14.08 <
WBC: E	0-7 (%)	01/10/92	0.91
WBC: M	3.5-9 (%)	01/10/92	6.85
WBC: B	0-1.5 (%)	01/10/92	0.47
PLATELETS	130-400 (10 ³ /MM ³)	01/10/92	235.00
NA+	135-145 (MMOL/L)	01/10/92	136.00
K+	3.6-4.8 (MMOL/L)	01/10/92	4.27
CL-	98-108 (MMOL/L)	01/10/92	95.00 <
Ca++	8.5-10.5 (MG/DL)	01/10/92	9.44
PO4--	2.7-4.5 (MG/DL)	01/10/92	4.04
SGOT	0-37 (U/L)	01/10/92	21.00
SGPT	0-40 (U/L)	01/10/92	21.00
GAMMA GT	11-49 (U/L)	01/10/92	40.00
LDH	230-460 (U/L)	01/10/92	428.00
ALK. PHOSPH.	53-128 (U/L)	01/10/92	64.00
GLUCOSE	0.6-1 (G/L)	01/10/92	1.02 >
UREA	0.18-0.43 (G/L)	01/10/92	0.38
CREATININE	0.7-1.3 (MG/DL)	01/10/92	0.96
CREATININE CLEARANCE			53.07
URIC ACID	3.4-7.3 (MG/DL)	01/10/92	4.40
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/10/92	0.72
DIR BILIRUBIN	0-0.36 (MG/DL)	01/10/92	0.14
TOT. PROTEINS	6.7-7.9 (G/DL)	01/10/92	6.50 <
ALBUMINE	52-68 (%)	01/10/92	59.00
TOT. CHOLEST.	155-280 (MG/DL)	01/10/92	223.00
TRIGLYCERIDES	60-241 (MG/DL)	01/10/92	64.00
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/10/92	3.10
GLOBULINS ALPHA 2	6.2-11 (%)	01/10/92	11.90 >
GLOBULINS BETA	10.5-15 (%)	01/10/92	13.00
GLOBULINS GAMMA	12-21 (%)	01/10/92	13.00
ESR/SEDIMENT. RATE 1st h	0-7 (MM)	01/10/92	5.00
ESR/SEDIMENT. RATE 2nd h	4-15 (MM)	01/10/92	11.00

2043

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARNACIA C9589089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 5 Patient: 7MD Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date
			Screen
			26/10/93
			value (c)
Laboratory test	Range value	Range date	
HB	14-18 (G/DL)	01/10/92	15.90
HT	41-53 (%)	01/10/92	46.10
RBC	4.7-6.1 (10 ⁶ /MM ³)	01/10/92	5.04
WBC	4.5-11 (10 ³ /MM ³)	01/10/92	7.35
WBC: N	40-74 (%)	01/10/92	67.80
WBC: L	19-48 (%)	01/10/92	21.60
WBC: E	0-7 (%)	01/10/92	1.00
WBC: M	3.5-9 (%)	01/10/92	9.20 >
WBC: B	0-1.5 (%)	01/10/92	0.90
PLATELETS	130-400 (10 ³ /MM ³)	01/10/92	241.00
NA+	135-145 (MMOL/L)	01/10/92	144.00
K+	3.6-4.8 (MMOL/L)	01/10/92	4.10
CL-	98-108 (MMOL/L)	01/10/92	104.00
Ca ⁺⁺	8.5-10.5 (MG/DL)	01/10/92	9.09
PO ₄ ⁻⁻⁻	2.7-4.5 (MG/DL)	01/10/92	3.09
SGOT	0-37 (U/L)	01/10/92	18.00
SGPT	0-40 (U/L)	01/10/92	11.00
GAMMA GT	11-49 (U/L)	01/10/92	17.00
LDH	230-460 (U/L)	01/10/92	305.00
ALK. PHOSPH.	53-128 (U/L)	01/10/92	67.00
GLUCOSE	0.6-1 (G/L)	01/10/92	1.39 >>
UREA	0.18-0.43 (G/L)	01/10/92	0.26
CREATININE	0.7-1.3 (MG/DL)	01/10/92	1.43 >
CREATININE CLEARANCE			43.26
URIC ACID	3.4-7.3 (MG/DL)	01/10/92	6.80
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/10/92	0.56
DIR BILIRUBIN	0-0.36 (MG/DL)	01/10/92	0.16
TOT. PROTEINS	6.7-7.9 (G/DL)	01/10/92	6.70
ALBUMINE	52-68 (%)	01/10/92	56.70
TOT. CHOLEST.	155-280 (MG/DL)	01/10/92	151.00 <
TRIGLYCERIDES	60-241 (MG/DL)	01/10/92	150.00
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/10/92	3.00
GLOBULINS ALPHA 2	6.2-11 (%)	01/10/92	10.70
GLOBULINS BETA	10.5-15 (%)	01/10/92	12.50
GLOBULINS GAMMA	12-21 (%)	01/10/92	17.10
ESR/SEDIMENT. RATE	0-7 (MM)	01/10/92	
1st h			6.00
ESR/SEDIMENT. RATE	4-15 (MM)	01/10/92	
2nd h			13.00

2044

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARNACIA CNS 930089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 5 Patient: BMD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			24/10/93		09/12/93		06/01/94	
			value	(c)	value	(c)	value	(c)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/10/92	15.00		12.80		13.80	
HT	36-46 (X)	01/10/92	42.40		36.80		40.30	
RBC	4.2-5.4 (10 ⁶ /MM ³)	01/10/92	4.43		4.03 <		4.30	
HBC	4.5-11 (10 ⁶ /MM ³)	01/10/92	8.40		4.68		6.66	
HBC: N	40-74 (X)	01/10/92			66.10		63.30	
HBC: L	19-48 (X)	01/10/92			23.20		24.80	
HBC: E	0-7 (X)	01/10/92			0.40		0.50	
HBC: M	3.5-9 (X)	01/10/92			9.80 >		10.70 >	
HBC: B	0-1.5 (X)	01/10/92			0.50		0.80	
PLATELETS	130-400 (10 ³ /MM ³)	01/10/92	250.00		213.00		251.00	
NA+	135-145 (MMOL/L)	01/10/92	139.00		138.00		140.00	
K+	3.6-4.8 (MMOL/L)	01/10/92	3.95		3.46 <		3.88	
CL-	98-108 (MMOL/L)	01/10/92	104.00		96.00 <		101.00	
Ca++	8.5-10.5 (MG/DL)	01/10/92	10.10		9.43		9.18	
PO4--	2.7-4.5 (MG/DL)	01/10/92			3.05		3.31	
SGOT	0-31 (U/L)	01/10/92	19.00		26.00		14.00	
SGPT	0-31 (U/L)	01/10/92	14.00		26.00		10.00	
GAMMA GT	7-32 (U/L)	01/10/92	9.00		21.10		9.00	
LDH	230-460 (U/L)	01/10/92	331.00		383.00		317.00	
ALK. PHOSPH.	42-98 (U/L)	01/10/92	64.00		67.00		73.00	
GLUCOSE	0.6-1 (G/L)	01/10/92	1.50 >>		1.52 >>		1.19 >	
UREA	0.18-0.43 (G/L)	01/10/92	0.37		0.32		0.28	
CREATININE	0.7-1.3 (MG/DL)	01/10/92	1.08		0.97		1.02	
CREATININE CLEARANCE	90-139 (ML/MIN)	01/10/92	65.65					
URIC ACID	2.4-5.7 (MG/DL)	01/10/92	4.58		5.10		5.20	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/10/92	0.59		0.50		0.73	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/10/92	0.15		0.12		0.14	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/10/92	7.52		6.40 <		6.90	
ALBUMINE	52-68 (X)	01/10/92			51.10 <		55.50	
TOT. CHOLEST.	155-280 (MG/DL)	01/10/92			182.00		196.00	
TRIGLYCERIDES	60-241 (MG/DL)	01/10/92			188.00		103.00	
GLOBULINS ALPHA 1	2.5-4.8 (X)	01/10/92			3.30		1.80 <	
GLOBULINS ALPHA 2	6.2-11 (X)	01/10/92			9.80		7.80	
GLOBULINS BETA	10.5-15 (X)	01/10/92			14.70		13.30	
GLOBULINS GAMMA	12-21 (X)	01/10/92			21.10 >		21.60 >	
ESR/SEDIMENT. RATE 3-12 (MM)		01/10/92						
1st h					22.00		20.00	
ESR/SEDIMENT. RATE 6-24 (MM)		01/10/92						
2nd h					39.00		36.00	

2045

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS 330089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 5 Patient: 9ND Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			09/11/93		14/12/93		11/01/94	
			value	(⊖)	value	(⊖)	value	(⊖)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/11/93	15.20		14.80		15.20	
HT	36-46 (X)	01/11/93	43.70		42.80		45.40	
RBC	4.2-5.4 (10 ⁶ /MM ³)	01/11/93	5.31		5.21		5.52 >	
WBC	4.5-11 (10 ³ /MM ³)	01/11/93	7.60		5.87		5.59	
WBC: N	40-74 (X)	01/11/93	67.87		66.62		70.00	
WBC: L	19-48 (X)	01/11/93	20.42		21.34		18.20 <	
WBC: E	0-7 (X)	01/11/93	3.10		2.59		3.00	
WBC: M	3.5-9 (X)	01/11/93	7.22		6.80		8.10	
WBC: B	0-1.5 (X)	01/11/93	1.39		2.65 >>		0.70	
PLATELETS	130-400 (10 ³ /MM ³)	01/11/93	245.00		235.00		260.00	
NA+	135-145 (MMOL/L)	01/11/93			136.00		138.00	
K+	3.6-4.8 (MMOL/L)	01/11/93			4.84 >		4.04	
CL-	98-108 (MMOL/L)	01/11/93			100.00		104.00	
Ca++	8.5-10.5 (MG/DL)	01/11/93	9.81		9.15		9.73	
PO4--	2.7-4.5 (MG/DL)	01/11/93	3.23		3.28		3.11	
SCOT	0-31 (U/L)	01/11/93	25.00		24.00		35.00 >	
SGPT	0-31 (U/L)	01/11/93	27.00		35.00 >		68.00 >>	
GAMMA GT	7-32 (U/L)	01/11/93	14.00		15.00		25.00	
LDH	230-460 (U/L)	01/11/93	423.00		431.00		370.00	
ALK. PHOSPH.	42-98 (U/L)	01/11/93	85.00		77.00		102.00 >	
GLUCOSE	0.6-1 (G/L)	01/11/93	0.90		0.79		0.69	
UREA	0.18-0.43 (G/L)	01/11/93	0.34		0.31		0.39	
CREATININE	0.7-1.3 (MG/DL)	01/11/93	0.90		0.83		0.90	
CREATININE CLEARANCE			63.11					
URIC ACID	2.4-5.7 (MG/DL)	01/11/93	3.60		3.60		3.80	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/11/93	0.40		0.51		0.44	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/11/93	0.02				0.04	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/11/93	7.50		6.80		7.00	
TOT. CHOLEST.	155-280 (MG/DL)	01/11/93	309.00 >		268.00		284.00 >	
TRIGLYCERIDES	60-241 (MG/DL)	01/11/93	269.00 >		125.00		144.00	
TSH	0.1-5 (UU/ML)	01/11/93	0.56					
T4	0.8-1.9 (NG/DL)	01/11/93	1.70					
ESR/SEDIMENT. RATE 1st h	3-12 (MM)	01/11/93					14.00	
ESR/SEDIMENT. RATE 2nd h	8-24 (MM)	01/11/93					27.00	

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

2046

(⊖) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C8560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 5 Patient: 10MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date
			Screen
			10/11/93
			value (c)
Laboratory test	Range value	Range date	
HB	12-16 (G/DL)	01/10/92	14.10
HT	36-46 (%)	01/10/92	40.70
RBC	4.2-5.4 (10 ⁶ /MM ³)	01/10/92	4.63
WBC	4.5-11 (10 ³ /MM ³)	01/10/92	7.61
WBC: N	40-74 (%)	01/10/92	60.90
WBC: L	19-48 (%)	01/10/92	28.50
WBC: E	0-7 (%)	01/10/92	2.90
WBC: M	3.5-9 (%)	01/10/92	6.50
WBC: B	0-1.5 (%)	01/10/92	1.20
PLATELETS	130-400 (10 ³ /MM ³)	01/10/92	165.00
NA+	135-145 (MMOL/L)	01/10/92	144.00
K+	3.6-4.8 (MMOL/L)	01/10/92	4.56
CL-	98-108 (MMOL/L)	01/10/92	100.00
Ca++	8.5-10.5 (MG/DL)	01/10/92	10.20
SGOT	0-31 (U/L)	01/10/92	20.00
SGPT	0-31 (U/L)	01/10/92	21.00
GAMMA GT	7-32 (U/L)	01/10/92	220.00 >>
LDH	230-460 (U/L)	01/10/92	313.00 >>
ALK. PHOSPH.	42-98 (U/L)	01/10/92	124.00 >
UREA	0.18-0.43 (G/L)	01/10/92	0.41
CREATININE	0.7-1.3 (MG/DL)	01/10/92	1.21
CREATININE CLEARANCE			35.56
URIC ACID	2.4-5.7 (MG/DL)	01/10/92	3.80
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/10/92	0.16
DIR BILIRUBIN	0-0.36 (MG/DL)	01/10/92	0.05
TOT. PROTEINS	6.7-7.9 (G/DL)	01/10/92	7.50
ALBUMINE	52-68 (%)	01/10/92	68.60 >
TOT. CHOLEST.	155-280 (MG/DL)	01/10/92	239.00
TRIGLYCERIDES	60-241 (MG/DL)	01/10/92	248.00 >
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/10/92	1.60 <<
GLOBULINS ALPHA 2	6.2-11 (%)	01/10/92	8.70
GLOBULINS BETA	10.5-15 (%)	01/10/92	10.90
GLOBULINS GAMMA	12-21 (%)	01/10/92	10.20 <
ESR/SEDIMENT. RATE	3-12 (MM)	01/10/92	
1st h			4.00
ESR/SEDIMENT. RATE	8-24 (MM)	01/10/92	
2nd h			9.00

2047

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C 580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 5 Patient: 11MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			01/12/93	
			value	(c)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	01/10/92	16.20	>
HT	36-46 (%)	01/10/92	46.60	>
RBC	4.2-5.4 (10 ⁶ /MM ³)	01/10/92	5.07	
WBC	4.5-11 (10 ³ /MM ³)	01/10/92	11.42	>
WBC: N	40-74 (%)	01/10/92	81.04	>
WBC: L	19-48 (%)	01/10/92	10.91	<<
WBC: E	0-7 (%)	01/10/92	1.99	
WBC: M	3.5-9 (%)	01/10/92	4.63	
WBC: B	0-1.5 (%)	01/10/92	1.43	
PLATELETS	130-400 (10 ³ /MM ³)	01/10/92	195.00	
NA+	135-145 (MMOL/L)	01/10/92	142.00	
K+	3.6-4.8 (MMOL/L)	01/10/92	4.24	
CL-	98-108 (MMOL/L)	01/10/92	104.00	
Ca++	8.5-10.5 (MG/DL)	01/10/92	10.05	
PO4--	2.7-4.5 (MG/DL)	01/10/92	2.80	
SGOT	0-31 (U/L)	01/10/92	17.00	
SGPT	0-31 (U/L)	01/10/92	26.00	
GAMMA GT	7-32 (U/L)	01/10/92	18.00	
LDH	230-460 (U/L)	01/10/92	579.00	>
ALK. PHOSPH.	42-98 (U/L)	01/10/92	85.00	
UREA	0.18-0.43 (G/L)	01/10/92	0.61	>
CREATININE	0.7-1.3 (MG/DL)	01/10/92	1.21	
CREATININE CLEARANCE			48.44	
URIC ACID	2.4-5.7 (MG/DL)	01/10/92	3.50	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/10/92	1.35	>
DIR BILIRUBIN	0-0.36 (MG/DL)	01/10/92	0.28	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/10/92	7.40	
TOT. CHOLEST.	155-280 (MG/DL)	01/10/92	170.00	
TRIGLYCERIDES	60-241 (MG/DL)	01/10/92	118.00	
ESR/SEDIMENT. RATE	3-12 (MM)	01/10/92		
1st h			7.00	
ESR/SEDIMENT. RATE	8-24 (MM)	01/10/92		
2nd h			15.00	

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

2048

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN 590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 5 Patient: 12MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	Day 28
			21/12/93	04/02/94
			value (⊕)	value (⊕)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	01/10/92	12.60	
HT	36-46 (2)	01/10/92	37.30	
RBC	4.2-5.4 (10 ⁶ /MM ³)	01/10/92	4.01	<
MBC	4.5-11 (10 ³ /MM ³)	01/10/92	8.33	
PLATELETS	130-400 (10 ³ /MM ³)	01/10/92	416.00	>
NA+	135-145 (MMOL/L)	01/10/92	147.00	> 138.00
K+	3.6-4.8 (MMOL/L)	01/10/92	3.79	4.50
CL-	98-108 (MMOL/L)	01/10/92	103.00	105.00
Ca++	8.5-10.5 (MG/DL)	01/10/92		9.72
PO4--	2.7-4.5 (MG/DL)	01/10/92		3.96
SGOT	0-31 (U/L)	01/10/92	16.00	25.00
SGPT	0-31 (U/L)	01/10/92	17.00	29.00
GAMMA GT	7-32 (U/L)	01/10/92		25.00
LDH	230-460 (U/L)	01/10/92	307.00	450.00
ALK. PHOSPH.	42-98 (U/L)	01/10/92		190.00 >
GLUCOSE	0.6-1 (G/L)	01/10/92	0.90	0.87
UREA	0.18-0.43 (G/L)	01/10/92	0.40	0.46 >
CREATININE	0.7-1.3 (MG/DL)	01/10/92	1.12	
CREATININE CLEARANCE	90-139 (ML/MIN)	01/10/92	61.41	
URIC ACID	2.4-5.7 (MG/DL)	01/10/92		7.40 >
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/10/92		0.33
DIR BILIRUBIN	0-0.36 (MG/DL)	01/10/92		0.01
TOT. PROTEINS	6.7-7.9 (G/DL)	01/10/92		7.80
TOT. CHOLEST.	155-280 (MG/DL)	01/10/92		259.00
TRIGLYCERIDES	60-241 (MG/DL)	01/10/92		144.00
ESR/SEDIMENT. RATE	3-12 (MM)	01/10/92		
1st h				42.00
ESR/SEDIMENT. RATE	8-24 (MM)	01/10/92		
2nd h				68.00

2049

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 5 Patient: 1DT Treatment: Imipramine Sex: Female

Laboratory test			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			09/11/92		09/12/92		06/01/93	
			value	(φ)	value	(φ)	value	(φ)
Range value	Range date							
HB	12-16 (G/DL)	01/10/92	14.70		15.40		14.40	
HT	36-46 (X)	01/10/92	43.90		45.30		42.10	
RBC	4.2-5.4 (10 ⁶ /MM ³)	01/10/92	5.03		5.18		4.90	
HBC	4.5-11 (10 ³ /MM ³)	01/10/92	10.90		9.52		7.42	
HBC: N	40-74 (X)	01/10/92	62.80		66.60		59.90	
HBC: L	19-48 (X)	01/10/92	27.10		22.30		26.10	
HBC: E	0-7 (X)	01/10/92	1.80		2.31		3.13	
HBC: M	3.5-9 (X)	01/10/92	7.74		8.25		10.10 >	
HBC: B	0-1.5 (X)	01/10/92	0.59		0.60		0.83	
PLATELETS	130-400 (10 ³ /MM ³)	01/10/92	347.00		343.00		327.00	
NA+	135-145 (MMOL/L)	01/10/92	143.00		141.00		145.00	
K+	3.6-4.8 (MMOL/L)	01/10/92	3.69		4.31		4.51	
CL-	98-108 (MMOL/L)	01/10/92	102.00		104.00		106.00	
Ca++	8.5-10.5 (MG/DL)	01/10/92	9.33		9.90		9.64	
PO4--	2.7-4.5 (MG/DL)	01/10/92	2.78		2.00 <<		2.23 <<	
SGOT	0-31 (U/L)	01/10/92	16.00		16.00		21.00	
SGPT	0-31 (U/L)	01/10/92	16.00		16.00		17.00	
GAMMA GT	7-32 (U/L)	01/10/92	33.00 >		26.00		28.00	
LDH	230-460 (U/L)	01/10/92	279.00		276.00		335.00	
ALK. PHOSPH.	42-98 (U/L)	01/10/92	86.00					
GLUCOSE	0.6-1 (G/L)	01/10/92					0.97	
UREA	0.18-0.43 (G/L)	01/10/92	0.28		0.38		0.32	
CREATININE	0.7-1.3 (MG/DL)	01/10/92	0.97		0.95		0.97	
CREATININE CLEARANCE	90-139 (ML/MIN)	01/10/92	69.86					
URIC ACID	2.4-5.7 (MG/DL)	01/10/92	5.10		4.30			
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/10/92	0.55		0.50		0.55	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/10/92	0.13		0.14		0.06	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/10/92	6.90		7.00			
ALBUMINE	52-68 (X)	01/10/92	59.20		49.50 <		52.10	
TOT. CHOLEST.	155-280 (MG/DL)	01/10/92	228.00		206.00		209.00	
TRIGLYCERIDES	60-241 (MG/DL)	01/10/92	137.00		163.00		119.00	
GLOBULINS ALPHA 1	2.5-4.8 (X)	01/10/92	2.60		1.30 <<		2.30 <	
GLOBULINS ALPHA 2	6.2-11 (X)	01/10/92	7.80		6.50		8.90	
GLOBULINS BETA	10.5-15 (X)	01/10/92	15.40 >		9.50 <		15.20 >	
GLOBULINS GAMMA	12-21 (X)	01/10/92	15.00		33.20 >>		21.60 >	
TSH	0.1-5 (UU/ML)	01/10/92	0.76					
T4	4.5-13 (UG/DL)	01/10/92	9.30					
ESR/SEDIMENT. RATE	3-12 (MM)	01/10/92						
1st h			9.00				13.00	
ESR/SEDIMENT. RATE	8-24 (MM)	01/10/92						
2nd h			19.00				26.00	

2050

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C8560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 5 Patient: ZDT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			16/12/92		22/01/93		24/02/93	
			value	(†)	value	(†)	value	(†)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	15/12/92	11.50	<	8.90	<<	10.20	<
	11.5-16.4 (G/DL)	17/01/93						
HT	36-46 (X)	15/12/92	33.60	<	28.20	<<	33.10	<
	35-49 (X)	17/01/93						
RBC	4.2-5.4 (10 ⁶ /MM ³)	15/12/92	3.77	<	3.11	<<	3.57	<<
HBC	4.5-11 (10 ³ /MM ³)	15/12/92	8.84					
	4000-11000 (/MM ³)	17/01/93			4960.00		10330.0	
HBC: N	40-74 (X)	15/12/92	73.00					
	36-66 (X)	17/01/93			62.00		77.00	>
HBC: L	19-48 (X)	15/12/92	17.00	<	26.00		13.00	<<
	20-45 (X)	17/01/93						
HBC: E	0-7 (X)	15/12/92	3.00					
	0-6 (X)	17/01/93			7.00		3.00	>
HBC: M	3.5-9 (X)	15/12/92	7.00					
	0-10 (X)	17/01/93			5.00		6.00	>
HBC: B	0-1 (X)	17/01/93			1.00		0.00	>
PLATELETS	130-400 (10 ³ /MM ³)	15/12/92	310.00					
	150-400 (10 ³ /MM ³)	17/01/93			396.00		352.00	
NA+	135-145 (MMOL/L)	15/12/92	141.00					
	3.6-4.8 (MMOL/L)	15/12/92			4.33			
K+	98-108 (MMOL/L)	15/12/92	103.00					
CL-	8.5-10.5 (MG/DL)	15/12/92	8.44					
Ca++	2.7-4.5 (MG/DL)	15/12/92	1.81	<<				
PO4--	0-31 (U/L)	15/12/92	55.00	>				
SGOT	1-44 (IU/L)	17/01/93			34.00		15.00	
	0-31 (U/L)	15/12/92	32.00	>				
SGPT	1-35 (IU/L)	17/01/93			37.00		28.00	
	7-32 (U/L)	15/12/92	20.00					
GAMMA GT	10-60 (IU/L)	17/01/93			111.00		88.00	>
	230-460 (U/L)	15/12/92	785.00	>				
LDH	200-600 (IU/L)	17/01/93			499.00		554.00	
ALK. PHOSPH.	42-98 (U/L)	15/12/92	79.00					
	30-130 (IU/L)	17/01/93			259.00		152.00	>
GLUCOSE	0.6-1 (G/L)	15/12/92	1.09	>				
	70-110 (MG/DL)	17/01/93			85.00			
UREA	0.18-0.43 (G/L)	15/12/92	0.71	>>				
	20-45 (MG/DL)	17/01/93			38.00		54.00	>
CREATININE	0.7-1.3 (MG/DL)	15/12/92	0.78					
	0.5-1.5 (MG/DL)	17/01/93			0.90		0.80	
CREATININE CLEARANCE	90-139 (ML/MIN)	15/12/92	31.60					
URIC ACID	2.4-5.7 (MG/DL)	15/12/92	6.60	>				
	3.4-7 (MG/DL)	17/01/93			3.60		4.20	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	15/12/92	0.64					
	0.1-1 (MG/DL)	17/01/93			0.50		0.50	
DIR BILIRUBIN	0-0.36 (MG/DL)	15/12/92	0.18					
TOT. PROTEINS	6.7-7.9 (G/DL)	15/12/92	5.50	<				
	65-80 (G/L)	17/01/93			53.00		59.00	<
ALBUMINE	52-68 (X)	15/12/92	50.10	<				
	53-65 (X)	17/01/93			43.80		36.40	<<
TOT. CHOLEST.	155-280 (MG/DL)	15/12/92	222.00					
	150-250 (MG/DL)	17/01/93			213.00		228.00	
TRIGLYCERIDES	60-241 (MG/DL)	15/12/92	106.00					
	30-140 (MG/DL)	17/01/93			74.00		84.00	
GLOBULINS ALPHA 1	2.5-4.8 (X)	15/12/92	5.20	>				
	1.5-5 (X)	17/01/93			10.10		10.80	>>
GLOBULINS ALPHA 2	6.2-11 (X)	15/12/92	10.30					
	7-13 (X)	17/01/93			17.80		20.30	>>
GLOBULINS BETA	10.5-15 (X)	15/12/92	16.30	>				
	10.8-14.8 (X)	17/01/93			11.60		12.20	
GLOBULINS GAMMA	12-21 (X)	15/12/92	18.20					
	12-22 (X)	17/01/93			16.80		20.00	

(CONTINUED)

2051

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C8590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 5 Patient: ZDT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			16/12/92		22/01/93		24/02/93	
			value	(*)	value	(*)	value	(*)
Laboratory test	Range value	Range date						
TSH	0.1-5 (UU/ML)	15/12/92	1.25					
T4	4.5-13 (UG/DL)	15/12/92	6.70					
ESR/SEDIMENT. RATE	3-12 (MM)	15/12/92	40.00					
1st h	3-5 (MM)	17/01/93		108.00				
ESR/SEDIMENT. RATE	8-24 (MM)	15/12/92	67.00					
2nd h	7-12 (MM)	17/01/93		132.00				

2052

(*) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done (*) missing range value

PHARMACIA C8560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 5 Patient: SDT Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 21		Day 56	
			18/03/93		13/04/93		18/05/93	
			value	(⊕)	value	(⊕)	value	(⊕)
Laboratory test	Range value	Range date						
HB	13.5-17.5 (G/DL)	01/03/93	15.90		16.00		15.00	
HT	41-53 (X)	01/03/93	46.00		48.00		45.00	
RBC	4.5-5.9 (10 ⁶ /MM ³)	01/03/93	4.96		5.13		4.83	
WBC	3900-8000 (/MM ³)	01/03/93	6660.00		6900.00		6340.00	
WBC: N	30-70 (X)	01/03/93	50.00		55.00		52.00	
WBC: L	20-55 (X)	01/03/93	37.00		32.00		34.00	
WBC: E	0-5 (X)	01/03/93	2.00		3.00		2.00	
WBC: M	0-8 (X)	01/03/93	10.00	>	9.00	>	11.00	
WBC: B	0-2 (X)	01/03/93	1.00		1.00		1.00	
PLATELETS	150-400 (10 ³ /MM ³)	01/03/93	195.00		234.00		218.00	
NA+	130-155 (MEQ/L)	01/03/93	145.00		144.00		145.00	
K+	3.5-5.1 (MEQ/L)	01/03/93	3.90		4.10		4.00	
CL-	90-110 (MEQ/L)	01/03/93	104.00		100.00		102.00	
Ca++	8.4-10 (MG/DL)	01/03/93	9.50		9.50		9.00	
PO4--	2.3-3.7 (MG/DL)	01/03/93	3.50		3.80	>	3.10	
SGOT	0-25 (IU/L)	01/03/93	7.80		6.30		9.70	
SGPT	0-24 (IU/L)	01/03/93	6.60		9.40		9.50	
GAMMA GT	3-40 (IU/L)	01/03/93	14.00		13.00		14.00	
LDH	120-240 (IU/L)	01/03/93	182.00		122.00		157.00	
ALK. PHOSPH.	62-176 (IU/L)	01/03/93	97.00		90.00		100.00	
GLUCOSE	83-110 (MG/DL)	01/03/93	88.00		68.00	<	82.00	
CREATININE	0.7-1.3 (MG/DL)	01/03/93	1.09		1.13		1.37	
CREATININE CLEARANCE	()	01/03/93	52.98	()				
URIC ACID	3.5-7 (MG/DL)	01/03/93	5.00		4.90		5.00	
TOT BILIRUBIN	0.2-1.2 (MG/DL)	01/03/93	0.99		0.79		0.91	
DIR BILIRUBIN	0-0.4 (MG/DL)	01/03/93	0.26		0.17		0.25	
TOT. PROTEINS	6-8.3 (G/DL)	01/03/93	7.20		7.10		7.40	
ALBUMINE	44-58 (X)	01/03/93			52.90		54.50	
TOT. CHOLEST.	140-250 (MG/DL)	01/03/93	201.00		181.00		204.00	
TRIGLYCERIDES	62-180 (MG/DL)	01/03/93	114.00		84.00		97.00	
GLOBULINS ALPHA 1	3-5.6 (X)	01/03/93	4.90		4.40		4.70	
GLOBULINS ALPHA 2	10-16 (X)	01/03/93	11.40		11.20		11.30	
GLOBULINS BETA	10-15 (X)	01/03/93	13.70		13.40		13.10	
GLOBULINS GAMMA	16-24 (X)	01/03/93	17.30		18.00		16.40	
TSH	0.5-4 (IU/ML)	01/03/93	0.12					
T4	4.5-10 (UG/DL)	01/03/93	8.40					
ESR/SEDIMENT. RATE	0-15 (MM)	01/03/93						
1st h					34.00		30.00	
ESR/SEDIMENT. RATE	0-30 (MM)	01/03/93						
2nd h					57.00		53.00	

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

2053

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value () missing range value

PHARMACIA C8510089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 5 Patient: 4DT Treatment: Reboxetine Sex: Male

			Vixit number / Laboratory date	
			Screen	
			26/01/93	
			value	(*)
Laboratory test	Range value	Range date		
HB	14-18 (G/DL)	01/10/92	13.70	<
HT	41-53 (X)	01/10/92	40.30	<
RBC	4.7-6.1 (10 ⁶ /MM ³)	01/10/92	4.48	<
WBC	4.5-11 (10 ³ /MM ³)	01/10/92	6.77	
WBC: N	40-74 (X)	01/10/92	64.00	
WBC: L	19-48 (X)	01/10/92	24.00	
WBC: E	0-7 (X)	01/10/92	2.00	
WBC: M	3.5-9 (X)	01/10/92	9.00	
PLATELETS	130-400 (10 ³ /MM ³)	01/10/92	254.00	
CL-	98-108 (MMOL/L)	01/10/92	101.00	
Ca++	8.5-10.5 (MG/DL)	01/10/92	8.89	
PO4--	2.7-4.5 (MG/DL)	01/10/92	2.43	<
SGOT	0-37 (U/L)	01/10/92	23.00	
SGPT	0-40 (U/L)	01/10/92	19.00	
GAMMA GT	11-49 (U/L)	01/10/92	8.00	<
LDH	230-460 (U/L)	01/10/92	482.00	>
ALK. PHOSPH.	53-128 (U/L)	01/10/92	97.00	
GLUCOSE	0.6-1 (G/L)	01/10/92	0.83	
UREA	0.18-0.43 (G/L)	01/10/92	0.40	
CREATININE	0.7-1.3 (MG/DL)	01/10/92	1.35	>
CREATININE CLEARANCE	80-125 (ML/MIN)	01/10/92	38.48	
URIC ACID	3.4-7.3 (MG/DL)	01/10/92	7.50	>
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/10/92	0.32	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/10/92	7.20	
TOT. CHOLEST.	155-280 (MG/DL)	01/10/92	263.00	
TRIGLYCERIDES	60-241 (MG/DL)	01/10/92	264.00	>

2054

(*) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 5 Patient: SDT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 28	
			09/02/93		19/03/93	
			value	(ϕ)	value	(ϕ)
Laboratory test	Range value	Range date				
HB	12-16 (G/DL)	01/10/92	14.00		14.90	
HT	36-46 (X)	01/10/92	41.20		43.20	
RBC	4.2-5.4 (10 ⁶ /MM ³)	01/10/92	4.61		4.80	
WBC	4.5-11 (10 ³ /MM ³)	01/10/92	6.43		7.94	
PLATELETS	130-400 (10 ³ /MM ³)	01/10/92	310.00		432.00	>
NA+	135-145 (MMOL/L)	01/10/92	141.00		140.00	
K+	3.6-4.8 (MMOL/L)	01/10/92	4.09		3.96	
CL-	98-108 (MMOL/L)	01/10/92	96.00	<	100.00	
Ca++	8.5-10.5 (MG/DL)	01/10/92	9.76		9.95	
PO4--	2.7-4.5 (MG/DL)	01/10/92	3.49		3.48	
SGOT	0-31 (U/L)	01/10/92	24.00		30.00	
SGPT	0-31 (U/L)	01/10/92	28.00		26.00	
GAMMA GT	7-32 (U/L)	01/10/92	24.00		21.00	
LDH	230-460 (U/L)	01/10/92	483.00	>	494.00	>
ALK. PHOSPH.	42-98 (U/L)	01/10/92	92.00			
GLUCOSE	0.6-1 (G/L)	01/10/92	1.07	>	2.08	>>
UREA	0.18-0.43 (G/L)	01/10/92	0.64	>	0.61	>
CREATININE	0.7-1.3 (MG/DL)	01/10/92	1.31	>	1.19	
CREATININE CLEARANCE			56.48			
URIC ACID	2.4-5.7 (MG/DL)	01/10/92	5.40		5.60	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/10/92	0.18		0.50	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/10/92	0.03			
TOT. PROTEINS	6.7-7.9 (G/DL)	01/10/92	7.30		6.90	
ALBUMINE	52-68 (X)	01/10/92	56.70			
TOT. CHOLEST.	155-280 (MG/DL)	01/10/92	234.00		214.00	
TRIGLYCERIDES	60-241 (MG/DL)	01/10/92	154.00		145.00	
GLOBULINS ALPHA 1	2.5-4.8 (X)	01/10/92	2.40	<		
GLOBULINS ALPHA 2	6.2-11 (X)	01/10/92	9.60			
GLOBULINS BETA	10.5-15 (X)	01/10/92	14.80			
GLOBULINS GAMMA	12-21 (X)	01/10/92	16.50			
TSH	0.1-5 (UU/ML)	01/10/92	1.48			
T4	4.5-13 (UG/DL)	01/10/92	6.20			

2055

(ϕ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACTIA C0530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 5 Patient: 6DT Treatment: Reboxetine Sex: Female

Laboratory test	Range value	Range date	Visit number / Laboratory date			
			Screen		Day 28	
			19/02/93		26/03/93	
			value (φ)	value (φ)	value (φ)	value (φ)
HB	12-16 (G/DL)	01/10/92	13.30		15.10	
HT	36-46 (Σ)	01/10/92	42.10		43.30	
RBC	4.2-5.4 (10 ⁶ /MM ³)	01/10/92	4.47		4.95	
WBC	4.5-11 (10 ³ /MM ³)	01/10/92	5.49		6.17	
WBC: N	40-74 (Σ)	01/10/92			51.90	
WBC: L	19-48 (Σ)	01/10/92			35.10	
WBC: E	0-7 (Σ)	01/10/92			2.56	
WBC: M	3.5-9 (Σ)	01/10/92			9.65 >	
WBC: B	0-1.5 (Σ)	01/10/92			0.78	
PLATELETS	130-400 (10 ³ /MM ³)	01/10/92	255.00		291.00	
NA+	135-145 (MMOL/L)	01/10/92			146.00 >	
K+	3.6-4.8 (MMOL/L)	01/10/92			4.46	
CL-	98-108 (MMOL/L)	01/10/92			101.00	
Ca++	8.5-10.5 (MG/DL)	01/10/92	8.91		9.70	
PO4--	2.7-4.5 (MG/DL)	01/10/92			4.26	
SGOT	0-31 (U/L)	01/10/92	18.00		23.00	
SGPT	0-31 (U/L)	01/10/92	12.00		15.00	
GAMMA GT	7-32 (U/L)	01/10/92	15.00		15.00	
LDH	230-460 (U/L)	01/10/92	423.00		352.00	
ALK. PHOSPH.	42-98 (U/L)	01/10/92	64.00		71.00	
GLUCOSE	0.6-1 (G/L)	01/10/92	0.77		0.90	
UREA	0.18-0.43 (G/L)	01/10/92	0.45 >		0.45 >	
CREATININE	0.7-1.3 (MG/DL)	01/10/92	1.22		1.09	
CREATININE CLEARANCE		01/10/92	35.10			
URIC ACID	2.4-5.7 (MG/DL)	01/10/92	2.60		3.40	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/10/92	0.30		0.47	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/10/92			0.07	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/10/92	7.00		7.30	
ALBUMINE	52-68 (Σ)	01/10/92	60.70		62.10	
TOT. CHOLEST.	155-280 (MG/DL)	01/10/92	310.00 >		321.00 >	
TRIGLYCERIDES	60-241 (MG/DL)	01/10/92	130.00		114.00	
GLOBULINS ALPHA 1	2.5-4.8 (Σ)	01/10/92	2.90		2.10 <	
GLOBULINS ALPHA 2	6.2-11 (Σ)	01/10/92	10.70		8.80	
GLOBULINS BETA	10.5-15 (Σ)	01/10/92	12.30		13.40	
GLOBULINS GAMMA	12-21 (Σ)	01/10/92	13.50		13.60	
TSH	0.1-5 (UU/ML)	01/10/92	2.50			

2056

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C 580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 5 Patient: 7DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			07/03/93		09/04/93		11/05/93	
			value	(†)	value	(†)	value	(†)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/03/93	13.50		13.90		14.50	
HT	36-46 (%)	01/03/93	41.20		39.80		43.00	
RBC	4.2-5.4 (10 ⁶ /MM ³)	01/03/93	4.41		4.48		4.85	
WBC	4.5-11 (10 ³ /MM ³)	01/03/93	5.98		6.96		6.99	
WBC: N	40-74 (%)	01/03/93			70.00		73.00	
WBC: L	19-48 (%)	01/03/93			17.00	<	17.40	
WBC: E	0-7 (%)	01/03/93			1.00		1.10	
WBC: M	3.5-9 (%)	01/03/93			12.00	>>	8.40	
WBC: B	0-1.5 (%)	01/03/93					0.10	
PLATELETS	130-400 (10 ³ /MM ³)	01/03/93	335.00		319.00		383.00	
NA+	135-145 (MMOL/L)	01/03/93			135.00		133.00	
K+	3.6-4.8 (MMOL/L)	01/03/93			4.09		3.48	
CL-	98-108 (MMOL/L)	01/03/93			96.00	<	93.00	
Ca++	8.5-10.5 (MG/DL)	01/03/93	9.57		9.42		10.22	
PO4--	2.7-4.5 (MG/DL)	01/03/93			3.40		3.51	
SGOT	0-31 (U/L)	01/03/93	20.00		21.00		25.00	
SGPT	0-31 (U/L)	01/03/93	20.00		27.00		33.00	
GAMMA GT	7-32 (U/L)	01/03/93	21.00		20.00		22.00	
LDH	230-460 (U/L)	01/03/93	366.00		331.00		313.00	
ALK. PHOSPH.	42-98 (U/L)	01/03/93	57.00		72.00		74.00	
GLUCOSE	0.6-1 (G/L)	01/03/93	0.70		0.88		0.95	
UREA	0.18-0.43 (G/L)	01/03/93	0.35		0.24		0.24	
CREATININE	0.7-1.3 (MG/DL)	01/03/93	1.19		0.94		0.82	
CREATININE CLEARANCE	90-139 (ML/MIN)	01/03/93	50.40					
URIC ACID	2.4-5.7 (MG/DL)	01/03/93	3.50		4.40		3.90	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/03/93	0.61		0.44		0.82	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/03/93	0.11		0.07		0.21	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/03/93	7.40		6.90		7.20	
ALBUMINE	52-68 (%)	01/03/93	63.90		66.90			
TOT. CHOLEST.	155-280 (MG/DL)	01/03/93	302.00	>	271.00		280.00	
TRIGLYCERIDES	60-241 (MG/DL)	01/03/93	98.00		131.00		103.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/03/93	2.00	<	2.10	<		
GLOBULINS ALPHA 2	6.2-11 (%)	01/03/93	11.60	>	10.30			
GLOBULINS BETA	10.5-15 (%)	01/03/93	11.80		11.40			
GLOBULINS GAMMA	12-21 (%)	01/03/93	10.70	<	9.40	<		
TSH	0.1-5 (UU/ML)	01/03/93	1.18					
T4	0.8-1.9 (NG/DL)	01/03/93	1.50					

2057

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CN9350089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 5 Patient: 8DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 56	
			30/04/93		26/05/93		24/06/93	
			value	(⊖)	value	(⊖)	value	(⊖)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	29/04/93	13.70		14.20		13.90	
HT	36-46 (X)	29/04/93	40.20		42.20		41.00	
RBC	4.2-5.4 (10 ⁶ /UL)	29/04/93	4.53		4.71		4.64	
WBC	4.5-11 (10 ³ /UL)	29/04/93	7.77		7.23		6.23	
WBC: N	40-74 (X)	29/04/93	63.00		66.10		63.20	
WBC: L	19-48 (X)	29/04/93	28.00		25.50		26.10	
WBC: E	0-7 (X)	29/04/93	1.00		1.50		2.30	
WBC: M	3.5-9 (X)	29/04/93	9.00		6.60		7.10	
WBC: B	0-1.5 (X)	20/05/93			0.30		1.30	
PLATELETS	130-400 (10 ³ /MM ³)	29/04/93	281.00		323.00		324.00	
NA+	135-145 (MMOL/L)	29/04/93	143.00		141.00		142.00	
K+	3.6-4.8 (MMOL/L)	29/04/93	3.89		3.85		3.99	
CL-	98-108 (MMOL/L)	29/04/93	106.00		101.00		102.00	
Ca++	8.5-10.5 (MG/DL)	29/04/93	9.85		9.76		9.72	
PO4--	2.7-4.5 (MG/DL)	29/04/93	3.98		2.79		2.86	
SGOT	0-31 (U/L)	29/04/93	21.00		21.00		17.00	
SGPT	0-31 (U/L)	29/04/93	31.00		34.00	>	24.00	
GAMMA GT	7-32 (U/L)	29/04/93	20.00		19.00		16.00	
LDH	230-460 (U/L)	29/04/93	389.00		397.00		348.00	
ALK. PHOSPH.	42-98 (U/L)	29/04/93	79.00		86.00		92.00	
GLUCOSE	0.6-1 (G/L)	29/04/93	0.98				0.92	
UREA	0.18-0.43 (G/L)	29/04/93	0.44	>	0.40		0.34	
CREATININE	0.7-1.3 (MG/DL)	29/04/93	1.25		1.36	>	1.22	
CREATININE CLEARANCE	90-139 (ML/MIN)	29/04/93	52.23					
URIC ACID	2.4-5.7 (MG/DL)	29/04/93	5.20		5.50		5.60	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	29/04/93	0.41		0.26		0.43	
DIR BILIRUBIN	0-0.36 (MG/DL)	29/04/93	0.05		0.09		0.10	
TOT. PROTEINS	6.7-7.9 (G/DL)	29/04/93	6.90		7.40		7.20	
ALBUMINE	3.5-5 (G/DL)	29/04/93	3.80					
	52-68 (X)	20/05/93			59.70		52.80	
TOT. CHOLEST.	155-280 (MG/DL)	29/04/93	247.00		287.00	>	276.00	
TRIGLYCERIDES	60-241 (MG/DL)	29/04/93	156.00		155.00		153.00	
GLOBULINS ALPHA 1	2.5-4.8 (X)	29/04/93	3.30		2.40	<	3.80	
GLOBULINS ALPHA 2	6.2-11 (X)	29/04/93	11.90	>	8.90		11.30	
GLOBULINS BETA	10.5-15 (X)	29/04/93	15.00		13.70		15.00	
GLOBULINS GAMMA	12-21 (X)	29/04/93	14.30		15.30		17.10	
TSH	0.1-5 (UU/ML)	29/04/93	2.12					
T4	0.8-1.9 (NG/DL)	29/04/93	1.20					

2058

(⊖) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN9590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 5 Patient: 9DT Treatment: Roboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			30/04/93		25/05/93		23/07/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/10/92	14.20		15.50		15.00	
HT	36-46 (%)	01/10/92	44.20		44.90		42.80	
RBC	4.2-5.4 (10 ⁶ /MM ³)	01/10/92	4.80		5.08		4.78	
WBC	4.5-11 (10 ³ /MM ³)	01/10/92	7.50		3.46	<	5.19	
WBC: N	40-74 (%)	01/10/92			57.50		81.00	>
WBC: L	19-48 (%)	01/10/92			26.90		14.20	<
WBC: E	0-7 (%)	01/10/92			8.00	>	0.80	
WBC: M	3.5-9 (%)	01/10/92			7.20		3.70	
WBC: B	0-1.5 (%)	01/10/92			0.50		0.30	
PLATELETS	130-400 (10 ³ /MM ³)	01/10/92	173.00		189.00		278.00	
NA+	135-145 (MMOL/L)	01/10/92	140.00		139.00		139.00	
K+	3.6-4.8 (MMOL/L)	01/10/92	3.77		3.59	<	4.24	
CL-	98-108 (MMOL/L)	01/10/92	104.00		93.00	<	94.00	<
Ca++	8.5-10.5 (MG/DL)	01/10/92	10.10		9.76		9.67	
PO4--	2.7-4.5 (MG/DL)	01/10/92	2.50	<	3.08		3.65	
SGOT	0-31 (U/L)	01/10/92	20.00		20.00		19.00	
SGPT	0-31 (U/L)	01/10/92	14.00		18.00		18.00	
GAMMA GT	7-32 (U/L)	01/10/92	20.00		22.00		17.00	
LDH	230-460 (U/L)	01/10/92	362.00		343.00		301.00	
ALK. PHOSPH.	42-98 (U/L)	01/10/92	65.00		81.00		75.00	
GLUCOSE	0.6-1 (G/L)	01/10/92	1.10	>	0.80		0.77	
UREA	0.18-0.43 (G/L)	01/10/92	0.28		0.43		0.41	
CREATININE	0.7-1.3 (MG/DL)	01/10/92	1.06		1.12		0.88	
CREATININE CLEARANCE			30.76					
URIC ACID	2.4-5.7 (MG/DL)	01/10/92			3.80		3.00	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/10/92			0.75		0.64	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/10/92			0.16		0.22	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/10/92			6.60	<	6.60	<
ALBUMINE	52-68 (%)	01/10/92			60.00		59.70	
TOT. CHOLEST.	155-280 (MG/DL)	01/10/92			334.00	>	285.00	>
TRIGLYCERIDES	60-241 (MG/DL)	01/10/92			133.00		90.00	
GLOBULINS ALPHA 1	2.5-4.8 (%)	01/10/92			3.10		3.90	
GLOBULINS ALPHA 2	6.2-11 (%)	01/10/92			10.60		11.00	
GLOBULINS BETA	10.5-15 (%)	01/10/92			12.70		12.90	
GLOBULINS GAMMA	12-21 (%)	01/10/92			13.60		12.50	
ESR/SEDIMENT. RATE 1st h	3-12 (MM)	01/10/92			8.00			
ESR/SEDIMENT. RATE 2nd h	8-24 (MM)	01/10/92			16.00			

2059

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CN9530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 5 Patient: 10DT Treatment: Imipramine Sex: Male

			Visit number / Laboratory date
			Screen
			04/05/93
			value (φ)
Laboratory test	Range value	Range date	
HB	14-18 (G/DL)	01/10/92	14.10
HT	41-53 (X)	01/10/92	41.30
RBC	4.7-6.1 (10 ⁶ /MM ³)	01/10/92	4.39 <
WBC	4.5-11 (10 ³ /MM ³)	01/10/92	5.43
WBC: N	40-74 (X)	01/10/92	60.80
WBC: L	19-48 (X)	01/10/92	29.10
WBC: E	0-7 (X)	01/10/92	1.39
WBC: M	3.5-9 (X)	01/10/92	8.15
WBC: B	0-1.5 (X)	01/10/92	0.61
PLATELETS	130-400 (10 ³ /MM ³)	01/10/92	238.00
NA+	135-145 (MMOL/L)	01/10/92	142.00
K+	3.6-4.8 (MMOL/L)	01/10/92	4.26
CL-	98-108 (MMOL/L)	01/10/92	104.00
Ca++	8.5-10.5 (MG/DL)	01/10/92	9.63
PO4--	2.7-4.5 (MG/DL)	01/10/92	2.90
SGOT	0-37 (U/L)	01/10/92	43.00 >
SGPT	0-40 (U/L)	01/10/92	108.00 >>
GAMMA GT	11-49 (U/L)	01/10/92	263.00 >>
LDH	230-460 (U/L)	01/10/92	378.00
ALK. PHOSPH.	53-128 (U/L)	01/10/92	185.00 >
GLUCOSE	0.6-1 (G/L)	01/10/92	1.03 >
UREA	0.18-0.43 (G/L)	01/10/92	0.38
CREATININE	0.7-1.3 (MG/DL)	01/10/92	1.27
CREATININE CLEARANCE			54.15
URIC ACID	3.4-7.3 (MG/DL)	01/10/92	4.10
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/10/92	0.57
DIR BILIRUBIN	0-0.36 (MG/DL)	01/10/92	0.21
TOT. PROTEINS	6.7-7.9 (G/DL)	01/10/92	7.00
ALBUMINE	52-68 (X)	01/10/92	55.60
TOT. CHOLEST.	155-280 (MG/DL)	01/10/92	221.00
TRIGLYCERIDES	60-241 (MG/DL)	01/10/92	149.00
GLOBULINS ALPHA 1	2.5-4.8 (X)	01/10/92	3.70
GLOBULINS ALPHA 2	6.2-11 (X)	01/10/92	9.70
GLOBULINS BETA	10.5-15 (X)	01/10/92	12.60
GLOBULINS GAMMA	12-21 (X)	01/10/92	18.40
ESR/SEDIMENT. RATE 1st h	0-7 (MM)	01/10/92	28.00
ESR/SEDIMENT. RATE 2nd h	4-15 (MM)	01/10/92	50.00

2060

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN950089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 5 Patient: 11DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	Day 21
			05/05/93	26/05/93
Laboratory test	Range value	Range date	value (†)	value (‡)
HB	12-16 (G/DL)	04/05/93	12.50	12.90
HT	36-46 (X)	04/05/93	35.80 <	37.90
RBC	4.2-5.4 (10 ⁶ /UL)	04/05/93	4.01 <	4.21
MBC	4.5-11 (10 ³ /UL)	04/05/93	5.16	5.54
MBC: N	40-74 (X)	04/05/93	65.30	57.60
MBC: L	19-48 (X)	04/05/93	23.20	31.20
MBC: E	0-7 (X)	04/05/93	2.76	1.50
MBC: M	3.5-9 (X)	04/05/93	7.14	9.00
MBC: B	0-1.5 (X)	04/05/93	1.54 >	0.70
PLATELETS	130-400 (10 ³ /MM3)	04/05/93	339.00	357.00
NA+	135-145 (MMOL/L)	04/05/93	137.00	136.00
K+	3.6-4.8 (MMOL/L)	04/05/93	4.26	4.21
CL-	98-108 (MMOL/L)	04/05/93	100.00	96.00 <
Ca++	8.5-10.5 (MG/DL)	04/05/93	9.56	9.45
PO4--	2.7-4.5 (MG/DL)	04/05/93	3.05	3.27
SGOT	0-31 (U/L)	04/05/93	22.00	18.00
SGPT	0-31 (U/L)	04/05/93	22.00	16.00
GAMMA GT	7-32 (U/L)	04/05/93	16.00	16.00
LDH	230-460 (U/L)	04/05/93	259.00	302.00
ALK. PHOSPH.	42-98 (U/L)	04/05/93	74.00	69.00
GLUCOSE	0.6-1 (G/L)	04/05/93	0.80	0.98
UREA	0.18-0.43 (G/L)	04/05/93	0.28	0.31
CREATININE	0.7-1.3 (MG/DL)	04/05/93	0.94	0.87
CREATININE CLEARANCE			43.80	
URIC ACID	2.4-5.7 (MG/DL)	04/05/93	2.80	3.00
TOT BILIRUBIN	0.04-1.13 (MG/DL)	04/05/93	0.24	0.43
DIR BILIRUBIN	0-0.36 (MG/DL)	04/05/93	0.04	0.08
TOT. PROTEINS	6.7-7.9 (G/DL)	04/05/93	7.10	7.50
ALBUMINE	52-68 (X)	04/05/93	52.40	
TOT. CHOLEST.	155-280 (MG/DL)	04/05/93	254.00	211.00
TRIGLYCERIDES	60-241 (MG/DL)	04/05/93	126.00	70.00
GLOBULINS ALPHA 1	2.5-4.8 (X)	04/05/93	2.00 <	
GLOBULINS ALPHA 2	6.2-11 (X)	04/05/93	8.20	
GLOBULINS BETA	10.5-15 (X)	04/05/93	15.80 >	
GLOBULINS GAMMA	12-21 (X)	04/05/93	21.70 >	
TSH	0.1-5 (UU/ML)	04/05/93	1.40	
T4	0.8-1.9 (NG/DL)	04/05/93	1.50	
ESR/SEDIMENT. RATE	3-12 (MM)	04/05/93		
1st h				9.00
ESR/SEDIMENT. RATE	8-24 (MM)	04/05/93		
2nd h				18.00

2061

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done (‡) missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS00089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 5 Patient: 12DT Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			18/05/93		15/06/93		27/07/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	01/10/92	14.34		13.60	<	14.10	
HT	41-53 (X)	01/10/92	42.31		40.00	<	40.60 <	
RBC	4.7-6.1 (10 ⁶ /MM ³)	01/10/92	4.58 <		4.32	<	4.41 <	
HBC	4.5-11 (10 ³ /MM ³)	01/10/92	5.29		6.14		6.43	
HBC: N	40-74 (X)	01/10/92	60.39		57.60		63.20	
HBC: L	19-48 (X)	01/10/92	25.59		29.80		25.90	
HBC: E	0-7 (X)	01/10/92	1.41		1.40		1.40	
HBC: M	3.5-9 (X)	01/10/92	12.25 >>		9.80	>	9.20 >	
HBC: B	0-1.5 (X)	01/10/92	0.36		1.30		0.30	
PLATELETS	130-400 (10 ³ /MM ³)	01/10/92	194.80		203.00		232.00	
NA+	135-145 (MMOL/L)	01/10/92			130.00	<	135.00	
K+	3.6-4.8 (MMOL/L)	01/10/92			5.32	>	4.80	
CL-	98-108 (MMOL/L)	01/10/92			91.00	<	98.00	
Ca++	8.5-10.5 (MG/DL)	01/10/92	9.10		9.30		9.77	
PO4--	2.7-4.5 (MG/DL)	01/10/92	3.52		3.51		4.16	
SGOT	0-37 (U/L)	01/10/92	32.00		23.00		22.00	
SGPT	0-40 (U/L)	01/10/92	17.00		15.00		16.00	
GAMMA GT	11-49 (U/L)	01/10/92	25.00		41.00		43.00	
LDH	230-460 (U/L)	01/10/92			360.00		353.00	
ALK. PHOSPH.	53-128 (U/L)	01/10/92			153.00	>	157.00 >	
GLUCOSE	0.6-1 (G/L)	01/10/92	0.85		0.86		0.93	
UREA	0.18-0.43 (G/L)	01/10/92	0.37		0.42		0.39	
CREATININE	0.7-1.3 (MG/DL)	01/10/92	1.14		1.18		1.46 >	
CREATININE CLEARANCE	80-125 (ML/MIN)	01/10/92	54.11					
URIC ACID	3.4-7.3 (MG/DL)	01/10/92	5.20		4.60		5.10	
TOT BILIRUBIN	0.04-1.13 (MG/DL)	01/10/92	0.80		0.54		0.65	
DIR BILIRUBIN	0-0.36 (MG/DL)	01/10/92			0.13		0.17	
TOT. PROTEINS	6.7-7.9 (G/DL)	01/10/92	6.90		6.70		6.90	
ALBUMINE	52-68 (X)	01/10/92			57.20		58.20	
TOT. CHOLEST.	155-280 (MG/DL)	01/10/92	266.00		233.00		216.00	
TRIGLYCERIDES	60-241 (MG/DL)	01/10/92	114.00		120.00		93.00	
GLOBULINS ALPHA 1	2.5-4.8 (X)	01/10/92			2.80		3.80	
GLOBULINS ALPHA 2	6.2-11 (X)	01/10/92			11.30	>	12.00 >	
GLOBULINS BETA	10.5-15 (X)	01/10/92			13.20		13.50	
GLOBULINS GAMMA	12-21 (X)	01/10/92			15.50		12.50	

2062

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN 590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 6 Patient: 1MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date							
			Day 7		Day 28		Day 56		Screen	
			18/11/92		10/12/92		07/01/93		12/11/92	
			value	(c)	value	(c)	value	(c)	value	(c)
Laboratory test	Range value	Range date								
HB	12-16 (G/DL)	02/10/92	14.20		14.00		13.70			
HT	34-47 (Z)	02/10/92	41.30		40.50		38.80			
RBC	4-5.8 (10 ⁶ /MM ³)	02/10/92	4.16		4.12		3.97	<		
WBC	4000-10000 (/MM ³)	02/10/92	4700.00		4800.00		5300.00			
WBC: N	40-70 (Z)	02/10/92	58.10		59.10		66.70			
WBC: L	20-50 (Z)	02/10/92	36.20		35.50		29.30			
WBC: E	0-8 (Z)	02/10/92	3.20		2.30		2.40			
WBC: M	0-13 (Z)	02/10/92	2.40		2.80		1.60			
WBC: B	0-3 (Z)	02/10/92	0.10		0.30		0.10			
PLATELETS	150-400 (10 ³ /MM ³)	02/10/92	277.00		263.00		289.00			
NA+	136-147 (MMOL/L)	02/10/92			139.00		138.00		140.00	
K+	3.6-5.5 (MMOL/L)	02/10/92			4.40		4.40		5.40	
CL-	95-110 (MMOL/L)	02/10/92			99.00		99.00		98.00	
Ca++	8.3-10.5 (MG/DL)	02/10/92			9.03		8.78		8.87	
PO4--	2.4-4.8 (MG/DL)	02/10/92			3.80		3.60		4.10	
SGOT	5-40 (U/L)	02/10/92			14.00		14.00		16.00	
SGPT	5-40 (U/L)	02/10/92			9.00		10.00		14.00	
GAMMA GT	0-40 (U/L)	02/10/92			72.00 >		63.00 >		59.00 >	
LDH	150-460 (U/L)	02/10/92			300.00		271.00		426.00	
ALK. PHOSPH.	40-350 (U/L)	02/10/92			185.00		172.00		171.00	
GLUCOSE	50-120 (MG/DL)	02/10/92			66.00		66.00		67.00	
UREA	8-48 (MG/DL)	02/10/92			31.00		29.00		34.00	
CREATININE	0.3-1.25 (MG/DL)	02/10/92			0.86		0.79		0.90	
CREATININE CLEARANCE	80-140 (ML/MIN)	02/10/92							58.50	
URIC ACID	2-6.5 (MG/DL)	02/10/92			7.33 >		7.62 >		6.98 >	
TOT BILIRUBIN	0.1-1 (MG/DL)	02/10/92			0.34		0.27		0.31	
DIR BILIRUBIN	0-0.9 (MG/DL)	02/10/92							0.07	
TOT. PROTEINS	6.1-8 (G/DL)	02/10/92			6.61		6.59		6.76	
ALBUMINE	55-72 (Z)	02/10/92			63.30		60.80		64.00	
TOT. CHOLEST.	120-250 (MG/DL)	02/10/92			315.00 >		261.00 >		298.00 >	
TRIGLYCERIDES	40-170 (MG/DL)	02/10/92			245.00 >>		249.00 >>		341.00 >>	
GLOBULINS ALPHA 1	2-6 (Z)	02/10/92			3.00		3.50		3.20	
GLOBULINS ALPHA 2	6-11 (Z)	02/10/92			7.90		8.40		8.60	
GLOBULINS BETA	9-14 (Z)	02/10/92			10.70		12.50		10.80	
GLOBULINS GAMMA	10-20 (Z)	02/10/92			15.10		14.80		13.40	
TSH	0.1-4 (UUI/ML)	02/10/92							1.44	
T4	4.8-12.8 (UG/DL)	02/10/92							5.30	
ESR/SEDIMENT. RATE 1st h	1-20 (MM)	02/10/92			13.00		18.00		16.00	

2063

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS 550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 6 Patient: 2ND Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	Day 7
			09/11/92	18/11/92
			value (⊕)	value (⊕)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	02/10/92	15.10	15.40
HT	34-47 (%)	02/10/92	46.30	48.00 >
RBC	4-5.8 (10 ⁶ /MM ³)	02/10/92	5.11	5.36
WBC	4000-10000 (/MM ³)	02/10/92	6200.00	5900.00
WBC: N	40-70 (%)	02/10/92	64.90	59.90
WBC: L	20-50 (%)	02/10/92	27.10	30.70
WBC: E	0-8 (%)	02/10/92	3.70	6.30
WBC: M	0-13 (%)	02/10/92	3.50	2.70
WBC: B	0-3 (%)	02/10/92	0.70	0.40
PLATELETS	150-400 (10 ³ /MM ³)	02/10/92	240.00	236.00
NA+	136-147 (MMOL/L)	02/10/92	142.00	
K+	3.6-5.5 (MMOL/L)	02/10/92	4.10	
CL-	95-110 (MMOL/L)	02/10/92	107.00	
Ca++	8.3-10.5 (MG/DL)	02/10/92	9.48	
PO4--	2.4-4.8 (MG/DL)	02/10/92	3.60	
SGOT	5-40 (U/L)	02/10/92	19.00	
SGPT	5-40 (U/L)	02/10/92	25.00	
GAMMA GT	0-40 (U/L)	02/10/92	33.00	
ALK. PHOSPH.	40-350 (U/L)	02/10/92	315.00	
GLUCOSE	50-120 (MG/DL)	02/10/92	163.00 >>	114.00
UREA	8-48 (MG/DL)	02/10/92	30.00	30.00
CREATININE	0.3-1.25 (MG/DL)	02/10/92	0.82	0.85
CREATININE CLEARANCE	80-140 (ML/MIN)	02/10/92	81.30	
TOT BILIRUBIN	0.1-1 (MG/DL)	02/10/92	0.93	
DIR BILIRUBIN	0-0.9 (MG/DL)	02/10/92	0.22	
TOT. PROTEINS	6.1-8 (G/DL)	02/10/92	7.72	7.30
ALBUMINE	55-72 (%)	02/10/92	62.60	
TOT. CHOLEST.	120-250 (MG/DL)	02/10/92	352.00 >>	373.00 >>
TRIGLYCERIDES	40-170 (MG/DL)	02/10/92	329.00 >>	305.00 >>
GLOBULINS ALPHA 1	2-6 (%)	02/10/92	3.40	
GLOBULINS ALPHA 2	6-11 (%)	02/10/92	9.10	
GLOBULINS BETA	9-14 (%)	02/10/92	12.20	
GLOBULINS GAMMA	10-20 (%)	02/10/92	12.70	
TSH	0.1-4 (UUI/ML)	02/10/92	0.84	
T4	4.8-12.8 (UG/DL)	02/10/92	8.50	

2064

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS 530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 6 Patient: 3ND Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			02/12/92		30/12/92		28/01/93	
			value	(†)	value	(†)	value	(†)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	02/10/92	13.70		14.90		13.50	
HT	34-47 (Z)	02/10/92	41.70		45.30		40.10	
RBC	4-5.8 (10 ⁶ /MM ³)	02/10/92	4.51		4.88		4.35	
WBC	4000-10000 (/MM ³)	02/10/92	5000.00		5700.00		4800.00	
WBC: N	40-70 (Z)	02/10/92	54.40		60.20		61.50	
WBC: L	20-50 (Z)	02/10/92	38.10		34.20		32.60	
WBC: E	0-8 (Z)	02/10/92	3.00		1.90		3.60	
WBC: M	0-13 (Z)	02/10/92	4.10		3.30		2.20	
WBC: B	0-3 (Z)	02/10/92	0.40		0.40		0.10	
PLATELETS	150-400 (10 ³ /MM ³)	02/10/92	231.00		250.00		196.00	
NA+	136-147 (MMOL/L)	02/10/92	141.00		143.00		141.00	
K+	3.6-5.5 (MMOL/L)	02/10/92	4.40		4.10		4.40	
CL-	95-110 (MMOL/L)	02/10/92	103.00		105.00		105.00	
Ca++	8.3-10.5 (MG/DL)	02/10/92	9.07		9.26		8.95	
PO4--	2.4-4.8 (MG/DL)	02/10/92	3.60		3.40		3.10	
SGOT	5-40 (U/L)	02/10/92	14.00		16.00		14.00	
SGPT	5-40 (U/L)	02/10/92	12.00		13.00		10.00	
GAMMA GT	0-40 (U/L)	02/10/92	23.00		21.00		20.00	
LDH	150-460 (U/L)	02/10/92	266.00		319.00			
ALK. PHOSPH.	40-350 (U/L)	02/10/92	147.00		141.00		134.00	
GLUCOSE	50-120 (MG/DL)	02/10/92	138.00	>	146.00	>	116.00	
UREA	8-48 (MG/DL)	02/10/92	24.00		26.00		24.00	
CREATININE	0.3-1.25 (MG/DL)	02/10/92	0.85		0.79		0.76	
CREATININE CLEARANCE	80-140 (ML/MIN)	02/10/92	62.70					
URIC ACID	2-6.5 (MG/DL)	02/10/92	3.64		3.08		4.10	
TOT BILIRUBIN	0.1-1 (MG/DL)	02/10/92	0.38		0.41		0.40	
DIR BILIRUBIN	0-0.9 (MG/DL)	02/10/92	0.08				0.10	
TOT. PROTEINS	6.1-8 (G/DL)	02/10/92	6.23		6.57		6.30	
ALBUMINE	55-72 (Z)	02/10/92	71.90		68.40		72.90	
TOT. CHOLEST.	120-250 (MG/DL)	02/10/92	274.00	>	277.00	>	274.00	
TRIGLYCERIDES	40-170 (MG/DL)	02/10/92	162.00		143.00		100.00	
GLOBULINS ALPHA 1	2-6 (Z)	02/10/92	3.30		4.00		3.50	
GLOBULINS ALPHA 2	6-11 (Z)	02/10/92	7.80		8.60		7.50	
GLOBULINS BETA	9-14 (Z)	02/10/92	10.00		11.40		10.10	
GLOBULINS GAMMA	10-20 (Z)	02/10/92	7.00	<	7.60	<	6.00	
TSH	0.1-4 (UUI/ML)	02/10/92	1.82					
T4	4.8-12.8 (UG/DL)	02/10/92	7.00					
ESR/SEDIMENT. RATE 1st h	1-20 (MM)	02/10/92	10.00		6.00		12.00	

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

2065

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 6 Patient: 4MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	Day 28
			08/12/92	11/01/93
			value (φ)	value (φ)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	02/10/92	14.90	14.20
HT	34-47 (%)	02/10/92	44.80	42.40
RBC	4-5.8 (10 ⁶ /MM ³)	02/10/92	4.93	4.66
MBC	4000-10000 (/MM ³)	02/10/92	7900.00	8400.00
MBC: N	40-70 (%)	02/10/92	66.30	83.60 >
MBC: L	20-50 (%)	02/10/92	28.00	12.20 <<
MBC: E	0-8 (%)	02/10/92	2.90	2.20
MBC: M	0-13 (%)	02/10/92	2.40	1.90
MBC: B	0-3 (%)	02/10/92	0.30	0.10
PLATELETS	150-400 (10 ³ /MM ³)	02/10/92	385.00	400.00
NA+	136-147 (MMOL/L)	02/10/92	142.00	141.00
K+	3.6-5.5 (MMOL/L)	02/10/92	4.30	4.50
CL-	95-110 (MMOL/L)	02/10/92	100.00	102.00
Ca++	8.3-10.5 (MG/DL)	02/10/92	10.30	10.14
PO4--	2.4-4.8 (MG/DL)	02/10/92	4.20	3.40
SGOT	5-40 (U/L)	02/10/92	22.00	23.00
SGPT	5-40 (U/L)	02/10/92	18.00	19.00
GAMMA GT	0-40 (U/L)	02/10/92	18.00	13.00
LDH	150-460 (U/L)	02/10/92	310.00	468.00 >
ALK. PHOSPH.	40-350 (U/L)	02/10/92	217.00	181.00
GLUCOSE	50-120 (MG/DL)	02/10/92	86.00	93.00
UREA	8-48 (MG/DL)	02/10/92	44.00	46.00
CREATININE	0.3-1.25 (MG/DL)	02/10/92	1.23	1.25
CREATININE CLEARANCE			43.50	
URIC ACID	2-6.5 (MG/DL)	02/10/92	5.64	
TOT BILIRUBIN	0.1-1 (MG/DL)	02/10/92	0.45	0.43
TOT. PROTEINS	6.1-8 (G/DL)	02/10/92	7.88	7.67
ALBUMINE	55-72 (%)	02/10/92	59.90	57.70
TOT. CHOLEST.	120-250 (MG/DL)	02/10/92	244.00	225.00
TRIGLYCERIDES	40-170 (MG/DL)	02/10/92	103.00	122.00
GLOBULINS ALPHA 1	2-6 (%)	02/10/92	3.20	3.60
GLOBULINS ALPHA 2	6-11 (%)	02/10/92	9.40	11.20 >
GLOBULINS BETA	9-14 (%)	02/10/92	11.20	11.80
GLOBULINS GAMMA	10-20 (%)	02/10/92	16.30	15.70
TSH	0.1-4 (UUI/ML)	02/10/92	1.26	
T4	4.8-12.8 (UG/DL)	02/10/92	7.10	
ESR/SEDIMENT. RATE 1st h	1-20 (MM)	02/10/92	35.00	52.00

2066

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN 590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 6 Patient: SMD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			02/04/93		30/04/93		28/05/93	
			value	(c)	value	(c)	value	(c)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	02/10/92	12.60		13.70		12.50	
HT	34-47 (X)	02/10/92	36.60		43.20		37.90	
RBC	4-5.8 (10 ⁶ /MM ³)	02/10/92	4.22		4.89		4.31	
WBC	4000-10000 (/MM ³)	02/10/92	5700.00		5500.00		5000.00	
WBC: N	40-70 (X)	02/10/92	67.10		63.00		54.90	
WBC: L	20-50 (X)	02/10/92	27.80		28.80		34.50	
WBC: E	0-8 (X)	02/10/92	0.60		3.60		5.90	
WBC: M	0-13 (X)	02/10/92	4.20		3.80		4.90	
WBC: B	0-3 (X)	02/10/92	0.30		0.80		0.40	
PLATELETS	150-400 (10 ³ /MM ³)	02/10/92			333.00			
NA+	136-147 (MMOL/L)	02/10/92	141.00		141.00		142.00	
K+	3.6-5.5 (MMOL/L)	02/10/92	5.00		4.30		3.11 <	
CL-	95-110 (MMOL/L)	02/10/92	104.00		103.00		102.00	
Ca++	8.3-10.5 (MG/DL)	02/10/92	9.05		9.18		9.07	
PO4--	2.4-4.8 (MG/DL)	02/10/92	3.60		4.00		4.20	
SGOT	5-40 (U/L)	02/10/92	12.00		13.00		13.00	
SGPT	5-40 (U/L)	02/10/92	24.00		14.00		14.00	
GAMMA GT	0-40 (U/L)	02/10/92	14.00		11.00		10.00	
LDH	150-460 (U/L)	02/10/92	266.00		255.00		275.00	
ALK. PHOSPH.	40-350 (U/L)	02/10/92	127.00		135.00		115.00	
GLUCOSE	50-120 (MG/DL)	02/10/92	85.00		50.00		85.00	
UREA	8-48 (MG/DL)	02/10/92	37.00		48.00		49.00 >	
CREATININE	0.3-1.25 (MG/DL)	02/10/92	0.96		1.00		0.85	
CREATININE CLEARANCE	80-140 (ML/MIN)	02/10/92	49.00					
URIC ACID	2-6.5 (MG/DL)	02/10/92			3.36		3.10	
TOT BILIRUBIN	0.1-1 (MG/DL)	02/10/92	0.46		0.65		0.69	
DIR BILIRUBIN	0-0.9 (MG/DL)	02/10/92	0.14		0.18		0.11	
TOT. PROTEINS	6.1-8 (G/DL)	02/10/92	6.76		7.35		6.69	
ALBUMINE	55-72 (X)	02/10/92	67.00		68.00		67.60	
TOT. CHOLEST.	120-250 (MG/DL)	02/10/92	199.00		250.00		265.00 >	
TRIGLYCERIDES	40-170 (MG/DL)	02/10/92	94.00		97.00		89.00	
GLOBULINS ALPHA 1	2-6 (X)	02/10/92	2.80		2.20		2.30	
GLOBULINS ALPHA 2	6-11 (X)	02/10/92	6.60		5.40 <		6.20	
GLOBULINS BETA	9-14 (X)	02/10/92	10.00		9.60		10.50	
GLOBULINS GAMMA	10-20 (X)	02/10/92	14.00		14.80		13.40	
TSH	0.1-4 (UUI/ML)	02/10/92	1.12					
T4	4.8-12.8 (UG/DL)	02/10/92	7.00					

2067

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CN 580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 6 Patient: 6MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	Day 28
			28/04/93	26/05/93
Laboratory test	Range value	Range date	value (†)	value (‡)
HB	12-16 (G/DL)	02/10/92	14.80	15.70
HT	34-47 (X)	02/10/92	44.30	46.70
RBC	4-5.8 (10 ⁶ /MM ³)	02/10/92	4.84	5.26
MBC	4000-10000 (/MM ³)	02/10/92	8800.00	6600.00
MBC: N	40-70 (X)	02/10/92	54.30	51.80
MBC: L	20-50 (X)	02/10/92	32.00	35.00
MBC: E	0-8 (X)	02/10/92	10.10 >	9.40 >
MBC: M	0-13 (X)	02/10/92	3.00	3.40
MBC: B	0-3 (X)	02/10/92	0.50	0.40
NA+	136-147 (MMOL/L)	02/10/92	144.00	140.00
K+	3.6-5.5 (MMOL/L)	02/10/92	4.10	4.30
CL-	95-110 (MMOL/L)	02/10/92	100.00	98.00
Ca++	8.3-10.5 (MG/DL)	02/10/92	9.96	10.14
PO4--	2.4-4.8 (MG/DL)	02/10/92	3.00	3.60
SGOT	5-40 (U/L)	02/10/92	24.00	35.00
SGPT	5-40 (U/L)	02/10/92	21.00	29.00
GAMMA GT	0-40 (U/L)	02/10/92	14.00	15.00
LDH	150-460 (U/L)	02/10/92	354.00	362.00
ALK. PHOSPH.	40-350 (U/L)	02/10/92	149.00	125.00
GLUCOSE	50-120 (MG/DL)	02/10/92	90.00	102.00
UREA	8-48 (MG/DL)	02/10/92	31.00	52.00 >
CREATININE	0.3-1.25 (MG/DL)	02/10/92	1.43 >	1.75 >
CREATININE CLEARANCE	80-140 (ML/MIN)	02/10/92	29.54	5.47
URIC ACID	2-6.5 (MG/DL)	02/10/92	5.47	0.77
TOT BILIRUBIN	0.1-1 (MG/DL)	02/10/92	0.51	0.25
DIR BILIRUBIN	0-0.9 (MG/DL)	02/10/92	0.12	7.90
TOT. PROTEINS	6.1-8 (G/DL)	02/10/92	7.60	65.70
ALBUMINE	55-72 (X)	02/10/92	64.40	318.00 >
TOT. CHOLEST.	120-250 (MG/DL)	02/10/92	253.00 >	148.00
TRIGLYCERIDES	40-170 (MG/DL)	02/10/92	193.00 >	2.60
GLOBULINS ALPHA 1	2-6 (X)	02/10/92	2.60	6.60
GLOBULINS ALPHA 2	6-11 (X)	02/10/92	6.60	9.60
GLOBULINS BETA	9-14 (X)	02/10/92	10.10	16.30
GLOBULINS GAMMA	10-20 (X)	02/10/92	16.30	15.50
TSH	0.1-4 (UUI/ML)	02/10/92	0.74	
T4	4.8-12.8 (UG/DL)	02/10/92	5.70	
ESR/SEDIMENT. RATE 1st h	1-20 (MM)	02/10/92		6.00

2068

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C9590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 6 Patient: 7MD Treatment: Roboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			18/10/93		17/11/93		14/12/93	
			value	(⊕)	value	(⊕)	value	(⊕)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	02/10/92	12.80		12.80		13.70	
HT	34-47 (%)	02/10/92	37.90		37.90		40.00	
RBC	4-5.8 (10 ⁶ /MM3)	02/10/92	4.29		4.39		4.62	
HBC	4000-10000 (/MM3)	02/10/92	5000.00		5200.00		6100.00	
HBC: N	40-70 (%)	02/10/92	52.90		45.00		53.80	
HBC: L	20-50 (%)	02/10/92	35.90		44.50		39.40	
HBC: E	0-8 (%)	02/10/92	2.70		6.10		1.70	
HBC: M	0-13 (%)	02/10/92	7.90		4.10		4.80	
HBC: B	0-3 (%)	02/10/92	0.60		0.30		0.00	
PLATELETS	150-400 (10 ³ /MM3)	02/10/92	223.00		234.00		310.00	
NA+	136-147 (MMOL/L)	02/10/92	139.00		138.00		138.00	
K+	3.6-5.5 (MMOL/L)	02/10/92	4.50		4.30		4.50	
CL-	95-110 (MMOL/L)	02/10/92	98.00		99.00		95.00	
Ca++	8.3-10.5 (MG/DL)	02/10/92	9.55		9.61		9.88	
PO4--	2.4-4.8 (MG/DL)	02/10/92			4.00		4.00	
SGOT	5-40 (U/L)	02/10/92	22.00		28.00		26.00	
SGPT	5-40 (U/L)	02/10/92	14.00		26.00		17.00	
GAMMA GT	0-40 (U/L)	02/10/92	17.00		11.00		16.00	
LDH	150-460 (U/L)	02/10/92			410.00		487.00 >	
ALK. PHOSPH.	40-350 (U/L)	02/10/92	234.00		225.00		248.00	
GLUCOSE	50-120 (MG/DL)	02/10/92	71.00		81.00		91.00	
UREA	8-48 (MG/DL)	02/10/92	29.00		27.00		27.00	
CREATININE	0.3-1.25 (MG/DL)	02/10/92	1.00		1.05		1.15	
CREATININE CLEARANCE	80-140 (ML/MIN)	02/10/92	45.29					
URIC ACID	2-6.5 (MG/DL)	02/10/92	3.88		2.90		3.73	
TOT BILIRUBIN	0.1-1 (MG/DL)	02/10/92	0.36		0.57		0.60	
DIR BILIRUBIN	0-0.9 (MG/DL)	02/10/92	0.10		0.06		0.22	
TOT. PROTEINS	6.1-8 (G/DL)	02/10/92	7.39		7.16		7.86	
ALBUMINE	55-72 (%)	02/10/92	65.40		65.00		66.00	
TOT. CHOLEST.	120-250 (MG/DL)	02/10/92	288.00 >		254.00 >		283.00 >	
TRIGLYCERIDES	40-170 (MG/DL)	02/10/92	51.00		82.00		82.00	
GLOBULINS ALPHA 1	2-6 (%)	02/10/92	3.70		3.20		3.50	
GLOBULINS ALPHA 2	6-11 (%)	02/10/92	6.80		6.70		6.30	
GLOBULINS BETA	9-14 (%)	02/10/92	10.70		10.40		10.40	
GLOBULINS GAMMA	10-20 (%)	02/10/92	13.40		14.70		13.80	
TSH	0.1-4 (UUI/ML)	02/10/92	0.33					
T4	4.8-12.8 (UG/DL)	02/10/92	8.50					
ESR/SEDIMENT. RATE 1st h	1-20 (MM)	02/10/92			5.00		7.00	

2069

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN 9590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 6 Patient: 8ND Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			19/11/93		22/12/93		17/01/94	
			value	(†)	value	(†)	value	(†)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	02/10/92	14.50		13.00		14.00	
HT	34-47 (%)	02/10/92	43.40		39.70		42.40	
RBC	4-5.8 (10 ⁶ /MM ³)	02/10/92	4.47		4.15		4.40	
HBC	4000-10000 (/MM ³)	02/10/92	9900.00		6800.00		5800.00	
HBC: N	40-70 (%)	02/10/92	69.20		68.50		53.90	
HBC: L	20-50 (%)	02/10/92	21.60		24.42		36.20	
HBC: E	0-8 (%)	02/10/92	3.10		2.10		3.50	
HBC: M	0-13 (%)	02/10/92	5.90		2.60		6.00	
HBC: B	0-3 (%)	02/10/92	0.20		0.50		0.50	
PLATELETS	150-400 (10 ³ /MM ³)	02/10/92	326.00		312.00		304.00	
NA+	136-147 (MMOL/L)	02/10/92	139.00		141.00		141.00	
K+	3.6-5.5 (MMOL/L)	02/10/92	5.00		4.90		4.50	
CL-	95-110 (MMOL/L)	02/10/92	103.00		101.00		99.00	
Ca++	8.3-10.5 (MG/DL)	02/10/92	10.16		9.78		9.72	
SGOT	5-40 (U/L)	02/10/92	44.00 >		35.00		27.00	
SGPT	5-40 (U/L)	02/10/92	47.00 >		28.00		21.00	
GAMMA GT	0-40 (U/L)	02/10/92	10.00		8.00		11.00	
LDH	150-460 (U/L)	02/10/92	510.00 >					
ALK. PHOSPH.	40-350 (U/L)	02/10/92	278.00		308.00		330.00	
GLUCOSE	50-120 (MG/DL)	02/10/92	124.00 >		85.00		85.00	
UREA	8-48 (MG/DL)	02/10/92	47.00		44.00		38.00	
CREATININE	0.3-1.25 (MG/DL)	02/10/92	0.79		1.06		1.09	
CREATININE CLEARANCE	80-140 (ML/MIN)	02/10/92	71.74					
URIC ACID	2-6.5 (MG/DL)	02/10/92	4.72		5.62		5.74	
TOT BILIRUBIN	0.1-1 (MG/DL)	02/10/92	0.77		0.46		0.44	
DIR BILIRUBIN	0-0.9 (MG/DL)	02/10/92	0.64		0.06		0.09	
TOT. PROTEINS	6.1-8 (G/DL)	02/10/92	7.94		8.04 >		7.80	
ALBUMINE	55-72 (%)	02/10/92	55.90		56.60		60.60	
TOT. CHOLEST.	120-250 (MG/DL)	02/10/92	238.00		247.00		226.00	
TRIGLYCERIDES	40-170 (MG/DL)	02/10/92	129.00		126.00		127.00	
GLOBULINS ALPHA 1	2-6 (%)	02/10/92	3.00		3.00		2.30	
GLOBULINS ALPHA 2	6-11 (%)	02/10/92	10.30		10.40		7.90	
GLOBULINS BETA	9-14 (%)	02/10/92	11.20		10.80		10.10	
GLOBULINS GAMMA	10-20 (%)	02/10/92	19.60		19.20		19.10	
TSH	0.1-4 (UUI/ML)	02/10/92	0.49					
T4	4.8-12.8 (UG/DL)	02/10/92	9.50					
ESR/SEDIMENT. RATE	1-20 (MM)	02/10/92						
1st h					23.00		26.00	

2070

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS 330089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 6 Patient: 1DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			13/10/92		17/11/92		16/12/92	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	02/10/92	12.80		13.90		13.40	
HT	34-47 (X)	02/10/92	40.30		40.90		40.40	
RBC	4-5.8 (10 ⁶ /MM ³)	02/10/92	4.20		4.36		4.32	
WBC	4000-10000 (/MM ³)	02/10/92	5600.00		5800.00		8900.00	
WBC: N	40-70 (X)	02/10/92	59.50		52.10		69.70	
WBC: L	20-50 (X)	02/10/92	31.20		37.80		24.30	
WBC: E	0-8 (X)	02/10/92	1.80		2.30		0.30	
WBC: M	0-13 (X)	02/10/92	7.20		7.30		4.90	
WBC: B	0-3 (X)	02/10/92	0.40		0.50		0.80	
PLATELETS	150-400 (10 ³ /MM ³)	02/10/92	256.00		250.00		244.00	
NA+	136-147 (MMOL/L)	02/10/92	143.00		135.00	<	138.00	
K+	3.6-5.5 (MMOL/L)	02/10/92	4.30		4.20		5.50	
CL-	95-110 (MMOL/L)	02/10/92	103.00		98.00		105.00	
Ca++	8.3-10.5 (MG/DL)	02/10/92	9.51		9.49		9.36	
PO4--	2.4-4.8 (MG/DL)	02/10/92	3.10		2.80		2.90	
SGOT	5-40 (U/L)	02/10/92	22.00		19.00		20.00	
SGPT	5-40 (U/L)	02/10/92	16.00		18.00		15.00	
GAMMA GT	0-40 (U/L)	02/10/92	22.00		23.00		20.00	
LDH	150-460 (U/L)	02/10/92	409.00				434.00	
ALK. PHOSPH.	40-350 (U/L)	02/10/92	141.00		167.00		174.00	
GLUCOSE	50-120 (MG/DL)	02/10/92	107.00		108.00		107.00	
UREA	8-48 (MG/DL)	02/10/92	29.00		24.00		34.00	
CREATININE	0.3-1.25 (MG/DL)	02/10/92	0.79		0.87		0.83	
CREATININE CLEARANCE	80-140 (ML/MIN)	02/10/92	76.50					
URIC ACID	2-6.5 (MG/DL)	02/10/92	3.85				4.59	
TOT BILIRUBIN	0.1-1 (MG/DL)	02/10/92	0.56		0.62		0.34	
DIR BILIRUBIN	0-0.9 (MG/DL)	02/10/92	0.16		0.24			
TOT. PROTEINS	6.1-8 (G/DL)	02/10/92	6.96		7.62		7.22	
ALBUMINE	55-72 (X)	02/10/92	71.00		64.80		64.20	
TOT. CHOLEST.	120-250 (MG/DL)	02/10/92	240.00		269.00	>	239.00	
TRIGLYCERIDES	40-170 (MG/DL)	02/10/92	90.00		125.00		183.00 >	
GLOBULINS ALPHA 1	2-6 (X)	02/10/92	2.70		4.00		4.30	
GLOBULINS ALPHA 2	6-11 (X)	02/10/92	6.50		7.90		7.90	
GLOBULINS BETA	9-14 (X)	02/10/92	9.90		11.60		11.00	
GLOBULINS GAMMA	10-20 (X)	02/10/92	9.90	<	11.70		12.90	
TSH	0.1-4 (UUI/ML)	02/10/92	0.35					
T4	4.8-12.8 (UG/DL)	02/10/92	9.70					
ESR/SEDIMENT. RATE 1st h	1-20 (MM)	02/10/92	17.00				17.00	

2071

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value and laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CN 5540089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 6 Patient: 2DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date
			Screen
			18/01/93
			value (°)
Laboratory test	Range value	Range date	
HB	12-16 (G/DL)	02/10/92	15.00
HT	34-47 (%)	02/10/92	45.30
RBC	4-5.8 (10 ⁶ /MM ³)	02/10/92	4.79
WBC	4000-10000 (/MM ³)	02/10/92	10300.0 >
WBC: N	40-70 (%)	02/10/92	65.30
WBC: L	20-50 (%)	02/10/92	24.80
WBC: E	0-8 (%)	02/10/92	6.30
WBC: M	0-13 (%)	02/10/92	3.20
WBC: B	0-3 (%)	02/10/92	0.40
PLATELETS	150-400 (10 ³ /MM ³)	02/10/92	291.00
NA+	136-147 (MMOL/L)	02/10/92	142.00
K+	3.6-5.5 (MMOL/L)	02/10/92	4.60
CL-	95-110 (MMOL/L)	02/10/92	101.00
Ca++	8.3-10.5 (MG/DL)	02/10/92	9.89
PO4--	2.4-4.8 (MG/DL)	02/10/92	3.60
SGOT	5-40 (U/L)	02/10/92	34.00
SGPT	5-40 (U/L)	02/10/92	41.00 >
GAMMA GT	0-40 (U/L)	02/10/92	124.00 >>
LDH	150-460 (U/L)	02/10/92	367.00
ALK. PHOSPH.	40-350 (U/L)	02/10/92	249.00
GLUCOSE	50-120 (MG/DL)	02/10/92	81.00
UREA	8-48 (MG/DL)	02/10/92	36.00
CREATININE	0.3-1.25 (MG/DL)	02/10/92	1.23
CREATININE CLEARANCE			57.70
URIC ACID	2-6.5 (MG/DL)	02/10/92	3.83
TOT BILIRUBIN	0.1-1 (MG/DL)	02/10/92	0.42
TOT. PROTEINS	6.1-8 (G/DL)	02/10/92	8.03 >
ALBUMINE	55-72 (%)	02/10/92	62.10
TOT. CHOLEST.	120-250 (MG/DL)	02/10/92	383.00 >>
TRIGLYCERIDES	40-170 (MG/DL)	02/10/92	84.00
GLOBULINS ALPHA 1	2-6 (%)	02/10/92	3.30
GLOBULINS ALPHA 2	6-11 (%)	02/10/92	7.00
GLOBULINS BETA	9-14 (%)	02/10/92	11.40
GLOBULINS GAMMA	10-20 (%)	02/10/92	16.20
ESR/SEDIMENT. RATE 1st h	1-20 (MM)	02/10/92	6.00

2072

(°) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value and laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN950089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 6 Patient: 3DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			18/03/93		05/05/93		02/06/93	
			value	(ϕ)	value	(ϕ)	value	(ϕ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	02/10/92	14.60		15.00		14.00	
HT	34-47 (%)	02/10/92	44.60		43.90		39.70	
RBC	4-5.8 (10 ⁶ /MM ³)	02/10/92	4.74		4.76		4.37	
HBC	4000-10000 (/MM ³)	02/10/92	6200.00		5300.00		5400.00	
HBC: N	40-70 (%)	02/10/92	54.20		47.50		43.90	
HBC: L	20-50 (%)	02/10/92	40.50		45.70		45.50	
HBC: E	0-8 (%)	02/10/92	1.30		0.50		0.20	
HBC: M	0-13 (%)	02/10/92	3.60		5.70		5.70	
HBC: B	0-3 (%)	02/10/92	0.40		0.50		0.60	
PLATELETS	150-400 (10 ³ /MM ³)	02/10/92	358.00		280.00		218.00	
NA+	136-147 (MMOL/L)	02/10/92	140.00		143.00		140.00	
K+	3.6-5.5 (MMOL/L)	02/10/92	4.20		4.20		4.20	
CL-	95-110 (MMOL/L)	02/10/92	100.00		100.00		100.00	
Ca++	8.3-10.5 (MG/DL)	02/10/92	9.53		9.28		9.07	
PO4--	2.4-4.8 (MG/DL)	02/10/92	3.60		3.30		3.40	
SGOT	5-40 (U/L)	02/10/92	16.00		23.00		30.00	
SGPT	5-40 (U/L)	02/10/92	17.00		26.00		34.00	
GAMMA GT	0-40 (U/L)	02/10/92	18.00		26.00		23.00	
LDH	150-460 (U/L)	02/10/92			316.00		356.00	
ALK. PHOSPH.	40-350 (U/L)	02/10/92	151.00		109.00		151.00	
GLUCOSE	50-120 (MG/DL)	02/10/92	66.00		88.00		64.00	
UREA	8-48 (MG/DL)	02/10/92			40.00		49.00 >	
CREATININE	0.3-1.25 (MG/DL)	02/10/92	1.31 >		1.35 >		1.28 >	
CREATININE CLEARANCE	80-140 (ML/MIN)	02/10/92	111.35					
URIC ACID	2-6.5 (MG/DL)	02/10/92	5.51		4.32			
TOT BILIRUBIN	0.1-1 (MG/DL)	02/10/92	0.40		0.49		0.65	
DIR BILIRUBIN	0-0.9 (MG/DL)	02/10/92	0.14		0.12		0.03	
TOT. PROTEINS	6.1-8 (G/DL)	02/10/92	6.86		7.44		7.30	
ALBUMINE	55-72 (%)	02/10/92	68.50		68.50		66.10	
TOT. CHOLEST.	120-250 (MG/DL)	02/10/92	198.00		238.00		217.00	
TRIGLYCERIDES	40-170 (MG/DL)	02/10/92	160.00		178.00 >		205.00 >	
GLOBULINS ALPHA 1	2-6 (%)	02/10/92	3.30		3.00		2.80	
GLOBULINS ALPHA 2	6-11 (%)	02/10/92	6.70		5.90 <		6.80	
GLOBULINS BETA	9-14 (%)	02/10/92	9.80		9.80		11.90	
GLOBULINS GAMMA	10-20 (%)	02/10/92	11.70		12.80		12.40	
TSH	0.1-4 (UUI/ML)	02/10/92	0.56					
T4	4.8-12.8 (UG/DL)	02/10/92	10.20					
ESR/SEDIMENT. RATE 1st h	1-20 (MM)	02/10/92	7.00					

2073

(ϕ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN5590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 6 Patient: 4DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			28/04/93		02/06/93		30/06/93	
			value	(ϕ)	value	(ϕ)	value	(ϕ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	02/10/92	13.70		15.00		14.40	
HT	34-47 (%)	02/10/92	42.80		43.50		43.30	
RBC	4-5.8 (10 ⁶ /MM ³)	02/10/92	4.99		5.01		5.03	
WBC	4000-10000 (/MM ³)	02/10/92	6700.00		5000.00		5300.00	
WBC: N	40-70 (%)	02/10/92	61.70		50.10		43.10	
WBC: L	20-50 (%)	02/10/92	29.70		39.30		45.60	
WBC: E	0-8 (%)	02/10/92	3.40		4.20		5.70	
WBC: M	0-13 (%)	02/10/92	4.50		5.80		5.30	
WBC: B	0-3 (%)	02/10/92	0.60		0.60		0.40	
PLATELETS	150-400 (10 ³ /MM ³)	02/10/92	253.00		262.00		231.00	
NA+	136-147 (MMOL/L)	02/10/92	140.00		143.00		138.00	
K+	3.6-5.5 (MMOL/L)	02/10/92	3.90		4.70		3.80	
CL-	95-110 (MMOL/L)	02/10/92	104.00		103.00		99.00	
Ca++	8.3-10.5 (MG/DL)	02/10/92	9.25		9.18		9.07	
PO4--	2.4-4.8 (MG/DL)	02/10/92	2.90		3.40		3.70	
SGOT	5-40 (U/L)	02/10/92	21.00		18.00		19.00	
SGPT	5-40 (U/L)	02/10/92	20.00		15.00		16.00	
GAMMA GT	0-40 (U/L)	02/10/92	10.00		11.00		9.00	
LDH	150-460 (U/L)	02/10/92	493.00	>			329.00	
ALK. PHOSPH.	40-350 (U/L)	02/10/92	144.00		173.00		155.00	
GLUCOSE	50-120 (MG/DL)	02/10/92	80.00		56.00		74.00	
UREA	8-48 (MG/DL)	02/10/92	35.00		29.00		27.00	
CREATININE	0.3-1.25 (MG/DL)	02/10/92	1.12		1.08		1.00	
CREATININE CLEARANCE	80-140 (ML/MIN)	02/10/92	49.26					
URIC ACID	2-6.5 (MG/DL)	02/10/92	4.21		3.74		3.94	
TOT BILIRUBIN	0.1-1 (MG/DL)	02/10/92	0.39		0.38		0.55	
DIR BILIRUBIN	0-0.9 (MG/DL)	02/10/92	0.01		0.13		0.15	
TOT. PROTEINS	6.1-8 (G/DL)	02/10/92	6.84		7.59		7.15	
ALBUMINE	55-72 (%)	02/10/92	67.30		66.40		65.10	
TOT. CHOLEST.	120-250 (MG/DL)	02/10/92	250.00		281.00	>	255.00	>
TRIGLYCERIDES	40-170 (MG/DL)	02/10/92	113.00		84.00		94.00	
GLOBULINS ALPHA 1	2-6 (%)	02/10/92	3.20		4.00		3.00	
GLOBULINS ALPHA 2	6-11 (%)	02/10/92	7.40		6.70		8.10	
GLOBULINS BETA	9-14 (%)	02/10/92	10.60		10.80		11.10	
GLOBULINS GAMMA	10-20 (%)	02/10/92	11.50		12.10		12.70	
TSH	0.1-4 (UUI/ML)	02/10/92	1.12					
T4	4.8-12.8 (UG/DL)	02/10/92	7.70					
ESR/SEDIMENT. RATE 1st h	1-20 (MM)	02/10/92	10.00		4.00		3.00	

2074

(ϕ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN 589089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 6 Patient: SDT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			17/11/93		17/12/93		14/01/94	
			value	(c)	value	(c)	value	(c)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	02/10/92	13.30		14.80		14.60	
HT	34-47 (X)	02/10/92	40.90		42.80		42.30	
RBC	4-5.8 (10 ⁶ /MM ³)	02/10/92	4.27		4.48		4.45	
WBC	4000-10000 (/MM ³)	02/10/92	5700.00		7200.00		7100.00	
WBC: N	40-70 (%)	02/10/92	63.70		68.50		65.90	
WBC: L	20-50 (%)	02/10/92	31.90		24.70		27.80	
WBC: E	0-8 (%)	02/10/92	2.50		3.30		2.50	
WBC: M	0-13 (%)	02/10/92	1.80		3.20		3.70	
WBC: B	0-3 (%)	02/10/92	0.00		0.30		0.10	
PLATELETS	150-400 (10 ³ /MM ³)	02/10/92	268.00		293.00		306.00	
NA+	136-147 (MMOL/L)	02/10/92	142.00		138.00		141.00	
K+	3.6-5.5 (MMOL/L)	02/10/92	4.80		4.60		4.90	
CL-	95-110 (MMOL/L)	02/10/92	106.00		104.00		104.00	
Ca++	8.3-10.5 (MG/DL)	02/10/92	9.04		9.59		9.47	
PO4--	2.4-4.8 (MG/DL)	02/10/92	3.40		3.60		3.70	
SGOT	5-40 (U/L)	02/10/92	24.00		29.00		32.00	
SGPT	5-40 (U/L)	02/10/92	19.00		28.00		29.00	
GAMMA GT	0-40 (U/L)	02/10/92	66.00	>	66.00	>	79.00	
LDH	150-460 (U/L)	02/10/92	364.00		376.00		422.00	
ALK. PHOSPH.	40-350 (U/L)	02/10/92	204.00		258.00		264.00	
GLUCOSE	50-120 (MG/DL)	02/10/92	99.00		109.00		108.00	
UREA	8-48 (MG/DL)	02/10/92	36.00		40.00		34.00	
CREATININE	0.3-1.25 (MG/DL)	02/10/92	0.96		0.88		0.89	
CREATININE CLEARANCE	80-140 (ML/MIN)	02/10/92	71.91					
URIC ACID	2-6.5 (MG/DL)	02/10/92	5.26		5.11		4.61	
TOT BILIRUBIN	0.1-1 (MG/DL)	02/10/92	0.62		0.27		0.60	
DIR BILIRUBIN	0-0.9 (MG/DL)	02/10/92	0.05		0.08		0.01	
TOT. PROTEINS	6.1-8 (G/DL)	02/10/92	7.20		7.94		7.97	
ALBUMINE	55-72 (%)	02/10/92	63.00		60.10		62.30	
TOT. CHOLEST.	120-250 (MG/DL)	02/10/92	205.00		205.00		210.00	
TRIGLYCERIDES	40-170 (MG/DL)	02/10/92	161.00		197.00	>	227.00	
GLOBULINS ALPHA 1	2-6 (X)	02/10/92	2.20		2.10		2.20	
GLOBULINS ALPHA 2	6-11 (X)	02/10/92	8.10		6.80		7.90	
GLOBULINS BETA	9-14 (X)	02/10/92	11.60		12.80		11.80	
GLOBULINS GAMMA	10-20 (X)	02/10/92	15.10		18.20		15.80	
TSH	0.1-4 (UUI/ML)	02/10/92	0.95					
T4	4.8-12.8 (UG/DL)	02/10/92	6.60					
ESR/SEDIMENT. RATE 1st h	1-20 (MM)	02/10/92	16.00		30.00		40.00	

2075

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C9590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 7 Patient: 1MD Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			06/01/93		05/02/93		05/03/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	26/11/92	13.50	<	11.80	<<	13.20	<
HT	36-54 (X)	26/11/92	42.10		39.80		39.00	
RBC	4-5 (10 ⁶ /MM ³)	26/11/92	4.36		4.60		4.10	
HBC	3000-11000 (/MM ³)	26/11/92	5600.00		5700.00		7200.00	
HBC: N	40-75 (X)	26/11/92			48.00		58.00	
HBC: L	20-40 (X)	26/11/92			40.00		32.00	
HBC: E	1-4 (X)	26/11/92			8.00	>>	3.00	
HBC: M	4-8 (X)	26/11/92			4.00		6.00	
HBC: B	0-1 (X)	26/11/92			0.00		1.00	
PLATELETS	150000-400000 (/MM ³)	26/11/92			219000		241000	
NA+	135-155 (NEQ/L)	26/11/92	141.70		141.00		144.00	
K+	3.1-5.5 (NEQ/L)	26/11/92	4.16		4.76		4.60	
CL-	98-107 (NEQ/L)	26/11/92	95.00	<	105.00		114.00	>
Ca++	88-102 (MG/L)	26/11/92	98.00		87.00	<	87.00	<
PO4--	2.5-4.8 (MG/DL)	26/11/92	4.42		3.95		3.20	
SGOT	0-18 (U/L)	26/11/92	8.00		11.00		8.00	
SGPT	0-22 (U/L)	26/11/92	8.00		14.00		14.00	
GAMMA GT	0-25 (U/L)	26/11/92	10.00		6.50		8.00	
LDH	120-240 (U/L)	26/11/92	140.00		142.00		195.00	
ALK. PHOSPH.	0-90 (U/L)	26/11/92	69.00		90.00		141.00	>
GLUCOSE	76-120 (MG/DL)	26/11/92	95.00		91.00		74.00	<
UREA	10-50 (MG/DL)	26/11/92	55.80	>	55.80	>	38.00	
CREATININE	0.7-1.35 (MG/DL)	26/11/92	0.56	<	1.12		1.10	
CREATININE	()	26/11/92	121.13	()				
CLEARANCE								
URIC ACID	0-7 (MG/DL)	26/11/92	2.25		5.70		7.50	>
TOT BILIRUBIN	0-1 (MG/DL)	26/11/92	0.56		0.35		0.30	
DIR BILIRUBIN	0-0.25 (MG/DL)	26/11/92	0.08		0.03		0.10	
TOT. PROTEINS	6.6-8.7 (G/DL)	26/11/92	7.97		5.80	<	6.50	<
ALBUMINE	3.97-5.34 (G/DL)	26/11/92			3.50	<	4.20	
TOT. CHOLEST.	0-260 (MG/DL)	26/11/92	195.00		205.00		246.00	
TRIGLYCERIDES	0-172 (MG/DL)	26/11/92	133.00		134.00		208.00	>
GLOBULINS ALPHA 1	0.11-0.32 (G/DL)	26/11/92			0.20		0.30	
GLOBULINS ALPHA 2	0.53-1.12 (G/DL)	26/11/92			0.70		0.70	
GLOBULINS BETA	0.42-0.87 (G/DL)	26/11/92			0.70		0.70	
GLOBULINS GAMMA	0.53-1.97 (G/DL)	26/11/92			0.80		0.80	
TSH	0.2-6 (MU/L)	26/11/92	2.20					
T4	45-135 (NG/ML)	26/11/92	75.00					
ESR/SEDIMENT. RATE	0-20 (MM)	26/11/92						
1st h			4.00				21.00	

2076

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C9580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 7 Patient: 3MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			19/04/93		19/05/93		14/06/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	26/11/92	14.40		14.30		12.90	
HT	36-54 (%)	26/11/92	33.50	<	37.40		34.90	<
RBC	4-5 (10 ⁶ /MM3)	26/11/92	4.17		4.35		4.00	
WBC	3000-11000 (/MM3)	26/11/92	8000.00		6500.00		4800.00	
WBC: N	40-75 (%)	26/11/92	60.00		68.00		50.00	
WBC: L	20-40 (%)	26/11/92	20.00		16.00	<	36.00	
WBC: E	1-4 (%)	26/11/92	8.00	>>	4.00		3.00	
WBC: M	4-8 (%)	26/11/92	12.00	>>	10.00	>	10.00	>
WBC: B	0-1 (%)	26/11/92	0.00		2.00	>>	1.00	
PLATELETS	150000-400000 (/MM3)	26/11/92	332000				228000	
NA+	135-155 (MEQ/L)	26/11/92	139.60		134.20	<	135.00	
K+	3.1-5.5 (MEQ/L)	26/11/92	4.31		4.91		4.71	
CL-	98-107 (MEQ/L)	26/11/92	103.00		98.00		101.00	
Ca++	88-102 (MG/L)	26/11/92	103.00	>	99.50		82.60	<
PO4--	2.5-4.8 (MG/DL)	26/11/92	4.72		3.93		3.82	
SGOT	0-15 (U/L)	26/11/92	13.00		9.00		7.00	
SGPT	0-17 (U/L)	26/11/92	13.00		9.00		13.00	
GAMMA GT	0-18 (U/L)	26/11/92	8.00		12.00		14.00	
LDH	120-240 (U/L)	26/11/92	247.00	>	237.00		169.00	
ALK. PHOSPH.	0-90 (U/L)	26/11/92	81.00		66.00		69.00	
GLUCOSE	76-120 (MG/DL)	26/11/92	91.00		94.00		91.00	
UREA	10-50 (MG/DL)	26/11/92	22.60		20.50		29.50	
CREATININE	0.55-1.1 (MG/DL)	26/11/92	1.00		1.01		0.96	
CREATININE CLEARANCE		26/11/92	54.18	()				
URIC ACID	0-5.7 (MG/DL)	26/11/92	4.20		2.00		4.30	
TOT BILIRUBIN	0-1 (MG/DL)	26/11/92	0.71		0.38		0.27	
DIR BILIRUBIN	0-0.25 (MG/DL)	26/11/92	0.07		0.06		0.00	
TOT. PROTEINS	6.6-8.7 (G/DL)	26/11/92	7.00		7.42		7.94	
ALBUMINE	3.97-5.34 (G/DL)	26/11/92	4.30				4.00	
TOT. CHOLEST.	0-260 (MG/DL)	26/11/92	249.00		261.00	>	236.00	
TRIGLYCERIDES	0-172 (MG/DL)	26/11/92	125.00		85.00		61.00	
GLOBULINS ALPHA 1	0.11-0.32 (G/DL)	26/11/92	0.20				0.10	<
GLOBULINS ALPHA 2	0.53-1.12 (G/DL)	26/11/92	0.70				0.60	
GLOBULINS BETA	0.42-0.87 (G/DL)	26/11/92	0.80				0.70	
GLOBULINS GAMMA	0.53-1.97 (G/DL)	26/11/92	1.00				0.70	
TSH	0.2-6 (MU/L)	26/11/92	7.20					
T4	45-135 (NG/ML)	26/11/92	73.00					

2077

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C050089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 7 Patient: 4MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	Day 28
			16/04/93	24/05/93
			value (€)	value (€)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	15/03/93	13.60	13.30
HT	36-54 (X)	15/03/93	39.00	37.10
RBC	4-5 (10 ⁶ /MM ³)	15/03/93	4.20	4.07
MBC	3-11 (10 ³ /ML)	15/03/93	7.30	
	3000-11000 (/MM ³)	23/05/93		6300.00
MBC: N	40-75 (X)	15/03/93	74.00	70.00
MBC: L	20-40 (X)	15/03/93	16.00 <	20.00
MBC: E	1-4 (X)	15/03/93	1.00	3.00
MBC: M	4-8 (X)	15/03/93	8.00	6.00
MBC: B	0-1 (X)	15/03/93	1.00	1.00
PLATELETS	150-400 (10 ³ /ML)	15/03/93	222.00	
NA+	135-155 (MEQ/L)	15/03/93	139.00	141.70
K+	3.1-5.5 (MEQ/L)	15/03/93	4.30	4.97
CL-	98-107 (MEQ/L)	15/03/93	105.00	99.00
Ca++	8.7-10.8 (MG/DL)	15/03/93	9.30	
	88-102 (MG/L)	23/05/93		94.40
PO4--	2.5-4.8 (MG/DL)	15/03/93	3.40	3.90
SGOT	0-15 (U/L)	15/03/93	6.00	7.00
SGPT	0-17 (U/L)	15/03/93	9.00	9.00
GAMMA GT	0-18 (U/L)	15/03/93	11.00	11.00
LDH	120-240 (U/L)	15/03/93	226.00	171.00
ALK. PHOSPH.	0-90 (U/L)	15/03/93	78.00	58.00
GLUCOSE	76-120 (MG/DL)	15/03/93	146.00 >	92.00
UREA	10-50 (MG/DL)	15/03/93	27.00	26.30
CREATININE	0.55-1.1 (MG/DL)	15/03/93	0.60	0.66
CREATININE CLEARANCE	()	15/03/93	71.17 ()	
URIC ACID	0-5.7 (MG/DL)	15/03/93	4.10	5.10
TOT BILIRUBIN	0-1 (MG/DL)	15/03/93	0.70	0.37
DIR BILIRUBIN	0-0.25 (MG/DL)	15/03/93	0.20	0.03
TOT. PROTEINS	6.6-8.7 (G/DL)	15/03/93	6.30 <	6.35 <
ALBUMINE	3.97-5.34 (G/DL)	15/03/93	3.70 <	
TOT. CHOLEST.	0-260 (MG/DL)	15/03/93	238.00	271.00 >
TRIGLYCERIDES	0-172 (MG/DL)	15/03/93	121.00	169.00
GLOBULINS ALPHA 1	0.11-0.32 (G/DL)	15/03/93	0.30	
GLOBULINS ALPHA 2	0.53-1.12 (G/DL)	15/03/93	0.90	
GLOBULINS BETA	0.42-0.87 (G/DL)	15/03/93	0.90 >	
GLOBULINS GAMMA	0.53-1.97 (G/DL)	15/03/93	0.60	
TSH	0.2-6 (MU/L)	15/03/93	0.80	
T4	45-135 (NG/ML)	15/03/93	82.00	
ESR/SEDIMENT. RATE 1st h	0-20 (MM)	15/03/93	40.00	

2078

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARNACIA CN580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 7 Patient: 342ND Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			22/02/93		24/03/93		19/04/93	
			value	(*)	value	(*)	value	(*)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	20/02/93	15.60		14.60		14.60	
HT	36-54 (%)	20/02/93	36.80		48.80		36.60	
RBC	4-5 (10 ⁶ /MM ³)	20/02/93	5.63 >		5.23 >		4.36	
HBC	3000-11000 (/MM ³)	20/02/93	8500.00		9100.00		8600.00	
HBC: N	40-75 (%)	20/02/93	56.00		76.00 >		86.00 >	
HBC: L	20-40 (%)	20/02/93	26.00		12.00 <<		12.00 <<	
HBC: E	1-4 (%)	20/02/93	2.00		2.00		0.00 <	
HBC: M	4-8 (%)	20/02/93	16.00 >>		8.00		2.00 <	
HBC: B	0-1 (%)	20/02/93	0.00		2.00 >>		0.00	
PLATELETS	150000-400000 (/MM ³)	20/02/93	270000		220000		229000	
NA+	135-155 (MEQ/L)	20/02/93	140.80		140.80		140.80	
K+	3.1-5.5 (MEQ/L)	20/02/93	3.77		4.06		3.89	
CL-	98-107 (MEQ/L)	20/02/93	103.00		100.00		102.00	
Ca++	88-102 (MG/L)	20/02/93	102.00		102.00		104.00 >	
PO4--	2.5-4.8 (MG/DL)	20/02/93	4.45		4.02		4.99 >	
SGOT	0-15 (U/L)	20/02/93	14.00		8.00		9.00	
SGPT	0-17 (U/L)	20/02/93	10.00		13.00		7.00	
GAMMA GT	0-18 (U/L)	20/02/93	9.00		11.00		5.50	
LDH	120-240 (U/L)	20/02/93	212.00		201.00		216.00	
ALK. PHOSPH.	0-90 (U/L)	20/02/93	83.00		90.00		98.00 >	
GLUCOSE	76-120 (MG/DL)	20/02/93	116.00		91.00		70.00 <	
UREA	10-50 (MG/DL)	20/02/93	30.20		32.90		35.60	
CREATININE	0.55-1.1 (MG/DL)	20/02/93	0.78		0.73		0.77	
CREATININE CLEARANCE		20/02/93	63.18 (*)					
URIC ACID	0-5.7 (MG/DL)	20/02/93	5.40		4.20		5.30	
TOT BILIRUBIN	0-1 (MG/DL)	20/02/93	0.69		0.80		1.39 >	
DIR BILIRUBIN	0-0.25 (MG/DL)	20/02/93	0.10		0.03		0.08	
TOT. PROTEINS	6.6-8.7 (G/DL)	20/02/93	8.50		7.10		8.00	
ALBUMINE	3.97-5.34 (G/DL)	20/02/93	5.00		3.50 <		4.60	
TOT. CHOLEST.	0-260 (MG/DL)	20/02/93	270.00 >		185.00		256.00	
TRIGLYCERIDES	0-172 (MG/DL)	20/02/93	137.00		98.00		156.00	
GLOBULINS ALPHA 1	0.11-0.32 (G/DL)	20/02/93	0.30		0.30		0.20	
GLOBULINS ALPHA 2	0.53-1.12 (G/DL)	20/02/93	0.72		0.60		0.70	
GLOBULINS BETA	0.42-0.87 (G/DL)	20/02/93	1.20 >>		1.10 >		1.20 >>	
GLOBULINS GAMMA	0.53-1.97 (G/DL)	20/02/93	0.70		1.20		1.20	
TSH	0.15-5.5 (MU/L)	20/02/93	1.20					
T4	5-12 (UG/DL)	20/02/93	8.90					
ESR/SEDIMENT. RATE 1st h	0-20 (MM)	20/02/93	24.00				24.00	

2079

(*) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done (*) missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C959089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 8 Patient: IMD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			28/09/92		26/10/92		24/11/92	
			value	(☺)	value	(☺)	value	(☺)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/09/92	12.70		13.60		12.90	
HT	37-45 (X)	01/09/92	39.00		42.00		40.00	
RBC	4.1-5.5 (10 ⁶ /MM ³)	01/09/92	4.35		4.70		4.38	
WBC	4-9 (10 ³ /MM ³)	01/09/92	6.50					
	4000-9000 (MM ³)	01/10/92			5350.00		5850.00	
WBC: N	45-70 (%)	01/09/92	57.00		57.00		57.00	
WBC: L	25-40 (%)	01/09/92	35.00		35.00		41.00 >	
WBC: E	0-4 (%)	01/09/92	2.00		3.00		3.00	
WBC: M	4-8 (%)	01/09/92	5.00		5.00		5.00	
WBC: B	0-1 (%)	01/09/92	1.00		1.00		1.00	
PLATELETS	150-300 (10 ³ /MM ³)	01/09/92	349.00 >		345.00 >		344.00 >	
NA+	137-145 (MMOL/L)	01/09/92	139.00		147.00 >		137.00	
K+	3.6-5.5 (MMOL/L)	01/09/92	3.70		4.50		3.90	
CL-	101-111 (MMOL/L)	01/09/92	104.00		104.00		102.00	
Ca++	8.5-10.6 (MG/DL)	01/09/92	9.20		9.10		8.70	
PO4--	2.5-4.5 (MG/DL)	01/09/92	3.90		4.10		4.30	
SGOT	7-56 (UI/L)	01/09/92	29.00		21.00		28.00	
SGPT	5-35 (UI/L)	01/09/92	18.00		13.00		16.00	
GAMMA GT	8-78 (UI/L)	01/09/92	32.00		20.00		26.00	
LDH	297-537 (UI/L)	01/09/92	522.00		675.00 >		713.00 >	
ALK. PHOSPH.	38-150 (UI/L)	01/09/92	97.00		84.00		97.00	
GLUCOSE	50-100 (MG/DL)	01/09/92	75.00		70.00		80.00	
UREA	15-45 (MG/DL)	01/10/92			38.00		24.00	
CREATININE	0.5-1.2 (MG/DL)	01/09/92	1.08		1.04		1.10	
CREATININE CLEARANCE	100-140 (ML/MIN)	01/09/92	46.00					
URIC ACID	2.5-8.5 (MG/DL)	01/09/92	5.50		3.00		3.70	
TOT BILIRUBIN	0.2-1.3 (MG/DL)	01/09/92	0.65		0.64		1.05	
DIR BILIRUBIN	0-0.4 (MG/DL)	01/09/92	0.13		0.14		0.98 >>	
TOT. PROTEINS	6.3-8.2 (G/DL)	01/09/92	7.65		7.50		7.40	
ALBUMINE	3.5-5.5 (G/DL)	01/09/92	4.90					
	55-77 (%)	01/10/92			57.50		56.20	
TOT. CHOLEST.	90-260 (MG/DL)	01/09/92	194.00		186.00		201.00	
TRIGLYCERIDES	40-160 (MG/DL)	01/09/92	84.00		86.00		105.00	
GLOBULINS ALPHA 1	2.2-5.2 (%)	01/09/92	2.70		3.90		4.00	
GLOBULINS ALPHA 2	9-14 (%)	01/09/92	8.40 <		11.20		11.30	
GLOBULINS BETA	8-13 (%)	01/09/92	7.90 <		9.30		10.10	
GLOBULINS GAMMA	10-18 (%)	01/09/92	16.90		18.30 >		18.70 >	
TSH	0.2-5 (UU/ML)	01/09/92	0.10					
T4	4.5-12.5 (UG/DL)	01/09/92	10.40					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/09/92	18.00		26.00		34.00	

2080

(☺) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C850089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 8 Patient: 2ND Treatment: Reboxetine Sex: Female

Laboratory test			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			28/09/92		26/10/92		24/11/92	
			value	(e)	value	(e)	value	(e)
Range value	Range date							
HB	12-16 (G/DL)	10/09/92	14.70		15.30		14.80	
HT	37-45 (%)	10/09/92	46.00 >		46.00 >		44.00	
RBC	4.1-5.5 (10 ⁶ /MM ³)	10/09/92	4.86		5.04		4.68	
WBC	4-9 (10 ³ /MM ³)	10/09/92	5.10					
	4000-9000 (MM ³)	10/10/92			6880.00		6880.00	
WBC: N	45-70 (%)	10/09/92	64.00		70.00		73.00 >	
WBC: L	25-40 (%)	10/09/92	25.00		20.00 <		18.00 <	
WBC: E	0-4 (%)	10/09/92	2.00		2.00		1.00	
WBC: M	4-8 (%)	10/09/92	9.00 >		7.00		7.00	
WBC: B	0-1 (%)	10/09/92	0.00		1.00		0.00	
PLATELETS	150-300 (10 ³ /MM ³)	10/09/92	108.00 <		231.00		199.00	
NA+	137-145 (MMOL/L)	10/09/92	138.00		140.00		137.00	
K+	3.6-5.5 (MMOL/L)	10/09/92	3.80		4.30		4.50	
CL-	101-111 (MMOL/L)	10/09/92	100.00 <		105.00		97.00 <	
Ca++	8.5-10.6 (MG/DL)	10/09/92	8.60		8.90		9.10	
PO4--	2.5-4.5 (MG/DL)	10/09/92	4.20		3.80		5.20 >>	
SGOT	7-56 (UI/L)	10/09/92	26.00		28.00		25.00	
SGPT	5-35 (UI/L)	10/09/92	28.00		19.00		25.00	
GAMMA GT	8-78 (UI/L)	10/09/92	29.00		26.00		23.00	
LDH	297-537 (UI/L)	10/09/92	736.00 >		893.00 >		994.00 >	
ALK. PHOSPH.	38-150 (UI/L)	10/09/92	85.00		77.00		77.00	
GLUCOSE	50-100 (MG/DL)	10/09/92	70.00		84.00			
UREA	15-45 (MG/DL)	10/10/92					53.00 >	
CREATININE	0.5-1.2 (MG/DL)	10/09/92	0.75		0.83		0.86	
CREATININE CLEARANCE	100-140 (ML/MIN)	10/09/92	102.00					
URIC ACID	2.5-8.5 (MG/DL)	10/09/92	4.40		4.30		4.10	
TOT BILIRUBIN	0.2-1.3 (MG/DL)	10/09/92	1.18		0.74		1.20	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/92	0.09		0.17		0.40	
TOT. PROTEINS	6.3-8.2 (G/DL)	10/09/92	7.39		7.13		7.48	
ALBUMINE	3.5-5.5 (G/DL)	10/09/92	4.81					
	55-77 (%)	10/10/92			60.97		53.70 <	
TOT. CHOLEST.	90-260 (MG/DL)	10/09/92	240.00		203.00		186.00	
TRIGLYCERIDES	40-160 (MG/DL)	10/09/92	73.00		59.00		77.00	
GLOBULINS ALPHA 1	2.2-5.2 (%)	10/09/92	3.50		3.50		6.40 >	
GLOBULINS ALPHA 2	9-14 (%)	10/09/92	10.30		11.40		13.40	
GLOBULINS BETA	8-13 (%)	10/09/92	10.10		11.00		11.90	
GLOBULINS GAMMA	10-18 (%)	10/09/92	10.90		13.30		14.60	
TSH	0.2-5 (UU/ML)	10/09/92	2.90					
T4	4.5-12.5 (UG/DL)	10/09/92	10.80					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	10/09/92	12.00		12.00		10.00	

2081

(e) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARNACIA C 050089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 8 Patient: 3MD Treatment: Imipranine Sex: Female

			Visit number / Laboratory date	
			Screen	
			07/09/92	
			value	(*)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	01/09/92	12.90	
HT	37-45 (%)	01/09/92	40.00	
RBC	4.1-5.5 (10 ⁶ /MM ³)	01/09/92	4.33	
WBC	4-9 (10 ³ /MM ³)	01/09/92	14.20	>>
WBC: N	45-70 (%)	01/09/92	76.00	>
WBC: L	25-40 (%)	01/09/92	17.00	<<
WBC: E	0-4 (%)	01/09/92	1.00	
WBC: M	4-8 (%)	01/09/92	6.00	
WBC: B	0-1 (%)	01/09/92	1.00	
PLATELETS	150-300 (10 ³ /MM ³)	01/09/92	404.00	>>
NA+	137-145 (MMOL/L)	01/09/92	139.00	
K+	3.6-5.5 (MMOL/L)	01/09/92	3.80	
CL-	101-111 (MMOL/L)	01/09/92	103.00	
Ca++	8.5-10.6 (MG/DL)	01/09/92	9.50	
PO4--	2.5-4.5 (MG/DL)	01/09/92	3.80	
SGOT	7-56 (UI/L)	01/09/92	17.00	
SGPT	5-35 (UI/L)	01/09/92	12.00	
GAMMA GT	8-78 (UI/L)	01/09/92	56.00	
LDR	297-537 (UI/L)	01/09/92	507.00	
ALK. PHOSPH.	38-150 (UI/L)	01/09/92	128.00	
GLUCOSE	50-100 (MG/DL)	01/09/92	88.00	
CREATININE	0.5-1.2 (MG/DL)	01/09/92	0.57	
CREATININE CLEARANCE	100-140 (ML/MIN)	01/09/92	74.00	
URIC ACID	2.5-8.5 (MG/DL)	01/09/92	3.00	
TOT BILIRUBIN	0.2-1.3 (MG/DL)	01/09/92	0.61	
DIR BILIRUBIN	0-0.4 (MG/DL)	01/09/92	0.15	
TOT. PROTEINS	6.3-8.2 (G/DL)	01/09/92	6.20	<
ALBUMINE	55-77 (%)	01/09/92	62.00	
TOT. CHOLEST.	90-260 (MG/DL)	01/09/92	280.00	>
TRIGLYCERIDES	40-160 (MG/DL)	01/09/92	150.00	
GLOBULINS ALPHA 1	2.2-5.2 (%)	01/09/92	4.00	
GLOBULINS ALPHA 2	9-14 (%)	01/09/92	18.10	>
GLOBULINS BETA	8-13 (%)	01/09/92	8.90	
GLOBULINS GAMMA	10-18 (%)	01/09/92	6.60	<<
TSH	0.2-5 (UU/ML)	01/09/92	0.10	
T4	4.5-12.5 (UG/DL)	01/09/92	11.60	
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/09/92	43.00	

2082

(*) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C050089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 8 Patient: 4ND Treatment: Imipramine Sex: Male

			Visit number / Laboratory date	
			Screen	
			28/07/92	
			value	(*)
Laboratory test	Range value	Range date		
HB	14-18 (G/DL)	01/06/92	13.60	<
HT	40-54 (Z)	01/06/92	41.00	
RBC	4.1-5.5 (10 ⁶ /MM ³)	01/06/92	4.28	
WBC	4-9 (10 ³ /MM ³)	01/06/92	9.00	
WBC: N	45-70 (%)	01/06/92	59.00	
WBC: L	25-40 (%)	01/06/92	27.00	
WBC: E	0-4 (%)	01/06/92	8.00	>>
WBC: M	4-8 (%)	01/06/92	6.00	
WBC: B	0-1 (%)	01/06/92	1.00	
PLATELETS	150-300 (10 ³ /MM ³)	01/06/92	288.00	
NA+	137-145 (MMOL/L)	01/06/92	140.00	
K+	3.6-5.5 (MMOL/L)	01/06/92	4.20	
CL-	101-111 (MMOL/L)	01/06/92	102.00	
Ca++	8.5-10.6 (MG/DL)	01/06/92	8.90	
PO4--	2.5-4.5 (MG/DL)	01/06/92	2.90	
SGOT	7-56 (UI/L)	01/06/92	16.00	
SGPT	5-35 (UI/L)	01/06/92	19.00	
GAMMA GT	8-78 (UI/L)	01/06/92	35.00	
LDH	297-537 (UI/L)	01/06/92	445.00	
ALK. PHOSPH.	38-150 (UI/L)	01/06/92	77.00	
GLUCOSE	50-100 (MG/DL)	01/06/92	93.00	
CREATININE	0.5-1.2 (MG/DL)	01/06/92	0.90	
CREATININE CLEARANCE	100-140 (ML/MIN)	01/06/92	51.00	
URIC ACID	2.5-8.5 (MG/DL)	01/06/92	3.70	
TOT BILIRUBIN	0.2-1.3 (MG/DL)	01/06/92	0.53	
DIR BILIRUBIN	0-0.4 (MG/DL)	01/06/92	0.09	
TOT. PROTEINS	6.3-8.2 (G/DL)	01/06/92	6.31	
ALBUMINE	3.5-5.5 (G/DL)	01/06/92	4.69	
TOT. CHOLEST.	90-260 (MG/DL)	01/06/92	160.00	
TRIGLYCERIDES	40-160 (MG/DL)	01/06/92	160.00	
GLOBULINS ALPHA 1	2.2-5.2 (%)	01/06/92	4.80	
GLOBULINS ALPHA 2	9-14 (%)	01/06/92	10.20	
GLOBULINS BETA	8-13 (%)	01/06/92	10.80	
GLOBULINS GAMMA	10-18 (%)	01/06/92	15.20	
TSH	0.2-5 (UU/ML)	01/06/92	0.39	
T4	4.5-12.5 (UG/DL)	01/06/92	8.00	
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/06/92	5.00	

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

2083

(*) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C0560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 8 Patient: 701ND Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			05/10/92		05/11/92		04/12/92	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	01/06/92	13.70	<	16.80		14.40	
HT	40-54 (%)	01/06/92	42.00		51.00		45.00	
RBC	4.1-5.5 (10 ⁶ /MM ³)	01/06/92	4.43		5.44		4.66	
WBC	4-9 (10 ³ /MM ³)	01/06/92	6.19		8.46		7.28	
WBC: N	45-70 (%)	01/06/92	55.00		65.00		60.00	
WBC: L	25-40 (%)	01/06/92	32.00		26.00		26.00	
WBC: E	0-4 (%)	01/06/92	5.00	>	4.00		7.00	
WBC: H	4-8 (%)	01/06/92	7.00		5.00		6.00	
WBC: B	0-1 (%)	01/06/92	1.00		1.00		1.00	
PLATELETS	150-300 (10 ³ /MM ³)	01/06/92			236.00		243.00	
NA+	137-145 (MMOL/L)	01/06/92	139.00		140.00		138.00	
K+	3.6-5.5 (MMOL/L)	01/06/92	4.70		4.00		4.10	
CL-	101-111 (MMOL/L)	01/06/92	106.00		99.00	<	100.00	
Ca++	8.5-10.6 (MG/DL)	01/06/92	9.30		10.10		9.40	
PO4--	2.5-4.5 (MG/DL)	01/06/92	3.30		4.30		3.70	
SGOT	7-56 (UI/L)	01/06/92	25.00		36.00		26.00	
SGPT	5-35 (UI/L)	01/06/92	18.00		19.00		19.00	
GAMMA GT	8-78 (UI/L)	01/06/92	22.00		28.00		28.00	
LDH	297-537 (UI/L)	01/06/92	552.00	>	552.00	>	634.00	
ALK. PHOSPH.	38-150 (UI/L)	01/06/92	88.00		160.00	>	128.00	
GLUCOSE	50-100 (MG/DL)	01/06/92	71.00		82.00		76.00	
UREA	15-45 (MG/DL)	01/06/92			45.00		29.00	
CREATININE	0.5-1.2 (MG/DL)	01/06/92	0.98		1.00		0.95	
CREATININE CLEARANCE	100-140 (ML/MIN)	01/06/92	56.00					
URIC ACID	2.5-8.5 (MG/DL)	01/06/92	6.40		6.50		5.10	
TOT BILIRUBIN	0.2-1.3 (MG/DL)	01/06/92	0.64		1.36	>	1.35	
DIR BILIRUBIN	0-0.4 (MG/DL)	01/06/92	0.18		0.39		0.32	
TOT. PROTEINS	6.3-8.2 (G/DL)	01/06/92	6.37		8.49	>	8.49	
ALBUMINE	3.5-5.5 (G/DL)	01/06/92	4.15		4.50		4.64	
TOT. CHOLEST.	90-260 (MG/DL)	01/06/92	186.00		261.00	>	226.00	
TRIGLYCERIDES	40-160 (MG/DL)	01/06/92	102.00		119.00		82.00	
GLOBULINS ALPHA 1	2.2-5.2 (%)	01/06/92	2.40		4.70		3.90	
GLOBULINS ALPHA 2	9-14 (%)	01/06/92	8.00	<	13.90		12.10	
GLOBULINS BETA	8-13 (%)	01/06/92	9.10		13.50	>	11.40	
GLOBULINS GAMMA	10-18 (%)	01/06/92	15.20		20.50	>	18.10	
TSH	0.2-5 (UU/ML)	01/06/92	1.24					
T4	4.5-12.5 (UG/DL)	01/06/92	9.00					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/06/92	4.00		12.00		9.00	

2084

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C0580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 8 Patient: 702MD Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			14/10/92		13/11/92		03/12/92	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	01/06/92	12.50	<	13.00	<	13.00	<
HT	40-54 (%)	01/06/92	39.00	<	38.00	<	40.00	<
RBC	4.1-5.5 (10 ⁶ /MM ³)	01/06/92	3.99	<	3.96	<	4.13	<
WBC	4-9 (10 ³ /MM ³)	01/06/92	5.81		5.21		4.65	
WBC: N	45-70 (%)	01/06/92	48.00		46.00		42.00	<
WBC: L	25-40 (%)	01/06/92	37.00		43.00	>	47.00	>
WBC: E	0-4 (%)	01/06/92	3.00		3.00		3.00	
WBC: M	4-8 (%)	01/06/92	11.00	>>	8.00		7.00	
WBC: B	0-1 (%)	01/06/92	1.00		1.00		1.00	
PLATELETS	150-300 (10 ³ /MM ³)	01/06/92	238.00		245.00		221.00	
NA+	137-145 (MMOL/L)	01/06/92	141.00		139.00		135.00	<
K+	3.6-5.5 (MMOL/L)	01/06/92	4.50		5.00		4.80	
CL-	101-111 (MMOL/L)	01/06/92	101.00		101.00		99.00	<
Ca++	8.5-10.6 (MG/DL)	01/06/92	9.40		9.30		9.10	
PO4--	2.5-4.5 (MG/DL)	01/06/92	3.00		3.70		3.60	
SGOT	7-56 (UI/L)	01/06/92	20.00		23.00		20.00	
SGPT	5-35 (UI/L)	01/06/92	22.00		23.00		22.00	
GAMMA GT	8-78 (UI/L)	01/06/92	36.00		28.00		28.00	
LDH	297-537 (UI/L)	01/06/92	413.00		471.00		436.00	
ALK. PHOSPH.	38-150 (UI/L)	01/06/92	76.00		71.00		64.00	
GLUCOSE	50-100 (MG/DL)	01/06/92	71.00		76.00		78.00	
UREA	15-45 (MG/DL)	01/06/92			47.00	>	44.00	
CREATININE	0.5-1.2 (MG/DL)	01/06/92	0.94		0.96		1.01	
CREATININE CLEARANCE	100-140 (ML/MIN)	01/06/92	50.00					
URIC ACID	2.5-8.5 (MG/DL)	01/06/92	3.10		3.20		3.20	
TOT BILIRUBIN	0.2-1.3 (MG/DL)	01/06/92	0.45		1.06		1.03	
DIR BILIRUBIN	0-0.4 (MG/DL)	01/06/92	0.09		0.24		0.22	
TOT. PROTEINS	6.3-8.2 (G/DL)	01/06/92	7.30		7.49		7.16	
ALBUMINE	3.5-5.5 (G/DL)	01/06/92	4.21		4.20		4.42	
TOT. CHOLEST.	90-260 (MG/DL)	01/06/92	262.00	>	302.00	>	307.00	>
TRIGLYCERIDES	40-160 (MG/DL)	01/06/92	63.00		73.00		74.00	
GLOBULINS ALPHA 1	2.2-5.2 (%)	01/06/92	5.60	>	5.10		2.00	<
GLOBULINS ALPHA 2	9-14 (%)	01/06/92	11.40		11.90		10.40	
GLOBULINS BETA	8-13 (%)	01/06/92	10.60		10.60		9.80	
GLOBULINS GAMMA	10-18 (%)	01/06/92	14.60		16.30		16.10	
TSH	0.2-5 (UU/ML)	01/06/92	0.99					
T4	4.5-12.5 (UG/DL)	01/06/92	8.60					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/06/92	29.00		24.00		20.00	

2085

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CN9530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 8 Patient: 703ND Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			19/11/92		08/03/93		05/04/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/06/92	13.90		13.10		13.30	
HT	37-45 (%)	01/06/92	41.00		39.00		41.00	
RBC	4.1-5.5 (10 ⁶ /MM ³)	01/06/92	4.71		4.44		4.64	
MBC	4-9 (10 ⁶ /MM ³)	01/06/92	6.61		5.45		6.56	
MBC: N	45-70 (%)	01/06/92	48.00		41.00	<	49.00	
MBC: L	25-40 (%)	01/06/92	35.00		44.00	>	38.00	
MBC: E	0-4 (%)	01/06/92	5.00	>	4.00		4.00	
MBC: M	4-8 (%)	01/06/92	11.00	>>	9.00	>	8.00	
MBC: B	0-1 (%)	01/06/92	1.00		1.00		1.00	
PLATELETS	150-300 (10 ³ /MM ³)	01/06/92	284.00		231.00		298.00	
NA+	137-145 (MMOL/L)	01/06/92	141.00		140.00		139.00	
K+	3.6-5.5 (MMOL/L)	01/06/92	4.70		4.60		4.80	
CL-	101-111 (MMOL/L)	01/06/92	106.00		105.00		103.00	
Ca++	8.5-10.6 (MG/DL)	01/06/92	8.90		8.60		8.30	
PO4--	2.5-4.5 (MG/DL)	01/06/92	4.30		4.50		4.10	
SGOT	7-56 (UI/L)	01/06/92	20.00		22.00		17.00	
SGPT	5-35 (UI/L)	01/06/92	15.00		17.00		16.00	
GAMMA GT	8-78 (UI/L)	01/06/92	65.00		59.00		42.00	
LDH	297-537 (UI/L)	01/06/92	481.00		317.00		325.00	
ALK. PHOSPH.	38-150 (UI/L)	01/06/92	112.00		107.00		13.00	
GLUCOSE	50-100 (MG/DL)	01/06/92	82.00		86.00		79.00	
UREA	15-45 (MG/DL)	01/06/92	42.00		35.00		35.00	
CREATININE	0.5-1.2 (MG/DL)	01/06/92	1.10		1.06		1.19	
CREATININE CLEARANCE	100-140 (ML/MIN)	01/06/92	56.00					
URIC ACID	2.5-8.5 (MG/DL)	01/06/92	4.50		4.10		4.10	
TOT BILIRUBIN	0.2-1.3 (MG/DL)	01/06/92	1.22		1.10			
DIR BILIRUBIN	0-0.4 (MG/DL)	01/06/92			0.12			
TOT. PROTEINS	6.3-8.2 (G/DL)	01/06/92	6.65		7.22		7.54	
ALBUMINE	3.5-5.5 (G/DL)	01/06/92	3.53		3.63		3.43	
TOT. CHOLEST.	90-260 (MG/DL)	01/06/92	177.00		209.00		182.00	
TRIGLYCERIDES	40-160 (MG/DL)	01/06/92	145.00		116.00		145.00	
GLOBULINS ALPHA 1	2.2-5.2 (%)	01/06/92	3.80		3.10		4.30	
GLOBULINS ALPHA 2	9-14 (%)	01/06/92	10.70		10.40		10.00	
GLOBULINS BETA	8-13 (%)	01/06/92	10.80		11.50		14.50	
GLOBULINS GAMMA	10-18 (%)	01/06/92	21.00	>	21.90	>	25.80	
TSH	0.2-5 (UU/ML)	01/06/92	0.34					
T4	4.5-12.5 (UG/DL)	01/06/92	6.90					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/06/92			24.00		33.00	

2086

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARNACIA CN9530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 8 Patient: 704MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			06/01/93		09/03/93		05/04/93	
			value	(*)	value	(*)	value	(*)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/06/92	13.60		13.40		11.40	<
HT	37-45 (%)	01/06/92	42.00		41.00		35.00	<
RBC	4.1-5.5 (10 ⁶ /MM ³)	01/06/92	4.82		4.65		3.97	<
HBC	4-9 (10 ³ /MM ³)	01/06/92	5.13		6.55		8.20	
HBC: N	45-70 (%)	01/06/92	70.00		53.00		56.00	
HBC: L	25-40 (%)	01/06/92	20.00	<	37.00		34.00	
HBC: E	0-4 (%)	01/06/92	2.00		3.00		2.00	
HBC: M	4-8 (%)	01/06/92	7.00		7.00		7.00	
HBC: B	0-1 (%)	01/06/92	1.00		1.00		1.00	
PLATELETS	150-300 (10 ³ /MM ³)	01/06/92	192.00		192.00		215.00	
NA+	137-145 (MMOL/L)	01/06/92	136.00	<	138.00		141.00	
K+	3.6-5.5 (MMOL/L)	01/06/92	4.20		4.20		4.70	
CL-	101-111 (MMOL/L)	01/06/92	99.00	<	101.00		105.00	
Ca++	8.5-10.6 (MG/DL)	01/06/92	9.90		8.80		8.40	<
PO4--	2.5-4.5 (MG/DL)	01/06/92	4.40		4.70	>	4.70	>
SGOT	7-56 (UI/L)	01/06/92	21.00		16.00		13.00	
SGPT	5-35 (UI/L)	01/06/92	18.00		14.00		17.00	
GAMMA GT	8-78 (UI/L)	01/06/92	33.00		28.00		27.00	
LDH	297-537 (UI/L)	01/06/92			366.00		348.00	
ALK. PHOSPH.	38-150 (UI/L)	01/06/92			142.00		125.00	
GLUCOSE	50-100 (MG/DL)	01/06/92	67.00		78.00		80.00	
UREA	15-45 (MG/DL)	01/06/92	66.00	>	85.00	>>	88.00	>>
CREATININE	0.5-1.2 (MG/DL)	01/06/92	1.25	>	1.73	>	2.11	>>
CREATININE CLEARANCE	100-140 (ML/MIN)	01/06/92	34.00					
URIC ACID	2.5-8.5 (MG/DL)	01/06/92	7.40		8.00		7.50	
TOT BILIRUBIN	0.2-1.3 (MG/DL)	01/06/92	1.00		0.91		1.08	
DIR BILIRUBIN	0-0.4 (MG/DL)	01/06/92			0.09			
TOT. PROTEINS	6.3-8.2 (G/DL)	01/06/92	7.20		7.15		6.40	<
ALBUMINE	3.5-5.5 (G/DL)	01/06/92	3.65		3.73		3.00	<
TOT. CHOLEST.	90-260 (MG/DL)	01/06/92	250.00		301.00	>	253.00	
TRIGLYCERIDES	40-160 (MG/DL)	01/06/92	71.00		124.00		82.00	
GLOBULINS ALPHA 1	2.2-5.2 (%)	01/06/92	4.00		3.70		4.80	
GLOBULINS ALPHA 2	9-14 (%)	01/06/92	14.60	>	12.90		15.00	>
GLOBULINS BETA	8-13 (%)	01/06/92	11.20		11.90		11.60	
GLOBULINS GAMMA	10-18 (%)	01/06/92	19.20	>	19.20	>	21.70	>
TSH	0.2-5 (UU/ML)	01/06/92	1.42					
T4	4.5-12.5 (UG/DL)	01/06/92	7.20					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/06/92			24.00		37.00	

2087

(*) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done (*) missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARNACIA CNB510089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 8 Patient: 1DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			22/09/92		23/10/92		21/11/92	
			value	(†)	value	(†)	value	(†)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	15/09/92	16.00		14.00		13.80	
HT	37-45 (%)	15/09/92	51.00	>	43.00		43.00	
RBC	4.1-5.5 (10 ⁶ /MM ³)	15/09/92	5.60	>	4.87		4.74	
WBC	4-9 (10 ³ /MM ³)	15/09/92	10.70	>	6.82		6.17	
WBC: N	45-70 (%)	15/09/92	67.00		61.00		65.00	
WBC: L	25-40 (%)	15/09/92	25.00		30.00		24.00	<
WBC: E	0-4 (%)	15/09/92	2.00		2.00		2.00	
WBC: M	4-8 (%)	15/09/92	6.00		7.00		9.00	>
WBC: B	0-1 (%)	15/09/92	0.00		1.00		1.00	
PLATELETS	150-300 (10 ³ /MM ³)	15/09/92	328.00	>	285.00		273.00	
NA+	137-145 (MMOL/L)	15/09/92	139.00		135.00	<	137.00	
K+	3.6-5.5 (MMOL/L)	15/09/92	4.00		4.40		4.30	
CL-	101-111 (MMOL/L)	15/09/92	101.00		97.00	<	99.00	<
Ca++	8.5-10.6 (MG/DL)	15/09/92	9.20		8.90		8.70	
PO4--	2.5-4.5 (MG/DL)	15/09/92	3.20		3.10		3.50	
SGOT	7-56 (UI/L)	15/09/92	30.00		25.00		18.00	
SGPT	5-35 (UI/L)	15/09/92	38.00	>	31.00		23.00	
GAMMA GT	8-78 (UI/L)	15/09/92	87.00	>	57.00			
LDH	297-537 (UI/L)	15/09/92	620.00	>	522.00			
ALK. PHOSPH.	38-150 (UI/L)	15/09/92	191.00	>	139.00		134.00	
GLUCOSE	50-100 (MG/DL)	15/09/92	96.00				87.00	
UREA	15-45 (MG/DL)	15/09/92	40.00		40.00		23.00	
CREATININE	0.5-1.2 (MG/DL)	15/09/92	1.04		1.07		1.14	
CREATININE CLEARANCE	100-140 (ML/MIN)	15/09/92	50.00					
URIC ACID	2.5-8.5 (MG/DL)	15/09/92	3.50		3.80		3.70	
TOT BILIRUBIN	0.2-1.3 (MG/DL)	15/09/92	0.78		0.80		1.08	
DIR BILIRUBIN	0-0.4 (MG/DL)	15/09/92	0.24		0.24		0.22	
TOT. PROTEINS	6.3-8.2 (G/DL)	15/09/92	8.40	>	7.09		7.05	
ALBUMINE	55-77 (%)	15/09/92	51.10	<	57.20			
TOT. CHOLEST.	3.5-5.5 (G/DL)	15/11/92					3.98	
TRIGLYCERIDES	90-260 (MG/DL)	15/09/92	313.00	>	242.00		287.00	>
GLOBULINS ALPHA 1	40-160 (MG/DL)	15/09/92	180.00	>	146.00		142.00	
GLOBULINS ALPHA 2	2.2-5.2 (%)	15/09/92	5.50	>	4.00		4.20	
GLOBULINS BETA	9-14 (%)	15/09/92	13.30		12.80		12.90	
GLOBULINS GAMMA	8-13 (%)	15/09/92	12.10		10.50		11.40	
TSH	10-18 (U/ml)	15/09/92	17.60		10.50		15.00	
T4	0.2-5 (UU/ML)	15/09/92	3.44					
ESR/SEDIMENT. RATE 1st h	4.5-12.5 (UC/DL)	15/09/92	13.50					
	0-10 (MM)	15/09/92			13.00		53.00	

2088

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN 530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 8 Patient: ZDT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			22/09/92		26/10/92		24/11/92	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	20/09/92	13.80		14.40		14.10	
HT	37-45 (%)	20/09/92	43.00		44.00		44.00	
RBC	4.1-5.5 (10 ⁶ /MM ³)	20/09/92	4.84		4.95		4.84	
WBC	4-9 (10 ³ /MM ³)	20/09/92	6.80		7.16		6.63	
WBC: N	45-70 (%)	20/09/92	48.00		55.00		55.00	
WBC: L	25-40 (%)	20/09/92	40.00		31.00		33.00	
WBC: E	0-4 (%)	20/09/92	1.00		1.00		1.00	
WBC: M	4-8 (%)	20/09/92	11.00	>>	12.00	>>	11.00	
WBC: B	0-1 (%)	20/09/92	1.00		1.00		0.00	
PLATELETS	150-300 (10 ³ /MM ³)	20/09/92	260.00		254.00		262.00	
NA+	137-145 (MMOL/L)	20/09/92	144.00		141.00		141.00	
K+	3.6-5.5 (MMOL/L)	20/09/92	4.60		4.50		5.00	
CL-	101-111 (MMOL/L)	20/09/92	109.00		105.00		109.00	
Ca++	8.5-10.6 (MG/DL)	20/09/92	9.40		9.00		8.90	
PO4--	2.5-4.5 (MG/DL)	20/09/92	3.20		2.80		3.20	
SGOT	7-56 (UI/L)	20/09/92	30.00		26.00		38.00	
SGPT	5-35 (UI/L)	20/09/92	27.00		25.00		23.00	
GAMMA GT	8-78 (UI/L)	20/09/92	23.00		22.00		23.00	
LDH	297-537 (UI/L)	20/09/92	838.00	>	680.00	>	1294.00	
ALK. PHOSPH.	38-150 (UI/L)	20/09/92	74.00		70.00		78.00	
GLUCOSE	50-100 (MG/DL)	20/09/92	72.00		90.00		100.00	
UREA	15-45 (MG/DL)	20/09/92			47.00	>	50.00	
CREATININE	0.5-1.2 (MG/DL)	20/09/92	1.16		1.17		1.16	
CREATININE CLEARANCE	100-140 (ML/MIN)	20/09/92	32.00					
URIC ACID	2.5-8.5 (MG/DL)	20/09/92	5.20		5.00		5.40	
TOT BILIRUBIN	0.2-1.3 (MG/DL)	20/09/92	0.58		0.65		1.36	
DIR BILIRUBIN	0-0.4 (MG/DL)	20/09/92	0.05		0.04		0.37	
TOT. PROTEINS	6.3-8.2 (G/DL)	20/09/92	7.67		7.49		8.07	
ALBUMINE	55-77 (%)	20/09/92	57.70		54.90	<	50.40	
TOT. CHOLEST.	90-260 (MG/DL)	20/09/92	248.00		244.00		265.00	
TRIGLYCERIDES	40-160 (MG/DL)	20/09/92	154.00		109.00		137.00	
GLOBULINS ALPHA 1	2.2-5.2 (%)	20/09/92	3.20		3.00		3.90	
GLOBULINS ALPHA 2	9-14 (%)	20/09/92	11.20		12.90		15.10	
GLOBULINS BETA	8-13 (%)	20/09/92	12.10		13.00		12.50	
GLOBULINS GAMMA	10-18 (%)	20/09/92	15.90		16.20		17.80	
TSH	0.2-5 (UU/ML)	20/09/92	1.72					
T4	4.5-12.5 (UG/DL)	20/09/92	6.00					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	20/09/92	28.00		16.00		24.00	

2089

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C0580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 8 Patient: 3DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			29/09/92		02/11/92		27/11/92	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/06/92	12.40		12.70		13.70	
HT	37-45 (X)	01/06/92	39.00		40.00		45.00	
RBC	4.1-5.5 (10 ⁶ /MM3)	01/06/92	4.25		4.32		4.73	
WBC	4-9 (10 ³ /MM3)	01/06/92	7.40		7.43		7.05	
WBC: N	45-70 (%)	01/06/92	60.00		48.00		46.00	
WBC: L	25-40 (%)	01/06/92	28.00		42.00	>	44.00 >	
WBC: E	0-4 (%)	01/06/92	2.00		2.00		3.00	
WBC: M	4-8 (%)	01/06/92	9.00	>	8.00		7.00	
WBC: B	0-1 (%)	01/06/92	1.00		1.00		1.00	
PLATELETS	150-300 (10 ³ /MM3)	01/06/92	300.00		367.00	>	338.00 >	
NA+	137-145 (MMOL/L)	01/06/92	142.00		139.00		140.00	
K+	3.6-5.5 (MMOL/L)	01/06/92	4.30		4.40		4.40	
CL-	101-111 (MMOL/L)	01/06/92	101.00		101.00		105.00	
Ca++	8.5-10.6 (MG/DL)	01/06/92	9.50		9.70		9.00	
PO4--	2.5-4.5 (MG/DL)	01/06/92	3.30		4.30		3.80	
SGOT	7-56 (UI/L)	01/06/92	28.00		27.00		19.00	
SGPT	5-35 (UI/L)	01/06/92	16.00		31.00		28.00	
GAMMA GT	8-78 (UI/L)	01/06/92	24.00		25.00		25.00	
LDH	297-537 (UI/L)	01/06/92	466.00		472.00		510.00	
ALK. PHOSPH.	38-150 (UI/L)	01/06/92	87.00		119.00		124.00	
GLUCOSE	50-100 (MG/DL)	01/06/92	71.00		82.00		83.00	
UREA	15-45 (MG/DL)	01/06/92			36.00		36.00	
CREATININE	0.5-1.2 (MG/DL)	01/06/92	0.81		0.78		0.78	
CREATININE CLEARANCE			48.00					
URIC ACID	2.5-8.5 (MG/DL)	01/06/92	3.40		3.10		4.00	
TOT BILIRUBIN	0.2-1.3 (MG/DL)	01/06/92	0.76		0.99		1.13	
DIR BILIRUBIN	0-0.4 (MG/DL)	01/06/92	0.20		0.20		0.23	
TOT. PROTEINS	6.3-8.2 (G/DL)	01/06/92	6.70		6.15	<	6.45	
ALBUMINE	3.5-5.5 (G/DL)	01/06/92	4.01		3.60		3.70	
TOT. CHOLEST.	90-260 (MG/DL)	01/06/92	235.00		203.00		238.00	
TRIGLYCERIDES	40-160 (MG/DL)	01/06/92	61.00		95.00		98.00	
GLOBULINS ALPHA 1	2.2-5.2 (%)	01/06/92	3.40		4.00		4.80	
GLOBULINS ALPHA 2	9-14 (%)	01/06/92	13.30		12.10		14.00	
GLOBULINS BETA	8-13 (%)	01/06/92	9.80		9.50		9.20	
GLOBULINS GAMMA	10-18 (%)	01/06/92	13.60		15.50		14.80	
TSH	0.2-5 (UU/ML)	01/06/92	0.68					
T4	4.5-12.5 (UG/DL)	01/06/92	10.00					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/06/92	19.00		8.00		8.00	

2090

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS 089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 8 Patient: 4DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			21/09/92		27/10/92		27/11/92	
			value	(☺)	value	(☺)	value	(☺)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/06/92	13.30		13.80		13.70	
HT	37-45 (%)	01/06/92	41.00		42.00		43.00	
RBC	4.1-5.5 (10 ⁶ /MM ³)	01/06/92	4.57		4.52		4.51	
WBC	4-9 (10 ³ /MM ³)	01/06/92	10.80	>	9.47	>	7.75	
WBC: N	45-70 (%)	01/06/92	62.00		59.00		52.00	
WBC: L	25-40 (%)	01/06/92	30.00		32.00		39.00	
WBC: E	0-4 (%)	01/06/92	2.00		3.00		2.00	
WBC: M	4-8 (%)	01/06/92	5.00		5.00		6.00	
WBC: B	0-1 (%)	01/06/92	1.00		1.00		1.00	
PLATELETS	150-300 (10 ³ /MM ³)	01/06/92	364.00	>	423.00	>>	353.00	
NA+	137-145 (MMOL/L)	01/06/92	135.00	<	137.00		135.00	
K+	3.6-5.5 (MMOL/L)	01/06/92	4.70		5.00		4.40	
CL-	101-111 (MMOL/L)	01/06/92	101.00		102.00		98.00	
Ca++	8.5-10.6 (MG/DL)	01/06/92	9.80		10.00		9.60	
PO4--	2.5-4.5 (MG/DL)	01/06/92	4.60	>	3.80		4.30	
SGOT	7-56 (UI/L)	01/06/92	15.00		14.00		15.00	
SGPT	5-35 (UI/L)	01/06/92	15.00		15.00		18.00	
GAMMA GT	8-78 (UI/L)	01/06/92	41.00		38.00		38.00	
LDH	297-537 (UI/L)	01/06/92			230.00	<	245.00	
ALK. PHOSPH.	38-150 (UI/L)	01/06/92	114.00		104.00		102.00	
GLUCOSE	50-100 (MG/DL)	01/06/92	84.00		74.00		71.00	
UREA	15-45 (MG/DL)	01/06/92			34.00		35.00	
CREATININE	0.5-1.2 (MG/DL)	01/06/92	1.08		1.14		1.13	
CREATININE CLEARANCE	100-140 (ML/MIN)	01/06/92	40.00					
URIC ACID	2.5-8.5 (MG/DL)	01/06/92	6.20		6.20		6.10	
TOT BILIRUBIN	0.2-1.3 (MG/DL)	01/06/92	0.69		0.87		1.40	
DIR BILIRUBIN	0-0.4 (MG/DL)	01/06/92	0.26		0.15		0.30	
TOT. PROTEINS	6.3-8.2 (G/DL)	01/06/92	7.13		7.46		7.13	
ALBUMINE	3.5-5.5 (G/DL)	01/06/92	3.99		4.49		4.32	
TOT. CHOLEST.	90-260 (MG/DL)	01/06/92	253.00		255.00		257.00	
TRIGLYCERIDES	40-160 (MG/DL)	01/06/92	186.00	>	186.00	>	260.00	
GLOBULINS ALPHA 1	2.2-5.2 (%)	01/06/92	4.10		3.30		2.90	
GLOBULINS ALPHA 2	9-14 (%)	01/06/92	15.30	>	12.70		14.10	
GLOBULINS BETA	8-13 (%)	01/06/92	13.20	>	12.70		14.40	
GLOBULINS GAMMA	10-18 (%)	01/06/92	11.50		11.30		11.40	
TSH	0.2-5 (UU/ML)	01/06/92	6.09					
T4	4.5-12.5 (UG/DL)	01/06/92	9.80					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/06/92	15.00		52.00		27.00	

2091

(☺) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN 9350089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 8 Patient: 701DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			01/10/92		05/11/92		04/12/92	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	20/09/92	13.90		14.80		15.20	
HT	37-45 (%)	20/09/92	44.00		45.00		48.00 >	
RBC	4.1-5.5 (10 ⁶ /MM ³)	20/09/92	4.78		4.82		5.03	
HBC	4-9 (10 ³ /MM ³)	20/09/92	8.53		9.24 >		8.94	
HBC: N	45-70 (%)	20/09/92	57.00		58.00		64.00	
HBC: L	25-40 (%)	20/09/92	32.00		33.00		30.00	
HBC: E	0-4 (%)	20/09/92	3.00		2.00		2.00	
HBC: M	4-8 (%)	20/09/92	7.00		7.00		3.00 <	
HBC: B	0-1 (%)	20/09/92	1.00		1.00		1.00	
PLATELETS	150-300 (10 ³ /MM ³)	20/09/92	285.00		189.00		296.00	
NA+	137-145 (MMOL/L)	20/09/92	140.00		138.00		139.00	
K+	3.6-5.5 (MMOL/L)	20/09/92	4.50		4.50		4.60	
CL-	101-111 (MMOL/L)	20/09/92	106.00		103.00		103.00	
Ca++	8.5-10.6 (MG/DL)	20/09/92	9.30		9.10		9.10	
PO4--	2.5-4.5 (MG/DL)	20/09/92	4.50		4.80 >		4.60 >	
SGOT	7-56 (UI/L)	20/09/92	23.00		28.00		24.00	
SGPT	5-35 (UI/L)	20/09/92	23.00		18.00		25.00	
GAMMA GT	8-78 (UI/L)	20/09/92	25.00		29.00		31.00	
LDH	297-537 (UI/L)	01/11/92			758.00 >			
ALK. PHOSPH.	38-150 (UI/L)	20/09/92	81.00		70.00		103.00	
GLUCOSE	50-100 (MG/DL)	20/09/92	123.00 >		264.00 >>		337.00 >>	
UREA	15-45 (MG/DL)	01/11/92			42.00		41.00	
CREATININE	0.5-1.2 (MG/DL)	20/09/92	0.75		0.83		0.86	
CREATININE CLEARANCE	100-140 (ML/MIN)	20/09/92	90.00					
URIC ACID	2.5-8.5 (MG/DL)	20/09/92	6.20		5.90		6.00	
TOT BILIRUBIN	0.2-1.3 (MG/DL)	20/09/92	0.64		1.26		1.04	
DIR BILIRUBIN	0-0.4 (MG/DL)	20/09/92	0.20		0.40		0.21	
TOT. PROTEINS	6.3-8.2 (G/DL)	20/09/92	6.61		7.70		7.97	
ALBUMINE	55-77 (%)	20/09/92	52.30 <					
TOT. CHOLEST.	3.5-5.5 (G/DL)	01/11/92			4.16		4.16	
TRIGLYCERIDES	90-260 (MG/DL)	20/09/92	210.00		234.00		269.00 >	
GLOBULINS ALPHA 1	40-160 (MG/DL)	20/09/92	186.00 >		352.00 >>		404.00 >>	
GLOBULINS ALPHA 2	2.2-5.2 (%)	20/09/92	4.50		3.20		3.40	
GLOBULINS BETA	9-14 (%)	20/09/92	14.30 >		15.80 >		14.50 >	
GLOBULINS GAMMA	8-13 (%)	20/09/92	13.80 >		12.80		14.10 >	
TSH	10-18 (X)	20/09/92	15.00		14.00		15.90	
T4	0.2-5 (UU/ML)	20/09/92	3.84					
ESR/SEDIMENT. RATE 1st h	4.5-12.5 (UG/DL)	20/09/92	7.00					
	0-10 (MM)	20/09/92	26.00		16.00		20.00	

2092

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARNACIA CN 580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 8 Patient: 702DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			07/09/92		05/11/92		03/12/92	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	05/09/92	13.40		14.50		12.70	
HT	37-45 (X)	05/09/92	42.00		39.00		41.00	
RBC	4.1-5.5 (10 ⁶ /MM ³)	05/09/92	4.56		4.18		4.30	
WBC	4-9 (10 ³ /MM ³)	05/09/92	7.20		6.87		6.01	
WBC: N	45-70 (X)	05/09/92	71.00 >		53.00		56.00	
WBC: L	25-40 (X)	05/09/92	23.00 <		36.00		36.00	
WBC: E	0-4 (X)	05/09/92	1.00		2.00		3.00	
WBC: M	4-8 (X)	05/09/92	5.00		8.00		4.00	
WBC: B	0-1 (X)	05/09/92	1.00		1.00		1.00	
PLATELETS	150-300 (10 ³ /MM ³)	05/09/92	328.00 >		323.00 >		365.00 >	
NA+	137-145 (MMOL/L)	05/09/92	139.00		141.00		140.00	
K+	3.6-5.5 (MMOL/L)	05/09/92	4.90		4.70		4.60	
CL-	101-111 (MMOL/L)	05/09/92	106.00		102.00		103.00	
Ca++	8.5-10.6 (MG/DL)	05/09/92	9.40		9.00		8.90	
PO4--	2.5-4.5 (MG/DL)	05/09/92	3.30		4.00		3.90	
SGOT	7-56 (UI/L)	05/09/92	23.00		20.00		23.00	
SGPT	5-35 (UI/L)	05/09/92	11.00		16.00		18.00	
GAMMA GT	8-78 (UI/L)	05/09/92	16.00		17.00		17.00	
LDH	297-537 (UI/L)	05/09/92	755.00 >		477.00		491.00	
ALK. PHOSPH.	38-150 (UI/L)	05/09/92	94.00		102.00		103.00	
GLUCOSE	50-100 (MG/DL)	01/11/92			79.00		75.00	
UREA	15-45 (MG/DL)	01/11/92			34.00		53.00 >	
CREATININE	0.5-1.2 (MG/DL)	05/09/92	1.17		1.51 >		1.37 >	
CREATININE CLEARANCE	100-140 (ML/MIN)	05/09/92	33.00					
URIC ACID	2.5-8.5 (MG/DL)	05/09/92	4.20		5.10		4.60	
TOT BILIRUBIN	0.2-1.3 (MG/DL)	05/09/92	1.13		1.15		1.20	
DIR BILIRUBIN	0-0.4 (MG/DL)	05/09/92	0.29		0.27		0.29	
TOT. PROTEINS	6.3-8.2 (G/DL)	05/09/92	7.74		8.01		8.43 >	
ALBUMINE	55-77 (X)	05/09/92	47.10 <					
TOT. CHOLEST.	3.5-5.5 (G/DL)	01/11/92			3.68		3.96	
TRIGLYCERIDES	90-260 (MG/DL)	05/09/92	249.00		242.00		236.00	
GLOBULINS ALPHA 1	40-160 (MG/DL)	05/09/92	173.00 >		100.00		141.00	
GLOBULINS ALPHA 2	2.2-5.2 (X)	05/09/92	2.50		3.30		3.50	
GLOBULINS BETA	9-14 (X)	05/09/92	13.20		11.10		11.00	
GLOBULINS GAMMA	8-13 (X)	05/09/92	10.50		10.30		10.40	
TSH	10-18 (X)	05/09/92	26.70 >>		29.40 >>		27.50 >>	
T4	0.2-5 (UU/ML)	05/09/92	1.21					
ESR/SEDIMENT. RATE 1st h	4.5-12.5 (UG/DL)	05/09/92	7.00					
	0-10 (MM)	05/09/92	46.00		27.00		28.00	

2093

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN 520089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 8 Patient: 703DT Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			03/12/92		09/03/93		05/04/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	01/06/92	11.00	<<	12.30	<	10.80 <<	
HT	40-54 (X)	01/06/92	33.00	<<	38.00	<	35.00 <	
RBC	4.1-5.5 (10 ⁶ /MM ³)	01/06/92	3.96	<	4.33		3.99 <	
WBC	4-9 (10 ³ /MM ³)	01/06/92	5.00		6.29		6.81	
WBC: N	45-70 (X)	01/06/92	41.00	<	44.00	<	54.00	
WBC: L	25-40 (X)	01/06/92	41.00	>	36.00		32.00	
WBC: E	0-4 (X)	01/06/92	5.00	>	4.00		1.00	
WBC: M	4-8 (X)	01/06/92	13.00	>>	15.00	>>	12.00 >>	
WBC: B	0-1 (X)	01/06/92	1.00		1.00		2.00 >>	
PLATELETS	150-300 (10 ³ /MM ³)	01/06/92	330.00	>	372.00	>	816.00 >>	
NA+	137-145 (MMOL/L)	01/06/92	138.00		138.00		135.00 <	
K+	3.6-5.5 (MMOL/L)	01/06/92	4.10		5.00		5.10	
CL-	101-111 (MMOL/L)	01/06/92	100.00	<	99.00	<	98.00 <	
Ca++	8.5-10.6 (MG/DL)	01/06/92	9.30		9.20		8.80	
PO4--	2.5-4.5 (MG/DL)	01/06/92	3.90		3.70		4.50	
SGOT	7-56 (UI/L)	01/06/92	21.00		22.00		79.00 >	
SGPT	5-35 (UI/L)	01/06/92	21.00		22.00		31.00	
GAMMA GT	8-78 (UI/L)	01/06/92	28.00		27.00		29.00	
LDH	297-537 (UI/L)	01/06/92	516.00		450.00		519.00	
ALK. PHOSPH.	38-150 (UI/L)	01/06/92	89.00		95.00			
GLUCOSE	50-100 (MG/DL)	01/06/92	79.00		90.00		100.00	
UREA	15-45 (MG/DL)	01/06/92	12.00	<	15.00		10.00 <	
CREATININE	0.5-1.2 (MG/DL)	01/06/92	1.40	>	1.02			
CREATININE CLEARANCE	100-140 (ML/MIN)	01/06/92	54.00					
URIC ACID	2.5-8.5 (MG/DL)	01/06/92	6.80		7.10		6.30	
TOT BILIRUBIN	0.2-1.3 (MG/DL)	01/06/92	0.51		0.93			
DIR BILIRUBIN	0-0.4 (MG/DL)	01/06/92	0.09		0.15			
TOT. PROTEINS	6.3-8.2 (G/DL)	01/06/92	6.56		7.29		7.51	
ALBUMINE	3.5-5.5 (G/DL)	01/06/92			3.97		2.80 <	
TOT. CHOLEST.	90-260 (MG/DL)	01/06/92	183.00		212.00		196.00	
TRIGLYCERIDES	40-160 (MG/DL)	01/06/92	68.00		105.00		83.00	
GLOBULINS ALPHA 1	2.2-5.2 (X)	01/06/92			3.10		6.60 >	
GLOBULINS ALPHA 2	9-14 (X)	01/06/92			11.50		15.90 >	
GLOBULINS BETA	8-13 (X)	01/06/92			11.10		13.10 >	
GLOBULINS GAMMA	10-18 (X)	01/06/92			19.80	>	27.00 >>	
TSH	0.2-5 (UU/ML)	01/06/92	2.00					
T4	4.5-12.5 (UG/DL)	01/06/92	6.30					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/06/92			47.00		125.00	

2094

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARNACIA CN530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 8 Patient: 704DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			15/10/92		09/03/93		05/04/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/06/92	13.10		14.00		13.80	
HT	37-45 (X)	01/06/92	42.00		42.00		43.00	
RBC	4.1-5.5 (10 ⁶ /MM ³)	01/06/92	4.14		4.24		4.28	
HBC	4-9 (10 ³ /MM ³)	01/06/92	6.86		6.33		6.75	
HBC: N	45-70 (X)	01/06/92	44.00	<	48.00		47.00	
HBC: L	25-40 (X)	01/06/92	41.00	>	36.00		41.00	>
HBC: E	0-4 (X)	01/06/92	2.00		4.00		2.00	
HBC: M	4-8 (X)	01/06/92	12.00	>>	10.00	>	10.00	>
HBC: B	0-1 (X)	01/06/92	1.00		2.00	>>	1.00	
PLATELETS	150-300 (10 ³ /MM ³)	01/06/92	400.00	>>	447.00	>>	268.00	
NA+	137-145 (MMOL/L)	01/06/92	138.00		137.00		138.00	
K+	3.6-5.5 (MMOL/L)	01/06/92	4.40		4.30		4.00	
CL-	101-111 (MMOL/L)	01/06/92	103.00		101.00		103.00	
Ca++	8.5-10.6 (MG/DL)	01/06/92	9.00		9.20		8.90	
PO4--	2.5-4.5 (MG/DL)	01/06/92	4.10		4.30		4.40	
SGOT	7-56 (UI/L)	01/06/92	25.00		31.00		26.00	
SGPT	5-35 (UI/L)	01/06/92	38.00	>	42.00	>	38.00	>
GAMMA GT	8-78 (UI/L)	01/06/92			34.00		30.00	
LDH	297-537 (UI/L)	01/06/92			481.00		517.00	
ALK. PHOSPH.	38-150 (UI/L)	01/06/92	124.00		129.00		115.00	
GLUCOSE	50-100 (MG/DL)	01/06/92	66.00		70.00		85.00	
UREA	15-45 (MG/DL)	01/06/92	29.00		28.00		25.00	
CREATININE	0.5-1.2 (MG/DL)	01/06/92	0.99		0.87		0.81	
CREATININE CLEARANCE	100-140 (ML/MIN)	01/06/92	67.00					
URIC ACID	2.5-8.5 (MG/DL)	01/06/92	5.20		5.20		5.10	
TOT BILIRUBIN	0.2-1.3 (MG/DL)	01/06/92	1.00		0.98			
DIR BILIRUBIN	0-0.4 (MG/DL)	01/06/92	0.22		0.08			
TOT. PROTEINS	6.3-8.2 (G/DL)	01/06/92	6.39		6.95		6.76	
ALBUMINE	3.5-5.5 (G/DL)	01/06/92	4.10		4.08		3.68	
TOT. CHOLEST.	90-260 (MG/DL)	01/06/92	227.00		230.00		208.00	
TRIGLYCERIDES	40-160 (MG/DL)	01/06/92	113.00		80.00		79.00	
GLOBULINS ALPHA 1	2.2-5.2 (X)	01/06/92	4.50		5.00		5.60	>
GLOBULINS ALPHA 2	9-14 (X)	01/06/92	10.30		12.60		12.80	
GLOBULINS BETA	8-13 (X)	01/06/92	11.00		12.40		13.20	>
GLOBULINS GAMMA	10-18 (X)	01/06/92	9.90	<	11.20		13.80	
TSH	0.2-5 (UU/ML)	01/06/92	0.95					
T4	4.5-12.5 (UG/DL)	01/06/92	8.20					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/06/92	6.00		30.00		15.00	

2095

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CN9530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 9 Patient: 1MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			21/09/93		26/10/93		23/11/93	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	13/09/93	14.50		14.80		14.80	
HT	37-47 (%)	13/09/93	45.00		45.00		46.00	
RBC	4200000-5400000 (/MM3)	13/09/93						
			5550000 >		5130000		5550000 >	
WBC	4800-8100 (/MM3)	13/09/93	5150.00		5000.00		4500.00 <	
WBC: N	60-75 (%)	13/09/93	64.00		76.00 >		64.00	
WBC: L	20-30 (%)	13/09/93	27.00		20.00		30.00	
WBC: E	2-4 (%)	13/09/93	1.00 <		0.00 <		1.00 <	
WBC: M	2-8 (%)	13/09/93	8.00		4.00		5.00	
WBC: B	0-1 (%)	13/09/93	0.00		0.00		0.00	
PLATELETS	200000-400000 (/MM3)	13/09/93						
			310000		318000		277000	
NA+	135-145 (MEQ/L)	13/09/93	140.00		138.00		134.00 <	
K+	3.5-5 (MEQ/L)	13/09/93	4.10		4.10		4.30	
CL-	90-110 (MEQ/L)	13/09/93	105.00		105.00		100.00	
Ca++	4.5-5.5 (MEQ/L)	13/09/93	5.50		5.00		5.50	
PO4--	2.5-4.8 (MG/DL)	13/09/93	2.80		3.30		2.85	
SGOT	3-20 (UI/L)	13/09/93	6.20		8.20		11.00	
SGPT	3-20 (UI/L)	13/09/93	5.80		5.80		9.10	
GAMMA GT	3-18 (UI/L)	13/09/93	17.30		3.60		8.60	
LDH	80-240 (UI/L)	13/09/93	80.00		138.00		98.00	
ALK. PHOSPH.	15-70 (UI/L)	13/09/93	19.00		25.70		40.70	
GLUCOSE	70-110 (MG/DL)	13/09/93	77.50		95.00		87.00	
UREA	15-35 (MG/DL)	13/09/93	15.00		35.00		26.20	
CREATININE	0.4-1.2 (MG/DL)	13/09/93	0.50		0.88		0.59	
CREATININE CLEARANCE			105.00					
URIC ACID	1.5-7 (MG/DL)	13/09/93	4.30		5.20		4.50	
TOT BILIRUBIN	0.2-1.2 (MG/DL)	13/09/93	0.68		0.65		0.75	
DIR BILIRUBIN	0-0.3 (MG/DL)	13/09/93	0.10		0.05		0.05	
TOT. PROTEINS	6-8.5 (G/DL)	13/09/93	6.60		6.50		6.70	
ALBUMINE	3.5-5.5 (G/DL)	13/09/93	3.90		3.90		3.90	
TOT. CHOLEST.	150-250 (MG/DL)	13/09/93	200.00		222.00		206.00	
TRIGLYCERIDES	50-150 (MG/DL)	13/09/93	59.00		147.00		77.00	
GLOBULINS ALPHA 1	3-7 (%)	13/09/93	4.90		4.90		5.20	
GLOBULINS ALPHA 2	7-11 (%)	13/09/93	7.50		7.30		7.70	
GLOBULINS BETA	10-14 (%)	13/09/93	11.30		11.80		12.30	
GLOBULINS GAMMA	14-22 (%)	13/09/93	17.30		16.00		16.60	
TSH	0.5-6.5 (UU/ML)	13/09/93	0.80					
T4	4.5-11.5 (UG/DL)	13/09/93	11.00					

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARNACIA CN0300089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 9 Patient: ZND Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			24/09/93		29/10/93		26/11/93	
			value	(*)	value	(*)	value	(*)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	13/09/93	13.70		13.20		14.00	
HT	37-47 (%)	13/09/93	42.00		41.00		42.00	
RBC	4200000-5400000 (/MM3)	13/09/93						
			5140000		5070000		5190000	
HBC	4800-8100 (/MM3)	13/09/93	7800.00		6900.00		9200.00 >	
HBC: N	60-75 (%)	13/09/93	65.00		70.00		57.00 <	
HBC: L	20-30 (%)	13/09/93	25.00		22.00		36.00 >	
HBC: E	2-4 (%)	13/09/93	5.00 >		4.00		1.00 <	
HBC: M	2-8 (%)	13/09/93	5.00		4.00		6.00	
HBC: B	0-1 (%)	13/09/93	0.00		0.00		0.00	
PLATELETS	200000-400000 (/MM3)	13/09/93						
			255000		290000		325000	
NA+	135-145 (MEQ/L)	13/09/93	135.00		140.00		136.00	
K+	3.5-5 (MEQ/L)	13/09/93	3.70		4.40		3.40 <	
CL-	90-110 (MEQ/L)	13/09/93	95.00		96.00		106.00	
Ca++	4.5-5.5 (MEQ/L)	13/09/93	4.50		5.00		5.00	
PO4--	2.5-4.8 (MG/DL)	13/09/93	3.60		4.50		3.50	
SGOT	3-20 (UI/L)	13/09/93	4.80		7.20		14.50	
SGPT	3-20 (UI/L)	13/09/93	4.80		10.60		19.30	
GAMMA GT	3-18 (UI/L)	13/09/93	5.20		5.40		4.80	
LDH	80-240 (UI/L)	13/09/93	87.00		82.90		112.90	
ALK. PHOSPH.	15-70 (UI/L)	13/09/93	31.70		43.90		37.60	
GLUCOSE	70-110 (MG/DL)	13/09/93	100.00		88.00		100.00	
UREA	15-35 (MG/DL)	13/09/93	23.00		36.80 >		27.00	
CREATININE	0.4-1.2 (MG/DL)	13/09/93	0.55		0.67		0.58	
CREATININE CLEARANCE			107.00					
URIC ACID	1.5-7 (MG/DL)	13/09/93	4.50		5.00		6.00	
TOT BILIRUBIN	0.2-1.2 (MG/DL)	13/09/93	0.55		0.65		0.60	
DIR BILIRUBIN	0-0.3 (MG/DL)	13/09/93	0.00		0.03		0.00	
TOT. PROTEINS	6-8.5 (G/DL)	13/09/93	7.20		7.20		7.50	
ALBUMINE	3.5-5.5 (G/DL)	13/09/93	3.70		3.70		4.20	
TOT. CHOLEST.	150-250 (MG/DL)	13/09/93	274.00 >		314.00 >		270.00 >	
TRIGLYCERIDES	50-150 (MG/DL)	13/09/93	85.50		150.00		113.00	
GLOBULINS ALPHA 1	3-7 (%)	13/09/93	6.10		5.50		5.60	
GLOBULINS ALPHA 2	7-11 (%)	13/09/93	10.40		9.60		9.50	
GLOBULINS BETA	10-14 (%)	13/09/93	13.80		12.70		12.40	
GLOBULINS GAMMA	14-22 (%)	13/09/93	18.40		20.80		16.50	
TSH	0.5-6.5 (UU/ML)	13/09/93	2.00					
T4	4.5-11.5 (UG/DL)	13/09/93	11.00					

2097

(*) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done (*) missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS 550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 9 Patient: 4MD Treatment: Imipramine Sex: Female

Laboratory test			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			05/10/93		10/11/93		08/12/93	
			value	(⊕)	value	(⊕)	value	(⊕)
HB	12-16 (G/DL)	13/09/93	14.20		14.30		14.60	
HT	37-47 (X)	13/09/93	42.00		43.00		43.00	
RBC	4200000-5400000 (/MM3)	13/09/93	4750000		4950000		4910000	
HBC	4800-8100 (/MM3)	13/09/93	3700.00 <		4100.00 <		3800.00 <	
HBC: N	60-75 (%)	13/09/93	58.00 <		60.00		60.00	
HBC: L	20-30 (%)	13/09/93	34.00 >		34.00 >		30.00	
HBC: E	2-4 (X)	13/09/93	3.00		1.00 <		5.00 >	
HBC: M	2-8 (X)	13/09/93	5.00		5.00		5.00	
HBC: B	0-1 (X)	13/09/93	0.00		0.00		0.00	
PLATELETS	200000-400000 (/MM3)	13/09/93	320000		335000		295000	
NA+	135-145 (MEQ/L)	13/09/93	135.00		132.00 <		135.00	
K+	3.5-5 (MEQ/L)	13/09/93	3.60		3.30 <		3.60	
CL-	90-110 (MEQ/L)	13/09/93	105.00		105.00		100.00	
Ca++	4.5-5.5 (MEQ/L)	13/09/93	5.00		4.80		5.50	
PO4--	2.5-4.8 (MG/DL)	13/09/93	3.80		3.50		4.00	
SGOT	3-20 (UI/L)	13/09/93	10.60		9.10		12.50	
SGPT	3-20 (UI/L)	13/09/93	10.60		7.70		7.70	
GAMMA GT	3-18 (UI/L)	13/09/93	8.10		7.20		9.40	
LDH	80-240 (UI/L)	13/09/93	174.00		200.00		158.40	
ALK. PHOSPH.	15-70 (UI/L)	13/09/93	59.80		59.80		49.70	
GLUCOSE	70-110 (MG/DL)	13/09/93	70.00		84.00		73.50	
UREA	15-35 (MG/DL)	13/09/93	22.00		34.00		35.00	
CREATININE	0.4-1.2 (MG/DL)	13/09/93	0.75		0.80		0.67	
URIC ACID	1.5-7 (MG/DL)	13/09/93	5.90		6.40		7.00	
TOT BILIRUBIN	0.2-1.2 (MG/DL)	13/09/93	0.75		0.63		0.63	
DIR BILIRUBIN	0-0.3 (MG/DL)	13/09/93	0.05		0.00		0.03	
TOT. PROTEINS	6-8.5 (G/DL)	13/09/93	6.50		6.70		6.50	
ALBUMINE	3.5-5.5 (G/DL)	13/09/93	3.80		3.90		3.70	
TOT. CHOLEST.	150-250 (MG/DL)	13/09/93	200.00		175.00		187.00	
TRIGLYCERIDES	50-150 (MG/DL)	13/09/93	56.00		69.00		66.00	
GLOBULINS ALPHA 1	3-7 (X)	13/09/93	5.50		5.50		5.50	
GLOBULINS ALPHA 2	7-11 (X)	13/09/93	7.10		7.90		7.40	
GLOBULINS BETA	10-14 (X)	13/09/93	8.60 <		10.80		9.90 <	
GLOBULINS GAMMA	14-22 (X)	13/09/93	20.40		17.60		20.30	
TSH	0.5-6.5 (UU/ML)	13/09/93	2.20					
T4	4.5-11.5 (UG/DL)	13/09/93	9.80					

2098

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CN550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 9 Patient: SMD Treatment: Reboxetine Sex: Female

Laboratory test			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			19/10/93		23/11/93		21/12/93	
			value	(φ)	value	(φ)	value	(φ)
Range value	Range date							
HB	12-16 (G/DL)	13/09/93	13.00		13.50		13.00	
HT	37-47 (X)	13/09/93	38.00		40.00		39.00	
RBC	4200000-5400000 (/MM3)	13/09/93						
			4590000		4720000		4570000	
MBC	4800-8100 (/MM3)	13/09/93	7750.00		6850.00		9400.00 >	
MBC: N	60-75 (X)	13/09/93	70.00		77.00 >		65.00	
MBC: L	20-30 (X)	13/09/93	17.00 <		15.00 <		19.00 <	
MBC: E	2-4 (X)	13/09/93	4.00		5.00 >		11.00 >>	
MBC: M	2-8 (X)	13/09/93	9.00 >		3.00		4.00	
MBC: B	0-1 (X)	13/09/93	0.00		0.00		1.00	
PLATELETS	200000-400000 (/MM3)	13/09/93						
			280000		235000		305000	
NA+	135-145 (MEQ/L)	13/09/93	135.00		136.00		137.00	
K+	3.5-5 (MEQ/L)	13/09/93	4.20		4.30		3.90	
CL-	90-110 (MEQ/L)	13/09/93	108.00		106.00		105.00	
Ca++	4.5-5.5 (MEQ/L)	13/09/93	4.60		5.00		4.50	
PO4--	2.5-4.8 (MG/DL)	13/09/93	3.90		4.50		4.50	
SGOT	3-20 (UI/L)	13/09/93	20.20 >		16.40		16.60	
SGPT	3-20 (UI/L)	13/09/93	17.80		13.50		12.00	
GAMMA GT	3-18 (UI/L)	13/09/93	4.40		10.20		7.10	
LDH	80-240 (UI/L)	13/09/93	176.80		135.00		197.90	
ALK. PHOSPH.	15-70 (UI/L)	13/09/93	31.70		33.80		56.10	
GLUCOSE	70-110 (MG/DL)	13/09/93	106.00		100.00		109.00	
UREA	15-35 (MG/DL)	13/09/93	22.90		21.60		25.50	
CREATININE	0.4-1.2 (MG/DL)	13/09/93	0.63		0.55		0.60	
CREATININE CLEARANCE	70-140 (ML/MIN)	13/09/93	108.00					
URIC ACID	1.5-7 (MG/DL)	13/09/93	5.40		5.00		5.40	
TOT BILIRUBIN	0.2-1.2 (MG/DL)	13/09/93	0.69		0.74		0.58	
DIR BILIRUBIN	0-0.3 (MG/DL)	13/09/93	0.00		0.05		0.00	
TOT. PROTEINS	6-8.5 (G/DL)	13/09/93	7.10		7.30		7.30	
ALBUMINE	3.5-5.5 (G/DL)	13/09/93	4.00		4.10		3.80	
TOT. CHOLEST.	150-250 (MG/DL)	13/09/93	168.00		193.00		194.00	
TRIGLYCERIDES	50-150 (MG/DL)	13/09/93	117.00		98.50		105.00	
GLOBULINS ALPHA 1	3-7 (X)	13/09/93	5.20		4.80		5.00	
GLOBULINS ALPHA 2	7-11 (X)	13/09/93	7.10		8.20		8.40	
GLOBULINS BETA	10-14 (X)	13/09/93	11.50		11.70		10.90	
GLOBULINS GAMMA	14-22 (X)	13/09/93	19.90		19.10		23.70 >	
TSH	0.5-6.5 (UU/ML)	13/09/93	2.20					
T4	4.5-11.5 (UG/DL)	13/09/93	8.40					

2099

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS 990089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 9 Patient: 6MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			27/10/93	
			value	(*)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	13/09/93	14.70	
HT	37-47 (%)	13/09/93	41.00	
RBC	4200000-5400000 (/MM3)	13/09/93	5090000	
WBC	4800-8100 (/MM3)	13/09/93	3500.00	<
WBC: N	60-75 (%)	13/09/93	62.00	
WBC: L	20-30 (%)	13/09/93	32.00	>
WBC: E	2-4 (%)	13/09/93	3.00	
WBC: M	2-8 (%)	13/09/93	3.00	
WBC: B	0-1 (%)	13/09/93	0.00	
PLATELETS	200000-400000 (/MM3)	13/09/93	202000	
NA+	135-145 (MEQ/L)	13/09/93	140.00	
K+	3.5-5 (MEQ/L)	13/09/93	4.70	
CL-	90-110 (MEQ/L)	13/09/93	100.00	
Ca++	4.5-5.5 (MEQ/L)	13/09/93	5.00	
PO4--	2.5-4.8 (MG/DL)	13/09/93	3.10	
SGOT	3-20 (UI/L)	13/09/93	16.30	
SGPT	3-20 (UI/L)	13/09/93	13.50	
GAMMA GT	3-18 (UI/L)	13/09/93	6.60	
LDH	80-240 (UI/L)	13/09/93	210.00	
ALK. PHOSPH.	15-70 (UI/L)	13/09/93	42.20	
GLUCOSE	70-110 (MG/DL)	13/09/93	74.00	
UREA	15-35 (MG/DL)	13/09/93	24.70	
CREATININE	0.4-1.2 (MG/DL)	13/09/93	0.79	
CREATININE CLEARANCE			100.00	
URIC ACID	1.5-7 (MG/DL)	13/09/93	4.50	
TOT BILIRUBIN	0.2-1.2 (MG/DL)	13/09/93	0.46	
DIR BILIRUBIN	0-0.3 (MG/DL)	13/09/93	0.00	
TOT. PROTEINS	6-8.5 (G/DL)	13/09/93	6.90	
ALBUMINE	3.5-5.5 (G/DL)	13/09/93	3.40	<
TOT. CHOLEST.	150-250 (MG/DL)	13/09/93	207.00	
TRIGLYCERIDES	50-150 (MG/DL)	13/09/93	111.00	
GLOBULINS ALPHA 1	3-7 (%)	13/09/93	7.00	
GLOBULINS ALPHA 2	7-11 (%)	13/09/93	10.10	
GLOBULINS BETA	10-14 (%)	13/09/93	13.30	
GLOBULINS GAMMA	14-22 (%)	13/09/93	20.40	
TSH	0.5-6.5 (UU/ML)	13/09/93	2.50	
T4	4.5-11.5 (UG/DL)	13/09/93	8.40	

2100

(*) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN 950089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 9 Patient: 7MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			03/11/93	
			value	(€)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	13/09/93	13.80	
HT	37-47 (%)	13/09/93	44.00	
RBC	4200000-5400000 (/MM3)	13/09/93	5170000	
WBC	4800-8100 (/MM3)	13/09/93	5400.00	
WBC: N	60-75 (%)	13/09/93	59.00	<
WBC: L	20-30 (%)	13/09/93	39.00	>
WBC: E	2-4 (%)	13/09/93	0.00	<
WBC: M	2-8 (%)	13/09/93	2.00	
WBC: B	0-1 (%)	13/09/93	0.00	
PLATELETS	200000-400000 (/MM3)	13/09/93	357000	
NA+	135-145 (MEQ/L)	13/09/93	138.00	
K+	3.5-5 (MEQ/L)	13/09/93	3.70	
CL-	90-110 (MEQ/L)	13/09/93	108.00	
Ca++	4.5-5.5 (MEQ/L)	13/09/93	5.40	
PO4--	2.5-4.8 (MG/DL)	13/09/93	4.10	
SGOT	3-20 (UI/L)	13/09/93	10.40	
SGPT	3-20 (UI/L)	13/09/93	12.00	
GAMMA GT	3-18 (UI/L)	13/09/93	6.10	
LDH	80-240 (UI/L)	13/09/93	102.70	
ALK. PHOSPH.	15-70 (UI/L)	13/09/93	65.40	
GLUCOSE	70-110 (MG/DL)	13/09/93	168.00	>>
UREA	15-35 (MG/DL)	13/09/93	31.50	
CREATININE	0.4-1.2 (MG/DL)	13/09/93	0.74	
CREATININE CLEARANCE	70-140 (ML/MIN)	13/09/93	108.00	
URIC ACID	1.5-7 (MG/DL)	13/09/93	6.00	
TOT BILIRUBIN	0.2-1.2 (MG/DL)	13/09/93	0.53	
DIR BILIRUBIN	0-0.3 (MG/DL)	13/09/93	0.00	
TOT. PROTEINS	6-8.5 (G/DL)	13/09/93	7.00	
ALBUMINE	3.5-5.5 (G/DL)	13/09/93	4.00	
TOT. CHOLEST.	150-250 (MG/DL)	13/09/93	298.00	>
TRIGLYCERIDES	50-150 (MG/DL)	13/09/93	256.00	>>
GLOBULINS ALPHA 1	3-7 (%)	13/09/93	5.30	
GLOBULINS ALPHA 2	7-11 (%)	13/09/93	8.20	
GLOBULINS BETA	10-14 (%)	13/09/93	11.40	
GLOBULINS GAMMA	14-22 (%)	13/09/93	18.00	
TSH	0.5-6.5 (UU/ML)	13/09/93	1.80	
T4	4.5-11.5 (UG/DL)	13/09/93	10.00	

2101

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN5390089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 9 Patient: 1DT Treatment: Imipramine Sex: Female

Laboratory test			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			08/12/93		12/01/94		09/02/94	
			value	(φ)	value	(φ)	value	(φ)
Range value	Range date							
HB	12-16 (G/DL)	13/09/93	14.20		13.80		13.40	
HT	37-47 (X)	13/09/93	39.00		38.00		38.00	
RBC	4200000-5400000 (/MM3)	13/09/93						
			4780000		4570000		4390000	
NBC	4800-8100 (/MM3)	13/09/93	4850.00		4500.00		4750.00	
NBC: N	60-75 (%)	13/09/93	49.00	<	54.00	<	53.00	
NBC: L	20-30 (%)	13/09/93	40.00	>>	42.00	>>	42.00	
NBC: E	2-4 (%)	13/09/93	4.00		1.00		0.00	
NBC: M	2-8 (%)	13/09/93	7.00		3.00		5.00	
NBC: B	0-1 (%)	13/09/93	0.00		0.00		0.00	
PLATELETS	200000-400000 (/MM3)	13/09/93						
			310000		322000		285000	
NA+	135-145 (NEQ/L)	13/09/93	135.00		136.00		140.00	
K+	3.5-5 (NEQ/L)	13/09/93	4.20		4.50		4.60	
CL-	90-110 (NEQ/L)	13/09/93	100.00		100.00		104.00	
Ca++	4.5-5.5 (MEQ/L)	13/09/93	5.10		4.90		4.00	
PO4--	2.5-4.8 (MG/DL)	13/09/93	4.30		3.70		4.50	
SGOT	3-20 (UI/L)	13/09/93	10.60		10.10		8.60	
SGPT	3-20 (UI/L)	13/09/93	8.70		8.70		7.70	
GAMMA GT	3-18 (UI/L)	13/09/93	4.10		3.40		4.40	
LDH	80-240 (UI/L)	13/09/93	173.00		205.00		134.60	
ALK. PHOSPH.	15-70 (UI/L)	13/09/93	39.20		42.20		31.70	
GLUCOSE	70-110 (MG/DL)	13/09/93	82.00		94.00		96.00	
UREA	15-35 (MG/DL)	13/09/93	25.30		23.10		24.50	
CREATININE	0.4-1.2 (MG/DL)	13/09/93	0.60		0.54		0.71	
CREATININE CLEARANCE	70-140 (ML/MIN)	13/09/93	100.00					
URIC ACID	1.5-7 (MG/DL)	13/09/93	5.70		5.40		4.80	
TOT BILIRUBIN	0.2-1.2 (MG/DL)	13/09/93	0.52		0.71		0.58	
DIR BILIRUBIN	0-0.3 (MG/DL)	13/09/93	0.00		0.05		0.00	
TOT. PROTEINS	6-8.5 (G/DL)	13/09/93	7.50		7.20		7.20	
ALBUMINE	3.5-5.5 (G/DL)	13/09/93	4.00		4.00		3.70	
TOT. CHOLEST.	150-250 (MG/DL)	13/09/93	200.00		206.00		200.00	
TRIGLYCERIDES	50-150 (MG/DL)	13/09/93	106.00		38.00	<	96.00	
GLOBULINS ALPHA 1	3-7 (X)	13/09/93	6.20		6.60		5.90	
GLOBULINS ALPHA 2	7-11 (X)	13/09/93	8.90		8.50		8.20	
GLOBULINS BETA	10-14 (X)	13/09/93	11.70		11.20		12.00	
GLOBULINS GAMMA	14-22 (X)	13/09/93	19.90		18.20		22.50	
TSH	0.5-6.5 (UU/ML)	13/09/93	1.00					
T4	4.5-11.5 (UG/DL)	13/09/93	7.00					

2102

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS 1990089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 9 Patient: ZDT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			15/12/93		19/01/94		16/02/94	
			value	(†)	value	(†)	value	(†)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	13/09/93	14.00		15.00		15.00	
HT	37-47 (%)	13/09/93	44.00		44.00		44.00	
RBC	4200000-5400000 (/MM3)	13/09/93						
			5320000		5060000		5340000	
WBC	4800-8100 (/MM3)	13/09/93	4000.00 <		4150.00 <		3550.00 <	
WBC: N	60-75 (%)	13/09/93	59.00 <		66.00		55.00 <	
WBC: L	20-30 (%)	13/09/93	33.00 >		28.00		39.00 >	
WBC: E	2-4 (%)	13/09/93	3.00		2.00		0.00 <	
WBC: M	2-8 (%)	13/09/93	5.00		4.00		6.00	
WBC: B	0-1 (%)	13/09/93	0.00		0.00		0.00	
PLATELETS	200000-400000 (/MM3)	13/09/93						
			318000		305000		280000	
NA+	135-145 (MEQ/L)	13/09/93	134.00 <		136.00		135.00	
K+	3.5-5 (MEQ/L)	13/09/93	3.10 <		3.80		3.10 <	
CL-	90-110 (MEQ/L)	13/09/93	95.00		105.00		104.00	
Ca++	4.5-5.5 (MEQ/L)	13/09/93	5.00		4.70		4.70	
PO4--	2.5-4.8 (MG/DL)	13/09/93	3.20		3.50		3.90	
SGOT	3-20 (UI/L)	13/09/93	10.10		12.50		10.60	
SGPT	3-20 (UI/L)	13/09/93	9.60		7.70		7.60	
GAMMA GT	3-18 (UI/L)	13/09/93	13.10		12.00		10.10	
LDH	80-240 (UI/L)	13/09/93	218.70		208.00		230.00	
ALK. PHOSPH.	15-70 (UI/L)	13/09/93	47.20		40.70		53.80	
GLUCOSE	70-110 (MG/DL)	13/09/93	91.00		97.00		90.00	
UREA	15-35 (MG/DL)	13/09/93	15.00		22.00		19.40	
CREATININE	0.4-1.2 (MG/DL)	13/09/93	0.52		0.59		0.65	
CREATININE CLEARANCE			95.00					
URIC ACID	1.5-7 (MG/DL)	13/09/93	6.00		6.40		7.20 >	
TOT BILIRUBIN	0.2-1.2 (MG/DL)	13/09/93	0.50		0.44		0.40	
DIR BILIRUBIN	0-0.3 (MG/DL)	13/09/93	0.00		0.00		0.00	
TOT. PROTEINS	6-8.5 (G/DL)	13/09/93	7.10		7.00		7.20	
ALBUMINE	3.5-5.5 (G/DL)	13/09/93	3.60		3.50		3.70	
TOT. CHOLEST.	150-250 (MG/DL)	13/09/93	165.00		193.00		227.00	
TRIGLYCERIDES	50-150 (MG/DL)	13/09/93	117.00		104.00		135.00	
GLOBULINS ALPHA 1	3-7 (%)	13/09/93	6.50		6.80		6.20	
GLOBULINS ALPHA 2	7-11 (%)	13/09/93	9.00		8.20		7.90	
GLOBULINS BETA	10-14 (%)	13/09/93	12.50		11.70		12.20	
GLOBULINS GAMMA	14-22 (%)	13/09/93	21.30		23.30 >		22.30 >	
TSH	0.5-6.5 (UU/ML)	13/09/93	1.60					
T4	4.5-11.5 (UG/DL)	13/09/93	8.80					

2103

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN0390089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 9 Patient: SDT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			05/10/93		10/11/93		08/12/93	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	13/09/93	14.00		14.50		13.70	
BT	37-47 (°C)	13/09/93	43.00		44.00		42.00	
RBC	4200000-5400000 (/MM3)	13/09/93						
			4920000		5050000		4850000	
MBC	4800-8100 (/MM3)	13/09/93	6300.00		5200.00		5450.00	
MBC: N	60-75 (%)	13/09/93	67.00		59.00	<	66.00	
MBC: L	20-30 (%)	13/09/93	27.00		32.00	>	24.00	
MBC: E	2-4 (%)	13/09/93	2.00		5.00	>	4.00	
MBC: M	2-8 (%)	13/09/93	4.00		4.00		6.00	
MBC: B	0-1 (%)	13/09/93	0.00		0.00		0.00	
PLATELETS	200000-400000 (/MM3)	13/09/93						
			235000		240000		280000	
NA+	135-145 (MEQ/L)	13/09/93	134.00	<	140.00		138.00	
K+	3.5-5 (MEQ/L)	13/09/93	3.60		3.80		3.70	
CL-	90-110 (MEQ/L)	13/09/93	100.00		110.00		102.00	
Ca++	4.5-5.5 (MEQ/L)	13/09/93	4.50		5.00		4.80	
PO4--	2.5-4.8 (MG/DL)	13/09/93	3.60		3.60		2.80	
SGOT	3-20 (UI/L)	13/09/93	22.20	>	10.10		14.50	
SGPT	3-20 (UI/L)	13/09/93	13.50		7.70		10.60	
GAMMA GT	3-18 (UI/L)	13/09/93	4.10		3.20		8.20	
LDH	80-240 (UI/L)	13/09/93	181.00		220.00		159.20	
ALK. PHOSPH.	15-70 (UI/L)	13/09/93	48.00		47.20		36.00	
GLUCOSE	70-110 (MG/DL)	13/09/93	78.00		96.00		85.00	
UREA	15-35 (MG/DL)	13/09/93	14.50	<	24.50		21.60	
CREATININE	0.4-1.2 (MG/DL)	13/09/93	0.57		0.63		0.61	
CREATININE CLEARANCE			108.00					
URIC ACID	1.5-7 (MG/DL)	13/09/93	4.60		5.50		4.70	
TOT BILIRUBIN	0.2-1.2 (MG/DL)	13/09/93	0.56		0.69		0.59	
DIR BILIRUBIN	0-0.3 (MG/DL)	13/09/93	0.00		0.00		0.18	
TOT. PROTEINS	6-8.5 (G/DL)	13/09/93	7.20		7.80		7.00	
ALBUMINE	3.5-5.5 (G/DL)	13/09/93	4.00		4.00		3.50	
TOT. CHOLEST.	150-250 (MG/DL)	13/09/93	276.00	>	208.00		244.00	
TRIGLYCERIDES	50-150 (MG/DL)	13/09/93	80.00		120.00		100.00	
GLOBULINS ALPHA 1	3-7 (%)	13/09/93	5.40		6.30		6.20	
GLOBULINS ALPHA 2	7-11 (%)	13/09/93	8.20		8.80		9.50	
GLOBULINS BETA	10-14 (%)	13/09/93	13.30		12.20		12.70	
GLOBULINS GAMMA	14-22 (%)	13/09/93	17.60		15.60		21.60	
TSH	0.5-6.5 (UU/ML)	13/09/93	1.80					
T4	4.5-11.5 (UG/DL)	13/09/93	9.30					

2104

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS 00089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 9 Patient: SBT Treatment: Reboxetine Sex: Female

Laboratory test			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			09/11/93		14/12/93		11/01/94	
			value	(φ)	value	(φ)	value	(φ)
Range value	Range date							
HB	12-16 (G/DL)	13/09/93	13.00		13.90		13.60	
HT	37-47 (%)	13/09/93	39.00		40.00		40.00	
RBC	4200000-5400000 (/MM3)	13/09/93						
MBC	4800-8100 (/MM3)	13/09/93	4650000		4870000		4750000	
MBC: N	60-75 (%)	13/09/93	5100.00		3500.00	<	2950.00 <<	
MBC: L	20-30 (%)	13/09/93	55.00	<	48.00	<	45.00 <	
MBC: E	2-4 (%)	13/09/93	37.00	>	42.00	>>	44.00 >>	
MBC: M	2-8 (%)	13/09/93	1.00	<	1.00	<	4.00	
MBC: B	0-1 (%)	13/09/93	7.00		9.00	>	7.00	
PLATELETS	200000-400000 (/MM3)	13/09/93	0.00		0.00		0.00	
NA+	135-145 (MEQ/L)	13/09/93	297000		275000		258000	
K+	3.5-5 (MEQ/L)	13/09/93	134.00	<	135.00	<	134.00 <	
CL-	90-110 (MEQ/L)	13/09/93	3.40	<	4.00		3.50	
Ca++	4.5-5.5 (MEQ/L)	13/09/93	100.00		102.00		108.00	
PO4--	2.5-4.8 (MG/DL)	13/09/93	4.80		4.40	<	5.00	
SGOT	3-20 (UI/L)	13/09/93	3.20		3.00		2.80	
SGPT	3-20 (UI/L)	13/09/93	10.60		18.30		10.30	
GAMMA GT	3-18 (UI/L)	13/09/93	9.60		9.60		9.60	
LDH	80-240 (UI/L)	13/09/93	5.60		9.10		16.10	
ALK. PHOSPH.	15-70 (UI/L)	13/09/93	210.00		230.00		135.00	
GLUCOSE	70-110 (MG/DL)	13/09/93	65.40		60.00		54.00	
UREA	15-35 (MG/DL)	13/09/93	81.50		90.50		82.00	
CREATININE	0.4-1.2 (MG/DL)	13/09/93	25.50		24.80		22.00	
CREATININE CLEARANCE	70-140 (ML/MIN)	13/09/93	0.57		0.51		0.58	
URIC ACID	1.5-7 (MG/DL)	13/09/93	100.00					
TOT BILIRUBIN	0.2-1.2 (MG/DL)	13/09/93	5.20		4.80		5.00	
DIR BILIRUBIN	0-0.3 (MG/DL)	13/09/93	0.60		0.52		0.58	
TOT. PROTEINS	6-8.5 (G/DL)	13/09/93	0.05		0.00		0.00	
ALBUMINE	3.5-5.5 (G/DL)	13/09/93	6.00		6.00		6.80	
TOT. CHOLEST.	150-250 (MG/DL)	13/09/93	3.50		3.30	<	3.80	
TRIGLYCERIDES	50-150 (MG/DL)	13/09/93	273.00	>	284.00	>	320.00 >	
GLOBULINS ALPHA 1	3-7 (%)	13/09/93	131.00		134.00		128.00	
GLOBULINS ALPHA 2	7-11 (%)	13/09/93	5.80		6.20		6.60	
GLOBULINS BETA	10-14 (%)	13/09/93	7.30		8.00		7.50	
GLOBULINS GAMMA	14-22 (%)	13/09/93	12.50		11.50		11.10	
TSH	0.5-6.5 (U/ml)	13/09/93	16.10		19.30		18.90	
T4	4.5-11.5 (UG/DL)	13/09/93	1.60					
			7.90					

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN930089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: IMD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			24/09/93		29/10/93		26/11/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	10/09/93	14.60		14.80		14.00	
HT	37-47 (%)	10/09/93	42.00		43.00		43.00	
RBC	3.8-5.4 (10 ⁶ /MM ³)	10/09/93	4.80		4.70		4.70	
WBC	4-11 (10 ⁶ /MM ³)	10/09/93	8.50		7.90		6.00	
WBC: N	40-70 (%)	10/09/93	56.00		61.00		63.00	
WBC: L	20-40 (%)	10/09/93	33.00		30.00		30.00	
WBC: E	1-5 (%)	10/09/93	2.00		2.00		2.00	
WBC: M	4-8 (%)	10/09/93	9.00 >		7.00		5.00	
WBC: B	0-1 (%)	10/09/93	0.00		0.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	341.00		366.00		261.00	
NA+	138-146 (MEQ/L)	10/09/93	141.00		142.00		143.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.30		4.20		4.40	
CL-	96-106 (MEQ/L)	10/09/93	102.00		101.00		100.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	9.70		9.90		9.00	
PO4--	3.4-4.5 (MG/DL)	10/09/93	3.10 <		3.20 <		3.40	
SGOT	0-40 (MU/ML)	10/09/93	35.00		33.00		19.00	
SGPT	0-40 (MU/ML)	10/09/93	37.00		38.00		24.00	
GAMMA GT	7-51 (MU/ML)	10/09/93	48.00		42.00		37.00	
LDH	230-460 (MU/ML)	10/09/93	242.00		237.00		266.00	
ALK. PHOSPH.	65-306 (MU/ML)	10/09/93	288.00		275.00		322.00 >	
GLUCOSE	70-110 (MG/DL)	10/09/93	120.00 >		108.00		123.00 >	
UREA	10-50 (MG/DL)	10/09/93	40.00		36.00		40.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	1.00		1.00		1.20	
CREATININE CLEARANCE	70-160 (ML/MIN)	10/09/93	44.80					
URIC ACID	2.4-5.7 (MG/DL)	10/09/93	4.50		4.40		3.30	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.70		0.80		1.10	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.30		0.40		0.50 >	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	7.30		7.20		7.10	
ALBUMINE	3.5-5 (G/DL)	10/09/93	4.10		4.00		4.10	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	254.00 >		233.00		253.00 >	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	402.00 >>		365.00 >>		400.00 >>	
GLOBULINS ALPHA 1	4-7 (%)	10/09/93	4.40		3.90 <		4.60	
GLOBULINS ALPHA 2	7-11 (%)	10/09/93	8.70		9.10		8.90	
GLOBULINS BETA	11-14 (%)	10/09/93	12.90		15.00 >		12.20	
GLOBULINS GAMMA	15-22 (%)	10/09/93	17.20		16.40		16.50	
TSH	0.5-4.5 (UU/ML)	10/09/93	2.54					
T4	4.8-12.9 (UG/DL)	10/09/93	7.50					

2106

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 0550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: 2ND Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			24/09/93		29/10/93		26/11/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	10/09/93	14.40		14.20		14.20	
HT	40-54 (%)	10/09/93	43.00		42.00		43.00	
RBC	4.3-6.1 (10 ⁶ /MM ³)	10/09/93	5.00		4.90		4.90	
WBC	4-11 (10 ⁶ /MM ³)	10/09/93	5.90		4.00		6.00	
WBC: N	40-70 (%)	10/09/93	47.00		55.00		60.00	
WBC: L	20-40 (%)	10/09/93	40.00		38.00		35.00	
WBC: E	1-5 (%)	10/09/93	3.00		3.00		1.00	
WBC: M	4-8 (%)	10/09/93	10.00	>	4.00		4.00	
WBC: B	0-1 (%)	10/09/93	0.00		0.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	311.00		251.00		200.00	
NA+	138-146 (MEQ/L)	10/09/93	139.00		141.00		141.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.40		4.30		4.30	
CL-	96-106 (MEQ/L)	10/09/93	102.00		102.00		101.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	9.30		9.60		9.40	
PO4--	3.4-4.5 (MG/DL)	10/09/93	3.00	<	3.50		3.20 <	
SGOT	0-40 (MU/ML)	10/09/93	25.00		26.00		28.00	
SGPT	0-40 (MU/ML)	10/09/93	21.00		20.00		23.00	
GAMMA GT	11-33 (MU/ML)	10/09/93	19.00		23.00		21.00	
LDH	230-460 (MU/ML)	10/09/93	215.00	<	215.00	<	232.00	
ALK. PHOSPH.	65-306 (MU/ML)	10/09/93	187.00		194.00		194.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	105.00		96.00		102.00	
UREA	10-50 (MG/DL)	10/09/93	25.00		28.00		26.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	1.10		1.20		1.00	
CREATININE CLEARANCE	70-160 (ML/MIN)	10/09/93	121.10					
URIC ACID	3.4-7 (MG/DL)	10/09/93	4.70		4.30		4.60	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	2.10	>	1.80	>	2.00 >	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.90	>>	0.80	>>	0.80 >>	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	6.90		7.00		7.00	
ALBUMINE	3.5-5 (G/DL)	10/09/93	4.10		4.20		4.10	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	218.00		223.00		222.00	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	128.00		141.00		114.00	
GLOBULINS ALPHA 1	4-7 (%)	10/09/93	3.50	<	3.10	<	4.10	
GLOBULINS ALPHA 2	7-11 (%)	10/09/93	7.30		8.10		8.00	
GLOBULINS BETA	11-14 (%)	10/09/93	14.00		11.90		13.30	
GLOBULINS GAMMA	15-22 (%)	10/09/93	15.80		16.90		16.00	
TSH	0.5-4.5 (UU/ML)	10/09/93	1.90					
T4	4.8-12.9 (UG/DL)	10/09/93	6.50					

2107

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS 550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: 3ND Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			24/09/93		29/10/93		26/11/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	10/09/93	14.60		14.80		14.00	
HT	40-54 (%)	10/09/93	44.00		45.00		43.00	
RBC	4.3-6.1 (10 ⁶ /MM ³)	10/09/93	5.30		5.30		5.10	
WBC	4-11 (10 ⁶ /MM ³)	10/09/93	7.10		7.00		7.00	
WBC: N	40-70 (%)	10/09/93	63.00		57.00		63.00	
WBC: L	20-40 (%)	10/09/93	27.00		30.00		25.00	
WBC: E	1-5 (%)	10/09/93	3.00		4.00		2.00	
WBC: M	4-8 (%)	10/09/93	7.00		9.00 >		>	
WBC: B	0-1 (%)	10/09/93	0.00		0.00		1.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	241.00		311.00		316.00	
NA+	138-146 (MEQ/L)	10/09/93	139.00		139.00		143.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.60		4.40		3.80	
CL-	96-106 (MEQ/L)	10/09/93	103.00		101.00		98.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	9.50		9.80		8.90	
PO4--	3.4-4.5 (MG/DL)	10/09/93	3.30 <		3.40		3.00 <	
SGOT	0-40 (IU/ML)	10/09/93	34.00		42.00 >		20.00	
SGPT	0-40 (IU/ML)	10/09/93	92.00 >>		75.00 >		28.00	
GAMMA GT	11-33 (IU/ML)	10/09/93	151.00 >>		100.00 >>		50.00 >	
LDH	230-460 (IU/ML)	10/09/93	308.00		316.00		271.00	
ALK. PHOSPH.	65-306 (IU/ML)	10/09/93	212.00		227.00		180.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	150.00 >>		128.00 >		109.00	
UREA	10-50 (MG/DL)	10/09/93	21.00		23.00		21.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	1.10		1.20		1.20	
CREATININE CLEARANCE			79.40					
URIC ACID	3.4-7 (MG/DL)	10/09/93	6.60		6.10		6.10	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.40		0.50		0.70	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.20		0.20		0.20	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	7.50		7.40		7.40	
ALBUMINE	3.5-5 (G/DL)	10/09/93	4.20		4.10		4.20	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	276.00 >		255.00 >		234.00	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	167.00		161.00		131.00	
GLOBULINS ALPHA 1	4-7 (%)	10/09/93	5.20		3.90 <		4.30	
GLOBULINS ALPHA 2	7-11 (%)	10/09/93	9.30		7.40		9.00	
GLOBULINS BETA	11-14 (%)	10/09/93	11.50		14.80 >		12.50	
GLOBULINS GAMMA	15-22 (%)	10/09/93	18.00		18.50		17.40	
TSH	0.5-4.5 (UU/ML)	10/09/93	1.68					
T4	4.8-12.9 (UG/DL)	10/09/93	7.20					

2108

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C9590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: 4MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			28/09/93		03/11/93		30/11/93	
			value	(#)	value	(#)	value	(#)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	10/09/93	13.40		13.20		14.80	
HT	37-47 (%)	10/09/93	41.00		41.00		46.00	
RBC	3.8-5.4 (10 ⁶ /MM ³)	10/09/93	4.70		4.80		5.00	
WBC	4-11 (10 ⁶ /MM ³)	10/09/93	6.80		6.30		6.60	
WBC: N	40-70 (%)	10/09/93	51.00		58.00		45.00	
WBC: L	20-40 (%)	10/09/93	33.00		30.00		35.00	
WBC: E	1-5 (%)	10/09/93	7.00	>>	3.00		13.00 >>	
WBC: M	4-8 (%)	10/09/93	9.00	>	9.00	>	7.00	
WBC: B	0-1 (%)	10/09/93	0.00		0.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	581.00	>	490.00		368.00	
NA+	138-146 (MEQ/L)	10/09/93	140.00		141.00		142.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.80		4.70		4.70	
CL-	96-106 (MEQ/L)	10/09/93	103.00		102.00		98.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	9.50		9.60		8.80	
PO4--	3.4-4.5 (MG/DL)	10/09/93	3.60		3.70		3.50	
SGOT	0-40 (NU/ML)	10/09/93	41.00	>	38.00		24.00	
SGPT	0-40 (NU/ML)	10/09/93	88.00	>>	50.00	>	17.00	
GAMMA GT	7-51 (NU/ML)	10/09/93	27.00		29.00		68.00 >	
LDH	230-460 (NU/ML)	10/09/93	404.00		393.00		403.00	
ALK. PHOSPH.	65-306 (NU/ML)	10/09/93	377.00	>	381.00	>	292.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	98.00		100.00		95.00	
UREA	10-50 (MG/DL)	10/09/93	22.00		23.00		31.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	0.80		0.90		1.10	
CREATININE CLEARANCE	70-160 (ML/MIN)	10/09/93	83.00					
URIC ACID	2.4-5.7 (MG/DL)	10/09/93	3.80		4.00		3.80	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.30		0.40		0.70	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.20		0.20		0.30	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	7.00		7.10		7.70	
ALBUMINE	3.5-5 (G/DL)	10/09/93	3.90		4.00		4.60	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	192.00		186.00		170.00	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	110.00		115.00		99.00	
GLOBULINS ALPHA 1	4-7 (%)	10/09/93	5.00		4.80		4.00	
GLOBULINS ALPHA 2	7-11 (%)	10/09/93	8.10		7.60		7.90	
GLOBULINS BETA	11-14 (%)	10/09/93	13.90		14.10	>	12.50	
GLOBULINS GAMMA	15-22 (%)	10/09/93	17.30		17.20		15.90	
TSH	0.5-4.5 (UU/ML)	10/09/93	0.73					
T4	4.8-12.9 (UG/DL)	10/09/93	7.30					

2109

(#) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: SMD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			29/09/93		03/11/93		30/11/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	10/09/93	13.70		14.00		13.60	
HT	37-47 (%)	10/09/93	41.00		43.00		42.00	
RBC	3.8-5.4 (10 ⁶ /MM ³)	10/09/93	5.00		5.00		5.00	
WBC	4-11 (10 ⁶ /MM ³)	10/09/93	5.90		6.20		5.60	
WBC: N	40-70 (%)	10/09/93	69.00		63.00		56.00	
WBC: L	20-40 (%)	10/09/93	24.00		30.00		29.00	
WBC: E	1-5 (%)	10/09/93	3.00		2.00		8.00 >>	
WBC: M	4-8 (%)	10/09/93	4.00		5.00		7.00	
WBC: B	0-1 (%)	10/09/93	0.00		0.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	274.00		265.00		262.00	
HA+	138-146 (MEQ/L)	10/09/93	140.00		142.00		145.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.40		4.30		4.50	
CL-	96-106 (MEQ/L)	10/09/93	102.00		101.00		101.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	9.70		9.80		9.00	
PO4--	3.4-4.5 (MG/DL)	10/09/93	3.20 <		3.40		3.10 <	
SGOT	0-40 (MU/ML)	10/09/93	19.00		20.00		21.00	
SGPT	0-40 (MU/ML)	10/09/93	14.00		15.00		20.00	
GAMMA GT	7-51 (MU/ML)	10/09/93	31.00		32.00		39.00	
LDH	230-460 (MU/ML)	10/09/93	473.00 >		456.00		431.00	
ALK. PHOSPH.	65-306 (MU/ML)	10/09/93	241.00		237.00		268.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	114.00 >		99.00		130.00 >	
UREA	10-50 (MG/DL)	10/09/93	27.00		30.00		31.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	0.90		1.00		1.10	
CREATININE CLEARANCE	70-160 (ML/MIN)	10/09/93	102.00					
URIC ACID	2.4-5.7 (MG/DL)	10/09/93	4.20		4.40		4.50	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.50		0.40		0.60	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.20		0.20		0.30	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	7.20		7.30		7.40	
ALBUMINE	3.5-5 (G/DL)	10/09/93	3.90		4.00		3.80	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	202.00		205.00		206.00	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	89.00		95.00		84.00	
GLOBULINS ALPHA 1	4-7 (%)	10/09/93	3.50 <		4.00		4.80	
GLOBULINS ALPHA 2	7-11 (%)	10/09/93	7.90		7.60		8.70	
GLOBULINS BETA	11-14 (%)	10/09/93	15.00 >		14.30 >		13.50	
GLOBULINS GAMMA	15-22 (%)	10/09/93	19.40		19.30		21.60	
TSH	0.5-4.5 (UU/ML)	10/09/93	3.82					
T4	4.8-12.9 (UG/DL)	10/09/93	10.00					

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

2110

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARNACIA C8580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: GMD Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			01/10/93		05/11/93		03/12/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	10/09/93	12.60	<	12.90	<	12.10	<
HT	40-54 (%)	10/09/93	40.00		41.00		38.00	<
RBC	4.3-6.1 (10 ⁶ /MM ³)	10/09/93	4.40		4.30		4.30	
WBC	4-11 (10 ⁶ /MM ³)	10/09/93	9.20		8.30		8.90	
WBC: N	40-70 (%)	10/09/93	73.00	>	67.00		70.00	
WBC: L	20-40 (%)	10/09/93	22.00		25.00		20.00	
WBC: E	1-5 (%)	10/09/93	0.00	<	2.00		3.00	
WBC: M	4-8 (%)	10/09/93	5.00		6.00		7.00	
WBC: B	0-1 (%)	10/09/93	0.00		0.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	173.00		186.00		201.00	
NA+	138-146 (MEQ/L)	10/09/93	140.00		141.00		143.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.70		4.50		4.60	
CL-	96-106 (MEQ/L)	10/09/93	101.00		100.00		98.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	9.30		9.20		8.30	<
PO4--	3.4-4.5 (MG/DL)	10/09/93	2.90	<	3.00	<	2.90	<
SGOT	0-40 (IU/ML)	10/09/93	17.00		18.00		22.00	
SGPT	0-40 (IU/ML)	10/09/93	18.00		19.00		17.00	
GAMMA GT	11-33 (IU/ML)	10/09/93	22.00		24.00		25.00	
LDH	230-460 (IU/ML)	10/09/93	260.00		243.00		267.00	
ALK. PHOSPH.	65-306 (IU/ML)	10/09/93	358.00	>	348.00	>	305.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	106.00		102.00		108.00	
UREA	10-50 (MG/DL)	10/09/93	39.00		36.00		29.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	1.10		1.00		1.20	
CREATININE CLEARANCE			93.00					
URIC ACID	3.4-7 (MG/DL)	10/09/93	2.90	<	3.20	<	2.90	<
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.60		0.60		0.50	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.20		0.30		0.30	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	7.40		7.30		7.20	
ALBUMINE	3.5-5 (G/DL)	10/09/93	4.20		4.20		4.00	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	149.00	<	166.00		137.00	<
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	71.00		90.00		134.00	
GLOBULINS ALPHA 1	4-7 (%)	10/09/93	3.20	<	4.10		4.10	
GLOBULINS ALPHA 2	7-11 (%)	10/09/93	6.50	<	5.90	<	7.50	
GLOBULINS BETA	11-14 (%)	10/09/93	13.40		13.30		14.00	
GLOBULINS GAMMA	15-22 (%)	10/09/93	20.60		19.20		18.80	
TSH	0.5-4.5 (IU/ML)	10/09/93	1.47					
T4	4.8-12.9 (UG/DL)	10/09/93	5.30					

2111

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C05E0089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: 7ND Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			01/10/93		05/11/93		03/12/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	10/09/93	15.30		15.00		15.10	
HT	40-54 (X)	10/09/93	45.00		42.00		47.00	
RBC	4.3-6.1 (10 ⁶ /MM ³)	10/09/93	5.60		5.50		5.50	
MBC	4-11 (10 ⁶ /MM ³)	10/09/93	5.70		5.60		6.30	
MBC: N	40-70 (X)	10/09/93	64.00		61.00		67.00	
MBC: L	20-40 (X)	10/09/93	27.00		30.00		24.00	
MBC: E	1-5 (X)	10/09/93	2.00		2.00		1.00	
MBC: M	4-8 (X)	10/09/93	7.00		7.00		8.00	
MBC: B	0-1 (X)	10/09/93	0.00		0.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	358.00		340.00		238.00	
NA+	138-146 (MEQ/L)	10/09/93	141.00		142.00		144.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.40		4.30		4.40	
CL-	96-106 (MEQ/L)	10/09/93	102.00		101.00		96.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	9.70		9.80		9.20	
PO4--	3.4-4.5 (MG/DL)	10/09/93	2.10	<<	2.50	<<	2.80	
SGOT	0-40 (MU/ML)	10/09/93	33.00		30.00		31.00	
SGPT	0-40 (MU/ML)	10/09/93	20.00		24.00		38.00	
GAMMA GT	11-33 (MU/ML)	10/09/93	22.00		24.00		23.00	
LDH	230-460 (MU/ML)	10/09/93	371.00		386.00		390.00	
ALK. PHOSPH.	65-306 (MU/ML)	10/09/93	259.00		251.00		253.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	114.00	>	104.00		105.00	
UREA	10-50 (MG/DL)	10/09/93	37.00		35.00		31.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	1.10		1.00		1.40	
CREATININE CLEARANCE	70-160 (ML/MIN)	10/09/93	78.10					
URIC ACID	3.4-7 (MG/DL)	10/09/93	3.80		4.10		3.00	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	1.30		0.90		2.20	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.40		0.40		0.70	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	7.30		7.30		8.10	
ALBUMINE	3.5-5 (G/DL)	10/09/93	4.10		4.00		4.30	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	258.00	>	268.00	>	200.00	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	171.00		171.00		191.00	
GLOBULINS ALPHA 1	4-7 (X)	10/09/93	4.50		3.10	<	4.90	
GLOBULINS ALPHA 2	7-11 (X)	10/09/93	9.00		4.70	<<	8.70	
GLOBULINS BETA	11-14 (X)	10/09/93	16.30	>	18.00	>	13.20	
GLOBULINS GAMMA	15-22 (X)	10/09/93	14.00	<	19.40		20.10	
TSH	0.5-4.5 (UU/ML)	10/09/93	1.22					
T4	4.8-12.9 (UG/DL)	10/09/93	6.10					

2112

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 095549089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: SMD Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			08/10/93		12/11/93		10/12/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	10/09/93	14.40		14.50		14.20	
HT	40-54 (%)	10/09/93	44.00		44.00		43.00	
RBC	4.3-6.1 (10 ⁶ /MM ³)	10/09/93	4.70		4.60		4.60	
WBC	4-11 (10 ⁶ /MM ³)	10/09/93	6.80		6.00		7.00	
WBC: N	40-70 (%)	10/09/93	69.00		65.00		65.00	
WBC: L	20-40 (%)	10/09/93	20.00		25.00		24.00	
WBC: E	1-5 (%)	10/09/93	4.00		3.00		5.00	
WBC: M	4-8 (%)	10/09/93	7.00		7.00		6.00	
WBC: B	0-1 (%)	10/09/93	0.00		0.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	157.00		168.00		180.00	
NA+	138-146 (MEQ/L)	10/09/93	141.00		141.00		142.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.90		4.80		4.50	
CL-	96-106 (MEQ/L)	10/09/93	101.00		100.00		99.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	8.30	<	9.00		8.50	
PO4--	3.4-4.5 (MG/DL)	10/09/93	3.40		3.60		3.30	
SGOT	0-40 (IU/ML)	10/09/93	27.00		29.00		25.00	
SGPT	0-40 (IU/ML)	10/09/93	34.00		36.00		31.00	
GAMMA GT	11-33 (IU/ML)	10/09/93	36.00	>	38.00	>	34.00	
LDH	230-460 (IU/ML)	10/09/93	287.00		277.00		281.00	
ALK. PHOSPH.	65-306 (IU/ML)	10/09/93	248.00		258.00		238.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	100.00		97.00		99.00	
UREA	10-50 (MG/DL)	10/09/93	54.00	>	41.00		48.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	1.10		1.20		1.00	
CREATININE CLEARANCE	70-160 (ML/MIN)	10/09/93	88.00					
URIC ACID	3.4-7 (MG/DL)	10/09/93	4.00		4.50		3.80	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.40		0.40		0.40	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.20		0.20		0.10	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	6.70		6.90		6.90	
ALBUMINE	3.5-5 (G/DL)	10/09/93	4.10		4.00		4.00	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	234.00		228.00		251.00	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	107.00		118.00		118.00	
GLOBULINS ALPHA 1	4-7 (%)	10/09/93	2.80	<<	2.30	<<	3.90	
GLOBULINS ALPHA 2	7-11 (%)	10/09/93	5.30	<	5.00	<	6.00	
GLOBULINS BETA	11-14 (%)	10/09/93	13.10		15.10	>	13.30	
GLOBULINS GAMMA	15-22 (%)	10/09/93	17.60		19.70		18.80	
TSH	0.5-4.5 (UU/ML)	10/09/93	1.76					
T4	4.8-12.9 (UG/DL)	10/09/93	10.50					

2113

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: 9MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			12/11/93		17/12/93		14/01/94	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	10/09/93	13.60		13.50		13.40	
HT	37-47 (%)	10/09/93	42.00		42.00		41.00	
RBC	3.8-5.4 (10 ⁶ /MM ³)	10/09/93	4.60		4.60		4.40	
HBC	4-11 (10 ⁶ /MM ³)	10/09/93	9.30		8.70		9.00	
HBC: N	40-70 (%)	10/09/93	50.00		55.00		58.00	
HBC: L	20-40 (%)	10/09/93	35.00		32.00		31.00	
HBC: E	1-5 (%)	10/09/93	6.00	>	6.00	>	5.00	
HBC: M	4-8 (%)	10/09/93	9.00	>	7.00		6.00	
HBC: B	0-1 (%)	10/09/93	0.00		0.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	267.00		280.00		259.00	
NA+	138-146 (MEQ/L)	10/09/93	144.00		142.00		142.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.20		4.10		4.20	
CL-	96-106 (MEQ/L)	10/09/93	100.00		98.00		99.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	8.80		9.00		9.30	
PO4--	3.4-4.5 (MG/DL)	10/09/93	3.90		4.00		4.10	
SGOT	0-40 (MU/ML)	10/09/93	22.00		23.00		25.00	
SGPT	0-40 (MU/ML)	10/09/93	17.00		25.00		20.00	
GAMMA GT	7-51 (MU/ML)	10/09/93	27.00		30.00		31.00	
LDH	230-460 (MU/ML)	10/09/93	334.00		291.00		327.00	
ALK. PHOSPH.	65-306 (MU/ML)	10/09/93	301.00		303.00		308.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	93.00		89.00		90.00	
UREA	10-50 (MG/DL)	10/09/93	33.00		32.00		30.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	0.90		1.00		1.00	
CREATININE CLEARANCE	70-160 (ML/MIN)	10/09/93	49.00					
URIC ACID	2.4-5.7 (MG/DL)	10/09/93	3.50		3.90		4.00	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.70		0.80		0.60	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.40		0.40		0.40	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	6.70		6.80		6.80	
ALBUMINE	3.5-5 (G/DL)	10/09/93	3.90		3.90		4.00	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	230.00		227.00		210.00	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	136.00		142.00		144.00	
GLOBULINS ALPHA 1	4-7 (%)	10/09/93	1.90	<<	2.00	<<	1.80	
GLOBULINS ALPHA 2	7-11 (%)	10/09/93	7.50		7.30		7.00	
GLOBULINS BETA	11-14 (%)	10/09/93	15.30	>	15.10	>	13.80	
GLOBULINS GAMMA	15-22 (%)	10/09/93	17.10		18.20		18.60	
TSH	0.5-4.5 (UU/ML)	10/09/93	1.51					
T4	4.8-12.9 (UG/DL)	10/09/93	6.50					

2114

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C9584089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: 10MD Treatment: Imipramine Sex: Female

Laboratory test			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			15/10/93		19/11/93		17/12/93	
			value	(φ)	value	(φ)	value	(φ)
Range value	Range date							
HE	12-16 (G/DL)	10/09/93	14.40		14.00		14.20	
HT	37-47 (X)	10/09/93	43.00		42.00		43.00	
RBC	3.8-5.4 (10 ⁶ /MM ³)	10/09/93	4.80		4.80		4.80	
MBC	4-11 (10 ⁶ /MM ³)	10/09/93	5.80		6.10		5.10	
MBC: N	40-70 (X)	10/09/93	68.00		66.00		50.00	
MBC: L	20-40 (X)	10/09/93	21.00		24.00		33.00	
MBC: E	1-5 (X)	10/09/93	2.00		3.00		3.00	
MBC: M	4-8 (X)	10/09/93	9.00	>	7.00		13.00 >>	
MBC: B	0-1 (X)	10/09/93	0.00		0.00		1.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	305.00		312.00		300.00	
NA+	138-146 (MEQ/L)	10/09/93	143.00		141.00		141.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.30		4.20		4.40	
CL-	96-106 (MEQ/L)	10/09/93	104.00		102.00		101.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	10.20		10.10		9.50	
PO4--	3.4-4.5 (MG/DL)	10/09/93	2.70	<<	2.90	<	2.90 <	
SGOT	0-40 (NU/ML)	10/09/93	27.00		2.60		21.00	
SGPT	0-40 (NU/ML)	10/09/93	29.00		30.00		17.00	
GAMMA GT	7-51 (NU/ML)	10/09/93	40.00		36.00		37.00	
LDH	230-460 (NU/ML)	10/09/93	359.00		348.00		262.00	
ALK. PHOSPH.	65-306 (NU/ML)	10/09/93	354.00	>	326.00	>	399.00 >	
GLUCOSE	70-110 (MG/DL)	10/09/93	92.00		90.00		88.00	
UREA	10-50 (MG/DL)	10/09/93	29.00		28.00		28.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	0.90		0.90		0.90	
CREATININE CLEARANCE	70-160 (ML/MIN)	10/09/93	51.00					
URIC ACID	2.4-5.7 (MG/DL)	10/09/93	3.20		3.30		2.90	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.60		0.70		0.40	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.30		0.30		0.20	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	6.70		6.80		6.60	
ALBUMINE	3.5-5 (G/DL)	10/09/93	3.90		3.90		4.20	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	255.00	>	216.00		239.00 >	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	156.00		141.00		216.00 >	
GLOBULINS ALPHA 1	4-7 (X)	10/09/93	2.70	<<	2.90	<	4.00	
GLOBULINS ALPHA 2	7-11 (X)	10/09/93	8.50		8.80		7.90	
GLOBULINS BETA	11-14 (X)	10/09/93	13.90		14.00		14.10 >	
GLOBULINS GAMMA	15-22 (X)	10/09/93	16.70		16.90		10.40 <<	
TSH	0.5-4.5 (UU/ML)	10/09/93	7.55					
T4	4.8-12.9 (UG/DL)	10/09/93	6.20					

2115

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C8580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: 11MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			15/10/93		19/11/93		17/12/93	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	10/09/93	13.60		13.70		13.20	
HT	37-47 (X)	10/09/93	40.00		40.00		41.00	
RBC	3.8-5.4 (10 ⁶ /MM ³)	10/09/93	4.50		4.50		4.80	
WBC	4-11 (10 ⁶ /MM ³)	10/09/93	6.60		6.20		5.80	
WBC: N	40-70 (X)	10/09/93	70.00		65.00		62.00	
WBC: L	20-40 (X)	10/09/93	21.00		24.00		30.00	
WBC: E	1-5 (X)	10/09/93	2.00		3.00		3.00	
WBC: M	4-8 (X)	10/09/93	7.00		8.00		5.00	
WBC: B	0-1 (X)	10/09/93	0.00		0.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	316.00		290.00		320.00	
NA+	138-146 (MEQ/L)	10/09/93	141.00		142.00		141.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.30		4.40		4.20	
CL-	96-106 (MEQ/L)	10/09/93	103.00		104.00		101.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	9.90		10.00		9.40	
PO4--	3.4-4.5 (MG/DL)	10/09/93	3.00	<	3.10	<	3.30	
SGOT	0-40 (NU/ML)	10/09/93	24.00		22.00		27.00	
SGPT	0-40 (NU/ML)	10/09/93	26.00		26.00		28.00	
GAMMA GT	7-51 (NU/ML)	10/09/93	34.00		38.00		42.00	
LDH	230-460 (NU/ML)	10/09/93	186.00	<	195.00	<	193.00	
ALK. PHOSPH.	65-306 (NU/ML)	10/09/93	271.00		281.00		260.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	88.00		97.00		94.00	
UREA	10-50 (MG/DL)	10/09/93	30.00		31.00		28.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	0.90		1.00		1.00	
CREATININE CLEARANCE	70-160 (ML/MIN)	10/09/93	60.00					
URIC ACID	2.4-5.7 (MG/DL)	10/09/93	5.00		4.80		4.70	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.50		0.60		0.50	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.20		0.30		0.20	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	7.10		7.00		7.00	
ALBUMINE	3.5-5 (G/DL)	10/09/93	4.00		4.00		3.90	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	236.00		216.00		199.00	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	110.00		135.00		141.00	
GLOBULINS ALPHA 1	4-7 (X)	10/09/93	3.20	<	3.10	<	3.00	
GLOBULINS ALPHA 2	7-11 (X)	10/09/93	6.50	<	6.70	<	6.30	
GLOBULINS BETA	11-14 (X)	10/09/93	14.40	>	14.10	>	13.90	
GLOBULINS GAMMA	15-22 (X)	10/09/93	19.60		19.00		21.10	
TSH	0.5-4.5 (U/ML)	10/09/93	4.30					
T4	4.8-12.9 (UG/DL)	10/09/93	6.00					

2116

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C9590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: 12ND Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			19/10/93		23/11/93		21/12/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	10/09/93	12.90	<	12.70	<	13.20	<
HT	40-54 (X)	10/09/93	39.00	<	38.00	<	40.00	
RBC	4.3-6.1 (10 ⁶ /MM ³)	10/09/93	4.60		4.40		4.80	
WBC	4-11 (10 ⁶ /MM ³)	10/09/93	7.00		5.70		5.60	
WBC: N	40-70 (X)	10/09/93	64.00		67.00		68.00	
WBC: L	20-40 (X)	10/09/93	28.00		23.00		25.00	
WBC: E	1-5 (X)	10/09/93	2.00		4.00		2.00	
WBC: M	4-8 (X)	10/09/93	6.00		6.00		5.00	
WBC: B	0-1 (X)	10/09/93	0.00		0.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	286.00		274.00		269.00	
NA+	138-146 (MEQ/L)	10/09/93	142.00		142.00		142.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.30		4.10		4.40	
CL-	96-106 (MEQ/L)	10/09/93	98.00		99.00		100.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	9.70		10.30		9.50	
PO4--	3.4-4.5 (MG/DL)	10/09/93	3.30	<	3.50		3.50	
SGOT	0-40 (MU/ML)	10/09/93	24.00		28.00		27.00	
SGPT	0-40 (MU/ML)	10/09/93	28.00		32.00		29.00	
GAMMA GT	11-33 (MU/ML)	10/09/93	40.00	>	37.00	>	34.00	>
LDH	230-460 (MU/ML)	10/09/93	247.00		257.00		262.00	
ALK. PHOSPH.	65-306 (MU/ML)	10/09/93	276.00		266.00		270.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	101.00		93.00		94.00	
UREA	10-50 (MG/DL)	10/09/93	32.00		33.00		30.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	1.10		1.10		1.00	
CREATININE CLEARANCE	70-160 (ML/MIN)	10/09/93	66.00					
URIC ACID	3.4-7 (MG/DL)	10/09/93	4.50		4.70		4.30	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.70		0.60		0.70	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.40		0.40		0.30	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	6.90		7.00		7.00	
ALBUMINE	3.5-5 (G/DL)	10/09/93	3.80		3.80		4.10	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	193.00		215.00		174.00	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	160.00		172.00		143.00	
GLOBULINS ALPHA 1	4-7 (X)	10/09/93	2.00	<<	3.00	<	3.10	<
GLOBULINS ALPHA 2	7-11 (X)	10/09/93	7.40		7.10		8.20	
GLOBULINS BETA	11-14 (X)	10/09/93	11.50		13.80		14.00	
GLOBULINS GAMMA	15-22 (X)	10/09/93	24.00	>	21.80		16.00	
TSH	0.5-4.5 (UU/ML)	10/09/93	4.38					
T4	4.8-12.9 (UG/DL)	10/09/93	8.40					

2117

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C9564089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: 15MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			22/10/93		26/11/93		23/12/93	
			value	(*)	value	(*)	value	(*)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	10/09/93	13.20		13.50		13.00	
HT	37-47 (%)	10/09/93	40.00		41.00		40.00	
RBC	3.8-5.4 (10 ⁶ /MM ³)	10/09/93	4.20		4.30		4.30	
WBC	4-11 (10 ⁶ /MM ³)	10/09/93	7.40		7.10		7.50	
WBC: N	40-70 (%)	10/09/93	62.00		65.00		64.00	
WBC: L	20-40 (%)	10/09/93	27.00		25.00		25.00	
WBC: E	1-5 (%)	10/09/93	3.00		2.00		4.00	
WBC: M	4-8 (%)	10/09/93	8.00		8.00		7.00	
WBC: B	0-1 (%)	10/09/93	0.00		0.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	236.00		242.00		249.00	
NA+	138-146 (MEQ/L)	10/09/93	141.00		140.00		142.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.20		4.30		4.40	
CL-	96-106 (MEQ/L)	10/09/93	102.00		103.00		101.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	10.10		9.90		10.20	
PO4--	3.4-4.5 (MG/DL)	10/09/93	3.60		3.50		3.90	
SGOT	0-40 (NU/ML)	10/09/93	26.00		24.00		3.90	
SGPT	0-40 (NU/ML)	10/09/93	28.00		28.00		29.00	
GAMMA GT	7-51 (NU/ML)	10/09/93	34.00		36.00		32.00	
LDH	230-460 (NU/ML)	10/09/93	240.00		251.00		259.00	
ALK. PHOSPH.	65-306 (NU/ML)	10/09/93	186.00		230.00		221.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	100.00		98.00		92.00	
UREA	10-50 (MG/DL)	10/09/93	29.00		30.00		28.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	0.90		1.10		1.00	
CREATININE CLEARANCE	70-160 (ML/MIN)	10/09/93	55.00					
URIC ACID	2.4-5.7 (MG/DL)	10/09/93	4.30		4.60		4.40	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.80		0.90		0.90	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.50	>	0.50	>	0.50	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	6.90		7.00		7.00	
ALBUMINE	3.5-5 (G/DL)	10/09/93	4.00		3.90		4.00	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	210.00		202.00		225.00	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	175.00		180.00		211.00	
GLOBULINS ALPHA 1	4-7 (%)	10/09/93	3.00	<	2.90	<	3.10	
GLOBULINS ALPHA 2	7-11 (%)	10/09/93	7.10		7.00		8.00	
GLOBULINS BETA	11-14 (%)	10/09/93	12.90		13.20		11.50	
GLOBULINS GAMMA	15-22 (%)	10/09/93	19.00		21.20		20.30	
TSH	0.5-4.5 (UU/ML)	10/09/93	2.27					
T4	4.8-12.9 (UG/DL)	10/09/93	8.10					

2118

(*) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C8560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: 17MD Treatment: Reboxetine Sex: Female

Laboratory test			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			29/10/93		03/12/93		30/12/93	
			value	(φ)	value	(φ)	value	(φ)
Range value	Range date							
HB	12-16 (G/DL)	10/09/93	13.00		12.80		12.70	
HT	37-47 (X)	10/09/93	41.00		40.00		39.00	
RBC	3.8-5.4 (10 ⁶ /MM ³)	10/09/93	4.30		4.20		4.10	
MBC	4-11 (10 ⁶ /MM ³)	10/09/93	7.00		6.90		7.50	
MBC: N	40-70 (X)	10/09/93	62.00		61.00		65.00	
MBC: L	20-40 (X)	10/09/93	28.00		27.00		24.00	
MBC: E	1-5 (X)	10/09/93	3.00		4.00		3.00	
MBC: M	4-8 (X)	10/09/93	7.00		7.00		8.00	
MBC: B	0-1 (X)	10/09/93	0.00		1.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	274.00		293.00		290.00	
NA+	138-146 (MEQ/L)	10/09/93	141.00		142.00		142.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.20		4.00		4.30	
CL-	96-106 (MEQ/L)	10/09/93	99.00		100.00		101.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	10.20		9.90		9.80	
PO4--	3.4-4.5 (MG/DL)	10/09/93	4.00		3.50		3.60	
SGOT	0-40 (MU/ML)	10/09/93	28.00		28.00		27.00	
SGPT	0-40 (MU/ML)	10/09/93	32.00		30.00		29.00	
GAMMA GT	7-51 (MU/ML)	10/09/93	39.00		36.00		37.00	
LDH	230-460 (MU/ML)	10/09/93	247.00		225.00 <		263.00	
ALK. PHOSPH.	65-306 (MU/ML)	10/09/93	220.00		236.00		231.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	96.00		94.00		95.00	
UREA	10-50 (MG/DL)	10/09/93	32.00		31.00		33.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	1.10		1.00		1.00	
CLEARANCE			63.00					
URIC ACID	2.4-5.7 (MG/DL)	10/09/93	5.00		5.00		5.10	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.70		0.80		0.80	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.30		0.40		0.40	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	6.90		7.00		7.20	
ALBUMINE	3.5-5 (G/DL)	10/09/93	3.90		4.10		4.00	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	219.00		220.00		232.00	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	174.00		180.00		181.00	
GLOBULINS ALPHA 1	4-7 (X)	10/09/93	3.60 <		3.30 <		3.40 <	
GLOBULINS ALPHA 2	7-11 (X)	10/09/93	5.40 <		5.80 <		6.00 <	
GLOBULINS BETA	11-14 (X)	10/09/93	12.30		12.10		12.20	
GLOBULINS GAMMA	15-22 (X)	10/09/93	22.20 >		20.20		22.80 >	
TSH	0.5-4.5 (U/ML)	10/09/93	2.10					
T4	4.8-12.9 (UG/DL)	10/09/93	9.10					

2119

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C8560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: 18ND Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			29/10/93		03/12/93		30/12/93	
			value	(c)	value	(c)	value	(c)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	10/09/93	12.80		12.70		12.60	
HT	37-47 (X)	10/09/93	39.00		39.00		38.00	
RBC	3.8-5.4 (10 ⁶ /MM ³)	10/09/93	4.10		4.10		4.10	
WBC	4-11 (10 ⁶ /MM ³)	10/09/93	6.90		6.70		6.80	
WBC: N	40-70 (X)	10/09/93	57.00		59.00		59.00	
WBC: L	20-40 (X)	10/09/93	31.00		30.00		31.00	
WBC: E	1-5 (X)	10/09/93	4.00		4.00		2.00	
WBC: M	4-8 (X)	10/09/93	8.00		7.00		8.00	
WBC: B	0-1 (X)	10/09/93	0.00		0.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	306.00		288.00		291.00	
NA+	138-146 (MEQ/L)	10/09/93	142.00		141.00		141.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.10		4.00		4.20	
CL-	96-106 (MEQ/L)	10/09/93	98.00		99.00		99.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	9.60		9.50		10.20	
PO4--	3.4-4.5 (MG/DL)	10/09/93	3.70		3.80		3.30	<
SGOT	0-40 (IU/ML)	10/09/93	20.00		21.00		22.00	
SGPT	0-40 (IU/ML)	10/09/93	26.00		25.00		28.00	
GAMMA GT	7-51 (IU/ML)	10/09/93	33.00		34.00		33.00	
LDH	230-460 (IU/ML)	10/09/93	255.00		256.00		257.00	
ALK. PHOSPH.	65-306 (IU/ML)	10/09/93	227.00		230.00		219.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	97.00		98.00		94.00	
UREA	10-50 (MG/DL)	10/09/93	30.00		29.00		30.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	1.00		1.00		1.00	
CREATININE CLEARANCE			49.00					
URIC ACID	2.4-5.7 (MG/DL)	10/09/93	4.80		5.00		4.90	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.40		0.40		0.40	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.20		0.20		0.20	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	7.20		7.20		7.20	
ALBUMINE	3.5-5 (G/DL)	10/09/93	4.10		4.00		4.10	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	236.00		259.00	>	240.00	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	154.00		136.00		163.00	
GLOBULINS ALPHA 1	4-7 (X)	10/09/93	2.50	<<	2.70	<<	2.50	<<
GLOBULINS ALPHA 2	7-11 (X)	10/09/93	8.60		8.00		8.40	
GLOBULINS BETA	11-14 (X)	10/09/93	14.00		13.50		13.60	
GLOBULINS GAMMA	15-22 (X)	10/09/93	17.90		20.20		18.50	
TSH	0.5-4.5 (UU/ML)	10/09/93	3.16					
T4	4.8-12.9 (UG/DL)	10/09/93	7.00					

2120

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C9560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: 20MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			29/10/93		03/12/93		30/12/93	
			value	(*)	value	(*)	value	(*)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	10/09/93	13.20		13.50		13.00	
HT	37-47 (X)	10/09/93	41.00		41.00		40.00	
RBC	3.8-5.4 (10 ⁶ /MM ³)	10/09/93	4.30		4.30		4.30	
WBC	4-11 (10 ⁶ /MM ³)	10/09/93	6.50		6.90		6.40	
WBC: N	40-70 (X)	10/09/93	62.00		63.00		59.00	
WBC: L	20-40 (X)	10/09/93	30.00		27.00		26.00	
WBC: E	1-5 (X)	10/09/93	2.00		2.00		6.00 >	
WBC: M	4-8 (X)	10/09/93	6.00		8.00		8.00	
WBC: B	0-1 (X)	10/09/93	0.00		0.00		1.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	263.00		247.00		284.00	
NA+	138-146 (MEQ/L)	10/09/93	142.00		141.00		141.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.20		4.30		4.30	
CL-	96-106 (MEQ/L)	10/09/93	97.00		100.00		99.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	9.80		9.90		10.10	
PO4--	3.4-4.5 (MG/DL)	10/09/93	2.70 <<		2.90 <		3.00 <	
SGOT	0-40 (MU/ML)	10/09/93	26.00		26.00		30.00	
SGPT	0-40 (MU/ML)	10/09/93	28.00		28.00		32.00	
GAMMA GT	7-51 (MU/ML)	10/09/93	38.00		36.00		36.00	
LDH	230-460 (MU/ML)	10/09/93	297.00		281.00		274.00	
ALK. PHOSPH.	65-306 (MU/ML)	10/09/93	242.00		237.00		236.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	90.00		93.00		95.00	
UREA	10-50 (MG/DL)	10/09/93	28.00		29.00		30.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	1.00		1.20		1.10	
CREATININE CLEARANCE	70-160 (ML/MIN)	10/09/93	66.00					
URIC ACID	2.4-5.7 (MG/DL)	10/09/93	5.20		6.00 >		5.00	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.40		0.50		0.30	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.30		0.20		0.10	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	7.10		7.10		7.20	
ALBUMINE	3.5-5 (G/DL)	10/09/93	3.90		4.10		4.00	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	181.00		210.00		177.00	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	125.00		146.00		123.00	
GLOBULINS ALPHA 1	4-7 (X)	10/09/93	2.90 <		3.30 <		3.00 <	
GLOBULINS ALPHA 2	7-11 (X)	10/09/93	8.20		7.90		7.40	
GLOBULINS BETA	11-14 (X)	10/09/93	14.50 >		14.40 >		13.90	
GLOBULINS GAMMA	15-22 (X)	10/09/93	19.50		16.60		20.10	
TSH	0.5-4.5 (UU/ML)	10/09/93	1.84					
T4	4.8-12.9 (UG/DL)	10/09/93	6.10					

2121

(*) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done (*) missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C0560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: 1DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			23/11/93		28/12/93		25/01/94	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	10/09/93	13.80		13.60		14.00	
HT	37-47 (%)	10/09/93	42.00		42.00		43.00	
RBC	3.8-5.4 (10 ⁶ /MM ³)	10/09/93	4.50		4.50		4.60	
WBC	4-11 (10 ⁶ /MM ³)	10/09/93	7.30		7.00		6.80	
WBC: N	40-70 (%)	10/09/93	49.00		54.00		55.00	
WBC: L	20-40 (%)	10/09/93	40.00		36.00		34.00	
WBC: E	1-5 (%)	10/09/93	3.00		4.00		4.00	
WBC: M	4-8 (%)	10/09/93	7.00		6.00		7.00	
WBC: B	0-1 (%)	10/09/93	1.00		0.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	257.00		263.00		249.00	
NA+	138-146 (MEQ/L)	10/09/93	145.00		144.00		144.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.30		4.40		4.30	
CL-	96-106 (MEQ/L)	10/09/93	101.00		102.00		101.00	
Ca ⁺⁺	8.5-10.5 (MG/DL)	10/09/93	8.80		9.00		8.90	
PO ₄ ⁻⁻	3.4-4.5 (MG/DL)	10/09/93	3.60		3.70		3.40	
SGOT	0-40 (NU/ML)	10/09/93	22.00		23.00		23.00	
SGPT	0-40 (NU/ML)	10/09/93	17.00		18.00		18.00	
GAMMA GT	7-51 (NU/ML)	10/09/93	27.00		30.00		31.00	
LDH	230-460 (NU/ML)	10/09/93	334.00		335.00		327.00	
ALK. PHOSPH.	65-306 (NU/ML)	10/09/93	316.00	>	324.00	>	340.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	93.00		92.00		91.00	
UREA	10-50 (MG/DL)	10/09/93	33.00		32.00		34.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	0.90		1.00		0.90	
CREATININE	70-160 (ML/MIN)	10/09/93	66.00					
CLEARANCE								
URIC ACID	2.4-5.7 (MG/DL)	10/09/93	3.10		3.30		3.60	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.70		0.70		0.80	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.40		0.40		0.40	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	6.50		6.60		6.70	
ALBUMINE	3.5-5 (G/DL)	10/09/93	4.00		4.00		4.00	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	244.00	>	230.00		252.00	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	141.00		137.00		139.00	
GLOBULINS ALPHA 1	4-7 (%)	10/09/93	3.10	<	3.00	<	2.90	
GLOBULINS ALPHA 2	7-11 (%)	10/09/93	9.00		8.90		9.10	
GLOBULINS BETA	11-14 (%)	10/09/93	11.30		11.50		11.40	
GLOBULINS GAMMA	15-22 (%)	10/09/93	15.00		15.90		16.90	
TSH	0.5-4.5 (UU/ML)	10/09/93	2.51					
T ₄	4.8-12.9 (UG/DL)	10/09/93	7.50					

2122

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARNACIA C 850089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: ZDT Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			23/11/93		28/12/93		25/01/94	
			value	(c)	value	(c)	value	(c)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	10/09/93	13.70	<	13.50	<	14.00	
HT	40-54 (%)	10/09/93	40.00		40.00		41.00	
RBC	4.3-6.1 (10 ⁶ /MM ³)	10/09/93	4.30		4.40		4.40	
HBC	4-11 (10 ⁶ /MM ³)	10/09/93	8.10		7.90		8.40	
HBC: N	40-70 (%)	10/09/93	62.00		59.00		58.00	
HBC: L	20-40 (%)	10/09/93	27.00		31.00		28.00	
HBC: E	1-5 (%)	10/09/93	4.00		4.00		5.00	
HBC: M	4-8 (%)	10/09/93	7.00		6.00		9.00 >	
HBC: B	0-1 (%)	10/09/93	0.00		0.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	249.00		253.00		266.00	
NA+	138-146 (MEQ/L)	10/09/93	143.00		144.00		142.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.30		4.20		4.10	
CL-	96-106 (MEQ/L)	10/09/93	98.00		99.00		100.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	9.40		10.00		9.90	
PO4--	3.4-4.5 (MG/DL)	10/09/93	3.70		3.60		3.80	
SGOT	0-40 (MU/ML)	10/09/93	23.00		24.00		28.00	
SGPT	0-40 (MU/ML)	10/09/93	26.00		26.00		32.00	
GAMMA GT	11-33 (MU/ML)	10/09/93	34.00 >		32.00		36.00 >	
LDH	230-460 (MU/ML)	10/09/93	320.00		316.00		324.00	
ALK. PHOSPH.	65-306 (MU/ML)	10/09/93	297.00		291.00		316.00 >	
GLUCOSE	70-110 (MG/DL)	10/09/93	88.00		89.00		94.00	
UREA	10-50 (MG/DL)	10/09/93	32.00		31.00		31.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	0.80		0.90		0.90	
CREATININE CLEARANCE	70-160 (ML/MIN)	10/09/93	72.00					
URIC ACID	3.4-7 (MG/DL)	10/09/93	5.00		4.90		4.90	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.90		0.80		0.80	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.40		0.40		0.40	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	6.90		6.90		7.00	
ALBUMINE	3.5-5 (G/DL)	10/09/93	4.00		3.90		4.00	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	251.00 >		244.00 >		272.00 >	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	194.00		202.00 >		191.00	
GLOBULINS ALPHA 1	4-7 (%)	10/09/93	2.50	<<	2.60	<<	2.40 <<	
GLOBULINS ALPHA 2	7-11 (%)	10/09/93	8.30		8.40		8.80	
GLOBULINS BETA	11-14 (%)	10/09/93	14.10 >		13.90		13.80	
GLOBULINS GAMMA	15-22 (%)	10/09/93	17.20		18.60		17.90	
TSH	0.5-4.5 (UU/ML)	10/09/93	5.35					
T4	4.8-12.9 (UG/DL)	10/09/93	6.90					

2123

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C9560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: 3DT Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			24/11/93		29/12/93		26/01/94	
			value	(⊕)	value	(⊕)	value	(⊕)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	10/09/93	14.00		13.80 <		14.10	
HT	40-54 (%)	10/09/93	42.00		41.00		43.00	
RBC	4.3-6.1 (10 ⁶ /MM ³)	10/09/93	4.60		4.50		4.80	
WBC	4-11 (10 ⁶ /MM ³)	10/09/93	5.30		5.00		5.10	
WBC: N	40-70 (%)	10/09/93	60.00		61.00		62.00	
WBC: L	20-40 (%)	10/09/93	27.00		26.00		28.00	
WBC: E	1-5 (%)	10/09/93	3.00		4.00		2.00	
WBC: M	4-8 (%)	10/09/93	9.00 >		9.00 >		8.00	
WBC: B	0-1 (%)	10/09/93	1.00		0.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	225.00		237.00		216.00	
NA+	138-146 (MEQ/L)	10/09/93	141.00		142.00		142.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.30		4.40		4.20	
CL-	96-106 (MEQ/L)	10/09/93	99.00		100.00		98.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	9.60		9.50		9.70	
PO4--	3.4-4.5 (MG/DL)	10/09/93	4.10		4.00		4.30	
SGOT	0-40 (NU/ML)	10/09/93	28.00		30.00		26.00	
SGPT	0-40 (NU/ML)	10/09/93	32.00		34.00		28.00	
GAMMA GT	11-33 (NU/ML)	10/09/93	40.00 >		32.00		30.00	
LDH	230-460 (NU/ML)	10/09/93	286.00		271.00		295.00	
ALK. PHOSPH.	65-306 (NU/ML)	10/09/93	195.00		190.00		216.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	99.00		96.00		94.00	
UREA	10-50 (MG/DL)	10/09/93	30.00		31.00		29.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	0.90		1.10		1.00	
CREATININE CLEARANCE	70-160 (ML/MIN)	10/09/93	70.00					
URIC ACID	3.4-7 (MG/DL)	10/09/93	4.60		5.00		4.80	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.80		0.70		0.90	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.40		0.30		0.50 >	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	7.10		7.00		7.00	
ALBUMINE	3.5-5 (G/DL)	10/09/93	4.00		3.80		4.00	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	211.00 >		226.00		236.00 >	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	231.00 >		194.00		210.00 >	
GLOBULINS ALPHA 1	4-7 (%)	10/09/93	1.90 <<		4.00		3.80 <	
GLOBULINS ALPHA 2	7-11 (%)	10/09/93	7.60		8.50		7.80	
GLOBULINS BETA	11-14 (%)	10/09/93	13.10		14.20 >		13.50	
GLOBULINS GAMMA	15-22 (%)	10/09/93	21.10		19.00		17.70	
TSH	0.5-4.5 (UU/ML)	10/09/93	4.71					
T4	4.8-12.9 (UG/DL)	10/09/93	5.80					

2124

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C959089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: 4DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			24/11/93		29/12/93		26/01/94	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	10/09/93	12.90		12.50		13.10	
HT	37-47 (X)	10/09/93	38.00		38.00		39.00	
RBC	3.8-5.4 (10 ⁶ /MM ³)	10/09/93	4.00		4.10		4.20	
WBC	4-11 (10 ⁶ /MM ³)	10/09/93	7.50		7.10		7.40	
WBC: N	40-70 (X)	10/09/93	58.00		60.00		61.00	
WBC: L	20-40 (X)	10/09/93	31.00		28.00		27.00	
WBC: E	1-5 (X)	10/09/93	3.00		4.00		5.00	
WBC: M	4-8 (X)	10/09/93	8.00		8.00		7.00	
WBC: B	0-1 (X)	10/09/93	0.00		0.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	193.00		203.00		219.00	
NA+	138-146 (MEQ/L)	10/09/93	141.00		142.00		143.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.30		4.40		4.20	
CL-	96-106 (MEQ/L)	10/09/93	98.00		99.00		100.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	9.50		9.30		9.90	
PO4--	3.4-4.5 (MG/DL)	10/09/93	3.60		4.10		4.20	
SGOT	0-40 (MU/ML)	10/09/93	28.00		26.00		29.00	
SGPT	0-40 (MU/ML)	10/09/93	32.00		30.00		33.00	
GAMMA GT	7-51 (MU/ML)	10/09/93	36.00		38.00		40.00	
LDH	230-460 (MU/ML)	10/09/93	286.00		274.00		269.00	
ALK. PHOSPH.	65-306 (MU/ML)	10/09/93	234.00		216.00		190.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	95.00		96.00		93.00	
UREA	10-50 (MG/DL)	10/09/93	30.00		31.00		32.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	0.90		1.10		1.10	
CREATININE CLEARANCE	70-160 (ML/MIN)	10/09/93	53.00					
URIC ACID	2.4-5.7 (MG/DL)	10/09/93	4.20		4.50		4.90	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.60		0.50		0.70	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.30		0.20		0.40	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	7.00		7.10		7.10	
ALBUMINE	3.5-5 (G/DL)	10/09/93	3.90		3.80		4.00	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	165.00		194.00		188.00	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	222.00 >		171.00		194.00	
GLOBULINS ALPHA 1	4-7 (X)	10/09/93	1.80 <<		3.00 <		3.80 <	
GLOBULINS ALPHA 2	7-11 (X)	10/09/93	6.60 <		8.10		9.00	
GLOBULINS BETA	11-14 (X)	10/09/93	12.50		13.50		12.50	
GLOBULINS GAMMA	15-22 (X)	10/09/93	23.20 >		21.90		18.30	
TSH	0.5-4.5 (U/ML)	10/09/93	3.49					
T4	4.8-12.9 (UG/DL)	10/09/93	7.10					

2125

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C8560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: 5DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			26/11/93		30/12/93		28/01/94	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	10/09/93	12.90		12.50		12.70	
HT	37-47 (%)	10/09/93	40.00		39.00		38.00	
RBC	3.8-5.4 (10 ⁶ /MM ³)	10/09/93	4.60		4.40		4.20	
WBC	4-11 (10 ⁶ /MM ³)	10/09/93	5.90		6.20		6.00	
WBC: N	40-70 (%)	10/09/93	58.00		57.00		59.00	
WBC: L	20-40 (%)	10/09/93	28.00		30.00		29.00	
WBC: E	1-5 (%)	10/09/93	4.00		5.00		3.00	
WBC: M	4-8 (%)	10/09/93	10.00	>	8.00		9.00	
WBC: B	0-1 (%)	10/09/93	0.00		0.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	220.00		235.00		237.00	
NA+	138-146 (MEQ/L)	10/09/93	142.00		141.00		143.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.30		4.40		4.20	
CL-	96-106 (MEQ/L)	10/09/93	99.00		101.00		98.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	10.10		10.20		10.00	
PO4--	3.4-4.5 (MG/DL)	10/09/93	3.60		3.90		4.10	
SGOT	0-40 (NU/ML)	10/09/93	29.00		26.00		28.00	
SGPT	0-40 (NU/ML)	10/09/93	31.00		30.00		30.00	
GAMMA GT	7-51 (NU/ML)	10/09/93	27.00		25.00		28.00	
LDH	230-460 (NU/ML)	10/09/93	253.00		286.00		263.00	
ALK. PHOSPH.	65-306 (NU/ML)	10/09/93	300.00		275.00		294.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	91.00		92.00		96.00	
UREA	10-50 (MG/DL)	10/09/93	31.00		32.00		29.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	0.90		1.00		1.00	
CREATININE CLEARANCE	70-160 (ML/MIN)	10/09/93	56.00					
URIC ACID	2.4-5.7 (MG/DL)	10/09/93	4.30		4.40		4.80	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.60		0.70		0.70	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.30		0.30		0.30	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	7.20		7.10		7.00	
ALBUMINE	3.5-5 (G/DL)	10/09/93	4.00		3.90		4.10	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	186.00		202.00		199.00	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	141.00		135.00		137.00	
GLOBULINS ALPHA 1	4-7 (%)	10/09/93	4.00		4.20		4.20	
GLOBULINS ALPHA 2	7-11 (%)	10/09/93	8.10		9.00		9.10	
GLOBULINS BETA	11-14 (%)	10/09/93	12.50		13.40		12.90	
GLOBULINS GAMMA	15-22 (%)	10/09/93	19.90		18.50		15.30	
TSH	0.5-4.5 (U/ML)	10/09/93	0.81					
T4	4.8-12.9 (UG/DL)	10/09/93	6.30					

2126

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C8560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: 6DT Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			26/11/93		30/12/93		28/01/94	
			value	(c)	value	(c)	value	(c)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	10/09/93	13.50	<	13.30	<	13.40	<
HT	40-54 (X)	10/09/93	42.00		43.00		44.00	
RBC	4.3-6.1 (10 ⁶ /MM3)	10/09/93	4.70		5.00		5.10	
RBC	4-11 (10 ⁶ /MM3)	10/09/93	6.80		7.30		6.70	
RBC: N	40-70 (X)	10/09/93	53.00		58.00		62.00	
RBC: L	20-40 (X)	10/09/93	30.00		29.00		28.00	
RBC: E	1-5 (X)	10/09/93	6.00	>	4.00		4.00	
RBC: M	4-8 (X)	10/09/93	10.00	>	9.00	>	6.00	
RBC: B	0-1 (X)	10/09/93	1.00		0.00		0.00	
PLATELETS	150-500 (10 ³ /MM3)	10/09/93	287.00		265.00		275.00	
NA+	138-146 (MEQ/L)	10/09/93	143.00		142.00		144.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.50		4.40		4.20	
CL-	96-106 (MEQ/L)	10/09/93	101.00		100.00		98.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	9.90		9.80		10.10	
PO4--	3.4-4.5 (MG/DL)	10/09/93	3.80		4.10		4.20	
SGOT	0-40 (NU/ML)	10/09/93	30.00		26.00		25.00	
SGPT	0-40 (NU/ML)	10/09/93	34.00		28.00		28.00	
GAMMA GT	11-33 (NU/ML)	10/09/93	38.00	>	35.00	>	30.00	
LDH	230-460 (NU/ML)	10/09/93	235.00		252.00		251.00	
ALK. PHOSPH.	65-306 (NU/ML)	10/09/93	199.00		210.00		176.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	100.00		94.00		98.00	
UREA	10-50 (MG/DL)	10/09/93	33.00		32.00		34.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	1.10		1.00		1.20	
CREATININE CLEARANCE			74.00					
URIC ACID	3.4-7 (MG/DL)	10/09/93	4.30		5.00		4.90	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.60		0.80		0.90	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.30		0.40		0.50	>
TOT. PROTEINS	6-8 (G/DL)	10/09/93	7.00		7.20		7.20	
ALBUMINE	3.5-5 (G/DL)	10/09/93	3.90		4.00		3.80	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	193.00		216.00		190.00	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	152.00		164.00		149.00	
GLOBULINS ALPHA 1	4-7 (X)	10/09/93	4.30		4.20		4.20	
GLOBULINS ALPHA 2	7-11 (X)	10/09/93	8.20		7.80		8.30	
GLOBULINS BETA	11-14 (X)	10/09/93	12.00		12.50		13.20	
GLOBULINS GAMMA	15-22 (X)	10/09/93	19.80		19.90		21.50	
TSH	0.5-4.5 (UU/ML)	10/09/93	4.35					
T4	4.8-12.9 (UG/DL)	10/09/93	9.80					

2127

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C0560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: 7DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			26/11/93		30/12/93		28/01/94	
			value	(c)	value	(c)	value	(c)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	10/09/93	14.00		14.20		13.90	
HT	37-47 (X)	10/09/93	41.00		41.00		40.00	
RBC	3.8-5.4 (10 ⁶ /MM ³)	10/09/93	4.70		4.60		4.50	
WBC	4-11 (10 ⁶ /MM ³)	10/09/93	6.60		7.10		7.20	
WBC: N	40-70 (X)	10/09/93	61.00		63.00		62.00	
WBC: L	20-40 (X)	10/09/93	32.00		30.00		29.00	
WBC: E	1-5 (X)	10/09/93	2.00		3.00		4.00	
WBC: M	4-8 (X)	10/09/93	5.00		4.00		5.00	
WBC: B	0-1 (X)	10/09/93	0.00		0.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	241.00		253.00		261.00	
NA+	138-146 (MEQ/L)	10/09/93	142.00		141.00		140.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.30		4.40		4.20	
CL-	96-106 (MEQ/L)	10/09/93	102.00		101.00		99.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	9.90		9.80		10.00	
PO4--	3.4-4.5 (MG/DL)	10/09/93	3.80		4.20		4.10	
SGOT	0-40 (NU/ML)	10/09/93	26.00		28.00		25.00	
SGPT	0-40 (NU/ML)	10/09/93	30.00		32.00		31.00	
GAMMA GT	7-51 (NU/ML)	10/09/93	34.00		38.00		36.00	
LDH	230-460 (NU/ML)	10/09/93	291.00		275.00		274.00	
ALK. PHOSPH.	65-306 (NU/ML)	10/09/93	316.00	>	295.00		286.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	90.00		94.00		92.00	
UREA	10-50 (MG/DL)	10/09/93	29.00		31.00		30.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	1.00		1.20		1.10	
CREATININE CLEARANCE	70-160 (ML/MIN)	10/09/93	63.00					
URIC ACID	2.4-5.7 (MG/DL)	10/09/93	4.50		4.40		4.70	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.60		0.70		0.80	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.30		0.40		0.40	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	6.80		7.00		7.00	
ALBUMINE	3.5-5 (G/DL)	10/09/93	3.70		3.80		3.80	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	184.00		195.00		176.00	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	136.00		128.00		108.00	
GLOBULINS ALPHA 1	4-7 (X)	10/09/93	4.50		4.40		4.30	
GLOBULINS ALPHA 2	7-11 (X)	10/09/93	8.10		8.50		8.50	
GLOBULINS BETA	11-14 (X)	10/09/93	11.90		12.90		13.00	
GLOBULINS GAMMA	15-22 (X)	10/09/93	21.10		19.90		19.90	
TSH	0.5-4.5 (UU/ML)	10/09/93	2.58					
T4	4.8-12.9 (UG/DL)	10/09/93	6.50					

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C 0530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: SBT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			26/11/93		30/12/93		28/01/94	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	10/09/93	13.80		14.00		13.90	
HT	37-47 (X)	10/09/93	44.00		44.00		43.00	
RBC	3.8-5.4 (10 ⁶ /MM ³)	10/09/93	5.50 >		5.20		5.00	
WBC	4-11 (10 ⁶ /MM ³)	10/09/93	6.60		7.50		8.10	
WBC: N	40-70 (X)	10/09/93	72.00 >		62.00		60.00	
WBC: L	20-40 (X)	10/09/93	22.00		25.00		28.00	
WBC: E	1-5 (X)	10/09/93	0.00 <		3.00		2.00	
WBC: M	4-8 (X)	10/09/93	6.00		9.00 >		10.00 >	
WBC: S	0-1 (X)	10/09/93	0.00		1.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	276.00		264.00		294.00	
NA+	138-146 (MEQ/L)	10/09/93	143.00		141.00		141.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.30		4.20		4.40	
CL-	96-106 (MEQ/L)	10/09/93	102.00		101.00		100.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	9.40		9.70		9.90	
PO4--	3.4-4.5 (MG/DL)	10/09/93	2.80 <<		4.50		3.60	
SGOT	0-40 (NU/ML)	10/09/93	25.00		27.00		29.00	
SGPT	0-40 (NU/ML)	10/09/93	18.00		25.00		30.00	
GAMMA GT	7-51 (NU/ML)	10/09/93	19.00		18.00		22.00	
LDH	230-460 (NU/ML)	10/09/93	375.00		352.00		356.00	
ALK. PHOSPH.	65-306 (NU/ML)	10/09/93	202.00		200.00		231.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	102.00		98.00		99.00	
UREA	10-50 (MG/DL)	10/09/93	19.00		20.00		23.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	1.20		1.30		1.10	
CREATININE CLEARANCE	70-160 (ML/MIN)	10/09/93	66.00					
URIC ACID	2.4-5.7 (MG/DL)	10/09/93	3.00		3.40		3.80	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	1.10		1.00		0.90	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.40		0.50 >		0.40	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	7.20		7.30		7.40	
ALBUMINE	3.5-5 (G/DL)	10/09/93	4.00		3.90		3.90	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	224.00		237.00		210.00	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	96.00		89.00		103.00	
GLOBULINS ALPHA 1	4-7 (X)	10/09/93	4.40		4.30		4.20	
GLOBULINS ALPHA 2	7-11 (X)	10/09/93	8.70		8.90		9.30	
GLOBULINS BETA	11-14 (X)	10/09/93	12.50		13.10		13.60	
GLOBULINS GAMMA	15-22 (X)	10/09/93	18.80		20.30		18.00	
TSH	0.5-4.5 (UU/ML)	10/09/93	1.11					
T4	4.8-12.9 (UG/DL)	10/09/93	10.20					

2129

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN 580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: 9DT Treatment: Imipramine Sex: Male

Laboratory test			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			30/11/93		04/01/94		01/02/94	
			value	(c)	value	(c)	value	(c)
Range value	Range date							
HB	14-18 (G/DL)	10/09/93	13.00	<	13.40	<	13.30	<
HT	40-54 (%)	10/09/93	41.00		42.00		41.00	
RBC	4.3-6.1 (10 ⁶ /MM ³)	10/09/93	4.70		4.80		4.60	
WBC	4-11 (10 ⁶ /MM ³)	10/09/93	5.50		6.30		6.00	
WBC: N	40-70 (%)	10/09/93	61.00		60.00		59.00	
WBC: L	20-40 (%)	10/09/93	27.00		28.00		30.00	
WBC: E	1-5 (%)	10/09/93	3.00		4.00		4.00	
WBC: M	4-8 (%)	10/09/93	9.00	>	8.00		7.00	
WBC: B	0-1 (%)	10/09/93	0.00		0.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	220.00		231.00		244.00	
NA+	138-146 (MEQ/L)	10/09/93	141.00		143.00		142.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.00		4.40		4.10	
CL-	96-106 (MEQ/L)	10/09/93	103.00		100.00		102.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	9.90		9.90		10.10	
PO4--	3.4-4.5 (MG/DL)	10/09/93	4.10		4.20		4.50	
SGOT	0-40 (MU/ML)	10/09/93	20.00		24.00		23.00	
SGPT	0-40 (MU/ML)	10/09/93	17.00		20.00		26.00	
GAMMA GT	11-33 (MU/ML)	10/09/93	22.00		26.00		20.00	
LDH	230-460 (MU/ML)	10/09/93	299.00		286.00		310.00	
ALK. PHOSPH.	65-306 (MU/ML)	10/09/93	188.00		178.00		175.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	96.00		99.00		92.00	
UREA	10-50 (MG/DL)	10/09/93	33.00		31.00		31.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	0.90		0.80		1.20	
CREATININE CLEARANCE	70-160 (ML/MIN)	10/09/93	79.00					
URIC ACID	3.4-7 (MG/DL)	10/09/93	4.10		4.60		4.90	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.90		1.00		0.80	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.40		0.50	>	0.40	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	7.30		7.20		7.30	
ALBUMINE	3.5-5 (G/DL)	10/09/93	4.10		4.20		4.20	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	135.00	<	165.00		179.00	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	110.00		142.00		136.00	
GLOBULINS ALPHA 1	4-7 (%)	10/09/93	4.20		3.90	<	3.80	<
GLOBULINS ALPHA 2	7-11 (%)	10/09/93	7.90		7.70		7.90	
GLOBULINS BETA	11-14 (%)	10/09/93	13.00		12.50		12.00	
GLOBULINS GAMMA	15-22 (%)	10/09/93	18.70		17.60		18.80	
TSH	0.5-4.5 (UU/ML)	10/09/93	2.05					
T4	4.8-12.9 (UG/DL)	10/09/93	5.90					

2130

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value and laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 0554089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: 10DT Treatment: Roboxetine Sex: Female

Laboratory test			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			30/11/93		04/01/94		01/02/94	
			value	(ϕ)	value	(ϕ)	value	(ϕ)
Range value	Range date							
HB	12-16 (G/DL)	10/09/93	13.20		13.40		13.80	
HT	37-47 (%)	10/09/93	40.00		41.00		42.00	
RBC	3.8-5.4 (10 ⁶ /MM ³)	10/09/93	4.40		4.60		4.70	
WBC	4-11 (10 ⁶ /MM ³)	10/09/93	7.20		7.90		8.00	
WBC: N	40-70 (%)	10/09/93	59.00		61.00		60.00	
WBC: L	20-40 (%)	10/09/93	26.00		28.00		28.00	
WBC: E	1-5 (%)	10/09/93	4.00		3.00		2.00	
WBC: M	4-8 (%)	10/09/93	10.00	>	8.00		10.00	
WBC: B	0-1 (%)	10/09/93	1.00		0.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	194.00		216.00		234.00	
NA+	138-146 (MEQ/L)	10/09/93	143.00		142.00		142.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.10		4.00		4.20	
CL-	96-106 (MEQ/L)	10/09/93	99.00		101.00		100.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	10.20		10.00		9.80	
PO4--	3.4-4.5 (MG/DL)	10/09/93	4.20		4.40		4.30	
SGOT	0-40 (MU/ML)	10/09/93	31.00		32.00		34.00	
SGPT	0-40 (MU/ML)	10/09/93	35.00		38.00		37.00	
GAMMA GT	7-51 (MU/ML)	10/09/93	27.00		30.00		32.00	
LDH	230-460 (MU/ML)	10/09/93	255.00		260.00		236.00	
ALK. PHOSPH.	65-306 (MU/ML)	10/09/93	147.00		159.00		194.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	101.00		93.00		90.00	
UREA	10-50 (MG/DL)	10/09/93	29.00		28.00		32.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	1.10		1.00		0.90	
CREATININE CLEARANCE	70-160 (ML/MIN)	10/09/93	76.00					
URIC ACID	2.4-5.7 (MG/DL)	10/09/93	3.80		3.90		3.80	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.60		0.70		0.80	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.30		0.30		0.40	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	6.80		6.70		6.90	
ALBUMINE	3.5-5 (G/DL)	10/09/93	3.90		3.80		3.80	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	235.00		256.00	>	250.00	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	181.00		175.00		174.00	
GLOBULINS ALPHA 1	4-7 (%)	10/09/93	4.60		4.30		4.40	
GLOBULINS ALPHA 2	7-11 (%)	10/09/93	7.80		7.00		8.10	
GLOBULINS BETA	11-14 (%)	10/09/93	12.50		12.80		13.60	
GLOBULINS GAMMA	15-22 (%)	10/09/93	17.70		19.20		18.80	
TSH	0.5-4.5 (UU/ML)	10/09/93	2.45					
T4	4.8-12.9 (UG/DL)	10/09/93	7.10					

2131

(ϕ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done (ϕ) missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARNACIA 0955089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: 11DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			30/11/93		04/01/94		01/02/94	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	10/09/93	12.60		12.90		13.00	
HT	37-47 (%)	10/09/93	39.00		41.00		41.00	
RBC	3.8-5.4 (10 ⁶ /MM ³)	10/09/93	4.10		4.30		4.30	
WBC	4-11 (10 ⁶ /MM ³)	10/09/93	6.10		6.30		6.90	
WBC: N	40-70 (%)	10/09/93	62.00		63.00		60.00	
WBC: L	20-40 (%)	10/09/93	29.00		27.00		30.00	
WBC: E	1-5 (%)	10/09/93	2.00		2.00		3.00	
WBC: M	4-8 (%)	10/09/93	7.00		8.00		7.00	
WBC: B	0-1 (%)	10/09/93	0.00		0.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	225.00		233.00		232.00	
NA+	138-146 (MEQ/L)	10/09/93	143.00		142.00		141.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.20		3.90		4.00	
CL-	96-106 (MEQ/L)	10/09/93	99.00		96.00		98.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	8.80		8.60		9.10	
PO4--	3.4-4.5 (MG/DL)	10/09/93	3.50		4.00		4.30	
SDOT	0-40 (NU/ML)	10/09/93	38.00		42.00 >		39.00	
SGPT	0-40 (NU/ML)	10/09/93	40.00		44.00 >		43.00 >	
GAMMA GT	7-51 (NU/ML)	10/09/93	34.00		32.00		37.00	
LDH	230-460 (NU/ML)	10/09/93	380.00		339.00		410.00	
ALK. PHOSPH.	65-306 (NU/ML)	10/09/93	138.00		172.00		194.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	89.00		88.00		88.00	
UREA	10-50 (MG/DL)	10/09/93	36.00		34.00		36.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	1.10		0.80		0.80	
CREATININE CLEARANCE	70-160 (ML/MIN)	10/09/93	69.00					
URIC ACID	2.4-5.7 (MG/DL)	10/09/93	3.40		3.10		4.70	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.60		0.60		0.70	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.30		0.30		0.40	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	7.70		7.70		7.70	
ALBUMINE	3.5-5 (G/DL)	10/09/93	4.20		4.10		4.00	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	176.00		165.00		190.00	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	93.00		104.00		96.00	
GLOBULINS ALPHA 1	4-7 (%)	10/09/93	5.00		4.90		5.10	
GLOBULINS ALPHA 2	7-11 (%)	10/09/93	9.10		9.60		9.60	
GLOBULINS BETA	11-14 (%)	10/09/93	12.30		12.50		13.40	
GLOBULINS GAMMA	15-22 (%)	10/09/93	19.00		19.70		19.90	
TSH	0.5-4.5 (UU/ML)	10/09/93	2.55					
T4	4.8-12.9 (UG/DL)	10/09/93	4.90					

2132

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C950089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: 12DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			30/11/93		04/01/94		01/02/94	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	10/09/93	13.00		13.20		13.10	
HT	37-47 (%)	10/09/93	40.00		41.00		41.00	
RBC	3.8-5.4 (10 ⁶ /MM ³)	10/09/93	4.20		4.40		4.50	
WBC	4-11 (10 ⁶ /MM ³)	10/09/93	7.30		8.80		9.00	
WBC: N	40-70 (%)	10/09/93	57.00		59.00		58.00	
WBC: L	20-40 (%)	10/09/93	31.00		30.00		32.00	
WBC: E	1-5 (%)	10/09/93	4.00		3.00		3.00	
WBC: M	4-8 (%)	10/09/93	8.00		7.00		7.00	
WBC: B	0-1 (%)	10/09/93	0.00		1.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	186.00		202.00		217.00	
NA+	138-146 (MEQ/L)	10/09/93	141.00		142.00		142.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.30		4.10		4.10	
CL-	96-106 (MEQ/L)	10/09/93	102.00		101.00		99.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	10.10		9.90		9.80	
PO4--	3.4-4.5 (MG/DL)	10/09/93	3.90		4.30		4.00	
SGOT	0-40 (MU/ML)	10/09/93	28.00		30.00		26.00	
SGPT	0-40 (MU/ML)	10/09/93	32.00		34.00		30.00	
GAMMA GT	7-51 (MU/ML)	10/09/93	27.00		28.00		34.00	
LDH	230-460 (MU/ML)	10/09/93	318.00		294.00		310.00	
ALK. PHOSPH.	65-306 (MU/ML)	10/09/93	215.00		210.00		218.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	103.00		110.00		99.00	
UREA	10-50 (MG/DL)	10/09/93	32.00		34.00		35.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	1.20		1.30		1.40	
CREATININE	70-160 (ML/MIN)	10/09/93						
CLEARANCE			58.00					
URIC ACID	2.4-5.7 (MG/DL)	10/09/93	5.00		4.90		4.90	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.80		0.90		0.80	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.40		0.40		0.30	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	7.30		7.40		7.40	
ALBUMINE	3.5-5 (G/DL)	10/09/93	4.10		4.00		4.20	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	245.00	>	250.00	>	235.00	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	118.00		121.00		108.00	
GLOBULINS ALPHA 1	4-7 (%)	10/09/93	4.00		4.20		4.30	
GLOBULINS ALPHA 2	7-11 (%)	10/09/93	8.60		9.00		10.00	
GLOBULINS BETA	11-14 (%)	10/09/93	13.20		14.40	>	12.90	
GLOBULINS GAMMA	15-22 (%)	10/09/93	18.00		18.30		16.00	
TSH	0.5-4.5 (UU/ML)	10/09/93	2.93					
T4	4.8-12.9 (UG/DL)	10/09/93	6.40					

2133

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 08560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: 13DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory data					
			Screen		Day 28		Day 56	
			19/10/93		23/11/93		21/12/93	
			value	(ϕ)	value	(ϕ)	value	(ϕ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	10/09/93	14.50		14.60		14.30	
HT	37-47 (X)	10/09/93	41.00		41.00		42.00	
RBC	3.8-5.4 (10 ⁶ /MM ³)	10/09/93	4.90		4.80		5.00	
WBC	4-11 (10 ⁶ /MM ³)	10/09/93	6.90		6.70		7.20	
WBC: N	40-70 (X)	10/09/93	59.00		62.00		61.00	
WBC: L	20-40 (X)	10/09/93	30.00		30.00		29.00	
WBC: E	1-5 (X)	10/09/93	3.00		2.00		4.00	
WBC: M	4-8 (X)	10/09/93	8.00		6.00		6.00	
WBC: B	0-1 (X)	10/09/93	0.00		0.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	264.00		272.00		256.00	
NA+	138-146 (MEQ/L)	10/09/93	140.00		141.00		141.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.20		4.30		4.10	
CL-	96-106 (MEQ/L)	10/09/93	97.00		98.00		98.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	9.30		9.50		9.40	
PO4--	3.4-4.5 (MG/DL)	10/09/93	3.00	<	3.20	<	3.10	<
SGOT	0-40 (MU/ML)	10/09/93	28.00		26.00		24.00	
SGPT	0-40 (MU/ML)	10/09/93	26.00		28.00		28.00	
GAMMA GT	7-51 (MU/ML)	10/09/93	38.00		41.00		34.00	
LDH	230-460 (MU/ML)	10/09/93	270.00		263.00		251.00	
ALK. PHOSPH.	65-306 (MU/ML)	10/09/93	144.00		139.00		136.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	92.00		94.00		94.00	
UREA	10-50 (MG/DL)	10/09/93	32.00		28.00		30.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	1.10		1.00		1.00	
CREATININE CLEARANCE	70-160 (ML/MIN)	10/09/93	54.00					
URIC ACID	2.4-5.7 (MG/DL)	10/09/93	6.10	>	4.70		5.80	>
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.90		0.70		0.80	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.40		0.30		0.40	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	7.20		7.00		7.10	
ALBUMINE	3.5-5 (G/DL)	10/09/93	4.10		4.00		4.00	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	237.00		191.00		246.00	>
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	193.00		180.00		185.00	
GLOBULINS ALPHA 1	4-7 (X)	10/09/93	3.60	<	2.90	<	3.40	<
GLOBULINS ALPHA 2	7-11 (X)	10/09/93	7.50		5.60	<	6.90	<
GLOBULINS BETA	11-14 (X)	10/09/93	14.10	>			13.50	
GLOBULINS GAMMA	15-22 (X)	10/09/93	17.80		21.20		19.90	
TSH	0.5-4.5 (UU/ML)	10/09/93	2.91					
T4	4.8-12.9 (UG/DL)	10/09/93	6.60					

2134

(ϕ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CN9590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: 14DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			22/10/93		26/11/93		23/12/93	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	10/09/93	13.50		13.80		13.40	
HT	37-47 (%)	10/09/93	40.00		41.00		40.00	
RBC	3.8-5.4 (10 ⁶ /MM ³)	10/09/93	4.40		4.50		4.30	
WBC	4-11 (10 ⁶ /MM ³)	10/09/93	9.30		9.00		8.80	
WBC: N	40-70 (%)	10/09/93	62.00		63.00		63.00	
WBC: L	20-40 (%)	10/09/93	25.00		24.00		25.00	
WBC: E	1-5 (%)	10/09/93	5.00		4.00		5.00	
WBC: M	4-8 (%)	10/09/93	8.00		9.00	>	7.00	
WBC: B	0-1 (%)	10/09/93	0.00		0.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	286.00		270.00		259.00	
NA+	138-146 (MEQ/L)	10/09/93	142.00		141.00		140.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.10		4.20		4.00	
CL-	96-106 (MEQ/L)	10/09/93	99.00		101.00		102.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	9.30		9.20		9.70	
PO4--	3.4-4.5 (MG/DL)	10/09/93	2.90	<	3.20	<	3.30	
SGOT	0-40 (MU/ML)	10/09/93	25.00		26.00		25.00	
SGPT	0-40 (MU/ML)	10/09/93	28.00		28.00		27.00	
GAMMA GT	7-51 (MU/ML)	10/09/93	36.00		36.00		35.00	
LDH	230-460 (MU/ML)	10/09/93	227.00	<	251.00		241.00	
ALK. PHOSPH.	65-306 (MU/ML)	10/09/93	173.00		188.00		150.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	90.00		91.00		93.00	
UREA	10-50 (MG/DL)	10/09/93	30.00		32.00		31.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	1.00		1.00		1.10	
CREATININE CLEARANCE	70-160 (ML/MIN)	10/09/93	61.00					
URIC ACID	2.4-5.7 (MG/DL)	10/09/93	3.90		4.20		4.40	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.40		0.50		0.60	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.20		0.20		0.30	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	7.00		7.00		7.10	
ALBUMINE	3.5-5 (G/DL)	10/09/93	4.10		4.00		4.10	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	183.00		205.00		211.00	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	145.00		151.00		152.00	
GLOBULINS ALPHA 1	4-7 (%)	10/09/93	2.20	<<	2.50	<<	2.30	
GLOBULINS ALPHA 2	7-11 (%)	10/09/93	6.70	<	6.60	<	6.40	
GLOBULINS BETA	11-14 (%)	10/09/93	12.50		12.40		12.80	
GLOBULINS GAMMA	15-22 (%)	10/09/93	20.00		21.40		20.80	
TSH	0.5-4.5 (UU/ML)	10/09/93	1.99					
T4	4.8-12.9 (UG/DL)	10/09/93	5.10					

2135

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CN 590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: 16DT Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			22/10/93		26/11/93		23/12/93	
			value	(#)	value	(#)	value	(#)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	10/09/93	13.00	<	13.20	<	13.00	<
HT	40-54 (%)	10/09/93	40.00		41.00		40.00	
RBC	4.3-6.1 (10 ⁶ /MM ³)	10/09/93	4.40		4.60		4.50	
WBC	4-11 (10 ⁶ /MM ³)	10/09/93	8.60		7.90		7.70	
WBC: N	40-70 (%)	10/09/93	58.00		57.00		60.00	
WBC: L	20-40 (%)	10/09/93	30.00		29.00		29.00	
WBC: E	1-5 (%)	10/09/93	4.00		6.00	>	4.00	
WBC: M	4-8 (%)	10/09/93	8.00		8.00		7.00	
WBC: B	0-1 (%)	10/09/93	0.00		0.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	263.00		250.00		274.00	
NA+	138-146 (MEQ/L)	10/09/93	140.00		142.00		141.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.20		4.20		4.30	
CL-	96-106 (MEQ/L)	10/09/93	97.00		99.00		99.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	9.50		9.80		9.70	
PO4--	3.4-4.5 (MG/DL)	10/09/93	3.80		4.00		4.10	
SGOT	0-40 (MU/ML)	10/09/93	26.00		27.00		28.00	
SGPT	0-40 (MU/ML)	10/09/93	28.00		29.00		30.00	
GAMMA GT	11-33 (MU/ML)	10/09/93	34.00	>	37.00	>	38.00	>
LDH	230-460 (MU/ML)	10/09/93	241.00		262.00		253.00	
ALK. PHOSPH.	65-306 (MU/ML)	10/09/93	198.00		200.00		209.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	94.00		95.00		95.00	
UREA	10-50 (MG/DL)	10/09/93	31.00		30.00		33.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	0.90		1.10		1.00	
CREATININE CLEARANCE			58.00					
URIC ACID	3.4-7 (MG/DL)	10/09/93	4.20		4.80		4.80	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.50		0.60		0.80	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.30		0.30		0.40	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	6.90		7.00		7.10	
ALBUMINE	3.5-5 (G/DL)	10/09/93	4.00		3.90		4.10	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	193.00		189.00		187.00	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	157.00		146.00		155.00	
GLOBULINS ALPHA 1	4-7 (%)	10/09/93	2.50	<<	2.60	<<	2.40	<<
GLOBULINS ALPHA 2	7-11 (%)	10/09/93	6.30	<	6.40	<	7.00	
GLOBULINS BETA	11-14 (%)	10/09/93	12.90		12.50		12.10	
GLOBULINS GAMMA	15-22 (%)	10/09/93	20.30		22.80	>	19.90	
TSH	0.5-4.5 (UU/ML)	10/09/93	2.91					
T4	4.8-12.9 (UG/DL)	10/09/93	6.00					

(#) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C19580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 10 Patient: 19DT Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			29/10/93		03/12/93		30/12/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	10/09/93	13.20	<	13.50	<	13.90	<
HT	40-54 (%)	10/09/93	41.00		42.00		42.00	
RBC	4.3-6.1 (10 ⁶ /MM ³)	10/09/93	4.50		4.70		4.50	
WBC	4-11 (10 ⁶ /MM ³)	10/09/93	7.00		7.40		7.90	
WBC: N	40-70 (%)	10/09/93	61.00		57.00		62.00	
WBC: L	20-40 (%)	10/09/93	25.00		30.00		26.00	
WBC: E	1-5 (%)	10/09/93	4.00		4.00		4.00	
WBC: M	4-8 (%)	10/09/93	10.00	>	9.00	>	8.00	
WBC: B	0-1 (%)	10/09/93	0.00		0.00		0.00	
PLATELETS	150-500 (10 ³ /MM ³)	10/09/93	256.00		231.00		232.00	
NA+	138-146 (MEQ/L)	10/09/93	142.00		141.00		141.00	
K+	3.8-5.3 (MEQ/L)	10/09/93	4.10		4.20		4.00	
CL-	96-106 (MEQ/L)	10/09/93	96.00		97.00		97.00	
Ca++	8.5-10.5 (MG/DL)	10/09/93	9.70		9.80		10.20	
PO4--	3.4-4.5 (MG/DL)	10/09/93	3.00	<	3.30	<	3.60	
SGOT	0-40 (MU/ML)	10/09/93	28.00		27.00		29.00	
SGPT	0-40 (MU/ML)	10/09/93	32.00		30.00		32.00	
GAMMA GT	11-33 (MU/ML)	10/09/93	40.00	>	39.00	>	39.00	>
LDH	230-460 (MU/ML)	10/09/93	194.00	<	215.00	<	186.00	<
ALK. PHOSPH.	65-306 (MU/ML)	10/09/93	230.00		221.00		242.00	
GLUCOSE	70-110 (MG/DL)	10/09/93	93.00		91.00		94.00	
UREA	10-50 (MG/DL)	10/09/93	32.00		35.00		35.00	
CREATININE	0.6-1.6 (MG/DL)	10/09/93	0.90		0.90		0.90	
CREATININE CLEARANCE			68.00					
URIC ACID	3.4-7 (MG/DL)	10/09/93	3.80		4.40		4.50	
TOT BILIRUBIN	0.1-1.3 (MG/DL)	10/09/93	0.60		0.40		0.50	
DIR BILIRUBIN	0-0.4 (MG/DL)	10/09/93	0.30		0.20		0.20	
TOT. PROTEINS	6-8 (G/DL)	10/09/93	7.00		7.10		7.10	
ALBUMINE	3.5-5 (G/DL)	10/09/93	3.90		3.90		4.10	
TOT. CHOLEST.	150-240 (MG/DL)	10/09/93	203.00		195.00		219.00	
TRIGLYCERIDES	0-200 (MG/DL)	10/09/93	146.00		138.00		163.00	
GLOBULINS ALPHA 1	4-7 (X)	10/09/93	2.30	<<	2.40	<<	2.60	<<
GLOBULINS ALPHA 2	7-11 (X)	10/09/93	7.20		7.10		7.10	
GLOBULINS BETA	11-14 (X)	10/09/93	12.90		12.70		11.90	
GLOBULINS GAMMA	15-22 (X)	10/09/93	21.90		22.90	>	20.60	
TSH	0.5-4.5 (UU/ML)	10/09/93	2.93					
T4	4.8-12.9 (UG/DL)	10/09/93	4.70					

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNP 180089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 12 Patient: 1MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			15/04/93		09/06/93		23/06/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	10-16 (G/DL)	15/04/93	13.80		13.40		13.70	
HT	37-48 (X)	15/04/93	41.00		40.10		40.70	
RBC	4.2-5.9 (10 ⁶ /MM ³)	15/04/93	4.65		4.52		4.55	
RBC	4300-10800	15/04/93						
	(10 ³ /MM ³)		5200.00		5100.00		5400.00	
RBC: N	30-70 (X)	15/04/93			51.00		51.00	
RBC: L	15-40 (X)	15/04/93			35.50		39.00	
RBC: E	0-5 (X)	15/04/93			5.50	>	5.20	
RBC: M	0-15 (X)	15/04/93			7.80		5.60	
RBC: B	0-10 (X)	15/04/93			0.00		1.50	
PLATELETS	150000-400000	15/04/93						
	(/MM ³)		167000		221000		205000	
NA+	135-145 (MMOL/L)	15/04/93	144.00		138.00		137.00	
K+	3.5-5.1 (MMOL/L)	15/04/93	4.30		4.10		4.10	
CL-	95-110 (MMOL/L)	15/04/93	103.00		102.00		97.00	
Ca++	2.1-2.7 (MMOL/L)	15/04/93	2.29		2.14		2.16	
PO4--	1-1.5 (MMOL/L)	18/05/93					1.01	
SGOT	9-35 (UI/L)	15/04/93	18.00		20.00		21.00	
SGPT	7-50 (UI/L)	15/04/93	9.00		16.00		19.00	
GAMMA GT	4-65 (UI/L)	15/04/93	26.00		28.00		28.00	
LDH	110-210 (UI/L)	18/05/93			337.00	>		
ALK. PHOSPH.	30-110 (UI/L)	15/04/93	69.00		63.00		67.00	
GLUCOSE	3.9-5.8 (UI/L)	15/04/93	4.40		4.50		4.70	
UREA	3-8.5 (MMOL/L)	15/04/93	8.90	>	9.60	>	10.10	
CREATININE	60-110 (UMOL/L)	15/04/93	106.00		90.00		96.00	
URIC ACID	150-360 (UMOL/L)	18/05/93					233.00	
TOT. BILIRUBIN	2.3-18.8 (UMOL/L)	15/04/93	14.30		16.70		13.00	
DIR. BILIRUBIN	0.8-4 (UMOL/L)	15/04/93	2.60		3.60		2.10	
TOT. PROTEINS	60-83 (G/L)	15/04/93	64.00		61.00		64.00	
ALBUMINE	37-42 (G/L)	15/04/93	39.00		36.60	<	38.00	
TOT. CHOLEST.	3.6-6.4 (MMOL/L)	15/04/93	5.70		5.80		5.70	
TRIGLYCERIDES	0.4-1.5 (MMOL/L)	15/04/93	0.70		1.00		1.10	
GLOBULINS ALPHA 1	2-4 (X)	15/04/93	3.00					
	1-3 (G/L)	18/05/93			1.70		1.90	
GLOBULINS ALPHA 2	6-10 (X)	15/04/93	9.20					
	4-7 (G/L)	18/05/93			6.20		6.90	
GLOBULINS BETA	8-12 (X)	15/04/93	10.90					
	5-8 (G/L)	18/05/93			6.50		7.50	
GLOBULINS GAMMA	12-19 (X)	15/04/93	15.70					
	8-12 (G/L)	18/05/93			10.00		9.80	
TSH	0.2-4 (IU/ML)	15/04/93	1.60					
T4	7-17 (PG/KL)	15/04/93	10.00					

2138

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C1560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 12 Patient: 1DT Treatment: Roboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			18/05/93		22/06/93		15/07/93	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	10-16 (G/DL)	18/05/93	13.50		12.70		15.00	
HT	37-48 (%)	18/05/93	41.50		37.90		45.80	
RBC	4.2-5.9 (10 ⁶ /MM ³)	18/05/93	4.76		4.58		5.45	
WBC	4300-10800 (10 ³ /MM ³)	18/05/93	5400.00		5600.00		4700.00	
WBC: N	30-70 (%)	18/05/93	60.00		69.00		56.00	
WBC: L	15-40 (%)	18/05/93	30.80		23.00		37.00	
WBC: E	0-5 (%)	18/05/93	3.40		1.50		1.60	
WBC: M	0-15 (%)	18/05/93	5.80		6.00		5.30	
WBC: B	0-10 (%)	18/05/93	0.40		1.00		0.10	
PLATELETS	150000-400000 (/MM ³)	18/05/93	263000		273000		223000	
NA+	135-145 (MMOL/L)	18/05/93	140.00		134.00	<	138.00	
K+	3.5-5.1 (MMOL/L)	18/05/93	3.90		4.00		4.10	
CL-	95-110 (MMOL/L)	18/05/93	102.00		97.00		96.00	
Ca++	2.1-2.7 (MMOL/L)	18/05/93	2.29		2.40		2.45	
PO4--	1-1.5 (MMOL/L)	18/05/93	1.09		1.01		1.00	
SGOT	9-35 (UI/L)	18/05/93	16.00		21.00		19.00	
SGPT	7-50 (UI/L)	18/05/93	21.00		21.00		21.00	
GAMMA GT	4-65 (UI/L)	18/05/93	23.00		20.00		23.00	
ALK. PHOSPH.	30-110 (UI/L)	18/05/93	88.00		88.00		105.00	
GLUCOSE	3.9-5.5 (UI/L)	18/05/93	16.60	>>	16.70	>>	15.30 >>	
UREA	3-8.5 (MMOL/L)	18/05/93	8.60	>	6.70		5.80	
CREATININE	60-110 (UMOL/L)	18/05/93	85.00		87.00		90.00	
URIC ACID	150-360 (UMOL/L)	18/05/93	148.00	<	117.00	<	130.00 <	
TOT BILIRUBIN	2.3-18.8 (UMOL/L)	18/05/93	8.60		8.50		9.80	
DIR BILIRUBIN	0.8-4 (UMOL/L)	18/05/93	2.20		1.90		2.40	
TOT. PROTEINS	60-83 (G/L)	18/05/93	64.00		64.00		71.00	
ALBUMINE	37-42 (G/L)	18/05/93	38.00		38.00		44.70 >	
TOT. CHOLEST.	3.6-6.4 (MMOL/L)	18/05/93	6.60	>	6.00		7.40 >	
TRIGLYCERIDES	0.4-1.5 (MMOL/L)	18/05/93	1.20		1.23		1.10	
GLOBULINS ALPHA 1	1-3 (G/L)	18/05/93	2.00		2.60		2.30	
GLOBULINS ALPHA 2	4-7 (G/L)	18/05/93	6.30		7.30	>	6.80	
GLOBULINS BETA	5-8 (G/L)	18/05/93	7.00		7.50		8.90 >	
GLOBULINS GAMMA	8-12 (G/L)	18/05/93	8.40		8.60		8.30	
TSH	0.2-4 (UU/ML)	18/05/93	1.00					
T4	7-17 (PG/ML)	18/05/93	14.00					

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value.

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C9580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 13 Patient: 1MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			21/03/93		06/05/93		03/06/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	21/03/93	11.20	<	11.50	<	12.10	
HT	33-47 (%)	21/03/93	34.00		35.00		37.00	
RBC	4-5.5 (10 ⁶ /MM ³)	21/03/93	3.80	<	3.88	<	4.03	
WBC	4-10 (10 ³ /MM ³)	21/03/93	6.00		6.30		6.60	
WBC: N	45-74 (%)	21/03/93	59.00		67.00		70.00	
WBC: L	16-45 (%)	21/03/93	33.00		27.00		27.00	
WBC: E	0-7 (%)	21/03/93	5.00		0.00		3.00	
WBC: M	4-10 (%)	21/03/93	3.00	<	3.00	<	0.00 <	
WBC: B	0-2 (%)	21/03/93	0.00		3.00	>>	0.00	
PLATELETS	150-300 (10 ³ /MM ³)	21/03/93	228.00		230.00		250.00	
NA+	135-145 (MMOL/L)	21/03/93	143.00		139.00		138.00	
K+	3.5-5 (MMOL/L)	21/03/93	4.20		4.80		4.40	
CL-	95-105 (MMOL/L)	21/03/93	102.00		100.00		97.00	
Ca++	2.2-2.5 (MMOL/L)	21/03/93	2.34		2.43		2.42	
PO4--	0.8-1.6 (MMOL/L)	21/03/93	1.25		1.27		1.32	
SGOT	0-25 (UI/L)	21/03/93	27.00	>	32.00	>	28.00 >	
SGPT	0-25 (UI/L)	21/03/93	27.00	>	27.00	>	23.00	
GAMMA GT	8-38 (UI/L)	21/03/93	31.00		31.00		32.00	
LDH	160-320 (UI/L)	21/03/93	121.00	<	160.00		137.00 <	
ALK. PHOSPH.	70-220 (UI/L)	21/03/93	76.00		77.00		76.00	
GLUCOSE	3.6-6.5 (MMOL/L)	21/03/93	4.20		4.10		4.20	
UREA	3.3-6.64 (MMOL/L)	21/03/93	6.20		6.60		7.90 >	
CREATININE	70-115 (UMOL/L)	21/03/93	80.00		85.00		88.00	
URIC ACID	200-360 (UMOL/L)	21/03/93	247.00		167.00	<	187.00 <	
TOT. BILIRUBIN	0-20 (UMOL/L)	21/03/93	5.00		4.00		5.30	
TOT. PROTEINS	60-80 (G/L)	21/03/93	59.00	<	63.00		62.00	
ALBUMINE	36-48 (G/L)	21/03/93	37.80		37.20		40.70	
TOT. CHOLEST.	3.87-6.45 (MMOL/L)	21/03/93	6.55	>	6.75	>	6.18	
TRIGLYCERIDES	0.57-1.71 (MMOL/L)	21/03/93	2.02	>	1.62		1.81 >	
GLOBULINS ALPHA 1	1-3 (G/L)	21/03/93	2.10		2.20		2.20	
GLOBULINS ALPHA 2	4-8 (G/L)	21/03/93	5.00		5.70		5.50	
GLOBULINS BETA	5-10 (G/L)	21/03/93	7.90		9.00		8.00	
GLOBULINS GAMMA	7-13 (G/L)	21/03/93	6.20	<	8.70		5.60 <	
TSH	0.2-4 (MUI/L)	21/03/93	1.46					
T4	42-97 (UG/L)	21/03/93	46.60					

2140

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARNACIA 0590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 13 Patient: ZND Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			02/12/93		07/01/94		08/02/94	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	02/02/93	12.70		11.40 <	9.20 <<		
HT	33-47 (X)	02/02/93	37.00		35.00	28.00 <<		
RBC	4-5.5 (10 ⁶ /MM ³)	02/02/93	3.95 <		3.62 <	2.84 <<		
HBC	4-10 (10 ³ /MM ³)	02/02/93	4.70		10.70 >	4.70		
HBC: N	45-74 (%)	02/02/93	61.00		84.00 >	65.00		
HBC: L	16-45 (%)	02/02/93	37.00		15.00 <	34.00		
HBC: E	0-7 (%)	02/02/93	1.00		0.00	0.00		
HBC: M	4-10 (%)	02/02/93	2.00 <		1.00 <	1.00 <		
HBC: B	0-2 (%)	02/02/93	0.00		0.00	0.00		
PLATELETS	150-300 (10 ³ /MM ³)	02/02/93	222.00		261.00	347.00 >		
NA+	135-145 (MMOL/L)	02/02/93	139.00		137.00	138.00		
K+	3.5-5 (MMOL/L)	02/02/93	3.40 <		3.10 <	3.50		
CL-	95-105 (MMOL/L)	02/02/93	100.00		101.00	101.00		
Ca++	2.2-2.5 (MMOL/L)	02/02/93	2.42		2.23	2.10 <		
PO4--	0.8-1.6 (MMOL/L)	02/02/93	1.11		0.75 <	1.04		
SGOT	0-25 (UI/L)	02/02/93	15.00		14.00	15.00		
SGPT	0-25 (UI/L)	02/02/93	12.00		12.00	10.00		
GAMMA GT	8-38 (UI/L)	02/02/93	6.00 <		6.00 <	12.00		
LDH	160-320 (UI/L)	02/02/93	143.00 <		159.00 <	199.00		
ALK. PHOSPH.	70-220 (UI/L)	02/02/93	97.00		219.00	172.00		
GLUCOSE	3.6-6.5 (MMOL/L)	02/02/93	4.60		4.30	4.30		
UREA	3.3-6.64 (MMOL/L)	02/02/93	5.10		10.70 >>	5.40		
CREATININE	70-115 (UMOL/L)	02/02/93	94.00		113.00	81.00		
CREATININE CLEARANCE	()	02/02/93	25.00 ()					
URIC ACID	200-360 (UMOL/L)	02/02/93	295.00		436.00 >	205.00		
TOT BILIRUBIN	0-20 (UMOL/L)	02/02/93	12.90		8.70	10.90		
TOT. PROTEINS	60-80 (G/L)	02/02/93	61.00		58.00 <	48.00 <<		
ALBUMINE	36-48 (G/L)	02/02/93	37.50		31.50 <	23.20 <<		
TOT. CHOLEST.	3.87-6.45 (MMOL/L)	02/02/93	5.62		4.59	3.73 <		
TRIGLYCERIDES	0.87-1.71 (MMOL/L)	02/02/93	1.00		1.26	1.29		
GLOBULINS ALPHA 1	1-3 (G/L)	02/02/93	2.10		3.30 >	3.30 >		
GLOBULINS ALPHA 2	4-8 (G/L)	02/02/93	5.10		5.90	6.40		
GLOBULINS BETA	5-10 (G/L)	02/02/93	6.00		6.50	5.30		
GLOBULINS GAMMA	7-13 (G/L)	02/02/93	10.10		10.60	9.50		
TSH	0.2-4 (MUI/L)	02/02/93	2.62					
T4	42-97 (UG/L)	02/02/93	86.00					

2141

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C956089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 13 Patient: 3ND Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			28/01/94		03/03/94		06/04/94	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	02/02/93	13.80		14.00		14.30	
HT	38-52 (%)	02/02/93	42.00		44.00		43.00	
RBC	4.2-5.7 (10 ⁶ /MM ³)	02/02/93	4.59		4.85		4.73	
WBC	4-10 (10 ³ /MM ³)	02/02/93	7.50		8.00		8.20	
WBC: N	45-74 (%)	02/02/93	61.00		59.00		59.00	
WBC: L	16-45 (%)	02/02/93	34.00		35.00		36.00	
WBC: E	0-7 (%)	02/02/93	3.00		4.00		1.00	
WBC: M	4-10 (%)	02/02/93	2.00	<	2.00	<	4.00	
WBC: B	0-2 (%)	02/02/93	0.00		0.00		0.00	
PLATELETS	150-300 (10 ³ /MM ³)	02/02/93	232.00		236.00		234.00	
NA+	135-145 (MMOL/L)	02/02/93	148.00	>	142.00		142.00	
K+	3.5-5 (MMOL/L)	02/02/93	4.20		3.90		4.10	
CL-	95-105 (MMOL/L)	02/02/93	105.00		103.00		100.00	
Ca++	2.2-2.5 (MMOL/L)	02/02/93	2.41		2.33		2.29	
PO4--	0.8-1.6 (MMOL/L)	02/02/93	1.03		0.93		1.02	
SGOT	0-25 (UI/L)	02/02/93	15.00		15.00		17.00	
SGPT	0-25 (UI/L)	02/02/93	23.00		20.00		23.00	
GAMMA GT	8-38 (UI/L)	02/02/93	16.00		14.00		15.00	
LDH	160-320 (UI/L)	02/02/93	173.00		195.00		227.00	
ALK. PHOSPH.	70-220 (UI/L)	02/02/93	56.00	<	63.00	<	69.00	
GLUCOSE	3.6-6.5 (MMOL/L)	02/02/93	5.50		4.90		4.60	
UREA	3.3-6.64 (MMOL/L)	02/02/93	5.00		3.70		3.60	
CREATININE	70-115 (UMOL/L)	02/02/93	89.00		87.00		85.00	
CREATININE	()	02/02/93						
CLEARANCE			70.00	()				
URIC ACID	200-360 (UMOL/L)	02/02/93	272.00		321.00		294.00	
TOT BILIRUBIN	0-20 (UMOL/L)	02/02/93	8.60		9.60		8.10	
TOT. PROTEINS	60-80 (G/L)	02/02/93	62.00		59.00	<	60.00	
ALBUMINE	36-48 (G/L)	02/02/93	40.90		40.60		39.10	
TOT. CHOLEST.	3.87-6.45 (MMOL/L)	02/02/93	7.51	>	7.19	>	7.53	
TRIGLYCERIDES	0.57-1.71 (MMOL/L)	02/02/93	0.66		1.24		0.94	
GLOBULINS ALPHA 1	1-3 (G/L)	02/02/93	1.70		1.60		1.90	
GLOBULINS ALPHA 2	4-8 (G/L)	02/02/93	5.20		4.30		5.10	
GLOBULINS BETA	5-10 (G/L)	02/02/93	7.10		6.10		7.20	
GLOBULINS GAMMA	7-13 (G/L)	02/02/93	6.90	<	6.20	<	6.60	
TSH	0.2-4 (MUI/L)	02/02/93	2.95					
T4	10.4-24.3 (PMOL/L)	02/02/93	21.00					

2142

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C5590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 13 Patient: 1DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			13/09/93		21/10/93		18/11/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	02/02/93	14.50		14.40		14.10	
HT	33-47 (X)	02/02/93	42.00		44.00		42.00	
RBC	4-5.5 (10 ⁶ /MM ³)	02/02/93	4.70		4.82		4.58	
HBC	4-10 (10 ³ /MM ³)	02/02/93	7.10		4.80		6.00	
HBC: N	45-74 (X)	02/02/93	75.00	>	70.00		73.00	
HBC: L	16-45 (X)	02/02/93	20.00		28.00		21.00	
HBC: E	0-7 (X)	02/02/93	0.00		0.00		2.00	
HBC: M	4-10 (X)	02/02/93	5.00		2.00	<	3.00	
HBC: B	0-2 (X)	02/02/93	0.00		0.00		1.00	
PLATELETS	150-300 (10 ³ /MM ³)	02/02/93	276.00		240.00		253.00	
NA+	135-145 (MMOL/L)	02/02/93	134.00	<	139.00		139.00	
K+	3.5-5 (MMOL/L)	02/02/93	3.50		3.40	<	3.90	
CL-	95-105 (MMOL/L)	02/02/93	95.00		100.00		101.00	
Ca++	2.2-2.5 (MMOL/L)	02/02/93	2.35		2.37		2.40	
PO4--	0.8-1.6 (MMOL/L)	02/02/93	1.07		1.07		1.20	
SGOT	0-25 (UI/L)	02/02/93	12.00		13.00		13.00	
SGPT	0-25 (UI/L)	02/02/93	11.00		12.00		9.00	
GAMMA GT	8-38 (UI/L)	02/02/93	16.00		18.00		16.00	
LDH	160-320 (UI/L)	02/02/93	199.00		180.00		178.00	
ALK. PHOSPH.	70-220 (UI/L)	02/02/93	168.00		153.00		134.00	
GLUCOSE	3.6-6.5 (MMOL/L)	02/02/93	5.20		5.00		4.80	
UREA	3.3-6.64 (MMOL/L)	02/02/93	4.00		4.20		3.90	
CREATININE	70-115 (UMOL/L)	02/02/93	69.00	<	67.00	<	67.00	
CREATININE CLEARANCE	()	02/02/93	47.00	()				
URIC ACID	200-360 (UMOL/L)	02/02/93	121.00	<	131.00	<	128.00	
TOT BILIRUBIN	0-20 (UMOL/L)	02/02/93	8.70		16.20		6.40	
TOT. PROTEINS	60-80 (G/L)	02/02/93	64.00		63.00		64.00	
ALBUMINE	36-48 (G/L)	02/02/93	40.60		42.50		43.90	
TOT. CHOLEST.	3.87-6.45 (MMOL/L)	02/02/93	4.62		5.16		5.82	
TRIGLYCERIDES	0.57-1.71 (MMOL/L)	02/02/93	0.73		0.87		0.90	
GLOBULINS ALPHA 1	1-3 (G/L)	02/02/93	2.60		2.80		2.60	
GLOBULINS ALPHA 2	4-8 (G/L)	02/02/93	5.80		5.20		5.10	
GLOBULINS BETA	5-10 (G/L)	02/02/93	7.20		6.40		6.20	
GLOBULINS GAMMA	7-13 (G/L)	02/02/93	7.50		5.90	<	6.00	
TSH	0.2-4 (MUI/L)	02/02/93	3.29					
T4	0.8-2 (NG/DL)	02/02/93	1.83					

2143

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 09554089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 13 Patient: ZDT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			27/09/93		22/11/93		17/12/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	02/02/93	12.40		11.20 <		10.80 <	
HT	33-47 (X)	02/02/93	39.00		33.00		34.00	
RBC	4-5.5 (10 ⁶ /MM ³)	02/02/93	4.12		3.65 <		3.68 <	
WBC	4-10 (10 ³ /MM ³)	02/02/93	7.30		11.20 >		10.30 >	
WBC: N	45-74 (%)	02/02/93	54.00		62.00		68.00	
WBC: L	16-45 (%)	02/02/93	39.00		28.00		30.00	
WBC: E	0-7 (%)	02/02/93	4.00		3.00		0.00	
WBC: M	4-10 (%)	02/02/93	3.00 <		7.00		2.00 <	
WBC: B	0-2 (%)	02/02/93	0.00		0.00		0.00	
PLATELETS	150-300 (10 ³ /MM ³)	02/02/93	386.00 >		523.00 >>		601.00 >>	
NA+	135-145 (MMOL/L)	02/02/93	142.00		143.00		142.00	
K+	3.5-5 (MMOL/L)	02/02/93	3.50		3.00 <		2.80 <<	
CL-	95-105 (MMOL/L)	02/02/93	103.00		103.00		103.00	
Ca ⁺⁺	2.2-2.5 (MMOL/L)	02/02/93	2.22		2.21		2.26	
PO ₄ ⁻⁻	0.8-1.6 (MMOL/L)	02/02/93	1.02		0.86		1.03	
SGOT	0-25 (UI/L)	02/02/93	15.00		1.60		11.00	
SGPT	0-25 (UI/L)	02/02/93	23.00		23.00		13.00	
GAMMA GT	8-38 (UI/L)	02/02/93	27.00		50.00 >		35.00	
LDH	160-320 (UI/L)	02/02/93	240.00		207.00		204.00	
ALK. PHOSPH.	70-220 (UI/L)	02/02/93	95.00		149.00		152.00	
GLUCOSE	3.6-6.5 (MMOL/L)	02/02/93	4.80		3.90		4.60	
UREA	3.3-6.64 (MMOL/L)	02/02/93	10.10 >>		7.90 >		7.80 >	
CREATININE	70-115 (UMOL/L)	02/02/93	81.00		86.00		84.00	
CREATININE CLEARANCE	()	02/02/93	41.00 ()					
URIC ACID	200-360 (UMOL/L)	02/02/93	360.00		259.00		360.00	
TOT BILIRUBIN	0-20 (UMOL/L)	02/02/93	3.70		4.70		3.70	
TOT. PROTEINS	60-80 (G/L)	02/02/93	60.00		59.00 <		58.00 <	
ALBUMINE	36-48 (G/L)	02/02/93	36.80		37.40		35.60 <	
TOT. CHOLEST.	3.87-6.45 (MMOL/L)	02/02/93	9.08 >>		7.04 >		8.50 >>	
TRIGLYCERIDES	0.57-1.71 (MMOL/L)	02/02/93	1.97 >		0.97		0.97	
GLOBULINS ALPHA 1	1-3 (G/L)	02/02/93	1.90		2.10		2.00	
GLOBULINS ALPHA 2	4-8 (G/L)	02/02/93	6.50		7.40		7.50	
GLOBULINS BETA	5-10 (G/L)	02/02/93	7.30		8.20		8.30	
GLOBULINS GAMMA	7-13 (G/L)	02/02/93	5.50 <		3.70 <<		4.30 <<	
TSH	0.2-4 (MUI/L)	02/02/93	1.79					
T4	54-125 (NMOL/L)	02/02/93	120.00					

2144

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARNACIA C0530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 13 Patient: 3DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			25/10/93		07/12/93		04/01/94	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	02/02/93	13.70		13.20		12.90	
HT	33-47 (Z)	02/02/93	40.00		40.00		39.00	
RBC	4-5.5 (10 ⁶ /MM ³)	02/02/93	4.40		4.43		4.34	
WBC	4-10 (10 ³ /MM ³)	02/02/93	4.90		4.30		4.20	
WBC: N	45-74 (Z)	02/02/93	65.00		61.00		63.00	
WBC: L	16-45 (Z)	02/02/93	31.00		29.00		29.00	
WBC: E	0-7 (Z)	02/02/93	2.00		6.00		0.00	
WBC: M	4-10 (Z)	02/02/93	2.00	<	4.00		6.00	
WBC: B	0-2 (Z)	02/02/93	0.00		0.00		2.00	
PLATELETS	150-300 (10 ³ /MM ³)	02/02/93	292.00		258.00		286.00	
NA+	135-145 (MMOL/L)	02/02/93	145.00		141.00		141.00	
K+	3.5-5 (MMOL/L)	02/02/93	3.50		3.40	<	3.60	
CL-	95-105 (MMOL/L)	02/02/93	102.00		101.00		102.00	
Ca++	2.2-2.5 (MMOL/L)	02/02/93	2.33		2.36		2.47	
PO4--	0.8-1.6 (MMOL/L)	02/02/93	1.05		1.16		0.87	
SGOT	0-25 (UI/L)	02/02/93	12.00		10.00		14.00	
SGPT	0-25 (UI/L)	02/02/93	12.00		11.00		15.00	
GAMMA GT	8-38 (UI/L)	02/02/93	13.00		10.00		13.00	
LDH	160-320 (UI/L)	02/02/93			201.00		200.00	
ALK. PHOSPH.	70-220 (UI/L)	02/02/93	110.00		123.00		135.00	
GLUCOSE	3.6-6.5 (MMOL/L)	02/02/93	5.80		5.10		6.20	
UREA	3.3-6.64 (MMOL/L)	02/02/93	5.30		5.80		5.10	
CREATININE	70-115 (UMOL/L)	02/02/93	73.00		83.00		84.00	
URIC ACID	200-360 (UMOL/L)	02/02/93	345.00		352.00		320.00	
TOT. BILIRUBIN	0-20 (UMOL/L)	02/02/93	8.90		9.70		8.80	
TOT. PROTEINS	60-80 (G/L)	02/02/93	67.00		66.00		69.00	
ALBUMINE	36-48 (G/L)	02/02/93	42.20		37.00		44.70	
TOT. CHOLEST.	3.87-6.45 (MMOL/L)	02/02/93	7.77	>	8.60	>>	9.60	
TRIGLYCERIDES	0.57-1.71 (MMOL/L)	02/02/93	0.81		1.34		1.24	
GLOBULINS ALPHA 1	1-3 (G/L)	02/02/93	2.20		2.90		2.20	
GLOBULINS ALPHA 2	4-8 (G/L)	02/02/93	5.00		5.60		4.80	
GLOBULINS BETA	5-10 (G/L)	02/02/93	8.40		9.90		8.20	
GLOBULINS GAMMA	7-13 (G/L)	02/02/93	8.90		10.40		8.90	
TSH	0.2-4 (MUI/L)	02/02/93	0.69					
T4	8-18.9 (NG/L)	02/02/93	15.90					

2145

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN520089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 13 Patient: 4DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			27/01/94		03/03/94		05/04/94	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	02/02/93	12.50		12.50		12.60	
HT	33-47 (X)	02/02/93	38.00		38.00		39.00	
RBC	4-5.5 (10 ⁶ /MM ³)	02/02/93	3.97 <		4.07		4.07	
MBC	4-10 (10 ³ /MM ³)	02/02/93	6.50		5.70		5.80	
MBC: N	45-74 (X)	02/02/93	63.00		68.00		73.00	
MBC: L	16-45 (X)	02/02/93	31.00		28.00		22.00	
MBC: E	0-7 (X)	02/02/93	3.00		1.00		0.00	
MBC: M	4-10 (X)	02/02/93	1.00 <		3.00 <		4.00	
MBC: B	0-2 (X)	02/02/93	2.00		0.00		1.00	
PLATELETS	150-300 (10 ³ /MM ³)	02/02/93	326.00 >		396.00 >>		369.00 >	
NA+	135-145 (MMOL/L)	02/02/93	143.00		134.00 <		141.00	
K+	3.5-5 (MMOL/L)	02/02/93	3.80		4.40		3.80	
CL-	95-105 (MMOL/L)	02/02/93	106.00 >		97.00		102.00	
Ca++	2.2-2.5 (MMOL/L)	02/02/93	2.40		2.39		2.39	
PO4--	0.8-1.6 (MMOL/L)	02/02/93	1.13		1.26		0.73 <	
SGOT	0-25 (UI/L)	02/02/93	18.00		16.00		15.00	
SGPT	0-25 (UI/L)	02/02/93	17.00		15.00		12.00	
GAMMA GT	8-38 (UI/L)	02/02/93	19.00		16.00		13.00	
LDH	160-320 (UI/L)	02/02/93	210.00		201.00		172.00	
ALK. PHOSPH.	70-220 (UI/L)	02/02/93	125.00		139.00		128.00	
GLUCOSE	3.6-6.5 (MMOL/L)	02/02/93	5.00		4.80		5.20	
UREA	3.3-6.64 (MMOL/L)	02/02/93	5.00		5.00		5.60	
CREATININE	70-145 (UMOL/L)	02/02/93	100.00		90.00		92.00	
URIC ACID	200-360 (UMOL/L)	02/02/93	408.00 >		348.00		382.00 >	
TOT. BILIRUBIN	0-20 (UMOL/L)	02/02/93	7.20		8.10		7.10	
TOT. PROTEINS	60-80 (G/L)	02/02/93	64.00		64.00		63.00	
ALBUMINE	36-48 (G/L)	02/02/93	38.50		40.60		37.60	
TOT. CHOLEST.	3.87-6.45 (MMOL/L)	02/02/93	7.51 >		6.25		6.83 >	
TRIGLYCERIDES	0.57-1.71 (MMOL/L)	02/02/93	1.59		1.24		1.33	
GLOBULINS ALPHA 1	1-3 (G/L)	02/02/93	2.30		2.10		2.20	
GLOBULINS ALPHA 2	4-8 (G/L)	02/02/93	5.80		5.20		5.60	
GLOBULINS BETA	5-10 (G/L)	02/02/93	7.10		6.60		7.40	
GLOBULINS GAMMA	7-13 (G/L)	02/02/93	10.10		9.30		10.00	
TSH	0.2-4 (MUI/L)	02/02/93	1.39					
T4	10.4-24.3 (PMOL/L)	02/02/93	15.50					

2146

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C 950089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 14 Patient: 1MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	Day 28
			01/04/94	04/05/94
			value (€)	value (€)
Laboratory test	Range value	Range date		
HB	12-17 (G/DL)	01/04/94	13.00	16.50
HT	34-52 (X)	01/04/94	40.00	49.00
RBC	4000000-5500000 (/MM3)	01/04/94	4150000	4990000
MBC	4000-10000 (/MM3)	01/04/94	4710.00	7140.00
MBC: N	45-74 (X)	01/04/94	45.40	63.80
MBC: L	16-45 (X)	01/04/94	41.90	28.50
MBC: E	0-7 (X)	01/04/94	2.20	0.80
MBC: M	4-10 (X)	01/04/94	8.10	5.40
MBC: B	0-2 (X)	01/04/94	0.70	0.60
PLATELETS	150000-450000 (/MM3)	01/04/94	197000	251000
NA+	135-145 (MEQ/L)	01/04/94	140.00	142.00
K+	3.5-5.5 (MEQ/L)	01/04/94	4.20	5.00
CL-	95-108 (MEQ/L)	01/04/94	104.00	
Ca++	84-98 (MG/L)	01/04/94	88.00	95.00
PO4--	25-49 (MG/L)	01/04/94	33.00	31.00
SGOT	25-41 (UI/L)	01/04/94	18.00	23.00
SGPT	3-36 (UI/L)	01/04/94	33.00	39.00
GAMMA GT	15-85 (UI/L)	01/04/94	16.00	16.00
LDH	100-190 (UI/L)	01/04/94	125.00	206.00
ALK. PHOSPH.	35-115 (UI/L)	01/04/94	80.00	
GLUCOSE	0.72-1.2 (G/L)	01/04/94	0.81	0.84
UREA	0.21-0.56 (G/L)	01/04/94	0.31	
CREATININE	7-14 (MG/L)	01/04/94	9.00	
URIC ACID	20-60 (MG/L)	01/04/94	39.00	
TOT. BILIRUBIN	0-15 (MG/L)	01/04/94	4.00	
TOT. PROTEINS	60-78 (G/L)	01/04/94	61.00	70.00
ALBUMINE	32-50 (G/L)	01/04/94	36.50	40.90
TOT. CHOLEST.	1.2-2 (G/L)	01/04/94	2.34	2.54
TRIGLYCERIDES	0.3-1.3 (G/L)	01/04/94	1.02	0.97
GLOBULINS ALPHA 1	1-4 (G/L)	01/04/94	2.70	3.10
GLOBULINS ALPHA 2	5-11 (G/L)	01/04/94	5.70	7.00
GLOBULINS BETA	6-13 (G/L)	01/04/94	6.60	9.00
GLOBULINS GAMMA	7-15 (G/L)	01/04/94	9.50	9.90
TSH	0.1-3.5 (MUI/L)	01/04/94	1.18	
T4	0.9-1.7 (NG/DL)	01/04/94	1.08	

2147

(4) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C9560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 15 Patient: 1ND Treatment: Roboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			24/02/93		29/03/93		30/04/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	08/01/93	14.20		14.10		16.40 >	
HT	37-48 (X)	08/01/93	42.00		43.40		47.90	
RBC	4.15-4.9 (10 ¹² /L)	08/01/93	4.63		4.97 >		5.37 >	
WBC	4.3-10.8 (10 ⁹ /L)	08/01/93	6.00		6.80		7.90	
WBC: N	45-74 (%)	08/01/93	56.00		48.60		51.80	
WBC: L	16-45 (%)	08/01/93	38.00		42.20		39.30	
WBC: E	0-7 (%)	08/01/93	2.00		0.00		0.00	
WBC: M	4-10 (%)	08/01/93	4.00		9.20		8.90	
WBC: B	0-2 (%)	08/01/93	0.00		0.00		0.00	
PLATELETS	150-350 (10 ⁹ /L)	08/01/93	277.00		297.00		201.00	
NA+	136-145 (MEQ/L)	08/01/93	140.00		139.00		140.00	
K+	3.5-5 (MEQ/L)	08/01/93	3.84		4.01		4.20	
CL-	95-108 (MEQ/L)	08/01/93	107.00		101.00		105.00	
Ca++	85-105 (MG/L)	08/01/93	84.40 <		82.00 <		83.30 <	
PO4--	25-45 (MG/L)	08/01/93	36.00		39.00		39.20	
SGOT	8-50 (UI/L)	08/01/93	11.30		8.20		19.70	
SGPT	8-30 (UI/L)	08/01/93	14.60		10.10		10.90	
GAMMA GT	5-36 (UI/L)	08/01/93	8.00		8.00		9.00	
LDH	160-330 (UI/L)	08/01/93	275.00		232.00		383.00 >	
ALK. PHOSPH.	80-220 (UI/L)	08/01/93	127.00		139.00		160.00	
GLUCOSE	0.7-1 (G/L)	08/01/93	0.83		0.78		0.70	
UREA	0.2-0.4 (G/L)	08/01/93	0.13 <		0.25		0.23	
CREATININE	6-13 (MG/L)	08/01/93	6.40		6.60		7.10	
CREATININE	()	08/01/93						
CLEARANCE			70.64 ()					
URIC ACID	40-70 (MG/L)	08/01/93	34.40 <		36.10 <		35.40 <	
TOT BILIRUBIN	5-11 (MG/L)	08/01/93	15.70 >		13.60 >		15.20 <	
DIR BILIRUBIN	0-2.5 (MG/L)	08/01/93	3.40 >		4.60 >		4.00 >	
TOT. PROTEINS	60-75 (G/L)	08/01/93	67.70		64.20		73.00	
ALBUMINE	30-48 (G/L)	08/01/93	30.70		30.60		29.90 <	
TOT. CHOLEST.	1.4-2.6 (G/L)	08/01/93	1.46		1.33 <		1.56	
TRIGLYCERIDES	0.25-1.5 (G/L)	08/01/93	0.48		0.41		0.61	
GLOBULINS ALPHA 1	1.8-4.8 (G/L)	08/01/93	3.20		2.70		2.90	
GLOBULINS ALPHA 2	3.3-11 (G/L)	08/01/93	5.60		5.40		5.50	
GLOBULINS BETA	5.4-12.8 (G/L)	08/01/93	7.20		6.60		7.00	
GLOBULINS GAMMA	6.6-17.6 (G/L)	08/01/93	20.80 >		18.70 >		18.70 >	
TSH	0.15-30 (UUI/L)	08/01/93	21.10					
T4	10.5-25.5 (PMOL/L)	08/01/93	21.10					
ESR/SEDIMENT. RATE	0-10 (MM)	08/01/93						
1st h			40.00		28.00			

2148

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 15 Patient: 2MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			02/03/93	
			value	(φ)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	08/01/93	11.60	<
HT	37-48 (%)	08/01/93	33.00	<
RBC	4.15-4.9 (10 ¹² /L)	08/01/93	3.37	<<
HBC	4.3-10.8 (10 ⁹ /L)	08/01/93	5.50	
HBC: N	45-74 (%)	08/01/93	74.00	
HBC: L	16-45 (%)	08/01/93	17.20	
HBC: M	4-10 (%)	08/01/93	8.80	
PLATELETS	150-350 (10 ⁹ /L)	08/01/93	227.00	
NA+	136-145 (MEQ/L)	08/01/93	140.00	
K+	3.5-5 (MEQ/L)	08/01/93	3.89	
CL-	95-108 (MEQ/L)	08/01/93	105.00	
Ca++	85-105 (MG/L)	08/01/93	91.00	
PO4--	25-45 (MG/L)	08/01/93	43.60	
SGOT	8-50 (UI/L)	08/01/93	10.00	
SGPT	8-30 (UI/L)	08/01/93	10.80	
GAMMA GT	5-36 (UI/L)	08/01/93	23.00	
LDH	160-330 (UI/L)	08/01/93	222.00	
ALK. PHOSPH.	80-220 (UI/L)	08/01/93	140.00	
GLUCOSE	0.7-1 (G/L)	08/01/93	0.91	
UREA	0.2-0.4 (G/L)	08/01/93	0.46	>
CREATININE	6-13 (MG/L)	08/01/93	9.80	
CREATININE	()	08/01/93		
CLEARANCE			43.80	()
URIC ACID	40-70 (MG/L)	08/01/93	63.60	
TOT BILIRUBIN	5-11 (MG/L)	08/01/93	7.60	
DIR BILIRUBIN	0-2.5 (MG/L)	08/01/93	1.50	
TOT. PROTEINS	60-75 (G/L)	08/01/93	65.80	
ALBUMINE	30-48 (G/L)	08/01/93	39.30	
TOT. CHOLEST.	1.4-2.6 (G/L)	08/01/93	2.29	
TRIGLYCERIDES	0.25-1.5 (G/L)	08/01/93	0.92	
GLOBULINS ALPHA 1	1.8-4.8 (G/L)	08/01/93	2.90	
GLOBULINS ALPHA 2	3.3-11 (G/L)	08/01/93	6.30	
GLOBULINS BETA	5.4-12.8 (G/L)	08/01/93	9.00	
GLOBULINS GAMMA	6.6-17.6 (G/L)	08/01/93	6.40	<
TSH	0.15-30 (UI/L)	08/01/93	1.79	
T4	10.5-25.5 (PMOL/L)	08/01/93	19.20	

2149

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CN 530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 15 Patient: SHD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			05/05/93		03/06/93		02/07/93	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	08/01/93	12.80		11.30 <	12.40		
HT	37-48 (X)	08/01/93	38.00		36.30 <	34.50 <		
RBC	4.15-4.9 (10 ¹² /L)	08/01/93	3.88 <		3.84 <	4.08 <		
HBC	4.3-10.8 (10 ⁹ /L)	08/01/93	7.20		4.90	7.20		
HBC: N	45-74 (X)	08/01/93			66.60	75.10 >		
HBC: L	16-45 (X)	08/01/93			25.40	17.50		
HBC: E	0-7 (X)	08/01/93			0.00	0.00		
HBC: M	4-10 (X)	08/01/93			8.00	7.40		
HBC: B	0-2 (X)	08/01/93			0.00	0.00		
PLATELETS	150-350 (10 ⁹ /L)	08/01/93	472.00 >>		371.00 >	300.00		
NA+	136-145 (MEQ/L)	08/01/93	143.00		139.00	141.00		
K+	3.5-5 (MEQ/L)	08/01/93	3.62		3.65	3.70		
CL-	95-108 (MEQ/L)	08/01/93	107.00		102.00	103.00		
Ca++	85-105 (MG/L)	08/01/93	98.40		90.90	92.00		
PO4--	25-45 (MG/L)	08/01/93	20.80 <<		39.60	42.00		
SGOT	8-50 (UI/L)	08/01/93	14.60		8.70	8.00		
SGPT	8-30 (UI/L)	08/01/93	27.60		11.50	10.00		
GAMMA GT	5-36 (UI/L)	08/01/93	30.00		16.00	14.00		
LDH	160-330 (UI/L)	08/01/93	268.00		225.00	278.00		
ALK. PHOSPH.	80-220 (UI/L)	08/01/93	117.00		110.00	132.00		
GLUCOSE	0.7-1 (G/L)	08/01/93	0.81		0.84	0.88		
UREA	0.2-0.4 (G/L)	08/01/93	0.46 >		0.46 >	0.33		
CREATININE	6-13 (MG/L)	08/01/93	6.30		6.30	6.80		
CREATININE CLEARANCE	(l)	08/01/93	46.83 (l)					
URIC ACID	40-70 (MG/L)	08/01/93	22.50 <		32.80 <	33.00 <		
TOT BILIRUBIN	5-11 (MG/L)	08/01/93	5.90		6.40	8.00		
DIR BILIRUBIN	0-2.5 (MG/L)	08/01/93	1.20		1.30	3.00 >		
TOT. PROTEINS	60-75 (G/L)	08/01/93	65.60		61.80	65.00		
ALBUMINE	30-48 (G/L)	08/01/93	34.20		34.60	36.70		
TOT. CHOLEST.	1.4-2.6 (G/L)	08/01/93	2.41		2.49	2.51		
TRIGLYCERIDES	0.25-1.5 (G/L)	08/01/93	1.63 >		1.02	0.86		
GLOBULINS ALPHA 1	1.8-4.8 (G/L)	08/01/93	3.30		3.70	3.30		
GLOBULINS ALPHA 2	3.3-11 (G/L)	08/01/93	6.10		6.00	6.60		
GLOBULINS BETA	5.4-12.8 (G/L)	08/01/93	8.20		7.80	8.00		
GLOBULINS GAMMA	6.6-17.6 (G/L)	08/01/93	8.20		7.90	8.40		
TSH	0.15-30 (UI/L)	08/01/93	11.40					
T4	10.5-25.5 (PNOL/L)	08/01/93	13.24					

2150

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done (l) missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 15 Patient: 4MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			12/07/93		12/08/93		09/09/93	
			value	(†)	value	(†)	value	(†)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	08/01/93	10.70	<	10.00	<<	12.10	
HT	37-48 (%)	08/01/93	33.80	<	30.30	<<	37.40	
RBC	4.15-4.9 (10 ¹² /L)	08/01/93	3.83	<	3.46	<<	4.42	
WBC	4.3-10.8 (10 ⁹ /L)	08/01/93	7.10		7.40		6.80	
WBC: N	45-74 (%)	08/01/93	70.10		73.10		74.10 >	
WBC: L	16-45 (%)	08/01/93	19.50		17.50		17.30	
WBC: E	0-7 (%)	08/01/93	0.00		0.00		0.00	
WBC: M	4-10 (%)	08/01/93	10.50	>	9.40		8.70	
WBC: B	0-2 (%)	08/01/93	0.00		0.00		0.00	
PLATELETS	150-350 (10 ⁹ /L)	08/01/93	345.00		332.00		311.00	
NA+	136-145 (MEQ/L)	08/01/93	143.00		140.00		139.00	
K+	3.5-5 (MEQ/L)	08/01/93	3.86		4.22		4.55	
CL-	95-108 (MEQ/L)	08/01/93	103.00		103.00		103.00	
Ca ⁺⁺	85-105 (MG/L)	08/01/93	84.40	<	84.20	<	87.20	
PO4 ⁻⁻	25-45 (MG/L)	08/01/93	32.20		37.70		32.00	
SGOT	8-50 (UI/L)	08/01/93	5.50	<	6.00	<	8.40	
SGPT	8-30 (UI/L)	08/01/93	8.30		8.90		7.20 <	
GAMMA GT	5-36 (UI/L)	08/01/93	18.00		12.00		9.00	
LDH	160-330 (UI/L)	08/01/93	246.00		179.00		247.00	
ALK. PHOSPH.	80-220 (UI/L)	08/01/93	165.00		183.00		191.00	
GLUCOSE	0.7-1 (G/L)	08/01/93	0.90		0.90		0.96	
UREA	0.2-0.4 (G/L)	08/01/93	0.22		0.27		0.37	
CREATININE	6-13 (MG/L)	08/01/93	7.80		8.50		10.80	
CREATININE CLEARANCE	()	08/01/93	62.21 ()					
URIC ACID	40-70 (MG/L)	08/01/93	64.10		58.80		62.00	
TOT BILIRUBIN	5-11 (MG/L)	08/01/93	6.30		6.40		8.80	
DIR BILIRUBIN	0-2.5 (MG/L)	08/01/93	1.30		1.00		1.70	
TOT. PROTEINS	60-75 (G/L)	08/01/93	57.80	<	57.00	<	66.20	
ALBUMINE	30-48 (G/L)	08/01/93	29.80	<	31.20		33.20	
TOT. CHOLEST.	1.4-2.6 (G/L)	08/01/93	1.72		1.58		1.66	
TRIGLYCERIDES	0.25-1.5 (G/L)	08/01/93	1.28		0.97		0.96	
GLOBULINS ALPHA 1	1.8-4.8 (G/L)	08/01/93	3.30		3.30		3.20	
GLOBULINS ALPHA 2	3.3-11 (G/L)	08/01/93	5.60		5.80		7.70	
GLOBULINS BETA	5.4-12.8 (G/L)	08/01/93	6.40		6.60		7.30	
GLOBULINS GAMMA	6.6-17.6 (G/L)	08/01/93	4.40	<<	9.80		11.60	
TSH	0.15-30 (UUI/L)	08/01/93	1.79					
T4	10.5-25.5 (PMOL/L)	08/01/93	16.20					

2151

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CN 550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 15 Patient: 111ND Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date
			Screen
			06/10/93
			value (†)
Laboratory test	Range value	Range date	
HB	12-16 (G/DL)	08/01/93	11.60 <
HT	37-48 (%)	08/01/93	36.10 <
RBC	4.15-4.9 (10 ¹² /L)	08/01/93	4.00 <
WBC	4.3-10.8 (10 ⁹ /L)	08/01/93	4.50
WBC: N	45-74 (%)	08/01/93	52.10
WBC: L	16-45 (%)	08/01/93	40.00
WBC: E	0-7 (%)	08/01/93	0.00
WBC: M	4-10 (%)	08/01/93	7.40
WBC: B	0-2 (%)	08/01/93	0.00
PLATELETS	150-350 (10 ⁹ /L)	08/01/93	287.00
NA+	136-145 (MEQ/L)	08/01/93	141.00
K+	3.5-5 (MEQ/L)	08/01/93	3.75
CL-	95-108 (MEQ/L)	08/01/93	104.00
Ca++	85-105 (MG/L)	08/01/93	94.00
PO4--	25-45 (MG/L)	08/01/93	43.40
SGOT	8-50 (UI/L)	08/01/93	10.70
SGPT	8-30 (UI/L)	08/01/93	16.60
GAMMA GT	5-36 (UI/L)	08/01/93	13.00
ALK. PHOSPH.	80-220 (UI/L)	08/01/93	136.00
GLUCOSE	0.7-1 (G/L)	08/01/93	0.99
UREA	0.2-0.4 (G/L)	08/01/93	0.25
CREATININE	6-13 (MG/L)	08/01/93	7.50
CREATININE CLEARANCE	()	08/01/93	71.76 ()
URIC ACID	40-70 (MG/L)	08/01/93	54.10
TOT BILIRUBIN	5-11 (MG/L)	08/01/93	6.30
DIR BILIRUBIN	0-2.5 (MG/L)	08/01/93	1.20
TOT. PROTEINS	60-75 (G/L)	08/01/93	62.40
ALBUMINE	30-48 (G/L)	08/01/93	34.30
TOT. CHOLEST.	1.4-2.6 (G/L)	08/01/93	1.89
TRIGLYCERIDES	0.25-1.5 (G/L)	08/01/93	1.42
GLOBULINS ALPHA 1	1.8-4.8 (G/L)	08/01/93	3.60
GLOBULINS ALPHA 2	3.3-11 (G/L)	08/01/93	6.90
GLOBULINS BETA	5.4-12.8 (G/L)	08/01/93	8.70
GLOBULINS GAMMA	6.6-17.6 (G/L)	08/01/93	6.30 <
TSH	0.15-30 (UUI/L)	08/01/93	2.12
T4	10.5-25.5 (PMOL/L)	08/01/93	16.40

2152

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 15 Patient: 112MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			24/11/93		04/01/94		24/01/94	
			value	(c)	value	(c)	value	(c)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	08/01/93	10.50	<	11.00	<	11.90	<
HT	37-48 (X)	08/01/93	35.40	<	33.80	<	37.80	
RBC	4.15-4.9 (10~12/L)	08/01/93	3.97	<	3.92	<	4.41	
MBC	4.3-10.8 (10~9/L)	08/01/93	4.60		5.70		4.80	
MBC: N	45-74 (X)	08/01/93			63.90		59.60	
MBC: L	16-45 (X)	08/01/93			28.40		32.50	
MBC: E	0-7 (X)	08/01/93			7.70	>	0.00	
MBC: M	4-10 (X)	08/01/93			0.00	<	7.90	
MBC: B	0-2 (X)	08/01/93			0.00	<	0.00	
PLATELETS	150-350 (10~9/L)	08/01/93	272.00		285.00		280.00	
NA+	136-145 (MEQ/L)	08/01/93	141.00		139.00		141.00	
K+	3.5-5 (MEQ/L)	08/01/93	4.28		4.42		4.58	
CL-	95-108 (MEQ/L)	08/01/93	106.00		104.00		103.00	
Ca++	85-105 (MG/L)	08/01/93	95.20		90.00		93.80	
PO4--	25-45 (MG/L)	08/01/93	32.30		31.10		33.20	
SGOT	8-50 (UI/L)	08/01/93	8.20		9.90		11.10	
SGPT	8-30 (UI/L)	08/01/93	8.50		10.20		23.50	
GAMMA GT	5-36 (UI/L)	08/01/93	15.00		20.00		114.00	>>
LDH	160-330 (UI/L)	08/01/93			204.00		210.00	
ALK. PHOSPH.	80-220 (UI/L)	08/01/93	187.00		194.00		267.00	>
GLUCOSE	0.7-1 (G/L)	08/01/93	0.77		0.68	<	0.73	
UREA	0.2-0.4 (G/L)	08/01/93	0.58	>	0.57	>	0.51	>
CREATININE	6-13 (MG/L)	08/01/93	10.70		11.40		11.20	
CREATININE CLEARANCE	(l)	08/01/93	46.79	(c)				
URIC ACID	40-70 (MG/L)	08/01/93	84.50	>	74.00	>	79.70	>
TOT BILIRUBIN	5-11 (MG/L)	08/01/93	5.80		5.60		5.40	
DIR BILIRUBIN	0-2.5 (MG/L)	08/01/93	1.00		3.10	>	1.10	
TOT. PROTEINS	60-75 (G/L)	08/01/93	64.90		63.40		66.00	
ALBUMINE	30-48 (G/L)	08/01/93	37.30		36.10		36.30	
TOT. CHOLEST.	1.4-2.6 (G/L)	08/01/93	1.89		1.69		1.64	
TRIGLYCERIDES	0.25-1.5 (G/L)	08/01/93	1.78	>	1.63	>	1.95	>
GLOBULINS ALPHA 1	1.8-4.8 (G/L)	08/01/93	2.40		2.40		2.20	
GLOBULINS ALPHA 2	3.3-11 (G/L)	08/01/93	6.40		6.00		6.10	
GLOBULINS BETA	5.4-12.8 (G/L)	08/01/93	8.20		7.90		7.80	
GLOBULINS GAMMA	6.6-17.6 (G/L)	08/01/93	7.80		8.60		8.90	
TSH	0.15-30 (UUI/L)	08/01/93	0.54					
T4	10.5-25.5 (PMOL/L)	08/01/93	21.20					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	08/01/93					22.00	

2153

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CME50089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 15 Patient: 1DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			19/07/93		23/08/93		20/09/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	08/01/93	14.20		15.50		15.00	
HT	37-48 (X)	08/01/93	42.70		46.10		46.60	
RBC	4.15-4.9 (10 ¹² /L)	08/01/93	4.70		4.66		4.92 >	
WBC	4.3-10.8 (10 ⁹ /L)	08/01/93	4.80		6.50		6.60	
WBC: N	45-74 (%)	08/01/93	46.40		52.40			
WBC: L	16-45 (%)	08/01/93	44.80		39.30			
WBC: E	0-7 (%)	08/01/93	0.00		0.00			
WBC: M	4-10 (%)	08/01/93	8.90		8.30			
WBC: B	0-2 (%)	08/01/93	0.00		0.00			
PLATELETS	150-350 (10 ⁹ /L)	08/01/93	175.00		209.00		237.00	
NA+	136-145 (MEQ/L)	08/01/93	140.00		136.00		137.00	
K+	3.5-5 (MEQ/L)	08/01/93	4.03		4.45		3.93	
CL-	95-108 (MEQ/L)	08/01/93	104.00		103.00		105.00	
Ca++	85-105 (MG/L)	08/01/93	104.00		106.00 >		108.00 >	
PO4--	25-45 (MG/L)	08/01/93	24.40 <		23.10 <		18.00 <<	
SGOT	8-50 (UI/L)	08/01/93	40.40		19.20		11.00	
SGPT	8-30 (UI/L)	08/01/93	73.00 >>		37.60 >		14.80	
GAMMA GT	5-36 (UI/L)	08/01/93	20.00		15.00		11.00	
LDH	160-330 (UI/L)	08/01/93	221.00				229.00	
ALK. PHOSPH.	80-220 (UI/L)	08/01/93	314.00 >		379.00 >		405.00 >	
GLUCOSE	0.7-1 (G/L)	08/01/93	1.45 >>		1.66 >>		3.16 >>	
UREA	0.2-0.4 (G/L)	08/01/93	0.30		0.30		0.39	
CREATININE	6-13 (MG/L)	08/01/93	7.30		6.80		6.30	
CREATININE CLEARANCE	()	08/01/93	59.17 ()					
URIC ACID	40-70 (MG/L)	08/01/93	46.70		41.40		35.30 <	
TOT BILIRUBIN	5-11 (MG/L)	08/01/93	9.50		8.80		9.10	
DIR BILIRUBIN	0-2.5 (MG/L)	08/01/93	2.00		2.30		2.00	
TOT. PROTEINS	60-75 (G/L)	08/01/93	63.00		66.80		61.00	
ALBUMINE	30-48 (G/L)	08/01/93	36.90		35.10		34.70	
TOT. CHOLEST.	1.4-2.6 (G/L)	08/01/93	1.75		1.68		1.90	
TRIGLYCERIDES	0.25-1.5 (G/L)	08/01/93	1.43		0.92		1.12	
GLOBULINS ALPHA 1	1.8-4.8 (G/L)	08/01/93	2.40		2.70		2.40	
GLOBULINS ALPHA 2	3.3-11 (G/L)	08/01/93	5.80		6.50		7.20	
GLOBULINS BETA	5.4-12.8 (G/L)	08/01/93	9.30		8.70		9.10	
GLOBULINS GAMMA	6.6-17.6 (G/L)	08/01/93	9.90		10.20		9.40	
TSH	0.15-30 (UUI/L)	08/01/93	7.24					
T4	10.5-25.5 (PNOL/L)	08/01/93	12.60					

2154

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS 390089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 15 Patient: 2DT Treatment: Imipramine Sex: Female

Laboratory test			Visit number / Laboratory date					
			Screen		Day 56		Day 28	
			09/02/94		19/04/94		22/03/94	
			value	(φ)	value	(φ)	value	(φ)
Range value	Range date							
HB	12-16 (G/DL)	08/01/93	11.70	<	12.40			
HT	37-48 (X)	08/01/93	35.90	<	37.60			
RBC	4.15-4.9 (10 ¹² /L)	08/01/93	3.98	<	4.10	<		
WBC	4.3-10.8 (10 ⁹ /L)	08/01/93	7.60		7.10			
WBC: N	45-74 (%)	08/01/93	58.50		49.50			
WBC: L	16-45 (%)	08/01/93	37.70		35.80			
WBC: E	0-7 (%)	08/01/93	0.00		6.80			
WBC: M	4-10 (%)	08/01/93	3.80	<	0.00	<		
WBC: B	0-2 (%)	08/01/93	0.00		0.30			
PLATELETS	150-350 (10 ⁹ /L)	08/01/93	256.00		296.00			
NA+	136-145 (MEQ/L)	08/01/93	141.00		140.00	141.00		
K+	3.5-5 (MEQ/L)	08/01/93	4.50		4.60	4.12		
CL-	95-108 (MEQ/L)	08/01/93	106.00		100.00	100.00		
Ca++	85-105 (MG/L)	08/01/93	88.00		86.90	88.20		
PO4--	25-45 (MG/L)	08/01/93	38.60		35.60	34.70		
SGOT	8-50 (UI/L)	08/01/93	10.90			10.00		
SGPT	8-30 (UI/L)	08/01/93	8.00			7.20	<	
GAMMA GT	5-36 (UI/L)	08/01/93	20.00			25.00		
LDH	160-330 (UI/L)	08/01/93	222.00		256.00	275.00		
ALK. PHOSPH.	80-220 (UI/L)	08/01/93	140.00			135.00		
GLUCOSE	0.7-1 (G/L)	08/01/93	0.70		0.77	0.76		
UREA	0.2-0.4 (G/L)	08/01/93	0.36		0.29	0.29		
CREATININE	6-13 (MG/L)	08/01/93	10.10		10.60	9.80		
CREATININE CLEARANCE	(l)	08/01/93	49.30	(l)				
URIC ACID	40-70 (MG/L)	08/01/93	39.40	<		27.00	<	
TOT BILIRUBIN	5-11 (MG/L)	08/01/93	4.60	<		6.20		
DIR BILIRUBIN	0-2.5 (MG/L)	08/01/93	1.10			2.20		
TOT. PROTEINS	60-75 (G/L)	08/01/93	65.50		67.30	66.40		
ALBUMINE	30-48 (G/L)	08/01/93	36.70		34.90	37.20		
TOT. CHOLEST.	1.4-2.6 (G/L)	08/01/93	2.30			2.19		
TRIGLYCERIDES	0.25-1.5 (G/L)	08/01/93	0.80			0.82		
GLOBULINS ALPHA 1	1.8-4.8 (G/L)	08/01/93	2.70		3.00	3.40		
GLOBULINS ALPHA 2	3.3-11 (G/L)	08/01/93	6.50		6.30	6.70		
GLOBULINS BETA	5.4-12.8 (G/L)	08/01/93	8.20		7.40	7.60		
GLOBULINS GAMMA	6.6-17.6 (G/L)	08/01/93	7.90		9.40	9.50		
TSH	0.15-30 (UUI/L)	08/01/93	1.13					
T4	10.5-25.5 (PMOL/L)	08/01/93	18.20					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	08/01/93			15.00	20.00		

2155

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done (l) missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN 5310089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 16 Patient: 1MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			29/01/93		17/03/93		14/04/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	11.5-17 (G/DL)	03/01/93	10.20	<	11.80		12.20	
HT	36-52 (%)	03/01/93	29.80	<<	34.90	<	36.90	
RBC	4.5-5.5 (10 ⁶ /MM ³)	03/01/93	3.28	<<	3.84	<	4.03	
WBC	4-10 (10 ³ /MM ³)	03/01/93	6.00		5.10		6.20	
WBC: N	2-7.5 (10 ³ /MM ³)	03/01/93	3.00		2.35		2.67	
WBC: L	1.5-4 (10 ³ /MM ³)	03/01/93	2.52		2.40		3.04	
WBC: E	0.04-0.5 (10 ³ /MM ³)	03/01/93	0.06		0.15		0.19	
WBC: M	0.2-1 (10 ³ /MM ³)	03/01/93	0.42		0.20		0.31	
PLATELETS	200-400 (10 ³ /MM ³)	03/01/93	187.00	<	293.00		279.00	
NA+	136-144 (MMOL/L)	03/01/93	141.00		137.00		141.00	
K+	3.6-5 (MMOL/L)	03/01/93	4.30		5.20	>	4.10	
CL-	95-105 (MMOL/L)	03/01/93	100.00		100.00		101.00	
Ca++	2.1-2.6 (MMOL/L)	03/01/93	2.42		2.57		2.46	
PO4--	0.8-1.4 (MMOL/L)	03/01/93	0.68	<	0.99		1.05	
SGOT	5-25 (UI/L)	03/01/93	11.00		12.00		11.00	
SGPT	5-35 (UI/L)	03/01/93	9.00		11.00		14.00	
GAMMA GT	5-25 (UI/L)	03/01/93	37.00	>	19.00		23.00	
LDH	160-320 (UI/L)	03/01/93	221.00		212.00		205.00	
ALK. PHOSPH.	35-85 (UI/L)	03/01/93	95.00	>	82.00		86.00	
GLUCOSE	4.4-6.2 (MMOL/L)	03/01/93	5.60		5.30		6.70	
UREA	3.3-8.3 (MMOL/L)	03/01/93	7.00		9.90	>	8.10	
CREATININE	55-115 (UMOL/L)	03/01/93	128.00	>	115.00		99.00	
URIC ACID	180-380 (UMOL/L)	03/01/93	402.00	>	397.00	>	342.00	
TOT BILIRUBIN	0-20 (UMOL/L)	03/01/93	7.00		8.00		7.00	
DIR BILIRUBIN	0-5 (UMOL/L)	03/01/93			3.00		3.00	
TOT. PROTEINS	63-80 (G/L)	03/01/93	58.00	<	66.00		68.00	
ALBUMINE	38-50 (G/L)	03/01/93			36.20	<	41.80	
TOT. CHOLEST.	0-5.2 (MMOL/L)	03/01/93	4.87		6.68	>	6.71	
TRIGLYCERIDES	0-1.6 (MMOL/L)	03/01/93	1.13		0.88		1.02	
GLOBULINS ALPHA 1	1-4 (G/L)	03/01/93			2.70		2.60	
GLOBULINS ALPHA 2	4-9 (G/L)	03/01/93			6.40		5.80	
GLOBULINS BETA	6-12 (G/L)	03/01/93			9.40		8.50	
GLOBULINS GAMMA	7-15 (G/L)	03/01/93			11.30		9.20	
TSH	0.3-5 (U/ML)	03/01/93	1.29					
T4	9.2-22.7 (PMOL/L)	03/01/93	15.00					

2156

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS 950089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 16 Patient: 2ND Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			08/04/93		12/05/93		09/06/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	11.5-17 (G/DL)	01/03/93	14.10		14.80		15.00	
HT	36-52 (%)	01/03/93	41.20		42.60		44.60	
RBC	4-5.8 (10 ⁶ /MM ³)	01/03/93	4.13		4.33		4.52	
WBC	4-10 (10 ³ /MM ³)	01/03/93	3.40 <		4.20		3.90 <	
WBC: N	2-7.5 (10 ³ /MM ³)	01/03/93	2.01		2.06		2.42	
WBC: L	1.5-4 (10 ³ /MM ³)	01/03/93	1.12 <		1.76		1.17 <	
WBC: E	0.04-0.5 (10 ³ /MM ³)	01/03/93	0.03 <		0.08		0.04	
WBC: M	0.2-1 (10 ³ /MM ³)	01/03/93	0.24		0.29		0.27	
PLATELETS	200-400 (10 ³ /MM ³)	01/03/93	149.00 <		206.00		198.00 <	
NA+	136-144 (MMOL/L)	01/03/93			136.00		136.00	
K+	3.6-5 (MMOL/L)	01/03/93			4.20		3.90	
CL-	95-105 (MMOL/L)	01/03/93			94.00 <		95.00	
Ca++	2.1-2.6 (MMOL/L)	01/03/93	2.38				2.45	
PO4--	0.8-1.4 (MMOL/L)	01/03/93	1.33				1.22	
SGOT	5-25 (UI/L)	01/03/93	8.00		8.00		9.00	
SGPT	5-35 (UI/L)	01/03/93	9.00		6.00		7.00	
GAMMA GT	5-25 (UI/L)	01/03/93	7.00		8.00		8.00	
LDH	160-320 (UI/L)	01/03/93	201.00		176.00		189.00	
ALK. PHOSPH.	35-85 (UI/L)	01/03/93	43.00		45.00		49.00	
GLUCOSE	4.4-6.2 (MMOL/L)	01/03/93	4.80		5.20		6.20	
UREA	3.6-8.2 (MMOL/L)	01/03/93	4.70		3.30 <		2.70 <	
CREATININE	55-115 (UMOL/L)	01/03/93	71.00		68.00		62.00	
URIC ACID	180-380 (UMOL/L)	01/03/93	209.00		205.00		141.00 <	
TOT BILIRUBIN	0-20 (UMOL/L)	01/03/93	8.00		10.00		9.00	
DIR BILIRUBIN	0-5 (UMOL/L)	01/03/93	3.00		3.00		3.00	
TOT. PROTEINS	63-80 (G/L)	01/03/93	65.00		71.00		73.00	
ALBUMINE	38-50 (G/L)	01/03/93	42.90		45.50		45.20	
TOT. CHOLEST.	0-5.2 (MMOL/L)	01/03/93	4.13		4.27		4.19	
TRIGLYCERIDES	0-1.6 (MMOL/L)	01/03/93	0.70		0.59		0.60	
GLOBULINS ALPHA 1	1-4 (G/L)	01/03/93	2.10		2.40		2.60	
GLOBULINS ALPHA 2	4-9 (G/L)	01/03/93	4.60		5.00		5.20	
GLOBULINS BETA	6-12 (G/L)	01/03/93	6.90		8.20		8.70	
GLOBULINS GAMMA	7-15 (G/L)	01/03/93	8.50		9.90		10.30	
TSH	0.3-5 (MU/ML)	01/03/93	1.72					
T4	9.2-22.7 (PMOL/L)	01/03/93	15.70					

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN950089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 16 Patient: 3MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	Day 28
			05/05/93	04/06/93
			value (φ)	value (φ)
Laboratory test	Range value	Range date		
HB	11.5-17 (G/DL)	03/01/93	13.10	13.40
HT	36-52 (X)	03/01/93	39.20	39.70
RBC	4.5-5.5 (10 ⁶ /MM ³)	03/01/93	4.07 <	4.18 <
MBC	4-10 (10 ³ /MM ³)	03/01/93	5.60	8.30
MBC: N	2-7.5 (10 ³ /MM ³)	03/01/93	3.08	6.06
MBC: L	1.5-4 (10 ³ /MM ³)	03/01/93	2.13	1.83
MBC: E	0.04-0.5 (10 ³ /MM ³)	03/01/93		0.11
MBC: M	0.2-1 (10 ³ /MM ³)	03/01/93	0.28	0.33
PLATELETS	200-400 (10 ³ /MM ³)	03/01/93	249.00	287.00
NA+	136-144 (MMOL/L)	03/01/93	143.00	141.00
K+	3.6-5 (MMOL/L)	03/01/93	4.60	5.30 >
CL-	95-105 (MMOL/L)	03/01/93	102.00	101.00
Ca++	2.1-2.6 (MMOL/L)	03/01/93	2.43	2.44
PO4--	0.8-1.4 (MMOL/L)	03/01/93	1.13	1.06
SGOT	5-25 (UI/L)	03/01/93	15.00	13.00
SGPT	5-25 (UI/L)	03/01/93	12.00	17.00
GAMMA GT	5-25 (UI/L)	03/01/93	49.00 >	55.00 >>
LDH	160-320 (UI/L)	03/01/93	250.00	250.00
ALK. PHOSPH.	35-85 (UI/L)	03/01/93	78.00	114.00 >
GLUCOSE	4.4-6.2 (MMOL/L)	03/01/93	5.20	5.00
UREA	3.3-8.3 (MMOL/L)	03/01/93	4.50	4.00
CREATININE	55-115 (UMOL/L)	03/01/93	67.00	66.00
URIC ACID	180-380 (UMOL/L)	03/01/93	214.00	160.00 <
TOT BILIRUBIN	0-20 (UMOL/L)	03/01/93	9.00	9.00
DIR BILIRUBIN	0-5 (UMOL/L)	03/01/93	3.00	3.00
TOT. PROTEINS	63-80 (G/L)	03/01/93	75.00	71.00
ALBUMINE	38-50 (G/L)	03/01/93	44.70	41.20
TOT. CHOLEST.	0-5.2 (MMOL/L)	03/01/93	5.69 >	5.79 >
TRIGLYCERIDES	0-1.6 (MMOL/L)	03/01/93	0.91	0.86
GLOBULINS ALPHA 1	1-4 (G/L)	03/01/93	3.60	3.10
GLOBULINS ALPHA 2	4-9 (G/L)	03/01/93	6.20	6.30
GLOBULINS BETA	6-12 (G/L)	03/01/93	10.80	10.30
GLOBULINS GAMMA	7-15 (G/L)	03/01/93	9.80	10.00
TSH	0.3-5 (UU/ML)	03/01/93	0.77	
T4	9.2-22.7 (PMOL/L)	03/01/93	11.70	

2158

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN9390089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 16 Patient: 4MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			18/04/94		16/05/94		14/06/94	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	11.5-17 (G/DL)	18/04/94	12.70					
	12-16 (G/DL)	16/05/94		14.00		13.70		
HT	36-52 (X)	18/04/94	38.00					
	37-47 (X)	16/05/94		41.00		41.00		
RBC	4.5-5.5 (10 ⁶ /MM ³)	18/04/94	4.12 <					
	4200000-5400000 (/MM ³)	16/05/94		4460000		4490000		
WBC	4-10 (10 ³ /MM ³)	18/04/94	6.80					
	4000-10000 (/MM ³)	16/05/94		6300.00		6100.00		
WBC: N	2-7.5 (10 ³ /MM ³)	18/04/94	4.42					
	45-74 (%)	16/05/94		57.00		65.00		
WBC: L	1.5-4 (10 ³ /MM ³)	18/04/94	1.84					
	16-45 (%)	16/05/94		31.00		25.00		
WBC: E	0.04-0.5 (10 ³ /MM ³)	18/04/94	0.07					
	0-7 (%)	16/05/94		1.00		2.00		
WBC: M	0.2-1 (10 ³ /MM ³)	18/04/94	0.41					
	4-10 (%)	16/05/94		10.00		8.00		
WBC: B	0.01-0.1 (10 ³ /MM ³)	18/04/94	0.07					
	0-2 (%)	16/05/94		1.00		0.00		
PLATELETS	200-400 (10 ³ /MM ³)	18/04/94	247.00					
	150000-400000 (/MM ³)	16/05/94		286000		251000		
NA+	136-144 (MMOL/L)	18/04/94	140.00					
	133-142 (MEQ/L)	16/05/94		136.00		135.00		
K+	3.6-5 (MMOL/L)	18/04/94	3.40 <					
	3.5-4.5 (MEQ/L)	16/05/94		3.90		3.60		
CL-	95-105 (MEQ/L)	18/04/94	101.00					
	95-110 (MEQ/L)	16/05/94		104.00		103.00		
Ca++	2.1-2.6 (MMOL/L)	18/04/94	2.32					
	88-102 (MG/L)	16/05/94		85.00 <		84.00 <		
PO4--	0.8-1.4 (MMOL/L)	18/04/94	0.82					
	27-48 (MG/L)	16/05/94		34.00		25.00 <		
SGOT	5-25 (U/L)	18/04/94	7.00					
	5-25 (UI/L)	16/05/94		12.00		12.00		
SGPT	5-35 (U/L)	18/04/94	5.00					
	5-27 (UI/L)	16/05/94		8.00		9.00		
GAMMA GT	5-25 (U/L)	18/04/94	12.00					
	5-22 (UI/L)	16/05/94		16.00		9.00		
LDH	160-320 (U/L)	18/04/94	222.00					
	140-280 (UI/L)	16/05/94		144.00		250.00		
ALK. PHOSPH.	35-85 (U/L)	18/04/94	115.00 >					
	30-100 (UI/L)	16/05/94		117.00 >		57.00		
GLUCOSE	4.4-6.2 (MMOL/L)	18/04/94	4.40					
	0.7-1.1 (G/L)	16/05/94		0.92		0.90		
UREA	3.3-8.3 (MMOL/L)	18/04/94	4.60					
	0.15-0.45 (G/L)	16/05/94		0.19		0.23		
CREATININE	55-115 (UMOL/L)	18/04/94	69.00					
	5-13 (MG/L)	16/05/94		7.10		6.20		
URIC ACID	180-380 (UMOL/L)	18/04/94	167.00 <					
	25-60 (MG/L)	16/05/94		34.00		25.00		
TOT BILIRUBIN	0-20 (UMOL/L)	18/04/94	9.00					
	0-10 (MG/L)	16/05/94		4.00		3.30		
DIR BILIRUBIN	0-5 (UMOL/L)	18/04/94	3.00					
TOT. PROTEINS	63-80 (G/L)	18/04/94	64.00					
	65-80 (G/L)	16/05/94		65.00		58.00 <		
ALBUMINE	38-50 (G/L)	18/04/94	34.50 <					
	52-62 (%)	16/05/94		59.00		68.90 >		
TOT. CHOLEST.	0-5.2 (MMOL/L)	18/04/94	5.81 >					
	1.5-2.7 (G/L)	16/05/94		2.30		2.05		
TRIGLYCERIDES	0-1.6 (MMOL/L)	18/04/94	0.93					

2159

(CONTINUED)

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS 0089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 16 Patient: 4MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			18/04/94		16/05/94		14/06/94	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
TRIGLYCERIDES	0.5-1.5 (G/L)	16/05/94						
GLOBULINS ALPHA 1	1-4 (G/L)	18/04/94	3.10		1.03		1.04	
	1.5-4.5 (X)	16/05/94			1.40	<	0.90 <<	
GLOBULINS ALPHA 2	4-9 (G/L)	18/04/94	6.00		10.40		8.00	
	6-12 (X)	16/05/94			11.80		9.60 <	
GLOBULINS BETA	6-12 (G/L)	18/04/94	9.10		11.80		9.60 <	
	11-17 (X)	16/05/94			17.40		12.60	
GLOBULINS GAMMA	7-15 (G/L)	18/04/94	11.30					
	11-19 (X)	16/05/94						
TSH	0.3-5 (UU/ML)	18/04/94	0.84					
T4	9.2-22.7 (PMOL/L)	18/04/94	16.20					

2160

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA 09550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 16 Patient: 1DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	Day 14
			12/02/93	26/02/93
			value (φ)	value (φ)
Laboratory test	Range value	Range date		
HB	11.5-17 (G/DL)	03/01/93	12.10	12.20
HT	36-52 (%)	03/01/93	35.40 <	35.60 <
RBC	4.5-5.5 (10 ⁶ /MM3)	03/01/93	3.64 <<	3.68 <<
MBC	4-10 (10 ³ /MM3)	03/01/93	4.10	4.70
MBC: N	2-7.5 (10 ³ /MM3)	03/01/93	1.89 <	2.26
MBC: L	1.5-4 (10 ³ /MM3)	03/01/93	1.80	1.97
MBC: E	0.04-0.5 (10 ³ /MM3)	03/01/93	0.12	0.14
MBC: M	0.2-1 (10 ³ /MM3)	03/01/93	0.29	0.28
MBC: B	0.01-0.1 (10 ³ /MM3)	03/01/93		0.05
PLATELETS	200-400 (10 ³ /MM3)	03/01/93	281.00	316.00
NA+	136-144 (MMOL/L)	03/01/93	140.00	140.00
K+	3.6-5 (MMOL/L)	03/01/93	4.30	4.50
CL-	95-105 (MMOL/L)	03/01/93	100.00	100.00
Ca++	2.1-2.6 (MMOL/L)	03/01/93	2.37	2.36
PO4--	0.8-1.4 (MMOL/L)	03/01/93	1.40	1.23
SGOT	5-25 (UI/L)	03/01/93	10.00	10.00
SGPT	5-35 (UI/L)	03/01/93	8.00	10.00
GAMMA GT	5-25 (UI/L)	03/01/93	11.00	10.00
LDH	160-320 (UI/L)	03/01/93	212.00	
ALK. PHOSPH.	35-85 (UI/L)	03/01/93	37.00	41.00
GLUCOSE	4.4-6.2 (MMOL/L)	03/01/93	4.80	4.40
UREA	3.3-8.3 (MMOL/L)	03/01/93	4.40	4.40
CREATININE	55-115 (UMOL/L)	03/01/93	68.00	68.00
URIC ACID	180-380 (UMOL/L)	03/01/93	255.00	215.00
TOT BILIRUBIN	0-20 (UMOL/L)	03/01/93	5.00	6.00
DIR BILIRUBIN	0-5 (UMOL/L)	03/01/93	2.00	2.00
TOT. PROTEINS	63-80 (G/L)	03/01/93	61.00 <	60.00 <
ALBUMINE	38-50 (G/L)	03/01/93	33.80 <	32.20 <
TOT. CHOLEST.	0-5.2 (MMOL/L)	03/01/93	6.14 >	6.08 >
TRIGLYCERIDES	0-1.6 (MMOL/L)	03/01/93	0.64	0.68
GLOBULINS ALPHA 1	1-4 (G/L)	03/01/93	2.90	2.60
GLOBULINS ALPHA 2	4-9 (G/L)	03/01/93	6.20	6.80
GLOBULINS BETA	6-12 (G/L)	03/01/93	8.40	9.20
GLOBULINS GAMMA	7-15 (G/L)	03/01/93	9.70	9.20
TSH	0.3-5 (UU/ML)	03/01/93	1.33	
T4	9.2-22.7 (PMOL/L)	03/01/93	12.60	

2161

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA 09536089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 16 Patient: ZDT Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			29/04/93		01/06/93		28/06/93	
			value	(⊕)	value	(⊕)	value	(⊕)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	02/03/93	14.40		14.00	14.20		
	11.5-17 (G/DL)	31/05/93						
HT	38-52 (%)	02/03/93	43.60		40.80	42.30		
	36-52 (%)	31/05/93						
RBC	4.2-5.7 (10 ⁶ /MM ³)	02/03/93	4.60		4.37	4.40		
	4-5.8 (10 ⁶ /MM ³)	31/05/93			6.50	6.60		
HBC	4-10 (10 ³ /MM ³)	02/03/93	5.40		6.50	6.60		
HBC: N	2-7.5 (10 ³ /MM ³)	31/05/93			3.58	3.50		
HBC: L	1.5-4 (10 ³ /MM ³)	31/05/93			2.41	2.64		
HBC: E	0.04-0.5 (10 ³ /MM ³)	31/05/93			0.13	0.13		
HBC: H	0.2-1 (10 ³ /MM ³)	31/05/93			0.33	0.33		
HBC: B	0.01-0.1 (10 ³ /MM ³)	31/05/93			0.07			
PLATELETS	150000-400000 (/MM ³)	02/03/93	177000					
	200-400 (10 ³ /MM ³)	31/05/93			208.00	224.00		
NA+	136-144 (MMOL/L)	02/03/93	137.00		142.00	139.00		
K+	3.6-5 (MMOL/L)	02/03/93	4.50		4.80	4.40		
CL-	95-105 (MMOL/L)	02/03/93	96.00		101.00	101.00		
Ca++	2.1-2.6 (MMOL/L)	02/03/93	2.50		2.42	2.33		
PO4--	0.8-1.4 (MMOL/L)	02/03/93	0.61	<<	1.21	0.84		
SGOT	5-25 (UI/L)	02/03/93	10.00		30.00	48.00	>	
SGPT	5-35 (UI/L)	02/03/93	14.00		71.00	75.00	>>	
GAMMA GT	5-25 (UI/L)	02/03/93	16.00		30.00	26.00	>	
LDH	160-320 (UI/L)	02/03/93	249.00		256.00	327.00	>	
ALK. PHOSPH.	35-85 (UI/L)	02/03/93	59.00		65.00	74.00		
GLUCOSE	4.4-6.2 (MMOL/L)	02/03/93	5.50		5.30	6.10		
UREA	3.6-8.2 (MMOL/L)	02/03/93	4.20		4.40	6.20		
CREATININE	55-115 (UMOL/L)	02/03/93	75.00		71.00	84.00		
URIC ACID	180-380 (UMOL/L)	02/03/93	272.00			397.00	>	
TOT BILIRUBIN	0-20 (UMOL/L)	02/03/93	12.00		9.00	11.00		
DIR BILIRUBIN	0-5 (UMOL/L)	02/03/93	3.00		3.00	3.00		
TOT. PROTEINS	63-80 (G/L)	02/03/93	77.00		72.00	74.00		
ALBUMINE	38-50 (G/L)	02/03/93	47.90		44.20	45.90		
TOT. CHOLEST.	0-5.2 (MMOL/L)	02/03/93	5.07			5.17		
TRIGLYCERIDES	0-1.6 (MMOL/L)	02/03/93	0.61		1.09	0.78		
GLOBULINS ALPHA 1	1-4 (G/L)	02/03/93	2.20		2.20	2.50		
GLOBULINS ALPHA 2	4-9 (G/L)	02/03/93	5.00		4.80	5.10		
GLOBULINS BETA	6-12 (G/L)	02/03/93	8.00		8.30	7.50		
GLOBULINS GAMMA	7-15 (G/L)	02/03/93	14.00		12.60	13.00		
TSH	0.3-5 (UU/ML)	02/03/93	1.08					
T4	9.2-22.7 (PMOL/L)	02/03/93	15.50					

2162

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 09569089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 16 Patient: 3DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 14	
			22/07/93		11/08/93	
			value	(φ)	value	(φ)
Laboratory test	Range value	Range date				
HB	11.5-17 (G/DL)	03/01/93	13.40		13.70	
HT	36-52 (Z)	03/01/93	39.50		39.90	
RBC	4.5-5.5 (10 ⁶ /MM ³)	03/01/93	4.40	<	4.49	
WBC	4-10 (10 ³ /MM ³)	03/01/93	4.90		6.80	
WBC: N	2-7.5 (10 ³ /MM ³)	03/01/93	2.84		3.54	
WBC: L	1.5-4 (10 ³ /MM ³)	03/01/93	1.57		2.58	
WBC: E	0.04-0.5 (10 ³ /MM ³)	03/01/93	0.05		0.07	
WBC: M	0.2-1 (10 ³ /MM ³)	03/01/93	0.39		0.54	
WBC: B	0.01-0.1 (10 ³ /MM ³)	03/01/93	0.05		0.07	
PLATELETS	200-400 (10 ³ /MM ³)	03/01/93	235.00		315.00	
NA+	136-144 (MMOL/L)	03/01/93	136.00		133.00	
K+	3.6-5 (MMOL/L)	03/01/93	3.50	<	3.30	
CL-	95-105 (MMOL/L)	03/01/93	93.00	<	83.00	
Ca++	2.1-2.6 (MMOL/L)	03/01/93	2.38		2.31	
PO4--	0.8-1.4 (MMOL/L)	03/01/93			1.14	
SGOT	5-25 (UI/L)	03/01/93	12.00		9.00	
SGPT	5-35 (UI/L)	03/01/93	10.00		13.00	
GAMMA GT	5-25 (UI/L)	03/01/93	17.00		18.00	
LDH	160-320 (UI/L)	03/01/93	208.00		206.00	
ALK. PHOSPH.	35-85 (UI/L)	03/01/93	64.00		61.00	
GLUCOSE	4.4-6.2 (MMOL/L)	03/01/93	5.20		7.30	
UREA	3.3-8.3 (MMOL/L)	03/01/93	3.40		6.90	
CREATININE	55-115 (UMOL/L)	03/01/93	70.00		82.00	
URIC ACID	180-380 (UMOL/L)	03/01/93	319.00		334.00	
TOT BILIRUBIN	0-20 (UMOL/L)	03/01/93	11.00		9.00	
DIR BILIRUBIN	0-5 (UMOL/L)	03/01/93	2.00		3.00	
TOT. PROTEINS	63-80 (G/L)	03/01/93	63.00		62.00	
ALBUMINE	38-50 (G/L)	03/01/93	39.20		39.20	
TOT. CHOLEST.	0-5.2 (MMOL/L)	03/01/93	6.27	>	4.84	
TRIGLYCERIDES	0-1.6 (MMOL/L)	03/01/93	0.42			
GLOBULINS ALPHA 1	1-4 (G/L)	03/01/93	2.40		2.20	
GLOBULINS ALPHA 2	4-9 (G/L)	03/01/93	5.10		5.80	
GLOBULINS BETA	6-12 (G/L)	03/01/93	8.60		7.30	
GLOBULINS GAMMA	7-15 (G/L)	03/01/93	7.60		7.40	
TSH	0.3-5 (UU/ML)	03/01/93	0.46			
T4	9.2-22.7 (PMOL/L)	03/01/93	15.90			

2163

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARNACIA 09554089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 17 Patient: IND Treatment: Roboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			23/03/93		28/04/93		25/05/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	7.5-10 (MMOL/L)	01/03/93	8.60		9.50			
HT	0.4-0.52 (L/L)	01/03/93	0.41		0.45			
RBC	4-5.5 (10 ⁶ /MM ³)	01/03/93	4.41		4.79			
HBC	4-10 (10 ³ /MM ³)	01/03/93	7.70		6.80			
HBC: N	2.5-7 (10 ³ /MM ³)	01/03/93	5.39		4.76			
HBC: L	1.25-4 (10 ³ /MM ³)	01/03/93	1.69		1.50			
HBC: M	0.2-0.8 (10 ³ /MM ³)	01/03/93	0.62		0.54			
PLATELETS	150-450 (10 ³ /MM ³)	01/03/93	248.00		273.00			
NA+	135-145 (MMOL/L)	01/03/93	137.00		136.00		139.00	
K+	3.6-4.8 (MMOL/L)	01/03/93	4.50		3.80		4.50	
CL-	96-106 (MMOL/L)	01/03/93	98.00		96.00		97.00	
Ca++	2.2-2.6 (MMOL/L)	01/03/93	2.30		2.32		2.47	
PO4--	0.87-1.5 (MMOL/L)	01/03/93	1.01		1.10			
SGOT	3-26 (UI/L)	01/03/93	21.00		19.00		15.00	
SGPT	3-29 (UI/L)	01/03/93	13.00		22.00		12.00	
GAMMA GT	5-25 (UI/L)	01/03/93	11.00		15.00		12.00	
LDH	160-320 (UI/L)	01/03/93	261.00					
ALK. PHOSPH.	73-207 (UI/L)	01/03/93	137.00		120.00		128.00	
GLUCOSE	4-6 (MMOL/L)	01/03/93	5.90		5.60		5.10	
UREA	2.5-7 (MMOL/L)	01/03/93	7.90	>	5.60		11.90	>>
CREATININE	50-100 (UMOL/L)	01/03/93	61.00		85.00		71.00	>>
CREATININE CLEARANCE	()	01/03/93						
URIC ACID	150-420 (MMOL/L)	01/03/93	53.50	()				
TOT. BILIRUBIN	2-18 (UMOL/L)	01/03/93	193.00		231.00		200.00	
TOT. PROTEINS	65-75 (G/L)	01/03/93	3.00		11.00		4.00	
ALBUMINE	32-47 (G/L)	01/03/93	68.00		67.00		70.00	
TOT. CHOLEST.	3-6 (MMOL/L)	01/03/93	44.60	>	47.30	>	49.60	>
TRIGLYCERIDES	0.5-1.5 (MMOL/L)	01/03/93	6.10	>	6.10	>	6.90	>
GLOBULINS ALPHA 1	1-3 (G/L)	01/03/93	1.41		1.40		1.17	
GLOBULINS ALPHA 2	4-7 (G/L)	01/03/93	2.60		2.20		2.50	
GLOBULINS BETA	4-7 (G/L)	01/03/93	4.80		4.50		4.50	
GLOBULINS GAMMA	5-8 (G/L)	01/03/93	6.60		6.20		6.40	
TSH	8-12 (G/L)	01/03/93	7.50	<	6.80	<	7.00	<
T4	0.1-4.5 (MUI/L)	01/03/93	2.74				2.16	
T4	10-26 (PMOL/L)	01/03/93	19.90				15.90	

2164

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 0554089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 17 Patient: 2ND Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			13/04/93		18/05/93		16/06/93	
			value	(⊕)	value	(⊕)	value	(⊕)
Laboratory test	Range value	Range date						
HB	7.5-10 (MMOL/L)	01/03/93	8.30		8.30			
HT	0.4-0.52 (L/L)	01/03/93	0.40		0.40			
RBC	4-5.5 (10 ⁶ /MM3)	01/03/93	4.39		3.99 <			
WBC	4-10 (10 ³ /MM3)	01/03/93	8.50		6.50			
WBC: N	2.5-7 (10 ³ /MM3)	01/03/93	6.55		4.23			
WBC: L	1.25-4 (10 ³ /MM3)	01/03/93	1.79		1.76			
WBC: E	0.1-0.4 (10 ³ /MM3)	01/03/93	0.00 <		0.00 <			
WBC: M	0.2-0.8 (10 ³ /MM3)	01/03/93	0.17 <		0.52			
WBC: B	0-0.2 (10 ³ /MM3)	01/03/93	0.00		0.00			
PLATELETS	150-450 (10 ³ /MM3)	01/03/93	424.00		416.00			
NA+	135-145 (MMOL/L)	01/03/93	140.00		140.00	140.00		
K+	3.6-4.8 (MMOL/L)	01/03/93	4.20		4.50	4.50		
CL-	96-106 (MMOL/L)	01/03/93	102.00		104.00	100.00		
Ca++	2.2-2.6 (MMOL/L)	01/03/93	2.37		2.12 <	2.21		
PO4--	0.87-1.5 (MMOL/L)	01/03/93	1.18		1.12	1.12		
SGOT	3-26 (UI/L)	01/03/93	19.00		13.00	14.00		
SGPT	3-29 (UI/L)	01/03/93	10.00		6.00	13.00		
GAMMA GT	5-25 (UI/L)	01/03/93	19.00		18.00	42.00 >		
LDH	160-320 (UI/L)	01/03/93	242.00		206.00	215.00		
ALK. PHOSPH.	78-207 (UI/L)	01/03/93	146.00		132.00	182.00		
GLUCOSE	4-6 (MMOL/L)	01/03/93	6.10 >		4.20	4.40		
UREA	2.5-7 (MMOL/L)	01/03/93	4.60		6.70	5.30		
CREATININE	50-100 (UMOL/L)	01/03/93	77.00		68.00	73.00		
CREATININE CLEARANCE	()	01/03/93	39.90 ()					
URIC ACID	150-420 (MMOL/L)	01/03/93	275.00		212.00	207.00		
TOT BILIRUBIN	2-18 (UMOL/L)	01/03/93	8.00		6.00	5.00		
DIR BILIRUBIN	0-7 (UMOL/L)	01/03/93	0.00		0.00			
TOT. PROTEINS	65-75 (G/L)	01/03/93	71.00		65.00	69.00		
ALBUMINE	32-47 (G/L)	01/03/93	43.00		37.70	37.70		
TOT. CHOLEST.	3-6 (MMOL/L)	01/03/93	5.60		5.60	6.00		
TRIGLYCERIDES	0.5-1.5 (MMOL/L)	01/03/93	1.18		1.03	1.12		
GLOBULINS ALPHA 1	1-3 (G/L)	01/03/93	2.70		2.30	3.50 >		
GLOBULINS ALPHA 2	4-7 (G/L)	01/03/93	6.00		6.40	7.70 >		
GLOBULINS BETA	5-8 (G/L)	01/03/93	8.00		7.30	8.40 >		
GLOBULINS GAMMA	8-12 (G/L)	01/03/93	11.20		11.30	11.60		
TSH	0.1-4.5 (MUI/L)	01/03/93	0.76		0.96			
T4	10-26 (PMOL/L)	01/03/93	24.50		22.20			

2165

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 9530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 17 Patient: 3MD Treatment: Imipranine Sex: Female

			Visit number / Laboratory date
			Screen
			04/11/93
			value (⊕)
Laboratory test	Range value	Range date	
HB	7.5-10 (MMOL/L)	01/03/93	7.60
HT	0.4-0.52 (L/L)	01/03/93	0.36 <
RBC	4-5.5 (10 ⁶ /MM3)	01/03/93	4.03
WBC	4-10 (10 ³ /MM3)	01/03/93	5.10
WBC: N	2.5-7 (10 ³ /MM3)	01/03/93	4.03
WBC: L	1.25-4 (10 ³ /MM3)	01/03/93	0.82 <<
WBC: E	0.1-0.4 (10 ³ /MM3)	01/03/93	0.00 <
WBC: M	0.2-0.8 (10 ³ /MM3)	01/03/93	0.26
WBC: B	0-0.2 (10 ³ /MM3)	01/03/93	0.00
PLATELETS	150-450 (10 ³ /MM3)	01/03/93	268.00
NA+	135-145 (MMOL/L)	01/03/93	137.00
K+	3.6-4.8 (MMOL/L)	01/03/93	4.40
CL-	96-106 (MMOL/L)	01/03/93	97.00
Ca++	2.2-2.6 (MMOL/L)	01/03/93	2.09 <
PO4--	0.87-1.5 (MMOL/L)	01/03/93	0.99
SGOT	3-26 (UI/L)	01/03/93	15.00
SGPT	3-29 (UI/L)	01/03/93	12.00
GAMMA GT	5-25 (UI/L)	01/03/93	9.00
LDH	160-320 (UI/L)	01/03/93	248.00
ALK. PHOSPH.	75-207 (UI/L)	01/03/93	98.00
GLUCOSE	4-6 (MMOL/L)	01/03/93	4.60
UREA	2.5-7 (MMOL/L)	01/03/93	10.00 >
CREATININE	50-100 (UMOL/L)	01/03/93	59.00
CREATININE	()	01/03/93	
CLEARANCE			52.15 ()
URIC ACID	150-420 (MMOL/L)	01/03/93	148.00 <
TOT BILIRUBIN	2-18 (UMOL/L)	01/03/93	5.00
TOT. PROTEINS	65-75 (G/L)	01/03/93	56.00 <
ALBUMINE	32-47 (G/L)	01/03/93	36.10
TOT. CHOLEST.	3-6 (MMOL/L)	01/03/93	6.00
TRIGLYCERIDES	0.5-1.5 (MMOL/L)	01/03/93	1.10
GLOBULINS ALPHA 1	1-3 (G/L)	01/03/93	2.00
GLOBULINS ALPHA 2	4-7 (G/L)	01/03/93	4.90
GLOBULINS BETA	5-8 (G/L)	01/03/93	5.90
GLOBULINS GAMMA	8-12 (G/L)	01/03/93	7.20 <
TSH	0.1-4.5 (MUI/L)	01/03/93	0.43
T4	10-26 (PMOL/L)	01/03/93	18.60

2166

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 0550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 17 Patient: 4MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			06/01/94		08/02/94		08/03/94	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	7.5-10 (MMOL/L)	01/03/93	8.20		8.40		8.60	
HT	0.4-0.52 (L/L)	01/03/93	0.40		0.39 <		0.41	
RBC	4-5.5 (10 ⁶ /MM ³)	01/03/93	4.67		4.60		4.78	
WBC	4-10 (10 ³ /MM ³)	01/03/93	6.30		5.70		8.10	
WBC: N	2.5-7 (10 ³ /MM ³)	01/03/93	4.60		3.76		5.67	
WBC: L	1.25-4 (10 ³ /MM ³)	01/03/93	1.32		1.60		2.11	
WBC: E	0.1-0.4 (10 ³ /MM ³)	01/03/93	0.00 <					
WBC: M	0.2-0.8 (10 ³ /MM ³)	01/03/93	0.38		0.34		0.32	
WBC: B	0-0.2 (10 ³ /MM ³)	01/03/93	0.00					
PLATELETS	150-450 (10 ³ /MM ³)	01/03/93	215.00		253.00		264.00	
NA+	135-145 (MMOL/L)	01/03/93	140.00		140.00		135.00	
K+	3.6-4.8 (MMOL/L)	01/03/93	4.70		4.10		4.30	
CL-	96-106 (MMOL/L)	01/03/93	102.00		103.00		97.00	
Ca ⁺⁺	2.2-2.6 (MMOL/L)	01/03/93	2.13 <		2.27		2.28	
PO ₄ ⁻⁻	0.87-1.5 (MMOL/L)	01/03/93	1.14		1.06		1.29	
SGOT	3-26 (UI/L)	01/03/93	22.00		9.00		12.00	
SGPT	3-29 (UI/L)	01/03/93	8.00		13.00		20.00	
GAMMA GT	5-25 (UI/L)	01/03/93	9.00		9.00		14.00	
LDH	160-320 (UI/L)	01/03/93	169.00				229.00	
ALK. PHOSPH.	73-207 (UI/L)	01/03/93	67.00 <		65.00 <		81.00	
GLUCOSE	4-6 (MMOL/L)	01/03/93	3.90 <		4.70		5.20	
UREA	2.5-7 (MMOL/L)	01/03/93	3.50		3.10		3.00	
CREATININE	50-100 (UMOL/L)	01/03/93	73.00		67.00		73.00	
CREATININE CLEARANCE	()	01/03/93	53.15 ()					
URIC ACID	150-420 (MMOL/L)	01/03/93			137.00 <		173.00	
TOT BILIRUBIN	2-18 (UMOL/L)	01/03/93	5.00		5.00		2.00	
DIR BILIRUBIN	0-7 (UMOL/L)	01/03/93	0.00					
TOT. PROTEINS	65-75 (G/L)	01/03/93	57.00 <		60.00 <		60.00 <	
ALBUMINE	32-47 (G/L)	01/03/93	41.40		40.60		39.80	
TOT. CHOLEST.	3-6 (MMOL/L)	01/03/93	5.00		5.00		5.00	
TRIGLYCERIDES	0.5-1.5 (MMOL/L)	01/03/93	1.22		0.85		1.27	
GLOBULINS ALPHA 1	1-3 (G/L)	01/03/93	4.10 >>		2.60		2.60	
GLOBULINS ALPHA 2	4-7 (G/L)	01/03/93	5.00		4.20		4.50	
GLOBULINS BETA	5-8 (G/L)	01/03/93	6.40		5.30		5.40	
GLOBULINS GAMMA	8-12 (G/L)	01/03/93	6.10 <		7.40 <		7.70 <	
TSH	0.1-4.5 (MUI/L)	01/03/93	1.45					
T4	10-26 (PMOL/L)	01/03/93	14.20					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/03/93					2.00	

2167

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C8560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 17 Patient: 211MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			10/05/94		14/06/94		19/07/94	
			value	(†)	value	(†)	value	(†)
Laboratory test	Range value	Range date						
HB	7.5-10 (MMOL/L)	10/05/94	7.40	<	7.90		7.90	
HT	0.4-0.52 (L/L)	10/05/94	0.36	<	0.39	<	0.38	
RBC	4-5.5 (10 ⁶ /MM ³)	10/05/94	3.99	<	4.32		4.32	
WBC	4-10 (10 ³ /MM ³)	10/05/94	4.90		8.20		8.00	
WBC: N	2.5-7 (10 ³ /MM ³)	10/05/94	2.84		5.82		5.44	
WBC: L	1.25-4 (10 ³ /MM ³)	10/05/94	1.67		1.80		1.92	
WBC: E	0.1-0.4 (10 ³ /MM ³)	10/05/94	0.00	<	0.00	<	0.00	
WBC: M	0.2-0.8 (10 ³ /MM ³)	10/05/94	0.39		0.57		0.64	
WBC: B	0-0.2 (10 ³ /MM ³)	10/05/94	0.00		0.00		0.00	
PLATELETS	150-450 (10 ³ /MM ³)	10/05/94	265.00		496.00	>	403.00	
NA+	135-145 (MMOL/L)	10/05/94	139.00		138.00		139.00	
K+	3.6-4.8 (MMOL/L)	10/05/94	4.80		4.70		3.80	
CL-	96-106 (MMOL/L)	10/05/94	105.00		98.00		97.00	
Ca++	2.2-2.6 (MMOL/L)	10/05/94	2.22		2.40		2.22	
PO4--	0.87-1.5 (MMOL/L)	14/06/94			1.11		1.14	
SGOT	3-26 (UI/L)	10/05/94	13.00		17.00		13.00	
SGPT	3-29 (UI/L)	10/05/94	8.00		13.00		9.00	
GAMMA GT	5-26 (UI/L)	10/05/94	10.00		28.00	>	17.00	
LDH	160-320 (UI/L)	10/05/94	167.00		223.00		256.00	
ALK. PHOSPH.	73-207 (UI/L)	10/05/94	129.00		218.00	>	192.00	
GLUCOSE	4-6 (MMOL/L)	10/05/94	4.40		5.30		5.60	
BUN	()	14/06/94					10.20 ()	
UREA	2.5-7 (MMOL/L)	10/05/94	7.70	>	11.20	>>		
CREATININE	50-100 (UMOL/L)	10/05/94	106.00	>	109.00	>	120.00	
CREATININE CLEARANCE	()	10/05/94						
URIC ACID	150-420 (MMOL/L)	10/05/94	35.50 ()				506.00	
TOT BILIRUBIN	2-18 (UMOL/L)	10/05/94	384.00		2.00		5.00	
TOT. PROTEINS	65-75 (G/L)	10/05/94	8.00		74.00		75.00	
ALBUMINE	52-62 (G/L)	10/05/94	73.00					
TOT. CHOLEST.	32-47 (G/L)	14/06/94	47.60	<				
TRIGLYCERIDES	3-6 (MMOL/L)	10/05/94			42.30		44.30	
GLOBULINS ALPHA 1	0.5-1.5 (MMOL/L)	10/05/94	5.50		7.00	>	6.90	
GLOBULINS ALPHA 2	1-3 (G/L)	14/06/94	1.41		1.63	>	1.35	
GLOBULINS BETA	1.5-4.5 (G/L)	10/05/94	2.50					
GLOBULINS GAMMA	1-3 (G/L)	14/06/94			2.20		2.30	
TSH	6-12 (G/L)	10/05/94	14.20	>				
T4	4-7 (G/L)	14/06/94			6.90		5.60	
	11-17 (G/L)	10/05/94	16.50					
	5-8 (G/L)	14/06/94			10.20	>	10.10	
	11-19 (G/L)	10/05/94	19.20	>				
	8-12 (G/L)	14/06/94			12.40	>	12.80	
	0.1-4.5 (NUI/L)	10/05/94	1.41					
	10-26 (PMOL/L)	10/05/94	18.10					

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA 9550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 17 Patient: 1DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			18/04/93		21/05/93	
			value	(ϕ)	value	(ϕ)
Laboratory test	Range value	Range date				
HB	7.5-10 (MMOL/L)	01/03/93	8.00		7.50	
HT	0.4-0.52 (L/L)	01/03/93	0.38	<	0.36	
RBC	4-5.5 (10 ⁶ /MM3)	01/03/93	4.37		4.17	
WBC	4-10 (10 ³ /MM3)	01/03/93	5.80		6.10	
WBC: N	2.5-7 (10 ³ /MM3)	01/03/93	4.12		4.21	
WBC: L	1.25-4 (10 ³ /MM3)	01/03/93	1.45		1.53	
WBC: E	0.1-0.4 (10 ³ /MM3)	01/03/93	0.00	<	0.00	
WBC: M	0.2-0.8 (10 ³ /MM3)	01/03/93	0.23		0.37	
WBC: B	0-0.2 (10 ³ /MM3)	01/03/93	0.00		0.00	
PLATELETS	150-450 (10 ³ /MM3)	01/03/93	266.00		250.00	
NA+	135-145 (MMOL/L)	01/03/93	138.00		137.00	
K+	3.6-4.8 (MMOL/L)	01/03/93	4.00		4.10	
CL-	96-106 (MMOL/L)	01/03/93	102.00		103.00	
Ca ⁺⁺	2.2-2.6 (MMOL/L)	01/03/93	2.13	<	1.99	
PO ₄ ⁻⁻	0.87-1.5 (MMOL/L)	01/03/93	0.94		1.11	
SGOT	3-26 (UI/L)	01/03/93	16.00		12.00	
SGPT	3-29 (UI/L)	01/03/93	20.00		11.00	
GAMMA GT	5-25 (UI/L)	01/03/93	10.00		12.00	
LDH	160-320 (UI/L)	01/03/93	232.00		185.00	
ALK. PHOSPH.	73-207 (UI/L)	01/03/93	114.00		103.00	
GLUCOSE	4-6 (MMOL/L)	01/03/93	5.50		5.10	
UREA	2.5-7 (MMOL/L)	01/03/93	5.20		5.60	
CREATININE	50-100 (UMOL/L)	01/03/93	77.00		69.00	
CREATININE	()	01/03/93				
CLEARANCE			42.83	()		
URIC ACID	150-420 (MMOL/L)	01/03/93	177.00		144.00	
TOT BILIRUBIN	2-18 (UMOL/L)	01/03/93	8.00		4.00	
DIR BILIRUBIN	0-7 (UMOL/L)	01/03/93	0.00			
TOT. PROTEINS	65-75 (G/L)	01/03/93	70.00		63.00	
ALBUMINE	32-47 (G/L)	01/03/93	42.00		40.20	
TOT. CHOLEST.	3-6 (MMOL/L)	01/03/93	7.60	>	4.21	
TRIGLYCERIDES	0.5-1.5 (MMOL/L)	01/03/93	1.13		1.05	
GLOBULINS ALPHA 1	1-3 (G/L)	01/03/93	2.20		2.20	
GLOBULINS ALPHA 2	4-7 (G/L)	01/03/93	4.70		4.70	
GLOBULINS BETA	5-8 (G/L)	01/03/93	7.20		7.10	
GLOBULINS GAMMA	8-12 (G/L)	01/03/93	10.50		8.80	
TSH	0.1-4.5 (MUI/L)	01/03/93	1.97			
T ₄	10-26 (PMOL/L)	01/03/93	15.20			

2169

(ϕ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA 0530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 17 Patient: ZDT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			07/06/93		04/08/93		31/08/93	
			value	(ø)	value	(ø)	value	(ø)
Laboratory test	Range value	Range date						
HB	7.5-10 (MMOL/L)	01/03/93	9.10		9.20		9.00	
HT	0.4-0.52 (L/L)	01/03/93	0.42		0.43		0.43	
RBC	4-5.5 (10 ⁶ /MM ³)	01/03/93	4.50		4.59		4.53	
WBC	4-10 (10 ³ /MM ³)	01/03/93	4.90		5.50		6.10	
WBC: N	2.5-7 (10 ³ /MM ³)	01/03/93	3.72		3.47			
WBC: L	1.25-4 (10 ³ /MM ³)	01/03/93	0.98 <		1.91			
WBC: E	0.1-0.4 (10 ³ /MM ³)	01/03/93	0.00 <		0.00 <			
WBC: M	0.2-0.8 (10 ³ /MM ³)	01/03/93	0.20		0.33			
WBC: B	0-0.2 (10 ³ /MM ³)	01/03/93	0.00		0.00			
PLATELETS	150-450 (10 ³ /MM ³)	01/03/93	160.00		201.00		219.00	
NA+	135-145 (MMOL/L)	01/03/93	144.00		143.00		142.00	
K+	3.6-4.8 (MMOL/L)	01/03/93	3.60		4.70		4.40	
CL-	96-106 (MMOL/L)	01/03/93	103.00		100.00		97.00	
Ca++	2.2-2.6 (MMOL/L)	01/03/93	2.17 <		2.27		2.21	
PO4--	0.87-1.5 (MMOL/L)	01/03/93	0.94		1.24		1.92 >>	
SGOT	3-26 (UI/L)	01/03/93	20.00		20.00		21.00	
SGPT	3-29 (UI/L)	01/03/93	26.00		31.00 >		32.00 >	
GAMMA GT	5-25 (UI/L)	01/03/93	9.00		10.00		8.00	
LDH	160-320 (UI/L)	01/03/93			200.00		205.00	
ALK. PHOSPH.	73-207 (UI/L)	01/03/93	118.00		128.00		128.00	
GLUCOSE	4-6 (MMOL/L)	01/03/93	7.30 >		5.30		5.60	
UREA	2.5-7 (MMOL/L)	01/03/93	4.00		4.30		5.00	
CREATININE	50-100 (UMOL/L)	01/03/93	53.00		58.00		45.00 <	
CREATININE CLEARANCE	()	01/03/93	72.83 ()					
URIC ACID	150-420 (MMOL/L)	01/03/93	183.00		134.00 <		166.00	
TOT BILIRUBIN	2-18 (UMOL/L)	01/03/93	13.00		18.00		17.00	
DIR BILIRUBIN	0-7 (UMOL/L)	01/03/93	0.00		0.00		0.00	
TOT. PROTEINS	65-75 (G/L)	01/03/93	75.00		83.00 >		79.00 >	
ALBUMINE	32-47 (G/L)	01/03/93	48.50 >		46.10		49.20 >	
TOT. CHOLEST.	3-6 (MMOL/L)	01/03/93	7.30 >		8.00 >>		7.00 >	
TRIGLYCERIDES	0.5-1.5 (MMOL/L)	01/03/93	0.72		1.18		0.79	
GLOBULINS ALPHA 1	1-3 (G/L)	01/03/93	2.20		3.30 >		2.40	
GLOBULINS ALPHA 2	4-7 (G/L)	01/03/93	4.90		7.60 >		5.50	
GLOBULINS BETA	5-8 (G/L)	01/03/93	6.40		10.50 >>		7.50 >	
GLOBULINS GAMMA	8-12 (G/L)	01/03/93	13.10 >		15.60 >		14.20 >	
TSH	0.1-4.5 (MUI/L)	01/03/93	0.75					
T4	10-26 (PMOL/L)	01/03/93	18.50					

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

2170

(ø) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 09530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 17 Patient: 3DT Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			12/10/93		16/11/93		22/12/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	7.5-10 (MMOL/L)	01/03/93	7.50		8.50		9.10	
HT	0.4-0.52 (L/L)	01/03/93	0.36 <		0.39 <		0.42	
RBC	4-5.5 (10 ⁶ /MM ³)	01/03/93	3.84 <		4.35		4.80	
WBC	4-10 (10 ³ /MM ³)	01/03/93	4.20		5.90		6.90	
WBC: N	2.5-7 (10 ³ /MM ³)	01/03/93	2.94		4.48		5.45	
WBC: L	1.25-4 (10 ³ /MM ³)	01/03/93	0.97 <		1.00 <		0.97 <	
WBC: E	0.1-0.4 (10 ³ /MM ³)	01/03/93	0.00 <		0.00 <		0.00 <	
WBC: M	0.2-0.8 (10 ³ /MM ³)	01/03/93	0.29		0.41		0.48	
WBC: B	0-0.2 (10 ³ /MM ³)	01/03/93	0.00		0.00		0.00	
PLATELETS	150-450 (10 ³ /MM ³)	01/03/93	142.00 <		139.00 <		134.00 <	
NA+	135-145 (MMOL/L)	01/03/93	142.00		140.00		138.00	
K+	3.6-4.8 (MMOL/L)	01/03/93	4.40		4.30		4.70	
CL-	96-106 (MMOL/L)	01/03/93	102.00		102.00		102.00	
Ca++	2.2-2.6 (MMOL/L)	01/03/93	2.24		2.16 <		2.24	
PO4--	0.87-1.5 (MMOL/L)	01/03/93	0.77 <		0.97		1.02	
SGOT	3-26 (UI/L)	01/03/93	16.00		22.00		21.00	
SGPT	3-29 (UI/L)	01/03/93	26.00		33.00 >		22.00	
GAMMA GT	5-25 (UI/L)	01/03/93	22.00		38.00 >		42.00 >	
LDH	160-320 (UI/L)	01/03/93	221.00		176.00		251.00	
ALK. PHOSPH.	73-207 (UI/L)	01/03/93	104.00		76.00		106.00	
GLUCOSE	4-6 (MMOL/L)	01/03/93	4.30		4.90		7.00 >	
UREA	2.5-7 (MMOL/L)	01/03/93	9.40 >		8.20 >		8.00 >	
CREATININE	50-100 (UMOL/L)	01/03/93	128.00 >		101.00 >		120.00 >	
CREATININE	()	01/03/93						
CLEARANCE			44.90 ()					
URIC ACID	150-420 (MMOL/L)	01/03/93			355.00		477.00 >	
TOT BILIRUBIN	2-18 (UMOL/L)	01/03/93	7.00		5.00		2.00	
DIR BILIRUBIN	0-7 (UMOL/L)	01/03/93	0.00		0.00			
TOT. PROTEINS	65-75 (G/L)	01/03/93	60.00 <		64.00 <		67.00	
ALBUMINE	32-47 (G/L)	01/03/93	39.30		38.50		41.80	
TOT. CHOLEST.	3-6 (MMOL/L)	01/03/93	2.90 <		4.60		5.40	
TRIGLYCERIDES	0.5-1.5 (MMOL/L)	01/03/93	1.96 >>		1.68 >		3.26 >>	
GLOBULINS ALPHA 1	1-3 (G/L)	01/03/93	1.60		2.00		1.80	
GLOBULINS ALPHA 2	4-7 (G/L)	01/03/93	3.20 <		5.20		5.30	
GLOBULINS BETA	5-8 (G/L)	01/03/93	6.70		7.70		7.50	
GLOBULINS GAMMA	8-12 (G/L)	01/03/93	9.10		10.50		10.60	
TSH	0.1-4.5 (MUI/L)	01/03/93	1.90					
T4	10-26 (PMOL/L)	01/03/93	18.00					

2171

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 0953089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 17 Patient: 4DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			24/12/93		16/02/94		15/03/94	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	7.5-10 (MMOL/L)	01/03/93	7.70		7.90		7.90	
HT	0.4-0.52 (L/L)	01/03/93	0.37 <		0.38 <		0.39 <	
RBC	4-5.5 (10 ⁶ /MM3)	01/03/93	4.22		4.31		4.35	
WBC	4-10 (10 ³ /MM3)	01/03/93	8.30		4.90		6.90	
WBC: N	2.5-7 (10 ³ /MM3)	01/03/93	6.89		3.92		4.83	
WBC: L	1.25-4 (10 ³ /MM3)	01/03/93	0.91 <		0.69 <<		1.52	
WBC: E	0.1-0.4 (10 ³ /MM3)	01/03/93	0.00 <		0.00 <		0.00 <	
WBC: M	0.2-0.8 (10 ³ /MM3)	01/03/93	0.50		0.29		0.55	
WBC: B	0-0.2 (10 ³ /MM3)	01/03/93	0.00		0.00		0.00	
PLATELETS	150-450 (10 ³ /MM3)	01/03/93	321.00		247.00		324.00	
NA+	135-145 (MMOL/L)	01/03/93	139.00		134.00 <		138.00	
K+	3.6-4.8 (MMOL/L)	01/03/93	3.80		4.70		4.40	
CL-	96-106 (MMOL/L)	01/03/93	104.00		99.00		104.00	
Ca++	2.2-2.6 (MMOL/L)	01/03/93	2.26		2.14 <		2.28	
PO4--	0.87-1.5 (MMOL/L)	01/03/93	0.98		0.78 <		1.16	
SGOT	3-26 (UI/L)	01/03/93	15.00		54.00 >>		12.00	
SGPT	3-29 (UI/L)	01/03/93	14.00		65.00 >>		9.00	
GAMMA GT	5-25 (UI/L)	01/03/93	8.00		37.00 >		15.00	
LDH	160-320 (UI/L)	01/03/93	406.00 >		474.00 >		290.00	
ALK. PHOSPH.	73-207 (UI/L)	01/03/93	74.00		148.00		78.00	
GLUCOSE	4-6 (MMOL/L)	01/03/93	7.20 >		6.00		5.90	
UREA	2.5-7 (MMOL/L)	01/03/93	7.90 >		7.60 >		8.50 >	
CREATININE	50-100 (UMOL/L)	01/03/93	65.00		59.00		72.00	
CREATININE CLEARANCE	()	01/03/93	52.50 ()					
URIC ACID	150-420 (MMOL/L)	01/03/93	188.00		177.00		248.00	
TOT BILIRUBIN	2-18 (UMOL/L)	01/03/93	5.00		5.00		3.00	
TOT. PROTEINS	65-75 (G/L)	01/03/93	59.00 <		61.00 <		68.00	
ALBUMINE	32-47 (G/L)	01/03/93	41.70		39.00		45.60	
TOT. CHOLEST.	3-6 (MMOL/L)	01/03/93	5.70		6.00		7.30 >	
TRIGLYCERIDES	0.5-1.5 (MMOL/L)	01/03/93	1.05		1.30		1.12	
GLOBULINS ALPHA 1	1-3 (G/L)	01/03/93	2.10		3.10 >		2.50	
GLOBULINS ALPHA 2	4-7 (G/L)	01/03/93	3.50 <		5.40		4.80	
GLOBULINS BETA	5-8 (G/L)	01/03/93	5.70		7.40		7.80	
GLOBULINS GAMMA	8-12 (G/L)	01/03/93	6.00 <		6.00 <		7.80 <	
TSH	0.1-4.5 (MUI/L)	01/03/93	1.08					
T4	10-26 (PMOL/L)	01/03/93	14.30					

2172

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 0953089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 17 Patient: 211DT Treatment: Reboxetine Sex: Female

Laboratory test			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			14/02/94		06/05/94		09/06/94	
			value	(φ)	value	(φ)	value	(φ)
Range value	Range date							
HB	7.5-10 (MMOL/L)	01/03/93	8.00		7.30	<	7.60	
HT	0.4-0.52 (L/L)	01/03/93	0.38	<	0.34	<	0.37	
RBC	4-5.5 (10 ⁶ /MM3)	01/03/93	4.10		3.70	<	3.99	
WBC	4-10 (10 ³ /MM3)	01/03/93	6.50		10.60	>	7.20	
WBC; N	2.5-7 (10 ³ /MM3)	01/03/93	4.55		5.94		4.39	
WBC: L	1.25-4 (10 ³ /MM3)	01/03/93	1.63		2.76		1.66	
WBC: E	0.1-0.4 (10 ³ /MM3)	01/03/93			0.42	>	0.29	
WBC: M	0.2-0.8 (10 ³ /MM3)	01/03/93	0.33		1.38	>>	0.86	
PLATELETS	150-450 (10 ³ /MM3)	01/03/93	263.00		382.00		358.00	
NA+	135-145 (MMOL/L)	01/03/93	144.00		141.00		141.00	
K+	3.6-4.8 (MMOL/L)	01/03/93	4.90	>	3.60		4.30	
CL-	96-106 (MMOL/L)	01/03/93	105.00		103.00		100.00	
Ca++	2.2-2.6 (MMOL/L)	01/03/93	2.32		2.24		2.40	
PO4--	0.87-1.5 (MMOL/L)	01/03/93			0.95			
SGOT	3-26 (UI/L)	01/03/93	19.00		11.00		12.00	
SGPT	3-29 (UI/L)	01/03/93	17.00		8.00		13.00	
GAMMA GT	5-25 (UI/L)	01/03/93	23.00		23.00		15.00	
LDH	160-320 (UI/L)	01/03/93	327.00	>	245.00		265.00	
ALK. PHOSPH.	73-207 (UI/L)	01/03/93	165.00		226.00	>	186.00	
GLUCOSE	4-6 (MMOL/L)	01/03/93	5.50		4.50		4.50	
UREA	2.5-7 (MMOL/L)	01/03/93	8.50	>	11.20	>>	8.60	
CREATININE	50-100 (UMOL/L)	01/03/93	124.00	>	127.00	>	116.00	
CREATININE CLEARANCE	(l)	01/03/93	31.60	(l)				
URIC ACID	150-420 (MMOL/L)	01/03/93	235.00		320.00			
TOT BILIRUBIN	2-18 (UMOL/L)	01/03/93	14.00		3.00			
TOT. PROTEINS	65-75 (G/L)	01/03/93	62.00	<	61.00	<	70.00	
ALBUMINE	32-47 (G/L)	01/03/93	37.60		32.60			
TOT. CHOLEST.	3-6 (MMOL/L)	01/03/93	3.30		6.80	>		
TRIGLYCERIDES	0.5-1.5 (MMOL/L)	01/03/93	1.23					
GLOBULINS ALPHA 1	1-3 (G/L)	01/03/93			2.70			
GLOBULINS ALPHA 2	4-7 (G/L)	01/03/93			5.50	>		
GLOBULINS BETA	5-8 (G/L)	01/03/93			7.80			
GLOBULINS GAMMA	8-12 (G/L)	01/03/93			8.70		10.10	
TSH	0.1-4.5 (MUI/L)	01/03/93	0.74					
T4	10-26 (PMOL/L)	01/03/93	24.90					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/03/93	50.00					

2173

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done (l) missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 09530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 18 Patient: 1KD Treatment: Inipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			19/05/93		23/06/93		21/07/93	
			value	(*)	value	(*)	value	(*)
Laboratory test	Range value	Range date						
HB	11.8-17 (G/DL)	30/09/90	12.60		13.10		14.10	
HT	36-52 (%)	30/09/90	35.10	<	37.10		40.40	
RBC	3800000-5500000 (/MM3)	30/09/90						
			4110000		4340000		4670000	
WBC	4000-9000 (/MM3)	30/09/90	3400.00	<	2800.00	<	4000.00	
WBC: N	40-74 (%)	30/09/90	69.00		70.00		79.00	
WBC: L	19-48 (%)	30/09/90	20.00		17.00	<	13.00	
WBC: E	0-7 (%)	30/09/90	2.00		4.00		0.00	
WBC: M	3-9 (%)	30/09/90	8.00		8.00		7.00	
WBC: B	0-1.5 (%)	30/09/90	1.00		1.00		1.00	
PLATELETS	150000-400000 (/MM3)	30/09/90						
			234000		245000		257000	
NA+	135-145 (MEQ/L)	30/09/90	140.00		132.00	<	136.00	
K+	3.5-5 (MEQ/L)	30/09/90	4.30		4.20		3.90	
CL-	95-105 (MEQ/L)	30/09/90	99.00		93.00	<	97.00	
Ca++	2.1-2.6 (MMOL/L)	30/09/90	2.30		2.37		2.47	
PO4--	0.96-1.28 (MMOL/L)	30/09/90	0.86	<	0.89	<	0.86	
SGOT	6-25 (UI/L)	30/09/90	12.00		13.00		14.00	
SGPT	6-25 (UI/L)	30/09/90	7.00		7.00		9.00	
GAMMA GT	5-30 (UI/L)	30/09/90	24.00		18.00		23.00	
LDH	160-320 (UI/L)	30/09/90	231.00		278.00		224.00	
ALK. PHOSPH.	70-207 (UI/L)	30/09/90	141.00		171.00		183.00	
GLUCOSE	3.9-6.1 (MMOL/L)	30/09/90	4.93		4.82		4.99	
UREA	2.5-8.3 (MMOL/L)	30/09/90	4.34		4.00		4.67	
CREATININE	53-107 (UMOL/L)	30/09/90	74.34		79.65		93.81	
CREATININE CLEARANCE	()	30/09/90						
			52.82	()				
URIC ACID	119-410 (UMOL/L)	30/09/90	315.35		208.25		285.60	
TOT BILIRUBIN	0-10 (MG/L)	30/09/90	8.03		3.07		5.47	
DIR BILIRUBIN	0-1 (MG/L)	30/09/90	0.70		0.20		0.60	
TOT. PROTEINS	65-85 (G/L)	30/09/90	67.00		72.00		76.00	
ALBUMINE	37-42 (G/L)	30/09/90	45.80	>	45.30	>	49.60	
TOT. CHOLEST.	3.9-6.24 (MMOL/L)	30/09/90	8.82	>>	7.61	>	8.51	
TRIGLYCERIDES	0.5-1.5 (G/L)	30/09/90	1.46		1.50		1.75	
GLOBULINS ALPHA 1	1-3 (G/L)	30/09/90	0.90	<	2.60		2.70	
GLOBULINS ALPHA 2	4-7 (G/L)	30/09/90	4.60		6.60		5.90	
GLOBULINS BETA	5-8 (G/L)	30/09/90	7.00		8.10	>	8.50	
GLOBULINS GAMMA	8-12 (G/L)	30/09/90	8.70		9.40		9.30	

2174

(*) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 0959089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 18 Patient: 2MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	Day 28
			26/05/93	26/06/93
			value (†)	value (‡)
Laboratory test	Range value	Range date		
HB	11.8-17 (G/DL)	30/09/90	14.00	14.50
HT	36-52 (X)	30/09/90	41.90	43.90
RBC	3800000-5500000 (/MM3)	30/09/90	4690000	4750000
NBC	4000-9000 (/MM3)	30/09/90	5100.00	5600.00
NBC: N	40-74 (X)	30/09/90	58.00	48.00
NBC: L	19-48 (X)	30/09/90	34.00	43.00
NBC: E	0-7 (X)	30/09/90	1.00	2.00
NBC: M	3-9 (X)	30/09/90	6.00	5.00
NBC: B	0-1.5 (X)	30/09/90	1.00	2.00 >>
PLATELETS	150000-400000 (/MM3)	30/09/90	449000 >	434000 >
NA+	135-145 (MEQ/L)	30/09/90	138.00	141.00
K+	3.5-5 (MEQ/L)	30/09/90	3.80	3.90
CL-	95-105 (MEQ/L)	30/09/90	98.00	99.00
Ca++	2.1-2.6 (MMOL/L)	30/09/90	2.32	2.37
PO4--	0.96-1.28 (MMOL/L)	30/09/90	0.83 <	0.92 <
SGOT	6-25 (UI/L)	30/09/90	14.00	13.00
SGPT	6-25 (UI/L)	30/09/90	13.00	12.00
GAMMA GT	5-30 (UI/L)	30/09/90	10.00	11.00
LDH	160-320 (UI/L)	30/09/90	228.00	192.00
ALK. PHOSPH.	70-207 (UI/L)	30/09/90	186.00	186.00
GLUCOSE	3.9-6.1 (MMOL/L)	30/09/90	5.93	5.10
UREA	2.5-8.3 (MMOL/L)	30/09/90	4.17	4.67
CREATININE	53-107 (UMOL/L)	30/09/90	90.27	84.96
CREATININE CLEARANCE	()	30/09/90	38.98 ()	
URIC ACID	119-410 (UMOL/L)	30/09/90	238.00	232.05
TOT BILIRUBIN	0-10 (MG/L)	30/09/90	2.56	5.64
DIR BILIRUBIN	0-1 (MG/L)	30/09/90	0.10	0.30
TOT. PROTEINS	65-85 (G/L)	30/09/90	67.00	75.00
ALBUMINE	37-42 (G/L)	30/09/90	41.10	47.30 >
TOT. CHOLEST.	3.9-6.24 (MMOL/L)	30/09/90	5.44	6.99 >
TRIGLYCERIDES	0.5-1.5 (G/L)	30/09/90	0.89	0.77 >
GLOBULINS ALPHA 1	1-3 (G/L)	30/09/90	2.20	2.00
GLOBULINS ALPHA 2	4-7 (G/L)	30/09/90	5.80	5.40
GLOBULINS BETA	5-8 (G/L)	30/09/90	7.50	8.20 >
GLOBULINS GAMMA	8-12 (G/L)	30/09/90	10.40	12.10 >
TSH	0.3-4 (MU/L)	30/09/90	0.88	
T4	0.9-1.9 (UG/DL)	30/09/90	1.29	

2175

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 03550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 18 Patient: 3MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 49	
			13/08/93		10/09/93		01/10/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	11.8-17 (G/DL)	30/09/90	13.50		14.60		16.20	
HT	36-52 (%)	30/09/90	40.60		43.30		50.00	
RBC	3800000-5500000 (/MM3)	30/09/90						
			4230000		4480000		5030000	
HBC	4000-9000 (/MM3)	30/09/90	7200.00		6100.00		9400.00 >	
HBC: N	40-74 (%)	30/09/90	54.00		59.00		62.00	
HBC: L	19-48 (%)	30/09/90	36.00		29.00		30.00	
HBC: E	0-7 (%)	30/09/90	4.00		4.00		2.00	
HBC: M	3-9 (%)	30/09/90	5.00		7.00		5.00	
HBC: B	0-1.5 (%)	30/09/90	1.00		1.00		1.00	
PLATELETS	150000-400000 (/MM3)	30/09/90						
			373000		298000		327000	
NA+	135-145 (MEQ/L)	30/09/90	145.00		141.00		142.00	
K+	3.5-5 (MEQ/L)	30/09/90	4.80		3.90		4.00	
CL-	95-105 (MEQ/L)	30/09/90	106.00 >		100.00		91.00 <	
Ca++	2.1-2.6 (MMOL/L)	30/09/90	2.50		2.37		2.65 >	
PO4--	0.96-1.28 (MMOL/L)	30/09/90	0.92 <		1.08		0.92 <	
SGOT	6-25 (UI/L)	30/09/90	21.00		15.00		14.00	
SGPT	6-25 (UI/L)	30/09/90	12.00		19.00		15.00	
GAMMA GT	5-30 (UI/L)	30/09/90	26.00		39.00 >		36.00 >	
LDH	160-320 (UI/L)	30/09/90	348.00 >		276.00		319.00	
ALK. PHOSPH.	70-207 (UI/L)	30/09/90	49.00 <		95.00		127.00	
GLUCOSE	3.9-6.1 (MMOL/L)	30/09/90	5.10		6.66 >		8.76 >>	
UREA	2.5-8.3 (MMOL/L)	30/09/90	7.51		6.34		7.34	
CREATININE	53-107 (UMOL/L)	30/09/90	113.28 >		101.77		113.28 >	
CREATININE CLEARANCE	()	30/09/90						
			36.25 ()					
URIC ACID	119-410 (UMOL/L)	30/09/90	309.40		261.80		327.25	
TOT BILIRUBIN	0-10 (MG/L)	30/09/90	5.40		7.12		9.91	
DIR BILIRUBIN	0-1 (MG/L)	30/09/90	0.20		1.00		0.10	
TOT. PROTEINS	65-85 (G/L)	30/09/90	68.00		66.00		83.00	
ALBUMINE	37-42 (G/L)	30/09/90	39.00		39.30		51.30 >	
TOT. CHOLEST.	3.9-6.24 (MMOL/L)	30/09/90	6.16		7.12 >		6.96 >	
TRIGLYCERIDES	0.5-1.5 (G/L)	30/09/90	2.52 >>		1.32		1.75 >	
GLOBULINS ALPHA 1	1-3 (G/L)	30/09/90	2.90		1.90		2.50	
GLOBULINS ALPHA 2	4-7 (G/L)	30/09/90	6.20		7.20 >		7.60 >	
GLOBULINS BETA	5-8 (G/L)	30/09/90	11.60 >>		8.50 >		11.20 >>	
GLOBULINS GAMMA	8-12 (G/L)	30/09/90	8.30		9.10		10.40	
TSH	0.3-4 (MU/L)	30/09/90	1.50					
T4	0.9-1.9 (UG/DL)	30/09/90	1.23					

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CMS 0089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 18 Patient: 4MD Treatment: Roboxetine Sex: Female

Laboratory test			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			30/09/93		30/10/93		27/11/93	
			value	(φ)	value	(φ)	value	(φ)
HB	11.8-17 (G/DL)	30/09/90	12.90		11.30	<	13.10	
HT	36-52 (X)	30/09/90	39.00		34.00	<	38.50	
RBC	3800000-5500000 (/MM3)	30/09/90	4200000		3730000	<	4090000	
MBC	4000-9000 (/MM3)	30/09/90	5400.00		4900.00		8900.00	
MBC: N	40-74 (%)	30/09/90	58.00		53.00		60.00	
MBC: L	19-48 (%)	30/09/90	33.00		36.00		27.00	
MBC: E	0-7 (%)	30/09/90	1.00		2.00		1.00	
MBC: M	3-9 (%)	30/09/90	7.00		8.00		12.00	
MBC: B	0-1.5 (%)	30/09/90	1.00		1.00		0.00	
PLATELETS	150000-400000 (/MM3)	30/09/90	248000		232000		200000	
NA+	135-145 (MEQ/L)	30/09/90	141.00		140.00		139.00	
K+	3.5-5 (MEQ/L)	30/09/90	3.60		4.40			
CL-	95-105 (MEQ/L)	30/09/90	100.00		103.00		100.00	
Ca++	2.1-2.6 (MMOL/L)	30/09/90	2.20		2.15		2.32	
PO4--	0.96-1.28 (MMOL/L)	30/09/90	1.12		0.99		1.28	
SGOT	6-25 (UI/L)	30/09/90	12.00		9.00		10.00	
SGPT	6-25 (UI/L)	30/09/90	6.00		6.00		6.00	
GAMMA GT	5-30 (UI/L)	30/09/90	5.00		5.00		5.00	
LDH	160-320 (UI/L)	30/09/90	244.00		220.00		277.00	
ALK. PHOSPH.	70-207 (UI/L)	30/09/90	97.00		92.00		127.00	
GLUCOSE	3.9-6.1 (MMOL/L)	30/09/90	4.55		4.16		4.77	
UREA	2.5-8.3 (MMOL/L)	30/09/90	4.50		5.51		8.18	
CREATININE	53-107 (UMOL/L)	30/09/90	100.89		101.77		102.66	
CREATININE CLEARANCE	()	30/09/90	32.73 ()					
URIC ACID	119-410 (UMOL/L)	30/09/90	226.10		226.10		243.95	
TOT BILIRUBIN	0-10 (MG/L)	30/09/90	10.77 >		7.86		6.15	
DIR BILIRUBIN	0-1 (MG/L)	30/09/90	0.80		0.20		0.50	
TOT. PROTEINS	65-85 (G/L)	30/09/90	66.00		63.00	<	73.00	
ALBUMINE	37-42 (G/L)	30/09/90	36.50	<	33.10	<	40.70	
TOT. CHOLEST.	3.9-6.24 (MMOL/L)	30/09/90	5.36		5.26		5.77	
TRIGLYCERIDES	0.5-1.5 (G/L)	30/09/90	0.76		0.81		1.08	
GLOBULINS ALPHA 1	1-3 (G/L)	30/09/90	2.30		1.90		2.60	
GLOBULINS ALPHA 2	4-7 (G/L)	30/09/90	6.30		5.60		6.90	
GLOBULINS BETA	5-8 (G/L)	30/09/90	11.20 >>		8.10 >		12.20 >>	
GLOBULINS GAMMA	8-12 (G/L)	30/09/90	9.70		14.20 >		10.60	
TSH	0.3-4 (MU/L)	30/09/90	2.04					
T4	0.9-1.9 (UG/DL)	30/09/90	1.59					

2177

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 0554089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 18 Patient: 1DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			04/08/93		08/09/93		06/10/93	
			value	(c)	value	(c)	value	(c)
Laboratory test	Range value	Range date						
HB	11.8-17 (G/DL)	30/09/90	13.00		12.00		12.50	
HT	36-52 (X)	30/09/90	36.90		34.40	<	36.70	
RBC	3800000-5500000 (/MM3)	30/09/90						
			4110000		3730000	<	4010000	
WBC	4000-9000 (/MM3)	30/09/90	5900.00		6600.00		6000.00	
WBC: N	40-74 (X)	30/09/90	58.00		58.00		49.00	
WBC: L	19-48 (X)	30/09/90	31.00		28.00		32.00	
WBC: E	0-7 (X)	30/09/90	5.00		5.00		11.00	
WBC: M	3-9 (X)	30/09/90	6.00		8.00		7.00	
WBC: B	0-1.5 (X)	30/09/90	0.00		1.00		1.00	
PLATELETS	150000-400000 (/MM3)	30/09/90						
			285000		298000		278000	
NA+	135-145 (MEQ/L)	30/09/90	145.00		129.00	<	136.00	
K+	3.5-5 (MEQ/L)	30/09/90	3.90		3.90		4.20	
CL-	95-105 (MEQ/L)	30/09/90	104.00		89.00	<	95.00	
Ca++	2.1-2.6 (MMOL/L)	30/09/90	2.42		2.42		2.32	
PO4--	0.96-1.28 (MMOL/L)	30/09/90	1.08		1.18		1.28	
SGOT	6-25 (UI/L)	30/09/90	13.00		11.00		10.00	
SGPT	6-25 (UI/L)	30/09/90	7.00		6.00		7.00	
GAMMA GT	5-30 (UI/L)	30/09/90	12.00		14.00		12.00	
LDH	160-320 (UI/L)	30/09/90	199.00		245.00		207.00	
ALK. PHOSPH.	70-207 (UI/L)	30/09/90	100.00		140.00		149.00	
GLUCOSE	3.9-6.1 (MMOL/L)	30/09/90	5.16		4.38		4.88	
UREA	2.5-8.3 (MMOL/L)	30/09/90	6.01		7.34		7.84	
CREATININE	53-107 (UMOL/L)	30/09/90	73.45		73.45		84.07	
CREATININE CLEARANCE	(l)	30/09/90	33.16	(l)				
URIC ACID	119-410 (UMOL/L)	30/09/90	196.35		184.45		220.15	
TOT BILIRUBIN	0-10 (MG/L)	30/09/90	7.18		2.56		1.71	
DIR BILIRUBIN	0-1 (MG/L)	30/09/90	0.60		0.60		0.34	
TOT. PROTEINS	65-85 (G/L)	30/09/90	72.00		66.00		70.00	
ALBUMINE	37-42 (G/L)	30/09/90	41.00		39.70		40.50	
TOT. CHOLEST.	3.9-6.24 (MMOL/L)	30/09/90	6.68	>	5.83		6.42	
TRIGLYCERIDES	0.5-1.5 (G/L)	30/09/90	1.16		1.23		1.61	
GLOBULINS ALPHA 1	1-3 (G/L)	30/09/90	1.90		2.20		2.10	
GLOBULINS ALPHA 2	4-7 (G/L)	30/09/90	5.80		5.70		6.10	
GLOBULINS BETA	5-8 (G/L)	30/09/90	9.00	>	7.30		8.50	
GLOBULINS GAMMA	8-12 (G/L)	30/09/90	14.30	>	11.10		12.80	
TSH	0.3-4 (MU/L)	30/09/90	1.18					
T4	0.9-1.9 (UG/DL)	30/09/90	1.30					

2178

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done (l) missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 0590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 18 Patient: ZDT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	Day 28
			04/11/93	07/12/93
			value (€)	value (€)
Laboratory test	Range value	Range date		
HB	11.8-17 (G/DL)	30/09/90	15.00	14.70
HT	36-52 (%)	30/09/90	42.80	43.10
RBC	3800000-5500000 (/MM3)	30/09/90	4510000	4420000
WBC	4000-9000 (/MM3)	30/09/90	8400.00	7400.00
WBC: N	40-74 (%)	30/09/90	68.00	69.00
WBC: L	19-48 (%)	30/09/90	26.00	22.00
WBC: E	0-7 (%)	30/09/90	1.00	1.00
WBC: M	3-9 (%)	30/09/90	5.00	7.00
WBC: B	0-1.5 (%)	30/09/90	0.00	1.00
PLATELETS	150000-400000 (/MM3)	30/09/90	334000	396000
NA+	135-145 (MEQ/L)	30/09/90	139.00	141.00
K+	3.5-5 (MEQ/L)	30/09/90	4.20	3.90
CL-	95-105 (MEQ/L)	30/09/90	96.00	96.00
Ca++	2.1-2.6 (MMOL/L)	30/09/90	2.45	2.52
PO4--	0.96-1.28 (MMOL/L)	30/09/90	1.08	1.15
SGOT	6-25 (UI/L)	30/09/90	11.00	10.00
SGPT	6-25 (UI/L)	30/09/90	10.00	6.00
GAMMA GT	5-30 (UI/L)	30/09/90	27.00	15.00
LDH	160-320 (UI/L)	30/09/90	160.00	216.00
ALK. PHOSPH.	70-207 (UI/L)	30/09/90	147.00	119.00
GLUCOSE	3.9-6.1 (MMOL/L)	30/09/90	5.60	6.38 >
UREA	2.5-8.3 (MMOL/L)	30/09/90	5.84	5.17
CREATININE	53-107 (UMOL/L)	30/09/90	94.69	88.50
CREATININE CLEARANCE	()	30/09/90	41.72 ()	
URIC ACID	119-410 (UMOL/L)	30/09/90	202.30	279.65
TOT BILIRUBIN	0-10 (MG/L)	30/09/90	8.60	7.52
DIR BILIRUBIN	0-1 (MG/L)	30/09/90	1.80 >	0.90
TOT. PROTEINS	65-85 (G/L)	30/09/90	70.00	80.00
ALBUMINE	37-42 (G/L)	30/09/90	47.50 >	50.30 >
TOT. CHOLEST.	3.9-6.24 (MMOL/L)	30/09/90	6.57 >	6.94 >
TRIGLYCERIDES	0.5-1.5 (G/L)	30/09/90	0.59	0.76
GLOBULINS ALPHA 1	1-3 (G/L)	30/09/90	1.60	2.20
GLOBULINS ALPHA 2	4-7 (G/L)	30/09/90	5.30	5.40
GLOBULINS BETA	5-8 (G/L)	30/09/90	7.50	8.10 >
GLOBULINS GAMMA	8-12 (G/L)	30/09/90	8.10	9.10

2179

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 05510089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 20 Patient: 3ND Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date
			Screen
			05/07/93
			value (e)
Laboratory test	Range value	Range date	
HB	11.9-14.3 (G/DL)	05/07/93	12.80
HT	38-45 (%)	05/07/93	38.40
RBC	4000000-4700000 (/MM3)	05/07/93	4240000
WBC	5000-9000 (/MM3)	05/07/93	4380.00 <
WBC: N	55-70 (%)	05/07/93	57.20
WBC: L	20-40 (%)	05/07/93	32.00
WBC: E	1-3 (%)	05/07/93	1.30
WBC: M	0-8 (%)	05/07/93	7.10
WBC: B	0-1 (%)	05/07/93	0.30
NA+	137-145 (MMOL/L)	05/07/93	138.00
K+	3.5-5 (MMOL/L)	05/07/93	3.60
CL-	100-108 (MMOL/L)	05/07/93	98.00 <
Ca++	85-105 (MG/L)	05/07/93	95.00
PO4--	25-45 (MG/L)	05/07/93	41.10
SGOT	9-40 (UI/ML)	05/07/93	21.00
SGPT	9-40 (UI/ML)	05/07/93	16.00
GAMMA GT	8-50 (U/L)	05/07/93	11.00
LDH	200-480 (U/L)	05/07/93	361.00
GLUCOSE	0.8-1.2 (MMOL/L)	05/07/93	0.95
TOT. PROTEINS	66-80 (G/L)	05/07/93	65.00 <
ALBUMINE	32-50 (G/L)	05/07/93	35.70
TOT. CHOLEST.	1.45-2.4 (G/L)	05/07/93	2.65 >
TRIGLYCERIDES	0.35-1.31 (G/L)	05/07/93	0.88
GLOBULINS ALPHA 1	1-4 (G/L)	05/07/93	1.70
GLOBULINS ALPHA 2	5-11 (G/L)	05/07/93	6.80
GLOBULINS BETA	6-13 (G/L)	05/07/93	11.40
GLOBULINS GAMMA	7-15 (G/L)	05/07/93	9.43
TSH	0.2-3.2 (UUI/ML)	05/07/93	0.84
T4	10-25 (NG/L)	05/07/93	18.20

2180

(e) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C0560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 22 Patient: 1MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date
			Screen
			24/06/93
			value (€)
Laboratory test	Range value	Range date	
HB	12-16 (G/DL)	24/06/93	13.70
HT	36-42 (Z)	24/06/93	40.30
RBC	3.68-5.3 (10 ⁶ /MM ³)	24/06/93	4.41
NBC	4-10.7 (10 ³ /MM ³)	24/06/93	4.90
NBC: N	50-70 (Z)	24/06/93	67.00
NBC: L	20-40 (Z)	24/06/93	21.00
NBC: E	2-4 (Z)	24/06/93	3.00
NBC: M	2-8 (Z)	24/06/93	8.00
NBC: B	0-1 (Z)	24/06/93	1.00
PLATELETS	100-300 (10 ³ /MM ³)	24/06/93	382.00 >
NA+	130-149 (MMOL/L)	24/06/93	140.00
K+	3.66-5.35 (MMOL/L)	24/06/93	4.00
CL-	94-109 (MMOL/L)	24/06/93	108.00
Ca++	2.24-2.78 (MMOL/L)	24/06/93	2.59
PO4--	0.87-1.45 (MMOL/L)	24/06/93	1.54 >
SGOT	0-18 (U/L)	24/06/93	18.00
SGPT	0-18 (U/L)	24/06/93	17.00
GAMMA GT	4-18 (U/L)	24/06/93	22.00 >
LDH	120-240 (U/L)	24/06/93	178.00
ALK. PHOSPH.	60-170 (U/L)	24/06/93	83.00
GLUCOSE	3.54-5.68 (MMOL/L)	24/06/93	6.20 >
BUN	1.7-8.3 (MMOL/L)	24/06/93	7.20
CREATININE	50-98 (UMOL/L)	24/06/93	96.00
CREATININE CLEARANCE	()	24/06/93	50.40 ()
URIC ACID	142-339 (UMOL/L)	24/06/93	268.00
TOT BILIRUBIN	3.6-21.9 (UMOL/L)	24/06/93	14.00
TOT. PROTEINS	65.6-86.5 (G/L)	24/06/93	72.00
ALBUMINE	58-70 (Z)	24/06/93	67.20
TOT. CHOLEST.	3.5-6.5 (MMOL/L)	24/06/93	8.70 >>
TRIGLYCERIDES	1.7-2.3 (MMOL/L)	24/06/93	0.90 <
GLOBULINS ALPHA 1	1.5-4 (Z)	24/06/93	3.30
GLOBULINS ALPHA 2	2.5-10 (Z)	24/06/93	8.10
GLOBULINS BETA	7-13 (Z)	24/06/93	10.10
GLOBULINS GAMMA	10-19 (Z)	24/06/93	11.40
TSH	0.3-4 (MU/L)	24/06/93	1.00
T4	52-148 (NMOL/L)	24/06/93	113.00
ESR/SEDIMENT. RATE	5-18 (MM)	24/06/93	22.00
1st h			
ESR/SEDIMENT. RATE	6-20 (MM)	24/06/93	36.00
2nd h			

2181

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN 9150089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 23 Patient: 1ND Treatment: Reboxetine Sex: Female

			Visit number / Laboratory data					
			Screen		Day 28		Day 56	
			28/01/93		26/02/93		26/03/93	
			value	(ϕ)	value	(ϕ)	value	(ϕ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/01/93	14.30		13.80		13.50	
HT	37-47 (X)	01/01/93	42.10		41.30		39.80	
RBC	4.2-5.4 (10 ⁶ /MM ³)	01/01/93	4.51		4.47		4.41	
WBC	4.8-10.8 (10 ³ /MM ³)	01/01/93			5.02		8.30	
WBC: N	45-78 (X)	01/01/93			74.70		69.70	
WBC: L	18-45 (X)	01/01/93		<	15.00		22.20	
WBC: E	0-5 (X)	01/01/93			1.00		0.30	
WBC: M	2-12 (X)	01/01/93			8.60		5.70	
WBC: B	0-1 (X)	01/01/93			0.70		0.40	
PLATELETS	125-400 (10 ³ /UL)	01/01/93	341.00		399.00		341.00	
NA+	135-150 (MMOL/L)	01/01/93	141.00		142.00		141.00	
K+	3.6-5.3 (MMOL/L)	01/01/93	3.60		3.50		3.60	
CL-	97-108 (MMOL/L)	01/01/93	104.00		104.00		100.00	
Ca++	2.1-2.7 (MMOL/L)	01/01/93	2.40		2.40		2.40	
PO4--	2-4.9 (MG/DL)	01/01/93	3.00		3.50		3.10	
SGOT	0-18 (U/L)	01/01/93	5.00		7.00		6.00	
SGPT	0-22 (U/L)	01/01/93	6.00		7.00		8.00	
GAMMA GT	0-18 (U/L)	01/01/93	8.00		10.00		9.00	
LDH	80-240 (U/L)	01/01/93	160.00		152.00		169.00	
ALK. PHOSPH.	50-200 (U/L)	01/01/93	73.00		104.00		107.00	
GLUCOSE	70-110 (MG/DL)	01/01/93	90.00		95.00		144.00	>>
BUN	0-25 (MG/DL)	01/01/93	11.00		16.00		10.00	
CREATININE	0-1.3 (MG/DL)	01/01/93	0.70		0.80		0.80	
CREATININE CLEARANCE			107.00					
URIC ACID	0-5.7 (MG/DL)	01/01/93	7.00	>	11.00	>>	3.10	
TOT BILIRUBIN	0-1.3 (MG/DL)	01/01/93	0.60		0.80		0.40	
DIR BILIRUBIN	0-0.3 (MG/DL)	01/01/93			0.40	>		
TOT. PROTEINS	6.2-8.2 (G/DL)	01/01/93	6.90		7.30		7.60	
ALBUMINE	58-72 (X)	01/01/93	66.00		65.80			
TOT. CHOLEST.	120-200 (MG/DL)	01/01/93	225.00	>	266.00	>>	257.00	>
TRIGLYCERIDES	75-200 (MG/DL)	01/01/93	117.00		181.00		187.00	
GLOBULINS ALPHA 1	2-4.2 (X)	01/01/93	2.60		2.60			
GLOBULINS ALPHA 2	6.5-10.3 (X)	01/01/93	7.90		7.80			
GLOBULINS BETA	6.7-11.2 (X)	01/01/93	11.70	>	12.00	>		
GLOBULINS GAMMA	11.8-20.9 (X)	01/01/93	11.80		11.80			
TSH	0.1-4 (UU/ML)	01/01/93	7.10					
T4	0.92-1.82 (NG/DL)	01/01/93	0.90					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/01/93	9.00		5.00		7.00	
ESR/SEDIMENT. RATE 2nd h	0-20 (MM)	01/01/93	16.00		10.00		22.00	

(ϕ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C9550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 23 Patient: 2ND Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			27/01/93		01/03/93		29/03/93	
			value	(⊕)	value	(⊕)	value	(⊕)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/01/93	12.90		13.90		15.30	
HT	37-47 (X)	01/01/93	38.10		42.90		48.00	>
RBC	4.2-5.4 (10 ⁶ /MM ³)	01/01/93	4.25		4.55		5.24	>
WBC	4.8-10.8 (10 ³ /MM ³)	01/01/93						
			6.10		4.00	<	5.50	
WBC: N	45-78 (%)	01/01/93	64.50		65.00		71.00	
WBC: L	18-45 (%)	01/01/93	23.90		23.00		20.00	
WBC: E	0-5 (%)	01/01/93	3.40		3.90		0.00	
WBC: M	2-12 (%)	01/01/93	5.20		5.00		5.00	
WBC: B	0-1 (%)	01/01/93	1.40	>>	1.40	>>	3.00	>>
PLATELETS	125-400 (10 ³ /UL)	01/01/93	311.00		251.00		236.00	
NA+	135-150 (MMOL/L)	01/01/93	143.00		142.00		140.00	
K+	3.6-5.3 (MMOL/L)	01/01/93	3.80		4.20		3.70	
CL-	97-108 (MMOL/L)	01/01/93	106.00		100.00			
Ca++	2.1-2.7 (MMOL/L)	01/01/93	2.40		2.30		2.40	
PO4--	2-4.9 (MG/DL)	01/01/93	2.90		3.10		3.20	
SGOT	0-18 (U/L)	01/01/93	15.00		76.00	>>	13.00	
SGPT	0-22 (U/L)	01/01/93	31.00	>	95.00	>>	15.00	
GAMMA GT	0-18 (U/L)	01/01/93	7.00		5.00		5.00	
LDH	80-240 (U/L)	01/01/93	204.00		268.00	>	254.00	>
ALK. PHOSPH.	50-200 (U/L)	01/01/93	88.00		95.00		97.00	
GLUCOSE	70-110 (MG/DL)	01/01/93	143.00	>			105.00	
BUN	0-25 (MG/DL)	01/01/93	15.00		11.00		17.00	
CREATININE	0-1.3 (MG/DL)	01/01/93	1.00		1.00		1.00	
CREATININE CLEARANCE			71.00					
URIC ACID	0-5.7 (MG/DL)	01/01/93	7.00	>	5.80	>	4.90	
TOT BILIRUBIN	0-1.3 (MG/DL)	01/01/93	0.70		0.60		0.70	
DIR BILIRUBIN	0-0.3 (MG/DL)	01/01/93			0.30			
TOT. PROTEINS	6.2-8.2 (G/DL)	01/01/93	7.10		6.60		7.60	
ALBUMINE	58-72 (%)	01/01/93	63.00		61.90		54.40	<
TOT. CHOLEST.	120-200 (MG/DL)	01/01/93	246.00	>	202.00	>	226.00	>
TRIGLYCERIDES	75-200 (MG/DL)	01/01/93	200.00		100.00		102.00	
GLOBULINS ALPHA 1	2-4.2 (%)	01/01/93	3.10		3.40		4.30	>
GLOBULINS ALPHA 2	6.5-10.3 (%)	01/01/93	8.10		8.10		9.60	
GLOBULINS BETA	6.7-11.2 (%)	01/01/93	12.00	>	12.90	>	13.30	>
GLOBULINS GAMMA	11.8-20.9 (%)	01/01/93	14.10		14.10		18.10	
TSH	0.1-4 (UU/ML)	01/01/93	2.90					
T4	0.92-1.82 (NG/DL)	01/01/93	1.80					
ESR/SEDIMENT. RATE	0-10 (MM)	01/01/93						
1st h			10.00		5.00			
ESR/SEDIMENT. RATE	0-20 (MM)	01/01/93						
2nd h			16.00		16.00			

2183

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 09530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 23 Patient: 3MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			18/03/93		19/04/93		17/05/93	
			value	(†)	value	(†)	value	(†)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/01/93	13.00		13.50		13.50	
HT	37-47 (X)	01/01/93	38.60		41.80		41.80	
RBC	4.2-5.4 (10 ⁶ /MM ³)	01/01/93	4.35		4.58		4.58	
WBC	4.8-10.8 (10 ³ /MM ³)	01/01/93						
			7.10		6.80		5.50	
WBC: N	45-78 (X)	01/01/93	64.70		71.10		64.40	
WBC: L	18-45 (X)	01/01/93	29.60		19.60		25.10	
WBC: E	0-5 (X)	01/01/93	0.60		1.20		1.90	
WBC: M	2-12 (X)	01/01/93	6.40		5.80		6.00	
WBC: B	0-1 (X)	01/01/93	0.60		0.70		0.60	
PLATELETS	125-400 (10 ³ /UL)	01/01/93	241.00		207.00		181.00	
NA+	135-150 (MMOL/L)	01/01/93	146.00		140.00		142.00	
K+	3.6-5.3 (MMOL/L)	01/01/93	3.80		3.70		3.60	
CL-	97-108 (MMOL/L)	01/01/93	100.00		100.00		100.00	
Ca++	2.1-2.7 (MMOL/L)	01/01/93	2.30		2.50		2.40	
PO4--	2-4.9 (MG/DL)	01/01/93	3.40		3.60		3.40	
SGOT	0-18 (U/L)	01/01/93	5.00		6.00		7.00	
SGPT	0-22 (U/L)	01/01/93	9.00		8.00		8.00	
GAMMA GT	0-18 (U/L)	01/01/93	9.00		11.00		9.00	
LDH	80-240 (U/L)	01/01/93	148.00		161.00		148.00	
ALK. PHOSPH.	50-200 (U/L)	01/01/93	103.00		118.00		123.00	
GLUCOSE	70-110 (MG/DL)	01/01/93	105.00					
BUN	0-25 (MG/DL)	01/01/93	13.00		10.00		11.00	
CREATININE	0-1.3 (MG/DL)	01/01/93	0.60		0.90		0.70	
CREATININE CLEARANCE	90-110 (ML/MIN)	01/01/93						
			57.60				100.00	
URIC ACID	0-5.7 (MG/DL)	01/01/93	4.30		4.80		4.80	
TOT BILIRUBIN	0-1.3 (MG/DL)	01/01/93	0.60		0.50		0.70	
TOT. PROTEINS	6.2-8.2 (G/DL)	01/01/93	6.90		7.60		6.90	
ALBUMINE	58-72 (X)	01/01/93	63.00		64.00		65.00	
TOT. CHOLEST.	120-200 (MG/DL)	01/01/93	192.00		263.00	>>	233.00 >	
TRIGLYCERIDES	75-200 (MG/DL)	01/01/93	115.00		95.00		93.00	
GLOBULINS ALPHA 1	2-4.2 (X)	01/01/93	3.20		3.70		3.00	
GLOBULINS ALPHA 2	6.5-10.3 (X)	01/01/93	9.30		8.50		9.00	
GLOBULINS BETA	6.7-11.2 (X)	01/01/93	9.20		9.40		8.50	
GLOBULINS GAMMA	11.8-20.9 (X)	01/01/93	15.10		14.50		14.40	
TSH	0.1-4 (UU/ML)	01/01/93	0.50				0.20	
T4	0.92-1.82 (NG/DL)	01/01/93	1.35				1.70	
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/01/93	10.00		14.00		5.00	
ESR/SEDIMENT. RATE 2nd h	0-20 (MM)	01/01/93	32.00		35.00		20.00	

2184

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA 0530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 1B.0

LABORATORY DATA

Centre: 23 Patient: 4MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			19/03/93		27/04/93		25/05/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/01/93	13.10		12.60		12.00	
HT	37-47 (%)	01/01/93	39.40		39.40		36.20 <	
RBC	4.2-5.4 (10 ⁶ /MM ³)	01/01/93	4.54		4.54		4.21	
WBC	4.8-10.8 (10 ³ /MM ³)	01/01/93						
			8.80		8.90		7.60	
WBC: N	45-78 (%)	01/01/93	64.70		68.60		62.00	
WBC: L	18-45 (%)	01/01/93	26.10		30.90		20.00	
WBC: E	0-5 (%)	01/01/93	1.40		3.70		4.00	
WBC: M	2-12 (%)	01/01/93	6.10		4.80		2.00	
WBC: B	0-1 (%)	01/01/93	0.60		0.80		0.60	
PLATELETS	125-400 (10 ³ /UL)	01/01/93	304.00		296.00		288.00	
NA+	135-150 (MMOL/L)	01/01/93	142.00		143.00		144.00	
K+	3.6-5.3 (MMOL/L)	01/01/93	3.90		3.30 <		4.00	
CL-	97-108 (MMOL/L)	01/01/93	97.00		101.00		103.00	
Ca++	2.1-2.7 (MMOL/L)	01/01/93	2.40		2.40		2.30	
PO4--	2-4.9 (MG/DL)	01/01/93	2.60		3.20		2.90	
SGOT	0-18 (U/L)	01/01/93	12.00		13.00		10.00	
SGPT	0-22 (U/L)	01/01/93	19.00		20.00		16.00	
GAMMA GT	0-18 (U/L)	01/01/93	7.00		9.00		5.00	
LDH	80-240 (U/L)	01/01/93	224.00		181.00		181.00	
ALK. PHOSPH.	50-200 (U/L)	01/01/93	153.00		161.00		147.00	
GLUCOSE	70-110 (MG/DL)	01/01/93	108.00				98.00	
BUN	0-25 (MG/DL)	01/01/93	22.00		23.00		20.00	
CREATININE	0-1.3 (MG/DL)	01/01/93	0.80		1.20		1.00	
CREATININE CLEARANCE			65.30				98.00	
URIC ACID	0-5.7 (MG/DL)	01/01/93	1.60		5.90 >		6.80 >	
TOT BILIRUBIN	0-1.3 (MG/DL)	01/01/93	0.70		0.70		1.00	
TOT. PROTEINS	6.2-8.2 (G/DL)	01/01/93	7.40		7.50		7.50	
ALBUMINE	58-72 (%)	01/01/93	57.00 <		62.00		61.20	
TOT. CHOLEST.	120-200 (MG/DL)	01/01/93	218.00 >		220.00 >		264.00 >>	
TRIGLYCERIDES	75-200 (MG/DL)	01/01/93	173.00		145.00		257.00 >	
GLOBULINS ALPHA 1	2-4.2 (%)	01/01/93	3.30		2.90		3.60	
GLOBULINS ALPHA 2	6.5-10.3 (%)	01/01/93	13.90 >>		11.80 >		11.20 >	
GLOBULINS BETA	6.7-11.2 (%)	01/01/93	11.40 >		10.40		10.40 >	
GLOBULINS GAMMA	11.8-20.9 (%)	01/01/93	14.30		13.40		12.60	
TSH	0.1-4 (UU/ML)	01/01/93	1.30				2.90	
T4	0.92-1.82 (NG/DL)	01/01/93	1.55				1.20	
ESR/SEDIMENT. RATE	0-10 (MM)	01/01/93						
1st h			12.00		15.00		33.00	
ESR/SEDIMENT. RATE	0-20 (MM)	01/01/93						
2nd h			30.00		28.00		60.00	

2185

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value and laboratory not done () missing range value

PHARMACIA 0954089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 23 Patient: SMD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			24/04/93	
			value	(φ)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	01/01/93	11.80	<
HT	37-47 (Z)	01/01/93	37.60	
RBC	4.2-5.4 (10 ⁶ /MM ³)	01/01/93	3.99	<
WBC	4.8-10.8 (10 ³ /MM ³)	01/01/93	4.30	<
WBC: N	45-78 (%)	01/01/93	56.10	
WBC: L	18-45 (%)	01/01/93	25.50	
WBC: E	0-5 (%)	01/01/93	9.90	>>
WBC: M	2-12 (%)	01/01/93	6.20	
WBC: B	0-1 (%)	01/01/93	1.00	
PLATELETS	125-400 (10 ³ /UL)	01/01/93	328.00	
NA+	135-150 (MMOL/L)	01/01/93	144.00	
K+	3.6-5.3 (MMOL/L)	01/01/93	4.30	
CL-	97-108 (MMOL/L)	01/01/93	106.00	
Ca++	2.1-2.7 (MMOL/L)	01/01/93	2.50	
PO4--	2-4.9 (MG/DL)	01/01/93	4.00	
SGOT	0-18 (U/L)	01/01/93	7.00	
SGPT	0-22 (U/L)	01/01/93	10.00	
GAMMA GT	0-18 (U/L)	01/01/93	10.00	
LDH	80-240 (U/L)	01/01/93	169.00	
ALK. PHOSPH.	50-200 (U/L)	01/01/93	108.00	
GLUCOSE	70-110 (MG/DL)	01/01/93	79.00	
BUN	0-25 (MG/DL)	01/01/93	16.00	
CREATININE	0-1.3 (MG/DL)	01/01/93	0.80	
CREATININE CLEARANCE	90-110 (ML/MIN)	01/01/93	100.00	
URIC ACID	0-5.7 (MG/DL)	01/01/93	3.70	
TOT BILIRUBIN	0-1.3 (MG/DL)	01/01/93	0.50	
TOT. PROTEINS	6.2-8.2 (G/DL)	01/01/93	7.50	
ALBUMINE	58-72 (%)	01/01/93	63.00	
TOT. CHOLEST.	120-200 (MG/DL)	01/01/93	321.00	>>
TRIGLYCERIDES	75-200 (MG/DL)	01/01/93	176.00	
GLOBULINS ALPHA 1	2-4.2 (%)	01/01/93	2.90	
GLOBULINS ALPHA 2	6.5-10.3 (%)	01/01/93	10.80	>
GLOBULINS BETA	6.7-11.2 (%)	01/01/93	10.20	
GLOBULINS GAMMA	11.8-20.9 (%)	01/01/93	13.10	
TSH	0.1-4 (UU/ML)	01/01/93	0.10	
T4	0.92-1.82 (NG/DL)	01/01/93	1.34	
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/01/93	19.00	
ESR/SEDIMENT. RATE 2nd h	0-20 (MM)	01/01/93	45.00	

2186

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 09530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 23 Patient: 6MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 49	
			29/06/93		02/08/93		18/08/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HE	12-16 (G/DL)	01/01/93	12.90		14.00		13.60	
HT	37-47 (%)	01/01/93	42.10		45.30		43.30	
RBC	4.2-5.4 (10 ⁶ /MM ³)	01/01/93	4.71		5.10		5.04	
HBC	4.8-10.8 (10 ³ /MM ³)	01/01/93						
HBC: N	45-78 (%)	01/01/93	6.40		6.70		5.90	
HBC: L	18-45 (%)	01/01/93	75.60		72.60		73.20	
HBC: E	0-5 (%)	01/01/93	14.40	<	18.40		17.30	
HBC: M	2-12 (%)	01/01/93	1.30		0.60		1.50	
HBC: B	0-1 (%)	01/01/93	6.30		5.90		6.10	
PLATELETS	125-400 (10 ³ /UL)	01/01/93	0.40		0.40		0.10	
NA+	135-150 (MMOL/L)	01/01/93	225.00		212.00		213.00	
K+	3.6-5.3 (MMOL/L)	01/01/93	143.00		143.00		146.00	
CL-	97-108 (MMOL/L)	01/01/93	4.50		4.20		4.40	
Ca++	2.1-2.7 (MMOL/L)	01/01/93	101.00		101.00		103.00	
PO4--	2-4.9 (MG/DL)	01/01/93	2.50		2.60		2.60	
SGOT	0-22 (U/L)	01/01/93	3.50		3.30		3.10	
SGPT	0-18 (U/L)	01/01/93	7.00		13.00		7.00	
GAMMA GT	0-22 (U/L)	01/01/93	8.00		11.00		9.00	
LDH	80-240 (U/L)	01/01/93	7.00		7.00		7.00	
ALK. PHOSPH.	50-200 (U/L)	01/01/93	121.00		142.00		131.00	
GLUCOSE	70-110 (MG/DL)	01/01/93	104.00		123.00		104.00	
BUN	0-25 (MG/DL)	01/01/93	107.00					
CREATININE	0-1.3 (MG/DL)	01/01/93	15.00					
CREATININE CLEARANCE	90-110 (ML/MIN)	01/01/93	1.00		0.90		1.00	
URIC ACID	0-5.7 (MG/DL)	01/01/93	48.80					
TOT. BILIRUBIN	0-1.3 (MG/DL)	01/01/93	3.80		4.40		4.90	
TOT. PROTEINS	6.2-8.2 (G/DL)	01/01/93	0.70		0.70		0.80	
ALBUMINE	58-72 (%)	01/01/93	7.20		7.70		6.30	
TOT. CHOLEST.	120-200 (MG/DL)	01/01/93	64.00		64.50		64.00	
TRIGLYCERIDES	75-200 (MG/DL)	01/01/93	253.00	>	246.00	>	255.00	
GLOBULINS ALPHA 1	2-4.2 (%)	01/01/93	80.00		119.00		123.00	
GLOBULINS ALPHA 2	6.5-10.3 (%)	01/01/93	2.70		3.10		3.20	
GLOBULINS BETA	6.7-11.2 (%)	01/01/93	10.40	>	9.70		9.90	
GLOBULINS GAMMA	11.8-20.9 (%)	01/01/93	8.80		9.10		9.80	
TSH	0.1-4 (U/ML)	01/01/93	14.40		13.60		13.30	
T4	0.92-1.82 (NG/DL)	01/01/93	0.13					
ESR/SEDIMENT. RATE	0-10 (MM)	01/01/93	1.76					
1st h					19.00			
ESR/SEDIMENT. RATE	0-20 (MM)	01/01/93						
2nd h					41.00			

2187

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 0550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 25 Patient: 1MD Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date	
			Screen	Day 28
			27/08/93	24/09/93
			value (♠)	value (♠)
Laboratory test	Range value	Range date		
HB	14-18 (G/DL)	01/01/90	15.70	13.60 <
HT	42-52 (%)	01/01/90	46.80	39.00 <
RBC	4.3-5.9 (10 ⁶ /MM ³)	01/01/90	5.21	4.40
WBC	4000-8000 (/MM ³)	01/01/90	6800.00	5000.00
WBC: N	50-70 (%)	01/01/90	65.70	
WBC: L	25-40 (%)	01/01/90	25.40	21.00 <
WBC: E	2-4 (%)	01/01/90	1.70 <	
WBC: M	2-8 (%)	01/01/90	7.00	7.00
WBC: B	0-1 (%)	01/01/90	0.20	
PLATELETS	150000-400000 (/MM ³)	01/01/90		
NA+	135-150 (MEQ/L)	01/01/90	180000	210000
K+	3.6-5.2 (MEQ/L)	01/01/90	136.00	142.00
CL-	99-111 (MEQ/L)	01/01/90	3.59 <	4.50
Ca++	4.4-8.5 (MEQ/L)	01/01/90	102.00	107.00
PO4--	2.5-5 (MG/DL)	01/01/90	2.27 <<	4.80
SGOT	5-18 (U/L)	01/01/90	3.50	
SGPT	5-22 (U/L)	01/01/90	13.70	15.00
GAMMA GT	6-28 (U/L)	01/01/90	11.30	13.00
LDH	120-240 (U/L)	01/01/90	11.00	9.00
ALK. PHOSPH.	80-170 (U/L)	01/01/90	195.00	154.00
GLUCOSE	70-110 (MG/DL)	01/01/90	140.00	105.00
BUN	10-50 (MG/DL)	01/01/90	75.00	127.00 >
CREATININE	0.7-1.2 (MG/DL)	01/01/90	75.00 >>	1.60 >
CREATININE CLEARANCE	98-156 (ML/MIN)	01/01/90	1.20	
URIC ACID	3.4-7 (MG/DL)	01/01/90	70.00	
TOT BILIRUBIN	0-1 (MG/DL)	01/01/90	8.50 >	4.80
DIR BILIRUBIN	0-0.24 (MG/DL)	01/01/90	0.54	0.70
TOT. PROTEINS	6.5-7.9 (G/DL)	01/01/90	0.17	
ALBUMINE	51.8-65.4 (%)	01/01/90	8.10 >	8.30 >
TOT. CHOLEST.	120-220 (MG/DL)	01/01/90	46.80 <	52.50
TRIGLYCERIDES	74-172 (MG/DL)	01/01/90	175.00	224.00 >
GLOBULINS ALPHA 1	2.2-5.6 (%)	01/01/90	130.00	121.00
GLOBULINS ALPHA 2	5-10.2 (%)	01/01/90	2.50	3.30
GLOBULINS BETA	8.8-15.6 (%)	01/01/90	7.70	9.20
GLOBULINS GAMMA	11.9-23.3 (%)	01/01/90	8.80	10.80
TSH	0.5-4.2 (UU/ML)	01/01/90	22.00	24.10 >
T4	68-185 (NNOL/L)	01/01/90	0.54	
ESR/SEDIMENT. RATE 1st h	2-10 (MM)	01/01/90	112.00	
ESR/SEDIMENT. RATE 2nd h	11-20 (MM)	01/01/90	35.00	28.00
			58.00	46.00

(♠) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done (♠) missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 09550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 25 Patient: 2ND Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			25/11/93		23/12/93		21/01/94	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/01/90	14.30		13.90		14.10	
HT	37-47 (X)	01/01/90	46.00		43.00		44.00	
RBC	3.9-5.3 (10 ⁶ /MM ³)	01/01/90	5.09		4.87		4.87	
MBC	4000-8000 (/MM ³)	01/01/90	7200.00		6600.00		5200.00	
MBC: N	50-70 (X)	01/01/90	69.00		76.00	>	70.00	
MBC: L	25-40 (X)	01/01/90	22.00	<	19.00	<	24.00	
MBC: E	2-4 (X)	01/01/90	3.00		2.00		4.00	
MBC: M	2-8 (X)	01/01/90	4.00		1.00	<	2.00	
MBC: B	0-1 (X)	01/01/90	0.00		0.00		0.00	
PLATELETS	150000-400000 (/MM ³)	01/01/90	221000		190000		211000	
NA+	135-150 (MEQ/L)	01/01/90	141.00		139.00		140.00	
K+	3.6-5.2 (MEQ/L)	01/01/90	4.10		4.50		4.60	
CL-	99-111 (MEQ/L)	01/01/90	107.00		104.00			
Ca++	4.4-8.5 (MEQ/L)	01/01/90	5.00		5.10		5.00	
PO4--	2.5-5 (MG/DL)	01/01/90	2.70		2.80		2.30	
SGOT	5-15 (U/L)	01/01/90	12.00		9.00		8.00	
SGPT	5-17 (U/L)	01/01/90	23.00	>	9.00		8.00	
GAMMA GT	4-18 (U/L)	01/01/90	32.00	>	12.00		12.00	
LDH	120-240 (U/L)	01/01/90	159.00		145.00		161.00	
ALK. PHOSPH.	80-170 (U/L)	01/01/90	148.00		121.00		137.00	
GLUCOSE	70-110 (MG/DL)	01/01/90	98.00		98.00		101.00	
BUN	10-50 (MG/DL)	01/01/90	33.00		33.00		26.00	
CREATININE	0.5-1 (MG/DL)	01/01/90	1.10	>	1.00		1.10	
CREATININE CLEARANCE			46.00					
URIC ACID	2.4-5.7 (MG/DL)	01/01/90	7.10	>	5.70		5.50	
TOT BILIRUBIN	0-1 (MG/DL)	01/01/90	0.80		0.90		0.80	
TOT. PROTEINS	6.5-7.9 (G/DL)	01/01/90	7.00		7.90		7.20	
ALBUMINE	51.8-65.4 (X)	01/01/90	57.50		54.80		59.20	
TOT. CHOLEST.	120-220 (MG/DL)	01/01/90	271.00	>	233.00	>	242.00	
TRIGLYCERIDES	74-172 (MG/DL)	01/01/90	147.00		87.00		106.00	
GLOBULINS ALPHA 1	2.2-5.6 (X)	01/01/90	3.90		3.60		3.30	
GLOBULINS ALPHA 2	5-10.2 (X)	01/01/90	9.00		12.90	>	8.70	
GLOBULINS BETA	8.8-15.6 (X)	01/01/90	15.80	>	13.10		14.90	
GLOBULINS GAMMA	11.9-23.3 (X)	01/01/90	13.80		15.60		13.80	
TSH	0.1-4 (UU/ML)	01/01/90	0.38					
T4	5-12.5 (UG/DL)	01/01/90	9.80					
ESR/SEDIMENT. RATE	4-12 (MM)	01/01/90						
1st h			16.00		25.00		17.00	
ESR/SEDIMENT. RATE	11-20 (MM)	01/01/90						
2nd h			28.00		40.00		30.00	

2189

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 0530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 26 Patient: 1MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			27/04/93		21/05/93		21/06/93	
			value	(*)	value	(*)	value	(*)
Laboratory test	Range value	Range date						
HB	7.4-12 (MMOL/L)	25/04/93	7.96		8.20		8.19	
HT	0.36-0.84 (L/L)	25/04/93	0.40		0.42		0.43	
RBC	4.2-6.2 (10 ⁶ /MM ³)	25/04/93	4.18	<	4.18	<		
HBC	3.8-10 (10 ³ /MM ³)	25/04/93	4.60		5.30		5.50	
HBC: N	36-84 (%)	25/04/93	54.00					
HBC: L	20-42 (%)	25/04/93	34.00					
HBC: E	0-5 (%)	25/04/93	4.00					
HBC: M	0-10 (%)	25/04/93	7.00					
HBC: B	0-1 (%)	25/04/93	1.00					
PLATELETS	150-300 (10 ³ /MM ³)	25/04/93	240.00		240.00			
NA+	136-143 (MMOL/L)	25/04/93	144.00	>	143.00		147.00 >	
K+	3.6-5 (MMOL/L)	25/04/93	4.33		5.38	>	4.70	
CL-	101-111 (MMOL/L)	25/04/93	107.00		105.00		106.00	
Ca++	2.27-2.64 (MMOL/L)	25/04/93	2.21	<	2.44		2.41	
PO4--	0.77-1.42 (MMOL/L)	25/04/93	1.45	>	1.17		1.28	
SGOT	5-35 (U/L)	25/04/93	22.00		15.00		22.00	
SGPT	7-56 (U/L)	25/04/93	33.00		25.00		21.00	
GAMMA GT	8-78 (U/L)	25/04/93	26.00		32.00		24.00	
LDH	300-540 (U/L)	25/04/93	479.00		586.00	>	531.00	
ALK. PHOSPH.	38-126 (U/L)	25/04/93	75.00		88.00		93.00	
GLUCOSE	3.35-5.55 (MMOL/L)	25/04/93	5.08		5.02		3.84	
BUN	2.5-7.5 (MMOL/L)	25/04/93	6.25		4.41		3.51	
CREATININE	62-130 (UMOL/L)	25/04/93	82.00		87.70		87.50	
CREATININE CLEARANCE	(l)	25/04/93	123.88	(*)				
URIC ACID	161-506 (UMOL/L)	25/04/93	252.00				385.00	
TOT. BILIRUBIN	3.4-22 (UMOL/L)	25/04/93	10.10		11.70		8.80	
DIR. BILIRUBIN	0-5 (UMOL/L)	25/04/93			6.40	>	6.50 >	
TOT. PROTEINS	63-85 (G/L)	25/04/93	64.00		67.00		66.70	
ALBUMINE	39-50 (G/L)	25/04/93	41.40		38.40	<	40.20	
TOT. CHOLEST.	0-5.2 (MMOL/L)	25/04/93	5.55	>	5.88	>	5.98 >	
TRIGLYCERIDES	0.4-1.8 (MMOL/L)	25/04/93	0.55		2.21	>	1.75	
GLOBULINS ALPHA 1	0.03-0.06 (RATIO)	25/04/93	0.03	<	0.02	<<		
	3-6 (%)	20/06/93					2.00 <<	
GLOBULINS ALPHA 2	0.05-0.1 (RATIO)	25/04/93	0.12	>	0.11	>		
	5-10 (%)	20/06/93					11.50 >	
GLOBULINS BETA	0.09-0.14 (RATIO)	25/04/93	0.08	<	0.08	<		
	9-14 (%)	20/06/93					7.60 <	
GLOBULINS GAMMA	0.12-0.2 (RATIO)	25/04/93	0.14		0.12			
	12-20 (%)	20/06/93					8.60 <	
TSH	0.24-2.9 (UUI/ML)	25/04/93	0.92					
T4	5.1-12.4 (UG/DL)	25/04/93	7.20					
ESR/SEDIMENT. RATE	2-10 (MM)	25/04/93						
1st h			11.00		16.00		12.00	
ESR/SEDIMENT. RATE	11-20 (MM)	25/04/93						
2nd h			30.00		39.00		41.00	

2190

(*) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARNACIA 0550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 26 Patient: 1DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	Day 28
			25/06/93	26/07/93
			value (€)	value (€)
Laboratory test	Range value	Range date		
HB	7.4-12 (MMOL/L)	01/05/93	8.60	8.10
HT	0.36-0.84 (L/L)	01/05/93	0.42	0.40
RBC	4.2-6.2 (10 ⁶ /MM ³)	01/05/93	4.36	4.12 <
MBC	3.8-10 (10 ³ /MM ³)	01/05/93	7.90	5.30
MBC: N	0.36-0.84 (L/L)	01/05/93	0.70	0.73
MBC: L	0.2-0.42 (L/L)	01/05/93	0.20	0.24
MBC: E	0-0.05 (L/L)	01/05/93	0.02	
MBC: M	0-0.1 (L/L)	01/05/93	0.05	0.03
PLATELETS	150-300 (10 ³ /MM ³)	01/05/93	200.00	195.00
NA+	136-143 (MMOL/L)	01/05/93	144.00 >	151.00 >
K+	3.6-5 (MMOL/L)	01/05/93	3.90	4.22
CL-	101-111 (MMOL/L)	01/05/93	104.00	107.00
Ca++	2.27-2.64 (MMOL/L)	01/05/93	2.36	2.23 <
PO4--	0.77-1.42 (MMOL/L)	01/05/93	0.91	1.06
SGOT	5-35 (U/L)	01/05/93	20.00	
SGPT	7-56 (U/L)	01/05/93	18.00	
GAMMA GT	8-78 (U/L)	01/05/93	20.00	
LDH	300-540 (U/L)	01/05/93	377.00	
ALK. PHOSPH.	38-126 (U/L)	01/05/93	58.00	
GLUCOSE	3.35-5.55 (MMOL/L)	01/05/93	6.48 >	
BUN	2.5-7.5 (MMOL/L)	01/05/93	2.72	4.50
CREATININE	62-130 (UMOL/L)	01/05/93	73.70	82.00
CREATININE CLEARANCE	()	01/05/93	48.80 ()	
URIC ACID	161-506 (UMOL/L)	01/05/93	218.00	262.00
TOT BILIRUBIN	3.4-22 (UMOL/L)	01/05/93	10.80	9.30
DIR BILIRUBIN	0-5 (UMOL/L)	01/05/93	5.00	7.10 >
TOT. PROTEINS	63-85 (G/L)	01/05/93	66.80	57.90 <
ALBUMINE	39-50 (G/L)	01/05/93	38.90	39.00
TOT. CHOLEST.	0-5.2 (MMOL/L)	01/05/93	5.54 >	5.70 >
TRIGLYCERIDES	0.4-1.8 (MMOL/L)	01/05/93	1.26	1.01
GLOBULINS ALPHA 1	0.03-0.06 (RATIO)	01/05/93		0.03
GLOBULINS ALPHA 2	0.05-0.1 (RATIO)	01/05/93		0.11 >
GLOBULINS BETA	0.09-0.14 (RATIO)	01/05/93		0.09
GLOBULINS GAMMA	0.12-0.2 (RATIO)	01/05/93		0.05 <<
TSH	0.24-2.9 (UUI/ML)	01/05/93	0.59	
T4	5.1-12.4 (UG/DL)	01/05/93	9.90	
ESR/SEDIMENT. RATE	2-10 (MM)	01/05/93		
1st h			15.00	
ESR/SEDIMENT. RATE	11-20 (MM)	01/05/93		
2nd h			30.00	

2191

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C9589089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 27 Patient: 1ND Treatment: Imipramine Sex: Male

			Visit number / Laboratory date	
			Screen	
			01/02/93	
			value	(*)
Laboratory test	Range value	Range date		
HB	12-18 (G/DL)	01/02/93	15.70	
HT	0.37-0.54 (L/L)	01/02/93	0.45	
RBC	4.2-6.3 (10 ⁶ /MM ³)	01/02/93	4.82	
HBC	4.3-10 (10 ³ /MM ³)	01/02/93	5.80	
HBC: L	20.5-51.1 (%)	01/02/93	19.70	<
HBC: M	0.11-0.59 (10 ³ /MM ³)	01/02/93	0.20	
PLATELETS	140-440 (10 ³ /MM ³)	01/02/93	220.00	
NA+	137-147 (MMOL/L)	01/02/93	145.00	
K+	3.5-5.3 (MMOL/L)	01/02/93	3.60	
CL-	98-111 (MMOL/L)	01/02/93	107.00	
Ca++	2.1-2.7 (MMOL/L)	01/02/93	2.40	
PO4--	2.3-4.2 (MG/DL)	01/02/93	3.30	
SGOT	0-18 (U/L)	01/02/93	9.00	
SGPT	0-28 (U/L)	01/02/93	10.00	
GAMMA GT	0-28 (U/L)	01/02/93	14.00	
LDH	0-200 (U/L)	01/02/93	179.00	
ALK. PHOSPH.	68-195 (U/L)	01/02/93	123.00	
GLUCOSE	70-117 (MG/DL)	01/02/93	78.00	
BUN	0-52 (MG/DL)	01/02/93	32.00	
CREATININE	0-1.39 (MG/DL)	01/02/93	1.00	
CREATININE CLEARANCE	80-120 (ML/MIN)	01/02/93	77.00	
URIC ACID	2.9-7.4 (MG/DL)	01/02/93	7.00	
TOT BILIRUBIN	0-1.54 (MG/DL)	01/02/93	1.40	
DIR BILIRUBIN	0-0.3 (MG/DL)	01/02/93	0.40	>
TOT. PROTEINS	6.6-8.3 (G/DL)	01/02/93	7.20	
ALBUMINE	3.7-5.4 (G/DL)	01/02/93	4.70	
TOT. CHOLEST.	150-260 (MG/DL)	01/02/93	232.00	
TRIGLYCERIDES	0-170 (MG/DL)	01/02/93	125.00	
GLOBULINS ALPHA 1	0.12-0.28 (G/DL)	01/02/93	0.30	>
GLOBULINS ALPHA 2	0.45-0.82 (G/DL)	01/02/93	0.60	
GLOBULINS BETA	0.74-1.1 (G/DL)	01/02/93	0.90	
GLOBULINS GAMMA	0.88-1.6 (G/DL)	01/02/93	1.20	
TSH	0.1-3.5 (UU/ML)	01/02/93	1.40	
T4	4.5-12.5 (UG/DL)	01/02/93	7.30	
ESR/SEDIMENT. RATE 1st h	6-11 (MM)	01/02/93	7.00	
ESR/SEDIMENT. RATE 2nd h	5-18 (MM)	01/02/93	18.00	

2192

(*) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN 5510089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 28 Patient: 1MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			13/04/93		18/05/93		15/06/93	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/04/93	12.70		12.60		12.40	
HT	35-47 (%)	01/04/93	39.00		40.00		40.00	
RBC	3.8-5.2 (10 ⁶ /MM ³)	01/04/93	4.30		4.20		4.10	
HBC	4000-10000 (/MM ³)	01/04/93	6700.00		3200.00	<	4100.00	
HBC: N	50-70 (%)	01/04/93	63.00		50.00		48.00	
HBC: L	25-40 (%)	01/04/93	23.00	<	35.00		34.00	
HBC: E	0-4 (%)	01/04/93	5.00	>	2.00		4.00	
HBC: M	0-8 (%)	01/04/93	7.00		8.00		10.00	
HBC: B	0-2 (%)	01/04/93	1.00		2.00		1.00	
PLATELETS	200-300 (10 ³ /MM ³)	01/04/93	292.00		299.00		265.00	
NA+	135-144 (MMOL/L)	01/04/93	147.00	>			149.00	
K+	3.5-5.6 (MMOL/L)	01/04/93	4.00		3.90		4.70	
CL-	95-108 (MMOL/L)	01/04/93	106.00				102.00	
Ca++	2.1-2.6 (MMOL/L)	01/04/93	2.49		2.58		2.44	
PO4--	0.81-1.45 (MMOL/L)	01/04/93	1.19				2.12	
SGOT	0-18 (U/L)	01/04/93	10.00		9.00		12.00	
SGPT	0-22 (U/L)	01/04/93	5.00		9.00		14.00	
GAMMA GT	0-28 (U/L)	01/04/93	12.00		9.00		8.00	
LDH	0-240 (U/L)	01/04/93	240.00		236.00		220.00	
ALK. PHOSPH.	60-200 (U/L)	01/04/93	140.00		101.00		96.00	
GLUCOSE	60-110 (MG/DL)	01/04/93	50.00	<	63.00		66.00	
BUN	0-50 (MG/DL)	01/04/93	33.00		40.00		41.00	
CREATININE	0-1.4 (MG/DL)	01/04/93	1.00		1.23		1.07	
CREATININE CLEARANCE	96-160 (ML/MIN)	01/04/93	56.00					
URIC ACID	2-6 (MG/DL)	01/04/93	4.30		3.90		4.40	
TOT BILIRUBIN	0-1 (MG/DL)	01/04/93	0.48		0.23		0.26	
TOT. PROTEINS	6-8 (G/DL)	01/04/93	6.90		7.20		6.70	
ALBUMINE	58.8-69.6 (%)	01/04/93	65.40		64.00		65.40	
TOT. CHOLEST.	0-220 (MG/DL)	01/04/93	278.00	>	236.00	>	248.00	
TRIGLYCERIDES	0-172 (MG/DL)	01/04/93	94.00		130.00		160.00	
GLOBULINS ALPHA 1	1.8-3.8 (%)	01/04/93	3.50		3.20		3.60	
GLOBULINS ALPHA 2	3.7-13.1 (%)	01/04/93	8.70		8.30		8.30	
GLOBULINS BETA	8.9-13.6 (%)	01/04/93	10.10		16.00	>	13.70	
GLOBULINS GAMMA	8.4-18.3 (%)	01/04/93	12.40		8.50		8.90	
TSH	0.2-5 (UU/ML)	01/04/93	0.70					
T4	4-13 (UG/DL)	01/04/93	5.90					
ESR/SEDIMENT. RATE 1st h	1-13 (MM)	01/04/93	8.00		9.00			
ESR/SEDIMENT. RATE 2nd h	1-20 (MM)	01/04/93	14.00		18.00			

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C9580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 28 Patient: ZND Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			20/04/93		25/05/93		22/06/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/04/93	14.00		13.80		13.50	
HT	35-47 (Z)	01/04/93	44.00		42.00		45.00	
RBC	3.8-5.2 (10 ⁶ /MM ³)	01/04/93	4.70		4.70		4.60	
WBC	4000-10000 (/MM ³)	01/04/93	6900.00		5800.00		5400.00	
WBC: N	50-70 (%)	01/04/93	61.00		49.00	<	46.00	
WBC: L	25-40 (%)	01/04/93	27.00		37.00		44.00	
WBC: E	0-4 (%)	01/04/93	1.00		2.00		1.00	
WBC: M	0-8 (%)	01/04/93	7.00		9.00	>	7.00	
WBC: B	0-2 (%)	01/04/93	1.00		1.00		1.00	
PLATELETS	200-300 (10 ³ /MM ³)	01/04/93	179.00	<	201.00		194.00	
NA+	135-144 (MMOL/L)	01/04/93	144.00		136.00		135.00	
K+	3.5-5.6 (MMOL/L)	01/04/93	4.30		3.60		4.40	
CL-	95-108 (MMOL/L)	01/04/93	97.00		97.00		99.00	
Ca++	2.1-2.6 (MMOL/L)	01/04/93	2.40		2.33		2.34	
PO4--	0.81-1.45 (MMOL/L)	01/04/93	1.90	>>	1.06		1.95	
SGOT	0-18 (U/L)	01/04/93	8.00		7.00		8.00	
SGPT	0-22 (U/L)	01/04/93	6.00		7.00		6.00	
GAMMA GT	0-28 (U/L)	01/04/93	8.00		8.00		8.00	
LDH	0-240 (U/L)	01/04/93	139.00		144.00		149.00	
ALK. PHOSPH.	60-200 (U/L)	01/04/93	148.00		113.00		119.00	
GLUCOSE	60-110 (MG/DL)	01/04/93	63.00		62.00		72.00	
BUN	0-50 (MG/DL)	01/04/93	30.00		22.00		26.00	
CREATININE	0-1.4 (MG/DL)	01/04/93	0.90		0.85		0.91	
CREATININE CLEARANCE	96-160 (ML/MIN)	01/04/93	59.16					
URIC ACID	2-6 (MG/DL)	01/04/93	3.80		3.70		3.90	
TOT. BILIRUBIN	0-1 (MG/DL)	01/04/93	0.34		0.46		0.39	
TOT. PROTEINS	6-8 (G/DL)	01/04/93	6.50		6.60		6.60	
ALBUMINE	58.8-69.6 (%)	01/04/93	63.30		65.70		60.90	
TOT. CHOLEST.	0-220 (MG/DL)	01/04/93	239.00	>	202.00		211.00	
TRIGLYCERIDES	0-172 (MG/DL)	01/04/93	150.00		85.00		120.00	
GLOBULINS ALPHA 1	1.8-3.8 (Z)	01/04/93	3.00		3.10		2.80	
GLOBULINS ALPHA 2	3.7-13.1 (Z)	01/04/93	9.40		8.30		9.60	
GLOBULINS BETA	8.9-13.6 (Z)	01/04/93	13.60		12.80		13.20	
GLOBULINS GAMMA	8.4-18.3 (Z)	01/04/93	10.70		10.00		13.50	
TSH	0.2-5 (UU/ML)	01/04/93	0.40					
T4	4-13 (UG/DL)	01/04/93	6.20					
ESR/SEDIMENT. RATE	1-13 (MM)	01/04/93						
1st h			4.00		9.00		11.00	
ESR/SEDIMENT. RATE	1-20 (MM)	01/04/93						
2nd h			10.00		18.00		17.00	

2194

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 0550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 28 Patient: 3MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			20/04/93		25/05/93		22/06/93	
			value	(ø)	value	(ø)	value	(ø)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/04/93	14.20		12.80		13.20	
HT	35-47 (%)	01/04/93	39.00		40.00		40.00	
RBC	3.8-5.2 (10 ⁶ /MM ³)	01/04/93	4.80		4.80		4.80	
WBC	4000-10000 (/MM ³)	01/04/93	8100.00		7100.00		11520.0 >	
WBC: N	50-70 (%)	01/04/93	60.00		59.00		69.00	
WBC: L	25-40 (%)	01/04/93	31.00		30.00		23.00 <	
WBC: E	0-4 (%)	01/04/93	2.00		3.00		1.00	
WBC: M	0-8 (%)	01/04/93	6.00		5.00		6.00	
WBC: B	0-2 (%)	01/04/93	1.00		1.00		0.00	
PLATELETS	200-300 (10 ³ /MM ³)	01/04/93	228.00		259.00		234.00	
NA+	135-144 (MMOL/L)	01/04/93	143.00		140.00		144.00	
K+	3.5-5.6 (MMOL/L)	01/04/93	3.60		3.80		3.80	
CL-	95-108 (MMOL/L)	01/04/93	102.00		101.00		107.00	
Ca++	2.1-2.6 (MMOL/L)	01/04/93	2.33		2.39		2.28	
PO4--	0.81-1.45 (MMOL/L)	01/04/93	1.09		1.13		1.07	
SGOT	0-18 (U/L)	01/04/93	10.00		10.00		10.00	
SGPT	0-22 (U/L)	01/04/93	12.00		13.00		10.00	
GAMMA GT	0-28 (U/L)	01/04/93	12.00		12.00		12.00	
LDH	0-240 (U/L)	01/04/93	269.00 >		275.00 >		271.00 >	
ALK. PHOSPH.	60-200 (U/L)	01/04/93	166.00		135.00		155.00	
GLUCOSE	60-110 (MG/DL)	01/04/93	82.00		59.00 <		71.00	
BUN	0-50 (MG/DL)	01/04/93	44.00		52.00 >		41.00	
CREATININE	0-1.4 (MG/DL)	01/04/93	1.06		0.93		0.98	
CREATININE CLEARANCE			50.94					
URIC ACID	2-6 (MG/DL)	01/04/93	4.90		0.27 <		4.30	
TOT BILIRUBIN	0-1 (MG/DL)	01/04/93	0.48		0.27		0.41	
TOT. PROTEINS	6-8 (G/DL)	01/04/93	6.90		6.90		7.00	
ALBUMINE	58.8-69.6 (%)	01/04/93	64.80		62.40		62.90	
TOT. CHOLEST.	0-220 (MG/DL)	01/04/93	260.00 >		227.00 >		233.00 >	
TRIGLYCERIDES	0-172 (MG/DL)	01/04/93	250.00 >>		194.00 >		190.00 >	
GLOBULINS ALPHA 1	1.8-3.8 (%)	01/04/93	2.50		3.40		3.20	
GLOBULINS ALPHA 2	3.7-13.1 (%)	01/04/93	7.60		7.60		8.30	
GLOBULINS BETA	8.9-13.6 (%)	01/04/93	13.30		14.80 >		14.10 >	
GLOBULINS GAMMA	8.4-18.3 (%)	01/04/93	11.80		11.70		11.60	
TSH	0.2-5 (UU/ML)	01/04/93	0.90					
T4	4-13 (UG/DL)	01/04/93	7.80					
ESR/SEDIMENT. RATE 1st h	1-13 (MM)	01/04/93	9.00		9.00		25.00	
ESR/SEDIMENT. RATE 2nd h	1-20 (MM)	01/04/93	25.00		15.00		50.00	

2195

(ø) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 0530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 28 Patient: 4ND Treatment: Imipramine Sex: Male

Laboratory test			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			26/04/93		01/06/93		29/06/93	
			value	(⊕)	value	(⊕)	value	(⊕)
HB	12-16 (G/DL)	01/04/93	14.00		13.00		14.20	
HT	35-47 (X)	01/04/93	41.00		42.00		46.00	
RBC	3.8-5.2 (10 ⁶ /MM ³)	01/04/93	4.60		4.30		4.60	
WBC	4000-10000 (/MM ³)	01/04/93	5000.00		5700.00		5800.00	
WBC: N	50-70 (%)	01/04/93	63.00		63.00		57.00	
WBC: L	25-40 (%)	01/04/93	27.00		23.00	<	29.00	
WBC: E	0-4 (%)	01/04/93	2.00		1.00		2.00	
WBC: M	0-8 (%)	01/04/93	6.00		11.00	>>	10.00 >	
WBC: B	0-2 (%)	01/04/93	1.00		1.00		1.00	
PLATELETS	200-300 (10 ³ /MM ³)	01/04/93	188.00	<	136.00	<<	174.00 <	
NA+	135-144 (MMOL/L)	01/04/93	140.00		148.00	>	145.00 >	
K+	3.5-5.6 (MMOL/L)	01/04/93	4.00		4.90		4.70	
CL-	95-108 (MMOL/L)	01/04/93	102.00		107.00		103.00	
Ca++	2.1-2.6 (MMOL/L)	01/04/93	2.29		2.26		2.49	
PO4--	0.81-1.45 (MMOL/L)	01/04/93	0.86				2.27 >>	
SGOT	0-18 (U/L)	01/04/93	5.00		8.00		8.00	
SGPT	0-22 (U/L)	01/04/93	6.00		5.00		5.00	
GAMMA GT	0-28 (U/L)	01/04/93	13.00		11.00		14.00	
LDH	0-240 (U/L)	01/04/93	178.00		173.00		178.00	
ALK. PHOSPH.	60-200 (U/L)	01/04/93	131.00		128.00		116.00	
GLUCOSE	60-110 (MG/DL)	01/04/93	113.00	>	64.00		73.00	
BUN	0-50 (MG/DL)	01/04/93	37.00		35.00		46.00	
CREATININE	0-1.4 (MG/DL)	01/04/93	1.27		1.19		1.19	
CREATININE CLEARANCE			38.30					
URIC ACID	2.5-6.8 (MG/DL)	01/04/93	6.10		4.80		6.00	
TOT. BILIRUBIN	0-1 (MG/DL)	01/04/93	0.70		0.49		0.53	
TOT. PROTEINS	6-8 (G/DL)	01/04/93	6.50		6.10		6.50	
ALBUMINE	58.8-69.6 (%)	01/04/93	62.60		64.60		56.50 <	
TOT. CHOLEST.	0-220 (MG/DL)	01/04/93	230.00	>	194.00		216.00 >	
TRIGLYCERIDES	0-172 (MG/DL)	01/04/93	132.00		178.00	>	190.00 >	
GLOBULINS ALPHA 1	1.8-3.8 (X)	01/04/93	3.70		2.90		3.50	
GLOBULINS ALPHA 2	3.7-13.1 (X)	01/04/93	9.60		8.90		13.30 >	
GLOBULINS BETA	8.9-13.6 (X)	01/04/93	12.90		12.80		15.20 >	
GLOBULINS GAMMA	8.4-18.3 (X)	01/04/93	11.20		10.80		11.50	
TSH	0.2-5 (U/ML)	01/04/93	0.80					
T4	4-13 (UG/DL)	01/04/93	6.60					
ESR/SEDIMENT. RATE	1-13 (MM)	01/04/93						
1st h			20.00				15.00	
ESR/SEDIMENT. RATE	1-20 (MM)	01/04/93						
2nd h			43.00				40.00	

2196

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARNACIA 9550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 28 Patient: 5MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			10/05/93		22/06/93		20/07/93	
			value	(#)	value	(#)	value	(#)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/04/93	13.10		13.80		13.60	
HT	35-47 (X)	01/04/93	40.00		43.00		40.00	
RBC	3.8-5.2 (10 ⁶ /MM ³)	01/04/93	4.20		4.40		4.30	
WBC	4000-10000 (/MM ³)	01/04/93	4900.00		6100.00		6400.00	
WBC: N	50-70 (%)	01/04/93	58.00		55.00		57.00	
WBC: L	25-40 (%)	01/04/93	31.00		31.00		29.00	
WBC: E	0-4 (%)	01/04/93	2.00		3.00		5.00	>
WBC: M	0-8 (%)	01/04/93	6.00		9.00	>	6.00	
WBC: B	0-2 (%)	01/04/93	1.00		1.00		1.00	
PLATELETS	200-300 (10 ³ /MM ³)	01/04/93	163.00	<	232.00		234.00	
NA+	135-144 (MMOL/L)	01/04/93	150.00	>	140.00		146.00	>
K+	3.5-5.6 (MMOL/L)	01/04/93	3.10	<	3.70		4.70	
CL-	95-108 (MMOL/L)	01/04/93	102.00		97.00		107.00	
Ca++	2.1-2.6 (MMOL/L)	01/04/93	2.24		2.28		2.10	
PO4--	0.81-1.45 (MMOL/L)	01/04/93	2.22	>>	2.12	>>	1.13	
SGOT	0-18 (U/L)	01/04/93	8.00		5.00		7.00	
SGPT	0-22 (U/L)	01/04/93	6.00		6.00		7.00	
GAMMA GT	0-28 (U/L)	01/04/93	16.00		18.00		19.00	
LDH	0-240 (U/L)	01/04/93	218.00		217.00		184.00	
ALK. PHOSPH.	60-200 (U/L)	01/04/93	138.00		168.00		162.00	
GLUCOSE	60-110 (MG/DL)	01/04/93	104.00		112.00	>	74.00	
BUN	0-50 (MG/DL)	01/04/93	35.00		36.00		35.00	
CREATININE	0-1.4 (MG/DL)	01/04/93	1.03		1.11		1.06	
CREATININE CLEARANCE			63.39					
URIC ACID	2-6 (MG/DL)	01/04/93	4.00		4.10		4.10	
TOT BILIRUBIN	0-1 (MG/DL)	01/04/93	0.52		0.53		0.50	
TOT. PROTEINS	6-8 (G/DL)	01/04/93	6.60		6.90		6.70	
ALBUMINE	58.8-69.6 (%)	01/04/93	68.20		60.40		67.70	
TOT. CHOLEST.	0-220 (MG/DL)	01/04/93	277.00	>	295.00	>>	290.00	>>
TRIGLYCERIDES	0-172 (MG/DL)	01/04/93	97.00		124.00		133.00	
GLOBULINS ALPHA 1	1.8-3.8 (%)	01/04/93	2.50		3.20		2.70	
GLOBULINS ALPHA 2	3.7-13.1 (%)	01/04/93	7.10		9.10		7.70	
GLOBULINS BETA	8.9-13.6 (%)	01/04/93	10.20		12.60		9.80	
GLOBULINS GAMMA	8.4-18.3 (%)	01/04/93	12.00		14.80		12.10	
TSH	0.2-5 (UU/ML)	01/04/93	3.50					
T4	4-13 (UG/DL)	01/04/93	4.90					
ESR/SEDIMENT. RATE 1st h	1-13 (MM)	01/04/93						
ESR/SEDIMENT. RATE 2nd h	1-20 (MM)	01/04/93			15.00		17.00	
					26.00		25.00	

2197

(#) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARNACIA 0955089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 28 Patient: 1DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			13/04/93		19/05/93		17/06/93	
			value	(*)	value	(*)	value	(*)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/04/93	11.80	<	12.40		11.60 <	
HT	35-47 (%)	01/04/93	37.00		40.00		40.00	
RBC	3.8-5.2 (10 ⁶ /MM ³)	01/04/93	4.00		4.30		3.80	
WBC	4000-10000 (/MM ³)	01/04/93	5600.00		5000.00		5100.00	
WBC: N	50-70 (%)	01/04/93	66.00		63.00		54.00	
WBC: L	25-40 (%)	01/04/93	20.00	<	24.00	<	28.00	
WBC: E	0-4 (%)	01/04/93	4.00		4.00		2.00	
WBC: M	0-8 (%)	01/04/93	8.00		6.00		10.00 >	
WBC: B	0-2 (%)	01/04/93	1.00		1.00		1.00	
PLATELETS	200-300 (10 ³ /MM ³)	01/04/93	282.00		266.00		182.00 <	
NA+	135-144 (MMOL/L)	01/04/93	135.00		135.00		144.00	
K+	3.5-5.6 (MMOL/L)	01/04/93	4.60		4.30		4.30	
CL-	95-108 (MMOL/L)	01/04/93	91.00	<	96.00		98.00	
Ca++	2.1-2.6 (MMOL/L)	01/04/93	2.64	>	2.40		2.14	
PO4--	0.81-1.45 (MMOL/L)	01/04/93	1.47	>	1.00			
SGOT	0-18 (U/L)	01/04/93	10.00		10.00		17.00	
SGPT	0-22 (U/L)	01/04/93	9.00		6.00		10.00	
GAMMA GT	0-28 (U/L)	01/04/93	9.00		14.00		13.00	
LDH	0-240 (U/L)	01/04/93	239.00		248.00	>	265.00 >	
ALK. PHOSPH.	60-200 (U/L)	01/04/93	111.00		136.00		112.00	
GLUCOSE	60-110 (MG/DL)	01/04/93			63.00		64.00	
BUN	0-50 (MG/DL)	01/04/93	38.00		31.00		36.00	
CREATININE	0-1.4 (MG/DL)	01/04/93	1.19		0.97		1.18	
CREATININE CLEARANCE			21.31					
URIC ACID	2-6 (MG/DL)	01/04/93	3.30		3.90		3.60	
TOT BILIRUBIN	0-1 (MG/DL)	01/04/93	0.41		0.56		0.49	
TOT. PROTEINS	6-8 (G/DL)	01/04/93	6.90		7.20		6.50	
ALBUMINE	58.8-69.6 (%)	01/04/93	64.90		62.10		62.90	
TOT. CHOLEST.	0-220 (MG/DL)	01/04/93	260.00	>	262.00	>	235.00 >	
TRIGLYCERIDES	0-172 (MG/DL)	01/04/93	97.00		60.00		87.00	
GLOBULINS ALPHA 1	1.8-3.8 (%)	01/04/93	3.10		3.10		3.10	
GLOBULINS ALPHA 2	3.7-13.1 (%)	01/04/93	7.30		9.50		8.00	
GLOBULINS BETA	8.9-13.6 (%)	01/04/93	13.70	>	10.80		11.30	
GLOBULINS GAMMA	8.4-18.3 (%)	01/04/93	10.90		14.50		14.70	
TSH	0.2-5 (UU/ML)	01/04/93	1.40					
T4	4-13 (UG/DL)	01/04/93	9.10					
ESR/SEDIMENT. RATE 1st h	1-13 (MM)	01/04/93	13.00		20.00			
ESR/SEDIMENT. RATE 2nd h	1-20 (MM)	01/04/93	24.00		48.00			

2198

(*) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done (*) missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 09554089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 28 Patient: ZDT Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			20/04/93		25/05/93		22/06/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/04/93	15.20		15.30		15.60	
HT	35-47 (X)	01/04/93	45.00		44.00		52.00	>
RBC	3.8-5.2 (10 ⁶ /MM ³)	01/04/93	4.80		4.70		5.10	
WBC	4000-10000 (/MM ³)	01/04/93	6600.00		8900.00		7600.00	
WBC: N	50-70 (X)	01/04/93	63.00		60.00		68.00	
WBC: L	25-40 (X)	01/04/93	25.00		27.00		21.00	<
WBC: E	0-4 (X)	01/04/93	2.00		1.00		0.00	
WBC: M	0-8 (X)	01/04/93	8.00		9.00		8.00	>
WBC: B	0-2 (X)	01/04/93	1.00		1.00		1.00	
PLATELETS	200-300 (10 ³ /MM ³)	01/04/93	158.00	<	94.00	<<	145.00	<
NA+	135-144 (MMOL/L)	01/04/93	139.00		134.00	<	138.00	
K+	3.5-5.6 (MMOL/L)	01/04/93	4.30		4.40		5.30	
CL-	95-108 (MMOL/L)	01/04/93	101.00		97.00		93.00	<
Ca++	2.1-2.6 (MMOL/L)	01/04/93	2.29		2.38		2.30	
PO4--	0.81-1.45 (MMOL/L)	01/04/93	0.79	<	0.76	<	2.49	>>
SGOT	0-18 (U/L)	01/04/93	7.00		9.00		24.00	>
SGPT	0-22 (U/L)	01/04/93	5.00		5.00		9.00	
GAMMA GT	0-28 (U/L)	01/04/93	40.00	>	46.00	>	44.00	>
LDH	0-240 (U/L)	01/04/93	187.00		234.00		240.00	
ALK. PHOSPH.	60-200 (U/L)	01/04/93	133.00		141.00		125.00	
GLUCOSE	60-110 (MG/DL)	01/04/93	81.00		75.00		69.00	
BUN	0-50 (MG/DL)	01/04/93	43.00		48.00		46.00	
CREATININE	0-1.4 (MG/DL)	01/04/93	1.16		1.28		1.41	>
CREATININE CLEARANCE			47.22					
URIC ACID	2.5-6.8 (MG/DL)	01/04/93	6.00		6.50		6.10	
TOT BILIRUBIN	0-1 (MG/DL)	01/04/93	0.74		0.77		0.68	
TOT. PROTEINS	6-8 (G/DL)	01/04/93	6.50		7.20		7.30	
ALBUMINE	58.8-69.6 (X)	01/04/93	61.80		60.20		56.20	<
TOT. CHOLEST.	0-220 (MG/DL)	01/04/93	223.00	>	242.00	>	228.00	>
TRIGLYCERIDES	0-172 (MG/DL)	01/04/93	125.00		155.00		142.00	
GLOBULINS ALPHA 1	1.8-3.8 (X)	01/04/93	2.40		3.20		2.60	
GLOBULINS ALPHA 2	3.7-13.1 (X)	01/04/93	8.10		9.70		10.20	
GLOBULINS BETA	8.9-13.6 (X)	01/04/93	12.80		13.40		15.20	>
GLOBULINS GAMMA	8.4-18.3 (X)	01/04/93	14.90		13.60		15.80	
TSH	0.2-5 (UU/ML)	01/04/93	1.10					
T4	4-13 (UG/DL)	01/04/93	8.80					
ESR/SEDIMENT. RATE 1st h	1-13 (MM)	01/04/93						
ESR/SEDIMENT. RATE 2nd h	1-20 (MM)	01/04/93	6.00		15.00		35.00	
			19.00		30.00		60.00	

2199

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 9550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 28 Patient: 3DT Treatment: Imipramine Sex: Male

			Visit number / Laboratory date			
			Screen		Day 56	
			03/05/93		06/07/93	
			value	(c)	value	(c)
Laboratory test	Range value	Range date				
HB	12-16 (G/DL)	01/04/93	14.30		13.80	
HT	35-47 (%)	01/04/93	44.00		46.00	
RBC	3.8-5.2 (10 ⁶ /MM ³)	01/04/93	4.70		4.70	
WBC	4000-10000 (/MM ³)	01/04/93	4500.00		5400.00	
WBC: N	50-70 (%)	01/04/93	63.00		46.00 <	
WBC: L	25-40 (%)	01/04/93	27.00		45.00 >	
WBC: E	0-4 (%)	01/04/93	1.00		1.00	
WBC: M	0-8 (%)	01/04/93	6.00		6.00	
WBC: B	0-2 (%)	01/04/93	1.00		1.00	
PLATELETS	200-300 (10 ³ /MM ³)	01/04/93	217.00		222.00	
NA+	135-144 (MMOL/L)	01/04/93	149.00 >		146.00 >	
K+	3.5-5.6 (MMOL/L)	01/04/93	4.70		4.70	
CL-	95-108 (MMOL/L)	01/04/93	101.00		103.00	
Ca++	2.1-2.6 (MMOL/L)	01/04/93	2.52		2.37	
PO4--	0.81-1.45 (MMOL/L)	01/04/93	2.01 >>		2.25 >>	
SGOT	0-18 (U/L)	01/04/93	13.00		11.00	
SGPT	0-22 (U/L)	01/04/93	7.00		10.00	
GAMMA GT	0-28 (U/L)	01/04/93	16.00		16.00	
LDH	0-240 (U/L)	01/04/93	158.00		165.00	
ALK. PHOSPH.	60-200 (U/L)	01/04/93	125.00		126.00	
GLUCOSE	60-110 (MG/DL)	01/04/93	71.00		72.00	
BUN	0-50 (MG/DL)	01/04/93	39.00		45.00	
CREATININE	0-1.4 (MG/DL)	01/04/93	1.29		1.23	
CREATININE CLEARANCE			57.33			
URIC ACID	2.5-6.8 (MG/DL)	01/04/93	4.30		4.30	
TOT BILIRUBIN	0-1 (MG/DL)	01/04/93	1.11 >		1.30 >	
TOT. PROTEINS	6-8 (G/DL)	01/04/93	6.90		6.80	
ALBUMINE	58.8-69.6 (%)	01/04/93	68.70		65.00	
TOT. CHOLEST.	0-220 (MG/DL)	01/04/93	227.00 >		193.00	
TRIGLYCERIDES	0-172 (MG/DL)	01/04/93	74.00		103.00	
GLOBULINS ALPHA 1	1.8-3.8 (%)	01/04/93	2.90		3.00	
GLOBULINS ALPHA 2	3.7-13.1 (%)	01/04/93	7.80		10.00	
GLOBULINS BETA	8.9-13.6 (%)	01/04/93	12.20		12.20	
GLOBULINS GAMMA	8.4-18.3 (%)	01/04/93	8.40		9.80	
T4	4-13 (UG/DL)	01/04/93	9.60			
ESR/SEDIMENT. RATE	1-13 (MM)	01/04/93				
1st h			12.00		5.00	
ESR/SEDIMENT. RATE	1-20 (MM)	01/04/93				
2nd h			20.00		10.00	

2200

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C5560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 30 Patient: 1ND Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 35		Day 56	
			13/04/93		26/05/93		22/06/93	
			value	(†)	value	(†)	value	(†)
Laboratory test	Range value	Range date						
HB	11.5-16.5 (G/DL)	01/01/92	13.80		14.20		14.40	
HT	0.37-0.47 (L/L)	01/01/92	0.41		0.42		0.44	
RBC	3.8-5.8 (10 ¹² /L)	01/01/92	4.53		4.66		4.88	
WBC	3.5-11 (10 ⁹ /L)	01/01/92	11.20	>	11.00		9.60	
WBC: N	2.5-7.5 (10 ⁹ /L)	01/01/92	9.10	>	9.30	>	7.40	
WBC: L	1.5-4 (10 ⁹ /L)	01/01/92	1.30	<	1.00	<<	1.30	
WBC: E	0-0.4 (10 ⁹ /L)	01/01/92	0.10		0.10		0.10	
WBC: M	0.2-0.8 (10 ⁹ /L)	01/01/92	0.50		0.50		0.70	
PLATELETS	150-400 (10 ⁹ /L)	01/01/92	471.00	>	339.00		355.00	
NA+	136-148 (MMOL/L)	01/01/92	143.00		138.00		138.00	
K+	3.5-5 (MMOL/L)	01/01/92	3.70		4.20		3.90	
CL-	95-105 (MMOL/L)	01/01/92					94.00	
Ca++	2.1-2.6 (MMOL/L)	01/01/92	2.42		2.52		2.54	
PO4--	0.8-1.4 (MMOL/L)	01/01/92			1.05		1.00	
ALK. PHOSPH.	40-130 (IU/L)	01/01/92	233.00	>	200.00	>	205.00	
CREATININE	50-125 (UMOL/L)	01/01/92	93.00		96.00		108.00	
URIC ACID	0.1-0.4 (MMOL/L)	01/01/92					0.28	
TOT. BILLIRUBIN	5-17 (UMOL/L)	01/01/92	2.00	<	4.00	<	4.00	
TOT. PROTEINS	62-80 (G/L)	01/01/92	75.00		78.00		81.00	
ALBUMINE	36-52 (G/L)	01/01/92	39.00		44.00		48.00	
TOT. CHOLEST.	3-6.5 (MMOL/L)	01/01/92	5.20		5.40		5.40	
TRIGLYCERIDES	0.2-1.9 (MMOL/L)	01/01/92	1.43		2.25	>	1.57	
TSH	0.2-4.2 (MU/L)	01/01/92	0.36					
ESR/SEDIMENT. RATE 1st h	0-35 (MM)	01/01/92	79.00		22.00			

2201

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARNACIA CH 550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 30 Patient: ZMD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date
			Screen
			12/07/93
			value (φ)
Laboratory test	Range value	Range date	
HB	11.5-16.5 (G/DL)	01/01/92	13.70
HT	0.37-0.47 (L/L)	01/01/92	0.47
RBC	3.8-5.8 (10 ¹² /L)	01/01/92	4.77
WBC	3.5-11 (10 ⁹ /L)	01/01/92	9.70
WBC: N	2.5-7.5 (10 ⁹ /L)	01/01/92	5.90
WBC: L	1.5-4 (10 ⁹ /L)	01/01/92	2.80
WBC: E	0-0.4 (10 ⁹ /L)	01/01/92	0.20
WBC: M	0.2-0.8 (10 ⁹ /L)	01/01/92	0.70
PLATELETS	150-400 (10 ⁹ /L)	01/01/92	229.00
NA+	136-148 (MMOL/L)	01/01/92	142.00
K+	3.5-5 (MMOL/L)	01/01/92	4.40
CL-	95-105 (MMOL/L)	01/01/92	99.00
Ca++	2.1-2.6 (MMOL/L)	01/01/92	2.32
PO4--	0.8-1.4 (MMOL/L)	01/01/92	1.03
ALK. PHOSPH.	40-130 (IU/L)	01/01/92	114.00
UREA	2.5-6.5 (MMOL/L)	01/01/92	4.20
CREATININE	50-125 (UMOL/L)	01/01/92	90.00
URIC ACID	0.1-0.4 (MMOL/L)	01/01/92	0.43 >
TOT BILIRUBIN	5-17 (UMOL/L)	01/01/92	9.00
TOT. PROTEINS	62-80 (G/L)	01/01/92	69.00
ALBUMINE	36-52 (G/L)	01/01/92	42.00
TOT. CHOLEST.	3-6.5 (MMOL/L)	01/01/92	5.50
TRIGLYCERIDES	0.2-1.9 (MMOL/L)	01/01/92	2.10 >
TSH	0.2-4.2 (MU/L)	01/01/92	0.91
ESR/SEDIMENT. RATE 1st h	0-35 (MM)	01/01/92	11.00

2202

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA 09554089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 30 Patient: 3MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 21		Day 56	
			25/10/93		29/11/93		05/01/94	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	11.5-16.5 (G/DL)	01/01/92	16.40		15.60		14.90	
HT	0.37-0.47 (L/L)	01/01/92	0.46		0.44		0.43	
RBC	3.8-5.8 (10 ¹² /L)	01/01/92	5.35		5.20		5.07	
WBC	3.5-11 (10 ⁹ /L)	01/01/92	12.00	>	9.90		7.40	
WBC: N	2.5-7.5 (10 ⁹ /L)	01/01/92	8.20	>	6.80		4.80	
WBC: L	1.5-4 (10 ⁹ /L)	01/01/92	2.40		2.10		1.70	
WBC: E	0-0.4 (10 ⁹ /L)	01/01/92	0.10		0.10		0.20	
WBC: M	0.2-0.8 (10 ⁹ /L)	01/01/92	1.20	>>	0.80		0.60	
PLATELETS	150-400 (10 ⁹ /L)	01/01/92	299.00		301.00		250.00	
NA+	136-148 (MMOL/L)	01/01/92	143.00		141.00		140.00	
K+	3.5-5 (MMOL/L)	01/01/92	4.00		3.60		4.10	
CL-	95-105 (MMOL/L)	01/01/92	84.00	<<	95.00		95.00	
Ca++	2.1-2.6 (MMOL/L)	01/01/92	2.60		2.51		2.51	
PO4--	0.8-1.4 (MMOL/L)	01/01/92	0.95		1.15		0.89	
SGOT	0-40 (IU/L)	01/01/92			20.00		23.00	
GAMMA GT	0-50 (IU/L)	01/01/92	57.00	>	46.00			
ALK. PHOSPH.	40-130 (IU/L)	01/01/92	173.00	>	202.00	>	200.00	
UREA	2.5-6.5 (MMOL/L)	01/01/92	6.70	>			6.30	
CREATININE	50-125 (UMOL/L)	01/01/92	107.00		94.00		93.00	
URIC ACID	0.1-0.4 (MMOL/L)	01/01/92	0.49	>	0.48	>	0.48	
TOT. BILIRUBIN	5-17 (UMOL/L)	01/01/92	5.00		8.00		8.00	
TOT. PROTEINS	62-80 (G/L)	01/01/92	69.00		69.00		68.00	
ALBUMINE	36-52 (G/L)	01/01/92	44.00		44.00		43.00	
TOT. CHOLEST.	3-6.5 (MMOL/L)	01/01/92	7.20	>	7.80	>	7.80	
TRIGLYCERIDES	0.2-1.9 (MMOL/L)	01/01/92					1.86	
TSH	0.2-4.2 (MU/L)	01/01/92	0.87					
ESR/SEDIMENT. RATE 1st h	0-35 (MM)	01/01/92	4.00				11.00	

2203

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 0959089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 30 Patient: 4MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			29/10/93		02/12/93		30/12/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	11.5-16.5 (G/DL)	01/01/92	13.60		13.60		13.60	
HT	0.37-0.47 (L/L)	01/01/92	0.40		0.39		0.40	
RBC	3.8-5.8 (10 ¹² /L)	01/01/92	4.33		4.31		4.37	
WBC	3.5-11 (10 ⁹ /L)	01/01/92	6.90		7.80		6.70	
WBC: N	2.5-7.5 (10 ⁹ /L)	01/01/92	5.40		5.50		4.90	
WBC: L	1.5-4 (10 ⁹ /L)	01/01/92	1.00	<<	1.30	<	1.20	
WBC: E	0-0.4 (10 ⁹ /L)	01/01/92	0.20		0.20		0.20	
WBC: M	0.2-0.8 (10 ⁹ /L)	01/01/92	0.30		0.70		0.40	
PLATELETS	150-400 (10 ⁹ /L)	01/01/92	241.00		296.00		250.00	
NA+	136-148 (MMOL/L)	01/01/92	142.00		141.00		142.00	
K+	3.5-5 (MMOL/L)	01/01/92	4.00		4.80		4.10	
CL-	95-105 (MMOL/L)	01/01/92	99.00		104.00		99.00	
Ca++	2.1-2.6 (MMOL/L)	01/01/92	2.36		2.40		2.30	
PO4--	0.8-1.4 (MMOL/L)	01/01/92	1.15		1.39		1.04	
SGOT	0-40 (IU/L)	01/01/92	20.00		17.00		17.00	
ALK. PHOSPH.	40-130 (IU/L)	01/01/92	79.00		92.00		93.00	
UREA	2.5-6.5 (MMOL/L)	01/01/92	6.30				5.90	
CREATININE	50-125 (UMOL/L)	01/01/92	99.00		91.00		90.00	
URIC ACID	0.1-0.4 (MMOL/L)	01/01/92	0.38		0.34		0.38	
TOT BILIRUBIN	5-17 (UMOL/L)	01/01/92	5.00		1.00	<	5.00	
TOT. PROTEINS	62-80 (G/L)	01/01/92	67.00		71.00		72.00	
ALBUMINE	36-52 (G/L)	01/01/92	43.00		45.00		43.00	
TOT. CHOLEST.	3-6.5 (MMOL/L)	01/01/92	5.40		5.20		5.40	
TRIGLYCERIDES	0.2-1.9 (MMOL/L)	01/01/92	2.07	>	4.22	>>	2.11	
TSH	0.2-4.2 (MU/L)	01/01/92	0.81					
ESR/SEDIMENT. RATE 1st h	0-35 (MM)	01/01/92	14.00		25.00		25.00	

2204

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA 09550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 30 Patient: SMD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date
			Screen
			10/12/93
			value (c)
Laboratory test	Range value	Range date	
HB	11.5-16.5 (G/DL)	01/01/92	12.90
HT	0.37-0.47 (L/L)	01/01/92	0.37 <
RBC	3.8-5.8 (10 ¹² /L)	01/01/92	4.54
HBC	3.5-11 (10 ⁹ /L)	01/01/92	9.90
HBC: N	2.5-7.5 (10 ⁹ /L)	01/01/92	7.30
HBC: L	1.5-4 (10 ⁹ /L)	01/01/92	1.20 <
HBC: E	0-0.4 (10 ⁹ /L)	01/01/92	0.60 >>
HBC: M	0.2-0.8 (10 ⁹ /L)	01/01/92	0.70
PLATELETS	150-400 (10 ⁹ /L)	01/01/92	269.00
NA+	136-148 (MMOL/L)	01/01/92	122.00 <<
K+	3.5-5 (MMOL/L)	01/01/92	3.10 <
CL-	95-105 (MMOL/L)	01/01/92	84.00 <<
Ca++	2.1-2.6 (MMOL/L)	01/01/92	2.42
PO4--	0.8-1.4 (MMOL/L)	01/01/92	1.08
GAMMA GT	0-50 (IU/L)	01/01/92	36.00
ALK. PHOSPH.	40-130 (IU/L)	01/01/92	91.00
UREA	2.5-6.5 (MMOL/L)	01/01/92	3.90
CREATININE	50-125 (UMOL/L)	01/01/92	96.00
URIC ACID	0.1-0.4 (MMOL/L)	01/01/92	0.38
TOT BILIRUBIN	5-17 (UMOL/L)	01/01/92	7.00
TOT. PROTEINS	62-80 (G/L)	01/01/92	80.00
ALBUMINE	36-52 (G/L)	01/01/92	47.00
TOT. CHOLEST.	3-6.5 (MMOL/L)	01/01/92	6.00
TRIGLYCERIDES	0.2-1.9 (MMOL/L)	01/01/92	1.28
TSH	0.2-4.2 (MU/L)	01/01/92	0.72

2205

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARNACIA 0550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 31 Patient: 1ND Treatment: Imipramine Sex: Female

			Visit number / Laboratory data	
			Screen	Day 14
			18/09/92	09/10/92
			value (c)	value (c)
Laboratory test	Range value	Range date		
HB	11.5-16.5 (G/DL)	01/06/92	14.09	13.80
HT	0.37-0.47 (L/L)	01/06/92	0.42	0.40
RBC	3.8-5.8 (10 ¹² /L)	01/06/92	4.55	4.31
WBC	4-11 (10 ⁹ /L)	01/06/92	6.50	5.10
WBC: L	1.5-4 (10 ⁹ /L)	01/06/92	1.20 <	
WBC: M	0.2-0.8 (10 ⁹ /L)	01/06/92	0.80	
PLATELETS	150-400 (10 ⁹ /L)	01/06/92	312.00	326.00
NA+	135-145 (MMOL/L)	01/06/92	139.00	130.00 <
K+	3.5-5 (MMOL/L)	01/06/92	4.80	4.60
Ca++	2.2-2.7 (MMOL/L)	01/06/92	2.70	2.40
PO4--	0.8-1.4 (MMOL/L)	01/06/92	1.12	1.09
SGOT	7-40 (IU/L)	01/06/92	29.00	25.00
GAMMA GT	5-40 (IU/L)	01/06/92	18.00	21.00
LDH	100-350 (IU/L)	01/06/92	294.00	215.00
ALK. PHOSPH.	30-100 (IU/L)	01/06/92	114.00 >	135.00 >
GLUCOSE	2.8-8.3 (MMOL/L)	01/06/92	4.70	5.60
UREA	3-7 (MMOL/L)	01/06/92	6.00	4.10
CREATININE	50-125 (UMOL/L)	01/06/92	88.00	50.00
CREATININE CLEARANCE	()	01/06/92	31.00 ()	
TOT. BILIRUBIN	0-17 (UMOL/L)	01/06/92	12.00	9.00
TOT. PROTEINS	60-80 (G/L)	01/06/92	75.00	68.00
ALBUMINE	35-50 (G/L)	01/06/92	47.00	42.00
TOT. CHOLEST.	3-6.1 (MMOL/L)	01/06/92	6.00	5.30
TRIGLYCERIDES	0.5-2 (MMOL/L)	01/06/92	0.95	0.74
T4	50-150 (NMOL/L)	01/06/92	100.00	
ESR/SEDIMENT. RATE 1st h	2-20 (MM)	01/06/92	8.00	

2206

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 09536089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 31 Patient: 2MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 35		Day 56	
			24/11/92		08/01/93		08/02/93	
			value	(⊕)	value	(⊕)	value	(⊕)
Laboratory test	Range value	Range date						
HB	11.5-16.5 (G/DL)	01/06/92	15.20		14.50		13.60	
HT	0.37-0.47 (L/L)	01/06/92	0.44		0.42		0.39	
RBC	3.8-5.8 (10 ¹² /L)	01/06/92			4.85		4.50	
HBC	4-11 (10 ⁹ /L)	01/06/92	4.60		3.80 <		5.10	
HBC: N	2-7.5 (10 ⁹ /L)	01/06/92	2.90		2.50		3.40	
HBC: L	1.5-4 (10 ⁹ /L)	01/06/92	1.20 <		1.00 <<		1.10 <	
HBC: E	0.04-0.4 (10 ⁹ /L)	01/06/92	0.10		0.10		0.20	
HBC: M	0.2-0.8 (10 ⁹ /L)	01/06/92	0.40		0.20		0.40	
PLATELETS	150-400 (10 ⁹ /L)	01/06/92	191.00		232.00		219.00	
NA+	135-145 (MMOL/L)	01/06/92	139.00		137.00		134.00 <	
K+	3.5-5 (MMOL/L)	01/06/92	4.00		4.20		3.80	
Ca++	2.2-2.7 (MMOL/L)	01/06/92			2.54		2.50	
PO4--	0.8-1.4 (MMOL/L)	01/06/92	0.73 <		1.04		1.07	
SGOT	7-40 (IU/L)	01/06/92	27.00		14.00		21.00	
GAMMA GT	5-40 (IU/L)	01/06/92	29.00		17.00		5.00	
LDH	100-350 (IU/L)	01/06/92	194.00		200.00		206.00	
ALK. PHOSPH.	30-100 (IU/L)	01/06/92	132.00 >		131.00 >		131.00 >	
GLUCOSE	2.8-8.3 (MMOL/L)	01/06/92	5.50		5.00		5.50	
UREA	3-7 (MMOL/L)	01/06/92	5.50		5.20		7.10 >	
CREATININE	50-125 (UMOL/L)	01/06/92	84.00		83.00		62.00	
CREATININE CLEARANCE	()	01/06/92	34.80 ()					
URIC ACID	150-470 (UMOL/L)	01/06/92			410.00			
TOT BILIRUBIN	0-17 (UMOL/L)	01/06/92	8.00		10.00		11.00	
TOT. PROTEINS	60-80 (G/L)	01/06/92	74.00		73.00		74.00	
ALBUMINE	35-50 (G/L)	01/06/92	46.00		47.00		45.00	
TOT. CHOLEST.	3-6.1 (MMOL/L)	01/06/92	3.70		4.00		3.40	
TRIGLYCERIDES	0.5-2 (MMOL/L)	01/06/92	1.05		0.95		1.18	
TSH	0.5-5 (MU/L)	01/06/92	0.40					
T4	50-150 (NMOL/L)	01/06/92	143.00					
ESR/SEDIMENT. RATE 1st h	2-20 (MM)	01/06/92	6.00		8.00		13.00	

2207

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARNACIA 09554089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 31 Patient: 3MD Treatment: Imipramine Sex: Male

			Visit number / Laboratory date
			Screen
			01/12/92
			value (⊕)
Laboratory test	Range value	Range date	
HB	13-18 (G/DL)	01/06/92	14.70
HT	0.4-0.54 (L/L)	01/06/92	0.43
RBC	4.5-6.5 (10 ¹² /L)	01/06/92	4.82
WBC	4-11 (10 ⁹ /L)	01/06/92	7.80
PLATELETS	150-400 (10 ⁹ /L)	01/06/92	307.00
NA+	135-145 (MMOL/L)	01/06/92	138.00
K+	3.5-5 (MMOL/L)	01/06/92	4.20
Ca++	2.2-2.7 (MMOL/L)	01/06/92	2.40
SGOT	7-40 (IU/L)	01/06/92	10.00
GAMMA GT	10-55 (IU/L)	01/06/92	24.00
LDH	100-350 (IU/L)	01/06/92	201.00
ALK. PHOSPH.	30-100 (IU/L)	01/06/92	137.00 >
GLUCOSE	2.8-8.3 (MMOL/L)	01/06/92	9.50 >
UREA	3-7 (MMOL/L)	01/06/92	6.90
TOT BILIRUBIN	0-17 (UMOL/L)	01/06/92	11.00
TOT. PROTEINS	60-80 (G/L)	01/06/92	75.00
ALBUMINE	35-50 (G/L)	01/06/92	44.00
TOT. CHOLEST.	3-6.1 (MMOL/L)	01/06/92	4.00
TRIGLYCERIDES	0.5-2 (MMOL/L)	01/06/92	2.09 >
T4	50-150 (NMOL/L)	01/06/92	87.50
ESR/SEDIMENT. RATE 1st h	2-20 (MM)	01/06/92	20.00

2208

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 058089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 31 Patient: 1DT Treatment: Roboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 35		Day 28	
			15/09/92		04/11/92		23/10/92	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	11.5-16.5 (G/DL)	01/06/92	13.00		13.20			
HT	0.37-0.47 (L/L)	01/06/92	0.39		0.40			
RBC	3.8-5.8 (10 ¹² /L)	01/06/92	4.80		4.97			
WBC	4-11 (10 ⁹ /L)	01/06/92	7.10		6.30			
WBC: L	1.5-4 (10 ⁹ /L)	01/06/92	1.90		1.70			
WBC: M	0.2-0.8 (10 ⁹ /L)	01/06/92	0.40		0.70			
PLATELETS	150-400 (10 ⁹ /L)	01/06/92	232.00		285.00			
NA+	135-145 (MMOL/L)	01/06/92	140.00		134.00	<	133.00 <	
K+	3.5-5 (MMOL/L)	01/06/92	3.80		3.90		4.10	
Ca++	2.2-2.7 (MMOL/L)	01/06/92	2.53		2.27		2.62	
PO4--	0.8-1.4 (MMOL/L)	01/06/92	0.73	<	0.74	<	0.80	
SGOT	7-40 (IU/L)	01/06/92	25.00		17.00		23.00	
GAMMA GT	5-40 (IU/L)	01/06/92	20.00		24.00		29.00	
LDH	100-350 (IU/L)	01/06/92	203.00		212.00		233.00	
ALK. PHOSPH.	30-100 (IU/L)	01/06/92	125.00	>	94.00		98.00	
GLUCOSE	2.8-8.3 (MMOL/L)	01/06/92	6.30		8.10		9.20 >	
UREA	3-7 (MMOL/L)	01/06/92	3.00		3.90		5.00	
CREATININE	50-125 (UMOL/L)	01/06/92	80.00		88.00		94.00	
CREATININE	()	01/06/92						
CLEARANCE			54.05	()				
TOT. BILIRUBIN	0-17 (UMOL/L)	01/06/92	5.00		4.00		5.00	
TOT. PROTEINS	60-80 (G/L)	01/06/92	73.00		73.00		74.00	
ALBUMINE	35-50 (G/L)	01/06/92	42.00		41.00		45.00	
TOT. CHOLEST.	3-6.1 (MMOL/L)	01/06/92	6.00		5.70		5.90	
TRIGLYCERIDES	0.5-2 (MMOL/L)	01/06/92	1.23		1.00		0.96	
T4	50-150 (NMOL/L)	01/06/92	116.00					
ESR/SEDIMENT. RATE	2-20 (MM)	01/06/92						
1st h			12.00		6.00		10.00	

2209

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA 09536089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 32 Patient: 1ND Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			19/03/93		21/04/93		19/05/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	11.5-16.5 (G/DL)	01/01/93	14.00		14.50		14.40	
HT	0.37-0.47 (L/L)	01/01/93	0.41		0.43		0.42	
RBC	3.8-5.5 (10 ¹² /L)	01/01/93	4.67		4.85		4.79	
HBC	4-11 (10 ⁹ /L)	01/01/93	6.80		7.30		6.30	
HBC: N	2-8 (10 ⁹ /L)	01/01/93	3.60		3.70		3.10	
HBC: L	1.5-4 (10 ⁹ /L)	01/01/93	2.50		2.80		2.50	
HBC: E	0.04-0.4 (10 ⁹ /L)	01/01/93	0.10		0.20		0.10	
HBC: M	0.2-0.8 (10 ⁹ /L)	01/01/93	0.60		0.60		0.60	
HBC: B	0.01-0.1 (10 ⁹ /L)	01/01/93	0.00	<	0.00	<	0.00	
PLATELETS	150-450 (10 ⁹ /L)	01/01/93	328.00		338.00		323.00	
NA+	135-145 (MMOL/L)	01/01/93	133.00	<	132.00	<	136.00	
K+	3.5-4.8 (MMOL/L)	01/01/93	3.60		3.60		4.00	
CL-	95-108 (MMOL/L)	01/01/93	95.00		97.00		100.00	
Ca++	2.25-2.65 (MMOL/L)	01/01/93	2.87	>	2.88	>	2.56	
PO4--	0.8-1.4 (MMOL/L)	01/01/93	0.93		1.00		1.06	
SGOT	15-30 (IU/L)	01/01/93	25.00		27.00		25.00	
GAMMA GT	7-33 (IU/L)	01/01/93	115.00	>>	71.00	>>	68.00	
LDH	160-400 (IU/L)	01/01/93	180.00		193.00		167.00	
ALK. PHOSPH.	30-105 (IU/L)	01/01/93	107.00	>	97.00		97.00	
GLUCOSE	3-10 (MMOL/L)	01/01/93	6.30		5.50		5.50	
UREA	2.5-7 (MMOL/L)	01/01/93	4.40		4.10		3.60	
CREATININE	50-100 (UMOL/L)	01/01/93	99.00		93.00		86.00	
CREATININE	()	01/01/93						
CLEARANCE			58.30	()				
URIC ACID	0.14-0.34 (MMOL/L)	01/01/93	0.27		0.22		0.25	
TOT BILIRUBIN	2-17 (UMOL/L)	01/01/93	9.00		14.00		10.00	
DIR BILIRUBIN	0-5 (UMOL/L)	01/01/93	2.00		4.00		3.00	
TOT. PROTEINS	62-82 (G/L)	01/01/93	82.00		82.00		79.00	
ALBUMINE	36-52 (G/L)	01/01/93	46.00		48.00		45.00	
TSH	0.3-5 (MU/L)	01/01/93	1.66					
T4	60-160 (NMOL/L)	01/01/93	93.00					
ESR/SEDIMENT. RATE	0-30 (MM)	01/01/93						
1st h			27.00		19.00		15.00	

2210

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centro: 32 Patient: ZMD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			07/04/93		12/05/93		09/06/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	11.5-16.5 (G/DL)	01/01/93	14.10		14.50		14.30	
HT	0.37-0.47 (L/L)	01/01/93	0.40		0.43		0.42	
RBC	3.8-5.5 (10 ¹² /L)	01/01/93	4.85		5.12		5.03	
WBC	4-11 (10 ⁹ /L)	01/01/93	8.00		6.30		6.20	
WBC: N	2-8 (10 ⁹ /L)	01/01/93	4.70		3.70		3.80	
WBC: L	1.5-4 (10 ⁹ /L)	01/01/93	2.20		1.60		1.50	
WBC: E	0.04-0.4 (10 ⁹ /L)	01/01/93	0.20		0.30		0.20	
WBC: M	0.2-0.8 (10 ⁹ /L)	01/01/93	0.80		0.60		0.70	
WBC: B	0.01-0.1 (10 ⁹ /L)	01/01/93	0.10		0.10		0.00 <	
PLATELETS	150-450 (10 ⁹ /L)	01/01/93	195.00		220.00		241.00	
NA+	135-145 (MMOL/L)	01/01/93	137.00		134.00 <		137.00	
K+	3.5-4.8 (MMOL/L)	01/01/93	3.00 <		3.80		3.70	
CL-	95-108 (MMOL/L)	01/01/93	103.00		99.00		102.00	
Ca++	2.25-2.65 (MMOL/L)	01/01/93	2.32		2.32		2.37	
PO4--	0.8-1.4 (MMOL/L)	01/01/93	1.26		1.21		1.38	
SGOT	15-30 (IU/L)	01/01/93	22.00		38.00 >		89.00 >>	
CANNA GT	7-33 (IU/L)	01/01/93	16.00		22.00		40.00 >	
LDH	160-400 (IU/L)	01/01/93	188.00		183.00		270.00	
ALK. PHOSPH.	30-105 (IU/L)	01/01/93	73.00		94.00		96.00	
GLUCOSE	3-10 (MMOL/L)	01/01/93	6.00		5.10			
UREA	2.5-7 (MMOL/L)	01/01/93	7.70 >		5.70		5.90	
CREATININE	50-100 (UMOL/L)	01/01/93	102.00 >		98.00		105.00 >	
CREATININE CLEARANCE	()	01/01/93	52.76 ()					
URIC ACID	0.14-0.34 (MMOL/L)	01/01/93	0.46 >>		0.34		0.37 >	
TOT BILIRUBIN	2-17 (UMOL/L)	01/01/93	8.00		5.00		6.00	
DIR BILIRUBIN	0-5 (UMOL/L)	01/01/93	2.00		2.00		4.00	
TOT. PROTEINS	62-82 (G/L)	01/01/93	72.00				72.00	
ALBUMINE	36-52 (G/L)	01/01/93	47.00		47.00		44.00	
TOT. CHOLEST.	3.5-5.2 (MMOL/L)	01/01/93	6.20 >		6.40 >		6.00 >	
TRIGLYCERIDES	0.3-2.3 (MMOL/L)	01/01/93	1.90		1.60		2.30	
TSH	0.3-5 (MU/L)	01/01/93	4.52					
T4	60-160 (NMOL/L)	01/01/93	75.00					
ESR/SEDIMENT. RATE 1st h	0-30 (MM)	01/01/93					7.00	

2211

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS 59089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 32 Patient: 3MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			15/04/93		19/05/93		16/06/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	11.5-16.5 (G/DL)	01/01/93	14.90		13.90		14.00	
HT	0.37-0.47 (L/L)	01/01/93	0.45		0.41		0.40	
RBC	3.8-5.5 (10 ¹² /L)	01/01/93	5.00		4.68		4.67	
HBC	4-11 (10 ⁹ /L)	01/01/93	5.60		6.60		6.80	
WBC: N	2-8 (10 ⁹ /L)	01/01/93	3.30		3.80		3.60	
WBC: L	1.5-4 (10 ⁹ /L)	01/01/93	1.70		2.20		2.60	
WBC: E	0.04-0.4 (10 ⁹ /L)	01/01/93	0.20		0.10		0.10	
WBC: M	0.2-0.8 (10 ⁹ /L)	01/01/93	0.30		0.40		0.50	
WBC: B	0.01-0.1 (10 ⁹ /L)	01/01/93	0.10		0.10		0.00 <	
PLATELETS	150-450 (10 ⁹ /L)	01/01/93	345.00		359.00		414.00	
NA+	135-145 (MMOL/L)	01/01/93	139.00		137.00		136.00	
K+	3.5-4.8 (MMOL/L)	01/01/93	4.10		3.80		3.60	
CL-	95-108 (MMOL/L)	01/01/93	97.00		97.00		96.00	
Ca ⁺⁺	2.25-2.65 (MMOL/L)	01/01/93	2.50		2.28		2.47	
PO ₄ ⁻⁻	0.8-1.4 (MMOL/L)	01/01/93	1.63 >>		1.20		1.07	
SGOT	15-30 (IU/L)	01/01/93	21.00		19.00		29.00	
GAMMA GT	7-33 (IU/L)	01/01/93	16.00		20.00		25.00	
LDH	160-400 (IU/L)	01/01/93	199.00		190.00		213.00	
ALK. PHOSPH.	30-105 (IU/L)	01/01/93	71.00		70.00		70.00	
GLUCOSE	3-10 (MMOL/L)	01/01/93	2.40 <		5.20		5.10	
UREA	2.5-7 (MMOL/L)	01/01/93	6.80		5.80		7.40 >	
CREATININE	50-100 (UMOL/L)	01/01/93	111.00 >		102.00 >		96.00	
CREATININE CLEARANCE	()	01/01/93	40.20 ()					
URIC ACID	0.14-0.34 (MMOL/L)	01/01/93	0.47 >>		0.44 >		0.54 >>	
TOT BILIRUBIN	2-17 (UMOL/L)	01/01/93	10.00		12.00		14.00	
DIR BILIRUBIN	0-5 (UMOL/L)	01/01/93	3.00		2.00		4.00	
TOT. PROTEINS	62-82 (G/L)	01/01/93	81.00		71.00		77.00	
ALBUMINE	36-52 (G/L)	01/01/93	45.00		40.00		45.00	
TRIGLYCERIDES	0.3-2.3 (MMOL/L)	01/01/93	1.80		1.70		1.10	
TSH	0.3-5 (MU/L)	01/01/93	0.81					
T ₄	60-160 (NMOL/L)	01/01/93	103.00					
ESR/SEDIMENT. RATE 1st h	0-30 (MM)	01/01/93	2.00		17.00		23.00	

2212

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA 09584089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 32 Patient: 4ND Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date
			Screen
			08/09/93
			value (⊕)
Laboratory test	Range value	Range date	
HB	11.5-16.5 (G/DL)	01/01/93	13.00
HT	0.37-0.47 (L/L)	01/01/93	0.38
RBC	3.8-5.5 (10 ¹² /L)	01/01/93	4.06
WBC	4-11 (10 ⁹ /L)	01/01/93	8.80
WBC: N	2-8 (10 ⁹ /L)	01/01/93	5.60
WBC: L	1.5-4 (10 ⁹ /L)	01/01/93	2.50
WBC: E	0.04-0.4 (10 ⁹ /L)	01/01/93	0.10
WBC: M	0.2-0.8 (10 ⁹ /L)	01/01/93	0.50
WBC: B	0.01-0.1 (10 ⁹ /L)	01/01/93	0.10
PLATELETS	150-450 (10 ⁹ /L)	01/01/93	247.00
NA+	135-145 (MMOL/L)	01/01/93	138.00
K+	3.5-4.8 (MMOL/L)	01/01/93	4.50
CL-	95-108 (MMOL/L)	01/01/93	109.00 >
Ca++	2.25-2.65 (MMOL/L)	01/01/93	2.25
PO4--	0.8-1.4 (MMOL/L)	01/01/93	1.03
SGOT	15-30 (IU/L)	01/01/93	18.00
GAMMA GT	7-33 (IU/L)	01/01/93	23.00
LDH	160-400 (IU/L)	01/01/93	180.00
ALK. PHOSPH.	30-105 (IU/L)	01/01/93	70.00
GLUCOSE	3-10 (MMOL/L)	01/01/93	4.20
UREA	2.5-7 (MMOL/L)	01/01/93	5.00
CREATININE	50-100 (UMOL/L)	01/01/93	102.00 >
CREATININE CLEARANCE	()	01/01/93	41.84 ()
URIC ACID	0.14-0.34 (MMOL/L)	01/01/93	0.25
TOT BILIRUBIN	2-17 (UMOL/L)	01/01/93	4.00
DIR BILIRUBIN	0-5 (UMOL/L)	01/01/93	1.00
TOT. PROTEINS	62-82 (G/L)	01/01/93	69.00
ALBUMINE	36-52 (G/L)	01/01/93	37.00
TOT. CHOLEST.	3.5-5.2 (MMOL/L)	01/01/93	6.70 >
TSH	0.3-5 (MU/L)	01/01/93	1.96
T4	60-160 (NMOL/L)	01/01/93	99.00
ESR/SEDIMENT. RATE 1st h	0-30 (MM)	01/01/93	21.00

2213

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C9554089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 32 Patient: SMD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	Day 28
			27/10/93	02/12/93
			value (€)	value (€)
Laboratory test	Range value	Range date		
HB	11.5-16.5 (G/DL)	01/01/93	14.00	15.00
HT	0.37-0.47 (L/L)	01/01/93	0.42	0.44
RBC	3.8-5.5 (10 ¹² /L)	01/01/93	4.58	4.79
MBC	4-11 (10 ⁹ /L)	01/01/93	5.90	10.60
MBC: N	2-8 (10 ⁹ /L)	01/01/93	4.00	8.10 >
MBC: L	1.5-4 (10 ⁹ /L)	01/01/93	1.40 <	1.60
MBC: E	0.04-0.4 (10 ⁹ /L)	01/01/93	0.00 <	0.10
MBC: M	0.2-0.8 (10 ⁹ /L)	01/01/93	0.50	0.80
MBC: B	0.01-0.1 (10 ⁹ /L)	01/01/93	0.00 <	0.00 <
PLATELETS	150-450 (10 ⁹ /L)	01/01/93	225.00	240.00
NA+	135-145 (MMOL/L)	01/01/93	141.00	141.00
K+	3.5-4.8 (MMOL/L)	01/01/93	4.50	4.20
CL-	95-108 (MMOL/L)	01/01/93	102.00	104.00
Ca++	2.25-2.65 (MMOL/L)	01/01/93	2.32	2.26
PO4--	0.8-1.4 (MMOL/L)	01/01/93	1.33	1.36
SGOT	15-30 (IU/L)	01/01/93	12.00 <	18.00
GAMMA GT	7-33 (IU/L)	01/01/93	19.00	19.00
LDH	160-400 (IU/L)	01/01/93	146.00 <	177.00
ALK. PHOSPH.	30-105 (IU/L)	01/01/93	56.00	56.00
GLUCOSE	3-10 (MMOL/L)	01/01/93	4.80	4.90
UREA	2.5-7 (MMOL/L)	01/01/93	4.50	4.80
CREATININE	50-100 (UMOL/L)	01/01/93	101.00 >	101.00 >
CREATININE CLEARANCE	()	01/01/93	31.90 ()	
URIC ACID	0.14-0.34 (MMOL/L)	01/01/93	0.27	0.26
TOT BILIRUBIN	2-17 (UMOL/L)	01/01/93	7.00	7.00
DIR BILIRUBIN	0-5 (UMOL/L)	01/01/93	2.00	2.00
TOT. PROTEINS	62-82 (G/L)	01/01/93	72.00	
ALBUMINE	36-52 (G/L)	01/01/93	43.00	39.00
TOT. CHOLEST.	3.5-5.2 (MMOL/L)	01/01/93	7.30 >>	6.20 >
TRIGLYCERIDES	0.3-2.3 (MMOL/L)	01/01/93	0.70	1.10
TSH	0.3-5 (MU/L)	01/01/93	7.89	
T4	60-160 (NMOL/L)	01/01/93	80.00	
ESR/SEDIMENT. RATE 1st h	0-30 (MM)	01/01/93		3.00

2214

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 055089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 32 Patient: 6HD Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			06/10/93		16/12/93		12/01/94	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	01/01/93	13.00		13.20		13.20	
HT	0.4-0.51 (L/L)	01/01/93	0.37 <		0.39 <		0.39 <	
RBC	4.5-6.2 (10 ¹² /L)	01/01/93	4.10 <		4.24 <		4.24 <	
WBC	4-11 (10 ⁹ /L)	01/01/93	6.60		5.70		5.70	
WBC: N	2-8 (10 ⁹ /L)	01/01/93	3.70		3.10		3.10	
WBC: L	1.5-4 (10 ⁹ /L)	01/01/93	2.00		1.40 <		1.40 <	
WBC: E	0.04-0.4 (10 ⁹ /L)	01/01/93	0.50 >		0.50 >		0.50 >	
WBC: M	0.2-0.8 (10 ⁹ /L)	01/01/93	0.40		0.60		0.60	
WBC: B	0.01-0.1 (10 ⁹ /L)	01/01/93	0.00 <		0.10		0.10	
PLATELETS	150-450 (10 ⁹ /L)	01/01/93	178.00		206.00		206.00	
NA+	135-145 (MMOL/L)	01/01/93	138.00		137.00		136.00	
K+	3.5-4.8 (MMOL/L)	01/01/93	4.40		4.30		4.50	
CL-	95-108 (MMOL/L)	01/01/93	101.00		100.00		101.00	
Ca++	2.25-2.65 (MMOL/L)	01/01/93	2.32		2.23 <		2.34	
PO4--	0.8-1.4 (MMOL/L)	01/01/93	1.20		1.32		1.19	
SGOT	15-40 (IU/L)	01/01/93			18.00		18.00	
GAMMA GT	10-50 (IU/L)	01/01/93	24.00		24.00		30.00	
LDH	160-400 (IU/L)	01/01/93	206.00		199.00		197.00	
ALK. PHOSPH.	30-105 (IU/L)	01/01/93	70.00		79.00		84.00	
GLUCOSE	3-10 (MMOL/L)	01/01/93	5.20		6.50		6.50	
UREA	2.5-7 (MMOL/L)	01/01/93	5.80		5.50		6.90	
CREATININE	60-110 (UMOL/L)	01/01/93	109.00		117.00 >		97.00	
URIC ACID	0.14-0.34 (MMOL/L)	01/01/93	0.28				0.23	
TOT BILIRUBIN	2-17 (UMOL/L)	01/01/93	6.00		6.00		8.00	
DIR BILIRUBIN	0-5 (UMOL/L)	01/01/93	2.00		2.00		2.00	
TOT. PROTEINS	62-82 (G/L)	01/01/93	69.00		70.00		70.00	
ALBUMINE	36-52 (G/L)	01/01/93	42.00		41.00		41.00	
TOT. CHOLEST.	3.5-5.2 (MMOL/L)	01/01/93	5.20		5.20		5.10	
TRIGLYCERIDES	0.3-2.3 (MMOL/L)	01/01/93	1.80		1.50		1.50	
TSH	0.3-5 (MU/L)	01/01/93	2.29					
T4	60-160 (NMOL/L)	01/01/93	116.00					
ESR/SEDIMENT. RATE	0-20 (MM)	01/01/93						
1st h			1.00		34.00		18.00	

2215

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C8560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 35 Patient: 1MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date
			Screen
			25/01/93
			value (e)
Laboratory test	Range value	Range date	
HB	12-18 (G/DL)	01/01/93	13.30
HT	36-52 (X)	01/01/93	39.90
RBC	4-5.2 (10 ⁶ /MM ³)	01/01/93	4.16
WBC	4-9 (10 ³ /MM ³)	01/01/93	7.80
WBC: N	40-80 (X)	01/01/93	62.10
WBC: L	18-45 (X)	01/01/93	21.40
WBC: E	0-6 (X)	01/01/93	0.40
WBC: M	1-10 (X)	01/01/93	6.50
WBC: B	0-2 (X)	01/01/93	0.80
PLATELETS	100-450 (10 ³ /MM ³)	01/01/93	337.00
NA+	133-145 (MMOL/L)	01/01/93	140.00
K+	3.5-5.1 (MMOL/L)	01/01/93	4.66
CL-	95-107 (MMOL/L)	01/01/93	98.00
Ca ⁺⁺	8.4-10.5 (MG/DL)	01/01/93	9.40
PO ₄ ⁻⁻	2.4-4.5 (MG/DL)	01/01/93	3.60
GAMMA GT	3-27 (U/L)	01/01/93	28.00 >
LDH	70-240 (U/L)	01/01/93	167.00
ALK. PHOSPH.	60-190 (U/L)	01/01/93	147.00
GLUCOSE	65-110 (MG/DL)	01/01/93	115.00 >
UREA	15-45 (MG/DL)	01/01/93	29.00
CREATININE	0.2-1.2 (MG/DL)	01/01/93	0.63
CREATININE CLEARANCE	75-125 (ML/MIN)	01/01/93	73.44
URIC ACID	3.5-7.2 (MG/DL)	01/01/93	3.80
TOT BILIRUBIN	0-1.2 (MG/DL)	01/01/93	0.21
DIR BILIRUBIN	0-0.3 (MG/DL)	01/01/93	0.00
TOT. PROTEINS	6-8 (G/DL)	01/01/93	7.10
ALBUMINE	3-4.5 (G/DL)	01/01/93	3.85
TOT. CHOLEST.	170-250 (MG/DL)	01/01/93	217.00
TRIGLYCERIDES	75-175 (MG/DL)	01/01/93	157.00
GLOBULINS ALPHA 1	2.5-6 (X)	01/01/93	3.90
GLOBULINS ALPHA 2	7.5-14.5 (X)	01/01/93	14.10
GLOBULINS BETA	8-13 (X)	01/01/93	17.50 >>
GLOBULINS GAMMA	10-18 (X)	01/01/93	10.40
TSH	0.1-5 (UIU/ML)	01/01/93	0.94
T4	4.8-12 (UIU/DL)	01/01/93	9.50
ESR/SEDIMENT. RATE 1st h	1-14 (MM)	01/01/93	
ESR/SEDIMENT. RATE 2nd h	4-25 (MM)	01/01/93	36.00
			63.00

2216

(e) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARNACIA C 950089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 35 Patient: ZND Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 28	
			05/02/93		30/03/93	
			value	(€)	value	(€)
Laboratory test	Range value	Range date				
HB	12-18 (G/DL)	01/01/93	14.60		10.30 <	
HT	36-52 (X)	01/01/93	42.70		31.50 <	
RBC	4-5.2 (10 ⁶ /MM ³)	01/01/93	4.70		3.40 <<	
MBC	4-9 (10 ³ /MM ³)	01/01/93	11.30 >		12.40 >>	
MBC: N	40-80 (X)	01/01/93	74.00		83.00 >	
MBC: L	18-45 (X)	01/01/93	18.00		5.00 <<	
MBC: E	0-6 (X)	01/01/93	0.00		5.00 >	
MBC: M	1-10 (X)	01/01/93	8.00		4.00 >	
MBC: B	0-2 (X)	01/01/93	0.00		1.00 >>	
PLATELETS	100-450 (10 ³ /MM ³)	01/01/93	309.00		589.00 >>	
NA+	133-145 (MMOL/L)	01/01/93	138.00		132.00 <	
K+	3.5-5.1 (MMOL/L)	01/01/93	4.65		4.90 >	
CL-	95-107 (MMOL/L)	01/01/93	104.00		97.00 >	
Ca++	8.4-10.5 (MG/DL)	01/01/93	9.90		9.00 >	
PO4--	2.4-4.5 (MG/DL)	01/01/93	3.00		3.00 >	
SCOT	0-18 (U/L)	01/01/93	10.00		9.00 >	
SGPT	0-22 (U/L)	01/01/93	9.00		19.00 >	
GAMMA GT	3-27 (U/L)	01/01/93	5.00		15.00 >	
LDH	70-240 (U/L)	01/01/93	256.00 >		141.00 >	
ALK. PHOSPH.	60-190 (U/L)	01/01/93	136.00		167.00 >	
GLUCOSE	65-110 (MG/DL)	01/01/93	103.00		81.00 >	
UREA	15-45 (MG/DL)	01/01/93	34.00		65.00 >	
CREATININE	0.2-1.2 (MG/DL)	01/01/93	1.00		1.10 >	
CREATININE CLEARANCE			49.60			
URIC ACID	3.5-7.2 (MG/DL)	01/01/93	5.50		4.90 >	
TOT BILIRUBIN	0-1.2 (MG/DL)	01/01/93	0.50		0.48 >	
DIR BILIRUBIN	0-0.3 (MG/DL)	01/01/93	0.36 >		0.17 >	
TOT. PROTEINS	6-8 (G/DL)	01/01/93	5.80 <		6.40 <	
ALBUMINE	3-4.5 (G/DL)	01/01/93	3.00		2.40 <	
TOT. CHOLEST.	170-250 (MG/DL)	01/01/93	265.00 >		200.00 >	
TRIGLYCERIDES	75-175 (MG/DL)	01/01/93	184.00 >		144.00 >	
GLOBULINS ALPHA 1	2.5-6 (X)	01/01/93	3.20			
GLOBULINS ALPHA 2	7.5-14.5 (X)	01/01/93	13.40			
GLOBULINS BETA	8-13 (X)	01/01/93	12.30			
GLOBULINS GAMMA	10-18 (X)	01/01/93	12.70			
TSH	0.1-5 (UIU/ML)	01/01/93	1.40			
T4	4.8-12 (UIU/DL)	01/01/93	8.00			
ESR/SEDIMENT. RATE	1-14 (MM)	01/01/93				
1st h			18.00		92.00	
ESR/SEDIMENT. RATE	4-25 (MM)	01/01/93				
2nd h			55.00		128.00	

2217

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C8550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 35 Patient: 3MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date
			Screen
			27/03/93
			value (φ)
Laboratory test	Range value	Range date	
HB	12-18 (G/DL)	01/01/93	15.00
HT	36-52 (%)	01/01/93	45.20
RBC	4-5.2 (10 ⁶ /MM ³)	01/01/93	5.00
WBC	4-9 (10 ³ /MM ³)	01/01/93	8.90
WBC: N	40-80 (%)	01/01/93	77.10
WBC: L	18-45 (%)	01/01/93	12.90 <
WBC: E	0-6 (%)	01/01/93	0.50
WBC: M	1-10 (%)	01/01/93	8.20
WBC: B	0-2 (%)	01/01/93	0.90
PLATELETS	100-450 (10 ³ /MM ³)	01/01/93	106.00
NA+	133-145 (MMOL/L)	01/01/93	139.00
K+	3.5-5.1 (MMOL/L)	01/01/93	4.10
CL-	95-107 (MMOL/L)	01/01/93	102.00
Ca++	8.4-10.5 (MG/DL)	01/01/93	9.60
SGOT	0-18 (U/L)	01/01/93	10.00
SGPT	0-22 (U/L)	01/01/93	13.00
GAMMA GT	3-27 (U/L)	01/01/93	10.00
LDH	70-240 (U/L)	01/01/93	155.00
GLUCOSE	65-110 (MG/DL)	01/01/93	210.00 >>
UREA	15-45 (MG/DL)	01/01/93	53.00 >
CREATININE	0.2-1.2 (MG/DL)	01/01/93	1.30 >
URIC ACID	3.5-7.2 (MG/DL)	01/01/93	8.40 >
TOT BILIRUBIN	0-1.2 (MG/DL)	01/01/93	0.90
DIR BILIRUBIN	0-0.3 (MG/DL)	01/01/93	0.00
TOT. PROTEINS	6-8 (G/DL)	01/01/93	6.80
ALBUMINE	3-4.5 (G/DL)	01/01/93	3.40
TOT. CHOLEST.	170-250 (MG/DL)	01/01/93	198.00
TRIGLYCERIDES	75-175 (MG/DL)	01/01/93	132.00
GLOBULINS ALPHA 1	2.5-6 (%)	01/01/93	4.60
GLOBULINS ALPHA 2	7.5-14.5 (%)	01/01/93	11.20
GLOBULINS BETA	8-13 (%)	01/01/93	14.60 >
GLOBULINS GAMMA	10-18 (%)	01/01/93	12.80
TSH	0.1-5 (UIU/ML)	01/01/93	0.93
T4	4.8-12 (UG/DL)	01/01/93	12.00
ESR/SEDIMENT. RATE 1st h	1-14 (MM)	01/01/93	27.00
ESR/SEDIMENT. RATE 2nd h	4-25 (MM)	01/01/93	54.00

2218

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C9554089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 35 Patient: 4ND Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			15/04/93		17/05/93		14/06/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-18 (G/DL)	01/01/93	11.80	<	13.40		12.80	
HT	36-52 (%)	01/01/93	35.70	<	40.20		38.00	
RBC	4-5.2 (10 ⁶ /MM ³)	01/01/93	3.87	<	4.30		4.14	
WBC	4-9 (10 ³ /MM ³)	01/01/93	7.10		9.00		7.60	
WBC: N	40-80 (%)	01/01/93	63.00		59.00		60.00	
WBC: L	18-45 (%)	01/01/93	27.00		33.00		29.00	
WBC: E	0-6 (%)	01/01/93	0.00		1.00		3.00	
WBC: M	1-10 (%)	01/01/93	8.00		7.00		9.00	
WBC: B	0-2 (%)	01/01/93	0.00		0.00		0.00	
PLATELETS	100-450 (10 ³ /MM ³)	01/01/93	323.00		253.00		286.00	
NA+	133-145 (MMOL/L)	01/01/93	137.00		136.00		134.00	
K+	3.5-5.1 (MMOL/L)	01/01/93	3.95		3.50		3.64	
CL-	95-107 (MMOL/L)	01/01/93	99.00		96.00		94.00 <	
Ca++	8.4-10.5 (MG/DL)	01/01/93	9.30		10.10		9.20	
PO4--	2.4-4.5 (MG/DL)	01/01/93	3.30				3.80	
SGOT	0-18 (U/L)	01/01/93	10.00		9.00		9.00	
SGPT	0-22 (U/L)	01/01/93	10.00		7.00		9.00	
GAMMA GT	3-27 (U/L)	01/01/93	10.00		8.00		8.00	
LDH	70-240 (U/L)	01/01/93	156.00		173.00		143.00	
ALK. PHOSPH.	60-190 (U/L)	01/01/93	138.00		129.00		106.00	
GLUCOSE	65-110 (MG/DL)	01/01/93	116.00	>	109.00		96.00	
UREA	15-45 (MG/DL)	01/01/93	64.00	>	74.00	>>	48.00 >	
CREATININE	0.2-1.2 (MG/DL)	01/01/93	1.30	>	1.40	>>	1.10	
URIC ACID	3.5-7.2 (MG/DL)	01/01/93	6.80		4.00		4.10	
TOT BILIRUBIN	0-1.2 (MG/DL)	01/01/93	0.70		0.65		0.50	
DIR BILIRUBIN	0-0.3 (MG/DL)	01/01/93	0.16		0.12		0.06	
TOT. PROTEINS	6-8 (G/DL)	01/01/93	6.90		6.80		6.20	
ALBUMINE	3-4.5 (G/DL)	01/01/93			3.70		3.09	
TOT. CHOLEST.	170-250 (MG/DL)	01/01/93	218.00		238.00		207.00	
TRIGLYCERIDES	75-175 (MG/DL)	01/01/93	126.00		174.00		107.00	
GLOBULINS ALPHA 1	2.5-6 (%)	01/01/93	4.50		7.30	>	3.10	
GLOBULINS ALPHA 2	7.5-14.5 (%)	01/01/93	13.80		14.80	>	11.20	
GLOBULINS BETA	8-13 (%)	01/01/93	13.10	>	21.10	>>	13.20 >	
GLOBULINS GAMMA	10-18 (%)	01/01/93	13.00		24.90	>>	13.20	
TSH	0.1-5 (UIU/ML)	01/01/93	1.30					
T4	4.8-12 (UG/DL)	01/01/93	9.30					
ESR/SEDIMENT. RATE	1-14 (MM)	01/01/93						
1st h			58.00		46.00			
ESR/SEDIMENT. RATE	4-25 (MM)	01/01/93						
2nd h			114.00		90.00			

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

2219

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C850089

REBOXETINE - PROTOCOL: 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 35 Patient: 5ND Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			02/07/93		05/08/93		02/09/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-18 (G/DL)	01/01/93	15.90		15.40		16.70	
HT	36-52 (X)	01/01/93	46.40		44.40		50.20	
RBC	4-5.2 (10 ⁶ /MM ³)	01/01/93	5.20		4.90		5.40 >	
MBC	4-9 (10 ³ /MM ³)	01/01/93	4.90		6.40		5.20	
MBC: N	40-80 (X)	01/01/93	76.00		70.00		61.00	
MBC: L	18-45 (X)	01/01/93	13.00 <		15.00 <		29.00	
MBC: E	0-6 (X)	01/01/93	4.00		9.00 >>		4.00	
MBC: M	1-10 (X)	01/01/93	6.00		5.00		4.00	
MBC: B	0-2 (X)	01/01/93	1.00		0.00		2.00	
PLATELETS	100-450 (10 ³ /MM ³)	01/01/93	177.00		186.00		192.00	
NA+	133-145 (MMOL/L)	01/01/93	142.00		138.00		140.00	
K+	3.5-5.1 (MMOL/L)	01/01/93	4.06		3.90		4.06	
CL-	95-107 (MMOL/L)	01/01/93	102.00		102.00		101.00	
Ca++	8.4-10.5 (MG/DL)	01/01/93	10.10		10.40		10.60 >	
PO4--	2.4-4.5 (MG/DL)	01/01/93	2.70		3.30		2.90 >	
SGOT	0-18 (U/L)	01/01/93	9.00		8.00		8.00	
SGPT	0-22 (U/L)	01/01/93	10.00		8.00		10.00	
GAMMA GT	3-27 (U/L)	01/01/93	16.00		17.00		15.00	
LDH	70-240 (U/L)	01/01/93	155.00		158.00		165.00	
ALK. PHOSPH.	60-190 (U/L)	01/01/93	137.00		125.00		121.00	
GLUCOSE	65-110 (MG/DL)	01/01/93	101.00		96.00		118.00 >	
UREA	15-45 (MG/DL)	01/01/93	15.00		31.00		29.00	
CREATININE	0.2-1.2 (MG/DL)	01/01/93	1.00		1.10		1.00	
CREATININE CLEARANCE			58.81					
URIC ACID	3.5-7.2 (MG/DL)	01/01/93	3.40 <		3.70		3.50	
TOT BILIRUBIN	0-1.2 (MG/DL)	01/01/93	0.98		0.56		0.67	
DIR BILIRUBIN	0-0.3 (MG/DL)	01/01/93	0.24		0.14		0.24	
TOT. PROTEINS	6-8 (G/DL)	01/01/93	7.20		7.10		7.10	
ALBUMINE	3-4.5 (G/DL)	01/01/93	4.29		3.40		4.12	
TOT. CHOLEST.	170-250 (MG/DL)	01/01/93	184.00		208.00		246.00	
TRIGLYCERIDES	75-175 (MG/DL)	01/01/93	93.00		103.00		99.00	
GLOBULINS ALPHA 1	2.5-6 (X)	01/01/93	3.40		3.20		2.90	
GLOBULINS ALPHA 2	7.5-14.5 (X)	01/01/93	9.40		11.10		9.50	
GLOBULINS BETA	8-13 (X)	01/01/93	13.30 >		17.90 >>		15.70 >	
GLOBULINS GAMMA	10-18 (X)	01/01/93	14.30		18.90 >		13.90	
TSH	0.1-5 (UIU/ML)	01/01/93	1.20					
T4	4.8-12 (UG/DL)	01/01/93	5.10					
ESR/SEDIMENT. RATE 1-14 (MM)								
1st h			10.00		16.00		9.00	
ESR/SEDIMENT. RATE 4-25 (MM)		01/01/93						
2nd h			32.00		36.00		27.00	

2220

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C9580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 35 Patient: 6ND Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	Day 28
			19/01/94	16/02/94
			value (†)	value (†)
Laboratory test	Range value	Range date		
HB	12-18 (G/DL)	01/01/93	14.80	14.80
HT	36-52 (%)	01/01/93	42.50	41.90
RBC	4-5.2 (10 ⁶ /MM ³)	01/01/93	4.80	4.78
WBC	4-9 (10 ³ /MM ³)	01/01/93	5.30	7.80
WBC: N	40-80 (%)	01/01/93	49.00	76.00
WBC: L	18-45 (%)	01/01/93	45.00	18.00
WBC: E	0-6 (%)	01/01/93	1.00	1.00
WBC: M	1-10 (%)	01/01/93	4.00	2.00
WBC: B	0-2 (%)	01/01/93	1.00	2.00
PLATELETS	100-450 (10 ³ /MM ³)	01/01/93	242.00	236.00
NA+	133-145 (MMOL/L)	01/01/93	140.00	139.00
K+	3.5-5.1 (MMOL/L)	01/01/93	4.49	4.63
CL-	95-107 (MMOL/L)	01/01/93	104.00	102.00
Ca++	8.4-10.5 (MG/DL)	01/01/93	9.70	10.00
PO4--	2.4-4.5 (MG/DL)	01/01/93	3.80	4.90 >
SGOT	0-18 (U/L)	01/01/93	8.00	14.00
SGPT	0-22 (U/L)	01/01/93	9.00	22.00
GAMMA GT	3-27 (U/L)	01/01/93	9.00	31.00 >
LDH	70-240 (U/L)	01/01/93	162.00	193.00
ALK. PHOSPH.	60-190 (U/L)	01/01/93	104.00	122.00
GLUCOSE	65-110 (MG/DL)	01/01/93	111.00 >	119.00 >
UREA	15-45 (MG/DL)	01/01/93	49.00 >	63.00 >
CREATININE	0.2-1.2 (MG/DL)	01/01/93	1.00	1.00
URIC ACID	3.5-7.2 (MG/DL)	01/01/93	3.50	5.30
TOT. BILIRUBIN	0-1.2 (MG/DL)	01/01/93	0.55	0.32
DIR. BILIRUBIN	0-0.3 (MG/DL)	01/01/93	0.05	0.06
TOT. PROTEINS	6-8 (G/DL)	01/01/93	6.70	6.70
ALBUMINE	3-4.5 (G/DL)	01/01/93	3.68	3.87
TOT. CHOLEST.	170-250 (MG/DL)	01/01/93	233.00	227.00
TRIGLYCERIDES	75-175 (MG/DL)	01/01/93	244.00 >>	441.00 >>
GLOBULINS ALPHA 1	2.5-6 (%)	01/01/93	3.20	3.60
GLOBULINS ALPHA 2	7.5-14.5 (%)	01/01/93	9.60	9.70
GLOBULINS BETA	8-13 (%)	01/01/93	15.90 >	15.40 >
GLOBULINS GAMMA	10-18 (%)	01/01/93	12.20	10.80
TSH	0.1-5 (UIU/ML)	01/01/93	0.83	
T4	4.8-12 (UG/DL)	01/01/93	8.10	
ESR/SEDIMENT. RATE	1-14 (MM)	01/01/93		
1st h			16.00	26.00
ESR/SEDIMENT. RATE	4-25 (MM)	01/01/93		
2nd h			37.00	50.00

2221

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 0560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 35 Patient: 7MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 28	
			08/12/93		06/01/94	
			value	(€)	value	(€)
Laboratory test	Range value	Range date				
HB	12-18 (G/DL)	01/01/93	11.40	<	11.30 <	
HT	36-52 (%)	01/01/93	33.20	<	33.20 <	
RBC	4-5.2 (10 ⁶ /MM ³)	01/01/93	4.11		4.07	
MBC	4-9 (10 ³ /MM ³)	01/01/93	2.90	<	3.20 <	
MBC: N	40-80 (%)	01/01/93	74.00		73.00	
MBC: L	18-45 (%)	01/01/93	15.00	<	16.00 <	
MBC: E	0-6 (%)	01/01/93	2.00		3.00	
MBC: M	1-10 (%)	01/01/93	6.00		5.00	
MBC: B	0-2 (%)	01/01/93	2.00		3.00 >>	
PLATELETS	100-450 (10 ³ /MM ³)	01/01/93	119.00		188.00	
NA+	133-145 (MMOL/L)	01/01/93	142.00		140.00	
K+	3.5-5.1 (MMOL/L)	01/01/93	3.37	<	3.73	
CL-	95-107 (MMOL/L)	01/01/93	110.00	>	105.00	
Ca++	8.4-10.5 (MG/DL)	01/01/93	9.50		9.50	
PO4--	2.4-4.5 (MG/DL)	01/01/93	3.50		3.60	
SGOT	0-18 (U/L)	01/01/93	11.00		7.00	
SGPT	0-22 (U/L)	01/01/93	11.00		6.00	
GAMMA GT	3-27 (U/L)	01/01/93	27.00		26.00	
LDH	70-240 (U/L)	01/01/93	204.00		194.00	
ALK. PHOSPH.	60-190 (U/L)	01/01/93	123.00		143.00	
GLUCOSE	65-110 (MG/DL)	01/01/93	95.00		95.00	
UREA	15-45 (MG/DL)	01/01/93	22.00		22.00	
CREATININE	0.2-1.2 (MG/DL)	01/01/93	1.00		1.00	
CREATININE CLEARANCE			71.38			
URIC ACID	3.5-7.2 (MG/DL)	01/01/93	4.60		4.40	
TOT BILIRUBIN	0-1.2 (MG/DL)	01/01/93	0.73		0.68	
DIR BILIRUBIN	0-0.3 (MG/DL)	01/01/93	0.17		0.17	
TOT. PROTEINS	6-8 (G/DL)	01/01/93	6.20		6.10	
ALBUMINE	3-4.5 (G/DL)	01/01/93	3.35		2.94 <	
TOT. CHOLEST.	170-250 (MG/DL)	01/01/93	212.00		234.00	
TRIGLYCERIDES	75-175 (MG/DL)	01/01/93	141.00		180.00 >	
GLOBULINS ALPHA 1	2.5-6 (%)	01/01/93	4.20		4.60	
GLOBULINS ALPHA 2	7.5-14.5 (%)	01/01/93	10.70		11.50	
GLOBULINS BETA	8-13 (%)	01/01/93	13.40	>	13.40 >	
GLOBULINS GAMMA	10-18 (%)	01/01/93	13.00		13.00	
TSM	0.1-5 (UIU/ML)	01/01/93	0.00			
T4	4.8-12 (UG/DL)	01/01/93	12.00			
ESR/SEDIMENT. RATE	1-14 (MM)	01/01/93				
1st h			30.00		27.00	
ESR/SEDIMENT. RATE	4-25 (MM)	01/01/93				
2nd h			60.00		66.00	

2222

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 9554089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 35 Patient: 8MD Treatment: Imipranine Sex: Female

			Visit number / Laboratory date	
			Screen	Day 28
			31/01/94	28/02/94
			value (e)	value (e)
Laboratory test	Range value	Range date		
HB	12-18 (G/DL)	01/01/93	10.20 <	11.90 <
HT	36-52 (X)	01/01/93	31.50 <	35.00 <
RBC	4-5.2 (10 ⁶ /MM ³)	01/01/93	3.45 <	3.92 <
WBC	4-9 (10 ³ /MM ³)	01/01/93	3.30 <	5.50
WBC: N	40-80 (%)	01/01/93	70.00	78.00
WBC: L	18-45 (%)	01/01/93	24.00	20.00
WBC: E	0-6 (%)	01/01/93	0.00	0.00
WBC: M	1-10 (%)	01/01/93	6.00	1.00
WBC: B	0-2 (%)	01/01/93	0.00	1.00
PLATELETS	100-450 (10 ³ /MM ³)	01/01/93	328.00	336.00
NA+	133-145 (MMOL/L)	01/01/93	141.00	138.00
K+	3.5-5.1 (MMOL/L)	01/01/93	4.30	3.97
CL-	95-107 (MMOL/L)	01/01/93	104.00	98.00
Ca++	8.4-10.5 (MG/DL)	01/01/93	9.10	9.00
PO4--	2.4-4.5 (MG/DL)	01/01/93	3.60	3.70
SGOT	0-18 (U/L)	01/01/93	4.00	7.00
SGPT	0-22 (U/L)	01/01/93	4.00	7.00
GAMMA GT	3-27 (U/L)	01/01/93	5.00	3.00
LDH	70-240 (U/L)	01/01/93	150.00	137.00
ALK. PHOSPH.	60-190 (U/L)	01/01/93	216.00 >	134.00
GLUCOSE	65-110 (MG/DL)	01/01/93	97.00	103.00
UREA	15-45 (MG/DL)	01/01/93	26.00	
CREATININE	0.2-1.2 (MG/DL)	01/01/93	0.60	0.60
CREATININE CLEARANCE			84.15	
URIC ACID	3.5-7.2 (MG/DL)	01/01/93	2.70 <	2.80 <
TOT BILIRUBIN	0-1.2 (MG/DL)	01/01/93	0.41	0.33
DIR BILIRUBIN	0-0.3 (MG/DL)	01/01/93	0.07	0.10
TOT. PROTEINS	6-8 (G/DL)	01/01/93	6.00	6.40
ALBUMINE	3-4.5 (G/DL)	01/01/93	3.85	4.30
TOT. CHOLEST.	170-250 (MG/DL)	01/01/93	194.00	198.00
TRIGLYCERIDES	75-175 (MG/DL)	01/01/93	132.00	103.00
GLOBULINS ALPHA 1	2.5-6 (%)	01/01/93	3.50	2.90
GLOBULINS ALPHA 2	7.5-14.5 (%)	01/01/93	8.80	7.00 <
GLOBULINS BETA	8-13 (%)	01/01/93	11.80	11.00
GLOBULINS GAMMA	10-18 (%)	01/01/93	11.80	13.00
TSH	0.1-5 (UIU/NL)	01/01/93	1.70	
T4	4.8-12 (UG/DL)	01/01/93	5.00	
ESR/SEDIMENT. RATE 1st h	4-14 (MM)	01/01/93	14.00	
ESR/SEDIMENT. RATE 2nd h	4-25 (MM)	01/01/93	35.00	

2223

(e) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARNACIA 9550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 35 Patient: 1DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			17/02/93		01/04/93		27/04/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-18 (G/DL)	01/01/93	12.30		12.20		12.90	
HT	36-52 (X)	01/01/93	36.20		36.00		37.70	
RBC	4-5.2 (10 ⁶ /MM ³)	01/01/93	4.07		4.08		4.31	
HBC	4-9 (10 ³ /MM ³)	01/01/93	6.40		6.30		6.80	
HBC: N	40-80 (X)	01/01/93	51.00		57.00		36.00 <	
HBC: L	18-45 (X)	01/01/93	42.00		37.00		53.00 >	
HBC: E	0-6 (X)	01/01/93	1.00		1.00		1.00	
HBC: M	1-10 (X)	01/01/93	6.00		4.00		9.00	
HBC: B	0-2 (X)	01/01/93	0.00		1.00		1.00	
PLATELETS	100-450 (10 ³ /MM ³)	01/01/93	193.00		378.00		334.00	
NA+	133-145 (MMOL/L)	01/01/93	142.00		141.00		141.00	
K+	3.5-5.1 (MMOL/L)	01/01/93	4.41		4.68		4.89	
CL-	95-107 (MMOL/L)	01/01/93	104.00		103.00		103.00	
Ca++	8.4-10.5 (MG/DL)	01/01/93	9.80		9.60			
PO4--	2.4-4.5 (MG/DL)	01/01/93	3.90		4.00			
SGOT	0-18 (U/L)	01/01/93	9.00		9.00		9.00	
SGPT	0-22 (U/L)	01/01/93	7.00		7.00		8.00	
GAMMA GT	3-27 (U/L)	01/01/93	8.00		9.00		10.00	
LDH	70-240 (U/L)	01/01/93	170.00		91.00		78.00	
ALK. PHOSPH.	60-190 (U/L)	01/01/93	93.00		106.00		95.00	
GLUCOSE	65-110 (MG/DL)	01/01/93	99.00		86.00		94.00	
UREA	15-45 (MG/DL)	01/01/93	31.00		24.00		18.00	
CREATININE	0.2-1.2 (MG/DL)	01/01/93	0.90		0.80		0.80	
CREATININE CLEARANCE	75-125 (ML/MIN)	01/01/93	66.80					
URIC ACID	3.5-7.2 (MG/DL)	01/01/93	5.70		5.30		4.80	
TOT BILIRUBIN	0-1.2 (MG/DL)	01/01/93	0.40		0.31		0.42	
DIR BILIRUBIN	0-0.3 (MG/DL)	01/01/93					0.08	
TOT. PROTEINS	6-8 (G/DL)	01/01/93	6.20		6.60		6.40	
ALBUMINE	3-4.5 (G/DL)	01/01/93			3.41		3.15	
TOT. CHOLEST.	170-250 (MG/DL)	01/01/93	252.00 >		229.00		204.00 >	
TRIGLYCERIDES	75-175 (MG/DL)	01/01/93	152.00		146.00		184.00 >	
GLOBULINS ALPHA 1	2.5-6 (X)	01/01/93	2.60		2.80		2.20 <	
GLOBULINS ALPHA 2	7.5-14.5 (X)	01/01/93	14.00		12.90		13.70	
GLOBULINS BETA	8-13 (X)	01/01/93	12.50		12.30		10.40	
GLOBULINS GAMMA	10-18 (X)	01/01/93	9.30 <		11.00		11.00	
TSH	0.1-5 (UIU/ML)	01/01/93	4.50					
T4	4.8-12 (UG/DL)	01/01/93	5.90					
ESR/SEDIMENT. RATE 1-14 (MM)		01/01/93						
1st h			9.00		23.00		21.00	
ESR/SEDIMENT. RATE 4-25 (MM)		01/01/93						
2nd h			27.00		60.00		50.00	

2224

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 955089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 35 Patient: 2DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			02/03/93		30/03/93		27/04/93	
			value	(†)	value	(†)	value	(†)
Laboratory test	Range value	Range date						
HB	12-18 (G/DL)	01/01/93	13.20		12.90		13.20	
HT	36-52 (X)	01/01/93	40.30		38.60		38.70	
RBC	4-5.2 (10 ⁶ /MM ³)	01/01/93	4.47		4.36		4.38	
WBC	4-9 (10 ³ /MM ³)	01/01/93	4.10		3.80	<	4.50	
WBC: N	40-80 (X)	01/01/93	66.00		62.00		51.00	
WBC: L	18-45 (X)	01/01/93	30.00		32.00		40.00	
WBC: E	0-6 (X)	01/01/93	0.00		0.00		2.00	
WBC: M	1-10 (X)	01/01/93	4.00		4.00		5.00	
WBC: B	0-2 (X)	01/01/93	0.00		2.00		2.00	
PLATELETS	100-450 (10 ³ /MM ³)	01/01/93	350.00		284.00		287.00	
NA+	133-145 (MMOL/L)	01/01/93	140.00		137.00		137.00	
K+	3.5-5.1 (MMOL/L)	01/01/93	5.02		4.15		4.85	
CL-	95-107 (MMOL/L)	01/01/93	104.00		100.00		101.00	
Ca++	8.4-10.5 (MG/DL)	01/01/93	9.70		9.50		9.50	
PO4--	2.4-4.5 (MG/DL)	01/01/93	3.70				4.50	
SGOT	0-18 (U/L)	01/01/93	9.00		11.00		12.00	
SGPT	0-22 (U/L)	01/01/93	7.00		9.00		11.00	
GAMMA GT	3-27 (U/L)	01/01/93	17.00		14.00		18.00	
LDH	70-240 (U/L)	01/01/93	199.00				251.00 >	
ALK. PHOSPH.	60-190 (U/L)	01/01/93	126.00		146.00		176.00	
GLUCOSE	65-110 (MG/DL)	01/01/93	100.00		105.00		94.00	
UREA	15-45 (MG/DL)	01/01/93	40.00		29.00		32.00	
CREATININE	0.2-1.2 (MG/DL)	01/01/93	1.00		0.80		0.80	
CREATININE CLEARANCE			57.80					
URIC ACID	3.5-7.2 (MG/DL)	01/01/93	3.20	<	3.90		5.40	
TOT BILIRUBIN	0-1.2 (MG/DL)	01/01/93	0.67		0.43		0.55	
DIR BILIRUBIN	0-0.3 (MG/DL)	01/01/93	0.07				0.17	
TOT. PROTEINS	6-8 (G/DL)	01/01/93	7.10		6.80		6.80	
ALBUMINE	3-4.5 (G/DL)	01/01/93			3.66		4.00	
TOT. CHOLEST.	170-250 (MG/DL)	01/01/93	286.00 >		316.00 >		269.00 >	
GLOBULINS ALPHA 1	2.5-6 (X)	01/01/93			3.70		2.60	
GLOBULINS ALPHA 2	7.5-14.5 (X)	01/01/93			10.30		10.60	
GLOBULINS BETA	8-13 (X)	01/01/93			12.00		12.30	
GLOBULINS GAMMA	10-18 (X)	01/01/93			11.40		12.60	
TSH	0.1-5 (UIU/ML)	01/01/93	1.50					
T4	4.8-12 (UG/DL)	01/01/93	7.20					
ESR/SEDIMENT. RATE	1-14 (MM)	01/01/93						
1st h			15.00				13.00	
ESR/SEDIMENT. RATE	4-25 (MM)	01/01/93						
2nd h			38.00				37.00	

2225

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA 0530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 35 Patient: 3DT Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			30/03/93		28/04/93		26/05/93	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	12-18 (G/DL)	01/01/93	13.70		13.00		14.00	
HT	36-52 (Z)	01/01/93	43.50		40.70		44.10	
RBC	4-5.2 (10 ⁶ /MM ³)	01/01/93	4.90		4.70		5.10	
WBC	4-9 (10 ³ /MM ³)	01/01/93	4.30		4.80		4.90	
WBC: N	40-80 (%)	01/01/93	51.00		38.00	<	59.00	
WBC: L	18-45 (%)	01/01/93	39.50		48.00	>	34.00	
WBC: E	0-6 (%)	01/01/93	2.20		3.00		0.00	
WBC: M	1-10 (%)	01/01/93	5.80		8.00		12.00	
WBC: B	0-2 (%)	01/01/93	0.50		3.00	>>	0.00	
PLATELETS	100-450 (10 ³ /MM ³)	01/01/93	184.00		188.00		199.00	
NA+	133-145 (MMOL/L)	01/01/93	142.00		135.00		143.00	
K+	3.5-5.1 (MMOL/L)	01/01/93	4.45		4.38		4.80	
CL-	95-107 (MMOL/L)	01/01/93	104.00		104.00		100.00	
Ca++	8.4-10.5 (MG/DL)	01/01/93	9.10		9.50		9.40	
PO4--	2.4-4.5 (MG/DL)	01/01/93	2.70		3.40		3.20	
SGOT	0-18 (U/L)	01/01/93	11.00		10.00		19.00	
SGPT	0-22 (U/L)	01/01/93	14.00		11.00		39.00	
GAMMA GT	3-27 (U/L)	01/01/93	11.00		9.00		12.00	
LDH	70-240 (U/L)	01/01/93	177.00		109.00		185.00	
ALK. PHOSPH.	60-190 (U/L)	01/01/93	97.00		83.00		107.00	
GLUCOSE	65-110 (MG/DL)	01/01/93	113.00	>	108.00		121.00	
UREA	15-45 (MG/DL)	01/01/93	27.00		46.00	>	37.00	
CREATININE	0.2-1.2 (MG/DL)	01/01/93	1.05		1.20		1.00	
CREATININE CLEARANCE	75-125 (ML/MIN)	01/01/93	60.80					
URIC ACID	3.5-7.2 (MG/DL)	01/01/93	4.20		4.20		4.70	
TOT BILIRUBIN	0-1.2 (MG/DL)	01/01/93	0.53		0.17		0.31	
DIR BILIRUBIN	0-0.3 (MG/DL)	01/01/93	0.00		0.10		0.07	
TOT. PROTEINS	6-8 (G/DL)	01/01/93	7.40		6.50		6.60	
ALBUMINE	3-4.5 (G/DL)	01/01/93	3.30		4.05		3.83	
TOT. CHOLEST.	170-250 (MG/DL)	01/01/93	247.00		242.00		167.00	
TRIGLYCERIDES	75-175 (MG/DL)	01/01/93	130.00		253.00	>>	138.00	
GLOBULINS ALPHA 1	2.5-6 (%)	01/01/93	2.80		2.90		2.70	
GLOBULINS ALPHA 2	7.5-14.5 (%)	01/01/93	8.40		10.50		8.40	
GLOBULINS BETA	8-13 (%)	01/01/93	12.80		11.30		12.60	
GLOBULINS GAMMA	10-18 (%)	01/01/93	13.50		13.30		12.70	
TSH	0.1-5 (UIU/ML)	01/01/93	2.20					
T4	4.8-12 (NG/DL)	01/01/93	6.80					
ESR/SEDIMENT. RATE 1st h	1-14 (MM)	01/01/93	8.00		12.00		10.00	
ESR/SEDIMENT. RATE 2nd h	4-25 (MM)	01/01/93	22.00		32.00		30.00	

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

2226

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN9580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 35 Patient: 4DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			21/04/93		11/05/93		21/06/93	
			value	(⊕)	value	(⊕)	value	(⊕)
Laboratory test	Range value	Range date						
HB	12-18 (G/DL)	01/01/93	13.80		13.90		14.30	
HT	36-52 (X)	01/01/93	39.00		39.20		40.50	
RBC	4-5.2 (10 ⁶ /MM ³)	01/01/93	4.54		4.50		4.80	
WBC	4-9 (10 ³ /MM ³)	01/01/93	3.40	<	3.30	<	3.50	
WBC: N	40-80 (X)	01/01/93	49.00		42.00		59.00	
WBC: L	18-45 (X)	01/01/93	41.00		48.00	>	36.00	
WBC: E	0-6 (X)	01/01/93	1.00		1.00		0.00	
WBC: M	1-10 (X)	01/01/93	8.00		9.00		5.00	
WBC: B	0-2 (X)	01/01/93	0.00		0.00		0.00	
PLATELETS	100-450 (10 ³ /MM ³)	01/01/93	229.00		237.00		148.00	
NA+	133-145 (MMOL/L)	01/01/93	139.00		142.00		139.00	
K+	3.5-5.1 (MMOL/L)	01/01/93	4.23		4.90		4.30	
CL-	95-107 (MMOL/L)	01/01/93	109.00	>	107.00		103.00	
Ca++	8.4-10.5 (MG/DL)	01/01/93	9.40		9.50		8.90	
PO4--	2.4-4.5 (MG/DL)	01/01/93	3.80		4.00		2.60	
SGOT	0-18 (U/L)	01/01/93	6.00		8.00		10.00	
SGPT	0-22 (U/L)	01/01/93	7.00		9.00		10.00	
GAMMA GT	3-27 (U/L)	01/01/93	12.00		10.00		15.00	
LDH	70-240 (U/L)	01/01/93	142.00		130.00		156.00	
ALK. PHOSPH.	60-190 (U/L)	01/01/93	127.00		129.00		149.00	
GLUCOSE	65-110 (MG/DL)	01/01/93	102.00		103.00		115.00	
UREA	15-45 (MG/DL)	01/01/93	42.00		42.00		42.00	
CREATININE	0.2-1.2 (MG/DL)	01/01/93	0.90		0.90		0.80	
CREATININE CLEARANCE	75-125 (ML/MIN)	01/01/93	88.23					
URIC ACID	3.5-7.2 (MG/DL)	01/01/93	5.20		5.30		4.80	
TOT BILIRUBIN	0-1.2 (MG/DL)	01/01/93			0.50		0.45	
DIR BILIRUBIN	0-0.3 (MG/DL)	01/01/93			0.02		0.09	
TOT. PROTEINS	6-8 (G/DL)	01/01/93	7.60		6.00		6.20	
ALBUMINE	3-4.5 (G/DL)	01/01/93			3.60		3.48	
TOT. CHOLEST.	170-250 (MG/DL)	01/01/93	304.00	>	219.00		239.00	
TRIGLYCERIDES	75-175 (MG/DL)	01/01/93	313.00	>>	170.00		265.00	
GLOBULINS ALPHA 1	2.5-6 (X)	01/01/93	3.70		3.00		3.00	
GLOBULINS ALPHA 2	7.5-14.5 (X)	01/01/93	11.50		10.00		9.20	
GLOBULINS BETA	8-13 (X)	01/01/93	13.60	>	13.00		13.30	
GLOBULINS GAMMA	10-18 (X)	01/01/93	14.00		10.30		9.70	
TSH	0.1-5 (UIU/ML)	01/01/93	0.90					
T4	4.8-12 (UG/DL)	01/01/93	6.30					
ESR/SEDIMENT. RATE	1-14 (MM)	01/01/93						
1st h			6.00		13.00			
ESR/SEDIMENT. RATE	4-25 (MM)	01/01/93						
2nd h			21.00		35.00			

2227

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C8550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 35 Patient: SDT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			01/09/93		29/09/93		27/10/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-18 (G/DL)	01/01/93	12.90		12.60		12.80	
HT	36-52 (%)	01/01/93	38.80		38.10		40.00	
RBC	4-5.2 (10 ⁶ /MM ³)	01/01/93	4.57		4.51		4.72	
WBC	4-9 (10 ³ /MM ³)	01/01/93	4.50		4.00		4.60	
WBC: N	40-80 (%)	01/01/93	43.00		55.00		66.00	
WBC: L	18-45 (%)	01/01/93	44.00		36.00		28.00	
WBC: E	0-6 (%)	01/01/93	5.00		4.00		2.00	
WBC: M	1-10 (%)	01/01/93	8.00		4.00		4.00	
WBC: B	0-2 (%)	01/01/93	0.00		1.00		0.00	
PLATELETS	100-450 (10 ³ /MM ³)	01/01/93	160.00		165.00		185.00	
NA+	133-145 (MMOL/L)	01/01/93	140.00		138.00		135.00	
K+	3.5-5.1 (MMOL/L)	01/01/93	3.75		4.13		4.49	
CL-	95-107 (MMOL/L)	01/01/93	105.00		102.00		94.00 <	
Ca++	8.4-10.5 (MG/DL)	01/01/93	9.40		9.50		9.50	
PO4--	2.4-4.5 (MG/DL)	01/01/93	3.60		2.90		4.20	
SGOT	0-18 (U/L)	01/01/93	6.00		8.00		8.00	
SGPT	0-22 (U/L)	01/01/93	5.00		6.00		11.00	
GAMMA GT	3-27 (U/L)	01/01/93	13.00		30.00 >		25.00	
LDH	70-240 (U/L)	01/01/93	122.00		200.00		144.00	
ALK. PHOSPH.	60-190 (U/L)	01/01/93	96.00		116.00		127.00	
GLUCOSE	65-110 (MG/DL)	01/01/93	122.00 >				140.00 >	
UREA	15-45 (MG/DL)	01/01/93	60.00 >		65.00 >		81.00 >>	
CREATININE	0.2-1.2 (MG/DL)	01/01/93	1.20		1.20		1.50 >	
CREATININE CLEARANCE			38.29					
URIC ACID	3.5-7.2 (MG/DL)	01/01/93	6.50		5.50		5.60	
TOT BILIRUBIN	0-1.2 (MG/DL)	01/01/93	0.36		0.47		0.41	
DIR BILIRUBIN	0-0.3 (MG/DL)	01/01/93	0.14				0.03	
TOT. PROTEINS	6-8 (G/DL)	01/01/93	6.10		6.20		6.60	
ALBUMINE	3-4.5 (G/DL)	01/01/93	3.10		3.13		3.65	
TOT. CHOLEST.	170-250 (MG/DL)	01/01/93	209.00		210.00		212.00	
TRIGLYCERIDES	75-175 (MG/DL)	01/01/93	126.00		198.00 >		309.00 >>	
GLOBULINS ALPHA 1	2.5-6 (%)	01/01/93	3.70		3.40		3.50	
GLOBULINS ALPHA 2	7.5-14.5 (%)	01/01/93	9.70		11.50		10.00	
GLOBULINS BETA	8-13 (%)	01/01/93	13.60 >		13.20 >		14.10 >	
GLOBULINS GAMMA	10-18 (%)	01/01/93	12.30		11.70		13.00	
TSH	0.1-5 (UIU/ML)	01/01/93	0.74					
T4	4.8-12 (UG/DL)	01/01/93	7.60					
ESR/SEDIMENT. RATE	1-14 (MM)	01/01/93						
1st h					8.00		15.00	
ESR/SEDIMENT. RATE	4-25 (MM)	01/01/93						
2nd h					26.00		33.00	

2228

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C9560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 35 Patient: GDT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			12/10/93		16/11/93		14/12/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-18 (G/DL)	01/01/93	13.70		14.80		14.00	
HT	36-52 (X)	01/01/93	39.70		41.90		40.50	
RBC	4-5.2 (10 ⁶ /MM ³)	01/01/93	4.43		4.69		4.49	
HBC	4-9 (10 ³ /MM ³)	01/01/93	4.90		5.80		5.40	
HBC: N	40-80 (X)	01/01/93	72.00		57.00		52.00	
HBC: L	18-45 (X)	01/01/93	20.00		33.00		35.00	
HBC: E	0-6 (X)	01/01/93	2.00		1.00		0.00	
HBC: M	1-10 (X)	01/01/93	4.00		9.00		11.00 >	
HBC: B	0-2 (X)	01/01/93	2.00		0.00		2.00	
PLATELETS	100-450 (10 ³ /MM ³)	01/01/93	208.00		229.00		214.00	
NA+	133-145 (MMOL/L)	01/01/93	146.00 >		141.00		139.00	
K+	3.5-5.1 (MMOL/L)	01/01/93	4.50		4.68		4.28	
CL-	95-107 (MMOL/L)	01/01/93	104.00		99.00		96.00	
Ca++	8.4-10.5 (MG/DL)	01/01/93	9.90		10.50		10.00	
PO4--	2.4-4.5 (MG/DL)	01/01/93	5.60 >>		3.50		3.40	
SGOT	0-18 (U/L)	01/01/93	13.00		15.00		11.00	
SGPT	0-22 (U/L)	01/01/93	21.00		25.00 >		18.00	
GAMMA GT	3-27 (U/L)	01/01/93	19.00		18.00		14.00	
LDH	70-240 (U/L)	01/01/93	177.00		186.00		167.00	
ALK. PHOSPH.	60-190 (U/L)	01/01/93	99.00		113.00		107.00	
GLUCOSE	65-110 (MG/DL)	01/01/93	209.00 >>		182.00 >>		174.00 >>	
UREA	15-45 (MG/DL)	01/01/93	50.00 >		37.00		38.00	
CREATININE	0.2-1.2 (MG/DL)	01/01/93	1.30 >		1.00		1.00	
CREATININE CLEARANCE	75-125 (ML/MIN)	01/01/93	58.47					
URIC ACID	3.5-7.2 (MG/DL)	01/01/93	7.50 >		6.00		5.60	
TOT BILIRUBIN	0-1.2 (MG/DL)	01/01/93	0.27		0.41		0.35	
DIR BILIRUBIN	0-0.3 (MG/DL)	01/01/93	0.14		0.10		0.04	
TOT. PROTEINS	6-8 (G/DL)	01/01/93	6.40		7.00		6.70	
ALBUMINE	3-4.5 (G/DL)	01/01/93	3.90		4.25		3.94	
TOT. CHOLEST.	170-250 (MG/DL)	01/01/93	275.00 >		287.00 >		256.00 >	
TRIGLYCERIDES	75-175 (MG/DL)	01/01/93	545.00 >>		354.00 >>		308.00 >>	
GLOBULINS ALPHA 1	2.5-6 (X)	01/01/93			3.40		3.70	
GLOBULINS ALPHA 2	7.5-14.5 (X)	01/01/93			9.70		11.20	
GLOBULINS BETA	8-13 (X)	01/01/93			12.60		14.30 >	
GLOBULINS GAMMA	10-18 (X)	01/01/93			9.50 <		11.60	
TSH	0.1-5 (UIU/ML)	01/01/93	0.25					
T4	4.8-12 (UG/DL)	01/01/93	6.50					
ESR/SEDIMENT. RATE 1st h	1-14 (MM)	01/01/93	5.00		4.00		4.00	
ESR/SEDIMENT. RATE 2nd h	4-25 (MM)	01/01/93	16.00		12.00		12.00	

2229

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C8550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 35 Patient: 7DT Treatment: Roboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	Day 28
			15/10/93	16/11/93
			value (ø)	value (ø)
Laboratory test	Range value	Range date		
HB	12-18 (G/DL)	01/01/93	13.90	14.10
HT	36-52 (%)	01/01/93	41.40	41.80
RBC	4-5.2 (10 ⁶ /MM3)	01/01/93	4.50	4.50
WBC	4-9 (10 ³ /MM3)	01/01/93	13.60 >>	9.10 >
WBC: N	40-80 (%)	01/01/93	86.00 >	72.00 <<
WBC: L	18-45 (%)	01/01/93	11.00 <<	15.00 <
WBC: E	0-6 (%)	01/01/93	0.00	1.00
WBC: M	1-10 (%)	01/01/93	3.00	11.00 >
WBC: B	0-2 (%)	01/01/93	0.00	1.00
PLATELETS	100-450 (10 ³ /MM3)	01/01/93	320.00	387.00
NA+	133-145 (MMOL/L)	01/01/93	142.00	143.00
K+	3.5-5.1 (MMOL/L)	01/01/93	4.88	4.55
CL-	95-107 (MMOL/L)	01/01/93	106.00	103.00
Ca++	8.4-10.5 (MG/DL)	01/01/93	9.60	10.10
PO4--	2.4-4.5 (MG/DL)	01/01/93	4.10	3.60
SGOT	0-18 (U/L)	01/01/93	6.00	8.00
SGPT	0-22 (U/L)	01/01/93	10.00	12.00
GAMMA GT	3-27 (U/L)	01/01/93	15.00	11.00
LDH	70-240 (U/L)	01/01/93	175.00	246.00 >
ALK. PHOSPH.	60-190 (U/L)	01/01/93	87.00	110.00
GLUCOSE	65-110 (MG/DL)	01/01/93	115.00 >	84.00
UREA	15-45 (MG/DL)	01/01/93	53.00 >	39.00
CREATININE	0.2-1.2 (MG/DL)	01/01/93	0.70	0.70
CREATININE CLEARANCE			70.33	
URIC ACID	3.5-7.2 (MG/DL)	01/01/93	3.80	3.30 <
TOT BILIRUBIN	0-1.2 (MG/DL)	01/01/93	1.28 >	0.63
DIR BILIRUBIN	0-0.3 (MG/DL)	01/01/93	0.23	0.05
TOT. PROTEINS	6-8 (G/DL)	01/01/93	6.20	6.60
ALBUMINE	3-4.5 (G/DL)	01/01/93	3.37	3.61
TOT. CHOLEST.	170-250 (MG/DL)	01/01/93	208.00	217.00
TRIGLYCERIDES	75-175 (MG/DL)	01/01/93	144.00	148.00
GLOBULINS ALPHA 1	2.5-6 (%)	01/01/93	3.00	3.80
GLOBULINS ALPHA 2	7.5-14.5 (%)	01/01/93	9.50	10.20
GLOBULINS BETA	8-13 (%)	01/01/93	12.00	11.90
GLOBULINS GAMMA	10-18 (%)	01/01/93	10.90	10.00
TSH	0.1-5 (UIU/ML)	01/01/93	0.12	
T4	4.8-12 (UG/DL)	01/01/93	9.00	
ESR/SEDIMENT. RATE 1st h	1-14 (MM)	01/01/93	3.00	5.00
ESR/SEDIMENT. RATE 2nd h	4-25 (MM)	01/01/93	7.00	16.00

2230

(ø) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C8560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 35 Patient: ADT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			10/01/94		07/02/94		07/03/94	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-18 (G/DL)	01/01/93	12.80		12.60		12.50	
HT	36-52 (%)	01/01/93	39.00		38.50		38.60	
RBC	4-5.2 (10 ⁶ /MM ³)	01/01/93	4.62		4.70		4.64	
WBC	4-9 (10 ³ /MM ³)	01/01/93	5.90		11.30	>	6.10	
WBC: N	40-80 (%)	01/01/93	79.00		78.00		72.00	
WBC: L	18-45 (%)	01/01/93	12.00	<<	12.00	<<	20.00	
WBC: E	0-6 (%)	01/01/93	2.00		0.00		1.00	
WBC: M	1-10 (%)	01/01/93	7.00		8.00		6.00	
WBC: B	0-2 (%)	01/01/93	0.00		0.00		0.00	
PLATELETS	100-450 (10 ³ /MM ³)	01/01/93	386.00		396.00		410.00	
NA+	133-145 (MMOL/L)	01/01/93	138.00		134.00		139.00	
K+	3.5-5.1 (MMOL/L)	01/01/93	4.11		4.03		4.26	
CL-	95-107 (MMOL/L)	01/01/93	101.00		92.00	<	99.00	
Ca++	8.4-10.5 (MG/DL)	01/01/93	10.50		10.30		9.80	
PO4--	2.4-4.5 (MG/DL)	01/01/93	3.70		3.10		3.20	
SGOT	0-18 (U/L)	01/01/93	9.00		8.00		7.00	
SGPT	0-22 (U/L)	01/01/93	12.00		9.00		6.00	
GAMMA GT	3-27 (U/L)	01/01/93	11.00		10.00		6.00	
LDH	70-240 (U/L)	01/01/93	184.00		216.00		165.00	
ALK. PHOSPH.	60-190 (U/L)	01/01/93	89.00		110.00		166.00	
GLUCOSE	65-110 (MG/DL)	01/01/93	88.00		121.00	>	88.00	
UREA	15-45 (MG/DL)	01/01/93	31.00		36.00		24.00	
CREATININE	0.2-1.2 (MG/DL)	01/01/93	0.90		1.00		0.80	
CREATININE CLEARANCE	75-125 (ML/MIN)	01/01/93	35.76					
URIC ACID	3.5-7.2 (MG/DL)	01/01/93	2.20	<	3.50		2.50	
TOT BILIRUBIN	0-1.2 (MG/DL)	01/01/93	0.45		0.40		0.27	
DIR BILIRUBIN	0-0.3 (MG/DL)	01/01/93	0.11		0.02		0.09	
TOT. PROTEINS	6-8 (G/DL)	01/01/93	6.70		6.90		6.70	
ALBUMINE	3-4.5 (G/DL)	01/01/93	3.91		3.45		3.71	
TOT. CHOLEST.	170-250 (MG/DL)	01/01/93	191.00		173.00		187.00	
TRIGLYCERIDES	75-175 (MG/DL)	01/01/93	69.00	<	62.00	<	134.00	
GLOBULINS ALPHA 1	2.5-6 (%)	01/01/93	3.30		3.30		4.00	
GLOBULINS ALPHA 2	7.5-14.5 (%)	01/01/93	9.80		11.80		10.40	
GLOBULINS BETA	8-13 (%)	01/01/93	11.10		8.20		10.30	
GLOBULINE GAMMA	10-18 (%)	01/01/93	17.30		17.30		19.90	
TSH	0.1-5 (UIU/ML)	01/01/93	0.34					
T4	4.8-12 (UG/DL)	01/01/93	11.00					
ESR/SEDIMENT. RATE 1-14 (MM)		01/01/93						
1st h			9.00		21.00		26.00	
ESR/SEDIMENT. RATE 4-25 (MM)		01/01/93						
2nd h			27.00		45.00		54.00	

2231

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C8560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 1MD Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			15/01/93		12/02/93		09/03/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	12/01/93	13.30		13.80		11.10 <	
HT	38-54 (%)	12/01/93	40.00		40.00		33.00 <	
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	4.59		4.81		3.91 <	
WBC	4-10 (10 ³ /MM ³)	12/01/93	4.90		13.80 >>		13.40 >>	
WBC: N	40-70 (%)	12/01/93	63.00		82.00 >			
WBC: L	20-40 (%)	12/01/93	26.00		7.00 <<			
WBC: E	0-5 (%)	12/01/93	1.00		0.00			
WBC: M	0-10 (%)	12/01/93	9.00		2.00			
WBC: B	0-1 (%)	12/01/93	1.00		0.00			
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	148.00		177.00		153.00 <	
NA+	135-145 (MEQ/L)	12/01/93	138.00		132.00 <		133.00 <	
K+	3.6-5.1 (MEQ/L)	12/01/93	4.00		4.90		3.50 <	
CL-	92-110 (MEQ/L)	12/01/93	100.00		90.00 <		88.00 <	
Ca++	8.5-10.3 (MG/DL)	12/01/93	9.40		9.50			
PO4--	2.5-4.8 (MG/DL)	12/01/93	3.80		3.80			
SGOT	0-23 (U/L)	12/01/93	9.00		14.00		10.00	
SGPT	0-26 (U/L)	12/01/93	5.00		8.00		5.00	
GAMMA GT	5-32 (U/L)	12/01/93	28.00		33.00 >			
LDH	160-320 (U/L)	12/01/93	211.00		270.00		247.00	
ALK. PHOSPH.	73-207 (U/L)	12/01/93	195.00		183.00			
GLUCOSE	70-105 (MG/DL)	12/01/93	99.00		125.00 >		211.00 >>	
UREA	10-50 (MG/DL)	12/01/93	34.00		40.00		39.00	
CREATININE	0.7-1.3 (MG/DL)	12/01/93	0.90		1.00		1.00	
CREATININE CLEARANCE			57.17					
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	5.90		4.90			
TOT BILIRUBIN	0.2-1 (MG/DL)	12/01/93	0.56		0.55			
DIR BILIRUBIN	0-0.2 (MG/DL)	12/01/93	0.20		0.00			
TOT. PROTEINS	6-8 (G/DL)	12/01/93	7.50		7.70		6.20	
ALBUMINE	58.8-69.6 (%)	12/01/93	60.20		49.90 <			
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	165.00		138.00 <			
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	84.00		48.00			
GLOBULINS ALPHA 1	1.9-3.8 (%)	12/01/93	3.20		5.30 >>			
GLOBULINS ALPHA 2	3.7-13.1 (%)	12/01/93	9.40		12.50			
GLOBULINS BETA	8.9-13.6 (%)	12/01/93	12.00		15.60 >			
GLOBULINS GAMMA	8.4-18.3 (%)	12/01/93	15.20		16.70			
TSH	0-7.3 (MUI/ML)	12/01/93	1.60					
T4	4.5-12 (UG/DL)	12/01/93	8.26					
ESR/SEDIMENT. RATE	0-10 (MM)	12/01/93						
1st h			27.00		45.00			
ESR/SEDIMENT. RATE	0-20 (MM)	12/01/93						
2nd h			56.00		81.00			

2232

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 055089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 2ND Treatment: Roboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			27/01/93		02/03/93		30/03/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	12/01/93	13.90		15.30			
HT	38-54 (X)	12/01/93	39.00		43.00			
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	4.36		4.81			
WBC	4-10 (10 ³ /MM ³)	12/01/93	4.70		6.20			
WBC: N	40-70 (X)	12/01/93	56.00		60.00			
WBC: L	20-40 (X)	12/01/93	34.00		32.00			
WBC: E	0-5 (X)	12/01/93	2.00		2.00			
WBC: M	0-10 (X)	12/01/93	8.00		5.00			
WBC: B	0-1 (X)	12/01/93	0.00		0.00			
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	161.00		230.00			
NA+	135-145 (MEQ/L)	12/01/93	142.00		143.00	136.00		
K+	3.6-5.1 (MEQ/L)	12/01/93	3.70		5.60 >	4.50		
CL-	92-110 (MEQ/L)	12/01/93	103.00		104.00	99.00		
Ca++	8.5-10.3 (MG/DL)	12/01/93	10.20		10.20	10.00		
PO4--	2.5-4.8 (MG/DL)	12/01/93	2.70		2.50	2.20 <		
SGOT	0-23 (U/L)	12/01/93	19.00		61.00 >>	18.00		
SGPT	0-26 (U/L)	12/01/93	22.00		32.00 >	16.00		
GAMMA GT	5-32 (U/L)	12/01/93	15.00		11.00	21.00		
LDH	160-320 (U/L)	12/01/93	282.00		827.00 >>	302.00		
ALK. PHOSPH.	73-207 (U/L)	12/01/93	117.00			165.00		
GLUCOSE	70-105 (MG/DL)	12/01/93	115.00 >		187.00 >>	203.00 >>		
UREA	10-50 (MG/DL)	12/01/93	21.00		27.00	41.00		
CREATININE	0.7-1.3 (MG/DL)	12/01/93	0.90		1.00	1.10		
CREATININE CLEARANCE	85-125 (ML/MIN)	12/01/93	74.50					
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	4.00		5.00	5.60		
TOT BILIRUBIN	0.2-1 (MG/DL)	12/01/93	0.61		0.35	0.19 <		
DIR BILIRUBIN	0-0.2 (MG/DL)	12/01/93	0.00		0.10	0.05		
TOT. PROTEINS	6-8 (G/DL)	12/01/93	7.70		7.90	7.40		
ALBUMINE	58.8-69.6 (X)	12/01/93	63.90		58.70 <			
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	215.00		240.00	241.00		
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	126.00		210.00 >	389.00 >>		
GLOBULINS ALPHA 1	1.9-3.8 (X)	12/01/93	3.00			3.30		
GLOBULINS ALPHA 2	3.7-13.1 (X)	12/01/93	8.40			10.80		
GLOBULINS BETA	8.9-13.6 (X)	12/01/93	13.10			14.90 >		
GLOBULINS GAMMA	8.4-18.3 (X)	12/01/93	11.50		12.40			
TSH	0-7.3 (MUI/ML)	12/01/93	3.16					
T4	4.5-12 (UG/DL)	12/01/93	10.10					
ESR/SEDIMENT. RATE 0-10 (MM)		12/01/93						
1st h			10.00		22.00	2.00		
ESR/SEDIMENT. RATE 0-20 (MM)		12/01/93						
2nd h			22.00		45.00	8.00		

2233

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 0552089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 3MD Treatment: Imipramine Sex: Female

Laboratory test			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			05/02/93		05/03/93		02/04/93	
			value	(†)	value	(†)	value	(†)
HR	12-16 (G/DL)	12/01/93	10.70	<	9.50	<<	14.50	
HT	38-54 (X)	12/01/93	35.00	<	27.00	<<	42.00	
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	3.79	<	3.08	<<	4.68	
WBC	4-10 (10 ³ /MM ³)	12/01/93	8.00		6.80		11.00	
WBC: N	40-70 (X)	12/01/93	78.00	>	81.00	>	86.00	
WBC: L	20-40 (X)	12/01/93	14.00	<	11.00	<<	8.00	
WBC: E	0-5 (X)	12/01/93	5.00		3.00		0.00	
WBC: M	0-10 (X)	12/01/93	3.00		3.00		6.00	
WBC: B	0-1 (X)	12/01/93	0.00		0.00		0.00	
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	365.00		162.00		290.00	
NA+	135-145 (MEQ/L)	12/01/93	139.00		134.00	<	132.00	
K+	3.6-5.1 (MEQ/L)	12/01/93	4.20		3.50	<	4.20	
CL-	92-110 (MEQ/L)	12/01/93	96.00		89.00	<	88.00	
Ca++	8.5-10.3 (MG/DL)	12/01/93	9.70		8.70		9.70	
PO4--	2.5-4.8 (MG/DL)	12/01/93	3.10		2.50		3.20	
SGOT	0-23 (U/L)	12/01/93	15.00		39.00	>	15.00	
SGPT	0-26 (U/L)	12/01/93	11.00		24.00		13.00	
GAMMA GT	5-32 (U/L)	12/01/93	43.00	>	46.00	>	45.00	
LDH	160-320 (U/L)	12/01/93	276.00				279.00	
ALK. PHOSPH.	73-207 (U/L)	12/01/93	138.00				231.00	
GLUCOSE	70-105 (MG/DL)	12/01/93	88.00		81.00		138.00	
UREA	10-50 (MG/DL)	12/01/93	49.00		72.00	>	38.00	
CREATININE	0.7-1.3 (MG/DL)	12/01/93	1.20		1.10		0.90	
CREATININE CLEARANCE	85-125 (ML/MIN)	12/01/93	24.70					
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	5.10		5.70		3.60	
TOT BILIRUBIN	0.2-1 (MG/DL)	12/01/93	0.33		0.42		0.28	
DIR BILIRUBIN	0-0.2 (MG/DL)	12/01/93	0.10		0.20		0.10	
TOT. PROTEINS	6-8 (G/DL)	12/01/93	6.70		5.50	<	6.50	
ALBUMINE	58.8-69.6 (X)	12/01/93	54.20	<	56.50	<	51.70	
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	236.00		180.00		242.00	
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	131.00		81.00		105.00	
GLOBULINS ALPHA 1	1.9-3.8 (X)	12/01/93	5.20	>>	7.70	>>	7.60	
GLOBULINS ALPHA 2	3.7-13.1 (X)	12/01/93	15.50	>	16.60	>	17.20	
GLOBULINS BETA	8.9-13.6 (X)	12/01/93	12.70		10.50		11.60	
GLOBULINS GAMMA	8.4-18.3 (X)	12/01/93	12.40		8.70		11.90	
TSH	0-7.3 (MUI/ML)	12/01/93	1.43					
T4	4.5-12 (UG/DL)	12/01/93	10.10					
ESR/SEDIMENT. RATE	0-10 (MM)	12/01/93						
1st h			67.00		100.00		86.00	
ESR/SEDIMENT. RATE	0-20 (MM)	12/01/93						
2nd h			98.00		110.00		100.00	

2234

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CME590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 4ND Treatment: Roboxetine Sex: Female

Laboratory test			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			03/03/93		06/04/93		03/05/93	
			value	(c)	value	(c)	value	(c)
Range value	Range date							
HB	12-16 (G/DL)	12/01/93	15.20		14.90		16.90 >	
HT	38-54 (X)	12/01/93	45.00		43.00		50.00	
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	4.80		4.68		5.33	
RBC	4-10 (10 ³ /MM ³)	12/01/93	5.00		4.60		7.60	
RBC: N	40-70 (X)	12/01/93	65.00		61.00		74.00 >	
RBC: L	20-40 (X)	12/01/93	23.00		28.00		18.00 <	
RBC: E	0-5 (X)	12/01/93	2.00		2.00		1.00	
RBC: M	0-10 (X)	12/01/93	10.00		9.00		7.00	
RBC: B	0-1 (X)	12/01/93	1.00		0.00		0.00	
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	234.00		226.00		282.00	
NA+	135-145 (MEQ/L)	12/01/93	139.00		132.00 <		140.00	
K+	3.6-5.1 (MEQ/L)	12/01/93	4.80		4.30		4.40	
CL-	92-110 (MEQ/L)	12/01/93	101.00		94.00		94.00	
Ca++	8.5-10.3 (MG/DL)	12/01/93	9.00		9.00		9.90	
PO4--	2.5-4.8 (MG/DL)	12/01/93	2.50		3.20		3.30	
SGOT	0-23 (U/L)	12/01/93	15.00		17.00		26.00 >	
SGPT	0-26 (U/L)	12/01/93	12.00		12.00		20.00	
GAMMA GT	5-32 (U/L)	12/01/93	5.00		5.00		5.00	
LDH	160-320 (U/L)	12/01/93	212.00		259.00		296.00	
ALK. PHOSPH.	73-207 (U/L)	12/01/93	150.00		116.00		152.00	
GLUCOSE	70-105 (MG/DL)	12/01/93	93.00		91.00		89.00	
UREA	10-50 (MG/DL)	12/01/93	20.00		30.00		37.00	
CREATININE	0.7-1.3 (MG/DL)	12/01/93	0.90		0.80		1.00	
CREATININE CLEARANCE	85-125 (ML/MIN)	12/01/93	47.00					
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	4.40		3.20		5.00	
TOT BILIRUBIN	0.2-1 (MG/DL)	12/01/93	0.46		0.55		0.76	
DIR BILIRUBIN	0-0.2 (MG/DL)	12/01/93	0.10		0.10		0.20	
TOT. PROTEINS	6-8 (G/DL)	12/01/93	5.90 <				7.30 <	
ALBUMINE	58.8-69.6 (X)	12/01/93	63.10		67.50		64.90	
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	178.00		191.00		239.00	
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	62.00		64.00		56.00	
GLOBULINS ALPHA 1	1.9-3.8 (X)	12/01/93	3.80		3.30		3.10	
GLOBULINS ALPHA 2	3.7-13.1 (X)	12/01/93	11.40		11.00		10.50	
GLOBULINS BETA	8.9-13.6 (X)	12/01/93	11.20		9.70		10.50	
GLOBULINS GAMMA	8.4-18.3 (X)	12/01/93	10.60		8.60		11.00	
TSH	0-7.3 (MUI/ML)	12/01/93	6.87					
T4	4.5-12 (UG/DL)	12/01/93	6.33					
ESR/SEDIMENT. RATE	0-10 (MM)	12/01/93						
1st h			10.00		8.00		5.00	
ESR/SEDIMENT. RATE	0-20 (MM)	12/01/93						
2nd h			20.00		16.00		19.00	

2235

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA 09530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: SMD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			20/04/93		24/05/93		18/06/93	
			value	(*)	value	(*)	value	(*)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	12/01/93	14.70		15.30		15.10	
HT	38-54 (X)	12/01/93	45.00		46.00		46.00	
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	5.18		5.16		5.19	
WBC	4-10 (10 ³ /MM ³)	12/01/93	6.50		6.70		5.90	
WBC: N	40-70 (X)	12/01/93	60.00		57.00		58.00	
WBC: L	20-40 (X)	12/01/93	31.00		37.00		36.00	
WBC: E	0-5 (X)	12/01/93	2.00		2.00		2.00	
WBC: M	0-10 (X)	12/01/93	7.00		3.00		4.00	
WBC: B	0-1 (X)	12/01/93	0.00		1.00		1.00	
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	268.00		279.00		257.00	
NA+	135-145 (MEQ/L)	12/01/93	141.00		145.00		144.00	
K+	3.6-5.1 (MEQ/L)	12/01/93	4.30		4.40		4.00	
CL-	92-110 (MEQ/L)	12/01/93	99.00		103.00		105.00	
Ca++	8.5-10.3 (MG/DL)	12/01/93	9.40		9.80		9.50	
PO4--	2.5-4.8 (MG/DL)	12/01/93	2.70		3.20		2.80	
SGOT	0-23 (U/L)	12/01/93	17.00		15.00		13.00	
SGPT	0-26 (U/L)	12/01/93	12.00		12.00		14.00	
GAMMA GT	5-32 (U/L)	12/01/93	9.00		11.00		12.00	
LDH	160-320 (U/L)	12/01/93	204.00		163.00		139.00 <	
ALK. PHOSPH.	73-207 (U/L)	12/01/93	132.00		141.00		130.00	
GLUCOSE	70-105 (MG/DL)	12/01/93	108.00 >		104.00		102.00	
UREA	10-50 (MG/DL)	12/01/93	38.00		41.00		35.00	
CREATININE	0.7-1.3 (MG/DL)	12/01/93	1.10		1.50 >		1.00	
CREATININE CLEARANCE	85-125 (ML/MIN)	12/01/93	50.80					
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	4.90		5.50		5.60	
TOT BILLIRUBIN	0.2-1 (MG/DL)	12/01/93	0.81		0.37		0.58	
DIR BILLIRUBIN	0-0.2 (MG/DL)	12/01/93	0.00		0.10		0.20	
TOT. PROTEINS	6-8 (G/DL)	12/01/93	7.70		7.80		7.80	
ALBUMINE	58.8-69.6 (X)	12/01/93	62.20		57.80 <		62.10	
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	221.00		226.00		214.00	
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	117.00		188.00		148.00	
GLOBULINS ALPHA 1	1.9-3.8 (X)	12/01/93	3.10		3.80		3.40	
GLOBULINS ALPHA 2	3.7-13.1 (X)	12/01/93	8.70		9.70		9.60	
GLOBULINS BETA	8.9-13.6 (X)	12/01/93	12.40		13.00		13.10	
GLOBULINS GAMMA	8.4-18.3 (X)	12/01/93	13.50		15.60		11.90	
TSH	0-7.3 (MUI/ML)	12/01/93	3.64					
T4	4.5-12 (UG/DL)	12/01/93	6.45					
ESR/SEDIMENT. RATE	0-10 (MM)	12/01/93						
1st h					26.00		21.00	
ESR/SEDIMENT. RATE	0-20 (MM)	12/01/93						
2nd h					56.00		48.00	

2236

(*) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value and laboratory not done (*) missing range value

PHARMACIA 9150089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 6ND Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			07/04/93		07/06/93		25/06/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	06/04/93	12.60		12.30		12.30	
HT	38-54 (X)	06/04/93	39.00		37.00	<	37.70	
	34-47 (X)	24/06/93						
RBC	4-5.5 (10 ⁶ /MM ³)	06/04/93	5.06		4.55			
	3.6-5.2 (10 ⁶ /MM ³)	24/06/93					4.58	
WBC	4-10 (10 ³ /MM ³)	06/04/93	4.80		4.00			
	3.6-10.2 (10 ³ /MM ³)	24/06/93						
WBC: N	40-70 (X)	06/04/93	79.00	>	64.00		3.30 <	
	50-70 (X)	24/06/93					56.00	
WBC: L	20-40 (X)	06/04/93	14.00	<	31.00		33.00	
WBC: E	0-5 (X)	06/04/93	1.00		1.00			
	1-4 (X)	24/06/93					3.00	
WBC: M	0-10 (X)	06/04/93	5.00		3.00			
	2-14 (X)	24/06/93					7.00	
WBC: B	0-1 (X)	06/04/93	1.00		1.00			
	0-4 (X)	24/06/93					1.00	
PLATELETS	100-400 (10 ³ /MM ³)	06/04/93	282.00		281.00			
	150-400 (10 ³ /MM ³)	24/06/93					274.00	
NA+	135-145 (MEQ/L)	06/04/93	140.00		143.00			
	135-153 (MMOL/L)	24/06/93					142.00	
K+	3.6-5.1 (MEQ/L)	06/04/93	4.00		4.60			
	3.5-5.3 (MMOL/L)	24/06/93					4.70	
CL-	92-110 (MEQ/L)	06/04/93	98.00		102.00			
	96-109 (MMOL/L)	24/06/93					106.00	
Ca++	8.5-10.3 (MG/DL)	06/04/93			10.40	>		
	2.12-2.6 (MMOL/L)	24/06/93					2.40	
PO4--	2.5-4.8 (MG/DL)	06/04/93			3.30			
	0.64-1.6 (MMOL/L)	24/06/93					1.19	
SGOT	0-23 (U/L)	06/04/93	15.00		12.00			
	0-21 (U/L)	24/06/93					9.00	
SGPT	0-24 (U/L)	06/04/93	14.00		10.00			
	0-22 (U/L)	24/06/93					5.00	
GAMMA GT	5-32 (U/L)	06/04/93	12.00		11.00			
	5-25 (U/L)	24/06/93					11.00	
LDH	160-320 (U/L)	06/04/93	255.00		226.00		213.00	
ALK. PHOSPH.	73-207 (U/L)	06/04/93	144.00		137.00		160.00	
GLUCOSE	70-105 (MG/DL)	06/04/93	105.00		90.00			
	70-110 (MG/DL)	24/06/93					80.00	
UREA	10-50 (MG/DL)	06/04/93	35.00		31.00		31.00	
CREATININE	0.7-1.3 (MG/DL)	06/04/93	0.70		1.50	>		
	0.6-1.2 (MG/DL)	24/06/93					0.93	
CREATININE CLEARANCE	85-125 (ML/MIN)	06/04/93	93.60					
URIC ACID	2.6-6.8 (MG/DL)	06/04/93	5.80		6.50			
	2.4-5.7 (MG/DL)	24/06/93					6.10 >	
TOT BILIRUBIN	0.2-1 (MG/DL)	06/04/93	0.29		0.16	<		
	0-1 (MG/DL)	24/06/93					0.32	
DIR BILIRUBIN	0-0.2 (MG/DL)	06/04/93	0.10		0.00		0.02	
TOT. PROTEINS	6-8 (G/DL)	06/04/93	7.40		7.00			
	6.6-8.7 (G/DL)	24/06/93					6.90	
ALBUMINE	58.8-69.6 (X)	06/04/93	64.40		66.50			
	54-66 (X)	24/06/93					62.60	
TOT. CHOLEST.	120-230 (MG/DL)	06/04/93	264.00	>	295.00	>	248.00 >	
TRIGLYCERIDES	30-200 (MG/DL)	06/04/93	137.00		255.00	>		
	70-180 (MG/DL)	24/06/93					156.00	
GLOBULINS ALPHA 1	1.9-3.8 (X)	06/04/93	2.70		2.60			
	1.5-4.5 (X)	24/06/93					2.80	
GLOBULINS ALPHA 2	3.7-13.1 (X)	06/04/93	9.50		8.90			
	6.5-12.5 (X)	24/06/93					9.00	
GLOBULINS BETA	8.9-13.6 (X)	06/04/93	12.20		11.70			
	10-14.5 (X)	24/06/93					11.20	

(CONTINUED)

2237

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 0550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 6MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			07/04/93		07/06/93		25/06/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
GLOBULINS GAMMA	8.4-18.3 (X)	06/04/93	11.20		10.20			
	10-18 (X)	24/06/93				14.40		
TSH	0-7.3 (MUI/ML)	06/04/93	0.70					
T4	4.5-12 (UG/DL)	06/04/93	8.30					
ESR/SEDIMENT. RATE	0-10 (MM)	06/04/93	10.00		14.00			
1st h	2-10 (MM)	24/06/93				12.00		
ESR/SEDIMENT. RATE	0-20 (MM)	06/04/93						
2nd h			23.00		34.00			

2238

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C0560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 7MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			14/05/93		10/06/93		07/07/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	13/05/93	14.40		13.70		14.70	
HT	38-54 (X)	13/05/93	42.00				44.00	
	37-47 (X)	09/06/93			39.40			
RBC	4-5.5 (10 ⁶ /MM ³)	13/05/93	4.50				4.54	
	4-5 (10 ⁶ /MM ³)	09/06/93			4.90			
WBC	4-10 (10 ³ /MM ³)	13/05/93	6.00				8.70	
	4000-10000 (/MM ³)	09/06/93			8740.00			
WBC: N	40-70 (%)	13/05/93	54.00				66.00	
	45-70 (%)	09/06/93			59.00			
WBC: L	20-40 (%)	13/05/93	41.00	>			25.00	
	25-45 (%)	09/06/93			34.00			
WBC: E	0-5 (%)	13/05/93	2.00				2.00	
	0-6 (%)	09/06/93			1.00			
WBC: M	0-10 (%)	13/05/93	2.00				7.00	
	0-9 (%)	09/06/93			6.00			
WBC: B	0-1 (%)	13/05/93	0.00				0.00	
	0-2 (%)	09/06/93			0.00			
PLATELETS	100-400 (10 ³ /MM ³)	13/05/93	222.00				313.00	
	150-450 (10 ³ /MM ³)	09/06/93			301.00			
NA+	135-145 (MEQ/L)	13/05/93	139.00				136.00	
	137-147 (MEQ/L)	09/06/93			140.00			
K+	3.6-5.1 (MEQ/L)	13/05/93	4.50				5.10	
	3.5-5.5 (MEQ/L)	09/06/93			4.90			
CL-	92-110 (MEQ/L)	13/05/93	95.00				95.00	
	99-110 (MEQ/L)	09/06/93			99.00			
Ca++	8.5-10.3 (MG/DL)	13/05/93	9.90				10.20	
	4-5.5 (MEQ/L)	09/06/93			5.00			
PO4--	2.5-4.8 (MG/DL)	13/05/93	4.40				3.30	
	2.5-4.5 (MG/DL)	09/06/93			4.80	>		
SGOT	0-23 (U/L)	13/05/93	10.00				16.00	
	5-18 (U/L)	09/06/93			7.00			
SGPT	0-24 (U/L)	13/05/93	9.00				18.00	
	5-23 (U/L)	09/06/93			10.00			
GAMMA GT	5-32 (U/L)	13/05/93	16.00				18.00	
	4-28 (U/L)	09/06/93			14.00			
LDH	160-320 (U/L)	13/05/93	150.00	<			226.00	
	100-225 (U/L)	09/06/93			135.00			
ALK. PHOSPH.	73-207 (U/L)	13/05/93	110.00				188.00	
	60-170 (U/L)	09/06/93			138.00			
GLUCOSE	70-105 (MG/DL)	13/05/93	81.00				217.00	
	55-110 (MG/DL)	09/06/93			160.00	>>		
UREA	10-50 (MG/DL)	13/05/93	29.00				42.00	
	20-45 (MG/DL)	09/06/93			37.00			
CREATININE	0.7-1.3 (MG/DL)	13/05/93	0.70				0.90	
	0.5-1.2 (MG/DL)	09/06/93			0.81			
CREATININE CLEARANCE	85-125 (ML/MIN)	13/05/93	49.50					
URIC ACID	2.6-6.8 (MG/DL)	13/05/93	2.60				4.20	
	2-7 (MG/DL)	09/06/93			3.80			
TOT BILIRUBIN	0.2-1 (MG/DL)	13/05/93	0.56				0.50	
	0.1-0.9 (MG/DL)	09/06/93			0.69			
DIR BILIRUBIN	0-0.2 (MG/DL)	13/05/93	0.10				0.00	
TOT. PROTEINS	6-8 (G/DL)	13/05/93	7.50				8.70	
	6.5-8.5 (G/DL)	09/06/93			8.10			
ALBUMINE	58.8-69.6 (%)	13/05/93	55.20	<			59.00	
	50-65 (%)	09/06/93			50.20			
TOT. CHOLEST.	120-230 (MG/DL)	13/05/93	241.00	>			281.00	
	30-200 (MG/DL)	13/05/93	218.00	>	285.00	>	130.00	
TRIGLYCERIDES	50-150 (MG/DL)	09/06/93			120.00			
GLOBULINS ALPHA 1	1.9-3.8 (%)	13/05/93	4.60	>			3.00	
	1-5 (%)	09/06/93			3.50			
GLOBULINS ALPHA 2	3.7-13.1 (%)	13/05/93	12.10				9.80	

(CONTINUED)

2239

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C9580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 7ND Treatment: Roboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			14/05/93		10/06/93		07/07/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
GLOBULINS ALPHA 2	8-13 (%)	09/06/93			10.20			
GLOBULINS BETA	8.9-13.6 (%)	13/05/93	15.40	>			13.60	
	8-18 (%)	09/06/93			13.40			
GLOBULINS GAMMA	8.4-18.3 (%)	13/05/93	12.80				14.60	
	12-21 (%)	09/06/93			22.70	>		
TSH	0-7.3 (MUI/ML)	13/05/93	0.67					
T4	4.5-12 (UG/DL)	13/05/93	8.46					
ESR/SEDIMENT. RATE	0-10 (MM)	13/05/93	30.00				62.00	
1st h	1-10 (MM)	09/06/93			27.00			
ESR/SEDIMENT. RATE	0-20 (MM)	13/05/93	61.00				75.00	
2nd h	1-30 (MM)	09/06/93			38.00			

2240

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 953089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 8MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			12/05/93		22/06/93		20/07/93	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	12/01/93	14.40		14.20		14.00	
HT	38-54 (%)	12/01/93	42.00		42.00		41.00	
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	4.89		4.78		4.70	
WBC	4-10 (10 ³ /MM ³)	12/01/93	4.80		5.70		4.50	
WBC: N	40-70 (%)	12/01/93	66.00		76.00 >		73.00 >	
WBC: L	20-40 (%)	12/01/93	26.00		17.00 <		23.00 <	
WBC: E	0-5 (%)	12/01/93	3.00		2.00		1.00	
WBC: M	0-10 (%)	12/01/93	4.00		4.00		4.00	
WBC: B	0-1 (%)	12/01/93	1.00		0.00		0.00	
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	188.00		185.00		172.00	
NA+	135-145 (MEQ/L)	12/01/93	140.00		141.00		137.00	
K+	3.6-5.1 (MEQ/L)	12/01/93	4.40		4.50		3.90	
CL-	92-110 (MEQ/L)	12/01/93	101.00		101.00		99.00	
Ca++	8.5-10.3 (MG/DL)	12/01/93	10.10		9.80		9.80	
PO4--	2.5-4.8 (MG/DL)	12/01/93	2.50		2.10 <<		2.00 <<	
SGOT	0-23 (U/L)	12/01/93	13.00		11.00		24.00 >	
SGPT	0-26 (U/L)	12/01/93	11.00		9.00		41.00 >	
GAMMA GT	5-32 (U/L)	12/01/93	14.00		12.00		13.00	
LDH	160-320 (U/L)	12/01/93	248.00		281.00		279.00	
ALK. PHOSPH.	73-207 (U/L)	12/01/93	150.00		158.00		151.00	
GLUCOSE	70-105 (MG/DL)	12/01/93	119.00 >		113.00 >		123.00 >	
UREA	10-50 (MG/DL)	12/01/93	43.00		38.00		40.00	
CREATININE	0.7-1.3 (MG/DL)	12/01/93	1.10		1.20		1.30	
CREATININE CLEARANCE	85-125 (ML/MIN)	12/01/93	81.10					
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	4.20		4.40		4.70	
TOT BILIRUBIN	0.2-1 (MG/DL)	12/01/93	0.59		0.37		0.53	
DIR BILIRUBIN	0-0.2 (MG/DL)	12/01/93	0.20		0.10		0.20	
TOT. PROTEINS	6-8 (G/DL)	12/01/93	7.40		7.70		7.50	
ALBUMINE	58.8-69.6 (%)	12/01/93	50.70 <		61.30		58.50 <	
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	210.00		203.00		203.00	
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	104.00		86.00		130.00	
GLOBULINS ALPHA 1	1.9-3.8 (%)	12/01/93	3.30		2.80		3.00	
GLOBULINS ALPHA 2	3.7-13.1 (%)	12/01/93	10.50		8.60		8.60	
GLOBULINS BETA	8.9-13.6 (%)	12/01/93	15.40 >		13.60		14.80 >	
GLOBULINS GAMMA	8.4-18.3 (%)	12/01/93	20.10 >		13.70		15.10	
TSH	0-7.3 (MUI/ML)	12/01/93	1.48					
T4	4.5-12 (UG/DL)	12/01/93	7.18					
ESR/SEDIMENT. RATE	0-10 (MM)	12/01/93						
1st h			12.00		27.00		20.00	
ESR/SEDIMENT. RATE	0-20 (MM)	12/01/93						
2nd h			34.00		51.00		47.00	

2241

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 03550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 9ND Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			13/06/93		13/07/93		10/08/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	12/01/93	15.30		12.90		11.90 <	
HT	38-54 (X)	12/01/93	45.00		39.00		36.00 <	
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	5.11		4.44		4.29	
HBC	4-10 (10 ³ /MM ³)	12/01/93	9.90		7.20		8.50	
HBC: N	40-70 (X)	12/01/93	75.00 >		53.00		74.00 >	
HBC: L	20-40 (X)	12/01/93	20.00		26.00		17.00 <	
HBC: E	0-5 (X)	12/01/93	0.00		16.00 >>		4.00	
HBC: M	0-10 (X)	12/01/93	5.00		5.00		6.00	
HBC: B	0-1 (X)	12/01/93	0.00		0.00		0.00	
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	315.00		486.00 >		436.00 >	
NA+	135-145 (MEQ/L)	12/01/93	140.00		135.00		135.00	
K+	3.6-5.1 (MEQ/L)	12/01/93	4.10		5.10		3.80	
CL-	92-110 (MEQ/L)	12/01/93	100.00		97.00		96.00	
Ca++	8.5-10.3 (MG/DL)	12/01/93	10.10		10.00		9.20	
PO4--	2.5-4.8 (MG/DL)	12/01/93			2.10 <<		2.70	
SGOT	0-23 (U/L)	12/01/93	8.00		8.00		7.00	
SGPT	0-26 (U/L)	12/01/93	6.00		5.00		2.00	
GAMMA GT	5-32 (U/L)	12/01/93	49.00 >		36.00 >		32.00	
LDH	160-320 (U/L)	12/01/93	216.00		282.00		203.00	
ALK. PHOSPH.	73-207 (U/L)	12/01/93	252.00 >		213.00 >		219.00 >	
GLUCOSE	70-105 (MG/DL)	12/01/93	91.00		95.00		87.00	
UREA	10-50 (MG/DL)	12/01/93	51.00 >		44.00		34.00	
CREATININE	0.7-1.3 (MG/DL)	12/01/93	1.80 >		1.70 >		2.30 >>	
CREATININE CLEARANCE	75-115 (ML/MIN)	12/01/93	30.40					
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	12.00 >>		7.80 >		10.80 >>	
TOT BILIRUBIN	0.2-1 (MG/DL)	12/01/93	0.48		0.28		0.52	
DIR BILIRUBIN	0-0.2 (MG/DL)	12/01/93	0.19		0.20		0.30 >	
TOT. PROTEINS	6-8 (G/DL)	12/01/93	6.70		7.10		6.00	
ALBUMINE	58.8-69.6 (X)	12/01/93	60.10		49.30 <		48.60 <	
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	221.00		184.00		199.00	
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	94.00		129.00		97.00	
GLOBULINS ALPHA 1	1.9-3.8 (X)	12/01/93	3.70		5.20 >>		7.10 >>	
GLOBULINS ALPHA 2	3.7-13.1 (X)	12/01/93	13.20 >		15.00 >		15.50 >	
GLOBULINS BETA	8.9-13.6 (X)	12/01/93	14.20 >		15.70 >		14.30 >	
GLOBULINS GAMMA	8.4-18.3 (X)	12/01/93	8.70		14.80		14.40	
TSH	0-7.3 (MUI/ML)	12/01/93	1.10					
T4	4.5-12 (UG/DL)	12/01/93	12.20					
ESR/SEDIMENT. RATE 0-10 (MM)		12/01/93						
1st h			51.00		111.00		88.00	
ESR/SEDIMENT. RATE 0-20 (MM)		12/01/93						
2nd h			82.00		120.00		115.00	

2242

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 10MD Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			03/06/93		19/07/93		16/08/93	
			value	(⊕)	value	(⊕)	value	(⊕)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	12/01/93	14.70		14.00		14.30	
HT	38-54 (X)	12/01/93	44.00		42.00		45.00	
	34-47 (X)	16/08/93						
RBC	4-5.5 (10 ⁶ /MM3)	12/01/93	4.65		4.41		4.70	
	3.6-5.2 (10 ⁶ /MM3)	16/08/93						
WBC	4-10 (10 ³ /MM3)	12/01/93	7.60		8.30		7.20	
	3.6-10.2 (10 ³ /MM3)	16/08/93						
WBC: N	40-70 (X)	12/01/93	80.00 >		79.00 >		72.00 >	
	50-70 (X)	16/08/93						
WBC: L	20-40 (X)	12/01/93	15.00 <		15.00 <		18.00 <	
WBC: E	0-5 (X)	12/01/93	1.00		2.00		3.00	
	1-4 (X)	16/08/93						
WBC: M	0-10 (X)	12/01/93	3.00		3.00		6.00	
	2-14 (X)	16/08/93						
WBC: B	0-1 (X)	12/01/93	1.00		1.00		1.00	
	0-4 (X)	16/08/93						
PLATELETS	100-400 (10 ³ /MM3)	12/01/93	257.00		346.00		302.00	
	150-400 (10 ³ /MM3)	16/08/93						
NA+	135-145 (MEQ/L)	12/01/93	139.00		138.00		142.20	
	135-153 (MMOL/L)	16/08/93						
K+	3.4-5.1 (MEQ/L)	12/01/93	5.20 >		5.00		5.70 >	
	3.5-5.3 (MMOL/L)	16/08/93						
CL-	92-110 (MEQ/L)	12/01/93	100.00				105.00	
	96-109 (MMOL/L)	16/08/93						
Ca++	8.5-10.3 (MG/DL)	12/01/93	10.30		10.00		2.57	
	2.12-2.6 (MMOL/L)	16/08/93						
PO4--	2.5-4.8 (MG/DL)	12/01/93	2.30 <		2.00 <<		1.01	
	0.64-1.61 (MMOL/L)	16/08/93						
SGOT	0-23 (U/L)	12/01/93	14.00		13.00		14.00	
	0-21 (U/L)	16/08/93						
SGPT	0-26 (U/L)	12/01/93	10.00		14.00		14.00	
	0-22 (U/L)	16/08/93						
GAMMA GT	5-32 (U/L)	12/01/93	12.00		15.00		16.00	
	5-25 (U/L)	16/08/93						
LDH	160-320 (U/L)	12/01/93	268.00		224.00		253.00	
ALK. PHOSPH.	73-207 (U/L)	12/01/93	93.00				116.00	
GLUCOSE	70-105 (MG/DL)	12/01/93	72.00		133.00 >		121.00 >	
	70-110 (MG/DL)	16/08/93						
UREA	10-50 (MG/DL)	12/01/93	51.00 >		47.00		49.00	
CREATININE	0.7-1.3 (MG/DL)	12/01/93	1.60 >		1.50 >		1.32 >	
	0.6-1.2 (MG/DL)	16/08/93						
CREATININE CLEARANCE	75-115 (ML/MIN)	12/01/93	36.09				4.40	
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	4.40		4.60		5.10	
	2.4-5.7 (MG/DL)	16/08/93						
TOT BILIRUBIN	0.2-1 (MG/DL)	12/01/93	0.60		0.40		0.64	
	0-1 (MG/DL)	16/08/93						
DIR BILIRUBIN	0-0.2 (MG/DL)	12/01/93	0.23 >		0.00		0.01	
	0-0.25 (MG/DL)	16/08/93						
TOT. PROTEINS	6-8 (G/DL)	12/01/93	6.90		7.00		7.50	
	6.6-8.7 (G/DL)	16/08/93						
ALBUMINE	58.8-69.6 (X)	12/01/93	62.80		63.60		59.20	
	54-66 (X)	16/08/93						
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	257.00				270.00 >	
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	93.00				79.00	
	70-180 (MG/DL)	16/08/93						
GLOBULINS ALPHA 1	1.9-3.8 (X)	12/01/93	3.30		3.70		3.00	
	1.5-4.5 (X)	16/08/93						
GLOBULINS ALPHA 2	3.7-13.1 (X)	12/01/93	5.30		6.80		7.10	
	6.5-12.5 (X)	16/08/93						
GLOBULINS BETA	8.9-13.6 (X)	12/01/93	14.10 >		13.20			

2243

(CONTINUED)

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C0520089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 10MD Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			03/06/93		19/07/93		16/08/93	
			value	(⚡)	value	(⚡)	value	(⚡)
Laboratory test	Range value	Range date						
GLOBULINS BETA	10-14.5 (%)	16/08/93						
GLOBULINS GAMMA	8.4-18.3 (%)	12/01/93	14.70		12.80		13.80	
	10-18 (%)	16/08/93					16.90	
TSH	0-7.3 (mIU/ML)	12/01/93	0.89					
T4	4.5-12 (UG/DL)	12/01/93	11.50					
ESR/SEDIMENT. RATE	0-10 (MM)	12/01/93	3.00		15.00			
1st h	2-10 (MM)	16/08/93					9.00	
ESR/SEDIMENT. RATE	0-20 (MM)	12/01/93						
2nd h			8.00		33.00			

2244

(⚡) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value and laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 0550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 11MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			06/07/93		29/07/93		02/09/93	
			value	(†)	value	(†)	value	(†)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	12/01/93	11.80	<	11.70	<	11.20	<
HT	38-54 (Z)	12/01/93	39.00		38.00		36.00	<
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	4.96				4.71	<
WBC	4-10 (10 ³ /MM ³)	12/01/93			6.50		6.00	
WBC: N	40-70 (%)	12/01/93	60.00		64.00		65.00	
WBC: L	20-40 (%)	12/01/93	33.00		31.00		27.00	
WBC: E	0-5 (%)	12/01/93	4.00		2.00		2.00	
WBC: M	0-10 (%)	12/01/93	4.00		3.00		6.00	
WBC: B	0-1 (%)	12/01/93	1.00		1.00		0.00	
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	336.00		315.00		349.00	
NA+	135-145 (MEQ/L)	12/01/93	138.00		137.00		138.00	
K+	3.6-5.1 (MEQ/L)	12/01/93	4.10		4.80		3.80	
CL-	92-110 (MEQ/L)	12/01/93	100.00		98.00		98.00	
Ca++	8.5-10.3 (MG/DL)	12/01/93	10.00		10.80	>	10.10	
PO4--	2.5-4.8 (MG/DL)	12/01/93	3.00		3.10		2.80	
SGOT	0-23 (U/L)	12/01/93	10.00		10.00		7.00	
SGPT	0-26 (U/L)	12/01/93	8.00		8.00		7.00	
GAMMA GT	5-32 (U/L)	12/01/93	31.00		66.00	>>	33.00	>
LDH	160-320 (U/L)	12/01/93	223.00		192.00		204.00	
ALK. PHOSPH.	73-207 (U/L)	12/01/93	154.00		191.00		192.00	
GLUCOSE	70-105 (MG/DL)	12/01/93	94.00		89.00		94.00	
UREA	10-50 (MG/DL)	12/01/93	25.00		32.00		34.00	
CREATININE	0.7-1.3 (MG/DL)	12/01/93	1.30		1.40	>	1.20	
CREATININE CLEARANCE			27.76					
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	5.20		4.60		4.80	
TOT. BILIRUBIN	0.2-1 (MG/DL)	12/01/93	0.46		0.27		0.36	
DIR. BILIRUBIN	0-0.2 (MG/DL)	12/01/93	0.20		0.10		0.10	
TOT. PROTEINS	6-8 (G/DL)	12/01/93	8.10	>	7.80		7.40	
ALBUMINE	58.8-69.6 (%)	12/01/93	59.00		62.10		54.80	<
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	315.00	>	293.00	>	279.00	<
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	149.00		175.00		156.00	
GLOBULINS ALPHA 1	1.9-3.8 (%)	12/01/93	3.90	>	3.20		4.50	>
GLOBULINS ALPHA 2	3.7-13.1 (%)	12/01/93	11.90		11.00		13.40	>
GLOBULINS BETA	8.9-13.6 (%)	12/01/93	13.40		13.30		13.30	
GLOBULINS GAMMA	8.4-18.3 (%)	12/01/93	11.70		10.40		14.00	
TSH	0-7.3 (MUI/ML)	12/01/93	0.27					
T4	4.5-12 (UG/DL)	12/01/93	8.27					
ESR/SEDIMENT. RATE	0-10 (MM)	12/01/93						
1st h			17.00		20.00		22.00	
ESR/SEDIMENT. RATE	0-20 (MM)	12/01/93						
2nd h			40.00		47.00		54.00	

2245

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 0510089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 12MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	
			13/09/93	
			value	(φ)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	12/01/93	11.00	<
HT	38-54 (%)	12/01/93	32.00	<<
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	3.60	<
WBC	4-10 (10 ³ /MM ³)	12/01/93	8.90	
WBC: N	40-70 (%)	12/01/93	79.00	>
WBC: L	20-40 (%)	12/01/93	11.00	<<
WBC: E	0-5 (%)	12/01/93	1.00	
WBC: M	0-10 (%)	12/01/93	9.00	
WBC: B	0-1 (%)	12/01/93	1.00	
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	478.00	>
NA+	135-145 (MEQ/L)	12/01/93	135.00	
K+	3.6-5.1 (MEQ/L)	12/01/93	4.60	
CL-	92-110 (MEQ/L)	12/01/93	94.00	
Ca++	8.5-10.3 (MG/DL)	12/01/93	8.70	
PO4--	2.5-4.8 (MG/DL)	12/01/93	3.50	
SGOT	0-23 (U/L)	12/01/93	6.00	
SGPT	0-26 (U/L)	12/01/93	5.00	
GAMMA GT	5-32 (U/L)	12/01/93	13.00	
LDH	160-320 (U/L)	12/01/93	186.00	
ALK. PHOSPH.	73-207 (U/L)	12/01/93	125.00	
GLUCOSE	70-105 (MG/DL)	12/01/93	84.00	
UREA	10-50 (MG/DL)	12/01/93	20.00	
CREATININE	0.7-1.3 (MG/DL)	12/01/93	0.80	
CREATININE CLEARANCE			48.95	
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	2.80	
TOT BILIRUBIN	0.2-1 (MG/DL)	12/01/93	0.60	
DIR BILIRUBIN	0-0.2 (MG/DL)	12/01/93	0.20	
TOT. PROTEINS	6-8 (G/DL)	12/01/93	5.80	<
ALBUMINE	58.8-69.6 (%)	12/01/93	57.90	<
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	123.00	<
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	62.00	
GLOBULINS ALPHA 1	1.9-3.8 (%)	12/01/93	4.80	>
GLOBULINS ALPHA 2	3.7-13.1 (%)	12/01/93	12.50	
GLOBULINS BETA	8.9-13.6 (%)	12/01/93	11.10	
GLOBULINS GAMMA	8.4-18.3 (%)	12/01/93	13.90	
TSH	0-7.3 (MUI/ML)	12/01/93	1.39	
T4	4.5-12 (UG/DL)	12/01/93	7.00	
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	12/01/93	12.00	
ESR/SEDIMENT. RATE 2nd h	0-20 (MM)	12/01/93	31.00	

2246

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C9560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 13MD Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date
			Screen
			17/09/93
			value (⊕)
Laboratory test	Range value	Range date	
HB	12-16 (G/DL)	12/01/93	12.80
HT	38-54 (Z)	12/01/93	37.00 <
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	4.08
HBC	4-10 (10 ³ /MM ³)	12/01/93	8.40
HBC: N	40-70 (Z)	12/01/93	68.00
HBC: L	20-40 (Z)	12/01/93	22.00
HBC: E	0-5 (Z)	12/01/93	2.00
HBC: M	0-10 (Z)	12/01/93	9.00
HBC: B	0-1 (Z)	12/01/93	0.00
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	366.00
NA+	135-145 (MEQ/L)	12/01/93	134.00 <
K+	3.6-5.1 (MEQ/L)	12/01/93	4.30
CL-	92-110 (MEQ/L)	12/01/93	89.00 <
Ca++	8.5-10.3 (MG/DL)	12/01/93	9.00
PO4--	2.5-4.8 (MG/DL)	12/01/93	2.80
SGOT	0-23 (U/L)	12/01/93	19.00
SGPT	0-26 (U/L)	12/01/93	13.00
GAMMA GT	5-32 (U/L)	12/01/93	35.00 >
LDH	160-320 (U/L)	12/01/93	274.00
ALK. PHOSPH.	73-207 (U/L)	12/01/93	313.00 >
GLUCOSE	70-105 (MG/DL)	12/01/93	100.00
UREA	10-50 (MG/DL)	12/01/93	26.00
CREATININE	0.7-1.3 (MG/DL)	12/01/93	1.30
CREATININE CLEARANCE			36.23
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	3.30
TOT BILIRUBIN	0.2-1 (MG/DL)	12/01/93	0.54
DIR BILIRUBIN	0-0.2 (MG/DL)	12/01/93	0.20
TOT. PROTEINS	6-8 (G/DL)	12/01/93	5.70 <
ALBUMINE	58.8-69.6 (Z)	12/01/93	61.50
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	265.00 >
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	238.00 >
GLOBULINS ALPHA 1	1.9-3.8 (Z)	12/01/93	2.40
GLOBULINS ALPHA 2	3.7-13.1 (Z)	12/01/93	14.90 >
GLOBULINS BETA	8.9-13.6 (Z)	12/01/93	13.20
GLOBULINS GAMMA	8.4-18.3 (Z)	12/01/93	8.10 <
TSH	0-7.3 (MUI/ML)	12/01/93	1.02
T4	4.5-12 (UG/DL)	12/01/93	6.56
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	12/01/93	48.00
ESR/SEDIMENT. RATE 2nd h	0-20 (MM)	12/01/93	85.00

2247

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 9539089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 14MD Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			03/11/93		30/11/93		28/12/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	12/01/93	15.30		15.20		15.10	
HT	38-54 (%)	12/01/93	45.00		46.00		46.00	
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	5.17		5.14		5.17	
WBC	4-10 (10 ³ /MM ³)	12/01/93	4.80		7.70		6.00	
WBC: N	40-70 (%)	12/01/93	52.00		72.00	>	69.00	
WBC: L	20-40 (%)	12/01/93	36.00		20.00		24.00	
WBC: E	0-5 (%)	12/01/93	4.00		3.00		3.00	
WBC: M	0-10 (%)	12/01/93	6.00		4.00		3.00	
WBC: B	0-1 (%)	12/01/93	2.00	>>	1.00		1.00	
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	180.00		210.00		221.00	
NA+	135-145 (MEQ/L)	12/01/93	138.00		141.00		137.00	
K+	3.6-5.1 (MEQ/L)	12/01/93	4.00		4.30		4.40	
CL-	92-110 (MEQ/L)	12/01/93	101.00		99.00		98.00	
Ca++	8.5-10.3 (MG/DL)	12/01/93	9.60		9.00		9.10	
PO4--	2.5-4.8 (MG/DL)	12/01/93	3.20		2.70		2.60	
SGOT	0-23 (U/L)	12/01/93	11.00		18.00		14.00	
SGPT	0-26 (U/L)	12/01/93	8.00		23.00		14.00	
GAMMA GT	5-32 (U/L)	12/01/93	8.00		13.00		12.00	
LDH	160-320 (U/L)	12/01/93	185.00		219.00		206.00	
ALK. PHOSPH.	73-207 (U/L)	12/01/93	128.00		184.00		195.00	
GLUCOSE	70-105 (MG/DL)	12/01/93	82.00		92.00		109.00	
UREA	10-50 (MG/DL)	12/01/93	27.00		38.00		46.00	
CREATININE	0.7-1.3 (MG/DL)	12/01/93	1.50	>	2.00	>>	1.50	
CREATININE CLEARANCE	75-115 (ML/MIN)	12/01/93	46.00					
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	6.30		5.50		6.10	
TOT BILIRUBIN	0.2-1 (MG/DL)	12/01/93	0.71		0.25		0.23	
DIR BILIRUBIN	0-0.2 (MG/DL)	12/01/93	0.20		0.10		0.05	
TOT. PROTEINS	6-8 (G/DL)	12/01/93	7.10		7.70		7.50	
ALBUMINE	58.8-69.6 (%)	12/01/93	61.90		58.60	<	54.40	
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	187.00		207.00		217.00	
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	80.00		167.00		237.00	
GLOBULINS ALPHA 1	1.9-3.8 (%)	12/01/93	2.60		2.90		2.50	
GLOBULINS ALPHA 2	3.7-13.1 (%)	12/01/93	7.90		9.40		8.60	
GLOBULINS BETA	8.9-13.6 (%)	12/01/93	12.60		12.70		15.30	
GLOBULINS GAMMA	8.4-18.3 (%)	12/01/93	15.00		16.40		19.20	
TSH	0-7.3 (MUI/ML)	12/01/93	0.63					
T4	4.5-12 (UG/DL)	12/01/93	9.07					
ESR/SEDIMENT. RATE	0-10 (MM)	12/01/93						
1st h			3.00		10.00		5.00	
ESR/SEDIMENT. RATE	0-20 (MM)	12/01/93						
2nd h			7.00		24.00		10.00	

2248

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 15MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	
			06/10/93	
			value	(c)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	12/01/93	14.30	
HT	38-54 (%)	12/01/93	41.00	
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	4.56	
WBC	4-10 (10 ³ /MM ³)	12/01/93	13.60	>>
WBC: N	40-70 (%)	12/01/93	84.00	>
WBC: L	20-40 (%)	12/01/93	10.00	<<
WBC: E	0-5 (%)	12/01/93	1.00	
WBC: M	0-10 (%)	12/01/93	5.00	
WBC: B	0-1 (%)	12/01/93	1.00	
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	374.00	
NA+	135-145 (MEQ/L)	12/01/93	133.00	<
K+	3.6-5.1 (MEQ/L)	12/01/93	4.00	
CL-	92-110 (MEQ/L)	12/01/93	100.00	
Ca++	8.5-10.3 (MG/DL)	12/01/93	11.10	>
PO4--	2.5-4.8 (MG/DL)	12/01/93	3.00	
SGOT	0-23 (U/L)	12/01/93	26.00	>
SGPT	0-26 (U/L)	12/01/93	21.00	
GAMMA GT	5-32 (U/L)	12/01/93	17.00	
LDH	160-320 (U/L)	12/01/93	277.00	
ALK. PHOSPH.	73-207 (U/L)	12/01/93	91.00	
GLUCOSE	70-105 (MG/DL)	12/01/93	103.00	
UREA	10-50 (MG/DL)	12/01/93	67.00	>
CREATININE	0.7-1.3 (MG/DL)	12/01/93	1.50	>
CREATININE CLEARANCE			31.78	
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	8.60	>
TOT BILIRUBIN	0.2-1 (MG/DL)	12/01/93	0.60	
DIR BILIRUBIN	0-0.2 (MG/DL)	12/01/93	0.20	
TOT. PROTEINS	6-8 (G/DL)	12/01/93	6.20	
ALBUMINE	58.8-69.6 (%)	12/01/93	57.50	<
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	223.00	
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	185.00	
GLOBULINS ALPHA 1	1.9-3.8 (%)	12/01/93	3.70	
GLOBULINS ALPHA 2	3.7-13.1 (%)	12/01/93	11.90	
GLOBULINS BETA	8.9-13.6 (%)	12/01/93	14.50	>
GLOBULINS GAMMA	8.4-18.3 (%)	12/01/93	12.30	
TSH	0-7.3 (MUI/ML)	12/01/93	1.75	
T4	4.5-12 (UG/DL)	12/01/93	8.01	
ESR/SEDIMENT. RATE	0-10 (MM)	12/01/93		
1st h			15.00	
ESR/SEDIMENT. RATE	0-20 (MM)	12/01/93		
2nd h			34.00	

2249

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C 560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 16MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			03/11/93		06/12/93		03/01/94	
			value	(c)	value	(c)	value	(c)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	12/01/93	15.30		13.70		13.70	
HT	38-54 (X)	12/01/93	45.00		39.00		40.00	
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	4.93		4.37		4.45	
WBC	4-10 (10 ³ /MM ³)	12/01/93	6.10		5.80		6.22	
WBC: N	40-70 (X)	12/01/93	70.00		66.00		60.00	
WBC: L	20-40 (X)	12/01/93	25.00		27.00		33.00	
WBC: E	0-5 (X)	12/01/93	3.00		3.00		4.00	
WBC: M	0-10 (X)	12/01/93	2.00		4.00		3.00	
WBC: B	0-1 (X)	12/01/93	0.00		0.00		0.00	
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	168.00		149.00		159.00	
NA+	135-145 (MEQ/L)	12/01/93	140.00		145.00		140.00	
K+	3.6-5.1 (MEQ/L)	12/01/93	4.40		4.30		4.30	
CL-	92-110 (MEQ/L)	12/01/93	98.00		101.00		101.00	
Ca++	8.5-10.3 (MG/DL)	12/01/93	9.50		9.40		9.00	
PO4--	2.5-4.8 (MG/DL)	12/01/93	3.30		3.60		3.30	
SGOT	0-23 (U/L)	12/01/93	13.00		15.00		13.00	
SGPT	0-26 (U/L)	12/01/93	11.00		12.00		11.00	
GAMMA GT	5-32 (U/L)	12/01/93	29.00		21.00		23.00	
LDH	160-320 (U/L)	12/01/93	272.00		236.00		279.00	
ALK. PHOSPH.	73-207 (U/L)	12/01/93	110.00		106.00		114.00	
GLUCOSE	70-105 (MG/DL)	12/01/93	115.00	>	91.00		87.00	
UREA	10-50 (MG/DL)	12/01/93	44.00		47.00		44.00	
CREATININE	0.7-1.3 (MG/DL)	12/01/93	1.10		1.30		1.30	
CREATININE CLEARANCE	85-125 (ML/MIN)	12/01/93	60.95					
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	6.20		7.50	>	6.40	
TOT BILIRUBIN	0.2-1 (MG/DL)	12/01/93	0.54		0.31		0.21	
DIR BILIRUBIN	0-0.2 (MG/DL)	12/01/93	0.10		0.10		0.10	
TOT. PROTEINS	6-8 (G/DL)	12/01/93	7.40		6.90		6.80	
ALBUMINE	58.8-69.6 (X)	12/01/93	60.20		61.90		57.70	<
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	238.00		200.00		213.00	
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	134.00		165.00		221.00	>
GLOBULINS ALPHA 1	1.9-3.8 (X)	12/01/93	2.90		3.10		2.80	
GLOBULINS ALPHA 2	3.7-13.1 (X)	12/01/93	10.30		12.10		11.20	
GLOBULINS BETA	8.9-13.6 (X)	12/01/93	14.30	>	11.40		14.20	>
GLOBULINS GAMMA	8.4-18.3 (X)	12/01/93	12.30		11.50		14.10	
TSH	0-7.3 (MUI/ML)	12/01/93	0.96					
T4	4.5-12 (UG/DL)	12/01/93	10.80					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	12/01/93	11.00		11.00		13.00	
ESR/SEDIMENT. RATE 2nd h	0-20 (MM)	12/01/93	31.00		24.00		52.00	

2250

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARNACIA C8580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 17MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date
			Screen
			28/10/93
			value (c)
Laboratory test	Range value	Range date	
HB	12-16 (G/DL)	12/01/93	14.60
HT	38-54 (%)	12/01/93	41.90
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	4.50
WBC	4-10 (10 ³ /MM ³)	12/01/93	6.30
WBC: N	40-70 (%)	12/01/93	61.80
WBC: L	20-40 (%)	12/01/93	29.50
WBC: E	0-5 (%)	12/01/93	1.30
WBC: M	0-10 (%)	12/01/93	6.60
WBC: B	0-1 (%)	12/01/93	0.80
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	188.00
NA+	135-145 (MEQ/L)	12/01/93	132.00 <
K+	3.6-5.1 (MEQ/L)	12/01/93	4.20
CL-	92-110 (MEQ/L)	12/01/93	92.00
Ca++	8.5-10.3 (MG/DL)	12/01/93	10.10
SGOT	0-23 (U/L)	12/01/93	16.00
SGPT	0-26 (U/L)	12/01/93	25.00
GAMMA GT	5-32 (U/L)	12/01/93	18.00
LDH	160-320 (U/L)	12/01/93	238.00
ALK. PHOSPH.	73-207 (U/L)	12/01/93	136.00
GLUCOSE	70-105 (MG/DL)	12/01/93	129.00 >
UREA	10-50 (MG/DL)	12/01/93	52.00 >
CREATININE	0.7-1.3 (MG/DL)	12/01/93	1.10
CREATININE CLEARANCE			40.90
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	6.10
TOT BILIRUBIN	0.2-1 (MG/DL)	12/01/93	1.60 >
DIR BILIRUBIN	0-0.2 (MG/DL)	12/01/93	0.39 >
TOT. PROTEINS	6-8 (G/DL)	12/01/93	6.70
ALBUMINE	58.8-69.6 (%)	12/01/93	53.00 <
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	185.00
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	112.00
GLOBULINS ALPHA 1	1.9-3.8 (%)	12/01/93	4.50 >
GLOBULINS ALPHA 2	3.7-13.1 (%)	12/01/93	10.20
GLOBULINS BETA	8.9-13.6 (%)	12/01/93	14.90 >
GLOBULINS GAMMA	8.4-18.3 (%)	12/01/93	17.30
TSH	0-7.3 (MUI/ML)	12/01/93	1.00
T4	4.5-12 (UG/DL)	12/01/93	9.74
ESR/SEDIMENT. RATE 0-10 (MM)		12/01/93	
1st h			20.00
ESR/SEDIMENT. RATE 0-20 (MM)		12/01/93	
2nd h			42.00

2251

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 0550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 18ND Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			11/01/94		10/02/94		09/03/94	
			value	(⊕)	value	(⊕)	value	(⊕)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	12/01/93	14.70		13.20		13.10	
HT	38-54 (X)	12/01/93	44.00		40.00		38.50	
RBC	4-5.5 (10-6/MM3)	12/01/93	4.67		4.20		4.00	
WBC	4-10 (10-3/MM3)	12/01/93	5.60		6.40		4.60	
WBC: N	40-70 (X)	12/01/93	72.00	>	74.00	>	57.30	
WBC: L	20-40 (X)	12/01/93	23.00		19.00	<	30.00	
WBC: E	0-5 (X)	12/01/93	1.00		1.60		4.50	
WBC: M	0-10 (X)	12/01/93	3.00		4.80		6.70	
WBC: B	0-1 (X)	12/01/93	1.00		0.60		1.65 >>	
PLATELETS	100-400 (10-3/MM3)	12/01/93	145.00		151.00		98.00 <	
NA+	135-145 (MEQ/L)	12/01/93	143.00		136.00		141.00	
K+	3.6-5.1 (MEQ/L)	12/01/93	3.80		4.30		4.80	
CL-	92-110 (MEQ/L)	12/01/93	103.00		96.00		100.00	
Ca++	8.5-10.3 (MG/DL)	12/01/93	9.40		9.10		8.70	
PO4--	2.5-4.8 (MG/DL)	12/01/93	3.00		2.80		3.30	
SGOT	0-23 (U/L)	12/01/93	12.00		7.00		10.00	
SGPT	0-26 (U/L)	12/01/93	16.00		15.00		15.00	
GAMMA GT	5-32 (U/L)	12/01/93	19.00		17.00		16.00	
LDH	160-320 (U/L)	12/01/93	244.00		165.00		236.00	
ALK. PHOSPH.	73-207 (U/L)	12/01/93	116.00		91.00		82.00	
GLUCOSE	70-105 (MG/DL)	12/01/93	158.00	>>	131.00	>	94.00	
UREA	10-50 (MG/DL)	12/01/93	48.00		34.00		47.00	
CREATININE	0.7-1.3 (MG/DL)	12/01/93	1.10		0.90		0.90	
CREATININE CLEARANCE	85-125 (ML/MIN)	12/01/93	45.75					
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	5.40		5.10		5.60	
TOT BILIRUBIN	0.2-1 (MG/DL)	12/01/93	0.52		0.46		0.55	
DIR BILIRUBIN	0-0.2 (MG/DL)	12/01/93	0.19		0.10		0.15	
TOT. PROTEINS	6-8 (G/DL)	12/01/93	7.20		6.50		6.50	
ALBUMINE	58.8-69.6 (X)	12/01/93	62.30		55.60	<	55.20 <	
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	226.00		207.00		212.00	
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	165.00		110.00		161.00	
GLOBULINS ALPHA 1	1.9-3.8 (X)	12/01/93	3.20		4.70	>	3.70	
GLOBULINS ALPHA 2	3.7-13.1 (X)	12/01/93	8.50		11.70		8.70	
GLOBULINS BETA	8.9-13.6 (X)	12/01/93	13.50		11.70		14.20 >	
GLOBULINS GAMMA	8.4-18.3 (X)	12/01/93	12.60		16.40		18.20	
TSH	0-7.3 (MUI/ML)	12/01/93	1.64					
T4	4.5-12 (UG/DL)	12/01/93	12.50					
ESR/SEDIMENT. RATE	0-10 (MM)	12/01/93						
1st h			12.00		20.00		9.00	
ESR/SEDIMENT. RATE	0-20 (MM)	12/01/93						
2nd h			22.00		42.00		18.00	

2252

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 0530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 19ND Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date
			Screen
			14/01/94
			value (φ)
Laboratory test	Range value	Range date	
HB	12-16 (G/DL)	12/01/93	12.90
HT	38-54 (%)	12/01/93	39.00
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	4.37
WBC	4-10 (10 ³ /MM ³)	12/01/93	6.40
WBC: N	40-70 (%)	12/01/93	77.00 >
WBC: L	20-40 (%)	12/01/93	14.00 <
WBC: E	0-5 (%)	12/01/93	2.00
WBC: M	0-10 (%)	12/01/93	6.00
WBC: B	0-1 (%)	12/01/93	0.00
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	324.00
NA+	135-145 (MEQ/L)	12/01/93	141.00
K+	3.6-5.1 (MEQ/L)	12/01/93	4.50
CL-	92-110 (MEQ/L)	12/01/93	102.00
Ca++	8.5-10.3 (MG/DL)	12/01/93	9.60
SGOT	0-23 (U/L)	12/01/93	12.00
SGPT	0-26 (U/L)	12/01/93	17.00
ALK. PHOSPH.	73-207 (U/L)	12/01/93	84.00
GLUCOSE	70-105 (MG/DL)	12/01/93	106.00 >
CREATININE	0.7-1.3 (MG/DL)	12/01/93	0.90
CREATININE CLEARANCE	85-125 (ML/MIN)	12/01/93	42.42
TOT BILIRUBIN	0.2-1 (MG/DL)	12/01/93	0.43
DIR BILIRUBIN	0-0.2 (MG/DL)	12/01/93	0.10
TOT. PROTEINS	6-8 (G/DL)	12/01/93	6.90
ALBUMINE	58.8-69.6 (%)	12/01/93	61.90
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	237.00
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	113.00
GLOBULINS ALPHA 1	1.9-3.8 (%)	12/01/93	4.00 >
GLOBULINS ALPHA 2	3.7-13.1 (%)	12/01/93	11.30
GLOBULINS BETA	8.9-13.6 (%)	12/01/93	11.00
GLOBULINS GAMMA	8.4-18.3 (%)	12/01/93	11.80
TSH	0-7.3 (MUI/ML)	12/01/93	1.22
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	12/01/93	16.00
ESR/SEDIMENT. RATE 2nd h	0-20 (MM)	12/01/93	43.00

2253

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 0530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 20ND Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			24/01/94		28/02/94		28/03/94	
			value	(⊕)	value	(⊕)	value	(⊕)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	12/01/93	13.10		13.30		14.30	
HT	38-54 (X)	12/01/93	38.00		38.00		41.00	
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	3.85 <		4.01		4.26	
WBC	4-10 (10 ³ /MM ³)	12/01/93	3.60 <		3.90 <		4.40	
WBC: N	40-70 (X)	12/01/93	50.00		55.00		64.00	
WBC: L	20-40 (X)	12/01/93	41.00 >		37.00		31.00	
WBC: E	0-5 (X)	12/01/93	3.00		3.00		1.00	
WBC: M	0-10 (X)	12/01/93	5.00		4.00		4.00	
WBC: B	0-1 (X)	12/01/93	1.00		1.00		1.00	
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	209.00		214.00		210.00	
NA+	135-145 (MEQ/L)	12/01/93	146.00 >		143.00		144.00	
K+	3.6-5.1 (MEQ/L)	12/01/93	4.20		4.20		4.30	
CL-	92-110 (MEQ/L)	12/01/93	109.00		104.00		109.00	
Ca++	8.5-10.3 (MG/DL)	12/01/93	9.40		9.30		9.70	
PO4--	2.5-4.8 (MG/DL)	12/01/93	3.10		3.80		3.40	
SGOT	0-23 (U/L)	12/01/93	11.00		12.00		14.00	
SGPT	0-26 (U/L)	12/01/93	9.00		13.00		11.00	
GAMMA GT	5-32 (U/L)	12/01/93	27.00		71.00 >>		49.00 >	
LDH	160-320 (U/L)	12/01/93	203.00		230.00		258.00	
ALK. PHOSPH.	73-207 (U/L)	12/01/93	175.00		214.00 >		227.00 >	
GLUCOSE	70-105 (MG/DL)	12/01/93	88.00		87.00		92.00	
UREA	10-50 (MG/DL)	12/01/93	34.00		43.00		43.00	
CREATININE	0.7-1.3 (MG/DL)	12/01/93	1.10		1.10		1.10	
CREATININE CLEARANCE	85-125 (ML/MIN)	12/01/93	55.00					
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	4.40		4.10		4.60	
TOT BILIRUBIN	0.2-1 (MG/DL)	12/01/93	0.45		0.45		0.44	
DIR BILIRUBIN	0-0.2 (MG/DL)	12/01/93	0.10		0.10		0.10	
TOT. PROTEINS	6-8 (G/DL)	12/01/93	6.10		6.30		7.30	
ALBUMINE	58.8-69.6 (X)	12/01/93	66.20		61.40		61.70	
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	284.00 >		316.00 >		353.00 >>	
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	93.00		117.00		145.00	
GLOBULINS ALPHA 1	1.9-3.8 (X)	12/01/93	3.00		3.60		3.90 >	
GLOBULINS ALPHA 2	3.7-13.1 (X)	12/01/93	8.60		9.60		9.90	
GLOBULINS BETA	8.9-13.6 (X)	12/01/93	12.10		15.50 >		12.90	
GLOBULINS GAMMA	8.4-18.3 (X)	12/01/93	10.10		9.80		11.60	
TSH	0-7.3 (MUI/ML)	12/01/93	0.92					
T4	4.5-12 (UG/DL)	12/01/93	6.96					
ESR/SEDIMENT. RATE	0-10 (MM)	12/01/93						
1st h			6.00		8.00		12.00	
ESR/SEDIMENT. RATE	0-20 (MM)	12/01/93						
2nd h			18.00		22.00		38.00	

2254

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 0650089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 1DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			01/02/93		02/03/93		30/03/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	12/01/93	14.60		14.50		15.50	
HT	38-54 (X)	12/01/93	43.00		43.00		46.00	
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	4.85		4.77		5.10	
WBC	4-10 (10 ³ /MM ³)	12/01/93	4.50		4.90		4.60	
WBC: N	40-70 (X)	12/01/93	60.00		62.00		60.00	
WBC: L	20-40 (X)	12/01/93	33.00		30.00		33.00	
WBC: E	0-5 (X)	12/01/93	2.00		2.00		1.00	
WBC: M	0-10 (X)	12/01/93	4.00		6.00		5.00	
WBC: B	0-1 (X)	12/01/93	1.00		1.00		1.00	
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	213.00		207.00		192.00	
NA+	135-145 (MEQ/L)	12/01/93	142.00		139.00		139.00	
K+	3.6-5.1 (MEQ/L)	12/01/93	5.10		5.40 >		5.60 >	
CL-	92-110 (MEQ/L)	12/01/93	104.00		100.00		100.00	
Ca ⁺⁺	8.5-10.3 (MG/DL)	12/01/93	10.20		10.10		10.10	
PO ₄ ⁻⁻	2.5-4.8 (MG/DL)	12/01/93	2.70		3.00		2.80	
SGOT	0-23 (U/L)	12/01/93	13.00		20.00		20.00	
SGPT	0-26 (U/L)	12/01/93	14.00		26.00		28.00 >	
GAMMA GT	5-32 (U/L)	12/01/93	14.00		26.00		35.00 >	
LDH	160-320 (U/L)	12/01/93	215.00		228.00		231.00	
ALK. PHOSPH.	73-207 (U/L)	12/01/93	138.00				180.00	
GLUCOSE	70-105 (MG/DL)	12/01/93	104.00		107.00 >		100.00	
UREA	10-50 (MG/DL)	12/01/93	43.00		35.00		38.00	
CREATININE	0.7-1.3 (MG/DL)	12/01/93	1.00		1.10		1.10	
CREATININE CLEARANCE	85-125 (ML/MIN)	12/01/93	56.89					
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	5.80		5.50		5.60	
TOT BILIRUBIN	0.2-1 (MG/DL)	12/01/93			0.37		0.41	
DIR BILIRUBIN	0-0.2 (MG/DL)	12/01/93			0.10		0.10	
TOT. PROTEINS	6-8 (G/DL)	12/01/93	7.20		6.90		7.40	
ALBUMINE	58.8-69.6 (X)	12/01/93	66.40		64.00		61.40	
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	293.00 >		272.00 >		259.00	
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	99.00		95.00		138.00	
GLOBULINS ALPHA 1	1.9-3.8 (X)	12/01/93	3.10		4.00 >		3.60	
GLOBULINS ALPHA 2	3.7-13.1 (X)	12/01/93	8.80		9.80		10.40	
GLOBULINS BETA	8.9-13.6 (X)	12/01/93	14.00 >		11.90		12.70	
GLOBULINS GAMMA	8.4-18.3 (X)	12/01/93	7.80 <		10.20		12.50	
TSH	0-7.3 (MUI/ML)	12/01/93	1.23					
T4	4.5-12 (UG/DL)	12/01/93	8.05					
ESR/SEDIMENT. RATE 0-10 (MM)		12/01/93						
1st h			15.00		19.00		13.00	
ESR/SEDIMENT. RATE 0-20 (MM)		12/01/93						
2nd h			33.00		48.00		33.00	

2255

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 06590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: ZDT Treatment: Roboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			18/02/93		25/03/93		22/04/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	12/01/93	14.00		14.00		12.70	
HT	38-54 (%)	12/01/93	40.00		41.00		38.00	
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	4.49		4.53		4.15	
WBC	4-10 (10 ³ /MM ³)	12/01/93	5.90		4.50		4.10	
WBC: N	40-70 (%)	12/01/93	68.00		66.00		65.00	
WBC: L	20-40 (%)	12/01/93	25.00		28.00		27.00	
WBC: E	0-5 (%)	12/01/93	1.00		1.00		2.00	
WBC: M	0-10 (%)	12/01/93	5.00		5.00		5.00	
WBC: B	0-1 (%)	12/01/93	1.00		0.00		1.00	
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	238.00		245.00		221.00	
NA+	135-145 (MEQ/L)	12/01/93	144.00		139.00		140.00	
K+	3.6-5.1 (MEQ/L)	12/01/93	4.90		4.90		4.70	
CL-	92-110 (MEQ/L)	12/01/93	104.00		99.00		101.00	
Ca++	8.5-10.3 (MG/DL)	12/01/93	10.20		10.60	>	9.50	
PO4--	2.5-4.8 (MG/DL)	12/01/93	3.20		3.50		2.90	
SGOT	0-23 (U/L)	12/01/93	17.00		14.00		17.00	
SGPT	0-26 (U/L)	12/01/93	20.00		18.00		24.00	
GAMMA GT	5-32 (U/L)	12/01/93	23.00		23.00		22.00	
LDH	160-320 (U/L)	12/01/93	275.00		223.00		239.00	
ALK. PHOSPH.	73-207 (U/L)	12/01/93	148.00		147.00		135.00	
GLUCOSE	70-105 (MG/DL)	12/01/93	99.00		88.00		127.00	
UREA	10-50 (MG/DL)	12/01/93	26.00		30.00		30.00	
CREATININE	0.7-1.3 (MG/DL)	12/01/93	0.90		1.00		1.00	
CREATININE CLEARANCE	85-125 (ML/MIN)	12/01/93	69.60					
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	5.00		4.70		4.80	
TOT BILIRUBIN	0.2-1 (MG/DL)	12/01/93	0.46		0.42		0.44	
DIR BILIRUBIN	0-0.2 (MG/DL)	12/01/93	0.10		0.10		0.10	
TOT. PROTEINS	6-8 (G/DL)	12/01/93	8.20	>	7.70		7.40	
ALBUMINE	58.8-69.6 (%)	12/01/93	71.80	>	65.20		61.70	
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	267.00	>	239.00		233.00	
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	138.00		167.00		143.00	
GLOBULINS ALPHA 1	1.9-3.8 (%)	12/01/93	2.00		2.70		2.80	
GLOBULINS ALPHA 2	3.7-13.1 (%)	12/01/93	7.10		9.00		9.10	
GLOBULINS BETA	8.9-13.6 (%)	12/01/93	11.70		13.00		12.70	
GLOBULINS GAMMA	8.4-18.3 (%)	12/01/93	7.40	<	10.00		13.60	
TSH	0-7.3 (MUI/ML)	12/01/93	0.48					
T4	4.5-12 (UG/DL)	12/01/93	7.72					
ESR/SEDIMENT. RATE 0-10 (MM)		12/01/93						
1st h			22.00		24.00		25.00	
ESR/SEDIMENT. RATE 0-20 (MM)		12/01/93						
2nd h			49.00		48.00		50.00	

2256

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 0550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 3DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			16/02/93		30/03/93		27/04/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	12/01/93	11.50	<	11.60	<	10.70	<<
HT	58-54 (X)	12/01/93	33.00	<	34.00	<	31.00	<<
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	3.77	<	3.81	<	3.50	<
WBC	4-10 (10 ³ /MM ³)	12/01/93	8.20		6.90		5.40	
WBC: N	40-70 (X)	12/01/93	78.00	>	63.00		66.00	
WBC: L	20-40 (X)	12/01/93	15.00	<	27.00		28.00	
WBC: E	0-5 (X)	12/01/93	1.00		4.00		2.00	
WBC: M	0-10 (X)	12/01/93	6.00		6.00		3.00	
WBC: B	0-1 (X)	12/01/93	1.00		1.00		1.00	
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	364.00		336.00		313.00	
NA+	135-145 (MEQ/L)	12/01/93	140.00		139.00		136.00	
K+	3.6-5.1 (MEQ/L)	12/01/93	3.90		5.20	>	4.30	
CL-	92-110 (MEQ/L)	12/01/93	105.00		100.00		96.00	
Ca++	8.5-10.3 (MG/DL)	12/01/93	10.10		10.60	>	10.20	
PO4--	2.5-4.8 (MG/DL)	12/01/93	2.90		2.70		2.60	
SGOT	0-23 (U/L)	12/01/93	19.00		15.00		18.00	
SGPT	0-26 (U/L)	12/01/93	11.00		9.00		11.00	
GAMMA GT	5-32 (U/L)	12/01/93	11.00		11.00		8.00	
LDH	160-320 (U/L)	12/01/93	215.00		228.00		223.00	
ALK. PHOSPH.	73-207 (U/L)	12/01/93	100.00		107.00		105.00	
GLUCOSE	70-105 (MG/DL)	12/01/93	111.00	>	74.00		95.00	
UREA	10-50 (MG/DL)	12/01/93	49.00		65.00	>	61.00	>
CREATININE	0.7-1.3 (MG/DL)	12/01/93	0.90		1.30		1.20	
CREATININE CLEARANCE	85-125 (ML/MIN)	12/01/93	44.70					
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	6.60		6.40		5.60	
TOT BILIRUBIN	0.2-1 (MG/DL)	12/01/93	0.58		0.36		0.38	
DIR BILIRUBIN	0-0.2 (MG/DL)	12/01/93	0.20		0.10		0.00	
TOT. PROTEINS	6-8 (G/DL)	12/01/93	7.70		7.60		7.40	
ALBUMINE	58.8-69.6 (X)	12/01/93	68.10		63.80		61.10	
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	255.00		247.00		256.00	
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	77.00		66.00		58.00	
GLOBULINS ALPHA 1	1.9-3.8 (X)	12/01/93	3.30		2.90		3.50	
GLOBULINS ALPHA 2	3.7-13.1 (X)	12/01/93	7.30		9.60		8.80	
GLOBULINS BETA	8.9-13.6 (X)	12/01/93	10.50		11.40		12.20	
GLOBULINS GAMMA	8.4-18.3 (X)	12/01/93	10.90		12.20		14.40	
TSH	0-7.3 (MUI/ML)	12/01/93	1.77					
T4	4.5-12 (UG/DL)	12/01/93	9.57					
ESR/SEDIMENT. RATE 0-10 (MM)		12/01/93						
1st h			17.00		18.00		20.00	
ESR/SEDIMENT. RATE 0-20 (MM)		12/01/93						
2nd h			35.00		38.00		50.00	

2257

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARNACIA 0558089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 4DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			08/03/93		08/04/93		06/05/93	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	12/01/93	13.20		14.20		13.90	
HT	38-54 (X)	12/01/93	39.00		42.00		42.00	
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	4.33		4.67		4.57	
WBC	4-10 (10 ³ /MM ³)	12/01/93	5.00		5.40		5.40	
WBC: N	40-70 (X)	12/01/93	61.00		58.00		61.00	
WBC: L	20-40 (X)	12/01/93	31.00		34.00		34.00	
WBC: E	0-5 (X)	12/01/93	1.00		1.00		1.00	
WBC: M	0-10 (X)	12/01/93	7.00		6.00		4.00	
WBC: B	0-1 (X)	12/01/93	1.00		1.00		0.00	
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	235.00		235.00		247.00	
NA+	135-145 (MEQ/L)	12/01/93	140.00		142.00		138.00	
K+	3.6-5.1 (MEQ/L)	12/01/93	4.30		4.50		4.80	
CL-	92-110 (MEQ/L)	12/01/93	103.00		100.00		98.00	
Ca++	8.5-10.3 (MG/DL)	12/01/93	9.60		9.60		10.70 >	
PO4--	2.5-4.8 (MG/DL)	12/01/93	3.10		3.70		3.30	
SGOT	0-23 (U/L)	12/01/93	15.00		15.00		16.00	
SGPT	0-26 (U/L)	12/01/93	10.00		12.00		11.00	
GAMMA GT	5-32 (U/L)	12/01/93	9.00		11.00		12.00	
LDH	160-320 (U/L)	12/01/93	292.00		227.00		227.00	
ALK. PHOSPH.	73-207 (U/L)	12/01/93	238.00 >		269.00 >		262.00 >	
GLUCOSE	70-105 (MG/DL)	12/01/93	93.00		72.00		106.00 >	
UREA	10-50 (MG/DL)	12/01/93	33.00		27.00		43.00	
CREATININE	0.7-1.3 (MG/DL)	12/01/93	1.00		1.00		1.10	
CREATININE CLEARANCE	85-125 (ML/MIN)	12/01/93	45.80					
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	6.60		6.10		6.30	
TOT BILIRUBIN	0.2-1 (MG/DL)	12/01/93	0.57		0.42		0.48	
DIR BILIRUBIN	0-0.2 (MG/DL)	12/01/93	0.01		0.10		0.10	
TOT. PROTEINS	6-8 (G/DL)	12/01/93	7.90		8.40 >		7.80	
ALBUMINE	58.8-69.6 (X)	12/01/93	57.60 <		60.60		56.20 <	
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	245.00		266.00 >		261.00 >	
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	94.00		121.00		98.00	
GLOBULINS ALPHA 1	1.9-3.8 (X)	12/01/93	3.50		3.50		3.40	
GLOBULINS ALPHA 2	3.7-13.1 (X)	12/01/93	10.90		9.50		10.90	
GLOBULINS BETA	8.9-13.6 (X)	12/01/93	14.50 >		14.50 >		14.70 >	
GLOBULINS GAMMA	8.4-18.3 (X)	12/01/93	13.60		11.80		14.80	
TSH	0-7.3 (MUI/ML)	12/01/93	1.36					
T4	4.5-12 (UG/DL)	12/01/93	10.10					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	12/01/93	34.00		43.00		49.00	
ESR/SEDIMENT. RATE 2nd h	0-20 (MM)	12/01/93	67.00		75.00		90.00	

2258

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 0550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centro: 36 Patient: SDT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date
			Screen
			11/03/93
			value (€)
Laboratory test	Range value	Range date	
HB	12-16 (G/DL)	12/01/93	15.90
HT	38-54 (%)	12/01/93	44.00
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	5.18
HBC	4-10 (10 ³ /MM ³)	12/01/93	9.30
HBC: N	40-70 (%)	12/01/93	70.00
HBC: L	20-40 (%)	12/01/93	22.00
HBC: E	0-5 (%)	12/01/93	1.00
HBC: M	0-10 (%)	12/01/93	0.00
HBC: B	0-1 (%)	12/01/93	0.00
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	286.00
NA+	135-145 (MEQ/L)	12/01/93	138.00
K+	3.6-5.1 (MEQ/L)	12/01/93	4.20
CL-	92-110 (MEQ/L)	12/01/93	99.00
Ca++	8.5-10.3 (MG/DL)	12/01/93	9.70
PO4--	2.5-4.8 (MG/DL)	12/01/93	3.30
SGOT	0-23 (U/L)	12/01/93	18.00
SGPT	0-26 (U/L)	12/01/93	25.00
GAMMA GT	5-32 (U/L)	12/01/93	27.00
LDH	160-320 (U/L)	12/01/93	327.00 >
ALK. PHOSPH.	73-207 (U/L)	12/01/93	209.00 >
GLUCOSE	70-105 (MG/DL)	12/01/93	174.00 >>
UREA	10-50 (MG/DL)	12/01/93	18.00
CREATININE	0.7-1.3 (MG/DL)	12/01/93	0.70
CREATININE CLEARANCE			100.80
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	2.60
TOT. PROTEINS	6-8 (G/DL)	12/01/93	8.10 >
ALBUMINE	58.8-69.6 (%)	12/01/93	67.40
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	260.00
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	150.00
GLOBULINS ALPHA 1	1.9-3.8 (%)	12/01/93	2.30
GLOBULINS ALPHA 2	3.7-13.1 (%)	12/01/93	7.30
GLOBULINS BETA	8.9-13.6 (%)	12/01/93	12.40
GLOBULINS GAMMA	8.4-18.3 (%)	12/01/93	10.70
TSH	0-7.3 (MUI/ML)	12/01/93	5.41
T4	4.5-12 (UG/DL)	12/01/93	8.65
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	12/01/93	8.00
ESR/SEDIMENT. RATE 2nd h	0-20 (MM)	12/01/93	20.00

2259

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 0538089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 6DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			02/04/93		14/05/93		04/06/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	12/01/93	13.70		13.50		13.70	
HT	38-54 (X)	12/01/93	41.00		40.00		40.00	
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	4.61		4.50		4.47	
HBC	4-10 (10 ³ /MM ³)	12/01/93	7.60		8.00		7.30	
HBC: N	40-70 (X)	12/01/93	68.00		68.00		70.00	
HBC: L	20-40 (X)	12/01/93	27.00		28.00		24.00	
HBC: E	0-5 (X)	12/01/93	1.00		1.00		1.00	
HBC: M	0-10 (X)	12/01/93	4.00		3.00		5.00	
HBC: B	0-1 (X)	12/01/93	1.00		1.00		0.00	
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	266.00		267.00		274.00	
NA+	135-145 (MEQ/L)	12/01/93	139.00		139.00		139.00	
K+	3.6-5.1 (MEQ/L)	12/01/93	4.50		4.60		5.00	
CL-	92-110 (MEQ/L)	12/01/93	99.00		99.00		97.00	
Ca++	8.5-10.3 (MG/DL)	12/01/93	9.60		9.60		9.90	
PO4--	2.5-4.8 (MG/DL)	12/01/93	3.70		3.60		3.40	
SGOT	0-23 (U/L)	12/01/93	19.00		17.00		18.00	
SGPT	0-26 (U/L)	12/01/93	11.00		20.00		24.00	
GAMMA GT	5-32 (U/L)	12/01/93	18.00		24.00		27.00	
LDH	160-320 (U/L)	12/01/93	236.00		214.00		255.00	
ALK. PHOSPH.	73-207 (U/L)	12/01/93	100.00		128.00		133.00	
GLUCOSE	70-105 (MG/DL)	12/01/93	141.00	>>	150.00	>>	129.00 >	
UREA	10-50 (MG/DL)	12/01/93	25.00		22.00		21.00	
CREATININE	0.7-1.3 (MG/DL)	12/01/93	0.90		0.90		0.90	
CREATININE CLEARANCE	85-125 (ML/MIN)	12/01/93	57.70					
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	5.70		4.20		4.60	
TOT BILIRUBIN	0.2-1 (MG/DL)	12/01/93	0.53		0.19 <		0.48	
DIR BILIRUBIN	0-0.2 (MG/DL)	12/01/93	0.00		0.10		0.10	
TOT. PROTEINS	6-8 (G/DL)	12/01/93	7.30		8.40 >		7.60	
ALBUMINE	58.8-69.6 (X)	12/01/93	64.20		60.70		62.70	
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	308.00 >		307.00 >		305.00 >	
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	178.00		320.00 >>		184.00	
GLOBULINS ALPHA 1	1.9-3.8 (X)	12/01/93	2.80		2.90		2.90	
GLOBULINS ALPHA 2	3.7-13.1 (X)	12/01/93	9.70		10.40		9.90	
GLOBULINS BETA	8.9-13.6 (X)	12/01/93	12.60		14.50 >		15.30 >	
GLOBULINS GAMMA	8.4-18.3 (X)	12/01/93	10.70		11.50		9.20	
TSH	0-7.3 (MUI/ML)	12/01/93	1.10					
T4	4.5-12 (UG/DL)	12/01/93	8.10					
ESR/SEDIMENT. RATE 0-10 (MM)		12/01/93						
1st h			12.00		6.00		20.00	
ESR/SEDIMENT. RATE 0-20 (MM)		12/01/93						
2nd h			30.00		16.00		44.00	

2260

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 0512089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 7DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date
			Screen
			15/04/93
			value (c)
Laboratory test	Range value	Range date	
HB	12-16 (G/DL)	12/01/93	13.80
HT	38-54 (%)	12/01/93	43.00
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	4.84
WBC	4-10 (10 ³ /MM ³)	12/01/93	7.70
WBC: N	40-70 (%)	12/01/93	65.00
WBC: L	20-40 (%)	12/01/93	26.00
WBC: E	0-5 (%)	12/01/93	3.00
WBC: M	0-10 (%)	12/01/93	5.00
WBC: B	0-1 (%)	12/01/93	1.00
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	233.00
NA+	135-145 (MEQ/L)	12/01/93	140.00
K+	3.6-5.1 (MEQ/L)	12/01/93	4.40
CL-	92-110 (MEQ/L)	12/01/93	97.00
Ca++	8.5-10.3 (MG/DL)	12/01/93	9.60
PO4--	2.5-4.8 (MG/DL)	12/01/93	3.00
SGOT	0-23 (U/L)	12/01/93	14.00
SGPT	0-26 (U/L)	12/01/93	12.00
GAMMA GT	5-32 (U/L)	12/01/93	19.00
LDH	160-320 (U/L)	12/01/93	244.00
ALK. PHOSPH.	73-207 (U/L)	12/01/93	211.00 >
GLUCOSE	70-105 (MG/DL)	12/01/93	185.00 >>
UREA	10-50 (MG/DL)	12/01/93	38.00
CREATININE	0.7-1.3 (MG/DL)	12/01/93	0.80
CREATININE CLEARANCE	85-125 (ML/MIN)	12/01/93	56.40
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	3.20
TOT BILIRUBIN	0.2-1 (MG/DL)	12/01/93	0.52
DIR BILIRUBIN	0-0.2 (MG/DL)	12/01/93	0.10
TOT. PROTEINS	6-8 (G/DL)	12/01/93	7.10
ALBUMINE	58.8-69.6 (%)	12/01/93	69.20
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	244.00
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	104.00
GLOBULINS ALPHA 1	1.9-3.8 (%)	12/01/93	2.70
GLOBULINS ALPHA 2	3.7-13.1 (%)	12/01/93	8.40
GLOBULINS BETA	8.9-13.6 (%)	12/01/93	11.20
GLOBULINS GAMMA	8.4-18.3 (%)	12/01/93	8.50
ESR/SEDIMENT. RATE	0-10 (MM)	12/01/93	
1st h			10.00
ESR/SEDIMENT. RATE	0-20 (MM)	12/01/93	
2nd h			23.00

2261

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C9580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: SDT Treatment: Roboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 35		Day 63	
			04/05/93		16/06/93		16/07/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	12/01/93	11.60	<	12.70		12.00	
HT	38-54 (%)	12/01/93	33.00	<	37.00	<	35.00	<
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	3.92	<	4.22		3.89	<
WBC	4-10 (10 ³ /MM ³)	12/01/93	6.41		5.79		5.70	
WBC: N	40-70 (%)	12/01/93	75.00	>	63.00		64.00	
WBC: L	20-40 (%)	12/01/93	20.00		24.00		27.00	
WBC: E	0-5 (%)	12/01/93	1.00		2.00		4.00	
WBC: M	0-10 (%)	12/01/93	3.00		10.00		4.00	
WBC: B	0-1 (%)	12/01/93	1.00		1.00		1.00	
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	217.00		278.00		288.00	
NA+	135-145 (MEQ/L)	12/01/93	135.00		139.00		135.00	
K+	3.6-5.1 (MEQ/L)	12/01/93	3.40	<	4.70		4.00	
CL-	92-110 (MEQ/L)	12/01/93	96.00		97.00		97.00	
Ca++	8.5-10.3 (MG/DL)	12/01/93	9.30		10.50	>	10.00	
PO4--	2.5-4.8 (MG/DL)	12/01/93			2.70		3.00	
SGOT	0-23 (U/L)	12/01/93	14.00		14.00		11.00	
SGPT	0-26 (U/L)	12/01/93	10.00		16.00		9.00	
GAMMA GT	5-32 (U/L)	12/01/93	9.00		16.00		17.00	
LDH	160-320 (U/L)	12/01/93	206.00		220.00		215.00	
ALK. PHOSPH.	73-207 (U/L)	12/01/93	99.00		119.00		127.00	
GLUCOSE	70-105 (MG/DL)	12/01/93	205.00	>>	85.00		82.00	
UREA	10-50 (MG/DL)	12/01/93	38.00		30.00		36.00	
CREATININE	0.7-1.3 (MG/DL)	12/01/93	0.80		0.90		1.00	
CREATININE CLEARANCE			49.00					
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	3.00		4.10		4.00	
TOT BILIRUBIN	0.2-1 (MG/DL)	12/01/93	0.38		0.22		0.00	<
DIR BILIRUBIN	0-0.2 (MG/DL)	12/01/93	0.07		0.10		0.00	
TOT. PROTEINS	6-8 (G/DL)	12/01/93	6.80		7.80		8.00	
ALBUMINE	58.8-69.6 (%)	12/01/93	63.30		62.40		58.90	
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	211.00		255.00		265.00	>
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	139.00		244.00	>	334.00	>>
GLOBULINS ALPHA 1	1.9-3.8 (%)	12/01/93	2.80		2.90		2.70	
GLOBULINS ALPHA 2	3.7-13.1 (%)	12/01/93	8.40		9.00		9.60	
GLOBULINS BETA	8.9-13.6 (%)	12/01/93	12.40		12.80		13.60	
GLOBULINS GAMMA	8.4-18.3 (%)	12/01/93	13.20		12.80		15.20	
TSH	0-7.3 (MUI/ML)	12/01/93	0.59					
T4	4.5-12 (UG/DL)	12/01/93	10.10					
ESR/SEDIMENT. RATE	0-10 (MM)	12/01/93						
1st h			15.00		37.00		29.00	
ESR/SEDIMENT. RATE	0-20 (MM)	12/01/93						
2nd h			33.00		71.00		70.00	

2262

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C9554089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 9DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			24/06/93		19/07/93		23/08/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	12/01/93	14.60		15.20		14.80	
HT	38-54 (%)	12/01/93	43.00		45.00		42.00	
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	4.75		4.96		4.79	
WBC	4-10 (10 ³ /MM ³)	12/01/93	4.00		4.90		5.30	
WBC: N	40-70 (%)	12/01/93	53.00		65.00		58.00	
WBC: L	20-40 (%)	12/01/93	36.00		25.00		31.00	
WBC: E	0-5 (%)	12/01/93	6.00	>	4.00		5.00	
WBC: M	0-10 (%)	12/01/93	5.00		5.00		5.00	
WBC: B	0-1 (%)	12/01/93	1.00		1.00		1.00	
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	203.00		244.00		210.00	
NA+	135-145 (MEQ/L)	12/01/93	141.00		136.00		138.00	
K+	3.6-5.1 (MEQ/L)	12/01/93	4.60		5.00		4.40	
CL-	92-110 (MEQ/L)	12/01/93	102.00		98.00		102.00	
Ca++	8.5-10.3 (MG/DL)	12/01/93	10.40	>	11.00	>	10.00	
PO4--	2.5-4.8 (MG/DL)	12/01/93	3.40		3.00		2.90	
SGOT	0-23 (U/L)	12/01/93	14.00		11.00		18.00	
SGPT	0-26 (U/L)	12/01/93	9.00		7.00		13.00	
GAMMA GT	5-32 (U/L)	12/01/93	11.00		13.00		11.00	
LDH	160-320 (U/L)	12/01/93	270.00		270.00		299.00	
ALK. PHOSPH.	73-207 (U/L)	12/01/93	82.00		107.00		104.00	
GLUCOSE	70-105 (MG/DL)	12/01/93	98.00		82.00		107.00	
UREA	10-50 (MG/DL)	12/01/93	30.00		30.00		28.00	
CREATININE	0.7-1.3 (MG/DL)	12/01/93	1.30		1.00		1.20	
CREATININE CLEARANCE	85-125 (ML/MIN)	12/01/93	44.79					
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	6.20		5.00		5.10	
TOT BILIRUBIN	0.2-1 (MG/DL)	12/01/93	0.68		0.00	<	0.35	
DIR BILIRUBIN	0-0.2 (MG/DL)	12/01/93	0.20		0.00		0.10	
TOT. PROTEINS	6-8 (G/DL)	12/01/93	7.50		8.00		7.00	
ALBUMINE	58.8-69.6 (%)	12/01/93	60.50		64.20		64.80	
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	304.00	>	275.00	>	248.00	
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	147.00		167.00		219.00	
GLOBULINS ALPHA 1	1.9-3.8 (%)	12/01/93	3.90	>	2.60		2.90	
GLOBULINS ALPHA 2	3.7-13.1 (%)	12/01/93	9.10		8.40		6.90	
GLOBULINS BETA	8.9-13.6 (%)	12/01/93	11.50		10.90		10.70	
GLOBULINS GAMMA	8.4-18.3 (%)	12/01/93	15.00		13.90		14.70	
TSH	0-7.3 (MUI/ML)	12/01/93	1.75					
T4	4.5-12 (UG/DL)	12/01/93	10.50					
ESR/SEDIMENT. RATE 0-10 (MM)		12/01/93						
1st h			8.00		10.00		4.00	
ESR/SEDIMENT. RATE 0-20 (MM)		12/01/93						
2nd h			17.00		25.00		10.00	

2263

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS 590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 10DT Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			18/10/93		19/11/93		28/12/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	12/01/93	13.30		13.20			
	14-18 (G/DL)	20/12/93				14.00		
HT	38-54 (X)	12/01/93	37.00	<	38.00			
	39-53 (X)	20/12/93				39.50		
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	4.02		3.94	<		
	4.5-6.3 (10 ⁶ /MM ³)	20/12/93				4.15	<	
WBC	4-10 (10 ³ /MM ³)	12/01/93	8.30		6.40			
	4.3-11 (10 ³ /MM ³)	20/12/93				8.55		
WBC: N	40-70 (X)	12/01/93	73.00	>	62.00			
	50-65 (X)	20/12/93				68.30	>	
WBC: L	20-40 (X)	12/01/93	20.00		31.00			
	25-45 (X)	20/12/93				23.50	<	
WBC: E	0-5 (X)	12/01/93	2.00		2.00			
	0-6 (X)	20/12/93				1.50		
WBC: M	0-10 (X)	12/01/93	5.00		5.00			
	2-10 (X)	20/12/93				6.10		
WBC: B	0-1 (X)	12/01/93	1.00		0.00			
	0-2 (X)	20/12/93				0.60		
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	171.00		132.00			
	1.4-4.4 (10 ⁵ /MM ³)	20/12/93				1.49		
NA+	135-145 (MEQ/L)	12/01/93	135.00		140.00			
	136-148 (MEQ/L)	20/12/93				146.00		
K+	3.6-5.1 (MEQ/L)	12/01/93	3.40	<	3.90			
	3.5-5.5 (MEQ/L)	20/12/93				5.20		
CL-	92-110 (MEQ/L)	12/01/93	99.00		102.00			
Ca++	8.5-10.3 (MG/DL)	12/01/93	10.00		9.30			
	40-52 (MG/L)	20/12/93				43.50		
PO4--	2.5-4.8 (MG/DL)	12/01/93	2.10	<<	2.40	<	2.81	
SGOT	0-23 (U/L)	12/01/93	42.00	>	12.00			
	5-25 (U/L)	20/12/93				14.00		
SGPT	0-26 (U/L)	12/01/93	18.00		12.00			
	5-29 (U/L)	20/12/93				22.00		
GAMMA GT	5-32 (U/L)	12/01/93	12.00		10.00			
	8-38 (U/L)	20/12/93				16.00		
LDH	160-320 (U/L)	12/01/93	248.00		186.00			
ALK. PHOSPH.	73-207 (U/L)	12/01/93	107.00		111.00			
GLUCOSE	70-105 (MG/DL)	12/01/93	107.00	>	97.00			
	60-140 (MG/DL)	20/12/93				126.00		
UREA	10-50 (MG/DL)	12/01/93	30.00		33.00			
	20-50 (MG/DL)	20/12/93				42.00		
CREATININE	0.7-1.3 (MG/DL)	12/01/93	1.30		1.20			
	0.4-1.5 (MG/DL)	20/12/93				1.34		
CREATININE CLEARANCE	75-115 (ML/MIN)	12/01/93	41.40					
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	4.70		5.00			
	3.5-7 (MG/DL)	20/12/93				5.10		
TOT BILIRUBIN	0.2-1 (MG/DL)	12/01/93	0.80		0.47			
	0-1.1 (MG/DL)	20/12/93				0.30		
DIR BILIRUBIN	0-0.2 (MG/DL)	12/01/93	0.30	>	0.10			
	0-0.25 (MG/DL)	20/12/93				0.10		
TOT. PROTEINS	6-8 (G/DL)	12/01/93	6.20		6.70			
ALBUMINE	58.8-69.6 (X)	12/01/93	67.60		65.10			
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	160.00		160.00			
	50-220 (MG/DL)	20/12/93				240.00	>	
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	126.00		134.00			
	50-190 (MG/DL)	20/12/93				263.00	>>	
GLOBULINS ALPHA 1	1.9-3.8 (X)	12/01/93	3.00		3.50			
GLOBULINS ALPHA 2	3.7-13.1 (X)	12/01/93	7.50		9.60			
GLOBULINS BETA	8.9-13.6 (X)	12/01/93	10.90		11.90			
GLOBULINS GAMMA	8.4-18.3 (X)	12/01/93	11.10		9.90			
TSH	0-7.3 (MUI/ML)	12/01/93	0.68					
T4	4.5-12 (UG/DL)	12/01/93	8.56					

2264

(CONTINUED)

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNE540089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 10DT Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			18/10/93		19/11/93		28/12/93	
			value	(⚡)	value	(⚡)	value	(⚡)
Laboratory test	Range value	Range date						
ESR/SEDIMENT. RATE 0-10 (MM)		12/01/93						
1st h			11.00		14.00		7.00	
ESR/SEDIMENT. RATE 0-20 (MM)		12/01/93						
2nd h			26.00		30.00		16.00	

2265

(⚡) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value and laboratory not done () missing range value

PHARMACIA CNS 590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 11DT Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date	
			Screen	
			28/10/93	
			value	(φ)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	12/01/93	12.50	
HT	38-54 (%)	12/01/93	38.00	
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	3.92	<
WBC	4-10 (10 ³ /MM ³)	12/01/93	8.00	
WBC: N	40-70 (%)	12/01/93	46.00	
WBC: L	20-40 (%)	12/01/93	48.00	>
WBC: E	0-5 (%)	12/01/93	2.00	
WBC: M	0-10 (%)	12/01/93	4.00	
WBC: B	0-1 (%)	12/01/93	1.00	
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	227.00	
NA+	135-145 (MEQ/L)	12/01/93	143.00	
K+	3.6-5.1 (MEQ/L)	12/01/93	5.20	>
CL-	92-110 (MEQ/L)	12/01/93	102.00	
Ca++	8.5-10.3 (MG/DL)	12/01/93	10.10	
PO4--	2.5-4.8 (MG/DL)	12/01/93	3.20	
SGOT	0-23 (U/L)	12/01/93	10.00	
SGPT	0-26 (U/L)	12/01/93	5.00	
GAMMA GT	5-32 (U/L)	12/01/93	17.00	
LDH	160-320 (U/L)	12/01/93	218.00	
ALK. PHOSPH.	73-207 (U/L)	12/01/93	123.00	
GLUCOSE	70-105 (MG/DL)	12/01/93	103.00	
UREA	10-50 (MG/DL)	12/01/93	28.00	
CREATININE	0.7-1.3 (MG/DL)	12/01/93	1.50	>
CREATININE CLEARANCE			31.60	
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	8.80	>
TOT BILIRUBIN	0.2-1 (MG/DL)	12/01/93	0.34	
DIR BILIRUBIN	0-0.2 (MG/DL)	12/01/93	0.10	
TOT. PROTEINS	6-8 (G/DL)	12/01/93	6.70	
ALBUMINE	58.8-69.6 (%)	12/01/93	63.10	>
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	295.00	>
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	267.00	>>
GLOBULINS ALPHA 1	1.9-3.8 (%)	12/01/93	3.50	
GLOBULINS ALPHA 2	3.7-13.1 (%)	12/01/93	15.60	>
GLOBULINS BETA	8.9-13.6 (%)	12/01/93	10.00	
GLOBULINS GAMMA	8.4-18.3 (%)	12/01/93	7.80	<
TSH	0-7.3 (MUI/ML)	12/01/93	1.04	
T4	4.5-12 (UG/DL)	12/01/93	5.07	
ESR/SEDIMENT. RATE	0-10 (MM)	12/01/93		
1st h			42.00	
ESR/SEDIMENT. RATE	0-20 (MM)	12/01/93		
2nd h			80.00	

2266

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 09536089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 36 Patient: 12DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			13/12/93		18/01/94		15/02/94	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	12/01/93	12.40		13.90		12.40	
HT	38-54 (%)	12/01/93	39.00		43.00		37.00 <	
RBC	4-5.5 (10 ⁶ /MM ³)	12/01/93	4.08		4.47		3.95 <	
WBC	4-10 (10 ³ /MM ³)	12/01/93	6.20		7.70		6.10	
WBC: N	40-70 (%)	12/01/93	51.00		64.00		66.00	
WBC: L	20-40 (%)	12/01/93	34.00		25.00		25.00	
WBC: E	0-5 (%)	12/01/93	6.00 >		4.00		5.00	
WBC: M	0-10 (%)	12/01/93	8.00		6.00		3.00	
WBC: B	0-1 (%)	12/01/93	1.00		0.00		1.00	
PLATELETS	100-400 (10 ³ /MM ³)	12/01/93	342.00		342.00		291.00	
NA+	135-145 (MEQ/L)	12/01/93	140.00		140.00		142.00	
K+	3.6-5.1 (MEQ/L)	12/01/93	3.80		4.00		4.20	
CL-	92-110 (MEQ/L)	12/01/93	97.00		95.00		105.00	
Ca++	8.5-10.3 (MG/DL)	12/01/93	8.70		8.60		8.90	
PO4--	2.5-4.8 (MG/DL)	12/01/93	3.30		3.50		4.20	
SGOT	0-23 (U/L)	12/01/93	11.00		12.00		13.00	
SGPT	0-23 (U/L)	12/01/93	10.00		11.00		11.00	
GAMMA GT	5-32 (U/L)	12/01/93	8.00		9.00		9.00	
LDH	160-320 (U/L)	12/01/93	268.00		305.00		258.00	
ALK. PHOSPH.	73-207 (U/L)	12/01/93	113.00		126.00		126.00	
GLUCOSE	70-105 (MG/DL)	12/01/93	88.00		86.00		106.00 >	
UREA	10-50 (MG/DL)	12/01/93	32.00		38.00		54.00 >	
CREATININE	0.7-1.3 (MG/DL)	12/01/93	1.10		1.10		1.20	
CREATININE CLEARANCE	85-125 (ML/MIN)	12/01/93	29.83					
URIC ACID	2.6-6.8 (MG/DL)	12/01/93	4.60		4.70		5.20	
TOT BILIRUBIN	0.2-1 (MG/DL)	12/01/93	0.42		0.35		0.29	
DIR BILIRUBIN	0-0.2 (MG/DL)	12/01/93	0.10		0.00		0.10	
TOT. PROTEINS	6-8 (G/DL)	12/01/93	6.30		7.60		6.50	
ALBUMINE	58.8-69.6 (%)	12/01/93	56.50 <		58.00 <		58.10 <	
TOT. CHOLEST.	150-260 (MG/DL)	12/01/93	172.00		227.00		208.00	
TRIGLYCERIDES	30-200 (MG/DL)	12/01/93	53.00		64.00		62.00	
GLOBULINS ALPHA 1	1.9-3.8 (%)	12/01/93	2.60		2.30		2.90	
GLOBULINS ALPHA 2	3.7-13.1 (%)	12/01/93	9.20		9.70		9.10	
GLOBULINS BETA	8.9-13.6 (%)	12/01/93	14.90 >		13.90 >		14.10 >	
GLOBULINS GAMMA	8.4-18.3 (%)	12/01/93	16.80		16.10		15.80	
TSH	0-7.3 (MUI/ML)	12/01/93	0.78					
T4	4.5-12 (UG/DL)	12/01/93	10.80					
ESR/SEDIMENT. RATE 0-10 (MM)		12/01/93						
1st h			15.00		26.00		27.00	
ESR/SEDIMENT. RATE 0-20 (MM)		12/01/93						
2nd h			36.00		45.00		55.00	

2267

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 0956089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 37 Patient: 3MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	
			12/03/93	
			value	(*)
Laboratory test	Range value	Range date		
HB	12-18 (G/DL)	02/02/93	12.60	
HT	37-56 (%)	02/02/93	38.10	
RBC	4200-6200 (10 ⁹ /L)	02/02/93	4390.00	
NBC	4000-10000 (10 ⁶ /L)	02/02/93	7940.00	
NBC: N	50-70 (%)	02/02/93	76.60	>
NBC: L	20-40 (%)	02/02/93	12.00	<<
NBC: E	0-5 (%)	02/02/93	0.90	
NBC: M	2-10 (%)	02/02/93	9.20	
NBC: B	0-2 (%)	02/02/93	0.10	
PLATELETS	150-400 (10 ⁹ /L)	02/02/93	286.00	
NA+	136-146 (MMOL/L)	02/02/93	138.00	
K+	3.5-5 (MMOL/L)	02/02/93	4.00	
CL-	95-105 (MMOL/L)	02/02/93	102.00	
Ca++	2-2.6 (MMOL/L)	02/02/93	2.22	
PO4--	0.79-1.56 (MMOL/L)	02/02/93	0.75	<
SGOT	0-25 (UI/L)	02/02/93	16.00	
SGPT	0-29 (UI/L)	02/02/93	23.00	
GAMMA GT	0-38 (UI/L)	02/02/93	17.00	
LDH	138-276 (UI/L)	02/02/93	337.00	>
ALK. PHOSPH.	0-207 (UI/L)	02/02/93	116.00	
GLUCOSE	0.6-1.2 (G/L)	02/02/93	0.98	
UREA	0.1-0.5 (G/L)	02/02/93	0.34	
CREATININE	0-1.4 (MG/DL)	02/02/93	0.94	
CREATININE CLEARANCE			43.56	
URIC ACID	2.4-7 (MG/DL)	02/02/93	5.00	
TOT BILIRUBIN	0-1.5 (MG/DL)	02/02/93	0.83	
DIR BILIRUBIN	0-0.5 (MG/DL)	02/02/93	0.23	
ALBUMINE	3.5-5 (G/DL)	02/02/93	0.17	<<
TOT. CHOLEST.	1.5-2.5 (G/L)	02/02/93	2.34	
TRIGLYCERIDES	0.4-1.72 (G/L)	02/02/93	1.34	
TSH	0.2-5 (UU/ML)	02/02/93	2.10	
T4	0.8-1 (MG/DL)	02/02/93	1.50	

2268

(*) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C9580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 41 Patient: 1MD Treatment: Imipramine Sex: Male

			Visit number / Laboratory date
			Screen
			15/02/94
			value (€)
Laboratory test	Range value	Range date	
HB	13.2-17 (G/DL)	01/01/92	13.70
HT	0.4-0.54 (L/L)	01/01/92	0.43
RBC	4.2-5.8 (10 ¹² /L)	01/01/92	4.63
HBC	3.8-11 (10 ⁹ /L)	01/01/92	5.61
HBC: N	40-75 (%)	01/01/92	76.00 >
HBC: L	20-45 (%)	01/01/92	17.00 <
HBC: E	1-6 (%)	01/01/92	0.80 <
HBC: M	2-10 (%)	01/01/92	6.20
PLATELETS	150-400 (10 ⁹ /L)	01/01/92	291.00
NA+	135-150 (MMOL/L)	01/01/92	142.00
K+	3.6-5 (MMOL/L)	01/01/92	4.94
CL-	95-108 (MMOL/L)	01/01/92	107.00
Ca++	2.1-2.6 (MMOL/L)	01/01/92	2.36
PO4--	0.8-1.4 (MMOL/L)	01/01/92	1.18
SGOT	0-41 (IU/L)	01/01/92	38.00
SGPT	0-45 (IU/L)	01/01/92	78.00 >
GAMMA GT	0-60 (IU/L)	01/01/92	33.00
ALK. PHOSPH.	30-135 (IU/L)	01/01/92	112.00
UREA	2.5-8.4 (MMOL/L)	01/01/92	7.10
CREATININE	45-120 (UMOL/L)	01/01/92	112.00
CREATININE CLEARANCE			59.00
URIC ACID	180-450 (UMOL/L)	01/01/92	256.00
TOT BILIRUBIN	3-20 (UMOL/L)	01/01/92	4.80
TOT. PROTEINS	60-80 (G/L)	01/01/92	65.00
ALBUMINE	34-50 (G/L)	01/01/92	42.00
TOT. CHOLEST.	3-6 (MMOL/L)	01/01/92	4.83
TRIGLYCERIDES	0.8-2 (MMOL/L)	01/01/92	2.13 >
GLOBULINS ALPHA 1	1.5-3.8 (G/L)	01/01/92	2.00
GLOBULINS ALPHA 2	3.2-9.7 (G/L)	01/01/92	6.90
GLOBULINS BETA	5.2-10 (G/L)	01/01/92	6.30
GLOBULINS GAMMA	5.2-14.5 (G/L)	01/01/92	7.80
TSH	0.3-3.5 (MU/L)	01/01/92	0.60
T4	58-160 (NMOL/L)	01/01/92	94.00
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/01/92	1.00

2269

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA 09510089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 41 Patient: 2ND Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			18/02/94		23/03/94		20/04/94	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	13.2-17 (G/DL)	15/02/94	13.40		13.10	<	13.70	
HT	0.4-0.54 (L/L)	15/02/94	0.40	<	0.40		0.42	
RBC	4.2-5.8 (10 ¹² /L)	15/02/94	4.41		4.39		4.48	
MBC	3.8-11 (10 ⁹ /L)	15/02/94	8.00		9.10		8.15	
MBC: N	2.2-7.5 (10 ⁹ /L)	15/02/94	4.40					
	40-75 (%)	20/03/94			68.00			
MBC: L	1.2-4 (10 ⁹ /L)	15/02/94	2.60					
	20-45 (%)	20/03/94			24.00			
MBC: E	0-0.5 (10 ⁹ /L)	15/02/94	0.10					
	1-6 (%)	20/03/94			5.00			
MBC: M	0.2-1 (10 ⁹ /L)	15/02/94	0.70					
	2-10 (%)	20/03/94			1.00	<		
MBC: B	0-1 (%)	20/03/94			1.00			
PLATELETS	150-400 (10 ⁹ /L)	15/02/94	343.00		436.00	>	362.00	
NA+	135-150 (MMOL/L)	15/02/94	143.00		137.00		139.60	
K+	3.6-5 (MMOL/L)	15/02/94	4.25		4.50		5.16	
CL-	95-108 (MMOL/L)	20/03/94			104.00		100.00	
Ca++	2.1-2.6 (MMOL/L)	15/02/94	2.27		2.45		2.44	
PO4--	0.8-1.4 (MMOL/L)	15/02/94	1.40		1.27		1.54	
SGOT	0-41 (IU/L)	20/03/94			20.00		23.00	
SGPT	0-45 (IU/L)	15/02/94	26.00		19.00		24.00	
GAMMA GT	0-60 (IU/L)	15/02/94	19.00		14.00		13.00	
ALK. PHOSPH.	30-135 (IU/L)	15/02/94	84.00		96.00		93.00	
GLUCOSE	2.8-8.9 (MMOL/L)	15/02/94	5.60		7.80		3.70	
UREA	2.5-8.4 (MMOL/L)	20/03/94			3.00		4.30	
CREATININE	45-120 (UMOL/L)	15/02/94	53.00		95.00		109.00	
CREATININE CLEARANCE	70-152 (ML/MIN)	15/02/94	95.30					
URIC ACID	180-450 (UMOL/L)	20/03/94			211.00		216.00	
TOT BILIRUBIN	3-20 (UMOL/L)	15/02/94	8.00		5.30		3.40	
TOT. PROTEINS	60-80 (G/L)	15/02/94	67.00		67.00		67.00	
ALBUMINE	34-50 (G/L)	15/02/94	44.00		43.00		43.00	
TOT. CHOLEST.	3-6 (MMOL/L)	20/03/94			4.60		4.56	
TRIGLYCERIDES	0.8-2 (MMOL/L)	20/03/94			1.35		1.34	
GLOBULINS ALPHA 1	1.5-3.8 (G/L)	15/02/94	2.60		2.10		2.40	
GLOBULINS ALPHA 2	3.2-9.7 (G/L)	15/02/94	6.00		8.10		6.20	
GLOBULINS BETA	5.2-10 (G/L)	15/02/94	6.20		5.30		6.80	
GLOBULINS GAMMA	5.2-14.5 (G/L)	15/02/94	7.20		8.50		8.60	
T4	7-26 (PMOL/L)	15/02/94	17.00					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	20/03/94			1.00		1.00	

2270

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARNACIA 0550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 41 Patient: 3ND Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			14/02/94		25/03/94		22/04/94	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	13.2-17 (G/DL)	01/01/92	13.20		14.00		13.40	
HT	0.4-0.54 (L/L)	01/01/92	0.38	<	0.42		0.41	
RBC	4.2-5.8 (10 ¹² /L)	01/01/92	4.38		4.86		4.52	
HBC	3.8-11 (10 ⁹ /L)	01/01/92	5.16		3.58	<	4.58	
WBC: N	40-75 (%)	01/01/92	75.00		59.90		63.50	
WBC: L	20-45 (%)	01/01/92	16.00	<	30.80		25.50	
WBC: E	1-6 (%)	01/01/92	0.60	<	0.50	<	0.80	
WBC: M	2-10 (%)	01/01/92	8.00		7.90		9.40	
WBC: B	0-1 (%)	01/01/92	0.50		0.60		0.80	
PLATELETS	150-400 (10 ⁹ /L)	01/01/92	283.00		176.00		198.00	
NA+	135-150 (MMOL/L)	01/01/92	142.00		142.00		145.00	
K+	3.6-5 (MMOL/L)	01/01/92	4.10		4.01		4.18	
CL-	95-108 (MMOL/L)	01/01/92	104.00		108.00		103.00	
Ca++	2.1-2.6 (MMOL/L)	01/01/92	2.11		2.30		2.29	
PO4--	0.8-1.4 (MMOL/L)	01/01/92	1.09		0.95		1.03	
SGOT	0-41 (IU/L)	01/01/92	25.00		17.00		21.00	
SGPT	0-45 (IU/L)	01/01/92	18.00		13.00		18.00	
GAMMA GT	0-60 (IU/L)	01/01/92	36.00		18.00		17.00	
ALK. PHOSPH.	30-135 (IU/L)	01/01/92	61.00		66.00		66.00	
GLUCOSE	2.8-8.9 (MMOL/L)	01/01/92	10.70	>	6.50		6.70	
UREA	2.5-8.4 (MMOL/L)	01/01/92	7.80		14.00	>>	8.30	
CREATININE	45-120 (UMOL/L)	01/01/92	91.00		103.00		102.00	
CREATININE CLEARANCE	70-152 (ML/MIN)	01/01/92	55.00					
URIC ACID	180-450 (UMOL/L)	01/01/92	324.00		350.00		267.00	
TOT. BILIRUBIN	3-20 (UMOL/L)	01/01/92	17.90		29.50	>	24.90	
TOT. PROTEINS	60-80 (G/L)	01/01/92	61.00		65.00		68.00	
ALBUMINE	34-50 (G/L)	01/01/92	39.00		40.00		41.00	
TOT. CHOLEST.	3-6 (MMOL/L)	01/01/92	4.26		5.57		5.43	
TRIGLYCERIDES	0.8-2 (MMOL/L)	01/01/92	1.18		1.24		1.76	
GLOBULINS ALPHA 1	1.5-3.8 (G/L)	01/01/92	2.60		2.10		2.40	
GLOBULINS ALPHA 2	3.2-9.7 (G/L)	01/01/92	6.00		6.00		6.20	
GLOBULINS BETA	5.2-10 (G/L)	01/01/92	6.20		7.40		8.20	
GLOBULINS GAMMA	5.2-14.5 (G/L)	01/01/92	7.20		9.50		10.20	
TSH	0.3-3.5 (MU/L)	01/01/92	3.00					
T4	58-160 (NMOL/L)	01/01/92	106.00					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/01/92	1.00		2.00		2.00	

2271

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 09530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 41 Patient: 4MD Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			21/02/94		28/03/94		25/04/94	
			value	(⊕)	value	(⊕)	value	(⊕)
Laboratory test	Range value	Range date						
HB	13.2-17 (G/DL)	01/01/92	13.80		13.10 <	13.70		
HT	0.4-0.54 (L/L)	01/01/92	0.42		0.41	0.43		
RBC	4.2-5.8 (10 ¹² /L)	01/01/92	4.51		4.37	4.38		
WBC	3.8-11 (10 ⁹ /L)	01/01/92	5.12		7.08	6.61		
WBC: N	40-75 (%)	01/01/92	66.00		60.70	58.10		
WBC: L	20-45 (%)	01/01/92	22.90		29.00	30.60		
WBC: E	1-6 (%)	01/01/92	1.10		0.50 <	0.40 <		
WBC: M	2-10 (%)	01/01/92	10.00		9.40	10.00		
WBC: B	0-1 (%)	01/01/92	0.10		0.40	0.90		
PLATELETS	150-400 (10 ⁹ /L)	01/01/92	207.00		256.00	235.00		
NA+	135-150 (MMOL/L)	01/01/92	136.00		141.00	138.00		
K+	3.6-5 (MMOL/L)	01/01/92	4.75		4.50	4.84		
CL-	95-108 (MMOL/L)	01/01/92	102.00		108.00	103.00		
Ca++	2.1-2.6 (MMOL/L)	01/01/92	2.41		2.35	2.40		
PO4--	0.8-1.4 (MMOL/L)	01/01/92	1.43 >		1.20	1.27		
SGOT	0-41 (IU/L)	01/01/92	22.00		21.00	28.00		
SGPT	0-45 (IU/L)	01/01/92	16.00		12.00	18.00		
GAMMA GT	0-60 (IU/L)	01/01/92	13.00		12.00	13.00		
ALK. PHOSPH.	30-135 (IU/L)	01/01/92	115.00		114.00	117.00		
GLUCOSE	2.8-8.9 (MMOL/L)	01/01/92	6.40		8.50	12.90 >>		
UREA	2.5-8.4 (MMOL/L)	01/01/92	7.90			7.60		
CREATININE	45-120 (UMOL/L)	01/01/92	93.00		88.00	94.00		
CREATININE CLEARANCE	70-152 (ML/MIN)	01/01/92	70.00					
URIC ACID	180-450 (UMOL/L)	01/01/92	257.00		248.00	221.00		
TOT. BILIRUBIN	3-20 (UMOL/L)	01/01/92	8.40		9.70	10.20		
TOT. PROTEINS	60-80 (G/L)	01/01/92	74.00		69.00	71.00		
ALBUMINE	34-50 (G/L)	01/01/92	47.00		44.00	44.00		
TOT. CHOLEST.	3-6 (MMOL/L)	01/01/92	6.10 >		4.90	4.95		
TRIGLYCERIDES	0.8-2 (MMOL/L)	01/01/92	1.34		2.07 >	1.98		
GLOBULINS ALPHA 1	1.5-3.8 (G/L)	01/01/92	2.30		2.20	2.20		
GLOBULINS ALPHA 2	3.2-9.7 (G/L)	01/01/92	6.63		5.80	6.40		
GLOBULINS BETA	5.2-10 (G/L)	01/01/92	8.50		7.80	8.20		
GLOBULINS GAMMA	5.2-14.5 (G/L)	01/01/92	10.10		9.20	10.20		
TSH	0.3-3.5 (MU/L)	01/01/92	0.70					
T4	58-160 (NMOL/L)	01/01/92	73.00					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/01/92	2.00		2.00			

2272

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 09530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 41 Patient: SMD Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			18/02/94		31/03/94		28/04/94	
			value	(*)	value	(*)	value	(*)
Laboratory test	Range value	Range date						
HB	13.2-17 (G/DL)	01/01/92	15.00		15.30		15.00	
HT	0.4-0.54 (L/L)	01/01/92	0.44		0.44		0.46	
RBC	4.2-5.8 (10 ¹² /L)	01/01/92	5.29		5.13		5.20	
WBC	3.8-11 (10 ⁹ /L)	01/01/92	3.87		5.12		4.59	
WBC: N	40-75 (%)	01/01/92	57.00		66.50		65.60	
WBC: L	20-45 (%)	01/01/92	26.00		25.40		24.00	
WBC: E	1-6 (%)	01/01/92	2.00		0.70	<	0.70	
WBC: M	2-10 (%)	01/01/92	12.00	>	6.60		8.60	
WBC: B	0-1 (%)	01/01/92	1.60	>>	0.80		1.10	
PLATELETS	150-400 (10 ⁹ /L)	01/01/92	209.00		243.00		259.00	
NA+	135-150 (MMOL/L)	01/01/92	140.00		134.90	<	139.70	
K+	3.6-5 (MMOL/L)	01/01/92	4.43		4.83		4.64	
CL-	95-108 (MMOL/L)	01/01/92	102.00		102.00		102.00	
Ca++	2.1-2.6 (MMOL/L)	01/01/92	2.39		2.49		2.42	
PO4--	0.8-1.4 (MMOL/L)	01/01/92	1.17		1.42	>	1.28	
SGOT	0-41 (IU/L)	01/01/92	39.00		34.00		41.00	
SGPT	0-45 (IU/L)	01/01/92	55.00	>	63.00	>	55.00	
GAMMA GT	0-60 (IU/L)	01/01/92	38.00		31.00		34.00	
ALK. PHOSPH.	30-135 (IU/L)	01/01/92	116.00		114.00		100.00	
GLUCOSE	2.8-8.9 (MMOL/L)	01/01/92	5.30		8.40		6.50	
UREA	2.5-8.4 (MMOL/L)	01/01/92	6.30					
CREATININE	45-120 (UMOL/L)	01/01/92	101.00		107.00		92.00	
CREATININE CLEARANCE	70-152 (ML/MIN)	01/01/92						
URIC ACID	180-450 (UMOL/L)	01/01/92	64.00					
TOT BILIRUBIN	3-20 (UMOL/L)	01/01/92	399.00		345.00		319.00	
TOT. PROTEINS	60-80 (G/L)	01/01/92	4.90		6.50		9.30	
ALBUMINE	34-50 (G/L)	01/01/92	73.00		69.00		68.00	
TOT. CHOLEST.	3-6 (MMOL/L)	01/01/92	44.00		44.00		43.00	
TRIGLYCERIDES	0.8-2 (MMOL/L)	01/01/92	5.80		5.35		4.86	
GLOBULINS ALPHA 1	1.5-3.8 (G/L)	01/01/92	2.55	>	2.05	>	1.63	
GLOBULINS ALPHA 2	3.2-9.7 (G/L)	01/01/92	2.60		2.00		2.30	
GLOBULINS BETA	5.2-10 (G/L)	01/01/92	6.70		5.50		5.60	
GLOBULINS GAMMA	5.2-14.5 (G/L)	01/01/92	9.50		8.40		7.70	
TSH	0.3-3.5 (MU/L)	01/01/92	10.20		9.10		9.40	
T4	58-160 (NMOL/L)	01/01/92	1.50					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/01/92	74.00					
			2.00		2.00		1.00	

2273

(*) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done (*) missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 0959089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 42 Patient: 1MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			12/10/93		22/11/93		20/12/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12.5-16.5 (G/DL)	05/10/93	13.60		11.50		11.30 <	
	11.5-15.5 (G/DL)	15/11/93						
HT	0.37-0.47 (L/L)	05/10/93	0.40		0.33 <		0.35 <	
	0.35-0.47 (L/L)	15/11/93						
RBC	3.8-5.8 (10 ¹² /L)	05/10/93	4.80		4.13		3.87	
	3.8-5.4 (10 ¹² /L)	15/11/93						
WBC	4-11 (10 ⁹ /L)	05/10/93	8.50		7.66		4.65	
	3.8-11 (10 ⁹ /L)	15/11/93						
WBC: N	2-7.5 (10 ⁹ /L)	05/10/93	5.90		75.80 >		70.20	
	40-75 (%)	15/11/93						
WBC: L	1.5-4 (10 ⁹ /L)	05/10/93	2.00		19.80 <		23.50	
	20-45 (%)	15/11/93						
WBC: E	0-0.4 (10 ⁹ /L)	05/10/93	0.10		0.20 <		0.30 <	
	1-6 (%)	15/11/93						
WBC: M	0.2-0.8 (10 ⁹ /L)	05/10/93	0.40		3.80		5.60	
	2-10 (%)	15/11/93						
WBC: B	0-0.1 (10 ⁹ /L)	05/10/93	0.10		0.40		0.40	
	0-1 (%)	15/11/93						
PLATELETS	150-400 (10 ⁹ /L)	05/10/93	327.00		337.00		258.00	
	132-444 (MMOL/L)	05/10/93	141.00					
NA+	135-150 (MMOL/L)	15/11/93			142.60		140.80	
	3.4-5 (MMOL/L)	05/10/93	4.40		4.87		4.28	
K+	3.6-5 (MMOL/L)	15/11/93						
CL-	98-107 (MMOL/L)	05/10/93	103.00		105.00		108.00	
	95-108 (MMOL/L)	15/11/93						
Ca++	2.1-2.55 (MMOL/L)	05/10/93	2.81 >		2.85 >		2.57	
	2.1-2.6 (MMOL/L)	15/11/93						
PO4--	0.81-1.45 (MMOL/L)	05/10/93	0.98		1.45 >		0.99	
	0.8-1.4 (MMOL/L)	15/11/93						
SGOT	5-40 (IU/L)	05/10/93	4.00 <					
	7-56 (IU/L)	05/10/93	21.00					
SGPT	7-56 (IU/L)	05/10/93	31.00					
GAMMA GT	8-78 (IU/L)	05/10/93			45.00 >		26.00	
	0-40 (IU/L)	15/11/93						
LDH	313-618 (IU/L)	05/10/93	375.00					
	38-126 (IU/L)	05/10/93	88.00		103.00		83.00	
ALK. PHOSPH.	30-135 (IU/L)	15/11/93						
GLUCOSE	4.4-7 (MMOL/L)	05/10/93	6.90		7.80		6.70	
	2.8-8.9 (MMOL/L)	15/11/93						
UREA	2.5-7.5 (MMOL/L)	05/10/93	7.00		6.90		5.00	
	2.5-8.4 (MMOL/L)	15/11/93						
CREATININE	44-106 (UMOL/L)	05/10/93	81.00		90.00		89.00	
	45-120 (UMOL/L)	15/11/93						
URIC ACID	()	05/10/93	5.00 ()		337.00		367.00 >	
	165-350 (UMOL/L)	15/11/93						
TOT BILIRUBIN	3-22 (UMOL/L)	05/10/93	5.00		3.10		3.70	
	3-20 (UMOL/L)	15/11/93						
DIR BILIRUBIN	0-6 (UMOL/L)	05/10/93	3.00					
TOT. PROTEINS	63-82 (G/L)	05/10/93	71.00		71.00		71.00	
	60-80 (G/L)	15/11/93						
ALBUMINE	32-50 (G/L)	05/10/93	40.00		42.00		43.00	
	34-50 (G/L)	15/11/93						
TOT. CHOLEST.	0-5.7 (MMOL/L)	05/10/93	6.20 >		7.20 >		5.89	
	3-6 (MMOL/L)	15/11/93						
TRIGLYCERIDES	0-1.7 (MMOL/L)	05/10/93	4.18 >>		6.48 >>		5.56 >>	
	0.8-2 (MMOL/L)	15/11/93						
GLOBULINS ALPHA 1	1.5-3.8 (G/L)	15/11/93			2.40		1.70	
	3.2-9.7 (G/L)	15/11/93			10.00 >		7.40	
GLOBULINS ALPHA 2	5.2-10 (G/L)	15/11/93			7.10		8.20	
GLOBULINS BETA	5.2-14.5 (G/L)	15/11/93			9.50		10.70	
GLOBULINS GAMMA	0.17-2.9 (MU/L)	05/10/93	1.09					
TSH	10-28 (PMOL/L)	05/10/93	14.20					
T4								

2274

(CONTINUED)

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CN930089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 42 Patient: 1MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			12/10/93		22/11/93		20/12/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date	15.00		25.00		8.00	
ESR/SEDIMENT. RATE 1st h	3-15 (MM) 0-10 (MM)	05/10/93 15/11/93						

2275

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C9584089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 42 Patient: 2ND Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			12/10/93		22/11/93		20/12/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12.5-16.5 (G/DL)	10/10/93	14.00		12.80		13.40	
	11.5-15.5 (G/DL)	15/11/93						
HT	0.37-0.47 (L/L)	10/10/93	0.41		0.37		0.39	
	0.35-0.47 (L/L)	15/11/93						
RBC	3.8-5.8 (10 ¹² /L)	10/10/93	4.46		4.16		4.28	
	3.8-5.4 (10 ¹² /L)	15/11/93						
WBC	4-11 (10 ⁹ /L)	10/10/93	11.00		9.92		9.32	
	3.8-11 (10 ⁹ /L)	15/11/93						
WBC: N	2-7.5 (10 ⁹ /L)	10/10/93	6.00		58.10		60.40	
	40-75 (%)	15/11/93						
WBC: L	1.5-4 (10 ⁹ /L)	10/10/93	3.70		30.80		30.40	
	20-45 (%)	15/11/93						
WBC: E	0-0.4 (10 ⁹ /L)	10/10/93	0.20		1.50		0.50 <	
	1-6 (%)	15/11/93						
WBC: M	0.2-0.8 (10 ⁹ /L)	10/10/93	0.80		8.80		7.60	
	2-10 (%)	15/11/93						
WBC: B	0-0.1 (10 ⁹ /L)	10/10/93	0.30 >>		0.80		1.10 >	
	0-1 (%)	15/11/93						
PLATELETS	150-400 (10 ⁹ /L)	10/10/93	480.00 >		397.00		446.00 >	
	132-144 (MMOL/L)	10/10/93	139.00					
NA+	135-150 (MMOL/L)	15/11/93			146.50		142.40	
K+	3.4-5 (MMOL/L)	10/10/93	3.70		3.78		4.05	
	3.6-5 (MMOL/L)	15/11/93						
CL-	98-107 (MMOL/L)	10/10/93	100.00		110.00 >		103.00	
	95-108 (MMOL/L)	15/11/93						
Ca++	2.1-2.55 (MMOL/L)	10/10/93	2.37		2.33		2.32	
	2.1-2.6 (MMOL/L)	15/11/93						
PO4--	0.81-1.45 (MMOL/L)	10/10/93	1.30		1.39		1.25	
	0.8-1.4 (MMOL/L)	15/11/93						
SGOT	5-40 (IU/L)	10/10/93	39.00		135.00 >>		22.00	
	0-41 (IU/L)	15/11/93			190.00 >>		15.00	
SGPT	0-45 (IU/L)	15/11/93						
GAMMA GT	8-78 (IU/L)	10/10/93	28.00		85.00 >>		39.00	
	0-40 (IU/L)	15/11/93						
LDH	313-618 (IU/L)	10/10/93	517.00					
ALK. PHOSPH.	38-126 (IU/L)	10/10/93	118.00		133.00		114.00	
	30-135 (IU/L)	15/11/93						
GLUCOSE	4.4-7 (MMOL/L)	10/10/93	6.20		7.90		7.70	
	2.8-8.9 (MMOL/L)	15/11/93						
UREA	2.5-7.5 (MMOL/L)	10/10/93	6.90		6.10		5.70	
	2.5-8.4 (MMOL/L)	15/11/93						
CREATININE	44-106 (UMOL/L)	10/10/93	93.00		108.00		101.00	
	45-120 (UMOL/L)	15/11/93			339.00		376.00 >	
URIC ACID	165-350 (UMOL/L)	15/11/93						
TOT BILIRUBIN	3-22 (UMOL/L)	10/10/93	6.00		3.40		5.30	
	3-20 (UMOL/L)	15/11/93						
DIR BILIRUBIN	0-6 (UMOL/L)	10/10/93	3.00					
TOT. PROTEINS	63-82 (G/L)	10/10/93	75.00		71.00		72.00	
	60-80 (G/L)	15/11/93						
ALBUMINE	32-50 (G/L)	10/10/93	39.00		43.00		43.00	
	34-50 (G/L)	15/11/93						
TOT. CHOLEST.	0-5.7 (MMOL/L)	10/10/93	7.80 >>		6.61 >		6.57 >	
	3-6 (MMOL/L)	15/11/93						
TRIGLYCERIDES	0-1.7 (MMOL/L)	10/10/93	1.74 >		1.66		2.31 >	
	0.8-2 (MMOL/L)	15/11/93						
GLOBULINS ALPHA 1	1.5-3.8 (G/L)	15/11/93			2.80		2.80	
	3.2-9.7 (G/L)	15/11/93			6.50		6.60	
GLOBULINS ALPHA 2	5.2-10 (G/L)	15/11/93			8.30		8.50	
GLOBULINS BETA	5.2-14.5 (G/L)	15/11/93			10.40		11.10	
GLOBULINS GAMMA	0.17-2.9 (MU/L)	10/10/93	0.79					
TSH	10-28 (PMOL/L)	10/10/93	15.40					

(CONTINUED)

2276

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 0554089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 42 Patient: 2MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			12/10/93		22/11/93		20/12/93	
			value	(†)	value	(†)	value	(†)
Laboratory test	Range value	Range date						
ESR/SEDIMENT. RATE 1st h	3-15 (MM) 0-10 (MM)	10/10/93 15/11/93	17.00		8.00		7.00	

2277

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value and laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 03550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 42 Patient: 3MD Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			02/11/93		22/12/93		19/01/94	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	13.2-17 (G/DL)	01/07/93	9.90	<<	9.00	<<	9.20	<<
HT	0.4-0.54 (L/L)	01/07/93	0.30	<<	0.26	<<	0.28	<<
RBC	4.2-5.8 (10 ¹² /L)	01/07/93	2.71	<<	2.49	<<	2.51	<<
HBC	3.8-11 (10 ⁹ /L)	01/07/93	7.32		7.17		6.21	
HBC: N	40-75 (%)	01/07/93	60.20		67.00		63.00	
HBC: L	20-45 (%)	01/07/93	26.80		21.40		23.70	
HBC: E	1-6 (%)	01/07/93	4.00		3.10		2.70	
HBC: M	2-10 (%)	01/07/93	7.90		7.80		9.80	
HBC: B	0-1 (%)	01/07/93	1.10	>	0.80		0.80	
PLATELETS	150-400 (10 ⁹ /L)	01/07/93	549.00	>>	619.00	>>	515.00	>
NA+	135-150 (MMOL/L)	01/07/93	142.10		137.80		140.40	
K+	3.6-5 (MMOL/L)	01/07/93	4.95		4.45		4.44	
CL-	95-108 (MMOL/L)	01/07/93	110.00	>	104.00		105.00	
Ca++	2.1-2.6 (MMOL/L)	01/07/93	2.37		2.22		2.30	
PO4--	0.8-1.4 (MMOL/L)	01/07/93	1.16		1.01		1.12	
SGOT	0-41 (IU/L)	01/07/93	25.00		22.00		21.00	
SGPT	0-45 (IU/L)	01/07/93	13.00		17.00		13.00	
GAMMA GT	0-60 (IU/L)	01/07/93	17.00		21.00		20.00	
ALK. PHOSPH.	30-135 (IU/L)	01/07/93	72.00		68.00		73.00	
GLUCOSE	2.8-8.9 (MMOL/L)	01/07/93	5.30		4.90		5.70	
UREA	2.5-8.4 (MMOL/L)	01/07/93	9.10	>	7.00		7.00	
CREATININE	45-120 (UMOL/L)	01/07/93	131.00	>	119.00		120.00	
URIC ACID	180-450 (UMOL/L)	01/07/93	536.00	>	525.00	>	503.00	>
TOT BILIRUBIN	3-20 (UMOL/L)	01/07/93	1.16	<	5.10		5.10	
TOT. PROTEINS	60-80 (G/L)	01/07/93	74.00		67.00		70.00	
ALBUMINE	34-50 (G/L)	01/07/93	47.00		42.00		44.00	
TOT. CHOLEST.	3-6 (MMOL/L)	01/07/93	4.86		4.28		4.58	
TRIGLYCERIDES	0.8-2 (MMOL/L)	01/07/93	1.75		1.42		1.52	
GLOBULINS ALPHA 1	1.5-3.8 (G/L)	01/07/93	3.30		3.20		2.80	
GLOBULINS ALPHA 2	3.2-9.7 (G/L)	01/07/93	5.70		6.40		5.20	
GLOBULINS BETA	5.2-10 (G/L)	01/07/93	8.30		6.70		7.70	
GLOBULINS GAMMA	5.2-14.5 (G/L)	01/07/93	9.70		8.70		10.30	
TSH	0.3-3.5 (MU/L)	01/07/93	1.60					
T4	58-160 (NMOL/L)	01/07/93	67.00					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/07/93	21.00		74.00			

2278

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 9554089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 42 Patient: 10T Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			02/11/93		22/12/93		19/01/94	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	11.5-15.5 (G/DL)	01/07/93	13.30		13.30		13.60	
HT	0.35-0.47 (L/L)	01/07/93	0.39		0.40		0.40	
RBC	3.8-5.4 (10 ¹² /L)	01/07/93	4.65		4.42		4.52	
WBC	3.8-11 (10 ⁹ /L)	01/07/93	6.89		6.79		6.34	
WBC: N	40-75 (%)	01/07/93	62.90		63.50		70.30	
WBC: L	20-45 (%)	01/07/93	26.10		28.00		23.10	
WBC: E	1-6 (%)	01/07/93	0.60	<	0.80	<	0.90	
WBC: M	2-10 (%)	01/07/93	10.20	>	7.30		5.50	
WBC: B	0-1 (%)	01/07/93	0.20		0.40		0.20	
PLATELETS	150-400 (10 ⁹ /L)	01/07/93	243.00		279.00		246.00	
NA+	135-150 (MMOL/L)	01/07/93	143.80		142.00		144.40	
K+	3.6-5 (MMOL/L)	01/07/93	3.80		4.07		5.05	
CL-	95-108 (MMOL/L)	01/07/93	108.00		104.00		106.00	
Ca++	2.1-2.6 (MMOL/L)	01/07/93	2.40		2.24		2.39	
PO4--	0.8-1.4 (MMOL/L)	01/07/93	1.04		1.02		1.27	
SGOT	0-41 (IU/L)	01/07/93	14.00		14.00		13.00	
SGPT	0-45 (IU/L)	01/07/93	10.00		8.00		11.00	
GAMMA GT	0-40 (IU/L)	01/07/93	22.00		22.00		23.00	
ALK. PHOSPH.	30-135 (IU/L)	01/07/93	94.00				94.00	
GLUCOSE	2.8-8.9 (MMOL/L)	01/07/93	4.90		5.50		5.10	
UREA	2.5-8.4 (MMOL/L)	01/07/93	4.50		5.00		5.40	
CREATININE	45-120 (UMOL/L)	01/07/93	135.00	>	139.00	>	141.00	
URIC ACID	165-350 (UMOL/L)	01/07/93	315.00		306.00		374.00	
TOT. BILIRUBIN	3-20 (UMOL/L)	01/07/93	7.20		9.00		5.80	
TOT. PROTEINS	60-80 (G/L)	01/07/93	77.00		67.00		69.00	
ALBUMINE	34-50 (G/L)	01/07/93	45.00		42.00		44.00	
TOT. CHOLEST.	3-6 (MMOL/L)	01/07/93	6.99	>	6.70	>	6.39	
TRIGLYCERIDES	0.8-2 (MMOL/L)	01/07/93	1.70		1.48		2.18	
GLOBULINS ALPHA 1	1.5-3.8 (G/L)	01/07/93	2.90		2.30		2.90	
GLOBULINS ALPHA 2	3.2-9.7 (G/L)	01/07/93	7.70		6.00		6.50	
GLOBULINS BETA	5.2-10 (G/L)	01/07/93	9.00		7.20		7.50	
GLOBULINS GAMMA	5.2-14.5 (G/L)	01/07/93	12.40		9.50		8.10	
TSH	0.3-3.5 (MU/L)	01/07/93	0.50					
T4	58-160 (NMOL/L)	01/07/93	103.00					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/07/93	18.00		15.00		12.00	

2279

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C95 89089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 42 Patient: 2DT Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date
			Screen
			22/11/93
			value (c)
Laboratory test	Range value	Range date	
HB	13.2-17 (G/DL)	01/07/93	13.50
HT	0.4-0.54 (L/L)	01/07/93	0.39 <
RBC	4.2-5.8 (10 ¹² /L)	01/07/93	4.11 <
HBC	3.8-11 (10 ⁹ /L)	01/07/93	6.32
HBC: N	40-75 (%)	01/07/93	68.20
HBC: L	20-45 (%)	01/07/93	23.90
HBC: E	1-6 (%)	01/07/93	0.80 <
HBC: M	2-10 (%)	01/07/93	6.80
HBC: B	0-1 (%)	01/07/93	0.40
PLATELETS	150-400 (10 ⁹ /L)	01/07/93	229.00
NA+	135-150 (MMOL/L)	01/07/93	139.80
K+	3.6-5 (MMOL/L)	01/07/93	4.52
CL-	95-108 (MMOL/L)	01/07/93	103.00
Ca++	2.1-2.6 (MMOL/L)	01/07/93	2.33
PD4--	0.8-1.4 (MMOL/L)	01/07/93	1.41 >
SGOT	0-41 (IU/L)	01/07/93	26.00
SGPT	0-45 (IU/L)	01/07/93	15.00
GAMMA GT	0-60 (IU/L)	01/07/93	25.00
ALK. PHOSPH.	30-135 (IU/L)	01/07/93	74.00
GLUCOSE	2.8-8.9 (MMOL/L)	01/07/93	6.90
UREA	2.5-8.4 (MMOL/L)	01/07/93	6.70
CREATININE	45-120 (UMOL/L)	01/07/93	107.00
URIC ACID	180-450 (UMOL/L)	01/07/93	390.00
TOT BILIRUBIN	3-20 (UMOL/L)	01/07/93	9.80
TOT. PROTEINS	60-80 (G/L)	01/07/93	72.00
ALBUMINE	34-50 (G/L)	01/07/93	45.00
TOT. CHOLEST.	3-6 (MMOL/L)	01/07/93	6.82 >
TRIGLYCERIDES	0.8-2 (MMOL/L)	01/07/93	2.22 >
GLOBULINS ALPHA 1	1.5-3.8 (G/L)	01/07/93	1.90
GLOBULINS ALPHA 2	3.2-9.7 (G/L)	01/07/93	6.20
GLOBULINS BETA	5.2-10 (G/L)	01/07/93	8.40
GLOBULINS GAMMA	5.2-14.5 (G/L)	01/07/93	10.50
TSH	0.3-3.5 (MU/L)	01/07/93	1.10
T4	58-160 (NMOL/L)	01/07/93	97.00
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/07/93	5.00

2280

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARNACIA CMS 50089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 43 Patient: SMD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	Day 28
			10/12/93	10/01/94
			value (€)	value (€)
Laboratory test	Range value	Range date		
HB	11.5-16.5 (G/DL)	01/01/92	15.10	13.90
HT	0.35-0.47 (L/L)	01/01/92	0.47	0.41
RBC	3.9-5.6 (10 ¹² /L)	01/01/92	4.92	4.37
MBC	3.5-12 (10 ⁹ /L)	01/01/92	4.95	4.60
MBC: N	2.5-8 (10 ⁹ /L)	01/01/92	3.64	3.14
MBC: L	1.2-4 (10 ⁹ /L)	01/01/92	1.08 <	1.15 <
MBC: E	0-0.5 (10 ⁹ /L)	01/01/92	0.00	0.00
MBC: M	0.1-1.1 (10 ⁹ /L)	01/01/92	0.21	0.30
MBC: B	0-0.1 (10 ⁹ /L)	01/01/92	0.02	0.01
PLATELETS	150-400 (10 ⁹ /L)	01/01/92	195.00	178.00
NA+	134-144 (MMOL/L)	01/01/92	140.00	133.00 <
K+	3.4-4.7 (MMOL/L)	01/01/92	4.10	4.00
CL-	95-107 (MMOL/L)	01/01/92	104.00	99.00
Ca++	2.05-2.55 (MMOL/L)	01/01/92	2.22	2.07
PO4--	0.6-1.6 (MMOL/L)	01/01/92	0.83	0.91
SGOT	8-39 (U/L)	01/01/92	14.00	17.00
GAMMA GT	15-51 (U/L)	01/01/92	23.00	25.00
LDH	116-224 (U/L)	01/01/92	107.00 <	109.00 <
ALK. PHOSPH.	36-104 (U/L)	01/01/92	45.00	40.00
GLUCOSE	3.8-6.6 (MMOL/L)	01/01/92	9.30 >>	5.00
UREA	2.4-8.4 (MMOL/L)	01/01/92	7.90	9.30 >
CREATININE	0.035-0.13 (MMOL/L)	01/01/92	0.08	0.06
CREATININE CLEARANCE	()	01/01/92	73.53 ()	
URIC ACID	0.19-0.45 (MMOL/L)	01/01/92	0.22	0.15 <
TOT BILIRUBIN	3-19 (UMOL/L)	01/01/92	14.00	10.00
DIR BILIRUBIN	1-5 (UMOL/L)	01/01/92	4.00	4.00
TOT. PROTEINS	61-79 (G/L)	01/01/92	66.00	62.00
ALBUMINE	38-52 (G/L)	01/01/92	40.00	38.00
TOT. CHOLEST.	4.1-8.5 (MMOL/L)	01/01/92	4.60	4.90
TRIGLYCERIDES	0.1-2.1 (MMOL/L)	01/01/92	1.80	1.60
T4	74-134 (NMOL/L)	01/01/92	83.00	

2281

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 0959089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 43 Patient: 6ND Treatment: Imipramine Sex: Female

			Visit number / Laboratory date							
			Screen		Day 28		Day 56		Day 21	
			14/02/94		18/03/94		15/04/94		08/03/94	
			value	(€)	value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date								
HB	11.5-16.5 (G/DL)	01/01/92	14.10		13.70		13.10			
HT	0.35-0.47 (L/L)	01/01/92	0.42		0.42		0.40			
RBC	3.9-5.6 (10 ¹² /L)	01/01/92	4.74		4.60		4.39			
WBC	3.5-12 (10 ⁹ /L)	01/01/92	8.02		6.30		6.42			
WBC: N	2.5-8 (10 ⁹ /L)	01/01/92	5.41		4.00		4.00			
WBC: L	1.2-4 (10 ⁹ /L)	01/01/92	2.14		1.80		2.06			
WBC: E	0-0.5 (10 ⁹ /L)	01/01/92	0.00		0.10		0.03			
WBC: M	0.1-1.1 (10 ⁹ /L)	01/01/92	0.43		0.37		0.31			
WBC: B	0-0.1 (10 ⁹ /L)	01/01/92	0.01		0.02		0.02			
PLATELETS	150-400 (10 ⁹ /L)	01/01/92	249.00		241.00		232.00			
NA+	134-144 (MMOL/L)	01/01/92	135.00				138.00		134.00	
K+	3.4-4.7 (MMOL/L)	01/01/92	3.30 <				3.60		3.90	
CL-	95-107 (MMOL/L)	01/01/92	100.00				97.00		97.00	
Ca++	2.05-2.55 (MMOL/L)	01/01/92	2.39		2.35		2.20			
PO4--	0.6-1.6 (MMOL/L)	01/01/92	1.02		1.20		1.11			
SGOT	8-39 (U/L)	01/01/92	14.00				20.00		13.00	
GAMMA GT	15-51 (U/L)	01/01/92	28.00		26.00		24.00			
LDH	116-224 (U/L)	01/01/92	122.00				115.00 <			
ALK. PROSPH.	36-104 (U/L)	01/01/92	66.00		77.00		68.00			
GLUCOSE	3.8-6.6 (MMOL/L)	01/01/92	9.30 >>				5.50		8.10 >	
UREA	2.4-8.4 (MMOL/L)	01/01/92	6.20				6.20		5.50	
CREATININE	0.035-0.13 (MMOL/L)	01/01/92					0.09		0.07	
CREATININE CLEARANCE	()	01/01/92	83.70 ()							
URIC ACID	0.19-0.45 (MMOL/L)	01/01/92	0.38		0.32		0.39			
TOT BILIRUBIN	3-19 (UMOL/L)	01/01/92	6.00				4.00		6.00	
DIR BILIRUBIN	1-5 (UMOL/L)	01/01/92	2.00				2.00		3.00	
TOT. PROTEINS	61-79 (G/L)	01/01/92	72.00				71.00		73.00	
ALBUMINE	38-52 (G/L)	01/01/92	38.00		40.00		39.00			
TOT. CHOLEST.	4.1-8.5 (MMOL/L)	01/01/92	4.90		5.80					
TRIGLYCERIDES	0.1-2.1 (MMOL/L)	01/01/92	1.00		1.40					
T4	74-134 (NMOL/L)	01/01/92	139.00							

2282

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C8590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 43 Patient: 1DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 28	
			19/02/93		19/03/93	
			value	(φ)	value	(φ)
Laboratory test	Range value	Range date				
HB	11.5-16.5 (G/DL)	01/01/92	13.40		13.70	
HT	0.35-0.47 (L/L)	01/01/92	0.43		0.43	
RBC	3.9-5.6 (10 ¹² /L)	01/01/92	4.26		4.38	
WBC	3.5-12 (10 ⁹ /L)	01/01/92	7.42		6.82	
WBC: N	2.5-8 (10 ⁹ /L)	01/01/92	6.04		4.18	
WBC: L	1.2-4 (10 ⁹ /L)	01/01/92	1.06 <		2.13	
WBC: E	0-0.5 (10 ⁹ /L)	01/01/92	0.04		0.11	
WBC: M	0.1-1.1 (10 ⁹ /L)	01/01/92	0.23		0.35	
WBC: B	0-0.1 (10 ⁹ /L)	01/01/92	0.04		0.04	
PLATELETS	150-400 (10 ⁹ /L)	01/01/92	274.00		338.00	
NA+	134-144 (MMOL/L)	01/01/92	136.00		134.00	
K+	3.4-4.7 (MMOL/L)	01/01/92	4.20		3.60	
CL-	95-107 (MMOL/L)	01/01/92	102.00		98.00	
Ca++	2.05-2.55 (MMOL/L)	01/01/92	2.47		2.42	
PO4--	0.6-1.6 (MMOL/L)	01/01/92	0.98		1.33	
SGOT	8-39 (U/L)	01/01/92	23.00		20.00	
GAMMA GT	15-51 (U/L)	01/01/92	41.00		66.00 >	
LDH	116-224 (U/L)	01/01/92	309.00 >		250.00 >	
ALK. PHOSPH.	36-104 (U/L)	01/01/92	89.00		136.00 >	
GLUCOSE	3.8-6.6 (MMOL/L)	01/01/92	11.60 >>		5.40	
UREA	2.4-8.4 (MMOL/L)	01/01/92	5.30		8.90 >	
CREATININE	0.035-0.13 (MMOL/L)	01/01/92	0.07		0.09	
CREATININE	()	01/01/92				
CLEARANCE			82.66 ()			
URIC ACID	0.19-0.45 (MMOL/L)	01/01/92	0.27			
TOT BILIRUBIN	3-19 (UMOL/L)	01/01/92	8.00		9.00	
DIR BILIRUBIN	1-5 (UMOL/L)	01/01/92	3.00		4.00	
TOT. PROTEINS	61-79 (G/L)	01/01/92	72.00		65.00	
ALBUMINE	38-52 (G/L)	01/01/92	41.00		40.00	
TOT. CHOLEST.	4.1-8.5 (MMOL/L)	01/01/92	5.30		5.40	
TRIGLYCERIDES	0.1-2.1 (MMOL/L)	01/01/92	1.30		2.10	
TSH	0.5-6.5 (MIU/L)	01/01/92	0.80			
T4	74-134 (NMOL/L)	01/01/92	158.00			

2283

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA 0953089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 43 Patient: 2DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 21	
			10/05/93		02/06/93	
			value	(±)	value	(±)
Laboratory test	Range value	Range date				
HB	11.5-16.5 (G/DL)	01/01/92	14.00		13.90	
HT	0.35-0.47 (L/L)	01/01/92	0.40		0.41	
RBC	3.9-5.6 (10 ¹² /L)	01/01/92	4.31		4.45	
WBC	3.5-12 (10 ⁹ /L)	01/01/92	9.91		7.47	
WBC: N	2.5-8 (10 ⁹ /L)	01/01/92	7.97		4.90	
WBC: L	1.2-4 (10 ⁹ /L)	01/01/92	1.46		2.08	
WBC: E	0-0.5 (10 ⁹ /L)	01/01/92	0.06		0.04	
WBC: M	0.1-1.1 (10 ⁹ /L)	01/01/92	0.35		0.39	
WBC: B	0-0.1 (10 ⁹ /L)	01/01/92	0.08		0.06	
PLATELETS	150-400 (10 ⁹ /L)	01/01/92	366.00		432.00 >	
NA+	134-144 (MMOL/L)	01/01/92	133.00 <		136.00	
K+	3.4-4.7 (MMOL/L)	01/01/92	4.60		4.70	
CL-	95-107 (MMOL/L)	01/01/92	97.00		99.00	
Ca++	2.05-2.55 (MMOL/L)	01/01/92	2.33		2.43	
PO4--	0.6-1.6 (MMOL/L)	01/01/92	1.09		0.74	
SCOT	8-39 (U/L)	01/01/92	26.00		23.00	
GAMMA GT	15-51 (U/L)	01/01/92	48.00		45.00	
LDH	116-224 (U/L)	01/01/92	235.00 >		232.00 >	
ALK. PHOSPH.	36-104 (U/L)	01/01/92	69.00		71.00	
GLUCOSE	3.8-6.6 (MMOL/L)	01/01/92	10.80 >>		5.90	
UREA	2.4-8.4 (MMOL/L)	01/01/92	4.60		3.40	
CREATININE	0.035-0.13 (MMOL/L)	01/01/92	0.09		0.07	
CREATININE CLEARANCE	()	01/01/92	63.01 ()			
URIC ACID	0.19-0.45 (MMOL/L)	01/01/92	0.34		0.30	
TOT BILIRUBIN	3-19 (UMOL/L)	01/01/92	12.00		13.00	
DIR BILIRUBIN	1-5 (UMOL/L)	01/01/92	3.00		5.00	
TOT. PROTEINS	61-79 (G/L)	01/01/92	78.00		79.00	
ALBUMINE	38-52 (G/L)	01/01/92	41.00		42.00	
TOT. CHOLEST.	4.1-8.5 (MMOL/L)	01/01/92	5.80		6.10	
TRIGLYCERIDES	0.1-2.1 (MMOL/L)	01/01/92	1.30		1.10	
TSH	0.5-6.5 (MIU/L)	01/01/92	0.62			
T4	74-134 (NMOL/L)	01/01/92	129.00			

2284

(±) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA 09530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 43 Patient: 3DT Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			15/09/93		13/10/93		10/11/93	
			value	(*)	value	(*)	value	(*)
Laboratory test	Range value	Range date						
HB	13.5-17.5 (G/DL)	01/01/92	15.20		13.50		13.40 <	
HT	0.4-0.54 (L/L)	01/01/92	0.47		0.41		0.41	
RBC	4.5-6.5 (10 ¹² /L)	01/01/92	4.93		4.33 <		4.34 <	
HBC	3.5-10 (10 ⁹ /L)	01/01/92	6.68		6.24		5.83	
HBC: N	1.5-6.5 (10 ⁹ /L)	01/01/92	4.79		4.27		3.65	
HBC: L	1.2-4 (10 ⁹ /L)	01/01/92	1.46		1.46		1.67	
HBC: E	0-0.5 (10 ⁹ /L)	01/01/92	0.05		0.12		0.17	
HBC: M	0.1-1.1 (10 ⁹ /L)	01/01/92	0.33		0.35		0.30	
HBC: B	0-0.1 (10 ⁹ /L)	01/01/92	0.05		0.04		0.04	
PLATELETS	150-400 (10 ⁹ /L)	01/01/92	194.00		186.00		185.00	
NA+	134-144 (MMOL/L)	01/01/92	139.00		138.00		135.00	
K+	3.4-4.7 (MMOL/L)	01/01/92	4.80 >		4.60		4.10	
CL-	95-107 (MMOL/L)	01/01/92	102.00		101.00		102.00	
Ca ⁺⁺	2.05-2.55 (MMOL/L)	01/01/92	2.32		2.28		2.24	
PO4 ⁻⁻	0.6-1.6 (MMOL/L)	01/01/92	1.42		1.33		1.41	
SGOT	8-39 (U/L)	01/01/92	23.00		26.00		21.00	
GAMMA GT	15-51 (U/L)	01/01/92	34.00		35.00		35.00	
LDH	116-224 (U/L)	01/01/92	149.00		178.00		168.00	
ALK. PHOSPH.	36-104 (U/L)	01/01/92	59.00		60.00		64.00	
GLUCOSE	3.8-6.6 (MMOL/L)	01/01/92	5.30		4.80		6.50	
UREA	2.4-8.4 (MMOL/L)	01/01/92	5.40		6.90		6.40	
CREATININE	0.035-0.13 (MMOL/L)	01/01/92						
CREATININE CLEARANCE	(l)	01/01/92	105.44 (*)					
URIC ACID	0.19-0.45 (MMOL/L)	01/01/92	0.43		0.38		0.41	
TOT BILIRUBIN	3-19 (UMOL/L)	01/01/92	17.00		13.00		12.00	
DIR BILIRUBIN	1-5 (UMOL/L)	01/01/92	4.00		3.00		3.00	
TOT. PROTEINS	61-79 (G/L)	01/01/92	76.00		73.00		75.00	
ALBUMINE	38-52 (G/L)	01/01/92	45.00		43.00		44.00	
TOT. CHOLEST.	4.1-8.5 (MMOL/L)	01/01/92	5.20		5.60		5.30	
TRIGLYCERIDES	0.1-2.1 (MMOL/L)	01/01/92	1.80		3.90 >>		4.30 >>	
TSH	0.5-6.5 (MIU/L)	01/01/92	0.50					
T4	74-134 (NMOL/L)	01/01/92	94.00					

2285

(*) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done (l) missing range value

PHARMACIA 0530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 43 Patient: 4DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date
			Screen
			23/09/93
			value (⊕)
Laboratory test	Range value	Range date	
HB	11.5-16.5 (G/DL)	01/01/92	13.80
HT	0.35-0.47 (L/L)	01/01/92	0.45
RBC	3.9-5.6 (10 ¹² /L)	01/01/92	5.00
WBC	3.5-12 (10 ⁹ /L)	01/01/92	8.93
WBC: N	2.5-8 (10 ⁹ /L)	01/01/92	6.85
WBC: L	1.2-4 (10 ⁹ /L)	01/01/92	1.50
WBC: E	0-0.5 (10 ⁹ /L)	01/01/92	0.06
WBC: M	0.1-1.1 (10 ⁹ /L)	01/01/92	0.46
WBC: B	0-0.1 (10 ⁹ /L)	01/01/92	0.06
PLATELETS	150-400 (10 ⁹ /L)	01/01/92	232.00
NA+	134-144 (MMOL/L)	01/01/92	140.00
K+	3.4-4.7 (MMOL/L)	01/01/92	4.50
CL-	95-107 (MMOL/L)	01/01/92	101.00
Ca++	2.05-2.55 (MMOL/L)	01/01/92	2.40
PO4--	0.6-1.6 (MMOL/L)	01/01/92	1.15
SGOT	8-39 (U/L)	01/01/92	22.00
GAMMA GT	15-51 (U/L)	01/01/92	44.00
LDH	116-224 (U/L)	01/01/92	191.00
ALK. PHOSPH.	36-104 (U/L)	01/01/92	72.00
GLUCOSE	3.8-6.6 (MMOL/L)	01/01/92	5.80
UREA	2.4-8.4 (MMOL/L)	01/01/92	4.00
CREATININE	0.035-0.13 (MMOL/L)	01/01/92	0.07
CREATININE CLEARANCE	()	01/01/92	105.19 ()
URIC ACID	0.19-0.45 (MMOL/L)	01/01/92	0.37
TOT BILIRUBIN	3-19 (UMOL/L)	01/01/92	21.00 >
DIR BILIRUBIN	1-5 (UMOL/L)	01/01/92	3.00
TOT. PROTEINS	61-79 (G/L)	01/01/92	70.00
ALBUMINE	38-52 (G/L)	01/01/92	40.00
TOT. CHOLEST.	4.1-8.5 (MMOL/L)	01/01/92	6.10
TRIGLYCERIDES	0.1-2.1 (MMOL/L)	01/01/92	1.60
TSH	0.5-6.5 (MIU/L)	01/01/92	1.18
T4	74-134 (NMOL/L)	01/01/92	104.00

2286

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA 953089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 44 Patient: 1ND Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			02/09/93		30/09/93		28/10/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	11.5-16.5 (G/DL)	01/01/92	12.40		13.10		12.70	
HT	0.35-0.47 (L/L)	01/01/92	0.35		0.37		0.37	
RBC	3.9-5.6 (10 ¹² /L)	01/01/92	4.23		4.37		4.27	
WBC	4-11 (10 ⁹ /L)	01/01/92	8.00		8.20		8.00	
WBC: N	57-67 (%)	01/01/92	71.20 >		66.00		67.90 >	
WBC: L	23-33 (%)	01/01/92	23.50		30.00		28.10	
WBC: E	1-3 (%)	01/01/92	0.90 <				1.10	
WBC: M	3-7 (%)	01/01/92	4.10		4.00		2.60 <	
WBC: B	0-0.75 (%)	01/01/92	0.30				0.30	
PLATELETS	135-400 (10 ⁹ /L)	01/01/92	191.00		233.00		216.00	
NA+	136-148 (MMOL/L)	01/01/92	139.00		140.00		139.00	
K+	3.6-5.2 (MMOL/L)	01/01/92	4.30		4.30		4.40	
Ca++	2.1-2.6 (MMOL/L)	01/01/92	2.34		2.30		2.33	
PO4--	0.83-1.49 (MMOL/L)	01/01/92	0.86		1.09		1.04	
SGOT	0-50 (U/L)	01/01/92	23.00		22.00		17.00	
GAMMA GT	0-30 (U/L)	01/01/92	27.00		23.00		24.00	
ALK. PHOSPH.	90-300 (U/L)	01/01/92	85.00 <		94.00		115.00	
GLUCOSE	3-5.5 (MMOL/L)	01/01/92	6.70 >		7.50 >>		4.40	
UREA	2.3-6.9 (MMOL/L)	01/01/92	4.40		5.20		5.10	
CREATININE	60-100 (UMOL/L)	01/01/92	97.00		96.00		109.00 >	
TOT. BILIRUBIN	2-18 (UMOL/L)	01/01/92	5.00		4.00		2.00	
TOT. PROTEINS	62-82 (G/L)	01/01/92	69.00		71.00		73.00	
ALBUMINE	36-52 (G/L)	01/01/92	42.00		40.00		40.00	
TOT. CHOLEST.	0-6.2 (MMOL/L)	01/01/92	5.90		4.60		5.40	
TRIGLYCERIDES	0-2.43 (MMOL/L)	01/01/92	2.60 >		2.40 >		3.10 >>	
TSH	0.3-4 (U/ML)	01/01/92	3.00					
T4	8.5-19 (PMOL/L)	01/01/92	10.70					
ESR/SEDIMENT. RATE 1st h	3-15 (MM)	01/01/92	10.00		4.00			

2287

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 9550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 44 . Patient: 2MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			17/09/93		18/10/93		15/11/93	
			value	(*)	value	(*)	value	(*)
Laboratory test	Range value	Range date						
HB	11.5-16.5 (G/DL)	01/01/92	14.60		14.60		14.70	
HT	0.35-0.47 (L/L)	01/01/92	0.42		0.42		0.43	
RBC	3.9-5.6 (10 ¹² /L)	01/01/92	4.64		4.60		4.66	
HBC	4-11 (10 ⁹ /L)	01/01/92	7.30		7.50		6.40	
HBC: N	57-67 (%)	01/01/92	72.00	>	74.90	>	66.80	
HBC: L	23-33 (%)	01/01/92	22.60	<	19.00	<	25.90	
HBC: E	1-3 (%)	01/01/92	1.80		0.90	<		
HBC: M	3-7 (%)	01/01/92	3.20		5.10		5.20	
HBC: B	0-0.75 (%)	01/01/92	0.80	>	0.10			
PLATELETS	135-400 (10 ⁹ /L)	01/01/92	298.00		316.00		290.00	
NA+	136-148 (MMOL/L)	01/01/92	141.00		142.00		143.00	
K+	3.6-5.2 (MMOL/L)	01/01/92	4.10		4.10		4.60	
Ca++	2.1-2.6 (MMOL/L)	01/01/92	2.37		2.40		2.52	
PO4--	0.83-1.49 (MMOL/L)	01/01/92	1.01		1.02		0.94	
SGOT	0-50 (U/L)	01/01/92	15.00		19.00		45.00	
GAMMA GT	0-30 (U/L)	01/01/92	15.00		14.00		69.00 >>	
ALK. PHOSPH.	90-300 (U/L)	01/01/92	160.00		188.00		224.00	
GLUCOSE	3-5.5 (MMOL/L)	01/01/92	5.80	>			4.70	
UREA	2.3-6.9 (MMOL/L)	01/01/92	4.20				4.80	
CREATININE	60-100 (UMOL/L)	01/01/92	113.00	>	94.00		96.00	
TOT. BILIRUBIN	2-18 (UMOL/L)	01/01/92	8.00		18.00		4.00	
TOT. PROTEINS	62-82 (G/L)	01/01/92	62.00		72.00		72.00	
ALBUMINE	36-52 (G/L)	01/01/92	44.00		42.00		44.00	
TOT. CHOLEST.	0-6.2 (MMOL/L)	01/01/92	8.70	>>	7.10	>	7.40 >	
TRIGLYCERIDES	0-2.13 (MMOL/L)	01/01/92	2.00				2.50 >	
TSH	0.3-4 (U/ML)	01/01/92	0.50					
T4	8.5-19 (PMOL/L)	01/01/92	16.10					
ESR/SEDIMENT. RATE 1st h	3-15 (MM)	01/01/92	4.00		10.00		5.00	

2288

(*) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done (*) missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 0550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 44 Patient: 3MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			12/10/93		11/11/93		09/12/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	11.5-16.5 (G/DL)	01/01/92	14.60		13.80		14.80	
HT	0.35-0.47 (L/L)	01/01/92	0.42		0.40		0.42	
RBC	3.9-5.6 (10 ¹² /L)	01/01/92	4.30		4.12		4.41	
WBC	4-11 (10 ⁹ /L)	01/01/92	7.50		6.10		6.40	
WBC: N	57-67 (%)	01/01/92	72.20 >		63.40		66.70	
WBC: L	23-33 (%)	01/01/92	24.30		32.30		29.80	
WBC: E	1-3 (%)	01/01/92	1.30		0.80 <		1.70	
WBC: M	3-7 (%)	01/01/92	1.70 <		2.80 <		0.90 <	
WBC: B	0-0.75 (%)	01/01/92	0.50		0.70		0.90 >	
PLATELETS	135-400 (10 ⁹ /L)	01/01/92	306.00		284.00		268.00	
NA+	136-148 (MMOL/L)	01/01/92	139.00		139.00		145.00	
K+	3.6-5.2 (MMOL/L)	01/01/92	4.50		4.10		4.30	
Ca++	2.1-2.6 (MMOL/L)	01/01/92	2.39		2.42		2.45	
PO4--	0.83-1.49 (MMOL/L)	01/01/92	1.29		1.19		1.38	
SGOT	0-50 (U/L)	01/01/92	20.00		17.00		27.00	
GAMMA GT	0-30 (U/L)	01/01/92	28.00		16.00		18.00	
ALK. PHOSPH.	90-300 (U/L)	01/01/92	148.00		154.00		170.00	
GLUCOSE	3-5.5 (MMOL/L)	01/01/92	5.30		4.60		7.10 >	
UREA	2.3-6.9 (MMOL/L)	01/01/92	4.40		4.20		5.20	
CREATININE	60-100 (UMOL/L)	01/01/92	70.00		84.00		95.00	
TOT. BILIRUBIN	2-18 (UMOL/L)	01/01/92	4.00		2.00		3.00	
TOT. PROTEINS	62-82 (G/L)	01/01/92	73.00		68.00		71.00	
ALBUMINE	36-52 (G/L)	01/01/92	44.00		45.00		46.00	
TOT. CHOLEST.	0-6.2 (MMOL/L)	01/01/92	9.30 >>		6.50 >		7.50 >	
TRIGLYCERIDES	0-2.13 (MMOL/L)	01/01/92	2.70 >		2.30 >		3.30 >>	
ESR/SEDIMENT. RATE 1st h	3-15 (MM)	01/01/92	13.00		4.00		5.00	

2289

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 059089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 44 Patient: 4ND Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			26/01/94		28/02/94		28/03/94	
			value	(#)	value	(#)	value	(#)
Laboratory test	Range value	Range date						
HB	13.5-18 (G/DL)	01/01/92	12.60	<	12.70	<	11.80	<<
HT	0.4-0.54 (L/L)	01/01/92	0.36	<	0.37	<	0.34	<<
RBC	4.5-6.5 (10 ¹² /L)	01/01/92	3.88	<	4.18	<	3.90	<
WBC	4-11 (10 ⁹ /L)	01/01/92	4.20		7.10		4.60	
WBC: N	57-67 (%)	01/01/92	74.00	>	82.50	>	84.80	>
WBC: L	23-33 (%)	01/01/92	19.70	<	11.80	<<	10.80	<<
WBC: E	1-3 (%)	01/01/92	0.50	<	0.60	<	0.40	<
WBC: M	3-7 (%)	01/01/92	5.30		4.80		3.30	
WBC: B	0-0.75 (%)	01/01/92	0.50		0.30		0.70	
PLATELETS	135-400 (10 ⁹ /L)	01/01/92	172.00		213.00		170.00	
NA+	136-148 (MMOL/L)	01/01/92	145.00		137.00		133.00	<
K+	3.6-5.2 (MMOL/L)	01/01/92	4.30		4.30		4.20	
Ca++	2.1-2.6 (MMOL/L)	01/01/92	2.38		2.37		2.20	
PO4--	0.9-1.38 (MMOL/L)	01/01/92	1.08		0.91		1.34	
SGOT	0-50 (U/L)	01/01/92	32.00		45.00		36.00	
GAMMA GT	0-40 (U/L)	01/01/92	12.00		13.00		14.00	
ALK. PHOSPH.	90-300 (U/L)	01/01/92	98.00		143.00		115.00	
GLUCOSE	3-5.5 (MMOL/L)	01/01/92	3.60		5.60	>	5.40	
UREA	2.3-6.9 (MMOL/L)	01/01/92	5.40		3.60		5.40	
CREATININE	76-120 (UMOL/L)	01/01/92	105.00		97.00		106.00	
TOT BILIRUBIN	2-18 (UMOL/L)	01/01/92	5.00		8.00		5.00	
TOT. PROTEINS	62-82 (G/L)	01/01/92	62.00		67.00		63.00	
ALBUMINE	36-52 (G/L)	01/01/92	38.00		41.00		37.00	
TOT. CHOLEST.	0-6.2 (MMOL/L)	01/01/92	5.40		5.00		5.70	
TRIGLYCERIDES	0-2.13 (MMOL/L)	01/01/92	1.30		0.80		0.90	
TSH	0.3-4 (U/ML)	01/01/92	1.00					
T4	8.5-19 (PMOL/L)	01/01/92	13.20					
ESR/SEDIMENT. RATE 1st h	1-10 (MM)	01/01/92	10.00		30.00		31.00	

2290

(#) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARNACIA 9550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 44 Patient: 1DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			30/07/93		31/08/93		06/10/93	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	11.5-16.5 (G/DL)	01/01/92	13.70		15.00		13.90	
HT	0.35-0.47 (L/L)	01/01/92	0.41		0.44		0.41	
RBC	3.9-5.6 (10 ¹² /L)	01/01/92	5.08		5.41		5.06	
WBC	4-11 (10 ⁹ /L)	01/01/92	6.70		8.00		7.90	
WBC: N	57-67 (%)	01/01/92	62.10		60.70			
WBC: L	23-33 (%)	01/01/92	32.00		35.40 >			
WBC: E	1-3 (%)	01/01/92			1.10			
WBC: M	3-7 (%)	01/01/92	4.20		1.90 <			
WBC: B	0-0.75 (%)	01/01/92			0.90 >			
PLATELETS	135-400 (10 ⁹ /L)	01/01/92	277.00		320.00		304.00	
NA+	136-148 (MMOL/L)	01/01/92	141.00		141.00		137.00	
K+	3.6-5.2 (MMOL/L)	01/01/92	4.20		4.50		4.60	
Ca++	2.1-2.6 (MMOL/L)	01/01/92	2.30		2.38		2.22	
PO4--	0.83-1.49 (MMOL/L)	01/01/92	1.05		1.16		1.12	
SGOT	0-50 (U/L)	01/01/92	25.00		25.00		26.00	
GAMMA GT	0-30 (U/L)	01/01/92	14.00		18.00		14.00	
ALK. PHOSPH.	90-300 (U/L)	01/01/92	168.00		208.00		194.00	
GLUCOSE	3-5.5 (MMOL/L)	01/01/92	4.20		5.20		4.00	
UREA	2.3-6.9 (MMOL/L)	01/01/92			5.90		6.80	
CREATININE	60-100 (UMOL/L)	01/01/92	89.00		93.00		85.00	
TOT. BILIRUBIN	2-18 (UMOL/L)	01/01/92	9.00		9.00		17.00	
TOT. PROTEINS	62-82 (G/L)	01/01/92	68.00		69.00		64.00	
ALBUMINE	36-52 (G/L)	01/01/92	43.00		45.00		40.00	
TOT. CHOLEST.	0-6.2 (MMOL/L)	01/01/92	7.10 >		7.80 >		7.70 >	
TRIGLYCERIDES	0-2.13 (MMOL/L)	01/01/92	2.20 >		1.20		1.60	
TSH	0.3-4 (UU/ML)	01/01/92	0.30					
T4	8.5-19 (PMOL/L)	01/01/92	15.90					
ESR/SEDIMENT. RATE 1st h	3-15 (MM)	01/01/92	6.00				4.00	

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

2291

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA 9850089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 45 Patient: 1MD Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			11/11/93		24/12/93		20/01/94	
			value	(†)	value	(†)	value	(†)
Laboratory test	Range value	Range date						
HB	13-17 (G/DL)	01/01/92	13.80		14.10		14.70	
HT	0.4-0.51 (L/L)	01/01/92	0.41		0.44		0.46	
RBC	4.4-5.5 (10 ¹² /L)	01/01/92	4.66		4.79		4.98	
WBC	3.7-10 (10 ⁹ /L)	01/01/92	3.00 <		6.30		5.90	
WBC: N	2-7 (10 ⁹ /L)	01/01/92	1.80 <		3.90		3.30	
WBC: L	1-3 (10 ⁹ /L)	01/01/92	1.10		1.90		1.90	
WBC: E	0-0.7 (10 ⁹ /L)	01/01/92	0.20					
WBC: M	0.2-1 (10 ⁹ /L)	01/01/92	0.00 <					
WBC: B	0-0.2 (10 ⁹ /L)	01/01/92	0.00					
PLATELETS	130-400 (10 ⁹ /L)	01/01/92	132.00		209.00		205.00	
NA+	136-149 (MMOL/L)	01/01/92	140.00		139.00		142.00	
K+	3.8-5.5 (MMOL/L)	01/01/92	4.40		5.30		4.90	
Ca ⁺⁺	2.15-2.65 (MMOL/L)	01/01/92	2.28		2.37		2.33	
PO4 ⁻⁻	0.8-1.4 (MMOL/L)	01/01/92	0.92		1.15		1.12	
SGOT	5-35 (IU/L)	01/01/92	51.00 >		14.00			
SGPT	10-40 (IU/L)	01/01/92	50.00 >		17.00			
GAMMA GT	0-50 (IU/L)	01/01/92					21.00	
LDH	10-500 (IU/L)	01/01/92			259.00			
ALK. PHOSPH.	30-130 (IU/L)	01/01/92	50.00		53.00		57.00	
GLUCOSE	3.5-5.5 (MMOL/L)	01/01/92	5.30		6.60 >		5.40	
UREA	2.5-6.5 (MMOL/L)	01/01/92	3.50					
CREATININE	55-125 (UMOL/L)	01/01/92	102.00		108.00		103.00	
URIC ACID	0.1-0.4 (MMOL/L)	01/01/92	0.32		0.43 >		0.44 >	
TOT BILIRUBIN	2-17 (UMOL/L)	01/01/92	14.00		12.00		9.00	
TOT. PROTEINS	65-80 (G/L)	01/01/92	71.00		71.00		71.00	
ALBUMINE	33-55 (G/L)	01/01/92	39.00		43.00		40.00	
TOT. CHOLEST.	4-6.5 (MMOL/L)	01/01/92	3.80 <				4.20	
TRIGLYCERIDES	0-2 (MMOL/L)	01/01/92	1.31				1.42	
TSH	0.4-3.8 (MU/L)	01/01/92	0.70					
T4	50-150 (NMOL/L)	01/01/92	100.00					

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA ~~NS-0089~~

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 45 Patient: 2MD Treatment: Imipramine Sex: Male

			Visit number / Laboratory date
			Screen
			24/11/93
			value (†)
Laboratory test	Range value	Range date	
HB	13-17 (G/DL)	01/01/92	11.60 <
HT	0.4-0.51 (L/L)	01/01/92	0.37 <
RBC	4.4-5.5 (10 ¹² /L)	01/01/92	3.61 <<
WBC	3.7-10 (10 ⁹ /L)	01/01/92	4.90
WBC: N	2-7 (10 ⁹ /L)	01/01/92	3.10
WBC: L	1-3 (10 ⁹ /L)	01/01/92	1.10
WBC: E	0-0.7 (10 ⁹ /L)	01/01/92	0.20
WBC: M	0.2-1 (10 ⁹ /L)	01/01/92	0.20
WBC: B	0-0.2 (10 ⁹ /L)	01/01/92	0.20
PLATELETS	130-400 (10 ⁹ /L)	01/01/92	310.00
NA+	136-149 (MMOL/L)	01/01/92	136.00
K+	3.8-5.5 (MMOL/L)	01/01/92	5.20
Ca++	2.15-2.65 (MMOL/L)	01/01/92	2.26
PO4--	0.8-1.4 (MMOL/L)	01/01/92	1.30
SGOT	5-35 (IU/L)	01/01/92	59.00 >
GAMMA GT	0-50 (IU/L)	01/01/92	19.00
ALK. PHOSPH.	30-130 (IU/L)	01/01/92	76.00
UREA	2.5-6.5 (MMOL/L)	01/01/92	6.20
CREATININE	55-125 (UMOL/L)	01/01/92	115.00
URIC ACID	0.1-0.4 (MMOL/L)	01/01/92	0.37
TOT BILIRUBIN	2-17 (UMOL/L)	01/01/92	17.00
TOT. PROTEINS	65-80 (G/L)	01/01/92	76.00
ALBUMINE	33-55 (G/L)	01/01/92	35.00

2293

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA 9850089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 45 Patient: 1DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			08/07/93		08/09/93		06/10/93	
			value	(†)	value	(†)	value	(†)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	07/07/93	13.30		13.30		13.30	
HT	0.37-0.45 (L/L)	07/07/93	0.41		0.41		0.42	
RBC	3.8-4.8 (10 ¹² /L)	07/07/93	4.58		4.44		4.48	
WBC	3.7-10 (10 ⁹ /L)	07/07/93	6.60		5.20		7.40	
WBC: N	2-7 (10 ⁹ /L)	07/07/93	3.50				4.20	
	40-80 (%)	07/09/93			69.00			
WBC: L	1-3 (10 ⁹ /L)	07/07/93	2.40				2.80	
	20-40 (%)	07/09/93			23.00			
WBC: E	1-6 (%)	07/09/93			0.00	<		
WBC: M	2-10 (%)	07/09/93			8.00			
WBC: B	0-2 (%)	07/09/93			0.00			
PLATELETS	130-400 (10 ⁹ /L)	07/07/93	308.00		255.00		326.00	
NA+	136-149 (MMOL/L)	07/07/93	140.00		141.00		141.00	
K+	3.8-5.5 (MMOL/L)	07/07/93	4.00		3.90		4.30	
Ca ⁺⁺	2.15-2.65 (MMOL/L)	07/07/93	2.27		2.18		2.20	
PO ₄ ⁻⁻	0.8-1.4 (MMOL/L)	07/07/93	1.35		1.36		1.37	
SGOT	5-35 (IU/L)	07/07/93	76.00	>>	20.00			
SGPT	10-40 (IU/L)	07/07/93	23.00		17.00			
GAMMA GT	0-30 (IU/L)	07/07/93	11.00		11.00			
ALK. PHOSPH.	30-130 (IU/L)	07/07/93	76.00		95.00		104.00	
GLUCOSE	3.5-5.5 (MMOL/L)	07/07/93	4.70				5.30	
UREA	2.5-6.5 (MMOL/L)	05/10/93					6.80	
CREATININE	55-125 (UMOL/L)	07/07/93	85.00		96.00		95.00	
URIC ACID	0.1-0.4 (MMOL/L)	07/07/93	0.68	>>	0.38		0.40	
TOT. BILIRUBIN	2-17 (UMOL/L)	07/07/93	8.00		9.00		8.00	
TOT. PROTEINS	65-80 (G/L)	07/07/93	77.00		71.00		75.00	
ALBUMINE	33-55 (G/L)	07/07/93	43.00		41.00		41.00	
TOT. CHOLEST.	4-6.5 (MMOL/L)	07/07/93	8.40	>	8.40			
TRIGLYCERIDES	0-1.5 (MMOL/L)	07/07/93	3.93	>>	3.93	>>		

2294

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 9850089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 46 Patient: 1MD Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			21/09/93		26/10/93		23/11/93	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	13.2-17 (G/DL)	01/01/92	15.80		16.00		15.40	
HT	0.4-0.54 (L/L)	01/01/92	0.49		0.49		0.48	
RBC	4.2-5.8 (10 ¹² /L)	01/01/92	4.87		5.00		4.92	
HBC	3.8-11 (10 ⁹ /L)	01/01/92	5.80		5.91		5.78	
HBC: N	2.2-7.5 (10 ⁹ /L)	01/01/92	3.47		3.71		3.59	
HBC: L	1.2-4 (10 ⁹ /L)	01/01/92	1.76		1.44		1.66	
HBC: E	0-0.5 (10 ⁹ /L)	01/01/92	0.09		0.05		0.09	
HBC: M	0.2-1 (10 ⁹ /L)	01/01/92	0.44		0.67		0.39	
HBC: B	0-0.15 (10 ⁹ /L)	01/01/92	0.04		0.04		0.06	
PLATELETS	150-400 (10 ⁹ /L)	01/01/92	169.00		154.00		180.00	
NA+	135-150 (MMOL/L)	01/01/92	141.00		141.50		142.30	
K+	3.6-5 (MMOL/L)	01/01/92	4.46		4.90		4.86	
CL-	95-108 (MMOL/L)	01/01/92	103.00		105.00		104.00	
Ca++	2.1-2.6 (MMOL/L)	01/01/92			2.29		2.26	
PO4--	0.8-1.4 (MMOL/L)	01/01/92	1.16		1.08		1.00	
SGOT	0-41 (IU/L)	01/01/92	26.00		40.00		23.00	
SGPT	0-45 (IU/L)	01/01/92	38.00		68.00 >		38.00	
GAMMA GT	0-60 (IU/L)	01/01/92	50.00		94.00 >		68.00 >	
ALK. PHOSPH.	30-135 (IU/L)	01/01/92	61.00		80.00		71.00	
GLUCOSE	2.8-8.9 (MMOL/L)	01/01/92	6.30		7.70		7.90	
UREA	2.5-8.4 (MMOL/L)	01/01/92	6.50		5.80		7.50	
CREATININE	45-120 (UMOL/L)	01/01/92	125.00 >		125.00 >		121.00 >	
URIC ACID	180-450 (UMOL/L)	01/01/92	360.00		359.00		418.00	
TOT BILIRUBIN	3-20 (UMOL/L)	01/01/92	7.40		5.80		6.90	
TOT. PROTEINS	60-80 (G/L)	01/01/92	77.00		74.00		74.00	
ALBUMINE	34-50 (G/L)	01/01/92	47.00		45.00		43.00	
TOT. CHOLEST.	0-6 (MMOL/L)	01/01/92	4.54		4.67		4.73	
TRIGLYCERIDES	0.8-2 (MMOL/L)	01/01/92			1.75		2.19 >	
GLOBULINS ALPHA 1	1.5-3.8 (G/L)	01/01/92	2.50		2.50		2.50	
GLOBULINS ALPHA 2	3.2-9.7 (G/L)	01/01/92	8.20		9.40		8.30	
GLOBULINS BETA	5.2-10 (G/L)	01/01/92	8.10		8.50		8.50	
GLOBULINS GAMMA	5.2-14.5 (G/L)	01/01/92	11.20		11.60		11.70	
T4	58-160 (NMOL/L)	01/01/92	88.00					
ESR/SEDIMENT. RATE	0-10 (MM)	01/01/92						
1st h					5.00		5.00	

2295

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 9650089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 46 Patient: 2ND Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	Day 21
			13/10/93	09/11/93
			value (⊕)	value (⊕)
Laboratory test	Range value	Range date		
HB	11.5-15.5 (G/DL)	01/01/92	14.60	14.50
HT	0.35-0.47 (L/L)	01/01/92	0.45	0.44
RBC	3.8-5.4 (10 ¹² /L)	01/01/92	5.09	4.99
MBC	3.8-11 (10 ⁹ /L)	01/01/92	10.90	9.22
MBC: N	2.2-7.5 (10 ⁹ /L)	01/01/92	7.68 >	6.36
MBC: L	1.2-4 (10 ⁹ /L)	01/01/92	2.21	2.09
MBC: E	0-0.5 (10 ⁹ /L)	01/01/92	0.70 >>	0.90 >>
MBC: M	0.2-1 (10 ⁹ /L)	01/01/92	0.86	0.61
MBC: B	0-0.15 (10 ⁹ /L)	01/01/92	0.08	0.80 >>
PLATELETS	150-400 (10 ⁹ /L)	01/01/92	348.00	369.00
NA+	135-150 (MMOL/L)	01/01/92	133.50 <	134.80 <
K+	3.6-5 (MMOL/L)	01/01/92	3.66	4.69
CL-	95-108 (MMOL/L)	01/01/92	97.00	97.00
Ca++	2.1-2.6 (MMOL/L)	01/01/92	2.43	2.46
PO4--	0.8-1.4 (MMOL/L)	01/01/92	1.10	1.13
SGOT	0-41 (IU/L)	01/01/92	21.00	22.00
SGPT	0-45 (IU/L)	01/01/92	16.00	16.00
GAMMA GT	0-40 (IU/L)	01/01/92	14.00	14.00
ALK. PHOSPH.	30-135 (IU/L)	01/01/92	89.00	119.00
GLUCOSE	2.8-8.9 (MMOL/L)	01/01/92	5.20	6.40
UREA	2.5-8.4 (MMOL/L)	01/01/92	5.90	5.10
CREATININE	45-120 (UMOL/L)	01/01/92	107.00	101.00
URIC ACID	165-350 (UMOL/L)	01/01/92	287.00	216.00
TOT. BILIRUBIN	3-20 (UMOL/L)	01/01/92	5.60	5.90
TOT. PROTEINS	60-80 (G/L)	01/01/92	74.00	75.00
ALBUMINE	34-50 (G/L)	01/01/92	48.00	47.00
TOT. CHOLEST.	0-6 (MMOL/L)	01/01/92	5.50	6.16 >
TRIGLYCERIDES	0.8-2 (MMOL/L)	01/01/92	1.25	1.05
GLOBULINS ALPHA 1	1.5-3.8 (G/L)	01/01/92	2.90	3.20
GLOBULINS ALPHA 2	3.2-9.7 (G/L)	01/01/92	6.70	8.00
GLOBULINS BETA	5.2-10 (G/L)	01/01/92	7.30	7.80
GLOBULINS GAMMA	5.2-14.5 (G/L)	01/01/92	9.10	9.10
TSH	0.3-3.5 (MU/L)	01/01/92	1.30	
T4	58-160 (NMOL/L)	01/01/92	128.00	
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/01/92	3.00	5.00

2296

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA 955089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 1B.0

LABORATORY DATA

Centre: 46 Patient: 3ND Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			25/11/93		30/12/93		27/01/94	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	11.5-15.5 (G/DL)	01/01/92	14.40		14.50		15.00	
HT	0.35-0.47 (L/L)	01/01/92	0.45		0.43		0.47	
RBC	3.8-5.4 (10 ¹² /L)	01/01/92	5.11		4.98		5.24	
WBC	3.8-11 (10 ⁹ /L)	01/01/92	5.27		5.21		6.45	
WBC: N	2.2-7.5 (10 ⁹ /L)	01/01/92	2.47		2.47		3.52	
WBC: L	1.2-4 (10 ⁹ /L)	01/01/92	2.31		2.32		2.24	
WBC: E	0-0.5 (10 ⁹ /L)	01/01/92	0.09		0.03		0.08	
WBC: M	0.2-1 (10 ⁹ /L)	01/01/92	0.34		0.35		0.52	
WBC: B	0-0.15 (10 ⁹ /L)	01/01/92	0.06		0.04		0.09	
PLATELETS	150-400 (10 ⁹ /L)	01/01/92	250.00		222.00		244.00	
NA+	135-150 (MMOL/L)	01/01/92	141.80		139.40		140.20	
K+	3.6-5 (MMOL/L)	01/01/92	4.44		4.22		4.13	
CL-	95-108 (MMOL/L)	01/01/92	105.00		103.00		100.00	
Ca ⁺⁺	2.1-2.6 (MMOL/L)	01/01/92	2.39		2.38		2.26	
PO ₄ ⁻⁻	0.8-1.4 (MMOL/L)	01/01/92	1.08		1.21		1.28	
SGOT	0-41 (IU/L)	01/01/92	20.00		19.00		24.00	
SGPT	0-45 (IU/L)	01/01/92	18.00		20.00		23.00	
GAMMA GT	0-40 (IU/L)	01/01/92	20.00		17.00		16.00	
ALK. PHOSPH.	30-135 (IU/L)	01/01/92	133.00		134.00		150.00 >	
GLUCOSE	2.8-8.9 (MMOL/L)	01/01/92	5.60		5.30		4.20	
UREA	2.5-8.4 (MMOL/L)	01/01/92	4.00		5.30		5.40	
CREATININE	45-120 (UMOL/L)	01/01/92	84.00		71.00		81.00	
URIC ACID	165-350 (UMOL/L)	01/01/92	179.00		167.00		181.00	
TOT. BILIRUBIN	3-20 (UMOL/L)	01/01/92	6.00		2.80 <		4.60	
TOT. PROTEINS	60-80 (G/L)	01/01/92	66.00		71.00		70.00	
ALBUMINE	34-50 (G/L)	01/01/92	43.00		44.00		43.00	
TOT. CHOLEST.	0-6 (MMOL/L)	01/01/92	6.99 >		6.43 >		6.06 >	
TRIGLYCERIDES	0.8-2 (MMOL/L)	01/01/92	1.27		0.87		1.26	
GLOBULINS ALPHA 1	1.5-3.8 (G/L)	01/01/92	2.00		2.60		3.10	
GLOBULINS ALPHA 2	3.2-9.7 (G/L)	01/01/92	5.90		7.30		6.90	
GLOBULINS BETA	5.2-10 (G/L)	01/01/92	6.80		7.30		7.60	
GLOBULINS GAMMA	5.2-14.5 (G/L)	01/01/92	8.30		9.80		9.40	
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/01/92			1.00			

2297

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARNACIA 98574089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 46 Patient: 4MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date
			Screen
			03/12/93
			value (c)
Laboratory test	Range value	Range date	
HB	11.5-15.5 (G/DL)	01/01/92	11.90
HT	0.35-0.47 (L/L)	01/01/92	0.35 <
RBC	3.8-5.4 (10 ¹² /L)	01/01/92	4.02
MBC	3.8-11 (10 ⁹ /L)	01/01/92	8.49
MBC: N	2.2-7.5 (10 ⁹ /L)	01/01/92	6.29
MBC: L	1.2-4 (10 ⁹ /L)	01/01/92	1.77
MBC: E	0-0.5 (10 ⁹ /L)	01/01/92	0.03
MBC: M	0.2-1 (10 ⁹ /L)	01/01/92	0.37
MBC: B	0-0.15 (10 ⁹ /L)	01/01/92	0.03
PLATELETS	150-400 (10 ⁹ /L)	01/01/92	271.00
NA+	135-150 (MMOL/L)	01/01/92	140.70
K+	3.6-5 (MMOL/L)	01/01/92	3.81
CL-	95-108 (MMOL/L)	01/01/92	97.00
Ca++	2.1-2.6 (MMOL/L)	01/01/92	2.42
PO4--	0.8-1.4 (MMOL/L)	01/01/92	1.02
SGOT	0-41 (IU/L)	01/01/92	19.00
SGPT	0-45 (IU/L)	01/01/92	19.00
GAMMA GT	0-40 (IU/L)	01/01/92	7.00
ALK. PHOSPH.	30-135 (IU/L)	01/01/92	115.00
GLUCOSE	2.8-8.9 (MMOL/L)	01/01/92	7.70
UREA	2.5-8.4 (MMOL/L)	01/01/92	10.50 >
CREATININE	45-120 (UMOL/L)	01/01/92	97.00
CREATININE CLEARANCE			31.00
URIC ACID	165-350 (UMOL/L)	01/01/92	313.00
TOT BILIRUBIN	3-20 (UMOL/L)	01/01/92	9.00
TOT. PROTEINS	60-80 (G/L)	01/01/92	68.00
ALBUMINE	34-50 (G/L)	01/01/92	46.00
TOT. CHOLEST.	0-6 (MMOL/L)	01/01/92	6.93 >
TRIGLYCERIDES	0.8-2 (MMOL/L)	01/01/92	1.06
GLOBULINS ALPHA 1	1.5-3.8 (G/L)	01/01/92	2.50
GLOBULINS ALPHA 2	3.2-9.7 (G/L)	01/01/92	5.80
GLOBULINS BETA	5.2-10 (G/L)	01/01/92	6.70
GLOBULINS GAMMA	5.2-14.5 (G/L)	01/01/92	7.00
TSH	0.3-3.5 (MU/L)	01/01/92	0.70
T4	58-160 (NMOL/L)	01/01/92	141.00

2298

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS-26089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 48 Patient: 1DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	
			24/06/93	
			value	(*)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	12/06/93	11.60	<
HT	37-47 (%)	12/06/93	34.00	<
RBC	3.8-5.8 (10 ¹² /L)	12/06/93	3.72	<
WBC	4-11 (10 ⁹ /L)	12/06/93	4.70	
WBC: N	2-8 (10 ⁹ /L)	12/06/93	3.44	
WBC: L	0.7-4 (10 ⁹ /L)	12/06/93	0.88	
WBC: E	0-0.44 (10 ⁹ /L)	12/06/93	0.03	
WBC: M	0-1 (10 ⁹ /L)	12/06/93	0.25	
WBC: B	0-0.2 (10 ⁹ /L)	12/06/93	0.01	
PLATELETS	150-450 (10 ⁹ /L)	12/06/93	422.00	
NA+	135-146 (MMOL/L)	12/06/93	137.00	
K+	3.5-5 (MMOL/L)	12/06/93	4.70	
SGOT	0-35 (U/L)	12/06/93	21.00	
GAMMA GT	2-32 (U/L)	12/06/93	160.00	>>
LDH	90-180 (U/L)	12/06/93	216.00	>
ALK. PHOSPH.	45-130 (U/L)	12/06/93	282.00	>>
CREATININE	50-120 (UMOL/L)	12/06/93	70.00	
URIC ACID	0.12-0.42 (MMOL/L)	12/06/93	0.16	
TOT BILIRUBIN	2-20 (UMOL/L)	12/06/93	4.00	
TOT. PROTEINS	60-80 (G/L)	12/06/93	61.00	
ALBUMINE	35-50 (G/L)	12/06/93	40.00	
TOT. CHOLEST.	4-5.5 (MMOL/L)	12/06/93	5.50	
TRIGLYCERIDES	0.3-2 (MMOL/L)	12/06/93	0.90	
TSH	0.3-7 (MU/L)	12/06/93	1.20	
T4	11-26 (PMOL/L)	12/06/93	16.30	

2299

(*) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done (*) missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 9550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 48 Patient: ZDT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 42	
			25/06/93		26/07/93		05/08/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	12/06/93	15.60		15.10			
HT	37-47 (%)	12/06/93	46.00		45.00			
RBC	3.8-5.8 (10 ¹² /L)	12/06/93	5.22		5.14			
HBC	4-11 (10 ⁹ /L)	12/06/93	5.50		5.60			
HBC: N	2-8 (10 ⁹ /L)	12/06/93	3.27		3.33			
HBC: L	0.7-4 (10 ⁹ /L)	12/06/93	1.82		1.73			
HBC: E	0-0.44 (10 ⁹ /L)	12/06/93	0.18		0.08			
HBC: M	0-1 (10 ⁹ /L)	12/06/93	0.05		0.27			
HBC: B	0-0.2 (10 ⁹ /L)	12/06/93	0.03		0.04			
PLATELETS	150-450 (10 ⁹ /L)	12/06/93	295.00		307.00			
NA+	135-146 (MMOL/L)	12/06/93	141.00		134.00 <	134.00 <		
K+	3.5-5 (MMOL/L)	12/06/93	3.90		4.30	4.30		
Ca ⁺⁺	2.1-2.65 (MMOL/L)	12/06/93	2.55		2.49	2.49		
PO ₄ ⁻⁻	0.8-1.5 (MMOL/L)	12/06/93	1.08		1.04	1.04		
SGOT	0-35 (U/L)	12/06/93	24.00		30.00	35.00		
GAMMA GT	2-32 (U/L)	12/06/93	28.00		24.00	24.00		
ALK. PHOSPH.	45-130 (U/L)	12/06/93	89.00		91.00	96.00		
GLUCOSE	3.3-7.8 (MMOL/L)	12/06/93			4.90	4.40		
CREATININE	50-120 (UMOL/L)	12/06/93	90.00		80.00	80.00		
URIC ACID	0.12-0.42 (MMOL/L)	12/06/93	0.39					
TOT BILIRUBIN	2-20 (UMOL/L)	12/06/93	10.00		9.00	12.00		
TOT. PROTEINS	60-80 (G/L)	12/06/93	73.00		72.00	70.00		
ALBUMINE	35-50 (G/L)	12/06/93	47.00		47.00	48.00		
TOT. CHOLEST.	4-5.5 (MMOL/L)	12/06/93	5.40		5.30	5.10		
TRIGLYCERIDES	0.3-2 (MMOL/L)	12/06/93	1.40		1.20	1.20		

2300

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 09550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 291 Patient: 1MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	Day 28
			19/03/93	19/04/93
			value (⊕)	value (⊕)
Laboratory test	Range value	Range date		
HB	12-16 (G/DL)	01/03/93	13.80	13.70
HT	36-46 (X)	01/03/93	40.40	40.00
RBC	4.2-5.4 (10 ⁶ /MM ³)	01/03/93	4.10 <	4.13 <
WBC	4000-9400 (/MM ³)	01/03/93	6400.00	6500.00
WBC: N	50-70 (X)	01/03/93	48.00 <	43.00 <
WBC: L	25-40 (X)	01/03/93	47.00 >	48.00 >
WBC: E	0-4 (X)	01/03/93	4.00	4.00
WBC: M	2-13 (X)	01/03/93	1.00 <	4.00
WBC: B	0-1 (X)	01/03/93	0.00	1.00
PLATELETS	150-440 (10 ³ /MM ³)	01/03/93	228.00	232.00
NA+	134-150 (MMOL/L)	01/03/93	144.30	144.00
K+	3.5-5.6 (MMOL/L)	01/03/93	4.10	4.30
CL-	94-111 (MMOL/L)	01/03/93	107.00	108.00
Ca++	2.05-2.55 (MMOL/L)	01/03/93	2.30	2.36
PO4--	2.5-4.8 (MG/DL)	01/03/93	3.50	4.36
SGOT	5-15 (U/L)	01/03/93	7.00	8.00
SGPT	5-22 (U/L)	01/03/93	7.00	9.00
GAMMA GT	5-18 (U/L)	01/03/93	8.00	6.00
LDH	120-240 (U/L)	01/03/93	190.00	195.00
ALK. PHOSPH.	60-170 (U/L)	01/03/93	41.00 <	45.00 <
GLUCOSE	60-110 (MG/DL)	01/03/93	75.10	91.00
BUN	10-50 (MG/DL)	01/03/93	40.00	38.00
CREATININE	0.5-1.2 (MG/DL)	01/03/93	0.90	1.00
CREATININE CLEARANCE			40.00	
URIC ACID	2.4-5.7 (MG/DL)	01/03/93	4.60	3.70
TOT BILIRUBIN	0-1 (MG/DL)	01/03/93	0.50	0.19
DIR BILIRUBIN	0-0.25 (MG/DL)	01/03/93	0.50 >>	
TOT. PROTEINS	6.2-8.5 (G/DL)	01/03/93	6.80	7.20
ALBUMINE	57-68 (X)	01/03/93	65.00	69.00 >
TOT. CHOLEST.	100-200 (MG/DL)	01/03/93	302.00 >>	269.00 >>
TRIGLYCERIDES	50-175 (MG/DL)	01/03/93	89.00	145.00
GLOBULINS ALPHA 1	2-4.5 (X)	01/03/93	2.80	2.80
GLOBULINS ALPHA 2	5-9 (X)	01/03/93	8.40	8.40
GLOBULINS BETA	9-13 (X)	01/03/93	9.60	9.60
GLOBULINS GAMMA	10-20 (X)	01/03/93	10.20	10.20
TSH	0.17-2.87 (UU/ML)	01/03/93	0.40	
T4	5-13 (UG/DL)	01/03/93	7.70	
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/03/93	12.00	9.00
ESR/SEDIMENT. RATE 2nd h	11-20 (MM)	01/03/93	26.00	18.00

2301

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C056089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 291 Patient: 2ND Treatment: Reboxetine Sex: Female

			Visit number / Laboratory data					
			Screen		Day 28		Day 56	
			15/04/93		18/05/93		14/06/93	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/03/93	13.80		14.60		14.40	
HT	36-46 (X)	01/03/93	46.80 >		40.00			
RBC	4.2-5.4 (10 ⁶ /MM ³)	01/03/93	4.00 <		4.34		4.32	
WBC	4000-9400 (/MM ³)	01/03/93	5600.00		5800.00		6000.00	
WBC: N	50-70 (%)	01/03/93	56.00		58.00		57.00	
WBC: L	25-40 (%)	01/03/93	41.00 >		38.00		38.00	
WBC: E	0-4 (%)	01/03/93	2.00		2.00		3.00	
WBC: M	2-13 (%)	01/03/93	0.00 <		1.00 <		1.00 <	
WBC: B	0-1 (%)	01/03/93	1.00		1.00		1.00	
PLATELETS	150-440 (10 ³ /MM ³)	01/03/93	280.00		106.00 <			
NA+	134-150 (MMOL/L)	01/03/93	141.00		137.00		138.00	
K+	3.5-5.6 (MMOL/L)	01/03/93	3.80		4.30		4.00	
CL-	94-111 (MMOL/L)	01/03/93	112.00 >		109.00		105.00	
Ca++	2.05-2.55 (MMOL/L)	01/03/93	2.28		2.28		2.44	
PO4--	2.5-4.8 (MG/DL)	01/03/93	2.59		3.27		2.84	
SGOT	5-15 (U/L)	01/03/93	11.00		11.00		1.00 <	
SGPT	5-22 (U/L)	01/03/93	13.00		13.00		1.00 <	
GAHHA GT	5-18 (U/L)	01/03/93	12.00		12.00		15.00	
LDH	120-240 (U/L)	01/03/93	143.00		175.00			
ALK. PHOSPH.	60-170 (U/L)	01/03/93			95.00		95.00	
GLUCOSE	60-110 (MG/DL)	01/03/93	90.00				103.00	
BUN	10-50 (MG/DL)	01/03/93	30.00				25.00	
CREATININE	0.5-1.2 (MG/DL)	01/03/93	0.80					
CREATININE CLEARANCE			65.64					
URIC ACID	2.4-5.7 (MG/DL)	01/03/93	3.60		4.10		4.00	
TOT BILIRUBIN	0-1 (MG/DL)	01/03/93	0.31		0.35		0.38	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/03/93	0.12					
TOT. PROTEINS	6.2-8.5 (G/DL)	01/03/93	6.60		5.20 <		6.80	
ALBUMINE	57-68 (X)	01/03/93	69.40 >		67.70		59.40	
TOT. CHOLEST.	100-200 (MG/DL)	01/03/93	228.00 >		376.00 >>		378.00 >>	
TRIGLYCERIDES	50-175 (MG/DL)	01/03/93	208.00 >		323.00 >>			
GLOBULINS ALPHA 1	2-4.5 (X)	01/03/93	2.60		3.40		3.70	
GLOBULINS ALPHA 2	5-9 (X)	01/03/93	4.70 <		8.80		7.10	
GLOBULINS BETA	9-13 (X)	01/03/93	9.70		8.90 <		13.20 >	
GLOBULINS GAMMA	10-20 (X)	01/03/93	13.60		11.20		16.60	
TSH	0.17-2.87 (UU/ML)	01/03/93	0.70					
T4	5-13 (UG/DL)	01/03/93	8.20					
ESR/SEDIMENT. RATE	0-10 (MM)	01/03/93						
1st h			6.00		8.00		11.00	
ESR/SEDIMENT. RATE	11-20 (MM)	01/03/93						
2nd h			10.00		20.00		23.00	

2302

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C9584089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 291 Patient: 3MD Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			20/04/93		17/05/93		14/06/93	
			value	(†)	value	(†)	value	(†)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	01/03/93	14.50		14.50		14.00	
HT	38-52 (%)	01/03/93	42.00		42.00		39.00	
RBC	4.5-6.3 (10 ⁶ /MM ³)	01/03/93	4.54		4.61		4.26	<
WBC	4000-9400 (/MM ³)	01/03/93	4900.00		4500.00		4300.00	
WBC: N	50-70 (%)	01/03/93	41.00	<	58.00		56.00	
WBC: L	25-40 (%)	01/03/93	52.00	>	36.00		38.00	
WBC: E	0-4 (%)	01/03/93	2.00		3.00		4.00	
WBC: M	2-13 (%)	01/03/93	4.00		2.00		2.00	
WBC: B	0-1 (%)	01/03/93	1.00		1.00		0.00	
PLATELETS	150-440 (10 ³ /MM ³)	01/03/93	179.00		166.00		170.00	
NA+	134-150 (MMOL/L)	01/03/93	141.00		138.00		136.00	
K+	3.5-5.6 (MMOL/L)	01/03/93	4.80		5.30		4.80	
CL-	94-111 (MMOL/L)	01/03/93	129.00	>>	104.00		106.00	
Ca++	2.05-2.55 (MMOL/L)	01/03/93	2.34		2.31		2.26	<
PO4--	2.5-4.8 (MG/DL)	01/03/93	3.19		2.27	<	2.15	<
SGOT	5-18 (U/L)	01/03/93	10.00		15.00		10.00	
SGPT	5-24 (U/L)	01/03/93	13.00		17.00		14.00	
GAMMA GT	5-28 (U/L)	01/03/93	17.00		12.00		23.00	
LDH	120-240 (U/L)	01/03/93	175.00					
ALK. PHOSPH.	60-170 (U/L)	01/03/93	126.00		128.00		111.00	
GLUCOSE	60-110 (MG/DL)	01/03/93	139.00	>	124.00	>	130.00	>
BUN	10-50 (MG/DL)	01/03/93	31.00		42.00		40.00	
CREATININE	0.5-1.4 (MG/DL)	01/03/93	1.40		1.20		0.90	
CREATININE CLEARANCE	80-160 (ML/MIN)	01/03/93	63.70					
URIC ACID	2.4-7 (MG/DL)	01/03/93	6.20		8.00	>	6.70	
TOT BILIRUBIN	0-1 (MG/DL)	01/03/93	0.85		0.84		0.72	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/03/93	0.15		0.30	>		
TOT. PROTEINS	6.2-8.5 (G/DL)	01/03/93	7.90		7.00		6.50	
ALBUMINE	57-68 (%)	01/03/93	70.40	>	60.40		64.00	
TOT. CHOLEST.	100-200 (MG/DL)	01/03/93	255.00	>	248.00	>	281.00	>>
TRIGLYCERIDES	50-175 (MG/DL)	01/03/93	131.00		64.00		85.00	
GLOBULINS ALPHA 1	2-4.5 (%)	01/03/93	2.70		4.00		3.00	
GLOBULINS ALPHA 2	5-9 (%)	01/03/93	7.90		10.50	>	9.10	>
GLOBULINS BETA	9-13 (%)	01/03/93	9.20		9.00		11.00	
GLOBULINS GAMMA	10-20 (%)	01/03/93	9.80	<	16.10		12.90	
TSH	0.17-2.87 (UU/ML)	01/03/93	1.13					
T4	5-13 (UG/DL)	01/03/93	6.80					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/03/93	7.00		8.00		9.00	
ESR/SEDIMENT. RATE 2nd h	11-20 (MM)	01/03/93	14.00		16.00		16.00	

2303

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C0560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 291 Patient: 4ND Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			28/04/93		01/06/93		28/06/93	
			value	(ø)	value	(ø)	value	(ø)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	01/03/93	14.90		15.20		15.20	
HT	38-52 (X)	01/03/93	44.00		43.00		42.00	
RBC	4.5-6.3 (10 ⁶ /MM ³)	01/03/93	4.88		4.88		4.71	
WBC	4000-9400 (/MM ³)	01/03/93	5800.00		5800.00		5300.00	
WBC: N	50-70 (X)	01/03/93	52.00		51.00		64.00	
WBC: L	25-40 (X)	01/03/93	42.00 >		42.00 >		32.00	
WBC: E	0-4 (X)	01/03/93	4.00		4.00		2.00	
WBC: M	2-13 (X)	01/03/93	1.00 <		2.00		0.00 <	
WBC: B	0-1 (X)	01/03/93	1.00		1.00		0.00	
PLATELETS	150-440 (10 ³ /MM ³)	01/03/93	224.00		251.00		214.00	
NA+	134-150 (MMOL/L)	01/03/93	142.00		137.00		129.00 <	
K+	3.5-5.6 (MMOL/L)	01/03/93	4.10		4.00		3.90	
CL-	94-111 (MMOL/L)	01/03/93			104.00		110.00	
Ca++	2.05-2.55 (MMOL/L)	01/03/93			2.32		2.15	
PO4--	2.5-4.8 (MG/DL)	01/03/93			2.35 <		2.94	
SGOT	5-18 (U/L)	01/03/93	19.00 >		9.00		10.00	
SGPT	5-24 (U/L)	01/03/93	12.00		12.00		15.00	
GAMMA GT	5-28 (U/L)	01/03/93	31.00 >		32.00 >		35.00 >	
LDH	120-240 (U/L)	01/03/93	232.00		150.00		129.00	
ALK. PHOSPH.	60-170 (U/L)	01/03/93	122.00		177.00 >		168.00	
GLUCOSE	60-110 (MG/DL)	01/03/93	109.00		99.00		113.00 >	
BUN	10-50 (MG/DL)	01/03/93	29.00		29.00		29.00	
CREATININE	0.5-1.4 (MG/DL)	01/03/93	1.50 >		1.30		1.20	
CREATININE CLEARANCE	80-160 (ML/MIN)	01/03/93	52.60					
URIC ACID	2.4-7 (MG/DL)	01/03/93	5.50		5.70		6.20	
TOT BILIRUBIN	0-1 (MG/DL)	01/03/93	0.57		0.87		0.66	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/03/93	0.13				0.16	
TOT. PROTEINS	6.2-8.5 (G/DL)	01/03/93	7.50		7.40		7.30	
ALBUMINE	57-68 (X)	01/03/93	57.80		62.90		64.40	
TOT. CHOLEST.	100-200 (MG/DL)	01/03/93	232.00 >		256.00 >		304.00 >>	
TRIGLYCERIDES	50-175 (MG/DL)	01/03/93	199.00 >		150.00		267.00 >>	
GLOBULINS ALPHA 1	2-4.5 (X)	01/03/93	2.50		2.40		2.30	
GLOBULINS ALPHA 2	5-9 (X)	01/03/93	9.90 >		6.60		5.60	
GLOBULINS BETA	9-13 (X)	01/03/93	9.80		9.40		10.70	
GLOBULINS GAMMA	10-20 (X)	01/03/93	20.00		18.70		17.00	
ESR/SEDIMENT. RATE	0-10 (MM)	01/03/93						
1st h			20.00		5.00			
ESR/SEDIMENT. RATE	11-20 (MM)	01/03/93						
2nd h			34.00		14.00			

2304

(ø) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS 9690089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 291 Patient: 1DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			21/04/93		20/05/93		16/06/93	
			value	(⊕)	value	(⊕)	value	(⊕)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/03/93	14.90		14.70		15.10	
HT	36-46 (X)	01/03/93	43.00		41.00		42.00	
RBC	4.2-5.4 (10 ⁶ /MM ³)	01/03/93	4.64		4.48		4.54	
WBC	4000-9400 (/MM ³)	01/03/93	6400.00		4600.00		6400.00	
WBC: N	50-70 (%)	01/03/93	58.00		58.00		48.00 <	
WBC: L	25-40 (%)	01/03/93	34.00		36.00		40.00	
WBC: E	0-4 (%)	01/03/93	2.00		2.00		2.00	
WBC: M	2-13 (%)	01/03/93	6.00		2.00		10.00	
WBC: B	0-1 (%)	01/03/93	0.00		2.00 >>		0.00	
PLATELETS	150-440 (10 ³ /MM ³)	01/03/93	293.00		273.00		281.00	
NA+	134-150 (MMOL/L)	01/03/93	141.00		142.00		143.00	
K+	3.5-5.6 (MMOL/L)	01/03/93	4.20		4.20		3.60	
CL-	94-111 (MMOL/L)	01/03/93	110.00		107.00		101.00	
Ca++	2.05-2.55 (MMOL/L)	01/03/93	2.28				2.30	
PO4--	2.5-4.8 (MG/DL)	01/03/93	3.48		2.46 <		2.81	
SGOT	5-15 (U/L)	01/03/93	12.00		17.00 >		15.00	
SGPT	5-22 (U/L)	01/03/93	22.00		29.00 >		25.00 >	
GAMMA GT	5-18 (U/L)	01/03/93	8.00		9.00		9.00	
LDH	120-240 (U/L)	01/03/93	269.00 >		257.00 >		280.00 >	
ALK. PHOSPH.	60-170 (U/L)	01/03/93	133.00		139.00		106.00	
GLUCOSE	60-110 (MG/DL)	01/03/93	127.00 >		156.00 >>		134.00 >	
BUN	10-50 (MG/DL)	01/03/93	53.00 >		37.00		23.00	
CREATININE	0.5-1.2 (MG/DL)	01/03/93	1.00		0.80		0.90	
CREATININE CLEARANCE	80-160 (ML/MIN)	01/03/93	55.52					
URIC ACID	2.4-5.7 (MG/DL)	01/03/93	4.40		5.40		5.30	
TOT BILIRUBIN	0-1 (MG/DL)	01/03/93	0.24		0.73		0.85	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/03/93	0.16		0.33 >			
TOT. PROTEINS	6.2-8.5 (G/DL)	01/03/93	7.40		6.70		6.80	
ALBUMINE	57-68 (%)	01/03/93			65.10		63.40	
TOT. CHOLEST.	100-200 (MG/DL)	01/03/93	190.00		240.00 >		233.00 >	
TRIGLYCERIDES	50-175 (MG/DL)	01/03/93	99.00		99.00		144.00	
GLOBULINS ALPHA 1	2-4.5 (%)	01/03/93			3.00		4.10	
GLOBULINS ALPHA 2	5-9 (%)	01/03/93			9.00		10.10 >	
GLOBULINS BETA	9-13 (%)	01/03/93			9.60		8.40 <	
GLOBULINS GAMMA	10-20 (%)	01/03/93			13.30		14.00	
TSH	0.17-2.87 (UU/ML)	01/03/93	0.47					
T4	5-13 (UG/DL)	01/03/93	6.80					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/03/93	18.00				18.00	
ESR/SEDIMENT. RATE 2nd h	11-20 (MM)	01/03/93	34.00				38.00	

2305

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN950089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 291 Patient: 2DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			06/04/93		17/05/93		16/06/93	
			value	(c)	value	(c)	value	(c)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/03/93	13.90		14.10		12.00	
HT	36-46 (%)	01/03/93	43.80		40.00		34.00 <	
RBC	4.2-5.4 (10 ⁶ /MM ³)	01/03/93	4.60		4.36		3.84 <	
HBC	4000-9400 (/MM ³)	01/03/93	7600.00		7200.00		9000.00	
HBC: N	50-70 (%)	01/03/93	51.00		52.00		54.00	
HBC: L	25-40 (%)	01/03/93	45.00 >		44.00 >		42.00 >	
HBC: E	0-4 (%)	01/03/93	3.00		2.00		4.00	
HBC: M	2-13 (%)	01/03/93	1.00 <		1.00 <		0.00 <	
HBC: B	0-1 (%)	01/03/93	0.00		1.00		0.00	
PLATELETS	150-440 (10 ³ /MM ³)	01/03/93	215.00		243.00		154.00	
NA+	134-150 (MMOL/L)	01/03/93	137.00		135.00		142.00	
K+	3.5-5.6 (MMOL/L)	01/03/93	4.10		4.00		3.90	
CL-	94-111 (MMOL/L)	01/03/93			95.00		106.00	
Ca++	2.05-2.55 (MMOL/L)	01/03/93	2.37		2.36		2.39	
PO4--	2.5-4.8 (MG/DL)	01/03/93	3.50		2.97		2.92	
SGOT	5-15 (U/L)	01/03/93	9.00		9.00		10.00	
SGPT	5-22 (U/L)	01/03/93	11.00		14.00		11.00	
GAMMA GT	5-18 (U/L)	01/03/93	23.00 >		28.00 >		12.00	
LDH	120-240 (U/L)	01/03/93	193.00		171.00		187.00	
ALK. PHOSPH.	60-170 (U/L)	01/03/93	106.00		122.00		132.00	
GLUCOSE	60-110 (MG/DL)	01/03/93	108.00		95.00		136.00 >	
BUN	10-50 (MG/DL)	01/03/93	45.00		30.00		29.00	
CREATININE	0.5-1.2 (MG/DL)	01/03/93	1.09		1.10		1.10	
CREATININE CLEARANCE	80-160 (ML/MIN)	01/03/93	57.00					
URIC ACID	2.4-5.7 (MG/DL)	01/03/93	6.90 >		6.40 >		6.40 >	
TOT BILIRUBIN	0-1 (MG/DL)	01/03/93	0.40		0.42		0.52	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/03/93			0.16		0.10	
TOT. PROTEINS	6.2-8.5 (G/DL)	01/03/93	6.70		6.90		6.70	
ALBUMINE	57-68 (%)	01/03/93			58.80		68.90 >	
TOT. CHOLEST.	100-200 (MG/DL)	01/03/93	241.00 >		288.00 >>		267.00 >>	
TRIGLYCERIDES	50-175 (MG/DL)	01/03/93	100.00		145.00		210.00 >	
GLOBULINS ALPHA 1	2-4.5 (%)	01/03/93			4.40		3.10	
GLOBULINS ALPHA 2	5-9 (%)	01/03/93			14.20 >>		6.30	
GLOBULINS BETA	9-13 (%)	01/03/93			8.20 <		9.80	
GLOBULINS GAMMA	10-20 (%)	01/03/93			14.40		11.90	
TSH	0.17-2.87 (UU/ML)	01/03/93	1.10					
T4	5-13 (UG/DL)	01/03/93	8.00					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/03/93	20.00		12.00		40.00	
ESR/SEDIMENT. RATE 2nd h	11-20 (MM)	01/03/93	34.00		28.00		78.00	

2306

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS 550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 291 Patient: SDT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date
			Screen
			22/04/93
			value (c)
Laboratory test	Range value	Range date	
HB	12-16 (G/DL)	01/03/93	14.70
HT	36-46 (%)	01/03/93	43.00
RBC	4.2-5.4 (10 ⁶ /MM ³)	01/03/93	4.66
WBC	4000-9400 (/MM ³)	01/03/93	3900.00 <
PLATELETS	150-440 (10 ³ /MM ³)	01/03/93	191.00
NA+	134-150 (MMOL/L)	01/03/93	141.00
K+	3.5-5.6 (MMOL/L)	01/03/93	4.50
CL-	94-111 (MMOL/L)	01/03/93	112.00 >
Ca++	2.05-2.55 (MMOL/L)	01/03/93	2.35
PO4--	2.5-4.8 (MG/DL)	01/03/93	3.34
SGOT	5-15 (U/L)	01/03/93	12.00
SGPT	5-22 (U/L)	01/03/93	9.00
GAMMA GT	5-18 (U/L)	01/03/93	7.00
LDH	120-240 (U/L)	01/03/93	161.00
ALK. PHOSPH.	60-170 (U/L)	01/03/93	88.00
GLUCOSE	60-110 (MG/DL)	01/03/93	91.00
BUN	10-50 (MG/DL)	01/03/93	57.00 >
CREATININE	0.5-1.2 (MG/DL)	01/03/93	1.40 >
CREATININE CLEARANCE	80-160 (ML/MIN)	01/03/93	41.60
URIC ACID	2.4-5.7 (MG/DL)	01/03/93	6.40 >
TOT BILIRUBIN	0-1 (MG/DL)	01/03/93	0.45
TOT. PROTEINS	6.2-8.5 (G/DL)	01/03/93	7.10
ALBUMINE	57-68 (%)	01/03/93	57.00
TOT. CHOLEST.	100-200 (MG/DL)	01/03/93	249.00 >
TRIGLYCERIDES	50-175 (MG/DL)	01/03/93	63.00
GLOBULINS ALPHA 1	2-4.5 (%)	01/03/93	3.80
GLOBULINS ALPHA 2	5-9 (%)	01/03/93	9.30 >
GLOBULINS BETA	9-13 (%)	01/03/93	12.40
GLOBULINS GAMMA	10-20 (%)	01/03/93	12.50
TSH	0.17-2.87 (UU/ML)	01/03/93	1.56
T4	5-13 (UG/DL)	01/03/93	7.10

2307

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN5740089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 291 Patient: 4DT Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			05/05/93		02/06/93		28/06/93	
			value	(†)	value	(†)	value	(†)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	01/03/93	13.80	<	14.70		13.30 <	
HT	38-52 (%)	01/03/93	38.00		40.00		36.00 <	
RBC	4.5-6.3 (10 ⁶ /MM ³)	01/03/93	4.28	<	4.62		4.07 <	
WBC	4000-9400 (/MM ³)	01/03/93	5200.00		5200.00		4500.00	
WBC: N	50-70 (%)	01/03/93	52.00		54.00		52.00	
WBC: L	25-40 (%)	01/03/93	45.00	>	42.00	>	48.00 >	
WBC: E	0-4 (%)	01/03/93	1.00		1.00		0.00	
WBC: M	2-18 (%)	01/03/93	1.00	<	2.00		0.00 <	
WBC: B	0-1 (%)	01/03/93	1.00		1.00		0.00	
PLATELETS	150-440 (10 ³ /MM ³)	01/03/93	193.00		160.00		171.00	
NA+	134-150 (MMOL/L)	01/03/93	136.00		141.00		137.00	
K+	3.5-5.6 (MMOL/L)	01/03/93	3.90		3.80		4.30	
CL-	94-111 (MMOL/L)	01/03/93	110.00		103.00			
Ca++	2.05-2.55 (MMOL/L)	01/03/93	2.33		2.40		2.29	
PO4--	2.5-4.8 (MG/DL)	01/03/93	3.02		2.89			
SGOT	5-18 (U/L)	01/03/93	8.00		9.00		9.00	
SGPT	5-24 (U/L)	01/03/93	5.00		7.00		7.00	
GAMMA GT	5-28 (U/L)	01/03/93	9.00		10.00		9.00	
LDH	120-240 (U/L)	01/03/93	162.00		175.00		175.00	
ALK. PHOSPH.	60-170 (U/L)	01/03/93	106.00		90.00		88.00	
GLUCOSE	60-110 (MG/DL)	01/03/93	209.00	>>	184.00	>>	115.00 >	
BUN	10-50 (MG/DL)	01/03/93	65.00	>	44.00		43.00	
CREATININE	0.5-1.4 (MG/DL)	01/03/93	1.10		1.20		0.90	
CREATININE	80-160 (ML/MIN)	01/03/93						
CLEARANCE			51.20					
URIC ACID	2.4-7 (MG/DL)	01/03/93	5.50		4.80		4.20	
TOT BILIRUBIN	0-1 (MG/DL)	01/03/93	0.38		0.79		0.64	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/03/93	0.12				0.12	
TOT. PROTEINS	6.2-8.5 (G/DL)	01/03/93	6.80		7.10		6.80	
ALBUMINE	57-68 (%)	01/03/93	61.80		65.60			
TOT. CHOLEST.	100-200 (MG/DL)	01/03/93	221.00	>	209.00	>	243.00 >	
TRIGLYCERIDES	50-175 (MG/DL)	01/03/93	98.00		84.00		152.00	
GLOBULINS ALPHA 1	2-4.5 (%)	01/03/93	4.70	>	3.30			
GLOBULINS ALPHA 2	5-9 (%)	01/03/93	11.50	>	9.40	>		
GLOBULINS BETA	9-13 (%)	01/03/93	10.40		9.70			
GLOBULINS GAMMA	10-20 (%)	01/03/93	11.60		12.00			
TSH	0.47-2.87 (UU/ML)	01/03/93	0.95					
T4	5-13 (UG/DL)	01/03/93	7.50					
ESR/SEDIMENT. RATE	0-10 (MM)	01/03/93						
1st h			4.00		3.00			
ESR/SEDIMENT. RATE	11-20 (MM)	01/03/93						
2nd h			18.00		12.00			

2308

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 9340089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 291 Patient: 250T Treatment: Imipramine Sex: Female

Laboratory test			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			03/11/93		07/12/93		11/01/94	
			value	(¢)	value	(¢)	value	(¢)
Range value	Range date							
HB	12-16 (G/DL)	01/03/93	12.00		11.40	<	11.50	<
HT	36-46 (%)	01/03/93	34.00	<	34.00	<	34.00	<
RBC	4.2-5.4 (10 ⁶ /MM ³)	01/03/93	3.80	<	3.71	<	3.77	<
WBC	4000-9400 (/MM ³)	01/03/93	8300.00		10100.0	>	8700.00	
WBC: N	50-70 (%)	01/03/93	58.00		60.00		50.00	
WBC: L	25-40 (%)	01/03/93	42.00	>	34.00		46.00	>
WBC: E	0-4 (%)	01/03/93	0.00		0.00		2.00	
WBC: M	2-13 (%)	01/03/93	0.00	<	6.00		2.00	
WBC: B	0-1 (%)	01/03/93	0.00		0.00		0.00	
PLATELETS	150-440 (10 ³ /MM ³)	01/03/93	170.00		195.00		186.00	
NA+	134-150 (MMOL/L)	01/03/93	147.00		139.00		141.00	
K+	3.5-5.6 (MMOL/L)	01/03/93	4.40		4.20		4.30	
CL-	94-111 (MMOL/L)	01/03/93	113.00	>	108.00		101.00	
Ca++	2.05-2.55 (MMOL/L)	01/03/93	2.44		2.34		2.33	
PO4--	2.5-4.8 (MG/DL)	01/03/93	3.52		3.07		3.26	
SGOT	5-15 (U/L)	01/03/93	8.00		13.00		8.00	
SGPT	5-22 (U/L)	01/03/93	10.00		19.00		9.00	
GAMMA GT	5-18 (U/L)	01/03/93	11.00		18.00		12.00	
LDH	120-240 (U/L)	01/03/93	139.00		171.00		187.00	
ALK. PHOSPH.	60-170 (U/L)	01/03/93	117.00		182.00	>	197.00	>
GLUCOSE	60-110 (MG/DL)	01/03/93	117.00	>	121.00	>	98.00	
BUN	10-50 (MG/DL)	01/03/93	32.00		38.00		34.00	
CREATININE	0.5-1.2 (MG/DL)	01/03/93	1.10		1.10		1.20	
CREATININE CLEARANCE			41.10					
URIC ACID	2.4-5.7 (MG/DL)	01/03/93	5.80	>	3.00		5.00	
TOT BILIRUBIN	0-1 (MG/DL)	01/03/93	0.44		0.44		0.34	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/03/93	0.11				0.07	
TOT. PROTEINS	6.2-8.5 (G/DL)	01/03/93	6.70		7.30		7.30	
ALBUMINE	57-68 (%)	01/03/93	64.20		63.80		58.90	
TOT. CHOLEST.	100-200 (MG/DL)	01/03/93	239.00	>	268.00	>>	256.00	>
TRIGLYCERIDES	50-175 (MG/DL)	01/03/93	192.00	>	365.00	>>	256.00	>>
GLOBULINS ALPHA 1	2-4.5 (%)	01/03/93	3.50		3.80		4.00	
GLOBULINS ALPHA 2	5-9 (%)	01/03/93	9.60	>	7.90		9.20	>
GLOBULINS BETA	9-13 (%)	01/03/93	10.20		11.40		11.00	
GLOBULINS GAMMA	10-20 (%)	01/03/93	12.50		13.10		16.90	
TSH	0.17-2.87 (UU/ML)	01/03/93	0.71					
T4	5-13 (UG/DL)	01/03/93	8.50					
ESR/SEDIMENT. RATE	0-10 (MM)	01/03/93						
1st h			10.00		14.00		15.00	
ESR/SEDIMENT. RATE	11-20 (MM)	01/03/93						
2nd h			23.00		28.00		30.00	

2309

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CNS 9560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 291 Patient: 26DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			08/06/93		07/07/93		04/08/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/03/93	14.40		13.70		13.40	
HT	36-46 (%)	01/03/93	40.00		38.00		39.00	
RBC	4.2-5.4 (10 ⁶ /MM ³)	01/03/93	4.66		4.35		4.41	
WBC	4000-9400 (/MM ³)	01/03/93	6000.00		6700.00		5300.00	
WBC: N	50-70 (%)	01/03/93	38.00	<	32.00	<<	44.00	
WBC: L	25-40 (%)	01/03/93	60.00	>>	66.00	>>	54.00	
WBC: E	0-4 (%)	01/03/93	0.00		0.00		0.00	
WBC: M	2-13 (%)	01/03/93	2.00		2.00		2.00	
WBC: B	0-1 (%)	01/03/93	0.00		0.00		0.00	
PLATELETS	150-440 (10 ³ /MM ³)	01/03/93	202.00		230.00		216.00	
NA+	134-150 (MMOL/L)	01/03/93	143.00		140.00		142.00	
K+	3.5-5.6 (MMOL/L)	01/03/93	3.80		3.90		4.20	
CL-	94-111 (MMOL/L)	01/03/93	111.00		114.00	>	110.00	
Ca++	2.05-2.55 (MMOL/L)	01/03/93	2.28		2.24		2.25	
PO4--	2.5-4.8 (MG/DL)	01/03/93	3.60		3.79		3.11	
SGOT	5-15 (U/L)	01/03/93	9.00		11.00		10.00	
SGPT	5-22 (U/L)	01/03/93	18.00		13.00		20.00	
GAMMA GT	5-18 (U/L)	01/03/93	9.00		11.00		12.00	
LDH	120-240 (U/L)	01/03/93	227.00				252.00	
ALK. PHOSPH.	60-170 (U/L)	01/03/93	127.00		126.00		138.00	
GLUCOSE	60-110 (MG/DL)	01/03/93	120.00	>	125.00	>	111.00	
BUN	10-50 (MG/DL)	01/03/93	31.00		37.00		36.00	
CREATININE	0.5-1.2 (MG/DL)	01/03/93	0.80				0.90	
CREATININE CLEARANCE	80-160 (ML/MIN)	01/03/93	48.50					
URIC ACID	2.4-5.7 (MG/DL)	01/03/93	5.40		6.50	>	6.80	
TOT BILIRUBIN	0-1 (MG/DL)	01/03/93	0.26		0.28		0.48	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/03/93	0.03		0.04			
TOT. PROTEINS	6.2-8.5 (G/DL)	01/03/93	6.70		6.30		7.40	
ALBUMINE	57-68 (%)	01/03/93	68.60	>	59.10		66.40	
TOT. CHOLEST.	100-200 (MG/DL)	01/03/93	244.00	>	191.00		215.00	
TRIGLYCERIDES	50-175 (MG/DL)	01/03/93	117.00				91.00	
GLOBULINS ALPHA 1	2-4.5 (%)	01/03/93	2.90		3.80		2.30	
GLOBULINS ALPHA 2	5-9 (%)	01/03/93	8.00		11.20	>	8.40	
GLOBULINS BETA	9-13 (%)	01/03/93	8.90	<	11.40		10.30	
GLOBULINS GAMMA	10-20 (%)	01/03/93	11.60		14.50		12.60	
TSH	0.17-2.87 (UU/ML)	01/03/93	0.55					
T4	5-13 (UG/DL)	01/03/93	6.10					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/03/93	8.00		12.00		3.00	
ESR/SEDIMENT. RATE 2nd h	11-20 (MM)	01/03/93	18.00		25.00		14.00	

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C9550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 291 Patient: 27DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			03/11/93		02/12/93		13/01/94	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/03/93	14.50		13.40		13.70	
HT	36-46 (X)	01/03/93	42.00		40.00		41.10	
RBC	4.2-5.4 (10 ⁶ /MM ³)	01/03/93	4.37		4.09 <		4.22	
WBC	4000-9400 (/MM ³)	01/03/93	6600.00		4600.00		5200.00	
WBC: N	50-70 (X)	01/03/93	50.00		34.00 <<		46.00 <	
WBC: L	25-40 (X)	01/03/93	48.00 >		58.00 >>		44.00 >	
WBC: E	0-4 (X)	01/03/93	0.00		2.00		2.00	
WBC: M	2-13 (X)	01/03/93	0.00 <		6.00		6.00	
WBC: B	0-1 (X)	01/03/93	0.00		0.00		0.00	
PLATELETS	150-440 (10 ³ /MM ³)	01/03/93	215.00		205.00		212.00	
NA+	134-150 (MMOL/L)	01/03/93	140.00		141.00		144.00	
K+	3.5-5.6 (MMOL/L)	01/03/93	7.10 >>		4.70		4.70	
CL-	94-111 (MMOL/L)	01/03/93	111.00		109.00		106.00	
Ca++	2.05-2.55 (MMOL/L)	01/03/93	2.55		2.27		2.40	
PO4--	2.5-4.8 (MG/DL)	01/03/93	4.34		2.77		3.09	
SGOT	5-15 (U/L)	01/03/93	11.00		9.00		9.00	
SGPT	5-22 (U/L)	01/03/93	8.00		10.00		8.00	
GAMMA GT	5-18 (U/L)	01/03/93	9.00		8.00		11.00	
LDH	120-240 (U/L)	01/03/93	190.00		154.00		181.00	
ALK. PHOSPH.	60-170 (U/L)	01/03/93	201.00 >		182.00 >		224.00 >	
GLUCOSE	60-110 (MG/DL)	01/03/93	93.00		107.00		108.00	
BUN	10-50 (MG/DL)	01/03/93	39.00		34.00		55.00 >	
CREATININE	0.5-1.2 (MG/DL)	01/03/93	0.90		0.80		1.00	
CREATININE CLEARANCE			45.50					
URIC ACID	2.4-5.7 (MG/DL)	01/03/93	5.40		3.10		4.10	
TOT BILIRUBIN	0-1 (MG/DL)	01/03/93	0.52		0.32		0.45	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/03/93	0.18		0.17		0.06	
TOT. PROTEINS	6.2-8.5 (G/DL)	01/03/93	7.40		7.10		7.50	
ALBUMINE	57-68 (X)	01/03/93	62.00		62.60		58.90	
TOT. CHOLEST.	100-200 (MG/DL)	01/03/93	262.00 >>		222.00 >		225.00 >	
TRIGLYCERIDES	50-175 (MG/DL)	01/03/93	118.00		184.00 >		136.00	
GLOBULINS ALPHA 1	2-4.5 (X)	01/03/93	3.50		3.50		3.60	
GLOBULINS ALPHA 2	5-9 (X)	01/03/93	9.60 >		7.90		9.90 >	
GLOBULINS BETA	9-13 (X)	01/03/93	12.10		10.40		13.10 >	
GLOBULINS GAMMA	10-20 (X)	01/03/93	12.80		15.60		14.50	
TSH	0.17-2.87 (UU/ML)	01/03/93	0.81					
T4	5-13 (UG/DL)	01/03/93	8.80					
ESR/SEDIMENT. RATE 0-10 (MM)		01/03/93						
1st h			9.00		14.00		12.00	
ESR/SEDIMENT. RATE 11-20 (MM)		01/03/93						
2nd h			15.00		28.00		30.00	

2311

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN0580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 291 Patient: 28DT Treatment: Imipramine Sex: Female

Laboratory test			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			18/11/93		17/12/93		12/01/94	
			value	(c)	value	(c)	value	(c)
Range value	Range date							
HB	12-16 (G/DL)	01/03/93	11.70	<	12.30		13.00	
HT	36-46 (%)	01/03/93	28.00	<<	38.00		39.00	
RBC	4.2-5.4 (10 ⁶ /MM ³)	01/03/93	2.83	<<	3.85	<	4.00	
HBC	4000-9400 (/MM ³)	01/03/93	5800.00		6600.00		5900.00	
HBC: N	50-70 (%)	01/03/93	42.00	<	60.00		46.00	
HBC: L	25-40 (%)	01/03/93	54.00	>>	32.00		54.00	
HBC: E	0-4 (%)	01/03/93	0.00		0.00		0.00	
HBC: M	2-13 (%)	01/03/93	4.00		6.00		0.00	
HBC: B	0-1 (%)	01/03/93	0.00		0.00		0.00	
PLATELETS	150-440 (10 ³ /MM ³)	01/03/93	377.00		233.00		274.00	
NA+	134-150 (MMOL/L)	01/03/93	140.00		136.00		142.00	
K+	3.5-5.6 (MMOL/L)	01/03/93	4.20		6.70	>>	4.10	
CL-	94-111 (MMOL/L)	01/03/93	101.00		99.00			
Ca++	2.05-2.55 (MMOL/L)	01/03/93	2.43		2.34		2.46	
PO4--	2.5-4.8 (MG/DL)	01/03/93	3.27		2.88			
SGOT	5-15 (U/L)	01/03/93	10.00		10.00		8.00	
SGPT	5-22 (U/L)	01/03/93	12.00		14.00		11.00	
GAMMA GT	5-18 (U/L)	01/03/93	21.00	>	12.00		15.00	
LDH	120-240 (U/L)	01/03/93	196.00		199.00		211.00	
ALK. PHOSPH.	60-170 (U/L)	01/03/93	130.00		149.00		140.00	
GLUCOSE	60-140 (MG/DL)	01/03/93	221.00	>>	311.00	>>	140.00	
BUN	10-50 (MG/DL)	01/03/93	40.00		40.00		43.00	
CREATININE	0.5-1.2 (MG/DL)	01/03/93	1.20		1.30	>	1.30	
CREATININE CLEARANCE	80-160 (ML/MIN)	01/03/93	46.60					
URIC ACID	2.4-5.7 (MG/DL)	01/03/93	4.60		4.00		4.30	
TOT BILIRUBIN	0-1 (MG/DL)	01/03/93	0.36		0.35		0.49	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/03/93					0.11	
TOT. PROTEINS	6.2-8.5 (G/DL)	01/03/93	7.40		7.60		8.20	
ALBUMINE	57-68 (%)	01/03/93	59.60		56.60	<	55.60	
TOT. CHOLEST.	100-200 (MG/DL)	01/03/93	346.00	>>	317.00	>>	312.00	
TRIGLYCERIDES	50-175 (MG/DL)	01/03/93	581.00	>>	946.00	>>	668.00	
GLOBULINS ALPHA 1	2-4.5 (%)	01/03/93	3.30		4.30		4.40	
GLOBULINS ALPHA 2	5-9 (%)	01/03/93	9.30	>	10.50	>	9.50	
GLOBULINS BETA	9-13 (%)	01/03/93	11.20		13.70	>	14.10	
GLOBULINS GAMMA	10-20 (%)	01/03/93	16.60		14.90		16.40	
TSH	0.17-2.87 (UU/ML)	01/03/93	1.34					
T4	5-13 (UG/DL)	01/03/93	10.10					
ESR/SEDIMENT. RATE	0-10 (MM)	01/03/93						
1st h			15.00		17.00		11.00	
ESR/SEDIMENT. RATE	11-20 (MM)	01/03/93						
2nd h			23.00		30.00		20.00	

2312

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C9550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 292 Patient: SMD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			11/02/93		01/04/93		27/04/93	
			value	(⊕)	value	(⊕)	value	(⊕)
Laboratory test	Range value	Range date						
HB	11-16 (G/DL)	01/02/93	14.40		14.20		14.40	
HT	36-47 (X)	01/02/93	40.50		42.30		41.10	
RBC	3.8-5.2 (10 ⁶ /MM ³)	01/02/93	4.92		4.13		4.38	
MBC	5000-9000 (/MM ³)	01/02/93	4700.00	<	5900.00		5700.00	<
MBC: N	53-75 (%)	01/02/93	62.00		61.00		38.00	<
MBC: L	25-40 (%)	01/02/93	33.00		32.00		54.00	>>
MBC: E	2-4 (%)	01/02/93	1.00	<	1.00	<	1.00	<
MBC: M	2-8 (%)	01/02/93	4.00		6.00		7.00	
MBC: B	0-1 (%)	01/02/93	0.00		0.00		0.00	
PLATELETS	150-300 (10 ³ /MM ³)	01/02/93	286.00		400.00	>>	190.00	
NA+	137-147 (MMOL/L)	01/02/93	145.00		136.00	<	142.00	
K+	3.6-5.5 (MMOL/L)	01/02/93	4.10		4.50		3.80	
CL-	101-111 (MEQ/L)	01/02/93	110.00		105.00		103.00	
Ca++	2.25-2.6 (MMOL/L)	01/02/93	2.22	<	2.38		2.40	
PO4--	0.8-1.6 (MMOL/L)	01/02/93	1.00		1.38		1.26	
SGOT	4-13 (U/L)	01/02/93	5.90		7.20		7.00	
SGPT	5-19 (U/L)	01/02/93	9.30		9.80		9.00	
GAMMA GT	4-18 (U/L)	01/02/93	27.60	>	20.70	>	18.30	>
LDH	80-240 (U/L)	01/02/93	156.00		148.00		186.00	
ALK. PHOSPH.	40-190 (U/L)	01/02/93	76.00		113.00		86.00	
GLUCOSE	70-115 (MG/DL)	01/02/93	99.00		90.00		97.00	
BUN	20-40 (MG/DL)	01/02/93	39.00		43.00	>	29.00	
CREATININE	0.6-1.1 (MG/DL)	01/02/93	0.92		0.79		0.77	
CREATININE CLEARANCE	75-160 (ML/MIN)	01/02/93	55.09					
URIC ACID	2.4-5.7 (MG/DL)	01/02/93	4.53		3.54		4.45	
TOT BILIRUBIN	0-1.1 (MG/DL)	01/02/93	0.74		0.99		0.41	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/02/93	0.11		0.05		0.27	>
TOT. PROTEINS	67-82 (G/L)	01/02/93	64.20	<	69.10		69.20	
ALBUMINE	31.2-51.5 (G/L)	01/02/93	45.90		43.12		45.60	
TOT. CHOLEST.	140-250 (MG/DL)	01/02/93	282.00	>	243.00		278.00	>
TRIGLYCERIDES	0-200 (MG/DL)	01/02/93	67.00		105.00		145.00	
GLOBULINS ALPHA 1	1.9-4.8 (G/L)	01/02/93	1.48	<	3.20		2.42	
GLOBULINS ALPHA 2	4.9-11.6 (G/L)	01/02/93	4.37	<	9.20		5.54	
GLOBULINS BETA	5.4-11 (G/L)	01/02/93	6.81		10.43		8.44	
GLOBULINS GAMMA	7.4-13.3 (G/L)	01/02/93	5.59	<	10.00		7.27	<
TSH	0.17-2.87 (MU/L)	01/02/93	1.65					
T4	48-120 (UG/L)	01/02/93	43.00					
ESR/SEDIMENT. RATE	0-10 (MM)	01/02/93						
1st h			11.00		8.00		7.00	
ESR/SEDIMENT. RATE	0-20 (MM)	01/02/93						
2nd h			22.00		21.00		19.00	

2313

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CN950089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 292 Patient: 6MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			11/02/93		01/04/93		28/04/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	11-16 (G/DL)	01/02/93	14.10		13.60		13.20	
HT	36-47 (%)	01/02/93	40.10		40.20		35.90 <	
RBC	3.8-5.2 (10 ⁶ /MM ³)	01/02/93	4.83		4.38		4.16	
WBC	5000-9000 (/MM ³)	01/02/93	5500.00		5700.00		7600.00	
WBC: N	53-75 (%)	01/02/93	61.00		55.00		65.00	
WBC: L	25-40 (%)	01/02/93	32.00		38.00		29.00	
WBC: E	2-4 (%)	01/02/93	1.00 <		2.00		2.00	
WBC: M	2-8 (%)	01/02/93	5.00		5.00		4.00	
WBC: B	0-1 (%)	01/02/93	1.00		0.00		0.00	
PLATELETS	150-300 (10 ³ /MM ³)	01/02/93	347.00 >		185.00		392.00 >>	
NA+	137-147 (MMOL/L)	01/02/93	143.00		142.00		140.00	
K+	3.6-5.5 (MMOL/L)	01/02/93	4.80		3.80		4.40	
CL-	101-111 (MMOL/L)	01/02/93	100.00 <		103.00		101.00	
Ca++	2.25-2.6 (MMOL/L)	01/02/93	2.38		2.40		2.38	
PO4--	0.8-1.6 (MMOL/L)	01/02/93	1.11		1.26		1.31	
SGOT	4-33 (U/L)	01/02/93	10.00		7.00		6.80	
SGPT	5-19 (U/L)	01/02/93	16.00		9.00		3.50 <	
GAMMA GT	4-18 (U/L)	01/02/93	13.30		18.30 >		6.60	
LDH	80-240 (U/L)	01/02/93	82.00		186.00		121.00	
ALK. PHOSPH.	40-190 (U/L)	01/02/93	128.00		86.00		81.00	
GLUCOSE	70-115 (MG/DL)	01/02/93	117.00 >		97.00		116.00 >	
BUN	20-40 (MG/DL)	01/02/93	49.00 >		29.00		29.00	
CREATININE	0.6-1.1 (MG/DL)	01/02/93	1.06		0.77		1.12 >	
CREATININE CLEARANCE	75-160 (ML/MIN)	01/02/93	53.83					
URIC ACID	2.4-5.7 (MG/DL)	01/02/93	7.85 >>		4.45		4.06	
TOT BILIRUBIN	0-1.1 (MG/DL)	01/02/93	0.38		0.41		0.60	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/02/93	0.05		0.05		0.07	
TOT. PROTEINS	67-82 (G/L)	01/02/93	72.70		71.00		71.20	
ALBUMINE	31.2-51.5 (G/L)	01/02/93	44.71		42.46		46.14	
TOT. CHOLEST.	140-250 (MG/DL)	01/02/93	319.00 >		278.00 >		266.00 >	
TRIGLYCERIDES	0-200 (MG/DL)	01/02/93	252.00 >		145.00		149.00	
GLOBULINS ALPHA 1	1.9-4.8 (G/L)	01/02/93	1.96		2.84		1.57 <	
GLOBULINS ALPHA 2	4.9-11.6 (G/L)	01/02/93	6.83		7.38		5.20	
GLOBULINS BETA	5.4-11 (G/L)	01/02/93	9.96		9.23		9.04	
GLOBULINS GAMMA	7.4-13.3 (G/L)	01/02/93	9.23		9.09		9.33	
TSH	0.17-2.87 (MU/L)	01/02/93	0.60					
T4	48-120 (UG/L)	01/02/93	68.00					
ESR/SEDIMENT. RATE 0-10 (MM) 1st h		01/02/93	9.00		10.00		12.00	
ESR/SEDIMENT. RATE 0-20 (MM) 2nd h		01/02/93	21.00		23.00		21.00	

2314

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN0550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 292 Patient: 7MD Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			29/03/93		18/05/93		15/06/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	28/03/93	13.50		13.40		13.90	
HT	40-54 (%)	28/03/93	37.70	<	37.80	<	38.60	
RBC	4.4-5.9 (10 ⁶ /MM ³)	28/03/93	4.54	<	4.35	<	4.54	
WBC	5000-9000 (/MM ³)	28/03/93	4500.00	<	5700.00	<	4100.00	
WBC: N	53-75 (%)	28/03/93	59.00	<	52.00	<	50.00	
WBC: L	25-40 (%)	28/03/93	28.00	>	40.00	>	41.00	
WBC: E	2-4 (%)	28/03/93	0.00	<	1.00	<	2.00	
WBC: M	2-8 (%)	28/03/93	12.00	>>	7.00	>	7.00	
WBC: B	0-1 (%)	28/03/93	0.00		0.00		0.00	
PLATELETS	150-300 (10 ³ /MM ³)	28/03/93	326.00	>	263.00	>	272.00	
NA+	137-147 (MMOL/L)	28/03/93	145.00		145.00		143.00	
K+	3.6-5.5 (MMOL/L)	28/03/93	4.50		5.00		4.30	
CL-	101-111 (MEQ/L)	28/03/93	106.00		105.00		104.00	
Ca++	2.25-2.6 (MMOL/L)	28/03/93	2.47		2.46		2.40	
PO4--	0.8-1.6 (MMOL/L)	28/03/93	1.07					
	2.5-4.8 (MG/DL)	17/05/93			3.05		2.64	
SGOT	5-17 (U/L)	28/03/93	6.90		15.90		12.20	
SGPT	5-23 (U/L)	28/03/93	5.50		19.00		14.30	
GAMMA GT	6-28 (U/L)	28/03/93	9.50		14.90		11.20	
LDH	80-240 (U/L)	28/03/93	124.00		190.00		226.00	
ALK. PHOSPH.	50-190 (U/L)	28/03/93	62.00		83.00		58.00	
GLUCOSE	70-115 (MG/DL)	28/03/93	104.00		93.00		89.00	
BUN	20-40 (MG/DL)	28/03/93	55.00	>	29.00	>	25.00	
CREATININE	0.7-1.3 (MG/DL)	28/03/93	1.08		0.82		0.87	
CREATININE CLEARANCE		28/03/93	60.63					
URIC ACID	3.4-7 (MG/DL)	28/03/93	5.95		4.18		3.50	
TOT BILIRUBIN	0-1.1 (MG/DL)	28/03/93	0.45		0.41		0.45	
DIR BILIRUBIN	0-0.25 (MG/DL)	28/03/93	0.10		0.07		0.06	
TOT. PROTEINS	67-82 (G/L)	28/03/93	76.20		72.10		70.60	
ALBUMINE	31.2-51.5 (G/L)	28/03/93	48.39		45.06		42.29	
TOT. CHOLEST.	140-250 (MGX)	28/03/93	290.00	>		>		
	140-250 (MG/DL)	17/05/93			205.00		263.00	
TRIGLYCERIDES	0-200 (MGX)	28/03/93	101.00					
	0-200 (MG/DL)	17/05/93			56.00		88.00	
GLOBULINS ALPHA 1	1.9-4.8 (G/L)	28/03/93	2.13		1.95		2.26	
GLOBULINS ALPHA 2	4.9-11.6 (G/L)	28/03/93	5.26		7.79		6.35	
GLOBULINS BETA	5.4-11 (G/L)	28/03/93	10.97		7.86		10.24	
GLOBULINS GAMMA	7.4-13.3 (G/L)	28/03/93	9.45		9.37		9.46	
TSH	0.17-2.87 (MU/L)	28/03/93	0.25					
T4	48-120 (UG/L)	28/03/93	95.00					
ESR/SEDIMENT. RATE	0-8 (MM)	28/03/93						
1st h			12.00		13.00		10.00	
ESR/SEDIMENT. RATE	0-16 (MM)	28/03/93						
2nd h			26.00		22.00		21.00	

2315

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNP 900089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 292 Patient: 8ND Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			02/04/93		19/05/93		17/06/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	01/04/93	13.70		13.80		13.20	
HT	40-54 (X)	01/04/93	39.00 <		39.70 <		36.90 <	
RBC	4.4-5.9 (10 ⁶ /MM ³)	01/04/93	4.30 <		4.07 <		4.20 <	
WBC	5000-9000 (/MM ³)	01/04/93	6100.00		4300.00 <		5400.00	
WBC: N	53-75 (X)	01/04/93	68.00		61.00		56.00	
WBC: L	25-40 (X)	01/04/93	23.00 <		30.00		36.00	
WBC: E	2-4 (X)	01/04/93	1.00 <		1.00 <		2.00	
WBC: M	2-8 (X)	01/04/93	8.00		7.00		6.00	
WBC: B	0-1 (X)	01/04/93	0.00		1.00		0.00	
PLATELETS	150-300 (10 ³ /MM ³)	01/04/93	283.00		152.00		201.00	
NA+	137-147 (MMOL/L)	01/04/93	140.00		142.00		147.00	
K+	3.6-5.5 (MMOL/L)	01/04/93	4.30		4.90		5.30	
CL-	101-111 (MMOL/L)	01/04/93	104.00		99.00 <		107.00	
Ca++	2.25-2.6 (MMOL/L)	01/04/93	2.36		2.41		2.26	
PO4--	0.8-1.6 (MMOL/L)	01/04/93	1.04		1.02			
	2.5-4.8 (MG/DL)	16/06/93					3.14	
SGOT	5-17 (U/L)	01/04/93	7.90		6.30		13.80	
SGPT	5-23 (U/L)	01/04/93	6.90		5.20		18.40	
GAMMA GT	6-28 (U/L)	01/04/93	6.20		7.40		32.40 >	
LDH	80-240 (U/L)	01/04/93	192.00		247.00 >		178.00	
ALK. PHOSPH.	50-190 (U/L)	01/04/93	65.00		80.00		130.00	
GLUCOSE	70-115 (MG/DL)	01/04/93	95.00		117.00 >		154.00 >>	
BUN	20-40 (MG/DL)	01/04/93	15.00 <		34.00		31.00	
CREATININE	0.7-1.3 (MG/DL)	01/04/93	1.05		1.12		0.98	
CREATININE CLEARANCE			59.52					
URIC ACID	3.4-7 (MG/DL)	01/04/93	4.34		4.98		4.22	
TOT BILIRUBIN	0-1.1 (MG/DL)	01/04/93	0.65		0.72		0.51	
DIR BILIRUBIN	0-0.25 (MG/DL)	01/04/93	0.12		0.11		0.12	
TOT. PROTEINS	67-82 (G/L)	01/04/93	68.40		78.20		69.20	
ALBUMINE	31.2-51.5 (G/L)	01/04/93	47.61		51.38		43.32	
TOT. CHOLEST.	140-250 (MG/DL)	01/04/93	163.00		254.00 >		237.00	
TRIGLYCERIDES	0-200 (MG/DL)	01/04/93	59.00		130.00		160.00	
GLOBULINS ALPHA 1	1.9-4.8 (G/L)	01/04/93	1.98		1.96		2.15	
GLOBULINS ALPHA 2	4.9-11.6 (G/L)	01/04/93	4.86 <		5.71		5.12	
GLOBULINS BETA	5.4-11 (G/L)	01/04/93	6.91		8.68		10.45	
GLOBULINS GAMMA	7.4-13.3 (G/L)	01/04/93	7.05 <		10.56		8.17	
TSH	0.17-2.87 (MU/L)	01/04/93	0.72					
T4	48-120 (UG/L)	01/04/93	61.00					
ESR/SEDIMENT. RATE 1st h	0-8 (MM)	01/04/93	8.00		6.00		5.00	
ESR/SEDIMENT. RATE 2nd h	0-16 (MM)	01/04/93	22.00		18.00		11.00	

2316

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA 03550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 292 Patient: 21MD Treatment: Imipranine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			30/04/93		04/06/93		02/07/93	
			value	(c)	value	(c)	value	(c)
Laboratory test	Range value	Range date						
HB	11-16 (G/DL)	29/04/93	14.10		14.58		14.80	
HT	36-47 (X)	29/04/93	38.90		39.40		41.60	
RBC	3.8-5.2 (10 ⁶ /MM ³)	29/04/93	4.36		4.77		4.61	
WBC	5000-9000 (/MM ³)	29/04/93	6400.00		8800.00		5300.00	
WBC: N	53-75 (X)	29/04/93	47.00	<	46.00	<	47.00	
WBC: L	25-40 (X)	29/04/93	44.00	>	43.00	>	42.00	
WBC: E	2-4 (X)	29/04/93	2.00		3.00		0.00	
WBC: M	2-8 (X)	29/04/93	7.00		8.00		9.00	
WBC: B	0-1 (X)	29/04/93	0.00		0.00		2.00	
PLATELETS	150-300 (10 ³ /MM ³)	29/04/93	290.00		237.00		201.00	
NA+	137-147 (MMOL/L)	29/04/93	145.00		142.00		147.00	
K+	3.6-5.5 (MMOL/L)	29/04/93	4.70		4.70		4.50	
CL-	101-111 (MEQ/L)	29/04/93	102.00		109.00		108.00	
Ca++	2.25-2.6 (MMOL/L)	29/04/93	2.77	>	2.47		2.41	
PO4--	2.5-4.8 (MG/DL)	29/04/93	2.77		3.71		3.65	
SGOT	4-13 (U/L)	29/04/93	9.10		6.70		7.90	
SGPT	5-19 (U/L)	29/04/93	11.60		7.50		12.50	
GAMMA GT	4-18 (U/L)	29/04/93	31.10	>	9.10		15.10	
LDH	80-240 (U/L)	29/04/93	121.00		83.00		158.00	
ALK. PHOSPH.	40-190 (U/L)	29/04/93	122.00		88.00		116.00	
GLUCOSE	70-115 (MG/DL)	29/04/93	106.00		106.00		96.00	
BUN	20-40 (MG/DL)	29/04/93	40.00		28.00		33.00	
CREATININE	0.6-1.1 (MG/DL)	29/04/93	0.98		1.10		1.28	
CREATININE CLEARANCE	75-160 (ML/MIN)	29/04/93	64.37					
URIC ACID	2.4-5.7 (MG/DL)	29/04/93	7.72	>>	4.63		6.35	
TOT BILIRUBIN	0-1.1 (MG/DL)	29/04/93	0.56		1.17	>	0.66	
DIR BILIRUBIN	0-0.25 (MG/DL)	29/04/93	0.04		0.18		0.12	
TOT. PROTEINS	67-82 (G/L)	29/04/93	75.40		71.30		71.10	
ALBUMINE	31.2-51.5 (G/L)	29/04/93	49.31		44.28		45.10	
TOT. CHOLEST.	140-250 (MG/DL)	29/04/93	228.00		268.00	>	259.00	
TRIGLYCERIDES	0-200 (MG/DL)	29/04/93	141.00		122.00		174.00	
GLOBULINS ALPHA 1	1.9-4.8 (G/L)	29/04/93	1.58	<	2.50		2.29	
GLOBULINS ALPHA 2	4.9-11.6 (G/L)	29/04/93	4.45	<	7.20		5.66	
GLOBULINS BETA	5.4-11 (G/L)	29/04/93	9.35		10.27		10.68	
GLOBULINS GAMMA	7.4-13.3 (G/L)	29/04/93	10.63		7.06	<	7.96	
TSH	0.17-2.87 (MU/L)	29/04/93	0.58					
T4	48-120 (UG/L)	29/04/93	64.00					
ESR/SEDIMENT. RATE	0-10 (MM)	29/04/93						
1st h			8.00		6.00		10.00	
ESR/SEDIMENT. RATE	0-20 (MM)	29/04/93						
2nd h			19.00		17.00		18.00	

2317

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C0550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 292 Patient: 22MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			05/05/93		16/06/93		14/07/93	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	11-16 (G/DL)	04/05/93	13.30		14.10		14.60	
HT	36-47 (Z)	04/05/93	36.70		39.40		41.70	
RBC	3.8-5.2 (10 ⁶ /MM ³)	04/05/93	4.10		4.32		5.19	
WBC	5000-9000 (/MM ³)	04/05/93	4500.00	<	8700.00		4400.00	<
WBC: N	53-75 (Z)	04/05/93	49.00	<	55.00		51.00	<
WBC: L	25-40 (Z)	04/05/93	41.00	>	34.00		38.00	
WBC: E	2-4 (Z)	04/05/93	3.00		2.00		2.00	
WBC: M	2-8 (Z)	04/05/93	7.00		9.00	>	8.00	
WBC: B	0-1 (Z)	04/05/93	0.00		0.00		1.00	
PLATELETS	150-300 (10 ³ /MM ³)	04/05/93	248.00		247.00		278.00	>
NA+	137-147 (MMOL/L)	04/05/93	142.00		142.00		148.00	>
K+	3.6-5.5 (MMOL/L)	04/05/93	5.30		4.40		4.50	
CL-	101-111 (MEQ/L)	04/05/93	101.00		101.00		107.00	
Ca++	2.25-2.6 (MMOL/L)	04/05/93	2.44		2.53		2.47	
PO4--	2.5-4.8 (MG/DL)	04/05/93	2.70		2.11	<<	2.97	
SGOT	4-13 (U/L)	04/05/93	11.00		8.10		9.00	
SGPT	5-19 (U/L)	04/05/93	15.60		14.30		8.50	
GAMMA GT	4-18 (U/L)	04/05/93	8.20		23.10	>	12.90	
LDH	80-240 (U/L)	04/05/93	147.00		146.00		154.00	
ALK. PHOSPH.	40-190 (U/L)	04/05/93	82.00		92.00		106.00	
GLUCOSE	70-115 (MG/DL)	04/05/93	104.00		104.00		108.00	
BUN	20-40 (MG/DL)	04/05/93	42.00	>	40.00		41.00	>
CREATININE	0.6-1.1 (MG/DL)	04/05/93	1.09		1.26	>	1.28	>
CREATININE CLEARANCE	75-160 (ML/MIN)	04/05/93	56.10					
URIC ACID	2.4-5.7 (MG/DL)	04/05/93	4.19		7.45	>>	6.20	>
TOT BILIRUBIN	0-1.1 (MG/DL)	04/05/93	0.52		0.56		0.66	
DIR BILIRUBIN	0-0.25 (MG/DL)	04/05/93	0.05		0.07		0.12	
TOT. PROTEINS	67-82 (G/L)	04/05/93	74.20		74.40		76.80	
ALBUMINE	31.2-51.5 (G/L)	04/05/93	48.23		47.47		51.46	
TOT. CHOLEST.	140-250 (MG/DL)	04/05/93	215.00		218.00		233.00	
TRIGLYCERIDES	0-200 (MG/DL)	04/05/93	194.00		148.00		112.00	
GLOBULINS ALPHA 1	1.9-4.8 (G/L)	04/05/93	1.78	<	2.01		2.15	
GLOBULINS ALPHA 2	4.9-11.6 (G/L)	04/05/93	5.34		6.77		5.07	
GLOBULINS BETA	5.4-11 (G/L)	04/05/93	8.61		10.64		10.52	
GLOBULINS GAMMA	7.4-13.3 (G/L)	04/05/93	10.17		7.51		7.68	
TSH	0.17-2.87 (MU/L)	04/05/93	1.13					
T4	48-120 (UG/L)	04/05/93	89.00					
ESR/SEDIMENT. RATE	0-10 (MM)	04/05/93						
1st h			11.00		8.00		11.00	
ESR/SEDIMENT. RATE	0-20 (MM)	04/05/93						
2nd h			21.00		19.00		21.00	

2318

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN 5310089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 292 Patient: 23MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			10/05/93		23/06/93		21/07/93	
			value	(#)	value	(#)	value	(#)
Laboratory test	Range value	Range date						
HB	11-16 (G/DL)	09/05/93	14.00		14.50		14.70	
HT	36-47 (%)	09/05/93	38.50		40.30		40.90	
RBC	3.8-5.2 (10 ⁶ /MM ³)	09/05/93	4.34		4.73		4.72	
WBC	5000-9000 (/MM ³)	09/05/93	6300.00		6100.00		6100.00	
WBC: N	53-75 (%)	09/05/93	57.00		55.00		59.00	
WBC: L	25-40 (%)	09/05/93	33.00		36.00		33.00	
WBC: E	2-4 (%)	09/05/93	2.00		1.00	<	2.00	
WBC: M	2-8 (%)	09/05/93	8.00		8.00		6.00	
WBC: B	0-1 (%)	09/05/93	0.00		1.00		0.00	
PLATELETS	150-300 (10 ³ /MM ³)	09/05/93	222.00		230.00		226.00	
NA+	137-147 (MMOL/L)	09/05/93	147.00		139.00		143.00	
K+	3.6-5.5 (MMOL/L)	09/05/93	4.40		4.40		4.70	
CL-	101-111 (MMOL/L)	09/05/93	108.00		102.00		102.00	
Ca++	2.25-2.6 (MMOL/L)	09/05/93	2.26		2.44		2.42	
PO4--	2.5-4.8 (MG/DL)	09/05/93	3.04		3.15		2.58	
SGOT	4-13 (U/L)	09/05/93	11.20		8.00		8.40	
SGPT	5-19 (U/L)	09/05/93	11.00		8.50		10.60	
GAMMA GT	4-18 (U/L)	09/05/93	4.60		4.90		11.80	
LDH	80-240 (U/L)	09/05/93	213.00		174.00		156.00	
ALK. PHOSPH.	40-190 (U/L)	09/05/93	79.00		96.00		85.00	
GLUCOSE	70-115 (MG/DL)	09/05/93	110.00		95.00		127.00 >	
BUN	20-40 (MG/DL)	09/05/93	43.00 >		36.00		39.00	
CREATININE	0.6-1.1 (MG/DL)	09/05/93	1.07		0.93		1.25 >	
CREATININE CLEARANCE	75-160 (ML/MIN)	09/05/93	52.02					
URIC ACID	2.4-5.7 (MG/DL)	09/05/93	3.68		3.92		5.45	
TOT BILIRUBIN	0-1.1 (MG/DL)	09/05/93	0.33		0.85		0.66	
DIR BILIRUBIN	0-0.25 (MG/DL)	09/05/93	0.02		0.20		0.12	
TOT. PROTEINS	67-82 (G/L)	09/05/93	71.20		74.80		71.90	
ALBUMIN	31.2-51.5 (G/L)	09/05/93	43.22		50.64		43.86	
TOT. CHOLEST.	140-250 (MG/DL)	09/05/93	237.00		264.00 >		220.00	
TRIGLYCERIDES	0-200 (MG/DL)	09/05/93	121.00		102.00		118.00	
GLOBULINS ALPHA 1	1.9-4.8 (G/L)	09/05/93	2.06		1.80 <		2.09	
GLOBULINS ALPHA 2	4.9-11.6 (G/L)	09/05/93	5.48		5.91		7.19	
GLOBULINS BETA	5.4-11 (G/L)	09/05/93	8.90		9.50		11.43 >	
GLOBULINS GAMMA	7.4-13.3 (G/L)	09/05/93	11.53		6.88 <		7.33 <	
TSH	0.17-2.87 (MU/L)	09/05/93	0.52					
T4	48-120 (UG/L)	09/05/93	70.00					
ESR/SEDIMENT. RATE 0-10 (MM)		09/05/93						
1st h			12.00		10.00		9.00	
ESR/SEDIMENT. RATE 0-20 (MM)		09/05/93						
2nd h			21.00		23.00		21.00	

2319

(#) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C3510089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 292 Patient: 24ND Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			28/05/93		02/07/93		30/07/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	27/05/93	15.20		15.50		15.80	
HT	40-54 (X)	27/05/93	42.90		42.90		43.60	
RBC	4.4-5.9 (10 ⁶ /MM ³)	27/05/93	5.13		4.72		4.75	
WBC	5000-9000 (/MM ³)	27/05/93	6800.00		7600.00		7600.00	
WBC: N	53-75 (%)	27/05/93	61.00		62.00		54.00	
WBC: L	25-40 (%)	27/05/93	30.00		28.00		36.00	
WBC: E	2-4 (%)	27/05/93	2.00		3.00		3.00	
WBC: M	2-8 (%)	27/05/93	7.00		7.00		7.00	
WBC: B	0-1 (%)	27/05/93	0.00		0.00		0.00	
PLATELETS	150-300 (10 ³ /MM ³)	27/05/93	268.00		249.00		265.00	
NA+	137-147 (MMOL/L)	27/05/93	147.00		145.00		144.00	
K+	3.6-5.5 (MMOL/L)	27/05/93	4.20		4.20		4.10	
CL-	101-111 (MEQ/L)	27/05/93	99.00 <		101.00		103.00	
Ca++	2.25-2.6 (MMOL/L)	27/05/93	2.41		2.51		2.57	
PO4--	2.5-4.8 (MG/DL)	27/05/93	3.21		3.03		2.39 <	
SGOT	5-17 (U/L)	27/05/93	10.50		7.70		10.90	
SGPT	5-23 (U/L)	27/05/93	7.50		15.00		17.40	
GAMMA GT	6-28 (U/L)	27/05/93	8.50		11.60		20.10	
LDH	80-240 (U/L)	27/05/93	186.00		135.00		149.00	
ALK. PHOSPH.	50-190 (U/L)	27/05/93	91.00		116.00		108.00	
GLUCOSE	70-115 (MG/DL)	27/05/93	94.00		80.00		111.00	
BUN	20-40 (MG/DL)	27/05/93	42.00 >		35.00		31.00	
CREATININE	0.7-1.3 (MG/DL)	27/05/93	0.89		1.05		1.30	
CREATININE CLEARANCE	75-160 (ML/MIN)	27/05/93	94.13					
URIC ACID	3.4-7 (MG/DL)	27/05/93	6.11		5.19		4.12	
TOT BILIRUBIN	0-1.1 (MG/DL)	27/05/93	0.60		0.46		0.64	
DIR BILIRUBIN	0-0.25 (MG/DL)	27/05/93	0.08		0.11		0.06	
TOT. PROTEINS	67-82 (G/L)	27/05/93	72.60		71.50		78.20	
ALBUMINE	31.2-51.5 (G/L)	27/05/93	47.77		47.55		50.05	
TOT. CHOLEST.	140-250 (MG/DL)	27/05/93	231.00		206.00		230.00	
TRIGLYCERIDES	0-200 (MG/DL)	27/05/93	99.00		88.00		78.00	
GLOBULINS ALPHA 1	1.9-4.8 (G/L)	27/05/93	1.96		2.72		2.03	
GLOBULINS ALPHA 2	4.9-11.6 (G/L)	27/05/93	5.52		5.79		5.47	
GLOBULINS BETA	5.4-11 (G/L)	27/05/93	8.35		8.37		10.79	
GLOBULINS GAMMA	7.4-13.3 (G/L)	27/05/93	9.00		7.08 <		9.85	
TSH	0.17-2.87 (MU/L)	27/05/93	0.10					
T4	48-120 (UG/L)	27/05/93	88.00					
ESR/SEDIMENT. RATE 0-8 (MM)		27/05/93						
1st h			8.00		6.00		8.00	
ESR/SEDIMENT. RATE 0-16 (MM)		27/05/93						
2nd h			14.00		15.00		16.00	

2320

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C 558089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 292 Patient: SDT Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			12/02/93		01/04/93		29/04/93	
			value	(*)	value	(*)	value	(*)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	11/02/93	15.50		14.70		14.60	
HT	40-54 (X)	11/02/93	42.90		42.60		40.50	
RBC	4.4-5.9 (10 ⁶ /MM ³)	11/02/93	4.85		5.10		4.38 <	
WBC	5000-9000 (/MM ³)	11/02/93	5600.00		4610.00 <		9600.00 >	
	5000-9000 (/MM ³)	28/04/93						
WBC: N	53-75 (X)	11/02/93	45.00 <		60.00		63.00	
WBC: L	25-40 (X)	11/02/93	46.00 >		30.00		28.00	
WBC: E	2-4 (X)	11/02/93	2.00		2.00		3.00	
WBC: M	2-8 (X)	11/02/93	7.00		8.00		6.00	
WBC: B	0-1 (X)	11/02/93	0.00		0.00		0.00	
PLATELETS	150-300 (10 ³ /MM ³)	11/02/93	246.00		262.00		276.00	
NA+	137-147 (MMOL/L)	11/02/93	144.00		141.00		140.00	
K+	3.6-5.5 (MMOL/L)	11/02/93	4.30		4.40		4.60	
CL-	101-111 (MMOL/L)	11/02/93	108.00		100.00 <		105.00	
Ca++	2.25-2.6 (MMOL/L)	11/02/93	2.24 <		2.31		2.40	
PO4--	0.8-1.6 (MMOL/L)	11/02/93	0.91		1.02			
	2.5-4.8 (MG/DL)	28/04/93					3.80	
SGOT	5-17 (U/L)	11/02/93	10.70		8.00		7.40	
SGPT	5-23 (U/L)	11/02/93	17.70		10.40		8.30	
GAMMA GT	6-28 (U/L)	11/02/93	37.30 >		8.20		8.30	
LDH	80-240 (U/L)	11/02/93	135.00		192.00		201.00	
ALK. PHOSPH.	50-190 (U/L)	11/02/93	67.00		98.00		107.00	
GLUCOSE	70-115 (MG/DL)	11/02/93	116.00 >		113.00		97.00	
BUN	20-40 (MG/DL)	11/02/93	52.00 >		39.00		37.00	
CREATININE	0.7-1.3 (MG/DL)	11/02/93	1.27		0.77		0.82	
CREATININE CLEARANCE	75-160 (ML/MIN)	11/02/93	54.23					
URIC ACID	3.4-7 (MG/DL)	11/02/93	7.91 >		3.34 <		3.16 <	
TOT BILIRUBIN	0-1.1 (MG/DL)	11/02/93	1.04		0.23		0.37	
DIR BILIRUBIN	0-0.25 (MG/DL)	11/02/93	0.21		0.06		0.06	
TOT. PROTEINS	67-82 (G/L)	11/02/93	69.20		68.90		71.20	
ALBUMINE	31.2-51.5 (G/L)	11/02/93	43.94		45.82		44.93	
TOT. CHOLEST.	140-250 (MG/DL)	11/02/93	225.00		247.00		255.00 >	
TRIGLYCERIDES	0-200 (MG/DL)	11/02/93	189.00		124.00		68.00	
GLOBULINS ALPHA 1	1.9-4.8 (G/L)	11/02/93	1.59 <		2.20		3.20	
GLOBULINS ALPHA 2	4.9-11.6 (G/L)	11/02/93	4.71 <		5.17		7.12	
GLOBULINS BETA	5.4-11 (G/L)	11/02/93	9.96		8.75		7.76	
GLOBULINS GAMMA	7.4-13.3 (G/L)	11/02/93	9.50		6.96 <		8.19	
TSH	0.17-2.87 (MU/L)	11/02/93	0.43					
T4	48-120 (UG/L)	11/02/93	73.00					
ESR/SEDIMENT. RATE	0-8 (MM)	11/02/93						
1st h			9.00		12.00		10.00	
ESR/SEDIMENT. RATE	0-16 (MM)	11/02/93						
2nd h			19.00		24.00		26.00	

2321

(*) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C9550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 292 Patient: 6DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			16/02/93		13/04/93		10/05/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	11-16 (G/DL)	15/02/93	14.20		13.50		13.30	
HT	36-47 (X)	15/02/93	39.50		42.50		37.30	
RBC	3.8-5.2 (10 ⁶ /MM ³)	15/02/93	4.66		4.54		4.52	
WBC	5000-9000 (/MM ³)	15/02/93	4900.00	<	4500.00	<	6500.00	
WBC: N	53-75 (%)	15/02/93	46.00	<	55.00		53.00	
WBC: L	25-40 (%)	15/02/93	45.00	>	37.00		37.00	
WBC: E	2-4 (%)	15/02/93	3.00		0.00	<	2.00	
WBC: M	2-8 (%)	15/02/93	6.00		8.00		8.00	
WBC: B	0-1 (%)	15/02/93	0.00		0.00		0.00	
PLATELETS	150-300 (10 ³ /MM ³)	15/02/93	257.00		284.00		337.00 >	
NA+	137-147 (MMOL/L)	15/02/93	143.00		145.00		139.00	
K+	3.6-5.5 (MMOL/L)	15/02/93	5.10		4.50		4.40	
CL-	101-111 (MEQ/L)	15/02/93	108.00		106.00		101.00	
Ca++	2.25-2.6 (MMOL/L)	15/02/93	2.41		2.47		2.30	
PO4--	0.8-1.6 (MMOL/L)	15/02/93	1.17		1.07			
	2.5-4.8 (MG/DL)	09/05/93					3.29	
SGOT	4-13 (U/L)	15/02/93	7.20		6.90		8.10	
SGPT	5-19 (U/L)	15/02/93	7.20		5.50		5.30	
GAMMA GT	4-18 (U/L)	15/02/93	13.10		9.50		6.90	
LDH	80-240 (U/L)	15/02/93	152.00		124.00		168.00	
ALK. PHOSPH.	40-190 (U/L)	15/02/93	103.00		62.00		48.00	
GLUCOSE	70-115 (MG/DL)	15/02/93	103.00		106.00		97.00	
BUN	20-40 (MG/DL)	15/02/93	41.00	>	47.00	>	23.00	
CREATININE	0.6-1.1 (MG/DL)	15/02/93	1.06		1.08		0.99	
CREATININE CLEARANCE			62.48					
URIC ACID	2.4-5.7 (MG/DL)	15/02/93	4.28		5.95	>	4.87	
TOT BILIRUBIN	0-1.1 (MG/DL)	15/02/93	0.50		0.45		0.36	
DIR BILIRUBIN	0-0.25 (MG/DL)	15/02/93	0.10				0.08	
TOT. PROTEINS	67-82 (G/L)	15/02/93	70.90		78.10		73.00	
ALBUMINE	31.2-51.5 (G/L)	15/02/93	44.67		46.08		47.01	
TOT. CHOLEST.	140-250 (MG/DL)	15/02/93	301.00	>	290.00	>	261.00 >	
TRIGLYCERIDES	0-200 (MG/DL)	15/02/93	119.00		101.00		57.00	
GLOBULINS ALPHA 1	1.9-4.8 (G/L)	15/02/93	1.99		2.42		2.07	
GLOBULINS ALPHA 2	4.9-11.6 (G/L)	15/02/93	5.10		7.65		5.90	
GLOBULINS BETA	5.4-11 (G/L)	15/02/93	8.79		10.23		8.63	
GLOBULINS GAMMA	7.4-13.3 (G/L)	15/02/93	10.35		11.64		10.11	
TSH	0.17-2.87 (MU/L)	15/02/93	0.67					
T4	48-120 (UG/L)	15/02/93	85.00					
ESR/SEDIMENT. RATE	0-10 (MM)	15/02/93	12.00		10.00		8.00	
1st h								
ESR/SEDIMENT. RATE	0-20 (MM)	15/02/93	21.00		19.00		21.00	
2nd h								

2322

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN9180089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 292 Patient: 7DT Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			16/02/93		15/04/93		13/05/93	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	15/02/93	13.20		12.90 <	12.80 <		
HT	40-54 (X)	15/02/93	38.80 <		38.90 <	36.10 <		
RBC	4.4-5.9 (10 ⁶ /MM ³)	15/02/93	4.62		5.21	4.03 <		
HBC	5000-9000 (/MM ³)	15/02/93	7900.00		6400.00	5000.00		
HBC: N	53-75 (X)	15/02/93	62.00		54.00	56.00		
HBC: L	25-40 (X)	15/02/93	32.00		40.00	35.00		
HBC: E	2-4 (X)	15/02/93	1.00 <		0.00 <	1.00 <		
HBC: M	2-8 (X)	15/02/93	4.00		6.00	8.00		
HBC: B	0-1 (X)	15/02/93	1.00		0.00	0.00		
PLATELETS	150-300 (10 ³ /MM ³)	15/02/93	215.00		224.00	348.00 >		
NA+	137-147 (MMOL/L)	15/02/93	144.00		144.00	144.00		
K+	3.6-5.5 (MMOL/L)	15/02/93	4.20		3.60	4.40		
CL-	101-111 (MEQ/L)	15/02/93	105.00		93.00 <	103.00		
Ca++	2.25-2.6 (MMOL/L)	15/02/93	2.37		2.36	2.39		
PO4--	0.8-1.6 (MMOL/L)	15/02/93	1.27		1.00			
	2.5-4.8 (MG/DL)	12/05/93				3.50		
SGOT	5-17 (U/L)	15/02/93	9.30		12.10	7.50		
SGPT	5-23 (U/L)	15/02/93	10.30		14.00	8.60		
GAMMA GT	6-28 (U/L)	15/02/93	20.70		4.90 <	9.00		
LDH	80-240 (U/L)	15/02/93	141.00		285.00 >	147.00		
ALK. PHOSPH.	50-190 (U/L)	15/02/93	81.00		122.00	115.00		
GLUCOSE	70-115 (MG/DL)	15/02/93	102.00		128.00 >	128.00 >		
BUN	20-40 (MG/DL)	15/02/93	48.00 >		40.00	32.00		
CREATININE	0.7-1.3 (MG/DL)	15/02/93	1.03		0.81	0.91		
CREATININE CLEARANCE			70.20					
URIC ACID	3.4-7 (MG/DL)	15/02/93	5.40		6.03	4.38		
TOT BILIRUBIN	0-1.1 (MG/DL)	15/02/93	0.71		0.53	0.32		
DIR BILIRUBIN	0-0.25 (MG/DL)	15/02/93	0.05		0.05	0.11		
TOT. PROTEINS	67-82 (G/L)	15/02/93	72.60		70.20	76.20		
ALBUMINE	31.2-51.5 (G/L)	15/02/93	44.60		44.93	46.86		
TOT. CHOLEST.	140-250 (MG/DL)	15/02/93	307.00 >		261.00 >	301.00 >		
TRIGLYCERIDES	0-200 (MG/DL)	15/02/93	260.00 >		242.00 >	183.00		
GLOBULINS ALPHA 1	1.9-4.8 (G/L)	15/02/93	2.65		1.97	2.29		
GLOBULINS ALPHA 2	4.9-11.6 (G/L)	15/02/93	5.81		5.76	5.87		
GLOBULINS BETA	5.4-11 (G/L)	15/02/93	10.75		7.79	9.98		
GLOBULINS GAMMA	7.4-13.3 (G/L)	15/02/93	9.79		9.76	11.28		
TSH	0.17-2.87 (MU/L)	15/02/93	0.70					
T4	48-120 (UG/L)	15/02/93	81.00					
ESR/SEDIMENT. RATE 1st h	0-8 (MM)	15/02/93	11.00		9.00	7.00		
ESR/SEDIMENT. RATE 2nd h	0-16 (MM)	15/02/93	21.00		18.00	20.00		

2323

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN0950089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 292 Patient: 8DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			16/03/93		06/05/93		03/06/93	
			value	(⊕)	value	(⊕)	value	(⊕)
Laboratory test	Range value	Range date						
HB	11-16 (G/DL)	15/03/93	13.50		13.40		13.70	
HT	36-47 (%)	15/03/93	38.30		37.40		38.90	
RBC	3.8-5.2 (10 ⁶ /MM ³)	15/03/93	4.57		4.24		4.56	
WBC	5000-9000 (/MM ³)	15/03/93	5900.00		5700.00		4900.00 <	
WBC: N	53-75 (%)	15/03/93	51.00 <		51.00 <		44.00 <	
WBC: L	25-40 (%)	15/03/93	42.00 >		40.00		47.00 >	
WBC: E	2-4 (%)	15/03/93	2.00		1.00 <		2.00	
WBC: M	2-8 (%)	15/03/93	5.00		7.00		7.00	
WBC: B	0-1 (%)	15/03/93	0.00		1.00		0.00	
PLATELETS	150-300 (10 ³ /MM ³)	15/03/93	204.00		243.00		241.00	
NA+	137-147 (MMOL/L)	15/03/93	145.00		146.00		144.00	
K+	3.6-5.5 (MMOL/L)	15/03/93	4.60		4.10		4.20	
CL-	101-111 (MEQ/L)	15/03/93	112.00 >		105.00		103.00	
Ca++	2.25-2.6 (MMOL/L)	15/03/93	2.45		2.43		2.24 <	
PO4--	0.8-1.6 (MMOL/L)	15/03/93	1.32				1.09	
	2.5-4.8 (MG/DL)	05/05/93			3.14			
SGOT	4-43 (U/L)	15/03/93	8.00		8.20		11.10	
SGPT	5-19 (U/L)	15/03/93	6.90		8.30		19.20 >	
GAMMA GT	4-18 (U/L)	15/03/93	9.80		10.20		23.30 >	
LDH	80-240 (U/L)	15/03/93	163.00		183.00		91.00	
ALK. PHOSPH.	40-190 (U/L)	15/03/93	200.00 >		82.00		79.00	
GLUCOSE	70-115 (MG/DL)	15/03/93	98.00		99.00		87.00	
BUN	20-40 (MG/DL)	15/03/93	51.00 >		33.00		35.00	
CREATININE	0.6-1.1 (MG/DL)	15/03/93	0.99		1.14 >		1.10	
CREATININE CLEARANCE			57.09					
URIC ACID	2.4-5.7 (MG/DL)	15/03/93	3.79		6.59 >		5.68	
TOT BILIRUBIN	0-1.1 (MG/DL)	15/03/93	0.93		0.61		0.62	
DIR BILIRUBIN	0-0.25 (MG/DL)	15/03/93	0.19		0.05		0.15	
TOT. PROTEINS	67-82 (G/L)	15/03/93	70.10		75.80		72.90	
ALBUMINE	31.2-51.5 (G/L)	15/03/93	43.53		46.47		47.75	
TOT. CHOLEST.	140-250 (MG/DL)	15/03/93	180.00		200.00		184.00	
TRIGLYCERIDES	0-200 (MG/DL)	15/03/93	117.00		113.00		163.00	
GLOBULINS ALPHA 1	1.9-4.8 (G/L)	15/03/93	1.82 <		2.12		1.82 <	
GLOBULINS ALPHA 2	4.9-11.6 (G/L)	15/03/93	8.20		5.91		4.45 <	
GLOBULINS BETA	5.4-11 (G/L)	15/03/93	7.99		9.17		8.68	
GLOBULINS GAMMA	7.4-13.3 (G/L)	15/03/93	8.55		12.13		10.21	
TSH	0.17-2.87 (MU/L)	15/03/93	0.88					
T4	48-120 (UG/L)	15/03/93	91.00					
ESR/SEDIMENT. RATE	0-10 (MM)	15/03/93						
1st h			9.00					
ESR/SEDIMENT. RATE	0-20 (MM)	15/03/93						
2nd h			23.00					

2324

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARNACIA CN9550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 292 Patient: 21DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			30/04/93		01/06/93		28/06/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	11-16 (G/DL)	29/04/93	13.20		13.00		13.30	
HT	36-47 (%)	29/04/93	37.00		36.40		37.20	
RBC	3.8-5.2 (10 ⁶ /MM ³)	29/04/93	3.98		4.32		4.09	
WBC	5000-9000 (/MM ³)	29/04/93	4700.00 <		4200.00 <		3600.00 <	
WBC: N	53-75 (%)	29/04/93	53.00		41.00 <		41.00 <	
WBC: L	25-40 (%)	29/04/93	40.00		45.00 >		48.00 >	
WBC: E	2-4 (%)	29/04/93	3.00		2.00		1.00 <	
WBC: M	2-8 (%)	29/04/93	4.00		12.00 >>		10.00 >	
WBC: B	0-1 (%)	29/04/93	0.00		0.00		1.00	
PLATELETS	150-300 (10 ³ /MM ³)	29/04/93	304.00 >		241.00		208.00	
NA+	137-147 (MMOL/L)	29/04/93	143.00		144.00		141.00	
K+	3.6-5.5 (MMOL/L)	29/04/93	4.60		4.80		3.90	
CL-	101-111 (MMOL/L)	29/04/93	96.00 <		100.00 <		101.00	
Ca++	2.25-2.6 (MMOL/L)	29/04/93	2.53		2.34		2.35	
PO4--	0.8-1.6 (MMOL/L)	29/04/93	1.52					
	2.5-4.8 (NG/DL)	01/06/93			3.29		3.02	
SGOT	4-13 (U/L)	29/04/93	6.30		6.30		11.10	
SGPT	5-19 (U/L)	29/04/93	7.70		7.40		13.90	
GAMMA GT	4-18 (U/L)	29/04/93	7.30		5.20		18.90 >	
LDH	80-240 (U/L)	29/04/93	102.00		129.00		204.00	
ALK. PHOSPH.	40-190 (U/L)	29/04/93	96.00		69.00		136.00	
GLUCOSE	70-115 (MG/DL)	29/04/93	90.00		113.00		99.00	
BUN	20-40 (MG/DL)	29/04/93	37.00		37.00		41.00 >	
CREATININE	0.6-1.1 (MG/DL)	29/04/93	1.14 >		0.90		0.96	
CREATININE CLEARANCE		29/04/93	49.90					
URIC ACID	2.4-5.7 (MG/DL)	29/04/93	5.05		4.51		5.83 >	
TOT BILIRUBIN	0-1.1 (MG/DL)	29/04/93	1.28 >		0.51		0.38	
DIR BILIRUBIN	0-0.25 (MG/DL)	29/04/93	0.06		0.09		0.17	
TOT. PROTEINS	67-82 (G/L)	29/04/93	73.90		72.90		68.40	
ALBUMINE	31.2-51.5 (G/L)	29/04/93	49.73		50.67		41.86	
TOT. CHOLEST.	140-250 (MG/DL)	29/04/93	218.00		279.00 >		261.00 >	
TRIGLYCERIDES	0-200 (MG/DL)	29/04/93	125.00		142.00		93.00	
GLOBULINS ALPHA 1	1.9-4.8 (G/L)	29/04/93	1.18 <<		1.90		2.80	
GLOBULINS ALPHA 2	4.9-11.6 (G/L)	29/04/93	4.66 <		4.81 <		5.27	
GLOBULINS BETA	5.4-11 (G/L)	29/04/93	7.46		8.53		9.03	
GLOBULINS GAMMA	7.4-13.3 (G/L)	29/04/93	10.72		7.00 <		9.44	
TSH	0.17-2.87 (MU/L)	29/04/93	0.90					
T4	48-120 (UG/L)	29/04/93	55.00					
ESR/SEDIMENT. RATE	0-10 (MM)	29/04/93						
1st h			14.00		10.00		10.00	
ESR/SEDIMENT. RATE	0-20 (MM)	29/04/93						
2nd h			24.00		22.00		22.00	

2325

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CN 580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 292 Patient: 22DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			30/04/93		01/06/93		29/06/93	
			value	(†)	value	(†)	value	(†)
Laboratory test	Range value	Range date						
HB	11-16 (G/DL)	29/04/93	14.40		14.90		14.80	
HT	36-47 (Z)	29/04/93	39.90		42.20		41.20	
RBC	3.8-5.2 (10 ⁶ /MM ³)	29/04/93	4.31		4.48		4.70	
WBC	5000-9000 (/MM ³)	29/04/93	6000.00		8300.00		4500.00	<
WBC: N	53-75 (%)	29/04/93	56.00		55.00		58.00	
WBC: L	25-40 (%)	29/04/93	35.00		38.00		35.00	<
WBC: E	2-4 (%)	29/04/93	3.00		1.00	<	1.00	<
WBC: M	2-8 (%)	29/04/93	6.00		6.00		6.00	
WBC: B	0-1 (%)	29/04/93	0.00		0.00		0.00	
PLATELETS	150-300 (10 ³ /MM ³)	29/04/93	194.00		207.00		224.00	
NA+	137-147 (MMOL/L)	29/04/93	146.00		145.00		144.00	
K+	3.6-5.5 (MMOL/L)	29/04/93	4.90		4.20		4.20	
CL-	101-111 (MEQ/L)	29/04/93	105.00		104.00		105.00	
Ca++	2.25-2.6 (MMOL/L)	29/04/93	2.63	>	2.38		2.20	<
PO4--	2.5-4.8 (MG/DL)	29/04/93	2.29	<	2.52		2.94	
SGOT	4-13 (U/L)	29/04/93	10.60		11.10		9.10	
SGPT	5-19 (U/L)	29/04/93	10.70		17.90		10.30	
GAMMA GT	4-18 (U/L)	29/04/93	18.20	>	21.50	>	20.30	>
LDH	80-240 (U/L)	29/04/93	106.00		159.00		137.00	
ALK. PHOSPH.	40-190 (U/L)	29/04/93	82.00		124.00		70.00	
GLUCOSE	70-115 (MG/DL)	29/04/93	109.00		108.00		95.00	
BUN	20-40 (MG/DL)	29/04/93	21.00		43.00	>	44.00	>
CREATININE	0.6-1.1 (MG/DL)	29/04/93	1.09		1.22	>	0.97	
CREATININE CLEARANCE	75-160 (ML/MIN)	29/04/93	51.50					
URIC ACID	2.4-5.7 (MG/DL)	29/04/93	6.41	>	5.28		4.94	
TOT BILLIRUBIN	0-1.1 (MG/DL)	29/04/93	0.53		0.50		0.88	
DIR BILLIRUBIN	0-0.25 (MG/DL)	29/04/93	0.07		0.15		0.23	
TOT. PROTEINS	67-82 (G/L)	29/04/93	73.80		70.60		68.70	
ALBUMINE	31.2-51.5 (G/L)	29/04/93	49.35		46.53		48.91	
TOT. CHOLEST.	140-250 (MG/DL)	29/04/93	178.00		253.00	>	242.00	
TRIGLYCERIDES	0-200 (MG/DL)	29/04/93	98.00		193.00		148.00	
GLOBULINS ALPHA 1	1.9-4.8 (G/L)	29/04/93	1.77	<	1.84	<	1.58	<
GLOBULINS ALPHA 2	4.9-11.6 (G/L)	29/04/93	7.08		7.34		3.85	<
GLOBULINS BETA	5.4-11 (G/L)	29/04/93	6.72		8.68		7.01	
GLOBULINS GAMMA	7.4-13.3 (G/L)	29/04/93	9.08		6.21	<	7.35	<
TSH	0.17-2.87 (MU/L)	29/04/93	0.79					
T4	48-120 (UG/L)	29/04/93	75.00					
ESR/SEDIMENT. RATE	0-10 (MM)	29/04/93						
1st h			11.00		9.00		8.00	
ESR/SEDIMENT. RATE	0-20 (MM)	29/04/93						
2nd h			23.00		22.00		16.00	

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN950089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 292 Patient: 23DT Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			03/05/93		09/06/93		08/07/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	02/05/93	15.20		15.60		15.80	
HT	40-54 (%)	02/05/93	42.50		44.00		43.70	
RBC	4.4-5.9 (10 ⁶ /MM ³)	02/05/93	4.92		5.16		4.80	
HBC	5000-9000 (/MM ³)	02/05/93	6000.00		7500.00		6300.00	
HBC: N	53-75 (%)	02/05/93	56.00		55.00		51.00 <	
HBC: L	25-40 (%)	02/05/93	36.00		33.00		38.00	
HBC: E	2-4 (%)	02/05/93	2.00		2.00		2.00	
HBC: N	2-8 (%)	02/05/93	6.00		10.00 >		9.00 >	
HBC: B	0-1 (%)	02/05/93	0.00		0.00		0.00	
PLATELETS	150-300 (10 ³ /MM ³)	02/05/93	166.00		207.00		175.00 <	
NA+	137-147 (MMOL/L)	02/05/93	146.00		144.00		148.00 >	
K+	3.6-5.5 (MMOL/L)	02/05/93	4.30		4.00		4.40	
CL-	101-111 (MMOL/L)	02/05/93	104.00		100.00 <		108.00 >	
Ca ⁺⁺	2.25-2.6 (MMOL/L)	02/05/93	2.31		2.40		2.94 >	
PO ₄ ⁻	2.5-4.8 (MG/DL)	02/05/93	2.65		2.76		3.12	
SGOT	5-17 (U/L)	02/05/93	8.10		6.30		9.40	
SGPT	5-23 (U/L)	02/05/93	12.20		7.50		15.80	
GAMMA GT	6-28 (U/L)	02/05/93	11.90		6.10		11.30	
LDH	80-240 (U/L)	02/05/93	155.00		152.00		191.00	
ALK. PHOSPH.	50-190 (U/L)	02/05/93	101.00		79.00		98.00	
GLUCOSE	70-115 (MG/DL)	02/05/93	112.00		105.00		115.00	
BUN	20-40 (MG/DL)	02/05/93	31.00		38.00		35.00	
CREATININE	0.7-1.3 (MG/DL)	02/05/93	1.03		1.12		0.94	
CREATININE CLEARANCE			71.60					
URIC ACID	3.4-7 (MG/DL)	02/05/93	6.21		5.20		5.67	
TOT BILIRUBIN	0-1.1 (MG/DL)	02/05/93	0.56		0.37		0.29	
DIR BILIRUBIN	0-0.25 (MG/DL)	02/05/93	0.07		0.06		0.14	
TOT. PROTEINS	67-82 (G/L)	02/05/93	67.90		65.40 <		67.70	
ALBUMINE	31.2-51.5 (G/L)	02/05/93	44.27		44.08		46.31	
TOT. CHOLEST.	140-250 (MG/DL)	02/05/93	234.00		234.00		289.00 >	
TRIGLYCERIDES	0-200 (MG/DL)	02/05/93	487.00 >>		336.00 >>		358.00 >>	
GLOBULINS ALPHA 1	1.9-4.8 (G/L)	02/05/93	1.60 <		1.90		1.83 <	
GLOBULINS ALPHA 2	4.9-11.6 (G/L)	02/05/93	7.47		4.71 <		4.47 <	
GLOBULINS BETA	5.4-11 (G/L)	02/05/93	8.28		8.76		9.14	
GLOBULINS GAMMA	7.4-13.3 (G/L)	02/05/93	6.25 <		5.95 <		5.89 <	
TSH	0.17-2.87 (MU/L)	02/05/93	0.55					
T4	48-120 (UG/L)	02/05/93	80.00					
ESR/SEDIMENT. RATE	0-8 (MM)	02/05/93						
1st h			5.00		7.00			
ESR/SEDIMENT. RATE	0-16 (MM)	02/05/93						
2nd h			17.00		16.00			

2327

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN0330089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 292 Patient: 24DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			21/05/93		29/06/93		27/07/93	
			value	(¢)	value	(¢)	value	(¢)
Laboratory test	Range value	Range date						
HB	11-16 (G/DL)	20/05/93	12.70		12.90		12.60	
HT	36-47 (%)	20/05/93	35.40	<	35.60	<	36.20	
RBC	3.8-5.2 (10 ⁶ /MM ³)	20/05/93	4.44		4.46		4.10	
WBC	5000-9000 (/MM ³)	20/05/93	5800.00		6600.00		6200.00	
WBC: N	53-75 (%)	20/05/93	61.00		59.00		63.00	
WBC: L	25-40 (%)	20/05/93	32.00		31.00		30.00	
WBC: E	2-4 (%)	20/05/93	1.00	<	1.00	<	0.00	
WBC: M	2-8 (%)	20/05/93	5.00		8.00		7.00	
WBC: B	0-1 (%)	20/05/93	1.00		1.00		0.00	
PLATELETS	150-300 (10 ³ /MM ³)	20/05/93	232.00		307.00	>	339.00	
NA+	137-147 (MMOL/L)	20/05/93	142.00		144.00		147.00	
K+	3.6-5.5 (MMOL/L)	20/05/93	3.90		4.10		4.20	
CL-	101-111 (MMOL/L)	20/05/93	99.00	<	111.00		104.00	
Ca++	2.25-2.6 (MMOL/L)	20/05/93	2.38		2.41		2.42	
PO4--	2.5-4.8 (MG/DL)	20/05/93	2.80		3.09		3.17	
SGOT	4-13 (U/L)	20/05/93	10.20		7.90		10.30	
SGPT	5-19 (U/L)	20/05/93	6.70		11.20		11.90	
GAMMA GT	4-18 (U/L)	20/05/93	8.00		16.00		8.60	
LDH	80-240 (U/L)	20/05/93	193.00		190.00		165.00	
ALK. PHOSPH.	40-190 (U/L)	20/05/93	46.00		143.00		55.00	
GLUCOSE	70-115 (MG/DL)	20/05/93	97.00		106.00		104.00	
BUN	20-40 (MG/DL)	20/05/93	27.00		29.00		27.00	
CREATININE	0.6-1.1 (MG/DL)	20/05/93	0.98		0.78		0.81	
CREATININE CLEARANCE	75-160 (ML/MIN)	20/05/93	58.94					
URIC ACID	2.4-5.7 (MG/DL)	20/05/93	4.96		5.64		4.99	
TOT BILIRUBIN	0-1.1 (MG/DL)	20/05/93	0.75		0.64		1.03	
DIR BILIRUBIN	0-0.25 (MG/DL)	20/05/93	0.16		0.06		0.05	
TOT. PROTEINS	67-82 (G/L)	20/05/93	74.20		72.40		68.60	
ALBUMINE	31.2-51.5 (G/L)	20/05/93	46.45		43.51		40.15	
TOT. CHOLEST.	140-250 (MG/DL)	20/05/93	239.00		211.00		249.00	
TRIGLYCERIDES	0-200 (MG/DL)	20/05/93	88.00		74.00		83.00	
GLOBULINS ALPHA 1	1.9-4.8 (G/L)	20/05/93	2.15		2.32		2.87	
GLOBULINS ALPHA 2	4.9-11.6 (G/L)	20/05/93	5.12		5.43		7.18	
GLOBULINS BETA	5.4-11 (G/L)	20/05/93	10.31		11.37	>	10.12	
GLOBULINS GAMMA	7.4-13.3 (G/L)	20/05/93	10.17		9.77		8.14	
TSH	0.17-2.87 (MU/L)	20/05/93	0.36					
T4	48-120 (UG/L)	20/05/93	91.00					
ESR/SEDIMENT. RATE	0-10 (MM)	20/05/93						
1st h			8.00		10.00		8.00	
ESR/SEDIMENT. RATE	0-20 (MM)	20/05/93						
2nd h			21.00		20.00		21.00	

2328

(¢) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN950089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 293 Patient: 9ND Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			12/02/93		18/03/93		15/04/93	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/01/92	13.40		13.80		13.20	
HT	36-46 (%)	01/01/92	43.00		42.00		42.00	
RBC	4.1-5.4 (10 ⁶ /MM ³)	01/01/92	4.30		4.30		4.20	
WBC	4-10 (10 ³ /MM ³)	01/01/92	8.60		7.60		7.60	
WBC: N	63-73 (%)	01/01/92	67.00		64.00		64.00	
WBC: L	19-52 (%)	01/01/92	27.00		29.00		29.00	
WBC: E	0-4 (%)	01/01/92	2.00		1.00		3.00	
WBC: M	0-8 (%)	01/01/92	3.00		4.00		3.00	
WBC: B	0-2 (%)	01/01/92	1.00		1.00		1.00	
PLATELETS	140-440 (10 ³ /MM ³)	01/01/92	300.00		325.00		325.00	
NA+	135-145 (MMOL/L)	01/01/92	142.00		141.00		141.00	
K+	3.8-5 (MMOL/L)	01/01/92	3.90		3.90		4.00	
Ca++	2.2-2.75 (MMOL/L)	01/01/92	2.50		2.52		2.54	
SGOT	0-15 (U/L)	01/01/92	12.00		14.00		11.00	
SGPT	0-17 (U/L)	01/01/92	9.00		12.00		9.00	
GAMMA GT	0-18 (U/L)	01/01/92	13.00		17.00		16.00	
LDH	120-240 (U/L)	01/01/92	146.00		152.00		151.00	
ALK. PHOSPH.	60-170 (U/L)	01/01/92	152.00		150.00		154.00	
GLUCOSE	60-110 (MG/DL)	01/01/92	96.00		86.00		102.00	
BUN	10-50 (MG/DL)	01/01/92	36.00		36.00		40.00	
CREATININE	0.5-1 (MG/DL)	01/01/92	0.90		1.00		1.00	
CREATININE CLEARANCE	()	01/01/92	54.10	()				
URIC ACID	2.4-5.7 (MG/DL)	01/01/92	5.10		5.30		5.40	
TOT BILIRUBIN	0-1.1 (MG/DL)	01/01/92	0.60		0.60		0.60	
TOT. PROTEINS	6.6-8.7 (G/DL)	01/01/92	6.80		6.80		6.90	
ALBUMINE	53-68 (%)	01/01/92	66.00		67.00		67.00	
TOT. CHOLEST.	0-200 (MG/DL)	01/01/92	217.00	>	225.00	>	232.00	
TRIGLYCERIDES	0-300 (MG/DL)	01/01/92	196.00		189.00		205.00	
GLOBULINS ALPHA 1	1.5-4 (%)	01/01/92	5.00	>	5.00	>	6.00	
GLOBULINS ALPHA 2	5-10 (%)	01/01/92	9.00		8.00		9.00	
GLOBULINS BETA	8-13 (%)	01/01/92	8.00		9.00		7.00	
GLOBULINS GAMMA	10-19 (%)	01/01/92	12.00		12.00		11.00	
TSH	0.25-3.1 (UW/ML)	01/01/92	1.70					
T4	5-11.5 (UG/DL)	01/01/92	7.00					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/01/92	4.00		5.00		2.00	
ESR/SEDIMENT. RATE 2nd h	0-20 (MM)	01/01/92	7.00		9.00		9.00	

2329

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CN950089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 293 Patient: 10ND Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			16/03/93		20/04/93		18/05/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/01/92	14.10		14.20		14.20	
HT	36-46 (%)	01/01/92	43.00		43.00		42.00	
RBC	4.1-5.4 (10 ⁶ /MM ³)	01/01/92	4.20		4.20		4.10	
WBC	4-10 (10 ³ /MM ³)	01/01/92	7.60		9.00		8.40	
WBC: N	63-73 (%)	01/01/92	65.00		67.00		62.00 <	
WBC: L	19-52 (%)	01/01/92	29.00		24.00		28.00	
WBC: E	0-4 (%)	01/01/92	3.00		3.00		5.00 >	
WBC: M	0-8 (%)	01/01/92	2.00		4.00		4.00	
WBC: B	0-2 (%)	01/01/92	1.00		2.00		1.00	
PLATELETS	140-440 (10 ³ /MM ³)	01/01/92	325.00		350.00		350.00	
NA+	135-145 (MMOL/L)	01/01/92	144.00		142.00		142.00	
K+	3.8-5 (MMOL/L)	01/01/92	4.00		3.90		3.90	
Ca++	2.2-2.75 (MMOL/L)	01/01/92	2.52		2.51		2.50	
SGOT	0-15 (U/L)	01/01/92	13.00		12.00		12.00	
SGPT	0-17 (U/L)	01/01/92	11.00		9.00		11.00	
GAMMA GT	0-18 (U/L)	01/01/92	17.00		16.00		19.00 >	
LDH	120-240 (U/L)	01/01/92	151.00		149.00		154.00	
ALK. PHOSPH.	60-170 (U/L)	01/01/92	155.00		157.00		151.00	
GLUCOSE	60-110 (MG/DL)	01/01/92	99.00		76.00		88.00	
BUN	10-50 (MG/DL)	01/01/92	36.00		36.00		36.00	
CREATININE	0.5-1 (MG/DL)	01/01/92	1.00		1.10 >		1.00	
CREATININE CLEARANCE	()	01/01/92	65.20 ()					
URIC ACID	2.4-5.7 (MG/DL)	01/01/92	5.30		5.20		5.70	
TOT BILIRUBIN	0-1.1 (MG/DL)	01/01/92	0.60		0.60		0.70	
TOT. PROTEINS	6.6-8.7 (G/DL)	01/01/92	6.70		6.70		6.80	
ALBUMINE	53-68 (%)	01/01/92	68.00		67.00		67.00	
TOT. CHOLEST.	0-200 (MG/DL)	01/01/92	189.00		181.00		191.00	
TRIGLYCERIDES	0-300 (MG/DL)	01/01/92	192.00		201.00		202.00	
GLOBULINS ALPHA 1	1.5-4 (%)	01/01/92	6.00 >>		7.00 >>		7.00 >>	
GLOBULINS ALPHA 2	5-10 (%)	01/01/92	9.00		9.00		8.00	
GLOBULINS BETA	8-13 (%)	01/01/92	7.00 <		8.00		7.00 <	
GLOBULINS GAMMA	10-19 (%)	01/01/92	10.00		9.00 <		11.00	
TSH	0.25-3.1 (UU/ML)	01/01/92	1.90					
T ₄	5-11.5 (UG/DL)	01/01/92	6.80					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/01/92	5.00		6.00		6.00	
ESR/SEDIMENT. RATE 2nd h	0-20 (MM)	01/01/92	11.00		12.00		13.00	

2330

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range).
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CN9591089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 293 Patient: 11MD Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			08/07/93		09/08/93		06/09/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	14-18 (G/DL)	01/01/92	13.10	<	13.20	<	13.30	<
HT	38-52 (X)	01/01/92	41.00		42.00		42.00	
RBC	4.5-6 (10 ⁶ /MM ³)	01/01/92	5.10		4.90		4.80	
WBC	4-10 (10 ³ /MM ³)	01/01/92	6.40		7.20		7.60	
WBC: N	63-73 (X)	01/01/92	65.00		66.00		69.00	
WBC: L	19-52 (X)	01/01/92	27.00		22.00		19.00	
WBC: E	0-4 (X)	01/01/92	2.00		4.00		4.00	
WBC: M	0-8 (X)	01/01/92	4.00		5.00		6.00	
WBC: B	0-2 (X)	01/01/92	2.00		3.00	>>	2.00	
PLATELETS	140-440 (10 ³ /MM ³)	01/01/92	325.00		350.00		275.00	>
NA+	135-145 (MMOL/L)	01/01/92	144.00		149.00	>	147.00	>
K+	3.8-5 (MMOL/L)	01/01/92	4.00		3.80		3.90	
Ca++	2.2-2.75 (MMOL/L)	01/01/92	2.51		2.56		2.51	
SGOT	0-18 (U/L)	01/01/92	13.00		15.00		15.00	
SGPT	0-22 (U/L)	01/01/92	16.00		12.00		11.00	
GAMMA GT	0-28 (U/L)	01/01/92	13.00		17.00		13.00	
LDH	120-240 (U/L)	01/01/92	227.00		225.00		219.00	
ALK. PHOSPH.	60-170 (U/L)	01/01/92	160.00		156.00		151.00	
GLUCOSE	60-110 (MG/DL)	01/01/92	96.00		104.00		98.00	
BUN	10-50 (MG/DL)	01/01/92	36.00		40.00		36.00	
CREATININE	0.6-1.1 (MG/DL)	01/01/92	1.00		1.10		1.00	
CREATININE	()	01/01/92						
CLEARANCE			75.00	()				
URIC ACID	3.4-7 (MG/DL)	01/01/92	5.10		5.40		5.20	
TOT. BILIRUBIN	0-1.1 (MG/DL)	01/01/92	0.70		0.60		0.70	
TOT. PROTEINS	6.6-8.7 (G/DL)	01/01/92	6.90		6.80		6.70	
ALBUMINE	55-70 (X)	01/01/92	67.00		68.00		67.00	
TOT. CHOLEST.	0-200 (MG/DL)	01/01/92	198.00		201.00	>	189.00	>
TRIGLYCERIDES	0-200 (MG/DL)	01/01/92	212.00	>	224.00	>	211.00	>
GLOBULINS ALPHA 1	1.5-4 (X)	01/01/92	3.00		5.00	>	7.00	>>
GLOBULINS ALPHA 2	5-10 (X)	01/01/92	11.00	>	10.00		9.00	
GLOBULINS BETA	8-13 (X)	01/01/92	9.00		8.00		7.00	<
GLOBULINS GAMMA	10-19 (X)	01/01/92	10.00		9.00	<	8.00	<
TSH	0.25-3.1 (UU/ML)	01/01/92	4.90					
T4	5-11.5 (UG/DL)	01/01/92	8.10					
ESR/SEDIMENT. RATE	0-10 (MM)	01/01/92						
1st h			6.00		8.00		6.00	
ESR/SEDIMENT. RATE	0-20 (MM)	01/01/92						
2nd h			12.00		11.00		12.00	

2331

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CN930089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 293 Patient: 12MD Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date	
			Screen	Day 28
			09/09/93	14/10/93
			value (†)	value (†)
Laboratory test	Range value	Range date		
HB	14-18 (G/DL)	01/01/92	13.30 <	13.40 <
HT	38-52 (X)	01/01/92	42.00	43.00
RBC	4.5-6 (10 ⁶ /MM ³)	01/01/92	4.50	4.40 <
HBC	4-10 (10 ³ /MM ³)	01/01/92	7.60	8.40
HBC: N	63-73 (X)	01/01/92	67.00	65.00
HBC: L	19-52 (X)	01/01/92	24.00	27.00
HBC: E	0-4 (X)	01/01/92	3.00	4.00
HBC: M	0-8 (X)	01/01/92	4.00	3.00
HBC: B	0-2 (X)	01/01/92	2.00	1.00
PLATELETS	140-440 (10 ³ /MM ³)	01/01/92	300.00	275.00
NA+	135-145 (MMOL/L)	01/01/92	141.00	140.00
K+	3.8-5 (MMOL/L)	01/01/92	3.90	3.80
Ca++	2.2-2.75 (MMOL/L)	01/01/92	2.54	2.52
SGOT	0-18 (U/L)	01/01/92	12.00	11.00
SGPT	0-22 (U/L)	01/01/92	14.00	15.00
GAMMA GT	0-28 (U/L)	01/01/92	15.00	13.00
LDH	120-240 (U/L)	01/01/92	221.00	217.00
ALK. PHOSPH.	60-170 (U/L)	01/01/92	157.00	154.00
GLUCOSE	60-110 (MG/DL)	01/01/92	92.00	96.00
BUN	10-50 (MG/DL)	01/01/92	36.00	36.00
CREATININE	0.6-1.1 (MG/DL)	01/01/92	1.00	0.90
CREATININE CLEARANCE	()	01/01/92	94.00 ()	
URIC ACID	3.4-7 (MG/DL)	01/01/92	6.90	6.40
TOT BILIRUBIN	0-1.1 (MG/DL)	01/01/92	0.60	0.70
TOT. PROTEINS	6.6-8.7 (G/DL)	01/01/92	6.80	6.70
ALBUMINE	55-70 (X)	01/01/92	68.00	67.00
TOT. CHOLEST.	0-200 (MG/DL)	01/01/92	179.00	157.00
TRIGLYCERIDES	0-200 (MG/DL)	01/01/92	201.00 >	213.00 >
GLOBULINS ALPHA 1	1.5-4 (X)	01/01/92	4.00	5.00 >
GLOBULINS ALPHA 2	5-10 (X)	01/01/92	10.00	10.00
GLOBULINS BETA	8-13 (X)	01/01/92	9.00	8.00
GLOBULINS GAMMA	10-19 (X)	01/01/92	9.00 <	10.00
TSH	0.25-3.1 (UU/ML)	01/01/92	4.80	
T4	5-11.5 (UG/DL)	01/01/92	7.90	
ESR/SEDIMENT. RATE	0-10 (MM)	01/01/92		
1st h			7.00	8.00
ESR/SEDIMENT. RATE	0-20 (MM)	01/01/92		
2nd h			13.00	12.00

2332

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA ~~CMS~~ 550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 293 Patient: 9DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			19/05/93		23/06/93		21/07/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/01/92	13.20		13.10		13.20	
HT	36-46 (X)	01/01/92	41.00		42.00		42.00	
RBC	4.1-5.4 (10 ⁶ /MM ³)	01/01/92	4.60		4.30		4.30	
WBC	4-10 (10 ³ /MM ³)	01/01/92	6.40		7.20		7.60	
WBC: N	63-73 (X)	01/01/92	71.00		65.00		64.00	
WBC: L	19-52 (X)	01/01/92	21.00		28.00		25.00	
WBC: E	0-4 (X)	01/01/92	3.00		4.00		5.00 >	
WBC: M	0-8 (X)	01/01/92	4.00		1.00		5.00	
WBC: B	0-2 (X)	01/01/92	1.00		2.00		1.00	
PLATELETS	140-440 (10 ³ /MM ³)	01/01/92	300.00		325.00		350.00	
NA+	135-145 (MMOL/L)	01/01/92	141.00		139.00		138.00	
K+	3.8-5 (MMOL/L)	01/01/92	4.00		3.90		3.80	
Ca++	2.2-2.75 (MMOL/L)	01/01/92	2.61		2.59		2.55	
SGOT	0-15 (U/L)	01/01/92	12.00		11.00		13.00	
SGPT	0-17 (U/L)	01/01/92	13.00		14.00		15.00	
GAMMA GT	0-18 (U/L)	01/01/92	10.00		12.00		10.00	
LDH	120-240 (U/L)	01/01/92	161.00		163.00			
ALK. PHOSPH.	60-170 (U/L)	01/01/92	150.00		154.00		155.00	
GLUCOSE	60-110 (MG/DL)	01/01/92	79.00		89.00		92.00	
BUN	10-50 (MG/DL)	01/01/92	40.00		40.00		36.00	
CREATININE	0.5-1 (MG/DL)	01/01/92	0.90		1.00		1.00	
CREATININE CLEARANCE	()	01/01/92	79.90 ()					
URIC ACID	2.4-5.7 (MG/DL)	01/01/92	5.10		5.40		5.60	
TOT BILIRUBIN	0-1.1 (MG/DL)	01/01/92	0.70		0.70		0.70	
TOT. PROTEINS	6.6-8.7 (G/DL)	01/01/92	8.60		8.60		8.70	
ALBUMINE	53-68 (X)	01/01/92	68.00		69.00 >		66.00	
TOT. CHOLEST.	0-200 (MG/DL)	01/01/92	189.00		172.00		192.00	
TRIGLYCERIDES	0-300 (MG/DL)	01/01/92	194.00		201.00		211.00	
GLOBULINS ALPHA 1	1.5-4 (X)	01/01/92	7.00 >>		8.00 >>		7.00 >>	
GLOBULINS ALPHA 2	5-10 (X)	01/01/92	8.00		7.00		10.00	
GLOBULINS BETA	8-13 (X)	01/01/92	9.00		9.00		8.00	
GLOBULINS GAMMA	10-19 (X)	01/01/92	8.00 <		8.00 <		9.00 <	
TSH	0.25-3.1 (UU/ML)	01/01/92	1.80					
T4	5-11.5 (UG/DL)	01/01/92	6.40					
ESR/SEDIMENT. RATE	0-10 (MM)	01/01/92						
1st h			4.00		5.00		4.00	
ESR/SEDIMENT. RATE	0-20 (MM)	01/01/92						
2nd h			11.00		13.00		8.00	

2333

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C8590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 293 Patient: 10DT Treatment: Imipramine Sex: Female

Laboratory test			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			15/07/93		17/08/93		14/09/93	
			value	(ϕ)	value	(ϕ)	value	(ϕ)
Range value	Range date							
HB	12-16 (G/DL)	01/01/92	13.70		13.90		13.80	
HT	36-46 (X)	01/01/92	43.00		43.00		43.00	
RBC	4.1-5.4 (10 ⁶ /MM3)	01/01/92	4.40		4.30		4.20	
WBC	4-10 (10 ³ /MM3)	01/01/92	9.60		7.60		8.40	
WBC: N	63-73 (X)	01/01/92	69.00		67.00		66.00	
WBC: L	19-52 (X)	01/01/92	28.00		29.00		21.00	
WBC: E	0-4 (X)	01/01/92	1.00		1.00		4.00	
WBC: M	0-8 (X)	01/01/92	2.00		1.00		6.00	
WBC: B	0-2 (X)	01/01/92	0.00		0.00		3.00 >>	
PLATELETS	140-440 (10 ³ /MM3)	01/01/92	275.00		300.00		325.00	
NA+	135-145 (MMOL/L)	01/01/92	144.00		145.00		147.00 >	
K+	3.8-5 (MMOL/L)	01/01/92	3.90		3.80		3.90	
Ca++	2.2-2.75 (MMOL/L)	01/01/92	2.57		2.58		2.54	
SGOT	0-15 (U/L)	01/01/92	13.00		12.00		11.00	
SGPT	0-17 (U/L)	01/01/92	9.00		10.00		10.00	
GAMMA GT	0-18 (U/L)	01/01/92	12.00		17.00		12.00	
LDH	120-240 (U/L)	01/01/92	144.00		140.00		156.00	
ALK. PHOSPH.	60-170 (U/L)	01/01/92	155.00		154.00		150.00	
GLUCOSE	60-110 (MG/DL)	01/01/92	88.00		79.00		82.00	
BUN	10-50 (MG/DL)	01/01/92	40.00		36.00		40.00	
CREATININE	0.5-1 (MG/DL)	01/01/92	0.90		0.85		1.00	
CREATININE	()	01/01/92						
CLEARANCE			82.20	()				
URIC ACID	2.4-5.7 (MG/DL)	01/01/92	5.60		5.40		5.50	
TOT BILIRUBIN	0-1.1 (MG/DL)	01/01/92	0.70		0.90		0.80	
TOT. PROTEINS	6.6-8.7 (G/DL)	01/01/92	6.70		6.80		6.70	
ALBUMINE	53-68 (X)	01/01/92	67.00		66.00		67.00	
TOT. CHOLEST.	0-200 (MG/DL)	01/01/92	209.00 >		211.00 >		224.00 >	
TRIGLYCERIDES	0-300 (MG/DL)	01/01/92	211.00		232.00		217.00	
GLOBULINS ALPHA 1	1.5-4 (X)	01/01/92	6.00 >>		7.00 >>		6.00 >>	
GLOBULINS ALPHA 2	5-10 (X)	01/01/92	9.00		8.00		9.00	
GLOBULINS BETA	8-13 (X)	01/01/92	7.00 <		8.00		7.00 <	
GLOBULINS GAMMA	10-19 (X)	01/01/92	11.00		11.00		11.00	
TSH	0.25-3.1 (UU/ML)	01/01/92	1.80					
T4	5-11.5 (UG/DL)	01/01/92	7.20					
ESR/SEDIMENT. RATE	0-10 (MM)	01/01/92						
1st h			4.00		5.00		6.00	
ESR/SEDIMENT. RATE	0-20 (MM)	01/01/92						
2nd h			8.00		11.00		9.00	

2334

(ϕ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CN 599089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 293 Patient: 11DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date
			Screen
			12/11/93
			value (⚡)
Laboratory test	Range value	Range date	
HB	12-16 (G/DL)	01/01/92	12.90
HT	36-46 (X)	01/01/92	42.00
RBC	4.1-5.4 (10 ⁶ /MM ³)	01/01/92	4.30
WBC	4-10 (10 ³ /MM ³)	01/01/92	8.40
WBC: N	63-73 (X)	01/01/92	67.00
WBC: L	19-52 (X)	01/01/92	21.00
WBC: E	0-4 (X)	01/01/92	5.00 >
WBC: M	0-8 (X)	01/01/92	5.00
WBC: B	0-2 (X)	01/01/92	2.00
PLATELETS	140-440 (10 ³ /MM ³)	01/01/92	250.00
NA+	135-145 (MMOL/L)	01/01/92	142.00
K+	3.8-5 (MMOL/L)	01/01/92	3.80
Ca++	2.2-2.75 (MMOL/L)	01/01/92	2.54
SGOT	0-15 (U/L)	01/01/92	12.00
SGPT	0-17 (U/L)	01/01/92	11.00
GAMMA GT	0-18 (U/L)	01/01/92	14.00
LDH	120-240 (U/L)	01/01/92	142.00
ALK. PHOSPH.	60-170 (U/L)	01/01/92	151.00
GLUCOSE	60-110 (MG/DL)	01/01/92	134.00 >
BUN	10-50 (MG/DL)	01/01/92	40.00
CREATININE	0.5-1 (MG/DL)	01/01/92	1.00
CREATININE CLEARANCE		01/01/92	62.70 ()
URIC ACID	2.4-5.7 (MG/DL)	01/01/92	5.70
TOT BILIRUBIN	0-1.1 (MG/DL)	01/01/92	0.60
TOT. PROTEINS	6.6-8.7 (G/DL)	01/01/92	6.80
ALBUMINE	53-68 (X)	01/01/92	69.00 >
TOT. CHOLEST.	0-200 (MG/DL)	01/01/92	211.00 >
TRIGLYCERIDES	0-300 (MG/DL)	01/01/92	208.00
GLOBULINS ALPHA 1	1.5-4 (X)	01/01/92	7.00 >>
GLOBULINS ALPHA 2	5-10 (X)	01/01/92	9.00
GLOBULINS BETA	8-13 (X)	01/01/92	5.00 <<
GLOBULINS GAMMA	10-19 (X)	01/01/92	10.00
TSH	0.25-3.1 (UU/ML)	01/01/92	1.90
T4	5-11.5 (UG/DL)	01/01/92	7.20
ESR/SEDIMENT. RATE	0-10 (MM)	01/01/92	
1st h			6.00
ESR/SEDIMENT. RATE	0-20 (MM)	01/01/92	
2nd h			13.00

2335

(⚡) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN5590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 293 Patient: 12DT Treatment: Raboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			10/12/93		10/01/94		07/02/94	
			value	(ϕ)	value	(ϕ)	value	(ϕ)
Laboratory test	Range value	Range date						
HB	12-16 (G/DL)	01/01/92	13.20		13.40		13.20	
HT	36-46 (%)	01/01/92	42.00		43.00		42.00	
RBC	4.1-5.4 (10 ⁶ /MM ³)	01/01/92	5.00		5.10		5.00	
HBC	4-10 (10 ³ /MM ³)	01/01/92	7.20		8.40		8.80	
HBC: N	63-73 (%)	01/01/92	67.00		62.00	<	61.00	<
HBC: L	19-52 (%)	01/01/92	26.00		29.00		27.00	
HBC: E	0-4 (%)	01/01/92	2.00		4.00		4.00	
HBC: H	0-8 (%)	01/01/92	5.00		4.00		7.00	
HBC: B	0-2 (%)	01/01/92	0.00		1.00		1.00	
PLATELETS	140-440 (10 ³ /MM ³)	01/01/92	300.00		275.00		250.00	
NA+	135-145 (MMOL/L)	01/01/92	142.00		144.00		148.00	>
K+	3.8-5 (MMOL/L)	01/01/92	3.90		4.00		3.90	
Ca++	2.2-2.75 (MMOL/L)	01/01/92	2.52		2.54		2.55	
SGOT	0-15 (U/L)	01/01/92	12.00		13.00		12.00	
SGPT	0-17 (U/L)	01/01/92	11.00		9.00		11.00	
GAMMA GT	0-18 (U/L)	01/01/92	13.00		15.00		14.00	
LDH	120-240 (U/L)	01/01/92	224.00		221.00		224.00	
ALK. PHOSPH.	60-170 (U/L)	01/01/92	159.00		155.00		154.00	
GLUCOSE	60-110 (MG/DL)	01/01/92	102.00		104.00		111.00	>
BUN	10-50 (MG/DL)	01/01/92	36.00		40.00		40.00	
CREATININE	0.5-1 (MG/DL)	01/01/92	1.10	>	1.00		1.00	
CREATININE	()	01/01/92						
CLEARANCE			54.95	()				
URIC ACID	2.4-5.7 (MG/DL)	01/01/92	5.40		5.70		5.60	
TOT BILIRUBIN	0-1.1 (MG/DL)	01/01/92	0.70		0.60		0.70	
TOT. PROTEINS	6.6-8.7 (G/DL)	01/01/92	6.80		6.90		6.80	
ALBUMINE	53-68 (%)	01/01/92	68.00		67.00		67.00	
TOT. CHOLEST.	0-200 (MG/DL)	01/01/92	192.00		199.00		178.00	
TRIGLYCERIDES	0-300 (MG/DL)	01/01/92	207.00		219.00		212.00	
GLOBULINS ALPHA 1	1.5-4 (%)	01/01/92	4.00		5.00	>	6.00	>>
GLOBULINS ALPHA 2	5-10 (%)	01/01/92	11.00	>	12.00	>	13.00	>
GLOBULINS BETA	8-13 (%)	01/01/92	10.00		9.00		8.00	
GLOBULINS GAMMA	10-19 (%)	01/01/92	7.00	<	7.00	<	5.00	<<
TSH	0.25-3.1 (UU/ML)	01/01/92	4.70					
T4	5-11.5 (UG/DL)	01/01/92	7.90					
ESR/SEDIMENT. RATE	0-10 (MM)	01/01/92						
1st h			7.00		8.00		10.00	
ESR/SEDIMENT. RATE	0-20 (MM)	01/01/92						
2nd h			10.00		12.00		12.00	

2336

(ϕ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C 856089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 294 Patient: 13ND Treatment: Imipramine Sex: Female

Laboratory test			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			15/02/93		15/03/93		13/04/93	
			value	(φ)	value	(φ)	value	(φ)
Range value	Range date							
HB	12.8-16 (G/DL)	15/02/93	14.20		13.80		14.20	
HT	37-47 (%)	15/02/93	42.00		44.00		39.00	
RBC	4.5-5 (10 ⁶ /MM ³)	15/02/93	4.60		4.70		4.70	
HBC	3.5-9 (10 ³ /MM ³)	15/02/93	4.60		4.50		4.70	
HBC: N	37-73 (%)	15/02/93	42.00		48.00		42.00	
HBC: L	20-55 (%)	15/02/93	39.00		35.00		47.00	
HBC: E	0.5-11 (%)	15/02/93	8.70		8.50		4.50	
HBC: M	2.5-10 (%)	15/02/93	9.30		7.60		5.50	
HBC: B	0-2 (%)	15/02/93	1.00		0.80		1.00	
PLATELETS	150-400 (10 ³ /MM ³)	15/02/93	320.00		360.00		325.00	
NA+	134-148 (MMOL/L)	15/02/93	137.50		142.00		146.00	
K+	3.8-5.2 (MMOL/L)	15/02/93	5.10		4.20		4.20	
CL-	94-110 (MMOL/L)	15/02/93	96.00		98.00		96.00	
Ca++	2.05-2.55 (MMOL/L)	15/02/93	2.10					
	4.1-5.1 (MEQ/L)	15/03/93			4.80		4.80	
PO4--	25-48 (MG/L)	15/02/93	32.70		32.80		43.20	
SGOT	5-18 (U/L)	15/02/93	12.00		9.00		15.00	
SGPT	5-22 (U/L)	15/02/93	14.00		10.00		10.00	
GAMMA GT	4-28 (U/L)	15/02/93	7.00		16.00		12.00	
LDH	120-240 (U/L)	15/02/93	205.00		185.00		185.00	
ALK. PHOSPH.	60-170 (U/L)	15/02/93	122.00		92.00		120.00	
GLUCOSE	60-110 (MG/DL)	15/02/93	93.00		73.00		88.00	
BUN	10-50 (MG/DL)	15/02/93	46.00		43.00		23.00	
CREATININE	0.3-1.2 (MG/DL)	15/02/93	1.00		0.70		0.70	
CREATININE CLEARANCE			32.47					
URIC ACID	2.4-7 (MG/DL)	15/02/93	4.90		6.40		5.30	
TOT BILIRUBIN	0-1 (MG/DL)	15/02/93	0.80		0.60		0.40	
TOT. PROTEINS	6.6-8.7 (G/DL)	15/02/93	6.00	<	6.80		6.90	
ALBUMINE	3.7-5.5 (G/DL)	15/02/93	4.20		4.20		4.80	
TOT. CHOLEST.	0-200 (MG/DL)	15/02/93	211.00	>	221.00	>	185.00	
TRIGLYCERIDES	50-180 (MG/DL)	15/02/93	99.00		97.00		98.00	
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	15/02/93	0.20		0.20		0.10	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	15/02/93	0.60		0.50		0.80	
GLOBULINS BETA	0.4-0.9 (G/DL)	15/02/93	0.70		0.60		0.70	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	15/02/93	0.90		1.00		0.70	
TSH	0.2-4 (UU/ML)	15/02/93	1.20					
T4	5-11.5 (UG/DL)	15/02/93	6.80					
ESR/SEDIMENT. RATE	0-10 (MM)	15/02/93						
1st h			10.00		11.00		10.00	
ESR/SEDIMENT. RATE	0-30 (MM)	15/02/93						
2nd h			15.00		20.00		15.00	

2337

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range).
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 294 Patient: 14MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory data					
			Screen		Day 28		Day 56	
			15/02/93		15/03/93		13/04/93	
			value	(†)	value	(†)	value	(†)
Laboratory test	Range value	Range date						
HB	12.8-16 (G/DL)	01/02/93	13.40		14.60		14.80	
HT	37-47 (%)	01/02/93	39.00		42.00		44.00	
RBC	4.5-5 (10 ⁶ /MM ³)	01/02/93	4.70		4.70		4.80	
WBC	3.5-9 (10 ³ /MM ³)	01/02/93	4.20		8.20		7.60	
WBC: N	37-73 (%)	01/02/93	53.00		42.00		45.00	
WBC: L	20-55 (%)	01/02/93	35.00		44.00		35.00	
WBC: E	0.5-11 (%)	01/02/93	1.20		7.80		6.20	
WBC: M	2.5-10 (%)	01/02/93	7.70		5.20		8.40	
WBC: B	0-2 (%)	01/02/93	1.30		1.00		1.00	
PLATELETS	150-400 (10 ³ /MM ³)	01/02/93	315.00		305.00		325.00	
NA+	134-148 (MMOL/L)	01/02/93	143.00		146.00		145.00	
K+	3.8-5.2 (MMOL/L)	01/02/93	4.60		4.20		4.80	
CL-	94-110 (MMOL/L)	01/02/93	96.00		96.00		102.00	
Ca++	4.1-5.1 (MEQ/L)	01/02/93	4.20		5.00		5.30	
PO4--	25-48 (MG/L)	01/02/93	32.40		32.40		42.40	
SGOT	5-18 (U/L)	01/02/93	12.00		12.00		14.00	
SGPT	5-22 (U/L)	01/02/93	11.00		14.00		16.00	
GAMMA GT	4-28 (U/L)	01/02/93	7.00		12.00		10.00	
LDH	120-240 (U/L)	01/02/93	177.00		143.00		200.00	
ALK. PHOSPH.	60-170 (U/L)	01/02/93	103.00		110.00		88.00	
GLUCOSE	60-110 (MG/DL)	01/02/93	83.40		98.00		72.00	
BUN	10-50 (MG/DL)	01/02/93	31.00		31.00		22.40	
CREATININE	0.3-1.2 (MG/DL)	01/02/93	0.98		0.60		0.70	
CREATININE CLEARANCE	80-160 (ML/MIN)	01/02/93	31.21					
URIC ACID	2.4-7 (MG/DL)	01/02/93	5.10		4.30		3.50	
TOT BILIRUBIN	0-1 (MG/DL)	01/02/93	0.70		0.70		0.60	
TOT. PROTEINS	6.6-8.7 (G/DL)	01/02/93	6.70		7.00		7.20	
ALBUMINE	3.7-5.5 (G/DL)	01/02/93	4.80		4.20		5.30	
TOT. CHOLEST.	0-200 (MG/DL)	01/02/93	324.00	>>	204.00	>	195.00	
TRIGLYCERIDES	50-180 (MG/DL)	01/02/93	84.60		125.00		87.00	
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	01/02/93	0.20		0.20		0.20	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	01/02/93	0.70		0.60		0.40	
GLOBULINS BETA	0.4-0.9 (G/DL)	01/02/93	0.50		0.70		0.40	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	01/02/93	0.80		1.00		1.10	
TSH	0.2-4 (UU/ML)	01/02/93	1.35					
T4	5-11.5 (UG/DL)	01/02/93	10.60					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/02/93	5.00				6.00	
ESR/SEDIMENT. RATE 2nd h	0-30 (MM)	01/02/93	10.00				12.00	

2338

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C 580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 294 Patient: 15MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			22/02/93		22/03/93		20/04/93	
			value	(⊕)	value	(⊕)	value	(⊕)
Laboratory test	Range value	Range date						
HB	12.8-16 (G/DL)	01/02/93	14.20		14.40		14.20	
HT	37-47 (X)	01/02/93	39.00		41.00		38.00	
RBC	4.5-5 (10 ⁶ /MM ³)	01/02/93	4.70		3.90 <		4.60	
WBC	3.5-9 (10 ³ /MM ³)	01/02/93	8.10		9.20 >		4.70	
WBC: N	37-73 (%)	01/02/93	45.00		48.00		48.00	
WBC: L	20-55 (%)	01/02/93	38.00		36.00		35.00	
WBC: E	0.5-11 (%)	01/02/93	8.40		9.20		7.40	
WBC: M	2.5-10 (%)	01/02/93	7.40		6.80		8.00	
WBC: B	0-2 (%)	01/02/93	1.20		0.00		1.00	
PLATELETS	150-400 (10 ³ /MM ³)	01/02/93	325.00		420.00 >		320.00	
NA+	134-148 (MMOL/L)	01/02/93	142.00		145.00		138.00	
K+	3.8-5.2 (MMOL/L)	01/02/93	4.10		4.60		4.20	
CL-	94-110 (MMOL/L)	01/02/93	98.00		99.00		99.00	
Ca++	4.1-5.1 (MEQ/L)	01/02/93	4.80		5.20 >		4.50	
PO4--	25-48 (MG/L)	01/02/93	35.80		36.20		46.20	
SGOT	5-18 (U/L)	01/02/93	13.00		14.00		11.00	
SGPT	5-22 (U/L)	01/02/93	17.00		15.00		10.00	
GAMMA GT	4-28 (U/L)	01/02/93	21.00		20.00		17.00	
LDH	120-240 (U/L)	01/02/93	180.00		175.00		130.00	
ALK. PHOSPH.	60-170 (U/L)	01/02/93	90.00		102.00		120.00	
GLUCOSE	60-110 (MG/DL)	01/02/93	75.00		98.00		98.00	
BUN	10-50 (MG/DL)	01/02/93	35.00		30.00		35.00	
CREATININE	0.3-1.2 (MG/DL)	01/02/93	0.80		0.70		0.80	
CREATININE CLEARANCE			57.10					
URIC ACID	2.4-7 (MG/DL)	01/02/93	5.40		6.00		5.40	
TOT BILIRUBIN	0-1 (MG/DL)	01/02/93	0.70		0.80		0.50	
TOT. PROTEINS	6.6-8.7 (G/DL)	01/02/93	6.90		6.40 <		7.40	
ALBUMINE	3.7-5.5 (G/DL)	01/02/93	5.10		5.20		5.00	
TOT. CHOLEST.	0-200 (MG/DL)	01/02/93	255.00 >		242.00 >		225.00 >	
TRIGLYCERIDES	50-180 (MG/DL)	01/02/93	179.00		125.00		75.00	
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	01/02/93	0.20		0.20		0.20	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	01/02/93	0.40		0.50		0.40	
GLOBULINS BETA	0.4-0.9 (G/DL)	01/02/93	0.40		0.40		0.70	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	01/02/93	1.20		1.10		1.00	
TSH	0.2-4 (UU/ML)	01/02/93	3.10					
T4	5-11.5 (UG/DL)	01/02/93	7.10					
ESR/SEDIMENT. RATE	0-10 (MM)	01/02/93						
1st h			6.00		10.00		7.00	
ESR/SEDIMENT. RATE	0-30 (MM)	01/02/93						
2nd h			15.00		15.00		12.00	

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN 530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 294 Patient: 16MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			23/02/93		23/03/93		20/04/93	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	12.8-16 (G/DL)	01/02/93	15.20		14.20		13.20	
HT	37-47 (X)	01/02/93	42.00		43.00		39.00	
RBC	4.5-5 (10 ⁶ /MM3)	01/02/93	4.80		4.70		4.60	
WBC	3.5-9 (10 ³ /MM3)	01/02/93	7.20		7.00		4.20	
WBC: N	37-73 (X)	01/02/93	56.00		45.00		55.00	
WBC: L	20-55 (X)	01/02/93	34.00		40.00		34.00	
WBC: E	0.5-11 (X)	01/02/93	0.50		6.80		8.00	
WBC: M	2.5-10 (X)	01/02/93	8.50		7.20		3.00	
WBC: B	0-2 (X)	01/02/93	1.00		1.00		0.00	
PLATELETS	150-400 (10 ³ /MM3)	01/02/93	300.00		325.00		260.00	
NA+	134-148 (MMOL/L)	01/02/93	142.00		145.00		140.00	
K+	3.8-5.2 (MMOL/L)	01/02/93	3.70 <		4.20		4.20	
CL-	94-110 (MMOL/L)	01/02/93	98.00		96.00		96.00	
Ca++	4.1-5.1 (MEQ/L)	01/02/93	4.28		4.20		4.80	
PO4--	25-48 (MG/L)	01/02/93	34.20		32.40		43.20	
SGOT	5-18 (U/L)	01/02/93	10.00		8.00		12.00	
SGPT	5-22 (U/L)	01/02/93	15.00		10.00		20.00	
GAMMA GT	4-28 (U/L)	01/02/93	8.00		12.00		22.00	
LDH	120-240 (U/L)	01/02/93	151.00		195.00		185.00	
ALK. PHOSPH.	60-170 (U/L)	01/02/93	83.00		125.00		145.00	
GLUCOSE	60-110 (MG/DL)	01/02/93	79.00		96.00		78.00	
BUN	10-50 (MG/DL)	01/02/93	28.00		30.00		25.00	
CREATININE	0.3-1.2 (MG/DL)	01/02/93	1.10		0.60		0.60	
CREATININE CLEARANCE	80-160 (ML/MIN)	01/02/93	52.90					
URIC ACID	2.4-7 (MG/DL)	01/02/93	5.20		4.80		2.80	
TOT BILIRUBIN	0-1 (MG/DL)	01/02/93	0.75		0.80		0.50	
TOT. PROTEINS	6.6-8.7 (G/DL)	01/02/93	6.60		7.20		6.90	
ALBUMINE	3.7-5.5 (G/DL)	01/02/93	4.20		5.00		4.20	
TOT. CHOLEST.	0-200 (MG/DL)	01/02/93	228.00 >		212.00 >		202.00 >	
TRIGLYCERIDES	50-180 (MG/DL)	01/02/93	119.00		98.00		78.00	
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	01/02/93	0.20		0.20		0.30	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	01/02/93	0.60		0.40		0.60	
GLOBULINS BETA	0.4-0.9 (G/DL)	01/02/93	0.50		0.60		0.50	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	01/02/93	1.10		0.70		0.80	
TSH	0.2-4 (UU/ML)	01/02/93	2.60					
T4	5-11.5 (UG/DL)	01/02/93	7.50					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/02/93	7.00		5.00		7.00	
ESR/SEDIMENT. RATE 2nd h	0-30 (MM)	01/02/93	15.00		12.00		14.00	

2340

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARNACIA C 580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 294 Patient: 25MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			14/06/93		12/07/93		09/08/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HR	12.8-16 (G/DL)	01/02/93	14.40		13.80		14.20	
HT	37-47 (X)	01/02/93	42.00		43.00		42.00	
RBC	4.5-5 (10 ⁶ /MM ³)	01/02/93	4.80		4.70		4.70	
WBC	3.5-9 (10 ³ /MM ³)	01/02/93	4.80		4.50		4.80	
WBC: N	37-73 (X)	01/02/93	46.00		42.00		52.00	
WBC: L	20-55 (X)	01/02/93	37.00		37.00		43.00	
WBC: E	0.5-11 (X)	01/02/93	8.20		6.50		0.70	
WBC: M	2.5-10 (X)	01/02/93	4.50		8.40		4.80	
WBC: B	0-2 (X)	01/02/93	1.00		0.00		1.00	
PLATELETS	150-400 (10 ³ /MM ³)	01/02/93	310.00		210.00		280.00	
NA+	134-148 (MMOL/L)	01/02/93	139.00		142.00		142.00	
K+	3.8-5.2 (MMOL/L)	01/02/93	4.00		4.80		4.00	
CL-	94-110 (MMOL/L)	01/02/93	96.00		98.00		96.00	
Ca++	4.1-5.1 (MEQ/L)	01/02/93	5.00		5.10		4.80	
PO4--	25-48 (MG/L)	01/02/93	36.40		36.40		36.40	
SGOT	5-18 (U/L)	01/02/93	9.00		12.00		10.00	
SGPT	5-22 (U/L)	01/02/93	8.00		8.00		12.00	
GAMMA GT	4-28 (U/L)	01/02/93	14.00		10.00		8.00	
LDH	120-240 (U/L)	01/02/93	159.00		160.00		184.00	
ALK. PHOSPH.	60-170 (U/L)	01/02/93	166.00		146.00		142.00	
GLUCOSE	60-110 (MG/DL)	01/02/93	92.00		94.00		86.00	
BUN	10-50 (MG/DL)	01/02/93	25.00		32.00		34.00	
CREATININE	0.3-1.2 (MG/DL)	01/02/93	0.90		0.70		0.90	
CREATININE CLEARANCE	80-160 (ML/MIN)	01/02/93	65.80					
URIC ACID	2.4-7 (MG/DL)	01/02/93	6.00		4.30		4.30	
TOT BILIRUBIN	0-1 (MG/DL)	01/02/93	0.32		0.70		0.70	
TOT. PROTEINS	6.6-8.7 (G/DL)	01/02/93	7.10		7.40		7.20	
ALBUMINE	3.7-5.5 (G/DL)	01/02/93	4.20		4.20		4.80	
TOT. CHOLEST.	0-200 (MG/DL)	01/02/93	242.00 >		242.00 >		224.00 >	
TRIGLYCERIDES	50-180 (MG/DL)	01/02/93	175.00		136.00		98.00	
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	01/02/93	0.20		0.10		0.20	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	01/02/93	0.40		0.60		0.50	
GLOBULINS BETA	0.4-0.9 (G/DL)	01/02/93	0.80		0.60		0.50	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	01/02/93	1.20		1.00		0.90	
TSH	0.2-4 (U/ML)	01/02/93	3.20					
T4	5-11.5 (UG/DL)	01/02/93	7.80					
ESR/SEDIMENT. RATE	0-10 (MM)	01/02/93						
1st h			10.00		8.00		14.00	
ESR/SEDIMENT. RATE	0-30 (MM)	01/02/93						
2nd h			18.00		15.00		22.00	

2341

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 0580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 294 Patient: 26MD Treatment: Imipramine Sex: Female

Laboratory test			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			14/06/93		12/07/93		09/08/93	
			value	(φ)	value	(φ)	value	(φ)
Range value	Range date							
HB	12.8-16 (G/DL)	01/02/93	14.30		14.20		14.20	
HT	37-47 (X)	01/02/93	41.00		44.00		38.00	
RBC	4.5-5 (10 ⁶ /MM ³)	01/02/93	4.70		4.70		4.80	
WBC	3.5-9 (10 ³ /MM ³)	01/02/93	4.50		5.20		6.20	
WBC: N	37-73 (X)	01/02/93	42.00		52.00		42.00	
WBC: L	20-55 (X)	01/02/93	38.00		37.00		35.00	
WBC: E	0.5-11 (X)	01/02/93	10.20		1.40		6.40	
WBC: M	2.5-10 (X)	01/02/93	8.20		3.40		6.80	
WBC: B	0-2 (X)	01/02/93	1.00		0.00		1.00	
PLATELETS	150-400 (10 ³ /MM ³)	01/02/93	320.00		320.00		280.00	
NA+	134-148 (MMOL/L)	01/02/93	142.00		143.00		146.00	
K+	3.8-5.2 (MMOL/L)	01/02/93	4.20		4.20		4.80	
CL-	94-110 (MMOL/L)	01/02/93	96.00		96.00		98.00	
Ca++	4.1-5.1 (MEQ/L)	01/02/93	4.40		4.80		5.00	
PO4--	25-48 (MG/L)	01/02/93	38.40		36.30		32.40	
SGOT	5-18 (U/L)	01/02/93	5.00		10.00		12.00	
SGPT	5-22 (U/L)	01/02/93	8.00		12.00		10.00	
GAMMA GT	4-28 (U/L)	01/02/93	8.00		7.00		8.00	
LDH	120-240 (U/L)	01/02/93	151.00		167.00		148.00	
ALK. PHOSPH.	60-170 (U/L)	01/02/93	170.00		172.00		167.00	
GLUCOSE	60-110 (MG/DL)	01/02/93	110.00		98.00		82.00	
BUN	10-50 (MG/DL)	01/02/93	64.00	>	59.00	>	49.00	
CREATININE	0.3-1.2 (MG/DL)	01/02/93	1.10		1.06		1.00	
CREATININE CLEARANCE	80-160 (ML/MIN)	01/02/93	40.32					
URIC ACID	2.4-7 (MG/DL)	01/02/93	5.40		4.80		4.80	
TOT BILIRUBIN	0-1 (MG/DL)	01/02/93	0.00		0.80		0.70	
TOT. PROTEINS	6.6-8.7 (G/DL)	01/02/93	7.90		8.00		6.90	
ALBUMINE	3.7-5.5 (G/DL)	01/02/93	4.20		4.30		4.80	
TOT. CHOLEST.	0-200 (MG/DL)	01/02/93	233.00	>	232.00	>	208.00	
TRIGLYCERIDES	50-180 (MG/DL)	01/02/93	126.00		108.00		102.00	
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	01/02/93	0.20		0.20		0.20	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	01/02/93	0.40		0.40		0.50	
GLOBULINS BETA	0.4-0.9 (G/DL)	01/02/93	0.70		0.50		0.80	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	01/02/93	1.00		0.90		1.00	
TSH	0.2-4 (UU/ML)	01/02/93	3.20					
T4	5-11.5 (UG/DL)	01/02/93	6.70					
ESR/SEDIMENT. RATE	0-10 (MM)	01/02/93						
1st h			12.00		8.00		10.00	
ESR/SEDIMENT. RATE	0-30 (MM)	01/02/93						
2nd h			18.00		12.00		15.00	

2342

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C9559089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 294 Patient: 27MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	Day 28
			15/06/93	13/07/93
			value (⊕)	value (⊕)
Laboratory test	Range value	Range date		
HB	12.8-16 (G/DL)	01/02/93	14.80	13.20
HT	37-47 (Z)	01/02/93	42.00	42.00
RBC	4.5-5 (10 ⁶ /MM ³)	01/02/93	4.70	4.70
WBC	3.5-9 (10 ³ /MM ³)	01/02/93	4.20	4.00
WBC: N	37-73 (Z)	01/02/93	47.00	52.00
WBC: L	20-55 (Z)	01/02/93	35.00	35.00
WBC: E	0.5-11 (Z)	01/02/93	10.80	8.60
WBC: M	2.5-10 (Z)	01/02/93	6.40	3.40
WBC: B	0-2 (Z)	01/02/93	0.80	1.00
PLATELETS	150-400 (10 ³ /MM ³)	01/02/93	280.00	275.00
NA+	134-148 (MMOL/L)	01/02/93	142.00	142.00
K+	3.8-5.2 (MMOL/L)	01/02/93	4.60	4.60
CL-	94-110 (MMOL/L)	01/02/93	96.00	98.00
Ca++	4.1-5.1 (MEQ/L)	01/02/93	4.80	4.80
PO4--	25-48 (MG/L)	01/02/93	32.80	46.80
SGOT	5-18 (U/L)	01/02/93	18.00	12.00
SGPT	5-22 (U/L)	01/02/93	19.00	18.00
GAMMA GT	4-28 (U/L)	01/02/93	14.00	22.00
LDH	120-240 (U/L)	01/02/93	225.00	148.00
ALK. PHOSPH.	60-170 (U/L)	01/02/93	162.00	162.00
GLUCOSE	60-110 (MG/DL)	01/02/93	98.00	84.00
BUN	10-50 (MG/DL)	01/02/93	42.00	38.00
CREATININE	0.3-1.2 (MG/DL)	01/02/93	0.70	0.70
CREATININE CLEARANCE		01/02/93	103.04	
URIC ACID	2.4-7 (MG/DL)	01/02/93	6.90	5.80
TOT BILIRUBIN	0-1 (MG/DL)	01/02/93	0.70	0.70
TOT. PROTEINS	6.6-8.7 (G/DL)	01/02/93	7.40	7.80
ALBUMINE	3.7-5.5 (G/DL)	01/02/93	4.80	4.80
TOT. CHOLEST.	0-200 (MG/DL)	01/02/93	294.00 >>	284.00 >>
TRIGLYCERIDES	50-180 (MG/DL)	01/02/93	214.00 >	186.00 >
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	01/02/93	0.20	0.20
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	01/02/93	0.40	0.50
GLOBULINS BETA	0.4-0.9 (G/DL)	01/02/93	0.50	0.70
GLOBULINS GAMMA	0.7-1.4 (G/DL)	01/02/93	0.90	1.00
TSH	0.2-4 (UU/ML)	01/02/93	1.40	
T4	5-11.5 (UG/DL)	01/02/93	7.30	
ESR/SEDIMENT. RATE 0-10 (MM)		01/02/93		
1st h			10.00	10.00
ESR/SEDIMENT. RATE 0-30 (MM)		01/02/93		
2nd h			18.00	15.00

2343

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done (⊖) missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C0580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 294 Patient: 28MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			15/06/93		13/07/93		09/08/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12.8-16 (G/DL)	01/02/93	13.20		13.40		15.40	
HT	37-47 (X)	01/02/93	39.00		43.00		39.40	
RBC	4.5-5 (10~6/MM3)	01/02/93	4.70		4.80		4.70	
WBC	3.5-9 (10~3/MM3)	01/02/93	5.60		4.80		6.20	
WBC: N	37-73 (X)	01/02/93	53.00		46.00		50.00	
WBC: L	20-55 (X)	01/02/93	38.00		35.00		37.00	
WBC: E	0.5-11 (X)	01/02/93	4.30		6.40		6.00	
WBC: M	2.5-10 (X)	01/02/93	3.80		7.20		6.00	
WBC: B	0-2 (X)	01/02/93	0.90		1.00		1.00	
PLATELETS	150-400 (10~3/MM3)	01/02/93	325.00		280.00		340.00	
NA+	134-148 (MMOL/L)	01/02/93	142.00		142.00		146.00	
K+	3.8-5.2 (MMOL/L)	01/02/93	4.20		4.20		4.20	
CL-	94-110 (MMOL/L)	01/02/93	96.00		96.80		98.00	
Ca++	4.1-5.1 (MEQ/L)	01/02/93	5.10		4.80		4.80	
PO4--	25-48 (MG/L)	01/02/93	42.40		32.40		36.40	
SGOT	5-18 (U/L)	01/02/93	12.00		16.00		16.00	
SGPT	5-22 (U/L)	01/02/93	10.00		18.00		15.00	
GAMMA GT	4-28 (U/L)	01/02/93	22.00		24.00		26.00	
LDH	120-240 (U/L)	01/02/93	160.00		186.00		186.00	
ALK. PHOSPH.	60-170 (U/L)	01/02/93	125.00		146.00		142.00	
GLUCOSE	60-110 (MG/DL)	01/02/93	85.00		82.00		92.00	
BUN	10-50 (MG/DL)	01/02/93	32.00		25.00		32.00	
CREATININE	0.3-1.2 (MG/DL)	01/02/93	0.70		0.70		0.80	
CREATININE CLEARANCE	80-160 (ML/MIN)	01/02/93	60.24					
URIC ACID	2.4-7 (MG/DL)	01/02/93	5.80		4.80		7.40 >	
TOT BILIRUBIN	0-1 (MG/DL)	01/02/93	0.80		0.60		0.40	
TOT. PROTEINS	6.6-8.7 (G/DL)	01/02/93	7.40		6.90		6.90	
ALBUMINE	3.7-5.5 (G/DL)	01/02/93	4.20		4.20		4.20	
TOT. CHOLEST.	0-200 (MG/DL)	01/02/93	267.00	>>	248.00 >		256.00 >	
TRIGLYCERIDES	50-180 (MG/DL)	01/02/93	108.00		142.00		142.00	
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	01/02/93	0.10		0.20		0.10	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	01/02/93	0.40		0.50		0.40	
GLOBULINS BETA	0.4-0.9 (G/DL)	01/02/93	0.40		0.60		0.50	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	01/02/93	0.90		0.80		0.90	
TSH	0.2-4 (UU/ML)	01/02/93	3.20					
T4	5-11.5 (UG/DL)	01/02/93	8.40					
ESR/SEDIMENT. RATE	0-10 (MM)	01/02/93						
1st h			10.00				8.00	
ESR/SEDIMENT. RATE	0-30 (MM)	01/02/93						
2nd h			15.00				15.00	

2344

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C950089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 294 Patient: 13DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			08/03/93		05/04/93		04/05/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12.8-16 (G/DL)	01/02/93	14.40		14.20		15.40	
HT	37-47 (X)	01/02/93	39.00		38.00		39.00	
RBC	4.5-5 (10 ⁶ /MM ³)	01/02/93	4.60		4.70		4.60	
WBC	3.5-9 (10 ³ /MM ³)	01/02/93	4.20		5.10		4.80	
WBC: N	37-73 (%)	01/02/93	52.00		53.00		52.00	
WBC: L	20-55 (%)	01/02/93	35.00		35.00		36.00	
WBC: E	0.5-11 (%)	01/02/93	6.00		6.50		7.50	
WBC: M	2.5-10 (%)	01/02/93	6.00		4.50		4.50	
WBC: B	0-2 (%)	01/02/93	1.00		1.00		0.00	
PLATELETS	150-400 (10 ³ /MM ³)	01/02/93	375.00		285.00		320.00	
NA+	134-148 (MMOL/L)	01/02/93	146.00		145.00		145.00	
K+	3.8-5.2 (MMOL/L)	01/02/93	4.70		4.20		4.20	
CL-	94-110 (MMOL/L)	01/02/93	98.00		98.00		95.00	
Ca++	4.1-5.1 (MEQ/L)	01/02/93	4.59		4.80		4.90	
PO4--	25-48 (MG/L)	01/02/93	32.40		32.30		36.40	
SGOT	5-18 (U/L)	01/02/93	10.00		10.00		8.00	
SGPT	5-22 (U/L)	01/02/93	9.00		12.00		12.00	
GAMMA GT	4-28 (U/L)	01/02/93	12.00		14.00		10.00	
LDH	120-240 (U/L)	01/02/93	175.00		175.00		185.00	
ALK. PHOSPH.	60-170 (U/L)	01/02/93	110.00		115.00		120.00	
GLUCOSE	60-110 (MG/DL)	01/02/93	94.00		85.00		82.00	
BUN	10-50 (MG/DL)	01/02/93	38.00		32.00		36.00	
CREATININE	0.3-1.2 (MG/DL)	01/02/93	0.83		0.70		1.00	
CREATININE CLEARANCE	80-160 (ML/MIN)	01/02/93	48.99					
URIC ACID	2.4-7 (MG/DL)	01/02/93	4.30		3.40		5.30	
TOT BILIRUBIN	0-1 (MG/DL)	01/02/93	0.43		0.80		0.80	
TOT. PROTEINS	6.6-8.7 (G/DL)	01/02/93	6.80		7.20		7.20	
ALBUMINE	3.7-5.5 (G/DL)	01/02/93	4.20		4.40		4.50	
TOT. CHOLEST.	0-200 (MG/DL)	01/02/93	243.00	>	235.00	>	239.00	
TRIGLYCERIDES	50-180 (MG/DL)	01/02/93	92.70		98.00		102.00	
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	01/02/93	0.20		0.20		0.10	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	01/02/93	0.40		0.50		0.40	
GLOBULINS BETA	0.4-0.9 (G/DL)	01/02/93	0.40		0.40		0.50	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	01/02/93	0.90		0.90		1.00	
TSH	0.2-4 (UU/ML)	01/02/93	2.40					
T4	5-11.5 (UG/DL)	01/02/93	7.20					
ESR/SEDIMENT. RATE	0-10 (MM)	01/02/93						
1st h			5.00		7.00		7.00	
ESR/SEDIMENT. RATE	0-30 (MM)	01/02/93						
2nd h			12.00		10.00		15.00	

2345

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C950089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 294 Patient: 14DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			08/03/93		05/04/93		04/05/93	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	12.8-16 (G/DL)	01/02/93	14.20		14.00		13.20	
HT	37-47 (X)	01/02/93	39.00		37.00		38.00	
RBC	4.5-5 (10 ⁶ /MM ³)	01/02/93	4.60		4.80		5.00	
WBC	3.5-9 (10 ³ /MM ³)	01/02/93	5.20		4.90		4.80	
WBC: N	37-73 (X)	01/02/93	49.00		48.00		58.00	
WBC: L	20-55 (X)	01/02/93	35.00		37.00		32.00	
WBC: E	0.5-11 (X)	01/02/93	6.80		6.60		4.50	
WBC: M	2.5-10 (X)	01/02/93	8.20		8.40		4.50	
WBC: B	0-2 (X)	01/02/93	1.00		0.00		1.00	
PLATELETS	150-400 (10 ³ /MM ³)	01/02/93	300.00		300.00		180.00	
NA+	134-148 (MMOL/L)	01/02/93	136.00		139.00		145.00	
K+	3.8-5.2 (MMOL/L)	01/02/93	4.80		4.10		4.20	
CL-	94-110 (MMOL/L)	01/02/93	96.00		97.00		95.00	
Ca++	4.1-5.1 (MEQ/L)	01/02/93	4.80		4.20		4.80	
PO4--	25-48 (MG/L)	01/02/93	46.20		45.80		46.20	
SGOT	5-18 (U/L)	01/02/93	13.00		14.00		12.00	
SGPT	5-22 (U/L)	01/02/93	12.00		7.00		10.00	
GAMMA GT	4-28 (U/L)	01/02/93	16.00		8.00		14.00	
LDH	120-240 (U/L)	01/02/93	170.00		165.00		185.00	
ALK. PHOSPH.	60-170 (U/L)	01/02/93	114.00		121.00		120.00	
GLUCOSE	60-110 (MG/DL)	01/02/93	96.00		96.00		86.00	
BUN	10-50 (MG/DL)	01/02/93	39.00		38.00		31.00	
CREATININE	0.3-1.2 (MG/DL)	01/02/93	0.64		0.70		0.70	
CREATININE CLEARANCE			87.44					
URIC ACID	2.4-7 (MG/DL)	01/02/93	3.70		4.20		4.50	
TOT BILIRUBIN	0-1 (MG/DL)	01/02/93	0.55		0.70		1.00	
TOT. PROTEINS	6.6-8.7 (G/DL)	01/02/93	6.60		6.70		6.90	
ALBUMINE	3.7-5.5 (G/DL)	01/02/93	4.20		4.30		4.20	
TOT. CHOLEST.	0-200 (MG/DL)	01/02/93	259.00	>	248.00	>	269.00	
TRIGLYCERIDES	50-180 (MG/DL)	01/02/93	109.00		98.00		172.00	
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	01/02/93	0.20		0.20		0.20	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	01/02/93	0.50		0.40		0.60	
GLOBULINS BETA	0.4-0.9 (G/DL)	01/02/93	0.40		0.40		0.50	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	01/02/93	1.10		0.80		0.80	
TSH	0.2-4 (U/ML)	01/02/93	3.00					
T4	5-11.5 (UG/DL)	01/02/93	7.90					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/02/93	10.00		10.00		10.00	
ESR/SEDIMENT. RATE 2nd h	0-30 (MM)	01/02/93	17.00		15.00		18.00	

2346

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C5530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 294 Patient: 15DT Treatment: Imipranine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			09/03/93		06/04/93		04/05/93	
			value	(†)	value	(†)	value	(†)
Laboratory test	Range value	Range date						
HB	12.8-16 (G/DL)	01/02/93	14.20		14.60		14.20	
HT	37-47 (X)	01/02/93	37.00		42.00		38.00	
RBC	4.5-5 (10 ⁶ /MM ³)	01/02/93	4.60		4.60		4.70	
WBC	3.5-9 (10 ³ /MM ³)	01/02/93	4.90		4.20		4.20	
WBC: N	37-73 (X)	01/02/93	43.00		39.00		48.00	
WBC: L	20-55 (X)	01/02/93	35.00		37.00		36.00	
WBC: E	0.5-11 (X)	01/02/93	6.40		7.40		6.80	
WBC: M	2.5-10 (X)	01/02/93	8.20		8.20		8.20	
WBC: B	0-2 (X)	01/02/93	0.00		1.00		1.00	
PLATELETS	150-400 (10 ³ /MM ³)	01/02/93	379.00		284.00		297.00	
NA+	134-148 (MMOL/L)	01/02/93	138.00		146.00		145.00	
K+	3.8-5.2 (MMOL/L)	01/02/93	4.50		4.80		4.20	
CL-	94-110 (MMOL/L)	01/02/93	96.00		97.00		95.00	
Ca++	4.1-5.1 (MEQ/L)	01/02/93	4.28		4.80		4.80	
PO4--	25-48 (NG/L)	01/02/93	38.30		32.40		42.80	
SGOT	5-18 (U/L)	01/02/93	15.00		10.00		16.00	
SGPT	5-22 (U/L)	01/02/93	22.00		12.00		14.00	
GAMMA GT	4-28 (U/L)	01/02/93	28.00		18.00		18.00	
LDH	120-240 (U/L)	01/02/93	159.00		195.00		192.00	
ALK. PHOSPH.	60-170 (U/L)	01/02/93	125.00		145.00		145.00	
GLUCOSE	60-110 (MG/DL)	01/02/93	72.00		79.00		80.00	
BUN	10-50 (MG/DL)	01/02/93	37.00		31.00		34.00	
CREATININE	0.3-1.2 (MG/DL)	01/02/93	0.90		0.70		0.70	
CREATININE CLEARANCE	80-160 (ML/MIN)	01/02/93	59.48					
URIC ACID	2.4-7 (MG/DL)	01/02/93	5.50		4.50		5.40	
TOT BILIRUBIN	0-1 (MG/DL)	01/02/93	0.50		0.70		0.80	
TOT. PROTEINS	6.6-8.7 (G/DL)	01/02/93	7.40		6.90		7.40	
ALBUMINE	3.7-5.5 (G/DL)	01/02/93	4.30		4.80		5.10	
TOT. CHOLEST.	0-200 (MG/DL)	01/02/93	235.00	>	225.00	>	242.00	
TRIGLYCERIDES	50-180 (MG/DL)	01/02/93	169.00		178.00		168.00	
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	01/02/93	0.20		0.30		0.20	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	01/02/93	0.70		0.50		0.50	
GLOBULINS BETA	0.4-0.9 (G/DL)	01/02/93	0.80		0.60		0.80	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	01/02/93	0.80		0.90		0.90	
TSH	0.2-4 (UU/ML)	01/02/93	2.60					
T4	5-11.5 (UG/DL)	01/02/93	6.70					
ESR/SEDIMENT. RATE	0-10 (MM)	01/02/93						
1st h			10.00		10.00		10.00	
ESR/SEDIMENT. RATE	0-30 (MM)	01/02/93						
2nd h			15.00		18.00		14.00	

2347

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C9590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 294 Patient: 16DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			09/03/93		06/04/93		04/05/93	
			value	(†)	value	(†)	value	(†)
Laboratory test	Range value	Range date						
HB	12.8-16 (G/DL)	01/02/93	14.20		15.20		14.20	
HT	37-47 (%)	01/02/93	39.00		42.00		43.00	
RBC	4.5-5 (10 ⁶ /MM ³)	01/02/93	4.70		4.50		4.70	
WBC	3.5-9 (10 ³ /MM ³)	01/02/93	4.80		4.80		6.20	
WBC: N	37-73 (%)	01/02/93	44.00		52.00		42.00	
WBC: L	20-55 (%)	01/02/93	35.00		36.00		37.00	
WBC: E	0.5-11 (%)	01/02/93	6.50		3.20		6.40	
WBC: M	2.5-10 (%)	01/02/93	8.40		7.40		7.40	
WBC: B	0-2 (%)	01/02/93	1.00		1.00		1.00	
PLATELETS	150-400 (10 ³ /MM ³)	01/02/93	325.00		298.00		326.00	
NA+	134-148 (MMOL/L)	01/02/93	138.00		142.00		142.00	
K+	3.8-5.2 (MMOL/L)	01/02/93	4.00		4.80		4.10	
CL-	94-110 (MMOL/L)	01/02/93	102.00		104.00		102.00	
Ca++	4.1-5.1 (MEQ/L)	01/02/93	4.40		5.00		4.80	
PO4--	25-48 (MG/L)	01/02/93	47.20		38.40		42.40	
SGOT	5-18 (U/L)	01/02/93	11.00		16.00		16.00	
SGPT	5-22 (U/L)	01/02/93	8.00		20.00		20.00	
GAMMA GT	4-28 (U/L)	01/02/93	9.00		16.00		22.00	
LDH	120-240 (U/L)	01/02/93	148.00		180.00		170.00	
ALK. PHOSPH.	60-170 (U/L)	01/02/93	122.00		120.00		125.00	
GLUCOSE	60-110 (MG/DL)	01/02/93	79.00		80.00		86.00	
BUN	10-50 (MG/DL)	01/02/93	24.00		31.00		32.00	
CREATININE	0.3-1.2 (MG/DL)	01/02/93	1.00		0.70		1.00	
CREATININE CLEARANCE	80-160 (ML/MIN)	01/02/93	56.92					
URIC ACID	2.4-7 (MG/DL)	01/02/93	4.80		5.20		4.50	
TOT BILIRUBIN	0-1 (MG/DL)	01/02/93	0.37		0.70		0.60	
TOT. PROTEINS	6.6-8.7 (G/DL)	01/02/93	7.60		6.90		6.90	
ALBUMINE	3.7-5.5 (G/DL)	01/02/93	4.80		4.20		4.80	
TOT. CHOLEST.	0-200 (MG/DL)	01/02/93	278.00	>>	252.00	>	224.00	
TRIGLYCERIDES	50-180 (MG/DL)	01/02/93	125.00		100.00		102.00	
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	01/02/93	0.30		0.20		0.20	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	01/02/93	0.70		0.40		0.60	
GLOBULINS BETA	0.4-0.9 (G/DL)	01/02/93	0.80		0.60		0.50	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	01/02/93	0.80		0.60	<	0.90	
TSH	0.2-4 (UU/ML)	01/02/93	2.40					
T4	5-11.5 (UG/DL)	01/02/93	8.40					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/02/93	10.00		12.00		10.00	
ESR/SEDIMENT. RATE 2nd h	0-30 (MM)	01/02/93	20.00		20.00		16.00	

2348

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CIPROFLOXACIN 500/89

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 294 Patient: 29DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			14/06/93		12/07/93		09/08/93	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	12.8-16 (G/DL)	01/02/93	12.80		13.40		12.90	
HT	37-47 (X)	01/02/93	42.00		39.00		39.20	
RBC	4.5-5 (10 ⁶ /MM ³)	01/02/93	4.70		4.70		4.70	
WBC	3.5-9 (10 ³ /MM ³)	01/02/93	8.20		6.20		4.20	
WBC: N	37-73 (X)	01/02/93	43.00		42.00		48.00	
WBC: L	20-55 (X)	01/02/93	37.00		38.00		40.00	
WBC: E	0.5-11 (X)	01/02/93	6.40		7.20		7.20	
WBC: M	2.5-10 (X)	01/02/93	8.40		6.40		4.80	
WBC: B	0-2 (X)	01/02/93	1.00		0.10		0.00	
PLATELETS	150-400 (10 ³ /MM ³)	01/02/93	320.00		300.00		220.00	
NA+	134-148 (MMOL/L)	01/02/93	140.00		142.00		145.00	
K+	3.8-5.2 (MMOL/L)	01/02/93	4.70		4.20		4.10	
CL-	94-110 (MMOL/L)	01/02/93	97.00		96.00		98.00	
Ca++	4.1-5.1 (MEQ/L)	01/02/93	4.40		4.70		4.80	
PO4--	25-48 (MG/L)	01/02/93	32.80		42.60		42.30	
SGOT	5-18 (U/L)	01/02/93	7.00		12.00		12.00	
SGPT	5-22 (U/L)	01/02/93	7.00		7.00		8.00	
GAMMA GT	4-28 (U/L)	01/02/93	14.00		7.00		8.00	
LDH	120-240 (U/L)	01/02/93	200.00		145.00		176.00	
ALK. PHOSPH.	60-170 (U/L)	01/02/93	166.00		162.00		141.00	
GLUCOSE	60-110 (MG/DL)	01/02/93	98.00		98.00		82.00	
BUN	10-50 (MG/DL)	01/02/93	48.00		42.00		43.00	
CREATININE	0.3-1.2 (MG/DL)	01/02/93	0.90		0.70		0.80	
CREATININE CLEARANCE	80-160 (ML/MIN)	01/02/93	45.49					
URIC ACID	2.4-7 (MG/DL)	01/02/93	3.10		4.20		5.20	
TOT BILIRUBIN	0-1 (MG/DL)	01/02/93	0.44		0.70		0.40	
TOT. PROTEINS	6.6-8.7 (G/DL)	01/02/93	7.40		7.20		6.80	
ALBUMINE	3.7-5.5 (G/DL)	01/02/93	4.20		4.20		4.70	
TOT. CHOLEST.	0-200 (MG/DL)	01/02/93	250.00	>	234.00	>	243.00	
TRIGLYCERIDES	50-180 (MG/DL)	01/02/93	71.00		102.00		75.00	
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	01/02/93	0.10		0.20		0.10	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	01/02/93	0.40		0.50		0.40	
GLOBULINS BETA	0.4-0.9 (G/DL)	01/02/93	0.50		0.60		0.40	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	01/02/93	0.70		0.90		0.80	
TSH	0.2-4 (UU/ML)	01/02/93	2.40					
T4	5-11.5 (UG/DL)	01/02/93	7.20					
ESR/SEDIMENT. RATE	0-10 (MM)	01/02/93						
1st h			8.00		10.00		7.00	
ESR/SEDIMENT. RATE	0-30 (MM)	01/02/93						
2nd h			17.00		17.00		12.00	

2349

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C9550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 294 Patient: 30DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			14/06/93		12/07/93		09/08/93	
			value	(†)	value	(‡)	value	(‡)
Laboratory test	Range value	Range date						
HB	12.8-16 (G/DL)	01/02/93	13.20		13.40		14.20	
HT	37-47 (X)	01/02/93	42.00		42.00		42.00	
RBC	4.5-5 (10 ⁶ /MM ³)	01/02/93	4.70		4.70		4.80	
WBC	3.5-9 (10 ³ /MM ³)	01/02/93	4.30		5.70		5.20	
WBC: N	37-73 (X)	01/02/93	52.00		48.00		45.00	
WBC: L	20-55 (X)	01/02/93	35.00		37.00		38.00	
WBC: E	0.5-11 (X)	01/02/93	0.80		4.20		2.40	
WBC: M	2.5-10 (X)	01/02/93	3.40		6.30		4.90	
WBC: B	0-2 (X)	01/02/93	0.20		0.80		0.60	
PLATELETS	150-400 (10 ³ /MM ³)	01/02/93	320.00		375.00		320.00	
NA+	134-148 (MMOL/L)	01/02/93	138.00		142.00		136.00	
K+	3.8-5.2 (MMOL/L)	01/02/93	4.40		4.30		4.10	
CL-	94-110 (MMOL/L)	01/02/93	96.00		96.00		96.00	
Ca++	4.1-5.1 (MEQ/L)	01/02/93	4.60		4.80		4.40	
PO4--	25-48 (MG/L)	01/02/93	32.80		32.80		30.70	
SGOT	5-18 (U/L)	01/02/93	11.00		17.00		14.00	
SGPT	5-22 (U/L)	01/02/93	18.00		16.00		16.00	
GAMMA GT	4-28 (U/L)	01/02/93	21.00		12.00		18.00	
LDH	120-240 (U/L)	01/02/93	222.00		182.00		130.00	
ALK. PHOSPH.	60-170 (U/L)	01/02/93	118.00		121.00		142.00	
GLUCOSE	60-110 (MG/DL)	01/02/93	93.00		98.00		78.00	
BUN	10-50 (MG/DL)	01/02/93	30.00		28.00		27.00	
CREATININE	0.3-1.2 (MG/DL)	01/02/93	1.00		0.70		0.80	
CREATININE CLEARANCE			48.08					
URIC ACID	2.4-7 (MG/DL)	01/02/93	4.40		3.80		3.80	
TOT BILIRUBIN	0-1 (MG/DL)	01/02/93	0.40		0.70		0.40	
TOT. PROTEINS	6.6-8.7 (G/DL)	01/02/93	6.80		7.20		7.20	
ALBUMINE	3.7-5.5 (G/DL)	01/02/93	4.20		4.20		4.20	
TOT. CHOLEST.	0-200 (MG/DL)	01/02/93	252.00	>	243.00	>	238.00	
TRIGLYCERIDES	50-180 (MG/DL)	01/02/93	128.00		143.00		78.00	
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	01/02/93	0.20		0.20		0.20	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	01/02/93	0.50		0.40		0.50	
GLOBULINS BETA	0.4-0.9 (G/DL)	01/02/93	0.40		0.60		0.60	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	01/02/93	0.90		0.80		0.80	
TSH	0.2-4 (UU/ML)	01/02/93	2.80					
T4	5-11.5 (UG/DL)	01/02/93	7.30					
ESR/SEDIMENT. RATE	0-10 (MM)	01/02/93						
1st h			10.00		8.00		7.00	
ESR/SEDIMENT. RATE	0-30 (MM)	01/02/93						
2nd h			12.00		17.00		12.00	

2350

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CN930089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 294 Patient: 31DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			21/06/93		19/07/93		16/08/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	12.8-16 (G/DL)	01/02/93	13.00		13.30		14.40	
HT	37-47 (X)	01/02/93	43.00		44.00		44.00	
RBC	4.5-5 (10 ⁶ /MM ³)	01/02/93	4.90		4.50		4.60	
RBC	3.5-9 (10 ⁶ /MM ³)	01/02/93	4.50		6.20		5.50	
RBC: N	37-73 (X)	01/02/93	53.00		47.00		54.00	
RBC: L	20-55 (X)	01/02/93	43.00		36.00		38.00	
RBC: E	0.5-11 (X)	01/02/93	0.70		10.40		3.40	
RBC: M	2.5-10 (X)	01/02/93	3.20		6.20		4.00	
RBC: B	0-2 (X)	01/02/93	0.10		0.40		0.60	
PLATELETS	150-400 (10 ³ /MM ³)	01/02/93	280.00		320.00		370.00	
NA+	134-148 (MMOL/L)	01/02/93	141.00		146.00		142.00	
K+	3.8-5.2 (MMOL/L)	01/02/93	4.50		4.60		3.90	
CL-	94-110 (MMOL/L)	01/02/93	97.00		95.00		94.00	
Ca++	4.1-5.1 (MEQ/L)	01/02/93	4.50		4.60		4.30	
PO4--	25-48 (MG/L)	01/02/93	33.20		34.40		29.40	
SGOT	5-18 (U/L)	01/02/93	10.00		14.00		10.00	
SGPT	5-22 (U/L)	01/02/93	12.00		8.00		12.00	
GAMMA GT	4-28 (U/L)	01/02/93	17.00		10.00		10.00	
LDH	120-240 (U/L)	01/02/93	210.00		176.00		122.00	
ALK. PHOSPH.	60-170 (U/L)	01/02/93	110.00		119.00		128.00	
GLUCOSE	60-110 (MG/DL)	01/02/93	86.00		102.00		93.00	
BUN	10-50 (MG/DL)	01/02/93	24.00		24.00		22.00	
CREATININE	0.3-1.2 (MG/DL)	01/02/93	0.70		0.80		0.70	
CREATININE CLEARANCE	80-160 (ML/MIN)	01/02/93	74.40					
URIC ACID	2.4-7 (MG/DL)	01/02/93	4.20		4.20		4.20	
TOT BILIRUBIN	0-1 (MG/DL)	01/02/93	0.50		0.80		0.40	
TOT. PROTEINS	6.6-8.7 (G/DL)	01/02/93	6.40	<	6.80		6.40	
ALBUMINE	3.7-5.5 (G/DL)	01/02/93	4.40		4.30		4.30	
TOT. CHOLEST.	0-200 (MG/DL)	01/02/93	228.00	>	218.00	>	203.00	
TRIGLYCERIDES	50-180 (MG/DL)	01/02/93	94.00		96.00		96.00	
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	01/02/93	0.20		0.30		0.20	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	01/02/93	0.40		0.40		0.50	
GLOBULINS BETA	0.4-0.9 (G/DL)	01/02/93	0.70		0.60		0.60	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	01/02/93	0.90		0.90		0.80	
TSH	0.2-4 (U/ML)	01/02/93	2.80					
T4	5-11.5 (UG/DL)	01/02/93	6.90					
ESR/SEDIMENT. RATE	0-10 (MM)	01/02/93						
1st h			7.00		7.00		8.00	
ESR/SEDIMENT. RATE	0-30 (MM)	01/02/93						
2nd h			12.00		10.00		15.00	

2351

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C 980089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 294 Patient: 32DT Treatment: Imipramine Sex: Male

Laboratory test			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			21/06/93		19/07/93		16/08/93	
			value	(€)	value	(€)	value	(€)
Range value	Range date							
HB	12.8-16 (G/DL)	01/02/93	13.80		13.80		14.00	
HT	37-47 (%)	01/02/93	38.00		43.00		37.40	
RBC	4.5-5 (10 ⁶ /MM ³)	01/02/93	4.70		4.40 <		4.60	
WBC	3.5-9 (10 ³ /MM ³)	01/02/93	5.20		5.00		4.70	
WBC: N	37-73 (%)	01/02/93	44.00		48.00		46.00	
WBC: L	20-55 (%)	01/02/93	37.00		37.00		42.00	
WBC: E	0.5-11 (%)	01/02/93	6.20		6.80		6.40	
WBC: M	2.5-10 (%)	01/02/93	6.80		7.40		4.80	
WBC: B	0-2 (%)	01/02/93	0.10		0.80		0.80	
PLATELETS	150-400 (10 ³ /MM ³)	01/02/93	365.00		310.00		305.00	
NA+	134-148 (MMOL/L)	01/02/93	136.00		142.00		143.00	
K+	3.8-5.2 (MMOL/L)	01/02/93	4.70		5.20		4.00	
CL-	94-110 (MMOL/L)	01/02/93	98.00		96.00		96.00	
Ca++	4.1-5.1 (MEQ/L)	01/02/93	4.33		4.80		4.60	
PO4--	25-48 (MG/L)	01/02/93	37.50		32.40		42.40	
SGOT	5-18 (U/L)	01/02/93	14.00		10.00		12.00	
SGPT	5-22 (U/L)	01/02/93	21.00		12.00		14.00	
GAMMA GT	4-28 (U/L)	01/02/93	17.00		10.00		10.00	
LDH	120-240 (U/L)	01/02/93	145.00		195.00		185.00	
ALK. PHOSPH.	60-170 (U/L)	01/02/93	134.00		148.00		140.00	
GLUCOSE	60-110 (MG/DL)	01/02/93	98.00		84.00		92.00	
BUN	10-50 (MG/DL)	01/02/93	29.00		29.00		22.00	
CREATININE	0.3-1.2 (MG/DL)	01/02/93	0.80		0.80		0.80	
CREATININE CLEARANCE	80-160 (ML/MIN)	01/02/93	92.40					
URIC ACID	2.4-7 (MG/DL)	01/02/93	5.60		6.40		4.60	
TOT BILIRUBIN	0-1 (MG/DL)	01/02/93	0.30		0.60		0.70	
TOT. PROTEINS	6.6-8.7 (G/DL)	01/02/93	7.80		6.80		6.80	
ALBUMINE	3.7-5.5 (G/DL)	01/02/93	4.20		4.40		5.00	
TOT. CHOLEST.	0-200 (MG/DL)	01/02/93	254.00 >		264.00 >>		245.00 >	
TRIGLYCERIDES	50-180 (MG/DL)	01/02/93	175.00		152.00		102.00	
GLOBULINS ALPHA 1	0.1-0.3 (G/DL)	01/02/93	0.20		0.20		0.10	
GLOBULINS ALPHA 2	0.4-0.8 (G/DL)	01/02/93	0.70		0.40		0.40	
GLOBULINS BETA	0.4-0.9 (G/DL)	01/02/93	0.80		0.60		0.60	
GLOBULINS GAMMA	0.7-1.4 (G/DL)	01/02/93	0.90		0.80		0.70	
TSH	0.2-4 (UU/ML)	01/02/93	3.40					
T4	5-11.5 (UG/DL)	01/02/93	6.40					
ESR/SEDIMENT. RATE	0-10 (MM)	01/02/93						
1st h			17.00		10.00		8.00	
ESR/SEDIMENT. RATE	0-30 (MM)	01/02/93						
2nd h			24.00		19.00		15.00	

2352

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CN580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 295 Patient: 17MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			20/04/93		17/05/93		15/06/93	
			value	(⊕)	value	(⊕)	value	(⊕)
Laboratory test	Range value	Range date						
HB	11-16 (G/DL)	01/04/93	13.80		14.20		13.90	
HT	36-47 (Z)	01/04/93	37.90		38.90		38.80	
RBC	3.8-5.2 (10 ⁶ /MM ³)	01/04/93	4.43		4.61		4.55	
WBC	5-9 (10 ³ /MM ³)	01/04/93	8.00		7.80		8.90	
WBC: N	50-70 (Z)	01/04/93	50.00		46.00	<	47.00	<
WBC: L	25-40 (Z)	01/04/93	39.00		43.00	>	40.00	>
WBC: E	2-4 (Z)	01/04/93	3.00		1.00	<	2.00	<
WBC: M	2-8 (Z)	01/04/93	8.00		9.00	>	9.00	>
WBC: B	0-1 (Z)	01/04/93	0.00		0.00		1.00	
PLATELETS	150-300 (10 ³ /MM ³)	01/04/93	310.00	>	323.00	>	325.00	>
NA+	137-147 (MMOL/L)	01/04/93	148.00	>	145.00		145.00	
K+	3.6-5.5 (MMOL/L)	01/04/93	3.70		3.60		3.80	
CL-	101-111 (MMOL/L)	01/04/93	98.00	<	102.00		108.00	
Ca++	2.25-2.6 (MMOL/L)	01/04/93	2.47		2.38		2.40	
PO4--	2.7-4.7 (MG/DL)	01/04/93	2.91		2.47	<	2.88	
SGOT	4-13 (U/L)	01/04/93	12.00		14.10	>	11.40	
SGPT	5-19 (U/L)	01/04/93	14.00		23.20	>	13.40	
GAMMA GT	4-18 (U/L)	01/04/93	22.00	>	25.30	>	20.80	>
LDH	80-240 (U/L)	01/04/93	162.00		178.00		161.00	
ALK. PHOSPH.	40-190 (U/L)	01/04/93	88.00		99.00		85.00	
GLUCOSE	76-110 (MG/DL)	01/04/93	110.00		120.00	>	111.00	>
BUN	20-40 (MG/DL)	01/04/93	52.00	>	51.00	>	43.00	>
CREATININE	0.6-1.1 (MG/DL)	01/04/93	1.30	>	1.37	>	1.13	>
CREATININE CLEARANCE			43.00					
URIC ACID	2.4-5.7 (MG/DL)	01/04/93	8.10	>>	8.44	>>	6.46	>
TOT BILIRUBIN	0-1.1 (MG/DL)	01/04/93	0.61		0.56		0.66	
TOT. PROTEINS	6.7-8.2 (G/DL)	01/04/93	7.85		7.79		8.01	
ALBUMINE	32-55 (G/L)	01/04/93	61.00	>	62.60	>	59.80	>
TOT. CHOLEST.	140-250 (MG/DL)	01/04/93	199.00		147.00		191.00	
TRIGLYCERIDES	0-200 (MG/DL)	01/04/93	182.00		147.00		205.00	>
GLOBULINS ALPHA 1	2.5-4.5 (Z)	01/04/93	3.10		3.40		3.40	
GLOBULINS ALPHA 2	8-12 (Z)	01/04/93	10.10		9.60		7.70	<
GLOBULINS BETA	9-14 (Z)	01/04/93	9.40		9.80		12.70	
GLOBULINS GAMMA	10-18 (Z)	01/04/93	16.50		14.60		16.40	
TSH	0.17-2.87 (MU/L)	01/04/93	1.48					
T4	48-120 (UG/L)	01/04/93	93.00					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/04/93	6.00		4.00		5.00	
ESR/SEDIMENT. RATE 2nd h	0-20 (MM)	01/04/93	15.00		15.00		14.00	

2353

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C 9530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 295 Patient: 18MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			20/04/93		21/05/93		18/06/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	11-16 (G/DL)	01/04/93	13.80		13.60		14.20	
HT	36-47 (X)	01/04/93	36.10		37.20		38.30	
RBC	3.8-5.2 (10 ⁶ /MM ³)	01/04/93	4.18		4.10		4.30	
WBC	5-9 (10 ³ /MM ³)	01/04/93	4.60	<	5.60		6.10	
WBC: N	50-70 (X)	01/04/93	53.00		56.00		52.00	
WBC: L	25-40 (X)	01/04/93	36.00		31.00		35.00	
WBC: E	2-4 (X)	01/04/93	2.00		3.00		2.00	
WBC: M	2-8 (X)	01/04/93	7.00		8.00		7.00	
WBC: B	0-1 (X)	01/04/93	0.00		0.00		0.00	
PLATELETS	150-300 (10 ³ /MM ³)	01/04/93	240.00		287.00		264.00	
NA+	137-147 (MMOL/L)	01/04/93	143.00		144.00		145.00	
K+	3.6-5.5 (MMOL/L)	01/04/93	4.60		5.10		4.90	
CL-	101-111 (MMOL/L)	01/04/93	102.00		105.00		105.00	
Ca++	2.25-2.6 (MMOL/L)	01/04/93	2.37		2.42		2.38	
PO4--	2.7-4.7 (MG/DL)	01/04/93	2.96		2.87		3.31	
SGOT	4-13 (U/L)	01/04/93	6.30		6.30		8.40	
SGPT	5-19 (U/L)	01/04/93	6.30		6.30		8.10	
GAMMA GT	4-18 (U/L)	01/04/93	9.80		4.40		6.90	
LDH	80-240 (U/L)	01/04/93	168.00		158.00		164.00	
ALK. PHOSPH.	40-190 (U/L)	01/04/93	92.00		94.00		102.00	
GLUCOSE	76-110 (MG/DL)	01/04/93	117.00	>	110.00		101.00	
BUN	20-40 (MG/DL)	01/04/93	47.00	>	47.00	>	44.00	>
CREATININE	0.6-1.1 (MG/DL)	01/04/93	1.32	>	1.28	>	1.11	>
CREATININE CLEARANCE	95-160 (ML/MIN)	01/04/93	35.00					
URIC ACID	2.4-5.7 (MG/DL)	01/04/93	5.28		5.09		4.84	
TOT BILIRUBIN	0-1.1 (NG/DL)	01/04/93	0.53		0.55		0.62	
TOT. PROTEINS	6.7-8.2 (G/DL)	01/04/93	7.33		7.29		7.41	
ALBUMINE	32-55 (G/L)	01/04/93	61.50	>	61.90	>	64.40	>
TOT. CHOLEST.	140-250 (MG/DL)	01/04/93	304.00	>	269.00	>	241.00	
TRIGLYCERIDES	0-200 (MG/DL)	01/04/93	101.00		134.00		168.00	
GLOBULINS ALPHA 1	2.5-4.5 (X)	01/04/93	2.90		3.00		3.40	
GLOBULINS ALPHA 2	8-12 (X)	01/04/93	8.70		8.50		6.80	<
GLOBULINS BETA	9-14 (X)	01/04/93	14.20	>	13.50		12.90	
GLOBULINS GAMMA	10-18 (X)	01/04/93	12.70		13.20		12.50	
TSH	0.17-2.87 (MU/L)	01/04/93	2.23					
T4	48-120 (UG/L)	01/04/93	96.00					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/04/93	2.00		4.00		4.00	
ESR/SEDIMENT. RATE 2nd h	0-20 (MM)	01/04/93	10.00		8.00		9.00	

2354

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 06590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 295 Patient: 19ND Treatment: Imipramine Sex: Male

Laboratory test			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			13/05/93		11/06/93		09/07/93	
			value	(φ)	value	(φ)	value	(φ)
Range value	Range date							
HB	13-18 (G/DL)	01/04/93	14.30		14.80		14.90	
HT	40-54 (X)	01/04/93	40.20		41.20		43.00	
RBC	4.4-5.9 (10 ⁶ /MM ³)	01/04/93	4.47		4.61		4.72	
WBC	5-9 (10 ³ /MM ³)	01/04/93	5.70		6.10		7.40	
WBC: N	50-70 (%)	01/04/93	52.00		51.00		52.00	
WBC: L	25-40 (%)	01/04/93	40.00		39.00		36.00	
WBC: E	2-4 (%)	01/04/93	1.00	<	1.00	<	2.00	
WBC: M	2-8 (%)	01/04/93	7.00		7.00		6.00	
WBC: B	0-1 (%)	01/04/93	0.00		1.00		1.00	
PLATELETS	150-300 (10 ³ /MM ³)	01/04/93	269.00		269.00		310.00 >	
NA+	137-147 (MMOL/L)	01/04/93	144.00		141.00		143.00	
K+	3.6-5.5 (MMOL/L)	01/04/93	4.20		4.00		4.20	
CL-	101-111 (MMOL/L)	01/04/93	104.00		105.00		106.00	
Ca++	2.25-2.6 (MMOL/L)	01/04/93	2.43		2.37		2.43	
PO4--	2.7-4.5 (MG/DL)	01/04/93	2.42	<	2.66	<	2.83	
SGOT	5-17 (U/L)	01/04/93	8.00		8.40		9.10	
SGPT	5-23 (U/L)	01/04/93	11.30		11.80		12.20	
GAMMA GT	6-28 (U/L)	01/04/93	17.20		19.60		18.30	
LDH	80-240 (U/L)	01/04/93	144.00		138.00		142.00	
ALK. PHOSPH.	40-190 (U/L)	01/04/93	101.00		91.00		88.00	
GLUCOSE	76-110 (MG/DL)	01/04/93	108.00		110.00		102.00	
BUN	20-40 (MG/DL)	01/04/93	37.00		37.00		47.00 >	
CREATININE	0.7-1.3 (MG/DL)	01/04/93	1.07		1.04		1.08	
CREATININE CLEARANCE			74.90					
URIC ACID	3.4-7 (MG/DL)	01/04/93	4.95		5.90		6.20	
TOT BILIRUBIN	0-1.1 (MG/DL)	01/04/93	0.30		0.50		0.80	
TOT. PROTEINS	6.7-8.2 (G/DL)	01/04/93	7.69		7.60		7.81	
ALBUMINE	32-55 (G/L)	01/04/93	69.10 >		65.20 >		63.20 >	
TOT. CHOLEST.	140-250 (MG/DL)	01/04/93	238.00		258.00 >		243.00	
TRIGLYCERIDES	0-200 (MG/DL)	01/04/93	125.00		212.00 >		208.00 >	
GLOBULINS ALPHA 1	2.5-4.5 (%)	01/04/93	2.10 <		2.30 <		2.90	
GLOBULINS ALPHA 2	8-12 (%)	01/04/93	8.40		6.40 <		6.90 <	
GLOBULINS BETA	9-14 (%)	01/04/93	8.60 <		12.30		13.10	
GLOBULINS GAMMA	10-18 (%)	01/04/93	11.80		13.80		13.90	
TSH	0.17-2.87 (MU/L)	01/04/93	0.24					
T4	48-120 (UG/L)	01/04/93	71.00					
ESR/SEDIMENT. RATE	0-10 (MM)	01/04/93						
1st h			2.00		5.00		4.00	
ESR/SEDIMENT. RATE	0-20 (MM)	01/04/93						
2nd h			10.00		9.00		9.00	

2355

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNP 10089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 295 Patient: 20ND Treatment: Imipramine Sex: Female

Laboratory test			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			13/05/93		11/06/93		09/07/93	
			value	(φ)	value	(φ)	value	(φ)
Range value	Range date							
HB	11-16 (G/DL)	01/04/93	13.30		15.00		15.10	
HT	36-47 (X)	01/04/93	37.20		41.30		41.50	
RBC	3.8-5.2 (10 ⁶ /MM ³)	01/04/93	4.36		4.87		4.78	
MBC	5-9 (10 ³ /MM ³)	01/04/93	8.50		10.10	>	9.10	
MBC: N	50-70 (X)	01/04/93	69.00		62.00		57.00	
MBC: L	25-40 (X)	01/04/93	27.00		28.00		31.00	
MBC: E	2-4 (X)	01/04/93	2.00		2.00		3.00	
MBC: M	2-8 (X)	01/04/93	3.00		7.00		6.00	
MBC: B	0-1 (X)	01/04/93	0.00		0.00		0.00	
PLATELETS	150-300 (10 ³ /MM ³)	01/04/93	140.00	<	253.00		278.00	
NA+	137-147 (MMOL/L)	01/04/93	146.00		143.00		144.00	
K+	3.6-5.5 (MMOL/L)	01/04/93	4.50		3.90		4.00	
CL-	101-111 (MMOL/L)	01/04/93	112.00	>	111.00		109.00	
Ca++	2.25-2.6 (MMOL/L)	01/04/93	2.35		2.41		2.48	
PO4--	2.7-4.7 (MG/DL)	01/04/93	1.89	<<	2.53	<	2.68	
SGOT	4-13 (U/L)	01/04/93	13.70	>	9.10		10.10	
SGPT	5-19 (U/L)	01/04/93	14.70		12.20		12.80	
GAMMA GT	4-18 (U/L)	01/04/93	9.30		9.00		13.00	
LDH	80-240 (U/L)	01/04/93	173.00		149.00		154.00	
ALK. PHOSPH.	40-190 (U/L)	01/04/93	49.00		53.00		56.00	
GLUCOSE	76-110 (MG/DL)	01/04/93	75.00	<	102.00		98.00	
BUN	20-40 (MG/DL)	01/04/93	24.00		19.00	<	22.00	
CREATININE	0.6-1.1 (MG/DL)	01/04/93	1.00		1.05		0.92	
CREATININE CLEARANCE			51.20					
URIC ACID	2.4-5.7 (MG/DL)	01/04/93	3.80		3.84		3.94	
TOT BILIRUBIN	0-1.1 (MG/DL)	01/04/93	0.21		0.55		0.78	
TOT. PROTEINS	6.7-8.2 (G/DL)	01/04/93	6.57	<	7.01		7.24	
ALBUMINE	32-55 (G/L)	01/04/93	66.90	>	64.60	>	60.60	
TOT. CHOLEST.	140-250 (MG/DL)	01/04/93	143.00		130.00	<	144.00	
TRIGLYCERIDES	0-200 (MG/DL)	01/04/93	109.00		118.00		132.00	
GLOBULINS ALPHA 1	2.5-4.5 (X)	01/04/93	3.80		3.70		3.80	
GLOBULINS ALPHA 2	8-12 (X)	01/04/93	9.60		9.40		9.10	
GLOBULINS BETA	9-14 (X)	01/04/93	11.70		12.70		13.20	
GLOBULINS GAMMA	10-18 (X)	01/04/93	8.00	<	9.70	<	13.30	
TSH	0.17-2.87 (MU/L)	01/04/93	0.35					
T4	48-120 (UG/L)	01/04/93	95.00					
ESR/SEDIMENT. RATE	0-10 (MM)	01/04/93						
1st h			2.00		4.00		6.00	
ESR/SEDIMENT. RATE	0-20 (MM)	01/04/93						
2nd h			6.00		11.00		12.00	

2356

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CN950089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 295 Patient: 17DT Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			23/04/93		27/05/93		24/06/93	
			value	(†)	value	(†)	value	(†)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	01/04/93	15.10		15.70		16.20	
HT	40-54 (%)	01/04/93	42.20		44.10		44.80	
RBC	4.4-5.9 (10 ⁶ /MM ³)	01/04/93	4.75		4.98		5.30	
WBC	5-9 (10 ³ /MM ³)	01/04/93	10.80 >		10.70 >		7.20	
WBC: N	50-70 (%)	01/04/93	50.00		66.00		49.00 <	
WBC: L	25-40 (%)	01/04/93	39.00		23.00 <		40.00	
WBC: E	2-4 (%)	01/04/93	3.00		1.00 <		1.00 <	
WBC: M	2-8 (%)	01/04/93	8.00		9.00 >		9.00 >	
WBC: B	0-1 (%)	01/04/93	0.00		1.00		0.00	
PLATELETS	150-300 (10 ³ /MM ³)	01/04/93	164.00		151.00		221.00	
NA+	137-147 (MMOL/L)	01/04/93	144.00		147.00		145.00	
K+	3.6-5.5 (MMOL/L)	01/04/93	4.10		4.40		4.80	
CL-	101-111 (MMOL/L)	01/04/93	102.00		104.00		111.00	
Ca++	2.25-2.6 (MMOL/L)	01/04/93	2.28		2.27		2.56	
PO4--	2.7-4.5 (MG/DL)	01/04/93	2.01 <<		2.47 <		3.16	
SGOT	5-17 (U/L)	01/04/93	4.80 <		9.40		8.60	
SGPT	5-23 (U/L)	01/04/93	5.80		15.70		15.80	
GAMMA GT	6-28 (U/L)	01/04/93	17.60		17.00		13.80	
LDH	80-240 (U/L)	01/04/93	154.00		158.00		185.00	
ALK. PHOSPH.	40-190 (U/L)	01/04/93	119.00		128.00		185.00	
GLUCOSE	76-110 (MG/DL)	01/04/93	135.00 >		99.00		117.00 >	
BUN	20-40 (MG/DL)	01/04/93	52.00 >		41.00 >		36.00	
CREATININE	0.7-1.3 (MG/DL)	01/04/93	1.21		1.29		0.97	
CREATININE CLEARANCE	98-156 (ML/MIN)	01/04/93	64.00					
URIC ACID	3.4-7 (MG/DL)	01/04/93	5.97		5.58		6.33	
TOT BILIRUBIN	0-1.1 (MG/DL)	01/04/93	0.84		0.77		0.55	
TOT. PROTEINS	6.7-8.2 (G/DL)	01/04/93	7.26		7.56		6.64 <	
ALBUMINE	32-55 (G/L)	01/04/93	59.20 >		64.60 >		69.60 >	
TOT. CHOLEST.	140-250 (MG/DL)	01/04/93	168.00		185.00		228.00	
TRIGLYCERIDES	0-200 (MG/DL)	01/04/93	73.00		84.00		173.00	
GLOBULINS ALPHA 1	2.5-4.5 (%)	01/04/93	2.90		2.30 <		2.90	
GLOBULINS ALPHA 2	8-12 (%)	01/04/93	8.20		6.70 <		6.80 <	
GLOBULINS BETA	9-14 (%)	01/04/93	13.00		11.20		12.90	
GLOBULINS GAMMA	10-18 (%)	01/04/93	16.60		15.20		17.80	
TSH	0.17-2.87 (MU/L)	01/04/93	1.02					
T4	48-120 (UG/L)	01/04/93	62.00					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/04/93	5.00		3.00		3.00	
ESR/SEDIMENT. RATE 2nd h	0-20 (MM)	01/04/93	12.00		8.00		7.00	

2357

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C0550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 295 Patient: 18DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			27/04/93		27/05/93		24/06/93	
			value	(†)	value	(†)	value	(†)
Laboratory test	Range value	Range date						
HB	11-16 (G/DL)	01/04/93	12.90		14.10		14.80	
HT	36-47 (X)	01/04/93	36.10		38.30		41.20	
RBC	3.8-5.2 (10 ⁶ /MM ³)	01/04/93	4.06		4.15		4.58	
WBC	5-9 (10 ³ /MM ³)	01/04/93	7.30		5.90		7.60	
WBC: N	50-70 (X)	01/04/93	57.00		51.00		54.00	
WBC: L	25-40 (X)	01/04/93	35.00		39.00		38.00	
WBC: E	2-4 (X)	01/04/93	2.00		2.00		2.00	
WBC: M	2-8 (X)	01/04/93	6.00		7.00		6.00	
WBC: B	0-1 (X)	01/04/93	0.00		0.00		0.00	
PLATELETS	150-300 (10 ³ /MM ³)	01/04/93	350.00 >		273.00		194.00	
NA+	137-147 (MMOL/L)	01/04/93	147.00		142.00		144.00	
K+	3.6-5.5 (MMOL/L)	01/04/93	4.60		4.10		5.10	
CL-	101-111 (MMOL/L)	01/04/93	105.00		100.00 <		110.00	
Ca++	2.25-2.6 (MMOL/L)	01/04/93	2.29		2.48		2.49	
PO4--	2.7-4.7 (MG/DL)	01/04/93	2.50 <		3.09		2.87	
SGOT	4-13 (U/L)	01/04/93	9.80		8.40		10.10	
SGPT	5-19 (U/L)	01/04/93	11.20		12.80		11.50	
GAMMA GT	4-18 (U/L)	01/04/93	32.90 >		15.90		11.30	
LDH	80-240 (U/L)	01/04/93	156.00		124.00		152.00	
ALK. PHOSPH.	40-190 (U/L)	01/04/93	95.00		92.00		63.00	
GLUCOSE	76-110 (MG/DL)	01/04/93	107.00		123.00 >		114.00 >	
BUN	20-40 (MG/DL)	01/04/93	27.00		35.00		36.00	
CREATININE	0.6-1.1 (MG/DL)	01/04/93	0.85		0.78		1.03	
CREATININE CLEARANCE	95-160 (ML/MIN)	01/04/93	59.20					
URIC ACID	2.4-5.7 (MG/DL)	01/04/93	3.82		5.32		6.36 >	
TOT BILIRUBIN	0-1.1 (MG/DL)	01/04/93	0.37		0.51		0.61	
TOT. PROTEINS	6.7-8.2 (G/DL)	01/04/93	6.95		7.30		6.76	
ALBUMINE	32-55 (G/L)	01/04/93	59.60 >		65.30 >		67.80 >	
TOT. CHOLEST.	140-250 (MG/DL)	01/04/93	288.00 >		304.00 >		237.00	
TRIGLYCERIDES	0-200 (MG/DL)	01/04/93	161.00		234.00 >		163.00	
GLOBULINS ALPHA 1	2.5-4.5 (X)	01/04/93	3.50		2.60		2.80	
GLOBULINS ALPHA 2	8-12 (X)	01/04/93	11.90		8.20		10.20	
GLOBULINS BETA	9-14 (X)	01/04/93	13.90		13.60		12.10	
GLOBULINS GAMMA	10-18 (X)	01/04/93	11.10		10.40		10.20	
TSH	0.17-2.87 (MU/L)	01/04/93	0.63					
T4	48-120 (UG/L)	01/04/93	76.00					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/04/93	4.00		4.00		2.00	
ESR/SEDIMENT. RATE 2nd h	0-20 (MM)	01/04/93	8.00		8.00		7.00	

2358

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN9590089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 295 Patient: 19DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			07/05/93		07/06/93		05/07/93	
			value	(c)	value	(c)	value	(c)
Laboratory test	Range value	Range date						
HB	11-16 (G/DL)	01/04/93	14.60		15.00		13.70	
HT	36-47 (X)	01/04/93	40.00		41.90		38.20	
RBC	3.8-5.2 (10 ⁶ /MM ³)	01/04/93	4.84		5.06		4.61	
WBC	5-9 (10 ³ /MM ³)	01/04/93	7.30		9.01		8.90	
WBC: N	50-70 (X)	01/04/93	59.00		64.00		72.00	
WBC: L	25-40 (X)	01/04/93	28.00		26.00		19.00	
WBC: E	2-4 (X)	01/04/93	0.00	<	2.00		1.00	
WBC: M	2-8 (X)	01/04/93	8.00		8.00		8.00	
WBC: B	0-1 (X)	01/04/93	1.00		0.00		0.00	
PLATELETS	150-300 (10 ³ /MM ³)	01/04/93	177.00		180.00		225.00	
NA+	137-147 (MMOL/L)	01/04/93	148.00	>	149.00	>	145.00	
K+	3.6-5.5 (MMOL/L)	01/04/93	4.50		4.80		4.10	
CL-	101-111 (MMOL/L)	01/04/93	107.00		103.00		112.00	
Ca++	2.25-2.6 (MMOL/L)	01/04/93	2.22	<	2.57		2.37	
PO4--	2.7-4.7 (MG/DL)	01/04/93	2.60	<	2.55	<	2.59	
SGOT	4-13 (U/L)	01/04/93	6.40		6.30		7.40	
SGPT	5-19 (U/L)	01/04/93	6.00		7.10		8.10	
GAMMA GT	4-18 (U/L)	01/04/93	9.80		9.30		9.70	
LDH	80-240 (U/L)	01/04/93	142.00		166.00		169.00	
ALK. PHOSPH.	40-190 (U/L)	01/04/93	114.00		121.00		108.00	
GLUCOSE	76-110 (MG/DL)	01/04/93	111.00	>	109.00		106.00	
BUN	20-40 (MG/DL)	01/04/93	33.00		37.00		47.00	
CREATININE	0.6-1.1 (MG/DL)	01/04/93	0.88		0.86		0.83	
CREATININE CLEARANCE	95-160 (ML/MIN)	01/04/93	70.20					
URIC ACID	2.4-5.7 (MG/DL)	01/04/93	4.98		3.70		3.96	
TOT BILIRUBIN	0-1.1 (MG/DL)	01/04/93	0.31		0.30		0.33	
TOT. PROTEINS	6.7-8.2 (G/DL)	01/04/93	7.25		7.96		7.32	
ALBUMINE	32-55 (G/L)	01/04/93	62.30	>	61.50	>	59.70	
TOT. CHOLEST.	140-250 (MG/DL)	01/04/93	214.00		241.00		229.00	
TRIGLYCERIDES	0-200 (MG/DL)	01/04/93	206.00	>	157.00		209.00	
GLOBULINS ALPHA 1	2.5-4.5 (X)	01/04/93	2.90		3.10		4.00	
GLOBULINS ALPHA 2	8-12 (X)	01/04/93	9.00		9.90		11.10	
GLOBULINS BETA	9-14 (X)	01/04/93	12.30		11.80		12.20	
GLOBULINS GAMMA	10-18 (X)	01/04/93	13.60		13.70		12.90	
TSH	0.17-2.87 (MU/L)	01/04/93	0.39					
T4	48-120 (UG/L)	01/04/93	106.00					
ESR/SEDIMENT. RATE	0-10 (MM)	01/04/93						
1st h			8.00		5.00		8.00	
ESR/SEDIMENT. RATE	0-20 (MM)	01/04/93						
2nd h			16.00		9.00		12.00	

2359

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CN 930089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 295 Patient: 20DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			10/05/93		08/06/93		06/07/93	
			value	(⊖)	value	(⊕)	value	(⊕)
Laboratory test	Range value	Range date						
HB	11-16 (G/DL)	01/04/93	14.90		14.90		15.10	
HT	36-47 (Z)	01/04/93	41.30		41.70		42.30	
RBC	3.8-5.2 (10 ⁶ /MM ³)	01/04/93	4.45		4.51		4.56	
WBC	5-9 (10 ³ /MM ³)	01/04/93	6.30		6.50		6.90	
WBC: N	50-70 (Z)	01/04/93	47.00	<	51.00		48.00	<
WBC: L	25-40 (Z)	01/04/93	40.00		36.00		41.00	>
WBC: E	2-4 (Z)	01/04/93	2.00		3.00		2.00	
WBC: M	2-8 (Z)	01/04/93	9.00	>	8.00		8.00	
WBC: B	0-1 (Z)	01/04/93	0.00		1.00		0.00	
PLATELETS	150-300 (10 ³ /MM ³)	01/04/93	305.00	>	301.00	>	333.00	>
NA+	137-147 (MMOL/L)	01/04/93	145.00		148.00	>	143.00	
K+	3.6-5.5 (MMOL/L)	01/04/93	4.90		5.20		5.00	
CL-	101-111 (MMOL/L)	01/04/93	109.00		100.00	<	107.00	
Ca++	2.25-2.6 (MMOL/L)	01/04/93	2.62	>	2.46		2.42	
PO4--	2.7-4.7 (MG/DL)	01/04/93	3.27		3.15		3.28	
SGOT	4-13 (U/L)	01/04/93	7.30		7.10		6.70	
SGPT	5-19 (U/L)	01/04/93	6.30		7.00		5.90	
GAMMA GT	4-18 (U/L)	01/04/93	10.30		9.80		10.30	
LDH	80-240 (U/L)	01/04/93	172.00		192.00		163.00	
ALK. PHOSPH.	40-190 (U/L)	01/04/93	144.00		156.00		151.00	
GLUCOSE	76-110 (MG/DL)	01/04/93	118.00	>	98.00		112.00	>
BUN	20-40 (MG/DL)	01/04/93	43.00	>	32.00		35.00	
CREATININE	0.6-1.1 (MG/DL)	01/04/93	0.84		0.84		0.81	
CREATININE CLEARANCE	95-160 (ML/MIN)	01/04/93	82.00					
URIC ACID	2.4-5.7 (MG/DL)	01/04/93	3.87		3.49		4.15	
TOT BILIRUBIN	0-1.1 (MG/DL)	01/04/93	0.57		0.52		0.48	
TOT. PROTEINS	6.7-8.2 (G/DL)	01/04/93	7.44		7.78		7.65	
ALBUMINE	32-55 (G/L)	01/04/93	59.90	>	61.00	>	59.60	>
TOT. CHOLEST.	140-250 (MG/DL)	01/04/93	249.00		248.00		237.00	
TRIGLYCERIDES	0-200 (MG/DL)	01/04/93	151.00		205.00	>	238.00	>
GLOBULINS ALPHA 1	2.5-4.5 (Z)	01/04/93	3.50		3.20		2.90	
GLOBULINS ALPHA 2	8-12 (Z)	01/04/93	11.20		13.20	>	11.90	
GLOBULINS BETA	9-14 (Z)	01/04/93	11.60		9.10		9.90	
GLOBULINS GAMMA	10-18 (Z)	01/04/93	18.80	>	13.20		15.70	
TSH	0.17-2.87 (MU/L)	01/04/93	1.39					
T4	48-120 (UG/L)	01/04/93	104.00					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/04/93	4.00		4.00		5.00	
ESR/SEDIMENT. RATE 2nd h	0-20 (MM)	01/04/93	15.00		12.00		12.00	

2360

(⊖) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C8520089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 381 Patient: 1MD Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			06/12/93		05/01/94		03/02/94	
			value	(♣)	value	(♣)	value	(♣)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	01/12/93	11.50	<	11.50	<	12.00	<
RBC	4.5-6 (10 ⁹ /L)	01/12/93	3.89	<	3.88	<	3.97	<
HBC	4-11 (10 ⁹ /L)	01/12/93	5.60		9.80		7.20	
WBC: N	2-7.5 (10 ⁹ /L)	01/12/93	4.40		6.80			
WBC: L	1-4 (10 ⁹ /L)	01/12/93	0.80	<	2.10			
WBC: E	0.1-0.4 (10 ⁹ /L)	01/12/93	0.10		0.30			
WBC: M	0.2-0.8 (10 ⁹ /L)	01/12/93	0.30		0.50			
WBC: B	0-0.1 (10 ⁹ /L)	01/12/93			0.10			
PLATELETS	150-500 (10 ⁹ /L)	01/12/93	288.00		440.00		333.00	
NA+	135-145 (MMOL/L)	01/12/93	140.00		141.00		138.00	
K+	3.6-5 (MMOL/L)	01/12/93	3.80		4.70		3.50	<
CL-	94-104 (MMOL/L)	01/12/93			105.00	>		
Ca++	2.1-2.6 (MMOL/L)	01/12/93			2.33		2.36	
PO4--	0.8-1.4 (MMOL/L)	01/12/93			1.40		1.30	
SGOT	10-42 (IU/L)	01/12/93	14.00		14.00			
ALK. PHOSPH.	40-120 (IU/L)	01/12/93			81.00		65.00	
GLUCOSE	3-5.5 (MMOL/L)	01/12/93			6.10	>	6.00	>
UREA	2.9-7.5 (MMOL/L)	01/12/93	4.30		5.70		6.50	
CREATININE	60-120 (UMOL/L)	01/12/93	82.00		82.00		89.00	
URIC ACID	0.1-0.4 (MMOL/L)	01/12/93	0.27		0.31		0.30	
TOT. BILIRUBIN	0-17 (UMOL/L)	01/12/93	11.00		7.00		9.00	
DIR. BILIRUBIN	0-3.4 (UMOL/L)	01/12/93			3.00			
TOT. PROTEINS	60-80 (G/L)	01/12/93	67.00		73.00		68.00	
ALBUMINE	36-50 (G/L)	01/12/93	39.00		42.00		40.00	
TOT. CHOLEST.	0-5.2 (MMOL/L)	01/12/93	4.50		5.10		5.50	>
TRIGLYCERIDES	0.5-2.2 (MMOL/L)	01/12/93			1.20		1.10	
TSH	0.4-4 (MU/L)	01/12/93	0.60					
T4	50-160 (NMOL/L)	01/12/93	90.00					
ESR/SEDIMENT. RATE 1st h	2-10 (MM)	01/12/93	11.00		33.00		11.00	

2361

(♣) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C 8560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 381 Patient: 2MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date			
			Screen		Day 28	
			02/02/94		02/03/94	
			value	(€)	value	(€)
Laboratory test	Range value	Range date				
HB	115-160 (G/L)	01/02/94	124.00			
	11.5-16 (G/DL)	01/03/94		12.40		
RBC	3.8-5.5 (10 ¹² /L)	01/02/94	4.21	4.09		
WBC	4-11 (10 ⁹ /L)	01/02/94	6.40	6.60		
WBC: N	2-7.5 (10 ⁹ /L)	01/02/94	4.80	4.80		
WBC: L	1-4 (10 ⁹ /L)	01/02/94	1.00	1.10		
WBC: E	0.1-0.4 (10 ⁹ /L)	01/02/94	0.10	0.10		
WBC: M	0.2-0.8 (10 ⁹ /L)	01/02/94	0.50	0.50		
WBC: B	0-0.1 (10 ⁹ /L)	01/03/94		0.10		
PLATELETS	150-500 (10 ⁹ /L)	01/02/94	254.00	293.00		
NA+	135-145 (MMOL/L)	01/02/94	141.00	135.00		
K+	3.6-5 (MMOL/L)	01/02/94	3.90	3.20	<	
CL-	94-104 (MMOL/L)	01/02/94	104.00	97.00		
Ca++	2.1-2.6 (MMOL/L)	01/02/94	2.20	2.40		
PO4--	0.8-1.4 (MMOL/L)	01/02/94	0.80	0.90		
SGOT	10-42 (IU/L)	01/02/94	14.00	17.00		
ALK. PROSPH.	40-120 (IU/L)	01/02/94	60.00	63.00		
GLUCOSE	3-5.5 (MMOL/L)	01/02/94	4.80	5.70	>	
UREA	2.9-7.5 (MMOL/L)	01/02/94	2.90	3.00		
CREATININE	60-120 (UMOL/L)	01/02/94	64.00	66.00		
URIC ACID	0.1-0.4 (MMOL/L)	01/02/94	0.22	0.29		
TOT BILIRUBIN	0-17 (UMOL/L)	01/02/94	8.00	7.00		
DIR BILIRUBIN	0-3.4 (UMOL/L)	01/02/94	1.00	1.00		
TOT. PROTEINS	60-80 (G/L)	01/02/94	70.00	73.00		
ALBUMINE	36-50 (G/L)	01/02/94	41.00	42.00		
TOT. CHOLEST.	0-5.2 (MMOL/L)	01/02/94	5.50	5.80	>	
TRIGLYCERIDES	0.5-2.2 (MMOL/L)	01/02/94	1.00	1.10		
TSH	0.4-4 (MU/L)	01/02/94	2.00			
T4	50-160 (NMOL/L)	01/02/94	161.00			
ESR/SEDIMENT. RATE 1st h	2-10 (MM)	01/02/94	15.00	26.00		

2362

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C 580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 381 Patient: 4MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date
			Screen
			25/02/94
			value (c)
Laboratory test	Range value	Range date	
HB	115-160 (G/L)	01/09/93	146.00
RBC	3.8-5.5 (10 ¹² /L)	01/09/93	4.91
WBC	4-11 (10 ⁹ /L)	01/09/93	11.40 >
WBC: N	2-7.5 (10 ⁹ /L)	01/09/93	8.10 >
WBC: L	1-4 (10 ⁹ /L)	01/09/93	2.00
WBC: E	0.1-0.4 (10 ⁹ /L)	01/09/93	0.20
WBC: M	0.2-0.8 (10 ⁹ /L)	01/09/93	0.90 >
WBC: B	0-0.1 (10 ⁹ /L)	01/09/93	0.20 >>
PLATELETS	150-500 (10 ⁹ /L)	01/09/93	182.00
NA+	135-145 (MMOL/L)	01/09/93	138.00
K+	3.6-5 (MMOL/L)	01/09/93	5.20 >
CL-	94-104 (MMOL/L)	01/09/93	100.00
Ca++	2.1-2.6 (MMOL/L)	01/09/93	2.45
PO4--	0.8-1.4 (MMOL/L)	01/09/93	1.10
SGOT	10-42 (IU/L)	01/09/93	20.00
ALK. PHOSPH.	40-120 (IU/L)	01/09/93	87.00
GLUCOSE	3-5.5 (MMOL/L)	01/09/93	17.10 >>
UREA	2.9-7.5 (MMOL/L)	01/09/93	9.80 >
CREATININE	60-120 (UMOL/L)	01/09/93	138.00 >
URIC ACID	0.1-0.4 (MMOL/L)	01/09/93	0.53 >>
TOT BILIRUBIN	0-17 (UMOL/L)	01/09/93	13.00
DIR BILIRUBIN	0-3.4 (UMOL/L)	01/09/93	1.00
TOT. PROTEINS	60-80 (G/L)	01/09/93	76.00
ALBUMINE	36-50 (G/L)	01/09/93	43.00
TOT. CHOLEST.	0-5.2 (MMOL/L)	01/09/93	4.80
TRIGLYCERIDES	0.5-2.2 (MMOL/L)	01/09/93	2.00
TSH	0.4-4 (MU/L)	01/09/93	0.40
T4	50-160 (NMOL/L)	01/09/93	104.00
ESR/SEDIMENT. RATE 1st h	2-10 (MM)	01/09/93	15.00

2363

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA CN580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 381 Patient: 3DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	
			08/02/94	
			value	(c)
Laboratory test	Range value	Range date		
HB	11.5-16 (G/DL)	05/02/94	16.60	>
RBC	3.8-5.5 (10 ¹² /L)	05/02/94	4.71	
WBC	4-11 (10 ⁹ /L)	05/02/94	9.70	
PLATELETS	150-500 (10 ⁹ /L)	05/02/94	305.00	
NA+	135-145 (MMOL/L)	05/02/94	140.00	
K+	3.6-5 (MMOL/L)	05/02/94	3.70	
Ca++	2.1-2.6 (MMOL/L)	05/02/94	2.26	
PO4--	0.8-1.4 (MMOL/L)	05/02/94	1.20	
LDH	210-420 (IU/L)	05/02/94	388.00	
ALK. PHOSPH.	40-120 (IU/L)	05/02/94	42.00	
GLUCOSE	3-5.5 (MMOL/L)	05/02/94	5.30	
UREA	2.9-7.5 (MMOL/L)	05/02/94	1.80	<
URIC ACID	0.1-0.4 (MMOL/L)	05/02/94	0.29	
TOT. BILIRUBIN	0-17 (UMOL/L)	05/02/94	9.00	
ALBUMINE	36-50 (G/L)	05/02/94	37.00	
TOT. CHOLEST.	0-5.2 (MMOL/L)	05/02/94	4.90	
TSH	0.4-4 (MU/L)	05/02/94	0.70	
ESR/SEDIMENT. RATE 1st h	2-10 (MM)	05/02/94	2.00	

2364

(+) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C 950089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 382 Patient: SHD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			12/11/93		08/12/93		12/01/94	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	11.5-16 (G/DL)	10/11/93	12.20		11.10 <		12.40	
RBC	3.8-5.5 (10 ¹² /L)	10/11/93	3.65 <		3.58 <		4.25	
WBC	4-11 (10 ⁹ /L)	10/11/93	6.30		10.40		14.50 >>	
WBC: N	2-7.5 (10 ⁹ /L)	10/11/93	4.20		8.20 >		12.70 >>	
WBC: L	1-4 (10 ⁹ /L)	10/11/93	1.20		1.30		1.10	
WBC: E	0.1-0.4 (10 ⁹ /L)	10/11/93	0.20		0.10			
WBC: M	0.2-0.8 (10 ⁹ /L)	10/11/93	0.70		0.80		0.60	
WBC: B	0-0.1 (10 ⁹ /L)	10/11/93					0.10	
PLATELETS	150-500 (10 ⁹ /L)	10/11/93	245.00		276.00		271.00	
NA+	135-145 (MMOL/L)	10/11/93	134.00 <		125.00 <		126.00 <	
K+	3.6-5 (MMOL/L)	10/11/93	4.60		4.20		4.70	
CL-	94-104 (MMOL/L)	10/11/93	92.00 <					
Ca ⁺⁺	2.1-2.6 (MMOL/L)	10/11/93	2.51		2.50		2.42	
PO4 ⁻⁻	0.8-1.4 (MMOL/L)	10/11/93	1.00		1.10		1.00	
SGOT	10-42 (IU/L)	10/11/93	28.00				27.00	
ALK. PHOSPH.	40-120 (IU/L)	10/11/93	92.00		135.00 >		139.00 >	
GLUCOSE	3-5.5 (MMOL/L)	10/11/93	6.30 >				6.90 >	
UREA	2.9-7.5 (MMOL/L)	10/11/93	4.00		2.40 <		3.50	
CREATININE	60-120 (UMOL/L)	10/11/93	77.00		66.00		66.00	
URIC ACID	0.1-0.4 (MMOL/L)	10/11/93	0.31				0.20	
TOT BILIRUBIN	0-17 (UMOL/L)	10/11/93	9.00				19.00 >	
DIR BILIRUBIN	0-3.4 (UMOL/L)	10/11/93	3.00				1.00	
TOT. PROTEINS	60-80 (G/L)	10/11/93	70.00		72.00		69.00	
ALBUMINE	36-50 (G/L)	10/11/93	41.00		41.00		39.00	
TOT. CHOLEST.	0-5.2 (MMOL/L)	10/11/93	5.10				5.00	
TRIGLYCERIDES	0.5-2.2 (MMOL/L)	10/11/93	1.60				0.80	
TSH	0.4-4 (MU/L)	10/11/93	0.80					
T4	50-160 (NMOL/L)	10/11/93	90.00					
ESR/SEDIMENT. RATE 1st h	2-10 (MM)	10/11/93	59.00				42.00	

2365

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C8580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 382 Patient: 6MD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			12/11/93		10/12/93		07/01/94	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	115-160 (G/L)	01/11/93	125.00			123.00		
	11.5-16 (G/DL)	01/12/93		13.20				
RBC	3.8-5.5 (10 ¹² /L)	01/11/93	4.31	4.62		4.40		
WBC	4-11 (10 ⁹ /L)	01/11/93	8.00	6.90		8.10		
WBC: N	2-7.5 (10 ⁹ /L)	01/11/93	4.20	3.90		5.00		
WBC: L	1-4 (10 ⁹ /L)	01/11/93	3.00	2.40		2.50		
WBC: E	0.1-0.4 (10 ⁹ /L)	01/11/93	0.20	0.10		0.10		
WBC: M	0.2-0.8 (10 ⁹ /L)	01/11/93	0.50	0.40		0.40		
WBC: B	0-0.1 (10 ⁹ /L)	01/11/93	0.10	0.10		0.10		
PLATELETS	150-500 (10 ⁹ /L)	01/11/93	351.00	377.00		360.00		
NA+	135-145 (MMOL/L)	01/11/93	142.00	139.00		139.00		
K+	3.6-5 (MMOL/L)	01/11/93	4.00	4.50		4.50		
CL-	94-104 (MMOL/L)	01/12/93		101.00		100.00		
Ca++	2.1-2.6 (MMOL/L)	01/11/93	2.40	2.43		2.40		
PO4--	0.8-1.4 (MMOL/L)	01/11/93	1.20	1.20		1.30		
SGOT	10-42 (IU/L)	01/11/93	22.00	21.00		21.00		
ALK. PHOSPH.	40-120 (IU/L)	01/11/93	73.00	69.00		74.00		
GLUCOSE	3-5.5 (MMOL/L)	01/11/93	5.80 >	5.90 >		5.30		
UREA	2.9-7.5 (MMOL/L)	01/11/93	11.00 >	7.20		9.30 >		
CREATININE	60-120 (UMOL/L)	01/11/93	116.00	104.00		99.00		
URIC ACID	0.1-0.4 (MMOL/L)	01/11/93	0.48 >	0.47 >		0.46 >		
TOT BILIRUBIN	0-17 (UMOL/L)	01/11/93	8.00	11.00		6.00		
DIR BILIRUBIN	0-3.4 (UMOL/L)	01/11/93	1.00	1.00		1.00		
TOT. PROTEINS	60-80 (G/L)	01/11/93	68.00	70.00		68.00		
ALBUMINE	36-50 (G/L)	01/11/93	42.00	42.00		41.00		
TSH	0.4-4 (MU/L)	01/11/93	4.00					
T4	50-160 (NMOL/L)	01/11/93	75.00					
ESR/SEDIMENT. RATE 1st h	2-10 (MM)	01/11/93	44.00	37.00		44.00		

2366

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C8959089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centro: 382 Patient: 7ND Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			20/12/93		14/01/94		14/02/94	
			value	(⊕)	value	(⊕)	value	(⊕)
Laboratory test	Range value	Range date						
HB	115-160 (G/L)	10/12/93	122.00		130.00			
	11.5-16 (G/DL)	10/02/94				12.10		
RBC	3.8-5.5 (10 ⁹ /L)	10/12/93	4.07		4.23		4.00	
HRC	4-11 (10 ⁹ /L)	10/12/93	5.50		7.30		5.50	
HBC: N	2-7.5 (10 ⁹ /L)	10/12/93	3.30				3.00	
HBC: L	1-4 (10 ⁹ /L)	10/12/93	1.40				1.70	
HBC: E	0.1-0.4 (10 ⁹ /L)	10/12/93	0.30				0.30	
HBC: M	0.2-0.8 (10 ⁹ /L)	10/12/93	0.50				0.50	
PLATELETS	150-500 (10 ⁹ /L)	10/12/93	250.00		273.00		259.00	
NA+	135-145 (MMOL/L)	10/12/93	141.00		140.00		137.00	
K+	3.6-5 (MMOL/L)	10/12/93	4.50		5.00		4.30	
CL-	94-104 (MMOL/L)	10/12/93	107.00 >		109.00 >		105.00 >	
Ca++	2.1-2.6 (MMOL/L)	10/12/93	2.33		2.40		2.38	
PO4--	0.8-1.4 (MMOL/L)	10/12/93	1.10		1.30		1.30	
SGOT	10-42 (IU/L)	10/12/93			24.00		25.00	
ALK. PHOSPH.	40-120 (IU/L)	10/12/93	58.00		61.00		68.00	
GLUCOSE	3-5.5 (MMOL/L)	10/12/93	4.90		4.40			
UREA	2.9-7.5 (MMOL/L)	10/12/93	8.40 >		7.80 >		7.10	
CREATININE	60-120 (UMOL/L)	10/12/93	89.00		84.00		73.00	
URIC ACID	0.1-0.4 (MMOL/L)	10/12/93	0.26		0.24		0.21	
TOT BILIRUBIN	0-17 (UMOL/L)	10/12/93	24.00 >		8.00		5.00	
DIR BILIRUBIN	0-3.4 (UMOL/L)	10/12/93	1.00		1.00		1.00	
TOT. PROTEINS	60-80 (G/L)	10/12/93	58.00 <		55.00 <		61.00	
ALBUMINE	36-50 (G/L)	10/12/93	38.00		37.00		41.00	
TOT. CHOLEST.	0-5.2 (MMOL/L)	10/12/93	5.40 >		5.90 >		6.10 >	
TRIGLYCERIDES	0.5-2.2 (MMOL/L)	10/12/93	1.40		1.30		1.10	
TSH	0.4-4 (MU/L)	10/12/93	1.00					
T4	50-160 (NMOL/L)	10/12/93	88.00					
ESR/SEDIMENT. RATE 1st h	2-10 (MM)	10/12/93	12.00		7.00			

2367

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value and laboratory not done () missing range value

PHARMACIA C0560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 382 Patient: 8MD Treatment: Imipramine Sex: Male

			Visit number / Laboratory date
			Screen
			24/01/94
			value (c)
Laboratory test	Range value	Range date	
HB	13-18 (G/DL)	20/01/94	11.50 <
RBC	4.5-6 (10 ¹² /L)	20/01/94	4.18 <
WBC	4-11 (10 ⁹ /L)	20/01/94	8.50
WBC: N	2-7.5 (10 ⁹ /L)	20/01/94	6.70
WBC: L	1-4 (10 ⁹ /L)	20/01/94	1.00
WBC: E	0.1-0.4 (10 ⁹ /L)	20/01/94	0.10
WBC: M	0.2-0.8 (10 ⁹ /L)	20/01/94	0.60
WBC: B	0-0.1 (10 ⁹ /L)	20/01/94	0.10
PLATELETS	150-500 (10 ⁹ /L)	20/01/94	263.00
NA+	135-145 (MMOL/L)	20/01/94	131.00 <
K+	3.6-5 (MMOL/L)	20/01/94	4.60
Ca ⁺⁺	2.1-2.6 (MMOL/L)	20/01/94	2.51
PO4 ⁻⁻	0.8-1.4 (MMOL/L)	20/01/94	1.30
ALK. PHOSPH.	40-120 (IU/L)	20/01/94	107.00
GLUCOSE	3-5.5 (MMOL/L)	20/01/94	5.20
UREA	2.9-7.5 (MMOL/L)	20/01/94	15.40 >>
CREATININE	60-120 (UMOL/L)	20/01/94	150.00 >
URIC ACID	0.1-0.4 (MMOL/L)	20/01/94	0.46 >
TOT BILIRUBIN	0-17 (UMOL/L)	20/01/94	10.00
DIR BILIRUBIN	0-3.4 (UMOL/L)	20/01/94	1.00
TOT. PROTEINS	60-80 (G/L)	20/01/94	64.00
ALBUMINE	36-50 (G/L)	20/01/94	39.00
TOT. CHOLEST.	0-5.2 (MMOL/L)	20/01/94	4.60
TRIGLYCERIDES	0.5-2.2 (MMOL/L)	20/01/94	1.00
TSH	0.4-4 (MU/L)	20/01/94	0.70
T4	50-160 (NMOL/L)	20/01/94	76.00

2368

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C950089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 382 Patient: 9ND Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			11/02/94		11/03/94		08/04/94	
			value	(€)	value	(€)	value	(€)
Laboratory test	Range value	Range date						
HB	11.5-16 (G/DL)	01/02/94	10.20	<	10.10	<		
	115-160 (G/L)	01/04/94					112.00 <	
RBC	3.8-5.5 (10~12/L)	01/02/94	3.54	<	3.61	<	3.93	
WBC	4-11 (10~9/L)	01/02/94	6.20		5.10		4.70	
WBC: N	2-7.5 (10~9/L)	01/02/94	4.80		3.80		3.30	
WBC: L	1-4 (10~9/L)	01/02/94	0.70	<<	0.70	<<	0.80 <	
WBC: E	0.1-0.4 (10~9/L)	01/02/94	0.10		0.10		0.10	
WBC: M	0.2-0.8 (10~9/L)	01/02/94	0.50		0.40		0.40	
WBC: B	0-0.1 (10~9/L)	01/02/94	0.10		0.10		0.10	
PLATELETS	150-500 (10~9/L)	01/02/94	272.00		293.00		240.00	
NA+	135-145 (MMOL/L)	01/02/94	138.00		136.00		139.00	
K+	3.6-5 (MMOL/L)	01/02/94	3.40	<	4.50		4.30	
CL-	94-104 (MMOL/L)	01/02/94			99.00			
Ca++	2.1-2.6 (MMOL/L)	01/02/94	2.27		2.27		2.42	
PO4--	0.8-1.4 (MMOL/L)	01/02/94	0.90		1.10		1.10	
SGOT	10-42 (IU/L)	01/02/94	21.00		18.00		18.00	
LDH	210-420 (IU/L)	01/02/94	417.00				378.00	
ALK. PHOSPH.	40-120 (IU/L)	01/02/94	60.00		75.00		85.00	
GLUCOSE	3-5.5 (MMOL/L)	01/02/94	5.20		4.80		4.20	
UREA	2.9-7.5 (MMOL/L)	01/02/94	3.10		3.40		4.30	
CREATININE	60-120 (UMOL/L)	01/02/94			63.00			
URIC ACID	0.1-0.4 (MMOL/L)	01/02/94	0.18		0.18		0.24	
TOT BILIRUBIN	0-17 (UMOL/L)	01/02/94	9.00		8.00		8.00	
DIR BILIRUBIN	0-3.4 (UMOL/L)	01/02/94			1.00			
TOT. PROTEINS	60-80 (G/L)	01/02/94			66.00			
ALBUMINE	36-50 (G/L)	01/02/94	40.00		39.00		44.00	
TOT. CHOLEST.	0-5.2 (MMOL/L)	01/02/94	5.30	>	5.20		6.60 >	
TRIGLYCERIDES	0.5-2.2 (MMOL/L)	01/02/94			0.90			
TSH	0.4-4 (MU/L)	01/02/94	0.60					
T4	50-160 (NMOL/L)	01/02/94	88.00					
ESR/SEDIMENT. RATE 1st h	2-10 (MM)	01/02/94	68.00		58.00		44.00	

2369

(€) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C9550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 382 Patient: 10MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date
			Screen
			11/02/94
			value (c)
Laboratory test	Range value	Range date	
HB	115-160 (G/L)	01/07/93	133.00
RBC	3.8-5.5 (10 ¹² /L)	01/07/93	4.62
WBC	4-11 (10 ⁹ /L)	01/07/93	8.10
WBC: N	2-7.5 (10 ⁹ /L)	01/07/93	4.80
WBC: L	1-4 (10 ⁹ /L)	01/07/93	1.80
WBC: E	0.1-0.4 (10 ⁹ /L)	01/07/93	0.10
WBC: M	0.2-0.8 (10 ⁹ /L)	01/07/93	1.30 >>
WBC: B	0-0.1 (10 ⁹ /L)	01/07/93	0.10
PLATELETS	150-500 (10 ⁹ /L)	01/07/93	315.00
NA+	135-145 (MMOL/L)	01/07/93	137.00
K+	3.6-5 (MMOL/L)	01/07/93	4.40
CL-	94-104 (MMOL/L)	01/07/93	102.00
Ca++	2.1-2.6 (MMOL/L)	01/07/93	2.28
PO4--	0.8-1.4 (MMOL/L)	01/07/93	1.00
SGOT	10-42 (IU/L)	01/07/93	24.00
ALK. PHOSPH.	40-120 (IU/L)	01/07/93	76.00
GLUCOSE	3-5.5 (MMOL/L)	01/07/93	8.40 >>
UREA	2.9-7.5 (MMOL/L)	01/07/93	7.20
CREATININE	60-120 (UMOL/L)	01/07/93	89.00
URIC ACID	0.1-0.4 (MMOL/L)	01/07/93	0.35
TOT BILIRUBIN	0-17 (UMOL/L)	01/07/93	3.00
DIR BILIRUBIN	0-3.4 (UMOL/L)	01/07/93	1.00
TOT. PROTEINS	60-80 (G/L)	01/07/93	66.00
ALBUMINE	36-50 (G/L)	01/07/93	39.00
TOT. CHOLEST.	0-5.2 (MMOL/L)	01/07/93	4.20
TRIGLYCERIDES	0.5-2.2 (MMOL/L)	01/07/93	2.10
TSH	0.4-4 (MU/L)	01/07/93	0.10
T4	50-160 (NMOL/L)	01/07/93	141.00
ESR/SEDIMENT. RATE 1st h	2-10 (MM)	01/07/93	15.00

2370

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C8560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 382 Patient: 5DT Treatment: Reboxetine Sex: Male

			Visit number / Laboratory date
			Screen
			20/10/93
			value (⚡)
Laboratory test	Range value	Range date	
HB	13-18 (G/DL)	15/10/93	10.70 <<
RBC	4.5-6 (10 ¹² /L)	15/10/93	2.93 <<
WBC	4-11 (10 ⁹ /L)	15/10/93	11.90 >
WBC: N	2-7.5 (10 ⁹ /L)	15/10/93	8.30 >
WBC: L	1-4 (10 ⁹ /L)	15/10/93	2.00
WBC: E	0.1-0.4 (10 ⁹ /L)	15/10/93	0.10
WBC: M	0.2-0.8 (10 ⁹ /L)	15/10/93	1.40 >>
WBC: B	0-0.1 (10 ⁹ /L)	15/10/93	0.10
PLATELETS	150-500 (10 ⁹ /L)	15/10/93	360.00
NA+	135-145 (MMOL/L)	15/10/93	131.00 <
K+	3.6-5 (MMOL/L)	15/10/93	4.70
CL-	94-104 (MMOL/L)	15/10/93	99.00
Ca++	2.1-2.6 (MMOL/L)	15/10/93	2.35
PD4--	0.8-1.4 (MMOL/L)	15/10/93	1.30
SGOT	10-42 (IU/L)	15/10/93	18.00
ALK. PHOSPH.	40-120 (IU/L)	15/10/93	131.00 >
GLUCOSE	3-5.5 (MMOL/L)	15/10/93	5.80 >
UREA	2.9-7.5 (MMOL/L)	15/10/93	2.10 <
CREATININE	60-120 (UMOL/L)	15/10/93	82.00
URIC ACID	0.1-0.4 (MMOL/L)	15/10/93	0.24
TOT BILIRUBIN	0-17 (UMOL/L)	15/10/93	10.00
DIR BILIRUBIN	0-3.4 (UMOL/L)	15/10/93	1.00
TOT. PROTEINS	60-80 (G/L)	15/10/93	71.00
ALBUMINE	36-50 (G/L)	15/10/93	39.00
TOT. CHOLEST.	0-5.2 (MMOL/L)	15/10/93	6.10 >
TSH	0.4-4 (MU/L)	15/10/93	1.20
ESR/SEDIMENT. RATE	2-10 (MM)	15/10/93	
1st h			60.00

2371

(⚡) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C9580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 382 Patient: 6DT Treatment: Imipramine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			22/10/93		19/11/93		17/12/93	
			value	(†)	value	(†)	value	(†)
Laboratory test	Range value	Range date						
HB	115-160 (G/L)	01/07/93	137.00		123.00		123.00	
RBC	3.8-5.5 (10 ¹² /L)	01/07/93	4.91		4.43		4.38	
WBC	4-11 (10 ⁹ /L)	01/07/93	8.10		8.40		8.40	
WBC: N	2-7.5 (10 ⁹ /L)	01/07/93	5.20		5.70		5.20	
WBC: L	1-4 (10 ⁹ /L)	01/07/93	2.00		1.50		2.00	
WBC: E	0.1-0.4 (10 ⁹ /L)	01/07/93	0.30		0.30		0.40	
WBC: M	0.2-0.8 (10 ⁹ /L)	01/07/93	0.50		0.80		0.10 <	
WBC: B	0-0.1 (10 ⁹ /L)	01/07/93	0.10		0.10		0.10	
PLATELETS	150-500 (10 ⁹ /L)	01/07/93	212.00		220.00		216.00	
NA+	135-145 (MMOL/L)	01/07/93	136.00		137.00		137.00	
K+	3.6-5 (MMOL/L)	01/07/93	5.00		3.80		3.80	
CL-	94-104 (MMOL/L)	01/07/93			98.00		98.00	
Ca++	2.1-2.6 (MMOL/L)	01/07/93			2.21		2.21	
PO4--	0.8-1.4 (MMOL/L)	01/07/93			1.20		1.20	
SGOT	10-42 (IU/L)	01/07/93	27.00		29.00			
ALK. PHOSPH.	40-120 (IU/L)	01/07/93	67.00		65.00		73.00	
GLUCOSE	3-5.5 (MMOL/L)	01/07/93	21.30 >>		17.40 >>		10.90 >>	
UREA	2.9-7.5 (MMOL/L)	01/07/93	6.60		6.60		8.20 >	
CREATININE	60-120 (UMOL/L)	01/07/93	124.00 >		109.00		106.00	
URIC ACID	0.1-0.4 (MMOL/L)	01/07/93			0.39		0.39	
TOT BILIRUBIN	0-17 (UMOL/L)	01/07/93	12.00		7.00		3.00	
DIR BILIRUBIN	0-3.4 (UMOL/L)	01/07/93			2.00			
TOT. PROTEINS	60-80 (G/L)	01/07/93	70.00		66.00		65.00	
ALBUMINE	36-50 (G/L)	01/07/93	43.00		39.00		40.00	
TOT. CHOLEST.	0-5.2 (MMOL/L)	01/07/93	7.00 >>		7.00 >>		7.30 >>	
TRIGLYCERIDES	0.5-2.2 (MMOL/L)	01/07/93	1.80		1.80		1.50	
TSH	0.4-4 (MU/L)	01/07/93	1.40					
T4	50-160 (NMOL/L)	01/07/93	90.00					
ESR/SEDIMENT. RATE 1st h	2-10 (MM)	01/07/93	10.00		22.00			

2372

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C 560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 382 Patient: 7DT Treatment: Imipramine Sex: Male

			Visit number / Laboratory date
			Screen
			22/10/93
			value (⊕)
Laboratory test	Range value	Range date	
HB	130-180 (G/L)	01/07/93	131.00
RBC	4.5-6 (10 ¹² /L)	01/07/93	4.04 <
WBC	4-11 (10 ⁹ /L)	01/07/93	10.50
WBC: N	2-7.5 (10 ⁹ /L)	01/07/93	6.10
WBC: L	1-4 (10 ⁹ /L)	01/07/93	3.40
WBC: E	0.1-0.4 (10 ⁹ /L)	01/07/93	0.20
WBC: M	0.2-0.8 (10 ⁹ /L)	01/07/93	0.60
WBC: B	0-0.1 (10 ⁹ /L)	01/07/93	0.20 >>
PLATELETS	150-500 (10 ⁹ /L)	01/07/93	360.00
NA+	135-145 (MMOL/L)	01/07/93	141.00
K+	3.6-5 (MMOL/L)	01/07/93	4.60
CL-	94-104 (MMOL/L)	01/07/93	105.00 >
Ca++	2.1-2.6 (MMOL/L)	01/07/93	2.46
PO4--	0.8-1.4 (MMOL/L)	01/07/93	1.10
SGOT	10-42 (IU/L)	01/07/93	18.00
ALK. PHOSPH.	40-120 (IU/L)	01/07/93	63.00
GLUCOSE	3-5.5 (MMOL/L)	01/07/93	5.40
UREA	2.9-7.5 (MMOL/L)	01/07/93	7.20
CREATININE	60-120 (UMOL/L)	01/07/93	144.00 >
URIC ACID	0.1-0.4 (MMOL/L)	01/07/93	0.31
TOT BILIRUBIN	0-17 (UMOL/L)	01/07/93	14.00
ALBUMINE	36-50 (G/L)	01/07/93	41.00
TOT. CHOLEST.	0-5.2 (MMOL/L)	01/07/93	7.20 >>
TRIGLYCERIDES	0.5-2.2 (MMOL/L)	01/07/93	2.00
TSH	0.4-4 (MU/L)	01/07/93	1.00

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

2373

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C9554089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 382 Patient: 8DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			22/12/93		19/01/94		16/02/94	
			value	(†)	value	(†)	value	(†)
Laboratory test	Range value	Range date						
HB	11.5-16 (G/DL)	20/12/93	11.30	<	11.80			
	115-160 (G/L)	15/02/94				118.00		
RBC	3.8-5.5 (10 ¹² /L)	20/12/93	3.78	<	4.18		4.16	
WBC	4-11 (10 ⁹ /L)	20/12/93	12.20	>	9.60		8.10	
WBC: N	2-7.5 (10 ⁹ /L)	20/12/93	10.40	>>	7.30		6.00	
WBC: L	1-4 (10 ⁹ /L)	20/12/93	0.70	<<	1.10		1.20	
WBC: E	0.1-0.4 (10 ⁹ /L)	20/12/93	0.20		0.10		0.10	
WBC: M	0.2-0.8 (10 ⁹ /L)	20/12/93	0.90	>	1.00	>	0.70	
WBC: B	0-0.1 (10 ⁹ /L)	20/12/93			0.10		0.10	
PLATELETS	150-500 (10 ⁹ /L)	20/12/93	331.00		397.00		334.00	
NA+	135-145 (MMOL/L)	20/12/93	132.00	<	137.00		139.00	
K+	3.6-5 (MMOL/L)	20/12/93	3.20	<	3.10	<	2.80 <<	
CL-	94-104 (MMOL/L)	20/12/93	105.00	>	111.00	>	112.00 >	
Ca++	2.1-2.6 (MMOL/L)	20/12/93	2.16		2.34		2.41	
PO4--	0.8-1.4 (MMOL/L)	20/12/93	0.60	<<	0.80		0.80	
SGOT	10-42 (IU/L)	20/12/93	23.00		17.00		21.00	
ALK. PHOSPH.	40-120 (IU/L)	20/12/93	80.00		410.00	>>	410.00 >>	
GLUCOSE	3-5.5 (MMOL/L)	20/12/93	5.80	>	5.20			
UREA	2.9-7.5 (MMOL/L)	20/12/93	5.80		4.50		4.00	
CREATININE	60-120 (UMOL/L)	20/12/93	69.00		78.00		77.00	
URIC ACID	0.1-0.4 (MMOL/L)	20/12/93	0.22		0.27		0.30	
TOT BILIRUBIN	0-17 (UMOL/L)	20/12/93	9.00		5.00		5.00	
DIR BILIRUBIN	0-3.4 (UMOL/L)	20/12/93	1.00		1.00		1.00	
TOT. PROTEINS	60-80 (G/L)	20/12/93	58.00	<	65.00		68.00	
ALBUMINE	36-50 (G/L)	20/12/93	36.00		38.00		39.00	
TOT. CHOLEST.	0-5.2 (MMOL/L)	20/12/93	5.70	>	6.20	>	6.50 >	
TRIGLYCERIDES	0.5-2.2 (MMOL/L)	20/12/93	2.20		2.50	>	2.00	
TSH	0.4-4 (MU/L)	20/12/93	0.70					
T4	50-160 (NMOL/L)	20/12/93	100.00					
ESR/SEDIMENT. RATE 1st h	2-10 (MM)	20/12/93	28.00					

2374

(†) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA 09580089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 382 Patient: 9DT Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date	
			Screen	
			06/02/94	
			value	(*)
Laboratory test	Range value	Range date		
HB	115-160 (G/L)	01/07/93	130.00	
RBC	3.8-5.5 (10 ¹² /L)	01/07/93	5.02	
WBC	4-11 (10 ⁹ /L)	01/07/93	13.90	>
WBC: N	2-7.5 (10 ⁹ /L)	01/07/93	11.40	>>
WBC: L	1-4 (10 ⁹ /L)	01/07/93	1.39	
WBC: M	0.2-0.8 (10 ⁹ /L)	01/07/93	1.11	>>
PLATELETS	150-500 (10 ⁹ /L)	01/07/93	279.00	
NA+	135-145 (MMOL/L)	01/07/93	135.00	
K+	3.6-5 (MMOL/L)	01/07/93	5.30	>
CL-	94-104 (MMOL/L)	01/07/93	106.00	>
Ca++	2.1-2.6 (MMOL/L)	01/07/93	2.40	
PO4--	0.8-1.4 (MMOL/L)	01/07/93	0.60	<<
SGOT	10-42 (IU/L)	01/07/93	16.00	
ALK. PHOSPH.	40-120 (IU/L)	01/07/93	68.00	
GLUCOSE	3-5.5 (MMOL/L)	01/07/93	5.70	>
UREA	2.9-7.5 (MMOL/L)	01/07/93	6.50	
CREATININE	60-120 (UMOL/L)	01/07/93	139.00	>
URIC ACID	0.1-0.4 (MMOL/L)	01/07/93	0.44	>
TOT. BILIRUBIN	0-17 (UMOL/L)	01/07/93	16.00	
TOT. PROTEINS	60-80 (G/L)	01/07/93	58.00	<
ALBUMINE	36-50 (G/L)	01/07/93	35.00	<
TOT. CHOLEST.	0-5.2 (MMOL/L)	01/07/93	3.20	
TRIGLYCERIDES	0.5-2.2 (MMOL/L)	01/07/93	1.40	
TSH	0.4-4 (MU/L)	01/07/93	2.10	
T4	50-160 (NMOL/L)	01/07/93	120.00	

2075

(*) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
< out of range (value lower than min range) > out of range (value higher than max range)
** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS 530089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 3301 Patient: 1ND Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date
			Screen
			18/09/92
			value (⊕)
Laboratory test	Range value	Range date	
HB	11.5-16.5 (G/DL)	01/09/92	9.80 <
HT	37-47 (%)	01/09/92	31.30 <<
RBC	3.5-5.8 (10 ¹² /L)	01/09/92	4.32
WBC	4-11 (10 ⁹ /L)	01/09/92	7.70
WBC: N	2-8 (10 ⁹ /L)	01/09/92	5.46
WBC: L	1.2-4 (10 ⁹ /L)	01/09/92	1.38
WBC: E	0-0.4 (10 ⁹ /L)	01/09/92	0.06
WBC: M	0.2-0.8 (10 ⁹ /L)	01/09/92	0.42
WBC: B	0-0.2 (10 ⁹ /L)	01/09/92	0.03
PLATELETS	150-450 (10 ⁹ /L)	01/09/92	503.00 >
NA+	136-148 (MMOL/L)	01/09/92	133.00 <
K+	3.8-5 (MMOL/L)	01/09/92	5.30 >
SGOT	0-40 (IU/L)	01/09/92	15.00
ALK. PHOSPH.	65-300 (IU/L)	01/09/92	337.00 >
GLUCOSE	3-5.5 (MMOL/L)	01/09/92	6.70 >
UREA	2.5-6.5 (MMOL/L)	01/09/92	6.50
CREATININE	60-120 (UMOL/L)	01/09/92	62.00
CREATININE CLEARANCE	80-125 (ML/MIN)	01/09/92	64.00
TOT BILIRUBIN	1-17 (UMOL/L)	01/09/92	5.00
TOT. PROTEINS	62-80 (G/L)	01/09/92	73.00
ALBUMINE	36-52 (G/L)	01/09/92	36.00
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/09/92	54.00

2376

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C0560089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 3301 Patient: 2ND Treatment: Imipramine Sex: Male

			Visit number / Laboratory date					
			Screen		Day 28		Day 56	
			06/01/93		11/02/93		08/03/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	13-18 (G/DL)	01/09/92	12.00	<	11.70	<	12.30	<
HT	40-54 (%)	01/09/92	37.30	<	37.80	<	37.90	<
RBC	4-6.5 (10 ¹² /L)	01/09/92	4.53		4.41		4.64	
WBC	4-11 (10 ⁹ /L)	01/09/92	7.90		5.70		8.00	
WBC: N	2-8 (10 ⁹ /L)	01/09/92	5.11		3.41		5.18	
WBC: L	1.2-4 (10 ⁹ /L)	01/09/92	1.83		1.37		1.74	
WBC: E	0-0.4 (10 ⁹ /L)	01/09/92	0.03		0.14		0.23	
WBC: M	0.2-0.8 (10 ⁹ /L)	01/09/92	0.55		0.53		0.59	
WBC: B	0-0.2 (10 ⁹ /L)	01/09/92	0.03		0.04		0.07	
PLATELETS	150-450 (10 ⁹ /L)	01/09/92	179.00		200.00		225.00	
NA+	136-148 (MMOL/L)	01/09/92	138.00		133.00	<	137.00	
K+	3.8-5 (MMOL/L)	01/09/92	4.40		5.80	>>	5.10	>
Ca ⁺⁺	2.1-2.6 (MMOL/L)	01/09/92	2.16		2.22		2.23	
PO ₄ ⁻⁻	0.8-1.4 (MMOL/L)	01/09/92	1.22		1.21		1.51	>
SGOT	0-40 (IU/L)	01/09/92	13.00		18.00		16.00	
GAMMA GT	0-60 (IU/L)	01/09/92	14.00		12.00		17.00	
ALK. PHOSPH.	65-300 (IU/L)	01/09/92	213.00		224.00		268.00	
GLUCOSE	3-5.5 (MMOL/L)	01/09/92	6.40	>	5.20		5.20	
UREA	2.5-6.5 (MMOL/L)	01/09/92	6.30		6.20		6.50	
CREATININE	60-120 (UMOL/L)	01/09/92	110.00		111.00		107.00	
CREATININE CLEARANCE	80-125 (ML/MIN)	01/09/92	40.00					
URIC ACID	0.1-0.4 (MMOL/L)	01/09/92	0.22		0.19		0.20	
TOT BILIRUBIN	1-17 (UMOL/L)	01/09/92	6.00		5.00		5.00	
TOT. PROTEINS	62-80 (G/L)	01/09/92	62.00		65.00		69.00	
ALBUMINE	36-52 (G/L)	01/09/92	36.00		34.00	<	38.00	
TOT. CHOLEST.	3-6.5 (MMOL/L)	01/09/92	6.40		6.40		6.80	>
TRIGLYCERIDES	0.2-1.9 (MMOL/L)	01/09/92	1.80		1.40		3.70	>>
TSH	0.4-4 (MU/L)	01/09/92	0.65					
T ₄	9-26 (PMOL/L)	01/09/92	17.00					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/09/92	5.00		3.00		11.00	

2377

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C9554089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 3301 Patient: 3ND Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date					
			Screen		Day 28		Day 35	
			12/01/93		18/02/93		09/03/93	
			value	(φ)	value	(φ)	value	(φ)
Laboratory test	Range value	Range date						
HB	11.5-16.5 (G/DL)	01/09/92	13.30		14.00		12.80	
HT	37-47 (%)	01/09/92	37.50		39.80		35.50 <	
RBC	3.5-5.8 (10 ¹² /L)	01/09/92	4.46		4.61		4.18	
WBC	4-11 (10 ⁹ /L)	01/09/92	5.70		6.50		5.90	
WBC: N	2-8 (10 ⁹ /L)	01/09/92	4.57		5.55		4.94	
WBC: L	1.2-4 (10 ⁹ /L)	01/09/92	0.67 <<		0.50 <<		0.50 <<	
WBC: E	0-0.4 (10 ⁹ /L)	01/09/92	0.02		0.03		0.01	
WBC: M	0.2-0.8 (10 ⁹ /L)	01/09/92	0.33		0.36		0.36	
WBC: B	0-0.2 (10 ⁹ /L)	01/09/92	0.02		0.02		0.01	
PLATELETS	150-450 (10 ⁹ /L)	01/09/92	292.00		281.00		291.00	
NA+	136-148 (MMOL/L)	01/09/92	144.00		141.00		139.00	
K+	3.8-5 (MMOL/L)	01/09/92	4.60				3.90	
Ca++	2.1-2.6 (MMOL/L)	01/09/92	2.36				2.22	
PO4--	0.8-1.4 (MMOL/L)	01/09/92	0.92				1.12	
SGOT	0-40 (IU/L)	01/09/92	17.00		20.00		18.00	
GAMMA GT	0-60 (IU/L)	01/09/92			16.00		20.00	
ALK. PHOSPH.	65-300 (IU/L)	01/09/92	234.00		242.00		215.00	
GLUCOSE	3-5.5 (MMOL/L)	01/09/92	6.70 >					
UREA	2.5-6.5 (MMOL/L)	01/09/92	7.10 >		8.00 >		6.10	
CREATININE	60-120 (UMOL/L)	01/09/92	78.00		88.00		81.00	
CREATININE CLEARANCE		01/09/92	59.80					
URIC ACID	0.1-0.4 (MMOL/L)	01/09/92	0.30		0.26		0.24	
TOT BILIRUBIN	1-17 (UMOL/L)	01/09/92	14.00		21.00 >		1.90	
TOT. PROTEINS	62-80 (G/L)	01/09/92	68.00		69.00		62.00	
ALBUMINE	36-52 (G/L)	01/09/92	40.00		38.00		37.00	
TOT. CHOLEST.	3-6.5 (MMOL/L)	01/09/92	5.40		5.10		5.70	
TRIGLYCERIDES	0.2-1.9 (MMOL/L)	01/09/92	1.10		1.20		0.90	
TSH	0.4-4 (MU/L)	01/09/92	1.18					
T4	9-26 (PMOL/L)	01/09/92	14.00					
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/09/92	6.00				18.00	

2378

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARNACIA 095 50089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 3302 Patient: SMD Treatment: Reboxetine Sex: Female

			Visit number / Laboratory date
			Screen
			30/10/92
			value (⊕)
Laboratory test	Range value	Range date	
HB	11.5-16.5 (G/DL)	01/07/92	11.70
HT	37-47 (X)	01/07/92	33.50 <
RBC	3.5-5.8 (10 ¹² /L)	01/07/92	3.85
WBC	4-11 (10 ⁹ /L)	01/07/92	8.80
WBC: N	2-8 (10 ⁹ /L)	01/07/92	7.15
WBC: L	1.2-4 (10 ⁹ /L)	01/07/92	0.98 <
WBC: E	0-0.4 (10 ⁹ /L)	01/07/92	0.03
WBC: M	0.2-0.8 (10 ⁹ /L)	01/07/92	0.47
WBC: B	0-0.2 (10 ⁹ /L)	01/07/92	0.03
PLATELETS	150-450 (10 ⁹ /L)	01/07/92	321.00
NA+	136-148 (MMOL/L)	01/07/92	134.00 <
K+	3.8-5 (MMOL/L)	01/07/92	7.60 >>
Ca++	2.1-2.6 (MMOL/L)	01/07/92	2.18
PO4--	0.8-1.4 (MMOL/L)	01/07/92	1.40
SGOT	0-40 (IU/L)	01/07/92	7.00
GAMMA GT	0-60 (IU/L)	01/07/92	10.00
ALK. PHOSPH.	65-300 (IU/L)	01/07/92	294.00
GLUCOSE	3-5.5 (MMOL/L)	01/07/92	5.00
UREA	2.5-6.5 (MMOL/L)	01/07/92	23.20 >>
CREATININE	60-120 (UMOL/L)	01/07/92	218.00 >>
CREATININE CLEARANCE	80-125 (ML/MIN)	01/07/92	18.60
TOT BILIRUBIN	1-17 (UMOL/L)	01/07/92	7.00
TOT. PROTEINS	62-80 (G/L)	01/07/92	65.00
ALBUMINE	36-52 (G/L)	01/07/92	38.00
TOT. CHOLEST.	3-6.5 (MMOL/L)	01/07/92	3.90
TRIGLYCERIDES	0.2-1.9 (MMOL/L)	01/07/92	2.00 >
TSH	0.4-4 (MU/L)	01/07/92	1.09
T4	9-26 (PMOL/L)	01/07/92	17.00

2379

(⊕) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

PHARMACIA C9554089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 3302 Patient: 6MD Treatment: Imipramine Sex: Female

			Visit number / Laboratory date
			Screen
			24/06/93
			value (c)
Laboratory test	Range value	Range date	
HB	11.5-16.5 (G/DL)	01/07/92	12.80
HT	37-47 (%)	01/07/92	39.50
RBC	3.5-5.8 (10 ¹² /L)	01/07/92	4.32
WBC	4-11 (10 ⁹ /L)	01/07/92	10.10
WBC: N	2-8 (10 ⁹ /L)	01/07/92	6.19
WBC: L	1.2-4 (10 ⁹ /L)	01/07/92	2.99
WBC: E	0-0.4 (10 ⁹ /L)	01/07/92	0.01
WBC: M	0.2-0.8 (10 ⁹ /L)	01/07/92	0.65
WBC: B	0-0.2 (10 ⁹ /L)	01/07/92	0.03
PLATELETS	150-450 (10 ⁹ /L)	01/07/92	362.00
NA+	136-148 (MMOL/L)	01/07/92	136.00
K+	3.8-5 (MMOL/L)	01/07/92	4.20
SGOT	0-40 (IU/L)	01/07/92	19.00
GAMMA GT	0-60 (IU/L)	01/07/92	23.00
ALK. PHOSPH.	65-300 (IU/L)	01/07/92	174.00
GLUCOSE	3-5.5 (MMOL/L)	01/07/92	5.20
UREA	2.5-6.5 (MMOL/L)	01/07/92	4.90
CREATININE	60-120 (UMOL/L)	01/07/92	89.00
TOT. BILIRUBIN	1-17 (UMOL/L)	01/07/92	2.00
TOT. PROTEINS	62-80 (G/L)	01/07/92	71.00
ALBUMINE	36-52 (G/L)	01/07/92	38.00
TOT. CHOLEST.	3-6.5 (MMOL/L)	01/07/92	2.90 <
TRIGLYCERIDES	0.2-1.9 (MMOL/L)	01/07/92	0.60
TSH	0.4-4 (MU/L)	01/07/92	1.04
T4	9-26 (PMOL/L)	01/07/92	17.00
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/07/92	11.00

2380

(c) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA C9550089

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.0

LABORATORY DATA

Centre: 3302 Patient: 7ND Treatment: Imipramine Sex: Female

			Visit number / Laboratory date	
			Screen	Day 56
			11/11/93	07/01/94
			value (φ)	value (φ)
Laboratory test	Range value	Range date		
HB	11.5-16.5 (G/DL)	01/07/92	14.60	12.80
HT	37-47 (%)	01/07/92		37.80
RBC	3.5-5.8 (10 ¹² /L)	01/07/92	5.08	4.68
MBC	4-11 (10 ⁹ /L)	01/07/92	8.90	1.70 <<
MBC: N	2-8 (10 ⁹ /L)	01/07/92	4.40	0.02 <<
MBC: L	1.2-4 (10 ⁹ /L)	01/07/92	2.55	1.41
MBC: E	0-0.4 (10 ⁹ /L)	01/07/92	0.15	0.01
MBC: M	0.2-0.8 (10 ⁹ /L)	01/07/92	1.15 >>	0.03 <
MBC: B	0-0.2 (10 ⁹ /L)	01/07/92	0.02	0.01
PLATELETS	150-450 (10 ⁹ /L)	01/07/92	147.00 <	171.00
NA+	136-148 (MMOL/L)	01/07/92	124.00 <	136.00
K+	3.8-5 (MMOL/L)	01/07/92	3.60 <	4.10
SGOT	0-40 (IU/L)	01/07/92	10.00	13.00
GAMMA GT	0-60 (IU/L)	01/07/92		29.00
ALK. PHOSPH.	65-300 (IU/L)	01/07/92	220.00	373.00 >
GLUCOSE	3-5.5 (MMOL/L)	01/07/92	4.90	4.70
UREA	2.5-6.5 (MMOL/L)	01/07/92	4.50	4.50
CREATININE	60-120 (UMOL/L)	01/07/92	82.00	108.00
URIC ACID	0.1-0.4 (MMOL/L)	01/07/92		0.41 >
TOT. BILIRUBIN	1-17 (UMOL/L)	01/07/92	14.00	15.00
TOT. PROTEINS	62-80 (G/L)	01/07/92	71.00	
ALBUMINE	36-52 (G/L)	01/07/92	42.00	35.00 <
TOT. CHOLEST.	3-6.5 (MMOL/L)	01/07/92	7.00 >	7.00 >
TRIGLYCERIDES	0.2-1.9 (MMOL/L)	01/07/92	1.30	1.50
ESR/SEDIMENT. RATE 1st h	0-10 (MM)	01/07/92	10.00	26.00

2381

(φ) << clinically relevant (value lower than min range) >> clinically relevant (value higher than max range)
 < out of range (value lower than min range) > out of range (value higher than max range)
 ** missing laboratory test value nd laboratory not done () missing range value

9550089

1

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 16.1

CREATININE AND CREATININE CLEARANCE VALUES CALCULATED AS PER PROTOCOL

Centre	Patient	Treatment	Sex	Age (years)	Height (kg)	CREATININE (µg)	UNIT	MIN	MAX	CREATININE (mg/dl)	CREATININE CLEARANCE (ml/min) (a)	
1	1ND	Reboxetine	Female	76	59	0.09	MMOL/L	0.04	0.14	1.02	43.63	
	1DT	Reboxetine	Male	78	72	0.1	MMOL/L	0.04	0.14	1.13	39.58	
	2ND	Imipramine	Male	65	72	0.08	MMOL/L	0.04	0.14	0.90	82.88	
	2DT	Imipramine	Male	73	75	0.09	MMOL/L	0.04	0.14	1.02	68.55	
	3ND	Imipramine	Female	65	75	0.1	MMOL/L	0.04	0.14	1.13	58.50	
	3DT	Reboxetine	Male	68	60	0.09	MMOL/L	0.04	0.14	1.02	58.93	
	4ND	Reboxetine	Female	76	48	0.09	MMOL/L	0.04	0.14	1.02	35.50	
	4DT	Imipramine	Male	74	64	0.12	MMOL/L	0.04	0.14	1.36	43.22	
	2	1ND	Reboxetine	Male	71	79	0.08	MMOL/L	0.04	0.14	0.90	83.66
		1ND	Reboxetine	Female	71	57	88	UMOL/L	55	120	1.00	46.48
	5	1ND	Reboxetine	Female	83	65	0.88	MG/DL	0.7	1.3	0.88	49.53
		1DT	Imipramine	Female	68	80	0.97	MG/DL	0.7	1.3	0.97	69.86
2ND		Reboxetine	Male	78	85	1.45	MG/DL	0.7	1.3	1.45	50.48	
2DT		Imipramine	Female	90	42	0.78	MG/DL	0.7	1.3	0.78	31.67	
3ND		Imipramine	Female	71	90	0.82	MG/DL	0.7	1.3	0.82	89.10	
3DT		Reboxetine	Male	74	63	1.09	MG/DL	0.7	1.3	1.09	52.98	
4ND		Imipramine	Male	80	70	1.5	MG/DL	0.7	1.3	1.50	38.89	
4DT		Reboxetine	Male	81	64	1.35	MG/DL	0.7	1.3	1.35	38.85	
5ND		Reboxetine	Female	66	64	1.07	MG/DL	0.7	1.3	1.07	61.47	
5DT		Imipramine	Female	66	85	1.31	MG/DL	0.7	1.3	1.31	56.49	
6ND		Imipramine	Male	69	61	0.96	MG/DL	0.7	1.3	0.96	62.66	
6DT		Reboxetine	Female	70	52	1.22	MG/DL	0.7	1.3	1.22	35.10	
7ND		Reboxetine	Male	85	81	1.43	MG/DL	0.7	1.3	1.43	43.27	
8ND		Imipramine	Female	68	83.7	1.19	MG/DL	0.7	1.3	1.19	50.42	
8DT		Imipramine	Female	66	75	1.25	MG/DL	0.7	1.3	1.25	65.65	
9ND		Reboxetine	Female	68	69	0.9	MG/DL	0.7	1.3	0.90	64.94	
9DT	Reboxetine	Female	77	44	1.06	MG/DL	0.7	1.3	1.06	30.77		
10ND	Imipramine	Female	71	53	1.21	MG/DL	0.7	1.3	1.21	35.56		
11ND	Imipramine	Male	74	73	1.27	MG/DL	0.7	1.3	1.27	54.13		
11DT	Imipramine	Female	68	69.2	1.21	MG/DL	0.7	1.3	1.21	48.44		
12ND	Reboxetine	Female	70	50	0.94	MG/DL	0.7	1.3	0.94	43.80		
12DT	Reboxetine	Female	66	79	1.12	MG/DL	0.7	1.3	1.12	61.41		
12DT	Imipramine	Male	80	74	1.14	MG/DL	0.7	1.3	1.14	54.09		
6	1ND	Reboxetine	Female	70	64	0.9	MG/DL	0.3	1.25	0.90	58.56	
	1DT	Reboxetine	Female	72	64	0.79	MG/DL	0.3	1.25	0.79	64.81	
	2DT	Imipramine	Female	70	81	0.82	MG/DL	0.3	1.25	0.82	81.35	
2DT	Reboxetine	Female	68	71	1.23	MG/DL	0.3	1.25	1.23	48.90		

(a) $((140 - \text{AGE}) * \text{WEIGHT}) / (\text{alfa} * \text{CREATININE})$
Sex = M ==> alfa=72 Sex = F ==> alfa=85

2382

9550089

2

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.1

CREATININE AND CREATININE CLEARANCE VALUES CALCULATED AS PER PROTOCOL

Centre	Patient	Treatment	Sex	Age (years)	Weight (Kg)	CREATININE	UNIT	MIN	MAX	CREATININE (mg/dl)	CREATININE CLEARANCE (ml/min) (a)
6	3ND	Reboxetine	Female	68	63	0.85	MG/DL	0.3	1.25	0.85	62.78
	3DT	Imipramine	Female	65	64.5	1.31	MG/DL	0.3	1.25	1.31	43.44
	4ND	Imipramine	Female	71	66	1.23	MG/DL	0.3	1.25	1.23	43.56
	4DT	Imipramine	Female	69	70	1.12	MG/DL	0.3	1.25	1.12	52.21
	5ND	Imipramine	Female	74	58.5	0.96	MG/DL	0.3	1.25	0.96	49.47
	5DT	Reboxetine	Female	68	81.5	0.96	MG/DL	0.3	1.25	0.96	71.91
	6ND	Reboxetine	Female	77	57	1.43	MG/DL	0.3	1.25	1.43	29.54
	8ND	Imipramine	Female	74	55	0.79	MG/DL	0.3	1.25	0.79	45.29
7	1ND	Imipramine	Male	66	66	0.56	MG/DL	0.7	1.35	0.56	121.15
	3ND	Imipramine	Female	67	63	1	MG/DL	0.55	1.1	1.00	54.11
	4ND	Reboxetine	Female	74	55	0.6	MG/DL	0.55	1.1	0.60	71.18
	342ND	Reboxetine	Female	67	59	0.78	MG/DL	0.55	1.1	0.78	64.96
8	1ND	Reboxetine	Female	68	58	1.08	MG/DL	0.5	1.2	1.08	45.49
	1DT	Imipramine	Female	83	65	1.04	MG/DL	0.5	1.2	1.04	41.91
	2ND	Reboxetine	Female	69	92	0.75	MG/DL	0.5	1.2	0.75	102.46
	2DT	Imipramine	Female	62	62	1.16	MG/DL	0.5	1.2	1.16	32.07
	3ND	Imipramine	Female	72	52	0.57	MG/DL	0.5	1.2	0.57	72.98
	3DT	Reboxetine	Female	78	53	0.81	MG/DL	0.5	1.2	0.81	47.73
	4ND	Imipramine	Male	70	56	0.9	MG/DL	0.5	1.2	0.90	60.49
	4DT	Reboxetine	Female	72	59	1.08	MG/DL	0.5	1.2	1.08	43.70
	701ND	Imipramine	Male	70	56	0.98	MG/DL	0.5	1.2	0.98	55.56
	701DT	Reboxetine	Female	74	87	0.75	MG/DL	0.5	1.2	0.75	90.07
	702ND	Reboxetine	Male	70	48	0.94	MG/DL	0.5	1.2	0.94	49.65
	702DT	Imipramine	Female	83	58	1.17	MG/DL	0.5	1.2	1.17	33.24
	703ND	Imipramine	Female	71	76	1.1	MG/DL	0.5	1.2	1.10	56.09
	703DT	Imipramine	Male	79	90	1.4	MG/DL	0.5	1.2	1.40	54.46
	704ND	Imipramine	Female	76	57	1.25	MG/DL	0.5	1.2	1.25	34.33
	704DT	Reboxetine	Female	67	79.5	0.99	MG/DL	0.5	1.2	0.99	68.97
12	1ND	Reboxetine	Female	84	48	106	UMOL/L	60	110	1.20	26.37
	1DT	Reboxetine	Female	85	51	85	UMOL/L	60	110	0.96	34.32
13	1ND	Reboxetine	Female	80	36	80	UMOL/L	70	115	0.90	28.08
	1DT	Imipramine	Female	82	50	69	UMOL/L	70	115	0.78	43.71
	2ND	Imipramine	Female	94	48	94	UMOL/L	70	115	1.06	24.43
	2DT	Reboxetine	Female	76	50	81	UMOL/L	70	115	0.92	41.09
	3ND	Imipramine	Male	79	77	89	UMOL/L	70	115	1.01	64.80
	3DT	Imipramine	Female	79	58	73	UMOL/L	70	115	0.83	50.40
	4DT	Reboxetine	Female	89	50	100	UMOL/L	70	115	1.13	26.52

(a) $\frac{(140 - \text{AGE}) \times \text{WEIGHT}}{72}$ / $(\text{ALFA} \times \text{CREATININE})$
Sex = M ==> ALFA=72 Sex = F ==> ALFA=85

23003

9550089

3

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE – PROTOCOL 20124/035
Listing No.: 18.1

CREATININE AND CREATININE CLEARANCE VALUES CALCULATED AS PER PROTOCOL

Centre	Patient	Treatment	Sex	Age (years)	Weight (Kg)	CREATININE	UNIT	MIN	MAX	CREATININE (mg/dl)	CREATININE CLEARANCE (ml/min) (a)
14	1ND	Reboxetine	Female	81	64	9	MG/L	7	14	0.90	49.36
15	1ND	Reboxetine	Female	77	61	6.4	MG/L	6	13	0.64	70.64
	1DT	Reboxetine	Female	86	68	7.3	MG/L	6	13	0.73	59.18
	2ND	Imipramine	Female	84	65.2	9.8	MG/L	6	13	0.98	43.89
	2DT	Imipramine	Female	89	83	10.1	MG/L	6	13	1.01	49.51
	3ND	Reboxetine	Female	83	64	6.3	MG/L	6	13	0.63	46.83
	4ND	Imipramine	Female	86	75	7.8	MG/L	6	13	0.78	61.09
11ND	11ND	Reboxetine	Female	85	61	7.5	MG/L	6	13	0.75	71.76
	112ND	Imipramine	Female	84	76	10.7	MG/L	6	13	1.07	46.79
16	1ND	Reboxetine	Female	85	50	128	UHOL/L	55	115	1.45	22.34
	1DT	Imipramine	Female	74	60	68	UHOL/L	55	115	0.77	60.56
	2ND	Imipramine	Male	72	61	71	UHOL/L	55	115	0.80	71.73
	2DT	Reboxetine	Male	71	58.5	75	UHOL/L	55	115	0.85	66.08
	3ND	Imipramine	Female	68	50	67	UHOL/L	55	115	0.76	55.88
	3DT	Imipramine	Female	70	70	70	UHOL/L	55	115	0.79	67.60
4ND	4ND	Reboxetine	Female	75	57	69	UHOL/L	55	115	0.78	55.84
	4DT	Reboxetine	Female	75	57	69	UHOL/L	55	115	0.78	55.84
17	1ND	Reboxetine	Female	71	45.5	61	UHOL/L	50	100	0.69	53.53
	1DT	Reboxetine	Female	81	54	77	UHOL/L	50	100	0.87	43.03
	2ND	Imipramine	Female	87	56	77	UHOL/L	50	100	0.87	40.09
	2DT	Reboxetine	Female	76	58	53	UHOL/L	50	100	0.60	72.84
	3ND	Imipramine	Female	74	45	59	UHOL/L	50	100	0.67	52.35
	3DT	Imipramine	Male	79	77	128	UHOL/L	50	100	1.45	45.05
	4ND	Reboxetine	Female	65	50	73	UHOL/L	50	100	0.83	53.42
	4DT	Imipramine	Female	81	56	65	UHOL/L	50	100	0.74	52.86
	211ND	Reboxetine	Female	70	52	106	UHOL/L	50	100	1.20	35.71
	211DT	Reboxetine	Female	83	66	124	UHOL/L	50	100	1.40	31.55
18	1ND	Imipramine	Female	81	64	74.34	UHOL/L	53	107	0.84	52.83
	1DT	Imipramine	Female	80	39	73.45	UHOL/L	53	107	0.83	33.13
	2ND	Imipramine	Female	68	47	90.27	UHOL/L	53	107	1.02	38.99
	2DT	Reboxetine	Female	71	55	94.69	UHOL/L	53	107	1.07	41.68
	3ND	Reboxetine	Female	82	68	113.23	UHOL/L	53	107	1.28	36.21
4ND	Reboxetine	Female	79	52	100.89	UHOL/L	53	107	1.14	32.70	
20	3ND	Reboxetine	Female	80	53						

(a) $(\frac{140 - \text{AGE}}{72} * \text{WEIGHT}) / (\text{alfa} * \text{CREATININE})$
Sex = M ==> alfa=72 Sex = F ==> alfa=85

2384

9550089

4

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RSD

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.1

CREATININE AND CREATININE CLEARANCE VALUES CALCULATED AS PER PROTOCOL

Centre	Patient	Treatment	Sex	Age (years)	Weight (kg)	CREATININE	UNIT	MIN	MAX	CREATININE (mg/dl)	CREATININE CLEARANCE (ml/min) (a)
22	1MD	Reboxetine	Female	81	47	96	UMOL/L	50	98	1.09	30.04
23	1MD	Reboxetine	Female	71	58.9	0.7	MG/DL	0	1.3	0.70	68.30
	2MD	Reboxetine	Female	69	63	1	MG/DL	0	1.3	1.00	52.62
	3MD	Imipramine	Female	80	49	0.6	MG/DL	0	1.3	0.60	57.65
	4MD	Imipramine	Female	80	74	0.8	MG/DL	0	1.3	0.80	65.29
	5MD	Imipramine	Female	69	64	0.8	MG/DL	0	1.3	0.80	66.82
	6MD	Imipramine	Female	72	61	1	MG/DL	0	1.3	1.00	48.80
25	1MD	Reboxetine	Male	68	60.8	1.2	MG/DL	0.7	1.2	1.20	50.67
	2MD	Imipramine	Female	67	57.6	1.1	MG/DL	0.5	1	1.10	44.97
26	1MD	Imipramine	Female	69	88	82	UMOL/L	62	130	0.93	79.24
	1DT	Reboxetine	Female	68	48	73.7	UMOL/L	62	130	0.83	48.77
27	1MD	Imipramine	Male	79	60.5	1	MG/DL	0	1.39	1.00	51.26
28	1MD	Reboxetine	Female	70	86.5	1	MG/DL	0	1.4	1.00	71.24
	1DT	Imipramine	Female	91	44	1.19	MG/DL	0	1.4	1.19	21.31
	2MD	Imipramine	Female	86	71	0.9	MG/DL	0	1.4	0.90	50.12
	2DT	Reboxetine	Male	82	68	1.16	MG/DL	0	1.4	1.16	47.22
	3MD	Reboxetine	Female	66	85	1.06	MG/DL	0	1.4	1.06	69.81
	3DT	Imipramine	Male	69	75	1.29	MG/DL	0	1.4	1.29	57.33
4MD	Imipramine	Male	87	78	1.27	MG/DL	0	1.4	1.27	45.21	
	Reboxetine	Female	66	75	1.03	MG/DL	0	1.4	1.03	63.39	
30	1MD	Imipramine	Female	87	45.4	93	UMOL/L	50	125	1.05	26.91
	2MD	Reboxetine	Female	74	73	90	UMOL/L	50	125	1.02	55.67
	3MD	Imipramine	Female	86	94	107	UMOL/L	50	125	1.21	28.34
	4MD	Reboxetine	Female	78	66.6	99	UMOL/L	50	125	1.12	43.38
	5MD	Imipramine	Female	75	69	96	UMOL/L	50	125	1.09	48.59
31	1MD	Imipramine	Female	76	41	88	UMOL/L	50	125	1.00	31.01
	1DT	Reboxetine	Female	77	66	80	UMOL/L	50	125	0.90	54.05
	3MD	Imipramine	Male	79	46.1	84	UMOL/L	50	125	0.95	34.82

(a) $((140 - \text{AGE}) * \text{WEIGHT}) / (\text{alpha} * \text{CREATININE})$
Sex = M ==> alpha=72. Sex = F ==> alpha=85

23 00 01.

9550089

5

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.1

CREATININE AND CREATININE CLEARANCE VALUES CALCULATED AS PER PROTOCOL

Centre	Patient	Treatment	Sex	Age (years)	Weight (kg)	CREATININE	UNIT	MIN	MAX	CREATININE (ng/dL)	CREATININE CLEARANCE (mL/MIN) (a)
32	1MD	Imipramine	Female	66	75	99	UMOL/L	50	100	1.12	58.30
	2MD	Imipramine	Female	70	75	102	UMOL/L	50	100	1.15	53.53
	3MD	Reboxetine	Female	67	58	141	UMOL/L	50	100	1.26	39.67
	4MD	Reboxetine	Female	68	57	102	UMOL/L	50	100	1.15	41.84
	5MD	Reboxetine	Female	78	50	101	UMOL/L	50	100	1.14	51.92
	6MD	Imipramine	Male	81	99	109	UMOL/L	60	110	1.23	65.79
35	1MD	Reboxetine	Female	71	57	0.63	MG/DL	0.2	1.2	0.63	73.45
	1DT	Reboxetine	Female	69	72	0.9	MG/DL	0.2	1.2	0.90	66.82
	2MD	Imipramine	Female	72	62	1	MG/DL	0.2	1.2	1.00	49.60
	2DT	Imipramine	Female	67	65.6	1	MG/DL	0.2	1.2	1.00	56.34
	3MD	Imipramine	Female	66	69	1.3	MG/DL	0.2	1.2	1.30	46.21
	3DT	Imipramine	Male	74	73	1.05	MG/DL	0.2	1.2	1.05	63.73
	4MD	Reboxetine	Male	90	54.5	1.3	MG/DL	0.2	1.2	1.30	29.11
	4DT	Reboxetine	Female	65	90	0.9	MG/DL	0.2	1.2	0.90	88.24
	5MD	Reboxetine	Male	70	60.5	1	MG/DL	0.2	1.2	1.00	58.82
	5DT	Imipramine	Female	77	62	1.2	MG/DL	0.2	1.2	1.20	38.29
	6MD	Reboxetine	Female	69	91	1	MG/DL	0.2	1.2	1.00	76.01
	6DT	Imipramine	Female	69	91	1.3	MG/DL	0.2	1.2	1.30	58.47
	7MD	Imipramine	Female	74	82	1	MG/DL	0.2	1.2	1.00	63.67
	7DT	Reboxetine	Female	78	67.5	0.7	MG/DL	0.2	1.2	0.70	70.34
8MD	Imipramine	Female	74	58	0.6	MG/DL	0.2	1.2	0.60	75.06	
8DT	Reboxetine	Female	72	38	0.9	MG/DL	0.2	1.2	0.90	33.78	
36	1MD	Imipramine	Male	83	64.9	0.9	MG/DL	0.7	1.3	0.90	57.09
	1DT	Imipramine	Female	78	78.4	1	MG/DL	0.7	1.3	1.00	57.19
	2MD	Reboxetine	Female	65	76	0.9	MG/DL	0.7	1.3	0.90	74.51
	2DT	Reboxetine	Female	66	72	0.9	MG/DL	0.7	1.3	0.90	69.65
	3MD	Imipramine	Female	84	45	1.2	MG/DL	0.7	1.3	1.20	24.71
	3DT	Imipramine	Female	80	57.5	0.9	MG/DL	0.7	1.3	0.90	45.10
	4MD	Reboxetine	Female	79	65	1	MG/DL	0.7	1.3	1.00	46.20
	4DT	Reboxetine	Female	74	59.5	1	MG/DL	0.7	1.3	1.00	50.89
	5MD	Reboxetine	Female	79	78	1.1	MG/DL	0.7	1.3	1.10	50.89
	5DT	Imipramine	Female	65	80	0.7	MG/DL	0.7	1.3	0.70	100.84
	6MD	Imipramine	Female	65	74.3	0.7	MG/DL	0.7	1.3	0.70	93.66
	6DT	Imipramine	Female	72	62	0.9	MG/DL	0.7	1.3	0.90	55.11
	7MD	Reboxetine	Female	81	50	0.7	MG/DL	0.7	1.3	0.70	49.58
	7DT	Reboxetine	Female	75	59	0.8	MG/DL	0.7	1.3	0.80	56.40
8MD	Imipramine	Female	67	104	1.1	MG/DL	0.7	1.3	1.10	81.20	
8DT	Reboxetine	Female	80	55.7	0.8	MG/DL	0.7	1.3	0.80	49.15	
9MD	Reboxetine	Male	82	68	1.8	MG/DL	0.7	1.3	1.80	30.43	
9DT	Imipramine	Female	65	66	1.3	MG/DL	0.7	1.3	1.30	44.80	

(a) $((140 - \text{AGE}) * \text{WEIGHT}) / (\text{alfa} * \text{CREATININE})$
Sex = M ==> alfa=72 Sex = F ==> alfa=85

2386

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

6

PHARMACIA CMS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.1

CREATININE AND CREATININE CLEARANCE VALUES CALCULATED AS PER PROTOCOL

Centre	Patient	Treatment	Sex	Age (years)	Weight (Kg)	CREATININE	UNIT	MIN	MAX	CREATININE (mg/dl)	CREATININE CLEARANCE (ml/min) (a)	
36	10ND	Reboxetine	Male	77	66	1.6	MG/DL	0.7	1.3	1.60	36.09	
	10DT	Reboxetine	Male	79	75	1.3	MG/DL	0.7	1.3	1.30	48.88	
	11ND	Imipramine	Female	81	52	1.3	MG/DL	0.7	1.3	1.30	27.76	
	11DT	Reboxetine	Male	78	65	1.5	MG/DL	0.7	1.3	1.50	37.31	
	12ND	Imipramine	Female	78	53.7	0.8	MG/DL	0.7	1.3	0.80	48.96	
	12DT	Imipramine	Female	81	65	1.1	MG/DL	0.7	1.3	1.10	28.40	
	13ND	Reboxetine	Male	76	53	1.3	MG/DL	0.7	1.3	1.30	36.24	
	13DT	Imipramine	Male	71	71	1.5	MG/DL	0.7	1.3	1.50	46.02	
	14ND	Imipramine	Female	75	60.5	1.5	MG/DL	0.7	1.3	1.50	31.79	
	14DT	Imipramine	Female	72	71	1.1	MG/DL	0.7	1.3	1.10	51.64	
	15ND	Reboxetine	Female	80	54	1.1	MG/DL	0.7	1.3	1.10	34.65	
	17ND	Imipramine	Female	78	69	1.1	MG/DL	0.7	1.3	1.10	45.75	
	18ND	Reboxetine	Female	81	55	0.9	MG/DL	0.7	1.3	0.90	42.42	
	19ND	Imipramine	Female	70	74	1.1	MG/DL	0.7	1.3	1.10	55.40	
	37	3ND	Reboxetine	Female	81	59	0.94	MG/DL	0	1.4	0.94	43.57
	41	1ND	Imipramine	Male	69	74	112	UHOL/L	45	120	1.27	57.60
		2ND	Reboxetine	Male	68	57	53	UHOL/L	45	120	0.60	95.07
		3ND	Imipramine	Male	85	73	91	UHOL/L	45	120	1.03	54.17
		4ND	Reboxetine	Male	74	77	93	UHOL/L	45	120	1.05	67.09
		5ND	Reboxetine	Male	69	72	101	UHOL/L	45	120	1.14	62.14
42	1ND	Imipramine	Female	73	71.8	81	UHOL/L	44	106	0.92	61.77	
	2ND	Imipramine	Female	79	57	135	UHOL/L	45	120	1.53	26.79	
	2DT	Reboxetine	Female	79	52	93	UHOL/L	44	106	1.05	35.47	
	3ND	Imipramine	Male	68	77.4	107	UHOL/L	45	120	1.21	63.95	
43	1DT	Reboxetine	Female	77	60	0.069	MGOL/L	0.035	0.13	0.78	56.97	
	2DT	Imipramine	Female	77	59	0.089	MGOL/L	0.035	0.13	1.01	43.43	
	3DT	Imipramine	Male	72	94	0.106	MGOL/L	0.035	0.13	1.22	72.67	
	4DT	Reboxetine	Female	79	80	0.07	MGOL/L	0.035	0.13	0.75	72.50	
	5ND	Imipramine	Female	70	55	0.079	MGOL/L	0.035	0.13	0.89	50.68	
	6ND	Imipramine	Female	74	65	0.075	MGOL/L	0.035	0.13	0.85	59.49	
44	1ND	Reboxetine	Female	76	71	97	UHOL/L	60	100	1.10	48.72	
	1DT	Reboxetine	Female	76	61.7	89	UHOL/L	60	100	1.01	46.14	
	2ND	Reboxetine	Female	73	73.85	113	UHOL/L	60	100	1.28	45.54	
	3ND	Imipramine	Female	73	64.15	70	UHOL/L	60	100	0.79	63.86	
4ND	Imipramine	Male	81	65.3	105	UHOL/L	76	120	1.19	45.05		

(a) ((140 - AGE) * WEIGHT) / (alfa * CREATININE)
Sex = M ==> alfa=72 Sex = F ==> alfa=85

2387

9550089

9550089

7

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.1

CREATININE AND CREATININE CLEARANCE VALUES CALCULATED AS PER PROTOCOL

Centre	Patient	Treatment	Sex	Age (years)	Weight (Kg)	CREATININE	UNIT	MIN	MAX	CREATININE (mg/dl)	CREATININE CLEARANCE (ML/MIN) (a)
45	1ND	Reboxetine	Male	76	78	102	UMOL/L	55	125	1.15	60.09
	1DT	Imipramine	Female	79	56.5	85	UMOL/L	55	125	0.96	42.17
	2ND	Imipramine	Male	77	55	115	UMOL/L	55	125	1.30	36.99
46	1ND	Imipramine	Male	69	113	125	UMOL/L	45	120	1.41	78.80
	2ND	Imipramine	Female	72	54	107	UMOL/L	45	120	1.21	35.69
	3ND	Reboxetine	Female	73	60.2	84	UMOL/L	45	120	0.95	49.34
	4ND	Reboxetine	Female	78	45.3	97	UMOL/L	45	120	1.10	30.41
48	1DT	Reboxetine	Female	74	41.7	70	UMOL/L	50	120	0.79	40.89
	2DT	Imipramine	Female	65	73.6	90	UMOL/L	50	120	1.02	63.79
291	1ND	Imipramine	Female	80	51	0.9	MG/DL	0.5	1.2	0.90	40.00
	1DT	Reboxetine	Female	81	80	1	MG/DL	0.5	1.2	1.00	55.53
	2ND	Reboxetine	Female	68	62	0.8	MG/DL	0.5	1.2	0.80	65.65
	2DT	Reboxetine	Female	73	80	1.09	MG/DL	0.5	1.2	1.09	57.85
	3ND	Imipramine	Male	67	88	1.4	MG/DL	0.5	1.4	1.40	63.73
	3DT	Imipramine	Female	73	74	1.4	MG/DL	0.5	1.2	1.40	41.66
	4ND	Reboxetine	Male	68	79	1.5	MG/DL	0.5	1.4	1.50	52.67
	4DT	Imipramine	Male	87	58	1.1	MG/DL	0.5	1.4	1.10	38.81
	25DT	Imipramine	Female	80	64	1.1	MG/DL	0.5	1.2	1.10	41.07
	26DT	Reboxetine	Female	81	56	0.8	MG/DL	0.5	1.2	0.80	48.59
	27DT	Reboxetine	Female	88	67	0.9	MG/DL	0.5	1.2	0.90	45.54
	28DT	Imipramine	Female	73	71	1.2	MG/DL	0.5	1.2	1.20	46.64
	292	5ND	Imipramine	Female	73	64.3	0.92	MG/DL	0.6	1.1	0.92
5DT		Reboxetine	Male	79	81.3	1.27	MG/DL	0.7	1.3	1.27	54.24
6ND		Reboxetine	Female	71	70.3	1.06	MG/DL	0.6	1.1	1.06	53.84
6DT		Imipramine	Female	69	79.3	1.06	MG/DL	0.6	1.1	1.06	62.49
7ND		Reboxetine	Male	82	69.7	1.08	MG/DL	0.7	1.3	1.08	51.99
7DT		Imipramine	Male	68	72.3	1.03	MG/DL	0.7	1.3	1.03	70.19
8ND		Imipramine	Male	68	62.5	1.05	MG/DL	0.7	1.3	1.05	59.52
8DT		Reboxetine	Female	72	72.8	0.99	MG/DL	0.6	1.1	0.99	57.96
21ND		Imipramine	Female	72	66.8	0.98	MG/DL	0.6	1.1	0.98	54.53
21DT		Reboxetine	Female	79	67.2	1.14	MG/DL	0.6	1.1	1.14	42.30
22ND		Imipramine	Female	67	60.3	1.09	MG/DL	0.6	1.1	1.09	47.51
22DT		Imipramine	Female	81	68.5	1.09	MG/DL	0.6	1.1	1.09	43.62
23ND		Reboxetine	Female	75	72.8	1.07	MG/DL	0.6	1.1	1.07	52.03
23DT	Reboxetine	Male	69	74.8	1.03	MG/DL	0.7	1.3	1.03	71.61	
24ND	Reboxetine	Male	75	92.8	0.89	MG/DL	0.7	1.3	0.89	94.13	

(a) $((140 - \text{AGE}) * \text{WEIGHT}) / (\text{alfa} * \text{CREATININE})$
Sex = M ==> alfa=72 Sex = F ==> alfa=85

23
23
23
23

9550089

8

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.1

CREATININE AND CREATININE CLEARANCE VALUES CALCULATED AS PER PROTOCOL

Centre	Patient	Treatment	Sex	Age (years)	Weight (Kg)	CREATININE	UNIT	MIN	MAX	CREATININE (mg/dl)	CREATININE CLEARANCE (ML/MIN) (a)	
292	24DT	Imipramine	Female	68	68.2	0.98	MG/DL	0.6	1.1	0.98	58.95	
293	9ND	Imipramine	Female	80	69	0.9	MG/DL	0.5	1	0.90	54.12	
	9DT	Imipramine	Female	67	71	0.9	MG/DL	0.5	1	0.90	67.75	
	10ND	Reboxetine	Female	65	74	1	MG/DL	0.5	1	1.00	65.29	
	10DT	Imipramine	Female	66	72	0.9	MG/DL	0.5	1	0.90	69.65	
	11ND	Imipramine	Male	65	72	1	MG/DL	0.6	1.1	1.00	75.00	
	11DT	Reboxetine	Female	68	74	1	MG/DL	0.5	1	1.00	62.68	
	12ND	Reboxetine	Male	56	81	1	MG/DL	0.6	1.1	1.00	94.50	
	12DT	Reboxetine	Female	69	73	1.1	MG/DL	0.5	1	1.10	55.43	
	294	13ND	Imipramine	Female	80	56	1	MG/DL	0.3	1.2	1.00	39.53
		13DT	Reboxetine	Female	68	48	0.83	MG/DL	0.3	1.2	0.83	48.99
		14ND	Reboxetine	Female	82	50	0.98	MG/DL	0.3	1.2	0.98	34.81
		14DT	Imipramine	Female	73	71	0.64	MG/DL	0.3	1.2	0.64	87.44
15ND		Imipramine	Female	82	67	0.8	MG/DL	0.3	1.2	0.80	57.15	
15DT		Imipramine	Female	75	70	0.9	MG/DL	0.3	1.2	0.90	59.48	
16ND		Reboxetine	Female	65	66	1.1	MG/DL	0.3	1.2	1.10	52.94	
16DT		Reboxetine	Female	81	82	1	MG/DL	0.3	1.2	1.00	56.92	
25ND		Imipramine	Female	71	73	0.9	MG/DL	0.3	1.2	0.90	65.84	
26ND		Imipramine	Female	75	58	1.1	MG/DL	0.3	1.2	1.10	40.32	
27ND		Reboxetine	Female	67	84	0.7	MG/DL	0.3	1.2	0.70	103.06	
28ND		Reboxetine	Female	76	56	0.7	MG/DL	0.3	1.2	0.70	60.24	
29DT		Reboxetine	Female	80	58	0.9	MG/DL	0.3	1.2	0.90	45.49	
30DT		Reboxetine	Female	79	67	1	MG/DL	0.3	1.2	1.00	48.08	
31DT		Imipramine	Female	80	73.8	0.7	MG/DL	0.3	1.2	0.70	74.42	
32DT		Imipramine	Male	73	79.4	0.8	MG/DL	0.3	1.2	0.80	92.36	
295	17ND	Reboxetine	Female	64	64	1.3	MG/DL	0.6	1.1	1.30	44.02	
	17DT	Imipramine	Male	65	75	1.21	MG/DL	0.7	1.3	1.21	64.57	
	18ND	Reboxetine	Female	73	60	1.32	MG/DL	0.6	1.1	1.32	35.83	
	18DT	Imipramine	Female	71	62	0.85	MG/DL	0.6	1.1	0.85	59.21	
	19ND	Imipramine	Male	66	78	1.07	MG/DL	0.7	1.3	1.07	74.82	
	19DT	Reboxetine	Female	69	74	0.88	MG/DL	0.6	1.1	0.88	70.24	
	20ND	Imipramine	Female	82	75	1	MG/DL	0.6	1.1	1.00	51.18	
	20DT	Reboxetine	Female	66	80	0.84	MG/DL	0.6	1.1	0.84	82.91	
	381	1MD	Reboxetine	Male	86	63.3	82	UMOL/L	60	120	0.93	51.18
		2MD	Reboxetine	Female	67	44.2	64	UMOL/L	60	120	0.72	52.43
3DT		Reboxetine	Female	77	50	138	UMOL/L	60	120	1.56	23.12	
4ND		Imipramine	Female	88	59	138	UMOL/L	60	120	1.56	23.12	

(a) $((140 - \text{AGE}) * \text{WEIGHT}) / (\text{alfa} * \text{CREATININE})$
Sex = M ==> alfa=72 Sex = F ==> alfa=85

2309

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 18.1

CREATININE AND CREATININE CLEARANCE VALUES CALCULATED AS PER PROTOCOL

Centre	Patient	Treatment	Sex	Age (years)	Weight (kg)	CREATININE	UNIT	MIN	MAX	CREATININE (mg/dl)	CREATININE CLEARANCE (ml/min) (a)
332	5MD	Imipramine	Female	74	47.7	77	UMOL/L	60	120	0.87	42.52
	5DT	Reboxetine	Male	63	65.9	82	UMOL/L	60	120	0.93	75.98
	6ND	Reboxetine	Female	74	63.2	116	UMOL/L	60	120	1.31	37.40
	6DT	Imipramine	Female	79	63.5	124	UMOL/L	60	120	1.40	32.49
	7ND	Reboxetine	Female	88	52	89	UMOL/L	60	120	1.01	31.60
	7DT	Imipramine	Male	82	89.2	144	UMOL/L	60	120	1.63	44.11
	8ND	Imipramine	Male	83	56.7	150	UMOL/L	60	120	1.70	26.59
	9ND	Reboxetine	Female	86	56.4	69	UMOL/L	60	120	0.78	45.82
	9DT	Reboxetine	Female	78	58.4	139	UMOL/L	60	120	1.57	31.17
	10ND	Imipramine	Female	85	48.5	89	UMOL/L	60	120	1.01	31.17
3301	1ND	Reboxetine	Female	76	62	62	UMOL/L	60	120	0.70	66.56
	3ND	Reboxetine	Female	71	65	78	UMOL/L	60	120	0.88	59.80
3302	5ND	Reboxetine	Female	84	69.6	218	UMOL/L	60	120	2.47	18.59
	6ND	Imipramine	Female	73	44.9	89	UMOL/L	60	120	1.01	35.15
	7ND	Imipramine	Female	93	52.5	82	UMOL/L	60	120	0.93	31.30

2390

(a) $((140 - \text{AGE}) * \text{WEIGHT}) / (\text{alfa} * \text{CREATININE})$
 Sex = M ==> alfa=72 Sex = F ==> alfa=85

9550089

1

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 18.1

CREATININE AND TESTED CREATININE CLEARANCE VALUES

Centre	Patient	Treatment	Sex	Age (years)	Weight (Kg)	CREATININE	UNIT	MIN	MAX	CREATININE CLEARANCE	UNIT	MIN	MAX	
4	1HD	Imipramine	Male	74	75	0.12	MMOL/L	0.05	0.11	0.8	ML/SEC	1	1.8	
	9	1DT	Imipramine	Female	71	72	0.5	MG/DL	0.4	1.2	105	ML/MIN	70	140
		2ND	Reboxetine	Female	67	58	0.6	MG/DL	0.4	1.2	100	ML/MIN	70	140
		3DT	Imipramine	Female	66	56	0.55	MG/DL	0.4	1.2	107	ML/MIN	70	140
		4ND	Reboxetine	Female	72	92	0.52	MG/DL	0.4	1.2	95	ML/MIN	70	140
		5ND	Imipramine	Female	65	55	0.57	MG/DL	0.4	1.2	108	ML/MIN	70	140
		6ND	Reboxetine	Female	82	82	0.75	MG/DL	0.4	1.2	108	ML/MIN	70	140
		7ND	Imipramine	Female	70	65	0.63	MG/DL	0.4	1.2	108	ML/MIN	70	140
8DT		Reboxetine	Female	65	51	0.79	MG/DL	0.4	1.2	100	ML/MIN	70	140	
10	1ND	Imipramine	Female	69	56	0.74	MG/DL	0.4	1.2	108	ML/MIN	70	140	
	2ND	Reboxetine	Female	65	89	0.57	MG/DL	0.4	1.2	100	ML/MIN	70	140	
	3ND	Imipramine	Female	67	68	1	MG/DL	0.6	1.6	44.8	ML/MIN	70	160	
	4DT	Reboxetine	Female	71	60	0.9	MG/DL	0.6	1.6	56	ML/MIN	70	160	
	5DT	Imipramine	Male	64	81	1.1	MG/DL	0.6	1.6	121.1	ML/MIN	70	160	
	6DT	Reboxetine	Male	70	76	0.8	MG/DL	0.6	1.6	72	ML/MIN	70	160	
	7DT	Imipramine	Male	74	80	1.1	MG/DL	0.6	1.6	79.4	ML/MIN	70	160	
	8DT	Reboxetine	Male	72	67	0.9	MG/DL	0.6	1.6	70	ML/MIN	70	160	
	9DT	Imipramine	Female	68	70	0.8	MG/DL	0.6	1.6	83	ML/MIN	70	160	
	10DT	Reboxetine	Female	73	85	0.9	MG/DL	0.6	1.6	53	ML/MIN	70	160	
	11DT	Imipramine	Male	67	58	0.9	MG/DL	0.6	1.6	102	ML/MIN	70	160	
	12DT	Reboxetine	Male	70	65	1.1	MG/DL	0.6	1.6	56	ML/MIN	70	160	
	13DT	Imipramine	Male	71	80	1.1	MG/DL	0.6	1.6	93	ML/MIN	70	160	
	14DT	Reboxetine	Male	69	68	1.1	MG/DL	0.6	1.6	74	ML/MIN	70	160	
	15DT	Imipramine	Female	73	80	1.1	MG/DL	0.6	1.6	78.1	ML/MIN	70	160	
	16DT	Reboxetine	Female	68	50	1.1	MG/DL	0.6	1.6	63	ML/MIN	70	160	
	17DT	Imipramine	Male	73	80	1.1	MG/DL	0.6	1.6	88	ML/MIN	70	160	
	18DT	Reboxetine	Male	68	60	1.2	MG/DL	0.6	1.6	66	ML/MIN	70	160	
	19DT	Imipramine	Female	70	68	0.9	MG/DL	0.6	1.6	49	ML/MIN	70	160	
	20DT	Reboxetine	Female	72	62	0.9	MG/DL	0.6	1.6	79	ML/MIN	70	160	
3301	1ND	Imipramine	Female	72	65	0.9	MG/DL	0.6	1.6	51	ML/MIN	70	160	
	2ND	Reboxetine	Female	67	70	1.1	MG/DL	0.6	1.6	76	ML/MIN	70	160	
	3ND	Imipramine	Female	67	58	0.9	MG/DL	0.6	1.6	60	ML/MIN	70	160	
	4ND	Reboxetine	Female	72	57	1.1	MG/DL	0.6	1.6	59	ML/MIN	70	160	
	5ND	Imipramine	Male	64	64	1.1	MG/DL	0.6	1.6	66	ML/MIN	70	160	
	6ND	Reboxetine	Male	67	73	1.2	MG/DL	0.6	1.6	58	ML/MIN	70	160	
	7ND	Imipramine	Female	63	63	1.1	MG/DL	0.6	1.6	54	ML/MIN	70	160	
	8ND	Reboxetine	Female	70	60	1	MG/DL	0.6	1.6	61	ML/MIN	70	160	
	9ND	Imipramine	Female	69	74	0.9	MG/DL	0.6	1.6	55	ML/MIN	70	160	
	10ND	Reboxetine	Female	74	80	0.9	MG/DL	0.6	1.6	58	ML/MIN	70	160	
	11ND	Imipramine	Male	70	74	1.1	MG/DL	0.6	1.6	63	ML/MIN	70	160	
	12ND	Reboxetine	Female	73	58	1.1	MG/DL	0.6	1.6	49	ML/MIN	70	160	
	13ND	Imipramine	Female	66	74	1	MG/DL	0.6	1.6	68	ML/MIN	70	160	
	14ND	Reboxetine	Male	69	62	0.9	MG/DL	0.6	1.6	66	ML/MIN	70	160	
	15ND	Imipramine	Female	71	71	1	MG/DL	0.6	1.6	66	ML/MIN	70	160	
	16ND	Reboxetine	Female	71	71	1	MG/DL	0.6	1.6	66	ML/MIN	70	160	
	17ND	Imipramine	Female	71	71	1	MG/DL	0.6	1.6	66	ML/MIN	70	160	
	18ND	Reboxetine	Female	71	71	1	MG/DL	0.6	1.6	66	ML/MIN	70	160	
	19ND	Imipramine	Female	71	71	1	MG/DL	0.6	1.6	66	ML/MIN	70	160	
	20ND	Reboxetine	Female	71	71	1	MG/DL	0.6	1.6	66	ML/MIN	70	160	
3301	2ND	Imipramine	Male	85	39	110	UMOL/L	60	120	40	ML/MIN	80	125	

2391

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 19.0
 URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	Urinalysis test											
										Specific Gravity	Albumin	Sugar	RBC	WBC							
1	1ND	Reboxetine	Female	Evaluated	05/11/92	30/12/92	56	Screen	30/10/92	0 Normal	Normal	Normal	Normal	Normal	Normal						
								Day 28	02/12/92	28 Normal	Normal	Normal	Normal	Normal	Normal						
								Day 56	30/12/92	56 Normal	Normal	Normal	Normal	Normal	Normal						
								1DT	Reboxetine	Male	Evaluated	26/11/93	20/01/94	56	Screen	19/11/93	0 Normal	Normal	Normal	Normal	Normal
															Day 28	23/12/93	28 Normal	Normal	Normal	Normal	Normal
															Day 56	20/01/94	56 Normal	Normal	Normal	Normal	Normal
	2ND	Imipramine	Male	Evaluated	17/11/92	11/01/93	56	Screen	04/11/92	0 Normal	Normal	Normal	Normal	Normal							
								Day 28	14/12/92	28 Not done	Not done	Not done	Not done	Not done							
								Day 56	11/01/93	56 Normal	Normal	Normal	Normal	Normal							
	2DT	Imipramine	Male	Only screening	09/12/93	22/12/93	14	Screen	06/12/93	0 Normal	Normal	Normal	Normal	Normal							
								3ND	Imipramine	Female	Evaluated	03/06/93	28/07/93	56	Screen	26/05/93	0 Normal	Normal	Normal	Normal	
															Day 28	30/06/93	28 Normal	Normal	Normal	Normal	Normal
Day 56	28/07/93	56 Not done	Normal	Normal	Normal	Normal															
2	3DT	Reboxetine	Male	Evaluated	10/12/93	03/02/94	56	Screen	08/12/93	0 Not done	Normal	Normal	Normal	Abnormal							
								Day 28	07/01/94	29 Normal	Normal	Normal	Normal	Normal							
								Day 56	03/02/94	56 Normal	Normal	Normal	Normal	Normal							
	4ND	Reboxetine	Female	Evaluated	19/10/93	13/12/93	56	Screen	18/10/93	0 Normal	Normal	Normal	Normal	Normal							
								Day 28	17/11/93	30 Normal	Normal	Normal	Normal	Normal							
								Day 56	13/12/93	56 Normal	Normal	Normal	Normal	Normal							
4DT	Imipramine	Male	Evaluated	01/02/94	24/02/94	24	Screen	31/01/94	0 Normal	Normal	Normal	Normal	Normal								
							Day 28	24/02/94	24 Normal	Normal	Normal	Normal	Normal								
							1ND	Reboxetine	Male	Evaluated	15/01/93	08/02/93	25	Screen	11/01/93	0 Normal	Normal	Normal	Normal	Normal	
Day 28	12/02/93	29 Normal	Normal	Normal	Normal	Normal															
Day 49	23/06/93	50 Normal	Normal	Normal	Normal	Normal															
3	1ND	Reboxetine	Female	Evaluated	05/05/93	22/06/93	49	Screen	27/04/93	0 Normal	Normal	Normal	Normal	Normal							
								Day 28	03/06/93	30 Normal	Normal	Normal	Normal	Normal							
								Day 49	23/06/93	50 Normal	Normal	Normal	Normal	Normal							
4	1ND	Imipramine	Male	Evaluated	25/11/92	29/12/92	35	Screen	20/11/92	0 Normal	Normal	Normal	Normal	Normal							
								Day 28	22/12/92	28 Normal	Normal	Normal	Normal	Normal							
																		(*) days of treatment			

23
 23
 23

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 19.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period			Urinalysis test								
					Start date	End date	Days	Assessment	Date	(*)	Specific Gravity	Albumin	Sugar	RBC	WBC	
4	1MD	Imipramine	Male	Evaluated	25/11/92	29/12/92	35	Day 35	29/12/92	35	Normal	Normal	Normal	Normal	Normal	Normal
5	1HD	Reboxetine	Female	Only screening	30/10/92	10/11/92	12	Screen	23/10/92	0	Not done	Normal	Normal	Normal	Normal	Normal
	1DT	Imipramine	Female	Evaluated	11/11/92	06/01/93	57	Screen Day 28 Day 56	09/11/92 09/12/92 06/01/93	0 29 57	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
	2HD	Reboxetine	Male	Evaluated	24/11/92	18/01/93	56	Screen Day 28 Day 56	16/11/92 21/12/92 18/01/93	0 28 56	Normal Normal Not done	Normal Normal Not done	Normal Normal Not done	Normal Normal Not done	Normal Normal Not done	
	2DT	Imipramine	Female	Evaluated	23/12/92	14/02/93	54	Screen Day 28 Day 56	16/12/92 22/01/93 24/02/93	0 31 64	Normal Abnormal Not done	Normal Normal Not done	Normal Abnormal Not done	Normal Abnormal Not done	Normal Abnormal Not done	
	3MD	Imipramine	Female	Evaluated	17/03/93	11/05/93	56	Screen Day 28 Day 56	09/03/93 13/04/93 11/05/93	0 28 56	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
	3DT	Reboxetine	Male	Without Urinal	27/03/93	21/05/93	56	Screen Day 21 Day 56	18/03/93 13/04/93 18/05/93	0 18 53	Not done Not done Not done	Not done Not done Not done	Not done Not done Not done	Not done Not done Not done	Not done Not done Not done	
	4MD	Imipramine	Male	Evaluated	24/11/92	18/01/93	56	Screen Day 28 Day 56	18/11/92 21/12/92 18/01/93	0 28 56	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
	4DT	Reboxetine	Male	Without Urinal	03/02/93	02/03/93	28	Screen	26/01/93	0	Not done	Not done	Not done	Not done	Not done	
	5MD	Reboxetine	Male	Without Urinal	04/08/93	15/08/93	12	Screen	28/07/93	0	Not done	Not done	Not done	Not done	Not done	
	5DT	Reboxetine	Female	Only screening	17/02/93	17/03/93	29	Screen Day 28	09/02/93 19/03/93	0 31	Normal Not done	Not done Not done	Not done Not done	Normal Not done	Abnormal Not done	
	6MD	Imipramine	Male	Without Urinal	05/08/93	18/08/93	14	Screen	29/07/93	0	Not done	Not done	Not done	Not done	Not done	

(*) days of treatment

9550089

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

3

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 19.0
 URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period			Urinalysis test							
					Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	MBC
5	6DT	Reboxetine	Female	Without Urinal	27/02/93	23/04/93	56	Screen Day 28	19/02/93 26/03/93	0 28	Not done Not done	Not done Not done	Not done Not done	Not done Not done	Not done Not done
	7ND	Reboxetine	Male	Without Urinal	27/10/93	16/11/93	21	Screen	26/10/93	0	Not done	Not done	Not done	Not done	Not done
	7DT	Imipramine	Female	Without Urinal	13/03/93	07/05/93	56	Screen Day 28 Day 56	07/03/93 09/04/93 11/05/93	0 28 60	Not done Not done Not done	Not done Not done Not done	Not done Not done Not done	Not done Not done Not done	Not done Not done Not done
	8ND	Imipramine	Female	Only screening	11/11/93	05/01/94	56	Screen Day 28 Day 56	26/10/93 09/12/93 06/01/94	0 29 57	Not done Not done Not done	Not done Not done Not done	Not done Not done Not done	Normal Not done Not done	Normal Not done Not done
	8DT	Imipramine	Female	Without Urinal	05/05/93	29/06/93	56	Screen Day 21 Day 56	30/04/93 26/05/93 24/06/93	0 22 51	Not done Not done Not done	Not done Not done Not done	Not done Not done Not done	Not done Not done Not done	Not done Not done Not done
9ND	9ND	Reboxetine	Female	Without Urinal	16/11/93	10/01/94	56	Screen Day 28 Day 56	09/11/93 14/12/93 11/01/94	0 29 57	Not done Not done Not done	Not done Not done Not done	Not done Not done Not done	Not done Not done Not done	Not done Not done Not done
	9DT	Reboxetine	Female	Without Urinal	02/05/93	25/06/93	55	Screen Day 28 Day 56	30/04/93 25/05/93 23/07/93	0 24 83	Not done Not done Not done	Not done Not done Not done	Not done Not done Not done	Not done Not done Not done	Not done Not done Not done
10ND	Imipramine	Female	Only screening	25/11/93	08/12/93	14	Screen	10/11/93	0	Not done	Not done	Normal	Normal	Normal	
10DT	Imipramine	Male	Without Urinal	06/05/93	10/05/93	5	Screen	04/05/93	0	Not done	Not done	Not done	Not done	Not done	
11ND	Imipramine	Female	Without Urinal	02/12/93	05/01/94	35	Screen Day 28	01/12/93 29/12/93	0 28	Not done Not done	Not done Not done	Not done Not done	Not done Not done	Not done Not done	
11DT	Reboxetine	Female	Without Urinal	11/05/93	07/06/93	28	Screen Day 21	05/05/93 26/05/93	0 16	Not done Not done	Not done Not done	Not done Not done	Not done Not done	Not done Not done	

(*) days of treatment

2394

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 19.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period			Urinalysis test								
					Start date	End date	Days	Assessment	Date	Specific gravity	Albumin	Sugar	RBC	WBC		
5	12ND	Reboxetine	Female	Without Urinal	06/01/94	03/03/94	57	Screen	21/12/93	0	Not done	Not done	Not done	Not done	Not done	Not done
								Day 28	04/02/94	30	Not done	Not done	Not done	Not done	Not done	Not done
								Day 56	04/03/94	58	Not done	Not done	Not done	Not done	Not done	Not done
								Screen	18/05/93	0	Normal	Normal	Normal	Normal	Normal	Normal
								Day 28	15/06/93	26	Not done	Not done	Not done	Not done	Not done	Not done
6	1ND	Reboxetine	Female	Only screening	21/05/93	15/07/93	56	Screen	27/07/93	68	Not done	Not done	Not done	Not done	Not done	
								Day 28	12/11/92	0	Normal	Normal	Normal	Normal	Normal	
								Day 56	10/12/92	28	Normal	Normal	Normal	Normal	Normal	
								Screen	07/01/93	56	Normal	Normal	Normal	Normal	Normal	
								Day 28	13/10/92	0	Normal	Normal	Normal	Normal	Normal	
7	1DT	Reboxetine	Female	Evaluated	21/10/92	16/12/92	57	Screen	17/11/92	57	Normal	Normal	Normal	Normal	Normal	
								Day 28	13/10/92	0	Normal	Normal	Normal	Normal	Normal	
								Day 56	17/11/92	28	Normal	Normal	Normal	Normal	Normal	
								Screen	09/11/92	0	Normal	Normal	Abnormal	Normal	Abnormal	
								Day 7	18/11/92	8	Normal	Normal	Abnormal	Normal	Normal	
8	2ND	Imipramine	Female	Evaluated	11/11/92	17/11/92	7	Screen	18/01/93	0	Net done	Normal	Normal	Normal	Normal	
								Screen	02/12/92	0	Net done	Normal	Normal	Normal	Abnormal	
								Day 28	30/12/92	28	Normal	Normal	Abnormal	Normal	Abnormal	
								Day 56	28/01/93	57	Normal	Normal	Normal	Normal	Abnormal	
								Screen	18/03/93	0	Net done	Normal	Normal	Normal	Normal	
9	3ND	Reboxetine	Female	Evaluated	03/12/92	27/01/93	56	Screen	05/05/93	23	Normal	Normal	Normal	Normal	Normal	
								Day 28	02/06/93	56	Normal	Normal	Normal	Normal	Normal	
								Day 56	02/06/93	56	Normal	Normal	Normal	Normal	Normal	
								Screen	08/12/92	0	Normal	Normal	Normal	Normal	Normal	
								Day 28	11/01/93	28	Net done	Normal	Normal	Normal	Normal	
10	4ND	Imipramine	Female	Evaluated	15/12/92	18/01/93	35	Screen	28/06/93	0	Net done	Normal	Normal	Normal	Abnormal	
								Day 28	02/06/93	29	Net done	Normal	Normal	Normal	Normal	
								Day 56	30/06/93	57	Normal	Normal	Normal	Normal	Abnormal	
								Screen	02/04/93	0	Normal	Normal	Normal	Normal	Abnormal	
								Day 28	30/04/93	28	Normal	Normal	Normal	Normal	Abnormal	

(*): days of treatment

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

5

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 19.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period			Urinalysis test								
					Start date	End date	Days	Assessment	Date	Specific gravity	Albumin	Sugar	RBC	WBC		
6	5HD	Imipramine	Female	Evaluated	03/04/93	28/05/93	56	Day 56	28/05/93	56	Normal	Normal	Normal	Normal	Normal	Normal
	5DT	Reboxetine	Female	Evaluated	20/11/93	14/01/94	56	Screen	17/11/93	0	Normal	Normal	Normal	Normal	Normal	Normal
								Day 28	17/12/93	28	Normal	Normal	Normal	Normal	Normal	Normal
	6HD	Reboxetine	Female	Evaluated	29/04/93	01/06/93	34	Screen	28/04/93	0	Normal	Normal	Normal	Normal	Normal	Normal
								Day 28	26/05/93	28	Normal	Normal	Normal	Normal	Normal	Normal
	7HD	Reboxetine	Female	Evaluated	20/10/93	14/12/93	56	Screen	18/10/93	0	Not done	Normal	Normal	Abnormal	Abnormal	Abnormal
								Day 28	17/11/93	29	Normal	Normal	Normal	Normal	Normal	Normal
	8HD	Imipramine	Female	Evaluated	23/11/93	17/01/94	56	Screen	14/12/93	56	Normal	Normal	Normal	Normal	Normal	Normal
								Day 56	17/01/94	30	Not done	Normal	Normal	Normal	Normal	Normal
	7	1HD	Imipramine	Male	Evaluated	09/01/93	19/03/93	64	Screen	06/01/93	0	Normal	Normal	Normal	Normal	Normal
									Day 28	05/02/93	28	Not done	Not done	Not done	Not done	Not done
		3MD	Imipramine	Female	Evaluated	23/04/93	17/06/93	56	Screen	05/03/93	56	Normal	Normal	Normal	Normal	Normal
Day 56									19/04/93	0	Not done	Normal	Normal	Normal	Normal	Normal
4MD		Reboxetine	Female	Evaluated	24/04/93	29/05/93	36	Screen	16/04/93	0	Normal	Normal	Normal	Normal	Normal	
								Day 28	24/05/93	31	Normal	Normal	Normal	Normal	Normal	Normal
342HD	Reboxetine	Female	Evaluated	23/02/93	19/04/93	56	Screen	22/02/93	0	Normal	Normal	Normal	Normal	Normal		
							Day 28	19/03/93	30	Normal	Normal	Normal	Normal	Normal	Normal	
8	1HD	Reboxetine	Female	Evaluated	30/09/92	24/11/92	56	Screen	19/04/93	56	Not done	Not done	Not done	Not done	Not done	
								Day 28	26/10/92	27	Normal	Normal	Normal	Normal	Normal	Normal
1DT	Imipramine	Female	Evaluated	28/09/92	22/11/92	56	Screen	24/11/92	56	Normal	Normal	Normal	Normal	Normal		
							Day 28	23/10/92	26	Normal	Normal	Normal	Normal	Normal	Normal	

(*) days of treatment

9550089

6

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 19.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period			Urinalysis test								
					Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC	
8	10T	Imipramine	Female	Evaluated	28/09/92	22/11/92	56	Day 56	21/11/92	55	Normal	Normal	Normal	Normal	Normal	Normal
	20D	Reboxetine	Female	Evaluated	30/09/92	24/11/92	56	Screen Day 28 Day 56	25/09/92 26/10/92 24/11/92	0 27 56	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Abnormal Normal	Normal Normal Normal	
	20T	Imipramine	Female	Evaluated	30/09/92	24/11/92	56	Screen Day 28 Day 56	22/09/92 26/10/92 24/11/92	0 27 56	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Abnormal Normal Normal	
	30D	Imipramine	Female	Only screening	02/10/92	10/10/92	9	Screen	07/09/92	0	Normal	Normal	Normal	Normal	Abnormal	Abnormal
	30T	Reboxetine	Female	Evaluated	02/10/92	26/11/92	56	Screen Day 28 Day 56	29/09/92 02/11/92 27/11/92	0 32 57	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Abnormal Normal Normal	
	40D	Imipramine	Male	Only screening	02/10/92	27/10/92	26	Screen	28/07/92	0	Normal	Normal	Normal	Normal	Normal	Normal
	40T	Reboxetine	Female	Evaluated	02/10/92	26/11/92	56	Screen Day 28 Day 56	21/09/92 27/10/92 27/11/92	0 26 57	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Abnormal Normal Normal	
	701MD	Imipramine	Male	Evaluated	09/10/92	03/12/92	56	Screen Day 28 Day 56	05/10/92 05/11/92 04/12/92	0 28 57	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
	701DT	Reboxetine	Female	Evaluated	09/10/92	03/12/92	56	Screen Day 28 Day 56	01/10/92 05/11/92 04/12/92	0 28 57	Normal Normal Normal	Normal Normal Normal	Normal Normal Abnormal	Normal Normal Normal	Normal Normal Abnormal	
	702MD	Reboxetine	Male	Evaluated	16/10/92	10/12/92	56	Screen Day 28 Day 56	16/10/92 13/11/92 03/12/92	0 29 49	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Abnormal Normal Normal	Abnormal Normal Normal	
	702DT	Imipramine	Female	Evaluated	09/10/92	03/12/92	56	Screen Day 28 Day 56	07/09/92 05/11/92 03/12/92	0 28 56	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Abnormal Abnormal Abnormal	

(*) days of treatment

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 19.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	Urinalysis test			
										Specific gravity	Albumin	Sugar	RBC
8	703MD	Imipramine	Female	Evaluated	09/02/93	05/04/93	56	Screen	19/11/92	Normal	Normal	Normal	Normal
								Day 28	08/03/93	Normal	Normal	Normal	Normal
								Day 56	05/04/93	Normal	Normal	Normal	Normal
	703DT	Imipramine	Male	Evaluated	09/02/93	05/04/93	56	Screen	03/12/92	Normal	Normal	Normal	Normal
								Day 28	09/03/93	Normal	Normal	Normal	Normal
								Day 56	05/04/93	Normal	Normal	Normal	Normal
	704MD	Reboxetine	Female	Evaluated	09/02/93	05/04/93	56	Screen	06/01/93	Normal	Normal	Normal	Normal
								Day 28	09/03/93	Normal	Normal	Normal	Normal
								Day 56	05/04/93	Normal	Normal	Normal	Normal
	704DT	Reboxetine	Female	Evaluated	09/02/93	05/04/93	56	Screen	15/10/92	Normal	Normal	Normal	Normal
								Day 28	09/03/93	Normal	Normal	Normal	Normal
								Day 56	05/04/93	Normal	Normal	Normal	Normal
9	1ND	Imipramine	Female	Evaluated	28/09/93	23/11/93	57	Screen	21/09/93	Normal	Normal	Normal	Normal
								Day 28	26/10/93	Normal	Normal	Normal	Normal
								Day 56	23/11/93	Normal	Normal	Normal	Normal
1DT	Imipramine	Female	Evaluated	15/12/93	08/02/94	56	Screen	08/12/93	Normal	Normal	Normal	Normal	
							Day 28	12/01/94	Normal	Normal	Normal	Normal	
							Day 56	09/02/94	Normal	Normal	Normal	Normal	
2MD	Reboxetine	Female	Evaluated	01/10/93	25/11/93	56	Screen	24/09/93	Normal	Normal	Normal	Normal	
							Day 28	29/10/93	Normal	Normal	Normal	Normal	
							Day 56	26/11/93	Normal	Normal	Normal	Normal	
2DT	Imipramine	Female	Evaluated	22/12/93	15/02/94	56	Screen	15/12/93	Normal	Normal	Normal	Normal	
							Day 28	19/01/94	Normal	Normal	Normal	Normal	
							Day 56	16/02/94	Normal	Normal	Normal	Normal	
3DT	Reboxetine	Female	Evaluated	13/10/93	07/12/93	56	Screen	05/10/93	Normal	Normal	Normal	Normal	
							Day 28	10/11/93	Normal	Normal	Normal	Normal	
							Day 56	08/12/93	Normal	Normal	Normal	Normal	
4MD	Imipramine	Female	Evaluated	13/10/93	07/12/93	56	Screen	05/10/93	Normal	Normal	Normal	Normal	
							Day 28	10/11/93	Normal	Normal	Normal	Normal	
							Day 56	08/12/93	Normal	Normal	Normal	Normal	

(*): days of treatment

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 19.0
URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	Urinalysis test					
										Specific gravity	Albumin	Sugar	RBC		
9	4ND	Imipramine	Female	Evaluated	19/10/93	07/12/93	56	Day 28 Day 56	10/11/93 08/12/93	29 Normal 57 Normal	Normal Normal	Normal Normal	Normal Normal	Normal Normal	
	5ND	Reboxetine	Female	Evaluated	26/10/93	21/12/93	57	Screen Day 28 Day 56	19/10/93 23/11/93 21/12/93	0 Normal 29 Normal 57 Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
	6ND	Imipramine	Female	Only screening	03/11/93	05/11/93	3	Screen	27/10/93	0 Normal	Normal	Normal	Normal	Normal	Normal
	7ND	Imipramine	Female	Only screening	10/11/93	11/11/93	2	Screen	03/11/93	0 Normal	Normal	Normal	Normal	Normal	Normal
	8DT	Reboxetine	Female	Evaluated	16/11/93	10/01/94	56	Screen Day 28 Day 56	09/11/93 14/12/93 11/01/94	0 Normal 29 Normal 57 Normal	Normal Normal Normal	Normal Normal Normal	Abnormal Normal Normal	Abnormal Normal Normal	
	1ND	Imipramine	Female	Evaluated	02/10/93	26/11/93	56	Screen Day 28 Day 56	24/09/93 29/10/93 26/11/93	0 Normal 28 Normal 56 Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal
	1DT	Reboxetine	Female	Evaluated	01/12/93	25/01/94	56	Screen Day 28 Day 56	23/11/93 28/12/93 25/01/94	0 Normal 28 Normal 56 Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal
	2ND	Reboxetine	Male	Evaluated	02/10/93	26/11/93	56	Screen Day 28 Day 56	24/09/93 29/10/93 26/11/93	0 Normal 28 Normal 56 Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal
	2DT	Imipramine	Male	Evaluated	01/12/93	25/01/94	56	Screen Day 28 Day 56	23/11/93 28/12/93 25/01/94	0 Normal 28 Normal 56 Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal
	3ND	Reboxetine	Male	Evaluated	02/10/93	26/11/93	56	Screen Day 28 Day 56	24/09/93 29/10/93 26/11/93	0 Normal 28 Normal 56 Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal
3DT	Imipramine	Male	Evaluated	02/12/93	26/01/94	56	Screen Day 28 Day 56	24/11/93 29/12/93 26/01/94	0 Normal 28 Normal 56 Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	

(*) days of treatment

9550089

9

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 19.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	Urinalysis test				
										Specific gravity	Albumin	Sugar	RBC	
10	4ND	Imipramine	Female	Evaluated	06/10/93	30/11/93	56	Screen	28/09/93	0	Normal	Normal	Normal	Normal
									Day 28	29	Normal	Normal	Normal	Normal
									Day 56	56	Normal	Normal	Normal	Normal
4DT	Reboxetine	Female	Evaluated	02/12/93	26/01/94	56	Screen	24/11/93	0	Normal	Normal	Normal	Normal	
								Day 28	28	Normal	Normal	Normal	Normal	
								Day 56	56	Normal	Normal	Normal	Normal	
5ND	Imipramine	Female	Evaluated	06/10/93	30/11/93	56	Screen	29/09/93	0	Normal	Normal	Normal	Normal	
								Day 28	29	Normal	Normal	Normal	Normal	
								Day 56	56	Normal	Normal	Normal	Normal	
5DT	Reboxetine	Female	Evaluated	04/12/93	28/01/94	56	Screen	26/11/93	0	Normal	Normal	Normal	Normal	
								Day 28	27	Normal	Normal	Normal	Normal	
								Day 56	56	Normal	Normal	Normal	Normal	
6ND	Reboxetine	Male	Evaluated	09/10/93	03/12/93	56	Screen	01/10/93	0	Normal	Normal	Normal	Normal	
								Day 28	28	Normal	Normal	Normal	Normal	
								Day 56	56	Normal	Normal	Normal	Normal	
6DT	Reboxetine	Male	Evaluated	04/12/93	28/01/94	56	Screen	26/11/93	0	Normal	Normal	Normal	Normal	
								Day 28	27	Normal	Normal	Normal	Normal	
								Day 56	56	Normal	Normal	Normal	Normal	
7ND	Imipramine	Male	Evaluated	09/10/93	03/12/93	56	Screen	01/10/93	0	Normal	Normal	Normal	Normal	
								Day 28	28	Normal	Normal	Normal	Normal	
								Day 56	56	Normal	Normal	Normal	Normal	
7DT	Imipramine	Female	Evaluated	04/12/93	28/01/94	56	Screen	26/11/93	0	Normal	Normal	Normal	Normal	
								Day 28	27	Normal	Normal	Normal	Normal	
								Day 56	56	Normal	Normal	Normal	Normal	
8ND	Reboxetine	Male	Evaluated	16/10/93	10/12/93	56	Screen	08/10/93	0	Normal	Normal	Normal	Normal	
								Day 28	28	Normal	Normal	Normal	Normal	
								Day 56	56	Normal	Normal	Normal	Normal	
8DT	Imipramine	Female	Evaluated	04/12/93	28/01/94	56	Screen	26/11/93	0	Normal	Normal	Normal	Normal	
								Day 28	28	Normal	Normal	Normal	Normal	
								Day 56	56	Normal	Normal	Normal	Normal	

2400

(*): days of treatment

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

10

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 19.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period			Urinalysis test								
					Start date	End date	Days	Assessment	Date	(*)	Specific Gravity	Albumin	Sugar	RBC	WBC	
10	8DT	Imipramine	Female	Evaluated	04/12/93	28/01/94	56	Day 28 Day 56	30/12/93 28/01/94	27 56	Normal Normal	Normal Normal	Normal Normal	Normal Normal	Normal Normal	Normal Normal
	9ND	Reboxetine	Female	Evaluated	20/11/93	14/01/94	56	Screen Day 28 Day 56	12/11/93 17/12/93 14/01/94	0 28 56	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal
	9DT	Imipramine	Male	Evaluated	08/12/93	01/02/94	56	Screen Day 28 Day 56	30/11/93 04/01/94 01/02/94	0 28 56	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal
	10ND	Imipramine	Female	Evaluated	23/10/93	17/12/93	56	Screen Day 28 Day 56	15/10/93 19/11/93 17/12/93	0 28 56	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal
	10DT	Reboxetine	Female	Evaluated	08/12/93	01/02/94	56	Screen Day 28 Day 56	30/11/93 04/01/94 01/02/94	0 28 56	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal
	11ND	Imipramine	Female	Evaluated	23/10/93	17/12/93	56	Screen Day 28 Day 56	15/10/93 19/11/93 17/12/93	0 28 56	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal
	11DT	Imipramine	Female	Evaluated	08/12/93	01/02/94	56	Screen Day 28 Day 56	30/11/93 04/01/94 01/02/94	0 28 56	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal
	12ND	Reboxetine	Male	Evaluated	27/10/93	21/12/93	56	Screen Day 28 Day 56	19/10/93 23/11/93 21/12/93	0 28 56	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal
	12DT	Reboxetine	Female	Evaluated	08/12/93	01/02/94	56	Screen Day 28 Day 56	30/11/93 04/01/94 01/02/94	0 28 56	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal
	13DT	Reboxetine	Female	Evaluated	27/10/93	21/12/93	56	Screen Day 28 Day 56	19/10/93 23/11/93 21/12/93	0 28 56	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal

(*) days of treatment

9550089

2401

9550089

12

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 19.0
URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period			Urinalysis test								
					Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC	
13	1M	Reboxetine	Female	Evaluated	08/04/93	02/06/93	56	Day 28 Day 56	06/05/93 08/06/93	29 Normal 57 Normal	Normal Normal	Normal Normal	Normal Normal	Normal Normal	Normal Normal	
	1F	Imipramine	Female	Evaluated	23/09/93	17/11/93	56	Screen Day 28 Day 56	13/09/93 21/10/93 18/11/93	0 Normal 29 Normal 57 Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
	2M	Imipramine	Female	Evaluated	11/12/93	04/02/94	56	Screen Day 28 Day 56	02/12/93 07/01/94 08/02/94	0 Normal 28 Normal 60 Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Abnormal	Normal Normal Abnormal	
	2F	Reboxetine	Female	Evaluated	22/10/93	17/12/93	57	Screen Day 28 Day 56	27/09/93 22/11/93 17/12/93	0 Normal 32 Normal 57 Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
	3M	Imipramine	Male	Evaluated	03/02/94	31/03/94	57	Screen Day 28 Day 56	28/01/94 03/03/94 06/04/94	0 Normal 29 Normal 63 Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
	3F	Imipramine	Female	Evaluated	09/11/93	04/01/94	57	Screen Day 28 Day 56	25/10/93 07/12/93 04/01/94	0 Normal 29 Normal 57 Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
	4F	Reboxetine	Female	Evaluated	03/02/94	31/03/94	57	Screen Day 28 Day 56	27/01/94 03/03/94 05/04/94	0 Normal 29 Normal 62 Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
	14	1M	Reboxetine	Female	Evaluated	06/04/94	02/05/94	27	Screen Day 28	01/04/94 04/05/94	0 Normal 29 Normal	Normal Normal	Normal Normal	Normal Normal	Normal Normal	Normal Normal
	15	1M	Reboxetine	Female	Evaluated	01/03/93	25/04/93	56	Screen Day 28 Day 56	26/02/93 29/03/93 30/04/93	0 Normal 29 Normal 61 Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal
	16	1F	Reboxetine	Female	Evaluated	26/07/93	19/09/93	56	Screen Day 28 Day 56	19/07/93 23/08/93 20/09/93	0 Normal 29 Normal 57 Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal

2403

(*) days of treatment

9550089

13

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 19.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date (*)	Urinalysis test					
										Specific Gravity	Albumin	Sugar	RBC	WBC	
15	2ND	Imipramine	Female	Only screening	24/03/93	02/04/93	10	Screen	02/03/93	0	Normal	Normal	Normal	Normal	Normal
	2DT	Imipramine	Female	Evaluated	22/02/94	18/04/94	56	Screen Day 23 Day 56	09/02/94 22/03/94 19/04/94	0 29 57	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
	3ND	Reboxetine	Female	Evaluated	06/05/93	30/06/93	56	Screen Day 28 Day 56	05/05/93 03/06/93 02/07/93	0 29 58	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
	4ND	Imipramine	Female	Evaluated	15/07/93	08/09/93	56	Screen Day 28 Day 56	12/07/93 12/08/93 09/09/93	0 29 57	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
	11ND	Reboxetine	Female	Only screening	08/10/93	28/10/93	21	Screen	06/10/93	0	Normal	Normal	Normal	Normal	Normal
	112ND	Imipramine	Female	Evaluated	29/11/93	23/01/94	56	Screen Day 28 Day 56	24/11/93 04/01/94 24/01/94	0 37 57	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
16	1ND	Reboxetine	Female	Evaluated	18/02/93	14/04/93	56	Screen Day 28 Day 56	29/01/93 17/03/93 14/04/93	0 28 56	Normal Not done Not done	Normal Normal Normal	Normal Not done Normal	Abnormal Not done Normal	
	1DT	Imipramine	Female	Without Urinal	18/02/93	26/02/93	9	Screen Day 14	12/02/93 26/02/93	0 9	Not done Not done	Normal Not done	Normal Not done	Not done Not done	
	2ND	Imipramine	Male	Evaluated	15/04/93	09/06/93	56	Screen Day 28 Day 56	08/04/93 12/05/93 09/06/93	0 28 56	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Missing	
	2DI	Reboxetine	Male	Evaluated	04/05/93	28/06/93	56	Screen Day 28 Day 56	29/04/93 01/06/93 28/06/93	0 29 56	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
	3ND	Imipramine	Female	Evaluated	09/05/93	09/06/93	32	Screen Day 28	05/05/93 04/06/93	0 27	Normal Normal	Not done Normal	Normal Normal	Abnormal Normal	

(*) days of treatment

2404

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

14

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 19.0
URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	Urinalysis test			
										Specific gravity	Albumin	Sugar	WBC
16	3DT	Imipramine	Female	Without Urinal	29/07/93	10/08/93	13	Screen	22/07/93	0 Normal	Normal	Normal	Not done
								Day 14	11/08/93	14 Not done	Normal	Normal	Not done
	4ND	Reboxetine	Female	Evaluated	19/04/94	13/06/94	56	Screen	18/04/94	0 Normal	Abnormal	Normal	Normal
								Day 28	16/05/94	28 Normal	Normal	Normal	Normal
17	1ND	Reboxetine	Female	Evaluated	31/03/93	25/05/93	56	Screen	23/03/93	0 Normal	Normal	Normal	Normal
								Day 28	28/04/93	29 Normal	Normal	Normal	Normal
	1DT	Reboxetine	Female	Evaluated	28/04/93	17/05/93	20	Screen	18/04/93	0 Normal	Normal	Normal	Normal
								Day 21	21/05/93	24 Normal	Normal	Normal	Normal
2ND	2DT	Imipramine	Female	Evaluated	21/04/93	15/06/93	56	Screen	13/04/93	0 Normal	Normal	Normal	Normal
								Day 28	18/05/93	28 Normal	Normal	Normal	Normal
	2DT	Reboxetine	Female	Evaluated	07/07/93	31/08/93	56	Screen	07/06/93	0 Normal	Abnormal	Normal	Normal
								Day 28	04/08/93	29 Normal	Normal	Normal	Normal
3ND	3DT	Imipramine	Female	Only screening	06/11/93	19/11/93	14	Screen	04/11/93	0 Normal	Normal	Normal	Normal
								Day 56	16/06/93	57 Normal	Normal	Normal	Normal
	3DT	Imipramine	Male	Evaluated	19/10/93	13/12/93	56	Screen	12/10/93	0 Normal	Normal	Normal	Normal
								Day 28	16/11/93	29 Normal	Normal	Normal	Normal
4ND	4DT	Reboxetine	Female	Evaluated	12/01/94	09/03/94	57	Screen	06/01/94	0 Normal	Normal	Normal	Normal
								Day 28	08/02/94	28 Normal	Normal	Normal	Normal
	4DT	Imipramine	Female	Evaluated	19/01/94	15/03/94	56	Screen	24/12/93	0 Normal	Normal	Normal	Normal
								Day 28	16/02/94	29 Normal	Normal	Normal	Normal
4DT	Imipramine	Female	Evaluated	19/01/94	15/03/94	56	Screen	15/03/94	56 Normal	Normal	Normal	Normal	
							Day 56	15/03/94	56 Normal	Normal	Normal	Normal	

9550089

2405

(*) days of treatment

9550089

15

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124-035
Listing No.: 19.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	Urinalysis test									
										Specific gravity	Albumin	Sugar	RBC	RBC	Sugar	Albumin	Specific gravity	Albumin	Sugar
17	211ND	Reboxetine	Female	Evaluated	19/05/94	13/07/94	56	Screen	10/05/94	0	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	
								Day 28	14/06/94	27	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	
								Day 56	19/07/94	62	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	
								Screen	14/02/94	0	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	
								Day 28	06/05/94	32	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	
								Day 56	09/06/94	66	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	
18	1ND	Imipramine	Female	Without screen	27/05/93	21/07/93	56	Screen	19/05/93	0	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Not done	
								Day 28	25/06/93	28	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	
								Day 56	21/07/93	56	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	
								Screen	04/08/93	0	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Abnormal
								Day 28	08/09/93	28	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Abnormal
								Day 56	06/10/93	56	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal
20	2ND	Imipramine	Female	Evaluated	30/05/93	26/06/93	28	Screen	26/05/93	0	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	
								Day 28	26/06/93	28	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	
								Screen	04/11/93	0	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal
								Day 28	07/12/93	29	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal
								Screen	13/08/93	0	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Abnormal
								Day 28	10/09/93	28	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Abnormal
23	1ND	Reboxetine	Female	Evaluated	03/10/93	27/11/93	56	Screen	30/09/93	0	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	
								Day 28	30/10/93	28	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	
								Day 56	27/11/93	56	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	
								Screen	05/07/93	0	Not done	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Not done
								Day 28	24/06/93	0	Not done	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal
								Day 56	26/03/93	56	Not done	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal

(*): days of treatment

2406

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

16

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 19.0
URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period			Urinalysis test							
					Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC
23	2ND	Reboxetine	Female	Evaluated	56	02/02/93	29/03/93	Screen	27/01/93	0	Not done	Normal	Normal	Normal	Normal
									01/03/93	28	Normal	Normal	Normal	Normal	Normal
									29/03/93	56	Not done	Normal	Normal	Normal	Normal
3ND	3ND	Imipramine	Female	Evaluated	56	23/03/93	17/05/93	18/03/93	0	Not done	Normal	Normal	Normal	Normal	
								19/04/93	28	Not done	Normal	Normal	Normal	Normal	
								17/05/93	56	Not done	Normal	Normal	Normal	Normal	
4ND	4ND	Imipramine	Female	Evaluated	56	31/03/93	25/05/93	19/03/93	0	Not done	Normal	Normal	Normal	Normal	
								27/04/93	28	Not done	Normal	Abnormal	Abnormal	Abnormal	
								25/05/93	56	Not done	Normal	Normal	Normal	Normal	
5ND	5ND	Imipramine	Female	Only screening	9	05/05/93	13/05/93	24/04/93	0	Not done	Normal	Normal	Normal	Normal	
								29/06/93	0	Not done	Normal	Normal	Normal	Normal	
								02/08/93	43	Not done	Normal	Normal	Abnormal	Abnormal	
6ND	6ND	Imipramine	Female	Evaluated	43	06/07/93	17/08/93	18/08/93	44	Not done	Normal	Normal	Normal	Normal	
								27/08/93	1	Normal	Normal	Normal	Normal	Normal	
								24/09/93	29	Not done	Normal	Normal	Normal	Normal	
25	1ND	Reboxetine	Male	Evaluated	36	27/08/93	01/10/93	25/11/93	0	Not done	Normal	Normal	Normal	Normal	
								23/12/93	28	Not done	Normal	Normal	Normal	Normal	
								21/01/94	57	Not done	Normal	Normal	Normal	Normal	
26	1ND	Imipramine	Female	Evaluated	56	27/04/93	21/06/93	27/04/93	1	Not done	Normal	Normal	Normal	Abnormal	
								21/05/93	25	Not done	Normal	Normal	Normal	Normal	
								21/06/93	56	Not done	Normal	Normal	Normal	Normal	
27	1DT	Reboxetine	Female	Evaluated	44	29/06/93	11/08/93	25/06/93	0	Not done	Normal	Normal	Normal	Abnormal	
								26/07/93	28	Not done	Normal	Normal	Normal	Normal	
								01/02/93	0	Normal	Normal	Normal	Normal	Normal	
28	1ND	Reboxetine	Female	Evaluated	56	20/04/93	14/06/93	19/04/93	0	Normal	Normal	Normal	Normal	Normal	
								18/05/93	29	Normal	Normal	Normal	Normal	Normal	
															(*) days of treatment

9550089

2407

9550089

17

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 19.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period			Urinalysis test								
					Start date	End date	Days	Assessment	Date	(*)	Specific Gravity	Albumin	Sugar	RBC	MBC	
28	1ND	Reboxetine	Female	Evaluated	20/04/93	14/06/93	56	Day 56	15/06/93	57	Normal	Normal	Normal	Normal	Normal	Normal
	10T	Imipramine	Female	Evaluated	22/04/93	16/06/93	56	Screen	13/04/93	0	Normal	Normal	Normal	Normal	Normal	Normal
								Day 28	19/05/93	28	Normal	Normal	Normal	Normal	Normal	Normal
	2ND	Imipramine	Female	Evaluated	26/04/93	21/06/93	57	Screen	20/04/93	0	Normal	Normal	Normal	Normal	Normal	Normal
								Day 28	25/05/93	30	Normal	Normal	Normal	Normal	Normal	Normal
	2DT	Reboxetine	Male	Evaluated	27/04/93	21/06/93	56	Screen	20/04/93	0	Normal	Normal	Normal	Normal	Normal	Normal
								Day 28	25/05/93	29	Normal	Normal	Normal	Normal	Normal	Normal
	3ND	Reboxetine	Female	Evaluated	27/04/93	21/06/93	56	Screen	20/04/93	0	Normal	Normal	Normal	Normal	Normal	Normal
								Day 28	25/05/93	29	Normal	Normal	Normal	Normal	Normal	Normal
	3DT	Imipramine	Male	Only screening	11/05/93	05/07/93	56	Screen	03/05/93	0	Normal	Normal	Normal	Normal	Normal	Normal
Day 56								06/07/93	57	Not done	Not done	Not done	Not done	Not done	Not done	
30	4ND	Imipramine	Male	Evaluated	04/05/93	28/06/93	56	Screen	26/04/93	0	Normal	Normal	Normal	Normal	Normal	
								Day 28	01/06/93	29	Not done	Not done	Not done	Not done	Not done	Not done
	5ND	Reboxetine	Female	Evaluated	25/05/93	19/07/93	56	Screen	10/05/93	0	Normal	Normal	Normal	Normal	Normal	
								Day 28	22/06/93	29	Normal	Normal	Normal	Normal	Normal	Normal
	1ND	Imipramine	Female	Only screening	21/04/93	17/06/93	58	Screen	13/04/93	0	Normal	Normal	Normal	Normal	Normal	
								Day 35	26/05/93	36	Not done	Not done	Not done	Not done	Not done	Not done
	2ND	Reboxetine	Female	Without Urinal	16/07/93	18/07/93	3	Screen	12/07/93	0	Not done	Not done	Not done	Not done	Not done	
								Day 56	22/06/93	63	Not done	Not done	Not done	Not done	Not done	Not done
	3ND	Imipramine	Female	Evaluated	08/11/93	03/01/94	57	Screen	25/10/93	0	Normal	Normal	Normal	Normal	Normal	
								Day 21	29/11/93	22	Normal	Normal	Normal	Normal	Normal	Normal
							Day 56	05/01/94	59	Normal	Normal	Normal	Normal	Normal		

(*) days of treatment

9550089

18

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 19.0
 URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period			Urinalysis test								
					Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	MBC	
30	4ND	Reboxetine	Female	Evaluated	59	02/11/93	30/12/93	Screen	29/10/93	0	Normal	Normal	Normal	Normal	Normal	Normal
									Day 28	31	Normal	Normal	Normal	Normal	Normal	Normal
									Day 56	59	Normal	Normal	Normal	Normal	Normal	Normal
31	5ND	Imipramine	Female	Only screening	6	18/12/93	23/12/93	Screen	10/12/93	0	Normal	Normal	Normal	Normal	Normal	
								13	Screen	18/09/92	0	Normal	Normal	Normal	Normal	Normal
								Day 14	17	Normal	Normal	Normal	Normal	Normal	Normal	
31	1DT	Reboxetine	Female	Evaluated	36	23/09/92	28/10/92	Screen	15/09/92	0	Normal	Normal	Normal	Normal	Normal	
								Day 28	31	Normal	Normal	Normal	Normal	Normal	Normal	
								Day 35	43	Normal	Normal	Normal	Normal	Normal	Normal	
32	1ND	Imipramine	Female	Evaluated	59	02/12/92	29/01/93	Screen	24/11/92	0	Normal	Normal	Normal	Normal	Normal	
								Day 35	38	Normal	Normal	Normal	Normal	Normal	Normal	
								Day 56	69	Normal	Normal	Normal	Normal	Normal	Normal	
32	3ND	Imipramine	Male	Only screening	3	14/12/92	16/12/92	Screen	01/12/92	0	Normal	Normal	Normal	Normal	Normal	
								56	Screen	19/03/93	0	Normal	Normal	Normal	Normal	Normal
								Day 56	56	Normal	Normal	Normal	Normal	Normal	Normal	
32	2ND	Imipramine	Female	Evaluated	56	15/04/93	09/06/93	Screen	07/04/93	0	Normal	Normal	Normal	Normal	Normal	
								Day 28	28	Normal	Normal	Normal	Normal	Normal	Normal	
								Day 56	56	Normal	Normal	Normal	Normal	Normal	Normal	
33	3ND	Reboxetine	Female	Evaluated	56	22/04/93	16/06/93	Screen	15/04/93	0	Normal	Normal	Normal	Normal	Normal	
								Day 28	28	Normal	Normal	Normal	Normal	Normal	Normal	
								Day 56	56	Normal	Normal	Normal	Normal	Normal	Normal	
34	4ND	Reboxetine	Female	Only screening	20	07/10/93	26/10/93	Screen	08/09/93	0	Normal	Normal	Normal	Normal	Normal	
								22	Screen	27/10/93	0	Normal	Normal	Normal	Normal	Normal
								Day 28	29	Normal	Normal	Normal	Normal	Normal	Normal	

(*) days of treatment

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 19.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period			Urinalysis test							
					Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	MBC
32	6HD	Imipramine	Male	Evaluated	17/11/93	12/01/94	57	Screen Day 28 Day 56	06/10/93 16/12/93 12/01/94	0 Normal 30 Not done 57 Normal	Normal Not done Normal	Normal Not done Normal	Normal Not done Normal	Normal Not done Normal	Normal Not done Normal
35	1HD	Reboxetine	Female	Only screening	26/01/93	14/02/93	20	Screen	25/01/93	0 Normal	Normal	Normal	Normal	Normal	Normal
	1DT	Reboxetine	Female	Evaluated	03/03/93	27/04/93	56	Screen Day 28 Day 56	17/02/93 01/04/93 27/04/93	0 Normal 30 Normal 56 Normal	Normal Normal Not done	Normal Normal Normal	Normal Normal Normal	Normal Normal Abnormal	Normal Normal Abnormal
	2HD	Imipramine	Female	Evaluated	03/03/93	31/03/93	29	Screen Day 28	05/02/93 30/03/93	0 Normal 28 Normal	Normal Normal	Normal Normal	Normal Normal	Normal Normal	Normal Normal
	2DT	Imipramine	Female	Only screening	03/03/93	27/04/93	56	Screen Day 28 Day 56	02/03/93 30/03/93 27/04/93	0 Normal 28 Not done 56 Not done	Normal Not done Not done	Normal Not done Not done	Normal Not done Not done	Normal Not done Not done	Normal Not done Not done
	3HD	Imipramine	Female	Only screening	30/03/93	05/04/93	7	Screen	27/03/93	0 Normal	Normal	Abnormal	Normal	Abnormal	Abnormal
	3DT	Imipramine	Male	Evaluated	31/03/93	26/05/93	57	Screen Day 28 Day 56	30/03/93 28/04/93 26/05/93	0 Normal 29 Normal 57 Normal	Normal Normal Abnormal	Abnormal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal
	4HD	Reboxetine	Male	Evaluated	20/04/93	14/06/93	56	Screen Day 28 Day 56	15/04/93 17/05/93 14/06/93	0 Not done 28 Normal 56 Normal	Normal Abnormal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Abnormal Normal
	4DT	Reboxetine	Female	Evaluated	27/04/93	21/06/93	56	Screen Day 28 Day 56	21/04/93 11/05/93 21/06/93	0 Normal 15 Normal 56 Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Abnormal	Normal Normal Abnormal
	5HD	Reboxetine	Male	Evaluated	09/07/93	02/09/93	56	Screen Day 28 Day 56	02/07/93 03/08/93 02/09/93	0 Normal 28 Not done 56 Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal
	5DT	Imipramine	Female	Evaluated	02/09/93	27/10/93	56	Screen	01/09/93	0 Normal	Abnormal	Normal	Normal	Normal	Normal

2410

(*) days of treatment

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 19.0

URINALYSIS

Treatment	Sex	Patient type	Treatment period			Assessment	Date	(*)	Urinalysis test				N
			Start date	End date	Days				Specific gravity	Albumin	Sugar	RBC	
pramipexole	Female	Evaluated	02/09/93	27/10/93	56	Day 28	29/09/93	28	Normal	Normal	Normal	Normal	N
						Day 56	27/10/93	56	Not done	Normal	Normal	Normal	N
oxetidine	Female	Evaluated	21/01/94	02/03/94	41	Screen	19/01/94	0	Normal	Normal	Normal	Normal	N
						Day 28	16/02/94	27	Normal	Normal	Normal	Normal	N
pramipexole	Female	Evaluated	20/10/93	14/12/93	56	Screen	12/10/93	0	Normal	Normal	Abnormal	Normal	P
						Day 28	14/11/93	28	Normal	Normal	Normal	Normal	P
						Day 56	14/12/93	56	Normal	Normal	Normal	Normal	P
pramipexole	Female	Evaluated	10/12/93	17/01/94	39	Screen	08/12/93	0	Normal	Abnormal	Normal	Normal	P
						Day 28	06/01/94	28	Not done	Abnormal	Normal	Normal	P
oxetidine	Female	Evaluated	20/10/93	16/11/93	28	Screen	15/10/93	0	Not done	Normal	Abnormal	Normal	P
						Day 28	16/11/93	28	Normal	Normal	Abnormal	Normal	P
pramipexole	Female	Evaluated	01/02/94	21/03/94	49	Screen	31/01/94	0	Normal	Normal	Normal	Normal	P
						Day 28	28/02/94	28	Normal	Normal	Normal	Normal	P
oxetidine	Female	Evaluated	11/01/94	07/03/94	56	Screen	10/01/94	0	Normal	Normal	Normal	Normal	P
						Day 28	07/02/94	28	Normal	Normal	Normal	Normal	P
pramipexole	Male	Evaluated	16/01/93	08/03/93	52	Screen	15/01/93	0	Normal	Normal	Normal	Normal	P
						Day 28	12/02/93	28	Normal	Abnormal	Normal	Normal	P
						Day 56	09/03/93	53	Not done	Not done	Not done	Not done	P
pramipexole	Female	Evaluated	03/02/93	30/03/93	56	Screen	01/02/93	0	Normal	Normal	Normal	Normal	P
						Day 28	02/03/93	28	Normal	Normal	Normal	Normal	P
						Day 56	30/03/93	56	Normal	Normal	Normal	Normal	P
oxetidine	Female	Without screen	03/02/93	30/03/93	56	Screen	27/01/93	0	Not done	Not done	Not done	Not done	P
						Day 28	02/03/93	28	Normal	Normal	Normal	Normal	P
						Day 56	30/03/93	56	Normal	Normal	Normal	Normal	P
oxetidine	Female	Evaluated	25/02/93	22/04/93	57	Screen	18/02/93	0	Normal	Normal	Normal	Normal	P
						Day 28	25/03/93	29	Normal	Normal	Normal	Normal	P
						Day 56	22/04/93	57	Normal	Normal	Normal	Normal	P

(*) days of treatment

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9550089

21

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 19.0
 URINALYSIS

Centro	Patient	Treatment	Sex	Patient type	Treatment period			Urinalysis test							
					Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	MBC
36	3MD	Imipramine	Female	Evaluated	06/02/93	02/04/93	56	Screen Day 28 Day 56	05/02/93 05/03/93 02/04/93	0 28 56	Normal Normal Normal	Normal Normal Normal	Normal Abnormal Normal	Normal Abnormal Normal	Normal Abnormal Normal
	3DT	Imipramine	Female	Evaluated	02/05/93	27/04/93	57	Screen Day 28 Day 56	16/02/93 30/03/93 27/04/93	0 29 57	Normal Normal Not done	Normal Normal Not done	Normal Normal Not done	Normal Normal Not done	Normal Normal Not done
	4MD	Reboxetine	Female	Evaluated	09/03/93	01/05/93	54	Screen Day 28 Day 56	03/03/93 06/04/93 03/05/93	0 29 56	Normal Normal Normal	Normal Normal Normal	Normal Abnormal Normal	Abnormal Abnormal Normal	Abnormal Abnormal Normal
	4DT	Reboxetine	Female	Evaluated	12/03/93	06/05/93	56	Screen Day 28 Day 56	08/03/93 08/04/93 06/05/93	0 28 56	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Abnormal Normal	Normal Abnormal Normal
	5MD	Reboxetine	Female	Evaluated	24/04/93	18/06/93	56	Screen Day 28 Day 56	20/04/93 24/05/93 18/06/93	0 31 56	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal
	5DT	Imipramine	Female	Only screening	03/04/93	07/04/93	5	Screen	11/03/93	0	Normal	Normal	Normal	Normal	Normal
	6MD	Imipramine	Female	Evaluated	01/05/93	25/06/93	56	Screen Day 28 Day 56	07/04/93 07/06/93 25/06/93	0 38 56	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal
	6DT	Imipramine	Female	Evaluated	10/04/93	04/06/93	56	Screen Day 28 Day 56	02/04/93 14/05/93 04/06/93	0 35 56	Normal Normal Normal	Normal Normal Normal	Normal Normal Abnormal	Normal Normal Normal	Normal Normal Normal
	7MD	Reboxetine	Female	Evaluated	13/05/93	07/07/93	56	Screen Day 28 Day 56	16/05/93 10/06/93 07/07/93	2 29 56	Normal Abnormal Normal	Normal Abnormal Normal	Abnormal Normal Abnormal	Normal Normal Normal	Normal Abnormal Abnormal
	7DT	Reboxetine	Female	Only screening	01/05/93	07/05/93	7	Screen	15/04/93	0	Normal	Normal	Normal	Normal	Normal

(*) days of treatment

2412

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 10.0
URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	Urinalysis test					
										(*)	Specific gravity	Albumin	Sugar	RBC	MBC
36	8ND	Imipramine	Female	Evaluated	26/05/93	20/07/93	56	Screen Day 28 Day 56	12/05/93 22/06/93 20/07/93	0 Normal 28 Normal 56 Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
	8DT	Reboxetine	Female	Evaluated	15/05/93	16/07/93	63	Screen Day 35 Day 63	04/05/93 18/06/93 16/07/93	0 Normal 35 Normal 63 Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
	9ND	Reboxetine	Male	Evaluated	16/06/93	10/08/93	56	Screen Day 28 Day 56	13/06/93 13/07/93 10/08/93	0 Normal 28 Normal 56 Not done	Normal Normal Net done	Normal Normal Net done	Normal Normal Net done	Abnormal Normal Not done	
	9DT	Imipramine	Female	Evaluated	29/06/93	19/08/93	52	Screen Day 28 Day 56	26/06/93 19/07/93 23/08/93	0 Normal 21 Normal 56 Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
	10ND	Reboxetine	Male	Evaluated	22/06/93	16/08/93	56	Screen Day 28 Day 56	03/06/93 19/07/93 16/08/93	0 Normal 28 Normal 56 Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
	10DT	Reboxetine	Male	Only screening	26/10/93	20/12/93	56	Screen Day 28 Day 56	18/10/93 19/11/93 28/12/93	0 Normal 25 Not done 64 Not done	Normal Net done Net done	Normal Net done Net done	Normal Net done Net done	Normal Not done Not done	
	11ND	Imipramine	Female	Evaluated	09/07/93	02/09/93	56	Screen Day 28 Day 56	06/07/93 29/07/93 02/09/93	0 Normal 21 Normal 56 Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
	11DT	Reboxetine	Male	Without Urinal	10/11/93	19/12/93	40	Screen	28/10/93	0 Not done	Net done	Net done	Net done	Net done	Net done
	12ND	Imipramine	Female	Only screening	24/09/93	05/10/93	12	Screen	13/09/93	0 Normal	Normal	Normal	Normal	Normal	Normal
	12DT	Imipramine	Female	Without screen	22/12/93	15/02/94	56	Screen Day 28 Day 56	13/12/93 18/01/94 15/02/94	0 Not done 28 Not done 56 Normal	Net done Net done Normal	Net done Net done Normal	Net done Net done Abnormal	Net done Net done Normal	
	13ND	Reboxetine	Male	Daily screening	21/09/93	14/10/93	24	Screen	17/09/93	0 Normal	Abnormal	Normal	Normal	Normal	Abnormal

(*) days of treatment

2413

9550089

23

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CIS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 19.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period			Urinalysis test							
					Start date	End date	Days	Assessment	Date	Specific Gravity	Albumin	Sugar	RBC	MBC	
36	14ND	Imipramine	Male	Evaluated	03/11/93	28/12/93	56	Screen	03/11/93	1 Normal	Normal	Normal	Normal	Normal	Normal
								Day 28	30/11/93	28 Normal	Normal	Normal	Normal	Normal	
								Day 56	28/12/93	56 Normal	Normal	Normal	Normal	Normal	
15ND	Reboxetine	Female	Only screening	23/10/93	09/11/93	18	Screen	06/10/93	0 Normal	Abnormal	Normal	Normal	Normal		
							Screen	03/11/93	0 Normal	Normal	Normal	Normal	Normal		
16ND	Imipramine	Female	Evaluated	09/11/93	03/01/94	56	Screen	06/12/93	28 Normal	Normal	Normal	Abnormal	Normal		
							Day 28	06/12/93	28 Normal	Normal	Normal	Abnormal	Normal		
							Day 56	03/01/94	56 Normal	Normal	Normal	Normal	Normal		
17ND	Reboxetine	Female	Without Urinal	10/11/93	11/11/93	2	Screen	28/10/93	0 Not done	Not done	Not done	Not done	Not done		
							Screen	11/01/94	0 Not done	Not done	Not done	Not done	Not done		
18ND	Imipramine	Female	Without Urinal	13/01/94	09/03/94	56	Screen	10/02/94	29 Not done	Not done	Not done	Not done	Not done		
							Day 28	10/02/94	29 Not done	Not done	Not done	Not done	Not done		
							Day 56	09/03/94	56 Not done	Not done	Not done	Not done	Not done		
19ND	Reboxetine	Female	Only screening	15/01/94	22/01/94	8	Screen	14/01/94	0 Normal	Normal	Normal	Normal	Normal		
							Screen	24/01/94	0 Not done	Not done	Not done	Not done	Not done		
20ND	Imipramine	Female	Without screen	01/02/94	28/03/94	56	Screen	24/01/94	0 Not done	Not done	Not done	Not done	Not done		
							Day 28	28/02/94	28 Normal	Normal	Normal	Normal	Normal		
							Day 56	28/03/94	56 Not done	Not done	Not done	Not done	Not done		
37	Reboxetine	Female	Only screening	18/03/93	24/03/93	7	Screen	12/03/93	0 Not done	Normal	Normal	Normal	Abnormal		
							Screen	15/02/94	0 Normal	Normal	Normal	Normal	Normal		
41	Imipramine	Male	Only screening	22/02/94	24/02/94	3	Screen	18/02/94	0 Normal	Normal	Normal	Normal	Normal		
							Day 28	23/03/94	29 Normal	Normal	Normal	Normal	Normal		
							Day 56	20/04/94	57 Normal	Normal	Normal	Normal	Normal		
3ND	Imipramine	Male	Evaluated	25/02/94	21/04/94	56	Screen	14/02/94	0 Normal	Normal	Normal	Normal	Normal		
							Day 28	25/03/94	29 Normal	Normal	Normal	Normal	Normal		
							Day 56	22/04/94	57 Normal	Normal	Normal	Normal	Normal		
4ND	Reboxetine	Male	Evaluated	28/02/94	24/04/94	56	Screen	21/02/94	0 Normal	Normal	Normal	Normal	Normal		
							Screen	21/02/94	0 Normal	Normal	Normal	Normal	Normal		

2414

(*): days of treatment

9550089

24

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 49.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	Urinalysis test					
										Specific gravity	Albumin	Sugar	RBC	WBC	
41	4M	Reboxetine	Male	Evaluated	28/02/94	24/04/94	56	Day 28	28/03/94	29	Normal	Normal	Normal	Normal	Normal
								Day 56	25/04/94	57	Normal	Normal	Normal	Normal	Normal
	5M	Reboxetine	Male	Evaluated	03/03/94	27/04/94	56	Screen	18/02/94	0	Normal	Normal	Normal	Normal	Normal
								Day 28	31/03/94	29	Normal	Normal	Normal	Normal	Normal
								Day 56	28/04/94	57	Normal	Normal	Normal	Normal	Normal
								Screen	12/10/93	0	Normal	Normal	Normal	Normal	Normal
42	1M	Imipramine	Female	Evaluated	26/10/93	20/12/93	56	Day 28	22/11/93	28	Normal	Normal	Normal	Normal	Normal
								Day 56	20/12/93	56	Normal	Normal	Normal	Normal	Normal
								Screen	02/11/93	0	Normal	Normal	Normal	Normal	Normal
								Day 28	22/12/93	28	Normal	Normal	Normal	Normal	Normal
24	1M	Imipramine	Female	Evaluated	25/11/93	19/01/94	56	Day 28	19/01/94	56	Normal	Normal	Normal	Normal	Normal
								Day 56	19/01/94	56	Normal	Normal	Normal	Normal	Normal
								Screen	12/10/93	0	Normal	Normal	Normal	Normal	Normal
								Day 28	22/11/93	28	Normal	Normal	Normal	Normal	Normal
43	2M	Reboxetine	Female	Evaluated	26/10/93	20/12/93	56	Day 28	12/10/93	0	Normal	Normal	Normal	Normal	Normal
								Day 56	20/12/93	56	Normal	Normal	Normal	Normal	Normal
								Screen	12/10/93	0	Normal	Normal	Normal	Normal	Normal
								Day 28	22/11/93	28	Normal	Normal	Normal	Normal	Normal
44	2M	Reboxetine	Male	Only screening	09/12/93	10/12/93	2	Screen	22/11/93	0	Normal	Normal	Normal	Normal	Normal
								Screen	02/11/93	0	Normal	Normal	Normal	Normal	Normal
								Day 28	22/12/93	28	Normal	Normal	Normal	Normal	Normal
								Day 56	19/01/94	56	Normal	Normal	Normal	Normal	Normal
45	1M	Reboxetine	Female	Evaluated	19/02/93	02/04/93	43	Day 28	19/02/93	1	Normal	Normal	Normal	Normal	Normal
								Day 56	19/03/93	29	Normal	Normal	Normal	Normal	Normal
								Screen	10/05/93	0	Normal	Normal	Normal	Normal	Abnormal
								Day 21	02/06/93	23	Normal	Normal	Normal	Normal	Normal
30T	3M	Imipramine	Male	Evaluated	15/09/93	10/11/93	57	Screen	15/09/93	1	Normal	Normal	Normal	Normal	Normal
								Day 28	13/10/93	29	Normal	Normal	Normal	Normal	Abnormal
								Day 56	10/11/93	57	Normal	Normal	Normal	Normal	Normal
								Screen	23/09/93	1	Normal	Normal	Normal	Normal	Normal

(*) days of treatment

9550089

25

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 19.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period			Urinalysis test							
					Start date	End date	Days	Assessment	Date	(*) Gravity	Albumin	Sugar	RBC	WBC	
43	5ND	Imipramine	Female	Evaluated	10/12/93	12/01/94	34	Screen	10/12/93	1 Normal	Normal	Normal	Normal	Abnormal	Normal
								Day 28	10/01/94	32 Normal	Normal	Normal	Normal	Normal	
	6ND	Imipramine	Female	Evaluated	16/02/94	14/04/94	58	Screen	14/02/94	0 Normal	Normal	Normal	Normal	Abnormal	Abnormal
								Day 28	16/03/94	31 Normal	Normal	Normal	Normal	Abnormal	Abnormal
								Day 56	15/04/94	59 Normal	Normal	Normal	Normal	Normal	Abnormal
	1ND	Reboxetine	Female	Evaluated	03/09/93	28/10/93	56	Screen	02/09/93	0 Normal	Normal	Normal	Normal	Normal	Normal
								Day 28	30/09/93	28 Normal	Normal	Normal	Normal	Normal	Normal
								Day 56	28/10/93	56 Normal	Normal	Normal	Normal	Normal	Normal
	1DT	Reboxetine	Female	Evaluated	31/07/93	24/09/93	56	Screen	30/07/93	0 Not done	Normal	Normal	Normal	Normal	Abnormal
								Day 28	31/08/93	32 Normal	Normal	Normal	Normal	Normal	Normal
Day 56								06/10/93	68 Normal	Normal	Abnormal	Normal	Normal	Normal	
2ND	Reboxetine	Female	Evaluated	20/09/93	15/11/93	57	Screen	17/09/93	0 Normal	Not done	Not done	Normal	Abnormal	Abnormal	
							Day 28	18/10/93	29 Normal	Normal	Normal	Normal	Normal	Normal	
							Day 56	15/11/93	57 Normal	Normal	Normal	Normal	Normal	Normal	
3ND	Imipramine	Female	Evaluated	14/10/93	09/12/93	57	Screen	12/10/93	0 Normal	Normal	Normal	Normal	Normal	Normal	
							Day 28	11/11/93	29 Normal	Normal	Normal	Normal	Abnormal	Abnormal	
							Day 56	09/12/93	57 Normal	Normal	Normal	Normal	Normal	Abnormal	
4ND	Imipramine	Male	Evaluated	31/01/94	28/03/94	57	Screen	26/01/94	0 Normal	Abnormal	Normal	Normal	Normal	Abnormal	
							Day 28	28/02/94	29 Not done	Normal	Normal	Normal	Normal	Normal	
							Day 56	28/03/94	57 Not done	Normal	Normal	Normal	Normal	Normal	
1ND	Reboxetine	Male	Evaluated	25/11/93	20/01/94	57	Screen	11/11/93	0 Normal	Normal	Normal	Normal	Normal	Normal	
							Day 28	24/12/93	30 Normal	Normal	Normal	Normal	Normal	Normal	
							Day 56	20/01/94	57 Not done	Not done	Not done	Not done	Not done	Not done	
1DT	Imipramine	Female	Without Urinal	12/08/93	06/10/93	56	Screen	08/07/93	0 Normal	Normal	Normal	Normal	Not done	Not done	
							Day 28	08/08/93	28 Not done	Normal	Normal	Normal	Normal	Not done	
							Day 56	06/10/93	56 Normal	Normal	Normal	Normal	Normal	Not done	
2ND	Imipramine	Male	Only screening	07/12/93	26/12/93	20	Screen	24/11/93	0 Normal	Normal	Normal	Normal	Normal	Normal	
							Screen	21/09/93	0 Normal	Normal	Normal	Normal	Normal	Normal	
1ND	Imipramine	Male	Without screen	28/09/93	23/11/93	57	Screen	21/09/93	0 Normal	Normal	Normal	Normal	Normal	Not done	
							Screen	21/09/93	0 Normal	Normal	Normal	Normal	Normal	Normal	

(*) days of treatment

2416

9550089

26

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 19.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period			Urinalysis test										
					Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	MBC			
46	1HD	Imipramine	Male	Without screen	28/09/93	23/11/93	57	Day 28	26/10/93	29 Normal	Normal	Normal	Normal	Normal	Normal	Normal		
								Day 56	23/11/93	57 Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	
								Screen	13/10/93	0 Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal
48	2HD	Imipramine	Female	Without Urinal	19/10/93	08/11/93	21	Day 21	09/11/93	22 Normal	Normal	Normal	Normal	Normal	Normal	Normal		
								Screen	25/11/93	0 Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal
								Day 28	30/12/93	29 Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal
291	1DT	Reboxetine	Female	Without Urinal	08/12/93	11/12/93	4	Screen	03/12/93	0 Normal	Normal	Normal	Normal	Normal	Normal	Normal		
								Screen	24/06/93	1 Not done	Normal	Normal	Normal	Normal	Normal	Normal	Normal	
								Day 28	25/06/93	0 Not done	Normal	Normal	Normal	Normal	Normal	Normal	Normal	
48	2DT	Imipramine	Female	Evaluated	28/06/93	04/08/93	38	Day 28	26/07/93	29 Normal	Normal	Normal	Normal	Normal	Normal	Normal		
								Day 42	05/08/93	39 Not done	Not done	Not done	Not done	Not done	Not done	Not done	Not done	
								Screen	19/03/93	0 Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	
291	1DT	Imipramine	Female	Evaluated	22/03/93	25/04/93	35	Day 28	19/04/93	29 Normal	Normal	Normal	Normal	Normal	Normal	Normal		
								Screen	21/04/93	0 Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	
								Day 28	20/05/93	29 Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	
291	2HD	Reboxetine	Female	Evaluated	22/04/93	16/06/93	56	Day 56	16/06/93	56 Normal	Normal	Normal	Normal	Normal	Normal	Normal		
								Screen	15/04/93	0 Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	
								Day 28	18/05/93	29 Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	
291	2DT	Reboxetine	Female	Evaluated	22/04/93	14/06/93	56	Day 56	14/06/93	56 Normal	Normal	Normal	Normal	Normal	Normal	Normal		
								Screen	06/04/93	0 Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	
								Day 28	17/05/93	26 Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	
291	3HD	Imipramine	Male	Evaluated	19/04/93	13/06/93	56	Day 28	20/04/93	2 Normal	Normal	Normal	Normal	Normal	Normal	Normal		
								Day 56	17/05/93	29 Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	
								Screen	14/06/93	57 Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	

2417

(*) days of treatment

9550089

27

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 19.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	Urinalysis test				
										Specific gravity	Albumin	Sugar	MBC	
291	30T	Imipramine	Female	Daily screening	14/05/93	20/05/93	7	Screen	22/04/93	0	Normal	Normal	Normal	Normal
	40D	Reboxetine	Male	Evaluated	03/05/93	28/06/93	57	Screen Day 28 Day 56	28/04/93 01/06/93 28/06/93	0 30 57	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal
	40T	Imipramine	Male	Evaluated	05/05/93	29/06/93	56	Screen Day 28 Day 56	05/05/93 02/06/93 28/06/93	1 29 55	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal
	250T	Imipramine	Female	Evaluated	04/11/93	30/12/93	57	Screen Day 28 Day 56	03/11/93 07/12/93 11/01/94	0 34 69	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal
	260T	Reboxetine	Female	Evaluated	09/06/93	03/08/93	56	Screen Day 28 Day 56	08/06/93 07/07/93 04/08/93	0 29 57	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal
	270T	Reboxetine	Female	Evaluated	04/11/93	30/12/93	57	Screen Day 28 Day 56	03/11/93 02/12/93 13/01/94	0 29 71	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal
	280T	Imipramine	Female	Evaluated	18/11/93	17/01/94	61	Screen Day 28 Day 56	18/11/93 17/12/93 12/01/94	1 30 56	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal
292	50D	Imipramine	Female	Evaluated	03/03/93	27/04/93	56	Screen Day 28 Day 56	11/02/93 01/04/93 27/04/93	0 30 56	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal
	50T	Reboxetine	Male	Evaluated	06/03/93	29/04/93	55	Screen Day 28 Day 56	12/02/93 01/04/93 29/04/93	0 27 55	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal
	60D	Reboxetine	Female	Evaluated	04/03/93	28/04/93	56	Screen Day 28 Day 56	11/02/93 01/04/93 28/04/93	0 29 56	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal

2418

(*) days of treatment

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

28

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 19.0
 URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Start date	End date	Days	Assessment	Date	Urinalysis test			
										Specific gravity	Albumin	Sugar	RBC
292	6DT	Imipramine	Female	Evaluated	16/05/93	10/05/93	56	Screen	16/02/93	0 Normal	Normal	Normal	Normal
								Day 28	13/04/93	29 Normal	Normal	Normal	Normal
								Day 56	10/05/93	56 Normal	Normal	Normal	Normal
7MD	Reboxetine	Male	Evaluated	21/04/93	15/06/93	56	Screen	29/03/93	0 Normal	Normal	Normal	Normal	
							Day 28	18/05/93	28 Normal	Normal	Normal	Normal	
							Day 56	15/06/93	56 Normal	Normal	Normal	Normal	
7DT	Imipramine	Male	Evaluated	19/03/93	13/05/93	56	Screen	16/02/93	0 Normal	Normal	Normal	Normal	
							Day 28	15/04/93	28 Normal	Normal	Normal	Normal	
							Day 56	13/05/93	56 Normal	Normal	Normal	Normal	
8MD	Imipramine	Male	Evaluated	23/04/93	17/06/93	56	Screen	02/04/93	0 Normal	Normal	Normal	Normal	
							Day 28	19/05/93	27 Normal	Normal	Normal	Normal	
							Day 56	17/06/93	56 Normal	Normal	Normal	Normal	
8DT	Reboxetine	Female	Evaluated	09/04/93	03/06/93	56	Screen	16/03/93	0 Normal	Normal	Normal	Normal	
							Day 28	06/05/93	28 Normal	Normal	Normal	Normal	
							Day 56	03/06/93	56 Normal	Normal	Normal	Normal	
21MD	Imipramine	Female	Evaluated	08/05/93	02/07/93	56	Screen	30/04/93	0 Normal	Normal	Normal	Normal	
							Day 28	04/06/93	28 Normal	Normal	Normal	Normal	
							Day 56	02/07/93	56 Normal	Normal	Normal	Normal	
21DT	Reboxetine	Female	Evaluated	04/05/93	28/06/93	56	Screen	30/04/93	0 Normal	Normal	Normal	Normal	
							Day 28	01/06/93	29 Normal	Normal	Normal	Normal	
							Day 56	28/06/93	56 Normal	Normal	Normal	Normal	
22MD	Imipramine	Female	Evaluated	20/05/93	14/07/93	56	Screen	05/05/93	0 Normal	Normal	Normal	Normal	
							Day 28	16/06/93	28 Normal	Normal	Normal	Normal	
							Day 56	14/07/93	56 Normal	Normal	Normal	Normal	
22DT	Imipramine	Female	Evaluated	05/05/93	29/06/93	56	Screen	30/04/93	0 Normal	Normal	Normal	Normal	
							Day 28	01/06/93	28 Normal	Normal	Normal	Normal	
							Day 56	29/06/93	56 Normal	Normal	Normal	Normal	
23MD	Reboxetine	Female	Evaluated	27/05/93	21/07/93	56	Screen	10/05/93	0 Normal	Normal	Normal	Normal	
							Day 28	23/06/93	28 Normal	Normal	Normal	Normal	
							Day 56	21/07/93	56 Normal	Normal	Normal	Normal	

(*): days of treatment

9550089

2419

9550089

29

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RD
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 19.0
 URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period			Urinalysis test								
					Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC	
292	23DT	Reboxetine	Male	Evaluated	14/05/93	08/07/93	56	Screen	03/05/93	0	Normal	Normal	Normal	Normal	Normal	Normal
								Day 28	09/06/93	27	Normal	Normal	Normal	Normal	Normal	Normal
								Day 56	08/07/93	56	Normal	Normal	Normal	Normal	Normal	Normal
	24MD	Reboxetine	Male	Evaluated	05/06/93	30/07/93	56	Screen	28/05/93	0	Normal	Normal	Normal	Normal	Normal	Normal
								Day 28	02/07/93	28	Normal	Normal	Normal	Normal	Normal	Normal
								Day 56	30/07/93	56	Normal	Normal	Normal	Normal	Normal	Normal
24DT	Imipramine	Female	Evaluated	02/06/93	27/07/93	56	Screen	21/05/93	0	Normal	Normal	Normal	Normal	Normal	Normal	
							Day 28	29/06/93	28	Normal	Normal	Normal	Normal	Normal	Normal	
							Day 56	27/07/93	56	Normal	Normal	Normal	Normal	Normal	Normal	
293	9MD	Imipramine	Female	Evaluated	18/02/93	14/04/93	56	Screen	12/02/93	0	Normal	Normal	Normal	Normal	Normal	
								Day 28	18/03/93	29	Normal	Normal	Normal	Normal	Normal	Normal
								Day 56	15/04/93	57	Normal	Normal	Normal	Normal	Normal	Normal
9DT	Imipramine	Female	Evaluated	26/05/93	20/07/93	56	Screen	19/05/93	0	Normal	Normal	Normal	Normal	Normal		
							Day 28	23/06/93	29	Normal	Normal	Normal	Normal	Normal	Normal	
							Day 56	21/07/93	57	Normal	Normal	Normal	Normal	Normal	Normal	
10MD	Reboxetine	Female	Evaluated	23/03/93	17/05/93	56	Screen	16/03/93	0	Normal	Normal	Normal	Normal	Normal		
							Day 28	20/04/93	29	Normal	Normal	Normal	Normal	Normal	Normal	
							Day 56	18/05/93	57	Normal	Normal	Normal	Normal	Normal	Normal	
10DT	Imipramine	Female	Evaluated	20/07/93	13/09/93	56	Screen	15/07/93	0	Normal	Normal	Normal	Normal	Normal		
							Day 28	17/08/93	29	Normal	Normal	Normal	Normal	Normal	Normal	
							Day 56	14/09/93	57	Normal	Normal	Normal	Normal	Normal	Normal	
11MD	Imipramine	Male	Evaluated	12/07/93	05/09/93	56	Screen	08/07/93	0	Normal	Normal	Normal	Normal	Normal		
							Day 28	09/08/93	29	Normal	Normal	Normal	Normal	Normal	Normal	
							Day 56	06/09/93	57	Normal	Normal	Normal	Normal	Normal	Normal	
11DT	Reboxetine	Female	Only screening	18/11/93	01/12/93	14	Screen	12/11/93	0	Normal	Normal	Abnormal	Normal	Normal		
							Screen	09/09/93	0	Normal	Normal	Normal	Normal	Normal		
							Day 28	14/10/93	29	Normal	Normal	Normal	Normal	Normal		
12MD	Reboxetine	Male	Evaluated	16/09/93	27/10/93	42	Screen	09/09/93	0	Normal	Normal	Normal	Normal	Normal		
							Day 28	14/10/93	29	Normal	Normal	Normal	Normal	Normal		
							Screen	14/10/93	29	Normal	Normal	Normal	Normal	Normal		

(*) days of treatment

2420

9550089

30

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 19.0
URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period			Urinalysis test								
					Start date	End date	Days	Assessment	Date	(*)	Specific gravity	Albumin	Sugar	RBC	WBC	
293	12DT	Reboxetine	Female	Evaluated	13/12/93	06/02/94	56	Screen Day 28 Day 56	10/12/93 10/01/94 07/02/94	0 Normal 29 Normal 57 Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
294	13MD	Imipramine	Female	Evaluated	15/02/93	12/04/93	57	Screen Day 28 Day 56	15/02/93 15/03/93 13/04/93	1 Not done 29 Not done 58 Not done	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
	13DT	Reboxetine	Female	Evaluated	08/03/93	03/05/93	57	Screen Day 28 Day 56	08/03/93 05/04/93 04/05/93	1 Not done 29 Not done 58 Not done	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
	14MD	Reboxetine	Female	Evaluated	15/02/93	12/04/93	57	Screen Day 28 Day 56	15/02/93 15/03/93 13/04/93	1 Normal 29 Not done 58 Not done	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
	14DT	Imipramine	Female	Evaluated	08/03/93	03/05/93	57	Screen Day 28 Day 56	08/03/93 05/04/93 04/05/93	1 Not done 29 Not done 58 Not done	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
	15MD	Imipramine	Female	Evaluated	22/02/93	19/04/93	57	Screen Day 28 Day 56	22/02/93 22/03/93 20/04/93	1 Not done 29 Not done 58 Not done	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
	15DT	Imipramine	Female	Evaluated	09/03/93	03/05/93	56	Screen Day 28 Day 56	09/03/93 06/04/93 04/05/93	1 Not done 29 Not done 57 Not done	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
	16MD	Reboxetine	Female	Evaluated	23/02/93	19/04/93	56	Screen Day 28 Day 56	23/02/93 23/03/93 20/04/93	1 Normal 29 Not done 57 Not done	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
	16DT	Reboxetine	Female	Evaluated	09/03/93	03/05/93	56	Screen Day 28 Day 56	09/03/93 06/04/93 04/05/93	1 Not done 29 Not done 57 Not done	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
	25MD	Imipramine	Female	Evaluated	14/06/93	08/08/93	56	Screen Day 28 Day 56	14/06/93	1 Not done	Normal	Normal	Normal	Normal	Normal	Normal

(*) days of treatment

2421

9550089

31

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PBARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 19.0
URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period			Urinalysis test								
					Start date	End date	Days	Assessment	Date	(*)	Specific Gravity	Albumin	Sugar	RBC	WBC	
294	25ND	Imipramine	Female	Evaluated	14/06/93	08/08/93	56	Day 28	12/07/93	29	Not done	Normal	Normal	Normal	Normal	Normal
								Day 56	09/08/93	57	Not done	Normal	Normal	Normal	Normal	
	26ND	Imipramine	Female	Evaluated	14/06/93	08/08/93	56	Screen	14/06/93	1	Not done	Normal	Normal	Normal	Normal	Normal
								Day 28	12/07/93	29	Not done	Normal	Normal	Normal	Normal	
	27ND	Reboxetine	Female	Evaluated	15/06/93	02/08/93	49	Screen	15/06/93	1	Not done	Abnormal	Normal	Normal	Normal	Normal
								Day 28	13/07/93	29	Not done	Normal	Normal	Normal	Normal	
	28ND	Reboxetine	Female	Evaluated	15/06/93	09/08/93	56	Screen	15/06/93	1	Not done	Normal	Normal	Normal	Normal	Normal
								Day 28	13/07/93	29	Not done	Normal	Normal	Normal	Normal	
	29ND	Reboxetine	Female	Evaluated	14/06/93	08/08/93	56	Screen	14/06/93	1	Not done	Normal	Normal	Normal	Normal	Normal
								Day 28	12/07/93	29	Not done	Normal	Normal	Normal	Normal	
	30ND	Reboxetine	Female	Evaluated	14/06/93	08/08/93	56	Screen	14/06/93	1	Not done	Normal	Normal	Normal	Normal	Normal
								Day 28	12/07/93	29	Not done	Normal	Normal	Normal	Normal	
31ND	Imipramine	Female	Evaluated	14/06/93	08/08/93	56	Screen	14/06/93	1	Not done	Normal	Normal	Normal	Normal	Normal	
							Day 28	12/07/93	29	Not done	Abnormal	Normal	Normal	Normal		
32ND	Imipramine	Male	Evaluated	21/06/93	15/08/93	56	Screen	21/06/93	1	Not done	Normal	Normal	Normal	Normal	Normal	
							Day 28	19/07/93	29	Not done	Normal	Normal	Normal	Normal		
17ND	Reboxetine	Female	Evaluated	21/04/93	15/06/93	56	Screen	20/04/93	0	Normal	Normal	Normal	Normal	Normal		
							Day 28	17/05/93	27	Normal	Normal	Normal	Normal	Normal		
17ND	Imipramine	Male	Evaluated	27/04/93	23/06/93	58	Screen	23/04/93	0	Normal	Normal	Normal	Normal	Normal		
							Day 28	27/05/93	31	Normal	Normal	Normal	Normal	Normal		
							Day 56	24/06/93	59	Normal	Normal	Normal	Normal	Normal		

(*) days of treatment

2422

PHARMACIA CNS RBD
REBOXETINE - PROTOCOL 20124/035
Listing No.: 19.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period		Days	Assessment	Date	Urinalysis test						
					Start date	End date				(*)	Specific gravity	Albumin	Sugar	RBC	WBC	
295	18ND	Reboxetine	Female	Evaluated	56	23/04/93	17/06/93	Screen	20/04/93	0	Normal	Normal	Normal	Normal	Normal	Normal
								Day 28	21/05/93	29	Normal	Normal	Normal	Normal	Normal	Normal
								Day 56	18/06/93	57	Normal	Normal	Normal	Normal	Normal	Normal
18DY	18DY	Imipramine	Female	Evaluated	56	29/04/93	23/06/93	Screen	27/04/93	0	Normal	Normal	Normal	Normal	Normal	
								Day 28	27/05/93	29	Normal	Normal	Normal	Normal	Normal	Normal
								Day 56	24/06/93	57	Normal	Normal	Normal	Normal	Normal	Normal
19HD	19HD	Imipramine	Male	Evaluated	56	14/05/93	08/07/93	Screen	13/05/93	0	Normal	Normal	Normal	Normal	Normal	
								Day 28	11/06/93	29	Normal	Normal	Normal	Normal	Normal	Normal
								Day 56	09/07/93	57	Normal	Normal	Normal	Normal	Normal	Normal
19DT	19DT	Reboxetine	Female	Evaluated	56	10/05/93	04/07/93	Screen	07/05/93	0	Normal	Normal	Normal	Normal	Normal	
								Day 28	07/06/93	29	Normal	Normal	Normal	Normal	Normal	Normal
								Day 56	05/07/93	57	Normal	Normal	Normal	Normal	Normal	Normal
20ND	20ND	Imipramine	Female	Evaluated	56	14/05/93	08/07/93	Screen	13/05/93	0	Normal	Normal	Normal	Normal	Normal	
								Day 28	11/06/93	29	Normal	Normal	Normal	Normal	Normal	Normal
								Day 56	09/07/93	57	Normal	Normal	Normal	Normal	Normal	Normal
20DT	20DT	Reboxetine	Female	Evaluated	56	12/05/93	06/07/93	Screen	10/05/93	0	Normal	Normal	Normal	Normal	Normal	
								Day 28	08/06/93	28	Normal	Normal	Normal	Normal	Normal	Normal
								Day 56	06/07/93	56	Normal	Normal	Normal	Normal	Normal	Normal
381	18D	Reboxetine	Male	Evaluated	56	10/12/93	03/02/94	Screen	06/12/93	0	Normal	Normal	Normal	Normal	Normal	
								Day 28	05/01/94	27	Not done	Normal	Normal	Normal	Normal	Normal
								Day 56	03/02/94	56	Normal	Normal	Normal	Normal	Normal	Normal
382	28D	Reboxetine	Female	Evaluated	34	02/02/94	07/03/94	Screen	02/02/94	1	Normal	Normal	Normal	Normal	Normal	
								Day 28	02/03/94	29	Normal	Normal	Normal	Normal	Normal	Normal
								Screen	08/02/94	1	Normal	Normal	Normal	Normal	Normal	Normal
382	30T	Reboxetine	Female	Only screening	19	08/02/94	26/02/94	Screen	25/02/94	0	Normal	Normal	Normal	Normal	Normal	
								Screen	14/03/94	0	Normal	Normal	Normal	Normal	Normal	
								Screen	01/03/94	0	Normal	Normal	Normal	Normal	Normal	
382	58D	Imipramine	Female	Evaluated	59	15/11/93	12/01/94	Screen	12/11/93	0	Not done	Normal	Normal	Normal	Normal	
								Day 28	08/12/93	24	Not done	Normal	Normal	Normal	Normal	
								Day 56	12/01/94	59	Not done	Not done	Not done	Not done	Not done	

(*) days of treatment

9550089

9550089

33

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 19.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period			Urinalysis test								
					Start date	End date	Days	Assessment	Date	Specific gravity	Albumin	Sugar	RBC	MBC		
332	5DT	Reboxetine	Male	Without Urinal	21/10/93	12/11/93	23	Screen	20/10/93	0	Not done	Not done	Not done	Not done	Not done	Not done
	6ND	Reboxetine	Female	Evaluated	12/11/93	07/01/94	57	Screen	12/11/93	1	Not done	Normal	Normal	Normal	Normal	Normal
								Day 28	29	Normal	Normal	Normal	Normal	Normal		
	6DT	Imipramine	Female	Evaluated	22/10/93	17/12/93	57	Screen	22/10/93	1	Normal	Normal	Normal	Normal	Normal	Normal
								Day 28	29	Normal	Abnormal	Abnormal	Normal	Abnormal		
	7ND	Reboxetine	Female	Evaluated	20/12/93	07/02/94	50	Screen	20/12/93	1	Not done	Normal	Normal	Normal	Normal	Normal
								Day 28	26	Normal	Normal	Normal	Normal	Abnormal		
	7DT	Imipramine	Male	Only screening	22/10/93	26/10/93	5	Screen	22/10/93	1	Not done	Normal	Normal	Normal	Normal	Normal
								Day 56	26	Normal	Normal	Normal	Normal	Normal		
	8ND	Imipramine	Male	Only screening	26/01/94	11/02/94	17	Screen	24/01/94	0	Not done	Normal	Normal	Normal	Normal	Normal
								Day 56	19	Normal	Normal	Normal	Normal	Normal		
	9ND	Reboxetine	Female	Evaluated	11/02/94	08/04/94	57	Screen	11/02/94	1	Normal	Normal	Normal	Normal	Normal	Normal
Day 28								29	Normal	Normal	Normal	Normal	Normal			
9DT	Reboxetine	Female	Only screening	08/02/94	09/03/94	30	Screen	06/02/94	0	Normal	Normal	Normal	Normal	Normal	Abnormal	
							Day 28	30	Not done	Not done	Not done	Not done	Not done			
10ND	Imipramine	Female	Only screening	11/02/94	16/02/94	6	Screen	11/02/94	1	Normal	Abnormal	Normal	Abnormal	Abnormal	Abnormal	
							Day 28	18	Not done	Not done	Not done	Not done	Not done			
3301	1ND	Reboxetine	Female	Without Urinal	24/09/92	24/09/92	1	Screen	18/09/92	0	Not done	Not done	Not done	Not done	Not done	Not done
								Day 28	06	Normal	Normal	Normal	Normal	Normal		
2ND	Imipramine	Male	Evaluated	12/01/93	09/03/93	57	Screen	06/01/93	0	Normal	Normal	Normal	Normal	Normal	Normal	
							Day 28	31	Not done	Not done	Not done	Not done	Not done			

(*) days of treatment

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

34

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 19.0

URINALYSIS

Centre	Patient	Treatment	Sex	Patient type	Treatment period			Urinalysis test								
					Start date	End date	Days Assessment	Date	(*)	Specific Gravity	Albumin	Sugar	RBC	WBC		
3301	2ND	Imipramine	Male	Evaluated	12/01/93	09/03/93	57	Day 56	08/03/93	56	Normal	Normal	Normal	Normal	Normal	Normal
3ND		Reboxetine	Female	Evaluated	16/01/93	18/02/93	34	Screen Day 28 Day 35	12/01/93 18/02/93 09/03/93	0 34 53	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	Normal Normal Normal	
3302	5ND	Reboxetine	Female	Without Urinal	07/11/92	27/11/92	21	Screen	30/10/92	0	Not done	Not done	Not done	Not done	Not done	Not done
6ND		Imipramine	Female	Without Urinal	26/06/93	16/07/93	21	Screen	24/06/93	0	Normal	Normal	Normal	Normal	Not done	Not done
7ND		Imipramine	Female	Evaluated	13/11/93	08/01/94	57	Screen Day 56	11/11/93 07/01/94	0 56	Normal Normal	Normal Normal	Normal Normal	Normal Normal	Normal Normal	Normal Normal

2425

(*) days of treatment

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min.)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing (beats/min)		
1	1DT	Reboxetine	Male	Screen	19/11/93	36.20	18	52.00	120	80	76	110	70	82
				Day 0	22/11/93	36.10		56.00	120	80	74	110	65	80
				Day 7	02/12/93	36.20		55.00	140	80	74	135	70	76
				Day 14	09/12/93	36.30		55.00	120	75	68	115	70	72
				Day 21	16/12/93	36.00		56.00	120	70	66	115	70	70
				Day 28	23/12/93	36.10		56.00	125	80	66	120	75	68
	1HD	Reboxetine	Female	Screen	30/10/92	36.40	20	59.00	160	80	74	136	84	90
				Day 0	04/11/92	36.40		60.00	140	68	78	130	70	98
				Day 7	11/11/92	36.30		59.00	140	75	68	126	78	96
				Day 14	18/11/92	36.70		60.00	132	72	82	120	76	92
				Day 21	25/11/92	36.70		61.00	148	82	78	158	84	78
				Day 28	02/12/92	37.20		60.00	160	78	78	150	90	86
2DT	2DT	Imipramine	Male	Screen	03/12/93	36.00	18	75.00	130	80	96	125	70	100
				Day 0	08/12/93	36.10		75.00	135	85	102	125	70	100
				Day 7	16/12/93	36.00		74.00	120	70	74	110	60	78
				Day 14	22/12/93	36.00		73.50	125	75	82	115	70	84
				Screen	16/11/92	37.00	32	72.00	152	80	74	152	88	86
				Day 0	16/11/92	37.00		72.00	152	80	74	152	88	86
	2HD	Imipramine	Male	Day 7	23/11/92	36.70		70.00	150	80	70	144	80	72
				Day 14	30/11/92	36.40		71.00	148	78	72	120	80	96
				Day 21	08/12/92	36.00		72.00	142	80	69	144	80	75
				Day 28	14/12/92	36.30		72.00	142	80	69	144	80	75
				Day 49	06/01/93	36.20		74.00	150	96	80	130	80	96
				Day 56	11/01/93	36.20		72.00	150	86	80	136	80	96
3DT	3DT	Reboxetine	Male	Screen	08/12/93	36.10	16	60.00	140	80	82	130	75	84
				Day 0	09/12/93	36.00		60.00	140	85	70	130	80	74
				Day 7	15/12/93	36.10		61.00	130	80	80	125	75	82
				Day 14	23/12/93	36.00		61.00	125	80	78	120	75	78
				Day 21	30/12/93	36.10		60.50	130	80	68	125	70	72
				Day 28	06/01/94	36.00		60.50	140	80	68	130	70	74
	3HD	Reboxetine	Male	Day 35	13/01/94	36.10		61.00	130	80	74	120	70	76
				Day 42	20/01/94	36.10		60.50	135	80	78	125	75	82
				Day 49	27/01/94	36.10		60.00	130	75	78	125	70	72
				Screen	08/12/93	36.10		60.00	140	80	82	130	75	84
				Day 0	09/12/93	36.00		60.00	140	85	70	130	80	74
				Day 7	15/12/93	36.10		61.00	130	80	80	125	75	82

2426

9550089

2

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing		
1	3DI	Reboxetine	Male	Day 56	03/02/94	36.10		61.00	130	75	74	125	70	76
				Screen	27/05/93	36.00		75.00	150	70	72	150	70	84
				Day 0	02/06/93	36.00	20	75.00	160	74	68	150	70	68
				Day 7	09/06/93	36.00		75.60	150	80	72	150	80	72
				Day 14	16/06/93	36.00		75.50	140	70	80	140	70	80
				Day 21	23/06/93	35.50		75.80	150	86	80	152	86	80
				Day 28	30/06/93	36.00		76.00	170	88	84	180	90	96
				Day 35	07/07/93	35.40		76.80	160	84	80	150	90	84
				Day 42	14/07/93	35.40		78.20	162	90	78	160	88	88
				Day 49	21/07/93	35.50		76.50	150	82	88	144	84	96
Day 56	28/07/93	35.40		76.50	110	60	86	140	85	90				
4DT	Impipramine	Male	Screen	31/01/94	36.20	16	64.00	155	70	82	145	70	84	
			Day 0	31/01/94	36.20		66.50	155	70	82	145	70	84	
			Day 7	07/02/94	36.00		67.00	150	80	80	140	75	78	
			Day 14	14/02/94	36.20		66.80	145	75	80	140	70	76	
			Day 21	21/02/94	36.10		67.00	140	80	78	140	70	76	
			Screen	18/10/93	36.00	24	48.00	120	70	92	110	60	108	
			Day 0	18/10/93	36.00		48.50	120	70	92	110	60	108	
			Day 7	25/10/93	36.00		47.00	130	75	98	120	70	102	
			Day 14	01/11/93	36.00		47.50	130	80	82	120	75	86	
			Day 21	08/11/93	36.00		48.30	135	75	60	125	70	55	
Day 28	15/11/93	36.20		49.00	135	80	68	130	70	72				
Day 35	22/11/93	36.20		48.00	130	80	64	125	70	60				
Day 42	29/11/93	36.10		47.70	135	80	84	120	70	80				
Day 49	06/12/93	36.00		48.00	130	80	74	120	70	70				
Day 56	13/12/93	36.20		47.00	130	80	96	120	75	98				
2	1RD	Reboxetine	Male	Screen	07/01/93	36.80	30	79.00	150	90	74	170	100	76
				Day 0	14/01/93	37.00		78.20	164	96	96	170	110	98
				Day 7	21/01/93	37.20		79.00	166	106	100	160	100	96
				Day 14	28/01/93	36.70		76.50	156	96	82	163	100	80
				Day 21	04/02/93	36.70		78.40	160	98	92	164	96	98
				Day 28	11/02/93	37.00		77.10	146	94	84	150	100	94
				Screen	23/04/93	36.00	20	57.00	160	80	94	140	90	
				Day 0	05/05/93	36.00		56.00	150	90	80	140	90	
				Day 7	12/05/93	36.40		56.00	168	110	100	118	95	128
				Day 14	19/05/93	36.50		57.00	160	110	104	130	100	128
Day 21	26/05/93	36.00		55.00	165	110	108	140	110	132				
Day 28	02/06/93	36.00		56.00	160	110	100	125	100	120				
Day 35	09/06/93	35.60		56.00	155	110	100	130	100	120				

2427

9550089

3

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE						
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	Standing Heart Rate (beats/min)			
3	1MD	Reboxetine	Female	Day 42	16/06/93	36.20		54.00	190	118	104	118	126		
				Day 49	22/06/93	36.40		54.00	175	110	104	125	128		
4	1MD	Imipramine	Male	Screen	20/11/92	36.80	15	75.00	132	86	68	118	90	72	
				Day 0	24/11/92	36.90		75.00	135	85	68	120	90	72	
				Day 7	01/12/92	36.40		75.00	120	95	70	110	95	80	72
				Day 14	08/12/92	36.00		73.20	110	70	70	100	65	72	76
				Day 21	15/12/92	36.40		73.10	120	72	72	140	80	76	76
				Day 28	22/12/92	36.60		76.00	125	95	76	120	95	76	76
				Day 35	29/12/92	36.60		75.50	130	90	72	130	100	76	76
5	1DT	Imipramine	Female	Screen	09/11/92	36.00	17	80.00	120	80	90	120	85	96	
				Day 0	14/11/92	36.20		80.00	120	80	90	120	85	96	
				Day 7	18/11/92	36.50		80.50	120	80	96	110	65	106	
				Day 14	23/11/92	35.80		81.00	120	80	90	120	85	90	
				Day 21	02/12/92	36.00		81.00	130	80	90	120	80	84	
				Day 28	09/12/92	36.20		81.00	110	80	92	115	80	90	
				Day 35	16/12/92	36.50		81.00	110	80	84	115	80	90	
6	1MD	Reboxetine	Female	Day 42	23/12/92	36.40		81.50	115	80	84	115	75	84	
				Day 49	30/12/92	36.00		81.00	110	75	84	110	80	90	
				Day 56	06/01/93	35.80		81.00	110	80	90	110	85	84	
				Screen	23/10/92	36.00	17	65.00	120	80	96	120	85	102	
				Day 0	29/10/92	36.20		65.00	110	75	84	120	80	90	
				Day 7	05/11/92	36.50		64.50	120	80	86	120	75	90	
				Day 14	12/11/92	36.80		64.00	120	80	92	115	75	102	
7	2DT	Imipramine	Female	Screen	16/12/92	36.00	17	42.00	100	60	100	100	65	102	
				Day 0	22/12/92	36.30		42.00	100	65	96	95	65	90	
				Day 7	29/12/92	37.20		41.00	95	60	102	95	60	96	
				Day 14	05/01/93	36.40		41.00	100	60	96	95	65	90	
				Day 21	12/01/93	36.30		41.50	90	65	84	90	60	90	
				Day 28	19/01/93	37.70		40.50	95	55	96	95	60	100	
				Day 35	26/01/93	36.40		41.00	95	55	96	95	60	90	
8	2MD	Reboxetine	Male	Day 42	02/02/93	37.10		40.50	85	40	84	90	45	84	
				Day 49	09/02/93	36.40		41.00	90	60	84	90	65	90	
				Day 56	16/02/93	37.00		41.00	95	55	90	95	60	96	
				Screen	15/11/92	36.00	17	85.00	140	80	84	135	85	90	
				Day 0	23/11/92	36.30		87.00	140	80	80	135	80	96	
				Day 7	30/11/92	36.20		88.50	130	80	80	120	80	72	
				Day 14	07/12/92	35.00		89.00	140	80	84	150	80	76	
9	1MD	Reboxetine	Female	Day 21	14/12/92	35.00		89.50	130	80	80	140	80		
				Day 28	21/12/92	35.20		89.00	130	85	86	135	80	72	

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
5	2ND	Reboxetine	Male	Day 35	28/12/92	35.80		88.50	135	80	86	140	85	90
				Day 42	04/01/93	35.00		89.00	130	85	76	135	85	84
				Day 49	11/01/93	35.30		88.50	135	80	76	140	85	80
	Day 56	18/01/93	35.40		87.50	140	85	86	140	85	90			
	3BT	Reboxetine	Male	Screen	18/03/93	35.00	18	63.00	130	85	80	125	85	72
				Day 0	26/03/93	36.20		63.00	120	82	64	132	80	62
				Day 7	02/04/93	35.30		63.50	125	75	62	125	80	86
				Day 14	09/04/93	36.10		63.00	140	90	68	136	92	86
				Day 21	16/04/93	36.30		63.50	125	80	72	120	75	88
Day 28				23/04/93	36.10		64.00	126	90	65	135	90	86	
Day 35				30/04/93	36.30		64.00	120	80	83	125	80	86	
Day 42				07/05/93	35.80		63.50	125	80	72	130	80	79	
Day 49				14/05/93	35.40		63.50	125	75	66	120	80	89	
Day 56	21/05/93	35.80		63.50	136	86	76	132	90	72				
3ND	Imipramine	Female	Screen	09/03/93	35.00	17	90.00	156	80	92	160	85	96	
			Day 0	16/03/93	36.50		90.00	146	80	80	150	90	88	
			Day 7	23/03/93	36.20		89.50	150	90	82	154	92	90	
			Day 14	30/03/93	36.60		90.00	160	80	84	160	80	90	
			Day 21	06/04/93	37.00		89.00	152	84	88	152	84	84	
			Day 28	13/04/93	36.20		88.50	144	80	72	150	80	78	
			Day 35	20/04/93	36.40		89.00	140	80	80	144	82	80	
			Day 42	27/04/93	36.00		88.50	140	80	72	140	80	78	
			Day 49	04/05/93	36.00		88.00	145	85	72	145	85	72	
Day 56	11/05/93	35.80		88.00	145	85	72	145	85	80				
4DT	Reboxetine	Male	Screen	28/01/93	36.00	16	64.00	115	65	72	130	80	86	
			Day 0	02/02/93	36.60		61.00	115	65	72	135	95	96	
			Day 7	09/02/93	36.40		61.00	115	70	72	120	80	86	
			Day 14	16/02/93	36.80		63.00	160	100	72	160	90	76	
			Day 21	23/02/93	36.70		63.00	130	80	76	145	50	64	
			Day 28	02/03/93	36.00		60.00	140	75	72	145	75	72	
			Screen	18/11/92	36.00	18	70.00	130	70	90	130	75	96	
			Day 0	23/11/92	36.20		70.00	130	60	84	130	75	90	
			Day 7	30/11/92	35.80		70.00	110	70	72	115	75	78	
Day 14	07/12/92	36.20		70.00	125	70	72	125	70	84				
Day 21	14/12/92	36.40		70.50	130	80	72	130	75	72				
Day 28	21/12/92	36.00		70.50	130	80	72	130	80	66				
Day 35	28/12/92	36.10		70.00	125	75	72	125	70	66				
Day 42	04/01/93	36.80		72.00	120	84	84	125	70	80				
Day 49	11/01/93	36.30		71.50	120	70	84	125	70	72				
Day 56	18/01/93	36.10		71.50	130	80	84	125	75	76				

2429

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing (beats/min)		
5	SDT	Reboxetine	Female	Screen	07/02/93	36.70	20	85.00	110	80	80	115	80	76
				Day 0	16/02/93	36.70		85.00	105	70	76	110	75	76
				Day 7	23/02/93	36.60		85.00	155	75	76	140	75	80
				Day 14	02/03/93	36.60		84.00	140	105	84	130	95	84
				Day 21	09/03/93	36.70		84.00	150	100	80	150	100	96
	Day 28	19/03/93	36.90		84.00	140	90	84	145	90	80			
5	5ND	Reboxetine	Male	Screen	28/07/93	36.50	19	64.00	140	80	80	130	80	88
				Day 0	04/08/93	36.60		64.00	150	75	76	140	70	68
				Day 7	11/08/93	36.60		65.00	135	95	68	140	90	68
				Day 14	16/08/93	36.70		63.00	165	95	80	150	95	76
6	6DT	Reboxetine	Female	Screen	19/02/93	36.00	16	52.00	135	65	65	120	65	96
				Day 0	26/02/93	36.00		52.00	120	65	90	120	70	84
				Day 7	05/03/93	36.10		51.00	120	65	72	120	70	80
				Day 14	12/03/93	35.80		50.50	115	65	78	115	70	72
				Day 21	19/03/93	35.80		50.00	120	65	76	120	70	72
				Day 28	26/03/93	36.30		49.50	120	65	78	115	65	84
				Day 35	02/04/93	36.10		51.00	110	75	84	115	75	80
				Day 42	09/04/93	35.00		51.00	120	75	86	115	70	80
				Day 49	16/04/93	35.00		51.50	120	75	80	115	70	78
				Day 56	23/04/93	36.00		51.50	115	75	86	110	75	80
6	6ND	Imipramine	Male	Screen	25/07/93	36.70	20	61.00	130	70	86	130	70	86
				Day 0	05/08/93	36.70		61.00	150	90	80	145	80	84
				Day 7	12/08/93	36.70		61.00	150	80	76	155	85	76
				Day 14	19/08/93	36.70		62.00	140	80	76	140	80	76
7	7DT	Imipramine	Female	Screen	07/03/93	36.00	14	68.00	110	70	80	110	75	86
				Day 0	12/03/93	36.20		68.00	110	70	80	115	75	72
				Day 7	19/03/93	36.00		68.00	120	70	80	110	70	76
				Day 14	26/03/93	36.50		68.50	115	70	80	120	70	72
				Day 21	02/04/93	36.20		69.00	110	70	66	110	75	72
				Day 28	09/04/93	36.00		68.00	120	70	82	115	75	80
				Day 35	16/04/93	36.00		68.50	120	70	80	125	70	82
				Day 42	23/04/93	35.70		68.50	120	70	80	125	75	78
				Day 49	30/04/93	35.00		68.00	115	75	80	120	70	82
				Day 56	07/05/93	36.00		68.50	120	80	66	120	75	72
7	7ND	Reboxetine	Male	Screen	17/10/93		20	81.00	140	80	76	140	70	76
				Day 0	26/10/93	36.80		80.00	140	90	76	120	90	72
				Day 7	03/11/93			80.00	140	90	80	140	100	84

9550089

2430

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)			
5	7HD	Reboxetine	Male	Day 14	10/11/93	36.70		82.00	125	85	76	130	85	72
				Day 21	17/11/93	36.70		82.00	130	75	76	130	65	80
8DT	Imipramine	Female	Screen	30/04/93		35.00	17	75.00	130	75	90	125	75	96
			Day 0	04/05/93	35.00		75.00	135	80	86	130	80	86	86
			Day 7	11/05/93	35.40		75.00	130	75	82	135	70	86	86
			Day 14	18/05/93	35.00		74.50	130	80	82	125	75	86	86
			Day 21	25/05/93	35.00		74.50	125	75	86	120	70	86	86
			Day 28	01/06/93	35.00		74.00	130	80	86	130	80	86	86
			Day 35	08/06/93	35.00		75.00	125	70	90	125	75	96	96
			Day 42	15/06/93	36.00		74.50	125	70	82	130	75	86	86
			Day 49	22/06/93	35.00		74.50	125	70	80	125	70	82	82
			Day 56	29/06/93	34.70		75.50	130	80	86	130	80	86	84
8HD	Imipramine	Female	Screen	05/11/93		36.00	22	83.70	140	80	90	135	80	100
			Day 0	11/11/93	36.50		83.70	140	80	90	135	80	100	100
			Day 7	17/11/93	36.70		83.30	160	110	88	150	100	100	100
			Day 14	24/11/93	35.50		82.40	130	90	84	130	100	100	100
			Day 21	02/12/93	36.20		81.80	160	100	80	140	90	88	88
			Day 28	09/12/93	37.60		81.30	160	100	88	125	70	100	100
			Day 35	15/12/93	36.20		81.00	120	80	80	110	70	84	84
			Day 42	22/12/93	36.20		81.00	140	90	88	140	80	100	100
			Day 49	29/12/93	36.20		80.10	110	70	56	120	80	76	76
			Day 56	05/01/94	36.20		80.00	140	90	76	135	80	88	88
9DT	Reboxetine	Female	Screen	30/04/93		35.00	16	44.00	130	80	80	130	75	86
			Day 0	01/05/93	35.00		44.00	150	70	86	150	75	86	86
			Day 7	08/05/93	36.00		44.00	130	80	86	135	80	82	82
			Day 14	15/05/93	36.00		43.50	170	100	90	165	100	90	90
			Day 21	22/05/93	35.80		44.00	140	80	72	140	85	80	80
			Day 35	04/06/93	36.70		45.00	130	70	76	130	70	76	76
			Day 42	11/06/93	36.70		44.00	120	70	76	120	70	76	76
Day 49	18/06/93	36.70		44.00	120	70	76	120	70	76	76			
Day 56	25/06/93	36.60		44.00	140	70	76	140	70	76	76			
9HD	Reboxetine	Female	Screen	09/11/93		35.00	18	69.00	140	90	76	140	90	76
			Day 0	16/11/93	35.80		69.50	140	90	68	140	90	80	80
			Day 7	22/11/93	36.20		69.50	140	80	70	130	70	78	78
			Day 14	29/11/93	36.20		69.50	140	80	80	130	70	76	76
			Day 21	06/12/93	36.20		69.50	140	80	80	130	70	76	76
			Day 35	20/12/93	36.20		70.00	120	70	76	120	70	72	72
			Day 49	03/01/94	36.20		70.00	110	70	84	110	70	48	48
Day 56	10/01/94	36.00		70.00	130	70	84	120	60	50	50			

2431

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXYTINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE						
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing			
5	10DT	Imipramine	Male	Screen	04/05/93	36.00	17	75.00	140	85	86	140	90	90	
				Day 0	05/05/93	35.70		75.00	140	80	72	145	80	72	86
				Day 7	12/05/93	36.00		74.00	145	80	90	145	85	86	
	10MD	Imipramine	Female	Screen	17/11/93	36.70	20	53.00	120	60	88	130	60	70	
				Day 0	24/11/93	36.70		53.00	135	75	76	135	75	76	
				Day 7	01/12/93	36.50		53.00	140	80	78	140	80	78	76
	11DT	Reboxetine	Female	Screen	04/05/93	35.40	19	50.00	115	70	80	120	70	86	
				Day 0	10/05/93	36.00		51.00	120	70	92	110	70	92	
				Day 7	17/05/93	35.00		51.00	125	75	88	120	85	90	90
	11MD	Imipramine	Female	Day 14	24/05/93	35.00		48.50	120	70	86	115	70	90	
				Day 21	31/05/93	36.10		49.00	120	80	93	135	80	90	90
				Day 28	07/06/93	35.00		49.00	125	70	82	130	75	90	90
	12DT	Imipramine	Male	Screen	25/11/93	36.50	20	69.20	130	80	88	120	70	80	
				Day 0	02/12/93	36.50		68.50	120	70	86	120	70	80	80
				Day 7	08/12/93	36.50		68.00	130	70	88	110	70	88	88
	12MD	Reboxetine	Female	Day 14	15/12/93	36.50		67.00	150	70	88	110	70	88	
				Day 21	22/12/93	36.40		67.00	180	80	104	110	70	96	96
				Day 28	07/01/94	35.00		67.00	180	80	104	110	70	96	96
	12DT	Imipramine	Male	Screen	18/05/93	35.00	18	74.00	140	85	72	135	85	70	
				Day 0	20/05/93	35.00		75.00	140	85	79	140	85	72	72
				Day 7	27/05/93	35.00		74.00	140	80	72	140	75	70	80
	12MD	Reboxetine	Female	Day 14	03/06/93	35.40		74.00	140	80	72	140	85	76	
				Day 21	10/06/93	35.40		74.50	135	80	72	140	80	70	70
				Day 28	17/06/93	35.00		74.50	140	80	79	140	85	72	72
	12DT	Imipramine	Male	Day 35	24/06/93	35.40		72.00	145	80	72	145	85	72	
				Day 42	01/07/93	35.30		72.00	140	85	70	140	85	68	68
				Day 49	08/07/93	35.60		72.00	150	85	70	145	85	72	72
	12MD	Reboxetine	Female	Day 56	15/07/93	36.70		72.00	165	95	72	165	95	72	
				Screen	21/12/93	36.60	21	79.00	155	90	72	150	90	76	76
				Day 0	07/01/94	36.70		78.00	140	90	64	145	80	64	64
	12MD	Reboxetine	Female	Day 7	14/01/94	36.70		78.00	140	80	72	145	80	68	
				Day 14	21/01/94	36.70		80.00	140	70	76	140	90	68	68
				Day 21	28/01/94	36.70		80.00	140	70	76	140	90	68	68
	12MD	Reboxetine	Female	Day 28	04/02/94	36.70		80.00	140	100	72	150	95	68	
				Day 35	11/02/94	36.60		81.00	155	95	76	150	90	72	72
				Day 42	18/02/94	36.50		81.00	155	95	76	155	95	76	76
	12MD	Reboxetine	Female	Day 49	25/02/94	36.70		80.50	160	90	76	155	95	84	
				Day 56	04/03/94	36.60		81.00	160	70	84	160	95	84	84
				Day 56	04/03/94	36.60		81.00	150	75	76	140	90	80	80

9550089

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing Heart Rate (beats/min)		
6	10T	Reboxetine	Female	Screen	13/10/92	36.80	20	64.00	160	80	76	150	75	84
				Day 0	20/10/92	36.70		64.00	160	80	72	150	75	84
				Day 7	27/10/92	36.80		65.00	165	80	72	135	75	84
				Day 14	03/11/92	36.70		64.00	155	80	84	120	70	92
				Day 21	10/11/92	36.60		63.50	170	100	80	140	90	88
				Day 28	17/11/92	36.80		64.00	130	90	80	130	80	96
				Day 35	24/11/92	36.90		64.00	160	90	76	140	80	92
				Day 42	01/12/92	36.70		64.50	155	80	80	140	75	88
				Day 49	08/12/92	36.50		65.00	145	80	76	140	70	80
				Day 56	16/12/92	36.60		65.00	150	80	80	140	70	72
18D	Reboxetine	Female	Screen	08/11/92	36.70	18	64.00	150	100	82	160	105	88	
			Day 0	12/11/92	36.70		64.00	150	100	82	160	105	88	
			Day 7	19/11/92	36.80		64.00	145	95	80	155	95	84	
			Day 14	26/11/92	36.70		64.50	150	95	80	165	100	84	
			Day 21	03/12/92	36.60		64.80	145	95	76	150	100	82	
			Day 28	10/12/92	36.70		65.00	150	95	72	135	90	84	
			Day 35	17/12/92	36.70		65.00	145	95	72	150	95	76	
			Day 42	24/12/92	36.80		65.20	150	95	76	140	90	82	
			Day 49	31/12/92	36.80		65.50	155	105	80	160	110	86	
			Day 56	07/01/93	36.80		65.50	150	95	78	155	95	80	
20T	Reboxetine	Female	Screen	18/01/93	36.70	22	71.00	130	80	68	140	85	76	
			Day 0	20/01/93	36.80		71.00	135	85	78	148	90	86	
			Day 7	27/01/93	36.70		71.00	135	80	72	145	85	80	
28D	Imipramine	Female	Screen	05/11/92	36.70	18	81.00	160	100	76	150	90	80	
			Day 0	10/11/92	36.80		81.00	160	105	80	140	105	100	
			Day 7	17/11/92	36.70		81.00	150	100	80	155	100	92	
30T	Imipramine	Female	Screen	05/03/93	36.40		64.50	149	80	72	140	80	72	
			Day 0	07/04/93	36.70		64.60	145	80	72	140	80	74	
			Day 7	14/04/93	36.70		64.00	140	85	76	140	90	76	
			Day 14	21/04/93	36.70		63.50	125	80	84	128	80	82	
			Day 21	28/04/93	36.40		63.80	105	60	84	100	60	84	
			Day 28	05/05/93	36.40		64.00	110	75	92	105	75	96	
			Day 35	12/05/93	36.60		63.50	105	70	80	100	65	84	
			Day 42	19/05/93	36.80		64.00	130	80	84	130	80	82	
			Day 49	26/05/93	36.70		64.30	110	70	84	110	70	84	
			Day 56	02/06/93	36.60		63.50	105	65	84	110	70	86	
38D	Reboxetine	Female	Screen	27/11/92	36.80	20	63.00	130	60	80	140	60	84	
			Screen	27/11/92	36.80		63.00	130	60	80	140	60	84	

24 43 33

9550089

9

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE						
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing Heart Rate (beats/min)			
6	SND	Reboxetine	Female	Day 0	02/12/92	36.70		63.00	140	84	60	150	60	88	
				Day 7	09/12/92	36.50		61.00	140	100	140	80	100	100	88
				Day 14	16/12/92	35.70		61.00	130	60	80	110	65	88	88
				Day 21	23/12/92	36.00		61.00	125	65	80	120	60	88	84
				Day 28	30/12/92	36.00		61.00	130	60	80	120	60	84	84
				Day 35	06/01/93	36.00		61.50	140	80	80	130	70	92	92
	Day 42	13/01/93	36.20		62.00	130	70	80	120	70	84	84			
	Day 49	20/01/93	36.50		62.00	140	65	72	130	60	72	72			
	Day 56	27/01/93	36.00		62.50	135	65	80	130	70	88	88			
	4DT	Imipramine	Female	Screen	28/04/93	36.60	20	70.00	120	68	80	120	85	92	
				Day 0	04/05/93	36.60		70.00	125	80	68	120	85	96	96
				Day 7	12/05/93	36.70		72.00	150	80	60	130	60	92	92
Day 14				19/05/93	36.20		69.00	120	80	80	130	80	80	80	
Day 21				26/05/93	36.50		70.00	120	90	72	110	70	80	80	
Day 28				02/06/93	36.20		70.00	125	85	76	120	90	80	80	
Day 35	09/06/93	36.50		69.00	135	80	68	130	100	92	92				
Day 42	16/06/93	36.50		69.00	130	60	76	115	90	80	80				
Day 49	23/06/93	36.00		69.00	115	70	68	120	70	76	76				
Day 56	30/06/93	36.30		69.00	100	70	80	110	80	80	88				
4MD	Imipramine	Female	Screen	08/12/92	36.80	20	66.00	155	80	105	165	110	88		
			Day 0	14/12/92	36.80		64.50	150	95	84	160	100	88	88	
			Day 7	21/12/92	36.70		64.00	155	100	78	160	100	86	86	
			Day 14	28/12/92	36.70		64.00	145	95	84	130	90	92	92	
			Day 21	04/01/93	36.80		64.40	160	90	82	125	75	94	94	
			Day 28	11/01/93	36.70		64.50	130	80	76	110	70	84	84	
	Day 35	18/01/93	36.80		65.00	125	75	72	110	70	84	84			
	5DT	Reboxetine	Female	Screen	12/11/93	36.70	16	81.50	180	80	80	170	90	72	
				Day 0	19/11/93	36.50		82.00	180	80	64	185	70	68	68
				Day 7	26/11/93	36.30		80.00	180	80	76	185	85	80	80
				Day 14	03/12/93	36.60		80.50	145	80	72	165	100	68	68
				Day 21	10/12/93	36.50		80.00	170	100	76	150	90	80	80
Day 28				17/12/93	36.10		82.00	170	90	80	170	100	84	84	
Day 35	24/12/93	36.20		82.00	160	65	76	160	70	84	84				
Day 42	31/12/93	36.50		82.50	165	75	84	150	80	88	88				
Day 49	07/01/94	36.80		82.50	165	90	64	150	80	80	80				
Day 56	14/01/94	36.30		82.00	130	70	68	130	80	76	76				
5MD	Imipramine	Female	Screen	30/03/93	36.60		58.50	120	74	70	130	70	72		
			Day 0	02/04/93	36.70		59.00	130	70	74	130	60	72	72	
			Day 7	09/04/93	36.50		60.00	110	70	80	100	65	84	84	
			Day 14	16/04/93	36.50		59.50	120	80	80	100	125	80	80	
			Day 21	23/04/93	36.70		59.50	105	75	80	100	70	84	84	

2434

9550089

10

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE					
									lying	standing	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	Heart Rate (beats/min)
6	5ND	Imipramine	Female	Day 2B	30/04/93	36.70		59.00	75	80	100	70	82	
				Day 3S	07/05/93	36.30		60.50	75	82	105	105	75	84
				Day 4Z	14/05/93	36.40		60.50	60	84	100	95	60	82
				Day 49	21/05/93	36.70		61.50	70	88	100	100	70	84
	Day 56	28/05/93	36.00		60.00	70	92	105	105	65	96			
	6ND	Reboxetine	Female	Screen	23/04/93				57.00	75	92	150	70	96
				Day 0	28/04/93	36.50		57.00	80	84	160	80	86	
				Day 7	05/05/93	36.50		58.00	75	98	125	75	100	
				Day 14	12/05/93	36.80		56.00	75	116	100	75	120	
				Day 21	19/05/93	36.50		58.50	75	112	125	75	116	
				Day 28	26/05/93	36.50		54.50	95	116	150	100	120	
				Screen	08/10/93			55.00	110	120	160	90	88	
Day 0				19/10/93	36.80	18	54.50	100	104	150	90	84		
Day 7	26/10/93	36.50		55.00	200	100	160	90	80					
Day 14	02/11/93	36.50		55.00	180	90	100	85	84					
Day 21	09/11/93	36.20		56.00	170	90	76	165	80					
Day 28	16/11/93	36.70		56.00	190	90	84	180	90					
Day 35	23/11/93	36.40		55.00	180	90	88	170	95					
Day 42	30/11/93	36.40		55.50	180	90	92	180	95					
Day 49	07/12/93	36.30		56.00	170	100	80	160	100					
Day 56	14/12/93	36.20		55.00	180	90	80	180	90					
8ND	Imipramine	Female	Screen	17/11/93				73.00	80	60	145	90	68	
			Day 0	22/11/93	36.00	20	73.00	165	60	160	90	64		
			Day 7	29/11/93	37.00		73.50	160	64	150	90	68		
			Day 14	06/12/93	36.40		75.00	150	56	145	85	60		
			Day 21	13/12/93	36.10		75.00	150	52	120	85	56		
			Day 28	20/12/93	36.20		75.00	140	64	130	90	88		
			Day 35	27/12/93	36.00		75.00	140	52	90	80	64		
			Day 42	03/01/94	36.00		73.00	140	48	105	75	52		
			Day 49	10/01/94	36.60		74.00	125	70	110	80	64		
			Day 56	17/01/94	36.70		75.00	130	70	120	70	72		
			Screen	06/01/93			66.00	75	76	120	85	66		
			Day 0	08/01/93	36.30	15	64.00	120	76	120	75	66		
Day 7	15/01/93	36.60		65.00	120	88	110	70	84					
Day 14	22/01/93	36.80		65.50	134	88	120	76	88					
Day 21	29/01/93	36.60		65.00	120	68	130	70	84					
Day 28	05/02/93	36.70		66.00	110	76	90	60	80					
Day 35	12/02/93	36.40		65.00	120	80	120	80	80					
Day 42	19/02/93	36.70		66.00	142	86	138	86	80					
Day 49	26/02/93	36.00		65.50	145	80	130	80	72					
Day 56	05/03/93	36.60		65.50	132	80	124	80	72					

2435

PHARMACIA CMS RED
 RENOXITINE - PROTOCOL 20124/035
 Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATA

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE						
									S.E.P. (mmHg)	D.I.B.P. (mmHg)	Heart Rate (beats/min)	Standing Heart Rate (beats/min)			
7	30D	Imipramine	Female	Screen	15/04/93	36.00	16	63.00	115	75	76	130	90	92	
				Day 7	22/04/93	36.40		63.00	118	75	86	120	95	84	82
				Day 14	29/04/93	36.40		63.50	120	75	88	110	70	88	88
				Day 21	06/05/93	36.20		63.00	125	80	68	100	70	76	76
				Day 28	13/05/93	36.40		61.00	120	70	68	90	60	92	92
				Day 35	20/05/93	36.30		63.00	120	70	64	110	60	88	88
	4ND	Reboxetine	Female	Screen	15/04/93	36.10	16	63.00	110	70	68	110	60	55	68
				Day 7	22/04/93	36.50		61.50	110	68	72	130	80	80	76
				Day 14	29/04/93	36.10		54.50	110	60	72	140	70	72	72
				Day 21	06/05/93	36.40		54.40	120	70	88	120	70	80	80
				Day 28	13/05/93	36.00		53.80	120	60	80	115	65	80	80
				Day 35	20/05/93	36.30		54.60	130	60	80	120	70	100	100
3	34210	Reboxetine	Female	Screen	16/02/93	36.00		59.00	160	95	80	140	90	100	
				Day 7	23/02/93	36.50		55.00	160	80	86	110	70	92	92
				Day 14	02/03/93	36.00		56.00	130	90	92	120	90	100	100
				Day 21	09/03/93	36.60		56.00	110	60	70	100	90	72	72
				Day 28	16/03/93	36.00		57.00	120	60	80	120	60	86	86
				Day 35	23/03/93	36.90		57.00	120	70	88	115	60	80	84
	4DT	Imipramine	Female	Screen	21/09/92	36.30		65.00	129	80	84	120	80	84	
				Day 7	28/09/92	36.50		64.00	158	80	80	150	80	82	82
				Day 14	05/10/92	36.00		65.00	148	70	80	160	75	82	82
				Day 21	12/10/92	36.80		65.00	148	80	82	135	80	84	84
				Day 28	19/10/92	36.50		66.00	140	90	84	140	90	82	82
				Day 35	26/10/92	36.00		66.00	150	80	80	145	80	90	90
10D	Reboxetine	Female	Screen	16/11/92	36.70		66.00	140	75	90	160	75	90		
			Day 7	23/11/92	36.40		67.00	135	80	80	140	80	82	82	
			Day 14	30/11/92	36.50		58.00	130	80	72	135	80	84	84	
			Day 21	07/12/92	36.50		58.00	140	80	72	135	80	80	80	
			Day 28	14/12/92	36.50		58.00	140	80	72	135	80	80	80	
			Day 35	21/12/92	36.40		58.00	140	80	72	135	80	80	80	

9550089

12

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0
VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE						
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	
8	1M	Reboxetine	Female	Day 7	06/10/92	35.80			160	90	84	160	90	84	84
				Day 14	14/10/92	36.80			145	90	92	145	90	92	92
				Day 21	21/10/92	36.40			140	75	86	140	80	80	90
				Day 28	27/10/92	36.50			150	90	100	165	90	96	96
				Day 35	04/11/92	36.50			150	85	100	150	90	100	100
				Day 42	11/11/92	36.30			160	80	96	155	80	92	92
Day 49	18/11/92	36.50			150	80	90	145	80	90	90				
Day 56	25/11/92	36.30			150	85	100	145	80	96	96				
2D	2D	Imipramine	Female	Screen	23/09/92	36.70	21	62.00	129	80	78	126	85	90	90
				Day 0	30/09/92	36.30			160	70	80	150	80	84	84
				Day 7	07/10/92	36.40			160	80	96	160	80	94	94
				Day 14	14/10/92	35.80			160	80	92	155	80	90	90
				Day 21	21/10/92	35.80			165	80	90	140	80	86	86
				Day 28	28/10/92	36.50			145	80	90	140	70	90	90
Day 35	04/11/92	36.80			140	76	90	145	80	86	86				
Day 42	11/11/92	36.50			130	70	84	130	80	84	84				
Day 49	18/11/92	36.60			130	75	90	130	70	96	96				
Day 56	25/11/92	36.80			140	80	82	135	75	84	84				
2M	2M	Reboxetine	Female	Screen	23/09/92	36.30		92.00	145	90	96	140	90	100	
				Day 0	30/09/92	36.50			140	80	80	140	80	82	82
				Day 7	07/10/92	36.60			150	90	84	150	90	82	82
				Day 14	14/10/92	36.20			145	90	86	150	85	80	80
				Day 21	21/10/92	35.80			145	90	82	140	90	84	84
				Day 28	28/10/92	36.20			140	85	90	140	80	92	92
Day 35	04/11/92	36.20			140	75	90	140	80	90	90				
Day 42	11/11/92	36.20			140	75	90	140	80	88	88				
Day 49	18/11/92	36.50			140	90	90	145	85	90	90				
Day 56	24/11/92	36.60			140	90	86	140	80	92	92				
3D	3D	Reboxetine	Female	Screen	22/09/92	36.80		53.00	115	70	84	120	70	86	
				Day 0	02/10/92	35.90			130	60	90	120	60	82	82
				Day 7	09/10/92	36.40			140	60	100	140	65	100	100
				Day 14	16/10/92	35.90			130	70	96	140	70	92	92
				Day 21	23/10/92	36.40			140	60	92	115	70	94	94
				Day 28	30/10/92	36.20			130	70	90	130	75	92	92
Day 35	06/11/92	36.30			130	60	90	130	65	92	92				
Day 42	13/11/92	36.00			120	60	100	120	65	92	92				
Day 49	20/11/92	36.20			115	70	90	120	70	92	92				
Day 56	27/11/92	36.50			125	70	100	125	70	96	96				
3M	3M	Imipramine	Female	Screen	25/09/92	36.00	21	52.00	130	75	82	130	80	86	
				Day 0	02/10/92	36.50			120	60	90	110	60	92	92
Day 7	08/10/92	36.40			115	70	92	120	70	86	86				

2437

9550089

13

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing Heart Rate (beats/min)		
8	40T	Reboxetine	Female	Screen	25/09/92	36.00	22	59.00	110	60	86	115	65	84
				Day 0	02/10/92	36.30		59.00	110	60	84	110	60	84
				Day 7	09/10/92	36.80		59.00	110	70	86	110	60	82
				Day 14	16/10/92	36.50		59.50	110	75	80	110	60	82
				Day 21	23/10/92	36.20		61.50	110	60	84	120	70	86
				Day 28	30/10/92	36.00		61.50	105	70	94	105	70	92
	40D	Imipramine	Male	Screen	25/09/92	36.40	24	56.00	160	80	90	160	85	92
				Day 0	02/10/92	36.50		56.00	130	60	92	130	75	84
				Day 7	09/10/92	36.20		56.00	140	80	92	140	80	92
				Day 14	16/10/92	36.20		55.50	140	80	92	140	80	92
				Day 21	23/10/92	36.00		55.50	120	95	90	120	95	92
				Day 28	30/10/92	36.50		55.50	120	95	90	120	95	92
701DT	Reboxetine	Female	Screen	29/09/92	36.50	24	87.00	120	80	86	120	75	84	
			Day 0	09/10/92	36.00		85.00	120	80	92	125	80	90	
			Day 7	16/10/92	36.50		85.50	120	75	90	120	75	86	
			Day 14	23/10/92	36.70		86.00	160	90	96	160	95	92	
			Day 21	30/10/92	36.80		88.00	150	90	88.00	145	85	85	
			Day 28	06/11/92	36.70		84.00	140	70	92	140	70	94	
	701MD	Imipramine	Male	Screen	02/10/92	36.50	20	56.00	100	60	72	100	60	72
				Day 0	09/10/92	36.20		56.00	110	70	92	100	70	90
				Day 7	16/10/92	36.30		56.00	140	70	90	105	75	82
				Day 14	23/10/92	36.40		55.00	120	70	90	120	70	90
				Day 21	30/10/92	36.10		54.50	115	76	80	120	75	82
				Day 28	06/11/92	36.20		54.00	110	60	100	110	70	96
702DT	Reboxetine	Female	Screen	02/10/92	36.50	20	56.00	100	60	72	100	60	72	
			Day 0	09/10/92	36.20		56.00	110	70	92	100	70	90	
			Day 7	16/10/92	36.30		56.00	140	70	90	105	75	82	
			Day 14	23/10/92	36.40		55.00	120	70	90	120	70	90	
			Day 21	30/10/92	36.10		54.50	115	76	80	120	75	82	
			Day 28	06/11/92	36.30		54.00	110	60	100	110	70	96	
	702MD	Imipramine	Female	Screen	02/10/92	36.50	21	56.00	100	60	72	100	60	72
				Day 0	09/10/92	36.20		56.00	110	70	92	100	70	90
				Day 7	16/10/92	35.90		55.50	140	70	92	105	70	92
				Day 14	23/10/92	36.30		55.50	110	70	92	110	80	90
				Day 21	30/10/92	36.20		55.50	110	70	92	110	80	90
				Day 28	06/11/92	36.20		55.50	110	70	92	110	80	90

2438

9550089

14

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg) standing	D.B.P. (mmHg) standing	Heart Rate (beats/min) standing
8	702DT	Imipramine	Female	Day 21	30/10/92	35.90		58.00	120	80	72	120	80	74
				Day 28	06/11/92	35.90		57.50	125	70	70	130	75	72
				Day 35	13/11/92	36.20		57.00	145	75	78	145	75	76
				Day 42	20/11/92	36.50		57.00	120	75	80	125	75	82
				Day 49	27/11/92	36.50		57.00	135	85	90	135	85	86
	Day 56	04/12/92	36.60		57.00	125	70	90	120	70	86			
	702MD	Reboxetine	Male	Screen	09/10/92	36.50	19	48.00	140	80	76	140	60	78
				Day 0	16/10/92	36.80		48.00	140	75	80	140	75	75
				Day 7	23/10/92	36.50		47.50	120	65	80	125	70	82
				Day 14	30/10/92	36.00		48.00	120	80	76	120	80	76
Day 21				06/11/92	36.20		48.50	105	90	100	100	60	90	
Day 28	13/11/92	36.50		47.50	105	80	110	110	70	76				
Day 35	30/11/92	36.40		47.50	110	70	105	105	70	82				
Day 42	27/11/92	36.40		47.00	100	60	82	150	60	82				
Day 49	04/12/92	36.00		48.00	110	65	90	110	70	90				
Day 56	11/12/92	36.40		47.50	110	70	90	110	75	92				
703DT	Imipramine	Male	Screen	26/01/93	36.30	24	90.00	140	75	90	145	80	90	
			Day 0	09/02/93	36.70		88.00	150	80	80	150	80	80	
			Day 7	16/02/93	36.30		88.00	140	80	80	110	80	81	
			Day 14	23/02/93	36.60		88.00	140	85	90	140	85	82	
			Day 21	02/03/93	36.00		89.00	145	86	88	145	80	86	
	Day 28	09/03/93	36.40		88.00	160	80	80	140	80	76			
	Day 35	16/03/93	36.40		88.00	140	60	80	165	80	82			
	Day 42	22/03/93	36.00		86.00	160	85	90	140	80	82			
	Day 49	29/03/93	36.20		86.00	160	80	90	160	90	90			
	Day 56	05/04/93	36.50		86.00	150	70	90	160	80	86			
703MD	Imipramine	Female	Screen	26/01/93	36.60	24	76.00	95	60	70	90	60	80	
			Day 0	09/02/93	36.00		76.00	95	70	86	95	70	84	
			Day 7	16/02/93	36.80		76.00	120	80	80	100	75	82	
			Day 14	23/02/93	36.50		76.00	120	75	90	125	80	86	
			Day 21	02/03/93	36.50		75.50	110	70	82	110	75	80	
	Day 28	09/03/93	37.00		75.50	110	60	80	100	70	86			
	Day 35	16/03/93	36.30		76.00	140	80	84	120	80	80			
	Day 42	22/03/93	36.40		76.00	110	60	86	110	70	82			
	Day 49	29/03/93	36.30		76.00	120	60	90	100	70	82			
	Day 56	05/04/93	36.30		75.50	120	60	90	120	70	86			
704DT	Reboxetine	Female	Screen	26/01/93	36.30	22	79.50	110	65	78	115	70	80	
			Day 0	09/02/93	36.10		80.00	110	70	72	105	70	70	
			Day 7	16/02/93	36.30		80.00	130	70	100	120	70	100	
			Day 14	23/02/93	36.30		81.00	120	70	88	120	75	86	
			Day 21	02/03/93	36.00		78.60	135	65	100	140	70	92	

2439

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RSD

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	Standing Heart Rate (beats/min)		
8	704DT	Reboxetine	Female	Day 28	09/03/93	36.30		80.40	100	60	96	130	70	80
				Day 35	16/03/93	36.30		80.00	110	60	88	120	60	90
				Day 42	22/03/93	36.50		81.00	150	70	102	150	75	100
				Day 49	29/03/93	36.70		80.50	120	60	90	110	80	90
				Day 56	05/04/93	36.50		79.50	150	70	100	120	80	96
				Screen	26/01/93	36.40	20	57.00	155	80	60	160	80	80
	704MD	Reboxetine	Female	Day 0	09/02/93	36.20		57.00	160	80	82	150	80	82
				Day 7	16/02/93	36.40		56.50	145	80	64	150	90	66
				Day 14	23/02/93	36.50		56.50	140	80	60	145	80	68
				Day 21	02/03/93	36.50		56.50	150	65	66	150	80	66
				Day 28	09/03/93	36.50		56.50	160	90	70	150	80	62
				Day 35	16/03/93	36.30		57.00	170	80	64	170	80	66
9	1DT	Imipramine	Female	Day 42	22/03/93	36.30		57.00	180	100	96	180	90	96
				Day 49	29/03/93	36.50		56.50	160	90	90	140	95	90
				Day 56	06/04/93	36.50		56.00	130	95	90	170	90	92
				Screen	08/12/93	36.00	20	58.00	120	70	70	120	65	70
				Day 0	15/12/93	36.00		58.00	120	70	72	120	65	72
				Day 7	22/12/93	36.00		58.00	120	70	72	115	65	72
	1MD	Imipramine	Female	Day 14	29/12/93	36.00		58.00	120	70	70	110	70	70
				Day 21	05/01/94	36.00		58.00	120	75	72	115	70	72
				Day 28	12/01/94	36.00		58.00	120	70	70	110	70	70
				Day 35	19/01/94	36.00		58.00	120	70	72	110	65	72
				Day 42	26/01/94	36.00		58.00	115	70	74	110	60	74
				Day 49	02/02/94	36.00		58.00	120	70	72	110	60	72
1ND	Imipramine	Female	Day 09/02/94	09/02/94	36.00		58.00	120	70	74	110	65	74	
			Screen	21/09/93	36.20	20	72.00	140	90	74	140	80	74	
			Day 0	28/09/93	36.20		68.00	140	90	74	140	80	74	
			Day 7	05/10/93	36.00		72.00	110	70	86	110	65	86	
			Day 14	13/10/93	36.00		73.00	110	75	84	110	65	82	
			Day 21	19/10/93	36.00		74.00	110	80	72	110	60	80	
	2DT	Imipramine	Female	Day 28	26/10/93	36.00		74.00	110	75	76	110	70	76
				Day 35	03/11/93	36.20		74.00	110	70	74	110	65	74
				Day 42	09/11/93	36.20		74.00	110	80	70	110	75	70
				Day 49	16/11/93	36.20		74.00	130	80	74	130	80	74
				Day 56	23/11/93	36.20		74.00	130	80	74	125	80	74
				Screen	15/12/93	36.00	20	92.00	140	90	76	140	90	76
2DT	Imipramine	Female	Day 0	22/12/93	36.00		92.00	140	90	80	135	85	80	
			Day 7	29/12/93	36.00		92.00	140	90	76	135	85	80	
			Day 14	05/01/94	36.00		91.00	140	90	74	135	85	74	
			Day 21	12/01/94	36.00		91.00	140	90	76	140	85	74	
			Day 28	19/01/94	36.00		91.00	140	90	80	130	85	78	
			Day 35	26/01/94	36.00		91.00	140	90	80	130	85	78	

9550089

2440

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE						
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	
9	2DT	Imipramine	Female	Day 35	26/01/94	36.00		89.00	140	90	80	130	80	80	
				Day 42	02/02/94	36.00		89.00	140	90	76	130	80	76	
				Day 49	09/02/94	36.00		89.00	140	90	74	135	85	74	
					Day 56	16/02/94	36.00		89.00	140	90	78	135	80	78
	2HD	Reboxetine	Female	Screen	24/09/93	36.00	20	56.00	130	70	72	130	70	72	
				Day 0	01/10/93	36.00		56.00	130	90	76	130	100	76	
				Day 7	08/10/93	36.00		55.00	130	90	80	130	100	76	
				Day 14	15/10/93	36.20		54.00	130	105	68	135	100	68	
				Day 21	22/10/93	36.20		54.00	130	105	64	130	100	64	
Day 28				29/10/93	36.00		55.00	130	100	76	125	100	76		
Day 35				05/11/93	36.00		54.00	130	100	74	120	100	74		
Day 42				12/11/93	36.20		53.00	140	90	74	130	90	74		
Day 49				19/11/93	36.50		53.00	140	90	72	130	90	72		
				Day 56	26/11/93	36.00		53.00	130	100	78	120	100	78	
3DT	Reboxetine	Female	Screen	05/10/93	36.00		55.00	110	70	80	110	65	76		
			Day 0	13/10/93	36.20	20	56.00	110	70	72	110	65	72		
			Day 7	20/10/93	36.20		56.00	110	70	76	110	60	76		
			Day 14	27/10/93	36.00		56.00	110	70	74	110	70	74		
			Day 21	03/11/93	36.00		56.50	110	70	74	110	75	74		
			Day 28	10/11/93	36.00		56.00	110	70	76	105	70	76		
			Day 35	17/11/93	36.20		56.50	110	70	76	110	75	76		
			Day 42	24/11/93	36.20		56.00	110	65	74	110	70	74		
			Day 49	01/12/93	36.00		57.00	110	80	84	110	60	84		
				Day 56	08/12/93	36.00		57.00	110	70	80	110	60	84	
4HD	Imipramine	Female	Screen	05/10/93	36.00		82.00	130	70	80	140	70	80		
			Day 0	13/10/93	36.20	20	83.00	200	100	74	220	100	74		
			Day 7	20/10/93	36.20		83.00	180	110	78	170	100	78		
			Day 14	27/10/93	36.20		82.00	160	120	80	160	130	80		
			Day 21	03/11/93	36.10		82.00	150	120	80	150	120	80		
			Day 28	10/11/93	36.00		82.50	150	80	82	140	80	82		
			Day 35	17/11/93	36.20		82.50	130	80	80	130	80	80		
			Day 42	24/11/93	36.00		82.00	130	80	76	125	80	76		
			Day 49	01/12/93	36.00		82.00	130	80	72	125	80	72		
				Day 56	08/12/93	36.00		81.50	130	80	74	125	80	74	
5HD	Reboxetine	Female	Screen	19/10/93	36.00		65.00	130	70	80	130	70	80		
			Day 0	26/10/93	36.00	20	65.00	120	80	74	120	80	74		
			Day 7	03/11/93	36.00		64.00	120	75	80	120	80	80		
			Day 14	09/11/93	36.20		64.00	120	80	78	120	80	78		
			Day 21	16/11/93	36.50		64.00	130	80	76	130	75	76		
			Day 28	23/11/93	36.10		63.00	110	70	70	110	70	70		
			Day 35	30/11/93	36.20		63.00	100	70	68	100	70	68		

9550089

17

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 20.0
 VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE								
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)			
9	5HD	Reboxetine	Female	Day 42	07/12/93	36.10		65.00	110	80	70	110	80	70			
				Day 49	14/12/93	36.10		63.00	100	70	68	100	70	68			
				Day 56	21/12/93	36.10		63.00	100	70	72	100	65	72			
	6HD	Imipramine	Female	Screen	27/10/93	36.00	20	51.00	140	90	80	140	85	80			
				Day 0	03/11/93	36.30		51.00	140	85	80	135	80	80			
				Day 7	10/11/93	36.20		51.00	140	80	78	130	80	78			
	7HD	Imipramine	Female	Screen	03/11/93	36.00	20	56.00	120	80	72	120	80	72			
				Day 0	10/11/93	36.00		57.00	130	80	72	120	80	72			
				Day 7	17/11/93	36.00		57.00	130	80	76	125	80	76			
	10	8DT	Reboxetine	Female	Screen	09/11/93	36.00	20	89.00	140	90	72	135	90	70		
					Day 0	16/11/93	36.00		89.00	140	90	76	130	90	76		
					Day 7	23/11/93	36.20		89.00	140	90	74	130	90	74		
					Day 14	30/11/93	36.00		89.00	140	90	76	135	90	76		
					Day 21	07/12/93	36.00		89.00	140	90	74	130	90	74		
					Day 28	14/12/93	36.00		89.00	140	90	76	130	90	76		
Day 35					21/12/93	36.00		89.00	140	90	74	130	85	74			
Day 42					28/12/93	36.00		89.00	140	90	74	135	85	74			
Day 49					04/01/94	36.20		89.00	140	90	78	135	85	78			
Day 56					11/01/94	36.00		90.00	140	90	76	130	85	76			
10D					Reboxetine	Female	Screen	23/11/93	36.20	16	60.00	130	90	66	135	90	72
							Day 0	30/11/93	36.20		60.00	130	85	64	125	85	68
							Day 7	07/12/93	36.10		60.00	125	85	64	130	80	72
10D					Imipramine	Female	Screen	24/09/93	36.00	16	68.00	125	80	92	120	80	96
							Day 0	01/10/93	36.10		67.00	135	85	76	135	80	82
	Day 7	08/10/93	36.00				67.00	135	85	78	130	80	84				
	Day 14	15/10/93	36.20				67.00	130	80	76	130	80	84				
	Day 21	22/10/93	35.90				67.00	130	90	84	125	80	86				
	Day 28	29/10/93	36.20				68.00	125	85	74	120	90	78				
	Day 35	05/11/93	36.10				68.00	130	80	76	135	75	78				
	Day 42	12/11/93	36.20				68.00	130	85	74	135	80	82				
	Day 49	19/11/93	36.40				68.00	125	85	82	130	80	86				
	Day 56	26/11/93	36.00				68.00	135	80	74	130	90	76				

9550089

18

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 20.0
 VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE						
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing			
10	2DT	Imipramine	Male	Screen	23/11/93	35.90	18	72.90	120	70	76	125	75	82	
				Day 0	30/11/93	35.90		72.00	130	90	74	130	85	78	85
				Day 7	07/12/93	36.20		72.00	140	80	78	130	75	82	82
				Day 14	14/12/93	36.00		72.00	130	80	82	135	90	84	84
				Day 21	21/12/93	36.10		72.00	135	90	78	130	85	84	84
				Day 28	28/12/93	36.00		72.00	135	90	58	125	80	70	70
	Day 35	04/01/94	35.80		72.00	140	80	70	130	85	72	72			
	Day 42	11/01/94	36.00		72.00	140	80	68	125	75	66	66			
	Day 49	18/01/94	36.10		72.00	125	90	62	120	85	68	68			
	Day 56	25/01/94	36.10		72.00	140	80	84	130	75	90	90			
	20	2HD	Reboxetine	Male	Screen	24/09/93	35.90	15	81.00	135	90	86	140	90	90
					Day 0	01/10/93	36.00		80.00	145	95	82	140	90	86
Day 7					08/10/93	36.30		80.00	140	90	74	140	80	78	78
Day 14					15/10/93	36.40		80.00	145	95	66	135	90	93	93
Day 21					22/10/93	36.10		81.00	140	90	76	135	80	86	86
Day 28					29/10/93	36.00		81.00	135	90	82	140	85	86	86
Day 35		05/11/93	36.20		81.00	150	85	82	140	90	78	78			
Day 42		12/11/93	36.10		81.00	160	90	82	135	95	86	86			
Day 49		19/11/93	36.00		82.00	140	85	86	135	80	92	92			
Day 56		26/11/93	36.20		82.00	140	80	84	135	90	88	88			
30		3DT	Imipramine	Male	Screen	24/11/93	36.30	16	80.00	140	90	70	135	85	76
					Day 0	01/12/93	36.00		80.00	140	85	76	130	80	80
	Day 7				08/12/93	36.10		80.00	140	90	74	130	85	82	82
	Day 14				15/12/93	36.10		80.00	140	90	74	130	85	74	74
	Day 21				22/12/93	36.20		80.00	135	85	72	130	80	76	76
	Day 28				29/12/93	35.90		80.00	130	90	70	135	85	78	78
	Day 35	05/01/94	36.10		80.00	135	85	76	140	80	82	82			
	Day 42	12/01/94	36.00		81.00	140	90	78	130	85	82	82			
	Day 49	19/01/94	36.20		80.00	135	80	84	130	70	86	86			
	Day 56	26/01/94	36.30		80.00	150	85	70	140	90	72	72			
	30	3HD	Reboxetine	Male	Screen	24/09/93	36.20	13	76.00	140	85	72	140	80	76
					Day 0	01/10/93	36.00		75.00	135	80	70	130	80	80
Day 7					08/10/93	36.10		75.00	140	80	78	135	75	84	84
Day 14					15/10/93	35.90		75.00	145	85	70	140	80	76	76
Day 21					22/10/93	36.20		75.00	150	85	72	145	80	80	80
Day 28					29/10/93	36.00		74.00	140	90	68	145	85	72	72
Day 35		05/11/93	36.00		75.00	140	80	60	135	75	70	70			
Day 42		12/11/93	36.00		75.00	135	90	64	140	85	72	72			
Day 49		19/11/93	36.10		76.00	140	90	64	140	85	74	74			
Day 56		26/11/93	36.20		75.00	140	90	62	135	85	85	85			

2443

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE				
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing (beats/min)	
10	4DI	Reboxetine	Female	Screen	24/11/93	36.00	14	70.00	135	85	66	90	72
				Day 0	01/12/93	36.20		70.00	145	90	64	85	68
				Day 7	08/12/93	36.10		70.00	140	80	72	135	75
				Day 14	15/12/93	36.20		70.00	145	85	68	140	90
				Day 21	22/12/93	36.10		70.00	140	80	76	130	80
				Day 28	29/12/93	36.00		70.00	130	85	74	130	80
				Day 35	05/01/94	36.00		71.00	130	75	76	135	80
				Day 42	12/01/94	36.10		71.00	135	85	70	140	80
				Day 49	19/01/94	36.20		71.00	135	75	72	130	80
				Day 56	26/01/94	36.10		72.00	145	85	74	135	80
10	4WD	Imipramine	Female	Screen	28/09/93	35.90	15	67.00	130	90	70	90	74
				Day 0	05/10/93	36.00		67.00	130	90	68	125	85
				Day 7	12/10/93	35.90		66.00	130	80	66	125	75
				Day 14	19/10/93	36.10		66.00	135	90	62	130	90
				Day 21	26/10/93	36.30		67.00	135	80	62	130	75
				Day 28	03/11/93	36.10		67.00	135	85	62	140	80
				Day 35	09/11/93	36.10		67.00	130	80	78	135	75
				Day 42	16/11/93	36.00		67.00	125	85	70	130	80
				Day 49	23/11/93	36.20		67.00	125	80	70	120	80
				Day 56	30/11/93	36.00		67.00	130	85	66	125	80
10	5DI	Reboxetine	Female	Screen	26/11/93	35.90	18	58.00	130	70	66	70	70
				Day 0	03/12/93	36.00		58.00	135	75	64	130	70
				Day 7	10/12/93	36.20		58.00	140	80	76	130	75
				Day 14	17/12/93	36.20		58.00	140	80	56	130	70
				Day 21	23/12/93	35.90		58.00	125	75	60	130	70
				Day 28	30/12/93	36.00		58.00	135	80	62	130	70
				Day 35	07/01/94	36.20		58.00	135	80	64	140	75
				Day 42	14/01/94	36.10		58.00	130	120	58	130	75
				Day 49	21/01/94	36.30		58.00	140	85	74	135	80
				Day 56	28/01/94	36.30		58.00	145	90	60	135	80
10	5ND	Imipramine	Female	Screen	29/09/93	36.20	17	85.00	140	95	64	95	68
				Day 0	05/10/93	36.10		85.00	150	90	64	140	85
				Day 7	12/10/93	36.00		85.00	145	85	72	150	90
				Day 14	19/10/93	36.20		85.00	135	80	66	140	80
				Day 21	26/10/93	36.10		85.00	135	85	70	140	80
				Day 28	03/11/93	36.10		83.00	140	90	66	135	72
				Day 35	09/11/93	36.30		82.00	140	85	72	130	80
				Day 42	16/11/93	36.00		82.00	145	90	62	140	80
				Day 49	23/11/93	36.10		81.00	150	85	68	140	80
				Day 56	30/11/93	36.00		81.00	140	90	60	140	80

9550089

20

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 20.0
 VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing (beats/min)		
10	60T	Reboxetine	Male	Screen	26/11/93	36.20	15	68.00	130	70	74	140	80	78
				Day 0	03/12/93	36.10		68.00	145	80	82	135	85	86
				Day 7	10/12/93	36.00		68.00	145	80	86	140	75	88
				Day 14	17/12/93	35.80		68.00	135	85	86	125	80	90
				Day 21	23/12/93	36.10		68.00	130	80	82	125	85	88
				Day 28	30/12/93	36.00		68.00	140	80	80	130	75	84
				Day 35	07/01/94	35.90		66.00	130	75	78	130	80	84
				Day 42	14/01/94	36.00		64.00	145	85	84	135	80	90
				Day 49	21/01/94	36.10		63.00	130	80	82	120	75	88
				Day 56	28/01/94	36.10		63.00	135	80	72	140	75	78
60D	Reboxetine	Male	Screen	01/10/93	36.60	14	65.00	125	85	76	120	80	80	
			Day 0	08/10/93	36.30		64.00	130	90	74	125	85	78	
			Day 7	15/10/93	36.20		64.00	125	80	72	120	75	82	
			Day 14	22/10/93	36.10		64.00	130	80	82	125	70	86	
			Day 21	29/10/93	36.00		64.00	125	80	74	130	75	82	
			Day 28	05/11/93	36.20		64.00	140	80	74	130	80	78	
			Day 35	12/11/93	35.90		64.00	130	90	70	135	85	76	
			Day 42	19/11/93	36.30		63.00	135	80	76	130	80	82	
			Day 49	26/11/93	36.10		64.00	145	85	84	140	80	88	
			Day 56	03/12/93	36.20		64.00	145	85	74	140	80	80	
70T	Imipramine	Female	Screen	26/11/93	36.00	16	80.00	140	90	86	135	85	92	
			Day 0	03/12/93	36.10		80.00	150	90	94	145	85	98	
			Day 7	10/12/93	36.20		80.00	140	70	90	145	80	96	
			Day 14	17/12/93	36.00		80.00	140	70	78	140	85	86	
			Day 21	23/12/93	36.10		80.00	150	90	86	145	85	92	
			Day 28	30/12/93	36.20		80.00	150	90	88	140	85	94	
			Day 35	07/01/94	35.90		79.00	135	85	88	130	90	96	
			Day 42	14/01/94	36.00		79.00	140	90	94	135	80	102	
			Day 49	21/01/94	36.20		79.00	145	85	92	140	80	100	
			Day 56	28/01/94	36.10		79.00	135	90	90	140	85	94	
70D	Imipramine	Male	Screen	01/10/93	35.90	17	80.00	130	90	70	125	85	76	
			Day 0	08/10/93	36.20		80.00	135	85	74	130	85	78	
			Day 7	15/10/93	36.10		80.00	130	80	68	125	85	76	
			Day 14	22/10/93	36.00		80.00	130	80	82	120	85	86	
			Day 21	29/10/93	36.30		80.00	140	80	74	130	80	82	
			Day 28	05/11/93	36.00		80.00	130	80	68	120	85	76	
			Day 35	12/11/93	35.90		80.00	135	85	74	140	90	80	
			Day 42	19/11/93	36.20		80.00	140	80	70	130	80	74	
			Day 49	26/11/93	36.10		80.00	130	90	76	120	80	84	
			Day 56	03/12/93	36.40		80.00	125	85	76	130	90	76	

24451

9550089

21

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE						
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing			
10	80T	Imipramine	Female	Screen	26/11/93	36.00	16	60.00	135	85	60	130	80	68	
				Day 0	03/12/93	36.10		60.00	130	80	62	120	75	70	70
				Day 7	10/12/93	36.10		60.00	135	95	66	130	85	80	70
				Day 14	17/12/93	36.00		60.00	130	80	64	125	80	66	66
				Day 21	23/12/93	35.80		60.00	125	90	60	120	85	68	68
				Day 28	30/12/93	36.20		60.00	140	90	60	130	80	72	72
				Day 35	07/01/94	36.10		60.00	130	85	64	125	80	68	68
Day 42	14/01/94	36.10		60.00	140	95	66	130	90	70	70				
Day 49	21/01/94	36.10		60.00	130	80	68	125	75	74	74				
Day 56	28/01/94	36.00		60.00	130	90	68	135	85	72	72				
80D	Reboxetine	Male	Screen	08/10/93	36.00	15	50.00	145	95	84	140	90	86		
			Day 0	15/10/93	36.30		50.00	135	95	84	140	95	90	90	
			Day 7	22/10/93	35.80		50.00	150	90	88	145	95	82	82	
			Day 14	29/10/93	36.10		50.00	145	95	76	140	90	82	82	
			Day 21	05/11/93	36.20		50.00	140	85	72	145	80	78	78	
			Day 28	12/11/93	36.10		50.00	150	85	66	140	80	70	70	
			Day 35	19/11/93	36.20		49.00	145	85	72	150	90	82	82	
Day 42	26/11/93	36.20		50.00	150	95	74	145	85	82	82				
Day 49	03/12/93	36.10		50.00	150	82	76	140	80	80	80				
Day 56	10/12/93	36.00		51.00	125	95	74	135	90	76	76				
90T	Imipramine	Male	Screen	30/11/93	36.10	14	62.00	150	90	76	145	90	80		
			Day 0	07/12/93	36.20		62.00	135	70	74	130	70	78	78	
			Day 7	14/12/93	36.10		62.00	130	70	66	120	75	74	74	
			Day 14	21/12/93	36.00		62.00	130	80	74	120	75	78	78	
			Day 21	28/12/93	36.20		62.00	145	80	78	140	85	84	84	
			Day 28	04/01/94	36.10		62.00	140	80	78	135	75	80	80	
			Day 35	11/01/94	36.00		62.00	135	85	70	130	80	74	74	
Day 42	18/01/94	36.20		62.00	150	80	70	135	75	74	74				
Day 49	25/01/94	36.30		62.00	140	80	76	130	75	82	82				
Day 56	01/02/94	36.10		62.00	135	85	72	130	80	78	78				
90D	Reboxetine	Female	Screen	12/11/93	36.10	17	68.00	115	60	94	110	60	98		
			Day 0	19/11/93	36.00		68.00	145	60	94	135	80	102	102	
			Day 7	26/11/93	36.10		68.00	115	75	94	120	70	98	98	
			Day 14	03/12/93	36.10		68.00	125	85	94	115	75	100	100	
			Day 21	10/12/93	36.20		68.00	120	75	80	115	70	94	94	
			Day 28	17/12/93	36.10		68.00	120	60	88	115	70	96	96	
			Day 35	23/12/93	36.00		69.00	115	75	86	110	70	90	90	
Day 42	30/12/93	36.00		69.00	125	75	94	120	70	102	102				
Day 49	07/01/94	35.80		69.00	120	70	88	110	70	96	96				
Day 56	14/01/94	36.10		69.00	115	80	92	120	70	94	94				

2446

9550089

22

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
 REBOMETINE - PROTOCOL 20124/035
 Listing No.: 20.0
 VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE									
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing						
10	10DT	Reboxetine	Female	Screen	30/11/93	36.40	16	70.00	135	85	60	125	80	64				
				Day 0	07/12/93	36.10		70.00	125	85	70	120	75	78	72			
				Day 7	14/12/93	36.20		70.00	125	80	66	125	80	66	80			
				Day 14	21/12/93	36.20		70.00	130	90	64	120	85	68	82			
				Day 21	28/12/93	36.20		70.00	135	85	74	130	80	74	82			
				Day 28	04/01/94	35.90		70.00	125	80	70	120	85	74	74			
				Day 35	11/01/94	36.00		69.00	130	90	74	120	80	74	82			
				Day 42	18/01/94	35.90		69.00	130	75	64	120	70	74	74			
				Day 49	25/01/94	36.20		70.00	130	70	68	125	75	72	72			
				Day 56	01/02/94	36.10		70.00	130	80	60	125	85	68	68			
				10	10DD	Imipramine	Female	Screen	15/10/93	36.10	15	65.00	140	100	78	135	95	86
								Day 0	22/10/93	36.20		65.00	145	90	72	145	85	76
Day 7	29/10/93	36.00						65.00	140	90	78	135	85	86	86			
Day 14	05/11/93	36.20						65.00	140	85	72	150	90	76	76			
Day 21	12/11/93	36.00						65.00	135	90	84	130	90	92	90			
Day 28	19/11/93	36.10						65.00	145	90	88	140	90	90	90			
Day 35	26/11/93	36.20						65.00	140	85	84	135	90	88	88			
Day 42	03/12/93	36.00						65.00	145	90	76	140	85	84	84			
Day 49	10/12/93	36.10						66.00	135	90	74	130	80	76	76			
Day 56	17/12/93	36.40						65.00	150	90	76	140	90	84	84			
10	11DT	Imipramine	Female					Screen	30/11/93	35.90	17	57.00	140	90	72	135	85	76
								Day 0	07/12/93	36.00		56.00	145	90	74	140	85	80
				Day 7	14/12/93	36.10		56.00	150	90	78	140	90	80	80			
				Day 14	21/12/93	36.20		57.00	135	90	78	130	85	82	82			
				Day 21	28/12/93	36.10		57.00	140	85	72	135	80	78	78			
				Day 28	04/01/94	36.20		57.00	135	80	66	130	80	72	72			
				Day 35	11/01/94	35.90		57.00	140	80	76	145	75	74	74			
				Day 42	18/01/94	36.00		57.00	155	90	72	145	90	78	78			
				Day 49	25/01/94	36.10		58.00	140	90	72	130	80	78	78			
				Day 56	01/02/94	36.00		57.00	135	85	74	140	80	78	78			
				10	11DD	Imipramine	Female	Screen	15/10/93	36.30	16	58.00	130	85	66	130	80	70
								Day 0	22/10/93	35.90		58.00	145	80	60	140	75	66
Day 7	29/10/93	36.20						57.00	140	90	64	130	80	66	66			
Day 14	05/11/93	36.10						58.00	135	85	68	130	80	70	70			
Day 21	12/11/93	36.20						58.00	140	90	68	135	85	70	70			
Day 28	19/11/93	36.00						57.00	140	80	58	130	75	64	64			
Day 35	26/11/93	36.20						58.00	130	85	64	125	90	70	70			
Day 42	03/12/93	36.00						58.00	140	85	60	130	80	70	70			
Day 49	10/12/93	36.20						58.00	135	85	64	130	90	72	72			
Day 56	17/12/93	36.20						58.00	130	80	70	125	85	74	74			

2447

9550089

23

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE								
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	Standing Heart Rate (beats/min)					
10	12DT	Reboxetine	Female	Screen	30/11/93	36.20	16	73.00	150	90	90	145	85	100			
				Day 0	07/12/93	36.00		73.00	140	90	78	135	90	88	88		
				Day 7	14/12/93	36.20		73.00	135	85	98	140	90	102	102		
				Day 14	21/12/93	36.20		73.00	140	90	94	140	90	85	98		
				Day 21	28/12/93	36.20		74.00	145	90	96	140	90	135	85		
				Day 28	04/01/94	36.30		73.00	145	85	98	140	90	140	104		
				Day 35	11/01/94	36.00		73.00	135	90	84	125	85	90	85		
				Day 42	18/01/94	36.10		73.00	135	85	94	125	80	96	96		
				Day 49	25/01/94	36.20		74.00	150	90	92	140	85	98	98		
				Day 56	01/02/94	35.90		73.00	145	95	88	135	90	90	94		
				12HD	Reboxetine	Male	Screen	19/10/93	36.00	14	64.00	130	90	74	125	80	82
							Day 0	26/10/93	36.30		64.00	130	90	70	135	85	78
Day 7	03/11/93	36.00					64.00	140	90	74	135	85	80				
Day 14	09/11/93	36.10					64.00	140	90	76	135	85	82				
Day 21	16/11/93	36.20					64.00	140	90	72	145	80	82				
Day 28	23/11/93	36.10					64.00	135	90	70	130	85	72				
Day 35	30/11/93	36.00					65.00	150	90	84	140	90	88				
Day 42	07/12/93	36.16					65.00	140	85	78	145	80	84				
Day 49	14/12/93	36.30					65.00	145	85	78	140	80	84				
Day 56	21/12/93	36.20					65.00	135	90	64	130	80	72				
13DT	Reboxetine	Female	Screen				19/10/93	36.10	14	63.00	120	70	62	130	70	68	
			Day 0				26/10/93	36.00		63.00	125	85	70	120	75	72	
			Day 7	03/11/93	36.10		63.00	130	80	62	120	75	66				
			Day 14	09/11/93	36.20		63.00	130	80	72	120	75	70				
			Day 21	16/11/93	36.10		63.00	140	80	66	130	75	72				
			Day 28	23/11/93	36.10		63.00	140	80	62	130	75	68				
			Day 35	30/11/93	36.10		62.00	145	75	68	140	80	74				
			Day 42	07/12/93	36.20		61.00	135	80	64	140	75	70				
			Day 49	14/12/93	36.30		62.00	130	80	66	125	85	70				
			Day 56	21/12/93	36.00		63.00	135	85	70	130	90	74				
			14DT	Imipramine	Female	Screen	22/10/93	36.20	15	60.00	120	70	62	110	65	68	
						Day 0	29/10/93	36.10		60.00	115	75	62	110	70	66	
Day 7	05/11/93	36.10					60.00	120	80	74	110	75	82				
Day 14	12/11/93	35.80					60.00	125	75	64	120	80	68				
Day 21	19/11/93	36.20					60.00	130	85	76	125	80	78				
Day 28	26/11/93	36.00					60.00	130	90	66	125	85	72				
Day 35	03/12/93	36.10					60.00	130	90	66	125	80	74				
Day 42	10/12/93	36.00					59.00	130	90	72	130	85	76				
Day 49	17/12/93	36.00					58.00	130	85	70	120	90	74				
Day 56	23/12/93	35.90					58.00	115	75	62	120	70	68				

2448

9550089

24

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CMS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE						
									lying	Sitting	standing	Heart Rate (beats/min)			
									S.B.P. (mmHg)	D.B.P. (mmHg)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)		
10	45ND	Reboxetine	Female	Screen	22/10/93	36.00	18	80.00	145	85	74	140	80	78	
				Day 0	29/10/93	36.00		80.00	130	80	78	120	80	80	84
				Day 7	05/11/93	36.20		80.00	125	85	72	115	90	90	76
				Day 14	12/11/93	36.10		80.00	130	80	70	120	75	70	74
				Day 21	19/11/93	36.30		80.00	125	75	74	115	70	70	78
				Day 28	26/11/93	36.20		80.00	125	75	76	120	70	70	80
				Day 35	03/12/93	36.20		80.00	125	80	84	115	75	75	88
				Day 42	10/12/93	36.10		81.00	135	80	74	120	70	70	88
				Day 49	17/12/93	36.20		80.00	130	80	84	120	75	88	84
				Day 56	23/12/93	36.20		81.00	135	75	74	130	70	70	80
16DT	Imipramine	Male	Screen	22/10/93	36.00	16	74.00	135	90	86	135	90	88		
			Day 0	29/10/93	35.80		74.00	145	90	84	140	90	86		
			Day 7	05/11/93	36.20		74.00	130	80	70	120	75	74		
			Day 14	12/11/93	36.10		74.00	130	90	76	120	80	82		
			Day 21	19/11/93	36.00		74.00	135	85	74	130	75	78		
			Day 28	26/11/93	36.10		74.00	140	90	86	145	90	94		
			Day 35	03/12/93	36.00		73.00	130	80	86	120	75	90		
			Day 42	10/12/93	36.20		73.00	135	80	90	125	75	94		
			Day 49	17/12/93	36.20		74.00	135	85	88	130	80	94		
			Day 56	23/12/93	36.20		74.00	135	85	86	130	80	92		
17ND	Reboxetine	Female	Screen	29/10/93	36.50	16	58.00	145	90	60	140	90	64		
			Day 0	05/11/93	36.00		57.00	135	90	84	125	80	86		
			Day 7	12/11/93	36.10		57.00	150	100	78	145	95	86		
			Day 14	19/11/93	36.30		57.00	130	75	76	140	80	86		
			Day 21	26/11/93	36.30		58.00	130	80	76	140	90	82		
			Day 28	03/12/93	36.20		58.00	135	85	58	140	80	64		
			Day 35	10/12/93	36.10		58.00	135	90	62	130	85	66		
			Day 42	17/12/93	36.00		58.00	140	80	60	130	80	64		
			Day 49	23/12/93	35.80		58.00	145	90	70	140	85	72		
			Day 56	30/12/93	36.00		59.00	140	80	58	135	85	64		
18ND	Imipramine	Female	Screen	29/10/93	36.40	14	74.00	135	85	76	130	80	82		
			Day 0	05/11/93	36.10		73.00	130	70	82	130	75	86		
			Day 7	12/11/93	36.20		73.00	135	85	74	130	80	78		
			Day 14	19/11/93	36.00		73.00	140	90	76	130	80	84		
			Day 21	26/11/93	36.10		72.00	145	85	78	140	90	84		
			Day 28	03/12/93	36.10		73.00	140	85	70	135	80	76		
			Day 35	10/12/93	36.20		74.00	145	85	70	135	80	74		
			Day 42	17/12/93	36.20		74.00	140	90	76	135	90	82		
			Day 49	23/12/93	36.00		75.00	145	90	76	135	80	84		
			Day 56	30/12/93	36.10		75.00	150	90	78	140	80	82		

2449

9550089

25

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 20.0
 VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE									
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)				
10	19DT	Reboxetine	Male	Screen	29/10/93	36.30	17	62.00	135	85	94	130	80	98				
				Day 0	05/11/93	36.30		62.00	130	90	96	125	85	98				
				Day 7	12/11/93	36.10		62.00	135	90	96	130	85	100				
				Day 14	19/11/93	36.20		62.00	130	80	92	135	80	102				
				Day 21	26/11/93	36.20		62.00	140	90	92	135	85	98				
				Day 28	03/12/93	36.00		62.00	125	85	94	130	90	102				
				Day 35	10/12/93	36.10		62.00	150	90	88	135	85	94				
				Day 42	17/12/93	36.00		63.00	135	90	86	130	90	94				
				Day 49	23/12/93	36.20		63.00	130	90	96	135	80	100				
				Day 56	30/12/93	36.20		62.00	135	80	90	130	90	98				
				20MD	20MD	Reboxetine	Female	Screen	29/10/93	36.20	18	71.00	150	90	74	140	90	76
								Day 0	05/11/93	36.00		71.00	150	90	76	140	85	82
Day 7	12/11/93	36.30						70.00	145	85	76	140	90	80				
Day 14	19/11/93	36.20						70.00	140	90	72	145	80	82				
Day 21	26/11/93	36.10						69.00	160	90	82	150	90	86				
Day 28	03/12/93	36.00						69.00	145	85	78	140	90	86				
Day 35	10/12/93	35.90						68.00	150	90	78	145	80	84				
Day 42	17/12/93	36.10						68.00	140	90	78	145	85	86				
Day 49	23/12/93	36.10						68.00	140	95	78	145	80	86				
Day 56	30/12/93	36.10						67.00	140	90	74	135	90	76				
12	1DT	Reboxetine	Female					Screen	15/05/93	37.00		51.00	140	80	80	130	85	85
								Day 0	19/05/93	37.00		50.00	140	80	80	130	80	80
				Day 7	27/05/93	37.00		50.60	130	70	84	135	70	90				
				Day 14	03/06/93	37.00		49.00	130	70	92	120	70	90				
				Day 21	10/06/93	37.00		49.20	125	70	83	105	60	90				
				Day 28	17/06/93	37.00		49.00	125	70	83	105	60	90				
				Day 35	24/06/93	37.00		50.00	135	70	90	130	70	96				
				Day 42	01/07/93	37.00		49.00	120	60	85	115	60	86				
				Day 49	08/07/93	37.00		48.50	115	60	80	110	60	82				
				Day 56	15/07/93	37.00		48.00	140	70	78							
				1ND	1ND	Reboxetine	Female	Screen	18/04/93	37.00		48.00	140	75	84	120	70	80
								Day 0	27/04/93	37.00		47.80	140	80	85	120	75	80
Day 7	05/05/93	37.00						47.60	140	70	76	115	80	105				
Day 14	12/05/93	37.00						47.40	130	80	80	125	80	85				
Day 21	19/05/93	37.00						47.40	150	90	83	140	85	80				
Day 28	26/05/93	37.00						47.00	135	80	85	115	75	88				
Day 35	02/06/93	37.00						47.00	130	75	90	120	60	100				
Day 42	09/06/93	37.00						47.50	120	60	85	95	50	110				
Day 49	16/06/93	37.00						47.20	150	80	80	125	70	95				
Day 56	23/06/93	37.00						47.00	140	70	80	130	70	80				

2450

9550089

26

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE									
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing D.B.P. (mmHg)	Heart Rate (beats/min)					
13	10T	Imipramine	Female	Screen	17/09/93	37.00	20	50.00	140	80	60	130	70	64				
				Day 0	23/09/93	36.80		52.80	140	80	60	145	80	60	60			
				Day 7	30/09/93	36.80		53.00	130	70	60	130	70	64	64			
				Day 14	07/10/93	37.00		53.00	130	80	80	140	90	84	84			
				Day 21	14/10/93	37.00		53.00	140	80	80	140	90	80	80			
				Day 28	21/10/93	37.00		52.00	145	80	72	140	88	72	72			
				Day 35	28/10/93	37.00		52.00	160	90	72	160	90	76	76			
				Day 42	04/11/93	36.80		53.00	140	80	72	140	80	76	76			
				Day 49	11/11/93	36.70		53.00	140	80	70	140	80	76	76			
				Day 56	18/11/93	37.00		52.00	140	80	64	140	80	70	70			
				14	10D	Reboxetine	Female	Screen	27/03/93	37.00	16	36.00	130	70	80	140	80	84
								Day 0	08/04/93	37.00		36.00	120	80	70	110	70	80
Day 7	15/04/93	37.00						38.00	110	70	68	100	60	68	68			
Day 14	22/04/93	37.00						38.00	120	80	72	130	90	80	80			
Day 21	29/04/93	37.00						36.00	120	80	72	130	90	80	80			
Day 28	06/05/93	36.80						37.00	140	80	62	130	70	62	62			
Day 35	13/05/93	37.00						37.00	140	80	68	140	80	72	72			
Day 42	20/05/93	37.00						36.00	130	80	68	140	90	72	72			
Day 49	27/05/93	37.00						37.00	130	80	64	120	70	68	68			
Day 56	03/06/93	37.00						37.00	130	80	70	140	90	74	74			
20	20T	Reboxetine	Female					Screen	13/10/93	37.00	16	50.00	160	80	80	160	80	88
								Day 0	22/10/93	36.20		50.60	170	100	88	170	100	88
				Day 7	29/10/93	36.50		51.00	160	80	80	150	80	80	80			
				Day 14	05/11/93	36.80		52.00	155	90	100	150	80	100	100			
				Day 21	12/11/93	36.80		53.00	170	100	110	170	100	110	110			
				Day 28	19/11/93	37.00		53.00	150	80	96	140	70	100	100			
				Day 35	26/11/93	37.00		53.00	140	80	90	140	80	90	90			
				Day 42	03/12/93	37.00		53.00	150	90	90	140	80	100	100			
				Day 49	10/12/93	37.00		53.00	140	80	88	130	70	100	100			
				Day 56	17/12/93	37.00		54.00	150	80	80	140	70	88	88			
				20	20D	Imipramine	Female	Screen	26/11/93	36.80	20	48.00	150	80	88	160	90	100
								Day 0	10/12/93	37.20		47.60	150	80	88	160	90	92
Day 7	17/12/93	37.20						47.00	140	80	80	150	80	84	84			
Day 14	24/12/93	36.80						44.60	150	90	80	140	80	80	80			
Day 21	31/12/93	37.00						44.60	140	90	92	150	100	100	100			
Day 28	07/01/94	37.20						48.00	110	70	96	120	80	100	100			
Day 35	14/01/94	37.40						41.10	120	80	100	110	70	108	108			
Day 42	21/01/94	36.80						40.00	140	80	88	130	70	100	100			
Day 49	28/01/94	37.00						41.80	140	80	80	120	60	100	100			
Day 56	04/02/94	37.20						40.00	140	80	80	140	70	88	88			

9550089

27

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE										
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing (beats/min)							
13	30F	Imipramine	Female	Screen	08/11/93	37.00	20	58.00	150	80	80	140	70	84					
				Day 0	09/11/93	37.00		58.20	150	80	80	150	80	80	80				
				Day 7	16/11/93	36.80		58.00	100	70	84	100	60	80	84				
				Day 14	23/11/93	36.80		58.00	130	90	80	140	80	80	84				
				Day 21	30/11/93	36.80		58.80	140	80	80	145	90	84	84				
				Day 28	07/12/93	37.00		59.00	140	80	80	140	80	84	84				
				Day 35	14/12/93	36.80		59.00	140	80	80	150	90	64	64				
				Day 42	21/12/93	36.80		58.60	140	80	80	140	80	84	84				
				Day 49	28/12/93	36.50		59.00	140	80	84	150	90	80	80				
				Day 56	04/01/94	37.00		59.00	140	80	80	150	90	80	84				
				14	30D	Imipramine	Male	Screen	28/01/94	37.00	18	77.00	150	80	80	160	90	94	
								Day 0	03/02/94	37.00		77.00	160	90	104	160	90	100	100
								Day 7	10/02/94	37.00		77.00	160	90	84	150	90	84	84
Day 14	17/02/94	36.80						77.00	140	80	80	140	80	84	84				
Day 21	24/02/94	37.00						77.00	170	100	100	160	100	100	100				
Day 28	03/03/94	37.00						77.50	160	90	100	160	90	100	100				
Day 35	10/03/94	37.00						79.40	160	100	100	160	100	100	100				
Day 42	17/03/94	36.80						79.20	160	80	90	150	70	100	100				
Day 49	24/03/94	37.00						79.00	160	90	84	150	80	80	80				
Day 56	31/03/94	37.00																	
14	10D	Reboxetine	Female					Screen	27/01/94	37.00	18	50.00	140	80	80	150	90	84	
								Day 0	03/02/94	37.00		50.00	150	90	70	140	80	80	72
								Day 7	10/02/94	36.80		51.00	140	80	70	150	90	74	74
				Day 14	17/02/94	36.80		50.80	140	80	80	140	80	80	80				
				Day 21	24/02/94	36.70		49.80	130	70	76	140	80	80	80				
				Day 28	03/03/94	37.00		50.00	150	90	80	140	80	84	84				
				Day 35	10/03/94	37.20		50.50	140	80	80	140	80	88	88				
				Day 42	17/03/94	36.50		51.00	140	80	80	150	90	84	84				
				Day 49	24/03/94	37.00		51.00	140	80	80	140	90	80	80				
				Day 56	31/03/94	37.00		51.00	150	90	80	160	100	90	90				
				15	10D	Reboxetine	Female	Screen	31/03/94	37.00	24	64.00	140	80	72	150	90	82	
								Day 0	05/04/94	36.80		63.50	140	80		150	80	80	80
								Day 7	12/04/94	37.00		63.80	135	75		140	80	80	80
Day 14	20/04/94	37.00						64.00	140	80	60	145	90	60	60				
Day 21	27/04/94	36.60						66.00	140	80	60	150	80	60	60				
Day 28	04/05/94	37.00						62.50	150	90	65	155	90	65	65				
Screen	19/07/93	37.20	25					68.00	140	70	60	130	70	65	65				
Day 0	26/07/93	37.00						68.00	150	80	60	140	75	70	70				
Day 7	02/08/93	36.80						68.00	160	80	66	150	80	70	70				

9550089

28

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 20.0
 VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE							
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	Heart Rate (beats/min)				
15	1DT	Reboxetine	Female	Day 14	09/08/93	36.60		68.00	160	80	62	140	70	70		
				Day 21	16/08/93	36.90		68.00	160	70	66	150	80	72	80	
				Day 28	23/08/93	36.90		68.00	140	80	66	150	80	80	80	
				Day 35	30/08/93	36.90		68.00	140	80	60	140	70	66	70	66
				Day 42	06/09/93	36.60		68.00	160	70	60	150	80	72	80	72
15	1DT	Reboxetine	Female	Day 49	13/09/93	36.80		68.00	150	70	72	140	60	80		
				Day 56	20/09/93	37.00		68.00	140	80	86	130	70	92	92	
				Screen	23/02/93	37.00		61.00	135	70	76	140	70	80	80	
				Day 0	01/03/93	37.10	24	61.00	140	70	76	130	70	80	80	
				Day 7	08/03/93	37.30		61.00	130	70	72	140	75	80	80	
21	2DT	Imipramine	Female	Day 14	15/03/93	37.40		61.00	130	90	72	130	70	76		
				Day 21	22/03/93	36.60		61.00	130	80	64	130	70	80	80	
				Day 28	29/03/93	36.70		61.00	150	90	82	140	85	88	88	
				Day 35	05/04/93	36.70		61.00	140	90	72	130	70	76	76	
				Day 42	13/04/93	37.00		61.00	160	100	76	140	80	80	80	
				Day 49	19/04/93	37.80		61.00	150	90	72	140	70	76	76	
				Day 56	26/04/93	36.80		61.00	150	90	76	130	80	80	80	
				Screen	07/02/94	36.80	18	83.00	140	90	72	160	90	80	80	
				Day 0	22/02/94	36.80		83.00	150	80	88	140	80	92	92	
				Day 7	01/03/94	36.90		83.00	120	70	80	120	70	86	86	
21	2DT	Imipramine	Female	Day 14	08/03/94	37.00		83.50	140	80	88	135	70	88		
				Day 21	15/03/94	36.80		83.50	140	80	80	140	70	84	84	
				Day 28	22/03/94	36.90		83.50	150	90	88	140	80	88	88	
				Day 35	29/03/94	36.90		84.00	160	80	80	150	80	88	88	
				Day 42	05/04/94	36.80		84.00	140	80	80	130	80	84	84	
				Day 49	12/04/94	37.10		84.00	120	80	84	120	70	84	84	
				Day 56	19/04/94	37.00		84.00	120	70	84	120	70	84	88	
				Screen	02/03/93	37.10		65.20	120	60	76	130	70	68	68	
				Day 0	24/03/93	37.00		65.20	140	90	72	130	90	72	72	
				Day 7	31/03/93	37.40		65.00	120	60	84	130	75	70	70	
21	2DT	Imipramine	Female	Day 14	08/04/93	36.70		65.00	120	60	76	140	80	84		
				Screen	03/05/93	37.00		44.00	130	75	72	120	70	80	80	
				Day 0	06/05/93	36.00		44.00	140	80	76	150	70	72	72	
				Day 7	13/05/93	37.20		44.00	160	80	80	150	70	88	88	
				Day 14	20/05/93	36.80		44.00	110	70	80	130	80	72	72	
				Day 21	27/05/93	37.00		44.00	120	60	72	130	60	80	80	
				Day 28	03/06/93	36.80		44.00	130	70	72	110	60	76	76	
				Day 35	10/06/93	37.00		44.00	120	60	76	130	65	80	80	
				Day 42	17/06/93	37.00		44.00	120	60	76	120	60	80	80	
				Day 49	24/06/93	36.80		44.00	140	80	76	130	70	80	80	
21	2DT	Imipramine	Female	Day 56	01/07/93	37.00		44.00	120	70	76	130	70	80		

9550089

29

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE								
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing					
15	4MD	Imipramine	Female	Screen	12/07/93	37.50	22	75.00	150	70	84	140	70	76			
				Day 0	15/07/93	37.50		75.00	160	70	84	140	70	80	80		
				Day 7	22/07/93	36.80		75.00	200	100	88	140	75	80	80		
				Day 14	29/07/93	36.80		75.00	150	80	96	145	75	92	86		
				Day 21	05/08/93	37.20		75.00	160	70	88	150	80	86	80		
				Day 28	12/08/93	36.60		75.00	140	80	72	130	70	80	80		
				Day 35	19/08/93	37.50		75.00	160	80	84	150	85	80	80		
				Day 42	26/08/93	37.20		75.00	140	90	72	130	90	76	76		
				Day 49	02/09/93	37.30		75.00	140	75	86	150	80	80	80		
				Day 56	09/09/93	37.40		75.00	150	100	72	130	90	70	70		
				11MD	Reboxetine	Female	Screen	05/10/93	36.70	18	61.00	130	70	72	130	70	76
							Day 0	08/10/93	36.80		61.00	130	70	72	130	60	76
							Day 7	15/10/93	36.50		61.00	130	70	68	125	60	72
							Day 14	22/10/93	37.00		61.00	125	70	68	120	60	76
							Day 21	29/10/93	36.80		61.00	130	80	72	120	70	76
112MD	Imipramine	Female	Screen				22/11/93	36.80	24	76.00	130	70	72	130	75	80	
			Day 0	29/11/93	36.90		78.00	140	80	80	140	70	84				
			Day 7	06/12/93	36.80		78.00	140	80	76	130	70	80				
			Day 14	13/12/93	36.80		78.00	135	80	72	135	75	80				
			Day 21	20/12/93	37.00		78.00	150	90	72	140	80	76				
			Day 28	27/12/93	36.80		78.00	140	80	82	130	80	86				
			Day 35	03/01/94	36.80		78.00	140	80	76	135	80	84				
			Day 42	10/01/94	36.90		79.00	170	90	76	160	90	84				
			Day 49	17/01/94	37.00		79.00	135	70	84	130	70	88				
			Day 56	24/01/94	36.90		79.00	145	70	76	140	60	80				
			16	Imipramine	Female	Screen	11/02/93	36.90		60.00	130	80	78	120	80	84	
						Day 0	17/02/93	36.90		60.00	130	80	84	120	80	94	
						Day 7	24/02/93	36.90		60.00	135	80	72	120	80	90	
						Day 14	27/02/93			59.50	125	80	80	120	75	84	
						Screen	11/02/93	36.80	26	50.00	150	70	72	140	90	68	
Day 0	17/02/93	36.90					50.00	140	60	64	160	60	68				
1MD	Reboxetine	Female	Day 7	24/02/93			50.50	140	80	68	120	60	74				
			Day 14	03/03/93			50.00	140	75	70	130	70	82				
			Day 21	10/03/93			50.00	145	80	68	135	70	72				
			Day 28	17/03/93			51.00	160	80	72	150	70	80				
			Day 35	24/03/93			51.00	140	80	76	130	75	76				
			Day 42	31/03/93			51.50	150	90	76	140	80	80				
			Day 49	07/04/93			51.00	145	80	70	150	80	76				
			Day 56	14/04/93			51.00	160	70	96	150	70	100				

9550089

30

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE																																					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing																																		
16	2DT	Reboxetine	Male	Screen	23/04/93	36.80	22	58.50	150	90	76	120	80	76																																
				Day 0	03/05/93										160	90	80	120	80	84																										
				Day 7	10/05/93										150	90	82	120	90	92																										
				Day 14	17/05/93										145	85	80	120	80	96																										
				Day 21	24/05/93										150	85	80	120	70	94																										
				Day 28	01/06/93										150	80	68	120	80	80																										
				Day 35	07/06/93										140	80	72	130	90	80																										
				Day 42	16/06/93										150	80	68	130	70	76																										
				Day 49	21/06/93										150	80	72	120	65	80																										
				Day 56	28/06/93										140	80	72	120	80	96																										
				2ND	2ND										Imipramine	Male	Screen	07/06/93	37.00	20	61.00	160	100	72	160	100	84																			
																	Day 0	16/06/93										160	80	72	130	80	84													
																	Day 7	24/06/93										150	100	68	130	80	64													
																	Day 14	08/06/93										130	70	84	105	80	88													
																	Day 21	05/05/93										160	90	64	130	90	92													
																	Day 28	12/05/93										120	70	84	90	60	96													
Day 35	22/05/93	130	70			68	100	70	72																																					
Day 42	28/05/93	130	90			80	115	80	88																																					
Day 49	02/06/93	140	80			76	120	70	84																																					
Day 56	09/06/93	110	80			72	130	90	80																																					
3DT	3DT	Imipramine	Female			Screen	21/07/93	36.90	19	70.00	160	90	88	150			80	72																												
						Day 0	28/07/93																					140	70	60	140	80	72													
						Day 7	04/08/93																					180	90	98	140	70	60													
						Day 14	10/08/93																					220	100	104																
						3ND	3ND																					Imipramine	Female	Screen	04/05/93	36.80	19	50.00	140	68	70	130	74	70						
																														Day 0	08/05/93										140	70	72	150	90	88
				Day 7	15/05/93										130	80			80	140	70	84																								
				Day 14	24/05/93										120	70			74	130	80	84																								
				Day 21	29/05/93										120	70			80	110	60	84																								
				Day 35	17/06/93										130	80			76																											
				4ND	4ND										Reboxetine	Female			Screen	12/04/94	36.80	20	57.00	150	85	76	160			80	80															
																			Day 0	18/04/94																					160	80	70	160	85	72
																			Day 7	25/04/94																					155	80	70	150	90	76
																			Day 14	02/05/94																					160	80	72	150	75	76
																			Day 21	09/05/94																					150	80	76	150	90	80
																			Day 28	16/05/94																					160	80	70	150	70	76
Day 35	24/05/94	150	80					72	160	75	84																																			
Day 42	30/05/94	160	80					70	155	85	82																																			
Day 49	06/06/94	150	80					76	150	90	84																																			

2455*

9550089

31

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE						
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing			
16	4HD	Reboxetine	Female	Day 56	13/06/94			57.00	160	80	76	150	80	86	
17	1DT	Reboxetine	Female	Screen	18/04/93										
				Day 0	28/04/93	37.10	16	54.00	150	90	70	160	90	80	
				Day 7	04/05/93	37.10		54.00	150	90	74	160	90	74	
				Day 14	11/05/93	37.00		54.00	150	90	76	160	90	77	
				Day 21	18/05/93	37.10		54.50	150	90	75	160	90	76	
1ND	Reboxetine	Female	Screen	23/03/93	36.80										
			Day 0	30/03/93	36.90	22	45.50	150	90	72	150	80	84		
			Day 7	06/04/93	36.80		45.50	160	100	75	155	90	75		
			Day 14	13/04/93	36.80		46.00	160	100	96	150	90	92		
			Day 21	20/04/93	36.70		46.00	125	85	84	105	65	105		
			Day 28	27/04/93	37.00		46.00	145	75	75	135	95	90		
			Day 35	04/05/93	36.90		44.00	145	80	65	130	80	80		
Day 42	11/05/93	37.10		44.00	130	85	92	140	80	92					
Day 49	18/05/93	37.00		43.00	150	90	84	140	80	88					
Day 56	25/05/93	36.90		43.00	130	90	92	140	85	104					
2DT	Reboxetine	Female	Screen	04/07/93	37.20										
			Day 0	07/07/93	37.10		58.00	150	80	80	160	80	90		
			Day 7	13/07/93	37.10		58.00	150	80	78	160	80	80		
			Day 14	21/07/93	37.20		58.00	150	90	80	150	80	82		
			Day 21	28/07/93	37.00		58.00	150	90	85	150	80	88		
			Day 28	04/08/93	37.20		58.00	150	80	80	150	90	88		
			Day 35	11/08/93	37.00		58.00	150	80	80	160	90	82		
Day 42	18/08/93	37.10		58.00	150	80	80	160	80	80					
Day 49	25/08/93	37.10		58.00	150	80	80	160	80	82					
Day 56	01/09/93	37.10		58.50	150	80	80	160	80	80					
2ND	Imipramine	Female	Screen	13/04/93	37.20										
			Day 0	20/04/93	37.20	17	56.00	170	100	82	170	90	84		
			Day 7	27/04/93	37.10		56.00	170	100	82	170	90	84		
			Day 14	04/05/93	37.10		56.00	170	100	84	170	90	84		
			Day 21	11/05/93	37.00		56.00	160	100	80	150	90	81		
			Day 28	18/05/93	37.10		56.00	170	100	80	160	90	81		
			Day 35	26/05/93	37.10		56.00	160	100	79	150	90	80		
Day 42	02/06/93	37.00		56.50	160	90	80	150	90	80					
Day 49	09/06/93	37.00		56.00	160	90	80	150	90	82					
Day 56	16/06/93	37.00		56.00	160	100	82	150	90	82					
3DT	Imipramine	Male	Screen	18/10/93	37.00										
			Day 0	18/10/93	37.00	16	77.00	160	80	64	170	80	64		
			Day 7	26/10/93	37.00		77.00	170	80	73	170	80	73		

2456

9550089

32

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE						
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing (beats/min)			
17	3DT	Imipramine	Male	Day 14	02/11/93	37.00		77.00	160	80	70	170	80	70	
				Day 21	09/11/93	37.00		77.00	160	80	70	160	80	70	70
				Day 28	16/11/93	37.00		77.00	160	80	72	170	80	80	72
				Day 35	23/11/93	37.00		77.00	160	80	68	160	80	68	80
				Day 42	30/11/93	37.00		77.00	170	80	66	170	80	66	80
				Day 49	07/12/93	37.00		77.00	170	80	68	170	80	68	80
	3MD	Imipramine	Female	Screen	25/10/93	37.20	24	45.00	130	70	60	120	70	75	
				Day 0	05/11/93	36.80		45.00	130	70	68	120	70	75	
				Day 7	12/11/93	36.90		45.00	130	70	80	140	70	80	
				Day 14	19/11/93	36.90		45.00	130	80	88	120	70	80	
				Screen	24/12/93	37.00	17	56.00	140	80	63	140	80	70	
				Day 0	19/01/94	37.00		56.00	140	80	63	140	80	64	
2457	4DT	Imipramine	Female	Day 7	26/01/94	37.00		56.00	148	80	72	150	80	74	
				Day 14	02/02/94	37.00		56.00	150	70	70	140	80	71	
				Day 21	09/02/94	37.20		56.00	140	80	70	140	80	72	
				Day 28	16/02/94	37.00		56.00	140	80	70	140	80	72	
				Day 35	23/02/94	37.00		55.50	140	80	71	150	80	74	
				Day 42	02/03/94	37.00		55.50	140	80	72	140	90	74	
				Day 49	09/03/94	37.00		55.50	140	70	72	140	70	72	
				Day 56	16/03/94	37.00		55.00	140	80	70	135	80	69	
				Screen	10/01/94	37.00	16	50.00	120	80	66	120	80	68	
				Day 0	12/01/94	37.00		50.00	120	80	66	130	80	68	
				Day 7	19/01/94	37.00		50.00	120	80	67	130	80	70	
				Day 14	26/01/94	37.20		50.00	110	70	68	120	80	70	
Day 21	02/02/94	37.00		51.00	120	80	68	120	80	70					
Day 28	09/02/94	37.00		51.00	120	80	70	120	80	71					
Day 35	16/02/94	37.00		51.00	120	80	70	120	80	75					
Day 42	23/02/94	37.00		51.00	130	80	71	130	80	70					
Day 49	02/03/94	37.00		51.00	120	80	69	120	80	70					
Day 56	09/03/94	37.00		51.00	120	80	65	120	80	68					
4MD	Reboxetine	Female	Screen	28/02/94	37.00		66.00	130	80	67	140	80	69		
			Day 0	05/04/94	37.00	18	66.00	130	80	67	140	80	68		
			Day 7	12/04/94	37.00		66.00	120	80	67	130	80	67		
			Day 14	19/04/94	37.00		66.00	120	80	67	130	80	67		
			Day 21	26/04/94	37.00		66.00	130	80	68	130	80	70		
			Day 28	03/05/94	37.00		66.00	120	80	66	130	80	67		
Day 35	10/05/94	37.00		66.00	130	80	68	130	80	70					
Day 42	17/05/94	37.00		66.00	130	80	66	130	80	66					
Day 49	24/05/94	37.00		66.00	130	80	70	130	80	70					
Day 56	31/05/94	37.00		66.00	140	80	76	140	90	78					

9550089

33

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	Standing Heart Rate (beats/min)		
17	211HD	Reboxetine	Female	Screen	10/05/94	37.00	18	52.00	130	80	65	120	80	63
				Day 0	19/05/94	37.00		52.00	130	80	63	130	80	65
				Day 7	26/05/94	37.00		52.00	130	80	64	130	80	64
				Day 14	02/06/94	37.00		52.00	130	80	64	140	82	66
				Day 21	09/06/94	37.00		52.00	130	80	64	140	80	66
				Day 28	16/06/94	37.00		52.00	130	80	64	140	80	61
				Day 35	23/06/94	37.00		52.00	130	80	66	130	90	68
				Day 42	30/06/94	37.00		52.00	120	80	65	120	80	66
				Day 49	07/07/94	37.00		52.00	120	80	65	120	90	65
				Day 56	19/07/94	37.00		52.00	120	80	65	120	80	65
18	1DT	Imipramine	Female	Screen	03/08/93	37.10	14	39.00	150	90	96	160	100	96
				Day 0	11/08/93	37.30		39.30	130	70	80	140	80	84
				Day 7	18/08/93	37.20		39.50	110	70	72	130	80	80
				Day 14	25/08/93	36.80		40.50	120	80	76	120	70	80
				Day 21	01/09/93	36.80		40.50	120	80	72	130	70	76
				Day 28	08/09/93	36.20		41.00	130	70	80	130	80	84
				Day 35	15/09/93	37.30		40.50	130	80	72	140	90	76
				Day 42	22/09/93	37.30		40.50	130	70	70	150	80	80
				Day 49	29/09/93	37.10		40.60	110	70	76	120	80	76
				Day 56	06/10/93	37.10		42.00	120	70	76	125	70	80
19	1ND	Imipramine	Female	Screen	18/05/93	37.00	16	64.00	130	80	72	110	70	84
				Day 0	26/05/93	37.00		64.00	130	80	72	110	70	84
				Day 7	02/06/93	36.90		63.00	110	60	84	100	60	79
				Day 14	09/06/93	37.50		62.50	120	80	74	120	50	73
				Day 21	16/06/93	36.80		61.50	130	80	76	140	90	74
				Day 28	23/06/93	36.60		61.00	130	80	72	120	80	88
				Day 35	30/06/93	36.90		60.00	150	70	68	160	60	76
				Day 42	07/07/93	36.80		60.00	140	80	72	130	70	74
				Day 49	14/07/93	36.90		60.10	160	90	76	150	100	80
				Day 56	21/07/93	37.00		60.20	150	90	70	120	90	76
20	2DT	Reboxetine	Female	Screen	04/11/93	37.10	16	55.00	160	90	100	160	80	104
				Day 0	08/11/93	36.50		55.00	160	90	98	135	80	92
				Day 7	15/11/93	36.60		55.00	140	90	92	120	80	96
				Day 14	22/11/93	36.80		55.40	150	90	88	140	100	84
				Day 21	29/11/93	36.50		55.40	120	80	88	120	70	84
				Day 28	07/12/93	37.00		54.00	160	90	100	155	100	104
21	2ND	Imipramine	Female	Screen	22/05/93	36.50	10	47.00	160	100	80	170	100	88
				Day 0	29/05/93	36.60		46.80	145	70	80	150	80	84
				Day 7	05/06/93	36.50		46.40	150	80	80	145	90	96

9550089

34

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R2D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing Heart Rate (beats/min)		
18	2HD	Imipramine	Female	Day 14	12/06/93	36.70		46.00	140	90	84	140	80	100
				Day 21	19/06/93	36.50		47.00	100	80	80	130	80	84
				Day 28	26/06/93	36.60		46.80	120	70	88	110	70	80
3HD	3HD	Reboxetine	Female	Screen	06/08/93	37.00	20	68.00	150	100	70	150	100	80
				Day 0	13/08/93	36.80		68.00	140	80	72	140	70	80
				Day 7	20/08/93	36.50		68.20	150	100	80	140	80	84
				Day 14	27/08/93	36.80		68.40	150	70	72	150	80	76
				Day 21	03/09/93	36.70		68.20	150	100	80	150	90	84
				Day 28	10/09/93	36.70		68.00	140	70	84	145	80	88
4HD	4HD	Reboxetine	Female	Day 35	17/09/93	36.90		68.20	160	100	88	160	90	84
				Day 42	24/09/93	37.10		68.50	140	70	68	145	80	72
				Day 49	01/10/93	37.20		68.40	150	100	76	150	90	80
				Screen	28/09/93	36.80	17	52.00	130	90	88	130	80	68
20	3HD	Reboxetine	Female	Day 0	02/10/93	36.90		52.00	110	70	76	120	80	
				Day 7	09/10/93	36.70		52.00	130	80	72	120	80	
				Day 14	16/10/93	37.00		52.00	110	50	70	130	70	
				Day 21	23/10/93	36.50		53.00	135	70	72	110	60	
				Day 28	30/10/93	36.60		53.00	135	80	72	110	60	
				Day 35	06/11/93	37.00		53.00	140	80	80	130	70	
22	1HD	Reboxetine	Female	Day 42	13/11/93	37.00		53.00	120	60	72	120	70	
				Day 49	20/11/93	36.70		53.00	130	80	72	120	70	
				Day 56	27/11/93	36.80		53.00	140	90	80	130	80	
23	1HD	Reboxetine	Female	Screen	02/07/93	37.00		53.00	130	70	80	130	70	
				Day 0	09/07/93	37.00		53.00	120	70	76	120	70	
				Day 7	16/07/93	37.00		53.00	105	70	76	105	70	
22	1HD	Reboxetine	Female	Screen	24/06/93	36.90		47.00	150	80	80	140	90	
				Day 0	24/06/93	36.50		46.00	150	90	72	110	60	
				Day 7	30/06/93	37.00		46.00	150	95	76	145	95	
23	1HD	Reboxetine	Female	Screen	28/01/93	36.90	15	58.90	150	90	72	140	90	
				Day 0	28/01/93	36.90		60.00	150	90	72	140	90	
				Day 7	05/02/93	37.20		58.80	140	80	72	125	80	
				Day 14	12/02/93	37.30		57.80	140	90	72	130	80	
				Day 21	19/02/93	37.00		58.00	140	80	72	120	80	
				Day 28	26/02/93	37.00		58.50	130	80	84	140	80	
23	1HD	Reboxetine	Female	Day 35	05/03/93	36.80		59.50	150	75	88	140	80	
				Day 42	12/03/93	37.10		60.70	130	80	76	120	80	
				Day 49	19/03/93	36.50		60.90	130	80	70	120	70	
				Day 56	26/03/93	36.50		61.50	130	80	70	135	70	

2459

9550089

35

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE											
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	Standing D.B.P. (mmHg)	Heart Rate (beats/min)							
23	2ND	Reboxetine	Female	Screen	28/01/93	36.90	15	63.00	150	90	80	160	80	88						
				Day 0	01/02/93	37.30		61.00	138	80	96	142	90	142	90	92				
				Day 7	08/02/93	37.40		63.80	130	90	80	140	95	140	95	80				
				Day 14	15/02/93	37.50		62.30	140	80	96	130	90	100	90	100				
				Day 21	22/02/93	37.40		62.30	140	80	96	160	90	100	90	104				
				Day 28	01/03/93	37.30		65.30	140	90	80	145	90	80	90	80				
				Day 35	08/03/93	36.70		65.50	135	75	76	120	80	88	80	88				
				Day 42	15/03/93	36.70		65.70	130	70	72	125	75	75	75	76				
				Day 49	22/03/93	37.40		63.90	155	90	72	145	95	95	145	88				
				Day 56	29/03/93	37.10		63.60	145	85	84	150	95	95	150	92				
				3ND	3ND	Imipramine	Female	Screen	18/03/93	37.30	15	49.00	120	70	100	130	80	104		
								Day 0	23/03/93	37.30		49.00	120	70	100	130	80	130	80	104
								Day 7	29/03/93	37.00		49.50	120	70	90	125	80	125	80	94
								Day 14	05/04/93	36.70		50.10	160	95	88	145	80	145	80	88
								Day 21	12/04/93	37.40		51.00	140	85	92	150	90	150	90	104
Day 28	19/04/93	37.60						51.50	130	90	96	150	100	150	100	96				
Day 35	26/04/93	37.60						51.20	130	90	100	140	80	140	80	115				
Day 42	03/05/93	37.00						51.50	150	80	84	150	90	150	90	88				
Day 49	10/05/93	37.00						52.00	130	70	88	160	100	160	100	96				
Day 56	17/05/93	36.90						52.20	140	80	90	145	90	145	90	96				
4ND	4ND	Imipramine	Female					Screen	19/03/93	37.00	15	74.00	130	80	86	135	80	88		
								Day 0	30/03/93	36.60		74.00	120	80	86	125	90	125	90	90
								Day 7	06/04/93	37.10		72.00	145	65	96	145	80	145	80	100
								Day 14	13/04/93	37.80		72.30	160	80	88	165	90	165	90	88
								Day 21	20/04/93	37.20		72.00	150	80	84	155	85	155	85	88
				Day 28	27/04/93	36.40		70.50	150	80	80	165	90	165	90	80				
				Day 35	04/05/93	37.60		70.20	125	75	84	140	80	140	80	84				
				Day 42	11/05/93	37.30		70.00	140	80	100	135	85	135	85	84				
				Day 49	18/05/93	36.80		70.00	160	80	80	140	80	140	80	80				
				Day 56	25/05/93	36.50		70.20	140	80	80	145	80	145	80	86				
				5ND	5ND	Imipramine	Female	Screen	24/04/93	37.00	15	64.00	120	80	96	140	80	100		
								Day 0	05/05/93	36.50		66.50	130	80	80	140	80	140	80	84
								Day 7	11/05/93	36.50		68.00	140	80	100	130	80	130	80	88
								Day 14	13/05/93	36.70		67.50	155	80	96	130	85	130	85	98
								6ND	6ND	Imipramine	Female	Screen	02/07/93	37.30	24	61.00	140	60	108	160
Day 0	05/07/93	37.60										61.40	175	100	76	160	90	160	90	80
Day 7	12/07/93	36.80										61.00	150	90	104	150	90	150	90	96
Day 14	19/07/93	36.70										61.10	160	95	100	160	95	160	95	92
Day 21	26/07/93	36.40										61.00	170	90	80	150	80	150	80	88

2460

9550089

36

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RD

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE						
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing Heart Rate (beats/min)			
23	6ND	Imipramine	Female	Day 28	02/08/93	36.30		61.40	160	95	96	170	90	92	
				Day 35	10/08/93	36.70		63.50	180	100	116	150	80	80	88
				Day 42	17/08/93	36.80		60.50	135	75	86	180	95	112	112
				Day 49	18/08/93	37.60		60.50	160	90	88	180	95	118	118
25	1ND	Reboxetine	Male	Screen	27/08/93	36.60	20	60.80	140	80	60	90	60	92	
				Day 0	27/08/93	36.60		60.80	140	80	60	90	60	92	
				Day 7	03/09/93	36.50		61.00	150	80	68	110	70	84	
				Day 14	10/09/93	36.20		59.90	130	80	64	100	70	80	
				Day 21	16/09/93	36.40		59.00	135	80	64	110	70	80	
				Day 28	24/09/93	36.00		58.30	130	80	68	130	80	78	
				Day 35	01/10/93	37.40		58.90	130	80	72	135	100	72	
26	2ND	Imipramine	Female	Screen	22/11/93	36.80	28	57.60	160	90	84	120	75	90	
				Day 0	26/11/93	36.80		57.60	135	80	94	130	75	96	
				Day 7	02/12/93	36.80		57.20	140	90	82	160	100	96	
				Day 14	09/12/93	36.80		57.20	120	70	72	140	90	80	
				Day 21	16/12/93	36.90		57.30	110	70	72	140	90	88	
				Day 28	23/12/93	36.80		56.80	110	70	80	130	90	92	
				Day 35	30/12/93	36.80		57.50	120	80	86	135	90	92	
				Day 42	16/01/94	36.70		56.90	110	70	76	130	80	80	
				Day 49	13/01/94	36.90		56.90	110	80	76	125	90	80	
				Day 56	21/01/94	36.70		57.10	110	80	80	130	95	104	
26	1DT	Reboxetine	Female	Screen	25/06/93	36.70	15	48.00	140	80	82	150	90	96	
				Day 0	28/06/93	36.80		48.00	130	80	96	140	90	104	
				Day 7	05/07/93	36.80		48.00	140	80	88	140	90	92	
				Day 14	12/07/93	36.80		48.10	140	80	92	150	90	96	
				Day 21	19/07/93	36.30		47.80	140	90	88	140	80	96	
27	1ND	Imipramine	Female	Screen	23/04/93	36.60	16	88.00	130	80	88	160	90	96	
				Day 0	26/04/93	36.40		82.00	140	80	86	150	90	92	
				Day 7	03/05/93	36.30		82.00	140	100	88	150	100	96	
				Day 14	10/05/93	36.30		83.40	130	80	84	150	100	92	
				Day 21	17/05/93	36.80		85.80	140	90	88	140	100	96	
				Day 28	24/05/93	36.30		85.30	140	90	82	150	100	86	
				Day 35	31/05/93	36.70		85.80	130	90	84	140	100	96	
				Day 42	07/06/93	36.70		85.80	150	90	84	140	100	96	
				Day 49	14/06/93	36.70		85.30	150	90	82	140	80	94	
				Day 56	21/06/93	36.70		85.30	150	90	82	140	80	94	
27	1ND	Imipramine	Male	Screen	01/02/93	36.40	16	60.50	170	100	84	175	100	90	

2461

9550089

37

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATA

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing		
27	1ND	Imipramine	Male	Day 0	02/02/93	36.00		61.80	130	100	92	150	90	92
				Day 7	09/02/93	36.40		61.30			110	70	60	120
28	1DT	Imipramine	Female	Screen	13/04/93	36.60	15	44.00	170	100	55	195	110	58
				Day 0	22/04/93	36.50		44.00	190	95	70	200	100	65
				Day 7	29/04/93	36.30		43.00	135	60	62	145	85	66
				Day 14	06/05/93	36.50		43.00	145	70	66	155	70	64
				Day 21	13/05/93	36.40		43.00	170	70	64	180	70	60
				Day 28	19/05/93	36.50		43.00	170	80	64	180	60	67
				Day 35	27/05/93	36.50		42.00	145	70	60	155	70	62
				Day 42	03/06/93	36.50		42.00	155	90	67	165	110	67
				Day 49	10/06/93	36.60		42.00	160	70	69	175	70	66
				Day 56	17/06/93	36.40		42.00	160	70	73	175	70	68
2462	1ND	Reboxetine	Female	Screen	13/04/93	36.50	16	86.50	165	85	64	150	110	68
				Day 0	20/04/93	36.30		86.50	135	80	70	140	90	72
				Day 7	27/04/93	36.70		86.50	140	90	71	145	100	76
				Day 14	04/05/93	36.60		85.00	140	75	79	150	80	84
				Day 21	11/05/93	36.30		86.00	140	75	80	150	80	84
				Day 28	18/05/93	36.50		85.00	150	80	64	160	80	70
				Day 35	25/05/93	36.40		86.00	120	70	68	130	70	72
				Day 42	01/06/93	36.70		86.00	125	70	69	135	75	73
				Day 49	08/06/93	36.50		85.00	125	70	62	170	74	66
				Day 56	15/06/93	36.40		85.00	135	70	70	140	70	76
2DT	2DT	Reboxetine	Male	Screen	20/04/93	36.40	14	68.00	150	70	62	160	80	64
				Day 0	27/04/93	36.70		68.00	140	75	70	157	88	73
				Day 7	04/05/93	36.70		69.00	150	90	86	160	100	91
				Day 14	11/05/93	36.50		69.00	115	90	110	120	92	120
				Day 21	18/05/93	36.60		69.00	170	123	64	140	103	101
				Day 28	25/05/93	36.40		69.00	125	90	100	130	100	106
				Day 35	01/06/93	36.60		69.00	170	100	78	180	110	85
				Day 42	08/06/93	36.40		69.00	155	100	94	160	111	90
				Day 49	15/06/93	36.60		68.00	150	95	94	155	100	98
				Day 56	22/06/93	36.30		68.00	135	105	92	140	110	95
2ND	2ND	Imipramine	Female	Screen	20/04/93	36.40	15	71.00	130	80	70	140	80	72
				Day 0	26/04/93	36.60		71.00	125	70	79	130	75	77
				Day 7	03/05/93	36.40		71.00	100	70	63	102	73	67
				Day 14	10/05/93	36.60		71.00	115	70	70	120	70	71
				Day 21	17/05/93	36.40		70.00	125	70	72	130	80	80
				Day 28	24/05/93	36.40		70.00	145	80	62	150	80	66
				Day 35	31/05/93	36.60		70.00	100	70	88	110	75	92
				Day 42	07/06/93	36.50		70.00	120	70	80	125	70	84
				Day 49	14/06/93	36.60		70.00	125	70	80	130	70	81

9550089

38

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 20.0
 VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing (beats/min)		
28	2ND	Imipranine	Female	Day 56	22/06/93	36.40		70.00	105	70	72	110	70	80
	3DT	Imipranine	Male	Screen	03/05/93	36.50	15	75.00	140	80	80	135	70	78
				Day 0	11/05/93	36.60		74.00	150	90	80	150	90	90
				Day 7	18/05/93	36.50		75.00	135	80	80	140	90	84
				Day 14	25/05/93	36.50		75.00	130	80	86	135	85	92
				Day 21	01/06/93	36.70		73.00	135	80	96	140	90	100
				Day 28	08/06/93	36.60		75.00	125	80	80	130	85	84
				Day 35	15/06/93	36.40		75.00	130	95	95	135	100	100
				Day 42	22/06/93	36.40		74.00	120	75	86	125	80	92
				Day 49	29/06/93	36.50		73.00	130	86	86	135	80	90
				Day 56	06/07/93	36.60		73.00	130	80	90	140	80	90
	3ND	Reboxetine	Female	Screen	20/04/93	36.40	15	85.00	190	100	90	200	110	93
				Day 0	27/04/93	36.40		83.00	170	90	82	180	100	89
				Day 7	04/05/93	36.60		84.00	140	85	94	145	90	97
				Day 14	11/05/93	36.60		83.00	135	80	100	140	90	108
				Day 21	18/05/93	36.50		83.00	155	95	90	160	100	97
				Day 28	25/05/93	36.30		83.00	140	90	86	150	100	91
				Day 35	01/06/93	36.30		82.00	145	95	90	150	100	96
				Day 42	08/06/93	36.40		82.00	150	90	90	155	90	99
				Day 49	15/06/93	36.60		82.00	165	95	98	170	100	102
				Day 56	22/06/93	36.60		81.00	145	95	90	150	100	98
	4ND	Imipranine	Male	Screen	26/04/93	36.60	15	78.00	100	60	72	110	70	76
				Day 0	04/05/93	36.60		76.00	135	75	79	140	70	82
				Day 7	11/05/93	36.50		76.00	135	72	79	121	56	79
				Day 14	18/05/93	36.70		76.00	152	83	68	124	60	76
				Day 21	25/05/93	36.30		76.00	105	60	62	110	70	66
				Day 28	01/06/93	36.50		76.00	100	60	58	110	60	60
				Day 35	08/06/93	36.40		77.00	120	60	80	125	70	83
				Day 42	15/06/93	36.50		77.00	115	60	62	120	60	67
				Day 49	22/06/93	36.50		76.00	135	70	70	140	70	76
				Day 56	29/06/93	36.40		75.00	125	75	70	130	80	75
	5ND	Reboxetine	Female	Screen	10/05/93	36.60	15	78.00	120	70	80	110	70	88
				Day 0	25/05/93	36.30		77.00	125	70	76	130	70	80
				Day 7	01/06/93	36.40		76.00	130	75	80	120	80	85
				Day 14	08/06/93	36.30		79.00	110	70	70	120	75	76
				Day 21	15/06/93	36.60		79.00	110	75	80	120	80	80
				Day 28	22/06/93	36.30		76.00	135	95	51	140	100	56
				Day 35	29/06/93	36.50		76.00	125	70	76	130	70	82
				Day 42	06/07/93	36.60		76.00	125	70	76	130	70	80
				Day 49	13/07/93	36.40		77.00	135	75	95	140	75	98
				Day 56	20/07/93	36.50		77.00	145	75	72	150	80	80

2463

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE								
									Lying			Standing					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)			
30	1HD	Inipramine	Female	Screen	13/04/93	36.40		45.40	192	110	88	170	98	96			
				Day 0	22/04/93	36.20		45.40	188	108	86	180	100	96	96		
				Day 7	29/04/93	36.50		47.90	188	108	86	148	98	94	94		
				Day 14	06/05/93	36.50		47.60	170	110	86	152	108	96	96		
				Day 21	13/05/93	36.50		48.00	172	106	100	154	100	82	82		
				Day 28	20/05/93	36.40		50.20	174	112	86	152	100	88	88		
				Day 35	27/05/93	35.50		50.00	182	108	96	158	118	84	84		
				Day 42	03/06/93	36.30		50.30	182	100	92	148	92	86	86		
				Day 49	10/06/93	36.50		49.00	182	104	84	152	98	90	90		
				Day 56	17/06/93	36.40		49.00	182	104	88	160	102	96	96		
				2ND	Reboxetine	Female	Screen	12/07/93	36.50		73.00	208	102	74	192	98	68
							Day 0	19/07/93	36.40		73.20	198	102	74	192	98	68
							Day 7	19/07/93	36.40		73.20	198	102	74	192	98	68
				3ND	Inipramine	Female	Screen	25/10/93	36.30	20	54.00	134	92	76	142	90	92
							Day 0	08/11/93	36.40		54.00	134	92	76	142	90	90
Day 7	15/11/93	36.60					54.00	182	98	84	148	102	96				
Day 14	22/11/93	36.40					54.00	158	100	87	150	102	94				
Day 21	29/11/93	36.60					54.20	160	102	88	150	102	94				
Day 28	06/12/93	36.40					54.30	154	102	86	142	96	90				
Day 35	13/12/93	36.70					54.50	156	102	86	142	96	94				
Day 42	20/12/93	36.50					55.20	158	102	88	146	98	96				
Day 49	27/12/93	36.40					55.20	158	98	82	146	96	90				
Day 56	04/01/94	36.40					55.20	158	98	82	146	96	90				
4ND	Reboxetine	Female	Screen				29/10/93	36.30	18	66.60	174	106	72	172	110	72	
			Day 0				02/11/93	36.60		65.20	178	106	72	170	108	74	
			Day 7				09/11/93	36.40		65.40	160	120	80	164	126	84	
			Day 14				16/11/93	36.40		65.00	172	106	84	164	120	84	
			Day 21				23/11/93	36.40		65.00	149	106	72	158	100	80	
			Day 28	30/11/93	36.50		65.00	162	120	82	166	124	84				
			Day 35	07/12/93	36.40		67.60	156	104	76	142	98	84				
			Day 42	14/12/93	36.50		66.70	168	104	68	154	100	74				
			Day 49	21/12/93	36.50		66.60	156	98	68	144	86	76				
			Day 56	28/12/93	36.20		69.20	160	96	72	164	112	84				
			5ND	Inipramine	Female	Screen	10/12/93	36.50	18	69.00	140	80	106	132	76	110	
						Day 0	17/12/93	36.40		68.30	138	90	109	132	76	114	
						Day 7	24/12/93	36.50		68.00	142	98	111	136	94	116	
			31	1DT	Reboxetine	Female	Screen	15/09/92	36.20	20	66.00	190	90	84	190	90	96
							Day 0	23/09/92	36.20		66.00	200	100	80	200	100	88

9550089

2464

9550089

40

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RSD

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (KG)	Sitting			Standing		
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
31	1DT	Reboxetine	Female	Day 7	30/09/92	36.60		65.00	175	100	116	170	100	116
				Day 14	07/10/92	36.40		64.50	180	80	100	190	90	104
				Day 21	14/10/92	36.50		64.50	180	90	84	180	100	96
				Day 28	23/10/92	36.50		64.00	170	80	96	160	80	100
	Day 35	28/10/92	36.00		64.00	160	80	100	155	80	104			
	1MD	Imipramine	Female	Screen	18/09/92	36.20	16	41.00	160	100	72	150	90	92
				Day 0	23/09/92	36.20		40.00	160	80	80	160	80	80
				Day 7	30/09/92	36.30		41.00	150	80	80	150	80	80
				Day 14	05/10/92	36.30		40.00	170	90	84	130	80	84
	2MD	Reboxetine	Female	Screen	26/11/92	36.20	20	46.10	160	80	80	155	80	80
				Day 0	02/12/92	36.90		45.10	88	80	88	76	76	
				Day 7	11/12/92	36.30		44.70	150	90	84	140	90	88
Day 14				18/12/92	36.60		45.00	140	70	92	135	70	92	
Day 21				24/12/92	36.60		44.70	140	75	92	135	70	92	
Day 28				01/01/93	36.20		45.70	130	70	84	120	70	88	
Day 35				11/01/93	36.00		45.70	150	70	94	150	80	94	
Day 42				18/01/93	35.20		45.00	150	80	92	150	80	104	
Day 49	26/01/93	35.80		46.00	140	80	88	135	80	92				
Day 56	08/02/93	35.80		45.00	160	80	92	160	90	92				
3MD	Imipramine	Male	Screen	01/12/92	36.20	20	68.00	160	80	96	150	70	96	
			Day 0	10/12/92	36.20		66.20	170	100	76	145	90	96	
			Day 7	17/12/92	36.20		66.00	150	90	120	120	70	100	
			Screen	15/03/93	37.00	16	75.00	150	90	90	150	90	75	
32	1MD	Imipramine	Female	Day 0	24/03/93	37.00		75.00	150	90	70	150	90	70
				Day 7	31/03/93	37.00		75.00	150	90	70	150	90	70
				Day 14	07/04/93	37.00		74.00	150	80	70	140	80	75
				Day 21	14/04/93	37.00		73.50	150	90	65	150	90	70
	Day 28	21/04/93	37.00		73.50	150	90	65	150	90	65			
	Day 35	29/04/93	37.00		74.00	150	80	75	150	80	70			
	Day 42	05/05/93	37.00		74.00	150	80	65	150	80	70			
	Day 49	12/05/93	37.00		74.00	160	90	70	150	80	75			
	Day 56	19/05/93	37.00		74.00	150	90	64	150	90	70			
	2MD	Imipramine	Female	Screen	02/04/93	37.00	18	75.00	165	85	75	160	80	75
				Day 0	14/04/93	37.00		75.00	148	80	72	130	80	72
				Day 7	21/04/93	37.00		73.50	130	80	80	110	70	85
Day 14				29/04/93	37.00		73.50	135	80	80	120	80	90	
Day 21	05/05/93	37.00		73.00	160	85	85	140	80	90				
Day 28	12/05/93	37.00		73.00	155	85	80	140	85	85				
Day 35	19/05/93	37.00		72.00	130	80	80	120	80	80				

2465

9550089

41

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE						
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing (beats/min)			
32	2ND	Imipramine	Female	Day 42	26/05/93	37.00		71.00	130	80	80	120	80	85	
				Day 49	01/06/93	37.00		74.00	140	90	84	130	90	88	88
				Day 56	09/06/93	37.00		73.00	140	80	80	120	80	90	90
	3ND	Reboxetine	Female	Screen	06/04/93	37.00	16	58.00	170	100	90	160	100	100	80
				Day 0	21/04/93	37.00		58.00	180	100	65	180	100	70	70
				Day 7	29/04/93	37.00			170	100	60	160	100	70	70
Day 14				05/05/93	37.00			170	100	68	160	100	70	70	
Day 21				12/05/93	37.00			155	90	72	150	90	80	80	
4ND	Reboxetine	Female	Day 28	19/05/93	37.00			140	80	70	130	80	70	70	
			Day 35	26/05/93	37.00			140	90	70	140	90	70	70	
			Day 42	01/06/93	37.00		60.00			120	80	76	110	90	76
			Day 49	09/06/93	37.00		59.50			130	80	68	120	80	75
			Day 56	16/06/93	37.00		59.50			150	90	64	140	90	70
5ND	Reboxetine	Female	Screen	03/09/93	37.00	18	57.00	130	80	80	130	80	80	80	
			Day 0	06/10/93	37.00		57.20	140	80	80	140	80	90	90	
			Day 7	13/10/93	37.00		57.20	150	80	85	160	90	95	95	
			Day 14	21/10/93	37.00		57.60	130	80	80	140	90	95	95	
			Day 21	27/10/93	37.00		57.20	140	80	80	150	90	90	90	
			Day 28	04/11/93	37.00		57.20	140	80	80	150	90	90	90	
6ND	Imipramine	Male	Screen	27/10/93	37.00	18	50.00	180	100	75	180	100	100	80	
			Day 0	02/11/93	37.00		50.00	180	100	70	180	100	80	80	
			Day 7	10/11/93	37.00		50.00	160	90	80	150	90	88	88	
			Day 14	17/11/93	37.00		50.00	180	100	80	170	100	88	88	
			Day 21	24/11/93	37.00		49.00	180	100	80	170	100	80	80	
			Day 28	01/12/93	37.00		50.00	170	100	80	160	100	80	80	
7ND	Imipramine	Male	Screen	06/10/93	37.00	18	99.00	170	100	75	165	100	100	90	
			Day 0	17/11/93	37.00		99.00	160	90	76	160	95	88	88	
			Day 7	24/11/93	37.00		99.00	150	100	75	150	100	85	85	
			Day 14	01/12/93	37.00		99.00	160	100	80	150	100	85	85	
			Day 21	08/12/93	37.00		99.00	170	100	72	160	100	80	80	
			Day 28	15/12/93	37.00		99.00	160	100	80	150	90	80	80	
35	Reboxetine	Female	Day 49	05/01/94	37.00		100.00	190	100	80	180	100	100	85	
			Day 56	12/01/94	37.00		100.00	150	80	75	140	85	80	80	
			Screen	02/03/93	36.50	20	72.00	110	70	80	135	90	80	80	
			Day 0	02/03/93	36.50		72.00	110	70	80	135	90	80	80	
			Day 7	09/03/93	36.70		71.00	160	75	76	150	70	72	72	
			Day 14	16/03/93	36.80		70.00	145	80	72	145	80	76	76	
35	Reboxetine	Female	Day 21	23/03/93	36.40		71.00	130	74	71	130	75	75		
			Day 28	30/03/93	36.60		69.00	70	72	140	80	72	72		
			Day 35	06/04/93	36.70		71.00	130	70	68	120	70	70		
			Day 42	13/04/93	36.70		71.00	130	70	68	120	70	70		

2466

9550089

42

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RAD
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 20.0
 VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
35	10T	Reboxetine	Female	Day 42	13/04/93	36.60		71.00	140	80	72	140	70	72
				Day 49	20/04/93	37.80		68.00	135	65	76	130	70	76
				Day 56	27/04/93	36.30		70.00	130	90	70	140	80	74
18D	Reboxetine	Female	Screen	25/01/93	36.80	20	57.00	130	80	64	110	60	72	
			Day 0	25/01/93	36.80		57.00	130	80	64	110	60	72	
			Day 7	01/02/93	36.80		58.00	120	60	68	115	55	72	
			Day 14	08/02/93	36.80		59.00	175	80	68	105	70	88	
			Day 21	15/02/93	36.80		59.50	150	60	72	125	70	76	
20T	Imipramine	Female	Screen	02/03/93	36.20	20	65.60	120	80	80	140	90	106	
			Day 0	02/03/93	36.20		65.60	140	80	80	140	90	106	
			Day 7	09/03/93	35.90		66.80	120	70	80	110	65	88	
			Day 14	16/03/93	36.20		65.00	145	70	92	125	70	92	
			Day 21	23/03/93	36.40		65.50	150	90	80	140	85	92	
			Day 28	30/03/93	36.60		66.00	150	90	76	140	85	80	
			Day 35	06/04/93	36.80		66.00	138	90	78	145	90	72	
28D	Imipramine	Female	Day 42	13/04/93	36.80		66.00	150	90	82	140	85	84	
			Day 49	20/04/93	36.80		65.50	135	85	84	135	85	92	
			Day 56	27/04/93	36.80		65.50	140	85	88	125	80	109	
			Screen	02/03/93	35.60	18	62.00	140	70	80	145	80	80	
			Day 0	02/03/93	35.60		62.00	140	70	80	145	80	80	
28D	Imipramine	Female	Day 7	09/03/93	36.30		61.00	110	60	76	120	60	80	
			Day 14	16/03/93	36.70		61.00	110	70	72	105	80	74	
			Day 21	23/03/93	37.00		62.00	120	70	80	120	75	80	
			Day 28	30/03/93	36.40		60.50	90	50	76	100	50	76	
			Screen	30/03/93	36.00	20	73.00	140	75	72	140	75	76	
30T	Imipramine	Male	Day 0	30/03/93	36.50		73.00	160	80	72	150	80	80	
			Day 7	06/04/93	36.80		74.00	130	80	88	120	90	96	
			Day 14	14/04/93	36.80		74.00	145	80	88	150	85	92	
			Day 21	21/04/93	36.60		74.00	155	85	92	138	80	100	
			Day 28	28/04/93	36.80		75.00	140	80	84	135	75	100	
			Day 35	05/05/93	36.80		76.00	152	88	92	140	88	100	
			Day 42	12/05/93	36.80		75.50	145	85	88	135	75	92	
38D	Imipramine	Female	Day 49	19/05/93	36.80		74.00	165	95	88	150	85	100	
			Day 56	26/05/93	36.80		74.00	125	80	96	135	80	96	
			Screen	29/03/93	36.00	20	69.00	130	80	88	160	100	90	
38D	Imipramine	Female	Day 0	29/03/93	36.00		69.00	130	80	88	160	100	90	
			Day 7	05/04/93	36.80		69.00	140	90	88	120	80	80	

2467

9550089

43

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 2012&/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing		
35	4DT	Reboxetine	Female	Screen	22/04/93	36.40	15	90.00	130	80	84	120	70	84
				Day 0	26/04/93	36.70		92.00	130	80	84	120	70	84
				Day 7	03/05/93	36.60		90.00	120	70	84	110	65	84
				Day 14	10/05/93	36.40		90.00	115	70	84	105	80	84
				Day 21	17/05/93	36.20		91.40	115	80	88	120	80	88
				Day 28	24/05/93	36.40		91.00	105	60	88	100	60	80
				Day 35	31/05/93	36.60		92.00	130	70	88	130	80	88
				Day 42	07/06/93	36.20		91.50	110	60	84	100	60	84
				Day 49	14/06/93	36.80		92.00	110	60	76	120	60	80
				Day 56	21/06/93	36.80		91.50	120	70	80	120	70	80
				Screen	16/04/93	36.00	12	56.50	120	70	104	150	75	110
				Day 0	19/04/93	36.00		57.00	120	70	104	150	75	110
Day 7	26/04/93	36.90		56.50	100	60	92	130	70	96				
Day 14	03/05/93	36.70		56.50	140	70	96	125	60	104				
Day 21	10/05/93	36.20		57.00	130	65	103	115	70	107				
Day 28	17/05/93	36.30		57.00	120	80	100	125	80	120				
Day 35	24/05/93	36.50		56.50	125	80	108	130	80	144				
Day 42	31/05/93	36.20		58.00	120	60	108	110	50	128				
Day 49	07/06/93	36.70		58.50	90	55	80	80	50	92				
Day 56	14/06/93	35.80		58.00	140	80	100	145	70	108				
50T	5DT	Imipramine	Female	Screen	01/09/93	36.80	19	62.00	150	90	64	130	90	60
				Day 0	01/09/93	36.80		62.00	150	90	64	130	90	60
				Day 7	08/09/93	35.50		62.00	120	80	64	110	70	64
				Day 14	15/09/93	36.10		62.00	170	110	64	165	110	64
				Day 21	22/09/93	36.50		63.00	135	80	68	120	80	76
				Day 28	29/09/93	35.90		61.00	150	80	72	130	100	72
				Day 35	06/10/93	35.50		63.00	160	100	72	150	90	80
				Day 42	13/10/93	36.10		62.00	130	70	76	110	90	76
				Day 49	20/10/93	35.20		61.50	150	95	72	130	100	68
				Day 56	27/10/93	34.00		61.00	140	90	76	130	90	76
				Screen	02/07/93	36.40	18	60.50	135	75	84	130	75	88
				Day 0	08/07/93	36.80		60.50	130	80	72	130	70	78
Day 7	15/07/93	36.70		59.00	105	70	104	120	60	100				
Day 14	22/07/93	36.00		61.00	155	80	84	110	70	96				
Day 21	29/07/93	36.40		60.00	120	75	88	120	65	84				
Day 28	05/08/93	36.50		63.20	125	70	74	110	80	88				
Day 35	12/08/93	36.00		61.00	110	60	80	100	60	80				
Day 42	19/08/93	36.50		60.00	130	80	80	130	80	80				
Day 49	26/08/93	36.40		62.00	140	80	88	160	90	88				
Day 56	02/09/93	36.60		62.00	140	80	96	140	80	96				
60T	6DT	Imipramine	Female	Screen	12/10/93	36.80	20	91.00	170	90	88	160	90	88
				Day 0	12/10/93	36.80		91.00	170	90	88	160	90	88

2468

9550089

44

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE						
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing (beats/min)			
35	6DT	Imipramine	Female	Day 0	19/10/93	36.80		91.00	160	90	76	155	90	80	
				Day 7	26/10/93	36.80		91.00	160	85	76	160	95	84	84
				Day 14	02/11/93	36.80		91.00	165	90	84	160	90	88	88
				Day 21	09/11/93	36.40		90.00	145	85	84	150	90	80	80
				Day 28	16/11/93	36.80		90.00	155	80	84	160	85	85	80
				Day 35	23/11/93	36.80		89.00	150	80	80	160	80	84	84
6ND	Reboxetine	Female	Screen	19/01/94	37.00	19	91.00	135	70	68	130	70	72		
			Day 0	20/01/94	37.00		91.00	130	70	72	130	70	78		
			Day 7	27/01/94	37.40		90.00	160	100	88	140	90	92		
			Day 14	03/02/94	36.90		91.00	125	90	100	155	90	100		
			Day 21	10/02/94	36.80		90.00	170	90	84	170	90	88		
			Day 28	17/02/94	36.80		87.00	180	110	88	180	110	100		
7DT	Reboxetine	Female	Screen	15/10/93	35.60	21	67.50	140	85	64	150	90	76		
			Day 0	19/10/93	34.60		67.50	110	70	60	125	70	68		
			Day 7	26/10/93	36.60		68.50	150	80	60	130	80	64		
			Day 14	02/11/93	34.80		71.00	130	70	64	140	80	68		
			Day 21	09/11/93	34.60		67.00	120	90	68	135	90	68		
			Day 28	16/11/93	36.80		69.00	130	80	68	125	70	64		
7ND	Imipramine	Female	Screen	08/12/93	36.00	20	82.00	135	80	88	130	80	88		
			Day 0	09/12/93	36.20		82.00	130	70	72	120	60	80		
			Day 7	16/12/93	36.50		81.00	130	80	72	120	70	92		
			Day 14	23/12/93	36.20		79.60	140	90	80	105	70	90		
			Day 21	30/12/93	36.40		80.00	145	80	72	110	70	80		
			Day 28	06/01/94	36.50		77.50	150	70	80	120	85	100		
8DT	Reboxetine	Female	Screen	10/01/94	36.10	19	98.00	120	70	76	120	80	68		
			Day 0	10/01/94	36.50		97.00	120	80	68	125	90	68		
			Day 7	17/01/94	37.00		96.40	135	65	76	110	60	88		
			Day 14	24/01/94	36.40		98.00	100	60	72	120	70	84		
			Day 21	31/01/94	36.60		98.00	110	70	78	120	60	76		
			Day 28	07/02/94	36.70		96.00	130	70	80	120	90	84		
8DT	Reboxetine	Female	Day 35	14/02/94	37.00		95.00	140	70	84	110	70	88		
			Day 42	21/02/94	36.60		96.00	120	75	84	105	70	88		
			Day 49	28/02/94	36.70		95.00	150	75	80	115	70	92		
			Day 56	07/03/94	36.70		95.00	130	70	96	120	70	104		

942 942

9550089

45

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 20.0
 VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE					
									lying	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing	S.B.P. (mmHg)
35	88D	Imipramine	Female	Screen	31/01/94	36.80	15	58.00	150	90	68	140	90	76
				Day 0	31/01/94	36.40		59.00	150	90	68	140	90	78
				Day 7	07/02/94	36.30		56.00	130	70	80	120	70	80
				Day 14	14/02/94	35.00		58.00	140	80	84	150	100	92
				Day 21	21/02/94	36.50		59.00	160	70	80	160	70	84
				Day 28	28/02/94	35.20		56.00	150	70	76	160	85	80
				Day 35	07/03/94	35.90		58.00	175	100	84	160	90	84
				Day 42	14/03/94	34.70		56.00	160	90	88	155	85	84
				Day 49	21/03/94	36.70		55.50	150	85	86	145	85	85
				36	10T	Imipramine	Female	Screen	29/01/93	36.60	16	78.40	180	100
Day 0	02/02/93	36.70						78.40	180	100	80	145	95	84
Day 7	09/02/93	36.60						78.20	160	95	84	140	95	82
Day 14	16/02/93	36.60						77.00	160	110	86	140	100	82
Day 21	23/02/93	36.50						77.00	170	100	92	150	100	88
Day 28	02/03/93	36.60						77.00	160	100	80	140	100	76
Day 35	09/03/93	36.50						77.00	120	70	60	100	60	90
Day 42	16/03/93	36.40						78.00	180	100	80	150	100	84
Day 49	23/03/93	36.60						78.00	180	100	86	160	100	76
Day 56	30/03/93	36.60						78.00	180	100	80	180	100	80
18D	Imipramine	Male	Screen	15/01/93	36.60	18	64.90	150	70	70	110	60	72	
			Day 0	15/01/93	36.60		64.90	150	70	70	110	60	72	
			Day 7	22/01/93	36.50		63.10	135	80	72	105	80	76	
			Day 14	29/01/93	36.70		62.30	120	70	70	105	80	79	
			Day 21	05/02/93	36.60		62.50	120	70	96	100	70	104	
			Day 28	12/02/93	38.00		62.70	100	70	104	80	50	96	
			Day 35	19/02/93	36.60		62.40	130	80	80	105	60	70	
			Day 42	26/02/93	36.20		62.40	130	70	88	125	50	80	
			Day 49	05/03/93	36.40		58.70	140	80	80	100	60	80	
			20T	Reboxetine	Female	Screen	18/02/93	36.50	16	72.00	150	90	70	140
Day 0	25/02/93	36.50					72.00	150	90	70	140	90	72	
Day 7	04/03/93	36.40					71.00	120	80	70	120	80	66	
Day 14	11/03/93	36.60					71.00	120	80	60	120	80	62	
Day 21	18/03/93	36.20					71.00	120	80	70	120	80	72	
Day 28	25/03/93	36.50					71.00	150	80	88	120	70	68	
Day 35	01/04/93	36.30					71.00	100	80	70	120	80	68	
Day 42	08/04/93	36.40					70.00	120	80	60	130	80	62	
Day 49	15/04/93	36.30					70.00	130	85	60	130	90	85	
Day 56	22/04/93	36.40					70.00	120	80	64	120	80	62	
28D	Reboxetine	Female	Screen	27/01/93	36.40	16	76.00	180	110	84	160	110	82	
			Day 56	22/04/93	36.40		76.00	180	110	84	160	110	82	

2470

9550089

46

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing		
36	2ND	Reboxetine	Female	Day 0	02/02/93	36.60		76.00	180	110	84	160	110	82
				Day 7	09/02/93	36.50		76.00	105	65	84	130	80	92
				Day 14	16/02/93	36.40		76.00	145	70	100	140	75	96
				Day 21	23/02/93	36.40		73.00	110	80	76	100	80	72
				Day 28	02/03/93	36.60		73.00	120	80	84	100	80	80
				Day 35	09/03/93	36.60		74.00	160	90	80	130	80	76
36	2ND	Reboxetine	Female	Day 42	16/03/93	36.30		75.00	120	80	76	130	90	80
				Day 49	23/03/93	36.60		75.00	110	70	68	120	85	68
				Day 56	30/03/93	36.40		75.00	130	90	70	130	90	74
				Screen	25/02/93	36.40	18	57.50	130	70	92	130	80	88
				Day 0	01/03/93	36.30		57.50	130	70	92	130	80	88
				Day 7	08/03/93	36.40		54.00	140	70	84	145	85	88
36	2ND	Reboxetine	Female	Day 14	15/03/93	36.40		58.00	110	60	74	120	60	82
				Day 21	22/03/93	36.60		58.00	130	75	84	130	80	84
				Day 28	29/03/93	36.30		58.00	130	80	80	130	80	76
				Day 35	05/04/93	36.30		58.00	150	90	72	150	90	76
				Day 42	12/04/93	36.60		57.00	120	80	60	100	70	82
				Day 49	20/04/93	36.60		57.00	140	90	60	140	90	64
36	2ND	Reboxetine	Female	Day 56	27/04/93	36.40		57.00	130	80	80	130	80	82
				Screen	01/02/93	36.50	18	45.00	150	70	92	130	80	96
				Day 0	05/02/93	36.50		45.00	150	70	92	130	80	96
				Day 7	12/02/93	36.20		44.00	130	50	88	130	65	92
				Day 14	19/02/93	36.60		45.00	190	110	78	160	90	82
				Day 21	26/02/93	36.40		46.00	140	80	78	120	75	80
36	2ND	Reboxetine	Female	Day 28	05/03/93	36.80		45.00	140	70	76	100	60	72
				Day 35	12/03/93	36.60		46.00	150	70	78	150	100	80
				Day 42	19/03/93	36.20		46.00	140	100	60	120	90	62
				Day 49	26/03/93	36.90		46.00	120	60	100	120	60	90
				Day 56	02/04/93	36.30		46.00	140	70	118	110	60	90
				Screen	04/03/93	36.60	14	59.50	160	100	70	160	100	72
36	2ND	Reboxetine	Female	Day 0	11/03/93	36.60		59.50	160	100	70	160	90	72
				Day 7	18/03/93	36.60		60.00	140	90	70	120	80	74
				Day 14	25/03/93	36.40		60.00	120	80	80	120	80	84
				Day 21	01/04/93	36.20		60.00	140	90	84	120	90	76
				Day 28	08/04/93	36.40		59.00	130	80	110	130	90	100
				Day 35	15/04/93	36.40		59.00	140	80	80	140	90	82
36	2ND	Reboxetine	Female	Day 42	22/04/93	36.60		59.00	140	80	84	130	95	80
				Day 49	29/04/93	36.60		59.00	160	105	78	130	105	80
				Day 56	06/05/93	36.30		59.00	140	90	90	140	90	90
				Screen	02/03/93	36.00	15	63.00	140	70	72	140	80	72
				Day 0	08/03/93	36.00		63.00	140	70	72	140	80	72

2471

9550089

47

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/03S
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
36	4MD	Reboxetine	Female	Day 7	15/03/93	36.00		63.00	125	70	74	140	70	78
				Day 14	22/03/93	36.80		63.00	130	70	78	130	75	78
				Day 21	29/03/93	36.80		62.50	125	80	84	125	85	84
				Day 28	05/04/93	36.30		62.50	130	90	84	140	80	76
				Day 35	12/04/93	36.60		62.50	135	80	72	125	85	80
				Day 42	19/04/93	36.60		62.50	145	80	72	130	80	84
				Day 49	26/04/93	36.40		62.00	150	90	60	150	90	58
Day 56	03/05/93	36.30		62.00	160	90	52	150	90	52				
5DT	5MD	Imipramine	Female	Screen	25/03/93	36.60	16	80.00	140	80	84	145	80	84
				Day 0	02/04/93	36.60		80.00	140	80	84	145	80	84
2472	5MD	Reboxetine	Female	Screen	20/04/93	36.80	18	78.00	160	90	88	150	85	84
				Day 0	23/04/93	36.80		78.00	160	90	88	150	85	84
				Day 7	30/04/93	36.20		77.00	150	95	88	150	80	88
				Day 14	07/05/93	36.40		77.00	140	90	72	150	90	80
				Day 21	14/05/93	36.60		77.00	160	90	76	145	90	80
				Day 28	21/05/93	36.60		77.00	165	95	86	145	95	80
				Day 35	28/05/93	36.60		77.00	160	90	80	130	80	82
				Day 42	04/06/93	36.70		77.00	160	90	80	140	90	82
				Day 49	11/06/93	36.60		77.00	150	100	86	140	90	105
				Day 56	18/06/93	36.30		77.00	150	95	102	140	90	100
6DT	6MD	Imipramine	Female	Screen	31/03/93	36.60	15	62.00	130	80	64	120	80	68
				Day 0	09/04/93	36.30		62.00	130	80	64	120	80	68
				Day 7	16/04/93	36.60		61.00	130	80	62	130	80	60
				Day 14	23/04/93	36.60		60.00	120	80	64	120	80	68
				Day 21	30/04/93	36.60		60.00	140	90	72	140	80	70
				Day 28	07/05/93	36.60		60.00	135	90	72	140	90	76
				Day 35	14/05/93	36.50		60.00	115	85	76	120	80	76
Day 42	21/05/93	36.30		60.00	120	85	72	110	85	70				
Day 49	28/05/93	36.40		60.00	135	95	76	140	90	76				
Day 56	04/06/93	36.30		60.00	140	90	76	140	90	74				
6MD	6MD	Imipramine	Female	Screen	29/04/93	36.10	16	74.30	150	90	80	130	85	82
				Day 0	30/04/93	36.60		74.30	150	90	80	130	85	82
				Day 7	07/05/93	36.40		75.00	140	90	80	130	90	82
				Day 14	14/05/93	36.80		75.00	120	85	84	110	85	86
				Day 21	21/05/93	36.60		74.00	120	80	76	110	80	76
				Day 28	28/05/93	36.60		74.00	125	85	70	110	80	72
				Day 35	04/06/93	36.40		74.00	140	90	90	130	80	92
Day 42	11/06/93	36.30		75.00	150	90	80	160	90	82				
Day 49	18/06/93	36.50		75.00	120	80	80	120	80	80				
Day 56	25/06/93	36.30		75.00	120	80	60	120	80	60				

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing Heart Rate (beats/min)		
36	7DT	Reboxetine	Female	Screen	15/04/93	36.30	17	59.00	170	70	88	160	70	86
				Day 0	30/04/93	36.30		59.00	170	70	88	160	70	86
				Day 7	07/05/93	36.30		59.00	150	80	96	140	80	92
7ND	Reboxetine	Female	Screen	03/05/93	36.70	16	50.00	115	60	72	110	65	84	
			Day 0	12/05/93	36.70		50.50	115	60	72	110	65	84	
			Day 7	19/05/93	36.20		50.70	110	60	72	100	60	96	
			Day 14	26/05/93	36.20		50.50	120	70	72	120	65	100	
			Day 21	02/06/93	36.60		50.50	110	60	62	105	65	86	
			Day 28	09/06/93	36.70		50.50	140	90	86	140	95	88	
			Day 35	16/06/93	36.20		53.00	130	80	80	130	80	85	
			Day 42	23/06/93	36.20		53.00	130	80	80	130	80	85	
			Day 49	30/06/93	36.60		52.00	120	55	82	110	35	86	
			Day 56	07/07/93	36.40		52.00	130	80	82	130	90	85	
			8DT	Reboxetine	Female	Screen	12/05/93	36.50	15	55.70	130	90	80	120
Day 0	19/05/93	36.60					55.70	130	90	80	125	90	80	
Day 14	26/05/93	36.60					56.60	130	95	70	125	95	72	
Day 21	04/06/93	36.30					56.50	130	80	82	125	80	86	
Day 28	11/06/93	36.60					56.50	150	90	80	130	90	78	
Day 35	18/06/93	36.50					56.50	140	80	80	140	80	76	
Day 42	25/06/93	36.60					56.50	130	80	66	130	80	66	
Day 49	02/07/93	36.50					56.50	140	80	68	140	80	68	
Day 56	09/07/93	36.40					59.00	145	75	88	140	80	84	
Day 63	16/07/93	36.40					59.00	135	80	92	140	80	83	
8ND	Imipramine	Female				Screen	07/05/93	36.40	14	104.00	140	90	66	140
			Day 0	25/05/93	36.60		104.00	140	90	66	140	90	68	
			Day 7	01/06/93	36.60		104.00	140	90	80	140	90	72	
			Day 14	08/06/93	36.40		104.00	140	90	80	140	90	84	
			Day 21	15/06/93	36.20		104.00	145	90	60	150	100	60	
			Day 28	22/06/93	36.40		104.00	120	80	62	120	80	64	
			Day 35	29/06/93	36.40		104.00	130	80	68	130	80	68	
			Day 42	06/07/93	36.20		104.00	150	90	64	150	90	62	
			Day 49	13/07/93	36.60		104.00	150	90	68	145	90	62	
			Day 56	20/07/93	36.30		108.00	155	90	80	140	90	92	
			9DT	Imipramine	Female	Screen	23/06/93	36.40	16	66.00	140	90	60	150
Day 0	28/06/93	36.50					66.00	140	90	60	150	90	58	
Day 7	05/07/93	36.40					66.00	150	100	66	130	90	65	
Day 14	12/07/93	36.40					67.00	130	85	68	130	90	72	
Day 21	19/07/93	36.50					67.00	140	85	68	145	90	68	
Day 28	26/07/93	36.40					67.00	160	95	66	150	95	66	

9550089

2433

9550089

49

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE						
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing			
36	90I	Imipramine	Female	Day 35	02/08/93	36.40		65.00	140	95	60	120	80	62	
				Day 42	09/08/93	36.40		65.00	120	80	60	120	80	80	65
				Day 49	16/08/93	36.40		65.00	120	80	64	120	80	80	66
	Day 56	23/08/93	36.60		64.00	100	64	125	90	66	66	66			
	90D	Reboxetine	Male	Screen	12/06/93	37.60	20	68.00	140	90	80	150	70	86	
				Day 0	15/06/93	37.60		68.00	140	90	80	150	70	80	
				Day 7	22/06/93	36.40		68.00	145	70	88	140	70	80	
				Day 14	29/06/93	37.20		69.10	150	70	76	160	80	72	
				Day 21	06/07/93	36.60		65.30	140	80	90	150	80	88	
Day 28				13/07/93	36.80		64.00	125	80	96	110	80	98		
Day 35				20/07/93	36.20		64.00	120	80	120	125	80	120		
Day 42				27/07/93	36.40		57.00	140	70	162	140	70	150		
Day 49				03/08/93	36.70		56.00	130	60	108	125	60	116		
Day 56	10/08/93	36.60		56.00	130	65	100	125	60	104					
100I	Reboxetine	Male	Screen	22/10/93	36.30	15	75.00	170	85	70	140	85	70		
			Day 0	25/10/93	36.30		75.00	170	85	70	140	85	70		
			Day 7	01/11/93	36.20		76.00	160	80	76	130	75	72		
			Day 14	08/11/93	36.00		73.00	140	80	76	130	70	75		
			Day 21	15/11/93	36.40		73.00	120	80	66	110	80	62		
			Day 28	22/11/93	36.20		73.00	120	80	60	110	80	60		
			Day 35	29/11/93	36.50		73.00	130	80	64	130	90	68		
			Day 42	06/12/93	36.40		73.00	130	80	66	130	80	66		
			Day 49	13/12/93	36.40		73.00	120	80	64	120	80	66		
Day 56	20/12/93	36.60		73.00	150	90	68	150	90	74					
100D	Reboxetine	Male	Screen	09/06/93	36.70	25	66.00	130	70	68	115	70	76		
			Day 0	21/06/93	36.70		66.00	130	70	68	115	70	76		
			Day 7	28/06/93	36.50		65.00	120	70	76	100	60	64		
			Day 14	05/07/93	36.50		65.00	100	80	66	100	80	64		
			Day 21	12/07/93	36.60		68.00	110	80	68	110	80	70		
			Day 28	19/07/93	36.60		68.00	110	70	72	110	70	68		
			Day 35	26/07/93	36.40		67.50	130	90	76	130	90	78		
			Day 42	02/08/93	36.60		67.50	120	80	76	120	80	72		
			Day 49	09/08/93	36.60		67.50	110	80	78	100	80	82		
Day 56	16/08/93	36.40		67.50	110	80	66	110	80	68					
110I	Reboxetine	Male	Screen	30/10/93	36.60	18	65.00	140	90	60	130	80	60		
			Day 0	09/11/93	36.60		65.00	140	90	60	130	80	60		
			Day 7	16/11/93	36.50		65.00	130	90	62	130	90	60		
			Day 14	23/11/93	36.40		64.00	120	80	80	130	80	86		
			Day 21	30/11/93	36.00		63.00	115	60	76	115	60	76		
			Day 28	07/12/93	36.60		63.00	120	80	64	120	80	66		
Day 35	14/12/93	36.50		63.00	150	80	60	120	80	62					

2474

9550089

50

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 20.0
 VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing Heart Rate (beats/min)		
36	11ND	Imipramine	Female	Screen	05/07/93	36.40	18	52.00	100	84	160	100	86	
				Day 0	08/07/93	36.40		52.00	100	84	160	100	86	
				Day 7	15/07/93	36.60		54.00	145	80	140	85	84	
				Day 14	22/07/93	36.30		53.00	130	90	120	90	88	
				Day 21	29/07/93	36.40		53.50	120	80	120	80	85	
				Day 28	05/08/93	36.40		53.00	120	80	120	80	90	
				Day 35	12/08/93	36.60		54.50	110	80	110	80	84	
12DT	12DT	Imipramine	Female	Screen	20/12/93	36.40	16	45.00	65	76	165	75	80	
				Day 0	21/12/93	36.40		45.00	60	76	165	75	80	
				Day 7	28/12/93	36.30		47.00	170	75	170	80	84	
				Day 14	04/01/94	36.50		48.50	148	60	145	70	92	
				Day 21	11/01/94	36.70		50.00	188	80	92	150	80	
				Day 28	18/01/94	36.10		49.00	160	70	140	65	80	
				Day 35	25/01/94	36.40		49.00	140	80	140	80	62	
12ND	12ND	Imipramine	Female	Screen	17/09/93	36.90	16	53.70	80	104	140	70	112	
				Day 0	23/09/93	36.90		53.70	150	80	140	70	112	
				Day 7	30/09/93	36.20		53.70	140	90	140	90	82	
				Day 14	05/10/93	37.40		54.00	180	90	180	90	105	
				Screen	17/09/93	36.60	16	53.00	170	110	88	120	90	80
				Day 0	20/09/93	36.60		53.00	170	100	88	120	90	80
				Day 7	27/09/93	36.20		50.00	160	80	80	100	80	80
14ND	14ND	Imipramine	Male	Screen	02/11/93	36.00	14	71.00	80	52	130	80	68	
				Day 0	02/11/93	36.00		71.00	148	80	130	80	68	
				Day 7	09/11/93	36.40		72.50	110	50	90	50	72	
				Day 14	16/11/93	36.20		72.00	135	85	72	120	80	
				Day 21	23/11/93	36.40		72.00	140	110	66	140	110	60
				Day 28	30/11/93	36.40		72.00	150	90	64	110	80	68
				Day 35	07/12/93	36.60		72.00	150	90	66	120	100	72
Day 42	14/12/93	36.60		72.00	150	100	60	140	110	60				
Day 49	21/12/93	36.40		72.00	140	90	60	120	90	60				

2475

9550089

51

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE					
									Lying			Standing		
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
36	14MD	Imipramine	Male	Day 56	28/12/93	36.40		75.00	140	90	64	140	90	64
15MD	Reboxetine	Female	Screen	15/10/93		36.20		60.50	190	70	80	130	75	88
			Day 0	22/10/93	16	36.20		60.50	190	70	80	130	75	88
			Day 7	29/10/93		36.40		60.00	170	90	80	150	80	82
			Day 14	05/11/93		36.60		60.00	140	70	80	140	70	82
16MD	Imipramine	Female	Screen	02/11/93		36.40		71.00	140	90	66	120	80	64
			Day 0	08/11/93	15	36.40		71.00	140	90	66	120	80	64
			Day 7	15/11/93		36.60		70.00	130	90	76	125	90	68
			Day 14	22/11/93		36.40		70.00	150	90	78	150	90	70
			Day 21	29/11/93		36.20		70.00	110	80	66	110	80	68
			Day 28	06/12/93		36.60		70.00	140	90	80	120	90	76
			Day 35	13/12/93		36.60		70.00	120	80	78	120	80	82
			Day 42	20/12/93		36.60		70.00	150	90	66	150	80	72
17MD	Reboxetine	Female	Screen	05/11/93		36.40		54.00	140	80	64	140	80	64
			Day 0	09/11/93	15	36.40		54.00	140	80	64	140	80	64
18MD	Imipramine	Female	Screen	11/01/94		36.60		69.00	150	90	120	140	90	100
			Day 0	12/01/94	18	36.60		69.00	150	90	120	140	90	100
			Day 7	19/01/94		36.40		69.00	140	70	100	110	70	104
			Day 14	26/01/94		36.60		70.00	150	80	84	120	60	98
			Day 21	02/02/94		36.60		70.00	140	80	100	100	65	88
			Day 28	09/02/94		36.60		70.00	150	90	88	100	70	92
			Day 35	16/02/94		36.60		70.00	110	60	88	150	80	84
			Day 42	23/02/94		36.80		70.00	140	80	100	110	60	80
19MD	Reboxetine	Female	Screen	14/01/94		36.60		55.00	150	90	70	120	80	66
			Day 0	14/01/94	16	36.60		55.00	150	90	70	120	80	66
20MD	Imipramine	Female	Screen	23/01/94		36.60		74.00	140	70	92	145	70	92
			Day 0	30/01/94	15	37.00		74.00	140	70	92	145	70	92
20MD	Imipramine	Female	Day 7	07/02/94		36.80		72.00	135	70	88	135	75	88
			Day 14	14/02/94		36.20		71.00	110	80	60	130	100	88
			Day 21	21/02/94		36.70		75.00	170	70	84	160	70	84
			Day 28	28/02/94		36.80		75.00	140	90	96	150	85	92
			Day 35	07/03/94		36.80		72.00	150	80	86	130	80	86

2476

9550089

52

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE						
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing			
36	20ND	Imipramine	Female	Day 42	14/03/94	37.10		73.00	140	80	90	130	80	96	
				Day 49	21/03/94	36.60		73.00	140	90	84	140	90	82	82
				Day 56	28/03/94	36.20		73.00	140	80	70	140	80	74	74
37	3ND	Reboxetine	Female	Screen	11/03/93	36.10	14	59.00	125	75	79	110	70	88	
				Day 0	18/03/93			59.00	140	80	95	130	80	95	95
41	1ND	Imipramine	Male	Screen	15/02/94	36.00	19	74.00	140	85	76	135	80	78	
				Day 0	22/02/94	36.80		73.50	135	80	76	130	80	72	72
				Day 7	01/03/94	37.00		73.00	135	80	75	135	75	74	74
2ND	Reboxetine	Male	Screen	18/02/94	37.00		57.00	140	65	60	135	65	64		
			Day 0	23/02/94	37.00		57.00	135	80	84	135	75	80	80	
			Day 7	02/03/94	36.80		58.00	130	80	76	130	80	78	78	
			Day 14	09/03/94	37.00		59.00	135	85	74	130	80	76	76	
			Day 21	16/03/94	36.80		60.00	135	80	74	130	80	76	76	
			Day 28	23/03/94	37.00		60.50	135	80	72	130	80	76	76	
			Day 35	30/03/94	36.90		60.50	135	85	74	135	80	78	78	
			Day 42	06/04/94	37.10		61.00	130	85	84	130	80	88	88	
			Day 49	13/04/94	36.80		60.50	130	80	82	130	75	84	84	
			Day 56	20/04/94	37.00		60.50	130	80	80	130	80	82	82	
3ND	Imipramine	Male	Screen	14/02/94	36.00		73.00	130	65	66	130	60	68		
			Day 0	25/02/94	36.50	17	73.00	130	70	68	130	65	70	70	
			Day 7	04/03/94	36.50		73.00	135	70	68	130	70	68	68	
			Day 14	11/03/94	36.80		72.50	130	75	70	130	70	74	74	
			Day 21	18/03/94	36.80		72.00	130	80	72	130	75	76	76	
Day 35	01/04/94	36.50		71.30	130	85	72	130	85	76	76				
Day 42	08/04/94	36.20		71.00	130	80	68	130	75	70	70				
Day 49	15/04/94	36.80		71.00	130	80	68	130	80	68	68				
4ND	Reboxetine	Male	Screen	21/02/94	37.00		77.00	125	65	68	125	65	66		
			Day 0	28/02/94	36.50	16	77.00	130	65	58	130	60	60	60	
			Day 7	07/03/94	36.50		76.50	135	65	60	130	65	60	60	
			Day 14	14/03/94	37.00		76.80	135	70	62	130	70	64	64	
			Day 21	21/03/94	36.80		76.70	130	75	60	130	70	62	62	
			Day 28	28/03/94	37.00		76.00	130	75	62	130	70	66	66	
			Day 35	04/04/94	36.90		75.60	130	80	58	130	75	58	58	
			Day 42	11/04/94	36.80		75.00	130	80	62	130	75	62	62	
			Day 49	18/04/94	37.00		74.00	135	85	60	130	85	60	60	
			5ND	Reboxetine	Male	Screen	18/02/94	36.80		72.00	135	85	82	130	80
Day 0	03/03/94	37.00				17	72.00	140	85	76	135	85	78	78	

2477

9550089

53

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RD
REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0
VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE						
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	Heart Rate (beats/min)			
41	5HD	Reboxetine	Male	Day 7	10/03/94	36.80		71.50	135	85	74	130	80	78	
				Day 14	17/03/94	37.00		71.20	140	85	76	135	80	78	78
				Day 21	24/03/94	36.80		71.00	135	85	76	130	85	76	76
				Day 28	31/03/94	36.80		69.70	130	80	74	130	80	76	74
				Day 35	07/04/94	36.90		69.50	135	80	72	135	80	74	74
				Day 42	14/04/94	37.00		69.50	135	85	72	130	80	76	76
				Day 49	21/04/94	36.80		69.50	130	85	70	130	80	80	72
				Screen	02/11/93	36.50	18	57.00	146	78	68	144	76	144	76
42	1DT	Imipramine	Female	Day 0	24/11/93	36.50		57.00	146	78	68	144	80	70	
				Day 7	01/12/93	36.40		56.50	144	74	70	142	74	70	
				Day 14	08/12/93	36.50		56.00	152	78	80	150	80	82	82
				Day 21	15/12/93	36.50		57.00	144	88	76	142	86	76	76
				Day 28	22/12/93	36.30		57.50	145	86	68	142	86	70	70
				Day 35	29/12/93	36.40		56.00	146	80	78	144	78	80	80
				Day 42	05/01/94	36.50		57.00	142	82	82	140	82	82	82
				Day 49	12/01/94	36.40		57.20	146	80	82	144	82	84	76
43	1ND	Imipramine	Female	Screen	12/10/93	36.50		71.80	146	78	70	144	78	68	
				Day 0	25/10/93	37.00	18	71.80	146	78	74	144	78	74	74
				Day 7	01/11/93	36.50		71.50	148	78	76	146	74	76	76
				Day 14	08/11/93	36.40		71.50	144	78	78	140	78	78	78
				Day 21	15/11/93	36.30		71.00	146	80	78	148	80	78	78
				Day 28	22/11/93	36.50		72.50	146	76	74	146	74	74	74
				Day 35	29/11/93	36.40		72.00	142	76	72	142	74	72	72
				Day 42	06/12/93	36.50		72.50	138	72	70	136	72	72	72
2DT	2DT	Reboxetine	Male	Screen	22/11/93	36.50	22	77.40	132	82	82	130	80	78	
				Day 0	08/12/93	36.50		78.10	138	76	78	136	78	80	80
				Day 7	15/12/93	36.30		78.00	140	78	76	138	78	76	76
				Screen	12/10/93	36.40	14	52.00	142	72	80	142	70	78	78
2ND	2ND	Reboxetine	Female	Day 0	25/10/93	36.40		52.00	138	72	74	138	72	74	
				Day 7	01/11/93	36.40		52.00	142	76	76	140	74	74	74
				Day 14	08/11/93	36.00		51.50	144	74	76	142	74	74	74
				Day 21	15/11/93	36.40		51.40	140	76	72	142	76	72	72
				Day 28	22/11/93	36.50		52.00	144	78	74	146	80	74	74
				Day 35	29/11/93	36.40		52.00	142	76	76	144	76	76	76
				Day 42	06/12/93	36.50		52.50	144	78	76	144	78	78	78
				Day 49	13/12/93	36.40		54.50	140	70	82	142	72	80	80

9550089

54

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE						
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing Heart Rate (beats/min)			
42	3MD	Imipramine	Male	Screen	02/11/93	36.50	22	87.20	148	82	80	146	80	84	
				Day 0	24/11/93	36.50		87.50	148	80	78	146	80	82	82
				Day 7	01/12/93	36.50		87.00	146	78	78	146	78	78	78
				Day 14	08/12/93	36.30		87.50	144	74	78	144	74	74	78
				Day 21	15/12/93	36.50		88.00	146	76	76	146	76	76	76
				Day 28	22/12/93	36.30		88.00	144	72	74	142	72	74	74
				Day 35	29/12/93	36.50		88.00	148	80	80	146	80	80	80
				Day 42	05/01/94	36.50		88.00	146	80	80	146	80	80	80
				Day 49	12/01/94	36.30		88.50	146	82	78	144	80	78	78
				Day 56	19/01/94	36.00		88.60	152	82	78	148	80	80	80
43	1DT	Reboxetine	Female	Screen	19/02/93	36.90	13	60.00	164	90	78	148	90	78	
				Day 0	19/02/93	36.90		60.00	164	90	78	148	90	78	
				Day 7	26/02/93	37.00		58.50	150	84	80	144	84	84	
				Day 14	05/03/93	36.80		58.00	150	90	82	154	92	86	
				Day 21	12/03/93	36.90		56.50	144	94	80	140	94	80	
				Day 28	19/03/93	37.00		55.50	136	90	84	152	90	80	
				Day 35	26/03/93	36.90		55.00	142	90	78	140	86	82	
				Day 42	02/04/93	37.00		55.00	144	92	80	138	86	84	
				Screen	10/05/93	36.80		59.00	166	98	84	164	98	84	84
				Day 0	11/05/93	36.80		59.00	166	98	84	164	98	84	84
Day 7	18/05/93	36.90		58.50	166	100	78	168	100	78	78				
Day 14	25/05/93	37.00		59.00	160	100	80	164	100	84	84				
Day 21	01/06/93	37.00		57.50	150	86	84	146	90	88	88				
3DT	Imipramine	Male	Screen	15/09/93	36.80	15	94.00	130	80	76	132	80	78		
			Day 0	15/09/93	37.90		94.00	130	80	76	132	80	78		
			Day 7	22/09/93	37.00		93.50	120	76	80	110	70	80		
			Day 14	28/09/93	36.90		92.50	116	80	82	116	80	84		
			Day 21	05/10/93	36.80		94.00	125	75	84	115	65	90		
			Day 28	13/10/93	36.90		94.00	130	80	80	120	85	84		
			Day 35	20/10/93	37.00		94.00	120	84	82	114	80	84		
			Day 42	27/10/93	37.00		93.50	120	84	86	110	70	86		
			Day 49	03/11/93	37.00		93.00	130	90	82	110	80	88		
			Day 56	10/11/93	36.90		95.00	120	75	76	110	65	84		
4DT	Reboxetine	Female	Screen	23/09/93	36.80	14	80.00	170	80	82	164	80	82		
			Day 0	23/09/93	36.80		80.00	170	80	82	168	84	82		
			Day 7	30/09/93	36.90		80.00	164	84	76	160	84	80		
			Day 14	07/10/93	36.90		80.00	160	82	76	160	84	80		
			Day 21	14/10/93	37.00		80.50	164	84	80	160	84	82		
			Day 28	21/10/93	36.90		80.00	160	84	78	164	84	80		
			Day 35	28/10/93	36.80		81.00	166	82	80	162	80	80		
			Day 42	04/11/93	36.90		81.00	164	84	78	164	82	80		

2479

9550089

55

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE									
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing						
43	40T	Reboxetine	Female	Day 49	11/11/93	37.00		81.00	164	84	80	164	80	80				
				Day 56	18/11/93	37.00		81.00	166	84	80	166	84	80				
	50D	Imipramine	Female	Screen	10/12/93	36.80	16	55.00	136	86	84	134	86	84				
				Day 0	10/12/93	37.00		55.00	150	86	82	150	82	82				
				Day 7	17/12/93	37.00		54.50	140	96	88	110	90	88				
				Day 14	24/12/93	37.00		54.50	144	86	80	142	86	80				
				Day 21	31/12/93	36.90		54.00	120	80	84	104	80	84				
	Day 28	07/01/94	37.00		54.00	110	80	86	90	70	90							
	Day 35	12/01/94	37.00		53.00	154	90	86	150	90	82							
	44	60D	Imipramine	Female	Screen	16/02/94	36.90	14	65.00	124	70	78	112	70	88			
Day 0					16/02/94	36.90		65.00	124	70	78	112	70	88				
Day 7					23/02/94	36.80		64.00	110	70	80	104	70	80				
Day 14					03/03/94	37.00		64.50	114	70	80	102	74	82				
Day 21					11/03/94	36.90		63.00	114	70	80	90	60	82				
Day 28					17/03/94	36.90		66.00	100	60	78	90	60	78				
Day 35					24/03/94	36.90		67.00	116	70	78	110	60	78				
Day 42					31/03/94	36.80		67.00	104	60	78	90	60	80				
Day 49					07/04/94	36.80		67.00	114	72	82	108	70	82				
Day 56					14/04/94	36.90		66.50	108	76	84	100	72	86				
44	10T	Reboxetine	Female	Screen	30/07/93	36.50	20	61.70	128	70	84	128	80	84				
				Day 0	30/07/93	36.50		61.70	128	70	84	128	80	84				
				Day 7	06/08/93	35.50		63.30	130	80	80	120	80	80				
				Day 14	13/08/93	36.50		63.60	120	75	78	115	75	78				
				Day 21	20/08/93	37.00		63.00	150	75	92	120	70	88				
				Day 28	27/08/93	37.00		62.50	140	75	96	120	70	96				
				Day 35	03/09/93	36.80		62.00	135	65	83	125	70	96				
				Day 56	06/10/93	36.70		61.70	140	100	74	140	80	80				
				44	10D	Reboxetine	Female	Screen	02/09/93	37.00	20	71.00	165	80	88	175	83	88
								Day 0	02/09/93	37.00		71.00	165	80	88	175	83	88
Day 7	09/09/93	36.50						70.10	178	98	88	150	90	92				
Day 21	23/09/93	36.60						70.00	130	80	75	130	75	75				
Day 28	30/09/93	37.00						70.00	160	90	84	150	80	84				
Day 35	07/10/93	37.00						70.00	140	110	96	140	90	96				
Day 42	14/10/93	37.00						70.00	150	95	96	150	93	92				
Day 49	21/10/93	37.00						70.00	125	80	72	125	80	72				
Day 56	28/10/93	37.30						70.00	160	98	78	160	90	82				
44	20D	Reboxetine	Female					Screen	17/09/93	36.20	22	73.85	190	130	88	160	100	92
				Day 0	17/09/93	36.20		73.80	190	130	88	160	100	92				
				Day 7	27/09/93	36.90		75.50	130	70	88	130	65	85				

2480

9550089

56

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R8D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE						
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing			
44	2ND	Reboxetine	Female	Day 14	04/10/93	37.00		73.80	150	80	80	155	85	80	
				Day 21	11/10/93	36.80		73.00	150	80	80	155	80	80	80
				Day 28	18/10/93	36.40		75.00	170	100	80	150	90	88	88
				Day 35	25/10/93	36.80		75.00	130	70	88	120	88	88	88
				Day 42	01/11/93	37.00		75.00	130	70	92	120	86	86	86
				Day 49	08/11/93	36.00		73.00	150	100	90	160	90	84	84
44	3ND	Imipramine	Female	Day 56	15/11/93	35.50		72.60	140	90	90	160	90	90	
				Screen	12/10/93	37.50	21	64.15	160	120	74	160	110	82	82
				Day 0	14/10/93	37.00		64.20	160	120	76	160	108	84	84
				Day 7	21/10/93	37.00		66.50	140	80	88	120	80	96	96
				Day 21	06/11/93	36.80		68.00	120	90	92	115	76	100	100
				Day 28	13/11/93	36.80		63.80	140	90	90	130	100	84	84
44	4ND	Imipramine	Male	Day 35	18/11/93	36.80		64.00	122	84	88	122	82	100	
				Day 42	25/11/93	37.10		64.00	120	78	76	140	78	96	96
				Day 49	02/12/93	36.80		63.30	115	75	90	145	80	100	100
				Day 56	09/12/93	36.80		62.80	115	75	96	100	75	100	100
				Screen	24/01/94	36.70	30	65.30	140	80	74	150	100	72	72
				Day 0	31/01/94	36.60		69.00	140	80	72	140	80	72	72
45	1DT	Imipramine	Female	Day 7	07/02/94	36.40		67.40	150	80	70	150	90	70	
				Day 14	14/02/94	36.80		68.40	122	72	68	102	72	68	68
				Day 21	21/02/94	36.80		67.50	120	80	82	120	60	82	82
				Day 28	28/02/94	37.00		67.50	140	70	88	110	70	88	88
				Day 35	07/03/94	36.80		70.40	118	70	68	105	70	76	76
				Day 42	14/03/94	37.00		67.00	110	80	76	130	80	80	80
45	45	Imipramine	Female	Day 49	21/03/94	36.00		66.50	100	50	88	98	50	90	
				Day 56	28/03/94	37.00		67.00	130	70	70	110	70	70	70
				Screen	08/07/93	36.60	14	56.50	140	90	76	140	95	80	80
				Day 0	11/08/93	36.40		57.90	150	85	72	150	50	72	72
				Day 7	18/08/93	37.10		58.10	150	85	88	115	75	100	100
				Day 14	25/08/93	37.00		57.20	155	85	72	140	90	90	90
45	1ND	Reboxetine	Male	Day 21	01/09/93	37.10		58.30	165	95	88	120	80	88	
				Day 28	08/09/93	36.30		57.40	125	85	92	110	80	96	96
				Day 35	15/09/93	36.20		57.40	140	80	80	115	80	88	88
				Day 42	22/09/93	36.80		57.70	140	90	92	120	80	90	90
				Day 49	29/09/93	36.40		58.10	160	90	80	125	85	92	92
				Day 56	06/10/93	36.80		57.70	150	90	88	140	90	90	90
45	1ND	Reboxetine	Male	Screen	11/11/93	35.60	14	78.00	130	80	70	130	80	70	
				Day 0	25/11/93	36.60		74.90	140	80	80	140	90	80	80
				Day 7	02/12/93	37.00		77.60	150	85	80	115	75	88	88
				Day 14	09/12/93	36.60		74.50	150	90	80	140	90	80	80
45	1ND	Reboxetine	Male	Day 21	16/12/93	37.00		74.50	150	90	80	125	80	80	
				Day 21	16/12/93	37.00		74.50	150	90	80	125	80	80	80

2401

9550089

57

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE						
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing Heart Rate (beats/min)			
45	1ND	Reboxetine	Male	Day 28	24/12/93	37.00		75.40	170	90	80	130	80	88	
				Day 42	06/01/94	37.00		75.60	130	90	80	130	90	80	72
				Day 56	20/01/94	37.00		77.90	150	90	68	145	90	80	88
2ND	1ND	Imipramine	Male	Screen	24/11/93	37.00	18	55.00	130	70	80	130	70	80	
				Day 0	07/12/93	37.00		54.90	135	85	82	130	75	88	
				Day 14	21/12/93	37.00		47.90	120	65	100	120	55	120	
46	1ND	Imipramine	Male	Screen	21/09/93	36.80	18	113.00	135	80	72	165	85	68	
				Day 0	28/09/93	36.60		113.00	130	75	82	135	75	78	
				Day 7	05/10/93	36.80		112.00	125	75	80	130	75	80	
				Day 14	12/10/93	36.60		111.00	125	80	76	125	75	80	
				Day 21	19/10/93	36.80		110.00	105	80	62	110	65	86	
				Day 28	26/10/93	36.80		109.00	125	80	64	131	82	80	
				Day 35	02/11/93	36.80		110.00	120	85	62	125	85	86	
				Day 42	09/11/93	36.80		110.00	120	85	64	120	85	82	
				Day 56	23/11/93	36.80		112.00	138	95	70	135	84	66	
				2ND	1ND	Imipramine	Female	Screen	13/10/93	36.60	18	54.00	125	80	74
Day 0	16/10/93	36.60						53.50	120	80	76	125	85	78	
Day 7	27/10/93	36.60						53.00	130	85	82	125	85	78	
Day 14	01/11/93	36.60						54.00	120	85	78	120	80	76	
Day 21	09/11/93	36.60						55.00	125	85	78	125	85	82	
3ND	1ND	Reboxetine	Female	Screen	25/11/93	36.60	21	60.20	125	75	75	125	75	54	
				Day 0	02/12/93	36.60		60.00	130	80	67	130	80	72	
				Day 7	09/12/93	36.80		60.00	135	80	106	130	80	98	
				Day 14	16/12/93	36.60		60.20	125	85	96	130	80	94	
				Day 21	23/12/93	36.40		61.00	125	85	84	130	80	86	
				Day 28	30/12/93	36.60		60.50	125	80	86	125	75	82	
				Day 35	06/01/94	36.80		60.00	125	75	80	125	80	84	
				Day 42	13/01/94	36.80		60.50	130	70	80	125	75	78	
				Day 49	20/01/94	37.00		60.50	130	70	80	125	80	84	
				Day 56	27/01/94	36.60		60.50	125	80	80	120	80	78	
4ND	1ND	Reboxetine	Female	Screen	03/12/93	36.80	18	45.30	125	75	87	125	80	85	
				Day 0	08/12/93	36.60		45.00	130	85	85	130	90	87	
48	1DT	Reboxetine	Female	Screen	16/06/93	36.90	18	41.70	136	90	80	140	70	84	
				Day 0	23/06/93	36.00		40.30	140	74	90	140	76		

2402

9550089

58

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE					
									Lying		Standing			
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
48	2DT	Imipramine	Female	Screen	25/06/93	36.60	22	73.60	148	80	80	150	84	86
				Day 0	28/06/93	36.80		73.60	140	90	86	140	88	86
				Day 7	05/07/93			73.20	150	95	86	148	88	88
				Day 14	12/07/93			72.50	150	98	86	148	96	86
				Day 21	19/07/93			72.00	155	100	80	148	94	86
				Day 28	26/07/93			70.00	150	100	82	146	96	84
Day 35	02/08/93			68.30	160	100	80	130	90	86				
Day 42	05/08/93			66.90	165	85	96	140	85	112				
291	1DT	Reboxetine	Female	Screen	21/04/93	37.00	17	80.00	130	85	80	128	85	100
				Day 0	22/04/93			81.00	130	84	90	130	86	92
				Day 7	29/04/93			81.00	150	100	88	150	89	92
				Day 14	06/05/93			81.00	160	100	88	150	100	90
				Day 21	13/05/93			81.00	150	100	80	145	85	80
				Day 28	20/05/93			81.00	165	80	84	146	84	86
Day 35	27/05/93			81.00	146	82	80	144	80	82				
Day 42	03/06/93			81.40	136	80	80	128	80	84				
Day 49	10/06/93			81.40	139	80	82	130	80	80				
Day 56	16/06/93			81.50	125	84	84	130	84	86				
248	1HD	Imipramine	Female	Screen	19/03/93	37.00	16	51.00	120	80	76	118	80	78
				Day 0	22/03/93			51.00	130	80	72	125	84	70
				Day 7	29/03/93			51.00	130	84	70	124	84	74
				Day 14	05/04/93			51.20	132	80	68	130	75	74
				Day 21	13/04/93			51.50	120	80	68	115	84	76
				Day 28	19/04/93			51.40	124	82	70	120	84	74
Day 35	26/04/93			37.00		80	72	125	80	80				
201	2DT	Reboxetine	Female	Screen	01/04/93	36.80	18	80.00	150	85	80	155	84	84
				Day 0	22/04/93			80.40	155	85	88	150	83	93
				Day 7	29/04/93			80.40	150	84	80	145	80	84
				Day 14	06/05/93			81.00	150	90	80	145	90	84
				Day 21	13/05/93			80.50	148	84	84	140	90	80
				Day 28	20/05/93			80.60	145	80	78	145	84	76
Day 35	27/05/93			81.00	150	90	80	150	90	76				
Day 42	03/06/93			81.00	149	80	76	143	84	78				
Day 49	10/06/93			81.00	150	80	80	145	80	84				
Day 56	16/06/93			81.50	150	95	84	150	80	80				
2ND	2DT	Reboxetine	Female	Screen	15/04/93	37.00	18	62.00	150	83	76	145	80	70
				Day 0	20/04/93			62.00	150	85	76	143	80	70
				Day 7	27/04/93			62.00	140	80	80	135	80	80
				Day 14	04/05/93			62.00	130	84	76	130	80	80
				Day 21	11/05/93			62.00	125	85	70	128	80	84
				Day 28	18/05/93			37.00		80	70	145	84	78

9550089

59

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE						
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	Heart Rate standing (beats/min)			
291	2M	Reboxetine	Female	Day 35	25/05/93	37.00		61.00	145	90	78	150	94	80	
				Day 42	01/06/93	37.00		60.80	150	90	74	145	85	70	70
				Day 49	08/06/93	37.00		60.00	145	80	76	144	84	80	80
				Day 56	14/06/93	37.00		60.00	130	90	80	128	90	80	
				Screen	22/04/93	37.00	18	74.00	130	85	64	128	86	68	68
				Day 0	14/05/93	37.00		74.00	130	85	64	128	86	68	68
				Day 7	21/05/93	37.00		74.00	134	80	64	130	84	65	
				Screen	19/04/93	37.20	18	88.00	120	80	64	120	82	66	66
				Day 0	19/04/93	37.20		88.00	120	80	64	120	82	66	66
				Day 7	26/04/93	37.00		88.00	128	84	68	120	80	60	60
				Day 14	03/05/93	37.00		88.10	120	80	66	118	81	60	60
				Day 21	10/05/93	37.00		88.00	124	84	68	120	80	64	64
				Day 28	17/05/93	37.00		88.00	120	84	60	118	88	64	64
				Day 35	24/05/93	37.00		88.50	135	80	74	120	82	78	78
				Day 42	01/06/93	37.00		88.50	125	80	76	125	80	76	76
				Day 49	07/06/93	37.00		88.50	123	85	78	120	88	80	80
				Day 56	14/06/93	37.10		88.00	115	75	76	110	80	80	80
				Screen	05/05/93	37.00	17	58.00	130	60	60	128	60	68	68
				Day 0	05/05/93	37.00		58.00	130	60	74	128	60	78	78
				Day 7	12/05/93	37.00		58.00	130	65	70	130	60	72	72
				Day 14	19/05/93	37.00		58.00	128	70	70	130	70	74	74
				Day 21	26/05/93	37.00		58.80	120	80	68	124	84	64	64
				Day 28	02/06/93	37.00		60.00	120	75	68	115	70	68	68
				Day 35	09/06/93	37.00		60.00	120	80	70	124	80	64	64
				Day 42	16/06/93	37.00		60.00	125	80	70	120	84	70	70
				Day 49	23/06/93	37.40		60.00	120	80	70	120	84	70	70
				Day 56	30/06/93	37.00		60.00	120	80	72	118	80	70	70
				Screen	03/05/93	37.00	18	79.00	120	80	60	120	84	64	64
				Day 0	03/05/93	37.00		79.00	120	80	60	120	84	64	64
				Day 7	10/05/93	37.00		79.00	110	75	64	120	80	68	68
				Day 14	17/05/93	37.00		79.00	120	84	65	120	80	63	63
				Day 21	24/05/93	37.00		79.00	128	80	68	125	84	64	64
				Day 28	01/06/93	37.00		79.00	120	80	62	118	82	60	60
				Day 35	08/06/93	37.00		79.00	120	84	64	120	80	64	64
				Day 42	15/06/93	37.00		79.00	120	80	60	115	82	64	64
				Day 49	22/06/93	37.00		79.00	124	82	62	118	80	68	68
				Day 56	29/06/93	37.20		79.00	120	80	64	120	80	68	68
				Screen	03/11/93	37.00	14	64.00	130	65	65	130	70	68	68
				Day 0	04/11/93	37.00		64.00	135	70	68	132	68	70	70

2484

9550089

60

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
291	250T	Imipramine	Female	Day 7	11/11/93	37.00		64.00	160	70	78	150	74	80
				Day 14	18/11/93	37.40		64.00		80	72			
				Day 21	25/11/93	37.00		64.00		80	70			
				Day 28	02/12/93	37.00		63.00		75	72	138	78	74
				Day 35	09/12/93	37.00		63.50		73	70	138	76	76
				Day 42	16/12/93	37.00		64.00		80	74	140	82	72
				Day 49	23/12/93	37.00		64.00		80	70	135	80	74
				Day 56	03/01/94	37.00		64.00		80	74	130	84	72
				Screen	08/06/93	36.50	16	56.00		90	78	130	90	84
				Day 0	08/06/93	36.50		56.00		90	78	130	90	84
260T	260T	Reboxetine	Female	Day 7	16/06/93	36.50		56.00	140	90	80	138	85	84
				Day 14	23/06/93	36.50		56.00		94	80	143	94	80
				Day 21	30/06/93	36.50		56.00		85	78	130	88	80
				Day 28	07/07/93	36.50		56.00		80	84	145	84	84
				Day 35	14/07/93	37.00		56.50		85	84	145	88	88
				Day 42	21/07/93	37.00		56.50		85	78	120	80	80
				Day 49	28/07/93	37.00		57.00		80	80	128	80	80
				Day 56	04/08/93	37.00		57.00		84	78	125	85	80
				Screen	03/11/93	37.00	15	67.00		90	76	146	90	78
				Day 0	04/11/93	37.00		67.00		85	72	140	90	76
270T	270T	Reboxetine	Female	Day 7	11/11/93	37.00		67.00	160	105	72	160	100	76
				Day 14	18/11/93	37.00		67.00		90	76	183	92	80
				Day 21	25/11/93	37.00		68.00		80	74	150	90	80
				Day 28	02/12/93	37.00		68.00		80	70	135	84	76
				Day 35	09/12/93	37.00		68.00		82	74	140	80	70
				Day 42	16/12/93	37.00		68.00		85	70	140	80	74
				Day 49	23/12/93	37.00		68.50		80	74	136	82	74
				Day 56	03/01/94	37.00		69.00		90	76	150	92	80
				Screen	18/11/93	37.00	15	71.00		90	80	147	89	80
				Day 0	18/11/93	37.00		71.00		85	76	145	80	78
280T	280T	Imipramine	Female	Day 7	26/11/93	37.00		71.00	168	80	70	145	82	74
				Day 14	03/12/93	37.00		71.00		90	80	150	86	80
				Day 21	11/12/93	37.00		71.00		90	80	148	85	80
				Day 28	20/12/93	37.00		71.00		90	80	150	90	84
				Day 35	08/01/94	37.20		71.50		90	80	150	90	84
				Day 42	16/01/94	37.00		71.50		85	78	146	80	78
				Day 49	23/01/94	37.00		71.50		85	78	146	80	78
				Day 56	10/02/94	37.60		71.50		86	84	148	80	80
				Screen	22/02/93	37.10	16	81.30		60	76	120	65	80
				Day 0	05/03/93	36.80		80.20		75	76	125	75	84
292	292	Reboxetine	Male	Day 7	12/03/93	37.00		80.20	135	75	76	130	80	84
				Day 14	19/03/93	36.90		79.80		70	72	135	75	76

24 00 01

9550089

61

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE									
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	Heart Rate standing (beats/min)						
292	5DT	Reboxetine	Male	Day 21	26/03/93	37.10		79.40	150	75	68	140	80	76				
				Day 28	02/04/93	37.00		79.20	150	75	72	155	80	80	80			
				Day 35	08/04/93	37.10		79.00	145	75	68	150	80	76	76			
				Day 42	15/04/93	36.90		78.50	140	70	72	145	75	72	72			
				Day 49	22/04/93	36.60		79.10	155	75	68	145	80	76	76			
				Day 56	29/04/93	36.90		79.40	160	80	72	150	85	80	80			
32406	5ND	Imipramine	Female	Screen	17/02/93	37.10	16	64.30	125	75	68	120	80	76				
				Day 0	02/03/93	36.90		64.10	120	75	68	125	75	72	72			
				Day 7	09/03/93	37.20		64.40	130	75	72	120	80	76	76			
				Day 14	16/03/93	36.90		64.20	125	75	68	120	80	72	72			
				Day 21	23/03/93	36.90		64.10	135	80	72	125	75	80	80			
				Day 28	30/03/93	37.10		64.60	130	75	68	125	80	80	80			
				Day 35	06/04/93	36.70		64.40	130	65	68	130	70	72	72			
				Day 42	13/04/93	36.90		64.90	130	70	72	130	65	80	80			
				Day 49	20/04/93	36.60		64.60	135	75	76	130	80	80	80			
				Day 56	27/04/93	36.70		64.10	140	80	72	135	85	80	80			
				6ND	6DT	Imipramine	Female	Screen	05/03/93	36.80	17	79.30	165	80	80	160	80	76
								Day 0	12/03/93	37.10		79.00	160	85	72	155	90	76
Day 7	19/03/93	37.10						79.30	160	85	72	150	85	80	80			
Day 14	26/03/93	37.10						79.10	160	80	76	150	85	80	80			
Day 21	02/04/93	37.00						78.70	165	80	72	155	85	80	80			
Day 28	09/04/93	36.90						79.20	155	75	76	150	80	80	80			
Day 35	16/04/93	37.10						79.60	150	80	72	145	85	80	80			
Day 42	23/04/93	37.10						78.90	150	75	72	145	75	76	76			
Day 49	30/04/93	36.90						78.50	145	75	68	140	80	72	72			
Day 56	07/05/93	36.70						78.20	150	80	72	140	85	76	76			
7DT	7DT	Reboxetine	Female					Screen	19/02/93	36.90	15	70.30	160	80	80	175	90	84
								Day 0	03/03/93	37.10		70.60	160	85	76	150	85	84
				Day 7	10/03/93	36.80		70.80	160	80	76	150	85	84	84			
				Day 14	17/03/93	37.10		70.60	160	85	76	150	90	84	84			
				Day 21	24/03/93	37.10		70.20	150	75	76	145	80	84	84			
				Day 28	31/03/93	37.10		70.40	155	85	68	150	70	76	76			
				Day 35	07/04/93	37.10		69.80	150	75	72	145	80	80	80			
				Day 42	14/04/93	36.80		70.10	155	80	68	150	85	76	76			
				Day 49	21/04/93	36.80		69.80	160	75	72	150	80	76	76			
				Day 56	28/04/93	36.70		70.30	155	85	76	150	85	80	80			
				7DT	7DT	Imipramine	Male	Screen	08/03/93	36.70	14	72.30	145	75	68	140	80	76
								Day 0	15/03/93	36.80		72.10	150	75	72	145	80	76
Day 7	22/03/93	36.80						71.80	150	80	72	145	80	80	80			
Day 14	01/04/93	37.00						72.20	145	75	76	140	80	80	80			
				Day 21	08/04/93	36.70		72.50	150	75	68	145	80	72				

9550089

62

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R2D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE						
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing S.B.P. (mmHg)			
292	70F	Imipramine	Male	Day 28	15/04/93	36.80		72.20	150	75	76	145	75	76	
				Day 35	22/04/93	37.10		71.90	155	75	76	150	80	80	80
				Day 42	29/04/93	36.80		71.50	150	70	72	150	80	80	70
				Day 49	06/05/93	36.90		71.30	160	80	72	150	80	80	76
				Day 56	13/05/93	36.70		71.10	150	80	72	155	85	80	80
7HD	7HD	Reboxetine	Male	Screen	30/03/93	36.50	16	69.70	125	65	72	120	70	80	
				Day 0	20/04/93	36.80		69.40	130	75	80	125	80	84	84
				Day 7	27/04/93	36.90		69.10	130	75	76	130	80	80	84
				Day 14	04/05/93	36.70		69.50	125	70	72	130	75	80	80
				Day 21	11/05/93	36.70		60.70	125	75	76	130	80	80	80
				Day 28	18/05/93	36.70		69.50	130	75	76	125	80	80	80
				Day 35	25/05/93	36.90		69.90	135	78	76	130	70	84	84
				Day 42	01/06/93	36.80		69.50	135	75	76	130	80	80	84
				Day 49	08/06/93	37.10		69.30	130	75	76	135	80	80	80
				Day 56	15/06/93	36.70		64.50	140	75	72	135	80	80	80
				8DI	8DI	Reboxetine	Female	Screen	22/03/93	36.80	14	72.80	125	80	72
Day 0	08/04/93	36.90						72.20	130	80	76	125	75	80	80
Day 7	15/04/93	36.80						72.00	135	80	76	125	85	80	80
Day 14	22/04/93	37.10						71.40	140	75	72	135	80	80	80
Day 21	29/04/93	36.80						71.10	145	80	68	140	85	72	80
Day 28	06/05/93	36.90						70.90	140	70	72	145	75	80	80
Day 35	13/05/93	36.80						70.70	135	75	76	130	80	84	84
Day 42	21/05/93	36.90						70.50	140	80	72	135	85	80	80
Day 49	27/05/93	36.90						70.80	145	75	76	140	80	84	84
Day 56	03/06/93	36.70						70.10	140	75	80	135	80	84	84
8HD	8HD	Imipramine	Male					Screen	01/04/93	36.80	16	62.50	150	80	76
				Day 0	22/04/93	37.00		62.40	150	75	72	145	80	80	80
				Day 7	29/04/93	36.80		62.70	155	75	76	145	80	80	80
				Day 14	06/05/93	36.70		62.40	150	70	68	145	75	76	76
				Day 21	13/05/93	36.90		62.60	155	75	72	150	80	76	76
				Day 28	19/05/93	36.70		62.40	160	80	68	150	75	72	72
				Day 35	27/05/93	36.80		62.00	165	75	72	150	75	76	76
				Day 42	03/06/93	36.70		62.20	150	70	78	145	75	80	80
				Day 49	09/06/93	36.70		61.90	160	80	68	150	85	76	76
				Day 56	17/06/93	36.90		62.20	155	80	76	150	75	80	80
				21DI	21DI	Reboxetine	Female	Screen	30/04/93	36.50	15	67.20	165	80	84
Day 0	03/05/93	36.70						67.00	160	80	76	150	75	80	80
Day 7	10/05/93	36.90						67.10	165	80	68	150	80	72	80
Day 14	17/05/93	36.90						67.20	165	80	72	155	75	76	76
Day 21	24/05/93	36.50						66.90	155	75	68	160	80	76	76
Day 28	01/06/93	36.50		67.20	160	80	72	150	75	80	80				

2487

9550089

63

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACTA CMS R&D
 REBOXETINE - PROTOCOL 20124/D35
 Listing No.: 20.0
 VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing Heart Rate (beats/min)		
292	21DT	Reboxetine	Female	Day 35	07/06/93	36.80		67.30	150	80	72	155	85	80
				Day 42	14/06/93	36.70		67.60	155	80	72	150	75	76
				Day 49	21/06/93	36.30		67.20	150	70	68	150	75	76
				Day 56	28/06/93	36.80		67.50	100	80	72	150	85	80
292	21HD	Imipramine	Female	Screen	30/04/93	36.70	15	66.80	160	80	80	155	75	84
				Day 0	07/05/93	36.80		66.60	150	80	76	150	85	80
				Day 7	14/05/93	36.70		66.30	150	80	68	150	85	72
				Day 14	21/05/93	36.70		66.20	160	85	76	150	90	80
				Day 21	28/05/93	36.90		66.50	155	75	68	150	80	68
				Day 28	04/06/93	36.50		65.90	155	75	72	150	80	80
				Day 35	12/06/93	36.70		66.40	160	85	68	150	90	72
				Day 42	18/06/93	36.90		66.20	155	80	72	150	85	76
				Day 49	25/06/93	36.90		66.50	150	80	68	145	85	76
				Day 56	02/07/93	36.70		66.30	155	80	72	150	80	76
292	22DT	Imipramine	Female	Screen	30/04/93	37.10	15	68.50	155	80	80	150	85	85
				Day 0	04/05/93	36.90		68.30	160	80	72	155	85	72
				Day 7	11/05/93	36.90		68.00	155	80	68	150	90	76
				Day 14	18/05/93	36.90		68.00	150	80	72	150	85	78
				Day 21	23/05/93	36.70		67.90	160	80	76	150	84	80
				Day 28	01/06/93	36.80		68.20	150	80	72	155	85	72
				Day 35	08/06/93	36.70		68.10	150	80	72	145	85	72
				Day 42	15/06/93	36.90		68.30	160	80	68	150	85	72
				Day 49	22/06/93	36.70		68.00	155	85	72	150	90	76
				Day 56	29/06/93	36.90		68.20	160	80	72	150	85	76
22HD	Imipramine	Female	Screen	05/05/93	36.80		60.30	145	75	72	140	80	76	
			Day 0	19/05/93	36.70	17	60.10	140	80	76	140	85	80	
			Day 7	26/05/93	36.70		60.40	145	75	72	140	80	80	
			Day 14	02/06/93	37.00		60.20	150	76	72	145	85	80	
			Day 21	09/06/93	36.90		60.40	140	75	68	135	80	76	
			Day 28	16/06/93	36.90		60.40	150	80	72	145	85	76	
			Day 35	23/06/93	36.70		60.50	145	75	68	150	80	76	
			Day 42	30/06/93	36.80		60.20	150	75	72	145	80	76	
			Day 49	07/07/93	36.70		60.60	145	75	72	140	70	76	
			Day 56	14/07/93	36.90		60.40	150	80	68	145	85	72	
23DT	Reboxetine	Male	Screen	03/05/93	36.70		74.80	140	75	72	145	80	76	
			Day 0	13/05/93	36.80	14	74.50	135	70	68	140	75	72	
			Day 7	21/05/93	36.70		74.10	135	70	72	130	75	80	
			Day 14	27/05/93	36.70		74.10	145	75	72	140	80	80	
			Day 21	03/06/93	36.80		74.60	140	70	72	140	75	76	
			Day 28	09/06/93	36.80		74.00	150	80	68	140	85	72	
Day 35	17/06/93	36.70		73.90	145	75	76	140	80	80				

9550089

64

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE						
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	
292	23DT	Reboxetine	Male	Day 42	24/06/93	36.80		73.60	140	80	72	135	85	80	
				Day 49	01/07/93	36.90		73.40	145	75	72	140	80	76	76
				Day 56	08/07/93	36.70		73.60	150	80	72	140	75	68	68
293	23MD	Reboxetine	Female	Screen	10/05/93	36.40	15	72.80	160	80	72	150	85	80	
				Day 0	26/05/93	36.90		72.50	150	80	72	155	85	76	76
				Day 7	02/06/93	36.90		72.50	155	80	72	150	75	80	80
				Day 14	09/06/93	36.80		72.30	165	80	72	160	85	76	76
				Day 21	16/06/93	36.70		72.60	155	75	72	150	80	80	80
				Day 28	23/06/93	36.60		72.10	150	80	68	150	85	76	76
				Day 35	30/06/93	36.80		71.70	145	75	72	150	80	80	80
				Day 42	07/07/93	36.70		71.40	140	70	68	145	85	72	72
				Day 49	14/07/93	36.70		71.20	150	80	72	145	75	72	72
				Day 56	21/07/93	36.70		71.00	145	75	72	150	70	76	76
				293	24DT	Imipramine	Female	Screen	21/05/93	36.20	15	68.20	150	80	68
Day 0	01/06/93	36.50						68.30	160	80	72	145	85	76	
Day 7	08/06/93	36.70						68.20	160	80	76	150	85	80	80
Day 14	15/06/93	36.30						68.40	155	80	72	150	85	80	80
Day 21	22/06/93	36.50						68.10	150	70	68	150	75	76	76
Day 28	29/06/93	36.80						68.40	155	75	82	150	80	80	80
Day 35	06/07/93	36.90						68.20	150	80	76	145	80	80	80
Day 42	13/07/93	36.70						68.00	150	80	68	145	85	72	72
Day 49	20/07/93	36.70						68.40	145	75	72	140	80	72	72
Day 56	27/07/93	36.60						67.90	155	80	72	145	75	76	76
293	24MD	Reboxetine	Male					Screen	28/05/93	37.10	15	92.80	155	80	72
				Day 0	04/06/93	36.90		92.50	160	80	80	155	84	84	84
				Day 7	11/06/93	36.70		92.10	160	80	72	165	85	76	76
				Day 14	18/06/93	36.50		92.40	150	80	72	145	75	80	80
				Day 21	25/06/93	36.70		92.20	155	80	72	150	80	76	76
				Day 28	02/07/93	36.60		92.00	160	80	68	150	85	68	68
				Day 35	09/07/93	36.70		91.30	165	85	68	155	90	64	64
				Day 42	16/07/93	36.70		91.80	155	80	68	150	75	72	72
				Day 49	23/07/93	36.90		91.40	150	80	64	150	85	68	68
				Day 56	30/07/93	36.60		91.00	160	80	72	155	85	76	76
				293	9DT	Imipramine	Female	Screen	19/05/93	37.20	25	71.00	150	85	78
Day 0	26/05/93	37.00						71.00	150	90	74	140	95	84	
Day 7	02/06/93	37.00						71.00	150	85	76	140	95	86	
Day 14	09/06/93	37.10						71.00	160	90	80	150	100	88	
Day 21	16/06/93	37.00						71.00	155	85	80	145	90	84	
Day 28	23/06/93	37.00						71.50	150	80	78	145	75	80	
Day 35	30/06/93	37.00						71.50	150	80	74	145	75	84	
Day 42	07/07/93	37.10		72.00	145	80	76	140	75	84					

9550089

65

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 20.0
 VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	Heart Rate (beats/min)		
293	90T	Imipramine	Female	Day 49	44/07/93	37.10		72.50	160	90	84	165	100	92
				Day 56	21/07/93	37.20		72.50	150	85	72	155	90	76
9ND	9ND	Imipramine	Female	Screen	12/02/93	37.20	24	69.00	155	80	76	160	85	92
				Day 0	18/02/93	37.20		69.00	150	80	76	155	85	84
				Day 7	25/02/93	37.10		69.00	145	80	80	140	75	84
				Day 14	04/03/93	37.00		69.00	150	85	80	145	75	80
				Day 21	11/03/93	37.10		69.00	160	85	84	150	90	84
				Day 28	18/03/93	37.00		69.00	150	90	80	145	85	84
				Day 35	25/03/93	37.00		69.50	150	85	80	140	85	84
				Day 42	01/04/93	37.00		69.50	160	80	80	150	75	88
				Day 49	08/04/93	37.20		70.00	155	80	76	145	90	84
				Day 56	15/04/93	37.10		71.00	155	85	72	140	85	78
10DT	10DT	Imipramine	Female	Screen	15/07/93	37.10	25	72.00	150	90	76	155	85	84
				Day 0	20/07/93	37.10		72.00	150	80	70	145	75	76
				Day 7	27/07/93	37.50		72.00	150	85	74	140	85	84
				Day 14	03/08/93	37.20		72.00	140	75	80	135	80	84
				Day 21	10/08/93	37.00		72.50	150	85	76	140	90	84
				Day 28	17/08/93	37.20		72.50	140	85	72	145	90	80
				Day 35	24/08/93	37.00		73.00	150	90	76	145	90	84
				Day 42	31/08/93	37.10		73.00	160	85	76	150	90	84
				Day 49	07/09/93	36.90		74.00	160	90	76	150	100	88
				Day 56	14/09/93	37.00		74.00	150	85	72	145	95	92
10ND	10ND	Reboxetine	Female	Screen	16/03/93	36.90	26	74.00	150	85	72	145	80	84
				Day 0	23/03/93	36.90		74.00	150	85	72	145	80	80
				Day 7	30/03/93	37.00		74.00	150	85	74	145	85	78
				Day 14	06/04/93	37.10		74.00	145	85	74	140	80	78
				Day 21	13/04/93	37.00		74.50	150	80	74	150	75	76
				Day 28	20/04/93	37.00		74.50	145	85	74	140	80	78
Day 35	27/04/93	37.00		74.50	150	80	74	145	90	80				
Day 42	04/05/93	37.10		75.00	150	85	76	145	95	92				
Day 49	11/05/93	37.10		75.00	145	80	88	135	95	92				
Day 56	18/05/93	37.10		75.50	150	85	75	140	90	80				
11DT	11DT	Reboxetine	Female	Screen	12/11/93	36.80	26	74.00	145	85	74	150	85	80
				Day 0	18/11/93	36.80		74.00	140	80	72	140	75	76
				Day 7	25/11/93	36.90		74.00	140	80	74	135	65	84
				Day 14	02/12/93	36.70		74.50	150	85	72	140	75	80
11ND	11ND	Imipramine	Male	Screen	08/07/93	37.10	27	72.00	140	75	72	135	70	80
				Day 0	12/07/93	37.30		72.00	150	80	76	145	85	80
				Day 7	19/07/93	37.20		72.00	160	85	72	170	90	76

2490

9550089

66

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 20.0
 VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE					
									Lying			Standing		
						S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)			
293	11ND	Imipramine	Male	Day 14	26/07/93	37.10		72.90	150	80	72	160	85	76
				Day 21	02/08/93	37.00		72.90	145	85	78	150	90	84
				Day 28	09/08/93	37.00		72.50	150	85	74	140	90	78
				Day 35	16/08/93	37.00		72.50	160	90	72	170	90	76
				Day 42	23/08/93	37.20		73.00	170	90	76	160	95	84
				Day 49	30/08/93	37.40		73.00	160	80	72	155	90	78
	12DT	Reboxetine	Female	Day 56	06/09/93	37.20		73.00	150	90	72	145	95	80
				Screen	10/12/93	36.70	25	73.00	140	80	72	135	75	68
				Day 0	13/12/93	36.70		73.00	150	80	74	150	80	70
				Day 7	20/12/93	36.50		73.50	150	90	72	140	75	76
				Day 14	27/12/93	36.50		73.50	140	80	72	130	90	80
				Day 21	03/01/94	36.20		74.00	130	70	76	135	80	80
	12ND	Reboxetine	Male	Day 28	10/01/94	36.70		73.50	135	70	80	130	80	84
				Day 35	17/01/94	36.20		74.00	140	80	80	135	85	88
				Day 42	24/01/94	36.40		74.00	140	80	84	150	85	88
				Day 49	31/01/94	36.20		75.00	150	85	84	145	85	88
				Day 56	07/02/94	36.20		75.00	140	80	82	135	75	90
				Screen	09/09/93	37.20	26	81.00	140	80	68	130	75	72
	12ND	Reboxetine	Male	Day 0	16/09/93	37.10		81.00	145	80	76	135	85	80
				Day 7	23/09/93	37.00		81.00	150	80	74	140	75	80
				Day 14	30/09/93	36.80		81.00	125	75	72	120	80	78
				Day 21	07/10/93	37.20		81.50	130	76	76	125	75	74
				Day 28	14/10/93	37.10		82.00	140	80	72	135	85	72
				Day 35	21/10/93	36.80		82.50	145	85	70	140	80	68
	13DT	Reboxetine	Female	Day 42	28/10/93	36.70		82.50	150	90	74	155	90	70
				Screen	08/03/93	37.20	24	48.00	140	80	64	150	80	74
				Day 0	08/03/93	37.20		48.00	140	80	64	150	80	74
				Day 7	15/03/93	36.80		48.40	130	80	67	140	80	72
				Day 14	22/03/93	37.20		48.10	140	80	78	150	90	82
				Day 21	29/03/93	37.00		48.20	130	70	62	140	75	68
	13ND	Imipramine	Female	Day 28	05/04/93	37.20		48.40	140	80	74	145	80	80
				Day 35	13/04/93	37.00		48.10	120	80	62	130	80	68
				Day 42	20/04/93	36.80		48.20	130	75	65	130	80	68
				Day 49	27/04/93	37.10		48.10	140	80	68	140	85	75
				Day 56	04/05/93	37.40		48.00	160	90	57	170	90	68
				Screen	15/02/93	36.80	24	56.00	110	60	52	100	60	56
	13ND	Imipramine	Female	Day 0	15/02/93	36.80		56.00	110	60	62	100	60	66
				Day 7	22/02/93	37.20		55.80	110	65	68	115	60	64
				Day 14	01/03/93	37.10		56.20	100	60	56	105	60	62
				Day 21	08/03/93	36.90		56.40	110	65	58	115	70	62
				Day 28	15/03/93	37.20		56.20	100	65	62	110	70	68
				Screen	15/03/93	37.20		56.20	100	65	62	110	70	68

2491

9550089

67

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE						
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing Heart Rate (beats/min)			
294	13HD	Imipramine	Female	Day 35	22/03/93	37.00		54.80	110	65	62	115	65	68	
				Day 42	29/03/93	36.20		54.60	120	70	64	120	75	68	68
				Day 49	05/04/93	37.40		54.40	110	70	62	120	70	70	70
		Day 56	13/04/93	37.00		54.80	120	65	68	120	70	70	70		
	14DT	Imipramine	Female	Screen	08/03/93	36.90	24	71.00	140	90	60	145	90	68	
				Day 0	08/03/93	36.90		71.00	140	90	60	145	90	68	
				Day 7	15/03/93	37.20		71.20	150	70	72	140	70	74	
				Day 14	22/03/93	37.20		71.10	140	90	63	150	90	70	
				Day 21	29/03/93	36.80		71.40	160	80	72	150	90	76	
Day 28				05/04/93	37.40		71.20	160	90	72	160	95	76		
Day 35				13/04/93	36.90		70.80	160	80	78	150	80	82		
Day 42				20/04/93	37.20		71.60	140	90	82	150	100	86		
Day 49				27/04/93	37.00		71.20	150	80	68	150	85	74		
Day 56				04/05/93	37.20		71.20	150	90	72	155	95	78		
14HD				Reboxetine	Female	Screen	15/02/93	37.20	17	50.00	130	70	54	135	80
	Day 0	15/02/93	37.20				50.50	130	70	54	135	80	62		
	Day 7	22/02/93	37.40				50.80	120	80	66	135	80	64		
	Day 14	01/03/93	37.20				50.40	120	65	62	125	70	68		
	Day 21	08/03/93	36.90				50.60	110	65	70	120	70	74		
	Day 28	15/03/93	37.40				50.80	120	60	64	125	70	72		
	Day 35	22/03/93	36.80				51.20	120	70	70	130	75	68		
	Day 42	29/03/93	37.20				50.40	125	75	72	130	75	70		
	Day 49	05/04/93	37.20				50.50	120	65	72	130	70	78		
	Day 56	13/04/93	36.80				50.40	125	70	78	130	75	70		
	15DT	Imipramine	Female			Screen	09/03/93	38.20	24	70.00	160	80	68	160	90
Day 0				09/03/93	38.20		70.00	160	80	68	160	90	84		
Day 7				16/03/93	36.20		70.40	150	80	72	150	90	78		
Day 14				23/03/93	37.00		70.00	140	80	70	150	80	78		
Day 21				30/03/93	37.20		69.80	140	90	68	150	80	72		
Day 28				06/04/93	38.20		70.20	150	80	74	150	85	80		
Day 35				13/04/93	37.40		70.60	150	80	72	150	90	78		
Day 42				20/04/93	37.00		70.20	150	80	78	150	90	82		
Day 49				27/04/93	37.20		70.00	150	90	68	150	90	76		
Day 56				04/05/93	36.80		70.40	140	80	74	150	90	78		
15HD				Imipramine	Female	Screen	22/02/93	37.20	18	67.00	130	80	68	140	80
	Day 0	22/02/93	37.20				67.00	130	80	68	140	80	73		
	Day 7	01/03/93	37.20				67.00	130	80	68	140	80	73		
	Day 14	08/03/93	37.20				67.30	130	80	62	135	80	70		
	Day 21	15/03/93	36.90				67.10	120	70	72	125	70	78		
	Day 28	22/03/93	37.20				68.20	140	80	97	145	80	92		
Day 35	29/03/93	37.00		67.80	130	80	69	135	80	73					

9550089

68

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing		
294	15HD	Imipramine	Female	Day 42	05/04/93	36.90		68.00	120	70	72	125	70	78
				Day 49	13/04/93	37.40		67.20	140	85	77	140	90	86
				Day 56	20/04/93	37.00		67.00	130	80	68	140	80	92
				Screen	09/03/93	36.40	30	82.00	140	90	72	145	90	78
				Day 0	09/03/93	36.40		82.00	140	90	72	145	90	78
				Day 7	16/03/93	37.20		82.20	130	80	68	140	80	76
				Day 14	23/03/93	36.80		79.80	140	75	72	140	80	78
				Day 21	30/03/93	37.10		82.10	130	70	68	140	85	78
				Day 28	06/04/93	36.80		82.00	140	80	68	150	90	76
				Day 35	13/04/93	37.20		82.20	160	90	72	165	90	78
				Day 42	20/04/93	36.90		81.70	150	80	62	150	85	68
				Day 49	27/04/93	37.10		79.60	140	75	62	150	80	68
				Day 56	04/05/93	37.00		79.20	140	70	60	150	80	68
				Screen	23/02/93	37.20	16	66.00	130	80	64	135	80	72
				Day 0	23/02/93	37.20		66.00	130	80	64	135	80	72
				Day 7	02/03/93	36.70		65.80	120	70	65	125	75	74
				Day 14	09/03/93	36.20		66.20	130	80	72	135	85	78
				Day 21	16/03/93	37.80		66.40	120	80	64	130	85	72
				Day 28	23/03/93	37.20		65.40	110	70	68	120	75	76
				Day 35	30/03/93	37.40		66.00	120	70	68	130	85	72
				Day 42	06/04/93	36.20		65.80	140	85	92	145	85	94
				Day 49	13/04/93	37.00		65.40	130	85	68	135	90	78
				Day 56	20/04/93	36.80		65.90	135	80	68	140	85	76
				Screen	14/06/93	37.20	13	73.00	150	80	83	160	90	92
				Day 0	14/06/93	37.20		73.00	150	80	83	160	90	92
				Day 7	21/06/93	38.20		72.80	150	90	68	140	95	84
				Day 14	28/06/93	37.80		72.60	150	80	72	170	90	88
				Day 21	05/07/93	37.20		73.20	140	90	62	160	100	78
				Day 28	12/07/93	36.20		73.20	150	80	95	150	90	98
				Day 35	19/07/93	37.60		72.80	150	80	78	160	90	92
				Day 42	26/07/93	36.20		72.60	140	80	68	150	85	79
				Day 49	02/08/93	37.40		72.90	140	80	68	145	80	78
				Day 56	09/08/93	37.40		73.20	150	90	81	155	90	94
				Screen	14/06/93	38.20	23	58.00	150	90	63	160	95	76
				Day 0	14/06/93	38.20		58.00	150	90	63	160	95	76
				Day 7	21/06/93	37.40		58.40	160	90	68	180	100	78
				Day 14	28/06/93	37.40		59.00	170	95	78	180	100	92
				Day 21	05/07/93	36.20		58.80	160	90	68	160	90	72
				Day 28	12/07/93	37.80		59.20	160	90	79	170	95	85
				Day 35	19/07/93	37.40		59.20	160	90	72	165	90	79
				Day 42	26/07/93	37.40		58.20	170	90	68	170	100	78

9550089

69

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
294	26MD	Imipramine	Female	Day 49	02/08/93	37.40		58.60	150	80	68	165	90	82
				Day 56	09/08/93	38.00		58.20	180	100	63	190	100	72
294	27MD	Reboxetine	Female	Screen	15/06/93	37.40	26	84.00	160	80	66	160	90	82
				Day 0	15/06/93	37.40		84.00	160	80	66	160	90	82
				Day 7	22/06/93	37.60		82.40	145	80	78	150	85	88
				Day 14	29/06/93	37.20		82.50	150	90	82	160	100	88
				Day 21	06/07/93	36.80		82.00	145	80	72	150	80	80
				Day 28	13/07/93	37.20		82.40	140	90	63	145	90	72
				Day 35	20/07/93	36.20		83.40	160	80	78	150	90	92
				Day 42	27/07/93	36.80		82.80	160	80	72	165	80	84
				Day 49	03/08/93	36.40		83.10	150	75	72	160	80	92
				Day 56	10/08/93	37.40		83.40	120	80	65	130	80	78
294	28MD	Reboxetine	Female	Screen	15/06/93	37.40	25	56.00	120	80	65	130	80	78
				Day 0	15/06/93	37.40		56.00	120	80	65	130	80	78
				Day 7	22/06/93	37.80		58.80	120	75	72	120	80	78
				Day 14	29/06/93	36.80		58.20	120	70	68	130	80	82
				Day 21	06/07/93	37.20		56.10	120	70	62	130	75	78
				Day 28	13/07/93	38.20		55.60	140	90	71	140	80	86
				Day 35	20/07/93	37.20		55.40	140	80	72	160	90	88
				Day 42	27/07/93	37.10		55.80	130	80	82	140	80	89
				Day 49	03/08/93	37.00		55.40	120	70	72	120	80	86
				Day 56	10/08/93	37.20		55.20	150	80	88	150	90	96
294	29DT	Reboxetine	Female	Screen	14/06/93	37.40	22	58.00	160	80	82	180	100	96
				Day 0	14/06/93	37.40		58.00	160	80	82	180	100	96
				Day 7	21/06/93	36.80		58.40	170	80	82	180	80	86
				Day 14	28/06/93	37.60		58.20	170	80	76	180	90	84
				Day 21	05/07/93	37.40		55.20	160	80	86	170	90	92
				Day 28	12/07/93	37.20		55.20	180	80	97	180	90	102
Day 35	19/07/93	38.10		53.20	170	80	92	180	90	98				
Day 42	26/07/93	37.20		52.40	160	90	76	180	100	92				
Day 49	02/08/93	37.10		52.40	170	80	82	180	90	86				
Day 56	09/08/93	37.20		52.40	170	90	92	180	100	98				
30DT	30DT	Reboxetine	Female	Screen	14/06/93	37.20	16	67.00	160	80	93	160	90	98
				Day 0	14/06/93	37.20		67.00	160	80	93	160	90	98
				Day 7	21/06/93	36.90		70.00	160	80	93	160	90	98
				Day 14	28/06/93	36.80		68.20	140	80	89	150	90	96
				Day 21	05/07/93	37.20		70.80	140	80	82	150	80	96
				Day 28	12/07/93	37.20		69.80	145	75	76	150	80	88
Day 35	19/07/93	37.20		69.20	140	80	99	150	90	104				
Day 42	26/07/93	36.80		69.20	140	80	82	150	80	94				
Day 49	02/08/93	37.10		68.40	150	80	86	150	80	92				
Day 56	09/08/93	37.10		69.40	140	70	78	140	80	90				
Day 56	09/08/93	37.10		69.80	140	80	89	150	80	96				

9550089

70

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE									
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing						
294	31DT	Imipramine	Female	Screen	21/06/93	36.40	21	73.80	140	80	91	140	90	97				
				Day 0	21/06/93	37.40		73.80	140	80	91	140	90	90	97			
				Day 7	28/06/93	37.20		72.80	140	80	89	150	90	90	96			
				Day 14	05/07/93	37.20		73.20	140	85	86	150	90	90	94			
				Day 21	12/07/93	37.80		73.00	150	90	78	160	95	92	92			
				Day 28	19/07/93	37.80		73.80	150	90	78	160	100	94	94			
				Day 35	26/07/93	37.40		73.80	140	90	76	150	95	98	98			
				Day 42	02/08/93	37.20		73.20	150	90	92	155	90	98	98			
				Day 49	09/08/93	37.40		73.40	140	90	86	150	90	90	90			
				Day 56	16/08/93	37.90		73.20	150	90	92	160	90	98	98			
				295	17DT	Imipramine	Male	Screen	21/06/93	37.60	18	79.40	150	90	92	160	95	98
								Day 0	21/06/93	37.60		79.40	150	90	92	160	95	98
Day 7	28/06/93	36.90						79.20	160	90	92	170	95	96				
Day 14	05/07/93	37.20						78.90	150	90	86	160	90	92				
Day 21	12/07/93	37.40						79.00	140	80	92	150	90	95				
Day 28	19/07/93	37.40						79.20	150	90	92	160	90	97				
Day 35	26/07/93	36.80						79.40	150	90	86	155	90	94				
Day 42	02/08/93	36.80						79.20	140	80	82	145	80	89				
Day 49	09/08/93	38.20						78.90	140	85	92	150	90	102				
Day 56	16/08/93	37.40						78.20	145	80	96	150	85	99				
295	17DT	Imipramine	Male					Screen	23/04/93	37.00	18	75.00	130	80	86	140	80	90
								Day 0	26/04/93	37.00		75.00	140	85	84	135	70	90
				Day 7	06/05/93	36.50		75.00	145	85	96	135	70	100				
				Day 14	13/05/93	36.50		75.00	140	80	92	130	75	96				
				Day 21	21/05/93	36.00		75.00	140	80	88	135	70	94				
				Day 28	27/05/93	36.00		75.00	130	70	92	130	85	86				
				Day 35	03/06/93	36.00		75.00	140	70	88	130	70	92				
				Day 42	11/06/93	36.00		75.00	130	70	94	120	75	86				
				Day 49	17/06/93	36.00		75.00	140	80	88	130	70	98				
				Day 56	24/06/93	36.00		75.00	140	80	80	130	70	86				
				295	17ND	Reboxetine	Female	Screen	20/04/93	36.00	22	64.00	140	80	90	145	70	94
								Day 0	20/04/93	36.00		64.00	140	80	90	145	70	94
Day 7	27/04/93	36.00						64.00	140	80	90	135	70	92				
Day 14	04/05/93	36.00						64.50	145	80	86	140	80	88				
Day 21	11/05/93	36.00						64.50	140	80	84	140	70	90				
Day 28	18/05/93	36.00						64.50	150	70	86	140	70	86				
Day 35	25/05/93	36.00						65.00	155	70	84	150	80	78				
Day 42	01/06/93	36.00						65.00	160	80	84	150	70	78				
Day 49	08/06/93	36.00						63.50	155	80	76	150	70	80				
Day 56	15/06/93	36.00						63.50	150	70	80	145	80	76				

9550089

71

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 20.0
 VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE								
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	Heart Rate (beats/min)					
295	18DT	Imipramine	Female	Screen	27/04/93	36.00	24	62.00	145	85	84	140	90	86			
				Day 0	29/04/93	36.00		62.00	150	85	80	140	80	84			
				Day 7	06/05/93	36.00		62.00	140	80	80	145	80	82			
				Day 14	13/05/93	36.00		62.00	135	80	80	140	70	86			
				Day 21	21/05/93	36.00		62.00	140	80	76	135	70	82			
				Day 28	27/05/93	36.00		62.00	140	80	74	135	70	76			
				Day 35	03/06/93	36.00		62.00	145	80	74	140	70	80			
				Day 42	11/06/93	36.00		62.00	140	80	76	135	70	72			
				Day 49	17/06/93	36.00		62.00	140	70	80	135	70	84			
				Day 56	24/06/93	36.00		62.00	145	70	80	140	75	82			
				18ND	Reboxetine	Female	Screen	20/04/93	36.50	24	60.00	150	80	85	140	70	90
							Day 0	23/04/93	36.00		60.00	150	70	86	145	70	90
							Day 7	30/04/93	36.00		60.00	150	80	85	140	80	72
							Day 14	07/05/93	36.00		60.00	140	85	72	130	70	70
							Day 21	14/05/93	36.00		60.00	150	85	72	140	70	70
Day 28	21/05/93	36.00					60.00	160	80	74	150	85	72				
Day 35	28/05/93	36.00					60.00	150	80	70	145	90	72				
Day 42	04/06/93	36.00					60.00	155	85	70	150	70	72				
Day 49	11/06/93	36.00					60.00	140	80	75	145	70	80				
Day 56	18/06/93	36.00					60.00	150	80	64	150	70	72				
19DT	Reboxetine	Female	Screen				07/05/93	36.00	30	74.00	160	80	90	160	70	95	
			Day 0				10/05/93	36.00		74.00	155	80	90	150	80	94	
			Day 7				17/05/93	36.00		74.00	165	70	86	160	85	90	
			Day 14				24/05/93	36.00		74.00	160	70	88	155	80	92	
			Day 21				01/06/93	36.00		74.00	155	70	84	150	80	86	
			Day 28	07/06/93	36.00		74.00	160	70	80	150	70	84				
			Day 35	14/06/93	36.00		74.00	165	85	88	155	70	84				
			Day 42	21/06/93	36.00		74.00	155	85	88	150	70	96				
			Day 49	28/06/93	36.00		74.00	160	85	96	150	70	94				
			Day 56	05/07/93	36.00		74.00	150	70	90	145	80	92				
			19ND	Imipramine	Male	Screen	13/05/93	36.00	28	78.00	130	70	84	125	80	90	
						Day 0	14/05/93	36.00		78.00	130	70	80	120	70	86	
						Day 7	21/05/93	36.00		78.00	130	80	80	130	70	84	
						Day 14	28/05/93	36.00		78.00	130	70	76	130	80	78	
						Day 21	04/06/93	36.00		78.00	135	80	82	138	70	84	
Day 28	11/06/93	36.00					78.00	130	70	70	125	70	76				
Day 35	18/06/93	36.00					78.00	135	70	74	130	80	78				
Day 42	25/06/93	36.00					78.00	140	70	84	130	70	76				
Day 49	02/07/93	36.00					78.00	130	70	82	140	70	80				
Day 56	09/07/93	36.00					78.00	130	70	70	135	70	72				

2496

9550089

72

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE					
									Lying			Standing		
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
295	200T	Reboxetine	Female	Screen	10/05/93	36.00	26	80.00	140	70	76	130	70	80
				Day 0	11/05/93	36.00		80.00	140	70	80	130	70	76
				Day 7	18/05/93	36.00		80.00	130	70	76	135	80	80
				Day 14	25/05/93	36.00		80.00	135	80	80	130	80	84
				Day 21	01/06/93	36.00		80.00	140	70	76	135	80	80
				Day 28	08/06/93	36.00		80.00	140	70	88	135	80	92
				Day 35	15/06/93	36.00		80.00	140	70	88	140	70	86
				Day 42	22/06/93	36.00		80.00	145	70	88	140	70	86
				Day 49	29/06/93	36.00		80.00	145	70	88	140	70	90
				Day 56	06/07/93	36.00		80.00	150	80	82	145	75	86
2497	20ND	Imipramine	Female	Screen	13/05/93	36.00	28	75.00	155	90	72	160	80	76
				Day 0	14/05/93	36.00		75.00	155	90	72	160	80	72
				Day 7	21/05/93	36.00		75.00	140	90	76	140	80	82
				Day 14	28/05/93	36.00		75.00	150	85	72	135	80	84
				Day 21	04/06/93	36.00		75.00	150	85	84	145	70	86
				Day 28	11/06/93	36.00		74.50	155	80	78	145	75	82
				Day 35	18/06/93	36.00		74.50	145	80	78	150	80	84
				Day 42	25/06/93	36.00		74.50	155	90	76	150	95	82
				Day 49	02/07/93	36.00		74.50	150	80	72	145	80	84
				Day 56	09/07/93	36.00		74.50	150	80	72	145	80	84
381	1ND	Reboxetine	Male	Screen	06/12/93	36.40	24	63.30	140	70	80	160	70	90
				Day 0	10/12/93	36.00		63.30	140	70	78	110	70	86
				Day 7	17/12/93	36.40		65.00	120	80	80	110	75	86
				Day 14	23/12/93	35.60		65.00	160	100	80	130	90	84
				Day 21	30/12/93	36.40		66.80	160	100	80	140	90	88
				Day 28	06/01/94	36.40		71.40	130	90	78	130	85	88
				Day 35	13/01/94	36.00		72.00	140	90	84	135	90	86
				Day 42	20/01/94	36.00		72.00	130	90	84	135	85	88
				Day 49	27/01/94	36.00		70.60	140	95	88	145	100	88
				Day 56	03/02/94	36.00		70.60	140	95	88	145	100	88
2ND	2ND	Reboxetine	Female	Screen	01/02/94	36.40	22	44.20	130	85	88	130	85	86
				Day 0	02/02/94	36.40		45.60	130	85	88	130	85	86
				Day 7	09/02/94	36.60		47.50	140	100	96	160	80	80
				Day 14	16/02/94	36.20		44.20	140	110	60	130	90	60
				Day 21	23/02/94	36.40		44.20	125	65	70	120	60	66
				Day 28	03/03/94	36.50		44.20	120	70	80	115	60	76
Day 35	08/03/94	36.50		44.00	120	70	80	115	65	76				
30T	30T	Reboxetine	Female	Screen	08/02/94	35.00	20	50.00	180	80	80	165	110	92
				Day 0	08/02/94	35.00		50.00	180	80	80	165	110	92

9550089

73

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (KG)	BLOOD PRESSURE AND HEART RATE					
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)
381	30T	Reboxetine	Female	Day 7	15/02/94	35.60		51.30	165	100	96	150	100	100
				Day 14	22/02/94	35.60		50.40	165	100	92	155	100	96
				Day 21	01/03/94	36.00			190	120	100	150	120	110
382	44D	Imipramine	Female	Screen	25/02/94	36.50	24	59.00	160	90	78	140	80	80
				Day 0	28/02/94	36.50		59.00	160	90	78	140	80	80
				Day 7	07/03/94	36.00		59.00	140	80	78	140	80	78
				Day 14	14/03/94	36.50		59.50	150	80	80	150	80	80
382	50T	Reboxetine	Male	Screen	20/10/93	37.50	32	65.90	150	80	80	120	65	72
				Day 0	21/10/93	36.50		65.90	150	80	100	120	65	72
				Day 7	28/10/93	37.00		66.00	160	90	80	70	50	108
				Day 14	05/11/93	36.50		65.50	190	100	100	100	50	110
				Screen	11/11/93	36.00	20	47.70	140	90	92	170	110	92
382	50D	Imipramine	Female	Day 0	15/11/93	36.00		48.40	130	60	90	120	75	90
				Day 7	23/11/93	36.00		48.30	150	80	84	140	80	82
				Day 14	01/12/93	36.00		47.20	120	70	84	150	90	88
				Day 21	08/12/93	36.00		46.00	130	80	90	110	70	92
				Day 28	15/12/93	37.00		46.20	130	80	120	110	70	88
				Day 35	20/12/93	36.00		45.00	160	90	90	150	100	94
				Day 42	29/12/93	36.00		44.00	130	90	90	110	70	110
				Day 49	05/01/94	36.80		44.00	150	80	84	145	75	84
				Day 56	12/01/94	36.80		41.50	130	80	94	120	80	90
				Screen	22/10/93	36.00	33	65.50	190	90	70	170	60	90
				Day 0	22/10/93	36.80		65.50	190	90	70	185	90	80
Day 7	29/10/93	37.00		64.00	180	90	70	190	90	70				
Day 14	05/11/93	37.00		62.40	200	100	100	175	90	100				
Day 21	12/11/93	36.50		63.40	200	95	100	190	90	110				
Day 28	19/11/93	36.50		63.90	190	90	92	195	110	92				
Day 35	26/11/93	37.00		64.50	195	100	92	170	90	94				
Day 42	03/12/93	36.50		63.30	200	90	90	170	70	90				
Day 49	10/12/93	36.80		62.50	220	90	80	210	90	80				
Day 56	17/12/93	36.80		64.00	170	80	60	165	90	64				
382	60T	Imipramine	Female	Screen	12/11/93	36.50	30	63.20	150	80	88	140	70	90
				Day 0	12/11/93	36.50		63.20	150	80	88	140	70	90
				Day 7	19/11/93	36.50		63.00	120	50	76	110	60	74
				Day 14	26/11/93	36.70		63.30	110	70	80	100	60	78
				Day 21	03/12/93	36.50		62.70	115	70	80	110	70	78
				Day 28	10/12/93	36.80		62.50	110	70	80	110	70	78
Day 35	17/12/93	36.00		61.50	115	70	80	110	65	78				
Day 42	24/12/93	36.00		62.40	150	70	76	120	70	80				

2498

9550089

74

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE				
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing Heart Rate (beats/min)	
382	6HD	Reboxetine	Female	Day 49	31/12/93	36.00		63.10	70	80	110	70	78
				Day 56	07/01/94	36.50		62.60	60	78	100	60	80
7DI	7DI	Imipramine	Male	Screen	22/10/93	36.50	30	89.20	80	66	150	75	70
				Day 0	22/10/93	36.50		89.20	80	62	150	75	68
				Day 7	29/10/93			90	60	90			
				Screen	17/12/93	36.50	24	52.00	90	78	140	70	76
				Day 0	20/12/93	36.50		52.00	90	77	140	70	75
				Day 7	28/12/93			52.00	80	77	100	60	80
				Day 14	31/12/93	36.00		53.50	70	76	100	60	80
Day 21	07/01/94	36.00		52.00	70	78	120	70	80				
Day 28	14/01/94	36.50		51.50	60	82	110	60	80				
Day 35	27/01/94	36.00		51.10	70	84	145	70	82				
Day 42	24/01/94	36.20		52.00	80	80	125	75	78				
Day 49	31/01/94	36.00		52.00	80	84	140	75	86				
Day 56	07/02/94	36.20		52.00	70	84	120	70	80				
8DI	8DI	Reboxetine	Female	Screen	22/12/93	36.50	24	56.30	90	80	150	80	90
				Day 0	22/12/93	36.50		56.30	90	80	150	80	90
				Day 7	29/12/93	36.00		59.00	78	108	128	70	108
				Day 14	05/01/94	36.70		58.00	95	72	120	90	86
				Day 21	12/01/94	36.50		57.20	90	88	140	80	84
				Day 28	19/01/94	37.00		57.20	90	80	140	70	88
				Day 35	26/01/94	36.50		57.20	90	88	140	80	84
Day 42	02/02/94	36.00		57.00	70	86	135	65	84				
Day 49	09/02/94	36.10		56.90	60	86	130	70	88				
Day 56	16/02/94	36.50		56.90	80	88	120	80	86				
8ND	8ND	Imipramine	Male	Screen	24/01/94	36.00	14	57.00	55	70	90	50	74
				Day 0	26/01/94	36.00		57.00	55	55	90	50	50
				Day 7	03/02/94	36.20		56.90	60	68	106	60	72
				Day 14	09/02/94	36.50		60.30	70	60	100	70	60
9DI	9DI	Reboxetine	Female	Screen	06/02/94	37.00	20	90.00	50	110	150	90	112
				Day 0	07/02/94	37.00		88.00	60	94	130	70	99
				Day 7	14/02/94	37.00		89.80	70	100	100	60	88
				Day 14	21/02/94	36.00		86.00	70	80	120	70	80
				Day 21	28/02/94	36.50		130	70	80	120	70	80
Day 28	09/03/94			130	70	80	120	70	80				
9ND	9ND	Reboxetine	Female	Screen	11/02/94	36.00	22	58.40	80	84	150	75	82
				Day 0	11/02/94	36.00		58.40	80	84	150	75	82

3749

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

75

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (kg)	BLOOD PRESSURE AND HEART RATE							
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing				
382	9ND	Reboxetine	Female	Day 7	18/02/94	36.50		58.00	130	80	86	120	80	84		
				Day 14	25/02/94	36.80		56.40	120	70	88	110	70	86	86	
				Day 21	04/03/94	36.40		56.20	145	80	86	140	85	84	84	
				Day 28	11/03/94	36.50		55.00	120	90	84	110	90	80	80	80
				Day 35	18/03/94	36.20		56.00	110	70	72	100	90	70	70	70
				Day 42	26/03/94	36.60		55.20	130	90	70	120	90	72	80	72
				Day 49	01/04/94	36.00		54.80	130	88	80	125	80	78		
				Day 56	08/04/94	36.50		56.30	130	80	74	120	80	78	78	
3301	10ND	Imipramine	Female	Screen	11/02/94	36.50	25	48.50	150	105	80	130	95	88		
				Day 0	11/02/94	36.50		48.50	150	105	80	130	95	88		
				Day 7	18/02/94	36.50		48.50	170	105	110	120	70	120		
				Screen	16/09/92	37.00	17	62.00	130	70	68	120	80	74		
				Day 0	24/09/92	37.00		62.10	130	70	70	120	80	80		
2500	2ND	Imipramine	Male	Screen	02/01/93	37.00	30	39.00	120	70	72	120	70	84		
				Day 0	12/01/93	37.00		39.00	120	70	72	120	80	80		
				Day 7	19/01/93	36.80		40.00	120	60	72	120	70	80		
				Day 14	26/01/93	35.40		38.00	125	65	80	115	55	92		
				Day 21	03/02/93	36.40		39.00	125	70	76	120	60	82		
				Day 28	10/02/93	35.40		40.00	120	70	76	110	50	78		
				Day 35	17/02/93	36.50		42.00	120	70	71	120	70	74		
				Day 42	24/02/93	36.50		42.00	120	70	74	124	80	80		
				Day 49	03/03/93	36.50		42.00	125	68	71	124	70	74		
				Day 56	10/03/93	36.00		42.10	128	72	74	120	70	76		
3302	3ND	Reboxetine	Female	Screen	09/01/93	36.00	20	65.00	160	70	83	160	65	72		
				Day 0	16/01/93	36.00		65.00	160	70	74	160	66	66		
				Day 7	23/01/93	36.80		64.00	150	85	70	160	90	72		
				Day 14	30/01/93	36.70		64.00	150	80	72	160	90	76		
				Day 21	06/02/93	36.50		63.50	140	80	82	156	90	86		
				Day 28	13/02/93	36.00		64.00	160	74	74	154	70	74		
3302	5ND	Reboxetine	Female	Screen	30/10/92	37.00	19	69.60	130	85	76	136	80	80		
				Day 0	07/11/92	37.00		69.60	130	75	76	130	70	78		
				Day 7	14/11/92	36.50		69.00	125	80	80	120	80	82		
				Day 14	21/11/92	36.50		65.30	130	80	70	126	80	72		
				Day 21	27/11/92	37.00		64.30	123	75	74	130	75	74		
3302	6ND	Imipramine	Female	Screen	23/06/93	36.70	20	44.90	150	85	86	150	85	90		
				Day 0	25/06/93	36.70		44.90	155	85	86	150	85	88		
				Day 7	03/07/93	36.70		45.10	170	100	86	170	100	88		

9550089

9550089

76

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035

Listing No.: 20.0

VITAL SIGNS AND ASSESSMENT DATES

Centre	Patient	Treatment	Sex	Visit	Date	Body Temperature (°C)	Respiratory Rate (breaths/min)	Body Weight (Kg)	BLOOD PRESSURE AND HEART RATE				
									S.B.P. (mmHg)	D.B.P. (mmHg)	Heart Rate (beats/min)	standing	
3302	6HD	Imipramine	Female	Day 14	10/07/93	36.50		45.10	165	86	165	90	86
				Day 21	17/07/93	36.50		44.50	170	88	170	90	90
7HD		Imipramine	Female	Screen	10/11/93	36.50	19	52.50	160	74	160	80	80
				Day 0	13/11/93	36.50		52.00	160	72	160	80	78
				Day 7	20/11/93	36.50		52.20	160	76	164	85	78
				Day 14	29/11/93	36.50		50.50	160	74	160	85	78
				Day 21	06/12/93	36.50		52.70	160	72	160	85	76
				Day 28	13/12/93	36.50		53.00	160	74	160	80	78
				Day 35	22/12/93	36.50		53.00	160	74	160	80	76
				Day 42	29/12/93	36.50		53.00	154	68	160	80	72
				Day 49	06/01/94	36.50		53.00	154	68	160	84	78
				Day 56	13/01/94	36.50		54.00	160	72	160	90	74

2501

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0
ECG TRACINGS

Contro	Patient	Treatment	Sex	Treatment period		Visit	days of treat.	Assessment	E.C.G.		Abnormality
				Start date	End date				Date	Value	
1	1MD	Reboxetine	Female	05/11/92	30/12/92	Screen	-1	Screening	04/11/92	Abnormal	LEFT VENTRICULAR HYPERTROPHY MYOCARDIAL ISCHEMIA
						Day 28	27	1-28 days	02/12/92	Abnormal	LEFT VENTRICULAR HYPERTROPHY CONDUCTION DISORDER
						Day 56	55	29-56 days	30/12/92	Abnormal	LEFT VENTRICULAR HYPERTROPHY
	1DT	Reboxetine	Male	26/11/93	20/01/94	Screen	-8	Screening	18/11/93	Normal	
						Day 28	27	1-28 days	23/12/93	Normal	
						Day 56	55	29-56 days	20/01/94	Abnormal	A-V BLOCK 1ST DEGREE
	2MD	Imipramine	Male	17/11/92	11/01/93	Screen	-1	Screening	16/11/92	Normal	
						Day 28	27	1-28 days	14/12/92	Normal	
						Day 56	56	29-56 days	12/01/93	Normal	
	2DT	Imipramine	Male	09/12/93	22/12/93	Screen	-2	Screening	07/12/93	Abnormal	SINUS TACHYCARDIA (> 100)
						Screen	-3	Screening	31/05/93	Normal	
Day 28						27	1-28 days	30/06/93	Abnormal	A-V BLOCK 1ST DEGREE RIGHT BUNDLE BRANCH BLOCK	
3MD	Imipramine	Female	03/06/93	28/07/93	Screen	55	29-56 days	28/07/93	Abnormal	A-V BLOCK 1ST DEGREE RIGHT BUNDLE BRANCH BLOCK	
					Screen	-1	Screening	09/12/93	Normal		
					Day 28	31	1-28 days	10/01/94	Normal		
3DT	Reboxetine	Male	10/12/93	03/02/94	Screen	-1	Screening	09/12/93	Normal		
					Day 28	55	29-56 days	03/02/94	Normal		
					Day 56	55	29-56 days	03/02/94	Normal		
4MD	Reboxetine	Female	19/10/93	13/12/93	Screen	-5	Screening	14/10/93	Normal		
					Day 28	27	1-28 days	15/11/93	Normal		
					Day 56	55	29-56 days	13/12/93	Normal		
4DT	Imipramine	Male	01/02/94	24/02/94	Screen	0	Screening	01/02/94	Abnormal	LEFT BUNDLE BRANCH BLOCK	
					Day 28	23	1-28 days	24/02/94	Abnormal	LEFT BUNDLE BRANCH BLOCK	
					Screen	-13	Screening	02/01/93	Normal	VENTRICULAR ECTOPIC BEATS - OCCASIONAL NON SPECIFIC ST-T WAVE CHANGES	
2	Reboxetine	Male	15/01/93	08/02/93	Screen	27	1-28 days	11/02/93	Abnormal		
					Screen	-8	Screening	27/04/93	Normal		
					Day 28	30	1-28 days	04/06/93	Normal		
3	Reboxetine	Female	05/05/93	22/06/93	Screen	48	29-56 days	22/06/93	Normal		
					Day 28	48	29-56 days	22/06/93	Normal		
					Day 49	48	29-56 days	22/06/93	Normal		

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

2

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0
ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period		Visit	days of treat.	Assessment	E.C.G.		
				Start date	End date				Date	Value	Abnormality
4	1ND	Imipramine	Male	25/11/92	29/12/92	Screen Day 28	-5 27	Screening 1-28 days	20/11/92 22/12/92	Abnormal Abnormal	A-V BLOCK 1ST DEGREE SINUS TACHYCARDIA (> 100) NON SPECIFIC ST-T WAVE CHANGES
5	1ND	Reboxetine	Female	30/10/92	10/11/92	Screen	-10	Screening	20/10/92	Normal	
	1DT	Imipramine	Female	11/11/92	06/01/93	Screen Day 56	-2 56	Screening 29-56 days	09/11/92 06/01/93	Normal Normal	
	2ND	Reboxetine	Male	24/11/92	18/01/93	Screen	-9	Screening	15/11/92	Abnormal	ATRIAL ECTOPIC BEATS - OCCASIONAL A-V BLOCK 1ST DEGREE PREVIOUS MYOCARDIAL INFARCTION LEFT ANTERIOR HEMIBLOCK EPILEPTIC DISTURBANCES PREVIOUS MYOCARDIAL INFARCTION LEFT ANTERIOR HEMIBLOCK PREVIOUS MYOCARDIAL INFARCTION LEFT ANTERIOR HEMIBLOCK
	2DT	Imipramine	Female	23/12/92	14/02/93	Screen Day 28 Day 56	-9 26 62	Screening 1-28 days 29-56 days	14/12/92 18/01/93 23/02/93	Normal Normal Normal	
	3ND	Imipramine	Female	17/03/93	11/05/93	Screen Day 28 Day 56	-8 27 55	Screening 1-28 days 29-56 days	09/03/93 13/04/93 11/05/93	Normal Normal Normal	
	3DT	Reboxetine	Male	27/03/93	21/05/93	Screen Day 28 Day 56	-9 27 52	Screening 1-28 days 29-56 days	18/03/93 23/04/93 18/05/93	Abnormal Abnormal Abnormal	MYOCARDIAL ISCHEMIA MYOCARDIAL ISCHEMIA MYOCARDIAL ISCHEMIA
	4ND	Imipramine	Male	24/11/92	18/01/93	Screen Day 28 Day 56	-6 27 55	Screening 1-28 days 29-56 days	18/11/92 21/12/92 18/01/93	Normal Normal Normal	
	4DT	Reboxetine	Male	03/02/93	02/03/93	Screen Day 28	-6 27	Screening 1-28 days	28/01/93 02/03/93	Normal Normal	
	5ND	Reboxetine	Male	04/08/93	15/08/93	Screen	-7	Screening	28/07/93	Normal	

2503

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

3

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 21.0
 ECG TRACINGS

Centre	Patient	Treatment	Sex	-Treatment period-		Visit	days of treat.	Assessment	Date	Value	Abnormality
				Start date	End date						
5	5DT	Reboxetine	Female	17/02/93	17/03/93	Screen Day 28	-8 35	Screening 1-28 days	09/02/93 24/03/93	Normal Normal	
	6MD	Imipramine	Male	05/08/93	18/08/93	Screen	-7	Screening	29/07/93	Normal	
	6DT	Reboxetine	Female	27/02/93	23/04/93	Screen Day 28 Day 56	-8 27 55	Screening 1-28 days 29-56 days	19/02/93 24/03/93 23/04/93	Normal Normal Normal	
	7MD	Reboxetine	Male	27/10/93	16/11/93	Screen	-10	Screening	17/10/93	Normal	
	7DT	Imipramine	Female	19/03/93	07/05/93	Screen Day 28 Day 56	-6 27 55	Screening 1-28 days 29-56 days	07/03/93 09/04/93 07/05/93	Normal Abnormal Abnormal	RIGHT BUNDLE BRANCH BLOCK RIGHT BUNDLE BRANCH BLOCK
	8MD	Imipramine	Female	11/11/93	05/01/94	Screen Day 28 Day 56	-18 28 56	Screening 1-28 days 29-56 days	24/10/93 09/12/93 06/01/94	Abnormal Normal Normal	A-V BLOCK 1ST DEGREE
	8DT	Imipramine	Female	05/05/93	29/06/93	Screen Day 28 Day 56	-5 27 55	Screening 1-28 days 29-56 days	30/04/93 01/06/93 29/06/93	Normal Normal Normal	
	9MD	Reboxetine	Female	16/11/93	10/01/94	Screen Day 28 Day 56	-7 28 56	Screening 1-28 days 29-56 days	09/11/93 14/12/93 11/01/94	Normal Normal Normal	
	9DT	Reboxetine	Female	02/05/93	25/06/93	Screen Day 21 Day 56	-2 16 82	Screening 1-28 days 29-56 days	30/04/93 18/05/93 23/07/93	Normal Normal Normal	
	10MD	Imipramine	Female	25/11/93	08/12/93	Screen	-8	Screening	17/11/93	Normal	
	10DT	Imipramine	Male	06/05/93	10/05/93	Screen	-5	Screening	01/05/93	Normal	
	11MD	Imipramine	Female	02/12/93	05/01/94	Screen	-7	Screening	25/11/93	Normal	

204

9550089

4

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PRAXINACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0
ECG TRACINGS

Centre	Patient	Treatment	Sex	_Treatment period_		Visit	days of treat.	Assessment	E.C.G.		
				Start date	End date				Date	Value	Abnormality
5	11DT	Reboxetine	Female	11/05/93	07/06/93	Screen	-6	Screening	05/05/93	Normal	
	12ND	Reboxetine	Female	06/01/94	03/03/94	Screen Day 28	-16 29	Screening 1-28 days	21/12/93 04/02/94	Normal Normal	
	12DT	Imipramine	Male	21/05/93	15/07/93	Screen Day 56	-3 55	Screening 29-56 days	18/05/93 15/07/93	Normal Normal	
	1ND	Reboxetine	Female	13/11/92	07/01/93	Screen Day 28 Day 56	-1 27 56	Screening 1-28 days 29-56 days	12/11/92 10/12/92 08/01/93	Normal Normal Normal	
	1DT	Reboxetine	Female	21/10/92	16/12/92	Screen Day 28 Day 56	-8 27 56	Screening 1-28 days 29-56 days	13/10/92 17/11/92 16/12/92	Normal Normal Normal	
	2ND	Imipramine	Female	11/11/92	17/11/92	Screen	-2	Screening	09/11/92	Normal	
	2DT	Reboxetine	Female	21/01/93	27/01/93	Screen Day 7	8 8	Screening 1-28 days	29/01/93 29/01/93	Abnormal Abnormal	LEFT VENTRICULAR HYPERTROPHY LEFT VENTRICULAR HYPERTROPHY
	3ND	Reboxetine	Female	03/12/92	27/01/93	Screen Day 21 Day 56	-1 21 55	Screening 1-28 days 29-56 days	02/12/92 24/12/92 27/01/93	Normal Normal Normal	
	3DT	Imipramine	Female	08/04/93	02/06/93	Screen Day 28 Day 56	-20 27 55	Screening 1-28 days 29-56 days	19/03/93 05/05/93 02/06/93	Normal Abnormal Normal	MYOCARDIAL ISCHEMIA
	4ND	Imipramine	Female	15/12/92	18/01/93	Screen Day 35	-6 34	Screening 29-56 days	09/12/92 18/01/93	Abnormal Normal	LEFT VENTRICULAR HYPERTROPHY
4DT	Imipramine	Female	05/05/93	29/06/93	Screen Day 28 Day 56	-2 28 56	Screening 1-28 days 29-56 days	03/05/93 02/06/93 30/06/93	Normal Normal Normal		
5ND	Imipramine	Female	03/04/93	28/05/93	Screen	-1	Screening	02/04/93	Normal		

9550089

5

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0

E.C.G.

Centre	Patient	Treatment	Sex	_Treatment period_		Visit	days of treat, Assessment	Date	Value	Abnormality	
				Start date	End date						
6	5ND	Imipramine	Female	05/04/93	28/05/93	Day 28	27 1-28 days	30/04/93	Normal	VENTRICULAR ECTOPIC BEATS - OCCASIONAL	
						Day 56	55 29-56 days	28/05/93	Abnormal		
	5OT	Reboxetine	Female	20/11/93	14/01/94	Screen	-3 Screening	17/11/93	Normal		
						Day 28	27 1-28 days	17/12/93	Normal		
							Day 56	55 29-56 days	14/01/94	Normal	
							Screen	-2 Screening	27/04/93	Abnormal	LEFT VENTRICULAR HYPERTROPHY LEFT VENTRICULAR HYPERTROPHY RIGHT VENTRICULAR HYPERTROPHY
							Day 28	29 1-28 days	28/05/93	Abnormal	
							Screen	-2 Screening	18/10/93	Normal	
							Day 28	28 1-28 days	17/11/93	Normal	
							Day 56	56 29-56 days	15/12/93	Normal	
	7	8ND	Imipramine	Female	23/11/93	17/01/94	Screen	-4 Screening	19/11/93	Abnormal	SINUS BRADYCARDIA (< 60) SINUS BRADYCARDIA (< 60) SINUS BRADYCARDIA (< 60)
							Day 28	29 1-28 days	22/12/93	Abnormal	
							Day 56	55 29-56 days	17/01/94	Abnormal	
							Screen	-3 Screening	06/01/93	Normal	
							Day 28	27 1-28 days	05/02/93	Normal	
							Day 56	59 29-56 days	09/03/93	Normal	
							Screen	-10 Screening	13/04/93	Normal	RIPOLARIZATION DISTURBANCES RIPOLARIZATION DISTURBANCES
							Day 28	26 1-28 days	19/05/93	Abnormal	
							Day 56	55 29-56 days	17/06/93	Abnormal	
							Screen	-9 Screening	15/04/93	Normal	
							Day 28	30 1-28 days	24/05/93	Abnormal	LEFT ANTERIOR HEMIBLOCK
							Day 56	56 29-56 days	17/02/93	Abnormal	
8	342ND	Reboxetine	Female	23/02/93	19/04/93	Screen	-6 Screening	24/03/93	Normal	NON SPECIFIC ST-T WAVE CHANGES	
						Day 28	29 1-28 days	24/03/93	Normal		
							Day 56	56 29-56 days	20/04/93	Normal	
							Screen	-6 Screening	24/09/92	Normal	
							Day 28	27 1-28 days	27/10/92	Abnormal	SINUS TACHYCARDIA (> 100) SINUS TACHYCARDIA (> 100)
							Day 56	56 29-56 days	25/11/92	Abnormal	
							Screen	-5 Screening	23/09/92	Abnormal	SINUS TACHYCARDIA (> 100) VENTRICULAR ECTOPIC BEATS - OCCASIONAL
							Screen	-5 Screening	22/11/92	Abnormal	

25
06

9550089

6

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0
ECG TRACINGS

Centre	Patient	Treatment	Sex	_Treatment period_		Visit	days of treat.	Assessment	E.C.G.		
				Start date	End date				Date	Value	Abnormality
8	1DT	Imipramine	Female	28/09/92	22/11/92	Screen	-5	Screening	23/09/92	Abnormal	RIPOLARIZATION DISTURBANCES
						Day 28	25	1-28 days	23/10/92	Abnormal	MYOCARDIAL ISCHEMIA
						Day 56	53	29-56 days	20/11/92	Normal	
2ND	Reboxetine	Female	30/09/92	24/11/92	Screen	-7	Screening	23/09/92	Abnormal	SINUS TACHYCARDIA (> 100) BIFASCICULAR BLOCK	
					Day 28	27	1-28 days	27/10/92	Abnormal	CONDUCTION DISORDER RIGHT BUNDLE BRANCH BLOCK	
					Day 56	55	29-56 days	24/11/92	Abnormal	RIGHT BUNDLE BRANCH BLOCK LEFT ANTERIOR HEKIBLOCK	
2DT	Imipramine	Female	30/09/92	24/11/92	Screen	-7	Screening	23/09/92	Abnormal	CONDUCTION DISORDER	
					Day 28	27	1-28 days	27/10/92	Abnormal	RIGHT BUNDLE BRANCH BLOCK	
					Day 56	55	29-56 days	24/11/92	Abnormal	RIGHT BUNDLE BRANCH BLOCK	
3ND	Imipramine	Female	02/10/92	10/10/92	Screen	-3	Screening	29/09/92	Normal		
					Screen	-3	Screening	29/09/92	Abnormal	PREVIOUS MYOCARDIAL INFARCTION	
					Day 28	28	1-28 days	30/10/92	Normal		
3DT	Reboxetine	Female	02/10/92	26/11/92	Screen	56	29-56 days	27/11/92	Abnormal	SINUS TACHYCARDIA (> 100)	
					Day 28	28	1-28 days	27/11/92	Abnormal		
					Day 56	56	29-56 days	27/11/92	Abnormal		
4ND	Imipramine	Male	02/10/92	27/10/92	Screen	-3	Screening	29/09/92	Normal		
					Screen	-3	Screening	29/09/92	Abnormal	SINUS TACHYCARDIA (> 100)	
					Day 28	28	1-28 days	30/10/92	Abnormal	PREVIOUS MYOCARDIAL INFARCTION VENTRICULAR ECTOPIC BEATS - OCCASIONAL	
4DT	Reboxetine	Female	02/10/92	26/11/92	Screen	56	29-56 days	27/11/92	Abnormal	PREVIOUS MYOCARDIAL INFARCTION VENTRICULAR ECTOPIC BEATS - OCCASIONAL	
					Day 28	28	1-28 days	27/11/92	Abnormal		
					Day 56	56	29-56 days	27/11/92	Abnormal		
701ND	Imipramine	Male	09/10/92	03/12/92	Screen	-3	Screening	06/10/92	Normal		
					Day 28	28	1-28 days	06/11/92	Abnormal	CONDUCTION DISORDER	
					Day 56	56	29-56 days	04/12/92	Abnormal	VENTRICULAR ECTOPIC BEATS - OCCASIONAL	
701DT	Reboxetine	Female	09/10/92	03/12/92	Screen	-8	Screening	01/10/92	Normal		
					Day 28	28	1-28 days	06/11/92	Abnormal	SINUS TACHYCARDIA (> 100)	
					Day 56	56	29-56 days	04/12/92	Abnormal	SINUS TACHYCARDIA (> 100)	
702ND	Reboxetine	Male	16/10/92	10/12/92	Screen	-3	Screening	13/10/92	Normal		
					Day 28	28	1-28 days	13/11/92	Normal		
					Day 56	59	29-56 days	14/12/92	Normal		

2507

9550089

7

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0

E.C.G.
ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period		Visit	days of treat.	Assessment	Date	Value	Abnormality
				Start date	End date						
8	702DT	Imipramine	Female	09/10/92	03/12/92	Screen	-3	Screening	06/10/92	Normal	
						Day 28	28	1-28 days	06/11/92	Normal	
						Day 56	56	29-56 days	06/12/92	Normal	
703HD	Imipramine	Female	09/02/93	05/04/93	Screen	-13	Screening	27/01/93	Normal		
					Day 28	24	1-28 days	05/03/93	Normal		
					Day 56	50	29-56 days	31/03/93	Abnormal	A-V BLOCK 1ST DEGREE CONDUCTION DISORDER	
703DT	Imipramine	Male	09/02/93	05/04/93	Screen	-15	Screening	25/01/93	Abnormal	SINUS TACHYCARDIA (> 100) VENTRICULAR ECTOPIC BEATS - OCCASIONAL	
					Day 28	28	1-28 days	09/03/93	Normal		
					Day 56	50	29-56 days	31/03/93	Normal		
704HD	Reboxetine	Female	09/02/93	05/04/93	Screen	-20	Screening	20/01/93	Abnormal	SINUS BRADYCARDIA (< 60) LEFT VENTRICULAR HYPERTROPHY MYOCARDIAL ISCHEMIA MYOCARDIAL ISCHEMIA PREVIOUS MYOCARDIAL INFARCTION	
					Day 28	28	1-28 days	09/03/93	Abnormal	SINUS BRADYCARDIA (< 60)	
					Day 49	45	29-56 days	26/03/93	Abnormal	A-V BLOCK 1ST DEGREE LEFT VENTRICULAR HYPERTROPHY PREVIOUS MYOCARDIAL INFARCTION	
704DT	Reboxetine	Female	09/02/93	05/04/93	Screen	-102	Screening	30/10/92	Normal		
					Day 28	24	1-28 days	05/03/93	Abnormal	SINUS TACHYCARDIA (> 100)	
					Day 56	50	29-56 days	31/03/93	Abnormal	SINUS TACHYCARDIA (> 100)	
9	1ND	Imipramine	Female	23/09/93	23/11/93	Screen	-7	Screening	21/09/93	Normal	
						Day 28	28	1-28 days	26/10/93	Normal	
						Day 56	56	29-56 days	23/11/93	Normal	
1DT	Imipramine	Female	15/12/93	08/02/94	Screen	-7	Screening	08/12/93	Normal		
					Day 28	28	1-28 days	12/01/94	Normal		
					Day 56	56	29-56 days	09/02/94	Normal		
2ND	Reboxetine	Female	01/10/93	25/11/93	Screen	-7	Screening	24/09/93	Normal		
					Day 28	28	1-28 days	29/10/93	Normal		
					Day 56	56	29-56 days	26/11/93	Normal		

2508

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

8

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0
ECC TRACINGS

Centre	Patient	Treatment	Sex	Treatment period		Visit	days of treat.	Assessment	E.C.G.	
				Start date	End date				Date	Value
9	2DT	Imipramine	Female	22/12/93	15/02/94	Screen	-7	Screening	15/12/93	Normal
						Day 28	28	1-28 days	19/01/94	Normal
	3DT	Reboxetine	Female	13/10/93	07/12/93	Day 56	56	29-56 days	16/02/94	Normal
						Screen	-8	Screening	05/10/93	Normal
	4ND	Imipramine	Female	13/10/93	07/12/93	Day 28	28	1-28 days	10/11/93	Normal
						Day 56	56	29-56 days	08/12/93	Normal
	5ND	Reboxetine	Female	26/10/93	21/12/93	Screen	-8	Screening	05/10/93	Normal
						Day 28	28	1-28 days	10/11/93	Normal
	6ND	Imipramine	Female	03/11/93	05/11/93	Day 56	56	29-56 days	08/12/93	Normal
						Screen	-7	Screening	19/10/93	Normal
7ND	Imipramine	Female	10/11/93	11/11/93	Day 28	28	1-28 days	23/11/93	Normal	
					Day 56	56	29-56 days	21/12/93	Normal	
8DT	Reboxetine	Female	16/11/93	10/01/94	Screen	-7	Screening	27/10/93	Normal	
					Day 28	28	1-28 days	03/11/93	Normal	
10	1ND	Imipramine	Female	02/10/93	26/11/93	Screen	-8	Screening	24/09/93	Abnormal
						Day 28	27	1-28 days	29/10/93	Abnormal
1DT	Reboxetine	Female	01/12/93	25/01/94	Day 56	55	29-56 days	26/11/93	Abnormal	
					Screen	-8	Screening	23/11/93	Normal	
2ND	Reboxetine	Male	02/10/93	26/11/93	Day 28	27	1-28 days	28/12/93	Normal	
					Day 56	55	29-56 days	25/01/94	Normal	
2DT	Imipramine	Male	01/12/93	25/01/94	Screen	-8	Screening	24/09/93	Normal	
					Day 28	27	1-28 days	29/10/93	Normal	
					Day 56	55	29-56 days	26/11/93	Normal	
					Screen	-8	Screening	23/11/93	Normal	
					Day 28	27	1-28 days	28/12/93	Normal	
					Day 56	55	29-56 days	25/01/94	Normal	
					Screen	-8	Screening	24/09/93	Normal	
					Day 28	27	1-28 days	29/10/93	Normal	
					Day 56	55	29-56 days	26/11/93	Normal	
					Screen	-8	Screening	23/11/93	Normal	
					Day 28	27	1-28 days	28/12/93	Normal	
					Day 56	55	29-56 days	25/01/94	Normal	
					Screen	-8	Screening	24/09/93	Normal	
					Day 28	27	1-28 days	29/10/93	Normal	
					Day 56	55	29-56 days	26/11/93	Normal	
					Screen	-8	Screening	23/11/93	Normal	
					Day 28	27	1-28 days	28/12/93	Normal	
					Day 56	55	29-56 days	25/01/94	Normal	
					Screen	-8	Screening	24/09/93	Normal	
					Day 28	27	1-28 days	29/10/93	Normal	
					Day 56	55	29-56 days	26/11/93	Normal	
					Screen	-8	Screening	23/11/93	Normal	
					Day 28	27	1-28 days	28/12/93	Normal	
					Day 56	55	29-56 days	25/01/94	Normal	
					Screen	-8	Screening	24/09/93	Normal	
					Day 28	27	1-28 days	29/10/93	Normal	
					Day 56	55	29-56 days	26/11/93	Normal	
					Screen	-8	Screening	23/11/93	Normal	
					Day 28	27	1-28 days	28/12/93	Normal	
					Day 56	55	29-56 days	25/01/94	Normal	
					Screen	-8	Screening	24/09/93	Normal	
					Day 28	27	1-28 days	29/10/93	Normal	
					Day 56	55	29-56 days	26/11/93	Normal	
					Screen	-8	Screening	23/11/93	Normal	
					Day 28	27	1-28 days	28/12/93	Normal	
					Day 56	55	29-56 days	25/01/94	Normal	
					Screen	-8	Screening	24/09/93	Normal	
					Day 28	27	1-28 days	29/10/93	Normal	
					Day 56	55	29-56 days	26/11/93	Normal	
					Screen	-8	Screening	23/11/93	Normal	
					Day 28	27	1-28 days	28/12/93	Normal	
					Day 56	55	29-56 days	25/01/94	Normal	
					Screen	-8	Screening	24/09/93	Normal	
					Day 28	27	1-28 days	29/10/93	Normal	
					Day 56	55	29-56 days	26/11/93	Normal	
					Screen	-8	Screening	23/11/93	Normal	
					Day 28	27	1-28 days	28/12/93	Normal	
					Day 56	55	29-56 days	25/01/94	Normal	
					Screen	-8	Screening	24/09/93	Normal	
					Day 28	27	1-28 days	29/10/93	Normal	
					Day 56	55	29-56 days	26/11/93	Normal	
					Screen	-8	Screening	23/11/93	Normal	
					Day 28	27	1-28 days	28/12/93	Normal	
					Day 56	55	29-56 days	25/01/94	Normal	
					Screen	-8	Screening	24/09/93	Normal	
					Day 28	27	1-28 days	29/10/93	Normal	
					Day 56	55	29-56 days	26/11/93	Normal	
					Screen	-8	Screening	23/11/93	Normal	
					Day 28	27	1-28 days	28/12/93	Normal	
					Day 56	55	29-56 days	25/01/94	Normal	
					Screen	-8	Screening	24/09/93	Normal	
					Day 28	27	1-28 days	29/10/93	Normal	
					Day 56	55	29-56 days	26/11/93	Normal	
					Screen	-8	Screening	23/11/93	Normal	
					Day 28	27	1-28 days	28/12/93	Normal	
					Day 56	55	29-56 days	25/01/94	Normal	
					Screen	-8	Screening	24/09/93	Normal	
					Day 28	27	1-28 days	29/10/93	Normal	
					Day 56	55	29-56 days	26/11/93	Normal	
					Screen	-8	Screening	23/11/93	Normal	
					Day 28	27	1-28 days	28/12/93	Normal	
					Day 56	55	29-56 days	25/01/94	Normal	
					Screen	-8	Screening	24/09/93	Normal	
					Day 28	27	1-28 days	29/10/93	Normal	
					Day 56	55	29-56 days	26/11/93	Normal	
					Screen	-8	Screening	23/11/93	Normal	
					Day 28	27	1-28 days	28/12/93	Normal	
					Day 56	55	29-56 days	25/01/94	Normal	
					Screen	-8	Screening	24/09/93	Normal	
					Day 28	27	1-28 days	29/10/93	Normal	
					Day 56	55	29-56 days	26/11/93	Normal	
					Screen	-8	Screening	23/11/93	Normal	
					Day 28	27	1-28 days	28/12/93	Normal	
					Day 56	55	29-56 days	25/01/94	Normal	
					Screen	-8	Screening	24/09/93	Normal	
					Day 28	27	1-28 days	29/10/93	Normal	
					Day 56	55	29-56 days	26/11/93	Normal	
					Screen	-8	Screening	23/11/93	Normal	
					Day 28	27	1-28 days	28/12/93	Normal	
					Day 56	55	29-56 days	25/01/94	Normal	
					Screen	-8	Screening	24/09/93	Normal	
					Day 28	27	1-28 days	29/10/93	Normal	
					Day 56	55	29-56 days	26/11/93	Normal	
					Screen	-8	Screening	23/11/93	Normal	
					Day 28	27	1-28 days	28/12/93	Normal	
					Day 56	55	29-56 days	25/01/94	Normal	
					Screen	-8	Screening	24/09/93	Normal	
					Day 28	27	1-28 days	29/10/93	Normal	
					Day 56	55	29-56 days	26/11/93	Normal	
					Screen	-8	Screening	23/11/93	Normal	
					Day 28	27	1-28 days	28/12/93	Normal	
					Day 56	55	29-56 days	25/01/94	Normal	
					Screen	-8	Screening	24/09/93	Normal	
					Day 28	27	1-28 days	29/10/93	Normal	
					Day 56	55	29-56 days	26/11/93	Normal	
					Screen	-8	Screening	23/11/93	Normal	
					Day 28	27	1-28 days	28/12/93	Normal	
					Day 56	55	29-56 days	25/01/94	Normal	
					Screen	-8	Screening	24/09/93	Normal	
					Day 28	27	1-28 days	29/10/93	Normal	
					Day 56	55	29-56 days	26/11/93	Normal	
					Screen	-8	Screening	23/11/93	Normal	
					Day 28	27	1-28 days	28/12/93	Normal	
					Day 56	55	29-56 days	25/01/94	Normal	
					Screen	-8	Screening	24/09/93	Normal	
					Day 28	27	1-28 days	29/10/93	Normal	
					Day 56	55	29-56 days	26/11/93	Normal	
					Screen	-8	Screening	23/11/93	Normal	
					Day 28	27	1-28 days	28/12/93	Normal	
					Day 56	55	29-56 days	25/01/94	Normal	
					Screen	-8	Screening	24/09/93	Normal	
					Day 28	27	1-28 days	29/10/93	Normal	
					Day 56	55	29-56 days	26/11/93	Normal	
					Screen	-8	Screening	23/11/93	Normal	
					Day 28	27	1-28 days	28/12/93	Normal	
					Day 56	55	29-56 days	25/01/94	Normal	
					Screen	-8	Screening	24/09/93	Normal	
					Day 28	27	1-28 days	29/10/93	Normal	
					Day 56	55	29-56 days	26/11/93	Normal	
					Screen	-8	Screening	23/11/93	Normal	
					Day 28	27	1-28 days	28/12/93	Normal	
					Day 56	55	29-56 days	25/01/94	Normal	
					Screen	-8	Screening	24/09/93	Normal	
					Day 28	27	1-28 days	29/10/93	Normal	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

9

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 21.0
 ECC TRACINGS

Centre	Patient	Treatment	Sex	Treatment period		Visit	days of treat.	Assessment	Date	Value	Abnormality
				Start date	End date						
10	3ND	Reboxetine	Male	02/10/93	26/11/93	Screen	-8	Screening	24/09/93	Normal	
						Day 28	27	1-28 days	25/10/93	Normal	
						Day 56	55	29-56 days	26/11/93	Normal	
	3DT	Imipramine	Male	02/12/93	26/01/94	Screen	-8	Screening	24/11/93	Normal	
						Day 28	27	1-28 days	25/12/93	Normal	
						Day 56	55	29-56 days	25/01/94	Normal	
	4ND	Imipramine	Female	06/10/93	30/11/93	Screen	-8	Screening	28/09/93	Normal	
						Day 28	28	1-28 days	03/11/93	Normal	
						Day 56	55	29-56 days	30/11/93	Normal	
	4DT	Reboxetine	Female	02/12/93	26/01/94	Screen	-8	Screening	26/11/93	Normal	
						Day 28	27	1-28 days	29/12/93	Normal	
						Day 56	55	29-56 days	26/01/94	Normal	
	5ND	Imipramine	Female	06/10/93	30/11/93	Screen	-7	Screening	29/09/93	Normal	
						Day 28	28	1-28 days	03/11/93	Normal	
						Day 56	55	29-56 days	30/11/93	Normal	
	5DT	Reboxetine	Female	04/12/93	28/01/94	Screen	-8	Screening	26/11/93	Normal	
						Day 28	26	1-28 days	30/12/93	Normal	
						Day 56	55	29-56 days	28/01/94	Normal	
	6ND	Reboxetine	Male	09/10/93	03/12/93	Screen	-8	Screening	01/10/93	Normal	
						Day 28	27	1-28 days	05/11/93	Normal	
						Day 56	55	29-56 days	03/12/93	Normal	
	6DT	Reboxetine	Male	04/12/93	28/01/94	Screen	-8	Screening	26/11/93	Normal	
						Day 28	26	1-28 days	30/12/93	Normal	
						Day 56	55	29-56 days	28/01/94	Normal	
	7ND	Imipramine	Male	09/10/93	03/12/93	Screen	-8	Screening	01/10/93	Normal	
						Day 28	27	1-28 days	05/11/93	Normal	
						Day 56	55	29-56 days	03/12/93	Normal	
	7DT	Imipramine	Female	04/12/93	28/01/94	Screen	-8	Screening	26/11/93	Normal	
						Day 28	26	1-28 days	30/12/93	Normal	
						Day 56	55	29-56 days	28/01/94	Normal	

2510

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

10

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0
EKG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period		Visit	days of treat.	Assessment	E.C.G.	
				Start date	End date				Date	Value
10	8HD	Reboxetine	Male	16/10/93	10/12/93	Screen Day 28 Day 56	-8 27 55	Screening 1-28 days 29-56 days	08/10/93 12/11/93 10/12/93	Normal Normal Normal
	8DT	Imipramine	Female	04/12/93	28/01/94	Screen Day 28 Day 56	-8 26 55	Screening 1-28 days 29-56 days	26/11/93 30/12/93 28/01/94	Normal Normal Normal
	9ND	Reboxetine	Female	20/11/93	14/01/94	Screen Day 28 Day 56	-8 27 55	Screening 1-28 days 29-56 days	12/11/93 17/12/93 14/01/94	Normal Normal Normal
	9DT	Imipramine	Male	08/12/93	01/02/94	Screen Day 28 Day 56	-8 27 55	Screening 1-28 days 29-56 days	30/11/93 04/01/94 01/02/94	Normal Normal Normal
23	10HD	Imipramine	Female	23/10/93	17/12/93	Screen Day 28 Day 56	-8 27 55	Screening 1-28 days 29-56 days	15/10/93 19/11/93 17/12/93	Normal Normal Normal
57	10DT	Reboxetine	Female	08/12/93	01/02/94	Screen Day 28 Day 56	-8 27 55	Screening 1-28 days 29-56 days	30/11/93 04/01/94 01/02/94	Normal Normal Normal
11	11ND	Imipramine	Female	23/10/93	17/12/93	Screen Day 28 Day 56	-8 27 55	Screening 1-28 days 29-56 days	15/10/93 19/11/93 17/12/93	Normal Normal Normal
	11DT	Imipramine	Female	08/12/93	01/02/94	Screen Day 28 Day 56	-8 27 55	Screening 1-28 days 29-56 days	30/11/93 04/01/94 01/02/94	Normal Normal Normal
	12ND	Reboxetine	Male	27/10/93	21/12/93	Screen Day 28 Day 56	-8 27 55	Screening 1-28 days 29-56 days	19/10/93 23/11/93 21/12/93	Normal Normal Normal
	12DT	Reboxetine	Female	08/12/93	01/02/94	Screen Day 28 Day 56	-8 27 55	Screening 1-28 days 29-56 days	30/11/93 04/01/94 01/02/94	Normal Normal Normal

9550089

11

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0
ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period		Visit	days of treat.	Assessment	E.C.G.		Abnormality
				Start date	End date				Date	Value	
10	130T	Reboxetine	Female	27/10/93	21/12/93	Screen	-8	Screening	19/10/93	Normal	
						Day 28	27	1-28 days	23/11/93	Normal	
						Day 56	55	29-56 days	21/12/93	Normal	
	140T	Imipramine	Female	30/10/93	23/12/93	Screen	-8	Screening	22/10/93	Normal	
						Day 28	27	1-28 days	26/11/93	Normal	
						Day 56	54	29-56 days	23/12/93	Normal	
	150D	Reboxetine	Female	30/10/93	23/12/93	Screen	-28	Screening	02/10/93	Normal	
						Day 28	27	1-28 days	26/11/93	Normal	
						Day 56	54	29-56 days	23/12/93	Normal	
	160T	Imipramine	Male	30/10/93	23/12/93	Screen	-8	Screening	22/10/93	Normal	
Day 28						27	1-28 days	26/11/93	Normal		
Day 56						54	29-56 days	23/12/93	Normal		
170D	Reboxetine	Female	06/11/93	30/12/93	Screen	-8	Screening	29/10/93	Abnormal	SINUS BRADYCARDIA (< 60)	
					Day 28	27	1-28 days	03/12/93	Abnormal		
					Day 56	54	29-56 days	30/12/93	Abnormal		
180D	Imipramine	Female	06/11/93	30/12/93	Screen	-8	Screening	29/10/93	Normal		
					Day 28	27	1-28 days	03/12/93	Normal		
					Day 56	54	29-56 days	30/12/93	Normal		
190T	Reboxetine	Male	06/11/93	30/12/93	Screen	-8	Screening	29/10/93	Normal		
					Day 28	27	1-28 days	03/12/93	Normal		
					Day 56	54	29-56 days	30/12/93	Normal		
200D	Reboxetine	Female	06/11/93	30/12/93	Screen	-8	Screening	29/10/93	Normal		
					Day 28	27	1-28 days	03/12/93	Normal		
					Day 56	54	29-56 days	30/12/93	Normal		
12	100D	Reboxetine	Female	28/04/93	22/06/93	Screen	-9	Screening	19/04/93	Normal	
						Day 28	28	1-28 days	26/05/93	Normal	
11	100T	Reboxetine	Female	20/05/93	14/07/93	Screen	-1	Screening	19/05/93	Abnormal	VENTRICULAR ECTOPIC BEATS - OCCASIONAL LEFT BUNDLE BRANCH BLOCK VENTRICULAR ECTOPIC BEATS - OCCASIONAL LEFT BUNDLE BRANCH BLOCK ATRIAL ECTOPIC BEATS - OCCASIONAL LEFT BUNDLE BRANCH BLOCK
						Day 28	33	1-28 days	22/06/93	Abnormal	
						Day 56	62	29-56 days	21/07/93	Abnormal	

9550089

12

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 21.0
 ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period		Visit	days of treat.	Assessment	Date	Value	Abnormality
				Start date	End date						
13	1ND	Reboxetine	Female	08/04/93	02/06/93	Screen	-20	Screening	19/03/93	Normal	
						Day 28	28	1-28 days	06/05/93	Normal	
						Day 56	56	29-56 days	03/06/93	Normal	
	1DT	Imipramine	Female	23/09/93	17/11/93	Screen	-6	Screening	17/09/93	Normal	
						Day 28	28	1-28 days	21/10/93	Normal	
						Day 56	61	29-56 days	23/11/93	Normal	
	2ND	Imipramine	Female	11/12/93	04/02/94	Screen	-8	Screening	03/12/93	Normal	
						Day 28	29	1-28 days	09/01/94	Normal	
						Day 56	58	29-56 days	07/02/94	Abnormal	MYOCARDIAL ISCHEMIA
	3DT OR 1-3	Reboxetine	Female	22/10/93	17/12/93	Screen	-1	Screening	21/10/93	Normal	
						Day 28	28	1-28 days	19/11/93	Normal	
						Day 56	58	29-56 days	19/12/93	Normal	
	3ND	Imipramine	Male	03/02/94	31/03/94	Screen	-6	Screening	28/01/94	Abnormal	LEFT VENTRICULAR HYPERTROPHY
Day 28						32	1-28 days	07/03/94	Abnormal	LEFT VENTRICULAR HYPERTROPHY	
Day 56						59	29-56 days	03/04/94	Abnormal	LEFT VENTRICULAR HYPERTROPHY	
3DT	Imipramine	Female	09/11/93	04/01/94	Screen	-18	Screening	22/10/93	Normal		
					Day 28	35	1-28 days	14/12/93	Normal		
					Day 56	57	29-56 days	05/01/94	Normal		
4DT	Reboxetine	Female	03/02/94	31/03/94	Screen	-23	Screening	11/01/94	Normal		
					Day 28	27	1-28 days	02/03/94	Normal		
					Day 56	56	29-56 days	31/03/94	Normal		
14	1ND	Reboxetine	Female	06/04/94	02/05/94	Screen	-13	Screening	24/03/94	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 28	27	1-28 days	03/05/94	Normal	NON SPECIFIC ST-T WAVE CHANGES
15	1ND	Reboxetine	Female	01/03/93	25/04/93	Screen	-6	Screening	23/02/93	Abnormal	VENTRICULAR ECTOPIC BEATS - OCCASIONAL
						Day 28	28	1-28 days	29/02/93	Abnormal	VENTRICULAR ECTOPIC BEATS - OCCASIONAL
						Day 56	59	29-56 days	29/04/93	Abnormal	VENTRICULAR ECTOPIC BEATS - OCCASIONAL
1DT	Reboxetine	Female	26/07/93	19/09/93	Screen	-47	Screening	09/06/93	Normal	ATRIAL ECTOPIC BEATS - OCCASIONAL	
					Day 28	28	1-28 days	23/08/93	Abnormal		
					Day 56	56	29-56 days	20/09/93	Normal		

9550089

13

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/03S
Listing No.: 21.0
ECC TRACINGS

Centre	Patient	Treatment	Sex	Treatment period		Visit	days of treat.	Assessment	E.C.G.		
				Start date	End date				Date	Value	Abnormality
15	2ND	Imipramine	Female	24/03/93	02/04/93	Screen	-22	Screening	02/03/93	Abnormal	RIGHT BUNDLE BRANCH BLOCK
	2DT	Imipramine	Female	22/02/94	18/04/94	Screen	-13	Screening	09/02/94	Abnormal	VENTRICULAR ECTOPIC BEATS - OCCASIONAL
						Day 28	28	1-28 days	22/03/94	Normal	
						Day 56	56	29-56 days	19/04/94	Normal	
	3MD	Reboxetine	Female	06/05/93	30/06/93	Screen	-2	Screening	04/05/93	Abnormal	OTHER
						Day 28	28	1-28 days	03/06/93	Abnormal	VENTRICULAR ECTOPIC BEATS - OCCASIONAL
						Day 56	57	29-56 days	02/07/93	Normal	
	4MD	Imipramine	Female	15/07/93	08/09/93	Screen	-3	Screening	12/07/93	Abnormal	SINUS TACHYCARDIA (> 100)
						Day 28	28	1-28 days	12/08/93	Normal	
						Day 56	55	29-56 days	08/09/93	Normal	
	11MD	Reboxetine	Female	08/10/93	28/10/93	Screen	-3	Screening	05/10/93	Normal	
						Day 28	-6	Screening	29/11/93	Normal	
						Day 56	35	1-28 days	09/01/94	Normal	
	112MD	Imipramine	Female	29/11/93	23/01/94	Screen	56	29-56 days	24/01/94	Normal	
						Day 28	-20	Screening	29/01/93	Normal	
Day 56						27	1-28 days	17/03/93	Normal		
16	1MD	Reboxetine	Female	18/02/93	14/04/93	Screen	55	29-56 days	14/04/93	Normal	
						Day 28	-6	Screening	12/02/93	Abnormal	LEFT BUNDLE BRANCH BLOCK
						Day 56	11	1-28 days	01/03/93	Normal	
2ND	Imipramine	Male	15/04/93	09/06/93	Screen	-6	Screening	09/04/93	Normal		
					Day 28	27	1-28 days	12/05/93	Normal		
					Day 56	55	29-56 days	09/06/93	Normal		
2DT	Reboxetine	Male	04/05/93	28/06/93	Screen	-4	Screening	30/04/93	Normal		
					Day 28	28	1-28 days	01/06/93	Normal		
					Day 56	55	29-56 days	28/06/93	Normal		
3MD	Imipramine	Female	09/05/93	09/06/93	Screen	-3	Screening	06/05/93	Normal		
					Day 28	26	1-28 days	04/06/93	Normal		

2514

9550089

14

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0
ECG TRACINGS

Centre	Patient	Treatment	Sex	_Treatment period_		Visit	days of treat.	Assessment	Date	Value	Abnormality
				Start date	End date						
16	30T	Imipramine	Female	29/07/93	10/08/93	Screen	-7	Screening	22/07/93	Normal	
						Day 14	13	1-28 days	11/08/93	Normal	
	40D	Reboxetine	Female	19/04/94	13/06/94	Screen	-1	Screening	18/04/94	Normal	
						Day 28	27	1-28 days	16/05/94	Normal	
17	10D	Reboxetine	Female	31/03/93	25/05/93	Screen	-8	Screening	23/03/93	Abnormal	VENTRIC. ECTOPIC BEATS-FREQUENT (>6/MM)
						Day 28	28	1-28 days	28/04/93	Abnormal	ATEIAL ECTOPIC BEATS - FREQUENT (> 6/MM)
	10T	Reboxetine	Female	28/04/93	17/05/93	Screen	-10	Screening	25/05/93	Abnormal	ATEIAL ECTOPIC BEATS - FREQUENT (> 6/MM)
						Day 21	23	1-28 days	21/05/93	Abnormal	RIGHT BUNDLE BRANCH BLOCK LEFT ANTERIOR HEMIBLOCK RIGHT BUNDLE BRANCH BLOCK LEFT ANTERIOR HEMIBLOCK
20 CT 1-1 CT	20D	Imipramine	Female	21/04/93	15/06/93	Screen	-8	Screening	13/04/93	Abnormal	LEFT VENTRICULAR HYPERTROPHY
						Day 28	27	1-28 days	18/05/93	Abnormal	LEFT VENTRICULAR HYPERTROPHY
	20T	Reboxetine	Female	07/07/93	31/08/93	Screen	-30	Screening	16/06/93	Abnormal	LEFT VENTRICULAR HYPERTROPHY
						Day 56	28	1-28 days	04/08/93	Abnormal	LEFT VENTRICULAR HYPERTROPHY
30D	Imipramine	Female	06/11/93	19/11/93	Screen	-2	Screening	07/06/93	Abnormal	LEFT VENTRICULAR HYPERTROPHY	
					Screen	-2	Screening	04/11/93	Abnormal	SINUS BRADYCARDIA (< 60)	
	30T	Imipramine	Male	19/10/93	13/12/93	Screen	-5	Screening	14/10/93	Abnormal	OTHER
						Day 56	28	1-28 days	16/11/93	Abnormal	OTHER
40D	Reboxetine	Female	12/01/94	09/03/94	Screen	-2	Screening	14/12/93	Normal		
					Day 56	56	29-56 days	09/03/94	Abnormal	SINUS TACHYCARDIA (> 100)	
	40T	Imipramine	Female	19/01/94	15/03/94	Screen	-301	Screening	10/01/94	Normal	
						Day 56	28	1-28 days	24/03/93	Normal	
210D	Reboxetine	Female	19/05/94	13/07/94	Screen	-9	Screening	16/02/94	Normal		
					Screen	-9	Screening	15/03/94	Normal		
	210T	Reboxetine	Female	19/05/94	13/07/94	Screen	-9	Screening	10/05/94	Abnormal	SINUS BRADYCARDIA (< 60)
						Screen	-9	Screening	10/05/94	Abnormal	SINUS BRADYCARDIA (< 60)

9550089

15

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0

EKG TRACINGS

Centre	Patient	Treatment	Sex	_Treatment period_		Visit	days of treat.	Assessment	E.C.G.		
				Start date	End date				Date	Value	Abnormality
17	211ND	Reboxetine	Female	19/05/94	13/07/94	Day 28	26	1-28 days	14/06/94	Normal	
						Day 56	61	29-56 days	19/07/94	Normal	
						Screen	-39	Screening	25/02/94	Abnormal	OTHER
18	211DT	Reboxetine	Female	05/04/94	30/05/94	Day 28	31	1-28 days	06/05/94	Abnormal	LEFT ANTERIOR HEMIBLOCK
						Day 56	55	29-56 days	30/05/94	Abnormal	LEFT ANTERIOR HEMIBLOCK
						Screen	-3	Screening	24/05/93	Abnormal	RIGHT BUNDLE BRANCH BLOCK
18	1ND	Imipramine	Female	27/05/93	21/07/93	Day 28	27	1-28 days	23/06/93	Abnormal	RIGHT BUNDLE BRANCH BLOCK
						Day 56	55	29-56 days	21/07/93	Abnormal	RIGHT BUNDLE BRANCH BLOCK
						Screen	-9	Screening	03/08/93	Normal	
18	1DT	Imipramine	Female	12/08/93	06/10/93	Day 28	27	1-28 days	08/09/93	Normal	
						Day 56	55	29-56 days	08/10/93	Normal	
						Screen	-2	Screening	28/05/93	Normal	
18	2DT	Reboxetine	Female	09/11/93	06/12/93	Day 28	27	1-28 days	26/06/93	Normal	
						Screen	-5	Screening	04/11/93	Normal	
						Day 49	48	29-56 days	07/12/93	Normal	
18	3ND	Reboxetine	Female	14/08/93	01/10/93	Day 28	-7	Screening	07/08/93	Abnormal	LEFT AXIAL DEVIATION
						Day 49	27	1-28 days	10/09/93	Abnormal	LEFT AXIAL DEVIATION
						Screen	48	29-56 days	01/10/93	Abnormal	CONDUCTION DISORDER
20	4ND	Reboxetine	Female	03/10/93	27/11/93	Day 28	-3	Screening	30/09/93	Normal	
						Day 56	55	29-56 days	30/10/93	Normal	
						Screen	-3	Screening	06/07/93	Normal	
22	1ND	Reboxetine	Female	25/06/93	30/06/93	Screen	-2	Screening	23/06/93	Normal	
						Screen	-2	Screening	28/01/93	Normal	
						Day 56	55	29-56 days	26/02/93	Normal	
23	1ND	Reboxetine	Female	30/01/93	26/03/93	Day 28	-2	Screening	28/01/93	Normal	
						Day 56	55	29-56 days	26/02/93	Normal	
						Screen	-4	Screening	29/01/93	Normal	

9550089

16

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0
ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period		Visit	days of treat.	Assessment	Date	Value	Abnormality
				Start date	End date						
23	2ND	Reboxetine	Female	02/02/93	29/03/93	Day 28	27	1-28 days	01/03/93	Normal	
				Day 56	55	29-56 days	29/03/93	Normal			
	3ND	Imipramine	Female	23/03/93	17/05/93	Screen	-5	Screening	18/03/93	Normal	
				Day 28	27	1-28 days	19/04/93	Normal			
	Day 56	55	29-56 days	17/05/93	Abnormal	SINUS TACHYCARDIA (> 100)					
	4ND	Imipramine	Female	31/03/93	25/05/93	Screen	-12	Screening	19/03/93	Normal	
Day 28				27	1-28 days	27/04/93	Abnormal	NON SPECIFIC ST-T WAVE CHANGES			
Day 56	55	29-56 days	25/05/93	Normal							
5ND	Imipramine	Female	05/05/93	13/05/93	Screen	-11	Screening	24/04/93	Normal		
			Screen								
6ND	Imipramine	Female	06/07/93	17/08/93	Screen	-1	Screening	05/07/93	Normal		
			Day 28	27	1-28 days	02/08/93	Normal				
Day 43	43	29-56 days	18/08/93	Normal							
25	1ND	Reboxetine	Male	27/08/93	01/10/93	Screen	0	Screening	27/08/93	Abnormal	A-V BLOCK 1ST DEGREE
				Day 28	28	1-28 days	24/09/93	Abnormal	VENTRIC. ECTOPIC BEATS-FREQUENT (>6/MN)		
26	2ND	Imipramine	Female	26/11/93	20/01/94	Screen	-2	Screening	24/11/93	Abnormal	SINUS TACHYCARDIA (> 100)
				Day 28	27	1-28 days	23/12/93	Abnormal	PREVIOUS MYOCARDIAL INFARCTION		
Day 56	56	29-56 days	21/01/94	Normal							
27	1ND	Imipramine	Female	27/04/93	21/06/93	Screen	-4	Screening	23/04/93	Abnormal	LEFT VENTRICULAR HYPERTROPHY
				Day 28	24	1-28 days	21/05/93	Normal	MYOCARDIAL ISCHEMIA		
Day 56	55	29-56 days	21/06/93	Abnormal	OTHER						
28	1ND	Reboxetine	Female	29/06/93	11/08/93	Screen	-4	Screening	25/06/93	Abnormal	SINUS TACHYCARDIA (> 100)
				Day 28	27	1-28 days	26/07/93	Abnormal	SINUS TACHYCARDIA (> 100)		
27	1ND	Imipramine	Male	02/02/93	08/02/93	Screen	-1	Screening	01/02/93	Abnormal	ATRIAL ECTOPIC BEATS - OCCASIONAL
				Screen							
28	1ND	Reboxetine	Female	20/04/93	14/06/93	Screen	-7	Screening	19/04/93	Normal	
				Day 28	28	1-28 days	18/05/93	Normal			
Day 56	56	29-56 days	15/06/93	Normal							

2517

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	_Treatment period_		Visit	days of treat.	Assessment	Date	Value	Abnormality
				Start date	End date						
28	1DT	Imipramine	Female	22/04/93	16/06/93	Screen	-9	Screening	13/04/93	Normal	
						Day 28	27	1-28 days	19/05/93	Normal	
						Day 56	56	29-56 days	17/06/93	Normal	
29	2HD	Imipramine	Female	26/04/93	21/06/93	Screen	-6	Screening	20/04/93	Normal	
						Day 28	29	1-28 days	25/05/93	Normal	
						Day 56	57	29-56 days	22/06/93	Normal	
30	2DT	Reboxetine	Male	27/04/93	21/06/93	Screen	-7	Screening	20/04/93	Normal	
						Day 28	28	1-28 days	25/05/93	Normal	
						Day 56	56	29-56 days	22/06/93	Normal	
31	3MD	Reboxetine	Female	27/04/93	21/06/93	Screen	-7	Screening	20/04/93	Normal	
						Day 28	28	1-28 days	25/05/93	Normal	
						Day 56	56	29-56 days	22/06/93	Normal	
32	3DT	Imipramine	Male	11/05/93	05/07/93	Screen	-8	Screening	03/05/93	Normal	
						Day 28	28	1-28 days	08/06/93	Normal	
						Day 56	56	29-56 days	06/07/93	Normal	
33	4HD	Imipramine	Male	04/05/93	28/06/93	Screen	-8	Screening	26/04/93	Normal	
						Day 28	28	1-28 days	01/06/93	Normal	
						Day 56	56	29-56 days	29/06/93	Normal	
30	5HD	Reboxetine	Female	25/05/93	19/07/93	Screen	-15	Screening	10/05/93	Normal	
						Day 28	28	1-28 days	22/06/93	Normal	
						Day 56	56	29-56 days	20/07/93	Normal	
30	1HD	Imipramine	Female	21/04/93	17/06/93	Screen	-1	Screening	20/04/93	Normal	VENTRICULAR ECTOPIC BEATS - OCCASIONAL
						Day 28	29	1-28 days	20/05/93	Abnormal	ATRIAL FIBRILLATION / FLUTTER
						Day 56	62	29-56 days	22/06/93	Abnormal	VENTRICULAR ECTOPIC BEATS - OCCASIONAL ATRIAL FIBRILLATION / FLUTTER
2HD	Reboxetine	Female	16/07/93	18/07/93	Screen	-11	Screening	05/07/93	Abnormal	ATRIAL ECTOPIC BEATS - OCCASIONAL	
					Screen	-14	Screening	25/10/93	Normal		
3MD	Imipramine	Female	08/11/93	03/01/94	Screen	23	1-28 days	01/12/93	Normal		
					Day 21	58	29-56 days	05/01/94	Normal		
					Day 56						

9550089

18

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0
ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period		Visit	days of treat.	Assessment	E.C.G.		
				Start date	End date				Date	Value	Abnormality
30	4ND	Reboxetine	Female	02/11/93	30/12/93	Screen	-5	Screening	28/10/93	Normal	
						Day 28	37	1-28 days	09/12/93	Normal	
						Day 56	58	29-56 days	30/12/93	Normal	
31	5ND	Imipramine	Female	18/12/93	23/12/93	Screen	-4	Screening	14/12/93	Abnormal	SINUS TACHYCARDIA (> 100)
						Screen	-5	Screening	18/09/92	Abnormal	PREVIOUS MYOCARDIAL INFARCTION
						Day 14	16	1-28 days	09/10/92	Abnormal	PREVIOUS MYOCARDIAL INFARCTION
32	1DT	Reboxetine	Female	23/09/92	28/10/92	Screen	-5	Screening	18/09/92	Normal	
						Day 28	30	1-28 days	23/10/92	Normal	
						Screen	-8	Screening	24/11/92	Abnormal	PREVIOUS MYOCARDIAL INFARCTION
32	2ND	Reboxetine	Female	02/12/92	29/01/93	Screen	37	29-56 days	08/01/93	Abnormal	NON SPECIFIC ST-T WAVE CHANGES
						Day 35	75	29-56 days	15/02/93	Abnormal	PREVIOUS MYOCARDIAL INFARCTION
						Day 56	-13	Screening	01/12/92	Abnormal	NON SPECIFIC ST-T WAVE CHANGES
32	3ND	Imipramine	Male	14/12/92	16/12/92	Screen	-6	Screening	19/09/93	Abnormal	SINUS BRADYCARDIA (< 60)
						Screen	28	1-28 days	22/04/93	Abnormal	ATRIAL ECTOPIC BEATS - COUPLETS
						Day 56	56	29-56 days	20/05/93	Abnormal	NON SPECIFIC ST-T WAVE CHANGES
32	4ND	Imipramine	Female	25/03/93	19/05/93	Screen	-9	Screening	06/04/93	Normal	LEFT ANTERIOR HEMIBLOCK
						Day 28	28	1-28 days	13/05/93	Normal	ATRIAL ECTOPIC BEATS - FREQUENT (> 6/MM)
						Day 56	56	29-56 days	10/06/93	Normal	LEFT ANTERIOR HEMIBLOCK
32	2ND	Imipramine	Female	15/04/93	09/06/93	Screen	-7	Screening	15/04/93	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 28	28	1-28 days	20/05/93	Abnormal	LEFT VENTRICULAR HYPERTROPHY
						Day 56	57	29-56 days	18/06/93	Abnormal	OTHER
32	3ND	Reboxetine	Female	22/04/93	16/06/93	Screen	-17	Screening	20/09/93	Normal	LEFT VENTRICULAR HYPERTROPHY
						Day 28	-8	Screening	27/10/93	Normal	
						Day 56					
32	4ND	Reboxetine	Female	07/10/93	26/10/93	Screen	-8	Screening			
						Screen					
						Screen					
32	5ND	Reboxetine	Female	04/11/93	25/11/93	Screen					
						Screen					
						Screen					

9550089

19

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	_Treatment period		Visit	days of treat.	Assessment	E.C.G.		
				Start date	End date				Date	Value	Abnormality
32	6ND	Imipramine	Male	17/11/93	12/01/94	Screen	-21	Screening	27/10/93	Abnormal	LEFT POSTERIOR HEMIBLOCK TRIFASCICULAR BLOCK
35	1ND	Reboxetine	Female	26/01/93	14/02/93	Screen	0	Screening	26/01/93	Normal	
	1DT	Reboxetine	Female	03/03/93	27/04/93	Screen Day 28 Day 56	-1 29 55	Screening 1-28 days 29-56 days	02/03/93 01/04/93 27/04/93	Normal Normal Normal	
	2ND	Imipramine	Female	03/03/93	31/03/93	Screen Day 28	-22 23	Screening 1-28 days	09/02/93 26/03/93	Abnormal Abnormal	ATRIAL FIBRILLATION / FLUTTER RIPOLARIZATION DISTURBANCES ATRIAL FIBRILLATION / FLUTTER RIPOLARIZATION DISTURBANCES
	2DT	Imipramine	Female	03/03/93	27/04/93	Screen Day 28 Day 56	-2 27 55	Screening 1-28 days 29-56 days	01/03/93 30/03/93 27/04/93	Normal Normal Normal	
	3ND	Imipramine	Female	30/03/93	05/04/93	Screen	-1	Screening	29/03/93	Abnormal	ATRIAL FIBRILLATION / FLUTTER
	3DT	Imipramine	Male	31/03/93	26/05/93	Screen Day 28 Day 56	-1 28 56	Screening 1-28 days 29-56 days	30/03/93 28/04/93 26/05/93	Normal Normal Normal	
	4ND	Reboxetine	Male	20/04/93	14/06/93	Screen Day 28 Day 56	-19 27 56	Screening 1-28 days 29-56 days	01/04/93 17/05/93 15/06/93	Normal Normal Normal	
	4DT	Reboxetine	Female	27/04/93	21/06/93	Screen Day 56	-7 55	Screening 29-56 days	20/04/93 21/06/93	Abnormal Abnormal	RIGHT BUNDLE BRANCH BLOCK RIGHT BUNDLE BRANCH BLOCK
	5ND	Reboxetine	Male	09/07/93	02/09/93	Screen Day 28 Day 56	-6 27 55	Screening 1-28 days 29-56 days	03/07/93 05/08/93 02/09/93	Abnormal Abnormal Abnormal	RIGHT BUNDLE BRANCH BLOCK RIGHT BUNDLE BRANCH BLOCK RIGHT BUNDLE BRANCH BLOCK
	5DT	Imipramine	Female	02/09/93	27/10/93	Screen Day 28	-1 27	Screening 1-28 days	01/09/93 29/09/93	Abnormal Normal	SINUS BRADYCARDIA (< 60)
	6ND	Reboxetine	Female	21/01/94	02/03/94	Screen	-2	Screening	19/01/94	Abnormal	LEFT ANTERIOR HEMIBLOCK

9550089

20

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PEARMAZIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0

EKG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period		Visit	days of treat.	Assessment	E.C.G.		
				Start date	End date				Date	Value	Abnormality
35	6ND	Reboxetine	Female	21/01/94	02/03/94	Day 28	26	1-28 days	16/02/94	Abnormal	LEFT BUNDLE BRANCH BLOCK
	6DT	Imipramine	Female	20/10/93	14/12/93	Screen Day 28	-8	Screening 1-28 days	12/10/93	Normal	
						Day 56	55	29-56 days	16/11/93	Normal	
									14/12/93	Normal	
	7ND	Imipramine	Female	10/12/93	17/01/94	Screen Day 28	-2	Screening 1-28 days	08/12/93	Abnormal	MYOCARDIAL ISCHEMIA
							27	1-28 days	06/01/94	Abnormal	MYOCARDIAL ISCHEMIA
	7DT	Reboxetine	Female	20/10/93	16/11/93	Screen Day 28	-5	Screening 1-28 days	15/10/93	Abnormal	ATRIAL FIBRILLATION / FLUTTER
							27	1-28 days	16/11/93	Abnormal	ATRIAL FIBRILLATION / FLUTTER
	8ND	Imipramine	Female	01/02/94	21/03/94	Screen Day 28	-1	Screening 1-28 days	31/01/94	Abnormal	LEFT BUNDLE BRANCH BLOCK
							27	1-28 days	28/02/94	Abnormal	LEFT BUNDLE BRANCH BLOCK
	8DT	Reboxetine	Female	11/01/94	07/03/94	Screen Day 28	-1	Screening 1-28 days	10/01/94	Normal	
						Day 56	55	29-56 days	07/02/94	Normal	
									07/03/94	Normal	
36	1ND	Imipramine	Male	16/01/93	08/03/93	Screen Day 28	-24	Screening 1-28 days	23/12/92	Abnormal	RIGHT BUNDLE BRANCH BLOCK
							26	1-28 days	11/02/93	Abnormal	RIGHT BUNDLE BRANCH BLOCK
	1DT	Imipramine	Female	05/02/93	30/03/93	Screen Day 28	-2	Screening 1-28 days	01/02/93	Abnormal	LEFT BUNDLE BRANCH BLOCK
						Day 56	55	29-56 days	02/03/93	Abnormal	CONDUCTION DISORDER
									30/03/93	Abnormal	CONDUCTION DISORDER
										Abnormal	SINUS TACHYCARDIA (> 100)
											NON SPECIFIC ST-T WAVE CHANGES
	2ND	Reboxetine	Female	03/02/93	30/03/93	Screen Day 28	-7	Screening 1-28 days	27/01/93	Normal	
						Day 56	55	29-56 days	02/03/93	Normal	
									30/03/93	Abnormal	CONDUCTION DISORDER
	2DT	Reboxetine	Female	25/02/93	22/04/93	Screen Day 28	-1	Screening 1-28 days	26/02/93	Normal	
						Day 56	56	29-56 days	30/03/93	Normal	
									22/04/93	Normal	
	3ND	Imipramine	Female	06/02/93	02/04/93	Screen Day 28	-12	Screening 1-28 days	25/01/93	Abnormal	LEFT VENTRICULAR HYPERTROPHY
							27	1-28 days	05/03/93	Abnormal	RIPOLARIZATION DISTURBANCES
											LEFT VENTRICULAR HYPERTROPHY
											RIPOLARIZATION DISTURBANCES

2521

9550089

21

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PIARNACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period		Visit	days of treat.	Assessment	E.C.G.		
				Start date	End date				Date	Value	Abnormality
36	3ND	Imipramine	Female	06/02/93	02/04/93	Day 56	55	29-56 days	02/04/93	Abnormal	NON SPECIFIC ST-T WAVE CHANGES
	3DT	Imipramine	Female	02/03/93	27/04/93	Screen Day 28	-14	Screening 1-28 days	16/02/93	Abnormal	A-V BLOCK 1ST DEGREE
						Day 56	49	29-56 days	30/03/93	Abnormal	NON SPECIFIC ST-T WAVE CHANGES
									20/04/93	Normal	
	4ND	Reboxetine	Female	09/03/93	01/05/93	Screen Day 28	-6	Screening 1-28 days	03/03/93	Abnormal	A-V BLOCK 1ST DEGREE
						Day 56	35	29-56 days	13/04/93	Abnormal	A-V BLOCK 1ST DEGREE
									03/05/93	Abnormal	LEFT ANTERIOR HEMIBLOCK
										Abnormal	OTHER
										Abnormal	A-V BLOCK 1ST DEGREE
										Abnormal	LEFT ANTERIOR HEMIBLOCK
	4ND	Reboxetine	Female	12/03/93	06/05/93	Screen Day 28	-31	Screening 1-28 days	09/02/93	Normal	
						Day 56	27	29-56 days	08/04/93	Abnormal	SINUS TACHYCARDIA (> 100)
							55	29-56 days	06/05/93	Normal	
	5ND	Reboxetine	Female	24/04/93	18/06/93	Screen Day 28	-4	Screening 1-28 days	20/04/93	Normal	
						Day 56	54	29-56 days	24/05/93	Normal	
									17/06/93	Abnormal	SINUS TACHYCARDIA (> 100)
											LEFT ANTERIOR HEMIBLOCK
											NON SPECIFIC ST-T WAVE CHANGES
											CONDUCTION DISORDER
	5DT	Imipramine	Female	03/04/93	07/04/93	Screen	-23	Screening	11/03/93	Normal	
	6ND	Imipramine	Female	01/05/93	25/06/93	Screen Day 28	-25	Screening 1-28 days	06/04/93	Normal	
						Day 56	55	29-56 days	28/05/93	Abnormal	NON SPECIFIC ST-T WAVE CHANGES
									25/06/93	Normal	
	6DT	Imipramine	Female	10/04/93	04/06/93	Screen Day 28	-8	Screening 1-28 days	02/04/93	Normal	
						Day 56	34	29-56 days	14/05/93	Normal	
							55	29-56 days	04/06/93	Normal	
	7ND	Reboxetine	Female	13/05/93	07/07/93	Screen Day 28	-30	Screening 1-28 days	13/04/93	Abnormal	SINUS TACHYCARDIA (> 100)
						Day 56	28	29-56 days	10/06/93	Normal	
							55	29-56 days	07/07/93	Abnormal	SINUS TACHYCARDIA (> 100)
											RIPOLARIZATION DISTURBANCES
	7DT	Reboxetine	Female	01/05/93	07/05/93	Screen	-16	Screening	15/04/93	Abnormal	LEFT BUNDLE BRANCH BLOCK

9550089

22

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0

E.C.G.

Centre	Patient	Treatment	Sex	Treatment period		visit	days of treat.	Assessment	Date	Value	Abnormality
				Start date	End date						
36	BND	Imipramine	Female	26/05/93	20/07/93	Screen	-14	Screening	12/05/93	Normal	
						Day 28	28	1-28 days	23/06/93	Normal	
						Day 56	55	29-56 days	20/07/93	Normal	
80T	Reboxetine	Female	15/05/93	16/07/93	Screen	-10	Screening	05/05/93	Normal		
					Day 35	37	29-56 days	21/06/93	Abnormal	SINUS TACHYCARDIA (> 100) CONDUCTION DISORDER	
					Day 63	65	29-56 days	19/07/93	Abnormal		
98D	Reboxetine	Male	16/06/93	10/08/93	Screen	-2	Screening	14/06/93	Abnormal	SINUS TACHYCARDIA (> 100) RIGHT BUNDLE BRANCH BLOCK	
					Day 28	27	1-28 days	13/07/93	Abnormal	SINUS TACHYCARDIA (> 100) RIGHT BUNDLE BRANCH BLOCK	
					Day 56	55	29-56 days	10/08/93	Abnormal	SINUS TACHYCARDIA (> 100) ATRIAL FIBRILLATION / FLUTTER RIGHT BUNDLE BRANCH BLOCK LEFT ANTERIOR HEMIBLOCK	
90T	Imipramine	Female	29/06/93	19/08/93	Screen	-6	Screening	23/06/93	Normal		
					Day 28	20	1-28 days	19/07/93	Normal		
					Day 56	55	29-56 days	23/08/93	Normal		
10MD	Reboxetine	Male	22/06/93	16/08/93	Screen	-19	Screening	03/06/93	Abnormal	SINUS BRADYCARDIA (< 60) ATRIAL FIBRILLATION / FLUTTER LEFT ANTERIOR HEMIBLOCK ATRIAL FIBRILLATION / FLUTTER LEFT ANTERIOR HEMIBLOCK	
					Day 28	27	1-28 days	19/07/93	Abnormal		
					Day 56	56	29-56 days	17/08/93	Normal		
100T	Reboxetine	Male	26/10/93	20/12/93	Screen	-1	Screening	25/10/93	Abnormal	LEFT ANTERIOR HEMIBLOCK SINUS BRADYCARDIA (< 60)	
					Day 28	27	1-28 days	22/11/93	Abnormal	LEFT ANTERIOR HEMIBLOCK	
					Day 56	55	29-56 days	02/09/93	Abnormal	SINUS TACHYCARDIA (> 100) A-V BLOCK 1ST DEGREE A-V BLOCK 1ST DEGREE	
110D	Reboxetine	Male	10/11/93	19/12/93	Screen	-13	Screening	28/10/93	Abnormal	SINUS BRADYCARDIA (< 60) RIGHT BUNDLE BRANCH BLOCK LEFT POSTERIOR HEMIBLOCK	
					Day 28	31	1-28 days	09/08/93	Abnormal		
					Day 56	55	29-56 days	02/09/93	Abnormal		

2
5
2
3

9550089

23

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RD
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 21.0
 ECC TRACINGS

Centre	Patient	Treatment	Sex	Treatment period		Visit	days of treat.	Assessment	E.C.G.		
				Start date	End date				Date	Value	Abnormality
36	12ND	Imipramine	Female	24/09/93	05/10/93	Screen	-11	Screening	13/09/93	Abnormal	RIPOLARIZATION DISTURBANCES
	12DT	Imipramine	Female	22/12/93	15/02/94	Screen Day 28 Day 56	-9 23 56	Screening 1-28 days 29-56 days	13/12/93 14/01/94 16/02/94	Normal Normal Normal	
	13ND	Reboxetine	Male	21/09/93	14/10/93	Screen	-40	Screening	12/08/93	Normal	
	14ND	Imipramine	Male	03/11/93	28/12/93	Screen Day 28 Day 56	-1 27 56	Screening 1-28 days 29-56 days	02/11/93 30/11/93 29/12/93	Abnormal Normal Normal	SINUS BRADYCARDIA (< 60)
37	15ND	Reboxetine	Female	23/10/93	09/11/93	Screen	-18	Screening	05/10/93	Normal	
41	16ND	Imipramine	Female	09/11/93	03/01/94	Screen Day 28 Day 56	-5 27 43	Screening 1-28 days 29-56 days	04/11/93 06/12/93 22/12/93	Abnormal Abnormal Abnormal	ATRIAL FIBRILLATION / FLUTTER LEFT VENTRICULAR HYPERTROPHY ATRIAL FIBRILLATION / FLUTTER LEFT VENTRICULAR HYPERTROPHY CONDUCTION DISORDER ATRIAL FIBRILLATION / FLUTTER
	17ND	Reboxetine	Female	10/11/93	11/11/93	Screen	-5	Screening	05/11/93	Abnormal	LEFT VENTRICULAR HYPERTROPHY
	18ND	Imipramine	Female	13/01/94	09/03/94	Screen Day 28 Day 56	0 28 56	Screening 1-28 days 29-56 days	13/01/94 10/02/94 10/03/94	Abnormal Normal Normal	SINUS TACHYCARDIA (> 100)
	19ND	Reboxetine	Female	15/01/94	22/01/94	Screen	-18	Screening	28/12/93	Abnormal	LEFT ANTERIOR HEMIBLOCK
	20ND	Imipramine	Female	01/02/94	28/03/94	Screen Day 28 Day 56	-4 27 55	Screening 1-28 days 29-56 days	28/01/94 28/02/94 28/03/94	Abnormal Abnormal Abnormal	LEFT ANTERIOR HEMIBLOCK LEFT ANTERIOR HEMIBLOCK LEFT ANTERIOR HEMIBLOCK
37	3ND	Reboxetine	Female	18/03/93	24/03/93	Screen	-2	Screening	16/03/93	Normal	
41	1ND	Imipramine	Male	22/02/94	24/02/94	Screen	-7	Screening	15/02/94	Normal	

9550089

24

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0

E.C.G.

Centre	Patient	Treatment	Sex	Treatment period		Visit	days of treat.	Assessment	Date	Value	Abnormality	
				Start date	End date							
41	2ND	Reboxetine	Male	23/02/94	19/04/94	Screen	-5	Screening	18/02/94	Normal		
						Day 28	28	1-28 days	23/03/94	Normal		
						Day 56	55	29-56 days	19/04/94	Normal		
	3ND	Imipramine	Male	25/02/94	21/04/94	Screen	-9	Screening	16/02/94	Normal		
						Day 28	28	1-28 days	25/03/94	Normal		
						Screen	-7	Screening	21/02/94	Abnormal	LEFT VENTRICULAR HYPERTROPHY	
	4ND	Reboxetine	Male	28/02/94	24/04/94	Screen	31	1-28 days	31/03/94	Abnormal	SINUS BRADYCARDIA (< 60)	
						Day 28					LEFT VENTRICULAR HYPERTROPHY	
						Screen	-13	Screening	18/02/94	Normal		
	42	5ND	Reboxetine	Male	03/03/94	27/04/94	Screen	28	1-28 days	31/03/94	Normal	
							Day 28					
							Screen	-12	Screening	14/10/93	Normal	
1ND		Imipramine	Female	26/10/93	20/12/93	Screen	26	1-28 days	21/11/93	Normal		
						Day 28	55	29-56 days	20/12/93	Normal		
						Day 56						
1DT		Imipramine	Female	25/11/93	19/01/94	Screen	-23	Screening	02/11/93	Abnormal	PREVIOUS MYOCARDIAL INFARCTION	
						Day 28	26	1-28 days	21/12/93	Abnormal	PREVIOUS MYOCARDIAL INFARCTION	
						Day 56	54	29-56 days	18/01/94	Abnormal	PREVIOUS MYOCARDIAL INFARCTION	
2ND		Reboxetine	Female	26/10/93	20/12/93	Screen	-12	Screening	14/10/93	Normal		
						Day 28	26	1-28 days	21/11/93	Normal		
						Day 56	55	29-56 days	20/12/93	Normal		
2DT	Reboxetine	Male	09/12/93	10/12/93	Screen	-16	Screening	23/11/93	Normal			
					Screen	-23	Screening	02/11/93	Normal			
					Day 28	26	1-28 days	21/12/93	Normal			
3ND	Imipramine	Male	25/11/93	19/01/94	Screen	54	29-56 days	18/01/94	Normal			
					Day 28							
					Day 56							
4DT	Reboxetine	Female	19/02/93	02/04/93	Screen	0	Screening	19/02/93	Normal			
					Day 28	28	1-28 days	19/03/93	Normal			
					Screen	-1	Screening	10/05/93	Normal			
2DT	Imipramine	Female	11/05/93	01/06/93	Screen	22	1-28 days	02/06/93	Normal			
					Day 21							

9550089

25

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0
ECG TRACINGS

Centre	Patient	Treatment	Sex	_Treatment period_		Visit	days of treat.	Assessment	E.C.G.		
				Start date	End date				Date	Value	Abnormality
43	30T	Imipramine	Male	15/09/93	10/11/93	Screen	0	Screening	15/09/93	Normal	
						Day 28	28	1-28 days	13/10/93	Normal	
						Day 56	56	29-56 days	10/11/93	Normal	
	40T	Reboxetine	Female	23/09/93	18/11/93	Screen	0	Screening	23/09/93	Normal	
						Day 28	0	Screening	10/12/93	Normal	
						Day 56	31	1-28 days	10/01/94	Normal	
	50D	Imipramine	Female	10/12/93	12/01/94	Screen	-2	Screening	14/02/94	Abnormal	RIGHT BUNDLE BRANCH BLOCK
						Day 28	29	1-28 days	17/03/94	Abnormal	RIGHT BUNDLE BRANCH BLOCK
						Day 56	57	29-56 days	14/04/94	Abnormal	RIGHT BUNDLE BRANCH BLOCK
	60D	Imipramine	Female	16/02/94	14/04/94	Screen	-3	Screening	31/08/93	Normal	
						Day 28	27	1-28 days	30/09/93	Normal	
						Day 56	55	29-56 days	28/10/93	Abnormal	NON SPECIFIC ST-T WAVE CHANGES
10T	Reboxetine	Female	03/09/93	28/10/93	Screen	-1	Screening	30/07/93	Normal		
					Day 28	31	1-28 days	31/08/93	Abnormal	MYOCARDIAL ISCHEMIA	
					Day 56	67	29-56 days	06/10/93	Abnormal	MYOCARDIAL ISCHEMIA	
20D	Reboxetine	Female	20/09/93	15/11/93	Screen	-6	Screening	14/09/93	Abnormal	RIGHT BUNDLE BRANCH BLOCK	
					Day 28	30	1-28 days	20/10/93	Abnormal	RIGHT BUNDLE BRANCH BLOCK	
					Day 56	56	29-56 days	15/11/93	Abnormal	RIGHT BUNDLE BRANCH BLOCK	
30D	Imipramine	Female	14/10/93	09/12/93	Screen	-3	Screening	11/10/93	Normal		
					Day 28	28	1-28 days	11/11/93	Normal		
					Day 56	56	29-56 days	09/12/93	Normal		
40D	Imipramine	Male	31/01/94	28/03/94	Day 28	28	1-28 days	28/02/94	Normal		
					Day 56	56	29-56 days	28/03/94	Normal		
					Screen	-16	Screening	09/11/93	Normal		
45	Reboxetine	Male	25/11/93	20/01/94	Day 28	29	1-28 days	24/12/93	Abnormal	OTHER	
					Day 56	56	29-56 days	20/01/94	Abnormal	OTHER	
					Screen	-35	Screening	08/07/93	Abnormal	OTHER	
10T	Imipramine	Female	12/08/93	06/10/93	Day 28	27	1-28 days	08/09/93	Abnormal	LEFT ANTERIOR HEMIBLOCK	

25
26

9550089

26

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0
ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period		Visit	days of treat.	Assessment	Date	Value	Abnormality
				Start date	End date						
45	1DT	Imipramine	Female	12/08/93	06/10/93	Day 56	55	29-56 days	06/10/93	Normal	
	2ND	Imipramine	Male	07/12/93	26/12/93	Screen	-32	Screening	05/11/93	Abnormal	SINUS TACHYCARDIA (> 100) VENTRICULAR ECTOPIC BEATS - OCCASIONAL
46	1HD	Imipramine	Male	28/09/93	23/11/93	Screen	-7	Screening	21/09/93	Normal	
						Day 28	28	1-28 days	26/10/93	Normal	
						Day 56	56	29-56 days	23/11/93	Normal	
	2ND	Imipramine	Female	19/10/93	08/11/93	Screen	-1	Screening	18/10/93	Normal	
						Day 21	21	1-28 days	09/11/93	Normal	
47	3ND	Reboxetine	Female	02/12/93	27/01/94	Screen	-7	Screening	25/11/93	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 28	28	1-28 days	30/12/93	Normal	
						Day 56	56	29-56 days	27/01/94	Normal	
48	4ND	Reboxetine	Female	08/12/93	11/12/93	Screen	-5	Screening	03/12/93	Normal	
	1DT	Reboxetine	Female	24/06/93	24/06/93	Screen	-1	Screening	23/06/93	Normal	
	2DT	Imipramine	Female	28/06/93	04/08/93	Screen	-3	Screening	25/06/93	Normal	
						Day 28	28	1-28 days	26/07/93	Normal	
						Day 42	38	29-56 days	05/08/93	Abnormal	SINUS TACHYCARDIA (> 100)
291	1HD	Imipramine	Female	22/03/93	25/04/93	Screen	-3	Screening	19/03/93	Normal	
						Day 28	29	1-28 days	20/04/93	Normal	
	1DT	Reboxetine	Female	22/04/93	16/06/93	Screen	-1	Screening	21/04/93	Normal	
						Day 28	28	1-28 days	20/05/93	Normal	
						Day 56	55	29-56 days	16/06/93	Normal	
	2ND	Reboxetine	Female	20/04/93	14/06/93	Screen	-5	Screening	15/04/93	Normal	
						Day 28	28	1-28 days	18/05/93	Normal	
						Day 56	55	29-56 days	14/06/93	Normal	
	2DT	Reboxetine	Female	22/04/93	16/06/93	Screen	-21	Screening	01/04/93	Normal	
						Day 28	25	1-28 days	17/05/93	Normal	
						Day 56	55	29-56 days	16/06/93	Normal	

9550089

27

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0

E.C.G.

Centre	Patient	Treatment	Sex	Treatment period		Visit	days of treat.	Assessment	Date	Value	Abnormality
				Start date	End date						
291	3ND	Imipramine	Male	19/04/93	13/06/93	Screen	-7	Screening	12/04/93	Normal	
						Day 28	28	1-28 days	17/05/93	Normal	
						Day 56	56	29-56 days	14/06/93	Normal	
	3DT	Imipramine	Female	14/05/93	20/05/93	Screen	-22	Screening	22/04/93	Normal	
						Screen	0	Screening	03/05/93	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 28	29	1-28 days	01/06/93	Normal	
	4ND	Reboxetine	Male	03/05/93	28/06/93	Day 28	56	29-56 days	28/06/93	Normal	
						Day 56	56	29-56 days	28/06/93	Normal	
						Screen	0	Screening	05/05/93	Normal	
	4DT	Imipramine	Male	05/05/93	29/06/93	Day 28	28	1-28 days	02/06/93	Normal	
						Day 56	54	29-56 days	28/06/93	Normal	
						Screen	-1	Screening	03/11/93	Abnormal	VENTRICULAR ECTOPIC BEATS - OCCASIONAL RIGHT BUNDLE BRANCH BLOCK ATR. ECTOPIC BEATS SUPRAVEN. TACHYCARDIA
25DT	Imipramine	Female	04/11/93	30/12/93	Screen	33	1-28 days	07/12/93	Abnormal		
					Day 28	33	1-28 days	07/12/93	Abnormal		
					Screen	-1	Screening	08/06/93	Normal		
26DT	Reboxetine	Female	09/06/93	03/08/93	Screen	27	1-28 days	06/07/93	Normal		
					Day 28	27	1-28 days	06/07/93	Normal		
					Day 56	56	29-56 days	04/08/93	Normal		
27DT	Reboxetine	Female	04/11/93	30/12/93	Screen	-1	Screening	03/11/93	Normal		
					Day 28	28	1-28 days	02/12/93	Normal		
					Screen	0	Screening	18/11/93	Normal		
28DT	Imipramine	Female	18/11/93	17/01/94	Day 28	29	1-28 days	17/12/93	Normal		
					Day 56	60	29-56 days	17/01/94	Normal		
					Screen	-14	Screening	17/02/93	Normal		
292	5ND	Imipramine	Female	03/03/93	27/04/93	Day 28	27	1-28 days	30/03/93	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 56	55	29-56 days	27/04/93	Normal	
						Screen	-12	Screening	22/02/93	Normal	
5DT	Reboxetine	Male	06/03/93	29/04/93	Screen	27	1-28 days	02/04/93	Normal		
					Day 28	54	29-56 days	29/04/93	Normal		
					Day 56	54	29-56 days	29/04/93	Normal		
6ND	Reboxetine	Female	04/03/93	28/04/93	Screen	-13	Screening	19/02/93	Abnormal	MYOCARDIAL ISCHEMIA	
					Screen	-13	Screening	19/02/93	Abnormal	MYOCARDIAL ISCHEMIA	
					Screen	-13	Screening	19/02/93	Abnormal	MYOCARDIAL ISCHEMIA	

9550089

28

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period		Visit	days of treat.	Assessment	Date	Value	Abnormality
				Start date	End date						
292	6ND	Reboxetine	Female	04/03/93	28/04/93	Day 28	27	1-28 days	31/03/93	Abnormal	MYOCARDIAL ISCHEMIA
						Day 56	55	29-56 days	28/04/93	Abnormal	MYOCARDIAL ISCHEMIA
6DI	Imipramine	Female	16/03/93	10/05/93	Screen	-11	Screening	05/03/93	Normal		
					Day 28	28	1-28 days	13/04/93	Normal		
7HD	Reboxetine	Male	21/04/93	15/06/93	Day 56	55	29-56 days	10/05/93	Normal		
					Screen	-22	Screening	30/03/93	Normal		
7DI	Imipramine	Male	19/03/93	13/05/93	Day 28	27	1-28 days	18/05/93	Normal		
					Day 56	55	29-56 days	15/06/93	Normal		
8ND	Imipramine	Male	23/04/93	17/06/93	Screen	-11	Screening	08/03/93	Normal		
					Day 28	27	1-28 days	15/04/93	Normal		
8DI	Reboxetine	Female	09/04/93	03/06/93	Day 56	55	29-56 days	13/05/93	Normal		
					Screen	-22	Screening	01/04/93	Abnormal	SINUS BRADYCARDIA (< 60)	
21ND	Imipramine	Female	08/05/93	02/07/93	Day 28	26	1-28 days	19/05/93	Normal		
					Day 56	55	29-56 days	17/06/93	Normal		
21DI	Reboxetine	Female	04/05/93	28/06/93	Screen	-18	Screening	22/03/93	Normal		
					Day 28	27	1-28 days	06/05/93	Normal		
22ND	Imipramine	Female	20/05/93	14/07/93	Day 56	55	29-56 days	03/06/93	Normal		
					Screen	-8	Screening	30/04/93	Normal		
22DI	Reboxetine	Female	04/05/93	28/06/93	Day 28	27	1-28 days	04/06/93	Normal		
					Day 56	55	29-56 days	02/07/93	Normal		
23ND	Imipramine	Female	05/05/93	29/06/93	Screen	-4	Screening	30/04/93	Normal		
					Day 28	28	1-28 days	01/06/93	Normal		
23DI	Reboxetine	Female	27/05/93	21/07/93	Day 56	55	29-56 days	28/06/93	Normal		
					Screen	-15	Screening	05/05/93	Normal		
23ND	Imipramine	Female	05/05/93	29/06/93	Day 28	27	1-28 days	16/05/93	Normal		
					Day 56	55	29-56 days	14/07/93	Normal		
23DI	Reboxetine	Female	27/05/93	21/07/93	Screen	-5	Screening	30/04/93	Normal		
					Day 28	27	1-28 days	01/06/93	Normal		
23DI	Reboxetine	Female	27/05/93	21/07/93	Day 56	55	29-56 days	29/06/93	Normal		
					Screen	-17	Screening	10/05/93	Normal		

9550089

29

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	_Treatment period_		Visit	days of treat.	Assessment	E.C.G.	
				Start date	End date				Date	Value
292	23HD	Reboxetine	Female	27/05/93	21/07/93	Day 28 Day 56	27 1-28 days 55 29-56 days		23/06/93 21/07/93	Normal Normal
	23DT	Reboxetine	Male	14/05/93	08/07/93	Screen Day 28 Day 56	-11 Screening 26 1-28 days 55 29-56 days		03/05/93 09/06/93 08/07/93	Abnormal Abnormal Abnormal
	24HD	Reboxetine	Male	05/06/93	30/07/93	Screen Day 28 Day 56	-8 Screening 27 1-28 days 55 29-56 days		28/05/93 02/07/93 30/07/93	Normal Normal Normal
	24DT	Imipramine	Female	02/06/93	27/07/93	Screen Day 28 Day 56	-12 Screening 27 1-28 days 55 29-56 days		21/05/93 29/06/93 27/07/93	Normal Normal Normal
	9HD	Imipramine	Female	18/02/93	14/04/93	Screen Day 28 Day 56	-6 Screening 28 1-28 days 56 29-56 days		12/02/93 18/03/93 15/04/93	Normal Normal Normal
	9DT	Imipramine	Female	26/05/93	20/07/93	Screen Day 28 Day 56	-7 Screening 28 1-28 days 56 29-56 days		19/05/93 23/06/93 21/07/93	Normal Normal Normal
	10HD	Reboxetine	Female	23/03/93	17/05/93	Screen Day 28 Day 56	-7 Screening 28 1-28 days 55 29-56 days		16/03/93 20/04/93 17/05/93	Normal Normal Normal
	10DT	Imipramine	Female	20/07/93	13/09/93	Screen Day 28 Day 56	-5 Screening 28 1-28 days 56 29-56 days		15/07/93 17/08/93 14/09/93	Normal Normal Normal
	11HD	Imipramine	Male	12/07/93	05/09/93	Screen Day 28 Day 56	0 Screening 28 1-28 days 56 29-56 days		12/07/93 09/08/93 06/09/93	Normal Normal Normal
	11DT	Reboxetine	Female	18/11/93	01/12/93	Screen	-6 Screening		12/11/93	Normal
	12HD	Reboxetine	Male	16/09/93	27/10/93	Screen Day 28	-7 Screening 28 1-28 days		09/09/93 14/10/93	Normal Normal

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

30

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0
ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period		Visit	days of treat.	Assessment	E.C.G.		
				Start date	End date				Date	Value	Abnormality
293	12DT	Reboxetine	Female	15/12/93	06/02/94	Screen	-3	Screening	10/12/93	Normal	
						Day 28	28	1-28 days	10/01/94	Normal	
						Day 56	56	29-56 days	07/02/94	Normal	
294	13HD	Imipramine	Female	15/02/93	12/04/93	Screen	0	Screening	15/02/93	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 28	28	1-28 days	15/03/93	Normal	
						Day 56	57	29-56 days	13/04/93	Normal	
295	13DT	Reboxetine	Female	08/03/93	03/05/93	Screen	7	Screening	15/03/93	Normal	
						Day 28	28	1-28 days	05/04/93	Normal	
						Day 56	57	29-56 days	04/05/93	Abnormal	SINUS BRADYCARDIA (< 60)
300	14HD	Reboxetine	Female	15/02/93	12/04/93	Screen	0	Screening	15/02/93	Normal	
						Day 28	28	1-28 days	15/03/93	Normal	
						Day 56	57	29-56 days	13/04/93	Normal	
301	14DT	Imipramine	Female	08/03/93	03/05/93	Screen	0	Screening	08/03/93	Normal	
						Day 28	28	1-28 days	05/04/93	Normal	
						Day 56	57	29-56 days	04/05/93	Normal	
302	15HD	Imipramine	Female	22/02/93	19/04/93	Screen	0	Screening	22/02/93	Normal	
						Day 28	28	1-28 days	22/03/93	Normal	
						Day 56	57	29-56 days	20/04/93	Normal	
303	15DT	Imipramine	Female	09/03/93	03/05/93	Screen	0	Screening	09/03/93	Normal	
						Day 28	28	1-28 days	06/04/93	Normal	
						Day 56	56	29-56 days	04/05/93	Normal	
304	16HD	Reboxetine	Female	23/02/93	19/04/93	Screen	0	Screening	23/02/93	Normal	
						Day 28	28	1-28 days	23/03/93	Normal	
						Day 56	56	29-56 days	20/04/93	Normal	
305	16DT	Reboxetine	Female	09/03/93	03/05/93	Screen	0	Screening	09/03/93	Normal	
						Day 28	28	1-28 days	06/04/93	Normal	
						Day 56	56	29-56 days	04/05/93	Normal	
306	25HD	Imipramine	Female	14/06/93	08/08/93	Screen	0	Screening	14/06/93	Normal	
						Day 28	28	1-28 days	12/07/93	Normal	
						Day 56	56	29-56 days	09/08/93	Normal	

9550089

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

31

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0
ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period		Visit	days of treat.	Assessment	E.C.G.		
				Start date	End date				Date	Value	Abnormality
294	26MD	Imipramine	Female	14/06/93	08/08/93	Screen	0	Screening	14/06/93	Normal	
						Day 28	28	1-28 days	12/07/93	Normal	
						Day 56	56	29-56 days	09/08/93	Normal	
295	27MD	Reboxetine	Female	15/06/93	02/08/93	Screen	0	Screening	15/06/93	Normal	
						Day 28	28	1-28 days	13/07/93	Normal	
						Day 56	56	29-56 days	09/08/93	Normal	
296	28MD	Reboxetine	Female	15/06/93	09/08/93	Screen	0	Screening	15/06/93	Normal	
						Day 28	28	1-28 days	13/07/93	Normal	
						Day 56	56	29-56 days	09/08/93	Normal	
297	29DT	Reboxetine	Female	14/06/93	08/08/93	Screen	0	Screening	14/06/93	Normal	
						Day 28	28	1-28 days	12/07/93	Normal	
						Day 56	56	29-56 days	09/08/93	Normal	
298	30DT	Reboxetine	Female	14/06/93	08/08/93	Screen	0	Screening	14/06/93	Normal	
						Day 28	28	1-28 days	12/07/93	Normal	
						Day 56	56	29-56 days	09/08/93	Normal	
299	31DT	Imipramine	Female	21/06/93	15/08/93	Screen	0	Screening	21/06/93	Normal	
						Day 28	28	1-28 days	19/07/93	Normal	
						Day 56	56	29-56 days	16/08/93	Normal	
300	32DT	Imipramine	Male	21/06/93	15/08/93	Screen	0	Screening	21/06/93	Normal	
						Day 28	28	1-28 days	19/07/93	Normal	
						Day 56	56	29-56 days	16/08/93	Normal	
301	17MD	Reboxetine	Female	21/04/93	15/06/93	Screen	-1	Screening	20/04/93	Abnormal	OTHER
						Day 28	27	1-28 days	18/05/93	Abnormal	OTHER
						Day 56	55	29-56 days	15/06/93	Abnormal	OTHER
302	17DT	Imipramine	Male	27/04/93	23/06/93	Screen	-4	Screening	23/04/93	Abnormal	ATRIAL FIBRILLATION / FLUTTER
						Day 28	30	1-28 days	27/05/93	Abnormal	ATRIAL FIBRILLATION / FLUTTER
						Day 56	58	29-56 days	24/06/93	Abnormal	ATRIAL FIBRILLATION / FLUTTER
303	18MD	Reboxetine	Female	23/04/93	17/06/93	Screen	-3	Screening	20/04/93	Abnormal	SINUS BRADYCARDIA (< 60)
						Day 28	28	1-28 days	21/05/93	Normal	
						Day 56	56	29-56 days	18/06/93	Abnormal	SINUS BRADYCARDIA (< 60)

9550089

32

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0

ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period		Visit	days of treat.	Assessment	Date	Value	Abnormality
				Start date	End date						
295	180T	Imipramine	Female	29/04/93	23/06/93	Screen Day 28	-2	Screening	27/04/93	Normal	
						Screen Day 56	28	1-28 days	27/05/93	Normal	
						Screen Day 56	56	29-56 days	24/06/93	Normal	
190D	190D	Imipramine	Male	14/05/93	08/07/93	Screen Day 28	-1	Screening	13/05/93	Abnormal	PREVIOUS MYOCARDIAL INFARCTION
						Screen Day 56	28	1-28 days	11/06/93	Abnormal	PREVIOUS MYOCARDIAL INFARCTION
						Screen Day 56	56	29-56 days	09/07/93	Abnormal	PREVIOUS MYOCARDIAL INFARCTION
190T	190T	Reboxetine	Female	10/05/93	04/07/93	Screen Day 28	-3	Screening	07/05/93	Normal	
						Screen Day 56	28	1-28 days	07/06/93	Normal	
						Screen Day 56	56	29-56 days	05/07/93	Normal	
200D	200D	Imipramine	Female	14/05/93	08/07/93	Screen Day 28	-1	Screening	13/05/93	Normal	
						Screen Day 56	28	1-28 days	11/06/93	Normal	
						Screen Day 56	56	29-56 days	09/07/93	Normal	
200T	200T	Reboxetine	Female	12/05/93	06/07/93	Screen Day 28	-2	Screening	10/05/93	Normal	
						Screen Day 56	27	1-28 days	08/06/93	Normal	
						Screen Day 56	55	29-56 days	06/07/93	Normal	
381	1ND	Reboxetine	Male	10/12/93	03/02/94	Screen Day 28	-4	Screening	06/12/93	Normal	ATRIAL ECTOPIC BEATS - OCCASIONAL
						Screen Day 28	26	1-28 days	05/01/94	Abnormal	A-V BLOCK 1ST DEGREE
2ND	2ND	Reboxetine	Female	02/02/94	07/03/94	Screen Day 28	0	Screening	02/02/94	Abnormal	VENTRICULAR ECTOPIC BEATS - OCCASIONAL
						Screen Day 28	28	1-28 days	02/03/94	Abnormal	MYOCARDIAL ISCHEMIA
						Screen Day 28	0	Screening	08/02/94	Normal	SINUS TACHYCARDIA (> 100)
3ND	3ND	Reboxetine	Female	08/02/94	26/02/94	Screen Day 28	-4	Screening	25/02/94	Abnormal	ATRIAL FIBRILLATION / FLUTTER
						Screen Day 28	23	1-28 days	08/12/93	Normal	LEFT VENTRICULAR HYPERTROPHY
4ND	4ND	Imipramine	Female	01/03/94	14/03/94	Screen Day 28	0	Screening	08/02/94	Normal	MYOCARDIAL ISCHEMIA
						Screen Day 28	23	1-28 days	11/11/93	Normal	
						Screen Day 56	58	29-56 days	12/01/94	Abnormal	SINUS TACHYCARDIA (> 100)
382	5ND	Imipramine	Female	15/11/93	12/01/94	Screen Day 28	0	Screening	08/12/93	Normal	ATRIAL ECTOPIC BEATS - OCCASIONAL
						Screen Day 56	23	1-28 days	12/01/94	Abnormal	VENTRICULAR ECTOPIC BEATS - OCCASIONAL
						Screen Day 56	58	29-56 days	12/01/94	Abnormal	VENTRICULAR ECTOPIC BEATS - OCCASIONAL

9550089

33

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/035
Listing No.: 21.0
ECC TRACINGS

Centre	Patient	Treatment	Sex	Treatment period		Visit	days of treat.	Assessment	Date	Value	Abnormality
				Start date	End date						
362	5DT	Reboxetine	Male	21/10/93	12/11/93	Screen	-4	Screening	17/10/93	Normal	
	6ND	Reboxetine	Female	12/11/93	07/01/94	Screen Day 28 Day 56	0 33 56	Screening 1-28 days 29-56 days	12/11/93 15/12/93 07/01/94	Normal Normal Normal	
	6DT	Imipramine	Female	22/10/93	17/12/93	Screen	0	Screening	22/10/93	Abnormal	ATRIAL FIBRILLATION / FLUTTER MYOCARDIAL ISCHEMIA OTHER
						Day 28	28	1-28 days	19/11/93	Abnormal	ATRIAL FIBRILLATION / FLUTTER LEFT VENTRICULAR HYPERTROPHY MYOCARDIAL ISCHEMIA
						Day 56	56	29-56 days	17/12/93	Abnormal	SINUS BRADYCARDIA (< 60) VENTRICULAR ECTOPIC BEATS - OCCASIONAL ATRIAL FIBRILLATION / FLUTTER LEFT VENTRICULAR HYPERTROPHY MYOCARDIAL ISCHEMIA
	7ND	Reboxetine	Female	20/12/93	07/02/94	Screen Day 28 Day 56	0 25 49	Screening 1-28 days 29-56 days	20/12/93 14/01/94 07/02/94	Normal Normal Normal	
	7DT	Imipramine	Male	22/10/93	26/10/93	Screen	0	Screening	22/10/93	Abnormal	LEFT VENTRICULAR HYPERTROPHY MYOCARDIAL ISCHEMIA PREVIOUS MYOCARDIAL INFARCTION
	8ND	Imipramine	Male	26/01/94	11/02/94	Screen	-6	Screening	20/01/94	Abnormal	ATRIAL ECTOPIC BEATS - OCCASIONAL VENTRICULAR ECTOPIC BEATS - OCCASIONAL ATRIAL FIBRILLATION / FLUTTER LEFT VENTRICULAR HYPERTROPHY MYOCARDIAL ISCHEMIA
	8DT	Reboxetine	Female	22/12/93	15/02/94	Screen Day 56	0 63	Screening 29-56 days	22/12/93 23/02/94	Normal Abnormal	ATRIAL ECTOPIC BEATS - OCCASIONAL VENTRICULAR ECTOPIC BEATS - OCCASIONAL PREVIOUS MYOCARDIAL INFARCTION
	9ND	Reboxetine	Female	11/02/94	08/04/94	Screen Day 28 Day 49	0 28 48	Screening 1-28 days 29-56 days	11/02/94 11/03/94 31/03/94	Normal Abnormal Abnormal	SINUS TACHYCARDIA (> 100) ATRIAL ECTOPIC BEATS - OCCASIONAL MYOCARDIAL ISCHEMIA

2534

9550089

34

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/035
 Listing No.: 21.0
 ECG TRACINGS

Centre	Patient	Treatment	Sex	Treatment period		Visit	days of treat.	Assessment	Date	Value	Abnormality
				Start date	End date						
382	90T	Reboxetine	Female	08/02/94	09/03/94	Screen	-2	Screening	06/02/94	Normal	
	108D	Imipramine	Female	11/02/94	16/02/94	Screen	0	Screening	11/02/94	Abnormal	SINUS TACHYCARDIA (> 100) ATRIAL ECTOPIC BEATS - OCCASIONAL VENTRICULAR ECTOPIC BEATS - OCCASIONAL LEFT VENTRICULAR HYPERTROPHY
3301	18D	Reboxetine	Female	24/09/92	24/09/92	Screen	-7	Screening	17/09/92	Normal	
	28D	Imipramine	Male	12/01/93	09/03/93	Screen Day 28 Day 56	-6 29 55	Screening 1-28 days 29-56 days	06/01/93 10/02/93 08/03/93	Abnormal Normal Normal	OTHER
	33D	Reboxetine	Female	16/01/93	18/02/93	Screen Day 28	-4	Screening 1-28 days	12/01/93 13/02/93	Normal Normal	
3302	58D	Reboxetine	Female	07/11/92	27/11/92	Screen	-8	Screening	30/10/92	Normal	
	68D	Imipramine	Female	26/06/93	16/07/93	Screen	-4	Screening	22/06/93	Normal	
	78D	Imipramine	Female	13/11/93	08/01/94	Screen Day 35	0 40	Screening 29-56 days	13/11/93 23/12/93	Normal Normal	

9550089

Pharmacia

Document 9550089

12.2.3 CRFs

Individual Patient CRFs are filed in the Study Master File.

090177e1803f200f\Approved\Approved On: 12-Nov-2002 22:22

2536